data_2af2_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2af2 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.511 -0.541 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 14.4 pttm -89.13 129.96 35.64 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.375 168.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.56 173.52 8.02 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 164.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.2 119.56 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.524 1.53 . . . . 0.0 108.475 -173.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.96 118.77 37.65 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 166.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.0 t -110.99 99.66 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.705 0.802 . . . . 0.0 109.397 177.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.95 132.56 35.89 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.564 168.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -135.5 132.51 37.4 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.048 1.339 . . . . 0.0 110.643 168.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.95 -97.95 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 171.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.87 119.77 9.95 Favored 'General case' 0 N--CA 1.44 -0.94 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 -166.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 41.02 -99.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 128.743 3.068 . . . . 0.0 113.358 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.88 -11.88 33.52 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 123.311 2.674 . . . . 0.0 113.828 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.89 115.05 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 120.32 1.418 . . . . 0.0 112.44 179.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -139.9 169.9 16.86 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 122.265 1.031 . . . . 0.0 111.005 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.96 110.29 0.55 Allowed Glycine 0 C--O 1.224 -0.476 0 CA-C-N 113.984 -1.462 . . . . 0.0 111.639 168.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.62 134.65 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.106 0.953 . . . . 0.0 109.339 169.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.1 mm -139.38 124.45 21.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 C-N-CA 125.996 1.718 . . . . 0.0 109.888 168.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -90.81 141.32 28.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 124.867 1.267 . . . . 0.0 110.571 166.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -113.94 101.53 9.34 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.686 1.194 . . . . 0.0 109.779 172.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -83.91 110.68 18.59 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 125.965 1.706 . . . . 0.0 111.172 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.7 tp60 -123.13 139.17 54.34 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.378 1.071 . . . . 0.0 110.989 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.94 -28.17 15.3 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 -168.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.277 0.0 OUTLIER -128.68 -106.76 0.3 Allowed 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.953 1.301 . . . . 0.0 109.508 166.628 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 88.4 p -152.96 -10.37 0.16 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 122.13 2.241 . . . . 0.0 116.358 -177.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -128.94 -13.91 4.52 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.377 1.471 . . . . 0.0 112.672 176.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 174.53 42.58 Favored Glycine 0 CA--C 1.543 1.812 0 C-N-CA 127.938 2.685 . . . . 0.0 113.885 175.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -79.91 157.32 23.99 Favored 'Trans proline' 0 CA--C 1.534 0.498 0 C-N-CA 123.546 2.831 . . . . 0.0 112.427 -168.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.2 t -118.21 136.89 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.97 0.908 . . . . 0.0 112.427 -166.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.516 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 7.1 tttp -93.57 124.31 37.47 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.597 1.159 . . . . 0.0 108.151 170.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.25 133.34 69.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.924 0.89 . . . . 0.0 110.29 -168.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -157.36 158.83 36.69 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.25 178.6 29.67 Favored Glycine 0 CA--C 1.528 0.849 0 C-N-CA 123.881 0.753 . . . . 0.0 114.799 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.0 p -115.69 125.35 52.72 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -167.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 9.7 mm -109.74 102.24 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 C-N-CA 125.224 1.41 . . . . 0.0 108.068 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -116.2 157.61 24.59 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.315 0.646 . . . . 0.0 112.194 -168.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.94 9.6 63.72 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 124.941 1.258 . . . . 0.0 112.448 -168.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 99.0 mt -83.33 167.93 17.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.688 1.195 . . . . 0.0 110.563 172.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -100.37 156.64 17.14 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 106.322 -1.732 . . . . 0.0 106.322 163.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -61.96 157.23 19.08 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-O 122.509 1.147 . . . . 0.0 113.429 -170.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.02 -176.83 36.37 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 122.147 0.859 . . . . 0.0 112.685 -173.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.466 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.2 mp -72.52 150.35 43.29 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.695 1.998 . . . . 0.0 111.895 -169.12 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -144.31 124.82 13.96 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.847 1.659 . . . . 0.0 110.462 174.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.04 148.33 36.38 Favored Glycine 0 N--CA 1.487 2.054 0 CA-C-O 118.723 -1.043 . . . . 0.0 112.869 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -149.84 97.53 2.61 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-N 118.325 1.062 . . . . 0.0 113.613 -166.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -130.25 134.29 47.13 Favored 'General case' 0 N--CA 1.483 1.196 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -166.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -85.36 113.94 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 122.015 0.912 . . . . 0.0 110.896 170.17 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -81.74 173.07 12.65 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 125.419 1.487 . . . . 0.0 114.109 -175.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -65.06 133.41 51.58 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 126.062 1.745 . . . . 0.0 106.54 165.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 67.83 -176.91 0.2 Allowed 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 124.275 1.988 . . . . 0.0 112.992 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.34 3.65 29.68 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 130.618 3.961 . . . . 0.0 111.52 168.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.47 ' C ' HD21 ' A' ' 53' ' ' ASN . 14.9 t0 -73.85 126.51 30.57 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 120.385 2.093 . . . . 0.0 109.51 172.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.659 ' ND2' ' HG1' ' A' ' 116' ' ' THR 0.279 0.1 OUTLIER -156.12 42.62 0.4 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 123.289 1.518 . . . . 0.0 112.708 168.46 . . . . . . . . 4 4 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 38.8 p -116.3 -25.7 7.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 112.737 -2.029 . . . . 0.0 113.905 -165.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 25.6 0.59 Allowed 'General case' 0 CA--C 1.552 1.039 0 CA-C-N 119.374 0.988 . . . . 0.0 112.109 168.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.69 -121.35 12.34 Favored Glycine 0 C--N 1.341 0.827 0 C-N-CA 125.573 1.558 . . . . 0.0 110.561 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -74.14 -13.68 60.85 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.17 39.44 0.45 Allowed 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 126.072 1.749 . . . . 0.0 111.72 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 69.8 m -148.29 -116.16 0.06 Allowed 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.306 2.243 . . . . 0.0 106.636 -169.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.59 109.98 0.71 Allowed 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 124.781 1.232 . . . . 0.0 112.23 169.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.57 -113.02 0.47 Allowed Glycine 0 CA--C 1.538 1.485 0 CA-C-O 117.928 -1.485 . . . . 0.0 109.574 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -82.67 -179.86 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 124.415 3.41 . . . . 0.0 108.102 165.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.29 123.07 32.52 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.673 0.789 . . . . 0.0 111.518 -172.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -26.03 131.77 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 129.419 3.088 . . . . 0.0 116.956 174.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -106.15 52.69 0.15 Allowed Pre-proline 0 CA--C 1.557 1.235 0 C-N-CA 124.883 1.273 . . . . 0.0 113.425 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -63.05 -25.3 73.57 Favored 'Trans proline' 0 C--N 1.355 0.896 0 CA-C-N 122.691 1.997 . . . . 0.0 112.937 -173.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 69.0 mt -99.5 -0.49 40.56 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.802 1.241 . . . . 0.0 113.797 172.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.4 t 70.57 58.87 0.23 Allowed 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 120.452 1.478 . . . . 0.0 114.073 168.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.06 176.01 10.04 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.446 1.498 . . . . 0.0 111.478 172.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.45 ' HZ2' ' HB2' ' A' ' 70' ' ' LYS . 4.1 ttmp? -70.8 173.29 7.49 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 129.497 3.119 . . . . 0.0 113.225 178.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -69.02 149.29 48.95 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.481 167.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 171.45 -157.45 27.95 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 116.884 1.513 . . . . 0.0 116.884 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.81 -70.29 0.43 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 118.013 1.965 . . . . 0.0 118.013 168.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -75.98 0.03 9.76 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 123.327 2.685 . . . . 0.0 114.506 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.98 -31.48 0.21 Allowed 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 119.301 0.955 . . . . 0.0 111.415 171.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -89.92 153.23 20.77 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.464 1.506 . . . . 0.0 111.26 167.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.7 tt0 -98.68 -27.82 13.81 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 126.356 1.863 . . . . 0.0 112.722 -170.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -78.8 -53.02 7.54 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 121.412 -0.805 . . . . 0.0 110.704 -169.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.7 ttt180 58.17 119.75 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 117.789 2.515 . . . . 0.0 117.789 163.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.8 m170 -58.5 143.08 46.94 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 118.458 -2.652 . . . . 0.0 112.942 169.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 91.2 t -58.26 -24.18 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.334 -0.854 . . . . 0.0 110.432 167.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -80.89 23.38 4.39 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 117.157 -1.913 . . . . 0.0 116.44 172.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -127.4 109.62 11.95 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 120.577 2.189 . . . . 0.0 111.533 -178.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -110.92 59.56 0.61 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.156 0.982 . . . . 0.0 110.742 172.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.79 -151.78 39.8 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.916 173.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.82 149.47 47.75 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.805 1.242 . . . . 0.0 108.619 169.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.26 106.47 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 124.559 1.144 . . . . 0.0 109.579 -174.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 38.7 m -96.14 114.67 26.39 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 124.451 1.1 . . . . 0.0 108.772 -174.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.73 154.11 19.18 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.666 1.187 . . . . 0.0 113.421 -172.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 12.1 t70 -94.6 176.84 6.13 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.513 1.125 . . . . 0.0 112.278 168.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.47 ' C ' ' H ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -73.57 -18.9 61.01 Favored 'General case' 0 N--CA 1.473 0.718 0 O-C-N 121.113 -0.992 . . . . 0.0 113.003 -176.587 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.37 15.23 0.48 Allowed 'General case' 0 CA--C 1.56 1.328 0 CA-C-O 122.974 1.369 . . . . 0.0 110.799 170.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 91' ' ' LYS . . . 82.29 12.74 80.18 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 128.131 2.776 . . . . 0.0 114.726 168.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.26 134.4 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 116.77 2.137 . . . . 0.0 116.77 -166.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.0 103.84 13.97 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.734 1.214 . . . . 0.0 107.822 166.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -94.89 109.36 21.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.944 0.878 . . . . 0.0 109.635 172.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -93.67 153.84 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 C-N-CA 124.825 1.25 . . . . 0.0 112.977 -169.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.2 p -149.6 125.74 10.69 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.933 0.893 . . . . 0.0 110.635 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.4 mt -144.98 157.99 13.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 128.548 2.739 . . . . 0.0 110.492 -169.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.516 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 12.4 tt0 -147.04 135.89 22.23 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.456 1.902 . . . . 0.0 107.055 167.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -155.79 144.92 20.69 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -166.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.0 p -122.15 49.25 1.6 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.326 1.05 . . . . 0.0 113.742 176.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.03 -3.63 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 124.769 1.227 . . . . 0.0 112.478 171.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.61 163.74 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 127.023 2.129 . . . . 0.0 110.004 174.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.0 t -157.13 163.84 38.49 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.524 1.529 . . . . 0.0 110.53 170.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.5 mp -77.3 66.36 3.06 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 120.195 1.361 . . . . 0.0 110.923 -171.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.89 104.0 9.24 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 125.431 1.492 . . . . 0.0 114.185 -167.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.49 -145.37 32.88 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.269 167.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -109.24 11.28 25.5 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.609 1.564 . . . . 0.0 112.086 -167.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -141.78 -9.77 0.92 Allowed 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -167.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.2 t -90.22 -87.85 0.18 Allowed 'General case' 0 N--CA 1.471 0.596 0 O-C-N 120.774 -1.204 . . . . 0.0 110.951 -171.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.294 0.1 OUTLIER -134.33 16.01 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 120.708 1.595 . . . . 0.0 112.505 167.356 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.39 141.04 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.25 3.97 83.0 Favored Glycine 0 N--CA 1.468 0.82 0 C-N-CA 124.451 1.024 . . . . 0.0 114.575 -175.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 44.2 ttt180 -100.38 176.36 5.38 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.286 1.434 . . . . 0.0 111.903 -167.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.659 ' HG1' ' ND2' ' A' ' 53' ' ' ASN . 18.8 m -118.62 143.05 47.07 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.942 1.697 . . . . 0.0 108.987 -179.056 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -117.62 141.89 47.85 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.581 1.152 . . . . 0.0 108.648 167.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.429 HG23 ' HE ' ' A' ' 143' ' ' ARG . 8.2 p -118.05 139.04 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.881 0.872 . . . . 0.0 111.52 172.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 4.7 p -110.81 133.64 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 O-C-N 124.293 0.996 . . . . 0.0 109.623 167.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 -99.94 159.45 15.07 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -60.6 -44.83 95.84 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.601 2.76 . . . . 0.0 114.714 -175.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 3.4 mppt? -127.35 -180.0 5.18 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.987 1.715 . . . . 0.0 113.163 -176.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.23 147.02 17.45 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.514 1.526 . . . . 0.0 112.428 173.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -102.53 137.04 41.3 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.821 1.648 . . . . 0.0 109.967 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -72.54 -43.31 63.68 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.964 -0.541 . . . . 0.0 111.673 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.0 mt 71.74 53.48 0.21 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.688 1.995 . . . . 0.0 111.967 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 158.43 -90.11 0.11 Allowed Glycine 0 N--CA 1.474 1.224 0 CA-C-N 119.598 1.09 . . . . 0.0 115.128 176.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.6 ttpm? -146.44 98.9 3.14 Favored 'General case' 0 N--CA 1.424 -1.76 0 C-N-CA 128.649 2.78 . . . . 0.0 107.745 177.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.5 -138.74 0.69 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 169.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -89.74 6.26 83.08 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.08 -175.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -157.99 168.92 25.77 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 120.372 2.086 . . . . 0.0 109.789 -169.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.91 -57.7 11.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.425 1.09 . . . . 0.0 110.836 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -41.24 -40.47 1.62 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 127.663 2.385 . . . . 0.0 114.562 178.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 64.1 p -55.12 -27.59 46.41 Favored 'General case' 0 N--CA 1.469 0.505 0 O-C-N 120.595 -1.315 . . . . 0.0 113.768 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 27.1 p -71.63 -28.02 63.49 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.557 1.143 . . . . 0.0 112.681 173.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -79.4 -56.98 3.93 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.771 1.628 . . . . 0.0 112.471 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.8 p -115.29 -14.84 11.65 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.525 1.306 . . . . 0.0 114.525 -170.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.49 -1.88 69.86 Favored Glycine 0 N--CA 1.466 0.65 0 O-C-N 123.902 0.751 . . . . 0.0 112.277 -169.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 66.16 17.56 10.77 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.671 1.188 . . . . 0.0 111.021 -176.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.6 -9.81 15.39 Favored 'General case' 0 CA--C 1.554 1.127 0 C-N-CA 123.898 0.879 . . . . 0.0 113.175 -168.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.67 -164.03 21.79 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.831 1.681 . . . . 0.0 112.937 178.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -63.68 175.67 1.05 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.797 1.239 . . . . 0.0 112.246 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.429 ' HE ' HG23 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -109.29 143.96 38.08 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 120.761 -1.212 . . . . 0.0 112.066 169.123 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -104.04 -94.72 0.33 Allowed 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.105 1.762 . . . . 0.0 109.052 173.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.34 149.18 38.78 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 122.379 1.085 . . . . 0.0 110.793 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 84.5 m -131.67 151.76 51.39 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 112.768 -2.014 . . . . 0.0 108.005 173.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.94 163.04 33.52 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 123.404 0.526 . . . . 0.0 113.899 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 25.1 t -113.5 160.87 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 125.358 1.463 . . . . 0.0 110.589 177.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.2 mt -114.65 123.26 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 124.222 1.009 . . . . 0.0 113.362 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -126.74 -168.73 12.62 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 126.144 1.83 . . . . 0.0 113.093 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.2 mp -104.63 131.78 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 121.57 -0.959 . . . . 0.0 111.033 -169.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.71 22.6 11.92 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.719 1.608 . . . . 0.0 113.61 -174.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.332 -0.188 0 C-N-CA 124.368 1.067 . . . . 0.0 110.47 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.825 0.345 . . . . 0.0 111.845 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -107.98 122.49 46.95 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.726 0.81 . . . . 0.0 109.411 175.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -99.18 131.17 45.41 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 174.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.86 169.52 8.54 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.652 1.181 . . . . 0.0 114.08 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -161.63 88.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 C-N-CA 128.114 2.566 . . . . 0.0 109.218 -169.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.72 142.73 35.18 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 120.415 -1.428 . . . . 0.0 111.005 176.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 4.2 t -126.7 106.23 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 3.1 mp -100.0 139.33 35.82 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.603 1.161 . . . . 0.0 108.21 169.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -155.95 175.18 14.29 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.126 1.37 . . . . 0.0 110.307 170.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 143.62 -46.3 0.84 Allowed Glycine 0 N--CA 1.474 1.201 0 C-N-CA 124.54 1.067 . . . . 0.0 113.68 169.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -78.01 67.2 3.8 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.535 1.534 . . . . 0.0 109.23 175.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.24 -111.34 0.38 Allowed Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.649 2.547 . . . . 0.0 112.625 -175.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -76.51 1.14 8.76 Favored 'Trans proline' 0 CA--C 1.536 0.603 0 C-N-CA 124.906 3.737 . . . . 0.0 114.168 -176.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 31.1 t -79.49 131.39 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 120.155 1.343 . . . . 0.0 111.283 171.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -130.13 160.84 32.56 Favored 'General case' 0 CA--C 1.516 -0.363 0 C-N-CA 125.127 1.371 . . . . 0.0 109.381 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.68 107.68 0.69 Allowed Glycine 0 CA--C 1.499 -0.926 0 CA-C-N 113.956 -1.474 . . . . 0.0 109.491 169.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.73 120.71 65.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.252 2.9 pp -130.53 139.49 51.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 122.376 1.084 . . . . 0.0 110.715 172.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -107.54 172.98 6.53 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 125.921 1.688 . . . . 0.0 110.523 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -152.66 165.74 34.32 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.773 0.829 . . . . 0.0 109.528 170.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -136.02 138.12 41.88 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.175 1.39 . . . . 0.0 109.584 166.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 59.4 tp60 -102.97 102.28 12.32 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.554 0.742 . . . . 0.0 110.749 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.46 ' HZ1' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -67.25 -45.0 78.0 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 120.51 -1.369 . . . . 0.0 113.703 176.158 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.46 ' CD ' ' HZ1' ' B' ' 23' ' ' LYS . 40.0 mp0 -147.7 138.98 23.62 Favored 'General case' 0 C--O 1.222 -0.379 0 C-N-CA 126.858 2.063 . . . . 0.0 108.394 168.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 76.0 p -50.33 -20.44 1.08 Allowed 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -169.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -112.98 0.46 15.06 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.141 1.376 . . . . 0.0 113.248 -173.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.72 -170.3 43.18 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.664 1.126 . . . . 0.0 113.624 -173.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -81.2 162.52 20.14 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.761 2.307 . . . . 0.0 109.923 168.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -135.47 143.24 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.481 1.112 . . . . 0.0 110.999 -174.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.418 ' HZ2' ' CD ' ' B' ' 100' ' ' GLU . 41.7 tttp -94.88 115.78 27.89 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.795 0.807 . . . . 0.0 110.153 167.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.94 144.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 166.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -144.56 -168.39 2.89 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 167.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.45 -153.82 17.22 Favored Glycine 0 N--CA 1.469 0.843 0 C-N-CA 124.84 1.21 . . . . 0.0 112.684 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 94.7 p -156.67 137.87 13.72 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 114.062 1.134 . . . . 0.0 114.062 -172.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.8 mm -104.96 119.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 169.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -131.91 144.62 50.98 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 121.192 1.814 . . . . 0.0 111.816 -171.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.7 -8.16 21.99 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 128.547 2.975 . . . . 0.0 113.374 -173.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 5.5 mp -71.44 156.48 39.41 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 129.327 3.051 . . . . 0.0 112.732 -176.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.6 t -74.48 168.32 19.95 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 164.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -75.52 146.1 40.81 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.167 -0.958 . . . . 0.0 112.976 177.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.72 -168.04 13.79 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 124.142 0.877 . . . . 0.0 113.017 -172.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.0 mt -76.12 147.43 38.58 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.896 2.078 . . . . 0.0 112.966 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . 0.401 ' HD1' ' HA ' ' B' ' 121' ' ' GLU . 87.2 m-70 -146.54 120.75 9.53 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.929 2.092 . . . . 0.0 110.501 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.06 145.86 37.05 Favored Glycine 0 N--CA 1.484 1.876 0 CA-C-O 117.536 -1.702 . . . . 0.0 112.333 -177.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -141.49 125.89 17.64 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 121.173 2.486 . . . . 0.0 113.074 -178.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 28.7 m80 -137.2 128.21 27.59 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -171.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -80.59 137.51 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 165.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -113.81 171.27 7.69 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 118.715 0.689 . . . . 0.0 111.466 173.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -72.63 138.72 46.92 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 125.184 1.394 . . . . 0.0 110.707 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 72.0 168.36 0.31 Allowed 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.6 1.96 . . . . 0.0 111.37 -168.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.32 16.62 60.19 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 164.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -87.35 110.45 20.25 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 125.9 1.68 . . . . 0.0 109.444 -168.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.519 HD22 HG23 ' B' ' 148' ' ' VAL . 2.2 p30 -159.23 34.48 0.2 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 116.132 1.901 . . . . 0.0 116.132 -174.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.321 1.3 p . . . . . 0 CA--C 1.536 0.426 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -164.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.797 0 CA-C-O 123.011 1.386 . . . . 0.0 114.413 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.15 -115.81 4.04 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.502 1.525 . . . . 0.0 111.773 176.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.58 175.52 10.96 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.968 3.112 . . . . 0.0 110.978 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.538 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -69.57 113.76 7.16 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.94 1.696 . . . . 0.0 109.192 176.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -55.15 145.43 21.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.832 1.301 . . . . 0.0 114.503 -168.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -111.05 66.77 0.55 Allowed Pre-proline 0 CA--C 1.55 0.977 0 C-N-CA 126.87 2.068 . . . . 0.0 112.16 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -60.64 -35.64 88.78 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.076 2.518 . . . . 0.0 113.329 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 72.9 mt -80.85 -1.32 42.76 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.728 1.211 . . . . 0.0 114.177 171.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t 71.22 47.02 0.41 Allowed 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 127.835 2.454 . . . . 0.0 111.073 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.7 mtp180 -103.02 171.99 7.07 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -169.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mpmm? -83.45 167.07 17.81 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 125.665 1.586 . . . . 0.0 109.449 162.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -78.32 168.46 19.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.357 1.063 . . . . 0.0 112.087 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.6 -134.95 7.65 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 124.719 1.152 . . . . 0.0 113.495 168.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.81 -80.77 0.33 Allowed Glycine 0 CA--C 1.541 1.657 0 CA-C-N 118.278 1.039 . . . . 0.0 115.335 -174.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.19 7.5 0.63 Allowed 'Trans proline' 0 CA--C 1.547 1.175 0 CA-C-N 120.846 2.323 . . . . 0.0 115.328 -177.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.35 6.57 0.29 Allowed 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 126.986 2.115 . . . . 0.0 113.366 169.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.6 156.71 45.66 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.406 2.282 . . . . 0.0 110.336 -170.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -97.43 -9.22 27.71 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.648 1.979 . . . . 0.0 112.126 -173.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -83.86 -95.81 0.06 Allowed 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.443 -0.786 . . . . 0.0 110.482 177.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 48.8 ttt180 68.49 115.98 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.513 1.925 . . . . 0.0 112.274 -170.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -55.21 154.31 5.96 Favored 'General case' 0 CA--C 1.552 1.022 0 O-C-N 119.505 -1.997 . . . . 0.0 114.813 171.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -84.91 58.18 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 C-N-CA 124.573 1.149 . . . . 0.0 109.492 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.61 67.75 0.02 OUTLIER Glycine 0 N--CA 1.469 0.852 0 C-N-CA 127.569 2.509 . . . . 0.0 109.59 -169.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -163.9 165.45 22.75 Favored 'General case' 0 CA--C 1.553 1.065 0 C-N-CA 128.78 2.832 . . . . 0.0 110.027 166.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 92.9 mt -131.39 -178.38 4.82 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.386 2.274 . . . . 0.0 107.331 168.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.46 -112.4 0.86 Allowed Glycine 0 N--CA 1.47 0.95 0 CA-C-N 118.309 0.504 . . . . 0.0 112.689 -179.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -137.11 164.17 29.06 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-O 121.643 0.735 . . . . 0.0 112.813 176.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.5 m -108.61 175.59 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 127.342 2.257 . . . . 0.0 109.354 171.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 m -141.34 140.25 33.72 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.525 1.53 . . . . 0.0 107.633 169.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.42 139.58 40.68 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.439 1.096 . . . . 0.0 112.814 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -82.62 154.35 24.98 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.717 2.007 . . . . 0.0 110.603 168.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.22 1.25 0.51 Allowed 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 117.621 2.452 . . . . 0.0 117.621 -169.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -76.24 -7.37 54.71 Favored 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 125.138 1.375 . . . . 0.0 109.783 164.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 93.77 20.67 30.73 Favored Glycine 0 C--N 1.337 0.594 0 C-N-CA 128.719 3.057 . . . . 0.0 112.482 177.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.7 p -127.68 133.51 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 119.09 1.445 . . . . 0.0 114.224 -168.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.93 131.24 41.07 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 165.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -81.77 142.46 32.59 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 104.105 -2.554 . . . . 0.0 104.105 166.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 t -125.9 127.02 70.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 CA-C-N 113.349 -1.751 . . . . 0.0 107.541 169.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.8 p -158.77 51.4 0.39 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.723 1.609 . . . . 0.0 110.105 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 mt -103.56 148.76 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.874 1.67 . . . . 0.0 113.317 -167.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.418 ' CD ' ' HZ2' ' B' ' 30' ' ' LYS . 5.6 mp0 -99.31 152.92 19.39 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 125.87 1.668 . . . . 0.0 109.457 174.054 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -153.81 148.49 26.36 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.787 -1.097 . . . . 0.0 111.039 167.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.6 p -118.55 53.65 0.97 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.279 1.032 . . . . 0.0 111.749 178.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.43 -35.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.958 168.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.92 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 CA-C-N 121.024 1.738 . . . . 0.0 111.151 167.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.0 m -160.92 162.43 32.03 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.474 1.509 . . . . 0.0 109.875 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -87.38 76.69 9.04 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.262 1.425 . . . . 0.0 109.172 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.3 t -158.21 104.82 1.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.468 0.651 . . . . 0.0 111.396 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.61 157.22 26.52 Favored Glycine 0 CA--C 1.526 0.763 0 CA-C-O 122.908 1.282 . . . . 0.0 112.445 -172.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -67.12 -21.26 65.85 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 131.391 3.876 . . . . 0.0 114.266 -169.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -107.56 14.88 25.32 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 128.58 2.752 . . . . 0.0 111.806 -175.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 81.0 p -101.67 -54.04 2.83 Favored 'General case' 0 CA--C 1.548 0.875 0 O-C-N 119.428 -2.045 . . . . 0.0 114.233 -174.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pt 178.51 -39.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 1 C-N-CA 133.941 4.897 . . . . 0.0 106.563 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm -57.71 131.08 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 N-CA-C 103.194 -2.891 . . . . 0.0 103.194 159.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.99 -18.97 8.24 Favored Glycine 0 CA--C 1.535 1.297 0 N-CA-C 117.046 1.578 . . . . 0.0 117.046 175.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.8 mtt180 -79.09 -178.09 5.96 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 126.408 1.883 . . . . 0.0 114.081 -177.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 8.8 t -120.19 170.03 9.7 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 127.929 2.492 . . . . 0.0 110.931 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tp -153.54 146.83 24.77 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.396 1.478 . . . . 0.0 111.358 171.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.43 137.34 56.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.622 1.569 . . . . 0.0 110.126 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 45.6 t -106.77 156.99 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -122.55 138.7 54.49 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.709 2.404 . . . . 0.0 111.905 -166.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . 0.401 ' HA ' ' HD1' ' B' ' 43' ' ' HIS . 20.7 tp10 -78.24 3.91 14.12 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -174.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -122.72 168.3 12.39 Favored 'General case' 0 CA--C 1.545 0.76 0 O-C-N 120.22 -1.55 . . . . 0.0 111.166 169.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.57 160.83 1.65 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.403 1.081 . . . . 0.0 111.223 169.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -107.72 149.13 28.53 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 122.732 0.413 . . . . 0.0 110.503 169.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -100.53 -8.84 22.66 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.794 2.038 . . . . 0.0 114.072 -171.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 54.09 70.35 0.62 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.81 1.644 . . . . 0.0 113.832 169.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.16 -51.99 4.47 Favored Glycine 0 N--CA 1.466 0.669 0 O-C-N 121.281 -0.887 . . . . 0.0 112.628 169.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.59 124.3 6.03 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 117.569 2.433 . . . . 0.0 117.569 173.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.24 0.62 Allowed Glycine 0 C--N 1.331 0.289 0 C-N-CA 129.67 3.509 . . . . 0.0 106.256 163.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -111.25 -57.72 0.48 Allowed Glycine 0 CA--C 1.53 0.991 0 N-CA-C 117.227 1.651 . . . . 0.0 117.227 -171.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . 0.571 HD22 ' ND2' ' B' ' 139' ' ' ASN . 0.1 OUTLIER -123.93 -175.62 3.27 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -161.545 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.02 -59.75 3.13 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 126.557 1.943 . . . . 0.0 111.452 171.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -50.56 -20.54 1.21 Allowed 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.81 1.781 . . . . 0.0 115.81 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.6 m -67.25 -40.73 86.31 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 119.838 -1.789 . . . . 0.0 112.302 170.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 22.1 p -82.75 -10.15 59.02 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 126.094 1.758 . . . . 0.0 113.674 -177.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.5 tttt -104.16 -77.18 0.58 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 128.42 2.688 . . . . 0.0 110.505 -168.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 22.2 p -79.2 -85.92 0.08 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 166.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 176.06 23.58 0.03 OUTLIER Glycine 0 CA--C 1.534 1.276 1 C-N-CA 131.431 4.348 . . . . 0.0 110.808 -177.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . 0.571 ' ND2' HD22 ' B' ' 131' ' ' ASN . 0.7 OUTLIER 56.98 17.46 3.37 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.005 1.722 . . . . 0.0 114.907 -174.918 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.96 6.37 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.174 0 N-CA-C 119.384 3.105 . . . . 0.0 119.384 -167.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 62.16 -23.93 0.06 OUTLIER Glycine 0 N--CA 1.475 1.252 0 C-N-CA 130.089 3.709 . . . . 0.0 120.442 166.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.7 t -165.38 159.99 17.65 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.535 1.667 . . . . 0.0 111.111 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.16 179.7 6.6 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.095 0.958 . . . . 0.0 109.892 167.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.33 3.8 pp -166.45 -154.02 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 129.49 3.116 . . . . 0.0 106.637 162.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.98 134.26 26.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.274 1.43 . . . . 0.0 112.811 -175.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.77 153.32 45.71 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.149 0.979 . . . . 0.0 111.01 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 176.81 37.44 Favored Glycine 0 N--CA 1.469 0.879 0 N-CA-C 116.186 1.235 . . . . 0.0 116.186 -170.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.519 HG23 HD22 ' B' ' 53' ' ' ASN . 0.5 OUTLIER -111.0 149.36 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.481 1.112 . . . . 0.0 109.181 174.155 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 30.7 mm -80.88 125.57 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 CA-C-N 119.788 1.176 . . . . 0.0 112.051 -175.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.96 164.98 12.46 Favored Glycine 0 N--CA 1.477 1.403 0 O-C-N 121.23 -0.919 . . . . 0.0 113.392 -176.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 4.7 mp -128.33 131.76 68.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.603 0.716 . . . . 0.0 112.018 -176.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.24 -3.77 18.16 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.084 0.953 . . . . 0.0 112.689 168.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 . . . . . 0 N--CA 1.465 0.319 0 C-N-CA 127.987 2.515 . . . . 0.0 111.179 -173.656 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.412 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.658 HD22 ' CG2' ' A' ' 148' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.426 ' HZ3' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.426 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.422 ' CG ' ' H ' ' A' ' 92' ' ' ASP . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.422 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.485 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.485 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.481 ' H ' ' CD ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.658 ' CG2' HD22 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . 0.4 ' HE3' ' O ' ' B' ' 152' ' ' ALA 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' B' ' 41' ' ' GLY . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . 0.442 ' H ' ' CD ' ' B' ' 40' ' ' GLU . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.482 HD21 ' H ' ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.8 t . . . . . 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.348 0 CA-C-O 122.073 0.939 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.469 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . 0.408 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.474 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.474 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . 0.408 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 105' ' ' SER . . . . . 0.453 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 111' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.4 ' O ' ' HE3' ' B' ' 3' ' ' LYS . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.412 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.658 HD22 ' CG2' ' A' ' 148' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.426 ' HZ3' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.426 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.422 ' CG ' ' H ' ' A' ' 92' ' ' ASP . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.422 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.485 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.485 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.481 ' H ' ' CD ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.658 ' CG2' HD22 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . 0.4 ' HE3' ' O ' ' B' ' 152' ' ' ALA 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' B' ' 41' ' ' GLY . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . 0.442 ' H ' ' CD ' ' B' ' 40' ' ' GLU . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.482 HD21 ' H ' ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.8 t . . . . . 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.348 0 CA-C-O 122.073 0.939 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.469 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . 0.408 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.474 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.474 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . 0.408 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 105' ' ' SER . . . . . 0.453 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 111' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.4 ' O ' ' HE3' ' B' ' 3' ' ' LYS . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t . . . . . 0 N--CA 1.465 0.307 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.4 ' HZ1' ' CG ' ' B' ' 52' ' ' ASP . 0.0 OUTLIER -84.83 104.54 14.88 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 122.046 0.927 . . . . 0.0 108.699 168.086 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -89.48 169.23 11.55 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.263 -0.898 . . . . 0.0 111.296 173.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 p -151.97 142.78 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.676 1.19 . . . . 0.0 110.741 -170.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.13 120.5 12.36 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.509 1.123 . . . . 0.0 109.526 168.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.5 t -105.31 97.16 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 174.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -78.12 111.47 14.07 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 123.83 0.852 . . . . 0.0 109.544 -172.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -152.04 155.15 37.39 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 116.604 2.075 . . . . 0.0 116.604 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.43 -39.76 0.24 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 129.891 3.615 . . . . 0.0 108.814 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.44 57.64 4.12 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 129.699 3.2 . . . . 0.0 112.933 -168.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.95 -103.72 0.05 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.358 2.409 . . . . 0.0 114.054 173.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -83.87 -8.05 10.22 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 124.893 3.729 . . . . 0.0 114.555 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.03 141.87 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 120.377 1.444 . . . . 0.0 109.92 173.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -157.81 161.76 38.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.227 -1.351 . . . . 0.0 110.513 167.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.01 119.25 2.92 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 113.658 -1.61 . . . . 0.0 109.576 169.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.07 133.23 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 166.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -136.14 143.19 36.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 122.703 1.24 . . . . 0.0 110.687 162.158 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.95 130.0 55.47 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 164.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 m-30 -114.2 132.43 56.11 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.205 1.002 . . . . 0.0 110.629 -179.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -108.56 117.11 33.32 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.02 1.328 . . . . 0.0 110.97 178.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -118.58 140.0 50.59 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 123.028 1.394 . . . . 0.0 113.27 173.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.551 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -87.01 -47.98 8.48 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 129.46 3.104 . . . . 0.0 113.739 -175.717 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -147.63 137.71 22.94 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 126.895 2.078 . . . . 0.0 110.44 -168.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 m -38.65 -57.65 1.16 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.939 1.696 . . . . 0.0 115.308 -169.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 -102.31 15.47 29.06 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 123.995 0.918 . . . . 0.0 111.765 -173.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.83 -170.85 30.06 Favored Glycine 0 CA--C 1.534 1.263 0 C-N-CA 124.776 1.179 . . . . 0.0 112.485 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -78.34 177.91 8.2 Favored 'Trans proline' 0 CA--C 1.536 0.588 0 C-N-CA 124.149 3.232 . . . . 0.0 112.818 -170.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.4 t -142.0 141.01 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 123.913 0.885 . . . . 0.0 111.173 -177.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -93.22 125.21 37.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.035 0.934 . . . . 0.0 109.56 169.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -117.5 125.25 73.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 127.674 2.389 . . . . 0.0 108.565 -169.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 7.0 p90 -153.87 162.39 41.27 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.611 0.72 . . . . 0.0 112.661 175.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.18 -158.21 27.15 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 125.145 1.355 . . . . 0.0 112.063 177.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.9 p -153.54 139.79 18.49 Favored 'General case' 0 C--O 1.237 0.403 0 O-C-N 122.396 -0.473 . . . . 0.0 112.07 -172.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -111.98 106.88 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.885 0.874 . . . . 0.0 108.668 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.02 128.13 54.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.758 2.423 . . . . 0.0 109.557 -165.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.4 -4.38 31.27 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.502 1.525 . . . . 0.0 112.109 -167.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.5 mt -65.53 162.45 18.05 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.593 1.197 . . . . 0.0 110.531 168.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -93.45 161.83 14.22 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 163.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -54.95 150.43 10.18 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.242 1.417 . . . . 0.0 113.352 -174.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.23 -177.57 36.59 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 124.758 1.17 . . . . 0.0 113.46 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.98 149.6 18.56 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 127.56 2.344 . . . . 0.0 112.588 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -145.65 134.0 21.83 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 126.125 1.77 . . . . 0.0 110.166 170.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.44 147.72 31.36 Favored Glycine 0 N--CA 1.481 1.664 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.142 173.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -156.85 106.27 2.24 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 119.03 1.415 . . . . 0.0 113.276 -172.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.04 153.12 30.47 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.801 1.408 . . . . 0.0 114.801 -168.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.538 HG22 ' H ' ' A' ' 116' ' ' THR . 0.4 OUTLIER -82.2 138.37 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 165.875 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -87.18 157.99 19.24 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.386 1.875 . . . . 0.0 113.907 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 21.8 tt0 -71.57 90.07 1.0 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 125.182 1.393 . . . . 0.0 109.231 178.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 94.6 142.35 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 128.64 2.776 . . . . 0.0 108.809 178.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.09 13.24 9.69 Favored Glycine 0 C--O 1.221 -0.715 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.627 169.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.446 ' HB2' ' H ' ' B' ' 5' ' ' VAL . 8.8 p-10 -88.44 47.67 1.53 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 124.578 2.132 . . . . 0.0 109.131 168.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -171.91 42.39 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 123.696 1.712 . . . . 0.0 110.104 -167.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.8 p -69.32 43.78 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 128.312 2.645 . . . . 0.0 117.455 -168.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -107.69 5.5 26.83 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.726 1.21 . . . . 0.0 109.345 164.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 51.56 -110.56 1.09 Allowed Glycine 0 C--N 1.347 1.178 0 C-N-CA 126.527 2.013 . . . . 0.0 112.938 168.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 69.5 m -53.32 -9.36 0.16 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 116.516 2.043 . . . . 0.0 116.516 178.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.4 t -124.99 19.02 8.45 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.455 1.65 . . . . 0.0 115.455 171.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.9 m -156.74 -40.51 0.07 Allowed 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 171.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.42 123.57 26.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.705 1.593 . . . . 0.0 112.191 -170.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -66.75 168.78 35.47 Favored Glycine 0 CA--C 1.538 1.48 0 CA-C-O 118.224 -1.32 . . . . 0.0 113.33 -175.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -56.48 176.21 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 125.007 3.805 . . . . 0.0 112.456 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.436 ' CD2' ' H ' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -68.06 114.22 6.39 Favored 'General case' 0 C--N 1.321 -0.644 0 O-C-N 121.484 -0.76 . . . . 0.0 112.615 -166.823 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -28.25 113.07 0.07 Allowed 'General case' 0 C--O 1.24 0.557 0 C-N-CA 127.489 2.316 . . . . 0.0 114.209 -172.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -111.61 50.59 0.33 Allowed Pre-proline 0 CA--C 1.551 0.997 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -174.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.11 -16.83 45.31 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 122.352 2.035 . . . . 0.0 112.51 177.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -79.42 -7.51 58.45 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.722 1.609 . . . . 0.0 112.456 168.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.9 t 64.26 49.74 2.51 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 128.437 2.695 . . . . 0.0 112.409 176.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 ptt180 -128.92 178.5 6.34 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.498 ' HA ' ' HE2' ' A' ' 70' ' ' LYS . 4.8 mmpt? -88.17 174.26 8.33 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.164 2.185 . . . . 0.0 112.375 -179.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -95.12 134.9 37.32 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 161.2 -123.17 1.18 Allowed Glycine 0 C--N 1.336 0.576 0 CA-C-O 119.72 -0.489 . . . . 0.0 113.682 168.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.66 -33.94 4.58 Favored Glycine 0 CA--C 1.545 1.952 0 CA-C-O 117.216 -1.88 . . . . 0.0 117.791 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -105.45 17.14 0.15 Allowed 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.619 2.879 . . . . 0.0 114.215 174.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.9 ptmm? -167.73 -22.02 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 127.389 2.276 . . . . 0.0 112.458 169.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -97.41 147.05 24.6 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 163.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -98.86 -6.58 28.78 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.445 1.898 . . . . 0.0 111.859 -171.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -77.4 -99.65 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.343 1.057 . . . . 0.0 110.035 -177.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 94.2 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 127.323 2.249 . . . . 0.0 111.179 174.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -58.31 156.96 9.18 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.569 1.147 . . . . 0.0 112.639 172.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.0 p -70.59 106.12 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.86 171.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.03 8.69 21.66 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 117.383 -1.787 . . . . 0.0 116.831 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.16 124.5 27.91 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 120.71 2.255 . . . . 0.0 109.545 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 97.5 mt -113.89 53.63 0.77 Allowed 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 120.575 1.534 . . . . 0.0 112.196 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.01 -141.99 42.49 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 121.56 -0.713 . . . . 0.0 111.659 174.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.67 127.43 45.16 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.482 0.713 . . . . 0.0 111.431 169.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.8 m -78.21 98.22 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.891 1.276 . . . . 0.0 108.985 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -93.3 117.41 30.04 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.822 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.49 139.88 30.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.806 1.242 . . . . 0.0 113.841 -174.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -72.32 156.74 38.77 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.146 2.178 . . . . 0.0 109.99 167.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.418 ' HZ1' ' CG ' ' A' ' 92' ' ' ASP . 1.6 pptp? -46.33 -25.38 0.63 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 128.294 2.638 . . . . 0.0 116.137 175.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.418 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 77.3 m-20 -76.42 -0.48 22.98 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.632 1.173 . . . . 0.0 111.525 174.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.36 41.79 11.2 Favored Glycine 0 C--N 1.335 0.526 0 C-N-CA 126.535 2.017 . . . . 0.0 112.783 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.5 p -143.21 129.0 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 N-CA-C 114.737 1.384 . . . . 0.0 114.737 176.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.57 124.15 35.52 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 165.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -111.55 135.64 51.86 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 124.496 1.118 . . . . 0.0 108.91 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.5 t -139.15 136.71 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -166.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.2 t -155.43 116.36 3.9 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.553 1.541 . . . . 0.0 110.579 168.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -145.51 155.4 13.3 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 128.965 2.906 . . . . 0.0 110.806 -169.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -128.23 132.23 48.77 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 167.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -145.51 138.1 25.88 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 124.486 1.114 . . . . 0.0 111.954 -168.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -116.94 51.38 1.0 Allowed 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 178.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.19 3.48 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.197 0 C-N-CA 123.831 0.853 . . . . 0.0 111.983 167.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.2 168.0 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 126.671 1.988 . . . . 0.0 110.376 177.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.0 m -154.4 156.09 36.19 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.001 0.92 . . . . 0.0 111.086 -173.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.7 mt -93.5 73.01 4.42 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.689 0.757 . . . . 0.0 110.681 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.84 144.91 44.97 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.384 1.474 . . . . 0.0 108.987 171.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -78.48 16.23 8.17 Favored Glycine 0 N--CA 1.479 1.539 0 N-CA-C 117.97 1.948 . . . . 0.0 117.97 -166.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -134.88 -89.26 0.35 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 125.794 1.638 . . . . 0.0 111.2 -169.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -87.39 4.81 41.6 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 120.595 -1.316 . . . . 0.0 113.168 -174.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -119.41 -141.7 0.35 Allowed 'General case' 0 CA--C 1.545 0.756 0 O-C-N 120.875 -1.141 . . . . 0.0 112.955 -168.629 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 51.5 mm -94.63 -28.87 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 O-C-N 120.595 -1.315 . . . . 0.0 114.389 -169.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.1 mm -55.06 133.05 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 119.191 0.905 . . . . 0.0 109.849 175.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.14 14.62 59.52 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.433 -1.204 . . . . 0.0 114.575 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -91.19 -169.99 2.51 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.408 1.604 . . . . 0.0 108.911 168.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.538 ' H ' HG22 ' A' ' 47' ' ' VAL . 6.4 m -145.63 114.37 6.85 Favored 'General case' 0 N--CA 1.484 1.227 0 O-C-N 119.599 -1.938 . . . . 0.0 108.02 -171.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 50.5 tp -89.74 132.73 35.05 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 124.943 1.297 . . . . 0.0 109.638 -175.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.4 m -118.84 153.79 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 C-N-CA 123.275 0.63 . . . . 0.0 110.628 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.76 152.13 15.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 163.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -115.21 147.36 40.44 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.094 1.357 . . . . 0.0 111.183 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -66.09 -22.52 66.41 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 119.838 -1.789 . . . . 0.0 113.601 -174.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.7 mmtm -131.62 176.98 7.86 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 119.772 -1.83 . . . . 0.0 113.998 173.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.22 145.04 27.69 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 112.977 -1.919 . . . . 0.0 110.9 169.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -79.03 169.2 18.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 122.188 0.994 . . . . 0.0 111.154 167.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.79 -38.49 53.91 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.203 164.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.8 mm? 63.35 60.32 1.16 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.957 2.503 . . . . 0.0 112.031 -171.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.59 -83.4 0.13 Allowed Glycine 0 N--CA 1.469 0.879 0 O-C-N 121.008 -1.058 . . . . 0.0 112.747 168.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -150.53 97.73 2.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.631 1.681 . . . . 0.0 110.921 169.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.459 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -74.09 176.07 47.3 Favored Glycine 0 CA--C 1.526 0.781 0 CA-C-N 112.086 -2.325 . . . . 0.0 107.651 163.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.09 29.79 0.15 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 127.599 2.523 . . . . 0.0 118.677 -167.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -148.03 -103.97 0.09 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 120.652 2.226 . . . . 0.0 111.528 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -163.22 -51.9 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 127.312 2.245 . . . . 0.0 108.58 -169.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 19.2 tp10 -50.17 -32.16 15.51 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 127.416 2.286 . . . . 0.0 112.351 169.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 77.6 p -53.24 -36.84 61.5 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 120.565 -1.334 . . . . 0.0 113.173 168.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 2.8 p -79.08 -20.99 47.39 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 172.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -79.79 -64.56 1.16 Allowed 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.5 1.046 . . . . 0.0 112.572 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 28.7 p -108.62 -9.52 15.29 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.842 1.657 . . . . 0.0 114.559 -174.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.2 -9.57 74.61 Favored Glycine 0 N--CA 1.471 1.031 0 CA-C-N 119.918 1.235 . . . . 0.0 111.781 -167.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 79.26 -44.1 0.32 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 129.245 3.018 . . . . 0.0 110.136 -179.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 56.62 11.77 0.96 Allowed 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 128.433 2.693 . . . . 0.0 116.649 167.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.43 -36.25 0.45 Allowed Glycine 0 CA--C 1.537 1.445 0 C-N-CA 125.951 1.739 . . . . 0.0 113.673 -167.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -173.88 -156.59 0.08 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.149 1.779 . . . . 0.0 111.551 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.05 -166.22 1.15 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.798 2.039 . . . . 0.0 108.197 165.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -176.96 -151.79 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.661 2.384 . . . . 0.0 107.378 -175.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.72 148.99 23.05 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 125.709 1.604 . . . . 0.0 112.568 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.8 p -148.45 148.71 30.59 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.092 0.957 . . . . 0.0 113.459 -176.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.2 136.61 5.1 Favored Glycine 0 N--CA 1.465 0.604 0 C-N-CA 124.299 0.952 . . . . 0.0 113.543 -170.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -76.24 148.58 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 124.676 1.19 . . . . 0.0 109.333 -178.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -83.63 103.68 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 171.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -101.46 175.41 25.68 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.861 1.696 . . . . 0.0 112.064 169.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -114.51 140.84 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.307 1.043 . . . . 0.0 112.495 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.05 51.29 0.79 Allowed 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 124.027 1.87 . . . . 0.0 112.765 -176.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 38.9 tt0 . . . . . 0 C--N 1.326 -0.445 0 CA-C-N 111.487 -2.597 . . . . 0.0 110.006 167.672 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 p -78.76 107.07 11.21 Favored 'General case' 0 CA--C 1.512 -0.515 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 169.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.68 156.06 17.28 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 169.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.59 178.29 8.57 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 130.138 3.375 . . . . 0.0 107.19 167.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . 0.446 ' H ' ' HB2' ' A' ' 52' ' ' ASP . 59.3 t -156.54 170.85 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.191 0 C-N-CA 127.03 2.132 . . . . 0.0 109.894 -169.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.36 142.69 19.44 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 127.28 2.232 . . . . 0.0 109.299 166.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.13 126.53 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.582 0.753 . . . . 0.0 110.085 173.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mp -97.26 140.25 32.02 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 125.287 1.435 . . . . 0.0 110.264 -172.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.8 ttpp -143.53 140.57 30.33 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.386 1.074 . . . . 0.0 111.535 170.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.39 -114.15 1.87 Allowed Glycine 0 CA--C 1.524 0.612 1 N-CA-C 102.471 -4.252 . . . . 0.0 102.471 163.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -157.7 127.15 5.93 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.406 1.882 . . . . 0.0 107.964 164.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.3 -141.96 17.31 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -167.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -84.72 -26.04 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.312 2.675 . . . . 0.0 113.938 -169.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -78.1 123.82 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.44 1.018 . . . . 0.0 110.873 -169.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.2 160.98 41.28 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.602 -175.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -139.85 160.15 26.11 Favored Glycine 0 C--O 1.224 -0.522 0 O-C-N 121.686 -0.634 . . . . 0.0 113.22 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -128.42 134.93 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 125.613 1.565 . . . . 0.0 107.852 168.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -137.82 112.93 9.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 C-N-CA 124.255 1.022 . . . . 0.0 109.792 172.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -76.59 153.25 35.49 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.391 1.076 . . . . 0.0 110.475 165.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.77 100.01 5.14 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 127.901 2.48 . . . . 0.0 108.762 172.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.83 126.87 50.13 Favored 'General case' 0 N--CA 1.466 0.356 0 O-C-N 121.534 -0.729 . . . . 0.0 109.663 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . 0.43 HE22 ' CB ' ' B' ' 105' ' ' SER . 55.2 tt0 -126.87 141.22 51.87 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.133 0.973 . . . . 0.0 112.159 -176.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.469 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -78.71 -50.43 11.41 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.469 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 27.1 mp0 -146.29 150.54 35.96 Favored 'General case' 0 C--O 1.222 -0.374 0 C-N-CA 125.798 1.639 . . . . 0.0 109.778 173.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.9 m -58.62 10.8 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 128.72 2.808 . . . . 0.0 117.543 -171.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -144.7 -9.44 0.62 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 127.772 2.429 . . . . 0.0 113.886 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.44 -179.89 49.84 Favored Glycine 0 CA--C 1.541 1.657 0 CA-C-N 119.946 1.248 . . . . 0.0 110.6 168.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -75.67 160.8 37.58 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.611 2.208 . . . . 0.0 113.155 -171.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -120.56 129.67 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 124.802 1.241 . . . . 0.0 109.228 176.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -95.9 128.38 42.74 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.405 1.098 . . . . 0.0 110.176 170.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 t -90.92 129.05 42.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 128.936 2.894 . . . . 0.0 108.666 172.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.5 p90 -152.87 156.85 39.78 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 170.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.02 -154.67 24.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 124.778 1.18 . . . . 0.0 111.521 -169.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 85.2 p -162.59 150.85 14.33 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -172.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -113.61 123.92 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 125.277 1.431 . . . . 0.0 108.279 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -114.64 153.8 29.53 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 126.097 1.759 . . . . 0.0 111.359 -174.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.37 60.3 Favored Glycine 0 N--CA 1.475 1.294 0 C-N-CA 125.33 1.443 . . . . 0.0 114.507 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.01 166.43 17.76 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.494 1.518 . . . . 0.0 112.25 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -75.08 146.85 41.11 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 163.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . 0.477 ' CD ' ' HZ2' ' B' ' 91' ' ' LYS . 73.6 tt0 -49.27 143.21 6.45 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 124.904 1.282 . . . . 0.0 110.958 169.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.66 -175.44 23.42 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 124.222 0.915 . . . . 0.0 114.015 -177.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.477 HD23 ' H ' ' B' ' 42' ' ' LEU . 0.5 OUTLIER -87.39 145.87 26.12 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 127.56 2.344 . . . . 0.0 112.358 -169.85 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -139.19 138.96 37.37 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 127.936 2.494 . . . . 0.0 111.61 -169.066 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.36 156.83 53.15 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 125.08 1.324 . . . . 0.0 112.415 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -157.25 99.51 1.79 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 118.17 0.985 . . . . 0.0 110.849 -168.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 3.0 p-80 -126.6 146.12 50.28 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-O 122.675 1.226 . . . . 0.0 113.133 -175.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -111.42 151.14 13.58 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.293 175.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -119.08 119.36 33.98 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.313 -170.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -74.27 57.58 0.68 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.808 0.731 . . . . 0.0 109.557 166.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -161.6 106.94 1.31 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 125.088 1.355 . . . . 0.0 109.987 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -94.77 -5.21 61.42 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 117.144 -1.92 . . . . 0.0 115.026 -176.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . 0.4 ' CG ' ' HZ1' ' A' ' 3' ' ' LYS . 0.2 OUTLIER -76.84 52.7 0.86 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 120.735 2.268 . . . . 0.0 111.847 -170.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 176.58 35.28 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 116.733 2.123 . . . . 0.0 116.733 -167.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.49 1.55 0 O-C-N 119.488 -2.007 . . . . 0.0 115.469 -172.22 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.75 0 CA-C-O 122.49 1.138 . . . . 0.0 113.383 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.62 -54.66 4.9 Favored Glycine 0 CA--C 1.544 1.888 0 CA-C-O 116.747 -2.141 . . . . 0.0 114.929 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -130.52 168.95 0.0 OUTLIER 'Trans proline' 0 C--N 1.355 0.918 0 C-N-CA 123.22 2.613 . . . . 0.0 116.346 -172.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.595 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -85.03 141.57 30.19 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.991 2.117 . . . . 0.0 112.874 166.031 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -70.17 144.97 51.81 Favored 'General case' 0 CA--C 1.545 0.76 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.911 164.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 43.2 m-20 -106.83 75.09 0.39 Allowed Pre-proline 0 CA--C 1.555 1.17 0 C-N-CA 125.554 1.541 . . . . 0.0 112.714 -177.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -56.79 -47.9 21.16 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 124.123 3.215 . . . . 0.0 113.141 -174.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.1 mp -78.93 2.02 21.67 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.034 1.734 . . . . 0.0 113.14 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 59.7 p 68.29 45.04 1.27 Allowed 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 128.736 2.814 . . . . 0.0 111.513 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.298 23.7 ptt180 -130.7 171.45 13.08 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -169.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.4 169.26 14.76 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 113.625 -1.625 . . . . 0.0 107.345 -172.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 46.9 t60 -63.51 164.11 9.93 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.989 168.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.62 -139.51 7.04 Favored Glycine 0 C--N 1.336 0.567 0 CA-C-O 119.532 -0.593 . . . . 0.0 112.303 169.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.87 -43.22 1.69 Allowed Glycine 0 CA--C 1.545 1.939 0 N-CA-C 119.186 2.434 . . . . 0.0 119.186 169.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -85.45 -12.34 6.67 Favored 'Trans proline' 0 C--N 1.356 0.959 0 CA-C-N 123.497 3.649 . . . . 0.0 113.519 173.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.29 1.92 0.97 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 126.829 2.051 . . . . 0.0 112.326 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.73 152.95 51.62 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 127.773 2.429 . . . . 0.0 108.632 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.94 -2.35 18.37 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.975 2.51 . . . . 0.0 113.072 -176.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -75.05 -102.74 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 169.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 73.72 141.48 0.06 Allowed 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 125.705 2.669 . . . . 0.0 111.927 172.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -78.77 148.11 33.08 Favored 'General case' 0 CA--C 1.551 1.018 0 CA-C-N 113.065 -1.879 . . . . 0.0 111.615 171.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 19.8 m -46.96 -41.5 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 CA-C-N 120.559 1.527 . . . . 0.0 111.366 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -99.29 104.84 2.94 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 164.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -157.01 129.95 7.74 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 125.634 1.574 . . . . 0.0 112.839 166.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -110.46 179.17 4.16 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 126.501 1.92 . . . . 0.0 110.392 170.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.82 -106.91 3.0 Favored Glycine 0 C--N 1.339 0.722 0 C-N-CA 124.774 1.178 . . . . 0.0 113.972 -171.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -127.11 158.64 36.48 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 123.919 0.888 . . . . 0.0 112.944 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.2 m -118.43 137.54 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 126.772 2.029 . . . . 0.0 109.216 168.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 90.5 m -125.12 115.69 20.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 121.195 1.816 . . . . 0.0 110.745 -173.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.06 137.33 36.76 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 124.751 1.22 . . . . 0.0 112.546 -176.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -73.62 178.49 4.69 Favored 'General case' 0 CA--C 1.541 0.629 0 O-C-N 124.148 0.905 . . . . 0.0 111.008 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.477 ' HZ2' ' CD ' ' B' ' 40' ' ' GLU . 3.3 ttmp? -76.96 66.46 2.8 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 123.45 1.595 . . . . 0.0 111.312 169.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -156.31 -45.29 0.07 Allowed 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 127.198 2.199 . . . . 0.0 108.807 175.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.85 -12.21 7.76 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 117.606 -1.664 . . . . 0.0 113.904 -172.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.6 p -81.21 121.76 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.555 1.677 . . . . 0.0 114.355 170.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.76 135.59 34.91 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.12 0.968 . . . . 0.0 108.478 164.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -77.0 148.0 36.5 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 123.0 1.381 . . . . 0.0 107.586 168.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.37 123.26 52.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 112.331 -2.213 . . . . 0.0 109.221 171.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.0 p -156.94 59.53 0.52 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.251 1.42 . . . . 0.0 112.546 -168.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.04 159.89 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 O-C-N 120.259 -1.526 . . . . 0.0 112.095 -173.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -145.3 155.06 42.98 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.044 2.138 . . . . 0.0 109.487 174.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -155.16 144.44 21.07 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.461 1.905 . . . . 0.0 110.328 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.0 p -113.92 49.32 1.0 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.7 t -151.3 14.57 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 123.617 0.767 . . . . 0.0 112.782 -170.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.25 166.64 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 O-C-N 119.66 -1.9 . . . . 0.0 110.723 -171.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 105' ' ' SER . . . . . 0.43 ' CB ' HE22 ' B' ' 22' ' ' GLN . 83.8 p -157.56 161.95 38.77 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 117.922 2.564 . . . . 0.0 117.922 171.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -78.78 72.91 5.32 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 126.831 2.052 . . . . 0.0 107.482 170.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 10.8 t -130.24 15.03 5.64 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -176.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 -63.74 0.33 Allowed Glycine 0 N--CA 1.474 1.219 0 N-CA-C 116.089 1.196 . . . . 0.0 116.089 169.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -119.44 -112.56 0.33 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 118.867 1.334 . . . . 0.0 109.53 -168.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -73.05 0.6 10.96 Favored 'General case' 0 CA--C 1.543 0.7 0 O-C-N 120.263 -1.523 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 54.0 p -71.08 -19.75 62.43 Favored 'General case' 0 CA--C 1.541 0.611 0 CA-C-O 116.587 -1.673 . . . . 0.0 114.305 169.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.305 3.9 pt 143.97 -11.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.114 1 C-N-CA 132.735 4.414 . . . . 0.0 116.227 168.831 . . . . . . . . 3 2 . 1 . 004 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.8 mm -76.08 148.15 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 120.266 1.394 . . . . 0.0 109.683 173.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 70.57 5.15 55.14 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 120.586 -1.321 . . . . 0.0 114.437 -175.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.9 ptt180 -79.31 156.1 28.19 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.135 1.374 . . . . 0.0 109.979 168.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.5 m -100.43 163.8 12.21 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.928 1.291 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 12.5 tp -148.85 126.5 11.74 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.032 1.733 . . . . 0.0 111.074 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 29.1 m -120.76 147.63 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.071 0.948 . . . . 0.0 110.906 167.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.4 p -104.58 154.68 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 124.434 1.094 . . . . 0.0 108.207 167.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 -120.35 159.76 24.4 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.252 1.421 . . . . 0.0 112.54 -173.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -84.8 -26.77 27.27 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 119.894 -1.754 . . . . 0.0 114.909 -168.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.31 179.84 3.92 Favored 'General case' 0 CA--C 1.545 0.785 0 O-C-N 119.606 -1.934 . . . . 0.0 108.702 166.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.39 151.4 47.21 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.105 0.962 . . . . 0.0 112.869 -176.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -75.65 143.37 42.25 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.215 0.531 . . . . 0.0 110.345 175.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -73.47 -20.05 60.79 Favored 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 123.714 0.806 . . . . 0.0 111.71 169.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 51.32 60.0 4.19 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.773 2.029 . . . . 0.0 112.191 -174.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.86 -26.26 25.11 Favored Glycine 0 N--CA 1.469 0.855 0 CA-C-O 117.797 -1.557 . . . . 0.0 116.539 168.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -159.51 100.87 1.5 Allowed 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 120.413 2.106 . . . . 0.0 112.424 176.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . 0.417 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -102.89 -132.46 7.67 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 166.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.88 12.07 49.5 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.462 1.505 . . . . 0.0 114.57 173.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -130.9 162.91 28.61 Favored 'General case' 0 C--N 1.344 0.345 0 CA-C-N 119.236 1.518 . . . . 0.0 114.387 -168.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -57.06 -59.64 4.77 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.301 1.441 . . . . 0.0 110.02 167.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -59.77 -14.59 15.25 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.689 1.596 . . . . 0.0 113.358 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 134' ' ' SER . . . . . 0.417 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 24.3 p -66.39 -28.0 68.29 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.883 1.219 . . . . 0.0 112.892 172.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 p -95.22 -31.31 13.55 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 127.135 2.174 . . . . 0.0 112.261 178.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 45.7 mttp -92.86 -23.66 18.73 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.652 1.581 . . . . 0.0 113.598 -173.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.7 p -138.69 -124.11 0.13 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 127.408 2.283 . . . . 0.0 105.034 164.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -126.86 8.37 7.24 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 125.466 1.507 . . . . 0.0 111.267 168.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 62.18 -79.74 0.02 OUTLIER 'General case' 0 C--N 1.347 0.492 0 C-N-CA 127.335 2.254 . . . . 0.0 110.066 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 60.64 29.92 19.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 126.397 1.879 . . . . 0.0 114.616 167.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.62 -42.4 1.27 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 125.768 1.652 . . . . 0.0 113.684 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.5 t -178.09 163.15 1.68 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.018 2.127 . . . . 0.0 111.315 175.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 80.4 mtt85 -73.26 177.04 5.39 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 125.159 1.384 . . . . 0.0 110.322 168.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.57 -128.57 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 124.306 1.042 . . . . 0.0 111.245 -172.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.82 153.88 39.74 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.947 1.299 . . . . 0.0 112.447 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -137.41 152.01 49.16 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.109 1.364 . . . . 0.0 111.887 -169.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.92 171.24 33.8 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.201 1.381 . . . . 0.0 112.15 169.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 79.7 t -119.35 147.42 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 169.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.8 mm -86.5 88.6 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 O-C-N 121.626 -0.671 . . . . 0.0 110.526 -179.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.16 -168.3 42.66 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 123.431 0.538 . . . . 0.0 113.405 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.44 161.2 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -170.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.4 -56.43 0.4 Allowed 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.134 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 N--CA 1.464 0.241 0 C-N-CA 126.04 1.736 . . . . 0.0 110.129 -169.766 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.0 m . . . . . 0 CA--C 1.508 -0.648 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.412 ' HE3' ' CG2' ' A' ' 5' ' ' VAL . 17.4 pttt -132.1 133.47 44.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 115.888 1.81 . . . . 0.0 115.888 -176.135 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.95 167.57 14.15 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 163.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.412 ' CG2' ' HE3' ' A' ' 3' ' ' LYS . 15.2 t -147.43 118.21 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 119.207 0.912 . . . . 0.0 112.158 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.26 84.53 5.19 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 168.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.2 t -76.4 79.42 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 105.025 -2.213 . . . . 0.0 105.025 176.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.2 mt -67.09 127.68 33.5 Favored 'General case' 0 C--O 1.224 -0.239 0 CA-C-O 122.205 1.002 . . . . 0.0 111.177 -162.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.1 tttm -159.67 -174.6 4.7 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.342 1.457 . . . . 0.0 111.672 174.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.24 -6.44 21.34 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 124.778 1.18 . . . . 0.0 113.008 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -116.96 145.62 43.52 Favored 'General case' 0 N--CA 1.433 -1.276 1 C-N-CA 133.291 4.636 . . . . 0.0 103.4 168.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.66 -70.87 0.99 Allowed Glycine 0 CA--C 1.535 1.298 0 C-N-CA 126.011 1.767 . . . . 0.0 112.966 -177.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -69.16 -32.31 21.32 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 123.715 2.943 . . . . 0.0 114.537 -170.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -95.71 144.39 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 119.707 1.14 . . . . 0.0 111.304 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -139.83 173.66 11.3 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.523 1.129 . . . . 0.0 109.174 168.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.52 178.5 33.83 Favored Glycine 0 N--CA 1.468 0.784 0 C-N-CA 124.465 1.031 . . . . 0.0 114.954 169.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.3 pt -153.45 56.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 C-N-CA 124.943 1.297 . . . . 0.0 111.992 -170.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 mm -87.03 98.64 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 O-C-N 120.566 -1.334 . . . . 0.0 110.66 -173.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.02 147.31 34.88 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.782 1.233 . . . . 0.0 110.253 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -128.25 79.08 1.88 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.045 1.338 . . . . 0.0 109.544 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -81.7 112.31 18.76 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.086 1.354 . . . . 0.0 112.188 -175.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -101.02 131.83 46.72 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.449 1.5 . . . . 0.0 109.199 171.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.413 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -96.53 -22.95 16.78 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 124.438 1.095 . . . . 0.0 113.453 174.805 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -103.26 -138.35 0.35 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.668 3.187 . . . . 0.0 110.405 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.2 p -151.29 34.0 0.57 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 127.533 2.333 . . . . 0.0 109.33 169.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -178.88 -28.77 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.369 1.467 . . . . 0.0 114.44 -167.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.63 -169.21 40.29 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 125.165 1.364 . . . . 0.0 113.248 177.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -68.0 138.63 44.59 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.313 2.675 . . . . 0.0 112.834 -171.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.4 t -96.43 132.87 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 124.37 1.068 . . . . 0.0 110.062 173.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -81.23 118.61 22.74 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 169.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.12 79.11 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 127.687 2.395 . . . . 0.0 108.702 -174.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -103.28 164.99 11.29 Favored 'General case' 0 CA--C 1.541 0.607 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.418 172.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.36 -164.32 28.37 Favored Glycine 0 C--O 1.224 -0.491 0 C-N-CA 125.383 1.468 . . . . 0.0 111.506 174.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.6 p -155.38 168.47 26.97 Favored 'General case' 0 C--N 1.319 -0.722 0 O-C-N 121.686 -0.89 . . . . 0.0 110.597 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 mp -128.24 126.55 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 C-N-CA 126.283 1.833 . . . . 0.0 107.27 174.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.68 143.76 45.6 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 122.888 2.585 . . . . 0.0 113.032 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.42 -1.94 16.1 Favored Glycine 0 CA--C 1.54 1.636 0 C-N-CA 128.146 2.784 . . . . 0.0 113.561 -169.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.9 mt -79.01 161.95 26.26 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.059 1.344 . . . . 0.0 113.203 -177.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.1 t -85.53 155.64 21.11 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 164.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.4 pt-20 -57.6 172.59 0.35 Allowed 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 115.782 1.771 . . . . 0.0 115.782 -174.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.32 -178.6 53.84 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.621 1.105 . . . . 0.0 113.228 174.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -62.36 142.52 57.77 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.09 1.756 . . . . 0.0 112.606 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -142.72 124.08 14.72 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 127.84 2.456 . . . . 0.0 108.507 177.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.97 149.28 51.71 Favored Glycine 0 N--CA 1.477 1.396 0 CA-C-N 120.585 1.539 . . . . 0.0 110.919 178.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -147.7 117.88 7.31 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.907 1.854 . . . . 0.0 111.566 172.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.4 OUTLIER -157.48 173.61 16.64 Favored 'General case' 0 C--O 1.236 0.367 0 O-C-N 121.104 -0.997 . . . . 0.0 109.741 -168.324 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.59 135.96 50.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 C-N-CA 124.214 1.006 . . . . 0.0 110.479 -166.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -77.18 176.18 8.97 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 122.849 0.46 . . . . 0.0 110.622 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -71.56 137.67 48.22 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.411 -0.806 . . . . 0.0 108.896 165.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 56.07 -169.05 0.09 Allowed 'General case' 0 CA--C 1.542 0.661 0 CA-C-O 123.665 1.698 . . . . 0.0 114.166 173.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.92 17.66 48.37 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-O 116.357 -2.357 . . . . 0.0 111.476 167.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.407 ' HA ' ' CG2' ' B' ' 5' ' ' VAL . 2.3 p30 -82.36 45.54 0.96 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.754 2.777 . . . . 0.0 112.454 -172.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -91.69 34.39 0.98 Allowed 'General case' 0 C--O 1.235 0.301 0 N-CA-C 115.546 1.684 . . . . 0.0 115.546 -166.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 28.6 p -114.45 -18.86 11.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -160.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.69 21.2 4.89 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-N 119.214 0.915 . . . . 0.0 110.902 165.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.4 -112.7 3.63 Favored Glycine 0 C--N 1.342 0.878 0 C-N-CA 125.646 1.594 . . . . 0.0 111.476 173.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.5 t -80.87 -16.7 52.93 Favored 'General case' 0 CA--C 1.545 0.766 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 168.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.1 40.02 0.53 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.633 1.573 . . . . 0.0 108.8 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -172.16 167.07 6.01 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 127.46 2.304 . . . . 0.0 110.003 -162.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -1.31 106.71 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 129.522 3.129 . . . . 0.0 116.947 168.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.76 -84.39 0.74 Allowed Glycine 0 CA--C 1.54 1.609 0 C-N-CA 126.861 2.172 . . . . 0.0 113.165 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.9 173.74 13.94 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 124.39 3.393 . . . . 0.0 112.708 -171.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -92.96 115.39 28.08 Favored 'General case' 0 CA--C 1.536 0.404 0 O-C-N 121.156 -0.965 . . . . 0.0 113.533 -168.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -43.89 130.4 5.75 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.135 1.374 . . . . 0.0 113.638 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 35.6 p-10 -145.27 68.49 13.67 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -168.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -61.11 -19.66 64.35 Favored 'Trans proline' 0 CA--C 1.54 0.784 0 C-N-CA 122.501 2.134 . . . . 0.0 112.058 169.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -76.88 -6.29 51.84 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.147 1.379 . . . . 0.0 113.608 171.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t 57.71 47.48 15.58 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 127.224 2.21 . . . . 0.0 112.233 174.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -111.24 173.01 6.54 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 114.657 1.354 . . . . 0.0 114.657 -175.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -89.04 176.14 7.11 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.187 2.195 . . . . 0.0 108.989 175.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.9 t60 -91.56 157.25 17.11 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.418 1.087 . . . . 0.0 113.674 -172.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.63 -129.73 4.62 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 124.021 0.82 . . . . 0.0 113.028 167.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 129.34 -30.05 3.73 Favored Glycine 0 CA--C 1.55 2.224 0 N-CA-C 119.763 2.665 . . . . 0.0 119.763 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -108.97 17.45 0.09 OUTLIER 'Trans proline' 0 CA--C 1.551 1.355 0 C-N-CA 124.933 3.756 . . . . 0.0 113.115 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.96 -26.17 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 128.286 2.634 . . . . 0.0 111.421 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.78 148.07 22.68 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.864 2.066 . . . . 0.0 106.157 162.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -100.67 -8.98 22.32 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 126.901 2.08 . . . . 0.0 113.08 -178.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.64 -82.03 0.09 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.076 0.95 . . . . 0.0 110.553 -176.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.292 37.6 ptt180 66.67 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 127.063 2.145 . . . . 0.0 113.393 175.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -59.49 165.19 2.98 Favored 'General case' 0 CA--C 1.551 0.986 0 O-C-N 119.596 -1.94 . . . . 0.0 113.337 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 74.3 t -57.27 -25.26 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.457 -1.402 . . . . 0.0 112.697 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.67 31.19 7.41 Favored Glycine 0 CA--C 1.539 1.558 0 CA-C-O 118.222 -1.321 . . . . 0.0 115.993 173.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -112.25 139.73 47.55 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 117.387 2.365 . . . . 0.0 117.387 -172.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 79.9 mt -144.9 166.01 26.5 Favored 'General case' 0 CA--C 1.555 1.15 1 C-N-CA 133.704 4.802 . . . . 0.0 104.031 165.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.71 -129.32 5.3 Favored Glycine 0 N--CA 1.473 1.147 0 C-N-CA 123.664 0.65 . . . . 0.0 113.606 -169.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -113.06 147.33 37.48 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 121.974 0.892 . . . . 0.0 113.085 169.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.66 174.19 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.682 1.993 . . . . 0.0 108.372 167.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -140.57 124.02 16.91 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 168.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.1 139.81 34.19 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 118.239 0.472 . . . . 0.0 111.913 169.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.65 157.27 37.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.712 1.605 . . . . 0.0 110.386 167.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.83 -0.59 0.69 Allowed 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 114.684 1.365 . . . . 0.0 114.684 170.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -99.64 5.59 45.81 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.816 2.046 . . . . 0.0 112.482 170.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.08 0.54 65.75 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 126.27 1.89 . . . . 0.0 116.49 168.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.12 136.2 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 CA-C-N 119.497 1.649 . . . . 0.0 112.9 -177.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.3 129.85 50.41 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 124.948 1.299 . . . . 0.0 107.745 166.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -92.31 148.97 21.72 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 122.577 1.179 . . . . 0.0 108.835 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.07 124.58 37.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.451 -1.704 . . . . 0.0 109.232 173.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.1 p -155.31 76.04 0.96 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.962 1.363 . . . . 0.0 111.491 -169.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.72 159.57 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.484 1.513 . . . . 0.0 110.221 -169.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -147.17 121.43 9.57 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 104.777 -2.305 . . . . 0.0 104.777 166.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -126.29 131.79 51.8 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.641 1.21 . . . . 0.0 113.061 -168.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.1 p -82.98 58.73 4.53 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.393 1.077 . . . . 0.0 110.162 177.19 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -152.25 -44.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 170.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.45 143.14 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 118.938 0.79 . . . . 0.0 110.876 -179.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.49 ' H ' ' CB ' ' A' ' 111' ' ' SER . 35.8 p -132.22 161.02 34.45 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 126.556 1.942 . . . . 0.0 112.075 173.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 31.0 mt -79.71 94.54 5.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 168.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -131.97 -15.46 2.99 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -169.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.05 -68.67 3.39 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 120.347 1.43 . . . . 0.0 111.622 -170.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -92.04 -60.77 1.77 Allowed 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.705 1.24 . . . . 0.0 113.824 -173.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 28.7 m-70 -80.64 1.56 29.39 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.84 1.656 . . . . 0.0 112.903 -164.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.49 ' CB ' ' H ' ' A' ' 105' ' ' SER . 18.9 m -162.42 -88.88 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.264 0 N-CA-C 115.71 1.744 . . . . 0.0 115.71 177.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.41 162.75 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.093 -1.004 . . . . 0.0 111.093 -173.012 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 114.54 140.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 1 C-N-CA 135.521 5.528 . . . . 0.0 107.374 -169.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.63 -25.62 1.71 Allowed Glycine 0 CA--C 1.535 1.317 0 CA-C-O 118.26 -1.3 . . . . 0.0 115.836 177.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 10.6 ptt180 -74.73 163.64 27.46 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 126.253 1.821 . . . . 0.0 111.466 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.3 m -121.37 110.81 16.54 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 124.635 1.174 . . . . 0.0 113.042 -169.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.6 tp -99.66 122.87 43.31 Favored 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 121.124 1.784 . . . . 0.0 111.346 -173.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 13.2 p -121.13 151.59 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 125.471 1.509 . . . . 0.0 113.315 179.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.4 p -103.9 143.28 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.035 0 C-N-CA 124.547 1.139 . . . . 0.0 110.344 166.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 40.6 m-70 -115.34 169.2 9.32 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 126.94 2.096 . . . . 0.0 115.123 -168.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -83.58 -30.17 27.21 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 116.075 1.88 . . . . 0.0 116.075 -173.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -107.0 170.18 8.1 Favored 'General case' 0 CA--C 1.546 0.805 0 CA-C-N 120.668 1.576 . . . . 0.0 111.881 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.57 163.89 6.51 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.022 1.329 . . . . 0.0 111.443 169.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -103.9 131.49 51.07 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.023 0.929 . . . . 0.0 110.422 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.88 -28.5 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 120.747 0.308 . . . . 0.0 111.656 177.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.0 mt 58.09 40.46 25.21 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.387 1.875 . . . . 0.0 112.446 173.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.27 -74.39 0.07 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 117.495 1.758 . . . . 0.0 117.495 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -139.06 -42.03 0.47 Allowed 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -164.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 54.64 -113.43 3.48 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 120.178 1.354 . . . . 0.0 110.47 -166.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -153.56 29.55 0.76 Allowed Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.222 1.867 . . . . 0.0 112.008 168.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.425 HD21 ' CD ' ' A' ' 133' ' ' GLU . 10.0 p-10 -166.48 171.3 12.0 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.773 1.629 . . . . 0.0 111.669 -164.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.406 ' CD ' ' HZ1' ' A' ' 136' ' ' LYS . 19.8 tt0 -67.62 -54.65 17.95 Favored 'General case' 0 N--CA 1.469 0.478 0 O-C-N 121.32 -0.862 . . . . 0.0 113.185 -169.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.425 ' CD ' HD21 ' A' ' 131' ' ' ASN . 0.3 OUTLIER -65.09 -19.51 66.02 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.043 0.937 . . . . 0.0 111.25 -171.864 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.4 m -67.67 -33.35 74.76 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.897 -1.127 . . . . 0.0 111.729 168.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.4 p -83.29 -18.94 37.29 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 124.783 1.233 . . . . 0.0 114.241 174.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.406 ' HZ1' ' CD ' ' A' ' 132' ' ' GLU . 94.5 mttt -105.99 -45.56 4.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.303 1.041 . . . . 0.0 113.57 -176.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.71 -26.33 12.33 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 116.829 -1.558 . . . . 0.0 113.87 177.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.63 12.44 47.56 Favored Glycine 0 N--CA 1.472 1.062 0 CA-C-N 119.327 0.967 . . . . 0.0 114.8 -173.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 60.38 8.95 1.78 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 118.975 1.387 . . . . 0.0 113.508 -174.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.84 -3.41 0.74 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -166.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.21 -160.04 25.67 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 126.694 2.092 . . . . 0.0 112.797 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 91.7 p -65.82 177.54 1.27 Allowed 'General case' 0 CA--C 1.547 0.828 0 O-C-N 122.026 -0.691 . . . . 0.0 112.139 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.5 ptt180 -136.2 132.37 35.8 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.923 -1.111 . . . . 0.0 112.749 -166.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.504 ' CD2' ' H ' ' A' ' 145' ' ' ALA 0.335 0.0 OUTLIER -103.35 -106.76 0.27 Allowed 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.154 1.381 . . . . 0.0 111.723 -175.677 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.504 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -77.23 135.18 38.45 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 119.635 1.107 . . . . 0.0 111.216 -173.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -141.88 154.86 45.43 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 126.107 1.763 . . . . 0.0 111.69 -172.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.7 130.01 3.5 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 123.818 0.723 . . . . 0.0 111.915 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -72.47 170.53 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 167.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.2 mm -129.56 126.39 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 O-C-N 120.738 -1.226 . . . . 0.0 113.331 -167.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -146.05 -126.24 1.77 Allowed Glycine 0 CA--C 1.539 1.591 0 C-N-CA 127.442 2.449 . . . . 0.0 114.617 -177.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 pp -147.46 68.67 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 120.642 -1.505 . . . . 0.0 113.932 -168.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.43 -20.43 54.54 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 120.567 -1.333 . . . . 0.0 114.462 -171.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 . . . . . 0 N--CA 1.472 0.633 0 C-N-CA 124.497 1.119 . . . . 0.0 112.699 175.187 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.442 0 CA-C-O 121.12 0.486 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.4 m -83.24 99.87 10.24 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -96.36 165.18 12.32 Favored 'General case' 0 CA--C 1.548 0.899 0 CA-C-O 122.864 1.316 . . . . 0.0 113.251 -176.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.34 172.73 13.43 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -168.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . 0.407 ' CG2' ' HA ' ' A' ' 52' ' ' ASP . 1.1 p -157.43 103.44 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 C-N-CA 127.25 2.22 . . . . 0.0 107.786 -169.051 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.27 130.42 35.02 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 120.472 -1.392 . . . . 0.0 111.699 171.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 20.6 t -93.48 71.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.179 0.992 . . . . 0.0 111.136 -173.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -80.48 114.72 19.58 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.469 0.652 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 13.2 ttpp -144.97 151.18 38.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.84 0.829 . . . . 0.0 112.428 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.45 149.96 18.76 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 166.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -79.1 64.88 4.13 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 123.408 1.575 . . . . 0.0 110.372 169.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.52 -175.45 46.24 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 129.101 3.239 . . . . 0.0 108.685 -171.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.18 22.21 0.38 Allowed 'Trans proline' 0 CA--C 1.547 1.153 0 C-N-CA 124.65 3.566 . . . . 0.0 114.916 -169.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 t -118.97 130.31 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 C-N-CA 126.993 2.117 . . . . 0.0 109.002 -170.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.71 160.88 31.97 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 124.099 0.96 . . . . 0.0 110.999 -170.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.01 169.05 33.58 Favored Glycine 0 CA--C 1.51 -0.262 0 C-N-CA 124.779 1.18 . . . . 0.0 112.23 168.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -132.35 133.18 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 171.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.0 mm -135.09 109.58 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 36.2 m120 -79.85 155.52 27.78 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 123.914 0.886 . . . . 0.0 111.959 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -139.27 152.65 47.44 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 167.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -146.88 132.57 18.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 119.133 0.879 . . . . 0.0 109.951 167.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -84.84 137.86 32.91 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 122.721 0.408 . . . . 0.0 111.117 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.439 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -93.48 -91.64 0.18 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.179 0.992 . . . . 0.0 110.618 169.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.439 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 31.9 mp0 -82.37 169.25 16.67 Favored 'General case' 0 C--O 1.217 -0.607 0 O-C-N 120.538 -1.351 . . . . 0.0 110.544 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -51.02 -45.25 61.17 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 114.298 1.222 . . . . 0.0 114.298 -172.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 22.0 m-80 -127.01 40.27 3.75 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.632 1.973 . . . . 0.0 110.294 166.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.66 162.76 53.61 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-O 118.717 -1.046 . . . . 0.0 111.461 173.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -66.4 161.72 39.66 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.503 2.802 . . . . 0.0 110.005 174.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.0 t -136.55 133.36 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 122.973 0.509 . . . . 0.0 110.967 -169.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -79.84 132.16 36.04 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 168.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.3 t -120.85 111.54 32.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 126.578 1.951 . . . . 0.0 108.739 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -140.11 153.27 46.66 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.366 0.603 . . . . 0.0 112.213 -173.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.49 -153.41 24.63 Favored Glycine 0 C--O 1.225 -0.433 0 C-N-CA 124.13 0.872 . . . . 0.0 111.507 178.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 12.6 p -157.1 158.66 36.79 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 114.045 1.128 . . . . 0.0 114.045 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -128.1 131.46 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 125.715 1.606 . . . . 0.0 107.912 -179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.1 ttpt -133.95 140.12 46.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 126.172 1.789 . . . . 0.0 110.617 -168.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.11 20.73 13.09 Favored Glycine 0 N--CA 1.481 1.638 0 C-N-CA 124.994 1.283 . . . . 0.0 114.373 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -117.91 165.9 13.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.756 2.822 . . . . 0.0 110.622 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.95 167.46 21.86 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.316 0.646 . . . . 0.0 110.205 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -64.65 -175.3 0.17 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 126.967 2.107 . . . . 0.0 114.549 171.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.33 -170.59 46.98 Favored Glycine 0 N--CA 1.47 0.944 0 O-C-N 120.388 -1.445 . . . . 0.0 112.432 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mt -77.01 155.16 32.79 Favored 'General case' 0 CA--C 1.545 0.757 0 O-C-N 121.172 -1.193 . . . . 0.0 110.02 177.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -147.63 123.57 10.68 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 127.931 2.493 . . . . 0.0 109.641 -172.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.34 151.16 36.2 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-N 120.926 1.694 . . . . 0.0 113.526 176.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -151.13 96.58 2.33 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.213 1.405 . . . . 0.0 112.171 -170.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.38 147.07 48.93 Favored 'General case' 0 N--CA 1.47 0.561 0 O-C-N 120.085 -1.634 . . . . 0.0 111.742 -167.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.66 120.19 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 122.484 1.135 . . . . 0.0 110.959 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -77.83 101.61 6.83 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -173.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -64.16 95.27 0.12 Allowed 'General case' 0 C--N 1.344 0.349 0 CA-C-O 123.116 1.436 . . . . 0.0 108.602 175.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 t80 177.55 -166.95 0.05 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 130.472 3.509 . . . . 0.0 104.349 -164.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.35 -122.02 3.5 Favored Glycine 0 CA--C 1.507 -0.43 0 CA-C-O 121.772 0.651 . . . . 0.0 112.477 171.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.07 152.83 39.85 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.684 1.594 . . . . 0.0 113.459 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 173.13 32.68 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 128.815 2.846 . . . . 0.0 108.843 -171.669 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 82.8 p . . . . . 0 CA--C 1.534 0.343 0 C-N-CA 127.439 2.295 . . . . 0.0 116.382 -165.806 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.871 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.82 -91.75 0.94 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.296 1.903 . . . . 0.0 112.223 -174.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -100.33 -177.32 0.17 Allowed 'Trans proline' 0 CA--C 1.535 0.561 1 C-N-CA 125.939 4.426 . . . . 0.0 111.728 176.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.426 ' CD2' ' N ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -79.98 130.36 35.21 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 168.741 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -58.97 147.09 35.67 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.855 1.262 . . . . 0.0 112.56 171.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 50.3 m-20 -108.81 77.87 0.86 Allowed Pre-proline 0 CA--C 1.554 1.097 0 C-N-CA 125.276 1.43 . . . . 0.0 111.843 -176.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -58.21 -49.18 13.15 Favored 'Trans proline' 0 C--N 1.353 0.81 0 C-N-CA 123.975 3.116 . . . . 0.0 113.216 -174.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 75.1 mt -78.83 -0.44 30.62 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 126.144 1.778 . . . . 0.0 112.871 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.2 t 58.77 43.82 17.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 127.518 2.327 . . . . 0.0 112.151 -173.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.1 mtp180 -92.31 176.43 6.48 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 120.878 -1.139 . . . . 0.0 112.489 -176.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.509 ' HE2' ' OE1' ' B' ' 78' ' ' GLU . 0.3 OUTLIER -97.24 170.26 9.22 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 126.18 1.792 . . . . 0.0 108.829 165.312 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -96.66 151.64 19.42 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -167.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.44 -106.03 0.34 Allowed Glycine 0 C--N 1.345 1.053 0 C-N-CA 124.796 1.189 . . . . 0.0 114.809 166.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.85 -29.2 8.69 Favored Glycine 0 CA--C 1.543 1.811 0 N-CA-C 119.85 2.7 . . . . 0.0 119.85 174.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -104.03 6.47 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.049 0 C-N-CA 123.657 2.904 . . . . 0.0 112.578 172.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.01 -31.25 0.13 Allowed 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.908 1.283 . . . . 0.0 110.893 169.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.05 150.13 27.71 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 162.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -96.19 -17.99 20.41 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.519 1.927 . . . . 0.0 112.138 -176.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . 0.509 ' OE1' ' HE2' ' B' ' 70' ' ' LYS . 3.7 mt-10 -78.05 -50.66 11.65 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 121.049 -1.032 . . . . 0.0 113.023 -172.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 45.75 97.88 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.127 1.371 . . . . 0.0 114.059 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.6 m80 -50.79 144.78 7.86 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 119.729 -1.857 . . . . 0.0 110.262 169.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 m -55.41 -29.99 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 CA-C-N 120.239 1.381 . . . . 0.0 112.12 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.26 49.24 3.48 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 125.025 1.298 . . . . 0.0 116.053 171.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -139.46 123.17 17.48 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.353 1.461 . . . . 0.0 110.071 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -113.55 50.29 0.92 Allowed 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 168.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 55.73 -112.13 2.91 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 125.343 1.449 . . . . 0.0 114.445 177.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -155.7 159.07 39.23 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 126.196 1.798 . . . . 0.0 110.563 -175.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.8 p -117.37 175.75 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 127.517 2.327 . . . . 0.0 109.685 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -133.92 150.17 51.31 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.98 1.712 . . . . 0.0 108.326 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -117.7 149.03 41.42 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.443 1.497 . . . . 0.0 112.779 173.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -83.52 150.05 26.23 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 128.229 2.612 . . . . 0.0 112.281 169.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.82 -2.48 1.85 Allowed 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.884 1.673 . . . . 0.0 115.143 177.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -90.93 7.96 37.53 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.485 1.514 . . . . 0.0 112.069 169.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.82 28.81 22.73 Favored Glycine 0 C--N 1.341 0.821 0 CA-C-O 117.361 -1.799 . . . . 0.0 114.656 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -141.64 139.26 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.138 1.469 . . . . 0.0 114.521 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.14 122.04 44.5 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.558 1.543 . . . . 0.0 108.685 165.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -79.21 140.0 37.8 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 165.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.262 0.3 OUTLIER -119.71 129.04 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-O 122.557 1.17 . . . . 0.0 112.576 166.96 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 28.8 m -147.8 78.63 1.46 Allowed 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.362 1.465 . . . . 0.0 109.729 -172.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -122.44 154.14 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.484 1.513 . . . . 0.0 111.614 -173.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.8 tt0 -142.14 148.39 38.22 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.989 1.715 . . . . 0.0 107.346 167.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -149.83 150.48 32.04 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 125.117 1.367 . . . . 0.0 111.934 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.2 p -116.78 51.86 0.97 Allowed 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.7 -48.64 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 124.4 1.08 . . . . 0.0 110.819 169.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.96 157.31 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 119.327 0.967 . . . . 0.0 112.785 177.502 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 95.0 p -156.54 150.89 25.41 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.164 1.786 . . . . 0.0 109.023 -170.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mp -80.95 54.06 2.11 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 122.128 0.965 . . . . 0.0 108.745 172.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -84.93 62.61 7.58 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.121 -0.987 . . . . 0.0 109.968 -177.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.92 -111.11 4.06 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 124.784 1.183 . . . . 0.0 112.837 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -127.99 -14.8 4.92 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 127.67 2.388 . . . . 0.0 114.518 -167.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.0 -32.14 8.44 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 114.49 1.292 . . . . 0.0 114.49 -169.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -85.98 -15.14 42.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.258 0.7 OUTLIER -177.37 -47.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 C-N-CA 127.564 2.346 . . . . 0.0 109.109 168.536 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -58.86 143.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 105.61 -1.996 . . . . 0.0 105.61 162.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.65 -16.4 1.4 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 126.769 2.128 . . . . 0.0 113.628 -175.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 ttm-85 -80.15 171.37 15.17 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.863 1.665 . . . . 0.0 111.854 176.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -113.14 154.52 26.5 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 125.379 1.471 . . . . 0.0 112.466 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 25.2 tp -121.15 138.25 54.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 128.246 2.619 . . . . 0.0 109.217 168.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -114.84 139.39 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 124.949 1.3 . . . . 0.0 109.872 168.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -119.57 133.99 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 171.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -110.94 151.06 28.35 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.767 1.227 . . . . 0.0 112.033 -168.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -79.2 -18.22 53.39 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -167.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 48.0 mttp -138.73 178.23 7.3 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 120.163 1.347 . . . . 0.0 113.569 177.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.91 130.51 37.61 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.282 1.433 . . . . 0.0 110.176 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -81.33 158.78 24.6 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 124.029 0.831 . . . . 0.0 109.221 170.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . 0.43 ' OD1' ' HE3' ' B' ' 128' ' ' LYS . 7.5 t70 -73.45 -43.29 60.63 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 119.306 -0.957 . . . . 0.0 109.3 168.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 2.0 mm? 70.15 53.14 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 127.123 2.169 . . . . 0.0 107.734 -168.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 161.22 -82.29 0.13 Allowed Glycine 0 N--CA 1.465 0.617 0 O-C-N 121.317 -0.864 . . . . 0.0 114.1 -175.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.561 ' H ' ' HE3' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -156.69 72.4 0.73 Allowed 'General case' 0 CA--C 1.549 0.938 0 N-CA-C 115.701 1.741 . . . . 0.0 115.701 -170.237 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -57.6 -24.81 54.03 Favored Glycine 0 CA--C 1.542 1.753 0 O-C-N 120.708 -1.245 . . . . 0.0 115.128 176.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.48 -28.38 0.49 Allowed Glycine 0 CA--C 1.534 1.24 0 N-CA-C 116.675 1.43 . . . . 0.0 116.675 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 62.2 m-80 -106.33 175.81 5.37 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 118.968 1.384 . . . . 0.0 113.098 -176.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . 0.447 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 13.1 tm-20 -51.64 -57.55 8.84 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.603 1.161 . . . . 0.0 108.904 166.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -41.33 -34.53 0.52 Allowed 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 126.236 1.814 . . . . 0.0 115.036 168.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.5 p -71.18 -9.96 58.97 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 119.318 -2.114 . . . . 0.0 115.836 -177.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.2 t -111.16 -7.98 14.43 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.166 1.387 . . . . 0.0 110.379 164.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.447 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 3.1 tttt -85.82 -50.33 7.22 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.737 1.615 . . . . 0.0 110.763 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 80.7 p -102.35 -35.52 8.79 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 128.686 2.794 . . . . 0.0 110.972 175.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.76 -9.63 52.05 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.045 1.783 . . . . 0.0 112.028 -169.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 75.96 30.93 0.71 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 129.446 3.098 . . . . 0.0 112.317 176.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.68 33.33 0.01 OUTLIER 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 178.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.55 -51.86 3.75 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 127.69 2.567 . . . . 0.0 114.79 175.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 170.9 157.39 0.07 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.862 1.665 . . . . 0.0 113.741 -174.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.33 134.0 34.52 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.413 1.085 . . . . 0.0 113.715 173.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.3 pp -104.7 -30.17 10.11 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.331 1.453 . . . . 0.0 113.469 179.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.81 161.55 36.94 Favored 'General case' 0 C--O 1.245 0.831 0 C-N-CA 125.705 1.602 . . . . 0.0 107.174 174.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.3 p -152.32 151.86 31.41 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 126.254 1.822 . . . . 0.0 108.525 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.46 145.69 11.77 Favored Glycine 0 C--O 1.224 -0.504 0 N-CA-C 115.632 1.013 . . . . 0.0 115.632 179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 16.3 t -78.17 145.9 9.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.283 1.033 . . . . 0.0 108.244 167.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.6 mm -89.53 101.17 11.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.914 0.886 . . . . 0.0 109.979 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.62 164.46 30.39 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 173.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -93.78 141.14 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 123.902 0.881 . . . . 0.0 111.354 172.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -141.91 166.19 25.39 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.956 1.703 . . . . 0.0 111.154 168.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.466 0.351 0 C-N-CA 123.265 0.626 . . . . 0.0 111.133 -167.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.508 -0.635 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.0 ttpt -99.0 106.74 19.03 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 122.641 1.21 . . . . 0.0 112.967 169.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.65 173.23 7.99 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 126.078 1.751 . . . . 0.0 109.041 167.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -161.78 162.66 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.353 0.661 . . . . 0.0 111.996 -173.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.52 134.01 19.75 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.566 1.146 . . . . 0.0 109.899 163.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.26 94.29 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.525 1.93 . . . . 0.0 107.058 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -79.3 134.58 36.62 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 126.708 2.003 . . . . 0.0 110.206 -173.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.4 mtpt -155.87 179.71 8.94 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.313 1.045 . . . . 0.0 113.687 178.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.5 -60.47 0.42 Allowed Glycine 0 C--N 1.334 0.445 0 C-N-CA 128.083 2.754 . . . . 0.0 108.721 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -82.1 69.69 8.86 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.101 1.761 . . . . 0.0 111.52 -168.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.44 -100.67 0.03 OUTLIER Glycine 0 CA--C 1.54 1.643 0 C-N-CA 126.957 2.218 . . . . 0.0 114.132 171.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -80.38 -7.66 13.86 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 125.04 3.827 . . . . 0.0 114.331 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.3 t -77.22 142.17 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 CA-C-N 119.983 1.265 . . . . 0.0 109.105 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.45 158.04 39.35 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 124.95 1.3 . . . . 0.0 109.414 169.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.51 108.64 0.57 Allowed Glycine 0 C--O 1.22 -0.777 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 169.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.94 131.41 37.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 118.676 1.238 . . . . 0.0 108.392 168.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.3 pp -149.41 126.61 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-O 122.764 1.269 . . . . 0.0 111.413 166.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -74.82 166.3 23.84 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.78 1.232 . . . . 0.0 111.329 169.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -141.49 93.25 2.55 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.734 2.014 . . . . 0.0 107.879 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.46 ' OE2' ' HE3' ' A' ' 23' ' ' LYS . 4.6 tm-20 -92.55 122.9 35.44 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.588 1.555 . . . . 0.0 110.121 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -120.01 132.24 55.41 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.869 0.842 . . . . 0.0 112.333 169.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.513 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -75.13 -42.01 57.17 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.269 1.827 . . . . 0.0 112.584 -177.017 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.329 0.0 OUTLIER -110.01 -122.46 0.27 Allowed 'General case' 0 CA--C 1.544 0.729 0 CA-C-O 116.887 -1.53 . . . . 0.0 110.215 169.068 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 48.9 m -144.07 -25.31 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-N 120.847 1.658 . . . . 0.0 114.752 -172.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.47 -17.8 6.9 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 120.45 -1.406 . . . . 0.0 114.108 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -150.69 4.86 Favored Glycine 0 CA--C 1.542 1.755 1 C-N-CA 131.0 4.143 . . . . 0.0 114.104 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -88.41 156.71 6.62 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.296 2.664 . . . . 0.0 114.365 -168.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.14 134.48 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.763 1.225 . . . . 0.0 109.632 -173.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -97.58 126.0 42.63 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.229 1.411 . . . . 0.0 109.902 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.6 t -123.8 122.39 64.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 C-N-CA 126.587 1.955 . . . . 0.0 109.146 -170.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -146.9 150.27 34.89 Favored 'General case' 0 C--O 1.24 0.57 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -178.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.59 -153.13 23.43 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.834 1.683 . . . . 0.0 111.039 -169.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.1 p -158.57 143.35 16.09 Favored 'General case' 0 C--O 1.238 0.485 0 O-C-N 121.794 -0.827 . . . . 0.0 113.097 -169.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.13 106.2 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 125.251 1.42 . . . . 0.0 109.616 173.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -111.29 144.59 40.23 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.704 2.002 . . . . 0.0 110.549 -167.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.01 -24.04 24.08 Favored Glycine 0 N--CA 1.475 1.241 0 C-N-CA 126.566 2.031 . . . . 0.0 112.108 -171.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.4 mp -68.13 111.45 4.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.254 1.822 . . . . 0.0 107.644 168.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.4 t -68.78 -27.32 65.78 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.259 1.577 . . . . 0.0 115.259 -169.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 178.58 -175.4 0.19 Allowed 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 130.744 3.617 . . . . 0.0 106.549 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.54 159.81 35.41 Favored Glycine 0 N--CA 1.469 0.845 0 C-N-CA 126.263 1.887 . . . . 0.0 116.038 167.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.8 mt -70.45 132.61 45.84 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.827 1.251 . . . . 0.0 109.008 168.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -129.52 120.08 24.78 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.409 1.483 . . . . 0.0 107.253 177.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.13 164.47 36.48 Favored Glycine 0 N--CA 1.475 1.245 0 CA-C-O 117.619 -1.656 . . . . 0.0 111.563 176.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.25 1.6 p90 -156.06 111.32 2.94 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 120.989 2.394 . . . . 0.0 113.569 169.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -122.14 147.08 46.59 Favored 'General case' 0 CA--C 1.551 0.991 0 O-C-N 119.979 -1.701 . . . . 0.0 111.082 -172.124 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -82.31 120.63 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.438 ' CE1' ' HG ' ' A' ' 57' ' ' CYS . 16.5 m-70 -71.12 111.85 6.81 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.43 -2.433 . . . . 0.0 104.43 168.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.424 ' H ' ' HA ' ' A' ' 63' ' ' HIS . 16.8 tt0 -64.39 116.86 6.5 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.148 -174.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.353 50.3 m-85 101.31 160.57 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 131.567 3.947 . . . . 0.0 113.708 -178.089 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.18 -14.7 55.63 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 114.746 -1.115 . . . . 0.0 114.48 -172.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.93 54.9 0.28 Allowed 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 128.887 2.875 . . . . 0.0 113.134 -169.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -170.33 -42.34 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 119.539 3.163 . . . . 0.0 119.539 -168.728 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.298 0.9 OUTLIER 49.75 -58.99 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 129.115 2.966 . . . . 0.0 117.339 -169.775 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 22.44 0.82 Allowed 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 127.748 2.419 . . . . 0.0 114.596 -171.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.41 -127.82 44.4 Favored Glycine 0 C--N 1.336 0.553 0 C-N-CA 125.49 1.519 . . . . 0.0 110.878 172.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.438 ' HG ' ' CE1' ' A' ' 48' ' ' HIS . 4.5 m -56.56 -10.37 0.96 Allowed 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 -179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.08 1.85 22.73 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 125.251 1.42 . . . . 0.0 112.623 171.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 9.0 t -164.94 -156.52 0.31 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 129.532 3.133 . . . . 0.0 106.361 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 74.88 -169.09 0.1 Allowed 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 123.761 1.743 . . . . 0.0 115.147 166.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.68 155.43 16.08 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 127.151 2.31 . . . . 0.0 108.735 166.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.417 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 96.6 Cg_endo -75.61 76.43 3.63 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 123.924 3.083 . . . . 0.0 108.293 171.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.424 ' HA ' ' H ' ' A' ' 49' ' ' GLU . 5.1 p80 47.27 72.39 0.25 Allowed 'General case' 0 C--O 1.236 0.351 0 C-N-CA 127.261 2.225 . . . . 0.0 112.674 167.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -40.84 141.22 0.61 Allowed 'General case' 0 C--O 1.221 -0.395 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.603 -174.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -101.3 67.48 0.06 OUTLIER Pre-proline 0 CA--C 1.549 0.938 0 CA-C-N 114.195 -1.366 . . . . 0.0 113.527 175.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -65.13 -18.47 61.57 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 121.829 1.686 . . . . 0.0 112.593 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -77.97 -5.11 50.18 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.188 1.395 . . . . 0.0 113.523 170.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.6 t 60.78 53.41 3.92 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 127.01 2.124 . . . . 0.0 112.177 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 -139.3 175.35 9.63 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 -167.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.68 158.89 30.67 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.353 1.461 . . . . 0.0 112.017 173.179 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.416 ' ND1' ' CE1' ' A' ' 63' ' ' HIS . 86.0 t60 -79.4 147.92 32.18 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.481 -0.781 . . . . 0.0 112.469 168.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 155.64 -111.93 0.5 Allowed Glycine 0 C--N 1.339 0.701 0 CA-C-O 118.029 -1.429 . . . . 0.0 114.09 167.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.11 -85.88 0.39 Allowed Glycine 0 CA--C 1.537 1.446 0 CA-C-O 117.486 -1.73 . . . . 0.0 114.6 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -55.54 -6.88 1.1 Allowed 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 124.458 3.438 . . . . 0.0 116.869 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -155.89 9.97 0.27 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 128.585 2.754 . . . . 0.0 112.238 -176.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -146.74 109.9 4.75 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 128.533 2.733 . . . . 0.0 109.624 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -64.35 -9.26 16.73 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 127.848 2.459 . . . . 0.0 114.719 -175.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -81.44 -91.83 0.06 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.76 0.824 . . . . 0.0 110.402 177.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.8 ttp-105 78.72 118.45 0.06 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.164 1.785 . . . . 0.0 111.141 171.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m80 -55.79 160.83 2.44 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.278 -1.514 . . . . 0.0 113.831 175.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.8 t -53.16 -50.74 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 121.047 1.749 . . . . 0.0 112.229 -170.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.7 3.06 Favored Glycine 0 C--N 1.341 0.833 0 N-CA-C 108.491 -1.844 . . . . 0.0 108.491 169.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -157.45 118.56 3.6 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.529 1.531 . . . . 0.0 109.512 179.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -105.16 165.57 11.0 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 126.099 1.76 . . . . 0.0 109.726 169.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.81 -136.77 8.57 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 125.249 1.404 . . . . 0.0 112.792 177.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.64 158.17 20.33 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 117.025 2.231 . . . . 0.0 117.025 -174.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.3 m -106.97 173.9 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 128.705 2.802 . . . . 0.0 110.188 167.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 t -141.74 141.27 33.25 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 125.552 1.541 . . . . 0.0 108.383 169.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.69 150.67 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 125.221 1.408 . . . . 0.0 111.589 178.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -100.64 158.79 15.68 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.884 1.673 . . . . 0.0 112.128 173.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -50.28 -21.93 1.58 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 129.099 2.959 . . . . 0.0 115.815 -169.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.26 0.94 54.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 128.58 2.752 . . . . 0.0 110.716 -172.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.32 32.05 6.24 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-O 117.477 -1.735 . . . . 0.0 114.052 173.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.2 p -155.66 133.53 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 117.512 2.412 . . . . 0.0 117.512 -171.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.65 129.22 40.02 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 163.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -88.59 145.49 25.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 168.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.7 t -131.85 122.27 49.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 113.251 -1.795 . . . . 0.0 107.934 167.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -146.35 58.81 1.21 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 127.687 2.395 . . . . 0.0 107.582 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 29.7 mt -116.77 155.65 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.498 1.519 . . . . 0.0 112.125 -166.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -135.99 130.24 33.3 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 167.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -132.69 144.71 50.5 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 125.353 1.461 . . . . 0.0 110.256 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.6 p -125.28 59.42 1.25 Allowed 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.276 1.431 . . . . 0.0 112.752 -167.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -156.31 -48.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 C-N-CA 123.008 0.523 . . . . 0.0 110.683 -174.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -82.32 158.79 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 164.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.2 p -160.24 168.85 24.46 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.064 1.345 . . . . 0.0 109.355 -175.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.3 mp -100.64 54.06 0.87 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.0 t -76.09 4.32 8.73 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 114.98 1.474 . . . . 0.0 114.98 -167.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 138.18 -86.83 0.22 Allowed Glycine 0 N--CA 1.462 0.39 0 N-CA-C 106.592 -2.603 . . . . 0.0 106.592 -169.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.99 -6.11 0.77 Allowed 'General case' 0 C--O 1.219 -0.526 0 C-N-CA 123.761 0.824 . . . . 0.0 113.199 168.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.429 ' CD2' ' H ' ' A' ' 110' ' ' HIS . 0.0 OUTLIER -73.03 -33.17 65.56 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 120.29 -1.506 . . . . 0.0 110.617 -165.112 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.0 p -105.78 -8.56 17.71 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 117.448 2.388 . . . . 0.0 117.448 -169.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.273 3.7 pt 176.69 -39.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 C-N-CA 127.698 2.399 . . . . 0.0 115.582 167.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.3 mm -49.47 125.03 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-N 121.605 2.002 . . . . 0.0 111.024 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.67 -7.01 66.87 Favored Glycine 0 CA--C 1.534 1.241 0 C-N-CA 125.766 1.65 . . . . 0.0 116.092 176.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.5 176.03 10.14 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.814 1.646 . . . . 0.0 110.622 170.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.1 t -132.97 129.03 37.69 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 120.185 1.357 . . . . 0.0 113.078 -174.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.2 tp -101.96 125.48 48.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.771 2.029 . . . . 0.0 109.523 -170.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -110.98 135.19 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 124.526 1.131 . . . . 0.0 109.595 174.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.2 p -92.63 141.51 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 C-N-CA 124.991 1.316 . . . . 0.0 109.088 168.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -112.95 168.42 9.71 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.097 2.559 . . . . 0.0 113.112 -168.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -86.61 -46.71 9.85 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 -168.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -99.9 -176.33 3.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 120.091 -1.631 . . . . 0.0 110.198 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.71 154.16 7.22 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 165.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 p30 -99.25 140.78 32.91 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.68 1.229 . . . . 0.0 110.792 167.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -78.62 -36.57 43.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 127.422 2.289 . . . . 0.0 112.213 -169.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 23.1 mt 55.82 47.83 19.44 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.717 1.207 . . . . 0.0 110.596 173.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 138.52 -62.25 0.57 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.415 -1.214 . . . . 0.0 115.9 171.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.39 87.39 1.31 Allowed 'General case' 0 CA--C 1.552 1.021 1 N-CA-C 122.417 4.229 . . . . 0.0 122.417 -166.5 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.71 -86.99 0.61 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 105.948 -2.861 . . . . 0.0 105.948 163.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -167.31 34.08 0.21 Allowed Glycine 0 N--CA 1.47 0.935 0 CA-C-O 119.03 -0.872 . . . . 0.0 114.827 171.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -164.05 150.34 11.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 119.513 1.657 . . . . 0.0 108.899 -167.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -48.3 -46.99 36.88 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.607 0.763 . . . . 0.0 112.275 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -50.51 -27.84 7.37 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 116.04 1.867 . . . . 0.0 116.04 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.1 p -53.25 -28.06 25.54 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-N 120.857 1.662 . . . . 0.0 112.656 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.9 t -113.51 -29.16 7.27 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 115.195 1.554 . . . . 0.0 115.195 170.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -67.65 -23.32 65.32 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 119.986 1.266 . . . . 0.0 113.355 178.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.9 p -141.11 -32.91 0.54 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.228 1.411 . . . . 0.0 114.236 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.39 5.16 49.39 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.587 1.565 . . . . 0.0 110.466 -164.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 51.53 30.99 6.96 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 127.311 2.244 . . . . 0.0 114.632 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.05 19.47 0.04 OUTLIER 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 118.06 2.615 . . . . 0.0 118.06 -166.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.62 8.05 37.64 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 119.437 2.535 . . . . 0.0 119.437 167.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 28.9 t 139.2 -178.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 1 C-N-CA 131.952 4.101 . . . . 0.0 111.183 170.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.08 154.22 37.62 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 126.18 1.792 . . . . 0.0 112.836 173.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.349 0.0 OUTLIER -133.31 -127.2 0.17 Allowed 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.972 2.109 . . . . 0.0 107.868 167.104 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.05 147.77 46.2 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.068 1.304 . . . . 0.0 114.472 -166.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.7 p -137.42 147.63 45.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.612 1.565 . . . . 0.0 113.952 176.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.61 142.43 8.41 Favored Glycine 0 N--CA 1.473 1.165 0 C-N-CA 124.621 1.105 . . . . 0.0 114.238 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 87.6 t -76.27 150.43 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 C-N-CA 124.725 1.21 . . . . 0.0 110.246 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.9 mm -81.31 83.69 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 O-C-N 121.562 -0.711 . . . . 0.0 109.721 173.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.72 -169.01 43.59 Favored Glycine 0 N--CA 1.474 1.231 0 C-N-CA 126.849 2.166 . . . . 0.0 112.912 175.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -142.74 155.39 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 115.324 1.602 . . . . 0.0 115.324 -168.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.84 -15.11 14.46 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.567 1.547 . . . . 0.0 112.844 169.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.476 0.85 0 C-N-CA 130.057 3.343 . . . . 0.0 109.117 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.775 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 17.2 m -78.19 77.03 4.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.713 1.205 . . . . 0.0 111.425 -168.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.259 17.3 pttm -81.13 130.49 35.05 Favored 'General case' 0 CA--C 1.547 0.85 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -174.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.38 172.42 12.76 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 127.744 2.417 . . . . 0.0 111.288 -176.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 7.0 p -148.38 146.81 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.41 1.084 . . . . 0.0 112.734 -166.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.16 96.56 2.9 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-O 122.516 1.151 . . . . 0.0 108.799 168.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 53.1 t -79.64 96.82 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 104.878 -2.267 . . . . 0.0 104.878 166.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.65 114.94 17.0 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 77.0 tttt -160.76 131.34 5.31 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.465 1.484 . . . . 0.0 114.747 -175.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -162.04 -35.16 0.02 OUTLIER Glycine 0 N--CA 1.474 1.204 0 C-N-CA 125.232 1.396 . . . . 0.0 111.519 168.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -77.26 58.38 1.61 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 130.98 3.712 . . . . 0.0 113.075 175.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.91 -96.39 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 C-N-CA 129.184 3.278 . . . . 0.0 115.569 169.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.94 -16.45 14.32 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.134 3.223 . . . . 0.0 113.91 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -86.37 141.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-N 119.698 1.135 . . . . 0.0 109.105 174.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -157.12 161.03 39.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.758 1.223 . . . . 0.0 110.629 167.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.471 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.05 99.92 0.79 Allowed Glycine 0 C--O 1.222 -0.632 0 C-N-CA 126.073 1.797 . . . . 0.0 110.694 173.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -87.64 93.61 4.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 118.983 1.391 . . . . 0.0 108.425 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 pp -113.88 152.73 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.96 1.362 . . . . 0.0 111.821 171.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -123.29 175.79 6.49 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.761 1.224 . . . . 0.0 110.262 175.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -140.1 139.77 35.92 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.249 1.019 . . . . 0.0 109.371 168.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -134.28 131.73 38.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 168.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -125.71 141.09 52.19 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 122.069 0.938 . . . . 0.0 109.962 174.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 6.6 mtmm -84.51 -31.16 24.62 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 125.686 1.594 . . . . 0.0 110.774 -174.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -123.28 -164.56 1.22 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 128.938 2.895 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 36.7 p -106.97 -37.17 6.41 Favored 'General case' 0 N--CA 1.472 0.674 0 O-C-N 120.719 -1.238 . . . . 0.0 110.617 166.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -112.79 5.07 17.36 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.391 1.476 . . . . 0.0 114.023 -175.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.46 -178.01 37.05 Favored Glycine 0 CA--C 1.54 1.649 0 CA-C-O 118.692 -1.06 . . . . 0.0 112.448 172.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.81 157.7 54.62 Favored 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 123.026 2.484 . . . . 0.0 113.552 -176.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 94.2 t -120.37 136.03 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 126.555 1.942 . . . . 0.0 110.93 -170.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.3 mptt -79.23 118.84 21.54 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.417 0.627 . . . . 0.0 111.733 169.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.3 124.92 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 125.549 1.54 . . . . 0.0 107.252 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -151.28 160.83 43.6 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 123.156 0.582 . . . . 0.0 112.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.32 175.58 13.91 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 123.846 0.736 . . . . 0.0 113.65 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 43.7 p -119.77 124.05 45.22 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 115.068 1.507 . . . . 0.0 115.068 -166.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . 0.471 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.0 mm -90.65 123.37 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 CA-C-O 116.878 -1.534 . . . . 0.0 109.973 168.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.2 tttt -132.82 132.64 42.39 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 122.219 2.282 . . . . 0.0 111.677 175.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.75 -9.76 6.07 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 127.42 2.438 . . . . 0.0 114.293 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -91.3 168.2 11.75 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.62 1.568 . . . . 0.0 112.535 173.332 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.8 t -77.28 166.93 22.55 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.811 0.844 . . . . 0.0 111.241 169.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -67.41 -172.84 0.25 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 125.742 1.617 . . . . 0.0 115.204 -173.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.14 -172.75 54.25 Favored Glycine 0 N--CA 1.477 1.378 0 C-N-CA 124.568 1.08 . . . . 0.0 114.009 176.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 54.2 mt -66.95 144.16 56.39 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 120.67 -1.488 . . . . 0.0 110.202 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -133.25 130.42 38.99 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.679 1.192 . . . . 0.0 109.905 170.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.99 152.01 51.2 Favored Glycine 0 N--CA 1.468 0.828 0 C-N-CA 124.644 1.116 . . . . 0.0 112.21 179.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -148.73 105.29 3.55 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 117.508 0.654 . . . . 0.0 109.979 -169.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.433 ' CD2' ' CD2' ' B' ' 63' ' ' HIS . 0.5 OUTLIER -143.84 158.3 43.78 Favored 'General case' 0 CA--C 1.54 0.57 0 O-C-N 120.538 -1.351 . . . . 0.0 109.847 -175.836 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.84 126.89 64.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 C-N-CA 126.051 1.74 . . . . 0.0 108.715 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 14.3 m-70 -77.18 116.85 18.16 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 168.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.86 162.21 29.77 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -168.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.4 t80 68.72 177.01 0.26 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 125.647 1.579 . . . . 0.0 111.879 -173.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.96 0.43 9.86 Favored Glycine 0 N--CA 1.469 0.878 0 CA-C-O 118.881 -0.955 . . . . 0.0 114.177 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -86.72 51.21 2.17 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.018 1.327 . . . . 0.0 108.725 -177.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 179.63 34.84 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.109 0 N-CA-C 116.186 1.921 . . . . 0.0 116.186 -166.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.406 HG23 ' H ' ' B' ' 54' ' ' THR . 5.5 p . . . . . 0 CA--C 1.551 1.015 0 C-N-CA 131.518 3.927 . . . . 0.0 120.591 -170.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.575 0 CA-C-O 122.631 1.205 . . . . 0.0 113.954 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.61 -158.97 32.54 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 125.871 1.7 . . . . 0.0 115.985 -169.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -74.56 -174.84 1.99 Allowed 'Trans proline' 0 CA--C 1.537 0.67 1 C-N-CA 126.239 4.626 . . . . 0.0 114.35 -169.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.684 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -65.14 96.58 0.21 Allowed 'General case' 0 N--CA 1.445 -0.689 1 C-N-CA 132.648 4.379 . . . . 0.0 109.166 -176.651 . . . . . . . . 4 4 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -56.5 146.86 23.45 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 123.953 1.835 . . . . 0.0 109.998 174.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 48.8 p-10 -107.72 57.81 0.22 Allowed Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 -176.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.57 -20.23 53.8 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.285 1.99 . . . . 0.0 111.74 169.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.0 mp -77.02 -3.88 41.31 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.925 1.29 . . . . 0.0 112.392 169.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t 57.61 87.73 0.06 Allowed 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 127.995 2.518 . . . . 0.0 113.027 174.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 179.17 176.62 0.58 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -169.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -84.14 176.93 8.45 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 128.111 2.565 . . . . 0.0 107.869 166.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.412 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 12.8 t60 -57.78 174.03 0.27 Allowed 'General case' 0 CA--C 1.546 0.791 0 O-C-N 120.39 -1.443 . . . . 0.0 111.813 169.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.83 -175.31 32.18 Favored Glycine 0 N--CA 1.465 0.599 0 O-C-N 121.272 -0.893 . . . . 0.0 113.427 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 136.37 -128.24 4.44 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 117.961 -1.466 . . . . 0.0 112.316 -170.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -48.0 -11.32 0.11 Allowed 'Trans proline' 0 CA--C 1.542 0.895 1 C-N-CA 126.009 4.473 . . . . 0.0 119.793 -172.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.65 -5.67 5.2 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 120.759 1.618 . . . . 0.0 114.157 169.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -126.48 178.19 6.02 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 127.401 2.28 . . . . 0.0 109.819 -168.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -106.72 -20.31 13.39 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.548 1.539 . . . . 0.0 111.989 -177.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -78.15 -92.32 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.695 0 O-C-N 121.06 -1.025 . . . . 0.0 113.204 -167.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 54.7 ttt180 78.38 93.61 0.06 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 126.328 1.851 . . . . 0.0 113.744 169.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -51.94 160.75 0.67 Allowed 'General case' 0 N--CA 1.481 1.101 0 O-C-N 119.974 -1.704 . . . . 0.0 112.594 166.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 p -68.04 -27.97 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 CA-C-N 121.229 1.831 . . . . 0.0 111.483 176.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -70.8 18.26 0.82 Allowed Glycine 0 CA--C 1.538 1.491 0 CA-C-O 117.109 -1.94 . . . . 0.0 116.277 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -121.04 110.51 16.33 Favored 'General case' 0 CA--C 1.55 0.951 0 CA-C-N 121.891 2.845 . . . . 0.0 112.312 -178.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -113.08 46.17 1.27 Allowed 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 123.361 1.553 . . . . 0.0 112.289 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.93 -141.24 45.32 Favored Glycine 0 CA--C 1.536 1.347 0 CA-C-N 114.054 -1.43 . . . . 0.0 115.499 169.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -116.15 140.16 49.58 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.722 1.209 . . . . 0.0 111.021 172.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -91.34 172.87 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 162.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -140.53 142.96 35.15 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 120.85 -1.156 . . . . 0.0 109.796 173.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -118.95 157.87 26.86 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.555 1.542 . . . . 0.0 113.187 -169.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -107.55 162.46 13.93 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 127.439 2.295 . . . . 0.0 112.543 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.683 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -63.66 -12.81 37.0 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.31 1.444 . . . . 0.0 114.333 173.757 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -70.45 -14.94 62.74 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-O 121.707 0.765 . . . . 0.0 109.93 171.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.16 9.23 55.98 Favored Glycine 0 C--N 1.337 0.625 0 C-N-CA 126.593 2.044 . . . . 0.0 112.848 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.2 p -110.39 138.62 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 125.164 1.385 . . . . 0.0 114.39 -178.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.65 97.13 6.5 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.598 1.959 . . . . 0.0 106.284 165.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -98.74 154.61 17.85 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.677 0.751 . . . . 0.0 111.089 174.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -150.66 150.95 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 116.231 1.938 . . . . 0.0 116.231 -173.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 51.6 p -157.46 105.83 2.09 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 124.226 1.01 . . . . 0.0 112.276 169.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 16.3 mt -136.85 151.56 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 126.969 2.108 . . . . 0.0 111.116 -178.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -109.43 107.29 17.38 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 167.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -96.87 138.16 34.85 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 127.285 2.234 . . . . 0.0 112.97 -176.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 82.5 p -108.05 49.93 0.79 Allowed 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 66.8 t -145.35 -44.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-O 118.585 -0.721 . . . . 0.0 112.231 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.94 162.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 120.148 1.34 . . . . 0.0 111.534 170.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' B' ' 111' ' ' SER . 90.2 p -157.4 149.63 22.69 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 125.678 1.591 . . . . 0.0 109.776 -175.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 60.01 4.22 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.436 . . . . 0.0 107.496 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.3 t -115.89 8.52 14.75 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -168.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.02 -49.65 4.01 Favored Glycine 0 N--CA 1.472 1.08 0 O-C-N 120.768 -1.207 . . . . 0.0 114.937 168.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -116.67 -58.68 2.05 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 119.074 1.437 . . . . 0.0 112.331 -170.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -83.21 5.26 23.5 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 125.433 1.493 . . . . 0.0 112.506 -171.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' B' ' 105' ' ' SER . 61.3 m -158.27 -115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.08 0.952 . . . . 0.0 112.668 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 38.6 pt -112.26 169.14 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 120.493 1.497 . . . . 0.0 112.408 -178.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.2 mm 91.24 117.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 1 C-N-CA 132.259 4.224 . . . . 0.0 105.641 -162.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.35 12.3 72.61 Favored Glycine 0 CA--C 1.534 1.238 0 CA-C-O 117.611 -1.661 . . . . 0.0 115.502 -176.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.82 169.03 10.78 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.585 2.193 . . . . 0.0 109.135 169.105 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . 0.261 13.3 t -131.7 113.5 13.64 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 123.417 2.826 . . . . 0.0 114.698 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 22.4 tp -88.49 140.67 29.23 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.474 1.91 . . . . 0.0 110.91 -169.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -127.07 142.62 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 124.065 0.946 . . . . 0.0 111.301 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.31 140.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 122.322 1.058 . . . . 0.0 110.097 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -102.96 148.59 25.48 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.834 -172.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.262 2.9 pp20? -80.05 -7.45 58.86 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 121.028 -1.045 . . . . 0.0 113.24 -170.267 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 58.2 mttp -126.66 176.44 7.22 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.824 2.05 . . . . 0.0 110.926 168.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -59.29 148.15 33.16 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.383 1.473 . . . . 0.0 111.278 169.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -91.41 138.08 31.86 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 167.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.68 -32.25 65.67 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 177.267 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.9 mt 66.62 66.24 0.45 Allowed 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.58 1.952 . . . . 0.0 111.284 169.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 149.13 -96.65 0.17 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 123.837 0.732 . . . . 0.0 111.311 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.421 ' HA ' ' HB3' ' B' ' 134' ' ' SER . 31.4 tttt -157.49 119.61 3.78 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.876 2.07 . . . . 0.0 110.906 167.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.14 -75.68 0.62 Allowed Glycine 0 CA--C 1.527 0.834 0 C-N-CA 126.382 1.944 . . . . 0.0 109.594 168.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -154.89 -12.22 0.06 OUTLIER Glycine 0 N--CA 1.47 0.954 0 N-CA-C 116.344 1.297 . . . . 0.0 116.344 175.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -109.53 -141.85 0.38 Allowed 'General case' 0 CA--C 1.548 0.881 0 CA-C-N 119.317 1.558 . . . . 0.0 110.03 -167.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -117.73 -48.74 2.56 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 120.619 1.554 . . . . 0.0 111.369 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -46.62 -32.3 3.4 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.412 1.885 . . . . 0.0 112.411 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 134' ' ' SER . . . . . 0.421 ' HB3' ' HA ' ' B' ' 128' ' ' LYS . 0.4 OUTLIER -49.21 -44.35 43.22 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 127.602 2.361 . . . . 0.0 113.041 169.723 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -95.15 -34.12 12.38 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 173.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -31.81 73.09 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.782 -1.199 . . . . 0.0 113.486 176.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 82.7 p -137.03 -27.1 1.0 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 116.759 -1.591 . . . . 0.0 114.612 -173.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.19 -2.79 31.31 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.668 1.127 . . . . 0.0 113.861 -168.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 12.9 t-20 55.89 9.96 0.51 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 126.279 1.831 . . . . 0.0 113.179 -169.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.36 24.96 0.02 OUTLIER 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 127.938 2.495 . . . . 0.0 116.826 -167.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.16 -139.17 19.52 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 126.555 2.026 . . . . 0.0 113.905 178.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.4 t -80.93 -148.16 0.06 Allowed 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.979 1.712 . . . . 0.0 109.6 168.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -140.71 155.81 46.37 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 120.353 -1.467 . . . . 0.0 110.098 172.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.412 HD12 ' H ' ' B' ' 145' ' ' ALA . 0.7 OUTLIER -109.72 -129.9 0.3 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 165.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . 0.412 ' H ' HD12 ' B' ' 144' ' ' LEU . . . -61.68 144.97 53.73 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.552 1.541 . . . . 0.0 113.823 -170.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.8 p -138.42 151.32 47.35 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 126.194 1.797 . . . . 0.0 113.135 176.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.0 139.53 6.02 Favored Glycine 0 N--CA 1.471 0.997 0 O-C-N 120.989 -1.069 . . . . 0.0 114.239 -176.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.4 t -77.98 145.96 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.045 0.938 . . . . 0.0 109.605 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 54.6 mt -81.36 90.47 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.293 1.037 . . . . 0.0 109.781 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.18 -171.45 45.55 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 126.39 1.948 . . . . 0.0 111.952 171.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . 0.427 HD12 ' H ' ' B' ' 151' ' ' ILE . 0.8 OUTLIER -127.58 124.46 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 115.737 1.755 . . . . 0.0 115.737 -167.641 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.19 0.08 47.01 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.965 2.106 . . . . 0.0 112.593 167.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 131.019 3.728 . . . . 0.0 115.692 -169.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.4 p . . . . . 0 N--CA 1.468 0.425 0 N-CA-C 117.725 2.491 . . . . 0.0 117.725 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -165.43 101.94 0.72 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.783 1.633 . . . . 0.0 108.855 168.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -75.3 176.05 7.78 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 119.864 1.211 . . . . 0.0 111.482 173.446 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 p -153.63 117.49 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 127.225 2.21 . . . . 0.0 106.897 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.24 107.29 18.29 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.349 1.06 . . . . 0.0 109.74 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.0 t -76.09 79.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.226 1.01 . . . . 0.0 108.406 174.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -76.99 92.41 3.7 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 173.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.476 ' HZ2' ' CG ' ' B' ' 11' ' ' ASP . 19.9 ttpp -157.91 119.68 3.64 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.897 0.879 . . . . 0.0 110.814 171.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.57 -102.28 0.54 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 106.663 -2.575 . . . . 0.0 106.663 166.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.42 ' CG ' ' HZ1' ' B' ' 9' ' ' LYS . 4.5 m-20 -144.98 109.86 5.07 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 125.938 1.695 . . . . 0.0 107.282 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.38 177.03 14.69 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 123.844 0.735 . . . . 0.0 114.209 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -68.37 20.76 0.13 Allowed 'Trans proline' 0 CA--C 1.542 0.89 1 C-N-CA 126.15 4.567 . . . . 0.0 116.696 -169.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.4 t -128.34 128.46 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 CA-C-N 120.447 1.476 . . . . 0.0 109.508 -174.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -144.19 172.74 12.49 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.829 0.823 . . . . 0.0 112.657 -176.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.16 165.79 31.36 Favored Glycine 0 CA--C 1.509 -0.282 0 CA-C-N 112.828 -1.987 . . . . 0.0 112.947 167.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.445 HG13 ' H ' ' A' ' 34' ' ' SER . 7.8 pt -139.83 52.98 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 113.22 -1.49 . . . . 0.0 112.024 -167.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -80.47 105.7 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 O-C-N 120.418 -1.426 . . . . 0.0 111.079 -169.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -83.0 156.28 23.5 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.506 1.522 . . . . 0.0 110.613 173.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -143.43 97.92 3.16 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.462 1.505 . . . . 0.0 109.677 175.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.72 136.32 37.38 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 119.884 -1.76 . . . . 0.0 107.202 173.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -152.91 -175.81 5.48 Favored 'General case' 0 CA--C 1.553 1.075 0 C-N-CA 127.78 2.432 . . . . 0.0 105.887 176.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.52 -15.29 0.49 Allowed 'General case' 0 CA--C 1.549 0.94 0 O-C-N 118.452 -2.655 . . . . 0.0 116.225 167.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -108.76 -174.27 2.47 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 127.869 2.468 . . . . 0.0 111.346 -174.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.3 p -81.33 -21.89 38.86 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 120.528 -1.358 . . . . 0.0 112.888 167.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -161.67 46.38 0.18 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.629 1.171 . . . . 0.0 113.399 -168.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.73 175.69 16.04 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 125.243 1.401 . . . . 0.0 110.637 169.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -74.67 157.95 43.78 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.032 1.821 . . . . 0.0 111.511 -169.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.5 t -131.3 149.4 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 125.097 1.359 . . . . 0.0 111.482 -167.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -116.51 103.74 10.72 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 123.641 0.776 . . . . 0.0 110.575 -175.175 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.5 t -80.22 119.85 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 126.834 2.054 . . . . 0.0 107.63 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 1.7 p90 -153.9 167.87 28.25 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.0 -155.75 15.93 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -170.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.445 ' H ' HG13 ' A' ' 17' ' ' ILE . 63.8 p -155.96 170.5 21.99 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 122.029 0.918 . . . . 0.0 113.345 -169.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.68 134.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 126.497 1.919 . . . . 0.0 107.256 169.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.18 150.23 33.39 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 121.63 2.013 . . . . 0.0 113.913 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.27 5.08 46.78 Favored Glycine 0 CA--C 1.539 1.581 0 C-N-CA 126.437 1.97 . . . . 0.0 112.285 -168.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -71.86 163.89 27.02 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.906 2.082 . . . . 0.0 111.055 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.5 t -81.32 155.81 25.83 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 164.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 74.7 tt0 -53.03 145.22 13.46 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.37 1.068 . . . . 0.0 111.349 169.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.09 -175.3 26.0 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 124.787 1.184 . . . . 0.0 114.146 -177.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -76.12 146.96 38.9 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 128.321 2.648 . . . . 0.0 114.464 -169.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -148.11 123.89 10.56 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.193 2.597 . . . . 0.0 109.911 -174.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.56 155.87 51.55 Favored Glycine 0 N--CA 1.479 1.512 0 CA-C-O 118.028 -1.429 . . . . 0.0 113.169 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.79 139.91 16.49 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 119.957 1.879 . . . . 0.0 114.375 172.285 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.415 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 9.0 p-80 -153.34 153.8 33.29 Favored 'General case' 0 CA--C 1.547 0.862 0 O-C-N 121.5 -0.75 . . . . 0.0 111.936 -179.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -98.36 112.44 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 123.946 0.899 . . . . 0.0 109.119 174.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.418 ' C ' ' H ' ' A' ' 50' ' ' PHE . 6.3 p80 -82.43 149.78 27.44 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 174.277 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -66.84 10.74 0.12 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 126.329 1.851 . . . . 0.0 114.304 -178.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 48' ' ' HIS . 13.3 m-85 -119.55 97.54 5.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 106.949 -1.501 . . . . 0.0 106.949 -169.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.24 -10.36 74.04 Favored Glycine 0 C--N 1.331 0.291 0 CA-C-O 117.885 -1.508 . . . . 0.0 111.17 166.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -73.7 123.25 23.73 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 104.381 -2.451 . . . . 0.0 104.381 164.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.517 ' ND2' ' HG1' ' A' ' 116' ' ' THR 0.312 0.0 OUTLIER -147.35 51.09 1.07 Allowed 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 123.782 1.753 . . . . 0.0 112.724 168.486 . . . . . . . . 4 4 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.414 HG21 ' H ' ' A' ' 53' ' ' ASN . 11.4 p -120.29 -23.89 6.08 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 112.173 -2.285 . . . . 0.0 112.755 -164.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -95.95 22.79 7.01 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.887 0.875 . . . . 0.0 111.603 168.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.76 -123.24 21.8 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 125.537 1.541 . . . . 0.0 111.913 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.7 p -67.49 -12.7 60.95 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 113.868 1.062 . . . . 0.0 113.868 173.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.69 39.24 0.61 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.412 1.485 . . . . 0.0 110.878 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 172.09 -55.37 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.39 2.276 . . . . 0.0 111.596 -169.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -97.54 153.39 18.2 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.73 -31.38 8.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 116.424 -2.32 . . . . 0.0 117.44 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -103.34 163.38 0.25 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 CA-C-N 122.124 2.962 . . . . 0.0 111.523 171.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.426 ' CD2' ' N ' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -137.24 107.78 6.53 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.558 1.143 . . . . 0.0 112.4 -166.678 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -58.97 154.66 14.93 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 114.141 -1.391 . . . . 0.0 111.998 169.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -119.7 77.68 21.29 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 127.712 2.405 . . . . 0.0 113.713 -170.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -63.64 -20.34 69.02 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.998 2.466 . . . . 0.0 113.445 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 53.6 mt -82.81 -2.49 54.7 Favored 'General case' 0 CA--C 1.543 0.685 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 170.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t 62.77 59.29 1.44 Allowed 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.611 1.564 . . . . 0.0 113.343 175.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.0 ptt180 -161.54 178.44 9.08 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -174.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.88 164.4 23.83 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 127.032 2.133 . . . . 0.0 110.006 173.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -62.88 168.23 4.08 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.735 0.814 . . . . 0.0 110.874 167.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 140.69 -156.0 25.12 Favored Glycine 0 N--CA 1.464 0.528 0 CA-C-O 119.11 -0.828 . . . . 0.0 113.808 171.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 -64.51 0.53 Allowed Glycine 0 CA--C 1.542 1.728 0 N-CA-C 117.924 1.93 . . . . 0.0 117.924 176.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -69.47 -19.46 37.47 Favored 'Trans proline' 0 C--N 1.349 0.6 0 CA-C-N 121.197 2.499 . . . . 0.0 114.722 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -134.66 -3.53 2.61 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 124.057 0.943 . . . . 0.0 112.758 179.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.56 147.81 50.73 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 128.344 2.658 . . . . 0.0 107.867 -173.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.66 -11.99 19.55 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 130.77 3.628 . . . . 0.0 112.67 -167.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -81.47 -94.04 0.05 OUTLIER 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.996 1.718 . . . . 0.0 106.992 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 47.5 ttt180 80.02 121.1 0.05 OUTLIER 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.539 1.536 . . . . 0.0 111.617 168.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -71.52 140.77 50.06 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 120.899 -1.126 . . . . 0.0 108.946 165.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -50.88 -28.81 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.57 8.78 79.13 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 119.362 0.983 . . . . 0.0 115.537 175.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -88.84 129.95 35.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 120.103 1.951 . . . . 0.0 112.028 -175.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.99 -179.7 4.02 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 128.288 2.635 . . . . 0.0 107.518 170.159 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -92.39 -120.19 2.7 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 122.761 1.201 . . . . 0.0 114.032 -172.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -140.58 152.96 45.89 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.887 1.275 . . . . 0.0 110.777 169.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -116.01 137.1 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 127.581 2.352 . . . . 0.0 109.894 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -102.93 132.24 49.3 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 119.322 0.964 . . . . 0.0 108.797 169.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.75 144.36 27.81 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-O 120.881 0.372 . . . . 0.0 111.068 168.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -60.7 169.88 1.67 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 126.077 1.751 . . . . 0.0 111.753 170.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.32 -15.16 9.26 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.204 1.402 . . . . 0.0 114.143 168.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.05 3.17 55.15 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 125.894 1.678 . . . . 0.0 114.026 169.534 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.9 13.87 76.64 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 120.082 -1.637 . . . . 0.0 115.287 169.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.44 134.72 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 125.846 1.659 . . . . 0.0 112.875 171.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.59 112.12 25.08 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 165.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -104.81 139.42 39.6 Favored 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 124.694 1.198 . . . . 0.0 109.568 -177.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.3 t -137.27 140.28 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 114.962 1.467 . . . . 0.0 114.962 -166.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 89.3 p -154.76 104.39 2.51 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.995 1.318 . . . . 0.0 111.73 173.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.0 mt -136.85 141.84 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.784 2.034 . . . . 0.0 110.431 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -110.22 134.93 51.73 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 166.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -139.03 140.54 38.15 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 125.919 1.687 . . . . 0.0 111.648 -167.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 13.3 p -121.4 52.04 1.25 Allowed 'General case' 0 CA--C 1.543 0.699 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 177.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -147.03 1.81 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -177.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.11 176.07 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.858 1.663 . . . . 0.0 110.206 169.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.581 ' H ' ' HB3' ' A' ' 111' ' ' SER . 90.4 p -154.84 164.28 39.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 126.647 1.979 . . . . 0.0 112.066 171.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.9 mp -78.58 67.85 4.43 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.17 2.188 . . . . 0.0 108.534 177.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -128.23 -5.8 5.44 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 -168.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.68 -24.88 3.57 Favored Glycine 0 N--CA 1.472 1.046 0 CA-C-N 120.492 1.496 . . . . 0.0 116.427 169.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -94.22 -100.82 0.15 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 126.286 1.834 . . . . 0.0 107.711 -169.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -83.67 2.27 38.42 Favored 'General case' 0 C--N 1.323 -0.568 0 O-C-N 120.009 -1.682 . . . . 0.0 112.321 -174.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.581 ' HB3' ' H ' ' A' ' 105' ' ' SER . 39.4 m -125.11 -120.08 0.27 Allowed 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 115.864 1.801 . . . . 0.0 115.864 -169.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 42.2 pt -125.05 172.41 12.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 O-C-N 119.953 -1.717 . . . . 0.0 109.027 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 3.1 mm 76.68 147.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 128.657 2.783 . . . . 0.0 105.951 -162.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.48 -51.6 4.23 Favored Glycine 0 C--O 1.222 -0.626 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.62 -177.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 40.2 mtt180 -71.41 178.33 3.49 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 127.541 2.336 . . . . 0.0 110.191 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.517 ' HG1' ' ND2' ' A' ' 53' ' ' ASN . 29.9 m -138.91 124.99 20.02 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.862 0.865 . . . . 0.0 111.609 -169.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 47.4 tp -92.24 115.1 27.79 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 125.367 1.467 . . . . 0.0 110.103 178.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 15.0 p -102.45 140.36 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 124.597 1.159 . . . . 0.0 109.549 171.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -113.86 142.91 24.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.977 1.711 . . . . 0.0 107.681 171.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -118.72 148.2 43.02 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.91 2.084 . . . . 0.0 111.105 -168.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -74.6 -20.16 60.03 Favored 'General case' 0 CA--C 1.541 0.624 0 O-C-N 120.518 -1.364 . . . . 0.0 114.67 -168.29 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -125.38 171.19 10.65 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 119.82 -1.8 . . . . 0.0 112.283 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.2 139.9 51.25 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 124.714 1.205 . . . . 0.0 111.951 -175.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -87.76 136.83 32.79 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 123.869 0.867 . . . . 0.0 109.747 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.85 -37.23 76.06 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.726 1.211 . . . . 0.0 110.102 173.074 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 63.16 69.81 0.56 Allowed 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 124.999 1.32 . . . . 0.0 108.399 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.31 -109.87 0.42 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 117.055 1.582 . . . . 0.0 117.055 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.16 36.06 0.14 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 128.545 2.738 . . . . 0.0 111.754 -167.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -48.9 -31.39 10.24 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.482 1.991 . . . . 0.0 117.976 -168.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 167.35 2.78 0.03 OUTLIER Glycine 0 N--CA 1.476 1.322 0 N-CA-C 118.249 2.06 . . . . 0.0 118.249 178.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -146.22 -170.43 3.49 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 119.088 1.444 . . . . 0.0 111.747 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -70.58 -56.91 5.41 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.411 1.085 . . . . 0.0 109.57 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.413 ' H ' ' CD ' ' A' ' 133' ' ' GLU . 1.2 mp0 -57.42 -28.12 62.99 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.876 1.67 . . . . 0.0 111.675 -174.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 42.8 m -46.25 -37.66 7.52 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 126.124 1.769 . . . . 0.0 112.789 171.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -111.92 -33.88 6.16 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -66.81 -24.22 66.15 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.0 0.92 . . . . 0.0 113.076 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 27.7 p -130.36 -32.68 1.74 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.885 1.674 . . . . 0.0 114.673 173.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.29 10.0 40.2 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -163.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 63.85 11.7 6.17 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.981 2.112 . . . . 0.0 114.483 177.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.0 19.07 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 117.326 2.343 . . . . 0.0 117.326 -167.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.76 -43.48 2.16 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 128.473 2.94 . . . . 0.0 115.266 168.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.5 t -168.69 169.34 10.17 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 118.512 1.156 . . . . 0.0 113.901 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.7 ptt-85 -71.5 158.96 35.33 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.168 1.387 . . . . 0.0 111.01 168.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 2.1 tm? -142.09 -103.31 0.14 Allowed 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 169.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -103.68 160.46 14.74 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.248 1.019 . . . . 0.0 111.471 172.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.7 p -142.35 140.43 32.09 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.165 2.186 . . . . 0.0 108.898 -177.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.25 135.64 4.62 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 118.048 1.979 . . . . 0.0 118.048 -175.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -75.02 139.52 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.513 1.125 . . . . 0.0 109.416 -178.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.9 mm -87.88 107.55 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 122.572 0.349 . . . . 0.0 110.919 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.71 -171.79 14.15 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.71 1.148 . . . . 0.0 113.23 173.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.43 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.2 pp -133.01 129.49 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 N-CA-C 114.989 1.477 . . . . 0.0 114.989 -173.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.5 -161.64 0.89 Allowed 'General case' 0 CA--C 1.545 0.75 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 165.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 . . . . . 0 N--CA 1.475 0.804 0 C-N-CA 131.6 3.96 . . . . 0.0 108.565 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.415 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -86.84 108.72 18.88 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 172.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttmm -97.16 123.34 40.9 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.024 -173.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -93.63 175.65 6.66 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.634 1.346 . . . . 0.0 114.634 179.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.92 103.65 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 128.621 2.769 . . . . 0.0 106.427 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.13 122.06 24.46 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.533 -0.729 . . . . 0.0 109.746 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.417 HG22 HD22 ' A' ' 53' ' ' ASN . 22.8 t -88.49 63.14 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 124.171 0.988 . . . . 0.0 108.802 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.335 1.3 pt? -82.85 79.04 9.35 Favored 'General case' 0 N--CA 1.477 0.907 0 O-C-N 121.272 -0.892 . . . . 0.0 113.075 -171.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . 0.42 ' HZ1' ' CG ' ' A' ' 11' ' ' ASP . 15.1 tttm -117.47 129.76 56.02 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 -173.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.12 158.08 19.01 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 165.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.476 ' CG ' ' HZ2' ' A' ' 9' ' ' LYS . 5.2 m-20 -72.1 92.45 1.33 Allowed 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 128.637 2.775 . . . . 0.0 109.246 -178.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.19 -153.61 21.95 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 127.102 2.286 . . . . 0.0 111.474 -176.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -86.1 7.66 4.88 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 125.0 3.8 . . . . 0.0 114.249 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -105.62 108.92 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 C-N-CA 125.146 1.378 . . . . 0.0 108.509 -177.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -159.7 166.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.668 1.187 . . . . 0.0 111.421 176.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.46 178.25 29.75 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 124.205 0.907 . . . . 0.0 113.862 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.0 pt -123.8 137.33 57.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 128.449 2.699 . . . . 0.0 109.726 171.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mm -136.98 113.12 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.534 1.061 . . . . 0.0 109.457 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -113.24 108.65 17.56 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.757 1.623 . . . . 0.0 112.501 -164.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -92.44 104.01 16.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.539 1.935 . . . . 0.0 110.281 -176.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -84.25 103.28 13.31 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.6 1.56 . . . . 0.0 110.781 172.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -97.69 119.09 35.64 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 121.814 0.816 . . . . 0.0 110.931 173.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -64.13 -42.85 96.66 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.09 1.756 . . . . 0.0 113.268 175.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -157.17 155.37 30.83 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 126.016 1.726 . . . . 0.0 111.596 168.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.7 p -45.05 -3.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 1 C-N-CA 131.739 4.016 . . . . 0.0 118.567 -171.235 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -157.72 20.9 0.27 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.661 1.985 . . . . 0.0 111.444 -168.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.24 173.67 15.64 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.312 1.91 . . . . 0.0 112.563 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -67.03 168.67 16.72 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.578 2.852 . . . . 0.0 111.401 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -138.88 133.5 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 122.744 0.418 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.8 mttp -92.41 124.22 36.3 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.28 0.562 . . . . 0.0 109.832 169.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.5 t -120.56 86.58 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 127.995 2.518 . . . . 0.0 108.472 -170.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -110.07 168.7 9.24 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 121.2 -0.938 . . . . 0.0 112.281 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.46 -159.5 28.44 Favored Glycine 0 N--CA 1.462 0.432 0 O-C-N 120.973 -1.079 . . . . 0.0 111.869 174.304 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -156.33 154.1 30.05 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -176.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.25 124.77 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.122 0.969 . . . . 0.0 109.997 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -119.39 146.58 45.23 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.841 1.257 . . . . 0.0 109.652 -178.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.38 10.66 38.16 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 124.916 1.246 . . . . 0.0 113.469 -169.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 76.8 mt -84.98 167.16 16.12 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.105 1.362 . . . . 0.0 111.651 168.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -94.78 156.5 16.35 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 164.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -59.98 148.62 34.69 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 123.727 0.811 . . . . 0.0 112.27 -177.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.67 -178.54 33.85 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 124.234 0.921 . . . . 0.0 113.506 -175.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -60.7 144.92 51.14 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 127.648 2.379 . . . . 0.0 114.013 -173.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -145.65 127.88 15.75 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 127.692 2.397 . . . . 0.0 109.985 175.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.26 158.09 52.35 Favored Glycine 0 N--CA 1.474 1.175 0 CA-C-N 119.239 0.927 . . . . 0.0 112.156 173.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -158.37 139.8 13.46 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.201 2.2 . . . . 0.0 112.061 166.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 19.1 p-80 -149.83 146.53 27.19 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 120.905 -1.122 . . . . 0.0 111.825 -176.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -91.4 138.51 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 124.568 1.147 . . . . 0.0 109.175 178.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -105.83 153.04 22.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 110.079 -178.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -67.68 12.04 0.12 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.732 1.151 . . . . 0.0 113.479 178.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -140.59 125.04 17.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 O-C-N 120.031 -1.668 . . . . 0.0 108.932 -168.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.56 -3.18 61.96 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 124.616 1.103 . . . . 0.0 114.33 170.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -75.5 123.09 24.87 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 118.135 0.968 . . . . 0.0 109.93 -169.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.87 20.48 3.83 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 114.787 1.402 . . . . 0.0 114.787 164.452 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.311 14.9 t . . . . . 0 C--N 1.324 -0.543 0 C-N-CA 123.227 0.611 . . . . 0.0 112.004 -166.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.596 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.39 176.78 47.51 Favored Glycine 0 CA--C 1.545 1.947 0 C-N-CA 125.094 1.33 . . . . 0.0 114.582 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -102.42 179.46 0.15 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 124.722 3.614 . . . . 0.0 113.576 -177.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.589 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -72.75 74.7 1.12 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.649 3.18 . . . . 0.0 111.985 172.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -30.21 132.96 0.07 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 129.137 2.975 . . . . 0.0 115.312 169.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -122.86 59.27 12.9 Favored Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -172.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -62.85 -16.69 55.3 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 122.755 2.303 . . . . 0.0 113.911 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.81 -5.76 54.24 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.034 1.334 . . . . 0.0 113.324 169.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t 65.16 50.27 1.85 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 127.966 2.507 . . . . 0.0 112.885 178.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.6 mtp180 -118.02 176.21 5.31 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 124.94 1.296 . . . . 0.0 112.86 -172.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.3 mptm? -95.41 175.93 6.38 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.698 2.399 . . . . 0.0 109.441 164.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -62.7 157.75 20.19 Favored 'General case' 0 CA--C 1.539 0.531 0 O-C-N 120.918 -1.114 . . . . 0.0 111.009 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -176.52 -175.79 44.15 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 114.914 0.726 . . . . 0.0 114.914 174.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.65 -120.89 0.98 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 125.27 1.414 . . . . 0.0 113.988 169.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -62.52 -16.35 51.64 Favored 'Trans proline' 0 CA--C 1.54 0.793 0 C-N-CA 123.855 3.037 . . . . 0.0 115.259 -173.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.75 -4.15 19.7 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.578 1.151 . . . . 0.0 112.988 169.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -159.15 110.47 2.08 Favored 'General case' 0 CA--C 1.543 0.706 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 -167.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -40.88 -10.7 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 131.241 3.816 . . . . 0.0 116.76 168.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.69 -77.44 0.09 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 120.067 1.303 . . . . 0.0 109.315 -177.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ttp-105 56.53 77.25 0.26 Allowed 'General case' 0 N--CA 1.475 0.818 0 O-C-N 120.79 -1.194 . . . . 0.0 113.141 164.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.3 m170 -48.32 164.46 0.05 Allowed 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.709 -1.244 . . . . 0.0 114.019 172.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.85 -14.16 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.23 13.59 31.03 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.957 1.742 . . . . 0.0 116.75 176.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -100.81 103.86 15.09 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 120.801 2.3 . . . . 0.0 113.414 -171.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 42.9 mt -96.64 41.22 1.11 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.528 -1.358 . . . . 0.0 112.417 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.12 -129.74 43.14 Favored Glycine 0 CA--C 1.537 1.412 0 O-C-N 119.713 -1.867 . . . . 0.0 112.361 -174.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -147.98 161.01 42.21 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.877 0.871 . . . . 0.0 112.142 175.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.4 124.07 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 127.778 2.431 . . . . 0.0 110.906 -172.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.2 m -95.78 129.86 42.88 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.386 0.674 . . . . 0.0 109.666 174.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.32 148.47 25.05 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.56 162.53 15.62 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 128.677 2.791 . . . . 0.0 110.01 169.058 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -40.79 -21.23 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 129.421 3.088 . . . . 0.0 117.609 177.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -75.73 0.16 18.82 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.54 -1.35 . . . . 0.0 112.166 171.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.51 24.41 76.83 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 125.895 1.712 . . . . 0.0 112.602 -170.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.2 p -116.8 128.14 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 CA-C-N 118.785 1.293 . . . . 0.0 113.156 -177.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.1 117.05 29.62 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 166.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -98.25 130.93 44.95 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 123.793 0.837 . . . . 0.0 109.009 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.69 143.0 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 117.011 2.226 . . . . 0.0 117.011 -174.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 77.8 p -143.94 82.36 1.71 Allowed 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 126.352 1.861 . . . . 0.0 111.533 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.8 mt -97.69 157.61 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 120.594 -1.316 . . . . 0.0 110.071 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -144.69 145.59 31.8 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 127.642 2.377 . . . . 0.0 107.463 168.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.34 159.95 40.34 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.836 1.255 . . . . 0.0 111.336 173.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 35.7 p -127.37 46.08 2.6 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.472 1.509 . . . . 0.0 112.955 -168.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 23.1 m -145.87 15.12 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.226 1.011 . . . . 0.0 113.574 -176.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -148.78 165.99 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.107 2.163 . . . . 0.0 109.386 -173.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -157.39 168.0 28.63 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 125.066 1.346 . . . . 0.0 109.983 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -98.73 80.03 2.5 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.99 1.716 . . . . 0.0 107.723 -171.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -122.14 -18.91 6.74 Favored 'General case' 0 CA--C 1.567 1.628 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -175.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.06 0.71 89.26 Favored Glycine 0 N--CA 1.492 2.408 0 O-C-N 118.554 -2.591 . . . . 0.0 117.778 166.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.66 -88.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.918 2.487 . . . . 0.0 108.569 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 86.8 m-70 -115.15 -9.06 12.34 Favored 'General case' 0 CA--C 1.559 1.299 1 C-N-CA 132.715 4.406 . . . . 0.0 111.113 168.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 48.8 m -82.46 -166.05 1.18 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.63 1.972 . . . . 0.0 110.992 -174.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.28 162.3 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.834 0 O-C-N 118.603 -2.56 . . . . 0.0 108.637 169.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 97.29 132.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.278 1 C-N-CA 133.75 4.82 . . . . 0.0 108.291 -168.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.22 5.51 34.88 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-O 117.565 -1.686 . . . . 0.0 115.815 176.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 62.2 mmt-85 -77.61 -177.08 4.6 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 127.138 2.175 . . . . 0.0 110.797 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 39.5 m -128.26 141.12 51.55 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 116.446 -1.74 . . . . 0.0 109.945 173.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.7 tp -113.19 111.22 21.71 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.846 1.259 . . . . 0.0 111.208 171.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.9 p -88.56 149.33 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 124.264 1.026 . . . . 0.0 109.563 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 33.2 t -121.77 142.23 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 168.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -99.26 136.85 38.61 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.324 2.25 . . . . 0.0 111.379 -173.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -75.97 -10.86 59.77 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 120.419 -1.426 . . . . 0.0 113.796 -171.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 50.8 mttp -114.95 172.95 6.74 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 126.26 1.824 . . . . 0.0 111.959 169.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.99 163.59 1.94 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.809 1.244 . . . . 0.0 112.188 169.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -121.03 135.07 55.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 127.299 2.24 . . . . 0.0 107.209 175.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -73.03 -33.24 65.6 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 118.223 0.465 . . . . 0.0 112.216 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 29.3 mt 69.19 50.39 0.57 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.872 1.669 . . . . 0.0 114.223 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.21 -26.83 8.47 Favored Glycine 0 N--CA 1.474 1.211 0 N-CA-C 119.924 2.73 . . . . 0.0 119.924 163.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 8.4 pttm -163.93 99.41 0.87 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 120.1 1.95 . . . . 0.0 114.826 176.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.69 -7.71 56.45 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.938 1.732 . . . . 0.0 114.042 170.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 101.11 -8.64 57.54 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 125.497 1.522 . . . . 0.0 113.736 -170.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 p-10 -117.98 153.21 34.04 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 128.443 2.697 . . . . 0.0 109.611 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -66.41 -48.67 69.33 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 114.108 1.151 . . . . 0.0 114.108 -167.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.08 -33.1 72.81 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.837 1.255 . . . . 0.0 111.943 -175.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 61.8 m -53.45 -31.23 44.54 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 119.724 1.147 . . . . 0.0 112.574 168.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 1.1 p -85.03 -46.99 10.66 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.94 1.296 . . . . 0.0 112.513 172.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -70.49 -35.63 73.36 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.807 1.243 . . . . 0.0 113.523 -173.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 37.1 p -135.1 -28.78 1.15 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.265 1.426 . . . . 0.0 113.471 -175.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' B' ' 140' ' ' ALA . . . 108.95 0.54 31.83 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 118.44 -1.2 . . . . 0.0 113.538 -171.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 66.9 -4.39 0.79 Allowed 'General case' 0 N--CA 1.482 1.14 0 CA-C-N 119.492 1.646 . . . . 0.0 113.78 175.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . 0.411 ' H ' ' C ' ' B' ' 138' ' ' GLY . . . -46.88 5.11 0.0 OUTLIER 'General case' 0 CA--C 1.565 1.545 1 C-N-CA 132.551 4.34 . . . . 0.0 121.497 -165.52 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.11 -69.9 3.21 Favored Glycine 0 CA--C 1.526 0.735 0 O-C-N 120.083 -1.636 . . . . 0.0 115.288 168.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.4 t -164.71 -152.4 0.17 Allowed 'General case' 0 N--CA 1.477 0.92 0 O-C-N 121.253 -1.145 . . . . 0.0 112.157 -171.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.65 148.87 29.81 Favored 'General case' 0 N--CA 1.47 0.557 0 O-C-N 120.427 -1.421 . . . . 0.0 113.991 176.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.465 ' CG ' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -97.85 -101.45 0.2 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.095 1.758 . . . . 0.0 110.099 169.54 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . 0.465 ' H ' ' CG ' ' B' ' 144' ' ' LEU . . . -91.3 166.73 12.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.986 1.714 . . . . 0.0 111.05 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -157.08 143.19 17.91 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 127.181 2.192 . . . . 0.0 108.545 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.76 171.08 40.1 Favored Glycine 0 N--CA 1.47 0.937 0 N-CA-C 117.354 1.702 . . . . 0.0 117.354 169.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -84.85 146.72 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.106 2.163 . . . . 0.0 110.577 -169.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 46.6 mm -86.43 103.09 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 125.649 1.58 . . . . 0.0 111.35 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.82 175.82 22.57 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.737 1.637 . . . . 0.0 113.134 171.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' B' ' 4' ' ' ALA 0.296 1.3 pp -114.78 139.21 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 177.762 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.4 159.66 30.27 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-O 122.951 1.358 . . . . 0.0 108.457 172.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 113.966 -1.47 . . . . 0.0 110.098 -177.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.5 p . . . . . 0 CA--C 1.517 -0.304 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptpp? -105.25 135.87 45.81 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -87.18 161.83 17.83 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 164.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 t -145.1 149.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 CA-C-N 119.705 1.139 . . . . 0.0 110.045 173.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.16 109.16 12.53 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.452 1.501 . . . . 0.0 108.187 166.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -82.61 112.07 19.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 168.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -79.36 99.35 7.1 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -156.13 127.18 6.97 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.586 0.754 . . . . 0.0 111.904 177.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.67 -104.81 1.28 Allowed Glycine 0 CA--C 1.527 0.821 0 N-CA-C 105.277 -3.129 . . . . 0.0 105.277 164.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -156.33 129.64 8.13 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.628 1.571 . . . . 0.0 108.352 167.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 124.22 168.87 12.98 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.61 2.052 . . . . 0.0 110.519 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 23.27 0.19 Allowed 'Trans proline' 0 CA--C 1.546 1.089 1 C-N-CA 125.745 4.297 . . . . 0.0 116.39 -169.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -117.26 111.87 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -157.27 158.24 35.74 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.324 -174.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.68 179.18 37.23 Favored Glycine 0 CA--C 1.508 -0.371 0 C-N-CA 126.129 1.823 . . . . 0.0 113.494 176.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -134.04 142.02 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.295 1.438 . . . . 0.0 109.054 168.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.0 mm -133.23 111.23 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 168.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -77.68 150.49 34.51 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.075 1.75 . . . . 0.0 110.934 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -135.43 78.52 1.73 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.765 2.026 . . . . 0.0 108.542 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -81.74 117.64 22.21 Favored 'General case' 0 C--N 1.34 0.182 0 CA-C-O 121.863 0.839 . . . . 0.0 113.157 -177.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp60 -105.57 167.68 9.6 Favored 'General case' 0 CA--C 1.549 0.942 0 CA-C-O 122.951 1.358 . . . . 0.0 109.424 169.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.504 ' HZ2' ' HG2' ' A' ' 28' ' ' PRO . 0.0 OUTLIER -132.89 -28.09 1.6 Allowed 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 130.088 3.355 . . . . 0.0 111.725 -177.807 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.421 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 3.3 mp0 -101.97 -132.13 0.27 Allowed 'General case' 0 CA--C 1.556 1.201 0 C-N-CA 124.621 1.168 . . . . 0.0 108.497 166.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 t -136.37 -82.04 0.39 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 120.249 -1.532 . . . . 0.0 107.681 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -76.24 72.16 3.0 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.069 0.85 . . . . 0.0 112.356 169.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.46 15.93 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 127.057 2.265 . . . . 0.0 111.16 171.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.504 ' HG2' ' HZ2' ' A' ' 23' ' ' LYS . 55.5 Cg_endo -70.3 158.4 56.37 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 123.395 2.73 . . . . 0.0 111.567 -177.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.7 t -129.14 136.16 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.24 0.616 . . . . 0.0 110.67 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.465 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 62.0 mttm -87.02 119.75 27.56 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 122.394 1.092 . . . . 0.0 110.827 176.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.9 t -103.1 125.3 57.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 128.82 2.848 . . . . 0.0 109.332 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.7 p90 -157.14 161.85 39.37 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 169.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.77 171.99 13.03 Favored Glycine 0 N--CA 1.466 0.669 0 C-N-CA 124.833 1.206 . . . . 0.0 112.11 -176.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.3 p -132.33 143.33 49.79 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 -167.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mm -116.73 126.37 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 124.869 1.268 . . . . 0.0 111.404 171.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 54.3 tttt -127.79 146.2 50.67 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.695 1.598 . . . . 0.0 111.755 -173.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.02 -34.57 3.82 Favored Glycine 0 N--CA 1.477 1.423 0 C-N-CA 126.347 1.927 . . . . 0.0 111.197 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.58 129.06 38.59 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 165.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -69.33 169.54 12.07 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 118.615 0.643 . . . . 0.0 110.998 171.33 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -54.02 158.79 2.0 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.325 1.85 . . . . 0.0 115.475 -171.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.27 179.11 35.61 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.333 0.968 . . . . 0.0 112.783 -173.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.8 mt -64.05 137.23 57.89 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 126.981 2.112 . . . . 0.0 111.935 -174.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -133.54 131.63 39.98 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.613 1.165 . . . . 0.0 108.472 168.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.36 157.31 46.13 Favored Glycine 0 N--CA 1.46 0.248 0 CA-C-O 118.994 -0.892 . . . . 0.0 111.277 -174.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -155.46 141.91 18.64 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.804 0.811 . . . . 0.0 112.763 169.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.9 p-80 -152.58 168.2 26.36 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 123.171 0.588 . . . . 0.0 109.838 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.27 135.57 41.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 123.964 0.905 . . . . 0.0 108.735 175.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -71.73 134.31 46.16 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 170.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -76.4 47.76 0.49 Allowed 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.225 1.194 . . . . 0.0 114.225 -170.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 173.8 156.99 0.13 Allowed 'General case' 0 C--O 1.237 0.425 0 C-N-CA 129.649 3.18 . . . . 0.0 108.35 177.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.25 0.46 20.76 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 117.823 1.889 . . . . 0.0 117.823 -178.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -67.67 42.86 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.535 1.934 . . . . 0.0 115.248 171.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -166.54 22.16 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -163.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.4 t -29.14 74.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 129.678 3.191 . . . . 0.0 117.407 173.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 159.35 -14.54 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.05 0 C-N-CA 130.775 3.63 . . . . 0.0 111.749 -169.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.77 -127.78 25.75 Favored Glycine 0 C--N 1.345 1.034 0 C-N-CA 124.858 1.218 . . . . 0.0 112.15 167.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 12.4 t -57.69 -10.86 1.77 Allowed 'General case' 0 CA--C 1.552 1.028 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.4 t -108.11 23.13 14.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.229 1.412 . . . . 0.0 113.576 171.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.0 m -152.05 -20.31 0.18 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 116.819 2.155 . . . . 0.0 116.819 169.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -153.41 162.93 40.78 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 120.644 1.565 . . . . 0.0 111.799 169.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.89 160.86 52.07 Favored Glycine 0 CA--C 1.539 1.586 0 CA-C-O 119.359 -0.69 . . . . 0.0 112.579 176.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -70.08 172.41 13.0 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 124.152 3.235 . . . . 0.0 111.177 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -15.86 89.18 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 118.865 2.913 . . . . 0.0 118.865 176.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -67.41 98.45 0.65 Allowed 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -75.63 102.42 0.72 Allowed Pre-proline 0 CA--C 1.548 0.871 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -165.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -72.13 -33.3 9.63 Favored 'Trans proline' 0 C--N 1.355 0.915 0 C-N-CA 123.252 2.635 . . . . 0.0 113.086 -168.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.98 -4.27 49.15 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.655 1.182 . . . . 0.0 112.656 175.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.4 t 56.5 49.12 15.41 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.014 1.726 . . . . 0.0 112.823 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 -103.72 174.45 5.86 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.789 1.236 . . . . 0.0 113.365 -173.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 ptmm? -74.22 164.59 26.43 Favored 'General case' 0 CA--C 1.547 0.837 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 161.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -80.14 168.76 18.72 Favored 'General case' 0 CA--C 1.543 0.682 0 O-C-N 121.086 -1.009 . . . . 0.0 112.365 173.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 131.51 -154.95 21.12 Favored Glycine 0 C--N 1.338 0.692 0 C-N-CA 125.818 1.675 . . . . 0.0 113.022 167.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.25 -15.2 0.4 Allowed Glycine 0 CA--C 1.539 1.558 0 N-CA-C 121.331 3.293 . . . . 0.0 121.331 166.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -112.43 -12.11 0.03 OUTLIER 'Trans proline' 0 CA--C 1.545 1.03 0 CA-C-N 121.87 2.835 . . . . 0.0 112.939 168.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.461 ' HE3' ' HB2' ' A' ' 128' ' ' LYS . 0.0 OUTLIER -126.56 -3.43 6.67 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 125.569 1.548 . . . . 0.0 112.666 175.625 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -108.51 175.06 5.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 128.53 2.732 . . . . 0.0 109.548 -175.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -116.85 -9.65 11.16 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.769 2.028 . . . . 0.0 112.629 -168.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -122.98 -59.16 1.61 Allowed 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -165.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 46.33 118.55 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 117.881 2.548 . . . . 0.0 117.881 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -58.4 165.57 2.04 Favored 'General case' 0 N--CA 1.48 1.071 0 O-C-N 119.37 -2.081 . . . . 0.0 111.583 169.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.313 7.1 p -77.19 -18.97 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 CA-C-N 120.116 1.326 . . . . 0.0 113.078 -176.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -94.16 27.78 12.4 Favored Glycine 0 CA--C 1.542 1.75 0 C-N-CA 125.458 1.504 . . . . 0.0 114.937 167.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -107.28 131.58 54.05 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 120.417 2.108 . . . . 0.0 115.088 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 65.2 mt -115.05 178.81 4.15 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.241 1.816 . . . . 0.0 109.818 167.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -89.53 -121.68 2.1 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.435 1.493 . . . . 0.0 114.511 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.8 m-80 -127.04 154.25 44.9 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.071 1.348 . . . . 0.0 111.65 172.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.03 102.85 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 127.347 2.259 . . . . 0.0 109.709 168.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 m -89.63 126.84 35.78 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 124.744 1.218 . . . . 0.0 110.018 -179.077 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.21 150.47 21.97 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -80.9 160.0 24.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 127.301 2.24 . . . . 0.0 109.73 167.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.3 pttp -47.98 -19.35 0.24 Allowed 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 128.185 2.594 . . . . 0.0 115.811 169.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -74.64 -11.68 60.25 Favored 'General case' 0 CA--C 1.547 0.863 0 O-C-N 120.753 -1.217 . . . . 0.0 111.784 171.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.07 15.09 55.08 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.015 2.245 . . . . 0.0 113.281 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.8 p -117.38 130.48 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.092 1.446 . . . . 0.0 113.322 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.36 97.34 7.84 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 165.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -89.68 148.93 23.01 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.961 0.886 . . . . 0.0 110.289 168.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.53 146.17 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.105 -1.407 . . . . 0.0 114.433 -169.073 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 76.7 p -160.23 90.43 0.89 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.384 1.074 . . . . 0.0 112.623 -176.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 175.77 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 C-N-CA 125.918 1.687 . . . . 0.0 113.236 -174.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.465 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 34.8 tt0 -144.75 146.9 32.38 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 128.302 2.641 . . . . 0.0 106.693 168.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -143.05 155.94 44.73 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 122.053 0.93 . . . . 0.0 111.052 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.6 p -121.08 64.71 0.87 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 127.069 2.148 . . . . 0.0 114.158 -166.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -156.83 -46.82 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 O-C-N 121.033 -1.042 . . . . 0.0 109.717 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.39 150.43 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 168.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -148.43 161.15 42.18 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.486 1.514 . . . . 0.0 111.259 -169.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 9.4 mt -78.04 97.85 5.53 Favored 'General case' 0 C--N 1.345 0.387 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 170.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.5 t -155.98 6.4 0.2 Allowed 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 -170.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.3 -119.88 5.04 Favored Glycine 0 C--N 1.342 0.865 0 CA-C-N 120.625 1.557 . . . . 0.0 109.713 168.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -62.41 -26.59 68.56 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 125.532 1.533 . . . . 0.0 111.209 -171.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.2 m170 -79.45 -24.25 42.56 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.302 1.041 . . . . 0.0 113.446 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.6 m -166.92 -110.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.6 mm -88.8 142.3 13.07 Favored 'Isoleucine or valine' 0 C--N 1.34 0.171 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 -176.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 92.19 133.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 131.526 3.93 . . . . 0.0 106.73 -164.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.28 15.27 81.69 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 117.211 -1.883 . . . . 0.0 115.823 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 26.5 mtt85 -117.05 176.92 4.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-N 120.426 2.113 . . . . 0.0 110.777 171.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -119.75 110.32 16.66 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 120.212 1.369 . . . . 0.0 112.104 -175.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 14.4 tp -90.1 127.41 36.08 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.601 1.161 . . . . 0.0 111.137 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.3 p -116.58 139.55 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.122 1.369 . . . . 0.0 110.491 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.408 HG23 ' H ' ' A' ' 145' ' ' ALA . 15.4 m -101.44 152.88 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 123.509 0.724 . . . . 0.0 109.436 167.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -119.45 145.68 46.06 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.665 1.586 . . . . 0.0 112.08 -170.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -71.22 -24.46 62.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.674 -1.266 . . . . 0.0 114.147 -171.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.5 mptt -112.78 177.16 4.73 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.321 1.449 . . . . 0.0 110.344 168.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.06 146.8 10.58 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.535 1.934 . . . . 0.0 111.45 168.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -83.86 140.86 31.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 161.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.1 -49.79 33.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 174.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 90.64 38.38 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 129.413 3.085 . . . . 0.0 113.292 175.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.82 26.68 8.34 Favored Glycine 0 N--CA 1.468 0.799 0 N-CA-C 117.73 1.852 . . . . 0.0 117.73 167.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.461 ' HB2' ' HE3' ' A' ' 75' ' ' LYS . 3.7 tttt -155.74 10.09 0.28 Allowed 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 117.131 2.271 . . . . 0.0 117.131 -175.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -67.74 117.55 8.87 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 107.051 -2.42 . . . . 0.0 107.051 167.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -69.89 43.14 0.49 Allowed Glycine 0 N--CA 1.477 1.375 0 C-N-CA 126.561 2.029 . . . . 0.0 115.473 -174.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -102.85 -82.62 0.49 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.302 1.841 . . . . 0.0 110.418 176.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 177.17 -69.31 0.01 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 131.154 3.781 . . . . 0.0 106.329 -173.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.66 -37.16 62.88 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.731 1.612 . . . . 0.0 114.675 -177.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.78 -18.6 62.94 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 119.119 -2.238 . . . . 0.0 114.542 179.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -99.34 -10.18 22.62 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 124.0 0.92 . . . . 0.0 113.073 170.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.2 mtpt -81.54 -75.55 0.28 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.5 1.52 . . . . 0.0 111.499 169.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 58.5 p -94.03 -28.16 15.9 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 120.121 1.328 . . . . 0.0 113.571 -177.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.45 -14.26 30.3 Favored Glycine 0 N--CA 1.468 0.813 0 CA-C-N 119.44 1.018 . . . . 0.0 110.925 -166.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 61.04 30.69 19.68 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 118.196 0.998 . . . . 0.0 112.714 165.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.9 28.36 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 128.582 2.753 . . . . 0.0 117.969 -167.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 67.38 -13.44 0.57 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 119.884 2.713 . . . . 0.0 119.884 167.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . 0.265 16.7 t 146.31 -171.56 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 130.268 3.427 . . . . 0.0 113.23 169.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.59 178.1 6.95 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 128.228 2.611 . . . . 0.0 114.587 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 17.9 tp -162.74 -115.6 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.653 1.581 . . . . 0.0 109.657 168.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.408 ' H ' HG23 ' A' ' 119' ' ' VAL . . . -99.24 169.98 8.99 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 125.895 1.678 . . . . 0.0 111.506 172.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.3 t -156.64 152.07 26.69 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.782 1.233 . . . . 0.0 111.872 -171.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.05 142.31 8.41 Favored Glycine 0 N--CA 1.473 1.138 0 C-N-CA 125.43 1.491 . . . . 0.0 113.189 178.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 72.1 t -80.73 150.05 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 CA-C-N 118.602 1.201 . . . . 0.0 111.282 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.6 mt -88.1 103.25 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 O-C-N 120.14 -1.6 . . . . 0.0 109.951 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.75 168.84 14.06 Favored Glycine 0 N--CA 1.473 1.142 0 C-N-CA 124.239 0.923 . . . . 0.0 113.242 176.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.58 124.04 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 118.847 1.323 . . . . 0.0 113.78 176.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.22 -32.57 13.63 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-O 121.726 0.774 . . . . 0.0 108.927 163.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 . . . . . 0 C--O 1.233 0.2 0 C-N-CA 128.903 2.881 . . . . 0.0 111.174 168.742 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.742 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 76.4 p -92.92 51.57 1.71 Allowed 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -166.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 58.1 mttp -78.12 131.84 37.42 Favored 'General case' 0 N--CA 1.473 0.678 0 O-C-N 119.193 -2.192 . . . . 0.0 114.004 -170.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -123.58 156.42 35.77 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.45 1.5 . . . . 0.0 109.015 169.139 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 38.1 t -140.75 146.85 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 123.495 0.718 . . . . 0.0 110.626 -171.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.63 116.04 19.69 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.057 0.943 . . . . 0.0 112.044 169.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -78.92 103.98 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 168.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.06 114.58 17.07 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtpm? -141.6 172.45 12.67 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 124.584 1.154 . . . . 0.0 111.766 -174.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.45 -59.85 0.68 Allowed Glycine 0 N--CA 1.465 0.626 0 C-N-CA 126.779 2.133 . . . . 0.0 110.059 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.41 59.49 5.45 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.809 1.244 . . . . 0.0 112.844 -168.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.57 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.973 2.702 . . . . 0.0 114.247 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.75 -17.1 37.81 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 123.661 2.907 . . . . 0.0 113.216 -178.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 t -87.61 124.29 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 119.487 1.04 . . . . 0.0 110.314 171.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.27 165.36 35.02 Favored 'General case' 0 C--O 1.224 -0.239 0 C-N-CA 123.871 0.868 . . . . 0.0 111.772 169.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.98 -179.22 31.76 Favored Glycine 0 N--CA 1.464 0.531 0 N-CA-C 115.664 1.026 . . . . 0.0 115.664 -176.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 10.1 pt -135.15 116.39 19.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 126.827 2.051 . . . . 0.0 107.858 166.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.98 117.86 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 169.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 62.2 m-20 -113.55 130.08 56.43 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.85 1.66 . . . . 0.0 110.852 -173.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -114.4 130.7 56.71 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.466 1.507 . . . . 0.0 110.198 -171.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -122.02 131.37 53.96 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.916 1.687 . . . . 0.0 110.178 172.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -124.62 140.5 52.88 Favored 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.344 -0.847 . . . . 0.0 109.063 167.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -99.57 -24.22 14.82 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 115.128 1.529 . . . . 0.0 115.128 -168.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 46.2 mp0 -143.16 146.96 34.19 Favored 'General case' 0 CA--C 1.512 -0.518 0 C-N-CA 127.911 2.484 . . . . 0.0 106.672 168.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.4 m -61.96 -21.18 64.59 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.452 1.278 . . . . 0.0 114.452 -172.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -107.11 0.17 23.27 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.949 1.7 . . . . 0.0 113.839 170.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.16 170.13 54.38 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.779 1.18 . . . . 0.0 111.358 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -71.66 157.88 54.72 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.267 1.978 . . . . 0.0 110.613 177.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -107.52 134.18 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 125.366 1.467 . . . . 0.0 108.116 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -96.84 126.3 41.9 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 167.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 42.3 t -108.01 124.31 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 125.941 1.697 . . . . 0.0 107.081 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -143.05 170.82 15.0 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.4 -153.5 19.17 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 124.596 1.093 . . . . 0.0 112.337 174.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 58.3 p -153.98 153.63 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 114.805 1.409 . . . . 0.0 114.805 -172.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.4 mp -124.83 133.47 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.808 1.643 . . . . 0.0 107.072 169.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -132.37 146.15 51.76 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.921 0.888 . . . . 0.0 112.778 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.58 -3.74 19.75 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 126.75 2.119 . . . . 0.0 114.582 -173.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.0 mt -74.28 173.5 10.11 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.546 1.138 . . . . 0.0 111.866 177.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.7 t -86.43 154.6 21.04 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 164.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -56.41 142.39 38.64 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 167.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.59 176.63 17.34 Favored Glycine 0 N--CA 1.472 1.038 0 C-N-CA 124.294 0.949 . . . . 0.0 113.451 -175.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.441 HD22 ' H ' ' B' ' 42' ' ' LEU . 1.8 pt? -89.14 126.01 35.28 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.951 1.7 . . . . 0.0 113.422 -169.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -123.18 146.23 47.96 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 127.818 2.447 . . . . 0.0 109.624 -178.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.07 155.97 33.6 Favored Glycine 0 N--CA 1.478 1.45 0 CA-C-N 121.133 1.788 . . . . 0.0 111.252 -177.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -153.81 135.59 14.5 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.658 1.729 . . . . 0.0 113.958 171.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' B' ' 120' ' ' HIS . 0.1 OUTLIER -158.4 159.8 36.16 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.132 0.973 . . . . 0.0 112.867 -178.222 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.68 117.37 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.211 1.404 . . . . 0.0 110.158 -175.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -74.83 -173.54 1.91 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 128.43 2.692 . . . . 0.0 113.649 -169.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -63.29 152.05 38.91 Favored 'General case' 0 CA--C 1.541 0.6 0 O-C-N 120.245 -1.534 . . . . 0.0 112.055 171.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.23 161.23 13.85 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 115.071 1.508 . . . . 0.0 115.071 -168.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 67.37 -79.62 0.16 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -85.79 54.03 2.98 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 123.789 1.757 . . . . 0.0 110.557 -169.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -173.57 8.04 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.836 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 175.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 27.4 p . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 119.619 3.192 . . . . 0.0 119.619 -165.549 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.592 0 N-CA-C 116.938 2.199 . . . . 0.0 116.938 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -73.02 -179.77 37.3 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 123.788 0.708 . . . . 0.0 112.009 169.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -60.9 167.65 8.42 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 124.484 3.456 . . . . 0.0 115.072 -165.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.624 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -57.05 86.36 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 127.53 2.332 . . . . 0.0 111.415 175.854 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -52.69 127.23 22.4 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.805 -1.088 . . . . 0.0 112.79 -167.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -117.78 65.77 5.15 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 125.964 1.706 . . . . 0.0 112.953 -168.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -64.05 -15.22 48.03 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.035 2.49 . . . . 0.0 113.618 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -79.32 -7.3 58.22 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.442 1.097 . . . . 0.0 113.118 170.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t 65.46 55.67 1.02 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.881 2.072 . . . . 0.0 112.194 175.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 mtm180 -121.4 178.36 4.83 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 -166.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 mttp -89.81 173.91 8.0 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 127.917 2.487 . . . . 0.0 112.468 169.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -109.14 146.38 34.18 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 117.283 2.327 . . . . 0.0 117.283 -168.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 129.82 -91.7 0.31 Allowed Glycine 0 C--N 1.343 0.967 0 C-N-CA 124.795 1.188 . . . . 0.0 112.468 166.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.62 -28.6 11.19 Favored Glycine 0 CA--C 1.551 2.302 0 N-CA-C 118.635 2.214 . . . . 0.0 118.635 174.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -87.36 -15.18 3.62 Favored 'Trans proline' 0 C--N 1.356 0.966 0 CA-C-N 122.797 3.298 . . . . 0.0 113.176 171.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.21 -48.62 1.45 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.247 1.419 . . . . 0.0 108.994 166.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -55.09 138.41 44.33 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.975 0.893 . . . . 0.0 110.884 171.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -87.93 -6.23 58.15 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 127.464 2.306 . . . . 0.0 113.0 -169.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -119.24 -56.57 2.07 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 115.543 1.683 . . . . 0.0 115.543 -174.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . 0.535 HH21 ' CG1' ' B' ' 103' ' ' VAL 0.278 3.4 ptt180 57.93 136.61 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.906 2.483 . . . . 0.0 115.346 -173.176 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -73.35 166.78 22.54 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 118.725 -2.484 . . . . 0.0 111.107 169.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.46 -31.92 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 120.311 -1.493 . . . . 0.0 113.997 -177.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -100.66 22.24 40.56 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 118.789 -1.006 . . . . 0.0 115.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -96.32 114.21 25.87 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -169.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.0 mt -101.56 171.88 7.3 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 104.425 -2.435 . . . . 0.0 104.425 158.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.63 -98.84 1.18 Allowed Glycine 0 N--CA 1.474 1.169 0 CA-C-N 119.026 0.83 . . . . 0.0 111.858 175.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -142.13 164.09 31.09 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -177.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.43 129.14 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 129.264 3.026 . . . . 0.0 111.147 -168.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.5 m -100.84 140.55 34.97 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.043 0.937 . . . . 0.0 110.072 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.44 157.86 16.32 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.931 0.892 . . . . 0.0 111.344 167.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -82.11 178.45 8.27 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.14 1.376 . . . . 0.0 112.154 171.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.12 -28.25 68.96 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.594 1.558 . . . . 0.0 113.365 172.048 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -76.42 2.71 12.85 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.336 1.054 . . . . 0.0 110.616 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.27 -0.59 83.83 Favored Glycine 0 C--N 1.342 0.883 0 C-N-CA 127.179 2.323 . . . . 0.0 114.19 172.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.69 132.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 126.107 1.763 . . . . 0.0 113.464 178.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.03 133.9 41.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.786 1.235 . . . . 0.0 108.703 165.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -98.38 118.27 34.66 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 7.5 t -98.43 124.01 51.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.2 173.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -155.1 87.8 1.14 Allowed 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.284 1.434 . . . . 0.0 110.95 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.87 148.64 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 126.441 1.896 . . . . 0.0 112.609 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -112.54 133.1 54.77 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.041 2.536 . . . . 0.0 106.008 168.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.74 130.05 27.12 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 125.238 1.415 . . . . 0.0 111.161 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 25.3 p -113.17 44.26 1.57 Allowed 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -174.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . 0.535 ' CG1' HH21 ' B' ' 79' ' ' ARG 0.315 9.8 p -161.16 -21.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 116.275 1.954 . . . . 0.0 116.275 166.851 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.56 164.45 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 122.189 2.268 . . . . 0.0 109.754 168.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 76.8 p -157.71 159.48 36.93 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 -173.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -92.51 57.13 2.88 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 127.651 2.38 . . . . 0.0 105.484 172.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -116.16 21.17 13.88 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -167.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.48 -53.21 4.65 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-O 117.932 -1.482 . . . . 0.0 115.356 167.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -99.41 -103.07 0.22 Allowed 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.282 1.515 . . . . 0.0 110.738 -167.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 20.3 m170 -76.32 8.62 3.22 Favored 'General case' 0 CA--C 1.551 1.016 0 O-C-N 119.357 -2.089 . . . . 0.0 114.418 -167.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 69.8 p -93.81 -131.03 0.14 Allowed 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 129.084 2.954 . . . . 0.0 114.202 -167.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 14.9 pt -113.76 -15.52 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 121.344 1.884 . . . . 0.0 115.919 175.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.7 mm -54.46 129.79 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 CA-C-N 120.607 1.549 . . . . 0.0 108.299 168.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.15 -2.32 52.06 Favored Glycine 0 CA--C 1.534 1.273 0 CA-C-N 120.199 1.363 . . . . 0.0 115.529 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -87.54 176.5 7.44 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.432 1.893 . . . . 0.0 109.972 169.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.55 109.97 6.6 Favored 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 120.45 1.477 . . . . 0.0 113.319 -169.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 27.4 tp -83.16 120.27 25.57 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 124.051 0.94 . . . . 0.0 109.67 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 p -121.85 139.58 48.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 125.998 1.719 . . . . 0.0 110.024 176.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 t -95.81 166.99 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 124.927 1.291 . . . . 0.0 107.672 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 73.4 m-70 -150.12 130.54 13.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.198 1.799 . . . . 0.0 107.877 -169.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 -53.76 -40.07 65.88 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 121.569 1.986 . . . . 0.0 115.691 -169.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.42 136.37 33.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 120.278 1.399 . . . . 0.0 109.674 175.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.82 159.71 1.6 Allowed 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.187 0.595 . . . . 0.0 110.935 165.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -82.75 146.89 28.75 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-O 123.217 1.484 . . . . 0.0 112.946 -171.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.31 -7.57 53.27 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 114.05 -1.432 . . . . 0.0 113.019 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.1 mt 57.75 55.26 5.6 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 127.163 2.185 . . . . 0.0 113.681 168.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.76 -67.09 0.93 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 175.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 103.85 6.74 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 124.963 1.305 . . . . 0.0 113.659 174.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -103.56 -71.9 0.88 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 107.03 -2.428 . . . . 0.0 107.03 164.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -130.28 -29.5 0.65 Allowed Glycine 0 CA--C 1.536 1.406 0 N-CA-C 119.15 2.42 . . . . 0.0 119.15 -173.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -166.41 173.81 9.6 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 122.036 2.918 . . . . 0.0 111.722 -167.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -42.82 -60.13 1.7 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.335 1.454 . . . . 0.0 113.878 -169.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 26.4 tp10 -35.96 -29.22 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 126.128 1.771 . . . . 0.0 114.395 172.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 83.9 p -63.61 -30.1 71.26 Favored 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 123.355 2.798 . . . . 0.0 115.824 174.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -108.08 -19.9 13.35 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 118.372 -0.823 . . . . 0.0 112.903 169.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -74.09 -49.3 24.61 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.633 1.173 . . . . 0.0 112.078 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 56.4 p -111.38 -95.35 0.43 Allowed 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 164.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.28 16.22 0.2 Allowed Glycine 0 CA--C 1.535 1.29 1 C-N-CA 131.2 4.238 . . . . 0.0 112.1 175.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . 0.427 ' C ' ' H ' ' B' ' 141' ' ' GLY . 5.9 t-20 50.99 34.03 9.96 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.352 1.861 . . . . 0.0 113.019 -174.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.34 24.98 0.08 Allowed 'General case' 0 CA--C 1.565 1.531 0 CA-C-O 121.929 0.871 . . . . 0.0 112.727 -169.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' B' ' 139' ' ' ASN . . . 72.09 -42.85 0.8 Allowed Glycine 0 N--CA 1.471 0.996 0 C-N-CA 129.924 3.63 . . . . 0.0 114.972 175.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 t -161.41 -156.39 0.44 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.541 1.537 . . . . 0.0 109.461 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -166.75 1.11 Allowed 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 127.105 2.162 . . . . 0.0 108.23 168.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -179.54 -173.6 0.26 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 128.328 2.651 . . . . 0.0 107.766 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.51 142.39 8.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.751 2.02 . . . . 0.0 112.154 174.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.2 p -151.9 159.57 43.78 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.908 1.683 . . . . 0.0 114.826 -167.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.78 142.53 8.32 Favored Glycine 0 CA--C 1.534 1.233 0 CA-C-O 118.795 -1.003 . . . . 0.0 114.837 173.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 26.5 t -79.51 135.42 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 125.222 1.409 . . . . 0.0 110.675 170.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.58 115.82 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 O-C-N 121.222 -0.924 . . . . 0.0 110.806 -174.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.76 174.94 15.7 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.942 1.258 . . . . 0.0 111.858 172.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -93.57 156.6 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 N-CA-C 115.337 1.606 . . . . 0.0 115.337 -168.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.51 -16.66 0.17 Allowed 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 126.914 2.085 . . . . 0.0 114.308 171.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 CA--C 1.533 0.311 0 C-N-CA 125.361 1.464 . . . . 0.0 112.911 168.168 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.423 ' HA ' ' H ' ' A' ' 22' ' ' GLN . 74.0 p . . . . . 0 N--CA 1.468 0.472 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.9 mttp -169.4 135.12 1.56 Allowed 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 127.322 2.249 . . . . 0.0 114.726 165.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.38 177.82 7.46 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 128.864 2.866 . . . . 0.0 110.188 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 p -155.26 127.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 C-N-CA 126.642 1.977 . . . . 0.0 108.903 -167.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.5 129.68 55.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.804 0.842 . . . . 0.0 111.495 170.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.3 t -102.13 95.39 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.666 1.186 . . . . 0.0 107.876 175.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -89.06 124.28 34.15 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.1 mtpt -143.45 175.36 9.99 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 121.958 0.885 . . . . 0.0 112.416 168.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.29 -65.2 0.16 Allowed Glycine 0 C--N 1.33 0.234 0 C-N-CA 125.571 1.558 . . . . 0.0 110.629 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.85 69.51 3.35 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.51 1.124 . . . . 0.0 111.27 -164.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 40.88 -102.61 0.03 OUTLIER Glycine 0 CA--C 1.536 1.361 0 C-N-CA 127.104 2.288 . . . . 0.0 113.373 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -68.93 -5.98 17.0 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 124.209 3.273 . . . . 0.0 114.459 -178.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.4 t -76.36 135.43 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 CA-C-N 120.151 1.342 . . . . 0.0 110.037 169.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.79 156.79 45.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.212 -1.358 . . . . 0.0 108.642 166.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.89 105.48 0.59 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 169.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.2 127.23 46.37 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 CA-C-N 117.824 0.812 . . . . 0.0 109.778 171.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 pp -137.42 121.73 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 122.435 1.112 . . . . 0.0 110.823 166.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -83.5 161.07 21.36 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.963 1.305 . . . . 0.0 109.048 164.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -138.29 130.14 28.22 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.526 0.731 . . . . 0.0 109.62 167.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.89 153.66 22.07 Favored 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 165.424 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.423 ' H ' ' HA ' ' A' ' 2' ' ' THR . 1.3 tm0? -157.9 140.85 14.96 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 124.726 1.21 . . . . 0.0 110.781 168.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.445 ' HZ1' ' CD ' ' A' ' 24' ' ' GLU 0.256 0.0 OUTLIER -82.3 -68.47 0.7 Allowed 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 175.434 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.445 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 20.7 mp0 -132.66 165.07 25.32 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.944 1.698 . . . . 0.0 110.77 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 m -56.01 -28.71 58.45 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -98.38 5.21 48.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.817 1.247 . . . . 0.0 112.729 172.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.59 149.57 19.27 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 125.014 1.292 . . . . 0.0 111.861 -176.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -69.75 174.79 8.97 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.836 3.024 . . . . 0.0 111.83 -178.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -133.54 153.42 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.811 1.244 . . . . 0.0 112.486 -168.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.3 mttm -120.75 112.48 18.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.459 1.104 . . . . 0.0 109.178 167.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -80.86 148.07 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 O-C-N 121.418 -0.801 . . . . 0.0 109.402 167.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.2 p90 -156.64 157.62 35.57 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.528 0.731 . . . . 0.0 112.182 165.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.88 -158.81 27.83 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.116 0.807 . . . . 0.0 115.116 -176.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.0 p -153.64 129.12 9.91 Favored 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -168.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mm -111.66 113.94 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.419 178.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . 0.26 0.0 OUTLIER -133.3 172.17 13.05 Favored 'General case' 0 C--N 1.345 0.37 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -178.582 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.54 1.09 59.11 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 126.928 2.204 . . . . 0.0 110.753 -166.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mt -87.21 173.55 9.15 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.869 1.268 . . . . 0.0 110.589 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.4 t -84.77 162.88 19.44 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 163.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -60.79 161.03 8.53 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-O 121.529 0.68 . . . . 0.0 112.205 169.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.48 -175.16 31.48 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.64 1.114 . . . . 0.0 112.812 -178.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.613 ' H ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -71.92 151.04 43.62 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 128.272 2.629 . . . . 0.0 112.398 -171.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -152.36 115.45 4.66 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 127.831 2.452 . . . . 0.0 110.087 -173.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.65 152.49 30.85 Favored Glycine 0 N--CA 1.487 2.065 0 CA-C-N 120.854 1.661 . . . . 0.0 113.368 -178.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -149.64 103.46 3.26 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.631 1.572 . . . . 0.0 111.054 -169.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -141.85 145.96 35.27 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 119.849 -1.782 . . . . 0.0 114.986 -164.12 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -96.76 142.76 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-N 118.618 0.645 . . . . 0.0 110.958 -174.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -115.19 125.15 53.05 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.838 1.255 . . . . 0.0 109.511 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -62.42 25.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 128.013 2.525 . . . . 0.0 115.318 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -149.48 126.62 11.33 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 127.843 2.457 . . . . 0.0 107.507 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.95 -19.82 66.64 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 126.513 2.006 . . . . 0.0 115.048 173.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -76.23 51.62 0.7 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 127.313 2.245 . . . . 0.0 113.55 -168.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -176.32 22.32 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.211 0 C-N-CA 126.599 1.959 . . . . 0.0 115.399 -167.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.8 t -66.85 44.45 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 128.319 2.648 . . . . 0.0 116.697 178.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.67 -11.06 9.09 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -174.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.17 -166.63 14.6 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 125.268 1.413 . . . . 0.0 112.762 -169.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 37.7 t -51.79 -20.67 2.3 Favored 'General case' 0 CA--C 1.551 0.987 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 -177.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -68.66 -6.77 27.94 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 115.088 1.514 . . . . 0.0 115.088 175.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.6 t -149.76 -26.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -90.58 112.41 24.1 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.972 -1.08 . . . . 0.0 111.273 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.28 -119.48 1.11 Allowed Glycine 0 CA--C 1.545 1.935 0 C-N-CA 124.652 1.12 . . . . 0.0 113.568 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.35 173.73 2.19 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 124.205 3.27 . . . . 0.0 110.81 169.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -94.9 114.56 26.43 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.5 0.72 . . . . 0.0 110.352 -172.437 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -58.59 146.25 36.59 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.281 1.032 . . . . 0.0 112.64 177.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -126.83 85.58 60.53 Favored Pre-proline 0 CA--C 1.551 1.01 0 C-N-CA 125.885 1.674 . . . . 0.0 112.96 -168.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -61.74 -34.37 83.39 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 123.341 2.694 . . . . 0.0 113.519 -176.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.16 -4.96 47.21 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.602 0.761 . . . . 0.0 112.809 174.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.8 t 62.85 47.23 4.6 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 127.125 2.17 . . . . 0.0 112.179 178.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.7 ptt180 -117.9 176.56 5.14 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 114.544 1.313 . . . . 0.0 114.544 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -70.67 159.67 34.01 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.763 1.225 . . . . 0.0 111.704 174.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -68.12 120.68 14.71 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 164.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.4 -168.83 18.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 115.209 0.844 . . . . 0.0 115.209 -166.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -93.69 0.55 Allowed Glycine 0 CA--C 1.536 1.371 0 CA-C-O 117.004 -1.998 . . . . 0.0 114.933 176.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -74.56 47.06 1.55 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 124.777 3.651 . . . . 0.0 115.318 -170.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.418 ' HE3' HD23 ' A' ' 126' ' ' LEU . 6.4 ptpt 179.79 -5.7 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.065 1 C-N-CA 133.212 4.605 . . . . 0.0 113.852 165.195 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -134.47 177.46 7.75 Favored 'General case' 0 CA--C 1.559 1.316 0 C-N-CA 127.363 2.265 . . . . 0.0 111.227 -166.263 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -109.73 -4.77 15.89 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 127.664 2.385 . . . . 0.0 112.538 -175.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -84.22 -113.11 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.251 1.42 . . . . 0.0 108.304 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.432 HH21 HG13 ' A' ' 103' ' ' VAL . 21.8 ttp180 91.68 119.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 127.475 2.31 . . . . 0.0 108.857 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m170 -57.03 159.23 4.37 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 121.498 -0.751 . . . . 0.0 109.692 168.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p -41.97 -33.22 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.374 1.47 . . . . 0.0 113.635 176.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -146.8 123.05 1.71 Allowed Glycine 0 CA--C 1.534 1.26 0 CA-C-O 122.415 1.008 . . . . 0.0 112.426 165.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -158.15 96.46 1.45 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 129.509 3.124 . . . . 0.0 107.42 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -96.07 52.37 1.29 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 122.028 0.918 . . . . 0.0 110.353 178.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.68 -114.55 0.94 Allowed Glycine 0 CA--C 1.526 0.76 0 C-N-CA 126.35 1.929 . . . . 0.0 113.467 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -133.37 138.46 46.32 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.78 1.232 . . . . 0.0 112.529 172.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.4 m -91.23 143.55 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 127.153 2.181 . . . . 0.0 109.723 171.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.6 m -122.39 123.59 41.69 Favored 'General case' 0 N--CA 1.474 0.742 0 O-C-N 120.848 -1.157 . . . . 0.0 110.424 -172.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.14 159.25 15.06 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 114.613 1.338 . . . . 0.0 114.613 -175.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.433 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 37.5 t70 -82.69 175.26 10.28 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.858 2.063 . . . . 0.0 112.381 169.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.449 ' H ' ' HE2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -71.44 -16.37 62.37 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.516 1.126 . . . . 0.0 113.795 172.336 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.59 -13.32 61.36 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 121.967 0.889 . . . . 0.0 109.92 166.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.18 -4.43 58.7 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 127.635 2.54 . . . . 0.0 114.473 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.9 p -91.59 127.75 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 120.946 2.373 . . . . 0.0 114.633 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.11 119.81 32.73 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 163.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -87.6 140.43 29.52 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 172.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.64 131.39 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 124.477 1.111 . . . . 0.0 112.328 -168.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.0 p -157.21 60.3 0.51 Allowed 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.39 1.476 . . . . 0.0 113.383 -176.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.0 mp -95.99 142.53 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 119.446 -2.033 . . . . 0.0 112.847 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -117.09 136.79 52.72 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 125.828 1.651 . . . . 0.0 108.424 168.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -153.82 146.16 23.92 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.896 1.279 . . . . 0.0 111.794 -169.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 32.5 t -118.69 55.01 0.93 Allowed 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.084 -0.962 . . . . 0.0 113.091 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.432 HG13 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -139.45 -31.37 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 166.484 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -97.18 159.53 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 122.451 1.119 . . . . 0.0 112.208 172.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 53.8 p -156.94 163.18 39.42 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 125.642 1.577 . . . . 0.0 110.062 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.3 mt -82.4 73.39 9.44 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 122.341 1.067 . . . . 0.0 108.874 171.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -132.85 157.74 44.27 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.091 2.156 . . . . 0.0 107.67 170.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -116.87 41.94 1.98 Allowed Glycine 0 N--CA 1.472 1.09 0 C-N-CA 124.847 1.213 . . . . 0.0 113.45 -170.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.17 -88.52 0.51 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 127.381 2.273 . . . . 0.0 106.858 -178.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.79 12.83 13.08 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 126.016 1.726 . . . . 0.0 110.99 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -92.09 -160.82 0.77 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 120.467 -1.396 . . . . 0.0 112.176 173.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 8.3 pt -94.08 -13.47 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 N-CA-C 117.017 2.228 . . . . 0.0 117.017 -168.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.3 mm -73.1 125.93 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 122.326 2.33 . . . . 0.0 110.482 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.76 -0.66 81.44 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 117.782 -1.565 . . . . 0.0 113.917 -173.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 30.9 ttp180 -92.18 167.61 11.92 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.435 1.894 . . . . 0.0 110.573 176.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -113.6 163.19 15.28 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 125.582 1.553 . . . . 0.0 112.639 -176.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 41.7 tp -137.29 126.18 24.15 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 127.426 2.29 . . . . 0.0 110.452 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.5 p -100.21 140.21 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 126.456 1.903 . . . . 0.0 110.987 173.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -107.27 143.05 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 CA-C-O 121.676 0.751 . . . . 0.0 109.313 165.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -122.27 162.85 20.7 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.985 1.714 . . . . 0.0 111.558 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 -27.41 44.84 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 120.264 -1.522 . . . . 0.0 114.848 -167.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 20.7 mmtm -130.5 -175.63 3.71 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.758 2.072 . . . . 0.0 114.357 -171.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.45 153.51 31.23 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.718 1.207 . . . . 0.0 111.79 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -102.38 131.53 48.96 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.405 1.082 . . . . 0.0 110.889 -174.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -78.82 -31.98 46.07 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.352 1.861 . . . . 0.0 113.479 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.418 HD23 ' HE3' ' A' ' 75' ' ' LYS . 2.7 mm? 56.0 63.48 2.01 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.353 1.861 . . . . 0.0 114.803 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.0 10.21 64.85 Favored Glycine 0 N--CA 1.467 0.764 0 N-CA-C 120.065 2.786 . . . . 0.0 120.065 161.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.3 pptp? -148.33 -5.6 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 119.468 3.136 . . . . 0.0 119.468 -165.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.06 27.96 0.79 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 120.881 1.673 . . . . 0.0 116.035 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.96 -23.68 2.57 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.566 1.555 . . . . 0.0 116.508 171.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -95.88 165.45 12.27 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 119.717 1.759 . . . . 0.0 111.777 -173.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -49.96 -57.88 6.61 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.993 1.317 . . . . 0.0 109.24 168.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.493 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 7.8 mm-40 -50.83 -38.77 50.79 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 126.297 1.839 . . . . 0.0 112.803 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 20.1 m -62.51 -32.09 72.96 Favored 'General case' 0 N--CA 1.464 0.259 0 O-C-N 121.081 -1.012 . . . . 0.0 113.432 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.273 1.6 t -118.17 -10.62 10.25 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 117.324 -1.322 . . . . 0.0 113.988 -175.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . 0.256 0.6 OUTLIER -90.81 -34.1 15.44 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 120.469 1.486 . . . . 0.0 113.306 168.72 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.493 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 0.2 OUTLIER -128.78 -17.58 4.0 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 126.042 1.737 . . . . 0.0 114.993 -176.593 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 96.61 12.64 50.16 Favored Glycine 0 N--CA 1.466 0.655 0 CA-C-N 120.454 1.479 . . . . 0.0 114.644 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 61.72 7.73 2.07 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 119.711 1.756 . . . . 0.0 113.832 177.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.19 10.5 0.02 OUTLIER 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 118.816 2.895 . . . . 0.0 118.816 -164.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.48 -160.4 32.98 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 126.31 1.909 . . . . 0.0 113.588 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.5 t -55.04 148.83 12.98 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.954 -0.733 . . . . 0.0 111.584 176.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.86 128.95 37.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 170.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.91 -119.23 0.3 Allowed 'General case' 0 C--O 1.238 0.497 0 O-C-N 124.382 1.051 . . . . 0.0 109.728 173.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.27 151.91 46.23 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-O 122.425 1.107 . . . . 0.0 112.02 -172.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.6 t -154.24 143.28 21.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.334 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.93 151.59 23.09 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 -169.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.454 ' CG1' ' HB ' ' B' ' 148' ' ' VAL . 2.7 p -79.52 156.2 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.126 0.97 . . . . 0.0 111.885 172.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.4 mm -103.22 111.08 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.59 1.156 . . . . 0.0 111.872 170.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.07 159.96 13.47 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.965 1.269 . . . . 0.0 112.576 175.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.53 139.19 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.147 -1.208 . . . . 0.0 112.231 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.21 -141.34 0.23 Allowed 'General case' 0 CA--C 1.549 0.933 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 161.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.471 0.59 0 C-N-CA 124.835 1.254 . . . . 0.0 111.595 168.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.557 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 88.6 m -77.55 99.87 5.88 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.046 1.339 . . . . 0.0 107.754 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 33.9 mtmm -117.05 132.63 56.64 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 123.954 0.902 . . . . 0.0 113.363 -170.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.67 157.69 46.0 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 129.931 3.292 . . . . 0.0 109.67 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 33.5 t -136.32 114.13 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.577 1.18 . . . . 0.0 110.853 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.58 96.05 6.05 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 113.823 -1.535 . . . . 0.0 107.628 167.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 34.4 m -86.03 115.55 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 165.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.4 mp -98.08 136.13 38.77 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.688 -174.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -157.97 121.8 4.08 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 119.741 1.155 . . . . 0.0 113.894 165.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -84.74 -115.41 0.72 Allowed Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 168.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -143.08 128.97 19.48 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.813 2.845 . . . . 0.0 106.011 -168.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.06 179.42 50.98 Favored Glycine 0 CA--C 1.537 1.421 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -167.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.45 49.56 2.68 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 125.293 3.995 . . . . 0.0 112.209 -176.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.65 112.65 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 126.334 1.853 . . . . 0.0 108.655 174.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 pm0 -158.71 166.53 31.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.651 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.96 171.92 35.05 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-O 122.133 0.851 . . . . 0.0 112.456 168.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 pp -121.63 122.76 67.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 166.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mm -131.36 101.9 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.38 148.32 39.29 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.249 1.02 . . . . 0.0 110.162 175.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.4 m-85 -126.61 116.37 20.91 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.171 1.789 . . . . 0.0 108.762 169.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.402 ' OE2' ' HE2' ' B' ' 23' ' ' LYS . 4.8 tm-20 -116.45 120.84 40.06 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 126.301 1.84 . . . . 0.0 112.537 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -113.92 130.01 56.55 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 122.127 0.965 . . . . 0.0 112.273 169.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.438 ' N ' ' HE2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -87.17 -28.73 22.26 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.077 0.951 . . . . 0.0 112.474 -172.122 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -158.36 136.07 10.4 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 128.046 2.538 . . . . 0.0 107.71 168.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.8 t -47.62 -42.35 24.0 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 129.048 2.939 . . . . 0.0 113.495 -176.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -84.92 -7.67 59.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.057 1.343 . . . . 0.0 113.25 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.3 -167.71 42.13 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 125.521 1.534 . . . . 0.0 112.148 173.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . 0.406 ' O ' ' HE3' ' B' ' 23' ' ' LYS . 20.7 Cg_endo -84.51 176.66 6.21 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.305 2.67 . . . . 0.0 111.669 178.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.82 143.46 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 125.817 1.647 . . . . 0.0 109.4 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 14.9 tttp -107.78 130.58 54.96 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.352 1.061 . . . . 0.0 109.567 168.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.57 126.5 74.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 126.025 1.73 . . . . 0.0 108.495 -177.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -148.28 160.5 42.91 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -177.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.91 -149.26 21.26 Favored Glycine 0 C--N 1.333 0.397 0 C-N-CA 124.077 0.846 . . . . 0.0 111.868 170.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -150.82 128.78 11.76 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -171.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 mp -96.33 136.52 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.646 1.179 . . . . 0.0 109.213 169.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.4 mtpt -130.52 154.4 47.84 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 112.521 -178.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.11 -0.19 57.31 Favored Glycine 0 N--CA 1.475 1.235 0 C-N-CA 124.942 1.258 . . . . 0.0 113.332 -170.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 91.1 mt -78.49 149.01 33.25 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 124.738 1.215 . . . . 0.0 112.017 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -78.17 149.28 33.78 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 165.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.63 141.34 32.2 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 126.614 1.966 . . . . 0.0 113.064 -178.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.87 -168.24 18.0 Favored Glycine 0 N--CA 1.472 1.06 0 O-C-N 120.89 -1.131 . . . . 0.0 113.817 -177.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.478 HD11 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -82.02 138.93 34.77 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 128.011 2.525 . . . . 0.0 115.966 -167.837 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -137.04 131.73 33.21 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 128.58 2.752 . . . . 0.0 109.728 -174.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.43 161.6 54.27 Favored Glycine 0 N--CA 1.47 0.96 0 C-N-CA 124.672 1.129 . . . . 0.0 114.632 -172.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -153.38 118.94 5.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.651 1.225 . . . . 0.0 113.128 -168.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -157.33 150.02 23.21 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 119.893 -1.754 . . . . 0.0 115.248 177.187 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -104.93 117.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.406 1.483 . . . . 0.0 110.097 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -98.36 146.67 25.46 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.853 2.061 . . . . 0.0 109.799 -173.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -70.32 148.38 48.55 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.494 -171.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 77.83 156.66 0.17 Allowed 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 127.65 2.38 . . . . 0.0 112.498 -173.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.5 -1.3 81.94 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.724 168.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -76.92 115.89 17.11 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 118.782 1.291 . . . . 0.0 110.823 -174.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.558 ' ND2' ' HG1' ' B' ' 116' ' ' THR 0.413 0.0 OUTLIER -144.21 43.64 1.43 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 123.502 1.62 . . . . 0.0 113.992 164.293 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.3 0.5 OUTLIER . . . . . 0 N--CA 1.455 -0.217 0 CA-C-N 112.58 -2.1 . . . . 0.0 111.936 174.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.745 0 N-CA-C 112.543 0.571 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.84 -63.93 3.56 Favored Glycine 0 CA--C 1.539 1.549 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.491 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -89.77 -180.0 1.99 Allowed 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 124.916 3.744 . . . . 0.0 111.959 169.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -79.67 128.74 33.78 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-O 123.201 1.477 . . . . 0.0 111.925 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -63.41 127.72 32.58 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 113.116 -1.857 . . . . 0.0 108.329 163.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 -121.19 58.48 7.53 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 123.675 0.79 . . . . 0.0 112.158 -171.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.31 -11.72 29.44 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.426 2.084 . . . . 0.0 113.873 -178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.3 mp -92.97 -8.27 43.57 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 114.121 1.156 . . . . 0.0 114.121 173.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.8 t 61.68 74.81 0.43 Allowed 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 119.957 1.253 . . . . 0.0 113.432 175.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -167.35 179.14 5.16 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.33 1.452 . . . . 0.0 112.562 -171.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HZ1' ' CD ' ' B' ' 78' ' ' GLU . 3.2 mppt? -85.55 171.43 11.73 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.995 1.718 . . . . 0.0 112.767 177.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -86.26 146.54 26.48 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.921 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.82 -108.21 0.49 Allowed Glycine 0 C--N 1.336 0.534 0 CA-C-O 119.063 -0.854 . . . . 0.0 114.875 165.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.59 -42.16 2.01 Favored Glycine 0 CA--C 1.555 2.589 0 CA-C-O 118.182 -1.343 . . . . 0.0 114.127 -168.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -84.32 15.38 2.18 Favored 'Trans proline' 0 CA--C 1.553 1.474 0 C-N-CA 124.241 3.294 . . . . 0.0 116.712 171.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -39.42 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 128.143 2.577 . . . . 0.0 110.376 165.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.1 137.01 56.75 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 161.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -99.82 -16.58 18.02 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.298 1.439 . . . . 0.0 111.258 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . 0.456 ' CD ' ' HZ1' ' B' ' 70' ' ' LYS . 26.6 mt-10 -79.4 -60.18 2.47 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.56 -0.712 . . . . 0.0 110.464 -171.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.2 ttt-85 71.91 127.47 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.528 1.931 . . . . 0.0 112.374 168.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -76.62 173.02 12.08 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 119.237 -2.164 . . . . 0.0 111.669 168.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.7 p -76.85 134.86 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.597 -1.314 . . . . 0.0 109.376 167.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.23 9.13 86.93 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 126.447 1.975 . . . . 0.0 115.801 -174.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 61.5 m-20 -78.25 114.96 17.62 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-N 119.902 1.851 . . . . 0.0 111.924 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 56.8 mt -99.57 179.06 4.67 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.812 0.845 . . . . 0.0 110.086 168.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -109.9 165.2 12.32 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 125.074 1.321 . . . . 0.0 112.445 174.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -74.63 150.84 39.44 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 -168.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.4 m -114.67 128.66 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 128.373 2.669 . . . . 0.0 111.097 -172.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.33 128.16 45.42 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.739 -1.225 . . . . 0.0 111.724 -178.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.05 135.06 35.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 169.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.06 154.47 23.2 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.626 1.97 . . . . 0.0 109.438 167.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.416 ' HZ1' ' CG ' ' B' ' 92' ' ' ASP . 1.7 pptp? -45.63 -21.8 0.13 Allowed 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 129.037 2.935 . . . . 0.0 116.847 176.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . 0.416 ' CG ' ' HZ1' ' B' ' 91' ' ' LYS . 77.8 m-20 -76.76 9.62 2.72 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.356 1.062 . . . . 0.0 111.408 172.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.2 35.54 42.97 Favored Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.338 2.399 . . . . 0.0 112.324 175.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 1.8 p -142.93 126.99 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 119.017 1.408 . . . . 0.0 114.65 -172.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.46 119.46 32.58 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 165.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.7 t0 -79.64 154.23 28.82 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.592 1.157 . . . . 0.0 109.724 169.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.3 144.2 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 168.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.7 p -156.24 58.5 0.58 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.635 1.574 . . . . 0.0 112.177 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 28.9 mt -80.35 148.68 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 120.237 -1.539 . . . . 0.0 111.334 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -128.84 137.5 51.52 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.908 2.083 . . . . 0.0 105.591 166.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -154.78 136.79 14.65 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.476 1.111 . . . . 0.0 111.604 -169.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.95 49.06 1.02 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 123.518 0.727 . . . . 0.0 112.932 178.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 t -149.46 20.15 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 124.858 1.263 . . . . 0.0 111.731 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -148.62 169.91 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 128.787 2.835 . . . . 0.0 107.944 169.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -156.88 157.3 34.64 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.837 -1.164 . . . . 0.0 110.129 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -99.2 60.79 1.2 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.121 1.369 . . . . 0.0 108.837 -178.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.8 m -84.88 -94.21 0.08 Allowed 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.995 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 163.62 60.66 0.02 OUTLIER Glycine 0 N--CA 1.473 1.139 0 O-C-N 120.836 -1.165 . . . . 0.0 113.263 -172.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . 0.553 ' CG ' ' H ' ' B' ' 110' ' ' HIS . 9.2 p-10 -161.24 -108.95 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 123.136 1.446 . . . . 0.0 108.978 -164.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . 0.553 ' H ' ' CG ' ' B' ' 109' ' ' ASP . 14.6 m-70 -107.57 -28.92 9.48 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 130.001 3.32 . . . . 0.0 110.821 173.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 79.9 p -48.44 -65.28 0.59 Allowed 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 128.222 2.609 . . . . 0.0 116.759 -167.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 33.8 mm -150.06 -51.46 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 128.003 2.521 . . . . 0.0 109.513 169.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 49.8 mm -65.3 120.69 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 169.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.78 10.86 69.08 Favored Glycine 0 CA--C 1.534 1.266 0 N-CA-C 114.585 0.594 . . . . 0.0 114.585 -170.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 20.2 ttt85 -108.79 -179.86 3.98 Favored 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.94 2.496 . . . . 0.0 109.672 171.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.558 ' HG1' ' ND2' ' B' ' 53' ' ' ASN . 14.6 t -148.11 130.35 15.56 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.132 -1.605 . . . . 0.0 112.938 179.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -101.53 134.09 45.19 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 119.294 0.952 . . . . 0.0 110.931 -175.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -118.74 137.09 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.204 1.402 . . . . 0.0 109.52 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.42 130.03 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-O 122.646 1.212 . . . . 0.0 108.142 168.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -107.22 152.98 23.36 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.642 1.977 . . . . 0.0 110.108 -172.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.77 -45.34 44.46 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 119.751 -1.843 . . . . 0.0 114.67 -166.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.11 171.55 7.32 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 120.949 1.704 . . . . 0.0 112.061 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.59 149.74 7.75 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 124.037 0.935 . . . . 0.0 112.538 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -75.87 134.44 40.31 Favored 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 168.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -41.18 68.77 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 175.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.3 mt 67.87 37.56 3.1 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 125.867 1.667 . . . . 0.0 111.44 170.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -171.2 -75.16 0.04 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.211 0.91 . . . . 0.0 113.441 169.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.8 ttpt -162.04 98.1 1.05 Allowed 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 126.85 2.06 . . . . 0.0 113.605 173.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.87 -135.98 0.71 Allowed Glycine 0 CA--C 1.537 1.413 0 CA-C-O 122.247 0.915 . . . . 0.0 113.417 169.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.89 -9.35 52.52 Favored Glycine 0 N--CA 1.474 1.172 0 N-CA-C 118.448 2.139 . . . . 0.0 118.448 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -164.8 175.47 9.61 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 120.514 2.157 . . . . 0.0 111.59 -169.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -48.07 -54.74 12.1 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 113.396 0.887 . . . . 0.0 113.396 -170.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -57.58 -10.52 1.55 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 114.476 1.287 . . . . 0.0 114.476 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.9 p -58.05 -49.96 75.1 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.884 1.674 . . . . 0.0 112.964 167.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 19.0 p -93.24 -18.1 22.9 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 178.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -85.12 -35.68 21.62 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.669 0.788 . . . . 0.0 112.867 176.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 59.8 p -115.33 -112.17 0.34 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.981 1.312 . . . . 0.0 107.479 167.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -142.6 21.45 2.37 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.875 2.179 . . . . 0.0 112.187 169.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.71 13.79 3.68 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.517 1.927 . . . . 0.0 113.466 -171.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.34 33.18 0.02 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 128.951 2.901 . . . . 0.0 118.559 -165.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.86 -54.8 3.01 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 126.905 2.193 . . . . 0.0 115.568 169.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -173.51 175.91 2.91 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 125.848 1.659 . . . . 0.0 111.97 -170.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -127.2 115.08 18.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.249 1.419 . . . . 0.0 110.461 -169.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.8 pp -110.53 -37.17 5.56 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -170.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.57 158.34 33.74 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 119.558 1.072 . . . . 0.0 113.136 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 20.3 p -156.45 163.78 39.03 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.471 2.309 . . . . 0.0 110.24 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.92 142.43 8.69 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 127.075 2.274 . . . . 0.0 110.246 171.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.454 ' HB ' ' CG1' ' A' ' 148' ' ' VAL . 1.6 t -88.17 146.8 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 CA-C-N 118.967 1.383 . . . . 0.0 108.68 -174.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.5 mm -77.33 120.56 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.013 -1.054 . . . . 0.0 112.94 -169.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.47 -172.4 18.77 Favored Glycine 0 N--CA 1.47 0.958 0 C-N-CA 125.824 1.678 . . . . 0.0 113.567 175.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -133.43 160.39 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 173.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.88 -39.31 0.09 Allowed 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 125.902 1.681 . . . . 0.0 111.368 168.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 . . . . . 0 C--O 1.241 0.612 0 C-N-CA 126.31 1.844 . . . . 0.0 112.824 169.937 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.2 t . . . . . 0 N--CA 1.467 0.407 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.2 102.71 14.16 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.929 -0.482 . . . . 0.0 112.022 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.01 166.67 22.54 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.784 0.72 . . . . 0.0 109.339 167.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.1 t -138.69 140.69 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 122.309 1.052 . . . . 0.0 112.798 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.85 113.15 19.24 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 114.089 -1.414 . . . . 0.0 109.12 165.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.03 80.63 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 127.276 2.23 . . . . 0.0 108.476 167.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -73.84 157.76 35.76 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.007 0.923 . . . . 0.0 111.238 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -148.66 158.51 44.19 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.39 162.68 13.65 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 127.549 2.5 . . . . 0.0 107.54 166.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.438 ' CG ' ' HZ3' ' B' ' 9' ' ' LYS . 2.1 m-20 -76.33 57.66 1.2 Allowed 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 126.837 2.055 . . . . 0.0 111.85 176.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.13 -167.53 40.0 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 128.436 2.922 . . . . 0.0 109.553 -175.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -80.1 42.55 1.34 Allowed 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 125.224 3.949 . . . . 0.0 112.306 -172.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -131.42 129.63 62.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 124.44 1.096 . . . . 0.0 109.165 -175.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -158.66 169.36 24.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.42 1.888 . . . . 0.0 109.074 -172.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 135.79 4.55 Favored Glycine 0 C--O 1.224 -0.469 0 C-N-CA 121.321 -0.466 . . . . 0.0 112.577 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.08 132.11 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 168.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 15.2 mm -139.09 112.77 6.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 C-N-CA 123.835 0.854 . . . . 0.0 110.838 173.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -78.49 144.32 35.83 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.976 0.91 . . . . 0.0 110.453 165.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -123.56 99.12 6.15 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.744 1.618 . . . . 0.0 109.886 172.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.88 105.34 11.09 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.664 1.186 . . . . 0.0 110.742 -179.629 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -79.29 83.1 5.37 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 120.926 -1.109 . . . . 0.0 108.537 169.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.432 ' HZ2' ' CD ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -59.51 -50.71 72.85 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 118.708 -0.663 . . . . 0.0 111.169 -179.855 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.432 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 13.3 mp0 -132.38 136.48 46.84 Favored 'General case' 0 C--O 1.224 -0.241 0 C-N-CA 124.271 1.028 . . . . 0.0 108.876 168.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.1 p -67.08 -4.73 10.7 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 126.163 1.785 . . . . 0.0 114.954 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.46 1.93 9.6 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 126.743 2.017 . . . . 0.0 112.06 173.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.45 -153.2 12.52 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.664 1.602 . . . . 0.0 111.192 -176.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -86.24 173.06 6.9 Favored 'Trans proline' 0 N--CA 1.451 -1.01 0 C-N-CA 122.788 2.325 . . . . 0.0 111.761 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.95 134.06 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.759 1.624 . . . . 0.0 108.498 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.559 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 14.4 tttp -101.24 121.78 42.48 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 169.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.4 t -121.14 118.82 57.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 125.924 1.689 . . . . 0.0 109.095 -168.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -140.65 161.9 36.65 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -178.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.65 -150.73 22.97 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 124.783 1.182 . . . . 0.0 112.415 -179.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 43.1 p -158.09 136.04 10.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -171.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -109.7 112.93 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.668 1.187 . . . . 0.0 108.494 178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -120.79 135.86 55.04 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.955 1.302 . . . . 0.0 111.446 -168.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.67 -2.08 15.47 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 127.191 2.329 . . . . 0.0 113.559 -173.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mp -69.0 -178.27 1.21 Allowed 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 125.829 1.651 . . . . 0.0 110.992 169.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -115.11 156.22 25.62 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 127.962 2.505 . . . . 0.0 105.266 164.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -48.37 146.15 3.0 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 127.032 2.133 . . . . 0.0 114.118 -175.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.83 -177.4 32.86 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 122.084 0.824 . . . . 0.0 113.393 -178.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.437 ' H ' HD11 ' A' ' 42' ' ' LEU . 1.1 mp -70.13 150.26 46.71 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.449 2.3 . . . . 0.0 112.068 -169.489 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -147.28 124.03 11.21 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.021 1.728 . . . . 0.0 110.32 175.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.43 155.43 32.44 Favored Glycine 0 N--CA 1.491 2.316 0 CA-C-N 120.281 1.4 . . . . 0.0 114.398 -174.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -146.1 102.11 3.59 Favored 'General case' 0 CA--C 1.552 1.051 0 CA-C-O 122.76 1.267 . . . . 0.0 113.77 -167.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -127.34 133.16 50.11 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.89 94.71 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 126.408 1.883 . . . . 0.0 110.355 174.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -73.75 108.84 6.82 Favored 'General case' 0 CA--C 1.557 1.242 0 O-C-N 120.604 -1.31 . . . . 0.0 114.36 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -31.03 106.23 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 127.408 2.283 . . . . 0.0 113.208 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 148.44 173.86 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 129.792 3.237 . . . . 0.0 109.758 -169.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.502 ' HA3' ' H ' ' B' ' 151' ' ' ILE . . . -116.85 -2.63 18.78 Favored Glycine 0 CA--C 1.549 2.201 0 C-N-CA 126.292 1.901 . . . . 0.0 109.859 160.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.52 ' C ' HD21 ' A' ' 53' ' ' ASN . 0.8 OUTLIER -75.69 147.22 39.57 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 128.008 2.523 . . . . 0.0 111.75 170.271 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.52 HD21 ' C ' ' A' ' 52' ' ' ASP 0.312 0.1 OUTLIER -173.53 17.47 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 119.041 2.978 . . . . 0.0 119.041 166.627 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.35 -12.52 32.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 120.083 -1.636 . . . . 0.0 114.315 -165.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.34 18.14 22.47 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.772 1.229 . . . . 0.0 112.678 172.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.66 -123.43 24.72 Favored Glycine 0 CA--C 1.529 0.933 0 O-C-N 120.697 -1.252 . . . . 0.0 112.243 174.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.3 m -72.5 -9.33 58.43 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 175.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -14.92 52.55 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 125.184 1.394 . . . . 0.0 111.407 169.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.7 m -95.28 -159.51 0.72 Allowed 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 127.41 2.284 . . . . 0.0 109.52 168.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.13 104.69 0.03 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 128.212 2.605 . . . . 0.0 116.374 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -63.07 166.72 23.77 Favored Glycine 0 CA--C 1.545 1.92 0 C-N-CA 125.869 1.699 . . . . 0.0 114.805 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -62.11 96.89 0.15 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 125.07 3.847 . . . . 0.0 113.173 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.1 p80 47.82 64.49 1.61 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 126.124 1.769 . . . . 0.0 113.24 169.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -32.11 137.83 0.05 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.383 1.873 . . . . 0.0 115.439 -178.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -106.01 63.66 0.16 Allowed Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 126.559 1.944 . . . . 0.0 113.084 177.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -62.78 -35.77 66.27 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.612 2.208 . . . . 0.0 111.898 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.1 tp -77.76 -5.18 49.79 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 124.727 1.211 . . . . 0.0 112.869 173.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t 71.27 51.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.945 2.098 . . . . 0.0 112.497 172.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -108.19 171.71 7.25 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -169.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.7 mttp -81.09 162.71 23.6 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.468 1.507 . . . . 0.0 109.521 165.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -72.36 151.72 42.51 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 121.012 -1.055 . . . . 0.0 112.151 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.73 -138.45 6.39 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 116.137 1.215 . . . . 0.0 116.137 169.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.77 -108.88 0.6 Allowed Glycine 0 CA--C 1.544 1.856 0 CA-C-O 116.835 -2.092 . . . . 0.0 114.934 -168.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -52.33 -3.65 0.11 Allowed 'Trans proline' 0 CA--C 1.546 1.103 1 C-N-CA 126.443 4.762 . . . . 0.0 120.068 -169.333 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.48 2.89 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 127.693 2.397 . . . . 0.0 112.594 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -123.91 175.81 6.7 Favored 'General case' 0 CA--C 1.557 1.249 0 C-N-CA 129.091 2.957 . . . . 0.0 109.02 -174.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -116.55 -13.71 10.9 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.671 2.388 . . . . 0.0 111.143 -175.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -91.59 -65.3 1.02 Allowed 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.769 1.228 . . . . 0.0 112.555 -168.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.457 HH21 ' CG ' ' A' ' 101' ' ' ASP . 1.4 ttt-85 52.91 77.07 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 120.088 1.313 . . . . 0.0 111.48 171.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -46.91 153.32 0.42 Allowed 'General case' 0 N--CA 1.478 0.971 0 O-C-N 120.264 -1.523 . . . . 0.0 112.298 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 p -43.95 -40.62 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 120.125 1.33 . . . . 0.0 113.715 -176.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -97.08 34.2 5.24 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 126.863 2.173 . . . . 0.0 117.21 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -114.68 128.17 56.16 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.992 1.717 . . . . 0.0 110.426 176.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.1 mt -122.41 53.75 1.23 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-O 122.031 0.92 . . . . 0.0 108.555 168.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 62.2 -132.53 45.49 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.411 1.482 . . . . 0.0 114.229 175.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -143.45 154.86 44.11 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.573 1.149 . . . . 0.0 110.591 175.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.94 104.04 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.618 1.567 . . . . 0.0 109.733 -175.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -91.68 125.46 36.41 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 124.01 0.924 . . . . 0.0 109.222 -175.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.97 156.05 17.78 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -173.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -82.85 166.35 19.03 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.037 1.735 . . . . 0.0 110.206 167.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.6 pttt -51.28 -24.03 4.12 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 127.521 2.328 . . . . 0.0 113.274 167.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -76.78 -0.73 24.91 Favored 'General case' 0 CA--C 1.55 0.954 0 C-N-CA 125.929 1.691 . . . . 0.0 112.016 172.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.21 7.32 84.59 Favored Glycine 0 CA--C 1.52 0.404 0 O-C-N 120.183 -1.573 . . . . 0.0 113.523 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -95.18 123.69 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 125.405 1.482 . . . . 0.0 112.142 174.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.85 134.49 36.16 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 163.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -79.29 150.62 31.46 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 168.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.3 t -131.2 123.24 53.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 113.287 -1.779 . . . . 0.0 109.855 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.1 m -147.12 70.94 1.2 Allowed 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.865 2.066 . . . . 0.0 109.198 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 31.3 mt -116.4 152.37 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 125.502 1.521 . . . . 0.0 111.711 -168.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.559 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 9.6 tt0 -145.48 137.28 25.37 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 127.172 2.189 . . . . 0.0 107.064 174.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.457 ' CG ' HH21 ' A' ' 79' ' ' ARG . 22.7 t70 -154.26 139.4 17.44 Favored 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -167.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -116.59 51.57 0.98 Allowed 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.6 t -128.62 -47.93 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -100.43 176.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.16 0.984 . . . . 0.0 112.005 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -157.94 176.03 13.07 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 120.693 -1.254 . . . . 0.0 110.696 172.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.4 mp -109.69 52.2 0.73 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.803 1.641 . . . . 0.0 109.46 -177.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.3 t -91.24 14.33 14.68 Favored 'General case' 0 CA--C 1.542 0.669 0 O-C-N 120.57 -1.331 . . . . 0.0 114.417 -174.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 102.47 -122.32 7.48 Favored Glycine 0 C--N 1.339 0.698 0 O-C-N 121.527 -0.733 . . . . 0.0 111.652 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -59.09 -52.7 64.59 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 126.934 2.094 . . . . 0.0 114.27 -163.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -88.48 9.43 23.72 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.737 1.615 . . . . 0.0 112.602 -174.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.21 -161.23 0.82 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 125.407 1.483 . . . . 0.0 113.937 -165.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.283 7.4 pt -88.96 1.16 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 175.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 38.8 mm -69.72 132.68 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 163.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.24 -12.11 55.79 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.763 -1.576 . . . . 0.0 115.631 -171.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.662 ' NE ' ' H ' ' A' ' 116' ' ' THR . 1.3 tpm_? -71.51 177.86 3.8 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.699 2.249 . . . . 0.0 108.486 178.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.662 ' H ' ' NE ' ' A' ' 115' ' ' ARG . 1.5 m -140.53 131.58 26.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 126.932 2.093 . . . . 0.0 106.717 175.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -87.22 137.8 32.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 125.542 1.776 . . . . 0.0 106.791 166.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 5.2 p -117.45 124.54 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.624 1.17 . . . . 0.0 108.427 168.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.42 145.18 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 O-C-N 124.94 1.4 . . . . 0.0 109.083 169.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 23.2 m-70 -117.34 161.76 19.01 Favored 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 125.16 1.384 . . . . 0.0 113.134 -170.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.54 -34.25 69.86 Favored 'General case' 0 N--CA 1.478 0.935 0 O-C-N 120.597 -1.314 . . . . 0.0 114.071 179.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.402 ' HE3' ' O ' ' A' ' 139' ' ' ASN . 17.9 ttpp -94.49 156.02 16.66 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 123.064 1.412 . . . . 0.0 113.766 -173.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.58 142.59 17.74 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.744 165.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -93.43 128.6 39.57 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 124.465 1.103 . . . . 0.0 110.641 -178.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.81 -21.65 59.17 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.697 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 72.3 mt 47.86 56.52 7.09 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 127.912 2.485 . . . . 0.0 111.219 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.16 -58.9 0.38 Allowed Glycine 0 N--CA 1.472 1.055 0 C-N-CA 125.864 1.697 . . . . 0.0 113.732 173.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp -126.05 77.55 1.69 Allowed 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 115.226 1.565 . . . . 0.0 115.226 -169.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.559 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -80.57 -95.23 0.4 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 107.196 -2.362 . . . . 0.0 107.196 165.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -150.03 8.58 0.81 Allowed Glycine 0 N--CA 1.474 1.173 0 N-CA-C 117.728 1.851 . . . . 0.0 117.728 -174.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.7 p30 -161.2 -177.7 6.23 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 120.4 2.1 . . . . 0.0 111.111 -176.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.435 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 20.9 tt0 -55.77 -51.89 65.85 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.207 0.912 . . . . 0.0 112.727 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.458 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 1.9 mm-40 -59.38 -23.84 62.93 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -170.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.559 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 27.3 m -57.15 -29.31 63.51 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 172.233 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -100.25 -15.14 18.18 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 118.067 -0.968 . . . . 0.0 113.473 173.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.435 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 94.7 mttt -86.55 -85.37 0.16 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 119.968 1.258 . . . . 0.0 110.77 171.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.458 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 62.5 p -73.24 -11.47 60.52 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 175.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.48 9.06 79.74 Favored Glycine 0 N--CA 1.467 0.705 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 -165.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.402 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 4.8 t-20 52.53 21.92 1.97 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.501 1.92 . . . . 0.0 109.135 -166.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.97 -11.78 21.13 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 114.726 1.38 . . . . 0.0 114.726 -166.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.93 -156.12 24.22 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 124.698 1.142 . . . . 0.0 113.072 169.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -67.98 154.83 40.79 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 126.55 1.94 . . . . 0.0 111.609 -175.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.62 129.85 34.84 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.581 0.752 . . . . 0.0 109.192 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.11 -64.19 1.1 Allowed 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.124 1.77 . . . . 0.0 110.276 -170.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.7 149.33 45.0 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 125.071 1.348 . . . . 0.0 110.531 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 63.7 m -139.08 146.63 40.98 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.047 1.739 . . . . 0.0 111.249 -176.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.08 142.93 8.72 Favored Glycine 0 N--CA 1.474 1.183 0 C-N-CA 124.804 1.192 . . . . 0.0 112.11 169.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.4 t -92.69 135.34 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 125.043 1.337 . . . . 0.0 109.312 -175.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.6 mm -77.55 115.77 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.718 -169.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.09 158.1 14.63 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.818 1.199 . . . . 0.0 113.426 -177.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -75.14 134.98 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.135 0.974 . . . . 0.0 113.326 -178.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.62 -177.35 6.53 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.711 2.404 . . . . 0.0 108.544 -170.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 . . . . . 0 N--CA 1.471 0.577 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 167.89 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.427 0 N-CA-C 113.013 0.745 . . . . 0.0 113.013 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.8 p -97.76 114.85 26.95 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.137 1.446 . . . . 0.0 108.879 171.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -113.07 125.37 54.31 Favored 'General case' 0 C--O 1.24 0.602 0 C-N-CA 125.098 1.359 . . . . 0.0 112.083 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.99 168.89 18.61 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 176.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 p -156.12 101.94 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 127.771 2.429 . . . . 0.0 107.836 -175.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.69 114.39 26.03 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.913 1.285 . . . . 0.0 111.403 -172.178 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.97 72.61 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 125.17 1.388 . . . . 0.0 109.585 -172.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.3 mp -77.92 115.71 17.87 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 121.437 -0.79 . . . . 0.0 109.838 178.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . 0.438 ' HZ3' ' CG ' ' A' ' 11' ' ' ASP . 4.1 ttpp -161.79 120.13 2.31 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.197 1.799 . . . . 0.0 111.021 164.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -137.07 -69.53 0.05 OUTLIER Glycine 0 N--CA 1.467 0.708 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 169.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.95 76.99 2.84 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 127.703 2.401 . . . . 0.0 110.594 -169.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.94 -102.06 0.05 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.424 1.964 . . . . 0.0 112.403 174.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -85.65 0.55 8.46 Favored 'Trans proline' 0 C--N 1.353 0.807 1 C-N-CA 125.783 4.322 . . . . 0.0 115.469 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.33 120.82 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-N 121.753 2.07 . . . . 0.0 109.486 169.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.99 166.36 24.27 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.132 1.373 . . . . 0.0 110.827 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.11 174.92 33.97 Favored Glycine 0 N--CA 1.466 0.634 0 CA-C-O 123.082 1.379 . . . . 0.0 116.115 173.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 pt -143.08 50.86 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 CA-C-N 112.833 -1.684 . . . . 0.0 112.013 -166.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 13.1 mm -81.46 119.36 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 O-C-N 120.033 -1.667 . . . . 0.0 110.957 -169.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -88.0 154.96 20.08 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.498 1.519 . . . . 0.0 110.414 169.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -143.54 108.05 4.83 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 169.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -98.38 117.82 33.65 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.994 1.109 . . . . 0.0 113.994 -173.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -96.17 139.55 32.16 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.794 1.238 . . . . 0.0 111.165 169.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.447 ' H ' ' HD2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -92.2 -36.15 13.43 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.408 2.283 . . . . 0.0 113.59 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -159.47 136.71 9.69 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 126.961 2.104 . . . . 0.0 109.034 169.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 60.3 p -19.43 -57.13 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 129.109 2.964 . . . . 0.0 116.935 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -95.24 2.91 55.0 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 127.342 2.257 . . . . 0.0 115.531 -172.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.24 168.16 54.44 Favored Glycine 0 CA--C 1.544 1.904 0 O-C-N 120.781 -1.199 . . . . 0.0 113.164 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -67.02 163.66 33.04 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.677 2.918 . . . . 0.0 110.297 170.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 77.4 t -131.26 138.74 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 CA-C-N 119.476 1.034 . . . . 0.0 111.642 -169.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 72.9 mttt -92.48 112.15 23.99 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.23 174.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.51 131.94 32.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 125.214 1.406 . . . . 0.0 109.119 170.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -154.27 165.72 35.42 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 168.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.05 175.92 21.47 Favored Glycine 0 N--CA 1.468 0.798 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -174.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -132.55 165.52 24.19 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -166.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -116.82 126.61 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.915 1.686 . . . . 0.0 107.895 168.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -126.17 132.93 51.7 Favored 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 124.905 1.282 . . . . 0.0 111.073 -177.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.44 -3.04 13.87 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.297 2.38 . . . . 0.0 112.801 -171.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.3 mt -66.93 162.73 21.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.051 0.925 . . . . 0.0 109.483 168.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -77.54 150.9 34.75 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 162.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -50.68 147.02 5.06 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 123.733 0.813 . . . . 0.0 110.306 168.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 104.06 -179.59 25.04 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.75 1.167 . . . . 0.0 113.486 -173.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.491 ' CD2' ' H ' ' B' ' 42' ' ' LEU . 1.9 pt? -84.99 145.28 27.79 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.374 2.67 . . . . 0.0 113.401 -169.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -147.36 147.3 30.17 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 128.88 2.872 . . . . 0.0 111.228 -167.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.11 156.1 49.88 Favored Glycine 0 N--CA 1.479 1.526 0 CA-C-O 117.991 -1.45 . . . . 0.0 113.618 174.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -154.43 98.07 2.07 Favored 'General case' 0 CA--C 1.553 1.07 0 C-N-CA 125.808 1.643 . . . . 0.0 111.623 -173.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -121.36 128.22 52.03 Favored 'General case' 0 N--CA 1.472 0.665 0 O-C-N 120.248 -1.532 . . . . 0.0 113.773 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -80.24 100.43 4.59 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 171.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -68.59 130.27 42.35 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 119.41 -2.056 . . . . 0.0 108.836 -170.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.05 48.67 0.12 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 128.699 2.8 . . . . 0.0 114.179 -165.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 178.66 138.73 0.09 Allowed 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 129.1 2.96 . . . . 0.0 107.054 178.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.09 -5.8 88.96 Favored Glycine 0 N--CA 1.469 0.891 0 CA-C-N 115.214 -0.903 . . . . 0.0 114.912 174.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -79.19 52.43 1.31 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.961 1.704 . . . . 0.0 112.408 -170.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.252 0.0 OUTLIER 175.89 64.98 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 116.686 2.106 . . . . 0.0 116.686 -169.64 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.7 t . . . . . 0 N--CA 1.48 1.029 0 O-C-N 120.425 -1.422 . . . . 0.0 113.282 167.155 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.405 0 CA-C-O 121.564 0.697 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -84.88 -139.83 4.75 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-O 118.54 -1.145 . . . . 0.0 111.268 169.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -72.41 176.32 8.84 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.015 3.143 . . . . 0.0 110.959 173.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.604 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -57.11 100.18 0.04 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 128.556 2.742 . . . . 0.0 109.559 170.052 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -49.62 146.34 4.3 Favored 'General case' 0 CA--C 1.538 0.485 0 O-C-N 124.148 0.905 . . . . 0.0 111.629 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -106.12 60.82 0.16 Allowed Pre-proline 0 CA--C 1.56 1.344 0 C-N-CA 126.334 1.853 . . . . 0.0 115.625 -171.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -61.42 -35.17 84.47 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.913 3.076 . . . . 0.0 113.457 -174.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 63.6 mt -79.65 -1.51 38.56 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.453 1.101 . . . . 0.0 113.542 176.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.3 t 58.37 58.03 3.61 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.597 1.159 . . . . 0.0 113.114 169.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -153.88 179.02 9.27 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -169.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 mtmp? -61.75 173.13 1.07 Allowed 'General case' 0 CA--C 1.541 0.622 0 CA-C-O 122.186 0.993 . . . . 0.0 111.98 174.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.441 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 63.6 t60 -123.09 148.73 45.32 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 116.35 1.982 . . . . 0.0 116.35 -166.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 121.65 -63.72 0.51 Allowed Glycine 0 C--N 1.339 0.709 0 C-N-CA 124.458 1.028 . . . . 0.0 115.278 162.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 88.14 -9.85 73.26 Favored Glycine 0 CA--C 1.548 2.14 1 N-CA-C 123.294 4.078 . . . . 0.0 123.294 168.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -89.26 -5.01 5.76 Favored 'Trans proline' 0 C--N 1.358 1.044 1 CA-C-N 124.605 4.202 . . . . 0.0 112.23 168.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.42 -25.18 0.11 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.319 1.847 . . . . 0.0 110.861 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.08 139.9 50.52 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 122.87 1.319 . . . . 0.0 109.433 164.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -90.44 -22.47 21.4 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 129.527 3.131 . . . . 0.0 113.009 -168.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -98.17 -79.92 0.46 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.21 1.404 . . . . 0.0 109.901 -172.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 87.92 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 127.45 2.3 . . . . 0.0 116.498 164.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -63.99 147.44 52.03 Favored 'General case' 0 N--CA 1.484 1.233 0 O-C-N 119.678 -1.889 . . . . 0.0 108.471 164.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.9 -10.03 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 CA-C-N 122.094 2.224 . . . . 0.0 112.372 -174.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.97 5.46 75.88 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.764 1.65 . . . . 0.0 114.695 169.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -97.9 132.26 43.64 Favored 'General case' 0 C--N 1.322 -0.623 0 O-C-N 119.666 -2.079 . . . . 0.0 111.758 -173.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 81.4 mt -130.35 176.62 7.98 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.697 1.999 . . . . 0.0 106.738 165.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.27 -138.87 6.34 Favored Glycine 0 N--CA 1.471 1.003 0 C-N-CA 123.863 0.744 . . . . 0.0 114.369 -171.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -102.47 151.1 22.69 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.36 1.064 . . . . 0.0 113.369 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -113.51 145.57 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 127.797 2.439 . . . . 0.0 110.728 169.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 54.8 m -134.23 122.54 22.9 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.215 0.916 . . . . 0.0 109.544 -174.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.12 151.56 22.14 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.61 160.25 14.86 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 130.189 3.395 . . . . 0.0 109.5 168.104 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -40.48 -26.66 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 128.616 2.766 . . . . 0.0 117.884 175.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -77.45 7.67 5.15 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.104 1.32 . . . . 0.0 112.029 173.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.9 8.87 87.25 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 127.247 2.356 . . . . 0.0 113.748 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 11.5 p -104.28 121.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 125.103 1.361 . . . . 0.0 112.684 -170.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.34 113.41 25.36 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 164.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -104.18 141.83 35.57 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.831 0.824 . . . . 0.0 111.314 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -117.65 147.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 CA-C-N 113.606 -1.634 . . . . 0.0 113.46 -170.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 17.4 p -161.17 60.0 0.29 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 125.258 1.423 . . . . 0.0 113.75 -175.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 24.4 mt -118.61 145.21 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 O-C-N 119.771 -1.83 . . . . 0.0 112.297 -172.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -104.03 121.53 43.37 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 165.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -112.44 134.87 53.73 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.679 1.192 . . . . 0.0 109.866 174.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.0 p -109.42 50.73 0.77 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.002 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 57.7 t -133.8 -39.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.863 1.665 . . . . 0.0 110.208 169.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.59 163.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-O 123.18 1.467 . . . . 0.0 113.393 176.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 105' ' ' SER . . . . . 0.54 ' H ' ' HB3' ' B' ' 111' ' ' SER . 58.1 m -159.43 147.67 17.61 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 127.14 2.176 . . . . 0.0 108.863 -172.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.1 mp -79.58 97.42 6.48 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 119.013 0.824 . . . . 0.0 109.05 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.8 m -114.07 -33.71 5.62 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.178 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.15 -29.39 10.73 Favored Glycine 0 N--CA 1.469 0.858 0 CA-C-O 118.91 -0.939 . . . . 0.0 111.822 -168.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -154.25 -46.66 0.09 Allowed 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 115.577 1.695 . . . . 0.0 115.577 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -82.61 0.96 40.55 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 126.142 1.777 . . . . 0.0 112.755 -168.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 111' ' ' SER . . . . . 0.54 ' HB3' ' H ' ' B' ' 105' ' ' SER . 4.9 m -163.85 -78.11 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 177.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.4 pt -129.17 167.3 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 O-C-N 120.749 -1.22 . . . . 0.0 109.797 167.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.2 mm 77.93 146.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 C-N-CA 129.452 3.101 . . . . 0.0 106.84 -162.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.95 -45.76 2.29 Favored Glycine 0 N--CA 1.468 0.8 0 CA-C-O 118.985 -0.897 . . . . 0.0 113.698 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.8 mtp85 -75.85 176.62 7.64 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.961 1.304 . . . . 0.0 111.117 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.44 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 5.9 t -124.5 164.95 18.67 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 117.529 -1.224 . . . . 0.0 110.931 -173.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -127.11 140.56 52.18 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 119.619 1.1 . . . . 0.0 108.886 167.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 p -122.8 136.2 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.345 1.458 . . . . 0.0 110.101 172.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.07 158.73 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.486 1.114 . . . . 0.0 110.233 175.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -131.76 140.3 49.19 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.42 1.088 . . . . 0.0 111.729 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -63.3 -27.92 69.66 Favored 'General case' 0 N--CA 1.475 0.792 0 O-C-N 120.042 -1.661 . . . . 0.0 115.119 -174.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.93 165.19 14.0 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 120.071 -1.643 . . . . 0.0 109.957 166.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.21 152.0 34.93 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 124.307 1.043 . . . . 0.0 111.42 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -86.55 159.95 19.11 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.302 1.841 . . . . 0.0 113.034 174.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.7 -49.7 17.51 Favored 'General case' 0 N--CA 1.485 1.304 0 CA-C-N 112.728 -2.033 . . . . 0.0 111.104 166.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.6 mm? 68.32 62.73 0.37 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 127.355 2.262 . . . . 0.0 110.167 -176.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 178.22 -111.61 0.33 Allowed Glycine 0 N--CA 1.47 0.901 0 O-C-N 121.583 -0.698 . . . . 0.0 111.748 -173.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -151.63 7.94 0.5 Allowed 'General case' 0 CA--C 1.566 1.584 0 C-N-CA 126.906 2.083 . . . . 0.0 112.551 169.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 34.86 -106.5 0.03 OUTLIER Glycine 0 C--N 1.35 1.324 0 C-N-CA 126.877 2.179 . . . . 0.0 114.071 169.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -129.71 21.83 4.98 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-O 117.958 -1.468 . . . . 0.0 114.16 169.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -165.37 168.57 16.65 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 120.393 2.096 . . . . 0.0 111.249 -171.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -61.85 -53.03 61.46 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.855 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -40.84 -37.74 0.82 Allowed 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.676 1.99 . . . . 0.0 114.637 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 54.9 m -56.02 -35.67 67.1 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 171.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -94.85 -23.56 17.42 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.935 1.243 . . . . 0.0 112.527 167.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -78.9 -33.62 45.43 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-N 119.981 1.264 . . . . 0.0 113.094 -171.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.2 m -135.71 -31.32 0.95 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 126.898 2.079 . . . . 0.0 110.616 -169.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . 0.403 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 125.49 -25.41 5.67 Favored Glycine 0 C--O 1.222 -0.599 0 C-N-CA 127.996 2.712 . . . . 0.0 111.714 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 113.14 -8.63 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.856 1 C-N-CA 131.995 4.118 . . . . 0.0 112.291 176.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -57.24 -7.35 0.53 Allowed 'General case' 0 CA--C 1.56 1.349 0 N-CA-C 118.466 2.765 . . . . 0.0 118.466 -163.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.76 -31.32 1.96 Allowed Glycine 0 N--CA 1.47 0.943 0 O-C-N 119.597 -1.939 . . . . 0.0 114.512 170.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -133.64 -173.39 3.22 Favored 'General case' 0 CA--C 1.544 0.743 0 O-C-N 121.752 -0.852 . . . . 0.0 112.717 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.24 -174.44 2.72 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 127.981 2.512 . . . . 0.0 108.837 172.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.441 ' CD2' ' H ' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -174.72 -160.1 0.09 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 130.156 3.382 . . . . 0.0 107.038 171.908 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . 0.441 ' H ' ' CD2' ' B' ' 144' ' ' LEU . . . -69.86 171.98 8.44 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 127.503 2.321 . . . . 0.0 113.781 -176.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -155.92 153.31 29.43 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.817 -168.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.96 141.15 7.66 Favored Glycine 0 N--CA 1.469 0.881 0 C-N-CA 125.347 1.451 . . . . 0.0 113.975 172.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 2.3 t -77.58 147.83 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.835 0.854 . . . . 0.0 110.164 171.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.7 mm -91.91 98.29 8.21 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 126.535 1.934 . . . . 0.0 110.836 -171.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.75 -171.6 30.31 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 124.564 1.078 . . . . 0.0 114.058 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . 0.502 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 3.4 mp -119.21 128.82 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.186 0 C-N-CA 126.042 1.737 . . . . 0.0 114.367 -169.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -100.69 -24.34 14.44 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.35 1.06 . . . . 0.0 112.18 169.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 CA--C 1.534 0.345 0 C-N-CA 126.974 2.109 . . . . 0.0 111.618 -175.097 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.465 0.301 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.297 6.3 ptpt -127.24 129.78 48.39 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 176.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.27 153.38 28.51 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 126.659 1.984 . . . . 0.0 109.376 174.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -122.65 142.67 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.106 1.363 . . . . 0.0 108.976 177.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -105.19 133.32 50.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 121.092 1.769 . . . . 0.0 110.33 166.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.5 t -118.22 109.24 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.576 1.15 . . . . 0.0 109.574 -175.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.63 140.83 48.5 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.544 1.538 . . . . 0.0 112.187 -172.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -160.8 164.25 31.57 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 168.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.439 ' HA3' ' HE3' ' B' ' 9' ' ' LYS . . . 82.23 73.22 1.23 Allowed Glycine 0 C--N 1.335 0.48 0 N-CA-C 120.706 3.043 . . . . 0.0 120.706 161.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -160.04 60.96 0.35 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 108.212 164.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.76 -172.41 21.8 Favored Glycine 0 CA--C 1.541 1.671 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -164.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -73.58 58.7 3.91 Favored 'Trans proline' 0 CA--C 1.534 0.493 1 C-N-CA 125.749 4.299 . . . . 0.0 110.044 173.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.95 133.76 53.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 125.728 1.611 . . . . 0.0 110.263 -168.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.8 163.65 38.72 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 126.353 1.861 . . . . 0.0 109.85 -169.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.29 148.26 17.98 Favored Glycine 0 C--N 1.33 0.196 0 CA-C-O 122.407 1.004 . . . . 0.0 115.556 176.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -123.25 138.54 52.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 126.318 1.847 . . . . 0.0 109.888 167.814 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.9 mm -140.57 127.09 21.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 C-N-CA 125.496 1.518 . . . . 0.0 108.235 166.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -85.79 141.2 29.84 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.906 1.682 . . . . 0.0 109.839 166.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -124.28 97.82 5.49 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.727 2.011 . . . . 0.0 107.29 176.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.62 116.43 28.73 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-O 123.436 1.588 . . . . 0.0 111.636 -172.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.401 HE22 ' C ' ' A' ' 25' ' ' SER . 22.1 tt0 -108.67 148.85 29.8 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.954 178.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.421 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -89.45 -26.15 21.11 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.637 1.175 . . . . 0.0 112.912 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -131.71 -151.58 0.47 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.389 1.876 . . . . 0.0 110.401 167.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.401 ' C ' HE22 ' A' ' 22' ' ' GLN . 30.6 t -111.41 -17.53 13.09 Favored 'General case' 0 CA--C 1.555 1.169 0 C-N-CA 125.315 1.446 . . . . 0.0 110.754 167.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -90.67 -24.32 20.5 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 127.661 2.384 . . . . 0.0 115.466 170.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.2 175.64 52.41 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 119.462 1.028 . . . . 0.0 114.79 -173.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.56 151.91 47.83 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.855 2.37 . . . . 0.0 110.718 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.86 128.73 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 177.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -88.97 119.41 29.47 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 169.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.24 133.29 59.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 125.69 1.596 . . . . 0.0 110.141 -176.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -156.08 156.54 34.52 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.543 0.737 . . . . 0.0 111.886 177.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.1 -149.74 16.71 Favored Glycine 0 C--N 1.333 0.394 0 O-C-N 121.924 -0.485 . . . . 0.0 112.963 171.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 53.6 p -155.39 115.11 3.68 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 122.976 0.511 . . . . 0.0 112.056 -169.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.06 125.41 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-O 117.299 -1.334 . . . . 0.0 107.593 170.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.8 tttp -124.75 140.67 52.72 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 121.891 2.132 . . . . 0.0 111.552 -176.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.88 -0.25 13.45 Favored Glycine 0 N--CA 1.476 1.343 0 C-N-CA 127.243 2.354 . . . . 0.0 114.661 -176.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.15 -178.82 1.37 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.603 1.561 . . . . 0.0 110.985 170.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.59 -42.42 5.93 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 117.209 -1.377 . . . . 0.0 113.511 169.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 176.48 -107.67 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.267 0 C-N-CA 128.773 2.829 . . . . 0.0 109.628 -178.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -39.54 148.38 0.15 Allowed Glycine 0 N--CA 1.479 1.511 0 C-N-CA 129.533 3.444 . . . . 0.0 119.885 -168.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -31.3 136.67 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 130.1 3.36 . . . . 0.0 117.796 -169.084 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.0 m-70 -130.32 140.5 50.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 128.94 2.896 . . . . 0.0 108.764 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.57 156.52 53.33 Favored Glycine 0 N--CA 1.474 1.22 0 C-N-CA 124.08 0.848 . . . . 0.0 111.981 175.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -155.44 105.65 2.48 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.157 0.983 . . . . 0.0 112.374 -168.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.03 140.04 32.51 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 119.936 -1.728 . . . . 0.0 115.185 -172.577 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -78.11 134.99 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 166.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m170 -112.9 176.74 4.89 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 126.889 2.075 . . . . 0.0 110.901 -174.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -74.55 132.55 41.91 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.566 1.147 . . . . 0.0 112.297 170.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -77.78 -178.49 5.43 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 127.798 2.439 . . . . 0.0 115.216 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.4 ' HA2' ' CA ' ' B' ' 152' ' ' ALA . . . 119.78 -118.26 3.86 Favored Glycine 0 CA--C 1.502 -0.774 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.288 -172.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -87.83 63.45 7.44 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 125.229 2.442 . . . . 0.0 108.015 177.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -77.18 56.92 1.35 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 113.297 -1.774 . . . . 0.0 110.794 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -124.81 -44.88 1.92 Allowed 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.394 1.478 . . . . 0.0 113.943 -168.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.22 10.58 0.74 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.587 1.155 . . . . 0.0 113.093 170.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.78 -150.59 51.48 Favored Glycine 0 CA--C 1.528 0.869 0 O-C-N 120.493 -1.38 . . . . 0.0 111.294 -173.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 27.9 p -61.39 -7.29 2.87 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 117.196 2.295 . . . . 0.0 117.196 -169.149 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -88.44 -12.98 41.56 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 119.547 1.067 . . . . 0.0 113.784 170.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.3 t -124.09 -36.33 2.71 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.465 1.03 . . . . 0.0 111.853 173.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -69.07 86.94 0.38 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 166.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -47.68 120.95 6.33 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 126.736 2.112 . . . . 0.0 114.353 -166.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -67.46 126.42 14.85 Favored 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.625 2.217 . . . . 0.0 111.598 -173.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 59.65 60.96 2.08 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 164.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -45.22 109.95 0.21 Allowed 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.667 1.587 . . . . 0.0 112.746 -178.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.4 p-10 -135.5 55.33 12.56 Favored Pre-proline 0 CA--C 1.546 0.795 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -169.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -62.56 -16.16 50.59 Favored 'Trans proline' 0 C--N 1.354 0.836 0 C-N-CA 122.447 2.098 . . . . 0.0 112.495 170.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.7 mt -78.04 -7.18 56.58 Favored 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 169.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.3 t 64.98 56.18 1.08 Allowed 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.995 1.718 . . . . 0.0 112.412 170.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtm-85 -120.45 172.41 7.84 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 116.061 1.874 . . . . 0.0 116.061 -167.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.61 153.2 37.43 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 128.561 2.744 . . . . 0.0 109.944 168.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -74.42 151.24 39.67 Favored 'General case' 0 CA--C 1.541 0.598 0 O-C-N 120.807 -1.183 . . . . 0.0 113.551 171.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.96 -123.64 2.07 Favored Glycine 0 C--N 1.34 0.77 0 CA-C-O 118.728 -1.04 . . . . 0.0 113.499 166.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.9 -48.79 0.92 Allowed Glycine 0 CA--C 1.546 1.985 0 N-CA-C 117.758 1.863 . . . . 0.0 117.758 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -87.29 9.36 3.94 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.508 2.805 . . . . 0.0 114.131 178.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.6 pttt -165.15 -27.05 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 126.256 1.822 . . . . 0.0 112.263 179.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -83.57 161.09 21.29 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 128.618 2.767 . . . . 0.0 109.406 166.104 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -95.64 -17.98 20.9 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 125.591 1.556 . . . . 0.0 112.334 -172.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -95.19 -68.34 0.81 Allowed 'General case' 0 C--O 1.231 0.105 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -167.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.497 HH22 HG22 ' A' ' 104' ' ' ILE . 63.4 ttt-85 68.36 125.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 123.191 1.472 . . . . 0.0 111.24 -176.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -66.09 169.96 6.29 Favored 'General case' 0 CA--C 1.554 1.098 0 O-C-N 119.1 -2.25 . . . . 0.0 111.86 167.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.3 t -68.17 -50.47 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 O-C-N 120.684 -1.26 . . . . 0.0 108.665 176.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.33 92.76 1.83 Allowed Glycine 0 CA--C 1.529 0.918 0 N-CA-C 107.651 -2.179 . . . . 0.0 107.651 165.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -157.42 143.72 17.84 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.471 1.509 . . . . 0.0 112.558 171.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.99 177.63 7.75 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 127.489 2.316 . . . . 0.0 107.243 168.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.2 -126.34 1.11 Allowed Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.331 1.443 . . . . 0.0 113.908 -173.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 38.2 p-10 -144.61 164.31 31.31 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -175.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 26.8 m -136.44 123.39 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.491 1.117 . . . . 0.0 111.703 -169.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 m -98.53 141.34 31.5 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.305 1.042 . . . . 0.0 108.706 171.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.29 156.03 16.61 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 172.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.58 158.58 24.34 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.306 1.842 . . . . 0.0 107.876 165.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.435 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 1.4 pptp? -50.06 -21.7 1.35 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.208 2.203 . . . . 0.0 116.605 177.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.435 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 77.3 m-20 -78.09 4.21 12.98 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 125.199 1.4 . . . . 0.0 111.963 172.184 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.08 12.22 82.75 Favored Glycine 0 C--O 1.225 -0.441 0 C-N-CA 126.847 2.165 . . . . 0.0 114.24 176.262 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -105.73 122.66 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 CA-C-N 119.114 1.457 . . . . 0.0 112.357 -178.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.91 95.85 10.05 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 125.277 1.431 . . . . 0.0 109.948 169.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -79.48 127.32 31.98 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.62 1.568 . . . . 0.0 109.673 175.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.1 p -134.68 144.69 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -171.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.2 t -156.69 115.88 3.42 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.656 1.182 . . . . 0.0 111.556 173.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.6 mt -139.56 158.5 27.69 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 128.918 2.887 . . . . 0.0 109.986 -173.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -135.47 136.2 41.1 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 124.975 1.31 . . . . 0.0 108.114 167.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -148.69 134.12 18.57 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.566 1.146 . . . . 0.0 110.628 -167.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.6 p -106.91 45.81 0.96 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.93 18.13 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.782 1.233 . . . . 0.0 110.919 -175.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.497 HG22 HH22 ' A' ' 79' ' ' ARG . 0.2 OUTLIER -146.91 154.95 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 128.433 2.693 . . . . 0.0 106.334 164.996 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.517 ' H ' ' HB3' ' A' ' 111' ' ' SER . 76.5 p -157.67 161.7 38.6 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.775 1.23 . . . . 0.0 110.839 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -88.05 86.19 7.08 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.0 t -113.74 -4.16 13.43 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.898 1.279 . . . . 0.0 113.75 -172.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.2 -47.33 1.49 Allowed Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.046 -0.864 . . . . 0.0 113.588 -177.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 36.2 p-10 -142.09 -51.24 0.4 Allowed 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.913 1.82 . . . . 0.0 115.913 -169.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.97 -8.82 59.24 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 126.069 1.747 . . . . 0.0 112.922 -166.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.517 ' HB3' ' H ' ' A' ' 105' ' ' SER . 69.0 m -134.03 -109.67 0.22 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.623 1.169 . . . . 0.0 109.343 -174.318 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.4 pt -117.35 169.79 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 122.033 0.921 . . . . 0.0 108.754 166.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 108.4 132.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.071 1 C-N-CA 134.974 5.31 . . . . 0.0 106.384 -165.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.95 -3.23 1.63 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 116.174 1.229 . . . . 0.0 116.174 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 46.7 ttm-85 -78.95 171.63 14.94 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.744 1.218 . . . . 0.0 110.316 -172.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.5 t -116.53 162.38 17.68 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.113 1.365 . . . . 0.0 110.275 -178.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.93 131.52 18.82 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.694 1.598 . . . . 0.0 109.239 178.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 82.4 t -116.21 133.97 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 125.138 1.375 . . . . 0.0 108.693 175.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 30.8 m -103.2 155.09 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 168.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.37 130.92 41.32 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.655 1.182 . . . . 0.0 109.917 -168.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -58.48 -18.44 28.9 Favored 'General case' 0 CA--C 1.549 0.935 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.1 mmtm -128.73 168.06 16.37 Favored 'General case' 0 N--CA 1.479 0.99 0 O-C-N 118.66 -2.525 . . . . 0.0 115.063 -171.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -48.64 136.18 13.67 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 126.379 1.872 . . . . 0.0 111.68 173.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -122.72 146.95 47.03 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 124.664 2.174 . . . . 0.0 113.47 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.84 -29.24 55.81 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 112.563 -2.108 . . . . 0.0 113.673 -166.045 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.4 mt 35.13 58.45 0.77 Allowed 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 128.376 2.67 . . . . 0.0 111.274 176.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 145.15 -101.31 0.24 Allowed Glycine 0 C--N 1.334 0.431 0 C-N-CA 125.117 1.341 . . . . 0.0 110.869 -172.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -156.7 121.97 4.68 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 126.65 1.98 . . . . 0.0 112.042 -167.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.83 -90.38 1.8 Allowed Glycine 0 N--CA 1.467 0.734 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 176.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.3 2.89 2.64 Favored Glycine 0 N--CA 1.472 1.098 0 C-N-CA 125.362 1.458 . . . . 0.0 115.306 179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -120.95 161.93 20.75 Favored 'General case' 0 N--CA 1.463 0.187 0 C-N-CA 124.454 1.102 . . . . 0.0 113.116 -169.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -60.23 -55.87 28.42 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.527 1.156 . . . . 0.0 108.807 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -57.74 -7.33 0.67 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.453 1.901 . . . . 0.0 114.579 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.7 p -68.01 -48.52 65.49 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.917 1.235 . . . . 0.0 112.342 171.21 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 64.7 p -83.51 -26.87 29.81 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.344 0.658 . . . . 0.0 112.311 176.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 mtpm? -75.55 -60.56 2.25 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 178.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.1 p -104.35 -45.23 4.73 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 119.983 1.265 . . . . 0.0 113.706 178.185 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 125.26 7.99 5.65 Favored Glycine 0 CA--C 1.524 0.653 0 C-N-CA 126.214 1.864 . . . . 0.0 113.103 -168.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 56.97 21.66 6.45 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 170.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.47 26.42 0.02 OUTLIER 'General case' 0 CA--C 1.568 1.646 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -169.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.97 -40.79 2.13 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 128.581 2.991 . . . . 0.0 115.894 169.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.43 ' HB3' ' H ' ' A' ' 143' ' ' ARG . 3.4 m -171.23 -150.13 0.06 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 126.028 1.731 . . . . 0.0 110.61 -175.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.43 ' H ' ' HB3' ' A' ' 142' ' ' SER . 0.0 OUTLIER -114.3 -163.44 0.87 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.815 1.646 . . . . 0.0 109.878 170.458 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -171.67 -155.27 0.1 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 128.112 2.565 . . . . 0.0 107.92 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.93 145.98 28.24 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.302 1.441 . . . . 0.0 111.189 174.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.6 p -128.11 147.58 50.55 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.317 179.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.27 174.72 32.65 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 116.043 1.177 . . . . 0.0 116.043 -172.004 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.0 t -143.26 154.38 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 C-N-CA 124.575 1.15 . . . . 0.0 110.827 -170.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 41.8 mt -89.53 116.68 31.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 126.217 1.807 . . . . 0.0 115.086 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.438 ' HA2' ' HA2' ' B' ' 114' ' ' GLY . . . -98.99 -179.01 31.81 Favored Glycine 0 CA--C 1.531 1.094 0 C-N-CA 127.393 2.425 . . . . 0.0 112.937 167.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -144.8 138.67 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 CA-C-N 119.059 1.43 . . . . 0.0 114.258 -174.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.425 ' CA ' ' HA2' ' B' ' 51' ' ' GLY . . . -105.06 -35.5 7.61 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.083 1.142 . . . . 0.0 114.083 171.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 CA--C 1.546 0.823 0 CA-C-O 122.725 1.25 . . . . 0.0 111.409 -170.376 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.802 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 40.0 p -74.38 110.96 9.09 Favored 'General case' 0 CA--C 1.512 -0.492 0 C-N-CA 125.731 1.612 . . . . 0.0 108.222 -172.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.1 mtmm -100.7 140.91 34.31 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -171.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.86 170.04 9.86 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.489 2.316 . . . . 0.0 111.485 173.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.38 145.79 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.393 1.877 . . . . 0.0 111.839 -175.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.36 139.09 33.0 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 123.846 0.858 . . . . 0.0 109.0 165.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.3 79.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 121.44 0.638 . . . . 0.0 109.967 169.116 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.8 mp -82.87 139.66 33.33 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . 0.439 ' HE3' ' HA3' ' A' ' 10' ' ' GLY . 5.7 ttpt -154.7 157.98 38.89 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 171.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.59 173.8 19.72 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 107.256 -2.337 . . . . 0.0 107.256 164.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -79.27 55.45 1.87 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.616 1.966 . . . . 0.0 111.047 172.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.9 -164.02 32.53 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.433 1.492 . . . . 0.0 112.454 -168.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.44 45.31 1.82 Allowed 'Trans proline' 0 CA--C 1.539 0.736 1 C-N-CA 125.933 4.422 . . . . 0.0 114.497 -168.193 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -133.75 132.75 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 177.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -156.48 164.19 38.53 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 124.747 1.219 . . . . 0.0 110.811 -169.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -149.39 106.2 0.32 Allowed Glycine 0 N--CA 1.462 0.399 0 C-N-CA 125.326 1.441 . . . . 0.0 110.757 176.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . 0.262 0.1 OUTLIER -118.03 103.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -170.031 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 21.6 mm -121.48 120.97 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.168 0.987 . . . . 0.0 110.324 -168.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.79 138.92 38.43 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.716 0.807 . . . . 0.0 111.65 169.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -120.56 119.03 31.73 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.299 1.44 . . . . 0.0 108.312 169.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -107.68 119.67 40.08 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.128 0.971 . . . . 0.0 111.439 174.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -79.01 95.75 5.58 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 168.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.27 -20.17 62.26 Favored 'General case' 0 N--CA 1.475 0.816 0 O-C-N 120.551 -1.343 . . . . 0.0 112.927 175.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -156.41 127.23 6.81 Favored 'General case' 0 C--O 1.216 -0.666 0 C-N-CA 124.328 1.051 . . . . 0.0 112.635 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 7.4 m -60.91 -21.34 63.27 Favored 'General case' 0 N--CA 1.48 1.056 0 N-CA-C 116.232 1.938 . . . . 0.0 116.232 -169.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -115.09 1.24 13.86 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.161 2.184 . . . . 0.0 112.191 175.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.2 -157.53 10.81 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.541 2.02 . . . . 0.0 111.927 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.87 165.89 25.9 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.942 2.428 . . . . 0.0 113.283 -170.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.5 t -116.55 137.92 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 126.349 1.86 . . . . 0.0 108.897 174.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -92.51 129.12 38.54 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 123.82 0.848 . . . . 0.0 109.225 167.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -114.99 125.57 72.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 C-N-CA 125.669 1.588 . . . . 0.0 109.093 175.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -151.7 154.63 36.7 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.872 0.869 . . . . 0.0 110.985 174.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.96 178.5 18.88 Favored Glycine 0 N--CA 1.462 0.395 0 CA-C-O 122.439 1.022 . . . . 0.0 113.7 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 23.5 p -114.13 140.18 48.72 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 115.821 1.785 . . . . 0.0 115.821 -164.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.16 108.1 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 125.701 1.6 . . . . 0.0 108.869 169.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -119.26 147.61 44.07 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 124.31 1.044 . . . . 0.0 109.994 -171.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.8 19.36 29.45 Favored Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.563 1.554 . . . . 0.0 111.531 -170.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 71.5 mt -92.35 -171.49 2.81 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.513 1.925 . . . . 0.0 108.717 167.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.48 150.99 48.38 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 130.404 3.482 . . . . 0.0 105.178 167.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -50.21 -9.6 0.05 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 129.61 3.164 . . . . 0.0 116.785 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -63.88 163.26 33.58 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.385 -1.447 . . . . 0.0 112.233 168.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -57.74 142.94 43.71 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 126.0 1.72 . . . . 0.0 111.18 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -131.32 128.39 39.65 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.356 1.062 . . . . 0.0 110.419 169.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.76 154.86 53.13 Favored Glycine 0 N--CA 1.47 0.965 0 CA-C-O 118.333 -1.26 . . . . 0.0 112.439 177.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -149.06 124.08 10.04 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 119.466 1.633 . . . . 0.0 112.033 -169.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -156.44 158.81 37.94 Favored 'General case' 0 C--O 1.238 0.474 0 O-C-N 120.415 -1.428 . . . . 0.0 112.773 178.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.9 m -101.15 126.79 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.012 1.325 . . . . 0.0 108.746 177.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.9 m-70 -76.8 177.7 7.42 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 122.73 1.253 . . . . 0.0 110.991 -178.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -62.91 154.75 29.29 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 162.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.54 -135.74 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 122.05 0.928 . . . . 0.0 112.011 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.425 ' HA2' ' CA ' ' A' ' 152' ' ' ALA . . . 91.65 -109.43 3.73 Favored Glycine 0 CA--C 1.495 -1.167 0 C-N-CA 123.889 0.757 . . . . 0.0 111.966 168.322 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.32 58.76 0.86 Allowed 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 127.081 2.152 . . . . 0.0 105.666 -174.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -62.15 -2.86 1.06 Allowed 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 116.376 1.991 . . . . 0.0 116.376 -165.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.343 0.6 OUTLIER . . . . . 0 N--CA 1.468 0.427 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -164.2 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.579 0 CA-C-O 120.826 0.346 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.75 131.44 27.26 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 123.955 0.788 . . . . 0.0 112.5 175.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.0 114.05 2.84 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.759 2.306 . . . . 0.0 107.125 169.1 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.417 ' CE1' ' ND1' ' B' ' 71' ' ' HIS 0.27 0.0 OUTLIER 48.04 78.34 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.57 1.948 . . . . 0.0 114.125 -178.336 . . . . . . . . 4 4 . 1 . 011 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -39.65 116.3 0.61 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.861 1.264 . . . . 0.0 110.559 169.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . 0.265 0.1 OUTLIER -122.41 73.37 40.32 Favored Pre-proline 0 CA--C 1.544 0.719 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -170.046 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -64.99 -24.78 59.84 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.821 2.347 . . . . 0.0 114.122 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.17 -6.43 56.54 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.077 0.951 . . . . 0.0 113.114 174.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.9 t 56.96 52.84 8.72 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.265 1.426 . . . . 0.0 113.508 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 mtp180 -109.34 179.1 4.25 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.662 1.185 . . . . 0.0 114.047 -169.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.97 175.44 9.07 Favored 'General case' 0 CA--C 1.548 0.885 0 O-C-N 120.591 -1.318 . . . . 0.0 108.633 162.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.417 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 83.6 t60 -110.85 152.47 26.64 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -167.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.35 -128.89 3.52 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-O 118.663 -1.076 . . . . 0.0 113.881 165.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 153.5 -40.05 0.69 Allowed Glycine 0 CA--C 1.546 1.969 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 176.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -112.23 29.99 0.03 OUTLIER 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 125.041 3.827 . . . . 0.0 111.608 169.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -158.93 -53.03 0.06 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 127.745 2.418 . . . . 0.0 106.332 -178.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -85.3 155.46 21.34 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.917 1.687 . . . . 0.0 108.865 163.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -103.93 -17.25 15.08 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.467 1.507 . . . . 0.0 112.34 172.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -74.44 -39.52 62.52 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 120.807 -1.183 . . . . 0.0 112.334 -170.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt85 33.28 90.92 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 127.33 2.252 . . . . 0.0 114.79 168.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.3 m80 -47.62 159.03 0.17 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.031 1.333 . . . . 0.0 112.511 178.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.8 m -71.08 87.29 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 119.063 0.847 . . . . 0.0 110.235 172.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.87 39.15 0.18 Allowed Glycine 0 CA--C 1.529 0.967 0 C-N-CA 126.361 1.934 . . . . 0.0 114.553 -173.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -134.33 118.08 17.09 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 125.466 1.506 . . . . 0.0 109.913 -173.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -105.66 -179.24 3.88 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.936 0.894 . . . . 0.0 109.44 169.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.41 -134.75 3.35 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 122.214 0.897 . . . . 0.0 112.455 179.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -112.75 142.2 45.67 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.723 0.809 . . . . 0.0 110.611 170.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 17.9 m -109.02 92.79 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 126.69 1.996 . . . . 0.0 109.104 173.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.5 m -82.53 132.29 35.2 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 173.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.37 171.62 8.93 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -83.83 162.72 20.48 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.118 1.367 . . . . 0.0 107.351 164.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.4 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -57.14 -14.84 4.44 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 172.217 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -72.3 -13.66 61.55 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 125.763 1.625 . . . . 0.0 111.71 172.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.51 4.53 67.94 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.015 1.769 . . . . 0.0 113.294 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -102.73 130.23 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 125.565 1.546 . . . . 0.0 113.788 177.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.82 108.41 19.9 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 165.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -98.61 113.66 25.8 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.102 0.953 . . . . 0.0 110.76 175.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -93.47 156.23 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 125.33 1.452 . . . . 0.0 113.807 -169.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.0 p -156.87 117.83 3.68 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.935 1.294 . . . . 0.0 111.098 173.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.7 mt -146.1 150.81 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 C-N-CA 128.78 2.832 . . . . 0.0 109.906 -176.225 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 -137.57 131.11 31.18 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.371 1.468 . . . . 0.0 107.57 168.101 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -155.4 152.19 28.76 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.901 1.074 . . . . 0.0 113.901 -168.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 86.3 p -116.49 59.34 0.74 Allowed 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 125.977 1.711 . . . . 0.0 114.184 -167.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 p -147.26 -2.61 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 116.357 1.984 . . . . 0.0 116.357 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.36 168.65 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 125.5 1.52 . . . . 0.0 110.785 177.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 57.9 p -147.97 170.42 17.75 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 115.571 1.693 . . . . 0.0 115.571 178.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mp -102.92 48.03 0.87 Allowed 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 168.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.3 m -85.27 33.66 0.56 Allowed 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.569 -1.332 . . . . 0.0 112.405 -176.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 87.97 65.77 1.33 Allowed Glycine 0 N--CA 1.469 0.862 0 C-N-CA 124.158 0.885 . . . . 0.0 112.767 176.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.315 0.0 OUTLIER 76.78 -21.74 0.31 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 127.673 2.389 . . . . 0.0 114.334 170.176 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -77.52 11.66 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 127.322 2.249 . . . . 0.0 112.886 -173.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -142.02 -72.2 0.33 Allowed 'General case' 0 CA--C 1.544 0.743 0 N-CA-C 116.512 2.041 . . . . 0.0 116.512 170.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.94 0.7 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 116.016 1.858 . . . . 0.0 116.016 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.6 mm -89.12 149.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 168.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . 0.438 ' HA2' ' HA2' ' A' ' 150' ' ' GLY . . . 77.72 6.78 87.19 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 114.561 0.585 . . . . 0.0 114.561 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.8 ttt180 -115.31 179.28 4.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.989 2.116 . . . . 0.0 111.462 -168.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.83 151.39 37.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 C-N-CA 124.034 0.934 . . . . 0.0 111.124 177.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 19.5 tp -128.31 140.91 51.61 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 127.13 2.172 . . . . 0.0 106.572 167.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.37 156.38 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 124.362 1.065 . . . . 0.0 110.592 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -125.87 134.04 67.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-O 122.514 1.149 . . . . 0.0 110.697 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -92.34 145.85 24.15 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.426 1.49 . . . . 0.0 112.258 -168.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -67.62 -39.92 84.69 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 121.086 -1.009 . . . . 0.0 111.996 -174.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -98.69 -179.99 4.49 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.582 1.153 . . . . 0.0 109.962 167.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.59 165.49 0.83 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.697 1.199 . . . . 0.0 111.541 168.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -107.87 148.25 29.84 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.739 0.78 . . . . 0.0 110.662 165.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.73 -20.81 45.54 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.595 1.958 . . . . 0.0 114.807 -169.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.9 mt 41.61 49.02 3.65 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 126.238 1.815 . . . . 0.0 113.993 169.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 135.71 -78.56 0.34 Allowed Glycine 0 N--CA 1.469 0.839 0 C-N-CA 124.894 1.235 . . . . 0.0 111.288 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.86 148.4 22.42 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 117.585 2.439 . . . . 0.0 117.585 170.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -157.67 -79.5 0.03 OUTLIER Glycine 0 C--N 1.332 0.315 0 C-N-CA 130.287 3.803 . . . . 0.0 106.901 171.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.6 -92.87 0.02 OUTLIER Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.056 1.789 . . . . 0.0 115.955 -169.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -131.03 -127.54 0.2 Allowed 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.169 -1.195 . . . . 0.0 113.03 -166.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.32 -53.78 4.08 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.292 3.037 . . . . 0.0 109.949 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -43.46 -33.64 1.14 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 128.3 2.64 . . . . 0.0 114.03 169.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.8 m -45.33 -36.43 4.15 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 126.639 1.975 . . . . 0.0 113.702 168.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -103.3 -20.27 14.16 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 126.126 1.77 . . . . 0.0 113.886 -173.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 41.9 mtpt -80.6 -36.5 32.67 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.053 0.941 . . . . 0.0 110.745 170.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 20.0 p -135.95 -108.88 0.2 Allowed 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 127.324 2.249 . . . . 0.0 107.953 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -165.94 148.18 13.35 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 127.597 2.522 . . . . 0.0 108.151 169.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -75.42 45.56 0.3 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.54 1.536 . . . . 0.0 112.572 -172.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.51 6.24 24.38 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -167.015 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.61 -47.29 0.42 Allowed Glycine 0 CA--C 1.536 1.39 0 N-CA-C 118.948 2.339 . . . . 0.0 118.948 168.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -175.31 -176.93 0.97 Allowed 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.547 1.674 . . . . 0.0 112.406 -169.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.29 142.43 19.29 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.978 1.311 . . . . 0.0 111.591 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -103.74 -20.7 13.86 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.706 1.203 . . . . 0.0 114.123 -176.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.56 147.05 22.87 Favored 'General case' 0 C--O 1.244 0.775 0 C-N-CA 124.486 1.114 . . . . 0.0 109.195 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 63.3 m -138.99 149.18 44.4 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 127.936 2.494 . . . . 0.0 108.774 -179.015 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.71 160.03 29.98 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 115.421 0.929 . . . . 0.0 115.421 -174.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 5.2 t -109.56 152.15 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.189 1.396 . . . . 0.0 109.789 172.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.3 mm -94.72 116.78 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 126.081 1.753 . . . . 0.0 112.07 -174.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.16 165.48 15.13 Favored Glycine 0 C--N 1.348 1.237 0 C-N-CA 124.358 0.98 . . . . 0.0 112.503 177.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -117.7 124.89 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.4 ' CA ' ' HA2' ' A' ' 51' ' ' GLY . . . -79.76 -25.06 41.12 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 121.596 0.712 . . . . 0.0 110.265 165.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 70.0 mt-30 . . . . . 0 CA--C 1.531 0.229 0 C-N-CA 125.74 1.616 . . . . 0.0 109.023 178.347 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 34.7 p . . . . . 0 CA--C 1.507 -0.699 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.4 ttmm -101.89 125.95 48.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.014 -1.903 . . . . 0.0 106.315 168.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.57 159.85 41.21 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 125.116 1.367 . . . . 0.0 111.325 -169.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.6 t -139.65 143.42 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.438 1.113 . . . . 0.0 112.907 -169.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.2 111.72 14.92 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 164.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.658 ' CG2' ' H ' ' B' ' 54' ' ' THR . 6.8 m -97.27 112.29 28.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 168.193 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.7 mp -96.87 107.61 20.14 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.529 1.132 . . . . 0.0 111.021 -168.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -155.29 124.4 6.23 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 121.782 0.801 . . . . 0.0 112.865 173.226 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.63 -41.34 0.02 OUTLIER Glycine 0 CA--C 1.53 0.985 0 C-N-CA 127.898 2.666 . . . . 0.0 109.478 167.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -79.26 59.37 2.79 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 128.337 2.655 . . . . 0.0 112.55 -174.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.96 -104.25 0.06 OUTLIER Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.867 2.175 . . . . 0.0 114.232 171.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.04 -9.6 14.13 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 124.656 3.571 . . . . 0.0 114.621 -175.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.6 t -90.41 138.69 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-N 120.448 1.476 . . . . 0.0 108.325 171.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -156.82 164.81 37.66 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.018 1.327 . . . . 0.0 109.944 169.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.04 174.02 34.64 Favored Glycine 0 CA--C 1.507 -0.42 0 C-N-CA 124.329 0.966 . . . . 0.0 111.432 167.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 pp -127.52 142.15 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 C-N-CA 124.533 1.133 . . . . 0.0 108.356 168.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -130.19 133.83 63.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.708 . . . . 0.0 109.201 170.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -103.23 141.58 35.65 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 110.095 169.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -124.87 119.68 29.52 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.612 1.565 . . . . 0.0 108.24 171.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -115.85 119.33 35.64 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.346 1.459 . . . . 0.0 110.561 -175.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -129.62 141.83 50.86 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 123.506 1.622 . . . . 0.0 113.802 -174.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.476 ' HE2' ' OE2' ' A' ' 24' ' ' GLU . 15.0 ptmt -82.93 -62.7 1.53 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.742 2.017 . . . . 0.0 114.189 -171.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.476 ' OE2' ' HE2' ' A' ' 23' ' ' LYS . 3.7 pm0 -133.48 172.81 12.22 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 126.215 1.806 . . . . 0.0 110.668 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 p -45.06 -54.03 7.17 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.37 1.868 . . . . 0.0 115.434 -168.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -96.2 7.75 45.63 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.795 1.638 . . . . 0.0 111.73 -178.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.24 150.46 37.11 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 125.27 1.414 . . . . 0.0 113.627 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -63.66 162.85 26.48 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 123.996 3.131 . . . . 0.0 110.373 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -129.86 130.76 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 C-N-CA 123.346 0.658 . . . . 0.0 110.046 -169.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -91.15 131.81 36.47 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 167.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.7 t -124.24 137.79 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 125.567 1.547 . . . . 0.0 109.132 -173.014 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.4 p90 -157.29 168.66 26.74 Favored 'General case' 0 N--CA 1.471 0.624 0 O-C-N 121.276 -0.89 . . . . 0.0 113.286 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.34 -157.68 27.35 Favored Glycine 0 C--N 1.335 0.498 0 C-N-CA 125.173 1.368 . . . . 0.0 111.204 170.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.5 p -155.5 147.5 23.44 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -122.07 122.19 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 -177.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 59.8 tttt -120.81 133.44 55.32 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.317 1.047 . . . . 0.0 110.579 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.26 4.29 16.14 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.931 2.205 . . . . 0.0 112.645 -168.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 98.0 mt -82.89 163.38 21.16 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 118.201 1.0 . . . . 0.0 111.467 169.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.9 t -96.81 145.65 25.64 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 126.038 1.735 . . . . 0.0 107.475 165.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.443 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.8 pm0 -51.19 143.35 11.14 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.196 2.598 . . . . 0.0 114.739 -173.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.76 -179.81 34.42 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 125.012 1.292 . . . . 0.0 113.464 -172.159 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -56.73 151.28 14.39 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 128.058 2.543 . . . . 0.0 113.555 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -147.96 138.82 23.22 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.905 1.682 . . . . 0.0 109.411 167.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.67 154.91 20.9 Favored Glycine 0 N--CA 1.48 1.604 0 C-N-CA 124.051 0.834 . . . . 0.0 113.115 172.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -158.58 95.37 1.32 Allowed 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 124.423 1.089 . . . . 0.0 112.262 -170.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -146.14 148.92 33.09 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.262 1.579 . . . . 0.0 115.262 -169.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -82.76 110.97 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.95 1.7 . . . . 0.0 110.186 171.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -82.65 165.97 19.56 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.795 2.038 . . . . 0.0 110.793 176.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -59.96 145.11 47.26 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 122.35 1.071 . . . . 0.0 111.469 -176.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -82.53 -114.93 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.709 1.604 . . . . 0.0 111.739 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.5 -96.06 1.73 Allowed Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -143.92 54.68 1.31 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 -172.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.29 7.3 p-10 -73.39 27.98 0.07 Allowed 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.412 ' CG2' ' HA ' ' B' ' 7' ' ' VAL . 8.4 p -90.36 -7.37 53.42 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.352 1.461 . . . . 0.0 113.772 -168.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.19 -4.23 35.93 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.057 1.743 . . . . 0.0 112.97 168.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.92 -101.52 0.27 Allowed Glycine 0 C--N 1.343 0.941 0 CA-C-N 120.056 1.298 . . . . 0.0 112.519 170.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.4 m -54.83 -17.88 4.12 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 175.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.03 7.07 23.5 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.297 1.439 . . . . 0.0 113.521 175.267 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.4 t -171.85 98.0 0.17 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.94 1.696 . . . . 0.0 108.342 178.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 149.6 58.86 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 130.559 3.544 . . . . 0.0 111.687 -169.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -61.84 147.96 48.08 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 126.279 1.895 . . . . 0.0 114.123 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.77 95.17 0.54 Allowed 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 124.796 3.664 . . . . 0.0 113.765 -168.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 p80 42.95 68.2 0.53 Allowed 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 126.517 1.927 . . . . 0.0 112.485 166.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -39.28 142.87 0.22 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-O 124.009 1.861 . . . . 0.0 115.085 -167.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 38.9 p-10 -104.41 48.95 0.08 OUTLIER Pre-proline 0 CA--C 1.554 1.121 0 C-N-CA 127.11 2.164 . . . . 0.0 114.352 -177.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -69.77 -15.81 37.22 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 121.941 1.729 . . . . 0.0 112.473 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.68 -3.16 42.72 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.769 1.628 . . . . 0.0 112.325 169.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.1 t 69.97 57.72 0.29 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.662 1.585 . . . . 0.0 113.029 168.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 ptm85 -152.6 176.41 11.75 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -169.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -91.24 168.17 11.79 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.35 1.46 . . . . 0.0 112.705 -179.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.6 t60 -75.95 160.56 29.76 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.427 1.091 . . . . 0.0 113.512 179.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 136.41 -113.64 1.08 Allowed Glycine 0 C--N 1.339 0.713 0 C-N-CA 125.392 1.472 . . . . 0.0 112.315 166.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.93 -56.52 0.54 Allowed Glycine 0 CA--C 1.537 1.449 0 N-CA-C 117.742 1.857 . . . . 0.0 117.742 171.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -81.24 -16.69 9.52 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 CA-C-N 121.54 2.67 . . . . 0.0 112.505 178.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.51 -5.73 4.2 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.804 1.242 . . . . 0.0 112.893 173.104 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -102.5 169.3 8.75 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.462 1.505 . . . . 0.0 110.377 178.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -101.08 -7.07 23.54 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 127.083 2.153 . . . . 0.0 112.729 -167.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -127.35 -82.94 0.61 Allowed 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 119.597 1.09 . . . . 0.0 113.583 -171.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 79.12 140.55 0.07 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 126.289 1.836 . . . . 0.0 113.546 170.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -82.95 -177.77 6.88 Favored 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 116.361 1.986 . . . . 0.0 116.361 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -66.97 -12.13 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 174.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -134.81 14.03 4.43 Favored Glycine 0 CA--C 1.531 1.085 0 CA-C-O 118.161 -1.355 . . . . 0.0 116.31 -171.014 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -92.84 112.6 24.62 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.654 1.727 . . . . 0.0 111.275 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.4 48.72 1.38 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 120.101 1.319 . . . . 0.0 111.874 177.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.94 -143.98 24.65 Favored Glycine 0 CA--C 1.536 1.367 0 O-C-N 121.211 -0.931 . . . . 0.0 114.93 172.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -131.95 158.07 42.38 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 126.184 1.793 . . . . 0.0 112.883 -179.385 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.7 m -114.17 106.74 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.165 1.786 . . . . 0.0 111.001 169.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.4 m -106.49 115.61 30.5 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.599 1.56 . . . . 0.0 110.229 -169.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.13 147.79 24.74 Favored 'General case' 0 CA--C 1.539 0.558 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -172.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -93.96 160.65 14.63 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 128.978 2.911 . . . . 0.0 109.685 168.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.83 -14.9 2.65 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 126.169 1.788 . . . . 0.0 115.698 -175.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.27 -5.3 26.75 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.757 -1.215 . . . . 0.0 112.11 171.318 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.82 15.53 65.28 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 127.008 2.242 . . . . 0.0 112.878 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.0 p -121.33 128.87 76.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.544 1.172 . . . . 0.0 113.699 -170.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.64 110.56 22.66 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 164.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -91.9 137.27 32.5 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 169.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -135.68 149.65 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 N-CA-C 116.801 2.148 . . . . 0.0 116.801 -168.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.9 m -155.21 127.37 7.7 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 126.052 1.741 . . . . 0.0 110.367 169.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 10.1 mm -140.82 166.44 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 129.026 2.93 . . . . 0.0 109.794 -173.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -155.29 154.61 32.38 Favored 'General case' 0 C--N 1.316 -0.87 0 C-N-CA 128.108 2.563 . . . . 0.0 107.825 170.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -155.79 150.99 26.7 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.938 1.295 . . . . 0.0 111.577 170.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -119.03 53.05 1.02 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.521 -1.218 . . . . 0.0 112.225 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 48.9 t -137.81 -43.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.3 1.44 . . . . 0.0 107.928 168.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.87 160.11 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 123.027 1.394 . . . . 0.0 110.93 167.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.483 ' H ' ' HB3' ' A' ' 111' ' ' SER . 3.6 p -156.29 168.87 25.97 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 128.762 2.825 . . . . 0.0 106.969 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -93.25 102.3 14.58 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -152.83 -6.91 0.19 Allowed 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -167.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.13 -95.83 2.13 Favored Glycine 0 C--N 1.336 0.546 0 O-C-N 120.927 -1.108 . . . . 0.0 111.613 173.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -69.97 -51.99 28.07 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.851 0.685 . . . . 0.0 112.851 -166.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -78.92 -27.81 43.78 Favored 'General case' 0 CA--C 1.539 0.547 0 O-C-N 120.271 -1.518 . . . . 0.0 112.358 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.483 ' HB3' ' H ' ' A' ' 105' ' ' SER . 8.2 m -118.88 -127.16 0.28 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.857 1.799 . . . . 0.0 115.857 -164.617 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.29 39.3 pt -111.03 173.69 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 O-C-N 119.769 -1.832 . . . . 0.0 108.682 166.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mm 90.49 136.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.843 1 C-N-CA 132.757 4.423 . . . . 0.0 107.25 -163.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 58.35 25.2 57.29 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.556 1.074 . . . . 0.0 114.687 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.1 ttm180 -122.17 156.29 34.0 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 126.614 1.965 . . . . 0.0 107.515 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.9 t -113.07 107.62 16.21 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 122.352 2.342 . . . . 0.0 115.694 -165.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 57.0 tp -76.99 128.92 35.39 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.72 0.808 . . . . 0.0 110.266 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -118.04 136.56 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.252 1.021 . . . . 0.0 109.127 169.352 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 m -93.04 144.74 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.384 -1.709 . . . . 0.0 106.384 168.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.7 m-70 -101.98 158.93 15.79 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-O 122.369 1.08 . . . . 0.0 112.987 -170.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -74.71 -35.64 62.71 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 -168.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -125.85 179.98 4.94 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 125.29 1.436 . . . . 0.0 112.597 173.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.25 140.47 38.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 126.683 1.993 . . . . 0.0 112.463 173.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -91.58 131.03 37.28 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.115 0.966 . . . . 0.0 111.057 178.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.419 ' OD1' ' HE3' ' A' ' 128' ' ' LYS . 0.3 OUTLIER -77.09 -18.93 57.65 Favored 'General case' 0 CA--C 1.554 1.118 0 N-CA-C 112.889 0.699 . . . . 0.0 112.889 174.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 41.3 mt 62.08 54.39 2.74 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.946 2.098 . . . . 0.0 113.686 173.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 118.62 -11.23 12.37 Favored Glycine 0 N--CA 1.475 1.246 0 N-CA-C 121.297 3.279 . . . . 0.0 121.297 164.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.47 ' HE3' ' H ' ' A' ' 128' ' ' LYS 0.252 0.0 OUTLIER -167.08 62.11 0.08 Allowed 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 118.192 2.664 . . . . 0.0 118.192 -173.626 . . . . . . . . 4 4 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -106.25 45.68 1.27 Allowed Glycine 0 N--CA 1.471 0.975 0 C-N-CA 127.041 2.257 . . . . 0.0 113.349 -172.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.21 -27.53 1.47 Allowed Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.62 1.105 . . . . 0.0 115.749 172.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -89.77 154.55 19.83 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 118.983 1.391 . . . . 0.0 110.381 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -55.33 -54.14 47.31 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-O 122.751 1.262 . . . . 0.0 109.108 167.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.522 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 6.4 tm-20 -51.89 -34.89 43.26 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 128.447 2.699 . . . . 0.0 112.593 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.0 p -60.03 -34.39 73.3 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.7 p -77.13 -14.37 59.81 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.61 1.164 . . . . 0.0 111.991 179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.3 mtpt -100.15 -53.76 3.05 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.516 1.926 . . . . 0.0 111.891 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.522 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 29.8 p -100.08 -34.42 10.07 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 117.659 -1.162 . . . . 0.0 113.781 -172.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.98 -3.2 28.64 Favored Glycine 0 CA--C 1.533 1.196 0 O-C-N 125.448 1.717 . . . . 0.0 113.715 -168.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.69 25.04 11.28 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 126.193 1.797 . . . . 0.0 112.738 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.82 46.39 0.29 Allowed 'General case' 0 CA--C 1.552 1.049 0 C-N-CA 126.799 2.04 . . . . 0.0 113.755 -168.157 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.04 -59.4 3.54 Favored Glycine 0 N--CA 1.467 0.728 0 C-N-CA 127.987 2.708 . . . . 0.0 113.692 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t 178.09 179.03 0.34 Allowed 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.11 2.164 . . . . 0.0 109.494 -169.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.64 153.66 35.02 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.03 -1.044 . . . . 0.0 111.018 169.75 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -135.14 -150.77 0.4 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.375 1.47 . . . . 0.0 108.63 169.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -52.93 141.96 20.64 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.274 1.43 . . . . 0.0 114.151 -173.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -134.72 154.67 51.46 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.983 1.313 . . . . 0.0 114.361 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.24 125.03 1.55 Allowed Glycine 0 CA--C 1.539 1.562 0 C-N-CA 124.646 1.117 . . . . 0.0 114.557 173.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -78.14 126.58 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 173.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 59.9 mt -78.41 124.51 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -167.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.76 167.97 13.96 Favored Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.847 1.213 . . . . 0.0 115.413 175.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.57 162.82 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 126.438 1.895 . . . . 0.0 113.416 -171.016 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -158.18 -40.97 0.06 Allowed 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.01 1.324 . . . . 0.0 112.032 169.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.47 0.538 0 C-N-CA 124.226 1.01 . . . . 0.0 112.159 169.096 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 70.9 p -134.08 125.43 28.02 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 166.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.3 mtmt -119.57 158.54 26.13 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -179.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . 0.404 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -144.58 151.99 39.87 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.98 1.312 . . . . 0.0 112.534 169.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 p -111.08 133.53 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 125.987 1.715 . . . . 0.0 110.673 177.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.54 110.94 21.3 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.774 -1.204 . . . . 0.0 110.088 167.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.412 ' HA ' ' CG2' ' A' ' 54' ' ' THR . 15.0 t -86.52 68.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 124.36 1.064 . . . . 0.0 112.063 -170.396 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -79.77 110.56 15.24 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 113.426 0.898 . . . . 0.0 113.426 -175.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mttm -157.62 129.55 7.03 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.71 1.204 . . . . 0.0 112.195 167.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.68 -56.9 0.01 OUTLIER Glycine 0 N--CA 1.468 0.772 0 C-N-CA 126.233 1.873 . . . . 0.0 109.885 169.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.58 72.29 3.24 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 125.989 1.715 . . . . 0.0 110.953 -176.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.64 -94.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.377 0 C-N-CA 127.844 2.64 . . . . 0.0 114.746 173.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -71.08 -20.98 28.03 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 123.964 3.109 . . . . 0.0 114.797 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.1 t -74.15 147.65 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 CA-C-N 121.483 1.947 . . . . 0.0 110.491 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.32 167.75 21.2 Favored 'General case' 0 CA--C 1.519 -0.228 0 C-N-CA 124.48 1.112 . . . . 0.0 109.651 167.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.8 59.58 0.4 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.874 169.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -75.41 127.42 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 117.776 0.788 . . . . 0.0 108.987 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.18 119.55 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 O-C-N 125.277 1.61 . . . . 0.0 109.741 176.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.2 121.27 23.41 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 124.915 1.286 . . . . 0.0 110.65 165.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -99.67 94.17 6.22 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.26 1.824 . . . . 0.0 106.135 167.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -98.25 113.66 25.67 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 124.311 1.044 . . . . 0.0 110.349 178.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . 0.434 ' OE1' ' HA ' ' B' ' 105' ' ' SER . 4.5 tt0 -113.13 139.01 49.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 122.678 1.228 . . . . 0.0 110.464 179.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.71 -5.05 54.43 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.1 1.36 . . . . 0.0 114.237 -171.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 mp0 -155.75 -168.24 2.73 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 130.078 3.351 . . . . 0.0 106.603 175.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.8 t -89.2 -21.13 23.43 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-N 119.957 1.253 . . . . 0.0 110.135 163.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -109.6 11.32 24.8 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 126.191 1.796 . . . . 0.0 115.232 -176.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.77 -179.75 38.85 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 124.423 1.011 . . . . 0.0 112.834 -177.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.23 161.47 20.23 Favored 'Trans proline' 0 CA--C 1.537 0.654 0 C-N-CA 123.346 2.697 . . . . 0.0 109.421 168.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.01 134.94 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.89 0.876 . . . . 0.0 111.734 -169.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.46 ' HZ2' ' CD ' ' B' ' 100' ' ' GLU . 50.6 mttp -87.84 126.14 34.86 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 165.531 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -123.75 89.03 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 127.362 2.265 . . . . 0.0 108.23 -169.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -119.09 156.24 30.08 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.799 0.84 . . . . 0.0 111.815 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.84 176.82 41.71 Favored Glycine 0 C--O 1.225 -0.439 0 O-C-N 121.479 -0.763 . . . . 0.0 113.437 -174.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -127.75 118.78 24.41 Favored 'General case' 0 C--O 1.239 0.543 0 O-C-N 122.054 -0.674 . . . . 0.0 111.948 -178.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.1 mm -92.08 117.8 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 169.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.3 pttt -139.41 137.34 35.58 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 123.185 0.594 . . . . 0.0 110.328 -168.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.29 0.68 54.01 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.871 1.7 . . . . 0.0 114.787 -173.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -91.3 -160.35 0.72 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 118.412 1.106 . . . . 0.0 111.304 169.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.6 t -112.19 155.99 23.06 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.293 1.837 . . . . 0.0 110.976 178.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -47.65 149.85 1.13 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.625 1.97 . . . . 0.0 111.879 169.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.75 38.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 124.009 0.814 . . . . 0.0 113.726 -178.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.425 ' CD1' ' H ' ' B' ' 42' ' ' LEU . 5.6 mp -65.87 144.51 56.77 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 128.921 2.888 . . . . 0.0 113.157 -171.284 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -140.53 124.05 16.97 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 126.608 1.963 . . . . 0.0 110.508 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.5 149.85 35.45 Favored Glycine 0 N--CA 1.476 1.334 0 C-N-CA 124.744 1.164 . . . . 0.0 112.391 176.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -146.52 102.2 3.55 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-O 121.861 0.838 . . . . 0.0 112.404 -164.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -129.45 126.23 38.26 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 120.855 -1.153 . . . . 0.0 110.427 -169.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.79 116.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.296 1.439 . . . . 0.0 108.984 171.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.531 ' C ' ' H ' ' B' ' 50' ' ' PHE . 21.8 m170 -78.86 122.25 25.85 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 121.307 -0.871 . . . . 0.0 110.381 -179.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.65 2.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 127.053 2.141 . . . . 0.0 115.426 170.03 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . 0.531 ' H ' ' C ' ' B' ' 48' ' ' HIS . 2.5 m-85 -137.16 81.51 1.88 Allowed 'General case' 0 N--CA 1.442 -0.839 1 C-N-CA 133.776 4.83 . . . . 0.0 100.94 -176.011 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.05 20.07 35.04 Favored Glycine 0 N--CA 1.467 0.73 0 O-C-N 121.655 -0.653 . . . . 0.0 113.225 173.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -68.99 49.06 0.07 Allowed 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.042 2.537 . . . . 0.0 113.085 171.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -178.74 131.45 0.12 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.414 1.486 . . . . 0.0 111.047 -168.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 54' ' ' THR . . . . . 0.658 ' H ' ' CG2' ' A' ' 7' ' ' VAL . 6.6 t . . . . . 0 N--CA 1.478 0.951 0 N-CA-C 116.236 1.939 . . . . 0.0 116.236 175.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.558 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.52 -82.19 0.51 Allowed Glycine 0 CA--C 1.54 1.616 0 C-N-CA 126.842 2.163 . . . . 0.0 112.059 178.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -85.83 178.14 4.43 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 125.15 3.9 . . . . 0.0 115.139 -172.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -103.4 123.8 47.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.203 1.401 . . . . 0.0 110.796 179.386 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -58.26 146.9 32.47 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 120.789 0.328 . . . . 0.0 110.418 167.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.21 107.73 21.56 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.597 0.759 . . . . 0.0 112.515 -178.179 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -68.81 -30.85 26.4 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.135 1.89 . . . . 0.0 111.844 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -76.98 -7.81 56.28 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.096 0.959 . . . . 0.0 112.709 175.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.7 m 57.76 56.46 4.8 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.627 1.171 . . . . 0.0 111.743 172.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.89 172.69 15.64 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.394 1.478 . . . . 0.0 110.704 -168.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -72.5 176.68 5.19 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 -171.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -49.23 155.09 0.73 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.447 2.017 . . . . 0.0 116.447 -167.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' B' ' 79' ' ' ARG . . . -75.61 69.33 2.07 Favored Glycine 0 N--CA 1.473 1.144 0 C-N-CA 128.892 3.139 . . . . 0.0 114.212 -169.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.46 135.84 13.62 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 114.608 0.603 . . . . 0.0 114.608 -173.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -84.58 -0.95 9.52 Favored 'Trans proline' 0 CA--C 1.548 1.207 0 C-N-CA 123.87 3.047 . . . . 0.0 109.597 163.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.454 ' HE2' ' O ' ' B' ' 125' ' ' ASP . 0.1 OUTLIER -118.37 -10.61 10.15 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.642 1.977 . . . . 0.0 114.167 177.613 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -110.7 149.48 30.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.362 1.065 . . . . 0.0 109.022 -167.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -67.35 -25.53 66.03 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -88.65 146.22 25.21 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-O 125.07 2.367 . . . . 0.0 109.319 169.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . 0.43 ' HA ' ' HA2' ' B' ' 72' ' ' GLY . 52.9 ttt-85 -167.03 106.67 0.6 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 112.545 -2.116 . . . . 0.0 113.293 -174.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -61.59 149.33 39.47 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.401 1.081 . . . . 0.0 109.157 162.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.3 -13.66 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 CA-C-N 120.891 1.678 . . . . 0.0 110.323 166.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.28 18.82 9.37 Favored Glycine 0 C--N 1.336 0.548 0 C-N-CA 127.235 2.35 . . . . 0.0 118.879 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.99 149.43 32.15 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 122.608 3.204 . . . . 0.0 112.917 168.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -107.64 174.95 5.66 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.575 1.55 . . . . 0.0 108.561 168.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.48 155.31 49.79 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 171.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -74.4 146.61 42.8 Favored 'General case' 0 CA--C 1.549 0.941 0 CA-C-O 121.658 0.742 . . . . 0.0 111.825 -170.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -101.21 119.56 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.996 1.719 . . . . 0.0 112.48 -168.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -98.58 126.88 44.3 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.331 1.052 . . . . 0.0 110.283 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.95 162.13 14.19 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 171.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -85.97 168.99 13.66 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.889 2.075 . . . . 0.0 113.123 170.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.24 61.93 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.644 1.978 . . . . 0.0 114.963 -177.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.35 2.35 18.89 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 125.643 1.577 . . . . 0.0 112.146 177.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.16 21.75 56.32 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 124.936 1.255 . . . . 0.0 113.458 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.13 134.39 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -179.091 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.09 130.3 54.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 124.828 1.251 . . . . 0.0 110.445 166.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -88.27 105.62 17.67 Favored 'General case' 0 C--O 1.232 0.165 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 163.126 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.93 129.9 36.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 114.954 -1.021 . . . . 0.0 108.631 169.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.1 m -146.38 94.21 2.42 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.387 1.075 . . . . 0.0 109.305 -176.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -130.9 159.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 126.346 1.858 . . . . 0.0 110.281 -174.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.46 ' CD ' ' HZ2' ' B' ' 30' ' ' LYS . 41.7 tt0 -139.77 142.2 36.77 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 128.077 2.551 . . . . 0.0 106.584 167.389 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -151.12 138.15 19.13 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.293 1.037 . . . . 0.0 111.876 -168.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 46.3 p -118.0 50.3 1.16 Allowed 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 177.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 p -147.26 4.64 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 171.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -122.71 160.89 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.576 1.551 . . . . 0.0 107.409 167.022 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 105' ' ' SER . . . . . 0.434 ' HA ' ' OE1' ' B' ' 22' ' ' GLN . 96.8 p -156.24 168.36 27.55 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 119.49 1.041 . . . . 0.0 113.626 -174.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -92.59 69.07 4.83 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.521 1.528 . . . . 0.0 110.055 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 5.7 m -117.56 160.02 21.92 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.775 1.63 . . . . 0.0 110.727 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 44.98 1.82 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 125.146 1.355 . . . . 0.0 114.468 -168.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -135.54 -84.63 0.39 Allowed 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.872 1.269 . . . . 0.0 110.449 -168.691 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -150.35 -2.82 0.37 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 127.74 2.416 . . . . 0.0 111.773 -176.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 95.0 p -61.09 -44.4 97.42 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.131 1.373 . . . . 0.0 114.11 -169.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 5.3 pt -154.16 -34.35 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 127.678 2.391 . . . . 0.0 111.223 166.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 45.1 mm -60.56 125.37 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 123.866 0.867 . . . . 0.0 108.765 -175.034 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.56 16.23 67.3 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 116.994 -2.003 . . . . 0.0 115.061 -178.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.4 mtm180 -79.62 168.21 19.68 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.841 1.82 . . . . 0.0 109.478 168.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 22.6 m -123.64 117.04 24.1 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.806 0.842 . . . . 0.0 110.31 175.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 37.6 tp -82.23 132.12 35.23 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 169.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -110.91 137.43 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.534 1.534 . . . . 0.0 108.751 165.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 p -109.77 130.36 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.968 0.89 . . . . 0.0 109.417 168.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . 0.475 ' CE1' HH11 ' B' ' 143' ' ' ARG . 21.7 m-70 -99.91 161.12 13.8 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.527 1.131 . . . . 0.0 113.669 -172.167 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -76.42 -25.49 54.52 Favored 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.701 1.371 . . . . 0.0 114.701 -174.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -118.85 176.68 5.16 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 119.667 1.121 . . . . 0.0 112.415 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.71 164.3 2.14 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.151 1.38 . . . . 0.0 111.967 168.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -113.97 145.08 42.03 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.949 1.7 . . . . 0.0 110.546 -178.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . 0.454 ' O ' ' HE2' ' B' ' 75' ' ' LYS . 0.0 OUTLIER -73.95 -35.46 64.55 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-O 118.775 -0.631 . . . . 0.0 111.214 172.38 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 11.6 mt 77.54 24.61 0.77 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.015 2.126 . . . . 0.0 113.481 177.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.83 -78.9 0.06 OUTLIER Glycine 0 N--CA 1.474 1.182 0 CA-C-N 120.47 1.486 . . . . 0.0 116.657 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -156.22 87.67 1.06 Allowed 'General case' 0 N--CA 1.44 -0.925 0 C-N-CA 126.38 1.872 . . . . 0.0 110.93 173.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . 0.43 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -65.64 -10.99 52.24 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 126.836 2.16 . . . . 0.0 114.081 174.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.16 -33.8 2.47 Favored Glycine 0 N--CA 1.47 0.948 0 C-N-CA 124.366 0.984 . . . . 0.0 114.942 168.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.6 p30 -92.79 -177.78 4.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.498 1.519 . . . . 0.0 110.366 -177.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . 0.411 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 76.8 tt0 -61.5 -62.66 1.66 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 122.773 0.429 . . . . 0.0 110.351 173.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . 0.419 ' HB3' HD21 ' B' ' 139' ' ' ASN . 0.8 OUTLIER -42.06 -30.75 0.3 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 129.278 3.031 . . . . 0.0 115.572 -176.039 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 134' ' ' SER . . . . . 0.43 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 97.1 p -63.07 -41.84 99.53 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.373 1.469 . . . . 0.0 113.333 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 72.7 p -81.93 -30.57 31.72 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 123.834 0.854 . . . . 0.0 113.208 173.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.411 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 19.7 tttt -70.85 -53.15 16.31 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.704 2.002 . . . . 0.0 110.226 -177.309 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 74.6 p -111.54 -113.63 0.32 Allowed 'General case' 0 C--N 1.342 0.253 0 C-N-CA 128.207 2.603 . . . . 0.0 106.33 172.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -144.19 12.2 2.07 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 130.191 3.758 . . . . 0.0 111.874 169.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . 0.419 HD21 ' HB3' ' B' ' 133' ' ' GLU . 5.3 t-20 56.64 14.89 1.9 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.889 1.675 . . . . 0.0 113.814 -172.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.42 22.21 0.03 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 116.563 2.061 . . . . 0.0 116.563 -168.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.11 -169.81 52.12 Favored Glycine 0 CA--C 1.529 0.963 0 O-C-N 120.136 -1.603 . . . . 0.0 113.295 -171.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.06 -169.85 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.279 1.432 . . . . 0.0 110.906 174.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . 0.475 HH11 ' CE1' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -137.3 146.5 44.72 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 115.622 1.712 . . . . 0.0 115.622 175.241 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.7 -121.96 0.06 Allowed 'General case' 0 CA--C 1.536 0.406 0 O-C-N 127.182 2.801 . . . . 0.0 106.451 164.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.35 154.86 41.37 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 122.932 1.349 . . . . 0.0 114.467 -166.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -139.16 152.02 47.09 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 126.381 1.872 . . . . 0.0 109.246 169.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.58 141.88 7.73 Favored Glycine 0 C--N 1.333 0.414 0 N-CA-C 114.369 0.508 . . . . 0.0 114.369 176.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -79.74 153.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.891 1.276 . . . . 0.0 110.464 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.19 109.73 20.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 124.878 1.271 . . . . 0.0 112.409 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.53 164.37 15.52 Favored Glycine 0 C--N 1.35 1.339 0 C-N-CA 125.204 1.383 . . . . 0.0 112.761 174.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 mp -87.36 113.37 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 O-C-N 121.548 -0.972 . . . . 0.0 112.193 -168.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.404 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -82.42 16.57 2.03 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 128.112 2.565 . . . . 0.0 112.658 169.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.436 0 C-N-CA 128.804 2.842 . . . . 0.0 111.991 170.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.518 -0.283 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -94.5 145.83 24.52 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.33 164.44 13.02 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 121.109 -0.994 . . . . 0.0 111.789 168.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.427 HG11 ' H ' ' B' ' 53' ' ' ASN . 1.2 p -112.45 164.22 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 172.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.77 81.25 1.5 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.993 1.317 . . . . 0.0 108.007 160.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.0 t -77.45 89.14 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.16 141.5 37.17 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.381 1.072 . . . . 0.0 112.167 -172.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -155.59 175.96 13.23 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 169.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 160.12 -95.08 0.14 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 127.283 2.373 . . . . 0.0 109.706 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -78.33 87.16 4.38 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 126.629 1.972 . . . . 0.0 112.406 -169.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.08 -98.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.991 2.234 . . . . 0.0 114.003 168.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -78.4 -2.35 12.42 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 125.191 3.927 . . . . 0.0 115.284 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.5 t -79.0 139.1 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 120.312 1.415 . . . . 0.0 110.389 171.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -148.6 170.45 18.09 Favored 'General case' 0 N--CA 1.462 0.169 0 C-N-CA 125.617 1.567 . . . . 0.0 110.494 169.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.57 162.76 28.73 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 114.877 -1.056 . . . . 0.0 111.559 165.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.3 tp -156.87 80.71 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 126.609 1.964 . . . . 0.0 107.737 -177.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mm -98.42 143.97 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.123 0.569 . . . . 0.0 110.1 175.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -114.7 148.99 37.49 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 128.93 2.892 . . . . 0.0 109.42 175.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -141.78 82.11 1.79 Allowed 'General case' 0 CA--C 1.557 1.216 0 C-N-CA 123.983 0.913 . . . . 0.0 112.757 -178.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.413 ' HG2' ' CZ3' ' A' ' 32' ' ' TRP . 1.2 pt-20 -78.97 130.54 35.67 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 121.367 1.894 . . . . 0.0 114.755 -174.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.59 HE22 ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -116.87 155.29 29.29 Favored 'General case' 0 CA--C 1.535 0.377 0 O-C-N 120.459 -1.4 . . . . 0.0 111.976 173.059 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -56.06 2.39 Favored 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.29 1.436 . . . . 0.0 112.64 -169.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.59 ' C ' HE22 ' A' ' 22' ' ' GLN . 0.4 OUTLIER -138.89 153.3 48.27 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 128.82 2.848 . . . . 0.0 107.739 169.406 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -48.45 -17.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 118.545 2.795 . . . . 0.0 118.545 -166.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -118.94 0.61 11.38 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.528 1.931 . . . . 0.0 113.405 -176.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.25 177.41 54.26 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.936 0.779 . . . . 0.0 112.829 176.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.91 177.52 8.62 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.293 3.329 . . . . 0.0 110.907 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 87.8 t -128.96 132.65 67.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 123.066 0.546 . . . . 0.0 110.128 178.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.43 122.39 34.83 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.9 t -103.47 128.02 56.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 126.002 1.721 . . . . 0.0 108.662 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.413 ' CZ3' ' HG2' ' A' ' 21' ' ' GLU . 3.1 p90 -144.83 157.71 44.06 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 122.84 0.456 . . . . 0.0 111.608 170.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.38 178.87 15.52 Favored Glycine 0 N--CA 1.463 0.465 0 O-C-N 121.259 -0.9 . . . . 0.0 112.427 -178.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 m -127.57 159.21 35.3 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 117.009 2.226 . . . . 0.0 117.009 -164.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.5 mm -123.73 124.5 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 127.2 2.2 . . . . 0.0 108.131 167.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -130.81 136.21 48.47 Favored 'General case' 0 CA--C 1.54 0.573 0 O-C-N 120.872 -1.142 . . . . 0.0 111.054 -169.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.41 -11.94 11.28 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.238 1.875 . . . . 0.0 113.557 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.9 mp -62.1 141.92 57.86 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 127.161 2.184 . . . . 0.0 109.062 169.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.6 t -71.59 -41.74 68.58 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -176.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 176.03 -160.62 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.743 1 C-N-CA 133.21 4.604 . . . . 0.0 105.168 178.469 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 74.24 173.42 29.28 Favored Glycine 0 N--CA 1.473 1.112 0 N-CA-C 117.165 1.626 . . . . 0.0 117.165 165.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.19 152.41 30.7 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.002 1.321 . . . . 0.0 109.61 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -153.1 142.15 21.33 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.872 1.669 . . . . 0.0 112.82 -171.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.22 163.23 7.18 Favored Glycine 0 N--CA 1.478 1.457 0 C-N-CA 124.867 1.223 . . . . 0.0 115.141 -174.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -160.45 84.55 0.71 Allowed 'General case' 0 CA--C 1.548 0.875 0 CA-C-O 122.672 1.225 . . . . 0.0 113.502 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -133.18 142.37 48.59 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 120.036 -1.665 . . . . 0.0 110.961 -171.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.4 m -109.23 128.71 64.96 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.167 0 CA-C-O 121.957 0.884 . . . . 0.0 109.046 176.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.8 m170 -76.09 156.8 33.54 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.762 -174.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -74.95 130.85 40.1 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 71.12 169.34 0.32 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-O 124.848 2.261 . . . . 0.0 113.862 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.512 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -102.68 11.01 56.29 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 129.589 3.471 . . . . 0.0 114.078 171.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.438 ' HA ' ' CG2' ' B' ' 5' ' ' VAL . 1.9 p30 -78.95 47.29 0.75 Allowed 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.27 2.535 . . . . 0.0 109.97 168.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.512 ' H ' ' C ' ' A' ' 51' ' ' GLY 0.31 0.1 OUTLIER -90.13 45.62 1.28 Allowed 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 115.533 1.679 . . . . 0.0 115.533 -165.661 . . . . . . . . 4 4 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.561 ' HG1' ' CG2' ' B' ' 17' ' ' ILE . 19.4 p -119.91 -38.06 3.01 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -163.533 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.26 13.13 24.4 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 126.206 1.802 . . . . 0.0 112.9 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.48 -123.87 34.16 Favored Glycine 0 C--N 1.341 0.852 0 C-N-CA 125.112 1.339 . . . . 0.0 111.512 175.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 70.2 m -58.82 -13.77 7.06 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.827 1.417 . . . . 0.0 114.827 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.57 1.43 29.68 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.004 1.322 . . . . 0.0 112.081 173.135 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.2 m -158.54 -131.21 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 127.253 2.221 . . . . 0.0 108.209 -174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.34 95.35 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 128.002 2.521 . . . . 0.0 114.638 -173.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.6 162.24 53.92 Favored Glycine 0 CA--C 1.531 1.04 0 N-CA-C 115.301 0.88 . . . . 0.0 115.301 -167.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -69.24 84.57 0.57 Allowed 'Trans proline' 0 C--N 1.354 0.855 1 C-N-CA 125.963 4.442 . . . . 0.0 111.104 -173.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.5 p80 51.65 59.29 4.67 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 127.971 2.509 . . . . 0.0 110.808 169.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -56.05 167.05 0.66 Allowed 'General case' 0 N--CA 1.445 -0.723 0 CA-C-O 126.043 2.83 . . . . 0.0 112.443 -173.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -118.88 73.67 12.3 Favored Pre-proline 0 C--N 1.314 -0.938 0 CA-C-N 110.837 -2.892 . . . . 0.0 112.275 -169.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.45 -23.72 75.14 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.018 2.479 . . . . 0.0 113.44 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 27.7 tp -86.64 -3.63 59.06 Favored 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.477 1.511 . . . . 0.0 113.191 170.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.7 t 68.15 49.69 0.83 Allowed 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.609 2.364 . . . . 0.0 112.578 176.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -106.67 170.91 7.65 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 115.224 1.564 . . . . 0.0 115.224 -168.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.5 mtmt -74.04 162.06 29.41 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.35 1.46 . . . . 0.0 109.247 164.434 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -86.83 142.63 27.94 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 172.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.4 -123.71 1.8 Allowed Glycine 0 C--N 1.341 0.815 0 N-CA-C 117.059 1.584 . . . . 0.0 117.059 164.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.47 -38.96 2.32 Favored Glycine 0 CA--C 1.546 1.998 0 N-CA-C 118.207 2.043 . . . . 0.0 118.207 -169.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -99.61 11.82 0.64 Allowed 'Trans proline' 0 CA--C 1.546 1.123 0 C-N-CA 123.955 3.104 . . . . 0.0 113.684 -176.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.67 -30.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 128.275 2.63 . . . . 0.0 109.893 167.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -75.31 152.89 38.13 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.153 0.978 . . . . 0.0 109.232 163.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -89.59 -26.13 20.96 Favored 'General case' 0 C--N 1.321 -0.664 1 C-N-CA 131.708 4.003 . . . . 0.0 111.679 -173.202 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -92.04 -71.29 0.65 Allowed 'General case' 0 C--N 1.34 0.164 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -169.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.4 ttt180 69.95 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.779 1.632 . . . . 0.0 112.861 -175.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -57.79 163.01 2.81 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 119.388 -2.07 . . . . 0.0 113.902 171.159 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.25 -38.16 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 119.353 0.979 . . . . 0.0 111.738 170.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.43 45.12 3.23 Favored Glycine 0 CA--C 1.533 1.158 0 N-CA-C 114.992 0.757 . . . . 0.0 114.992 177.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -137.44 134.46 35.87 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 120.824 -1.398 . . . . 0.0 111.154 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -127.6 53.49 1.75 Allowed 'General case' 0 CA--C 1.546 0.817 0 CA-C-O 122.111 0.958 . . . . 0.0 109.107 165.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.54 -138.26 42.76 Favored Glycine 0 C--N 1.342 0.882 0 C-N-CA 125.577 1.56 . . . . 0.0 113.129 172.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -141.71 150.86 42.39 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.031 0.933 . . . . 0.0 110.137 168.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.404 HG23 ' H ' ' A' ' 88' ' ' THR . 1.7 p -96.76 178.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 C-N-CA 127.659 2.384 . . . . 0.0 110.651 -174.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.404 ' H ' HG23 ' A' ' 87' ' ' VAL . 83.1 m -149.96 138.2 20.47 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 124.973 1.309 . . . . 0.0 110.056 178.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.15 140.45 38.29 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.105 1.362 . . . . 0.0 114.641 -176.139 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -77.79 146.03 36.06 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.761 1.624 . . . . 0.0 109.775 166.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.93 -16.35 0.13 Allowed 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 130.066 3.346 . . . . 0.0 118.08 175.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -75.26 1.23 14.09 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-N 119.762 1.164 . . . . 0.0 110.776 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.25 43.52 4.95 Favored Glycine 0 C--N 1.336 0.551 0 C-N-CA 128.054 2.74 . . . . 0.0 112.408 171.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.8 p -155.38 132.22 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 119.562 1.681 . . . . 0.0 115.14 -175.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.75 107.64 20.13 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 165.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -98.37 144.59 27.6 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.658 0.742 . . . . 0.0 110.088 169.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -121.92 146.11 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 N-CA-C 115.07 1.507 . . . . 0.0 115.07 -174.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.8 t -159.47 81.34 0.75 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 126.712 2.005 . . . . 0.0 111.837 175.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -127.95 158.08 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 127.152 2.181 . . . . 0.0 110.917 -174.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -126.15 138.63 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 167.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -134.45 145.8 49.19 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.273 1.029 . . . . 0.0 112.718 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 12.4 p -120.5 48.58 1.57 Allowed 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 114.575 1.324 . . . . 0.0 114.575 -179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.0 m -139.35 3.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.35 139.18 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.819 1.248 . . . . 0.0 109.043 168.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 46.6 p -112.04 176.69 4.92 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 118.718 0.69 . . . . 0.0 111.123 169.031 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.8 mt -82.31 107.64 15.14 Favored 'General case' 0 C--N 1.345 0.4 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 167.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -136.98 -13.24 1.65 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.47 31.97 71.34 Favored Glycine 0 C--N 1.342 0.879 0 CA-C-N 119.884 1.22 . . . . 0.0 115.155 172.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -170.44 -103.32 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.802 1.241 . . . . 0.0 108.026 -169.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -79.43 8.74 5.7 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.34 2.256 . . . . 0.0 112.329 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 55.5 m -149.85 -161.53 1.36 Allowed 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.241 1.416 . . . . 0.0 109.438 165.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 15.3 pt -82.41 161.37 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 O-C-N 120.171 -1.581 . . . . 0.0 113.835 -168.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 2.3 mm 106.44 147.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 1 C-N-CA 135.023 5.329 . . . . 0.0 110.118 -167.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.47 2.73 56.02 Favored Glycine 0 C--O 1.219 -0.803 0 CA-C-O 117.319 -1.823 . . . . 0.0 114.838 174.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 34.8 mtt-85 -106.22 -176.14 2.99 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.898 2.479 . . . . 0.0 110.338 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.0 t -120.29 145.43 47.08 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 119.554 1.07 . . . . 0.0 110.934 169.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.0 tp -101.32 133.52 45.78 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 127.086 2.154 . . . . 0.0 109.723 170.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.46 147.8 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.512 1.525 . . . . 0.0 110.576 168.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 91.7 t -129.03 151.15 35.36 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 C-N-CA 126.067 1.747 . . . . 0.0 107.035 173.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 74.3 m-70 -124.25 133.8 53.41 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.365 1.066 . . . . 0.0 113.17 -168.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.267 24.2 tp10 -84.81 39.07 0.73 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 -167.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -154.15 160.48 41.92 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.44 1.896 . . . . 0.0 109.5 169.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.57 118.36 8.08 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 169.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.5 157.93 20.3 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.477 1.132 . . . . 0.0 112.208 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -90.81 -9.49 46.27 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 128.587 2.755 . . . . 0.0 113.076 -169.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.3 mp 1.54 79.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 130.911 3.684 . . . . 0.0 116.194 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.21 -66.68 0.57 Allowed Glycine 0 N--CA 1.467 0.753 0 C-N-CA 125.068 1.318 . . . . 0.0 114.287 170.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.7 ttpp -157.49 93.28 1.28 Allowed 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.436 1.273 . . . . 0.0 114.436 -170.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.88 -113.74 2.18 Favored Glycine 0 C--O 1.235 0.216 0 N-CA-C 108.336 -1.906 . . . . 0.0 108.336 165.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -131.32 33.66 2.74 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.151 1.834 . . . . 0.0 113.328 177.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -159.58 159.83 33.7 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 118.78 1.29 . . . . 0.0 108.766 -171.229 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -68.73 -48.97 62.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.29 0.566 . . . . 0.0 110.093 -176.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.1 mp0 -38.63 -33.97 0.13 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.636 3.174 . . . . 0.0 113.591 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.9 p -59.88 -44.97 93.9 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.281 1.432 . . . . 0.0 114.021 175.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.8 t -81.7 -36.38 28.76 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 118.96 0.8 . . . . 0.0 111.283 168.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 16.6 tttt -56.88 -48.14 78.86 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.117 1.367 . . . . 0.0 111.991 -175.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -147.48 -10.79 0.41 Allowed 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 126.818 2.047 . . . . 0.0 115.009 -168.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.65 3.56 57.25 Favored Glycine 0 C--O 1.223 -0.575 0 CA-C-O 117.374 -1.792 . . . . 0.0 113.128 -173.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 67.54 -60.33 0.39 Allowed 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.043 2.137 . . . . 0.0 111.333 -172.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 68.41 -21.39 0.14 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 129.795 3.238 . . . . 0.0 115.571 168.585 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.61 -20.26 0.14 Allowed Glycine 0 CA--C 1.537 1.418 0 C-N-CA 126.904 2.192 . . . . 0.0 118.447 166.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.7 t -161.65 -173.11 3.6 Favored 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 127.626 2.371 . . . . 0.0 110.819 176.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.05 154.22 43.01 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.473 -1.392 . . . . 0.0 110.029 169.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.94 -129.11 0.22 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 123.43 0.692 . . . . 0.0 110.292 169.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.43 158.87 32.75 Favored 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 126.667 1.987 . . . . 0.0 113.113 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -140.79 161.58 37.46 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.922 2.089 . . . . 0.0 110.062 169.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.32 148.21 16.7 Favored Glycine 0 N--CA 1.472 1.038 0 O-C-N 121.272 -0.892 . . . . 0.0 112.918 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -78.56 161.78 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 C-N-CA 123.95 0.9 . . . . 0.0 109.773 177.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 36.8 mt -110.71 98.51 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 120.356 -1.465 . . . . 0.0 112.207 -175.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.45 167.07 22.14 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.712 1.625 . . . . 0.0 115.402 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.99 80.07 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 C-N-CA 127.91 2.484 . . . . 0.0 113.387 -175.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.36 26.24 0.22 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.657 1.583 . . . . 0.0 115.16 -175.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 . . . . . 0 N--CA 1.469 0.518 0 C-N-CA 129.413 3.085 . . . . 0.0 114.346 176.549 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 119.418 -0.325 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.9 m -79.78 108.69 13.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 125.333 1.453 . . . . 0.0 108.088 -171.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 27.6 mttt -99.43 118.59 36.39 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -171.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -83.35 169.25 15.83 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 127.71 2.404 . . . . 0.0 114.874 178.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -156.07 125.43 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 129.412 3.085 . . . . 0.0 107.55 175.608 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.07 139.38 47.64 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.088 0.955 . . . . 0.0 113.173 179.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 t -85.88 68.07 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.189 -0.914 . . . . 0.0 112.401 -168.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.12 103.13 5.17 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 122.208 1.004 . . . . 0.0 108.337 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -161.91 133.09 5.21 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 125.331 1.453 . . . . 0.0 109.713 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.25 -118.06 3.76 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -127.3 57.48 1.49 Allowed 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 126.046 1.738 . . . . 0.0 111.706 -164.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.5 -168.07 41.17 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 121.074 -1.016 . . . . 0.0 112.901 -171.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.55 -5.94 12.58 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 124.354 3.369 . . . . 0.0 115.444 -168.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.16 129.19 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 CA-C-N 120.258 1.39 . . . . 0.0 110.371 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -123.13 178.55 5.04 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 122.518 1.151 . . . . 0.0 110.29 168.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.2 163.01 31.29 Favored Glycine 0 CA--C 1.499 -0.942 0 CA-C-N 113.888 -1.506 . . . . 0.0 113.129 165.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.561 ' CG2' ' HG1' ' A' ' 54' ' ' THR . 2.3 pt -133.6 82.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 112.162 -2.019 . . . . 0.0 106.688 170.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.343 2.7 pp -89.49 109.87 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -112.74 133.54 54.71 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.523 2.329 . . . . 0.0 108.577 -170.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -124.48 147.06 48.58 Favored 'General case' 0 N--CA 1.474 0.766 0 O-C-N 121.028 -1.045 . . . . 0.0 111.178 -174.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -108.66 112.22 24.43 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.522 1.129 . . . . 0.0 111.717 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.3 99.04 10.87 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.407 ' HE2' ' HB2' ' B' ' 24' ' ' GLU . 0.2 OUTLIER -70.72 -28.8 65.0 Favored 'General case' 0 CA--C 1.539 0.53 0 O-C-N 121.415 -0.803 . . . . 0.0 113.108 170.276 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.407 ' HB2' ' HE2' ' B' ' 23' ' ' LYS . 43.1 tt0 -163.61 124.54 2.29 Favored 'General case' 0 C--O 1.222 -0.355 0 C-N-CA 124.689 1.196 . . . . 0.0 110.446 -166.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.0 p -60.86 -10.16 5.2 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 127.977 2.511 . . . . 0.0 114.8 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -132.93 15.16 4.28 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.239 1.816 . . . . 0.0 111.841 -171.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.42 -153.09 7.42 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 126.628 2.061 . . . . 0.0 111.724 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -85.29 167.05 10.69 Favored 'Trans proline' 0 N--CA 1.456 -0.733 0 C-N-CA 122.642 2.228 . . . . 0.0 112.202 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -119.78 140.22 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 124.993 1.317 . . . . 0.0 108.859 170.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -94.89 121.94 37.01 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 168.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.17 131.95 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 128.04 2.536 . . . . 0.0 109.071 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -156.05 -176.77 6.13 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 119.49 168.25 13.89 Favored Glycine 0 C--N 1.335 0.518 0 CA-C-O 122.079 0.822 . . . . 0.0 114.478 166.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 4.9 p -99.08 123.37 43.33 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -167.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 mp -98.5 118.08 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 166.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -129.01 132.29 47.5 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.551 1.54 . . . . 0.0 110.788 -166.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.26 -2.59 29.68 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 128.228 2.823 . . . . 0.0 111.939 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 22.4 mt -69.91 148.11 49.41 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 118.94 1.37 . . . . 0.0 112.598 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 26.8 m -76.37 143.97 40.39 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 125.614 1.565 . . . . 0.0 107.211 165.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -59.24 156.4 12.48 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.81 -179.45 35.55 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.668 0.652 . . . . 0.0 112.281 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.472 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -83.25 142.39 31.17 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 127.267 2.227 . . . . 0.0 113.846 -169.56 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 80.5 m-70 -134.01 125.78 28.85 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 129.093 2.957 . . . . 0.0 108.602 -176.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.09 148.64 28.15 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 125.492 1.52 . . . . 0.0 112.594 178.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -142.26 103.52 4.29 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.999 1.399 . . . . 0.0 111.528 -168.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.56 139.0 33.07 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 120.223 -1.548 . . . . 0.0 111.226 -175.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.88 115.52 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 176.154 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -71.86 -178.52 2.34 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 128.119 2.567 . . . . 0.0 111.172 -169.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.7 145.02 46.45 Favored 'General case' 0 CA--C 1.547 0.828 0 O-C-N 121.317 -0.864 . . . . 0.0 111.008 168.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -92.54 -170.95 2.62 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.28 1.832 . . . . 0.0 113.06 -169.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.17 -108.36 3.0 Favored Glycine 0 C--N 1.334 0.447 0 N-CA-C 115.694 1.037 . . . . 0.0 115.694 163.369 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -77.92 65.04 3.27 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.252 1.421 . . . . 0.0 110.567 -169.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.427 ' H ' HG11 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -165.52 162.59 19.27 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.714 1.376 . . . . 0.0 114.714 -168.598 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 39.5 p . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 116.65 2.093 . . . . 0.0 116.65 179.526 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.354 0 CA-C-O 121.43 0.633 . . . . 0.0 112.352 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.46 171.17 25.56 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.194 1.378 . . . . 0.0 113.765 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -65.34 169.41 12.48 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 124.493 3.462 . . . . 0.0 112.264 -173.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -20.19 86.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 128.504 2.722 . . . . 0.0 117.733 175.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -50.57 126.63 15.9 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 123.54 1.638 . . . . 0.0 114.053 -172.076 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.46 59.81 0.46 Allowed Pre-proline 0 CA--C 1.558 1.261 0 CA-C-N 112.194 -2.276 . . . . 0.0 115.851 -168.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -65.28 -27.53 55.8 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 123.355 2.704 . . . . 0.0 114.232 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -76.28 -3.99 39.58 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.195 0.998 . . . . 0.0 112.244 175.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t 63.54 50.58 2.76 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 126.002 1.721 . . . . 0.0 111.114 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -103.14 168.45 9.17 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.551 1.14 . . . . 0.0 111.757 -174.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.408 ' HE3' ' HD2' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -96.39 173.1 7.54 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.456 1.502 . . . . 0.0 107.287 164.433 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.404 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 29.5 t60 -63.88 164.5 10.12 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 119.981 -1.699 . . . . 0.0 113.715 -178.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 166.67 -174.44 42.07 Favored Glycine 0 N--CA 1.469 0.863 0 O-C-N 120.921 -1.112 . . . . 0.0 113.929 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.28 -154.26 25.38 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 -167.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -62.77 -1.75 2.94 Favored 'Trans proline' 0 CA--C 1.54 0.807 1 C-N-CA 125.849 4.366 . . . . 0.0 116.379 -172.623 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -120.89 -1.98 9.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.021 1.329 . . . . 0.0 113.641 170.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -131.04 176.79 7.96 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 126.746 2.018 . . . . 0.0 110.259 -168.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -100.15 -17.07 17.58 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 127.13 2.172 . . . . 0.0 113.803 -169.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -95.2 -100.34 0.16 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 118.565 0.621 . . . . 0.0 112.673 -176.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.2 ttp-105 85.77 97.28 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 126.825 2.05 . . . . 0.0 110.024 -175.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -49.67 156.83 0.63 Allowed 'General case' 0 N--CA 1.475 0.799 0 O-C-N 119.936 -1.727 . . . . 0.0 111.788 168.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 46.4 t -53.38 -21.5 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 119.266 0.939 . . . . 0.0 113.265 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.29 61.4 0.55 Allowed Glycine 0 CA--C 1.531 1.036 0 CA-C-O 118.573 -1.126 . . . . 0.0 114.105 169.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -123.52 124.68 43.37 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 119.642 1.721 . . . . 0.0 109.099 168.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.9 mt -132.18 49.22 2.34 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 119.268 0.94 . . . . 0.0 112.381 -176.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.94 -148.29 47.71 Favored Glycine 0 CA--C 1.534 1.277 0 O-C-N 121.101 -1.0 . . . . 0.0 113.49 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -129.76 137.27 50.44 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.781 1.233 . . . . 0.0 109.837 168.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -96.15 133.32 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 125.861 1.664 . . . . 0.0 110.227 179.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 32.1 m -108.94 136.81 47.87 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 124.222 1.009 . . . . 0.0 108.803 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.35 145.09 26.47 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 174.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -77.18 146.91 36.76 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.118 1.767 . . . . 0.0 110.499 167.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -63.91 -14.3 52.46 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.925 1.824 . . . . 0.0 115.925 -169.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -76.16 3.32 10.86 Favored 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 125.471 1.508 . . . . 0.0 111.481 171.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 100.36 29.41 6.71 Favored Glycine 0 C--N 1.342 0.892 0 C-N-CA 126.327 1.918 . . . . 0.0 114.719 168.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.1 139.51 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 120.227 2.014 . . . . 0.0 115.215 -169.048 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.49 99.29 7.07 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 124.401 1.08 . . . . 0.0 110.187 169.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -87.74 91.24 8.68 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-O 122.591 1.186 . . . . 0.0 109.169 172.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -75.85 158.64 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 CA-C-N 114.109 -1.405 . . . . 0.0 114.133 -167.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 82.4 p -155.0 105.93 2.59 Favored 'General case' 0 N--CA 1.471 0.584 0 O-C-N 120.61 -1.306 . . . . 0.0 111.782 -175.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.3 mt -137.43 153.19 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 126.708 2.003 . . . . 0.0 110.639 -176.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -139.01 136.14 35.02 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.26 1.824 . . . . 0.0 107.92 168.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -149.18 143.97 26.28 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 125.873 1.669 . . . . 0.0 111.013 -172.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -107.89 53.19 0.69 Allowed 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 113.29 0.848 . . . . 0.0 113.29 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.1 t -144.3 -42.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 124.29 1.036 . . . . 0.0 112.92 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.63 163.08 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 O-C-N 121.14 -0.975 . . . . 0.0 113.447 -176.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -156.57 154.24 29.93 Favored 'General case' 0 N--CA 1.476 0.838 0 O-C-N 119.91 -1.744 . . . . 0.0 113.341 174.033 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mp -84.85 46.43 1.26 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.008 1.323 . . . . 0.0 108.65 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.0 m -75.59 -34.63 60.66 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 116.091 1.886 . . . . 0.0 116.091 -166.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.62 18.41 Favored Glycine 0 CA--C 1.536 1.352 0 N-CA-C 115.578 0.991 . . . . 0.0 115.578 -174.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 p30 -116.74 -83.23 0.63 Allowed 'General case' 0 CA--C 1.549 0.905 0 C-N-CA 125.65 1.58 . . . . 0.0 111.003 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -143.42 -1.59 1.02 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 129.399 3.079 . . . . 0.0 111.922 -178.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 52.5 m -73.46 -91.54 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 126.488 1.915 . . . . 0.0 112.003 -169.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.7 pt -136.04 -26.34 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 175.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 mm -66.04 136.68 26.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 CA-C-N 122.826 2.557 . . . . 0.0 108.621 168.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.52 -16.53 6.22 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.018 0.818 . . . . 0.0 114.594 -172.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -79.07 178.39 8.08 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.528 1.131 . . . . 0.0 109.361 169.235 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.57 124.26 12.56 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.479 1.036 . . . . 0.0 111.902 -170.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 tp -89.27 120.36 30.57 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.0 p -99.89 130.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 124.14 0.976 . . . . 0.0 110.802 171.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.8 m -93.38 133.71 33.58 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 165.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -96.39 177.75 5.59 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 125.355 1.462 . . . . 0.0 111.155 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -84.76 -58.04 2.87 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 120.912 -1.118 . . . . 0.0 110.648 -173.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -95.34 177.99 5.66 Favored 'General case' 0 N--CA 1.471 0.593 0 O-C-N 120.746 -1.221 . . . . 0.0 110.537 169.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.03 146.09 28.36 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 168.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -86.89 163.09 17.37 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 123.145 1.45 . . . . 0.0 111.368 169.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.47 -8.83 57.98 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.105 1.762 . . . . 0.0 112.25 -170.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 95.6 mt 33.6 50.24 0.28 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 128.511 2.724 . . . . 0.0 113.276 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 159.84 -93.62 0.12 Allowed Glycine 0 C--N 1.333 0.41 0 O-C-N 121.678 -0.639 . . . . 0.0 114.336 -178.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.408 ' HD2' ' HE3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -159.16 127.38 5.08 Favored 'General case' 0 CA--C 1.55 0.978 0 C-N-CA 125.422 1.489 . . . . 0.0 112.422 -173.711 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -123.87 -19.05 2.8 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.593 1.092 . . . . 0.0 115.095 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 119.69 -14.49 10.65 Favored Glycine 0 N--CA 1.474 1.217 0 CA-C-O 118.34 -1.255 . . . . 0.0 116.227 171.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -98.11 165.12 12.04 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.875 1.838 . . . . 0.0 110.175 168.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -51.8 -55.83 17.51 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.328 1.051 . . . . 0.0 110.035 178.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -51.6 -33.29 32.3 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 128.041 2.536 . . . . 0.0 113.313 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -54.86 -46.37 74.67 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 121.137 1.789 . . . . 0.0 113.861 176.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -91.24 -31.67 16.05 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 172.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -74.11 -28.17 61.23 Favored 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.7 m -128.82 -44.68 1.32 Allowed 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.352 1.461 . . . . 0.0 111.672 -179.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . 0.404 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 122.16 7.92 7.49 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 127.781 2.61 . . . . 0.0 112.269 -167.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 61.08 -77.39 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 126.213 1.805 . . . . 0.0 109.382 -169.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 64.94 3.61 2.16 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 127.889 2.476 . . . . 0.0 117.482 164.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.49 -46.63 1.97 Allowed Glycine 0 N--CA 1.471 1.014 0 C-N-CA 125.398 1.475 . . . . 0.0 113.803 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.9 m -178.27 176.71 1.06 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 126.933 2.093 . . . . 0.0 112.002 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -79.43 173.63 12.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.586 0.754 . . . . 0.0 110.846 168.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -140.74 -79.55 0.27 Allowed 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.755 0.822 . . . . 0.0 109.964 169.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.47 43.89 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 126.4 1.88 . . . . 0.0 109.686 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -156.81 151.74 26.02 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.966 1.706 . . . . 0.0 111.833 -171.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.79 148.74 17.18 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 116.415 1.326 . . . . 0.0 116.415 176.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -74.56 140.68 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 117.627 0.713 . . . . 0.0 110.671 175.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.9 mm -81.24 118.4 28.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 C-N-CA 125.303 1.441 . . . . 0.0 111.566 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.6 -167.16 14.58 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 126.227 1.87 . . . . 0.0 112.613 169.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -134.28 138.37 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.265 1.426 . . . . 0.0 114.34 -169.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.68 -141.26 0.27 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.703 1.201 . . . . 0.0 110.337 174.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.464 0 C-N-CA 124.272 1.029 . . . . 0.0 110.279 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.471 0.603 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -168.37 157.38 9.03 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 115.403 1.631 . . . . 0.0 115.403 163.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.1 179.02 8.06 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 130.231 3.413 . . . . 0.0 107.181 169.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.66 108.29 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 122.645 1.212 . . . . 0.0 111.619 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -101.5 96.64 7.27 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 167.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.1 t -76.91 136.06 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 165.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mp -128.39 104.29 7.63 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.155 -0.966 . . . . 0.0 109.562 -178.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -160.43 151.39 18.92 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 124.24 1.016 . . . . 0.0 111.865 -178.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.17 -116.94 1.02 Allowed Glycine 0 CA--C 1.524 0.624 0 CA-C-O 123.089 1.383 . . . . 0.0 111.618 166.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -92.7 56.32 2.63 Favored 'General case' 0 C--N 1.312 -1.035 1 C-N-CA 132.635 4.374 . . . . 0.0 115.034 -164.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.4 -168.19 35.25 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.296 -1.32 . . . . 0.0 114.074 176.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -86.02 17.88 1.67 Allowed 'Trans proline' 0 CA--C 1.539 0.767 1 C-N-CA 125.686 4.257 . . . . 0.0 113.553 -171.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 t -111.08 120.84 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.87 1.213 . . . . 0.0 108.975 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 pm0 -160.25 162.31 33.66 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.52 173.65 33.64 Favored Glycine 0 N--CA 1.462 0.377 0 C-N-CA 124.368 0.985 . . . . 0.0 113.296 168.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -126.24 134.13 67.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 124.386 1.074 . . . . 0.0 108.86 170.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.8 mm -137.6 105.24 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 118.274 0.488 . . . . 0.0 110.231 -172.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -77.67 161.74 27.55 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.597 0.713 . . . . 0.0 111.662 172.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -137.17 111.22 8.32 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.897 1.679 . . . . 0.0 106.806 169.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -91.65 135.51 33.82 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 120.765 1.62 . . . . 0.0 109.794 172.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -132.1 145.99 51.75 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.825 0.821 . . . . 0.0 111.532 175.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.412 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -92.53 -34.74 13.94 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 124.624 1.169 . . . . 0.0 114.1 179.399 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.95 -154.42 0.55 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-N 120.66 1.573 . . . . 0.0 112.791 178.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 65.7 p -93.35 -0.23 56.68 Favored 'General case' 0 CA--C 1.538 0.518 0 O-C-N 119.228 -2.17 . . . . 0.0 115.469 -172.051 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -153.49 -8.71 0.16 Allowed 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 115.875 1.806 . . . . 0.0 115.875 -169.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.91 173.89 55.31 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 128.664 3.031 . . . . 0.0 114.023 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -78.22 139.36 16.75 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.046 2.497 . . . . 0.0 111.758 -175.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -108.84 132.9 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.418 1.087 . . . . 0.0 109.353 -170.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -99.07 113.21 25.3 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 122.172 0.987 . . . . 0.0 110.34 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.5 130.99 43.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 127.984 2.514 . . . . 0.0 109.14 -178.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.0 p90 -148.81 159.32 44.26 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.92 -157.12 27.21 Favored Glycine 0 C--O 1.225 -0.424 0 C-N-CA 126.058 1.79 . . . . 0.0 110.178 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.5 p -157.11 154.72 29.86 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 121.577 -0.955 . . . . 0.0 112.417 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 mp -121.67 130.91 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 125.599 1.56 . . . . 0.0 108.346 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.4 140.5 49.67 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.316 1.446 . . . . 0.0 111.012 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.52 11.6 11.51 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 126.17 1.843 . . . . 0.0 112.54 -168.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.7 mt -86.96 171.24 10.92 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.532 0.733 . . . . 0.0 109.54 169.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -80.53 -141.09 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 164.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.49 -154.13 0.37 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.939 1.296 . . . . 0.0 108.535 166.285 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 69.28 179.74 22.96 Favored Glycine 0 CA--C 1.532 1.147 0 O-C-N 120.398 -1.439 . . . . 0.0 115.331 168.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mp -87.52 154.77 20.36 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.973 1.709 . . . . 0.0 110.611 -176.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -150.67 103.52 3.11 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 127.323 2.249 . . . . 0.0 109.908 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.05 160.61 20.86 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 124.558 1.075 . . . . 0.0 114.185 -175.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -142.78 92.38 2.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 125.933 1.693 . . . . 0.0 109.186 -173.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -109.35 130.4 55.5 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.298 -1.501 . . . . 0.0 109.8 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 2.1 m -77.97 158.33 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -119.9 123.44 43.57 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 pm0 -57.47 147.16 27.33 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.774 0.797 . . . . 0.0 109.872 177.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 68.95 166.72 0.27 Allowed 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 126.111 2.862 . . . . 0.0 112.353 -176.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.81 10.8 18.4 Favored Glycine 0 N--CA 1.467 0.718 0 C-N-CA 128.198 2.809 . . . . 0.0 112.186 178.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -83.7 42.99 0.88 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 128.509 2.723 . . . . 0.0 114.055 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -179.88 -26.85 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 112.723 -2.035 . . . . 0.0 114.925 -166.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.389 43.4 p 27.74 -18.35 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 2 N-CA-C 123.535 4.643 . . . . 0.0 123.535 -167.625 . . . . . . . . 3 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.44 -0.37 57.36 Favored 'General case' 0 CA--C 1.549 0.91 0 CA-C-N 122.48 2.4 . . . . 0.0 114.278 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.9 -128.4 37.31 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 125.721 1.629 . . . . 0.0 111.396 177.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -51.62 -2.75 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.235 0 N-CA-C 117.215 2.302 . . . . 0.0 117.215 -176.665 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 85.7 m -110.63 11.37 22.82 Favored 'General case' 0 N--CA 1.481 1.108 0 O-C-N 119.795 -1.816 . . . . 0.0 113.782 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 t -155.79 -27.45 0.1 Allowed 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 115.92 1.822 . . . . 0.0 115.92 168.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.2 177.02 4.79 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.797 2.039 . . . . 0.0 108.912 166.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.79 -107.92 2.47 Favored Glycine 0 CA--C 1.541 1.719 0 CA-C-O 117.755 -1.58 . . . . 0.0 114.443 -169.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -101.69 -167.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.543 0.956 1 C-N-CA 127.23 5.287 . . . . 0.0 112.144 -174.623 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.629 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.6 OUTLIER -100.11 119.83 38.91 Favored 'General case' 0 CA--C 1.554 1.111 1 C-N-CA 132.292 4.237 . . . . 0.0 115.243 -178.274 . . . . . . . . 4 4 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -39.74 126.93 2.0 Allowed 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 130.074 3.35 . . . . 0.0 116.123 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 51.0 p-10 -121.6 32.72 0.21 Allowed Pre-proline 0 CA--C 1.557 1.212 0 N-CA-C 115.304 1.594 . . . . 0.0 115.304 -173.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -62.8 -20.66 71.8 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.959 3.106 . . . . 0.0 114.978 -167.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 60.5 mt -78.46 -1.78 35.34 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.09 1.356 . . . . 0.0 112.685 174.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.76 52.8 0.93 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 127.269 2.227 . . . . 0.0 111.765 173.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.4 ptt180 -156.97 -179.98 8.73 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -166.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.26 177.53 8.9 Favored 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.434 1.494 . . . . 0.0 113.983 -171.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -50.87 157.8 0.76 Allowed 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -169.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -80.85 67.75 3.52 Favored Glycine 0 N--CA 1.474 1.177 0 C-N-CA 125.601 1.572 . . . . 0.0 114.354 -167.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -97.06 128.37 9.53 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-O 118.913 -0.937 . . . . 0.0 114.583 -168.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -76.84 4.68 5.48 Favored 'Trans proline' 0 CA--C 1.545 1.071 0 C-N-CA 123.632 2.888 . . . . 0.0 111.713 167.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.56 -10.52 18.4 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.963 0.905 . . . . 0.0 111.863 168.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -123.37 139.73 53.74 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.155 0.982 . . . . 0.0 110.809 -166.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -66.81 -28.62 68.52 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.496 172.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -91.76 105.04 17.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 125.969 1.708 . . . . 0.0 106.946 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -140.11 112.69 7.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 129.065 2.946 . . . . 0.0 109.56 -170.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -58.71 152.29 19.15 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.094 1.357 . . . . 0.0 111.405 167.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 p -65.0 -13.75 15.43 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 171.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.02 43.64 1.36 Allowed Glycine 0 C--N 1.347 1.158 0 N-CA-C 118.26 2.064 . . . . 0.0 118.26 -168.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -147.68 143.6 27.75 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 119.891 1.845 . . . . 0.0 109.484 167.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.0 mt -108.67 54.37 0.66 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.638 0.732 . . . . 0.0 109.345 -175.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.09 -120.07 6.75 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 124.84 1.209 . . . . 0.0 112.239 -172.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.405 HD21 HD22 ' A' ' 126' ' ' LEU . 6.5 p30 -142.28 160.4 40.32 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.709 1.204 . . . . 0.0 109.717 170.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -99.17 151.4 4.73 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.763 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 164.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.9 m -134.55 120.86 20.17 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 124.736 1.214 . . . . 0.0 108.738 -177.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.46 140.2 29.71 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -175.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.409 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 46.0 t0 -81.9 160.07 23.5 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 128.155 2.582 . . . . 0.0 110.151 169.013 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.409 ' HZ3' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -53.47 -22.08 7.32 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 126.382 1.873 . . . . 0.0 114.944 -173.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -76.79 -3.9 40.69 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.445 2.298 . . . . 0.0 112.289 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.78 10.01 73.51 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 126.929 2.204 . . . . 0.0 114.477 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.83 137.54 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.583 1.553 . . . . 0.0 111.963 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -107.73 130.54 54.94 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.471 -0.936 . . . . 0.0 108.471 166.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -82.29 151.64 26.67 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 122.277 1.037 . . . . 0.0 109.499 170.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -134.08 129.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 112.81 -1.995 . . . . 0.0 111.867 164.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.2 p -157.85 54.05 0.47 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 124.4 1.08 . . . . 0.0 111.978 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.81 153.86 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 O-C-N 120.277 -1.515 . . . . 0.0 112.352 -171.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -129.28 139.9 51.63 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 125.845 1.658 . . . . 0.0 108.457 168.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -150.07 148.53 29.12 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.4 1.095 . . . . 0.0 111.662 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -107.5 55.61 0.65 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.082 1.753 . . . . 0.0 110.35 -171.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.6 p -152.47 11.32 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -169.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -153.58 163.09 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 127.158 2.183 . . . . 0.0 107.904 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.0 m -155.14 161.62 41.2 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 122.435 1.112 . . . . 0.0 112.56 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.5 tt -90.03 77.65 6.82 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 120.897 -1.127 . . . . 0.0 109.218 -169.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.7 t -83.3 -146.68 0.08 Allowed 'General case' 0 CA--C 1.547 0.841 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.704 167.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -137.73 23.06 3.11 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.105 1.812 . . . . 0.0 112.751 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -173.35 -70.09 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -163.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -94.01 11.15 30.75 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.576 2.35 . . . . 0.0 114.788 -164.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . 0.25 3.9 m -140.85 -100.6 0.15 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -178.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.5 pt -89.89 -57.32 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 CA-C-N 121.545 1.975 . . . . 0.0 111.345 169.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.0 mm -61.89 145.69 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 170.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 96.35 -38.92 2.94 Favored Glycine 0 CA--C 1.524 0.597 0 CA-C-O 118.09 -1.395 . . . . 0.0 113.606 176.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.7 ptt180 -83.31 170.07 14.99 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 119.212 1.506 . . . . 0.0 112.539 175.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.2 t -119.01 176.92 5.06 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.226 1.01 . . . . 0.0 113.457 174.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 22.2 tp -156.92 136.57 12.33 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 126.273 1.829 . . . . 0.0 113.536 -168.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.4 t -112.03 135.38 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.988 1.315 . . . . 0.0 110.478 170.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 m -93.31 151.85 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 168.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 65.8 m-70 -119.38 144.12 47.07 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.684 1.194 . . . . 0.0 113.007 -172.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -83.75 -16.67 43.93 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 120.956 -1.09 . . . . 0.0 113.25 -179.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -98.03 164.0 12.53 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 169.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.09 164.21 1.76 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.997 1.319 . . . . 0.0 112.041 170.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -124.16 141.01 52.42 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.103 1.761 . . . . 0.0 110.209 -177.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -73.39 -34.38 65.5 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 125.73 1.612 . . . . 0.0 110.862 177.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.405 HD22 HD21 ' A' ' 86' ' ' ASN . 42.6 mt 78.74 -24.19 0.22 Allowed 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 130.026 3.331 . . . . 0.0 113.272 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -137.23 -81.99 0.11 Allowed Glycine 0 N--CA 1.475 1.279 0 CA-C-N 121.379 1.9 . . . . 0.0 114.271 -175.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -158.23 139.21 13.13 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 128.29 2.636 . . . . 0.0 107.518 174.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -127.25 -119.87 2.29 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 126.708 2.099 . . . . 0.0 109.946 167.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -92.27 -33.57 7.58 Favored Glycine 0 N--CA 1.474 1.219 0 N-CA-C 117.629 1.811 . . . . 0.0 117.629 -167.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 32.6 p30 -114.44 172.09 7.23 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.384 1.473 . . . . 0.0 113.156 -168.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -48.58 -61.72 1.88 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 126.29 1.836 . . . . 0.0 110.506 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -41.1 -42.05 1.89 Allowed 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 128.509 2.724 . . . . 0.0 114.383 175.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 85.7 p -55.27 -28.83 56.07 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 121.499 1.954 . . . . 0.0 113.456 177.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -97.82 -32.65 11.6 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 113.806 1.039 . . . . 0.0 113.806 169.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -91.13 -15.12 29.93 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.547 1.939 . . . . 0.0 115.006 -169.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 77.2 p -137.3 -16.03 1.42 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 128.444 2.698 . . . . 0.0 112.81 170.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.04 12.24 60.47 Favored Glycine 0 C--N 1.341 0.861 0 C-N-CA 124.062 0.839 . . . . 0.0 112.284 -167.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.423 ' C ' ' H ' ' A' ' 141' ' ' GLY . 7.9 t-20 53.4 26.61 5.54 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.158 1.383 . . . . 0.0 111.563 -168.145 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.7 6.96 0.56 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.652 1.181 . . . . 0.0 113.732 -169.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.423 ' H ' ' C ' ' A' ' 139' ' ' ASN . . . 66.03 -37.14 0.15 Allowed Glycine 0 CA--C 1.531 1.073 1 C-N-CA 131.128 4.204 . . . . 0.0 117.753 168.551 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 46.3 t -175.92 140.64 0.43 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.291 1.437 . . . . 0.0 111.428 -168.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.7 ptt-85 -77.42 174.6 10.64 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 123.702 0.801 . . . . 0.0 113.158 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.44 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -152.52 -143.02 0.13 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.417 1.887 . . . . 0.0 107.426 177.355 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.44 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.4 167.42 14.69 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.312 1.845 . . . . 0.0 112.727 177.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -140.18 153.24 46.55 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 125.004 1.322 . . . . 0.0 111.122 -169.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.54 141.18 7.32 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 124.193 0.901 . . . . 0.0 113.381 171.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.8 163.24 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 166.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.2 mm -93.09 94.37 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 121.37 -0.831 . . . . 0.0 110.032 170.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.3 -178.79 48.46 Favored Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.047 1.784 . . . . 0.0 113.759 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -113.99 130.58 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 124.659 1.183 . . . . 0.0 112.809 -170.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.52 -3.48 58.33 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.266 1.826 . . . . 0.0 112.472 176.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 . . . . . 0 CA--C 1.533 0.294 0 C-N-CA 125.149 1.38 . . . . 0.0 110.183 175.524 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.29 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -77.45 111.65 13.38 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 123.003 1.382 . . . . 0.0 108.675 -168.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mtmm -101.05 113.34 26.25 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 113.949 -1.478 . . . . 0.0 114.479 -171.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.89 175.47 6.49 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 127.036 2.134 . . . . 0.0 110.636 167.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -159.65 137.87 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 126.283 1.833 . . . . 0.0 110.677 -169.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.13 134.03 55.22 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 124.107 0.963 . . . . 0.0 109.016 165.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.58 114.76 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.157 0.983 . . . . 0.0 108.455 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.14 130.91 44.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 126.29 1.836 . . . . 0.0 110.396 -167.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttt -150.57 175.63 11.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.485 1.114 . . . . 0.0 112.458 -177.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 139.97 -71.57 0.43 Allowed Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.868 2.651 . . . . 0.0 109.059 -172.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.71 69.79 1.81 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.813 2.045 . . . . 0.0 113.18 -169.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.6 -97.64 0.01 OUTLIER Glycine 0 CA--C 1.536 1.376 0 C-N-CA 127.607 2.527 . . . . 0.0 114.747 169.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -80.85 -16.41 10.17 Favored 'Trans proline' 0 C--N 1.352 0.727 0 C-N-CA 124.074 3.182 . . . . 0.0 114.304 -179.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 t -79.51 139.33 18.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 CA-C-N 120.561 1.528 . . . . 0.0 109.359 175.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.436 ' NE2' ' HZ3' ' B' ' 36' ' ' LYS . 0.0 OUTLIER -155.1 152.58 29.68 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 113.567 -1.651 . . . . 0.0 108.117 167.265 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.405 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.72 152.47 17.11 Favored Glycine 0 CA--C 1.488 -1.594 0 O-C-N 123.818 0.699 . . . . 0.0 111.817 172.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -126.7 130.87 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 166.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 11.1 mm -129.17 118.09 45.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 173.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -82.88 157.73 22.97 Favored 'General case' 0 N--CA 1.47 0.543 0 O-C-N 120.927 -1.108 . . . . 0.0 109.48 169.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -139.54 87.26 2.17 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.76 1.224 . . . . 0.0 108.139 179.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -86.91 124.15 32.81 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 121.299 -0.875 . . . . 0.0 112.034 174.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -113.82 134.84 54.54 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.869 0.842 . . . . 0.0 110.822 165.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.436 ' HZ2' ' HB3' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -91.33 -32.05 15.84 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 124.64 1.176 . . . . 0.0 112.552 179.188 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -99.14 -169.24 1.74 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.042 2.137 . . . . 0.0 109.836 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.9 m -118.28 -6.15 10.83 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 120.634 -1.291 . . . . 0.0 113.277 167.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 61.0 m-80 -141.67 19.89 2.18 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 126.36 1.864 . . . . 0.0 112.379 175.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.0 -158.17 14.22 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.596 2.046 . . . . 0.0 113.193 175.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.84 154.02 29.83 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.228 2.619 . . . . 0.0 113.776 -172.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.86 133.34 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 126.364 1.866 . . . . 0.0 110.377 178.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.564 ' HZ1' ' CD ' ' B' ' 100' ' ' GLU . 66.7 mttm -89.81 122.62 33.05 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.456 1.103 . . . . 0.0 110.607 171.315 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.19 84.66 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 128.081 2.553 . . . . 0.0 109.787 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 5.9 p90 -106.81 153.57 22.27 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 123.717 0.807 . . . . 0.0 111.234 169.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.01 -158.39 30.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 124.349 0.976 . . . . 0.0 112.141 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 91.8 p -159.41 136.04 9.26 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 -172.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . 0.405 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.5 mp -112.51 111.7 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 124.536 1.134 . . . . 0.0 109.77 173.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . 0.436 ' HZ3' ' NE2' ' B' ' 15' ' ' GLN . 22.2 pttp -116.43 133.63 55.8 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 123.829 0.852 . . . . 0.0 111.371 -169.301 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.66 -2.23 26.14 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 125.827 1.68 . . . . 0.0 114.792 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.3 pp -83.8 178.5 7.89 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 118.858 1.329 . . . . 0.0 109.59 169.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.72 163.33 22.52 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 124.052 0.941 . . . . 0.0 109.415 169.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' B' ' 40' ' ' GLU . 0.7 OUTLIER -52.56 178.54 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 177.724 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.31 -166.97 54.86 Favored Glycine 0 CA--C 1.527 0.827 0 O-C-N 120.274 -1.516 . . . . 0.0 112.958 172.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 77.3 mt -73.84 148.98 41.89 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.8 1.64 . . . . 0.0 111.764 -173.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -149.0 126.65 11.7 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 127.349 2.26 . . . . 0.0 110.437 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.55 157.1 25.67 Favored Glycine 0 N--CA 1.49 2.283 0 CA-C-O 117.625 -1.653 . . . . 0.0 112.756 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -157.58 110.84 2.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.469 2.308 . . . . 0.0 112.449 171.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.6 m80 -138.08 144.02 40.73 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 119.905 -1.747 . . . . 0.0 111.389 -175.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 132.63 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 C-N-CA 123.978 0.911 . . . . 0.0 110.118 177.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -75.37 117.42 17.15 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 168.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -73.37 60.46 0.62 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.469 1.908 . . . . 0.0 114.217 -168.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -179.4 164.25 1.31 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 128.983 2.913 . . . . 0.0 109.461 170.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.43 -10.29 55.87 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.245 0.926 . . . . 0.0 114.66 169.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -82.03 51.37 1.74 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 126.942 2.097 . . . . 0.0 110.439 -176.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 171.26 33.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 0.997 0 N-CA-C 115.805 1.779 . . . . 0.0 115.805 -164.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 118.184 2.661 . . . . 0.0 118.184 -168.971 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.619 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.27 158.91 20.55 Favored Glycine 0 CA--C 1.534 1.263 0 CA-C-O 117.672 -1.627 . . . . 0.0 110.728 169.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -55.04 103.52 0.1 Allowed 'Trans proline' 0 C--N 1.355 0.92 1 C-N-CA 125.663 4.242 . . . . 0.0 109.936 178.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 46.12 62.02 2.44 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 113.679 -1.601 . . . . 0.0 111.131 -175.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -37.62 134.19 0.71 Allowed 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.398 1.479 . . . . 0.0 112.183 -175.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -117.26 80.15 11.99 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -165.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.92 -13.32 34.12 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 123.101 2.534 . . . . 0.0 114.119 177.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -90.0 -6.69 55.34 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.85 1.26 . . . . 0.0 112.679 177.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.3 t 50.77 50.59 18.69 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 127.514 2.325 . . . . 0.0 114.703 -177.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -108.65 177.34 4.81 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 124.85 1.26 . . . . 0.0 113.065 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.431 ' HZ3' ' CD ' ' B' ' 78' ' ' GLU . 0.0 OUTLIER -81.11 164.69 22.22 Favored 'General case' 0 N--CA 1.47 0.555 0 O-C-N 121.342 -0.849 . . . . 0.0 110.73 167.146 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.516 ' CG ' ' H ' ' B' ' 72' ' ' GLY . 63.8 t60 -68.1 -176.33 0.7 Allowed 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 122.095 0.95 . . . . 0.0 113.111 -176.108 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . 0.516 ' H ' ' CG ' ' B' ' 71' ' ' HIS . . . 111.07 -154.52 16.61 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 124.513 1.054 . . . . 0.0 115.492 165.063 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 166.13 -89.38 0.1 Allowed Glycine 0 CA--C 1.528 0.864 0 CA-C-O 118.205 -1.331 . . . . 0.0 114.725 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -67.9 -1.12 6.35 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 123.049 2.5 . . . . 0.0 114.15 -175.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -129.24 -4.14 4.95 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 125.613 1.565 . . . . 0.0 112.631 168.288 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -153.19 112.84 3.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.932 1.293 . . . . 0.0 110.347 -169.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -64.13 -12.2 37.42 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.324 1.85 . . . . 0.0 114.572 -175.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . 0.431 ' CD ' ' HZ3' ' B' ' 70' ' ' LYS . 10.3 mt-10 -75.44 -22.67 57.16 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 120.235 1.379 . . . . 0.0 113.651 -170.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 12.4 ttp85 14.57 100.97 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 130.564 3.546 . . . . 0.0 115.325 164.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.1 m170 -51.49 155.75 1.45 Allowed 'General case' 0 CA--C 1.558 1.258 0 CA-C-O 117.272 -1.347 . . . . 0.0 109.834 168.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.316 85.3 t -74.57 -17.49 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-N 123.865 3.029 . . . . 0.0 110.231 -175.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.47 7.52 64.55 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 127.423 2.44 . . . . 0.0 114.404 166.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -98.93 119.25 37.4 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.838 1.819 . . . . 0.0 113.401 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 63.3 mt -102.27 -176.06 3.01 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 126.73 2.012 . . . . 0.0 106.015 164.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.23 -144.91 5.09 Favored Glycine 0 CA--C 1.534 1.275 0 O-C-N 120.891 -1.13 . . . . 0.0 114.114 -178.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.65 152.16 49.46 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 123.983 0.913 . . . . 0.0 109.818 168.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 9.8 p -113.72 142.18 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.57 1.948 . . . . 0.0 112.207 -168.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -115.08 120.01 38.36 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.047 1.129 . . . . 0.0 114.047 -169.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.49 155.34 17.89 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 119.043 2.979 . . . . 0.0 119.043 175.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -84.51 164.89 18.51 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-N 111.631 -2.532 . . . . 0.0 109.808 167.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.16 -12.45 5.17 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 115.129 1.529 . . . . 0.0 115.129 171.399 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.66 -27.32 61.18 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.837 1.655 . . . . 0.0 111.2 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.24 -2.27 54.46 Favored Glycine 0 CA--C 1.523 0.544 0 CA-C-O 117.661 -1.633 . . . . 0.0 114.355 -177.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 9.5 p -79.48 118.49 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 119.572 1.686 . . . . 0.0 112.352 168.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -89.02 119.56 29.65 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.454 1.502 . . . . 0.0 108.587 166.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -80.46 140.27 36.02 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 118.492 0.587 . . . . 0.0 110.593 174.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -128.75 134.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.267 -1.333 . . . . 0.0 110.437 166.617 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.3 p -156.61 56.67 0.55 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 122.762 1.267 . . . . 0.0 109.628 -169.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 54.8 mt -114.78 160.68 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 125.044 1.337 . . . . 0.0 111.285 -169.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.564 ' CD ' ' HZ1' ' B' ' 30' ' ' LYS . 31.3 tt0 -133.47 146.15 50.87 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.837 2.055 . . . . 0.0 108.467 169.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -140.35 125.75 18.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 124.702 1.201 . . . . 0.0 110.442 -169.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 79.4 p -107.04 57.72 0.63 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.745 1.218 . . . . 0.0 112.308 -172.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -154.56 -41.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.93 173.67 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.232 -0.918 . . . . 0.0 112.026 177.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 25.8 m -158.25 162.99 37.86 Favored 'General case' 0 N--CA 1.481 1.081 0 O-C-N 119.579 -1.95 . . . . 0.0 115.028 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.35 59.24 1.8 Allowed 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.611 2.364 . . . . 0.0 108.484 175.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.9 t -89.82 1.3 56.32 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.242 1.017 . . . . 0.0 113.276 -175.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.17 -32.46 1.11 Allowed Glycine 0 N--CA 1.474 1.179 0 C-N-CA 125.029 1.3 . . . . 0.0 114.818 177.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -123.51 -95.06 0.48 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.985 1.314 . . . . 0.0 112.76 -169.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -75.92 3.07 10.9 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 119.678 -1.889 . . . . 0.0 114.344 -164.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.9 t -107.2 -128.85 0.27 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.677 -175.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 pt -84.0 -18.64 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 121.516 1.962 . . . . 0.0 115.981 -179.142 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mm -69.4 134.3 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.389 0.995 . . . . 0.0 111.017 -171.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.22 -2.75 75.12 Favored Glycine 0 CA--C 1.533 1.213 0 CA-C-O 117.836 -1.535 . . . . 0.0 114.038 -178.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.6 mtm180 -86.58 158.33 19.53 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 119.476 1.638 . . . . 0.0 109.998 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.5 t -115.98 119.85 37.23 Favored 'General case' 0 N--CA 1.486 1.346 0 CA-C-N 120.41 1.459 . . . . 0.0 112.942 -168.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 36.6 tp -94.93 121.33 36.43 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 126.511 1.924 . . . . 0.0 110.476 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 p -107.39 126.32 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.6 1.16 . . . . 0.0 110.194 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 67.5 t -89.15 163.57 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 168.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.9 m-70 -123.8 138.21 54.54 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.964 1.306 . . . . 0.0 111.286 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.1 pp20? -70.94 -11.23 60.85 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.177 -1.577 . . . . 0.0 114.549 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -115.62 167.03 11.27 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.107 1.363 . . . . 0.0 112.707 168.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.07 150.54 7.97 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.773 1.629 . . . . 0.0 110.434 166.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -112.53 144.68 41.6 Favored 'General case' 0 C--O 1.243 0.735 0 CA-C-O 121.717 0.77 . . . . 0.0 112.762 -178.172 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -76.45 -25.29 54.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.571 1.548 . . . . 0.0 111.748 -177.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt 48.61 51.93 14.69 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 126.949 2.099 . . . . 0.0 111.473 170.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 170.21 -94.44 0.1 Allowed Glycine 0 C--N 1.334 0.43 0 N-CA-C 117.11 1.604 . . . . 0.0 117.11 173.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 ptpp? -163.27 30.46 0.09 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -164.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -51.64 -22.06 7.77 Favored Glycine 0 N--CA 1.477 1.404 0 N-CA-C 119.388 2.515 . . . . 0.0 119.388 -168.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 175.77 -18.68 0.04 OUTLIER Glycine 0 N--CA 1.474 1.182 0 N-CA-C 117.565 1.786 . . . . 0.0 117.565 174.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -144.68 179.37 7.34 Favored 'General case' 0 CA--C 1.545 0.782 0 CA-C-N 119.291 1.546 . . . . 0.0 113.56 -173.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . 0.262 0.0 OUTLIER -49.84 -63.91 0.97 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.848 2.059 . . . . 0.0 111.435 172.232 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -54.11 -33.7 58.37 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 121.593 1.997 . . . . 0.0 113.373 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.15 -32.81 62.41 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 121.083 1.765 . . . . 0.0 114.193 172.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -105.32 -12.53 16.02 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.435 1.094 . . . . 0.0 113.499 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.7 tttt -96.54 -35.82 10.97 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.381 1.873 . . . . 0.0 112.705 -178.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.2 p -126.78 -20.65 4.22 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 125.139 1.376 . . . . 0.0 114.689 175.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.58 13.83 42.95 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.554 1.073 . . . . 0.0 110.534 -166.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 66.43 -68.08 0.14 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.769 3.228 . . . . 0.0 110.111 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 57.69 -66.7 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 131.445 3.898 . . . . 0.0 113.243 177.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.35 -28.71 4.98 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 127.523 2.487 . . . . 0.0 111.977 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.2 t -166.49 -161.63 0.47 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 124.605 1.162 . . . . 0.0 112.108 173.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -119.53 -156.49 0.66 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 128.328 2.651 . . . . 0.0 109.558 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -179.82 -164.55 0.06 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.867 2.467 . . . . 0.0 107.275 -171.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.89 144.25 23.43 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 127.243 2.217 . . . . 0.0 111.532 176.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -144.36 147.84 33.95 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -175.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.04 150.01 19.92 Favored Glycine 0 N--CA 1.476 1.355 0 C-N-CA 124.693 1.14 . . . . 0.0 114.651 -174.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 5.0 t -82.37 150.25 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.67 -0.9 . . . . 0.0 113.059 178.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -77.26 78.9 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 C-N-CA 126.562 1.945 . . . . 0.0 110.94 171.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -97.02 -158.96 31.3 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.243 1.878 . . . . 0.0 112.644 173.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -136.69 148.87 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -95.91 -120.07 0.11 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 103.058 -2.941 . . . . 0.0 103.058 163.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.471 0.597 0 C-N-CA 123.787 0.835 . . . . 0.0 112.674 166.051 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.446 -0.672 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.462 ' HZ1' ' HB ' ' A' ' 5' ' ' VAL . 0.7 OUTLIER -146.06 138.94 25.7 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 116.413 2.005 . . . . 0.0 116.413 177.035 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 169.63 9.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 127.258 2.223 . . . . 0.0 111.439 171.358 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.462 ' HB ' ' HZ1' ' A' ' 3' ' ' LYS . 14.7 p -158.6 110.51 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.772 1.629 . . . . 0.0 111.739 173.177 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.79 116.29 12.0 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.755 1.222 . . . . 0.0 112.442 -167.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 p -81.42 84.51 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.69 100.69 8.83 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 173.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -159.68 80.12 0.72 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 123.482 0.713 . . . . 0.0 112.172 -172.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.03 8.02 3.53 Favored Glycine 0 N--CA 1.472 1.056 0 C-N-CA 125.813 1.673 . . . . 0.0 113.658 169.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -133.46 54.88 1.93 Allowed 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 125.761 1.624 . . . . 0.0 108.74 -168.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 29.51 -98.23 0.01 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 129.381 3.372 . . . . 0.0 115.735 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.3 -15.22 47.42 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 124.2 3.266 . . . . 0.0 115.001 -176.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 t -111.34 128.86 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 125.058 1.343 . . . . 0.0 108.515 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.98 162.68 40.32 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.82 -174.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.45 170.07 29.0 Favored Glycine 0 CA--C 1.505 -0.592 0 CA-C-O 122.571 1.095 . . . . 0.0 114.206 174.629 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -130.76 128.27 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 C-N-CA 126.618 1.967 . . . . 0.0 106.356 173.498 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -137.94 112.53 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 121.312 -0.867 . . . . 0.0 109.72 172.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 28.1 m-80 -75.75 157.78 33.09 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.032 0.933 . . . . 0.0 111.091 178.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -141.58 127.93 19.93 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.812 1.245 . . . . 0.0 107.823 168.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -91.66 120.19 32.21 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.017 0.826 . . . . 0.0 112.138 174.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 -88.49 78.45 7.86 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 118.658 -2.526 . . . . 0.0 105.701 167.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.7 ptmt -58.19 -41.52 84.12 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 120.909 -1.119 . . . . 0.0 110.669 175.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -155.19 142.46 19.43 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 129.41 3.084 . . . . 0.0 108.088 -166.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 m -48.23 -44.42 33.18 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 116.175 1.917 . . . . 0.0 116.175 -167.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -126.12 23.38 7.1 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.783 1.233 . . . . 0.0 112.0 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.75 167.82 53.58 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.134 -0.815 . . . . 0.0 112.481 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -65.73 151.36 84.67 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.37 2.047 . . . . 0.0 109.496 169.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -135.62 134.63 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-O 122.63 1.205 . . . . 0.0 110.702 -175.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 ttmm -81.03 128.26 33.51 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 114.056 -1.429 . . . . 0.0 108.212 167.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 64.0 t -124.91 111.17 26.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 126.846 2.058 . . . . 0.0 110.599 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.2 p90 -144.81 154.85 43.11 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -168.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 162.11 -138.94 5.66 Favored Glycine 0 C--N 1.335 0.496 0 O-C-N 120.903 -1.123 . . . . 0.0 112.895 172.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -154.08 131.61 11.37 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -169.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mm -117.34 126.6 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 123.944 0.898 . . . . 0.0 109.322 173.169 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -123.7 142.23 51.27 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.305 1.842 . . . . 0.0 110.763 -168.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.49 -16.41 57.87 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 125.946 1.736 . . . . 0.0 111.774 -169.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -65.01 113.02 3.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 167.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -60.13 -41.54 92.91 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.97 0.804 . . . . 0.0 111.627 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.3 -178.16 1.98 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.381 1.073 . . . . 0.0 113.017 -168.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 65.96 176.27 6.53 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.961 1.267 . . . . 0.0 115.544 166.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.39 142.88 46.96 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 169.348 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -127.03 127.72 45.2 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 127.493 2.317 . . . . 0.0 107.145 174.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.84 156.43 40.35 Favored Glycine 0 N--CA 1.467 0.766 0 CA-C-O 119.016 -0.88 . . . . 0.0 111.13 -176.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.41 130.61 17.48 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 118.037 0.919 . . . . 0.0 109.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -154.89 161.97 41.26 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 120.337 -1.477 . . . . 0.0 111.1 173.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.37 135.83 40.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-O 122.629 1.204 . . . . 0.0 110.92 176.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -73.53 176.69 5.9 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 126.562 1.945 . . . . 0.0 110.526 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -72.18 -14.36 61.79 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.608 1.706 . . . . 0.0 115.608 174.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.432 ' CG ' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 -157.03 172.97 17.73 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 129.757 3.223 . . . . 0.0 107.609 -167.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.17 30.28 4.44 Favored Glycine 0 C--O 1.223 -0.581 0 N-CA-C 108.677 -1.769 . . . . 0.0 108.677 165.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -82.24 109.53 16.61 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 119.408 1.604 . . . . 0.0 111.027 -166.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.299 1.9 p30 -159.18 32.54 0.2 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 117.915 2.561 . . . . 0.0 117.915 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -84.84 -35.54 22.19 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 126.078 1.751 . . . . 0.0 112.883 -167.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -115.06 -13.68 11.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.021 1.729 . . . . 0.0 113.429 177.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.58 -75.68 0.84 Allowed Glycine 0 CA--C 1.529 0.939 0 C-N-CA 124.49 1.043 . . . . 0.0 111.524 -174.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.8 m -65.65 -17.62 64.73 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.9 p -127.51 33.43 4.84 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.333 1.453 . . . . 0.0 112.103 171.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 97.7 p -179.42 106.67 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.334 1.853 . . . . 0.0 110.56 177.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 166.53 73.43 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 131.183 3.793 . . . . 0.0 109.097 175.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.62 107.87 2.38 Favored Glycine 0 CA--C 1.542 1.725 0 C-N-CA 125.194 1.378 . . . . 0.0 114.665 -169.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -86.56 101.09 0.58 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 124.041 3.161 . . . . 0.0 112.008 -168.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 55.44 39.73 31.19 Favored 'General case' 0 C--O 1.242 0.7 0 C-N-CA 127.495 2.318 . . . . 0.0 113.221 170.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -77.05 124.69 28.15 Favored 'General case' 0 C--O 1.234 0.269 0 O-C-N 120.365 -1.46 . . . . 0.0 108.148 169.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.79 135.09 8.98 Favored Pre-proline 0 CA--C 1.539 0.554 0 CA-C-N 114.048 -1.433 . . . . 0.0 112.252 -173.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -71.43 -2.42 11.24 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.051 2.501 . . . . 0.0 114.214 -172.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 26.8 mt -79.51 -20.01 48.27 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 118.947 0.794 . . . . 0.0 112.038 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t 49.07 50.98 17.05 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 125.247 1.419 . . . . 0.0 113.371 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.0 mtm-85 -112.53 178.51 4.27 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 125.251 1.42 . . . . 0.0 112.666 -173.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.49 ' HZ3' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -77.77 161.14 27.91 Favored 'General case' 0 CA--C 1.553 1.093 0 CA-C-N 118.504 0.593 . . . . 0.0 109.811 164.669 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.549 ' CG ' ' H ' ' A' ' 72' ' ' GLY . 82.1 t60 -66.51 -175.91 0.41 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.503 1.521 . . . . 0.0 112.542 -177.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.549 ' H ' ' CG ' ' A' ' 71' ' ' HIS . . . 107.26 -138.27 14.41 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 115.549 0.98 . . . . 0.0 115.549 165.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.89 -64.54 0.6 Allowed Glycine 0 CA--C 1.541 1.68 0 N-CA-C 116.941 1.536 . . . . 0.0 116.941 -174.322 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.95 -4.55 15.31 Favored 'Trans proline' 0 CA--C 1.544 1.011 0 CA-C-N 121.11 2.455 . . . . 0.0 114.427 -178.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.41 ' HE2' ' O ' ' A' ' 126' ' ' LEU . 0.0 OUTLIER -148.59 -1.47 0.52 Allowed 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 126.154 1.782 . . . . 0.0 114.207 172.101 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -124.19 148.34 47.34 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.395 2.278 . . . . 0.0 107.405 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.04 -20.68 30.07 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 127.3 2.24 . . . . 0.0 112.735 -168.732 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.49 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 29.8 mt-10 -83.68 -64.96 1.07 Allowed 'General case' 0 C--O 1.232 0.149 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -169.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 34.7 ttt-85 66.19 120.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.285 1.434 . . . . 0.0 111.724 -177.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -65.53 172.56 3.24 Favored 'General case' 0 CA--C 1.544 0.716 0 O-C-N 119.567 -1.958 . . . . 0.0 109.355 165.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -35.29 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.313 -1.492 . . . . 0.0 112.644 168.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.71 50.65 0.77 Allowed Glycine 0 CA--C 1.534 1.277 0 N-CA-C 117.007 1.563 . . . . 0.0 117.007 -169.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -124.45 119.17 28.41 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.56 -0.965 . . . . 0.0 113.291 -169.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -97.35 175.5 6.23 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.944 1.298 . . . . 0.0 108.586 167.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.59 170.18 29.4 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.676 1.132 . . . . 0.0 111.214 169.034 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -76.79 145.85 38.24 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.56 1.318 . . . . 0.0 114.56 -176.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.21 122.71 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 127.23 2.212 . . . . 0.0 109.27 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 99.0 m -110.73 121.59 45.71 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -169.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.53 142.02 32.59 Favored 'General case' 0 N--CA 1.445 -0.702 0 C-N-CA 125.582 1.553 . . . . 0.0 113.328 -172.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -91.91 148.33 22.3 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.127 -1.397 . . . . 0.0 110.906 168.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.26 -21.23 0.25 Allowed 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 128.61 2.764 . . . . 0.0 117.38 -170.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -74.97 -0.71 19.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 127.492 2.317 . . . . 0.0 111.818 177.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.06 32.16 6.27 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 117.365 -1.797 . . . . 0.0 114.059 170.322 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -152.85 132.53 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 N-CA-C 117.152 2.279 . . . . 0.0 117.152 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.52 109.71 22.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.96 164.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -91.5 133.3 35.63 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -141.0 145.94 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 118.515 2.783 . . . . 0.0 118.515 -168.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 93.8 p -142.81 105.52 4.5 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.39 1.876 . . . . 0.0 110.018 168.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.3 mt -107.17 150.85 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 C-N-CA 125.916 1.686 . . . . 0.0 108.929 169.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -144.45 138.29 27.57 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.954 1.702 . . . . 0.0 107.631 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -157.05 152.25 26.26 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.162 0.985 . . . . 0.0 112.252 -168.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.3 p -119.17 55.2 0.95 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.469 1.108 . . . . 0.0 113.609 -168.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.6 p -158.56 -27.34 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 124.756 1.222 . . . . 0.0 112.776 171.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.56 150.02 5.51 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.327 0 O-C-N 121.062 -1.024 . . . . 0.0 111.029 175.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 p -158.05 162.92 38.13 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 121.057 -1.027 . . . . 0.0 109.174 171.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mp -85.83 47.82 1.5 Allowed 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.413 -1.429 . . . . 0.0 110.923 -172.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.6 t -82.18 -0.48 45.22 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -172.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.48 -7.02 74.58 Favored Glycine 0 N--CA 1.477 1.368 0 N-CA-C 118.216 2.046 . . . . 0.0 118.216 169.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -121.15 -94.81 0.49 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.637 1.575 . . . . 0.0 110.46 -167.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m170 -91.49 5.76 48.21 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -168.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.3 p -107.43 -70.71 0.78 Allowed 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 117.532 2.419 . . . . 0.0 117.532 -166.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pt -159.28 -51.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 125.747 1.619 . . . . 0.0 113.324 -167.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.44 ' C ' ' H ' ' A' ' 115' ' ' ARG . 1.6 mp -86.43 145.62 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 125.89 1.676 . . . . 0.0 108.347 177.175 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.83 -22.08 2.99 Favored Glycine 0 N--CA 1.47 0.92 0 C-N-CA 124.585 1.088 . . . . 0.0 112.125 -167.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.44 ' H ' ' C ' ' A' ' 113' ' ' ILE . 41.8 mtt180 -85.38 176.81 8.06 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.851 2.06 . . . . 0.0 110.948 169.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -108.76 133.66 52.52 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 127.471 2.309 . . . . 0.0 108.032 171.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.5 tp -102.41 118.05 36.04 Favored 'General case' 0 CA--C 1.535 0.365 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 168.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -112.15 129.81 66.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 CA-C-N 119.253 0.933 . . . . 0.0 110.815 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 p -88.92 145.99 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 121.394 0.616 . . . . 0.0 109.837 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -102.92 161.55 13.66 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.817 1.647 . . . . 0.0 111.83 -175.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.13 -31.91 62.95 Favored 'General case' 0 N--CA 1.473 0.704 0 O-C-N 121.081 -1.012 . . . . 0.0 112.086 -173.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 27.6 mmtm -131.86 -178.92 5.1 Favored 'General case' 0 C--O 1.237 0.4 0 O-C-N 119.234 -2.166 . . . . 0.0 110.974 169.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.72 129.02 39.38 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 125.077 1.351 . . . . 0.0 109.298 -176.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.18 152.62 30.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 166.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.27 -17.92 61.27 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.945 178.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.41 ' O ' ' HE2' ' A' ' 75' ' ' LYS . 13.4 mt 61.77 41.96 11.2 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.037 1.335 . . . . 0.0 110.227 177.112 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 175.28 -97.08 0.11 Allowed Glycine 0 N--CA 1.471 0.999 0 N-CA-C 118.969 2.348 . . . . 0.0 118.969 177.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.0 pttt -162.69 37.26 0.11 Allowed 'General case' 0 CA--C 1.555 1.139 0 C-N-CA 127.99 2.516 . . . . 0.0 113.631 -167.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -55.07 -12.7 4.13 Favored Glycine 0 CA--C 1.539 1.535 0 N-CA-C 120.132 2.813 . . . . 0.0 120.132 -168.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.47 -28.8 0.5 Allowed Glycine 0 N--CA 1.477 1.379 0 CA-C-N 121.085 2.442 . . . . 0.0 118.038 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 22.1 p-10 -107.13 166.62 10.48 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 119.404 1.602 . . . . 0.0 109.656 174.143 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -57.05 -48.58 78.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 119.932 1.242 . . . . 0.0 109.67 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -48.54 -34.56 11.59 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.722 2.809 . . . . 0.0 113.046 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.6 p -57.7 -28.22 63.64 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 173.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.09 -23.82 10.68 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 169.674 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -59.18 -28.07 66.28 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.484 1.038 . . . . 0.0 111.467 172.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.9 p -133.87 -93.04 0.33 Allowed 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 166.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -158.12 24.81 0.4 Allowed Glycine 0 CA--C 1.537 1.428 0 C-N-CA 130.194 3.759 . . . . 0.0 109.224 168.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 67.11 -84.0 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.367 1.867 . . . . 0.0 107.787 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 66.52 2.15 2.38 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 127.821 2.448 . . . . 0.0 116.711 166.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.71 -57.81 3.01 Favored Glycine 0 CA--C 1.53 1.004 0 C-N-CA 125.683 1.611 . . . . 0.0 113.681 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.5 t -171.83 -177.4 1.95 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.166 1.387 . . . . 0.0 111.306 -171.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.8 164.88 13.18 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 121.151 -0.968 . . . . 0.0 111.926 172.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.439 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -150.94 -152.57 0.44 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 127.568 2.347 . . . . 0.0 106.577 174.817 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.439 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -37.47 112.15 0.19 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.8 2.04 . . . . 0.0 114.296 -170.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.5 t -109.29 138.96 44.86 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.065 2.146 . . . . 0.0 110.538 -175.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.5 -178.57 21.13 Favored Glycine 0 N--CA 1.469 0.899 0 C-N-CA 124.588 1.09 . . . . 0.0 114.32 -175.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.97 160.41 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 104.893 -2.262 . . . . 0.0 104.893 165.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 2.6 mm -135.04 130.56 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 CA-C-N 120.069 1.304 . . . . 0.0 112.434 -168.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.27 -114.04 1.37 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.668 1.604 . . . . 0.0 115.025 -175.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -158.38 129.25 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 118.877 1.338 . . . . 0.0 109.756 -177.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 -35.55 14.95 Favored 'General case' 0 N--CA 1.47 0.531 0 O-C-N 120.929 -1.107 . . . . 0.0 112.42 177.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 . . . . . 0 C--O 1.235 0.294 0 C-N-CA 127.264 2.226 . . . . 0.0 110.005 -171.524 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.549 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 99.2 m -79.17 105.21 10.34 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 169.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.66 122.52 40.84 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.709 1.203 . . . . 0.0 113.366 -168.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.52 178.12 8.37 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 120.911 -1.118 . . . . 0.0 114.005 -177.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.86 110.03 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 128.053 2.541 . . . . 0.0 106.784 169.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -99.3 133.28 43.82 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.951 0.9 . . . . 0.0 108.631 166.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -131.36 99.42 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 123.256 0.622 . . . . 0.0 110.965 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.8 mp -88.21 141.69 28.36 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 124.067 0.854 . . . . 0.0 109.867 169.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -156.07 168.16 28.13 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.913 1.685 . . . . 0.0 112.073 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.48 -101.95 0.19 Allowed Glycine 0 C--O 1.226 -0.398 0 N-CA-C 107.583 -2.207 . . . . 0.0 107.583 166.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -149.42 124.84 10.26 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 129.014 2.926 . . . . 0.0 106.095 -169.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.07 -177.69 44.61 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 124.544 1.069 . . . . 0.0 112.81 -174.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -71.92 30.22 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.093 1 C-N-CA 126.157 4.571 . . . . 0.0 115.11 -170.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.11 123.78 63.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.558 1.543 . . . . 0.0 109.441 -177.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.65 163.71 36.48 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 124.272 1.029 . . . . 0.0 109.585 176.05 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.67 108.78 0.79 Allowed Glycine 0 N--CA 1.461 0.302 0 CA-C-N 114.106 -1.406 . . . . 0.0 110.373 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.46 128.88 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 123.956 0.902 . . . . 0.0 109.401 169.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mm -134.82 124.51 43.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 123.864 0.866 . . . . 0.0 109.231 168.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -79.9 149.63 30.84 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 126.697 1.999 . . . . 0.0 109.924 165.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -143.97 101.97 3.82 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -108.83 116.86 32.78 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.367 1.067 . . . . 0.0 109.831 -169.572 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -116.96 142.28 47.15 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 122.652 1.215 . . . . 0.0 112.917 -172.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.409 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -90.74 -7.57 52.13 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.337 1.455 . . . . 0.0 114.61 -173.656 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.409 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 48.9 mp0 -150.22 -173.99 4.6 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 127.368 2.267 . . . . 0.0 108.24 173.024 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.6 p -75.4 -26.71 58.65 Favored 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.47 -0.769 . . . . 0.0 111.215 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -135.25 9.99 3.49 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.274 1.429 . . . . 0.0 114.101 -171.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.54 174.02 55.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.236 0.922 . . . . 0.0 111.555 169.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.11 166.13 30.85 Favored 'Trans proline' 0 CA--C 1.536 0.578 0 C-N-CA 122.712 2.274 . . . . 0.0 111.116 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.58 132.58 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 C-N-CA 124.876 1.27 . . . . 0.0 110.661 -168.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -88.52 127.81 35.54 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 168.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.8 t -116.91 124.19 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 126.011 1.724 . . . . 0.0 109.058 -171.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -155.41 157.29 36.8 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.152 -0.968 . . . . 0.0 113.269 177.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.13 -160.74 30.67 Favored Glycine 0 CA--C 1.52 0.364 0 O-C-N 121.553 -0.717 . . . . 0.0 113.706 -177.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 53.3 p -149.24 133.19 17.11 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 113.276 0.843 . . . . 0.0 113.276 -168.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -106.01 113.43 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 O-C-N 121.724 -0.61 . . . . 0.0 109.794 171.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.7 ptpt -110.78 157.96 19.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.164 1.385 . . . . 0.0 110.613 -170.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.28 8.29 75.09 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 123.861 0.743 . . . . 0.0 113.997 -173.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -81.15 -152.4 0.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 127.19 2.196 . . . . 0.0 107.865 168.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' THR . . . . . 0.422 HG23 ' H ' ' B' ' 40' ' ' GLU 0.282 7.9 t -137.14 -91.78 0.24 Allowed 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.996 1.318 . . . . 0.0 108.353 169.702 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . 0.422 ' H ' HG23 ' B' ' 39' ' ' THR . 0.0 OUTLIER -127.98 -56.55 1.27 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.438 1.495 . . . . 0.0 113.719 173.085 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.39 147.76 44.87 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 119.856 -1.778 . . . . 0.0 113.558 -169.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 mp -44.9 141.91 2.0 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.84 2.056 . . . . 0.0 112.619 -173.233 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -126.09 130.64 51.49 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.689 1.596 . . . . 0.0 109.276 170.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.76 163.01 41.08 Favored Glycine 0 N--CA 1.482 1.717 0 CA-C-N 120.292 1.406 . . . . 0.0 111.516 172.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -152.46 130.31 11.7 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 120.673 2.237 . . . . 0.0 112.513 168.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.28 146.36 21.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.473 1.109 . . . . 0.0 111.999 -168.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 p -82.63 135.1 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 O-C-N 121.632 -0.667 . . . . 0.0 110.653 168.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -78.19 159.01 28.81 Favored 'General case' 0 CA--C 1.559 1.304 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.141 165.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -67.32 110.89 3.73 Favored 'General case' 0 N--CA 1.469 0.497 0 O-C-N 119.473 -2.017 . . . . 0.0 110.258 171.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 4.3 m-30 142.31 167.37 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 1 C-N-CA 132.927 4.491 . . . . 0.0 110.176 175.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -131.13 14.83 5.39 Favored Glycine 0 C--O 1.222 -0.613 0 C-N-CA 126.42 1.962 . . . . 0.0 114.051 172.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -170.53 113.97 0.45 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.431 2.692 . . . . 0.0 103.972 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.04 -64.49 1.3 Allowed 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 114.354 1.242 . . . . 0.0 114.354 -164.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.462 0.139 0 C-N-CA 128.919 2.888 . . . . 0.0 113.275 170.018 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.542 0.664 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -69.62 -178.57 21.51 Favored Glycine 0 CA--C 1.538 1.476 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.553 173.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -62.72 168.34 10.32 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.647 2.231 . . . . 0.0 110.849 171.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -45.08 115.36 0.89 Allowed 'General case' 0 C--O 1.236 0.35 0 N-CA-C 115.575 1.695 . . . . 0.0 115.575 -178.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -45.58 117.46 1.45 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.832 166.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -120.84 65.82 13.24 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 115.103 -0.953 . . . . 0.0 113.152 -167.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.81 -4.87 14.18 Favored 'Trans proline' 0 CA--C 1.539 0.766 0 C-N-CA 123.304 2.669 . . . . 0.0 114.561 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -106.73 -6.11 18.05 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.198 0.999 . . . . 0.0 112.71 175.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 18.9 t 66.4 57.92 0.7 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.884 1.674 . . . . 0.0 114.722 171.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -154.06 -176.58 5.93 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 116.226 1.935 . . . . 0.0 116.226 -169.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -80.62 178.15 8.54 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.953 1.301 . . . . 0.0 112.194 -170.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -108.73 144.36 36.63 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.287 -1.324 . . . . 0.0 114.168 176.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 154.33 -102.2 0.22 Allowed Glycine 0 C--N 1.336 0.543 0 C-N-CA 126.37 1.938 . . . . 0.0 110.108 167.297 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -41.22 2.01 Favored Glycine 0 CA--C 1.542 1.774 0 CA-C-O 118.013 -1.437 . . . . 0.0 115.653 172.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_exo -79.62 -25.83 5.17 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 124.206 3.271 . . . . 0.0 112.12 168.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.79 -53.52 2.64 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.901 0.88 . . . . 0.0 110.49 168.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -63.84 106.16 0.96 Allowed 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.311 1.414 . . . . 0.0 111.88 172.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.8 mp0 -59.76 -9.75 3.12 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 129.259 3.023 . . . . 0.0 113.485 175.445 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -85.1 -98.02 0.06 Allowed 'General case' 0 N--CA 1.453 -0.321 0 O-C-N 121.411 -0.806 . . . . 0.0 110.684 174.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 94.09 133.37 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.169 1.787 . . . . 0.0 110.845 173.125 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -70.23 154.54 41.79 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 168.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.2 t -80.44 87.94 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 166.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.47 4.35 0.18 Allowed Glycine 0 CA--C 1.537 1.452 0 N-CA-C 117.672 1.829 . . . . 0.0 117.672 -169.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -150.65 150.51 31.22 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 119.828 1.814 . . . . 0.0 112.511 174.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.7 mt -124.16 49.05 1.82 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.116 169.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.97 -102.99 0.91 Allowed Glycine 0 CA--C 1.532 1.154 0 O-C-N 120.64 -1.287 . . . . 0.0 115.37 176.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -144.71 163.25 34.57 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.024 1.33 . . . . 0.0 113.505 -175.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.2 m -114.45 165.49 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 127.502 2.321 . . . . 0.0 110.115 170.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 62.6 m -146.43 141.31 27.01 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.903 1.281 . . . . 0.0 108.007 174.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . 0.416 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -97.49 164.35 12.48 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -173.097 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.0 -52.09 9.35 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.457 1.503 . . . . 0.0 113.248 -171.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.503 ' HZ1' ' CG ' ' B' ' 92' ' ' ASP . 9.4 pttp 151.62 -37.94 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.991 1 C-N-CA 133.775 4.83 . . . . 0.0 109.637 -168.93 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . 0.503 ' CG ' ' HZ1' ' B' ' 91' ' ' LYS . 34.9 m-20 -84.66 25.79 0.87 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.897 1.679 . . . . 0.0 111.021 -178.083 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.34 3.67 77.57 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.815 1.674 . . . . 0.0 115.56 174.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -109.34 129.41 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 119.011 1.406 . . . . 0.0 113.425 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.416 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -95.3 129.77 42.31 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 125.165 1.386 . . . . 0.0 107.766 165.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -116.93 130.62 56.82 Favored 'General case' 0 C--O 1.233 0.188 0 C-N-CA 125.012 1.325 . . . . 0.0 109.037 -172.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 45.5 t -130.26 137.19 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-N 114.16 -1.382 . . . . 0.0 114.239 -166.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.4 p -151.61 105.23 3.13 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 125.462 1.505 . . . . 0.0 111.635 177.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 22.3 mt -135.99 163.28 34.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 128.239 2.615 . . . . 0.0 110.45 -172.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -139.22 140.14 37.67 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 126.465 1.906 . . . . 0.0 107.089 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -146.01 143.18 29.28 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.491 1.116 . . . . 0.0 111.641 -169.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 9.0 p -118.4 46.04 1.89 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.039 -0.982 . . . . 0.0 112.57 -176.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . 0.272 4.4 p -156.12 20.32 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 174.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -131.45 160.52 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 120.65 -1.281 . . . . 0.0 108.344 167.121 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 51.4 m -158.03 168.87 25.92 Favored 'General case' 0 N--CA 1.47 0.573 0 O-C-N 120.691 -1.256 . . . . 0.0 112.192 175.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.29 64.23 1.6 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 125.974 1.709 . . . . 0.0 109.345 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.6 t -155.3 84.07 1.06 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.453 -1.405 . . . . 0.0 113.357 -169.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.29 -159.0 28.26 Favored Glycine 0 C--N 1.336 0.563 0 CA-C-O 122.997 1.332 . . . . 0.0 112.471 170.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -69.1 -19.7 64.06 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 127.57 2.348 . . . . 0.0 113.769 -167.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 64.7 m170 -97.3 7.9 45.63 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.112 1.365 . . . . 0.0 113.221 -175.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 73.2 m -81.98 176.79 9.26 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -165.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.02 -18.95 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 120.786 -1.196 . . . . 0.0 110.798 163.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mm -75.78 124.92 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 165.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.28 68.8 1.54 Allowed Glycine 0 CA--C 1.527 0.839 0 O-C-N 123.614 0.571 . . . . 0.0 113.462 -169.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -143.17 136.04 27.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.206 1.002 . . . . 0.0 109.579 168.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.6 t -96.42 77.8 2.99 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 124.864 1.266 . . . . 0.0 110.369 -173.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 54.5 tp -77.94 135.49 37.85 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.0 1.32 . . . . 0.0 109.881 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -129.64 146.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 126.067 1.747 . . . . 0.0 108.989 172.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 79.3 t -104.09 140.61 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 122.605 1.193 . . . . 0.0 107.897 168.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -95.6 160.02 14.71 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.625 2.37 . . . . 0.0 112.303 -170.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -80.97 -34.31 33.22 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 120.806 -1.184 . . . . 0.0 114.015 -167.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.4 mmmt -113.42 -176.52 2.92 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 120.176 -1.578 . . . . 0.0 112.428 173.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.29 143.64 27.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.64 1.176 . . . . 0.0 109.921 169.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.23 146.04 24.55 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.957 1.303 . . . . 0.0 109.041 172.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.41 -27.75 56.4 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 178.633 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 63.97 20.96 12.44 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.14 2.176 . . . . 0.0 114.34 174.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -150.68 -94.22 0.11 Allowed Glycine 0 N--CA 1.465 0.581 0 CA-C-N 120.583 1.538 . . . . 0.0 113.165 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 49.2 tttp -163.05 82.39 0.49 Allowed 'General case' 0 N--CA 1.432 -1.364 0 C-N-CA 127.172 2.189 . . . . 0.0 108.608 168.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.97 48.04 0.64 Allowed Glycine 0 CA--C 1.531 1.078 0 C-N-CA 126.778 2.133 . . . . 0.0 114.192 172.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 79.99 -10.97 37.67 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 118.084 1.994 . . . . 0.0 118.084 169.107 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 28.8 m-80 -115.28 177.78 4.53 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.765 2.282 . . . . 0.0 112.418 -169.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -59.11 -64.39 0.96 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.401 1.88 . . . . 0.0 108.992 165.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 48.7 mm-40 -47.8 -34.77 9.07 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.82 1.648 . . . . 0.0 113.37 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 8.8 m -55.97 -14.64 2.65 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 175.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 37.5 p -129.29 -24.56 2.82 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 168.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . 0.253 17.8 pttt -83.81 -6.0 59.33 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 115.764 1.765 . . . . 0.0 115.764 175.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 10.8 m -140.07 -44.64 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 124.948 1.299 . . . . 0.0 112.467 171.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.33 12.27 6.35 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.885 2.183 . . . . 0.0 114.151 -168.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 67.08 8.04 5.87 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 120.673 -1.487 . . . . 0.0 114.798 175.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.58 30.46 0.03 OUTLIER 'General case' 0 CA--C 1.564 1.506 0 N-CA-C 118.206 2.669 . . . . 0.0 118.206 -166.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.6 -51.4 3.37 Favored Glycine 0 N--CA 1.471 1.013 0 C-N-CA 127.218 2.342 . . . . 0.0 115.766 170.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 9.3 t -176.49 -163.1 0.09 Allowed 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.734 2.014 . . . . 0.0 110.545 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.21 142.27 17.03 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 119.77 -1.831 . . . . 0.0 115.739 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.74 -115.62 0.1 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 128.508 2.723 . . . . 0.0 111.266 -177.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.13 138.87 36.99 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 128.454 2.702 . . . . 0.0 111.114 -169.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -126.41 151.76 47.25 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 126.413 1.885 . . . . 0.0 112.274 -175.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.58 169.91 32.9 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 116.434 1.334 . . . . 0.0 116.434 -172.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . 0.273 0.4 OUTLIER -126.62 162.31 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 123.521 0.728 . . . . 0.0 109.753 170.066 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -120.95 127.64 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 124.412 1.085 . . . . 0.0 113.365 -166.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -123.89 -159.31 10.42 Favored Glycine 0 C--N 1.349 1.282 0 C-N-CA 125.039 1.304 . . . . 0.0 113.631 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -110.06 143.22 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 125.946 1.698 . . . . 0.0 111.959 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.432 ' HA ' ' CG ' ' A' ' 50' ' ' PHE . . . -124.49 37.98 4.29 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.456 1.902 . . . . 0.0 111.291 171.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.326 -0.429 0 C-N-CA 125.708 1.603 . . . . 0.0 109.829 -178.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 94.3 m . . . . . 0 N--CA 1.469 0.475 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.16 138.89 33.47 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -175.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.81 169.74 8.85 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 126.534 1.934 . . . . 0.0 112.18 173.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.3 t -147.48 153.89 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 127.95 2.5 . . . . 0.0 110.51 172.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.4 112.64 15.87 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 125.351 1.461 . . . . 0.0 107.168 165.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.6 m -82.66 90.95 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 173.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 25.0 mt -76.28 130.01 37.52 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.574 -172.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.1 mttm -152.29 -179.02 7.17 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.59 1.156 . . . . 0.0 113.152 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 134.84 -58.62 0.68 Allowed Glycine 0 N--CA 1.467 0.763 0 C-N-CA 125.968 1.747 . . . . 0.0 110.058 -178.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -78.44 69.04 4.57 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 122.087 0.946 . . . . 0.0 113.22 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 39.25 -100.38 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 C-N-CA 127.863 2.649 . . . . 0.0 115.71 169.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.98 -9.88 18.03 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 124.783 3.655 . . . . 0.0 114.56 -177.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 t -86.07 143.57 11.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-N 119.679 1.127 . . . . 0.0 110.008 172.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -156.36 158.24 37.04 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.51 168.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -117.18 126.83 7.12 Favored Glycine 0 C--O 1.22 -0.758 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 174.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.55 99.19 6.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 174.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -132.49 133.31 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 125.07 1.348 . . . . 0.0 109.525 -171.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -108.08 150.72 26.81 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.298 2.239 . . . . 0.0 111.208 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -122.22 134.75 54.7 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.567 1.947 . . . . 0.0 109.353 170.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -103.22 113.96 27.87 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 120.935 1.698 . . . . 0.0 110.904 172.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 37.1 tp60 -101.31 116.05 31.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 123.191 0.596 . . . . 0.0 109.488 172.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.1 pttp -102.9 -31.81 10.07 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 114.61 1.337 . . . . 0.0 114.61 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.7 mp0 -130.03 156.68 44.08 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 126.213 1.805 . . . . 0.0 108.766 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.0 m -55.68 -39.88 71.57 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 122.386 2.357 . . . . 0.0 116.244 -168.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.04 34.55 5.17 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.03 1.732 . . . . 0.0 110.422 167.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.89 153.47 51.35 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-O 118.129 -1.373 . . . . 0.0 111.021 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -66.38 142.7 67.01 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.123 2.549 . . . . 0.0 109.957 174.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.1 t -112.53 144.86 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.937 0.895 . . . . 0.0 110.879 -168.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.545 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 16.0 tttp -113.59 131.08 56.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.583 1.153 . . . . 0.0 108.804 167.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.96 144.49 16.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 127.872 2.469 . . . . 0.0 109.536 175.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -158.56 161.02 37.25 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.399 1.079 . . . . 0.0 113.185 172.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.63 -149.22 21.29 Favored Glycine 0 N--CA 1.469 0.865 0 C-N-CA 124.249 0.928 . . . . 0.0 112.693 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -153.57 148.75 26.9 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 16.9 mt -126.0 117.76 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 121.032 -1.043 . . . . 0.0 108.914 175.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.1 tttt -123.34 137.87 54.74 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 119.787 1.176 . . . . 0.0 112.168 -172.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.0 3.77 9.71 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 128.413 2.911 . . . . 0.0 113.886 -174.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.12 163.85 22.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 128.431 2.692 . . . . 0.0 112.074 176.302 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -95.07 158.4 15.48 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 166.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -64.07 145.22 56.29 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.99 -171.69 22.81 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.703 1.144 . . . . 0.0 114.591 -173.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 47.2 mt -66.23 146.94 54.04 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 125.532 1.533 . . . . 0.0 113.535 -169.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -144.99 128.59 17.11 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 127.01 2.124 . . . . 0.0 109.514 173.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.15 165.23 54.87 Favored Glycine 0 N--CA 1.473 1.137 0 CA-C-N 119.493 1.042 . . . . 0.0 112.292 -179.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.6 p90 -157.55 137.38 12.33 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.328 1.851 . . . . 0.0 113.706 167.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -148.58 163.87 35.94 Favored 'General case' 0 N--CA 1.451 -0.415 0 O-C-N 119.695 -1.878 . . . . 0.0 112.074 169.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -96.04 134.08 34.88 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-O 121.795 0.807 . . . . 0.0 110.266 173.159 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -71.51 116.06 11.42 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 103.66 -2.719 . . . . 0.0 103.66 168.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.588 ' H ' ' HA ' ' A' ' 63' ' ' HIS 0.305 3.6 tt0 -70.68 21.33 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.897 0 N-CA-C 115.988 1.847 . . . . 0.0 115.988 -168.513 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -132.82 148.94 52.31 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 126.872 2.069 . . . . 0.0 111.204 179.239 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.14 -17.77 42.08 Favored Glycine 0 N--CA 1.465 0.591 0 CA-C-O 117.129 -1.928 . . . . 0.0 115.155 169.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.472 ' C ' HD21 ' A' ' 53' ' ' ASN . 15.4 t0 -72.39 88.78 1.2 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.053 1.927 . . . . 0.0 106.945 168.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.472 HD21 ' C ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER 168.07 -34.39 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.469 2.308 . . . . 0.0 116.766 169.456 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 18.6 p 27.62 -40.55 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.042 2 C-N-CA 133.615 4.766 . . . . 0.0 122.91 179.24 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.2 13.72 2.22 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 127.53 2.332 . . . . 0.0 113.469 -173.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -148.04 34.33 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 124.657 1.122 . . . . 0.0 114.585 169.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.5 m -49.02 -19.99 0.48 Allowed 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -169.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.8 t -79.47 -4.49 51.47 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.454 1.101 . . . . 0.0 113.096 175.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 71.5 m -136.97 147.13 46.13 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.548 1.539 . . . . 0.0 110.739 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 63.51 -94.16 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.237 1.815 . . . . 0.0 113.126 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.54 -41.99 2.07 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 126.499 2.0 . . . . 0.0 116.413 -175.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -109.59 174.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.357 1.009 0 C-N-CA 123.194 2.596 . . . . 0.0 114.75 -175.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.664 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -97.16 134.68 40.16 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 129.99 3.316 . . . . 0.0 114.719 169.839 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -71.1 152.28 43.63 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 162.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 40.2 p-10 -125.75 60.11 31.22 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 124.252 1.021 . . . . 0.0 111.737 -177.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -61.79 -29.9 83.77 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.943 3.095 . . . . 0.0 115.057 -167.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 73.2 mt -75.9 -5.42 46.03 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 175.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t 66.83 110.02 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 130.027 3.331 . . . . 0.0 111.471 -177.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 171.92 172.03 0.1 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -169.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -64.17 169.57 4.38 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.699 2.4 . . . . 0.0 111.68 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -96.23 138.99 33.02 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.839 1.256 . . . . 0.0 113.981 170.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.14 -110.05 0.44 Allowed Glycine 0 C--N 1.336 0.533 0 C-N-CA 124.007 0.813 . . . . 0.0 112.79 167.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.92 -20.2 24.52 Favored Glycine 0 CA--C 1.535 1.289 0 CA-C-O 115.237 -2.98 . . . . 0.0 118.396 -172.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.67 -11.81 3.23 Favored 'Trans proline' 0 C--N 1.357 0.982 0 CA-C-N 123.192 3.496 . . . . 0.0 112.282 168.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -152.51 -25.25 0.17 Allowed 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.078 1.351 . . . . 0.0 113.14 169.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -72.59 93.06 1.56 Allowed 'General case' 0 C--N 1.342 0.282 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 166.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -66.77 -6.51 16.24 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 114.674 -1.148 . . . . 0.0 113.87 -179.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -78.74 -64.84 1.08 Allowed 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 125.657 1.583 . . . . 0.0 109.567 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 59.98 127.72 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 129.833 3.253 . . . . 0.0 117.881 167.367 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -56.93 154.04 10.13 Favored 'General case' 0 CA--C 1.55 0.961 0 O-C-N 120.391 -1.443 . . . . 0.0 111.857 171.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 p -68.47 -28.87 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 120.229 1.377 . . . . 0.0 111.287 -174.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.17 105.58 2.1 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 107.081 -2.407 . . . . 0.0 107.081 165.005 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -160.52 142.91 12.92 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 117.956 0.878 . . . . 0.0 113.309 177.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -120.91 175.43 6.05 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 126.196 1.798 . . . . 0.0 112.129 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -95.1 -153.68 30.37 Favored Glycine 0 CA--C 1.535 1.307 0 C-N-CA 125.905 1.717 . . . . 0.0 114.114 178.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.0 p30 -108.0 156.97 18.65 Favored 'General case' 0 N--CA 1.467 0.379 0 O-C-N 121.777 -0.837 . . . . 0.0 110.956 168.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -106.53 173.92 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 127.217 2.207 . . . . 0.0 109.749 176.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -138.16 143.72 40.43 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 125.177 1.391 . . . . 0.0 108.871 169.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.64 152.56 25.4 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 124.105 0.962 . . . . 0.0 112.879 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -88.85 164.52 15.16 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.745 1.618 . . . . 0.0 111.203 168.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -63.53 -10.83 19.89 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.536 1.534 . . . . 0.0 114.828 170.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.12 -18.07 63.22 Favored 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 118.852 0.751 . . . . 0.0 109.805 169.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 105.09 -7.49 44.21 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 127.83 2.633 . . . . 0.0 112.808 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.57 139.47 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 125.603 1.561 . . . . 0.0 113.485 -173.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.39 129.93 52.29 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 164.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -79.52 142.09 36.1 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 167.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -122.16 140.34 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 CA-C-O 122.22 1.01 . . . . 0.0 113.472 171.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.6 p -156.33 122.38 4.97 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.452 1.501 . . . . 0.0 109.814 168.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.2 mp -128.98 156.09 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 C-N-CA 125.739 1.616 . . . . 0.0 108.843 173.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.545 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 12.1 tt0 -157.37 135.84 11.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 126.574 1.95 . . . . 0.0 108.418 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -160.93 159.19 29.31 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 124.763 1.225 . . . . 0.0 112.431 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -121.16 48.19 1.7 Allowed 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.378 1.251 . . . . 0.0 114.378 172.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 57.3 t -137.95 -40.22 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.672 1.989 . . . . 0.0 109.961 169.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 pp -78.85 149.92 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 123.488 1.613 . . . . 0.0 114.474 172.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 94.6 p -155.26 169.53 23.97 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 126.635 1.974 . . . . 0.0 108.907 -176.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mp -96.36 48.26 1.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 172.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.3 t -103.06 -13.31 16.89 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 116.923 2.194 . . . . 0.0 116.923 -169.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 146.39 -88.05 0.16 Allowed Glycine 0 C--N 1.348 1.231 0 N-CA-C 120.124 2.809 . . . . 0.0 120.124 167.439 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -59.8 -61.01 2.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 C-N-CA 126.167 1.787 . . . . 0.0 115.215 -160.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 -125.3 1.3 7.77 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.177 1.391 . . . . 0.0 112.956 -174.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.7 p -78.45 -169.75 1.79 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.418 0.687 . . . . 0.0 112.35 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 3.3 pt -69.99 -30.16 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 O-C-N 118.954 -2.341 . . . . 0.0 114.105 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.9 mm -60.4 137.76 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-N 120.293 1.406 . . . . 0.0 110.493 171.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.98 -11.2 6.39 Favored Glycine 0 CA--C 1.527 0.797 0 CA-C-O 118.223 -1.321 . . . . 0.0 113.719 -177.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.17 139.38 39.9 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 120.035 1.917 . . . . 0.0 108.969 177.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 57.7 m -98.99 104.32 16.36 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -175.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 23.6 tp -80.26 120.08 23.87 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.108 1.363 . . . . 0.0 111.048 -177.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.87 138.87 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.62 1.568 . . . . 0.0 109.912 169.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.3 t -103.79 159.59 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 166.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -125.09 133.35 52.91 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.285 1.434 . . . . 0.0 111.24 -168.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.429 ' CD ' ' HZ2' ' A' ' 122' ' ' LYS . 15.8 tt0 -46.39 -35.62 5.67 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 127.569 2.348 . . . . 0.0 114.704 -178.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.429 ' HZ2' ' CD ' ' A' ' 121' ' ' GLU . 59.6 mttp -113.68 170.02 8.56 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.708 1.603 . . . . 0.0 112.512 -169.637 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.84 158.8 6.01 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.365 1.066 . . . . 0.0 110.642 167.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -138.29 142.53 39.81 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.272 1.029 . . . . 0.0 110.809 -168.161 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -85.91 -59.23 2.36 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 122.977 0.511 . . . . 0.0 111.891 176.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mp 65.93 84.95 0.15 Allowed 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 128.001 2.521 . . . . 0.0 113.9 -174.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 131.02 -29.97 3.43 Favored Glycine 0 N--CA 1.479 1.524 0 N-CA-C 118.888 2.315 . . . . 0.0 118.888 166.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -155.97 -58.92 0.1 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 119.474 1.637 . . . . 0.0 113.515 -169.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 44.22 -115.31 1.23 Allowed Glycine 0 C--N 1.34 0.754 0 C-N-CA 125.55 1.547 . . . . 0.0 111.55 -170.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.86 14.46 3.84 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-O 118.256 -1.302 . . . . 0.0 114.54 169.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -161.63 168.08 24.06 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 120.146 1.973 . . . . 0.0 112.853 -167.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.5 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 31.4 tt0 -47.98 -58.75 4.02 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.137 1.375 . . . . 0.0 112.082 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -46.75 -31.89 3.28 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -179.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -65.7 -23.21 66.71 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.432 -1.418 . . . . 0.0 113.716 178.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.0 t -99.84 -29.56 12.53 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.931 0.892 . . . . 0.0 111.917 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.5 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 19.1 tttt -71.19 -41.45 70.29 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.25 1.42 . . . . 0.0 113.503 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.5 p -124.48 -30.73 3.34 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.112 1.765 . . . . 0.0 112.801 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.98 -14.41 11.24 Favored Glycine 0 C--O 1.222 -0.648 0 C-N-CA 126.416 1.96 . . . . 0.0 111.184 -167.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 90.6 1.68 0.17 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.11 2.964 . . . . 0.0 112.346 178.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.54 -7.76 0.3 Allowed 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -168.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 64.96 7.91 32.49 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 120.327 2.891 . . . . 0.0 120.327 164.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.19 178.3 1.74 Allowed 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 121.166 2.483 . . . . 0.0 115.129 172.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 18.9 ptt-85 -76.4 -174.37 2.84 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.402 1.881 . . . . 0.0 109.883 165.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -177.76 -148.84 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 128.7 2.8 . . . . 0.0 107.504 165.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.28 144.24 55.86 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.079 0.952 . . . . 0.0 110.632 168.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.6 t -157.61 145.05 18.51 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.799 1.24 . . . . 0.0 112.312 -173.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.53 162.96 34.3 Favored Glycine 0 N--CA 1.474 1.176 0 C-N-CA 125.144 1.354 . . . . 0.0 112.46 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.8 p -78.87 153.29 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 118.795 1.298 . . . . 0.0 110.543 169.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mm -87.12 111.64 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 120.87 -1.144 . . . . 0.0 109.969 168.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.32 -155.8 23.55 Favored Glycine 0 CA--C 1.534 1.249 0 C-N-CA 125.659 1.6 . . . . 0.0 112.018 175.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.93 167.99 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-N 119.226 1.513 . . . . 0.0 113.616 177.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.96 -36.87 0.08 Allowed 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.979 1.712 . . . . 0.0 113.449 167.072 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . 0.299 27.6 pt20 . . . . . 0 C--O 1.235 0.31 0 C-N-CA 125.292 1.437 . . . . 0.0 114.307 -170.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.618 0 N-CA-C 112.632 0.604 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.7 m -79.79 105.85 11.39 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.354 1.462 . . . . 0.0 110.544 -167.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 24.3 mtmm -96.19 106.79 19.04 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 115.67 1.73 . . . . 0.0 115.67 -175.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.84 167.16 11.6 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.634 1.974 . . . . 0.0 111.034 167.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -158.44 151.65 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 C-N-CA 124.321 1.048 . . . . 0.0 113.554 -170.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.51 147.74 38.27 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.325 1.05 . . . . 0.0 109.471 162.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.19 121.54 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.382 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 168.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.9 mp -92.34 107.62 19.35 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 126.683 1.993 . . . . 0.0 107.829 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 35.9 tttt -131.47 149.17 52.63 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 120.032 1.287 . . . . 0.0 114.006 175.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.08 151.72 16.87 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 128.799 3.095 . . . . 0.0 107.092 166.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -72.07 88.95 1.11 Allowed 'General case' 0 C--N 1.318 -0.767 0 C-N-CA 126.71 2.004 . . . . 0.0 112.038 -167.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.97 -129.47 3.29 Favored Glycine 0 CA--C 1.536 1.374 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.888 -177.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -93.24 -10.73 1.75 Allowed 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 124.143 3.229 . . . . 0.0 115.368 -169.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.1 t -91.82 113.49 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 120.458 1.481 . . . . 0.0 110.382 -176.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -159.13 161.54 36.32 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.619 -1.173 . . . . 0.0 113.547 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.67 167.23 30.38 Favored Glycine 0 CA--C 1.502 -0.765 0 CA-C-N 115.264 -0.88 . . . . 0.0 113.072 166.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.71 135.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.781 -1.562 . . . . 0.0 106.781 167.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.73 128.25 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.609 0.718 . . . . 0.0 109.774 169.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -96.11 136.51 36.47 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 125.587 1.555 . . . . 0.0 110.555 177.46 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -109.39 94.12 4.87 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 127.534 2.334 . . . . 0.0 109.583 173.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -95.68 109.42 21.7 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 121.041 -1.037 . . . . 0.0 111.567 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -98.37 140.45 32.63 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 121.231 -0.918 . . . . 0.0 111.438 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -78.67 -27.59 45.21 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -175.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -161.04 156.87 25.27 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 128.274 2.63 . . . . 0.0 107.318 168.068 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -46.7 -22.06 0.26 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 130.168 3.387 . . . . 0.0 116.698 -170.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -124.83 -4.42 7.59 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 128.536 2.735 . . . . 0.0 112.31 -174.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.41 160.03 27.71 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 125.876 1.703 . . . . 0.0 110.99 172.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.13 159.62 51.25 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.197 2.598 . . . . 0.0 112.626 -170.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.0 t -108.68 128.06 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.793 1.237 . . . . 0.0 110.036 -172.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -81.96 125.16 30.44 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 171.135 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.65 116.82 53.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.611 1.164 . . . . 0.0 108.845 170.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -137.35 158.64 43.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.006 0.922 . . . . 0.0 110.807 169.348 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.42 164.12 9.85 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-O 121.643 0.579 . . . . 0.0 112.688 174.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -113.62 116.52 29.61 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -165.004 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mm -94.96 116.74 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 172.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -124.32 146.97 48.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.508 1.523 . . . . 0.0 111.196 -167.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -31.04 7.79 Favored Glycine 0 N--CA 1.471 0.986 0 C-N-CA 126.946 2.212 . . . . 0.0 112.143 -175.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.1 pp -76.0 128.24 34.62 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.511 1.124 . . . . 0.0 108.308 169.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -73.49 175.72 6.77 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.164 0.986 . . . . 0.0 111.888 -173.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -61.09 154.3 23.33 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -168.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.23 -175.02 29.18 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.399 1.0 . . . . 0.0 112.477 -175.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.3 mp -77.82 124.69 28.29 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 127.375 2.27 . . . . 0.0 112.078 -169.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -122.51 130.09 52.67 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.766 1.226 . . . . 0.0 107.976 171.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.32 165.84 38.87 Favored Glycine 0 N--CA 1.473 1.104 0 C-N-CA 126.443 1.973 . . . . 0.0 115.15 -169.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -156.58 99.96 1.91 Allowed 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 120.002 1.901 . . . . 0.0 112.764 -167.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -124.2 135.61 53.58 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 121.059 -1.025 . . . . 0.0 112.173 -169.564 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . 0.263 1.0 OUTLIER -102.84 141.14 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 119.077 0.853 . . . . 0.0 109.369 173.099 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.452 ' CG ' HG23 ' B' ' 116' ' ' THR . 0.3 OUTLIER -133.75 154.53 50.91 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.194 1.398 . . . . 0.0 112.732 -168.437 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -76.93 128.69 35.0 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -170.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.252 29.6 m-85 99.88 157.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 1 C-N-CA 132.732 4.413 . . . . 0.0 115.551 169.457 . . . . . . . . 3 2 . 1 . 016 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.92 -19.32 5.66 Favored Glycine 0 N--CA 1.471 1.014 0 C-N-CA 126.158 1.837 . . . . 0.0 113.176 177.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.46 51.94 0.07 Allowed 'General case' 0 CA--C 1.551 1.008 0 C-N-CA 127.558 2.343 . . . . 0.0 111.597 169.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -178.4 35.18 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -165.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 33.2 p . . . . . 0 CA--C 1.543 0.709 0 C-N-CA 128.608 2.763 . . . . 0.0 116.182 177.102 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.386 0 N-CA-C 113.476 0.917 . . . . 0.0 113.476 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.43 -175.15 48.72 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 124.638 1.113 . . . . 0.0 114.498 -177.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -83.31 -179.11 4.1 Favored 'Trans proline' 0 CA--C 1.539 0.752 1 C-N-CA 126.188 4.592 . . . . 0.0 111.774 175.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.425 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.7 p80 -80.7 107.37 13.45 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 122.452 1.12 . . . . 0.0 112.79 -174.336 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 136.81 5.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.57 1.948 . . . . 0.0 114.501 176.218 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.9 p-10 -116.81 47.4 0.62 Allowed Pre-proline 0 CA--C 1.55 0.965 0 CA-C-N 114.595 -1.184 . . . . 0.0 113.476 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -56.62 -30.47 83.49 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.819 3.012 . . . . 0.0 115.946 -168.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.4 mp -79.29 -4.94 53.14 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 124.468 1.107 . . . . 0.0 113.595 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 68.62 47.83 0.85 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 128.865 2.866 . . . . 0.0 111.115 -176.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.8 mmm180 -110.29 162.28 14.78 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 126.217 1.807 . . . . 0.0 111.011 -168.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 13.1 mmtm -74.43 173.26 10.55 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 167.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 30.1 t60 -50.88 158.22 0.71 Allowed 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -173.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.36 71.2 2.07 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.634 1.111 . . . . 0.0 113.634 -169.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -84.23 125.06 6.93 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -72.59 -11.89 26.52 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.001 1.801 . . . . 0.0 111.581 170.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.76 -5.91 13.29 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.168 0.987 . . . . 0.0 113.653 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -114.06 148.6 36.8 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.519 1.528 . . . . 0.0 108.281 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -74.68 -14.94 60.81 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 124.582 1.153 . . . . 0.0 111.82 -171.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -102.99 121.59 42.85 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.514 1.526 . . . . 0.0 107.678 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 -144.97 124.05 12.84 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 126.966 2.106 . . . . 0.0 110.788 -175.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 61.4 m170 -65.09 155.02 36.14 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.314 1.845 . . . . 0.0 110.842 164.724 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -55.95 -33.69 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.21 103.25 0.31 Allowed Glycine 0 C--N 1.345 1.061 0 N-CA-C 115.163 0.825 . . . . 0.0 115.163 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -159.53 146.88 16.94 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 130.329 3.452 . . . . 0.0 105.217 164.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 76.3 mt -128.96 56.34 1.68 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.779 0.799 . . . . 0.0 111.156 -168.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 59.91 -122.16 29.05 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.467 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -148.06 126.96 12.7 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.466 1.106 . . . . 0.0 110.785 -176.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -76.86 97.15 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.825 1.65 . . . . 0.0 109.314 177.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 92.0 m -97.6 120.91 38.83 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 113.338 -1.756 . . . . 0.0 109.253 -169.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.26 158.65 16.03 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -168.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -81.04 171.74 14.59 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.086 2.155 . . . . 0.0 112.158 168.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.585 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -67.26 -17.34 64.75 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.735 1.614 . . . . 0.0 114.017 174.28 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -71.6 -6.97 44.78 Favored 'General case' 0 CA--C 1.555 1.151 0 CA-C-O 122.433 1.111 . . . . 0.0 109.608 167.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.28 44.48 9.61 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 125.614 1.578 . . . . 0.0 109.895 173.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 13.3 p -142.54 130.31 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.523 1.129 . . . . 0.0 112.528 -177.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.21 94.91 5.77 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 124.512 1.125 . . . . 0.0 109.619 168.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -83.77 104.08 13.58 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 122.241 1.019 . . . . 0.0 109.834 168.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -80.34 154.22 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-N 113.961 -1.472 . . . . 0.0 111.741 -173.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 60.0 p -156.9 93.84 1.38 Allowed 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.182 -0.949 . . . . 0.0 112.719 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 21.2 mt -134.53 153.02 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 126.955 2.102 . . . . 0.0 111.394 -177.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -133.05 135.7 45.52 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 164.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -151.22 141.25 22.09 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 114.912 1.449 . . . . 0.0 114.912 -168.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.0 p -112.03 49.06 0.93 Allowed 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.6 t -123.13 4.99 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 C-N-CA 124.038 0.935 . . . . 0.0 111.158 174.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.24 170.75 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 C-N-CA 126.95 2.1 . . . . 0.0 110.509 -177.094 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -157.88 175.54 13.72 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.878 1.271 . . . . 0.0 110.817 169.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.6 mt -84.7 50.11 1.84 Allowed 'General case' 0 CA--C 1.548 0.893 0 O-C-N 120.204 -1.56 . . . . 0.0 109.609 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.4 t -81.79 25.22 0.56 Allowed 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 115.606 1.706 . . . . 0.0 115.606 -168.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.0 -51.59 3.86 Favored Glycine 0 C--N 1.336 0.542 0 C-N-CA 125.54 1.543 . . . . 0.0 115.087 168.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -101.2 -93.72 0.29 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 117.796 0.798 . . . . 0.0 111.137 -165.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 83.3 m-70 -84.05 2.56 38.58 Favored 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 1.1 t -95.42 -125.93 0.12 Allowed 'General case' 0 CA--C 1.551 0.994 0 O-C-N 119.793 -1.817 . . . . 0.0 113.066 -170.556 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 mm -80.08 -47.09 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-N 123.594 2.906 . . . . 0.0 113.222 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.1 mm -60.24 133.92 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 119.328 0.967 . . . . 0.0 108.936 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.53 6.18 65.49 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-O 118.574 -1.125 . . . . 0.0 115.037 178.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.65 164.08 19.91 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 119.115 1.458 . . . . 0.0 110.017 171.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.452 HG23 ' CG ' ' B' ' 48' ' ' HIS . 3.9 t -115.17 157.65 23.35 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.279 1.032 . . . . 0.0 110.046 175.528 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 17.9 tp -151.28 126.24 9.77 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.025 1.33 . . . . 0.0 112.22 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.9 p -116.46 134.99 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 126.152 1.781 . . . . 0.0 111.258 170.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -84.46 139.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.681 1.193 . . . . 0.0 108.865 169.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 66.2 m-70 -108.25 149.71 28.25 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.616 1.566 . . . . 0.0 112.705 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -73.65 -37.17 65.4 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -171.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -92.12 164.62 13.52 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 120.482 -1.386 . . . . 0.0 109.914 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.16 140.51 5.13 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.419 1.087 . . . . 0.0 111.216 169.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.65 129.29 37.46 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -73.57 0.7 11.86 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.892 2.077 . . . . 0.0 111.564 178.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 79.17 -37.65 0.19 Allowed 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.283 2.633 . . . . 0.0 114.07 168.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 143.22 47.77 0.04 OUTLIER Glycine 0 N--CA 1.477 1.378 0 CA-C-N 120.4 1.454 . . . . 0.0 114.975 -176.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.3 pttp -157.18 -113.46 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 -168.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 66.16 -3.84 2.98 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.652 2.072 . . . . 0.0 117.433 169.411 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.0 4.26 54.77 Favored Glycine 0 CA--C 1.536 1.392 0 CA-C-N 119.073 1.436 . . . . 0.0 114.053 -174.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 m-80 -119.12 156.8 29.12 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 125.722 1.609 . . . . 0.0 111.517 -176.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -54.11 -59.41 4.68 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.145 0.978 . . . . 0.0 109.238 166.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -54.7 -36.88 65.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.739 1.216 . . . . 0.0 113.169 -172.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.0 m -66.05 -13.28 59.7 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.695 1.998 . . . . 0.0 115.563 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -122.37 -20.04 6.24 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.882 0.873 . . . . 0.0 112.928 168.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -72.53 -46.66 53.5 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.121 1.368 . . . . 0.0 111.779 174.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.3 p -117.75 -34.21 4.28 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.221 1.008 . . . . 0.0 112.977 173.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.38 11.24 20.3 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 126.708 2.099 . . . . 0.0 111.972 -168.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 55.52 17.56 2.31 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 120.602 2.201 . . . . 0.0 113.29 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.33 25.07 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.073 0 C-N-CA 127.573 2.349 . . . . 0.0 116.145 -165.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.26 -51.63 3.93 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 127.558 2.504 . . . . 0.0 114.454 169.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 2.9 m 179.76 166.67 1.19 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.782 2.433 . . . . 0.0 111.906 -179.024 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.12 150.97 31.62 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.401 0.681 . . . . 0.0 110.887 173.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.31 -130.6 0.24 Allowed 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 126.739 2.016 . . . . 0.0 108.794 173.086 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.83 157.39 33.42 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 127.065 2.146 . . . . 0.0 114.437 -175.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -151.22 159.68 44.25 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -172.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.71 168.48 34.37 Favored Glycine 0 CA--C 1.543 1.825 0 C-N-CA 127.485 2.469 . . . . 0.0 113.842 175.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 54.2 t -124.83 138.2 54.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 C-N-CA 124.742 1.217 . . . . 0.0 108.563 174.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mm -79.04 122.6 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -166.354 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.62 -156.51 9.88 Favored Glycine 0 CA--C 1.542 1.773 0 C-N-CA 128.362 2.887 . . . . 0.0 113.141 169.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -142.08 147.39 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 C-N-CA 125.276 1.431 . . . . 0.0 114.702 -168.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.07 -22.43 10.56 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 125.499 1.519 . . . . 0.0 114.407 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 . . . . . 0 N--CA 1.471 0.606 0 C-N-CA 125.673 1.589 . . . . 0.0 112.453 -178.186 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.472 0.627 0 CA-C-O 121.657 0.741 . . . . 0.0 110.707 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.479 ' HE3' ' OE1' ' A' ' 153' ' ' GLN . 0.0 OUTLIER -77.98 117.71 19.57 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-N 114.741 -1.118 . . . . 0.0 112.053 169.289 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.4 178.59 6.44 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.429 1.091 . . . . 0.0 110.179 167.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -155.41 90.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 125.664 1.586 . . . . 0.0 109.981 -168.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.93 121.93 32.49 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.229 1.412 . . . . 0.0 110.573 174.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.0 p -95.75 126.68 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-N 118.9 0.773 . . . . 0.0 109.105 173.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mp -109.14 133.95 52.35 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.59 1.156 . . . . 0.0 108.627 169.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mtmt -157.77 133.12 8.9 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.267 1.427 . . . . 0.0 110.276 173.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.73 -81.08 0.63 Allowed Glycine 0 C--N 1.334 0.45 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -170.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -139.42 116.56 11.09 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 124.559 1.144 . . . . 0.0 108.987 -166.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.04 -101.41 0.03 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 128.988 3.185 . . . . 0.0 112.613 175.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -77.99 -9.46 16.74 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.275 2.65 . . . . 0.0 114.014 -174.047 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.8 t -88.46 126.19 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 121.33 1.877 . . . . 0.0 111.818 -176.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.87 159.11 43.13 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 125.162 1.385 . . . . 0.0 111.792 171.165 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.87 164.4 27.85 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 122.444 1.025 . . . . 0.0 113.811 169.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.79 133.93 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 125.127 1.371 . . . . 0.0 109.066 -179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.6 mm -137.7 121.92 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 CA-C-N 119.74 1.155 . . . . 0.0 110.683 169.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -88.57 145.84 25.48 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.981 167.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -121.62 109.62 14.99 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 168.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.78 112.59 24.31 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.85 0.75 . . . . 0.0 111.529 -176.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -93.49 135.31 34.86 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -114.52 -45.54 3.01 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.612 1.565 . . . . 0.0 114.688 -175.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -118.9 -179.76 3.91 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.25 1.42 . . . . 0.0 109.204 167.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.8 p -67.66 -25.91 65.94 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 119.162 -2.211 . . . . 0.0 114.221 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -141.04 9.5 2.12 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 126.407 1.883 . . . . 0.0 112.598 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.8 151.94 52.31 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.795 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -61.91 137.63 68.77 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 124.169 3.246 . . . . 0.0 110.36 -172.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 79.3 t -102.59 135.53 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 123.525 0.73 . . . . 0.0 109.889 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.44 ' HZ3' ' CD ' ' A' ' 100' ' ' GLU . 7.1 tttp -91.1 116.69 29.01 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 167.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.3 t -104.2 110.91 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 126.677 1.991 . . . . 0.0 108.7 -173.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -132.78 168.69 17.9 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 122.216 1.008 . . . . 0.0 113.143 -176.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.86 -155.48 26.15 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 124.87 1.224 . . . . 0.0 111.488 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -159.71 152.12 21.09 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -123.91 134.24 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 125.712 1.605 . . . . 0.0 107.865 -178.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.8 ptpt -149.58 152.03 34.81 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -172.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.1 12.12 52.94 Favored Glycine 0 CA--C 1.535 1.302 0 C-N-CA 125.256 1.407 . . . . 0.0 113.231 -168.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -111.86 164.7 12.79 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.005 2.122 . . . . 0.0 111.1 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.23 166.11 24.0 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.081 1.352 . . . . 0.0 111.438 176.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.31 -166.48 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 128.541 2.736 . . . . 0.0 113.661 -177.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.73 -178.38 42.78 Favored Glycine 0 CA--C 1.531 1.063 0 O-C-N 120.295 -1.503 . . . . 0.0 113.136 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.535 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -74.58 144.48 43.95 Favored 'General case' 0 CA--C 1.542 0.652 0 O-C-N 120.692 -1.476 . . . . 0.0 112.045 -178.065 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -136.8 151.29 49.0 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 128.789 2.836 . . . . 0.0 109.274 -177.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.29 173.83 26.69 Favored Glycine 0 N--CA 1.475 1.286 0 C-N-CA 125.317 1.437 . . . . 0.0 114.043 -174.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -159.93 122.46 3.4 Favored 'General case' 0 CA--C 1.554 1.122 0 C-N-CA 125.502 1.521 . . . . 0.0 112.754 -168.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 10.8 p-80 -152.07 134.14 15.01 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 118.705 -2.497 . . . . 0.0 113.607 167.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.6 m -84.99 146.0 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 CA-C-O 122.213 1.006 . . . . 0.0 108.948 170.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -107.13 176.09 5.28 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 124.021 1.867 . . . . 0.0 114.592 -168.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.492 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.2 pm0 -72.95 132.87 44.0 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 158.774 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 75.77 167.59 0.27 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 124.422 2.058 . . . . 0.0 115.148 169.119 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.34 0.28 57.05 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 111.41 -2.632 . . . . 0.0 109.96 163.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -69.92 138.08 52.11 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 165.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.416 HD22 ' CG2' ' A' ' 148' ' ' VAL . 0.8 OUTLIER -177.08 21.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 168.057 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.4 p -79.57 -14.33 58.92 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -163.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -108.1 10.05 28.18 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 124.5 1.12 . . . . 0.0 110.972 167.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.56 -138.06 35.46 Favored Glycine 0 CA--C 1.528 0.865 0 O-C-N 121.019 -1.05 . . . . 0.0 111.035 -171.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.2 m -57.17 -6.06 0.35 Allowed 'General case' 0 CA--C 1.549 0.928 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -174.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.5 t -103.13 0.71 32.24 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-N 119.966 1.257 . . . . 0.0 113.998 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.9 p -128.57 -18.37 3.95 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 168.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.37 153.98 35.73 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.326 1.851 . . . . 0.0 110.763 168.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.16 -173.78 28.81 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.239 0.923 . . . . 0.0 114.753 -170.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.41 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 40.9 Cg_endo -91.24 72.11 0.94 Allowed 'Trans proline' 0 CA--C 1.538 0.721 1 C-N-CA 125.401 4.068 . . . . 0.0 108.276 169.556 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.437 ' ND1' ' ND1' ' A' ' 71' ' ' HIS . 5.1 p80 43.9 70.04 0.36 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.958 1.703 . . . . 0.0 114.657 164.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -32.59 134.3 0.1 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 128.848 2.859 . . . . 0.0 117.901 -168.061 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 30.0 p-10 -103.75 34.25 0.05 OUTLIER Pre-proline 0 CA--C 1.559 1.302 0 N-CA-C 117.365 2.357 . . . . 0.0 117.365 -174.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -66.36 -15.17 47.15 Favored 'Trans proline' 0 C--N 1.357 1.003 0 CA-C-N 123.328 2.224 . . . . 0.0 115.068 -169.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -77.1 -0.84 26.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.099 1.359 . . . . 0.0 112.844 169.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.4 t 77.98 59.48 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.988 2.115 . . . . 0.0 112.3 168.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 ptm85 -149.72 169.35 21.24 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -67.57 156.7 36.14 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 127.889 2.476 . . . . 0.0 111.091 172.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.437 ' ND1' ' ND1' ' A' ' 63' ' ' HIS . 78.1 t60 -75.33 149.97 38.59 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.152 165.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.13 -145.36 12.76 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 116.508 -0.315 . . . . 0.0 113.052 166.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.411 ' H ' ' CB ' ' A' ' 76' ' ' ASP . . . 165.32 -98.15 0.15 Allowed Glycine 0 CA--C 1.535 1.286 0 CA-C-O 117.166 -1.908 . . . . 0.0 114.771 168.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -65.43 0.42 2.85 Favored 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 124.821 3.681 . . . . 0.0 116.397 -169.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.34 1.73 1.41 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 127.124 2.17 . . . . 0.0 112.486 175.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.586 ' CG ' ' H ' ' A' ' 77' ' ' GLU . 19.9 t0 -95.96 -178.96 4.53 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 128.321 2.648 . . . . 0.0 111.131 178.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.586 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 20.1 tt0 -98.43 -31.26 12.09 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 129.635 3.174 . . . . 0.0 112.04 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -127.51 -70.62 0.7 Allowed 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -166.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.499 HH22 ' HB ' ' A' ' 103' ' ' VAL . 1.1 ttt-85 83.69 128.88 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 127.038 2.135 . . . . 0.0 111.436 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -66.25 169.63 6.94 Favored 'General case' 0 CA--C 1.55 0.953 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 m -85.11 65.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 CA-C-O 122.707 1.242 . . . . 0.0 109.68 173.147 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.76 88.73 0.3 Allowed Glycine 0 C--O 1.223 -0.555 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -168.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -158.0 150.5 22.41 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 128.132 2.573 . . . . 0.0 109.597 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 77.5 mt -129.8 178.04 6.81 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 126.08 1.752 . . . . 0.0 109.3 169.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -84.55 -129.04 1.82 Allowed Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.376 0.989 . . . . 0.0 113.184 -176.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -147.7 169.73 19.06 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.437 1.095 . . . . 0.0 110.53 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.41 HG23 ' H ' ' A' ' 88' ' ' THR . 4.3 p -139.63 170.73 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.173 0.989 . . . . 0.0 110.765 -170.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.41 ' H ' HG23 ' A' ' 87' ' ' VAL . 15.5 m -140.78 138.52 34.17 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 125.727 1.611 . . . . 0.0 108.301 172.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.71 138.79 34.56 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.821 0.848 . . . . 0.0 110.563 176.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -87.43 162.8 17.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.64 1.176 . . . . 0.0 112.147 172.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -53.46 -19.06 3.17 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 127.783 2.433 . . . . 0.0 115.017 -170.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.68 4.07 48.49 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 128.241 2.616 . . . . 0.0 110.918 -173.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.68 26.84 21.54 Favored Glycine 0 C--N 1.341 0.829 0 C-N-CA 126.065 1.793 . . . . 0.0 113.907 172.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.18 132.3 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.4 129.21 43.8 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 126.159 1.783 . . . . 0.0 106.258 164.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -117.09 135.64 53.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 -178.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 51.3 t -125.24 129.81 73.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 114.114 -1.403 . . . . 0.0 114.381 -164.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.7 p -144.72 74.47 1.41 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.235 1.414 . . . . 0.0 112.52 176.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -101.09 159.39 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 120.604 -1.31 . . . . 0.0 111.481 -177.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.44 ' CD ' ' HZ3' ' A' ' 30' ' ' LYS . 6.6 tt0 -138.87 141.77 38.6 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.768 2.027 . . . . 0.0 107.941 172.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -145.42 141.2 28.19 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.229 1.411 . . . . 0.0 110.259 177.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.2 p -111.54 50.82 0.81 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -173.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.499 ' HB ' HH22 ' A' ' 79' ' ' ARG . 23.4 t -144.32 -42.97 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.207 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 168.468 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.43 155.52 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 CA-C-N 119.564 1.074 . . . . 0.0 112.095 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.9 p -156.98 167.67 29.77 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.565 -1.334 . . . . 0.0 113.351 177.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.12 56.8 1.31 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.956 1.36 . . . . 0.0 109.378 170.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.08 33.02 0.88 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.723 2.009 . . . . 0.0 111.428 168.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.4 -137.21 13.14 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 124.731 1.158 . . . . 0.0 111.928 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -93.65 -32.82 13.92 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 128.073 2.549 . . . . 0.0 115.766 -165.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -83.95 -8.23 59.22 Favored 'General case' 0 CA--C 1.545 0.758 0 O-C-N 120.305 -1.497 . . . . 0.0 111.607 -178.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 69.9 m -102.19 -40.6 6.72 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 115.416 1.636 . . . . 0.0 115.416 -170.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -169.49 -42.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.104 1.762 . . . . 0.0 114.134 171.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.85 141.51 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 168.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.68 8.85 61.05 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 116.31 -2.384 . . . . 0.0 113.896 -174.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -100.17 177.48 5.06 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 121.146 2.473 . . . . 0.0 109.62 169.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 27.2 m -120.91 146.72 46.32 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.855 1.662 . . . . 0.0 110.243 -175.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -127.33 143.36 51.24 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.858 1.663 . . . . 0.0 109.276 166.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.8 m -114.24 129.47 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 125.598 1.559 . . . . 0.0 109.569 169.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -98.56 120.53 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 168.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -96.81 153.71 17.72 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.333 1.453 . . . . 0.0 113.337 -168.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.26 -62.63 1.57 Allowed 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 124.427 1.091 . . . . 0.0 111.305 -172.741 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.44 176.47 6.28 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.86 -1.15 . . . . 0.0 111.437 170.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.37 146.25 44.96 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.23 1.012 . . . . 0.0 113.428 -169.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.66 112.8 17.27 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 166.226 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -78.72 -8.0 58.29 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.661 1.985 . . . . 0.0 114.922 -167.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 34.28 89.28 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 129.385 3.074 . . . . 0.0 114.915 177.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.41 -55.36 4.9 Favored Glycine 0 N--CA 1.469 0.851 0 C-N-CA 125.456 1.503 . . . . 0.0 112.54 168.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -153.91 110.22 3.3 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -174.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.97 -95.48 2.21 Favored Glycine 0 CA--C 1.513 -0.079 0 N-CA-C 104.116 -3.593 . . . . 0.0 104.116 163.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.55 14.81 3.91 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 117.938 -1.479 . . . . 0.0 114.321 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -121.63 173.66 7.3 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 119.993 1.896 . . . . 0.0 112.215 -169.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -75.56 -48.17 23.55 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 113.067 -1.879 . . . . 0.0 109.04 167.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -61.59 -19.2 61.95 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 176.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 21.1 m -51.34 -39.33 56.81 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 119.955 1.252 . . . . 0.0 112.776 171.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -94.78 -33.18 12.98 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 174.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 mtpt -75.27 -29.23 60.09 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 120.618 1.554 . . . . 0.0 114.823 -178.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.0 p -136.85 -23.33 1.18 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.436 ' C ' ' H ' ' A' ' 140' ' ' ALA . . . 98.36 8.15 55.21 Favored Glycine 0 C--O 1.221 -0.718 0 C-N-CA 124.733 1.158 . . . . 0.0 110.686 -167.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 62.05 -4.04 0.22 Allowed 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.344 1.858 . . . . 0.0 114.153 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.436 ' H ' ' C ' ' A' ' 138' ' ' GLY . . . -58.41 -3.7 0.31 Allowed 'General case' 0 CA--C 1.555 1.159 0 C-N-CA 129.058 2.943 . . . . 0.0 117.151 -165.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.81 -81.6 1.38 Allowed Glycine 0 CA--C 1.532 1.144 0 C-N-CA 125.764 1.65 . . . . 0.0 113.337 172.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.7 m -172.27 166.66 5.9 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.021 1.729 . . . . 0.0 112.255 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.407 ' H ' ' NE ' ' A' ' 143' ' ' ARG . 0.0 OUTLIER -100.38 144.4 29.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 116.698 2.11 . . . . 0.0 116.698 -173.073 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -90.53 -21.97 21.54 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 113.652 -1.613 . . . . 0.0 111.375 166.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.14 142.65 23.53 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 122.185 0.993 . . . . 0.0 111.004 173.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.1 p -136.94 147.78 46.58 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 127.887 2.475 . . . . 0.0 109.082 178.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.63 160.44 31.86 Favored Glycine 0 N--CA 1.469 0.874 0 N-CA-C 115.478 0.951 . . . . 0.0 115.478 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.416 ' CG2' HD22 ' A' ' 53' ' ' ASN . 99.3 t -104.74 143.71 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.527 1.131 . . . . 0.0 110.704 174.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 68.7 mt -84.89 95.41 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 126.383 1.873 . . . . 0.0 111.836 -169.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -91.62 177.75 40.71 Favored Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.0 1.285 . . . . 0.0 113.622 177.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -132.83 158.05 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.727 2.011 . . . . 0.0 112.206 -178.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -153.67 -25.76 0.14 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 174.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . 0.479 ' OE1' ' HE3' ' A' ' 3' ' ' LYS . 34.3 tt0 . . . . . 0 CA--C 1.537 0.458 0 O-C-N 121.009 -1.057 . . . . 0.0 110.802 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.419 0 CA-C-O 120.933 0.397 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.3 m -84.1 99.97 10.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -174.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . 0.451 ' HZ2' ' HB ' ' B' ' 5' ' ' VAL 0.271 0.0 OUTLIER -94.8 113.96 25.78 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-O 123.321 1.534 . . . . 0.0 112.963 178.295 . . . . . . . . 4 4 . 1 . 017 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.05 164.21 25.94 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 125.709 1.604 . . . . 0.0 111.166 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . 0.451 ' HB ' ' HZ2' ' B' ' 3' ' ' LYS . 1.3 p -156.03 140.53 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 125.767 1.627 . . . . 0.0 108.027 178.299 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.5 124.15 21.03 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 4.1 p -79.95 120.62 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 169.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -112.31 110.71 21.1 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 125.125 1.37 . . . . 0.0 108.427 169.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 tttt -157.06 160.28 38.77 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-O 121.499 0.666 . . . . 0.0 111.629 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.0 -35.83 0.84 Allowed Glycine 0 N--CA 1.468 0.802 0 C-N-CA 127.154 2.311 . . . . 0.0 110.005 174.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.41 58.19 2.56 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.867 2.067 . . . . 0.0 110.859 177.289 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 36.8 -98.31 0.01 OUTLIER Glycine 0 CA--C 1.535 1.334 0 C-N-CA 128.104 2.764 . . . . 0.0 114.288 -176.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.06 -13.2 15.76 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 123.869 3.046 . . . . 0.0 114.785 -176.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.21 137.51 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 121.262 1.846 . . . . 0.0 111.675 -176.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -126.49 162.12 26.36 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 124.357 1.063 . . . . 0.0 110.375 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -128.19 62.99 0.62 Allowed Glycine 0 N--CA 1.469 0.853 0 C-N-CA 125.262 1.41 . . . . 0.0 111.836 172.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.44 109.08 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 CA-C-N 118.358 1.079 . . . . 0.0 110.923 -168.686 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -110.8 150.88 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 169.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -129.46 129.15 44.25 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.054 2.142 . . . . 0.0 107.364 167.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -115.93 125.02 52.03 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 119.203 0.91 . . . . 0.0 109.834 178.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.65 127.39 52.38 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 123.726 0.81 . . . . 0.0 110.242 -178.619 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . 0.491 ' HG2' ' H ' ' B' ' 24' ' ' GLU . 52.4 tt0 -121.14 134.27 55.23 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 123.069 1.414 . . . . 0.0 112.57 170.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -82.89 0.4 44.39 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 126.485 1.914 . . . . 0.0 113.617 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.491 ' H ' ' HG2' ' B' ' 22' ' ' GLN . 43.4 mt-10 -157.64 -164.64 1.59 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 130.333 3.453 . . . . 0.0 108.495 -169.168 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -120.47 -6.6 9.77 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.895 1.278 . . . . 0.0 111.868 165.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -116.84 -45.95 2.76 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.745 1.618 . . . . 0.0 113.685 -171.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.38 -162.83 11.31 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 125.184 1.373 . . . . 0.0 114.133 -176.569 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.18 161.45 38.22 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.524 2.149 . . . . 0.0 112.69 -171.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 13.9 t -133.71 136.42 54.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.834 1.654 . . . . 0.0 109.833 -173.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -80.85 130.99 35.34 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.253 0.549 . . . . 0.0 110.049 171.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.36 105.44 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 127.735 2.414 . . . . 0.0 108.227 178.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -138.49 162.16 35.22 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.85 173.11 13.06 Favored Glycine 0 N--CA 1.467 0.737 0 C-N-CA 124.668 1.128 . . . . 0.0 114.261 171.331 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.3 p -110.65 120.59 42.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 114.86 1.43 . . . . 0.0 114.86 -167.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -92.01 117.12 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 167.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 pttt -137.81 136.61 37.37 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.511 0.725 . . . . 0.0 111.349 -167.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.57 -18.26 22.77 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 127.491 2.472 . . . . 0.0 113.636 -172.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.4 156.35 25.45 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.371 1.069 . . . . 0.0 111.705 172.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -69.25 166.13 19.08 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.258 1.423 . . . . 0.0 110.262 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -61.39 -176.36 0.07 Allowed 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 126.673 1.989 . . . . 0.0 115.197 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.42 177.28 51.83 Favored Glycine 0 N--CA 1.469 0.867 0 C-N-CA 124.905 1.24 . . . . 0.0 112.187 -179.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.565 ' CD2' ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -71.23 141.99 50.6 Favored 'General case' 0 CA--C 1.541 0.614 0 O-C-N 120.824 -1.398 . . . . 0.0 110.092 177.381 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -134.21 141.29 46.99 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 127.317 2.247 . . . . 0.0 107.957 176.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.98 155.94 48.53 Favored Glycine 0 N--CA 1.479 1.562 0 CA-C-N 120.494 1.497 . . . . 0.0 113.217 -174.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -147.27 105.5 3.76 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.91 1.355 . . . . 0.0 110.465 -171.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.476 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -145.4 145.22 31.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 120.804 -1.185 . . . . 0.0 110.4 -167.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . 0.411 ' CG2' ' HA2' ' B' ' 82' ' ' GLY . 34.5 m -115.03 120.7 65.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.278 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -176.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.476 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 3.7 m170 -74.93 152.1 38.84 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -173.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -73.05 94.05 1.85 Allowed 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 169.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 150.54 156.82 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 1 C-N-CA 132.351 4.26 . . . . 0.0 111.669 170.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.3 -21.19 42.28 Favored Glycine 0 C--N 1.337 0.621 0 C-N-CA 126.187 1.851 . . . . 0.0 111.294 164.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . 0.454 ' C ' HD21 ' B' ' 53' ' ' ASN . 29.9 t0 -58.05 157.42 8.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 165.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.568 ' ND2' ' HG1' ' B' ' 116' ' ' THR . 1.3 p30 162.65 31.26 0.0 OUTLIER 'General case' 0 C--O 1.241 0.62 0 C-N-CA 129.075 2.95 . . . . 0.0 111.496 165.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 18.2 p . . . . . 0 N--CA 1.455 -0.19 0 O-C-N 121.132 -0.98 . . . . 0.0 110.364 -168.423 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.249 0 CA-C-O 121.682 0.753 . . . . 0.0 112.017 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.08 -161.86 29.49 Favored Glycine 0 CA--C 1.54 1.602 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.568 173.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -78.03 -171.43 1.2 Allowed 'Trans proline' 0 CA--C 1.54 0.777 1 C-N-CA 126.257 4.638 . . . . 0.0 110.087 169.167 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.674 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 2.1 p80 -73.76 80.32 1.57 Allowed 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.303 2.641 . . . . 0.0 107.084 168.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -56.0 169.88 0.35 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 123.826 1.774 . . . . 0.0 110.889 174.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -104.13 51.94 0.08 OUTLIER Pre-proline 0 CA--C 1.555 1.142 0 CA-C-N 113.392 -1.731 . . . . 0.0 115.165 -167.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.45 -25.72 48.2 Favored 'Trans proline' 0 C--N 1.354 0.865 0 C-N-CA 122.33 2.02 . . . . 0.0 111.469 -177.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 39.5 mt -81.6 -6.49 59.05 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 172.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.9 t 69.34 59.86 0.32 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 125.652 1.581 . . . . 0.0 113.84 174.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.9 ptt180 -162.01 176.26 10.94 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 115.449 1.648 . . . . 0.0 115.449 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.2 170.95 11.94 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.888 1.275 . . . . 0.0 114.116 177.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.434 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 77.0 t60 -83.76 162.26 20.71 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.378 0.671 . . . . 0.0 111.501 167.636 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . 0.401 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 137.97 -102.39 0.37 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.377 1.941 . . . . 0.0 111.739 166.106 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.75 -53.44 0.71 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 116.958 -2.024 . . . . 0.0 117.498 172.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -87.86 -8.17 6.02 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.502 2.801 . . . . 0.0 111.25 176.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.467 ' HE2' ' HA ' ' B' ' 75' ' ' LYS . 0.1 OUTLIER -145.98 -16.64 0.46 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 176.248 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -101.67 92.45 4.87 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 103.181 -2.896 . . . . 0.0 103.181 159.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 56.2 mp0 -65.04 -4.88 5.2 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.676 1.191 . . . . 0.0 113.508 -176.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -74.61 -63.31 1.27 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.597 1.959 . . . . 0.0 107.711 178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 32.4 ttp180 67.83 119.79 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.959 2.207 . . . . 0.0 116.959 162.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -62.61 156.1 24.25 Favored 'General case' 0 N--CA 1.472 0.659 0 O-C-N 119.467 -2.021 . . . . 0.0 112.102 169.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -52.71 -32.75 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . 0.411 ' HA2' ' CG2' ' B' ' 47' ' ' VAL . . . -96.33 39.05 2.91 Favored Glycine 0 CA--C 1.534 1.26 0 N-CA-C 116.708 1.443 . . . . 0.0 116.708 -174.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -129.96 108.39 10.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.281 -1.129 . . . . 0.0 111.715 -172.385 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -109.79 47.41 0.95 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 122.467 1.127 . . . . 0.0 110.153 168.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.5 -101.67 0.03 OUTLIER Glycine 0 CA--C 1.528 0.879 0 C-N-CA 127.984 2.707 . . . . 0.0 114.103 174.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.8 p30 -154.86 161.74 41.34 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.592 1.557 . . . . 0.0 111.553 -175.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.9 p -137.85 124.81 28.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 C-N-CA 126.916 2.086 . . . . 0.0 109.605 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 55.5 m -107.73 123.89 49.2 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 114.707 -1.133 . . . . 0.0 111.19 -167.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.08 148.9 21.61 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 124.398 1.079 . . . . 0.0 112.509 -176.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -97.22 157.07 16.13 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.111 1.765 . . . . 0.0 112.236 169.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -24.94 24.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 127.246 2.219 . . . . 0.0 115.336 -169.067 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -79.65 5.75 12.42 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.984 1.714 . . . . 0.0 111.597 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.19 36.81 6.15 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 126.049 1.785 . . . . 0.0 113.2 171.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.27 138.39 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 117.31 2.337 . . . . 0.0 117.31 -172.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.93 93.07 3.97 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.72 2.008 . . . . 0.0 110.696 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -85.59 95.44 9.33 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-O 122.491 1.139 . . . . 0.0 110.665 172.271 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.75 152.89 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.513 -170.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.2 p -155.14 109.83 2.98 Favored 'General case' 0 CA--C 1.541 0.634 0 O-C-N 120.963 -1.086 . . . . 0.0 112.21 175.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.83 160.31 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 127.722 2.409 . . . . 0.0 110.12 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -134.32 141.14 46.82 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 164.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -144.59 152.38 40.43 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.528 1.131 . . . . 0.0 112.116 178.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.7 p -117.42 59.32 0.78 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.546 1.538 . . . . 0.0 111.654 -169.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -157.24 -42.09 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 174.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -79.21 154.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 O-C-N 121.883 -0.511 . . . . 0.0 110.628 169.353 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 9.2 p -155.26 170.37 22.03 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.329 1.052 . . . . 0.0 111.05 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.1 mp -86.56 55.53 3.59 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.092 -1.005 . . . . 0.0 111.649 -173.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.1 t -90.47 12.81 17.43 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 116.876 2.176 . . . . 0.0 116.876 -169.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.22 -38.65 3.19 Favored Glycine 0 N--CA 1.475 1.235 0 N-CA-C 118.695 2.238 . . . . 0.0 118.695 167.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -107.16 -105.46 0.34 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.541 1.136 . . . . 0.0 110.572 -166.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -76.23 11.77 1.41 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 126.187 1.795 . . . . 0.0 113.363 175.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 9.7 p -84.12 -158.35 0.32 Allowed 'General case' 0 CA--C 1.553 1.086 0 C-N-CA 127.013 2.125 . . . . 0.0 114.13 -175.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.39 8.1 pt -83.23 -9.39 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 O-C-N 119.666 -1.896 . . . . 0.0 114.234 168.284 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.5 mm -98.36 151.18 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 161.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 95.1 -41.12 2.56 Favored Glycine 0 N--CA 1.468 0.811 0 C-N-CA 124.342 0.973 . . . . 0.0 113.033 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . 0.488 HH21 ' HB2' ' B' ' 117' ' ' LEU . 0.2 OUTLIER -75.13 -179.56 4.45 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 127.49 2.316 . . . . 0.0 115.604 -169.579 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.568 ' HG1' ' ND2' ' B' ' 53' ' ' ASN . 5.1 t -103.43 176.18 5.23 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 127.437 2.295 . . . . 0.0 113.065 169.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . 0.488 ' HB2' HH21 ' B' ' 115' ' ' ARG . 33.9 tp -152.95 144.99 23.76 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.157 2.183 . . . . 0.0 110.363 170.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.45 150.2 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 O-C-N 123.284 0.365 . . . . 0.0 110.796 167.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.89 128.42 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 168.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -90.16 148.84 22.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.93 0.892 . . . . 0.0 112.518 -169.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.297 2.4 pp20? -77.51 -32.55 54.17 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.3 -0.875 . . . . 0.0 112.661 -174.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -90.54 169.07 11.34 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.322 -0.861 . . . . 0.0 110.061 165.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.72 149.65 34.8 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.125 0.97 . . . . 0.0 109.628 164.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -78.9 131.89 36.57 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 168.372 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -78.58 -11.05 59.94 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.178 0.991 . . . . 0.0 112.523 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mm? 70.25 -66.33 0.28 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 129.998 3.319 . . . . 0.0 111.339 -176.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 176.09 29.38 0.04 OUTLIER Glycine 0 N--CA 1.463 0.491 0 N-CA-C 116.171 1.228 . . . . 0.0 116.171 -169.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -126.12 -20.34 4.54 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 117.088 2.255 . . . . 0.0 117.088 -167.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.89 129.92 47.16 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 106.506 -2.638 . . . . 0.0 106.506 168.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -74.12 46.39 1.52 Allowed Glycine 0 N--CA 1.473 1.102 0 C-N-CA 126.387 1.946 . . . . 0.0 112.865 -171.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -103.23 -89.86 0.38 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.653 1.181 . . . . 0.0 110.947 -169.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 170.4 -76.66 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 131.213 3.805 . . . . 0.0 102.474 -167.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . 0.459 ' CD ' ' HG1' ' B' ' 137' ' ' THR . 2.2 tm-20 -35.66 -52.85 0.7 Allowed 'General case' 0 CA--C 1.54 0.584 1 C-N-CA 132.147 4.179 . . . . 0.0 112.92 171.628 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.6 m -47.37 -31.1 3.71 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 176.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.3 t -112.72 -8.03 13.79 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 119.449 1.022 . . . . 0.0 112.264 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 22.4 mmtp -84.25 -47.42 10.81 Favored 'General case' 0 CA--C 1.537 0.469 0 O-C-N 120.75 -1.219 . . . . 0.0 110.853 168.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.459 ' HG1' ' CD ' ' B' ' 133' ' ' GLU . 74.6 p -117.01 -34.17 4.49 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.786 1.634 . . . . 0.0 113.079 -173.271 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.13 2.89 31.59 Favored Glycine 0 N--CA 1.47 0.922 0 CA-C-O 118.353 -1.248 . . . . 0.0 113.805 -177.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 51.48 24.16 2.11 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 119.55 1.675 . . . . 0.0 114.168 177.145 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.09 20.08 0.08 Allowed 'General case' 0 CA--C 1.553 1.067 0 N-CA-C 115.748 1.759 . . . . 0.0 115.748 -166.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.8 -66.76 2.4 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 126.459 1.981 . . . . 0.0 114.288 173.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -175.69 -163.56 0.12 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.803 1.641 . . . . 0.0 109.532 -169.44 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.26 145.73 33.0 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 174.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -90.58 -103.84 0.1 Allowed 'General case' 0 CA--C 1.537 0.462 0 O-C-N 124.98 1.425 . . . . 0.0 107.557 170.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.03 147.22 50.35 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.443 0.697 . . . . 0.0 111.901 -177.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.33 151.76 51.71 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 127.093 2.157 . . . . 0.0 110.17 173.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.87 174.82 37.55 Favored Glycine 0 C--O 1.221 -0.678 0 N-CA-C 116.461 1.344 . . . . 0.0 116.461 -174.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -142.37 143.47 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.408 1.483 . . . . 0.0 109.502 -168.264 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.2 129.82 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -165.481 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.71 -155.66 7.12 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 125.232 1.396 . . . . 0.0 111.023 167.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.43 157.23 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.033 1.333 . . . . 0.0 113.285 -169.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.9 -41.1 14.25 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 161.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 . . . . . 0 CA--C 1.536 0.432 1 C-N-CA 132.764 4.425 . . . . 0.0 107.194 168.437 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.511 -0.536 0 CA-C-O 123.028 1.394 . . . . 0.0 111.345 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -87.8 107.1 18.5 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 166.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.02 167.48 12.06 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.537 1.535 . . . . 0.0 111.893 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -159.35 149.23 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.395 1.078 . . . . 0.0 112.013 -168.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.33 121.22 14.53 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.073 1.749 . . . . 0.0 108.918 167.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -103.71 99.16 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 167.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.2 mp -81.03 116.29 20.91 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -176.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 mtpt -144.77 157.55 44.13 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-N 119.272 0.942 . . . . 0.0 111.818 -172.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.45 -47.87 0.43 Allowed Glycine 0 N--CA 1.47 0.904 0 C-N-CA 126.505 2.002 . . . . 0.0 111.252 169.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.62 61.42 2.94 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 128.64 2.776 . . . . 0.0 112.344 -168.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.4 -99.81 0.02 OUTLIER Glycine 0 CA--C 1.534 1.266 0 C-N-CA 126.974 2.226 . . . . 0.0 112.904 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -82.11 -7.39 12.09 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.202 3.268 . . . . 0.0 114.867 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -86.42 136.07 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 121.244 1.838 . . . . 0.0 110.889 175.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.38 151.44 35.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 114.066 -1.424 . . . . 0.0 110.833 167.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -118.77 98.79 0.75 Allowed Glycine 0 C--O 1.22 -0.779 0 C-N-CA 125.485 1.517 . . . . 0.0 110.259 174.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -91.38 110.84 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 108.382 -0.969 . . . . 0.0 108.382 171.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.09 155.19 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-O 122.037 0.922 . . . . 0.0 110.713 168.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -130.96 156.2 45.51 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.476 1.51 . . . . 0.0 109.849 169.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -123.8 120.51 32.85 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.001 1.32 . . . . 0.0 108.651 168.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -98.44 119.86 37.86 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.246 1.018 . . . . 0.0 110.118 172.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.95 170.47 16.05 Favored 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 166.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.93 -46.88 0.53 Allowed 'General case' 0 CA--C 1.558 1.253 0 C-N-CA 128.135 2.574 . . . . 0.0 110.166 168.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.6 mp0 -81.68 116.1 21.24 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 120.456 1.48 . . . . 0.0 111.964 173.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -68.6 -9.69 51.22 Favored 'General case' 0 CA--C 1.552 1.047 0 O-C-N 119.223 -2.173 . . . . 0.0 114.439 -174.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -110.78 -2.94 15.97 Favored 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 127.22 2.208 . . . . 0.0 114.542 174.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.27 175.99 38.32 Favored Glycine 0 CA--C 1.542 1.734 0 CA-C-O 118.848 -0.973 . . . . 0.0 113.756 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -77.77 163.17 29.2 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 124.731 3.62 . . . . 0.0 110.739 175.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.2 t -138.08 145.57 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.672 0.789 . . . . 0.0 112.165 -165.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.402 ' HE3' ' OE1' ' A' ' 100' ' ' GLU . 0.1 OUTLIER -84.79 121.28 27.47 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.74 1.216 . . . . 0.0 111.425 169.766 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 94.6 t -101.16 133.47 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.852 2.061 . . . . 0.0 108.112 169.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -153.67 167.61 29.0 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.572 0.701 . . . . 0.0 112.658 171.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.51 -161.35 28.36 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 124.253 0.93 . . . . 0.0 113.432 172.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.8 p -154.35 118.98 4.87 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.519 0.727 . . . . 0.0 110.776 -169.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.413 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 2.2 mp -108.01 103.0 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.915 0.886 . . . . 0.0 109.019 -177.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -115.88 133.42 56.04 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.223 1.809 . . . . 0.0 111.934 -166.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.59 0.86 27.65 Favored Glycine 0 CA--C 1.536 1.399 0 C-N-CA 127.458 2.456 . . . . 0.0 113.26 -174.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 97.5 mt -70.57 162.74 28.31 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 118.508 1.154 . . . . 0.0 111.116 172.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.6 m -83.14 140.64 32.49 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 166.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -58.76 152.15 19.64 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.42 -172.67 29.17 Favored Glycine 0 CA--C 1.532 1.125 0 C-N-CA 124.241 0.924 . . . . 0.0 112.818 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.458 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -72.4 149.29 44.42 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.817 2.047 . . . . 0.0 112.329 -169.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -145.81 121.72 10.64 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.962 1.705 . . . . 0.0 110.14 173.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.62 147.76 23.46 Favored Glycine 0 N--CA 1.486 1.982 0 CA-C-N 119.992 1.269 . . . . 0.0 112.606 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -148.32 102.01 3.31 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 119.208 1.504 . . . . 0.0 112.408 -167.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m80 -150.27 169.86 20.35 Favored 'General case' 0 CA--C 1.52 -0.199 0 O-C-N 120.658 -1.276 . . . . 0.0 114.331 -168.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.6 m -75.73 129.93 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 113.608 -1.633 . . . . 0.0 109.871 166.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -80.86 137.71 36.18 Favored 'General case' 0 CA--C 1.551 0.986 0 N-CA-C 102.472 -3.159 . . . . 0.0 102.472 157.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -65.18 142.44 58.33 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -168.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 56.83 -169.05 0.1 Allowed 'General case' 0 C--O 1.241 0.623 0 C-N-CA 127.242 2.217 . . . . 0.0 113.898 175.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.472 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -136.69 5.71 3.76 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-O 116.78 -2.122 . . . . 0.0 113.525 -178.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -77.91 48.6 0.72 Allowed 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 121.336 2.568 . . . . 0.0 110.404 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.472 ' H ' ' C ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 172.65 5.87 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 118.359 2.726 . . . . 0.0 118.359 -169.35 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.4 p -31.37 -10.02 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.213 1 N-CA-C 124.607 5.04 . . . . 0.0 124.607 -167.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.02 35.67 0.06 Allowed 'General case' 0 CA--C 1.555 1.147 0 CA-C-N 123.504 2.865 . . . . 0.0 116.643 -169.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.1 -148.96 46.85 Favored Glycine 0 CA--C 1.526 0.734 0 O-C-N 120.784 -1.197 . . . . 0.0 111.617 172.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.3 p -64.42 -12.01 38.94 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 114.914 1.45 . . . . 0.0 114.914 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 p -80.01 -0.3 34.84 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.898 2.079 . . . . 0.0 112.833 178.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.1 m -155.87 177.49 11.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 127.655 2.382 . . . . 0.0 109.215 -176.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 77.1 -156.48 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 126.448 1.899 . . . . 0.0 113.96 172.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.2 -169.8 16.14 Favored Glycine 0 CA--C 1.541 1.674 0 C-N-CA 126.823 2.154 . . . . 0.0 114.931 -167.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -66.8 -177.03 0.83 Allowed 'Trans proline' 0 CA--C 1.539 0.761 1 C-N-CA 126.353 4.702 . . . . 0.0 113.588 177.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 114.26 21.88 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.625 1.17 . . . . 0.0 112.932 -170.514 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.427 ' CD2' ' HD3' ' A' ' 66' ' ' PRO . 8.8 t80 -41.43 128.44 3.07 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 127.385 2.274 . . . . 0.0 115.089 -169.616 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -112.0 45.92 0.27 Allowed Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 125.653 1.581 . . . . 0.0 114.281 -173.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.427 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 62.4 Cg_endo -69.15 -17.69 40.22 Favored 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 123.236 2.624 . . . . 0.0 111.722 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.5 mt -76.46 -7.14 54.49 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.201 1.4 . . . . 0.0 111.417 171.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.3 t 73.48 56.89 0.11 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 127.167 2.187 . . . . 0.0 112.267 171.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.16 172.45 16.92 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 116.52 2.044 . . . . 0.0 116.52 -167.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.465 ' HB3' ' HG1' ' A' ' 135' ' ' THR . 15.2 mmtp -82.57 173.81 11.62 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 127.149 2.18 . . . . 0.0 112.167 171.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.4 t60 -72.58 165.07 25.41 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.034 1.733 . . . . 0.0 113.616 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.46 -140.53 8.59 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 124.984 1.278 . . . . 0.0 114.499 167.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 131.87 -86.14 0.29 Allowed Glycine 0 CA--C 1.533 1.205 0 C-N-CA 126.287 1.898 . . . . 0.0 115.617 174.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -61.21 -9.77 13.58 Favored 'Trans proline' 0 CA--C 1.539 0.728 0 C-N-CA 124.748 3.632 . . . . 0.0 116.001 -169.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.34 -7.98 2.58 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.936 0.894 . . . . 0.0 112.767 167.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.421 ' CG ' ' H ' ' A' ' 78' ' ' GLU 0.314 0.0 OUTLIER -93.04 175.19 6.88 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -164.699 . . . . . . . . 4 4 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.406 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 56.0 mp0 -103.21 -22.95 13.66 Favored 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 131.391 3.876 . . . . 0.0 111.46 -168.391 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.421 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 2.9 mm-40 -105.94 -114.93 0.25 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 127.464 2.306 . . . . 0.0 110.132 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 103.27 119.18 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 130.892 3.677 . . . . 0.0 112.856 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.4 m170 -65.44 -176.87 0.36 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 126.388 1.875 . . . . 0.0 114.451 169.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.5 p -84.58 143.79 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 120.762 -1.212 . . . . 0.0 108.636 166.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.2 -2.52 9.25 Favored Glycine 0 CA--C 1.54 1.607 0 N-CA-C 117.455 1.742 . . . . 0.0 117.455 172.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -77.35 85.43 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-N 120.486 2.143 . . . . 0.0 109.553 167.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.0 mt -82.55 54.83 2.75 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.29 -176.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.47 -135.95 29.54 Favored Glycine 0 CA--C 1.528 0.859 0 C-N-CA 125.172 1.368 . . . . 0.0 114.386 170.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -136.86 145.0 43.88 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.058 0.943 . . . . 0.0 111.325 175.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -93.51 107.1 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 126.333 1.853 . . . . 0.0 109.579 176.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.2 m -99.9 113.89 26.75 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.677 1.191 . . . . 0.0 109.187 -175.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.03 158.26 15.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.896 1.679 . . . . 0.0 114.05 -171.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.39 -173.09 3.67 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.265 1.426 . . . . 0.0 112.597 169.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -83.7 -13.55 53.82 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 116.615 2.08 . . . . 0.0 116.615 176.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -75.36 -7.73 54.78 Favored 'General case' 0 CA--C 1.561 1.388 0 CA-C-O 122.845 1.307 . . . . 0.0 108.005 163.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.02 8.94 56.5 Favored Glycine 0 C--N 1.339 0.733 0 C-N-CA 128.26 2.838 . . . . 0.0 113.258 168.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 125.43 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 119.058 1.429 . . . . 0.0 113.839 -169.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 100.21 12.14 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 166.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -89.89 134.01 34.44 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.415 1.486 . . . . 0.0 109.099 177.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -141.31 137.42 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -167.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.3 p -153.59 119.5 5.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 125.757 1.623 . . . . 0.0 110.413 169.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.8 mt -147.15 147.47 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 C-N-CA 128.646 2.779 . . . . 0.0 110.358 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.402 ' OE1' ' HE3' ' A' ' 30' ' ' LYS . 2.0 tp10 -118.02 130.81 56.4 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.895 2.078 . . . . 0.0 105.98 167.057 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -139.36 134.38 32.41 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.853 0.861 . . . . 0.0 112.186 -172.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -114.69 46.46 1.4 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.175 1.176 . . . . 0.0 114.175 -179.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.57 7.11 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 C-N-CA 123.672 0.789 . . . . 0.0 112.865 167.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -133.33 161.37 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 C-N-CA 124.821 1.248 . . . . 0.0 109.056 168.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.3 p -148.61 162.32 39.92 Favored 'General case' 0 C--O 1.239 0.53 0 O-C-N 121.495 -0.753 . . . . 0.0 109.726 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -90.08 70.25 7.34 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 122.887 1.327 . . . . 0.0 109.39 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.6 t -106.69 142.85 35.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 114.296 -1.32 . . . . 0.0 109.343 168.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.21 10.93 52.14 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 127.573 2.511 . . . . 0.0 118.796 -165.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -129.31 -74.75 0.56 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.833 1.816 . . . . 0.0 110.292 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -95.26 -9.54 32.88 Favored 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.292 1.96 . . . . 0.0 116.292 -169.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 65.2 m -92.39 -123.54 0.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 CA-C-N 120.064 1.302 . . . . 0.0 113.66 -171.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.0 pt -115.95 14.86 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 119.61 -1.931 . . . . 0.0 115.727 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.8 mm -83.52 145.07 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 O-C-N 120.775 -1.203 . . . . 0.0 108.301 167.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 62.81 27.48 70.16 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 114.936 0.734 . . . . 0.0 114.936 168.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -106.3 153.8 21.66 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.471 1.108 . . . . 0.0 109.27 179.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.7 m -95.77 86.96 4.52 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.334 -0.854 . . . . 0.0 111.16 -167.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.8 tp -76.3 145.59 39.49 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-N 122.193 2.27 . . . . 0.0 113.457 -168.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.8 p -133.45 152.58 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 C-N-CA 126.751 2.021 . . . . 0.0 112.686 177.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -112.85 133.05 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 124.33 1.052 . . . . 0.0 108.216 164.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -89.61 152.75 21.23 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-O 122.292 1.044 . . . . 0.0 113.075 -176.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -68.01 -29.35 68.34 Favored 'General case' 0 N--CA 1.473 0.707 0 O-C-N 120.46 -1.4 . . . . 0.0 114.754 -174.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -119.8 169.56 10.02 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.976 1.31 . . . . 0.0 112.285 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -49.37 148.07 2.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.58 1.152 . . . . 0.0 110.555 169.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -96.45 133.45 40.86 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 123.647 0.592 . . . . 0.0 109.77 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -84.78 -13.89 49.83 Favored 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 125.44 1.496 . . . . 0.0 113.464 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 65.1 -38.34 0.25 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 130.817 3.647 . . . . 0.0 114.327 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.96 -32.6 0.05 OUTLIER Glycine 0 CA--C 1.519 0.281 0 CA-C-N 119.579 1.081 . . . . 0.0 115.343 170.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.78 69.69 0.99 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 117.379 2.363 . . . . 0.0 117.379 -172.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -79.55 -68.29 1.5 Allowed Glycine 0 N--CA 1.461 0.346 0 N-CA-C 106.27 -2.732 . . . . 0.0 106.27 164.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 174.65 21.31 0.02 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 124.819 1.199 . . . . 0.0 115.068 -178.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -149.23 161.79 41.32 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 119.374 1.587 . . . . 0.0 110.095 -179.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 35.1 tp10 -69.34 -45.9 68.35 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.905 1.282 . . . . 0.0 111.786 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.406 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 0.3 OUTLIER -45.39 -35.25 3.51 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.775 1.23 . . . . 0.0 113.417 176.16 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 33.4 t -58.7 -56.81 17.44 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 169.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.465 ' HG1' ' HB3' ' A' ' 70' ' ' LYS 0.292 0.0 OUTLIER -66.53 -9.72 37.66 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 123.98 0.912 . . . . 0.0 111.184 -178.013 . . . . . . . . 4 4 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.406 ' HZ2' ' CD ' ' A' ' 133' ' ' GLU . 48.7 mtmt -93.41 -50.45 5.44 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 119.333 0.969 . . . . 0.0 113.285 167.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 68.6 p -113.36 -24.38 9.36 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 -166.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.14 -3.08 47.55 Favored Glycine 0 C--O 1.22 -0.729 0 C-N-CA 125.203 1.383 . . . . 0.0 112.545 -168.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 54.66 16.04 1.25 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.898 1.679 . . . . 0.0 113.279 -177.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.59 27.27 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.763 2.025 . . . . 0.0 115.735 -165.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.7 -75.05 2.42 Favored Glycine 0 C--N 1.338 0.694 0 C-N-CA 127.254 2.359 . . . . 0.0 113.361 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.4 t -170.21 -150.31 0.08 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.546 1.138 . . . . 0.0 110.442 -171.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.89 123.5 47.18 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.366 1.067 . . . . 0.0 110.891 -173.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.513 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 1.7 tt -96.2 -137.4 0.25 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.86 2.064 . . . . 0.0 106.257 168.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.513 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -61.15 151.03 32.38 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 125.049 1.34 . . . . 0.0 112.375 -176.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -148.04 142.95 26.86 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 114.836 -1.074 . . . . 0.0 113.846 -172.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.23 114.88 0.63 Allowed Glycine 0 CA--C 1.528 0.9 0 C-N-CA 125.386 1.469 . . . . 0.0 113.039 -176.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -74.41 135.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 37.9 mt -74.98 124.35 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.055 0.542 . . . . 0.0 111.885 -167.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.08 -175.28 17.38 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 124.834 1.207 . . . . 0.0 113.27 173.087 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -124.83 152.12 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 126.581 1.953 . . . . 0.0 111.997 173.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.13 -8.19 2.31 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -178.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tm0? . . . . . 0 C--O 1.236 0.349 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 169.17 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.556 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -84.62 74.08 10.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 105.604 -1.998 . . . . 0.0 105.604 168.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ptpm? -76.01 121.58 22.96 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.39 -0.819 . . . . 0.0 110.328 -170.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.59 152.71 22.1 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.203 1.001 . . . . 0.0 110.939 -177.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -145.87 129.91 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.082 0.944 . . . . 0.0 111.288 -167.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -104.44 134.84 46.96 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.306 -1.315 . . . . 0.0 107.863 168.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.88 115.64 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 167.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -95.8 96.7 9.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 126.222 1.809 . . . . 0.0 108.942 -169.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -158.21 124.58 4.74 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.736 0.814 . . . . 0.0 110.233 175.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.25 -101.62 2.59 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 105.876 -2.89 . . . . 0.0 105.876 165.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -144.35 109.25 4.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 125.274 1.43 . . . . 0.0 109.702 -169.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.6 167.38 11.44 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 125.446 1.498 . . . . 0.0 111.648 -175.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -73.67 25.57 0.32 Allowed 'Trans proline' 0 CA--C 1.544 1.019 1 C-N-CA 125.361 4.041 . . . . 0.0 114.963 -170.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -122.68 119.83 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 119.605 1.093 . . . . 0.0 109.096 -178.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -158.66 158.15 33.22 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 114.684 -1.144 . . . . 0.0 112.357 -178.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.2 177.02 36.82 Favored Glycine 0 CA--C 1.506 -0.479 0 C-N-CA 124.843 1.211 . . . . 0.0 114.069 176.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -120.61 148.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 112.993 -1.603 . . . . 0.0 109.742 168.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.0 mm -128.81 130.84 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 166.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -100.41 141.84 32.71 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 126.31 1.844 . . . . 0.0 110.809 168.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -120.93 104.92 10.2 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.262 2.225 . . . . 0.0 108.845 171.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -99.78 103.18 14.79 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.842 0.857 . . . . 0.0 110.905 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -105.62 136.68 44.76 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 122.145 0.974 . . . . 0.0 109.27 169.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 16.6 pttp -98.71 -24.52 15.01 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 124.992 1.317 . . . . 0.0 113.692 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -163.93 134.84 4.47 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.061 2.144 . . . . 0.0 107.957 -164.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.5 p -51.83 -28.62 16.36 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 126.01 1.724 . . . . 0.0 114.873 -170.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -109.26 -6.18 15.63 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.558 1.543 . . . . 0.0 113.381 -176.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -88.22 165.97 34.69 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.86 1.219 . . . . 0.0 111.726 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.32 168.82 21.18 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.041 2.494 . . . . 0.0 111.902 -176.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.27 124.36 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 C-N-CA 123.828 0.851 . . . . 0.0 109.262 176.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.525 ' HZ3' ' CD ' ' B' ' 100' ' ' GLU . 67.7 mttm -81.54 128.59 34.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.625 -0.672 . . . . 0.0 109.427 169.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 63.2 t -108.81 127.09 65.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 126.093 1.757 . . . . 0.0 109.261 179.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -151.37 163.07 39.77 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 121.573 -0.705 . . . . 0.0 112.266 170.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.84 -166.24 33.37 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 123.702 0.668 . . . . 0.0 112.657 174.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.4 p -152.9 128.01 9.73 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 122.97 0.508 . . . . 0.0 111.665 -169.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 31.3 mt -118.72 124.77 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 125.019 1.328 . . . . 0.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . 0.415 ' HE3' ' O ' ' B' ' 92' ' ' ASP . 73.9 tttt -122.37 139.93 53.26 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 120.769 1.622 . . . . 0.0 111.595 -176.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.88 -0.51 9.17 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 127.863 2.649 . . . . 0.0 113.502 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 92.3 mt -75.73 170.3 16.45 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.16 1.384 . . . . 0.0 111.24 174.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.5 t -90.02 151.07 21.84 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 166.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -49.22 143.56 6.01 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.601 0.761 . . . . 0.0 111.513 171.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.32 -178.88 22.8 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 124.713 1.149 . . . . 0.0 113.239 -176.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.513 ' H ' ' CD2' ' B' ' 42' ' ' LEU . 1.7 pt? -80.59 149.54 29.87 Favored 'General case' 0 CA--C 1.553 1.066 0 C-N-CA 128.739 2.816 . . . . 0.0 113.732 -172.132 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -154.17 126.3 7.84 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 128.594 2.758 . . . . 0.0 110.685 -170.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.06 160.85 41.93 Favored Glycine 0 N--CA 1.482 1.766 0 CA-C-N 121.162 1.801 . . . . 0.0 113.914 -177.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.285 0.2 OUTLIER -159.38 138.21 10.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 128.182 2.593 . . . . 0.0 114.867 168.68 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 16.6 m80 -149.1 141.64 24.35 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 120.659 -1.276 . . . . 0.0 114.087 -169.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.02 106.94 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 126.768 2.027 . . . . 0.0 111.166 178.155 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.407 ' C ' ' H ' ' B' ' 50' ' ' PHE . 8.1 m170 -79.22 135.7 36.86 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.486 1.115 . . . . 0.0 110.732 -176.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -70.24 17.64 0.06 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.537 1.935 . . . . 0.0 112.513 171.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . 0.407 ' H ' ' C ' ' B' ' 48' ' ' HIS . 23.0 m-85 -144.07 92.66 2.35 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 126.427 1.891 . . . . 0.0 107.942 -167.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' B' ' 53' ' ' ASN . . . -83.29 7.73 66.78 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 116.967 -2.018 . . . . 0.0 111.012 167.442 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -77.1 49.79 0.7 Allowed 'General case' 0 N--CA 1.481 1.094 0 CA-C-O 124.779 2.228 . . . . 0.0 110.357 -176.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.402 ' H ' ' C ' ' B' ' 51' ' ' GLY . 0.4 OUTLIER 170.84 27.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 128.201 2.601 . . . . 0.0 113.574 -165.77 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 35.4 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 120.184 3.402 . . . . 0.0 120.184 -170.527 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.85 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -116.72 -99.79 2.13 Favored Glycine 0 CA--C 1.545 1.923 0 C-N-CA 125.315 1.436 . . . . 0.0 114.243 -174.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -92.0 177.26 1.76 Allowed 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.856 3.704 . . . . 0.0 113.429 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -115.26 126.02 54.01 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.862 2.465 . . . . 0.0 110.919 -175.491 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -48.84 149.33 1.84 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 129.253 3.021 . . . . 0.0 116.571 -169.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -111.65 44.11 0.23 Allowed Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 127.305 2.242 . . . . 0.0 113.695 -172.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -63.05 -30.54 76.1 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.705 2.27 . . . . 0.0 113.825 -169.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.66 -3.95 43.6 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.012 0.925 . . . . 0.0 112.582 173.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.0 t 77.27 58.91 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 127.368 2.267 . . . . 0.0 111.616 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 ptt180 -163.4 177.52 8.84 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 117.341 2.349 . . . . 0.0 117.341 -167.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -64.99 169.91 4.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.202 3.001 . . . . 0.0 114.276 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 52.7 t60 -107.2 146.68 31.08 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.712 2.005 . . . . 0.0 114.236 -169.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 126.92 -104.26 0.7 Allowed Glycine 0 N--CA 1.472 1.092 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 163.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.44 -35.62 3.55 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-O 116.367 -2.351 . . . . 0.0 118.271 167.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 14.43 0.85 Allowed 'Trans proline' 0 CA--C 1.549 1.251 0 CA-C-N 123.349 3.574 . . . . 0.0 113.153 168.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.49 -26.92 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 127.531 2.332 . . . . 0.0 110.847 169.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.32 0.0 OUTLIER -64.47 151.79 43.37 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 123.225 1.488 . . . . 0.0 113.774 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 60.4 mp0 -88.42 -10.36 49.47 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 111.241 -2.709 . . . . 0.0 114.358 -166.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -143.98 -53.57 0.34 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.411 1.005 . . . . 0.0 112.58 -169.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 80.52 125.18 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 127.446 2.299 . . . . 0.0 114.362 166.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.5 m170 -67.08 148.23 52.15 Favored 'General case' 0 CA--C 1.541 0.608 0 O-C-N 121.018 -1.051 . . . . 0.0 110.856 167.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -72.4 26.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 125.311 1.444 . . . . 0.0 113.781 171.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -154.03 23.45 0.69 Allowed Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.636 1.589 . . . . 0.0 114.864 -169.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -125.54 129.31 49.47 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 119.071 1.435 . . . . 0.0 110.048 -178.533 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 86.6 mt -107.77 41.9 1.44 Allowed 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.042 0.837 . . . . 0.0 110.711 168.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.97 -117.68 5.02 Favored Glycine 0 CA--C 1.537 1.439 0 O-C-N 120.476 -1.39 . . . . 0.0 113.436 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -140.27 146.98 39.29 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.46 1.504 . . . . 0.0 113.394 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.2 m -93.39 145.49 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 127.237 2.215 . . . . 0.0 110.247 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 2.7 m -110.55 125.53 53.45 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 119.466 1.03 . . . . 0.0 109.618 171.011 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.39 163.9 15.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.447 0.699 . . . . 0.0 112.546 169.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.29 178.72 4.97 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.851 1.661 . . . . 0.0 112.713 173.277 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.423 ' H ' ' HD3' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -58.22 -29.49 65.75 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.646 1.978 . . . . 0.0 116.314 171.955 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . 0.415 ' O ' ' HE3' ' B' ' 36' ' ' LYS . 28.9 t70 -78.18 -10.87 59.83 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 119.731 1.15 . . . . 0.0 111.099 171.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.54 11.82 46.5 Favored Glycine 0 C--N 1.334 0.464 0 CA-C-O 116.88 -2.067 . . . . 0.0 113.865 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.0 p -98.4 125.52 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 119.476 1.638 . . . . 0.0 113.357 179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.0 100.35 12.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.43 1.492 . . . . 0.0 108.04 165.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -87.37 143.25 27.34 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.242 1.017 . . . . 0.0 109.506 170.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.45 144.21 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 116.445 2.017 . . . . 0.0 116.445 -176.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.4 m -156.24 111.97 2.99 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.567 1.947 . . . . 0.0 111.161 174.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 13.2 mt -143.54 163.97 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 130.011 3.324 . . . . 0.0 109.571 -169.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.525 ' CD ' ' HZ3' ' B' ' 30' ' ' LYS . 35.2 tt0 -145.3 146.15 31.52 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 126.478 1.911 . . . . 0.0 107.757 168.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -144.69 132.05 20.76 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.935 0.894 . . . . 0.0 110.112 -175.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.8 p -113.54 46.04 1.34 Allowed 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.889 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.11 1.83 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 124.025 0.93 . . . . 0.0 111.687 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.46 171.42 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 126.35 1.86 . . . . 0.0 109.953 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 42.1 m -158.0 174.26 15.51 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 120.837 -1.164 . . . . 0.0 111.222 176.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 93.2 mt -109.54 54.03 0.67 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 127.407 2.283 . . . . 0.0 109.415 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.7 t -112.78 34.97 4.08 Favored 'General case' 0 CA--C 1.551 1.011 0 N-CA-C 115.626 1.714 . . . . 0.0 115.626 -168.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.92 -29.2 3.08 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 119.237 2.455 . . . . 0.0 119.237 165.345 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.251 17.7 t70 -99.41 -109.29 0.19 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 118.522 1.161 . . . . 0.0 108.448 -167.668 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -81.76 10.3 6.45 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.569 2.347 . . . . 0.0 112.703 175.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 m -60.76 -175.39 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.175 2.59 . . . . 0.0 115.081 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.282 11.6 pt -88.63 -3.91 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 119.941 -1.724 . . . . 0.0 114.424 172.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.7 mm -64.84 131.14 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 166.735 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.18 10.52 62.45 Favored Glycine 0 CA--C 1.524 0.653 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.281 -178.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -78.99 170.17 17.1 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 119.918 1.859 . . . . 0.0 109.836 173.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.455 ' HG1' HG23 ' B' ' 148' ' ' VAL . 91.8 m -112.33 112.5 24.12 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.108 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 48.5 tp -92.6 103.95 16.29 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 124.42 1.075 . . . . 0.0 109.459 177.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 13.7 p -86.4 149.53 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 167.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 37.9 t -128.41 143.76 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 167.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -106.0 163.08 13.04 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 125.665 1.586 . . . . 0.0 113.115 -168.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -76.28 -42.34 45.83 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.225 -175.101 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -110.56 176.07 5.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.822 1.649 . . . . 0.0 109.956 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.4 -176.59 6.29 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.252 0.549 . . . . 0.0 109.599 165.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -110.26 159.04 17.75 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.83 2.052 . . . . 0.0 113.032 -166.309 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -73.47 -14.21 61.2 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.904 1.282 . . . . 0.0 111.205 170.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 70.5 mt 54.08 61.45 3.05 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.124 1.77 . . . . 0.0 111.948 172.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.48 -54.15 3.47 Favored Glycine 0 N--CA 1.462 0.431 0 C-N-CA 125.688 1.613 . . . . 0.0 111.474 170.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.4 ttpt -126.9 72.9 1.37 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.676 1.19 . . . . 0.0 113.238 -168.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -83.56 -30.46 29.9 Favored Glycine 0 CA--C 1.534 1.274 0 C-N-CA 124.579 1.085 . . . . 0.0 112.429 169.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 120.8 32.36 1.11 Allowed Glycine 0 N--CA 1.472 1.08 0 C-N-CA 125.167 1.365 . . . . 0.0 113.561 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -153.4 -156.21 0.67 Allowed 'General case' 0 CA--C 1.554 1.121 0 C-N-CA 124.571 1.148 . . . . 0.0 109.644 -169.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -95.9 -52.47 4.05 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 120.765 1.621 . . . . 0.0 110.727 171.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -54.29 -28.53 42.61 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 127.774 2.43 . . . . 0.0 113.176 -172.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 88.9 p -57.56 -30.78 65.51 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 125.016 1.327 . . . . 0.0 112.453 174.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -107.07 -27.48 10.6 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 117.519 -1.229 . . . . 0.0 114.188 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.7 tptm -71.88 -24.14 61.62 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 120.994 1.725 . . . . 0.0 113.056 -176.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -133.54 -46.6 0.82 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 126.287 1.835 . . . . 0.0 110.78 167.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.81 -9.0 8.1 Favored Glycine 0 C--O 1.221 -0.701 0 C-N-CA 125.477 1.513 . . . . 0.0 110.479 -163.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 57.63 37.32 27.4 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 124.992 1.317 . . . . 0.0 112.166 176.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.04 30.06 0.11 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 115.069 1.507 . . . . 0.0 115.069 -169.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.58 -57.27 2.52 Favored Glycine 0 N--CA 1.47 0.962 0 C-N-CA 127.539 2.495 . . . . 0.0 114.44 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.1 t -174.79 172.05 3.04 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.3 1.84 . . . . 0.0 110.479 -174.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . 0.409 ' H ' ' HD3' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -82.67 157.28 23.42 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 121.173 -0.954 . . . . 0.0 111.599 170.631 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -128.84 -97.58 0.38 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 124.546 1.138 . . . . 0.0 108.402 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -95.65 162.26 13.69 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.355 1.062 . . . . 0.0 111.242 174.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 p -158.5 155.9 29.3 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.788 1.235 . . . . 0.0 113.277 173.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.52 176.12 35.5 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 126.176 1.846 . . . . 0.0 112.362 171.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.455 HG23 ' HG1' ' B' ' 116' ' ' THR . 76.7 t -107.3 157.29 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-N 118.247 1.024 . . . . 0.0 108.318 168.45 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 3.3 mt -87.24 110.85 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 123.886 0.874 . . . . 0.0 110.964 176.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -105.54 -165.47 23.56 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.554 1.549 . . . . 0.0 111.686 168.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -136.74 158.65 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 114.358 1.244 . . . . 0.0 114.358 -169.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -142.41 -19.61 0.69 Allowed 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 170.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.48 1.038 0 C-N-CA 125.317 1.447 . . . . 0.0 111.965 176.946 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 CA--C 1.512 -0.517 0 CA-C-O 122.772 1.272 . . . . 0.0 108.158 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.2 mtmm -98.91 132.66 44.07 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 112.616 -2.084 . . . . 0.0 113.924 171.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.62 168.7 13.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.029 0.932 . . . . 0.0 111.989 171.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.41 97.9 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 168.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -94.6 136.95 34.32 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 121.354 -0.842 . . . . 0.0 110.377 173.16 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -134.38 130.48 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 C-N-CA 124.164 0.986 . . . . 0.0 110.44 -176.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -116.31 145.45 43.18 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.589 2.356 . . . . 0.0 110.6 172.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.74 160.17 40.32 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.292 1.037 . . . . 0.0 113.158 168.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.3 161.86 25.0 Favored Glycine 0 CA--C 1.525 0.708 0 C-N-CA 127.246 2.355 . . . . 0.0 107.901 168.187 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -76.62 59.46 1.52 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.298 1.439 . . . . 0.0 113.629 -177.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.58 -163.17 35.79 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 126.732 2.111 . . . . 0.0 110.194 -176.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -77.27 32.52 0.43 Allowed 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 125.041 3.827 . . . . 0.0 112.698 -173.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 t -114.24 124.09 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 C-N-CA 125.525 1.53 . . . . 0.0 108.58 -174.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -141.44 156.7 45.75 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 124.283 1.033 . . . . 0.0 110.284 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.56 139.93 10.87 Favored Glycine 0 CA--C 1.503 -0.695 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.133 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.8 125.76 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 117.354 0.577 . . . . 0.0 109.613 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.1 mm -133.74 122.72 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -111.41 101.18 9.65 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-O 122.537 1.16 . . . . 0.0 109.614 169.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -77.58 138.58 39.23 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.823 1.649 . . . . 0.0 108.574 176.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -110.21 121.65 45.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 119.845 1.202 . . . . 0.0 111.168 166.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.407 ' NE2' ' H ' ' A' ' 27' ' ' GLY . 19.3 tp60 -82.48 128.59 34.42 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 163.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.59 -38.7 62.56 Favored 'General case' 0 CA--C 1.544 0.735 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 179.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -104.19 -129.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 129.653 3.181 . . . . 0.0 111.675 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.9 t -143.51 14.67 1.79 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.824 2.45 . . . . 0.0 110.209 167.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -168.07 -0.17 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 126.014 1.726 . . . . 0.0 115.426 -166.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.407 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -112.28 -151.58 11.49 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 125.849 1.69 . . . . 0.0 112.152 -177.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -71.61 173.26 12.82 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 124.24 3.293 . . . . 0.0 113.616 -175.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -142.9 141.84 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.463 1.105 . . . . 0.0 110.872 -174.171 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.551 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 8.2 tttp -101.7 121.8 42.73 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 167.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.2 t -104.01 114.52 43.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 125.574 1.549 . . . . 0.0 108.581 -177.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.6 p90 -138.55 156.32 47.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 122.308 1.051 . . . . 0.0 113.035 177.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.02 -164.49 27.53 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.465 1.507 . . . . 0.0 111.361 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 88.7 p -158.1 160.22 37.1 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.1 mm -120.14 120.54 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 C-N-CA 124.597 1.159 . . . . 0.0 112.023 176.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.0 mmtt -104.95 152.13 23.06 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.386 1.474 . . . . 0.0 111.684 -174.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.35 -0.35 53.79 Favored Glycine 0 N--CA 1.475 1.288 0 C-N-CA 125.243 1.402 . . . . 0.0 114.435 174.098 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -83.85 173.5 11.19 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 126.467 1.907 . . . . 0.0 112.612 178.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.3 t -81.8 175.59 10.3 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 160.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.53 -175.8 0.14 Allowed 'General case' 0 CA--C 1.557 1.249 0 CA-C-O 122.44 1.114 . . . . 0.0 113.497 175.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.32 -179.69 45.44 Favored Glycine 0 CA--C 1.533 1.202 0 O-C-N 120.478 -1.389 . . . . 0.0 114.478 173.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.8 mp -61.96 142.37 57.49 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 127.46 2.304 . . . . 0.0 111.359 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -143.53 117.8 9.59 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 126.864 2.066 . . . . 0.0 109.442 176.042 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.14 141.87 47.71 Favored Glycine 0 N--CA 1.478 1.491 0 CA-C-N 120.038 1.29 . . . . 0.0 111.484 -179.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.277 0.1 OUTLIER -150.95 130.52 13.03 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 118.966 1.383 . . . . 0.0 111.839 174.403 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.87 143.65 26.4 Favored 'General case' 0 CA--C 1.535 0.366 0 O-C-N 121.278 -0.889 . . . . 0.0 111.917 -164.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -98.0 105.81 17.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.874 1.669 . . . . 0.0 108.5 -178.549 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -74.45 144.86 44.05 Favored 'General case' 0 C--N 1.322 -0.617 0 O-C-N 121.548 -0.72 . . . . 0.0 109.325 175.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -46.89 132.56 11.52 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 167.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.492 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 77.35 146.02 0.09 Allowed 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 124.729 2.204 . . . . 0.0 114.14 174.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.436 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -120.14 6.69 11.93 Favored Glycine 0 N--CA 1.466 0.69 0 C-N-CA 126.714 2.102 . . . . 0.0 111.788 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -76.89 42.89 0.32 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.648 1.579 . . . . 0.0 109.658 168.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.436 ' H ' ' C ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER 168.95 42.45 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 125.314 1.446 . . . . 0.0 113.638 -164.567 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -63.38 -4.69 2.84 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 116.23 1.937 . . . . 0.0 116.23 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.85 30.26 1.62 Allowed 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 120.381 1.446 . . . . 0.0 112.527 -171.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.37 -139.75 45.94 Favored Glycine 0 N--CA 1.466 0.642 0 O-C-N 120.828 -1.17 . . . . 0.0 111.509 171.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.6 p -52.57 -31.77 37.71 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 176.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.2 t -87.16 43.43 1.1 Allowed 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.415 1.462 . . . . 0.0 112.225 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.5 p -179.87 -32.64 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 127.411 2.285 . . . . 0.0 113.755 172.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -143.46 139.5 29.92 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 120.151 1.341 . . . . 0.0 113.62 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.35 -115.61 0.93 Allowed Glycine 0 CA--C 1.544 1.864 0 CA-C-O 117.952 -1.471 . . . . 0.0 113.559 -175.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.12 -179.69 5.48 Favored 'Trans proline' 0 C--N 1.348 0.532 1 C-N-CA 125.634 4.223 . . . . 0.0 112.689 -178.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -81.57 71.73 8.59 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.429 1.092 . . . . 0.0 109.97 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -43.71 140.52 1.82 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.519 1.528 . . . . 0.0 111.469 170.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -158.18 155.11 25.4 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 117.774 -1.108 . . . . 0.0 112.668 170.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -73.04 -10.94 25.08 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.082 1.855 . . . . 0.0 114.341 -172.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -87.68 -10.14 52.14 Favored 'General case' 0 CA--C 1.542 0.658 0 CA-C-N 119.834 1.197 . . . . 0.0 113.464 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.2 t 49.55 49.46 19.89 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.804 1.641 . . . . 0.0 114.166 175.272 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.1 mtm-85 -99.03 176.45 5.57 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 126.071 1.749 . . . . 0.0 113.435 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -76.89 168.38 20.19 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 126.59 1.956 . . . . 0.0 109.428 165.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -84.05 159.71 21.11 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 124.001 0.921 . . . . 0.0 113.386 -173.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.15 -134.67 5.84 Favored Glycine 0 C--N 1.341 0.816 0 N-CA-C 114.697 0.639 . . . . 0.0 114.697 167.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 124.33 -92.02 0.43 Allowed Glycine 0 CA--C 1.541 1.689 0 CA-C-O 118.59 -1.117 . . . . 0.0 113.94 -169.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.88 6.63 0.15 Allowed 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 123.8 3.0 . . . . 0.0 117.453 -175.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.257 0.0 OUTLIER -155.93 7.39 0.22 Allowed 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 127.344 2.258 . . . . 0.0 113.379 169.443 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.21 167.79 18.58 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.775 2.43 . . . . 0.0 110.153 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -111.19 -15.51 13.64 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.498 1.919 . . . . 0.0 112.542 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -78.22 -69.49 0.55 Allowed 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.241 1.016 . . . . 0.0 111.014 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 59.25 109.49 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.701 1.6 . . . . 0.0 112.31 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 27.1 m170 -59.03 148.37 31.11 Favored 'General case' 0 CA--C 1.544 0.717 0 O-C-N 119.205 -2.184 . . . . 0.0 110.348 167.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.5 t -79.22 54.33 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-O 123.769 1.747 . . . . 0.0 109.099 166.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.09 20.05 0.09 OUTLIER Glycine 0 CA--C 1.542 1.752 0 C-N-CA 128.87 3.129 . . . . 0.0 114.306 -179.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -122.29 130.13 52.86 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.006 2.403 . . . . 0.0 113.854 -175.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 74.4 mt -113.52 45.47 1.42 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.491 0.716 . . . . 0.0 110.78 168.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.45 -124.85 6.89 Favored Glycine 0 CA--C 1.534 1.269 0 O-C-N 121.41 -0.806 . . . . 0.0 113.17 -176.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -129.19 144.07 51.08 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.067 0.947 . . . . 0.0 111.545 173.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -95.27 130.92 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 C-N-CA 125.602 1.561 . . . . 0.0 108.988 173.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.0 m -113.23 138.14 50.43 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 123.683 0.793 . . . . 0.0 112.175 -167.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.61 145.11 40.96 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 118.354 2.724 . . . . 0.0 118.354 -166.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -86.35 157.01 19.98 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 128.958 2.903 . . . . 0.0 111.314 169.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HZ2' ' CG ' ' A' ' 92' ' ' ASP . 1.6 pptp? -47.42 -23.29 0.57 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 128.215 2.606 . . . . 0.0 117.155 176.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.449 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 74.2 m-20 -76.45 3.65 10.76 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 119.844 1.202 . . . . 0.0 111.579 175.301 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.66 37.53 52.03 Favored Glycine 0 C--N 1.337 0.6 0 C-N-CA 125.23 1.395 . . . . 0.0 111.843 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -124.27 122.48 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.409 1.084 . . . . 0.0 110.621 176.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -84.3 118.11 23.99 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.427 1.491 . . . . 0.0 109.311 169.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.08 145.14 25.19 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.951 0.9 . . . . 0.0 112.079 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.82 138.17 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-N 114.001 -1.454 . . . . 0.0 114.823 169.423 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 m -155.27 62.27 0.63 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 127.058 2.143 . . . . 0.0 110.002 179.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.1 mt -95.58 154.56 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.346 1.858 . . . . 0.0 111.386 -176.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.551 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 6.1 tt0 -133.35 143.25 48.86 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 125.437 1.495 . . . . 0.0 108.461 168.706 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -156.25 149.66 24.59 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.487 1.115 . . . . 0.0 112.572 -169.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.1 p -119.26 53.55 1.02 Allowed 'General case' 0 CA--C 1.542 0.65 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.639 178.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.0 t -138.84 -42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.154 0.982 . . . . 0.0 111.686 174.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -85.88 156.07 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 119.301 0.955 . . . . 0.0 112.099 174.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -151.45 147.49 26.92 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 124.409 1.084 . . . . 0.0 111.052 177.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.3 mp -78.39 57.21 1.88 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 120.836 -1.165 . . . . 0.0 109.308 177.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.6 m -130.31 15.96 5.55 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.887 1.275 . . . . 0.0 113.749 -168.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.7 -170.17 28.45 Favored Glycine 0 N--CA 1.44 -1.042 0 CA-C-O 124.853 2.363 . . . . 0.0 116.28 167.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.29 -51.74 64.85 Favored 'General case' 0 C--N 1.311 -1.083 1 CA-C-N 108.143 -4.029 . . . . 0.0 111.239 -168.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -79.76 4.14 17.25 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.419 1.087 . . . . 0.0 112.977 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.7 t -108.62 -93.29 0.41 Allowed 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.13 0.972 . . . . 0.0 111.476 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.9 pt -141.66 5.76 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 40.3 mm -84.13 119.5 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.404 -1.435 . . . . 0.0 107.733 171.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.97 30.54 72.25 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 117.915 -1.492 . . . . 0.0 113.664 -178.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.9 mmt-85 -86.88 145.85 26.42 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 120.527 2.163 . . . . 0.0 111.268 173.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 39.1 m -89.95 104.91 17.43 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 119.539 1.063 . . . . 0.0 111.499 177.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 15.5 tp -85.64 112.49 21.04 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.626 0.771 . . . . 0.0 110.642 173.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 9.9 p -92.46 148.18 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 118.953 -0.546 . . . . 0.0 109.714 169.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.48 134.08 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 122.262 1.029 . . . . 0.0 109.346 166.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.644 ' CE1' ' HE ' ' A' ' 143' ' ' ARG . 18.5 m-70 -109.84 152.57 25.58 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 126.111 1.764 . . . . 0.0 111.617 -169.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.548 ' CD ' ' HZ3' ' A' ' 122' ' ' LYS . 5.3 tm-20 -79.48 -17.47 54.09 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 116.768 2.136 . . . . 0.0 116.768 -164.454 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.548 ' HZ3' ' CD ' ' A' ' 121' ' ' GLU . 0.0 OUTLIER -125.27 173.38 8.84 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 120.079 -1.638 . . . . 0.0 113.432 173.004 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.87 157.52 1.21 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.323 1.849 . . . . 0.0 112.439 172.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -97.79 131.35 44.38 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.974 0.892 . . . . 0.0 111.073 -176.273 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -26.6 62.38 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.53 1.932 . . . . 0.0 112.788 177.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.1 mt 54.09 53.63 10.81 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.917 1.687 . . . . 0.0 113.028 171.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.23 -25.37 27.33 Favored Glycine 0 N--CA 1.468 0.803 0 CA-C-O 118.218 -1.324 . . . . 0.0 114.99 170.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.354 6.4 mtmt -167.24 121.29 1.0 Allowed 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 164.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -143.53 -56.27 0.03 OUTLIER Glycine 0 CA--C 1.532 1.104 1 C-N-CA 131.177 4.227 . . . . 0.0 108.16 167.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -85.42 -93.18 0.8 Allowed Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.904 1.716 . . . . 0.0 114.032 177.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.583 ' CG ' ' H ' ' A' ' 132' ' ' GLU 0.27 0.8 OUTLIER -147.3 -96.69 0.09 Allowed 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 117.076 -1.44 . . . . 0.0 112.703 -169.3 . . . . . . . . 4 4 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.583 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 11.0 tt0 -111.97 -30.56 7.22 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 121.565 1.984 . . . . 0.0 114.396 170.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -61.36 -21.6 64.17 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.468 -2.02 . . . . 0.0 112.216 177.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.2 p -56.6 -25.55 53.14 Favored 'General case' 0 CA--C 1.54 0.583 1 C-N-CA 131.946 4.098 . . . . 0.0 113.376 164.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 p -116.23 -29.25 6.3 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 128.732 2.813 . . . . 0.0 112.974 -175.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 42.1 mttt -70.57 -56.71 5.88 Favored 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 169.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.7 p -99.08 -125.85 0.16 Allowed 'General case' 0 C--O 1.221 -0.42 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 167.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.14 28.88 1.53 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 129.006 3.193 . . . . 0.0 110.074 173.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 52.58 7.81 0.07 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 127.015 2.126 . . . . 0.0 115.168 -177.058 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.1 20.81 0.02 OUTLIER 'General case' 0 CA--C 1.56 1.358 0 C-N-CA 127.309 2.244 . . . . 0.0 116.681 -165.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.44 -144.83 34.91 Favored Glycine 0 CA--C 1.532 1.136 0 O-C-N 119.794 -1.816 . . . . 0.0 114.079 175.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.1 t -67.19 179.8 1.13 Allowed 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.392 1.077 . . . . 0.0 113.904 -174.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.644 ' HE ' ' CE1' ' A' ' 120' ' ' HIS . 95.4 mtt180 -124.7 114.53 19.43 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.911 1.684 . . . . 0.0 109.789 177.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -102.7 -24.76 13.72 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 125.772 1.629 . . . . 0.0 114.706 -171.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.78 158.81 35.96 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 124.497 1.119 . . . . 0.0 110.332 170.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.0 p -149.79 142.25 24.35 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.171 1.388 . . . . 0.0 109.503 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.57 175.77 34.84 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 115.388 0.915 . . . . 0.0 115.388 -170.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -133.1 152.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.018 1.327 . . . . 0.0 111.554 174.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 16.9 mt -83.82 115.51 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 127.646 2.378 . . . . 0.0 112.664 177.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.59 169.5 14.17 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 126.964 2.221 . . . . 0.0 114.532 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -104.95 88.52 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 117.489 2.403 . . . . 0.0 117.489 -168.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.34 -25.49 51.13 Favored 'General case' 0 N--CA 1.477 0.902 0 O-C-N 120.07 -1.644 . . . . 0.0 113.08 173.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 . . . . . 0 C--O 1.236 0.363 0 C-N-CA 126.931 2.092 . . . . 0.0 110.459 176.377 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.304 0 CA-C-O 121.283 0.563 . . . . 0.0 111.894 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.8 t -157.35 125.5 5.52 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 126.846 2.058 . . . . 0.0 107.683 167.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.51 143.29 32.41 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-O 122.686 1.231 . . . . 0.0 113.651 174.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 169.64 17.35 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.366 1.866 . . . . 0.0 110.128 175.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -153.36 150.14 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 119.88 1.218 . . . . 0.0 111.892 -169.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.34 117.54 18.27 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 127.336 2.254 . . . . 0.0 109.126 169.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 8.4 m -101.93 116.89 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.363 1.465 . . . . 0.0 108.546 168.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.51 123.59 43.91 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.957 1.303 . . . . 0.0 113.323 -168.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . 0.401 ' HG2' ' H ' ' B' ' 10' ' ' GLY 0.26 0.2 OUTLIER -160.44 171.07 19.71 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 117.741 2.497 . . . . 0.0 117.741 165.366 . . . . . . . . 4 4 . 1 . 019 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . 0.401 ' H ' ' HG2' ' B' ' 9' ' ' LYS . . . 132.97 36.64 0.27 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 129.606 3.479 . . . . 0.0 108.728 -174.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -159.23 55.29 0.4 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.045 1.338 . . . . 0.0 111.056 -167.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.85 -99.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 C-N-CA 127.266 2.365 . . . . 0.0 115.467 173.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -79.09 -14.33 13.52 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 123.949 3.099 . . . . 0.0 114.21 -176.179 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -98.86 141.37 16.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 120.398 1.454 . . . . 0.0 109.677 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 pm0 -150.81 163.77 37.83 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.892 2.077 . . . . 0.0 107.237 169.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.94 134.06 4.93 Favored Glycine 0 CA--C 1.5 -0.904 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.379 175.072 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -97.03 130.1 46.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -133.64 116.29 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 C-N-CA 125.18 1.392 . . . . 0.0 109.045 168.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 65.7 m-20 -100.0 146.4 26.77 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.422 1.089 . . . . 0.0 110.855 171.146 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -121.73 135.51 54.94 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 126.852 2.061 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.433 ' CD ' ' HZ1' ' B' ' 30' ' ' LYS . 4.5 tt0 -128.37 122.0 30.43 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.695 1.198 . . . . 0.0 110.762 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.8 tt0 -109.4 140.34 43.23 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 168.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -103.5 6.2 37.32 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -174.416 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 37.1 mp0 -152.5 -178.45 6.85 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 129.341 3.056 . . . . 0.0 108.102 170.001 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.6 p -82.15 -25.35 34.42 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.675 -1.266 . . . . 0.0 112.784 168.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -132.31 19.4 4.4 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 125.343 1.457 . . . . 0.0 113.179 -177.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.1 -168.88 42.05 Favored Glycine 0 CA--C 1.541 1.713 0 C-N-CA 125.482 1.515 . . . . 0.0 113.688 172.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.3 169.0 14.53 Favored 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 124.096 3.198 . . . . 0.0 112.376 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 71.3 t -128.56 138.42 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.171 1.388 . . . . 0.0 111.387 -177.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.433 ' HZ1' ' CD ' ' B' ' 21' ' ' GLU . 74.7 mttt -93.01 123.82 36.54 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 165.715 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.45 126.79 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.163 0.985 . . . . 0.0 110.8 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.8 p90 -146.74 164.32 33.13 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.959 0.885 . . . . 0.0 112.63 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.44 -153.58 25.42 Favored Glycine 0 C--N 1.334 0.452 0 C-N-CA 123.778 0.704 . . . . 0.0 112.47 176.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 60.6 p -153.16 119.52 5.54 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -168.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 mp -99.93 114.15 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 CA-C-O 118.265 -0.874 . . . . 0.0 109.941 173.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -122.18 133.84 54.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.929 1.241 . . . . 0.0 111.941 -175.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 132.05 -3.78 5.26 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 127.357 2.408 . . . . 0.0 114.271 176.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.9 178.58 4.52 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 126.565 1.946 . . . . 0.0 112.22 -171.766 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -70.16 156.4 39.27 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.647 1.579 . . . . 0.0 110.227 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.06 156.28 28.67 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 168.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.35 -170.48 35.68 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.426 1.012 . . . . 0.0 113.285 178.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.626 ' H ' ' CD2' ' B' ' 42' ' ' LEU . 0.4 OUTLIER -65.19 152.57 43.3 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.415 1.886 . . . . 0.0 113.594 -174.095 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -149.18 125.58 10.9 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 127.781 2.433 . . . . 0.0 109.457 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.17 147.43 21.91 Favored Glycine 0 N--CA 1.481 1.646 0 CA-C-N 120.502 1.501 . . . . 0.0 111.551 173.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -154.19 87.88 1.21 Allowed 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.064 1.745 . . . . 0.0 109.321 -167.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -127.16 153.7 45.72 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 121.229 -0.919 . . . . 0.0 112.474 -166.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.1 97.99 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.069 0.85 . . . . 0.0 110.902 -175.288 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -79.47 134.92 36.54 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.195 -170.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -72.34 174.34 7.45 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.354 1.862 . . . . 0.0 113.028 -167.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 63.12 4.73 1.66 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.934 1.694 . . . . 0.0 114.974 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.71 16.22 3.72 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 120.267 -1.52 . . . . 0.0 113.584 -163.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . 0.582 ' C ' HD21 ' B' ' 53' ' ' ASN . 5.9 t0 -89.45 115.4 26.86 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 125.824 1.649 . . . . 0.0 110.322 -168.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.582 HD21 ' C ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -165.14 34.98 0.06 Allowed 'General case' 0 C--O 1.239 0.514 0 CA-C-O 124.149 1.928 . . . . 0.0 116.177 -178.912 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.27 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.582 0 CA-C-N 114.261 -1.336 . . . . 0.0 112.959 -166.313 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.796 0 N-CA-C 118.111 2.634 . . . . 0.0 118.111 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -41.19 -46.41 4.23 Favored Glycine 0 CA--C 1.537 1.466 0 CA-C-O 116.459 -2.3 . . . . 0.0 115.497 -169.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -126.35 46.16 0.0 OUTLIER 'Trans proline' 0 C--N 1.356 0.925 0 CA-C-N 120.983 2.392 . . . . 0.0 115.52 -176.277 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.1 m170 78.6 78.34 0.06 Allowed 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.663 1.585 . . . . 0.0 112.916 167.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -48.06 138.75 8.88 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 161.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . 0.623 ' ND2' ' H ' ' B' ' 81' ' ' VAL . 9.3 t-20 -157.18 116.66 2.0 Favored Pre-proline 0 N--CA 1.472 0.67 0 N-CA-C 116.746 2.128 . . . . 0.0 116.746 171.019 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.57 -5.58 15.6 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 N-CA-C 116.65 1.75 . . . . 0.0 116.65 -179.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -91.25 -7.51 51.0 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 119.526 1.057 . . . . 0.0 112.387 173.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t 54.66 54.26 9.46 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 125.571 1.548 . . . . 0.0 114.82 170.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.72 176.59 5.45 Favored 'General case' 0 N--CA 1.477 0.924 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -171.053 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.4 ptpp? -79.14 155.55 28.65 Favored 'General case' 0 CA--C 1.545 0.756 0 O-C-N 121.218 -0.926 . . . . 0.0 112.34 176.147 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -79.31 152.67 30.36 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.149 0.98 . . . . 0.0 113.187 -177.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.36 -117.43 1.04 Allowed Glycine 0 C--N 1.339 0.746 0 C-N-CA 123.195 0.426 . . . . 0.0 113.986 167.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.67 -28.17 6.87 Favored Glycine 0 CA--C 1.542 1.741 0 N-CA-C 120.12 2.808 . . . . 0.0 120.12 168.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -93.02 -13.83 1.24 Allowed 'Trans proline' 0 CA--C 1.544 1.025 0 CA-C-N 123.203 3.502 . . . . 0.0 112.879 173.067 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.16 -1.39 0.65 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.576 1.55 . . . . 0.0 112.792 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.44 177.19 5.77 Favored 'General case' 0 CA--C 1.548 0.898 0 O-C-N 120.735 -1.228 . . . . 0.0 110.508 174.706 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -90.01 -23.63 21.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 129.324 3.05 . . . . 0.0 111.579 -172.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -129.63 -98.09 0.35 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.243 1.017 . . . . 0.0 112.881 -171.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 96.36 137.6 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 129.778 3.231 . . . . 0.0 110.577 -170.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -57.21 162.06 2.87 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.267 -1.521 . . . . 0.0 112.072 168.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . 0.623 ' H ' ' ND2' ' B' ' 65' ' ' ASN . 53.1 t -61.35 -37.6 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-N 120.403 1.456 . . . . 0.0 110.577 170.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.59 24.03 4.57 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.212 1.387 . . . . 0.0 115.933 170.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -109.39 127.72 54.58 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 116.523 2.046 . . . . 0.0 116.523 174.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.4 mt -115.31 169.26 9.27 Favored 'General case' 0 CA--C 1.56 1.35 0 N-CA-C 103.633 -2.728 . . . . 0.0 103.633 156.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.48 -126.22 1.95 Allowed Glycine 0 N--CA 1.48 1.605 0 C-N-CA 124.482 1.039 . . . . 0.0 114.265 -171.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -126.54 154.07 44.34 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.8 m -111.26 129.71 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.927 2.091 . . . . 0.0 110.568 -176.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -89.41 132.08 35.16 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.271 0.487 . . . . 0.0 110.181 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.58 162.11 13.45 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 124.849 1.26 . . . . 0.0 111.451 168.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.3 -174.77 3.16 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.085 1.354 . . . . 0.0 111.736 169.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.65 -10.02 47.43 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.73 -15.31 61.22 Favored 'General case' 0 CA--C 1.554 1.122 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 162.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.72 30.24 6.93 Favored Glycine 0 C--N 1.34 0.768 0 C-N-CA 127.272 2.368 . . . . 0.0 112.736 168.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -116.14 128.92 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 CA-C-N 119.854 1.827 . . . . 0.0 113.543 178.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 80.52 3.73 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 125.236 1.414 . . . . 0.0 110.215 167.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -77.85 123.7 27.07 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.682 1.593 . . . . 0.0 108.808 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.9 t -147.37 150.51 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -168.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 71.3 m -140.18 128.42 22.47 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 127.419 2.288 . . . . 0.0 108.367 166.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 34.7 mt -136.78 124.83 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 127.771 2.429 . . . . 0.0 108.928 -179.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 mp0 -117.4 115.69 25.72 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 126.307 1.843 . . . . 0.0 107.866 -175.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -140.46 144.32 36.01 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.933 0.873 . . . . 0.0 113.32 -168.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.2 p -110.89 51.1 0.78 Allowed 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 13.9 p -152.06 -38.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 167.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.288 0.1 OUTLIER -79.77 94.15 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 120.677 1.58 . . . . 0.0 110.888 172.549 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 38.4 p -102.14 153.21 20.15 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.148 1.779 . . . . 0.0 113.378 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.34 54.73 1.45 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.379 1.472 . . . . 0.0 110.851 -177.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.1 m -94.85 39.58 1.1 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 126.189 1.796 . . . . 0.0 112.128 -170.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 73.95 -39.46 0.97 Allowed Glycine 0 N--CA 1.475 1.271 0 C-N-CA 127.396 2.426 . . . . 0.0 115.83 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -161.65 -34.95 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.133 1.773 . . . . 0.0 111.962 -168.037 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 63.9 m-70 -75.85 -19.44 58.89 Favored 'General case' 0 C--O 1.226 -0.17 0 O-C-N 120.438 -1.413 . . . . 0.0 112.463 -167.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -142.62 -71.37 0.32 Allowed 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 122.793 0.437 . . . . 0.0 111.57 -172.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.25 2.3 pt -137.16 166.45 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 C-N-CA 125.252 1.421 . . . . 0.0 107.941 166.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.2 mm 86.72 144.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 131.308 3.843 . . . . 0.0 107.139 -163.06 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.43 3.45 25.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.133 0.873 . . . . 0.0 114.746 177.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 31.2 mtt180 -108.45 -172.45 2.06 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 128.785 2.834 . . . . 0.0 108.574 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 12.0 t -124.05 161.94 24.51 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 120.559 1.527 . . . . 0.0 109.423 166.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 tt -118.61 130.71 56.03 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 164.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 40.7 t -113.19 128.05 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 C-N-CA 125.098 1.359 . . . . 0.0 108.038 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -92.53 156.89 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 166.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.62 127.51 35.09 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.266 1.426 . . . . 0.0 108.752 -175.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -58.93 -14.52 9.38 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 118.122 2.638 . . . . 0.0 118.122 -166.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.8 mttp -137.45 177.33 7.95 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 124.042 3.11 . . . . 0.0 115.255 175.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.92 129.87 31.68 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 125.749 1.62 . . . . 0.0 110.888 -177.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -99.81 136.88 39.06 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 124.071 0.857 . . . . 0.0 110.327 171.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -81.49 -6.3 58.82 Favored 'General case' 0 CA--C 1.551 0.991 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 32.8 mt 60.69 67.89 0.79 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.314 1.846 . . . . 0.0 111.645 169.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.5 20.09 28.09 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 117.037 1.575 . . . . 0.0 117.037 168.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . 0.503 ' C ' ' H ' ' B' ' 130' ' ' GLY . 7.4 mtmp? -146.88 -57.86 0.27 Allowed 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 120.092 3.367 . . . . 0.0 120.092 -165.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -78.82 37.72 1.91 Allowed Glycine 0 N--CA 1.475 1.299 0 C-N-CA 128.64 3.019 . . . . 0.0 110.618 -169.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . 0.503 ' H ' ' C ' ' B' ' 128' ' ' LYS . . . 173.82 84.0 0.06 OUTLIER Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 -168.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -40.01 -24.96 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.935 0 C-N-CA 130.632 3.573 . . . . 0.0 114.827 167.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -116.98 -78.49 0.58 Allowed 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 127.177 2.191 . . . . 0.0 107.517 167.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -63.97 -36.47 84.09 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.066 1.135 . . . . 0.0 114.066 -166.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.8 t -71.31 -27.75 63.62 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 119.583 -1.948 . . . . 0.0 112.605 -177.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.316 8.9 t -83.41 -5.82 59.27 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 118.56 -0.733 . . . . 0.0 111.728 170.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -105.16 -68.2 0.87 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 124.882 1.273 . . . . 0.0 113.702 173.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.6 p -88.17 -32.28 18.7 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 125.347 1.459 . . . . 0.0 113.435 178.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 116.65 -23.92 9.95 Favored Glycine 0 N--CA 1.472 1.078 0 C-N-CA 125.32 1.438 . . . . 0.0 112.448 -168.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 10.2 t30 69.43 48.06 0.65 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 127.719 2.408 . . . . 0.0 110.014 178.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.87 31.3 0.06 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 127.402 2.281 . . . . 0.0 114.672 -169.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.49 -33.95 0.12 Allowed Glycine 0 CA--C 1.535 1.337 0 C-N-CA 128.614 3.007 . . . . 0.0 115.265 -172.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.7 t -160.16 -152.21 0.28 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.794 1.238 . . . . 0.0 112.398 178.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.52 -170.66 2.27 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 129.508 3.123 . . . . 0.0 107.706 174.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -174.41 -168.7 0.4 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.467 1.907 . . . . 0.0 107.372 -169.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.68 153.95 1.53 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.67 2.788 . . . . 0.0 113.45 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -144.9 160.92 40.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.187 1.795 . . . . 0.0 112.821 -178.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.56 131.25 3.21 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 124.555 1.074 . . . . 0.0 111.98 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 128.18 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -176.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 35.4 mt -84.95 112.85 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.591 1.956 . . . . 0.0 111.228 -168.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.52 -144.44 10.96 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.416 -0.673 . . . . 0.0 111.416 168.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.17 163.61 26.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 124.507 1.123 . . . . 0.0 112.714 -168.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.492 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.35 -34.14 0.3 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 129.174 2.989 . . . . 0.0 109.789 166.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.469 0.491 0 C-N-CA 126.387 1.875 . . . . 0.0 111.813 167.368 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.5 p . . . . . 0 C--O 1.221 -0.435 0 N-CA-C 115.684 1.735 . . . . 0.0 115.684 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 mttp -161.94 87.46 0.65 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.003 1.721 . . . . 0.0 110.685 166.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.98 152.35 28.02 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 123.83 0.852 . . . . 0.0 109.227 167.073 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -160.04 147.58 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.856 0.862 . . . . 0.0 111.85 -168.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.69 139.21 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 165.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 88.9 t -98.29 88.9 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.72 123.74 30.15 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 127.049 2.14 . . . . 0.0 108.914 -170.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -135.62 144.15 45.95 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 122.38 1.086 . . . . 0.0 113.676 -170.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -109.08 160.94 13.3 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 107.36 -2.296 . . . . 0.0 107.36 166.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.08 58.16 1.5 Allowed 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 127.001 2.121 . . . . 0.0 111.935 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.4 -160.92 34.72 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.965 2.221 . . . . 0.0 110.565 -172.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.85 41.73 1.17 Allowed 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 125.152 3.901 . . . . 0.0 112.104 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.14 111.94 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 127.086 2.154 . . . . 0.0 108.726 -169.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -159.69 168.7 25.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.448 179.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.18 137.43 5.39 Favored Glycine 0 CA--C 1.506 -0.495 0 CA-C-N 115.659 -0.701 . . . . 0.0 112.065 168.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.0 134.04 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 166.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 pp -130.98 129.87 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.539 1.136 . . . . 0.0 109.231 165.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -103.2 153.75 20.04 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.537 1.935 . . . . 0.0 112.392 168.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -138.13 111.12 7.77 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 126.436 1.894 . . . . 0.0 109.123 169.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -96.33 84.78 3.8 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.315 -1.491 . . . . 0.0 112.54 176.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -105.84 147.51 28.6 Favored 'General case' 0 C--O 1.222 -0.361 0 O-C-N 121.111 -0.993 . . . . 0.0 110.733 174.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.41 -15.14 9.11 Favored 'General case' 0 CA--C 1.551 1.005 0 C-N-CA 128.432 2.693 . . . . 0.0 112.49 -179.005 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.438 ' CD ' ' H ' ' A' ' 25' ' ' SER . 2.6 tm-20 -126.54 171.71 10.85 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 127.121 2.169 . . . . 0.0 110.594 -171.49 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.438 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 75.1 m -95.57 -26.5 15.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -177.304 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -126.58 -18.99 4.67 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 120.717 1.599 . . . . 0.0 114.904 -174.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.85 173.52 47.63 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.641 1.115 . . . . 0.0 112.973 176.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -80.95 171.04 14.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.847 3.031 . . . . 0.0 112.773 -176.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 t -140.48 136.1 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.34 1.456 . . . . 0.0 111.256 -170.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.45 ' HZ3' ' CD ' ' A' ' 100' ' ' GLU . 6.9 tmtm? -80.77 128.89 34.16 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 168.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 38.1 t -121.91 143.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.669 1.987 . . . . 0.0 108.664 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.5 p90 -156.59 161.55 39.93 Favored 'General case' 0 C--N 1.326 -0.426 0 O-C-N 121.06 -1.025 . . . . 0.0 111.292 173.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.68 151.4 9.83 Favored Glycine 0 N--CA 1.452 -0.281 0 N-CA-C 114.879 0.711 . . . . 0.0 114.879 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -109.7 108.53 18.95 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.081 -0.56 . . . . 0.0 110.182 170.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -85.21 141.38 14.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 126.273 1.829 . . . . 0.0 107.789 167.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -149.38 132.4 16.23 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.216 1.806 . . . . 0.0 109.133 -178.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 -19.26 37.18 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 126.084 1.802 . . . . 0.0 114.179 -171.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mp -62.96 130.94 46.97 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 119.55 1.675 . . . . 0.0 111.956 169.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -67.5 152.84 44.97 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.634 1.974 . . . . 0.0 109.268 168.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -53.61 153.6 4.23 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.7 1.6 . . . . 0.0 115.111 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.99 -176.63 40.93 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.723 1.154 . . . . 0.0 112.668 -177.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mt -63.76 153.83 35.18 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.521 1.528 . . . . 0.0 112.18 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -151.57 132.98 14.63 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 127.995 2.518 . . . . 0.0 108.701 169.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.91 142.77 46.86 Favored Glycine 0 N--CA 1.475 1.239 0 CA-C-O 118.905 -0.941 . . . . 0.0 112.263 178.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -132.93 102.83 5.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.939 1.696 . . . . 0.0 108.214 -175.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -139.65 136.92 34.8 Favored 'General case' 0 CA--C 1.537 0.464 0 O-C-N 120.736 -1.228 . . . . 0.0 110.946 -167.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -93.89 124.58 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 14.6 m-70 -72.06 -177.86 2.2 Favored 'General case' 0 CA--C 1.55 0.966 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 169.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -64.89 167.24 7.91 Favored 'General case' 0 CA--C 1.549 0.923 0 O-C-N 119.97 -1.706 . . . . 0.0 111.767 169.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -90.36 -144.53 0.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -173.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.62 -147.36 26.65 Favored Glycine 0 N--CA 1.428 -1.835 0 CA-C-O 124.97 2.428 . . . . 0.0 111.441 169.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.5 p-10 -88.0 54.03 2.95 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 109.453 -3.374 . . . . 0.0 109.674 -168.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.369 4.1 p30 -75.19 18.57 0.19 Allowed 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 121.221 3.785 . . . . 0.0 121.221 -157.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.402 ' CG2' ' HA ' ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -76.3 -23.37 54.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 117.588 2.44 . . . . 0.0 117.588 -162.704 . . . . . . . . 4 4 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.71 -4.07 29.0 Favored 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 169.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.51 -111.31 4.02 Favored Glycine 0 C--N 1.342 0.881 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 31.0 p -47.84 -28.69 2.73 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.42 -19.48 29.59 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.727 1.211 . . . . 0.0 113.755 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 49.6 m -119.85 -43.73 2.55 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.208 0.913 . . . . 0.0 113.273 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.5 80.76 3.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.418 1.087 . . . . 0.0 111.289 -170.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.42 123.33 9.83 Favored Glycine 0 CA--C 1.536 1.389 0 C-N-CA 125.001 1.286 . . . . 0.0 112.245 -177.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -63.34 119.84 7.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.142 2.561 . . . . 0.0 109.372 -174.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 34.27 66.93 0.24 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.155 1.782 . . . . 0.0 115.057 178.034 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -14.63 113.93 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 129.217 3.007 . . . . 0.0 114.505 174.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -114.53 38.6 0.22 Allowed Pre-proline 0 CA--C 1.555 1.138 0 C-N-CA 126.716 2.006 . . . . 0.0 115.448 -168.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -67.99 -14.6 41.57 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 122.668 2.246 . . . . 0.0 112.799 -177.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 64.3 mt -76.72 -6.73 53.39 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.169 1.388 . . . . 0.0 112.791 172.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.3 t 70.93 53.63 0.26 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 127.101 2.16 . . . . 0.0 113.009 174.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 20.6 mtm-85 -131.72 174.41 10.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -171.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mmtt -97.11 177.66 5.51 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 128.62 2.768 . . . . 0.0 110.193 166.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -81.62 154.13 26.31 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.807 1.41 . . . . 0.0 114.807 -169.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 158.38 -169.92 34.98 Favored Glycine 0 C--N 1.335 0.489 0 CA-C-N 115.277 -0.874 . . . . 0.0 113.93 166.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 173.13 -85.24 0.08 OUTLIER Glycine 0 CA--C 1.544 1.889 0 CA-C-O 117.9 -1.5 . . . . 0.0 114.192 168.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.05 19.04 0.16 Allowed 'Trans proline' 0 CA--C 1.553 1.459 1 C-N-CA 125.637 4.225 . . . . 0.0 116.635 -172.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.81 5.23 0.13 Allowed 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 128.144 2.578 . . . . 0.0 111.731 177.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.401 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 5.9 t70 -126.09 175.63 7.61 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 128.938 2.895 . . . . 0.0 112.922 -164.54 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 -129.88 -15.43 3.86 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 129.534 3.134 . . . . 0.0 111.833 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -85.89 -83.97 0.17 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.079 1.352 . . . . 0.0 112.486 177.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 72.35 112.43 0.06 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 126.488 1.915 . . . . 0.0 111.986 175.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -69.05 168.76 13.18 Favored 'General case' 0 CA--C 1.546 0.825 0 O-C-N 120.075 -1.641 . . . . 0.0 113.029 169.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -80.75 11.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 O-C-N 120.672 -1.268 . . . . 0.0 113.279 -178.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.95 10.21 7.48 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 126.766 2.127 . . . . 0.0 114.246 176.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -99.95 81.02 2.38 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 121.641 -0.917 . . . . 0.0 111.161 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.9 mt -79.17 48.71 0.89 Allowed 'General case' 0 CA--C 1.549 0.905 0 O-C-N 121.039 -1.038 . . . . 0.0 110.771 169.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.82 -118.7 9.31 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.541 1.543 . . . . 0.0 113.423 177.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.0 p30 -157.15 172.69 18.2 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.622 1.569 . . . . 0.0 112.64 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.9 p -133.63 125.11 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 C-N-CA 126.213 1.805 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 m -98.22 139.23 34.31 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.6 159.08 18.51 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.091 0.956 . . . . 0.0 113.418 172.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -89.4 154.66 19.88 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 126.83 2.052 . . . . 0.0 111.942 169.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.564 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 0.0 OUTLIER -59.42 -14.6 12.82 Favored 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.818 2.447 . . . . 0.0 115.553 178.2 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.564 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 27.4 m-20 -79.36 5.75 11.78 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 125.254 1.422 . . . . 0.0 112.941 168.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.26 40.59 9.05 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 125.708 1.623 . . . . 0.0 113.39 169.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.4 p -155.78 146.82 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 115.302 1.593 . . . . 0.0 115.302 -168.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.93 101.15 4.8 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 123.44 1.59 . . . . 0.0 109.604 167.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.54 79.29 1.8 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.249 2.219 . . . . 0.0 108.698 -173.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 70.9 t -93.23 147.81 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 127.31 2.244 . . . . 0.0 114.211 -167.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.6 t -150.51 116.51 5.6 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.23 1.412 . . . . 0.0 111.056 170.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.7 mt -140.11 168.97 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 128.296 2.638 . . . . 0.0 112.029 -168.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.45 ' CD ' ' HZ3' ' A' ' 30' ' ' LYS . 2.3 pm0 -136.28 136.42 39.78 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 127.909 2.484 . . . . 0.0 107.825 172.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -147.13 153.14 39.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 122.284 1.04 . . . . 0.0 113.373 -168.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 81.9 p -126.29 69.47 1.22 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.884 2.074 . . . . 0.0 110.898 -169.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.53 -35.71 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 124.211 1.004 . . . . 0.0 112.225 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -94.98 161.68 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.928 1.291 . . . . 0.0 112.225 174.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.1 p -158.07 177.64 11.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.233 1.013 . . . . 0.0 111.207 174.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -111.53 80.3 1.3 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.455 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.7 t -147.34 -171.0 3.69 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -127.69 87.83 0.33 Allowed Glycine 0 C--O 1.219 -0.824 0 O-C-N 120.444 -1.41 . . . . 0.0 113.046 -177.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -177.26 -54.19 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 129.057 2.943 . . . . 0.0 108.615 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -140.02 8.04 2.27 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 114.647 1.351 . . . . 0.0 114.647 -173.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.455 ' CB ' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -73.08 -161.4 0.09 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 126.334 1.853 . . . . 0.0 113.9 -172.768 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 36.9 pt -109.47 1.08 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.5 mm -62.25 126.38 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 CA-C-N 119.981 1.264 . . . . 0.0 107.633 168.462 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.76 16.84 76.35 Favored Glycine 0 CA--C 1.522 0.469 0 CA-C-O 117.953 -1.471 . . . . 0.0 115.118 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 -102.25 169.82 8.47 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 119.267 1.533 . . . . 0.0 109.741 -175.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 10.2 t -123.54 121.85 36.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 120.614 1.552 . . . . 0.0 112.067 -173.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.02 137.23 32.56 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 174.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.3 t -129.71 131.22 66.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 126.065 1.746 . . . . 0.0 107.741 172.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 34.5 m -106.27 138.8 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 172.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -95.26 148.34 22.51 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.602 0.761 . . . . 0.0 112.739 -169.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.316 2.7 pp20? -74.47 -21.48 59.57 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -171.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -113.32 169.42 8.96 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.236 1.015 . . . . 0.0 112.593 171.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.73 154.14 9.53 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.533 1.533 . . . . 0.0 109.547 166.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -119.17 155.99 30.64 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 114.498 1.295 . . . . 0.0 114.498 -169.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 129' ' ' GLY . 2.9 t0 -89.83 -38.17 13.94 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 117.471 2.397 . . . . 0.0 117.471 -167.388 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 63.8 42.78 5.88 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.516 1.927 . . . . 0.0 113.322 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 134.8 -77.38 0.37 Allowed Glycine 0 C--N 1.337 0.586 0 C-N-CA 124.466 1.031 . . . . 0.0 112.716 169.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.17 62.16 1.17 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 118.853 2.909 . . . . 0.0 118.853 -174.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.408 ' H ' ' CG ' ' A' ' 125' ' ' ASP . . . -71.72 -71.5 1.04 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 106.899 -2.48 . . . . 0.0 106.899 163.325 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -77.79 -91.35 0.3 Allowed Glycine 0 CA--C 1.528 0.88 0 C-N-CA 126.177 1.846 . . . . 0.0 114.487 -173.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -144.02 -145.31 0.17 Allowed 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 124.822 1.249 . . . . 0.0 111.876 -165.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -69.66 -49.93 48.99 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.751 1.16 . . . . 0.0 112.367 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.425 ' CD ' ' HZ3' ' A' ' 136' ' ' LYS . 0.4 OUTLIER -47.13 -27.34 1.38 Allowed 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 116.15 1.907 . . . . 0.0 116.15 171.499 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 48.7 m -51.77 -23.68 4.95 Favored 'General case' 0 CA--C 1.543 0.699 0 O-C-N 120.195 -1.565 . . . . 0.0 113.719 167.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.5 p -99.54 -26.9 13.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.749 1.619 . . . . 0.0 115.033 173.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.425 ' HZ3' ' CD ' ' A' ' 133' ' ' GLU . 31.6 mtpt -91.75 -24.82 19.32 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 124.103 0.961 . . . . 0.0 113.429 -176.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 39.6 p -123.31 -42.05 2.27 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.727 1.611 . . . . 0.0 112.83 169.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 105.81 18.99 10.7 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-O 118.864 -0.964 . . . . 0.0 111.091 -166.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 59.04 -1.7 0.11 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.58 2.352 . . . . 0.0 115.723 176.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.9 16.44 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.24 0 C-N-CA 128.822 2.849 . . . . 0.0 116.802 -165.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.27 -128.97 9.29 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 127.084 2.278 . . . . 0.0 111.658 -173.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.2 t -104.01 -168.22 1.47 Allowed 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.048 1.339 . . . . 0.0 113.122 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.65 151.41 36.18 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 120.629 -1.294 . . . . 0.0 110.925 168.445 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.3 tt -111.42 -66.81 1.04 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.699 2.0 . . . . 0.0 107.465 169.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -131.72 158.87 40.01 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.276 1.83 . . . . 0.0 110.31 177.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.0 p -156.38 151.74 26.69 Favored 'General case' 0 CA--C 1.553 1.062 0 C-N-CA 125.803 1.641 . . . . 0.0 113.171 -171.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.07 163.42 34.29 Favored Glycine 0 CA--C 1.542 1.762 0 C-N-CA 125.724 1.631 . . . . 0.0 114.205 172.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.8 t -107.54 137.59 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.455 1.127 . . . . 0.0 108.371 168.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.0 mt -81.31 126.88 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 127.513 2.325 . . . . 0.0 113.698 -169.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.0 -154.43 9.43 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 126.043 1.782 . . . . 0.0 112.412 168.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -131.17 146.15 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.607 1.163 . . . . 0.0 112.605 -178.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.04 15.82 Favored 'General case' 0 C--O 1.22 -0.476 0 C-N-CA 124.239 1.016 . . . . 0.0 109.472 174.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 . . . . . 0 C--O 1.239 0.524 0 C-N-CA 125.085 1.354 . . . . 0.0 108.746 173.441 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.401 0 CA-C-O 120.834 0.35 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.3 p -82.77 107.18 15.2 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.77 118.92 27.62 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 115.245 1.572 . . . . 0.0 115.245 -172.398 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.96 161.38 14.17 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.043 1.337 . . . . 0.0 111.957 169.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -148.73 116.04 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.784 2.034 . . . . 0.0 111.188 -169.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.75 125.61 29.6 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.161 -0.962 . . . . 0.0 110.106 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.402 ' HA ' ' CG2' ' A' ' 54' ' ' THR . 87.8 t -107.5 71.61 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.712 0.805 . . . . 0.0 111.291 -170.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 mp -83.56 130.42 35.0 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -169.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.6 mtpp -155.24 178.26 10.41 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.119 1.368 . . . . 0.0 113.119 172.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.73 -55.55 0.47 Allowed Glycine 0 C--O 1.224 -0.48 0 C-N-CA 127.175 2.322 . . . . 0.0 109.794 170.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -83.78 73.73 10.26 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.883 1.273 . . . . 0.0 110.481 -168.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.66 -103.58 0.06 OUTLIER Glycine 0 CA--C 1.538 1.471 0 C-N-CA 126.751 2.119 . . . . 0.0 113.136 176.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -79.87 -3.04 12.56 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 125.192 3.928 . . . . 0.0 114.724 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 42.0 t -77.53 128.37 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-N 120.025 1.284 . . . . 0.0 110.523 176.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -126.4 158.31 36.27 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 126.278 1.831 . . . . 0.0 109.181 167.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.01 101.91 0.28 Allowed Glycine 0 C--O 1.225 -0.415 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 168.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -102.43 106.02 19.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 C-N-CA 125.721 1.608 . . . . 0.0 106.676 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.2 mm -120.68 101.75 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.01 0.524 . . . . 0.0 109.964 -177.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -74.93 161.57 29.39 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 118.915 0.779 . . . . 0.0 110.523 172.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -146.73 100.47 3.33 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.947 2.099 . . . . 0.0 107.818 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 116.8 29.24 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.853 0.861 . . . . 0.0 112.017 -178.342 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -102.26 126.45 49.25 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.088 0.955 . . . . 0.0 110.767 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -49.78 20.71 Favored 'General case' 0 CA--C 1.55 0.963 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 171.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -151.5 134.56 15.86 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 128.757 2.823 . . . . 0.0 107.108 169.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 67.5 m -64.01 93.37 0.09 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.327 1.051 . . . . 0.0 112.268 178.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 p30 160.08 -32.66 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 131.081 3.753 . . . . 0.0 110.998 -174.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.6 173.18 45.41 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-O 119.241 -0.755 . . . . 0.0 111.936 172.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.04 166.9 19.34 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.422 2.748 . . . . 0.0 111.378 177.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 66.1 t -121.22 130.19 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 124.968 1.307 . . . . 0.0 109.017 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -86.87 119.24 26.88 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.73 0.776 . . . . 0.0 109.739 170.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.4 t -104.97 121.08 56.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 127.441 2.296 . . . . 0.0 108.813 -172.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -155.14 157.21 37.08 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.95 -135.64 4.87 Favored Glycine 0 N--CA 1.461 0.331 0 C-N-CA 124.709 1.147 . . . . 0.0 111.053 177.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.5 p -157.7 158.5 35.51 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 116.222 1.934 . . . . 0.0 116.222 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -121.24 104.72 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.561 1.144 . . . . 0.0 108.483 170.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -106.27 124.47 49.64 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.3 3.1 3.53 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.269 1.89 . . . . 0.0 113.916 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 55.6 mt -79.76 -172.03 3.13 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 124.194 0.998 . . . . 0.0 108.409 167.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -119.58 -29.08 5.16 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 171.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 175.9 -176.65 0.12 Allowed 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 130.462 3.505 . . . . 0.0 106.327 -178.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.38 160.71 35.44 Favored Glycine 0 N--CA 1.461 0.354 0 C-N-CA 125.677 1.608 . . . . 0.0 114.072 166.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mp -76.59 157.91 31.57 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 167.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -149.38 130.01 14.04 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 126.606 1.963 . . . . 0.0 108.681 -174.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.75 147.68 37.19 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 172.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.296 0.0 OUTLIER -138.32 133.56 33.17 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 123.947 1.832 . . . . 0.0 114.65 169.464 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -130.3 145.61 51.79 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.958 1.703 . . . . 0.0 111.63 -168.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -96.55 115.51 36.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 168.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -73.38 132.53 43.12 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 170.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -65.21 135.97 56.07 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 124.333 1.053 . . . . 0.0 112.037 -165.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 66.09 -169.93 0.2 Allowed 'General case' 0 CA--C 1.544 0.747 0 CA-C-O 123.274 1.511 . . . . 0.0 111.907 -175.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' B' ' 53' ' ' ASN . . . -135.55 2.85 3.85 Favored Glycine 0 C--O 1.225 -0.437 0 C-N-CA 126.602 2.049 . . . . 0.0 113.589 -175.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -79.63 49.62 1.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 121.246 2.523 . . . . 0.0 111.262 169.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.419 ' H ' ' C ' ' B' ' 51' ' ' GLY . 0.0 OUTLIER 176.42 28.26 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 112.079 -2.328 . . . . 0.0 115.293 -169.4 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.492 1.658 0 N-CA-C 120.687 3.588 . . . . 0.0 120.687 -168.51 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.376 0 N-CA-C 116.243 1.942 . . . . 0.0 116.243 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.76 126.79 32.82 Favored Glycine 0 CA--C 1.537 1.465 0 C-N-CA 125.448 1.499 . . . . 0.0 111.862 178.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -63.28 169.79 8.88 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 124.278 3.318 . . . . 0.0 112.484 -173.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.561 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -61.57 108.17 0.93 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.902 1.681 . . . . 0.0 112.722 -169.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -53.22 135.67 37.83 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 126.207 1.803 . . . . 0.0 115.729 -167.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -116.72 42.38 0.36 Allowed Pre-proline 0 CA--C 1.559 1.327 0 C-N-CA 128.131 2.572 . . . . 0.0 114.746 -175.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -65.9 -20.48 58.05 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.092 1.862 . . . . 0.0 112.38 177.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 6.5 mp -77.9 -3.93 44.21 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 126.72 2.008 . . . . 0.0 113.666 170.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.3 t 52.41 59.14 4.72 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 125.778 1.631 . . . . 0.0 114.726 169.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.0 ptt180 -163.1 179.24 7.64 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.109 0.964 . . . . 0.0 111.914 -168.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.16 169.92 2.51 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 -179.174 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -55.64 158.32 3.56 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.979 1.711 . . . . 0.0 114.456 -173.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -64.68 45.04 0.11 Allowed Glycine 0 N--CA 1.47 0.937 0 N-CA-C 120.915 3.126 . . . . 0.0 120.915 -164.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -75.95 124.44 7.4 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-N 119.835 1.818 . . . . 0.0 113.903 -169.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -74.71 -3.01 13.23 Favored 'Trans proline' 0 CA--C 1.546 1.094 0 CA-C-N 120.125 1.962 . . . . 0.0 110.319 166.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptmt -106.07 -3.58 21.4 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 127.94 2.496 . . . . 0.0 112.98 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.88 142.47 50.38 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.199 1.4 . . . . 0.0 109.351 -172.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -70.45 -18.09 62.99 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.984 -0.448 . . . . 0.0 111.79 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -98.48 122.16 41.33 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 125.292 1.437 . . . . 0.0 107.828 169.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.3 ttt85 -150.27 115.45 5.39 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.3 1.84 . . . . 0.0 109.466 -171.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -60.15 163.6 4.76 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 127.091 2.156 . . . . 0.0 112.2 166.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.23 -30.76 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 C-N-CA 124.775 1.23 . . . . 0.0 113.451 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.01 33.91 3.07 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 121.14 -0.975 . . . . 0.0 113.405 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 34.4 m-20 -144.36 155.12 43.65 Favored 'General case' 0 CA--C 1.529 0.173 0 N-CA-C 117.645 2.461 . . . . 0.0 117.645 -169.219 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.6 mt -113.1 -178.61 3.42 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 127.719 2.408 . . . . 0.0 107.796 164.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.39 -129.07 1.47 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.128 0.871 . . . . 0.0 113.369 176.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -103.09 162.58 12.83 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.064 0.946 . . . . 0.0 112.284 172.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.36 140.51 43.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 127.555 2.342 . . . . 0.0 108.179 166.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 91.1 m -127.76 124.23 37.23 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -165.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.95 144.06 30.26 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -82.37 163.13 21.91 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 126.679 1.992 . . . . 0.0 109.924 167.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -51.58 -17.93 0.98 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 126.777 2.031 . . . . 0.0 116.074 170.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.41 -23.49 57.01 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 126.753 2.021 . . . . 0.0 112.387 172.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.09 -3.94 60.5 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 125.603 1.573 . . . . 0.0 114.946 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.6 129.02 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 118.923 1.362 . . . . 0.0 112.232 168.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.95 126.65 43.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 164.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -79.91 142.36 35.22 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.9 p -124.33 130.78 73.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-N 114.086 -1.416 . . . . 0.0 111.152 165.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.1 p -155.91 69.87 0.68 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.539 1.936 . . . . 0.0 109.997 -169.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 14.9 mt -127.57 162.2 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.124 1.769 . . . . 0.0 113.285 -167.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -138.66 148.74 44.4 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 127.821 2.448 . . . . 0.0 106.916 166.275 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -148.48 143.13 26.5 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 125.254 1.422 . . . . 0.0 109.106 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.3 p -108.86 55.02 0.64 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.606 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.61 -40.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.707 1.603 . . . . 0.0 109.76 170.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -82.32 155.27 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 CA-C-O 122.549 1.166 . . . . 0.0 113.997 179.187 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 35.6 m -158.1 156.11 30.4 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.888 1.675 . . . . 0.0 111.37 172.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.3 mp -76.74 79.85 3.36 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 126.678 1.991 . . . . 0.0 107.934 176.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.95 -19.27 20.37 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 113.233 0.827 . . . . 0.0 113.233 -172.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 83.65 9.96 82.27 Favored Glycine 0 N--CA 1.472 1.095 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.663 -174.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -165.26 -37.22 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.861 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -169.277 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -131.84 7.29 4.38 Favored 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 116.934 2.198 . . . . 0.0 116.934 -165.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.0 m -161.07 -55.95 0.05 Allowed 'General case' 0 N--CA 1.479 0.977 0 O-C-N 119.368 -2.083 . . . . 0.0 115.766 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . 0.44 ' CG2' ' H ' ' B' ' 113' ' ' ILE . 68.2 mt -137.75 158.18 33.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 173.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . 0.44 ' H ' ' CG2' ' B' ' 112' ' ' ILE . 19.8 mm 83.32 102.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.267 1 C-N-CA 131.847 4.059 . . . . 0.0 106.498 -166.387 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.08 13.61 83.48 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-O 115.504 -2.831 . . . . 0.0 116.91 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -92.92 152.46 19.35 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 121.314 2.557 . . . . 0.0 109.05 175.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.6 t -107.68 109.72 21.4 Favored 'General case' 0 N--CA 1.487 1.398 0 CA-C-N 121.393 1.906 . . . . 0.0 112.962 -167.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -91.17 136.29 33.19 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.785 1.234 . . . . 0.0 110.42 -176.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 p -121.06 142.3 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 C-N-CA 125.702 1.601 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 m -107.47 140.27 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 123.61 0.764 . . . . 0.0 110.371 171.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -111.93 160.22 17.64 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-O 122.373 1.083 . . . . 0.0 113.029 -170.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -84.36 -33.21 23.87 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -99.11 167.72 10.52 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.57 1.077 . . . . 0.0 111.093 177.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.93 150.54 16.44 Favored 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 165.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -112.28 137.5 50.32 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.239 0.616 . . . . 0.0 109.723 173.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -79.91 -38.01 33.41 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 120.577 -0.449 . . . . 0.0 111.454 169.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . 0.269 1.8 mm? 86.1 63.6 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.759 2.423 . . . . 0.0 111.868 -169.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.0 -15.55 36.78 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 117.077 1.591 . . . . 0.0 117.077 166.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.81 -153.95 0.6 Allowed 'General case' 0 CA--C 1.552 1.026 0 CA-C-N 119.565 1.683 . . . . 0.0 109.885 169.379 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 122.41 -36.78 3.05 Favored Glycine 0 N--CA 1.471 1.02 0 O-C-N 120.688 -1.257 . . . . 0.0 113.149 -176.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.61 -16.18 0.32 Allowed Glycine 0 N--CA 1.475 1.272 0 N-CA-C 118.719 2.248 . . . . 0.0 118.719 169.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -122.01 169.13 11.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.21 2.005 . . . . 0.0 111.513 -174.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -62.66 -51.78 65.91 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.894 1.278 . . . . 0.0 109.711 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -49.29 -30.88 8.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.561 2.344 . . . . 0.0 113.548 174.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 92.1 p -60.2 -33.67 72.55 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 122.354 2.343 . . . . 0.0 113.957 171.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 33.0 p -62.66 -34.97 78.18 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.529 0.604 . . . . 0.0 111.461 177.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 38.7 mtpt -90.86 -39.1 12.52 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.997 1.719 . . . . 0.0 113.273 -174.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 53.8 p -104.93 -28.34 11.16 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 127.212 2.205 . . . . 0.0 114.181 -173.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.57 -28.98 13.23 Favored Glycine 0 N--CA 1.465 0.6 0 C-N-CA 125.857 1.694 . . . . 0.0 113.924 -168.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 96.98 -11.35 0.08 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 130.787 3.635 . . . . 0.0 109.736 -167.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.2 -17.48 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 131.334 3.853 . . . . 0.0 119.71 -168.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 96.96 176.33 35.0 Favored Glycine 0 CA--C 1.534 1.264 0 C-N-CA 127.058 2.266 . . . . 0.0 113.09 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 81.5 p -62.63 -74.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -168.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 170.21 158.16 0.06 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 127.44 2.296 . . . . 0.0 114.594 176.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.98 -128.8 0.19 Allowed 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 126.934 2.094 . . . . 0.0 106.639 163.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.14 150.08 43.7 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 119.347 0.976 . . . . 0.0 112.293 -171.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 36.4 t -143.37 147.74 35.14 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.994 0.918 . . . . 0.0 110.454 173.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.0 160.81 31.48 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 123.889 0.757 . . . . 0.0 114.599 177.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -78.49 152.27 5.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 121.816 -0.814 . . . . 0.0 111.971 174.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 44.8 mt -83.53 91.8 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 123.82 0.848 . . . . 0.0 111.772 169.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -80.14 -163.09 27.4 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.573 1.082 . . . . 0.0 113.181 169.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.1 141.01 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 125.351 1.46 . . . . 0.0 112.308 178.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -99.68 -7.09 26.12 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 124.175 0.99 . . . . 0.0 111.974 168.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.473 0.715 0 C-N-CA 127.922 2.489 . . . . 0.0 110.677 169.556 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.1 p . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 mtmm -86.98 122.29 30.63 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 174.181 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.13 162.6 12.97 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.394 1.878 . . . . 0.0 108.625 165.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' B' ' 52' ' ' ASP . 0.5 OUTLIER -160.05 134.78 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.499 1.12 . . . . 0.0 109.68 -168.604 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.6 137.91 54.54 Favored 'General case' 0 C--N 1.334 -0.095 0 CA-C-N 118.657 0.662 . . . . 0.0 112.311 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -95.19 115.54 34.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 167.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mp -95.01 117.02 29.43 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 169.505 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.419 ' HE3' ' O ' ' B' ' 10' ' ' GLY . 13.1 ttpt -156.26 144.93 20.13 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 121.332 -0.855 . . . . 0.0 113.068 174.81 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.93 -33.04 0.47 Allowed Glycine 0 C--N 1.335 0.482 0 N-CA-C 116.768 1.467 . . . . 0.0 116.768 166.847 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -90.27 70.3 7.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 122.808 1.289 . . . . 0.0 109.657 -166.256 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.02 -106.66 0.14 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 128.724 3.059 . . . . 0.0 111.479 -174.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -76.1 -4.0 14.56 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 124.045 3.163 . . . . 0.0 113.886 -177.4 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 t -91.27 133.88 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 120.162 1.346 . . . . 0.0 111.897 176.431 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.21 159.08 44.6 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 127.211 2.204 . . . . 0.0 107.79 176.678 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -151.3 133.94 4.45 Favored Glycine 0 C--O 1.229 -0.166 0 CA-C-O 122.023 0.791 . . . . 0.0 111.84 177.129 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.19 130.44 56.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 169.822 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.55 122.99 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 124.326 1.017 . . . . 0.0 110.118 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -97.83 150.25 21.48 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.952 1.301 . . . . 0.0 110.194 167.042 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -124.83 111.25 15.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.322 1.849 . . . . 0.0 108.043 168.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -93.64 122.59 36.24 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 169.534 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -100.05 116.23 31.59 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.854 168.268 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . 0.263 0.0 OUTLIER -57.01 -50.35 73.0 Favored 'General case' 0 C--N 1.34 0.186 0 CA-C-O 119.095 -0.479 . . . . 0.0 112.044 175.893 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -158.42 145.66 17.83 Favored 'General case' 0 C--O 1.225 -0.213 0 CA-C-O 118.514 -0.755 . . . . 0.0 110.171 163.284 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.7 t -32.1 -51.52 0.25 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.985 2.114 . . . . 0.0 115.715 -167.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -78.34 -1.85 35.27 Favored 'General case' 0 CA--C 1.552 1.048 0 N-CA-C 115.559 1.688 . . . . 0.0 115.559 -175.9 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.45 -179.48 39.44 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.198 1.38 . . . . 0.0 113.756 -178.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -81.43 134.57 8.95 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 122.694 2.262 . . . . 0.0 111.354 175.218 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 t -86.69 128.76 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 O-C-N 121.779 -0.576 . . . . 0.0 110.393 -175.493 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 tmtt? -87.06 123.32 32.01 Favored 'General case' 0 CA--C 1.541 0.607 0 O-C-N 121.782 -0.574 . . . . 0.0 109.806 174.001 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -99.43 140.98 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.714 0.806 . . . . 0.0 110.343 169.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -145.05 156.64 44.04 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.37 0.668 . . . . 0.0 111.549 168.192 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.54 -160.4 29.23 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 123.346 0.498 . . . . 0.0 112.887 176.76 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.1 p -155.99 138.47 14.94 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 122.538 -0.39 . . . . 0.0 111.984 -175.615 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.91 110.42 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -179.191 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -112.91 142.93 45.01 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 127.685 2.394 . . . . 0.0 110.828 -167.287 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.01 0.81 54.9 Favored Glycine 0 CA--C 1.53 0.991 0 C-N-CA 126.457 1.98 . . . . 0.0 113.312 -177.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.7 mt -73.49 159.37 33.3 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 118.031 0.916 . . . . 0.0 110.573 176.275 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.4 t -82.75 160.23 22.36 Favored 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 162.374 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -53.6 160.15 1.36 Allowed 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -179.794 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.11 -170.71 34.72 Favored Glycine 0 CA--C 1.526 0.766 0 C-N-CA 124.128 0.87 . . . . 0.0 113.001 178.608 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.409 HD13 ' H ' ' A' ' 42' ' ' LEU . 0.8 OUTLIER -79.18 153.13 30.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.827 1.251 . . . . 0.0 110.446 -175.249 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -147.03 114.29 6.26 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.539 2.336 . . . . 0.0 106.808 -177.088 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.87 154.09 28.58 Favored Glycine 0 N--CA 1.476 1.323 0 CA-C-N 119.887 1.221 . . . . 0.0 111.828 -176.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -157.4 135.11 10.69 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.629 1.214 . . . . 0.0 112.21 170.696 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.46 143.82 25.0 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 121.003 -1.061 . . . . 0.0 111.325 -170.03 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 15.9 m -85.08 136.84 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 167.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -104.72 179.22 4.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.91 1.684 . . . . 0.0 108.8 175.535 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.71 158.59 35.87 Favored 'General case' 0 N--CA 1.478 0.952 0 O-C-N 119.303 -2.123 . . . . 0.0 110.401 166.77 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 67.71 172.91 0.27 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.947 1.299 . . . . 0.0 112.298 174.648 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.04 10.33 63.84 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 126.588 2.042 . . . . 0.0 112.045 165.794 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -74.07 100.76 3.69 Favored 'General case' 0 N--CA 1.453 -0.286 0 O-C-N 121.848 -0.795 . . . . 0.0 109.381 -173.331 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.444 1.5 p30 -145.61 35.69 1.06 Allowed 'General case' 0 C--N 1.341 0.224 0 N-CA-C 119.427 3.121 . . . . 0.0 119.427 173.872 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.74 -36.74 5.08 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 117.548 -1.215 . . . . 0.0 112.66 -179.628 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.84 23.19 0.25 Allowed 'General case' 0 CA--C 1.554 1.133 0 CA-C-N 120.321 1.419 . . . . 0.0 113.518 169.919 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.06 -126.48 42.17 Favored Glycine 0 CA--C 1.528 0.863 0 O-C-N 120.523 -1.361 . . . . 0.0 112.105 176.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 77.2 m -68.85 -15.89 63.62 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 176.127 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.4 m -86.5 -19.96 28.77 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.272 1.429 . . . . 0.0 111.731 171.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.87 -50.46 12.21 Favored 'General case' 0 N--CA 1.476 0.835 0 O-C-N 121.37 -0.831 . . . . 0.0 110.87 169.146 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -148.62 131.26 15.9 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.029 0.919 . . . . 0.0 112.742 -177.499 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.09 -131.37 0.61 Allowed Glycine 0 CA--C 1.536 1.348 0 C-N-CA 126.69 2.09 . . . . 0.0 111.499 177.386 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -79.0 178.74 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 124.13 3.22 . . . . 0.0 111.001 174.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.06 83.39 4.36 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.062 1.345 . . . . 0.0 108.66 172.448 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -48.25 150.13 1.33 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.326 1.85 . . . . 0.0 113.225 -179.448 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -146.97 114.21 4.26 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 174.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.76 -17.21 33.2 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.502 2.135 . . . . 0.0 113.008 175.677 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.74 -11.57 59.99 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 119.163 0.892 . . . . 0.0 113.044 175.701 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 t 53.23 46.9 25.55 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 126.008 1.723 . . . . 0.0 113.718 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.6 mtp85 -104.44 168.14 9.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 127.612 2.365 . . . . 0.0 111.857 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.59 151.46 44.63 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 122.129 0.966 . . . . 0.0 110.682 168.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.469 ' CG ' ' H ' ' A' ' 72' ' ' GLY . 85.7 t60 -66.64 179.0 1.13 Allowed 'General case' 0 CA--C 1.545 0.754 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.105 164.334 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.469 ' H ' ' CG ' ' A' ' 71' ' ' HIS . . . 113.16 -125.45 7.01 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 168.447 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.67 -50.68 0.8 Allowed Glycine 0 CA--C 1.539 1.566 0 CA-C-O 118.411 -1.216 . . . . 0.0 114.449 -178.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -80.01 -27.2 3.92 Favored 'Trans proline' 0 C--N 1.353 0.814 0 C-N-CA 122.884 2.389 . . . . 0.0 115.032 173.509 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptpt -121.75 -14.26 8.15 Favored 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 120.506 1.503 . . . . 0.0 113.904 169.094 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.494 ' HA ' ' HZ3' ' A' ' 128' ' ' LYS . 13.5 t70 -105.84 153.47 21.88 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.866 1.266 . . . . 0.0 110.613 170.514 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -79.91 -14.6 58.51 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 125.995 1.718 . . . . 0.0 112.977 -169.584 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -103.83 -87.13 0.44 Allowed 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -166.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 84.82 133.24 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.287 1.835 . . . . 0.0 110.991 -173.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -59.82 156.69 13.68 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 125.776 1.63 . . . . 0.0 113.717 168.421 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.3 p -62.47 -36.54 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 CA-C-N 119.41 1.004 . . . . 0.0 112.925 179.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.8 102.1 1.92 Allowed Glycine 0 C--N 1.342 0.889 0 N-CA-C 106.027 -2.829 . . . . 0.0 106.027 167.596 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -162.34 147.89 12.75 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.012 1.115 . . . . 0.0 114.012 173.574 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 98.2 mt -121.7 173.47 7.43 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.558 1.943 . . . . 0.0 106.266 162.817 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.19 -107.88 1.31 Allowed Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.028 0.823 . . . . 0.0 112.758 -174.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -138.44 157.59 45.92 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.606 0.762 . . . . 0.0 111.432 169.182 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -96.67 159.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 C-N-CA 125.233 1.413 . . . . 0.0 108.362 167.048 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.0 m -148.37 118.74 7.35 Favored 'General case' 0 N--CA 1.476 0.869 0 O-C-N 121.392 -0.817 . . . . 0.0 110.141 -174.977 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.33 142.61 28.25 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 125.587 1.555 . . . . 0.0 114.891 -169.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -78.09 148.63 34.13 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 113.189 -1.823 . . . . 0.0 109.005 166.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.505 ' HZ2' ' CG ' ' A' ' 92' ' ' ASP . 7.0 pttp -39.08 -32.25 0.09 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 127.536 2.334 . . . . 0.0 115.768 169.663 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.505 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 28.2 m-20 -80.01 4.53 16.73 Favored 'General case' 0 CA--C 1.55 0.968 0 CA-C-N 119.978 1.263 . . . . 0.0 111.911 -178.776 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.45 -0.16 53.45 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 127.18 2.324 . . . . 0.0 115.434 168.581 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -113.79 131.89 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 119.273 1.536 . . . . 0.0 113.591 -174.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.86 132.42 44.22 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.405 164.65 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -77.9 152.2 33.41 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.243 1.021 . . . . 0.0 108.492 168.645 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.252 0.4 OUTLIER -128.43 126.65 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-N 113.78 -1.555 . . . . 0.0 112.277 165.997 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.7 t -157.81 89.07 1.0 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.226 1.011 . . . . 0.0 112.767 -177.01 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 4.2 mp -126.18 161.52 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 125.725 1.61 . . . . 0.0 110.811 176.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -140.3 137.72 34.38 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.493 2.717 . . . . 0.0 106.359 167.525 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -151.98 133.1 14.34 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 118.722 0.692 . . . . 0.0 112.48 -171.077 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.7 p -101.39 51.19 0.85 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.702 0.801 . . . . 0.0 112.261 175.976 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 41.0 t -130.98 -48.23 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.376 1.07 . . . . 0.0 108.511 169.207 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.53 155.12 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 122.839 1.304 . . . . 0.0 111.998 170.299 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.7 p -155.76 155.2 32.64 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 125.559 1.544 . . . . 0.0 109.968 -174.782 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -82.23 55.2 2.77 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 120.699 -1.25 . . . . 0.0 110.365 177.744 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.3 t -108.2 37.55 2.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.098 1.759 . . . . 0.0 113.282 -172.088 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 88.79 -143.93 17.9 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-O 122.426 1.014 . . . . 0.0 111.833 169.34 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -66.8 -44.64 80.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 123.881 1.8 . . . . 0.0 112.039 -166.988 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -85.19 -7.38 59.07 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 112.886 -1.961 . . . . 0.0 110.884 -170.705 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.4 t -118.82 -122.18 0.29 Allowed 'General case' 0 CA--C 1.547 0.86 0 CA-C-O 116.233 -1.842 . . . . 0.0 110.268 173.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.259 7.1 pt -124.49 67.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 CA-C-N 124.233 3.197 . . . . 0.0 116.911 178.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.4 mm -127.42 132.29 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 165.578 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.72 5.33 50.84 Favored Glycine 0 N--CA 1.472 1.082 0 CA-C-N 119.724 1.147 . . . . 0.0 115.772 177.228 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -80.78 178.21 8.53 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 118.535 1.168 . . . . 0.0 113.173 -170.105 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 36.5 m -101.37 138.67 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 127.351 2.26 . . . . 0.0 110.285 -177.593 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -138.18 135.27 35.48 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 124.242 0.964 . . . . 0.0 109.097 165.764 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 p -120.35 136.6 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 126.571 1.948 . . . . 0.0 108.911 176.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 16.6 m -101.97 149.52 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 166.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.5 m-70 -117.89 155.58 29.91 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.092 1.357 . . . . 0.0 111.928 -171.404 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -81.32 -33.99 32.18 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.815 1.246 . . . . 0.0 111.465 -171.036 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mmmt -92.58 165.05 13.19 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-N 119.375 0.989 . . . . 0.0 113.059 173.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.98 149.68 22.52 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.25 1.02 . . . . 0.0 109.354 165.043 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -99.88 135.29 41.52 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 169.108 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -77.91 -8.88 58.7 Favored 'General case' 0 N--CA 1.48 1.047 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 171.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.4 mt 62.73 48.66 4.1 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 124.97 1.308 . . . . 0.0 109.843 173.485 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.26 8.35 78.31 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 115.997 -2.557 . . . . 0.0 118.002 167.153 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.494 ' HZ3' ' HA ' ' A' ' 76' ' ' ASP . 9.6 mttp -121.34 4.88 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 120.64 3.57 . . . . 0.0 120.64 -168.304 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.75 112.32 4.37 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 165.064 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -71.45 43.41 0.71 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 126.337 1.922 . . . . 0.0 114.55 -175.156 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -103.53 -77.05 0.57 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.828 1.651 . . . . 0.0 110.567 -174.446 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 174.49 -80.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 130.73 3.612 . . . . 0.0 105.494 -170.808 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -34.28 -54.47 0.51 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 128.528 2.731 . . . . 0.0 113.878 175.213 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -65.11 -5.44 6.62 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -169.565 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.8 t -126.09 -25.48 3.55 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 123.989 0.916 . . . . 0.0 111.984 165.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.0 tttt -54.21 -33.26 57.84 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.348 1.859 . . . . 0.0 111.531 168.604 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.0 p -110.99 -67.76 0.98 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 162.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.457 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 152.72 -23.67 0.82 Allowed Glycine 0 CA--C 1.534 1.23 0 C-N-CA 129.803 3.573 . . . . 0.0 112.746 -168.294 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 110.83 -8.6 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.646 1 C-N-CA 131.768 4.027 . . . . 0.0 113.057 176.183 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.59 -17.45 2.14 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 116.526 2.046 . . . . 0.0 116.526 -169.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.96 -135.37 28.03 Favored Glycine 0 CA--C 1.526 0.72 0 C-N-CA 124.529 1.062 . . . . 0.0 113.604 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.09 131.97 23.37 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 124.868 1.267 . . . . 0.0 111.677 -176.226 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -65.71 173.56 2.77 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-O 121.371 0.605 . . . . 0.0 109.438 169.243 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -150.08 -146.63 0.2 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.808 1.643 . . . . 0.0 107.268 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.59 150.66 2.64 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 123.018 1.39 . . . . 0.0 110.843 171.203 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 4.8 t -146.37 152.75 39.6 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 124.602 1.161 . . . . 0.0 109.3 -174.636 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.68 158.14 28.29 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 125.388 1.471 . . . . 0.0 114.028 -178.323 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -109.79 141.85 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.252 1.021 . . . . 0.0 109.335 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 15.0 mm -78.69 92.67 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 123.791 0.836 . . . . 0.0 111.493 -175.365 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -81.19 -175.83 50.37 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 125.003 1.287 . . . . 0.0 113.011 168.702 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 4.8 mp -136.19 138.7 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 O-C-N 121.015 -1.285 . . . . 0.0 110.412 -172.325 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -122.2 3.58 9.81 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.212 1.005 . . . . 0.0 113.331 171.281 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 . . . . . 0 C--O 1.238 0.45 0 C-N-CA 126.75 2.02 . . . . 0.0 112.402 176.557 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-O 121.272 0.558 . . . . 0.0 112.187 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 18.7 p -78.64 113.28 16.55 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.483 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptmm? -76.31 156.26 33.54 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.776 1.751 . . . . 0.0 112.081 172.042 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . 0.415 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -149.17 165.03 33.03 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.047 2.539 . . . . 0.0 110.416 172.318 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 p -148.81 151.82 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.579 1.552 . . . . 0.0 110.764 -165.461 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.08 138.92 27.0 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.419 1.088 . . . . 0.0 110.515 168.1 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.65 84.74 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.911 0.884 . . . . 0.0 110.393 -169.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.272 0.9 OUTLIER -85.14 67.27 10.12 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 122.573 1.178 . . . . 0.0 113.075 -178.103 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt -97.95 111.73 23.92 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.053 173.367 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . 0.419 ' O ' ' HE3' ' A' ' 9' ' ' LYS . . . -78.39 -103.24 0.2 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 171.831 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -139.38 109.67 6.52 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -167.856 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 51.07 -116.75 4.78 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.913 2.197 . . . . 0.0 112.01 -173.517 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.09 -11.39 27.1 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 124.997 3.798 . . . . 0.0 115.543 -167.606 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.7 t -92.14 94.94 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 123.049 1.404 . . . . 0.0 108.248 169.119 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.09 160.95 43.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.598 174.669 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.15 179.04 29.02 Favored Glycine 0 C--O 1.235 0.2 0 CA-C-O 123.034 1.352 . . . . 0.0 114.213 179.256 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -119.04 139.76 45.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.95 -1.625 . . . . 0.0 110.063 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -127.86 135.65 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 166.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -122.91 143.77 49.66 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 125.44 1.496 . . . . 0.0 110.067 169.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -124.06 130.26 52.26 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.283 1.433 . . . . 0.0 108.262 170.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.98 120.47 41.49 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 124.333 1.053 . . . . 0.0 108.556 169.543 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -122.42 137.11 54.98 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 122.406 1.098 . . . . 0.0 108.896 168.546 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -105.89 -21.15 13.23 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.741 1.216 . . . . 0.0 113.063 -175.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -160.84 121.93 2.93 Favored 'General case' 0 C--O 1.222 -0.367 0 C-N-CA 127.692 2.397 . . . . 0.0 108.667 -164.126 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.1 m -59.25 -41.89 89.83 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.816 2.046 . . . . 0.0 113.179 -171.325 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -82.77 -4.5 58.03 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.502 1.921 . . . . 0.0 113.594 176.338 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.69 -175.94 33.89 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.742 1.639 . . . . 0.0 112.049 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.9 166.65 24.84 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.83 2.353 . . . . 0.0 112.117 178.896 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -115.42 137.79 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 169.441 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.43 129.06 39.72 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.739 0.816 . . . . 0.0 110.555 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -111.46 137.17 45.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 127.211 2.204 . . . . 0.0 109.832 -176.146 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 31.3 p90 -156.27 155.86 33.04 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 124.599 1.16 . . . . 0.0 110.972 168.619 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.32 140.47 3.06 Favored Glycine 0 C--N 1.332 0.351 0 CA-C-O 121.396 0.442 . . . . 0.0 114.1 -169.786 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 51.5 p -118.19 134.05 55.35 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.201 1.0 . . . . 0.0 110.178 -177.338 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -124.85 116.97 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 124.44 1.096 . . . . 0.0 110.435 -176.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 25.1 tptt -95.19 152.52 18.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.609 1.164 . . . . 0.0 109.393 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.87 -17.81 58.61 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.485 1.517 . . . . 0.0 113.722 -179.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 10.5 mp -69.89 119.33 13.95 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 118.457 1.128 . . . . 0.0 109.041 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -67.54 159.01 30.63 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 166.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -49.66 145.43 5.11 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.659 1.984 . . . . 0.0 114.591 -174.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 115.69 171.44 16.45 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 122.5 1.056 . . . . 0.0 113.864 -178.454 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.488 ' H ' ' CD2' ' B' ' 42' ' ' LEU . 1.5 pt? -80.12 133.32 36.07 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.325 1.85 . . . . 0.0 111.522 -175.828 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -135.55 165.09 26.34 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 128.214 2.606 . . . . 0.0 108.964 -172.757 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.17 157.56 20.03 Favored Glycine 0 N--CA 1.482 1.713 0 C-N-CA 125.455 1.502 . . . . 0.0 114.705 -173.052 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -151.13 118.64 6.06 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.137 1.375 . . . . 0.0 113.243 -168.752 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . 0.403 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -154.97 144.22 21.11 Favored 'General case' 0 CA--C 1.555 1.172 0 O-C-N 119.778 -1.826 . . . . 0.0 113.189 178.886 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -94.21 125.56 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 126.035 1.734 . . . . 0.0 110.154 171.076 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.403 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 7.6 m-70 -75.76 166.55 23.36 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.585 1.954 . . . . 0.0 111.042 179.174 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -75.63 133.54 40.84 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 167.321 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 74.57 167.74 0.29 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 128.015 2.526 . . . . 0.0 115.536 -178.58 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.21 -2.08 38.56 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 127.57 2.51 . . . . 0.0 114.269 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . 0.403 ' HA ' ' CG2' ' A' ' 5' ' ' VAL 0.255 10.9 t0 -76.79 111.38 12.25 Favored 'General case' 0 CA--C 1.491 -1.303 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 165.023 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.457 HD21 ' N ' ' B' ' 53' ' ' ASN 0.3 0.1 OUTLIER -144.73 38.3 1.22 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-O 124.225 1.964 . . . . 0.0 113.264 168.738 . . . . . . . . 4 4 . 1 . 021 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.0 p . . . . . 0 N--CA 1.446 -0.66 0 CA-C-N 112.093 -2.322 . . . . 0.0 111.852 -166.257 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.444 0 CA-C-O 121.238 0.542 . . . . 0.0 112.204 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.37 162.01 11.53 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 126.84 2.162 . . . . 0.0 110.015 -167.353 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 161.42 42.35 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 123.166 2.577 . . . . 0.0 112.164 -174.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -23.89 100.14 0.02 OUTLIER 'General case' 0 C--O 1.237 0.433 0 C-N-CA 129.436 3.094 . . . . 0.0 113.827 167.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . 0.41 ' CG ' ' HD3' ' B' ' 66' ' ' PRO . 3.1 t80 -55.5 127.52 30.07 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 123.681 1.705 . . . . 0.0 111.482 177.267 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 24.3 p-10 -103.07 39.38 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.42 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 -177.868 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . 0.41 ' HD3' ' CG ' ' B' ' 64' ' ' PHE . 75.4 Cg_endo -67.02 -14.01 42.02 Favored 'Trans proline' 0 C--N 1.36 1.133 0 C-N-CA 123.277 2.651 . . . . 0.0 112.666 -176.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.6 mt -75.23 -1.24 22.49 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.841 1.656 . . . . 0.0 112.189 175.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.5 t 62.3 58.91 1.67 Allowed 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.794 1.238 . . . . 0.0 113.132 167.495 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -152.82 175.1 13.26 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 114.799 1.407 . . . . 0.0 114.799 -167.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 168.66 19.45 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.108 0.956 . . . . 0.0 109.968 166.747 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.434 ' HE2' ' HA ' ' B' ' 125' ' ' ASP . 42.3 t60 -61.04 165.03 4.48 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 118.356 -0.831 . . . . 0.0 110.334 172.275 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 168.65 -169.67 41.83 Favored Glycine 0 N--CA 1.476 1.316 0 N-CA-C 117.533 1.773 . . . . 0.0 117.533 -172.947 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.78 -87.0 0.25 Allowed Glycine 0 CA--C 1.545 1.931 0 N-CA-C 121.112 3.205 . . . . 0.0 121.112 167.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -72.49 4.75 3.21 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 124.288 3.326 . . . . 0.0 114.459 -167.849 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . 0.27 0.0 OUTLIER -167.05 4.76 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 130.03 3.332 . . . . 0.0 112.804 175.398 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -128.16 138.54 52.53 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 126.79 2.036 . . . . 0.0 105.649 -179.496 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.82 -9.33 46.86 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 126.764 2.026 . . . . 0.0 114.844 -166.643 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -84.38 -84.61 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.911 0.778 . . . . 0.0 109.995 -175.667 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . 0.421 HH22 HG22 ' B' ' 104' ' ' ILE . 33.3 ttp85 78.84 102.45 0.07 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.77 2.028 . . . . 0.0 113.474 167.33 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 13.6 m170 -54.57 155.0 4.33 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 119.829 -1.794 . . . . 0.0 110.165 166.882 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -60.09 -30.41 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 119.708 1.14 . . . . 0.0 113.393 -169.612 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.38 -6.41 74.19 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-O 118.126 -1.375 . . . . 0.0 116.111 179.243 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -79.54 122.37 26.39 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 121.064 2.432 . . . . 0.0 109.902 -176.873 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -126.9 42.17 3.37 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 120.984 1.72 . . . . 0.0 113.455 177.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 60.25 -122.84 31.18 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.691 2.236 . . . . 0.0 118.691 166.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . 0.512 HD22 ' CD1' ' B' ' 126' ' ' LEU . 9.7 m120 -126.82 154.06 44.82 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 113.781 -1.209 . . . . 0.0 113.859 -169.091 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.2 m -130.77 125.55 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.432 1.493 . . . . 0.0 109.107 167.292 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 46.5 m -109.87 127.84 54.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.568 0.747 . . . . 0.0 109.045 -175.784 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.91 148.23 22.18 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.291 1.437 . . . . 0.0 114.078 -177.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -104.76 159.31 15.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.904 2.081 . . . . 0.0 110.154 167.145 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -71.35 8.44 1.04 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.583 2.068 . . . . 0.0 116.583 -168.679 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -76.7 -12.58 60.02 Favored 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 122.404 1.097 . . . . 0.0 108.9 164.221 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.93 40.42 7.1 Favored Glycine 0 C--N 1.337 0.601 0 C-N-CA 125.571 1.557 . . . . 0.0 110.412 -174.676 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.01 134.59 31.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.337 1.068 . . . . 0.0 113.384 177.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.04 120.35 40.29 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 162.728 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -115.43 140.39 49.18 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 122.365 1.079 . . . . 0.0 110.197 169.714 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.43 150.5 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-N 112.324 -2.216 . . . . 0.0 115.092 -169.395 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 p -153.01 119.47 5.59 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.28 1.032 . . . . 0.0 111.349 171.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.1 mt -145.07 159.35 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 128.321 2.649 . . . . 0.0 110.565 -170.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -140.67 140.96 35.06 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.162 1.785 . . . . 0.0 108.172 168.085 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.98 140.08 26.62 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.182 1.393 . . . . 0.0 111.253 -172.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.4 p -110.47 48.65 0.9 Allowed 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.664 0.987 . . . . 0.0 113.664 -175.442 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 33.0 m -148.84 -29.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 CA-C-O 117.997 -1.001 . . . . 0.0 113.144 167.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . 0.421 HG22 HH22 ' B' ' 79' ' ' ARG . 0.1 OUTLIER -76.88 154.11 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-N 121.164 1.802 . . . . 0.0 108.114 165.841 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 105' ' ' SER . . . . . 0.446 ' H ' ' HB3' ' B' ' 111' ' ' SER . 2.9 p -162.46 158.29 23.54 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 125.352 1.461 . . . . 0.0 109.116 -174.238 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -79.67 55.5 2.03 Favored 'General case' 0 CA--C 1.542 0.673 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 171.666 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 58.0 m -93.48 52.56 1.75 Allowed 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 124.245 1.018 . . . . 0.0 110.074 -173.24 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.87 -96.86 0.54 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 124.688 1.137 . . . . 0.0 111.413 -177.028 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -134.97 7.0 3.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 128.298 2.639 . . . . 0.0 110.596 179.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -79.43 -11.84 59.9 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.623 -1.298 . . . . 0.0 111.947 173.528 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 111' ' ' SER . . . . . 0.446 ' HB3' ' H ' ' B' ' 105' ' ' SER . 18.4 m -141.75 -98.69 0.13 Allowed 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 113.372 0.878 . . . . 0.0 113.372 -170.003 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.5 pt -119.56 164.19 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 120.744 -1.223 . . . . 0.0 109.376 168.257 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.9 mm 94.43 137.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 131.149 3.78 . . . . 0.0 105.772 -163.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.26 -15.0 12.94 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 117.809 -1.55 . . . . 0.0 116.569 177.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.5 mtt85 -87.01 -175.4 5.34 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 125.642 1.577 . . . . 0.0 110.147 177.334 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -140.31 126.9 20.27 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 119.382 0.992 . . . . 0.0 111.718 -174.114 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -95.08 141.64 28.48 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.937 1.295 . . . . 0.0 110.056 -177.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.43 136.0 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.235 1.014 . . . . 0.0 109.146 177.237 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -93.55 140.95 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-O 122.438 1.113 . . . . 0.0 110.454 170.208 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -130.97 165.51 23.0 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.147 1.779 . . . . 0.0 111.223 -170.706 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -84.07 -37.86 21.53 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -170.215 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 87.3 mttt -102.35 144.13 31.22 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 119.172 0.896 . . . . 0.0 112.369 -174.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.66 54.86 1.26 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.004 1.321 . . . . 0.0 112.33 168.853 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.29 -12.06 17.52 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.742 2.017 . . . . 0.0 114.524 -177.853 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . 0.434 ' HA ' ' HE2' ' B' ' 71' ' ' HIS . 20.9 t70 -65.25 -7.11 11.58 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 125.435 1.494 . . . . 0.0 114.637 -171.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . 0.512 ' CD1' HD22 ' B' ' 86' ' ' ASN . 0.0 OUTLIER -84.83 42.54 0.93 Allowed 'General case' 0 C--N 1.32 -0.685 0 O-C-N 119.383 -2.073 . . . . 0.0 114.789 179.168 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 63.14 8.41 23.45 Favored Glycine 0 N--CA 1.473 1.152 0 N-CA-C 117.401 1.72 . . . . 0.0 117.401 166.818 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 53.2 tttp -154.86 -59.25 0.11 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.54 1.136 . . . . 0.0 112.178 -167.889 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 37.99 -119.45 0.77 Allowed Glycine 0 CA--C 1.529 0.91 0 C-N-CA 126.071 1.796 . . . . 0.0 113.487 177.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -107.66 -22.81 7.15 Favored Glycine 0 CA--C 1.534 1.231 0 CA-C-O 117.75 -1.583 . . . . 0.0 116.9 -177.562 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -161.44 -178.08 6.4 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 121.22 2.51 . . . . 0.0 112.582 -172.073 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -47.49 -58.32 4.35 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 127.119 2.167 . . . . 0.0 113.128 -172.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -52.33 -21.01 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 115.37 1.618 . . . . 0.0 115.37 177.737 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 m -70.11 -27.33 64.5 Favored 'General case' 0 CA--C 1.549 0.905 0 O-C-N 119.644 -1.91 . . . . 0.0 112.526 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.5 t -79.67 -14.85 58.48 Favored 'General case' 0 N--CA 1.491 1.591 0 CA-C-N 119.853 1.206 . . . . 0.0 112.529 168.362 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mtpt -102.04 -91.44 0.33 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.285 1.834 . . . . 0.0 111.998 -177.853 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.2 p -74.88 -22.16 58.81 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 119.887 1.221 . . . . 0.0 113.986 178.532 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.96 3.46 62.02 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-O 115.497 -2.835 . . . . 0.0 111.145 -167.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 63.75 -68.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.167 2.587 . . . . 0.0 110.12 172.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 70.26 -15.56 0.34 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.689 2.796 . . . . 0.0 115.109 162.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.59 -53.34 4.51 Favored Glycine 0 N--CA 1.473 1.117 0 C-N-CA 126.936 2.207 . . . . 0.0 115.417 174.239 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.5 t -161.65 -166.1 1.42 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.685 0.794 . . . . 0.0 111.058 175.139 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . 0.441 ' N ' ' HE ' ' B' ' 143' ' ' ARG . 0.1 OUTLIER -132.22 142.87 49.59 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.376 1.87 . . . . 0.0 107.35 176.639 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -127.23 -105.37 0.32 Allowed 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.789 1.236 . . . . 0.0 109.663 175.667 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.87 161.85 26.45 Favored 'General case' 0 CA--C 1.544 0.718 0 CA-C-N 120.295 1.407 . . . . 0.0 113.9 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.5 p -152.83 142.74 22.15 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.699 1.6 . . . . 0.0 111.116 -169.141 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.04 126.61 1.78 Allowed Glycine 0 C--N 1.338 0.692 0 N-CA-C 115.86 1.104 . . . . 0.0 115.86 -169.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -79.01 144.97 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 123.81 0.844 . . . . 0.0 109.243 -179.735 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 26.4 mt -92.25 126.15 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 C-N-CA 124.622 1.169 . . . . 0.0 112.214 -179.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.92 171.99 14.04 Favored Glycine 0 CA--C 1.538 1.505 0 N-CA-C 117.214 1.646 . . . . 0.0 117.214 172.131 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -87.43 107.83 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.019 1.328 . . . . 0.0 112.564 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.415 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -79.69 -5.03 54.35 Favored 'General case' 0 CA--C 1.554 1.111 0 O-C-N 121.133 -0.979 . . . . 0.0 111.122 166.757 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 . . . . . 0 N--CA 1.47 0.529 0 C-N-CA 131.259 3.824 . . . . 0.0 111.103 172.05 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.7 p . . . . . 0 CA--C 1.54 0.562 0 N-CA-C 116.414 2.005 . . . . 0.0 116.414 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.279 0.0 OUTLIER -155.7 117.85 4.1 Favored 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 117.573 2.435 . . . . 0.0 117.573 168.072 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.1 156.77 36.02 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.062 2.545 . . . . 0.0 106.403 164.077 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 32.3 t -154.7 155.07 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 120.148 1.34 . . . . 0.0 114.248 -164.891 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.87 128.13 33.99 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 125.892 1.677 . . . . 0.0 110.285 168.045 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.05 92.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 127.154 2.181 . . . . 0.0 108.59 176.822 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -77.01 149.18 35.9 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 125.936 1.694 . . . . 0.0 112.624 -167.509 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -155.35 153.58 30.7 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.127 0.971 . . . . 0.0 111.84 171.012 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.4 -110.61 3.18 Favored Glycine 0 N--CA 1.466 0.684 1 N-CA-C 101.753 -4.539 . . . . 0.0 101.753 162.73 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . 0.276 0.3 OUTLIER -155.62 148.46 24.29 Favored 'General case' 0 N--CA 1.442 -0.86 0 C-N-CA 124.886 1.275 . . . . 0.0 108.959 162.143 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.23 -170.83 36.25 Favored Glycine 0 CA--C 1.54 1.624 0 N-CA-C 107.666 -2.173 . . . . 0.0 107.666 -163.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.74 37.68 0.43 Allowed 'Trans proline' 0 CA--C 1.545 1.063 1 C-N-CA 125.459 4.106 . . . . 0.0 114.308 -171.802 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -108.61 122.44 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.062 1.745 . . . . 0.0 108.433 172.672 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.92 166.49 25.84 Favored 'General case' 0 CA--C 1.519 -0.25 0 C-N-CA 125.52 1.528 . . . . 0.0 110.262 179.222 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 131.81 3.0 Favored Glycine 0 C--O 1.224 -0.521 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.986 167.732 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.63 131.23 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 O-C-N 121.511 -0.994 . . . . 0.0 109.266 168.416 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.2 mm -131.06 122.62 52.1 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 167.81 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -112.25 141.4 46.01 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 125.481 1.512 . . . . 0.0 111.813 169.054 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -116.93 108.76 16.19 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.906 1.682 . . . . 0.0 110.357 176.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HB2' ' CH2' ' A' ' 32' ' ' TRP . 0.0 OUTLIER -87.76 118.94 27.61 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 127.073 2.149 . . . . 0.0 109.978 169.62 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -148.69 140.29 23.53 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.678 0.791 . . . . 0.0 109.321 -179.395 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.82 -28.25 14.34 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -169.727 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.75 -139.86 0.1 Allowed 'General case' 0 CA--C 1.556 1.181 0 C-N-CA 125.494 1.518 . . . . 0.0 111.41 170.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.0 p -113.16 -11.73 13.24 Favored 'General case' 0 N--CA 1.482 1.14 0 O-C-N 118.987 -2.321 . . . . 0.0 115.758 -170.371 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -128.2 -16.67 4.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.453 1.901 . . . . 0.0 112.882 -177.579 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 171.08 48.05 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.548 1.547 . . . . 0.0 112.446 177.741 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -85.13 140.42 7.66 Favored 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 122.268 1.979 . . . . 0.0 111.856 -169.26 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -101.6 132.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.703 1.201 . . . . 0.0 109.487 -173.137 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 ttmp? -92.37 126.21 37.35 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.832 1.253 . . . . 0.0 109.178 169.344 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.8 t -110.19 127.78 66.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 126.069 1.748 . . . . 0.0 109.581 177.753 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.41 ' CH2' ' HB2' ' A' ' 21' ' ' GLU . 6.0 p90 -135.92 159.51 41.46 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.172 0.989 . . . . 0.0 111.434 170.342 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.64 -176.72 27.31 Favored Glycine 0 C--O 1.222 -0.651 0 O-C-N 121.718 -0.614 . . . . 0.0 114.041 -173.192 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.69 141.69 13.25 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.752 0.821 . . . . 0.0 111.543 -172.774 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mp -113.7 118.54 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 126.462 1.905 . . . . 0.0 109.315 -178.503 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -115.81 128.63 55.98 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 110.244 -171.606 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.23 6.34 9.02 Favored Glycine 0 N--CA 1.477 1.433 0 C-N-CA 125.568 1.556 . . . . 0.0 114.964 -177.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 31.6 mt -80.95 157.84 25.42 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.58 1.552 . . . . 0.0 111.609 173.599 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.9 t -75.41 151.95 38.07 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 163.398 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.58 147.05 23.26 Favored 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.593 1.088 . . . . 0.0 112.242 170.768 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 111.65 -175.74 17.67 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.854 1.216 . . . . 0.0 113.453 -174.791 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.5 mt -77.27 154.39 33.0 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.595 1.158 . . . . 0.0 112.144 -174.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -153.11 123.45 7.11 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 127.077 2.151 . . . . 0.0 110.13 -171.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.85 151.72 47.96 Favored Glycine 0 N--CA 1.474 1.218 0 CA-C-N 120.167 1.349 . . . . 0.0 112.439 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.32 0.0 OUTLIER -146.19 140.2 26.44 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 166.119 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.401 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -148.51 153.54 38.59 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 120.998 -1.064 . . . . 0.0 112.031 -166.63 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 m -80.0 152.54 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 122.698 0.399 . . . . 0.0 110.526 168.109 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -93.98 167.98 11.25 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.052 1.741 . . . . 0.0 113.297 175.374 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -65.96 87.77 0.1 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.511 3.124 . . . . 0.0 109.596 170.115 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 74.2 177.96 0.22 Allowed 'General case' 0 C--N 1.347 0.491 0 CA-C-O 123.072 1.415 . . . . 0.0 112.848 168.884 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -95.23 -4.28 61.22 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 125.435 1.493 . . . . 0.0 111.143 168.128 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -66.98 64.79 0.06 Allowed 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 128.844 2.858 . . . . 0.0 109.817 169.261 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 167.53 -39.02 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.505 2.722 . . . . 0.0 114.714 179.364 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.36 0.5 OUTLIER 55.02 -58.48 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 130.303 3.441 . . . . 0.0 116.327 -174.829 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -68.47 4.22 1.45 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.264 1.426 . . . . 0.0 113.916 179.746 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.89 -126.36 36.71 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 124.91 1.243 . . . . 0.0 111.394 171.023 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.66 -8.48 0.39 Allowed 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 117.302 2.334 . . . . 0.0 117.302 -171.753 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.9 t -107.31 -2.13 20.99 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.544 1.52 . . . . 0.0 114.815 171.522 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.6 m -119.01 -37.83 3.16 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.641 1.576 . . . . 0.0 112.699 173.212 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.57 170.87 15.35 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.2 1.8 . . . . 0.0 110.869 175.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -109.8 -69.81 0.63 Allowed Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.549 1.38 . . . . 0.0 116.549 -168.637 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -87.07 -174.16 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.47 1 C-N-CA 125.473 4.115 . . . . 0.0 114.234 -169.407 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -104.01 132.38 50.32 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 127.666 2.386 . . . . 0.0 111.781 -175.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -46.9 114.11 0.78 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.579 1.552 . . . . 0.0 111.484 168.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 54.0 p30 -112.3 32.04 0.11 Allowed Pre-proline 0 CA--C 1.555 1.148 0 N-CA-C 116.734 2.124 . . . . 0.0 116.734 -167.944 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -56.63 -23.12 47.22 Favored 'Trans proline' 0 C--N 1.354 0.86 0 C-N-CA 124.915 3.743 . . . . 0.0 117.319 -164.957 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -78.39 -0.41 29.02 Favored 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 174.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.7 t 66.58 55.5 0.79 Allowed 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 126.886 2.074 . . . . 0.0 110.318 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -143.36 170.99 14.74 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -165.93 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.506 ' HZ1' ' CD ' ' A' ' 78' ' ' GLU 0.31 0.0 OUTLIER -85.43 -178.64 6.76 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.365 1.866 . . . . 0.0 113.514 172.79 . . . . . . . . 4 4 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.42 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 78.2 t60 -99.42 139.78 34.58 Favored 'General case' 0 C--O 1.22 -0.487 0 C-N-CA 125.876 1.67 . . . . 0.0 112.747 -170.806 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.89 -143.95 11.38 Favored Glycine 0 C--N 1.34 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 113.902 173.808 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.06 -75.93 0.21 Allowed Glycine 0 CA--C 1.535 1.293 0 N-CA-C 118.594 2.198 . . . . 0.0 118.594 -175.989 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -70.85 -11.73 29.82 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.954 2.436 . . . . 0.0 113.054 -171.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -130.05 -0.78 4.67 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.684 1.593 . . . . 0.0 111.238 168.25 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.73 122.97 25.37 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 124.053 1.882 . . . . 0.0 111.801 -167.564 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.1 -27.77 69.62 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 129.815 3.246 . . . . 0.0 111.717 169.115 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.506 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 51.8 mm-40 -88.31 76.35 8.38 Favored 'General case' 0 C--O 1.214 -0.776 0 C-N-CA 126.319 1.848 . . . . 0.0 108.192 177.613 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.6 ttt180 -111.51 110.64 21.17 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 129.599 3.16 . . . . 0.0 109.022 -178.464 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -59.95 159.9 8.57 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 119.385 0.993 . . . . 0.0 112.597 169.925 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 m -43.1 -57.37 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -173.161 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.2 31.53 8.54 Favored Glycine 0 N--CA 1.472 1.067 0 C-N-CA 125.064 1.316 . . . . 0.0 113.298 172.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -76.94 121.97 24.21 Favored 'General case' 0 C--O 1.237 0.408 0 O-C-N 120.942 -1.328 . . . . 0.0 108.253 169.744 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -95.76 176.82 5.99 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 112.854 -1.975 . . . . 0.0 109.149 167.525 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.73 23.99 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 124.305 0.955 . . . . 0.0 113.371 -175.341 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -83.9 126.19 32.74 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 121.675 -0.897 . . . . 0.0 108.91 167.843 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.98 170.59 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 164.235 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 t -145.02 127.73 16.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 124.683 1.193 . . . . 0.0 109.751 174.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.2 144.85 26.64 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 113.183 0.809 . . . . 0.0 113.183 174.417 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -67.47 170.96 6.65 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.191 1.796 . . . . 0.0 110.946 168.528 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.76 -32.15 29.61 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.753 1.221 . . . . 0.0 112.854 168.527 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -73.41 -15.49 61.35 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.938 1.695 . . . . 0.0 112.283 177.123 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.22 14.47 64.13 Favored Glycine 0 CA--C 1.527 0.808 0 O-C-N 120.832 -1.167 . . . . 0.0 113.43 179.167 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.6 p -96.71 125.22 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 124.226 1.011 . . . . 0.0 109.916 168.209 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.69 122.0 43.09 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 168.229 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -88.99 145.29 25.59 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 123.089 1.423 . . . . 0.0 110.145 -179.314 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.77 125.69 74.56 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.002 172.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.4 m -155.13 85.77 1.09 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.126 1.77 . . . . 0.0 108.67 -173.121 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 12.9 mt -140.13 154.64 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 127.308 2.243 . . . . 0.0 111.53 -169.208 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -140.91 144.86 35.44 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.593 1.557 . . . . 0.0 108.233 168.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.98 144.84 21.59 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.624 1.169 . . . . 0.0 113.386 -166.821 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 55.2 p -116.7 49.37 1.17 Allowed 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -179.687 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.2 m -149.06 16.23 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 176.055 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.35 168.69 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 120.49 -1.381 . . . . 0.0 111.037 171.295 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.537 ' H ' ' HB3' ' A' ' 111' ' ' SER . 86.3 p -154.91 161.24 41.49 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.265 -0.897 . . . . 0.0 112.602 169.144 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.53 50.89 1.66 Allowed 'General case' 0 CA--C 1.542 0.636 0 O-C-N 121.15 -0.969 . . . . 0.0 111.44 175.732 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.1 t -87.85 -40.91 13.62 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.436 1.094 . . . . 0.0 112.925 178.725 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.46 12.27 38.95 Favored Glycine 0 N--CA 1.478 1.494 0 N-CA-C 115.535 0.974 . . . . 0.0 115.535 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -89.54 -92.71 0.12 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.581 2.352 . . . . 0.0 111.006 -179.672 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.3 m170 -96.65 -24.96 15.75 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 126.585 1.954 . . . . 0.0 109.291 174.283 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.537 ' HB3' ' H ' ' A' ' 105' ' ' SER . 53.4 m -79.16 -142.14 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.07 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -168.001 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.7 pt -94.98 -21.46 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -166.414 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mm -63.75 141.97 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.811 1.187 . . . . 0.0 109.666 170.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.13 28.08 62.93 Favored Glycine 0 CA--C 1.503 -0.663 0 CA-C-O 116.701 -2.166 . . . . 0.0 113.446 177.475 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 84.7 mtt-85 -129.78 178.31 6.61 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.532 1.666 . . . . 0.0 108.515 171.741 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 89.4 m -117.19 145.36 43.91 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 119.328 0.967 . . . . 0.0 110.02 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.1 tp -108.31 134.14 51.55 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 119.074 0.852 . . . . 0.0 109.511 169.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -110.33 144.62 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.822 1.649 . . . . 0.0 110.643 172.619 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.99 142.24 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.903 1.281 . . . . 0.0 110.226 170.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.401 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 44.9 m-70 -119.2 147.14 44.56 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.656 1.583 . . . . 0.0 114.563 -166.523 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -85.34 -17.29 37.23 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -166.73 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.9 169.48 8.89 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 120.087 -1.633 . . . . 0.0 111.082 172.718 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.6 133.6 55.84 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 168.727 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 40.2 t0 -83.36 154.03 24.26 Favored 'General case' 0 CA--C 1.54 0.571 0 O-C-N 123.272 0.357 . . . . 0.0 110.293 169.435 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -75.58 -50.9 14.16 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 165.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.2 mt 94.79 63.08 0.0 OUTLIER 'General case' 0 C--O 1.222 -0.358 0 C-N-CA 129.296 3.039 . . . . 0.0 109.299 -178.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.7 -25.63 16.58 Favored Glycine 0 N--CA 1.481 1.635 0 N-CA-C 117.069 1.588 . . . . 0.0 117.069 167.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -118.35 -144.96 0.37 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.181 1.792 . . . . 0.0 110.897 172.148 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.08 7.97 60.62 Favored Glycine 0 CA--C 1.536 1.352 0 O-C-N 120.356 -1.465 . . . . 0.0 113.23 -168.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.47 31.41 68.32 Favored Glycine 0 N--CA 1.472 1.057 0 N-CA-C 116.996 1.558 . . . . 0.0 116.996 167.802 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -150.1 172.6 15.01 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 119.856 1.828 . . . . 0.0 113.108 -173.514 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -47.91 -58.69 4.07 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.953 1.701 . . . . 0.0 112.938 176.599 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -65.1 -17.01 64.1 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.165 0.986 . . . . 0.0 113.433 -173.246 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.5 p -53.52 -45.74 69.85 Favored 'General case' 0 N--CA 1.469 0.494 0 O-C-N 120.824 -1.173 . . . . 0.0 113.089 174.245 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -96.31 -6.86 36.79 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.875 0.87 . . . . 0.0 112.018 -178.861 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.93 -48.2 5.52 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.708 1.14 . . . . 0.0 112.618 176.605 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 19.9 p -114.61 -25.14 8.44 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 174.867 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.42 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 121.97 -30.73 5.18 Favored Glycine 0 C--O 1.228 -0.226 0 C-N-CA 126.09 1.805 . . . . 0.0 112.356 -168.061 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 114.08 2.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 131.601 3.96 . . . . 0.0 112.645 -174.566 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.5 1.27 0.02 OUTLIER 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 120.251 3.426 . . . . 0.0 120.251 -168.692 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.59 -32.68 0.17 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 120.985 3.154 . . . . 0.0 120.985 165.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.0 m -167.4 141.36 3.64 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 120.272 2.036 . . . . 0.0 111.581 -172.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.53 134.68 54.83 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.741 1.155 . . . . 0.0 112.214 178.319 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -110.36 -22.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.08 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.71 161.19 13.25 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 119.95 1.25 . . . . 0.0 112.46 -177.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.9 p -155.47 166.76 32.55 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.332 1.453 . . . . 0.0 112.763 172.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.44 136.84 4.83 Favored Glycine 0 N--CA 1.48 1.579 0 C-N-CA 125.287 1.422 . . . . 0.0 113.583 177.168 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -83.6 133.48 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.469 1.108 . . . . 0.0 110.641 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.49 110.13 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.023 0.929 . . . . 0.0 111.301 -172.016 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.74 170.14 13.31 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 122.76 1.2 . . . . 0.0 113.916 173.268 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.0 pp -91.25 164.03 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.672 1.189 . . . . 0.0 112.137 -174.258 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.48 ' HA ' ' CD1' ' B' ' 50' ' ' PHE . . . -155.53 -20.61 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 167.072 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.476 0.832 0 C-N-CA 124.521 1.128 . . . . 0.0 110.166 170.366 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.7 t -80.26 118.78 22.23 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 167.507 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.87 121.37 45.09 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -178.885 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.03 166.2 11.38 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.861 1.264 . . . . 0.0 110.794 168.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.74 146.07 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 125.477 1.511 . . . . 0.0 111.903 -166.722 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.0 101.2 3.99 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 123.756 0.822 . . . . 0.0 111.269 169.621 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -84.02 95.5 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 168.031 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.4 mt -81.34 140.25 34.88 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 122.784 0.434 . . . . 0.0 110.78 -177.043 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 9.0 mtpp -149.24 179.26 8.05 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 121.166 -0.959 . . . . 0.0 112.81 170.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.43 -70.79 0.29 Allowed Glycine 0 C--N 1.335 0.505 0 C-N-CA 126.393 1.949 . . . . 0.0 111.238 178.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -87.09 78.83 8.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.78 0.8 . . . . 0.0 112.715 -165.373 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 49.09 -104.22 0.09 OUTLIER Glycine 0 CA--C 1.534 1.249 0 C-N-CA 126.565 2.031 . . . . 0.0 112.623 171.514 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -80.01 -1.2 11.24 Favored 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 125.181 3.921 . . . . 0.0 114.176 -179.24 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.49 134.62 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 119.715 1.143 . . . . 0.0 110.8 171.84 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -135.51 161.92 34.13 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 125.843 1.657 . . . . 0.0 109.939 168.231 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.5 144.8 16.44 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 167.205 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -142.18 102.04 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -122.4 137.6 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 C-N-CA 123.957 0.903 . . . . 0.0 109.394 -179.76 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.36 152.41 34.99 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.058 2.143 . . . . 0.0 109.147 172.131 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -138.89 89.29 2.35 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.215 1.806 . . . . 0.0 107.66 -174.81 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.8 120.31 33.9 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 118.084 0.402 . . . . 0.0 110.07 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -112.52 141.46 46.25 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 122.578 1.18 . . . . 0.0 112.18 174.41 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.409 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -86.36 -26.8 24.64 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 126.571 1.949 . . . . 0.0 114.18 -179.66 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.409 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 5.8 mp0 -122.94 -174.11 2.86 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.235 2.214 . . . . 0.0 109.885 174.506 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.2 m -98.52 -14.5 19.97 Favored 'General case' 0 N--CA 1.481 1.099 0 O-C-N 120.54 -1.35 . . . . 0.0 111.639 167.08 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -139.47 105.55 5.22 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.198 2.599 . . . . 0.0 107.181 169.34 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.61 -168.42 41.49 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 126.066 1.794 . . . . 0.0 110.637 -170.784 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -85.57 150.61 10.19 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.529 2.153 . . . . 0.0 111.848 -179.268 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 10.2 t -119.36 129.32 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.135 1.374 . . . . 0.0 110.111 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.6 ttmm -93.53 120.89 34.35 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.091 0.948 . . . . 0.0 110.514 174.47 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.3 t -106.25 112.54 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 C-N-CA 126.321 1.848 . . . . 0.0 108.046 -171.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -137.74 161.18 37.22 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -177.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 136.62 -139.72 10.87 Favored Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.533 1.539 . . . . 0.0 111.351 175.62 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 47.3 p -156.47 156.73 34.24 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 114.711 1.375 . . . . 0.0 114.711 -174.862 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 24.7 mm -123.43 126.64 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 168.692 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . 0.282 3.5 ptmt -140.33 157.21 45.91 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 115.313 1.597 . . . . 0.0 115.313 -177.534 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.23 6.4 33.9 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 127.103 2.287 . . . . 0.0 111.916 -167.872 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mt -94.79 172.27 8.27 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.992 1.317 . . . . 0.0 111.769 -172.751 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.27 150.65 36.95 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 165.427 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -53.3 -0.27 0.02 OUTLIER 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 129.796 3.238 . . . . 0.0 115.86 170.63 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -69.46 177.28 29.96 Favored Glycine 0 CA--C 1.537 1.43 0 O-C-N 120.149 -1.594 . . . . 0.0 113.605 169.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mp -78.37 160.0 28.04 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.381 1.472 . . . . 0.0 108.727 168.452 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -149.64 109.72 4.13 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.761 2.424 . . . . 0.0 109.857 -170.155 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.56 130.22 17.69 Favored Glycine 0 N--CA 1.477 1.37 0 CA-C-N 119.938 1.244 . . . . 0.0 111.864 176.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -125.62 137.73 53.89 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 120.151 1.976 . . . . 0.0 113.419 174.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.86 144.49 29.33 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.201 -0.937 . . . . 0.0 113.325 -176.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -81.27 136.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 166.075 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -74.74 168.4 19.92 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.826 1.25 . . . . 0.0 110.833 175.619 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.1 pm0 -59.61 -14.83 15.07 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -169.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . 0.48 ' CD1' ' HA ' ' A' ' 152' ' ' ALA . 31.3 m-85 -169.83 -179.26 3.21 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 129.147 2.979 . . . . 0.0 108.216 -168.849 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -125.92 11.32 7.39 Favored Glycine 0 N--CA 1.475 1.291 0 C-N-CA 125.505 1.526 . . . . 0.0 113.89 179.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -73.5 45.02 0.17 Allowed 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.755 1.222 . . . . 0.0 110.347 167.076 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -173.55 55.72 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 123.693 1.711 . . . . 0.0 114.726 -162.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 1.1 t . . . . . 0 CA--C 1.547 0.832 0 C-N-CA 126.592 1.957 . . . . 0.0 114.492 -179.647 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.535 0 CA-C-O 120.982 0.42 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -62.92 123.17 29.64 Favored Glycine 0 CA--C 1.543 1.843 0 CA-C-O 116.943 -2.032 . . . . 0.0 111.785 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.48 59.67 7.54 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 124.631 3.554 . . . . 0.0 116.632 -165.057 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.296 11.9 p80 52.7 59.01 4.78 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.19 2.596 . . . . 0.0 113.821 177.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . 0.413 ' CG ' ' N ' ' B' ' 65' ' ' ASN . 22.9 t80 -50.25 165.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 128.243 2.617 . . . . 0.0 114.938 177.553 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . 0.413 ' N ' ' CG ' ' B' ' 64' ' ' PHE . 1.0 OUTLIER -100.19 60.12 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.425 0 C-N-CA 131.296 3.838 . . . . 0.0 114.058 -170.078 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.02 -26.59 66.01 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.747 2.298 . . . . 0.0 113.764 -176.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.34 -2.49 58.63 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 126.627 1.971 . . . . 0.0 113.165 172.696 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.5 t 59.43 49.75 8.36 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.564 1.946 . . . . 0.0 112.447 -173.201 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -117.17 170.41 8.69 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.264 1.209 . . . . 0.0 114.264 -179.607 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.18 164.82 26.13 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-O 122.75 1.262 . . . . 0.0 109.325 166.29 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.547 ' CG ' ' H ' ' B' ' 72' ' ' GLY . 83.4 t60 -67.36 -176.17 0.56 Allowed 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.223 167.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . 0.547 ' H ' ' CG ' ' B' ' 71' ' ' HIS . . . 115.17 -128.93 8.32 Favored Glycine 0 CA--C 1.502 -0.723 0 N-CA-C 115.252 0.861 . . . . 0.0 115.252 164.305 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.05 -76.32 0.34 Allowed Glycine 0 CA--C 1.531 1.061 0 CA-C-O 118.002 -1.443 . . . . 0.0 111.749 -169.586 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.64 10.07 0.23 Allowed 'Trans proline' 0 CA--C 1.547 1.134 0 C-N-CA 124.302 3.335 . . . . 0.0 116.614 -178.766 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.5 tptm -166.07 -30.61 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.264 1.426 . . . . 0.0 112.48 -168.427 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -125.03 119.12 27.79 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.579 1.552 . . . . 0.0 108.148 167.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -46.31 -17.86 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 130.156 3.383 . . . . 0.0 116.418 -174.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -85.36 -79.61 0.23 Allowed 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -169.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . 0.486 ' HB3' HH11 ' B' ' 79' ' ' ARG . 1.1 ttp-105 78.42 110.71 0.07 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.734 1.614 . . . . 0.0 109.731 177.199 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -50.08 152.17 1.76 Allowed 'General case' 0 CA--C 1.549 0.937 0 O-C-N 120.566 -1.334 . . . . 0.0 113.494 172.224 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.7 t -52.82 -37.74 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 123.966 0.906 . . . . 0.0 112.434 176.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.78 96.79 1.21 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 108.264 -1.934 . . . . 0.0 108.264 167.345 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -156.2 146.29 21.36 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.96 1.304 . . . . 0.0 113.446 171.249 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 48.2 mt -130.82 167.06 19.52 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.203 1.801 . . . . 0.0 106.981 166.802 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -104.99 -161.82 23.8 Favored Glycine 0 N--CA 1.475 1.247 0 C-N-CA 124.67 1.128 . . . . 0.0 112.593 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -79.37 164.63 23.89 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 -177.283 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 p -125.99 157.29 36.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 C-N-CA 129.0 2.92 . . . . 0.0 108.524 166.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -135.15 133.72 39.44 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.068 0.947 . . . . 0.0 109.799 -177.205 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.05 158.49 15.41 Favored 'General case' 0 C--O 1.222 -0.347 0 N-CA-C 114.065 1.135 . . . . 0.0 114.065 -172.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -97.63 155.47 16.97 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.645 1.578 . . . . 0.0 108.718 166.406 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 6.2 pttm -47.2 -25.32 0.89 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 128.936 2.894 . . . . 0.0 115.249 -177.5 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.67 3.23 10.07 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.319 1.448 . . . . 0.0 110.986 178.294 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.18 2.42 60.68 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 129.765 3.555 . . . . 0.0 113.726 172.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.2 p -114.64 131.92 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-N 119.937 1.869 . . . . 0.0 114.889 -168.36 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.37 128.8 44.94 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.003 -1.453 . . . . 0.0 108.728 166.236 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -82.27 146.33 29.51 Favored 'General case' 0 N--CA 1.46 0.073 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 168.005 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.263 0.3 OUTLIER -129.36 135.62 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 114.289 -1.323 . . . . 0.0 114.252 166.285 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 2.9 p -157.2 57.13 0.52 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 125.591 1.556 . . . . 0.0 110.759 -169.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.3 mt -109.04 166.55 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 127.654 2.381 . . . . 0.0 111.593 -169.746 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -148.39 149.82 32.43 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 127.753 2.421 . . . . 0.0 109.081 171.881 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -146.63 145.46 30.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.36 1.464 . . . . 0.0 110.108 172.051 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.8 p -118.61 58.6 0.83 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.94 2.096 . . . . 0.0 113.041 -168.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 5.9 p -159.34 -37.18 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 113.27 0.841 . . . . 0.0 113.27 172.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.69 166.79 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-O 121.327 0.584 . . . . 0.0 110.773 171.444 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 36.8 m -156.57 175.8 13.55 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 120.752 -1.218 . . . . 0.0 112.615 178.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.6 mp -92.61 76.35 5.02 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.664 1.586 . . . . 0.0 107.448 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.27 122.7 32.3 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.359 1.463 . . . . 0.0 108.077 -176.409 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.99 59.68 4.97 Favored Glycine 0 N--CA 1.471 1.021 0 C-N-CA 125.152 1.358 . . . . 0.0 112.976 -169.721 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -156.26 -76.62 0.09 Allowed 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 124.467 1.107 . . . . 0.0 110.347 -168.704 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 m170 -129.66 4.88 5.06 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 126.979 2.111 . . . . 0.0 112.559 -167.625 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.6 -151.92 0.47 Allowed 'General case' 0 CA--C 1.555 1.173 0 C-N-CA 127.651 2.381 . . . . 0.0 112.835 -166.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.8 pt -95.88 -5.35 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 118.718 -2.488 . . . . 0.0 115.657 -177.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.2 mm -67.4 129.28 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 165.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 66.41 51.25 44.33 Favored Glycine 0 C--O 1.225 -0.439 0 CA-C-O 117.854 -1.526 . . . . 0.0 112.541 178.043 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 25.7 mtt180 -129.19 145.61 51.28 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 118.346 1.073 . . . . 0.0 110.095 167.332 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 24.6 m -86.86 108.91 18.97 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 124.378 1.071 . . . . 0.0 109.628 -171.886 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 14.6 tp -91.6 125.07 36.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 120.441 1.473 . . . . 0.0 110.854 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -110.82 142.27 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.584 1.553 . . . . 0.0 110.315 170.424 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 59.0 t -112.74 144.07 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 165.338 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -109.76 160.9 15.93 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 126.584 1.953 . . . . 0.0 112.182 -172.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.265 1.8 pp20? -82.43 -17.77 44.2 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -172.09 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -113.97 172.87 6.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 176.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.16 164.31 1.77 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 124.475 1.11 . . . . 0.0 109.899 166.789 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.2 p30 -113.66 147.12 38.7 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 123.237 1.494 . . . . 0.0 112.531 170.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -86.86 -22.69 25.62 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.134 1.374 . . . . 0.0 111.077 171.749 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 54.9 mt 71.41 -29.63 0.2 Allowed 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 128.765 2.826 . . . . 0.0 114.503 169.506 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -159.52 -47.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.701 0 CA-C-N 120.844 1.657 . . . . 0.0 114.594 174.052 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.08 100.21 2.9 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 117.254 2.316 . . . . 0.0 117.254 -168.465 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.17 -76.84 1.34 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 107.131 -2.388 . . . . 0.0 107.131 166.687 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -179.52 27.83 0.05 OUTLIER Glycine 0 CA--C 1.532 1.103 0 C-N-CA 126.382 1.944 . . . . 0.0 112.956 175.946 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -146.34 172.84 12.89 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.998 1.719 . . . . 0.0 111.08 -167.309 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -64.58 -63.06 1.22 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 110.814 -170.453 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.18 -23.64 36.39 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 128.935 2.894 . . . . 0.0 111.916 -173.558 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 52.2 m -53.58 -49.82 66.93 Favored 'General case' 0 N--CA 1.462 0.14 0 C-N-CA 123.721 0.808 . . . . 0.0 112.425 168.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 44.2 p -91.21 -34.5 14.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.158 1.383 . . . . 0.0 110.699 -174.375 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -81.9 -31.74 31.29 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.143 2.177 . . . . 0.0 113.085 -171.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.8 p -125.24 -93.3 0.5 Allowed 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 169.281 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -174.0 22.22 0.06 OUTLIER Glycine 0 CA--C 1.53 1.019 0 C-N-CA 128.647 3.022 . . . . 0.0 111.58 169.688 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 56.67 4.04 0.14 Allowed 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 127.83 2.452 . . . . 0.0 116.545 -169.307 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.98 -5.88 0.03 OUTLIER 'General case' 0 CA--C 1.557 1.226 0 N-CA-C 119.865 3.284 . . . . 0.0 119.865 -168.337 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 88.12 -165.95 34.85 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.718 1.628 . . . . 0.0 113.661 -176.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 18.7 t -66.86 160.61 25.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 122.14 0.971 . . . . 0.0 111.284 173.598 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.7 ptt85 -67.38 164.16 19.19 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 122.356 1.074 . . . . 0.0 111.684 169.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.316 2.9 pp -135.55 -134.7 0.15 Allowed 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 104.229 -2.508 . . . . 0.0 104.229 160.175 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.75 154.88 8.41 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-N 120.536 1.516 . . . . 0.0 114.678 -178.697 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.1 t -151.0 143.94 24.58 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.658 1.983 . . . . 0.0 111.212 -172.677 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.29 144.25 9.51 Favored Glycine 0 N--CA 1.477 1.39 0 C-N-CA 125.507 1.527 . . . . 0.0 113.465 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 20.5 t -83.47 141.57 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 CA-C-N 119.268 1.534 . . . . 0.0 110.592 177.451 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 73.8 mt -75.32 106.76 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 121.473 0.654 . . . . 0.0 109.65 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.7 -172.87 19.36 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 124.387 0.994 . . . . 0.0 111.793 168.174 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -100.01 149.24 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.87 0.843 . . . . 0.0 112.726 -176.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -103.22 -135.21 0.33 Allowed 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 166.62 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 N--CA 1.473 0.701 0 C-N-CA 126.001 1.72 . . . . 0.0 110.983 168.881 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.475 0.82 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 42.8 pttt -83.12 139.49 33.16 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.933 1.349 . . . . 0.0 114.212 -172.042 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.08 146.03 26.51 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 127.369 2.268 . . . . 0.0 107.753 167.409 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 33.0 t -154.95 143.54 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 119.567 1.076 . . . . 0.0 110.993 -175.2 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.87 95.63 2.88 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 123.767 0.827 . . . . 0.0 110.504 169.116 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.8 m -76.15 92.7 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-O 122.127 0.965 . . . . 0.0 109.618 170.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.2 mt -76.52 139.01 40.59 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.006 0.922 . . . . 0.0 109.553 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.6 ttmm -155.45 177.62 11.16 Favored 'General case' 0 CA--C 1.542 0.672 0 O-C-N 120.753 -1.217 . . . . 0.0 109.765 179.648 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.03 -33.83 3.91 Favored Glycine 0 N--CA 1.472 1.076 0 C-N-CA 124.279 0.942 . . . . 0.0 114.341 169.16 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.85 65.7 5.09 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 122.299 1.047 . . . . 0.0 110.146 175.905 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.06 -101.94 0.03 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.081 2.753 . . . . 0.0 113.146 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -83.24 -2.84 10.79 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 124.66 3.573 . . . . 0.0 114.441 -178.346 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -95.28 137.42 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 CA-C-N 120.697 1.59 . . . . 0.0 111.156 176.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -144.56 161.86 38.05 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 125.918 1.687 . . . . 0.0 109.697 172.321 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.452 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -134.63 106.18 0.59 Allowed Glycine 0 CA--C 1.502 -0.723 0 C-N-CA 124.34 0.971 . . . . 0.0 111.314 177.779 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.2 117.47 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 167.862 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -135.9 106.94 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-O 121.616 0.722 . . . . 0.0 109.369 169.293 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 -100.22 139.7 35.52 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.687 1.595 . . . . 0.0 110.885 -179.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -120.46 135.56 55.02 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 119.091 0.86 . . . . 0.0 110.85 179.206 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -115.1 114.86 25.88 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 127.078 2.151 . . . . 0.0 109.852 -172.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.8 tp60 -125.92 130.9 52.21 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 113.51 -1.677 . . . . 0.0 109.828 -170.398 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.516 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -99.33 -11.74 20.94 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 128.147 2.579 . . . . 0.0 114.129 -168.771 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.488 ' CD ' ' H ' ' A' ' 25' ' ' SER . 5.3 tm-20 -149.25 -172.02 4.03 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 127.918 2.487 . . . . 0.0 108.681 -172.376 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.488 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 0.8 OUTLIER -72.34 -57.18 4.41 Favored 'General case' 0 N--CA 1.474 0.726 0 O-C-N 118.778 -2.451 . . . . 0.0 111.601 169.677 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -123.37 -3.16 8.43 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.73 1.612 . . . . 0.0 114.918 -169.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.36 161.48 6.98 Favored Glycine 0 CA--C 1.537 1.446 0 CA-C-N 119.224 0.92 . . . . 0.0 110.955 168.372 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -66.85 143.94 68.94 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.327 2.018 . . . . 0.0 110.61 -170.035 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 37.3 t -107.62 129.87 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 123.262 0.625 . . . . 0.0 110.158 -173.159 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -79.64 125.77 30.05 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 49.9 t -112.42 130.73 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 128.456 2.703 . . . . 0.0 108.154 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -155.41 165.79 35.54 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 119.577 1.081 . . . . 0.0 113.249 175.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.27 -155.95 26.76 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 123.902 0.763 . . . . 0.0 113.655 172.726 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.9 p -149.53 128.36 12.53 Favored 'General case' 0 C--O 1.239 0.528 0 C-N-CA 123.319 0.648 . . . . 0.0 112.367 -169.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.452 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.0 mp -104.52 106.6 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 123.697 0.799 . . . . 0.0 109.599 175.371 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 tttp -117.14 133.64 55.75 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.38 1.072 . . . . 0.0 112.894 -168.903 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.56 9.37 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 128.318 2.866 . . . . 0.0 113.623 -177.621 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.8 mt -77.86 174.71 10.74 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.097 2.159 . . . . 0.0 113.37 -175.862 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.36 148.71 22.13 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 162.284 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.574 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.0 OUTLIER -53.79 -2.01 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 129.222 3.009 . . . . 0.0 115.825 176.065 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.31 174.34 17.46 Favored Glycine 0 CA--C 1.536 1.404 0 O-C-N 120.251 -1.531 . . . . 0.0 113.29 169.212 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.489 ' H ' HD22 ' A' ' 42' ' ' LEU . 2.0 pt? -88.31 138.17 31.67 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.778 2.031 . . . . 0.0 109.997 171.053 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -130.87 149.23 52.6 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 129.018 2.927 . . . . 0.0 108.615 -171.723 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -112.09 135.09 12.48 Favored Glycine 0 N--CA 1.486 1.991 0 CA-C-O 116.861 -2.077 . . . . 0.0 111.405 -172.554 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -135.74 133.28 37.85 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 121.165 2.482 . . . . 0.0 114.956 179.073 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.42 26.77 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.027 1.331 . . . . 0.0 109.801 -170.781 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.51 HG21 ' H ' ' A' ' 116' ' ' THR . 0.3 OUTLIER -86.33 118.35 32.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.263 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.742 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.0 m170 -77.71 163.03 26.53 Favored 'General case' 0 CA--C 1.549 0.931 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 176.157 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.18 133.97 55.93 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.816 -0.553 . . . . 0.0 110.745 -176.83 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.466 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 43.0 m-85 71.02 165.32 0.29 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.612 2.365 . . . . 0.0 115.348 170.123 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.44 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -116.21 -3.55 19.16 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 126.434 1.969 . . . . 0.0 113.654 177.684 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.0 m-20 -72.91 46.79 0.17 Allowed 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.076 1.35 . . . . 0.0 110.59 170.015 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.44 ' H ' ' C ' ' A' ' 51' ' ' GLY . 0.3 OUTLIER 174.45 40.1 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.635 2.374 . . . . 0.0 112.747 -167.541 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.0 t -53.71 19.97 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 129.78 3.232 . . . . 0.0 116.375 172.285 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.63 16.41 8.8 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 126.699 2.0 . . . . 0.0 112.715 -178.293 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.6 -144.02 41.42 Favored Glycine 0 N--CA 1.467 0.752 0 O-C-N 121.087 -1.008 . . . . 0.0 112.097 171.12 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 p -58.69 -23.24 59.12 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.748 1.018 . . . . 0.0 113.748 -178.011 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 13.0 t -90.52 42.64 1.11 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.364 1.066 . . . . 0.0 112.019 175.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 m 178.57 -35.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 129.577 3.151 . . . . 0.0 115.091 169.606 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.53 158.98 15.36 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -168.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.97 -153.93 17.76 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 126.004 1.764 . . . . 0.0 114.223 173.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -88.58 178.39 2.88 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 125.281 3.987 . . . . 0.0 112.107 -179.496 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.418 ' CE1' ' ND1' ' A' ' 71' ' ' HIS . 3.4 p80 -79.91 83.55 5.81 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 167.062 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -50.94 166.03 0.1 Allowed 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.34 2.256 . . . . 0.0 113.993 -174.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -108.11 57.84 0.23 Allowed Pre-proline 0 CA--C 1.552 1.031 0 C-N-CA 127.202 2.201 . . . . 0.0 112.25 -169.712 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -64.32 -28.82 63.52 Favored 'Trans proline' 0 C--N 1.354 0.838 0 CA-C-N 122.602 1.965 . . . . 0.0 113.272 -175.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.8 mp -82.13 -4.9 57.9 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.077 1.351 . . . . 0.0 113.171 170.533 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.8 t 65.37 54.15 1.2 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 127.242 2.217 . . . . 0.0 112.894 -175.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -121.51 174.37 6.82 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -170.912 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.7 mtmt -81.04 165.92 21.23 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.494 0.718 . . . . 0.0 110.719 167.18 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.428 ' CG ' ' H ' ' A' ' 72' ' ' GLY . 73.8 t60 -71.02 175.21 5.35 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.643 0.735 . . . . 0.0 111.645 167.758 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.428 ' H ' ' CG ' ' A' ' 71' ' ' HIS . . . 133.15 -138.16 9.92 Favored Glycine 0 CA--C 1.504 -0.599 0 C-N-CA 124.295 0.95 . . . . 0.0 112.173 167.629 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.78 -99.95 0.26 Allowed Glycine 0 CA--C 1.533 1.202 0 CA-C-O 115.811 -2.661 . . . . 0.0 109.845 -178.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -56.69 0.45 0.19 Allowed 'Trans proline' 0 CA--C 1.549 1.255 0 C-N-CA 124.126 3.218 . . . . 0.0 117.983 -178.742 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.0 pttt -134.86 -4.32 2.49 Favored 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.332 1.424 . . . . 0.0 114.276 167.339 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -155.82 112.11 3.11 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 126.051 1.74 . . . . 0.0 109.985 -175.555 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -62.21 -7.58 4.39 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -173.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -80.36 -9.02 59.74 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -173.048 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -17.36 118.53 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 129.446 3.098 . . . . 0.0 112.963 168.407 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.8 m80 -62.05 166.04 5.07 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.697 1.199 . . . . 0.0 111.61 177.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 32.5 m -76.33 29.58 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -178.469 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -148.28 9.99 1.13 Allowed Glycine 0 CA--C 1.532 1.096 0 C-N-CA 125.583 1.563 . . . . 0.0 115.166 -178.686 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -105.64 115.99 31.19 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.881 1.273 . . . . 0.0 113.209 -168.611 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.8 mp -91.2 170.7 9.79 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 163.459 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -79.79 -172.37 43.65 Favored Glycine 0 CA--C 1.529 0.941 0 O-C-N 121.372 -0.83 . . . . 0.0 112.238 171.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -78.42 144.11 36.15 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.422 -1.046 . . . . 0.0 112.512 172.6 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.3 p -114.51 139.43 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 128.003 2.521 . . . . 0.0 110.308 177.528 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.5 m -128.65 133.47 48.25 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.785 1.234 . . . . 0.0 110.586 -169.306 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.64 163.11 13.51 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 -176.2 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.43 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 31.4 t70 -83.32 169.8 15.26 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.106 1.362 . . . . 0.0 108.422 165.125 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.43 ' HZ2' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -62.02 -18.7 61.42 Favored 'General case' 0 N--CA 1.482 1.167 0 O-C-N 120.66 -1.275 . . . . 0.0 113.893 172.277 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -73.62 -3.03 25.52 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.59 1.556 . . . . 0.0 111.426 168.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.88 6.69 89.27 Favored Glycine 0 C--N 1.332 0.33 0 C-N-CA 126.155 1.836 . . . . 0.0 113.462 170.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -94.33 121.51 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 126.079 1.751 . . . . 0.0 111.541 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.89 99.12 10.42 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 167.148 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -79.9 143.86 33.9 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.543 1.537 . . . . 0.0 109.936 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.26 142.75 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 -176.503 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 p -149.89 109.98 4.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.417 1.487 . . . . 0.0 111.294 174.106 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.2 mt -138.08 158.73 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 127.295 2.238 . . . . 0.0 110.988 -171.157 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -145.39 144.33 30.6 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 126.353 1.861 . . . . 0.0 106.851 164.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -145.12 148.17 33.33 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 125.021 1.328 . . . . 0.0 110.597 179.373 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.32 49.69 0.95 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.674 0.789 . . . . 0.0 112.2 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.2 t -139.89 -47.7 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.211 1.404 . . . . 0.0 109.893 175.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -84.6 158.14 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-O 122.307 1.051 . . . . 0.0 113.201 175.592 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.9 p -157.03 171.51 20.33 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 115.316 1.599 . . . . 0.0 115.316 -171.614 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.01 80.25 9.1 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.41 1.484 . . . . 0.0 108.587 176.662 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 60.5 p -90.2 -170.95 2.94 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.564 0.697 . . . . 0.0 112.57 173.836 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.51 -43.77 5.12 Favored Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.363 0.982 . . . . 0.0 111.425 167.563 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 34.9 t0 -172.3 45.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.694 1.597 . . . . 0.0 111.787 -173.119 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -140.85 -40.53 0.4 Allowed 'General case' 0 N--CA 1.47 0.525 0 O-C-N 120.139 -1.601 . . . . 0.0 111.097 -172.16 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.9 m -90.67 -125.34 0.07 Allowed 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 127.988 2.515 . . . . 0.0 110.499 172.047 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.7 pt -102.7 -27.24 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 114.947 1.462 . . . . 0.0 114.947 -175.399 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 33.8 mm -60.46 138.23 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 168.374 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.67 8.25 73.84 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 117.366 -1.797 . . . . 0.0 113.631 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -122.17 174.12 7.16 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 119.913 1.856 . . . . 0.0 111.126 -174.17 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.51 ' H ' HG21 ' A' ' 47' ' ' VAL . 39.0 m -116.22 109.37 17.33 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.269 -1.519 . . . . 0.0 111.239 -163.328 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 33.9 tp -96.38 122.24 39.05 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.464 1.105 . . . . 0.0 110.64 -172.766 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 p -121.07 133.99 65.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.025 1.33 . . . . 0.0 108.839 175.203 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.3 t -90.67 152.64 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.225 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 165.053 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.03 138.55 54.43 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.745 2.018 . . . . 0.0 107.365 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.09 -46.3 79.08 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -167.256 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt -101.87 143.16 32.11 Favored 'General case' 0 C--N 1.329 -0.312 0 O-C-N 121.375 -0.828 . . . . 0.0 110.486 169.903 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.44 158.9 1.58 Allowed 'General case' 0 C--O 1.231 0.126 0 C-N-CA 125.027 1.331 . . . . 0.0 114.098 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -75.43 146.5 40.68 Favored 'General case' 0 N--CA 1.443 -0.823 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 165.599 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -68.54 -21.13 64.57 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.961 171.013 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.7 mt 85.33 -64.5 0.05 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 131.075 3.75 . . . . 0.0 108.582 -174.67 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.94 -75.75 0.98 Allowed Glycine 0 N--CA 1.464 0.559 0 C-N-CA 124.695 1.141 . . . . 0.0 110.887 -171.125 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -163.43 109.28 1.11 Allowed 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 168.583 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.44 21.74 0.69 Allowed Glycine 0 CA--C 1.545 1.965 0 C-N-CA 125.208 1.385 . . . . 0.0 116.509 172.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.25 10.94 73.43 Favored Glycine 0 N--CA 1.479 1.508 0 N-CA-C 118.551 2.18 . . . . 0.0 118.551 168.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.592 ' H ' ' HB3' ' A' ' 134' ' ' SER . 32.4 m-80 -127.24 179.47 5.43 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 119.872 1.836 . . . . 0.0 111.659 -173.559 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.31 -56.71 18.62 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 166.799 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.428 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 7.4 mm-40 -35.28 -31.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 128.839 2.855 . . . . 0.0 115.71 167.249 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.592 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 66.8 p -57.83 -24.44 57.44 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 117.435 2.383 . . . . 0.0 117.435 -166.842 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.282 3.4 t -133.02 -14.07 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 -179.203 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.2 ptmt -70.86 -47.37 59.69 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 120.297 1.408 . . . . 0.0 110.17 167.543 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.428 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 0.6 OUTLIER -105.24 -18.85 13.99 Favored 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.943 -177.326 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.23 5.86 67.14 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 124.144 0.878 . . . . 0.0 112.311 -168.426 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 74.72 2.42 4.04 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.451 2.301 . . . . 0.0 114.442 -170.296 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.66 106.26 0.76 Allowed 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 119.43 1.014 . . . . 0.0 111.398 -169.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -36.58 -7.44 0.0 OUTLIER Glycine 0 N--CA 1.493 2.439 1 C-N-CA 131.255 4.264 . . . . 0.0 122.836 -165.862 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 18.4 p 104.86 156.73 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 131.06 3.744 . . . . 0.0 113.315 166.556 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 61.85 131.32 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 117.826 2.528 . . . . 0.0 117.826 166.03 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 179.94 -165.83 0.07 Allowed 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 128.571 2.748 . . . . 0.0 108.451 168.171 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -55.98 151.47 11.77 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.975 1.31 . . . . 0.0 112.429 170.17 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.5 t -153.0 152.06 30.97 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.749 2.02 . . . . 0.0 112.573 -172.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.46 167.52 36.34 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 127.731 2.586 . . . . 0.0 110.716 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.9 p -98.5 141.78 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 CA-C-N 119.771 1.785 . . . . 0.0 109.382 169.632 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.3 mt -78.92 102.27 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 O-C-N 121.635 -0.666 . . . . 0.0 111.473 -175.266 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.32 177.2 29.65 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-O 122.601 1.112 . . . . 0.0 112.506 171.744 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -111.41 158.53 11.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 126.364 1.866 . . . . 0.0 110.993 175.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.29 -14.79 14.8 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.212 1.005 . . . . 0.0 112.228 167.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 . . . . . 0 C--O 1.237 0.419 0 C-N-CA 126.863 2.065 . . . . 0.0 108.377 -164.819 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.389 0 CA-C-O 121.842 0.83 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.4 t -118.53 130.28 55.83 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 124.357 1.063 . . . . 0.0 110.113 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -91.29 148.82 22.07 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 168.182 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.04 141.77 31.39 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 114.339 -1.3 . . . . 0.0 107.891 166.612 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 49.0 t -137.95 142.88 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 CA-C-O 121.675 0.75 . . . . 0.0 111.815 -169.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.1 132.29 55.99 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 122.437 1.113 . . . . 0.0 112.169 169.822 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -115.83 86.07 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 127.065 2.146 . . . . 0.0 107.027 169.642 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.61 117.32 17.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -158.03 134.24 9.42 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 119.279 0.945 . . . . 0.0 113.249 -170.297 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.07 -38.7 0.05 OUTLIER Glycine 0 N--CA 1.471 0.992 0 C-N-CA 125.659 1.6 . . . . 0.0 111.443 172.453 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.13 66.6 2.96 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 128.393 2.677 . . . . 0.0 112.188 -176.282 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.33 -102.48 0.05 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 127.111 2.291 . . . . 0.0 113.613 174.321 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -82.55 -11.85 10.34 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.907 3.072 . . . . 0.0 114.257 -176.845 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -91.13 136.08 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 CA-C-N 120.013 1.278 . . . . 0.0 110.124 -177.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.76 156.73 35.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.747 168.397 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -125.83 123.58 4.92 Favored Glycine 0 CA--C 1.503 -0.675 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.045 173.714 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.37 128.44 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 164.567 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.7 pp -136.34 134.77 49.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 164.279 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -106.25 151.48 24.74 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.107 1.363 . . . . 0.0 112.111 172.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -120.91 128.24 52.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.409 1.884 . . . . 0.0 112.165 169.772 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -104.08 112.42 25.41 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 128.885 2.874 . . . . 0.0 110.742 173.635 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -108.26 124.73 50.76 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.464 -0.773 . . . . 0.0 109.679 174.809 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.92 -42.06 21.96 Favored 'General case' 0 CA--C 1.551 0.996 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 176.045 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -134.56 133.72 40.57 Favored 'General case' 0 C--O 1.22 -0.485 0 C-N-CA 126.098 1.759 . . . . 0.0 109.989 170.269 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 97.9 p -70.48 79.17 0.56 Allowed 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 120.523 1.51 . . . . 0.0 113.278 -178.174 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.9 p30 158.47 -30.1 0.0 OUTLIER 'General case' 0 CA--C 1.548 0.871 1 C-N-CA 132.877 4.471 . . . . 0.0 111.176 -176.506 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.03 -172.92 43.06 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 126.099 1.809 . . . . 0.0 113.993 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -78.75 170.92 17.41 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 124.14 3.227 . . . . 0.0 112.444 -170.093 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 32.1 t -139.59 131.77 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 CA-C-O 121.482 0.658 . . . . 0.0 112.333 -167.753 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -87.48 129.06 35.21 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 167.594 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 t -110.5 138.84 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 126.322 1.849 . . . . 0.0 109.665 173.736 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 19.5 p90 -152.91 168.74 24.78 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.706 -0.621 . . . . 0.0 112.032 170.487 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.4 -161.94 29.36 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 114.757 0.663 . . . . 0.0 114.757 174.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 46.2 p -153.96 123.99 6.85 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.003 0.921 . . . . 0.0 111.631 -170.027 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . 0.413 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 2.7 mp -106.4 113.17 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 CA-C-O 117.709 -1.138 . . . . 0.0 111.388 177.169 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.0 mmmt -102.38 144.93 30.23 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 120.407 1.458 . . . . 0.0 109.374 -178.234 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.69 -4.23 14.81 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.232 1.396 . . . . 0.0 114.235 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -67.87 179.83 1.35 Allowed 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.367 1.067 . . . . 0.0 110.124 168.566 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -106.98 -32.27 7.95 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 117.763 -1.113 . . . . 0.0 113.892 172.108 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 173.39 -168.49 0.03 OUTLIER 'General case' 0 CA--C 1.556 1.207 1 C-N-CA 132.975 4.51 . . . . 0.0 105.174 178.876 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.5 161.96 28.43 Favored Glycine 0 CA--C 1.525 0.666 0 C-N-CA 126.1 1.809 . . . . 0.0 115.671 167.809 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.653 ' CD2' ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -66.33 150.29 49.08 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.261 2.625 . . . . 0.0 108.968 168.658 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -143.88 121.87 12.08 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.589 1.156 . . . . 0.0 111.945 179.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.02 147.13 41.88 Favored Glycine 0 N--CA 1.482 1.759 0 CA-C-N 119.934 1.243 . . . . 0.0 112.559 -179.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -150.25 111.06 4.3 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.071 1.349 . . . . 0.0 110.115 -173.812 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.89 152.78 35.61 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 119.8 -1.812 . . . . 0.0 114.587 -165.071 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.02 126.81 53.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-O 121.447 0.642 . . . . 0.0 111.336 -177.322 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -78.21 -179.31 6.13 Favored 'General case' 0 CA--C 1.544 0.717 1 C-N-CA 131.837 4.055 . . . . 0.0 114.444 -175.128 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . 0.415 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 1.2 pm0 -59.99 135.26 57.65 Favored 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 163.208 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.274 42.7 m-85 -0.29 -130.45 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.621 1 C-N-CA 132.105 4.162 . . . . 0.0 116.865 -169.254 . . . . . . . . 3 2 . 1 . 023 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -130.44 -2.9 4.84 Favored Glycine 0 N--CA 1.472 1.034 0 C-N-CA 124.524 1.059 . . . . 0.0 114.079 -169.676 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.83 48.32 1.2 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.333 1.853 . . . . 0.0 111.697 177.289 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.263 0.4 OUTLIER -176.89 43.9 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.489 1.516 . . . . 0.0 112.187 -168.937 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.482 1.129 0 C-N-CA 128.735 2.814 . . . . 0.0 115.969 171.768 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.097 0 N-CA-C 115.473 1.657 . . . . 0.0 115.473 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . 0.415 ' H ' ' CD ' ' B' ' 49' ' ' GLU . . . -99.3 -121.31 4.54 Favored Glycine 0 CA--C 1.544 1.902 0 C-N-CA 126.485 1.993 . . . . 0.0 115.082 -169.263 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -99.19 179.16 0.3 Allowed 'Trans proline' 0 C--N 1.35 0.618 1 C-N-CA 125.415 4.076 . . . . 0.0 111.566 -175.79 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.4 ' CE1' ' O ' ' B' ' 137' ' ' THR . 0.0 OUTLIER -76.5 110.87 11.41 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.009 177.479 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -48.05 128.82 14.31 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.633 1.973 . . . . 0.0 113.78 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -121.57 64.96 16.69 Favored Pre-proline 0 CA--C 1.548 0.886 0 C-N-CA 124.721 1.208 . . . . 0.0 112.596 -172.312 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -63.58 -22.51 70.5 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 123.679 2.919 . . . . 0.0 113.465 -175.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.9 mt -79.51 -4.95 53.66 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.502 1.521 . . . . 0.0 112.916 172.606 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.7 p 62.15 52.07 3.34 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 127.891 2.476 . . . . 0.0 111.448 177.569 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -126.41 174.15 8.82 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 114.419 1.266 . . . . 0.0 114.419 -169.252 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 45.7 pttt -78.88 169.01 18.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 128.051 2.541 . . . . 0.0 111.192 171.235 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.419 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 78.6 t60 -90.28 174.85 7.36 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 176.221 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . 0.419 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 129.24 -115.1 1.87 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 125.166 1.365 . . . . 0.0 113.48 166.57 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.03 -50.03 0.81 Allowed Glycine 0 CA--C 1.547 2.089 0 CA-C-O 117.859 -1.523 . . . . 0.0 116.196 173.044 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -88.64 -4.64 6.37 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 CA-C-N 121.425 2.613 . . . . 0.0 113.599 172.077 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 26.5 pttt -141.83 -1.35 1.27 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 124.256 1.022 . . . . 0.0 113.468 168.29 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -119.43 159.74 23.66 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.642 1.577 . . . . 0.0 110.099 169.496 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -81.96 -29.84 31.99 Favored 'General case' 0 CA--C 1.541 0.619 1 C-N-CA 132.486 4.314 . . . . 0.0 114.83 -171.321 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -98.51 -85.63 0.37 Allowed 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.714 -0.616 . . . . 0.0 111.165 -168.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ttp-105 80.93 121.22 0.05 OUTLIER 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.924 2.09 . . . . 0.0 111.16 176.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m80 -54.19 151.51 7.12 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 120.481 -1.387 . . . . 0.0 113.006 173.794 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -45.94 -48.38 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-O 119.048 -0.501 . . . . 0.0 112.104 -176.648 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.29 112.12 2.62 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-O 123.182 1.435 . . . . 0.0 113.117 169.411 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -155.56 107.14 2.58 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 130.659 3.584 . . . . 0.0 106.872 174.473 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 97.0 mt -89.09 54.06 2.87 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.558 0.743 . . . . 0.0 109.74 174.58 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.9 -107.56 0.14 Allowed Glycine 0 CA--C 1.532 1.107 0 C-N-CA 125.959 1.743 . . . . 0.0 113.652 177.449 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.74 146.16 24.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.367 1.467 . . . . 0.0 110.947 169.922 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.97 113.52 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 126.791 2.036 . . . . 0.0 110.359 -176.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -95.59 125.06 39.92 Favored 'General case' 0 N--CA 1.471 0.598 0 O-C-N 121.628 -0.67 . . . . 0.0 110.365 -175.189 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.38 148.62 24.01 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.738 1.215 . . . . 0.0 113.181 -175.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.432 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 24.7 t70 -76.71 174.91 9.88 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.49 1.516 . . . . 0.0 111.496 169.68 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.432 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -68.59 -13.38 62.3 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 121.101 -1.0 . . . . 0.0 113.109 173.018 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -74.62 -23.7 58.74 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.101 1.36 . . . . 0.0 110.588 171.217 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.12 -2.71 59.8 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 116.655 -2.192 . . . . 0.0 114.47 -177.75 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.33 133.18 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 119.959 1.88 . . . . 0.0 113.818 169.856 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.44 113.93 27.8 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 164.783 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -99.67 133.34 44.16 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.066 1.347 . . . . 0.0 108.978 -176.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -135.26 135.7 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.495 1.118 . . . . 0.0 112.825 -167.393 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 27.6 p -156.11 113.69 3.27 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.312 1.445 . . . . 0.0 111.304 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 6.6 mt -145.14 152.57 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 127.85 2.46 . . . . 0.0 110.606 -169.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -134.98 137.78 43.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.846 0.858 . . . . 0.0 108.737 167.376 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -145.12 153.21 41.16 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 125.385 1.474 . . . . 0.0 112.327 -172.163 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 37.4 p -125.67 45.26 2.64 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 178.603 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.4 22.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.891 1.276 . . . . 0.0 112.669 169.427 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.15 158.86 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 127.119 2.168 . . . . 0.0 108.025 164.685 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 60.4 p -156.03 156.84 35.12 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.657 0.783 . . . . 0.0 109.758 -177.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -83.25 63.41 7.2 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.681 -1.262 . . . . 0.0 110.243 -177.322 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 11.1 t -93.5 154.59 17.81 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 165.703 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.0 -28.41 72.02 Favored Glycine 0 N--CA 1.47 0.909 0 C-N-CA 127.047 2.261 . . . . 0.0 118.322 -164.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 p30 -148.13 -46.67 0.16 Allowed 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -168.79 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -82.73 -18.89 39.18 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.782 -1.199 . . . . 0.0 111.994 -171.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 74.7 m -99.14 -92.85 0.26 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.093 0.957 . . . . 0.0 111.097 -176.174 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.74 -18.49 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 176.584 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 40.2 mm -68.64 153.0 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 122.089 2.222 . . . . 0.0 107.263 167.238 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.48 66.0 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 119.297 -0.724 . . . . 0.0 112.97 175.687 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 15.8 mtp85 -114.54 133.19 55.98 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 176.719 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.598 ' HG1' HG23 ' B' ' 148' ' ' VAL . 5.5 m -80.29 140.69 36.06 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.352 1.861 . . . . 0.0 107.003 179.258 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.3 tp -129.83 128.53 42.49 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.028 0.931 . . . . 0.0 109.786 -174.566 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.62 133.19 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.103 0.961 . . . . 0.0 110.628 177.736 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -98.24 149.25 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 165.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.2 m-70 -120.76 138.16 54.15 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.274 1.43 . . . . 0.0 113.199 -169.655 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -73.61 -24.79 60.09 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 120.163 -1.585 . . . . 0.0 114.013 -173.338 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -93.22 164.8 13.1 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 122.192 0.996 . . . . 0.0 112.355 169.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.87 158.97 20.7 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.008 1.323 . . . . 0.0 111.625 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -103.45 151.95 22.21 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.84 0.856 . . . . 0.0 112.185 179.124 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -102.36 -3.24 27.42 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 127.378 2.271 . . . . 0.0 112.878 -177.993 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 45.85 56.45 5.97 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.132 1.773 . . . . 0.0 113.257 172.036 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.77 -54.1 1.68 Allowed Glycine 0 N--CA 1.471 1.033 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.014 173.023 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 134.55 18.86 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 172.314 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -160.21 -67.58 0.02 OUTLIER Glycine 0 CA--C 1.52 0.382 1 C-N-CA 130.723 4.011 . . . . 0.0 107.254 168.22 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -83.67 -111.14 0.56 Allowed Glycine 0 CA--C 1.533 1.188 0 C-N-CA 126.309 1.909 . . . . 0.0 117.039 -171.046 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -118.0 -159.13 0.74 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.431 2.292 . . . . 0.0 112.646 -163.307 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . 0.486 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 31.9 tt0 -49.34 -64.67 0.74 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.479 1.112 . . . . 0.0 112.033 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . 0.298 2.9 mt-10 -53.65 -10.37 0.27 Allowed 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 177.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 67.2 m -60.9 -47.76 84.92 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 122.133 2.242 . . . . 0.0 111.18 166.796 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 39.0 p -81.31 -38.14 27.25 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-O 119.102 -0.475 . . . . 0.0 111.347 176.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.486 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 14.9 tttt -68.63 -38.97 80.96 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.552 1.541 . . . . 0.0 113.88 -173.906 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.4 ' O ' ' CE1' ' B' ' 63' ' ' HIS . 33.9 p -121.78 -68.72 0.88 Allowed 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 116.974 -1.488 . . . . 0.0 109.696 172.742 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 163.71 17.37 0.02 OUTLIER Glycine 0 CA--C 1.536 1.375 0 C-N-CA 130.476 3.894 . . . . 0.0 113.621 -176.286 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . 0.257 2.3 t-20 41.98 35.34 0.54 Allowed 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 128.017 2.527 . . . . 0.0 114.819 -166.522 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.56 3.45 0.13 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.784 1.633 . . . . 0.0 115.232 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.9 -43.86 0.51 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 129.324 3.345 . . . . 0.0 117.257 168.664 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 32.5 t -173.09 168.55 4.77 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.768 1.627 . . . . 0.0 110.062 -168.316 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 28.5 mtt180 -111.07 -177.69 3.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 -169.85 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.431 ' CD2' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -171.31 -157.88 0.13 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 128.417 2.687 . . . . 0.0 107.138 -169.695 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . 0.431 ' H ' ' CD2' ' B' ' 144' ' ' LEU . . . -58.69 153.97 15.53 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -169.142 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -141.98 153.77 44.54 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 113.949 -1.478 . . . . 0.0 113.82 -172.109 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.99 -177.65 37.68 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 127.49 2.472 . . . . 0.0 111.485 176.627 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.598 HG23 ' HG1' ' B' ' 116' ' ' THR . 3.4 t -123.61 152.69 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 166.896 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.0 mm -75.7 102.31 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 174.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.18 -179.51 35.54 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 125.835 1.683 . . . . 0.0 111.14 169.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.24 154.55 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 117.602 0.701 . . . . 0.0 112.796 -167.604 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.466 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.23 -2.74 0.68 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 115.008 1.484 . . . . 0.0 115.008 165.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.234 0.262 0 C-N-CA 124.671 1.189 . . . . 0.0 111.071 168.78 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.44 ' HZ2' ' HG2' ' A' ' 28' ' ' PRO . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HG2' ' HZ2' ' A' ' 23' ' ' LYS . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.538 ' H ' HD11 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.486 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.456 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.486 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.408 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.496 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.496 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.408 ' CG ' ' HE2' ' A' ' 71' ' ' HIS . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.427 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.507 ' CD ' ' HZ1' ' A' ' 136' ' ' LYS . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.507 ' HZ1' ' CD ' ' A' ' 132' ' ' GLU . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.456 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.414 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.446 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.413 ' H ' HD22 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.453 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 111.365 0.135 . . . . 0.0 111.365 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . 0.437 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.433 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 024 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . 0.433 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.4 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.44 ' HZ2' ' HG2' ' A' ' 28' ' ' PRO . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HG2' ' HZ2' ' A' ' 23' ' ' LYS . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.538 ' H ' HD11 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.486 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.456 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.486 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.408 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.496 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.496 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.408 ' CG ' ' HE2' ' A' ' 71' ' ' HIS . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.427 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.507 ' CD ' ' HZ1' ' A' ' 136' ' ' LYS . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.507 ' HZ1' ' CD ' ' A' ' 132' ' ' GLU . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.456 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.414 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.446 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.413 ' H ' HD22 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.453 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 111.365 0.135 . . . . 0.0 111.365 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . 0.437 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.433 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 025 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . 0.433 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . 0.4 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.5 p . . . . . 0 N--CA 1.465 0.283 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.478 ' HZ2' HG22 ' A' ' 5' ' ' VAL . 0.8 OUTLIER -163.43 129.75 3.26 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 164.361 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.44 154.03 44.21 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.326 2.25 . . . . 0.0 108.289 167.682 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.478 HG22 ' HZ2' ' A' ' 3' ' ' LYS . 69.4 t -154.97 146.62 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 118.916 0.78 . . . . 0.0 112.778 -167.005 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.76 128.45 51.75 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.592 1.157 . . . . 0.0 109.321 165.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 29.0 m -113.71 127.1 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.597 1.159 . . . . 0.0 108.289 167.59 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.07 130.45 55.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.14 1.376 . . . . 0.0 109.913 -172.068 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -153.9 70.76 0.83 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.741 0.816 . . . . 0.0 110.869 170.222 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.1 -1.41 22.3 Favored Glycine 0 N--CA 1.469 0.851 0 CA-C-O 117.481 -1.733 . . . . 0.0 115.078 -173.958 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -156.08 110.32 2.81 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 119.151 1.476 . . . . 0.0 111.979 -169.74 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 31.66 -111.37 0.05 OUTLIER Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.168 2.318 . . . . 0.0 114.906 169.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -84.42 -2.05 9.85 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.597 2.865 . . . . 0.0 114.034 -175.778 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.0 t -102.05 135.37 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 120.445 1.475 . . . . 0.0 111.578 -168.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -127.24 171.93 11.03 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 122.87 1.319 . . . . 0.0 110.258 169.072 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.36 150.87 23.17 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 112.781 -2.008 . . . . 0.0 112.152 167.892 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -133.15 126.4 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 167.352 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mm -132.67 103.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -177.29 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -99.3 124.71 44.61 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.221 1.008 . . . . 0.0 112.151 177.107 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -104.69 156.45 17.97 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 127.303 2.241 . . . . 0.0 111.769 169.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -132.46 128.97 38.59 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.613 1.565 . . . . 0.0 108.597 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -139.56 145.49 38.69 Favored 'General case' 0 CA--C 1.532 0.287 0 O-C-N 120.822 -1.174 . . . . 0.0 111.151 -174.224 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.482 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -113.4 -31.37 6.58 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -167.39 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.434 ' CD ' ' H ' ' A' ' 25' ' ' SER . 1.4 tm-20 -157.94 154.66 28.16 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.683 1.593 . . . . 0.0 107.908 172.438 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.434 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.7 m -47.44 -40.53 18.32 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 128.302 2.641 . . . . 0.0 113.156 173.018 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -84.1 -0.55 52.34 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.984 1.714 . . . . 0.0 112.771 174.681 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.58 139.65 14.57 Favored Glycine 0 CA--C 1.538 1.526 0 O-C-N 120.427 -1.421 . . . . 0.0 112.985 -172.694 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -69.74 163.71 37.26 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 123.933 3.089 . . . . 0.0 111.339 178.925 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t -132.75 136.56 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.177 0.591 . . . . 0.0 112.164 -167.024 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -95.49 124.54 39.57 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.093 1.357 . . . . 0.0 109.548 172.153 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -107.7 153.0 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 C-N-CA 125.672 1.589 . . . . 0.0 111.415 168.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 42.6 p90 -156.72 164.05 38.58 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.291 1.437 . . . . 0.0 111.834 168.779 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.94 -154.21 24.74 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 124.139 0.876 . . . . 0.0 112.597 175.656 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 78.1 p -156.58 150.85 25.32 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.15 116.26 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 171.783 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -136.12 140.18 43.5 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.111 0.964 . . . . 0.0 112.566 -165.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.57 -16.22 37.62 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 126.809 2.147 . . . . 0.0 112.275 -168.789 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 pp -84.39 155.05 22.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-N 118.473 1.137 . . . . 0.0 112.01 172.879 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.7 m -62.02 154.15 27.54 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 127.371 2.269 . . . . 0.0 112.012 176.674 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.8 pm0 -51.0 169.61 0.04 OUTLIER 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.258 1.423 . . . . 0.0 114.57 168.674 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.43 -176.32 46.51 Favored Glycine 0 N--CA 1.472 1.086 0 O-C-N 120.792 -1.192 . . . . 0.0 112.358 -177.485 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.3 mp -75.92 148.36 38.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.456 -1.026 . . . . 0.0 110.019 -176.56 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -142.1 134.0 27.24 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.849 1.26 . . . . 0.0 109.2 173.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.2 152.13 49.52 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 177.75 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -150.5 118.0 6.1 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.806 2.042 . . . . 0.0 107.97 -169.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.474 ' NE2' ' CD2' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -153.89 145.2 23.01 Favored 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.116 -1.615 . . . . 0.0 111.221 -172.956 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.16 127.3 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.173 0.987 . . . . 0.0 110.647 170.248 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -72.83 -173.62 1.26 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 129.218 3.007 . . . . 0.0 110.349 177.414 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.468 ' CD ' ' H ' ' A' ' 49' ' ' GLU 0.268 1.9 pm0 -63.65 -120.31 0.0 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.081 1.752 . . . . 0.0 114.831 177.692 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -82.12 -168.03 1.79 Allowed 'General case' 0 CA--C 1.545 0.754 0 O-C-N 119.807 -1.808 . . . . 0.0 114.403 -167.129 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.58 9.45 60.59 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.067 1.794 . . . . 0.0 113.978 -179.354 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -108.98 38.79 2.18 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.986 1.714 . . . . 0.0 113.961 -173.769 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -172.43 22.27 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.858 1.313 . . . . 0.0 112.408 -165.082 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.1 p -44.33 5.8 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.613 1 C-N-CA 134.641 5.176 . . . . 0.0 118.784 -176.453 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.75 1.34 56.54 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.515 1.926 . . . . 0.0 112.87 172.579 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.84 -151.68 43.05 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 -179.135 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.1 t -51.26 -7.41 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.197 0 C-N-CA 127.206 2.203 . . . . 0.0 116.289 -176.42 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 58.5 p -87.95 18.51 4.14 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 120.162 -1.586 . . . . 0.0 113.318 169.2 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.9 m -169.81 -47.14 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 127.221 2.209 . . . . 0.0 109.761 -176.268 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.61 151.31 45.13 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.45 1.9 . . . . 0.0 112.128 172.526 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -98.01 -170.28 32.35 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 125.803 1.668 . . . . 0.0 112.505 -176.188 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -83.79 60.87 6.69 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.501 2.801 . . . . 0.0 109.885 178.185 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' ' NE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER 51.19 63.81 2.1 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.551 1.54 . . . . 0.0 112.773 168.272 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -28.29 113.57 0.07 Allowed 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 127.507 2.323 . . . . 0.0 111.854 175.679 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -78.11 103.59 1.45 Allowed Pre-proline 0 CA--C 1.545 0.773 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.795 -166.547 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -70.11 -21.12 32.3 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 121.899 1.733 . . . . 0.0 112.186 -174.516 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.89 -3.74 21.49 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.31 1.844 . . . . 0.0 112.677 175.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 t 54.18 44.24 29.44 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 125.25 1.42 . . . . 0.0 112.283 -169.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtm180 -92.2 171.19 9.24 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 120.994 -1.066 . . . . 0.0 111.37 174.378 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.75 164.64 18.41 Favored 'General case' 0 CA--C 1.547 0.858 0 O-C-N 121.23 -0.919 . . . . 0.0 109.762 167.792 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -80.31 142.54 34.42 Favored 'General case' 0 CA--C 1.536 0.414 0 O-C-N 120.265 -1.522 . . . . 0.0 111.718 -178.495 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 165.36 -131.5 2.41 Favored Glycine 0 N--CA 1.468 0.804 0 N-CA-C 115.859 1.104 . . . . 0.0 115.859 168.843 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.55 -41.7 1.72 Allowed Glycine 0 CA--C 1.543 1.822 0 N-CA-C 119.005 2.362 . . . . 0.0 119.005 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -95.39 -22.31 0.2 Allowed 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 121.885 2.843 . . . . 0.0 113.725 -175.798 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.5 pttt -132.26 -0.09 3.7 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.976 1.71 . . . . 0.0 112.21 175.348 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -138.72 155.49 48.19 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 130.869 3.668 . . . . 0.0 108.832 -176.428 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -107.07 -8.05 16.67 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 126.169 1.788 . . . . 0.0 112.911 -174.638 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.5 mm-40 -78.2 -20.21 52.31 Favored 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -172.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 4.52 102.14 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 130.445 3.498 . . . . 0.0 115.374 166.493 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -59.58 162.35 5.13 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.654 0.782 . . . . 0.0 112.03 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 92.2 t -49.62 -41.18 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 124.366 1.066 . . . . 0.0 113.722 171.125 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.8 8.39 66.21 Favored Glycine 0 CA--C 1.539 1.583 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 177.266 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -99.25 97.49 8.56 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-N 119.635 1.718 . . . . 0.0 111.866 -175.184 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 87.0 mt -108.81 54.54 0.65 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.455 1.102 . . . . 0.0 111.954 -175.436 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.42 -151.48 43.43 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 125.023 1.296 . . . . 0.0 114.248 177.186 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.7 p30 -135.16 169.28 17.69 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 125.509 1.524 . . . . 0.0 109.568 169.864 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -128.58 113.88 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.536 1.134 . . . . 0.0 109.832 -171.147 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.4 m -109.15 124.37 50.7 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 123.913 0.885 . . . . 0.0 108.939 -170.102 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.94 151.17 21.64 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 -172.87 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -88.06 151.89 22.42 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 127.758 2.423 . . . . 0.0 110.381 167.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.545 ' HZ1' ' CG ' ' A' ' 92' ' ' ASP . 1.5 pptp? -49.94 -17.71 0.42 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 129.2 3.0 . . . . 0.0 116.994 175.557 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.545 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 82.9 m-20 -75.65 0.75 16.54 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 124.266 1.026 . . . . 0.0 111.388 171.56 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.13 35.13 7.21 Favored Glycine 0 C--N 1.34 0.783 0 C-N-CA 125.996 1.76 . . . . 0.0 112.781 172.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.7 p -152.76 131.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.048 1.869 . . . . 0.0 116.048 -170.919 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.86 120.97 37.07 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 164.468 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -104.1 132.6 50.19 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.224 1.41 . . . . 0.0 107.747 177.118 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 49.1 t -134.41 141.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -165.608 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.9 t -157.46 119.27 3.73 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.333 1.853 . . . . 0.0 111.021 170.614 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.4 mt -135.47 145.59 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 126.233 1.813 . . . . 0.0 110.467 179.707 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.98 126.43 53.83 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 125.641 1.576 . . . . 0.0 106.945 166.269 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.82 144.46 50.24 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.925 0.89 . . . . 0.0 112.924 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 10.8 p -119.97 50.74 1.25 Allowed 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -177.381 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -154.72 6.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 N-CA-C 115.382 1.623 . . . . 0.0 115.382 168.642 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.64 152.79 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 120.77 -1.206 . . . . 0.0 109.851 177.726 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.411 ' H ' ' CB ' ' A' ' 111' ' ' SER . 52.4 p -155.43 179.3 9.31 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 120.982 -1.074 . . . . 0.0 112.691 -178.341 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.4 mp -81.72 48.35 1.19 Allowed 'General case' 0 CA--C 1.551 1.002 0 O-C-N 120.415 -1.428 . . . . 0.0 110.234 -174.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.9 t -88.16 43.92 1.16 Allowed 'General case' 0 CA--C 1.545 0.764 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 -168.454 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.19 -64.63 2.02 Favored Glycine 0 N--CA 1.475 1.248 0 C-N-CA 125.736 1.636 . . . . 0.0 116.072 168.249 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -149.41 16.67 0.92 Allowed 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 124.059 1.885 . . . . 0.0 110.595 -175.725 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 39.4 m-70 -126.31 5.7 7.02 Favored 'General case' 0 CA--C 1.545 0.771 0 O-C-N 120.004 -1.685 . . . . 0.0 112.873 -167.431 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.411 ' CB ' ' H ' ' A' ' 105' ' ' SER . 3.1 m -166.39 -103.12 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.74 1.216 . . . . 0.0 113.111 177.749 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.6 pt -117.72 28.13 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 CA-C-N 120.37 1.441 . . . . 0.0 113.679 -170.276 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -133.48 146.58 31.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 127.725 2.41 . . . . 0.0 105.578 164.084 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.12 30.38 75.68 Favored Glycine 0 C--O 1.22 -0.748 0 CA-C-O 118.869 -0.962 . . . . 0.0 113.101 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.7 mtt-85 -135.28 176.9 8.25 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.835 1.254 . . . . 0.0 109.351 176.345 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.4 m -132.52 116.11 16.32 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 119.689 1.131 . . . . 0.0 110.94 -170.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.7 tp -89.83 132.86 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.629 1.172 . . . . 0.0 110.308 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -124.23 150.26 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.027 1.331 . . . . 0.0 110.326 172.302 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -105.33 167.56 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-O 121.418 0.628 . . . . 0.0 110.823 167.06 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.72 127.69 37.35 Favored 'General case' 0 CA--C 1.547 0.849 0 O-C-N 120.942 -1.099 . . . . 0.0 110.697 -173.823 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? -69.87 -10.13 57.38 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -169.55 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -107.93 162.1 14.33 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 114.442 1.275 . . . . 0.0 114.442 171.496 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.79 139.4 58.76 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.507 1.923 . . . . 0.0 109.792 167.081 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -111.3 148.84 32.05 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.849 2.059 . . . . 0.0 113.8 -171.815 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.342 13.3 t0 -101.93 -15.83 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 115.556 1.687 . . . . 0.0 115.556 -179.725 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt 56.26 81.0 0.13 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.724 1.609 . . . . 0.0 114.061 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.9 -43.74 1.91 Allowed Glycine 0 N--CA 1.471 1.009 0 C-N-CA 125.275 1.417 . . . . 0.0 111.935 168.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -99.42 175.03 5.99 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.219 1.408 . . . . 0.0 110.204 167.604 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 131.02 -9.92 5.68 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 126.311 1.91 . . . . 0.0 114.116 -169.312 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.54 11.04 85.85 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 116.272 1.269 . . . . 0.0 116.272 168.394 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 13.9 p30 -138.82 174.52 10.43 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.891 1.276 . . . . 0.0 110.077 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -65.69 -54.82 22.19 Favored 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 115.012 1.486 . . . . 0.0 115.012 -171.577 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.41 -26.54 42.32 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.661 -0.649 . . . . 0.0 111.883 176.291 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -54.38 -35.97 63.4 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.29 -1.506 . . . . 0.0 114.634 177.253 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.9 -28.16 15.33 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 124.423 1.089 . . . . 0.0 112.49 178.504 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.19 -65.25 0.98 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.018 0.827 . . . . 0.0 111.922 178.823 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.9 p -92.25 -24.31 19.04 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 126.56 1.944 . . . . 0.0 112.168 -171.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.58 16.51 24.23 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 124.533 1.063 . . . . 0.0 112.494 -168.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 73.09 4.54 4.96 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.566 1.946 . . . . 0.0 113.768 178.294 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.8 -10.96 4.36 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 -169.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.06 -30.07 0.53 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 128.507 2.956 . . . . 0.0 117.779 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.411 ' C ' ' HE ' ' A' ' 143' ' ' ARG . 9.5 t -142.45 178.11 7.82 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.225 1.01 . . . . 0.0 110.469 -173.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.411 ' HE ' ' C ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -116.9 -175.58 2.81 Favored 'General case' 0 N--CA 1.473 0.725 0 O-C-N 120.59 -1.319 . . . . 0.0 110.102 -174.893 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.605 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -170.1 -158.96 0.18 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.76 2.024 . . . . 0.0 107.779 -176.07 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.605 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.26 159.7 30.75 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 127.057 2.143 . . . . 0.0 113.321 178.347 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -147.58 162.52 38.94 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.269 1.427 . . . . 0.0 112.985 -177.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.28 161.0 31.35 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 126.614 2.054 . . . . 0.0 112.228 169.333 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.1 t -78.54 160.83 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 CA-C-N 119.25 1.525 . . . . 0.0 110.869 170.403 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -103.1 113.12 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 CA-C-N 118.834 0.743 . . . . 0.0 110.643 167.838 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.2 -178.61 15.7 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 125.604 1.573 . . . . 0.0 113.23 -178.435 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.95 123.05 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 113.958 1.096 . . . . 0.0 113.958 -170.704 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.12 -31.05 61.0 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 122.921 1.343 . . . . 0.0 107.787 163.033 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.438 0 C-N-CA 125.481 1.512 . . . . 0.0 112.27 166.937 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.2 m -80.73 109.61 15.43 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 105.724 -1.954 . . . . 0.0 105.724 168.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.27 152.87 32.97 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 117.894 2.553 . . . . 0.0 117.894 -172.711 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.75 147.49 37.46 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 126.255 1.822 . . . . 0.0 108.886 168.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.05 157.29 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 123.459 0.704 . . . . 0.0 111.037 -166.918 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.54 139.61 46.7 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.658 1.183 . . . . 0.0 111.438 169.648 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.4 m -108.62 122.41 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 167.094 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.7 mp -99.98 75.86 1.89 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -164.453 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -105.61 100.74 10.29 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.257 1.423 . . . . 0.0 110.364 173.076 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.47 15.69 0.48 Allowed Glycine 0 N--CA 1.477 1.412 0 N-CA-C 115.68 1.032 . . . . 0.0 115.68 -178.11 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -159.61 136.78 9.6 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.625 2.37 . . . . 0.0 107.457 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -23.28 -80.26 0.01 OUTLIER Glycine 0 CA--C 1.537 1.451 0 C-N-CA 128.487 2.946 . . . . 0.0 116.083 -168.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -86.72 4.27 6.36 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 124.192 3.261 . . . . 0.0 113.949 -177.557 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 36.0 t -105.38 129.83 57.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 CA-C-O 122.872 1.32 . . . . 0.0 109.721 -172.446 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.2 168.29 19.13 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.777 1.631 . . . . 0.0 107.911 171.869 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.17 176.42 33.6 Favored Glycine 0 N--CA 1.464 0.543 0 O-C-N 120.432 -1.417 . . . . 0.0 113.546 176.488 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -158.31 103.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 126.687 1.995 . . . . 0.0 108.81 172.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.49 146.41 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 124.922 1.289 . . . . 0.0 111.594 176.636 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -119.12 168.99 10.32 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 127.268 2.227 . . . . 0.0 112.196 -171.034 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.38 98.86 3.21 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 127.263 2.225 . . . . 0.0 108.105 172.219 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -102.41 114.08 27.96 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 118.71 0.686 . . . . 0.0 111.581 -175.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -91.64 132.48 36.31 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.221 1.008 . . . . 0.0 110.948 176.227 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.4 ptmt -84.02 -30.79 25.83 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 179.349 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -162.17 144.73 11.37 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.19 2.196 . . . . 0.0 109.847 169.586 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 1.5 m -43.77 24.77 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 1 C-N-CA 137.957 6.503 . . . . 0.0 119.037 -174.767 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.6 p30 179.76 -24.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 128.371 2.668 . . . . 0.0 112.081 -170.194 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.6 165.11 54.3 Favored Glycine 0 CA--C 1.541 1.659 0 O-C-N 121.168 -0.958 . . . . 0.0 112.425 169.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -70.15 169.7 18.79 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 124.305 3.336 . . . . 0.0 113.12 -171.288 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 31.7 t -131.02 129.43 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.942 1.697 . . . . 0.0 110.503 -169.111 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -93.77 125.82 38.6 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-O 122.319 1.057 . . . . 0.0 109.902 170.56 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.06 128.16 39.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 127.585 2.354 . . . . 0.0 108.071 169.44 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -153.39 158.26 41.19 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 171.646 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.83 -141.99 12.79 Favored Glycine 0 N--CA 1.463 0.456 0 C-N-CA 125.08 1.324 . . . . 0.0 111.51 176.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 99.0 p -155.02 162.13 41.16 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 117.987 2.588 . . . . 0.0 117.987 -167.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 19.4 mm -130.4 123.93 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 C-N-CA 126.567 1.947 . . . . 0.0 107.445 168.067 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . 0.431 ' HZ3' ' CG ' ' B' ' 92' ' ' ASP . 57.8 tttp -122.24 136.49 54.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 122.854 2.57 . . . . 0.0 110.731 -178.63 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.26 -8.77 5.65 Favored Glycine 0 N--CA 1.474 1.202 0 C-N-CA 126.47 1.986 . . . . 0.0 114.094 -178.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 33.4 mt -70.22 172.97 7.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.096 1.358 . . . . 0.0 111.638 170.625 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 11.8 t -110.77 157.73 19.46 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 162.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -59.03 162.04 4.59 Favored 'General case' 0 CA--C 1.537 0.442 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -167.213 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.79 -179.15 34.07 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.671 -174.841 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -75.64 144.21 41.81 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.533 1.533 . . . . 0.0 113.0 -169.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -140.37 170.14 16.37 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 126.948 2.099 . . . . 0.0 109.567 176.462 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -124.93 166.06 17.79 Favored Glycine 0 N--CA 1.478 1.486 0 C-N-CA 125.132 1.349 . . . . 0.0 113.148 -174.196 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -156.46 162.32 39.99 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.951 2.1 . . . . 0.0 112.82 172.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 46.7 p-80 -156.14 163.91 39.04 Favored 'General case' 0 C--N 1.347 0.468 0 O-C-N 120.583 -1.323 . . . . 0.0 108.835 168.797 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -110.84 162.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 125.015 1.326 . . . . 0.0 108.857 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.419 ' CE1' ' HB ' ' B' ' 116' ' ' THR . 5.3 p80 -136.67 126.18 25.18 Favored 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 120.984 -1.072 . . . . 0.0 109.789 176.606 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -71.75 136.47 47.16 Favored 'General case' 0 N--CA 1.452 -0.357 0 O-C-N 123.932 0.77 . . . . 0.0 109.913 179.443 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 121.22 133.05 0.0 OUTLIER 'General case' 0 C--O 1.233 0.209 1 C-N-CA 133.958 4.903 . . . . 0.0 108.449 -176.149 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.42 2.89 61.15 Favored Glycine 0 C--O 1.222 -0.615 0 CA-C-O 118.211 -1.327 . . . . 0.0 114.019 178.717 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -103.13 51.58 0.79 Allowed 'General case' 0 CA--C 1.536 0.423 0 CA-C-N 120.24 2.02 . . . . 0.0 112.934 -179.15 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.1 37.73 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 126.669 1.987 . . . . 0.0 110.995 -171.472 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.3 p . . . . . 0 N--CA 1.469 0.504 1 C-N-CA 133.688 4.795 . . . . 0.0 115.948 -171.614 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.604 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.99 163.57 26.9 Favored Glycine 0 CA--C 1.544 1.897 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -173.201 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -66.09 125.29 13.86 Favored 'Trans proline' 0 C--N 1.352 0.716 0 C-N-CA 124.977 3.785 . . . . 0.0 111.322 178.378 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.318 1.9 p80 28.32 59.23 0.12 Allowed 'General case' 0 C--O 1.239 0.551 0 C-N-CA 130.278 3.431 . . . . 0.0 116.858 177.935 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -58.8 121.1 10.28 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 105.153 -2.166 . . . . 0.0 105.153 162.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -125.47 142.4 41.65 Favored Pre-proline 0 CA--C 1.543 0.683 0 C-N-CA 124.365 1.066 . . . . 0.0 113.799 -169.068 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -83.38 -15.08 7.8 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.323 2.682 . . . . 0.0 113.587 175.172 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 79.8 mt -93.88 -10.63 33.28 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 115.03 1.492 . . . . 0.0 115.03 -171.486 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t 46.12 58.69 4.26 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 169.474 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 4.6 ptt180 -143.88 -174.96 4.4 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 127.899 2.48 . . . . 0.0 111.06 -175.611 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.494 ' HZ3' ' CD ' ' B' ' 78' ' ' GLU 0.25 3.1 pttp -65.19 160.48 21.28 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 120.231 1.378 . . . . 0.0 112.706 175.963 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -96.95 138.62 34.21 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.777 -1.556 . . . . 0.0 113.326 -177.086 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.92 -151.33 20.19 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 127.075 2.274 . . . . 0.0 109.456 170.49 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.496 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 169.25 -32.99 0.18 Allowed Glycine 0 CA--C 1.528 0.87 0 N-CA-C 119.722 2.649 . . . . 0.0 119.722 169.004 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.3 24.18 0.22 Allowed 'Trans proline' 0 CA--C 1.554 1.52 0 CA-C-N 122.97 3.385 . . . . 0.0 113.013 167.787 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . 0.496 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -168.59 -41.39 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 129.865 3.266 . . . . 0.0 107.245 166.427 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.255 4.9 t70 -62.69 117.97 7.02 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 123.932 1.825 . . . . 0.0 109.599 -171.055 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . 0.433 ' CD ' ' HZ2' ' B' ' 75' ' ' LYS . 27.3 mp0 -72.48 -19.57 61.52 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 129.416 3.086 . . . . 0.0 114.471 -161.616 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . 0.494 ' CD ' ' HZ3' ' B' ' 70' ' ' LYS . 1.1 mp0 -105.71 -65.21 1.08 Allowed 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.022 0.529 . . . . 0.0 111.197 176.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 76.77 126.72 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 125.181 1.393 . . . . 0.0 114.352 165.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -73.78 159.54 32.78 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 124.608 1.163 . . . . 0.0 113.015 168.106 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -61.86 -47.75 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 120.931 -1.106 . . . . 0.0 110.142 173.529 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.56 31.38 1.67 Allowed Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.865 1.221 . . . . 0.0 115.369 176.587 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -115.71 117.39 30.14 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 121.368 -1.078 . . . . 0.0 108.941 170.291 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 87.1 mt -140.72 131.68 26.1 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 102.455 -3.165 . . . . 0.0 102.455 168.743 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.69 -144.77 16.07 Favored Glycine 0 N--CA 1.47 0.941 0 N-CA-C 119.698 2.639 . . . . 0.0 119.698 -163.534 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . 0.48 HD22 ' HA ' ' B' ' 124' ' ' ASP . 93.4 m-20 -72.96 159.86 33.02 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -165.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.3 p -133.05 177.28 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 130.387 3.475 . . . . 0.0 110.093 -171.185 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -155.76 132.79 10.67 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 119.666 1.121 . . . . 0.0 111.356 174.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.46 160.5 15.41 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.342 1.057 . . . . 0.0 113.776 176.283 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.48 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 38.5 t70 -92.08 177.2 6.24 Favored 'General case' 0 CA--C 1.552 1.041 0 C-N-CA 127.186 2.194 . . . . 0.0 112.663 170.293 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.48 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -66.74 -17.58 64.94 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 120.913 -1.117 . . . . 0.0 112.958 169.606 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . 0.431 ' CG ' ' HZ3' ' B' ' 36' ' ' LYS . 0.7 OUTLIER -70.81 -27.26 63.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.081 0.952 . . . . 0.0 110.449 168.838 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.97 -4.5 65.52 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 117.96 -1.467 . . . . 0.0 114.439 -177.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.99 131.06 35.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 118.736 1.268 . . . . 0.0 110.917 168.782 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.16 124.63 44.35 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 165.892 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -79.16 143.51 35.37 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.706 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.09 130.53 72.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.686 166.625 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 8.6 m -150.77 82.97 1.34 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.857 1.263 . . . . 0.0 110.537 -175.142 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.6 mt -130.91 142.48 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.605 1.562 . . . . 0.0 111.007 -172.671 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -100.69 145.14 28.82 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.356 1.862 . . . . 0.0 107.176 168.653 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.973 0.909 . . . . 0.0 109.432 169.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.6 p -131.31 51.96 2.1 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.225 1.01 . . . . 0.0 112.263 179.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -152.47 34.82 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 122.736 1.255 . . . . 0.0 111.43 169.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.1 172.17 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 126.688 1.995 . . . . 0.0 111.329 -169.655 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -159.78 153.76 23.2 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 120.817 -1.177 . . . . 0.0 112.685 169.275 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.7 mp -82.72 58.91 4.48 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.641 -1.287 . . . . 0.0 110.345 176.377 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.9 t -89.11 141.1 28.8 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.071 171.417 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -77.1 47.83 2.66 Favored Glycine 0 N--CA 1.474 1.217 0 C-N-CA 126.23 1.871 . . . . 0.0 115.584 -168.443 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -139.15 -90.98 0.19 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.847 2.459 . . . . 0.0 107.784 -170.398 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -150.45 -4.88 0.33 Allowed 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 127.878 2.471 . . . . 0.0 112.275 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.5 t -69.34 -0.39 6.23 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.162 -1.586 . . . . 0.0 114.6 -174.979 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.5 7.5 pt 149.36 8.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 1 C-N-CA 135.667 5.587 . . . . 0.0 115.365 168.092 . . . . . . . . 3 2 . 1 . 026 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 48.9 mm -87.12 168.94 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 O-C-N 120.56 -1.337 . . . . 0.0 109.232 165.696 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.32 -33.39 2.02 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 117.849 1.899 . . . . 0.0 117.849 166.109 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 ptt85 -74.8 174.12 9.62 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 125.77 1.628 . . . . 0.0 112.043 -169.898 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.419 ' HB ' ' CE1' ' B' ' 48' ' ' HIS . 3.1 m -130.12 154.12 47.81 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.166 0.986 . . . . 0.0 109.699 -174.311 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -133.26 145.51 50.57 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 125.376 1.47 . . . . 0.0 111.505 -169.668 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.7 p -128.14 135.76 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 126.194 1.797 . . . . 0.0 110.88 174.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 t -101.91 158.24 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 125.521 1.528 . . . . 0.0 108.392 169.858 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -128.21 153.25 47.12 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 127.799 2.44 . . . . 0.0 111.296 -173.115 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -75.32 -24.93 57.47 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.491 -178.819 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -100.54 171.16 7.9 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 119.704 1.138 . . . . 0.0 110.114 167.507 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -112.08 94.57 5.01 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 125.283 1.433 . . . . 0.0 111.925 -179.371 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.48 ' HA ' HD22 ' B' ' 86' ' ' ASN 0.267 25.5 t0 -152.97 146.92 25.36 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-O 123.561 1.648 . . . . 0.0 109.25 168.032 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -169.3 -52.27 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 130.467 3.507 . . . . 0.0 110.893 -178.245 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . 0.515 HD13 ' H ' ' B' ' 126' ' ' LEU 0.338 0.0 OUTLIER -86.07 59.32 5.56 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 116.575 2.065 . . . . 0.0 116.575 -163.094 . . . . . . . . 4 4 . 1 . 026 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.44 -9.12 0.88 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 117.839 1.896 . . . . 0.0 117.839 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.3 ptmt -160.21 21.62 0.16 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 116.763 2.134 . . . . 0.0 116.763 -169.218 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.5 -19.38 78.95 Favored Glycine 0 N--CA 1.472 1.079 0 CA-C-N 120.26 1.391 . . . . 0.0 113.489 178.938 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -151.24 -42.24 0.02 OUTLIER Glycine 0 N--CA 1.468 0.83 0 N-CA-C 116.665 1.426 . . . . 0.0 116.665 -178.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -163.08 -165.31 1.08 Allowed 'General case' 0 CA--C 1.546 0.815 0 CA-C-N 120.201 2.0 . . . . 0.0 113.514 -173.448 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -49.27 -56.07 10.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.382 1.473 . . . . 0.0 110.876 169.043 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.23 -16.22 31.6 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 20.8 m -55.0 -31.79 61.28 Favored 'General case' 0 N--CA 1.471 0.594 0 O-C-N 120.091 -1.631 . . . . 0.0 112.702 168.527 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.264 2.8 t -97.44 -8.49 29.23 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 174.08 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -87.68 -60.95 1.83 Allowed 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.289 -1.507 . . . . 0.0 111.202 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 28.5 p -102.87 -24.92 13.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 126.018 1.727 . . . . 0.0 114.413 -177.223 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.55 -22.87 35.95 Favored Glycine 0 C--O 1.213 -1.159 0 CA-C-O 117.93 -1.483 . . . . 0.0 110.075 -166.26 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 33.2 t30 56.83 19.11 4.22 Favored 'General case' 0 CA--C 1.548 0.875 0 CA-C-N 119.351 1.576 . . . . 0.0 112.387 173.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.76 -23.16 2.51 Favored 'General case' 0 CA--C 1.557 1.226 0 C-N-CA 129.079 2.952 . . . . 0.0 115.057 -171.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 93.94 -153.19 21.07 Favored Glycine 0 C--N 1.343 0.924 0 C-N-CA 126.692 2.091 . . . . 0.0 114.414 174.765 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.03 151.88 2.45 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.711 2.004 . . . . 0.0 113.481 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 15.1 mtp-105 -66.24 166.88 11.2 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.9 -1.125 . . . . 0.0 113.474 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tp -150.01 -152.6 0.45 Allowed 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 128.727 2.811 . . . . 0.0 106.911 166.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.29 178.3 7.23 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -178.668 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.5 p -158.16 159.18 35.89 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.107 1.363 . . . . 0.0 111.459 -173.28 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.38 170.52 34.53 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.696 1.617 . . . . 0.0 113.416 176.086 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.54 147.41 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.639 1.176 . . . . 0.0 110.007 179.346 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.2 mm -93.47 76.68 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.324 0.65 . . . . 0.0 110.042 -178.71 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.57 161.88 32.7 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 123.652 0.644 . . . . 0.0 112.225 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 mp -75.05 134.87 28.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -175.452 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.82 35.13 3.34 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.461 1.504 . . . . 0.0 113.485 -168.735 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 . . . . . 0 C--N 1.324 -0.518 0 C-N-CA 126.633 1.973 . . . . 0.0 110.691 -177.31 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m . . . . . 0 C--O 1.217 -0.648 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 ttmm -120.09 128.11 53.16 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -169.415 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 171.77 7.22 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.927 0.891 . . . . 0.0 112.921 169.407 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.43 155.01 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 129.72 3.208 . . . . 0.0 106.908 165.97 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.25 114.81 19.45 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.738 1.154 . . . . 0.0 109.559 166.742 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.7 t -88.57 76.42 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 125.185 1.394 . . . . 0.0 108.938 -171.91 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.47 103.96 9.75 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.034 -175.018 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 ttpp -160.92 132.16 5.53 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 123.274 0.63 . . . . 0.0 112.369 166.08 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.15 -95.5 1.94 Allowed Glycine 0 C--N 1.333 0.384 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 168.074 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.31 -177.1 3.41 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.013 1.725 . . . . 0.0 107.974 174.007 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 61.69 -173.55 7.32 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.732 2.11 . . . . 0.0 117.05 168.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.54 4.41 7.1 Favored 'Trans proline' 0 CA--C 1.543 0.941 1 C-N-CA 126.347 4.698 . . . . 0.0 113.836 178.593 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 m -79.43 138.03 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 126.848 2.059 . . . . 0.0 111.045 175.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.77 169.23 19.5 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 122.238 1.018 . . . . 0.0 109.801 165.707 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -141.17 149.01 20.71 Favored Glycine 0 CA--C 1.499 -0.92 0 CA-C-N 113.379 -1.737 . . . . 0.0 110.078 164.245 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -130.27 112.01 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 172.189 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 mm -135.61 102.44 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 121.469 -0.77 . . . . 0.0 111.077 -174.118 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -72.34 157.28 37.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.165 170.204 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -137.22 98.71 3.8 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 168.867 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -89.93 108.02 19.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 122.12 0.962 . . . . 0.0 109.75 172.291 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -101.58 149.03 24.53 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 166.104 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -13.53 10.57 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.3 1.44 . . . . 0.0 112.253 -175.36 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.37 -146.06 0.37 Allowed 'General case' 0 CA--C 1.556 1.203 0 C-N-CA 128.919 2.887 . . . . 0.0 108.017 173.236 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.2 p -139.68 -45.84 0.44 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 126.009 1.723 . . . . 0.0 108.294 166.647 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.9 m-80 -85.76 32.45 0.59 Allowed 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.057 1.743 . . . . 0.0 112.722 172.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.91 -175.06 13.91 Favored Glycine 0 CA--C 1.538 1.499 0 C-N-CA 125.726 1.632 . . . . 0.0 113.002 177.404 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -76.54 170.99 18.87 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 123.82 3.013 . . . . 0.0 111.507 177.909 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.8 t -132.99 123.62 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.971 0.908 . . . . 0.0 110.31 -170.669 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.0 tttm -87.13 114.33 23.65 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 122.909 1.338 . . . . 0.0 112.621 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 t -95.25 131.1 42.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 125.941 1.696 . . . . 0.0 108.628 -176.646 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -153.38 160.3 42.61 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 173.653 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.08 -149.37 18.85 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 125.151 1.358 . . . . 0.0 111.521 -173.047 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 83.8 p -157.62 159.09 36.66 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 114.318 1.229 . . . . 0.0 114.318 -173.661 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -121.56 117.5 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.461 1.505 . . . . 0.0 107.331 171.863 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -128.88 151.82 49.2 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 126.146 1.779 . . . . 0.0 112.052 -165.165 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.58 10.88 82.73 Favored Glycine 0 CA--C 1.531 1.063 0 CA-C-O 118.773 -1.015 . . . . 0.0 113.785 -178.693 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.26 169.08 10.02 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.94 1.296 . . . . 0.0 111.0 173.332 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 t -69.83 160.13 32.33 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.77 1.228 . . . . 0.0 110.257 173.603 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.94 168.76 0.6 Allowed 'General case' 0 CA--C 1.55 0.961 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 178.611 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.6 -175.26 50.68 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.693 1.14 . . . . 0.0 113.472 170.141 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.452 ' CD1' ' H ' ' A' ' 42' ' ' LEU . 5.2 mp -56.14 147.04 21.37 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.728 2.411 . . . . 0.0 111.324 178.628 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -142.98 116.01 8.86 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 126.206 1.802 . . . . 0.0 110.187 176.004 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.53 151.45 14.35 Favored Glycine 0 N--CA 1.483 1.814 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.89 173.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -151.02 105.53 3.25 Favored 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 118.984 1.392 . . . . 0.0 111.089 -165.519 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 11.8 m80 -145.57 160.18 42.03 Favored 'General case' 0 N--CA 1.471 0.597 0 O-C-N 119.431 -2.043 . . . . 0.0 113.909 -164.584 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . 0.288 0.4 OUTLIER -129.64 120.71 51.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 122.635 1.207 . . . . 0.0 111.489 -171.854 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -79.29 137.19 37.26 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.91 2.084 . . . . 0.0 109.785 175.829 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.0 pm0 -70.44 16.09 0.08 Allowed 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -178.232 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -126.75 144.23 51.01 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 124.425 1.09 . . . . 0.0 108.572 168.846 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.26 27.57 5.05 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.295 1.426 . . . . 0.0 111.539 168.38 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -86.94 173.1 9.55 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.432 1.493 . . . . 0.0 109.911 173.793 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.64 9.15 4.11 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 118.01 2.596 . . . . 0.0 118.01 164.561 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.4 t -61.3 71.32 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.244 2.217 . . . . 0.0 116.504 -168.57 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -141.84 -63.5 0.44 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 125.483 1.513 . . . . 0.0 112.804 168.068 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 166.59 -153.77 23.77 Favored Glycine 0 N--CA 1.47 0.911 0 O-C-N 120.761 -1.212 . . . . 0.0 112.52 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -56.11 -9.52 0.65 Allowed 'General case' 0 CA--C 1.552 1.022 0 N-CA-C 116.474 2.027 . . . . 0.0 116.474 -172.415 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 t -81.46 0.52 37.36 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.927 1.691 . . . . 0.0 113.256 173.725 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 60.9 m -159.39 178.42 9.94 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.564 1.945 . . . . 0.0 110.218 179.176 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 85.68 -125.73 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.502 1.921 . . . . 0.0 113.007 172.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 170.73 -153.9 21.83 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 125.677 1.608 . . . . 0.0 111.765 -169.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -109.32 57.58 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 123.619 2.879 . . . . 0.0 112.453 -174.547 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 61.95 87.83 0.09 Allowed 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.229 1.411 . . . . 0.0 108.338 -177.415 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -46.36 152.05 0.47 Allowed 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 113.15 -1.841 . . . . 0.0 111.447 -178.686 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -136.47 101.06 10.06 Favored Pre-proline 0 CA--C 1.551 1.018 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -164.94 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.93 -27.78 3.64 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.25 1.967 . . . . 0.0 111.072 -176.171 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.25 -6.04 55.73 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.526 1.53 . . . . 0.0 111.683 167.761 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.7 t 62.69 48.16 4.4 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.98 2.112 . . . . 0.0 111.487 178.252 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.9 mtp180 -99.02 170.63 8.58 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 124.475 1.11 . . . . 0.0 112.922 -172.54 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.6 mmtt -84.92 174.17 10.01 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.89 1.676 . . . . 0.0 108.614 163.55 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 62.8 t60 -70.6 149.87 46.63 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 120.782 -1.199 . . . . 0.0 112.066 170.301 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -174.51 -165.2 30.61 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 124.071 0.843 . . . . 0.0 114.035 176.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 131.92 -100.45 0.43 Allowed Glycine 0 CA--C 1.537 1.425 0 CA-C-O 117.571 -1.683 . . . . 0.0 116.811 170.001 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.51 -19.53 23.44 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 CA-C-N 122.093 2.947 . . . . 0.0 116.377 -168.928 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.9 3.16 4.88 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.24 2.216 . . . . 0.0 112.594 176.06 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -145.88 155.7 43.06 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -164.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.57 -7.87 49.01 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 128.363 2.665 . . . . 0.0 113.402 -168.943 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -78.04 -106.39 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 118.696 0.68 . . . . 0.0 109.847 172.769 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.9 ttt180 71.58 101.01 0.07 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.166 1.386 . . . . 0.0 110.359 -172.392 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -51.8 152.67 2.82 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.789 -1.194 . . . . 0.0 111.298 166.527 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 19.3 m -52.88 -33.89 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-N 120.571 1.532 . . . . 0.0 112.785 -175.166 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.75 102.24 1.56 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 124.696 1.141 . . . . 0.0 110.639 166.015 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -160.06 116.22 2.43 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.258 2.223 . . . . 0.0 108.775 177.524 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 92.0 mt -103.01 176.32 5.19 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.577 1.08 . . . . 0.0 108.973 168.148 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.15 173.81 54.97 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 167.342 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -74.65 151.49 39.3 Favored 'General case' 0 CA--C 1.55 0.973 0 N-CA-C 115.09 1.515 . . . . 0.0 115.09 -171.544 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.2 m -102.88 117.23 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 127.974 2.51 . . . . 0.0 109.732 179.07 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.9 m -96.82 119.45 35.31 Favored 'General case' 0 N--CA 1.478 0.948 0 O-C-N 120.531 -1.356 . . . . 0.0 111.234 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.39 140.13 37.52 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -76.37 168.66 19.67 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.076 1.751 . . . . 0.0 111.798 170.62 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.8 pttm -45.74 -28.35 1.02 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.136 2.574 . . . . 0.0 115.135 170.822 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.73 -1.56 56.41 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.4 1.48 . . . . 0.0 111.818 -177.505 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.9 24.87 39.88 Favored Glycine 0 C--N 1.342 0.901 0 C-N-CA 125.274 1.416 . . . . 0.0 114.024 177.636 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.6 p -129.91 129.11 65.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 CA-C-N 118.497 1.148 . . . . 0.0 113.902 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.67 129.54 39.94 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.426 1.09 . . . . 0.0 108.129 166.076 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -79.16 151.02 31.53 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 167.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.6 t -135.04 123.87 41.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 CA-C-N 112.444 -2.162 . . . . 0.0 109.199 167.623 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.9 p -155.51 50.2 0.55 Allowed 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 124.025 1.869 . . . . 0.0 111.357 -177.311 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -103.45 170.44 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 127.603 2.361 . . . . 0.0 112.324 -166.48 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.94 121.48 20.57 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 165.622 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -98.17 137.17 37.32 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.478 0.656 . . . . 0.0 109.251 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.4 p -118.24 53.47 0.97 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.932 -1.031 . . . . 0.0 112.253 -178.709 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 13.8 p -155.18 -36.78 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.06 0.944 . . . . 0.0 112.629 168.71 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.71 168.97 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 120.115 1.325 . . . . 0.0 110.573 169.016 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 26.5 p -153.6 162.21 41.47 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 124.381 1.072 . . . . 0.0 111.335 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -83.94 66.39 9.13 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-O 122.185 0.993 . . . . 0.0 109.077 173.971 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 73.5 m -112.45 6.32 18.54 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.737 1.615 . . . . 0.0 113.713 -172.523 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.03 -110.91 3.19 Favored Glycine 0 C--N 1.342 0.871 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 175.4 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -62.49 -35.88 80.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 123.16 1.457 . . . . 0.0 112.776 -176.087 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -89.06 -1.79 58.26 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 114.389 -1.278 . . . . 0.0 111.603 -171.081 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.0 m -168.16 -103.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.218 1.807 . . . . 0.0 113.783 170.137 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.2 pt -124.09 164.35 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 120.972 1.714 . . . . 0.0 112.311 -176.78 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 105.64 121.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.234 1 C-N-CA 133.859 4.864 . . . . 0.0 108.305 -167.832 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.17 32.86 85.59 Favored Glycine 0 CA--C 1.527 0.826 0 CA-C-O 119.057 -0.857 . . . . 0.0 113.179 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.63 179.5 3.95 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 127.317 2.247 . . . . 0.0 108.323 173.577 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 21.1 m -130.6 119.35 22.36 Favored 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 121.944 2.157 . . . . 0.0 111.592 -179.078 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 22.6 tp -92.35 119.25 31.73 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.554 1.542 . . . . 0.0 110.671 177.146 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.9 p -96.42 141.07 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.503 1.921 . . . . 0.0 111.111 174.647 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.9 p -118.08 137.34 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 122.046 0.927 . . . . 0.0 111.635 171.06 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.407 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 87.5 m-70 -99.72 161.95 13.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 125.231 1.412 . . . . 0.0 113.23 -170.128 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -83.7 -23.81 31.53 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -169.596 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -142.65 -174.85 4.27 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.737 0.815 . . . . 0.0 113.032 176.297 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.66 143.7 9.17 Favored 'General case' 0 C--N 1.341 0.206 0 C-N-CA 126.013 1.725 . . . . 0.0 111.215 172.163 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.99 149.6 24.07 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.789 1.636 . . . . 0.0 112.225 173.717 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -76.24 -10.05 59.11 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.762 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.2 mt 48.01 32.95 3.13 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 128.229 2.612 . . . . 0.0 113.235 177.175 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 165.63 -61.49 0.23 Allowed Glycine 0 N--CA 1.467 0.702 0 CA-C-N 120.492 1.496 . . . . 0.0 115.165 175.3 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -157.95 98.49 1.62 Allowed 'General case' 0 N--CA 1.428 -1.542 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 177.688 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.461 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -76.56 -115.12 0.14 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 126.222 1.868 . . . . 0.0 109.505 165.084 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -142.86 9.0 2.28 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 119.585 2.594 . . . . 0.0 119.585 -168.795 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -145.22 -169.38 3.19 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 120.651 2.226 . . . . 0.0 112.308 176.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.409 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 20.6 tt0 -62.18 -49.87 74.07 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 121.173 1.806 . . . . 0.0 112.271 178.24 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.38 -22.85 63.8 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 123.439 0.696 . . . . 0.0 112.007 -177.65 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.461 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 25.2 m -64.37 -5.4 5.14 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.954 1.465 . . . . 0.0 114.954 168.193 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -122.35 -20.11 6.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.342 1.457 . . . . 0.0 112.029 172.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.409 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 85.7 mttt -84.2 -69.85 0.61 Allowed 'General case' 0 CA--C 1.547 0.839 0 O-C-N 120.983 -1.073 . . . . 0.0 111.752 172.939 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -92.11 -13.45 30.74 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 177.646 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 83.5 21.72 57.71 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 119.454 1.024 . . . . 0.0 110.855 -165.716 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 52.15 36.23 18.62 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.596 1.958 . . . . 0.0 113.7 176.848 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.1 40.61 0.08 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 116.136 1.902 . . . . 0.0 116.136 -168.799 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.91 -64.06 1.95 Allowed Glycine 0 CA--C 1.528 0.865 0 C-N-CA 126.53 2.014 . . . . 0.0 112.469 -171.543 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 29.9 t -177.07 -150.45 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 C-N-CA 126.809 2.044 . . . . 0.0 109.547 -171.262 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.407 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -156.83 104.57 2.14 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.959 2.104 . . . . 0.0 112.479 -176.77 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.2 pp -72.85 -35.57 67.25 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.222 1.409 . . . . 0.0 114.653 -176.613 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.39 172.85 9.3 Favored 'General case' 0 C--O 1.239 0.54 0 C-N-CA 124.904 1.282 . . . . 0.0 111.767 -175.77 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.0 p -156.43 165.72 35.51 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 127.225 2.21 . . . . 0.0 111.048 175.15 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.45 147.28 15.56 Favored Glycine 0 C--N 1.337 0.617 0 C-N-CA 124.58 1.086 . . . . 0.0 114.036 -175.042 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -73.12 141.37 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.051 0.541 . . . . 0.0 110.124 175.017 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.5 mp -77.78 80.0 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.535 1.134 . . . . 0.0 109.506 169.384 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -79.36 171.34 54.83 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.084 1.325 . . . . 0.0 112.485 172.472 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.414 ' H ' ' HA3' ' B' ' 51' ' ' GLY . 2.4 mp -102.05 131.25 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 126.142 1.777 . . . . 0.0 111.435 -169.478 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.62 37.84 4.25 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.975 2.11 . . . . 0.0 110.706 -179.662 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.549 0 C-N-CA 129.353 3.061 . . . . 0.0 115.072 -167.525 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 121.786 0.803 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.93 106.22 4.05 Favored 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 124.428 1.091 . . . . 0.0 109.359 169.778 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 118.22 21.39 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 170.058 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.04 168.85 18.66 Favored 'General case' 0 CA--C 1.54 0.568 0 O-C-N 120.641 -1.287 . . . . 0.0 108.51 163.576 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.67 155.35 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.8 0.81 . . . . 0.0 113.026 -166.388 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.24 143.49 25.0 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.389 2.276 . . . . 0.0 107.386 165.757 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.1 m -113.05 117.79 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 168.098 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.89 125.99 33.74 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.064 0.946 . . . . 0.0 109.863 -168.848 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -146.2 177.08 9.26 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.354 1.062 . . . . 0.0 113.507 170.651 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.12 -65.97 0.25 Allowed Glycine 0 C--N 1.33 0.201 0 C-N-CA 126.497 1.999 . . . . 0.0 109.024 -176.666 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -103.09 85.01 2.43 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.966 2.106 . . . . 0.0 112.797 -167.165 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.06 -98.43 0.01 OUTLIER Glycine 0 CA--C 1.537 1.467 0 C-N-CA 127.071 2.272 . . . . 0.0 115.98 167.785 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -77.06 -8.69 17.77 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.617 2.878 . . . . 0.0 115.433 -173.549 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -98.31 138.82 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 CA-C-N 121.061 1.755 . . . . 0.0 110.866 176.14 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.5 pm0 -160.16 166.07 30.43 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 125.43 1.492 . . . . 0.0 110.801 171.255 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.31 175.61 33.94 Favored Glycine 0 CA--C 1.507 -0.422 0 C-N-CA 123.283 0.468 . . . . 0.0 113.398 169.227 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.02 146.62 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 123.445 0.698 . . . . 0.0 110.114 169.561 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.17 155.2 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 123.807 0.843 . . . . 0.0 110.108 167.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -127.67 148.32 50.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.8 1.24 . . . . 0.0 109.669 167.735 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -128.16 97.79 4.88 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.369 1.468 . . . . 0.0 110.395 178.563 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -81.36 106.53 13.4 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.367 1.067 . . . . 0.0 113.62 -176.148 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -101.7 140.57 35.82 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 165.298 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.33 -13.47 9.28 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 125.933 1.693 . . . . 0.0 112.361 169.782 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -97.45 -145.01 0.3 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 131.019 3.728 . . . . 0.0 109.772 173.089 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 57.7 m -163.61 40.57 0.09 Allowed 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 127.883 2.473 . . . . 0.0 107.772 168.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 p30 178.02 -42.51 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 126.682 1.993 . . . . 0.0 112.436 -167.133 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.86 -168.46 21.74 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 125.333 1.444 . . . . 0.0 113.435 178.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.42 172.43 9.07 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 124.381 3.387 . . . . 0.0 114.554 -169.741 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 65.2 t -140.95 133.59 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 123.994 0.918 . . . . 0.0 111.391 177.954 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 mttp -80.18 116.95 20.56 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.285 0.564 . . . . 0.0 110.449 169.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.1 t -98.95 114.49 36.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 125.547 1.539 . . . . 0.0 109.099 170.057 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.3 p90 -137.28 154.87 50.01 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 123.529 0.731 . . . . 0.0 111.676 169.887 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 159.92 166.8 19.51 Favored Glycine 0 C--N 1.336 0.576 0 N-CA-C 114.82 0.688 . . . . 0.0 114.82 177.806 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 13.0 p -132.52 126.69 33.5 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.278 1.031 . . . . 0.0 111.3 -170.072 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.0 mm -112.77 125.38 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 124.984 1.314 . . . . 0.0 111.14 174.772 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -130.53 135.62 48.11 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 120.575 1.534 . . . . 0.0 112.737 -169.096 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.74 -4.48 10.79 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 126.197 1.856 . . . . 0.0 114.058 -176.494 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -95.16 168.8 10.53 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.866 1.667 . . . . 0.0 111.724 170.464 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 m -69.36 152.77 44.55 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 127.18 2.192 . . . . 0.0 111.859 177.064 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 9.6 pm0 -51.95 157.07 1.34 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.867 1.667 . . . . 0.0 113.52 169.257 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.73 177.56 43.96 Favored Glycine 0 CA--C 1.539 1.555 0 O-C-N 120.653 -1.279 . . . . 0.0 114.567 -176.614 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 147.58 21.32 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 128.035 2.534 . . . . 0.0 114.635 -176.071 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -144.51 130.45 19.35 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 127.068 2.147 . . . . 0.0 109.737 175.643 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.39 156.31 31.93 Favored Glycine 0 N--CA 1.476 1.305 0 C-N-CA 125.001 1.286 . . . . 0.0 113.694 -175.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -150.4 141.09 22.66 Favored 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 -170.025 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -145.43 115.9 7.6 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 118.234 -0.889 . . . . 0.0 113.303 -170.136 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -87.85 98.24 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 167.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . 0.416 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 45.4 m170 -73.83 151.43 40.54 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 121.657 -0.652 . . . . 0.0 111.703 -170.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -49.93 126.19 13.64 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.017 1.727 . . . . 0.0 113.005 174.181 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 93.24 147.28 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 130.54 3.536 . . . . 0.0 114.443 172.128 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.414 ' HA3' ' H ' ' A' ' 151' ' ' ILE . . . -77.55 -7.5 87.14 Favored Glycine 0 CA--C 1.533 1.201 0 CA-C-O 117.558 -1.69 . . . . 0.0 113.096 168.257 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -86.39 132.1 34.04 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 120.313 2.056 . . . . 0.0 109.506 167.774 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.417 HD21 ' N ' ' B' ' 53' ' ' ASN 0.317 0.0 OUTLIER -157.85 28.33 0.27 Allowed 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 114.981 1.475 . . . . 0.0 114.981 179.243 . . . . . . . . 4 4 . 1 . 027 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 17.9 p . . . . . 0 N--CA 1.464 0.268 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -168.4 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.549 0.936 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.07 167.23 27.09 Favored Glycine 0 CA--C 1.542 1.722 0 C-N-CA 125.174 1.369 . . . . 0.0 113.758 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . 0.416 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 59.9 Cg_endo -64.74 89.95 0.18 Allowed 'Trans proline' 0 C--N 1.354 0.824 1 C-N-CA 125.881 4.387 . . . . 0.0 112.248 -170.097 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.379 0.1 OUTLIER 47.94 59.67 4.06 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 127.167 2.187 . . . . 0.0 113.79 175.85 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -47.72 129.88 14.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 111.884 -2.417 . . . . 0.0 109.541 168.034 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -110.21 66.33 0.44 Allowed Pre-proline 0 CA--C 1.549 0.931 0 C-N-CA 125.964 1.706 . . . . 0.0 114.823 -167.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -64.16 -21.04 67.84 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.002 2.468 . . . . 0.0 116.045 -169.417 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.38 -4.44 48.19 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.795 0.838 . . . . 0.0 112.703 172.488 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.0 t 67.36 46.99 1.34 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 128.691 2.797 . . . . 0.0 110.513 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.8 mtm-85 -109.5 167.1 10.38 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.059 -177.658 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -85.85 176.84 7.87 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 127.657 2.383 . . . . 0.0 108.175 167.016 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . 0.458 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 21.9 t60 -62.63 175.21 0.84 Allowed 'General case' 0 CA--C 1.544 0.745 0 O-C-N 121.336 -0.852 . . . . 0.0 112.812 173.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.68 -149.79 20.75 Favored Glycine 0 C--N 1.339 0.718 0 N-CA-C 115.641 1.016 . . . . 0.0 115.641 170.386 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.86 -117.3 2.17 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 125.727 1.632 . . . . 0.0 112.755 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -65.01 -11.37 29.5 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.786 2.991 . . . . 0.0 116.075 -169.305 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.53 -3.13 10.92 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 119.534 1.061 . . . . 0.0 113.145 168.737 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -152.17 98.03 2.37 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -166.783 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 63.9 mm-40 -39.72 -4.99 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 131.32 3.848 . . . . 0.0 118.47 171.316 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -74.0 -75.95 0.14 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 121.021 1.737 . . . . 0.0 110.116 170.522 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.254 0.0 OUTLIER 52.76 107.02 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 127.326 2.251 . . . . 0.0 113.869 -177.595 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -54.53 143.79 23.3 Favored 'General case' 0 CA--C 1.552 1.028 0 O-C-N 119.631 -1.918 . . . . 0.0 110.525 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 96.9 t -35.36 -59.26 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -168.123 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.78 18.71 16.68 Favored Glycine 0 N--CA 1.468 0.801 0 CA-C-O 119.335 -0.703 . . . . 0.0 112.989 176.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.46 89.68 2.88 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-N 119.526 1.663 . . . . 0.0 111.775 -167.633 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.11 163.35 37.71 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 114.634 -1.166 . . . . 0.0 113.578 -167.86 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 78.25 170.37 36.47 Favored Glycine 0 N--CA 1.472 1.044 0 N-CA-C 115.274 0.87 . . . . 0.0 115.274 168.46 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -134.48 149.54 50.73 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.908 1.283 . . . . 0.0 109.969 174.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.5 m -112.53 129.31 68.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.884 1.674 . . . . 0.0 109.204 169.505 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.7 m -113.15 133.81 54.86 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 121.24 -0.913 . . . . 0.0 109.903 -170.119 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.15 137.3 32.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.711 1.204 . . . . 0.0 113.522 -178.212 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.86 -59.25 2.86 Favored 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -168.212 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 172.81 -40.88 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 128.405 2.682 . . . . 0.0 110.731 -166.047 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -78.25 13.2 1.58 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 125.877 1.671 . . . . 0.0 112.281 174.154 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.77 25.56 70.57 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-O 118.932 -0.927 . . . . 0.0 113.38 -177.242 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -105.96 109.52 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 126.338 1.855 . . . . 0.0 110.991 176.155 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -79.28 108.84 13.08 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 168.175 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -110.53 159.04 17.88 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 122.313 1.054 . . . . 0.0 112.273 -176.412 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -149.6 148.0 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 CA-C-N 113.62 -1.627 . . . . 0.0 115.302 176.91 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -157.77 98.61 1.65 Allowed 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 124.2 1.0 . . . . 0.0 112.306 169.687 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 15.2 mt -139.7 152.3 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 127.522 2.329 . . . . 0.0 110.876 -172.746 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -117.53 127.23 53.78 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 165.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -117.28 146.49 43.28 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.517 1.527 . . . . 0.0 111.049 176.097 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 51.31 0.95 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.495 0.718 . . . . 0.0 112.913 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 47.2 t -136.39 -50.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.252 1.421 . . . . 0.0 109.635 175.336 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.84 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 CA-C-N 119.128 0.877 . . . . 0.0 111.747 174.656 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.88 161.66 39.67 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 119.888 -1.758 . . . . 0.0 111.251 -178.453 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.83 58.46 1.89 Allowed 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.88 1.324 . . . . 0.0 110.602 177.257 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.31 160.6 20.67 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 124.544 1.137 . . . . 0.0 108.8 168.128 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.25 -59.0 10.15 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 119.612 2.605 . . . . 0.0 119.612 -163.21 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -148.94 34.87 0.75 Allowed 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 122.862 1.315 . . . . 0.0 110.745 -172.142 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -158.01 4.08 0.12 Allowed 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 114.957 1.466 . . . . 0.0 114.957 -168.759 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 10.6 t -133.28 -91.21 0.37 Allowed 'General case' 0 N--CA 1.48 1.031 0 O-C-N 119.984 -1.698 . . . . 0.0 109.634 -178.313 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.283 5.4 pt -120.26 -14.66 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-N 121.185 1.811 . . . . 0.0 115.696 166.861 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm -82.75 152.64 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 161.122 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.05 41.71 86.58 Favored Glycine 0 N--CA 1.467 0.703 0 C-N-CA 124.103 0.858 . . . . 0.0 112.401 -176.446 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -144.88 171.16 14.82 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 127.242 2.217 . . . . 0.0 109.004 172.17 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.5 t -139.42 122.66 16.98 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.873 -1.142 . . . . 0.0 110.979 -177.694 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 39.8 tp -92.07 108.87 20.25 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -169.464 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.8 p -90.62 142.35 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 125.32 1.448 . . . . 0.0 110.117 168.136 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -120.66 146.09 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.458 0.646 . . . . 0.0 111.316 172.012 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -105.63 141.37 37.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.56 1.544 . . . . 0.0 114.369 -168.728 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.317 0.2 OUTLIER -72.03 -18.39 61.96 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 120.841 -1.162 . . . . 0.0 112.037 178.24 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mttp -104.29 162.92 12.79 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 124.466 1.106 . . . . 0.0 112.759 168.067 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.0 165.08 9.44 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.308 1.843 . . . . 0.0 110.789 167.046 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . 0.46 ' HB3' ' H ' ' B' ' 126' ' ' LEU . 12.4 m-20 -95.2 158.9 15.26 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 122.126 0.965 . . . . 0.0 113.177 169.712 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.34 -7.9 50.2 Favored 'General case' 0 CA--C 1.557 1.22 0 CA-C-N 113.715 -1.584 . . . . 0.0 112.561 167.026 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . 0.46 ' H ' ' HB3' ' B' ' 124' ' ' ASP . 96.3 mt 33.11 44.91 0.06 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 129.543 3.137 . . . . 0.0 114.068 -174.737 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.67 -52.38 0.83 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 115.854 1.101 . . . . 0.0 115.854 168.773 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -155.99 80.94 1.0 Allowed 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 117.046 2.239 . . . . 0.0 117.046 -169.22 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . 0.526 ' H ' ' HB3' ' B' ' 134' ' ' SER . . . -80.2 -115.02 0.29 Allowed Glycine 0 CA--C 1.524 0.625 0 C-N-CA 124.076 0.846 . . . . 0.0 111.009 166.389 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -137.9 11.72 3.65 Favored Glycine 0 N--CA 1.472 1.071 0 N-CA-C 116.893 1.517 . . . . 0.0 116.893 -169.338 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -144.12 174.84 10.52 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 119.819 1.81 . . . . 0.0 111.765 177.65 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . 0.51 ' CG ' ' HE3' ' B' ' 136' ' ' LYS . 3.2 tp10 -51.59 -64.27 0.87 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.463 1.505 . . . . 0.0 112.574 173.08 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -53.18 -31.15 41.29 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -179.638 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 134' ' ' SER . . . . . 0.526 ' HB3' ' H ' ' B' ' 129' ' ' GLY . 26.1 m -49.69 -39.23 36.09 Favored 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.832 1.651 . . . . 0.0 113.969 170.773 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.76 -58.32 2.14 Favored 'General case' 0 CA--C 1.52 -0.205 0 C-N-CA 127.191 2.196 . . . . 0.0 110.294 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.51 ' HE3' ' CG ' ' B' ' 132' ' ' GLU . 22.2 ttpp -61.98 -39.62 92.81 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.1 1.36 . . . . 0.0 113.47 -172.197 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 p -109.4 -79.04 0.58 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 119.523 1.056 . . . . 0.0 110.179 174.079 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 170.71 11.9 0.02 OUTLIER Glycine 0 CA--C 1.54 1.65 1 C-N-CA 131.625 4.44 . . . . 0.0 115.389 -179.006 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 58.97 -35.67 0.06 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 128.831 2.852 . . . . 0.0 117.257 -170.688 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.79 -44.19 1.0 Allowed 'General case' 0 CA--C 1.554 1.113 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -165.33 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.57 -82.05 1.53 Allowed Glycine 0 C--N 1.341 0.829 0 N-CA-C 117.108 1.603 . . . . 0.0 117.108 164.264 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.3 t -80.78 151.62 28.69 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 123.817 0.847 . . . . 0.0 111.143 -169.083 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.49 159.53 42.62 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.728 1.149 . . . . 0.0 113.966 -168.539 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.22 -9.07 2.0 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 125.574 1.796 . . . . 0.0 115.524 -171.39 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -173.3 149.42 1.75 Allowed 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.354 1.062 . . . . 0.0 111.12 -177.657 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.0 t -148.31 150.83 34.32 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.673 1.589 . . . . 0.0 111.413 177.712 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.9 138.03 5.71 Favored Glycine 0 N--CA 1.474 1.191 0 CA-C-N 119.367 0.985 . . . . 0.0 114.55 175.192 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -74.28 144.54 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.351 0.66 . . . . 0.0 111.264 -179.644 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 13.3 mm -84.65 105.97 14.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 CA-C-O 121.635 0.731 . . . . 0.0 111.764 179.291 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.87 -175.73 19.06 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 125.07 1.319 . . . . 0.0 111.456 168.235 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 3.9 mp -122.32 132.49 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 O-C-N 121.105 -1.233 . . . . 0.0 110.772 -169.732 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 -7.93 16.21 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.056 1.343 . . . . 0.0 113.071 171.145 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.305 0.7 OUTLIER . . . . . 0 C--O 1.238 0.451 0 C-N-CA 126.358 1.863 . . . . 0.0 112.734 -179.443 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.107 0.956 . . . . 0.0 111.646 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -75.91 161.66 28.77 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -167.655 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.44 164.2 28.32 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.996 1.318 . . . . 0.0 110.255 168.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.496 ' CG1' ' HA ' ' B' ' 52' ' ' ASP . 7.3 p -132.61 129.56 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 124.612 1.165 . . . . 0.0 109.265 -179.027 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.81 110.72 15.44 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 120.994 -1.066 . . . . 0.0 109.179 177.869 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 t -81.17 60.26 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 123.997 0.919 . . . . 0.0 111.563 -169.087 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.2 mp -76.72 116.87 17.78 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -167.779 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.4 mtmt -145.95 175.09 10.7 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 125.453 1.501 . . . . 0.0 111.896 179.021 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.92 -3.56 7.96 Favored Glycine 0 N--CA 1.474 1.233 0 N-CA-C 119.902 2.721 . . . . 0.0 119.902 166.832 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -137.29 83.11 1.97 Allowed 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 121.607 2.704 . . . . 0.0 110.163 178.827 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 38.44 -105.99 0.05 OUTLIER Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.522 2.011 . . . . 0.0 114.032 179.482 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -73.66 -5.84 17.73 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 124.279 3.32 . . . . 0.0 113.954 -176.25 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 t -94.06 126.65 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 125.066 1.346 . . . . 0.0 111.699 -177.347 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -146.61 168.32 21.58 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 126.818 2.047 . . . . 0.0 108.01 169.457 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.23 170.91 24.82 Favored Glycine 0 CA--C 1.507 -0.413 0 CA-C-N 115.224 -0.898 . . . . 0.0 112.606 168.317 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 pt -150.34 53.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 114.195 -1.002 . . . . 0.0 111.169 -167.657 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.6 mm -80.35 112.23 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 O-C-N 120.984 -1.072 . . . . 0.0 110.348 -169.447 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.09 149.23 33.93 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 125.18 1.392 . . . . 0.0 111.491 175.969 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -134.51 116.24 14.85 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.299 1.84 . . . . 0.0 108.641 178.099 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -97.97 112.38 24.34 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.919 1.288 . . . . 0.0 112.255 175.329 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.4 tp60 -107.4 129.32 54.94 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 125.338 1.455 . . . . 0.0 109.226 177.968 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.53 -48.99 6.94 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.85 0.86 . . . . 0.0 111.447 178.784 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.63 136.46 51.67 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 127.302 2.241 . . . . 0.0 108.933 174.695 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 m -62.55 0.62 0.46 Allowed 'General case' 0 N--CA 1.48 1.05 0 N-CA-C 117.594 2.442 . . . . 0.0 117.594 -168.919 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.6 m-80 -114.22 -9.89 12.81 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 127.727 2.411 . . . . 0.0 113.9 178.033 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.6 -178.09 33.9 Favored Glycine 0 CA--C 1.537 1.424 0 CA-C-N 119.491 1.041 . . . . 0.0 115.053 -169.372 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -70.82 160.09 50.51 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.592 3.528 . . . . 0.0 110.898 -178.486 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.9 t -129.81 138.04 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.929 -0.482 . . . . 0.0 111.083 -170.68 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -86.37 121.11 28.47 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 168.745 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.4 t -109.87 121.46 62.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.969 2.107 . . . . 0.0 108.692 -177.571 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -148.25 165.04 32.18 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 177.541 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.84 -173.37 14.67 Favored Glycine 0 N--CA 1.468 0.828 0 O-C-N 121.431 -0.793 . . . . 0.0 112.333 -178.741 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.85 167.32 21.98 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 -164.916 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -125.11 129.67 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 127.408 2.283 . . . . 0.0 108.421 171.709 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 44.8 pttt -115.33 159.01 21.59 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 120.316 1.416 . . . . 0.0 111.796 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.94 -6.97 73.4 Favored Glycine 0 N--CA 1.475 1.253 0 C-N-CA 125.371 1.462 . . . . 0.0 114.517 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 8.2 mp -62.86 153.17 34.07 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.872 2.069 . . . . 0.0 111.583 173.066 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -78.75 158.6 28.23 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 166.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -55.21 143.49 27.54 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.472 0.709 . . . . 0.0 112.87 175.607 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.09 -176.14 21.74 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 123.992 0.806 . . . . 0.0 114.84 177.44 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -68.29 139.19 55.93 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 127.775 2.43 . . . . 0.0 113.247 -171.124 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -145.45 120.37 9.99 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 128.565 2.746 . . . . 0.0 110.349 -174.711 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.98 22.88 Favored Glycine 0 N--CA 1.482 1.73 0 CA-C-O 117.095 -1.947 . . . . 0.0 112.716 -175.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -130.41 120.78 24.76 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.742 1.771 . . . . 0.0 113.478 177.522 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.414 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -154.3 156.11 36.37 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 115.195 -0.912 . . . . 0.0 112.843 -168.737 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 p -77.01 135.51 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 122.992 0.517 . . . . 0.0 109.844 171.305 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -112.48 171.97 7.2 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.895 1.678 . . . . 0.0 111.459 172.19 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -40.69 119.77 1.17 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.093 1.757 . . . . 0.0 113.178 -176.072 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -88.63 -164.43 1.13 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.846 2.458 . . . . 0.0 111.045 -177.328 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.71 -79.11 0.9 Allowed Glycine 0 C--N 1.334 0.464 0 N-CA-C 115.327 0.891 . . . . 0.0 115.327 167.076 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 44.9 p-10 -128.99 47.88 2.42 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 126.805 2.042 . . . . 0.0 115.19 -164.029 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 11.6 p30 -154.75 -30.73 0.11 Allowed 'General case' 0 N--CA 1.478 0.97 0 O-C-N 120.577 -1.327 . . . . 0.0 114.48 -172.68 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.342 12.4 t 21.15 35.88 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.6 1 C-N-CA 133.235 4.614 . . . . 0.0 120.408 173.251 . . . . . . . . 3 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -146.57 -2.78 0.64 Allowed 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 128.35 2.66 . . . . 0.0 111.101 169.652 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.42 -154.79 24.49 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.244 1.402 . . . . 0.0 114.0 175.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.2 t -46.86 -27.39 1.22 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.117 1.767 . . . . 0.0 115.263 -172.861 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 t -56.16 -14.51 2.77 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 126.715 2.006 . . . . 0.0 114.528 169.006 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.9 t -150.28 9.37 0.65 Allowed 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 127.044 2.138 . . . . 0.0 113.74 174.857 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -129.22 172.97 10.92 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 -168.167 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -97.95 -150.54 26.42 Favored Glycine 0 CA--C 1.546 2.021 0 C-N-CA 125.367 1.46 . . . . 0.0 115.383 -176.276 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -78.75 -170.03 0.91 Allowed 'Trans proline' 0 C--N 1.352 0.761 1 C-N-CA 127.831 5.688 . . . . 0.0 111.385 -179.651 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.414 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 12.2 m170 -62.69 116.51 5.26 Favored 'General case' 0 N--CA 1.451 -0.412 0 O-C-N 121.97 -0.456 . . . . 0.0 111.029 177.743 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 146.94 44.46 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -174.383 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -110.32 79.69 1.72 Allowed Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.656 1.354 . . . . 0.0 114.656 -176.117 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.81 -12.55 14.83 Favored 'Trans proline' 0 CA--C 1.54 0.778 0 C-N-CA 123.14 2.56 . . . . 0.0 112.071 168.12 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.1 mt -137.61 2.82 2.48 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.163 1.785 . . . . 0.0 112.797 -168.394 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 25.2 m 58.96 70.18 0.67 Allowed 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 124.824 1.249 . . . . 0.0 113.092 168.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -155.48 177.42 11.39 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 119.874 3.287 . . . . 0.0 119.874 -163.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.407 ' HE2' ' N ' ' A' ' 70' ' ' LYS . 0.7 OUTLIER -78.81 178.03 8.24 Favored 'General case' 0 CA--C 1.549 0.907 0 CA-C-N 113.992 -1.458 . . . . 0.0 111.499 168.057 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.441 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 83.7 t60 -115.85 159.81 21.01 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -168.701 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.441 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 136.37 -102.81 0.42 Allowed Glycine 0 C--N 1.333 0.378 0 C-N-CA 125.586 1.565 . . . . 0.0 109.829 166.54 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.55 -36.92 4.08 Favored Glycine 0 CA--C 1.549 2.17 0 CA-C-O 117.448 -1.751 . . . . 0.0 116.558 -177.034 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -73.45 -19.98 21.3 Favored 'Trans proline' 0 C--N 1.358 1.043 0 CA-C-N 122.156 2.978 . . . . 0.0 113.863 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.19 -1.42 0.74 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 125.488 1.515 . . . . 0.0 112.267 -175.011 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -122.37 139.92 53.27 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 128.701 2.8 . . . . 0.0 107.192 -178.15 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -97.43 -9.24 27.66 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 128.052 2.541 . . . . 0.0 112.647 -174.456 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -82.57 -82.49 0.14 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.087 0.858 . . . . 0.0 109.196 -178.708 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 79.95 110.92 0.07 Allowed 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 126.604 1.961 . . . . 0.0 114.213 164.74 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 8.4 m80 -62.43 128.52 36.4 Favored 'General case' 0 CA--C 1.546 0.811 0 O-C-N 119.784 -1.823 . . . . 0.0 107.247 167.098 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.2 p -39.83 -36.6 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.215 0 N-CA-C 118.556 2.798 . . . . 0.0 118.556 -167.185 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.65 19.51 36.04 Favored Glycine 0 N--CA 1.477 1.386 0 CA-C-N 120.283 1.401 . . . . 0.0 115.39 178.687 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -78.31 140.35 38.81 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 119.223 1.512 . . . . 0.0 112.315 174.798 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.3 -176.36 3.12 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 163.224 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.52 -137.21 2.65 Favored Glycine 0 N--CA 1.468 0.831 0 O-C-N 121.322 -0.861 . . . . 0.0 111.861 174.808 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.6 p30 -100.59 147.39 26.0 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 122.006 -0.702 . . . . 0.0 112.008 168.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.47 149.84 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 127.572 2.349 . . . . 0.0 107.328 169.183 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.4 m -107.94 140.29 41.29 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.774 -0.579 . . . . 0.0 110.058 179.204 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.43 138.7 31.34 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.725 0.81 . . . . 0.0 111.944 171.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -80.37 147.61 30.97 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.468 1.507 . . . . 0.0 109.991 168.168 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.547 ' HZ2' ' CG ' ' A' ' 92' ' ' ASP . 1.4 pptp? -46.69 -22.18 0.27 Allowed 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 128.605 2.762 . . . . 0.0 116.641 174.329 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.547 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 82.3 m-20 -76.13 0.27 19.48 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.177 1.391 . . . . 0.0 112.186 172.599 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.39 28.97 8.64 Favored Glycine 0 C--N 1.342 0.885 0 C-N-CA 125.987 1.756 . . . . 0.0 114.568 169.545 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.74 134.66 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 119.83 1.815 . . . . 0.0 115.282 -175.225 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.07 110.64 22.69 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 124.597 1.159 . . . . 0.0 107.907 166.334 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -106.71 137.9 43.88 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 122.356 1.074 . . . . 0.0 111.387 175.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -116.65 147.09 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-N 112.555 -2.111 . . . . 0.0 114.464 -168.649 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 82.8 p -158.93 90.1 0.97 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 178.655 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.3 mp -132.46 154.87 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 125.847 1.659 . . . . 0.0 112.968 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -117.76 115.99 26.13 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 164.039 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -117.57 114.54 23.57 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.327 1.061 . . . . 0.0 111.451 -171.375 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.6 p -84.03 54.91 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.472 -0.767 . . . . 0.0 111.686 -175.035 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.7 p -142.7 -17.55 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 114.75 1.389 . . . . 0.0 114.75 -169.813 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 pp -142.69 161.91 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.914 1.234 . . . . 0.0 112.622 -176.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.535 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.0 m -145.1 155.36 43.28 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 125.528 1.531 . . . . 0.0 113.601 -179.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.4 mp -83.67 56.94 3.83 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.781 1.632 . . . . 0.0 111.14 -175.449 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.03 -56.05 2.41 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.38 1.472 . . . . 0.0 110.543 178.365 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 143.38 -102.6 0.29 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 115.637 1.015 . . . . 0.0 115.637 169.572 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.81 -33.98 72.45 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 125.02 1.328 . . . . 0.0 111.873 175.002 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -80.02 1.0 29.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.036 1.734 . . . . 0.0 113.245 170.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.535 ' CB ' ' H ' ' A' ' 105' ' ' SER . 1.6 m -166.51 -90.42 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 169.846 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.385 7.6 pt -119.16 -99.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -179.015 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . 0.274 24.2 mm 37.11 -88.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 127.37 2.268 . . . . 0.0 113.794 -169.024 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.18 2.4 9.44 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-N 119.911 1.232 . . . . 0.0 115.091 175.612 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -79.38 152.1 30.58 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.571 1.685 . . . . 0.0 107.399 168.465 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.6 t -125.61 119.65 28.66 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 122.237 -0.289 . . . . 0.0 111.126 -168.871 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.72 130.3 34.71 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 124.461 1.104 . . . . 0.0 108.506 176.29 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.5 p -125.69 138.17 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.409 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 32.1 t -101.88 157.01 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 169.196 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.402 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 35.0 m-70 -130.22 146.68 51.86 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.619 1.568 . . . . 0.0 111.886 -167.372 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -71.56 -4.22 25.71 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.852 1.261 . . . . 0.0 114.044 -170.633 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 21.7 mmmt -127.68 160.36 31.91 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.061 1.345 . . . . 0.0 111.953 176.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.46 162.81 0.72 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.381 1.472 . . . . 0.0 112.505 169.719 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -111.27 130.18 55.74 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.302 1.841 . . . . 0.0 109.847 -175.336 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.265 1.0 OUTLIER -84.38 -8.15 59.08 Favored 'General case' 0 N--CA 1.48 1.04 0 N-CA-C 116.007 1.854 . . . . 0.0 116.007 -178.931 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 31.6 mt 63.73 42.18 6.43 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.576 1.95 . . . . 0.0 114.71 167.532 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 113.36 -38.11 3.34 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.447 1.022 . . . . 0.0 114.901 167.785 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.52 88.78 1.08 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 119.138 3.014 . . . . 0.0 119.138 169.62 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.4 -69.28 0.88 Allowed Glycine 0 CA--C 1.522 0.487 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 161.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.55 -107.94 3.25 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 117.714 1.846 . . . . 0.0 117.714 -168.557 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -102.56 -158.48 0.67 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.126 1.77 . . . . 0.0 113.861 -161.102 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.63 -47.68 49.63 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.133 0.573 . . . . 0.0 111.468 170.176 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -57.0 -34.28 67.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.007 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -52.43 -30.04 27.46 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 120.315 1.416 . . . . 0.0 112.04 170.109 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.2 p -97.55 -34.1 11.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 117.454 -1.26 . . . . 0.0 113.812 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -92.26 -46.23 7.82 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 114.651 1.352 . . . . 0.0 114.651 -176.835 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 17.9 p -90.81 -95.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.538 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 170.199 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -171.74 26.07 0.09 OUTLIER Glycine 0 CA--C 1.536 1.344 1 C-N-CA 132.568 4.89 . . . . 0.0 110.418 176.645 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.59 -7.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 129.488 3.115 . . . . 0.0 116.714 -168.989 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.44 -38.36 43.02 Favored 'General case' 0 CA--C 1.55 0.98 0 CA-C-N 119.958 1.254 . . . . 0.0 113.939 -169.401 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.0 -116.03 4.22 Favored Glycine 0 N--CA 1.47 0.906 0 O-C-N 121.024 -1.048 . . . . 0.0 112.577 172.482 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 20.7 m -44.88 115.52 0.9 Allowed 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.524 1.53 . . . . 0.0 114.69 -169.924 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.63 160.5 31.46 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 121.41 -0.806 . . . . 0.0 112.482 172.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.277 3.9 pp -142.28 -153.38 0.46 Allowed 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 126.829 2.052 . . . . 0.0 107.474 165.414 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.85 132.58 46.66 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 119.817 1.19 . . . . 0.0 113.269 -171.38 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.6 p -130.89 146.01 52.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 126.655 1.982 . . . . 0.0 111.63 -174.525 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.17 159.63 30.94 Favored Glycine 0 N--CA 1.472 1.038 0 N-CA-C 114.61 0.604 . . . . 0.0 114.61 179.362 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.59 161.85 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 C-N-CA 123.632 0.773 . . . . 0.0 109.676 168.409 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 27.8 mm -88.52 64.54 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 125.169 1.388 . . . . 0.0 110.096 178.773 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -68.82 139.49 33.08 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -174.06 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -77.76 144.78 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 O-C-N 121.719 -0.871 . . . . 0.0 111.16 -174.33 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.6 -17.16 10.03 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.162 2.185 . . . . 0.0 112.138 175.851 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 N--CA 1.468 0.468 0 C-N-CA 128.594 2.758 . . . . 0.0 113.428 175.27 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.502 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.2 m -78.14 106.09 9.8 Favored 'General case' 0 CA--C 1.51 -0.585 0 C-N-CA 124.766 1.226 . . . . 0.0 110.078 -172.763 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtmm -92.92 124.57 36.99 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 123.624 1.678 . . . . 0.0 113.305 178.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -115.66 175.37 5.56 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 127.256 2.222 . . . . 0.0 108.951 166.653 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -148.16 146.74 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -177.611 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.13 119.89 36.1 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 163.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -124.78 115.25 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 175.848 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -103.91 147.12 27.71 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.041 1.336 . . . . 0.0 111.052 -179.025 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -140.3 142.88 35.64 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.095 1.358 . . . . 0.0 109.442 164.884 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.36 -117.17 3.52 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-O 122.96 1.311 . . . . 0.0 111.348 173.116 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.74 49.68 1.85 Allowed 'General case' 0 C--N 1.314 -0.974 0 C-N-CA 126.715 2.006 . . . . 0.0 113.529 -163.146 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -81.25 0.71 Allowed Glycine 0 CA--C 1.538 1.502 0 CA-C-O 117.289 -1.839 . . . . 0.0 113.115 -175.78 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -98.29 -2.3 1.13 Allowed 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 123.818 3.012 . . . . 0.0 115.183 -169.726 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -89.88 125.88 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-N 121.049 1.749 . . . . 0.0 110.08 178.174 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -130.61 166.99 19.47 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 124.039 0.935 . . . . 0.0 112.713 174.93 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.93 104.26 0.31 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 114.118 -1.401 . . . . 0.0 111.176 169.046 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.33 127.43 47.33 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.114 0 CA-C-N 118.781 1.291 . . . . 0.0 109.278 169.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 mm -131.85 112.44 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 126.46 1.904 . . . . 0.0 108.662 170.882 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -82.87 139.39 33.47 Favored 'General case' 0 CA--C 1.542 0.667 0 O-C-N 120.988 -1.07 . . . . 0.0 111.553 169.302 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -115.84 103.82 11.02 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.545 1.538 . . . . 0.0 110.541 179.308 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -108.51 108.13 18.93 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.592 1.157 . . . . 0.0 113.31 179.186 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -97.93 160.91 14.01 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.816 1.246 . . . . 0.0 110.603 171.304 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.78 -21.19 8.55 Favored 'General case' 0 CA--C 1.544 0.729 0 N-CA-C 114.214 1.19 . . . . 0.0 114.214 178.934 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.48 -165.72 1.08 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 127.739 2.416 . . . . 0.0 108.788 168.21 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.2 m -110.79 -11.28 14.4 Favored 'General case' 0 N--CA 1.48 1.026 0 O-C-N 120.612 -1.305 . . . . 0.0 112.118 167.001 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 m-80 -138.05 101.1 4.33 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.743 2.017 . . . . 0.0 107.893 168.712 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.73 -175.1 37.46 Favored Glycine 0 CA--C 1.539 1.565 0 C-N-CA 125.325 1.441 . . . . 0.0 111.77 -175.464 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.41 149.6 80.53 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 123.197 2.598 . . . . 0.0 115.853 -168.497 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 t -124.31 133.83 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.454 1.501 . . . . 0.0 109.749 -177.536 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -78.8 125.07 28.87 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.628 0.771 . . . . 0.0 109.507 170.086 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.65 77.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 C-N-CA 127.414 2.286 . . . . 0.0 106.201 -178.541 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -102.02 154.91 18.54 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.957 170.819 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 170.2 -177.37 43.52 Favored Glycine 0 C--O 1.227 -0.335 0 O-C-N 121.361 -0.837 . . . . 0.0 113.806 -176.72 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 76.7 p -155.41 127.99 7.91 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 124.129 0.972 . . . . 0.0 111.192 -179.691 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.6 163.63 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 168.28 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 48.5 tttp -156.56 122.46 4.89 Favored 'General case' 0 N--CA 1.444 -0.739 0 O-C-N 120.851 -1.156 . . . . 0.0 108.588 165.247 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.52 1.03 12.32 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.277 1.894 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 62.0 mt -71.29 171.52 10.97 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 120.266 2.033 . . . . 0.0 110.046 168.648 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.0 t -91.42 158.04 16.73 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 163.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -58.88 147.07 35.25 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.412 1.085 . . . . 0.0 111.886 -178.75 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.04 -173.75 20.92 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 124.58 1.086 . . . . 0.0 112.266 -177.51 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.521 HD21 ' H ' ' B' ' 42' ' ' LEU . 1.4 pt? -87.38 140.57 29.4 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.781 2.032 . . . . 0.0 112.016 -172.308 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -143.03 138.34 29.9 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.506 2.322 . . . . 0.0 108.141 -177.21 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -89.07 139.41 15.24 Favored Glycine 0 N--CA 1.473 1.139 0 CA-C-N 121.709 2.049 . . . . 0.0 111.031 -175.019 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -137.1 140.14 41.74 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.013 1.906 . . . . 0.0 111.963 170.407 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -149.9 154.99 39.24 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 121.126 -0.984 . . . . 0.0 111.843 -174.344 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.71 151.09 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 124.683 1.193 . . . . 0.0 109.67 -179.052 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -86.94 176.13 7.81 Favored 'General case' 0 CA--C 1.546 0.815 0 CA-C-O 122.556 1.169 . . . . 0.0 112.911 178.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -74.68 112.29 10.73 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 160.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.77 -162.71 0.16 Allowed 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.502 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -118.85 33.85 4.59 Favored Glycine 0 C--N 1.342 0.865 0 C-N-CA 128.019 2.723 . . . . 0.0 111.549 178.852 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . 0.496 ' HA ' ' CG1' ' A' ' 5' ' ' VAL . 45.7 p-10 -116.91 69.29 0.75 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 124.048 1.88 . . . . 0.0 112.768 -169.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . 0.722 ' ND2' ' HG1' ' B' ' 116' ' ' THR . 0.3 OUTLIER -124.22 57.94 1.21 Allowed 'General case' 0 C--O 1.244 0.813 0 N-CA-C 116.62 2.081 . . . . 0.0 116.62 -160.939 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.278 13.2 p . . . . . 0 C--N 1.32 -0.712 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.603 -163.122 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.239 0.514 0 CA-C-O 121.08 0.467 . . . . 0.0 111.583 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.55 -115.57 2.37 Favored Glycine 0 CA--C 1.541 1.663 0 C-N-CA 127.21 2.338 . . . . 0.0 113.27 -178.213 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.72 157.21 62.78 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.983 3.789 . . . . 0.0 116.152 -164.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -38.59 101.28 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 127.011 2.124 . . . . 0.0 116.033 169.675 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -58.95 119.4 7.15 Favored 'General case' 0 CA--C 1.544 0.722 0 O-C-N 121.574 -0.704 . . . . 0.0 109.63 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -104.23 75.8 0.25 Allowed Pre-proline 0 CA--C 1.549 0.91 0 C-N-CA 127.335 2.254 . . . . 0.0 112.588 -172.445 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -56.61 -33.01 92.19 Favored 'Trans proline' 0 C--N 1.355 0.879 0 C-N-CA 123.532 2.822 . . . . 0.0 115.843 -168.934 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 97.3 mt -79.76 -3.35 47.24 Favored 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 175.413 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.9 t 65.73 52.23 1.33 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.734 2.014 . . . . 0.0 112.912 178.705 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 11.4 mtp180 -105.57 172.33 6.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 -169.313 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -81.09 172.69 13.39 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 122.769 0.428 . . . . 0.0 110.518 165.025 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -104.49 146.5 28.78 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -170.791 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.15 -140.6 11.95 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 113.641 -1.618 . . . . 0.0 113.323 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 149.91 -29.46 1.13 Allowed Glycine 0 CA--C 1.545 1.932 0 N-CA-C 118.399 2.12 . . . . 0.0 118.399 -179.432 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.83 -4.56 14.32 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 122.766 3.283 . . . . 0.0 112.998 168.535 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.93 -37.18 0.15 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.976 1.31 . . . . 0.0 109.752 165.853 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -61.39 109.26 1.1 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 123.621 1.676 . . . . 0.0 112.49 -176.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 pm0 -44.03 -30.71 0.77 Allowed 'General case' 0 C--N 1.318 -0.794 1 C-N-CA 134.058 4.943 . . . . 0.0 115.689 169.198 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -90.85 -62.96 1.34 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.936 0.789 . . . . 0.0 111.123 -176.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.269 32.1 ptt180 55.34 121.26 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 129.114 2.966 . . . . 0.0 115.346 -175.507 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -56.7 151.33 14.19 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 119.141 -2.224 . . . . 0.0 112.65 173.581 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 80.5 t -49.96 -56.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 CA-C-N 118.753 0.706 . . . . 0.0 110.603 -176.926 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.69 115.25 5.17 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 105.132 -3.187 . . . . 0.0 105.132 164.333 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -158.35 158.26 33.97 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.9 0.85 . . . . 0.0 112.675 172.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 83.1 mt -144.19 153.07 41.71 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.99 2.116 . . . . 0.0 106.439 168.335 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -113.06 -124.1 4.17 Favored Glycine 0 N--CA 1.471 1.026 0 C-N-CA 124.459 1.028 . . . . 0.0 111.046 172.443 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 -78.54 135.11 37.23 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -175.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.74 121.07 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 C-N-CA 131.082 3.753 . . . . 0.0 108.84 167.053 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.1 m -119.22 119.27 33.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.102 0.961 . . . . 0.0 110.963 -170.257 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.58 160.3 14.69 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.947 1.299 . . . . 0.0 113.972 -174.758 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -84.69 178.12 7.79 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 128.593 2.757 . . . . 0.0 112.633 170.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -20.85 65.81 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 120.865 -1.147 . . . . 0.0 113.2 169.387 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -73.77 -11.7 60.47 Favored 'General case' 0 CA--C 1.55 0.969 0 CA-C-O 121.791 0.805 . . . . 0.0 110.145 171.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.84 2.75 88.42 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.843 1.687 . . . . 0.0 113.462 176.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -84.11 134.67 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 125.491 1.517 . . . . 0.0 111.839 170.751 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.15 135.19 52.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 164.251 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -90.37 143.69 26.52 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.806 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 t -132.7 129.05 58.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 113.822 -1.535 . . . . 0.0 108.139 171.54 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.6 p -157.28 59.91 0.5 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 122.466 1.127 . . . . 0.0 112.506 -166.772 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.4 mt -120.2 158.03 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 124.991 1.316 . . . . 0.0 111.836 -171.264 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -138.56 127.7 24.14 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 166.598 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -144.48 145.29 31.79 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -167.637 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 72.2 p -104.47 52.37 0.75 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.06 1.344 . . . . 0.0 112.449 -168.85 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 31.3 m -149.74 6.31 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 115.434 1.642 . . . . 0.0 115.434 -169.508 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.03 172.01 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 125.518 1.527 . . . . 0.0 110.645 -176.288 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 88.0 p -157.26 160.73 38.92 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.717 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.02 51.7 1.13 Allowed 'General case' 0 CA--C 1.54 0.586 0 O-C-N 121.631 -0.668 . . . . 0.0 111.587 174.486 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.5 m -81.38 -52.43 7.28 Favored 'General case' 0 N--CA 1.474 0.754 0 O-C-N 121.689 -0.632 . . . . 0.0 112.692 -176.836 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.5 -30.19 4.31 Favored Glycine 0 N--CA 1.471 0.988 0 C-N-CA 124.425 1.012 . . . . 0.0 114.697 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -82.91 -53.18 6.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 122.108 0.956 . . . . 0.0 112.544 -168.867 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -139.05 4.73 2.28 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -166.082 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.0 m -113.59 -112.11 0.34 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 123.894 0.878 . . . . 0.0 113.331 -168.92 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 45.5 mm -106.29 -59.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.794 1.237 . . . . 0.0 111.573 -174.89 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.6 mm -58.16 138.32 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 106.069 -1.826 . . . . 0.0 106.069 166.289 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.7 59.13 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.758 -1.023 . . . . 0.0 114.023 -174.978 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mtt85 -127.43 176.68 7.27 Favored 'General case' 0 C--N 1.347 0.492 0 CA-C-N 119.292 1.546 . . . . 0.0 112.765 171.025 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 116' ' ' THR . . . . . 0.722 ' HG1' ' ND2' ' B' ' 53' ' ' ASN . 2.2 m -126.29 153.07 45.32 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 128.016 2.527 . . . . 0.0 109.183 169.029 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 13.1 tp -130.1 133.04 46.4 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.763 1.625 . . . . 0.0 109.167 176.446 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.73 139.15 44.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 C-N-CA 126.499 1.92 . . . . 0.0 110.767 176.403 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -106.11 140.78 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.129 1.372 . . . . 0.0 109.927 167.439 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -97.6 156.9 16.31 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.807 2.043 . . . . 0.0 111.147 177.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 8.2 tm-20 -77.11 -27.77 54.18 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.498 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -103.45 175.0 5.62 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.465 1.106 . . . . 0.0 111.845 168.685 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.85 152.68 42.44 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.174 1.79 . . . . 0.0 113.976 173.809 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -89.87 145.53 25.08 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 122.546 1.165 . . . . 0.0 113.168 169.792 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -76.8 -39.4 51.55 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -168.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 84.32 24.68 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 126.433 1.893 . . . . 0.0 113.812 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.34 57.77 2.3 Favored Glycine 0 C--N 1.343 0.959 0 C-N-CA 125.749 1.643 . . . . 0.0 114.906 168.06 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -158.68 -17.09 0.07 Allowed 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -168.203 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.08 16.35 2.8 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.612 1.577 . . . . 0.0 115.114 178.696 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.57 -2.17 24.4 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.316 1.436 . . . . 0.0 116.459 169.416 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -102.4 162.41 12.94 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 118.837 1.318 . . . . 0.0 109.551 -178.797 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -50.44 -62.83 1.35 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 122.175 0.988 . . . . 0.0 109.485 167.733 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . 0.494 ' HB3' HD21 ' B' ' 139' ' ' ASN . 0.4 OUTLIER -46.36 -31.14 2.42 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 128.898 2.879 . . . . 0.0 114.601 173.794 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 15.3 p -56.67 -30.31 63.25 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 120.556 -1.34 . . . . 0.0 113.927 178.066 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -121.57 -13.54 8.35 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 170.111 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.5 tttt -74.79 -15.22 60.76 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.633 1.173 . . . . 0.0 113.263 169.635 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.2 p -148.31 -25.46 0.34 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 126.623 1.969 . . . . 0.0 114.67 167.421 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.13 53.83 Favored Glycine 0 CA--C 1.536 1.4 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -163.228 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . 0.494 HD21 ' HB3' ' B' ' 133' ' ' GLU . 8.1 t-20 51.67 18.07 0.68 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.618 1.967 . . . . 0.0 113.923 179.009 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.36 -0.04 0.22 Allowed 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 127.806 2.442 . . . . 0.0 116.667 -167.764 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.84 -129.71 10.48 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.14 1.353 . . . . 0.0 115.886 168.236 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.42 134.34 28.69 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 127.735 2.414 . . . . 0.0 112.493 -178.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.92 146.98 33.22 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 121.265 -0.897 . . . . 0.0 109.887 171.093 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.3 tt -120.66 -134.83 0.32 Allowed 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 168.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.75 156.72 32.23 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 -176.854 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -146.48 161.84 39.57 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.706 1.202 . . . . 0.0 111.099 170.002 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.47 146.75 13.33 Favored Glycine 0 N--CA 1.468 0.831 0 C-N-CA 125.141 1.353 . . . . 0.0 112.525 -174.541 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.5 t -85.77 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 175.267 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 37.3 mt -123.19 114.14 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 120.097 -1.627 . . . . 0.0 111.878 -177.124 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.64 175.12 15.56 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 126.593 2.044 . . . . 0.0 115.037 -172.476 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -102.46 102.9 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.381 1.472 . . . . 0.0 112.65 -171.049 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.55 49.7 1.04 Allowed 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.535 1.934 . . . . 0.0 112.239 171.868 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 . . . . . 0 C--N 1.327 -0.378 0 C-N-CA 126.001 1.72 . . . . 0.0 111.387 177.738 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p . . . . . 0 N--CA 1.465 0.309 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.5 148.48 12.74 Favored 'General case' 0 C--O 1.238 0.469 0 C-N-CA 125.002 1.321 . . . . 0.0 112.413 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.65 161.23 39.89 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 126.293 1.837 . . . . 0.0 108.896 166.842 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -156.29 150.6 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 124.487 1.115 . . . . 0.0 109.333 -178.056 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.07 93.37 2.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.463 1.105 . . . . 0.0 108.841 167.526 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -76.88 87.94 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.89 1.276 . . . . 0.0 107.793 170.355 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -76.75 127.42 32.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 125.874 1.67 . . . . 0.0 109.637 -173.606 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -144.04 169.8 17.15 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.318 1.047 . . . . 0.0 112.174 -174.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.19 -48.7 0.64 Allowed Glycine 0 N--CA 1.467 0.739 0 C-N-CA 125.329 1.442 . . . . 0.0 112.739 171.399 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.89 64.0 6.21 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 122.219 1.009 . . . . 0.0 110.694 -169.158 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.15 -101.75 0.04 OUTLIER Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.236 2.35 . . . . 0.0 113.132 179.102 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.07 -14.28 21.03 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.852 3.035 . . . . 0.0 113.635 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -76.89 136.24 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 119.849 1.204 . . . . 0.0 109.618 179.079 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.45 159.1 35.33 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 125.997 2.808 . . . . 0.0 113.377 167.163 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -111.16 142.53 16.92 Favored Glycine 0 C--N 1.313 -0.739 1 CA-C-N 108.188 -4.097 . . . . 0.0 109.438 172.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 86.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 122.641 1.21 . . . . 0.0 108.417 175.19 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -106.91 143.94 16.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.705 167.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -119.67 135.73 54.7 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 127.762 2.425 . . . . 0.0 110.573 -178.374 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-30 -119.93 157.86 27.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.462 1.505 . . . . 0.0 110.862 178.247 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.84 146.29 37.35 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 130.489 3.516 . . . . 0.0 104.598 171.265 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -146.0 -174.24 4.37 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.149 1.78 . . . . 0.0 106.721 172.125 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 -24.01 0.47 Allowed 'General case' 0 CA--C 1.55 0.943 0 O-C-N 118.962 -2.336 . . . . 0.0 114.463 167.402 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -98.72 -172.81 2.38 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.673 1.989 . . . . 0.0 109.571 170.578 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.61 -1.84 29.5 Favored 'General case' 0 CA--C 1.547 0.851 0 O-C-N 121.328 -0.857 . . . . 0.0 112.049 168.341 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -145.63 -7.98 0.58 Allowed 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -170.054 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.06 -163.75 37.56 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 118.873 -0.96 . . . . 0.0 111.771 177.057 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -84.11 161.17 13.53 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 121.964 1.776 . . . . 0.0 112.429 -171.153 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.11 152.87 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.963 1.705 . . . . 0.0 109.606 -170.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -94.17 151.15 19.69 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 170.755 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 96.0 t -130.93 97.7 3.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 127.161 2.184 . . . . 0.0 107.096 166.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.3 p90 -124.98 160.02 29.92 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.681 0.792 . . . . 0.0 111.52 172.56 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.44 -155.2 16.37 Favored Glycine 0 N--CA 1.469 0.867 0 O-C-N 120.983 -1.073 . . . . 0.0 112.052 -179.179 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.8 p -149.44 151.9 34.77 Favored 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 117.962 2.579 . . . . 0.0 117.962 -167.421 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.8 mm -118.0 133.17 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 126.16 1.784 . . . . 0.0 108.358 169.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.13 160.24 43.45 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 120.049 1.295 . . . . 0.0 114.144 -172.482 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.42 3.55 61.3 Favored Glycine 0 CA--C 1.538 1.486 0 C-N-CA 126.9 2.19 . . . . 0.0 112.293 -167.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.8 mt -85.23 173.26 10.52 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.305 1.842 . . . . 0.0 112.926 -173.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 m -74.19 175.97 7.04 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.642 1.177 . . . . 0.0 108.057 164.291 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.29 -93.51 0.03 OUTLIER 'General case' 0 CA--C 1.558 1.252 0 O-C-N 119.958 -1.714 . . . . 0.0 113.04 179.263 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -61.51 97.47 0.14 Allowed Glycine 0 CA--C 1.529 0.965 0 C-N-CA 126.733 2.111 . . . . 0.0 117.667 -167.486 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 65.4 mt 62.85 131.75 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 129.185 2.994 . . . . 0.0 116.606 168.482 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.01 141.58 46.24 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 129.4 3.08 . . . . 0.0 107.486 179.752 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.78 155.14 51.81 Favored Glycine 0 N--CA 1.468 0.794 0 C-N-CA 124.659 1.123 . . . . 0.0 111.715 173.846 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -150.38 98.48 2.66 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -167.475 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.66 145.99 30.22 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 120.955 -1.091 . . . . 0.0 111.69 -168.461 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -102.2 119.68 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 126.149 1.78 . . . . 0.0 107.802 179.412 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -72.51 142.93 48.53 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.632 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -63.36 136.66 57.79 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -172.718 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 68.36 166.67 0.26 Allowed 'General case' 0 CA--C 1.543 0.68 0 CA-C-O 123.818 1.771 . . . . 0.0 113.995 175.338 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.31 -14.53 12.95 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 126.477 1.989 . . . . 0.0 114.413 -178.035 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -75.42 53.54 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 121.187 2.493 . . . . 0.0 112.757 -177.83 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 172.03 21.99 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.29 0 C-N-CA 128.318 2.647 . . . . 0.0 113.914 -167.065 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 76.5 p -36.1 -15.24 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 1 N-CA-C 122.332 4.197 . . . . 0.0 122.332 -170.463 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.41 15.37 4.49 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 122.097 2.226 . . . . 0.0 113.229 -174.052 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.92 -133.48 43.55 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 124.415 1.007 . . . . 0.0 111.908 174.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.9 t -58.46 -22.74 55.71 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 114.341 1.237 . . . . 0.0 114.341 -175.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . 0.256 15.0 t -90.95 42.6 1.11 Allowed 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 122.864 1.316 . . . . 0.0 112.291 171.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -179.87 -27.8 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.64 1.976 . . . . 0.0 115.659 172.095 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -134.93 142.69 46.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.529 1.532 . . . . 0.0 111.375 -168.702 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.31 -58.36 0.74 Allowed Glycine 0 CA--C 1.538 1.473 0 CA-C-O 117.636 -1.646 . . . . 0.0 115.053 -170.489 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -124.79 -177.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 124.151 3.234 . . . . 0.0 114.033 -169.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.419 ' N ' ' CD2' ' A' ' 63' ' ' HIS . 1.4 p80 -115.13 125.3 53.3 Favored 'General case' 0 C--N 1.328 -0.358 1 C-N-CA 131.839 4.056 . . . . 0.0 106.7 175.087 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -85.76 175.45 8.69 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 123.571 1.653 . . . . 0.0 110.56 -171.328 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -107.48 48.68 0.17 Allowed Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 126.129 1.772 . . . . 0.0 113.444 177.081 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -64.52 -26.01 62.42 Favored 'Trans proline' 0 C--N 1.359 1.125 0 CA-C-N 122.044 1.766 . . . . 0.0 112.609 -179.354 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 76.2 mt -79.21 0.32 28.95 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.588 1.555 . . . . 0.0 112.993 171.041 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.28 58.29 0.7 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.893 2.077 . . . . 0.0 112.464 173.598 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -157.55 176.55 12.48 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 117.704 2.483 . . . . 0.0 117.704 -167.234 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.77 177.53 8.83 Favored 'General case' 0 CA--C 1.56 1.332 0 C-N-CA 126.822 2.049 . . . . 0.0 112.57 173.269 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -105.67 143.82 33.29 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -177.77 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.76 -115.84 0.7 Allowed Glycine 0 C--N 1.336 0.559 0 CA-C-N 114.336 -1.302 . . . . 0.0 113.675 166.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.23 -67.41 0.51 Allowed Glycine 0 CA--C 1.545 1.966 0 CA-C-O 118.933 -0.926 . . . . 0.0 114.614 179.027 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -65.77 -2.65 6.79 Favored 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 125.374 4.049 . . . . 0.0 116.459 173.109 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.82 -29.37 0.24 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.407 1.483 . . . . 0.0 111.466 170.402 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.9 t0 -87.01 104.1 15.98 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.588 0.755 . . . . 0.0 110.53 166.422 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -63.12 -13.45 36.76 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.165 2.186 . . . . 0.0 114.072 176.815 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -76.89 -72.29 0.35 Allowed 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 119.303 0.956 . . . . 0.0 110.536 -179.804 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ttp180 77.45 114.09 0.07 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 126.901 2.081 . . . . 0.0 113.538 166.182 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -60.55 162.53 6.31 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 118.685 -2.509 . . . . 0.0 112.758 171.751 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -63.2 -29.93 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 O-C-N 121.231 -0.918 . . . . 0.0 112.52 172.691 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.12 12.32 54.61 Favored Glycine 0 CA--C 1.53 0.999 0 C-N-CA 124.696 1.141 . . . . 0.0 115.468 175.081 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -112.71 113.57 25.75 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-N 119.774 1.787 . . . . 0.0 114.439 -173.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.15 -173.76 4.9 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 163.164 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.46 -134.34 2.02 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 120.792 -1.193 . . . . 0.0 113.625 172.227 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.5 p30 -127.34 163.39 24.11 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.163 0.985 . . . . 0.0 108.95 168.535 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 136.4 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.131 0.972 . . . . 0.0 110.61 -171.686 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -110.6 135.87 50.57 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 175.292 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.12 156.26 18.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.524 0.678 . . . . 0.0 110.584 169.298 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.418 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 48.5 t0 -77.16 155.22 32.45 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.056 1.342 . . . . 0.0 108.497 166.861 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.418 ' HZ3' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -53.92 -25.36 19.98 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.999 1.72 . . . . 0.0 115.23 -169.305 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -76.65 -2.37 32.38 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.499 2.32 . . . . 0.0 112.273 179.101 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.65 30.18 7.37 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-O 117.937 -1.48 . . . . 0.0 114.12 172.334 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -144.81 131.54 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -178.188 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.27 112.72 24.4 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 164.799 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.0 t0 -106.33 128.65 54.17 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 170.803 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.46 145.18 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-N 113.429 -1.714 . . . . 0.0 114.4 -164.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 86.1 p -147.94 89.62 1.76 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.16 1.384 . . . . 0.0 112.087 179.566 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.06 149.31 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.505 1.522 . . . . 0.0 111.499 -174.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -135.68 138.29 42.64 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.842 2.057 . . . . 0.0 106.421 166.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -146.99 153.97 40.69 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 124.912 1.285 . . . . 0.0 112.241 -167.567 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -118.17 52.91 0.99 Allowed 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.382 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -154.66 16.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 115.889 1.811 . . . . 0.0 115.889 -178.781 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -139.63 176.37 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 125.937 1.695 . . . . 0.0 109.741 169.605 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 28.8 p -160.08 175.54 12.85 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 177.11 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -103.94 56.6 0.73 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.047 1.739 . . . . 0.0 110.409 176.953 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.5 t -107.91 -16.51 14.28 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 121.699 3.963 . . . . 0.0 121.699 -169.449 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 77.44 103.84 0.17 Allowed Glycine 0 CA--C 1.529 0.912 0 CA-C-N 121.233 1.833 . . . . 0.0 111.177 -171.011 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 85.77 -44.88 0.06 Allowed 'General case' 0 C--N 1.318 -0.777 1 C-N-CA 131.925 4.09 . . . . 0.0 111.376 166.909 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -85.78 3.03 43.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.862 1.265 . . . . 0.0 112.669 -176.573 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 p -138.22 -152.56 0.43 Allowed 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -166.951 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.8 pt -96.58 -17.35 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 120.382 -1.449 . . . . 0.0 112.516 168.298 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.1 mm -72.37 133.37 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 166.202 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.417 ' HA3' ' CD1' ' B' ' 151' ' ' ILE . . . 67.76 42.29 87.24 Favored Glycine 0 CA--C 1.532 1.134 0 O-C-N 124.36 1.037 . . . . 0.0 110.528 -168.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.99 148.86 35.85 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 127.04 2.136 . . . . 0.0 105.263 170.256 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 11.6 m -114.85 109.99 19.0 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.005 -1.059 . . . . 0.0 112.994 -165.038 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 11.2 tp -86.14 139.8 30.77 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 120.005 1.275 . . . . 0.0 114.224 -169.633 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.435 HG11 ' HE ' ' A' ' 143' ' ' ARG . 1.0 OUTLIER -132.68 149.3 31.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.284 168.232 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.64 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 164.762 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -127.3 131.92 50.4 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.144 1.378 . . . . 0.0 109.543 -176.62 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -60.63 -40.81 93.3 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.491 1.663 . . . . 0.0 115.491 -166.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -86.53 147.44 25.96 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 121.018 1.735 . . . . 0.0 110.898 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -33.58 125.58 0.41 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.568 1.947 . . . . 0.0 111.102 166.236 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 35.5 t0 -75.57 134.7 40.64 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 169.751 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.96 -34.67 66.64 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.889 0.876 . . . . 0.0 111.88 178.451 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.1 mt 62.74 33.18 15.65 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.621 1.568 . . . . 0.0 112.533 173.586 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -174.04 -72.75 0.05 OUTLIER Glycine 0 N--CA 1.468 0.815 0 N-CA-C 116.399 1.32 . . . . 0.0 116.399 174.845 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -164.85 67.74 0.14 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.548 1.139 . . . . 0.0 114.073 178.252 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.3 68.03 0.7 Allowed Glycine 0 CA--C 1.531 1.061 0 C-N-CA 127.001 2.239 . . . . 0.0 113.416 176.175 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.26 -14.9 31.43 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 125.944 1.735 . . . . 0.0 115.226 172.714 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -141.23 177.08 8.33 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 118.982 1.391 . . . . 0.0 112.039 -171.409 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -77.62 -43.06 32.73 Favored 'General case' 0 C--O 1.217 -0.627 0 CA-C-N 114.625 -1.171 . . . . 0.0 109.978 165.476 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -44.57 -40.32 5.63 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 173.121 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.82 -33.36 23.27 Favored 'General case' 0 N--CA 1.472 0.635 0 O-C-N 120.858 -1.151 . . . . 0.0 114.034 171.54 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.4 -24.05 20.88 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 125.565 1.546 . . . . 0.0 112.527 177.772 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -87.24 -13.66 43.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 176.907 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.8 p -129.8 -45.93 1.16 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.386 1.074 . . . . 0.0 113.385 176.508 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.8 -0.77 15.34 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 125.777 1.923 . . . . 0.0 111.793 -166.465 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 56.74 21.19 5.7 Favored 'General case' 0 N--CA 1.478 0.965 0 O-C-N 119.808 -1.995 . . . . 0.0 111.974 -175.754 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.92 30.02 0.08 Allowed 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -167.098 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.23 -35.24 0.42 Allowed Glycine 0 N--CA 1.476 1.358 0 C-N-CA 129.673 3.511 . . . . 0.0 117.588 168.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.0 t -171.3 -144.59 0.04 OUTLIER 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.476 1.11 . . . . 0.0 110.108 -169.293 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.435 ' HE ' HG11 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -142.37 -174.88 4.25 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 127.515 2.326 . . . . 0.0 110.447 172.929 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -174.42 -141.04 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 129.568 3.147 . . . . 0.0 109.008 168.18 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -51.24 138.71 20.2 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 128.341 2.656 . . . . 0.0 114.377 -168.479 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 87.3 m -126.06 134.83 51.29 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 127.942 2.497 . . . . 0.0 112.606 -169.613 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.32 153.56 23.94 Favored Glycine 0 N--CA 1.482 1.751 0 C-N-CA 125.29 1.424 . . . . 0.0 114.252 169.023 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -78.31 149.95 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 CA-C-N 120.278 2.039 . . . . 0.0 110.301 170.185 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 10.0 mm -83.13 104.39 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 106.733 -1.581 . . . . 0.0 106.733 166.049 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -106.15 146.79 16.12 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 124.348 0.975 . . . . 0.0 111.134 176.587 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.5 pp -79.86 173.7 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 122.908 0.483 . . . . 0.0 111.346 175.255 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.95 -126.86 0.03 OUTLIER 'General case' 0 C--O 1.224 -0.269 0 C-N-CA 125.823 1.649 . . . . 0.0 111.156 163.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.858 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -164.244 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 p -115.91 115.51 26.34 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.133 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.77 142.56 30.15 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 116.605 2.076 . . . . 0.0 116.605 169.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.24 132.25 42.89 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.841 2.456 . . . . 0.0 110.087 172.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 59.6 t -144.77 142.82 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 119.943 1.247 . . . . 0.0 111.786 -168.657 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -114.18 141.38 47.6 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.79 1.236 . . . . 0.0 113.853 171.929 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 15.0 m -104.06 99.62 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 167.383 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -78.91 130.35 35.52 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.722 1.209 . . . . 0.0 108.085 -175.63 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -156.18 174.47 15.33 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 -172.644 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.96 -43.03 1.35 Allowed Glycine 0 N--CA 1.471 1.002 0 C-N-CA 127.955 2.693 . . . . 0.0 111.32 172.792 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -82.96 59.17 4.74 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 127.932 2.493 . . . . 0.0 113.319 -168.633 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.41 -104.0 0.06 OUTLIER Glycine 0 CA--C 1.532 1.14 0 C-N-CA 127.537 2.494 . . . . 0.0 112.6 176.975 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.45 -14.62 16.11 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 123.618 2.878 . . . . 0.0 113.614 -177.564 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -90.05 128.79 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-N 120.096 1.317 . . . . 0.0 109.921 -178.542 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.471 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -146.06 155.12 42.56 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.848 173.121 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.27 153.14 20.64 Favored Glycine 0 C--O 1.227 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.229 177.569 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.04 117.21 54.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 C-N-CA 126.234 1.814 . . . . 0.0 106.514 168.715 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.3 mm -128.19 104.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 O-C-N 123.64 0.587 . . . . 0.0 110.049 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.53 156.13 27.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.111 1.764 . . . . 0.0 111.981 167.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -139.82 108.21 5.84 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 130.655 3.582 . . . . 0.0 107.339 170.071 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.27 130.85 53.31 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.194 1.398 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -126.12 154.68 42.8 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 122.277 1.037 . . . . 0.0 111.35 -176.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . 0.473 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 9.9 ptmm? -115.92 -24.35 8.17 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 128.298 2.639 . . . . 0.0 114.105 -177.512 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . 0.473 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 6.7 mp0 -135.79 162.25 33.32 Favored 'General case' 0 C--O 1.219 -0.502 0 CA-C-N 121.006 1.73 . . . . 0.0 112.877 173.649 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 p -64.94 -2.94 2.95 Favored 'General case' 0 N--CA 1.483 1.217 0 O-C-N 119.141 -2.224 . . . . 0.0 113.434 167.226 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.79 64.12 0.16 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 128.383 2.673 . . . . 0.0 109.754 -168.214 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.1 172.75 31.37 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.58 1.562 . . . . 0.0 113.411 -170.747 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.53 142.53 23.48 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.39 2.727 . . . . 0.0 110.683 178.634 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.05 132.6 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.158 0.983 . . . . 0.0 109.327 -172.606 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.413 ' HB2' ' HZ1' ' B' ' 30' ' ' LYS . 2.3 ttmp? -95.96 115.6 27.67 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 121.626 0.726 . . . . 0.0 111.226 179.061 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.6 t -93.55 121.35 44.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 127.105 2.162 . . . . 0.0 108.807 -179.123 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -148.25 164.88 32.65 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 177.859 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.02 -147.67 19.4 Favored Glycine 0 C--N 1.334 0.448 0 C-N-CA 125.111 1.339 . . . . 0.0 111.356 176.795 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -157.94 156.61 31.56 Favored 'General case' 0 C--O 1.237 0.407 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -175.783 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -124.39 133.67 68.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 125.284 1.433 . . . . 0.0 108.319 170.636 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -138.3 155.5 48.53 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -172.791 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.87 76.95 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.031 1.3 . . . . 0.0 114.022 -175.515 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -96.43 162.58 13.42 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 126.559 1.944 . . . . 0.0 112.11 179.503 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.23 154.24 1.26 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.458 2.703 . . . . 0.0 110.822 169.15 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -64.77 -60.34 3.2 Favored 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 120.717 1.599 . . . . 0.0 112.654 174.245 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -51.52 141.7 21.84 Favored Glycine 0 N--CA 1.472 1.075 0 C-N-CA 126.218 1.866 . . . . 0.0 114.733 -169.811 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . 0.506 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -40.74 136.88 1.29 Allowed 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 128.315 2.646 . . . . 0.0 115.243 -168.311 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -121.12 142.47 49.83 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 129.816 3.247 . . . . 0.0 109.173 -170.306 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.18 169.51 35.79 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.552 1.072 . . . . 0.0 111.879 172.436 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.2 t80 -160.43 57.95 0.34 Allowed 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.649 1.58 . . . . 0.0 110.728 -169.621 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -117.44 145.81 43.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.305 1.042 . . . . 0.0 113.401 -169.592 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -105.86 115.78 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.773 0.797 . . . . 0.0 109.189 -172.102 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m-70 -76.42 174.16 10.59 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 124.974 1.31 . . . . 0.0 110.119 179.537 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . 0.484 ' H ' ' CD ' ' B' ' 49' ' ' GLU . 1.9 pm0 -61.15 85.58 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 127.127 2.171 . . . . 0.0 115.074 -168.242 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 67.95 -157.99 0.21 Allowed 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.089 2.156 . . . . 0.0 111.865 168.974 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.75 -14.88 18.29 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.461 1.505 . . . . 0.0 112.077 -177.871 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . 0.454 ' CG ' ' HB ' ' A' ' 5' ' ' VAL . 7.5 t70 -62.57 56.52 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.023 1 C-N-CA 132.623 4.369 . . . . 0.0 110.6 169.555 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 16.3 p30 176.39 -11.01 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 128.079 2.552 . . . . 0.0 116.287 -174.388 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.315 8.4 t . . . . . 0 N--CA 1.498 1.952 2 N-CA-C 123.685 4.698 . . . . 0.0 123.685 176.268 . . . . . . . . 2 1 . 1 . 029 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 122.245 1.021 . . . . 0.0 113.173 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.79 -152.65 23.0 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 126.846 2.165 . . . . 0.0 111.312 178.796 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -109.08 49.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.596 2.864 . . . . 0.0 111.457 -178.326 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 56.77 82.69 0.11 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.932 1.293 . . . . 0.0 112.498 -179.2 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -40.49 131.62 2.21 Favored 'General case' 0 CA--C 1.542 0.673 0 CA-C-O 122.54 1.162 . . . . 0.0 113.089 169.557 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.7 p-10 -114.29 79.86 5.44 Favored Pre-proline 0 CA--C 1.547 0.838 0 C-N-CA 126.407 1.883 . . . . 0.0 112.457 -171.246 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -62.23 -14.52 38.73 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 123.114 2.543 . . . . 0.0 114.685 179.547 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -92.78 -4.0 53.79 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.111 1.364 . . . . 0.0 113.302 171.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 28.0 t 65.7 53.39 1.19 Allowed 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.366 1.866 . . . . 0.0 112.367 171.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -142.64 177.27 8.42 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -169.559 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.44 ' H ' ' HD2' ' B' ' 70' ' ' LYS . 1.3 mptt -79.41 175.4 10.63 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 126.441 1.897 . . . . 0.0 112.904 -178.228 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -97.49 136.61 37.67 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -176.805 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 139.83 -132.27 5.5 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 124.268 0.937 . . . . 0.0 113.596 167.421 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 146.04 -34.44 1.43 Allowed Glycine 0 CA--C 1.547 2.087 0 N-CA-C 118.234 2.054 . . . . 0.0 118.234 -177.037 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -78.4 -19.53 11.65 Favored 'Trans proline' 0 C--N 1.356 0.94 0 CA-C-N 122.263 3.032 . . . . 0.0 113.609 172.22 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -46.42 0.93 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 124.437 1.095 . . . . 0.0 109.917 167.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -56.14 126.04 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.976 0.893 . . . . 0.0 109.319 169.209 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -90.61 -5.86 55.35 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 128.973 2.909 . . . . 0.0 112.717 -168.341 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -100.58 -76.48 0.56 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 126.945 2.098 . . . . 0.0 110.773 -169.809 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 84.66 113.7 0.05 Allowed 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 126.519 1.928 . . . . 0.0 113.268 165.812 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -59.2 152.66 20.06 Favored 'General case' 0 CA--C 1.549 0.911 0 O-C-N 119.669 -1.894 . . . . 0.0 110.36 170.04 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -58.39 -30.98 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.891 -1.13 . . . . 0.0 112.681 178.223 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.35 37.47 3.42 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 126.619 2.057 . . . . 0.0 113.58 171.211 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -116.85 146.87 42.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 119.988 1.894 . . . . 0.0 115.737 173.892 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 79.1 mt -144.42 163.3 34.2 Favored 'General case' 0 CA--C 1.545 0.784 1 C-N-CA 132.102 4.161 . . . . 0.0 102.702 163.156 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.91 -87.06 0.99 Allowed Glycine 0 N--CA 1.468 0.829 0 O-C-N 121.926 -0.484 . . . . 0.0 113.428 -170.643 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -153.32 168.44 26.03 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 124.674 1.19 . . . . 0.0 113.479 -166.521 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.56 147.59 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 129.233 3.013 . . . . 0.0 110.214 -176.407 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 25.7 m -120.84 145.6 47.43 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 119.437 1.017 . . . . 0.0 109.991 -176.979 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.65 144.48 26.65 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.895 0.855 . . . . 0.0 111.666 175.95 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . 0.443 ' OD1' ' HE2' ' B' ' 91' ' ' LYS . 39.7 t0 -73.19 158.95 34.26 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.762 1.225 . . . . 0.0 109.813 168.921 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.443 ' HE2' ' OD1' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -52.33 -28.2 18.34 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 115.42 1.637 . . . . 0.0 115.42 -168.292 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.85 -2.25 29.19 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.544 1.538 . . . . 0.0 112.283 -178.51 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.08 39.16 7.54 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 125.221 1.391 . . . . 0.0 113.154 177.843 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 3.2 p -132.62 126.37 54.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 CA-C-N 118.629 1.215 . . . . 0.0 113.811 170.018 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.58 119.23 31.31 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.518 1.527 . . . . 0.0 107.929 165.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.46 151.15 31.0 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 167.419 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.29 0.5 OUTLIER -134.53 131.59 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 114.593 -1.185 . . . . 0.0 112.899 165.477 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 9.6 p -157.69 59.96 0.48 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.151 1.38 . . . . 0.0 113.164 -168.65 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -115.39 156.08 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 C-N-CA 126.787 2.035 . . . . 0.0 112.715 -171.582 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -128.67 146.49 50.86 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.733 1.613 . . . . 0.0 108.288 166.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -141.02 134.83 30.41 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.243 1.417 . . . . 0.0 110.222 -179.03 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -112.75 59.27 0.64 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.315 1.446 . . . . 0.0 112.234 -167.578 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.4 p -158.12 -36.5 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.132 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.13 170.97 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 123.332 0.653 . . . . 0.0 111.349 172.712 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.8 m -157.51 159.44 37.21 Favored 'General case' 0 N--CA 1.469 0.506 0 O-C-N 120.12 -1.612 . . . . 0.0 111.335 176.316 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.8 tt -81.12 75.02 8.1 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.056 0.942 . . . . 0.0 109.523 -173.627 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -138.97 152.18 47.47 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.761 1.625 . . . . 0.0 111.391 -174.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -101.91 68.54 0.39 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 126.968 2.223 . . . . 0.0 113.427 -169.29 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -154.43 -91.53 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.78 1.632 . . . . 0.0 110.362 -168.819 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -127.79 -4.43 5.81 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.742 2.017 . . . . 0.0 110.461 -170.048 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 16.4 m -92.6 -91.31 0.17 Allowed 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.523 1.929 . . . . 0.0 114.651 -166.066 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pt -135.36 -14.69 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 118.112 2.634 . . . . 0.0 118.112 176.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.0 mm -86.58 105.8 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 CA-C-N 122.113 2.233 . . . . 0.0 108.747 179.283 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.59 61.45 1.17 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.573 0.606 . . . . 0.0 112.944 -171.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 23.4 ptt180 -140.36 144.95 36.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.981 1.312 . . . . 0.0 109.239 167.305 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 2.3 t -109.39 102.09 11.01 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 124.243 1.017 . . . . 0.0 111.067 -166.665 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 29.2 tp -86.33 129.67 34.77 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 124.152 0.981 . . . . 0.0 109.774 -173.245 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 t -107.82 118.09 54.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 169.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 13.9 p -78.85 120.03 29.18 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.37 0 N-CA-C 100.483 -3.895 . . . . 0.0 100.483 161.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -106.45 142.52 35.97 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 117.766 -1.111 . . . . 0.0 109.38 -168.189 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.92 -42.94 80.87 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 122.154 2.252 . . . . 0.0 113.915 -166.718 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.456 ' HA ' ' HE3' ' B' ' 122' ' ' LYS . 0.0 OUTLIER -111.7 152.35 27.83 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 171.624 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.12 161.02 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.853 1.661 . . . . 0.0 112.258 171.68 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -94.47 151.35 19.44 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 177.833 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -71.8 -16.66 62.19 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.572 1.949 . . . . 0.0 112.875 176.482 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.3 mt 57.96 84.29 0.1 Allowed 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 127.028 2.131 . . . . 0.0 114.464 169.764 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.74 -47.48 3.42 Favored Glycine 0 N--CA 1.465 0.622 0 C-N-CA 125.502 1.525 . . . . 0.0 111.015 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -158.84 137.91 11.33 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.609 1.564 . . . . 0.0 110.448 168.646 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -141.37 -101.15 0.43 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 169.164 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.57 -24.49 10.96 Favored Glycine 0 N--CA 1.471 0.972 0 N-CA-C 116.705 1.442 . . . . 0.0 116.705 -168.576 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -165.46 174.18 10.26 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.882 1.341 . . . . 0.0 111.83 -169.225 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -49.86 -50.84 44.19 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 126.062 1.745 . . . . 0.0 113.449 -170.313 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . 0.45 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 13.7 mp0 -45.76 -25.79 0.55 Allowed 'General case' 0 C--N 1.318 -0.794 0 C-N-CA 128.27 2.628 . . . . 0.0 113.705 175.305 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.6 p -64.95 -45.06 87.32 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 120.119 1.327 . . . . 0.0 112.716 178.823 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -79.91 -39.72 29.76 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.18 0.592 . . . . 0.0 111.523 173.151 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.29 -18.64 52.25 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -173.033 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.9 p -152.71 -15.11 0.16 Allowed 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 177.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.04 -7.56 58.85 Favored Glycine 0 C--O 1.214 -1.155 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.313 -168.652 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 51.3 t30 55.57 35.49 25.28 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-N 120.613 2.206 . . . . 0.0 112.157 178.184 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.9 38.88 0.08 Allowed 'General case' 0 CA--C 1.563 1.451 0 N-CA-C 115.759 1.763 . . . . 0.0 115.759 -166.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.16 -84.46 0.41 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 127.109 2.29 . . . . 0.0 113.767 175.488 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t -160.52 172.8 16.55 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.155 0.982 . . . . 0.0 112.978 -178.041 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 154.83 25.62 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.126 1.37 . . . . 0.0 113.624 -171.488 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 19.5 tp -159.79 -177.55 6.43 Favored 'General case' 0 CA--C 1.56 1.342 0 C-N-CA 129.795 3.238 . . . . 0.0 104.878 169.836 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.73 129.91 20.36 Favored 'General case' 0 CA--C 1.556 1.185 0 N-CA-C 115.838 1.792 . . . . 0.0 115.838 -165.146 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.9 m -114.91 134.19 55.36 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 126.712 2.005 . . . . 0.0 112.645 -176.687 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.9 144.12 10.17 Favored Glycine 0 N--CA 1.486 2.006 0 CA-C-N 120.994 1.724 . . . . 0.0 117.172 177.297 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -81.12 140.74 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 118.169 0.985 . . . . 0.0 109.893 176.022 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.4 mm -77.68 107.33 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 170.584 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.16 36.45 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.555 1.55 . . . . 0.0 111.951 169.635 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . 0.417 ' CD1' ' HA3' ' A' ' 114' ' ' GLY . 1.1 pp -138.91 160.65 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 125.04 1.336 . . . . 0.0 112.89 177.822 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.58 1.3 0.44 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.644 1.978 . . . . 0.0 112.554 164.603 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tm0? . . . . . 0 N--CA 1.472 0.648 0 C-N-CA 126.636 1.975 . . . . 0.0 110.876 169.699 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 67.4 p . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.1 ttpt -161.55 126.18 3.44 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 118.529 2.789 . . . . 0.0 118.529 166.085 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.52 177.5 4.9 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 129.489 3.116 . . . . 0.0 107.006 164.346 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.54 151.15 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 -164.227 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.07 115.21 7.92 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 110.627 166.252 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 68.9 t -101.41 95.59 4.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.667 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.9 mp -79.34 152.51 30.42 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.13 1.372 . . . . 0.0 108.68 173.612 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -153.24 158.56 41.88 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -130.11 158.33 22.31 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.308 2.385 . . . . 0.0 107.957 166.151 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -71.94 83.59 0.95 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 126.817 2.047 . . . . 0.0 110.941 -177.446 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.09 -147.64 18.78 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 127.041 2.258 . . . . 0.0 110.158 -169.403 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -94.64 9.51 1.93 Allowed 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 124.794 3.663 . . . . 0.0 114.87 -169.841 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.63 134.16 34.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 CA-C-N 120.025 1.284 . . . . 0.0 110.393 -177.369 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.39 164.67 34.28 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.517 1.127 . . . . 0.0 111.486 178.865 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.52 97.79 0.42 Allowed Glycine 0 C--O 1.215 -1.042 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 169.042 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -96.41 106.61 18.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 118.519 1.159 . . . . 0.0 108.012 175.892 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 pt -133.59 150.13 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 122.241 1.019 . . . . 0.0 111.62 177.09 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -122.74 145.29 48.54 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.637 1.575 . . . . 0.0 110.329 179.416 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -120.94 105.07 10.32 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.936 1.694 . . . . 0.0 109.635 -173.895 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.1 121.16 28.31 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 177.369 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 11.0 tp60 -147.76 137.94 22.91 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.251 0.548 . . . . 0.0 111.186 175.507 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.456 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -91.96 -24.28 19.31 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -175.735 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.66 -155.65 0.61 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-N 120.136 1.335 . . . . 0.0 113.038 176.489 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 66.6 m -107.25 10.25 29.91 Favored 'General case' 0 CA--C 1.543 0.677 0 O-C-N 119.377 -2.077 . . . . 0.0 113.634 -179.095 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -131.27 -10.29 3.7 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 126.021 1.728 . . . . 0.0 114.746 -172.437 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.13 160.74 20.75 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 128.926 3.155 . . . . 0.0 112.657 -168.615 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.75 151.57 32.02 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 123.028 2.486 . . . . 0.0 109.718 175.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 67.4 t -119.71 137.65 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.166 1.387 . . . . 0.0 110.004 -168.166 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -84.41 127.09 33.8 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.512 0.596 . . . . 0.0 110.1 170.19 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 t -107.82 130.09 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 125.632 1.573 . . . . 0.0 108.346 171.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -151.14 165.9 32.48 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 123.342 0.657 . . . . 0.0 111.54 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 131.16 -148.9 19.07 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 124.993 1.283 . . . . 0.0 111.754 175.928 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 54.1 p -142.6 127.22 17.98 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -169.815 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 mm -101.3 112.77 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 124.676 1.19 . . . . 0.0 108.279 170.987 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.9 pttt -129.58 152.07 49.5 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.835 1.198 . . . . 0.0 112.698 -166.514 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.01 5.52 64.05 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.38 0.99 . . . . 0.0 112.599 -169.061 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -75.44 -161.63 0.16 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 127.405 2.282 . . . . 0.0 109.662 168.766 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -151.98 171.24 18.13 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 126.627 1.971 . . . . 0.0 108.183 169.331 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -49.04 136.84 13.96 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.851 1.66 . . . . 0.0 113.439 -168.876 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.51 -173.13 28.21 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-O 122.597 1.11 . . . . 0.0 112.511 173.202 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.413 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.5 OUTLIER -73.01 160.45 32.07 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.1 0.96 . . . . 0.0 111.373 -171.339 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -149.09 136.21 19.94 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 127.653 2.381 . . . . 0.0 108.867 176.62 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.17 148.71 32.48 Favored Glycine 0 N--CA 1.478 1.463 0 CA-C-O 119.261 -0.744 . . . . 0.0 111.964 171.226 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -153.15 78.71 1.17 Allowed 'General case' 0 CA--C 1.544 0.741 0 CA-C-O 122.88 1.324 . . . . 0.0 110.768 -168.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -124.73 157.86 34.66 Favored 'General case' 0 CA--C 1.516 -0.338 0 O-C-N 120.803 -1.186 . . . . 0.0 111.396 -169.428 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.508 HG12 HH11 ' A' ' 115' ' ' ARG . 1.7 m -87.65 151.52 3.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.24 176.628 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 8.4 m170 -113.88 168.79 9.5 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 104.102 -2.555 . . . . 0.0 104.102 160.175 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.75 -172.69 0.09 Allowed 'General case' 0 CA--C 1.554 1.11 0 N-CA-C 117.257 2.317 . . . . 0.0 117.257 -167.83 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -119.43 -36.58 3.32 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 128.203 2.601 . . . . 0.0 112.305 -175.739 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.19 -29.52 62.9 Favored Glycine 0 N--CA 1.47 0.93 1 C-N-CA 131.667 4.461 . . . . 0.0 114.588 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -123.97 151.23 43.9 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 163.045 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -148.98 101.55 3.18 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 119.11 3.004 . . . . 0.0 119.11 -166.493 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.4 ' C ' ' H ' ' A' ' 56' ' ' GLY 0.549 0.1 OUTLIER 112.48 -145.75 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.695 1 C-N-CA 133.673 4.789 . . . . 0.0 113.576 160.044 . . . . . . . . 5 4 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 49.05 -10.13 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 131.033 3.733 . . . . 0.0 117.91 -172.348 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 54' ' ' THR . . . 90.34 -132.12 11.11 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.968 2.223 . . . . 0.0 111.211 -176.915 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.9 m -62.78 -8.47 6.89 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 177.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.1 m -79.9 -24.07 41.38 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.922 1.289 . . . . 0.0 112.457 171.672 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -158.43 45.57 0.31 Allowed 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 116.193 1.923 . . . . 0.0 116.193 -169.2 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 176.96 125.45 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 127.807 2.443 . . . . 0.0 110.452 168.429 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -72.16 149.14 43.73 Favored Glycine 0 CA--C 1.541 1.667 0 O-C-N 120.736 -1.228 . . . . 0.0 114.372 -175.772 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -64.69 106.94 0.8 Allowed 'Trans proline' 0 C--N 1.354 0.822 1 C-N-CA 125.488 4.125 . . . . 0.0 111.604 -178.896 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.456 ' CE1' ' HA ' ' A' ' 137' ' ' THR 0.274 0.0 OUTLIER 36.04 57.18 1.0 Allowed 'General case' 0 C--O 1.234 0.247 0 C-N-CA 127.377 2.271 . . . . 0.0 112.468 170.458 . . . . . . . . 4 4 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -27.05 122.79 0.09 Allowed 'General case' 0 C--N 1.342 0.259 0 C-N-CA 128.285 2.634 . . . . 0.0 111.26 179.328 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 62.8 m-20 -71.84 101.26 0.37 Allowed Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -168.426 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -84.67 -12.46 7.49 Favored 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.157 2.571 . . . . 0.0 112.956 -167.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 92.0 mt -139.75 2.91 2.02 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 128.62 2.768 . . . . 0.0 110.717 -172.117 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 16.0 t 66.44 53.43 0.98 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.706 1.603 . . . . 0.0 114.022 175.675 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.79 179.57 4.94 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.978 1.711 . . . . 0.0 113.161 179.851 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.1 mmtt -73.57 173.61 9.46 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 121.654 0.74 . . . . 0.0 111.667 169.356 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 48.9 t60 -72.15 157.77 37.14 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 168.489 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.78 -126.19 2.69 Favored Glycine 0 C--N 1.339 0.72 0 N-CA-C 116.576 1.39 . . . . 0.0 116.576 165.725 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.85 -90.24 0.36 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 116.58 1.392 . . . . 0.0 116.58 -171.105 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.5 -2.21 4.84 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.946 3.097 . . . . 0.0 115.184 -173.325 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.312 3.3 ptmm? -144.08 4.13 1.24 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 126.433 1.893 . . . . 0.0 112.677 168.346 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -131.77 113.77 13.92 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 127.082 2.153 . . . . 0.0 109.168 177.038 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -71.16 -14.07 62.15 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 127.968 2.507 . . . . 0.0 114.082 -176.371 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -78.02 -62.06 1.8 Allowed 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.908 1.231 . . . . 0.0 109.295 175.361 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 74.6 ttt180 70.71 120.44 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 123.477 1.608 . . . . 0.0 112.831 169.592 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.8 m170 -66.98 136.58 55.53 Favored 'General case' 0 CA--C 1.543 0.694 0 O-C-N 118.96 -2.337 . . . . 0.0 109.217 164.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.0 t -53.74 -19.11 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 122.464 1.126 . . . . 0.0 111.636 166.281 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -92.16 41.09 2.82 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.255 2.36 . . . . 0.0 116.878 172.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -144.56 122.57 12.08 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 119.751 1.775 . . . . 0.0 111.865 -179.06 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.86 48.75 0.94 Allowed 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 123.811 1.767 . . . . 0.0 110.359 173.762 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.89 -133.48 52.71 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 126.122 1.82 . . . . 0.0 114.257 175.289 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.82 138.73 48.03 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.672 1.589 . . . . 0.0 110.11 171.495 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.0 p -92.95 127.45 45.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 166.327 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 24.4 m -115.39 119.48 36.4 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -176.27 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.99 156.96 17.31 Favored 'General case' 0 C--N 1.328 -0.353 0 O-C-N 123.667 0.604 . . . . 0.0 112.588 -177.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.73 168.54 19.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 126.403 1.881 . . . . 0.0 113.67 173.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.1 pptp? -60.11 -20.09 56.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.789 1.636 . . . . 0.0 113.79 168.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -80.95 0.04 37.25 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.006 1.322 . . . . 0.0 112.306 170.791 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 19.92 60.41 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 125.178 1.37 . . . . 0.0 114.099 174.633 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -134.16 138.85 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 119.04 1.42 . . . . 0.0 113.527 -176.54 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.79 123.31 40.45 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 165.655 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -97.74 118.8 35.09 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.581 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.12 140.08 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 CA-C-N 114.159 -1.382 . . . . 0.0 113.935 -165.733 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 77.4 p -155.65 123.2 5.57 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.594 1.558 . . . . 0.0 110.103 168.834 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -155.17 148.81 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 127.703 2.401 . . . . 0.0 109.992 -169.85 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -125.77 125.22 42.61 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 165.749 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -121.72 141.81 50.81 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.038 0.935 . . . . 0.0 110.994 -173.753 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -115.63 48.66 1.17 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.959 0.904 . . . . 0.0 112.863 -178.377 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.26 -4.81 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.459 1.104 . . . . 0.0 112.23 170.732 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.54 164.88 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 C-N-CA 125.951 1.7 . . . . 0.0 110.727 176.672 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 99.5 p -149.54 175.28 11.66 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 128.285 2.634 . . . . 0.0 109.072 178.098 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mp -86.16 93.4 9.02 Favored 'General case' 0 CA--C 1.543 0.684 0 O-C-N 120.809 -1.182 . . . . 0.0 109.33 173.249 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.2 t -152.45 153.88 34.42 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.753 1.221 . . . . 0.0 110.119 169.04 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -103.08 29.23 12.88 Favored Glycine 0 N--CA 1.472 1.041 0 C-N-CA 126.142 1.829 . . . . 0.0 113.27 -178.147 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -86.81 -96.55 0.08 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 126.022 1.729 . . . . 0.0 106.691 169.655 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m170 -107.39 -7.75 16.54 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.458 1.503 . . . . 0.0 111.806 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -76.15 -157.77 0.08 Allowed 'General case' 0 CA--C 1.558 1.259 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -174.999 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.271 10.9 pt -97.14 44.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 118.455 -2.653 . . . . 0.0 116.06 -172.006 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.9 mm -115.73 126.96 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 166.321 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.18 -4.2 34.06 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 117.208 -1.885 . . . . 0.0 115.077 173.309 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.508 HH11 HG12 ' A' ' 47' ' ' VAL . 3.1 ptp180 -78.82 153.47 30.64 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 120.795 2.297 . . . . 0.0 110.889 170.218 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 6.3 t -101.29 162.75 12.67 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 119.676 1.125 . . . . 0.0 112.917 177.466 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -130.44 137.98 50.09 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.788 2.035 . . . . 0.0 107.921 174.52 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.2 125.44 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.291 1.436 . . . . 0.0 109.969 175.24 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -90.2 143.08 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 171.84 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -106.64 158.35 17.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 122.009 0.909 . . . . 0.0 112.909 -174.567 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -71.56 -40.8 69.74 Favored 'General case' 0 CA--C 1.538 0.483 0 O-C-N 121.334 -0.854 . . . . 0.0 111.237 -169.07 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -116.82 174.73 5.92 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 124.706 1.202 . . . . 0.0 112.664 172.594 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.4 148.16 1.43 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.813 2.445 . . . . 0.0 112.252 172.422 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -110.29 142.57 41.73 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.282 1.033 . . . . 0.0 112.185 172.609 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -93.93 -8.3 40.56 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 176.888 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 77.09 -73.33 0.09 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 128.94 2.896 . . . . 0.0 111.516 169.301 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -95.8 -5.26 59.99 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 125.262 1.411 . . . . 0.0 113.539 -174.389 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt -158.23 -146.08 0.15 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 128.088 2.555 . . . . 0.0 112.539 173.15 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 133.31 -29.13 3.21 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 128.7 3.048 . . . . 0.0 110.617 -168.393 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 126.73 -17.03 6.47 Favored Glycine 0 N--CA 1.473 1.12 0 C-N-CA 126.282 1.896 . . . . 0.0 114.986 169.588 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -110.57 174.6 5.79 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.09 1.356 . . . . 0.0 113.683 -171.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -52.22 -59.67 4.12 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.319 1.848 . . . . 0.0 110.615 167.52 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.45 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 0.1 OUTLIER -46.57 -36.01 6.42 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.735 1.214 . . . . 0.0 112.51 169.433 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -66.47 -3.74 6.85 Favored 'General case' 0 N--CA 1.476 0.86 0 O-C-N 120.132 -1.605 . . . . 0.0 113.909 -175.936 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.1 p -119.96 -12.96 9.08 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 175.896 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 ptpt -113.25 -26.1 8.56 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 176.952 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.456 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 0.5 OUTLIER -127.96 -17.94 4.31 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 127.049 2.14 . . . . 0.0 113.809 179.497 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.03 -21.49 41.62 Favored Glycine 0 N--CA 1.467 0.724 0 C-N-CA 126.537 2.018 . . . . 0.0 111.969 177.361 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 71.46 36.65 1.26 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.94 1.696 . . . . 0.0 112.421 168.492 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.32 44.69 0.01 OUTLIER 'General case' 0 CA--C 1.575 1.941 0 C-N-CA 128.414 2.686 . . . . 0.0 117.41 -169.268 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.8 -57.21 2.62 Favored Glycine 0 N--CA 1.473 1.157 0 C-N-CA 127.84 2.638 . . . . 0.0 114.483 -177.986 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.9 t -168.17 171.11 9.7 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.727 1.211 . . . . 0.0 111.572 -178.584 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -85.04 148.29 26.23 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 120.726 -1.233 . . . . 0.0 110.608 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -128.01 -146.28 0.32 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.521 1.929 . . . . 0.0 109.26 175.935 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.79 155.37 30.54 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 127.146 2.178 . . . . 0.0 114.596 179.748 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.3 p -151.96 153.74 34.67 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.086 1.355 . . . . 0.0 114.084 -173.304 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.04 159.87 31.5 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 125.042 1.306 . . . . 0.0 113.407 178.057 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.458 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 3.6 t -106.45 142.91 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-N 118.717 1.259 . . . . 0.0 109.422 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mm -77.48 93.74 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 CA-C-O 122.232 1.015 . . . . 0.0 110.156 -178.676 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -92.27 174.94 37.38 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 125.884 1.707 . . . . 0.0 112.706 173.581 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.07 149.64 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -173.372 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.98 -17.58 4.37 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.552 1.941 . . . . 0.0 115.006 177.561 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 . . . . . 0 N--CA 1.472 0.627 0 C-N-CA 125.689 1.595 . . . . 0.0 112.592 176.864 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.279 0.561 . . . . 0.0 112.235 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.7 t -156.63 112.17 2.92 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 125.814 1.646 . . . . 0.0 108.458 167.878 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 10.1 pttt -111.93 171.72 7.33 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 116.45 2.019 . . . . 0.0 116.45 -173.315 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.87 168.32 14.02 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 128.457 2.703 . . . . 0.0 110.957 174.492 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.5 139.46 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 126.331 1.852 . . . . 0.0 111.861 -178.202 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.06 105.05 4.77 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.092 0.957 . . . . 0.0 109.477 165.041 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -92.13 130.81 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 166.358 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mp -92.07 143.41 26.48 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 123.554 0.742 . . . . 0.0 111.284 -178.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 tttm -156.14 175.93 13.33 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 168.903 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 148.8 -77.93 0.23 Allowed Glycine 0 CA--C 1.523 0.552 0 C-N-CA 128.463 2.935 . . . . 0.0 108.164 -172.936 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.74 75.49 3.39 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.021 1.728 . . . . 0.0 112.735 -168.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.73 -97.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.37 0 C-N-CA 127.503 2.478 . . . . 0.0 114.314 169.518 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -82.81 -1.34 10.46 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.958 3.772 . . . . 0.0 114.945 179.162 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.81 140.34 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 120.54 1.518 . . . . 0.0 110.047 170.749 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -139.71 168.03 20.76 Favored 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 125.684 1.594 . . . . 0.0 109.31 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -158.83 92.98 0.12 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.034 -1.426 . . . . 0.0 116.126 165.229 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.22 126.5 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-N 119.296 1.548 . . . . 0.0 110.723 175.931 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.7 mm -135.98 111.08 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 124.901 1.28 . . . . 0.0 110.977 176.113 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -74.8 146.62 41.91 Favored 'General case' 0 CA--C 1.546 0.819 0 O-C-N 121.328 -0.857 . . . . 0.0 110.009 166.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -128.76 100.64 5.79 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.707 1.603 . . . . 0.0 108.571 172.914 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -101.83 130.37 48.27 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -174.549 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -100.81 120.51 40.22 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.136 0.493 . . . . 0.0 111.41 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -75.06 -41.7 58.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 123.048 0.539 . . . . 0.0 111.204 168.678 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -156.58 133.58 10.42 Favored 'General case' 0 C--O 1.219 -0.52 0 C-N-CA 126.429 1.892 . . . . 0.0 110.321 168.309 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -60.42 -19.72 57.23 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 114.703 1.372 . . . . 0.0 114.703 -172.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -80.56 -6.26 57.98 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.655 1.182 . . . . 0.0 113.218 173.753 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.86 -164.34 11.22 Favored Glycine 0 CA--C 1.537 1.459 0 C-N-CA 126.546 2.022 . . . . 0.0 113.383 -172.935 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.37 155.52 25.06 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.271 2.647 . . . . 0.0 114.012 -169.25 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 84.5 t -102.6 137.35 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.766 1.626 . . . . 0.0 110.17 172.739 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -96.09 122.62 39.12 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 167.145 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.31 129.2 74.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 126.166 1.786 . . . . 0.0 107.856 -169.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.5 p90 -155.41 153.16 29.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 -178.679 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.64 -152.73 24.77 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 125.417 1.484 . . . . 0.0 109.92 179.717 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 69.0 p -159.04 147.42 18.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -175.074 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.0 mm -105.62 109.55 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.558 1.543 . . . . 0.0 109.078 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 44.9 tttp -120.75 133.43 55.33 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 119.463 1.029 . . . . 0.0 110.94 -168.887 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.66 -6.43 9.73 Favored Glycine 0 CA--C 1.541 1.681 0 C-N-CA 127.964 2.697 . . . . 0.0 113.839 -169.663 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -75.08 -179.89 4.61 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 126.373 1.869 . . . . 0.0 113.346 177.169 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -103.95 157.73 16.9 Favored 'General case' 0 C--O 1.239 0.553 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 162.521 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -64.86 168.94 5.65 Favored 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.741 1.385 . . . . 0.0 114.741 -170.84 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.59 -177.54 51.38 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.261 0.934 . . . . 0.0 114.161 -173.021 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.8 mp -66.97 149.33 50.78 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 127.298 2.239 . . . . 0.0 113.648 -174.156 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -140.5 133.42 29.19 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.726 1.61 . . . . 0.0 110.235 176.816 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.59 146.67 48.47 Favored Glycine 0 N--CA 1.475 1.257 0 CA-C-O 119.055 -0.858 . . . . 0.0 110.987 175.574 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -152.94 111.79 3.76 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.592 0.757 . . . . 0.0 111.852 -166.06 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -147.73 152.2 37.36 Favored 'General case' 0 N--CA 1.471 0.617 0 O-C-N 120.032 -1.667 . . . . 0.0 111.256 -169.852 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.41 131.41 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-O 123.719 1.724 . . . . 0.0 110.117 169.527 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 18.1 m-70 -76.08 108.69 9.16 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 165.448 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -68.75 21.62 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.238 2.215 . . . . 0.0 113.554 -169.288 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -153.81 131.74 11.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.976 1.71 . . . . 0.0 108.005 -171.158 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.28 -14.54 76.39 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 115.124 0.81 . . . . 0.0 115.124 178.427 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -69.91 74.07 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 127.023 2.129 . . . . 0.0 111.149 178.257 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 5.4 p30 164.02 -36.54 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 128.697 2.799 . . . . 0.0 115.237 -178.85 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.401 0.1 OUTLIER . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 130.457 3.503 . . . . 0.0 118.667 -173.625 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.684 0 CA-C-O 121.22 0.533 . . . . 0.0 111.381 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.05 178.39 49.08 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 118.774 -1.014 . . . . 0.0 113.713 173.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -64.71 -176.3 0.42 Allowed 'Trans proline' 0 C--N 1.356 0.928 1 C-N-CA 128.171 5.914 . . . . 0.0 113.097 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 63' ' ' HIS . . . . . 0.553 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.6 p80 -53.48 111.82 0.78 Allowed 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.215 1.406 . . . . 0.0 108.53 169.338 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -57.49 157.9 6.36 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 114.434 -1.257 . . . . 0.0 111.174 -178.854 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.26 49.78 0.01 OUTLIER Pre-proline 0 CA--C 1.566 1.59 0 N-CA-C 114.909 1.448 . . . . 0.0 114.909 172.497 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -65.74 -28.98 51.45 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.366 2.238 . . . . 0.0 114.247 -171.553 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 65.7 mt -75.79 -4.0 38.14 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 173.4 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 64.95 55.16 1.19 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.524 1.529 . . . . 0.0 112.827 170.231 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.33 178.92 8.73 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 124.899 1.279 . . . . 0.0 112.709 -171.274 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.462 ' HZ3' ' CD ' ' B' ' 77' ' ' GLU . 22.4 pttm -72.7 161.24 31.0 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.138 0.575 . . . . 0.0 111.173 -175.757 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -82.41 155.17 24.82 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 179.426 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 141.26 -108.93 0.57 Allowed Glycine 0 C--N 1.339 0.72 0 N-CA-C 114.246 0.458 . . . . 0.0 114.246 166.896 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.2 -19.61 34.38 Favored Glycine 0 CA--C 1.546 1.988 0 N-CA-C 119.145 2.418 . . . . 0.0 119.145 169.936 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -110.15 24.9 0.05 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 0 C-N-CA 124.248 3.299 . . . . 0.0 111.718 169.01 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 ptpt -165.85 -31.67 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 127.301 2.24 . . . . 0.0 110.646 170.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -84.2 136.72 33.85 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 128.469 2.708 . . . . 0.0 107.155 166.865 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 77' ' ' GLU . . . . . 0.462 ' CD ' ' HZ3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -87.63 -12.82 44.43 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 127.209 2.204 . . . . 0.0 113.523 -176.993 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -91.65 -98.65 0.12 Allowed 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.112 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 87.58 141.32 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 128.391 2.676 . . . . 0.0 113.573 174.599 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -69.67 154.99 41.2 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 116.938 -1.506 . . . . 0.0 107.872 162.73 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.326 7.1 p -76.5 -21.97 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-N 122.467 2.394 . . . . 0.0 111.104 177.173 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -69.11 20.81 0.4 Allowed Glycine 0 CA--C 1.537 1.436 0 C-N-CA 125.693 1.616 . . . . 0.0 115.327 169.202 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -124.63 118.16 25.88 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 120.785 2.292 . . . . 0.0 111.71 -176.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -97.75 170.81 8.73 Favored 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 166.378 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -76.04 175.5 52.27 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 166.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -70.65 145.93 50.32 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.559 -0.377 . . . . 0.0 111.104 -169.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 6.6 p -85.0 166.0 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 165.853 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -152.49 140.2 19.89 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.159 1.345 . . . . 0.0 112.688 -177.532 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 89' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -116.94 152.33 34.78 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -167.988 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -97.25 155.46 16.85 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 129.245 3.018 . . . . 0.0 110.943 170.573 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 91' ' ' LYS . . . . . 0.439 ' HZ3' ' CG ' ' B' ' 92' ' ' ASP . 1.7 pptp? -43.01 -24.02 0.06 Allowed 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 129.487 3.115 . . . . 0.0 117.27 175.479 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 92' ' ' ASP . . . . . 0.439 ' CG ' ' HZ3' ' B' ' 91' ' ' LYS . 73.1 m-20 -76.41 6.28 5.91 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 120.503 -1.373 . . . . 0.0 111.595 172.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.0 27.91 67.71 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 126.06 1.791 . . . . 0.0 112.801 178.564 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.5 p -115.71 120.28 64.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.09 0.956 . . . . 0.0 110.63 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -83.6 120.99 26.64 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.521 1.128 . . . . 0.0 108.728 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.42 146.3 28.51 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.852 0.834 . . . . 0.0 110.302 172.549 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.37 127.96 57.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.52 165.333 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -150.68 53.59 0.88 Allowed 'General case' 0 CA--C 1.545 0.757 0 CA-C-O 123.583 1.658 . . . . 0.0 109.204 -172.746 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.5 mp -105.03 160.85 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.241 1.816 . . . . 0.0 112.512 -166.587 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -140.23 142.12 35.84 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 128.153 2.581 . . . . 0.0 106.304 168.691 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -150.98 138.29 19.39 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 119.084 0.856 . . . . 0.0 111.393 -179.949 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.2 p -107.84 52.75 0.71 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.393 1.077 . . . . 0.0 111.815 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.63 -42.1 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.864 1.666 . . . . 0.0 108.967 177.172 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -87.9 144.64 8.78 Favored 'Isoleucine or valine' 0 C--N 1.344 0.338 0 CA-C-O 122.32 1.057 . . . . 0.0 110.463 167.468 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 10.3 p -148.86 168.41 23.08 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 124.201 1.001 . . . . 0.0 111.125 170.215 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -79.72 63.49 4.3 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 124.754 1.221 . . . . 0.0 108.628 174.737 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.0 t -84.55 -175.67 5.89 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.082 1.353 . . . . 0.0 110.342 169.086 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.06 -46.92 2.33 Favored Glycine 0 N--CA 1.475 1.265 0 O-C-N 120.924 -1.11 . . . . 0.0 113.832 177.016 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -125.27 -24.74 3.91 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -169.398 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 73.0 m-70 -97.71 7.98 45.48 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.558 1.543 . . . . 0.0 113.421 -171.554 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.62 -133.83 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -171.916 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.321 36.0 pt -81.28 -143.18 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 CA-C-N 119.431 1.014 . . . . 0.0 113.011 170.822 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm 59.49 124.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 127.597 2.359 . . . . 0.0 111.873 -165.56 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.05 19.68 61.69 Favored Glycine 0 N--CA 1.474 1.212 0 O-C-N 120.409 -1.432 . . . . 0.0 113.981 179.007 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? -99.93 172.45 7.22 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 127.157 2.183 . . . . 0.0 109.496 174.56 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.9 t -130.67 127.0 37.99 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-N 119.371 0.987 . . . . 0.0 112.287 177.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 16.7 tp -93.0 130.36 38.59 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 125.677 1.591 . . . . 0.0 110.322 -175.648 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.53 146.5 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 125.781 1.632 . . . . 0.0 111.323 175.514 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.3 p -121.78 142.14 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 123.48 0.712 . . . . 0.0 111.215 170.553 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -115.25 156.06 26.08 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 113.607 -168.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -73.67 -28.53 61.81 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -169.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -117.82 173.97 6.45 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.562 1.145 . . . . 0.0 112.228 176.721 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.8 134.06 56.25 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.368 1.467 . . . . 0.0 110.828 169.8 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -81.78 119.67 24.18 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.411 1.084 . . . . 0.0 111.277 173.6 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . 0.369 30.3 t0 -75.71 -4.88 42.86 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 170.47 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 5.4 mt 61.03 76.03 0.39 Allowed 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 126.221 1.808 . . . . 0.0 112.123 165.125 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.13 -12.71 48.78 Favored Glycine 0 N--CA 1.476 1.303 0 C-N-CA 123.174 0.416 . . . . 0.0 112.875 176.913 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mtpm? -115.38 179.0 4.09 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.883 2.473 . . . . 0.0 109.223 170.033 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 126.39 -28.81 4.68 Favored Glycine 0 N--CA 1.469 0.861 0 C-N-CA 125.681 1.61 . . . . 0.0 111.351 -168.931 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 104.43 -6.29 45.52 Favored Glycine 0 N--CA 1.474 1.185 0 N-CA-C 117.253 1.661 . . . . 0.0 117.253 166.609 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.0 p-10 -110.74 170.24 8.23 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.771 1.628 . . . . 0.0 110.258 176.159 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' HE2' ' B' ' 136' ' ' LYS . 24.2 tt0 -63.0 -41.65 99.63 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.514 -1.366 . . . . 0.0 110.412 -179.843 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -56.23 -27.88 56.49 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.369 2.267 . . . . 0.0 112.569 176.317 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.26 -23.04 54.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.566 1.076 . . . . 0.0 113.573 171.224 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.6 t -121.23 -13.05 8.56 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.373 1.619 . . . . 0.0 115.373 169.646 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.414 ' HE2' ' OE2' ' B' ' 132' ' ' GLU . 30.6 mttm -76.48 -23.96 53.82 Favored 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 121.009 1.732 . . . . 0.0 111.449 166.501 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 75.6 p -117.97 -114.21 0.33 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 104.3 -2.481 . . . . 0.0 104.3 165.386 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.24 -10.76 0.19 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 116.262 1.265 . . . . 0.0 116.262 169.136 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 114.85 -14.15 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 131.123 3.769 . . . . 0.0 112.737 177.819 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.08 4.9 0.11 Allowed 'General case' 0 CA--C 1.56 1.344 0 N-CA-C 117.497 2.406 . . . . 0.0 117.497 -174.34 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.8 -141.68 18.8 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.542 1.544 . . . . 0.0 113.466 174.808 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.0 t -68.64 -167.44 0.1 Allowed 'General case' 0 CA--C 1.544 0.732 0 CA-C-O 122.294 1.045 . . . . 0.0 111.965 175.909 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.88 155.79 44.69 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 124.428 1.091 . . . . 0.0 110.578 177.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.72 -123.19 0.29 Allowed 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 126.256 2.222 . . . . 0.0 105.034 164.003 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -66.91 160.71 25.65 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -166.394 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.8 t -147.88 152.08 37.0 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.445 1.898 . . . . 0.0 112.078 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.65 135.79 4.3 Favored Glycine 0 N--CA 1.483 1.829 0 CA-C-N 120.317 1.417 . . . . 0.0 115.667 -177.087 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 12.2 t -81.65 154.89 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 125.336 1.454 . . . . 0.0 111.779 -177.204 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 39.3 mt -95.46 93.82 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 126.455 1.902 . . . . 0.0 111.99 -176.358 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.24 173.63 30.35 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 125.614 1.578 . . . . 0.0 113.487 174.606 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.8 mp -95.49 85.98 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.095 1.887 . . . . 0.0 116.095 -167.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -73.78 18.92 0.12 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.961 1.704 . . . . 0.0 115.478 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 . . . . . 0 N--CA 1.466 0.364 0 C-N-CA 130.845 3.658 . . . . 0.0 114.712 -169.279 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.812 0 CA-C-O 119.813 -0.137 . . . . 0.0 111.107 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -77.2 115.79 17.28 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 14.4 pttm -89.13 129.96 35.64 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.375 168.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.56 173.52 8.02 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 164.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.2 119.56 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.524 1.53 . . . . 0.0 108.475 -173.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.96 118.77 37.65 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 166.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.0 t -110.99 99.66 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.705 0.802 . . . . 0.0 109.397 177.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.95 132.56 35.89 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.564 168.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -135.5 132.51 37.4 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.048 1.339 . . . . 0.0 110.643 168.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.95 -97.95 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 171.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.87 119.77 9.95 Favored 'General case' 0 N--CA 1.44 -0.94 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 -166.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 41.02 -99.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 128.743 3.068 . . . . 0.0 113.358 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.88 -11.88 33.52 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 123.311 2.674 . . . . 0.0 113.828 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.89 115.05 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 120.32 1.418 . . . . 0.0 112.44 179.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -139.9 169.9 16.86 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 122.265 1.031 . . . . 0.0 111.005 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.96 110.29 0.55 Allowed Glycine 0 C--O 1.224 -0.476 0 CA-C-N 113.984 -1.462 . . . . 0.0 111.639 168.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.62 134.65 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.106 0.953 . . . . 0.0 109.339 169.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.1 mm -139.38 124.45 21.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 C-N-CA 125.996 1.718 . . . . 0.0 109.888 168.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -90.81 141.32 28.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 124.867 1.267 . . . . 0.0 110.571 166.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -113.94 101.53 9.34 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.686 1.194 . . . . 0.0 109.779 172.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -83.91 110.68 18.59 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 125.965 1.706 . . . . 0.0 111.172 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.7 tp60 -123.13 139.17 54.34 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.378 1.071 . . . . 0.0 110.989 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.94 -28.17 15.3 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 -168.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.277 0.0 OUTLIER -128.68 -106.76 0.3 Allowed 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.953 1.301 . . . . 0.0 109.508 166.628 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 88.4 p -152.96 -10.37 0.16 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 122.13 2.241 . . . . 0.0 116.358 -177.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -128.94 -13.91 4.52 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.377 1.471 . . . . 0.0 112.672 176.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 174.53 42.58 Favored Glycine 0 CA--C 1.543 1.812 0 C-N-CA 127.938 2.685 . . . . 0.0 113.885 175.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -79.91 157.32 23.99 Favored 'Trans proline' 0 CA--C 1.534 0.498 0 C-N-CA 123.546 2.831 . . . . 0.0 112.427 -168.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.2 t -118.21 136.89 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.97 0.908 . . . . 0.0 112.427 -166.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.516 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 7.1 tttp -93.57 124.31 37.47 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.597 1.159 . . . . 0.0 108.151 170.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.25 133.34 69.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.924 0.89 . . . . 0.0 110.29 -168.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -157.36 158.83 36.69 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.25 178.6 29.67 Favored Glycine 0 CA--C 1.528 0.849 0 C-N-CA 123.881 0.753 . . . . 0.0 114.799 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.0 p -115.69 125.35 52.72 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -167.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 9.7 mm -109.74 102.24 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 C-N-CA 125.224 1.41 . . . . 0.0 108.068 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -116.2 157.61 24.59 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.315 0.646 . . . . 0.0 112.194 -168.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.94 9.6 63.72 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 124.941 1.258 . . . . 0.0 112.448 -168.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 99.0 mt -83.33 167.93 17.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.688 1.195 . . . . 0.0 110.563 172.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -100.37 156.64 17.14 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 106.322 -1.732 . . . . 0.0 106.322 163.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -61.96 157.23 19.08 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-O 122.509 1.147 . . . . 0.0 113.429 -170.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.02 -176.83 36.37 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 122.147 0.859 . . . . 0.0 112.685 -173.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.466 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.2 mp -72.52 150.35 43.29 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.695 1.998 . . . . 0.0 111.895 -169.12 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -144.31 124.82 13.96 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.847 1.659 . . . . 0.0 110.462 174.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.04 148.33 36.38 Favored Glycine 0 N--CA 1.487 2.054 0 CA-C-O 118.723 -1.043 . . . . 0.0 112.869 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -149.84 97.53 2.61 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-N 118.325 1.062 . . . . 0.0 113.613 -166.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -130.25 134.29 47.13 Favored 'General case' 0 N--CA 1.483 1.196 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -166.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -85.36 113.94 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 122.015 0.912 . . . . 0.0 110.896 170.17 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -81.74 173.07 12.65 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 125.419 1.487 . . . . 0.0 114.109 -175.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -65.06 133.41 51.58 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 126.062 1.745 . . . . 0.0 106.54 165.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 67.83 -176.91 0.2 Allowed 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 124.275 1.988 . . . . 0.0 112.992 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.34 3.65 29.68 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 130.618 3.961 . . . . 0.0 111.52 168.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.47 ' C ' HD21 ' A' ' 53' ' ' ASN . 14.9 t0 -73.85 126.51 30.57 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 120.385 2.093 . . . . 0.0 109.51 172.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.659 ' ND2' ' HG1' ' A' ' 116' ' ' THR 0.279 0.1 OUTLIER -156.12 42.62 0.4 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 123.289 1.518 . . . . 0.0 112.708 168.46 . . . . . . . . 4 4 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 38.8 p -116.3 -25.7 7.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 112.737 -2.029 . . . . 0.0 113.905 -165.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 25.6 0.59 Allowed 'General case' 0 CA--C 1.552 1.039 0 CA-C-N 119.374 0.988 . . . . 0.0 112.109 168.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.69 -121.35 12.34 Favored Glycine 0 C--N 1.341 0.827 0 C-N-CA 125.573 1.558 . . . . 0.0 110.561 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -74.14 -13.68 60.85 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.17 39.44 0.45 Allowed 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 126.072 1.749 . . . . 0.0 111.72 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 69.8 m -148.29 -116.16 0.06 Allowed 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.306 2.243 . . . . 0.0 106.636 -169.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.59 109.98 0.71 Allowed 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 124.781 1.232 . . . . 0.0 112.23 169.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.57 -113.02 0.47 Allowed Glycine 0 CA--C 1.538 1.485 0 CA-C-O 117.928 -1.485 . . . . 0.0 109.574 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -82.67 -179.86 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 124.415 3.41 . . . . 0.0 108.102 165.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.29 123.07 32.52 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.673 0.789 . . . . 0.0 111.518 -172.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -26.03 131.77 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 129.419 3.088 . . . . 0.0 116.956 174.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -106.15 52.69 0.15 Allowed Pre-proline 0 CA--C 1.557 1.235 0 C-N-CA 124.883 1.273 . . . . 0.0 113.425 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -63.05 -25.3 73.57 Favored 'Trans proline' 0 C--N 1.355 0.896 0 CA-C-N 122.691 1.997 . . . . 0.0 112.937 -173.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 69.0 mt -99.5 -0.49 40.56 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.802 1.241 . . . . 0.0 113.797 172.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.4 t 70.57 58.87 0.23 Allowed 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 120.452 1.478 . . . . 0.0 114.073 168.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.06 176.01 10.04 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.446 1.498 . . . . 0.0 111.478 172.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.45 ' HZ2' ' HB2' ' A' ' 70' ' ' LYS . 4.1 ttmp? -70.8 173.29 7.49 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 129.497 3.119 . . . . 0.0 113.225 178.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -69.02 149.29 48.95 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.481 167.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 171.45 -157.45 27.95 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 116.884 1.513 . . . . 0.0 116.884 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.81 -70.29 0.43 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 118.013 1.965 . . . . 0.0 118.013 168.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -75.98 0.03 9.76 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 123.327 2.685 . . . . 0.0 114.506 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.98 -31.48 0.21 Allowed 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 119.301 0.955 . . . . 0.0 111.415 171.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -89.92 153.23 20.77 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.464 1.506 . . . . 0.0 111.26 167.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.7 tt0 -98.68 -27.82 13.81 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 126.356 1.863 . . . . 0.0 112.722 -170.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -78.8 -53.02 7.54 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 121.412 -0.805 . . . . 0.0 110.704 -169.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.7 ttt180 58.17 119.75 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 117.789 2.515 . . . . 0.0 117.789 163.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.8 m170 -58.5 143.08 46.94 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 118.458 -2.652 . . . . 0.0 112.942 169.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 91.2 t -58.26 -24.18 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.334 -0.854 . . . . 0.0 110.432 167.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -80.89 23.38 4.39 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 117.157 -1.913 . . . . 0.0 116.44 172.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -127.4 109.62 11.95 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 120.577 2.189 . . . . 0.0 111.533 -178.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -110.92 59.56 0.61 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.156 0.982 . . . . 0.0 110.742 172.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.79 -151.78 39.8 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.916 173.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.82 149.47 47.75 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.805 1.242 . . . . 0.0 108.619 169.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.26 106.47 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 124.559 1.144 . . . . 0.0 109.579 -174.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 38.7 m -96.14 114.67 26.39 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 124.451 1.1 . . . . 0.0 108.772 -174.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.73 154.11 19.18 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.666 1.187 . . . . 0.0 113.421 -172.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 12.1 t70 -94.6 176.84 6.13 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.513 1.125 . . . . 0.0 112.278 168.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.47 ' C ' ' H ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -73.57 -18.9 61.01 Favored 'General case' 0 N--CA 1.473 0.718 0 O-C-N 121.113 -0.992 . . . . 0.0 113.003 -176.587 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.37 15.23 0.48 Allowed 'General case' 0 CA--C 1.56 1.328 0 CA-C-O 122.974 1.369 . . . . 0.0 110.799 170.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 91' ' ' LYS . . . 82.29 12.74 80.18 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 128.131 2.776 . . . . 0.0 114.726 168.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.26 134.4 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 116.77 2.137 . . . . 0.0 116.77 -166.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.0 103.84 13.97 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.734 1.214 . . . . 0.0 107.822 166.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -94.89 109.36 21.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.944 0.878 . . . . 0.0 109.635 172.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -93.67 153.84 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 C-N-CA 124.825 1.25 . . . . 0.0 112.977 -169.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.2 p -149.6 125.74 10.69 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.933 0.893 . . . . 0.0 110.635 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.4 mt -144.98 157.99 13.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 128.548 2.739 . . . . 0.0 110.492 -169.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.516 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 12.4 tt0 -147.04 135.89 22.23 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.456 1.902 . . . . 0.0 107.055 167.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -155.79 144.92 20.69 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -166.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.0 p -122.15 49.25 1.6 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.326 1.05 . . . . 0.0 113.742 176.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.03 -3.63 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 124.769 1.227 . . . . 0.0 112.478 171.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.61 163.74 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 127.023 2.129 . . . . 0.0 110.004 174.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.0 t -157.13 163.84 38.49 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.524 1.529 . . . . 0.0 110.53 170.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.5 mp -77.3 66.36 3.06 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 120.195 1.361 . . . . 0.0 110.923 -171.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.89 104.0 9.24 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 125.431 1.492 . . . . 0.0 114.185 -167.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.49 -145.37 32.88 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.269 167.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -109.24 11.28 25.5 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.609 1.564 . . . . 0.0 112.086 -167.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -141.78 -9.77 0.92 Allowed 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -167.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.2 t -90.22 -87.85 0.18 Allowed 'General case' 0 N--CA 1.471 0.596 0 O-C-N 120.774 -1.204 . . . . 0.0 110.951 -171.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.294 0.1 OUTLIER -134.33 16.01 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 120.708 1.595 . . . . 0.0 112.505 167.356 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.39 141.04 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.25 3.97 83.0 Favored Glycine 0 N--CA 1.468 0.82 0 C-N-CA 124.451 1.024 . . . . 0.0 114.575 -175.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 44.2 ttt180 -100.38 176.36 5.38 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.286 1.434 . . . . 0.0 111.903 -167.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.659 ' HG1' ' ND2' ' A' ' 53' ' ' ASN . 18.8 m -118.62 143.05 47.07 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.942 1.697 . . . . 0.0 108.987 -179.056 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -117.62 141.89 47.85 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.581 1.152 . . . . 0.0 108.648 167.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.429 HG23 ' HE ' ' A' ' 143' ' ' ARG . 8.2 p -118.05 139.04 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.881 0.872 . . . . 0.0 111.52 172.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 4.7 p -110.81 133.64 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 O-C-N 124.293 0.996 . . . . 0.0 109.623 167.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 -99.94 159.45 15.07 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -60.6 -44.83 95.84 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.601 2.76 . . . . 0.0 114.714 -175.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 3.4 mppt? -127.35 -180.0 5.18 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.987 1.715 . . . . 0.0 113.163 -176.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.23 147.02 17.45 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.514 1.526 . . . . 0.0 112.428 173.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -102.53 137.04 41.3 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.821 1.648 . . . . 0.0 109.967 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -72.54 -43.31 63.68 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.964 -0.541 . . . . 0.0 111.673 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.0 mt 71.74 53.48 0.21 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.688 1.995 . . . . 0.0 111.967 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 158.43 -90.11 0.11 Allowed Glycine 0 N--CA 1.474 1.224 0 CA-C-N 119.598 1.09 . . . . 0.0 115.128 176.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.6 ttpm? -146.44 98.9 3.14 Favored 'General case' 0 N--CA 1.424 -1.76 0 C-N-CA 128.649 2.78 . . . . 0.0 107.745 177.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.5 -138.74 0.69 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 169.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -89.74 6.26 83.08 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.08 -175.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -157.99 168.92 25.77 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 120.372 2.086 . . . . 0.0 109.789 -169.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.91 -57.7 11.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.425 1.09 . . . . 0.0 110.836 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -41.24 -40.47 1.62 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 127.663 2.385 . . . . 0.0 114.562 178.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 64.1 p -55.12 -27.59 46.41 Favored 'General case' 0 N--CA 1.469 0.505 0 O-C-N 120.595 -1.315 . . . . 0.0 113.768 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 27.1 p -71.63 -28.02 63.49 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.557 1.143 . . . . 0.0 112.681 173.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -79.4 -56.98 3.93 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.771 1.628 . . . . 0.0 112.471 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.8 p -115.29 -14.84 11.65 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.525 1.306 . . . . 0.0 114.525 -170.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.49 -1.88 69.86 Favored Glycine 0 N--CA 1.466 0.65 0 O-C-N 123.902 0.751 . . . . 0.0 112.277 -169.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 66.16 17.56 10.77 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.671 1.188 . . . . 0.0 111.021 -176.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.6 -9.81 15.39 Favored 'General case' 0 CA--C 1.554 1.127 0 C-N-CA 123.898 0.879 . . . . 0.0 113.175 -168.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.67 -164.03 21.79 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.831 1.681 . . . . 0.0 112.937 178.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -63.68 175.67 1.05 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.797 1.239 . . . . 0.0 112.246 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.429 ' HE ' HG23 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -109.29 143.96 38.08 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 120.761 -1.212 . . . . 0.0 112.066 169.123 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -104.04 -94.72 0.33 Allowed 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.105 1.762 . . . . 0.0 109.052 173.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.34 149.18 38.78 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 122.379 1.085 . . . . 0.0 110.793 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 84.5 m -131.67 151.76 51.39 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 112.768 -2.014 . . . . 0.0 108.005 173.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.94 163.04 33.52 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 123.404 0.526 . . . . 0.0 113.899 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 25.1 t -113.5 160.87 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 125.358 1.463 . . . . 0.0 110.589 177.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.2 mt -114.65 123.26 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 124.222 1.009 . . . . 0.0 113.362 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -126.74 -168.73 12.62 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 126.144 1.83 . . . . 0.0 113.093 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.2 mp -104.63 131.78 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 121.57 -0.959 . . . . 0.0 111.033 -169.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -118.71 22.6 11.92 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.719 1.608 . . . . 0.0 113.61 -174.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.332 -0.188 0 C-N-CA 124.368 1.067 . . . . 0.0 110.47 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.825 0.345 . . . . 0.0 111.845 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -107.98 122.49 46.95 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.726 0.81 . . . . 0.0 109.411 175.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -99.18 131.17 45.41 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 174.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.86 169.52 8.54 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.652 1.181 . . . . 0.0 114.08 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -161.63 88.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 C-N-CA 128.114 2.566 . . . . 0.0 109.218 -169.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.72 142.73 35.18 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 120.415 -1.428 . . . . 0.0 111.005 176.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 4.2 t -126.7 106.23 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 3.1 mp -100.0 139.33 35.82 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.603 1.161 . . . . 0.0 108.21 169.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -155.95 175.18 14.29 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.126 1.37 . . . . 0.0 110.307 170.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 143.62 -46.3 0.84 Allowed Glycine 0 N--CA 1.474 1.201 0 C-N-CA 124.54 1.067 . . . . 0.0 113.68 169.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -78.01 67.2 3.8 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.535 1.534 . . . . 0.0 109.23 175.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.24 -111.34 0.38 Allowed Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.649 2.547 . . . . 0.0 112.625 -175.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -76.51 1.14 8.76 Favored 'Trans proline' 0 CA--C 1.536 0.603 0 C-N-CA 124.906 3.737 . . . . 0.0 114.168 -176.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 31.1 t -79.49 131.39 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 120.155 1.343 . . . . 0.0 111.283 171.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -130.13 160.84 32.56 Favored 'General case' 0 CA--C 1.516 -0.363 0 C-N-CA 125.127 1.371 . . . . 0.0 109.381 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.68 107.68 0.69 Allowed Glycine 0 CA--C 1.499 -0.926 0 CA-C-N 113.956 -1.474 . . . . 0.0 109.491 169.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.73 120.71 65.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.252 2.9 pp -130.53 139.49 51.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 122.376 1.084 . . . . 0.0 110.715 172.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -107.54 172.98 6.53 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 125.921 1.688 . . . . 0.0 110.523 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -152.66 165.74 34.32 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.773 0.829 . . . . 0.0 109.528 170.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -136.02 138.12 41.88 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.175 1.39 . . . . 0.0 109.584 166.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 59.4 tp60 -102.97 102.28 12.32 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.554 0.742 . . . . 0.0 110.749 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.46 ' HZ1' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -67.25 -45.0 78.0 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 120.51 -1.369 . . . . 0.0 113.703 176.158 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.46 ' CD ' ' HZ1' ' B' ' 23' ' ' LYS . 40.0 mp0 -147.7 138.98 23.62 Favored 'General case' 0 C--O 1.222 -0.379 0 C-N-CA 126.858 2.063 . . . . 0.0 108.394 168.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 76.0 p -50.33 -20.44 1.08 Allowed 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -169.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -112.98 0.46 15.06 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.141 1.376 . . . . 0.0 113.248 -173.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.72 -170.3 43.18 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.664 1.126 . . . . 0.0 113.624 -173.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -81.2 162.52 20.14 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.761 2.307 . . . . 0.0 109.923 168.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -135.47 143.24 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.481 1.112 . . . . 0.0 110.999 -174.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.418 ' HZ2' ' CD ' ' B' ' 100' ' ' GLU . 41.7 tttp -94.88 115.78 27.89 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.795 0.807 . . . . 0.0 110.153 167.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.94 144.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 166.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -144.56 -168.39 2.89 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 167.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.45 -153.82 17.22 Favored Glycine 0 N--CA 1.469 0.843 0 C-N-CA 124.84 1.21 . . . . 0.0 112.684 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 94.7 p -156.67 137.87 13.72 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 114.062 1.134 . . . . 0.0 114.062 -172.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.8 mm -104.96 119.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 169.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -131.91 144.62 50.98 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 121.192 1.814 . . . . 0.0 111.816 -171.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.7 -8.16 21.99 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 128.547 2.975 . . . . 0.0 113.374 -173.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 5.5 mp -71.44 156.48 39.41 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 129.327 3.051 . . . . 0.0 112.732 -176.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.6 t -74.48 168.32 19.95 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 164.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -75.52 146.1 40.81 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.167 -0.958 . . . . 0.0 112.976 177.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.72 -168.04 13.79 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 124.142 0.877 . . . . 0.0 113.017 -172.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.0 mt -76.12 147.43 38.58 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.896 2.078 . . . . 0.0 112.966 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . 0.401 ' HD1' ' HA ' ' B' ' 121' ' ' GLU . 87.2 m-70 -146.54 120.75 9.53 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.929 2.092 . . . . 0.0 110.501 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.06 145.86 37.05 Favored Glycine 0 N--CA 1.484 1.876 0 CA-C-O 117.536 -1.702 . . . . 0.0 112.333 -177.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -141.49 125.89 17.64 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 121.173 2.486 . . . . 0.0 113.074 -178.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 28.7 m80 -137.2 128.21 27.59 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -171.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -80.59 137.51 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 165.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -113.81 171.27 7.69 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 118.715 0.689 . . . . 0.0 111.466 173.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -72.63 138.72 46.92 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 125.184 1.394 . . . . 0.0 110.707 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 72.0 168.36 0.31 Allowed 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.6 1.96 . . . . 0.0 111.37 -168.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.32 16.62 60.19 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 164.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -87.35 110.45 20.25 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 125.9 1.68 . . . . 0.0 109.444 -168.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.519 HD22 HG23 ' B' ' 148' ' ' VAL . 2.2 p30 -159.23 34.48 0.2 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 116.132 1.901 . . . . 0.0 116.132 -174.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.321 1.3 p -71.16 -72.31 0.22 Allowed 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -164.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -88.57 -19.31 26.5 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.718 1.377 . . . . 0.0 114.718 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.84 -139.89 12.04 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 125.901 1.715 . . . . 0.0 110.275 -169.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 24.3 p -45.56 -33.26 2.68 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 118.304 2.705 . . . . 0.0 118.304 -168.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.2 m -68.58 -25.29 64.81 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 124.432 1.093 . . . . 0.0 112.421 175.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.3 m -107.96 67.99 0.69 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 128.504 2.722 . . . . 0.0 107.597 169.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 79.54 139.95 0.07 Allowed 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.776 2.43 . . . . 0.0 114.413 175.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.15 -115.81 4.04 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.502 1.525 . . . . 0.0 111.773 176.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.58 175.52 10.96 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.968 3.112 . . . . 0.0 110.978 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.538 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -69.57 113.76 7.16 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.94 1.696 . . . . 0.0 109.192 176.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -55.15 145.43 21.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.832 1.301 . . . . 0.0 114.503 -168.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -111.05 66.77 0.55 Allowed Pre-proline 0 CA--C 1.55 0.977 0 C-N-CA 126.87 2.068 . . . . 0.0 112.16 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -60.64 -35.64 88.78 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.076 2.518 . . . . 0.0 113.329 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 72.9 mt -80.85 -1.32 42.76 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.728 1.211 . . . . 0.0 114.177 171.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t 71.22 47.02 0.41 Allowed 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 127.835 2.454 . . . . 0.0 111.073 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.7 mtp180 -103.02 171.99 7.07 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -169.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mpmm? -83.45 167.07 17.81 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 125.665 1.586 . . . . 0.0 109.449 162.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -78.32 168.46 19.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.357 1.063 . . . . 0.0 112.087 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.6 -134.95 7.65 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 124.719 1.152 . . . . 0.0 113.495 168.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.81 -80.77 0.33 Allowed Glycine 0 CA--C 1.541 1.657 0 CA-C-N 118.278 1.039 . . . . 0.0 115.335 -174.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.19 7.5 0.63 Allowed 'Trans proline' 0 CA--C 1.547 1.175 0 CA-C-N 120.846 2.323 . . . . 0.0 115.328 -177.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.35 6.57 0.29 Allowed 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 126.986 2.115 . . . . 0.0 113.366 169.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.6 156.71 45.66 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.406 2.282 . . . . 0.0 110.336 -170.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -97.43 -9.22 27.71 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.648 1.979 . . . . 0.0 112.126 -173.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -83.86 -95.81 0.06 Allowed 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.443 -0.786 . . . . 0.0 110.482 177.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 48.8 ttt180 68.49 115.98 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.513 1.925 . . . . 0.0 112.274 -170.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -55.21 154.31 5.96 Favored 'General case' 0 CA--C 1.552 1.022 0 O-C-N 119.505 -1.997 . . . . 0.0 114.813 171.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -84.91 58.18 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 C-N-CA 124.573 1.149 . . . . 0.0 109.492 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.61 67.75 0.02 OUTLIER Glycine 0 N--CA 1.469 0.852 0 C-N-CA 127.569 2.509 . . . . 0.0 109.59 -169.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -163.9 165.45 22.75 Favored 'General case' 0 CA--C 1.553 1.065 0 C-N-CA 128.78 2.832 . . . . 0.0 110.027 166.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 92.9 mt -131.39 -178.38 4.82 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.386 2.274 . . . . 0.0 107.331 168.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.46 -112.4 0.86 Allowed Glycine 0 N--CA 1.47 0.95 0 CA-C-N 118.309 0.504 . . . . 0.0 112.689 -179.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -137.11 164.17 29.06 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-O 121.643 0.735 . . . . 0.0 112.813 176.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.5 m -108.61 175.59 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 127.342 2.257 . . . . 0.0 109.354 171.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 m -141.34 140.25 33.72 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.525 1.53 . . . . 0.0 107.633 169.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.42 139.58 40.68 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.439 1.096 . . . . 0.0 112.814 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -82.62 154.35 24.98 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.717 2.007 . . . . 0.0 110.603 168.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.22 1.25 0.51 Allowed 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 117.621 2.452 . . . . 0.0 117.621 -169.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -76.24 -7.37 54.71 Favored 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 125.138 1.375 . . . . 0.0 109.783 164.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 93.77 20.67 30.73 Favored Glycine 0 C--N 1.337 0.594 0 C-N-CA 128.719 3.057 . . . . 0.0 112.482 177.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.7 p -127.68 133.51 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 119.09 1.445 . . . . 0.0 114.224 -168.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.93 131.24 41.07 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 165.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -81.77 142.46 32.59 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 104.105 -2.554 . . . . 0.0 104.105 166.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 t -125.9 127.02 70.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 CA-C-N 113.349 -1.751 . . . . 0.0 107.541 169.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.8 p -158.77 51.4 0.39 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.723 1.609 . . . . 0.0 110.105 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 mt -103.56 148.76 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.874 1.67 . . . . 0.0 113.317 -167.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.418 ' CD ' ' HZ2' ' B' ' 30' ' ' LYS . 5.6 mp0 -99.31 152.92 19.39 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 125.87 1.668 . . . . 0.0 109.457 174.054 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -153.81 148.49 26.36 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.787 -1.097 . . . . 0.0 111.039 167.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.6 p -118.55 53.65 0.97 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.279 1.032 . . . . 0.0 111.749 178.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.43 -35.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.958 168.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.92 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 CA-C-N 121.024 1.738 . . . . 0.0 111.151 167.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.0 m -160.92 162.43 32.03 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.474 1.509 . . . . 0.0 109.875 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -87.38 76.69 9.04 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.262 1.425 . . . . 0.0 109.172 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.3 t -158.21 104.82 1.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.468 0.651 . . . . 0.0 111.396 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.61 157.22 26.52 Favored Glycine 0 CA--C 1.526 0.763 0 CA-C-O 122.908 1.282 . . . . 0.0 112.445 -172.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -67.12 -21.26 65.85 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 131.391 3.876 . . . . 0.0 114.266 -169.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -107.56 14.88 25.32 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 128.58 2.752 . . . . 0.0 111.806 -175.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 81.0 p -101.67 -54.04 2.83 Favored 'General case' 0 CA--C 1.548 0.875 0 O-C-N 119.428 -2.045 . . . . 0.0 114.233 -174.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pt 178.51 -39.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 1 C-N-CA 133.941 4.897 . . . . 0.0 106.563 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm -57.71 131.08 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 N-CA-C 103.194 -2.891 . . . . 0.0 103.194 159.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.99 -18.97 8.24 Favored Glycine 0 CA--C 1.535 1.297 0 N-CA-C 117.046 1.578 . . . . 0.0 117.046 175.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.8 mtt180 -79.09 -178.09 5.96 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 126.408 1.883 . . . . 0.0 114.081 -177.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 8.8 t -120.19 170.03 9.7 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 127.929 2.492 . . . . 0.0 110.931 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tp -153.54 146.83 24.77 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.396 1.478 . . . . 0.0 111.358 171.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.43 137.34 56.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.622 1.569 . . . . 0.0 110.126 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 45.6 t -106.77 156.99 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -122.55 138.7 54.49 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.709 2.404 . . . . 0.0 111.905 -166.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . 0.401 ' HA ' ' HD1' ' B' ' 43' ' ' HIS . 20.7 tp10 -78.24 3.91 14.12 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -174.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -122.72 168.3 12.39 Favored 'General case' 0 CA--C 1.545 0.76 0 O-C-N 120.22 -1.55 . . . . 0.0 111.166 169.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.57 160.83 1.65 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.403 1.081 . . . . 0.0 111.223 169.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -107.72 149.13 28.53 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 122.732 0.413 . . . . 0.0 110.503 169.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -100.53 -8.84 22.66 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.794 2.038 . . . . 0.0 114.072 -171.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 54.09 70.35 0.62 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.81 1.644 . . . . 0.0 113.832 169.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.16 -51.99 4.47 Favored Glycine 0 N--CA 1.466 0.669 0 O-C-N 121.281 -0.887 . . . . 0.0 112.628 169.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.59 124.3 6.03 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 117.569 2.433 . . . . 0.0 117.569 173.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.24 0.62 Allowed Glycine 0 C--N 1.331 0.289 0 C-N-CA 129.67 3.509 . . . . 0.0 106.256 163.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -111.25 -57.72 0.48 Allowed Glycine 0 CA--C 1.53 0.991 0 N-CA-C 117.227 1.651 . . . . 0.0 117.227 -171.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . 0.571 HD22 ' ND2' ' B' ' 139' ' ' ASN . 0.1 OUTLIER -123.93 -175.62 3.27 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -161.545 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.02 -59.75 3.13 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 126.557 1.943 . . . . 0.0 111.452 171.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -50.56 -20.54 1.21 Allowed 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.81 1.781 . . . . 0.0 115.81 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.6 m -67.25 -40.73 86.31 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 119.838 -1.789 . . . . 0.0 112.302 170.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 22.1 p -82.75 -10.15 59.02 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 126.094 1.758 . . . . 0.0 113.674 -177.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.5 tttt -104.16 -77.18 0.58 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 128.42 2.688 . . . . 0.0 110.505 -168.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 22.2 p -79.2 -85.92 0.08 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 166.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 176.06 23.58 0.03 OUTLIER Glycine 0 CA--C 1.534 1.276 1 C-N-CA 131.431 4.348 . . . . 0.0 110.808 -177.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . 0.571 ' ND2' HD22 ' B' ' 131' ' ' ASN . 0.7 OUTLIER 56.98 17.46 3.37 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.005 1.722 . . . . 0.0 114.907 -174.918 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.96 6.37 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.174 0 N-CA-C 119.384 3.105 . . . . 0.0 119.384 -167.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 62.16 -23.93 0.06 OUTLIER Glycine 0 N--CA 1.475 1.252 0 C-N-CA 130.089 3.709 . . . . 0.0 120.442 166.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.7 t -165.38 159.99 17.65 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.535 1.667 . . . . 0.0 111.111 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.16 179.7 6.6 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.095 0.958 . . . . 0.0 109.892 167.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.33 3.8 pp -166.45 -154.02 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 129.49 3.116 . . . . 0.0 106.637 162.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.98 134.26 26.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.274 1.43 . . . . 0.0 112.811 -175.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.77 153.32 45.71 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.149 0.979 . . . . 0.0 111.01 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 176.81 37.44 Favored Glycine 0 N--CA 1.469 0.879 0 N-CA-C 116.186 1.235 . . . . 0.0 116.186 -170.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.519 HG23 HD22 ' B' ' 53' ' ' ASN . 0.5 OUTLIER -111.0 149.36 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.481 1.112 . . . . 0.0 109.181 174.155 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 30.7 mm -80.88 125.57 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 CA-C-N 119.788 1.176 . . . . 0.0 112.051 -175.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.96 164.98 12.46 Favored Glycine 0 N--CA 1.477 1.403 0 O-C-N 121.23 -0.919 . . . . 0.0 113.392 -176.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 4.7 mp -128.33 131.76 68.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.603 0.716 . . . . 0.0 112.018 -176.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.24 -3.77 18.16 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.084 0.953 . . . . 0.0 112.689 168.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 . . . . . 0 N--CA 1.465 0.319 0 C-N-CA 127.987 2.515 . . . . 0.0 111.179 -173.656 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.045 0 CA-C-O 116.674 -1.631 . . . . 0.0 108.931 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p -76.71 54.64 0.99 Allowed 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.888 1.675 . . . . 0.0 114.922 -168.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.412 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.658 HD22 ' CG2' ' A' ' 148' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.426 ' HZ3' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.426 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.422 ' CG ' ' H ' ' A' ' 92' ' ' ASP . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.422 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.485 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.485 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.481 ' H ' ' CD ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.658 ' CG2' HD22 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . 0.4 ' HE3' ' O ' ' B' ' 152' ' ' ALA 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' B' ' 41' ' ' GLY . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . 0.442 ' H ' ' CD ' ' B' ' 40' ' ' GLU . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.482 HD21 ' H ' ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.8 t -78.67 -16.8 56.87 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.25 11.83 7.63 Favored 'General case' 0 CA--C 1.55 0.959 0 O-C-N 121.157 -0.965 . . . . 0.0 111.508 167.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.12 -142.03 40.58 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.082 1.325 . . . . 0.0 111.684 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 4.6 t -60.32 -11.29 6.15 Favored 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 39.5 m -91.9 -21.24 20.71 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 126.619 1.968 . . . . 0.0 113.101 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.28 -47.03 15.18 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 119.356 0.98 . . . . 0.0 111.005 169.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.84 169.94 11.14 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.716 2.006 . . . . 0.0 109.361 173.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.469 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . 0.408 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.474 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.474 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . 0.408 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' SER . . . . . 0.453 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.4 ' O ' ' HE3' ' B' ' 3' ' ' LYS . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.045 0 CA-C-O 116.674 -1.631 . . . . 0.0 108.931 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p -76.71 54.64 0.99 Allowed 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.888 1.675 . . . . 0.0 114.922 -168.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.412 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.658 HD22 ' CG2' ' A' ' 148' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.426 ' HZ3' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.426 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.422 ' CG ' ' H ' ' A' ' 92' ' ' ASP . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.422 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.485 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.485 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.481 ' H ' ' CD ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.658 ' CG2' HD22 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . 0.4 ' HE3' ' O ' ' B' ' 152' ' ' ALA 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' B' ' 41' ' ' GLY . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . 0.442 ' H ' ' CD ' ' B' ' 40' ' ' GLU . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.482 HD21 ' H ' ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.8 t -78.67 -16.8 56.87 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.25 11.83 7.63 Favored 'General case' 0 CA--C 1.55 0.959 0 O-C-N 121.157 -0.965 . . . . 0.0 111.508 167.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.12 -142.03 40.58 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.082 1.325 . . . . 0.0 111.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 4.6 t -60.32 -11.29 6.15 Favored 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 39.5 m -91.9 -21.24 20.71 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 126.619 1.968 . . . . 0.0 113.101 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.28 -47.03 15.18 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 119.356 0.98 . . . . 0.0 111.005 169.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.84 169.94 11.14 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.716 2.006 . . . . 0.0 109.361 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.469 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . 0.408 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.474 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.474 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . 0.408 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' SER . . . . . 0.453 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.4 ' O ' ' HE3' ' B' ' 3' ' ' LYS . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -156.86 121.92 4.59 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 124.353 1.061 . . . . 0.0 109.606 176.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.4 ' HZ1' ' CG ' ' B' ' 52' ' ' ASP . 0.0 OUTLIER -84.83 104.54 14.88 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 122.046 0.927 . . . . 0.0 108.699 168.086 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -89.48 169.23 11.55 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.263 -0.898 . . . . 0.0 111.296 173.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.1 p -151.97 142.78 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.676 1.19 . . . . 0.0 110.741 -170.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.13 120.5 12.36 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.509 1.123 . . . . 0.0 109.526 168.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.5 t -105.31 97.16 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 174.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -78.12 111.47 14.07 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 123.83 0.852 . . . . 0.0 109.544 -172.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -152.04 155.15 37.39 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 116.604 2.075 . . . . 0.0 116.604 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.43 -39.76 0.24 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 129.891 3.615 . . . . 0.0 108.814 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.44 57.64 4.12 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 129.699 3.2 . . . . 0.0 112.933 -168.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.95 -103.72 0.05 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.358 2.409 . . . . 0.0 114.054 173.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -83.87 -8.05 10.22 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 124.893 3.729 . . . . 0.0 114.555 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.03 141.87 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 120.377 1.444 . . . . 0.0 109.92 173.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -157.81 161.76 38.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.227 -1.351 . . . . 0.0 110.513 167.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.01 119.25 2.92 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 113.658 -1.61 . . . . 0.0 109.576 169.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.07 133.23 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 166.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -136.14 143.19 36.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 122.703 1.24 . . . . 0.0 110.687 162.158 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.95 130.0 55.47 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 164.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 m-30 -114.2 132.43 56.11 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.205 1.002 . . . . 0.0 110.629 -179.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -108.56 117.11 33.32 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.02 1.328 . . . . 0.0 110.97 178.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -118.58 140.0 50.59 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 123.028 1.394 . . . . 0.0 113.27 173.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.551 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -87.01 -47.98 8.48 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 129.46 3.104 . . . . 0.0 113.739 -175.717 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -147.63 137.71 22.94 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 126.895 2.078 . . . . 0.0 110.44 -168.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 m -38.65 -57.65 1.16 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.939 1.696 . . . . 0.0 115.308 -169.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 -102.31 15.47 29.06 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 123.995 0.918 . . . . 0.0 111.765 -173.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.83 -170.85 30.06 Favored Glycine 0 CA--C 1.534 1.263 0 C-N-CA 124.776 1.179 . . . . 0.0 112.485 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -78.34 177.91 8.2 Favored 'Trans proline' 0 CA--C 1.536 0.588 0 C-N-CA 124.149 3.232 . . . . 0.0 112.818 -170.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.4 t -142.0 141.01 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 123.913 0.885 . . . . 0.0 111.173 -177.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -93.22 125.21 37.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.035 0.934 . . . . 0.0 109.56 169.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -117.5 125.25 73.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 127.674 2.389 . . . . 0.0 108.565 -169.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 7.0 p90 -153.87 162.39 41.27 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.611 0.72 . . . . 0.0 112.661 175.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.18 -158.21 27.15 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 125.145 1.355 . . . . 0.0 112.063 177.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.9 p -153.54 139.79 18.49 Favored 'General case' 0 C--O 1.237 0.403 0 O-C-N 122.396 -0.473 . . . . 0.0 112.07 -172.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -111.98 106.88 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.885 0.874 . . . . 0.0 108.668 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.02 128.13 54.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.758 2.423 . . . . 0.0 109.557 -165.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.4 -4.38 31.27 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.502 1.525 . . . . 0.0 112.109 -167.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.5 mt -65.53 162.45 18.05 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.593 1.197 . . . . 0.0 110.531 168.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -93.45 161.83 14.22 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 163.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -54.95 150.43 10.18 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.242 1.417 . . . . 0.0 113.352 -174.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.23 -177.57 36.59 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 124.758 1.17 . . . . 0.0 113.46 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.98 149.6 18.56 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 127.56 2.344 . . . . 0.0 112.588 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -145.65 134.0 21.83 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 126.125 1.77 . . . . 0.0 110.166 170.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.44 147.72 31.36 Favored Glycine 0 N--CA 1.481 1.664 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.142 173.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -156.85 106.27 2.24 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 119.03 1.415 . . . . 0.0 113.276 -172.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.04 153.12 30.47 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.801 1.408 . . . . 0.0 114.801 -168.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.538 HG22 ' H ' ' A' ' 116' ' ' THR . 0.4 OUTLIER -82.2 138.37 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 165.875 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -87.18 157.99 19.24 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.386 1.875 . . . . 0.0 113.907 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 21.8 tt0 -71.57 90.07 1.0 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 125.182 1.393 . . . . 0.0 109.231 178.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 94.6 142.35 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 128.64 2.776 . . . . 0.0 108.809 178.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.09 13.24 9.69 Favored Glycine 0 C--O 1.221 -0.715 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.627 169.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.446 ' HB2' ' H ' ' B' ' 5' ' ' VAL . 8.8 p-10 -88.44 47.67 1.53 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 124.578 2.132 . . . . 0.0 109.131 168.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -171.91 42.39 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 123.696 1.712 . . . . 0.0 110.104 -167.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.8 p -69.32 43.78 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 128.312 2.645 . . . . 0.0 117.455 -168.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -107.69 5.5 26.83 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.726 1.21 . . . . 0.0 109.345 164.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 51.56 -110.56 1.09 Allowed Glycine 0 C--N 1.347 1.178 0 C-N-CA 126.527 2.013 . . . . 0.0 112.938 168.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 69.5 m -53.32 -9.36 0.16 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 116.516 2.043 . . . . 0.0 116.516 178.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.4 t -124.99 19.02 8.45 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.455 1.65 . . . . 0.0 115.455 171.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.9 m -156.74 -40.51 0.07 Allowed 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 171.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.42 123.57 26.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.705 1.593 . . . . 0.0 112.191 -170.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -66.75 168.78 35.47 Favored Glycine 0 CA--C 1.538 1.48 0 CA-C-O 118.224 -1.32 . . . . 0.0 113.33 -175.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -56.48 176.21 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 125.007 3.805 . . . . 0.0 112.456 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.436 ' CD2' ' H ' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -68.06 114.22 6.39 Favored 'General case' 0 C--N 1.321 -0.644 0 O-C-N 121.484 -0.76 . . . . 0.0 112.615 -166.823 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -28.25 113.07 0.07 Allowed 'General case' 0 C--O 1.24 0.557 0 C-N-CA 127.489 2.316 . . . . 0.0 114.209 -172.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -111.61 50.59 0.33 Allowed Pre-proline 0 CA--C 1.551 0.997 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -174.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.11 -16.83 45.31 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 122.352 2.035 . . . . 0.0 112.51 177.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -79.42 -7.51 58.45 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.722 1.609 . . . . 0.0 112.456 168.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.9 t 64.26 49.74 2.51 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 128.437 2.695 . . . . 0.0 112.409 176.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.8 ptt180 -128.92 178.5 6.34 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.498 ' HA ' ' HE2' ' A' ' 70' ' ' LYS . 4.8 mmpt? -88.17 174.26 8.33 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.164 2.185 . . . . 0.0 112.375 -179.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -95.12 134.9 37.32 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 161.2 -123.17 1.18 Allowed Glycine 0 C--N 1.336 0.576 0 CA-C-O 119.72 -0.489 . . . . 0.0 113.682 168.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.66 -33.94 4.58 Favored Glycine 0 CA--C 1.545 1.952 0 CA-C-O 117.216 -1.88 . . . . 0.0 117.791 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -105.45 17.14 0.15 Allowed 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.619 2.879 . . . . 0.0 114.215 174.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.9 ptmm? -167.73 -22.02 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 127.389 2.276 . . . . 0.0 112.458 169.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -97.41 147.05 24.6 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 163.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -98.86 -6.58 28.78 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.445 1.898 . . . . 0.0 111.859 -171.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -77.4 -99.65 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.343 1.057 . . . . 0.0 110.035 -177.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 94.2 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 127.323 2.249 . . . . 0.0 111.179 174.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -58.31 156.96 9.18 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.569 1.147 . . . . 0.0 112.639 172.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.0 p -70.59 106.12 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.86 171.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.03 8.69 21.66 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 117.383 -1.787 . . . . 0.0 116.831 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.16 124.5 27.91 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 120.71 2.255 . . . . 0.0 109.545 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 97.5 mt -113.89 53.63 0.77 Allowed 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 120.575 1.534 . . . . 0.0 112.196 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.01 -141.99 42.49 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 121.56 -0.713 . . . . 0.0 111.659 174.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.67 127.43 45.16 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.482 0.713 . . . . 0.0 111.431 169.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.8 m -78.21 98.22 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.891 1.276 . . . . 0.0 108.985 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -93.3 117.41 30.04 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.822 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.49 139.88 30.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.806 1.242 . . . . 0.0 113.841 -174.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -72.32 156.74 38.77 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.146 2.178 . . . . 0.0 109.99 167.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.418 ' HZ1' ' CG ' ' A' ' 92' ' ' ASP . 1.6 pptp? -46.33 -25.38 0.63 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 128.294 2.638 . . . . 0.0 116.137 175.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.418 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 77.3 m-20 -76.42 -0.48 22.98 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.632 1.173 . . . . 0.0 111.525 174.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.36 41.79 11.2 Favored Glycine 0 C--N 1.335 0.526 0 C-N-CA 126.535 2.017 . . . . 0.0 112.783 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.5 p -143.21 129.0 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 N-CA-C 114.737 1.384 . . . . 0.0 114.737 176.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.57 124.15 35.52 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 165.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -111.55 135.64 51.86 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 124.496 1.118 . . . . 0.0 108.91 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.5 t -139.15 136.71 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -166.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.2 t -155.43 116.36 3.9 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.553 1.541 . . . . 0.0 110.579 168.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -145.51 155.4 13.3 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 128.965 2.906 . . . . 0.0 110.806 -169.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -128.23 132.23 48.77 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 167.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -145.51 138.1 25.88 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 124.486 1.114 . . . . 0.0 111.954 -168.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -116.94 51.38 1.0 Allowed 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 178.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.19 3.48 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.197 0 C-N-CA 123.831 0.853 . . . . 0.0 111.983 167.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.2 168.0 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 126.671 1.988 . . . . 0.0 110.376 177.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.0 m -154.4 156.09 36.19 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.001 0.92 . . . . 0.0 111.086 -173.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.7 mt -93.5 73.01 4.42 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.689 0.757 . . . . 0.0 110.681 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.84 144.91 44.97 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.384 1.474 . . . . 0.0 108.987 171.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -78.48 16.23 8.17 Favored Glycine 0 N--CA 1.479 1.539 0 N-CA-C 117.97 1.948 . . . . 0.0 117.97 -166.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -134.88 -89.26 0.35 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 125.794 1.638 . . . . 0.0 111.2 -169.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -87.39 4.81 41.6 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 120.595 -1.316 . . . . 0.0 113.168 -174.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -119.41 -141.7 0.35 Allowed 'General case' 0 CA--C 1.545 0.756 0 O-C-N 120.875 -1.141 . . . . 0.0 112.955 -168.629 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 51.5 mm -94.63 -28.87 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 O-C-N 120.595 -1.315 . . . . 0.0 114.389 -169.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.1 mm -55.06 133.05 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 119.191 0.905 . . . . 0.0 109.849 175.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.14 14.62 59.52 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.433 -1.204 . . . . 0.0 114.575 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -91.19 -169.99 2.51 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.408 1.604 . . . . 0.0 108.911 168.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.538 ' H ' HG22 ' A' ' 47' ' ' VAL . 6.4 m -145.63 114.37 6.85 Favored 'General case' 0 N--CA 1.484 1.227 0 O-C-N 119.599 -1.938 . . . . 0.0 108.02 -171.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 50.5 tp -89.74 132.73 35.05 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 124.943 1.297 . . . . 0.0 109.638 -175.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.4 m -118.84 153.79 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 C-N-CA 123.275 0.63 . . . . 0.0 110.628 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.76 152.13 15.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 163.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -115.21 147.36 40.44 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.094 1.357 . . . . 0.0 111.183 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -66.09 -22.52 66.41 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 119.838 -1.789 . . . . 0.0 113.601 -174.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.7 mmtm -131.62 176.98 7.86 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 119.772 -1.83 . . . . 0.0 113.998 173.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.22 145.04 27.69 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 112.977 -1.919 . . . . 0.0 110.9 169.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -79.03 169.2 18.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 122.188 0.994 . . . . 0.0 111.154 167.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.79 -38.49 53.91 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.203 164.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.8 mm? 63.35 60.32 1.16 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.957 2.503 . . . . 0.0 112.031 -171.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.59 -83.4 0.13 Allowed Glycine 0 N--CA 1.469 0.879 0 O-C-N 121.008 -1.058 . . . . 0.0 112.747 168.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -150.53 97.73 2.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.631 1.681 . . . . 0.0 110.921 169.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.459 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -74.09 176.07 47.3 Favored Glycine 0 CA--C 1.526 0.781 0 CA-C-N 112.086 -2.325 . . . . 0.0 107.651 163.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.09 29.79 0.15 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 127.599 2.523 . . . . 0.0 118.677 -167.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -148.03 -103.97 0.09 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 120.652 2.226 . . . . 0.0 111.528 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -163.22 -51.9 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 127.312 2.245 . . . . 0.0 108.58 -169.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 19.2 tp10 -50.17 -32.16 15.51 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 127.416 2.286 . . . . 0.0 112.351 169.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 77.6 p -53.24 -36.84 61.5 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 120.565 -1.334 . . . . 0.0 113.173 168.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 2.8 p -79.08 -20.99 47.39 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 172.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -79.79 -64.56 1.16 Allowed 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.5 1.046 . . . . 0.0 112.572 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 28.7 p -108.62 -9.52 15.29 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.842 1.657 . . . . 0.0 114.559 -174.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.2 -9.57 74.61 Favored Glycine 0 N--CA 1.471 1.031 0 CA-C-N 119.918 1.235 . . . . 0.0 111.781 -167.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 79.26 -44.1 0.32 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 129.245 3.018 . . . . 0.0 110.136 -179.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 56.62 11.77 0.96 Allowed 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 128.433 2.693 . . . . 0.0 116.649 167.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.43 -36.25 0.45 Allowed Glycine 0 CA--C 1.537 1.445 0 C-N-CA 125.951 1.739 . . . . 0.0 113.673 -167.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -173.88 -156.59 0.08 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.149 1.779 . . . . 0.0 111.551 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.05 -166.22 1.15 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.798 2.039 . . . . 0.0 108.197 165.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -176.96 -151.79 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.661 2.384 . . . . 0.0 107.378 -175.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.72 148.99 23.05 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 125.709 1.604 . . . . 0.0 112.568 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.8 p -148.45 148.71 30.59 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.092 0.957 . . . . 0.0 113.459 -176.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.2 136.61 5.1 Favored Glycine 0 N--CA 1.465 0.604 0 C-N-CA 124.299 0.952 . . . . 0.0 113.543 -170.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -76.24 148.58 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 124.676 1.19 . . . . 0.0 109.333 -178.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -83.63 103.68 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 171.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -101.46 175.41 25.68 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.861 1.696 . . . . 0.0 112.064 169.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -114.51 140.84 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.307 1.043 . . . . 0.0 112.495 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.05 51.29 0.79 Allowed 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 124.027 1.87 . . . . 0.0 112.765 -176.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 38.9 tt0 . . . . . 0 C--N 1.326 -0.445 0 CA-C-N 111.487 -2.597 . . . . 0.0 110.006 167.672 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 p -78.76 107.07 11.21 Favored 'General case' 0 CA--C 1.512 -0.515 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 169.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.68 156.06 17.28 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 169.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.59 178.29 8.57 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 130.138 3.375 . . . . 0.0 107.19 167.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . 0.446 ' H ' ' HB2' ' A' ' 52' ' ' ASP . 59.3 t -156.54 170.85 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.191 0 C-N-CA 127.03 2.132 . . . . 0.0 109.894 -169.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.36 142.69 19.44 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 127.28 2.232 . . . . 0.0 109.299 166.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.13 126.53 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.582 0.753 . . . . 0.0 110.085 173.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mp -97.26 140.25 32.02 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 125.287 1.435 . . . . 0.0 110.264 -172.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.8 ttpp -143.53 140.57 30.33 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.386 1.074 . . . . 0.0 111.535 170.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.39 -114.15 1.87 Allowed Glycine 0 CA--C 1.524 0.612 1 N-CA-C 102.471 -4.252 . . . . 0.0 102.471 163.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -157.7 127.15 5.93 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.406 1.882 . . . . 0.0 107.964 164.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.3 -141.96 17.31 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -167.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -84.72 -26.04 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.312 2.675 . . . . 0.0 113.938 -169.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -78.1 123.82 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.44 1.018 . . . . 0.0 110.873 -169.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.2 160.98 41.28 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.602 -175.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -139.85 160.15 26.11 Favored Glycine 0 C--O 1.224 -0.522 0 O-C-N 121.686 -0.634 . . . . 0.0 113.22 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -128.42 134.93 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 125.613 1.565 . . . . 0.0 107.852 168.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -137.82 112.93 9.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 C-N-CA 124.255 1.022 . . . . 0.0 109.792 172.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -76.59 153.25 35.49 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.391 1.076 . . . . 0.0 110.475 165.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.77 100.01 5.14 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 127.901 2.48 . . . . 0.0 108.762 172.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.83 126.87 50.13 Favored 'General case' 0 N--CA 1.466 0.356 0 O-C-N 121.534 -0.729 . . . . 0.0 109.663 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . 0.43 HE22 ' CB ' ' B' ' 105' ' ' SER . 55.2 tt0 -126.87 141.22 51.87 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.133 0.973 . . . . 0.0 112.159 -176.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.469 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -78.71 -50.43 11.41 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.469 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 27.1 mp0 -146.29 150.54 35.96 Favored 'General case' 0 C--O 1.222 -0.374 0 C-N-CA 125.798 1.639 . . . . 0.0 109.778 173.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.9 m -58.62 10.8 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 128.72 2.808 . . . . 0.0 117.543 -171.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -144.7 -9.44 0.62 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 127.772 2.429 . . . . 0.0 113.886 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.44 -179.89 49.84 Favored Glycine 0 CA--C 1.541 1.657 0 CA-C-N 119.946 1.248 . . . . 0.0 110.6 168.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -75.67 160.8 37.58 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.611 2.208 . . . . 0.0 113.155 -171.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -120.56 129.67 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 124.802 1.241 . . . . 0.0 109.228 176.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -95.9 128.38 42.74 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.405 1.098 . . . . 0.0 110.176 170.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 t -90.92 129.05 42.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 128.936 2.894 . . . . 0.0 108.666 172.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.5 p90 -152.87 156.85 39.78 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 170.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.02 -154.67 24.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 124.778 1.18 . . . . 0.0 111.521 -169.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 85.2 p -162.59 150.85 14.33 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -172.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -113.61 123.92 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 125.277 1.431 . . . . 0.0 108.279 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -114.64 153.8 29.53 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 126.097 1.759 . . . . 0.0 111.359 -174.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.37 60.3 Favored Glycine 0 N--CA 1.475 1.294 0 C-N-CA 125.33 1.443 . . . . 0.0 114.507 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.01 166.43 17.76 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.494 1.518 . . . . 0.0 112.25 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -75.08 146.85 41.11 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 163.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . 0.477 ' CD ' ' HZ2' ' B' ' 91' ' ' LYS . 73.6 tt0 -49.27 143.21 6.45 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 124.904 1.282 . . . . 0.0 110.958 169.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.66 -175.44 23.42 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 124.222 0.915 . . . . 0.0 114.015 -177.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.477 HD23 ' H ' ' B' ' 42' ' ' LEU . 0.5 OUTLIER -87.39 145.87 26.12 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 127.56 2.344 . . . . 0.0 112.358 -169.85 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -139.19 138.96 37.37 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 127.936 2.494 . . . . 0.0 111.61 -169.066 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.36 156.83 53.15 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 125.08 1.324 . . . . 0.0 112.415 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -157.25 99.51 1.79 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 118.17 0.985 . . . . 0.0 110.849 -168.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 3.0 p-80 -126.6 146.12 50.28 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-O 122.675 1.226 . . . . 0.0 113.133 -175.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -111.42 151.14 13.58 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.293 175.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -119.08 119.36 33.98 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.313 -170.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -74.27 57.58 0.68 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.808 0.731 . . . . 0.0 109.557 166.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -161.6 106.94 1.31 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 125.088 1.355 . . . . 0.0 109.987 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -94.77 -5.21 61.42 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 117.144 -1.92 . . . . 0.0 115.026 -176.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . 0.4 ' CG ' ' HZ1' ' A' ' 3' ' ' LYS . 0.2 OUTLIER -76.84 52.7 0.86 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 120.735 2.268 . . . . 0.0 111.847 -170.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 176.58 35.28 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 116.733 2.123 . . . . 0.0 116.733 -167.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 13.8 p -73.71 36.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 119.488 -2.007 . . . . 0.0 115.469 -172.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.4 -1.96 58.24 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.622 1.969 . . . . 0.0 113.916 -169.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.21 -149.58 34.26 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -169.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 31.7 p -64.01 -7.89 9.97 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 113.981 1.104 . . . . 0.0 113.981 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 30.9 p -77.57 6.51 7.05 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.856 1.262 . . . . 0.0 114.086 174.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.6 t -162.45 -155.12 0.34 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 126.433 1.893 . . . . 0.0 109.54 169.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 72.07 71.25 0.15 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.81 2.044 . . . . 0.0 113.383 169.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.62 -54.66 4.9 Favored Glycine 0 CA--C 1.544 1.888 0 CA-C-O 116.747 -2.141 . . . . 0.0 114.929 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -130.52 168.95 0.0 OUTLIER 'Trans proline' 0 C--N 1.355 0.918 0 C-N-CA 123.22 2.613 . . . . 0.0 116.346 -172.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.595 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -85.03 141.57 30.19 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.991 2.117 . . . . 0.0 112.874 166.031 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -70.17 144.97 51.81 Favored 'General case' 0 CA--C 1.545 0.76 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.911 164.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 43.2 m-20 -106.83 75.09 0.39 Allowed Pre-proline 0 CA--C 1.555 1.17 0 C-N-CA 125.554 1.541 . . . . 0.0 112.714 -177.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -56.79 -47.9 21.16 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 124.123 3.215 . . . . 0.0 113.141 -174.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.1 mp -78.93 2.02 21.67 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.034 1.734 . . . . 0.0 113.14 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 59.7 p 68.29 45.04 1.27 Allowed 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 128.736 2.814 . . . . 0.0 111.513 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.298 23.7 ptt180 -130.7 171.45 13.08 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -169.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.4 169.26 14.76 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 113.625 -1.625 . . . . 0.0 107.345 -172.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 46.9 t60 -63.51 164.11 9.93 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.989 168.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.62 -139.51 7.04 Favored Glycine 0 C--N 1.336 0.567 0 CA-C-O 119.532 -0.593 . . . . 0.0 112.303 169.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.87 -43.22 1.69 Allowed Glycine 0 CA--C 1.545 1.939 0 N-CA-C 119.186 2.434 . . . . 0.0 119.186 169.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -85.45 -12.34 6.67 Favored 'Trans proline' 0 C--N 1.356 0.959 0 CA-C-N 123.497 3.649 . . . . 0.0 113.519 173.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.29 1.92 0.97 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 126.829 2.051 . . . . 0.0 112.326 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.73 152.95 51.62 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 127.773 2.429 . . . . 0.0 108.632 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.94 -2.35 18.37 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.975 2.51 . . . . 0.0 113.072 -176.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -75.05 -102.74 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 169.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 73.72 141.48 0.06 Allowed 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 125.705 2.669 . . . . 0.0 111.927 172.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -78.77 148.11 33.08 Favored 'General case' 0 CA--C 1.551 1.018 0 CA-C-N 113.065 -1.879 . . . . 0.0 111.615 171.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 19.8 m -46.96 -41.5 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 CA-C-N 120.559 1.527 . . . . 0.0 111.366 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -99.29 104.84 2.94 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 164.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -157.01 129.95 7.74 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 125.634 1.574 . . . . 0.0 112.839 166.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -110.46 179.17 4.16 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 126.501 1.92 . . . . 0.0 110.392 170.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.82 -106.91 3.0 Favored Glycine 0 C--N 1.339 0.722 0 C-N-CA 124.774 1.178 . . . . 0.0 113.972 -171.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -127.11 158.64 36.48 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 123.919 0.888 . . . . 0.0 112.944 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.2 m -118.43 137.54 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 126.772 2.029 . . . . 0.0 109.216 168.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 90.5 m -125.12 115.69 20.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 121.195 1.816 . . . . 0.0 110.745 -173.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.06 137.33 36.76 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 124.751 1.22 . . . . 0.0 112.546 -176.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -73.62 178.49 4.69 Favored 'General case' 0 CA--C 1.541 0.629 0 O-C-N 124.148 0.905 . . . . 0.0 111.008 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.477 ' HZ2' ' CD ' ' B' ' 40' ' ' GLU . 3.3 ttmp? -76.96 66.46 2.8 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 123.45 1.595 . . . . 0.0 111.312 169.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -156.31 -45.29 0.07 Allowed 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 127.198 2.199 . . . . 0.0 108.807 175.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.85 -12.21 7.76 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 117.606 -1.664 . . . . 0.0 113.904 -172.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.6 p -81.21 121.76 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.555 1.677 . . . . 0.0 114.355 170.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.76 135.59 34.91 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.12 0.968 . . . . 0.0 108.478 164.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -77.0 148.0 36.5 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 123.0 1.381 . . . . 0.0 107.586 168.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.37 123.26 52.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 112.331 -2.213 . . . . 0.0 109.221 171.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.0 p -156.94 59.53 0.52 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.251 1.42 . . . . 0.0 112.546 -168.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.04 159.89 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 O-C-N 120.259 -1.526 . . . . 0.0 112.095 -173.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -145.3 155.06 42.98 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.044 2.138 . . . . 0.0 109.487 174.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -155.16 144.44 21.07 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.461 1.905 . . . . 0.0 110.328 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.0 p -113.92 49.32 1.0 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.7 t -151.3 14.57 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 123.617 0.767 . . . . 0.0 112.782 -170.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.25 166.64 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 O-C-N 119.66 -1.9 . . . . 0.0 110.723 -171.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' SER . . . . . 0.43 ' CB ' HE22 ' B' ' 22' ' ' GLN . 83.8 p -157.56 161.95 38.77 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 117.922 2.564 . . . . 0.0 117.922 171.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -78.78 72.91 5.32 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 126.831 2.052 . . . . 0.0 107.482 170.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 10.8 t -130.24 15.03 5.64 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -176.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 -63.74 0.33 Allowed Glycine 0 N--CA 1.474 1.219 0 N-CA-C 116.089 1.196 . . . . 0.0 116.089 169.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -119.44 -112.56 0.33 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 118.867 1.334 . . . . 0.0 109.53 -168.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -73.05 0.6 10.96 Favored 'General case' 0 CA--C 1.543 0.7 0 O-C-N 120.263 -1.523 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 54.0 p -71.08 -19.75 62.43 Favored 'General case' 0 CA--C 1.541 0.611 0 CA-C-O 116.587 -1.673 . . . . 0.0 114.305 169.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.305 3.9 pt 143.97 -11.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.114 1 C-N-CA 132.735 4.414 . . . . 0.0 116.227 168.831 . . . . . . . . 3 2 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.8 mm -76.08 148.15 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 120.266 1.394 . . . . 0.0 109.683 173.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 70.57 5.15 55.14 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 120.586 -1.321 . . . . 0.0 114.437 -175.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.9 ptt180 -79.31 156.1 28.19 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.135 1.374 . . . . 0.0 109.979 168.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.5 m -100.43 163.8 12.21 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.928 1.291 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 12.5 tp -148.85 126.5 11.74 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.032 1.733 . . . . 0.0 111.074 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 29.1 m -120.76 147.63 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.071 0.948 . . . . 0.0 110.906 167.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.4 p -104.58 154.68 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 124.434 1.094 . . . . 0.0 108.207 167.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 -120.35 159.76 24.4 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.252 1.421 . . . . 0.0 112.54 -173.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -84.8 -26.77 27.27 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 119.894 -1.754 . . . . 0.0 114.909 -168.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.31 179.84 3.92 Favored 'General case' 0 CA--C 1.545 0.785 0 O-C-N 119.606 -1.934 . . . . 0.0 108.702 166.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.39 151.4 47.21 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.105 0.962 . . . . 0.0 112.869 -176.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -75.65 143.37 42.25 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.215 0.531 . . . . 0.0 110.345 175.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -73.47 -20.05 60.79 Favored 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 123.714 0.806 . . . . 0.0 111.71 169.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 51.32 60.0 4.19 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.773 2.029 . . . . 0.0 112.191 -174.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.86 -26.26 25.11 Favored Glycine 0 N--CA 1.469 0.855 0 CA-C-O 117.797 -1.557 . . . . 0.0 116.539 168.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -159.51 100.87 1.5 Allowed 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 120.413 2.106 . . . . 0.0 112.424 176.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . 0.417 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -102.89 -132.46 7.67 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 166.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.88 12.07 49.5 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.462 1.505 . . . . 0.0 114.57 173.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -130.9 162.91 28.61 Favored 'General case' 0 C--N 1.344 0.345 0 CA-C-N 119.236 1.518 . . . . 0.0 114.387 -168.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -57.06 -59.64 4.77 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.301 1.441 . . . . 0.0 110.02 167.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -59.77 -14.59 15.25 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.689 1.596 . . . . 0.0 113.358 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 134' ' ' SER . . . . . 0.417 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 24.3 p -66.39 -28.0 68.29 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.883 1.219 . . . . 0.0 112.892 172.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 p -95.22 -31.31 13.55 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 127.135 2.174 . . . . 0.0 112.261 178.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 45.7 mttp -92.86 -23.66 18.73 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.652 1.581 . . . . 0.0 113.598 -173.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.7 p -138.69 -124.11 0.13 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 127.408 2.283 . . . . 0.0 105.034 164.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -126.86 8.37 7.24 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 125.466 1.507 . . . . 0.0 111.267 168.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 62.18 -79.74 0.02 OUTLIER 'General case' 0 C--N 1.347 0.492 0 C-N-CA 127.335 2.254 . . . . 0.0 110.066 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 60.64 29.92 19.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 126.397 1.879 . . . . 0.0 114.616 167.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.62 -42.4 1.27 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 125.768 1.652 . . . . 0.0 113.684 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.5 t -178.09 163.15 1.68 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.018 2.127 . . . . 0.0 111.315 175.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 80.4 mtt85 -73.26 177.04 5.39 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 125.159 1.384 . . . . 0.0 110.322 168.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.57 -128.57 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 124.306 1.042 . . . . 0.0 111.245 -172.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.82 153.88 39.74 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.947 1.299 . . . . 0.0 112.447 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -137.41 152.01 49.16 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.109 1.364 . . . . 0.0 111.887 -169.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.92 171.24 33.8 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.201 1.381 . . . . 0.0 112.15 169.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 79.7 t -119.35 147.42 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 169.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.8 mm -86.5 88.6 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 O-C-N 121.626 -0.671 . . . . 0.0 110.526 -179.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.16 -168.3 42.66 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 123.431 0.538 . . . . 0.0 113.405 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.44 161.2 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -170.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.4 -56.43 0.4 Allowed 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.134 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 N--CA 1.464 0.241 0 C-N-CA 126.04 1.736 . . . . 0.0 110.129 -169.766 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.681 0 CA-C-O 118.448 -0.786 . . . . 0.0 112.888 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.0 m -75.06 121.43 22.01 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 -174.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.412 ' HE3' ' CG2' ' A' ' 5' ' ' VAL . 17.4 pttt -132.1 133.47 44.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 115.888 1.81 . . . . 0.0 115.888 -176.135 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.95 167.57 14.15 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 163.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.412 ' CG2' ' HE3' ' A' ' 3' ' ' LYS . 15.2 t -147.43 118.21 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 119.207 0.912 . . . . 0.0 112.158 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.26 84.53 5.19 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 168.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.2 t -76.4 79.42 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 105.025 -2.213 . . . . 0.0 105.025 176.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.2 mt -67.09 127.68 33.5 Favored 'General case' 0 C--O 1.224 -0.239 0 CA-C-O 122.205 1.002 . . . . 0.0 111.177 -162.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.1 tttm -159.67 -174.6 4.7 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.342 1.457 . . . . 0.0 111.672 174.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.24 -6.44 21.34 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 124.778 1.18 . . . . 0.0 113.008 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -116.96 145.62 43.52 Favored 'General case' 0 N--CA 1.433 -1.276 1 C-N-CA 133.291 4.636 . . . . 0.0 103.4 168.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.66 -70.87 0.99 Allowed Glycine 0 CA--C 1.535 1.298 0 C-N-CA 126.011 1.767 . . . . 0.0 112.966 -177.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -69.16 -32.31 21.32 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 123.715 2.943 . . . . 0.0 114.537 -170.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -95.71 144.39 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 119.707 1.14 . . . . 0.0 111.304 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -139.83 173.66 11.3 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.523 1.129 . . . . 0.0 109.174 168.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.52 178.5 33.83 Favored Glycine 0 N--CA 1.468 0.784 0 C-N-CA 124.465 1.031 . . . . 0.0 114.954 169.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.3 pt -153.45 56.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 C-N-CA 124.943 1.297 . . . . 0.0 111.992 -170.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 mm -87.03 98.64 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 O-C-N 120.566 -1.334 . . . . 0.0 110.66 -173.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.02 147.31 34.88 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.782 1.233 . . . . 0.0 110.253 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -128.25 79.08 1.88 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.045 1.338 . . . . 0.0 109.544 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -81.7 112.31 18.76 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.086 1.354 . . . . 0.0 112.188 -175.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -101.02 131.83 46.72 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.449 1.5 . . . . 0.0 109.199 171.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.413 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -96.53 -22.95 16.78 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 124.438 1.095 . . . . 0.0 113.453 174.805 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -103.26 -138.35 0.35 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.668 3.187 . . . . 0.0 110.405 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.2 p -151.29 34.0 0.57 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 127.533 2.333 . . . . 0.0 109.33 169.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -178.88 -28.77 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.369 1.467 . . . . 0.0 114.44 -167.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.63 -169.21 40.29 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 125.165 1.364 . . . . 0.0 113.248 177.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -68.0 138.63 44.59 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.313 2.675 . . . . 0.0 112.834 -171.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.4 t -96.43 132.87 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 124.37 1.068 . . . . 0.0 110.062 173.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -81.23 118.61 22.74 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 169.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.12 79.11 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 127.687 2.395 . . . . 0.0 108.702 -174.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -103.28 164.99 11.29 Favored 'General case' 0 CA--C 1.541 0.607 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.418 172.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.36 -164.32 28.37 Favored Glycine 0 C--O 1.224 -0.491 0 C-N-CA 125.383 1.468 . . . . 0.0 111.506 174.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.6 p -155.38 168.47 26.97 Favored 'General case' 0 C--N 1.319 -0.722 0 O-C-N 121.686 -0.89 . . . . 0.0 110.597 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 mp -128.24 126.55 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 C-N-CA 126.283 1.833 . . . . 0.0 107.27 174.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.68 143.76 45.6 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 122.888 2.585 . . . . 0.0 113.032 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.42 -1.94 16.1 Favored Glycine 0 CA--C 1.54 1.636 0 C-N-CA 128.146 2.784 . . . . 0.0 113.561 -169.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.9 mt -79.01 161.95 26.26 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.059 1.344 . . . . 0.0 113.203 -177.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.1 t -85.53 155.64 21.11 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 164.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.4 pt-20 -57.6 172.59 0.35 Allowed 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 115.782 1.771 . . . . 0.0 115.782 -174.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.32 -178.6 53.84 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.621 1.105 . . . . 0.0 113.228 174.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -62.36 142.52 57.77 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.09 1.756 . . . . 0.0 112.606 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -142.72 124.08 14.72 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 127.84 2.456 . . . . 0.0 108.507 177.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.97 149.28 51.71 Favored Glycine 0 N--CA 1.477 1.396 0 CA-C-N 120.585 1.539 . . . . 0.0 110.919 178.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -147.7 117.88 7.31 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.907 1.854 . . . . 0.0 111.566 172.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.4 OUTLIER -157.48 173.61 16.64 Favored 'General case' 0 C--O 1.236 0.367 0 O-C-N 121.104 -0.997 . . . . 0.0 109.741 -168.324 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.59 135.96 50.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 C-N-CA 124.214 1.006 . . . . 0.0 110.479 -166.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -77.18 176.18 8.97 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 122.849 0.46 . . . . 0.0 110.622 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -71.56 137.67 48.22 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.411 -0.806 . . . . 0.0 108.896 165.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 56.07 -169.05 0.09 Allowed 'General case' 0 CA--C 1.542 0.661 0 CA-C-O 123.665 1.698 . . . . 0.0 114.166 173.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.92 17.66 48.37 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-O 116.357 -2.357 . . . . 0.0 111.476 167.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.407 ' HA ' ' CG2' ' B' ' 5' ' ' VAL . 2.3 p30 -82.36 45.54 0.96 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.754 2.777 . . . . 0.0 112.454 -172.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -91.69 34.39 0.98 Allowed 'General case' 0 C--O 1.235 0.301 0 N-CA-C 115.546 1.684 . . . . 0.0 115.546 -166.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 28.6 p -114.45 -18.86 11.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -160.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.69 21.2 4.89 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-N 119.214 0.915 . . . . 0.0 110.902 165.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.4 -112.7 3.63 Favored Glycine 0 C--N 1.342 0.878 0 C-N-CA 125.646 1.594 . . . . 0.0 111.476 173.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.5 t -80.87 -16.7 52.93 Favored 'General case' 0 CA--C 1.545 0.766 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 168.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.1 40.02 0.53 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.633 1.573 . . . . 0.0 108.8 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -172.16 167.07 6.01 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 127.46 2.304 . . . . 0.0 110.003 -162.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -1.31 106.71 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 129.522 3.129 . . . . 0.0 116.947 168.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.76 -84.39 0.74 Allowed Glycine 0 CA--C 1.54 1.609 0 C-N-CA 126.861 2.172 . . . . 0.0 113.165 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.9 173.74 13.94 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 124.39 3.393 . . . . 0.0 112.708 -171.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -92.96 115.39 28.08 Favored 'General case' 0 CA--C 1.536 0.404 0 O-C-N 121.156 -0.965 . . . . 0.0 113.533 -168.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -43.89 130.4 5.75 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.135 1.374 . . . . 0.0 113.638 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 35.6 p-10 -145.27 68.49 13.67 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -168.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -61.11 -19.66 64.35 Favored 'Trans proline' 0 CA--C 1.54 0.784 0 C-N-CA 122.501 2.134 . . . . 0.0 112.058 169.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -76.88 -6.29 51.84 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.147 1.379 . . . . 0.0 113.608 171.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t 57.71 47.48 15.58 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 127.224 2.21 . . . . 0.0 112.233 174.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -111.24 173.01 6.54 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 114.657 1.354 . . . . 0.0 114.657 -175.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -89.04 176.14 7.11 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.187 2.195 . . . . 0.0 108.989 175.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.9 t60 -91.56 157.25 17.11 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.418 1.087 . . . . 0.0 113.674 -172.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.63 -129.73 4.62 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 124.021 0.82 . . . . 0.0 113.028 167.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 129.34 -30.05 3.73 Favored Glycine 0 CA--C 1.55 2.224 0 N-CA-C 119.763 2.665 . . . . 0.0 119.763 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -108.97 17.45 0.09 OUTLIER 'Trans proline' 0 CA--C 1.551 1.355 0 C-N-CA 124.933 3.756 . . . . 0.0 113.115 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.96 -26.17 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 128.286 2.634 . . . . 0.0 111.421 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.78 148.07 22.68 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.864 2.066 . . . . 0.0 106.157 162.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -100.67 -8.98 22.32 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 126.901 2.08 . . . . 0.0 113.08 -178.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.64 -82.03 0.09 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.076 0.95 . . . . 0.0 110.553 -176.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.292 37.6 ptt180 66.67 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 127.063 2.145 . . . . 0.0 113.393 175.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -59.49 165.19 2.98 Favored 'General case' 0 CA--C 1.551 0.986 0 O-C-N 119.596 -1.94 . . . . 0.0 113.337 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 74.3 t -57.27 -25.26 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.457 -1.402 . . . . 0.0 112.697 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.67 31.19 7.41 Favored Glycine 0 CA--C 1.539 1.558 0 CA-C-O 118.222 -1.321 . . . . 0.0 115.993 173.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -112.25 139.73 47.55 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 117.387 2.365 . . . . 0.0 117.387 -172.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 79.9 mt -144.9 166.01 26.5 Favored 'General case' 0 CA--C 1.555 1.15 1 C-N-CA 133.704 4.802 . . . . 0.0 104.031 165.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.71 -129.32 5.3 Favored Glycine 0 N--CA 1.473 1.147 0 C-N-CA 123.664 0.65 . . . . 0.0 113.606 -169.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -113.06 147.33 37.48 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 121.974 0.892 . . . . 0.0 113.085 169.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.66 174.19 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.682 1.993 . . . . 0.0 108.372 167.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -140.57 124.02 16.91 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 168.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.1 139.81 34.19 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 118.239 0.472 . . . . 0.0 111.913 169.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.65 157.27 37.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.712 1.605 . . . . 0.0 110.386 167.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.83 -0.59 0.69 Allowed 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 114.684 1.365 . . . . 0.0 114.684 170.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -99.64 5.59 45.81 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.816 2.046 . . . . 0.0 112.482 170.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.08 0.54 65.75 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 126.27 1.89 . . . . 0.0 116.49 168.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.12 136.2 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 CA-C-N 119.497 1.649 . . . . 0.0 112.9 -177.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.3 129.85 50.41 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 124.948 1.299 . . . . 0.0 107.745 166.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -92.31 148.97 21.72 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 122.577 1.179 . . . . 0.0 108.835 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.07 124.58 37.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.451 -1.704 . . . . 0.0 109.232 173.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.1 p -155.31 76.04 0.96 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.962 1.363 . . . . 0.0 111.491 -169.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.72 159.57 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.484 1.513 . . . . 0.0 110.221 -169.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -147.17 121.43 9.57 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 104.777 -2.305 . . . . 0.0 104.777 166.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -126.29 131.79 51.8 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.641 1.21 . . . . 0.0 113.061 -168.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.1 p -82.98 58.73 4.53 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.393 1.077 . . . . 0.0 110.162 177.19 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -152.25 -44.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 170.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.45 143.14 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 118.938 0.79 . . . . 0.0 110.876 -179.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.49 ' H ' ' CB ' ' A' ' 111' ' ' SER . 35.8 p -132.22 161.02 34.45 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 126.556 1.942 . . . . 0.0 112.075 173.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 31.0 mt -79.71 94.54 5.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 168.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -131.97 -15.46 2.99 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -169.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.05 -68.67 3.39 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 120.347 1.43 . . . . 0.0 111.622 -170.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -92.04 -60.77 1.77 Allowed 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.705 1.24 . . . . 0.0 113.824 -173.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 28.7 m-70 -80.64 1.56 29.39 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.84 1.656 . . . . 0.0 112.903 -164.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.49 ' CB ' ' H ' ' A' ' 105' ' ' SER . 18.9 m -162.42 -88.88 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.264 0 N-CA-C 115.71 1.744 . . . . 0.0 115.71 177.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.41 162.75 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.093 -1.004 . . . . 0.0 111.093 -173.012 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 114.54 140.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 1 C-N-CA 135.521 5.528 . . . . 0.0 107.374 -169.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.63 -25.62 1.71 Allowed Glycine 0 CA--C 1.535 1.317 0 CA-C-O 118.26 -1.3 . . . . 0.0 115.836 177.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 10.6 ptt180 -74.73 163.64 27.46 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 126.253 1.821 . . . . 0.0 111.466 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.3 m -121.37 110.81 16.54 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 124.635 1.174 . . . . 0.0 113.042 -169.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.6 tp -99.66 122.87 43.31 Favored 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 121.124 1.784 . . . . 0.0 111.346 -173.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 13.2 p -121.13 151.59 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 125.471 1.509 . . . . 0.0 113.315 179.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.4 p -103.9 143.28 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.035 0 C-N-CA 124.547 1.139 . . . . 0.0 110.344 166.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 40.6 m-70 -115.34 169.2 9.32 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 126.94 2.096 . . . . 0.0 115.123 -168.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -83.58 -30.17 27.21 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 116.075 1.88 . . . . 0.0 116.075 -173.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -107.0 170.18 8.1 Favored 'General case' 0 CA--C 1.546 0.805 0 CA-C-N 120.668 1.576 . . . . 0.0 111.881 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.57 163.89 6.51 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.022 1.329 . . . . 0.0 111.443 169.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -103.9 131.49 51.07 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.023 0.929 . . . . 0.0 110.422 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.88 -28.5 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 120.747 0.308 . . . . 0.0 111.656 177.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.0 mt 58.09 40.46 25.21 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.387 1.875 . . . . 0.0 112.446 173.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.27 -74.39 0.07 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 117.495 1.758 . . . . 0.0 117.495 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -139.06 -42.03 0.47 Allowed 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -164.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 54.64 -113.43 3.48 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 120.178 1.354 . . . . 0.0 110.47 -166.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -153.56 29.55 0.76 Allowed Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.222 1.867 . . . . 0.0 112.008 168.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.425 HD21 ' CD ' ' A' ' 133' ' ' GLU . 10.0 p-10 -166.48 171.3 12.0 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.773 1.629 . . . . 0.0 111.669 -164.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.406 ' CD ' ' HZ1' ' A' ' 136' ' ' LYS . 19.8 tt0 -67.62 -54.65 17.95 Favored 'General case' 0 N--CA 1.469 0.478 0 O-C-N 121.32 -0.862 . . . . 0.0 113.185 -169.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.425 ' CD ' HD21 ' A' ' 131' ' ' ASN . 0.3 OUTLIER -65.09 -19.51 66.02 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.043 0.937 . . . . 0.0 111.25 -171.864 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.4 m -67.67 -33.35 74.76 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.897 -1.127 . . . . 0.0 111.729 168.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.4 p -83.29 -18.94 37.29 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 124.783 1.233 . . . . 0.0 114.241 174.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.406 ' HZ1' ' CD ' ' A' ' 132' ' ' GLU . 94.5 mttt -105.99 -45.56 4.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.303 1.041 . . . . 0.0 113.57 -176.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.71 -26.33 12.33 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 116.829 -1.558 . . . . 0.0 113.87 177.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.63 12.44 47.56 Favored Glycine 0 N--CA 1.472 1.062 0 CA-C-N 119.327 0.967 . . . . 0.0 114.8 -173.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 60.38 8.95 1.78 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 118.975 1.387 . . . . 0.0 113.508 -174.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.84 -3.41 0.74 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -166.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.21 -160.04 25.67 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 126.694 2.092 . . . . 0.0 112.797 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 91.7 p -65.82 177.54 1.27 Allowed 'General case' 0 CA--C 1.547 0.828 0 O-C-N 122.026 -0.691 . . . . 0.0 112.139 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.5 ptt180 -136.2 132.37 35.8 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.923 -1.111 . . . . 0.0 112.749 -166.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.504 ' CD2' ' H ' ' A' ' 145' ' ' ALA 0.335 0.0 OUTLIER -103.35 -106.76 0.27 Allowed 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.154 1.381 . . . . 0.0 111.723 -175.677 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.504 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -77.23 135.18 38.45 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 119.635 1.107 . . . . 0.0 111.216 -173.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.9 p -141.88 154.86 45.43 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 126.107 1.763 . . . . 0.0 111.69 -172.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.7 130.01 3.5 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 123.818 0.723 . . . . 0.0 111.915 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -72.47 170.53 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 167.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.2 mm -129.56 126.39 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 O-C-N 120.738 -1.226 . . . . 0.0 113.331 -167.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -146.05 -126.24 1.77 Allowed Glycine 0 CA--C 1.539 1.591 0 C-N-CA 127.442 2.449 . . . . 0.0 114.617 -177.514 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 pp -147.46 68.67 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 120.642 -1.505 . . . . 0.0 113.932 -168.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.43 -20.43 54.54 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 120.567 -1.333 . . . . 0.0 114.462 -171.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 . . . . . 0 N--CA 1.472 0.633 0 C-N-CA 124.497 1.119 . . . . 0.0 112.699 175.187 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.442 0 CA-C-O 121.12 0.486 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.4 m -83.24 99.87 10.24 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -96.36 165.18 12.32 Favored 'General case' 0 CA--C 1.548 0.899 0 CA-C-O 122.864 1.316 . . . . 0.0 113.251 -176.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.34 172.73 13.43 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -168.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . 0.407 ' CG2' ' HA ' ' A' ' 52' ' ' ASP . 1.1 p -157.43 103.44 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 C-N-CA 127.25 2.22 . . . . 0.0 107.786 -169.051 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.27 130.42 35.02 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 120.472 -1.392 . . . . 0.0 111.699 171.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 20.6 t -93.48 71.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.179 0.992 . . . . 0.0 111.136 -173.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -80.48 114.72 19.58 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.469 0.652 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 13.2 ttpp -144.97 151.18 38.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.84 0.829 . . . . 0.0 112.428 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.45 149.96 18.76 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 166.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -79.1 64.88 4.13 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 123.408 1.575 . . . . 0.0 110.372 169.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.52 -175.45 46.24 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 129.101 3.239 . . . . 0.0 108.685 -171.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.18 22.21 0.38 Allowed 'Trans proline' 0 CA--C 1.547 1.153 0 C-N-CA 124.65 3.566 . . . . 0.0 114.916 -169.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 t -118.97 130.31 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 C-N-CA 126.993 2.117 . . . . 0.0 109.002 -170.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.71 160.88 31.97 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 124.099 0.96 . . . . 0.0 110.999 -170.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.01 169.05 33.58 Favored Glycine 0 CA--C 1.51 -0.262 0 C-N-CA 124.779 1.18 . . . . 0.0 112.23 168.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -132.35 133.18 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 171.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.0 mm -135.09 109.58 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 36.2 m120 -79.85 155.52 27.78 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 123.914 0.886 . . . . 0.0 111.959 175.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -139.27 152.65 47.44 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 167.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -146.88 132.57 18.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 119.133 0.879 . . . . 0.0 109.951 167.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -84.84 137.86 32.91 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 122.721 0.408 . . . . 0.0 111.117 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.439 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -93.48 -91.64 0.18 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.179 0.992 . . . . 0.0 110.618 169.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.439 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 31.9 mp0 -82.37 169.25 16.67 Favored 'General case' 0 C--O 1.217 -0.607 0 O-C-N 120.538 -1.351 . . . . 0.0 110.544 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -51.02 -45.25 61.17 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 114.298 1.222 . . . . 0.0 114.298 -172.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 22.0 m-80 -127.01 40.27 3.75 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.632 1.973 . . . . 0.0 110.294 166.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.66 162.76 53.61 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-O 118.717 -1.046 . . . . 0.0 111.461 173.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -66.4 161.72 39.66 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.503 2.802 . . . . 0.0 110.005 174.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.0 t -136.55 133.36 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 122.973 0.509 . . . . 0.0 110.967 -169.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -79.84 132.16 36.04 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 168.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.3 t -120.85 111.54 32.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 126.578 1.951 . . . . 0.0 108.739 176.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -140.11 153.27 46.66 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.366 0.603 . . . . 0.0 112.213 -173.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.49 -153.41 24.63 Favored Glycine 0 C--O 1.225 -0.433 0 C-N-CA 124.13 0.872 . . . . 0.0 111.507 178.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 12.6 p -157.1 158.66 36.79 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 114.045 1.128 . . . . 0.0 114.045 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -128.1 131.46 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 125.715 1.606 . . . . 0.0 107.912 -179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.1 ttpt -133.95 140.12 46.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 126.172 1.789 . . . . 0.0 110.617 -168.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.11 20.73 13.09 Favored Glycine 0 N--CA 1.481 1.638 0 C-N-CA 124.994 1.283 . . . . 0.0 114.373 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -117.91 165.9 13.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.756 2.822 . . . . 0.0 110.622 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.95 167.46 21.86 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.316 0.646 . . . . 0.0 110.205 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -64.65 -175.3 0.17 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 126.967 2.107 . . . . 0.0 114.549 171.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.33 -170.59 46.98 Favored Glycine 0 N--CA 1.47 0.944 0 O-C-N 120.388 -1.445 . . . . 0.0 112.432 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mt -77.01 155.16 32.79 Favored 'General case' 0 CA--C 1.545 0.757 0 O-C-N 121.172 -1.193 . . . . 0.0 110.02 177.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -147.63 123.57 10.68 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 127.931 2.493 . . . . 0.0 109.641 -172.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.34 151.16 36.2 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-N 120.926 1.694 . . . . 0.0 113.526 176.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -151.13 96.58 2.33 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.213 1.405 . . . . 0.0 112.171 -170.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.38 147.07 48.93 Favored 'General case' 0 N--CA 1.47 0.561 0 O-C-N 120.085 -1.634 . . . . 0.0 111.742 -167.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.66 120.19 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 122.484 1.135 . . . . 0.0 110.959 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -77.83 101.61 6.83 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -173.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -64.16 95.27 0.12 Allowed 'General case' 0 C--N 1.344 0.349 0 CA-C-O 123.116 1.436 . . . . 0.0 108.602 175.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 t80 177.55 -166.95 0.05 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 130.472 3.509 . . . . 0.0 104.349 -164.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.35 -122.02 3.5 Favored Glycine 0 CA--C 1.507 -0.43 0 CA-C-O 121.772 0.651 . . . . 0.0 112.477 171.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.07 152.83 39.85 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.684 1.594 . . . . 0.0 113.459 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 173.13 32.68 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 128.815 2.846 . . . . 0.0 108.843 -171.669 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 82.8 p -68.25 12.27 0.13 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.439 2.295 . . . . 0.0 116.382 -165.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.07 -2.83 28.68 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 125.162 1.385 . . . . 0.0 113.254 169.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.6 -150.57 19.93 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.559 1.552 . . . . 0.0 112.432 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 p -54.75 -5.79 0.1 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 116.82 2.156 . . . . 0.0 116.82 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.9 t -76.18 7.18 4.44 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.721 1.609 . . . . 0.0 111.619 166.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.1 m -154.86 158.82 39.94 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 127.92 2.488 . . . . 0.0 109.739 172.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 61.49 -76.81 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 127.354 2.262 . . . . 0.0 113.997 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.82 -91.75 0.94 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.296 1.903 . . . . 0.0 112.223 -174.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -100.33 -177.32 0.17 Allowed 'Trans proline' 0 CA--C 1.535 0.561 1 C-N-CA 125.939 4.426 . . . . 0.0 111.728 176.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.426 ' CD2' ' N ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -79.98 130.36 35.21 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 168.741 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -58.97 147.09 35.67 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.855 1.262 . . . . 0.0 112.56 171.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 50.3 m-20 -108.81 77.87 0.86 Allowed Pre-proline 0 CA--C 1.554 1.097 0 C-N-CA 125.276 1.43 . . . . 0.0 111.843 -176.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -58.21 -49.18 13.15 Favored 'Trans proline' 0 C--N 1.353 0.81 0 C-N-CA 123.975 3.116 . . . . 0.0 113.216 -174.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 75.1 mt -78.83 -0.44 30.62 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 126.144 1.778 . . . . 0.0 112.871 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.2 t 58.77 43.82 17.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 127.518 2.327 . . . . 0.0 112.151 -173.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.1 mtp180 -92.31 176.43 6.48 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 120.878 -1.139 . . . . 0.0 112.489 -176.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.509 ' HE2' ' OE1' ' B' ' 78' ' ' GLU . 0.3 OUTLIER -97.24 170.26 9.22 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 126.18 1.792 . . . . 0.0 108.829 165.312 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -96.66 151.64 19.42 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -167.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.44 -106.03 0.34 Allowed Glycine 0 C--N 1.345 1.053 0 C-N-CA 124.796 1.189 . . . . 0.0 114.809 166.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.85 -29.2 8.69 Favored Glycine 0 CA--C 1.543 1.811 0 N-CA-C 119.85 2.7 . . . . 0.0 119.85 174.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -104.03 6.47 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.049 0 C-N-CA 123.657 2.904 . . . . 0.0 112.578 172.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.01 -31.25 0.13 Allowed 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.908 1.283 . . . . 0.0 110.893 169.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.05 150.13 27.71 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 162.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -96.19 -17.99 20.41 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.519 1.927 . . . . 0.0 112.138 -176.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . 0.509 ' OE1' ' HE2' ' B' ' 70' ' ' LYS . 3.7 mt-10 -78.05 -50.66 11.65 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 121.049 -1.032 . . . . 0.0 113.023 -172.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 45.75 97.88 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.127 1.371 . . . . 0.0 114.059 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.6 m80 -50.79 144.78 7.86 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 119.729 -1.857 . . . . 0.0 110.262 169.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 m -55.41 -29.99 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 CA-C-N 120.239 1.381 . . . . 0.0 112.12 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.26 49.24 3.48 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 125.025 1.298 . . . . 0.0 116.053 171.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -139.46 123.17 17.48 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.353 1.461 . . . . 0.0 110.071 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -113.55 50.29 0.92 Allowed 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 168.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 55.73 -112.13 2.91 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 125.343 1.449 . . . . 0.0 114.445 177.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -155.7 159.07 39.23 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 126.196 1.798 . . . . 0.0 110.563 -175.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.8 p -117.37 175.75 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 127.517 2.327 . . . . 0.0 109.685 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -133.92 150.17 51.31 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.98 1.712 . . . . 0.0 108.326 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -117.7 149.03 41.42 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.443 1.497 . . . . 0.0 112.779 173.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -83.52 150.05 26.23 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 128.229 2.612 . . . . 0.0 112.281 169.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.82 -2.48 1.85 Allowed 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.884 1.673 . . . . 0.0 115.143 177.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -90.93 7.96 37.53 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.485 1.514 . . . . 0.0 112.069 169.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.82 28.81 22.73 Favored Glycine 0 C--N 1.341 0.821 0 CA-C-O 117.361 -1.799 . . . . 0.0 114.656 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -141.64 139.26 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.138 1.469 . . . . 0.0 114.521 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.14 122.04 44.5 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.558 1.543 . . . . 0.0 108.685 165.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -79.21 140.0 37.8 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 165.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.262 0.3 OUTLIER -119.71 129.04 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-O 122.557 1.17 . . . . 0.0 112.576 166.96 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 28.8 m -147.8 78.63 1.46 Allowed 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.362 1.465 . . . . 0.0 109.729 -172.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -122.44 154.14 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.484 1.513 . . . . 0.0 111.614 -173.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.8 tt0 -142.14 148.39 38.22 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.989 1.715 . . . . 0.0 107.346 167.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -149.83 150.48 32.04 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 125.117 1.367 . . . . 0.0 111.934 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.2 p -116.78 51.86 0.97 Allowed 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.7 -48.64 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 124.4 1.08 . . . . 0.0 110.819 169.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.96 157.31 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 119.327 0.967 . . . . 0.0 112.785 177.502 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 95.0 p -156.54 150.89 25.41 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.164 1.786 . . . . 0.0 109.023 -170.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mp -80.95 54.06 2.11 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 122.128 0.965 . . . . 0.0 108.745 172.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -84.93 62.61 7.58 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.121 -0.987 . . . . 0.0 109.968 -177.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.92 -111.11 4.06 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 124.784 1.183 . . . . 0.0 112.837 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -127.99 -14.8 4.92 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 127.67 2.388 . . . . 0.0 114.518 -167.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.0 -32.14 8.44 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 114.49 1.292 . . . . 0.0 114.49 -169.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -85.98 -15.14 42.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.258 0.7 OUTLIER -177.37 -47.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 C-N-CA 127.564 2.346 . . . . 0.0 109.109 168.536 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -58.86 143.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 105.61 -1.996 . . . . 0.0 105.61 162.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.65 -16.4 1.4 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 126.769 2.128 . . . . 0.0 113.628 -175.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 4.5 ttm-85 -80.15 171.37 15.17 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.863 1.665 . . . . 0.0 111.854 176.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -113.14 154.52 26.5 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 125.379 1.471 . . . . 0.0 112.466 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 25.2 tp -121.15 138.25 54.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 128.246 2.619 . . . . 0.0 109.217 168.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -114.84 139.39 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 124.949 1.3 . . . . 0.0 109.872 168.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -119.57 133.99 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 171.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -110.94 151.06 28.35 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.767 1.227 . . . . 0.0 112.033 -168.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -79.2 -18.22 53.39 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -167.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 48.0 mttp -138.73 178.23 7.3 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 120.163 1.347 . . . . 0.0 113.569 177.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.91 130.51 37.61 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.282 1.433 . . . . 0.0 110.176 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -81.33 158.78 24.6 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 124.029 0.831 . . . . 0.0 109.221 170.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . 0.43 ' OD1' ' HE3' ' B' ' 128' ' ' LYS . 7.5 t70 -73.45 -43.29 60.63 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 119.306 -0.957 . . . . 0.0 109.3 168.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 2.0 mm? 70.15 53.14 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 127.123 2.169 . . . . 0.0 107.734 -168.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 161.22 -82.29 0.13 Allowed Glycine 0 N--CA 1.465 0.617 0 O-C-N 121.317 -0.864 . . . . 0.0 114.1 -175.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.561 ' H ' ' HE3' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -156.69 72.4 0.73 Allowed 'General case' 0 CA--C 1.549 0.938 0 N-CA-C 115.701 1.741 . . . . 0.0 115.701 -170.237 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -57.6 -24.81 54.03 Favored Glycine 0 CA--C 1.542 1.753 0 O-C-N 120.708 -1.245 . . . . 0.0 115.128 176.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.48 -28.38 0.49 Allowed Glycine 0 CA--C 1.534 1.24 0 N-CA-C 116.675 1.43 . . . . 0.0 116.675 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 62.2 m-80 -106.33 175.81 5.37 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 118.968 1.384 . . . . 0.0 113.098 -176.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . 0.447 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 13.1 tm-20 -51.64 -57.55 8.84 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.603 1.161 . . . . 0.0 108.904 166.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -41.33 -34.53 0.52 Allowed 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 126.236 1.814 . . . . 0.0 115.036 168.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 4.5 p -71.18 -9.96 58.97 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 119.318 -2.114 . . . . 0.0 115.836 -177.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.2 t -111.16 -7.98 14.43 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.166 1.387 . . . . 0.0 110.379 164.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.447 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 3.1 tttt -85.82 -50.33 7.22 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.737 1.615 . . . . 0.0 110.763 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 80.7 p -102.35 -35.52 8.79 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 128.686 2.794 . . . . 0.0 110.972 175.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.76 -9.63 52.05 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.045 1.783 . . . . 0.0 112.028 -169.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 75.96 30.93 0.71 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 129.446 3.098 . . . . 0.0 112.317 176.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.68 33.33 0.01 OUTLIER 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 178.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.55 -51.86 3.75 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 127.69 2.567 . . . . 0.0 114.79 175.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 170.9 157.39 0.07 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.862 1.665 . . . . 0.0 113.741 -174.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.33 134.0 34.52 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.413 1.085 . . . . 0.0 113.715 173.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.3 pp -104.7 -30.17 10.11 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.331 1.453 . . . . 0.0 113.469 179.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.81 161.55 36.94 Favored 'General case' 0 C--O 1.245 0.831 0 C-N-CA 125.705 1.602 . . . . 0.0 107.174 174.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.3 p -152.32 151.86 31.41 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 126.254 1.822 . . . . 0.0 108.525 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.46 145.69 11.77 Favored Glycine 0 C--O 1.224 -0.504 0 N-CA-C 115.632 1.013 . . . . 0.0 115.632 179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 16.3 t -78.17 145.9 9.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.283 1.033 . . . . 0.0 108.244 167.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.6 mm -89.53 101.17 11.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.914 0.886 . . . . 0.0 109.979 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.62 164.46 30.39 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 173.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -93.78 141.14 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 123.902 0.881 . . . . 0.0 111.354 172.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -141.91 166.19 25.39 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.956 1.703 . . . . 0.0 111.154 168.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.466 0.351 0 C-N-CA 123.265 0.626 . . . . 0.0 111.133 -167.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.946 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -157.68 123.87 4.78 Favored 'General case' 0 CA--C 1.508 -0.635 0 O-C-N 125.6 1.812 . . . . 0.0 107.884 -168.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.0 ttpt -99.0 106.74 19.03 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 122.641 1.21 . . . . 0.0 112.967 169.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.65 173.23 7.99 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 126.078 1.751 . . . . 0.0 109.041 167.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -161.78 162.66 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.353 0.661 . . . . 0.0 111.996 -173.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.52 134.01 19.75 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.566 1.146 . . . . 0.0 109.899 163.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.26 94.29 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.525 1.93 . . . . 0.0 107.058 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -79.3 134.58 36.62 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 126.708 2.003 . . . . 0.0 110.206 -173.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.4 mtpt -155.87 179.71 8.94 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.313 1.045 . . . . 0.0 113.687 178.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.5 -60.47 0.42 Allowed Glycine 0 C--N 1.334 0.445 0 C-N-CA 128.083 2.754 . . . . 0.0 108.721 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -82.1 69.69 8.86 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.101 1.761 . . . . 0.0 111.52 -168.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.44 -100.67 0.03 OUTLIER Glycine 0 CA--C 1.54 1.643 0 C-N-CA 126.957 2.218 . . . . 0.0 114.132 171.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -80.38 -7.66 13.86 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 125.04 3.827 . . . . 0.0 114.331 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.3 t -77.22 142.17 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 CA-C-N 119.983 1.265 . . . . 0.0 109.105 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.45 158.04 39.35 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 124.95 1.3 . . . . 0.0 109.414 169.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.51 108.64 0.57 Allowed Glycine 0 C--O 1.22 -0.777 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 169.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.94 131.41 37.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 118.676 1.238 . . . . 0.0 108.392 168.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.3 pp -149.41 126.61 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-O 122.764 1.269 . . . . 0.0 111.413 166.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -74.82 166.3 23.84 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.78 1.232 . . . . 0.0 111.329 169.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -141.49 93.25 2.55 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.734 2.014 . . . . 0.0 107.879 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.46 ' OE2' ' HE3' ' A' ' 23' ' ' LYS . 4.6 tm-20 -92.55 122.9 35.44 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.588 1.555 . . . . 0.0 110.121 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -120.01 132.24 55.41 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.869 0.842 . . . . 0.0 112.333 169.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.513 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -75.13 -42.01 57.17 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.269 1.827 . . . . 0.0 112.584 -177.017 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.329 0.0 OUTLIER -110.01 -122.46 0.27 Allowed 'General case' 0 CA--C 1.544 0.729 0 CA-C-O 116.887 -1.53 . . . . 0.0 110.215 169.068 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 48.9 m -144.07 -25.31 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-N 120.847 1.658 . . . . 0.0 114.752 -172.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.47 -17.8 6.9 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 120.45 -1.406 . . . . 0.0 114.108 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -150.69 4.86 Favored Glycine 0 CA--C 1.542 1.755 1 C-N-CA 131.0 4.143 . . . . 0.0 114.104 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -88.41 156.71 6.62 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.296 2.664 . . . . 0.0 114.365 -168.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.14 134.48 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.763 1.225 . . . . 0.0 109.632 -173.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -97.58 126.0 42.63 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.229 1.411 . . . . 0.0 109.902 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.6 t -123.8 122.39 64.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 C-N-CA 126.587 1.955 . . . . 0.0 109.146 -170.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -146.9 150.27 34.89 Favored 'General case' 0 C--O 1.24 0.57 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -178.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.59 -153.13 23.43 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.834 1.683 . . . . 0.0 111.039 -169.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.1 p -158.57 143.35 16.09 Favored 'General case' 0 C--O 1.238 0.485 0 O-C-N 121.794 -0.827 . . . . 0.0 113.097 -169.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -109.13 106.2 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 125.251 1.42 . . . . 0.0 109.616 173.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -111.29 144.59 40.23 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.704 2.002 . . . . 0.0 110.549 -167.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.01 -24.04 24.08 Favored Glycine 0 N--CA 1.475 1.241 0 C-N-CA 126.566 2.031 . . . . 0.0 112.108 -171.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.4 mp -68.13 111.45 4.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.254 1.822 . . . . 0.0 107.644 168.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.4 t -68.78 -27.32 65.78 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.259 1.577 . . . . 0.0 115.259 -169.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 178.58 -175.4 0.19 Allowed 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 130.744 3.617 . . . . 0.0 106.549 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.54 159.81 35.41 Favored Glycine 0 N--CA 1.469 0.845 0 C-N-CA 126.263 1.887 . . . . 0.0 116.038 167.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.8 mt -70.45 132.61 45.84 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.827 1.251 . . . . 0.0 109.008 168.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -129.52 120.08 24.78 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.409 1.483 . . . . 0.0 107.253 177.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.13 164.47 36.48 Favored Glycine 0 N--CA 1.475 1.245 0 CA-C-O 117.619 -1.656 . . . . 0.0 111.563 176.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.25 1.6 p90 -156.06 111.32 2.94 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 120.989 2.394 . . . . 0.0 113.569 169.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -122.14 147.08 46.59 Favored 'General case' 0 CA--C 1.551 0.991 0 O-C-N 119.979 -1.701 . . . . 0.0 111.082 -172.124 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -82.31 120.63 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.438 ' CE1' ' HG ' ' A' ' 57' ' ' CYS . 16.5 m-70 -71.12 111.85 6.81 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.43 -2.433 . . . . 0.0 104.43 168.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.424 ' H ' ' HA ' ' A' ' 63' ' ' HIS . 16.8 tt0 -64.39 116.86 6.5 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.148 -174.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.353 50.3 m-85 101.31 160.57 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 131.567 3.947 . . . . 0.0 113.708 -178.089 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.18 -14.7 55.63 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 114.746 -1.115 . . . . 0.0 114.48 -172.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.93 54.9 0.28 Allowed 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 128.887 2.875 . . . . 0.0 113.134 -169.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -170.33 -42.34 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 119.539 3.163 . . . . 0.0 119.539 -168.728 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.298 0.9 OUTLIER 49.75 -58.99 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 129.115 2.966 . . . . 0.0 117.339 -169.775 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 22.44 0.82 Allowed 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 127.748 2.419 . . . . 0.0 114.596 -171.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.41 -127.82 44.4 Favored Glycine 0 C--N 1.336 0.553 0 C-N-CA 125.49 1.519 . . . . 0.0 110.878 172.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.438 ' HG ' ' CE1' ' A' ' 48' ' ' HIS . 4.5 m -56.56 -10.37 0.96 Allowed 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 -179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.08 1.85 22.73 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 125.251 1.42 . . . . 0.0 112.623 171.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 9.0 t -164.94 -156.52 0.31 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 129.532 3.133 . . . . 0.0 106.361 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 74.88 -169.09 0.1 Allowed 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 123.761 1.743 . . . . 0.0 115.147 166.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.68 155.43 16.08 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 127.151 2.31 . . . . 0.0 108.735 166.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.417 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 96.6 Cg_endo -75.61 76.43 3.63 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 123.924 3.083 . . . . 0.0 108.293 171.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.424 ' HA ' ' H ' ' A' ' 49' ' ' GLU . 5.1 p80 47.27 72.39 0.25 Allowed 'General case' 0 C--O 1.236 0.351 0 C-N-CA 127.261 2.225 . . . . 0.0 112.674 167.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -40.84 141.22 0.61 Allowed 'General case' 0 C--O 1.221 -0.395 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.603 -174.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -101.3 67.48 0.06 OUTLIER Pre-proline 0 CA--C 1.549 0.938 0 CA-C-N 114.195 -1.366 . . . . 0.0 113.527 175.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -65.13 -18.47 61.57 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 121.829 1.686 . . . . 0.0 112.593 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -77.97 -5.11 50.18 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.188 1.395 . . . . 0.0 113.523 170.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.6 t 60.78 53.41 3.92 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 127.01 2.124 . . . . 0.0 112.177 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 -139.3 175.35 9.63 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 -167.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.68 158.89 30.67 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.353 1.461 . . . . 0.0 112.017 173.179 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -79.4 147.92 32.18 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.481 -0.781 . . . . 0.0 112.469 168.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 155.64 -111.93 0.5 Allowed Glycine 0 C--N 1.339 0.701 0 CA-C-O 118.029 -1.429 . . . . 0.0 114.09 167.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.11 -85.88 0.39 Allowed Glycine 0 CA--C 1.537 1.446 0 CA-C-O 117.486 -1.73 . . . . 0.0 114.6 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -55.54 -6.88 1.1 Allowed 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 124.458 3.438 . . . . 0.0 116.869 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -155.89 9.97 0.27 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 128.585 2.754 . . . . 0.0 112.238 -176.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -146.74 109.9 4.75 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 128.533 2.733 . . . . 0.0 109.624 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -64.35 -9.26 16.73 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 127.848 2.459 . . . . 0.0 114.719 -175.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -81.44 -91.83 0.06 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.76 0.824 . . . . 0.0 110.402 177.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.8 ttp-105 78.72 118.45 0.06 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.164 1.785 . . . . 0.0 111.141 171.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m80 -55.79 160.83 2.44 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.278 -1.514 . . . . 0.0 113.831 175.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.8 t -53.16 -50.74 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 121.047 1.749 . . . . 0.0 112.229 -170.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.7 3.06 Favored Glycine 0 C--N 1.341 0.833 0 N-CA-C 108.491 -1.844 . . . . 0.0 108.491 169.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -157.45 118.56 3.6 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.529 1.531 . . . . 0.0 109.512 179.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -105.16 165.57 11.0 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 126.099 1.76 . . . . 0.0 109.726 169.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.81 -136.77 8.57 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 125.249 1.404 . . . . 0.0 112.792 177.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.64 158.17 20.33 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 117.025 2.231 . . . . 0.0 117.025 -174.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.3 m -106.97 173.9 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 128.705 2.802 . . . . 0.0 110.188 167.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 t -141.74 141.27 33.25 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 125.552 1.541 . . . . 0.0 108.383 169.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.69 150.67 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 125.221 1.408 . . . . 0.0 111.589 178.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -100.64 158.79 15.68 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.884 1.673 . . . . 0.0 112.128 173.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -50.28 -21.93 1.58 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 129.099 2.959 . . . . 0.0 115.815 -169.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.26 0.94 54.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 128.58 2.752 . . . . 0.0 110.716 -172.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.32 32.05 6.24 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-O 117.477 -1.735 . . . . 0.0 114.052 173.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.2 p -155.66 133.53 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 117.512 2.412 . . . . 0.0 117.512 -171.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.65 129.22 40.02 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 163.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -88.59 145.49 25.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 168.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.7 t -131.85 122.27 49.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 113.251 -1.795 . . . . 0.0 107.934 167.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -146.35 58.81 1.21 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 127.687 2.395 . . . . 0.0 107.582 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 29.7 mt -116.77 155.65 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.498 1.519 . . . . 0.0 112.125 -166.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -135.99 130.24 33.3 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 167.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -132.69 144.71 50.5 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 125.353 1.461 . . . . 0.0 110.256 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.6 p -125.28 59.42 1.25 Allowed 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.276 1.431 . . . . 0.0 112.752 -167.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -156.31 -48.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 C-N-CA 123.008 0.523 . . . . 0.0 110.683 -174.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -82.32 158.79 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 164.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.2 p -160.24 168.85 24.46 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.064 1.345 . . . . 0.0 109.355 -175.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.3 mp -100.64 54.06 0.87 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.0 t -76.09 4.32 8.73 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 114.98 1.474 . . . . 0.0 114.98 -167.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 138.18 -86.83 0.22 Allowed Glycine 0 N--CA 1.462 0.39 0 N-CA-C 106.592 -2.603 . . . . 0.0 106.592 -169.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.99 -6.11 0.77 Allowed 'General case' 0 C--O 1.219 -0.526 0 C-N-CA 123.761 0.824 . . . . 0.0 113.199 168.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.429 ' CD2' ' H ' ' A' ' 110' ' ' HIS . 0.0 OUTLIER -73.03 -33.17 65.56 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 120.29 -1.506 . . . . 0.0 110.617 -165.112 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.0 p -105.78 -8.56 17.71 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 117.448 2.388 . . . . 0.0 117.448 -169.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.273 3.7 pt 176.69 -39.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 C-N-CA 127.698 2.399 . . . . 0.0 115.582 167.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.3 mm -49.47 125.03 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-N 121.605 2.002 . . . . 0.0 111.024 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.67 -7.01 66.87 Favored Glycine 0 CA--C 1.534 1.241 0 C-N-CA 125.766 1.65 . . . . 0.0 116.092 176.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.5 176.03 10.14 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.814 1.646 . . . . 0.0 110.622 170.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.1 t -132.97 129.03 37.69 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 120.185 1.357 . . . . 0.0 113.078 -174.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.2 tp -101.96 125.48 48.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.771 2.029 . . . . 0.0 109.523 -170.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -110.98 135.19 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 124.526 1.131 . . . . 0.0 109.595 174.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.2 p -92.63 141.51 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 C-N-CA 124.991 1.316 . . . . 0.0 109.088 168.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -112.95 168.42 9.71 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.097 2.559 . . . . 0.0 113.112 -168.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -86.61 -46.71 9.85 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 -168.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -99.9 -176.33 3.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 120.091 -1.631 . . . . 0.0 110.198 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.71 154.16 7.22 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 165.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 p30 -99.25 140.78 32.91 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.68 1.229 . . . . 0.0 110.792 167.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -78.62 -36.57 43.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 127.422 2.289 . . . . 0.0 112.213 -169.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 23.1 mt 55.82 47.83 19.44 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.717 1.207 . . . . 0.0 110.596 173.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 138.52 -62.25 0.57 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.415 -1.214 . . . . 0.0 115.9 171.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.39 87.39 1.31 Allowed 'General case' 0 CA--C 1.552 1.021 1 N-CA-C 122.417 4.229 . . . . 0.0 122.417 -166.5 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.71 -86.99 0.61 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 105.948 -2.861 . . . . 0.0 105.948 163.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -167.31 34.08 0.21 Allowed Glycine 0 N--CA 1.47 0.935 0 CA-C-O 119.03 -0.872 . . . . 0.0 114.827 171.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -164.05 150.34 11.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 119.513 1.657 . . . . 0.0 108.899 -167.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -48.3 -46.99 36.88 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.607 0.763 . . . . 0.0 112.275 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -50.51 -27.84 7.37 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 116.04 1.867 . . . . 0.0 116.04 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.1 p -53.25 -28.06 25.54 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-N 120.857 1.662 . . . . 0.0 112.656 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.9 t -113.51 -29.16 7.27 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 115.195 1.554 . . . . 0.0 115.195 170.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -67.65 -23.32 65.32 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 119.986 1.266 . . . . 0.0 113.355 178.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.9 p -141.11 -32.91 0.54 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.228 1.411 . . . . 0.0 114.236 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.39 5.16 49.39 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.587 1.565 . . . . 0.0 110.466 -164.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 51.53 30.99 6.96 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 127.311 2.244 . . . . 0.0 114.632 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.05 19.47 0.04 OUTLIER 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 118.06 2.615 . . . . 0.0 118.06 -166.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.62 8.05 37.64 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 119.437 2.535 . . . . 0.0 119.437 167.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 28.9 t 139.2 -178.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 1 C-N-CA 131.952 4.101 . . . . 0.0 111.183 170.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.08 154.22 37.62 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 126.18 1.792 . . . . 0.0 112.836 173.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.349 0.0 OUTLIER -133.31 -127.2 0.17 Allowed 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.972 2.109 . . . . 0.0 107.868 167.104 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.05 147.77 46.2 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.068 1.304 . . . . 0.0 114.472 -166.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.7 p -137.42 147.63 45.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.612 1.565 . . . . 0.0 113.952 176.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.61 142.43 8.41 Favored Glycine 0 N--CA 1.473 1.165 0 C-N-CA 124.621 1.105 . . . . 0.0 114.238 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 87.6 t -76.27 150.43 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 C-N-CA 124.725 1.21 . . . . 0.0 110.246 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.9 mm -81.31 83.69 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 O-C-N 121.562 -0.711 . . . . 0.0 109.721 173.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.72 -169.01 43.59 Favored Glycine 0 N--CA 1.474 1.231 0 C-N-CA 126.849 2.166 . . . . 0.0 112.912 175.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -142.74 155.39 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 115.324 1.602 . . . . 0.0 115.324 -168.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.84 -15.11 14.46 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.567 1.547 . . . . 0.0 112.844 169.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.476 0.85 0 C-N-CA 130.057 3.343 . . . . 0.0 109.117 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.775 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 17.2 m -78.19 77.03 4.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.713 1.205 . . . . 0.0 111.425 -168.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.259 17.3 pttm -81.13 130.49 35.05 Favored 'General case' 0 CA--C 1.547 0.85 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -174.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.38 172.42 12.76 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 127.744 2.417 . . . . 0.0 111.288 -176.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 7.0 p -148.38 146.81 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.41 1.084 . . . . 0.0 112.734 -166.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.16 96.56 2.9 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-O 122.516 1.151 . . . . 0.0 108.799 168.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 53.1 t -79.64 96.82 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 104.878 -2.267 . . . . 0.0 104.878 166.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.65 114.94 17.0 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 77.0 tttt -160.76 131.34 5.31 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.465 1.484 . . . . 0.0 114.747 -175.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -162.04 -35.16 0.02 OUTLIER Glycine 0 N--CA 1.474 1.204 0 C-N-CA 125.232 1.396 . . . . 0.0 111.519 168.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -77.26 58.38 1.61 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 130.98 3.712 . . . . 0.0 113.075 175.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.91 -96.39 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 C-N-CA 129.184 3.278 . . . . 0.0 115.569 169.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.94 -16.45 14.32 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.134 3.223 . . . . 0.0 113.91 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -86.37 141.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-N 119.698 1.135 . . . . 0.0 109.105 174.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -157.12 161.03 39.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.758 1.223 . . . . 0.0 110.629 167.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.471 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.05 99.92 0.79 Allowed Glycine 0 C--O 1.222 -0.632 0 C-N-CA 126.073 1.797 . . . . 0.0 110.694 173.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -87.64 93.61 4.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 118.983 1.391 . . . . 0.0 108.425 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 pp -113.88 152.73 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.96 1.362 . . . . 0.0 111.821 171.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -123.29 175.79 6.49 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.761 1.224 . . . . 0.0 110.262 175.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -140.1 139.77 35.92 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.249 1.019 . . . . 0.0 109.371 168.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -134.28 131.73 38.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 168.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -125.71 141.09 52.19 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 122.069 0.938 . . . . 0.0 109.962 174.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 6.6 mtmm -84.51 -31.16 24.62 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 125.686 1.594 . . . . 0.0 110.774 -174.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -123.28 -164.56 1.22 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 128.938 2.895 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 36.7 p -106.97 -37.17 6.41 Favored 'General case' 0 N--CA 1.472 0.674 0 O-C-N 120.719 -1.238 . . . . 0.0 110.617 166.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -112.79 5.07 17.36 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.391 1.476 . . . . 0.0 114.023 -175.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.46 -178.01 37.05 Favored Glycine 0 CA--C 1.54 1.649 0 CA-C-O 118.692 -1.06 . . . . 0.0 112.448 172.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.81 157.7 54.62 Favored 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 123.026 2.484 . . . . 0.0 113.552 -176.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 94.2 t -120.37 136.03 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 126.555 1.942 . . . . 0.0 110.93 -170.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.3 mptt -79.23 118.84 21.54 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.417 0.627 . . . . 0.0 111.733 169.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.3 124.92 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 125.549 1.54 . . . . 0.0 107.252 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -151.28 160.83 43.6 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 123.156 0.582 . . . . 0.0 112.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.32 175.58 13.91 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 123.846 0.736 . . . . 0.0 113.65 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 43.7 p -119.77 124.05 45.22 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 115.068 1.507 . . . . 0.0 115.068 -166.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . 0.471 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.0 mm -90.65 123.37 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 CA-C-O 116.878 -1.534 . . . . 0.0 109.973 168.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.2 tttt -132.82 132.64 42.39 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 122.219 2.282 . . . . 0.0 111.677 175.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.75 -9.76 6.07 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 127.42 2.438 . . . . 0.0 114.293 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -91.3 168.2 11.75 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.62 1.568 . . . . 0.0 112.535 173.332 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.8 t -77.28 166.93 22.55 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.811 0.844 . . . . 0.0 111.241 169.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -67.41 -172.84 0.25 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 125.742 1.617 . . . . 0.0 115.204 -173.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.14 -172.75 54.25 Favored Glycine 0 N--CA 1.477 1.378 0 C-N-CA 124.568 1.08 . . . . 0.0 114.009 176.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 54.2 mt -66.95 144.16 56.39 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 120.67 -1.488 . . . . 0.0 110.202 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -133.25 130.42 38.99 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.679 1.192 . . . . 0.0 109.905 170.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.99 152.01 51.2 Favored Glycine 0 N--CA 1.468 0.828 0 C-N-CA 124.644 1.116 . . . . 0.0 112.21 179.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -148.73 105.29 3.55 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 117.508 0.654 . . . . 0.0 109.979 -169.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.433 ' CD2' ' CD2' ' B' ' 63' ' ' HIS . 0.5 OUTLIER -143.84 158.3 43.78 Favored 'General case' 0 CA--C 1.54 0.57 0 O-C-N 120.538 -1.351 . . . . 0.0 109.847 -175.836 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.84 126.89 64.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 C-N-CA 126.051 1.74 . . . . 0.0 108.715 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 14.3 m-70 -77.18 116.85 18.16 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 168.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.86 162.21 29.77 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -168.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.4 t80 68.72 177.01 0.26 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 125.647 1.579 . . . . 0.0 111.879 -173.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.96 0.43 9.86 Favored Glycine 0 N--CA 1.469 0.878 0 CA-C-O 118.881 -0.955 . . . . 0.0 114.177 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -86.72 51.21 2.17 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.018 1.327 . . . . 0.0 108.725 -177.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 179.63 34.84 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.109 0 N-CA-C 116.186 1.921 . . . . 0.0 116.186 -166.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.406 HG23 ' H ' ' B' ' 54' ' ' THR . 5.5 p -54.12 32.52 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 131.518 3.927 . . . . 0.0 120.591 -170.678 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -142.11 -3.31 1.09 Allowed 'General case' 0 CA--C 1.558 1.252 0 C-N-CA 127.94 2.496 . . . . 0.0 113.113 168.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.42 -121.52 5.68 Favored Glycine 0 C--N 1.343 0.948 0 C-N-CA 124.808 1.194 . . . . 0.0 113.175 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 27.1 p -57.67 -24.47 56.88 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 -170.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.0 t -91.94 21.54 4.87 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.356 1.462 . . . . 0.0 113.48 174.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 71.2 m -151.54 -37.64 0.12 Allowed 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.802 1.641 . . . . 0.0 114.974 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.27 170.78 19.19 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 120.982 1.719 . . . . 0.0 113.954 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.61 -158.97 32.54 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 125.871 1.7 . . . . 0.0 115.985 -169.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -74.56 -174.84 1.99 Allowed 'Trans proline' 0 CA--C 1.537 0.67 1 C-N-CA 126.239 4.626 . . . . 0.0 114.35 -169.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.684 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -65.14 96.58 0.21 Allowed 'General case' 0 N--CA 1.445 -0.689 1 C-N-CA 132.648 4.379 . . . . 0.0 109.166 -176.651 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -56.5 146.86 23.45 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 123.953 1.835 . . . . 0.0 109.998 174.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 48.8 p-10 -107.72 57.81 0.22 Allowed Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 -176.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.57 -20.23 53.8 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.285 1.99 . . . . 0.0 111.74 169.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.0 mp -77.02 -3.88 41.31 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.925 1.29 . . . . 0.0 112.392 169.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t 57.61 87.73 0.06 Allowed 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 127.995 2.518 . . . . 0.0 113.027 174.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 179.17 176.62 0.58 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -169.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -84.14 176.93 8.45 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 128.111 2.565 . . . . 0.0 107.869 166.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 12.8 t60 -57.78 174.03 0.27 Allowed 'General case' 0 CA--C 1.546 0.791 0 O-C-N 120.39 -1.443 . . . . 0.0 111.813 169.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.83 -175.31 32.18 Favored Glycine 0 N--CA 1.465 0.599 0 O-C-N 121.272 -0.893 . . . . 0.0 113.427 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 136.37 -128.24 4.44 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 117.961 -1.466 . . . . 0.0 112.316 -170.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -48.0 -11.32 0.11 Allowed 'Trans proline' 0 CA--C 1.542 0.895 1 C-N-CA 126.009 4.473 . . . . 0.0 119.793 -172.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.65 -5.67 5.2 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 120.759 1.618 . . . . 0.0 114.157 169.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -126.48 178.19 6.02 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 127.401 2.28 . . . . 0.0 109.819 -168.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -106.72 -20.31 13.39 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.548 1.539 . . . . 0.0 111.989 -177.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -78.15 -92.32 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.695 0 O-C-N 121.06 -1.025 . . . . 0.0 113.204 -167.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 54.7 ttt180 78.38 93.61 0.06 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 126.328 1.851 . . . . 0.0 113.744 169.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -51.94 160.75 0.67 Allowed 'General case' 0 N--CA 1.481 1.101 0 O-C-N 119.974 -1.704 . . . . 0.0 112.594 166.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 p -68.04 -27.97 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 CA-C-N 121.229 1.831 . . . . 0.0 111.483 176.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -70.8 18.26 0.82 Allowed Glycine 0 CA--C 1.538 1.491 0 CA-C-O 117.109 -1.94 . . . . 0.0 116.277 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -121.04 110.51 16.33 Favored 'General case' 0 CA--C 1.55 0.951 0 CA-C-N 121.891 2.845 . . . . 0.0 112.312 -178.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -113.08 46.17 1.27 Allowed 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 123.361 1.553 . . . . 0.0 112.289 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.93 -141.24 45.32 Favored Glycine 0 CA--C 1.536 1.347 0 CA-C-N 114.054 -1.43 . . . . 0.0 115.499 169.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -116.15 140.16 49.58 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.722 1.209 . . . . 0.0 111.021 172.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -91.34 172.87 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 162.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -140.53 142.96 35.15 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 120.85 -1.156 . . . . 0.0 109.796 173.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -118.95 157.87 26.86 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.555 1.542 . . . . 0.0 113.187 -169.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -107.55 162.46 13.93 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 127.439 2.295 . . . . 0.0 112.543 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.683 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -63.66 -12.81 37.0 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.31 1.444 . . . . 0.0 114.333 173.757 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -70.45 -14.94 62.74 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-O 121.707 0.765 . . . . 0.0 109.93 171.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.16 9.23 55.98 Favored Glycine 0 C--N 1.337 0.625 0 C-N-CA 126.593 2.044 . . . . 0.0 112.848 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.2 p -110.39 138.62 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 125.164 1.385 . . . . 0.0 114.39 -178.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.65 97.13 6.5 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.598 1.959 . . . . 0.0 106.284 165.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -98.74 154.61 17.85 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.677 0.751 . . . . 0.0 111.089 174.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -150.66 150.95 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 116.231 1.938 . . . . 0.0 116.231 -173.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 51.6 p -157.46 105.83 2.09 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 124.226 1.01 . . . . 0.0 112.276 169.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 16.3 mt -136.85 151.56 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 126.969 2.108 . . . . 0.0 111.116 -178.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -109.43 107.29 17.38 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 167.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -96.87 138.16 34.85 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 127.285 2.234 . . . . 0.0 112.97 -176.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 82.5 p -108.05 49.93 0.79 Allowed 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 66.8 t -145.35 -44.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-O 118.585 -0.721 . . . . 0.0 112.231 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.94 162.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 120.148 1.34 . . . . 0.0 111.534 170.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' B' ' 111' ' ' SER . 90.2 p -157.4 149.63 22.69 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 125.678 1.591 . . . . 0.0 109.776 -175.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 60.01 4.22 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.436 . . . . 0.0 107.496 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.3 t -115.89 8.52 14.75 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -168.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.02 -49.65 4.01 Favored Glycine 0 N--CA 1.472 1.08 0 O-C-N 120.768 -1.207 . . . . 0.0 114.937 168.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -116.67 -58.68 2.05 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 119.074 1.437 . . . . 0.0 112.331 -170.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -83.21 5.26 23.5 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 125.433 1.493 . . . . 0.0 112.506 -171.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' B' ' 105' ' ' SER . 61.3 m -158.27 -115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.08 0.952 . . . . 0.0 112.668 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 38.6 pt -112.26 169.14 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 120.493 1.497 . . . . 0.0 112.408 -178.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.2 mm 91.24 117.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 1 C-N-CA 132.259 4.224 . . . . 0.0 105.641 -162.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.35 12.3 72.61 Favored Glycine 0 CA--C 1.534 1.238 0 CA-C-O 117.611 -1.661 . . . . 0.0 115.502 -176.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.82 169.03 10.78 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.585 2.193 . . . . 0.0 109.135 169.105 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . 0.261 13.3 t -131.7 113.5 13.64 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 123.417 2.826 . . . . 0.0 114.698 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 22.4 tp -88.49 140.67 29.23 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.474 1.91 . . . . 0.0 110.91 -169.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -127.07 142.62 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 124.065 0.946 . . . . 0.0 111.301 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.31 140.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 122.322 1.058 . . . . 0.0 110.097 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -102.96 148.59 25.48 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.834 -172.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.262 2.9 pp20? -80.05 -7.45 58.86 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 121.028 -1.045 . . . . 0.0 113.24 -170.267 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 58.2 mttp -126.66 176.44 7.22 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.824 2.05 . . . . 0.0 110.926 168.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -59.29 148.15 33.16 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.383 1.473 . . . . 0.0 111.278 169.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -91.41 138.08 31.86 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 167.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.68 -32.25 65.67 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 177.267 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.9 mt 66.62 66.24 0.45 Allowed 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.58 1.952 . . . . 0.0 111.284 169.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 149.13 -96.65 0.17 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 123.837 0.732 . . . . 0.0 111.311 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.421 ' HA ' ' HB3' ' B' ' 134' ' ' SER . 31.4 tttt -157.49 119.61 3.78 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.876 2.07 . . . . 0.0 110.906 167.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.14 -75.68 0.62 Allowed Glycine 0 CA--C 1.527 0.834 0 C-N-CA 126.382 1.944 . . . . 0.0 109.594 168.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -154.89 -12.22 0.06 OUTLIER Glycine 0 N--CA 1.47 0.954 0 N-CA-C 116.344 1.297 . . . . 0.0 116.344 175.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -109.53 -141.85 0.38 Allowed 'General case' 0 CA--C 1.548 0.881 0 CA-C-N 119.317 1.558 . . . . 0.0 110.03 -167.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -117.73 -48.74 2.56 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 120.619 1.554 . . . . 0.0 111.369 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -46.62 -32.3 3.4 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.412 1.885 . . . . 0.0 112.411 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 134' ' ' SER . . . . . 0.421 ' HB3' ' HA ' ' B' ' 128' ' ' LYS . 0.4 OUTLIER -49.21 -44.35 43.22 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 127.602 2.361 . . . . 0.0 113.041 169.723 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -95.15 -34.12 12.38 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 173.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -31.81 73.09 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.782 -1.199 . . . . 0.0 113.486 176.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 82.7 p -137.03 -27.1 1.0 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 116.759 -1.591 . . . . 0.0 114.612 -173.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.19 -2.79 31.31 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.668 1.127 . . . . 0.0 113.861 -168.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 12.9 t-20 55.89 9.96 0.51 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 126.279 1.831 . . . . 0.0 113.179 -169.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.36 24.96 0.02 OUTLIER 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 127.938 2.495 . . . . 0.0 116.826 -167.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.16 -139.17 19.52 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 126.555 2.026 . . . . 0.0 113.905 178.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.4 t -80.93 -148.16 0.06 Allowed 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.979 1.712 . . . . 0.0 109.6 168.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -140.71 155.81 46.37 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 120.353 -1.467 . . . . 0.0 110.098 172.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.412 HD12 ' H ' ' B' ' 145' ' ' ALA . 0.7 OUTLIER -109.72 -129.9 0.3 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 165.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . 0.412 ' H ' HD12 ' B' ' 144' ' ' LEU . . . -61.68 144.97 53.73 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.552 1.541 . . . . 0.0 113.823 -170.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.8 p -138.42 151.32 47.35 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 126.194 1.797 . . . . 0.0 113.135 176.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.0 139.53 6.02 Favored Glycine 0 N--CA 1.471 0.997 0 O-C-N 120.989 -1.069 . . . . 0.0 114.239 -176.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.4 t -77.98 145.96 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.045 0.938 . . . . 0.0 109.605 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 54.6 mt -81.36 90.47 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.293 1.037 . . . . 0.0 109.781 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.18 -171.45 45.55 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 126.39 1.948 . . . . 0.0 111.952 171.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . 0.427 HD12 ' H ' ' B' ' 151' ' ' ILE . 0.8 OUTLIER -127.58 124.46 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 115.737 1.755 . . . . 0.0 115.737 -167.641 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.19 0.08 47.01 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.965 2.106 . . . . 0.0 112.593 167.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 131.019 3.728 . . . . 0.0 115.692 -169.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 118.735 -0.65 . . . . 0.0 111.603 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.4 p -76.06 42.53 0.26 Allowed 'General case' 0 C--N 1.346 0.451 0 C-N-CA 128.958 2.903 . . . . 0.0 117.725 -164.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -165.43 101.94 0.72 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.783 1.633 . . . . 0.0 108.855 168.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -75.3 176.05 7.78 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 119.864 1.211 . . . . 0.0 111.482 173.446 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.4 p -153.63 117.49 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 127.225 2.21 . . . . 0.0 106.897 177.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.24 107.29 18.29 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.349 1.06 . . . . 0.0 109.74 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.0 t -76.09 79.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.226 1.01 . . . . 0.0 108.406 174.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -76.99 92.41 3.7 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 173.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.476 ' HZ2' ' CG ' ' B' ' 11' ' ' ASP . 19.9 ttpp -157.91 119.68 3.64 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.897 0.879 . . . . 0.0 110.814 171.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.57 -102.28 0.54 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 106.663 -2.575 . . . . 0.0 106.663 166.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.42 ' CG ' ' HZ1' ' B' ' 9' ' ' LYS . 4.5 m-20 -144.98 109.86 5.07 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 125.938 1.695 . . . . 0.0 107.282 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.38 177.03 14.69 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 123.844 0.735 . . . . 0.0 114.209 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -68.37 20.76 0.13 Allowed 'Trans proline' 0 CA--C 1.542 0.89 1 C-N-CA 126.15 4.567 . . . . 0.0 116.696 -169.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.4 t -128.34 128.46 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 CA-C-N 120.447 1.476 . . . . 0.0 109.508 -174.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -144.19 172.74 12.49 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.829 0.823 . . . . 0.0 112.657 -176.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.16 165.79 31.36 Favored Glycine 0 CA--C 1.509 -0.282 0 CA-C-N 112.828 -1.987 . . . . 0.0 112.947 167.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.445 HG13 ' H ' ' A' ' 34' ' ' SER . 7.8 pt -139.83 52.98 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 113.22 -1.49 . . . . 0.0 112.024 -167.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -80.47 105.7 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 O-C-N 120.418 -1.426 . . . . 0.0 111.079 -169.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -83.0 156.28 23.5 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.506 1.522 . . . . 0.0 110.613 173.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -143.43 97.92 3.16 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.462 1.505 . . . . 0.0 109.677 175.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.72 136.32 37.38 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 119.884 -1.76 . . . . 0.0 107.202 173.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -152.91 -175.81 5.48 Favored 'General case' 0 CA--C 1.553 1.075 0 C-N-CA 127.78 2.432 . . . . 0.0 105.887 176.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.52 -15.29 0.49 Allowed 'General case' 0 CA--C 1.549 0.94 0 O-C-N 118.452 -2.655 . . . . 0.0 116.225 167.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -108.76 -174.27 2.47 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 127.869 2.468 . . . . 0.0 111.346 -174.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.3 p -81.33 -21.89 38.86 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 120.528 -1.358 . . . . 0.0 112.888 167.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -161.67 46.38 0.18 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.629 1.171 . . . . 0.0 113.399 -168.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.73 175.69 16.04 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 125.243 1.401 . . . . 0.0 110.637 169.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -74.67 157.95 43.78 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.032 1.821 . . . . 0.0 111.511 -169.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.5 t -131.3 149.4 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 125.097 1.359 . . . . 0.0 111.482 -167.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -116.51 103.74 10.72 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 123.641 0.776 . . . . 0.0 110.575 -175.175 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.5 t -80.22 119.85 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 126.834 2.054 . . . . 0.0 107.63 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 1.7 p90 -153.9 167.87 28.25 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.0 -155.75 15.93 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -170.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.445 ' H ' HG13 ' A' ' 17' ' ' ILE . 63.8 p -155.96 170.5 21.99 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 122.029 0.918 . . . . 0.0 113.345 -169.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.68 134.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 126.497 1.919 . . . . 0.0 107.256 169.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.18 150.23 33.39 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 121.63 2.013 . . . . 0.0 113.913 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.27 5.08 46.78 Favored Glycine 0 CA--C 1.539 1.581 0 C-N-CA 126.437 1.97 . . . . 0.0 112.285 -168.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -71.86 163.89 27.02 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.906 2.082 . . . . 0.0 111.055 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.5 t -81.32 155.81 25.83 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 164.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 74.7 tt0 -53.03 145.22 13.46 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.37 1.068 . . . . 0.0 111.349 169.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.09 -175.3 26.0 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 124.787 1.184 . . . . 0.0 114.146 -177.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -76.12 146.96 38.9 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 128.321 2.648 . . . . 0.0 114.464 -169.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -148.11 123.89 10.56 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.193 2.597 . . . . 0.0 109.911 -174.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.56 155.87 51.55 Favored Glycine 0 N--CA 1.479 1.512 0 CA-C-O 118.028 -1.429 . . . . 0.0 113.169 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.79 139.91 16.49 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 119.957 1.879 . . . . 0.0 114.375 172.285 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.415 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 9.0 p-80 -153.34 153.8 33.29 Favored 'General case' 0 CA--C 1.547 0.862 0 O-C-N 121.5 -0.75 . . . . 0.0 111.936 -179.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -98.36 112.44 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 123.946 0.899 . . . . 0.0 109.119 174.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.418 ' C ' ' H ' ' A' ' 50' ' ' PHE . 6.3 p80 -82.43 149.78 27.44 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 174.277 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -66.84 10.74 0.12 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 126.329 1.851 . . . . 0.0 114.304 -178.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 48' ' ' HIS . 13.3 m-85 -119.55 97.54 5.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 106.949 -1.501 . . . . 0.0 106.949 -169.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.24 -10.36 74.04 Favored Glycine 0 C--N 1.331 0.291 0 CA-C-O 117.885 -1.508 . . . . 0.0 111.17 166.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -73.7 123.25 23.73 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 104.381 -2.451 . . . . 0.0 104.381 164.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.517 ' ND2' ' HG1' ' A' ' 116' ' ' THR 0.312 0.0 OUTLIER -147.35 51.09 1.07 Allowed 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 123.782 1.753 . . . . 0.0 112.724 168.486 . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.414 HG21 ' H ' ' A' ' 53' ' ' ASN . 11.4 p -120.29 -23.89 6.08 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 112.173 -2.285 . . . . 0.0 112.755 -164.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -95.95 22.79 7.01 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.887 0.875 . . . . 0.0 111.603 168.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.76 -123.24 21.8 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 125.537 1.541 . . . . 0.0 111.913 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.7 p -67.49 -12.7 60.95 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 113.868 1.062 . . . . 0.0 113.868 173.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.69 39.24 0.61 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.412 1.485 . . . . 0.0 110.878 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 172.09 -55.37 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.39 2.276 . . . . 0.0 111.596 -169.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -97.54 153.39 18.2 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.73 -31.38 8.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 116.424 -2.32 . . . . 0.0 117.44 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -103.34 163.38 0.25 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 CA-C-N 122.124 2.962 . . . . 0.0 111.523 171.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.426 ' CD2' ' N ' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -137.24 107.78 6.53 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.558 1.143 . . . . 0.0 112.4 -166.678 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -58.97 154.66 14.93 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 114.141 -1.391 . . . . 0.0 111.998 169.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -119.7 77.68 21.29 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 127.712 2.405 . . . . 0.0 113.713 -170.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -63.64 -20.34 69.02 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.998 2.466 . . . . 0.0 113.445 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 53.6 mt -82.81 -2.49 54.7 Favored 'General case' 0 CA--C 1.543 0.685 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 170.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t 62.77 59.29 1.44 Allowed 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.611 1.564 . . . . 0.0 113.343 175.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.0 ptt180 -161.54 178.44 9.08 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -174.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.88 164.4 23.83 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 127.032 2.133 . . . . 0.0 110.006 173.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -62.88 168.23 4.08 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.735 0.814 . . . . 0.0 110.874 167.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 140.69 -156.0 25.12 Favored Glycine 0 N--CA 1.464 0.528 0 CA-C-O 119.11 -0.828 . . . . 0.0 113.808 171.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 -64.51 0.53 Allowed Glycine 0 CA--C 1.542 1.728 0 N-CA-C 117.924 1.93 . . . . 0.0 117.924 176.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -69.47 -19.46 37.47 Favored 'Trans proline' 0 C--N 1.349 0.6 0 CA-C-N 121.197 2.499 . . . . 0.0 114.722 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -134.66 -3.53 2.61 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 124.057 0.943 . . . . 0.0 112.758 179.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.56 147.81 50.73 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 128.344 2.658 . . . . 0.0 107.867 -173.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.66 -11.99 19.55 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 130.77 3.628 . . . . 0.0 112.67 -167.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -81.47 -94.04 0.05 OUTLIER 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.996 1.718 . . . . 0.0 106.992 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 47.5 ttt180 80.02 121.1 0.05 OUTLIER 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.539 1.536 . . . . 0.0 111.617 168.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -71.52 140.77 50.06 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 120.899 -1.126 . . . . 0.0 108.946 165.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -50.88 -28.81 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.57 8.78 79.13 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 119.362 0.983 . . . . 0.0 115.537 175.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -88.84 129.95 35.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 120.103 1.951 . . . . 0.0 112.028 -175.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.99 -179.7 4.02 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 128.288 2.635 . . . . 0.0 107.518 170.159 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -92.39 -120.19 2.7 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 122.761 1.201 . . . . 0.0 114.032 -172.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -140.58 152.96 45.89 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.887 1.275 . . . . 0.0 110.777 169.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -116.01 137.1 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 127.581 2.352 . . . . 0.0 109.894 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -102.93 132.24 49.3 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 119.322 0.964 . . . . 0.0 108.797 169.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.75 144.36 27.81 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-O 120.881 0.372 . . . . 0.0 111.068 168.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -60.7 169.88 1.67 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 126.077 1.751 . . . . 0.0 111.753 170.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.32 -15.16 9.26 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.204 1.402 . . . . 0.0 114.143 168.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.05 3.17 55.15 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 125.894 1.678 . . . . 0.0 114.026 169.534 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.9 13.87 76.64 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 120.082 -1.637 . . . . 0.0 115.287 169.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.44 134.72 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 125.846 1.659 . . . . 0.0 112.875 171.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.59 112.12 25.08 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 165.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -104.81 139.42 39.6 Favored 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 124.694 1.198 . . . . 0.0 109.568 -177.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.3 t -137.27 140.28 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 114.962 1.467 . . . . 0.0 114.962 -166.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 89.3 p -154.76 104.39 2.51 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.995 1.318 . . . . 0.0 111.73 173.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.0 mt -136.85 141.84 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.784 2.034 . . . . 0.0 110.431 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -110.22 134.93 51.73 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 166.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -139.03 140.54 38.15 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 125.919 1.687 . . . . 0.0 111.648 -167.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 13.3 p -121.4 52.04 1.25 Allowed 'General case' 0 CA--C 1.543 0.699 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 177.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -147.03 1.81 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -177.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.11 176.07 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.858 1.663 . . . . 0.0 110.206 169.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.581 ' H ' ' HB3' ' A' ' 111' ' ' SER . 90.4 p -154.84 164.28 39.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 126.647 1.979 . . . . 0.0 112.066 171.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.9 mp -78.58 67.85 4.43 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.17 2.188 . . . . 0.0 108.534 177.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -128.23 -5.8 5.44 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 -168.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.68 -24.88 3.57 Favored Glycine 0 N--CA 1.472 1.046 0 CA-C-N 120.492 1.496 . . . . 0.0 116.427 169.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -94.22 -100.82 0.15 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 126.286 1.834 . . . . 0.0 107.711 -169.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -83.67 2.27 38.42 Favored 'General case' 0 C--N 1.323 -0.568 0 O-C-N 120.009 -1.682 . . . . 0.0 112.321 -174.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.581 ' HB3' ' H ' ' A' ' 105' ' ' SER . 39.4 m -125.11 -120.08 0.27 Allowed 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 115.864 1.801 . . . . 0.0 115.864 -169.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 42.2 pt -125.05 172.41 12.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 O-C-N 119.953 -1.717 . . . . 0.0 109.027 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 3.1 mm 76.68 147.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 128.657 2.783 . . . . 0.0 105.951 -162.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.48 -51.6 4.23 Favored Glycine 0 C--O 1.222 -0.626 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.62 -177.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 40.2 mtt180 -71.41 178.33 3.49 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 127.541 2.336 . . . . 0.0 110.191 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.517 ' HG1' ' ND2' ' A' ' 53' ' ' ASN . 29.9 m -138.91 124.99 20.02 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.862 0.865 . . . . 0.0 111.609 -169.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 47.4 tp -92.24 115.1 27.79 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 125.367 1.467 . . . . 0.0 110.103 178.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 15.0 p -102.45 140.36 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 124.597 1.159 . . . . 0.0 109.549 171.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -113.86 142.91 24.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.977 1.711 . . . . 0.0 107.681 171.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -118.72 148.2 43.02 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.91 2.084 . . . . 0.0 111.105 -168.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -74.6 -20.16 60.03 Favored 'General case' 0 CA--C 1.541 0.624 0 O-C-N 120.518 -1.364 . . . . 0.0 114.67 -168.29 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -125.38 171.19 10.65 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 119.82 -1.8 . . . . 0.0 112.283 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.2 139.9 51.25 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 124.714 1.205 . . . . 0.0 111.951 -175.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -87.76 136.83 32.79 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 123.869 0.867 . . . . 0.0 109.747 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.85 -37.23 76.06 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.726 1.211 . . . . 0.0 110.102 173.074 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 63.16 69.81 0.56 Allowed 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 124.999 1.32 . . . . 0.0 108.399 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.31 -109.87 0.42 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 117.055 1.582 . . . . 0.0 117.055 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.16 36.06 0.14 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 128.545 2.738 . . . . 0.0 111.754 -167.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -48.9 -31.39 10.24 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.482 1.991 . . . . 0.0 117.976 -168.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 167.35 2.78 0.03 OUTLIER Glycine 0 N--CA 1.476 1.322 0 N-CA-C 118.249 2.06 . . . . 0.0 118.249 178.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -146.22 -170.43 3.49 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 119.088 1.444 . . . . 0.0 111.747 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -70.58 -56.91 5.41 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.411 1.085 . . . . 0.0 109.57 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.413 ' H ' ' CD ' ' A' ' 133' ' ' GLU . 1.2 mp0 -57.42 -28.12 62.99 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.876 1.67 . . . . 0.0 111.675 -174.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 42.8 m -46.25 -37.66 7.52 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 126.124 1.769 . . . . 0.0 112.789 171.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -111.92 -33.88 6.16 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -66.81 -24.22 66.15 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.0 0.92 . . . . 0.0 113.076 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 27.7 p -130.36 -32.68 1.74 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.885 1.674 . . . . 0.0 114.673 173.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.29 10.0 40.2 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -163.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 63.85 11.7 6.17 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.981 2.112 . . . . 0.0 114.483 177.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.0 19.07 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 117.326 2.343 . . . . 0.0 117.326 -167.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.76 -43.48 2.16 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 128.473 2.94 . . . . 0.0 115.266 168.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.5 t -168.69 169.34 10.17 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 118.512 1.156 . . . . 0.0 113.901 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.7 ptt-85 -71.5 158.96 35.33 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.168 1.387 . . . . 0.0 111.01 168.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 2.1 tm? -142.09 -103.31 0.14 Allowed 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 169.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -103.68 160.46 14.74 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.248 1.019 . . . . 0.0 111.471 172.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.7 p -142.35 140.43 32.09 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.165 2.186 . . . . 0.0 108.898 -177.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.25 135.64 4.62 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 118.048 1.979 . . . . 0.0 118.048 -175.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -75.02 139.52 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.513 1.125 . . . . 0.0 109.416 -178.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.9 mm -87.88 107.55 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 122.572 0.349 . . . . 0.0 110.919 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.71 -171.79 14.15 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.71 1.148 . . . . 0.0 113.23 173.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.43 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.2 pp -133.01 129.49 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 N-CA-C 114.989 1.477 . . . . 0.0 114.989 -173.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.5 -161.64 0.89 Allowed 'General case' 0 CA--C 1.545 0.75 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 165.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 . . . . . 0 N--CA 1.475 0.804 0 C-N-CA 131.6 3.96 . . . . 0.0 108.565 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.415 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -86.84 108.72 18.88 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 172.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttmm -97.16 123.34 40.9 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.024 -173.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -93.63 175.65 6.66 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.634 1.346 . . . . 0.0 114.634 179.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.92 103.65 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 128.621 2.769 . . . . 0.0 106.427 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.13 122.06 24.46 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.533 -0.729 . . . . 0.0 109.746 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.417 HG22 HD22 ' A' ' 53' ' ' ASN . 22.8 t -88.49 63.14 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 124.171 0.988 . . . . 0.0 108.802 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.335 1.3 pt? -82.85 79.04 9.35 Favored 'General case' 0 N--CA 1.477 0.907 0 O-C-N 121.272 -0.892 . . . . 0.0 113.075 -171.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . 0.42 ' HZ1' ' CG ' ' A' ' 11' ' ' ASP . 15.1 tttm -117.47 129.76 56.02 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 -173.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.12 158.08 19.01 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 165.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.476 ' CG ' ' HZ2' ' A' ' 9' ' ' LYS . 5.2 m-20 -72.1 92.45 1.33 Allowed 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 128.637 2.775 . . . . 0.0 109.246 -178.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.19 -153.61 21.95 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 127.102 2.286 . . . . 0.0 111.474 -176.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -86.1 7.66 4.88 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 125.0 3.8 . . . . 0.0 114.249 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -105.62 108.92 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 C-N-CA 125.146 1.378 . . . . 0.0 108.509 -177.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -159.7 166.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.668 1.187 . . . . 0.0 111.421 176.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.46 178.25 29.75 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 124.205 0.907 . . . . 0.0 113.862 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.0 pt -123.8 137.33 57.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 128.449 2.699 . . . . 0.0 109.726 171.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mm -136.98 113.12 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.534 1.061 . . . . 0.0 109.457 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -113.24 108.65 17.56 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.757 1.623 . . . . 0.0 112.501 -164.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -92.44 104.01 16.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.539 1.935 . . . . 0.0 110.281 -176.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -84.25 103.28 13.31 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.6 1.56 . . . . 0.0 110.781 172.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -97.69 119.09 35.64 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 121.814 0.816 . . . . 0.0 110.931 173.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -64.13 -42.85 96.66 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.09 1.756 . . . . 0.0 113.268 175.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -157.17 155.37 30.83 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 126.016 1.726 . . . . 0.0 111.596 168.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.7 p -45.05 -3.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 1 C-N-CA 131.739 4.016 . . . . 0.0 118.567 -171.235 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -157.72 20.9 0.27 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.661 1.985 . . . . 0.0 111.444 -168.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.24 173.67 15.64 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.312 1.91 . . . . 0.0 112.563 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -67.03 168.67 16.72 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.578 2.852 . . . . 0.0 111.401 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -138.88 133.5 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 122.744 0.418 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.8 mttp -92.41 124.22 36.3 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.28 0.562 . . . . 0.0 109.832 169.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.5 t -120.56 86.58 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 127.995 2.518 . . . . 0.0 108.472 -170.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -110.07 168.7 9.24 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 121.2 -0.938 . . . . 0.0 112.281 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.46 -159.5 28.44 Favored Glycine 0 N--CA 1.462 0.432 0 O-C-N 120.973 -1.079 . . . . 0.0 111.869 174.304 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -156.33 154.1 30.05 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -176.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.25 124.77 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.122 0.969 . . . . 0.0 109.997 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -119.39 146.58 45.23 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.841 1.257 . . . . 0.0 109.652 -178.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.38 10.66 38.16 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 124.916 1.246 . . . . 0.0 113.469 -169.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 76.8 mt -84.98 167.16 16.12 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.105 1.362 . . . . 0.0 111.651 168.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -94.78 156.5 16.35 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 164.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -59.98 148.62 34.69 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 123.727 0.811 . . . . 0.0 112.27 -177.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.67 -178.54 33.85 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 124.234 0.921 . . . . 0.0 113.506 -175.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -60.7 144.92 51.14 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 127.648 2.379 . . . . 0.0 114.013 -173.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -145.65 127.88 15.75 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 127.692 2.397 . . . . 0.0 109.985 175.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.26 158.09 52.35 Favored Glycine 0 N--CA 1.474 1.175 0 CA-C-N 119.239 0.927 . . . . 0.0 112.156 173.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -158.37 139.8 13.46 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.201 2.2 . . . . 0.0 112.061 166.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 19.1 p-80 -149.83 146.53 27.19 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 120.905 -1.122 . . . . 0.0 111.825 -176.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -91.4 138.51 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 124.568 1.147 . . . . 0.0 109.175 178.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -105.83 153.04 22.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 110.079 -178.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -67.68 12.04 0.12 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.732 1.151 . . . . 0.0 113.479 178.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -140.59 125.04 17.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 O-C-N 120.031 -1.668 . . . . 0.0 108.932 -168.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.56 -3.18 61.96 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 124.616 1.103 . . . . 0.0 114.33 170.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -75.5 123.09 24.87 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 118.135 0.968 . . . . 0.0 109.93 -169.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.87 20.48 3.83 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 114.787 1.402 . . . . 0.0 114.787 164.452 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.311 14.9 t -127.04 -21.41 3.98 Favored 'General case' 0 C--N 1.324 -0.543 0 C-N-CA 123.227 0.611 . . . . 0.0 112.004 -166.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.2 9.43 3.78 Favored 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 122.206 1.003 . . . . 0.0 110.313 162.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 55.21 -105.17 0.35 Allowed Glycine 0 C--N 1.341 0.857 0 C-N-CA 127.406 2.431 . . . . 0.0 113.528 168.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.2 m -72.09 -11.06 60.58 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -111.95 28.24 8.93 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.676 1.19 . . . . 0.0 111.729 168.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.3 p -120.99 -161.3 0.89 Allowed 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.847 1.659 . . . . 0.0 112.734 175.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 62.79 -82.92 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 128.824 2.85 . . . . 0.0 112.803 -175.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.39 176.78 47.51 Favored Glycine 0 CA--C 1.545 1.947 0 C-N-CA 125.094 1.33 . . . . 0.0 114.582 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -102.42 179.46 0.15 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 124.722 3.614 . . . . 0.0 113.576 -177.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.589 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -72.75 74.7 1.12 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.649 3.18 . . . . 0.0 111.985 172.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -30.21 132.96 0.07 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 129.137 2.975 . . . . 0.0 115.312 169.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -122.86 59.27 12.9 Favored Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -172.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -62.85 -16.69 55.3 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 122.755 2.303 . . . . 0.0 113.911 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.81 -5.76 54.24 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.034 1.334 . . . . 0.0 113.324 169.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t 65.16 50.27 1.85 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 127.966 2.507 . . . . 0.0 112.885 178.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.6 mtp180 -118.02 176.21 5.31 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 124.94 1.296 . . . . 0.0 112.86 -172.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.3 mptm? -95.41 175.93 6.38 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.698 2.399 . . . . 0.0 109.441 164.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -62.7 157.75 20.19 Favored 'General case' 0 CA--C 1.539 0.531 0 O-C-N 120.918 -1.114 . . . . 0.0 111.009 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -176.52 -175.79 44.15 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 114.914 0.726 . . . . 0.0 114.914 174.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.65 -120.89 0.98 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 125.27 1.414 . . . . 0.0 113.988 169.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -62.52 -16.35 51.64 Favored 'Trans proline' 0 CA--C 1.54 0.793 0 C-N-CA 123.855 3.037 . . . . 0.0 115.259 -173.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.75 -4.15 19.7 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.578 1.151 . . . . 0.0 112.988 169.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -159.15 110.47 2.08 Favored 'General case' 0 CA--C 1.543 0.706 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 -167.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -40.88 -10.7 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 131.241 3.816 . . . . 0.0 116.76 168.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.69 -77.44 0.09 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 120.067 1.303 . . . . 0.0 109.315 -177.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.2 ttp-105 56.53 77.25 0.26 Allowed 'General case' 0 N--CA 1.475 0.818 0 O-C-N 120.79 -1.194 . . . . 0.0 113.141 164.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.3 m170 -48.32 164.46 0.05 Allowed 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.709 -1.244 . . . . 0.0 114.019 172.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.85 -14.16 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.23 13.59 31.03 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.957 1.742 . . . . 0.0 116.75 176.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -100.81 103.86 15.09 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 120.801 2.3 . . . . 0.0 113.414 -171.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 42.9 mt -96.64 41.22 1.11 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.528 -1.358 . . . . 0.0 112.417 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.12 -129.74 43.14 Favored Glycine 0 CA--C 1.537 1.412 0 O-C-N 119.713 -1.867 . . . . 0.0 112.361 -174.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -147.98 161.01 42.21 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.877 0.871 . . . . 0.0 112.142 175.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.4 124.07 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 127.778 2.431 . . . . 0.0 110.906 -172.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.2 m -95.78 129.86 42.88 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.386 0.674 . . . . 0.0 109.666 174.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.32 148.47 25.05 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.56 162.53 15.62 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 128.677 2.791 . . . . 0.0 110.01 169.058 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -40.79 -21.23 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 129.421 3.088 . . . . 0.0 117.609 177.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -75.73 0.16 18.82 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.54 -1.35 . . . . 0.0 112.166 171.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.51 24.41 76.83 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 125.895 1.712 . . . . 0.0 112.602 -170.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.2 p -116.8 128.14 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 CA-C-N 118.785 1.293 . . . . 0.0 113.156 -177.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.1 117.05 29.62 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 166.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -98.25 130.93 44.95 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 123.793 0.837 . . . . 0.0 109.009 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.69 143.0 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 117.011 2.226 . . . . 0.0 117.011 -174.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 77.8 p -143.94 82.36 1.71 Allowed 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 126.352 1.861 . . . . 0.0 111.533 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.8 mt -97.69 157.61 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 120.594 -1.316 . . . . 0.0 110.071 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -144.69 145.59 31.8 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 127.642 2.377 . . . . 0.0 107.463 168.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.34 159.95 40.34 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.836 1.255 . . . . 0.0 111.336 173.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 35.7 p -127.37 46.08 2.6 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.472 1.509 . . . . 0.0 112.955 -168.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 23.1 m -145.87 15.12 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.226 1.011 . . . . 0.0 113.574 -176.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -148.78 165.99 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.107 2.163 . . . . 0.0 109.386 -173.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 18.1 m -157.39 168.0 28.63 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 125.066 1.346 . . . . 0.0 109.983 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -98.73 80.03 2.5 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.99 1.716 . . . . 0.0 107.723 -171.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -122.14 -18.91 6.74 Favored 'General case' 0 CA--C 1.567 1.628 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -175.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.06 0.71 89.26 Favored Glycine 0 N--CA 1.492 2.408 0 O-C-N 118.554 -2.591 . . . . 0.0 117.778 166.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.66 -88.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.918 2.487 . . . . 0.0 108.569 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 86.8 m-70 -115.15 -9.06 12.34 Favored 'General case' 0 CA--C 1.559 1.299 1 C-N-CA 132.715 4.406 . . . . 0.0 111.113 168.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 48.8 m -82.46 -166.05 1.18 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.63 1.972 . . . . 0.0 110.992 -174.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.28 162.3 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.834 0 O-C-N 118.603 -2.56 . . . . 0.0 108.637 169.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 97.29 132.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.278 1 C-N-CA 133.75 4.82 . . . . 0.0 108.291 -168.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.22 5.51 34.88 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-O 117.565 -1.686 . . . . 0.0 115.815 176.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 62.2 mmt-85 -77.61 -177.08 4.6 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 127.138 2.175 . . . . 0.0 110.797 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 39.5 m -128.26 141.12 51.55 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 116.446 -1.74 . . . . 0.0 109.945 173.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.7 tp -113.19 111.22 21.71 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.846 1.259 . . . . 0.0 111.208 171.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.9 p -88.56 149.33 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 124.264 1.026 . . . . 0.0 109.563 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 33.2 t -121.77 142.23 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 168.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -99.26 136.85 38.61 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.324 2.25 . . . . 0.0 111.379 -173.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -75.97 -10.86 59.77 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 120.419 -1.426 . . . . 0.0 113.796 -171.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 50.8 mttp -114.95 172.95 6.74 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 126.26 1.824 . . . . 0.0 111.959 169.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.99 163.59 1.94 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.809 1.244 . . . . 0.0 112.188 169.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -121.03 135.07 55.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 127.299 2.24 . . . . 0.0 107.209 175.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -73.03 -33.24 65.6 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 118.223 0.465 . . . . 0.0 112.216 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 29.3 mt 69.19 50.39 0.57 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.872 1.669 . . . . 0.0 114.223 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.21 -26.83 8.47 Favored Glycine 0 N--CA 1.474 1.211 0 N-CA-C 119.924 2.73 . . . . 0.0 119.924 163.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 8.4 pttm -163.93 99.41 0.87 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 120.1 1.95 . . . . 0.0 114.826 176.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.69 -7.71 56.45 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.938 1.732 . . . . 0.0 114.042 170.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 101.11 -8.64 57.54 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 125.497 1.522 . . . . 0.0 113.736 -170.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 p-10 -117.98 153.21 34.04 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 128.443 2.697 . . . . 0.0 109.611 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -66.41 -48.67 69.33 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 114.108 1.151 . . . . 0.0 114.108 -167.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.08 -33.1 72.81 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.837 1.255 . . . . 0.0 111.943 -175.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 61.8 m -53.45 -31.23 44.54 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 119.724 1.147 . . . . 0.0 112.574 168.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 1.1 p -85.03 -46.99 10.66 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.94 1.296 . . . . 0.0 112.513 172.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -70.49 -35.63 73.36 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.807 1.243 . . . . 0.0 113.523 -173.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 37.1 p -135.1 -28.78 1.15 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.265 1.426 . . . . 0.0 113.471 -175.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' B' ' 140' ' ' ALA . . . 108.95 0.54 31.83 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 118.44 -1.2 . . . . 0.0 113.538 -171.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 66.9 -4.39 0.79 Allowed 'General case' 0 N--CA 1.482 1.14 0 CA-C-N 119.492 1.646 . . . . 0.0 113.78 175.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . 0.411 ' H ' ' C ' ' B' ' 138' ' ' GLY . . . -46.88 5.11 0.0 OUTLIER 'General case' 0 CA--C 1.565 1.545 1 C-N-CA 132.551 4.34 . . . . 0.0 121.497 -165.52 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.11 -69.9 3.21 Favored Glycine 0 CA--C 1.526 0.735 0 O-C-N 120.083 -1.636 . . . . 0.0 115.288 168.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.4 t -164.71 -152.4 0.17 Allowed 'General case' 0 N--CA 1.477 0.92 0 O-C-N 121.253 -1.145 . . . . 0.0 112.157 -171.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.65 148.87 29.81 Favored 'General case' 0 N--CA 1.47 0.557 0 O-C-N 120.427 -1.421 . . . . 0.0 113.991 176.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.465 ' CG ' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -97.85 -101.45 0.2 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.095 1.758 . . . . 0.0 110.099 169.54 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . 0.465 ' H ' ' CG ' ' B' ' 144' ' ' LEU . . . -91.3 166.73 12.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.986 1.714 . . . . 0.0 111.05 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -157.08 143.19 17.91 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 127.181 2.192 . . . . 0.0 108.545 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.76 171.08 40.1 Favored Glycine 0 N--CA 1.47 0.937 0 N-CA-C 117.354 1.702 . . . . 0.0 117.354 169.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -84.85 146.72 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.106 2.163 . . . . 0.0 110.577 -169.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 46.6 mm -86.43 103.09 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 125.649 1.58 . . . . 0.0 111.35 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.82 175.82 22.57 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.737 1.637 . . . . 0.0 113.134 171.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' B' ' 4' ' ' ALA 0.296 1.3 pp -114.78 139.21 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 177.762 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.4 159.66 30.27 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-O 122.951 1.358 . . . . 0.0 108.457 172.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 113.966 -1.47 . . . . 0.0 110.098 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.529 -0.748 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.5 p -75.76 109.97 9.79 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 128.501 2.721 . . . . 0.0 108.888 -171.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptpp? -105.25 135.87 45.81 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -87.18 161.83 17.83 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 164.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 t -145.1 149.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 CA-C-N 119.705 1.139 . . . . 0.0 110.045 173.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.16 109.16 12.53 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.452 1.501 . . . . 0.0 108.187 166.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -82.61 112.07 19.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 168.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -79.36 99.35 7.1 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -156.13 127.18 6.97 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.586 0.754 . . . . 0.0 111.904 177.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.67 -104.81 1.28 Allowed Glycine 0 CA--C 1.527 0.821 0 N-CA-C 105.277 -3.129 . . . . 0.0 105.277 164.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -156.33 129.64 8.13 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.628 1.571 . . . . 0.0 108.352 167.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 124.22 168.87 12.98 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.61 2.052 . . . . 0.0 110.519 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 23.27 0.19 Allowed 'Trans proline' 0 CA--C 1.546 1.089 1 C-N-CA 125.745 4.297 . . . . 0.0 116.39 -169.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -117.26 111.87 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -157.27 158.24 35.74 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.324 -174.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.68 179.18 37.23 Favored Glycine 0 CA--C 1.508 -0.371 0 C-N-CA 126.129 1.823 . . . . 0.0 113.494 176.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -134.04 142.02 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.295 1.438 . . . . 0.0 109.054 168.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.0 mm -133.23 111.23 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 168.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -77.68 150.49 34.51 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.075 1.75 . . . . 0.0 110.934 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -135.43 78.52 1.73 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.765 2.026 . . . . 0.0 108.542 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -81.74 117.64 22.21 Favored 'General case' 0 C--N 1.34 0.182 0 CA-C-O 121.863 0.839 . . . . 0.0 113.157 -177.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp60 -105.57 167.68 9.6 Favored 'General case' 0 CA--C 1.549 0.942 0 CA-C-O 122.951 1.358 . . . . 0.0 109.424 169.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.504 ' HZ2' ' HG2' ' A' ' 28' ' ' PRO . 0.0 OUTLIER -132.89 -28.09 1.6 Allowed 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 130.088 3.355 . . . . 0.0 111.725 -177.807 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.421 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 3.3 mp0 -101.97 -132.13 0.27 Allowed 'General case' 0 CA--C 1.556 1.201 0 C-N-CA 124.621 1.168 . . . . 0.0 108.497 166.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 t -136.37 -82.04 0.39 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 120.249 -1.532 . . . . 0.0 107.681 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -76.24 72.16 3.0 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.069 0.85 . . . . 0.0 112.356 169.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.46 15.93 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 127.057 2.265 . . . . 0.0 111.16 171.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.504 ' HG2' ' HZ2' ' A' ' 23' ' ' LYS . 55.5 Cg_endo -70.3 158.4 56.37 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 123.395 2.73 . . . . 0.0 111.567 -177.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.7 t -129.14 136.16 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.24 0.616 . . . . 0.0 110.67 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.465 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 62.0 mttm -87.02 119.75 27.56 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 122.394 1.092 . . . . 0.0 110.827 176.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.9 t -103.1 125.3 57.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 128.82 2.848 . . . . 0.0 109.332 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.7 p90 -157.14 161.85 39.37 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 169.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.77 171.99 13.03 Favored Glycine 0 N--CA 1.466 0.669 0 C-N-CA 124.833 1.206 . . . . 0.0 112.11 -176.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.3 p -132.33 143.33 49.79 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 -167.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mm -116.73 126.37 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 124.869 1.268 . . . . 0.0 111.404 171.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 54.3 tttt -127.79 146.2 50.67 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.695 1.598 . . . . 0.0 111.755 -173.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.02 -34.57 3.82 Favored Glycine 0 N--CA 1.477 1.423 0 C-N-CA 126.347 1.927 . . . . 0.0 111.197 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.58 129.06 38.59 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 165.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -69.33 169.54 12.07 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 118.615 0.643 . . . . 0.0 110.998 171.33 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -54.02 158.79 2.0 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.325 1.85 . . . . 0.0 115.475 -171.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.27 179.11 35.61 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.333 0.968 . . . . 0.0 112.783 -173.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.8 mt -64.05 137.23 57.89 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 126.981 2.112 . . . . 0.0 111.935 -174.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -133.54 131.63 39.98 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.613 1.165 . . . . 0.0 108.472 168.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.36 157.31 46.13 Favored Glycine 0 N--CA 1.46 0.248 0 CA-C-O 118.994 -0.892 . . . . 0.0 111.277 -174.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -155.46 141.91 18.64 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.804 0.811 . . . . 0.0 112.763 169.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.9 p-80 -152.58 168.2 26.36 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 123.171 0.588 . . . . 0.0 109.838 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.27 135.57 41.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 123.964 0.905 . . . . 0.0 108.735 175.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -71.73 134.31 46.16 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 170.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -76.4 47.76 0.49 Allowed 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.225 1.194 . . . . 0.0 114.225 -170.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 173.8 156.99 0.13 Allowed 'General case' 0 C--O 1.237 0.425 0 C-N-CA 129.649 3.18 . . . . 0.0 108.35 177.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.25 0.46 20.76 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 117.823 1.889 . . . . 0.0 117.823 -178.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -67.67 42.86 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.535 1.934 . . . . 0.0 115.248 171.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -166.54 22.16 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -163.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.4 t -29.14 74.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 129.678 3.191 . . . . 0.0 117.407 173.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 159.35 -14.54 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.05 0 C-N-CA 130.775 3.63 . . . . 0.0 111.749 -169.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.77 -127.78 25.75 Favored Glycine 0 C--N 1.345 1.034 0 C-N-CA 124.858 1.218 . . . . 0.0 112.15 167.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 12.4 t -57.69 -10.86 1.77 Allowed 'General case' 0 CA--C 1.552 1.028 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.4 t -108.11 23.13 14.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.229 1.412 . . . . 0.0 113.576 171.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.0 m -152.05 -20.31 0.18 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 116.819 2.155 . . . . 0.0 116.819 169.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -153.41 162.93 40.78 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 120.644 1.565 . . . . 0.0 111.799 169.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.89 160.86 52.07 Favored Glycine 0 CA--C 1.539 1.586 0 CA-C-O 119.359 -0.69 . . . . 0.0 112.579 176.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -70.08 172.41 13.0 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 124.152 3.235 . . . . 0.0 111.177 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -15.86 89.18 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 118.865 2.913 . . . . 0.0 118.865 176.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -67.41 98.45 0.65 Allowed 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -75.63 102.42 0.72 Allowed Pre-proline 0 CA--C 1.548 0.871 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -165.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -72.13 -33.3 9.63 Favored 'Trans proline' 0 C--N 1.355 0.915 0 C-N-CA 123.252 2.635 . . . . 0.0 113.086 -168.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.98 -4.27 49.15 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.655 1.182 . . . . 0.0 112.656 175.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.4 t 56.5 49.12 15.41 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.014 1.726 . . . . 0.0 112.823 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 -103.72 174.45 5.86 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.789 1.236 . . . . 0.0 113.365 -173.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 ptmm? -74.22 164.59 26.43 Favored 'General case' 0 CA--C 1.547 0.837 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 161.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -80.14 168.76 18.72 Favored 'General case' 0 CA--C 1.543 0.682 0 O-C-N 121.086 -1.009 . . . . 0.0 112.365 173.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 131.51 -154.95 21.12 Favored Glycine 0 C--N 1.338 0.692 0 C-N-CA 125.818 1.675 . . . . 0.0 113.022 167.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.25 -15.2 0.4 Allowed Glycine 0 CA--C 1.539 1.558 0 N-CA-C 121.331 3.293 . . . . 0.0 121.331 166.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -112.43 -12.11 0.03 OUTLIER 'Trans proline' 0 CA--C 1.545 1.03 0 CA-C-N 121.87 2.835 . . . . 0.0 112.939 168.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.461 ' HE3' ' HB2' ' A' ' 128' ' ' LYS . 0.0 OUTLIER -126.56 -3.43 6.67 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 125.569 1.548 . . . . 0.0 112.666 175.625 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -108.51 175.06 5.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 128.53 2.732 . . . . 0.0 109.548 -175.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -116.85 -9.65 11.16 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.769 2.028 . . . . 0.0 112.629 -168.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -122.98 -59.16 1.61 Allowed 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -165.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 46.33 118.55 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 117.881 2.548 . . . . 0.0 117.881 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -58.4 165.57 2.04 Favored 'General case' 0 N--CA 1.48 1.071 0 O-C-N 119.37 -2.081 . . . . 0.0 111.583 169.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.313 7.1 p -77.19 -18.97 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 CA-C-N 120.116 1.326 . . . . 0.0 113.078 -176.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -94.16 27.78 12.4 Favored Glycine 0 CA--C 1.542 1.75 0 C-N-CA 125.458 1.504 . . . . 0.0 114.937 167.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -107.28 131.58 54.05 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 120.417 2.108 . . . . 0.0 115.088 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 65.2 mt -115.05 178.81 4.15 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.241 1.816 . . . . 0.0 109.818 167.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -89.53 -121.68 2.1 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.435 1.493 . . . . 0.0 114.511 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.8 m-80 -127.04 154.25 44.9 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.071 1.348 . . . . 0.0 111.65 172.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.03 102.85 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 127.347 2.259 . . . . 0.0 109.709 168.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 m -89.63 126.84 35.78 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 124.744 1.218 . . . . 0.0 110.018 -179.077 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.21 150.47 21.97 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -80.9 160.0 24.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 127.301 2.24 . . . . 0.0 109.73 167.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.3 pttp -47.98 -19.35 0.24 Allowed 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 128.185 2.594 . . . . 0.0 115.811 169.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -74.64 -11.68 60.25 Favored 'General case' 0 CA--C 1.547 0.863 0 O-C-N 120.753 -1.217 . . . . 0.0 111.784 171.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.07 15.09 55.08 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.015 2.245 . . . . 0.0 113.281 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.8 p -117.38 130.48 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.092 1.446 . . . . 0.0 113.322 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.36 97.34 7.84 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 165.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -89.68 148.93 23.01 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.961 0.886 . . . . 0.0 110.289 168.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.53 146.17 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.105 -1.407 . . . . 0.0 114.433 -169.073 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 76.7 p -160.23 90.43 0.89 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.384 1.074 . . . . 0.0 112.623 -176.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 175.77 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 C-N-CA 125.918 1.687 . . . . 0.0 113.236 -174.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.465 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 34.8 tt0 -144.75 146.9 32.38 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 128.302 2.641 . . . . 0.0 106.693 168.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -143.05 155.94 44.73 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 122.053 0.93 . . . . 0.0 111.052 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.6 p -121.08 64.71 0.87 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 127.069 2.148 . . . . 0.0 114.158 -166.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -156.83 -46.82 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 O-C-N 121.033 -1.042 . . . . 0.0 109.717 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.39 150.43 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 168.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -148.43 161.15 42.18 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.486 1.514 . . . . 0.0 111.259 -169.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 9.4 mt -78.04 97.85 5.53 Favored 'General case' 0 C--N 1.345 0.387 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 170.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.5 t -155.98 6.4 0.2 Allowed 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 -170.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.3 -119.88 5.04 Favored Glycine 0 C--N 1.342 0.865 0 CA-C-N 120.625 1.557 . . . . 0.0 109.713 168.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -62.41 -26.59 68.56 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 125.532 1.533 . . . . 0.0 111.209 -171.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.2 m170 -79.45 -24.25 42.56 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.302 1.041 . . . . 0.0 113.446 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.6 m -166.92 -110.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.6 mm -88.8 142.3 13.07 Favored 'Isoleucine or valine' 0 C--N 1.34 0.171 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 -176.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 92.19 133.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 131.526 3.93 . . . . 0.0 106.73 -164.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.28 15.27 81.69 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 117.211 -1.883 . . . . 0.0 115.823 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 26.5 mtt85 -117.05 176.92 4.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-N 120.426 2.113 . . . . 0.0 110.777 171.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -119.75 110.32 16.66 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 120.212 1.369 . . . . 0.0 112.104 -175.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 14.4 tp -90.1 127.41 36.08 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.601 1.161 . . . . 0.0 111.137 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.3 p -116.58 139.55 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.122 1.369 . . . . 0.0 110.491 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.408 HG23 ' H ' ' A' ' 145' ' ' ALA . 15.4 m -101.44 152.88 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 123.509 0.724 . . . . 0.0 109.436 167.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -119.45 145.68 46.06 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.665 1.586 . . . . 0.0 112.08 -170.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -71.22 -24.46 62.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.674 -1.266 . . . . 0.0 114.147 -171.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.5 mptt -112.78 177.16 4.73 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.321 1.449 . . . . 0.0 110.344 168.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.06 146.8 10.58 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.535 1.934 . . . . 0.0 111.45 168.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -83.86 140.86 31.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 161.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.1 -49.79 33.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 174.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.5 mt 90.64 38.38 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 129.413 3.085 . . . . 0.0 113.292 175.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.82 26.68 8.34 Favored Glycine 0 N--CA 1.468 0.799 0 N-CA-C 117.73 1.852 . . . . 0.0 117.73 167.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.461 ' HB2' ' HE3' ' A' ' 75' ' ' LYS . 3.7 tttt -155.74 10.09 0.28 Allowed 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 117.131 2.271 . . . . 0.0 117.131 -175.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -67.74 117.55 8.87 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 107.051 -2.42 . . . . 0.0 107.051 167.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -69.89 43.14 0.49 Allowed Glycine 0 N--CA 1.477 1.375 0 C-N-CA 126.561 2.029 . . . . 0.0 115.473 -174.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -102.85 -82.62 0.49 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.302 1.841 . . . . 0.0 110.418 176.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 177.17 -69.31 0.01 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 131.154 3.781 . . . . 0.0 106.329 -173.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.66 -37.16 62.88 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.731 1.612 . . . . 0.0 114.675 -177.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.78 -18.6 62.94 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 119.119 -2.238 . . . . 0.0 114.542 179.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -99.34 -10.18 22.62 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 124.0 0.92 . . . . 0.0 113.073 170.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.2 mtpt -81.54 -75.55 0.28 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.5 1.52 . . . . 0.0 111.499 169.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 58.5 p -94.03 -28.16 15.9 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 120.121 1.328 . . . . 0.0 113.571 -177.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.45 -14.26 30.3 Favored Glycine 0 N--CA 1.468 0.813 0 CA-C-N 119.44 1.018 . . . . 0.0 110.925 -166.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 61.04 30.69 19.68 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 118.196 0.998 . . . . 0.0 112.714 165.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.9 28.36 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 128.582 2.753 . . . . 0.0 117.969 -167.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 67.38 -13.44 0.57 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 119.884 2.713 . . . . 0.0 119.884 167.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . 0.265 16.7 t 146.31 -171.56 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 130.268 3.427 . . . . 0.0 113.23 169.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.59 178.1 6.95 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 128.228 2.611 . . . . 0.0 114.587 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 17.9 tp -162.74 -115.6 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.653 1.581 . . . . 0.0 109.657 168.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.408 ' H ' HG23 ' A' ' 119' ' ' VAL . . . -99.24 169.98 8.99 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 125.895 1.678 . . . . 0.0 111.506 172.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.3 t -156.64 152.07 26.69 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.782 1.233 . . . . 0.0 111.872 -171.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.05 142.31 8.41 Favored Glycine 0 N--CA 1.473 1.138 0 C-N-CA 125.43 1.491 . . . . 0.0 113.189 178.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 72.1 t -80.73 150.05 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 CA-C-N 118.602 1.201 . . . . 0.0 111.282 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.6 mt -88.1 103.25 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 O-C-N 120.14 -1.6 . . . . 0.0 109.951 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.75 168.84 14.06 Favored Glycine 0 N--CA 1.473 1.142 0 C-N-CA 124.239 0.923 . . . . 0.0 113.242 176.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.58 124.04 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 118.847 1.323 . . . . 0.0 113.78 176.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.22 -32.57 13.63 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-O 121.726 0.774 . . . . 0.0 108.927 163.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 . . . . . 0 C--O 1.233 0.2 0 C-N-CA 128.903 2.881 . . . . 0.0 111.174 168.742 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.742 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 76.4 p -92.92 51.57 1.71 Allowed 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -166.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 58.1 mttp -78.12 131.84 37.42 Favored 'General case' 0 N--CA 1.473 0.678 0 O-C-N 119.193 -2.192 . . . . 0.0 114.004 -170.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -123.58 156.42 35.77 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.45 1.5 . . . . 0.0 109.015 169.139 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 38.1 t -140.75 146.85 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 123.495 0.718 . . . . 0.0 110.626 -171.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.63 116.04 19.69 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.057 0.943 . . . . 0.0 112.044 169.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -78.92 103.98 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 168.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.06 114.58 17.07 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtpm? -141.6 172.45 12.67 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 124.584 1.154 . . . . 0.0 111.766 -174.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.45 -59.85 0.68 Allowed Glycine 0 N--CA 1.465 0.626 0 C-N-CA 126.779 2.133 . . . . 0.0 110.059 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.41 59.49 5.45 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.809 1.244 . . . . 0.0 112.844 -168.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.57 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.973 2.702 . . . . 0.0 114.247 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.75 -17.1 37.81 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 123.661 2.907 . . . . 0.0 113.216 -178.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 t -87.61 124.29 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 119.487 1.04 . . . . 0.0 110.314 171.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.27 165.36 35.02 Favored 'General case' 0 C--O 1.224 -0.239 0 C-N-CA 123.871 0.868 . . . . 0.0 111.772 169.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.98 -179.22 31.76 Favored Glycine 0 N--CA 1.464 0.531 0 N-CA-C 115.664 1.026 . . . . 0.0 115.664 -176.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 10.1 pt -135.15 116.39 19.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 126.827 2.051 . . . . 0.0 107.858 166.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.98 117.86 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 169.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 62.2 m-20 -113.55 130.08 56.43 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.85 1.66 . . . . 0.0 110.852 -173.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -114.4 130.7 56.71 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.466 1.507 . . . . 0.0 110.198 -171.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -122.02 131.37 53.96 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.916 1.687 . . . . 0.0 110.178 172.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -124.62 140.5 52.88 Favored 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.344 -0.847 . . . . 0.0 109.063 167.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -99.57 -24.22 14.82 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 115.128 1.529 . . . . 0.0 115.128 -168.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 46.2 mp0 -143.16 146.96 34.19 Favored 'General case' 0 CA--C 1.512 -0.518 0 C-N-CA 127.911 2.484 . . . . 0.0 106.672 168.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.4 m -61.96 -21.18 64.59 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.452 1.278 . . . . 0.0 114.452 -172.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -107.11 0.17 23.27 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.949 1.7 . . . . 0.0 113.839 170.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.16 170.13 54.38 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.779 1.18 . . . . 0.0 111.358 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -71.66 157.88 54.72 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.267 1.978 . . . . 0.0 110.613 177.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -107.52 134.18 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 125.366 1.467 . . . . 0.0 108.116 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -96.84 126.3 41.9 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 167.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 42.3 t -108.01 124.31 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 125.941 1.697 . . . . 0.0 107.081 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -143.05 170.82 15.0 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.4 -153.5 19.17 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 124.596 1.093 . . . . 0.0 112.337 174.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 58.3 p -153.98 153.63 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 114.805 1.409 . . . . 0.0 114.805 -172.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.4 mp -124.83 133.47 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.808 1.643 . . . . 0.0 107.072 169.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -132.37 146.15 51.76 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.921 0.888 . . . . 0.0 112.778 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.58 -3.74 19.75 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 126.75 2.119 . . . . 0.0 114.582 -173.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.0 mt -74.28 173.5 10.11 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.546 1.138 . . . . 0.0 111.866 177.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.7 t -86.43 154.6 21.04 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 164.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -56.41 142.39 38.64 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 167.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.59 176.63 17.34 Favored Glycine 0 N--CA 1.472 1.038 0 C-N-CA 124.294 0.949 . . . . 0.0 113.451 -175.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.441 HD22 ' H ' ' B' ' 42' ' ' LEU . 1.8 pt? -89.14 126.01 35.28 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.951 1.7 . . . . 0.0 113.422 -169.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -123.18 146.23 47.96 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 127.818 2.447 . . . . 0.0 109.624 -178.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.07 155.97 33.6 Favored Glycine 0 N--CA 1.478 1.45 0 CA-C-N 121.133 1.788 . . . . 0.0 111.252 -177.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -153.81 135.59 14.5 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.658 1.729 . . . . 0.0 113.958 171.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' B' ' 120' ' ' HIS . 0.1 OUTLIER -158.4 159.8 36.16 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.132 0.973 . . . . 0.0 112.867 -178.222 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.68 117.37 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.211 1.404 . . . . 0.0 110.158 -175.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -74.83 -173.54 1.91 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 128.43 2.692 . . . . 0.0 113.649 -169.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -63.29 152.05 38.91 Favored 'General case' 0 CA--C 1.541 0.6 0 O-C-N 120.245 -1.534 . . . . 0.0 112.055 171.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.23 161.23 13.85 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 115.071 1.508 . . . . 0.0 115.071 -168.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 67.37 -79.62 0.16 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -85.79 54.03 2.98 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 123.789 1.757 . . . . 0.0 110.557 -169.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -173.57 8.04 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.836 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 175.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 27.4 p -66.36 44.61 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 119.619 3.192 . . . . 0.0 119.619 -165.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.71 -2.99 31.09 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 125.048 1.339 . . . . 0.0 110.73 165.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.96 -166.19 19.02 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.481 1.991 . . . . 0.0 111.957 -172.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . 0.439 ' C ' ' H ' ' B' ' 59' ' ' SER . 8.4 t -61.59 -14.15 27.9 Favored 'General case' 0 N--CA 1.472 0.662 0 O-C-N 120.673 -1.486 . . . . 0.0 114.122 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 t -76.46 36.81 0.16 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 126.052 1.741 . . . . 0.0 112.54 169.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' SER . . . . . 0.439 ' H ' ' C ' ' B' ' 57' ' ' CYS . 26.4 m 178.07 -53.02 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.972 1 C-N-CA 131.761 4.024 . . . . 0.0 111.807 -176.274 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.3 123.08 16.17 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 116.938 2.199 . . . . 0.0 116.938 -168.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -73.02 -179.77 37.3 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 123.788 0.708 . . . . 0.0 112.009 169.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -60.9 167.65 8.42 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 124.484 3.456 . . . . 0.0 115.072 -165.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.624 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -57.05 86.36 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 127.53 2.332 . . . . 0.0 111.415 175.854 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -52.69 127.23 22.4 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.805 -1.088 . . . . 0.0 112.79 -167.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -117.78 65.77 5.15 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 125.964 1.706 . . . . 0.0 112.953 -168.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -64.05 -15.22 48.03 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.035 2.49 . . . . 0.0 113.618 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -79.32 -7.3 58.22 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.442 1.097 . . . . 0.0 113.118 170.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t 65.46 55.67 1.02 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.881 2.072 . . . . 0.0 112.194 175.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 mtm180 -121.4 178.36 4.83 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 -166.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 mttp -89.81 173.91 8.0 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 127.917 2.487 . . . . 0.0 112.468 169.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -109.14 146.38 34.18 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 117.283 2.327 . . . . 0.0 117.283 -168.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 129.82 -91.7 0.31 Allowed Glycine 0 C--N 1.343 0.967 0 C-N-CA 124.795 1.188 . . . . 0.0 112.468 166.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.62 -28.6 11.19 Favored Glycine 0 CA--C 1.551 2.302 0 N-CA-C 118.635 2.214 . . . . 0.0 118.635 174.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -87.36 -15.18 3.62 Favored 'Trans proline' 0 C--N 1.356 0.966 0 CA-C-N 122.797 3.298 . . . . 0.0 113.176 171.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.21 -48.62 1.45 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.247 1.419 . . . . 0.0 108.994 166.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -55.09 138.41 44.33 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.975 0.893 . . . . 0.0 110.884 171.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -87.93 -6.23 58.15 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 127.464 2.306 . . . . 0.0 113.0 -169.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -119.24 -56.57 2.07 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 115.543 1.683 . . . . 0.0 115.543 -174.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . 0.535 HH21 ' CG1' ' B' ' 103' ' ' VAL 0.278 3.4 ptt180 57.93 136.61 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.906 2.483 . . . . 0.0 115.346 -173.176 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -73.35 166.78 22.54 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 118.725 -2.484 . . . . 0.0 111.107 169.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.46 -31.92 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 120.311 -1.493 . . . . 0.0 113.997 -177.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -100.66 22.24 40.56 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 118.789 -1.006 . . . . 0.0 115.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -96.32 114.21 25.87 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -169.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.0 mt -101.56 171.88 7.3 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 104.425 -2.435 . . . . 0.0 104.425 158.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.63 -98.84 1.18 Allowed Glycine 0 N--CA 1.474 1.169 0 CA-C-N 119.026 0.83 . . . . 0.0 111.858 175.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -142.13 164.09 31.09 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -177.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.43 129.14 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 129.264 3.026 . . . . 0.0 111.147 -168.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.5 m -100.84 140.55 34.97 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.043 0.937 . . . . 0.0 110.072 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.44 157.86 16.32 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.931 0.892 . . . . 0.0 111.344 167.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -82.11 178.45 8.27 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.14 1.376 . . . . 0.0 112.154 171.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.12 -28.25 68.96 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.594 1.558 . . . . 0.0 113.365 172.048 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -76.42 2.71 12.85 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.336 1.054 . . . . 0.0 110.616 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.27 -0.59 83.83 Favored Glycine 0 C--N 1.342 0.883 0 C-N-CA 127.179 2.323 . . . . 0.0 114.19 172.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.69 132.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 126.107 1.763 . . . . 0.0 113.464 178.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.03 133.9 41.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.786 1.235 . . . . 0.0 108.703 165.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -98.38 118.27 34.66 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 7.5 t -98.43 124.01 51.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.2 173.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -155.1 87.8 1.14 Allowed 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.284 1.434 . . . . 0.0 110.95 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.87 148.64 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 126.441 1.896 . . . . 0.0 112.609 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -112.54 133.1 54.77 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.041 2.536 . . . . 0.0 106.008 168.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.74 130.05 27.12 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 125.238 1.415 . . . . 0.0 111.161 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 25.3 p -113.17 44.26 1.57 Allowed 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -174.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . 0.535 ' CG1' HH21 ' B' ' 79' ' ' ARG 0.315 9.8 p -161.16 -21.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 116.275 1.954 . . . . 0.0 116.275 166.851 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.56 164.45 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 122.189 2.268 . . . . 0.0 109.754 168.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 76.8 p -157.71 159.48 36.93 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 -173.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -92.51 57.13 2.88 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 127.651 2.38 . . . . 0.0 105.484 172.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -116.16 21.17 13.88 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -167.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.48 -53.21 4.65 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-O 117.932 -1.482 . . . . 0.0 115.356 167.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -99.41 -103.07 0.22 Allowed 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.282 1.515 . . . . 0.0 110.738 -167.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 20.3 m170 -76.32 8.62 3.22 Favored 'General case' 0 CA--C 1.551 1.016 0 O-C-N 119.357 -2.089 . . . . 0.0 114.418 -167.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 69.8 p -93.81 -131.03 0.14 Allowed 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 129.084 2.954 . . . . 0.0 114.202 -167.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 14.9 pt -113.76 -15.52 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 121.344 1.884 . . . . 0.0 115.919 175.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.7 mm -54.46 129.79 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 CA-C-N 120.607 1.549 . . . . 0.0 108.299 168.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.15 -2.32 52.06 Favored Glycine 0 CA--C 1.534 1.273 0 CA-C-N 120.199 1.363 . . . . 0.0 115.529 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -87.54 176.5 7.44 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.432 1.893 . . . . 0.0 109.972 169.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.55 109.97 6.6 Favored 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 120.45 1.477 . . . . 0.0 113.319 -169.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 27.4 tp -83.16 120.27 25.57 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 124.051 0.94 . . . . 0.0 109.67 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 p -121.85 139.58 48.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 125.998 1.719 . . . . 0.0 110.024 176.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 t -95.81 166.99 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 124.927 1.291 . . . . 0.0 107.672 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 73.4 m-70 -150.12 130.54 13.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.198 1.799 . . . . 0.0 107.877 -169.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 -53.76 -40.07 65.88 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 121.569 1.986 . . . . 0.0 115.691 -169.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.42 136.37 33.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 120.278 1.399 . . . . 0.0 109.674 175.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.82 159.71 1.6 Allowed 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.187 0.595 . . . . 0.0 110.935 165.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -82.75 146.89 28.75 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-O 123.217 1.484 . . . . 0.0 112.946 -171.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.31 -7.57 53.27 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 114.05 -1.432 . . . . 0.0 113.019 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.1 mt 57.75 55.26 5.6 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 127.163 2.185 . . . . 0.0 113.681 168.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.76 -67.09 0.93 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 175.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 103.85 6.74 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 124.963 1.305 . . . . 0.0 113.659 174.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -103.56 -71.9 0.88 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 107.03 -2.428 . . . . 0.0 107.03 164.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -130.28 -29.5 0.65 Allowed Glycine 0 CA--C 1.536 1.406 0 N-CA-C 119.15 2.42 . . . . 0.0 119.15 -173.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -166.41 173.81 9.6 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 122.036 2.918 . . . . 0.0 111.722 -167.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -42.82 -60.13 1.7 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.335 1.454 . . . . 0.0 113.878 -169.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 26.4 tp10 -35.96 -29.22 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 126.128 1.771 . . . . 0.0 114.395 172.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 83.9 p -63.61 -30.1 71.26 Favored 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 123.355 2.798 . . . . 0.0 115.824 174.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -108.08 -19.9 13.35 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 118.372 -0.823 . . . . 0.0 112.903 169.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -74.09 -49.3 24.61 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.633 1.173 . . . . 0.0 112.078 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 56.4 p -111.38 -95.35 0.43 Allowed 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 164.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.28 16.22 0.2 Allowed Glycine 0 CA--C 1.535 1.29 1 C-N-CA 131.2 4.238 . . . . 0.0 112.1 175.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . 0.427 ' C ' ' H ' ' B' ' 141' ' ' GLY . 5.9 t-20 50.99 34.03 9.96 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.352 1.861 . . . . 0.0 113.019 -174.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.34 24.98 0.08 Allowed 'General case' 0 CA--C 1.565 1.531 0 CA-C-O 121.929 0.871 . . . . 0.0 112.727 -169.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' B' ' 139' ' ' ASN . . . 72.09 -42.85 0.8 Allowed Glycine 0 N--CA 1.471 0.996 0 C-N-CA 129.924 3.63 . . . . 0.0 114.972 175.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 t -161.41 -156.39 0.44 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.541 1.537 . . . . 0.0 109.461 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -166.75 1.11 Allowed 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 127.105 2.162 . . . . 0.0 108.23 168.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -179.54 -173.6 0.26 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 128.328 2.651 . . . . 0.0 107.766 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.51 142.39 8.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.751 2.02 . . . . 0.0 112.154 174.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.2 p -151.9 159.57 43.78 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.908 1.683 . . . . 0.0 114.826 -167.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.78 142.53 8.32 Favored Glycine 0 CA--C 1.534 1.233 0 CA-C-O 118.795 -1.003 . . . . 0.0 114.837 173.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 26.5 t -79.51 135.42 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 125.222 1.409 . . . . 0.0 110.675 170.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.58 115.82 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 O-C-N 121.222 -0.924 . . . . 0.0 110.806 -174.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.76 174.94 15.7 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.942 1.258 . . . . 0.0 111.858 172.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -93.57 156.6 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 N-CA-C 115.337 1.606 . . . . 0.0 115.337 -168.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.51 -16.66 0.17 Allowed 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 126.914 2.085 . . . . 0.0 114.308 171.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 CA--C 1.533 0.311 0 C-N-CA 125.361 1.464 . . . . 0.0 112.911 168.168 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.423 ' HA ' ' H ' ' A' ' 22' ' ' GLN . 74.0 p -79.5 38.03 0.36 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -159.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.9 mttp -169.4 135.12 1.56 Allowed 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 127.322 2.249 . . . . 0.0 114.726 165.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.38 177.82 7.46 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 128.864 2.866 . . . . 0.0 110.188 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.6 p -155.26 127.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 C-N-CA 126.642 1.977 . . . . 0.0 108.903 -167.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.5 129.68 55.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.804 0.842 . . . . 0.0 111.495 170.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 44.3 t -102.13 95.39 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.666 1.186 . . . . 0.0 107.876 175.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -89.06 124.28 34.15 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.1 mtpt -143.45 175.36 9.99 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 121.958 0.885 . . . . 0.0 112.416 168.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.29 -65.2 0.16 Allowed Glycine 0 C--N 1.33 0.234 0 C-N-CA 125.571 1.558 . . . . 0.0 110.629 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.85 69.51 3.35 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.51 1.124 . . . . 0.0 111.27 -164.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 40.88 -102.61 0.03 OUTLIER Glycine 0 CA--C 1.536 1.361 0 C-N-CA 127.104 2.288 . . . . 0.0 113.373 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -68.93 -5.98 17.0 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 124.209 3.273 . . . . 0.0 114.459 -178.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.4 t -76.36 135.43 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 CA-C-N 120.151 1.342 . . . . 0.0 110.037 169.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.79 156.79 45.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.212 -1.358 . . . . 0.0 108.642 166.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.89 105.48 0.59 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 169.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.2 127.23 46.37 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 CA-C-N 117.824 0.812 . . . . 0.0 109.778 171.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 pp -137.42 121.73 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 122.435 1.112 . . . . 0.0 110.823 166.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -83.5 161.07 21.36 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.963 1.305 . . . . 0.0 109.048 164.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -138.29 130.14 28.22 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.526 0.731 . . . . 0.0 109.62 167.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.89 153.66 22.07 Favored 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 165.424 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.423 ' H ' ' HA ' ' A' ' 2' ' ' THR . 1.3 tm0? -157.9 140.85 14.96 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 124.726 1.21 . . . . 0.0 110.781 168.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.445 ' HZ1' ' CD ' ' A' ' 24' ' ' GLU 0.256 0.0 OUTLIER -82.3 -68.47 0.7 Allowed 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 175.434 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.445 ' CD ' ' HZ1' ' A' ' 23' ' ' LYS . 20.7 mp0 -132.66 165.07 25.32 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.944 1.698 . . . . 0.0 110.77 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 m -56.01 -28.71 58.45 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -98.38 5.21 48.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.817 1.247 . . . . 0.0 112.729 172.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.59 149.57 19.27 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 125.014 1.292 . . . . 0.0 111.861 -176.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -69.75 174.79 8.97 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.836 3.024 . . . . 0.0 111.83 -178.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -133.54 153.42 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.811 1.244 . . . . 0.0 112.486 -168.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.3 mttm -120.75 112.48 18.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.459 1.104 . . . . 0.0 109.178 167.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -80.86 148.07 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 O-C-N 121.418 -0.801 . . . . 0.0 109.402 167.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.2 p90 -156.64 157.62 35.57 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.528 0.731 . . . . 0.0 112.182 165.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.88 -158.81 27.83 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.116 0.807 . . . . 0.0 115.116 -176.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.0 p -153.64 129.12 9.91 Favored 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -168.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mm -111.66 113.94 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.419 178.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . 0.26 0.0 OUTLIER -133.3 172.17 13.05 Favored 'General case' 0 C--N 1.345 0.37 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -178.582 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.54 1.09 59.11 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 126.928 2.204 . . . . 0.0 110.753 -166.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mt -87.21 173.55 9.15 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.869 1.268 . . . . 0.0 110.589 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.4 t -84.77 162.88 19.44 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 163.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -60.79 161.03 8.53 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-O 121.529 0.68 . . . . 0.0 112.205 169.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.48 -175.16 31.48 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.64 1.114 . . . . 0.0 112.812 -178.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.613 ' H ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -71.92 151.04 43.62 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 128.272 2.629 . . . . 0.0 112.398 -171.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -152.36 115.45 4.66 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 127.831 2.452 . . . . 0.0 110.087 -173.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.65 152.49 30.85 Favored Glycine 0 N--CA 1.487 2.065 0 CA-C-N 120.854 1.661 . . . . 0.0 113.368 -178.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -149.64 103.46 3.26 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.631 1.572 . . . . 0.0 111.054 -169.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -141.85 145.96 35.27 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 119.849 -1.782 . . . . 0.0 114.986 -164.12 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -96.76 142.76 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-N 118.618 0.645 . . . . 0.0 110.958 -174.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -115.19 125.15 53.05 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.838 1.255 . . . . 0.0 109.511 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -62.42 25.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 128.013 2.525 . . . . 0.0 115.318 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -149.48 126.62 11.33 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 127.843 2.457 . . . . 0.0 107.507 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.95 -19.82 66.64 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 126.513 2.006 . . . . 0.0 115.048 173.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -76.23 51.62 0.7 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 127.313 2.245 . . . . 0.0 113.55 -168.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -176.32 22.32 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.211 0 C-N-CA 126.599 1.959 . . . . 0.0 115.399 -167.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.8 t -66.85 44.45 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 128.319 2.648 . . . . 0.0 116.697 178.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.67 -11.06 9.09 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -174.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.17 -166.63 14.6 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 125.268 1.413 . . . . 0.0 112.762 -169.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 37.7 t -51.79 -20.67 2.3 Favored 'General case' 0 CA--C 1.551 0.987 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 -177.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -68.66 -6.77 27.94 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 115.088 1.514 . . . . 0.0 115.088 175.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.6 t -149.76 -26.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -90.58 112.41 24.1 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.972 -1.08 . . . . 0.0 111.273 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.28 -119.48 1.11 Allowed Glycine 0 CA--C 1.545 1.935 0 C-N-CA 124.652 1.12 . . . . 0.0 113.568 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.35 173.73 2.19 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 124.205 3.27 . . . . 0.0 110.81 169.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -94.9 114.56 26.43 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.5 0.72 . . . . 0.0 110.352 -172.437 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -58.59 146.25 36.59 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.281 1.032 . . . . 0.0 112.64 177.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -126.83 85.58 60.53 Favored Pre-proline 0 CA--C 1.551 1.01 0 C-N-CA 125.885 1.674 . . . . 0.0 112.96 -168.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -61.74 -34.37 83.39 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 123.341 2.694 . . . . 0.0 113.519 -176.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.16 -4.96 47.21 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.602 0.761 . . . . 0.0 112.809 174.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.8 t 62.85 47.23 4.6 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 127.125 2.17 . . . . 0.0 112.179 178.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.7 ptt180 -117.9 176.56 5.14 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 114.544 1.313 . . . . 0.0 114.544 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -70.67 159.67 34.01 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.763 1.225 . . . . 0.0 111.704 174.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -68.12 120.68 14.71 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 164.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.4 -168.83 18.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 115.209 0.844 . . . . 0.0 115.209 -166.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -93.69 0.55 Allowed Glycine 0 CA--C 1.536 1.371 0 CA-C-O 117.004 -1.998 . . . . 0.0 114.933 176.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -74.56 47.06 1.55 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 124.777 3.651 . . . . 0.0 115.318 -170.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.418 ' HE3' HD23 ' A' ' 126' ' ' LEU . 6.4 ptpt 179.79 -5.7 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.065 1 C-N-CA 133.212 4.605 . . . . 0.0 113.852 165.195 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -134.47 177.46 7.75 Favored 'General case' 0 CA--C 1.559 1.316 0 C-N-CA 127.363 2.265 . . . . 0.0 111.227 -166.263 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -109.73 -4.77 15.89 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 127.664 2.385 . . . . 0.0 112.538 -175.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -84.22 -113.11 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.251 1.42 . . . . 0.0 108.304 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.432 HH21 HG13 ' A' ' 103' ' ' VAL . 21.8 ttp180 91.68 119.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 127.475 2.31 . . . . 0.0 108.857 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m170 -57.03 159.23 4.37 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 121.498 -0.751 . . . . 0.0 109.692 168.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p -41.97 -33.22 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.374 1.47 . . . . 0.0 113.635 176.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -146.8 123.05 1.71 Allowed Glycine 0 CA--C 1.534 1.26 0 CA-C-O 122.415 1.008 . . . . 0.0 112.426 165.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -158.15 96.46 1.45 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 129.509 3.124 . . . . 0.0 107.42 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -96.07 52.37 1.29 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 122.028 0.918 . . . . 0.0 110.353 178.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.68 -114.55 0.94 Allowed Glycine 0 CA--C 1.526 0.76 0 C-N-CA 126.35 1.929 . . . . 0.0 113.467 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -133.37 138.46 46.32 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.78 1.232 . . . . 0.0 112.529 172.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.4 m -91.23 143.55 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 127.153 2.181 . . . . 0.0 109.723 171.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.6 m -122.39 123.59 41.69 Favored 'General case' 0 N--CA 1.474 0.742 0 O-C-N 120.848 -1.157 . . . . 0.0 110.424 -172.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.14 159.25 15.06 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 114.613 1.338 . . . . 0.0 114.613 -175.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.433 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 37.5 t70 -82.69 175.26 10.28 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.858 2.063 . . . . 0.0 112.381 169.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.449 ' H ' ' HE2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -71.44 -16.37 62.37 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.516 1.126 . . . . 0.0 113.795 172.336 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.59 -13.32 61.36 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 121.967 0.889 . . . . 0.0 109.92 166.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.18 -4.43 58.7 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 127.635 2.54 . . . . 0.0 114.473 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.9 p -91.59 127.75 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 120.946 2.373 . . . . 0.0 114.633 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.11 119.81 32.73 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 163.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -87.6 140.43 29.52 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 172.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.64 131.39 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 124.477 1.111 . . . . 0.0 112.328 -168.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.0 p -157.21 60.3 0.51 Allowed 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.39 1.476 . . . . 0.0 113.383 -176.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.0 mp -95.99 142.53 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 119.446 -2.033 . . . . 0.0 112.847 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -117.09 136.79 52.72 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 125.828 1.651 . . . . 0.0 108.424 168.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -153.82 146.16 23.92 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.896 1.279 . . . . 0.0 111.794 -169.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 32.5 t -118.69 55.01 0.93 Allowed 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.084 -0.962 . . . . 0.0 113.091 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.432 HG13 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -139.45 -31.37 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 166.484 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -97.18 159.53 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 122.451 1.119 . . . . 0.0 112.208 172.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 53.8 p -156.94 163.18 39.42 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 125.642 1.577 . . . . 0.0 110.062 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.3 mt -82.4 73.39 9.44 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 122.341 1.067 . . . . 0.0 108.874 171.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -132.85 157.74 44.27 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.091 2.156 . . . . 0.0 107.67 170.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -116.87 41.94 1.98 Allowed Glycine 0 N--CA 1.472 1.09 0 C-N-CA 124.847 1.213 . . . . 0.0 113.45 -170.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.17 -88.52 0.51 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 127.381 2.273 . . . . 0.0 106.858 -178.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.79 12.83 13.08 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 126.016 1.726 . . . . 0.0 110.99 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -92.09 -160.82 0.77 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 120.467 -1.396 . . . . 0.0 112.176 173.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 8.3 pt -94.08 -13.47 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 N-CA-C 117.017 2.228 . . . . 0.0 117.017 -168.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.3 mm -73.1 125.93 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 122.326 2.33 . . . . 0.0 110.482 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.76 -0.66 81.44 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 117.782 -1.565 . . . . 0.0 113.917 -173.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 30.9 ttp180 -92.18 167.61 11.92 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.435 1.894 . . . . 0.0 110.573 176.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -113.6 163.19 15.28 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 125.582 1.553 . . . . 0.0 112.639 -176.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 41.7 tp -137.29 126.18 24.15 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 127.426 2.29 . . . . 0.0 110.452 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.5 p -100.21 140.21 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 126.456 1.903 . . . . 0.0 110.987 173.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -107.27 143.05 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 CA-C-O 121.676 0.751 . . . . 0.0 109.313 165.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -122.27 162.85 20.7 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.985 1.714 . . . . 0.0 111.558 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 -27.41 44.84 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 120.264 -1.522 . . . . 0.0 114.848 -167.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 20.7 mmtm -130.5 -175.63 3.71 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.758 2.072 . . . . 0.0 114.357 -171.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.45 153.51 31.23 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.718 1.207 . . . . 0.0 111.79 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -102.38 131.53 48.96 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.405 1.082 . . . . 0.0 110.889 -174.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -78.82 -31.98 46.07 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.352 1.861 . . . . 0.0 113.479 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.418 HD23 ' HE3' ' A' ' 75' ' ' LYS . 2.7 mm? 56.0 63.48 2.01 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.353 1.861 . . . . 0.0 114.803 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.0 10.21 64.85 Favored Glycine 0 N--CA 1.467 0.764 0 N-CA-C 120.065 2.786 . . . . 0.0 120.065 161.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.3 pptp? -148.33 -5.6 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 119.468 3.136 . . . . 0.0 119.468 -165.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.06 27.96 0.79 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 120.881 1.673 . . . . 0.0 116.035 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.96 -23.68 2.57 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.566 1.555 . . . . 0.0 116.508 171.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -95.88 165.45 12.27 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 119.717 1.759 . . . . 0.0 111.777 -173.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -49.96 -57.88 6.61 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.993 1.317 . . . . 0.0 109.24 168.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.493 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 7.8 mm-40 -50.83 -38.77 50.79 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 126.297 1.839 . . . . 0.0 112.803 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 20.1 m -62.51 -32.09 72.96 Favored 'General case' 0 N--CA 1.464 0.259 0 O-C-N 121.081 -1.012 . . . . 0.0 113.432 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.273 1.6 t -118.17 -10.62 10.25 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 117.324 -1.322 . . . . 0.0 113.988 -175.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . 0.256 0.6 OUTLIER -90.81 -34.1 15.44 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 120.469 1.486 . . . . 0.0 113.306 168.72 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.493 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 0.2 OUTLIER -128.78 -17.58 4.0 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 126.042 1.737 . . . . 0.0 114.993 -176.593 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 96.61 12.64 50.16 Favored Glycine 0 N--CA 1.466 0.655 0 CA-C-N 120.454 1.479 . . . . 0.0 114.644 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 61.72 7.73 2.07 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 119.711 1.756 . . . . 0.0 113.832 177.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.19 10.5 0.02 OUTLIER 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 118.816 2.895 . . . . 0.0 118.816 -164.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.48 -160.4 32.98 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 126.31 1.909 . . . . 0.0 113.588 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.5 t -55.04 148.83 12.98 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.954 -0.733 . . . . 0.0 111.584 176.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.86 128.95 37.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 170.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.91 -119.23 0.3 Allowed 'General case' 0 C--O 1.238 0.497 0 O-C-N 124.382 1.051 . . . . 0.0 109.728 173.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.27 151.91 46.23 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-O 122.425 1.107 . . . . 0.0 112.02 -172.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.6 t -154.24 143.28 21.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.334 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.93 151.59 23.09 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 -169.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.454 ' CG1' ' HB ' ' B' ' 148' ' ' VAL . 2.7 p -79.52 156.2 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.126 0.97 . . . . 0.0 111.885 172.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.4 mm -103.22 111.08 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.59 1.156 . . . . 0.0 111.872 170.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.07 159.96 13.47 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.965 1.269 . . . . 0.0 112.576 175.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.53 139.19 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.147 -1.208 . . . . 0.0 112.231 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.21 -141.34 0.23 Allowed 'General case' 0 CA--C 1.549 0.933 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 161.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.471 0.59 0 C-N-CA 124.835 1.254 . . . . 0.0 111.595 168.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.557 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 88.6 m -77.55 99.87 5.88 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.046 1.339 . . . . 0.0 107.754 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 33.9 mtmm -117.05 132.63 56.64 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 123.954 0.902 . . . . 0.0 113.363 -170.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.67 157.69 46.0 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 129.931 3.292 . . . . 0.0 109.67 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 33.5 t -136.32 114.13 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.577 1.18 . . . . 0.0 110.853 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.58 96.05 6.05 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 113.823 -1.535 . . . . 0.0 107.628 167.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 34.4 m -86.03 115.55 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 165.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.4 mp -98.08 136.13 38.77 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.688 -174.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -157.97 121.8 4.08 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 119.741 1.155 . . . . 0.0 113.894 165.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -84.74 -115.41 0.72 Allowed Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 168.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -143.08 128.97 19.48 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.813 2.845 . . . . 0.0 106.011 -168.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.06 179.42 50.98 Favored Glycine 0 CA--C 1.537 1.421 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -167.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.45 49.56 2.68 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 125.293 3.995 . . . . 0.0 112.209 -176.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.65 112.65 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 126.334 1.853 . . . . 0.0 108.655 174.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 pm0 -158.71 166.53 31.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.651 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.96 171.92 35.05 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-O 122.133 0.851 . . . . 0.0 112.456 168.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 pp -121.63 122.76 67.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 166.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mm -131.36 101.9 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.38 148.32 39.29 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.249 1.02 . . . . 0.0 110.162 175.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.4 m-85 -126.61 116.37 20.91 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.171 1.789 . . . . 0.0 108.762 169.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.402 ' OE2' ' HE2' ' B' ' 23' ' ' LYS . 4.8 tm-20 -116.45 120.84 40.06 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 126.301 1.84 . . . . 0.0 112.537 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -113.92 130.01 56.55 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 122.127 0.965 . . . . 0.0 112.273 169.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.438 ' N ' ' HE2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -87.17 -28.73 22.26 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.077 0.951 . . . . 0.0 112.474 -172.122 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -158.36 136.07 10.4 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 128.046 2.538 . . . . 0.0 107.71 168.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.8 t -47.62 -42.35 24.0 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 129.048 2.939 . . . . 0.0 113.495 -176.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -84.92 -7.67 59.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.057 1.343 . . . . 0.0 113.25 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.3 -167.71 42.13 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 125.521 1.534 . . . . 0.0 112.148 173.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . 0.406 ' O ' ' HE3' ' B' ' 23' ' ' LYS . 20.7 Cg_endo -84.51 176.66 6.21 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.305 2.67 . . . . 0.0 111.669 178.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.82 143.46 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 125.817 1.647 . . . . 0.0 109.4 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 14.9 tttp -107.78 130.58 54.96 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.352 1.061 . . . . 0.0 109.567 168.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.57 126.5 74.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 126.025 1.73 . . . . 0.0 108.495 -177.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -148.28 160.5 42.91 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -177.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.91 -149.26 21.26 Favored Glycine 0 C--N 1.333 0.397 0 C-N-CA 124.077 0.846 . . . . 0.0 111.868 170.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -150.82 128.78 11.76 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -171.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 mp -96.33 136.52 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.646 1.179 . . . . 0.0 109.213 169.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.4 mtpt -130.52 154.4 47.84 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 112.521 -178.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.11 -0.19 57.31 Favored Glycine 0 N--CA 1.475 1.235 0 C-N-CA 124.942 1.258 . . . . 0.0 113.332 -170.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 91.1 mt -78.49 149.01 33.25 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 124.738 1.215 . . . . 0.0 112.017 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -78.17 149.28 33.78 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 165.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.63 141.34 32.2 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 126.614 1.966 . . . . 0.0 113.064 -178.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.87 -168.24 18.0 Favored Glycine 0 N--CA 1.472 1.06 0 O-C-N 120.89 -1.131 . . . . 0.0 113.817 -177.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.478 HD11 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -82.02 138.93 34.77 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 128.011 2.525 . . . . 0.0 115.966 -167.837 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -137.04 131.73 33.21 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 128.58 2.752 . . . . 0.0 109.728 -174.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.43 161.6 54.27 Favored Glycine 0 N--CA 1.47 0.96 0 C-N-CA 124.672 1.129 . . . . 0.0 114.632 -172.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -153.38 118.94 5.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.651 1.225 . . . . 0.0 113.128 -168.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -157.33 150.02 23.21 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 119.893 -1.754 . . . . 0.0 115.248 177.187 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -104.93 117.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.406 1.483 . . . . 0.0 110.097 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -98.36 146.67 25.46 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.853 2.061 . . . . 0.0 109.799 -173.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -70.32 148.38 48.55 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.494 -171.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 77.83 156.66 0.17 Allowed 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 127.65 2.38 . . . . 0.0 112.498 -173.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.5 -1.3 81.94 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.724 168.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -76.92 115.89 17.11 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 118.782 1.291 . . . . 0.0 110.823 -174.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.558 ' ND2' ' HG1' ' B' ' 116' ' ' THR 0.413 0.0 OUTLIER -144.21 43.64 1.43 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 123.502 1.62 . . . . 0.0 113.992 164.293 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.3 0.5 OUTLIER -128.06 -28.02 2.68 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 112.58 -2.1 . . . . 0.0 111.936 174.493 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.41 -22.4 54.78 Favored 'General case' 0 CA--C 1.561 1.394 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 158.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.55 -101.34 0.38 Allowed Glycine 0 C--N 1.345 1.038 0 C-N-CA 128.132 2.777 . . . . 0.0 116.23 164.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.4 t -64.58 -31.44 72.65 Favored 'General case' 0 CA--C 1.545 0.759 0 O-C-N 121.146 -1.208 . . . . 0.0 112.359 -170.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.2 t -94.47 0.09 55.1 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.53 1.532 . . . . 0.0 113.78 171.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 12.9 p -94.15 -53.98 3.75 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 123.64 0.776 . . . . 0.0 112.472 173.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.52 28.51 0.19 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.599 1.559 . . . . 0.0 112.543 -168.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.84 -63.93 3.56 Favored Glycine 0 CA--C 1.539 1.549 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.491 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -89.77 -180.0 1.99 Allowed 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 124.916 3.744 . . . . 0.0 111.959 169.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -79.67 128.74 33.78 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-O 123.201 1.477 . . . . 0.0 111.925 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -63.41 127.72 32.58 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 113.116 -1.857 . . . . 0.0 108.329 163.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 -121.19 58.48 7.53 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 123.675 0.79 . . . . 0.0 112.158 -171.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.31 -11.72 29.44 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.426 2.084 . . . . 0.0 113.873 -178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.3 mp -92.97 -8.27 43.57 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 114.121 1.156 . . . . 0.0 114.121 173.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.8 t 61.68 74.81 0.43 Allowed 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 119.957 1.253 . . . . 0.0 113.432 175.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -167.35 179.14 5.16 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.33 1.452 . . . . 0.0 112.562 -171.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HZ1' ' CD ' ' B' ' 78' ' ' GLU . 3.2 mppt? -85.55 171.43 11.73 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.995 1.718 . . . . 0.0 112.767 177.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -86.26 146.54 26.48 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.921 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.82 -108.21 0.49 Allowed Glycine 0 C--N 1.336 0.534 0 CA-C-O 119.063 -0.854 . . . . 0.0 114.875 165.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.59 -42.16 2.01 Favored Glycine 0 CA--C 1.555 2.589 0 CA-C-O 118.182 -1.343 . . . . 0.0 114.127 -168.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -84.32 15.38 2.18 Favored 'Trans proline' 0 CA--C 1.553 1.474 0 C-N-CA 124.241 3.294 . . . . 0.0 116.712 171.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -39.42 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 128.143 2.577 . . . . 0.0 110.376 165.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -66.1 137.01 56.75 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 161.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -99.82 -16.58 18.02 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.298 1.439 . . . . 0.0 111.258 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . 0.456 ' CD ' ' HZ1' ' B' ' 70' ' ' LYS . 26.6 mt-10 -79.4 -60.18 2.47 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.56 -0.712 . . . . 0.0 110.464 -171.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.2 ttt-85 71.91 127.47 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.528 1.931 . . . . 0.0 112.374 168.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -76.62 173.02 12.08 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 119.237 -2.164 . . . . 0.0 111.669 168.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.7 p -76.85 134.86 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.597 -1.314 . . . . 0.0 109.376 167.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.23 9.13 86.93 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 126.447 1.975 . . . . 0.0 115.801 -174.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 61.5 m-20 -78.25 114.96 17.62 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-N 119.902 1.851 . . . . 0.0 111.924 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 56.8 mt -99.57 179.06 4.67 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.812 0.845 . . . . 0.0 110.086 168.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -109.9 165.2 12.32 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 125.074 1.321 . . . . 0.0 112.445 174.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -74.63 150.84 39.44 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 -168.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.4 m -114.67 128.66 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 128.373 2.669 . . . . 0.0 111.097 -172.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.33 128.16 45.42 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.739 -1.225 . . . . 0.0 111.724 -178.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.05 135.06 35.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 169.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.06 154.47 23.2 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.626 1.97 . . . . 0.0 109.438 167.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.416 ' HZ1' ' CG ' ' B' ' 92' ' ' ASP . 1.7 pptp? -45.63 -21.8 0.13 Allowed 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 129.037 2.935 . . . . 0.0 116.847 176.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.416 ' CG ' ' HZ1' ' B' ' 91' ' ' LYS . 77.8 m-20 -76.76 9.62 2.72 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.356 1.062 . . . . 0.0 111.408 172.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.2 35.54 42.97 Favored Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.338 2.399 . . . . 0.0 112.324 175.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 1.8 p -142.93 126.99 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 119.017 1.408 . . . . 0.0 114.65 -172.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.46 119.46 32.58 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 165.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.7 t0 -79.64 154.23 28.82 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.592 1.157 . . . . 0.0 109.724 169.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.3 144.2 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 168.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.7 p -156.24 58.5 0.58 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.635 1.574 . . . . 0.0 112.177 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 28.9 mt -80.35 148.68 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 120.237 -1.539 . . . . 0.0 111.334 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -128.84 137.5 51.52 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.908 2.083 . . . . 0.0 105.591 166.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -154.78 136.79 14.65 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.476 1.111 . . . . 0.0 111.604 -169.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.95 49.06 1.02 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 123.518 0.727 . . . . 0.0 112.932 178.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 t -149.46 20.15 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 124.858 1.263 . . . . 0.0 111.731 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -148.62 169.91 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 128.787 2.835 . . . . 0.0 107.944 169.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -156.88 157.3 34.64 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.837 -1.164 . . . . 0.0 110.129 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -99.2 60.79 1.2 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.121 1.369 . . . . 0.0 108.837 -178.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.8 m -84.88 -94.21 0.08 Allowed 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.995 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 163.62 60.66 0.02 OUTLIER Glycine 0 N--CA 1.473 1.139 0 O-C-N 120.836 -1.165 . . . . 0.0 113.263 -172.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . 0.553 ' CG ' ' H ' ' B' ' 110' ' ' HIS . 9.2 p-10 -161.24 -108.95 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 123.136 1.446 . . . . 0.0 108.978 -164.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . 0.553 ' H ' ' CG ' ' B' ' 109' ' ' ASP . 14.6 m-70 -107.57 -28.92 9.48 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 130.001 3.32 . . . . 0.0 110.821 173.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 79.9 p -48.44 -65.28 0.59 Allowed 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 128.222 2.609 . . . . 0.0 116.759 -167.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 33.8 mm -150.06 -51.46 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 128.003 2.521 . . . . 0.0 109.513 169.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 49.8 mm -65.3 120.69 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 169.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.78 10.86 69.08 Favored Glycine 0 CA--C 1.534 1.266 0 N-CA-C 114.585 0.594 . . . . 0.0 114.585 -170.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 20.2 ttt85 -108.79 -179.86 3.98 Favored 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.94 2.496 . . . . 0.0 109.672 171.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.558 ' HG1' ' ND2' ' B' ' 53' ' ' ASN . 14.6 t -148.11 130.35 15.56 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.132 -1.605 . . . . 0.0 112.938 179.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -101.53 134.09 45.19 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 119.294 0.952 . . . . 0.0 110.931 -175.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -118.74 137.09 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.204 1.402 . . . . 0.0 109.52 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.42 130.03 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-O 122.646 1.212 . . . . 0.0 108.142 168.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -107.22 152.98 23.36 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.642 1.977 . . . . 0.0 110.108 -172.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.77 -45.34 44.46 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 119.751 -1.843 . . . . 0.0 114.67 -166.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.11 171.55 7.32 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 120.949 1.704 . . . . 0.0 112.061 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.59 149.74 7.75 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 124.037 0.935 . . . . 0.0 112.538 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -75.87 134.44 40.31 Favored 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 168.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -41.18 68.77 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 175.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.3 mt 67.87 37.56 3.1 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 125.867 1.667 . . . . 0.0 111.44 170.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -171.2 -75.16 0.04 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.211 0.91 . . . . 0.0 113.441 169.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.8 ttpt -162.04 98.1 1.05 Allowed 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 126.85 2.06 . . . . 0.0 113.605 173.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.87 -135.98 0.71 Allowed Glycine 0 CA--C 1.537 1.413 0 CA-C-O 122.247 0.915 . . . . 0.0 113.417 169.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.89 -9.35 52.52 Favored Glycine 0 N--CA 1.474 1.172 0 N-CA-C 118.448 2.139 . . . . 0.0 118.448 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -164.8 175.47 9.61 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 120.514 2.157 . . . . 0.0 111.59 -169.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -48.07 -54.74 12.1 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 113.396 0.887 . . . . 0.0 113.396 -170.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -57.58 -10.52 1.55 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 114.476 1.287 . . . . 0.0 114.476 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.9 p -58.05 -49.96 75.1 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.884 1.674 . . . . 0.0 112.964 167.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 19.0 p -93.24 -18.1 22.9 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 178.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -85.12 -35.68 21.62 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.669 0.788 . . . . 0.0 112.867 176.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 59.8 p -115.33 -112.17 0.34 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.981 1.312 . . . . 0.0 107.479 167.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -142.6 21.45 2.37 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.875 2.179 . . . . 0.0 112.187 169.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.71 13.79 3.68 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.517 1.927 . . . . 0.0 113.466 -171.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.34 33.18 0.02 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 128.951 2.901 . . . . 0.0 118.559 -165.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.86 -54.8 3.01 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 126.905 2.193 . . . . 0.0 115.568 169.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -173.51 175.91 2.91 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 125.848 1.659 . . . . 0.0 111.97 -170.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -127.2 115.08 18.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.249 1.419 . . . . 0.0 110.461 -169.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.8 pp -110.53 -37.17 5.56 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -170.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.57 158.34 33.74 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 119.558 1.072 . . . . 0.0 113.136 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 20.3 p -156.45 163.78 39.03 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.471 2.309 . . . . 0.0 110.24 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.92 142.43 8.69 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 127.075 2.274 . . . . 0.0 110.246 171.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.454 ' HB ' ' CG1' ' A' ' 148' ' ' VAL . 1.6 t -88.17 146.8 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 CA-C-N 118.967 1.383 . . . . 0.0 108.68 -174.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.5 mm -77.33 120.56 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.013 -1.054 . . . . 0.0 112.94 -169.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.47 -172.4 18.77 Favored Glycine 0 N--CA 1.47 0.958 0 C-N-CA 125.824 1.678 . . . . 0.0 113.567 175.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -133.43 160.39 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 173.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.88 -39.31 0.09 Allowed 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 125.902 1.681 . . . . 0.0 111.368 168.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 . . . . . 0 C--O 1.241 0.612 0 C-N-CA 126.31 1.844 . . . . 0.0 112.824 169.937 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.477 0 CA-C-O 119.111 -0.471 . . . . 0.0 110.099 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.2 t -161.04 116.81 2.19 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.29 2.636 . . . . 0.0 106.868 166.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.2 102.71 14.16 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.929 -0.482 . . . . 0.0 112.022 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.01 166.67 22.54 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.784 0.72 . . . . 0.0 109.339 167.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.1 t -138.69 140.69 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 122.309 1.052 . . . . 0.0 112.798 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.85 113.15 19.24 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 114.089 -1.414 . . . . 0.0 109.12 165.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.03 80.63 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 127.276 2.23 . . . . 0.0 108.476 167.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -73.84 157.76 35.76 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.007 0.923 . . . . 0.0 111.238 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -148.66 158.51 44.19 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.39 162.68 13.65 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 127.549 2.5 . . . . 0.0 107.54 166.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.438 ' CG ' ' HZ3' ' B' ' 9' ' ' LYS . 2.1 m-20 -76.33 57.66 1.2 Allowed 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 126.837 2.055 . . . . 0.0 111.85 176.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.13 -167.53 40.0 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 128.436 2.922 . . . . 0.0 109.553 -175.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -80.1 42.55 1.34 Allowed 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 125.224 3.949 . . . . 0.0 112.306 -172.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -131.42 129.63 62.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 124.44 1.096 . . . . 0.0 109.165 -175.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -158.66 169.36 24.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.42 1.888 . . . . 0.0 109.074 -172.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 135.79 4.55 Favored Glycine 0 C--O 1.224 -0.469 0 C-N-CA 121.321 -0.466 . . . . 0.0 112.577 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.08 132.11 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 168.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 15.2 mm -139.09 112.77 6.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 C-N-CA 123.835 0.854 . . . . 0.0 110.838 173.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -78.49 144.32 35.83 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.976 0.91 . . . . 0.0 110.453 165.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -123.56 99.12 6.15 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.744 1.618 . . . . 0.0 109.886 172.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.88 105.34 11.09 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.664 1.186 . . . . 0.0 110.742 -179.629 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -79.29 83.1 5.37 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 120.926 -1.109 . . . . 0.0 108.537 169.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.432 ' HZ2' ' CD ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -59.51 -50.71 72.85 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 118.708 -0.663 . . . . 0.0 111.169 -179.855 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.432 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 13.3 mp0 -132.38 136.48 46.84 Favored 'General case' 0 C--O 1.224 -0.241 0 C-N-CA 124.271 1.028 . . . . 0.0 108.876 168.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.1 p -67.08 -4.73 10.7 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 126.163 1.785 . . . . 0.0 114.954 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.46 1.93 9.6 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 126.743 2.017 . . . . 0.0 112.06 173.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.45 -153.2 12.52 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.664 1.602 . . . . 0.0 111.192 -176.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -86.24 173.06 6.9 Favored 'Trans proline' 0 N--CA 1.451 -1.01 0 C-N-CA 122.788 2.325 . . . . 0.0 111.761 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.95 134.06 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.759 1.624 . . . . 0.0 108.498 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.559 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 14.4 tttp -101.24 121.78 42.48 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 169.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.4 t -121.14 118.82 57.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 125.924 1.689 . . . . 0.0 109.095 -168.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -140.65 161.9 36.65 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -178.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.65 -150.73 22.97 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 124.783 1.182 . . . . 0.0 112.415 -179.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 43.1 p -158.09 136.04 10.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -171.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -109.7 112.93 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.668 1.187 . . . . 0.0 108.494 178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -120.79 135.86 55.04 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.955 1.302 . . . . 0.0 111.446 -168.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.67 -2.08 15.47 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 127.191 2.329 . . . . 0.0 113.559 -173.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mp -69.0 -178.27 1.21 Allowed 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 125.829 1.651 . . . . 0.0 110.992 169.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -115.11 156.22 25.62 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 127.962 2.505 . . . . 0.0 105.266 164.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -48.37 146.15 3.0 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 127.032 2.133 . . . . 0.0 114.118 -175.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.83 -177.4 32.86 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 122.084 0.824 . . . . 0.0 113.393 -178.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.437 ' H ' HD11 ' A' ' 42' ' ' LEU . 1.1 mp -70.13 150.26 46.71 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.449 2.3 . . . . 0.0 112.068 -169.489 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -147.28 124.03 11.21 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.021 1.728 . . . . 0.0 110.32 175.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.43 155.43 32.44 Favored Glycine 0 N--CA 1.491 2.316 0 CA-C-N 120.281 1.4 . . . . 0.0 114.398 -174.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -146.1 102.11 3.59 Favored 'General case' 0 CA--C 1.552 1.051 0 CA-C-O 122.76 1.267 . . . . 0.0 113.77 -167.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -127.34 133.16 50.11 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.89 94.71 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 126.408 1.883 . . . . 0.0 110.355 174.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -73.75 108.84 6.82 Favored 'General case' 0 CA--C 1.557 1.242 0 O-C-N 120.604 -1.31 . . . . 0.0 114.36 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -31.03 106.23 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 127.408 2.283 . . . . 0.0 113.208 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 148.44 173.86 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 129.792 3.237 . . . . 0.0 109.758 -169.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.502 ' HA3' ' H ' ' B' ' 151' ' ' ILE . . . -116.85 -2.63 18.78 Favored Glycine 0 CA--C 1.549 2.201 0 C-N-CA 126.292 1.901 . . . . 0.0 109.859 160.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.52 ' C ' HD21 ' A' ' 53' ' ' ASN . 0.8 OUTLIER -75.69 147.22 39.57 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 128.008 2.523 . . . . 0.0 111.75 170.271 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.52 HD21 ' C ' ' A' ' 52' ' ' ASP 0.312 0.1 OUTLIER -173.53 17.47 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 119.041 2.978 . . . . 0.0 119.041 166.627 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.35 -12.52 32.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 120.083 -1.636 . . . . 0.0 114.315 -165.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.34 18.14 22.47 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.772 1.229 . . . . 0.0 112.678 172.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.66 -123.43 24.72 Favored Glycine 0 CA--C 1.529 0.933 0 O-C-N 120.697 -1.252 . . . . 0.0 112.243 174.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.3 m -72.5 -9.33 58.43 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 175.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -14.92 52.55 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 125.184 1.394 . . . . 0.0 111.407 169.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.7 m -95.28 -159.51 0.72 Allowed 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 127.41 2.284 . . . . 0.0 109.52 168.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.13 104.69 0.03 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 128.212 2.605 . . . . 0.0 116.374 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -63.07 166.72 23.77 Favored Glycine 0 CA--C 1.545 1.92 0 C-N-CA 125.869 1.699 . . . . 0.0 114.805 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -62.11 96.89 0.15 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 125.07 3.847 . . . . 0.0 113.173 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.1 p80 47.82 64.49 1.61 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 126.124 1.769 . . . . 0.0 113.24 169.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -32.11 137.83 0.05 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.383 1.873 . . . . 0.0 115.439 -178.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -106.01 63.66 0.16 Allowed Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 126.559 1.944 . . . . 0.0 113.084 177.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -62.78 -35.77 66.27 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.612 2.208 . . . . 0.0 111.898 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.1 tp -77.76 -5.18 49.79 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 124.727 1.211 . . . . 0.0 112.869 173.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t 71.27 51.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.945 2.098 . . . . 0.0 112.497 172.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.5 mtp180 -108.19 171.71 7.25 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -169.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.7 mttp -81.09 162.71 23.6 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.468 1.507 . . . . 0.0 109.521 165.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -72.36 151.72 42.51 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 121.012 -1.055 . . . . 0.0 112.151 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.73 -138.45 6.39 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 116.137 1.215 . . . . 0.0 116.137 169.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.77 -108.88 0.6 Allowed Glycine 0 CA--C 1.544 1.856 0 CA-C-O 116.835 -2.092 . . . . 0.0 114.934 -168.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -52.33 -3.65 0.11 Allowed 'Trans proline' 0 CA--C 1.546 1.103 1 C-N-CA 126.443 4.762 . . . . 0.0 120.068 -169.333 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.48 2.89 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 127.693 2.397 . . . . 0.0 112.594 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -123.91 175.81 6.7 Favored 'General case' 0 CA--C 1.557 1.249 0 C-N-CA 129.091 2.957 . . . . 0.0 109.02 -174.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -116.55 -13.71 10.9 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.671 2.388 . . . . 0.0 111.143 -175.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -91.59 -65.3 1.02 Allowed 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.769 1.228 . . . . 0.0 112.555 -168.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.457 HH21 ' CG ' ' A' ' 101' ' ' ASP . 1.4 ttt-85 52.91 77.07 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 120.088 1.313 . . . . 0.0 111.48 171.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -46.91 153.32 0.42 Allowed 'General case' 0 N--CA 1.478 0.971 0 O-C-N 120.264 -1.523 . . . . 0.0 112.298 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 p -43.95 -40.62 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 120.125 1.33 . . . . 0.0 113.715 -176.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -97.08 34.2 5.24 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 126.863 2.173 . . . . 0.0 117.21 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -114.68 128.17 56.16 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.992 1.717 . . . . 0.0 110.426 176.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.1 mt -122.41 53.75 1.23 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-O 122.031 0.92 . . . . 0.0 108.555 168.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 62.2 -132.53 45.49 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.411 1.482 . . . . 0.0 114.229 175.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -143.45 154.86 44.11 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.573 1.149 . . . . 0.0 110.591 175.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.94 104.04 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.618 1.567 . . . . 0.0 109.733 -175.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -91.68 125.46 36.41 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 124.01 0.924 . . . . 0.0 109.222 -175.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.97 156.05 17.78 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -173.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -82.85 166.35 19.03 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.037 1.735 . . . . 0.0 110.206 167.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.6 pttt -51.28 -24.03 4.12 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 127.521 2.328 . . . . 0.0 113.274 167.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -76.78 -0.73 24.91 Favored 'General case' 0 CA--C 1.55 0.954 0 C-N-CA 125.929 1.691 . . . . 0.0 112.016 172.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.21 7.32 84.59 Favored Glycine 0 CA--C 1.52 0.404 0 O-C-N 120.183 -1.573 . . . . 0.0 113.523 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -95.18 123.69 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 125.405 1.482 . . . . 0.0 112.142 174.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.85 134.49 36.16 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 163.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -79.29 150.62 31.46 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 168.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.3 t -131.2 123.24 53.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 113.287 -1.779 . . . . 0.0 109.855 168.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.1 m -147.12 70.94 1.2 Allowed 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.865 2.066 . . . . 0.0 109.198 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 31.3 mt -116.4 152.37 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 125.502 1.521 . . . . 0.0 111.711 -168.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.559 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 9.6 tt0 -145.48 137.28 25.37 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 127.172 2.189 . . . . 0.0 107.064 174.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.457 ' CG ' HH21 ' A' ' 79' ' ' ARG . 22.7 t70 -154.26 139.4 17.44 Favored 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -167.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -116.59 51.57 0.98 Allowed 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.6 t -128.62 -47.93 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -100.43 176.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.16 0.984 . . . . 0.0 112.005 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -157.94 176.03 13.07 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 120.693 -1.254 . . . . 0.0 110.696 172.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.4 mp -109.69 52.2 0.73 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.803 1.641 . . . . 0.0 109.46 -177.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.3 t -91.24 14.33 14.68 Favored 'General case' 0 CA--C 1.542 0.669 0 O-C-N 120.57 -1.331 . . . . 0.0 114.417 -174.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 102.47 -122.32 7.48 Favored Glycine 0 C--N 1.339 0.698 0 O-C-N 121.527 -0.733 . . . . 0.0 111.652 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -59.09 -52.7 64.59 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 126.934 2.094 . . . . 0.0 114.27 -163.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -88.48 9.43 23.72 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.737 1.615 . . . . 0.0 112.602 -174.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.21 -161.23 0.82 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 125.407 1.483 . . . . 0.0 113.937 -165.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.283 7.4 pt -88.96 1.16 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 175.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 38.8 mm -69.72 132.68 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 163.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.24 -12.11 55.79 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.763 -1.576 . . . . 0.0 115.631 -171.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.662 ' NE ' ' H ' ' A' ' 116' ' ' THR . 1.3 tpm_? -71.51 177.86 3.8 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.699 2.249 . . . . 0.0 108.486 178.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.662 ' H ' ' NE ' ' A' ' 115' ' ' ARG . 1.5 m -140.53 131.58 26.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 126.932 2.093 . . . . 0.0 106.717 175.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -87.22 137.8 32.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 125.542 1.776 . . . . 0.0 106.791 166.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 5.2 p -117.45 124.54 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.624 1.17 . . . . 0.0 108.427 168.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.42 145.18 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 O-C-N 124.94 1.4 . . . . 0.0 109.083 169.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 23.2 m-70 -117.34 161.76 19.01 Favored 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 125.16 1.384 . . . . 0.0 113.134 -170.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.54 -34.25 69.86 Favored 'General case' 0 N--CA 1.478 0.935 0 O-C-N 120.597 -1.314 . . . . 0.0 114.071 179.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.402 ' HE3' ' O ' ' A' ' 139' ' ' ASN . 17.9 ttpp -94.49 156.02 16.66 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 123.064 1.412 . . . . 0.0 113.766 -173.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.58 142.59 17.74 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.744 165.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -93.43 128.6 39.57 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 124.465 1.103 . . . . 0.0 110.641 -178.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.81 -21.65 59.17 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.697 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 72.3 mt 47.86 56.52 7.09 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 127.912 2.485 . . . . 0.0 111.219 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.16 -58.9 0.38 Allowed Glycine 0 N--CA 1.472 1.055 0 C-N-CA 125.864 1.697 . . . . 0.0 113.732 173.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp -126.05 77.55 1.69 Allowed 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 115.226 1.565 . . . . 0.0 115.226 -169.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.559 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -80.57 -95.23 0.4 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 107.196 -2.362 . . . . 0.0 107.196 165.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -150.03 8.58 0.81 Allowed Glycine 0 N--CA 1.474 1.173 0 N-CA-C 117.728 1.851 . . . . 0.0 117.728 -174.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.7 p30 -161.2 -177.7 6.23 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 120.4 2.1 . . . . 0.0 111.111 -176.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.435 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 20.9 tt0 -55.77 -51.89 65.85 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.207 0.912 . . . . 0.0 112.727 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.458 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 1.9 mm-40 -59.38 -23.84 62.93 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -170.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.559 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 27.3 m -57.15 -29.31 63.51 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 172.233 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -100.25 -15.14 18.18 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 118.067 -0.968 . . . . 0.0 113.473 173.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.435 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 94.7 mttt -86.55 -85.37 0.16 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 119.968 1.258 . . . . 0.0 110.77 171.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.458 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 62.5 p -73.24 -11.47 60.52 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 175.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.48 9.06 79.74 Favored Glycine 0 N--CA 1.467 0.705 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 -165.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.402 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 4.8 t-20 52.53 21.92 1.97 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.501 1.92 . . . . 0.0 109.135 -166.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.97 -11.78 21.13 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 114.726 1.38 . . . . 0.0 114.726 -166.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.93 -156.12 24.22 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 124.698 1.142 . . . . 0.0 113.072 169.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -67.98 154.83 40.79 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 126.55 1.94 . . . . 0.0 111.609 -175.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.62 129.85 34.84 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.581 0.752 . . . . 0.0 109.192 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.11 -64.19 1.1 Allowed 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.124 1.77 . . . . 0.0 110.276 -170.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.7 149.33 45.0 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 125.071 1.348 . . . . 0.0 110.531 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 63.7 m -139.08 146.63 40.98 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.047 1.739 . . . . 0.0 111.249 -176.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.08 142.93 8.72 Favored Glycine 0 N--CA 1.474 1.183 0 C-N-CA 124.804 1.192 . . . . 0.0 112.11 169.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.4 t -92.69 135.34 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 125.043 1.337 . . . . 0.0 109.312 -175.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.6 mm -77.55 115.77 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.718 -169.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.09 158.1 14.63 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.818 1.199 . . . . 0.0 113.426 -177.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -75.14 134.98 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.135 0.974 . . . . 0.0 113.326 -178.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.62 -177.35 6.53 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.711 2.404 . . . . 0.0 108.544 -170.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 . . . . . 0 N--CA 1.471 0.577 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 167.89 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.427 0 N-CA-C 113.013 0.745 . . . . 0.0 113.013 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.8 p -97.76 114.85 26.95 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.137 1.446 . . . . 0.0 108.879 171.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -113.07 125.37 54.31 Favored 'General case' 0 C--O 1.24 0.602 0 C-N-CA 125.098 1.359 . . . . 0.0 112.083 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.99 168.89 18.61 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 176.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.9 p -156.12 101.94 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 127.771 2.429 . . . . 0.0 107.836 -175.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.69 114.39 26.03 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.913 1.285 . . . . 0.0 111.403 -172.178 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.97 72.61 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 125.17 1.388 . . . . 0.0 109.585 -172.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.3 mp -77.92 115.71 17.87 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 121.437 -0.79 . . . . 0.0 109.838 178.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . 0.438 ' HZ3' ' CG ' ' A' ' 11' ' ' ASP . 4.1 ttpp -161.79 120.13 2.31 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.197 1.799 . . . . 0.0 111.021 164.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -137.07 -69.53 0.05 OUTLIER Glycine 0 N--CA 1.467 0.708 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 169.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.95 76.99 2.84 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 127.703 2.401 . . . . 0.0 110.594 -169.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.94 -102.06 0.05 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.424 1.964 . . . . 0.0 112.403 174.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -85.65 0.55 8.46 Favored 'Trans proline' 0 C--N 1.353 0.807 1 C-N-CA 125.783 4.322 . . . . 0.0 115.469 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.33 120.82 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-N 121.753 2.07 . . . . 0.0 109.486 169.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.99 166.36 24.27 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.132 1.373 . . . . 0.0 110.827 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.11 174.92 33.97 Favored Glycine 0 N--CA 1.466 0.634 0 CA-C-O 123.082 1.379 . . . . 0.0 116.115 173.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 pt -143.08 50.86 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 CA-C-N 112.833 -1.684 . . . . 0.0 112.013 -166.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 13.1 mm -81.46 119.36 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 O-C-N 120.033 -1.667 . . . . 0.0 110.957 -169.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -88.0 154.96 20.08 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.498 1.519 . . . . 0.0 110.414 169.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -143.54 108.05 4.83 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 169.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -98.38 117.82 33.65 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.994 1.109 . . . . 0.0 113.994 -173.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -96.17 139.55 32.16 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.794 1.238 . . . . 0.0 111.165 169.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.447 ' H ' ' HD2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -92.2 -36.15 13.43 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.408 2.283 . . . . 0.0 113.59 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -159.47 136.71 9.69 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 126.961 2.104 . . . . 0.0 109.034 169.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 60.3 p -19.43 -57.13 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 129.109 2.964 . . . . 0.0 116.935 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -95.24 2.91 55.0 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 127.342 2.257 . . . . 0.0 115.531 -172.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.24 168.16 54.44 Favored Glycine 0 CA--C 1.544 1.904 0 O-C-N 120.781 -1.199 . . . . 0.0 113.164 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -67.02 163.66 33.04 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.677 2.918 . . . . 0.0 110.297 170.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 77.4 t -131.26 138.74 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 CA-C-N 119.476 1.034 . . . . 0.0 111.642 -169.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 72.9 mttt -92.48 112.15 23.99 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.23 174.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.51 131.94 32.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 125.214 1.406 . . . . 0.0 109.119 170.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -154.27 165.72 35.42 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 168.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.05 175.92 21.47 Favored Glycine 0 N--CA 1.468 0.798 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -174.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -132.55 165.52 24.19 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -166.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -116.82 126.61 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.915 1.686 . . . . 0.0 107.895 168.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -126.17 132.93 51.7 Favored 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 124.905 1.282 . . . . 0.0 111.073 -177.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.44 -3.04 13.87 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.297 2.38 . . . . 0.0 112.801 -171.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.3 mt -66.93 162.73 21.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.051 0.925 . . . . 0.0 109.483 168.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -77.54 150.9 34.75 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 162.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -50.68 147.02 5.06 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 123.733 0.813 . . . . 0.0 110.306 168.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 104.06 -179.59 25.04 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.75 1.167 . . . . 0.0 113.486 -173.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.491 ' CD2' ' H ' ' B' ' 42' ' ' LEU . 1.9 pt? -84.99 145.28 27.79 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.374 2.67 . . . . 0.0 113.401 -169.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -147.36 147.3 30.17 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 128.88 2.872 . . . . 0.0 111.228 -167.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.11 156.1 49.88 Favored Glycine 0 N--CA 1.479 1.526 0 CA-C-O 117.991 -1.45 . . . . 0.0 113.618 174.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -154.43 98.07 2.07 Favored 'General case' 0 CA--C 1.553 1.07 0 C-N-CA 125.808 1.643 . . . . 0.0 111.623 -173.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -121.36 128.22 52.03 Favored 'General case' 0 N--CA 1.472 0.665 0 O-C-N 120.248 -1.532 . . . . 0.0 113.773 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -80.24 100.43 4.59 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 171.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -68.59 130.27 42.35 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 119.41 -2.056 . . . . 0.0 108.836 -170.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.05 48.67 0.12 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 128.699 2.8 . . . . 0.0 114.179 -165.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 178.66 138.73 0.09 Allowed 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 129.1 2.96 . . . . 0.0 107.054 178.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.09 -5.8 88.96 Favored Glycine 0 N--CA 1.469 0.891 0 CA-C-N 115.214 -0.903 . . . . 0.0 114.912 174.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -79.19 52.43 1.31 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.961 1.704 . . . . 0.0 112.408 -170.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.252 0.0 OUTLIER 175.89 64.98 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 116.686 2.106 . . . . 0.0 116.686 -169.64 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.7 t -73.45 21.77 0.08 Allowed 'General case' 0 N--CA 1.48 1.029 0 O-C-N 120.425 -1.422 . . . . 0.0 113.282 167.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -132.37 9.65 4.39 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 126.151 1.781 . . . . 0.0 111.459 169.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 56.44 -124.93 36.48 Favored Glycine 0 C--N 1.345 1.034 0 O-C-N 121.135 -0.978 . . . . 0.0 112.229 174.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 74.2 m -60.21 -6.94 1.64 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 175.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.6 m -87.94 3.83 47.13 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 120.02 1.282 . . . . 0.0 111.456 168.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 74.8 m -151.64 -28.46 0.18 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 119.633 -1.917 . . . . 0.0 115.468 -177.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -123.16 168.92 11.79 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 120.301 1.409 . . . . 0.0 111.794 171.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -84.88 -139.83 4.75 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-O 118.54 -1.145 . . . . 0.0 111.268 169.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -72.41 176.32 8.84 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.015 3.143 . . . . 0.0 110.959 173.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.604 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -57.11 100.18 0.04 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 128.556 2.742 . . . . 0.0 109.559 170.052 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -49.62 146.34 4.3 Favored 'General case' 0 CA--C 1.538 0.485 0 O-C-N 124.148 0.905 . . . . 0.0 111.629 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -106.12 60.82 0.16 Allowed Pre-proline 0 CA--C 1.56 1.344 0 C-N-CA 126.334 1.853 . . . . 0.0 115.625 -171.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -61.42 -35.17 84.47 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.913 3.076 . . . . 0.0 113.457 -174.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 63.6 mt -79.65 -1.51 38.56 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.453 1.101 . . . . 0.0 113.542 176.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.3 t 58.37 58.03 3.61 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.597 1.159 . . . . 0.0 113.114 169.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -153.88 179.02 9.27 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -169.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 mtmp? -61.75 173.13 1.07 Allowed 'General case' 0 CA--C 1.541 0.622 0 CA-C-O 122.186 0.993 . . . . 0.0 111.98 174.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.418 ' CE1' ' CE1' ' B' ' 63' ' ' HIS . 63.6 t60 -123.09 148.73 45.32 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 116.35 1.982 . . . . 0.0 116.35 -166.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 121.65 -63.72 0.51 Allowed Glycine 0 C--N 1.339 0.709 0 C-N-CA 124.458 1.028 . . . . 0.0 115.278 162.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 88.14 -9.85 73.26 Favored Glycine 0 CA--C 1.548 2.14 1 N-CA-C 123.294 4.078 . . . . 0.0 123.294 168.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -89.26 -5.01 5.76 Favored 'Trans proline' 0 C--N 1.358 1.044 1 CA-C-N 124.605 4.202 . . . . 0.0 112.23 168.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.42 -25.18 0.11 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.319 1.847 . . . . 0.0 110.861 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.08 139.9 50.52 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 122.87 1.319 . . . . 0.0 109.433 164.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -90.44 -22.47 21.4 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 129.527 3.131 . . . . 0.0 113.009 -168.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -98.17 -79.92 0.46 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.21 1.404 . . . . 0.0 109.901 -172.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 87.92 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 127.45 2.3 . . . . 0.0 116.498 164.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -63.99 147.44 52.03 Favored 'General case' 0 N--CA 1.484 1.233 0 O-C-N 119.678 -1.889 . . . . 0.0 108.471 164.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.9 -10.03 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 CA-C-N 122.094 2.224 . . . . 0.0 112.372 -174.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.97 5.46 75.88 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.764 1.65 . . . . 0.0 114.695 169.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -97.9 132.26 43.64 Favored 'General case' 0 C--N 1.322 -0.623 0 O-C-N 119.666 -2.079 . . . . 0.0 111.758 -173.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 81.4 mt -130.35 176.62 7.98 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.697 1.999 . . . . 0.0 106.738 165.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.27 -138.87 6.34 Favored Glycine 0 N--CA 1.471 1.003 0 C-N-CA 123.863 0.744 . . . . 0.0 114.369 -171.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -102.47 151.1 22.69 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.36 1.064 . . . . 0.0 113.369 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 16.2 m -113.51 145.57 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 127.797 2.439 . . . . 0.0 110.728 169.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 54.8 m -134.23 122.54 22.9 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.215 0.916 . . . . 0.0 109.544 -174.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.12 151.56 22.14 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.61 160.25 14.86 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 130.189 3.395 . . . . 0.0 109.5 168.104 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -40.48 -26.66 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 128.616 2.766 . . . . 0.0 117.884 175.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -77.45 7.67 5.15 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.104 1.32 . . . . 0.0 112.029 173.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.9 8.87 87.25 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 127.247 2.356 . . . . 0.0 113.748 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 11.5 p -104.28 121.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 125.103 1.361 . . . . 0.0 112.684 -170.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.34 113.41 25.36 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 164.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -104.18 141.83 35.57 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.831 0.824 . . . . 0.0 111.314 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -117.65 147.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 CA-C-N 113.606 -1.634 . . . . 0.0 113.46 -170.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 17.4 p -161.17 60.0 0.29 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 125.258 1.423 . . . . 0.0 113.75 -175.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 24.4 mt -118.61 145.21 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 O-C-N 119.771 -1.83 . . . . 0.0 112.297 -172.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -104.03 121.53 43.37 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 165.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -112.44 134.87 53.73 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.679 1.192 . . . . 0.0 109.866 174.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.0 p -109.42 50.73 0.77 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.002 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 57.7 t -133.8 -39.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.863 1.665 . . . . 0.0 110.208 169.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.59 163.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-O 123.18 1.467 . . . . 0.0 113.393 176.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' SER . . . . . 0.54 ' H ' ' HB3' ' B' ' 111' ' ' SER . 58.1 m -159.43 147.67 17.61 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 127.14 2.176 . . . . 0.0 108.863 -172.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.1 mp -79.58 97.42 6.48 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 119.013 0.824 . . . . 0.0 109.05 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.8 m -114.07 -33.71 5.62 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.178 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.15 -29.39 10.73 Favored Glycine 0 N--CA 1.469 0.858 0 CA-C-O 118.91 -0.939 . . . . 0.0 111.822 -168.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -154.25 -46.66 0.09 Allowed 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 115.577 1.695 . . . . 0.0 115.577 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -82.61 0.96 40.55 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 126.142 1.777 . . . . 0.0 112.755 -168.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' SER . . . . . 0.54 ' HB3' ' H ' ' B' ' 105' ' ' SER . 4.9 m -163.85 -78.11 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 177.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.4 pt -129.17 167.3 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 O-C-N 120.749 -1.22 . . . . 0.0 109.797 167.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.2 mm 77.93 146.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 C-N-CA 129.452 3.101 . . . . 0.0 106.84 -162.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.95 -45.76 2.29 Favored Glycine 0 N--CA 1.468 0.8 0 CA-C-O 118.985 -0.897 . . . . 0.0 113.698 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.8 mtp85 -75.85 176.62 7.64 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.961 1.304 . . . . 0.0 111.117 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.44 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 5.9 t -124.5 164.95 18.67 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 117.529 -1.224 . . . . 0.0 110.931 -173.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -127.11 140.56 52.18 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 119.619 1.1 . . . . 0.0 108.886 167.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 p -122.8 136.2 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.345 1.458 . . . . 0.0 110.101 172.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.07 158.73 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.486 1.114 . . . . 0.0 110.233 175.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -131.76 140.3 49.19 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.42 1.088 . . . . 0.0 111.729 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -63.3 -27.92 69.66 Favored 'General case' 0 N--CA 1.475 0.792 0 O-C-N 120.042 -1.661 . . . . 0.0 115.119 -174.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.93 165.19 14.0 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 120.071 -1.643 . . . . 0.0 109.957 166.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.21 152.0 34.93 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 124.307 1.043 . . . . 0.0 111.42 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -86.55 159.95 19.11 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.302 1.841 . . . . 0.0 113.034 174.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.7 -49.7 17.51 Favored 'General case' 0 N--CA 1.485 1.304 0 CA-C-N 112.728 -2.033 . . . . 0.0 111.104 166.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.6 mm? 68.32 62.73 0.37 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 127.355 2.262 . . . . 0.0 110.167 -176.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 178.22 -111.61 0.33 Allowed Glycine 0 N--CA 1.47 0.901 0 O-C-N 121.583 -0.698 . . . . 0.0 111.748 -173.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -151.63 7.94 0.5 Allowed 'General case' 0 CA--C 1.566 1.584 0 C-N-CA 126.906 2.083 . . . . 0.0 112.551 169.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 34.86 -106.5 0.03 OUTLIER Glycine 0 C--N 1.35 1.324 0 C-N-CA 126.877 2.179 . . . . 0.0 114.071 169.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -129.71 21.83 4.98 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-O 117.958 -1.468 . . . . 0.0 114.16 169.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -165.37 168.57 16.65 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 120.393 2.096 . . . . 0.0 111.249 -171.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -61.85 -53.03 61.46 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.855 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -40.84 -37.74 0.82 Allowed 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.676 1.99 . . . . 0.0 114.637 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 54.9 m -56.02 -35.67 67.1 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 171.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -94.85 -23.56 17.42 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.935 1.243 . . . . 0.0 112.527 167.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -78.9 -33.62 45.43 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-N 119.981 1.264 . . . . 0.0 113.094 -171.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.2 m -135.71 -31.32 0.95 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 126.898 2.079 . . . . 0.0 110.616 -169.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . 0.403 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 125.49 -25.41 5.67 Favored Glycine 0 C--O 1.222 -0.599 0 C-N-CA 127.996 2.712 . . . . 0.0 111.714 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 113.14 -8.63 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.856 1 C-N-CA 131.995 4.118 . . . . 0.0 112.291 176.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -57.24 -7.35 0.53 Allowed 'General case' 0 CA--C 1.56 1.349 0 N-CA-C 118.466 2.765 . . . . 0.0 118.466 -163.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.76 -31.32 1.96 Allowed Glycine 0 N--CA 1.47 0.943 0 O-C-N 119.597 -1.939 . . . . 0.0 114.512 170.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -133.64 -173.39 3.22 Favored 'General case' 0 CA--C 1.544 0.743 0 O-C-N 121.752 -0.852 . . . . 0.0 112.717 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.24 -174.44 2.72 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 127.981 2.512 . . . . 0.0 108.837 172.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.441 ' CD2' ' H ' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -174.72 -160.1 0.09 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 130.156 3.382 . . . . 0.0 107.038 171.908 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . 0.441 ' H ' ' CD2' ' B' ' 144' ' ' LEU . . . -69.86 171.98 8.44 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 127.503 2.321 . . . . 0.0 113.781 -176.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -155.92 153.31 29.43 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.817 -168.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.96 141.15 7.66 Favored Glycine 0 N--CA 1.469 0.881 0 C-N-CA 125.347 1.451 . . . . 0.0 113.975 172.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 2.3 t -77.58 147.83 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.835 0.854 . . . . 0.0 110.164 171.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.7 mm -91.91 98.29 8.21 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 126.535 1.934 . . . . 0.0 110.836 -171.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.75 -171.6 30.31 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 124.564 1.078 . . . . 0.0 114.058 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . 0.502 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 3.4 mp -119.21 128.82 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.186 0 C-N-CA 126.042 1.737 . . . . 0.0 114.367 -169.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -100.69 -24.34 14.44 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.35 1.06 . . . . 0.0 112.18 169.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 CA--C 1.534 0.345 0 C-N-CA 126.974 2.109 . . . . 0.0 111.618 -175.097 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 118.07 -0.967 . . . . 0.0 108.553 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.41 98.73 11.94 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 166.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.297 6.3 ptpt -127.24 129.78 48.39 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 176.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.27 153.38 28.51 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 126.659 1.984 . . . . 0.0 109.376 174.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -122.65 142.67 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.106 1.363 . . . . 0.0 108.976 177.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -105.19 133.32 50.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 121.092 1.769 . . . . 0.0 110.33 166.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.5 t -118.22 109.24 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.576 1.15 . . . . 0.0 109.574 -175.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.63 140.83 48.5 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.544 1.538 . . . . 0.0 112.187 -172.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -160.8 164.25 31.57 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 168.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.439 ' HA3' ' HE3' ' B' ' 9' ' ' LYS . . . 82.23 73.22 1.23 Allowed Glycine 0 C--N 1.335 0.48 0 N-CA-C 120.706 3.043 . . . . 0.0 120.706 161.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -160.04 60.96 0.35 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 108.212 164.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.76 -172.41 21.8 Favored Glycine 0 CA--C 1.541 1.671 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -164.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -73.58 58.7 3.91 Favored 'Trans proline' 0 CA--C 1.534 0.493 1 C-N-CA 125.749 4.299 . . . . 0.0 110.044 173.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.95 133.76 53.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 125.728 1.611 . . . . 0.0 110.263 -168.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.8 163.65 38.72 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 126.353 1.861 . . . . 0.0 109.85 -169.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.29 148.26 17.98 Favored Glycine 0 C--N 1.33 0.196 0 CA-C-O 122.407 1.004 . . . . 0.0 115.556 176.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -123.25 138.54 52.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 126.318 1.847 . . . . 0.0 109.888 167.814 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.9 mm -140.57 127.09 21.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 C-N-CA 125.496 1.518 . . . . 0.0 108.235 166.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -85.79 141.2 29.84 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.906 1.682 . . . . 0.0 109.839 166.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -124.28 97.82 5.49 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.727 2.011 . . . . 0.0 107.29 176.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.62 116.43 28.73 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-O 123.436 1.588 . . . . 0.0 111.636 -172.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.401 HE22 ' C ' ' A' ' 25' ' ' SER . 22.1 tt0 -108.67 148.85 29.8 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.954 178.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.421 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -89.45 -26.15 21.11 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.637 1.175 . . . . 0.0 112.912 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -131.71 -151.58 0.47 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.389 1.876 . . . . 0.0 110.401 167.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.401 ' C ' HE22 ' A' ' 22' ' ' GLN . 30.6 t -111.41 -17.53 13.09 Favored 'General case' 0 CA--C 1.555 1.169 0 C-N-CA 125.315 1.446 . . . . 0.0 110.754 167.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -90.67 -24.32 20.5 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 127.661 2.384 . . . . 0.0 115.466 170.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.2 175.64 52.41 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 119.462 1.028 . . . . 0.0 114.79 -173.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.56 151.91 47.83 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.855 2.37 . . . . 0.0 110.718 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.86 128.73 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 177.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -88.97 119.41 29.47 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 169.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.24 133.29 59.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 125.69 1.596 . . . . 0.0 110.141 -176.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -156.08 156.54 34.52 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.543 0.737 . . . . 0.0 111.886 177.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.1 -149.74 16.71 Favored Glycine 0 C--N 1.333 0.394 0 O-C-N 121.924 -0.485 . . . . 0.0 112.963 171.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 53.6 p -155.39 115.11 3.68 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 122.976 0.511 . . . . 0.0 112.056 -169.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.06 125.41 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-O 117.299 -1.334 . . . . 0.0 107.593 170.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.8 tttp -124.75 140.67 52.72 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 121.891 2.132 . . . . 0.0 111.552 -176.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.88 -0.25 13.45 Favored Glycine 0 N--CA 1.476 1.343 0 C-N-CA 127.243 2.354 . . . . 0.0 114.661 -176.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.15 -178.82 1.37 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.603 1.561 . . . . 0.0 110.985 170.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.59 -42.42 5.93 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 117.209 -1.377 . . . . 0.0 113.511 169.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 176.48 -107.67 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.267 0 C-N-CA 128.773 2.829 . . . . 0.0 109.628 -178.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -39.54 148.38 0.15 Allowed Glycine 0 N--CA 1.479 1.511 0 C-N-CA 129.533 3.444 . . . . 0.0 119.885 -168.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -31.3 136.67 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 130.1 3.36 . . . . 0.0 117.796 -169.084 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.0 m-70 -130.32 140.5 50.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 128.94 2.896 . . . . 0.0 108.764 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.57 156.52 53.33 Favored Glycine 0 N--CA 1.474 1.22 0 C-N-CA 124.08 0.848 . . . . 0.0 111.981 175.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -155.44 105.65 2.48 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.157 0.983 . . . . 0.0 112.374 -168.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.03 140.04 32.51 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 119.936 -1.728 . . . . 0.0 115.185 -172.577 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -78.11 134.99 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 166.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m170 -112.9 176.74 4.89 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 126.889 2.075 . . . . 0.0 110.901 -174.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -74.55 132.55 41.91 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.566 1.147 . . . . 0.0 112.297 170.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -77.78 -178.49 5.43 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 127.798 2.439 . . . . 0.0 115.216 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.4 ' HA2' ' CA ' ' B' ' 152' ' ' ALA . . . 119.78 -118.26 3.86 Favored Glycine 0 CA--C 1.502 -0.774 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.288 -172.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -87.83 63.45 7.44 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 125.229 2.442 . . . . 0.0 108.015 177.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -77.18 56.92 1.35 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 113.297 -1.774 . . . . 0.0 110.794 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -124.81 -44.88 1.92 Allowed 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.394 1.478 . . . . 0.0 113.943 -168.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.22 10.58 0.74 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.587 1.155 . . . . 0.0 113.093 170.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.78 -150.59 51.48 Favored Glycine 0 CA--C 1.528 0.869 0 O-C-N 120.493 -1.38 . . . . 0.0 111.294 -173.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 27.9 p -61.39 -7.29 2.87 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 117.196 2.295 . . . . 0.0 117.196 -169.149 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -88.44 -12.98 41.56 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 119.547 1.067 . . . . 0.0 113.784 170.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.3 t -124.09 -36.33 2.71 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.465 1.03 . . . . 0.0 111.853 173.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -69.07 86.94 0.38 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 166.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -47.68 120.95 6.33 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 126.736 2.112 . . . . 0.0 114.353 -166.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -67.46 126.42 14.85 Favored 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.625 2.217 . . . . 0.0 111.598 -173.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 59.65 60.96 2.08 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 164.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -45.22 109.95 0.21 Allowed 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.667 1.587 . . . . 0.0 112.746 -178.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.4 p-10 -135.5 55.33 12.56 Favored Pre-proline 0 CA--C 1.546 0.795 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -169.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -62.56 -16.16 50.59 Favored 'Trans proline' 0 C--N 1.354 0.836 0 C-N-CA 122.447 2.098 . . . . 0.0 112.495 170.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.7 mt -78.04 -7.18 56.58 Favored 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 169.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.3 t 64.98 56.18 1.08 Allowed 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.995 1.718 . . . . 0.0 112.412 170.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtm-85 -120.45 172.41 7.84 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 116.061 1.874 . . . . 0.0 116.061 -167.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.61 153.2 37.43 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 128.561 2.744 . . . . 0.0 109.944 168.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -74.42 151.24 39.67 Favored 'General case' 0 CA--C 1.541 0.598 0 O-C-N 120.807 -1.183 . . . . 0.0 113.551 171.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.96 -123.64 2.07 Favored Glycine 0 C--N 1.34 0.77 0 CA-C-O 118.728 -1.04 . . . . 0.0 113.499 166.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.9 -48.79 0.92 Allowed Glycine 0 CA--C 1.546 1.985 0 N-CA-C 117.758 1.863 . . . . 0.0 117.758 179.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -87.29 9.36 3.94 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.508 2.805 . . . . 0.0 114.131 178.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.6 pttt -165.15 -27.05 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 126.256 1.822 . . . . 0.0 112.263 179.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -83.57 161.09 21.29 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 128.618 2.767 . . . . 0.0 109.406 166.104 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -95.64 -17.98 20.9 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 125.591 1.556 . . . . 0.0 112.334 -172.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -95.19 -68.34 0.81 Allowed 'General case' 0 C--O 1.231 0.105 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -167.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.497 HH22 HG22 ' A' ' 104' ' ' ILE . 63.4 ttt-85 68.36 125.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 123.191 1.472 . . . . 0.0 111.24 -176.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -66.09 169.96 6.29 Favored 'General case' 0 CA--C 1.554 1.098 0 O-C-N 119.1 -2.25 . . . . 0.0 111.86 167.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.3 t -68.17 -50.47 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 O-C-N 120.684 -1.26 . . . . 0.0 108.665 176.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.33 92.76 1.83 Allowed Glycine 0 CA--C 1.529 0.918 0 N-CA-C 107.651 -2.179 . . . . 0.0 107.651 165.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -157.42 143.72 17.84 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.471 1.509 . . . . 0.0 112.558 171.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.99 177.63 7.75 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 127.489 2.316 . . . . 0.0 107.243 168.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.2 -126.34 1.11 Allowed Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.331 1.443 . . . . 0.0 113.908 -173.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 38.2 p-10 -144.61 164.31 31.31 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -175.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 26.8 m -136.44 123.39 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.491 1.117 . . . . 0.0 111.703 -169.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 m -98.53 141.34 31.5 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.305 1.042 . . . . 0.0 108.706 171.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.29 156.03 16.61 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 172.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.58 158.58 24.34 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.306 1.842 . . . . 0.0 107.876 165.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.435 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 1.4 pptp? -50.06 -21.7 1.35 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.208 2.203 . . . . 0.0 116.605 177.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.435 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 77.3 m-20 -78.09 4.21 12.98 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 125.199 1.4 . . . . 0.0 111.963 172.184 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.08 12.22 82.75 Favored Glycine 0 C--O 1.225 -0.441 0 C-N-CA 126.847 2.165 . . . . 0.0 114.24 176.262 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -105.73 122.66 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 CA-C-N 119.114 1.457 . . . . 0.0 112.357 -178.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.91 95.85 10.05 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 125.277 1.431 . . . . 0.0 109.948 169.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -79.48 127.32 31.98 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.62 1.568 . . . . 0.0 109.673 175.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.1 p -134.68 144.69 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -171.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.2 t -156.69 115.88 3.42 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.656 1.182 . . . . 0.0 111.556 173.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.6 mt -139.56 158.5 27.69 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 128.918 2.887 . . . . 0.0 109.986 -173.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -135.47 136.2 41.1 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 124.975 1.31 . . . . 0.0 108.114 167.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -148.69 134.12 18.57 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.566 1.146 . . . . 0.0 110.628 -167.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.6 p -106.91 45.81 0.96 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.93 18.13 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.782 1.233 . . . . 0.0 110.919 -175.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.497 HG22 HH22 ' A' ' 79' ' ' ARG . 0.2 OUTLIER -146.91 154.95 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 128.433 2.693 . . . . 0.0 106.334 164.996 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.517 ' H ' ' HB3' ' A' ' 111' ' ' SER . 76.5 p -157.67 161.7 38.6 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.775 1.23 . . . . 0.0 110.839 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -88.05 86.19 7.08 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.0 t -113.74 -4.16 13.43 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.898 1.279 . . . . 0.0 113.75 -172.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.2 -47.33 1.49 Allowed Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.046 -0.864 . . . . 0.0 113.588 -177.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 36.2 p-10 -142.09 -51.24 0.4 Allowed 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.913 1.82 . . . . 0.0 115.913 -169.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.97 -8.82 59.24 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 126.069 1.747 . . . . 0.0 112.922 -166.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.517 ' HB3' ' H ' ' A' ' 105' ' ' SER . 69.0 m -134.03 -109.67 0.22 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.623 1.169 . . . . 0.0 109.343 -174.318 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.4 pt -117.35 169.79 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 122.033 0.921 . . . . 0.0 108.754 166.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 108.4 132.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.071 1 C-N-CA 134.974 5.31 . . . . 0.0 106.384 -165.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.95 -3.23 1.63 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 116.174 1.229 . . . . 0.0 116.174 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 46.7 ttm-85 -78.95 171.63 14.94 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.744 1.218 . . . . 0.0 110.316 -172.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.5 t -116.53 162.38 17.68 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.113 1.365 . . . . 0.0 110.275 -178.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.93 131.52 18.82 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.694 1.598 . . . . 0.0 109.239 178.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 82.4 t -116.21 133.97 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 125.138 1.375 . . . . 0.0 108.693 175.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 30.8 m -103.2 155.09 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 168.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.37 130.92 41.32 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.655 1.182 . . . . 0.0 109.917 -168.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -58.48 -18.44 28.9 Favored 'General case' 0 CA--C 1.549 0.935 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.1 mmtm -128.73 168.06 16.37 Favored 'General case' 0 N--CA 1.479 0.99 0 O-C-N 118.66 -2.525 . . . . 0.0 115.063 -171.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -48.64 136.18 13.67 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 126.379 1.872 . . . . 0.0 111.68 173.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -122.72 146.95 47.03 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 124.664 2.174 . . . . 0.0 113.47 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.84 -29.24 55.81 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 112.563 -2.108 . . . . 0.0 113.673 -166.045 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.4 mt 35.13 58.45 0.77 Allowed 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 128.376 2.67 . . . . 0.0 111.274 176.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 145.15 -101.31 0.24 Allowed Glycine 0 C--N 1.334 0.431 0 C-N-CA 125.117 1.341 . . . . 0.0 110.869 -172.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -156.7 121.97 4.68 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 126.65 1.98 . . . . 0.0 112.042 -167.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.83 -90.38 1.8 Allowed Glycine 0 N--CA 1.467 0.734 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 176.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.3 2.89 2.64 Favored Glycine 0 N--CA 1.472 1.098 0 C-N-CA 125.362 1.458 . . . . 0.0 115.306 179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -120.95 161.93 20.75 Favored 'General case' 0 N--CA 1.463 0.187 0 C-N-CA 124.454 1.102 . . . . 0.0 113.116 -169.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -60.23 -55.87 28.42 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.527 1.156 . . . . 0.0 108.807 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -57.74 -7.33 0.67 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.453 1.901 . . . . 0.0 114.579 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.7 p -68.01 -48.52 65.49 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.917 1.235 . . . . 0.0 112.342 171.21 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 64.7 p -83.51 -26.87 29.81 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.344 0.658 . . . . 0.0 112.311 176.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 mtpm? -75.55 -60.56 2.25 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 178.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.1 p -104.35 -45.23 4.73 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 119.983 1.265 . . . . 0.0 113.706 178.185 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 125.26 7.99 5.65 Favored Glycine 0 CA--C 1.524 0.653 0 C-N-CA 126.214 1.864 . . . . 0.0 113.103 -168.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 56.97 21.66 6.45 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 170.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.47 26.42 0.02 OUTLIER 'General case' 0 CA--C 1.568 1.646 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -169.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.97 -40.79 2.13 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 128.581 2.991 . . . . 0.0 115.894 169.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.43 ' HB3' ' H ' ' A' ' 143' ' ' ARG . 3.4 m -171.23 -150.13 0.06 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 126.028 1.731 . . . . 0.0 110.61 -175.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.43 ' H ' ' HB3' ' A' ' 142' ' ' SER . 0.0 OUTLIER -114.3 -163.44 0.87 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.815 1.646 . . . . 0.0 109.878 170.458 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -171.67 -155.27 0.1 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 128.112 2.565 . . . . 0.0 107.92 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.93 145.98 28.24 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.302 1.441 . . . . 0.0 111.189 174.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.6 p -128.11 147.58 50.55 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.317 179.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.27 174.72 32.65 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 116.043 1.177 . . . . 0.0 116.043 -172.004 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.0 t -143.26 154.38 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 C-N-CA 124.575 1.15 . . . . 0.0 110.827 -170.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 41.8 mt -89.53 116.68 31.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 126.217 1.807 . . . . 0.0 115.086 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.438 ' HA2' ' HA2' ' B' ' 114' ' ' GLY . . . -98.99 -179.01 31.81 Favored Glycine 0 CA--C 1.531 1.094 0 C-N-CA 127.393 2.425 . . . . 0.0 112.937 167.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -144.8 138.67 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 CA-C-N 119.059 1.43 . . . . 0.0 114.258 -174.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.425 ' CA ' ' HA2' ' B' ' 51' ' ' GLY . . . -105.06 -35.5 7.61 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.083 1.142 . . . . 0.0 114.083 171.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 CA--C 1.546 0.823 0 CA-C-O 122.725 1.25 . . . . 0.0 111.409 -170.376 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.802 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 40.0 p -74.38 110.96 9.09 Favored 'General case' 0 CA--C 1.512 -0.492 0 C-N-CA 125.731 1.612 . . . . 0.0 108.222 -172.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.1 mtmm -100.7 140.91 34.31 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -171.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.86 170.04 9.86 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.489 2.316 . . . . 0.0 111.485 173.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.38 145.79 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.393 1.877 . . . . 0.0 111.839 -175.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.36 139.09 33.0 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 123.846 0.858 . . . . 0.0 109.0 165.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.3 79.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 121.44 0.638 . . . . 0.0 109.967 169.116 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.8 mp -82.87 139.66 33.33 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . 0.439 ' HE3' ' HA3' ' A' ' 10' ' ' GLY . 5.7 ttpt -154.7 157.98 38.89 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 171.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.59 173.8 19.72 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 107.256 -2.337 . . . . 0.0 107.256 164.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -79.27 55.45 1.87 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.616 1.966 . . . . 0.0 111.047 172.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.9 -164.02 32.53 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.433 1.492 . . . . 0.0 112.454 -168.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.44 45.31 1.82 Allowed 'Trans proline' 0 CA--C 1.539 0.736 1 C-N-CA 125.933 4.422 . . . . 0.0 114.497 -168.193 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -133.75 132.75 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 177.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -156.48 164.19 38.53 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 124.747 1.219 . . . . 0.0 110.811 -169.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -149.39 106.2 0.32 Allowed Glycine 0 N--CA 1.462 0.399 0 C-N-CA 125.326 1.441 . . . . 0.0 110.757 176.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . 0.262 0.1 OUTLIER -118.03 103.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -170.031 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 21.6 mm -121.48 120.97 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.168 0.987 . . . . 0.0 110.324 -168.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.79 138.92 38.43 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.716 0.807 . . . . 0.0 111.65 169.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -120.56 119.03 31.73 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.299 1.44 . . . . 0.0 108.312 169.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -107.68 119.67 40.08 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.128 0.971 . . . . 0.0 111.439 174.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -79.01 95.75 5.58 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 168.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.27 -20.17 62.26 Favored 'General case' 0 N--CA 1.475 0.816 0 O-C-N 120.551 -1.343 . . . . 0.0 112.927 175.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -156.41 127.23 6.81 Favored 'General case' 0 C--O 1.216 -0.666 0 C-N-CA 124.328 1.051 . . . . 0.0 112.635 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 7.4 m -60.91 -21.34 63.27 Favored 'General case' 0 N--CA 1.48 1.056 0 N-CA-C 116.232 1.938 . . . . 0.0 116.232 -169.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -115.09 1.24 13.86 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.161 2.184 . . . . 0.0 112.191 175.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.2 -157.53 10.81 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.541 2.02 . . . . 0.0 111.927 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.87 165.89 25.9 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.942 2.428 . . . . 0.0 113.283 -170.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.5 t -116.55 137.92 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 126.349 1.86 . . . . 0.0 108.897 174.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -92.51 129.12 38.54 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 123.82 0.848 . . . . 0.0 109.225 167.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -114.99 125.57 72.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 C-N-CA 125.669 1.588 . . . . 0.0 109.093 175.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -151.7 154.63 36.7 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.872 0.869 . . . . 0.0 110.985 174.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.96 178.5 18.88 Favored Glycine 0 N--CA 1.462 0.395 0 CA-C-O 122.439 1.022 . . . . 0.0 113.7 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 23.5 p -114.13 140.18 48.72 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 115.821 1.785 . . . . 0.0 115.821 -164.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.16 108.1 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 125.701 1.6 . . . . 0.0 108.869 169.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -119.26 147.61 44.07 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 124.31 1.044 . . . . 0.0 109.994 -171.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.8 19.36 29.45 Favored Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.563 1.554 . . . . 0.0 111.531 -170.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 71.5 mt -92.35 -171.49 2.81 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.513 1.925 . . . . 0.0 108.717 167.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.48 150.99 48.38 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 130.404 3.482 . . . . 0.0 105.178 167.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -50.21 -9.6 0.05 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 129.61 3.164 . . . . 0.0 116.785 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -63.88 163.26 33.58 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.385 -1.447 . . . . 0.0 112.233 168.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -57.74 142.94 43.71 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 126.0 1.72 . . . . 0.0 111.18 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -131.32 128.39 39.65 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.356 1.062 . . . . 0.0 110.419 169.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.76 154.86 53.13 Favored Glycine 0 N--CA 1.47 0.965 0 CA-C-O 118.333 -1.26 . . . . 0.0 112.439 177.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -149.06 124.08 10.04 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 119.466 1.633 . . . . 0.0 112.033 -169.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -156.44 158.81 37.94 Favored 'General case' 0 C--O 1.238 0.474 0 O-C-N 120.415 -1.428 . . . . 0.0 112.773 178.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.9 m -101.15 126.79 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.012 1.325 . . . . 0.0 108.746 177.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.9 m-70 -76.8 177.7 7.42 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 122.73 1.253 . . . . 0.0 110.991 -178.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -62.91 154.75 29.29 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 162.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.54 -135.74 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 122.05 0.928 . . . . 0.0 112.011 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.425 ' HA2' ' CA ' ' A' ' 152' ' ' ALA . . . 91.65 -109.43 3.73 Favored Glycine 0 CA--C 1.495 -1.167 0 C-N-CA 123.889 0.757 . . . . 0.0 111.966 168.322 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.32 58.76 0.86 Allowed 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 127.081 2.152 . . . . 0.0 105.666 -174.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -62.15 -2.86 1.06 Allowed 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 116.376 1.991 . . . . 0.0 116.376 -165.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.343 0.6 OUTLIER -66.12 -33.21 75.27 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -164.2 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.53 8.55 40.26 Favored 'General case' 0 CA--C 1.552 1.048 0 CA-C-N 119.525 1.057 . . . . 0.0 113.198 168.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 55.66 -124.07 32.44 Favored Glycine 0 C--N 1.342 0.906 0 C-N-CA 125.034 1.302 . . . . 0.0 111.791 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t -56.23 -7.1 0.32 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 127.364 2.266 . . . . 0.0 115.695 176.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 23.4 m -115.73 30.2 7.5 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.534 1.533 . . . . 0.0 110.397 176.06 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 40.2 t -159.41 -55.77 0.06 Allowed 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.656 1.182 . . . . 0.0 110.723 170.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -94.77 141.52 28.53 Favored 'General case' 0 C--O 1.24 0.579 0 C-N-CA 124.058 0.943 . . . . 0.0 111.063 177.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.75 131.44 27.26 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 123.955 0.788 . . . . 0.0 112.5 175.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.0 114.05 2.84 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.759 2.306 . . . . 0.0 107.125 169.1 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.417 ' CE1' ' ND1' ' B' ' 71' ' ' HIS 0.27 0.0 OUTLIER 48.04 78.34 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.57 1.948 . . . . 0.0 114.125 -178.336 . . . . . . . . 4 4 . 1 . 011 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -39.65 116.3 0.61 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.861 1.264 . . . . 0.0 110.559 169.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . 0.265 0.1 OUTLIER -122.41 73.37 40.32 Favored Pre-proline 0 CA--C 1.544 0.719 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -170.046 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -64.99 -24.78 59.84 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.821 2.347 . . . . 0.0 114.122 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.17 -6.43 56.54 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.077 0.951 . . . . 0.0 113.114 174.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.9 t 56.96 52.84 8.72 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.265 1.426 . . . . 0.0 113.508 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 mtp180 -109.34 179.1 4.25 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.662 1.185 . . . . 0.0 114.047 -169.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.97 175.44 9.07 Favored 'General case' 0 CA--C 1.548 0.885 0 O-C-N 120.591 -1.318 . . . . 0.0 108.633 162.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.417 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 83.6 t60 -110.85 152.47 26.64 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -167.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.35 -128.89 3.52 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-O 118.663 -1.076 . . . . 0.0 113.881 165.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 153.5 -40.05 0.69 Allowed Glycine 0 CA--C 1.546 1.969 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 176.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -112.23 29.99 0.03 OUTLIER 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 125.041 3.827 . . . . 0.0 111.608 169.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -158.93 -53.03 0.06 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 127.745 2.418 . . . . 0.0 106.332 -178.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -85.3 155.46 21.34 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.917 1.687 . . . . 0.0 108.865 163.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -103.93 -17.25 15.08 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.467 1.507 . . . . 0.0 112.34 172.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -74.44 -39.52 62.52 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 120.807 -1.183 . . . . 0.0 112.334 -170.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt85 33.28 90.92 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 127.33 2.252 . . . . 0.0 114.79 168.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.3 m80 -47.62 159.03 0.17 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.031 1.333 . . . . 0.0 112.511 178.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.8 m -71.08 87.29 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 119.063 0.847 . . . . 0.0 110.235 172.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.87 39.15 0.18 Allowed Glycine 0 CA--C 1.529 0.967 0 C-N-CA 126.361 1.934 . . . . 0.0 114.553 -173.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -134.33 118.08 17.09 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 125.466 1.506 . . . . 0.0 109.913 -173.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -105.66 -179.24 3.88 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.936 0.894 . . . . 0.0 109.44 169.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.41 -134.75 3.35 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 122.214 0.897 . . . . 0.0 112.455 179.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -112.75 142.2 45.67 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.723 0.809 . . . . 0.0 110.611 170.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 17.9 m -109.02 92.79 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 126.69 1.996 . . . . 0.0 109.104 173.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.5 m -82.53 132.29 35.2 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 173.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.37 171.62 8.93 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -83.83 162.72 20.48 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.118 1.367 . . . . 0.0 107.351 164.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.4 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -57.14 -14.84 4.44 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 172.217 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -72.3 -13.66 61.55 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 125.763 1.625 . . . . 0.0 111.71 172.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.51 4.53 67.94 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.015 1.769 . . . . 0.0 113.294 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -102.73 130.23 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 125.565 1.546 . . . . 0.0 113.788 177.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.82 108.41 19.9 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 165.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -98.61 113.66 25.8 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.102 0.953 . . . . 0.0 110.76 175.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -93.47 156.23 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 125.33 1.452 . . . . 0.0 113.807 -169.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.0 p -156.87 117.83 3.68 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.935 1.294 . . . . 0.0 111.098 173.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.7 mt -146.1 150.81 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 C-N-CA 128.78 2.832 . . . . 0.0 109.906 -176.225 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 -137.57 131.11 31.18 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.371 1.468 . . . . 0.0 107.57 168.101 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -155.4 152.19 28.76 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.901 1.074 . . . . 0.0 113.901 -168.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 86.3 p -116.49 59.34 0.74 Allowed 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 125.977 1.711 . . . . 0.0 114.184 -167.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 p -147.26 -2.61 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 116.357 1.984 . . . . 0.0 116.357 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.36 168.65 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 125.5 1.52 . . . . 0.0 110.785 177.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 57.9 p -147.97 170.42 17.75 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 115.571 1.693 . . . . 0.0 115.571 178.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mp -102.92 48.03 0.87 Allowed 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 168.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.3 m -85.27 33.66 0.56 Allowed 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.569 -1.332 . . . . 0.0 112.405 -176.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 87.97 65.77 1.33 Allowed Glycine 0 N--CA 1.469 0.862 0 C-N-CA 124.158 0.885 . . . . 0.0 112.767 176.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.315 0.0 OUTLIER 76.78 -21.74 0.31 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 127.673 2.389 . . . . 0.0 114.334 170.176 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -77.52 11.66 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 127.322 2.249 . . . . 0.0 112.886 -173.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -142.02 -72.2 0.33 Allowed 'General case' 0 CA--C 1.544 0.743 0 N-CA-C 116.512 2.041 . . . . 0.0 116.512 170.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.94 0.7 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 116.016 1.858 . . . . 0.0 116.016 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.6 mm -89.12 149.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 168.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . 0.438 ' HA2' ' HA2' ' A' ' 150' ' ' GLY . . . 77.72 6.78 87.19 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 114.561 0.585 . . . . 0.0 114.561 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.8 ttt180 -115.31 179.28 4.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.989 2.116 . . . . 0.0 111.462 -168.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.83 151.39 37.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 C-N-CA 124.034 0.934 . . . . 0.0 111.124 177.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 19.5 tp -128.31 140.91 51.61 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 127.13 2.172 . . . . 0.0 106.572 167.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.37 156.38 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 124.362 1.065 . . . . 0.0 110.592 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -125.87 134.04 67.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-O 122.514 1.149 . . . . 0.0 110.697 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -92.34 145.85 24.15 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.426 1.49 . . . . 0.0 112.258 -168.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -67.62 -39.92 84.69 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 121.086 -1.009 . . . . 0.0 111.996 -174.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -98.69 -179.99 4.49 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.582 1.153 . . . . 0.0 109.962 167.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.59 165.49 0.83 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.697 1.199 . . . . 0.0 111.541 168.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -107.87 148.25 29.84 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.739 0.78 . . . . 0.0 110.662 165.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.73 -20.81 45.54 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.595 1.958 . . . . 0.0 114.807 -169.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.9 mt 41.61 49.02 3.65 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 126.238 1.815 . . . . 0.0 113.993 169.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 135.71 -78.56 0.34 Allowed Glycine 0 N--CA 1.469 0.839 0 C-N-CA 124.894 1.235 . . . . 0.0 111.288 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.86 148.4 22.42 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 117.585 2.439 . . . . 0.0 117.585 170.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -157.67 -79.5 0.03 OUTLIER Glycine 0 C--N 1.332 0.315 0 C-N-CA 130.287 3.803 . . . . 0.0 106.901 171.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.6 -92.87 0.02 OUTLIER Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.056 1.789 . . . . 0.0 115.955 -169.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -131.03 -127.54 0.2 Allowed 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.169 -1.195 . . . . 0.0 113.03 -166.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.32 -53.78 4.08 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.292 3.037 . . . . 0.0 109.949 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -43.46 -33.64 1.14 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 128.3 2.64 . . . . 0.0 114.03 169.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.8 m -45.33 -36.43 4.15 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 126.639 1.975 . . . . 0.0 113.702 168.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -103.3 -20.27 14.16 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 126.126 1.77 . . . . 0.0 113.886 -173.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 41.9 mtpt -80.6 -36.5 32.67 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.053 0.941 . . . . 0.0 110.745 170.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 20.0 p -135.95 -108.88 0.2 Allowed 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 127.324 2.249 . . . . 0.0 107.953 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -165.94 148.18 13.35 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 127.597 2.522 . . . . 0.0 108.151 169.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -75.42 45.56 0.3 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.54 1.536 . . . . 0.0 112.572 -172.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.51 6.24 24.38 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -167.015 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.61 -47.29 0.42 Allowed Glycine 0 CA--C 1.536 1.39 0 N-CA-C 118.948 2.339 . . . . 0.0 118.948 168.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -175.31 -176.93 0.97 Allowed 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.547 1.674 . . . . 0.0 112.406 -169.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.29 142.43 19.29 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.978 1.311 . . . . 0.0 111.591 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -103.74 -20.7 13.86 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.706 1.203 . . . . 0.0 114.123 -176.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -155.56 147.05 22.87 Favored 'General case' 0 C--O 1.244 0.775 0 C-N-CA 124.486 1.114 . . . . 0.0 109.195 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 63.3 m -138.99 149.18 44.4 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 127.936 2.494 . . . . 0.0 108.774 -179.015 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.71 160.03 29.98 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 115.421 0.929 . . . . 0.0 115.421 -174.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 5.2 t -109.56 152.15 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.189 1.396 . . . . 0.0 109.789 172.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.3 mm -94.72 116.78 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 126.081 1.753 . . . . 0.0 112.07 -174.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.16 165.48 15.13 Favored Glycine 0 C--N 1.348 1.237 0 C-N-CA 124.358 0.98 . . . . 0.0 112.503 177.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -117.7 124.89 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.4 ' CA ' ' HA2' ' A' ' 51' ' ' GLY . . . -79.76 -25.06 41.12 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 121.596 0.712 . . . . 0.0 110.265 165.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 70.0 mt-30 . . . . . 0 CA--C 1.531 0.229 0 C-N-CA 125.74 1.616 . . . . 0.0 109.023 178.347 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.802 0 CA-C-O 120.336 0.112 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 34.7 p -84.24 118.4 24.14 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -171.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.4 ttmm -101.89 125.95 48.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.014 -1.903 . . . . 0.0 106.315 168.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.57 159.85 41.21 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 125.116 1.367 . . . . 0.0 111.325 -169.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.6 t -139.65 143.42 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.438 1.113 . . . . 0.0 112.907 -169.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.2 111.72 14.92 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 164.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.658 ' CG2' ' H ' ' B' ' 54' ' ' THR . 6.8 m -97.27 112.29 28.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 168.193 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.7 mp -96.87 107.61 20.14 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.529 1.132 . . . . 0.0 111.021 -168.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -155.29 124.4 6.23 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 121.782 0.801 . . . . 0.0 112.865 173.226 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.63 -41.34 0.02 OUTLIER Glycine 0 CA--C 1.53 0.985 0 C-N-CA 127.898 2.666 . . . . 0.0 109.478 167.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -79.26 59.37 2.79 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 128.337 2.655 . . . . 0.0 112.55 -174.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.96 -104.25 0.06 OUTLIER Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.867 2.175 . . . . 0.0 114.232 171.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.04 -9.6 14.13 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 124.656 3.571 . . . . 0.0 114.621 -175.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.6 t -90.41 138.69 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-N 120.448 1.476 . . . . 0.0 108.325 171.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -156.82 164.81 37.66 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.018 1.327 . . . . 0.0 109.944 169.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.04 174.02 34.64 Favored Glycine 0 CA--C 1.507 -0.42 0 C-N-CA 124.329 0.966 . . . . 0.0 111.432 167.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 pp -127.52 142.15 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 C-N-CA 124.533 1.133 . . . . 0.0 108.356 168.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -130.19 133.83 63.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.708 . . . . 0.0 109.201 170.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -103.23 141.58 35.65 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 110.095 169.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -124.87 119.68 29.52 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.612 1.565 . . . . 0.0 108.24 171.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -115.85 119.33 35.64 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.346 1.459 . . . . 0.0 110.561 -175.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -129.62 141.83 50.86 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 123.506 1.622 . . . . 0.0 113.802 -174.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.476 ' HE2' ' OE2' ' A' ' 24' ' ' GLU . 15.0 ptmt -82.93 -62.7 1.53 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.742 2.017 . . . . 0.0 114.189 -171.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.476 ' OE2' ' HE2' ' A' ' 23' ' ' LYS . 3.7 pm0 -133.48 172.81 12.22 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 126.215 1.806 . . . . 0.0 110.668 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 p -45.06 -54.03 7.17 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.37 1.868 . . . . 0.0 115.434 -168.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -96.2 7.75 45.63 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.795 1.638 . . . . 0.0 111.73 -178.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.24 150.46 37.11 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 125.27 1.414 . . . . 0.0 113.627 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -63.66 162.85 26.48 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 123.996 3.131 . . . . 0.0 110.373 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -129.86 130.76 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 C-N-CA 123.346 0.658 . . . . 0.0 110.046 -169.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -91.15 131.81 36.47 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 167.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.7 t -124.24 137.79 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 125.567 1.547 . . . . 0.0 109.132 -173.014 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.4 p90 -157.29 168.66 26.74 Favored 'General case' 0 N--CA 1.471 0.624 0 O-C-N 121.276 -0.89 . . . . 0.0 113.286 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.34 -157.68 27.35 Favored Glycine 0 C--N 1.335 0.498 0 C-N-CA 125.173 1.368 . . . . 0.0 111.204 170.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.5 p -155.5 147.5 23.44 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -122.07 122.19 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 -177.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 59.8 tttt -120.81 133.44 55.32 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.317 1.047 . . . . 0.0 110.579 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.26 4.29 16.14 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.931 2.205 . . . . 0.0 112.645 -168.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 98.0 mt -82.89 163.38 21.16 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 118.201 1.0 . . . . 0.0 111.467 169.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.9 t -96.81 145.65 25.64 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 126.038 1.735 . . . . 0.0 107.475 165.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.443 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.8 pm0 -51.19 143.35 11.14 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.196 2.598 . . . . 0.0 114.739 -173.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.76 -179.81 34.42 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 125.012 1.292 . . . . 0.0 113.464 -172.159 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -56.73 151.28 14.39 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 128.058 2.543 . . . . 0.0 113.555 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -147.96 138.82 23.22 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.905 1.682 . . . . 0.0 109.411 167.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.67 154.91 20.9 Favored Glycine 0 N--CA 1.48 1.604 0 C-N-CA 124.051 0.834 . . . . 0.0 113.115 172.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -158.58 95.37 1.32 Allowed 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 124.423 1.089 . . . . 0.0 112.262 -170.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -146.14 148.92 33.09 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.262 1.579 . . . . 0.0 115.262 -169.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -82.76 110.97 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.95 1.7 . . . . 0.0 110.186 171.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -82.65 165.97 19.56 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.795 2.038 . . . . 0.0 110.793 176.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -59.96 145.11 47.26 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 122.35 1.071 . . . . 0.0 111.469 -176.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -82.53 -114.93 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.709 1.604 . . . . 0.0 111.739 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.5 -96.06 1.73 Allowed Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -143.92 54.68 1.31 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 -172.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.29 7.3 p-10 -73.39 27.98 0.07 Allowed 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.412 ' CG2' ' HA ' ' B' ' 7' ' ' VAL . 8.4 p -90.36 -7.37 53.42 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.352 1.461 . . . . 0.0 113.772 -168.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.19 -4.23 35.93 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.057 1.743 . . . . 0.0 112.97 168.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.92 -101.52 0.27 Allowed Glycine 0 C--N 1.343 0.941 0 CA-C-N 120.056 1.298 . . . . 0.0 112.519 170.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.4 m -54.83 -17.88 4.12 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 175.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.03 7.07 23.5 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.297 1.439 . . . . 0.0 113.521 175.267 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.4 t -171.85 98.0 0.17 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.94 1.696 . . . . 0.0 108.342 178.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 149.6 58.86 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 130.559 3.544 . . . . 0.0 111.687 -169.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -61.84 147.96 48.08 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 126.279 1.895 . . . . 0.0 114.123 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.77 95.17 0.54 Allowed 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 124.796 3.664 . . . . 0.0 113.765 -168.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 p80 42.95 68.2 0.53 Allowed 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 126.517 1.927 . . . . 0.0 112.485 166.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -39.28 142.87 0.22 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-O 124.009 1.861 . . . . 0.0 115.085 -167.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 38.9 p-10 -104.41 48.95 0.08 OUTLIER Pre-proline 0 CA--C 1.554 1.121 0 C-N-CA 127.11 2.164 . . . . 0.0 114.352 -177.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -69.77 -15.81 37.22 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 121.941 1.729 . . . . 0.0 112.473 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.68 -3.16 42.72 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.769 1.628 . . . . 0.0 112.325 169.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.1 t 69.97 57.72 0.29 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.662 1.585 . . . . 0.0 113.029 168.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 ptm85 -152.6 176.41 11.75 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -169.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -91.24 168.17 11.79 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.35 1.46 . . . . 0.0 112.705 -179.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.6 t60 -75.95 160.56 29.76 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.427 1.091 . . . . 0.0 113.512 179.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 136.41 -113.64 1.08 Allowed Glycine 0 C--N 1.339 0.713 0 C-N-CA 125.392 1.472 . . . . 0.0 112.315 166.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.93 -56.52 0.54 Allowed Glycine 0 CA--C 1.537 1.449 0 N-CA-C 117.742 1.857 . . . . 0.0 117.742 171.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -81.24 -16.69 9.52 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 CA-C-N 121.54 2.67 . . . . 0.0 112.505 178.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.51 -5.73 4.2 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.804 1.242 . . . . 0.0 112.893 173.104 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -102.5 169.3 8.75 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.462 1.505 . . . . 0.0 110.377 178.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -101.08 -7.07 23.54 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 127.083 2.153 . . . . 0.0 112.729 -167.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -127.35 -82.94 0.61 Allowed 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 119.597 1.09 . . . . 0.0 113.583 -171.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 79.12 140.55 0.07 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 126.289 1.836 . . . . 0.0 113.546 170.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -82.95 -177.77 6.88 Favored 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 116.361 1.986 . . . . 0.0 116.361 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -66.97 -12.13 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 174.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -134.81 14.03 4.43 Favored Glycine 0 CA--C 1.531 1.085 0 CA-C-O 118.161 -1.355 . . . . 0.0 116.31 -171.014 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -92.84 112.6 24.62 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.654 1.727 . . . . 0.0 111.275 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.4 48.72 1.38 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 120.101 1.319 . . . . 0.0 111.874 177.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.94 -143.98 24.65 Favored Glycine 0 CA--C 1.536 1.367 0 O-C-N 121.211 -0.931 . . . . 0.0 114.93 172.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -131.95 158.07 42.38 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 126.184 1.793 . . . . 0.0 112.883 -179.385 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.7 m -114.17 106.74 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.165 1.786 . . . . 0.0 111.001 169.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.4 m -106.49 115.61 30.5 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.599 1.56 . . . . 0.0 110.229 -169.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.13 147.79 24.74 Favored 'General case' 0 CA--C 1.539 0.558 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -172.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -93.96 160.65 14.63 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 128.978 2.911 . . . . 0.0 109.685 168.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.83 -14.9 2.65 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 126.169 1.788 . . . . 0.0 115.698 -175.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.27 -5.3 26.75 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.757 -1.215 . . . . 0.0 112.11 171.318 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.82 15.53 65.28 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 127.008 2.242 . . . . 0.0 112.878 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.0 p -121.33 128.87 76.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.544 1.172 . . . . 0.0 113.699 -170.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.64 110.56 22.66 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 164.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -91.9 137.27 32.5 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 169.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -135.68 149.65 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 N-CA-C 116.801 2.148 . . . . 0.0 116.801 -168.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.9 m -155.21 127.37 7.7 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 126.052 1.741 . . . . 0.0 110.367 169.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 10.1 mm -140.82 166.44 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 129.026 2.93 . . . . 0.0 109.794 -173.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -155.29 154.61 32.38 Favored 'General case' 0 C--N 1.316 -0.87 0 C-N-CA 128.108 2.563 . . . . 0.0 107.825 170.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -155.79 150.99 26.7 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.938 1.295 . . . . 0.0 111.577 170.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -119.03 53.05 1.02 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.521 -1.218 . . . . 0.0 112.225 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 48.9 t -137.81 -43.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.3 1.44 . . . . 0.0 107.928 168.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.87 160.11 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 123.027 1.394 . . . . 0.0 110.93 167.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.483 ' H ' ' HB3' ' A' ' 111' ' ' SER . 3.6 p -156.29 168.87 25.97 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 128.762 2.825 . . . . 0.0 106.969 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -93.25 102.3 14.58 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -152.83 -6.91 0.19 Allowed 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -167.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.13 -95.83 2.13 Favored Glycine 0 C--N 1.336 0.546 0 O-C-N 120.927 -1.108 . . . . 0.0 111.613 173.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -69.97 -51.99 28.07 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.851 0.685 . . . . 0.0 112.851 -166.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -78.92 -27.81 43.78 Favored 'General case' 0 CA--C 1.539 0.547 0 O-C-N 120.271 -1.518 . . . . 0.0 112.358 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.483 ' HB3' ' H ' ' A' ' 105' ' ' SER . 8.2 m -118.88 -127.16 0.28 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.857 1.799 . . . . 0.0 115.857 -164.617 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.29 39.3 pt -111.03 173.69 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 O-C-N 119.769 -1.832 . . . . 0.0 108.682 166.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mm 90.49 136.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.843 1 C-N-CA 132.757 4.423 . . . . 0.0 107.25 -163.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 58.35 25.2 57.29 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.556 1.074 . . . . 0.0 114.687 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.1 ttm180 -122.17 156.29 34.0 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 126.614 1.965 . . . . 0.0 107.515 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.9 t -113.07 107.62 16.21 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 122.352 2.342 . . . . 0.0 115.694 -165.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 57.0 tp -76.99 128.92 35.39 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.72 0.808 . . . . 0.0 110.266 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -118.04 136.56 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.252 1.021 . . . . 0.0 109.127 169.352 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 m -93.04 144.74 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.384 -1.709 . . . . 0.0 106.384 168.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.7 m-70 -101.98 158.93 15.79 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-O 122.369 1.08 . . . . 0.0 112.987 -170.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -74.71 -35.64 62.71 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 -168.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -125.85 179.98 4.94 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 125.29 1.436 . . . . 0.0 112.597 173.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.25 140.47 38.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 126.683 1.993 . . . . 0.0 112.463 173.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -91.58 131.03 37.28 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.115 0.966 . . . . 0.0 111.057 178.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.419 ' OD1' ' HE3' ' A' ' 128' ' ' LYS . 0.3 OUTLIER -77.09 -18.93 57.65 Favored 'General case' 0 CA--C 1.554 1.118 0 N-CA-C 112.889 0.699 . . . . 0.0 112.889 174.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 41.3 mt 62.08 54.39 2.74 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.946 2.098 . . . . 0.0 113.686 173.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 118.62 -11.23 12.37 Favored Glycine 0 N--CA 1.475 1.246 0 N-CA-C 121.297 3.279 . . . . 0.0 121.297 164.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.47 ' HE3' ' H ' ' A' ' 128' ' ' LYS 0.252 0.0 OUTLIER -167.08 62.11 0.08 Allowed 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 118.192 2.664 . . . . 0.0 118.192 -173.626 . . . . . . . . 4 4 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -106.25 45.68 1.27 Allowed Glycine 0 N--CA 1.471 0.975 0 C-N-CA 127.041 2.257 . . . . 0.0 113.349 -172.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.21 -27.53 1.47 Allowed Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.62 1.105 . . . . 0.0 115.749 172.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -89.77 154.55 19.83 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 118.983 1.391 . . . . 0.0 110.381 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -55.33 -54.14 47.31 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-O 122.751 1.262 . . . . 0.0 109.108 167.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.522 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 6.4 tm-20 -51.89 -34.89 43.26 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 128.447 2.699 . . . . 0.0 112.593 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.0 p -60.03 -34.39 73.3 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.7 p -77.13 -14.37 59.81 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.61 1.164 . . . . 0.0 111.991 179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.3 mtpt -100.15 -53.76 3.05 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.516 1.926 . . . . 0.0 111.891 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.522 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 29.8 p -100.08 -34.42 10.07 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 117.659 -1.162 . . . . 0.0 113.781 -172.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.98 -3.2 28.64 Favored Glycine 0 CA--C 1.533 1.196 0 O-C-N 125.448 1.717 . . . . 0.0 113.715 -168.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.69 25.04 11.28 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 126.193 1.797 . . . . 0.0 112.738 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.82 46.39 0.29 Allowed 'General case' 0 CA--C 1.552 1.049 0 C-N-CA 126.799 2.04 . . . . 0.0 113.755 -168.157 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.04 -59.4 3.54 Favored Glycine 0 N--CA 1.467 0.728 0 C-N-CA 127.987 2.708 . . . . 0.0 113.692 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t 178.09 179.03 0.34 Allowed 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.11 2.164 . . . . 0.0 109.494 -169.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.64 153.66 35.02 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.03 -1.044 . . . . 0.0 111.018 169.75 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -135.14 -150.77 0.4 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.375 1.47 . . . . 0.0 108.63 169.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -52.93 141.96 20.64 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.274 1.43 . . . . 0.0 114.151 -173.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -134.72 154.67 51.46 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.983 1.313 . . . . 0.0 114.361 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.24 125.03 1.55 Allowed Glycine 0 CA--C 1.539 1.562 0 C-N-CA 124.646 1.117 . . . . 0.0 114.557 173.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -78.14 126.58 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 173.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 59.9 mt -78.41 124.51 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -167.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.76 167.97 13.96 Favored Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.847 1.213 . . . . 0.0 115.413 175.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.57 162.82 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 126.438 1.895 . . . . 0.0 113.416 -171.016 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -158.18 -40.97 0.06 Allowed 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.01 1.324 . . . . 0.0 112.032 169.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.47 0.538 0 C-N-CA 124.226 1.01 . . . . 0.0 112.159 169.096 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 70.9 p -134.08 125.43 28.02 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 166.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.3 mtmt -119.57 158.54 26.13 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -179.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . 0.404 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -144.58 151.99 39.87 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.98 1.312 . . . . 0.0 112.534 169.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 p -111.08 133.53 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 125.987 1.715 . . . . 0.0 110.673 177.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.54 110.94 21.3 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.774 -1.204 . . . . 0.0 110.088 167.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.412 ' HA ' ' CG2' ' A' ' 54' ' ' THR . 15.0 t -86.52 68.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 124.36 1.064 . . . . 0.0 112.063 -170.396 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -79.77 110.56 15.24 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 113.426 0.898 . . . . 0.0 113.426 -175.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mttm -157.62 129.55 7.03 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.71 1.204 . . . . 0.0 112.195 167.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.68 -56.9 0.01 OUTLIER Glycine 0 N--CA 1.468 0.772 0 C-N-CA 126.233 1.873 . . . . 0.0 109.885 169.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.58 72.29 3.24 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 125.989 1.715 . . . . 0.0 110.953 -176.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.64 -94.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.377 0 C-N-CA 127.844 2.64 . . . . 0.0 114.746 173.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -71.08 -20.98 28.03 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 123.964 3.109 . . . . 0.0 114.797 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.1 t -74.15 147.65 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 CA-C-N 121.483 1.947 . . . . 0.0 110.491 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.32 167.75 21.2 Favored 'General case' 0 CA--C 1.519 -0.228 0 C-N-CA 124.48 1.112 . . . . 0.0 109.651 167.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.8 59.58 0.4 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.874 169.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -75.41 127.42 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 117.776 0.788 . . . . 0.0 108.987 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.18 119.55 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 O-C-N 125.277 1.61 . . . . 0.0 109.741 176.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.2 121.27 23.41 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 124.915 1.286 . . . . 0.0 110.65 165.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -99.67 94.17 6.22 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.26 1.824 . . . . 0.0 106.135 167.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -98.25 113.66 25.67 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 124.311 1.044 . . . . 0.0 110.349 178.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . 0.434 ' OE1' ' HA ' ' B' ' 105' ' ' SER . 4.5 tt0 -113.13 139.01 49.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 122.678 1.228 . . . . 0.0 110.464 179.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.71 -5.05 54.43 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.1 1.36 . . . . 0.0 114.237 -171.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 mp0 -155.75 -168.24 2.73 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 130.078 3.351 . . . . 0.0 106.603 175.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.8 t -89.2 -21.13 23.43 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-N 119.957 1.253 . . . . 0.0 110.135 163.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -109.6 11.32 24.8 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 126.191 1.796 . . . . 0.0 115.232 -176.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.77 -179.75 38.85 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 124.423 1.011 . . . . 0.0 112.834 -177.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.23 161.47 20.23 Favored 'Trans proline' 0 CA--C 1.537 0.654 0 C-N-CA 123.346 2.697 . . . . 0.0 109.421 168.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.01 134.94 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.89 0.876 . . . . 0.0 111.734 -169.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.46 ' HZ2' ' CD ' ' B' ' 100' ' ' GLU . 50.6 mttp -87.84 126.14 34.86 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 165.531 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -123.75 89.03 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 127.362 2.265 . . . . 0.0 108.23 -169.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -119.09 156.24 30.08 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.799 0.84 . . . . 0.0 111.815 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.84 176.82 41.71 Favored Glycine 0 C--O 1.225 -0.439 0 O-C-N 121.479 -0.763 . . . . 0.0 113.437 -174.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -127.75 118.78 24.41 Favored 'General case' 0 C--O 1.239 0.543 0 O-C-N 122.054 -0.674 . . . . 0.0 111.948 -178.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.1 mm -92.08 117.8 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 169.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.3 pttt -139.41 137.34 35.58 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 123.185 0.594 . . . . 0.0 110.328 -168.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.29 0.68 54.01 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.871 1.7 . . . . 0.0 114.787 -173.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -91.3 -160.35 0.72 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 118.412 1.106 . . . . 0.0 111.304 169.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.6 t -112.19 155.99 23.06 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.293 1.837 . . . . 0.0 110.976 178.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -47.65 149.85 1.13 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.625 1.97 . . . . 0.0 111.879 169.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.75 38.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 124.009 0.814 . . . . 0.0 113.726 -178.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.425 ' CD1' ' H ' ' B' ' 42' ' ' LEU . 5.6 mp -65.87 144.51 56.77 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 128.921 2.888 . . . . 0.0 113.157 -171.284 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -140.53 124.05 16.97 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 126.608 1.963 . . . . 0.0 110.508 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.5 149.85 35.45 Favored Glycine 0 N--CA 1.476 1.334 0 C-N-CA 124.744 1.164 . . . . 0.0 112.391 176.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -146.52 102.2 3.55 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-O 121.861 0.838 . . . . 0.0 112.404 -164.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -129.45 126.23 38.26 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 120.855 -1.153 . . . . 0.0 110.427 -169.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.79 116.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.296 1.439 . . . . 0.0 108.984 171.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.531 ' C ' ' H ' ' B' ' 50' ' ' PHE . 21.8 m170 -78.86 122.25 25.85 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 121.307 -0.871 . . . . 0.0 110.381 -179.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.65 2.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 127.053 2.141 . . . . 0.0 115.426 170.03 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . 0.531 ' H ' ' C ' ' B' ' 48' ' ' HIS . 2.5 m-85 -137.16 81.51 1.88 Allowed 'General case' 0 N--CA 1.442 -0.839 1 C-N-CA 133.776 4.83 . . . . 0.0 100.94 -176.011 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.05 20.07 35.04 Favored Glycine 0 N--CA 1.467 0.73 0 O-C-N 121.655 -0.653 . . . . 0.0 113.225 173.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -68.99 49.06 0.07 Allowed 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.042 2.537 . . . . 0.0 113.085 171.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -178.74 131.45 0.12 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.414 1.486 . . . . 0.0 111.047 -168.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 54' ' ' THR . . . . . 0.658 ' H ' ' CG2' ' A' ' 7' ' ' VAL . 6.6 t -152.31 14.7 0.6 Allowed 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 116.236 1.939 . . . . 0.0 116.236 175.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.44 25.58 10.52 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 119.293 0.951 . . . . 0.0 110.901 167.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.25 -119.63 15.17 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 124.634 1.111 . . . . 0.0 112.148 170.359 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 20.7 m -68.34 -24.28 64.8 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 118.161 -0.923 . . . . 0.0 113.395 174.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.5 m -81.54 45.83 0.91 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 120.287 1.403 . . . . 0.0 109.258 171.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -170.97 -59.71 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.922 1.689 . . . . 0.0 111.633 -176.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.05 172.93 15.54 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 -168.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.52 -82.19 0.51 Allowed Glycine 0 CA--C 1.54 1.616 0 C-N-CA 126.842 2.163 . . . . 0.0 112.059 178.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -85.83 178.14 4.43 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 125.15 3.9 . . . . 0.0 115.139 -172.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -103.4 123.8 47.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.203 1.401 . . . . 0.0 110.796 179.386 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -58.26 146.9 32.47 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 120.789 0.328 . . . . 0.0 110.418 167.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.21 107.73 21.56 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.597 0.759 . . . . 0.0 112.515 -178.179 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -68.81 -30.85 26.4 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.135 1.89 . . . . 0.0 111.844 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -76.98 -7.81 56.28 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.096 0.959 . . . . 0.0 112.709 175.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.7 m 57.76 56.46 4.8 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.627 1.171 . . . . 0.0 111.743 172.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.89 172.69 15.64 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.394 1.478 . . . . 0.0 110.704 -168.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -72.5 176.68 5.19 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 -171.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -49.23 155.09 0.73 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.447 2.017 . . . . 0.0 116.447 -167.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' B' ' 79' ' ' ARG . . . -75.61 69.33 2.07 Favored Glycine 0 N--CA 1.473 1.144 0 C-N-CA 128.892 3.139 . . . . 0.0 114.212 -169.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.46 135.84 13.62 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 114.608 0.603 . . . . 0.0 114.608 -173.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -84.58 -0.95 9.52 Favored 'Trans proline' 0 CA--C 1.548 1.207 0 C-N-CA 123.87 3.047 . . . . 0.0 109.597 163.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.454 ' HE2' ' O ' ' B' ' 125' ' ' ASP . 0.1 OUTLIER -118.37 -10.61 10.15 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.642 1.977 . . . . 0.0 114.167 177.613 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -110.7 149.48 30.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.362 1.065 . . . . 0.0 109.022 -167.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -67.35 -25.53 66.03 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -88.65 146.22 25.21 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-O 125.07 2.367 . . . . 0.0 109.319 169.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . 0.43 ' HA ' ' HA2' ' B' ' 72' ' ' GLY . 52.9 ttt-85 -167.03 106.67 0.6 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 112.545 -2.116 . . . . 0.0 113.293 -174.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -61.59 149.33 39.47 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.401 1.081 . . . . 0.0 109.157 162.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.3 -13.66 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 CA-C-N 120.891 1.678 . . . . 0.0 110.323 166.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.28 18.82 9.37 Favored Glycine 0 C--N 1.336 0.548 0 C-N-CA 127.235 2.35 . . . . 0.0 118.879 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.99 149.43 32.15 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 122.608 3.204 . . . . 0.0 112.917 168.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -107.64 174.95 5.66 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.575 1.55 . . . . 0.0 108.561 168.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.48 155.31 49.79 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 171.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -74.4 146.61 42.8 Favored 'General case' 0 CA--C 1.549 0.941 0 CA-C-O 121.658 0.742 . . . . 0.0 111.825 -170.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -101.21 119.56 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.996 1.719 . . . . 0.0 112.48 -168.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -98.58 126.88 44.3 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.331 1.052 . . . . 0.0 110.283 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.95 162.13 14.19 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 171.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -85.97 168.99 13.66 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.889 2.075 . . . . 0.0 113.123 170.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.24 61.93 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.644 1.978 . . . . 0.0 114.963 -177.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.35 2.35 18.89 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 125.643 1.577 . . . . 0.0 112.146 177.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.16 21.75 56.32 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 124.936 1.255 . . . . 0.0 113.458 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.13 134.39 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -179.091 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.09 130.3 54.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 124.828 1.251 . . . . 0.0 110.445 166.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -88.27 105.62 17.67 Favored 'General case' 0 C--O 1.232 0.165 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 163.126 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.93 129.9 36.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 114.954 -1.021 . . . . 0.0 108.631 169.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.1 m -146.38 94.21 2.42 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.387 1.075 . . . . 0.0 109.305 -176.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -130.9 159.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 126.346 1.858 . . . . 0.0 110.281 -174.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.46 ' CD ' ' HZ2' ' B' ' 30' ' ' LYS . 41.7 tt0 -139.77 142.2 36.77 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 128.077 2.551 . . . . 0.0 106.584 167.389 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -151.12 138.15 19.13 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.293 1.037 . . . . 0.0 111.876 -168.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 46.3 p -118.0 50.3 1.16 Allowed 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 177.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 p -147.26 4.64 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 171.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -122.71 160.89 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.576 1.551 . . . . 0.0 107.409 167.022 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 105' ' ' SER . . . . . 0.434 ' HA ' ' OE1' ' B' ' 22' ' ' GLN . 96.8 p -156.24 168.36 27.55 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 119.49 1.041 . . . . 0.0 113.626 -174.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -92.59 69.07 4.83 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.521 1.528 . . . . 0.0 110.055 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 5.7 m -117.56 160.02 21.92 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.775 1.63 . . . . 0.0 110.727 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 44.98 1.82 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 125.146 1.355 . . . . 0.0 114.468 -168.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -135.54 -84.63 0.39 Allowed 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.872 1.269 . . . . 0.0 110.449 -168.691 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -150.35 -2.82 0.37 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 127.74 2.416 . . . . 0.0 111.773 -176.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 95.0 p -61.09 -44.4 97.42 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.131 1.373 . . . . 0.0 114.11 -169.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 5.3 pt -154.16 -34.35 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 127.678 2.391 . . . . 0.0 111.223 166.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 45.1 mm -60.56 125.37 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 123.866 0.867 . . . . 0.0 108.765 -175.034 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.56 16.23 67.3 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 116.994 -2.003 . . . . 0.0 115.061 -178.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.4 mtm180 -79.62 168.21 19.68 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.841 1.82 . . . . 0.0 109.478 168.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 22.6 m -123.64 117.04 24.1 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.806 0.842 . . . . 0.0 110.31 175.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 37.6 tp -82.23 132.12 35.23 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 169.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -110.91 137.43 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.534 1.534 . . . . 0.0 108.751 165.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 p -109.77 130.36 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.968 0.89 . . . . 0.0 109.417 168.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . 0.475 ' CE1' HH11 ' B' ' 143' ' ' ARG . 21.7 m-70 -99.91 161.12 13.8 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.527 1.131 . . . . 0.0 113.669 -172.167 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -76.42 -25.49 54.52 Favored 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.701 1.371 . . . . 0.0 114.701 -174.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -118.85 176.68 5.16 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 119.667 1.121 . . . . 0.0 112.415 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.71 164.3 2.14 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.151 1.38 . . . . 0.0 111.967 168.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -113.97 145.08 42.03 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.949 1.7 . . . . 0.0 110.546 -178.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . 0.454 ' O ' ' HE2' ' B' ' 75' ' ' LYS . 0.0 OUTLIER -73.95 -35.46 64.55 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-O 118.775 -0.631 . . . . 0.0 111.214 172.38 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 11.6 mt 77.54 24.61 0.77 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.015 2.126 . . . . 0.0 113.481 177.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.83 -78.9 0.06 OUTLIER Glycine 0 N--CA 1.474 1.182 0 CA-C-N 120.47 1.486 . . . . 0.0 116.657 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -156.22 87.67 1.06 Allowed 'General case' 0 N--CA 1.44 -0.925 0 C-N-CA 126.38 1.872 . . . . 0.0 110.93 173.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . 0.43 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -65.64 -10.99 52.24 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 126.836 2.16 . . . . 0.0 114.081 174.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.16 -33.8 2.47 Favored Glycine 0 N--CA 1.47 0.948 0 C-N-CA 124.366 0.984 . . . . 0.0 114.942 168.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.6 p30 -92.79 -177.78 4.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.498 1.519 . . . . 0.0 110.366 -177.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . 0.411 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 76.8 tt0 -61.5 -62.66 1.66 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 122.773 0.429 . . . . 0.0 110.351 173.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . 0.419 ' HB3' HD21 ' B' ' 139' ' ' ASN . 0.8 OUTLIER -42.06 -30.75 0.3 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 129.278 3.031 . . . . 0.0 115.572 -176.039 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 134' ' ' SER . . . . . 0.43 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 97.1 p -63.07 -41.84 99.53 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.373 1.469 . . . . 0.0 113.333 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 72.7 p -81.93 -30.57 31.72 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 123.834 0.854 . . . . 0.0 113.208 173.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.411 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 19.7 tttt -70.85 -53.15 16.31 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.704 2.002 . . . . 0.0 110.226 -177.309 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 74.6 p -111.54 -113.63 0.32 Allowed 'General case' 0 C--N 1.342 0.253 0 C-N-CA 128.207 2.603 . . . . 0.0 106.33 172.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -144.19 12.2 2.07 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 130.191 3.758 . . . . 0.0 111.874 169.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . 0.419 HD21 ' HB3' ' B' ' 133' ' ' GLU . 5.3 t-20 56.64 14.89 1.9 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.889 1.675 . . . . 0.0 113.814 -172.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.42 22.21 0.03 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 116.563 2.061 . . . . 0.0 116.563 -168.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.11 -169.81 52.12 Favored Glycine 0 CA--C 1.529 0.963 0 O-C-N 120.136 -1.603 . . . . 0.0 113.295 -171.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.06 -169.85 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.279 1.432 . . . . 0.0 110.906 174.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . 0.475 HH11 ' CE1' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -137.3 146.5 44.72 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 115.622 1.712 . . . . 0.0 115.622 175.241 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.7 -121.96 0.06 Allowed 'General case' 0 CA--C 1.536 0.406 0 O-C-N 127.182 2.801 . . . . 0.0 106.451 164.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.35 154.86 41.37 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 122.932 1.349 . . . . 0.0 114.467 -166.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -139.16 152.02 47.09 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 126.381 1.872 . . . . 0.0 109.246 169.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.58 141.88 7.73 Favored Glycine 0 C--N 1.333 0.414 0 N-CA-C 114.369 0.508 . . . . 0.0 114.369 176.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -79.74 153.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.891 1.276 . . . . 0.0 110.464 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.19 109.73 20.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 124.878 1.271 . . . . 0.0 112.409 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.53 164.37 15.52 Favored Glycine 0 C--N 1.35 1.339 0 C-N-CA 125.204 1.383 . . . . 0.0 112.761 174.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 mp -87.36 113.37 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 O-C-N 121.548 -0.972 . . . . 0.0 112.193 -168.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.404 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -82.42 16.57 2.03 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 128.112 2.565 . . . . 0.0 112.658 169.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.436 0 C-N-CA 128.804 2.842 . . . . 0.0 111.991 170.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.925 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.5 t -159.64 132.52 6.8 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 124.981 1.312 . . . . 0.0 108.956 172.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -94.5 145.83 24.52 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.33 164.44 13.02 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 121.109 -0.994 . . . . 0.0 111.789 168.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.427 HG11 ' H ' ' B' ' 53' ' ' ASN . 1.2 p -112.45 164.22 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 172.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.77 81.25 1.5 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.993 1.317 . . . . 0.0 108.007 160.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.0 t -77.45 89.14 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.16 141.5 37.17 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.381 1.072 . . . . 0.0 112.167 -172.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -155.59 175.96 13.23 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 169.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 160.12 -95.08 0.14 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 127.283 2.373 . . . . 0.0 109.706 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -78.33 87.16 4.38 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 126.629 1.972 . . . . 0.0 112.406 -169.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.08 -98.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.991 2.234 . . . . 0.0 114.003 168.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -78.4 -2.35 12.42 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 125.191 3.927 . . . . 0.0 115.284 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.5 t -79.0 139.1 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 120.312 1.415 . . . . 0.0 110.389 171.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -148.6 170.45 18.09 Favored 'General case' 0 N--CA 1.462 0.169 0 C-N-CA 125.617 1.567 . . . . 0.0 110.494 169.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.57 162.76 28.73 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 114.877 -1.056 . . . . 0.0 111.559 165.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.3 tp -156.87 80.71 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 126.609 1.964 . . . . 0.0 107.737 -177.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mm -98.42 143.97 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.123 0.569 . . . . 0.0 110.1 175.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -114.7 148.99 37.49 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 128.93 2.892 . . . . 0.0 109.42 175.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -141.78 82.11 1.79 Allowed 'General case' 0 CA--C 1.557 1.216 0 C-N-CA 123.983 0.913 . . . . 0.0 112.757 -178.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.413 ' HG2' ' CZ3' ' A' ' 32' ' ' TRP . 1.2 pt-20 -78.97 130.54 35.67 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 121.367 1.894 . . . . 0.0 114.755 -174.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.59 HE22 ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -116.87 155.29 29.29 Favored 'General case' 0 CA--C 1.535 0.377 0 O-C-N 120.459 -1.4 . . . . 0.0 111.976 173.059 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -56.06 2.39 Favored 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.29 1.436 . . . . 0.0 112.64 -169.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.59 ' C ' HE22 ' A' ' 22' ' ' GLN . 0.4 OUTLIER -138.89 153.3 48.27 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 128.82 2.848 . . . . 0.0 107.739 169.406 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -48.45 -17.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 118.545 2.795 . . . . 0.0 118.545 -166.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -118.94 0.61 11.38 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.528 1.931 . . . . 0.0 113.405 -176.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.25 177.41 54.26 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.936 0.779 . . . . 0.0 112.829 176.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.91 177.52 8.62 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.293 3.329 . . . . 0.0 110.907 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 87.8 t -128.96 132.65 67.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 123.066 0.546 . . . . 0.0 110.128 178.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.43 122.39 34.83 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.9 t -103.47 128.02 56.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 126.002 1.721 . . . . 0.0 108.662 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.413 ' CZ3' ' HG2' ' A' ' 21' ' ' GLU . 3.1 p90 -144.83 157.71 44.06 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 122.84 0.456 . . . . 0.0 111.608 170.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.38 178.87 15.52 Favored Glycine 0 N--CA 1.463 0.465 0 O-C-N 121.259 -0.9 . . . . 0.0 112.427 -178.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 m -127.57 159.21 35.3 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 117.009 2.226 . . . . 0.0 117.009 -164.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.5 mm -123.73 124.5 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 127.2 2.2 . . . . 0.0 108.131 167.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -130.81 136.21 48.47 Favored 'General case' 0 CA--C 1.54 0.573 0 O-C-N 120.872 -1.142 . . . . 0.0 111.054 -169.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.41 -11.94 11.28 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.238 1.875 . . . . 0.0 113.557 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.9 mp -62.1 141.92 57.86 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 127.161 2.184 . . . . 0.0 109.062 169.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.6 t -71.59 -41.74 68.58 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -176.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 176.03 -160.62 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.743 1 C-N-CA 133.21 4.604 . . . . 0.0 105.168 178.469 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 74.24 173.42 29.28 Favored Glycine 0 N--CA 1.473 1.112 0 N-CA-C 117.165 1.626 . . . . 0.0 117.165 165.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.19 152.41 30.7 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.002 1.321 . . . . 0.0 109.61 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -153.1 142.15 21.33 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.872 1.669 . . . . 0.0 112.82 -171.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.22 163.23 7.18 Favored Glycine 0 N--CA 1.478 1.457 0 C-N-CA 124.867 1.223 . . . . 0.0 115.141 -174.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -160.45 84.55 0.71 Allowed 'General case' 0 CA--C 1.548 0.875 0 CA-C-O 122.672 1.225 . . . . 0.0 113.502 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -133.18 142.37 48.59 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 120.036 -1.665 . . . . 0.0 110.961 -171.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.4 m -109.23 128.71 64.96 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.167 0 CA-C-O 121.957 0.884 . . . . 0.0 109.046 176.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.8 m170 -76.09 156.8 33.54 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.762 -174.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -74.95 130.85 40.1 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 71.12 169.34 0.32 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-O 124.848 2.261 . . . . 0.0 113.862 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.512 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -102.68 11.01 56.29 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 129.589 3.471 . . . . 0.0 114.078 171.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.438 ' HA ' ' CG2' ' B' ' 5' ' ' VAL . 1.9 p30 -78.95 47.29 0.75 Allowed 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.27 2.535 . . . . 0.0 109.97 168.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.512 ' H ' ' C ' ' A' ' 51' ' ' GLY 0.31 0.1 OUTLIER -90.13 45.62 1.28 Allowed 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 115.533 1.679 . . . . 0.0 115.533 -165.661 . . . . . . . . 4 4 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.561 ' HG1' ' CG2' ' B' ' 17' ' ' ILE . 19.4 p -119.91 -38.06 3.01 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -163.533 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.26 13.13 24.4 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 126.206 1.802 . . . . 0.0 112.9 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.48 -123.87 34.16 Favored Glycine 0 C--N 1.341 0.852 0 C-N-CA 125.112 1.339 . . . . 0.0 111.512 175.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 70.2 m -58.82 -13.77 7.06 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.827 1.417 . . . . 0.0 114.827 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.57 1.43 29.68 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.004 1.322 . . . . 0.0 112.081 173.135 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.2 m -158.54 -131.21 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 127.253 2.221 . . . . 0.0 108.209 -174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.34 95.35 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 128.002 2.521 . . . . 0.0 114.638 -173.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.6 162.24 53.92 Favored Glycine 0 CA--C 1.531 1.04 0 N-CA-C 115.301 0.88 . . . . 0.0 115.301 -167.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -69.24 84.57 0.57 Allowed 'Trans proline' 0 C--N 1.354 0.855 1 C-N-CA 125.963 4.442 . . . . 0.0 111.104 -173.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.5 p80 51.65 59.29 4.67 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 127.971 2.509 . . . . 0.0 110.808 169.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -56.05 167.05 0.66 Allowed 'General case' 0 N--CA 1.445 -0.723 0 CA-C-O 126.043 2.83 . . . . 0.0 112.443 -173.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.4 p-10 -118.88 73.67 12.3 Favored Pre-proline 0 C--N 1.314 -0.938 0 CA-C-N 110.837 -2.892 . . . . 0.0 112.275 -169.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.45 -23.72 75.14 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.018 2.479 . . . . 0.0 113.44 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 27.7 tp -86.64 -3.63 59.06 Favored 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.477 1.511 . . . . 0.0 113.191 170.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.7 t 68.15 49.69 0.83 Allowed 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.609 2.364 . . . . 0.0 112.578 176.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -106.67 170.91 7.65 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 115.224 1.564 . . . . 0.0 115.224 -168.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.5 mtmt -74.04 162.06 29.41 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.35 1.46 . . . . 0.0 109.247 164.434 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -86.83 142.63 27.94 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 172.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.4 -123.71 1.8 Allowed Glycine 0 C--N 1.341 0.815 0 N-CA-C 117.059 1.584 . . . . 0.0 117.059 164.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.47 -38.96 2.32 Favored Glycine 0 CA--C 1.546 1.998 0 N-CA-C 118.207 2.043 . . . . 0.0 118.207 -169.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -99.61 11.82 0.64 Allowed 'Trans proline' 0 CA--C 1.546 1.123 0 C-N-CA 123.955 3.104 . . . . 0.0 113.684 -176.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.67 -30.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 128.275 2.63 . . . . 0.0 109.893 167.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -75.31 152.89 38.13 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.153 0.978 . . . . 0.0 109.232 163.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -89.59 -26.13 20.96 Favored 'General case' 0 C--N 1.321 -0.664 1 C-N-CA 131.708 4.003 . . . . 0.0 111.679 -173.202 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -92.04 -71.29 0.65 Allowed 'General case' 0 C--N 1.34 0.164 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -169.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.4 ttt180 69.95 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.779 1.632 . . . . 0.0 112.861 -175.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -57.79 163.01 2.81 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 119.388 -2.07 . . . . 0.0 113.902 171.159 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.25 -38.16 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 119.353 0.979 . . . . 0.0 111.738 170.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.43 45.12 3.23 Favored Glycine 0 CA--C 1.533 1.158 0 N-CA-C 114.992 0.757 . . . . 0.0 114.992 177.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -137.44 134.46 35.87 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 120.824 -1.398 . . . . 0.0 111.154 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -127.6 53.49 1.75 Allowed 'General case' 0 CA--C 1.546 0.817 0 CA-C-O 122.111 0.958 . . . . 0.0 109.107 165.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.54 -138.26 42.76 Favored Glycine 0 C--N 1.342 0.882 0 C-N-CA 125.577 1.56 . . . . 0.0 113.129 172.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -141.71 150.86 42.39 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.031 0.933 . . . . 0.0 110.137 168.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.404 HG23 ' H ' ' A' ' 88' ' ' THR . 1.7 p -96.76 178.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 C-N-CA 127.659 2.384 . . . . 0.0 110.651 -174.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.404 ' H ' HG23 ' A' ' 87' ' ' VAL . 83.1 m -149.96 138.2 20.47 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 124.973 1.309 . . . . 0.0 110.056 178.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.15 140.45 38.29 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.105 1.362 . . . . 0.0 114.641 -176.139 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -77.79 146.03 36.06 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.761 1.624 . . . . 0.0 109.775 166.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.93 -16.35 0.13 Allowed 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 130.066 3.346 . . . . 0.0 118.08 175.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -75.26 1.23 14.09 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-N 119.762 1.164 . . . . 0.0 110.776 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.25 43.52 4.95 Favored Glycine 0 C--N 1.336 0.551 0 C-N-CA 128.054 2.74 . . . . 0.0 112.408 171.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.8 p -155.38 132.22 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 119.562 1.681 . . . . 0.0 115.14 -175.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.75 107.64 20.13 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 165.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -98.37 144.59 27.6 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.658 0.742 . . . . 0.0 110.088 169.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -121.92 146.11 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 N-CA-C 115.07 1.507 . . . . 0.0 115.07 -174.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.8 t -159.47 81.34 0.75 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 126.712 2.005 . . . . 0.0 111.837 175.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -127.95 158.08 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 127.152 2.181 . . . . 0.0 110.917 -174.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -126.15 138.63 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 167.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -134.45 145.8 49.19 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.273 1.029 . . . . 0.0 112.718 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 12.4 p -120.5 48.58 1.57 Allowed 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 114.575 1.324 . . . . 0.0 114.575 -179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.0 m -139.35 3.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.35 139.18 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.819 1.248 . . . . 0.0 109.043 168.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 46.6 p -112.04 176.69 4.92 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 118.718 0.69 . . . . 0.0 111.123 169.031 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.8 mt -82.31 107.64 15.14 Favored 'General case' 0 C--N 1.345 0.4 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 167.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -136.98 -13.24 1.65 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.47 31.97 71.34 Favored Glycine 0 C--N 1.342 0.879 0 CA-C-N 119.884 1.22 . . . . 0.0 115.155 172.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -170.44 -103.32 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.802 1.241 . . . . 0.0 108.026 -169.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -79.43 8.74 5.7 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.34 2.256 . . . . 0.0 112.329 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 55.5 m -149.85 -161.53 1.36 Allowed 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.241 1.416 . . . . 0.0 109.438 165.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 15.3 pt -82.41 161.37 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 O-C-N 120.171 -1.581 . . . . 0.0 113.835 -168.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 2.3 mm 106.44 147.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 1 C-N-CA 135.023 5.329 . . . . 0.0 110.118 -167.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.47 2.73 56.02 Favored Glycine 0 C--O 1.219 -0.803 0 CA-C-O 117.319 -1.823 . . . . 0.0 114.838 174.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 34.8 mtt-85 -106.22 -176.14 2.99 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.898 2.479 . . . . 0.0 110.338 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.0 t -120.29 145.43 47.08 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 119.554 1.07 . . . . 0.0 110.934 169.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.0 tp -101.32 133.52 45.78 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 127.086 2.154 . . . . 0.0 109.723 170.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.46 147.8 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.512 1.525 . . . . 0.0 110.576 168.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 91.7 t -129.03 151.15 35.36 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 C-N-CA 126.067 1.747 . . . . 0.0 107.035 173.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 74.3 m-70 -124.25 133.8 53.41 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.365 1.066 . . . . 0.0 113.17 -168.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.267 24.2 tp10 -84.81 39.07 0.73 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 -167.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -154.15 160.48 41.92 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.44 1.896 . . . . 0.0 109.5 169.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.57 118.36 8.08 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 169.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.5 157.93 20.3 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.477 1.132 . . . . 0.0 112.208 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -90.81 -9.49 46.27 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 128.587 2.755 . . . . 0.0 113.076 -169.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.3 mp 1.54 79.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 130.911 3.684 . . . . 0.0 116.194 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.21 -66.68 0.57 Allowed Glycine 0 N--CA 1.467 0.753 0 C-N-CA 125.068 1.318 . . . . 0.0 114.287 170.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.7 ttpp -157.49 93.28 1.28 Allowed 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.436 1.273 . . . . 0.0 114.436 -170.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.88 -113.74 2.18 Favored Glycine 0 C--O 1.235 0.216 0 N-CA-C 108.336 -1.906 . . . . 0.0 108.336 165.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -131.32 33.66 2.74 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.151 1.834 . . . . 0.0 113.328 177.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -159.58 159.83 33.7 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 118.78 1.29 . . . . 0.0 108.766 -171.229 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -68.73 -48.97 62.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.29 0.566 . . . . 0.0 110.093 -176.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.1 mp0 -38.63 -33.97 0.13 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.636 3.174 . . . . 0.0 113.591 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.9 p -59.88 -44.97 93.9 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.281 1.432 . . . . 0.0 114.021 175.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.8 t -81.7 -36.38 28.76 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 118.96 0.8 . . . . 0.0 111.283 168.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 16.6 tttt -56.88 -48.14 78.86 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.117 1.367 . . . . 0.0 111.991 -175.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -147.48 -10.79 0.41 Allowed 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 126.818 2.047 . . . . 0.0 115.009 -168.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.65 3.56 57.25 Favored Glycine 0 C--O 1.223 -0.575 0 CA-C-O 117.374 -1.792 . . . . 0.0 113.128 -173.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 67.54 -60.33 0.39 Allowed 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.043 2.137 . . . . 0.0 111.333 -172.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 68.41 -21.39 0.14 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 129.795 3.238 . . . . 0.0 115.571 168.585 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.61 -20.26 0.14 Allowed Glycine 0 CA--C 1.537 1.418 0 C-N-CA 126.904 2.192 . . . . 0.0 118.447 166.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.7 t -161.65 -173.11 3.6 Favored 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 127.626 2.371 . . . . 0.0 110.819 176.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.05 154.22 43.01 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.473 -1.392 . . . . 0.0 110.029 169.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.94 -129.11 0.22 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 123.43 0.692 . . . . 0.0 110.292 169.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.43 158.87 32.75 Favored 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 126.667 1.987 . . . . 0.0 113.113 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -140.79 161.58 37.46 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.922 2.089 . . . . 0.0 110.062 169.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.32 148.21 16.7 Favored Glycine 0 N--CA 1.472 1.038 0 O-C-N 121.272 -0.892 . . . . 0.0 112.918 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -78.56 161.78 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 C-N-CA 123.95 0.9 . . . . 0.0 109.773 177.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 36.8 mt -110.71 98.51 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 120.356 -1.465 . . . . 0.0 112.207 -175.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.45 167.07 22.14 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.712 1.625 . . . . 0.0 115.402 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.99 80.07 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 C-N-CA 127.91 2.484 . . . . 0.0 113.387 -175.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.36 26.24 0.22 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.657 1.583 . . . . 0.0 115.16 -175.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 . . . . . 0 N--CA 1.469 0.518 0 C-N-CA 129.413 3.085 . . . . 0.0 114.346 176.549 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 119.418 -0.325 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.9 m -79.78 108.69 13.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 125.333 1.453 . . . . 0.0 108.088 -171.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 27.6 mttt -99.43 118.59 36.39 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -171.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -83.35 169.25 15.83 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 127.71 2.404 . . . . 0.0 114.874 178.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -156.07 125.43 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 129.412 3.085 . . . . 0.0 107.55 175.608 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.07 139.38 47.64 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.088 0.955 . . . . 0.0 113.173 179.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 t -85.88 68.07 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.189 -0.914 . . . . 0.0 112.401 -168.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.12 103.13 5.17 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 122.208 1.004 . . . . 0.0 108.337 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -161.91 133.09 5.21 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 125.331 1.453 . . . . 0.0 109.713 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.25 -118.06 3.76 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -127.3 57.48 1.49 Allowed 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 126.046 1.738 . . . . 0.0 111.706 -164.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.5 -168.07 41.17 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 121.074 -1.016 . . . . 0.0 112.901 -171.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.55 -5.94 12.58 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 124.354 3.369 . . . . 0.0 115.444 -168.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.16 129.19 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 CA-C-N 120.258 1.39 . . . . 0.0 110.371 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -123.13 178.55 5.04 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 122.518 1.151 . . . . 0.0 110.29 168.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.2 163.01 31.29 Favored Glycine 0 CA--C 1.499 -0.942 0 CA-C-N 113.888 -1.506 . . . . 0.0 113.129 165.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.561 ' CG2' ' HG1' ' A' ' 54' ' ' THR . 2.3 pt -133.6 82.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 112.162 -2.019 . . . . 0.0 106.688 170.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.343 2.7 pp -89.49 109.87 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -112.74 133.54 54.71 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.523 2.329 . . . . 0.0 108.577 -170.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -124.48 147.06 48.58 Favored 'General case' 0 N--CA 1.474 0.766 0 O-C-N 121.028 -1.045 . . . . 0.0 111.178 -174.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -108.66 112.22 24.43 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.522 1.129 . . . . 0.0 111.717 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.3 99.04 10.87 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.407 ' HE2' ' HB2' ' B' ' 24' ' ' GLU . 0.2 OUTLIER -70.72 -28.8 65.0 Favored 'General case' 0 CA--C 1.539 0.53 0 O-C-N 121.415 -0.803 . . . . 0.0 113.108 170.276 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.407 ' HB2' ' HE2' ' B' ' 23' ' ' LYS . 43.1 tt0 -163.61 124.54 2.29 Favored 'General case' 0 C--O 1.222 -0.355 0 C-N-CA 124.689 1.196 . . . . 0.0 110.446 -166.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.0 p -60.86 -10.16 5.2 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 127.977 2.511 . . . . 0.0 114.8 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -132.93 15.16 4.28 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.239 1.816 . . . . 0.0 111.841 -171.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.42 -153.09 7.42 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 126.628 2.061 . . . . 0.0 111.724 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -85.29 167.05 10.69 Favored 'Trans proline' 0 N--CA 1.456 -0.733 0 C-N-CA 122.642 2.228 . . . . 0.0 112.202 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -119.78 140.22 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 124.993 1.317 . . . . 0.0 108.859 170.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -94.89 121.94 37.01 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 168.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.17 131.95 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 128.04 2.536 . . . . 0.0 109.071 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -156.05 -176.77 6.13 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 119.49 168.25 13.89 Favored Glycine 0 C--N 1.335 0.518 0 CA-C-O 122.079 0.822 . . . . 0.0 114.478 166.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 4.9 p -99.08 123.37 43.33 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -167.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 mp -98.5 118.08 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 166.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -129.01 132.29 47.5 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.551 1.54 . . . . 0.0 110.788 -166.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.26 -2.59 29.68 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 128.228 2.823 . . . . 0.0 111.939 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 22.4 mt -69.91 148.11 49.41 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 118.94 1.37 . . . . 0.0 112.598 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 26.8 m -76.37 143.97 40.39 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 125.614 1.565 . . . . 0.0 107.211 165.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -59.24 156.4 12.48 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.81 -179.45 35.55 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.668 0.652 . . . . 0.0 112.281 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.472 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -83.25 142.39 31.17 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 127.267 2.227 . . . . 0.0 113.846 -169.56 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 80.5 m-70 -134.01 125.78 28.85 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 129.093 2.957 . . . . 0.0 108.602 -176.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.09 148.64 28.15 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 125.492 1.52 . . . . 0.0 112.594 178.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -142.26 103.52 4.29 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.999 1.399 . . . . 0.0 111.528 -168.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.56 139.0 33.07 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 120.223 -1.548 . . . . 0.0 111.226 -175.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.88 115.52 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 176.154 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -71.86 -178.52 2.34 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 128.119 2.567 . . . . 0.0 111.172 -169.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.7 145.02 46.45 Favored 'General case' 0 CA--C 1.547 0.828 0 O-C-N 121.317 -0.864 . . . . 0.0 111.008 168.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -92.54 -170.95 2.62 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.28 1.832 . . . . 0.0 113.06 -169.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.17 -108.36 3.0 Favored Glycine 0 C--N 1.334 0.447 0 N-CA-C 115.694 1.037 . . . . 0.0 115.694 163.369 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -77.92 65.04 3.27 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.252 1.421 . . . . 0.0 110.567 -169.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.427 ' H ' HG11 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -165.52 162.59 19.27 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.714 1.376 . . . . 0.0 114.714 -168.598 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 39.5 p -137.17 -45.77 0.57 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.65 2.093 . . . . 0.0 116.65 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -87.04 -57.12 3.08 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.077 0.853 . . . . 0.0 110.959 177.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.96 -82.64 0.32 Allowed Glycine 0 N--CA 1.466 0.691 0 C-N-CA 124.69 1.138 . . . . 0.0 110.97 -175.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.3 t -64.25 -9.8 19.63 Favored 'General case' 0 CA--C 1.554 1.1 0 CA-C-N 119.021 1.41 . . . . 0.0 114.02 178.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -126.84 34.93 4.69 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.861 2.465 . . . . 0.0 110.07 170.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 7.4 m -156.83 -55.58 0.08 Allowed 'General case' 0 N--CA 1.482 1.154 0 O-C-N 119.769 -1.832 . . . . 0.0 114.938 176.232 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.31 160.16 24.55 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.596 1.159 . . . . 0.0 112.352 -172.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.46 171.17 25.56 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.194 1.378 . . . . 0.0 113.765 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -65.34 169.41 12.48 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 124.493 3.462 . . . . 0.0 112.264 -173.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -20.19 86.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 128.504 2.722 . . . . 0.0 117.733 175.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -50.57 126.63 15.9 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 123.54 1.638 . . . . 0.0 114.053 -172.076 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.46 59.81 0.46 Allowed Pre-proline 0 CA--C 1.558 1.261 0 CA-C-N 112.194 -2.276 . . . . 0.0 115.851 -168.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -65.28 -27.53 55.8 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 123.355 2.704 . . . . 0.0 114.232 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -76.28 -3.99 39.58 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.195 0.998 . . . . 0.0 112.244 175.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t 63.54 50.58 2.76 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 126.002 1.721 . . . . 0.0 111.114 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -103.14 168.45 9.17 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.551 1.14 . . . . 0.0 111.757 -174.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.408 ' HE3' ' HD2' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -96.39 173.1 7.54 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.456 1.502 . . . . 0.0 107.287 164.433 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.404 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 29.5 t60 -63.88 164.5 10.12 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 119.981 -1.699 . . . . 0.0 113.715 -178.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 166.67 -174.44 42.07 Favored Glycine 0 N--CA 1.469 0.863 0 O-C-N 120.921 -1.112 . . . . 0.0 113.929 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.28 -154.26 25.38 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 -167.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -62.77 -1.75 2.94 Favored 'Trans proline' 0 CA--C 1.54 0.807 1 C-N-CA 125.849 4.366 . . . . 0.0 116.379 -172.623 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -120.89 -1.98 9.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.021 1.329 . . . . 0.0 113.641 170.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -131.04 176.79 7.96 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 126.746 2.018 . . . . 0.0 110.259 -168.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -100.15 -17.07 17.58 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 127.13 2.172 . . . . 0.0 113.803 -169.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -95.2 -100.34 0.16 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 118.565 0.621 . . . . 0.0 112.673 -176.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.2 ttp-105 85.77 97.28 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 126.825 2.05 . . . . 0.0 110.024 -175.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -49.67 156.83 0.63 Allowed 'General case' 0 N--CA 1.475 0.799 0 O-C-N 119.936 -1.727 . . . . 0.0 111.788 168.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 46.4 t -53.38 -21.5 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 119.266 0.939 . . . . 0.0 113.265 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.29 61.4 0.55 Allowed Glycine 0 CA--C 1.531 1.036 0 CA-C-O 118.573 -1.126 . . . . 0.0 114.105 169.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -123.52 124.68 43.37 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 119.642 1.721 . . . . 0.0 109.099 168.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.9 mt -132.18 49.22 2.34 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 119.268 0.94 . . . . 0.0 112.381 -176.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.94 -148.29 47.71 Favored Glycine 0 CA--C 1.534 1.277 0 O-C-N 121.101 -1.0 . . . . 0.0 113.49 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -129.76 137.27 50.44 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.781 1.233 . . . . 0.0 109.837 168.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -96.15 133.32 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 125.861 1.664 . . . . 0.0 110.227 179.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 32.1 m -108.94 136.81 47.87 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 124.222 1.009 . . . . 0.0 108.803 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.35 145.09 26.47 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 174.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -77.18 146.91 36.76 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.118 1.767 . . . . 0.0 110.499 167.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -63.91 -14.3 52.46 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.925 1.824 . . . . 0.0 115.925 -169.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -76.16 3.32 10.86 Favored 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 125.471 1.508 . . . . 0.0 111.481 171.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 100.36 29.41 6.71 Favored Glycine 0 C--N 1.342 0.892 0 C-N-CA 126.327 1.918 . . . . 0.0 114.719 168.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.1 139.51 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 120.227 2.014 . . . . 0.0 115.215 -169.048 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.49 99.29 7.07 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 124.401 1.08 . . . . 0.0 110.187 169.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -87.74 91.24 8.68 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-O 122.591 1.186 . . . . 0.0 109.169 172.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -75.85 158.64 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 CA-C-N 114.109 -1.405 . . . . 0.0 114.133 -167.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 82.4 p -155.0 105.93 2.59 Favored 'General case' 0 N--CA 1.471 0.584 0 O-C-N 120.61 -1.306 . . . . 0.0 111.782 -175.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.3 mt -137.43 153.19 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 126.708 2.003 . . . . 0.0 110.639 -176.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -139.01 136.14 35.02 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.26 1.824 . . . . 0.0 107.92 168.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -149.18 143.97 26.28 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 125.873 1.669 . . . . 0.0 111.013 -172.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -107.89 53.19 0.69 Allowed 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 113.29 0.848 . . . . 0.0 113.29 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.1 t -144.3 -42.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 124.29 1.036 . . . . 0.0 112.92 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.63 163.08 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 O-C-N 121.14 -0.975 . . . . 0.0 113.447 -176.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -156.57 154.24 29.93 Favored 'General case' 0 N--CA 1.476 0.838 0 O-C-N 119.91 -1.744 . . . . 0.0 113.341 174.033 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mp -84.85 46.43 1.26 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.008 1.323 . . . . 0.0 108.65 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.0 m -75.59 -34.63 60.66 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 116.091 1.886 . . . . 0.0 116.091 -166.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.62 18.41 Favored Glycine 0 CA--C 1.536 1.352 0 N-CA-C 115.578 0.991 . . . . 0.0 115.578 -174.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 p30 -116.74 -83.23 0.63 Allowed 'General case' 0 CA--C 1.549 0.905 0 C-N-CA 125.65 1.58 . . . . 0.0 111.003 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -143.42 -1.59 1.02 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 129.399 3.079 . . . . 0.0 111.922 -178.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 52.5 m -73.46 -91.54 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 126.488 1.915 . . . . 0.0 112.003 -169.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.7 pt -136.04 -26.34 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 175.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 mm -66.04 136.68 26.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 CA-C-N 122.826 2.557 . . . . 0.0 108.621 168.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.52 -16.53 6.22 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.018 0.818 . . . . 0.0 114.594 -172.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -79.07 178.39 8.08 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.528 1.131 . . . . 0.0 109.361 169.235 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.57 124.26 12.56 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.479 1.036 . . . . 0.0 111.902 -170.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 tp -89.27 120.36 30.57 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.0 p -99.89 130.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 124.14 0.976 . . . . 0.0 110.802 171.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.8 m -93.38 133.71 33.58 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 165.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -96.39 177.75 5.59 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 125.355 1.462 . . . . 0.0 111.155 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -84.76 -58.04 2.87 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 120.912 -1.118 . . . . 0.0 110.648 -173.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -95.34 177.99 5.66 Favored 'General case' 0 N--CA 1.471 0.593 0 O-C-N 120.746 -1.221 . . . . 0.0 110.537 169.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.03 146.09 28.36 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 168.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -86.89 163.09 17.37 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 123.145 1.45 . . . . 0.0 111.368 169.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.47 -8.83 57.98 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.105 1.762 . . . . 0.0 112.25 -170.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 95.6 mt 33.6 50.24 0.28 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 128.511 2.724 . . . . 0.0 113.276 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 159.84 -93.62 0.12 Allowed Glycine 0 C--N 1.333 0.41 0 O-C-N 121.678 -0.639 . . . . 0.0 114.336 -178.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.408 ' HD2' ' HE3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -159.16 127.38 5.08 Favored 'General case' 0 CA--C 1.55 0.978 0 C-N-CA 125.422 1.489 . . . . 0.0 112.422 -173.711 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -123.87 -19.05 2.8 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.593 1.092 . . . . 0.0 115.095 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 119.69 -14.49 10.65 Favored Glycine 0 N--CA 1.474 1.217 0 CA-C-O 118.34 -1.255 . . . . 0.0 116.227 171.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -98.11 165.12 12.04 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.875 1.838 . . . . 0.0 110.175 168.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -51.8 -55.83 17.51 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.328 1.051 . . . . 0.0 110.035 178.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -51.6 -33.29 32.3 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 128.041 2.536 . . . . 0.0 113.313 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -54.86 -46.37 74.67 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 121.137 1.789 . . . . 0.0 113.861 176.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -91.24 -31.67 16.05 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 172.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -74.11 -28.17 61.23 Favored 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.7 m -128.82 -44.68 1.32 Allowed 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.352 1.461 . . . . 0.0 111.672 -179.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . 0.404 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 122.16 7.92 7.49 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 127.781 2.61 . . . . 0.0 112.269 -167.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 61.08 -77.39 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 126.213 1.805 . . . . 0.0 109.382 -169.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 64.94 3.61 2.16 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 127.889 2.476 . . . . 0.0 117.482 164.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.49 -46.63 1.97 Allowed Glycine 0 N--CA 1.471 1.014 0 C-N-CA 125.398 1.475 . . . . 0.0 113.803 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.9 m -178.27 176.71 1.06 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 126.933 2.093 . . . . 0.0 112.002 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -79.43 173.63 12.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.586 0.754 . . . . 0.0 110.846 168.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -140.74 -79.55 0.27 Allowed 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.755 0.822 . . . . 0.0 109.964 169.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.47 43.89 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 126.4 1.88 . . . . 0.0 109.686 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -156.81 151.74 26.02 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.966 1.706 . . . . 0.0 111.833 -171.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.79 148.74 17.18 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 116.415 1.326 . . . . 0.0 116.415 176.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -74.56 140.68 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 117.627 0.713 . . . . 0.0 110.671 175.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.9 mm -81.24 118.4 28.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 C-N-CA 125.303 1.441 . . . . 0.0 111.566 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.6 -167.16 14.58 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 126.227 1.87 . . . . 0.0 112.613 169.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -134.28 138.37 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.265 1.426 . . . . 0.0 114.34 -169.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.68 -141.26 0.27 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.703 1.201 . . . . 0.0 110.337 174.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.464 0 C-N-CA 124.272 1.029 . . . . 0.0 110.279 -176.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.905 0 CA-C-O 117.458 -1.258 . . . . 0.0 108.674 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 p -79.16 48.27 0.85 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -167.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -168.37 157.38 9.03 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 115.403 1.631 . . . . 0.0 115.403 163.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.1 179.02 8.06 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 130.231 3.413 . . . . 0.0 107.181 169.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.66 108.29 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 122.645 1.212 . . . . 0.0 111.619 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -101.5 96.64 7.27 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 167.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.1 t -76.91 136.06 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 165.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mp -128.39 104.29 7.63 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.155 -0.966 . . . . 0.0 109.562 -178.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -160.43 151.39 18.92 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 124.24 1.016 . . . . 0.0 111.865 -178.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.17 -116.94 1.02 Allowed Glycine 0 CA--C 1.524 0.624 0 CA-C-O 123.089 1.383 . . . . 0.0 111.618 166.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -92.7 56.32 2.63 Favored 'General case' 0 C--N 1.312 -1.035 1 C-N-CA 132.635 4.374 . . . . 0.0 115.034 -164.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.4 -168.19 35.25 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.296 -1.32 . . . . 0.0 114.074 176.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -86.02 17.88 1.67 Allowed 'Trans proline' 0 CA--C 1.539 0.767 1 C-N-CA 125.686 4.257 . . . . 0.0 113.553 -171.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 t -111.08 120.84 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.87 1.213 . . . . 0.0 108.975 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 pm0 -160.25 162.31 33.66 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.52 173.65 33.64 Favored Glycine 0 N--CA 1.462 0.377 0 C-N-CA 124.368 0.985 . . . . 0.0 113.296 168.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -126.24 134.13 67.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 124.386 1.074 . . . . 0.0 108.86 170.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.8 mm -137.6 105.24 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 118.274 0.488 . . . . 0.0 110.231 -172.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -77.67 161.74 27.55 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.597 0.713 . . . . 0.0 111.662 172.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -137.17 111.22 8.32 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.897 1.679 . . . . 0.0 106.806 169.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -91.65 135.51 33.82 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 120.765 1.62 . . . . 0.0 109.794 172.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -132.1 145.99 51.75 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.825 0.821 . . . . 0.0 111.532 175.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.412 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -92.53 -34.74 13.94 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 124.624 1.169 . . . . 0.0 114.1 179.399 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.95 -154.42 0.55 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-N 120.66 1.573 . . . . 0.0 112.791 178.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 65.7 p -93.35 -0.23 56.68 Favored 'General case' 0 CA--C 1.538 0.518 0 O-C-N 119.228 -2.17 . . . . 0.0 115.469 -172.051 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -153.49 -8.71 0.16 Allowed 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 115.875 1.806 . . . . 0.0 115.875 -169.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.91 173.89 55.31 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 128.664 3.031 . . . . 0.0 114.023 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -78.22 139.36 16.75 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.046 2.497 . . . . 0.0 111.758 -175.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -108.84 132.9 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.418 1.087 . . . . 0.0 109.353 -170.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -99.07 113.21 25.3 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 122.172 0.987 . . . . 0.0 110.34 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -95.5 130.99 43.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 127.984 2.514 . . . . 0.0 109.14 -178.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.0 p90 -148.81 159.32 44.26 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.92 -157.12 27.21 Favored Glycine 0 C--O 1.225 -0.424 0 C-N-CA 126.058 1.79 . . . . 0.0 110.178 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.5 p -157.11 154.72 29.86 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 121.577 -0.955 . . . . 0.0 112.417 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 mp -121.67 130.91 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 125.599 1.56 . . . . 0.0 108.346 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.4 140.5 49.67 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.316 1.446 . . . . 0.0 111.012 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.52 11.6 11.51 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 126.17 1.843 . . . . 0.0 112.54 -168.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.7 mt -86.96 171.24 10.92 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.532 0.733 . . . . 0.0 109.54 169.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -80.53 -141.09 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 164.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.49 -154.13 0.37 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.939 1.296 . . . . 0.0 108.535 166.285 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 69.28 179.74 22.96 Favored Glycine 0 CA--C 1.532 1.147 0 O-C-N 120.398 -1.439 . . . . 0.0 115.331 168.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mp -87.52 154.77 20.36 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.973 1.709 . . . . 0.0 110.611 -176.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -150.67 103.52 3.11 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 127.323 2.249 . . . . 0.0 109.908 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.05 160.61 20.86 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 124.558 1.075 . . . . 0.0 114.185 -175.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -142.78 92.38 2.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 125.933 1.693 . . . . 0.0 109.186 -173.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -109.35 130.4 55.5 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.298 -1.501 . . . . 0.0 109.8 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 2.1 m -77.97 158.33 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -119.9 123.44 43.57 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 pm0 -57.47 147.16 27.33 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.774 0.797 . . . . 0.0 109.872 177.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 68.95 166.72 0.27 Allowed 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 126.111 2.862 . . . . 0.0 112.353 -176.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.81 10.8 18.4 Favored Glycine 0 N--CA 1.467 0.718 0 C-N-CA 128.198 2.809 . . . . 0.0 112.186 178.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -83.7 42.99 0.88 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 128.509 2.723 . . . . 0.0 114.055 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -179.88 -26.85 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 112.723 -2.035 . . . . 0.0 114.925 -166.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.389 43.4 p 27.74 -18.35 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 2 N-CA-C 123.535 4.643 . . . . 0.0 123.535 -167.625 . . . . . . . . 3 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.44 -0.37 57.36 Favored 'General case' 0 CA--C 1.549 0.91 0 CA-C-N 122.48 2.4 . . . . 0.0 114.278 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.9 -128.4 37.31 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 125.721 1.629 . . . . 0.0 111.396 177.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -51.62 -2.75 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.235 0 N-CA-C 117.215 2.302 . . . . 0.0 117.215 -176.665 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 85.7 m -110.63 11.37 22.82 Favored 'General case' 0 N--CA 1.481 1.108 0 O-C-N 119.795 -1.816 . . . . 0.0 113.782 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 t -155.79 -27.45 0.1 Allowed 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 115.92 1.822 . . . . 0.0 115.92 168.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.2 177.02 4.79 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.797 2.039 . . . . 0.0 108.912 166.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.79 -107.92 2.47 Favored Glycine 0 CA--C 1.541 1.719 0 CA-C-O 117.755 -1.58 . . . . 0.0 114.443 -169.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -101.69 -167.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.543 0.956 1 C-N-CA 127.23 5.287 . . . . 0.0 112.144 -174.623 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.629 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.6 OUTLIER -100.11 119.83 38.91 Favored 'General case' 0 CA--C 1.554 1.111 1 C-N-CA 132.292 4.237 . . . . 0.0 115.243 -178.274 . . . . . . . . 4 4 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -39.74 126.93 2.0 Allowed 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 130.074 3.35 . . . . 0.0 116.123 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 51.0 p-10 -121.6 32.72 0.21 Allowed Pre-proline 0 CA--C 1.557 1.212 0 N-CA-C 115.304 1.594 . . . . 0.0 115.304 -173.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -62.8 -20.66 71.8 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.959 3.106 . . . . 0.0 114.978 -167.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 60.5 mt -78.46 -1.78 35.34 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.09 1.356 . . . . 0.0 112.685 174.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.76 52.8 0.93 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 127.269 2.227 . . . . 0.0 111.765 173.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.4 ptt180 -156.97 -179.98 8.73 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -166.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.26 177.53 8.9 Favored 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.434 1.494 . . . . 0.0 113.983 -171.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -50.87 157.8 0.76 Allowed 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -169.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -80.85 67.75 3.52 Favored Glycine 0 N--CA 1.474 1.177 0 C-N-CA 125.601 1.572 . . . . 0.0 114.354 -167.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -97.06 128.37 9.53 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-O 118.913 -0.937 . . . . 0.0 114.583 -168.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -76.84 4.68 5.48 Favored 'Trans proline' 0 CA--C 1.545 1.071 0 C-N-CA 123.632 2.888 . . . . 0.0 111.713 167.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.56 -10.52 18.4 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.963 0.905 . . . . 0.0 111.863 168.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -123.37 139.73 53.74 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.155 0.982 . . . . 0.0 110.809 -166.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -66.81 -28.62 68.52 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.496 172.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -91.76 105.04 17.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 125.969 1.708 . . . . 0.0 106.946 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -140.11 112.69 7.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 129.065 2.946 . . . . 0.0 109.56 -170.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -58.71 152.29 19.15 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.094 1.357 . . . . 0.0 111.405 167.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 p -65.0 -13.75 15.43 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 171.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.02 43.64 1.36 Allowed Glycine 0 C--N 1.347 1.158 0 N-CA-C 118.26 2.064 . . . . 0.0 118.26 -168.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -147.68 143.6 27.75 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 119.891 1.845 . . . . 0.0 109.484 167.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.0 mt -108.67 54.37 0.66 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.638 0.732 . . . . 0.0 109.345 -175.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.09 -120.07 6.75 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 124.84 1.209 . . . . 0.0 112.239 -172.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.405 HD21 HD22 ' A' ' 126' ' ' LEU . 6.5 p30 -142.28 160.4 40.32 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.709 1.204 . . . . 0.0 109.717 170.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -99.17 151.4 4.73 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.763 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 164.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.9 m -134.55 120.86 20.17 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 124.736 1.214 . . . . 0.0 108.738 -177.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.46 140.2 29.71 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -175.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.409 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 46.0 t0 -81.9 160.07 23.5 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 128.155 2.582 . . . . 0.0 110.151 169.013 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.409 ' HZ3' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -53.47 -22.08 7.32 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 126.382 1.873 . . . . 0.0 114.944 -173.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -76.79 -3.9 40.69 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.445 2.298 . . . . 0.0 112.289 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.78 10.01 73.51 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 126.929 2.204 . . . . 0.0 114.477 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.83 137.54 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.583 1.553 . . . . 0.0 111.963 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -107.73 130.54 54.94 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.471 -0.936 . . . . 0.0 108.471 166.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -82.29 151.64 26.67 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 122.277 1.037 . . . . 0.0 109.499 170.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -134.08 129.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 112.81 -1.995 . . . . 0.0 111.867 164.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.2 p -157.85 54.05 0.47 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 124.4 1.08 . . . . 0.0 111.978 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.81 153.86 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 O-C-N 120.277 -1.515 . . . . 0.0 112.352 -171.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -129.28 139.9 51.63 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 125.845 1.658 . . . . 0.0 108.457 168.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -150.07 148.53 29.12 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.4 1.095 . . . . 0.0 111.662 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -107.5 55.61 0.65 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.082 1.753 . . . . 0.0 110.35 -171.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.6 p -152.47 11.32 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -169.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -153.58 163.09 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 127.158 2.183 . . . . 0.0 107.904 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.0 m -155.14 161.62 41.2 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 122.435 1.112 . . . . 0.0 112.56 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.5 tt -90.03 77.65 6.82 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 120.897 -1.127 . . . . 0.0 109.218 -169.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.7 t -83.3 -146.68 0.08 Allowed 'General case' 0 CA--C 1.547 0.841 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.704 167.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -137.73 23.06 3.11 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.105 1.812 . . . . 0.0 112.751 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -173.35 -70.09 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -163.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -94.01 11.15 30.75 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.576 2.35 . . . . 0.0 114.788 -164.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . 0.25 3.9 m -140.85 -100.6 0.15 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -178.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.5 pt -89.89 -57.32 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 CA-C-N 121.545 1.975 . . . . 0.0 111.345 169.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.0 mm -61.89 145.69 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 170.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 96.35 -38.92 2.94 Favored Glycine 0 CA--C 1.524 0.597 0 CA-C-O 118.09 -1.395 . . . . 0.0 113.606 176.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.7 ptt180 -83.31 170.07 14.99 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 119.212 1.506 . . . . 0.0 112.539 175.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.2 t -119.01 176.92 5.06 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.226 1.01 . . . . 0.0 113.457 174.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 22.2 tp -156.92 136.57 12.33 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 126.273 1.829 . . . . 0.0 113.536 -168.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.4 t -112.03 135.38 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.988 1.315 . . . . 0.0 110.478 170.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 m -93.31 151.85 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 168.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 65.8 m-70 -119.38 144.12 47.07 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.684 1.194 . . . . 0.0 113.007 -172.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -83.75 -16.67 43.93 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 120.956 -1.09 . . . . 0.0 113.25 -179.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -98.03 164.0 12.53 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 169.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.09 164.21 1.76 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.997 1.319 . . . . 0.0 112.041 170.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -124.16 141.01 52.42 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.103 1.761 . . . . 0.0 110.209 -177.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -73.39 -34.38 65.5 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 125.73 1.612 . . . . 0.0 110.862 177.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.405 HD22 HD21 ' A' ' 86' ' ' ASN . 42.6 mt 78.74 -24.19 0.22 Allowed 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 130.026 3.331 . . . . 0.0 113.272 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -137.23 -81.99 0.11 Allowed Glycine 0 N--CA 1.475 1.279 0 CA-C-N 121.379 1.9 . . . . 0.0 114.271 -175.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -158.23 139.21 13.13 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 128.29 2.636 . . . . 0.0 107.518 174.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -127.25 -119.87 2.29 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 126.708 2.099 . . . . 0.0 109.946 167.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -92.27 -33.57 7.58 Favored Glycine 0 N--CA 1.474 1.219 0 N-CA-C 117.629 1.811 . . . . 0.0 117.629 -167.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 32.6 p30 -114.44 172.09 7.23 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.384 1.473 . . . . 0.0 113.156 -168.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -48.58 -61.72 1.88 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 126.29 1.836 . . . . 0.0 110.506 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -41.1 -42.05 1.89 Allowed 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 128.509 2.724 . . . . 0.0 114.383 175.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 85.7 p -55.27 -28.83 56.07 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 121.499 1.954 . . . . 0.0 113.456 177.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -97.82 -32.65 11.6 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 113.806 1.039 . . . . 0.0 113.806 169.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -91.13 -15.12 29.93 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.547 1.939 . . . . 0.0 115.006 -169.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 77.2 p -137.3 -16.03 1.42 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 128.444 2.698 . . . . 0.0 112.81 170.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.04 12.24 60.47 Favored Glycine 0 C--N 1.341 0.861 0 C-N-CA 124.062 0.839 . . . . 0.0 112.284 -167.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.423 ' C ' ' H ' ' A' ' 141' ' ' GLY . 7.9 t-20 53.4 26.61 5.54 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.158 1.383 . . . . 0.0 111.563 -168.145 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.7 6.96 0.56 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.652 1.181 . . . . 0.0 113.732 -169.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.423 ' H ' ' C ' ' A' ' 139' ' ' ASN . . . 66.03 -37.14 0.15 Allowed Glycine 0 CA--C 1.531 1.073 1 C-N-CA 131.128 4.204 . . . . 0.0 117.753 168.551 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 46.3 t -175.92 140.64 0.43 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.291 1.437 . . . . 0.0 111.428 -168.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.7 ptt-85 -77.42 174.6 10.64 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 123.702 0.801 . . . . 0.0 113.158 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.44 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -152.52 -143.02 0.13 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.417 1.887 . . . . 0.0 107.426 177.355 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.44 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.4 167.42 14.69 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.312 1.845 . . . . 0.0 112.727 177.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -140.18 153.24 46.55 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 125.004 1.322 . . . . 0.0 111.122 -169.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.54 141.18 7.32 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 124.193 0.901 . . . . 0.0 113.381 171.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.8 163.24 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 166.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.2 mm -93.09 94.37 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 121.37 -0.831 . . . . 0.0 110.032 170.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.3 -178.79 48.46 Favored Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.047 1.784 . . . . 0.0 113.759 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -113.99 130.58 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 124.659 1.183 . . . . 0.0 112.809 -170.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.52 -3.48 58.33 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.266 1.826 . . . . 0.0 112.472 176.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 . . . . . 0 CA--C 1.533 0.294 0 C-N-CA 125.149 1.38 . . . . 0.0 110.183 175.524 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.29 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -77.45 111.65 13.38 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 123.003 1.382 . . . . 0.0 108.675 -168.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mtmm -101.05 113.34 26.25 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 113.949 -1.478 . . . . 0.0 114.479 -171.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.89 175.47 6.49 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 127.036 2.134 . . . . 0.0 110.636 167.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -159.65 137.87 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 126.283 1.833 . . . . 0.0 110.677 -169.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.13 134.03 55.22 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 124.107 0.963 . . . . 0.0 109.016 165.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.58 114.76 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.157 0.983 . . . . 0.0 108.455 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.14 130.91 44.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 126.29 1.836 . . . . 0.0 110.396 -167.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttt -150.57 175.63 11.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.485 1.114 . . . . 0.0 112.458 -177.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 139.97 -71.57 0.43 Allowed Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.868 2.651 . . . . 0.0 109.059 -172.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.71 69.79 1.81 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.813 2.045 . . . . 0.0 113.18 -169.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.6 -97.64 0.01 OUTLIER Glycine 0 CA--C 1.536 1.376 0 C-N-CA 127.607 2.527 . . . . 0.0 114.747 169.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -80.85 -16.41 10.17 Favored 'Trans proline' 0 C--N 1.352 0.727 0 C-N-CA 124.074 3.182 . . . . 0.0 114.304 -179.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 t -79.51 139.33 18.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 CA-C-N 120.561 1.528 . . . . 0.0 109.359 175.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.436 ' NE2' ' HZ3' ' B' ' 36' ' ' LYS . 0.0 OUTLIER -155.1 152.58 29.68 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 113.567 -1.651 . . . . 0.0 108.117 167.265 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.405 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.72 152.47 17.11 Favored Glycine 0 CA--C 1.488 -1.594 0 O-C-N 123.818 0.699 . . . . 0.0 111.817 172.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -126.7 130.87 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 166.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 11.1 mm -129.17 118.09 45.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 173.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -82.88 157.73 22.97 Favored 'General case' 0 N--CA 1.47 0.543 0 O-C-N 120.927 -1.108 . . . . 0.0 109.48 169.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -139.54 87.26 2.17 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.76 1.224 . . . . 0.0 108.139 179.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -86.91 124.15 32.81 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 121.299 -0.875 . . . . 0.0 112.034 174.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -113.82 134.84 54.54 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.869 0.842 . . . . 0.0 110.822 165.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.436 ' HZ2' ' HB3' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -91.33 -32.05 15.84 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 124.64 1.176 . . . . 0.0 112.552 179.188 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -99.14 -169.24 1.74 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.042 2.137 . . . . 0.0 109.836 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.9 m -118.28 -6.15 10.83 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 120.634 -1.291 . . . . 0.0 113.277 167.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 61.0 m-80 -141.67 19.89 2.18 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 126.36 1.864 . . . . 0.0 112.379 175.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.0 -158.17 14.22 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.596 2.046 . . . . 0.0 113.193 175.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.84 154.02 29.83 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.228 2.619 . . . . 0.0 113.776 -172.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.86 133.34 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 126.364 1.866 . . . . 0.0 110.377 178.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.564 ' HZ1' ' CD ' ' B' ' 100' ' ' GLU . 66.7 mttm -89.81 122.62 33.05 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.456 1.103 . . . . 0.0 110.607 171.315 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.19 84.66 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 128.081 2.553 . . . . 0.0 109.787 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 5.9 p90 -106.81 153.57 22.27 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 123.717 0.807 . . . . 0.0 111.234 169.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.01 -158.39 30.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 124.349 0.976 . . . . 0.0 112.141 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 91.8 p -159.41 136.04 9.26 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 -172.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . 0.405 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.5 mp -112.51 111.7 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 124.536 1.134 . . . . 0.0 109.77 173.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . 0.436 ' HZ3' ' NE2' ' B' ' 15' ' ' GLN . 22.2 pttp -116.43 133.63 55.8 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 123.829 0.852 . . . . 0.0 111.371 -169.301 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.66 -2.23 26.14 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 125.827 1.68 . . . . 0.0 114.792 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.3 pp -83.8 178.5 7.89 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 118.858 1.329 . . . . 0.0 109.59 169.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.72 163.33 22.52 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 124.052 0.941 . . . . 0.0 109.415 169.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' B' ' 40' ' ' GLU . 0.7 OUTLIER -52.56 178.54 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 177.724 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.31 -166.97 54.86 Favored Glycine 0 CA--C 1.527 0.827 0 O-C-N 120.274 -1.516 . . . . 0.0 112.958 172.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 77.3 mt -73.84 148.98 41.89 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.8 1.64 . . . . 0.0 111.764 -173.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -149.0 126.65 11.7 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 127.349 2.26 . . . . 0.0 110.437 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.55 157.1 25.67 Favored Glycine 0 N--CA 1.49 2.283 0 CA-C-O 117.625 -1.653 . . . . 0.0 112.756 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -157.58 110.84 2.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.469 2.308 . . . . 0.0 112.449 171.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.6 m80 -138.08 144.02 40.73 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 119.905 -1.747 . . . . 0.0 111.389 -175.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 132.63 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 C-N-CA 123.978 0.911 . . . . 0.0 110.118 177.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -75.37 117.42 17.15 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 168.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -73.37 60.46 0.62 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.469 1.908 . . . . 0.0 114.217 -168.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -179.4 164.25 1.31 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 128.983 2.913 . . . . 0.0 109.461 170.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.43 -10.29 55.87 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.245 0.926 . . . . 0.0 114.66 169.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -82.03 51.37 1.74 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 126.942 2.097 . . . . 0.0 110.439 -176.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 171.26 33.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 0.997 0 N-CA-C 115.805 1.779 . . . . 0.0 115.805 -164.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 37.4 p -40.26 -34.49 0.32 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 118.184 2.661 . . . . 0.0 118.184 -168.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 18.16 1.84 Allowed 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 -167.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 -141.3 20.29 Favored Glycine 0 CA--C 1.526 0.725 0 O-C-N 120.71 -1.244 . . . . 0.0 113.12 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.8 t -62.08 -5.96 2.62 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 115.399 1.629 . . . . 0.0 115.399 -174.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 11.2 t -80.15 -4.23 52.14 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.419 1.088 . . . . 0.0 112.293 170.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -149.04 159.49 44.18 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 119.993 1.269 . . . . 0.0 113.65 -177.156 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 61.0 -138.07 0.57 Allowed 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.883 2.073 . . . . 0.0 110.052 -168.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.27 158.91 20.55 Favored Glycine 0 CA--C 1.534 1.263 0 CA-C-O 117.672 -1.627 . . . . 0.0 110.728 169.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -55.04 103.52 0.1 Allowed 'Trans proline' 0 C--N 1.355 0.92 1 C-N-CA 125.663 4.242 . . . . 0.0 109.936 178.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 46.12 62.02 2.44 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 113.679 -1.601 . . . . 0.0 111.131 -175.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -37.62 134.19 0.71 Allowed 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.398 1.479 . . . . 0.0 112.183 -175.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -117.26 80.15 11.99 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -165.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.92 -13.32 34.12 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 123.101 2.534 . . . . 0.0 114.119 177.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -90.0 -6.69 55.34 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.85 1.26 . . . . 0.0 112.679 177.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.3 t 50.77 50.59 18.69 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 127.514 2.325 . . . . 0.0 114.703 -177.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -108.65 177.34 4.81 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 124.85 1.26 . . . . 0.0 113.065 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.431 ' HZ3' ' CD ' ' B' ' 78' ' ' GLU . 0.0 OUTLIER -81.11 164.69 22.22 Favored 'General case' 0 N--CA 1.47 0.555 0 O-C-N 121.342 -0.849 . . . . 0.0 110.73 167.146 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.516 ' CG ' ' H ' ' B' ' 72' ' ' GLY . 63.8 t60 -68.1 -176.33 0.7 Allowed 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 122.095 0.95 . . . . 0.0 113.111 -176.108 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . 0.516 ' H ' ' CG ' ' B' ' 71' ' ' HIS . . . 111.07 -154.52 16.61 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 124.513 1.054 . . . . 0.0 115.492 165.063 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 166.13 -89.38 0.1 Allowed Glycine 0 CA--C 1.528 0.864 0 CA-C-O 118.205 -1.331 . . . . 0.0 114.725 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -67.9 -1.12 6.35 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 123.049 2.5 . . . . 0.0 114.15 -175.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -129.24 -4.14 4.95 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 125.613 1.565 . . . . 0.0 112.631 168.288 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -153.19 112.84 3.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.932 1.293 . . . . 0.0 110.347 -169.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -64.13 -12.2 37.42 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.324 1.85 . . . . 0.0 114.572 -175.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . 0.431 ' CD ' ' HZ3' ' B' ' 70' ' ' LYS . 10.3 mt-10 -75.44 -22.67 57.16 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 120.235 1.379 . . . . 0.0 113.651 -170.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 12.4 ttp85 14.57 100.97 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 130.564 3.546 . . . . 0.0 115.325 164.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.1 m170 -51.49 155.75 1.45 Allowed 'General case' 0 CA--C 1.558 1.258 0 CA-C-O 117.272 -1.347 . . . . 0.0 109.834 168.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.316 85.3 t -74.57 -17.49 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-N 123.865 3.029 . . . . 0.0 110.231 -175.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.47 7.52 64.55 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 127.423 2.44 . . . . 0.0 114.404 166.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -98.93 119.25 37.4 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.838 1.819 . . . . 0.0 113.401 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 63.3 mt -102.27 -176.06 3.01 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 126.73 2.012 . . . . 0.0 106.015 164.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.23 -144.91 5.09 Favored Glycine 0 CA--C 1.534 1.275 0 O-C-N 120.891 -1.13 . . . . 0.0 114.114 -178.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.65 152.16 49.46 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 123.983 0.913 . . . . 0.0 109.818 168.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 9.8 p -113.72 142.18 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.57 1.948 . . . . 0.0 112.207 -168.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -115.08 120.01 38.36 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.047 1.129 . . . . 0.0 114.047 -169.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.49 155.34 17.89 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 119.043 2.979 . . . . 0.0 119.043 175.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -84.51 164.89 18.51 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-N 111.631 -2.532 . . . . 0.0 109.808 167.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.16 -12.45 5.17 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 115.129 1.529 . . . . 0.0 115.129 171.399 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.66 -27.32 61.18 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.837 1.655 . . . . 0.0 111.2 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.24 -2.27 54.46 Favored Glycine 0 CA--C 1.523 0.544 0 CA-C-O 117.661 -1.633 . . . . 0.0 114.355 -177.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 9.5 p -79.48 118.49 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 119.572 1.686 . . . . 0.0 112.352 168.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.447 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -89.02 119.56 29.65 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.454 1.502 . . . . 0.0 108.587 166.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -80.46 140.27 36.02 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 118.492 0.587 . . . . 0.0 110.593 174.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -128.75 134.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.267 -1.333 . . . . 0.0 110.437 166.617 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.3 p -156.61 56.67 0.55 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 122.762 1.267 . . . . 0.0 109.628 -169.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 54.8 mt -114.78 160.68 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 125.044 1.337 . . . . 0.0 111.285 -169.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.564 ' CD ' ' HZ1' ' B' ' 30' ' ' LYS . 31.3 tt0 -133.47 146.15 50.87 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.837 2.055 . . . . 0.0 108.467 169.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -140.35 125.75 18.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 124.702 1.201 . . . . 0.0 110.442 -169.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 79.4 p -107.04 57.72 0.63 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.745 1.218 . . . . 0.0 112.308 -172.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -154.56 -41.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.93 173.67 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.232 -0.918 . . . . 0.0 112.026 177.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 25.8 m -158.25 162.99 37.86 Favored 'General case' 0 N--CA 1.481 1.081 0 O-C-N 119.579 -1.95 . . . . 0.0 115.028 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.35 59.24 1.8 Allowed 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.611 2.364 . . . . 0.0 108.484 175.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.9 t -89.82 1.3 56.32 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.242 1.017 . . . . 0.0 113.276 -175.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.17 -32.46 1.11 Allowed Glycine 0 N--CA 1.474 1.179 0 C-N-CA 125.029 1.3 . . . . 0.0 114.818 177.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -123.51 -95.06 0.48 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.985 1.314 . . . . 0.0 112.76 -169.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -75.92 3.07 10.9 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 119.678 -1.889 . . . . 0.0 114.344 -164.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.9 t -107.2 -128.85 0.27 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.677 -175.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 pt -84.0 -18.64 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 121.516 1.962 . . . . 0.0 115.981 -179.142 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mm -69.4 134.3 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.389 0.995 . . . . 0.0 111.017 -171.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.22 -2.75 75.12 Favored Glycine 0 CA--C 1.533 1.213 0 CA-C-O 117.836 -1.535 . . . . 0.0 114.038 -178.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.6 mtm180 -86.58 158.33 19.53 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 119.476 1.638 . . . . 0.0 109.998 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.5 t -115.98 119.85 37.23 Favored 'General case' 0 N--CA 1.486 1.346 0 CA-C-N 120.41 1.459 . . . . 0.0 112.942 -168.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 36.6 tp -94.93 121.33 36.43 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 126.511 1.924 . . . . 0.0 110.476 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 p -107.39 126.32 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.6 1.16 . . . . 0.0 110.194 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 67.5 t -89.15 163.57 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 168.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.9 m-70 -123.8 138.21 54.54 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.964 1.306 . . . . 0.0 111.286 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.1 pp20? -70.94 -11.23 60.85 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.177 -1.577 . . . . 0.0 114.549 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -115.62 167.03 11.27 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.107 1.363 . . . . 0.0 112.707 168.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.07 150.54 7.97 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.773 1.629 . . . . 0.0 110.434 166.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -112.53 144.68 41.6 Favored 'General case' 0 C--O 1.243 0.735 0 CA-C-O 121.717 0.77 . . . . 0.0 112.762 -178.172 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -76.45 -25.29 54.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.571 1.548 . . . . 0.0 111.748 -177.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt 48.61 51.93 14.69 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 126.949 2.099 . . . . 0.0 111.473 170.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 170.21 -94.44 0.1 Allowed Glycine 0 C--N 1.334 0.43 0 N-CA-C 117.11 1.604 . . . . 0.0 117.11 173.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 ptpp? -163.27 30.46 0.09 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -164.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -51.64 -22.06 7.77 Favored Glycine 0 N--CA 1.477 1.404 0 N-CA-C 119.388 2.515 . . . . 0.0 119.388 -168.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 175.77 -18.68 0.04 OUTLIER Glycine 0 N--CA 1.474 1.182 0 N-CA-C 117.565 1.786 . . . . 0.0 117.565 174.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -144.68 179.37 7.34 Favored 'General case' 0 CA--C 1.545 0.782 0 CA-C-N 119.291 1.546 . . . . 0.0 113.56 -173.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . 0.262 0.0 OUTLIER -49.84 -63.91 0.97 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.848 2.059 . . . . 0.0 111.435 172.232 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -54.11 -33.7 58.37 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 121.593 1.997 . . . . 0.0 113.373 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.15 -32.81 62.41 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 121.083 1.765 . . . . 0.0 114.193 172.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -105.32 -12.53 16.02 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.435 1.094 . . . . 0.0 113.499 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.7 tttt -96.54 -35.82 10.97 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.381 1.873 . . . . 0.0 112.705 -178.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.2 p -126.78 -20.65 4.22 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 125.139 1.376 . . . . 0.0 114.689 175.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.58 13.83 42.95 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.554 1.073 . . . . 0.0 110.534 -166.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 66.43 -68.08 0.14 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.769 3.228 . . . . 0.0 110.111 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 57.69 -66.7 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 131.445 3.898 . . . . 0.0 113.243 177.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.35 -28.71 4.98 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 127.523 2.487 . . . . 0.0 111.977 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.2 t -166.49 -161.63 0.47 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 124.605 1.162 . . . . 0.0 112.108 173.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -119.53 -156.49 0.66 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 128.328 2.651 . . . . 0.0 109.558 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -179.82 -164.55 0.06 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.867 2.467 . . . . 0.0 107.275 -171.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.89 144.25 23.43 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 127.243 2.217 . . . . 0.0 111.532 176.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -144.36 147.84 33.95 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -175.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.04 150.01 19.92 Favored Glycine 0 N--CA 1.476 1.355 0 C-N-CA 124.693 1.14 . . . . 0.0 114.651 -174.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 5.0 t -82.37 150.25 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.67 -0.9 . . . . 0.0 113.059 178.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -77.26 78.9 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 C-N-CA 126.562 1.945 . . . . 0.0 110.94 171.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -97.02 -158.96 31.3 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.243 1.878 . . . . 0.0 112.644 173.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -136.69 148.87 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -95.91 -120.07 0.11 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 103.058 -2.941 . . . . 0.0 103.058 163.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.471 0.597 0 C-N-CA 123.787 0.835 . . . . 0.0 112.674 166.051 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 122.564 1.174 . . . . 0.0 111.849 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.3 t -157.37 171.09 21.01 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 130.276 3.43 . . . . 0.0 104.26 164.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.462 ' HZ1' ' HB ' ' A' ' 5' ' ' VAL . 0.7 OUTLIER -146.06 138.94 25.7 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 116.413 2.005 . . . . 0.0 116.413 177.035 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 169.63 9.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 127.258 2.223 . . . . 0.0 111.439 171.358 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.462 ' HB ' ' HZ1' ' A' ' 3' ' ' LYS . 14.7 p -158.6 110.51 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.772 1.629 . . . . 0.0 111.739 173.177 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.79 116.29 12.0 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.755 1.222 . . . . 0.0 112.442 -167.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 p -81.42 84.51 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.69 100.69 8.83 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 173.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -159.68 80.12 0.72 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 123.482 0.713 . . . . 0.0 112.172 -172.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.03 8.02 3.53 Favored Glycine 0 N--CA 1.472 1.056 0 C-N-CA 125.813 1.673 . . . . 0.0 113.658 169.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -133.46 54.88 1.93 Allowed 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 125.761 1.624 . . . . 0.0 108.74 -168.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 29.51 -98.23 0.01 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 129.381 3.372 . . . . 0.0 115.735 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.3 -15.22 47.42 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 124.2 3.266 . . . . 0.0 115.001 -176.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 t -111.34 128.86 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 125.058 1.343 . . . . 0.0 108.515 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.98 162.68 40.32 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.82 -174.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.45 170.07 29.0 Favored Glycine 0 CA--C 1.505 -0.592 0 CA-C-O 122.571 1.095 . . . . 0.0 114.206 174.629 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -130.76 128.27 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 C-N-CA 126.618 1.967 . . . . 0.0 106.356 173.498 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -137.94 112.53 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 121.312 -0.867 . . . . 0.0 109.72 172.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 28.1 m-80 -75.75 157.78 33.09 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.032 0.933 . . . . 0.0 111.091 178.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -141.58 127.93 19.93 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.812 1.245 . . . . 0.0 107.823 168.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -91.66 120.19 32.21 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.017 0.826 . . . . 0.0 112.138 174.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.8 tp60 -88.49 78.45 7.86 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 118.658 -2.526 . . . . 0.0 105.701 167.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.7 ptmt -58.19 -41.52 84.12 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 120.909 -1.119 . . . . 0.0 110.669 175.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -155.19 142.46 19.43 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 129.41 3.084 . . . . 0.0 108.088 -166.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 m -48.23 -44.42 33.18 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 116.175 1.917 . . . . 0.0 116.175 -167.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -126.12 23.38 7.1 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.783 1.233 . . . . 0.0 112.0 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.75 167.82 53.58 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.134 -0.815 . . . . 0.0 112.481 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -65.73 151.36 84.67 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.37 2.047 . . . . 0.0 109.496 169.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -135.62 134.63 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-O 122.63 1.205 . . . . 0.0 110.702 -175.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 ttmm -81.03 128.26 33.51 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 114.056 -1.429 . . . . 0.0 108.212 167.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 64.0 t -124.91 111.17 26.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 126.846 2.058 . . . . 0.0 110.599 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.2 p90 -144.81 154.85 43.11 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -168.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 162.11 -138.94 5.66 Favored Glycine 0 C--N 1.335 0.496 0 O-C-N 120.903 -1.123 . . . . 0.0 112.895 172.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -154.08 131.61 11.37 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -169.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mm -117.34 126.6 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 123.944 0.898 . . . . 0.0 109.322 173.169 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -123.7 142.23 51.27 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.305 1.842 . . . . 0.0 110.763 -168.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.49 -16.41 57.87 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 125.946 1.736 . . . . 0.0 111.774 -169.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -65.01 113.02 3.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 167.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -60.13 -41.54 92.91 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.97 0.804 . . . . 0.0 111.627 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.3 -178.16 1.98 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.381 1.073 . . . . 0.0 113.017 -168.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 65.96 176.27 6.53 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.961 1.267 . . . . 0.0 115.544 166.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.39 142.88 46.96 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 169.348 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -127.03 127.72 45.2 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 127.493 2.317 . . . . 0.0 107.145 174.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.84 156.43 40.35 Favored Glycine 0 N--CA 1.467 0.766 0 CA-C-O 119.016 -0.88 . . . . 0.0 111.13 -176.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.41 130.61 17.48 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 118.037 0.919 . . . . 0.0 109.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -154.89 161.97 41.26 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 120.337 -1.477 . . . . 0.0 111.1 173.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -104.37 135.83 40.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-O 122.629 1.204 . . . . 0.0 110.92 176.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -73.53 176.69 5.9 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 126.562 1.945 . . . . 0.0 110.526 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -72.18 -14.36 61.79 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.608 1.706 . . . . 0.0 115.608 174.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.432 ' CG ' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 -157.03 172.97 17.73 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 129.757 3.223 . . . . 0.0 107.609 -167.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.17 30.28 4.44 Favored Glycine 0 C--O 1.223 -0.581 0 N-CA-C 108.677 -1.769 . . . . 0.0 108.677 165.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -82.24 109.53 16.61 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 119.408 1.604 . . . . 0.0 111.027 -166.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.299 1.9 p30 -159.18 32.54 0.2 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 117.915 2.561 . . . . 0.0 117.915 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -84.84 -35.54 22.19 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 126.078 1.751 . . . . 0.0 112.883 -167.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -115.06 -13.68 11.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.021 1.729 . . . . 0.0 113.429 177.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.58 -75.68 0.84 Allowed Glycine 0 CA--C 1.529 0.939 0 C-N-CA 124.49 1.043 . . . . 0.0 111.524 -174.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.8 m -65.65 -17.62 64.73 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.9 p -127.51 33.43 4.84 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.333 1.453 . . . . 0.0 112.103 171.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 97.7 p -179.42 106.67 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.334 1.853 . . . . 0.0 110.56 177.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 166.53 73.43 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 131.183 3.793 . . . . 0.0 109.097 175.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.62 107.87 2.38 Favored Glycine 0 CA--C 1.542 1.725 0 C-N-CA 125.194 1.378 . . . . 0.0 114.665 -169.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -86.56 101.09 0.58 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 124.041 3.161 . . . . 0.0 112.008 -168.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 55.44 39.73 31.19 Favored 'General case' 0 C--O 1.242 0.7 0 C-N-CA 127.495 2.318 . . . . 0.0 113.221 170.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -77.05 124.69 28.15 Favored 'General case' 0 C--O 1.234 0.269 0 O-C-N 120.365 -1.46 . . . . 0.0 108.148 169.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.79 135.09 8.98 Favored Pre-proline 0 CA--C 1.539 0.554 0 CA-C-N 114.048 -1.433 . . . . 0.0 112.252 -173.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -71.43 -2.42 11.24 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.051 2.501 . . . . 0.0 114.214 -172.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 26.8 mt -79.51 -20.01 48.27 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 118.947 0.794 . . . . 0.0 112.038 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t 49.07 50.98 17.05 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 125.247 1.419 . . . . 0.0 113.371 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.0 mtm-85 -112.53 178.51 4.27 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 125.251 1.42 . . . . 0.0 112.666 -173.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.49 ' HZ3' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -77.77 161.14 27.91 Favored 'General case' 0 CA--C 1.553 1.093 0 CA-C-N 118.504 0.593 . . . . 0.0 109.811 164.669 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.549 ' CG ' ' H ' ' A' ' 72' ' ' GLY . 82.1 t60 -66.51 -175.91 0.41 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.503 1.521 . . . . 0.0 112.542 -177.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.549 ' H ' ' CG ' ' A' ' 71' ' ' HIS . . . 107.26 -138.27 14.41 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 115.549 0.98 . . . . 0.0 115.549 165.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.89 -64.54 0.6 Allowed Glycine 0 CA--C 1.541 1.68 0 N-CA-C 116.941 1.536 . . . . 0.0 116.941 -174.322 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.95 -4.55 15.31 Favored 'Trans proline' 0 CA--C 1.544 1.011 0 CA-C-N 121.11 2.455 . . . . 0.0 114.427 -178.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.41 ' HE2' ' O ' ' A' ' 126' ' ' LEU . 0.0 OUTLIER -148.59 -1.47 0.52 Allowed 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 126.154 1.782 . . . . 0.0 114.207 172.101 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -124.19 148.34 47.34 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.395 2.278 . . . . 0.0 107.405 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.04 -20.68 30.07 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 127.3 2.24 . . . . 0.0 112.735 -168.732 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.49 ' CD ' ' HZ3' ' A' ' 70' ' ' LYS . 29.8 mt-10 -83.68 -64.96 1.07 Allowed 'General case' 0 C--O 1.232 0.149 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -169.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 34.7 ttt-85 66.19 120.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.285 1.434 . . . . 0.0 111.724 -177.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -65.53 172.56 3.24 Favored 'General case' 0 CA--C 1.544 0.716 0 O-C-N 119.567 -1.958 . . . . 0.0 109.355 165.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -35.29 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.313 -1.492 . . . . 0.0 112.644 168.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.71 50.65 0.77 Allowed Glycine 0 CA--C 1.534 1.277 0 N-CA-C 117.007 1.563 . . . . 0.0 117.007 -169.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -124.45 119.17 28.41 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.56 -0.965 . . . . 0.0 113.291 -169.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -97.35 175.5 6.23 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.944 1.298 . . . . 0.0 108.586 167.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.59 170.18 29.4 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.676 1.132 . . . . 0.0 111.214 169.034 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -76.79 145.85 38.24 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.56 1.318 . . . . 0.0 114.56 -176.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.21 122.71 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 127.23 2.212 . . . . 0.0 109.27 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 99.0 m -110.73 121.59 45.71 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -169.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.53 142.02 32.59 Favored 'General case' 0 N--CA 1.445 -0.702 0 C-N-CA 125.582 1.553 . . . . 0.0 113.328 -172.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -91.91 148.33 22.3 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.127 -1.397 . . . . 0.0 110.906 168.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.26 -21.23 0.25 Allowed 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 128.61 2.764 . . . . 0.0 117.38 -170.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -74.97 -0.71 19.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 127.492 2.317 . . . . 0.0 111.818 177.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.06 32.16 6.27 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 117.365 -1.797 . . . . 0.0 114.059 170.322 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -152.85 132.53 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 N-CA-C 117.152 2.279 . . . . 0.0 117.152 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.52 109.71 22.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.96 164.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -91.5 133.3 35.63 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -141.0 145.94 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 118.515 2.783 . . . . 0.0 118.515 -168.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 93.8 p -142.81 105.52 4.5 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.39 1.876 . . . . 0.0 110.018 168.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.3 mt -107.17 150.85 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 C-N-CA 125.916 1.686 . . . . 0.0 108.929 169.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -144.45 138.29 27.57 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.954 1.702 . . . . 0.0 107.631 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -157.05 152.25 26.26 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.162 0.985 . . . . 0.0 112.252 -168.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.3 p -119.17 55.2 0.95 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.469 1.108 . . . . 0.0 113.609 -168.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.6 p -158.56 -27.34 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 124.756 1.222 . . . . 0.0 112.776 171.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.56 150.02 5.51 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.327 0 O-C-N 121.062 -1.024 . . . . 0.0 111.029 175.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 p -158.05 162.92 38.13 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 121.057 -1.027 . . . . 0.0 109.174 171.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mp -85.83 47.82 1.5 Allowed 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.413 -1.429 . . . . 0.0 110.923 -172.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.6 t -82.18 -0.48 45.22 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -172.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.48 -7.02 74.58 Favored Glycine 0 N--CA 1.477 1.368 0 N-CA-C 118.216 2.046 . . . . 0.0 118.216 169.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -121.15 -94.81 0.49 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.637 1.575 . . . . 0.0 110.46 -167.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m170 -91.49 5.76 48.21 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -168.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.3 p -107.43 -70.71 0.78 Allowed 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 117.532 2.419 . . . . 0.0 117.532 -166.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pt -159.28 -51.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 125.747 1.619 . . . . 0.0 113.324 -167.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.44 ' C ' ' H ' ' A' ' 115' ' ' ARG . 1.6 mp -86.43 145.62 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 125.89 1.676 . . . . 0.0 108.347 177.175 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.83 -22.08 2.99 Favored Glycine 0 N--CA 1.47 0.92 0 C-N-CA 124.585 1.088 . . . . 0.0 112.125 -167.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.44 ' H ' ' C ' ' A' ' 113' ' ' ILE . 41.8 mtt180 -85.38 176.81 8.06 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.851 2.06 . . . . 0.0 110.948 169.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -108.76 133.66 52.52 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 127.471 2.309 . . . . 0.0 108.032 171.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.5 tp -102.41 118.05 36.04 Favored 'General case' 0 CA--C 1.535 0.365 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 168.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -112.15 129.81 66.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 CA-C-N 119.253 0.933 . . . . 0.0 110.815 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 p -88.92 145.99 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 121.394 0.616 . . . . 0.0 109.837 169.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -102.92 161.55 13.66 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.817 1.647 . . . . 0.0 111.83 -175.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.13 -31.91 62.95 Favored 'General case' 0 N--CA 1.473 0.704 0 O-C-N 121.081 -1.012 . . . . 0.0 112.086 -173.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 27.6 mmtm -131.86 -178.92 5.1 Favored 'General case' 0 C--O 1.237 0.4 0 O-C-N 119.234 -2.166 . . . . 0.0 110.974 169.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.72 129.02 39.38 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 125.077 1.351 . . . . 0.0 109.298 -176.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.18 152.62 30.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 166.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.27 -17.92 61.27 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.945 178.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.41 ' O ' ' HE2' ' A' ' 75' ' ' LYS . 13.4 mt 61.77 41.96 11.2 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.037 1.335 . . . . 0.0 110.227 177.112 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 175.28 -97.08 0.11 Allowed Glycine 0 N--CA 1.471 0.999 0 N-CA-C 118.969 2.348 . . . . 0.0 118.969 177.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.0 pttt -162.69 37.26 0.11 Allowed 'General case' 0 CA--C 1.555 1.139 0 C-N-CA 127.99 2.516 . . . . 0.0 113.631 -167.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -55.07 -12.7 4.13 Favored Glycine 0 CA--C 1.539 1.535 0 N-CA-C 120.132 2.813 . . . . 0.0 120.132 -168.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.47 -28.8 0.5 Allowed Glycine 0 N--CA 1.477 1.379 0 CA-C-N 121.085 2.442 . . . . 0.0 118.038 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 22.1 p-10 -107.13 166.62 10.48 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 119.404 1.602 . . . . 0.0 109.656 174.143 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -57.05 -48.58 78.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 119.932 1.242 . . . . 0.0 109.67 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -48.54 -34.56 11.59 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.722 2.809 . . . . 0.0 113.046 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.6 p -57.7 -28.22 63.64 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 173.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.09 -23.82 10.68 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 169.674 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -59.18 -28.07 66.28 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.484 1.038 . . . . 0.0 111.467 172.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.9 p -133.87 -93.04 0.33 Allowed 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 166.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -158.12 24.81 0.4 Allowed Glycine 0 CA--C 1.537 1.428 0 C-N-CA 130.194 3.759 . . . . 0.0 109.224 168.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 67.11 -84.0 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.367 1.867 . . . . 0.0 107.787 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 66.52 2.15 2.38 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 127.821 2.448 . . . . 0.0 116.711 166.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.71 -57.81 3.01 Favored Glycine 0 CA--C 1.53 1.004 0 C-N-CA 125.683 1.611 . . . . 0.0 113.681 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.5 t -171.83 -177.4 1.95 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.166 1.387 . . . . 0.0 111.306 -171.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.8 164.88 13.18 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 121.151 -0.968 . . . . 0.0 111.926 172.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.439 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -150.94 -152.57 0.44 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 127.568 2.347 . . . . 0.0 106.577 174.817 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.439 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -37.47 112.15 0.19 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.8 2.04 . . . . 0.0 114.296 -170.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.5 t -109.29 138.96 44.86 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.065 2.146 . . . . 0.0 110.538 -175.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.5 -178.57 21.13 Favored Glycine 0 N--CA 1.469 0.899 0 C-N-CA 124.588 1.09 . . . . 0.0 114.32 -175.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.97 160.41 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 104.893 -2.262 . . . . 0.0 104.893 165.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 2.6 mm -135.04 130.56 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 CA-C-N 120.069 1.304 . . . . 0.0 112.434 -168.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.27 -114.04 1.37 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.668 1.604 . . . . 0.0 115.025 -175.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -158.38 129.25 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 118.877 1.338 . . . . 0.0 109.756 -177.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 -35.55 14.95 Favored 'General case' 0 N--CA 1.47 0.531 0 O-C-N 120.929 -1.107 . . . . 0.0 112.42 177.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 . . . . . 0 C--O 1.235 0.294 0 C-N-CA 127.264 2.226 . . . . 0.0 110.005 -171.524 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.549 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 99.2 m -79.17 105.21 10.34 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 169.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.66 122.52 40.84 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.709 1.203 . . . . 0.0 113.366 -168.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.52 178.12 8.37 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 120.911 -1.118 . . . . 0.0 114.005 -177.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.86 110.03 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 128.053 2.541 . . . . 0.0 106.784 169.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -99.3 133.28 43.82 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.951 0.9 . . . . 0.0 108.631 166.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -131.36 99.42 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 123.256 0.622 . . . . 0.0 110.965 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.8 mp -88.21 141.69 28.36 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 124.067 0.854 . . . . 0.0 109.867 169.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -156.07 168.16 28.13 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.913 1.685 . . . . 0.0 112.073 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.48 -101.95 0.19 Allowed Glycine 0 C--O 1.226 -0.398 0 N-CA-C 107.583 -2.207 . . . . 0.0 107.583 166.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -149.42 124.84 10.26 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 129.014 2.926 . . . . 0.0 106.095 -169.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.07 -177.69 44.61 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 124.544 1.069 . . . . 0.0 112.81 -174.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -71.92 30.22 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.093 1 C-N-CA 126.157 4.571 . . . . 0.0 115.11 -170.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.11 123.78 63.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.558 1.543 . . . . 0.0 109.441 -177.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.65 163.71 36.48 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 124.272 1.029 . . . . 0.0 109.585 176.05 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.67 108.78 0.79 Allowed Glycine 0 N--CA 1.461 0.302 0 CA-C-N 114.106 -1.406 . . . . 0.0 110.373 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.46 128.88 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 123.956 0.902 . . . . 0.0 109.401 169.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mm -134.82 124.51 43.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 123.864 0.866 . . . . 0.0 109.231 168.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -79.9 149.63 30.84 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 126.697 1.999 . . . . 0.0 109.924 165.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -143.97 101.97 3.82 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -108.83 116.86 32.78 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.367 1.067 . . . . 0.0 109.831 -169.572 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -116.96 142.28 47.15 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 122.652 1.215 . . . . 0.0 112.917 -172.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.409 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -90.74 -7.57 52.13 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.337 1.455 . . . . 0.0 114.61 -173.656 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.409 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 48.9 mp0 -150.22 -173.99 4.6 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 127.368 2.267 . . . . 0.0 108.24 173.024 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.6 p -75.4 -26.71 58.65 Favored 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.47 -0.769 . . . . 0.0 111.215 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -135.25 9.99 3.49 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.274 1.429 . . . . 0.0 114.101 -171.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.54 174.02 55.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.236 0.922 . . . . 0.0 111.555 169.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.11 166.13 30.85 Favored 'Trans proline' 0 CA--C 1.536 0.578 0 C-N-CA 122.712 2.274 . . . . 0.0 111.116 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.58 132.58 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 C-N-CA 124.876 1.27 . . . . 0.0 110.661 -168.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -88.52 127.81 35.54 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 168.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.8 t -116.91 124.19 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 126.011 1.724 . . . . 0.0 109.058 -171.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -155.41 157.29 36.8 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.152 -0.968 . . . . 0.0 113.269 177.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.13 -160.74 30.67 Favored Glycine 0 CA--C 1.52 0.364 0 O-C-N 121.553 -0.717 . . . . 0.0 113.706 -177.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 53.3 p -149.24 133.19 17.11 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 113.276 0.843 . . . . 0.0 113.276 -168.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -106.01 113.43 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 O-C-N 121.724 -0.61 . . . . 0.0 109.794 171.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.7 ptpt -110.78 157.96 19.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.164 1.385 . . . . 0.0 110.613 -170.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.28 8.29 75.09 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 123.861 0.743 . . . . 0.0 113.997 -173.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -81.15 -152.4 0.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 127.19 2.196 . . . . 0.0 107.865 168.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' THR . . . . . 0.422 HG23 ' H ' ' B' ' 40' ' ' GLU 0.282 7.9 t -137.14 -91.78 0.24 Allowed 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.996 1.318 . . . . 0.0 108.353 169.702 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . 0.422 ' H ' HG23 ' B' ' 39' ' ' THR . 0.0 OUTLIER -127.98 -56.55 1.27 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.438 1.495 . . . . 0.0 113.719 173.085 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.39 147.76 44.87 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 119.856 -1.778 . . . . 0.0 113.558 -169.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 mp -44.9 141.91 2.0 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.84 2.056 . . . . 0.0 112.619 -173.233 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -126.09 130.64 51.49 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.689 1.596 . . . . 0.0 109.276 170.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.76 163.01 41.08 Favored Glycine 0 N--CA 1.482 1.717 0 CA-C-N 120.292 1.406 . . . . 0.0 111.516 172.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -152.46 130.31 11.7 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 120.673 2.237 . . . . 0.0 112.513 168.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.28 146.36 21.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.473 1.109 . . . . 0.0 111.999 -168.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 p -82.63 135.1 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 O-C-N 121.632 -0.667 . . . . 0.0 110.653 168.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -78.19 159.01 28.81 Favored 'General case' 0 CA--C 1.559 1.304 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.141 165.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -67.32 110.89 3.73 Favored 'General case' 0 N--CA 1.469 0.497 0 O-C-N 119.473 -2.017 . . . . 0.0 110.258 171.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 4.3 m-30 142.31 167.37 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 1 C-N-CA 132.927 4.491 . . . . 0.0 110.176 175.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -131.13 14.83 5.39 Favored Glycine 0 C--O 1.222 -0.613 0 C-N-CA 126.42 1.962 . . . . 0.0 114.051 172.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -170.53 113.97 0.45 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.431 2.692 . . . . 0.0 103.972 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -116.04 -64.49 1.3 Allowed 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 114.354 1.242 . . . . 0.0 114.354 -164.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p 77.56 -55.86 0.52 Allowed 'General case' 0 N--CA 1.462 0.139 0 C-N-CA 128.919 2.888 . . . . 0.0 113.275 170.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 -52.28 11.17 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.236 1.014 . . . . 0.0 111.479 177.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.55 -139.56 11.02 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.789 1.662 . . . . 0.0 109.185 -169.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 45.2 m -49.95 -32.03 13.95 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -172.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 -8.27 0.99 Allowed 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 128.108 2.563 . . . . 0.0 114.363 173.089 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 38.7 m -159.03 42.12 0.23 Allowed 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 128.576 2.75 . . . . 0.0 107.41 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -170.22 72.59 0.07 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.282 2.233 . . . . 0.0 109.267 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -69.62 -178.57 21.51 Favored Glycine 0 CA--C 1.538 1.476 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.553 173.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -62.72 168.34 10.32 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.647 2.231 . . . . 0.0 110.849 171.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -45.08 115.36 0.89 Allowed 'General case' 0 C--O 1.236 0.35 0 N-CA-C 115.575 1.695 . . . . 0.0 115.575 -178.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -45.58 117.46 1.45 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.832 166.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -120.84 65.82 13.24 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 115.103 -0.953 . . . . 0.0 113.152 -167.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.81 -4.87 14.18 Favored 'Trans proline' 0 CA--C 1.539 0.766 0 C-N-CA 123.304 2.669 . . . . 0.0 114.561 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -106.73 -6.11 18.05 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.198 0.999 . . . . 0.0 112.71 175.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 18.9 t 66.4 57.92 0.7 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.884 1.674 . . . . 0.0 114.722 171.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -154.06 -176.58 5.93 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 116.226 1.935 . . . . 0.0 116.226 -169.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -80.62 178.15 8.54 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.953 1.301 . . . . 0.0 112.194 -170.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -108.73 144.36 36.63 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.287 -1.324 . . . . 0.0 114.168 176.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 154.33 -102.2 0.22 Allowed Glycine 0 C--N 1.336 0.543 0 C-N-CA 126.37 1.938 . . . . 0.0 110.108 167.297 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -41.22 2.01 Favored Glycine 0 CA--C 1.542 1.774 0 CA-C-O 118.013 -1.437 . . . . 0.0 115.653 172.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_exo -79.62 -25.83 5.17 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 124.206 3.271 . . . . 0.0 112.12 168.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.79 -53.52 2.64 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.901 0.88 . . . . 0.0 110.49 168.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -63.84 106.16 0.96 Allowed 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.311 1.414 . . . . 0.0 111.88 172.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.8 mp0 -59.76 -9.75 3.12 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 129.259 3.023 . . . . 0.0 113.485 175.445 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -85.1 -98.02 0.06 Allowed 'General case' 0 N--CA 1.453 -0.321 0 O-C-N 121.411 -0.806 . . . . 0.0 110.684 174.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 94.09 133.37 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.169 1.787 . . . . 0.0 110.845 173.125 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -70.23 154.54 41.79 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 168.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.2 t -80.44 87.94 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 166.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.47 4.35 0.18 Allowed Glycine 0 CA--C 1.537 1.452 0 N-CA-C 117.672 1.829 . . . . 0.0 117.672 -169.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -150.65 150.51 31.22 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 119.828 1.814 . . . . 0.0 112.511 174.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.7 mt -124.16 49.05 1.82 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.116 169.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.97 -102.99 0.91 Allowed Glycine 0 CA--C 1.532 1.154 0 O-C-N 120.64 -1.287 . . . . 0.0 115.37 176.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -144.71 163.25 34.57 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.024 1.33 . . . . 0.0 113.505 -175.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.2 m -114.45 165.49 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 127.502 2.321 . . . . 0.0 110.115 170.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 62.6 m -146.43 141.31 27.01 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.903 1.281 . . . . 0.0 108.007 174.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . 0.416 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -97.49 164.35 12.48 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -173.097 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.0 -52.09 9.35 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.457 1.503 . . . . 0.0 113.248 -171.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.503 ' HZ1' ' CG ' ' B' ' 92' ' ' ASP . 9.4 pttp 151.62 -37.94 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.991 1 C-N-CA 133.775 4.83 . . . . 0.0 109.637 -168.93 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.503 ' CG ' ' HZ1' ' B' ' 91' ' ' LYS . 34.9 m-20 -84.66 25.79 0.87 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.897 1.679 . . . . 0.0 111.021 -178.083 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.34 3.67 77.57 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.815 1.674 . . . . 0.0 115.56 174.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -109.34 129.41 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 119.011 1.406 . . . . 0.0 113.425 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.416 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -95.3 129.77 42.31 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 125.165 1.386 . . . . 0.0 107.766 165.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -116.93 130.62 56.82 Favored 'General case' 0 C--O 1.233 0.188 0 C-N-CA 125.012 1.325 . . . . 0.0 109.037 -172.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 45.5 t -130.26 137.19 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-N 114.16 -1.382 . . . . 0.0 114.239 -166.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.4 p -151.61 105.23 3.13 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 125.462 1.505 . . . . 0.0 111.635 177.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 22.3 mt -135.99 163.28 34.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 128.239 2.615 . . . . 0.0 110.45 -172.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -139.22 140.14 37.67 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 126.465 1.906 . . . . 0.0 107.089 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -146.01 143.18 29.28 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.491 1.116 . . . . 0.0 111.641 -169.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 9.0 p -118.4 46.04 1.89 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.039 -0.982 . . . . 0.0 112.57 -176.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . 0.272 4.4 p -156.12 20.32 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 174.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -131.45 160.52 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 120.65 -1.281 . . . . 0.0 108.344 167.121 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 51.4 m -158.03 168.87 25.92 Favored 'General case' 0 N--CA 1.47 0.573 0 O-C-N 120.691 -1.256 . . . . 0.0 112.192 175.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.29 64.23 1.6 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 125.974 1.709 . . . . 0.0 109.345 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.6 t -155.3 84.07 1.06 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.453 -1.405 . . . . 0.0 113.357 -169.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.29 -159.0 28.26 Favored Glycine 0 C--N 1.336 0.563 0 CA-C-O 122.997 1.332 . . . . 0.0 112.471 170.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -69.1 -19.7 64.06 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 127.57 2.348 . . . . 0.0 113.769 -167.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 64.7 m170 -97.3 7.9 45.63 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.112 1.365 . . . . 0.0 113.221 -175.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 73.2 m -81.98 176.79 9.26 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -165.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.02 -18.95 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 120.786 -1.196 . . . . 0.0 110.798 163.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mm -75.78 124.92 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 165.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.28 68.8 1.54 Allowed Glycine 0 CA--C 1.527 0.839 0 O-C-N 123.614 0.571 . . . . 0.0 113.462 -169.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -143.17 136.04 27.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.206 1.002 . . . . 0.0 109.579 168.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.6 t -96.42 77.8 2.99 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 124.864 1.266 . . . . 0.0 110.369 -173.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 54.5 tp -77.94 135.49 37.85 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.0 1.32 . . . . 0.0 109.881 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -129.64 146.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 126.067 1.747 . . . . 0.0 108.989 172.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 79.3 t -104.09 140.61 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 122.605 1.193 . . . . 0.0 107.897 168.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -95.6 160.02 14.71 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.625 2.37 . . . . 0.0 112.303 -170.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -80.97 -34.31 33.22 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 120.806 -1.184 . . . . 0.0 114.015 -167.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.4 mmmt -113.42 -176.52 2.92 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 120.176 -1.578 . . . . 0.0 112.428 173.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.29 143.64 27.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.64 1.176 . . . . 0.0 109.921 169.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.23 146.04 24.55 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.957 1.303 . . . . 0.0 109.041 172.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.41 -27.75 56.4 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 178.633 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 63.97 20.96 12.44 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.14 2.176 . . . . 0.0 114.34 174.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -150.68 -94.22 0.11 Allowed Glycine 0 N--CA 1.465 0.581 0 CA-C-N 120.583 1.538 . . . . 0.0 113.165 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 49.2 tttp -163.05 82.39 0.49 Allowed 'General case' 0 N--CA 1.432 -1.364 0 C-N-CA 127.172 2.189 . . . . 0.0 108.608 168.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.97 48.04 0.64 Allowed Glycine 0 CA--C 1.531 1.078 0 C-N-CA 126.778 2.133 . . . . 0.0 114.192 172.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 79.99 -10.97 37.67 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 118.084 1.994 . . . . 0.0 118.084 169.107 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 28.8 m-80 -115.28 177.78 4.53 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.765 2.282 . . . . 0.0 112.418 -169.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -59.11 -64.39 0.96 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.401 1.88 . . . . 0.0 108.992 165.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 48.7 mm-40 -47.8 -34.77 9.07 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.82 1.648 . . . . 0.0 113.37 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 8.8 m -55.97 -14.64 2.65 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 175.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 37.5 p -129.29 -24.56 2.82 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 168.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . 0.253 17.8 pttt -83.81 -6.0 59.33 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 115.764 1.765 . . . . 0.0 115.764 175.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 10.8 m -140.07 -44.64 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 124.948 1.299 . . . . 0.0 112.467 171.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.33 12.27 6.35 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.885 2.183 . . . . 0.0 114.151 -168.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 67.08 8.04 5.87 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 120.673 -1.487 . . . . 0.0 114.798 175.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.58 30.46 0.03 OUTLIER 'General case' 0 CA--C 1.564 1.506 0 N-CA-C 118.206 2.669 . . . . 0.0 118.206 -166.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.6 -51.4 3.37 Favored Glycine 0 N--CA 1.471 1.013 0 C-N-CA 127.218 2.342 . . . . 0.0 115.766 170.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 9.3 t -176.49 -163.1 0.09 Allowed 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.734 2.014 . . . . 0.0 110.545 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.21 142.27 17.03 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 119.77 -1.831 . . . . 0.0 115.739 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.74 -115.62 0.1 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 128.508 2.723 . . . . 0.0 111.266 -177.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.13 138.87 36.99 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 128.454 2.702 . . . . 0.0 111.114 -169.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -126.41 151.76 47.25 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 126.413 1.885 . . . . 0.0 112.274 -175.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.58 169.91 32.9 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 116.434 1.334 . . . . 0.0 116.434 -172.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . 0.273 0.4 OUTLIER -126.62 162.31 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 123.521 0.728 . . . . 0.0 109.753 170.066 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -120.95 127.64 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 124.412 1.085 . . . . 0.0 113.365 -166.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -123.89 -159.31 10.42 Favored Glycine 0 C--N 1.349 1.282 0 C-N-CA 125.039 1.304 . . . . 0.0 113.631 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -110.06 143.22 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 125.946 1.698 . . . . 0.0 111.959 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.432 ' HA ' ' CG ' ' A' ' 50' ' ' PHE . . . -124.49 37.98 4.29 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.456 1.902 . . . . 0.0 111.291 171.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.326 -0.429 0 C-N-CA 125.708 1.603 . . . . 0.0 109.829 -178.235 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.486 ' H3 ' ' CD ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.47 0.566 0 CA-C-O 117.08 -1.438 . . . . 0.0 108.141 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 94.3 m -83.84 76.63 10.0 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 120.523 1.511 . . . . 0.0 108.802 -172.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.16 138.89 33.47 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -175.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.81 169.74 8.85 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 126.534 1.934 . . . . 0.0 112.18 173.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.3 t -147.48 153.89 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 127.95 2.5 . . . . 0.0 110.51 172.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.4 112.64 15.87 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 125.351 1.461 . . . . 0.0 107.168 165.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.6 m -82.66 90.95 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 173.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 25.0 mt -76.28 130.01 37.52 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.574 -172.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.1 mttm -152.29 -179.02 7.17 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.59 1.156 . . . . 0.0 113.152 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 134.84 -58.62 0.68 Allowed Glycine 0 N--CA 1.467 0.763 0 C-N-CA 125.968 1.747 . . . . 0.0 110.058 -178.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -78.44 69.04 4.57 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 122.087 0.946 . . . . 0.0 113.22 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 39.25 -100.38 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 C-N-CA 127.863 2.649 . . . . 0.0 115.71 169.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.98 -9.88 18.03 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 124.783 3.655 . . . . 0.0 114.56 -177.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 t -86.07 143.57 11.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-N 119.679 1.127 . . . . 0.0 110.008 172.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -156.36 158.24 37.04 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.51 168.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -117.18 126.83 7.12 Favored Glycine 0 C--O 1.22 -0.758 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 174.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.55 99.19 6.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 174.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -132.49 133.31 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 125.07 1.348 . . . . 0.0 109.525 -171.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -108.08 150.72 26.81 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.298 2.239 . . . . 0.0 111.208 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -122.22 134.75 54.7 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.567 1.947 . . . . 0.0 109.353 170.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.486 ' CD ' ' H3 ' ' A' ' 1' ' ' ALA . 4.9 tp10 -103.22 113.96 27.87 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 120.935 1.698 . . . . 0.0 110.904 172.595 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 37.1 tp60 -101.31 116.05 31.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 123.191 0.596 . . . . 0.0 109.488 172.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.1 pttp -102.9 -31.81 10.07 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 114.61 1.337 . . . . 0.0 114.61 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.7 mp0 -130.03 156.68 44.08 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 126.213 1.805 . . . . 0.0 108.766 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.0 m -55.68 -39.88 71.57 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 122.386 2.357 . . . . 0.0 116.244 -168.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.04 34.55 5.17 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.03 1.732 . . . . 0.0 110.422 167.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.89 153.47 51.35 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-O 118.129 -1.373 . . . . 0.0 111.021 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -66.38 142.7 67.01 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.123 2.549 . . . . 0.0 109.957 174.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.1 t -112.53 144.86 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.937 0.895 . . . . 0.0 110.879 -168.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.545 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 16.0 tttp -113.59 131.08 56.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.583 1.153 . . . . 0.0 108.804 167.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.96 144.49 16.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 127.872 2.469 . . . . 0.0 109.536 175.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -158.56 161.02 37.25 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.399 1.079 . . . . 0.0 113.185 172.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.63 -149.22 21.29 Favored Glycine 0 N--CA 1.469 0.865 0 C-N-CA 124.249 0.928 . . . . 0.0 112.693 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -153.57 148.75 26.9 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 16.9 mt -126.0 117.76 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 121.032 -1.043 . . . . 0.0 108.914 175.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.1 tttt -123.34 137.87 54.74 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 119.787 1.176 . . . . 0.0 112.168 -172.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.0 3.77 9.71 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 128.413 2.911 . . . . 0.0 113.886 -174.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.12 163.85 22.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 128.431 2.692 . . . . 0.0 112.074 176.302 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -95.07 158.4 15.48 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 166.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -64.07 145.22 56.29 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.99 -171.69 22.81 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.703 1.144 . . . . 0.0 114.591 -173.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 47.2 mt -66.23 146.94 54.04 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 125.532 1.533 . . . . 0.0 113.535 -169.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -144.99 128.59 17.11 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 127.01 2.124 . . . . 0.0 109.514 173.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.15 165.23 54.87 Favored Glycine 0 N--CA 1.473 1.137 0 CA-C-N 119.493 1.042 . . . . 0.0 112.292 -179.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.6 p90 -157.55 137.38 12.33 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.328 1.851 . . . . 0.0 113.706 167.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -148.58 163.87 35.94 Favored 'General case' 0 N--CA 1.451 -0.415 0 O-C-N 119.695 -1.878 . . . . 0.0 112.074 169.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -96.04 134.08 34.88 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-O 121.795 0.807 . . . . 0.0 110.266 173.159 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -71.51 116.06 11.42 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 103.66 -2.719 . . . . 0.0 103.66 168.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.588 ' H ' ' HA ' ' A' ' 63' ' ' HIS 0.305 3.6 tt0 -70.68 21.33 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.897 0 N-CA-C 115.988 1.847 . . . . 0.0 115.988 -168.513 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -132.82 148.94 52.31 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 126.872 2.069 . . . . 0.0 111.204 179.239 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.14 -17.77 42.08 Favored Glycine 0 N--CA 1.465 0.591 0 CA-C-O 117.129 -1.928 . . . . 0.0 115.155 169.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.472 ' C ' HD21 ' A' ' 53' ' ' ASN . 15.4 t0 -72.39 88.78 1.2 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.053 1.927 . . . . 0.0 106.945 168.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.472 HD21 ' C ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER 168.07 -34.39 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.469 2.308 . . . . 0.0 116.766 169.456 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 18.6 p 27.62 -40.55 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.042 2 C-N-CA 133.615 4.766 . . . . 0.0 122.91 179.24 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.2 13.72 2.22 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 127.53 2.332 . . . . 0.0 113.469 -173.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -148.04 34.33 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 124.657 1.122 . . . . 0.0 114.585 169.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.5 m -49.02 -19.99 0.48 Allowed 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -169.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.8 t -79.47 -4.49 51.47 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.454 1.101 . . . . 0.0 113.096 175.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 71.5 m -136.97 147.13 46.13 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.548 1.539 . . . . 0.0 110.739 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 63.51 -94.16 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.237 1.815 . . . . 0.0 113.126 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.54 -41.99 2.07 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 126.499 2.0 . . . . 0.0 116.413 -175.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -109.59 174.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.357 1.009 0 C-N-CA 123.194 2.596 . . . . 0.0 114.75 -175.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.664 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -97.16 134.68 40.16 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 129.99 3.316 . . . . 0.0 114.719 169.839 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -71.1 152.28 43.63 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 162.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 40.2 p-10 -125.75 60.11 31.22 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 124.252 1.021 . . . . 0.0 111.737 -177.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -61.79 -29.9 83.77 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.943 3.095 . . . . 0.0 115.057 -167.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 73.2 mt -75.9 -5.42 46.03 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 175.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t 66.83 110.02 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 130.027 3.331 . . . . 0.0 111.471 -177.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 171.92 172.03 0.1 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -169.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -64.17 169.57 4.38 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.699 2.4 . . . . 0.0 111.68 168.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -96.23 138.99 33.02 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.839 1.256 . . . . 0.0 113.981 170.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.14 -110.05 0.44 Allowed Glycine 0 C--N 1.336 0.533 0 C-N-CA 124.007 0.813 . . . . 0.0 112.79 167.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.92 -20.2 24.52 Favored Glycine 0 CA--C 1.535 1.289 0 CA-C-O 115.237 -2.98 . . . . 0.0 118.396 -172.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.67 -11.81 3.23 Favored 'Trans proline' 0 C--N 1.357 0.982 0 CA-C-N 123.192 3.496 . . . . 0.0 112.282 168.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -152.51 -25.25 0.17 Allowed 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.078 1.351 . . . . 0.0 113.14 169.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -72.59 93.06 1.56 Allowed 'General case' 0 C--N 1.342 0.282 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 166.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -66.77 -6.51 16.24 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 114.674 -1.148 . . . . 0.0 113.87 -179.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -78.74 -64.84 1.08 Allowed 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 125.657 1.583 . . . . 0.0 109.567 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 59.98 127.72 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 129.833 3.253 . . . . 0.0 117.881 167.367 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -56.93 154.04 10.13 Favored 'General case' 0 CA--C 1.55 0.961 0 O-C-N 120.391 -1.443 . . . . 0.0 111.857 171.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 p -68.47 -28.87 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 120.229 1.377 . . . . 0.0 111.287 -174.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.17 105.58 2.1 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 107.081 -2.407 . . . . 0.0 107.081 165.005 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -160.52 142.91 12.92 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 117.956 0.878 . . . . 0.0 113.309 177.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -120.91 175.43 6.05 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 126.196 1.798 . . . . 0.0 112.129 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -95.1 -153.68 30.37 Favored Glycine 0 CA--C 1.535 1.307 0 C-N-CA 125.905 1.717 . . . . 0.0 114.114 178.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.0 p30 -108.0 156.97 18.65 Favored 'General case' 0 N--CA 1.467 0.379 0 O-C-N 121.777 -0.837 . . . . 0.0 110.956 168.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -106.53 173.92 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 127.217 2.207 . . . . 0.0 109.749 176.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -138.16 143.72 40.43 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 125.177 1.391 . . . . 0.0 108.871 169.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.64 152.56 25.4 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 124.105 0.962 . . . . 0.0 112.879 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -88.85 164.52 15.16 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.745 1.618 . . . . 0.0 111.203 168.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -63.53 -10.83 19.89 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.536 1.534 . . . . 0.0 114.828 170.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.12 -18.07 63.22 Favored 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 118.852 0.751 . . . . 0.0 109.805 169.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 105.09 -7.49 44.21 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 127.83 2.633 . . . . 0.0 112.808 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.57 139.47 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 125.603 1.561 . . . . 0.0 113.485 -173.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.39 129.93 52.29 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 164.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -79.52 142.09 36.1 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 167.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -122.16 140.34 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 CA-C-O 122.22 1.01 . . . . 0.0 113.472 171.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.6 p -156.33 122.38 4.97 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.452 1.501 . . . . 0.0 109.814 168.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.2 mp -128.98 156.09 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 C-N-CA 125.739 1.616 . . . . 0.0 108.843 173.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.545 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 12.1 tt0 -157.37 135.84 11.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 126.574 1.95 . . . . 0.0 108.418 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -160.93 159.19 29.31 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 124.763 1.225 . . . . 0.0 112.431 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -121.16 48.19 1.7 Allowed 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.378 1.251 . . . . 0.0 114.378 172.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 57.3 t -137.95 -40.22 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.672 1.989 . . . . 0.0 109.961 169.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 pp -78.85 149.92 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 123.488 1.613 . . . . 0.0 114.474 172.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 94.6 p -155.26 169.53 23.97 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 126.635 1.974 . . . . 0.0 108.907 -176.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mp -96.36 48.26 1.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 172.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.3 t -103.06 -13.31 16.89 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 116.923 2.194 . . . . 0.0 116.923 -169.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 146.39 -88.05 0.16 Allowed Glycine 0 C--N 1.348 1.231 0 N-CA-C 120.124 2.809 . . . . 0.0 120.124 167.439 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -59.8 -61.01 2.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 C-N-CA 126.167 1.787 . . . . 0.0 115.215 -160.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 -125.3 1.3 7.77 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.177 1.391 . . . . 0.0 112.956 -174.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.7 p -78.45 -169.75 1.79 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.418 0.687 . . . . 0.0 112.35 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 3.3 pt -69.99 -30.16 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 O-C-N 118.954 -2.341 . . . . 0.0 114.105 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.9 mm -60.4 137.76 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-N 120.293 1.406 . . . . 0.0 110.493 171.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.98 -11.2 6.39 Favored Glycine 0 CA--C 1.527 0.797 0 CA-C-O 118.223 -1.321 . . . . 0.0 113.719 -177.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.17 139.38 39.9 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 120.035 1.917 . . . . 0.0 108.969 177.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 57.7 m -98.99 104.32 16.36 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -175.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 23.6 tp -80.26 120.08 23.87 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.108 1.363 . . . . 0.0 111.048 -177.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.87 138.87 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.62 1.568 . . . . 0.0 109.912 169.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.3 t -103.79 159.59 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 166.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -125.09 133.35 52.91 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.285 1.434 . . . . 0.0 111.24 -168.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.429 ' CD ' ' HZ2' ' A' ' 122' ' ' LYS . 15.8 tt0 -46.39 -35.62 5.67 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 127.569 2.348 . . . . 0.0 114.704 -178.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.429 ' HZ2' ' CD ' ' A' ' 121' ' ' GLU . 59.6 mttp -113.68 170.02 8.56 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.708 1.603 . . . . 0.0 112.512 -169.637 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.84 158.8 6.01 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.365 1.066 . . . . 0.0 110.642 167.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -138.29 142.53 39.81 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.272 1.029 . . . . 0.0 110.809 -168.161 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -85.91 -59.23 2.36 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 122.977 0.511 . . . . 0.0 111.891 176.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mp 65.93 84.95 0.15 Allowed 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 128.001 2.521 . . . . 0.0 113.9 -174.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 131.02 -29.97 3.43 Favored Glycine 0 N--CA 1.479 1.524 0 N-CA-C 118.888 2.315 . . . . 0.0 118.888 166.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -155.97 -58.92 0.1 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 119.474 1.637 . . . . 0.0 113.515 -169.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 44.22 -115.31 1.23 Allowed Glycine 0 C--N 1.34 0.754 0 C-N-CA 125.55 1.547 . . . . 0.0 111.55 -170.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.86 14.46 3.84 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-O 118.256 -1.302 . . . . 0.0 114.54 169.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -161.63 168.08 24.06 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 120.146 1.973 . . . . 0.0 112.853 -167.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.5 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 31.4 tt0 -47.98 -58.75 4.02 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.137 1.375 . . . . 0.0 112.082 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -46.75 -31.89 3.28 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -179.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -65.7 -23.21 66.71 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.432 -1.418 . . . . 0.0 113.716 178.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.0 t -99.84 -29.56 12.53 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.931 0.892 . . . . 0.0 111.917 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.5 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 19.1 tttt -71.19 -41.45 70.29 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.25 1.42 . . . . 0.0 113.503 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.5 p -124.48 -30.73 3.34 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.112 1.765 . . . . 0.0 112.801 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.98 -14.41 11.24 Favored Glycine 0 C--O 1.222 -0.648 0 C-N-CA 126.416 1.96 . . . . 0.0 111.184 -167.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 90.6 1.68 0.17 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.11 2.964 . . . . 0.0 112.346 178.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.54 -7.76 0.3 Allowed 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -168.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 64.96 7.91 32.49 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 120.327 2.891 . . . . 0.0 120.327 164.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.19 178.3 1.74 Allowed 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 121.166 2.483 . . . . 0.0 115.129 172.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 18.9 ptt-85 -76.4 -174.37 2.84 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.402 1.881 . . . . 0.0 109.883 165.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -177.76 -148.84 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 128.7 2.8 . . . . 0.0 107.504 165.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.28 144.24 55.86 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.079 0.952 . . . . 0.0 110.632 168.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.6 t -157.61 145.05 18.51 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.799 1.24 . . . . 0.0 112.312 -173.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.53 162.96 34.3 Favored Glycine 0 N--CA 1.474 1.176 0 C-N-CA 125.144 1.354 . . . . 0.0 112.46 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.8 p -78.87 153.29 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 118.795 1.298 . . . . 0.0 110.543 169.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mm -87.12 111.64 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 120.87 -1.144 . . . . 0.0 109.969 168.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.32 -155.8 23.55 Favored Glycine 0 CA--C 1.534 1.249 0 C-N-CA 125.659 1.6 . . . . 0.0 112.018 175.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.93 167.99 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-N 119.226 1.513 . . . . 0.0 113.616 177.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.96 -36.87 0.08 Allowed 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.979 1.712 . . . . 0.0 113.449 167.072 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . 0.299 27.6 pt20 . . . . . 0 C--O 1.235 0.31 0 C-N-CA 125.292 1.437 . . . . 0.0 114.307 -170.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.618 0 N-CA-C 112.632 0.604 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.7 m -79.79 105.85 11.39 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.354 1.462 . . . . 0.0 110.544 -167.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 24.3 mtmm -96.19 106.79 19.04 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 115.67 1.73 . . . . 0.0 115.67 -175.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.84 167.16 11.6 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.634 1.974 . . . . 0.0 111.034 167.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -158.44 151.65 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 C-N-CA 124.321 1.048 . . . . 0.0 113.554 -170.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.51 147.74 38.27 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.325 1.05 . . . . 0.0 109.471 162.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.19 121.54 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.382 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 168.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.9 mp -92.34 107.62 19.35 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 126.683 1.993 . . . . 0.0 107.829 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 35.9 tttt -131.47 149.17 52.63 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 120.032 1.287 . . . . 0.0 114.006 175.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.08 151.72 16.87 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 128.799 3.095 . . . . 0.0 107.092 166.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -72.07 88.95 1.11 Allowed 'General case' 0 C--N 1.318 -0.767 0 C-N-CA 126.71 2.004 . . . . 0.0 112.038 -167.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.97 -129.47 3.29 Favored Glycine 0 CA--C 1.536 1.374 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.888 -177.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -93.24 -10.73 1.75 Allowed 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 124.143 3.229 . . . . 0.0 115.368 -169.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.1 t -91.82 113.49 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 120.458 1.481 . . . . 0.0 110.382 -176.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -159.13 161.54 36.32 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.619 -1.173 . . . . 0.0 113.547 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -150.67 167.23 30.38 Favored Glycine 0 CA--C 1.502 -0.765 0 CA-C-N 115.264 -0.88 . . . . 0.0 113.072 166.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.71 135.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.781 -1.562 . . . . 0.0 106.781 167.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.73 128.25 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.609 0.718 . . . . 0.0 109.774 169.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -96.11 136.51 36.47 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 125.587 1.555 . . . . 0.0 110.555 177.46 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -109.39 94.12 4.87 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 127.534 2.334 . . . . 0.0 109.583 173.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -95.68 109.42 21.7 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 121.041 -1.037 . . . . 0.0 111.567 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -98.37 140.45 32.63 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 121.231 -0.918 . . . . 0.0 111.438 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -78.67 -27.59 45.21 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -175.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -161.04 156.87 25.27 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 128.274 2.63 . . . . 0.0 107.318 168.068 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -46.7 -22.06 0.26 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 130.168 3.387 . . . . 0.0 116.698 -170.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -124.83 -4.42 7.59 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 128.536 2.735 . . . . 0.0 112.31 -174.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.41 160.03 27.71 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 125.876 1.703 . . . . 0.0 110.99 172.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.13 159.62 51.25 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.197 2.598 . . . . 0.0 112.626 -170.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.0 t -108.68 128.06 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.793 1.237 . . . . 0.0 110.036 -172.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -81.96 125.16 30.44 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 171.135 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.65 116.82 53.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.611 1.164 . . . . 0.0 108.845 170.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -137.35 158.64 43.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.006 0.922 . . . . 0.0 110.807 169.348 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.42 164.12 9.85 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-O 121.643 0.579 . . . . 0.0 112.688 174.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -113.62 116.52 29.61 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -165.004 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mm -94.96 116.74 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 172.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -124.32 146.97 48.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.508 1.523 . . . . 0.0 111.196 -167.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -31.04 7.79 Favored Glycine 0 N--CA 1.471 0.986 0 C-N-CA 126.946 2.212 . . . . 0.0 112.143 -175.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 3.1 pp -76.0 128.24 34.62 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.511 1.124 . . . . 0.0 108.308 169.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -73.49 175.72 6.77 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.164 0.986 . . . . 0.0 111.888 -173.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -61.09 154.3 23.33 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -168.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.23 -175.02 29.18 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.399 1.0 . . . . 0.0 112.477 -175.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.3 mp -77.82 124.69 28.29 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 127.375 2.27 . . . . 0.0 112.078 -169.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -122.51 130.09 52.67 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.766 1.226 . . . . 0.0 107.976 171.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.32 165.84 38.87 Favored Glycine 0 N--CA 1.473 1.104 0 C-N-CA 126.443 1.973 . . . . 0.0 115.15 -169.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -156.58 99.96 1.91 Allowed 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 120.002 1.901 . . . . 0.0 112.764 -167.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -124.2 135.61 53.58 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 121.059 -1.025 . . . . 0.0 112.173 -169.564 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . 0.263 1.0 OUTLIER -102.84 141.14 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 119.077 0.853 . . . . 0.0 109.369 173.099 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.452 ' CG ' HG23 ' B' ' 116' ' ' THR . 0.3 OUTLIER -133.75 154.53 50.91 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.194 1.398 . . . . 0.0 112.732 -168.437 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -76.93 128.69 35.0 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -170.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.252 29.6 m-85 99.88 157.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 1 C-N-CA 132.732 4.413 . . . . 0.0 115.551 169.457 . . . . . . . . 3 2 . 1 . 016 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.92 -19.32 5.66 Favored Glycine 0 N--CA 1.471 1.014 0 C-N-CA 126.158 1.837 . . . . 0.0 113.176 177.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.46 51.94 0.07 Allowed 'General case' 0 CA--C 1.551 1.008 0 C-N-CA 127.558 2.343 . . . . 0.0 111.597 169.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -178.4 35.18 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -165.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 33.2 p -63.6 40.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.608 2.763 . . . . 0.0 116.182 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -128.49 7.31 5.8 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.957 1.303 . . . . 0.0 112.779 173.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.44 -154.52 50.35 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 120.878 -1.139 . . . . 0.0 110.956 -173.248 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 85.7 m -57.93 -6.69 0.6 Allowed 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 117.691 2.478 . . . . 0.0 117.691 -169.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.3 t -84.85 5.84 27.16 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 120.258 1.39 . . . . 0.0 112.695 168.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 33.8 m -154.1 -35.47 0.1 Allowed 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 126.44 1.896 . . . . 0.0 113.834 172.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -88.18 141.03 28.89 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 125.352 1.461 . . . . 0.0 113.476 -175.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.43 -175.15 48.72 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 124.638 1.113 . . . . 0.0 114.498 -177.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -83.31 -179.11 4.1 Favored 'Trans proline' 0 CA--C 1.539 0.752 1 C-N-CA 126.188 4.592 . . . . 0.0 111.774 175.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.425 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.7 p80 -80.7 107.37 13.45 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 122.452 1.12 . . . . 0.0 112.79 -174.336 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 136.81 5.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.57 1.948 . . . . 0.0 114.501 176.218 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.9 p-10 -116.81 47.4 0.62 Allowed Pre-proline 0 CA--C 1.55 0.965 0 CA-C-N 114.595 -1.184 . . . . 0.0 113.476 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -56.62 -30.47 83.49 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.819 3.012 . . . . 0.0 115.946 -168.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.4 mp -79.29 -4.94 53.14 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 124.468 1.107 . . . . 0.0 113.595 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 68.62 47.83 0.85 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 128.865 2.866 . . . . 0.0 111.115 -176.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.8 mmm180 -110.29 162.28 14.78 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 126.217 1.807 . . . . 0.0 111.011 -168.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 13.1 mmtm -74.43 173.26 10.55 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 167.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 30.1 t60 -50.88 158.22 0.71 Allowed 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -173.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.36 71.2 2.07 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.634 1.111 . . . . 0.0 113.634 -169.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -84.23 125.06 6.93 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -72.59 -11.89 26.52 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.001 1.801 . . . . 0.0 111.581 170.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.76 -5.91 13.29 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.168 0.987 . . . . 0.0 113.653 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -114.06 148.6 36.8 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.519 1.528 . . . . 0.0 108.281 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -74.68 -14.94 60.81 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 124.582 1.153 . . . . 0.0 111.82 -171.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -102.99 121.59 42.85 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.514 1.526 . . . . 0.0 107.678 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 -144.97 124.05 12.84 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 126.966 2.106 . . . . 0.0 110.788 -175.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 61.4 m170 -65.09 155.02 36.14 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.314 1.845 . . . . 0.0 110.842 164.724 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -55.95 -33.69 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.21 103.25 0.31 Allowed Glycine 0 C--N 1.345 1.061 0 N-CA-C 115.163 0.825 . . . . 0.0 115.163 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -159.53 146.88 16.94 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 130.329 3.452 . . . . 0.0 105.217 164.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 76.3 mt -128.96 56.34 1.68 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.779 0.799 . . . . 0.0 111.156 -168.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 59.91 -122.16 29.05 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.467 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -148.06 126.96 12.7 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.466 1.106 . . . . 0.0 110.785 -176.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -76.86 97.15 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.825 1.65 . . . . 0.0 109.314 177.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 92.0 m -97.6 120.91 38.83 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 113.338 -1.756 . . . . 0.0 109.253 -169.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.26 158.65 16.03 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -168.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -81.04 171.74 14.59 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.086 2.155 . . . . 0.0 112.158 168.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.585 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -67.26 -17.34 64.75 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.735 1.614 . . . . 0.0 114.017 174.28 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -71.6 -6.97 44.78 Favored 'General case' 0 CA--C 1.555 1.151 0 CA-C-O 122.433 1.111 . . . . 0.0 109.608 167.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.28 44.48 9.61 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 125.614 1.578 . . . . 0.0 109.895 173.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 13.3 p -142.54 130.31 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.523 1.129 . . . . 0.0 112.528 -177.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.21 94.91 5.77 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 124.512 1.125 . . . . 0.0 109.619 168.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -83.77 104.08 13.58 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 122.241 1.019 . . . . 0.0 109.834 168.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -80.34 154.22 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-N 113.961 -1.472 . . . . 0.0 111.741 -173.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 60.0 p -156.9 93.84 1.38 Allowed 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.182 -0.949 . . . . 0.0 112.719 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 21.2 mt -134.53 153.02 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 126.955 2.102 . . . . 0.0 111.394 -177.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -133.05 135.7 45.52 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 164.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -151.22 141.25 22.09 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 114.912 1.449 . . . . 0.0 114.912 -168.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.0 p -112.03 49.06 0.93 Allowed 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.6 t -123.13 4.99 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 C-N-CA 124.038 0.935 . . . . 0.0 111.158 174.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.24 170.75 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 C-N-CA 126.95 2.1 . . . . 0.0 110.509 -177.094 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -157.88 175.54 13.72 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.878 1.271 . . . . 0.0 110.817 169.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.6 mt -84.7 50.11 1.84 Allowed 'General case' 0 CA--C 1.548 0.893 0 O-C-N 120.204 -1.56 . . . . 0.0 109.609 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.4 t -81.79 25.22 0.56 Allowed 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 115.606 1.706 . . . . 0.0 115.606 -168.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.0 -51.59 3.86 Favored Glycine 0 C--N 1.336 0.542 0 C-N-CA 125.54 1.543 . . . . 0.0 115.087 168.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -101.2 -93.72 0.29 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 117.796 0.798 . . . . 0.0 111.137 -165.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 83.3 m-70 -84.05 2.56 38.58 Favored 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 1.1 t -95.42 -125.93 0.12 Allowed 'General case' 0 CA--C 1.551 0.994 0 O-C-N 119.793 -1.817 . . . . 0.0 113.066 -170.556 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 mm -80.08 -47.09 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-N 123.594 2.906 . . . . 0.0 113.222 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.1 mm -60.24 133.92 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 119.328 0.967 . . . . 0.0 108.936 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.53 6.18 65.49 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-O 118.574 -1.125 . . . . 0.0 115.037 178.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.65 164.08 19.91 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 119.115 1.458 . . . . 0.0 110.017 171.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.452 HG23 ' CG ' ' B' ' 48' ' ' HIS . 3.9 t -115.17 157.65 23.35 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.279 1.032 . . . . 0.0 110.046 175.528 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 17.9 tp -151.28 126.24 9.77 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.025 1.33 . . . . 0.0 112.22 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.9 p -116.46 134.99 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 126.152 1.781 . . . . 0.0 111.258 170.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -84.46 139.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.681 1.193 . . . . 0.0 108.865 169.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 66.2 m-70 -108.25 149.71 28.25 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.616 1.566 . . . . 0.0 112.705 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -73.65 -37.17 65.4 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -171.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -92.12 164.62 13.52 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 120.482 -1.386 . . . . 0.0 109.914 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.16 140.51 5.13 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.419 1.087 . . . . 0.0 111.216 169.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.65 129.29 37.46 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -73.57 0.7 11.86 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.892 2.077 . . . . 0.0 111.564 178.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 79.17 -37.65 0.19 Allowed 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.283 2.633 . . . . 0.0 114.07 168.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 143.22 47.77 0.04 OUTLIER Glycine 0 N--CA 1.477 1.378 0 CA-C-N 120.4 1.454 . . . . 0.0 114.975 -176.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.3 pttp -157.18 -113.46 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 -168.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 66.16 -3.84 2.98 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.652 2.072 . . . . 0.0 117.433 169.411 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.0 4.26 54.77 Favored Glycine 0 CA--C 1.536 1.392 0 CA-C-N 119.073 1.436 . . . . 0.0 114.053 -174.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 m-80 -119.12 156.8 29.12 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 125.722 1.609 . . . . 0.0 111.517 -176.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -54.11 -59.41 4.68 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.145 0.978 . . . . 0.0 109.238 166.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -54.7 -36.88 65.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.739 1.216 . . . . 0.0 113.169 -172.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.0 m -66.05 -13.28 59.7 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.695 1.998 . . . . 0.0 115.563 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -122.37 -20.04 6.24 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.882 0.873 . . . . 0.0 112.928 168.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -72.53 -46.66 53.5 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.121 1.368 . . . . 0.0 111.779 174.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.3 p -117.75 -34.21 4.28 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.221 1.008 . . . . 0.0 112.977 173.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.38 11.24 20.3 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 126.708 2.099 . . . . 0.0 111.972 -168.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 55.52 17.56 2.31 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 120.602 2.201 . . . . 0.0 113.29 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.33 25.07 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.073 0 C-N-CA 127.573 2.349 . . . . 0.0 116.145 -165.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.26 -51.63 3.93 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 127.558 2.504 . . . . 0.0 114.454 169.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 2.9 m 179.76 166.67 1.19 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.782 2.433 . . . . 0.0 111.906 -179.024 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.12 150.97 31.62 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.401 0.681 . . . . 0.0 110.887 173.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.31 -130.6 0.24 Allowed 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 126.739 2.016 . . . . 0.0 108.794 173.086 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.83 157.39 33.42 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 127.065 2.146 . . . . 0.0 114.437 -175.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -151.22 159.68 44.25 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -172.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.71 168.48 34.37 Favored Glycine 0 CA--C 1.543 1.825 0 C-N-CA 127.485 2.469 . . . . 0.0 113.842 175.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 54.2 t -124.83 138.2 54.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 C-N-CA 124.742 1.217 . . . . 0.0 108.563 174.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mm -79.04 122.6 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -166.354 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.62 -156.51 9.88 Favored Glycine 0 CA--C 1.542 1.773 0 C-N-CA 128.362 2.887 . . . . 0.0 113.141 169.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -142.08 147.39 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 C-N-CA 125.276 1.431 . . . . 0.0 114.702 -168.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.07 -22.43 10.56 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 125.499 1.519 . . . . 0.0 114.407 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 . . . . . 0 N--CA 1.471 0.606 0 C-N-CA 125.673 1.589 . . . . 0.0 112.453 -178.186 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.439 ' H2 ' ' CD ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.585 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -96.9 116.68 29.61 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.146 0.979 . . . . 0.0 110.707 -169.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.479 ' HE3' ' OE1' ' A' ' 153' ' ' GLN . 0.0 OUTLIER -77.98 117.71 19.57 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-N 114.741 -1.118 . . . . 0.0 112.053 169.289 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.4 178.59 6.44 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.429 1.091 . . . . 0.0 110.179 167.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -155.41 90.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 125.664 1.586 . . . . 0.0 109.981 -168.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.93 121.93 32.49 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.229 1.412 . . . . 0.0 110.573 174.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.0 p -95.75 126.68 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-N 118.9 0.773 . . . . 0.0 109.105 173.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mp -109.14 133.95 52.35 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.59 1.156 . . . . 0.0 108.627 169.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mtmt -157.77 133.12 8.9 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.267 1.427 . . . . 0.0 110.276 173.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.73 -81.08 0.63 Allowed Glycine 0 C--N 1.334 0.45 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -170.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -139.42 116.56 11.09 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 124.559 1.144 . . . . 0.0 108.987 -166.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.04 -101.41 0.03 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 128.988 3.185 . . . . 0.0 112.613 175.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -77.99 -9.46 16.74 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.275 2.65 . . . . 0.0 114.014 -174.047 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.8 t -88.46 126.19 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 121.33 1.877 . . . . 0.0 111.818 -176.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.87 159.11 43.13 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 125.162 1.385 . . . . 0.0 111.792 171.165 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.87 164.4 27.85 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 122.444 1.025 . . . . 0.0 113.811 169.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.79 133.93 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 125.127 1.371 . . . . 0.0 109.066 -179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.6 mm -137.7 121.92 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 CA-C-N 119.74 1.155 . . . . 0.0 110.683 169.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -88.57 145.84 25.48 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.981 167.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -121.62 109.62 14.99 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 168.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.439 ' CD ' ' H2 ' ' A' ' 1' ' ' ALA . 0.3 OUTLIER -94.78 112.59 24.31 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.85 0.75 . . . . 0.0 111.529 -176.643 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -93.49 135.31 34.86 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -114.52 -45.54 3.01 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.612 1.565 . . . . 0.0 114.688 -175.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -118.9 -179.76 3.91 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.25 1.42 . . . . 0.0 109.204 167.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.8 p -67.66 -25.91 65.94 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 119.162 -2.211 . . . . 0.0 114.221 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -141.04 9.5 2.12 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 126.407 1.883 . . . . 0.0 112.598 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.8 151.94 52.31 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.795 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -61.91 137.63 68.77 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 124.169 3.246 . . . . 0.0 110.36 -172.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 79.3 t -102.59 135.53 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 123.525 0.73 . . . . 0.0 109.889 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.44 ' HZ3' ' CD ' ' A' ' 100' ' ' GLU . 7.1 tttp -91.1 116.69 29.01 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 167.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.3 t -104.2 110.91 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 126.677 1.991 . . . . 0.0 108.7 -173.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -132.78 168.69 17.9 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 122.216 1.008 . . . . 0.0 113.143 -176.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.86 -155.48 26.15 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 124.87 1.224 . . . . 0.0 111.488 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -159.71 152.12 21.09 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -123.91 134.24 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 125.712 1.605 . . . . 0.0 107.865 -178.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.8 ptpt -149.58 152.03 34.81 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -172.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.1 12.12 52.94 Favored Glycine 0 CA--C 1.535 1.302 0 C-N-CA 125.256 1.407 . . . . 0.0 113.231 -168.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -111.86 164.7 12.79 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.005 2.122 . . . . 0.0 111.1 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.23 166.11 24.0 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.081 1.352 . . . . 0.0 111.438 176.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.31 -166.48 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 128.541 2.736 . . . . 0.0 113.661 -177.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.73 -178.38 42.78 Favored Glycine 0 CA--C 1.531 1.063 0 O-C-N 120.295 -1.503 . . . . 0.0 113.136 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.535 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -74.58 144.48 43.95 Favored 'General case' 0 CA--C 1.542 0.652 0 O-C-N 120.692 -1.476 . . . . 0.0 112.045 -178.065 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -136.8 151.29 49.0 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 128.789 2.836 . . . . 0.0 109.274 -177.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.29 173.83 26.69 Favored Glycine 0 N--CA 1.475 1.286 0 C-N-CA 125.317 1.437 . . . . 0.0 114.043 -174.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -159.93 122.46 3.4 Favored 'General case' 0 CA--C 1.554 1.122 0 C-N-CA 125.502 1.521 . . . . 0.0 112.754 -168.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 10.8 p-80 -152.07 134.14 15.01 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 118.705 -2.497 . . . . 0.0 113.607 167.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.6 m -84.99 146.0 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 CA-C-O 122.213 1.006 . . . . 0.0 108.948 170.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -107.13 176.09 5.28 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 124.021 1.867 . . . . 0.0 114.592 -168.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.492 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.2 pm0 -72.95 132.87 44.0 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 158.774 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 75.77 167.59 0.27 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 124.422 2.058 . . . . 0.0 115.148 169.119 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.34 0.28 57.05 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 111.41 -2.632 . . . . 0.0 109.96 163.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -69.92 138.08 52.11 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 165.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.416 HD22 ' CG2' ' A' ' 148' ' ' VAL . 0.8 OUTLIER -177.08 21.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 168.057 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.4 p -79.57 -14.33 58.92 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -163.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -108.1 10.05 28.18 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 124.5 1.12 . . . . 0.0 110.972 167.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.56 -138.06 35.46 Favored Glycine 0 CA--C 1.528 0.865 0 O-C-N 121.019 -1.05 . . . . 0.0 111.035 -171.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.2 m -57.17 -6.06 0.35 Allowed 'General case' 0 CA--C 1.549 0.928 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -174.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.5 t -103.13 0.71 32.24 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-N 119.966 1.257 . . . . 0.0 113.998 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.9 p -128.57 -18.37 3.95 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 168.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.37 153.98 35.73 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.326 1.851 . . . . 0.0 110.763 168.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.16 -173.78 28.81 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.239 0.923 . . . . 0.0 114.753 -170.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.41 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 40.9 Cg_endo -91.24 72.11 0.94 Allowed 'Trans proline' 0 CA--C 1.538 0.721 1 C-N-CA 125.401 4.068 . . . . 0.0 108.276 169.556 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.432 ' CE1' ' ND1' ' A' ' 71' ' ' HIS . 5.1 p80 43.9 70.04 0.36 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.958 1.703 . . . . 0.0 114.657 164.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -32.59 134.3 0.1 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 128.848 2.859 . . . . 0.0 117.901 -168.061 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 30.0 p-10 -103.75 34.25 0.05 OUTLIER Pre-proline 0 CA--C 1.559 1.302 0 N-CA-C 117.365 2.357 . . . . 0.0 117.365 -174.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -66.36 -15.17 47.15 Favored 'Trans proline' 0 C--N 1.357 1.003 0 CA-C-N 123.328 2.224 . . . . 0.0 115.068 -169.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -77.1 -0.84 26.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.099 1.359 . . . . 0.0 112.844 169.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.4 t 77.98 59.48 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.988 2.115 . . . . 0.0 112.3 168.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 ptm85 -149.72 169.35 21.24 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -67.57 156.7 36.14 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 127.889 2.476 . . . . 0.0 111.091 172.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.432 ' ND1' ' CE1' ' A' ' 63' ' ' HIS . 78.1 t60 -75.33 149.97 38.59 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.152 165.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.13 -145.36 12.76 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 116.508 -0.315 . . . . 0.0 113.052 166.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.411 ' H ' ' CB ' ' A' ' 76' ' ' ASP . . . 165.32 -98.15 0.15 Allowed Glycine 0 CA--C 1.535 1.286 0 CA-C-O 117.166 -1.908 . . . . 0.0 114.771 168.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -65.43 0.42 2.85 Favored 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 124.821 3.681 . . . . 0.0 116.397 -169.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.34 1.73 1.41 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 127.124 2.17 . . . . 0.0 112.486 175.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.586 ' CG ' ' H ' ' A' ' 77' ' ' GLU . 19.9 t0 -95.96 -178.96 4.53 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 128.321 2.648 . . . . 0.0 111.131 178.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.586 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 20.1 tt0 -98.43 -31.26 12.09 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 129.635 3.174 . . . . 0.0 112.04 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -127.51 -70.62 0.7 Allowed 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -166.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.499 HH22 ' HB ' ' A' ' 103' ' ' VAL . 1.1 ttt-85 83.69 128.88 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 127.038 2.135 . . . . 0.0 111.436 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -66.25 169.63 6.94 Favored 'General case' 0 CA--C 1.55 0.953 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 m -85.11 65.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 CA-C-O 122.707 1.242 . . . . 0.0 109.68 173.147 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.76 88.73 0.3 Allowed Glycine 0 C--O 1.223 -0.555 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -168.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -158.0 150.5 22.41 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 128.132 2.573 . . . . 0.0 109.597 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 77.5 mt -129.8 178.04 6.81 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 126.08 1.752 . . . . 0.0 109.3 169.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -84.55 -129.04 1.82 Allowed Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.376 0.989 . . . . 0.0 113.184 -176.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -147.7 169.73 19.06 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.437 1.095 . . . . 0.0 110.53 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.41 HG23 ' H ' ' A' ' 88' ' ' THR . 4.3 p -139.63 170.73 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.173 0.989 . . . . 0.0 110.765 -170.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.41 ' H ' HG23 ' A' ' 87' ' ' VAL . 15.5 m -140.78 138.52 34.17 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 125.727 1.611 . . . . 0.0 108.301 172.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.71 138.79 34.56 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.821 0.848 . . . . 0.0 110.563 176.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -87.43 162.8 17.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.64 1.176 . . . . 0.0 112.147 172.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -53.46 -19.06 3.17 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 127.783 2.433 . . . . 0.0 115.017 -170.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.68 4.07 48.49 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 128.241 2.616 . . . . 0.0 110.918 -173.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.68 26.84 21.54 Favored Glycine 0 C--N 1.341 0.829 0 C-N-CA 126.065 1.793 . . . . 0.0 113.907 172.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.18 132.3 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.4 129.21 43.8 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 126.159 1.783 . . . . 0.0 106.258 164.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -117.09 135.64 53.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 -178.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 51.3 t -125.24 129.81 73.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 114.114 -1.403 . . . . 0.0 114.381 -164.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.7 p -144.72 74.47 1.41 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.235 1.414 . . . . 0.0 112.52 176.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -101.09 159.39 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 120.604 -1.31 . . . . 0.0 111.481 -177.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.44 ' CD ' ' HZ3' ' A' ' 30' ' ' LYS . 6.6 tt0 -138.87 141.77 38.6 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.768 2.027 . . . . 0.0 107.941 172.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -145.42 141.2 28.19 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.229 1.411 . . . . 0.0 110.259 177.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.2 p -111.54 50.82 0.81 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -173.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.499 ' HB ' HH22 ' A' ' 79' ' ' ARG . 23.4 t -144.32 -42.97 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.207 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 168.468 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.43 155.52 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 CA-C-N 119.564 1.074 . . . . 0.0 112.095 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.9 p -156.98 167.67 29.77 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.565 -1.334 . . . . 0.0 113.351 177.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.12 56.8 1.31 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.956 1.36 . . . . 0.0 109.378 170.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.08 33.02 0.88 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.723 2.009 . . . . 0.0 111.428 168.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.4 -137.21 13.14 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 124.731 1.158 . . . . 0.0 111.928 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -93.65 -32.82 13.92 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 128.073 2.549 . . . . 0.0 115.766 -165.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -83.95 -8.23 59.22 Favored 'General case' 0 CA--C 1.545 0.758 0 O-C-N 120.305 -1.497 . . . . 0.0 111.607 -178.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 69.9 m -102.19 -40.6 6.72 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 115.416 1.636 . . . . 0.0 115.416 -170.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -169.49 -42.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.104 1.762 . . . . 0.0 114.134 171.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.85 141.51 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 168.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.68 8.85 61.05 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 116.31 -2.384 . . . . 0.0 113.896 -174.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -100.17 177.48 5.06 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 121.146 2.473 . . . . 0.0 109.62 169.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 27.2 m -120.91 146.72 46.32 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.855 1.662 . . . . 0.0 110.243 -175.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -127.33 143.36 51.24 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.858 1.663 . . . . 0.0 109.276 166.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.8 m -114.24 129.47 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 125.598 1.559 . . . . 0.0 109.569 169.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -98.56 120.53 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 168.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -96.81 153.71 17.72 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.333 1.453 . . . . 0.0 113.337 -168.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.26 -62.63 1.57 Allowed 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 124.427 1.091 . . . . 0.0 111.305 -172.741 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.44 176.47 6.28 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.86 -1.15 . . . . 0.0 111.437 170.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.37 146.25 44.96 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.23 1.012 . . . . 0.0 113.428 -169.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.66 112.8 17.27 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 166.226 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -78.72 -8.0 58.29 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.661 1.985 . . . . 0.0 114.922 -167.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 34.28 89.28 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 129.385 3.074 . . . . 0.0 114.915 177.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.41 -55.36 4.9 Favored Glycine 0 N--CA 1.469 0.851 0 C-N-CA 125.456 1.503 . . . . 0.0 112.54 168.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -153.91 110.22 3.3 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -174.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.97 -95.48 2.21 Favored Glycine 0 CA--C 1.513 -0.079 0 N-CA-C 104.116 -3.593 . . . . 0.0 104.116 163.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.55 14.81 3.91 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 117.938 -1.479 . . . . 0.0 114.321 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -121.63 173.66 7.3 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 119.993 1.896 . . . . 0.0 112.215 -169.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -75.56 -48.17 23.55 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 113.067 -1.879 . . . . 0.0 109.04 167.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -61.59 -19.2 61.95 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 176.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 21.1 m -51.34 -39.33 56.81 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 119.955 1.252 . . . . 0.0 112.776 171.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -94.78 -33.18 12.98 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 174.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 mtpt -75.27 -29.23 60.09 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 120.618 1.554 . . . . 0.0 114.823 -178.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.0 p -136.85 -23.33 1.18 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.436 ' C ' ' H ' ' A' ' 140' ' ' ALA . . . 98.36 8.15 55.21 Favored Glycine 0 C--O 1.221 -0.718 0 C-N-CA 124.733 1.158 . . . . 0.0 110.686 -167.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 62.05 -4.04 0.22 Allowed 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.344 1.858 . . . . 0.0 114.153 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.436 ' H ' ' C ' ' A' ' 138' ' ' GLY . . . -58.41 -3.7 0.31 Allowed 'General case' 0 CA--C 1.555 1.159 0 C-N-CA 129.058 2.943 . . . . 0.0 117.151 -165.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.81 -81.6 1.38 Allowed Glycine 0 CA--C 1.532 1.144 0 C-N-CA 125.764 1.65 . . . . 0.0 113.337 172.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.7 m -172.27 166.66 5.9 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.021 1.729 . . . . 0.0 112.255 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.407 ' H ' ' NE ' ' A' ' 143' ' ' ARG . 0.0 OUTLIER -100.38 144.4 29.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 116.698 2.11 . . . . 0.0 116.698 -173.073 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -90.53 -21.97 21.54 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 113.652 -1.613 . . . . 0.0 111.375 166.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.14 142.65 23.53 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 122.185 0.993 . . . . 0.0 111.004 173.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.1 p -136.94 147.78 46.58 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 127.887 2.475 . . . . 0.0 109.082 178.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.63 160.44 31.86 Favored Glycine 0 N--CA 1.469 0.874 0 N-CA-C 115.478 0.951 . . . . 0.0 115.478 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.416 ' CG2' HD22 ' A' ' 53' ' ' ASN . 99.3 t -104.74 143.71 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.527 1.131 . . . . 0.0 110.704 174.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 68.7 mt -84.89 95.41 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 126.383 1.873 . . . . 0.0 111.836 -169.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -91.62 177.75 40.71 Favored Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.0 1.285 . . . . 0.0 113.622 177.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -132.83 158.05 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.727 2.011 . . . . 0.0 112.206 -178.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -153.67 -25.76 0.14 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 174.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . 0.479 ' OE1' ' HE3' ' A' ' 3' ' ' LYS . 34.3 tt0 . . . . . 0 CA--C 1.537 0.458 0 O-C-N 121.009 -1.057 . . . . 0.0 110.802 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.419 0 CA-C-O 120.933 0.397 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.3 m -84.1 99.97 10.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -174.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . 0.451 ' HZ2' ' HB ' ' B' ' 5' ' ' VAL 0.271 0.0 OUTLIER -94.8 113.96 25.78 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-O 123.321 1.534 . . . . 0.0 112.963 178.295 . . . . . . . . 4 4 . 1 . 017 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.05 164.21 25.94 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 125.709 1.604 . . . . 0.0 111.166 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . 0.451 ' HB ' ' HZ2' ' B' ' 3' ' ' LYS . 1.3 p -156.03 140.53 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 125.767 1.627 . . . . 0.0 108.027 178.299 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.5 124.15 21.03 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 4.1 p -79.95 120.62 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 169.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -112.31 110.71 21.1 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 125.125 1.37 . . . . 0.0 108.427 169.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 tttt -157.06 160.28 38.77 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-O 121.499 0.666 . . . . 0.0 111.629 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.0 -35.83 0.84 Allowed Glycine 0 N--CA 1.468 0.802 0 C-N-CA 127.154 2.311 . . . . 0.0 110.005 174.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.41 58.19 2.56 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.867 2.067 . . . . 0.0 110.859 177.289 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 36.8 -98.31 0.01 OUTLIER Glycine 0 CA--C 1.535 1.334 0 C-N-CA 128.104 2.764 . . . . 0.0 114.288 -176.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.06 -13.2 15.76 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 123.869 3.046 . . . . 0.0 114.785 -176.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.21 137.51 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 121.262 1.846 . . . . 0.0 111.675 -176.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -126.49 162.12 26.36 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 124.357 1.063 . . . . 0.0 110.375 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -128.19 62.99 0.62 Allowed Glycine 0 N--CA 1.469 0.853 0 C-N-CA 125.262 1.41 . . . . 0.0 111.836 172.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.44 109.08 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 CA-C-N 118.358 1.079 . . . . 0.0 110.923 -168.686 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -110.8 150.88 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 169.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -129.46 129.15 44.25 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.054 2.142 . . . . 0.0 107.364 167.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -115.93 125.02 52.03 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 119.203 0.91 . . . . 0.0 109.834 178.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.65 127.39 52.38 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 123.726 0.81 . . . . 0.0 110.242 -178.619 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . 0.491 ' HG2' ' H ' ' B' ' 24' ' ' GLU . 52.4 tt0 -121.14 134.27 55.23 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 123.069 1.414 . . . . 0.0 112.57 170.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -82.89 0.4 44.39 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 126.485 1.914 . . . . 0.0 113.617 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.491 ' H ' ' HG2' ' B' ' 22' ' ' GLN . 43.4 mt-10 -157.64 -164.64 1.59 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 130.333 3.453 . . . . 0.0 108.495 -169.168 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -120.47 -6.6 9.77 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.895 1.278 . . . . 0.0 111.868 165.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -116.84 -45.95 2.76 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.745 1.618 . . . . 0.0 113.685 -171.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.38 -162.83 11.31 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 125.184 1.373 . . . . 0.0 114.133 -176.569 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.18 161.45 38.22 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.524 2.149 . . . . 0.0 112.69 -171.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 13.9 t -133.71 136.42 54.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.834 1.654 . . . . 0.0 109.833 -173.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -80.85 130.99 35.34 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.253 0.549 . . . . 0.0 110.049 171.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.36 105.44 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 127.735 2.414 . . . . 0.0 108.227 178.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -138.49 162.16 35.22 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.85 173.11 13.06 Favored Glycine 0 N--CA 1.467 0.737 0 C-N-CA 124.668 1.128 . . . . 0.0 114.261 171.331 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.3 p -110.65 120.59 42.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 114.86 1.43 . . . . 0.0 114.86 -167.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -92.01 117.12 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 167.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 pttt -137.81 136.61 37.37 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.511 0.725 . . . . 0.0 111.349 -167.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.57 -18.26 22.77 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 127.491 2.472 . . . . 0.0 113.636 -172.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.4 156.35 25.45 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.371 1.069 . . . . 0.0 111.705 172.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -69.25 166.13 19.08 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.258 1.423 . . . . 0.0 110.262 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -61.39 -176.36 0.07 Allowed 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 126.673 1.989 . . . . 0.0 115.197 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.42 177.28 51.83 Favored Glycine 0 N--CA 1.469 0.867 0 C-N-CA 124.905 1.24 . . . . 0.0 112.187 -179.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.565 ' CD2' ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -71.23 141.99 50.6 Favored 'General case' 0 CA--C 1.541 0.614 0 O-C-N 120.824 -1.398 . . . . 0.0 110.092 177.381 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -134.21 141.29 46.99 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 127.317 2.247 . . . . 0.0 107.957 176.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.98 155.94 48.53 Favored Glycine 0 N--CA 1.479 1.562 0 CA-C-N 120.494 1.497 . . . . 0.0 113.217 -174.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -147.27 105.5 3.76 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.91 1.355 . . . . 0.0 110.465 -171.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.476 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -145.4 145.22 31.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 120.804 -1.185 . . . . 0.0 110.4 -167.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . 0.411 ' CG2' ' HA2' ' B' ' 82' ' ' GLY . 34.5 m -115.03 120.7 65.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.278 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -176.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.476 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 3.7 m170 -74.93 152.1 38.84 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -173.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -73.05 94.05 1.85 Allowed 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 169.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 150.54 156.82 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 1 C-N-CA 132.351 4.26 . . . . 0.0 111.669 170.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.3 -21.19 42.28 Favored Glycine 0 C--N 1.337 0.621 0 C-N-CA 126.187 1.851 . . . . 0.0 111.294 164.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . 0.454 ' C ' HD21 ' B' ' 53' ' ' ASN . 29.9 t0 -58.05 157.42 8.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 165.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.568 ' ND2' ' HG1' ' B' ' 116' ' ' THR . 1.3 p30 162.65 31.26 0.0 OUTLIER 'General case' 0 C--O 1.241 0.62 0 C-N-CA 129.075 2.95 . . . . 0.0 111.496 165.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 18.2 p -69.77 -41.64 74.89 Favored 'General case' 0 N--CA 1.455 -0.19 0 O-C-N 121.132 -0.98 . . . . 0.0 110.364 -168.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.9 25.32 3.71 Favored 'General case' 0 CA--C 1.556 1.182 0 C-N-CA 124.725 1.21 . . . . 0.0 111.892 166.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.79 -128.48 23.59 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 120.302 -1.499 . . . . 0.0 112.447 174.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 5.5 t -71.84 -12.31 61.22 Favored 'General case' 0 CA--C 1.547 0.835 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -98.69 50.22 0.98 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.842 1.257 . . . . 0.0 107.789 171.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -170.73 -81.3 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 -168.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -93.78 153.19 18.44 Favored 'General case' 0 C--O 1.234 0.249 0 O-C-N 121.455 -0.778 . . . . 0.0 112.017 173.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.08 -161.86 29.49 Favored Glycine 0 CA--C 1.54 1.602 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.568 173.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -78.03 -171.43 1.2 Allowed 'Trans proline' 0 CA--C 1.54 0.777 1 C-N-CA 126.257 4.638 . . . . 0.0 110.087 169.167 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.674 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 2.1 p80 -73.76 80.32 1.57 Allowed 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.303 2.641 . . . . 0.0 107.084 168.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -56.0 169.88 0.35 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 123.826 1.774 . . . . 0.0 110.889 174.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -104.13 51.94 0.08 OUTLIER Pre-proline 0 CA--C 1.555 1.142 0 CA-C-N 113.392 -1.731 . . . . 0.0 115.165 -167.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.45 -25.72 48.2 Favored 'Trans proline' 0 C--N 1.354 0.865 0 C-N-CA 122.33 2.02 . . . . 0.0 111.469 -177.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 39.5 mt -81.6 -6.49 59.05 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 172.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.9 t 69.34 59.86 0.32 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 125.652 1.581 . . . . 0.0 113.84 174.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.9 ptt180 -162.01 176.26 10.94 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 115.449 1.648 . . . . 0.0 115.449 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.2 170.95 11.94 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.888 1.275 . . . . 0.0 114.116 177.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.401 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 77.0 t60 -83.76 162.26 20.71 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.378 0.671 . . . . 0.0 111.501 167.636 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . 0.401 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 137.97 -102.39 0.37 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.377 1.941 . . . . 0.0 111.739 166.106 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.75 -53.44 0.71 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 116.958 -2.024 . . . . 0.0 117.498 172.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -87.86 -8.17 6.02 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.502 2.801 . . . . 0.0 111.25 176.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.467 ' HE2' ' HA ' ' B' ' 75' ' ' LYS . 0.1 OUTLIER -145.98 -16.64 0.46 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 176.248 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -101.67 92.45 4.87 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 103.181 -2.896 . . . . 0.0 103.181 159.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 56.2 mp0 -65.04 -4.88 5.2 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.676 1.191 . . . . 0.0 113.508 -176.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -74.61 -63.31 1.27 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.597 1.959 . . . . 0.0 107.711 178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 32.4 ttp180 67.83 119.79 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.959 2.207 . . . . 0.0 116.959 162.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -62.61 156.1 24.25 Favored 'General case' 0 N--CA 1.472 0.659 0 O-C-N 119.467 -2.021 . . . . 0.0 112.102 169.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -52.71 -32.75 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . 0.411 ' HA2' ' CG2' ' B' ' 47' ' ' VAL . . . -96.33 39.05 2.91 Favored Glycine 0 CA--C 1.534 1.26 0 N-CA-C 116.708 1.443 . . . . 0.0 116.708 -174.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -129.96 108.39 10.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.281 -1.129 . . . . 0.0 111.715 -172.385 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -109.79 47.41 0.95 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 122.467 1.127 . . . . 0.0 110.153 168.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.5 -101.67 0.03 OUTLIER Glycine 0 CA--C 1.528 0.879 0 C-N-CA 127.984 2.707 . . . . 0.0 114.103 174.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.8 p30 -154.86 161.74 41.34 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.592 1.557 . . . . 0.0 111.553 -175.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.9 p -137.85 124.81 28.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 C-N-CA 126.916 2.086 . . . . 0.0 109.605 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 55.5 m -107.73 123.89 49.2 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 114.707 -1.133 . . . . 0.0 111.19 -167.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.08 148.9 21.61 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 124.398 1.079 . . . . 0.0 112.509 -176.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -97.22 157.07 16.13 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.111 1.765 . . . . 0.0 112.236 169.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -24.94 24.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 127.246 2.219 . . . . 0.0 115.336 -169.067 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -79.65 5.75 12.42 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.984 1.714 . . . . 0.0 111.597 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.19 36.81 6.15 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 126.049 1.785 . . . . 0.0 113.2 171.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.27 138.39 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 117.31 2.337 . . . . 0.0 117.31 -172.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.93 93.07 3.97 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.72 2.008 . . . . 0.0 110.696 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -85.59 95.44 9.33 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-O 122.491 1.139 . . . . 0.0 110.665 172.271 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.75 152.89 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.513 -170.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.2 p -155.14 109.83 2.98 Favored 'General case' 0 CA--C 1.541 0.634 0 O-C-N 120.963 -1.086 . . . . 0.0 112.21 175.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.83 160.31 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 127.722 2.409 . . . . 0.0 110.12 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -134.32 141.14 46.82 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 164.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -144.59 152.38 40.43 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.528 1.131 . . . . 0.0 112.116 178.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.7 p -117.42 59.32 0.78 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.546 1.538 . . . . 0.0 111.654 -169.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -157.24 -42.09 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 174.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -79.21 154.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 O-C-N 121.883 -0.511 . . . . 0.0 110.628 169.353 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 9.2 p -155.26 170.37 22.03 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.329 1.052 . . . . 0.0 111.05 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.1 mp -86.56 55.53 3.59 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.092 -1.005 . . . . 0.0 111.649 -173.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.1 t -90.47 12.81 17.43 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 116.876 2.176 . . . . 0.0 116.876 -169.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.22 -38.65 3.19 Favored Glycine 0 N--CA 1.475 1.235 0 N-CA-C 118.695 2.238 . . . . 0.0 118.695 167.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -107.16 -105.46 0.34 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.541 1.136 . . . . 0.0 110.572 -166.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -76.23 11.77 1.41 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 126.187 1.795 . . . . 0.0 113.363 175.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 9.7 p -84.12 -158.35 0.32 Allowed 'General case' 0 CA--C 1.553 1.086 0 C-N-CA 127.013 2.125 . . . . 0.0 114.13 -175.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.39 8.1 pt -83.23 -9.39 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 O-C-N 119.666 -1.896 . . . . 0.0 114.234 168.284 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.5 mm -98.36 151.18 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 161.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 95.1 -41.12 2.56 Favored Glycine 0 N--CA 1.468 0.811 0 C-N-CA 124.342 0.973 . . . . 0.0 113.033 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . 0.488 HH21 ' HB2' ' B' ' 117' ' ' LEU . 0.2 OUTLIER -75.13 -179.56 4.45 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 127.49 2.316 . . . . 0.0 115.604 -169.579 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.568 ' HG1' ' ND2' ' B' ' 53' ' ' ASN . 5.1 t -103.43 176.18 5.23 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 127.437 2.295 . . . . 0.0 113.065 169.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . 0.488 ' HB2' HH21 ' B' ' 115' ' ' ARG . 33.9 tp -152.95 144.99 23.76 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.157 2.183 . . . . 0.0 110.363 170.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.45 150.2 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 O-C-N 123.284 0.365 . . . . 0.0 110.796 167.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.89 128.42 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 168.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -90.16 148.84 22.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.93 0.892 . . . . 0.0 112.518 -169.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.297 2.4 pp20? -77.51 -32.55 54.17 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.3 -0.875 . . . . 0.0 112.661 -174.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -90.54 169.07 11.34 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.322 -0.861 . . . . 0.0 110.061 165.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.72 149.65 34.8 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.125 0.97 . . . . 0.0 109.628 164.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -78.9 131.89 36.57 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 168.372 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -78.58 -11.05 59.94 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.178 0.991 . . . . 0.0 112.523 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mm? 70.25 -66.33 0.28 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 129.998 3.319 . . . . 0.0 111.339 -176.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 176.09 29.38 0.04 OUTLIER Glycine 0 N--CA 1.463 0.491 0 N-CA-C 116.171 1.228 . . . . 0.0 116.171 -169.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -126.12 -20.34 4.54 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 117.088 2.255 . . . . 0.0 117.088 -167.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.89 129.92 47.16 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 106.506 -2.638 . . . . 0.0 106.506 168.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -74.12 46.39 1.52 Allowed Glycine 0 N--CA 1.473 1.102 0 C-N-CA 126.387 1.946 . . . . 0.0 112.865 -171.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -103.23 -89.86 0.38 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.653 1.181 . . . . 0.0 110.947 -169.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 170.4 -76.66 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 131.213 3.805 . . . . 0.0 102.474 -167.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . 0.459 ' CD ' ' HG1' ' B' ' 137' ' ' THR . 2.2 tm-20 -35.66 -52.85 0.7 Allowed 'General case' 0 CA--C 1.54 0.584 1 C-N-CA 132.147 4.179 . . . . 0.0 112.92 171.628 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.6 m -47.37 -31.1 3.71 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 176.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.3 t -112.72 -8.03 13.79 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 119.449 1.022 . . . . 0.0 112.264 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 22.4 mmtp -84.25 -47.42 10.81 Favored 'General case' 0 CA--C 1.537 0.469 0 O-C-N 120.75 -1.219 . . . . 0.0 110.853 168.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.459 ' HG1' ' CD ' ' B' ' 133' ' ' GLU . 74.6 p -117.01 -34.17 4.49 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.786 1.634 . . . . 0.0 113.079 -173.271 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.13 2.89 31.59 Favored Glycine 0 N--CA 1.47 0.922 0 CA-C-O 118.353 -1.248 . . . . 0.0 113.805 -177.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 51.48 24.16 2.11 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 119.55 1.675 . . . . 0.0 114.168 177.145 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.09 20.08 0.08 Allowed 'General case' 0 CA--C 1.553 1.067 0 N-CA-C 115.748 1.759 . . . . 0.0 115.748 -166.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.8 -66.76 2.4 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 126.459 1.981 . . . . 0.0 114.288 173.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -175.69 -163.56 0.12 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.803 1.641 . . . . 0.0 109.532 -169.44 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.26 145.73 33.0 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 174.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -90.58 -103.84 0.1 Allowed 'General case' 0 CA--C 1.537 0.462 0 O-C-N 124.98 1.425 . . . . 0.0 107.557 170.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.03 147.22 50.35 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.443 0.697 . . . . 0.0 111.901 -177.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.33 151.76 51.71 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 127.093 2.157 . . . . 0.0 110.17 173.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.87 174.82 37.55 Favored Glycine 0 C--O 1.221 -0.678 0 N-CA-C 116.461 1.344 . . . . 0.0 116.461 -174.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -142.37 143.47 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.408 1.483 . . . . 0.0 109.502 -168.264 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.2 129.82 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -165.481 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.71 -155.66 7.12 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 125.232 1.396 . . . . 0.0 111.023 167.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.43 157.23 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.033 1.333 . . . . 0.0 113.285 -169.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.9 -41.1 14.25 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 161.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 . . . . . 0 CA--C 1.536 0.432 1 C-N-CA 132.764 4.425 . . . . 0.0 107.194 168.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 118.959 -0.543 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.03 55.22 1.8 Allowed 'General case' 0 CA--C 1.511 -0.536 0 CA-C-O 123.028 1.394 . . . . 0.0 111.345 -171.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -87.8 107.1 18.5 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 166.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.02 167.48 12.06 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.537 1.535 . . . . 0.0 111.893 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -159.35 149.23 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.395 1.078 . . . . 0.0 112.013 -168.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.33 121.22 14.53 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.073 1.749 . . . . 0.0 108.918 167.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -103.71 99.16 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 167.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.2 mp -81.03 116.29 20.91 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -176.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 mtpt -144.77 157.55 44.13 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-N 119.272 0.942 . . . . 0.0 111.818 -172.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.45 -47.87 0.43 Allowed Glycine 0 N--CA 1.47 0.904 0 C-N-CA 126.505 2.002 . . . . 0.0 111.252 169.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.62 61.42 2.94 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 128.64 2.776 . . . . 0.0 112.344 -168.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.4 -99.81 0.02 OUTLIER Glycine 0 CA--C 1.534 1.266 0 C-N-CA 126.974 2.226 . . . . 0.0 112.904 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -82.11 -7.39 12.09 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.202 3.268 . . . . 0.0 114.867 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -86.42 136.07 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 121.244 1.838 . . . . 0.0 110.889 175.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.38 151.44 35.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 114.066 -1.424 . . . . 0.0 110.833 167.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -118.77 98.79 0.75 Allowed Glycine 0 C--O 1.22 -0.779 0 C-N-CA 125.485 1.517 . . . . 0.0 110.259 174.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -91.38 110.84 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 108.382 -0.969 . . . . 0.0 108.382 171.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.09 155.19 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-O 122.037 0.922 . . . . 0.0 110.713 168.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -130.96 156.2 45.51 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.476 1.51 . . . . 0.0 109.849 169.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -123.8 120.51 32.85 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.001 1.32 . . . . 0.0 108.651 168.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -98.44 119.86 37.86 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.246 1.018 . . . . 0.0 110.118 172.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.95 170.47 16.05 Favored 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 166.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.93 -46.88 0.53 Allowed 'General case' 0 CA--C 1.558 1.253 0 C-N-CA 128.135 2.574 . . . . 0.0 110.166 168.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.6 mp0 -81.68 116.1 21.24 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 120.456 1.48 . . . . 0.0 111.964 173.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -68.6 -9.69 51.22 Favored 'General case' 0 CA--C 1.552 1.047 0 O-C-N 119.223 -2.173 . . . . 0.0 114.439 -174.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -110.78 -2.94 15.97 Favored 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 127.22 2.208 . . . . 0.0 114.542 174.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.27 175.99 38.32 Favored Glycine 0 CA--C 1.542 1.734 0 CA-C-O 118.848 -0.973 . . . . 0.0 113.756 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -77.77 163.17 29.2 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 124.731 3.62 . . . . 0.0 110.739 175.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.2 t -138.08 145.57 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.672 0.789 . . . . 0.0 112.165 -165.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.402 ' HE3' ' OE1' ' A' ' 100' ' ' GLU . 0.1 OUTLIER -84.79 121.28 27.47 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.74 1.216 . . . . 0.0 111.425 169.766 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 94.6 t -101.16 133.47 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.852 2.061 . . . . 0.0 108.112 169.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -153.67 167.61 29.0 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.572 0.701 . . . . 0.0 112.658 171.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.51 -161.35 28.36 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 124.253 0.93 . . . . 0.0 113.432 172.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.8 p -154.35 118.98 4.87 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.519 0.727 . . . . 0.0 110.776 -169.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.413 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 2.2 mp -108.01 103.0 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.915 0.886 . . . . 0.0 109.019 -177.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -115.88 133.42 56.04 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.223 1.809 . . . . 0.0 111.934 -166.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.59 0.86 27.65 Favored Glycine 0 CA--C 1.536 1.399 0 C-N-CA 127.458 2.456 . . . . 0.0 113.26 -174.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 97.5 mt -70.57 162.74 28.31 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 118.508 1.154 . . . . 0.0 111.116 172.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.6 m -83.14 140.64 32.49 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 166.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -58.76 152.15 19.64 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.42 -172.67 29.17 Favored Glycine 0 CA--C 1.532 1.125 0 C-N-CA 124.241 0.924 . . . . 0.0 112.818 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.458 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -72.4 149.29 44.42 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.817 2.047 . . . . 0.0 112.329 -169.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -145.81 121.72 10.64 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.962 1.705 . . . . 0.0 110.14 173.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.62 147.76 23.46 Favored Glycine 0 N--CA 1.486 1.982 0 CA-C-N 119.992 1.269 . . . . 0.0 112.606 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -148.32 102.01 3.31 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 119.208 1.504 . . . . 0.0 112.408 -167.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m80 -150.27 169.86 20.35 Favored 'General case' 0 CA--C 1.52 -0.199 0 O-C-N 120.658 -1.276 . . . . 0.0 114.331 -168.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.6 m -75.73 129.93 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 113.608 -1.633 . . . . 0.0 109.871 166.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -80.86 137.71 36.18 Favored 'General case' 0 CA--C 1.551 0.986 0 N-CA-C 102.472 -3.159 . . . . 0.0 102.472 157.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -65.18 142.44 58.33 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -168.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 56.83 -169.05 0.1 Allowed 'General case' 0 C--O 1.241 0.623 0 C-N-CA 127.242 2.217 . . . . 0.0 113.898 175.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.472 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -136.69 5.71 3.76 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-O 116.78 -2.122 . . . . 0.0 113.525 -178.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -77.91 48.6 0.72 Allowed 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 121.336 2.568 . . . . 0.0 110.404 169.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.472 ' H ' ' C ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 172.65 5.87 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 118.359 2.726 . . . . 0.0 118.359 -169.35 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.4 p -31.37 -10.02 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.213 1 N-CA-C 124.607 5.04 . . . . 0.0 124.607 -167.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.02 35.67 0.06 Allowed 'General case' 0 CA--C 1.555 1.147 0 CA-C-N 123.504 2.865 . . . . 0.0 116.643 -169.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.1 -148.96 46.85 Favored Glycine 0 CA--C 1.526 0.734 0 O-C-N 120.784 -1.197 . . . . 0.0 111.617 172.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.3 p -64.42 -12.01 38.94 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 114.914 1.45 . . . . 0.0 114.914 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 p -80.01 -0.3 34.84 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.898 2.079 . . . . 0.0 112.833 178.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.1 m -155.87 177.49 11.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 127.655 2.382 . . . . 0.0 109.215 -176.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 77.1 -156.48 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 126.448 1.899 . . . . 0.0 113.96 172.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.2 -169.8 16.14 Favored Glycine 0 CA--C 1.541 1.674 0 C-N-CA 126.823 2.154 . . . . 0.0 114.931 -167.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -66.8 -177.03 0.83 Allowed 'Trans proline' 0 CA--C 1.539 0.761 1 C-N-CA 126.353 4.702 . . . . 0.0 113.588 177.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 114.26 21.88 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.625 1.17 . . . . 0.0 112.932 -170.514 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.427 ' CD2' ' HD3' ' A' ' 66' ' ' PRO . 8.8 t80 -41.43 128.44 3.07 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 127.385 2.274 . . . . 0.0 115.089 -169.616 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -112.0 45.92 0.27 Allowed Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 125.653 1.581 . . . . 0.0 114.281 -173.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.427 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 62.4 Cg_endo -69.15 -17.69 40.22 Favored 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 123.236 2.624 . . . . 0.0 111.722 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.5 mt -76.46 -7.14 54.49 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.201 1.4 . . . . 0.0 111.417 171.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.3 t 73.48 56.89 0.11 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 127.167 2.187 . . . . 0.0 112.267 171.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.16 172.45 16.92 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 116.52 2.044 . . . . 0.0 116.52 -167.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.465 ' HB3' ' HG1' ' A' ' 135' ' ' THR . 15.2 mmtp -82.57 173.81 11.62 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 127.149 2.18 . . . . 0.0 112.167 171.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.4 t60 -72.58 165.07 25.41 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.034 1.733 . . . . 0.0 113.616 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.46 -140.53 8.59 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 124.984 1.278 . . . . 0.0 114.499 167.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 131.87 -86.14 0.29 Allowed Glycine 0 CA--C 1.533 1.205 0 C-N-CA 126.287 1.898 . . . . 0.0 115.617 174.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -61.21 -9.77 13.58 Favored 'Trans proline' 0 CA--C 1.539 0.728 0 C-N-CA 124.748 3.632 . . . . 0.0 116.001 -169.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.34 -7.98 2.58 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.936 0.894 . . . . 0.0 112.767 167.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.421 ' CG ' ' H ' ' A' ' 78' ' ' GLU 0.314 0.0 OUTLIER -93.04 175.19 6.88 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -164.699 . . . . . . . . 4 4 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.406 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 56.0 mp0 -103.21 -22.95 13.66 Favored 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 131.391 3.876 . . . . 0.0 111.46 -168.391 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.421 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 2.9 mm-40 -105.94 -114.93 0.25 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 127.464 2.306 . . . . 0.0 110.132 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 103.27 119.18 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 130.892 3.677 . . . . 0.0 112.856 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.4 m170 -65.44 -176.87 0.36 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 126.388 1.875 . . . . 0.0 114.451 169.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.5 p -84.58 143.79 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 120.762 -1.212 . . . . 0.0 108.636 166.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.2 -2.52 9.25 Favored Glycine 0 CA--C 1.54 1.607 0 N-CA-C 117.455 1.742 . . . . 0.0 117.455 172.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -77.35 85.43 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-N 120.486 2.143 . . . . 0.0 109.553 167.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.0 mt -82.55 54.83 2.75 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.29 -176.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.47 -135.95 29.54 Favored Glycine 0 CA--C 1.528 0.859 0 C-N-CA 125.172 1.368 . . . . 0.0 114.386 170.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -136.86 145.0 43.88 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.058 0.943 . . . . 0.0 111.325 175.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -93.51 107.1 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 126.333 1.853 . . . . 0.0 109.579 176.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.2 m -99.9 113.89 26.75 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.677 1.191 . . . . 0.0 109.187 -175.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.03 158.26 15.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.896 1.679 . . . . 0.0 114.05 -171.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.39 -173.09 3.67 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.265 1.426 . . . . 0.0 112.597 169.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -83.7 -13.55 53.82 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 116.615 2.08 . . . . 0.0 116.615 176.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -75.36 -7.73 54.78 Favored 'General case' 0 CA--C 1.561 1.388 0 CA-C-O 122.845 1.307 . . . . 0.0 108.005 163.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.02 8.94 56.5 Favored Glycine 0 C--N 1.339 0.733 0 C-N-CA 128.26 2.838 . . . . 0.0 113.258 168.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 125.43 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 119.058 1.429 . . . . 0.0 113.839 -169.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 100.21 12.14 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 166.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -89.89 134.01 34.44 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.415 1.486 . . . . 0.0 109.099 177.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -141.31 137.42 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -167.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.3 p -153.59 119.5 5.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 125.757 1.623 . . . . 0.0 110.413 169.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.8 mt -147.15 147.47 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 C-N-CA 128.646 2.779 . . . . 0.0 110.358 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.402 ' OE1' ' HE3' ' A' ' 30' ' ' LYS . 2.0 tp10 -118.02 130.81 56.4 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.895 2.078 . . . . 0.0 105.98 167.057 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -139.36 134.38 32.41 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.853 0.861 . . . . 0.0 112.186 -172.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -114.69 46.46 1.4 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.175 1.176 . . . . 0.0 114.175 -179.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.57 7.11 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 C-N-CA 123.672 0.789 . . . . 0.0 112.865 167.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -133.33 161.37 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 C-N-CA 124.821 1.248 . . . . 0.0 109.056 168.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.3 p -148.61 162.32 39.92 Favored 'General case' 0 C--O 1.239 0.53 0 O-C-N 121.495 -0.753 . . . . 0.0 109.726 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -90.08 70.25 7.34 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 122.887 1.327 . . . . 0.0 109.39 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.6 t -106.69 142.85 35.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 114.296 -1.32 . . . . 0.0 109.343 168.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.21 10.93 52.14 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 127.573 2.511 . . . . 0.0 118.796 -165.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -129.31 -74.75 0.56 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.833 1.816 . . . . 0.0 110.292 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -95.26 -9.54 32.88 Favored 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.292 1.96 . . . . 0.0 116.292 -169.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 65.2 m -92.39 -123.54 0.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 CA-C-N 120.064 1.302 . . . . 0.0 113.66 -171.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.0 pt -115.95 14.86 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 119.61 -1.931 . . . . 0.0 115.727 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.8 mm -83.52 145.07 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 O-C-N 120.775 -1.203 . . . . 0.0 108.301 167.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 62.81 27.48 70.16 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 114.936 0.734 . . . . 0.0 114.936 168.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -106.3 153.8 21.66 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.471 1.108 . . . . 0.0 109.27 179.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.7 m -95.77 86.96 4.52 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.334 -0.854 . . . . 0.0 111.16 -167.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.8 tp -76.3 145.59 39.49 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-N 122.193 2.27 . . . . 0.0 113.457 -168.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.8 p -133.45 152.58 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 C-N-CA 126.751 2.021 . . . . 0.0 112.686 177.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -112.85 133.05 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 124.33 1.052 . . . . 0.0 108.216 164.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -89.61 152.75 21.23 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-O 122.292 1.044 . . . . 0.0 113.075 -176.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -68.01 -29.35 68.34 Favored 'General case' 0 N--CA 1.473 0.707 0 O-C-N 120.46 -1.4 . . . . 0.0 114.754 -174.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -119.8 169.56 10.02 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.976 1.31 . . . . 0.0 112.285 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -49.37 148.07 2.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.58 1.152 . . . . 0.0 110.555 169.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -96.45 133.45 40.86 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 123.647 0.592 . . . . 0.0 109.77 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -84.78 -13.89 49.83 Favored 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 125.44 1.496 . . . . 0.0 113.464 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 65.1 -38.34 0.25 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 130.817 3.647 . . . . 0.0 114.327 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.96 -32.6 0.05 OUTLIER Glycine 0 CA--C 1.519 0.281 0 CA-C-N 119.579 1.081 . . . . 0.0 115.343 170.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.78 69.69 0.99 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 117.379 2.363 . . . . 0.0 117.379 -172.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -79.55 -68.29 1.5 Allowed Glycine 0 N--CA 1.461 0.346 0 N-CA-C 106.27 -2.732 . . . . 0.0 106.27 164.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 174.65 21.31 0.02 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 124.819 1.199 . . . . 0.0 115.068 -178.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -149.23 161.79 41.32 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 119.374 1.587 . . . . 0.0 110.095 -179.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 35.1 tp10 -69.34 -45.9 68.35 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.905 1.282 . . . . 0.0 111.786 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.406 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 0.3 OUTLIER -45.39 -35.25 3.51 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.775 1.23 . . . . 0.0 113.417 176.16 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 33.4 t -58.7 -56.81 17.44 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 169.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.465 ' HG1' ' HB3' ' A' ' 70' ' ' LYS 0.292 0.0 OUTLIER -66.53 -9.72 37.66 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 123.98 0.912 . . . . 0.0 111.184 -178.013 . . . . . . . . 4 4 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.406 ' HZ2' ' CD ' ' A' ' 133' ' ' GLU . 48.7 mtmt -93.41 -50.45 5.44 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 119.333 0.969 . . . . 0.0 113.285 167.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 68.6 p -113.36 -24.38 9.36 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 -166.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.14 -3.08 47.55 Favored Glycine 0 C--O 1.22 -0.729 0 C-N-CA 125.203 1.383 . . . . 0.0 112.545 -168.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 54.66 16.04 1.25 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.898 1.679 . . . . 0.0 113.279 -177.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.59 27.27 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.763 2.025 . . . . 0.0 115.735 -165.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.7 -75.05 2.42 Favored Glycine 0 C--N 1.338 0.694 0 C-N-CA 127.254 2.359 . . . . 0.0 113.361 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.4 t -170.21 -150.31 0.08 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.546 1.138 . . . . 0.0 110.442 -171.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.89 123.5 47.18 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.366 1.067 . . . . 0.0 110.891 -173.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.513 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 1.7 tt -96.2 -137.4 0.25 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.86 2.064 . . . . 0.0 106.257 168.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.513 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -61.15 151.03 32.38 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 125.049 1.34 . . . . 0.0 112.375 -176.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -148.04 142.95 26.86 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 114.836 -1.074 . . . . 0.0 113.846 -172.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.23 114.88 0.63 Allowed Glycine 0 CA--C 1.528 0.9 0 C-N-CA 125.386 1.469 . . . . 0.0 113.039 -176.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -74.41 135.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 37.9 mt -74.98 124.35 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.055 0.542 . . . . 0.0 111.885 -167.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.08 -175.28 17.38 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 124.834 1.207 . . . . 0.0 113.27 173.087 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -124.83 152.12 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 126.581 1.953 . . . . 0.0 111.997 173.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.13 -8.19 2.31 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -178.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tm0? . . . . . 0 C--O 1.236 0.349 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 169.17 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.556 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -84.62 74.08 10.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 105.604 -1.998 . . . . 0.0 105.604 168.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ptpm? -76.01 121.58 22.96 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.39 -0.819 . . . . 0.0 110.328 -170.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.59 152.71 22.1 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.203 1.001 . . . . 0.0 110.939 -177.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -145.87 129.91 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.082 0.944 . . . . 0.0 111.288 -167.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -104.44 134.84 46.96 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.306 -1.315 . . . . 0.0 107.863 168.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 93.2 t -116.88 115.64 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 167.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -95.8 96.7 9.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 126.222 1.809 . . . . 0.0 108.942 -169.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -158.21 124.58 4.74 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.736 0.814 . . . . 0.0 110.233 175.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.25 -101.62 2.59 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 105.876 -2.89 . . . . 0.0 105.876 165.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -144.35 109.25 4.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 125.274 1.43 . . . . 0.0 109.702 -169.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.6 167.38 11.44 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 125.446 1.498 . . . . 0.0 111.648 -175.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -73.67 25.57 0.32 Allowed 'Trans proline' 0 CA--C 1.544 1.019 1 C-N-CA 125.361 4.041 . . . . 0.0 114.963 -170.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -122.68 119.83 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 119.605 1.093 . . . . 0.0 109.096 -178.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -158.66 158.15 33.22 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 114.684 -1.144 . . . . 0.0 112.357 -178.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.2 177.02 36.82 Favored Glycine 0 CA--C 1.506 -0.479 0 C-N-CA 124.843 1.211 . . . . 0.0 114.069 176.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -120.61 148.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 112.993 -1.603 . . . . 0.0 109.742 168.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.0 mm -128.81 130.84 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 166.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -100.41 141.84 32.71 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 126.31 1.844 . . . . 0.0 110.809 168.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -120.93 104.92 10.2 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.262 2.225 . . . . 0.0 108.845 171.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -99.78 103.18 14.79 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.842 0.857 . . . . 0.0 110.905 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -105.62 136.68 44.76 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 122.145 0.974 . . . . 0.0 109.27 169.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 16.6 pttp -98.71 -24.52 15.01 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 124.992 1.317 . . . . 0.0 113.692 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -163.93 134.84 4.47 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.061 2.144 . . . . 0.0 107.957 -164.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.5 p -51.83 -28.62 16.36 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 126.01 1.724 . . . . 0.0 114.873 -170.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -109.26 -6.18 15.63 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.558 1.543 . . . . 0.0 113.381 -176.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -88.22 165.97 34.69 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.86 1.219 . . . . 0.0 111.726 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.32 168.82 21.18 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.041 2.494 . . . . 0.0 111.902 -176.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.27 124.36 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 C-N-CA 123.828 0.851 . . . . 0.0 109.262 176.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.525 ' HZ3' ' CD ' ' B' ' 100' ' ' GLU . 67.7 mttm -81.54 128.59 34.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.625 -0.672 . . . . 0.0 109.427 169.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 63.2 t -108.81 127.09 65.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 126.093 1.757 . . . . 0.0 109.261 179.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -151.37 163.07 39.77 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 121.573 -0.705 . . . . 0.0 112.266 170.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.84 -166.24 33.37 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 123.702 0.668 . . . . 0.0 112.657 174.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.4 p -152.9 128.01 9.73 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 122.97 0.508 . . . . 0.0 111.665 -169.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 31.3 mt -118.72 124.77 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 125.019 1.328 . . . . 0.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . 0.415 ' HE3' ' O ' ' B' ' 92' ' ' ASP . 73.9 tttt -122.37 139.93 53.26 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 120.769 1.622 . . . . 0.0 111.595 -176.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.88 -0.51 9.17 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 127.863 2.649 . . . . 0.0 113.502 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 92.3 mt -75.73 170.3 16.45 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.16 1.384 . . . . 0.0 111.24 174.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.5 t -90.02 151.07 21.84 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 166.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -49.22 143.56 6.01 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.601 0.761 . . . . 0.0 111.513 171.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.32 -178.88 22.8 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 124.713 1.149 . . . . 0.0 113.239 -176.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.513 ' H ' ' CD2' ' B' ' 42' ' ' LEU . 1.7 pt? -80.59 149.54 29.87 Favored 'General case' 0 CA--C 1.553 1.066 0 C-N-CA 128.739 2.816 . . . . 0.0 113.732 -172.132 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -154.17 126.3 7.84 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 128.594 2.758 . . . . 0.0 110.685 -170.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.06 160.85 41.93 Favored Glycine 0 N--CA 1.482 1.766 0 CA-C-N 121.162 1.801 . . . . 0.0 113.914 -177.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.285 0.2 OUTLIER -159.38 138.21 10.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 128.182 2.593 . . . . 0.0 114.867 168.68 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 16.6 m80 -149.1 141.64 24.35 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 120.659 -1.276 . . . . 0.0 114.087 -169.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.02 106.94 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 126.768 2.027 . . . . 0.0 111.166 178.155 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.407 ' C ' ' H ' ' B' ' 50' ' ' PHE . 8.1 m170 -79.22 135.7 36.86 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.486 1.115 . . . . 0.0 110.732 -176.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -70.24 17.64 0.06 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.537 1.935 . . . . 0.0 112.513 171.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . 0.407 ' H ' ' C ' ' B' ' 48' ' ' HIS . 23.0 m-85 -144.07 92.66 2.35 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 126.427 1.891 . . . . 0.0 107.942 -167.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' B' ' 53' ' ' ASN . . . -83.29 7.73 66.78 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 116.967 -2.018 . . . . 0.0 111.012 167.442 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -77.1 49.79 0.7 Allowed 'General case' 0 N--CA 1.481 1.094 0 CA-C-O 124.779 2.228 . . . . 0.0 110.357 -176.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.402 ' H ' ' C ' ' B' ' 51' ' ' GLY . 0.4 OUTLIER 170.84 27.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 128.201 2.601 . . . . 0.0 113.574 -165.77 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 35.4 p -39.42 -22.73 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 120.184 3.402 . . . . 0.0 120.184 -170.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.98 2.81 0.66 Allowed 'General case' 0 CA--C 1.553 1.068 0 N-CA-C 114.925 1.454 . . . . 0.0 114.925 171.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.99 -149.23 26.4 Favored Glycine 0 CA--C 1.526 0.747 0 O-C-N 120.924 -1.11 . . . . 0.0 112.256 174.096 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.6 t -62.3 -15.66 49.14 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 178.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 10.0 m -62.56 -1.46 0.82 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.297 1.439 . . . . 0.0 111.382 166.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -155.29 14.0 0.38 Allowed 'General case' 0 CA--C 1.548 0.883 0 O-C-N 119.712 -1.868 . . . . 0.0 114.215 178.17 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.12 155.75 38.48 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.39 1.45 . . . . 0.0 113.545 -169.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -116.72 -99.79 2.13 Favored Glycine 0 CA--C 1.545 1.923 0 C-N-CA 125.315 1.436 . . . . 0.0 114.243 -174.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -92.0 177.26 1.76 Allowed 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.856 3.704 . . . . 0.0 113.429 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -115.26 126.02 54.01 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.862 2.465 . . . . 0.0 110.919 -175.491 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -48.84 149.33 1.84 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 129.253 3.021 . . . . 0.0 116.571 -169.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -111.65 44.11 0.23 Allowed Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 127.305 2.242 . . . . 0.0 113.695 -172.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -63.05 -30.54 76.1 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.705 2.27 . . . . 0.0 113.825 -169.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.66 -3.95 43.6 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.012 0.925 . . . . 0.0 112.582 173.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.0 t 77.27 58.91 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 127.368 2.267 . . . . 0.0 111.616 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 ptt180 -163.4 177.52 8.84 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 117.341 2.349 . . . . 0.0 117.341 -167.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -64.99 169.91 4.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.202 3.001 . . . . 0.0 114.276 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 52.7 t60 -107.2 146.68 31.08 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.712 2.005 . . . . 0.0 114.236 -169.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 126.92 -104.26 0.7 Allowed Glycine 0 N--CA 1.472 1.092 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 163.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.44 -35.62 3.55 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-O 116.367 -2.351 . . . . 0.0 118.271 167.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 14.43 0.85 Allowed 'Trans proline' 0 CA--C 1.549 1.251 0 CA-C-N 123.349 3.574 . . . . 0.0 113.153 168.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.49 -26.92 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 127.531 2.332 . . . . 0.0 110.847 169.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.32 0.0 OUTLIER -64.47 151.79 43.37 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 123.225 1.488 . . . . 0.0 113.774 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 60.4 mp0 -88.42 -10.36 49.47 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 111.241 -2.709 . . . . 0.0 114.358 -166.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -143.98 -53.57 0.34 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.411 1.005 . . . . 0.0 112.58 -169.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 80.52 125.18 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 127.446 2.299 . . . . 0.0 114.362 166.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.5 m170 -67.08 148.23 52.15 Favored 'General case' 0 CA--C 1.541 0.608 0 O-C-N 121.018 -1.051 . . . . 0.0 110.856 167.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -72.4 26.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 125.311 1.444 . . . . 0.0 113.781 171.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -154.03 23.45 0.69 Allowed Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.636 1.589 . . . . 0.0 114.864 -169.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -125.54 129.31 49.47 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 119.071 1.435 . . . . 0.0 110.048 -178.533 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 86.6 mt -107.77 41.9 1.44 Allowed 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.042 0.837 . . . . 0.0 110.711 168.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.97 -117.68 5.02 Favored Glycine 0 CA--C 1.537 1.439 0 O-C-N 120.476 -1.39 . . . . 0.0 113.436 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -140.27 146.98 39.29 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.46 1.504 . . . . 0.0 113.394 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 28.2 m -93.39 145.49 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 127.237 2.215 . . . . 0.0 110.247 169.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 2.7 m -110.55 125.53 53.45 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 119.466 1.03 . . . . 0.0 109.618 171.011 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.39 163.9 15.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.447 0.699 . . . . 0.0 112.546 169.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.29 178.72 4.97 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.851 1.661 . . . . 0.0 112.713 173.277 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.423 ' H ' ' HD3' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -58.22 -29.49 65.75 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.646 1.978 . . . . 0.0 116.314 171.955 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.415 ' O ' ' HE3' ' B' ' 36' ' ' LYS . 28.9 t70 -78.18 -10.87 59.83 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 119.731 1.15 . . . . 0.0 111.099 171.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.54 11.82 46.5 Favored Glycine 0 C--N 1.334 0.464 0 CA-C-O 116.88 -2.067 . . . . 0.0 113.865 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.0 p -98.4 125.52 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 119.476 1.638 . . . . 0.0 113.357 179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.0 100.35 12.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.43 1.492 . . . . 0.0 108.04 165.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -87.37 143.25 27.34 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.242 1.017 . . . . 0.0 109.506 170.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.45 144.21 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 116.445 2.017 . . . . 0.0 116.445 -176.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.4 m -156.24 111.97 2.99 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.567 1.947 . . . . 0.0 111.161 174.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 13.2 mt -143.54 163.97 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 130.011 3.324 . . . . 0.0 109.571 -169.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.525 ' CD ' ' HZ3' ' B' ' 30' ' ' LYS . 35.2 tt0 -145.3 146.15 31.52 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 126.478 1.911 . . . . 0.0 107.757 168.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -144.69 132.05 20.76 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.935 0.894 . . . . 0.0 110.112 -175.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.8 p -113.54 46.04 1.34 Allowed 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.889 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.11 1.83 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 124.025 0.93 . . . . 0.0 111.687 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.46 171.42 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 126.35 1.86 . . . . 0.0 109.953 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 42.1 m -158.0 174.26 15.51 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 120.837 -1.164 . . . . 0.0 111.222 176.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 93.2 mt -109.54 54.03 0.67 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 127.407 2.283 . . . . 0.0 109.415 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.7 t -112.78 34.97 4.08 Favored 'General case' 0 CA--C 1.551 1.011 0 N-CA-C 115.626 1.714 . . . . 0.0 115.626 -168.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.92 -29.2 3.08 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 119.237 2.455 . . . . 0.0 119.237 165.345 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.251 17.7 t70 -99.41 -109.29 0.19 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 118.522 1.161 . . . . 0.0 108.448 -167.668 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -81.76 10.3 6.45 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.569 2.347 . . . . 0.0 112.703 175.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 m -60.76 -175.39 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.175 2.59 . . . . 0.0 115.081 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.282 11.6 pt -88.63 -3.91 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 119.941 -1.724 . . . . 0.0 114.424 172.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.7 mm -64.84 131.14 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 166.735 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.18 10.52 62.45 Favored Glycine 0 CA--C 1.524 0.653 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.281 -178.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -78.99 170.17 17.1 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 119.918 1.859 . . . . 0.0 109.836 173.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.455 ' HG1' HG23 ' B' ' 148' ' ' VAL . 91.8 m -112.33 112.5 24.12 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.108 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 48.5 tp -92.6 103.95 16.29 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 124.42 1.075 . . . . 0.0 109.459 177.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 13.7 p -86.4 149.53 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 167.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 37.9 t -128.41 143.76 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 167.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -106.0 163.08 13.04 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 125.665 1.586 . . . . 0.0 113.115 -168.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -76.28 -42.34 45.83 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.225 -175.101 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -110.56 176.07 5.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.822 1.649 . . . . 0.0 109.956 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.4 -176.59 6.29 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.252 0.549 . . . . 0.0 109.599 165.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -110.26 159.04 17.75 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.83 2.052 . . . . 0.0 113.032 -166.309 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -73.47 -14.21 61.2 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.904 1.282 . . . . 0.0 111.205 170.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 70.5 mt 54.08 61.45 3.05 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.124 1.77 . . . . 0.0 111.948 172.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.48 -54.15 3.47 Favored Glycine 0 N--CA 1.462 0.431 0 C-N-CA 125.688 1.613 . . . . 0.0 111.474 170.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.4 ttpt -126.9 72.9 1.37 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.676 1.19 . . . . 0.0 113.238 -168.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -83.56 -30.46 29.9 Favored Glycine 0 CA--C 1.534 1.274 0 C-N-CA 124.579 1.085 . . . . 0.0 112.429 169.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 120.8 32.36 1.11 Allowed Glycine 0 N--CA 1.472 1.08 0 C-N-CA 125.167 1.365 . . . . 0.0 113.561 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -153.4 -156.21 0.67 Allowed 'General case' 0 CA--C 1.554 1.121 0 C-N-CA 124.571 1.148 . . . . 0.0 109.644 -169.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -95.9 -52.47 4.05 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 120.765 1.621 . . . . 0.0 110.727 171.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -54.29 -28.53 42.61 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 127.774 2.43 . . . . 0.0 113.176 -172.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 88.9 p -57.56 -30.78 65.51 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 125.016 1.327 . . . . 0.0 112.453 174.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -107.07 -27.48 10.6 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 117.519 -1.229 . . . . 0.0 114.188 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.7 tptm -71.88 -24.14 61.62 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 120.994 1.725 . . . . 0.0 113.056 -176.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -133.54 -46.6 0.82 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 126.287 1.835 . . . . 0.0 110.78 167.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.81 -9.0 8.1 Favored Glycine 0 C--O 1.221 -0.701 0 C-N-CA 125.477 1.513 . . . . 0.0 110.479 -163.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 57.63 37.32 27.4 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 124.992 1.317 . . . . 0.0 112.166 176.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.04 30.06 0.11 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 115.069 1.507 . . . . 0.0 115.069 -169.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.58 -57.27 2.52 Favored Glycine 0 N--CA 1.47 0.962 0 C-N-CA 127.539 2.495 . . . . 0.0 114.44 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.1 t -174.79 172.05 3.04 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.3 1.84 . . . . 0.0 110.479 -174.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . 0.409 ' H ' ' HD3' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -82.67 157.28 23.42 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 121.173 -0.954 . . . . 0.0 111.599 170.631 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -128.84 -97.58 0.38 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 124.546 1.138 . . . . 0.0 108.402 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -95.65 162.26 13.69 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.355 1.062 . . . . 0.0 111.242 174.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 p -158.5 155.9 29.3 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.788 1.235 . . . . 0.0 113.277 173.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.52 176.12 35.5 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 126.176 1.846 . . . . 0.0 112.362 171.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.455 HG23 ' HG1' ' B' ' 116' ' ' THR . 76.7 t -107.3 157.29 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-N 118.247 1.024 . . . . 0.0 108.318 168.45 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 3.3 mt -87.24 110.85 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 123.886 0.874 . . . . 0.0 110.964 176.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -105.54 -165.47 23.56 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.554 1.549 . . . . 0.0 111.686 168.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -136.74 158.65 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 114.358 1.244 . . . . 0.0 114.358 -169.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -142.41 -19.61 0.69 Allowed 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 170.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.48 1.038 0 C-N-CA 125.317 1.447 . . . . 0.0 111.965 176.946 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.775 0 CA-C-O 117.258 -1.353 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -75.22 123.6 25.57 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 122.772 1.272 . . . . 0.0 108.158 -172.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.2 mtmm -98.91 132.66 44.07 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 112.616 -2.084 . . . . 0.0 113.924 171.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.62 168.7 13.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.029 0.932 . . . . 0.0 111.989 171.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.41 97.9 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 168.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -94.6 136.95 34.32 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 121.354 -0.842 . . . . 0.0 110.377 173.16 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -134.38 130.48 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 C-N-CA 124.164 0.986 . . . . 0.0 110.44 -176.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -116.31 145.45 43.18 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.589 2.356 . . . . 0.0 110.6 172.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.74 160.17 40.32 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.292 1.037 . . . . 0.0 113.158 168.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.3 161.86 25.0 Favored Glycine 0 CA--C 1.525 0.708 0 C-N-CA 127.246 2.355 . . . . 0.0 107.901 168.187 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -76.62 59.46 1.52 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.298 1.439 . . . . 0.0 113.629 -177.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.58 -163.17 35.79 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 126.732 2.111 . . . . 0.0 110.194 -176.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -77.27 32.52 0.43 Allowed 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 125.041 3.827 . . . . 0.0 112.698 -173.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 t -114.24 124.09 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 C-N-CA 125.525 1.53 . . . . 0.0 108.58 -174.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -141.44 156.7 45.75 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 124.283 1.033 . . . . 0.0 110.284 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.56 139.93 10.87 Favored Glycine 0 CA--C 1.503 -0.695 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.133 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.8 125.76 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 117.354 0.577 . . . . 0.0 109.613 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.1 mm -133.74 122.72 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -111.41 101.18 9.65 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-O 122.537 1.16 . . . . 0.0 109.614 169.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -77.58 138.58 39.23 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.823 1.649 . . . . 0.0 108.574 176.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -110.21 121.65 45.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 119.845 1.202 . . . . 0.0 111.168 166.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.407 ' NE2' ' H ' ' A' ' 27' ' ' GLY . 19.3 tp60 -82.48 128.59 34.42 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 163.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.59 -38.7 62.56 Favored 'General case' 0 CA--C 1.544 0.735 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 179.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -104.19 -129.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 129.653 3.181 . . . . 0.0 111.675 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.9 t -143.51 14.67 1.79 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.824 2.45 . . . . 0.0 110.209 167.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -168.07 -0.17 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 126.014 1.726 . . . . 0.0 115.426 -166.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.407 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -112.28 -151.58 11.49 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 125.849 1.69 . . . . 0.0 112.152 -177.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -71.61 173.26 12.82 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 124.24 3.293 . . . . 0.0 113.616 -175.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -142.9 141.84 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.463 1.105 . . . . 0.0 110.872 -174.171 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.551 ' HZ1' ' CD ' ' A' ' 100' ' ' GLU . 8.2 tttp -101.7 121.8 42.73 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 167.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.2 t -104.01 114.52 43.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 125.574 1.549 . . . . 0.0 108.581 -177.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.6 p90 -138.55 156.32 47.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 122.308 1.051 . . . . 0.0 113.035 177.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.02 -164.49 27.53 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.465 1.507 . . . . 0.0 111.361 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 88.7 p -158.1 160.22 37.1 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.1 mm -120.14 120.54 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 C-N-CA 124.597 1.159 . . . . 0.0 112.023 176.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.0 mmtt -104.95 152.13 23.06 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.386 1.474 . . . . 0.0 111.684 -174.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.35 -0.35 53.79 Favored Glycine 0 N--CA 1.475 1.288 0 C-N-CA 125.243 1.402 . . . . 0.0 114.435 174.098 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -83.85 173.5 11.19 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 126.467 1.907 . . . . 0.0 112.612 178.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.3 t -81.8 175.59 10.3 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 160.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.53 -175.8 0.14 Allowed 'General case' 0 CA--C 1.557 1.249 0 CA-C-O 122.44 1.114 . . . . 0.0 113.497 175.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.32 -179.69 45.44 Favored Glycine 0 CA--C 1.533 1.202 0 O-C-N 120.478 -1.389 . . . . 0.0 114.478 173.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.8 mp -61.96 142.37 57.49 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 127.46 2.304 . . . . 0.0 111.359 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -143.53 117.8 9.59 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 126.864 2.066 . . . . 0.0 109.442 176.042 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.14 141.87 47.71 Favored Glycine 0 N--CA 1.478 1.491 0 CA-C-N 120.038 1.29 . . . . 0.0 111.484 -179.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.277 0.1 OUTLIER -150.95 130.52 13.03 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 118.966 1.383 . . . . 0.0 111.839 174.403 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.87 143.65 26.4 Favored 'General case' 0 CA--C 1.535 0.366 0 O-C-N 121.278 -0.889 . . . . 0.0 111.917 -164.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -98.0 105.81 17.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.874 1.669 . . . . 0.0 108.5 -178.549 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -74.45 144.86 44.05 Favored 'General case' 0 C--N 1.322 -0.617 0 O-C-N 121.548 -0.72 . . . . 0.0 109.325 175.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -46.89 132.56 11.52 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 167.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.492 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 77.35 146.02 0.09 Allowed 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 124.729 2.204 . . . . 0.0 114.14 174.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.436 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -120.14 6.69 11.93 Favored Glycine 0 N--CA 1.466 0.69 0 C-N-CA 126.714 2.102 . . . . 0.0 111.788 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -76.89 42.89 0.32 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.648 1.579 . . . . 0.0 109.658 168.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.436 ' H ' ' C ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER 168.95 42.45 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 125.314 1.446 . . . . 0.0 113.638 -164.567 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -63.38 -4.69 2.84 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 116.23 1.937 . . . . 0.0 116.23 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.85 30.26 1.62 Allowed 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 120.381 1.446 . . . . 0.0 112.527 -171.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.37 -139.75 45.94 Favored Glycine 0 N--CA 1.466 0.642 0 O-C-N 120.828 -1.17 . . . . 0.0 111.509 171.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.6 p -52.57 -31.77 37.71 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 176.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.2 t -87.16 43.43 1.1 Allowed 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.415 1.462 . . . . 0.0 112.225 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.5 p -179.87 -32.64 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 127.411 2.285 . . . . 0.0 113.755 172.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -143.46 139.5 29.92 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 120.151 1.341 . . . . 0.0 113.62 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.35 -115.61 0.93 Allowed Glycine 0 CA--C 1.544 1.864 0 CA-C-O 117.952 -1.471 . . . . 0.0 113.559 -175.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.12 -179.69 5.48 Favored 'Trans proline' 0 C--N 1.348 0.532 1 C-N-CA 125.634 4.223 . . . . 0.0 112.689 -178.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -81.57 71.73 8.59 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.429 1.092 . . . . 0.0 109.97 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -43.71 140.52 1.82 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.519 1.528 . . . . 0.0 111.469 170.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -158.18 155.11 25.4 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 117.774 -1.108 . . . . 0.0 112.668 170.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -73.04 -10.94 25.08 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.082 1.855 . . . . 0.0 114.341 -172.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -87.68 -10.14 52.14 Favored 'General case' 0 CA--C 1.542 0.658 0 CA-C-N 119.834 1.197 . . . . 0.0 113.464 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.2 t 49.55 49.46 19.89 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.804 1.641 . . . . 0.0 114.166 175.272 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.1 mtm-85 -99.03 176.45 5.57 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 126.071 1.749 . . . . 0.0 113.435 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -76.89 168.38 20.19 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 126.59 1.956 . . . . 0.0 109.428 165.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -84.05 159.71 21.11 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 124.001 0.921 . . . . 0.0 113.386 -173.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.15 -134.67 5.84 Favored Glycine 0 C--N 1.341 0.816 0 N-CA-C 114.697 0.639 . . . . 0.0 114.697 167.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 124.33 -92.02 0.43 Allowed Glycine 0 CA--C 1.541 1.689 0 CA-C-O 118.59 -1.117 . . . . 0.0 113.94 -169.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.88 6.63 0.15 Allowed 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 123.8 3.0 . . . . 0.0 117.453 -175.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.257 0.0 OUTLIER -155.93 7.39 0.22 Allowed 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 127.344 2.258 . . . . 0.0 113.379 169.443 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.21 167.79 18.58 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.775 2.43 . . . . 0.0 110.153 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -111.19 -15.51 13.64 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.498 1.919 . . . . 0.0 112.542 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -78.22 -69.49 0.55 Allowed 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.241 1.016 . . . . 0.0 111.014 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 59.25 109.49 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.701 1.6 . . . . 0.0 112.31 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 27.1 m170 -59.03 148.37 31.11 Favored 'General case' 0 CA--C 1.544 0.717 0 O-C-N 119.205 -2.184 . . . . 0.0 110.348 167.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.5 t -79.22 54.33 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-O 123.769 1.747 . . . . 0.0 109.099 166.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.09 20.05 0.09 OUTLIER Glycine 0 CA--C 1.542 1.752 0 C-N-CA 128.87 3.129 . . . . 0.0 114.306 -179.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -122.29 130.13 52.86 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.006 2.403 . . . . 0.0 113.854 -175.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 74.4 mt -113.52 45.47 1.42 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.491 0.716 . . . . 0.0 110.78 168.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.45 -124.85 6.89 Favored Glycine 0 CA--C 1.534 1.269 0 O-C-N 121.41 -0.806 . . . . 0.0 113.17 -176.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -129.19 144.07 51.08 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.067 0.947 . . . . 0.0 111.545 173.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -95.27 130.92 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 C-N-CA 125.602 1.561 . . . . 0.0 108.988 173.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.0 m -113.23 138.14 50.43 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 123.683 0.793 . . . . 0.0 112.175 -167.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.61 145.11 40.96 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 118.354 2.724 . . . . 0.0 118.354 -166.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -86.35 157.01 19.98 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 128.958 2.903 . . . . 0.0 111.314 169.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HZ2' ' CG ' ' A' ' 92' ' ' ASP . 1.6 pptp? -47.42 -23.29 0.57 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 128.215 2.606 . . . . 0.0 117.155 176.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.449 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 74.2 m-20 -76.45 3.65 10.76 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 119.844 1.202 . . . . 0.0 111.579 175.301 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.66 37.53 52.03 Favored Glycine 0 C--N 1.337 0.6 0 C-N-CA 125.23 1.395 . . . . 0.0 111.843 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -124.27 122.48 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.409 1.084 . . . . 0.0 110.621 176.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -84.3 118.11 23.99 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.427 1.491 . . . . 0.0 109.311 169.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.08 145.14 25.19 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.951 0.9 . . . . 0.0 112.079 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.82 138.17 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-N 114.001 -1.454 . . . . 0.0 114.823 169.423 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 m -155.27 62.27 0.63 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 127.058 2.143 . . . . 0.0 110.002 179.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.1 mt -95.58 154.56 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.346 1.858 . . . . 0.0 111.386 -176.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.551 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 6.1 tt0 -133.35 143.25 48.86 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 125.437 1.495 . . . . 0.0 108.461 168.706 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -156.25 149.66 24.59 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.487 1.115 . . . . 0.0 112.572 -169.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.1 p -119.26 53.55 1.02 Allowed 'General case' 0 CA--C 1.542 0.65 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.639 178.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.0 t -138.84 -42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.154 0.982 . . . . 0.0 111.686 174.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -85.88 156.07 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 119.301 0.955 . . . . 0.0 112.099 174.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -151.45 147.49 26.92 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 124.409 1.084 . . . . 0.0 111.052 177.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.3 mp -78.39 57.21 1.88 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 120.836 -1.165 . . . . 0.0 109.308 177.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.6 m -130.31 15.96 5.55 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.887 1.275 . . . . 0.0 113.749 -168.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.7 -170.17 28.45 Favored Glycine 0 N--CA 1.44 -1.042 0 CA-C-O 124.853 2.363 . . . . 0.0 116.28 167.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.29 -51.74 64.85 Favored 'General case' 0 C--N 1.311 -1.083 1 CA-C-N 108.143 -4.029 . . . . 0.0 111.239 -168.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -79.76 4.14 17.25 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.419 1.087 . . . . 0.0 112.977 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.7 t -108.62 -93.29 0.41 Allowed 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.13 0.972 . . . . 0.0 111.476 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.9 pt -141.66 5.76 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 40.3 mm -84.13 119.5 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.404 -1.435 . . . . 0.0 107.733 171.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.97 30.54 72.25 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 117.915 -1.492 . . . . 0.0 113.664 -178.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.9 mmt-85 -86.88 145.85 26.42 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 120.527 2.163 . . . . 0.0 111.268 173.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 39.1 m -89.95 104.91 17.43 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 119.539 1.063 . . . . 0.0 111.499 177.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 15.5 tp -85.64 112.49 21.04 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.626 0.771 . . . . 0.0 110.642 173.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 9.9 p -92.46 148.18 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 118.953 -0.546 . . . . 0.0 109.714 169.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.48 134.08 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 122.262 1.029 . . . . 0.0 109.346 166.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.644 ' CE1' ' HE ' ' A' ' 143' ' ' ARG . 18.5 m-70 -109.84 152.57 25.58 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 126.111 1.764 . . . . 0.0 111.617 -169.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.548 ' CD ' ' HZ3' ' A' ' 122' ' ' LYS . 5.3 tm-20 -79.48 -17.47 54.09 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 116.768 2.136 . . . . 0.0 116.768 -164.454 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.548 ' HZ3' ' CD ' ' A' ' 121' ' ' GLU . 0.0 OUTLIER -125.27 173.38 8.84 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 120.079 -1.638 . . . . 0.0 113.432 173.004 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.87 157.52 1.21 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.323 1.849 . . . . 0.0 112.439 172.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -97.79 131.35 44.38 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.974 0.892 . . . . 0.0 111.073 -176.273 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -26.6 62.38 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.53 1.932 . . . . 0.0 112.788 177.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.1 mt 54.09 53.63 10.81 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.917 1.687 . . . . 0.0 113.028 171.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.23 -25.37 27.33 Favored Glycine 0 N--CA 1.468 0.803 0 CA-C-O 118.218 -1.324 . . . . 0.0 114.99 170.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.354 6.4 mtmt -167.24 121.29 1.0 Allowed 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 164.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -143.53 -56.27 0.03 OUTLIER Glycine 0 CA--C 1.532 1.104 1 C-N-CA 131.177 4.227 . . . . 0.0 108.16 167.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -85.42 -93.18 0.8 Allowed Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.904 1.716 . . . . 0.0 114.032 177.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.583 ' CG ' ' H ' ' A' ' 132' ' ' GLU 0.27 0.8 OUTLIER -147.3 -96.69 0.09 Allowed 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 117.076 -1.44 . . . . 0.0 112.703 -169.3 . . . . . . . . 4 4 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.583 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 11.0 tt0 -111.97 -30.56 7.22 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 121.565 1.984 . . . . 0.0 114.396 170.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -61.36 -21.6 64.17 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.468 -2.02 . . . . 0.0 112.216 177.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.2 p -56.6 -25.55 53.14 Favored 'General case' 0 CA--C 1.54 0.583 1 C-N-CA 131.946 4.098 . . . . 0.0 113.376 164.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 p -116.23 -29.25 6.3 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 128.732 2.813 . . . . 0.0 112.974 -175.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 42.1 mttt -70.57 -56.71 5.88 Favored 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 169.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.7 p -99.08 -125.85 0.16 Allowed 'General case' 0 C--O 1.221 -0.42 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 167.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.14 28.88 1.53 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 129.006 3.193 . . . . 0.0 110.074 173.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 52.58 7.81 0.07 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 127.015 2.126 . . . . 0.0 115.168 -177.058 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.1 20.81 0.02 OUTLIER 'General case' 0 CA--C 1.56 1.358 0 C-N-CA 127.309 2.244 . . . . 0.0 116.681 -165.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.44 -144.83 34.91 Favored Glycine 0 CA--C 1.532 1.136 0 O-C-N 119.794 -1.816 . . . . 0.0 114.079 175.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.1 t -67.19 179.8 1.13 Allowed 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.392 1.077 . . . . 0.0 113.904 -174.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.644 ' HE ' ' CE1' ' A' ' 120' ' ' HIS . 95.4 mtt180 -124.7 114.53 19.43 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.911 1.684 . . . . 0.0 109.789 177.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -102.7 -24.76 13.72 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 125.772 1.629 . . . . 0.0 114.706 -171.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.78 158.81 35.96 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 124.497 1.119 . . . . 0.0 110.332 170.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.0 p -149.79 142.25 24.35 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.171 1.388 . . . . 0.0 109.503 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.57 175.77 34.84 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 115.388 0.915 . . . . 0.0 115.388 -170.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -133.1 152.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.018 1.327 . . . . 0.0 111.554 174.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 16.9 mt -83.82 115.51 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 127.646 2.378 . . . . 0.0 112.664 177.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.59 169.5 14.17 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 126.964 2.221 . . . . 0.0 114.532 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -104.95 88.52 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 117.489 2.403 . . . . 0.0 117.489 -168.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.34 -25.49 51.13 Favored 'General case' 0 N--CA 1.477 0.902 0 O-C-N 120.07 -1.644 . . . . 0.0 113.08 173.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 . . . . . 0 C--O 1.236 0.363 0 C-N-CA 126.931 2.092 . . . . 0.0 110.459 176.377 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.304 0 CA-C-O 121.283 0.563 . . . . 0.0 111.894 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.8 t -157.35 125.5 5.52 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 126.846 2.058 . . . . 0.0 107.683 167.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.51 143.29 32.41 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-O 122.686 1.231 . . . . 0.0 113.651 174.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 169.64 17.35 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.366 1.866 . . . . 0.0 110.128 175.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -153.36 150.14 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 119.88 1.218 . . . . 0.0 111.892 -169.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.34 117.54 18.27 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 127.336 2.254 . . . . 0.0 109.126 169.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 8.4 m -101.93 116.89 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.363 1.465 . . . . 0.0 108.546 168.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.51 123.59 43.91 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.957 1.303 . . . . 0.0 113.323 -168.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . 0.401 ' HG2' ' H ' ' B' ' 10' ' ' GLY 0.26 0.2 OUTLIER -160.44 171.07 19.71 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 117.741 2.497 . . . . 0.0 117.741 165.366 . . . . . . . . 4 4 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . 0.401 ' H ' ' HG2' ' B' ' 9' ' ' LYS . . . 132.97 36.64 0.27 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 129.606 3.479 . . . . 0.0 108.728 -174.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -159.23 55.29 0.4 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.045 1.338 . . . . 0.0 111.056 -167.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.85 -99.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 C-N-CA 127.266 2.365 . . . . 0.0 115.467 173.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -79.09 -14.33 13.52 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 123.949 3.099 . . . . 0.0 114.21 -176.179 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -98.86 141.37 16.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 120.398 1.454 . . . . 0.0 109.677 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 pm0 -150.81 163.77 37.83 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.892 2.077 . . . . 0.0 107.237 169.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.94 134.06 4.93 Favored Glycine 0 CA--C 1.5 -0.904 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.379 175.072 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -97.03 130.1 46.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -133.64 116.29 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 C-N-CA 125.18 1.392 . . . . 0.0 109.045 168.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 65.7 m-20 -100.0 146.4 26.77 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.422 1.089 . . . . 0.0 110.855 171.146 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -121.73 135.51 54.94 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 126.852 2.061 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.433 ' CD ' ' HZ1' ' B' ' 30' ' ' LYS . 4.5 tt0 -128.37 122.0 30.43 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.695 1.198 . . . . 0.0 110.762 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.8 tt0 -109.4 140.34 43.23 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 168.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -103.5 6.2 37.32 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -174.416 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 37.1 mp0 -152.5 -178.45 6.85 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 129.341 3.056 . . . . 0.0 108.102 170.001 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.6 p -82.15 -25.35 34.42 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.675 -1.266 . . . . 0.0 112.784 168.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -132.31 19.4 4.4 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 125.343 1.457 . . . . 0.0 113.179 -177.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.1 -168.88 42.05 Favored Glycine 0 CA--C 1.541 1.713 0 C-N-CA 125.482 1.515 . . . . 0.0 113.688 172.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.3 169.0 14.53 Favored 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 124.096 3.198 . . . . 0.0 112.376 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 71.3 t -128.56 138.42 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.171 1.388 . . . . 0.0 111.387 -177.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.433 ' HZ1' ' CD ' ' B' ' 21' ' ' GLU . 74.7 mttt -93.01 123.82 36.54 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 165.715 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.45 126.79 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.163 0.985 . . . . 0.0 110.8 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.8 p90 -146.74 164.32 33.13 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.959 0.885 . . . . 0.0 112.63 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.44 -153.58 25.42 Favored Glycine 0 C--N 1.334 0.452 0 C-N-CA 123.778 0.704 . . . . 0.0 112.47 176.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 60.6 p -153.16 119.52 5.54 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -168.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.3 mp -99.93 114.15 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 CA-C-O 118.265 -0.874 . . . . 0.0 109.941 173.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -122.18 133.84 54.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.929 1.241 . . . . 0.0 111.941 -175.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 132.05 -3.78 5.26 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 127.357 2.408 . . . . 0.0 114.271 176.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.9 178.58 4.52 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 126.565 1.946 . . . . 0.0 112.22 -171.766 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -70.16 156.4 39.27 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.647 1.579 . . . . 0.0 110.227 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.06 156.28 28.67 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 168.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.35 -170.48 35.68 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.426 1.012 . . . . 0.0 113.285 178.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.626 ' H ' ' CD2' ' B' ' 42' ' ' LEU . 0.4 OUTLIER -65.19 152.57 43.3 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.415 1.886 . . . . 0.0 113.594 -174.095 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -149.18 125.58 10.9 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 127.781 2.433 . . . . 0.0 109.457 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.17 147.43 21.91 Favored Glycine 0 N--CA 1.481 1.646 0 CA-C-N 120.502 1.501 . . . . 0.0 111.551 173.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -154.19 87.88 1.21 Allowed 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.064 1.745 . . . . 0.0 109.321 -167.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -127.16 153.7 45.72 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 121.229 -0.919 . . . . 0.0 112.474 -166.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.1 97.99 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.069 0.85 . . . . 0.0 110.902 -175.288 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -79.47 134.92 36.54 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.195 -170.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -72.34 174.34 7.45 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.354 1.862 . . . . 0.0 113.028 -167.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 63.12 4.73 1.66 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.934 1.694 . . . . 0.0 114.974 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.71 16.22 3.72 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 120.267 -1.52 . . . . 0.0 113.584 -163.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . 0.582 ' C ' HD21 ' B' ' 53' ' ' ASN . 5.9 t0 -89.45 115.4 26.86 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 125.824 1.649 . . . . 0.0 110.322 -168.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.582 HD21 ' C ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -165.14 34.98 0.06 Allowed 'General case' 0 C--O 1.239 0.514 0 CA-C-O 124.149 1.928 . . . . 0.0 116.177 -178.912 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.27 0.1 OUTLIER -86.47 -43.0 13.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.261 -1.336 . . . . 0.0 112.959 -166.313 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.26 31.49 6.56 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.909 1.284 . . . . 0.0 113.067 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.57 -109.1 2.7 Favored Glycine 0 N--CA 1.468 0.818 0 O-C-N 121.033 -1.042 . . . . 0.0 112.329 169.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 56.0 m -75.93 -17.07 59.89 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 171.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.9 m -86.6 52.85 2.62 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 168.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m 172.03 -170.53 0.03 OUTLIER 'General case' 0 CA--C 1.56 1.335 0 C-N-CA 130.378 3.471 . . . . 0.0 106.488 -165.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.5 27.39 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 129.026 2.93 . . . . 0.0 118.111 -179.271 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -41.19 -46.41 4.23 Favored Glycine 0 CA--C 1.537 1.466 0 CA-C-O 116.459 -2.3 . . . . 0.0 115.497 -169.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -126.35 46.16 0.0 OUTLIER 'Trans proline' 0 C--N 1.356 0.925 0 CA-C-N 120.983 2.392 . . . . 0.0 115.52 -176.277 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.1 m170 78.6 78.34 0.06 Allowed 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.663 1.585 . . . . 0.0 112.916 167.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -48.06 138.75 8.88 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 161.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . 0.623 ' ND2' ' H ' ' B' ' 81' ' ' VAL . 9.3 t-20 -157.18 116.66 2.0 Favored Pre-proline 0 N--CA 1.472 0.67 0 N-CA-C 116.746 2.128 . . . . 0.0 116.746 171.019 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.57 -5.58 15.6 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 N-CA-C 116.65 1.75 . . . . 0.0 116.65 -179.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -91.25 -7.51 51.0 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 119.526 1.057 . . . . 0.0 112.387 173.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t 54.66 54.26 9.46 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 125.571 1.548 . . . . 0.0 114.82 170.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.72 176.59 5.45 Favored 'General case' 0 N--CA 1.477 0.924 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -171.053 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.4 ptpp? -79.14 155.55 28.65 Favored 'General case' 0 CA--C 1.545 0.756 0 O-C-N 121.218 -0.926 . . . . 0.0 112.34 176.147 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -79.31 152.67 30.36 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.149 0.98 . . . . 0.0 113.187 -177.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.36 -117.43 1.04 Allowed Glycine 0 C--N 1.339 0.746 0 C-N-CA 123.195 0.426 . . . . 0.0 113.986 167.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.67 -28.17 6.87 Favored Glycine 0 CA--C 1.542 1.741 0 N-CA-C 120.12 2.808 . . . . 0.0 120.12 168.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -93.02 -13.83 1.24 Allowed 'Trans proline' 0 CA--C 1.544 1.025 0 CA-C-N 123.203 3.502 . . . . 0.0 112.879 173.067 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.16 -1.39 0.65 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.576 1.55 . . . . 0.0 112.792 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.44 177.19 5.77 Favored 'General case' 0 CA--C 1.548 0.898 0 O-C-N 120.735 -1.228 . . . . 0.0 110.508 174.706 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -90.01 -23.63 21.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 129.324 3.05 . . . . 0.0 111.579 -172.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -129.63 -98.09 0.35 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.243 1.017 . . . . 0.0 112.881 -171.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 96.36 137.6 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 129.778 3.231 . . . . 0.0 110.577 -170.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -57.21 162.06 2.87 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.267 -1.521 . . . . 0.0 112.072 168.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . 0.623 ' H ' ' ND2' ' B' ' 65' ' ' ASN . 53.1 t -61.35 -37.6 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-N 120.403 1.456 . . . . 0.0 110.577 170.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.59 24.03 4.57 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.212 1.387 . . . . 0.0 115.933 170.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -109.39 127.72 54.58 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 116.523 2.046 . . . . 0.0 116.523 174.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.4 mt -115.31 169.26 9.27 Favored 'General case' 0 CA--C 1.56 1.35 0 N-CA-C 103.633 -2.728 . . . . 0.0 103.633 156.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.48 -126.22 1.95 Allowed Glycine 0 N--CA 1.48 1.605 0 C-N-CA 124.482 1.039 . . . . 0.0 114.265 -171.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -126.54 154.07 44.34 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.8 m -111.26 129.71 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.927 2.091 . . . . 0.0 110.568 -176.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -89.41 132.08 35.16 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.271 0.487 . . . . 0.0 110.181 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.58 162.11 13.45 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 124.849 1.26 . . . . 0.0 111.451 168.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.3 -174.77 3.16 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.085 1.354 . . . . 0.0 111.736 169.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.65 -10.02 47.43 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.73 -15.31 61.22 Favored 'General case' 0 CA--C 1.554 1.122 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 162.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.72 30.24 6.93 Favored Glycine 0 C--N 1.34 0.768 0 C-N-CA 127.272 2.368 . . . . 0.0 112.736 168.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -116.14 128.92 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 CA-C-N 119.854 1.827 . . . . 0.0 113.543 178.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 80.52 3.73 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 125.236 1.414 . . . . 0.0 110.215 167.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -77.85 123.7 27.07 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.682 1.593 . . . . 0.0 108.808 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.9 t -147.37 150.51 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -168.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 71.3 m -140.18 128.42 22.47 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 127.419 2.288 . . . . 0.0 108.367 166.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 34.7 mt -136.78 124.83 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 127.771 2.429 . . . . 0.0 108.928 -179.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 mp0 -117.4 115.69 25.72 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 126.307 1.843 . . . . 0.0 107.866 -175.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -140.46 144.32 36.01 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.933 0.873 . . . . 0.0 113.32 -168.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.2 p -110.89 51.1 0.78 Allowed 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 13.9 p -152.06 -38.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 167.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.288 0.1 OUTLIER -79.77 94.15 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 120.677 1.58 . . . . 0.0 110.888 172.549 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 38.4 p -102.14 153.21 20.15 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.148 1.779 . . . . 0.0 113.378 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.34 54.73 1.45 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.379 1.472 . . . . 0.0 110.851 -177.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.1 m -94.85 39.58 1.1 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 126.189 1.796 . . . . 0.0 112.128 -170.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 73.95 -39.46 0.97 Allowed Glycine 0 N--CA 1.475 1.271 0 C-N-CA 127.396 2.426 . . . . 0.0 115.83 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -161.65 -34.95 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.133 1.773 . . . . 0.0 111.962 -168.037 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 63.9 m-70 -75.85 -19.44 58.89 Favored 'General case' 0 C--O 1.226 -0.17 0 O-C-N 120.438 -1.413 . . . . 0.0 112.463 -167.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -142.62 -71.37 0.32 Allowed 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 122.793 0.437 . . . . 0.0 111.57 -172.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.25 2.3 pt -137.16 166.45 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 C-N-CA 125.252 1.421 . . . . 0.0 107.941 166.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.2 mm 86.72 144.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 131.308 3.843 . . . . 0.0 107.139 -163.06 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.43 3.45 25.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.133 0.873 . . . . 0.0 114.746 177.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 31.2 mtt180 -108.45 -172.45 2.06 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 128.785 2.834 . . . . 0.0 108.574 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 12.0 t -124.05 161.94 24.51 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 120.559 1.527 . . . . 0.0 109.423 166.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 tt -118.61 130.71 56.03 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 164.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 40.7 t -113.19 128.05 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 C-N-CA 125.098 1.359 . . . . 0.0 108.038 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -92.53 156.89 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 166.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.62 127.51 35.09 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.266 1.426 . . . . 0.0 108.752 -175.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -58.93 -14.52 9.38 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 118.122 2.638 . . . . 0.0 118.122 -166.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.8 mttp -137.45 177.33 7.95 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 124.042 3.11 . . . . 0.0 115.255 175.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.92 129.87 31.68 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 125.749 1.62 . . . . 0.0 110.888 -177.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -99.81 136.88 39.06 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 124.071 0.857 . . . . 0.0 110.327 171.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -81.49 -6.3 58.82 Favored 'General case' 0 CA--C 1.551 0.991 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 32.8 mt 60.69 67.89 0.79 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.314 1.846 . . . . 0.0 111.645 169.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.5 20.09 28.09 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 117.037 1.575 . . . . 0.0 117.037 168.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . 0.503 ' C ' ' H ' ' B' ' 130' ' ' GLY . 7.4 mtmp? -146.88 -57.86 0.27 Allowed 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 120.092 3.367 . . . . 0.0 120.092 -165.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -78.82 37.72 1.91 Allowed Glycine 0 N--CA 1.475 1.299 0 C-N-CA 128.64 3.019 . . . . 0.0 110.618 -169.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . 0.503 ' H ' ' C ' ' B' ' 128' ' ' LYS . . . 173.82 84.0 0.06 OUTLIER Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 -168.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -40.01 -24.96 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.935 0 C-N-CA 130.632 3.573 . . . . 0.0 114.827 167.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -116.98 -78.49 0.58 Allowed 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 127.177 2.191 . . . . 0.0 107.517 167.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -63.97 -36.47 84.09 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.066 1.135 . . . . 0.0 114.066 -166.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.8 t -71.31 -27.75 63.62 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 119.583 -1.948 . . . . 0.0 112.605 -177.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.316 8.9 t -83.41 -5.82 59.27 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 118.56 -0.733 . . . . 0.0 111.728 170.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -105.16 -68.2 0.87 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 124.882 1.273 . . . . 0.0 113.702 173.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.6 p -88.17 -32.28 18.7 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 125.347 1.459 . . . . 0.0 113.435 178.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 116.65 -23.92 9.95 Favored Glycine 0 N--CA 1.472 1.078 0 C-N-CA 125.32 1.438 . . . . 0.0 112.448 -168.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 10.2 t30 69.43 48.06 0.65 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 127.719 2.408 . . . . 0.0 110.014 178.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.87 31.3 0.06 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 127.402 2.281 . . . . 0.0 114.672 -169.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.49 -33.95 0.12 Allowed Glycine 0 CA--C 1.535 1.337 0 C-N-CA 128.614 3.007 . . . . 0.0 115.265 -172.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.7 t -160.16 -152.21 0.28 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.794 1.238 . . . . 0.0 112.398 178.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.52 -170.66 2.27 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 129.508 3.123 . . . . 0.0 107.706 174.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -174.41 -168.7 0.4 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.467 1.907 . . . . 0.0 107.372 -169.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.68 153.95 1.53 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.67 2.788 . . . . 0.0 113.45 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -144.9 160.92 40.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.187 1.795 . . . . 0.0 112.821 -178.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.56 131.25 3.21 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 124.555 1.074 . . . . 0.0 111.98 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 128.18 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -176.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 35.4 mt -84.95 112.85 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.591 1.956 . . . . 0.0 111.228 -168.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.52 -144.44 10.96 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.416 -0.673 . . . . 0.0 111.416 168.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.17 163.61 26.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 124.507 1.123 . . . . 0.0 112.714 -168.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.492 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.35 -34.14 0.3 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 129.174 2.989 . . . . 0.0 109.789 166.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.469 0.491 0 C-N-CA 126.387 1.875 . . . . 0.0 111.813 167.368 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 119.965 -0.064 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.5 p -78.51 53.76 1.35 Allowed 'General case' 0 C--O 1.221 -0.435 0 C-N-CA 127.582 2.353 . . . . 0.0 115.684 -164.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 mttp -161.94 87.46 0.65 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.003 1.721 . . . . 0.0 110.685 166.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.98 152.35 28.02 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 123.83 0.852 . . . . 0.0 109.227 167.073 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -160.04 147.58 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.856 0.862 . . . . 0.0 111.85 -168.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.69 139.21 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 165.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 88.9 t -98.29 88.9 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.72 123.74 30.15 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 127.049 2.14 . . . . 0.0 108.914 -170.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -135.62 144.15 45.95 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 122.38 1.086 . . . . 0.0 113.676 -170.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -109.08 160.94 13.3 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 107.36 -2.296 . . . . 0.0 107.36 166.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.08 58.16 1.5 Allowed 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 127.001 2.121 . . . . 0.0 111.935 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.4 -160.92 34.72 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.965 2.221 . . . . 0.0 110.565 -172.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.85 41.73 1.17 Allowed 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 125.152 3.901 . . . . 0.0 112.104 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.14 111.94 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 127.086 2.154 . . . . 0.0 108.726 -169.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -159.69 168.7 25.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.448 179.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.18 137.43 5.39 Favored Glycine 0 CA--C 1.506 -0.495 0 CA-C-N 115.659 -0.701 . . . . 0.0 112.065 168.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.0 134.04 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 166.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 pp -130.98 129.87 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.539 1.136 . . . . 0.0 109.231 165.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -103.2 153.75 20.04 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.537 1.935 . . . . 0.0 112.392 168.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -138.13 111.12 7.77 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 126.436 1.894 . . . . 0.0 109.123 169.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -96.33 84.78 3.8 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.315 -1.491 . . . . 0.0 112.54 176.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -105.84 147.51 28.6 Favored 'General case' 0 C--O 1.222 -0.361 0 O-C-N 121.111 -0.993 . . . . 0.0 110.733 174.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.41 -15.14 9.11 Favored 'General case' 0 CA--C 1.551 1.005 0 C-N-CA 128.432 2.693 . . . . 0.0 112.49 -179.005 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.438 ' CD ' ' H ' ' A' ' 25' ' ' SER . 2.6 tm-20 -126.54 171.71 10.85 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 127.121 2.169 . . . . 0.0 110.594 -171.49 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.438 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 75.1 m -95.57 -26.5 15.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -177.304 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -126.58 -18.99 4.67 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 120.717 1.599 . . . . 0.0 114.904 -174.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.85 173.52 47.63 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.641 1.115 . . . . 0.0 112.973 176.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -80.95 171.04 14.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.847 3.031 . . . . 0.0 112.773 -176.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 t -140.48 136.1 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.34 1.456 . . . . 0.0 111.256 -170.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.45 ' HZ3' ' CD ' ' A' ' 100' ' ' GLU . 6.9 tmtm? -80.77 128.89 34.16 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 168.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 38.1 t -121.91 143.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.669 1.987 . . . . 0.0 108.664 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.5 p90 -156.59 161.55 39.93 Favored 'General case' 0 C--N 1.326 -0.426 0 O-C-N 121.06 -1.025 . . . . 0.0 111.292 173.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.68 151.4 9.83 Favored Glycine 0 N--CA 1.452 -0.281 0 N-CA-C 114.879 0.711 . . . . 0.0 114.879 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -109.7 108.53 18.95 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.081 -0.56 . . . . 0.0 110.182 170.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -85.21 141.38 14.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 126.273 1.829 . . . . 0.0 107.789 167.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -149.38 132.4 16.23 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.216 1.806 . . . . 0.0 109.133 -178.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 -19.26 37.18 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 126.084 1.802 . . . . 0.0 114.179 -171.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.3 mp -62.96 130.94 46.97 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 119.55 1.675 . . . . 0.0 111.956 169.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -67.5 152.84 44.97 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.634 1.974 . . . . 0.0 109.268 168.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -53.61 153.6 4.23 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.7 1.6 . . . . 0.0 115.111 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.99 -176.63 40.93 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.723 1.154 . . . . 0.0 112.668 -177.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mt -63.76 153.83 35.18 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.521 1.528 . . . . 0.0 112.18 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 78.6 m-70 -151.57 132.98 14.63 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 127.995 2.518 . . . . 0.0 108.701 169.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.91 142.77 46.86 Favored Glycine 0 N--CA 1.475 1.239 0 CA-C-O 118.905 -0.941 . . . . 0.0 112.263 178.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -132.93 102.83 5.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.939 1.696 . . . . 0.0 108.214 -175.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -139.65 136.92 34.8 Favored 'General case' 0 CA--C 1.537 0.464 0 O-C-N 120.736 -1.228 . . . . 0.0 110.946 -167.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -93.89 124.58 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 14.6 m-70 -72.06 -177.86 2.2 Favored 'General case' 0 CA--C 1.55 0.966 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 169.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -64.89 167.24 7.91 Favored 'General case' 0 CA--C 1.549 0.923 0 O-C-N 119.97 -1.706 . . . . 0.0 111.767 169.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -90.36 -144.53 0.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -173.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.62 -147.36 26.65 Favored Glycine 0 N--CA 1.428 -1.835 0 CA-C-O 124.97 2.428 . . . . 0.0 111.441 169.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.5 p-10 -88.0 54.03 2.95 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 109.453 -3.374 . . . . 0.0 109.674 -168.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.369 4.1 p30 -75.19 18.57 0.19 Allowed 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 121.221 3.785 . . . . 0.0 121.221 -157.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.402 ' CG2' ' HA ' ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -76.3 -23.37 54.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 117.588 2.44 . . . . 0.0 117.588 -162.704 . . . . . . . . 4 4 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.71 -4.07 29.0 Favored 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 169.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.51 -111.31 4.02 Favored Glycine 0 C--N 1.342 0.881 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 31.0 p -47.84 -28.69 2.73 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.42 -19.48 29.59 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.727 1.211 . . . . 0.0 113.755 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 49.6 m -119.85 -43.73 2.55 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.208 0.913 . . . . 0.0 113.273 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.5 80.76 3.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.418 1.087 . . . . 0.0 111.289 -170.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.42 123.33 9.83 Favored Glycine 0 CA--C 1.536 1.389 0 C-N-CA 125.001 1.286 . . . . 0.0 112.245 -177.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -63.34 119.84 7.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.142 2.561 . . . . 0.0 109.372 -174.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 34.27 66.93 0.24 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.155 1.782 . . . . 0.0 115.057 178.034 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -14.63 113.93 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 129.217 3.007 . . . . 0.0 114.505 174.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -114.53 38.6 0.22 Allowed Pre-proline 0 CA--C 1.555 1.138 0 C-N-CA 126.716 2.006 . . . . 0.0 115.448 -168.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -67.99 -14.6 41.57 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 122.668 2.246 . . . . 0.0 112.799 -177.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 64.3 mt -76.72 -6.73 53.39 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.169 1.388 . . . . 0.0 112.791 172.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.3 t 70.93 53.63 0.26 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 127.101 2.16 . . . . 0.0 113.009 174.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 20.6 mtm-85 -131.72 174.41 10.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -171.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mmtt -97.11 177.66 5.51 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 128.62 2.768 . . . . 0.0 110.193 166.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -81.62 154.13 26.31 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.807 1.41 . . . . 0.0 114.807 -169.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 158.38 -169.92 34.98 Favored Glycine 0 C--N 1.335 0.489 0 CA-C-N 115.277 -0.874 . . . . 0.0 113.93 166.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 173.13 -85.24 0.08 OUTLIER Glycine 0 CA--C 1.544 1.889 0 CA-C-O 117.9 -1.5 . . . . 0.0 114.192 168.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.05 19.04 0.16 Allowed 'Trans proline' 0 CA--C 1.553 1.459 1 C-N-CA 125.637 4.225 . . . . 0.0 116.635 -172.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.81 5.23 0.13 Allowed 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 128.144 2.578 . . . . 0.0 111.731 177.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.401 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 5.9 t70 -126.09 175.63 7.61 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 128.938 2.895 . . . . 0.0 112.922 -164.54 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 -129.88 -15.43 3.86 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 129.534 3.134 . . . . 0.0 111.833 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -85.89 -83.97 0.17 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.079 1.352 . . . . 0.0 112.486 177.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 72.35 112.43 0.06 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 126.488 1.915 . . . . 0.0 111.986 175.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -69.05 168.76 13.18 Favored 'General case' 0 CA--C 1.546 0.825 0 O-C-N 120.075 -1.641 . . . . 0.0 113.029 169.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -80.75 11.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 O-C-N 120.672 -1.268 . . . . 0.0 113.279 -178.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.95 10.21 7.48 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 126.766 2.127 . . . . 0.0 114.246 176.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -99.95 81.02 2.38 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 121.641 -0.917 . . . . 0.0 111.161 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.9 mt -79.17 48.71 0.89 Allowed 'General case' 0 CA--C 1.549 0.905 0 O-C-N 121.039 -1.038 . . . . 0.0 110.771 169.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.82 -118.7 9.31 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.541 1.543 . . . . 0.0 113.423 177.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.0 p30 -157.15 172.69 18.2 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.622 1.569 . . . . 0.0 112.64 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.9 p -133.63 125.11 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 C-N-CA 126.213 1.805 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 m -98.22 139.23 34.31 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.6 159.08 18.51 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.091 0.956 . . . . 0.0 113.418 172.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -89.4 154.66 19.88 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 126.83 2.052 . . . . 0.0 111.942 169.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.564 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 0.0 OUTLIER -59.42 -14.6 12.82 Favored 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.818 2.447 . . . . 0.0 115.553 178.2 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.564 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 27.4 m-20 -79.36 5.75 11.78 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 125.254 1.422 . . . . 0.0 112.941 168.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.26 40.59 9.05 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 125.708 1.623 . . . . 0.0 113.39 169.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.4 p -155.78 146.82 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 115.302 1.593 . . . . 0.0 115.302 -168.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.93 101.15 4.8 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 123.44 1.59 . . . . 0.0 109.604 167.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.54 79.29 1.8 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.249 2.219 . . . . 0.0 108.698 -173.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 70.9 t -93.23 147.81 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 127.31 2.244 . . . . 0.0 114.211 -167.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.6 t -150.51 116.51 5.6 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.23 1.412 . . . . 0.0 111.056 170.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.7 mt -140.11 168.97 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 128.296 2.638 . . . . 0.0 112.029 -168.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.45 ' CD ' ' HZ3' ' A' ' 30' ' ' LYS . 2.3 pm0 -136.28 136.42 39.78 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 127.909 2.484 . . . . 0.0 107.825 172.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -147.13 153.14 39.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 122.284 1.04 . . . . 0.0 113.373 -168.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 81.9 p -126.29 69.47 1.22 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.884 2.074 . . . . 0.0 110.898 -169.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.53 -35.71 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 124.211 1.004 . . . . 0.0 112.225 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -94.98 161.68 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.928 1.291 . . . . 0.0 112.225 174.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.1 p -158.07 177.64 11.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.233 1.013 . . . . 0.0 111.207 174.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -111.53 80.3 1.3 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.455 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.7 t -147.34 -171.0 3.69 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -127.69 87.83 0.33 Allowed Glycine 0 C--O 1.219 -0.824 0 O-C-N 120.444 -1.41 . . . . 0.0 113.046 -177.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -177.26 -54.19 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 129.057 2.943 . . . . 0.0 108.615 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -140.02 8.04 2.27 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 114.647 1.351 . . . . 0.0 114.647 -173.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.455 ' CB ' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -73.08 -161.4 0.09 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 126.334 1.853 . . . . 0.0 113.9 -172.768 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 36.9 pt -109.47 1.08 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.5 mm -62.25 126.38 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 CA-C-N 119.981 1.264 . . . . 0.0 107.633 168.462 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.76 16.84 76.35 Favored Glycine 0 CA--C 1.522 0.469 0 CA-C-O 117.953 -1.471 . . . . 0.0 115.118 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 -102.25 169.82 8.47 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 119.267 1.533 . . . . 0.0 109.741 -175.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 10.2 t -123.54 121.85 36.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 120.614 1.552 . . . . 0.0 112.067 -173.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.02 137.23 32.56 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 174.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.3 t -129.71 131.22 66.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 126.065 1.746 . . . . 0.0 107.741 172.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 34.5 m -106.27 138.8 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 172.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -95.26 148.34 22.51 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.602 0.761 . . . . 0.0 112.739 -169.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.316 2.7 pp20? -74.47 -21.48 59.57 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -171.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -113.32 169.42 8.96 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.236 1.015 . . . . 0.0 112.593 171.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.73 154.14 9.53 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.533 1.533 . . . . 0.0 109.547 166.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -119.17 155.99 30.64 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 114.498 1.295 . . . . 0.0 114.498 -169.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 129' ' ' GLY . 2.9 t0 -89.83 -38.17 13.94 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 117.471 2.397 . . . . 0.0 117.471 -167.388 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 63.8 42.78 5.88 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.516 1.927 . . . . 0.0 113.322 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 134.8 -77.38 0.37 Allowed Glycine 0 C--N 1.337 0.586 0 C-N-CA 124.466 1.031 . . . . 0.0 112.716 169.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.17 62.16 1.17 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 118.853 2.909 . . . . 0.0 118.853 -174.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.408 ' H ' ' CG ' ' A' ' 125' ' ' ASP . . . -71.72 -71.5 1.04 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 106.899 -2.48 . . . . 0.0 106.899 163.325 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -77.79 -91.35 0.3 Allowed Glycine 0 CA--C 1.528 0.88 0 C-N-CA 126.177 1.846 . . . . 0.0 114.487 -173.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -144.02 -145.31 0.17 Allowed 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 124.822 1.249 . . . . 0.0 111.876 -165.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -69.66 -49.93 48.99 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.751 1.16 . . . . 0.0 112.367 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.425 ' CD ' ' HZ3' ' A' ' 136' ' ' LYS . 0.4 OUTLIER -47.13 -27.34 1.38 Allowed 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 116.15 1.907 . . . . 0.0 116.15 171.499 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 48.7 m -51.77 -23.68 4.95 Favored 'General case' 0 CA--C 1.543 0.699 0 O-C-N 120.195 -1.565 . . . . 0.0 113.719 167.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.5 p -99.54 -26.9 13.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.749 1.619 . . . . 0.0 115.033 173.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.425 ' HZ3' ' CD ' ' A' ' 133' ' ' GLU . 31.6 mtpt -91.75 -24.82 19.32 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 124.103 0.961 . . . . 0.0 113.429 -176.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 39.6 p -123.31 -42.05 2.27 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.727 1.611 . . . . 0.0 112.83 169.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 105.81 18.99 10.7 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-O 118.864 -0.964 . . . . 0.0 111.091 -166.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 59.04 -1.7 0.11 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.58 2.352 . . . . 0.0 115.723 176.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.9 16.44 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.24 0 C-N-CA 128.822 2.849 . . . . 0.0 116.802 -165.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.27 -128.97 9.29 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 127.084 2.278 . . . . 0.0 111.658 -173.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.2 t -104.01 -168.22 1.47 Allowed 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.048 1.339 . . . . 0.0 113.122 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.65 151.41 36.18 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 120.629 -1.294 . . . . 0.0 110.925 168.445 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.3 tt -111.42 -66.81 1.04 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.699 2.0 . . . . 0.0 107.465 169.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -131.72 158.87 40.01 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.276 1.83 . . . . 0.0 110.31 177.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.0 p -156.38 151.74 26.69 Favored 'General case' 0 CA--C 1.553 1.062 0 C-N-CA 125.803 1.641 . . . . 0.0 113.171 -171.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.07 163.42 34.29 Favored Glycine 0 CA--C 1.542 1.762 0 C-N-CA 125.724 1.631 . . . . 0.0 114.205 172.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.8 t -107.54 137.59 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.455 1.127 . . . . 0.0 108.371 168.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.0 mt -81.31 126.88 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 127.513 2.325 . . . . 0.0 113.698 -169.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.0 -154.43 9.43 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 126.043 1.782 . . . . 0.0 112.412 168.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -131.17 146.15 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.607 1.163 . . . . 0.0 112.605 -178.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.04 15.82 Favored 'General case' 0 C--O 1.22 -0.476 0 C-N-CA 124.239 1.016 . . . . 0.0 109.472 174.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 . . . . . 0 C--O 1.239 0.524 0 C-N-CA 125.085 1.354 . . . . 0.0 108.746 173.441 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.401 0 CA-C-O 120.834 0.35 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.3 p -82.77 107.18 15.2 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.77 118.92 27.62 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 115.245 1.572 . . . . 0.0 115.245 -172.398 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.96 161.38 14.17 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.043 1.337 . . . . 0.0 111.957 169.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -148.73 116.04 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.784 2.034 . . . . 0.0 111.188 -169.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.75 125.61 29.6 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.161 -0.962 . . . . 0.0 110.106 168.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.402 ' HA ' ' CG2' ' A' ' 54' ' ' THR . 87.8 t -107.5 71.61 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.712 0.805 . . . . 0.0 111.291 -170.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 mp -83.56 130.42 35.0 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -169.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.6 mtpp -155.24 178.26 10.41 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.119 1.368 . . . . 0.0 113.119 172.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.73 -55.55 0.47 Allowed Glycine 0 C--O 1.224 -0.48 0 C-N-CA 127.175 2.322 . . . . 0.0 109.794 170.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -83.78 73.73 10.26 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.883 1.273 . . . . 0.0 110.481 -168.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.66 -103.58 0.06 OUTLIER Glycine 0 CA--C 1.538 1.471 0 C-N-CA 126.751 2.119 . . . . 0.0 113.136 176.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -79.87 -3.04 12.56 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 125.192 3.928 . . . . 0.0 114.724 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 42.0 t -77.53 128.37 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-N 120.025 1.284 . . . . 0.0 110.523 176.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -126.4 158.31 36.27 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 126.278 1.831 . . . . 0.0 109.181 167.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.01 101.91 0.28 Allowed Glycine 0 C--O 1.225 -0.415 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 168.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -102.43 106.02 19.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 C-N-CA 125.721 1.608 . . . . 0.0 106.676 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.2 mm -120.68 101.75 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.01 0.524 . . . . 0.0 109.964 -177.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -74.93 161.57 29.39 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 118.915 0.779 . . . . 0.0 110.523 172.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -146.73 100.47 3.33 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.947 2.099 . . . . 0.0 107.818 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 116.8 29.24 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.853 0.861 . . . . 0.0 112.017 -178.342 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -102.26 126.45 49.25 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.088 0.955 . . . . 0.0 110.767 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -49.78 20.71 Favored 'General case' 0 CA--C 1.55 0.963 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 171.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -151.5 134.56 15.86 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 128.757 2.823 . . . . 0.0 107.108 169.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 67.5 m -64.01 93.37 0.09 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.327 1.051 . . . . 0.0 112.268 178.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 p30 160.08 -32.66 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 131.081 3.753 . . . . 0.0 110.998 -174.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.6 173.18 45.41 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-O 119.241 -0.755 . . . . 0.0 111.936 172.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.04 166.9 19.34 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.422 2.748 . . . . 0.0 111.378 177.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 66.1 t -121.22 130.19 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 124.968 1.307 . . . . 0.0 109.017 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -86.87 119.24 26.88 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.73 0.776 . . . . 0.0 109.739 170.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.4 t -104.97 121.08 56.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 127.441 2.296 . . . . 0.0 108.813 -172.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -155.14 157.21 37.08 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.95 -135.64 4.87 Favored Glycine 0 N--CA 1.461 0.331 0 C-N-CA 124.709 1.147 . . . . 0.0 111.053 177.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.5 p -157.7 158.5 35.51 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 116.222 1.934 . . . . 0.0 116.222 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -121.24 104.72 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.561 1.144 . . . . 0.0 108.483 170.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -106.27 124.47 49.64 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.3 3.1 3.53 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.269 1.89 . . . . 0.0 113.916 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 55.6 mt -79.76 -172.03 3.13 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 124.194 0.998 . . . . 0.0 108.409 167.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -119.58 -29.08 5.16 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 171.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 175.9 -176.65 0.12 Allowed 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 130.462 3.505 . . . . 0.0 106.327 -178.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.38 160.71 35.44 Favored Glycine 0 N--CA 1.461 0.354 0 C-N-CA 125.677 1.608 . . . . 0.0 114.072 166.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 mp -76.59 157.91 31.57 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 167.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -149.38 130.01 14.04 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 126.606 1.963 . . . . 0.0 108.681 -174.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.75 147.68 37.19 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 172.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.296 0.0 OUTLIER -138.32 133.56 33.17 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 123.947 1.832 . . . . 0.0 114.65 169.464 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -130.3 145.61 51.79 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.958 1.703 . . . . 0.0 111.63 -168.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -96.55 115.51 36.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 168.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -73.38 132.53 43.12 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 170.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -65.21 135.97 56.07 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 124.333 1.053 . . . . 0.0 112.037 -165.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 66.09 -169.93 0.2 Allowed 'General case' 0 CA--C 1.544 0.747 0 CA-C-O 123.274 1.511 . . . . 0.0 111.907 -175.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' B' ' 53' ' ' ASN . . . -135.55 2.85 3.85 Favored Glycine 0 C--O 1.225 -0.437 0 C-N-CA 126.602 2.049 . . . . 0.0 113.589 -175.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -79.63 49.62 1.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 121.246 2.523 . . . . 0.0 111.262 169.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.419 ' H ' ' C ' ' B' ' 51' ' ' GLY . 0.0 OUTLIER 176.42 28.26 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 112.079 -2.328 . . . . 0.0 115.293 -169.4 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 11.0 p -57.35 18.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 120.687 3.588 . . . . 0.0 120.687 -168.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.54 3.02 20.8 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-N 121.131 1.787 . . . . 0.0 113.955 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.04 -161.99 49.63 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 119.549 1.068 . . . . 0.0 113.156 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 18.6 t -52.3 -21.25 3.31 Favored 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 115.881 1.808 . . . . 0.0 115.881 -169.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.1 t -66.09 -10.6 42.09 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 125.835 1.654 . . . . 0.0 113.666 169.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.5 m -161.15 -4.42 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -171.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.04 144.32 47.62 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 116.243 1.942 . . . . 0.0 116.243 -166.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.76 126.79 32.82 Favored Glycine 0 CA--C 1.537 1.465 0 C-N-CA 125.448 1.499 . . . . 0.0 111.862 178.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -63.28 169.79 8.88 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 124.278 3.318 . . . . 0.0 112.484 -173.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.561 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -61.57 108.17 0.93 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.902 1.681 . . . . 0.0 112.722 -169.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -53.22 135.67 37.83 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 126.207 1.803 . . . . 0.0 115.729 -167.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -116.72 42.38 0.36 Allowed Pre-proline 0 CA--C 1.559 1.327 0 C-N-CA 128.131 2.572 . . . . 0.0 114.746 -175.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -65.9 -20.48 58.05 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.092 1.862 . . . . 0.0 112.38 177.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 6.5 mp -77.9 -3.93 44.21 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 126.72 2.008 . . . . 0.0 113.666 170.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.3 t 52.41 59.14 4.72 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 125.778 1.631 . . . . 0.0 114.726 169.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.0 ptt180 -163.1 179.24 7.64 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.109 0.964 . . . . 0.0 111.914 -168.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.16 169.92 2.51 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 -179.174 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 51.7 t60 -55.64 158.32 3.56 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.979 1.711 . . . . 0.0 114.456 -173.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -64.68 45.04 0.11 Allowed Glycine 0 N--CA 1.47 0.937 0 N-CA-C 120.915 3.126 . . . . 0.0 120.915 -164.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -75.95 124.44 7.4 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-N 119.835 1.818 . . . . 0.0 113.903 -169.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -74.71 -3.01 13.23 Favored 'Trans proline' 0 CA--C 1.546 1.094 0 CA-C-N 120.125 1.962 . . . . 0.0 110.319 166.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptmt -106.07 -3.58 21.4 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 127.94 2.496 . . . . 0.0 112.98 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.88 142.47 50.38 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.199 1.4 . . . . 0.0 109.351 -172.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -70.45 -18.09 62.99 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.984 -0.448 . . . . 0.0 111.79 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -98.48 122.16 41.33 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 125.292 1.437 . . . . 0.0 107.828 169.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.3 ttt85 -150.27 115.45 5.39 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.3 1.84 . . . . 0.0 109.466 -171.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -60.15 163.6 4.76 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 127.091 2.156 . . . . 0.0 112.2 166.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.23 -30.76 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 C-N-CA 124.775 1.23 . . . . 0.0 113.451 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.01 33.91 3.07 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 121.14 -0.975 . . . . 0.0 113.405 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 34.4 m-20 -144.36 155.12 43.65 Favored 'General case' 0 CA--C 1.529 0.173 0 N-CA-C 117.645 2.461 . . . . 0.0 117.645 -169.219 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.6 mt -113.1 -178.61 3.42 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 127.719 2.408 . . . . 0.0 107.796 164.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.39 -129.07 1.47 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.128 0.871 . . . . 0.0 113.369 176.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -103.09 162.58 12.83 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.064 0.946 . . . . 0.0 112.284 172.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.36 140.51 43.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 127.555 2.342 . . . . 0.0 108.179 166.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 91.1 m -127.76 124.23 37.23 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -165.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.95 144.06 30.26 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -82.37 163.13 21.91 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 126.679 1.992 . . . . 0.0 109.924 167.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -51.58 -17.93 0.98 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 126.777 2.031 . . . . 0.0 116.074 170.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.41 -23.49 57.01 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 126.753 2.021 . . . . 0.0 112.387 172.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.09 -3.94 60.5 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 125.603 1.573 . . . . 0.0 114.946 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.6 129.02 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 118.923 1.362 . . . . 0.0 112.232 168.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.95 126.65 43.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 164.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -79.91 142.36 35.22 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.9 p -124.33 130.78 73.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-N 114.086 -1.416 . . . . 0.0 111.152 165.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.1 p -155.91 69.87 0.68 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.539 1.936 . . . . 0.0 109.997 -169.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 14.9 mt -127.57 162.2 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.124 1.769 . . . . 0.0 113.285 -167.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -138.66 148.74 44.4 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 127.821 2.448 . . . . 0.0 106.916 166.275 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -148.48 143.13 26.5 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 125.254 1.422 . . . . 0.0 109.106 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.3 p -108.86 55.02 0.64 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.606 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.61 -40.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.707 1.603 . . . . 0.0 109.76 170.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -82.32 155.27 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 CA-C-O 122.549 1.166 . . . . 0.0 113.997 179.187 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 35.6 m -158.1 156.11 30.4 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.888 1.675 . . . . 0.0 111.37 172.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.3 mp -76.74 79.85 3.36 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 126.678 1.991 . . . . 0.0 107.934 176.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.95 -19.27 20.37 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 113.233 0.827 . . . . 0.0 113.233 -172.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 83.65 9.96 82.27 Favored Glycine 0 N--CA 1.472 1.095 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.663 -174.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -165.26 -37.22 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.861 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -169.277 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -131.84 7.29 4.38 Favored 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 116.934 2.198 . . . . 0.0 116.934 -165.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.0 m -161.07 -55.95 0.05 Allowed 'General case' 0 N--CA 1.479 0.977 0 O-C-N 119.368 -2.083 . . . . 0.0 115.766 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . 0.44 ' CG2' ' H ' ' B' ' 113' ' ' ILE . 68.2 mt -137.75 158.18 33.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 173.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . 0.44 ' H ' ' CG2' ' B' ' 112' ' ' ILE . 19.8 mm 83.32 102.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.267 1 C-N-CA 131.847 4.059 . . . . 0.0 106.498 -166.387 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.08 13.61 83.48 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-O 115.504 -2.831 . . . . 0.0 116.91 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -92.92 152.46 19.35 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 121.314 2.557 . . . . 0.0 109.05 175.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.6 t -107.68 109.72 21.4 Favored 'General case' 0 N--CA 1.487 1.398 0 CA-C-N 121.393 1.906 . . . . 0.0 112.962 -167.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -91.17 136.29 33.19 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.785 1.234 . . . . 0.0 110.42 -176.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 p -121.06 142.3 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 C-N-CA 125.702 1.601 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 m -107.47 140.27 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 123.61 0.764 . . . . 0.0 110.371 171.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -111.93 160.22 17.64 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-O 122.373 1.083 . . . . 0.0 113.029 -170.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -84.36 -33.21 23.87 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -99.11 167.72 10.52 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.57 1.077 . . . . 0.0 111.093 177.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.93 150.54 16.44 Favored 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 165.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -112.28 137.5 50.32 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.239 0.616 . . . . 0.0 109.723 173.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -79.91 -38.01 33.41 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 120.577 -0.449 . . . . 0.0 111.454 169.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . 0.269 1.8 mm? 86.1 63.6 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.759 2.423 . . . . 0.0 111.868 -169.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.0 -15.55 36.78 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 117.077 1.591 . . . . 0.0 117.077 166.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.81 -153.95 0.6 Allowed 'General case' 0 CA--C 1.552 1.026 0 CA-C-N 119.565 1.683 . . . . 0.0 109.885 169.379 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 122.41 -36.78 3.05 Favored Glycine 0 N--CA 1.471 1.02 0 O-C-N 120.688 -1.257 . . . . 0.0 113.149 -176.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.61 -16.18 0.32 Allowed Glycine 0 N--CA 1.475 1.272 0 N-CA-C 118.719 2.248 . . . . 0.0 118.719 169.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -122.01 169.13 11.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.21 2.005 . . . . 0.0 111.513 -174.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -62.66 -51.78 65.91 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.894 1.278 . . . . 0.0 109.711 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -49.29 -30.88 8.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.561 2.344 . . . . 0.0 113.548 174.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 92.1 p -60.2 -33.67 72.55 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 122.354 2.343 . . . . 0.0 113.957 171.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 33.0 p -62.66 -34.97 78.18 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.529 0.604 . . . . 0.0 111.461 177.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 38.7 mtpt -90.86 -39.1 12.52 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.997 1.719 . . . . 0.0 113.273 -174.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 53.8 p -104.93 -28.34 11.16 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 127.212 2.205 . . . . 0.0 114.181 -173.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.57 -28.98 13.23 Favored Glycine 0 N--CA 1.465 0.6 0 C-N-CA 125.857 1.694 . . . . 0.0 113.924 -168.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 96.98 -11.35 0.08 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 130.787 3.635 . . . . 0.0 109.736 -167.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.2 -17.48 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 131.334 3.853 . . . . 0.0 119.71 -168.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 96.96 176.33 35.0 Favored Glycine 0 CA--C 1.534 1.264 0 C-N-CA 127.058 2.266 . . . . 0.0 113.09 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 81.5 p -62.63 -74.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -168.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 170.21 158.16 0.06 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 127.44 2.296 . . . . 0.0 114.594 176.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.98 -128.8 0.19 Allowed 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 126.934 2.094 . . . . 0.0 106.639 163.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.14 150.08 43.7 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 119.347 0.976 . . . . 0.0 112.293 -171.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 36.4 t -143.37 147.74 35.14 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.994 0.918 . . . . 0.0 110.454 173.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.0 160.81 31.48 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 123.889 0.757 . . . . 0.0 114.599 177.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -78.49 152.27 5.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 121.816 -0.814 . . . . 0.0 111.971 174.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 44.8 mt -83.53 91.8 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 123.82 0.848 . . . . 0.0 111.772 169.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -80.14 -163.09 27.4 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.573 1.082 . . . . 0.0 113.181 169.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.1 141.01 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 125.351 1.46 . . . . 0.0 112.308 178.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -99.68 -7.09 26.12 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 124.175 0.99 . . . . 0.0 111.974 168.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.473 0.715 0 C-N-CA 127.922 2.489 . . . . 0.0 110.677 169.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 CA-C-O 120.856 0.36 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.1 p -152.04 119.45 5.99 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 125.108 1.363 . . . . 0.0 108.742 -169.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 mtmm -86.98 122.29 30.63 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 174.181 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.13 162.6 12.97 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.394 1.878 . . . . 0.0 108.625 165.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' B' ' 52' ' ' ASP . 0.5 OUTLIER -160.05 134.78 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.499 1.12 . . . . 0.0 109.68 -168.604 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.6 137.91 54.54 Favored 'General case' 0 C--N 1.334 -0.095 0 CA-C-N 118.657 0.662 . . . . 0.0 112.311 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -95.19 115.54 34.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 167.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mp -95.01 117.02 29.43 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 169.505 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.419 ' HE3' ' O ' ' B' ' 10' ' ' GLY . 13.1 ttpt -156.26 144.93 20.13 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 121.332 -0.855 . . . . 0.0 113.068 174.81 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.93 -33.04 0.47 Allowed Glycine 0 C--N 1.335 0.482 0 N-CA-C 116.768 1.467 . . . . 0.0 116.768 166.847 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -90.27 70.3 7.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 122.808 1.289 . . . . 0.0 109.657 -166.256 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.02 -106.66 0.14 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 128.724 3.059 . . . . 0.0 111.479 -174.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -76.1 -4.0 14.56 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 124.045 3.163 . . . . 0.0 113.886 -177.4 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 t -91.27 133.88 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 120.162 1.346 . . . . 0.0 111.897 176.431 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.21 159.08 44.6 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 127.211 2.204 . . . . 0.0 107.79 176.678 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -151.3 133.94 4.45 Favored Glycine 0 C--O 1.229 -0.166 0 CA-C-O 122.023 0.791 . . . . 0.0 111.84 177.129 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.19 130.44 56.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 169.822 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.55 122.99 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 124.326 1.017 . . . . 0.0 110.118 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -97.83 150.25 21.48 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.952 1.301 . . . . 0.0 110.194 167.042 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -124.83 111.25 15.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.322 1.849 . . . . 0.0 108.043 168.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -93.64 122.59 36.24 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 169.534 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -100.05 116.23 31.59 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.854 168.268 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . 0.263 0.0 OUTLIER -57.01 -50.35 73.0 Favored 'General case' 0 C--N 1.34 0.186 0 CA-C-O 119.095 -0.479 . . . . 0.0 112.044 175.893 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -158.42 145.66 17.83 Favored 'General case' 0 C--O 1.225 -0.213 0 CA-C-O 118.514 -0.755 . . . . 0.0 110.171 163.284 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.7 t -32.1 -51.52 0.25 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.985 2.114 . . . . 0.0 115.715 -167.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -78.34 -1.85 35.27 Favored 'General case' 0 CA--C 1.552 1.048 0 N-CA-C 115.559 1.688 . . . . 0.0 115.559 -175.9 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.45 -179.48 39.44 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.198 1.38 . . . . 0.0 113.756 -178.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -81.43 134.57 8.95 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 122.694 2.262 . . . . 0.0 111.354 175.218 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 t -86.69 128.76 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 O-C-N 121.779 -0.576 . . . . 0.0 110.393 -175.493 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 tmtt? -87.06 123.32 32.01 Favored 'General case' 0 CA--C 1.541 0.607 0 O-C-N 121.782 -0.574 . . . . 0.0 109.806 174.001 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -99.43 140.98 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.714 0.806 . . . . 0.0 110.343 169.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -145.05 156.64 44.04 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.37 0.668 . . . . 0.0 111.549 168.192 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.54 -160.4 29.23 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 123.346 0.498 . . . . 0.0 112.887 176.76 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.1 p -155.99 138.47 14.94 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 122.538 -0.39 . . . . 0.0 111.984 -175.615 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.91 110.42 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -179.191 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -112.91 142.93 45.01 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 127.685 2.394 . . . . 0.0 110.828 -167.287 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.01 0.81 54.9 Favored Glycine 0 CA--C 1.53 0.991 0 C-N-CA 126.457 1.98 . . . . 0.0 113.312 -177.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.7 mt -73.49 159.37 33.3 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 118.031 0.916 . . . . 0.0 110.573 176.275 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.4 t -82.75 160.23 22.36 Favored 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 162.374 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -53.6 160.15 1.36 Allowed 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -179.794 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.11 -170.71 34.72 Favored Glycine 0 CA--C 1.526 0.766 0 C-N-CA 124.128 0.87 . . . . 0.0 113.001 178.608 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.409 HD13 ' H ' ' A' ' 42' ' ' LEU . 0.8 OUTLIER -79.18 153.13 30.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.827 1.251 . . . . 0.0 110.446 -175.249 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -147.03 114.29 6.26 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.539 2.336 . . . . 0.0 106.808 -177.088 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.87 154.09 28.58 Favored Glycine 0 N--CA 1.476 1.323 0 CA-C-N 119.887 1.221 . . . . 0.0 111.828 -176.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -157.4 135.11 10.69 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.629 1.214 . . . . 0.0 112.21 170.696 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.46 143.82 25.0 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 121.003 -1.061 . . . . 0.0 111.325 -170.03 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 15.9 m -85.08 136.84 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 167.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -104.72 179.22 4.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.91 1.684 . . . . 0.0 108.8 175.535 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.71 158.59 35.87 Favored 'General case' 0 N--CA 1.478 0.952 0 O-C-N 119.303 -2.123 . . . . 0.0 110.401 166.77 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 67.71 172.91 0.27 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.947 1.299 . . . . 0.0 112.298 174.648 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.04 10.33 63.84 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 126.588 2.042 . . . . 0.0 112.045 165.794 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -74.07 100.76 3.69 Favored 'General case' 0 N--CA 1.453 -0.286 0 O-C-N 121.848 -0.795 . . . . 0.0 109.381 -173.331 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.444 1.5 p30 -145.61 35.69 1.06 Allowed 'General case' 0 C--N 1.341 0.224 0 N-CA-C 119.427 3.121 . . . . 0.0 119.427 173.872 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.74 -36.74 5.08 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 117.548 -1.215 . . . . 0.0 112.66 -179.628 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.84 23.19 0.25 Allowed 'General case' 0 CA--C 1.554 1.133 0 CA-C-N 120.321 1.419 . . . . 0.0 113.518 169.919 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.06 -126.48 42.17 Favored Glycine 0 CA--C 1.528 0.863 0 O-C-N 120.523 -1.361 . . . . 0.0 112.105 176.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 77.2 m -68.85 -15.89 63.62 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 176.127 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.4 m -86.5 -19.96 28.77 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.272 1.429 . . . . 0.0 111.731 171.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.87 -50.46 12.21 Favored 'General case' 0 N--CA 1.476 0.835 0 O-C-N 121.37 -0.831 . . . . 0.0 110.87 169.146 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -148.62 131.26 15.9 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.029 0.919 . . . . 0.0 112.742 -177.499 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.09 -131.37 0.61 Allowed Glycine 0 CA--C 1.536 1.348 0 C-N-CA 126.69 2.09 . . . . 0.0 111.499 177.386 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -79.0 178.74 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 124.13 3.22 . . . . 0.0 111.001 174.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.06 83.39 4.36 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.062 1.345 . . . . 0.0 108.66 172.448 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -48.25 150.13 1.33 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.326 1.85 . . . . 0.0 113.225 -179.448 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -146.97 114.21 4.26 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 174.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.76 -17.21 33.2 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.502 2.135 . . . . 0.0 113.008 175.677 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.74 -11.57 59.99 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 119.163 0.892 . . . . 0.0 113.044 175.701 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 t 53.23 46.9 25.55 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 126.008 1.723 . . . . 0.0 113.718 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.6 mtp85 -104.44 168.14 9.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 127.612 2.365 . . . . 0.0 111.857 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.59 151.46 44.63 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 122.129 0.966 . . . . 0.0 110.682 168.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.469 ' CG ' ' H ' ' A' ' 72' ' ' GLY . 85.7 t60 -66.64 179.0 1.13 Allowed 'General case' 0 CA--C 1.545 0.754 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.105 164.334 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.469 ' H ' ' CG ' ' A' ' 71' ' ' HIS . . . 113.16 -125.45 7.01 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 168.447 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.67 -50.68 0.8 Allowed Glycine 0 CA--C 1.539 1.566 0 CA-C-O 118.411 -1.216 . . . . 0.0 114.449 -178.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -80.01 -27.2 3.92 Favored 'Trans proline' 0 C--N 1.353 0.814 0 C-N-CA 122.884 2.389 . . . . 0.0 115.032 173.509 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptpt -121.75 -14.26 8.15 Favored 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 120.506 1.503 . . . . 0.0 113.904 169.094 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.494 ' HA ' ' HZ3' ' A' ' 128' ' ' LYS . 13.5 t70 -105.84 153.47 21.88 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.866 1.266 . . . . 0.0 110.613 170.514 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -79.91 -14.6 58.51 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 125.995 1.718 . . . . 0.0 112.977 -169.584 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -103.83 -87.13 0.44 Allowed 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -166.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 84.82 133.24 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.287 1.835 . . . . 0.0 110.991 -173.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -59.82 156.69 13.68 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 125.776 1.63 . . . . 0.0 113.717 168.421 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.3 p -62.47 -36.54 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 CA-C-N 119.41 1.004 . . . . 0.0 112.925 179.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.8 102.1 1.92 Allowed Glycine 0 C--N 1.342 0.889 0 N-CA-C 106.027 -2.829 . . . . 0.0 106.027 167.596 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -162.34 147.89 12.75 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.012 1.115 . . . . 0.0 114.012 173.574 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 98.2 mt -121.7 173.47 7.43 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.558 1.943 . . . . 0.0 106.266 162.817 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.19 -107.88 1.31 Allowed Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.028 0.823 . . . . 0.0 112.758 -174.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -138.44 157.59 45.92 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.606 0.762 . . . . 0.0 111.432 169.182 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -96.67 159.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 C-N-CA 125.233 1.413 . . . . 0.0 108.362 167.048 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.0 m -148.37 118.74 7.35 Favored 'General case' 0 N--CA 1.476 0.869 0 O-C-N 121.392 -0.817 . . . . 0.0 110.141 -174.977 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.33 142.61 28.25 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 125.587 1.555 . . . . 0.0 114.891 -169.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -78.09 148.63 34.13 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 113.189 -1.823 . . . . 0.0 109.005 166.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.505 ' HZ2' ' CG ' ' A' ' 92' ' ' ASP . 7.0 pttp -39.08 -32.25 0.09 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 127.536 2.334 . . . . 0.0 115.768 169.663 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.505 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 28.2 m-20 -80.01 4.53 16.73 Favored 'General case' 0 CA--C 1.55 0.968 0 CA-C-N 119.978 1.263 . . . . 0.0 111.911 -178.776 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.45 -0.16 53.45 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 127.18 2.324 . . . . 0.0 115.434 168.581 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -113.79 131.89 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 119.273 1.536 . . . . 0.0 113.591 -174.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.86 132.42 44.22 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.405 164.65 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -77.9 152.2 33.41 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.243 1.021 . . . . 0.0 108.492 168.645 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.252 0.4 OUTLIER -128.43 126.65 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-N 113.78 -1.555 . . . . 0.0 112.277 165.997 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.7 t -157.81 89.07 1.0 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.226 1.011 . . . . 0.0 112.767 -177.01 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 4.2 mp -126.18 161.52 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 125.725 1.61 . . . . 0.0 110.811 176.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -140.3 137.72 34.38 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.493 2.717 . . . . 0.0 106.359 167.525 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -151.98 133.1 14.34 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 118.722 0.692 . . . . 0.0 112.48 -171.077 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.7 p -101.39 51.19 0.85 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.702 0.801 . . . . 0.0 112.261 175.976 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 41.0 t -130.98 -48.23 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.376 1.07 . . . . 0.0 108.511 169.207 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.53 155.12 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 122.839 1.304 . . . . 0.0 111.998 170.299 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.7 p -155.76 155.2 32.64 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 125.559 1.544 . . . . 0.0 109.968 -174.782 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -82.23 55.2 2.77 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 120.699 -1.25 . . . . 0.0 110.365 177.744 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.3 t -108.2 37.55 2.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.098 1.759 . . . . 0.0 113.282 -172.088 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 88.79 -143.93 17.9 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-O 122.426 1.014 . . . . 0.0 111.833 169.34 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -66.8 -44.64 80.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 123.881 1.8 . . . . 0.0 112.039 -166.988 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -85.19 -7.38 59.07 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 112.886 -1.961 . . . . 0.0 110.884 -170.705 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.4 t -118.82 -122.18 0.29 Allowed 'General case' 0 CA--C 1.547 0.86 0 CA-C-O 116.233 -1.842 . . . . 0.0 110.268 173.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.259 7.1 pt -124.49 67.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 CA-C-N 124.233 3.197 . . . . 0.0 116.911 178.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.4 mm -127.42 132.29 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 165.578 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.72 5.33 50.84 Favored Glycine 0 N--CA 1.472 1.082 0 CA-C-N 119.724 1.147 . . . . 0.0 115.772 177.228 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -80.78 178.21 8.53 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 118.535 1.168 . . . . 0.0 113.173 -170.105 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 36.5 m -101.37 138.67 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 127.351 2.26 . . . . 0.0 110.285 -177.593 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -138.18 135.27 35.48 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 124.242 0.964 . . . . 0.0 109.097 165.764 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 p -120.35 136.6 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 126.571 1.948 . . . . 0.0 108.911 176.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 16.6 m -101.97 149.52 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 166.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.5 m-70 -117.89 155.58 29.91 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.092 1.357 . . . . 0.0 111.928 -171.404 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -81.32 -33.99 32.18 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.815 1.246 . . . . 0.0 111.465 -171.036 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mmmt -92.58 165.05 13.19 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-N 119.375 0.989 . . . . 0.0 113.059 173.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.98 149.68 22.52 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.25 1.02 . . . . 0.0 109.354 165.043 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -99.88 135.29 41.52 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 169.108 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -77.91 -8.88 58.7 Favored 'General case' 0 N--CA 1.48 1.047 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 171.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.4 mt 62.73 48.66 4.1 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 124.97 1.308 . . . . 0.0 109.843 173.485 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.26 8.35 78.31 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 115.997 -2.557 . . . . 0.0 118.002 167.153 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.494 ' HZ3' ' HA ' ' A' ' 76' ' ' ASP . 9.6 mttp -121.34 4.88 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 120.64 3.57 . . . . 0.0 120.64 -168.304 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.75 112.32 4.37 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 165.064 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -71.45 43.41 0.71 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 126.337 1.922 . . . . 0.0 114.55 -175.156 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -103.53 -77.05 0.57 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.828 1.651 . . . . 0.0 110.567 -174.446 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 174.49 -80.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 130.73 3.612 . . . . 0.0 105.494 -170.808 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -34.28 -54.47 0.51 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 128.528 2.731 . . . . 0.0 113.878 175.213 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -65.11 -5.44 6.62 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -169.565 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.8 t -126.09 -25.48 3.55 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 123.989 0.916 . . . . 0.0 111.984 165.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.0 tttt -54.21 -33.26 57.84 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.348 1.859 . . . . 0.0 111.531 168.604 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.0 p -110.99 -67.76 0.98 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 162.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.457 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 152.72 -23.67 0.82 Allowed Glycine 0 CA--C 1.534 1.23 0 C-N-CA 129.803 3.573 . . . . 0.0 112.746 -168.294 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 110.83 -8.6 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.646 1 C-N-CA 131.768 4.027 . . . . 0.0 113.057 176.183 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.59 -17.45 2.14 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 116.526 2.046 . . . . 0.0 116.526 -169.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.96 -135.37 28.03 Favored Glycine 0 CA--C 1.526 0.72 0 C-N-CA 124.529 1.062 . . . . 0.0 113.604 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.09 131.97 23.37 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 124.868 1.267 . . . . 0.0 111.677 -176.226 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -65.71 173.56 2.77 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-O 121.371 0.605 . . . . 0.0 109.438 169.243 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -150.08 -146.63 0.2 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.808 1.643 . . . . 0.0 107.268 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.59 150.66 2.64 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 123.018 1.39 . . . . 0.0 110.843 171.203 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 4.8 t -146.37 152.75 39.6 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 124.602 1.161 . . . . 0.0 109.3 -174.636 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.68 158.14 28.29 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 125.388 1.471 . . . . 0.0 114.028 -178.323 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -109.79 141.85 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.252 1.021 . . . . 0.0 109.335 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 15.0 mm -78.69 92.67 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 123.791 0.836 . . . . 0.0 111.493 -175.365 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -81.19 -175.83 50.37 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 125.003 1.287 . . . . 0.0 113.011 168.702 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 4.8 mp -136.19 138.7 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 O-C-N 121.015 -1.285 . . . . 0.0 110.412 -172.325 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -122.2 3.58 9.81 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.212 1.005 . . . . 0.0 113.331 171.281 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 . . . . . 0 C--O 1.238 0.45 0 C-N-CA 126.75 2.02 . . . . 0.0 112.402 176.557 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-O 121.272 0.558 . . . . 0.0 112.187 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 18.7 p -78.64 113.28 16.55 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.483 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptmm? -76.31 156.26 33.54 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.776 1.751 . . . . 0.0 112.081 172.042 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . 0.415 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -149.17 165.03 33.03 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.047 2.539 . . . . 0.0 110.416 172.318 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 p -148.81 151.82 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.579 1.552 . . . . 0.0 110.764 -165.461 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.08 138.92 27.0 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.419 1.088 . . . . 0.0 110.515 168.1 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.65 84.74 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.911 0.884 . . . . 0.0 110.393 -169.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.272 0.9 OUTLIER -85.14 67.27 10.12 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 122.573 1.178 . . . . 0.0 113.075 -178.103 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt -97.95 111.73 23.92 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.053 173.367 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . 0.419 ' O ' ' HE3' ' A' ' 9' ' ' LYS . . . -78.39 -103.24 0.2 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 171.831 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -139.38 109.67 6.52 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -167.856 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 51.07 -116.75 4.78 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.913 2.197 . . . . 0.0 112.01 -173.517 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.09 -11.39 27.1 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 124.997 3.798 . . . . 0.0 115.543 -167.606 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.7 t -92.14 94.94 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 123.049 1.404 . . . . 0.0 108.248 169.119 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.09 160.95 43.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.598 174.669 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.15 179.04 29.02 Favored Glycine 0 C--O 1.235 0.2 0 CA-C-O 123.034 1.352 . . . . 0.0 114.213 179.256 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -119.04 139.76 45.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.95 -1.625 . . . . 0.0 110.063 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -127.86 135.65 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 166.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -122.91 143.77 49.66 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 125.44 1.496 . . . . 0.0 110.067 169.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -124.06 130.26 52.26 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.283 1.433 . . . . 0.0 108.262 170.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.98 120.47 41.49 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 124.333 1.053 . . . . 0.0 108.556 169.543 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -122.42 137.11 54.98 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 122.406 1.098 . . . . 0.0 108.896 168.546 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -105.89 -21.15 13.23 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.741 1.216 . . . . 0.0 113.063 -175.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -160.84 121.93 2.93 Favored 'General case' 0 C--O 1.222 -0.367 0 C-N-CA 127.692 2.397 . . . . 0.0 108.667 -164.126 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.1 m -59.25 -41.89 89.83 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.816 2.046 . . . . 0.0 113.179 -171.325 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -82.77 -4.5 58.03 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.502 1.921 . . . . 0.0 113.594 176.338 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.69 -175.94 33.89 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.742 1.639 . . . . 0.0 112.049 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.9 166.65 24.84 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.83 2.353 . . . . 0.0 112.117 178.896 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -115.42 137.79 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 169.441 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.43 129.06 39.72 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.739 0.816 . . . . 0.0 110.555 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -111.46 137.17 45.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 127.211 2.204 . . . . 0.0 109.832 -176.146 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 31.3 p90 -156.27 155.86 33.04 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 124.599 1.16 . . . . 0.0 110.972 168.619 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.32 140.47 3.06 Favored Glycine 0 C--N 1.332 0.351 0 CA-C-O 121.396 0.442 . . . . 0.0 114.1 -169.786 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 51.5 p -118.19 134.05 55.35 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.201 1.0 . . . . 0.0 110.178 -177.338 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -124.85 116.97 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 124.44 1.096 . . . . 0.0 110.435 -176.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 25.1 tptt -95.19 152.52 18.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.609 1.164 . . . . 0.0 109.393 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.87 -17.81 58.61 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.485 1.517 . . . . 0.0 113.722 -179.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 10.5 mp -69.89 119.33 13.95 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 118.457 1.128 . . . . 0.0 109.041 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -67.54 159.01 30.63 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 166.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -49.66 145.43 5.11 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.659 1.984 . . . . 0.0 114.591 -174.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 115.69 171.44 16.45 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 122.5 1.056 . . . . 0.0 113.864 -178.454 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.488 ' H ' ' CD2' ' B' ' 42' ' ' LEU . 1.5 pt? -80.12 133.32 36.07 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.325 1.85 . . . . 0.0 111.522 -175.828 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -135.55 165.09 26.34 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 128.214 2.606 . . . . 0.0 108.964 -172.757 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.17 157.56 20.03 Favored Glycine 0 N--CA 1.482 1.713 0 C-N-CA 125.455 1.502 . . . . 0.0 114.705 -173.052 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -151.13 118.64 6.06 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.137 1.375 . . . . 0.0 113.243 -168.752 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . 0.403 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -154.97 144.22 21.11 Favored 'General case' 0 CA--C 1.555 1.172 0 O-C-N 119.778 -1.826 . . . . 0.0 113.189 178.886 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -94.21 125.56 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 126.035 1.734 . . . . 0.0 110.154 171.076 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.403 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 7.6 m-70 -75.76 166.55 23.36 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.585 1.954 . . . . 0.0 111.042 179.174 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -75.63 133.54 40.84 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 167.321 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 74.57 167.74 0.29 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 128.015 2.526 . . . . 0.0 115.536 -178.58 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.21 -2.08 38.56 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 127.57 2.51 . . . . 0.0 114.269 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . 0.403 ' HA ' ' CG2' ' A' ' 5' ' ' VAL 0.255 10.9 t0 -76.79 111.38 12.25 Favored 'General case' 0 CA--C 1.491 -1.303 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 165.023 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.457 HD21 ' N ' ' B' ' 53' ' ' ASN 0.3 0.1 OUTLIER -144.73 38.3 1.22 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-O 124.225 1.964 . . . . 0.0 113.264 168.738 . . . . . . . . 4 4 . 1 . 021 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.0 p -79.89 -34.03 39.44 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 112.093 -2.322 . . . . 0.0 111.852 -166.257 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.3 20.49 0.68 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 124.503 1.121 . . . . 0.0 110.605 163.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.34 -134.6 50.21 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 125.679 1.609 . . . . 0.0 112.136 -176.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 7.1 t -60.13 -8.43 2.44 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.305 1.842 . . . . 0.0 114.837 179.772 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.7 m -89.51 -18.92 25.73 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 126.528 1.931 . . . . 0.0 112.348 174.858 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 m -94.77 -170.24 2.18 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 123.767 0.827 . . . . 0.0 110.63 168.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 66.69 -96.06 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.661 1.984 . . . . 0.0 112.204 177.137 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.37 162.01 11.53 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 126.84 2.162 . . . . 0.0 110.015 -167.353 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 161.42 42.35 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 123.166 2.577 . . . . 0.0 112.164 -174.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -23.89 100.14 0.02 OUTLIER 'General case' 0 C--O 1.237 0.433 0 C-N-CA 129.436 3.094 . . . . 0.0 113.827 167.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . 0.41 ' CG ' ' HD3' ' B' ' 66' ' ' PRO . 3.1 t80 -55.5 127.52 30.07 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 123.681 1.705 . . . . 0.0 111.482 177.267 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 24.3 p-10 -103.07 39.38 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.42 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 -177.868 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . 0.41 ' HD3' ' CG ' ' B' ' 64' ' ' PHE . 75.4 Cg_endo -67.02 -14.01 42.02 Favored 'Trans proline' 0 C--N 1.36 1.133 0 C-N-CA 123.277 2.651 . . . . 0.0 112.666 -176.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.6 mt -75.23 -1.24 22.49 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.841 1.656 . . . . 0.0 112.189 175.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.5 t 62.3 58.91 1.67 Allowed 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.794 1.238 . . . . 0.0 113.132 167.495 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -152.82 175.1 13.26 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 114.799 1.407 . . . . 0.0 114.799 -167.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.53 168.66 19.45 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.108 0.956 . . . . 0.0 109.968 166.747 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.434 ' HE2' ' HA ' ' B' ' 125' ' ' ASP . 42.3 t60 -61.04 165.03 4.48 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 118.356 -0.831 . . . . 0.0 110.334 172.275 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 168.65 -169.67 41.83 Favored Glycine 0 N--CA 1.476 1.316 0 N-CA-C 117.533 1.773 . . . . 0.0 117.533 -172.947 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.78 -87.0 0.25 Allowed Glycine 0 CA--C 1.545 1.931 0 N-CA-C 121.112 3.205 . . . . 0.0 121.112 167.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -72.49 4.75 3.21 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 124.288 3.326 . . . . 0.0 114.459 -167.849 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . 0.27 0.0 OUTLIER -167.05 4.76 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 130.03 3.332 . . . . 0.0 112.804 175.398 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -128.16 138.54 52.53 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 126.79 2.036 . . . . 0.0 105.649 -179.496 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.82 -9.33 46.86 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 126.764 2.026 . . . . 0.0 114.844 -166.643 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -84.38 -84.61 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.911 0.778 . . . . 0.0 109.995 -175.667 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . 0.421 HH22 HG22 ' B' ' 104' ' ' ILE . 33.3 ttp85 78.84 102.45 0.07 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.77 2.028 . . . . 0.0 113.474 167.33 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 13.6 m170 -54.57 155.0 4.33 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 119.829 -1.794 . . . . 0.0 110.165 166.882 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -60.09 -30.41 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 119.708 1.14 . . . . 0.0 113.393 -169.612 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.38 -6.41 74.19 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-O 118.126 -1.375 . . . . 0.0 116.111 179.243 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -79.54 122.37 26.39 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 121.064 2.432 . . . . 0.0 109.902 -176.873 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -126.9 42.17 3.37 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 120.984 1.72 . . . . 0.0 113.455 177.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 60.25 -122.84 31.18 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.691 2.236 . . . . 0.0 118.691 166.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . 0.512 HD22 ' CD1' ' B' ' 126' ' ' LEU . 9.7 m120 -126.82 154.06 44.82 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 113.781 -1.209 . . . . 0.0 113.859 -169.091 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.2 m -130.77 125.55 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.432 1.493 . . . . 0.0 109.107 167.292 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 46.5 m -109.87 127.84 54.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.568 0.747 . . . . 0.0 109.045 -175.784 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.91 148.23 22.18 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.291 1.437 . . . . 0.0 114.078 -177.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -104.76 159.31 15.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.904 2.081 . . . . 0.0 110.154 167.145 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -71.35 8.44 1.04 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.583 2.068 . . . . 0.0 116.583 -168.679 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -76.7 -12.58 60.02 Favored 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 122.404 1.097 . . . . 0.0 108.9 164.221 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.93 40.42 7.1 Favored Glycine 0 C--N 1.337 0.601 0 C-N-CA 125.571 1.557 . . . . 0.0 110.412 -174.676 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.01 134.59 31.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.337 1.068 . . . . 0.0 113.384 177.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.04 120.35 40.29 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 162.728 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -115.43 140.39 49.18 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 122.365 1.079 . . . . 0.0 110.197 169.714 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.43 150.5 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-N 112.324 -2.216 . . . . 0.0 115.092 -169.395 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 p -153.01 119.47 5.59 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.28 1.032 . . . . 0.0 111.349 171.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.1 mt -145.07 159.35 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 128.321 2.649 . . . . 0.0 110.565 -170.186 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -140.67 140.96 35.06 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.162 1.785 . . . . 0.0 108.172 168.085 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.98 140.08 26.62 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.182 1.393 . . . . 0.0 111.253 -172.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.4 p -110.47 48.65 0.9 Allowed 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.664 0.987 . . . . 0.0 113.664 -175.442 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 33.0 m -148.84 -29.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 CA-C-O 117.997 -1.001 . . . . 0.0 113.144 167.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . 0.421 HG22 HH22 ' B' ' 79' ' ' ARG . 0.1 OUTLIER -76.88 154.11 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-N 121.164 1.802 . . . . 0.0 108.114 165.841 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 105' ' ' SER . . . . . 0.446 ' H ' ' HB3' ' B' ' 111' ' ' SER . 2.9 p -162.46 158.29 23.54 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 125.352 1.461 . . . . 0.0 109.116 -174.238 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -79.67 55.5 2.03 Favored 'General case' 0 CA--C 1.542 0.673 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 171.666 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 58.0 m -93.48 52.56 1.75 Allowed 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 124.245 1.018 . . . . 0.0 110.074 -173.24 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.87 -96.86 0.54 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 124.688 1.137 . . . . 0.0 111.413 -177.028 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -134.97 7.0 3.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 128.298 2.639 . . . . 0.0 110.596 179.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -79.43 -11.84 59.9 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.623 -1.298 . . . . 0.0 111.947 173.528 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 111' ' ' SER . . . . . 0.446 ' HB3' ' H ' ' B' ' 105' ' ' SER . 18.4 m -141.75 -98.69 0.13 Allowed 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 113.372 0.878 . . . . 0.0 113.372 -170.003 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.5 pt -119.56 164.19 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 120.744 -1.223 . . . . 0.0 109.376 168.257 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.9 mm 94.43 137.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 131.149 3.78 . . . . 0.0 105.772 -163.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.26 -15.0 12.94 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 117.809 -1.55 . . . . 0.0 116.569 177.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.5 mtt85 -87.01 -175.4 5.34 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 125.642 1.577 . . . . 0.0 110.147 177.334 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -140.31 126.9 20.27 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 119.382 0.992 . . . . 0.0 111.718 -174.114 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -95.08 141.64 28.48 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.937 1.295 . . . . 0.0 110.056 -177.516 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.43 136.0 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.235 1.014 . . . . 0.0 109.146 177.237 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -93.55 140.95 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-O 122.438 1.113 . . . . 0.0 110.454 170.208 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -130.97 165.51 23.0 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.147 1.779 . . . . 0.0 111.223 -170.706 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -84.07 -37.86 21.53 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -170.215 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 87.3 mttt -102.35 144.13 31.22 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 119.172 0.896 . . . . 0.0 112.369 -174.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.66 54.86 1.26 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.004 1.321 . . . . 0.0 112.33 168.853 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.29 -12.06 17.52 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.742 2.017 . . . . 0.0 114.524 -177.853 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . 0.434 ' HA ' ' HE2' ' B' ' 71' ' ' HIS . 20.9 t70 -65.25 -7.11 11.58 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 125.435 1.494 . . . . 0.0 114.637 -171.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . 0.512 ' CD1' HD22 ' B' ' 86' ' ' ASN . 0.0 OUTLIER -84.83 42.54 0.93 Allowed 'General case' 0 C--N 1.32 -0.685 0 O-C-N 119.383 -2.073 . . . . 0.0 114.789 179.168 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 63.14 8.41 23.45 Favored Glycine 0 N--CA 1.473 1.152 0 N-CA-C 117.401 1.72 . . . . 0.0 117.401 166.818 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 53.2 tttp -154.86 -59.25 0.11 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.54 1.136 . . . . 0.0 112.178 -167.889 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 37.99 -119.45 0.77 Allowed Glycine 0 CA--C 1.529 0.91 0 C-N-CA 126.071 1.796 . . . . 0.0 113.487 177.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -107.66 -22.81 7.15 Favored Glycine 0 CA--C 1.534 1.231 0 CA-C-O 117.75 -1.583 . . . . 0.0 116.9 -177.562 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -161.44 -178.08 6.4 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 121.22 2.51 . . . . 0.0 112.582 -172.073 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -47.49 -58.32 4.35 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 127.119 2.167 . . . . 0.0 113.128 -172.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -52.33 -21.01 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 115.37 1.618 . . . . 0.0 115.37 177.737 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 m -70.11 -27.33 64.5 Favored 'General case' 0 CA--C 1.549 0.905 0 O-C-N 119.644 -1.91 . . . . 0.0 112.526 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.5 t -79.67 -14.85 58.48 Favored 'General case' 0 N--CA 1.491 1.591 0 CA-C-N 119.853 1.206 . . . . 0.0 112.529 168.362 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mtpt -102.04 -91.44 0.33 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.285 1.834 . . . . 0.0 111.998 -177.853 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.2 p -74.88 -22.16 58.81 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 119.887 1.221 . . . . 0.0 113.986 178.532 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.96 3.46 62.02 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-O 115.497 -2.835 . . . . 0.0 111.145 -167.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 63.75 -68.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.167 2.587 . . . . 0.0 110.12 172.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 70.26 -15.56 0.34 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.689 2.796 . . . . 0.0 115.109 162.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.59 -53.34 4.51 Favored Glycine 0 N--CA 1.473 1.117 0 C-N-CA 126.936 2.207 . . . . 0.0 115.417 174.239 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.5 t -161.65 -166.1 1.42 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.685 0.794 . . . . 0.0 111.058 175.139 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . 0.441 ' N ' ' HE ' ' B' ' 143' ' ' ARG . 0.1 OUTLIER -132.22 142.87 49.59 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.376 1.87 . . . . 0.0 107.35 176.639 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -127.23 -105.37 0.32 Allowed 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.789 1.236 . . . . 0.0 109.663 175.667 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.87 161.85 26.45 Favored 'General case' 0 CA--C 1.544 0.718 0 CA-C-N 120.295 1.407 . . . . 0.0 113.9 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.5 p -152.83 142.74 22.15 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.699 1.6 . . . . 0.0 111.116 -169.141 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.04 126.61 1.78 Allowed Glycine 0 C--N 1.338 0.692 0 N-CA-C 115.86 1.104 . . . . 0.0 115.86 -169.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -79.01 144.97 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 123.81 0.844 . . . . 0.0 109.243 -179.735 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 26.4 mt -92.25 126.15 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 C-N-CA 124.622 1.169 . . . . 0.0 112.214 -179.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.92 171.99 14.04 Favored Glycine 0 CA--C 1.538 1.505 0 N-CA-C 117.214 1.646 . . . . 0.0 117.214 172.131 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -87.43 107.83 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.019 1.328 . . . . 0.0 112.564 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.415 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -79.69 -5.03 54.35 Favored 'General case' 0 CA--C 1.554 1.111 0 O-C-N 121.133 -0.979 . . . . 0.0 111.122 166.757 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 . . . . . 0 N--CA 1.47 0.529 0 C-N-CA 131.259 3.824 . . . . 0.0 111.103 172.05 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 CA-C-O 120.314 0.102 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.7 p -77.08 65.16 2.66 Favored 'General case' 0 CA--C 1.54 0.562 0 N-CA-C 116.414 2.005 . . . . 0.0 116.414 -165.846 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.279 0.0 OUTLIER -155.7 117.85 4.1 Favored 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 117.573 2.435 . . . . 0.0 117.573 168.072 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.1 156.77 36.02 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.062 2.545 . . . . 0.0 106.403 164.077 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 32.3 t -154.7 155.07 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 120.148 1.34 . . . . 0.0 114.248 -164.891 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.87 128.13 33.99 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 125.892 1.677 . . . . 0.0 110.285 168.045 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.05 92.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 127.154 2.181 . . . . 0.0 108.59 176.822 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -77.01 149.18 35.9 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 125.936 1.694 . . . . 0.0 112.624 -167.509 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -155.35 153.58 30.7 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.127 0.971 . . . . 0.0 111.84 171.012 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.4 -110.61 3.18 Favored Glycine 0 N--CA 1.466 0.684 1 N-CA-C 101.753 -4.539 . . . . 0.0 101.753 162.73 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . 0.276 0.3 OUTLIER -155.62 148.46 24.29 Favored 'General case' 0 N--CA 1.442 -0.86 0 C-N-CA 124.886 1.275 . . . . 0.0 108.959 162.143 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.23 -170.83 36.25 Favored Glycine 0 CA--C 1.54 1.624 0 N-CA-C 107.666 -2.173 . . . . 0.0 107.666 -163.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.74 37.68 0.43 Allowed 'Trans proline' 0 CA--C 1.545 1.063 1 C-N-CA 125.459 4.106 . . . . 0.0 114.308 -171.802 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -108.61 122.44 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.062 1.745 . . . . 0.0 108.433 172.672 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.92 166.49 25.84 Favored 'General case' 0 CA--C 1.519 -0.25 0 C-N-CA 125.52 1.528 . . . . 0.0 110.262 179.222 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 131.81 3.0 Favored Glycine 0 C--O 1.224 -0.521 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.986 167.732 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.63 131.23 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 O-C-N 121.511 -0.994 . . . . 0.0 109.266 168.416 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.2 mm -131.06 122.62 52.1 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 167.81 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -112.25 141.4 46.01 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 125.481 1.512 . . . . 0.0 111.813 169.054 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -116.93 108.76 16.19 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.906 1.682 . . . . 0.0 110.357 176.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HB2' ' CH2' ' A' ' 32' ' ' TRP . 0.0 OUTLIER -87.76 118.94 27.61 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 127.073 2.149 . . . . 0.0 109.978 169.62 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -148.69 140.29 23.53 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.678 0.791 . . . . 0.0 109.321 -179.395 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.82 -28.25 14.34 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -169.727 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.75 -139.86 0.1 Allowed 'General case' 0 CA--C 1.556 1.181 0 C-N-CA 125.494 1.518 . . . . 0.0 111.41 170.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.0 p -113.16 -11.73 13.24 Favored 'General case' 0 N--CA 1.482 1.14 0 O-C-N 118.987 -2.321 . . . . 0.0 115.758 -170.371 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -128.2 -16.67 4.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.453 1.901 . . . . 0.0 112.882 -177.579 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 171.08 48.05 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.548 1.547 . . . . 0.0 112.446 177.741 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -85.13 140.42 7.66 Favored 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 122.268 1.979 . . . . 0.0 111.856 -169.26 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -101.6 132.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.703 1.201 . . . . 0.0 109.487 -173.137 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 ttmp? -92.37 126.21 37.35 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.832 1.253 . . . . 0.0 109.178 169.344 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.8 t -110.19 127.78 66.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 126.069 1.748 . . . . 0.0 109.581 177.753 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.41 ' CH2' ' HB2' ' A' ' 21' ' ' GLU . 6.0 p90 -135.92 159.51 41.46 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.172 0.989 . . . . 0.0 111.434 170.342 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.64 -176.72 27.31 Favored Glycine 0 C--O 1.222 -0.651 0 O-C-N 121.718 -0.614 . . . . 0.0 114.041 -173.192 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.69 141.69 13.25 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.752 0.821 . . . . 0.0 111.543 -172.774 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mp -113.7 118.54 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 126.462 1.905 . . . . 0.0 109.315 -178.503 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -115.81 128.63 55.98 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 110.244 -171.606 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.23 6.34 9.02 Favored Glycine 0 N--CA 1.477 1.433 0 C-N-CA 125.568 1.556 . . . . 0.0 114.964 -177.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 31.6 mt -80.95 157.84 25.42 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.58 1.552 . . . . 0.0 111.609 173.599 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.9 t -75.41 151.95 38.07 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 163.398 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.58 147.05 23.26 Favored 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.593 1.088 . . . . 0.0 112.242 170.768 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 111.65 -175.74 17.67 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.854 1.216 . . . . 0.0 113.453 -174.791 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.5 mt -77.27 154.39 33.0 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.595 1.158 . . . . 0.0 112.144 -174.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -153.11 123.45 7.11 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 127.077 2.151 . . . . 0.0 110.13 -171.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.85 151.72 47.96 Favored Glycine 0 N--CA 1.474 1.218 0 CA-C-N 120.167 1.349 . . . . 0.0 112.439 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.32 0.0 OUTLIER -146.19 140.2 26.44 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 166.119 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.401 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -148.51 153.54 38.59 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 120.998 -1.064 . . . . 0.0 112.031 -166.63 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 m -80.0 152.54 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 122.698 0.399 . . . . 0.0 110.526 168.109 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -93.98 167.98 11.25 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.052 1.741 . . . . 0.0 113.297 175.374 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -65.96 87.77 0.1 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.511 3.124 . . . . 0.0 109.596 170.115 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 74.2 177.96 0.22 Allowed 'General case' 0 C--N 1.347 0.491 0 CA-C-O 123.072 1.415 . . . . 0.0 112.848 168.884 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -95.23 -4.28 61.22 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 125.435 1.493 . . . . 0.0 111.143 168.128 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -66.98 64.79 0.06 Allowed 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 128.844 2.858 . . . . 0.0 109.817 169.261 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 167.53 -39.02 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.505 2.722 . . . . 0.0 114.714 179.364 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.36 0.5 OUTLIER 55.02 -58.48 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 130.303 3.441 . . . . 0.0 116.327 -174.829 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -68.47 4.22 1.45 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.264 1.426 . . . . 0.0 113.916 179.746 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.89 -126.36 36.71 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 124.91 1.243 . . . . 0.0 111.394 171.023 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.66 -8.48 0.39 Allowed 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 117.302 2.334 . . . . 0.0 117.302 -171.753 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.9 t -107.31 -2.13 20.99 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.544 1.52 . . . . 0.0 114.815 171.522 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.6 m -119.01 -37.83 3.16 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.641 1.576 . . . . 0.0 112.699 173.212 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.57 170.87 15.35 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.2 1.8 . . . . 0.0 110.869 175.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -109.8 -69.81 0.63 Allowed Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.549 1.38 . . . . 0.0 116.549 -168.637 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -87.07 -174.16 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.47 1 C-N-CA 125.473 4.115 . . . . 0.0 114.234 -169.407 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -104.01 132.38 50.32 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 127.666 2.386 . . . . 0.0 111.781 -175.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -46.9 114.11 0.78 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.579 1.552 . . . . 0.0 111.484 168.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 54.0 p30 -112.3 32.04 0.11 Allowed Pre-proline 0 CA--C 1.555 1.148 0 N-CA-C 116.734 2.124 . . . . 0.0 116.734 -167.944 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -56.63 -23.12 47.22 Favored 'Trans proline' 0 C--N 1.354 0.86 0 C-N-CA 124.915 3.743 . . . . 0.0 117.319 -164.957 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -78.39 -0.41 29.02 Favored 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 174.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.7 t 66.58 55.5 0.79 Allowed 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 126.886 2.074 . . . . 0.0 110.318 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -143.36 170.99 14.74 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -165.93 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.506 ' HZ1' ' CD ' ' A' ' 78' ' ' GLU 0.31 0.0 OUTLIER -85.43 -178.64 6.76 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.365 1.866 . . . . 0.0 113.514 172.79 . . . . . . . . 4 4 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.42 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 78.2 t60 -99.42 139.78 34.58 Favored 'General case' 0 C--O 1.22 -0.487 0 C-N-CA 125.876 1.67 . . . . 0.0 112.747 -170.806 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.89 -143.95 11.38 Favored Glycine 0 C--N 1.34 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 113.902 173.808 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.06 -75.93 0.21 Allowed Glycine 0 CA--C 1.535 1.293 0 N-CA-C 118.594 2.198 . . . . 0.0 118.594 -175.989 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -70.85 -11.73 29.82 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.954 2.436 . . . . 0.0 113.054 -171.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -130.05 -0.78 4.67 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.684 1.593 . . . . 0.0 111.238 168.25 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.73 122.97 25.37 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 124.053 1.882 . . . . 0.0 111.801 -167.564 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.1 -27.77 69.62 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 129.815 3.246 . . . . 0.0 111.717 169.115 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.506 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 51.8 mm-40 -88.31 76.35 8.38 Favored 'General case' 0 C--O 1.214 -0.776 0 C-N-CA 126.319 1.848 . . . . 0.0 108.192 177.613 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.6 ttt180 -111.51 110.64 21.17 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 129.599 3.16 . . . . 0.0 109.022 -178.464 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -59.95 159.9 8.57 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 119.385 0.993 . . . . 0.0 112.597 169.925 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 m -43.1 -57.37 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -173.161 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.2 31.53 8.54 Favored Glycine 0 N--CA 1.472 1.067 0 C-N-CA 125.064 1.316 . . . . 0.0 113.298 172.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -76.94 121.97 24.21 Favored 'General case' 0 C--O 1.237 0.408 0 O-C-N 120.942 -1.328 . . . . 0.0 108.253 169.744 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -95.76 176.82 5.99 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 112.854 -1.975 . . . . 0.0 109.149 167.525 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.73 23.99 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 124.305 0.955 . . . . 0.0 113.371 -175.341 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -83.9 126.19 32.74 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 121.675 -0.897 . . . . 0.0 108.91 167.843 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.98 170.59 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 164.235 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 t -145.02 127.73 16.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 124.683 1.193 . . . . 0.0 109.751 174.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.2 144.85 26.64 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 113.183 0.809 . . . . 0.0 113.183 174.417 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -67.47 170.96 6.65 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.191 1.796 . . . . 0.0 110.946 168.528 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.76 -32.15 29.61 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.753 1.221 . . . . 0.0 112.854 168.527 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -73.41 -15.49 61.35 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.938 1.695 . . . . 0.0 112.283 177.123 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.22 14.47 64.13 Favored Glycine 0 CA--C 1.527 0.808 0 O-C-N 120.832 -1.167 . . . . 0.0 113.43 179.167 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.6 p -96.71 125.22 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 124.226 1.011 . . . . 0.0 109.916 168.209 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.69 122.0 43.09 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 168.229 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -88.99 145.29 25.59 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 123.089 1.423 . . . . 0.0 110.145 -179.314 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.77 125.69 74.56 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.002 172.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.4 m -155.13 85.77 1.09 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.126 1.77 . . . . 0.0 108.67 -173.121 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 12.9 mt -140.13 154.64 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 127.308 2.243 . . . . 0.0 111.53 -169.208 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -140.91 144.86 35.44 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.593 1.557 . . . . 0.0 108.233 168.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.98 144.84 21.59 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.624 1.169 . . . . 0.0 113.386 -166.821 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 55.2 p -116.7 49.37 1.17 Allowed 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -179.687 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.2 m -149.06 16.23 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 176.055 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.35 168.69 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 120.49 -1.381 . . . . 0.0 111.037 171.295 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.537 ' H ' ' HB3' ' A' ' 111' ' ' SER . 86.3 p -154.91 161.24 41.49 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.265 -0.897 . . . . 0.0 112.602 169.144 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -92.53 50.89 1.66 Allowed 'General case' 0 CA--C 1.542 0.636 0 O-C-N 121.15 -0.969 . . . . 0.0 111.44 175.732 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.1 t -87.85 -40.91 13.62 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.436 1.094 . . . . 0.0 112.925 178.725 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.46 12.27 38.95 Favored Glycine 0 N--CA 1.478 1.494 0 N-CA-C 115.535 0.974 . . . . 0.0 115.535 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -89.54 -92.71 0.12 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.581 2.352 . . . . 0.0 111.006 -179.672 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.3 m170 -96.65 -24.96 15.75 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 126.585 1.954 . . . . 0.0 109.291 174.283 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.537 ' HB3' ' H ' ' A' ' 105' ' ' SER . 53.4 m -79.16 -142.14 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.07 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -168.001 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.7 pt -94.98 -21.46 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -166.414 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mm -63.75 141.97 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.811 1.187 . . . . 0.0 109.666 170.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.13 28.08 62.93 Favored Glycine 0 CA--C 1.503 -0.663 0 CA-C-O 116.701 -2.166 . . . . 0.0 113.446 177.475 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 84.7 mtt-85 -129.78 178.31 6.61 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.532 1.666 . . . . 0.0 108.515 171.741 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 89.4 m -117.19 145.36 43.91 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 119.328 0.967 . . . . 0.0 110.02 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.1 tp -108.31 134.14 51.55 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 119.074 0.852 . . . . 0.0 109.511 169.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -110.33 144.62 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.822 1.649 . . . . 0.0 110.643 172.619 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.99 142.24 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.903 1.281 . . . . 0.0 110.226 170.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.401 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 44.9 m-70 -119.2 147.14 44.56 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.656 1.583 . . . . 0.0 114.563 -166.523 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -85.34 -17.29 37.23 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -166.73 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.9 169.48 8.89 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 120.087 -1.633 . . . . 0.0 111.082 172.718 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.6 133.6 55.84 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 168.727 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 40.2 t0 -83.36 154.03 24.26 Favored 'General case' 0 CA--C 1.54 0.571 0 O-C-N 123.272 0.357 . . . . 0.0 110.293 169.435 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -75.58 -50.9 14.16 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 165.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.2 mt 94.79 63.08 0.0 OUTLIER 'General case' 0 C--O 1.222 -0.358 0 C-N-CA 129.296 3.039 . . . . 0.0 109.299 -178.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.7 -25.63 16.58 Favored Glycine 0 N--CA 1.481 1.635 0 N-CA-C 117.069 1.588 . . . . 0.0 117.069 167.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -118.35 -144.96 0.37 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.181 1.792 . . . . 0.0 110.897 172.148 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.08 7.97 60.62 Favored Glycine 0 CA--C 1.536 1.352 0 O-C-N 120.356 -1.465 . . . . 0.0 113.23 -168.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.47 31.41 68.32 Favored Glycine 0 N--CA 1.472 1.057 0 N-CA-C 116.996 1.558 . . . . 0.0 116.996 167.802 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -150.1 172.6 15.01 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 119.856 1.828 . . . . 0.0 113.108 -173.514 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -47.91 -58.69 4.07 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.953 1.701 . . . . 0.0 112.938 176.599 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -65.1 -17.01 64.1 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.165 0.986 . . . . 0.0 113.433 -173.246 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.5 p -53.52 -45.74 69.85 Favored 'General case' 0 N--CA 1.469 0.494 0 O-C-N 120.824 -1.173 . . . . 0.0 113.089 174.245 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -96.31 -6.86 36.79 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.875 0.87 . . . . 0.0 112.018 -178.861 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.93 -48.2 5.52 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.708 1.14 . . . . 0.0 112.618 176.605 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 19.9 p -114.61 -25.14 8.44 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 174.867 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.42 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 121.97 -30.73 5.18 Favored Glycine 0 C--O 1.228 -0.226 0 C-N-CA 126.09 1.805 . . . . 0.0 112.356 -168.061 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 114.08 2.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 131.601 3.96 . . . . 0.0 112.645 -174.566 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.5 1.27 0.02 OUTLIER 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 120.251 3.426 . . . . 0.0 120.251 -168.692 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.59 -32.68 0.17 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 120.985 3.154 . . . . 0.0 120.985 165.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.0 m -167.4 141.36 3.64 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 120.272 2.036 . . . . 0.0 111.581 -172.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.53 134.68 54.83 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.741 1.155 . . . . 0.0 112.214 178.319 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -110.36 -22.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.08 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.71 161.19 13.25 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 119.95 1.25 . . . . 0.0 112.46 -177.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.9 p -155.47 166.76 32.55 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.332 1.453 . . . . 0.0 112.763 172.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.44 136.84 4.83 Favored Glycine 0 N--CA 1.48 1.579 0 C-N-CA 125.287 1.422 . . . . 0.0 113.583 177.168 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -83.6 133.48 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.469 1.108 . . . . 0.0 110.641 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.49 110.13 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.023 0.929 . . . . 0.0 111.301 -172.016 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.74 170.14 13.31 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 122.76 1.2 . . . . 0.0 113.916 173.268 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.0 pp -91.25 164.03 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.672 1.189 . . . . 0.0 112.137 -174.258 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.48 ' HA ' ' CD1' ' B' ' 50' ' ' PHE . . . -155.53 -20.61 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 167.072 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.476 0.832 0 C-N-CA 124.521 1.128 . . . . 0.0 110.166 170.366 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.7 t -80.26 118.78 22.23 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 167.507 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.87 121.37 45.09 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -178.885 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.03 166.2 11.38 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.861 1.264 . . . . 0.0 110.794 168.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.74 146.07 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 125.477 1.511 . . . . 0.0 111.903 -166.722 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.0 101.2 3.99 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 123.756 0.822 . . . . 0.0 111.269 169.621 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -84.02 95.5 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 168.031 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.4 mt -81.34 140.25 34.88 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 122.784 0.434 . . . . 0.0 110.78 -177.043 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 9.0 mtpp -149.24 179.26 8.05 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 121.166 -0.959 . . . . 0.0 112.81 170.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.43 -70.79 0.29 Allowed Glycine 0 C--N 1.335 0.505 0 C-N-CA 126.393 1.949 . . . . 0.0 111.238 178.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -87.09 78.83 8.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.78 0.8 . . . . 0.0 112.715 -165.373 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 49.09 -104.22 0.09 OUTLIER Glycine 0 CA--C 1.534 1.249 0 C-N-CA 126.565 2.031 . . . . 0.0 112.623 171.514 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -80.01 -1.2 11.24 Favored 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 125.181 3.921 . . . . 0.0 114.176 -179.24 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.49 134.62 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 119.715 1.143 . . . . 0.0 110.8 171.84 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -135.51 161.92 34.13 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 125.843 1.657 . . . . 0.0 109.939 168.231 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.5 144.8 16.44 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 167.205 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -142.18 102.04 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -122.4 137.6 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 C-N-CA 123.957 0.903 . . . . 0.0 109.394 -179.76 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.36 152.41 34.99 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.058 2.143 . . . . 0.0 109.147 172.131 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -138.89 89.29 2.35 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.215 1.806 . . . . 0.0 107.66 -174.81 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.8 120.31 33.9 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 118.084 0.402 . . . . 0.0 110.07 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -112.52 141.46 46.25 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 122.578 1.18 . . . . 0.0 112.18 174.41 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.409 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -86.36 -26.8 24.64 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 126.571 1.949 . . . . 0.0 114.18 -179.66 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.409 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 5.8 mp0 -122.94 -174.11 2.86 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.235 2.214 . . . . 0.0 109.885 174.506 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.2 m -98.52 -14.5 19.97 Favored 'General case' 0 N--CA 1.481 1.099 0 O-C-N 120.54 -1.35 . . . . 0.0 111.639 167.08 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -139.47 105.55 5.22 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.198 2.599 . . . . 0.0 107.181 169.34 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.61 -168.42 41.49 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 126.066 1.794 . . . . 0.0 110.637 -170.784 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -85.57 150.61 10.19 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.529 2.153 . . . . 0.0 111.848 -179.268 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 10.2 t -119.36 129.32 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.135 1.374 . . . . 0.0 110.111 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.6 ttmm -93.53 120.89 34.35 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.091 0.948 . . . . 0.0 110.514 174.47 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.3 t -106.25 112.54 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 C-N-CA 126.321 1.848 . . . . 0.0 108.046 -171.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -137.74 161.18 37.22 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -177.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 136.62 -139.72 10.87 Favored Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.533 1.539 . . . . 0.0 111.351 175.62 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 47.3 p -156.47 156.73 34.24 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 114.711 1.375 . . . . 0.0 114.711 -174.862 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 24.7 mm -123.43 126.64 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 168.692 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . 0.282 3.5 ptmt -140.33 157.21 45.91 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 115.313 1.597 . . . . 0.0 115.313 -177.534 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.23 6.4 33.9 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 127.103 2.287 . . . . 0.0 111.916 -167.872 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.5 mt -94.79 172.27 8.27 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.992 1.317 . . . . 0.0 111.769 -172.751 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.27 150.65 36.95 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 165.427 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -53.3 -0.27 0.02 OUTLIER 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 129.796 3.238 . . . . 0.0 115.86 170.63 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -69.46 177.28 29.96 Favored Glycine 0 CA--C 1.537 1.43 0 O-C-N 120.149 -1.594 . . . . 0.0 113.605 169.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mp -78.37 160.0 28.04 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.381 1.472 . . . . 0.0 108.727 168.452 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -149.64 109.72 4.13 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.761 2.424 . . . . 0.0 109.857 -170.155 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.56 130.22 17.69 Favored Glycine 0 N--CA 1.477 1.37 0 CA-C-N 119.938 1.244 . . . . 0.0 111.864 176.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -125.62 137.73 53.89 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 120.151 1.976 . . . . 0.0 113.419 174.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.86 144.49 29.33 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.201 -0.937 . . . . 0.0 113.325 -176.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -81.27 136.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 166.075 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -74.74 168.4 19.92 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.826 1.25 . . . . 0.0 110.833 175.619 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.1 pm0 -59.61 -14.83 15.07 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -169.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . 0.48 ' CD1' ' HA ' ' A' ' 152' ' ' ALA . 31.3 m-85 -169.83 -179.26 3.21 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 129.147 2.979 . . . . 0.0 108.216 -168.849 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -125.92 11.32 7.39 Favored Glycine 0 N--CA 1.475 1.291 0 C-N-CA 125.505 1.526 . . . . 0.0 113.89 179.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -73.5 45.02 0.17 Allowed 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.755 1.222 . . . . 0.0 110.347 167.076 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -173.55 55.72 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 123.693 1.711 . . . . 0.0 114.726 -162.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 1.1 t -76.62 13.59 0.96 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.592 1.957 . . . . 0.0 114.492 -179.647 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -113.8 3.16 15.39 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 115.223 1.564 . . . . 0.0 115.223 -170.905 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.33 -117.0 10.16 Favored Glycine 0 CA--C 1.527 0.838 0 O-C-N 121.343 -0.848 . . . . 0.0 111.495 174.733 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.7 p -51.46 -20.01 1.65 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.493 1.517 . . . . 0.0 115.043 174.334 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 60.0 m -104.02 -4.6 23.11 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.171 1.388 . . . . 0.0 112.693 -177.051 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m 168.08 106.37 0.01 OUTLIER 'General case' 0 C--O 1.235 0.299 0 C-N-CA 128.638 2.775 . . . . 0.0 106.401 177.033 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.48 98.49 0.19 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.815 2.046 . . . . 0.0 109.895 173.509 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -62.92 123.17 29.64 Favored Glycine 0 CA--C 1.543 1.843 0 CA-C-O 116.943 -2.032 . . . . 0.0 111.785 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.48 59.67 7.54 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 124.631 3.554 . . . . 0.0 116.632 -165.057 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.296 11.9 p80 52.7 59.01 4.78 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.19 2.596 . . . . 0.0 113.821 177.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . 0.413 ' CG ' ' N ' ' B' ' 65' ' ' ASN . 22.9 t80 -50.25 165.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 128.243 2.617 . . . . 0.0 114.938 177.553 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . 0.413 ' N ' ' CG ' ' B' ' 64' ' ' PHE . 1.0 OUTLIER -100.19 60.12 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.425 0 C-N-CA 131.296 3.838 . . . . 0.0 114.058 -170.078 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.02 -26.59 66.01 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.747 2.298 . . . . 0.0 113.764 -176.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.34 -2.49 58.63 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 126.627 1.971 . . . . 0.0 113.165 172.696 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.5 t 59.43 49.75 8.36 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.564 1.946 . . . . 0.0 112.447 -173.201 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -117.17 170.41 8.69 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.264 1.209 . . . . 0.0 114.264 -179.607 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.18 164.82 26.13 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-O 122.75 1.262 . . . . 0.0 109.325 166.29 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.547 ' CG ' ' H ' ' B' ' 72' ' ' GLY . 83.4 t60 -67.36 -176.17 0.56 Allowed 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.223 167.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . 0.547 ' H ' ' CG ' ' B' ' 71' ' ' HIS . . . 115.17 -128.93 8.32 Favored Glycine 0 CA--C 1.502 -0.723 0 N-CA-C 115.252 0.861 . . . . 0.0 115.252 164.305 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.05 -76.32 0.34 Allowed Glycine 0 CA--C 1.531 1.061 0 CA-C-O 118.002 -1.443 . . . . 0.0 111.749 -169.586 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.64 10.07 0.23 Allowed 'Trans proline' 0 CA--C 1.547 1.134 0 C-N-CA 124.302 3.335 . . . . 0.0 116.614 -178.766 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.5 tptm -166.07 -30.61 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.264 1.426 . . . . 0.0 112.48 -168.427 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -125.03 119.12 27.79 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.579 1.552 . . . . 0.0 108.148 167.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -46.31 -17.86 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 130.156 3.383 . . . . 0.0 116.418 -174.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -85.36 -79.61 0.23 Allowed 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -169.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . 0.486 ' HB3' HH11 ' B' ' 79' ' ' ARG . 1.1 ttp-105 78.42 110.71 0.07 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.734 1.614 . . . . 0.0 109.731 177.199 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -50.08 152.17 1.76 Allowed 'General case' 0 CA--C 1.549 0.937 0 O-C-N 120.566 -1.334 . . . . 0.0 113.494 172.224 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.7 t -52.82 -37.74 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 123.966 0.906 . . . . 0.0 112.434 176.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.78 96.79 1.21 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 108.264 -1.934 . . . . 0.0 108.264 167.345 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -156.2 146.29 21.36 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.96 1.304 . . . . 0.0 113.446 171.249 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 48.2 mt -130.82 167.06 19.52 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.203 1.801 . . . . 0.0 106.981 166.802 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -104.99 -161.82 23.8 Favored Glycine 0 N--CA 1.475 1.247 0 C-N-CA 124.67 1.128 . . . . 0.0 112.593 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -79.37 164.63 23.89 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 -177.283 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 p -125.99 157.29 36.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 C-N-CA 129.0 2.92 . . . . 0.0 108.524 166.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -135.15 133.72 39.44 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.068 0.947 . . . . 0.0 109.799 -177.205 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.05 158.49 15.41 Favored 'General case' 0 C--O 1.222 -0.347 0 N-CA-C 114.065 1.135 . . . . 0.0 114.065 -172.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -97.63 155.47 16.97 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.645 1.578 . . . . 0.0 108.718 166.406 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 6.2 pttm -47.2 -25.32 0.89 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 128.936 2.894 . . . . 0.0 115.249 -177.5 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.67 3.23 10.07 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.319 1.448 . . . . 0.0 110.986 178.294 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.18 2.42 60.68 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 129.765 3.555 . . . . 0.0 113.726 172.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.2 p -114.64 131.92 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-N 119.937 1.869 . . . . 0.0 114.889 -168.36 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.37 128.8 44.94 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.003 -1.453 . . . . 0.0 108.728 166.236 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -82.27 146.33 29.51 Favored 'General case' 0 N--CA 1.46 0.073 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 168.005 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.263 0.3 OUTLIER -129.36 135.62 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 114.289 -1.323 . . . . 0.0 114.252 166.285 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 2.9 p -157.2 57.13 0.52 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 125.591 1.556 . . . . 0.0 110.759 -169.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.3 mt -109.04 166.55 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 127.654 2.381 . . . . 0.0 111.593 -169.746 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -148.39 149.82 32.43 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 127.753 2.421 . . . . 0.0 109.081 171.881 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -146.63 145.46 30.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.36 1.464 . . . . 0.0 110.108 172.051 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.8 p -118.61 58.6 0.83 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.94 2.096 . . . . 0.0 113.041 -168.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 5.9 p -159.34 -37.18 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 113.27 0.841 . . . . 0.0 113.27 172.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.69 166.79 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-O 121.327 0.584 . . . . 0.0 110.773 171.444 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 36.8 m -156.57 175.8 13.55 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 120.752 -1.218 . . . . 0.0 112.615 178.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.6 mp -92.61 76.35 5.02 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.664 1.586 . . . . 0.0 107.448 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.27 122.7 32.3 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.359 1.463 . . . . 0.0 108.077 -176.409 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.99 59.68 4.97 Favored Glycine 0 N--CA 1.471 1.021 0 C-N-CA 125.152 1.358 . . . . 0.0 112.976 -169.721 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -156.26 -76.62 0.09 Allowed 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 124.467 1.107 . . . . 0.0 110.347 -168.704 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 m170 -129.66 4.88 5.06 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 126.979 2.111 . . . . 0.0 112.559 -167.625 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.6 -151.92 0.47 Allowed 'General case' 0 CA--C 1.555 1.173 0 C-N-CA 127.651 2.381 . . . . 0.0 112.835 -166.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.8 pt -95.88 -5.35 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 118.718 -2.488 . . . . 0.0 115.657 -177.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 4.2 mm -67.4 129.28 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 165.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 66.41 51.25 44.33 Favored Glycine 0 C--O 1.225 -0.439 0 CA-C-O 117.854 -1.526 . . . . 0.0 112.541 178.043 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 25.7 mtt180 -129.19 145.61 51.28 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 118.346 1.073 . . . . 0.0 110.095 167.332 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 24.6 m -86.86 108.91 18.97 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 124.378 1.071 . . . . 0.0 109.628 -171.886 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 14.6 tp -91.6 125.07 36.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 120.441 1.473 . . . . 0.0 110.854 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -110.82 142.27 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.584 1.553 . . . . 0.0 110.315 170.424 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 59.0 t -112.74 144.07 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 165.338 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -109.76 160.9 15.93 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 126.584 1.953 . . . . 0.0 112.182 -172.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.265 1.8 pp20? -82.43 -17.77 44.2 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -172.09 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -113.97 172.87 6.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 176.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.16 164.31 1.77 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 124.475 1.11 . . . . 0.0 109.899 166.789 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.2 p30 -113.66 147.12 38.7 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 123.237 1.494 . . . . 0.0 112.531 170.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -86.86 -22.69 25.62 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.134 1.374 . . . . 0.0 111.077 171.749 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 54.9 mt 71.41 -29.63 0.2 Allowed 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 128.765 2.826 . . . . 0.0 114.503 169.506 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -159.52 -47.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.701 0 CA-C-N 120.844 1.657 . . . . 0.0 114.594 174.052 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.08 100.21 2.9 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 117.254 2.316 . . . . 0.0 117.254 -168.465 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.17 -76.84 1.34 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 107.131 -2.388 . . . . 0.0 107.131 166.687 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -179.52 27.83 0.05 OUTLIER Glycine 0 CA--C 1.532 1.103 0 C-N-CA 126.382 1.944 . . . . 0.0 112.956 175.946 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -146.34 172.84 12.89 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.998 1.719 . . . . 0.0 111.08 -167.309 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -64.58 -63.06 1.22 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 110.814 -170.453 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.18 -23.64 36.39 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 128.935 2.894 . . . . 0.0 111.916 -173.558 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 52.2 m -53.58 -49.82 66.93 Favored 'General case' 0 N--CA 1.462 0.14 0 C-N-CA 123.721 0.808 . . . . 0.0 112.425 168.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 44.2 p -91.21 -34.5 14.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.158 1.383 . . . . 0.0 110.699 -174.375 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -81.9 -31.74 31.29 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.143 2.177 . . . . 0.0 113.085 -171.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.8 p -125.24 -93.3 0.5 Allowed 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 169.281 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -174.0 22.22 0.06 OUTLIER Glycine 0 CA--C 1.53 1.019 0 C-N-CA 128.647 3.022 . . . . 0.0 111.58 169.688 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 56.67 4.04 0.14 Allowed 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 127.83 2.452 . . . . 0.0 116.545 -169.307 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.98 -5.88 0.03 OUTLIER 'General case' 0 CA--C 1.557 1.226 0 N-CA-C 119.865 3.284 . . . . 0.0 119.865 -168.337 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 88.12 -165.95 34.85 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.718 1.628 . . . . 0.0 113.661 -176.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 18.7 t -66.86 160.61 25.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 122.14 0.971 . . . . 0.0 111.284 173.598 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.7 ptt85 -67.38 164.16 19.19 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 122.356 1.074 . . . . 0.0 111.684 169.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.316 2.9 pp -135.55 -134.7 0.15 Allowed 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 104.229 -2.508 . . . . 0.0 104.229 160.175 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.75 154.88 8.41 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-N 120.536 1.516 . . . . 0.0 114.678 -178.697 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.1 t -151.0 143.94 24.58 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.658 1.983 . . . . 0.0 111.212 -172.677 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.29 144.25 9.51 Favored Glycine 0 N--CA 1.477 1.39 0 C-N-CA 125.507 1.527 . . . . 0.0 113.465 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 20.5 t -83.47 141.57 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 CA-C-N 119.268 1.534 . . . . 0.0 110.592 177.451 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 73.8 mt -75.32 106.76 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 121.473 0.654 . . . . 0.0 109.65 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.7 -172.87 19.36 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 124.387 0.994 . . . . 0.0 111.793 168.174 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -100.01 149.24 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.87 0.843 . . . . 0.0 112.726 -176.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -103.22 -135.21 0.33 Allowed 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 166.62 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 N--CA 1.473 0.701 0 C-N-CA 126.001 1.72 . . . . 0.0 110.983 168.881 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.404 ' H3 ' ' CD ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 115.917 -1.992 . . . . 0.0 106.669 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m -90.74 97.14 11.0 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 122.12 2.236 . . . . 0.0 108.061 -179.472 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 42.8 pttt -83.12 139.49 33.16 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.933 1.349 . . . . 0.0 114.212 -172.042 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.08 146.03 26.51 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 127.369 2.268 . . . . 0.0 107.753 167.409 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 33.0 t -154.95 143.54 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 119.567 1.076 . . . . 0.0 110.993 -175.2 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.87 95.63 2.88 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 123.767 0.827 . . . . 0.0 110.504 169.116 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.8 m -76.15 92.7 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-O 122.127 0.965 . . . . 0.0 109.618 170.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.2 mt -76.52 139.01 40.59 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.006 0.922 . . . . 0.0 109.553 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.6 ttmm -155.45 177.62 11.16 Favored 'General case' 0 CA--C 1.542 0.672 0 O-C-N 120.753 -1.217 . . . . 0.0 109.765 179.648 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.03 -33.83 3.91 Favored Glycine 0 N--CA 1.472 1.076 0 C-N-CA 124.279 0.942 . . . . 0.0 114.341 169.16 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.85 65.7 5.09 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 122.299 1.047 . . . . 0.0 110.146 175.905 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.06 -101.94 0.03 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.081 2.753 . . . . 0.0 113.146 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -83.24 -2.84 10.79 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 124.66 3.573 . . . . 0.0 114.441 -178.346 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -95.28 137.42 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 CA-C-N 120.697 1.59 . . . . 0.0 111.156 176.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -144.56 161.86 38.05 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 125.918 1.687 . . . . 0.0 109.697 172.321 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.452 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -134.63 106.18 0.59 Allowed Glycine 0 CA--C 1.502 -0.723 0 C-N-CA 124.34 0.971 . . . . 0.0 111.314 177.779 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.2 117.47 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 167.862 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -135.9 106.94 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-O 121.616 0.722 . . . . 0.0 109.369 169.293 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 -100.22 139.7 35.52 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.687 1.595 . . . . 0.0 110.885 -179.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -120.46 135.56 55.02 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 119.091 0.86 . . . . 0.0 110.85 179.206 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.404 ' CD ' ' H3 ' ' A' ' 1' ' ' ALA . 4.7 tp10 -115.1 114.86 25.88 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 127.078 2.151 . . . . 0.0 109.852 -172.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.8 tp60 -125.92 130.9 52.21 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 113.51 -1.677 . . . . 0.0 109.828 -170.398 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.516 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -99.33 -11.74 20.94 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 128.147 2.579 . . . . 0.0 114.129 -168.771 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.488 ' CD ' ' H ' ' A' ' 25' ' ' SER . 5.3 tm-20 -149.25 -172.02 4.03 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 127.918 2.487 . . . . 0.0 108.681 -172.376 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.488 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 0.8 OUTLIER -72.34 -57.18 4.41 Favored 'General case' 0 N--CA 1.474 0.726 0 O-C-N 118.778 -2.451 . . . . 0.0 111.601 169.677 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -123.37 -3.16 8.43 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.73 1.612 . . . . 0.0 114.918 -169.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.36 161.48 6.98 Favored Glycine 0 CA--C 1.537 1.446 0 CA-C-N 119.224 0.92 . . . . 0.0 110.955 168.372 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -66.85 143.94 68.94 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.327 2.018 . . . . 0.0 110.61 -170.035 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 37.3 t -107.62 129.87 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 123.262 0.625 . . . . 0.0 110.158 -173.159 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -79.64 125.77 30.05 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 49.9 t -112.42 130.73 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 128.456 2.703 . . . . 0.0 108.154 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -155.41 165.79 35.54 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 119.577 1.081 . . . . 0.0 113.249 175.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.27 -155.95 26.76 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 123.902 0.763 . . . . 0.0 113.655 172.726 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.9 p -149.53 128.36 12.53 Favored 'General case' 0 C--O 1.239 0.528 0 C-N-CA 123.319 0.648 . . . . 0.0 112.367 -169.483 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.452 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.0 mp -104.52 106.6 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 123.697 0.799 . . . . 0.0 109.599 175.371 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 tttp -117.14 133.64 55.75 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.38 1.072 . . . . 0.0 112.894 -168.903 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.56 9.37 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 128.318 2.866 . . . . 0.0 113.623 -177.621 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.8 mt -77.86 174.71 10.74 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.097 2.159 . . . . 0.0 113.37 -175.862 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.36 148.71 22.13 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 162.284 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.574 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.0 OUTLIER -53.79 -2.01 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 129.222 3.009 . . . . 0.0 115.825 176.065 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.31 174.34 17.46 Favored Glycine 0 CA--C 1.536 1.404 0 O-C-N 120.251 -1.531 . . . . 0.0 113.29 169.212 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.489 ' H ' HD22 ' A' ' 42' ' ' LEU . 2.0 pt? -88.31 138.17 31.67 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.778 2.031 . . . . 0.0 109.997 171.053 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -130.87 149.23 52.6 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 129.018 2.927 . . . . 0.0 108.615 -171.723 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -112.09 135.09 12.48 Favored Glycine 0 N--CA 1.486 1.991 0 CA-C-O 116.861 -2.077 . . . . 0.0 111.405 -172.554 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -135.74 133.28 37.85 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 121.165 2.482 . . . . 0.0 114.956 179.073 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.42 26.77 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.027 1.331 . . . . 0.0 109.801 -170.781 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.51 HG21 ' H ' ' A' ' 116' ' ' THR . 0.3 OUTLIER -86.33 118.35 32.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.263 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.742 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.0 m170 -77.71 163.03 26.53 Favored 'General case' 0 CA--C 1.549 0.931 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 176.157 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.18 133.97 55.93 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.816 -0.553 . . . . 0.0 110.745 -176.83 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.466 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 43.0 m-85 71.02 165.32 0.29 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.612 2.365 . . . . 0.0 115.348 170.123 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.44 ' C ' ' H ' ' A' ' 53' ' ' ASN . . . -116.21 -3.55 19.16 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 126.434 1.969 . . . . 0.0 113.654 177.684 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.0 m-20 -72.91 46.79 0.17 Allowed 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.076 1.35 . . . . 0.0 110.59 170.015 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.44 ' H ' ' C ' ' A' ' 51' ' ' GLY . 0.3 OUTLIER 174.45 40.1 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.635 2.374 . . . . 0.0 112.747 -167.541 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.0 t -53.71 19.97 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 129.78 3.232 . . . . 0.0 116.375 172.285 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.63 16.41 8.8 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 126.699 2.0 . . . . 0.0 112.715 -178.293 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.6 -144.02 41.42 Favored Glycine 0 N--CA 1.467 0.752 0 O-C-N 121.087 -1.008 . . . . 0.0 112.097 171.12 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 p -58.69 -23.24 59.12 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.748 1.018 . . . . 0.0 113.748 -178.011 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 13.0 t -90.52 42.64 1.11 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.364 1.066 . . . . 0.0 112.019 175.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 m 178.57 -35.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 129.577 3.151 . . . . 0.0 115.091 169.606 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.53 158.98 15.36 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -168.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.97 -153.93 17.76 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 126.004 1.764 . . . . 0.0 114.223 173.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -88.58 178.39 2.88 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 125.281 3.987 . . . . 0.0 112.107 -179.496 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 3.4 p80 -79.91 83.55 5.81 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 167.062 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -50.94 166.03 0.1 Allowed 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.34 2.256 . . . . 0.0 113.993 -174.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -108.11 57.84 0.23 Allowed Pre-proline 0 CA--C 1.552 1.031 0 C-N-CA 127.202 2.201 . . . . 0.0 112.25 -169.712 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -64.32 -28.82 63.52 Favored 'Trans proline' 0 C--N 1.354 0.838 0 CA-C-N 122.602 1.965 . . . . 0.0 113.272 -175.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.8 mp -82.13 -4.9 57.9 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.077 1.351 . . . . 0.0 113.171 170.533 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.8 t 65.37 54.15 1.2 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 127.242 2.217 . . . . 0.0 112.894 -175.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -121.51 174.37 6.82 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -170.912 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.7 mtmt -81.04 165.92 21.23 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.494 0.718 . . . . 0.0 110.719 167.18 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.428 ' CG ' ' H ' ' A' ' 72' ' ' GLY . 73.8 t60 -71.02 175.21 5.35 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.643 0.735 . . . . 0.0 111.645 167.758 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.428 ' H ' ' CG ' ' A' ' 71' ' ' HIS . . . 133.15 -138.16 9.92 Favored Glycine 0 CA--C 1.504 -0.599 0 C-N-CA 124.295 0.95 . . . . 0.0 112.173 167.629 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.78 -99.95 0.26 Allowed Glycine 0 CA--C 1.533 1.202 0 CA-C-O 115.811 -2.661 . . . . 0.0 109.845 -178.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -56.69 0.45 0.19 Allowed 'Trans proline' 0 CA--C 1.549 1.255 0 C-N-CA 124.126 3.218 . . . . 0.0 117.983 -178.742 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.0 pttt -134.86 -4.32 2.49 Favored 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.332 1.424 . . . . 0.0 114.276 167.339 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -155.82 112.11 3.11 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 126.051 1.74 . . . . 0.0 109.985 -175.555 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -62.21 -7.58 4.39 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -173.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -80.36 -9.02 59.74 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -173.048 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -17.36 118.53 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 129.446 3.098 . . . . 0.0 112.963 168.407 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.8 m80 -62.05 166.04 5.07 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.697 1.199 . . . . 0.0 111.61 177.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 32.5 m -76.33 29.58 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -178.469 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -148.28 9.99 1.13 Allowed Glycine 0 CA--C 1.532 1.096 0 C-N-CA 125.583 1.563 . . . . 0.0 115.166 -178.686 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -105.64 115.99 31.19 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.881 1.273 . . . . 0.0 113.209 -168.611 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.8 mp -91.2 170.7 9.79 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 163.459 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -79.79 -172.37 43.65 Favored Glycine 0 CA--C 1.529 0.941 0 O-C-N 121.372 -0.83 . . . . 0.0 112.238 171.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -78.42 144.11 36.15 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.422 -1.046 . . . . 0.0 112.512 172.6 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.3 p -114.51 139.43 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 128.003 2.521 . . . . 0.0 110.308 177.528 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.5 m -128.65 133.47 48.25 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.785 1.234 . . . . 0.0 110.586 -169.306 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.64 163.11 13.51 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 -176.2 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.43 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 31.4 t70 -83.32 169.8 15.26 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.106 1.362 . . . . 0.0 108.422 165.125 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.43 ' HZ2' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -62.02 -18.7 61.42 Favored 'General case' 0 N--CA 1.482 1.167 0 O-C-N 120.66 -1.275 . . . . 0.0 113.893 172.277 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -73.62 -3.03 25.52 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.59 1.556 . . . . 0.0 111.426 168.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.88 6.69 89.27 Favored Glycine 0 C--N 1.332 0.33 0 C-N-CA 126.155 1.836 . . . . 0.0 113.462 170.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -94.33 121.51 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 126.079 1.751 . . . . 0.0 111.541 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.89 99.12 10.42 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 167.148 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -79.9 143.86 33.9 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.543 1.537 . . . . 0.0 109.936 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.26 142.75 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 -176.503 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 p -149.89 109.98 4.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.417 1.487 . . . . 0.0 111.294 174.106 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.2 mt -138.08 158.73 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 127.295 2.238 . . . . 0.0 110.988 -171.157 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -145.39 144.33 30.6 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 126.353 1.861 . . . . 0.0 106.851 164.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -145.12 148.17 33.33 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 125.021 1.328 . . . . 0.0 110.597 179.373 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.32 49.69 0.95 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.674 0.789 . . . . 0.0 112.2 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.2 t -139.89 -47.7 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.211 1.404 . . . . 0.0 109.893 175.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -84.6 158.14 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-O 122.307 1.051 . . . . 0.0 113.201 175.592 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.9 p -157.03 171.51 20.33 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 115.316 1.599 . . . . 0.0 115.316 -171.614 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.01 80.25 9.1 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.41 1.484 . . . . 0.0 108.587 176.662 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 60.5 p -90.2 -170.95 2.94 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.564 0.697 . . . . 0.0 112.57 173.836 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.51 -43.77 5.12 Favored Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.363 0.982 . . . . 0.0 111.425 167.563 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 34.9 t0 -172.3 45.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.694 1.597 . . . . 0.0 111.787 -173.119 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -140.85 -40.53 0.4 Allowed 'General case' 0 N--CA 1.47 0.525 0 O-C-N 120.139 -1.601 . . . . 0.0 111.097 -172.16 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.9 m -90.67 -125.34 0.07 Allowed 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 127.988 2.515 . . . . 0.0 110.499 172.047 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.7 pt -102.7 -27.24 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 114.947 1.462 . . . . 0.0 114.947 -175.399 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 33.8 mm -60.46 138.23 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 168.374 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.67 8.25 73.84 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 117.366 -1.797 . . . . 0.0 113.631 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -122.17 174.12 7.16 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 119.913 1.856 . . . . 0.0 111.126 -174.17 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.51 ' H ' HG21 ' A' ' 47' ' ' VAL . 39.0 m -116.22 109.37 17.33 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.269 -1.519 . . . . 0.0 111.239 -163.328 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 33.9 tp -96.38 122.24 39.05 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.464 1.105 . . . . 0.0 110.64 -172.766 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 p -121.07 133.99 65.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.025 1.33 . . . . 0.0 108.839 175.203 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.3 t -90.67 152.64 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.225 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 165.053 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.03 138.55 54.43 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.745 2.018 . . . . 0.0 107.365 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.09 -46.3 79.08 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -167.256 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt -101.87 143.16 32.11 Favored 'General case' 0 C--N 1.329 -0.312 0 O-C-N 121.375 -0.828 . . . . 0.0 110.486 169.903 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.44 158.9 1.58 Allowed 'General case' 0 C--O 1.231 0.126 0 C-N-CA 125.027 1.331 . . . . 0.0 114.098 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -75.43 146.5 40.68 Favored 'General case' 0 N--CA 1.443 -0.823 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 165.599 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -68.54 -21.13 64.57 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.961 171.013 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.7 mt 85.33 -64.5 0.05 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 131.075 3.75 . . . . 0.0 108.582 -174.67 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.94 -75.75 0.98 Allowed Glycine 0 N--CA 1.464 0.559 0 C-N-CA 124.695 1.141 . . . . 0.0 110.887 -171.125 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -163.43 109.28 1.11 Allowed 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 168.583 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.44 21.74 0.69 Allowed Glycine 0 CA--C 1.545 1.965 0 C-N-CA 125.208 1.385 . . . . 0.0 116.509 172.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.25 10.94 73.43 Favored Glycine 0 N--CA 1.479 1.508 0 N-CA-C 118.551 2.18 . . . . 0.0 118.551 168.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.592 ' H ' ' HB3' ' A' ' 134' ' ' SER . 32.4 m-80 -127.24 179.47 5.43 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 119.872 1.836 . . . . 0.0 111.659 -173.559 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.31 -56.71 18.62 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 166.799 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.428 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 7.4 mm-40 -35.28 -31.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 128.839 2.855 . . . . 0.0 115.71 167.249 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.592 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 66.8 p -57.83 -24.44 57.44 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 117.435 2.383 . . . . 0.0 117.435 -166.842 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.282 3.4 t -133.02 -14.07 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 -179.203 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.2 ptmt -70.86 -47.37 59.69 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 120.297 1.408 . . . . 0.0 110.17 167.543 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.428 ' HG1' ' CD ' ' A' ' 133' ' ' GLU . 0.6 OUTLIER -105.24 -18.85 13.99 Favored 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.943 -177.326 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.23 5.86 67.14 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 124.144 0.878 . . . . 0.0 112.311 -168.426 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 74.72 2.42 4.04 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.451 2.301 . . . . 0.0 114.442 -170.296 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.66 106.26 0.76 Allowed 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 119.43 1.014 . . . . 0.0 111.398 -169.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -36.58 -7.44 0.0 OUTLIER Glycine 0 N--CA 1.493 2.439 1 C-N-CA 131.255 4.264 . . . . 0.0 122.836 -165.862 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 18.4 p 104.86 156.73 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 131.06 3.744 . . . . 0.0 113.315 166.556 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 61.85 131.32 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 117.826 2.528 . . . . 0.0 117.826 166.03 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 179.94 -165.83 0.07 Allowed 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 128.571 2.748 . . . . 0.0 108.451 168.171 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -55.98 151.47 11.77 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.975 1.31 . . . . 0.0 112.429 170.17 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.5 t -153.0 152.06 30.97 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.749 2.02 . . . . 0.0 112.573 -172.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.46 167.52 36.34 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 127.731 2.586 . . . . 0.0 110.716 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.9 p -98.5 141.78 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 CA-C-N 119.771 1.785 . . . . 0.0 109.382 169.632 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.3 mt -78.92 102.27 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 O-C-N 121.635 -0.666 . . . . 0.0 111.473 -175.266 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.32 177.2 29.65 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-O 122.601 1.112 . . . . 0.0 112.506 171.744 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -111.41 158.53 11.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 126.364 1.866 . . . . 0.0 110.993 175.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.29 -14.79 14.8 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.212 1.005 . . . . 0.0 112.228 167.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 . . . . . 0 C--O 1.237 0.419 0 C-N-CA 126.863 2.065 . . . . 0.0 108.377 -164.819 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.389 0 CA-C-O 121.842 0.83 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.4 t -118.53 130.28 55.83 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 124.357 1.063 . . . . 0.0 110.113 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -91.29 148.82 22.07 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 168.182 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.04 141.77 31.39 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 114.339 -1.3 . . . . 0.0 107.891 166.612 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 49.0 t -137.95 142.88 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 CA-C-O 121.675 0.75 . . . . 0.0 111.815 -169.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.1 132.29 55.99 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 122.437 1.113 . . . . 0.0 112.169 169.822 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -115.83 86.07 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 127.065 2.146 . . . . 0.0 107.027 169.642 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.61 117.32 17.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -158.03 134.24 9.42 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 119.279 0.945 . . . . 0.0 113.249 -170.297 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.07 -38.7 0.05 OUTLIER Glycine 0 N--CA 1.471 0.992 0 C-N-CA 125.659 1.6 . . . . 0.0 111.443 172.453 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.13 66.6 2.96 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 128.393 2.677 . . . . 0.0 112.188 -176.282 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.33 -102.48 0.05 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 127.111 2.291 . . . . 0.0 113.613 174.321 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -82.55 -11.85 10.34 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.907 3.072 . . . . 0.0 114.257 -176.845 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -91.13 136.08 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 CA-C-N 120.013 1.278 . . . . 0.0 110.124 -177.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.76 156.73 35.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.747 168.397 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -125.83 123.58 4.92 Favored Glycine 0 CA--C 1.503 -0.675 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.045 173.714 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.37 128.44 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 164.567 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.7 pp -136.34 134.77 49.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 164.279 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -106.25 151.48 24.74 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.107 1.363 . . . . 0.0 112.111 172.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -120.91 128.24 52.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.409 1.884 . . . . 0.0 112.165 169.772 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -104.08 112.42 25.41 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 128.885 2.874 . . . . 0.0 110.742 173.635 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -108.26 124.73 50.76 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.464 -0.773 . . . . 0.0 109.679 174.809 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.92 -42.06 21.96 Favored 'General case' 0 CA--C 1.551 0.996 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 176.045 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -134.56 133.72 40.57 Favored 'General case' 0 C--O 1.22 -0.485 0 C-N-CA 126.098 1.759 . . . . 0.0 109.989 170.269 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 97.9 p -70.48 79.17 0.56 Allowed 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 120.523 1.51 . . . . 0.0 113.278 -178.174 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.9 p30 158.47 -30.1 0.0 OUTLIER 'General case' 0 CA--C 1.548 0.871 1 C-N-CA 132.877 4.471 . . . . 0.0 111.176 -176.506 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.03 -172.92 43.06 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 126.099 1.809 . . . . 0.0 113.993 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -78.75 170.92 17.41 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 124.14 3.227 . . . . 0.0 112.444 -170.093 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 32.1 t -139.59 131.77 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 CA-C-O 121.482 0.658 . . . . 0.0 112.333 -167.753 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -87.48 129.06 35.21 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 167.594 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 t -110.5 138.84 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 126.322 1.849 . . . . 0.0 109.665 173.736 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 19.5 p90 -152.91 168.74 24.78 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.706 -0.621 . . . . 0.0 112.032 170.487 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.4 -161.94 29.36 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 114.757 0.663 . . . . 0.0 114.757 174.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 46.2 p -153.96 123.99 6.85 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.003 0.921 . . . . 0.0 111.631 -170.027 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . 0.413 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 2.7 mp -106.4 113.17 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 CA-C-O 117.709 -1.138 . . . . 0.0 111.388 177.169 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.0 mmmt -102.38 144.93 30.23 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 120.407 1.458 . . . . 0.0 109.374 -178.234 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.69 -4.23 14.81 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.232 1.396 . . . . 0.0 114.235 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -67.87 179.83 1.35 Allowed 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.367 1.067 . . . . 0.0 110.124 168.566 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -106.98 -32.27 7.95 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 117.763 -1.113 . . . . 0.0 113.892 172.108 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 173.39 -168.49 0.03 OUTLIER 'General case' 0 CA--C 1.556 1.207 1 C-N-CA 132.975 4.51 . . . . 0.0 105.174 178.876 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.5 161.96 28.43 Favored Glycine 0 CA--C 1.525 0.666 0 C-N-CA 126.1 1.809 . . . . 0.0 115.671 167.809 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.653 ' CD2' ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -66.33 150.29 49.08 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.261 2.625 . . . . 0.0 108.968 168.658 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -143.88 121.87 12.08 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.589 1.156 . . . . 0.0 111.945 179.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.02 147.13 41.88 Favored Glycine 0 N--CA 1.482 1.759 0 CA-C-N 119.934 1.243 . . . . 0.0 112.559 -179.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -150.25 111.06 4.3 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.071 1.349 . . . . 0.0 110.115 -173.812 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.89 152.78 35.61 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 119.8 -1.812 . . . . 0.0 114.587 -165.071 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.02 126.81 53.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-O 121.447 0.642 . . . . 0.0 111.336 -177.322 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -78.21 -179.31 6.13 Favored 'General case' 0 CA--C 1.544 0.717 1 C-N-CA 131.837 4.055 . . . . 0.0 114.444 -175.128 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . 0.415 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 1.2 pm0 -59.99 135.26 57.65 Favored 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 163.208 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.274 42.7 m-85 -0.29 -130.45 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.621 1 C-N-CA 132.105 4.162 . . . . 0.0 116.865 -169.254 . . . . . . . . 3 2 . 1 . 023 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -130.44 -2.9 4.84 Favored Glycine 0 N--CA 1.472 1.034 0 C-N-CA 124.524 1.059 . . . . 0.0 114.079 -169.676 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -81.83 48.32 1.2 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.333 1.853 . . . . 0.0 111.697 177.289 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.263 0.4 OUTLIER -176.89 43.9 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.489 1.516 . . . . 0.0 112.187 -168.937 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 9.1 t -59.69 19.74 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 128.735 2.814 . . . . 0.0 115.969 171.768 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -117.38 4.23 12.53 Favored 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.972 1.709 . . . . 0.0 113.248 169.244 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.81 -144.82 38.98 Favored Glycine 0 N--CA 1.471 1.029 0 O-C-N 120.998 -1.064 . . . . 0.0 111.477 -177.878 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . 0.492 ' C ' ' H ' ' B' ' 59' ' ' SER . 26.7 p -55.74 -26.24 44.54 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -177.638 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.7 m -71.79 30.68 0.05 Allowed 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 126.407 1.883 . . . . 0.0 112.085 171.578 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 59' ' ' SER . . . . . 0.492 ' H ' ' C ' ' B' ' 57' ' ' CYS . 13.4 t -179.81 5.53 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.191 0 C-N-CA 130.392 3.477 . . . . 0.0 114.36 175.862 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.45 165.61 23.64 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 121.831 2.105 . . . . 0.0 115.473 -168.414 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . 0.415 ' H ' ' CD ' ' B' ' 49' ' ' GLU . . . -99.3 -121.31 4.54 Favored Glycine 0 CA--C 1.544 1.902 0 C-N-CA 126.485 1.993 . . . . 0.0 115.082 -169.263 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -99.19 179.16 0.3 Allowed 'Trans proline' 0 C--N 1.35 0.618 1 C-N-CA 125.415 4.076 . . . . 0.0 111.566 -175.79 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.4 ' CE1' ' O ' ' B' ' 137' ' ' THR . 0.0 OUTLIER -76.5 110.87 11.41 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.009 177.479 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -48.05 128.82 14.31 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.633 1.973 . . . . 0.0 113.78 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -121.57 64.96 16.69 Favored Pre-proline 0 CA--C 1.548 0.886 0 C-N-CA 124.721 1.208 . . . . 0.0 112.596 -172.312 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -63.58 -22.51 70.5 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 123.679 2.919 . . . . 0.0 113.465 -175.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.9 mt -79.51 -4.95 53.66 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.502 1.521 . . . . 0.0 112.916 172.606 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.7 p 62.15 52.07 3.34 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 127.891 2.476 . . . . 0.0 111.448 177.569 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -126.41 174.15 8.82 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 114.419 1.266 . . . . 0.0 114.419 -169.252 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 45.7 pttt -78.88 169.01 18.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 128.051 2.541 . . . . 0.0 111.192 171.235 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.419 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 78.6 t60 -90.28 174.85 7.36 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 176.221 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . 0.419 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 129.24 -115.1 1.87 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 125.166 1.365 . . . . 0.0 113.48 166.57 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.03 -50.03 0.81 Allowed Glycine 0 CA--C 1.547 2.089 0 CA-C-O 117.859 -1.523 . . . . 0.0 116.196 173.044 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -88.64 -4.64 6.37 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 CA-C-N 121.425 2.613 . . . . 0.0 113.599 172.077 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 26.5 pttt -141.83 -1.35 1.27 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 124.256 1.022 . . . . 0.0 113.468 168.29 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -119.43 159.74 23.66 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.642 1.577 . . . . 0.0 110.099 169.496 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -81.96 -29.84 31.99 Favored 'General case' 0 CA--C 1.541 0.619 1 C-N-CA 132.486 4.314 . . . . 0.0 114.83 -171.321 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -98.51 -85.63 0.37 Allowed 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.714 -0.616 . . . . 0.0 111.165 -168.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ttp-105 80.93 121.22 0.05 OUTLIER 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.924 2.09 . . . . 0.0 111.16 176.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m80 -54.19 151.51 7.12 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 120.481 -1.387 . . . . 0.0 113.006 173.794 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -45.94 -48.38 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-O 119.048 -0.501 . . . . 0.0 112.104 -176.648 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.29 112.12 2.62 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-O 123.182 1.435 . . . . 0.0 113.117 169.411 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -155.56 107.14 2.58 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 130.659 3.584 . . . . 0.0 106.872 174.473 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 97.0 mt -89.09 54.06 2.87 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.558 0.743 . . . . 0.0 109.74 174.58 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.9 -107.56 0.14 Allowed Glycine 0 CA--C 1.532 1.107 0 C-N-CA 125.959 1.743 . . . . 0.0 113.652 177.449 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.74 146.16 24.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.367 1.467 . . . . 0.0 110.947 169.922 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.97 113.52 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 126.791 2.036 . . . . 0.0 110.359 -176.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -95.59 125.06 39.92 Favored 'General case' 0 N--CA 1.471 0.598 0 O-C-N 121.628 -0.67 . . . . 0.0 110.365 -175.189 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.38 148.62 24.01 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.738 1.215 . . . . 0.0 113.181 -175.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.432 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 24.7 t70 -76.71 174.91 9.88 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.49 1.516 . . . . 0.0 111.496 169.68 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.432 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -68.59 -13.38 62.3 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 121.101 -1.0 . . . . 0.0 113.109 173.018 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -74.62 -23.7 58.74 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.101 1.36 . . . . 0.0 110.588 171.217 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.12 -2.71 59.8 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 116.655 -2.192 . . . . 0.0 114.47 -177.75 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.33 133.18 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 119.959 1.88 . . . . 0.0 113.818 169.856 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.44 113.93 27.8 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 164.783 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -99.67 133.34 44.16 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.066 1.347 . . . . 0.0 108.978 -176.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -135.26 135.7 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.495 1.118 . . . . 0.0 112.825 -167.393 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 27.6 p -156.11 113.69 3.27 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.312 1.445 . . . . 0.0 111.304 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 6.6 mt -145.14 152.57 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 127.85 2.46 . . . . 0.0 110.606 -169.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -134.98 137.78 43.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.846 0.858 . . . . 0.0 108.737 167.376 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -145.12 153.21 41.16 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 125.385 1.474 . . . . 0.0 112.327 -172.163 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 37.4 p -125.67 45.26 2.64 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 178.603 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.4 22.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.891 1.276 . . . . 0.0 112.669 169.427 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.15 158.86 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 127.119 2.168 . . . . 0.0 108.025 164.685 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 60.4 p -156.03 156.84 35.12 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.657 0.783 . . . . 0.0 109.758 -177.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -83.25 63.41 7.2 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.681 -1.262 . . . . 0.0 110.243 -177.322 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 11.1 t -93.5 154.59 17.81 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 165.703 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.0 -28.41 72.02 Favored Glycine 0 N--CA 1.47 0.909 0 C-N-CA 127.047 2.261 . . . . 0.0 118.322 -164.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 p30 -148.13 -46.67 0.16 Allowed 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -168.79 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -82.73 -18.89 39.18 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.782 -1.199 . . . . 0.0 111.994 -171.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 74.7 m -99.14 -92.85 0.26 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.093 0.957 . . . . 0.0 111.097 -176.174 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.74 -18.49 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 176.584 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 40.2 mm -68.64 153.0 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 122.089 2.222 . . . . 0.0 107.263 167.238 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.48 66.0 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 119.297 -0.724 . . . . 0.0 112.97 175.687 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 15.8 mtp85 -114.54 133.19 55.98 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 176.719 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.598 ' HG1' HG23 ' B' ' 148' ' ' VAL . 5.5 m -80.29 140.69 36.06 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.352 1.861 . . . . 0.0 107.003 179.258 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.3 tp -129.83 128.53 42.49 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.028 0.931 . . . . 0.0 109.786 -174.566 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.62 133.19 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.103 0.961 . . . . 0.0 110.628 177.736 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -98.24 149.25 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 165.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.2 m-70 -120.76 138.16 54.15 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.274 1.43 . . . . 0.0 113.199 -169.655 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -73.61 -24.79 60.09 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 120.163 -1.585 . . . . 0.0 114.013 -173.338 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -93.22 164.8 13.1 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 122.192 0.996 . . . . 0.0 112.355 169.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.87 158.97 20.7 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.008 1.323 . . . . 0.0 111.625 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -103.45 151.95 22.21 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.84 0.856 . . . . 0.0 112.185 179.124 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -102.36 -3.24 27.42 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 127.378 2.271 . . . . 0.0 112.878 -177.993 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 45.85 56.45 5.97 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.132 1.773 . . . . 0.0 113.257 172.036 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.77 -54.1 1.68 Allowed Glycine 0 N--CA 1.471 1.033 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.014 173.023 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 134.55 18.86 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 172.314 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -160.21 -67.58 0.02 OUTLIER Glycine 0 CA--C 1.52 0.382 1 C-N-CA 130.723 4.011 . . . . 0.0 107.254 168.22 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -83.67 -111.14 0.56 Allowed Glycine 0 CA--C 1.533 1.188 0 C-N-CA 126.309 1.909 . . . . 0.0 117.039 -171.046 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -118.0 -159.13 0.74 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.431 2.292 . . . . 0.0 112.646 -163.307 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . 0.486 ' CD ' ' HZ2' ' B' ' 136' ' ' LYS . 31.9 tt0 -49.34 -64.67 0.74 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.479 1.112 . . . . 0.0 112.033 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . 0.298 2.9 mt-10 -53.65 -10.37 0.27 Allowed 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 177.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 67.2 m -60.9 -47.76 84.92 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 122.133 2.242 . . . . 0.0 111.18 166.796 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 39.0 p -81.31 -38.14 27.25 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-O 119.102 -0.475 . . . . 0.0 111.347 176.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.486 ' HZ2' ' CD ' ' B' ' 132' ' ' GLU . 14.9 tttt -68.63 -38.97 80.96 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.552 1.541 . . . . 0.0 113.88 -173.906 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.4 ' O ' ' CE1' ' B' ' 63' ' ' HIS . 33.9 p -121.78 -68.72 0.88 Allowed 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 116.974 -1.488 . . . . 0.0 109.696 172.742 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 163.71 17.37 0.02 OUTLIER Glycine 0 CA--C 1.536 1.375 0 C-N-CA 130.476 3.894 . . . . 0.0 113.621 -176.286 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . 0.257 2.3 t-20 41.98 35.34 0.54 Allowed 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 128.017 2.527 . . . . 0.0 114.819 -166.522 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.56 3.45 0.13 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.784 1.633 . . . . 0.0 115.232 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.9 -43.86 0.51 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 129.324 3.345 . . . . 0.0 117.257 168.664 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 32.5 t -173.09 168.55 4.77 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.768 1.627 . . . . 0.0 110.062 -168.316 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 28.5 mtt180 -111.07 -177.69 3.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 -169.85 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.431 ' CD2' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -171.31 -157.88 0.13 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 128.417 2.687 . . . . 0.0 107.138 -169.695 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . 0.431 ' H ' ' CD2' ' B' ' 144' ' ' LEU . . . -58.69 153.97 15.53 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -169.142 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -141.98 153.77 44.54 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 113.949 -1.478 . . . . 0.0 113.82 -172.109 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.99 -177.65 37.68 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 127.49 2.472 . . . . 0.0 111.485 176.627 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.598 HG23 ' HG1' ' B' ' 116' ' ' THR . 3.4 t -123.61 152.69 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 166.896 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.0 mm -75.7 102.31 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 174.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.18 -179.51 35.54 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 125.835 1.683 . . . . 0.0 111.14 169.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.24 154.55 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 117.602 0.701 . . . . 0.0 112.796 -167.604 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.466 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.23 -2.74 0.68 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 115.008 1.484 . . . . 0.0 115.008 165.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.234 0.262 0 C-N-CA 124.671 1.189 . . . . 0.0 111.071 168.78 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.514 0 CA-C-O 118.395 -0.812 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m -77.2 113.0 14.48 Favored 'General case' 0 CA--C 1.511 -0.539 0 C-N-CA 127.839 2.456 . . . . 0.0 107.146 -171.178 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.44 ' HZ2' ' HG2' ' A' ' 28' ' ' PRO . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HG2' ' HZ2' ' A' ' 23' ' ' LYS . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.538 ' H ' HD11 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.486 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.456 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.486 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.408 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.496 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.496 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.408 ' CG ' ' HE2' ' A' ' 71' ' ' HIS . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.427 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.507 ' CD ' ' HZ1' ' A' ' 136' ' ' LYS . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.507 ' HZ1' ' CD ' ' A' ' 132' ' ' GLU . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.456 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.414 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.446 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.413 ' H ' HD22 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.453 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 16.9 p -92.91 -29.77 15.73 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.67 -51.24 36.47 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 118.192 0.451 . . . . 0.0 111.151 177.103 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.49 -134.95 7.55 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 126.195 1.855 . . . . 0.0 111.092 -173.24 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.8 t -54.42 -26.31 29.9 Favored 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -172.175 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 m -75.45 -34.36 60.96 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.866 1.267 . . . . 0.0 111.621 176.229 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 99.6 p -101.85 66.22 1.04 Allowed 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.183 1.793 . . . . 0.0 110.012 179.269 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.72 66.14 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.39 1.076 . . . . 0.0 111.365 -177.142 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . 0.437 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.433 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 024 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . 0.433 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.4 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.514 0 CA-C-O 118.395 -0.812 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m -77.2 113.0 14.48 Favored 'General case' 0 CA--C 1.511 -0.539 0 C-N-CA 127.839 2.456 . . . . 0.0 107.146 -171.178 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.44 ' HZ2' ' HG2' ' A' ' 28' ' ' PRO . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HG2' ' HZ2' ' A' ' 23' ' ' LYS . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.538 ' H ' HD11 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.486 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.456 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.486 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.408 ' HE2' ' CG ' ' A' ' 124' ' ' ASP . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.496 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.496 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.408 ' CG ' ' HE2' ' A' ' 71' ' ' HIS . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.427 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.507 ' CD ' ' HZ1' ' A' ' 136' ' ' LYS . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.427 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.507 ' HZ1' ' CD ' ' A' ' 132' ' ' GLU . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.456 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.414 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.446 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.413 ' H ' HD22 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.453 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 16.9 p -92.91 -29.77 15.73 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.67 -51.24 36.47 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 118.192 0.451 . . . . 0.0 111.151 177.103 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.49 -134.95 7.55 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 126.195 1.855 . . . . 0.0 111.092 -173.24 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.8 t -54.42 -26.31 29.9 Favored 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -172.175 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 m -75.45 -34.36 60.96 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.866 1.267 . . . . 0.0 111.621 176.229 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 99.6 p -101.85 66.22 1.04 Allowed 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.183 1.793 . . . . 0.0 110.012 179.269 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.72 66.14 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.39 1.076 . . . . 0.0 111.365 -177.142 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . 0.437 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.433 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 025 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . 0.433 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . 0.4 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.922 0 CA-C-O 118.284 -0.865 . . . . 0.0 110.029 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.5 p -77.76 56.02 1.45 Allowed 'General case' 0 C--N 1.345 0.383 0 C-N-CA 127.385 2.274 . . . . 0.0 115.7 -166.296 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.478 ' HZ2' HG22 ' A' ' 5' ' ' VAL . 0.8 OUTLIER -163.43 129.75 3.26 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 164.361 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.44 154.03 44.21 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.326 2.25 . . . . 0.0 108.289 167.682 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.478 HG22 ' HZ2' ' A' ' 3' ' ' LYS . 69.4 t -154.97 146.62 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 118.916 0.78 . . . . 0.0 112.778 -167.005 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.76 128.45 51.75 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.592 1.157 . . . . 0.0 109.321 165.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 29.0 m -113.71 127.1 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.597 1.159 . . . . 0.0 108.289 167.59 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.07 130.45 55.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.14 1.376 . . . . 0.0 109.913 -172.068 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -153.9 70.76 0.83 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.741 0.816 . . . . 0.0 110.869 170.222 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.1 -1.41 22.3 Favored Glycine 0 N--CA 1.469 0.851 0 CA-C-O 117.481 -1.733 . . . . 0.0 115.078 -173.958 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -156.08 110.32 2.81 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 119.151 1.476 . . . . 0.0 111.979 -169.74 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 31.66 -111.37 0.05 OUTLIER Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.168 2.318 . . . . 0.0 114.906 169.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -84.42 -2.05 9.85 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.597 2.865 . . . . 0.0 114.034 -175.778 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.0 t -102.05 135.37 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 120.445 1.475 . . . . 0.0 111.578 -168.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -127.24 171.93 11.03 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 122.87 1.319 . . . . 0.0 110.258 169.072 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.36 150.87 23.17 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 112.781 -2.008 . . . . 0.0 112.152 167.892 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -133.15 126.4 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 167.352 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mm -132.67 103.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -177.29 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -99.3 124.71 44.61 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.221 1.008 . . . . 0.0 112.151 177.107 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -104.69 156.45 17.97 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 127.303 2.241 . . . . 0.0 111.769 169.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -132.46 128.97 38.59 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.613 1.565 . . . . 0.0 108.597 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -139.56 145.49 38.69 Favored 'General case' 0 CA--C 1.532 0.287 0 O-C-N 120.822 -1.174 . . . . 0.0 111.151 -174.224 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.482 ' H ' ' HD2' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -113.4 -31.37 6.58 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -167.39 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.434 ' CD ' ' H ' ' A' ' 25' ' ' SER . 1.4 tm-20 -157.94 154.66 28.16 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.683 1.593 . . . . 0.0 107.908 172.438 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.434 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.7 m -47.44 -40.53 18.32 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 128.302 2.641 . . . . 0.0 113.156 173.018 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -84.1 -0.55 52.34 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.984 1.714 . . . . 0.0 112.771 174.681 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.58 139.65 14.57 Favored Glycine 0 CA--C 1.538 1.526 0 O-C-N 120.427 -1.421 . . . . 0.0 112.985 -172.694 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -69.74 163.71 37.26 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 123.933 3.089 . . . . 0.0 111.339 178.925 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t -132.75 136.56 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.177 0.591 . . . . 0.0 112.164 -167.024 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -95.49 124.54 39.57 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.093 1.357 . . . . 0.0 109.548 172.153 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -107.7 153.0 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 C-N-CA 125.672 1.589 . . . . 0.0 111.415 168.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 42.6 p90 -156.72 164.05 38.58 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.291 1.437 . . . . 0.0 111.834 168.779 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.94 -154.21 24.74 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 124.139 0.876 . . . . 0.0 112.597 175.656 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 78.1 p -156.58 150.85 25.32 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.15 116.26 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 171.783 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -136.12 140.18 43.5 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.111 0.964 . . . . 0.0 112.566 -165.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.57 -16.22 37.62 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 126.809 2.147 . . . . 0.0 112.275 -168.789 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.2 pp -84.39 155.05 22.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-N 118.473 1.137 . . . . 0.0 112.01 172.879 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.7 m -62.02 154.15 27.54 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 127.371 2.269 . . . . 0.0 112.012 176.674 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.8 pm0 -51.0 169.61 0.04 OUTLIER 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.258 1.423 . . . . 0.0 114.57 168.674 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.43 -176.32 46.51 Favored Glycine 0 N--CA 1.472 1.086 0 O-C-N 120.792 -1.192 . . . . 0.0 112.358 -177.485 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.3 mp -75.92 148.36 38.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.456 -1.026 . . . . 0.0 110.019 -176.56 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -142.1 134.0 27.24 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.849 1.26 . . . . 0.0 109.2 173.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.2 152.13 49.52 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 177.75 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -150.5 118.0 6.1 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.806 2.042 . . . . 0.0 107.97 -169.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.474 ' NE2' ' CD2' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -153.89 145.2 23.01 Favored 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.116 -1.615 . . . . 0.0 111.221 -172.956 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.16 127.3 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.173 0.987 . . . . 0.0 110.647 170.248 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -72.83 -173.62 1.26 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 129.218 3.007 . . . . 0.0 110.349 177.414 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.468 ' CD ' ' H ' ' A' ' 49' ' ' GLU 0.268 1.9 pm0 -63.65 -120.31 0.0 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.081 1.752 . . . . 0.0 114.831 177.692 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -82.12 -168.03 1.79 Allowed 'General case' 0 CA--C 1.545 0.754 0 O-C-N 119.807 -1.808 . . . . 0.0 114.403 -167.129 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.58 9.45 60.59 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.067 1.794 . . . . 0.0 113.978 -179.354 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -108.98 38.79 2.18 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.986 1.714 . . . . 0.0 113.961 -173.769 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -172.43 22.27 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.858 1.313 . . . . 0.0 112.408 -165.082 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.1 p -44.33 5.8 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.613 1 C-N-CA 134.641 5.176 . . . . 0.0 118.784 -176.453 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.75 1.34 56.54 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.515 1.926 . . . . 0.0 112.87 172.579 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.84 -151.68 43.05 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 -179.135 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.1 t -51.26 -7.41 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.197 0 C-N-CA 127.206 2.203 . . . . 0.0 116.289 -176.42 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 58.5 p -87.95 18.51 4.14 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 120.162 -1.586 . . . . 0.0 113.318 169.2 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.9 m -169.81 -47.14 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 127.221 2.209 . . . . 0.0 109.761 -176.268 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -70.61 151.31 45.13 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.45 1.9 . . . . 0.0 112.128 172.526 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -98.01 -170.28 32.35 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 125.803 1.668 . . . . 0.0 112.505 -176.188 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -83.79 60.87 6.69 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.501 2.801 . . . . 0.0 109.885 178.185 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' ' NE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER 51.19 63.81 2.1 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.551 1.54 . . . . 0.0 112.773 168.272 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -28.29 113.57 0.07 Allowed 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 127.507 2.323 . . . . 0.0 111.854 175.679 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -78.11 103.59 1.45 Allowed Pre-proline 0 CA--C 1.545 0.773 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.795 -166.547 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -70.11 -21.12 32.3 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 121.899 1.733 . . . . 0.0 112.186 -174.516 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.89 -3.74 21.49 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.31 1.844 . . . . 0.0 112.677 175.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 t 54.18 44.24 29.44 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 125.25 1.42 . . . . 0.0 112.283 -169.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtm180 -92.2 171.19 9.24 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 120.994 -1.066 . . . . 0.0 111.37 174.378 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.75 164.64 18.41 Favored 'General case' 0 CA--C 1.547 0.858 0 O-C-N 121.23 -0.919 . . . . 0.0 109.762 167.792 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -80.31 142.54 34.42 Favored 'General case' 0 CA--C 1.536 0.414 0 O-C-N 120.265 -1.522 . . . . 0.0 111.718 -178.495 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 165.36 -131.5 2.41 Favored Glycine 0 N--CA 1.468 0.804 0 N-CA-C 115.859 1.104 . . . . 0.0 115.859 168.843 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.55 -41.7 1.72 Allowed Glycine 0 CA--C 1.543 1.822 0 N-CA-C 119.005 2.362 . . . . 0.0 119.005 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -95.39 -22.31 0.2 Allowed 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 121.885 2.843 . . . . 0.0 113.725 -175.798 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.5 pttt -132.26 -0.09 3.7 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.976 1.71 . . . . 0.0 112.21 175.348 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -138.72 155.49 48.19 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 130.869 3.668 . . . . 0.0 108.832 -176.428 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -107.07 -8.05 16.67 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 126.169 1.788 . . . . 0.0 112.911 -174.638 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.5 mm-40 -78.2 -20.21 52.31 Favored 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -172.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 4.52 102.14 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 130.445 3.498 . . . . 0.0 115.374 166.493 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -59.58 162.35 5.13 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.654 0.782 . . . . 0.0 112.03 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 92.2 t -49.62 -41.18 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 124.366 1.066 . . . . 0.0 113.722 171.125 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.8 8.39 66.21 Favored Glycine 0 CA--C 1.539 1.583 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 177.266 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -99.25 97.49 8.56 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-N 119.635 1.718 . . . . 0.0 111.866 -175.184 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 87.0 mt -108.81 54.54 0.65 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.455 1.102 . . . . 0.0 111.954 -175.436 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.42 -151.48 43.43 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 125.023 1.296 . . . . 0.0 114.248 177.186 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.7 p30 -135.16 169.28 17.69 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 125.509 1.524 . . . . 0.0 109.568 169.864 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -128.58 113.88 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.536 1.134 . . . . 0.0 109.832 -171.147 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.4 m -109.15 124.37 50.7 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 123.913 0.885 . . . . 0.0 108.939 -170.102 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.94 151.17 21.64 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 -172.87 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -88.06 151.89 22.42 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 127.758 2.423 . . . . 0.0 110.381 167.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.545 ' HZ1' ' CG ' ' A' ' 92' ' ' ASP . 1.5 pptp? -49.94 -17.71 0.42 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 129.2 3.0 . . . . 0.0 116.994 175.557 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.545 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 82.9 m-20 -75.65 0.75 16.54 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 124.266 1.026 . . . . 0.0 111.388 171.56 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.13 35.13 7.21 Favored Glycine 0 C--N 1.34 0.783 0 C-N-CA 125.996 1.76 . . . . 0.0 112.781 172.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.7 p -152.76 131.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.048 1.869 . . . . 0.0 116.048 -170.919 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.86 120.97 37.07 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 164.468 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -104.1 132.6 50.19 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.224 1.41 . . . . 0.0 107.747 177.118 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 49.1 t -134.41 141.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -165.608 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.9 t -157.46 119.27 3.73 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.333 1.853 . . . . 0.0 111.021 170.614 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.4 mt -135.47 145.59 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 126.233 1.813 . . . . 0.0 110.467 179.707 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.98 126.43 53.83 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 125.641 1.576 . . . . 0.0 106.945 166.269 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.82 144.46 50.24 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.925 0.89 . . . . 0.0 112.924 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 10.8 p -119.97 50.74 1.25 Allowed 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -177.381 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -154.72 6.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 N-CA-C 115.382 1.623 . . . . 0.0 115.382 168.642 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.64 152.79 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 120.77 -1.206 . . . . 0.0 109.851 177.726 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.411 ' H ' ' CB ' ' A' ' 111' ' ' SER . 52.4 p -155.43 179.3 9.31 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 120.982 -1.074 . . . . 0.0 112.691 -178.341 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.4 mp -81.72 48.35 1.19 Allowed 'General case' 0 CA--C 1.551 1.002 0 O-C-N 120.415 -1.428 . . . . 0.0 110.234 -174.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.9 t -88.16 43.92 1.16 Allowed 'General case' 0 CA--C 1.545 0.764 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 -168.454 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.19 -64.63 2.02 Favored Glycine 0 N--CA 1.475 1.248 0 C-N-CA 125.736 1.636 . . . . 0.0 116.072 168.249 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -149.41 16.67 0.92 Allowed 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 124.059 1.885 . . . . 0.0 110.595 -175.725 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 39.4 m-70 -126.31 5.7 7.02 Favored 'General case' 0 CA--C 1.545 0.771 0 O-C-N 120.004 -1.685 . . . . 0.0 112.873 -167.431 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.411 ' CB ' ' H ' ' A' ' 105' ' ' SER . 3.1 m -166.39 -103.12 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.74 1.216 . . . . 0.0 113.111 177.749 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.6 pt -117.72 28.13 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 CA-C-N 120.37 1.441 . . . . 0.0 113.679 -170.276 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -133.48 146.58 31.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 127.725 2.41 . . . . 0.0 105.578 164.084 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.12 30.38 75.68 Favored Glycine 0 C--O 1.22 -0.748 0 CA-C-O 118.869 -0.962 . . . . 0.0 113.101 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.7 mtt-85 -135.28 176.9 8.25 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.835 1.254 . . . . 0.0 109.351 176.345 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.4 m -132.52 116.11 16.32 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 119.689 1.131 . . . . 0.0 110.94 -170.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.7 tp -89.83 132.86 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.629 1.172 . . . . 0.0 110.308 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -124.23 150.26 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.027 1.331 . . . . 0.0 110.326 172.302 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -105.33 167.56 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-O 121.418 0.628 . . . . 0.0 110.823 167.06 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.72 127.69 37.35 Favored 'General case' 0 CA--C 1.547 0.849 0 O-C-N 120.942 -1.099 . . . . 0.0 110.697 -173.823 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? -69.87 -10.13 57.38 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -169.55 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -107.93 162.1 14.33 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 114.442 1.275 . . . . 0.0 114.442 171.496 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.79 139.4 58.76 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.507 1.923 . . . . 0.0 109.792 167.081 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -111.3 148.84 32.05 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.849 2.059 . . . . 0.0 113.8 -171.815 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.342 13.3 t0 -101.93 -15.83 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 115.556 1.687 . . . . 0.0 115.556 -179.725 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt 56.26 81.0 0.13 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.724 1.609 . . . . 0.0 114.061 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.9 -43.74 1.91 Allowed Glycine 0 N--CA 1.471 1.009 0 C-N-CA 125.275 1.417 . . . . 0.0 111.935 168.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -99.42 175.03 5.99 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.219 1.408 . . . . 0.0 110.204 167.604 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 131.02 -9.92 5.68 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 126.311 1.91 . . . . 0.0 114.116 -169.312 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.54 11.04 85.85 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 116.272 1.269 . . . . 0.0 116.272 168.394 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 13.9 p30 -138.82 174.52 10.43 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.891 1.276 . . . . 0.0 110.077 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -65.69 -54.82 22.19 Favored 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 115.012 1.486 . . . . 0.0 115.012 -171.577 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.41 -26.54 42.32 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.661 -0.649 . . . . 0.0 111.883 176.291 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -54.38 -35.97 63.4 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.29 -1.506 . . . . 0.0 114.634 177.253 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.9 -28.16 15.33 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 124.423 1.089 . . . . 0.0 112.49 178.504 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.19 -65.25 0.98 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.018 0.827 . . . . 0.0 111.922 178.823 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.9 p -92.25 -24.31 19.04 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 126.56 1.944 . . . . 0.0 112.168 -171.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.58 16.51 24.23 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 124.533 1.063 . . . . 0.0 112.494 -168.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 73.09 4.54 4.96 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.566 1.946 . . . . 0.0 113.768 178.294 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.8 -10.96 4.36 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 -169.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.06 -30.07 0.53 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 128.507 2.956 . . . . 0.0 117.779 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.411 ' C ' ' HE ' ' A' ' 143' ' ' ARG . 9.5 t -142.45 178.11 7.82 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.225 1.01 . . . . 0.0 110.469 -173.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.411 ' HE ' ' C ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -116.9 -175.58 2.81 Favored 'General case' 0 N--CA 1.473 0.725 0 O-C-N 120.59 -1.319 . . . . 0.0 110.102 -174.893 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.605 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -170.1 -158.96 0.18 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.76 2.024 . . . . 0.0 107.779 -176.07 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.605 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.26 159.7 30.75 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 127.057 2.143 . . . . 0.0 113.321 178.347 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -147.58 162.52 38.94 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.269 1.427 . . . . 0.0 112.985 -177.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.28 161.0 31.35 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 126.614 2.054 . . . . 0.0 112.228 169.333 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.1 t -78.54 160.83 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 CA-C-N 119.25 1.525 . . . . 0.0 110.869 170.403 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -103.1 113.12 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 CA-C-N 118.834 0.743 . . . . 0.0 110.643 167.838 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.2 -178.61 15.7 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 125.604 1.573 . . . . 0.0 113.23 -178.435 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.95 123.05 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 113.958 1.096 . . . . 0.0 113.958 -170.704 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -75.12 -31.05 61.0 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 122.921 1.343 . . . . 0.0 107.787 163.033 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.438 0 C-N-CA 125.481 1.512 . . . . 0.0 112.27 166.937 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.2 m -80.73 109.61 15.43 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 105.724 -1.954 . . . . 0.0 105.724 168.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.27 152.87 32.97 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 117.894 2.553 . . . . 0.0 117.894 -172.711 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.75 147.49 37.46 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 126.255 1.822 . . . . 0.0 108.886 168.571 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.05 157.29 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 123.459 0.704 . . . . 0.0 111.037 -166.918 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.54 139.61 46.7 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.658 1.183 . . . . 0.0 111.438 169.648 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.4 m -108.62 122.41 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 167.094 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.7 mp -99.98 75.86 1.89 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -164.453 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -105.61 100.74 10.29 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.257 1.423 . . . . 0.0 110.364 173.076 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.47 15.69 0.48 Allowed Glycine 0 N--CA 1.477 1.412 0 N-CA-C 115.68 1.032 . . . . 0.0 115.68 -178.11 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -159.61 136.78 9.6 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.625 2.37 . . . . 0.0 107.457 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -23.28 -80.26 0.01 OUTLIER Glycine 0 CA--C 1.537 1.451 0 C-N-CA 128.487 2.946 . . . . 0.0 116.083 -168.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -86.72 4.27 6.36 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 124.192 3.261 . . . . 0.0 113.949 -177.557 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 36.0 t -105.38 129.83 57.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 CA-C-O 122.872 1.32 . . . . 0.0 109.721 -172.446 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.2 168.29 19.13 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.777 1.631 . . . . 0.0 107.911 171.869 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.17 176.42 33.6 Favored Glycine 0 N--CA 1.464 0.543 0 O-C-N 120.432 -1.417 . . . . 0.0 113.546 176.488 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -158.31 103.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 126.687 1.995 . . . . 0.0 108.81 172.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.49 146.41 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 124.922 1.289 . . . . 0.0 111.594 176.636 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -119.12 168.99 10.32 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 127.268 2.227 . . . . 0.0 112.196 -171.034 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.38 98.86 3.21 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 127.263 2.225 . . . . 0.0 108.105 172.219 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -102.41 114.08 27.96 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 118.71 0.686 . . . . 0.0 111.581 -175.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -91.64 132.48 36.31 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.221 1.008 . . . . 0.0 110.948 176.227 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.4 ptmt -84.02 -30.79 25.83 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 179.349 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -162.17 144.73 11.37 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.19 2.196 . . . . 0.0 109.847 169.586 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 1.5 m -43.77 24.77 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 1 C-N-CA 137.957 6.503 . . . . 0.0 119.037 -174.767 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.6 p30 179.76 -24.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 128.371 2.668 . . . . 0.0 112.081 -170.194 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.6 165.11 54.3 Favored Glycine 0 CA--C 1.541 1.659 0 O-C-N 121.168 -0.958 . . . . 0.0 112.425 169.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -70.15 169.7 18.79 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 124.305 3.336 . . . . 0.0 113.12 -171.288 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 31.7 t -131.02 129.43 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.942 1.697 . . . . 0.0 110.503 -169.111 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -93.77 125.82 38.6 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-O 122.319 1.057 . . . . 0.0 109.902 170.56 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.06 128.16 39.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 127.585 2.354 . . . . 0.0 108.071 169.44 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -153.39 158.26 41.19 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 171.646 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.83 -141.99 12.79 Favored Glycine 0 N--CA 1.463 0.456 0 C-N-CA 125.08 1.324 . . . . 0.0 111.51 176.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 99.0 p -155.02 162.13 41.16 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 117.987 2.588 . . . . 0.0 117.987 -167.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 19.4 mm -130.4 123.93 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 C-N-CA 126.567 1.947 . . . . 0.0 107.445 168.067 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . 0.431 ' HZ3' ' CG ' ' B' ' 92' ' ' ASP . 57.8 tttp -122.24 136.49 54.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 122.854 2.57 . . . . 0.0 110.731 -178.63 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.26 -8.77 5.65 Favored Glycine 0 N--CA 1.474 1.202 0 C-N-CA 126.47 1.986 . . . . 0.0 114.094 -178.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 33.4 mt -70.22 172.97 7.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.096 1.358 . . . . 0.0 111.638 170.625 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 11.8 t -110.77 157.73 19.46 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 162.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -59.03 162.04 4.59 Favored 'General case' 0 CA--C 1.537 0.442 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -167.213 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.79 -179.15 34.07 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.671 -174.841 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -75.64 144.21 41.81 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.533 1.533 . . . . 0.0 113.0 -169.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -140.37 170.14 16.37 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 126.948 2.099 . . . . 0.0 109.567 176.462 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -124.93 166.06 17.79 Favored Glycine 0 N--CA 1.478 1.486 0 C-N-CA 125.132 1.349 . . . . 0.0 113.148 -174.196 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -156.46 162.32 39.99 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.951 2.1 . . . . 0.0 112.82 172.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 46.7 p-80 -156.14 163.91 39.04 Favored 'General case' 0 C--N 1.347 0.468 0 O-C-N 120.583 -1.323 . . . . 0.0 108.835 168.797 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -110.84 162.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 125.015 1.326 . . . . 0.0 108.857 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.419 ' CE1' ' HB ' ' B' ' 116' ' ' THR . 5.3 p80 -136.67 126.18 25.18 Favored 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 120.984 -1.072 . . . . 0.0 109.789 176.606 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -71.75 136.47 47.16 Favored 'General case' 0 N--CA 1.452 -0.357 0 O-C-N 123.932 0.77 . . . . 0.0 109.913 179.443 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 121.22 133.05 0.0 OUTLIER 'General case' 0 C--O 1.233 0.209 1 C-N-CA 133.958 4.903 . . . . 0.0 108.449 -176.149 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.42 2.89 61.15 Favored Glycine 0 C--O 1.222 -0.615 0 CA-C-O 118.211 -1.327 . . . . 0.0 114.019 178.717 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -103.13 51.58 0.79 Allowed 'General case' 0 CA--C 1.536 0.423 0 CA-C-N 120.24 2.02 . . . . 0.0 112.934 -179.15 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.1 37.73 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 126.669 1.987 . . . . 0.0 110.995 -171.472 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.3 p -61.8 47.02 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.504 1 C-N-CA 133.688 4.795 . . . . 0.0 115.948 -171.614 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -152.28 -21.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.882 2.073 . . . . 0.0 112.53 178.481 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' B' ' 58' ' ' THR . . . 115.48 -161.89 12.69 Favored Glycine 0 C--N 1.344 0.992 0 CA-C-N 119.464 1.029 . . . . 0.0 113.298 170.623 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -52.78 1.17 0.01 OUTLIER 'General case' 0 CA--C 1.56 1.356 0 C-N-CA 128.213 2.605 . . . . 0.0 115.094 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 58' ' ' THR . . . . . 0.415 ' H ' ' C ' ' B' ' 56' ' ' GLY . 9.5 t -94.32 -11.85 29.21 Favored 'General case' 0 N--CA 1.481 1.088 0 O-C-N 119.193 -2.192 . . . . 0.0 112.896 168.051 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 75.0 m -132.86 0.26 3.5 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 125.023 1.329 . . . . 0.0 113.687 178.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -155.52 -176.49 5.97 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.343 1.857 . . . . 0.0 110.142 173.493 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.99 163.57 26.9 Favored Glycine 0 CA--C 1.544 1.897 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -173.201 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -66.09 125.29 13.86 Favored 'Trans proline' 0 C--N 1.352 0.716 0 C-N-CA 124.977 3.785 . . . . 0.0 111.322 178.378 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.318 1.9 p80 28.32 59.23 0.12 Allowed 'General case' 0 C--O 1.239 0.551 0 C-N-CA 130.278 3.431 . . . . 0.0 116.858 177.935 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -58.8 121.1 10.28 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 105.153 -2.166 . . . . 0.0 105.153 162.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -125.47 142.4 41.65 Favored Pre-proline 0 CA--C 1.543 0.683 0 C-N-CA 124.365 1.066 . . . . 0.0 113.799 -169.068 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -83.38 -15.08 7.8 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.323 2.682 . . . . 0.0 113.587 175.172 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 79.8 mt -93.88 -10.63 33.28 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 115.03 1.492 . . . . 0.0 115.03 -171.486 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t 46.12 58.69 4.26 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 169.474 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 4.6 ptt180 -143.88 -174.96 4.4 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 127.899 2.48 . . . . 0.0 111.06 -175.611 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.494 ' HZ3' ' CD ' ' B' ' 78' ' ' GLU 0.25 3.1 pttp -65.19 160.48 21.28 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 120.231 1.378 . . . . 0.0 112.706 175.963 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -96.95 138.62 34.21 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.777 -1.556 . . . . 0.0 113.326 -177.086 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.92 -151.33 20.19 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 127.075 2.274 . . . . 0.0 109.456 170.49 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.496 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 169.25 -32.99 0.18 Allowed Glycine 0 CA--C 1.528 0.87 0 N-CA-C 119.722 2.649 . . . . 0.0 119.722 169.004 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.3 24.18 0.22 Allowed 'Trans proline' 0 CA--C 1.554 1.52 0 CA-C-N 122.97 3.385 . . . . 0.0 113.013 167.787 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . 0.496 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -168.59 -41.39 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 129.865 3.266 . . . . 0.0 107.245 166.427 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.255 4.9 t70 -62.69 117.97 7.02 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 123.932 1.825 . . . . 0.0 109.599 -171.055 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . 0.433 ' CD ' ' HZ2' ' B' ' 75' ' ' LYS . 27.3 mp0 -72.48 -19.57 61.52 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 129.416 3.086 . . . . 0.0 114.471 -161.616 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . 0.494 ' CD ' ' HZ3' ' B' ' 70' ' ' LYS . 1.1 mp0 -105.71 -65.21 1.08 Allowed 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.022 0.529 . . . . 0.0 111.197 176.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 76.77 126.72 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 125.181 1.393 . . . . 0.0 114.352 165.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -73.78 159.54 32.78 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 124.608 1.163 . . . . 0.0 113.015 168.106 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -61.86 -47.75 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 120.931 -1.106 . . . . 0.0 110.142 173.529 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -77.56 31.38 1.67 Allowed Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.865 1.221 . . . . 0.0 115.369 176.587 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -115.71 117.39 30.14 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 121.368 -1.078 . . . . 0.0 108.941 170.291 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 87.1 mt -140.72 131.68 26.1 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 102.455 -3.165 . . . . 0.0 102.455 168.743 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.69 -144.77 16.07 Favored Glycine 0 N--CA 1.47 0.941 0 N-CA-C 119.698 2.639 . . . . 0.0 119.698 -163.534 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . 0.48 HD22 ' HA ' ' B' ' 124' ' ' ASP . 93.4 m-20 -72.96 159.86 33.02 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -165.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.3 p -133.05 177.28 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 130.387 3.475 . . . . 0.0 110.093 -171.185 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -155.76 132.79 10.67 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 119.666 1.121 . . . . 0.0 111.356 174.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.46 160.5 15.41 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.342 1.057 . . . . 0.0 113.776 176.283 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.48 ' CG ' ' H ' ' B' ' 91' ' ' LYS . 38.5 t70 -92.08 177.2 6.24 Favored 'General case' 0 CA--C 1.552 1.041 0 C-N-CA 127.186 2.194 . . . . 0.0 112.663 170.293 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.48 ' H ' ' CG ' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -66.74 -17.58 64.94 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 120.913 -1.117 . . . . 0.0 112.958 169.606 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.431 ' CG ' ' HZ3' ' B' ' 36' ' ' LYS . 0.7 OUTLIER -70.81 -27.26 63.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.081 0.952 . . . . 0.0 110.449 168.838 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.97 -4.5 65.52 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 117.96 -1.467 . . . . 0.0 114.439 -177.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.99 131.06 35.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 118.736 1.268 . . . . 0.0 110.917 168.782 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.16 124.63 44.35 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 165.892 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -79.16 143.51 35.37 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.706 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.09 130.53 72.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.686 166.625 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 8.6 m -150.77 82.97 1.34 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.857 1.263 . . . . 0.0 110.537 -175.142 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.6 mt -130.91 142.48 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.605 1.562 . . . . 0.0 111.007 -172.671 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -100.69 145.14 28.82 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.356 1.862 . . . . 0.0 107.176 168.653 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.973 0.909 . . . . 0.0 109.432 169.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.6 p -131.31 51.96 2.1 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.225 1.01 . . . . 0.0 112.263 179.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -152.47 34.82 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 122.736 1.255 . . . . 0.0 111.43 169.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.1 172.17 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 126.688 1.995 . . . . 0.0 111.329 -169.655 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -159.78 153.76 23.2 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 120.817 -1.177 . . . . 0.0 112.685 169.275 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.7 mp -82.72 58.91 4.48 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.641 -1.287 . . . . 0.0 110.345 176.377 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.9 t -89.11 141.1 28.8 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.071 171.417 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -77.1 47.83 2.66 Favored Glycine 0 N--CA 1.474 1.217 0 C-N-CA 126.23 1.871 . . . . 0.0 115.584 -168.443 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -139.15 -90.98 0.19 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.847 2.459 . . . . 0.0 107.784 -170.398 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -150.45 -4.88 0.33 Allowed 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 127.878 2.471 . . . . 0.0 112.275 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.5 t -69.34 -0.39 6.23 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.162 -1.586 . . . . 0.0 114.6 -174.979 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.5 7.5 pt 149.36 8.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 1 C-N-CA 135.667 5.587 . . . . 0.0 115.365 168.092 . . . . . . . . 3 2 . 1 . 026 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 48.9 mm -87.12 168.94 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 O-C-N 120.56 -1.337 . . . . 0.0 109.232 165.696 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.32 -33.39 2.02 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 117.849 1.899 . . . . 0.0 117.849 166.109 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 ptt85 -74.8 174.12 9.62 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 125.77 1.628 . . . . 0.0 112.043 -169.898 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.419 ' HB ' ' CE1' ' B' ' 48' ' ' HIS . 3.1 m -130.12 154.12 47.81 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.166 0.986 . . . . 0.0 109.699 -174.311 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -133.26 145.51 50.57 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 125.376 1.47 . . . . 0.0 111.505 -169.668 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.7 p -128.14 135.76 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 126.194 1.797 . . . . 0.0 110.88 174.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 t -101.91 158.24 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 125.521 1.528 . . . . 0.0 108.392 169.858 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -128.21 153.25 47.12 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 127.799 2.44 . . . . 0.0 111.296 -173.115 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -75.32 -24.93 57.47 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.491 -178.819 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -100.54 171.16 7.9 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 119.704 1.138 . . . . 0.0 110.114 167.507 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -112.08 94.57 5.01 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 125.283 1.433 . . . . 0.0 111.925 -179.371 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.48 ' HA ' HD22 ' B' ' 86' ' ' ASN 0.267 25.5 t0 -152.97 146.92 25.36 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-O 123.561 1.648 . . . . 0.0 109.25 168.032 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -169.3 -52.27 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 130.467 3.507 . . . . 0.0 110.893 -178.245 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . 0.515 HD13 ' H ' ' B' ' 126' ' ' LEU 0.338 0.0 OUTLIER -86.07 59.32 5.56 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 116.575 2.065 . . . . 0.0 116.575 -163.094 . . . . . . . . 4 4 . 1 . 026 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.44 -9.12 0.88 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 117.839 1.896 . . . . 0.0 117.839 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.3 ptmt -160.21 21.62 0.16 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 116.763 2.134 . . . . 0.0 116.763 -169.218 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.5 -19.38 78.95 Favored Glycine 0 N--CA 1.472 1.079 0 CA-C-N 120.26 1.391 . . . . 0.0 113.489 178.938 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -151.24 -42.24 0.02 OUTLIER Glycine 0 N--CA 1.468 0.83 0 N-CA-C 116.665 1.426 . . . . 0.0 116.665 -178.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -163.08 -165.31 1.08 Allowed 'General case' 0 CA--C 1.546 0.815 0 CA-C-N 120.201 2.0 . . . . 0.0 113.514 -173.448 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -49.27 -56.07 10.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.382 1.473 . . . . 0.0 110.876 169.043 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.23 -16.22 31.6 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 20.8 m -55.0 -31.79 61.28 Favored 'General case' 0 N--CA 1.471 0.594 0 O-C-N 120.091 -1.631 . . . . 0.0 112.702 168.527 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.264 2.8 t -97.44 -8.49 29.23 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 174.08 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -87.68 -60.95 1.83 Allowed 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.289 -1.507 . . . . 0.0 111.202 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 28.5 p -102.87 -24.92 13.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 126.018 1.727 . . . . 0.0 114.413 -177.223 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.55 -22.87 35.95 Favored Glycine 0 C--O 1.213 -1.159 0 CA-C-O 117.93 -1.483 . . . . 0.0 110.075 -166.26 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 33.2 t30 56.83 19.11 4.22 Favored 'General case' 0 CA--C 1.548 0.875 0 CA-C-N 119.351 1.576 . . . . 0.0 112.387 173.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.76 -23.16 2.51 Favored 'General case' 0 CA--C 1.557 1.226 0 C-N-CA 129.079 2.952 . . . . 0.0 115.057 -171.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 93.94 -153.19 21.07 Favored Glycine 0 C--N 1.343 0.924 0 C-N-CA 126.692 2.091 . . . . 0.0 114.414 174.765 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.03 151.88 2.45 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.711 2.004 . . . . 0.0 113.481 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 15.1 mtp-105 -66.24 166.88 11.2 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.9 -1.125 . . . . 0.0 113.474 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tp -150.01 -152.6 0.45 Allowed 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 128.727 2.811 . . . . 0.0 106.911 166.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.29 178.3 7.23 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -178.668 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.5 p -158.16 159.18 35.89 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.107 1.363 . . . . 0.0 111.459 -173.28 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.38 170.52 34.53 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.696 1.617 . . . . 0.0 113.416 176.086 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.54 147.41 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.639 1.176 . . . . 0.0 110.007 179.346 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.2 mm -93.47 76.68 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.324 0.65 . . . . 0.0 110.042 -178.71 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.57 161.88 32.7 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 123.652 0.644 . . . . 0.0 112.225 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 mp -75.05 134.87 28.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -175.452 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.82 35.13 3.34 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.461 1.504 . . . . 0.0 113.485 -168.735 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 . . . . . 0 C--N 1.324 -0.518 0 C-N-CA 126.633 1.973 . . . . 0.0 110.691 -177.31 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 118.221 -0.895 . . . . 0.0 108.826 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m -79.71 79.6 6.19 Favored 'General case' 0 C--O 1.217 -0.648 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.294 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 ttmm -120.09 128.11 53.16 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -169.415 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 171.77 7.22 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.927 0.891 . . . . 0.0 112.921 169.407 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.43 155.01 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 129.72 3.208 . . . . 0.0 106.908 165.97 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.25 114.81 19.45 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.738 1.154 . . . . 0.0 109.559 166.742 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.7 t -88.57 76.42 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 125.185 1.394 . . . . 0.0 108.938 -171.91 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.47 103.96 9.75 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.034 -175.018 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 ttpp -160.92 132.16 5.53 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 123.274 0.63 . . . . 0.0 112.369 166.08 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.15 -95.5 1.94 Allowed Glycine 0 C--N 1.333 0.384 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 168.074 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.31 -177.1 3.41 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.013 1.725 . . . . 0.0 107.974 174.007 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 61.69 -173.55 7.32 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.732 2.11 . . . . 0.0 117.05 168.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.54 4.41 7.1 Favored 'Trans proline' 0 CA--C 1.543 0.941 1 C-N-CA 126.347 4.698 . . . . 0.0 113.836 178.593 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 m -79.43 138.03 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 126.848 2.059 . . . . 0.0 111.045 175.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.77 169.23 19.5 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 122.238 1.018 . . . . 0.0 109.801 165.707 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -141.17 149.01 20.71 Favored Glycine 0 CA--C 1.499 -0.92 0 CA-C-N 113.379 -1.737 . . . . 0.0 110.078 164.245 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -130.27 112.01 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 172.189 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 mm -135.61 102.44 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 121.469 -0.77 . . . . 0.0 111.077 -174.118 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -72.34 157.28 37.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.165 170.204 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -137.22 98.71 3.8 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 168.867 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -89.93 108.02 19.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 122.12 0.962 . . . . 0.0 109.75 172.291 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -101.58 149.03 24.53 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 166.104 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -13.53 10.57 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.3 1.44 . . . . 0.0 112.253 -175.36 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.37 -146.06 0.37 Allowed 'General case' 0 CA--C 1.556 1.203 0 C-N-CA 128.919 2.887 . . . . 0.0 108.017 173.236 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.2 p -139.68 -45.84 0.44 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 126.009 1.723 . . . . 0.0 108.294 166.647 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.9 m-80 -85.76 32.45 0.59 Allowed 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.057 1.743 . . . . 0.0 112.722 172.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.91 -175.06 13.91 Favored Glycine 0 CA--C 1.538 1.499 0 C-N-CA 125.726 1.632 . . . . 0.0 113.002 177.404 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -76.54 170.99 18.87 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 123.82 3.013 . . . . 0.0 111.507 177.909 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.8 t -132.99 123.62 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.971 0.908 . . . . 0.0 110.31 -170.669 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.0 tttm -87.13 114.33 23.65 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 122.909 1.338 . . . . 0.0 112.621 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 t -95.25 131.1 42.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 125.941 1.696 . . . . 0.0 108.628 -176.646 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -153.38 160.3 42.61 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 173.653 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.08 -149.37 18.85 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 125.151 1.358 . . . . 0.0 111.521 -173.047 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 83.8 p -157.62 159.09 36.66 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 114.318 1.229 . . . . 0.0 114.318 -173.661 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -121.56 117.5 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.461 1.505 . . . . 0.0 107.331 171.863 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -128.88 151.82 49.2 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 126.146 1.779 . . . . 0.0 112.052 -165.165 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.58 10.88 82.73 Favored Glycine 0 CA--C 1.531 1.063 0 CA-C-O 118.773 -1.015 . . . . 0.0 113.785 -178.693 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.26 169.08 10.02 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.94 1.296 . . . . 0.0 111.0 173.332 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 t -69.83 160.13 32.33 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.77 1.228 . . . . 0.0 110.257 173.603 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.94 168.76 0.6 Allowed 'General case' 0 CA--C 1.55 0.961 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 178.611 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.6 -175.26 50.68 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.693 1.14 . . . . 0.0 113.472 170.141 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.452 ' CD1' ' H ' ' A' ' 42' ' ' LEU . 5.2 mp -56.14 147.04 21.37 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.728 2.411 . . . . 0.0 111.324 178.628 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -142.98 116.01 8.86 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 126.206 1.802 . . . . 0.0 110.187 176.004 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.53 151.45 14.35 Favored Glycine 0 N--CA 1.483 1.814 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.89 173.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -151.02 105.53 3.25 Favored 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 118.984 1.392 . . . . 0.0 111.089 -165.519 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 11.8 m80 -145.57 160.18 42.03 Favored 'General case' 0 N--CA 1.471 0.597 0 O-C-N 119.431 -2.043 . . . . 0.0 113.909 -164.584 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . 0.288 0.4 OUTLIER -129.64 120.71 51.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 122.635 1.207 . . . . 0.0 111.489 -171.854 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -79.29 137.19 37.26 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.91 2.084 . . . . 0.0 109.785 175.829 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.0 pm0 -70.44 16.09 0.08 Allowed 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -178.232 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -126.75 144.23 51.01 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 124.425 1.09 . . . . 0.0 108.572 168.846 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.26 27.57 5.05 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.295 1.426 . . . . 0.0 111.539 168.38 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -86.94 173.1 9.55 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.432 1.493 . . . . 0.0 109.911 173.793 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.64 9.15 4.11 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 118.01 2.596 . . . . 0.0 118.01 164.561 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.4 t -61.3 71.32 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.244 2.217 . . . . 0.0 116.504 -168.57 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -141.84 -63.5 0.44 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 125.483 1.513 . . . . 0.0 112.804 168.068 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 166.59 -153.77 23.77 Favored Glycine 0 N--CA 1.47 0.911 0 O-C-N 120.761 -1.212 . . . . 0.0 112.52 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -56.11 -9.52 0.65 Allowed 'General case' 0 CA--C 1.552 1.022 0 N-CA-C 116.474 2.027 . . . . 0.0 116.474 -172.415 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 t -81.46 0.52 37.36 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.927 1.691 . . . . 0.0 113.256 173.725 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 60.9 m -159.39 178.42 9.94 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.564 1.945 . . . . 0.0 110.218 179.176 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 85.68 -125.73 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.502 1.921 . . . . 0.0 113.007 172.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 170.73 -153.9 21.83 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 125.677 1.608 . . . . 0.0 111.765 -169.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -109.32 57.58 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 123.619 2.879 . . . . 0.0 112.453 -174.547 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 61.95 87.83 0.09 Allowed 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.229 1.411 . . . . 0.0 108.338 -177.415 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -46.36 152.05 0.47 Allowed 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 113.15 -1.841 . . . . 0.0 111.447 -178.686 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -136.47 101.06 10.06 Favored Pre-proline 0 CA--C 1.551 1.018 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -164.94 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.93 -27.78 3.64 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.25 1.967 . . . . 0.0 111.072 -176.171 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.25 -6.04 55.73 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.526 1.53 . . . . 0.0 111.683 167.761 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.7 t 62.69 48.16 4.4 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.98 2.112 . . . . 0.0 111.487 178.252 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.9 mtp180 -99.02 170.63 8.58 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 124.475 1.11 . . . . 0.0 112.922 -172.54 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.6 mmtt -84.92 174.17 10.01 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.89 1.676 . . . . 0.0 108.614 163.55 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 62.8 t60 -70.6 149.87 46.63 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 120.782 -1.199 . . . . 0.0 112.066 170.301 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -174.51 -165.2 30.61 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 124.071 0.843 . . . . 0.0 114.035 176.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 131.92 -100.45 0.43 Allowed Glycine 0 CA--C 1.537 1.425 0 CA-C-O 117.571 -1.683 . . . . 0.0 116.811 170.001 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.51 -19.53 23.44 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 CA-C-N 122.093 2.947 . . . . 0.0 116.377 -168.928 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.9 3.16 4.88 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.24 2.216 . . . . 0.0 112.594 176.06 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -145.88 155.7 43.06 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -164.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.57 -7.87 49.01 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 128.363 2.665 . . . . 0.0 113.402 -168.943 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -78.04 -106.39 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 118.696 0.68 . . . . 0.0 109.847 172.769 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.9 ttt180 71.58 101.01 0.07 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.166 1.386 . . . . 0.0 110.359 -172.392 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -51.8 152.67 2.82 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.789 -1.194 . . . . 0.0 111.298 166.527 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 19.3 m -52.88 -33.89 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-N 120.571 1.532 . . . . 0.0 112.785 -175.166 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.75 102.24 1.56 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 124.696 1.141 . . . . 0.0 110.639 166.015 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -160.06 116.22 2.43 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.258 2.223 . . . . 0.0 108.775 177.524 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 92.0 mt -103.01 176.32 5.19 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.577 1.08 . . . . 0.0 108.973 168.148 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.15 173.81 54.97 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 167.342 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -74.65 151.49 39.3 Favored 'General case' 0 CA--C 1.55 0.973 0 N-CA-C 115.09 1.515 . . . . 0.0 115.09 -171.544 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.2 m -102.88 117.23 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 127.974 2.51 . . . . 0.0 109.732 179.07 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.9 m -96.82 119.45 35.31 Favored 'General case' 0 N--CA 1.478 0.948 0 O-C-N 120.531 -1.356 . . . . 0.0 111.234 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.39 140.13 37.52 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -76.37 168.66 19.67 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.076 1.751 . . . . 0.0 111.798 170.62 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.8 pttm -45.74 -28.35 1.02 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.136 2.574 . . . . 0.0 115.135 170.822 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.73 -1.56 56.41 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.4 1.48 . . . . 0.0 111.818 -177.505 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.9 24.87 39.88 Favored Glycine 0 C--N 1.342 0.901 0 C-N-CA 125.274 1.416 . . . . 0.0 114.024 177.636 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.6 p -129.91 129.11 65.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 CA-C-N 118.497 1.148 . . . . 0.0 113.902 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.67 129.54 39.94 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.426 1.09 . . . . 0.0 108.129 166.076 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -79.16 151.02 31.53 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 167.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.6 t -135.04 123.87 41.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 CA-C-N 112.444 -2.162 . . . . 0.0 109.199 167.623 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.9 p -155.51 50.2 0.55 Allowed 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 124.025 1.869 . . . . 0.0 111.357 -177.311 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -103.45 170.44 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 127.603 2.361 . . . . 0.0 112.324 -166.48 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.94 121.48 20.57 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 165.622 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -98.17 137.17 37.32 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.478 0.656 . . . . 0.0 109.251 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.4 p -118.24 53.47 0.97 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.932 -1.031 . . . . 0.0 112.253 -178.709 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 13.8 p -155.18 -36.78 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.06 0.944 . . . . 0.0 112.629 168.71 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.71 168.97 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 120.115 1.325 . . . . 0.0 110.573 169.016 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 26.5 p -153.6 162.21 41.47 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 124.381 1.072 . . . . 0.0 111.335 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -83.94 66.39 9.13 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-O 122.185 0.993 . . . . 0.0 109.077 173.971 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 73.5 m -112.45 6.32 18.54 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.737 1.615 . . . . 0.0 113.713 -172.523 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.03 -110.91 3.19 Favored Glycine 0 C--N 1.342 0.871 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 175.4 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -62.49 -35.88 80.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 123.16 1.457 . . . . 0.0 112.776 -176.087 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -89.06 -1.79 58.26 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 114.389 -1.278 . . . . 0.0 111.603 -171.081 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.0 m -168.16 -103.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.218 1.807 . . . . 0.0 113.783 170.137 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.2 pt -124.09 164.35 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 120.972 1.714 . . . . 0.0 112.311 -176.78 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 105.64 121.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.234 1 C-N-CA 133.859 4.864 . . . . 0.0 108.305 -167.832 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.17 32.86 85.59 Favored Glycine 0 CA--C 1.527 0.826 0 CA-C-O 119.057 -0.857 . . . . 0.0 113.179 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.63 179.5 3.95 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 127.317 2.247 . . . . 0.0 108.323 173.577 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 21.1 m -130.6 119.35 22.36 Favored 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 121.944 2.157 . . . . 0.0 111.592 -179.078 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 22.6 tp -92.35 119.25 31.73 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.554 1.542 . . . . 0.0 110.671 177.146 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.9 p -96.42 141.07 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.503 1.921 . . . . 0.0 111.111 174.647 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.9 p -118.08 137.34 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 122.046 0.927 . . . . 0.0 111.635 171.06 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.407 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 87.5 m-70 -99.72 161.95 13.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 125.231 1.412 . . . . 0.0 113.23 -170.128 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -83.7 -23.81 31.53 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -169.596 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -142.65 -174.85 4.27 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.737 0.815 . . . . 0.0 113.032 176.297 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.66 143.7 9.17 Favored 'General case' 0 C--N 1.341 0.206 0 C-N-CA 126.013 1.725 . . . . 0.0 111.215 172.163 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.99 149.6 24.07 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.789 1.636 . . . . 0.0 112.225 173.717 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -76.24 -10.05 59.11 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.762 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.2 mt 48.01 32.95 3.13 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 128.229 2.612 . . . . 0.0 113.235 177.175 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 165.63 -61.49 0.23 Allowed Glycine 0 N--CA 1.467 0.702 0 CA-C-N 120.492 1.496 . . . . 0.0 115.165 175.3 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -157.95 98.49 1.62 Allowed 'General case' 0 N--CA 1.428 -1.542 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 177.688 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.461 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -76.56 -115.12 0.14 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 126.222 1.868 . . . . 0.0 109.505 165.084 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -142.86 9.0 2.28 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 119.585 2.594 . . . . 0.0 119.585 -168.795 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -145.22 -169.38 3.19 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 120.651 2.226 . . . . 0.0 112.308 176.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.409 ' CD ' ' HZ2' ' A' ' 136' ' ' LYS . 20.6 tt0 -62.18 -49.87 74.07 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 121.173 1.806 . . . . 0.0 112.271 178.24 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.38 -22.85 63.8 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 123.439 0.696 . . . . 0.0 112.007 -177.65 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.461 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 25.2 m -64.37 -5.4 5.14 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.954 1.465 . . . . 0.0 114.954 168.193 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -122.35 -20.11 6.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.342 1.457 . . . . 0.0 112.029 172.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.409 ' HZ2' ' CD ' ' A' ' 132' ' ' GLU . 85.7 mttt -84.2 -69.85 0.61 Allowed 'General case' 0 CA--C 1.547 0.839 0 O-C-N 120.983 -1.073 . . . . 0.0 111.752 172.939 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -92.11 -13.45 30.74 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 177.646 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 83.5 21.72 57.71 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 119.454 1.024 . . . . 0.0 110.855 -165.716 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 52.15 36.23 18.62 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.596 1.958 . . . . 0.0 113.7 176.848 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.1 40.61 0.08 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 116.136 1.902 . . . . 0.0 116.136 -168.799 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.91 -64.06 1.95 Allowed Glycine 0 CA--C 1.528 0.865 0 C-N-CA 126.53 2.014 . . . . 0.0 112.469 -171.543 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 29.9 t -177.07 -150.45 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 C-N-CA 126.809 2.044 . . . . 0.0 109.547 -171.262 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.407 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -156.83 104.57 2.14 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.959 2.104 . . . . 0.0 112.479 -176.77 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.2 pp -72.85 -35.57 67.25 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.222 1.409 . . . . 0.0 114.653 -176.613 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.39 172.85 9.3 Favored 'General case' 0 C--O 1.239 0.54 0 C-N-CA 124.904 1.282 . . . . 0.0 111.767 -175.77 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.0 p -156.43 165.72 35.51 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 127.225 2.21 . . . . 0.0 111.048 175.15 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.45 147.28 15.56 Favored Glycine 0 C--N 1.337 0.617 0 C-N-CA 124.58 1.086 . . . . 0.0 114.036 -175.042 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -73.12 141.37 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.051 0.541 . . . . 0.0 110.124 175.017 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.5 mp -77.78 80.0 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.535 1.134 . . . . 0.0 109.506 169.384 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -79.36 171.34 54.83 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.084 1.325 . . . . 0.0 112.485 172.472 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.414 ' H ' ' HA3' ' B' ' 51' ' ' GLY . 2.4 mp -102.05 131.25 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 126.142 1.777 . . . . 0.0 111.435 -169.478 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.62 37.84 4.25 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.975 2.11 . . . . 0.0 110.706 -179.662 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.549 0 C-N-CA 129.353 3.061 . . . . 0.0 115.072 -167.525 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 121.786 0.803 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.93 106.22 4.05 Favored 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 124.428 1.091 . . . . 0.0 109.359 169.778 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 118.22 21.39 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 170.058 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.04 168.85 18.66 Favored 'General case' 0 CA--C 1.54 0.568 0 O-C-N 120.641 -1.287 . . . . 0.0 108.51 163.576 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.67 155.35 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.8 0.81 . . . . 0.0 113.026 -166.388 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.24 143.49 25.0 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.389 2.276 . . . . 0.0 107.386 165.757 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.1 m -113.05 117.79 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 168.098 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.89 125.99 33.74 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.064 0.946 . . . . 0.0 109.863 -168.848 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -146.2 177.08 9.26 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.354 1.062 . . . . 0.0 113.507 170.651 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.12 -65.97 0.25 Allowed Glycine 0 C--N 1.33 0.201 0 C-N-CA 126.497 1.999 . . . . 0.0 109.024 -176.666 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -103.09 85.01 2.43 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.966 2.106 . . . . 0.0 112.797 -167.165 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.06 -98.43 0.01 OUTLIER Glycine 0 CA--C 1.537 1.467 0 C-N-CA 127.071 2.272 . . . . 0.0 115.98 167.785 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -77.06 -8.69 17.77 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.617 2.878 . . . . 0.0 115.433 -173.549 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -98.31 138.82 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 CA-C-N 121.061 1.755 . . . . 0.0 110.866 176.14 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.5 pm0 -160.16 166.07 30.43 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 125.43 1.492 . . . . 0.0 110.801 171.255 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.31 175.61 33.94 Favored Glycine 0 CA--C 1.507 -0.422 0 C-N-CA 123.283 0.468 . . . . 0.0 113.398 169.227 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.02 146.62 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 123.445 0.698 . . . . 0.0 110.114 169.561 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.17 155.2 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 123.807 0.843 . . . . 0.0 110.108 167.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -127.67 148.32 50.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.8 1.24 . . . . 0.0 109.669 167.735 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -128.16 97.79 4.88 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.369 1.468 . . . . 0.0 110.395 178.563 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -81.36 106.53 13.4 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.367 1.067 . . . . 0.0 113.62 -176.148 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -101.7 140.57 35.82 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 165.298 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.33 -13.47 9.28 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 125.933 1.693 . . . . 0.0 112.361 169.782 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -97.45 -145.01 0.3 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 131.019 3.728 . . . . 0.0 109.772 173.089 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 57.7 m -163.61 40.57 0.09 Allowed 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 127.883 2.473 . . . . 0.0 107.772 168.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 p30 178.02 -42.51 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 126.682 1.993 . . . . 0.0 112.436 -167.133 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.86 -168.46 21.74 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 125.333 1.444 . . . . 0.0 113.435 178.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.42 172.43 9.07 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 124.381 3.387 . . . . 0.0 114.554 -169.741 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 65.2 t -140.95 133.59 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 123.994 0.918 . . . . 0.0 111.391 177.954 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 mttp -80.18 116.95 20.56 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.285 0.564 . . . . 0.0 110.449 169.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.1 t -98.95 114.49 36.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 125.547 1.539 . . . . 0.0 109.099 170.057 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.3 p90 -137.28 154.87 50.01 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 123.529 0.731 . . . . 0.0 111.676 169.887 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 159.92 166.8 19.51 Favored Glycine 0 C--N 1.336 0.576 0 N-CA-C 114.82 0.688 . . . . 0.0 114.82 177.806 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 13.0 p -132.52 126.69 33.5 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.278 1.031 . . . . 0.0 111.3 -170.072 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.0 mm -112.77 125.38 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 124.984 1.314 . . . . 0.0 111.14 174.772 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -130.53 135.62 48.11 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 120.575 1.534 . . . . 0.0 112.737 -169.096 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.74 -4.48 10.79 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 126.197 1.856 . . . . 0.0 114.058 -176.494 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -95.16 168.8 10.53 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.866 1.667 . . . . 0.0 111.724 170.464 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 m -69.36 152.77 44.55 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 127.18 2.192 . . . . 0.0 111.859 177.064 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 9.6 pm0 -51.95 157.07 1.34 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.867 1.667 . . . . 0.0 113.52 169.257 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.73 177.56 43.96 Favored Glycine 0 CA--C 1.539 1.555 0 O-C-N 120.653 -1.279 . . . . 0.0 114.567 -176.614 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 147.58 21.32 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 128.035 2.534 . . . . 0.0 114.635 -176.071 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -144.51 130.45 19.35 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 127.068 2.147 . . . . 0.0 109.737 175.643 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.39 156.31 31.93 Favored Glycine 0 N--CA 1.476 1.305 0 C-N-CA 125.001 1.286 . . . . 0.0 113.694 -175.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -150.4 141.09 22.66 Favored 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 -170.025 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -145.43 115.9 7.6 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 118.234 -0.889 . . . . 0.0 113.303 -170.136 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -87.85 98.24 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 167.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.416 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 45.4 m170 -73.83 151.43 40.54 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 121.657 -0.652 . . . . 0.0 111.703 -170.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -49.93 126.19 13.64 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.017 1.727 . . . . 0.0 113.005 174.181 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 93.24 147.28 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 130.54 3.536 . . . . 0.0 114.443 172.128 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.414 ' HA3' ' H ' ' A' ' 151' ' ' ILE . . . -77.55 -7.5 87.14 Favored Glycine 0 CA--C 1.533 1.201 0 CA-C-O 117.558 -1.69 . . . . 0.0 113.096 168.257 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -86.39 132.1 34.04 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 120.313 2.056 . . . . 0.0 109.506 167.774 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.417 HD21 ' N ' ' B' ' 53' ' ' ASN 0.317 0.0 OUTLIER -157.85 28.33 0.27 Allowed 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 114.981 1.475 . . . . 0.0 114.981 179.243 . . . . . . . . 4 4 . 1 . 027 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 17.9 p -102.13 -22.71 14.16 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -168.4 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.73 6.45 47.46 Favored 'General case' 0 CA--C 1.551 0.992 0 C-N-CA 123.853 0.861 . . . . 0.0 110.694 165.885 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.57 -110.81 3.59 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 125.038 1.304 . . . . 0.0 111.775 171.578 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 72.1 m -71.03 -11.44 60.97 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -171.287 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -102.06 1.62 36.63 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.569 1.147 . . . . 0.0 113.101 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 68.6 m -99.9 -125.72 0.17 Allowed 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 124.846 1.258 . . . . 0.0 108.098 168.176 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.86 83.31 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.744 1.618 . . . . 0.0 114.297 171.743 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.07 167.23 27.09 Favored Glycine 0 CA--C 1.542 1.722 0 C-N-CA 125.174 1.369 . . . . 0.0 113.758 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . 0.416 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 59.9 Cg_endo -64.74 89.95 0.18 Allowed 'Trans proline' 0 C--N 1.354 0.824 1 C-N-CA 125.881 4.387 . . . . 0.0 112.248 -170.097 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.379 0.1 OUTLIER 47.94 59.67 4.06 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 127.167 2.187 . . . . 0.0 113.79 175.85 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -47.72 129.88 14.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 111.884 -2.417 . . . . 0.0 109.541 168.034 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -110.21 66.33 0.44 Allowed Pre-proline 0 CA--C 1.549 0.931 0 C-N-CA 125.964 1.706 . . . . 0.0 114.823 -167.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -64.16 -21.04 67.84 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.002 2.468 . . . . 0.0 116.045 -169.417 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.38 -4.44 48.19 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.795 0.838 . . . . 0.0 112.703 172.488 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.0 t 67.36 46.99 1.34 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 128.691 2.797 . . . . 0.0 110.513 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.8 mtm-85 -109.5 167.1 10.38 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.059 -177.658 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -85.85 176.84 7.87 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 127.657 2.383 . . . . 0.0 108.175 167.016 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . 0.458 ' HE2' ' CG ' ' B' ' 124' ' ' ASP . 21.9 t60 -62.63 175.21 0.84 Allowed 'General case' 0 CA--C 1.544 0.745 0 O-C-N 121.336 -0.852 . . . . 0.0 112.812 173.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.68 -149.79 20.75 Favored Glycine 0 C--N 1.339 0.718 0 N-CA-C 115.641 1.016 . . . . 0.0 115.641 170.386 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.86 -117.3 2.17 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 125.727 1.632 . . . . 0.0 112.755 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -65.01 -11.37 29.5 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.786 2.991 . . . . 0.0 116.075 -169.305 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.53 -3.13 10.92 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 119.534 1.061 . . . . 0.0 113.145 168.737 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -152.17 98.03 2.37 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -166.783 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 63.9 mm-40 -39.72 -4.99 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 131.32 3.848 . . . . 0.0 118.47 171.316 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -74.0 -75.95 0.14 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 121.021 1.737 . . . . 0.0 110.116 170.522 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.254 0.0 OUTLIER 52.76 107.02 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 127.326 2.251 . . . . 0.0 113.869 -177.595 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -54.53 143.79 23.3 Favored 'General case' 0 CA--C 1.552 1.028 0 O-C-N 119.631 -1.918 . . . . 0.0 110.525 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 96.9 t -35.36 -59.26 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -168.123 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.78 18.71 16.68 Favored Glycine 0 N--CA 1.468 0.801 0 CA-C-O 119.335 -0.703 . . . . 0.0 112.989 176.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.46 89.68 2.88 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-N 119.526 1.663 . . . . 0.0 111.775 -167.633 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.11 163.35 37.71 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 114.634 -1.166 . . . . 0.0 113.578 -167.86 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 78.25 170.37 36.47 Favored Glycine 0 N--CA 1.472 1.044 0 N-CA-C 115.274 0.87 . . . . 0.0 115.274 168.46 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -134.48 149.54 50.73 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.908 1.283 . . . . 0.0 109.969 174.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.5 m -112.53 129.31 68.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.884 1.674 . . . . 0.0 109.204 169.505 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.7 m -113.15 133.81 54.86 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 121.24 -0.913 . . . . 0.0 109.903 -170.119 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.15 137.3 32.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.711 1.204 . . . . 0.0 113.522 -178.212 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.86 -59.25 2.86 Favored 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -168.212 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 172.81 -40.88 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 128.405 2.682 . . . . 0.0 110.731 -166.047 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -78.25 13.2 1.58 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 125.877 1.671 . . . . 0.0 112.281 174.154 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.77 25.56 70.57 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-O 118.932 -0.927 . . . . 0.0 113.38 -177.242 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -105.96 109.52 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 126.338 1.855 . . . . 0.0 110.991 176.155 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -79.28 108.84 13.08 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 168.175 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -110.53 159.04 17.88 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 122.313 1.054 . . . . 0.0 112.273 -176.412 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -149.6 148.0 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 CA-C-N 113.62 -1.627 . . . . 0.0 115.302 176.91 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -157.77 98.61 1.65 Allowed 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 124.2 1.0 . . . . 0.0 112.306 169.687 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 15.2 mt -139.7 152.3 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 127.522 2.329 . . . . 0.0 110.876 -172.746 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -117.53 127.23 53.78 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 165.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -117.28 146.49 43.28 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.517 1.527 . . . . 0.0 111.049 176.097 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 51.31 0.95 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.495 0.718 . . . . 0.0 112.913 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 47.2 t -136.39 -50.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.252 1.421 . . . . 0.0 109.635 175.336 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.84 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 CA-C-N 119.128 0.877 . . . . 0.0 111.747 174.656 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.88 161.66 39.67 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 119.888 -1.758 . . . . 0.0 111.251 -178.453 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.83 58.46 1.89 Allowed 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.88 1.324 . . . . 0.0 110.602 177.257 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.31 160.6 20.67 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 124.544 1.137 . . . . 0.0 108.8 168.128 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.25 -59.0 10.15 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 119.612 2.605 . . . . 0.0 119.612 -163.21 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -148.94 34.87 0.75 Allowed 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 122.862 1.315 . . . . 0.0 110.745 -172.142 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -158.01 4.08 0.12 Allowed 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 114.957 1.466 . . . . 0.0 114.957 -168.759 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 10.6 t -133.28 -91.21 0.37 Allowed 'General case' 0 N--CA 1.48 1.031 0 O-C-N 119.984 -1.698 . . . . 0.0 109.634 -178.313 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.283 5.4 pt -120.26 -14.66 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-N 121.185 1.811 . . . . 0.0 115.696 166.861 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm -82.75 152.64 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 161.122 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.05 41.71 86.58 Favored Glycine 0 N--CA 1.467 0.703 0 C-N-CA 124.103 0.858 . . . . 0.0 112.401 -176.446 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -144.88 171.16 14.82 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 127.242 2.217 . . . . 0.0 109.004 172.17 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.5 t -139.42 122.66 16.98 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.873 -1.142 . . . . 0.0 110.979 -177.694 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 39.8 tp -92.07 108.87 20.25 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -169.464 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.8 p -90.62 142.35 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 125.32 1.448 . . . . 0.0 110.117 168.136 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -120.66 146.09 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.458 0.646 . . . . 0.0 111.316 172.012 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -105.63 141.37 37.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.56 1.544 . . . . 0.0 114.369 -168.728 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.317 0.2 OUTLIER -72.03 -18.39 61.96 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 120.841 -1.162 . . . . 0.0 112.037 178.24 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mttp -104.29 162.92 12.79 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 124.466 1.106 . . . . 0.0 112.759 168.067 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.0 165.08 9.44 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.308 1.843 . . . . 0.0 110.789 167.046 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . 0.46 ' HB3' ' H ' ' B' ' 126' ' ' LEU . 12.4 m-20 -95.2 158.9 15.26 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 122.126 0.965 . . . . 0.0 113.177 169.712 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.34 -7.9 50.2 Favored 'General case' 0 CA--C 1.557 1.22 0 CA-C-N 113.715 -1.584 . . . . 0.0 112.561 167.026 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . 0.46 ' H ' ' HB3' ' B' ' 124' ' ' ASP . 96.3 mt 33.11 44.91 0.06 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 129.543 3.137 . . . . 0.0 114.068 -174.737 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.67 -52.38 0.83 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 115.854 1.101 . . . . 0.0 115.854 168.773 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -155.99 80.94 1.0 Allowed 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 117.046 2.239 . . . . 0.0 117.046 -169.22 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . 0.526 ' H ' ' HB3' ' B' ' 134' ' ' SER . . . -80.2 -115.02 0.29 Allowed Glycine 0 CA--C 1.524 0.625 0 C-N-CA 124.076 0.846 . . . . 0.0 111.009 166.389 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -137.9 11.72 3.65 Favored Glycine 0 N--CA 1.472 1.071 0 N-CA-C 116.893 1.517 . . . . 0.0 116.893 -169.338 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -144.12 174.84 10.52 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 119.819 1.81 . . . . 0.0 111.765 177.65 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . 0.51 ' CG ' ' HE3' ' B' ' 136' ' ' LYS . 3.2 tp10 -51.59 -64.27 0.87 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.463 1.505 . . . . 0.0 112.574 173.08 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -53.18 -31.15 41.29 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -179.638 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 134' ' ' SER . . . . . 0.526 ' HB3' ' H ' ' B' ' 129' ' ' GLY . 26.1 m -49.69 -39.23 36.09 Favored 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.832 1.651 . . . . 0.0 113.969 170.773 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.76 -58.32 2.14 Favored 'General case' 0 CA--C 1.52 -0.205 0 C-N-CA 127.191 2.196 . . . . 0.0 110.294 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.51 ' HE3' ' CG ' ' B' ' 132' ' ' GLU . 22.2 ttpp -61.98 -39.62 92.81 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.1 1.36 . . . . 0.0 113.47 -172.197 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 p -109.4 -79.04 0.58 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 119.523 1.056 . . . . 0.0 110.179 174.079 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 170.71 11.9 0.02 OUTLIER Glycine 0 CA--C 1.54 1.65 1 C-N-CA 131.625 4.44 . . . . 0.0 115.389 -179.006 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 58.97 -35.67 0.06 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 128.831 2.852 . . . . 0.0 117.257 -170.688 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.79 -44.19 1.0 Allowed 'General case' 0 CA--C 1.554 1.113 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -165.33 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.57 -82.05 1.53 Allowed Glycine 0 C--N 1.341 0.829 0 N-CA-C 117.108 1.603 . . . . 0.0 117.108 164.264 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.3 t -80.78 151.62 28.69 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 123.817 0.847 . . . . 0.0 111.143 -169.083 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.49 159.53 42.62 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.728 1.149 . . . . 0.0 113.966 -168.539 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.22 -9.07 2.0 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 125.574 1.796 . . . . 0.0 115.524 -171.39 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -173.3 149.42 1.75 Allowed 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.354 1.062 . . . . 0.0 111.12 -177.657 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.0 t -148.31 150.83 34.32 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.673 1.589 . . . . 0.0 111.413 177.712 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.9 138.03 5.71 Favored Glycine 0 N--CA 1.474 1.191 0 CA-C-N 119.367 0.985 . . . . 0.0 114.55 175.192 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -74.28 144.54 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.351 0.66 . . . . 0.0 111.264 -179.644 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 13.3 mm -84.65 105.97 14.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 CA-C-O 121.635 0.731 . . . . 0.0 111.764 179.291 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.87 -175.73 19.06 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 125.07 1.319 . . . . 0.0 111.456 168.235 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 3.9 mp -122.32 132.49 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 O-C-N 121.105 -1.233 . . . . 0.0 110.772 -169.732 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 -7.93 16.21 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.056 1.343 . . . . 0.0 113.071 171.145 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.305 0.7 OUTLIER . . . . . 0 C--O 1.238 0.451 0 C-N-CA 126.358 1.863 . . . . 0.0 112.734 -179.443 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.485 ' H3 ' ' CD ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.69 0 CA-C-O 116.0 -1.952 . . . . 0.0 108.066 . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -91.94 77.56 5.42 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 122.671 2.487 . . . . 0.0 111.646 -169.677 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -75.91 161.66 28.77 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -167.655 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.44 164.2 28.32 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.996 1.318 . . . . 0.0 110.255 168.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.496 ' CG1' ' HA ' ' B' ' 52' ' ' ASP . 7.3 p -132.61 129.56 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 124.612 1.165 . . . . 0.0 109.265 -179.027 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.81 110.72 15.44 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 120.994 -1.066 . . . . 0.0 109.179 177.869 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.8 t -81.17 60.26 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 123.997 0.919 . . . . 0.0 111.563 -169.087 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.2 mp -76.72 116.87 17.78 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -167.779 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 34.4 mtmt -145.95 175.09 10.7 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 125.453 1.501 . . . . 0.0 111.896 179.021 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.92 -3.56 7.96 Favored Glycine 0 N--CA 1.474 1.233 0 N-CA-C 119.902 2.721 . . . . 0.0 119.902 166.832 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -137.29 83.11 1.97 Allowed 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 121.607 2.704 . . . . 0.0 110.163 178.827 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 38.44 -105.99 0.05 OUTLIER Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.522 2.011 . . . . 0.0 114.032 179.482 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -73.66 -5.84 17.73 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 124.279 3.32 . . . . 0.0 113.954 -176.25 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 t -94.06 126.65 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 125.066 1.346 . . . . 0.0 111.699 -177.347 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -146.61 168.32 21.58 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 126.818 2.047 . . . . 0.0 108.01 169.457 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.23 170.91 24.82 Favored Glycine 0 CA--C 1.507 -0.413 0 CA-C-N 115.224 -0.898 . . . . 0.0 112.606 168.317 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 pt -150.34 53.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 114.195 -1.002 . . . . 0.0 111.169 -167.657 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.6 mm -80.35 112.23 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 O-C-N 120.984 -1.072 . . . . 0.0 110.348 -169.447 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.09 149.23 33.93 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 125.18 1.392 . . . . 0.0 111.491 175.969 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -134.51 116.24 14.85 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.299 1.84 . . . . 0.0 108.641 178.099 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.485 ' CD ' ' H3 ' ' A' ' 1' ' ' ALA . 3.6 tp10 -97.97 112.38 24.34 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.919 1.288 . . . . 0.0 112.255 175.329 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.4 tp60 -107.4 129.32 54.94 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 125.338 1.455 . . . . 0.0 109.226 177.968 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.53 -48.99 6.94 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.85 0.86 . . . . 0.0 111.447 178.784 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.63 136.46 51.67 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 127.302 2.241 . . . . 0.0 108.933 174.695 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 m -62.55 0.62 0.46 Allowed 'General case' 0 N--CA 1.48 1.05 0 N-CA-C 117.594 2.442 . . . . 0.0 117.594 -168.919 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.6 m-80 -114.22 -9.89 12.81 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 127.727 2.411 . . . . 0.0 113.9 178.033 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.6 -178.09 33.9 Favored Glycine 0 CA--C 1.537 1.424 0 CA-C-N 119.491 1.041 . . . . 0.0 115.053 -169.372 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -70.82 160.09 50.51 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.592 3.528 . . . . 0.0 110.898 -178.486 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.9 t -129.81 138.04 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.929 -0.482 . . . . 0.0 111.083 -170.68 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -86.37 121.11 28.47 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 168.745 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.4 t -109.87 121.46 62.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.969 2.107 . . . . 0.0 108.692 -177.571 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -148.25 165.04 32.18 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 177.541 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.84 -173.37 14.67 Favored Glycine 0 N--CA 1.468 0.828 0 O-C-N 121.431 -0.793 . . . . 0.0 112.333 -178.741 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.85 167.32 21.98 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 -164.916 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -125.11 129.67 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 127.408 2.283 . . . . 0.0 108.421 171.709 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 44.8 pttt -115.33 159.01 21.59 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 120.316 1.416 . . . . 0.0 111.796 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.94 -6.97 73.4 Favored Glycine 0 N--CA 1.475 1.253 0 C-N-CA 125.371 1.462 . . . . 0.0 114.517 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 8.2 mp -62.86 153.17 34.07 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.872 2.069 . . . . 0.0 111.583 173.066 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -78.75 158.6 28.23 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 166.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -55.21 143.49 27.54 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.472 0.709 . . . . 0.0 112.87 175.607 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.09 -176.14 21.74 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 123.992 0.806 . . . . 0.0 114.84 177.44 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -68.29 139.19 55.93 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 127.775 2.43 . . . . 0.0 113.247 -171.124 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -145.45 120.37 9.99 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 128.565 2.746 . . . . 0.0 110.349 -174.711 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.98 22.88 Favored Glycine 0 N--CA 1.482 1.73 0 CA-C-O 117.095 -1.947 . . . . 0.0 112.716 -175.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -130.41 120.78 24.76 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.742 1.771 . . . . 0.0 113.478 177.522 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.414 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -154.3 156.11 36.37 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 115.195 -0.912 . . . . 0.0 112.843 -168.737 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 p -77.01 135.51 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 122.992 0.517 . . . . 0.0 109.844 171.305 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -112.48 171.97 7.2 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.895 1.678 . . . . 0.0 111.459 172.19 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -40.69 119.77 1.17 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.093 1.757 . . . . 0.0 113.178 -176.072 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -88.63 -164.43 1.13 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.846 2.458 . . . . 0.0 111.045 -177.328 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.71 -79.11 0.9 Allowed Glycine 0 C--N 1.334 0.464 0 N-CA-C 115.327 0.891 . . . . 0.0 115.327 167.076 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 44.9 p-10 -128.99 47.88 2.42 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 126.805 2.042 . . . . 0.0 115.19 -164.029 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 11.6 p30 -154.75 -30.73 0.11 Allowed 'General case' 0 N--CA 1.478 0.97 0 O-C-N 120.577 -1.327 . . . . 0.0 114.48 -172.68 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.342 12.4 t 21.15 35.88 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.6 1 C-N-CA 133.235 4.614 . . . . 0.0 120.408 173.251 . . . . . . . . 3 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -146.57 -2.78 0.64 Allowed 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 128.35 2.66 . . . . 0.0 111.101 169.652 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.42 -154.79 24.49 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.244 1.402 . . . . 0.0 114.0 175.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.2 t -46.86 -27.39 1.22 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.117 1.767 . . . . 0.0 115.263 -172.861 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 t -56.16 -14.51 2.77 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 126.715 2.006 . . . . 0.0 114.528 169.006 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.9 t -150.28 9.37 0.65 Allowed 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 127.044 2.138 . . . . 0.0 113.74 174.857 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -129.22 172.97 10.92 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 -168.167 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -97.95 -150.54 26.42 Favored Glycine 0 CA--C 1.546 2.021 0 C-N-CA 125.367 1.46 . . . . 0.0 115.383 -176.276 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -78.75 -170.03 0.91 Allowed 'Trans proline' 0 C--N 1.352 0.761 1 C-N-CA 127.831 5.688 . . . . 0.0 111.385 -179.651 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.414 ' CE1' ' CG ' ' A' ' 46' ' ' HIS . 12.2 m170 -62.69 116.51 5.26 Favored 'General case' 0 N--CA 1.451 -0.412 0 O-C-N 121.97 -0.456 . . . . 0.0 111.029 177.743 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 146.94 44.46 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -174.383 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -110.32 79.69 1.72 Allowed Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.656 1.354 . . . . 0.0 114.656 -176.117 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.81 -12.55 14.83 Favored 'Trans proline' 0 CA--C 1.54 0.778 0 C-N-CA 123.14 2.56 . . . . 0.0 112.071 168.12 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 85.1 mt -137.61 2.82 2.48 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.163 1.785 . . . . 0.0 112.797 -168.394 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 25.2 m 58.96 70.18 0.67 Allowed 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 124.824 1.249 . . . . 0.0 113.092 168.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -155.48 177.42 11.39 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 119.874 3.287 . . . . 0.0 119.874 -163.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.407 ' HE2' ' N ' ' A' ' 70' ' ' LYS . 0.7 OUTLIER -78.81 178.03 8.24 Favored 'General case' 0 CA--C 1.549 0.907 0 CA-C-N 113.992 -1.458 . . . . 0.0 111.499 168.057 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.441 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 83.7 t60 -115.85 159.81 21.01 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -168.701 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.441 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 136.37 -102.81 0.42 Allowed Glycine 0 C--N 1.333 0.378 0 C-N-CA 125.586 1.565 . . . . 0.0 109.829 166.54 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.55 -36.92 4.08 Favored Glycine 0 CA--C 1.549 2.17 0 CA-C-O 117.448 -1.751 . . . . 0.0 116.558 -177.034 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -73.45 -19.98 21.3 Favored 'Trans proline' 0 C--N 1.358 1.043 0 CA-C-N 122.156 2.978 . . . . 0.0 113.863 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.19 -1.42 0.74 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 125.488 1.515 . . . . 0.0 112.267 -175.011 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -122.37 139.92 53.27 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 128.701 2.8 . . . . 0.0 107.192 -178.15 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -97.43 -9.24 27.66 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 128.052 2.541 . . . . 0.0 112.647 -174.456 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -82.57 -82.49 0.14 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.087 0.858 . . . . 0.0 109.196 -178.708 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 79.95 110.92 0.07 Allowed 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 126.604 1.961 . . . . 0.0 114.213 164.74 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 8.4 m80 -62.43 128.52 36.4 Favored 'General case' 0 CA--C 1.546 0.811 0 O-C-N 119.784 -1.823 . . . . 0.0 107.247 167.098 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.2 p -39.83 -36.6 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.215 0 N-CA-C 118.556 2.798 . . . . 0.0 118.556 -167.185 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.65 19.51 36.04 Favored Glycine 0 N--CA 1.477 1.386 0 CA-C-N 120.283 1.401 . . . . 0.0 115.39 178.687 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -78.31 140.35 38.81 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 119.223 1.512 . . . . 0.0 112.315 174.798 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.3 -176.36 3.12 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 163.224 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.52 -137.21 2.65 Favored Glycine 0 N--CA 1.468 0.831 0 O-C-N 121.322 -0.861 . . . . 0.0 111.861 174.808 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.6 p30 -100.59 147.39 26.0 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 122.006 -0.702 . . . . 0.0 112.008 168.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.47 149.84 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 127.572 2.349 . . . . 0.0 107.328 169.183 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.4 m -107.94 140.29 41.29 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.774 -0.579 . . . . 0.0 110.058 179.204 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.43 138.7 31.34 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.725 0.81 . . . . 0.0 111.944 171.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -80.37 147.61 30.97 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.468 1.507 . . . . 0.0 109.991 168.168 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.547 ' HZ2' ' CG ' ' A' ' 92' ' ' ASP . 1.4 pptp? -46.69 -22.18 0.27 Allowed 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 128.605 2.762 . . . . 0.0 116.641 174.329 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.547 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 82.3 m-20 -76.13 0.27 19.48 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.177 1.391 . . . . 0.0 112.186 172.599 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.39 28.97 8.64 Favored Glycine 0 C--N 1.342 0.885 0 C-N-CA 125.987 1.756 . . . . 0.0 114.568 169.545 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.74 134.66 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 119.83 1.815 . . . . 0.0 115.282 -175.225 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.07 110.64 22.69 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 124.597 1.159 . . . . 0.0 107.907 166.334 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -106.71 137.9 43.88 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 122.356 1.074 . . . . 0.0 111.387 175.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -116.65 147.09 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-N 112.555 -2.111 . . . . 0.0 114.464 -168.649 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 82.8 p -158.93 90.1 0.97 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 178.655 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.3 mp -132.46 154.87 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 125.847 1.659 . . . . 0.0 112.968 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -117.76 115.99 26.13 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 164.039 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -117.57 114.54 23.57 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.327 1.061 . . . . 0.0 111.451 -171.375 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.6 p -84.03 54.91 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.472 -0.767 . . . . 0.0 111.686 -175.035 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.7 p -142.7 -17.55 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 114.75 1.389 . . . . 0.0 114.75 -169.813 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 pp -142.69 161.91 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.914 1.234 . . . . 0.0 112.622 -176.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.535 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.0 m -145.1 155.36 43.28 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 125.528 1.531 . . . . 0.0 113.601 -179.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.4 mp -83.67 56.94 3.83 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.781 1.632 . . . . 0.0 111.14 -175.449 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.03 -56.05 2.41 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.38 1.472 . . . . 0.0 110.543 178.365 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 143.38 -102.6 0.29 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 115.637 1.015 . . . . 0.0 115.637 169.572 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.81 -33.98 72.45 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 125.02 1.328 . . . . 0.0 111.873 175.002 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -80.02 1.0 29.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.036 1.734 . . . . 0.0 113.245 170.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.535 ' CB ' ' H ' ' A' ' 105' ' ' SER . 1.6 m -166.51 -90.42 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 169.846 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.385 7.6 pt -119.16 -99.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -179.015 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . 0.274 24.2 mm 37.11 -88.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 127.37 2.268 . . . . 0.0 113.794 -169.024 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.18 2.4 9.44 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-N 119.911 1.232 . . . . 0.0 115.091 175.612 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -79.38 152.1 30.58 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.571 1.685 . . . . 0.0 107.399 168.465 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.6 t -125.61 119.65 28.66 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 122.237 -0.289 . . . . 0.0 111.126 -168.871 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.72 130.3 34.71 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 124.461 1.104 . . . . 0.0 108.506 176.29 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.5 p -125.69 138.17 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.409 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 32.1 t -101.88 157.01 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 169.196 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.402 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 35.0 m-70 -130.22 146.68 51.86 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.619 1.568 . . . . 0.0 111.886 -167.372 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -71.56 -4.22 25.71 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.852 1.261 . . . . 0.0 114.044 -170.633 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 21.7 mmmt -127.68 160.36 31.91 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.061 1.345 . . . . 0.0 111.953 176.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.46 162.81 0.72 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.381 1.472 . . . . 0.0 112.505 169.719 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -111.27 130.18 55.74 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.302 1.841 . . . . 0.0 109.847 -175.336 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.265 1.0 OUTLIER -84.38 -8.15 59.08 Favored 'General case' 0 N--CA 1.48 1.04 0 N-CA-C 116.007 1.854 . . . . 0.0 116.007 -178.931 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 31.6 mt 63.73 42.18 6.43 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.576 1.95 . . . . 0.0 114.71 167.532 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 113.36 -38.11 3.34 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.447 1.022 . . . . 0.0 114.901 167.785 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.52 88.78 1.08 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 119.138 3.014 . . . . 0.0 119.138 169.62 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.4 -69.28 0.88 Allowed Glycine 0 CA--C 1.522 0.487 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 161.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.55 -107.94 3.25 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 117.714 1.846 . . . . 0.0 117.714 -168.557 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -102.56 -158.48 0.67 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.126 1.77 . . . . 0.0 113.861 -161.102 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.63 -47.68 49.63 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.133 0.573 . . . . 0.0 111.468 170.176 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -57.0 -34.28 67.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.007 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.0 p -52.43 -30.04 27.46 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 120.315 1.416 . . . . 0.0 112.04 170.109 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.2 p -97.55 -34.1 11.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 117.454 -1.26 . . . . 0.0 113.812 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -92.26 -46.23 7.82 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 114.651 1.352 . . . . 0.0 114.651 -176.835 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 17.9 p -90.81 -95.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.538 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 170.199 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -171.74 26.07 0.09 OUTLIER Glycine 0 CA--C 1.536 1.344 1 C-N-CA 132.568 4.89 . . . . 0.0 110.418 176.645 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.59 -7.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 129.488 3.115 . . . . 0.0 116.714 -168.989 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.44 -38.36 43.02 Favored 'General case' 0 CA--C 1.55 0.98 0 CA-C-N 119.958 1.254 . . . . 0.0 113.939 -169.401 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.0 -116.03 4.22 Favored Glycine 0 N--CA 1.47 0.906 0 O-C-N 121.024 -1.048 . . . . 0.0 112.577 172.482 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 20.7 m -44.88 115.52 0.9 Allowed 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.524 1.53 . . . . 0.0 114.69 -169.924 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.63 160.5 31.46 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 121.41 -0.806 . . . . 0.0 112.482 172.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . 0.277 3.9 pp -142.28 -153.38 0.46 Allowed 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 126.829 2.052 . . . . 0.0 107.474 165.414 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.85 132.58 46.66 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 119.817 1.19 . . . . 0.0 113.269 -171.38 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.6 p -130.89 146.01 52.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 126.655 1.982 . . . . 0.0 111.63 -174.525 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.17 159.63 30.94 Favored Glycine 0 N--CA 1.472 1.038 0 N-CA-C 114.61 0.604 . . . . 0.0 114.61 179.362 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.59 161.85 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 C-N-CA 123.632 0.773 . . . . 0.0 109.676 168.409 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 27.8 mm -88.52 64.54 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 125.169 1.388 . . . . 0.0 110.096 178.773 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -68.82 139.49 33.08 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -174.06 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -77.76 144.78 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 O-C-N 121.719 -0.871 . . . . 0.0 111.16 -174.33 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.6 -17.16 10.03 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.162 2.185 . . . . 0.0 112.138 175.851 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 N--CA 1.468 0.468 0 C-N-CA 128.594 2.758 . . . . 0.0 113.428 175.27 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.502 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.2 m -78.14 106.09 9.8 Favored 'General case' 0 CA--C 1.51 -0.585 0 C-N-CA 124.766 1.226 . . . . 0.0 110.078 -172.763 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtmm -92.92 124.57 36.99 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 123.624 1.678 . . . . 0.0 113.305 178.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -115.66 175.37 5.56 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 127.256 2.222 . . . . 0.0 108.951 166.653 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -148.16 146.74 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -177.611 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.13 119.89 36.1 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 163.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -124.78 115.25 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 175.848 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -103.91 147.12 27.71 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.041 1.336 . . . . 0.0 111.052 -179.025 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -140.3 142.88 35.64 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.095 1.358 . . . . 0.0 109.442 164.884 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.36 -117.17 3.52 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-O 122.96 1.311 . . . . 0.0 111.348 173.116 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.74 49.68 1.85 Allowed 'General case' 0 C--N 1.314 -0.974 0 C-N-CA 126.715 2.006 . . . . 0.0 113.529 -163.146 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -81.25 0.71 Allowed Glycine 0 CA--C 1.538 1.502 0 CA-C-O 117.289 -1.839 . . . . 0.0 113.115 -175.78 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -98.29 -2.3 1.13 Allowed 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 123.818 3.012 . . . . 0.0 115.183 -169.726 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -89.88 125.88 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-N 121.049 1.749 . . . . 0.0 110.08 178.174 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -130.61 166.99 19.47 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 124.039 0.935 . . . . 0.0 112.713 174.93 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.93 104.26 0.31 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 114.118 -1.401 . . . . 0.0 111.176 169.046 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.33 127.43 47.33 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.114 0 CA-C-N 118.781 1.291 . . . . 0.0 109.278 169.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 mm -131.85 112.44 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 126.46 1.904 . . . . 0.0 108.662 170.882 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -82.87 139.39 33.47 Favored 'General case' 0 CA--C 1.542 0.667 0 O-C-N 120.988 -1.07 . . . . 0.0 111.553 169.302 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -115.84 103.82 11.02 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.545 1.538 . . . . 0.0 110.541 179.308 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -108.51 108.13 18.93 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.592 1.157 . . . . 0.0 113.31 179.186 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -97.93 160.91 14.01 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.816 1.246 . . . . 0.0 110.603 171.304 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.78 -21.19 8.55 Favored 'General case' 0 CA--C 1.544 0.729 0 N-CA-C 114.214 1.19 . . . . 0.0 114.214 178.934 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.48 -165.72 1.08 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 127.739 2.416 . . . . 0.0 108.788 168.21 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.2 m -110.79 -11.28 14.4 Favored 'General case' 0 N--CA 1.48 1.026 0 O-C-N 120.612 -1.305 . . . . 0.0 112.118 167.001 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 m-80 -138.05 101.1 4.33 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.743 2.017 . . . . 0.0 107.893 168.712 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.73 -175.1 37.46 Favored Glycine 0 CA--C 1.539 1.565 0 C-N-CA 125.325 1.441 . . . . 0.0 111.77 -175.464 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.41 149.6 80.53 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 123.197 2.598 . . . . 0.0 115.853 -168.497 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 t -124.31 133.83 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.454 1.501 . . . . 0.0 109.749 -177.536 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -78.8 125.07 28.87 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.628 0.771 . . . . 0.0 109.507 170.086 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.65 77.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 C-N-CA 127.414 2.286 . . . . 0.0 106.201 -178.541 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -102.02 154.91 18.54 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.957 170.819 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 170.2 -177.37 43.52 Favored Glycine 0 C--O 1.227 -0.335 0 O-C-N 121.361 -0.837 . . . . 0.0 113.806 -176.72 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 76.7 p -155.41 127.99 7.91 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 124.129 0.972 . . . . 0.0 111.192 -179.691 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mp -79.6 163.63 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 168.28 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 48.5 tttp -156.56 122.46 4.89 Favored 'General case' 0 N--CA 1.444 -0.739 0 O-C-N 120.851 -1.156 . . . . 0.0 108.588 165.247 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.52 1.03 12.32 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.277 1.894 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 62.0 mt -71.29 171.52 10.97 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 120.266 2.033 . . . . 0.0 110.046 168.648 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.0 t -91.42 158.04 16.73 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 163.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -58.88 147.07 35.25 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.412 1.085 . . . . 0.0 111.886 -178.75 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.04 -173.75 20.92 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 124.58 1.086 . . . . 0.0 112.266 -177.51 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.521 HD21 ' H ' ' B' ' 42' ' ' LEU . 1.4 pt? -87.38 140.57 29.4 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.781 2.032 . . . . 0.0 112.016 -172.308 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -143.03 138.34 29.9 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.506 2.322 . . . . 0.0 108.141 -177.21 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -89.07 139.41 15.24 Favored Glycine 0 N--CA 1.473 1.139 0 CA-C-N 121.709 2.049 . . . . 0.0 111.031 -175.019 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -137.1 140.14 41.74 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.013 1.906 . . . . 0.0 111.963 170.407 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -149.9 154.99 39.24 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 121.126 -0.984 . . . . 0.0 111.843 -174.344 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.71 151.09 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 124.683 1.193 . . . . 0.0 109.67 -179.052 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -86.94 176.13 7.81 Favored 'General case' 0 CA--C 1.546 0.815 0 CA-C-O 122.556 1.169 . . . . 0.0 112.911 178.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -74.68 112.29 10.73 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 160.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.77 -162.71 0.16 Allowed 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.502 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -118.85 33.85 4.59 Favored Glycine 0 C--N 1.342 0.865 0 C-N-CA 128.019 2.723 . . . . 0.0 111.549 178.852 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . 0.496 ' HA ' ' CG1' ' A' ' 5' ' ' VAL . 45.7 p-10 -116.91 69.29 0.75 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 124.048 1.88 . . . . 0.0 112.768 -169.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . 0.722 ' ND2' ' HG1' ' B' ' 116' ' ' THR . 0.3 OUTLIER -124.22 57.94 1.21 Allowed 'General case' 0 C--O 1.244 0.813 0 N-CA-C 116.62 2.081 . . . . 0.0 116.62 -160.939 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.278 13.2 p -110.02 -54.89 2.52 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.603 -163.122 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.45 31.23 0.12 Allowed 'General case' 0 CA--C 1.557 1.215 0 C-N-CA 124.909 1.284 . . . . 0.0 113.079 167.684 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.25 -131.56 52.11 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 120.693 -1.254 . . . . 0.0 113.364 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 3.8 t -69.34 -7.54 38.22 Favored 'General case' 0 CA--C 1.548 0.894 0 N-CA-C 115.002 1.482 . . . . 0.0 115.002 -174.7 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 13.2 t -108.19 14.1 25.29 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.72 1.208 . . . . 0.0 112.341 169.528 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.7 t -107.39 -63.93 1.25 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.857 1.663 . . . . 0.0 109.098 169.574 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -166.52 134.05 2.66 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 124.816 1.246 . . . . 0.0 111.583 -178.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.55 -115.57 2.37 Favored Glycine 0 CA--C 1.541 1.663 0 C-N-CA 127.21 2.338 . . . . 0.0 113.27 -178.213 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.72 157.21 62.78 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.983 3.789 . . . . 0.0 116.152 -164.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -38.59 101.28 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 127.011 2.124 . . . . 0.0 116.033 169.675 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -58.95 119.4 7.15 Favored 'General case' 0 CA--C 1.544 0.722 0 O-C-N 121.574 -0.704 . . . . 0.0 109.63 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -104.23 75.8 0.25 Allowed Pre-proline 0 CA--C 1.549 0.91 0 C-N-CA 127.335 2.254 . . . . 0.0 112.588 -172.445 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -56.61 -33.01 92.19 Favored 'Trans proline' 0 C--N 1.355 0.879 0 C-N-CA 123.532 2.822 . . . . 0.0 115.843 -168.934 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 97.3 mt -79.76 -3.35 47.24 Favored 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 175.413 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.9 t 65.73 52.23 1.33 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.734 2.014 . . . . 0.0 112.912 178.705 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 11.4 mtp180 -105.57 172.33 6.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 -169.313 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -81.09 172.69 13.39 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 122.769 0.428 . . . . 0.0 110.518 165.025 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -104.49 146.5 28.78 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -170.791 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.15 -140.6 11.95 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 113.641 -1.618 . . . . 0.0 113.323 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 149.91 -29.46 1.13 Allowed Glycine 0 CA--C 1.545 1.932 0 N-CA-C 118.399 2.12 . . . . 0.0 118.399 -179.432 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.83 -4.56 14.32 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 122.766 3.283 . . . . 0.0 112.998 168.535 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.93 -37.18 0.15 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.976 1.31 . . . . 0.0 109.752 165.853 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -61.39 109.26 1.1 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 123.621 1.676 . . . . 0.0 112.49 -176.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 pm0 -44.03 -30.71 0.77 Allowed 'General case' 0 C--N 1.318 -0.794 1 C-N-CA 134.058 4.943 . . . . 0.0 115.689 169.198 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -90.85 -62.96 1.34 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.936 0.789 . . . . 0.0 111.123 -176.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.269 32.1 ptt180 55.34 121.26 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 129.114 2.966 . . . . 0.0 115.346 -175.507 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -56.7 151.33 14.19 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 119.141 -2.224 . . . . 0.0 112.65 173.581 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 80.5 t -49.96 -56.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 CA-C-N 118.753 0.706 . . . . 0.0 110.603 -176.926 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.69 115.25 5.17 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 105.132 -3.187 . . . . 0.0 105.132 164.333 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -158.35 158.26 33.97 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.9 0.85 . . . . 0.0 112.675 172.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 83.1 mt -144.19 153.07 41.71 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.99 2.116 . . . . 0.0 106.439 168.335 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -113.06 -124.1 4.17 Favored Glycine 0 N--CA 1.471 1.026 0 C-N-CA 124.459 1.028 . . . . 0.0 111.046 172.443 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 -78.54 135.11 37.23 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -175.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.74 121.07 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 C-N-CA 131.082 3.753 . . . . 0.0 108.84 167.053 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.1 m -119.22 119.27 33.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.102 0.961 . . . . 0.0 110.963 -170.257 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.58 160.3 14.69 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.947 1.299 . . . . 0.0 113.972 -174.758 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -84.69 178.12 7.79 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 128.593 2.757 . . . . 0.0 112.633 170.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -20.85 65.81 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 120.865 -1.147 . . . . 0.0 113.2 169.387 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -73.77 -11.7 60.47 Favored 'General case' 0 CA--C 1.55 0.969 0 CA-C-O 121.791 0.805 . . . . 0.0 110.145 171.603 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.84 2.75 88.42 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.843 1.687 . . . . 0.0 113.462 176.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -84.11 134.67 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 125.491 1.517 . . . . 0.0 111.839 170.751 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.15 135.19 52.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 164.251 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -90.37 143.69 26.52 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.806 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 t -132.7 129.05 58.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 113.822 -1.535 . . . . 0.0 108.139 171.54 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.6 p -157.28 59.91 0.5 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 122.466 1.127 . . . . 0.0 112.506 -166.772 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.4 mt -120.2 158.03 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 124.991 1.316 . . . . 0.0 111.836 -171.264 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -138.56 127.7 24.14 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 166.598 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -144.48 145.29 31.79 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -167.637 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 72.2 p -104.47 52.37 0.75 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.06 1.344 . . . . 0.0 112.449 -168.85 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 31.3 m -149.74 6.31 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 115.434 1.642 . . . . 0.0 115.434 -169.508 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.03 172.01 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 125.518 1.527 . . . . 0.0 110.645 -176.288 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 88.0 p -157.26 160.73 38.92 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.717 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.02 51.7 1.13 Allowed 'General case' 0 CA--C 1.54 0.586 0 O-C-N 121.631 -0.668 . . . . 0.0 111.587 174.486 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.5 m -81.38 -52.43 7.28 Favored 'General case' 0 N--CA 1.474 0.754 0 O-C-N 121.689 -0.632 . . . . 0.0 112.692 -176.836 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.5 -30.19 4.31 Favored Glycine 0 N--CA 1.471 0.988 0 C-N-CA 124.425 1.012 . . . . 0.0 114.697 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -82.91 -53.18 6.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 122.108 0.956 . . . . 0.0 112.544 -168.867 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -139.05 4.73 2.28 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -166.082 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.0 m -113.59 -112.11 0.34 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 123.894 0.878 . . . . 0.0 113.331 -168.92 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 45.5 mm -106.29 -59.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.794 1.237 . . . . 0.0 111.573 -174.89 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.6 mm -58.16 138.32 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 106.069 -1.826 . . . . 0.0 106.069 166.289 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.7 59.13 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.758 -1.023 . . . . 0.0 114.023 -174.978 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mtt85 -127.43 176.68 7.27 Favored 'General case' 0 C--N 1.347 0.492 0 CA-C-N 119.292 1.546 . . . . 0.0 112.765 171.025 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 116' ' ' THR . . . . . 0.722 ' HG1' ' ND2' ' B' ' 53' ' ' ASN . 2.2 m -126.29 153.07 45.32 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 128.016 2.527 . . . . 0.0 109.183 169.029 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 13.1 tp -130.1 133.04 46.4 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.763 1.625 . . . . 0.0 109.167 176.446 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.73 139.15 44.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 C-N-CA 126.499 1.92 . . . . 0.0 110.767 176.403 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -106.11 140.78 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.129 1.372 . . . . 0.0 109.927 167.439 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -97.6 156.9 16.31 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.807 2.043 . . . . 0.0 111.147 177.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 8.2 tm-20 -77.11 -27.77 54.18 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.498 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -103.45 175.0 5.62 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.465 1.106 . . . . 0.0 111.845 168.685 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.85 152.68 42.44 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.174 1.79 . . . . 0.0 113.976 173.809 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -89.87 145.53 25.08 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 122.546 1.165 . . . . 0.0 113.168 169.792 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -76.8 -39.4 51.55 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -168.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 84.32 24.68 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 126.433 1.893 . . . . 0.0 113.812 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 84.34 57.77 2.3 Favored Glycine 0 C--N 1.343 0.959 0 C-N-CA 125.749 1.643 . . . . 0.0 114.906 168.06 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -158.68 -17.09 0.07 Allowed 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -168.203 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.08 16.35 2.8 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.612 1.577 . . . . 0.0 115.114 178.696 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.57 -2.17 24.4 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.316 1.436 . . . . 0.0 116.459 169.416 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -102.4 162.41 12.94 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 118.837 1.318 . . . . 0.0 109.551 -178.797 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -50.44 -62.83 1.35 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 122.175 0.988 . . . . 0.0 109.485 167.733 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . 0.494 ' HB3' HD21 ' B' ' 139' ' ' ASN . 0.4 OUTLIER -46.36 -31.14 2.42 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 128.898 2.879 . . . . 0.0 114.601 173.794 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 15.3 p -56.67 -30.31 63.25 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 120.556 -1.34 . . . . 0.0 113.927 178.066 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -121.57 -13.54 8.35 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 170.111 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.5 tttt -74.79 -15.22 60.76 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.633 1.173 . . . . 0.0 113.263 169.635 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.2 p -148.31 -25.46 0.34 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 126.623 1.969 . . . . 0.0 114.67 167.421 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.13 53.83 Favored Glycine 0 CA--C 1.536 1.4 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -163.228 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . 0.494 HD21 ' HB3' ' B' ' 133' ' ' GLU . 8.1 t-20 51.67 18.07 0.68 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.618 1.967 . . . . 0.0 113.923 179.009 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.36 -0.04 0.22 Allowed 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 127.806 2.442 . . . . 0.0 116.667 -167.764 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.84 -129.71 10.48 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.14 1.353 . . . . 0.0 115.886 168.236 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.42 134.34 28.69 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 127.735 2.414 . . . . 0.0 112.493 -178.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.92 146.98 33.22 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 121.265 -0.897 . . . . 0.0 109.887 171.093 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.3 tt -120.66 -134.83 0.32 Allowed 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 168.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.75 156.72 32.23 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 -176.854 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -146.48 161.84 39.57 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.706 1.202 . . . . 0.0 111.099 170.002 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.47 146.75 13.33 Favored Glycine 0 N--CA 1.468 0.831 0 C-N-CA 125.141 1.353 . . . . 0.0 112.525 -174.541 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.5 t -85.77 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 175.267 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 37.3 mt -123.19 114.14 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 120.097 -1.627 . . . . 0.0 111.878 -177.124 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.64 175.12 15.56 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 126.593 2.044 . . . . 0.0 115.037 -172.476 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -102.46 102.9 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.381 1.472 . . . . 0.0 112.65 -171.049 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.55 49.7 1.04 Allowed 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.535 1.934 . . . . 0.0 112.239 171.868 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 . . . . . 0 C--N 1.327 -0.378 0 C-N-CA 126.001 1.72 . . . . 0.0 111.387 177.738 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 118.161 -0.923 . . . . 0.0 111.047 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p -84.23 43.61 0.96 Allowed 'General case' 0 C--N 1.348 0.531 0 C-N-CA 125.519 1.528 . . . . 0.0 112.92 -168.886 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.5 148.48 12.74 Favored 'General case' 0 C--O 1.238 0.469 0 C-N-CA 125.002 1.321 . . . . 0.0 112.413 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.65 161.23 39.89 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 126.293 1.837 . . . . 0.0 108.896 166.842 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -156.29 150.6 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 124.487 1.115 . . . . 0.0 109.333 -178.056 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.07 93.37 2.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.463 1.105 . . . . 0.0 108.841 167.526 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -76.88 87.94 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.89 1.276 . . . . 0.0 107.793 170.355 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -76.75 127.42 32.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 125.874 1.67 . . . . 0.0 109.637 -173.606 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -144.04 169.8 17.15 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.318 1.047 . . . . 0.0 112.174 -174.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.19 -48.7 0.64 Allowed Glycine 0 N--CA 1.467 0.739 0 C-N-CA 125.329 1.442 . . . . 0.0 112.739 171.399 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.89 64.0 6.21 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 122.219 1.009 . . . . 0.0 110.694 -169.158 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.15 -101.75 0.04 OUTLIER Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.236 2.35 . . . . 0.0 113.132 179.102 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.07 -14.28 21.03 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.852 3.035 . . . . 0.0 113.635 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -76.89 136.24 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 119.849 1.204 . . . . 0.0 109.618 179.079 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.45 159.1 35.33 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 125.997 2.808 . . . . 0.0 113.377 167.163 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -111.16 142.53 16.92 Favored Glycine 0 C--N 1.313 -0.739 1 CA-C-N 108.188 -4.097 . . . . 0.0 109.438 172.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 86.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 122.641 1.21 . . . . 0.0 108.417 175.19 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -106.91 143.94 16.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.705 167.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -119.67 135.73 54.7 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 127.762 2.425 . . . . 0.0 110.573 -178.374 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-30 -119.93 157.86 27.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.462 1.505 . . . . 0.0 110.862 178.247 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.84 146.29 37.35 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 130.489 3.516 . . . . 0.0 104.598 171.265 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -146.0 -174.24 4.37 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.149 1.78 . . . . 0.0 106.721 172.125 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 -24.01 0.47 Allowed 'General case' 0 CA--C 1.55 0.943 0 O-C-N 118.962 -2.336 . . . . 0.0 114.463 167.402 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -98.72 -172.81 2.38 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.673 1.989 . . . . 0.0 109.571 170.578 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.61 -1.84 29.5 Favored 'General case' 0 CA--C 1.547 0.851 0 O-C-N 121.328 -0.857 . . . . 0.0 112.049 168.341 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -145.63 -7.98 0.58 Allowed 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -170.054 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.06 -163.75 37.56 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 118.873 -0.96 . . . . 0.0 111.771 177.057 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -84.11 161.17 13.53 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 121.964 1.776 . . . . 0.0 112.429 -171.153 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.11 152.87 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.963 1.705 . . . . 0.0 109.606 -170.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -94.17 151.15 19.69 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 170.755 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 96.0 t -130.93 97.7 3.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 127.161 2.184 . . . . 0.0 107.096 166.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.3 p90 -124.98 160.02 29.92 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.681 0.792 . . . . 0.0 111.52 172.56 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.44 -155.2 16.37 Favored Glycine 0 N--CA 1.469 0.867 0 O-C-N 120.983 -1.073 . . . . 0.0 112.052 -179.179 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.8 p -149.44 151.9 34.77 Favored 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 117.962 2.579 . . . . 0.0 117.962 -167.421 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.8 mm -118.0 133.17 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 126.16 1.784 . . . . 0.0 108.358 169.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.13 160.24 43.45 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 120.049 1.295 . . . . 0.0 114.144 -172.482 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.42 3.55 61.3 Favored Glycine 0 CA--C 1.538 1.486 0 C-N-CA 126.9 2.19 . . . . 0.0 112.293 -167.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.8 mt -85.23 173.26 10.52 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.305 1.842 . . . . 0.0 112.926 -173.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 m -74.19 175.97 7.04 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.642 1.177 . . . . 0.0 108.057 164.291 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.29 -93.51 0.03 OUTLIER 'General case' 0 CA--C 1.558 1.252 0 O-C-N 119.958 -1.714 . . . . 0.0 113.04 179.263 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -61.51 97.47 0.14 Allowed Glycine 0 CA--C 1.529 0.965 0 C-N-CA 126.733 2.111 . . . . 0.0 117.667 -167.486 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 65.4 mt 62.85 131.75 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 129.185 2.994 . . . . 0.0 116.606 168.482 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.01 141.58 46.24 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 129.4 3.08 . . . . 0.0 107.486 179.752 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.78 155.14 51.81 Favored Glycine 0 N--CA 1.468 0.794 0 C-N-CA 124.659 1.123 . . . . 0.0 111.715 173.846 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -150.38 98.48 2.66 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -167.475 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.66 145.99 30.22 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 120.955 -1.091 . . . . 0.0 111.69 -168.461 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -102.2 119.68 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 126.149 1.78 . . . . 0.0 107.802 179.412 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -72.51 142.93 48.53 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.632 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -63.36 136.66 57.79 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -172.718 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 68.36 166.67 0.26 Allowed 'General case' 0 CA--C 1.543 0.68 0 CA-C-O 123.818 1.771 . . . . 0.0 113.995 175.338 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.31 -14.53 12.95 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 126.477 1.989 . . . . 0.0 114.413 -178.035 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -75.42 53.54 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 121.187 2.493 . . . . 0.0 112.757 -177.83 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 172.03 21.99 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.29 0 C-N-CA 128.318 2.647 . . . . 0.0 113.914 -167.065 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 76.5 p -36.1 -15.24 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 1 N-CA-C 122.332 4.197 . . . . 0.0 122.332 -170.463 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.41 15.37 4.49 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 122.097 2.226 . . . . 0.0 113.229 -174.052 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.92 -133.48 43.55 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 124.415 1.007 . . . . 0.0 111.908 174.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.9 t -58.46 -22.74 55.71 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 114.341 1.237 . . . . 0.0 114.341 -175.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . 0.256 15.0 t -90.95 42.6 1.11 Allowed 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 122.864 1.316 . . . . 0.0 112.291 171.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -179.87 -27.8 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.64 1.976 . . . . 0.0 115.659 172.095 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -134.93 142.69 46.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.529 1.532 . . . . 0.0 111.375 -168.702 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.31 -58.36 0.74 Allowed Glycine 0 CA--C 1.538 1.473 0 CA-C-O 117.636 -1.646 . . . . 0.0 115.053 -170.489 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -124.79 -177.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 124.151 3.234 . . . . 0.0 114.033 -169.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.419 ' N ' ' CD2' ' A' ' 63' ' ' HIS . 1.4 p80 -115.13 125.3 53.3 Favored 'General case' 0 C--N 1.328 -0.358 1 C-N-CA 131.839 4.056 . . . . 0.0 106.7 175.087 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -85.76 175.45 8.69 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 123.571 1.653 . . . . 0.0 110.56 -171.328 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -107.48 48.68 0.17 Allowed Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 126.129 1.772 . . . . 0.0 113.444 177.081 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -64.52 -26.01 62.42 Favored 'Trans proline' 0 C--N 1.359 1.125 0 CA-C-N 122.044 1.766 . . . . 0.0 112.609 -179.354 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 76.2 mt -79.21 0.32 28.95 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.588 1.555 . . . . 0.0 112.993 171.041 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.28 58.29 0.7 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.893 2.077 . . . . 0.0 112.464 173.598 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -157.55 176.55 12.48 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 117.704 2.483 . . . . 0.0 117.704 -167.234 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.77 177.53 8.83 Favored 'General case' 0 CA--C 1.56 1.332 0 C-N-CA 126.822 2.049 . . . . 0.0 112.57 173.269 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -105.67 143.82 33.29 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -177.77 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.76 -115.84 0.7 Allowed Glycine 0 C--N 1.336 0.559 0 CA-C-N 114.336 -1.302 . . . . 0.0 113.675 166.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.23 -67.41 0.51 Allowed Glycine 0 CA--C 1.545 1.966 0 CA-C-O 118.933 -0.926 . . . . 0.0 114.614 179.027 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -65.77 -2.65 6.79 Favored 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 125.374 4.049 . . . . 0.0 116.459 173.109 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.82 -29.37 0.24 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.407 1.483 . . . . 0.0 111.466 170.402 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.9 t0 -87.01 104.1 15.98 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.588 0.755 . . . . 0.0 110.53 166.422 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -63.12 -13.45 36.76 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.165 2.186 . . . . 0.0 114.072 176.815 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -76.89 -72.29 0.35 Allowed 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 119.303 0.956 . . . . 0.0 110.536 -179.804 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.0 ttp180 77.45 114.09 0.07 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 126.901 2.081 . . . . 0.0 113.538 166.182 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -60.55 162.53 6.31 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 118.685 -2.509 . . . . 0.0 112.758 171.751 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -63.2 -29.93 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 O-C-N 121.231 -0.918 . . . . 0.0 112.52 172.691 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.12 12.32 54.61 Favored Glycine 0 CA--C 1.53 0.999 0 C-N-CA 124.696 1.141 . . . . 0.0 115.468 175.081 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -112.71 113.57 25.75 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-N 119.774 1.787 . . . . 0.0 114.439 -173.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.15 -173.76 4.9 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 163.164 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.46 -134.34 2.02 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 120.792 -1.193 . . . . 0.0 113.625 172.227 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.5 p30 -127.34 163.39 24.11 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.163 0.985 . . . . 0.0 108.95 168.535 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 136.4 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.131 0.972 . . . . 0.0 110.61 -171.686 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -110.6 135.87 50.57 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 175.292 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.12 156.26 18.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.524 0.678 . . . . 0.0 110.584 169.298 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.418 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 48.5 t0 -77.16 155.22 32.45 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.056 1.342 . . . . 0.0 108.497 166.861 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.418 ' HZ3' ' CG ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -53.92 -25.36 19.98 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.999 1.72 . . . . 0.0 115.23 -169.305 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -76.65 -2.37 32.38 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.499 2.32 . . . . 0.0 112.273 179.101 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.65 30.18 7.37 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-O 117.937 -1.48 . . . . 0.0 114.12 172.334 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -144.81 131.54 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -178.188 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.27 112.72 24.4 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 164.799 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.0 t0 -106.33 128.65 54.17 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 170.803 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.46 145.18 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-N 113.429 -1.714 . . . . 0.0 114.4 -164.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 86.1 p -147.94 89.62 1.76 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.16 1.384 . . . . 0.0 112.087 179.566 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.06 149.31 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.505 1.522 . . . . 0.0 111.499 -174.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -135.68 138.29 42.64 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.842 2.057 . . . . 0.0 106.421 166.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -146.99 153.97 40.69 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 124.912 1.285 . . . . 0.0 112.241 -167.567 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -118.17 52.91 0.99 Allowed 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.382 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -154.66 16.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 115.889 1.811 . . . . 0.0 115.889 -178.781 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -139.63 176.37 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 125.937 1.695 . . . . 0.0 109.741 169.605 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 28.8 p -160.08 175.54 12.85 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 177.11 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -103.94 56.6 0.73 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.047 1.739 . . . . 0.0 110.409 176.953 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.5 t -107.91 -16.51 14.28 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 121.699 3.963 . . . . 0.0 121.699 -169.449 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 77.44 103.84 0.17 Allowed Glycine 0 CA--C 1.529 0.912 0 CA-C-N 121.233 1.833 . . . . 0.0 111.177 -171.011 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 85.77 -44.88 0.06 Allowed 'General case' 0 C--N 1.318 -0.777 1 C-N-CA 131.925 4.09 . . . . 0.0 111.376 166.909 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -85.78 3.03 43.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.862 1.265 . . . . 0.0 112.669 -176.573 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 p -138.22 -152.56 0.43 Allowed 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -166.951 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.8 pt -96.58 -17.35 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 120.382 -1.449 . . . . 0.0 112.516 168.298 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.1 mm -72.37 133.37 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 166.202 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.417 ' HA3' ' CD1' ' B' ' 151' ' ' ILE . . . 67.76 42.29 87.24 Favored Glycine 0 CA--C 1.532 1.134 0 O-C-N 124.36 1.037 . . . . 0.0 110.528 -168.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.99 148.86 35.85 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 127.04 2.136 . . . . 0.0 105.263 170.256 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 11.6 m -114.85 109.99 19.0 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.005 -1.059 . . . . 0.0 112.994 -165.038 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 11.2 tp -86.14 139.8 30.77 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 120.005 1.275 . . . . 0.0 114.224 -169.633 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.435 HG11 ' HE ' ' A' ' 143' ' ' ARG . 1.0 OUTLIER -132.68 149.3 31.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.284 168.232 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.64 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 164.762 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -127.3 131.92 50.4 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.144 1.378 . . . . 0.0 109.543 -176.62 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -60.63 -40.81 93.3 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.491 1.663 . . . . 0.0 115.491 -166.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -86.53 147.44 25.96 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 121.018 1.735 . . . . 0.0 110.898 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -33.58 125.58 0.41 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.568 1.947 . . . . 0.0 111.102 166.236 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 35.5 t0 -75.57 134.7 40.64 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 169.751 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.96 -34.67 66.64 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.889 0.876 . . . . 0.0 111.88 178.451 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.1 mt 62.74 33.18 15.65 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.621 1.568 . . . . 0.0 112.533 173.586 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -174.04 -72.75 0.05 OUTLIER Glycine 0 N--CA 1.468 0.815 0 N-CA-C 116.399 1.32 . . . . 0.0 116.399 174.845 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -164.85 67.74 0.14 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.548 1.139 . . . . 0.0 114.073 178.252 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.3 68.03 0.7 Allowed Glycine 0 CA--C 1.531 1.061 0 C-N-CA 127.001 2.239 . . . . 0.0 113.416 176.175 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.26 -14.9 31.43 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 125.944 1.735 . . . . 0.0 115.226 172.714 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -141.23 177.08 8.33 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 118.982 1.391 . . . . 0.0 112.039 -171.409 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -77.62 -43.06 32.73 Favored 'General case' 0 C--O 1.217 -0.627 0 CA-C-N 114.625 -1.171 . . . . 0.0 109.978 165.476 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -44.57 -40.32 5.63 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 173.121 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.82 -33.36 23.27 Favored 'General case' 0 N--CA 1.472 0.635 0 O-C-N 120.858 -1.151 . . . . 0.0 114.034 171.54 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.4 -24.05 20.88 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 125.565 1.546 . . . . 0.0 112.527 177.772 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -87.24 -13.66 43.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 176.907 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.8 p -129.8 -45.93 1.16 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.386 1.074 . . . . 0.0 113.385 176.508 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.8 -0.77 15.34 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 125.777 1.923 . . . . 0.0 111.793 -166.465 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 56.74 21.19 5.7 Favored 'General case' 0 N--CA 1.478 0.965 0 O-C-N 119.808 -1.995 . . . . 0.0 111.974 -175.754 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.92 30.02 0.08 Allowed 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -167.098 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.23 -35.24 0.42 Allowed Glycine 0 N--CA 1.476 1.358 0 C-N-CA 129.673 3.511 . . . . 0.0 117.588 168.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.0 t -171.3 -144.59 0.04 OUTLIER 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.476 1.11 . . . . 0.0 110.108 -169.293 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.435 ' HE ' HG11 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -142.37 -174.88 4.25 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 127.515 2.326 . . . . 0.0 110.447 172.929 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -174.42 -141.04 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 129.568 3.147 . . . . 0.0 109.008 168.18 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -51.24 138.71 20.2 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 128.341 2.656 . . . . 0.0 114.377 -168.479 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 87.3 m -126.06 134.83 51.29 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 127.942 2.497 . . . . 0.0 112.606 -169.613 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.32 153.56 23.94 Favored Glycine 0 N--CA 1.482 1.751 0 C-N-CA 125.29 1.424 . . . . 0.0 114.252 169.023 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -78.31 149.95 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 CA-C-N 120.278 2.039 . . . . 0.0 110.301 170.185 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 10.0 mm -83.13 104.39 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 106.733 -1.581 . . . . 0.0 106.733 166.049 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -106.15 146.79 16.12 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 124.348 0.975 . . . . 0.0 111.134 176.587 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.5 pp -79.86 173.7 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 122.908 0.483 . . . . 0.0 111.346 175.255 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.95 -126.86 0.03 OUTLIER 'General case' 0 C--O 1.224 -0.269 0 C-N-CA 125.823 1.649 . . . . 0.0 111.156 163.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.858 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -164.244 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 p -115.91 115.51 26.34 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.133 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.77 142.56 30.15 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 116.605 2.076 . . . . 0.0 116.605 169.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.24 132.25 42.89 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.841 2.456 . . . . 0.0 110.087 172.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 59.6 t -144.77 142.82 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 119.943 1.247 . . . . 0.0 111.786 -168.657 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -114.18 141.38 47.6 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.79 1.236 . . . . 0.0 113.853 171.929 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 15.0 m -104.06 99.62 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 167.383 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -78.91 130.35 35.52 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.722 1.209 . . . . 0.0 108.085 -175.63 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -156.18 174.47 15.33 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 -172.644 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.96 -43.03 1.35 Allowed Glycine 0 N--CA 1.471 1.002 0 C-N-CA 127.955 2.693 . . . . 0.0 111.32 172.792 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -82.96 59.17 4.74 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 127.932 2.493 . . . . 0.0 113.319 -168.633 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.41 -104.0 0.06 OUTLIER Glycine 0 CA--C 1.532 1.14 0 C-N-CA 127.537 2.494 . . . . 0.0 112.6 176.975 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.45 -14.62 16.11 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 123.618 2.878 . . . . 0.0 113.614 -177.564 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -90.05 128.79 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-N 120.096 1.317 . . . . 0.0 109.921 -178.542 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.471 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -146.06 155.12 42.56 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.848 173.121 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.27 153.14 20.64 Favored Glycine 0 C--O 1.227 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.229 177.569 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.04 117.21 54.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 C-N-CA 126.234 1.814 . . . . 0.0 106.514 168.715 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.3 mm -128.19 104.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 O-C-N 123.64 0.587 . . . . 0.0 110.049 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.53 156.13 27.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.111 1.764 . . . . 0.0 111.981 167.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -139.82 108.21 5.84 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 130.655 3.582 . . . . 0.0 107.339 170.071 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.27 130.85 53.31 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.194 1.398 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -126.12 154.68 42.8 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 122.277 1.037 . . . . 0.0 111.35 -176.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . 0.473 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 9.9 ptmm? -115.92 -24.35 8.17 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 128.298 2.639 . . . . 0.0 114.105 -177.512 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . 0.473 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 6.7 mp0 -135.79 162.25 33.32 Favored 'General case' 0 C--O 1.219 -0.502 0 CA-C-N 121.006 1.73 . . . . 0.0 112.877 173.649 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 p -64.94 -2.94 2.95 Favored 'General case' 0 N--CA 1.483 1.217 0 O-C-N 119.141 -2.224 . . . . 0.0 113.434 167.226 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.79 64.12 0.16 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 128.383 2.673 . . . . 0.0 109.754 -168.214 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.1 172.75 31.37 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.58 1.562 . . . . 0.0 113.411 -170.747 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.53 142.53 23.48 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.39 2.727 . . . . 0.0 110.683 178.634 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.05 132.6 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.158 0.983 . . . . 0.0 109.327 -172.606 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.413 ' HB2' ' HZ1' ' B' ' 30' ' ' LYS . 2.3 ttmp? -95.96 115.6 27.67 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 121.626 0.726 . . . . 0.0 111.226 179.061 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.6 t -93.55 121.35 44.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 127.105 2.162 . . . . 0.0 108.807 -179.123 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -148.25 164.88 32.65 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 177.859 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.02 -147.67 19.4 Favored Glycine 0 C--N 1.334 0.448 0 C-N-CA 125.111 1.339 . . . . 0.0 111.356 176.795 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -157.94 156.61 31.56 Favored 'General case' 0 C--O 1.237 0.407 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -175.783 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -124.39 133.67 68.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 125.284 1.433 . . . . 0.0 108.319 170.636 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -138.3 155.5 48.53 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -172.791 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.87 76.95 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.031 1.3 . . . . 0.0 114.022 -175.515 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -96.43 162.58 13.42 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 126.559 1.944 . . . . 0.0 112.11 179.503 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.23 154.24 1.26 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.458 2.703 . . . . 0.0 110.822 169.15 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -64.77 -60.34 3.2 Favored 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 120.717 1.599 . . . . 0.0 112.654 174.245 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -51.52 141.7 21.84 Favored Glycine 0 N--CA 1.472 1.075 0 C-N-CA 126.218 1.866 . . . . 0.0 114.733 -169.811 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . 0.506 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -40.74 136.88 1.29 Allowed 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 128.315 2.646 . . . . 0.0 115.243 -168.311 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -121.12 142.47 49.83 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 129.816 3.247 . . . . 0.0 109.173 -170.306 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.18 169.51 35.79 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.552 1.072 . . . . 0.0 111.879 172.436 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.2 t80 -160.43 57.95 0.34 Allowed 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.649 1.58 . . . . 0.0 110.728 -169.621 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -117.44 145.81 43.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.305 1.042 . . . . 0.0 113.401 -169.592 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -105.86 115.78 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.773 0.797 . . . . 0.0 109.189 -172.102 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m-70 -76.42 174.16 10.59 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 124.974 1.31 . . . . 0.0 110.119 179.537 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . 0.484 ' H ' ' CD ' ' B' ' 49' ' ' GLU . 1.9 pm0 -61.15 85.58 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 127.127 2.171 . . . . 0.0 115.074 -168.242 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 67.95 -157.99 0.21 Allowed 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.089 2.156 . . . . 0.0 111.865 168.974 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.75 -14.88 18.29 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.461 1.505 . . . . 0.0 112.077 -177.871 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . 0.454 ' CG ' ' HB ' ' A' ' 5' ' ' VAL . 7.5 t70 -62.57 56.52 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.023 1 C-N-CA 132.623 4.369 . . . . 0.0 110.6 169.555 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 16.3 p30 176.39 -11.01 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 128.079 2.552 . . . . 0.0 116.287 -174.388 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.315 8.4 t 7.21 30.1 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.952 2 N-CA-C 123.685 4.698 . . . . 0.0 123.685 176.268 . . . . . . . . 3 2 . 1 . 029 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -162.2 10.93 0.07 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 119.874 -1.766 . . . . 0.0 112.162 -176.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.86 -130.82 50.09 Favored Glycine 0 CA--C 1.523 0.585 0 C-N-CA 124.965 1.269 . . . . 0.0 114.048 172.296 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.2 t -57.9 -17.31 15.82 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 117.023 2.231 . . . . 0.0 117.023 -167.3 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 10.1 t -81.61 -6.57 59.13 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 120.253 1.388 . . . . 0.0 113.321 171.067 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 28.0 m -144.29 2.99 1.16 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -171.253 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.18 167.85 11.82 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 119.455 1.025 . . . . 0.0 113.173 -169.59 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.79 -152.65 23.0 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 126.846 2.165 . . . . 0.0 111.312 178.796 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -109.08 49.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.596 2.864 . . . . 0.0 111.457 -178.326 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 56.77 82.69 0.11 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.932 1.293 . . . . 0.0 112.498 -179.2 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -40.49 131.62 2.21 Favored 'General case' 0 CA--C 1.542 0.673 0 CA-C-O 122.54 1.162 . . . . 0.0 113.089 169.557 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.7 p-10 -114.29 79.86 5.44 Favored Pre-proline 0 CA--C 1.547 0.838 0 C-N-CA 126.407 1.883 . . . . 0.0 112.457 -171.246 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -62.23 -14.52 38.73 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 123.114 2.543 . . . . 0.0 114.685 179.547 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -92.78 -4.0 53.79 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.111 1.364 . . . . 0.0 113.302 171.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 28.0 t 65.7 53.39 1.19 Allowed 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.366 1.866 . . . . 0.0 112.367 171.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -142.64 177.27 8.42 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -169.559 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.44 ' H ' ' HD2' ' B' ' 70' ' ' LYS . 1.3 mptt -79.41 175.4 10.63 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 126.441 1.897 . . . . 0.0 112.904 -178.228 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -97.49 136.61 37.67 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -176.805 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 139.83 -132.27 5.5 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 124.268 0.937 . . . . 0.0 113.596 167.421 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 146.04 -34.44 1.43 Allowed Glycine 0 CA--C 1.547 2.087 0 N-CA-C 118.234 2.054 . . . . 0.0 118.234 -177.037 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -78.4 -19.53 11.65 Favored 'Trans proline' 0 C--N 1.356 0.94 0 CA-C-N 122.263 3.032 . . . . 0.0 113.609 172.22 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -46.42 0.93 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 124.437 1.095 . . . . 0.0 109.917 167.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -56.14 126.04 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.976 0.893 . . . . 0.0 109.319 169.209 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -90.61 -5.86 55.35 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 128.973 2.909 . . . . 0.0 112.717 -168.341 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -100.58 -76.48 0.56 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 126.945 2.098 . . . . 0.0 110.773 -169.809 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 84.66 113.7 0.05 Allowed 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 126.519 1.928 . . . . 0.0 113.268 165.812 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -59.2 152.66 20.06 Favored 'General case' 0 CA--C 1.549 0.911 0 O-C-N 119.669 -1.894 . . . . 0.0 110.36 170.04 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -58.39 -30.98 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.891 -1.13 . . . . 0.0 112.681 178.223 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.35 37.47 3.42 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 126.619 2.057 . . . . 0.0 113.58 171.211 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -116.85 146.87 42.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 119.988 1.894 . . . . 0.0 115.737 173.892 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 79.1 mt -144.42 163.3 34.2 Favored 'General case' 0 CA--C 1.545 0.784 1 C-N-CA 132.102 4.161 . . . . 0.0 102.702 163.156 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.91 -87.06 0.99 Allowed Glycine 0 N--CA 1.468 0.829 0 O-C-N 121.926 -0.484 . . . . 0.0 113.428 -170.643 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -153.32 168.44 26.03 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 124.674 1.19 . . . . 0.0 113.479 -166.521 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.56 147.59 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 129.233 3.013 . . . . 0.0 110.214 -176.407 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 25.7 m -120.84 145.6 47.43 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 119.437 1.017 . . . . 0.0 109.991 -176.979 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.65 144.48 26.65 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.895 0.855 . . . . 0.0 111.666 175.95 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . 0.443 ' OD1' ' HE2' ' B' ' 91' ' ' LYS . 39.7 t0 -73.19 158.95 34.26 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.762 1.225 . . . . 0.0 109.813 168.921 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.443 ' HE2' ' OD1' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -52.33 -28.2 18.34 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 115.42 1.637 . . . . 0.0 115.42 -168.292 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.85 -2.25 29.19 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.544 1.538 . . . . 0.0 112.283 -178.51 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.08 39.16 7.54 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 125.221 1.391 . . . . 0.0 113.154 177.843 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 3.2 p -132.62 126.37 54.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 CA-C-N 118.629 1.215 . . . . 0.0 113.811 170.018 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.58 119.23 31.31 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.518 1.527 . . . . 0.0 107.929 165.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.46 151.15 31.0 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 167.419 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.29 0.5 OUTLIER -134.53 131.59 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 114.593 -1.185 . . . . 0.0 112.899 165.477 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 9.6 p -157.69 59.96 0.48 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.151 1.38 . . . . 0.0 113.164 -168.65 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -115.39 156.08 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 C-N-CA 126.787 2.035 . . . . 0.0 112.715 -171.582 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -128.67 146.49 50.86 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.733 1.613 . . . . 0.0 108.288 166.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -141.02 134.83 30.41 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.243 1.417 . . . . 0.0 110.222 -179.03 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -112.75 59.27 0.64 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.315 1.446 . . . . 0.0 112.234 -167.578 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.4 p -158.12 -36.5 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.132 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.13 170.97 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 123.332 0.653 . . . . 0.0 111.349 172.712 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.8 m -157.51 159.44 37.21 Favored 'General case' 0 N--CA 1.469 0.506 0 O-C-N 120.12 -1.612 . . . . 0.0 111.335 176.316 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 4.8 tt -81.12 75.02 8.1 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.056 0.942 . . . . 0.0 109.523 -173.627 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -138.97 152.18 47.47 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.761 1.625 . . . . 0.0 111.391 -174.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -101.91 68.54 0.39 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 126.968 2.223 . . . . 0.0 113.427 -169.29 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -154.43 -91.53 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.78 1.632 . . . . 0.0 110.362 -168.819 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -127.79 -4.43 5.81 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.742 2.017 . . . . 0.0 110.461 -170.048 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 16.4 m -92.6 -91.31 0.17 Allowed 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.523 1.929 . . . . 0.0 114.651 -166.066 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pt -135.36 -14.69 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 118.112 2.634 . . . . 0.0 118.112 176.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 22.0 mm -86.58 105.8 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 CA-C-N 122.113 2.233 . . . . 0.0 108.747 179.283 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.59 61.45 1.17 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.573 0.606 . . . . 0.0 112.944 -171.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 23.4 ptt180 -140.36 144.95 36.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.981 1.312 . . . . 0.0 109.239 167.305 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 2.3 t -109.39 102.09 11.01 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 124.243 1.017 . . . . 0.0 111.067 -166.665 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 29.2 tp -86.33 129.67 34.77 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 124.152 0.981 . . . . 0.0 109.774 -173.245 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 t -107.82 118.09 54.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 169.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 13.9 p -78.85 120.03 29.18 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.37 0 N-CA-C 100.483 -3.895 . . . . 0.0 100.483 161.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -106.45 142.52 35.97 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 117.766 -1.111 . . . . 0.0 109.38 -168.189 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.92 -42.94 80.87 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 122.154 2.252 . . . . 0.0 113.915 -166.718 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.456 ' HA ' ' HE3' ' B' ' 122' ' ' LYS . 0.0 OUTLIER -111.7 152.35 27.83 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 171.624 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.12 161.02 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.853 1.661 . . . . 0.0 112.258 171.68 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -94.47 151.35 19.44 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 177.833 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -71.8 -16.66 62.19 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.572 1.949 . . . . 0.0 112.875 176.482 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.3 mt 57.96 84.29 0.1 Allowed 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 127.028 2.131 . . . . 0.0 114.464 169.764 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.74 -47.48 3.42 Favored Glycine 0 N--CA 1.465 0.622 0 C-N-CA 125.502 1.525 . . . . 0.0 111.015 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -158.84 137.91 11.33 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.609 1.564 . . . . 0.0 110.448 168.646 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -141.37 -101.15 0.43 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 169.164 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.57 -24.49 10.96 Favored Glycine 0 N--CA 1.471 0.972 0 N-CA-C 116.705 1.442 . . . . 0.0 116.705 -168.576 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -165.46 174.18 10.26 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.882 1.341 . . . . 0.0 111.83 -169.225 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -49.86 -50.84 44.19 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 126.062 1.745 . . . . 0.0 113.449 -170.313 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . 0.45 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 13.7 mp0 -45.76 -25.79 0.55 Allowed 'General case' 0 C--N 1.318 -0.794 0 C-N-CA 128.27 2.628 . . . . 0.0 113.705 175.305 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.6 p -64.95 -45.06 87.32 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 120.119 1.327 . . . . 0.0 112.716 178.823 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -79.91 -39.72 29.76 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.18 0.592 . . . . 0.0 111.523 173.151 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.29 -18.64 52.25 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -173.033 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.9 p -152.71 -15.11 0.16 Allowed 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 177.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.04 -7.56 58.85 Favored Glycine 0 C--O 1.214 -1.155 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.313 -168.652 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 51.3 t30 55.57 35.49 25.28 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-N 120.613 2.206 . . . . 0.0 112.157 178.184 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.9 38.88 0.08 Allowed 'General case' 0 CA--C 1.563 1.451 0 N-CA-C 115.759 1.763 . . . . 0.0 115.759 -166.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.16 -84.46 0.41 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 127.109 2.29 . . . . 0.0 113.767 175.488 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t -160.52 172.8 16.55 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.155 0.982 . . . . 0.0 112.978 -178.041 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 154.83 25.62 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.126 1.37 . . . . 0.0 113.624 -171.488 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 19.5 tp -159.79 -177.55 6.43 Favored 'General case' 0 CA--C 1.56 1.342 0 C-N-CA 129.795 3.238 . . . . 0.0 104.878 169.836 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.73 129.91 20.36 Favored 'General case' 0 CA--C 1.556 1.185 0 N-CA-C 115.838 1.792 . . . . 0.0 115.838 -165.146 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.9 m -114.91 134.19 55.36 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 126.712 2.005 . . . . 0.0 112.645 -176.687 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.9 144.12 10.17 Favored Glycine 0 N--CA 1.486 2.006 0 CA-C-N 120.994 1.724 . . . . 0.0 117.172 177.297 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 84.6 t -81.12 140.74 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 118.169 0.985 . . . . 0.0 109.893 176.022 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.4 mm -77.68 107.33 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 170.584 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.16 36.45 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.555 1.55 . . . . 0.0 111.951 169.635 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . 0.417 ' CD1' ' HA3' ' A' ' 114' ' ' GLY . 1.1 pp -138.91 160.65 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 125.04 1.336 . . . . 0.0 112.89 177.822 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.58 1.3 0.44 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.644 1.978 . . . . 0.0 112.554 164.603 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tm0? . . . . . 0 N--CA 1.472 0.648 0 C-N-CA 126.636 1.975 . . . . 0.0 110.876 169.699 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.758 0 CA-C-O 118.973 -0.537 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 67.4 p -78.82 64.66 3.85 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 127.132 2.173 . . . . 0.0 114.881 -166.241 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.1 ttpt -161.55 126.18 3.44 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 118.529 2.789 . . . . 0.0 118.529 166.085 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.52 177.5 4.9 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 129.489 3.116 . . . . 0.0 107.006 164.346 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.54 151.15 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 -164.227 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.07 115.21 7.92 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 110.627 166.252 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 68.9 t -101.41 95.59 4.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.667 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.9 mp -79.34 152.51 30.42 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.13 1.372 . . . . 0.0 108.68 173.612 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -153.24 158.56 41.88 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -130.11 158.33 22.31 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.308 2.385 . . . . 0.0 107.957 166.151 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -71.94 83.59 0.95 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 126.817 2.047 . . . . 0.0 110.941 -177.446 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.09 -147.64 18.78 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 127.041 2.258 . . . . 0.0 110.158 -169.403 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -94.64 9.51 1.93 Allowed 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 124.794 3.663 . . . . 0.0 114.87 -169.841 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.63 134.16 34.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 CA-C-N 120.025 1.284 . . . . 0.0 110.393 -177.369 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.39 164.67 34.28 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.517 1.127 . . . . 0.0 111.486 178.865 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.52 97.79 0.42 Allowed Glycine 0 C--O 1.215 -1.042 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 169.042 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -96.41 106.61 18.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 118.519 1.159 . . . . 0.0 108.012 175.892 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 pt -133.59 150.13 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 122.241 1.019 . . . . 0.0 111.62 177.09 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -122.74 145.29 48.54 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.637 1.575 . . . . 0.0 110.329 179.416 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -120.94 105.07 10.32 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.936 1.694 . . . . 0.0 109.635 -173.895 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.1 121.16 28.31 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 177.369 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 11.0 tp60 -147.76 137.94 22.91 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.251 0.548 . . . . 0.0 111.186 175.507 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.456 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -91.96 -24.28 19.31 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -175.735 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.66 -155.65 0.61 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-N 120.136 1.335 . . . . 0.0 113.038 176.489 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 66.6 m -107.25 10.25 29.91 Favored 'General case' 0 CA--C 1.543 0.677 0 O-C-N 119.377 -2.077 . . . . 0.0 113.634 -179.095 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -131.27 -10.29 3.7 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 126.021 1.728 . . . . 0.0 114.746 -172.437 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.13 160.74 20.75 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 128.926 3.155 . . . . 0.0 112.657 -168.615 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.75 151.57 32.02 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 123.028 2.486 . . . . 0.0 109.718 175.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 67.4 t -119.71 137.65 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.166 1.387 . . . . 0.0 110.004 -168.166 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -84.41 127.09 33.8 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.512 0.596 . . . . 0.0 110.1 170.19 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 t -107.82 130.09 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 125.632 1.573 . . . . 0.0 108.346 171.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -151.14 165.9 32.48 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 123.342 0.657 . . . . 0.0 111.54 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 131.16 -148.9 19.07 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 124.993 1.283 . . . . 0.0 111.754 175.928 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 54.1 p -142.6 127.22 17.98 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -169.815 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 mm -101.3 112.77 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 124.676 1.19 . . . . 0.0 108.279 170.987 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.9 pttt -129.58 152.07 49.5 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.835 1.198 . . . . 0.0 112.698 -166.514 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.01 5.52 64.05 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.38 0.99 . . . . 0.0 112.599 -169.061 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -75.44 -161.63 0.16 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 127.405 2.282 . . . . 0.0 109.662 168.766 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -151.98 171.24 18.13 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 126.627 1.971 . . . . 0.0 108.183 169.331 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -49.04 136.84 13.96 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.851 1.66 . . . . 0.0 113.439 -168.876 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.51 -173.13 28.21 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-O 122.597 1.11 . . . . 0.0 112.511 173.202 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.413 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.5 OUTLIER -73.01 160.45 32.07 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.1 0.96 . . . . 0.0 111.373 -171.339 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -149.09 136.21 19.94 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 127.653 2.381 . . . . 0.0 108.867 176.62 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.17 148.71 32.48 Favored Glycine 0 N--CA 1.478 1.463 0 CA-C-O 119.261 -0.744 . . . . 0.0 111.964 171.226 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -153.15 78.71 1.17 Allowed 'General case' 0 CA--C 1.544 0.741 0 CA-C-O 122.88 1.324 . . . . 0.0 110.768 -168.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -124.73 157.86 34.66 Favored 'General case' 0 CA--C 1.516 -0.338 0 O-C-N 120.803 -1.186 . . . . 0.0 111.396 -169.428 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.508 HG12 HH11 ' A' ' 115' ' ' ARG . 1.7 m -87.65 151.52 3.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.24 176.628 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 8.4 m170 -113.88 168.79 9.5 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 104.102 -2.555 . . . . 0.0 104.102 160.175 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.75 -172.69 0.09 Allowed 'General case' 0 CA--C 1.554 1.11 0 N-CA-C 117.257 2.317 . . . . 0.0 117.257 -167.83 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -119.43 -36.58 3.32 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 128.203 2.601 . . . . 0.0 112.305 -175.739 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.19 -29.52 62.9 Favored Glycine 0 N--CA 1.47 0.93 1 C-N-CA 131.667 4.461 . . . . 0.0 114.588 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -123.97 151.23 43.9 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 163.045 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -148.98 101.55 3.18 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 119.11 3.004 . . . . 0.0 119.11 -166.493 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.4 ' C ' ' H ' ' A' ' 56' ' ' GLY 0.549 0.1 OUTLIER 112.48 -145.75 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.695 1 C-N-CA 133.673 4.789 . . . . 0.0 113.576 160.044 . . . . . . . . 5 4 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 49.05 -10.13 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 131.033 3.733 . . . . 0.0 117.91 -172.348 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 54' ' ' THR . . . 90.34 -132.12 11.11 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.968 2.223 . . . . 0.0 111.211 -176.915 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.9 m -62.78 -8.47 6.89 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 177.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.1 m -79.9 -24.07 41.38 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.922 1.289 . . . . 0.0 112.457 171.672 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 m -158.43 45.57 0.31 Allowed 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 116.193 1.923 . . . . 0.0 116.193 -169.2 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 176.96 125.45 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 127.807 2.443 . . . . 0.0 110.452 168.429 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -72.16 149.14 43.73 Favored Glycine 0 CA--C 1.541 1.667 0 O-C-N 120.736 -1.228 . . . . 0.0 114.372 -175.772 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -64.69 106.94 0.8 Allowed 'Trans proline' 0 C--N 1.354 0.822 1 C-N-CA 125.488 4.125 . . . . 0.0 111.604 -178.896 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.456 ' CE1' ' HA ' ' A' ' 137' ' ' THR 0.274 0.0 OUTLIER 36.04 57.18 1.0 Allowed 'General case' 0 C--O 1.234 0.247 0 C-N-CA 127.377 2.271 . . . . 0.0 112.468 170.458 . . . . . . . . 4 4 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -27.05 122.79 0.09 Allowed 'General case' 0 C--N 1.342 0.259 0 C-N-CA 128.285 2.634 . . . . 0.0 111.26 179.328 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 62.8 m-20 -71.84 101.26 0.37 Allowed Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -168.426 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -84.67 -12.46 7.49 Favored 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.157 2.571 . . . . 0.0 112.956 -167.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 92.0 mt -139.75 2.91 2.02 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 128.62 2.768 . . . . 0.0 110.717 -172.117 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 16.0 t 66.44 53.43 0.98 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.706 1.603 . . . . 0.0 114.022 175.675 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.79 179.57 4.94 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.978 1.711 . . . . 0.0 113.161 179.851 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.1 mmtt -73.57 173.61 9.46 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 121.654 0.74 . . . . 0.0 111.667 169.356 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 48.9 t60 -72.15 157.77 37.14 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 168.489 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 143.78 -126.19 2.69 Favored Glycine 0 C--N 1.339 0.72 0 N-CA-C 116.576 1.39 . . . . 0.0 116.576 165.725 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.85 -90.24 0.36 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 116.58 1.392 . . . . 0.0 116.58 -171.105 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.5 -2.21 4.84 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.946 3.097 . . . . 0.0 115.184 -173.325 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.312 3.3 ptmm? -144.08 4.13 1.24 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 126.433 1.893 . . . . 0.0 112.677 168.346 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -131.77 113.77 13.92 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 127.082 2.153 . . . . 0.0 109.168 177.038 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -71.16 -14.07 62.15 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 127.968 2.507 . . . . 0.0 114.082 -176.371 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -78.02 -62.06 1.8 Allowed 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.908 1.231 . . . . 0.0 109.295 175.361 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 74.6 ttt180 70.71 120.44 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 123.477 1.608 . . . . 0.0 112.831 169.592 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.8 m170 -66.98 136.58 55.53 Favored 'General case' 0 CA--C 1.543 0.694 0 O-C-N 118.96 -2.337 . . . . 0.0 109.217 164.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.0 t -53.74 -19.11 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 122.464 1.126 . . . . 0.0 111.636 166.281 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -92.16 41.09 2.82 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.255 2.36 . . . . 0.0 116.878 172.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -144.56 122.57 12.08 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 119.751 1.775 . . . . 0.0 111.865 -179.06 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.86 48.75 0.94 Allowed 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 123.811 1.767 . . . . 0.0 110.359 173.762 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.89 -133.48 52.71 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 126.122 1.82 . . . . 0.0 114.257 175.289 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.82 138.73 48.03 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.672 1.589 . . . . 0.0 110.11 171.495 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.0 p -92.95 127.45 45.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 166.327 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 24.4 m -115.39 119.48 36.4 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -176.27 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.99 156.96 17.31 Favored 'General case' 0 C--N 1.328 -0.353 0 O-C-N 123.667 0.604 . . . . 0.0 112.588 -177.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.73 168.54 19.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 126.403 1.881 . . . . 0.0 113.67 173.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.1 pptp? -60.11 -20.09 56.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.789 1.636 . . . . 0.0 113.79 168.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -80.95 0.04 37.25 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.006 1.322 . . . . 0.0 112.306 170.791 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 19.92 60.41 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 125.178 1.37 . . . . 0.0 114.099 174.633 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -134.16 138.85 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 119.04 1.42 . . . . 0.0 113.527 -176.54 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.79 123.31 40.45 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 165.655 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -97.74 118.8 35.09 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.581 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.12 140.08 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 CA-C-N 114.159 -1.382 . . . . 0.0 113.935 -165.733 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 77.4 p -155.65 123.2 5.57 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.594 1.558 . . . . 0.0 110.103 168.834 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -155.17 148.81 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 127.703 2.401 . . . . 0.0 109.992 -169.85 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -125.77 125.22 42.61 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 165.749 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -121.72 141.81 50.81 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.038 0.935 . . . . 0.0 110.994 -173.753 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -115.63 48.66 1.17 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.959 0.904 . . . . 0.0 112.863 -178.377 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.26 -4.81 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.459 1.104 . . . . 0.0 112.23 170.732 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.54 164.88 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 C-N-CA 125.951 1.7 . . . . 0.0 110.727 176.672 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 99.5 p -149.54 175.28 11.66 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 128.285 2.634 . . . . 0.0 109.072 178.098 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mp -86.16 93.4 9.02 Favored 'General case' 0 CA--C 1.543 0.684 0 O-C-N 120.809 -1.182 . . . . 0.0 109.33 173.249 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.2 t -152.45 153.88 34.42 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.753 1.221 . . . . 0.0 110.119 169.04 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -103.08 29.23 12.88 Favored Glycine 0 N--CA 1.472 1.041 0 C-N-CA 126.142 1.829 . . . . 0.0 113.27 -178.147 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -86.81 -96.55 0.08 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 126.022 1.729 . . . . 0.0 106.691 169.655 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m170 -107.39 -7.75 16.54 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.458 1.503 . . . . 0.0 111.806 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -76.15 -157.77 0.08 Allowed 'General case' 0 CA--C 1.558 1.259 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -174.999 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.271 10.9 pt -97.14 44.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 118.455 -2.653 . . . . 0.0 116.06 -172.006 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.9 mm -115.73 126.96 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 166.321 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.18 -4.2 34.06 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 117.208 -1.885 . . . . 0.0 115.077 173.309 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.508 HH11 HG12 ' A' ' 47' ' ' VAL . 3.1 ptp180 -78.82 153.47 30.64 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 120.795 2.297 . . . . 0.0 110.889 170.218 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 6.3 t -101.29 162.75 12.67 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 119.676 1.125 . . . . 0.0 112.917 177.466 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -130.44 137.98 50.09 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.788 2.035 . . . . 0.0 107.921 174.52 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.2 125.44 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.291 1.436 . . . . 0.0 109.969 175.24 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -90.2 143.08 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 171.84 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -106.64 158.35 17.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 122.009 0.909 . . . . 0.0 112.909 -174.567 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -71.56 -40.8 69.74 Favored 'General case' 0 CA--C 1.538 0.483 0 O-C-N 121.334 -0.854 . . . . 0.0 111.237 -169.07 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -116.82 174.73 5.92 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 124.706 1.202 . . . . 0.0 112.664 172.594 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.4 148.16 1.43 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.813 2.445 . . . . 0.0 112.252 172.422 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -110.29 142.57 41.73 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.282 1.033 . . . . 0.0 112.185 172.609 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -93.93 -8.3 40.56 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 176.888 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 77.09 -73.33 0.09 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 128.94 2.896 . . . . 0.0 111.516 169.301 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -95.8 -5.26 59.99 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 125.262 1.411 . . . . 0.0 113.539 -174.389 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt -158.23 -146.08 0.15 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 128.088 2.555 . . . . 0.0 112.539 173.15 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 133.31 -29.13 3.21 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 128.7 3.048 . . . . 0.0 110.617 -168.393 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 126.73 -17.03 6.47 Favored Glycine 0 N--CA 1.473 1.12 0 C-N-CA 126.282 1.896 . . . . 0.0 114.986 169.588 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -110.57 174.6 5.79 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.09 1.356 . . . . 0.0 113.683 -171.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -52.22 -59.67 4.12 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.319 1.848 . . . . 0.0 110.615 167.52 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.45 ' CD ' ' HG1' ' A' ' 137' ' ' THR . 0.1 OUTLIER -46.57 -36.01 6.42 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.735 1.214 . . . . 0.0 112.51 169.433 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -66.47 -3.74 6.85 Favored 'General case' 0 N--CA 1.476 0.86 0 O-C-N 120.132 -1.605 . . . . 0.0 113.909 -175.936 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.1 p -119.96 -12.96 9.08 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 175.896 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 ptpt -113.25 -26.1 8.56 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 176.952 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.456 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 0.5 OUTLIER -127.96 -17.94 4.31 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 127.049 2.14 . . . . 0.0 113.809 179.497 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.03 -21.49 41.62 Favored Glycine 0 N--CA 1.467 0.724 0 C-N-CA 126.537 2.018 . . . . 0.0 111.969 177.361 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 71.46 36.65 1.26 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.94 1.696 . . . . 0.0 112.421 168.492 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.32 44.69 0.01 OUTLIER 'General case' 0 CA--C 1.575 1.941 0 C-N-CA 128.414 2.686 . . . . 0.0 117.41 -169.268 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.8 -57.21 2.62 Favored Glycine 0 N--CA 1.473 1.157 0 C-N-CA 127.84 2.638 . . . . 0.0 114.483 -177.986 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.9 t -168.17 171.11 9.7 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.727 1.211 . . . . 0.0 111.572 -178.584 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -85.04 148.29 26.23 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 120.726 -1.233 . . . . 0.0 110.608 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -128.01 -146.28 0.32 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.521 1.929 . . . . 0.0 109.26 175.935 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.79 155.37 30.54 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 127.146 2.178 . . . . 0.0 114.596 179.748 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.3 p -151.96 153.74 34.67 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.086 1.355 . . . . 0.0 114.084 -173.304 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.04 159.87 31.5 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 125.042 1.306 . . . . 0.0 113.407 178.057 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.458 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 3.6 t -106.45 142.91 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-N 118.717 1.259 . . . . 0.0 109.422 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mm -77.48 93.74 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 CA-C-O 122.232 1.015 . . . . 0.0 110.156 -178.676 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -92.27 174.94 37.38 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 125.884 1.707 . . . . 0.0 112.706 173.581 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.07 149.64 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -173.372 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.98 -17.58 4.37 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.552 1.941 . . . . 0.0 115.006 177.561 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 . . . . . 0 N--CA 1.472 0.627 0 C-N-CA 125.689 1.595 . . . . 0.0 112.592 176.864 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.279 0.561 . . . . 0.0 112.235 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.7 t -156.63 112.17 2.92 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 125.814 1.646 . . . . 0.0 108.458 167.878 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 10.1 pttt -111.93 171.72 7.33 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 116.45 2.019 . . . . 0.0 116.45 -173.315 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.87 168.32 14.02 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 128.457 2.703 . . . . 0.0 110.957 174.492 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.5 139.46 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 126.331 1.852 . . . . 0.0 111.861 -178.202 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.06 105.05 4.77 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.092 0.957 . . . . 0.0 109.477 165.041 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -92.13 130.81 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 166.358 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mp -92.07 143.41 26.48 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 123.554 0.742 . . . . 0.0 111.284 -178.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 tttm -156.14 175.93 13.33 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 168.903 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 148.8 -77.93 0.23 Allowed Glycine 0 CA--C 1.523 0.552 0 C-N-CA 128.463 2.935 . . . . 0.0 108.164 -172.936 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.74 75.49 3.39 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.021 1.728 . . . . 0.0 112.735 -168.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.73 -97.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.37 0 C-N-CA 127.503 2.478 . . . . 0.0 114.314 169.518 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -82.81 -1.34 10.46 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.958 3.772 . . . . 0.0 114.945 179.162 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.81 140.34 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 120.54 1.518 . . . . 0.0 110.047 170.749 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -139.71 168.03 20.76 Favored 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 125.684 1.594 . . . . 0.0 109.31 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -158.83 92.98 0.12 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.034 -1.426 . . . . 0.0 116.126 165.229 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.22 126.5 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-N 119.296 1.548 . . . . 0.0 110.723 175.931 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.7 mm -135.98 111.08 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 124.901 1.28 . . . . 0.0 110.977 176.113 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -74.8 146.62 41.91 Favored 'General case' 0 CA--C 1.546 0.819 0 O-C-N 121.328 -0.857 . . . . 0.0 110.009 166.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -128.76 100.64 5.79 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.707 1.603 . . . . 0.0 108.571 172.914 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -101.83 130.37 48.27 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -174.549 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -100.81 120.51 40.22 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.136 0.493 . . . . 0.0 111.41 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -75.06 -41.7 58.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 123.048 0.539 . . . . 0.0 111.204 168.678 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -156.58 133.58 10.42 Favored 'General case' 0 C--O 1.219 -0.52 0 C-N-CA 126.429 1.892 . . . . 0.0 110.321 168.309 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -60.42 -19.72 57.23 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 114.703 1.372 . . . . 0.0 114.703 -172.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -80.56 -6.26 57.98 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.655 1.182 . . . . 0.0 113.218 173.753 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.86 -164.34 11.22 Favored Glycine 0 CA--C 1.537 1.459 0 C-N-CA 126.546 2.022 . . . . 0.0 113.383 -172.935 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.37 155.52 25.06 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.271 2.647 . . . . 0.0 114.012 -169.25 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 84.5 t -102.6 137.35 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.766 1.626 . . . . 0.0 110.17 172.739 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -96.09 122.62 39.12 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 167.145 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.31 129.2 74.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 126.166 1.786 . . . . 0.0 107.856 -169.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.5 p90 -155.41 153.16 29.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 -178.679 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.64 -152.73 24.77 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 125.417 1.484 . . . . 0.0 109.92 179.717 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 69.0 p -159.04 147.42 18.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -175.074 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 6.0 mm -105.62 109.55 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.558 1.543 . . . . 0.0 109.078 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 44.9 tttp -120.75 133.43 55.33 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 119.463 1.029 . . . . 0.0 110.94 -168.887 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.66 -6.43 9.73 Favored Glycine 0 CA--C 1.541 1.681 0 C-N-CA 127.964 2.697 . . . . 0.0 113.839 -169.663 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -75.08 -179.89 4.61 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 126.373 1.869 . . . . 0.0 113.346 177.169 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -103.95 157.73 16.9 Favored 'General case' 0 C--O 1.239 0.553 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 162.521 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -64.86 168.94 5.65 Favored 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.741 1.385 . . . . 0.0 114.741 -170.84 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.59 -177.54 51.38 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.261 0.934 . . . . 0.0 114.161 -173.021 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.8 mp -66.97 149.33 50.78 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 127.298 2.239 . . . . 0.0 113.648 -174.156 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -140.5 133.42 29.19 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.726 1.61 . . . . 0.0 110.235 176.816 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.59 146.67 48.47 Favored Glycine 0 N--CA 1.475 1.257 0 CA-C-O 119.055 -0.858 . . . . 0.0 110.987 175.574 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -152.94 111.79 3.76 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.592 0.757 . . . . 0.0 111.852 -166.06 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -147.73 152.2 37.36 Favored 'General case' 0 N--CA 1.471 0.617 0 O-C-N 120.032 -1.667 . . . . 0.0 111.256 -169.852 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.41 131.41 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-O 123.719 1.724 . . . . 0.0 110.117 169.527 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 48' ' ' HIS . . . . . 0.466 ' CE1' ' HG ' ' B' ' 57' ' ' CYS . 18.1 m-70 -76.08 108.69 9.16 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 165.448 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -68.75 21.62 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.238 2.215 . . . . 0.0 113.554 -169.288 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -153.81 131.74 11.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.976 1.71 . . . . 0.0 108.005 -171.158 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.28 -14.54 76.39 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 115.124 0.81 . . . . 0.0 115.124 178.427 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -69.91 74.07 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 127.023 2.129 . . . . 0.0 111.149 178.257 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 5.4 p30 164.02 -36.54 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 128.697 2.799 . . . . 0.0 115.237 -178.85 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.401 0.1 OUTLIER 54.13 -47.4 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 130.457 3.503 . . . . 0.0 118.667 -173.625 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.98 21.23 6.9 Favored 'General case' 0 CA--C 1.549 0.906 0 CA-C-N 120.37 1.441 . . . . 0.0 113.643 -178.497 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 53.62 -128.67 39.88 Favored Glycine 0 C--N 1.34 0.782 0 C-N-CA 126.028 1.775 . . . . 0.0 112.919 169.248 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 57' ' ' CYS . . . . . 0.466 ' HG ' ' CE1' ' B' ' 48' ' ' HIS . 61.1 m -58.16 -7.79 0.92 Allowed 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 115.856 1.798 . . . . 0.0 115.856 178.245 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 34.5 m -103.89 -0.11 29.49 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 126.084 1.753 . . . . 0.0 111.61 177.213 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 74.4 m -146.31 7.08 1.0 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 171.753 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.68 -172.71 1.96 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.845 2.058 . . . . 0.0 111.381 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.05 178.39 49.08 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 118.774 -1.014 . . . . 0.0 113.713 173.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -64.71 -176.3 0.42 Allowed 'Trans proline' 0 C--N 1.356 0.928 1 C-N-CA 128.171 5.914 . . . . 0.0 113.097 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 63' ' ' HIS . . . . . 0.553 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.6 p80 -53.48 111.82 0.78 Allowed 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.215 1.406 . . . . 0.0 108.53 169.338 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -57.49 157.9 6.36 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 114.434 -1.257 . . . . 0.0 111.174 -178.854 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.26 49.78 0.01 OUTLIER Pre-proline 0 CA--C 1.566 1.59 0 N-CA-C 114.909 1.448 . . . . 0.0 114.909 172.497 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -65.74 -28.98 51.45 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.366 2.238 . . . . 0.0 114.247 -171.553 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 65.7 mt -75.79 -4.0 38.14 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 173.4 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 64.95 55.16 1.19 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.524 1.529 . . . . 0.0 112.827 170.231 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.33 178.92 8.73 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 124.899 1.279 . . . . 0.0 112.709 -171.274 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.462 ' HZ3' ' CD ' ' B' ' 77' ' ' GLU . 22.4 pttm -72.7 161.24 31.0 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.138 0.575 . . . . 0.0 111.173 -175.757 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -82.41 155.17 24.82 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 179.426 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 141.26 -108.93 0.57 Allowed Glycine 0 C--N 1.339 0.72 0 N-CA-C 114.246 0.458 . . . . 0.0 114.246 166.896 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.2 -19.61 34.38 Favored Glycine 0 CA--C 1.546 1.988 0 N-CA-C 119.145 2.418 . . . . 0.0 119.145 169.936 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -110.15 24.9 0.05 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 0 C-N-CA 124.248 3.299 . . . . 0.0 111.718 169.01 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 ptpt -165.85 -31.67 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 127.301 2.24 . . . . 0.0 110.646 170.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -84.2 136.72 33.85 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 128.469 2.708 . . . . 0.0 107.155 166.865 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 77' ' ' GLU . . . . . 0.462 ' CD ' ' HZ3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -87.63 -12.82 44.43 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 127.209 2.204 . . . . 0.0 113.523 -176.993 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -91.65 -98.65 0.12 Allowed 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.112 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 87.58 141.32 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 128.391 2.676 . . . . 0.0 113.573 174.599 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -69.67 154.99 41.2 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 116.938 -1.506 . . . . 0.0 107.872 162.73 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.326 7.1 p -76.5 -21.97 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-N 122.467 2.394 . . . . 0.0 111.104 177.173 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -69.11 20.81 0.4 Allowed Glycine 0 CA--C 1.537 1.436 0 C-N-CA 125.693 1.616 . . . . 0.0 115.327 169.202 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -124.63 118.16 25.88 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 120.785 2.292 . . . . 0.0 111.71 -176.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -97.75 170.81 8.73 Favored 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 166.378 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -76.04 175.5 52.27 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 166.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -70.65 145.93 50.32 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.559 -0.377 . . . . 0.0 111.104 -169.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 6.6 p -85.0 166.0 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 165.853 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -152.49 140.2 19.89 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.159 1.345 . . . . 0.0 112.688 -177.532 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 89' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -116.94 152.33 34.78 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -167.988 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -97.25 155.46 16.85 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 129.245 3.018 . . . . 0.0 110.943 170.573 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 91' ' ' LYS . . . . . 0.439 ' HZ3' ' CG ' ' B' ' 92' ' ' ASP . 1.7 pptp? -43.01 -24.02 0.06 Allowed 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 129.487 3.115 . . . . 0.0 117.27 175.479 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.439 ' CG ' ' HZ3' ' B' ' 91' ' ' LYS . 73.1 m-20 -76.41 6.28 5.91 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 120.503 -1.373 . . . . 0.0 111.595 172.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.0 27.91 67.71 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 126.06 1.791 . . . . 0.0 112.801 178.564 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.5 p -115.71 120.28 64.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.09 0.956 . . . . 0.0 110.63 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.42 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -83.6 120.99 26.64 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.521 1.128 . . . . 0.0 108.728 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.42 146.3 28.51 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.852 0.834 . . . . 0.0 110.302 172.549 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.37 127.96 57.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.52 165.333 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -150.68 53.59 0.88 Allowed 'General case' 0 CA--C 1.545 0.757 0 CA-C-O 123.583 1.658 . . . . 0.0 109.204 -172.746 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.5 mp -105.03 160.85 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.241 1.816 . . . . 0.0 112.512 -166.587 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -140.23 142.12 35.84 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 128.153 2.581 . . . . 0.0 106.304 168.691 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -150.98 138.29 19.39 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 119.084 0.856 . . . . 0.0 111.393 -179.949 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.2 p -107.84 52.75 0.71 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.393 1.077 . . . . 0.0 111.815 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.63 -42.1 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.864 1.666 . . . . 0.0 108.967 177.172 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -87.9 144.64 8.78 Favored 'Isoleucine or valine' 0 C--N 1.344 0.338 0 CA-C-O 122.32 1.057 . . . . 0.0 110.463 167.468 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 10.3 p -148.86 168.41 23.08 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 124.201 1.001 . . . . 0.0 111.125 170.215 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -79.72 63.49 4.3 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 124.754 1.221 . . . . 0.0 108.628 174.737 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.0 t -84.55 -175.67 5.89 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.082 1.353 . . . . 0.0 110.342 169.086 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.06 -46.92 2.33 Favored Glycine 0 N--CA 1.475 1.265 0 O-C-N 120.924 -1.11 . . . . 0.0 113.832 177.016 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -125.27 -24.74 3.91 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -169.398 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 73.0 m-70 -97.71 7.98 45.48 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.558 1.543 . . . . 0.0 113.421 -171.554 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.62 -133.83 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -171.916 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.321 36.0 pt -81.28 -143.18 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 CA-C-N 119.431 1.014 . . . . 0.0 113.011 170.822 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm 59.49 124.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 127.597 2.359 . . . . 0.0 111.873 -165.56 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.05 19.68 61.69 Favored Glycine 0 N--CA 1.474 1.212 0 O-C-N 120.409 -1.432 . . . . 0.0 113.981 179.007 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? -99.93 172.45 7.22 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 127.157 2.183 . . . . 0.0 109.496 174.56 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.9 t -130.67 127.0 37.99 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-N 119.371 0.987 . . . . 0.0 112.287 177.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 16.7 tp -93.0 130.36 38.59 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 125.677 1.591 . . . . 0.0 110.322 -175.648 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.53 146.5 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 125.781 1.632 . . . . 0.0 111.323 175.514 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.3 p -121.78 142.14 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 123.48 0.712 . . . . 0.0 111.215 170.553 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -115.25 156.06 26.08 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 113.607 -168.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -73.67 -28.53 61.81 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -169.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -117.82 173.97 6.45 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.562 1.145 . . . . 0.0 112.228 176.721 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.8 134.06 56.25 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.368 1.467 . . . . 0.0 110.828 169.8 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -81.78 119.67 24.18 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.411 1.084 . . . . 0.0 111.277 173.6 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . 0.369 30.3 t0 -75.71 -4.88 42.86 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 170.47 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 5.4 mt 61.03 76.03 0.39 Allowed 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 126.221 1.808 . . . . 0.0 112.123 165.125 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.13 -12.71 48.78 Favored Glycine 0 N--CA 1.476 1.303 0 C-N-CA 123.174 0.416 . . . . 0.0 112.875 176.913 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mtpm? -115.38 179.0 4.09 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.883 2.473 . . . . 0.0 109.223 170.033 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 126.39 -28.81 4.68 Favored Glycine 0 N--CA 1.469 0.861 0 C-N-CA 125.681 1.61 . . . . 0.0 111.351 -168.931 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 104.43 -6.29 45.52 Favored Glycine 0 N--CA 1.474 1.185 0 N-CA-C 117.253 1.661 . . . . 0.0 117.253 166.609 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.0 p-10 -110.74 170.24 8.23 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.771 1.628 . . . . 0.0 110.258 176.159 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 132' ' ' GLU . . . . . 0.414 ' OE2' ' HE2' ' B' ' 136' ' ' LYS . 24.2 tt0 -63.0 -41.65 99.63 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.514 -1.366 . . . . 0.0 110.412 -179.843 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -56.23 -27.88 56.49 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.369 2.267 . . . . 0.0 112.569 176.317 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.26 -23.04 54.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.566 1.076 . . . . 0.0 113.573 171.224 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.6 t -121.23 -13.05 8.56 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.373 1.619 . . . . 0.0 115.373 169.646 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.414 ' HE2' ' OE2' ' B' ' 132' ' ' GLU . 30.6 mttm -76.48 -23.96 53.82 Favored 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 121.009 1.732 . . . . 0.0 111.449 166.501 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 75.6 p -117.97 -114.21 0.33 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 104.3 -2.481 . . . . 0.0 104.3 165.386 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.24 -10.76 0.19 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 116.262 1.265 . . . . 0.0 116.262 169.136 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 114.85 -14.15 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 131.123 3.769 . . . . 0.0 112.737 177.819 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.08 4.9 0.11 Allowed 'General case' 0 CA--C 1.56 1.344 0 N-CA-C 117.497 2.406 . . . . 0.0 117.497 -174.34 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.8 -141.68 18.8 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.542 1.544 . . . . 0.0 113.466 174.808 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.0 t -68.64 -167.44 0.1 Allowed 'General case' 0 CA--C 1.544 0.732 0 CA-C-O 122.294 1.045 . . . . 0.0 111.965 175.909 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.88 155.79 44.69 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 124.428 1.091 . . . . 0.0 110.578 177.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.72 -123.19 0.29 Allowed 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 126.256 2.222 . . . . 0.0 105.034 164.003 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -66.91 160.71 25.65 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -166.394 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.8 t -147.88 152.08 37.0 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.445 1.898 . . . . 0.0 112.078 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.65 135.79 4.3 Favored Glycine 0 N--CA 1.483 1.829 0 CA-C-N 120.317 1.417 . . . . 0.0 115.667 -177.087 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 12.2 t -81.65 154.89 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 125.336 1.454 . . . . 0.0 111.779 -177.204 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 39.3 mt -95.46 93.82 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 126.455 1.902 . . . . 0.0 111.99 -176.358 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.24 173.63 30.35 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 125.614 1.578 . . . . 0.0 113.487 174.606 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.8 mp -95.49 85.98 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.095 1.887 . . . . 0.0 116.095 -167.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -73.78 18.92 0.12 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.961 1.704 . . . . 0.0 115.478 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 . . . . . 0 N--CA 1.466 0.364 0 C-N-CA 130.845 3.658 . . . . 0.0 114.712 -169.279 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.511 -0.541 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 152' ' ' ALA . 14.4 pttm -89.13 129.96 35.64 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.375 168.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -90.56 173.52 8.02 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 164.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.582 HG23 HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -138.2 119.56 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.524 1.53 . . . . 0.0 108.475 -173.784 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.96 118.77 37.65 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 166.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 HG22 ' B' ' 54' ' ' THR . 22.0 t -110.99 99.66 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.705 0.802 . . . . 0.0 109.397 177.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.95 132.56 35.89 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.564 168.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -135.5 132.51 37.4 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.048 1.339 . . . . 0.0 110.643 168.439 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.95 -97.95 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 171.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.87 119.77 9.95 Favored 'General case' 0 N--CA 1.44 -0.94 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 -166.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 41.02 -99.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 128.743 3.068 . . . . 0.0 113.358 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.88 -11.88 33.52 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 123.311 2.674 . . . . 0.0 113.828 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.89 115.05 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 120.32 1.418 . . . . 0.0 112.44 179.061 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -139.9 169.9 16.86 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 122.265 1.031 . . . . 0.0 111.005 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.96 110.29 0.55 Allowed Glycine 0 C--O 1.224 -0.476 0 CA-C-N 113.984 -1.462 . . . . 0.0 111.639 168.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.62 134.65 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.106 0.953 . . . . 0.0 109.339 169.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.1 mm -139.38 124.45 21.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 C-N-CA 125.996 1.718 . . . . 0.0 109.888 168.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -90.81 141.32 28.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 124.867 1.267 . . . . 0.0 110.571 166.012 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.633 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 71.4 m-85 -113.94 101.53 9.34 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.686 1.194 . . . . 0.0 109.779 172.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -83.91 110.68 18.59 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 125.965 1.706 . . . . 0.0 111.172 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.498 ' HB2' HD13 ' A' ' 106' ' ' LEU . 6.7 tp60 -123.13 139.17 54.34 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.378 1.071 . . . . 0.0 110.989 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.94 -28.17 15.3 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 -168.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.277 0.0 OUTLIER -128.68 -106.76 0.3 Allowed 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.953 1.301 . . . . 0.0 109.508 166.628 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 88.4 p -152.96 -10.37 0.16 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 122.13 2.241 . . . . 0.0 116.358 -177.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -128.94 -13.91 4.52 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.377 1.471 . . . . 0.0 112.672 176.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 174.53 42.58 Favored Glycine 0 CA--C 1.543 1.812 0 C-N-CA 127.938 2.685 . . . . 0.0 113.885 175.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -79.91 157.32 23.99 Favored 'Trans proline' 0 CA--C 1.534 0.498 0 C-N-CA 123.546 2.831 . . . . 0.0 112.427 -168.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.2 t -118.21 136.89 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.97 0.908 . . . . 0.0 112.427 -166.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -93.57 124.31 37.47 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.597 1.159 . . . . 0.0 108.151 170.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.25 133.34 69.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.924 0.89 . . . . 0.0 110.29 -168.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -157.36 158.83 36.69 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.25 178.6 29.67 Favored Glycine 0 CA--C 1.528 0.849 0 C-N-CA 123.881 0.753 . . . . 0.0 114.799 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.0 p -115.69 125.35 52.72 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -167.518 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 9.7 mm -109.74 102.24 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 C-N-CA 125.224 1.41 . . . . 0.0 108.068 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -116.2 157.61 24.59 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.315 0.646 . . . . 0.0 112.194 -168.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.94 9.6 63.72 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 124.941 1.258 . . . . 0.0 112.448 -168.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 99.0 mt -83.33 167.93 17.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.688 1.195 . . . . 0.0 110.563 172.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -100.37 156.64 17.14 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 106.322 -1.732 . . . . 0.0 106.322 163.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -61.96 157.23 19.08 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-O 122.509 1.147 . . . . 0.0 113.429 -170.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.02 -176.83 36.37 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 122.147 0.859 . . . . 0.0 112.685 -173.056 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.504 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.2 mp -72.52 150.35 43.29 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.695 1.998 . . . . 0.0 111.895 -169.12 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -144.31 124.82 13.96 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.847 1.659 . . . . 0.0 110.462 174.702 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.04 148.33 36.38 Favored Glycine 0 N--CA 1.487 2.054 0 CA-C-O 118.723 -1.043 . . . . 0.0 112.869 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.508 ' CE1' HD11 ' A' ' 117' ' ' LEU . 7.4 t80 -149.84 97.53 2.61 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-N 118.325 1.062 . . . . 0.0 113.613 -166.435 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.504 ' O ' HD22 ' A' ' 117' ' ' LEU . 9.9 m80 -130.25 134.29 47.13 Favored 'General case' 0 N--CA 1.483 1.196 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -166.308 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.792 HG23 ' HA2' ' A' ' 82' ' ' GLY . 0.0 OUTLIER -85.36 113.94 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 122.015 0.912 . . . . 0.0 110.896 170.17 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -81.74 173.07 12.65 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 125.419 1.487 . . . . 0.0 114.109 -175.156 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.449 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.6 pm0 -65.06 133.41 51.58 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 126.062 1.745 . . . . 0.0 106.54 165.288 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 67.83 -176.91 0.2 Allowed 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 124.275 1.988 . . . . 0.0 112.992 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.34 3.65 29.68 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 130.618 3.961 . . . . 0.0 111.52 168.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -73.85 126.51 30.57 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 120.385 2.093 . . . . 0.0 109.51 172.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.532 ' CG ' HG21 ' B' ' 7' ' ' VAL 0.279 7.6 p-10 -156.12 42.62 0.4 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 123.289 1.518 . . . . 0.0 112.708 168.46 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.753 ' CG2' HG22 ' B' ' 7' ' ' VAL . 38.8 p -116.3 -25.7 7.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 112.737 -2.029 . . . . 0.0 113.905 -165.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 25.6 0.59 Allowed 'General case' 0 CA--C 1.552 1.039 0 CA-C-N 119.374 0.988 . . . . 0.0 112.109 168.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.69 -121.35 12.34 Favored Glycine 0 C--N 1.341 0.827 0 C-N-CA 125.573 1.558 . . . . 0.0 110.561 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -74.14 -13.68 60.85 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.17 39.44 0.45 Allowed 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 126.072 1.749 . . . . 0.0 111.72 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 69.8 m -148.29 -116.16 0.06 Allowed 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.306 2.243 . . . . 0.0 106.636 -169.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.59 109.98 0.71 Allowed 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 124.781 1.232 . . . . 0.0 112.23 169.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.57 -113.02 0.47 Allowed Glycine 0 CA--C 1.538 1.485 0 CA-C-O 117.928 -1.485 . . . . 0.0 109.574 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -82.67 -179.86 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 124.415 3.41 . . . . 0.0 108.102 165.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.29 123.07 32.52 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.673 0.789 . . . . 0.0 111.518 -172.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -26.03 131.77 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 129.419 3.088 . . . . 0.0 116.956 174.401 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -106.15 52.69 0.15 Allowed Pre-proline 0 CA--C 1.557 1.235 0 C-N-CA 124.883 1.273 . . . . 0.0 113.425 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -63.05 -25.3 73.57 Favored 'Trans proline' 0 C--N 1.355 0.896 0 CA-C-N 122.691 1.997 . . . . 0.0 112.937 -173.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 69.0 mt -99.5 -0.49 40.56 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.802 1.241 . . . . 0.0 113.797 172.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.4 t 70.57 58.87 0.23 Allowed 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 120.452 1.478 . . . . 0.0 114.073 168.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.06 176.01 10.04 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.446 1.498 . . . . 0.0 111.478 172.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -70.8 173.29 7.49 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 129.497 3.119 . . . . 0.0 113.225 178.284 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -69.02 149.29 48.95 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.481 167.421 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 171.45 -157.45 27.95 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 116.884 1.513 . . . . 0.0 116.884 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.81 -70.29 0.43 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 118.013 1.965 . . . . 0.0 118.013 168.129 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -75.98 0.03 9.76 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 123.327 2.685 . . . . 0.0 114.506 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.98 -31.48 0.21 Allowed 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 119.301 0.955 . . . . 0.0 111.415 171.094 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -89.92 153.23 20.77 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.464 1.506 . . . . 0.0 111.26 167.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.7 tt0 -98.68 -27.82 13.81 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 126.356 1.863 . . . . 0.0 112.722 -170.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -78.8 -53.02 7.54 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 121.412 -0.805 . . . . 0.0 110.704 -169.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.7 ttt180 58.17 119.75 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 117.789 2.515 . . . . 0.0 117.789 163.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.8 m170 -58.5 143.08 46.94 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 118.458 -2.652 . . . . 0.0 112.942 169.169 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 91.2 t -58.26 -24.18 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.334 -0.854 . . . . 0.0 110.432 167.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.792 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -80.89 23.38 4.39 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 117.157 -1.913 . . . . 0.0 116.44 172.587 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -127.4 109.62 11.95 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 120.577 2.189 . . . . 0.0 111.533 -178.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.437 HD21 HD23 ' A' ' 117' ' ' LEU . 0.9 OUTLIER -110.92 59.56 0.61 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.156 0.982 . . . . 0.0 110.742 172.502 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.79 -151.78 39.8 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.916 173.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.82 149.47 47.75 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.805 1.242 . . . . 0.0 108.619 169.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.26 106.47 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 124.559 1.144 . . . . 0.0 109.579 -174.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 38.7 m -96.14 114.67 26.39 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 124.451 1.1 . . . . 0.0 108.772 -174.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.73 154.11 19.18 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.666 1.187 . . . . 0.0 113.421 -172.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.6 176.84 6.13 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.513 1.125 . . . . 0.0 112.278 168.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.434 ' HZ3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -73.57 -18.9 61.01 Favored 'General case' 0 N--CA 1.473 0.718 0 O-C-N 121.113 -0.992 . . . . 0.0 113.003 -176.587 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.37 15.23 0.48 Allowed 'General case' 0 CA--C 1.56 1.328 0 CA-C-O 122.974 1.369 . . . . 0.0 110.799 170.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.29 12.74 80.18 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 128.131 2.776 . . . . 0.0 114.726 168.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.26 134.4 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 116.77 2.137 . . . . 0.0 116.77 -166.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.0 103.84 13.97 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.734 1.214 . . . . 0.0 107.822 166.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -94.89 109.36 21.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.944 0.878 . . . . 0.0 109.635 172.091 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -93.67 153.84 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 C-N-CA 124.825 1.25 . . . . 0.0 112.977 -169.549 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.2 p -149.6 125.74 10.69 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.933 0.893 . . . . 0.0 110.635 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.4 mt -144.98 157.99 13.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 128.548 2.739 . . . . 0.0 110.492 -169.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -147.04 135.89 22.23 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.456 1.902 . . . . 0.0 107.055 167.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -155.79 144.92 20.69 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -166.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.0 p -122.15 49.25 1.6 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.326 1.05 . . . . 0.0 113.742 176.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.03 -3.63 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 124.769 1.227 . . . . 0.0 112.478 171.312 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.61 163.74 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 127.023 2.129 . . . . 0.0 110.004 174.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.0 t -157.13 163.84 38.49 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.524 1.529 . . . . 0.0 110.53 170.179 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.498 HD13 ' HB2' ' A' ' 22' ' ' GLN . 7.5 mp -77.3 66.36 3.06 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 120.195 1.361 . . . . 0.0 110.923 -171.095 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.89 104.0 9.24 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 125.431 1.492 . . . . 0.0 114.185 -167.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.49 -145.37 32.88 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.269 167.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -109.24 11.28 25.5 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.609 1.564 . . . . 0.0 112.086 -167.639 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -141.78 -9.77 0.92 Allowed 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -167.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.2 t -90.22 -87.85 0.18 Allowed 'General case' 0 N--CA 1.471 0.596 0 O-C-N 120.774 -1.204 . . . . 0.0 110.951 -171.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.294 0.1 OUTLIER -134.33 16.01 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 120.708 1.595 . . . . 0.0 112.505 167.356 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.39 141.04 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.25 3.97 83.0 Favored Glycine 0 N--CA 1.468 0.82 0 C-N-CA 124.451 1.024 . . . . 0.0 114.575 -175.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 44.2 ttt180 -100.38 176.36 5.38 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.286 1.434 . . . . 0.0 111.903 -167.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 18.8 m -118.62 143.05 47.07 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.942 1.697 . . . . 0.0 108.987 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.508 HD11 ' CE1' ' A' ' 45' ' ' PHE . 3.2 tm? -117.62 141.89 47.85 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.581 1.152 . . . . 0.0 108.648 167.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.2 p -118.05 139.04 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.881 0.872 . . . . 0.0 111.52 172.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 4.7 p -110.81 133.64 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 O-C-N 124.293 0.996 . . . . 0.0 109.623 167.132 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 -99.94 159.45 15.07 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -60.6 -44.83 95.84 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.601 2.76 . . . . 0.0 114.714 -175.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 3.4 mppt? -127.35 -180.0 5.18 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.987 1.715 . . . . 0.0 113.163 -176.192 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.23 147.02 17.45 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.514 1.526 . . . . 0.0 112.428 173.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -102.53 137.04 41.3 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.821 1.648 . . . . 0.0 109.967 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -72.54 -43.31 63.68 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.964 -0.541 . . . . 0.0 111.673 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.0 mt 71.74 53.48 0.21 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.688 1.995 . . . . 0.0 111.967 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 158.43 -90.11 0.11 Allowed Glycine 0 N--CA 1.474 1.224 0 CA-C-N 119.598 1.09 . . . . 0.0 115.128 176.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.6 ttpm? -146.44 98.9 3.14 Favored 'General case' 0 N--CA 1.424 -1.76 0 C-N-CA 128.649 2.78 . . . . 0.0 107.745 177.068 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.5 -138.74 0.69 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 169.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -89.74 6.26 83.08 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.08 -175.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -157.99 168.92 25.77 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 120.372 2.086 . . . . 0.0 109.789 -169.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.91 -57.7 11.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.425 1.09 . . . . 0.0 110.836 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -41.24 -40.47 1.62 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 127.663 2.385 . . . . 0.0 114.562 178.622 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 64.1 p -55.12 -27.59 46.41 Favored 'General case' 0 N--CA 1.469 0.505 0 O-C-N 120.595 -1.315 . . . . 0.0 113.768 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 27.1 p -71.63 -28.02 63.49 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.557 1.143 . . . . 0.0 112.681 173.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -79.4 -56.98 3.93 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.771 1.628 . . . . 0.0 112.471 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.8 p -115.29 -14.84 11.65 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.525 1.306 . . . . 0.0 114.525 -170.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.49 -1.88 69.86 Favored Glycine 0 N--CA 1.466 0.65 0 O-C-N 123.902 0.751 . . . . 0.0 112.277 -169.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 66.16 17.56 10.77 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.671 1.188 . . . . 0.0 111.021 -176.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.6 -9.81 15.39 Favored 'General case' 0 CA--C 1.554 1.127 0 C-N-CA 123.898 0.879 . . . . 0.0 113.175 -168.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.67 -164.03 21.79 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.831 1.681 . . . . 0.0 112.937 178.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -63.68 175.67 1.05 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.797 1.239 . . . . 0.0 112.246 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.29 143.96 38.08 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 120.761 -1.212 . . . . 0.0 112.066 169.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -104.04 -94.72 0.33 Allowed 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.105 1.762 . . . . 0.0 109.052 173.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.34 149.18 38.78 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 122.379 1.085 . . . . 0.0 110.793 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.47 ' HB3' HD21 ' A' ' 53' ' ' ASN . 84.5 m -131.67 151.76 51.39 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 112.768 -2.014 . . . . 0.0 108.005 173.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.94 163.04 33.52 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 123.404 0.526 . . . . 0.0 113.899 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 25.1 t -113.5 160.87 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 125.358 1.463 . . . . 0.0 110.589 177.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.2 mt -114.65 123.26 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 124.222 1.009 . . . . 0.0 113.362 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -126.74 -168.73 12.62 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 126.144 1.83 . . . . 0.0 113.093 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 151' ' ' ILE . 2.2 mp -104.63 131.78 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 121.57 -0.959 . . . . 0.0 111.033 -169.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.542 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -118.71 22.6 11.92 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.719 1.608 . . . . 0.0 113.61 -174.242 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.332 -0.188 0 C-N-CA 124.368 1.067 . . . . 0.0 110.47 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.825 0.345 . . . . 0.0 111.845 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -107.98 122.49 46.95 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.726 0.81 . . . . 0.0 109.411 175.245 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -99.18 131.17 45.41 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 174.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.86 169.52 8.54 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.652 1.181 . . . . 0.0 114.08 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -161.63 88.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 C-N-CA 128.114 2.566 . . . . 0.0 109.218 -169.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.72 142.73 35.18 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 120.415 -1.428 . . . . 0.0 111.005 176.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.753 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.2 t -126.7 106.23 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 3.1 mp -100.0 139.33 35.82 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.603 1.161 . . . . 0.0 108.21 169.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -155.95 175.18 14.29 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.126 1.37 . . . . 0.0 110.307 170.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 143.62 -46.3 0.84 Allowed Glycine 0 N--CA 1.474 1.201 0 C-N-CA 124.54 1.067 . . . . 0.0 113.68 169.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -78.01 67.2 3.8 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.535 1.534 . . . . 0.0 109.23 175.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.24 -111.34 0.38 Allowed Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.649 2.547 . . . . 0.0 112.625 -175.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -76.51 1.14 8.76 Favored 'Trans proline' 0 CA--C 1.536 0.603 0 C-N-CA 124.906 3.737 . . . . 0.0 114.168 -176.655 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 31.1 t -79.49 131.39 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 120.155 1.343 . . . . 0.0 111.283 171.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -130.13 160.84 32.56 Favored 'General case' 0 CA--C 1.516 -0.363 0 C-N-CA 125.127 1.371 . . . . 0.0 109.381 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.68 107.68 0.69 Allowed Glycine 0 CA--C 1.499 -0.926 0 CA-C-N 113.956 -1.474 . . . . 0.0 109.491 169.04 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.73 120.71 65.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.76 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.252 2.9 pp -130.53 139.49 51.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 122.376 1.084 . . . . 0.0 110.715 172.501 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -107.54 172.98 6.53 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 125.921 1.688 . . . . 0.0 110.523 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -152.66 165.74 34.32 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.773 0.829 . . . . 0.0 109.528 170.145 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -136.02 138.12 41.88 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.175 1.39 . . . . 0.0 109.584 166.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 59.4 tp60 -102.97 102.28 12.32 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.554 0.742 . . . . 0.0 110.749 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.497 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -67.25 -45.0 78.0 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 120.51 -1.369 . . . . 0.0 113.703 176.158 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 24' ' ' GLU . . . . . 0.497 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 40.0 mp0 -147.7 138.98 23.62 Favored 'General case' 0 C--O 1.222 -0.379 0 C-N-CA 126.858 2.063 . . . . 0.0 108.394 168.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 76.0 p -50.33 -20.44 1.08 Allowed 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -169.236 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -112.98 0.46 15.06 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.141 1.376 . . . . 0.0 113.248 -173.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.72 -170.3 43.18 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.664 1.126 . . . . 0.0 113.624 -173.475 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -81.2 162.52 20.14 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.761 2.307 . . . . 0.0 109.923 168.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -135.47 143.24 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.481 1.112 . . . . 0.0 110.999 -174.142 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HZ3' ' CD ' ' B' ' 100' ' ' GLU . 41.7 tttp -94.88 115.78 27.89 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.795 0.807 . . . . 0.0 110.153 167.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.94 144.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 166.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -144.56 -168.39 2.89 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 167.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.45 -153.82 17.22 Favored Glycine 0 N--CA 1.469 0.843 0 C-N-CA 124.84 1.21 . . . . 0.0 112.684 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 94.7 p -156.67 137.87 13.72 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 114.062 1.134 . . . . 0.0 114.062 -172.3 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.8 mm -104.96 119.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 169.085 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -131.91 144.62 50.98 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 121.192 1.814 . . . . 0.0 111.816 -171.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.7 -8.16 21.99 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 128.547 2.975 . . . . 0.0 113.374 -173.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.41 HD23 ' CD2' ' B' ' 43' ' ' HIS . 5.5 mp -71.44 156.48 39.41 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 129.327 3.051 . . . . 0.0 112.732 -176.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.6 t -74.48 168.32 19.95 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 164.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -75.52 146.1 40.81 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.167 -0.958 . . . . 0.0 112.976 177.439 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.72 -168.04 13.79 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 124.142 0.877 . . . . 0.0 113.017 -172.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.0 mt -76.12 147.43 38.58 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.896 2.078 . . . . 0.0 112.966 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CD2' HD23 ' B' ' 38' ' ' LEU . 87.2 m-70 -146.54 120.75 9.53 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.929 2.092 . . . . 0.0 110.501 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.06 145.86 37.05 Favored Glycine 0 N--CA 1.484 1.876 0 CA-C-O 117.536 -1.702 . . . . 0.0 112.333 -177.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.64 ' HB2' HG22 ' B' ' 119' ' ' VAL . 0.4 OUTLIER -141.49 125.89 17.64 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 121.173 2.486 . . . . 0.0 113.074 -178.546 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 28.7 m80 -137.2 128.21 27.59 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -171.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -80.59 137.51 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 165.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -113.81 171.27 7.69 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 118.715 0.689 . . . . 0.0 111.466 173.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -72.63 138.72 46.92 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 125.184 1.394 . . . . 0.0 110.707 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 72.0 168.36 0.31 Allowed 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.6 1.96 . . . . 0.0 111.37 -168.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.405 ' C ' HG11 ' A' ' 5' ' ' VAL . . . -93.32 16.62 60.19 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 164.443 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.409 ' HA ' HG21 ' A' ' 5' ' ' VAL . 15.5 t0 -87.35 110.45 20.25 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 125.9 1.68 . . . . 0.0 109.444 -168.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -159.23 34.48 0.2 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 116.132 1.901 . . . . 0.0 116.132 -174.126 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.582 HG22 HG23 ' A' ' 5' ' ' VAL 0.321 1.3 p . . . . . 0 CA--C 1.536 0.426 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -164.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.797 0 CA-C-O 123.011 1.386 . . . . 0.0 114.413 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.15 -115.81 4.04 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.502 1.525 . . . . 0.0 111.773 176.066 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.58 175.52 10.96 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.968 3.112 . . . . 0.0 110.978 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -69.57 113.76 7.16 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.94 1.696 . . . . 0.0 109.192 176.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -55.15 145.43 21.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.832 1.301 . . . . 0.0 114.503 -168.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -111.05 66.77 0.55 Allowed Pre-proline 0 CA--C 1.55 0.977 0 C-N-CA 126.87 2.068 . . . . 0.0 112.16 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -60.64 -35.64 88.78 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.076 2.518 . . . . 0.0 113.329 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 72.9 mt -80.85 -1.32 42.76 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.728 1.211 . . . . 0.0 114.177 171.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t 71.22 47.02 0.41 Allowed 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 127.835 2.454 . . . . 0.0 111.073 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.7 mtp180 -103.02 171.99 7.07 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -169.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mpmm? -83.45 167.07 17.81 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 125.665 1.586 . . . . 0.0 109.449 162.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -78.32 168.46 19.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.357 1.063 . . . . 0.0 112.087 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.6 -134.95 7.65 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 124.719 1.152 . . . . 0.0 113.495 168.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.81 -80.77 0.33 Allowed Glycine 0 CA--C 1.541 1.657 0 CA-C-N 118.278 1.039 . . . . 0.0 115.335 -174.154 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.19 7.5 0.63 Allowed 'Trans proline' 0 CA--C 1.547 1.175 0 CA-C-N 120.846 2.323 . . . . 0.0 115.328 -177.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.35 6.57 0.29 Allowed 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 126.986 2.115 . . . . 0.0 113.366 169.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.6 156.71 45.66 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.406 2.282 . . . . 0.0 110.336 -170.212 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -97.43 -9.22 27.71 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.648 1.979 . . . . 0.0 112.126 -173.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -83.86 -95.81 0.06 Allowed 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.443 -0.786 . . . . 0.0 110.482 177.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 48.8 ttt180 68.49 115.98 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.513 1.925 . . . . 0.0 112.274 -170.049 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -55.21 154.31 5.96 Favored 'General case' 0 CA--C 1.552 1.022 0 O-C-N 119.505 -1.997 . . . . 0.0 114.813 171.129 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -84.91 58.18 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 C-N-CA 124.573 1.149 . . . . 0.0 109.492 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.61 67.75 0.02 OUTLIER Glycine 0 N--CA 1.469 0.852 0 C-N-CA 127.569 2.509 . . . . 0.0 109.59 -169.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -163.9 165.45 22.75 Favored 'General case' 0 CA--C 1.553 1.065 0 C-N-CA 128.78 2.832 . . . . 0.0 110.027 166.137 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 92.9 mt -131.39 -178.38 4.82 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.386 2.274 . . . . 0.0 107.331 168.473 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.46 -112.4 0.86 Allowed Glycine 0 N--CA 1.47 0.95 0 CA-C-N 118.309 0.504 . . . . 0.0 112.689 -179.025 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -137.11 164.17 29.06 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-O 121.643 0.735 . . . . 0.0 112.813 176.087 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.5 m -108.61 175.59 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 127.342 2.257 . . . . 0.0 109.354 171.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 m -141.34 140.25 33.72 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.525 1.53 . . . . 0.0 107.633 169.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.42 139.58 40.68 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.439 1.096 . . . . 0.0 112.814 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -82.62 154.35 24.98 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.717 2.007 . . . . 0.0 110.603 168.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.22 1.25 0.51 Allowed 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 117.621 2.452 . . . . 0.0 117.621 -169.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -76.24 -7.37 54.71 Favored 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 125.138 1.375 . . . . 0.0 109.783 164.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 93.77 20.67 30.73 Favored Glycine 0 C--N 1.337 0.594 0 C-N-CA 128.719 3.057 . . . . 0.0 112.482 177.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.7 p -127.68 133.51 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 119.09 1.445 . . . . 0.0 114.224 -168.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.93 131.24 41.07 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 165.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -81.77 142.46 32.59 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 104.105 -2.554 . . . . 0.0 104.105 166.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 t -125.9 127.02 70.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 CA-C-N 113.349 -1.751 . . . . 0.0 107.541 169.708 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.8 p -158.77 51.4 0.39 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.723 1.609 . . . . 0.0 110.105 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 mt -103.56 148.76 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.874 1.67 . . . . 0.0 113.317 -167.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 100' ' ' GLU . . . . . 0.434 ' CD ' ' HZ3' ' B' ' 30' ' ' LYS . 5.6 mp0 -99.31 152.92 19.39 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 125.87 1.668 . . . . 0.0 109.457 174.054 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -153.81 148.49 26.36 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.787 -1.097 . . . . 0.0 111.039 167.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.6 p -118.55 53.65 0.97 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.279 1.032 . . . . 0.0 111.749 178.074 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.43 -35.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.958 168.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.92 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 CA-C-N 121.024 1.738 . . . . 0.0 111.151 167.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.0 m -160.92 162.43 32.03 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.474 1.509 . . . . 0.0 109.875 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -87.38 76.69 9.04 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.262 1.425 . . . . 0.0 109.172 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.3 t -158.21 104.82 1.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.468 0.651 . . . . 0.0 111.396 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.61 157.22 26.52 Favored Glycine 0 CA--C 1.526 0.763 0 CA-C-O 122.908 1.282 . . . . 0.0 112.445 -172.089 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -67.12 -21.26 65.85 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 131.391 3.876 . . . . 0.0 114.266 -169.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -107.56 14.88 25.32 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 128.58 2.752 . . . . 0.0 111.806 -175.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 81.0 p -101.67 -54.04 2.83 Favored 'General case' 0 CA--C 1.548 0.875 0 O-C-N 119.428 -2.045 . . . . 0.0 114.233 -174.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pt 178.51 -39.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 1 C-N-CA 133.941 4.897 . . . . 0.0 106.563 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm -57.71 131.08 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 N-CA-C 103.194 -2.891 . . . . 0.0 103.194 159.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.99 -18.97 8.24 Favored Glycine 0 CA--C 1.535 1.297 0 N-CA-C 117.046 1.578 . . . . 0.0 117.046 175.154 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.8 mtt180 -79.09 -178.09 5.96 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 126.408 1.883 . . . . 0.0 114.081 -177.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 8.8 t -120.19 170.03 9.7 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 127.929 2.492 . . . . 0.0 110.931 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tp -153.54 146.83 24.77 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.396 1.478 . . . . 0.0 111.358 171.065 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.43 137.34 56.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.622 1.569 . . . . 0.0 110.126 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.64 HG22 ' HB2' ' B' ' 45' ' ' PHE . 45.6 t -106.77 156.99 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 169.443 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -122.55 138.7 54.49 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.709 2.404 . . . . 0.0 111.905 -166.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -78.24 3.91 14.12 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -174.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -122.72 168.3 12.39 Favored 'General case' 0 CA--C 1.545 0.76 0 O-C-N 120.22 -1.55 . . . . 0.0 111.166 169.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.57 160.83 1.65 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.403 1.081 . . . . 0.0 111.223 169.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -107.72 149.13 28.53 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 122.732 0.413 . . . . 0.0 110.503 169.132 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -100.53 -8.84 22.66 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.794 2.038 . . . . 0.0 114.072 -171.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 54.09 70.35 0.62 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.81 1.644 . . . . 0.0 113.832 169.349 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.16 -51.99 4.47 Favored Glycine 0 N--CA 1.466 0.669 0 O-C-N 121.281 -0.887 . . . . 0.0 112.628 169.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.59 124.3 6.03 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 117.569 2.433 . . . . 0.0 117.569 173.856 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.24 0.62 Allowed Glycine 0 C--N 1.331 0.289 0 C-N-CA 129.67 3.509 . . . . 0.0 106.256 163.407 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -111.25 -57.72 0.48 Allowed Glycine 0 CA--C 1.53 0.991 0 N-CA-C 117.227 1.651 . . . . 0.0 117.227 -171.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 47.7 p30 -123.93 -175.62 3.27 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -161.545 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.02 -59.75 3.13 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 126.557 1.943 . . . . 0.0 111.452 171.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -50.56 -20.54 1.21 Allowed 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.81 1.781 . . . . 0.0 115.81 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.6 m -67.25 -40.73 86.31 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 119.838 -1.789 . . . . 0.0 112.302 170.103 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 22.1 p -82.75 -10.15 59.02 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 126.094 1.758 . . . . 0.0 113.674 -177.536 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.5 tttt -104.16 -77.18 0.58 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 128.42 2.688 . . . . 0.0 110.505 -168.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 22.2 p -79.2 -85.92 0.08 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 166.024 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 176.06 23.58 0.03 OUTLIER Glycine 0 CA--C 1.534 1.276 1 C-N-CA 131.431 4.348 . . . . 0.0 110.808 -177.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.3 t30 56.98 17.46 3.37 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.005 1.722 . . . . 0.0 114.907 -174.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.96 6.37 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.174 0 N-CA-C 119.384 3.105 . . . . 0.0 119.384 -167.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 62.16 -23.93 0.06 OUTLIER Glycine 0 N--CA 1.475 1.252 0 C-N-CA 130.089 3.709 . . . . 0.0 120.442 166.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.7 t -165.38 159.99 17.65 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.535 1.667 . . . . 0.0 111.111 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.16 179.7 6.6 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.095 0.958 . . . . 0.0 109.892 167.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.5 HD11 ' HB ' ' B' ' 119' ' ' VAL 0.33 3.8 pp -166.45 -154.02 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 129.49 3.116 . . . . 0.0 106.637 162.804 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.98 134.26 26.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.274 1.43 . . . . 0.0 112.811 -175.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.77 153.32 45.71 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.149 0.979 . . . . 0.0 111.01 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 176.81 37.44 Favored Glycine 0 N--CA 1.469 0.879 0 N-CA-C 116.186 1.235 . . . . 0.0 116.186 -170.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -111.0 149.36 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.481 1.112 . . . . 0.0 109.181 174.155 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 30.7 mm -80.88 125.57 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 CA-C-N 119.788 1.176 . . . . 0.0 112.051 -175.419 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.96 164.98 12.46 Favored Glycine 0 N--CA 1.477 1.403 0 O-C-N 121.23 -0.919 . . . . 0.0 113.392 -176.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 4.7 mp -128.33 131.76 68.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.603 0.716 . . . . 0.0 112.018 -176.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.24 -3.77 18.16 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.084 0.953 . . . . 0.0 112.689 168.252 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 . . . . . 0 N--CA 1.465 0.319 0 C-N-CA 127.987 2.515 . . . . 0.0 111.179 -173.656 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.489 HG21 ' ND2' ' B' ' 53' ' ' ASN . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.623 ' OD1' HG21 ' B' ' 7' ' ' VAL 0.307 14.9 p-10 -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.645 HG22 ' CG2' ' A' ' 54' ' ' THR . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.489 ' ND2' HG21 ' A' ' 7' ' ' VAL 0.29 0.6 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 4 4 . 1 . 002 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t . . . . . 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.348 0 CA-C-O 122.073 0.939 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.489 HG21 ' ND2' ' B' ' 53' ' ' ASN . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.623 ' OD1' HG21 ' B' ' 7' ' ' VAL 0.307 14.9 p-10 -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.645 HG22 ' CG2' ' A' ' 54' ' ' THR . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.489 ' ND2' HG21 ' A' ' 7' ' ' VAL 0.29 0.6 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t . . . . . 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.348 0 CA-C-O 122.073 0.939 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t . . . . . 0 N--CA 1.465 0.307 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.83 104.54 14.88 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 122.046 0.927 . . . . 0.0 108.699 168.086 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -89.48 169.23 11.55 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.263 -0.898 . . . . 0.0 111.296 173.596 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.487 HG21 ' HA ' ' B' ' 52' ' ' ASP . 3.1 p -151.97 142.78 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.676 1.19 . . . . 0.0 110.741 -170.213 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.13 120.5 12.36 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.509 1.123 . . . . 0.0 109.526 168.664 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.5 t -105.31 97.16 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 174.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -78.12 111.47 14.07 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 123.83 0.852 . . . . 0.0 109.544 -172.106 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -152.04 155.15 37.39 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 116.604 2.075 . . . . 0.0 116.604 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.43 -39.76 0.24 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 129.891 3.615 . . . . 0.0 108.814 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.44 57.64 4.12 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 129.699 3.2 . . . . 0.0 112.933 -168.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.95 -103.72 0.05 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.358 2.409 . . . . 0.0 114.054 173.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -83.87 -8.05 10.22 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 124.893 3.729 . . . . 0.0 114.555 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.03 141.87 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 120.377 1.444 . . . . 0.0 109.92 173.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -157.81 161.76 38.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.227 -1.351 . . . . 0.0 110.513 167.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.01 119.25 2.92 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 113.658 -1.61 . . . . 0.0 109.576 169.244 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.07 133.23 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 166.529 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.439 HD13 ' CE1' ' A' ' 20' ' ' PHE . 2.1 pp -136.14 143.19 36.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 122.703 1.24 . . . . 0.0 110.687 162.158 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.95 130.0 55.47 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 164.707 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.439 ' CE1' HD13 ' A' ' 18' ' ' ILE . 18.6 m-30 -114.2 132.43 56.11 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.205 1.002 . . . . 0.0 110.629 -179.056 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -108.56 117.11 33.32 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.02 1.328 . . . . 0.0 110.97 178.357 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -118.58 140.0 50.59 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 123.028 1.394 . . . . 0.0 113.27 173.502 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.518 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -87.01 -47.98 8.48 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 129.46 3.104 . . . . 0.0 113.739 -175.717 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -147.63 137.71 22.94 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 126.895 2.078 . . . . 0.0 110.44 -168.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 m -38.65 -57.65 1.16 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.939 1.696 . . . . 0.0 115.308 -169.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 -102.31 15.47 29.06 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 123.995 0.918 . . . . 0.0 111.765 -173.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.83 -170.85 30.06 Favored Glycine 0 CA--C 1.534 1.263 0 C-N-CA 124.776 1.179 . . . . 0.0 112.485 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -78.34 177.91 8.2 Favored 'Trans proline' 0 CA--C 1.536 0.588 0 C-N-CA 124.149 3.232 . . . . 0.0 112.818 -170.355 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.4 t -142.0 141.01 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 123.913 0.885 . . . . 0.0 111.173 -177.021 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -93.22 125.21 37.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.035 0.934 . . . . 0.0 109.56 169.573 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -117.5 125.25 73.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 127.674 2.389 . . . . 0.0 108.565 -169.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 7.0 p90 -153.87 162.39 41.27 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.611 0.72 . . . . 0.0 112.661 175.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.18 -158.21 27.15 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 125.145 1.355 . . . . 0.0 112.063 177.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.9 p -153.54 139.79 18.49 Favored 'General case' 0 C--O 1.237 0.403 0 O-C-N 122.396 -0.473 . . . . 0.0 112.07 -172.07 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -111.98 106.88 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.885 0.874 . . . . 0.0 108.668 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.02 128.13 54.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.758 2.423 . . . . 0.0 109.557 -165.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.4 -4.38 31.27 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.502 1.525 . . . . 0.0 112.109 -167.649 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.5 mt -65.53 162.45 18.05 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.593 1.197 . . . . 0.0 110.531 168.542 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -93.45 161.83 14.22 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 163.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -54.95 150.43 10.18 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.242 1.417 . . . . 0.0 113.352 -174.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.23 -177.57 36.59 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 124.758 1.17 . . . . 0.0 113.46 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.98 149.6 18.56 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 127.56 2.344 . . . . 0.0 112.588 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -145.65 134.0 21.83 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 126.125 1.77 . . . . 0.0 110.166 170.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.44 147.72 31.36 Favored Glycine 0 N--CA 1.481 1.664 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.142 173.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -156.85 106.27 2.24 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 119.03 1.415 . . . . 0.0 113.276 -172.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.04 153.12 30.47 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.801 1.408 . . . . 0.0 114.801 -168.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -82.2 138.37 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 165.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -87.18 157.99 19.24 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.386 1.875 . . . . 0.0 113.907 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 21.8 tt0 -71.57 90.07 1.0 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 125.182 1.393 . . . . 0.0 109.231 178.216 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 94.6 142.35 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 128.64 2.776 . . . . 0.0 108.809 178.129 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.09 13.24 9.69 Favored Glycine 0 C--O 1.221 -0.715 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.627 169.098 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' B' ' 5' ' ' VAL . 8.8 p-10 -88.44 47.67 1.53 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 124.578 2.132 . . . . 0.0 109.131 168.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -171.91 42.39 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 123.696 1.712 . . . . 0.0 110.104 -167.215 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.8 p -69.32 43.78 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 128.312 2.645 . . . . 0.0 117.455 -168.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -107.69 5.5 26.83 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.726 1.21 . . . . 0.0 109.345 164.396 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 51.56 -110.56 1.09 Allowed Glycine 0 C--N 1.347 1.178 0 C-N-CA 126.527 2.013 . . . . 0.0 112.938 168.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 69.5 m -53.32 -9.36 0.16 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 116.516 2.043 . . . . 0.0 116.516 178.214 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.4 t -124.99 19.02 8.45 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.455 1.65 . . . . 0.0 115.455 171.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.9 m -156.74 -40.51 0.07 Allowed 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 171.026 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.42 123.57 26.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.705 1.593 . . . . 0.0 112.191 -170.542 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -66.75 168.78 35.47 Favored Glycine 0 CA--C 1.538 1.48 0 CA-C-O 118.224 -1.32 . . . . 0.0 113.33 -175.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -56.48 176.21 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 125.007 3.805 . . . . 0.0 112.456 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.423 ' CD2' ' H ' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -68.06 114.22 6.39 Favored 'General case' 0 C--N 1.321 -0.644 0 O-C-N 121.484 -0.76 . . . . 0.0 112.615 -166.823 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -28.25 113.07 0.07 Allowed 'General case' 0 C--O 1.24 0.557 0 C-N-CA 127.489 2.316 . . . . 0.0 114.209 -172.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -111.61 50.59 0.33 Allowed Pre-proline 0 CA--C 1.551 0.997 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -174.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.11 -16.83 45.31 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 122.352 2.035 . . . . 0.0 112.51 177.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -79.42 -7.51 58.45 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.722 1.609 . . . . 0.0 112.456 168.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.9 t 64.26 49.74 2.51 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 128.437 2.695 . . . . 0.0 112.409 176.38 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.402 ' HD2' ' OE1' ' A' ' 78' ' ' GLU . 15.8 ptt180 -128.92 178.5 6.34 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.01 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.524 ' HE2' ' HA ' ' A' ' 70' ' ' LYS . 4.8 mmpt? -88.17 174.26 8.33 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.164 2.185 . . . . 0.0 112.375 -179.263 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -95.12 134.9 37.32 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.416 ' HA2' HD12 ' A' ' 126' ' ' LEU . . . 161.2 -123.17 1.18 Allowed Glycine 0 C--N 1.336 0.576 0 CA-C-O 119.72 -0.489 . . . . 0.0 113.682 168.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.66 -33.94 4.58 Favored Glycine 0 CA--C 1.545 1.952 0 CA-C-O 117.216 -1.88 . . . . 0.0 117.791 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -105.45 17.14 0.15 Allowed 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.619 2.879 . . . . 0.0 114.215 174.701 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.9 ptmm? -167.73 -22.02 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 127.389 2.276 . . . . 0.0 112.458 169.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -97.41 147.05 24.6 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 163.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -98.86 -6.58 28.78 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.445 1.898 . . . . 0.0 111.859 -171.112 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.402 ' OE1' ' HD2' ' A' ' 69' ' ' ARG . 3.7 mm-40 -77.4 -99.65 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.343 1.057 . . . . 0.0 110.035 -177.445 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 94.2 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 127.323 2.249 . . . . 0.0 111.179 174.104 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -58.31 156.96 9.18 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.569 1.147 . . . . 0.0 112.639 172.315 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.0 p -70.59 106.12 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.86 171.428 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.03 8.69 21.66 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 117.383 -1.787 . . . . 0.0 116.831 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.16 124.5 27.91 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 120.71 2.255 . . . . 0.0 109.545 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 97.5 mt -113.89 53.63 0.77 Allowed 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 120.575 1.534 . . . . 0.0 112.196 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.01 -141.99 42.49 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 121.56 -0.713 . . . . 0.0 111.659 174.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.67 127.43 45.16 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.482 0.713 . . . . 0.0 111.431 169.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.8 m -78.21 98.22 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.891 1.276 . . . . 0.0 108.985 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -93.3 117.41 30.04 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.822 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.49 139.88 30.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.806 1.242 . . . . 0.0 113.841 -174.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -72.32 156.74 38.77 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.146 2.178 . . . . 0.0 109.99 167.597 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -46.33 -25.38 0.63 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 128.294 2.638 . . . . 0.0 116.137 175.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -76.42 -0.48 22.98 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.632 1.173 . . . . 0.0 111.525 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.36 41.79 11.2 Favored Glycine 0 C--N 1.335 0.526 0 C-N-CA 126.535 2.017 . . . . 0.0 112.783 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.5 p -143.21 129.0 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 N-CA-C 114.737 1.384 . . . . 0.0 114.737 176.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.57 124.15 35.52 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 165.074 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -111.55 135.64 51.86 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 124.496 1.118 . . . . 0.0 108.91 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.5 t -139.15 136.71 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -166.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.2 t -155.43 116.36 3.9 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.553 1.541 . . . . 0.0 110.579 168.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -145.51 155.4 13.3 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 128.965 2.906 . . . . 0.0 110.806 -169.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -128.23 132.23 48.77 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 167.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -145.51 138.1 25.88 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 124.486 1.114 . . . . 0.0 111.954 -168.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -116.94 51.38 1.0 Allowed 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 178.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.19 3.48 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.197 0 C-N-CA 123.831 0.853 . . . . 0.0 111.983 167.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.2 168.0 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 126.671 1.988 . . . . 0.0 110.376 177.278 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.0 m -154.4 156.09 36.19 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.001 0.92 . . . . 0.0 111.086 -173.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.7 mt -93.5 73.01 4.42 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.689 0.757 . . . . 0.0 110.681 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.406 ' H ' ' HB2' ' A' ' 111' ' ' SER . 0.3 OUTLIER -117.84 144.91 44.97 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.384 1.474 . . . . 0.0 108.987 171.996 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -78.48 16.23 8.17 Favored Glycine 0 N--CA 1.479 1.539 0 N-CA-C 117.97 1.948 . . . . 0.0 117.97 -166.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -134.88 -89.26 0.35 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 125.794 1.638 . . . . 0.0 111.2 -169.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -87.39 4.81 41.6 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 120.595 -1.316 . . . . 0.0 113.168 -174.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.406 ' HB2' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -119.41 -141.7 0.35 Allowed 'General case' 0 CA--C 1.545 0.756 0 O-C-N 120.875 -1.141 . . . . 0.0 112.955 -168.629 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 51.5 mm -94.63 -28.87 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 O-C-N 120.595 -1.315 . . . . 0.0 114.389 -169.757 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.1 mm -55.06 133.05 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 119.191 0.905 . . . . 0.0 109.849 175.378 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.14 14.62 59.52 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.433 -1.204 . . . . 0.0 114.575 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -91.19 -169.99 2.51 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.408 1.604 . . . . 0.0 108.911 168.077 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 6.4 m -145.63 114.37 6.85 Favored 'General case' 0 N--CA 1.484 1.227 0 O-C-N 119.599 -1.938 . . . . 0.0 108.02 -171.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 50.5 tp -89.74 132.73 35.05 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 124.943 1.297 . . . . 0.0 109.638 -175.026 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.4 m -118.84 153.79 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 C-N-CA 123.275 0.63 . . . . 0.0 110.628 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.76 152.13 15.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 163.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -115.21 147.36 40.44 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.094 1.357 . . . . 0.0 111.183 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -66.09 -22.52 66.41 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 119.838 -1.789 . . . . 0.0 113.601 -174.118 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.7 mmtm -131.62 176.98 7.86 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 119.772 -1.83 . . . . 0.0 113.998 173.282 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.22 145.04 27.69 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 112.977 -1.919 . . . . 0.0 110.9 169.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.48 ' OD1' ' HB2' ' A' ' 140' ' ' ALA . 46.7 m-20 -79.03 169.2 18.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 122.188 0.994 . . . . 0.0 111.154 167.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.79 -38.49 53.91 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.203 164.04 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.416 HD12 ' HA2' ' A' ' 72' ' ' GLY . 1.8 mm? 63.35 60.32 1.16 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.957 2.503 . . . . 0.0 112.031 -171.465 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.59 -83.4 0.13 Allowed Glycine 0 N--CA 1.469 0.879 0 O-C-N 121.008 -1.058 . . . . 0.0 112.747 168.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -150.53 97.73 2.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.631 1.681 . . . . 0.0 110.921 169.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -74.09 176.07 47.3 Favored Glycine 0 CA--C 1.526 0.781 0 CA-C-N 112.086 -2.325 . . . . 0.0 107.651 163.448 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.09 29.79 0.15 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 127.599 2.523 . . . . 0.0 118.677 -167.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -148.03 -103.97 0.09 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 120.652 2.226 . . . . 0.0 111.528 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -163.22 -51.9 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 127.312 2.245 . . . . 0.0 108.58 -169.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 19.2 tp10 -50.17 -32.16 15.51 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 127.416 2.286 . . . . 0.0 112.351 169.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.593 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 77.6 p -53.24 -36.84 61.5 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 120.565 -1.334 . . . . 0.0 113.173 168.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 2.8 p -79.08 -20.99 47.39 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 172.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -79.79 -64.56 1.16 Allowed 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.5 1.046 . . . . 0.0 112.572 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 28.7 p -108.62 -9.52 15.29 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.842 1.657 . . . . 0.0 114.559 -174.258 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.2 -9.57 74.61 Favored Glycine 0 N--CA 1.471 1.031 0 CA-C-N 119.918 1.235 . . . . 0.0 111.781 -167.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 79.26 -44.1 0.32 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 129.245 3.018 . . . . 0.0 110.136 -179.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.48 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . . . 56.62 11.77 0.96 Allowed 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 128.433 2.693 . . . . 0.0 116.649 167.145 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.43 -36.25 0.45 Allowed Glycine 0 CA--C 1.537 1.445 0 C-N-CA 125.951 1.739 . . . . 0.0 113.673 -167.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -173.88 -156.59 0.08 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.149 1.779 . . . . 0.0 111.551 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.05 -166.22 1.15 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.798 2.039 . . . . 0.0 108.197 165.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -176.96 -151.79 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.661 2.384 . . . . 0.0 107.378 -175.586 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.72 148.99 23.05 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 125.709 1.604 . . . . 0.0 112.568 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.8 p -148.45 148.71 30.59 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.092 0.957 . . . . 0.0 113.459 -176.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.2 136.61 5.1 Favored Glycine 0 N--CA 1.465 0.604 0 C-N-CA 124.299 0.952 . . . . 0.0 113.543 -170.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -76.24 148.58 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 124.676 1.19 . . . . 0.0 109.333 -178.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -83.63 103.68 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 171.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -101.46 175.41 25.68 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.861 1.696 . . . . 0.0 112.064 169.068 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -114.51 140.84 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.307 1.043 . . . . 0.0 112.495 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.05 51.29 0.79 Allowed 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 124.027 1.87 . . . . 0.0 112.765 -176.329 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 38.9 tt0 . . . . . 0 C--N 1.326 -0.445 0 CA-C-N 111.487 -2.597 . . . . 0.0 110.006 167.672 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 p -78.76 107.07 11.21 Favored 'General case' 0 CA--C 1.512 -0.515 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 169.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.433 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -99.68 156.06 17.28 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 169.497 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.59 178.29 8.57 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 130.138 3.375 . . . . 0.0 107.19 167.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.403 ' H ' ' HB2' ' A' ' 52' ' ' ASP . 59.3 t -156.54 170.85 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.191 0 C-N-CA 127.03 2.132 . . . . 0.0 109.894 -169.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.36 142.69 19.44 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 127.28 2.232 . . . . 0.0 109.299 166.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.13 126.53 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.582 0.753 . . . . 0.0 110.085 173.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mp -97.26 140.25 32.02 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 125.287 1.435 . . . . 0.0 110.264 -172.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.8 ttpp -143.53 140.57 30.33 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.386 1.074 . . . . 0.0 111.535 170.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.39 -114.15 1.87 Allowed Glycine 0 CA--C 1.524 0.612 1 N-CA-C 102.471 -4.252 . . . . 0.0 102.471 163.203 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -157.7 127.15 5.93 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.406 1.882 . . . . 0.0 107.964 164.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.3 -141.96 17.31 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -167.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -84.72 -26.04 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.312 2.675 . . . . 0.0 113.938 -169.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -78.1 123.82 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.44 1.018 . . . . 0.0 110.873 -169.133 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.2 160.98 41.28 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.602 -175.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -139.85 160.15 26.11 Favored Glycine 0 C--O 1.224 -0.522 0 O-C-N 121.686 -0.634 . . . . 0.0 113.22 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -128.42 134.93 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 125.613 1.565 . . . . 0.0 107.852 168.413 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -137.82 112.93 9.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 C-N-CA 124.255 1.022 . . . . 0.0 109.792 172.125 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -76.59 153.25 35.49 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.391 1.076 . . . . 0.0 110.475 165.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.77 100.01 5.14 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 127.901 2.48 . . . . 0.0 108.762 172.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.433 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.8 OUTLIER -102.83 126.87 50.13 Favored 'General case' 0 N--CA 1.466 0.356 0 O-C-N 121.534 -0.729 . . . . 0.0 109.663 175.743 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLN . . . . . 0.465 HE22 ' CB ' ' B' ' 105' ' ' SER . 55.2 tt0 -126.87 141.22 51.87 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.133 0.973 . . . . 0.0 112.159 -176.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.479 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -78.71 -50.43 11.41 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 24' ' ' GLU . . . . . 0.479 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 27.1 mp0 -146.29 150.54 35.96 Favored 'General case' 0 C--O 1.222 -0.374 0 C-N-CA 125.798 1.639 . . . . 0.0 109.778 173.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.9 m -58.62 10.8 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 128.72 2.808 . . . . 0.0 117.543 -171.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -144.7 -9.44 0.62 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 127.772 2.429 . . . . 0.0 113.886 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.44 -179.89 49.84 Favored Glycine 0 CA--C 1.541 1.657 0 CA-C-N 119.946 1.248 . . . . 0.0 110.6 168.087 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -75.67 160.8 37.58 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.611 2.208 . . . . 0.0 113.155 -171.068 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -120.56 129.67 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 124.802 1.241 . . . . 0.0 109.228 176.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -95.9 128.38 42.74 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.405 1.098 . . . . 0.0 110.176 170.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 t -90.92 129.05 42.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 128.936 2.894 . . . . 0.0 108.666 172.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.5 p90 -152.87 156.85 39.78 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 170.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.02 -154.67 24.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 124.778 1.18 . . . . 0.0 111.521 -169.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 85.2 p -162.59 150.85 14.33 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -172.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -113.61 123.92 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 125.277 1.431 . . . . 0.0 108.279 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -114.64 153.8 29.53 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 126.097 1.759 . . . . 0.0 111.359 -174.16 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.37 60.3 Favored Glycine 0 N--CA 1.475 1.294 0 C-N-CA 125.33 1.443 . . . . 0.0 114.507 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.01 166.43 17.76 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.494 1.518 . . . . 0.0 112.25 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -75.08 146.85 41.11 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 163.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' GLU . . . . . 0.503 ' CD ' ' HZ2' ' B' ' 91' ' ' LYS . 73.6 tt0 -49.27 143.21 6.45 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 124.904 1.282 . . . . 0.0 110.958 169.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.66 -175.44 23.42 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 124.222 0.915 . . . . 0.0 114.015 -177.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.5 OUTLIER -87.39 145.87 26.12 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 127.56 2.344 . . . . 0.0 112.358 -169.85 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -139.19 138.96 37.37 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 127.936 2.494 . . . . 0.0 111.61 -169.066 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.36 156.83 53.15 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 125.08 1.324 . . . . 0.0 112.415 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -157.25 99.51 1.79 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 118.17 0.985 . . . . 0.0 110.849 -168.299 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.415 ' HB2' ' CE1' ' B' ' 71' ' ' HIS . 3.0 p-80 -126.6 146.12 50.28 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-O 122.675 1.226 . . . . 0.0 113.133 -175.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.6 HG12 ' HB2' ' B' ' 117' ' ' LEU . 0.5 OUTLIER -111.42 151.14 13.58 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.293 175.809 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -119.08 119.36 33.98 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.313 -170.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -74.27 57.58 0.68 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.808 0.731 . . . . 0.0 109.557 166.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -161.6 106.94 1.31 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 125.088 1.355 . . . . 0.0 109.987 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -94.77 -5.21 61.42 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 117.144 -1.92 . . . . 0.0 115.026 -176.664 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.487 ' HA ' HG21 ' A' ' 5' ' ' VAL . 0.2 OUTLIER -76.84 52.7 0.86 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 120.735 2.268 . . . . 0.0 111.847 -170.209 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 176.58 35.28 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 116.733 2.123 . . . . 0.0 116.733 -167.454 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.49 1.55 0 O-C-N 119.488 -2.007 . . . . 0.0 115.469 -172.22 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.75 0 CA-C-O 122.49 1.138 . . . . 0.0 113.383 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.62 -54.66 4.9 Favored Glycine 0 CA--C 1.544 1.888 0 CA-C-O 116.747 -2.141 . . . . 0.0 114.929 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -130.52 168.95 0.0 OUTLIER 'Trans proline' 0 C--N 1.355 0.918 0 C-N-CA 123.22 2.613 . . . . 0.0 116.346 -172.745 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.614 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -85.03 141.57 30.19 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.991 2.117 . . . . 0.0 112.874 166.031 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -70.17 144.97 51.81 Favored 'General case' 0 CA--C 1.545 0.76 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.911 164.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 43.2 m-20 -106.83 75.09 0.39 Allowed Pre-proline 0 CA--C 1.555 1.17 0 C-N-CA 125.554 1.541 . . . . 0.0 112.714 -177.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -56.79 -47.9 21.16 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 124.123 3.215 . . . . 0.0 113.141 -174.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.1 mp -78.93 2.02 21.67 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.034 1.734 . . . . 0.0 113.14 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 59.7 p 68.29 45.04 1.27 Allowed 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 128.736 2.814 . . . . 0.0 111.513 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 69' ' ' ARG . . . . . 0.454 ' HD2' ' OE1' ' B' ' 78' ' ' GLU 0.298 23.7 ptt180 -130.7 171.45 13.08 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -169.136 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.4 169.26 14.76 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 113.625 -1.625 . . . . 0.0 107.345 -172.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CE1' ' HB2' ' B' ' 46' ' ' HIS . 46.9 t60 -63.51 164.11 9.93 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.989 168.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.62 -139.51 7.04 Favored Glycine 0 C--N 1.336 0.567 0 CA-C-O 119.532 -0.593 . . . . 0.0 112.303 169.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.87 -43.22 1.69 Allowed Glycine 0 CA--C 1.545 1.939 0 N-CA-C 119.186 2.434 . . . . 0.0 119.186 169.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -85.45 -12.34 6.67 Favored 'Trans proline' 0 C--N 1.356 0.959 0 CA-C-N 123.497 3.649 . . . . 0.0 113.519 173.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.29 1.92 0.97 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 126.829 2.051 . . . . 0.0 112.326 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.73 152.95 51.62 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 127.773 2.429 . . . . 0.0 108.632 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.94 -2.35 18.37 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.975 2.51 . . . . 0.0 113.072 -176.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 78' ' ' GLU . . . . . 0.454 ' OE1' ' HD2' ' B' ' 69' ' ' ARG . 4.4 mm-40 -75.05 -102.74 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 169.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 73.72 141.48 0.06 Allowed 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 125.705 2.669 . . . . 0.0 111.927 172.837 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -78.77 148.11 33.08 Favored 'General case' 0 CA--C 1.551 1.018 0 CA-C-N 113.065 -1.879 . . . . 0.0 111.615 171.11 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 19.8 m -46.96 -41.5 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 CA-C-N 120.559 1.527 . . . . 0.0 111.366 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.511 ' C ' HG23 ' B' ' 47' ' ' VAL . . . -99.29 104.84 2.94 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 164.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -157.01 129.95 7.74 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 125.634 1.574 . . . . 0.0 112.839 166.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -110.46 179.17 4.16 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 126.501 1.92 . . . . 0.0 110.392 170.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.82 -106.91 3.0 Favored Glycine 0 C--N 1.339 0.722 0 C-N-CA 124.774 1.178 . . . . 0.0 113.972 -171.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -127.11 158.64 36.48 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 123.919 0.888 . . . . 0.0 112.944 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.2 m -118.43 137.54 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 126.772 2.029 . . . . 0.0 109.216 168.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 90.5 m -125.12 115.69 20.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 121.195 1.816 . . . . 0.0 110.745 -173.072 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.06 137.33 36.76 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 124.751 1.22 . . . . 0.0 112.546 -176.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -73.62 178.49 4.69 Favored 'General case' 0 CA--C 1.541 0.629 0 O-C-N 124.148 0.905 . . . . 0.0 111.008 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.503 ' HZ2' ' CD ' ' B' ' 40' ' ' GLU . 3.3 ttmp? -76.96 66.46 2.8 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 123.45 1.595 . . . . 0.0 111.312 169.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -156.31 -45.29 0.07 Allowed 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 127.198 2.199 . . . . 0.0 108.807 175.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.85 -12.21 7.76 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 117.606 -1.664 . . . . 0.0 113.904 -172.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.6 p -81.21 121.76 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.555 1.677 . . . . 0.0 114.355 170.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.76 135.59 34.91 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.12 0.968 . . . . 0.0 108.478 164.197 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -77.0 148.0 36.5 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 123.0 1.381 . . . . 0.0 107.586 168.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.37 123.26 52.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 112.331 -2.213 . . . . 0.0 109.221 171.487 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.0 p -156.94 59.53 0.52 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.251 1.42 . . . . 0.0 112.546 -168.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.04 159.89 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 O-C-N 120.259 -1.526 . . . . 0.0 112.095 -173.119 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -145.3 155.06 42.98 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.044 2.138 . . . . 0.0 109.487 174.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -155.16 144.44 21.07 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.461 1.905 . . . . 0.0 110.328 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.0 p -113.92 49.32 1.0 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.7 t -151.3 14.57 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 123.617 0.767 . . . . 0.0 112.782 -170.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.25 166.64 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 O-C-N 119.66 -1.9 . . . . 0.0 110.723 -171.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.465 ' CB ' HE22 ' B' ' 22' ' ' GLN . 83.8 p -157.56 161.95 38.77 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 117.922 2.564 . . . . 0.0 117.922 171.742 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -78.78 72.91 5.32 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 126.831 2.052 . . . . 0.0 107.482 170.49 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 10.8 t -130.24 15.03 5.64 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -176.67 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 -63.74 0.33 Allowed Glycine 0 N--CA 1.474 1.219 0 N-CA-C 116.089 1.196 . . . . 0.0 116.089 169.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -119.44 -112.56 0.33 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 118.867 1.334 . . . . 0.0 109.53 -168.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -73.05 0.6 10.96 Favored 'General case' 0 CA--C 1.543 0.7 0 O-C-N 120.263 -1.523 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 54.0 p -71.08 -19.75 62.43 Favored 'General case' 0 CA--C 1.541 0.611 0 CA-C-O 116.587 -1.673 . . . . 0.0 114.305 169.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.305 3.9 pt 143.97 -11.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.114 1 C-N-CA 132.735 4.414 . . . . 0.0 116.227 168.831 . . . . . . . . 3 2 . 1 . 004 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.8 mm -76.08 148.15 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 120.266 1.394 . . . . 0.0 109.683 173.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 70.57 5.15 55.14 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 120.586 -1.321 . . . . 0.0 114.437 -175.123 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.9 ptt180 -79.31 156.1 28.19 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.135 1.374 . . . . 0.0 109.979 168.745 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.5 m -100.43 163.8 12.21 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.928 1.291 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.6 ' HB2' HG12 ' B' ' 47' ' ' VAL . 12.5 tp -148.85 126.5 11.74 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.032 1.733 . . . . 0.0 111.074 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 29.1 m -120.76 147.63 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.071 0.948 . . . . 0.0 110.906 167.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.4 p -104.58 154.68 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 124.434 1.094 . . . . 0.0 108.207 167.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 -120.35 159.76 24.4 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.252 1.421 . . . . 0.0 112.54 -173.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -84.8 -26.77 27.27 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 119.894 -1.754 . . . . 0.0 114.909 -168.571 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.31 179.84 3.92 Favored 'General case' 0 CA--C 1.545 0.785 0 O-C-N 119.606 -1.934 . . . . 0.0 108.702 166.611 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.39 151.4 47.21 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.105 0.962 . . . . 0.0 112.869 -176.43 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -75.65 143.37 42.25 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.215 0.531 . . . . 0.0 110.345 175.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -73.47 -20.05 60.79 Favored 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 123.714 0.806 . . . . 0.0 111.71 169.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 51.32 60.0 4.19 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.773 2.029 . . . . 0.0 112.191 -174.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.86 -26.26 25.11 Favored Glycine 0 N--CA 1.469 0.855 0 CA-C-O 117.797 -1.557 . . . . 0.0 116.539 168.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -159.51 100.87 1.5 Allowed 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 120.413 2.106 . . . . 0.0 112.424 176.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 129' ' ' GLY . . . . . 0.494 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -102.89 -132.46 7.67 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 166.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.88 12.07 49.5 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.462 1.505 . . . . 0.0 114.57 173.155 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -130.9 162.91 28.61 Favored 'General case' 0 C--N 1.344 0.345 0 CA-C-N 119.236 1.518 . . . . 0.0 114.387 -168.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -57.06 -59.64 4.77 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.301 1.441 . . . . 0.0 110.02 167.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -59.77 -14.59 15.25 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.689 1.596 . . . . 0.0 113.358 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.494 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 24.3 p -66.39 -28.0 68.29 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.883 1.219 . . . . 0.0 112.892 172.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 p -95.22 -31.31 13.55 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 127.135 2.174 . . . . 0.0 112.261 178.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 45.7 mttp -92.86 -23.66 18.73 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.652 1.581 . . . . 0.0 113.598 -173.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.431 HG21 HH21 ' B' ' 143' ' ' ARG . 41.7 p -138.69 -124.11 0.13 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 127.408 2.283 . . . . 0.0 105.034 164.627 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -126.86 8.37 7.24 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 125.466 1.507 . . . . 0.0 111.267 168.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 62.18 -79.74 0.02 OUTLIER 'General case' 0 C--N 1.347 0.492 0 C-N-CA 127.335 2.254 . . . . 0.0 110.066 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 60.64 29.92 19.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 126.397 1.879 . . . . 0.0 114.616 167.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.62 -42.4 1.27 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 125.768 1.652 . . . . 0.0 113.684 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.5 t -178.09 163.15 1.68 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.018 2.127 . . . . 0.0 111.315 175.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.431 HH21 HG21 ' B' ' 137' ' ' THR . 80.4 mtt85 -73.26 177.04 5.39 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 125.159 1.384 . . . . 0.0 110.322 168.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.57 -128.57 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 124.306 1.042 . . . . 0.0 111.245 -172.028 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.82 153.88 39.74 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.947 1.299 . . . . 0.0 112.447 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -137.41 152.01 49.16 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.109 1.364 . . . . 0.0 111.887 -169.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.92 171.24 33.8 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.201 1.381 . . . . 0.0 112.15 169.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 79.7 t -119.35 147.42 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 169.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.8 mm -86.5 88.6 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 O-C-N 121.626 -0.671 . . . . 0.0 110.526 -179.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.16 -168.3 42.66 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 123.431 0.538 . . . . 0.0 113.405 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.44 161.2 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -170.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.4 -56.43 0.4 Allowed 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.134 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 N--CA 1.464 0.241 0 C-N-CA 126.04 1.736 . . . . 0.0 110.129 -169.766 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.505 HG23 HE22 ' A' ' 153' ' ' GLN . 40.0 m . . . . . 0 CA--C 1.508 -0.648 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.419 ' HE3' ' CG2' ' A' ' 5' ' ' VAL . 17.4 pttt -132.1 133.47 44.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 115.888 1.81 . . . . 0.0 115.888 -176.135 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 149' ' ' ILE . . . -86.95 167.57 14.15 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 163.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.419 ' CG2' ' HE3' ' A' ' 3' ' ' LYS . 15.2 t -147.43 118.21 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 119.207 0.912 . . . . 0.0 112.158 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.26 84.53 5.19 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 168.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.2 t -76.4 79.42 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 105.025 -2.213 . . . . 0.0 105.025 176.447 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.2 mt -67.09 127.68 33.5 Favored 'General case' 0 C--O 1.224 -0.239 0 CA-C-O 122.205 1.002 . . . . 0.0 111.177 -162.423 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.1 tttm -159.67 -174.6 4.7 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.342 1.457 . . . . 0.0 111.672 174.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.24 -6.44 21.34 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 124.778 1.18 . . . . 0.0 113.008 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -116.96 145.62 43.52 Favored 'General case' 0 N--CA 1.433 -1.276 1 C-N-CA 133.291 4.636 . . . . 0.0 103.4 168.478 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.66 -70.87 0.99 Allowed Glycine 0 CA--C 1.535 1.298 0 C-N-CA 126.011 1.767 . . . . 0.0 112.966 -177.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -69.16 -32.31 21.32 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 123.715 2.943 . . . . 0.0 114.537 -170.124 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -95.71 144.39 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 119.707 1.14 . . . . 0.0 111.304 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -139.83 173.66 11.3 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.523 1.129 . . . . 0.0 109.174 168.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.52 178.5 33.83 Favored Glycine 0 N--CA 1.468 0.784 0 C-N-CA 124.465 1.031 . . . . 0.0 114.954 169.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.3 pt -153.45 56.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 C-N-CA 124.943 1.297 . . . . 0.0 111.992 -170.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 mm -87.03 98.64 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 O-C-N 120.566 -1.334 . . . . 0.0 110.66 -173.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.02 147.31 34.88 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.782 1.233 . . . . 0.0 110.253 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -128.25 79.08 1.88 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.045 1.338 . . . . 0.0 109.544 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -81.7 112.31 18.76 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.086 1.354 . . . . 0.0 112.188 -175.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -101.02 131.83 46.72 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.449 1.5 . . . . 0.0 109.199 171.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.46 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -96.53 -22.95 16.78 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 124.438 1.095 . . . . 0.0 113.453 174.805 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -103.26 -138.35 0.35 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.668 3.187 . . . . 0.0 110.405 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.2 p -151.29 34.0 0.57 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 127.533 2.333 . . . . 0.0 109.33 169.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -178.88 -28.77 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.369 1.467 . . . . 0.0 114.44 -167.31 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.63 -169.21 40.29 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 125.165 1.364 . . . . 0.0 113.248 177.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -68.0 138.63 44.59 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.313 2.675 . . . . 0.0 112.834 -171.802 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.4 t -96.43 132.87 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 124.37 1.068 . . . . 0.0 110.062 173.175 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -81.23 118.61 22.74 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 169.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.12 79.11 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 127.687 2.395 . . . . 0.0 108.702 -174.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -103.28 164.99 11.29 Favored 'General case' 0 CA--C 1.541 0.607 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.418 172.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.36 -164.32 28.37 Favored Glycine 0 C--O 1.224 -0.491 0 C-N-CA 125.383 1.468 . . . . 0.0 111.506 174.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.6 p -155.38 168.47 26.97 Favored 'General case' 0 C--N 1.319 -0.722 0 O-C-N 121.686 -0.89 . . . . 0.0 110.597 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.67 HG21 HG11 ' A' ' 119' ' ' VAL . 4.3 mp -128.24 126.55 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 C-N-CA 126.283 1.833 . . . . 0.0 107.27 174.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.68 143.76 45.6 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 122.888 2.585 . . . . 0.0 113.032 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.42 -1.94 16.1 Favored Glycine 0 CA--C 1.54 1.636 0 C-N-CA 128.146 2.784 . . . . 0.0 113.561 -169.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.9 mt -79.01 161.95 26.26 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.059 1.344 . . . . 0.0 113.203 -177.205 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.1 t -85.53 155.64 21.11 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 164.091 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.4 pt-20 -57.6 172.59 0.35 Allowed 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 115.782 1.771 . . . . 0.0 115.782 -174.423 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.32 -178.6 53.84 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.621 1.105 . . . . 0.0 113.228 174.581 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -62.36 142.52 57.77 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.09 1.756 . . . . 0.0 112.606 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -142.72 124.08 14.72 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 127.84 2.456 . . . . 0.0 108.507 177.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.97 149.28 51.71 Favored Glycine 0 N--CA 1.477 1.396 0 CA-C-N 120.585 1.539 . . . . 0.0 110.919 178.011 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -147.7 117.88 7.31 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.907 1.854 . . . . 0.0 111.566 172.764 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -157.48 173.61 16.64 Favored 'General case' 0 C--O 1.236 0.367 0 O-C-N 121.104 -0.997 . . . . 0.0 109.741 -168.324 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.59 135.96 50.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 C-N-CA 124.214 1.006 . . . . 0.0 110.479 -166.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -77.18 176.18 8.97 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 122.849 0.46 . . . . 0.0 110.622 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 64' ' ' PHE . 1.2 pm0 -71.56 137.67 48.22 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.411 -0.806 . . . . 0.0 108.896 165.373 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 56.07 -169.05 0.09 Allowed 'General case' 0 CA--C 1.542 0.661 0 CA-C-O 123.665 1.698 . . . . 0.0 114.166 173.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.92 17.66 48.37 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-O 116.357 -2.357 . . . . 0.0 111.476 167.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.695 ' HA ' HG21 ' B' ' 5' ' ' VAL . 2.3 p30 -82.36 45.54 0.96 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.754 2.777 . . . . 0.0 112.454 -172.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.553 ' ND2' HG11 ' B' ' 7' ' ' VAL . 8.9 p-10 -91.69 34.39 0.98 Allowed 'General case' 0 C--O 1.235 0.301 0 N-CA-C 115.546 1.684 . . . . 0.0 115.546 -166.285 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.565 HG22 ' HA ' ' B' ' 7' ' ' VAL . 28.6 p -114.45 -18.86 11.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -160.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.69 21.2 4.89 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-N 119.214 0.915 . . . . 0.0 110.902 165.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.4 -112.7 3.63 Favored Glycine 0 C--N 1.342 0.878 0 C-N-CA 125.646 1.594 . . . . 0.0 111.476 173.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.5 t -80.87 -16.7 52.93 Favored 'General case' 0 CA--C 1.545 0.766 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 168.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.1 40.02 0.53 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.633 1.573 . . . . 0.0 108.8 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -172.16 167.07 6.01 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 127.46 2.304 . . . . 0.0 110.003 -162.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -1.31 106.71 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 129.522 3.129 . . . . 0.0 116.947 168.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.76 -84.39 0.74 Allowed Glycine 0 CA--C 1.54 1.609 0 C-N-CA 126.861 2.172 . . . . 0.0 113.165 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.9 173.74 13.94 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 124.39 3.393 . . . . 0.0 112.708 -171.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -92.96 115.39 28.08 Favored 'General case' 0 CA--C 1.536 0.404 0 O-C-N 121.156 -0.965 . . . . 0.0 113.533 -168.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 49' ' ' GLU . 40.2 t80 -43.89 130.4 5.75 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.135 1.374 . . . . 0.0 113.638 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 35.6 p-10 -145.27 68.49 13.67 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -168.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -61.11 -19.66 64.35 Favored 'Trans proline' 0 CA--C 1.54 0.784 0 C-N-CA 122.501 2.134 . . . . 0.0 112.058 169.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -76.88 -6.29 51.84 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.147 1.379 . . . . 0.0 113.608 171.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t 57.71 47.48 15.58 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 127.224 2.21 . . . . 0.0 112.233 174.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -111.24 173.01 6.54 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 114.657 1.354 . . . . 0.0 114.657 -175.373 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -89.04 176.14 7.11 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.187 2.195 . . . . 0.0 108.989 175.119 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.9 t60 -91.56 157.25 17.11 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.418 1.087 . . . . 0.0 113.674 -172.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 138.63 -129.73 4.62 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 124.021 0.82 . . . . 0.0 113.028 167.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 129.34 -30.05 3.73 Favored Glycine 0 CA--C 1.55 2.224 0 N-CA-C 119.763 2.665 . . . . 0.0 119.763 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -108.97 17.45 0.09 OUTLIER 'Trans proline' 0 CA--C 1.551 1.355 0 C-N-CA 124.933 3.756 . . . . 0.0 113.115 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.96 -26.17 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 128.286 2.634 . . . . 0.0 111.421 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.5 OUTLIER -94.78 148.07 22.68 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.864 2.066 . . . . 0.0 106.157 162.064 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -100.67 -8.98 22.32 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 126.901 2.08 . . . . 0.0 113.08 -178.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.64 -82.03 0.09 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.076 0.95 . . . . 0.0 110.553 -176.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.292 37.6 ptt180 66.67 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 127.063 2.145 . . . . 0.0 113.393 175.253 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -59.49 165.19 2.98 Favored 'General case' 0 CA--C 1.551 0.986 0 O-C-N 119.596 -1.94 . . . . 0.0 113.337 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 74.3 t -57.27 -25.26 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.457 -1.402 . . . . 0.0 112.697 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.67 31.19 7.41 Favored Glycine 0 CA--C 1.539 1.558 0 CA-C-O 118.222 -1.321 . . . . 0.0 115.993 173.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -112.25 139.73 47.55 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 117.387 2.365 . . . . 0.0 117.387 -172.06 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 79.9 mt -144.9 166.01 26.5 Favored 'General case' 0 CA--C 1.555 1.15 1 C-N-CA 133.704 4.802 . . . . 0.0 104.031 165.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.71 -129.32 5.3 Favored Glycine 0 N--CA 1.473 1.147 0 C-N-CA 123.664 0.65 . . . . 0.0 113.606 -169.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -113.06 147.33 37.48 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 121.974 0.892 . . . . 0.0 113.085 169.455 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.66 174.19 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.682 1.993 . . . . 0.0 108.372 167.187 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -140.57 124.02 16.91 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 168.418 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.1 139.81 34.19 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 118.239 0.472 . . . . 0.0 111.913 169.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.65 157.27 37.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.712 1.605 . . . . 0.0 110.386 167.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.83 -0.59 0.69 Allowed 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 114.684 1.365 . . . . 0.0 114.684 170.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -99.64 5.59 45.81 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.816 2.046 . . . . 0.0 112.482 170.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.08 0.54 65.75 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 126.27 1.89 . . . . 0.0 116.49 168.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.12 136.2 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 CA-C-N 119.497 1.649 . . . . 0.0 112.9 -177.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.3 129.85 50.41 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 124.948 1.299 . . . . 0.0 107.745 166.202 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -92.31 148.97 21.72 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 122.577 1.179 . . . . 0.0 108.835 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.07 124.58 37.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.451 -1.704 . . . . 0.0 109.232 173.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.1 p -155.31 76.04 0.96 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.962 1.363 . . . . 0.0 111.491 -169.013 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.72 159.57 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.484 1.513 . . . . 0.0 110.221 -169.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -147.17 121.43 9.57 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 104.777 -2.305 . . . . 0.0 104.777 166.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -126.29 131.79 51.8 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.641 1.21 . . . . 0.0 113.061 -168.516 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.1 p -82.98 58.73 4.53 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.393 1.077 . . . . 0.0 110.162 177.19 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -152.25 -44.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 170.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.45 143.14 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 118.938 0.79 . . . . 0.0 110.876 -179.189 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.518 ' H ' ' CB ' ' A' ' 111' ' ' SER . 35.8 p -132.22 161.02 34.45 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 126.556 1.942 . . . . 0.0 112.075 173.044 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 31.0 mt -79.71 94.54 5.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 168.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -131.97 -15.46 2.99 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -169.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.05 -68.67 3.39 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 120.347 1.43 . . . . 0.0 111.622 -170.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -92.04 -60.77 1.77 Allowed 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.705 1.24 . . . . 0.0 113.824 -173.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 28.7 m-70 -80.64 1.56 29.39 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.84 1.656 . . . . 0.0 112.903 -164.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' H ' ' A' ' 105' ' ' SER . 18.9 m -162.42 -88.88 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.264 0 N-CA-C 115.71 1.744 . . . . 0.0 115.71 177.221 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.41 162.75 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.093 -1.004 . . . . 0.0 111.093 -173.012 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 114.54 140.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 1 C-N-CA 135.521 5.528 . . . . 0.0 107.374 -169.421 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.63 -25.62 1.71 Allowed Glycine 0 CA--C 1.535 1.317 0 CA-C-O 118.26 -1.3 . . . . 0.0 115.836 177.11 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 10.6 ptt180 -74.73 163.64 27.46 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 126.253 1.821 . . . . 0.0 111.466 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.3 m -121.37 110.81 16.54 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 124.635 1.174 . . . . 0.0 113.042 -169.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.6 tp -99.66 122.87 43.31 Favored 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 121.124 1.784 . . . . 0.0 111.346 -173.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 143' ' ' ARG . 13.2 p -121.13 151.59 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 125.471 1.509 . . . . 0.0 113.315 179.119 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.678 HG13 ' CD2' ' A' ' 144' ' ' LEU . 7.4 p -103.9 143.28 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.035 0 C-N-CA 124.547 1.139 . . . . 0.0 110.344 166.493 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 40.6 m-70 -115.34 169.2 9.32 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 126.94 2.096 . . . . 0.0 115.123 -168.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -83.58 -30.17 27.21 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 116.075 1.88 . . . . 0.0 116.075 -173.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -107.0 170.18 8.1 Favored 'General case' 0 CA--C 1.546 0.805 0 CA-C-N 120.668 1.576 . . . . 0.0 111.881 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.57 163.89 6.51 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.022 1.329 . . . . 0.0 111.443 169.09 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -103.9 131.49 51.07 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.023 0.929 . . . . 0.0 110.422 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.88 -28.5 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 120.747 0.308 . . . . 0.0 111.656 177.17 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.0 mt 58.09 40.46 25.21 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.387 1.875 . . . . 0.0 112.446 173.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.27 -74.39 0.07 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 117.495 1.758 . . . . 0.0 117.495 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -139.06 -42.03 0.47 Allowed 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -164.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 54.64 -113.43 3.48 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 120.178 1.354 . . . . 0.0 110.47 -166.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -153.56 29.55 0.76 Allowed Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.222 1.867 . . . . 0.0 112.008 168.641 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -166.48 171.3 12.0 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.773 1.629 . . . . 0.0 111.669 -164.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -67.62 -54.65 17.95 Favored 'General case' 0 N--CA 1.469 0.478 0 O-C-N 121.32 -0.862 . . . . 0.0 113.185 -169.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.429 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 0.3 OUTLIER -65.09 -19.51 66.02 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.043 0.937 . . . . 0.0 111.25 -171.864 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.4 m -67.67 -33.35 74.76 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.897 -1.127 . . . . 0.0 111.729 168.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.4 p -83.29 -18.94 37.29 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 124.783 1.233 . . . . 0.0 114.241 174.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -105.99 -45.56 4.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.303 1.041 . . . . 0.0 113.57 -176.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.71 -26.33 12.33 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 116.829 -1.558 . . . . 0.0 113.87 177.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.63 12.44 47.56 Favored Glycine 0 N--CA 1.472 1.062 0 CA-C-N 119.327 0.967 . . . . 0.0 114.8 -173.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 60.38 8.95 1.78 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 118.975 1.387 . . . . 0.0 113.508 -174.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.84 -3.41 0.74 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -166.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.21 -160.04 25.67 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 126.694 2.092 . . . . 0.0 112.797 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 91.7 p -65.82 177.54 1.27 Allowed 'General case' 0 CA--C 1.547 0.828 0 O-C-N 122.026 -0.691 . . . . 0.0 112.139 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.463 ' HB2' HG21 ' A' ' 118' ' ' VAL . 27.5 ptt180 -136.2 132.37 35.8 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.923 -1.111 . . . . 0.0 112.749 -166.033 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.678 ' CD2' HG13 ' A' ' 119' ' ' VAL 0.335 0.0 OUTLIER -103.35 -106.76 0.27 Allowed 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.154 1.381 . . . . 0.0 111.723 -175.677 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.473 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -77.23 135.18 38.45 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 119.635 1.107 . . . . 0.0 111.216 -173.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.435 ' HB3' HG23 ' A' ' 118' ' ' VAL . 13.9 p -141.88 154.86 45.43 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 126.107 1.763 . . . . 0.0 111.69 -172.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.7 130.01 3.5 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 123.818 0.723 . . . . 0.0 111.915 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -72.47 170.53 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 167.785 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 4' ' ' ALA . 35.2 mm -129.56 126.39 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 O-C-N 120.738 -1.226 . . . . 0.0 113.331 -167.326 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -146.05 -126.24 1.77 Allowed Glycine 0 CA--C 1.539 1.591 0 C-N-CA 127.442 2.449 . . . . 0.0 114.617 -177.514 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 pp -147.46 68.67 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 120.642 -1.505 . . . . 0.0 113.932 -168.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.43 -20.43 54.54 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 120.567 -1.333 . . . . 0.0 114.462 -171.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLN . . . . . 0.505 HE22 HG23 ' A' ' 2' ' ' THR . 4.9 mm-40 . . . . . 0 N--CA 1.472 0.633 0 C-N-CA 124.497 1.119 . . . . 0.0 112.699 175.187 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.442 0 CA-C-O 121.12 0.486 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.4 m -83.24 99.87 10.24 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -96.36 165.18 12.32 Favored 'General case' 0 CA--C 1.548 0.899 0 CA-C-O 122.864 1.316 . . . . 0.0 113.251 -176.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.34 172.73 13.43 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -168.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.695 HG21 ' HA ' ' A' ' 52' ' ' ASP . 1.1 p -157.43 103.44 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 C-N-CA 127.25 2.22 . . . . 0.0 107.786 -169.051 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.27 130.42 35.02 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 120.472 -1.392 . . . . 0.0 111.699 171.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.565 ' HA ' HG22 ' A' ' 54' ' ' THR . 20.6 t -93.48 71.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.179 0.992 . . . . 0.0 111.136 -173.18 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -80.48 114.72 19.58 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.469 0.652 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 13.2 ttpp -144.97 151.18 38.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.84 0.829 . . . . 0.0 112.428 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.45 149.96 18.76 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 166.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -79.1 64.88 4.13 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 123.408 1.575 . . . . 0.0 110.372 169.102 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.52 -175.45 46.24 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 129.101 3.239 . . . . 0.0 108.685 -171.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.18 22.21 0.38 Allowed 'Trans proline' 0 CA--C 1.547 1.153 0 C-N-CA 124.65 3.566 . . . . 0.0 114.916 -169.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.454 HG11 HD13 ' B' ' 144' ' ' LEU . 1.3 t -118.97 130.31 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 C-N-CA 126.993 2.117 . . . . 0.0 109.002 -170.615 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.434 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -160.71 160.88 31.97 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 124.099 0.96 . . . . 0.0 110.999 -170.982 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.01 169.05 33.58 Favored Glycine 0 CA--C 1.51 -0.262 0 C-N-CA 124.779 1.18 . . . . 0.0 112.23 168.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.402 HG22 ' HB ' ' A' ' 54' ' ' THR . 1.0 OUTLIER -132.35 133.18 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 171.8 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.438 HD12 HG11 ' B' ' 97' ' ' VAL . 5.0 mm -135.09 109.58 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 19' ' ' ASN . . . . . 0.407 ' HB2' ' CE2' ' B' ' 32' ' ' TRP . 36.2 m120 -79.85 155.52 27.78 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 123.914 0.886 . . . . 0.0 111.959 175.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.439 ' CD2' HG22 ' B' ' 31' ' ' VAL . 5.5 m-85 -139.27 152.65 47.44 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 167.546 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -146.88 132.57 18.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 119.133 0.879 . . . . 0.0 109.951 167.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -84.84 137.86 32.91 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 122.721 0.408 . . . . 0.0 111.117 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.464 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -93.48 -91.64 0.18 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.179 0.992 . . . . 0.0 110.618 169.27 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 24' ' ' GLU . . . . . 0.464 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 31.9 mp0 -82.37 169.25 16.67 Favored 'General case' 0 C--O 1.217 -0.607 0 O-C-N 120.538 -1.351 . . . . 0.0 110.544 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -51.02 -45.25 61.17 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 114.298 1.222 . . . . 0.0 114.298 -172.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 22.0 m-80 -127.01 40.27 3.75 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.632 1.973 . . . . 0.0 110.294 166.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.66 162.76 53.61 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-O 118.717 -1.046 . . . . 0.0 111.461 173.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -66.4 161.72 39.66 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.503 2.802 . . . . 0.0 110.005 174.537 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.0 t -136.55 133.36 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 122.973 0.509 . . . . 0.0 110.967 -169.45 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -79.84 132.16 36.04 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 168.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.439 HG22 ' CD2' ' B' ' 20' ' ' PHE . 21.3 t -120.85 111.54 32.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 126.578 1.951 . . . . 0.0 108.739 176.75 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 32' ' ' TRP . . . . . 0.407 ' CE2' ' HB2' ' B' ' 19' ' ' ASN . 17.5 p90 -140.11 153.27 46.66 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.366 0.603 . . . . 0.0 112.213 -173.324 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.49 -153.41 24.63 Favored Glycine 0 C--O 1.225 -0.433 0 C-N-CA 124.13 0.872 . . . . 0.0 111.507 178.065 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 12.6 p -157.1 158.66 36.79 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 114.045 1.128 . . . . 0.0 114.045 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -128.1 131.46 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 125.715 1.606 . . . . 0.0 107.912 -179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.1 ttpt -133.95 140.12 46.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 126.172 1.789 . . . . 0.0 110.617 -168.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.11 20.73 13.09 Favored Glycine 0 N--CA 1.481 1.638 0 C-N-CA 124.994 1.283 . . . . 0.0 114.373 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.2 pt? -117.91 165.9 13.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.756 2.822 . . . . 0.0 110.622 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.95 167.46 21.86 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.316 0.646 . . . . 0.0 110.205 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -64.65 -175.3 0.17 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 126.967 2.107 . . . . 0.0 114.549 171.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.33 -170.59 46.98 Favored Glycine 0 N--CA 1.47 0.944 0 O-C-N 120.388 -1.445 . . . . 0.0 112.432 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mt -77.01 155.16 32.79 Favored 'General case' 0 CA--C 1.545 0.757 0 O-C-N 121.172 -1.193 . . . . 0.0 110.02 177.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -147.63 123.57 10.68 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 127.931 2.493 . . . . 0.0 109.641 -172.135 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.34 151.16 36.2 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-N 120.926 1.694 . . . . 0.0 113.526 176.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -151.13 96.58 2.33 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.213 1.405 . . . . 0.0 112.171 -170.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.38 147.07 48.93 Favored 'General case' 0 N--CA 1.47 0.561 0 O-C-N 120.085 -1.634 . . . . 0.0 111.742 -167.512 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.526 HG23 ' HA2' ' B' ' 82' ' ' GLY . 27.5 m -108.66 120.19 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 122.484 1.135 . . . . 0.0 110.959 177.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -77.83 101.61 6.83 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -173.684 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -64.16 95.27 0.12 Allowed 'General case' 0 C--N 1.344 0.349 0 CA-C-O 123.116 1.436 . . . . 0.0 108.602 175.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 t80 177.55 -166.95 0.05 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 130.472 3.509 . . . . 0.0 104.349 -164.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.35 -122.02 3.5 Favored Glycine 0 CA--C 1.507 -0.43 0 CA-C-O 121.772 0.651 . . . . 0.0 112.477 171.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.07 152.83 39.85 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.684 1.594 . . . . 0.0 113.459 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 17.4 p-10 173.13 32.68 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 128.815 2.846 . . . . 0.0 108.843 -171.669 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 82.8 p . . . . . 0 CA--C 1.534 0.343 0 C-N-CA 127.439 2.295 . . . . 0.0 116.382 -165.806 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.871 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.82 -91.75 0.94 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.296 1.903 . . . . 0.0 112.223 -174.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -100.33 -177.32 0.17 Allowed 'Trans proline' 0 CA--C 1.535 0.561 1 C-N-CA 125.939 4.426 . . . . 0.0 111.728 176.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.487 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -79.98 130.36 35.21 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 168.741 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -58.97 147.09 35.67 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.855 1.262 . . . . 0.0 112.56 171.281 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 50.3 m-20 -108.81 77.87 0.86 Allowed Pre-proline 0 CA--C 1.554 1.097 0 C-N-CA 125.276 1.43 . . . . 0.0 111.843 -176.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -58.21 -49.18 13.15 Favored 'Trans proline' 0 C--N 1.353 0.81 0 C-N-CA 123.975 3.116 . . . . 0.0 113.216 -174.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 75.1 mt -78.83 -0.44 30.62 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 126.144 1.778 . . . . 0.0 112.871 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.2 t 58.77 43.82 17.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 127.518 2.327 . . . . 0.0 112.151 -173.67 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.1 mtp180 -92.31 176.43 6.48 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 120.878 -1.139 . . . . 0.0 112.489 -176.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.513 ' HE2' ' OE1' ' B' ' 78' ' ' GLU . 0.3 OUTLIER -97.24 170.26 9.22 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 126.18 1.792 . . . . 0.0 108.829 165.312 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -96.66 151.64 19.42 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -167.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.44 -106.03 0.34 Allowed Glycine 0 C--N 1.345 1.053 0 C-N-CA 124.796 1.189 . . . . 0.0 114.809 166.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.85 -29.2 8.69 Favored Glycine 0 CA--C 1.543 1.811 0 N-CA-C 119.85 2.7 . . . . 0.0 119.85 174.146 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -104.03 6.47 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.049 0 C-N-CA 123.657 2.904 . . . . 0.0 112.578 172.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.01 -31.25 0.13 Allowed 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.908 1.283 . . . . 0.0 110.893 169.447 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.05 150.13 27.71 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 162.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -96.19 -17.99 20.41 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.519 1.927 . . . . 0.0 112.138 -176.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 78' ' ' GLU . . . . . 0.513 ' OE1' ' HE2' ' B' ' 70' ' ' LYS . 3.7 mt-10 -78.05 -50.66 11.65 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 121.049 -1.032 . . . . 0.0 113.023 -172.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 45.75 97.88 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.127 1.371 . . . . 0.0 114.059 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.6 m80 -50.79 144.78 7.86 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 119.729 -1.857 . . . . 0.0 110.262 169.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 m -55.41 -29.99 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 CA-C-N 120.239 1.381 . . . . 0.0 112.12 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.526 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -89.26 49.24 3.48 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 125.025 1.298 . . . . 0.0 116.053 171.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -139.46 123.17 17.48 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.353 1.461 . . . . 0.0 110.071 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -113.55 50.29 0.92 Allowed 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 168.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 55.73 -112.13 2.91 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 125.343 1.449 . . . . 0.0 114.445 177.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -155.7 159.07 39.23 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 126.196 1.798 . . . . 0.0 110.563 -175.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.8 p -117.37 175.75 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 127.517 2.327 . . . . 0.0 109.685 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -133.92 150.17 51.31 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.98 1.712 . . . . 0.0 108.326 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -117.7 149.03 41.42 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.443 1.497 . . . . 0.0 112.779 173.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -83.52 150.05 26.23 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 128.229 2.612 . . . . 0.0 112.281 169.719 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.82 -2.48 1.85 Allowed 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.884 1.673 . . . . 0.0 115.143 177.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -90.93 7.96 37.53 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.485 1.514 . . . . 0.0 112.069 169.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.82 28.81 22.73 Favored Glycine 0 C--N 1.341 0.821 0 CA-C-O 117.361 -1.799 . . . . 0.0 114.656 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -141.64 139.26 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.138 1.469 . . . . 0.0 114.521 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.14 122.04 44.5 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.558 1.543 . . . . 0.0 108.685 165.141 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -79.21 140.0 37.8 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 165.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 97' ' ' VAL . . . . . 0.438 HG11 HD12 ' B' ' 18' ' ' ILE 0.262 0.3 OUTLIER -119.71 129.04 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-O 122.557 1.17 . . . . 0.0 112.576 166.96 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 28.8 m -147.8 78.63 1.46 Allowed 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.362 1.465 . . . . 0.0 109.729 -172.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -122.44 154.14 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.484 1.513 . . . . 0.0 111.614 -173.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.8 tt0 -142.14 148.39 38.22 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.989 1.715 . . . . 0.0 107.346 167.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -149.83 150.48 32.04 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 125.117 1.367 . . . . 0.0 111.934 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.2 p -116.78 51.86 0.97 Allowed 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.7 -48.64 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 124.4 1.08 . . . . 0.0 110.819 169.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.96 157.31 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 119.327 0.967 . . . . 0.0 112.785 177.502 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 95.0 p -156.54 150.89 25.41 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.164 1.786 . . . . 0.0 109.023 -170.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mp -80.95 54.06 2.11 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 122.128 0.965 . . . . 0.0 108.745 172.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -84.93 62.61 7.58 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.121 -0.987 . . . . 0.0 109.968 -177.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.92 -111.11 4.06 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 124.784 1.183 . . . . 0.0 112.837 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -127.99 -14.8 4.92 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 127.67 2.388 . . . . 0.0 114.518 -167.542 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.0 -32.14 8.44 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 114.49 1.292 . . . . 0.0 114.49 -169.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -85.98 -15.14 42.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.258 0.7 OUTLIER -177.37 -47.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 C-N-CA 127.564 2.346 . . . . 0.0 109.109 168.536 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -58.86 143.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 105.61 -1.996 . . . . 0.0 105.61 162.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.65 -16.4 1.4 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 126.769 2.128 . . . . 0.0 113.628 -175.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 115' ' ' ARG . . . . . 0.52 HH11 ' HG3' ' B' ' 115' ' ' ARG . 4.5 ttm-85 -80.15 171.37 15.17 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.863 1.665 . . . . 0.0 111.854 176.145 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -113.14 154.52 26.5 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 125.379 1.471 . . . . 0.0 112.466 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 25.2 tp -121.15 138.25 54.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 128.246 2.619 . . . . 0.0 109.217 168.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -114.84 139.39 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 124.949 1.3 . . . . 0.0 109.872 168.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -119.57 133.99 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 171.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -110.94 151.06 28.35 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.767 1.227 . . . . 0.0 112.033 -168.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -79.2 -18.22 53.39 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -167.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 48.0 mttp -138.73 178.23 7.3 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 120.163 1.347 . . . . 0.0 113.569 177.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.91 130.51 37.61 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.282 1.433 . . . . 0.0 110.176 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -81.33 158.78 24.6 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 124.029 0.831 . . . . 0.0 109.221 170.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 125' ' ' ASP . . . . . 0.452 ' OD1' ' HE3' ' B' ' 128' ' ' LYS . 7.5 t70 -73.45 -43.29 60.63 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 119.306 -0.957 . . . . 0.0 109.3 168.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 2.0 mm? 70.15 53.14 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 127.123 2.169 . . . . 0.0 107.734 -168.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 161.22 -82.29 0.13 Allowed Glycine 0 N--CA 1.465 0.617 0 O-C-N 121.317 -0.864 . . . . 0.0 114.1 -175.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.537 ' H ' ' HE3' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -156.69 72.4 0.73 Allowed 'General case' 0 CA--C 1.549 0.938 0 N-CA-C 115.701 1.741 . . . . 0.0 115.701 -170.237 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -57.6 -24.81 54.03 Favored Glycine 0 CA--C 1.542 1.753 0 O-C-N 120.708 -1.245 . . . . 0.0 115.128 176.487 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.48 -28.38 0.49 Allowed Glycine 0 CA--C 1.534 1.24 0 N-CA-C 116.675 1.43 . . . . 0.0 116.675 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 131' ' ' ASN . . . . . 0.418 ' H ' ' HB3' ' B' ' 134' ' ' SER . 22.1 m120 -106.33 175.81 5.37 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 118.968 1.384 . . . . 0.0 113.098 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.1 tm-20 -51.64 -57.55 8.84 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.603 1.161 . . . . 0.0 108.904 166.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -41.33 -34.53 0.52 Allowed 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 126.236 1.814 . . . . 0.0 115.036 168.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' B' ' 131' ' ' ASN . 4.5 p -71.18 -9.96 58.97 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 119.318 -2.114 . . . . 0.0 115.836 -177.339 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.2 t -111.16 -7.98 14.43 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.166 1.387 . . . . 0.0 110.379 164.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -85.82 -50.33 7.22 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.737 1.615 . . . . 0.0 110.763 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 80.7 p -102.35 -35.52 8.79 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 128.686 2.794 . . . . 0.0 110.972 175.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.76 -9.63 52.05 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.045 1.783 . . . . 0.0 112.028 -169.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 75.96 30.93 0.71 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 129.446 3.098 . . . . 0.0 112.317 176.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.68 33.33 0.01 OUTLIER 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 178.444 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.55 -51.86 3.75 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 127.69 2.567 . . . . 0.0 114.79 175.006 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 170.9 157.39 0.07 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.862 1.665 . . . . 0.0 113.741 -174.328 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.33 134.0 34.52 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.413 1.085 . . . . 0.0 113.715 173.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.454 HD13 HG11 ' B' ' 14' ' ' VAL . 3.3 pp -104.7 -30.17 10.11 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.331 1.453 . . . . 0.0 113.469 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.81 161.55 36.94 Favored 'General case' 0 C--O 1.245 0.831 0 C-N-CA 125.705 1.602 . . . . 0.0 107.174 174.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.3 p -152.32 151.86 31.41 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 126.254 1.822 . . . . 0.0 108.525 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.46 145.69 11.77 Favored Glycine 0 C--O 1.224 -0.504 0 N-CA-C 115.632 1.013 . . . . 0.0 115.632 179.359 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 16.3 t -78.17 145.9 9.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.283 1.033 . . . . 0.0 108.244 167.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.6 mm -89.53 101.17 11.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.914 0.886 . . . . 0.0 109.979 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.62 164.46 30.39 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 173.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -93.78 141.14 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 123.902 0.881 . . . . 0.0 111.354 172.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -141.91 166.19 25.39 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.956 1.703 . . . . 0.0 111.154 168.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.466 0.351 0 C-N-CA 123.265 0.626 . . . . 0.0 111.133 -167.226 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.508 -0.635 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.0 ttpt -99.0 106.74 19.03 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 122.641 1.21 . . . . 0.0 112.967 169.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.65 173.23 7.99 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 126.078 1.751 . . . . 0.0 109.041 167.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.868 HG11 ' HA ' ' B' ' 52' ' ' ASP . 12.8 p -161.78 162.66 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.353 0.661 . . . . 0.0 111.996 -173.032 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.52 134.01 19.75 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.566 1.146 . . . . 0.0 109.899 163.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.26 94.29 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.525 1.93 . . . . 0.0 107.058 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -79.3 134.58 36.62 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 126.708 2.003 . . . . 0.0 110.206 -173.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.4 mtpt -155.87 179.71 8.94 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.313 1.045 . . . . 0.0 113.687 178.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.5 -60.47 0.42 Allowed Glycine 0 C--N 1.334 0.445 0 C-N-CA 128.083 2.754 . . . . 0.0 108.721 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -82.1 69.69 8.86 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.101 1.761 . . . . 0.0 111.52 -168.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.44 -100.67 0.03 OUTLIER Glycine 0 CA--C 1.54 1.643 0 C-N-CA 126.957 2.218 . . . . 0.0 114.132 171.695 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -80.38 -7.66 13.86 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 125.04 3.827 . . . . 0.0 114.331 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.3 t -77.22 142.17 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 CA-C-N 119.983 1.265 . . . . 0.0 109.105 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.45 158.04 39.35 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 124.95 1.3 . . . . 0.0 109.414 169.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -140.51 108.64 0.57 Allowed Glycine 0 C--O 1.22 -0.777 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.94 131.41 37.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 118.676 1.238 . . . . 0.0 108.392 168.632 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.3 pp -149.41 126.61 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-O 122.764 1.269 . . . . 0.0 111.413 166.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -74.82 166.3 23.84 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.78 1.232 . . . . 0.0 111.329 169.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -141.49 93.25 2.55 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.734 2.014 . . . . 0.0 107.879 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.447 ' OE2' ' HE3' ' A' ' 23' ' ' LYS . 4.6 tm-20 -92.55 122.9 35.44 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.588 1.555 . . . . 0.0 110.121 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -120.01 132.24 55.41 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.869 0.842 . . . . 0.0 112.333 169.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.554 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -75.13 -42.01 57.17 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.269 1.827 . . . . 0.0 112.584 -177.017 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.329 0.0 OUTLIER -110.01 -122.46 0.27 Allowed 'General case' 0 CA--C 1.544 0.729 0 CA-C-O 116.887 -1.53 . . . . 0.0 110.215 169.068 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 48.9 m -144.07 -25.31 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-N 120.847 1.658 . . . . 0.0 114.752 -172.126 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.47 -17.8 6.9 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 120.45 -1.406 . . . . 0.0 114.108 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -150.69 4.86 Favored Glycine 0 CA--C 1.542 1.755 1 C-N-CA 131.0 4.143 . . . . 0.0 114.104 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -88.41 156.71 6.62 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.296 2.664 . . . . 0.0 114.365 -168.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.14 134.48 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.763 1.225 . . . . 0.0 109.632 -173.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -97.58 126.0 42.63 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.229 1.411 . . . . 0.0 109.902 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.6 t -123.8 122.39 64.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 C-N-CA 126.587 1.955 . . . . 0.0 109.146 -170.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -146.9 150.27 34.89 Favored 'General case' 0 C--O 1.24 0.57 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -178.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.59 -153.13 23.43 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.834 1.683 . . . . 0.0 111.039 -169.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.1 p -158.57 143.35 16.09 Favored 'General case' 0 C--O 1.238 0.485 0 O-C-N 121.794 -0.827 . . . . 0.0 113.097 -169.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.44 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -109.13 106.2 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 125.251 1.42 . . . . 0.0 109.616 173.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -111.29 144.59 40.23 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.704 2.002 . . . . 0.0 110.549 -167.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.01 -24.04 24.08 Favored Glycine 0 N--CA 1.475 1.241 0 C-N-CA 126.566 2.031 . . . . 0.0 112.108 -171.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.4 mp -68.13 111.45 4.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.254 1.822 . . . . 0.0 107.644 168.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.4 t -68.78 -27.32 65.78 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.259 1.577 . . . . 0.0 115.259 -169.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 178.58 -175.4 0.19 Allowed 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 130.744 3.617 . . . . 0.0 106.549 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.54 159.81 35.41 Favored Glycine 0 N--CA 1.469 0.845 0 C-N-CA 126.263 1.887 . . . . 0.0 116.038 167.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.8 mt -70.45 132.61 45.84 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.827 1.251 . . . . 0.0 109.008 168.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -129.52 120.08 24.78 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.409 1.483 . . . . 0.0 107.253 177.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.13 164.47 36.48 Favored Glycine 0 N--CA 1.475 1.245 0 CA-C-O 117.619 -1.656 . . . . 0.0 111.563 176.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.25 1.6 p90 -156.06 111.32 2.94 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 120.989 2.394 . . . . 0.0 113.569 169.23 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -122.14 147.08 46.59 Favored 'General case' 0 CA--C 1.551 0.991 0 O-C-N 119.979 -1.701 . . . . 0.0 111.082 -172.124 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -82.31 120.63 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -71.12 111.85 6.81 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.43 -2.433 . . . . 0.0 104.43 168.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.478 ' H ' ' HA ' ' A' ' 63' ' ' HIS . 16.8 tt0 -64.39 116.86 6.5 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.148 -174.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.353 50.3 m-85 101.31 160.57 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 131.567 3.947 . . . . 0.0 113.708 -178.089 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.18 -14.7 55.63 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 114.746 -1.115 . . . . 0.0 114.48 -172.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG11 ' B' ' 5' ' ' VAL . 5.0 m-20 -71.93 54.9 0.28 Allowed 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 128.887 2.875 . . . . 0.0 113.134 -169.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -170.33 -42.34 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 119.539 3.163 . . . . 0.0 119.539 -168.728 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.298 0.9 OUTLIER 49.75 -58.99 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 129.115 2.966 . . . . 0.0 117.339 -169.775 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 22.44 0.82 Allowed 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 127.748 2.419 . . . . 0.0 114.596 -171.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.41 -127.82 44.4 Favored Glycine 0 C--N 1.336 0.553 0 C-N-CA 125.49 1.519 . . . . 0.0 110.878 172.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.5 m -56.56 -10.37 0.96 Allowed 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.08 1.85 22.73 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 125.251 1.42 . . . . 0.0 112.623 171.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 9.0 t -164.94 -156.52 0.31 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 129.532 3.133 . . . . 0.0 106.361 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 74.88 -169.09 0.1 Allowed 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 123.761 1.743 . . . . 0.0 115.147 166.117 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.68 155.43 16.08 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 127.151 2.31 . . . . 0.0 108.735 166.59 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -75.61 76.43 3.63 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 123.924 3.083 . . . . 0.0 108.293 171.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.478 ' HA ' ' H ' ' A' ' 49' ' ' GLU . 16.2 p-80 47.27 72.39 0.25 Allowed 'General case' 0 C--O 1.236 0.351 0 C-N-CA 127.261 2.225 . . . . 0.0 112.674 167.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -40.84 141.22 0.61 Allowed 'General case' 0 C--O 1.221 -0.395 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.603 -174.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -101.3 67.48 0.06 OUTLIER Pre-proline 0 CA--C 1.549 0.938 0 CA-C-N 114.195 -1.366 . . . . 0.0 113.527 175.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -65.13 -18.47 61.57 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 121.829 1.686 . . . . 0.0 112.593 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -77.97 -5.11 50.18 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.188 1.395 . . . . 0.0 113.523 170.078 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.6 t 60.78 53.41 3.92 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 127.01 2.124 . . . . 0.0 112.177 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 -139.3 175.35 9.63 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 -167.111 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.546 ' H ' ' HE3' ' A' ' 70' ' ' LYS . 0.5 OUTLIER -76.68 158.89 30.67 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.353 1.461 . . . . 0.0 112.017 173.179 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.467 ' ND1' ' CD2' ' A' ' 63' ' ' HIS . 86.0 t60 -79.4 147.92 32.18 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.481 -0.781 . . . . 0.0 112.469 168.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.467 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 155.64 -111.93 0.5 Allowed Glycine 0 C--N 1.339 0.701 0 CA-C-O 118.029 -1.429 . . . . 0.0 114.09 167.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.11 -85.88 0.39 Allowed Glycine 0 CA--C 1.537 1.446 0 CA-C-O 117.486 -1.73 . . . . 0.0 114.6 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -55.54 -6.88 1.1 Allowed 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 124.458 3.438 . . . . 0.0 116.869 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -155.89 9.97 0.27 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 128.585 2.754 . . . . 0.0 112.238 -176.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.467 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.6 OUTLIER -146.74 109.9 4.75 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 128.533 2.733 . . . . 0.0 109.624 179.106 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -64.35 -9.26 16.73 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 127.848 2.459 . . . . 0.0 114.719 -175.001 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -81.44 -91.83 0.06 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.76 0.824 . . . . 0.0 110.402 177.441 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.8 ttp-105 78.72 118.45 0.06 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.164 1.785 . . . . 0.0 111.141 171.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m80 -55.79 160.83 2.44 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.278 -1.514 . . . . 0.0 113.831 175.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.8 t -53.16 -50.74 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 121.047 1.749 . . . . 0.0 112.229 -170.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.7 3.06 Favored Glycine 0 C--N 1.341 0.833 0 N-CA-C 108.491 -1.844 . . . . 0.0 108.491 169.072 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -157.45 118.56 3.6 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.529 1.531 . . . . 0.0 109.512 179.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -105.16 165.57 11.0 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 126.099 1.76 . . . . 0.0 109.726 169.001 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.81 -136.77 8.57 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 125.249 1.404 . . . . 0.0 112.792 177.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.64 158.17 20.33 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 117.025 2.231 . . . . 0.0 117.025 -174.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.3 m -106.97 173.9 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 128.705 2.802 . . . . 0.0 110.188 167.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 t -141.74 141.27 33.25 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 125.552 1.541 . . . . 0.0 108.383 169.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.69 150.67 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 125.221 1.408 . . . . 0.0 111.589 178.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -100.64 158.79 15.68 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.884 1.673 . . . . 0.0 112.128 173.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -50.28 -21.93 1.58 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 129.099 2.959 . . . . 0.0 115.815 -169.302 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.26 0.94 54.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 128.58 2.752 . . . . 0.0 110.716 -172.277 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.32 32.05 6.24 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-O 117.477 -1.735 . . . . 0.0 114.052 173.552 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.2 p -155.66 133.53 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 117.512 2.412 . . . . 0.0 117.512 -171.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.65 129.22 40.02 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 163.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -88.59 145.49 25.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 168.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.7 t -131.85 122.27 49.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 113.251 -1.795 . . . . 0.0 107.934 167.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -146.35 58.81 1.21 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 127.687 2.395 . . . . 0.0 107.582 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 29.7 mt -116.77 155.65 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.498 1.519 . . . . 0.0 112.125 -166.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -135.99 130.24 33.3 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 167.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -132.69 144.71 50.5 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 125.353 1.461 . . . . 0.0 110.256 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.6 p -125.28 59.42 1.25 Allowed 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.276 1.431 . . . . 0.0 112.752 -167.59 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -156.31 -48.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 C-N-CA 123.008 0.523 . . . . 0.0 110.683 -174.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -82.32 158.79 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 164.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.2 p -160.24 168.85 24.46 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.064 1.345 . . . . 0.0 109.355 -175.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.3 mp -100.64 54.06 0.87 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.0 t -76.09 4.32 8.73 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 114.98 1.474 . . . . 0.0 114.98 -167.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 138.18 -86.83 0.22 Allowed Glycine 0 N--CA 1.462 0.39 0 N-CA-C 106.592 -2.603 . . . . 0.0 106.592 -169.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.99 -6.11 0.77 Allowed 'General case' 0 C--O 1.219 -0.526 0 C-N-CA 123.761 0.824 . . . . 0.0 113.199 168.759 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -73.03 -33.17 65.56 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 120.29 -1.506 . . . . 0.0 110.617 -165.112 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.0 p -105.78 -8.56 17.71 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 117.448 2.388 . . . . 0.0 117.448 -169.112 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.273 3.7 pt 176.69 -39.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 C-N-CA 127.698 2.399 . . . . 0.0 115.582 167.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.3 mm -49.47 125.03 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-N 121.605 2.002 . . . . 0.0 111.024 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.67 -7.01 66.87 Favored Glycine 0 CA--C 1.534 1.241 0 C-N-CA 125.766 1.65 . . . . 0.0 116.092 176.074 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.5 176.03 10.14 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.814 1.646 . . . . 0.0 110.622 170.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.1 t -132.97 129.03 37.69 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 120.185 1.357 . . . . 0.0 113.078 -174.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.2 tp -101.96 125.48 48.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.771 2.029 . . . . 0.0 109.523 -170.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -110.98 135.19 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 124.526 1.131 . . . . 0.0 109.595 174.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.581 HG13 HD22 ' A' ' 144' ' ' LEU . 2.2 p -92.63 141.51 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 C-N-CA 124.991 1.316 . . . . 0.0 109.088 168.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -112.95 168.42 9.71 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.097 2.559 . . . . 0.0 113.112 -168.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -86.61 -46.71 9.85 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 -168.183 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -99.9 -176.33 3.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 120.091 -1.631 . . . . 0.0 110.198 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.71 154.16 7.22 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 165.347 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 p30 -99.25 140.78 32.91 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.68 1.229 . . . . 0.0 110.792 167.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -78.62 -36.57 43.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 127.422 2.289 . . . . 0.0 112.213 -169.046 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 23.1 mt 55.82 47.83 19.44 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.717 1.207 . . . . 0.0 110.596 173.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 138.52 -62.25 0.57 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.415 -1.214 . . . . 0.0 115.9 171.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.39 87.39 1.31 Allowed 'General case' 0 CA--C 1.552 1.021 1 N-CA-C 122.417 4.229 . . . . 0.0 122.417 -166.5 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.71 -86.99 0.61 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 105.948 -2.861 . . . . 0.0 105.948 163.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -167.31 34.08 0.21 Allowed Glycine 0 N--CA 1.47 0.935 0 CA-C-O 119.03 -0.872 . . . . 0.0 114.827 171.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -164.05 150.34 11.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 119.513 1.657 . . . . 0.0 108.899 -167.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -48.3 -46.99 36.88 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.607 0.763 . . . . 0.0 112.275 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -50.51 -27.84 7.37 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 116.04 1.867 . . . . 0.0 116.04 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.1 p -53.25 -28.06 25.54 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-N 120.857 1.662 . . . . 0.0 112.656 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.9 t -113.51 -29.16 7.27 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 115.195 1.554 . . . . 0.0 115.195 170.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -67.65 -23.32 65.32 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 119.986 1.266 . . . . 0.0 113.355 178.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.9 p -141.11 -32.91 0.54 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.228 1.411 . . . . 0.0 114.236 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.39 5.16 49.39 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.587 1.565 . . . . 0.0 110.466 -164.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 51.53 30.99 6.96 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 127.311 2.244 . . . . 0.0 114.632 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.05 19.47 0.04 OUTLIER 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 118.06 2.615 . . . . 0.0 118.06 -166.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.62 8.05 37.64 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 119.437 2.535 . . . . 0.0 119.437 167.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 28.9 t 139.2 -178.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 1 C-N-CA 131.952 4.101 . . . . 0.0 111.183 170.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.08 154.22 37.62 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 126.18 1.792 . . . . 0.0 112.836 173.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.581 HD22 HG13 ' A' ' 119' ' ' VAL 0.349 0.0 OUTLIER -133.31 -127.2 0.17 Allowed 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.972 2.109 . . . . 0.0 107.868 167.104 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.05 147.77 46.2 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.068 1.304 . . . . 0.0 114.472 -166.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.7 p -137.42 147.63 45.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.612 1.565 . . . . 0.0 113.952 176.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.61 142.43 8.41 Favored Glycine 0 N--CA 1.473 1.165 0 C-N-CA 124.621 1.105 . . . . 0.0 114.238 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 87.6 t -76.27 150.43 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 C-N-CA 124.725 1.21 . . . . 0.0 110.246 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.9 mm -81.31 83.69 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 O-C-N 121.562 -0.711 . . . . 0.0 109.721 173.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.72 -169.01 43.59 Favored Glycine 0 N--CA 1.474 1.231 0 C-N-CA 126.849 2.166 . . . . 0.0 112.912 175.414 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -142.74 155.39 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 115.324 1.602 . . . . 0.0 115.324 -168.329 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.84 -15.11 14.46 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.567 1.547 . . . . 0.0 112.844 169.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.476 0.85 0 C-N-CA 130.057 3.343 . . . . 0.0 109.117 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.775 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 17.2 m -78.19 77.03 4.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.713 1.205 . . . . 0.0 111.425 -168.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.259 17.3 pttm -81.13 130.49 35.05 Favored 'General case' 0 CA--C 1.547 0.85 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -174.107 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.38 172.42 12.76 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 127.744 2.417 . . . . 0.0 111.288 -176.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.511 HG11 ' HA ' ' A' ' 52' ' ' ASP . 7.0 p -148.38 146.81 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.41 1.084 . . . . 0.0 112.734 -166.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.16 96.56 2.9 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-O 122.516 1.151 . . . . 0.0 108.799 168.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 53.1 t -79.64 96.82 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 104.878 -2.267 . . . . 0.0 104.878 166.071 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.65 114.94 17.0 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 77.0 tttt -160.76 131.34 5.31 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.465 1.484 . . . . 0.0 114.747 -175.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -162.04 -35.16 0.02 OUTLIER Glycine 0 N--CA 1.474 1.204 0 C-N-CA 125.232 1.396 . . . . 0.0 111.519 168.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -77.26 58.38 1.61 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 130.98 3.712 . . . . 0.0 113.075 175.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.91 -96.39 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 C-N-CA 129.184 3.278 . . . . 0.0 115.569 169.085 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.94 -16.45 14.32 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.134 3.223 . . . . 0.0 113.91 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -86.37 141.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-N 119.698 1.135 . . . . 0.0 109.105 174.235 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -157.12 161.03 39.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.758 1.223 . . . . 0.0 110.629 167.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.05 99.92 0.79 Allowed Glycine 0 C--O 1.222 -0.632 0 C-N-CA 126.073 1.797 . . . . 0.0 110.694 173.419 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -87.64 93.61 4.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 118.983 1.391 . . . . 0.0 108.425 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 pp -113.88 152.73 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.96 1.362 . . . . 0.0 111.821 171.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -123.29 175.79 6.49 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.761 1.224 . . . . 0.0 110.262 175.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -140.1 139.77 35.92 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.249 1.019 . . . . 0.0 109.371 168.516 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -134.28 131.73 38.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 168.382 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -125.71 141.09 52.19 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 122.069 0.938 . . . . 0.0 109.962 174.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 6.6 mtmm -84.51 -31.16 24.62 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 125.686 1.594 . . . . 0.0 110.774 -174.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -123.28 -164.56 1.22 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 128.938 2.895 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 36.7 p -106.97 -37.17 6.41 Favored 'General case' 0 N--CA 1.472 0.674 0 O-C-N 120.719 -1.238 . . . . 0.0 110.617 166.403 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -112.79 5.07 17.36 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.391 1.476 . . . . 0.0 114.023 -175.319 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.46 -178.01 37.05 Favored Glycine 0 CA--C 1.54 1.649 0 CA-C-O 118.692 -1.06 . . . . 0.0 112.448 172.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.81 157.7 54.62 Favored 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 123.026 2.484 . . . . 0.0 113.552 -176.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 94.2 t -120.37 136.03 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 126.555 1.942 . . . . 0.0 110.93 -170.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.3 mptt -79.23 118.84 21.54 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.417 0.627 . . . . 0.0 111.733 169.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.3 124.92 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 125.549 1.54 . . . . 0.0 107.252 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -151.28 160.83 43.6 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 123.156 0.582 . . . . 0.0 112.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.32 175.58 13.91 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 123.846 0.736 . . . . 0.0 113.65 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 43.7 p -119.77 124.05 45.22 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 115.068 1.507 . . . . 0.0 115.068 -166.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.556 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.0 mm -90.65 123.37 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 CA-C-O 116.878 -1.534 . . . . 0.0 109.973 168.633 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.2 tttt -132.82 132.64 42.39 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 122.219 2.282 . . . . 0.0 111.677 175.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.75 -9.76 6.07 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 127.42 2.438 . . . . 0.0 114.293 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.426 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.7 OUTLIER -91.3 168.2 11.75 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.62 1.568 . . . . 0.0 112.535 173.332 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.8 t -77.28 166.93 22.55 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.811 0.844 . . . . 0.0 111.241 169.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -67.41 -172.84 0.25 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 125.742 1.617 . . . . 0.0 115.204 -173.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.14 -172.75 54.25 Favored Glycine 0 N--CA 1.477 1.378 0 C-N-CA 124.568 1.08 . . . . 0.0 114.009 176.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 54.2 mt -66.95 144.16 56.39 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 120.67 -1.488 . . . . 0.0 110.202 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -133.25 130.42 38.99 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.679 1.192 . . . . 0.0 109.905 170.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.99 152.01 51.2 Favored Glycine 0 N--CA 1.468 0.828 0 C-N-CA 124.644 1.116 . . . . 0.0 112.21 179.403 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.514 ' CE1' HD21 ' B' ' 117' ' ' LEU . 2.8 t80 -148.73 105.29 3.55 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 117.508 0.654 . . . . 0.0 109.979 -169.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.433 ' CD2' ' CD2' ' B' ' 63' ' ' HIS . 0.5 OUTLIER -143.84 158.3 43.78 Favored 'General case' 0 CA--C 1.54 0.57 0 O-C-N 120.538 -1.351 . . . . 0.0 109.847 -175.836 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.84 126.89 64.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 C-N-CA 126.051 1.74 . . . . 0.0 108.715 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 14.3 m-70 -77.18 116.85 18.16 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 168.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.86 162.21 29.77 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -168.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.4 t80 68.72 177.01 0.26 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 125.647 1.579 . . . . 0.0 111.879 -173.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.96 0.43 9.86 Favored Glycine 0 N--CA 1.469 0.878 0 CA-C-O 118.881 -0.955 . . . . 0.0 114.177 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.868 ' HA ' HG11 ' A' ' 5' ' ' VAL . 4.1 t0 -86.72 51.21 2.17 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.018 1.327 . . . . 0.0 108.725 -177.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 179.63 34.84 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.109 0 N-CA-C 116.186 1.921 . . . . 0.0 116.186 -166.775 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.44 ' H ' HG23 ' B' ' 54' ' ' THR . 5.5 p . . . . . 0 CA--C 1.551 1.015 0 C-N-CA 131.518 3.927 . . . . 0.0 120.591 -170.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.575 0 CA-C-O 122.631 1.205 . . . . 0.0 113.954 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.61 -158.97 32.54 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 125.871 1.7 . . . . 0.0 115.985 -169.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -74.56 -174.84 1.99 Allowed 'Trans proline' 0 CA--C 1.537 0.67 1 C-N-CA 126.239 4.626 . . . . 0.0 114.35 -169.074 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.785 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -65.14 96.58 0.21 Allowed 'General case' 0 N--CA 1.445 -0.689 1 C-N-CA 132.648 4.379 . . . . 0.0 109.166 -176.651 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -56.5 146.86 23.45 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 123.953 1.835 . . . . 0.0 109.998 174.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 48.8 p-10 -107.72 57.81 0.22 Allowed Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 -176.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.57 -20.23 53.8 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.285 1.99 . . . . 0.0 111.74 169.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.0 mp -77.02 -3.88 41.31 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.925 1.29 . . . . 0.0 112.392 169.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t 57.61 87.73 0.06 Allowed 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 127.995 2.518 . . . . 0.0 113.027 174.172 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 69' ' ' ARG . . . . . 0.404 ' HD3' ' C ' ' B' ' 78' ' ' GLU . 13.0 ptp180 179.17 176.62 0.58 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -169.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -84.14 176.93 8.45 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 128.111 2.565 . . . . 0.0 107.869 166.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.412 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 12.8 t60 -57.78 174.03 0.27 Allowed 'General case' 0 CA--C 1.546 0.791 0 O-C-N 120.39 -1.443 . . . . 0.0 111.813 169.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.83 -175.31 32.18 Favored Glycine 0 N--CA 1.465 0.599 0 O-C-N 121.272 -0.893 . . . . 0.0 113.427 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 136.37 -128.24 4.44 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 117.961 -1.466 . . . . 0.0 112.316 -170.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -48.0 -11.32 0.11 Allowed 'Trans proline' 0 CA--C 1.542 0.895 1 C-N-CA 126.009 4.473 . . . . 0.0 119.793 -172.042 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.65 -5.67 5.2 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 120.759 1.618 . . . . 0.0 114.157 169.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -126.48 178.19 6.02 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 127.401 2.28 . . . . 0.0 109.819 -168.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -106.72 -20.31 13.39 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.548 1.539 . . . . 0.0 111.989 -177.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 78' ' ' GLU . . . . . 0.404 ' C ' ' HD3' ' B' ' 69' ' ' ARG . 25.9 mt-10 -78.15 -92.32 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.695 0 O-C-N 121.06 -1.025 . . . . 0.0 113.204 -167.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 54.7 ttt180 78.38 93.61 0.06 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 126.328 1.851 . . . . 0.0 113.744 169.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -51.94 160.75 0.67 Allowed 'General case' 0 N--CA 1.481 1.101 0 O-C-N 119.974 -1.704 . . . . 0.0 112.594 166.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 p -68.04 -27.97 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 CA-C-N 121.229 1.831 . . . . 0.0 111.483 176.205 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -70.8 18.26 0.82 Allowed Glycine 0 CA--C 1.538 1.491 0 CA-C-O 117.109 -1.94 . . . . 0.0 116.277 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -121.04 110.51 16.33 Favored 'General case' 0 CA--C 1.55 0.951 0 CA-C-N 121.891 2.845 . . . . 0.0 112.312 -178.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -113.08 46.17 1.27 Allowed 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 123.361 1.553 . . . . 0.0 112.289 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.93 -141.24 45.32 Favored Glycine 0 CA--C 1.536 1.347 0 CA-C-N 114.054 -1.43 . . . . 0.0 115.499 169.418 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -116.15 140.16 49.58 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.722 1.209 . . . . 0.0 111.021 172.331 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -91.34 172.87 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 162.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -140.53 142.96 35.15 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 120.85 -1.156 . . . . 0.0 109.796 173.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 95' ' ' ALA . . . -118.95 157.87 26.86 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.555 1.542 . . . . 0.0 113.187 -169.255 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -107.55 162.46 13.93 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 127.439 2.295 . . . . 0.0 112.543 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.768 ' HE2' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -63.66 -12.81 37.0 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.31 1.444 . . . . 0.0 114.333 173.757 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -70.45 -14.94 62.74 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-O 121.707 0.765 . . . . 0.0 109.93 171.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.16 9.23 55.98 Favored Glycine 0 C--N 1.337 0.625 0 C-N-CA 126.593 2.044 . . . . 0.0 112.848 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.2 p -110.39 138.62 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 125.164 1.385 . . . . 0.0 114.39 -178.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 89' ' ' ALA . . . -111.65 97.13 6.5 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.598 1.959 . . . . 0.0 106.284 165.759 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -98.74 154.61 17.85 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.677 0.751 . . . . 0.0 111.089 174.25 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -150.66 150.95 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 116.231 1.938 . . . . 0.0 116.231 -173.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 51.6 p -157.46 105.83 2.09 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 124.226 1.01 . . . . 0.0 112.276 169.171 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 16.3 mt -136.85 151.56 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 126.969 2.108 . . . . 0.0 111.116 -178.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -109.43 107.29 17.38 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 167.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -96.87 138.16 34.85 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 127.285 2.234 . . . . 0.0 112.97 -176.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 82.5 p -108.05 49.93 0.79 Allowed 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 66.8 t -145.35 -44.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-O 118.585 -0.721 . . . . 0.0 112.231 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.94 162.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 120.148 1.34 . . . . 0.0 111.534 170.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.54 ' H ' ' HB3' ' B' ' 111' ' ' SER . 90.2 p -157.4 149.63 22.69 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 125.678 1.591 . . . . 0.0 109.776 -175.053 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 60.01 4.22 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.436 . . . . 0.0 107.496 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.3 t -115.89 8.52 14.75 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -168.23 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.02 -49.65 4.01 Favored Glycine 0 N--CA 1.472 1.08 0 O-C-N 120.768 -1.207 . . . . 0.0 114.937 168.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -116.67 -58.68 2.05 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 119.074 1.437 . . . . 0.0 112.331 -170.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -83.21 5.26 23.5 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 125.433 1.493 . . . . 0.0 112.506 -171.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 111' ' ' SER . . . . . 0.54 ' HB3' ' H ' ' B' ' 105' ' ' SER . 61.3 m -158.27 -115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.08 0.952 . . . . 0.0 112.668 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 38.6 pt -112.26 169.14 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 120.493 1.497 . . . . 0.0 112.408 -178.02 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.2 mm 91.24 117.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 1 C-N-CA 132.259 4.224 . . . . 0.0 105.641 -162.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.35 12.3 72.61 Favored Glycine 0 CA--C 1.534 1.238 0 CA-C-O 117.611 -1.661 . . . . 0.0 115.502 -176.599 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.82 169.03 10.78 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.585 2.193 . . . . 0.0 109.135 169.105 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . 0.261 13.3 t -131.7 113.5 13.64 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 123.417 2.826 . . . . 0.0 114.698 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.514 HD21 ' CE1' ' B' ' 45' ' ' PHE . 22.4 tp -88.49 140.67 29.23 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.474 1.91 . . . . 0.0 110.91 -169.464 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -127.07 142.62 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 124.065 0.946 . . . . 0.0 111.301 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.31 140.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 122.322 1.058 . . . . 0.0 110.097 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -102.96 148.59 25.48 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.834 -172.247 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.262 2.9 pp20? -80.05 -7.45 58.86 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 121.028 -1.045 . . . . 0.0 113.24 -170.267 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 58.2 mttp -126.66 176.44 7.22 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.824 2.05 . . . . 0.0 110.926 168.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -59.29 148.15 33.16 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.383 1.473 . . . . 0.0 111.278 169.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -91.41 138.08 31.86 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 167.465 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.68 -32.25 65.67 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 177.267 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.9 mt 66.62 66.24 0.45 Allowed 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.58 1.952 . . . . 0.0 111.284 169.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 149.13 -96.65 0.17 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 123.837 0.732 . . . . 0.0 111.311 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.465 ' HA ' ' HB3' ' B' ' 134' ' ' SER . 31.4 tttt -157.49 119.61 3.78 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.876 2.07 . . . . 0.0 110.906 167.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.14 -75.68 0.62 Allowed Glycine 0 CA--C 1.527 0.834 0 C-N-CA 126.382 1.944 . . . . 0.0 109.594 168.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -154.89 -12.22 0.06 OUTLIER Glycine 0 N--CA 1.47 0.954 0 N-CA-C 116.344 1.297 . . . . 0.0 116.344 175.136 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -109.53 -141.85 0.38 Allowed 'General case' 0 CA--C 1.548 0.881 0 CA-C-N 119.317 1.558 . . . . 0.0 110.03 -167.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -117.73 -48.74 2.56 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 120.619 1.554 . . . . 0.0 111.369 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -46.62 -32.3 3.4 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.412 1.885 . . . . 0.0 112.411 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' B' ' 128' ' ' LYS . 0.4 OUTLIER -49.21 -44.35 43.22 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 127.602 2.361 . . . . 0.0 113.041 169.723 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -95.15 -34.12 12.38 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 173.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -31.81 73.09 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.782 -1.199 . . . . 0.0 113.486 176.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 82.7 p -137.03 -27.1 1.0 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 116.759 -1.591 . . . . 0.0 114.612 -173.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.19 -2.79 31.31 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.668 1.127 . . . . 0.0 113.861 -168.331 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 12.9 t-20 55.89 9.96 0.51 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 126.279 1.831 . . . . 0.0 113.179 -169.219 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.36 24.96 0.02 OUTLIER 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 127.938 2.495 . . . . 0.0 116.826 -167.05 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.16 -139.17 19.52 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 126.555 2.026 . . . . 0.0 113.905 178.643 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.4 t -80.93 -148.16 0.06 Allowed 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.979 1.712 . . . . 0.0 109.6 168.708 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -140.71 155.81 46.37 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 120.353 -1.467 . . . . 0.0 110.098 172.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.501 HD12 ' H ' ' B' ' 145' ' ' ALA . 0.7 OUTLIER -109.72 -129.9 0.3 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 165.935 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.501 ' H ' HD12 ' B' ' 144' ' ' LEU . . . -61.68 144.97 53.73 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.552 1.541 . . . . 0.0 113.823 -170.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.8 p -138.42 151.32 47.35 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 126.194 1.797 . . . . 0.0 113.135 176.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.0 139.53 6.02 Favored Glycine 0 N--CA 1.471 0.997 0 O-C-N 120.989 -1.069 . . . . 0.0 114.239 -176.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.4 t -77.98 145.96 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.045 0.938 . . . . 0.0 109.605 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 54.6 mt -81.36 90.47 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.293 1.037 . . . . 0.0 109.781 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.18 -171.45 45.55 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 126.39 1.948 . . . . 0.0 111.952 171.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.48 ' H ' HD12 ' B' ' 151' ' ' ILE . 0.8 OUTLIER -127.58 124.46 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 115.737 1.755 . . . . 0.0 115.737 -167.641 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.19 0.08 47.01 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.965 2.106 . . . . 0.0 112.593 167.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 131.019 3.728 . . . . 0.0 115.692 -169.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.4 p . . . . . 0 N--CA 1.468 0.425 0 N-CA-C 117.725 2.491 . . . . 0.0 117.725 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -165.43 101.94 0.72 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.783 1.633 . . . . 0.0 108.855 168.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.501 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -75.3 176.05 7.78 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 119.864 1.211 . . . . 0.0 111.482 173.446 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.654 HG21 ' HA ' ' B' ' 52' ' ' ASP . 1.4 p -153.63 117.49 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 127.225 2.21 . . . . 0.0 106.897 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.24 107.29 18.29 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.349 1.06 . . . . 0.0 109.74 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.0 t -76.09 79.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.226 1.01 . . . . 0.0 108.406 174.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -76.99 92.41 3.7 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 173.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 ttpp -157.91 119.68 3.64 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.897 0.879 . . . . 0.0 110.814 171.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.57 -102.28 0.54 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 106.663 -2.575 . . . . 0.0 106.663 166.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.98 109.86 5.07 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 125.938 1.695 . . . . 0.0 107.282 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.38 177.03 14.69 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 123.844 0.735 . . . . 0.0 114.209 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -68.37 20.76 0.13 Allowed 'Trans proline' 0 CA--C 1.542 0.89 1 C-N-CA 126.15 4.567 . . . . 0.0 116.696 -169.063 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 144' ' ' LEU . 1.4 t -128.34 128.46 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 CA-C-N 120.447 1.476 . . . . 0.0 109.508 -174.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -144.19 172.74 12.49 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.829 0.823 . . . . 0.0 112.657 -176.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.16 165.79 31.36 Favored Glycine 0 CA--C 1.509 -0.282 0 CA-C-N 112.828 -1.987 . . . . 0.0 112.947 167.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.469 HG13 ' H ' ' A' ' 34' ' ' SER . 7.8 pt -139.83 52.98 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 113.22 -1.49 . . . . 0.0 112.024 -167.007 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -80.47 105.7 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 O-C-N 120.418 -1.426 . . . . 0.0 111.079 -169.084 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -83.0 156.28 23.5 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.506 1.522 . . . . 0.0 110.613 173.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.501 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 66.1 m-85 -143.43 97.92 3.16 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.462 1.505 . . . . 0.0 109.677 175.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.72 136.32 37.38 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 119.884 -1.76 . . . . 0.0 107.202 173.393 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -152.91 -175.81 5.48 Favored 'General case' 0 CA--C 1.553 1.075 0 C-N-CA 127.78 2.432 . . . . 0.0 105.887 176.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.52 -15.29 0.49 Allowed 'General case' 0 CA--C 1.549 0.94 0 O-C-N 118.452 -2.655 . . . . 0.0 116.225 167.144 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -108.76 -174.27 2.47 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 127.869 2.468 . . . . 0.0 111.346 -174.095 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.3 p -81.33 -21.89 38.86 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 120.528 -1.358 . . . . 0.0 112.888 167.461 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -161.67 46.38 0.18 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.629 1.171 . . . . 0.0 113.399 -168.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.73 175.69 16.04 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 125.243 1.401 . . . . 0.0 110.637 169.429 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -74.67 157.95 43.78 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.032 1.821 . . . . 0.0 111.511 -169.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.5 t -131.3 149.4 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 125.097 1.359 . . . . 0.0 111.482 -167.202 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -116.51 103.74 10.72 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 123.641 0.776 . . . . 0.0 110.575 -175.175 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.5 t -80.22 119.85 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 126.834 2.054 . . . . 0.0 107.63 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 1.7 p90 -153.9 167.87 28.25 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.0 -155.75 15.93 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -170.798 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.469 ' H ' HG13 ' A' ' 17' ' ' ILE . 63.8 p -155.96 170.5 21.99 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 122.029 0.918 . . . . 0.0 113.345 -169.368 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.68 134.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 126.497 1.919 . . . . 0.0 107.256 169.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.18 150.23 33.39 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 121.63 2.013 . . . . 0.0 113.913 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.27 5.08 46.78 Favored Glycine 0 CA--C 1.539 1.581 0 C-N-CA 126.437 1.97 . . . . 0.0 112.285 -168.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -71.86 163.89 27.02 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.906 2.082 . . . . 0.0 111.055 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.5 t -81.32 155.81 25.83 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 164.313 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 74.7 tt0 -53.03 145.22 13.46 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.37 1.068 . . . . 0.0 111.349 169.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.09 -175.3 26.0 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 124.787 1.184 . . . . 0.0 114.146 -177.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -76.12 146.96 38.9 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 128.321 2.648 . . . . 0.0 114.464 -169.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -148.11 123.89 10.56 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.193 2.597 . . . . 0.0 109.911 -174.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.56 155.87 51.55 Favored Glycine 0 N--CA 1.479 1.512 0 CA-C-O 118.028 -1.429 . . . . 0.0 113.169 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.79 139.91 16.49 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 119.957 1.879 . . . . 0.0 114.375 172.285 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 9.0 p-80 -153.34 153.8 33.29 Favored 'General case' 0 CA--C 1.547 0.862 0 O-C-N 121.5 -0.75 . . . . 0.0 111.936 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -98.36 112.44 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 123.946 0.899 . . . . 0.0 109.119 174.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -82.43 149.78 27.44 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 174.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -66.84 10.74 0.12 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 126.329 1.851 . . . . 0.0 114.304 -178.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -119.55 97.54 5.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 106.949 -1.501 . . . . 0.0 106.949 -169.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.24 -10.36 74.04 Favored Glycine 0 C--N 1.331 0.291 0 CA-C-O 117.885 -1.508 . . . . 0.0 111.17 166.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.595 ' HA ' HG21 ' B' ' 5' ' ' VAL . 12.8 t0 -73.7 123.25 23.73 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 104.381 -2.451 . . . . 0.0 104.381 164.166 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.487 ' H ' HG23 ' A' ' 54' ' ' THR 0.312 5.7 p-10 -147.35 51.09 1.07 Allowed 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 123.782 1.753 . . . . 0.0 112.724 168.486 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.487 HG23 ' H ' ' A' ' 53' ' ' ASN . 11.4 p -120.29 -23.89 6.08 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 112.173 -2.285 . . . . 0.0 112.755 -164.442 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -95.95 22.79 7.01 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.887 0.875 . . . . 0.0 111.603 168.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.76 -123.24 21.8 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 125.537 1.541 . . . . 0.0 111.913 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.7 p -67.49 -12.7 60.95 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 113.868 1.062 . . . . 0.0 113.868 173.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.69 39.24 0.61 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.412 1.485 . . . . 0.0 110.878 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 172.09 -55.37 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.39 2.276 . . . . 0.0 111.596 -169.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -97.54 153.39 18.2 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.73 -31.38 8.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 116.424 -2.32 . . . . 0.0 117.44 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -103.34 163.38 0.25 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 CA-C-N 122.124 2.962 . . . . 0.0 111.523 171.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.491 ' HE1' ' HA ' ' A' ' 137' ' ' THR . 0.6 OUTLIER -137.24 107.78 6.53 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.558 1.143 . . . . 0.0 112.4 -166.678 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -58.97 154.66 14.93 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 114.141 -1.391 . . . . 0.0 111.998 169.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -119.7 77.68 21.29 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 127.712 2.405 . . . . 0.0 113.713 -170.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -63.64 -20.34 69.02 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.998 2.466 . . . . 0.0 113.445 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 53.6 mt -82.81 -2.49 54.7 Favored 'General case' 0 CA--C 1.543 0.685 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 170.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t 62.77 59.29 1.44 Allowed 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.611 1.564 . . . . 0.0 113.343 175.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.0 ptt180 -161.54 178.44 9.08 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -174.688 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.88 164.4 23.83 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 127.032 2.133 . . . . 0.0 110.006 173.66 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -62.88 168.23 4.08 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.735 0.814 . . . . 0.0 110.874 167.179 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 140.69 -156.0 25.12 Favored Glycine 0 N--CA 1.464 0.528 0 CA-C-O 119.11 -0.828 . . . . 0.0 113.808 171.198 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 -64.51 0.53 Allowed Glycine 0 CA--C 1.542 1.728 0 N-CA-C 117.924 1.93 . . . . 0.0 117.924 176.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -69.47 -19.46 37.47 Favored 'Trans proline' 0 C--N 1.349 0.6 0 CA-C-N 121.197 2.499 . . . . 0.0 114.722 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -134.66 -3.53 2.61 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 124.057 0.943 . . . . 0.0 112.758 179.319 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.56 147.81 50.73 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 128.344 2.658 . . . . 0.0 107.867 -173.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.427 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 0.0 OUTLIER -100.66 -11.99 19.55 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 130.77 3.628 . . . . 0.0 112.67 -167.631 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -81.47 -94.04 0.05 OUTLIER 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.996 1.718 . . . . 0.0 106.992 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.615 HH12 HG11 ' A' ' 103' ' ' VAL . 47.5 ttt180 80.02 121.1 0.05 OUTLIER 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.539 1.536 . . . . 0.0 111.617 168.597 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -71.52 140.77 50.06 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 120.899 -1.126 . . . . 0.0 108.946 165.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -50.88 -28.81 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.57 8.78 79.13 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 119.362 0.983 . . . . 0.0 115.537 175.286 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -88.84 129.95 35.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 120.103 1.951 . . . . 0.0 112.028 -175.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.99 -179.7 4.02 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 128.288 2.635 . . . . 0.0 107.518 170.159 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -92.39 -120.19 2.7 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 122.761 1.201 . . . . 0.0 114.032 -172.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -140.58 152.96 45.89 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.887 1.275 . . . . 0.0 110.777 169.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -116.01 137.1 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 127.581 2.352 . . . . 0.0 109.894 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -102.93 132.24 49.3 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 119.322 0.964 . . . . 0.0 108.797 169.47 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.75 144.36 27.81 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-O 120.881 0.372 . . . . 0.0 111.068 168.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -60.7 169.88 1.67 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 126.077 1.751 . . . . 0.0 111.753 170.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.32 -15.16 9.26 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.204 1.402 . . . . 0.0 114.143 168.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.05 3.17 55.15 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 125.894 1.678 . . . . 0.0 114.026 169.534 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.9 13.87 76.64 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 120.082 -1.637 . . . . 0.0 115.287 169.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.44 134.72 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 125.846 1.659 . . . . 0.0 112.875 171.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.59 112.12 25.08 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 165.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -104.81 139.42 39.6 Favored 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 124.694 1.198 . . . . 0.0 109.568 -177.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.3 t -137.27 140.28 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 114.962 1.467 . . . . 0.0 114.962 -166.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 89.3 p -154.76 104.39 2.51 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.995 1.318 . . . . 0.0 111.73 173.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.0 mt -136.85 141.84 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.784 2.034 . . . . 0.0 110.431 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -110.22 134.93 51.73 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 166.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -139.03 140.54 38.15 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 125.919 1.687 . . . . 0.0 111.648 -167.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 13.3 p -121.4 52.04 1.25 Allowed 'General case' 0 CA--C 1.543 0.699 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 177.137 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.615 HG11 HH12 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -147.03 1.81 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -177.469 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.11 176.07 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.858 1.663 . . . . 0.0 110.206 169.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.653 ' H ' ' HB3' ' A' ' 111' ' ' SER . 90.4 p -154.84 164.28 39.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 126.647 1.979 . . . . 0.0 112.066 171.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.9 mp -78.58 67.85 4.43 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.17 2.188 . . . . 0.0 108.534 177.214 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -128.23 -5.8 5.44 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 -168.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.68 -24.88 3.57 Favored Glycine 0 N--CA 1.472 1.046 0 CA-C-N 120.492 1.496 . . . . 0.0 116.427 169.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -94.22 -100.82 0.15 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 126.286 1.834 . . . . 0.0 107.711 -169.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -83.67 2.27 38.42 Favored 'General case' 0 C--N 1.323 -0.568 0 O-C-N 120.009 -1.682 . . . . 0.0 112.321 -174.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.653 ' HB3' ' H ' ' A' ' 105' ' ' SER . 39.4 m -125.11 -120.08 0.27 Allowed 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 115.864 1.801 . . . . 0.0 115.864 -169.287 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 42.2 pt -125.05 172.41 12.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 O-C-N 119.953 -1.717 . . . . 0.0 109.027 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.424 HD11 HG23 ' A' ' 151' ' ' ILE . 3.1 mm 76.68 147.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 128.657 2.783 . . . . 0.0 105.951 -162.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.48 -51.6 4.23 Favored Glycine 0 C--O 1.222 -0.626 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.62 -177.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 40.2 mtt180 -71.41 178.33 3.49 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 127.541 2.336 . . . . 0.0 110.191 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.9 m -138.91 124.99 20.02 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.862 0.865 . . . . 0.0 111.609 -169.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 47.4 tp -92.24 115.1 27.79 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 125.367 1.467 . . . . 0.0 110.103 178.255 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 15.0 p -102.45 140.36 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 124.597 1.159 . . . . 0.0 109.549 171.505 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -113.86 142.91 24.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.977 1.711 . . . . 0.0 107.681 171.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -118.72 148.2 43.02 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.91 2.084 . . . . 0.0 111.105 -168.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -74.6 -20.16 60.03 Favored 'General case' 0 CA--C 1.541 0.624 0 O-C-N 120.518 -1.364 . . . . 0.0 114.67 -168.29 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -125.38 171.19 10.65 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 119.82 -1.8 . . . . 0.0 112.283 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.2 139.9 51.25 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 124.714 1.205 . . . . 0.0 111.951 -175.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -87.76 136.83 32.79 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 123.869 0.867 . . . . 0.0 109.747 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.85 -37.23 76.06 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.726 1.211 . . . . 0.0 110.102 173.074 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 63.16 69.81 0.56 Allowed 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 124.999 1.32 . . . . 0.0 108.399 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.31 -109.87 0.42 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 117.055 1.582 . . . . 0.0 117.055 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.16 36.06 0.14 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 128.545 2.738 . . . . 0.0 111.754 -167.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -48.9 -31.39 10.24 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.482 1.991 . . . . 0.0 117.976 -168.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 167.35 2.78 0.03 OUTLIER Glycine 0 N--CA 1.476 1.322 0 N-CA-C 118.249 2.06 . . . . 0.0 118.249 178.042 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -146.22 -170.43 3.49 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 119.088 1.444 . . . . 0.0 111.747 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -70.58 -56.91 5.41 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.411 1.085 . . . . 0.0 109.57 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.496 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 1.2 mp0 -57.42 -28.12 62.99 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.876 1.67 . . . . 0.0 111.675 -174.268 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 42.8 m -46.25 -37.66 7.52 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 126.124 1.769 . . . . 0.0 112.789 171.465 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -111.92 -33.88 6.16 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -66.81 -24.22 66.15 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.0 0.92 . . . . 0.0 113.076 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.491 ' HA ' ' HE1' ' A' ' 63' ' ' HIS . 27.7 p -130.36 -32.68 1.74 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.885 1.674 . . . . 0.0 114.673 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.29 10.0 40.2 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -163.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 63.85 11.7 6.17 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.981 2.112 . . . . 0.0 114.483 177.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.0 19.07 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 117.326 2.343 . . . . 0.0 117.326 -167.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.76 -43.48 2.16 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 128.473 2.94 . . . . 0.0 115.266 168.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.5 t -168.69 169.34 10.17 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 118.512 1.156 . . . . 0.0 113.901 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.7 ptt-85 -71.5 158.96 35.33 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.168 1.387 . . . . 0.0 111.01 168.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.63 HD11 HG11 ' A' ' 14' ' ' VAL . 2.1 tm? -142.09 -103.31 0.14 Allowed 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 169.113 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.416 ' N ' HD13 ' A' ' 144' ' ' LEU . . . -103.68 160.46 14.74 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.248 1.019 . . . . 0.0 111.471 172.146 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.7 p -142.35 140.43 32.09 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.165 2.186 . . . . 0.0 108.898 -177.637 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.25 135.64 4.62 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 118.048 1.979 . . . . 0.0 118.048 -175.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -75.02 139.52 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.513 1.125 . . . . 0.0 109.416 -178.612 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.9 mm -87.88 107.55 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 122.572 0.349 . . . . 0.0 110.919 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.71 -171.79 14.15 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.71 1.148 . . . . 0.0 113.23 173.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.2 pp -133.01 129.49 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 N-CA-C 114.989 1.477 . . . . 0.0 114.989 -173.493 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.5 -161.64 0.89 Allowed 'General case' 0 CA--C 1.545 0.75 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 165.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 . . . . . 0 N--CA 1.475 0.804 0 C-N-CA 131.6 3.96 . . . . 0.0 108.565 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.415 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -86.84 108.72 18.88 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 172.688 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttmm -97.16 123.34 40.9 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.024 -173.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -93.63 175.65 6.66 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.634 1.346 . . . . 0.0 114.634 179.057 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.595 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -155.92 103.65 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 128.621 2.769 . . . . 0.0 106.427 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.13 122.06 24.46 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.533 -0.729 . . . . 0.0 109.746 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.408 ' HA ' HG22 ' A' ' 54' ' ' THR . 22.8 t -88.49 63.14 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 124.171 0.988 . . . . 0.0 108.802 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.465 ' HA ' ' HA3' ' B' ' 147' ' ' GLY 0.335 1.3 pt? -82.85 79.04 9.35 Favored 'General case' 0 N--CA 1.477 0.907 0 O-C-N 121.272 -0.892 . . . . 0.0 113.075 -171.824 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 tttm -117.47 129.76 56.02 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 -173.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.12 158.08 19.01 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 165.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -72.1 92.45 1.33 Allowed 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 128.637 2.775 . . . . 0.0 109.246 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.19 -153.61 21.95 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 127.102 2.286 . . . . 0.0 111.474 -176.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -86.1 7.66 4.88 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 125.0 3.8 . . . . 0.0 114.249 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -105.62 108.92 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 C-N-CA 125.146 1.378 . . . . 0.0 108.509 -177.253 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -159.7 166.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.668 1.187 . . . . 0.0 111.421 176.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.46 178.25 29.75 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 124.205 0.907 . . . . 0.0 113.862 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.434 HG13 ' H ' ' B' ' 34' ' ' SER . 3.0 pt -123.8 137.33 57.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 128.449 2.699 . . . . 0.0 109.726 171.286 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mm -136.98 113.12 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.534 1.061 . . . . 0.0 109.457 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -113.24 108.65 17.56 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.757 1.623 . . . . 0.0 112.501 -164.1 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.433 ' H ' ' HB3' ' B' ' 4' ' ' ALA . 30.4 m-85 -92.44 104.01 16.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.539 1.935 . . . . 0.0 110.281 -176.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -84.25 103.28 13.31 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.6 1.56 . . . . 0.0 110.781 172.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLN . . . . . 0.46 HE22 ' CB ' ' B' ' 105' ' ' SER . 3.1 tt0 -97.69 119.09 35.64 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 121.814 0.816 . . . . 0.0 110.931 173.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -64.13 -42.85 96.66 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.09 1.756 . . . . 0.0 113.268 175.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -157.17 155.37 30.83 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 126.016 1.726 . . . . 0.0 111.596 168.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.7 p -45.05 -3.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 1 C-N-CA 131.739 4.016 . . . . 0.0 118.567 -171.235 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -157.72 20.9 0.27 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.661 1.985 . . . . 0.0 111.444 -168.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.24 173.67 15.64 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.312 1.91 . . . . 0.0 112.563 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -67.03 168.67 16.72 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.578 2.852 . . . . 0.0 111.401 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -138.88 133.5 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 122.744 0.418 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.8 mttp -92.41 124.22 36.3 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.28 0.562 . . . . 0.0 109.832 169.167 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.5 t -120.56 86.58 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 127.995 2.518 . . . . 0.0 108.472 -170.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -110.07 168.7 9.24 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 121.2 -0.938 . . . . 0.0 112.281 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.46 -159.5 28.44 Favored Glycine 0 N--CA 1.462 0.432 0 O-C-N 120.973 -1.079 . . . . 0.0 111.869 174.304 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' SER . . . . . 0.434 ' H ' HG13 ' B' ' 17' ' ' ILE . 79.8 p -156.33 154.1 30.05 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -176.092 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.25 124.77 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.122 0.969 . . . . 0.0 109.997 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -119.39 146.58 45.23 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.841 1.257 . . . . 0.0 109.652 -178.048 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.38 10.66 38.16 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 124.916 1.246 . . . . 0.0 113.469 -169.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 76.8 mt -84.98 167.16 16.12 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.105 1.362 . . . . 0.0 111.651 168.444 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -94.78 156.5 16.35 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 164.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -59.98 148.62 34.69 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 123.727 0.811 . . . . 0.0 112.27 -177.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.67 -178.54 33.85 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 124.234 0.921 . . . . 0.0 113.506 -175.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -60.7 144.92 51.14 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 127.648 2.379 . . . . 0.0 114.013 -173.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -145.65 127.88 15.75 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 127.692 2.397 . . . . 0.0 109.985 175.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.26 158.09 52.35 Favored Glycine 0 N--CA 1.474 1.175 0 CA-C-N 119.239 0.927 . . . . 0.0 112.156 173.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -158.37 139.8 13.46 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.201 2.2 . . . . 0.0 112.061 166.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 19.1 p-80 -149.83 146.53 27.19 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 120.905 -1.122 . . . . 0.0 111.825 -176.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -91.4 138.51 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 124.568 1.147 . . . . 0.0 109.175 178.01 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -105.83 153.04 22.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 110.079 -178.74 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 49' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' B' ' 115' ' ' ARG . 24.0 tt0 -67.68 12.04 0.12 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.732 1.151 . . . . 0.0 113.479 178.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -140.59 125.04 17.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 O-C-N 120.031 -1.668 . . . . 0.0 108.932 -168.798 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.56 -3.18 61.96 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 124.616 1.103 . . . . 0.0 114.33 170.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.654 ' HA ' HG21 ' A' ' 5' ' ' VAL . 28.0 t0 -75.5 123.09 24.87 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 118.135 0.968 . . . . 0.0 109.93 -169.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.87 20.48 3.83 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 114.787 1.402 . . . . 0.0 114.787 164.452 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.311 14.9 t . . . . . 0 C--N 1.324 -0.543 0 C-N-CA 123.227 0.611 . . . . 0.0 112.004 -166.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.596 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.39 176.78 47.51 Favored Glycine 0 CA--C 1.545 1.947 0 C-N-CA 125.094 1.33 . . . . 0.0 114.582 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -102.42 179.46 0.15 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 124.722 3.614 . . . . 0.0 113.576 -177.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.646 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -72.75 74.7 1.12 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.649 3.18 . . . . 0.0 111.985 172.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -30.21 132.96 0.07 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 129.137 2.975 . . . . 0.0 115.312 169.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -122.86 59.27 12.9 Favored Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -172.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -62.85 -16.69 55.3 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 122.755 2.303 . . . . 0.0 113.911 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.81 -5.76 54.24 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.034 1.334 . . . . 0.0 113.324 169.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t 65.16 50.27 1.85 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 127.966 2.507 . . . . 0.0 112.885 178.29 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.6 mtp180 -118.02 176.21 5.31 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 124.94 1.296 . . . . 0.0 112.86 -172.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.3 mptm? -95.41 175.93 6.38 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.698 2.399 . . . . 0.0 109.441 164.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -62.7 157.75 20.19 Favored 'General case' 0 CA--C 1.539 0.531 0 O-C-N 120.918 -1.114 . . . . 0.0 111.009 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' B' ' 79' ' ' ARG . . . -176.52 -175.79 44.15 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 114.914 0.726 . . . . 0.0 114.914 174.51 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.65 -120.89 0.98 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 125.27 1.414 . . . . 0.0 113.988 169.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -62.52 -16.35 51.64 Favored 'Trans proline' 0 CA--C 1.54 0.793 0 C-N-CA 123.855 3.037 . . . . 0.0 115.259 -173.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.75 -4.15 19.7 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.578 1.151 . . . . 0.0 112.988 169.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -159.15 110.47 2.08 Favored 'General case' 0 CA--C 1.543 0.706 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 -167.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -40.88 -10.7 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 131.241 3.816 . . . . 0.0 116.76 168.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.69 -77.44 0.09 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 120.067 1.303 . . . . 0.0 109.315 -177.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.402 ' H ' ' HA3' ' B' ' 72' ' ' GLY . 15.2 ttp-105 56.53 77.25 0.26 Allowed 'General case' 0 N--CA 1.475 0.818 0 O-C-N 120.79 -1.194 . . . . 0.0 113.141 164.731 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.3 m170 -48.32 164.46 0.05 Allowed 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.709 -1.244 . . . . 0.0 114.019 172.134 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.85 -14.16 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.23 13.59 31.03 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.957 1.742 . . . . 0.0 116.75 176.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -100.81 103.86 15.09 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 120.801 2.3 . . . . 0.0 113.414 -171.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 42.9 mt -96.64 41.22 1.11 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.528 -1.358 . . . . 0.0 112.417 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.12 -129.74 43.14 Favored Glycine 0 CA--C 1.537 1.412 0 O-C-N 119.713 -1.867 . . . . 0.0 112.361 -174.214 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -147.98 161.01 42.21 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.877 0.871 . . . . 0.0 112.142 175.383 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.4 124.07 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 127.778 2.431 . . . . 0.0 110.906 -172.289 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.2 m -95.78 129.86 42.88 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.386 0.674 . . . . 0.0 109.666 174.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.32 148.47 25.05 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.56 162.53 15.62 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 128.677 2.791 . . . . 0.0 110.01 169.058 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -40.79 -21.23 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 129.421 3.088 . . . . 0.0 117.609 177.048 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -75.73 0.16 18.82 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.54 -1.35 . . . . 0.0 112.166 171.577 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.51 24.41 76.83 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 125.895 1.712 . . . . 0.0 112.602 -170.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.2 p -116.8 128.14 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 CA-C-N 118.785 1.293 . . . . 0.0 113.156 -177.244 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.1 117.05 29.62 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 166.117 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -98.25 130.93 44.95 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 123.793 0.837 . . . . 0.0 109.009 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.69 143.0 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 117.011 2.226 . . . . 0.0 117.011 -174.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 77.8 p -143.94 82.36 1.71 Allowed 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 126.352 1.861 . . . . 0.0 111.533 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.8 mt -97.69 157.61 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 120.594 -1.316 . . . . 0.0 110.071 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -144.69 145.59 31.8 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 127.642 2.377 . . . . 0.0 107.463 168.143 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.34 159.95 40.34 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.836 1.255 . . . . 0.0 111.336 173.206 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 35.7 p -127.37 46.08 2.6 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.472 1.509 . . . . 0.0 112.955 -168.163 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 23.1 m -145.87 15.12 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.226 1.011 . . . . 0.0 113.574 -176.075 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -148.78 165.99 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.107 2.163 . . . . 0.0 109.386 -173.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.46 ' CB ' HE22 ' B' ' 22' ' ' GLN . 18.1 m -157.39 168.0 28.63 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 125.066 1.346 . . . . 0.0 109.983 175.006 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 106' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' B' ' 22' ' ' GLN . 1.1 mm? -98.73 80.03 2.5 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.99 1.716 . . . . 0.0 107.723 -171.723 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -122.14 -18.91 6.74 Favored 'General case' 0 CA--C 1.567 1.628 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -175.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.06 0.71 89.26 Favored Glycine 0 N--CA 1.492 2.408 0 O-C-N 118.554 -2.591 . . . . 0.0 117.778 166.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.66 -88.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.918 2.487 . . . . 0.0 108.569 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 86.8 m-70 -115.15 -9.06 12.34 Favored 'General case' 0 CA--C 1.559 1.299 1 C-N-CA 132.715 4.406 . . . . 0.0 111.113 168.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 48.8 m -82.46 -166.05 1.18 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.63 1.972 . . . . 0.0 110.992 -174.188 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.452 HG22 ' H ' ' B' ' 113' ' ' ILE . 8.2 mm -71.28 162.3 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.834 0 O-C-N 118.603 -2.56 . . . . 0.0 108.637 169.151 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 113' ' ' ILE . . . . . 0.452 ' H ' HG22 ' B' ' 112' ' ' ILE . 1.4 mm 97.29 132.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.278 1 C-N-CA 133.75 4.82 . . . . 0.0 108.291 -168.632 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.22 5.51 34.88 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-O 117.565 -1.686 . . . . 0.0 115.815 176.278 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 115' ' ' ARG . . . . . 0.458 ' HD2' ' HA ' ' B' ' 49' ' ' GLU . 62.2 mmt-85 -77.61 -177.08 4.6 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 127.138 2.175 . . . . 0.0 110.797 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 39.5 m -128.26 141.12 51.55 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 116.446 -1.74 . . . . 0.0 109.945 173.072 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.7 tp -113.19 111.22 21.71 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.846 1.259 . . . . 0.0 111.208 171.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.9 p -88.56 149.33 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 124.264 1.026 . . . . 0.0 109.563 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 33.2 t -121.77 142.23 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 168.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -99.26 136.85 38.61 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.324 2.25 . . . . 0.0 111.379 -173.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -75.97 -10.86 59.77 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 120.419 -1.426 . . . . 0.0 113.796 -171.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 50.8 mttp -114.95 172.95 6.74 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 126.26 1.824 . . . . 0.0 111.959 169.204 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.99 163.59 1.94 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.809 1.244 . . . . 0.0 112.188 169.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -121.03 135.07 55.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 127.299 2.24 . . . . 0.0 107.209 175.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -73.03 -33.24 65.6 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 118.223 0.465 . . . . 0.0 112.216 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 29.3 mt 69.19 50.39 0.57 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.872 1.669 . . . . 0.0 114.223 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.21 -26.83 8.47 Favored Glycine 0 N--CA 1.474 1.211 0 N-CA-C 119.924 2.73 . . . . 0.0 119.924 163.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 8.4 pttm -163.93 99.41 0.87 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 120.1 1.95 . . . . 0.0 114.826 176.193 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.69 -7.71 56.45 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.938 1.732 . . . . 0.0 114.042 170.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 101.11 -8.64 57.54 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 125.497 1.522 . . . . 0.0 113.736 -170.118 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 p-10 -117.98 153.21 34.04 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 128.443 2.697 . . . . 0.0 109.611 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -66.41 -48.67 69.33 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 114.108 1.151 . . . . 0.0 114.108 -167.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.08 -33.1 72.81 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.837 1.255 . . . . 0.0 111.943 -175.395 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 61.8 m -53.45 -31.23 44.54 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 119.724 1.147 . . . . 0.0 112.574 168.118 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 1.1 p -85.03 -46.99 10.66 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.94 1.296 . . . . 0.0 112.513 172.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -70.49 -35.63 73.36 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.807 1.243 . . . . 0.0 113.523 -173.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 37.1 p -135.1 -28.78 1.15 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.265 1.426 . . . . 0.0 113.471 -175.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 108.95 0.54 31.83 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 118.44 -1.2 . . . . 0.0 113.538 -171.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 66.9 -4.39 0.79 Allowed 'General case' 0 N--CA 1.482 1.14 0 CA-C-N 119.492 1.646 . . . . 0.0 113.78 175.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -46.88 5.11 0.0 OUTLIER 'General case' 0 CA--C 1.565 1.545 1 C-N-CA 132.551 4.34 . . . . 0.0 121.497 -165.52 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.11 -69.9 3.21 Favored Glycine 0 CA--C 1.526 0.735 0 O-C-N 120.083 -1.636 . . . . 0.0 115.288 168.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.4 t -164.71 -152.4 0.17 Allowed 'General case' 0 N--CA 1.477 0.92 0 O-C-N 121.253 -1.145 . . . . 0.0 112.157 -171.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.65 148.87 29.81 Favored 'General case' 0 N--CA 1.47 0.557 0 O-C-N 120.427 -1.421 . . . . 0.0 113.991 176.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.402 ' CG ' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -97.85 -101.45 0.2 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.095 1.758 . . . . 0.0 110.099 169.54 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.402 ' H ' ' CG ' ' B' ' 144' ' ' LEU . . . -91.3 166.73 12.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.986 1.714 . . . . 0.0 111.05 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -157.08 143.19 17.91 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 127.181 2.192 . . . . 0.0 108.545 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 147' ' ' GLY . . . . . 0.465 ' HA3' ' HA ' ' B' ' 8' ' ' LEU . . . -164.76 171.08 40.1 Favored Glycine 0 N--CA 1.47 0.937 0 N-CA-C 117.354 1.702 . . . . 0.0 117.354 169.77 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -84.85 146.72 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.106 2.163 . . . . 0.0 110.577 -169.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 46.6 mm -86.43 103.09 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 125.649 1.58 . . . . 0.0 111.35 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.82 175.82 22.57 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.737 1.637 . . . . 0.0 113.134 171.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.455 ' HA ' ' HA ' ' B' ' 4' ' ' ALA 0.296 1.3 pp -114.78 139.21 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 177.762 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.4 159.66 30.27 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-O 122.951 1.358 . . . . 0.0 108.457 172.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 113.966 -1.47 . . . . 0.0 110.098 -177.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.5 p . . . . . 0 CA--C 1.517 -0.304 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptpp? -105.25 135.87 45.81 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -87.18 161.83 17.83 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 164.247 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 t -145.1 149.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 CA-C-N 119.705 1.139 . . . . 0.0 110.045 173.612 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.16 109.16 12.53 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.452 1.501 . . . . 0.0 108.187 166.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -82.61 112.07 19.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 168.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -79.36 99.35 7.1 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -156.13 127.18 6.97 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.586 0.754 . . . . 0.0 111.904 177.275 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.67 -104.81 1.28 Allowed Glycine 0 CA--C 1.527 0.821 0 N-CA-C 105.277 -3.129 . . . . 0.0 105.277 164.527 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -156.33 129.64 8.13 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.628 1.571 . . . . 0.0 108.352 167.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 124.22 168.87 12.98 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.61 2.052 . . . . 0.0 110.519 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 23.27 0.19 Allowed 'Trans proline' 0 CA--C 1.546 1.089 1 C-N-CA 125.745 4.297 . . . . 0.0 116.39 -169.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -117.26 111.87 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -157.27 158.24 35.74 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.324 -174.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.68 179.18 37.23 Favored Glycine 0 CA--C 1.508 -0.371 0 C-N-CA 126.129 1.823 . . . . 0.0 113.494 176.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -134.04 142.02 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.295 1.438 . . . . 0.0 109.054 168.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.0 mm -133.23 111.23 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 168.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -77.68 150.49 34.51 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.075 1.75 . . . . 0.0 110.934 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -135.43 78.52 1.73 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.765 2.026 . . . . 0.0 108.542 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -81.74 117.64 22.21 Favored 'General case' 0 C--N 1.34 0.182 0 CA-C-O 121.863 0.839 . . . . 0.0 113.157 -177.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp60 -105.57 167.68 9.6 Favored 'General case' 0 CA--C 1.549 0.942 0 CA-C-O 122.951 1.358 . . . . 0.0 109.424 169.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.89 -28.09 1.6 Allowed 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 130.088 3.355 . . . . 0.0 111.725 -177.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -101.97 -132.13 0.27 Allowed 'General case' 0 CA--C 1.556 1.201 0 C-N-CA 124.621 1.168 . . . . 0.0 108.497 166.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 t -136.37 -82.04 0.39 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 120.249 -1.532 . . . . 0.0 107.681 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -76.24 72.16 3.0 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.069 0.85 . . . . 0.0 112.356 169.288 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.46 15.93 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 127.057 2.265 . . . . 0.0 111.16 171.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.3 158.4 56.37 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 123.395 2.73 . . . . 0.0 111.567 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.7 t -129.14 136.16 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.24 0.616 . . . . 0.0 110.67 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.0 mttm -87.02 119.75 27.56 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 122.394 1.092 . . . . 0.0 110.827 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.9 t -103.1 125.3 57.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 128.82 2.848 . . . . 0.0 109.332 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.7 p90 -157.14 161.85 39.37 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 169.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.77 171.99 13.03 Favored Glycine 0 N--CA 1.466 0.669 0 C-N-CA 124.833 1.206 . . . . 0.0 112.11 -176.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.3 p -132.33 143.33 49.79 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 -167.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mm -116.73 126.37 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 124.869 1.268 . . . . 0.0 111.404 171.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 54.3 tttt -127.79 146.2 50.67 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.695 1.598 . . . . 0.0 111.755 -173.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.02 -34.57 3.82 Favored Glycine 0 N--CA 1.477 1.423 0 C-N-CA 126.347 1.927 . . . . 0.0 111.197 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.466 HD23 ' H ' ' A' ' 38' ' ' LEU . 0.2 OUTLIER -66.58 129.06 38.59 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 165.658 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -69.33 169.54 12.07 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 118.615 0.643 . . . . 0.0 110.998 171.33 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -54.02 158.79 2.0 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.325 1.85 . . . . 0.0 115.475 -171.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.27 179.11 35.61 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.333 0.968 . . . . 0.0 112.783 -173.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.8 mt -64.05 137.23 57.89 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 126.981 2.112 . . . . 0.0 111.935 -174.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -133.54 131.63 39.98 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.613 1.165 . . . . 0.0 108.472 168.224 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.36 157.31 46.13 Favored Glycine 0 N--CA 1.46 0.248 0 CA-C-O 118.994 -0.892 . . . . 0.0 111.277 -174.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -155.46 141.91 18.64 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.804 0.811 . . . . 0.0 112.763 169.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.9 p-80 -152.58 168.2 26.36 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 123.171 0.588 . . . . 0.0 109.838 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.27 135.57 41.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 123.964 0.905 . . . . 0.0 108.735 175.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -71.73 134.31 46.16 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 170.316 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -76.4 47.76 0.49 Allowed 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.225 1.194 . . . . 0.0 114.225 -170.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 173.8 156.99 0.13 Allowed 'General case' 0 C--O 1.237 0.425 0 C-N-CA 129.649 3.18 . . . . 0.0 108.35 177.495 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.25 0.46 20.76 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 117.823 1.889 . . . . 0.0 117.823 -178.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -67.67 42.86 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.535 1.934 . . . . 0.0 115.248 171.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -166.54 22.16 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -163.179 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.4 t -29.14 74.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 129.678 3.191 . . . . 0.0 117.407 173.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 159.35 -14.54 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.05 0 C-N-CA 130.775 3.63 . . . . 0.0 111.749 -169.143 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.77 -127.78 25.75 Favored Glycine 0 C--N 1.345 1.034 0 C-N-CA 124.858 1.218 . . . . 0.0 112.15 167.37 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 12.4 t -57.69 -10.86 1.77 Allowed 'General case' 0 CA--C 1.552 1.028 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.4 t -108.11 23.13 14.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.229 1.412 . . . . 0.0 113.576 171.012 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.0 m -152.05 -20.31 0.18 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 116.819 2.155 . . . . 0.0 116.819 169.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -153.41 162.93 40.78 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 120.644 1.565 . . . . 0.0 111.799 169.249 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.89 160.86 52.07 Favored Glycine 0 CA--C 1.539 1.586 0 CA-C-O 119.359 -0.69 . . . . 0.0 112.579 176.79 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -70.08 172.41 13.0 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 124.152 3.235 . . . . 0.0 111.177 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -15.86 89.18 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 118.865 2.913 . . . . 0.0 118.865 176.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -67.41 98.45 0.65 Allowed 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -75.63 102.42 0.72 Allowed Pre-proline 0 CA--C 1.548 0.871 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -165.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -72.13 -33.3 9.63 Favored 'Trans proline' 0 C--N 1.355 0.915 0 C-N-CA 123.252 2.635 . . . . 0.0 113.086 -168.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.98 -4.27 49.15 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.655 1.182 . . . . 0.0 112.656 175.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.4 t 56.5 49.12 15.41 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.014 1.726 . . . . 0.0 112.823 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 -103.72 174.45 5.86 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.789 1.236 . . . . 0.0 113.365 -173.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 ptmm? -74.22 164.59 26.43 Favored 'General case' 0 CA--C 1.547 0.837 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 161.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -80.14 168.76 18.72 Favored 'General case' 0 CA--C 1.543 0.682 0 O-C-N 121.086 -1.009 . . . . 0.0 112.365 173.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 131.51 -154.95 21.12 Favored Glycine 0 C--N 1.338 0.692 0 C-N-CA 125.818 1.675 . . . . 0.0 113.022 167.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.25 -15.2 0.4 Allowed Glycine 0 CA--C 1.539 1.558 0 N-CA-C 121.331 3.293 . . . . 0.0 121.331 166.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -112.43 -12.11 0.03 OUTLIER 'Trans proline' 0 CA--C 1.545 1.03 0 CA-C-N 121.87 2.835 . . . . 0.0 112.939 168.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.553 ' HE3' ' HB2' ' A' ' 128' ' ' LYS . 0.0 OUTLIER -126.56 -3.43 6.67 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 125.569 1.548 . . . . 0.0 112.666 175.625 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -108.51 175.06 5.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 128.53 2.732 . . . . 0.0 109.548 -175.723 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -116.85 -9.65 11.16 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.769 2.028 . . . . 0.0 112.629 -168.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -122.98 -59.16 1.61 Allowed 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -165.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 46.33 118.55 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 117.881 2.548 . . . . 0.0 117.881 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -58.4 165.57 2.04 Favored 'General case' 0 N--CA 1.48 1.071 0 O-C-N 119.37 -2.081 . . . . 0.0 111.583 169.691 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.313 7.1 p -77.19 -18.97 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 CA-C-N 120.116 1.326 . . . . 0.0 113.078 -176.489 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -94.16 27.78 12.4 Favored Glycine 0 CA--C 1.542 1.75 0 C-N-CA 125.458 1.504 . . . . 0.0 114.937 167.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -107.28 131.58 54.05 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 120.417 2.108 . . . . 0.0 115.088 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 65.2 mt -115.05 178.81 4.15 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.241 1.816 . . . . 0.0 109.818 167.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -89.53 -121.68 2.1 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.435 1.493 . . . . 0.0 114.511 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.436 HD22 HD11 ' A' ' 126' ' ' LEU . 11.8 m-80 -127.04 154.25 44.9 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.071 1.348 . . . . 0.0 111.65 172.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.03 102.85 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 127.347 2.259 . . . . 0.0 109.709 168.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 m -89.63 126.84 35.78 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 124.744 1.218 . . . . 0.0 110.018 -179.077 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.21 150.47 21.97 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -80.9 160.0 24.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 127.301 2.24 . . . . 0.0 109.73 167.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.3 pttp -47.98 -19.35 0.24 Allowed 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 128.185 2.594 . . . . 0.0 115.811 169.365 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -74.64 -11.68 60.25 Favored 'General case' 0 CA--C 1.547 0.863 0 O-C-N 120.753 -1.217 . . . . 0.0 111.784 171.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.07 15.09 55.08 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.015 2.245 . . . . 0.0 113.281 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.8 p -117.38 130.48 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.092 1.446 . . . . 0.0 113.322 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.36 97.34 7.84 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 165.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -89.68 148.93 23.01 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.961 0.886 . . . . 0.0 110.289 168.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.53 146.17 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.105 -1.407 . . . . 0.0 114.433 -169.073 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 76.7 p -160.23 90.43 0.89 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.384 1.074 . . . . 0.0 112.623 -176.118 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 175.77 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 C-N-CA 125.918 1.687 . . . . 0.0 113.236 -174.042 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -144.75 146.9 32.38 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 128.302 2.641 . . . . 0.0 106.693 168.443 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -143.05 155.94 44.73 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 122.053 0.93 . . . . 0.0 111.052 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.6 p -121.08 64.71 0.87 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 127.069 2.148 . . . . 0.0 114.158 -166.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -156.83 -46.82 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 O-C-N 121.033 -1.042 . . . . 0.0 109.717 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.39 150.43 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 168.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -148.43 161.15 42.18 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.486 1.514 . . . . 0.0 111.259 -169.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 9.4 mt -78.04 97.85 5.53 Favored 'General case' 0 C--N 1.345 0.387 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 170.074 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.5 t -155.98 6.4 0.2 Allowed 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 -170.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.3 -119.88 5.04 Favored Glycine 0 C--N 1.342 0.865 0 CA-C-N 120.625 1.557 . . . . 0.0 109.713 168.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -62.41 -26.59 68.56 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 125.532 1.533 . . . . 0.0 111.209 -171.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.2 m170 -79.45 -24.25 42.56 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.302 1.041 . . . . 0.0 113.446 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.6 m -166.92 -110.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.6 mm -88.8 142.3 13.07 Favored 'Isoleucine or valine' 0 C--N 1.34 0.171 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 -176.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 92.19 133.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 131.526 3.93 . . . . 0.0 106.73 -164.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.28 15.27 81.69 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 117.211 -1.883 . . . . 0.0 115.823 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 26.5 mtt85 -117.05 176.92 4.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-N 120.426 2.113 . . . . 0.0 110.777 171.027 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -119.75 110.32 16.66 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 120.212 1.369 . . . . 0.0 112.104 -175.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 14.4 tp -90.1 127.41 36.08 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.601 1.161 . . . . 0.0 111.137 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.3 p -116.58 139.55 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.122 1.369 . . . . 0.0 110.491 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.4 m -101.44 152.88 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 123.509 0.724 . . . . 0.0 109.436 167.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -119.45 145.68 46.06 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.665 1.586 . . . . 0.0 112.08 -170.113 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -71.22 -24.46 62.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.674 -1.266 . . . . 0.0 114.147 -171.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.5 mptt -112.78 177.16 4.73 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.321 1.449 . . . . 0.0 110.344 168.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.06 146.8 10.58 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.535 1.934 . . . . 0.0 111.45 168.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -83.86 140.86 31.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 161.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.1 -49.79 33.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 174.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.436 HD11 HD22 ' A' ' 86' ' ' ASN . 14.5 mt 90.64 38.38 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 129.413 3.085 . . . . 0.0 113.292 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.82 26.68 8.34 Favored Glycine 0 N--CA 1.468 0.799 0 N-CA-C 117.73 1.852 . . . . 0.0 117.73 167.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.553 ' HB2' ' HE3' ' A' ' 75' ' ' LYS . 3.7 tttt -155.74 10.09 0.28 Allowed 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 117.131 2.271 . . . . 0.0 117.131 -175.328 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -67.74 117.55 8.87 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 107.051 -2.42 . . . . 0.0 107.051 167.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -69.89 43.14 0.49 Allowed Glycine 0 N--CA 1.477 1.375 0 C-N-CA 126.561 2.029 . . . . 0.0 115.473 -174.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -102.85 -82.62 0.49 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.302 1.841 . . . . 0.0 110.418 176.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 177.17 -69.31 0.01 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 131.154 3.781 . . . . 0.0 106.329 -173.019 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.66 -37.16 62.88 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.731 1.612 . . . . 0.0 114.675 -177.244 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.56 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 0.7 OUTLIER -62.78 -18.6 62.94 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 119.119 -2.238 . . . . 0.0 114.542 179.549 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -99.34 -10.18 22.62 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 124.0 0.92 . . . . 0.0 113.073 170.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.2 mtpt -81.54 -75.55 0.28 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.5 1.52 . . . . 0.0 111.499 169.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 58.5 p -94.03 -28.16 15.9 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 120.121 1.328 . . . . 0.0 113.571 -177.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.45 -14.26 30.3 Favored Glycine 0 N--CA 1.468 0.813 0 CA-C-N 119.44 1.018 . . . . 0.0 110.925 -166.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.56 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 8.3 t-20 61.04 30.69 19.68 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 118.196 0.998 . . . . 0.0 112.714 165.391 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.9 28.36 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 128.582 2.753 . . . . 0.0 117.969 -167.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 67.38 -13.44 0.57 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 119.884 2.713 . . . . 0.0 119.884 167.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . 0.265 16.7 t 146.31 -171.56 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 130.268 3.427 . . . . 0.0 113.23 169.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.59 178.1 6.95 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 128.228 2.611 . . . . 0.0 114.587 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 17.9 tp -162.74 -115.6 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.653 1.581 . . . . 0.0 109.657 168.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -99.24 169.98 8.99 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 125.895 1.678 . . . . 0.0 111.506 172.303 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.3 t -156.64 152.07 26.69 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.782 1.233 . . . . 0.0 111.872 -171.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.05 142.31 8.41 Favored Glycine 0 N--CA 1.473 1.138 0 C-N-CA 125.43 1.491 . . . . 0.0 113.189 178.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 72.1 t -80.73 150.05 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 CA-C-N 118.602 1.201 . . . . 0.0 111.282 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.6 mt -88.1 103.25 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 O-C-N 120.14 -1.6 . . . . 0.0 109.951 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.75 168.84 14.06 Favored Glycine 0 N--CA 1.473 1.142 0 C-N-CA 124.239 0.923 . . . . 0.0 113.242 176.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.58 124.04 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 118.847 1.323 . . . . 0.0 113.78 176.281 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.22 -32.57 13.63 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-O 121.726 0.774 . . . . 0.0 108.927 163.421 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 . . . . . 0 C--O 1.233 0.2 0 C-N-CA 128.903 2.881 . . . . 0.0 111.174 168.742 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.742 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 76.4 p -92.92 51.57 1.71 Allowed 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -166.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 58.1 mttp -78.12 131.84 37.42 Favored 'General case' 0 N--CA 1.473 0.678 0 O-C-N 119.193 -2.192 . . . . 0.0 114.004 -170.215 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -123.58 156.42 35.77 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.45 1.5 . . . . 0.0 109.015 169.139 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 38.1 t -140.75 146.85 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 123.495 0.718 . . . . 0.0 110.626 -171.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.63 116.04 19.69 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.057 0.943 . . . . 0.0 112.044 169.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -78.92 103.98 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 168.489 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.06 114.58 17.07 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtpm? -141.6 172.45 12.67 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 124.584 1.154 . . . . 0.0 111.766 -174.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.45 -59.85 0.68 Allowed Glycine 0 N--CA 1.465 0.626 0 C-N-CA 126.779 2.133 . . . . 0.0 110.059 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.41 59.49 5.45 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.809 1.244 . . . . 0.0 112.844 -168.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.57 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.973 2.702 . . . . 0.0 114.247 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.75 -17.1 37.81 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 123.661 2.907 . . . . 0.0 113.216 -178.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 t -87.61 124.29 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 119.487 1.04 . . . . 0.0 110.314 171.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.27 165.36 35.02 Favored 'General case' 0 C--O 1.224 -0.239 0 C-N-CA 123.871 0.868 . . . . 0.0 111.772 169.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.98 -179.22 31.76 Favored Glycine 0 N--CA 1.464 0.531 0 N-CA-C 115.664 1.026 . . . . 0.0 115.664 -176.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 10.1 pt -135.15 116.39 19.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 126.827 2.051 . . . . 0.0 107.858 166.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.98 117.86 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 169.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 62.2 m-20 -113.55 130.08 56.43 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.85 1.66 . . . . 0.0 110.852 -173.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -114.4 130.7 56.71 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.466 1.507 . . . . 0.0 110.198 -171.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -122.02 131.37 53.96 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.916 1.687 . . . . 0.0 110.178 172.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -124.62 140.5 52.88 Favored 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.344 -0.847 . . . . 0.0 109.063 167.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -99.57 -24.22 14.82 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 115.128 1.529 . . . . 0.0 115.128 -168.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 46.2 mp0 -143.16 146.96 34.19 Favored 'General case' 0 CA--C 1.512 -0.518 0 C-N-CA 127.911 2.484 . . . . 0.0 106.672 168.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.4 m -61.96 -21.18 64.59 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.452 1.278 . . . . 0.0 114.452 -172.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -107.11 0.17 23.27 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.949 1.7 . . . . 0.0 113.839 170.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.16 170.13 54.38 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.779 1.18 . . . . 0.0 111.358 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -71.66 157.88 54.72 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.267 1.978 . . . . 0.0 110.613 177.339 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -107.52 134.18 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 125.366 1.467 . . . . 0.0 108.116 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -96.84 126.3 41.9 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 167.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 42.3 t -108.01 124.31 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 125.941 1.697 . . . . 0.0 107.081 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -143.05 170.82 15.0 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.4 -153.5 19.17 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 124.596 1.093 . . . . 0.0 112.337 174.096 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 58.3 p -153.98 153.63 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 114.805 1.409 . . . . 0.0 114.805 -172.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.4 mp -124.83 133.47 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.808 1.643 . . . . 0.0 107.072 169.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -132.37 146.15 51.76 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.921 0.888 . . . . 0.0 112.778 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.58 -3.74 19.75 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 126.75 2.119 . . . . 0.0 114.582 -173.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.0 mt -74.28 173.5 10.11 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.546 1.138 . . . . 0.0 111.866 177.335 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.7 t -86.43 154.6 21.04 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 164.447 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -56.41 142.39 38.64 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 167.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.59 176.63 17.34 Favored Glycine 0 N--CA 1.472 1.038 0 C-N-CA 124.294 0.949 . . . . 0.0 113.451 -175.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.712 HD23 ' H ' ' B' ' 42' ' ' LEU . 1.8 pt? -89.14 126.01 35.28 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.951 1.7 . . . . 0.0 113.422 -169.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -123.18 146.23 47.96 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 127.818 2.447 . . . . 0.0 109.624 -178.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.07 155.97 33.6 Favored Glycine 0 N--CA 1.478 1.45 0 CA-C-N 121.133 1.788 . . . . 0.0 111.252 -177.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -153.81 135.59 14.5 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.658 1.729 . . . . 0.0 113.958 171.681 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' B' ' 120' ' ' HIS . 0.1 OUTLIER -158.4 159.8 36.16 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.132 0.973 . . . . 0.0 112.867 -178.222 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.68 117.37 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.211 1.404 . . . . 0.0 110.158 -175.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -74.83 -173.54 1.91 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 128.43 2.692 . . . . 0.0 113.649 -169.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -63.29 152.05 38.91 Favored 'General case' 0 CA--C 1.541 0.6 0 O-C-N 120.245 -1.534 . . . . 0.0 112.055 171.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.23 161.23 13.85 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 115.071 1.508 . . . . 0.0 115.071 -168.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 67.37 -79.62 0.16 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.545 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -85.79 54.03 2.98 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 123.789 1.757 . . . . 0.0 110.557 -169.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -173.57 8.04 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.836 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 175.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 27.4 p . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 119.619 3.192 . . . . 0.0 119.619 -165.549 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.592 0 N-CA-C 116.938 2.199 . . . . 0.0 116.938 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -73.02 -179.77 37.3 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 123.788 0.708 . . . . 0.0 112.009 169.322 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -60.9 167.65 8.42 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 124.484 3.456 . . . . 0.0 115.072 -165.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -57.05 86.36 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 127.53 2.332 . . . . 0.0 111.415 175.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -52.69 127.23 22.4 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.805 -1.088 . . . . 0.0 112.79 -167.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -117.78 65.77 5.15 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 125.964 1.706 . . . . 0.0 112.953 -168.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -64.05 -15.22 48.03 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.035 2.49 . . . . 0.0 113.618 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -79.32 -7.3 58.22 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.442 1.097 . . . . 0.0 113.118 170.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t 65.46 55.67 1.02 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.881 2.072 . . . . 0.0 112.194 175.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 mtm180 -121.4 178.36 4.83 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 -166.359 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 mttp -89.81 173.91 8.0 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 127.917 2.487 . . . . 0.0 112.468 169.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -109.14 146.38 34.18 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 117.283 2.327 . . . . 0.0 117.283 -168.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 129.82 -91.7 0.31 Allowed Glycine 0 C--N 1.343 0.967 0 C-N-CA 124.795 1.188 . . . . 0.0 112.468 166.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.62 -28.6 11.19 Favored Glycine 0 CA--C 1.551 2.302 0 N-CA-C 118.635 2.214 . . . . 0.0 118.635 174.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -87.36 -15.18 3.62 Favored 'Trans proline' 0 C--N 1.356 0.966 0 CA-C-N 122.797 3.298 . . . . 0.0 113.176 171.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.21 -48.62 1.45 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.247 1.419 . . . . 0.0 108.994 166.379 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -55.09 138.41 44.33 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.975 0.893 . . . . 0.0 110.884 171.198 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -87.93 -6.23 58.15 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 127.464 2.306 . . . . 0.0 113.0 -169.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -119.24 -56.57 2.07 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 115.543 1.683 . . . . 0.0 115.543 -174.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.537 HH21 ' CG1' ' B' ' 103' ' ' VAL 0.278 3.4 ptt180 57.93 136.61 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.906 2.483 . . . . 0.0 115.346 -173.176 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -73.35 166.78 22.54 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 118.725 -2.484 . . . . 0.0 111.107 169.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.46 -31.92 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 120.311 -1.493 . . . . 0.0 113.997 -177.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -100.66 22.24 40.56 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 118.789 -1.006 . . . . 0.0 115.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -96.32 114.21 25.87 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -169.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.0 mt -101.56 171.88 7.3 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 104.425 -2.435 . . . . 0.0 104.425 158.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.63 -98.84 1.18 Allowed Glycine 0 N--CA 1.474 1.169 0 CA-C-N 119.026 0.83 . . . . 0.0 111.858 175.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -142.13 164.09 31.09 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -177.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.43 129.14 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 129.264 3.026 . . . . 0.0 111.147 -168.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.5 m -100.84 140.55 34.97 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.043 0.937 . . . . 0.0 110.072 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.44 157.86 16.32 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.931 0.892 . . . . 0.0 111.344 167.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -82.11 178.45 8.27 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.14 1.376 . . . . 0.0 112.154 171.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.12 -28.25 68.96 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.594 1.558 . . . . 0.0 113.365 172.048 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -76.42 2.71 12.85 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.336 1.054 . . . . 0.0 110.616 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.27 -0.59 83.83 Favored Glycine 0 C--N 1.342 0.883 0 C-N-CA 127.179 2.323 . . . . 0.0 114.19 172.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.69 132.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 126.107 1.763 . . . . 0.0 113.464 178.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.03 133.9 41.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.786 1.235 . . . . 0.0 108.703 165.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -98.38 118.27 34.66 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 7.5 t -98.43 124.01 51.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.2 173.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -155.1 87.8 1.14 Allowed 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.284 1.434 . . . . 0.0 110.95 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.87 148.64 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 126.441 1.896 . . . . 0.0 112.609 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -112.54 133.1 54.77 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.041 2.536 . . . . 0.0 106.008 168.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.74 130.05 27.12 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 125.238 1.415 . . . . 0.0 111.161 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 25.3 p -113.17 44.26 1.57 Allowed 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -174.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 103' ' ' VAL . . . . . 0.537 ' CG1' HH21 ' B' ' 79' ' ' ARG 0.315 9.8 p -161.16 -21.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 116.275 1.954 . . . . 0.0 116.275 166.851 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.56 164.45 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 122.189 2.268 . . . . 0.0 109.754 168.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 76.8 p -157.71 159.48 36.93 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 -173.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -92.51 57.13 2.88 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 127.651 2.38 . . . . 0.0 105.484 172.027 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -116.16 21.17 13.88 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -167.34 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.48 -53.21 4.65 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-O 117.932 -1.482 . . . . 0.0 115.356 167.391 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -99.41 -103.07 0.22 Allowed 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.282 1.515 . . . . 0.0 110.738 -167.222 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 20.3 m170 -76.32 8.62 3.22 Favored 'General case' 0 CA--C 1.551 1.016 0 O-C-N 119.357 -2.089 . . . . 0.0 114.418 -167.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 69.8 p -93.81 -131.03 0.14 Allowed 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 129.084 2.954 . . . . 0.0 114.202 -167.428 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 14.9 pt -113.76 -15.52 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 121.344 1.884 . . . . 0.0 115.919 175.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.7 mm -54.46 129.79 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 CA-C-N 120.607 1.549 . . . . 0.0 108.299 168.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.15 -2.32 52.06 Favored Glycine 0 CA--C 1.534 1.273 0 CA-C-N 120.199 1.363 . . . . 0.0 115.529 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -87.54 176.5 7.44 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.432 1.893 . . . . 0.0 109.972 169.587 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.55 109.97 6.6 Favored 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 120.45 1.477 . . . . 0.0 113.319 -169.52 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 27.4 tp -83.16 120.27 25.57 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 124.051 0.94 . . . . 0.0 109.67 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 p -121.85 139.58 48.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 125.998 1.719 . . . . 0.0 110.024 176.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 t -95.81 166.99 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 124.927 1.291 . . . . 0.0 107.672 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 73.4 m-70 -150.12 130.54 13.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.198 1.799 . . . . 0.0 107.877 -169.077 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 -53.76 -40.07 65.88 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 121.569 1.986 . . . . 0.0 115.691 -169.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.42 136.37 33.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 120.278 1.399 . . . . 0.0 109.674 175.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.82 159.71 1.6 Allowed 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.187 0.595 . . . . 0.0 110.935 165.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -82.75 146.89 28.75 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-O 123.217 1.484 . . . . 0.0 112.946 -171.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.31 -7.57 53.27 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 114.05 -1.432 . . . . 0.0 113.019 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.1 mt 57.75 55.26 5.6 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 127.163 2.185 . . . . 0.0 113.681 168.491 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.76 -67.09 0.93 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 175.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 103.85 6.74 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 124.963 1.305 . . . . 0.0 113.659 174.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -103.56 -71.9 0.88 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 107.03 -2.428 . . . . 0.0 107.03 164.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -130.28 -29.5 0.65 Allowed Glycine 0 CA--C 1.536 1.406 0 N-CA-C 119.15 2.42 . . . . 0.0 119.15 -173.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -166.41 173.81 9.6 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 122.036 2.918 . . . . 0.0 111.722 -167.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -42.82 -60.13 1.7 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.335 1.454 . . . . 0.0 113.878 -169.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 26.4 tp10 -35.96 -29.22 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 126.128 1.771 . . . . 0.0 114.395 172.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 83.9 p -63.61 -30.1 71.26 Favored 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 123.355 2.798 . . . . 0.0 115.824 174.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -108.08 -19.9 13.35 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 118.372 -0.823 . . . . 0.0 112.903 169.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -74.09 -49.3 24.61 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.633 1.173 . . . . 0.0 112.078 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 56.4 p -111.38 -95.35 0.43 Allowed 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 164.326 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.28 16.22 0.2 Allowed Glycine 0 CA--C 1.535 1.29 1 C-N-CA 131.2 4.238 . . . . 0.0 112.1 175.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 50.99 34.03 9.96 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.352 1.861 . . . . 0.0 113.019 -174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.34 24.98 0.08 Allowed 'General case' 0 CA--C 1.565 1.531 0 CA-C-O 121.929 0.871 . . . . 0.0 112.727 -169.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.09 -42.85 0.8 Allowed Glycine 0 N--CA 1.471 0.996 0 C-N-CA 129.924 3.63 . . . . 0.0 114.972 175.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 t -161.41 -156.39 0.44 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.541 1.537 . . . . 0.0 109.461 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -166.75 1.11 Allowed 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 127.105 2.162 . . . . 0.0 108.23 168.654 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -179.54 -173.6 0.26 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 128.328 2.651 . . . . 0.0 107.766 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.51 142.39 8.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.751 2.02 . . . . 0.0 112.154 174.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.2 p -151.9 159.57 43.78 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.908 1.683 . . . . 0.0 114.826 -167.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.78 142.53 8.32 Favored Glycine 0 CA--C 1.534 1.233 0 CA-C-O 118.795 -1.003 . . . . 0.0 114.837 173.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 26.5 t -79.51 135.42 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 125.222 1.409 . . . . 0.0 110.675 170.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.58 115.82 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 O-C-N 121.222 -0.924 . . . . 0.0 110.806 -174.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.76 174.94 15.7 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.942 1.258 . . . . 0.0 111.858 172.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -93.57 156.6 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 N-CA-C 115.337 1.606 . . . . 0.0 115.337 -168.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.51 -16.66 0.17 Allowed 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 126.914 2.085 . . . . 0.0 114.308 171.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 CA--C 1.533 0.311 0 C-N-CA 125.361 1.464 . . . . 0.0 112.911 168.168 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.525 ' HA ' ' H ' ' A' ' 22' ' ' GLN . 74.0 p . . . . . 0 N--CA 1.468 0.472 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.9 mttp -169.4 135.12 1.56 Allowed 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 127.322 2.249 . . . . 0.0 114.726 165.372 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.38 177.82 7.46 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 128.864 2.866 . . . . 0.0 110.188 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.451 HG11 ' CA ' ' B' ' 52' ' ' ASP . 1.6 p -155.26 127.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 C-N-CA 126.642 1.977 . . . . 0.0 108.903 -167.669 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.5 129.68 55.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.804 0.842 . . . . 0.0 111.495 170.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.407 HG22 HG22 ' B' ' 54' ' ' THR . 44.3 t -102.13 95.39 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.666 1.186 . . . . 0.0 107.876 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -89.06 124.28 34.15 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.1 mtpt -143.45 175.36 9.99 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 121.958 0.885 . . . . 0.0 112.416 168.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.29 -65.2 0.16 Allowed Glycine 0 C--N 1.33 0.234 0 C-N-CA 125.571 1.558 . . . . 0.0 110.629 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.85 69.51 3.35 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.51 1.124 . . . . 0.0 111.27 -164.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 40.88 -102.61 0.03 OUTLIER Glycine 0 CA--C 1.536 1.361 0 C-N-CA 127.104 2.288 . . . . 0.0 113.373 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -68.93 -5.98 17.0 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 124.209 3.273 . . . . 0.0 114.459 -178.374 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.4 t -76.36 135.43 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 CA-C-N 120.151 1.342 . . . . 0.0 110.037 169.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.79 156.79 45.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.212 -1.358 . . . . 0.0 108.642 166.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.89 105.48 0.59 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 169.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.2 127.23 46.37 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 CA-C-N 117.824 0.812 . . . . 0.0 109.778 171.157 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 pp -137.42 121.73 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 122.435 1.112 . . . . 0.0 110.823 166.268 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -83.5 161.07 21.36 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.963 1.305 . . . . 0.0 109.048 164.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -138.29 130.14 28.22 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.526 0.731 . . . . 0.0 109.62 167.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.89 153.66 22.07 Favored 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 165.424 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.525 ' H ' ' HA ' ' A' ' 2' ' ' THR . 0.0 OUTLIER -157.9 140.85 14.96 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 124.726 1.21 . . . . 0.0 110.781 168.908 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HZ2' ' CD ' ' A' ' 24' ' ' GLU 0.256 0.0 OUTLIER -82.3 -68.47 0.7 Allowed 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 175.434 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 20.7 mp0 -132.66 165.07 25.32 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.944 1.698 . . . . 0.0 110.77 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 m -56.01 -28.71 58.45 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -98.38 5.21 48.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.817 1.247 . . . . 0.0 112.729 172.376 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.59 149.57 19.27 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 125.014 1.292 . . . . 0.0 111.861 -176.07 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -69.75 174.79 8.97 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.836 3.024 . . . . 0.0 111.83 -178.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -133.54 153.42 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.811 1.244 . . . . 0.0 112.486 -168.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.3 mttm -120.75 112.48 18.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.459 1.104 . . . . 0.0 109.178 167.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -80.86 148.07 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 O-C-N 121.418 -0.801 . . . . 0.0 109.402 167.553 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.2 p90 -156.64 157.62 35.57 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.528 0.731 . . . . 0.0 112.182 165.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.88 -158.81 27.83 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.116 0.807 . . . . 0.0 115.116 -176.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.0 p -153.64 129.12 9.91 Favored 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -168.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mm -111.66 113.94 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.419 178.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . 0.26 0.0 OUTLIER -133.3 172.17 13.05 Favored 'General case' 0 C--N 1.345 0.37 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -178.582 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.54 1.09 59.11 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 126.928 2.204 . . . . 0.0 110.753 -166.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mt -87.21 173.55 9.15 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.869 1.268 . . . . 0.0 110.589 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.4 t -84.77 162.88 19.44 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 163.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -60.79 161.03 8.53 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-O 121.529 0.68 . . . . 0.0 112.205 169.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.48 -175.16 31.48 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.64 1.114 . . . . 0.0 112.812 -178.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.828 ' H ' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -71.92 151.04 43.62 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 128.272 2.629 . . . . 0.0 112.398 -171.933 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -152.36 115.45 4.66 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 127.831 2.452 . . . . 0.0 110.087 -173.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.65 152.49 30.85 Favored Glycine 0 N--CA 1.487 2.065 0 CA-C-N 120.854 1.661 . . . . 0.0 113.368 -178.518 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -149.64 103.46 3.26 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.631 1.572 . . . . 0.0 111.054 -169.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -141.85 145.96 35.27 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 119.849 -1.782 . . . . 0.0 114.986 -164.12 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -96.76 142.76 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-N 118.618 0.645 . . . . 0.0 110.958 -174.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -115.19 125.15 53.05 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.838 1.255 . . . . 0.0 109.511 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -62.42 25.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 128.013 2.525 . . . . 0.0 115.318 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -149.48 126.62 11.33 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 127.843 2.457 . . . . 0.0 107.507 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.95 -19.82 66.64 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 126.513 2.006 . . . . 0.0 115.048 173.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -76.23 51.62 0.7 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 127.313 2.245 . . . . 0.0 113.55 -168.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.433 ' HA ' HG21 ' B' ' 7' ' ' VAL . 1.4 p30 -176.32 22.32 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.211 0 C-N-CA 126.599 1.959 . . . . 0.0 115.399 -167.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.8 t -66.85 44.45 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 128.319 2.648 . . . . 0.0 116.697 178.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.67 -11.06 9.09 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -174.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.17 -166.63 14.6 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 125.268 1.413 . . . . 0.0 112.762 -169.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 37.7 t -51.79 -20.67 2.3 Favored 'General case' 0 CA--C 1.551 0.987 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 -177.259 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -68.66 -6.77 27.94 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 115.088 1.514 . . . . 0.0 115.088 175.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.6 t -149.76 -26.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -90.58 112.41 24.1 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.972 -1.08 . . . . 0.0 111.273 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.28 -119.48 1.11 Allowed Glycine 0 CA--C 1.545 1.935 0 C-N-CA 124.652 1.12 . . . . 0.0 113.568 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.35 173.73 2.19 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 124.205 3.27 . . . . 0.0 110.81 169.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -94.9 114.56 26.43 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.5 0.72 . . . . 0.0 110.352 -172.437 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -58.59 146.25 36.59 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.281 1.032 . . . . 0.0 112.64 177.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -126.83 85.58 60.53 Favored Pre-proline 0 CA--C 1.551 1.01 0 C-N-CA 125.885 1.674 . . . . 0.0 112.96 -168.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -61.74 -34.37 83.39 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 123.341 2.694 . . . . 0.0 113.519 -176.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.16 -4.96 47.21 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.602 0.761 . . . . 0.0 112.809 174.71 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.8 t 62.85 47.23 4.6 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 127.125 2.17 . . . . 0.0 112.179 178.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.7 ptt180 -117.9 176.56 5.14 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 114.544 1.313 . . . . 0.0 114.544 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -70.67 159.67 34.01 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.763 1.225 . . . . 0.0 111.704 174.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.424 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 84.6 t60 -68.12 120.68 14.71 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 164.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.4 -168.83 18.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 115.209 0.844 . . . . 0.0 115.209 -166.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -93.69 0.55 Allowed Glycine 0 CA--C 1.536 1.371 0 CA-C-O 117.004 -1.998 . . . . 0.0 114.933 176.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -74.56 47.06 1.55 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 124.777 3.651 . . . . 0.0 115.318 -170.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.498 ' HE3' HD23 ' A' ' 126' ' ' LEU . 6.4 ptpt 179.79 -5.7 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.065 1 C-N-CA 133.212 4.605 . . . . 0.0 113.852 165.195 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.421 ' H ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -134.47 177.46 7.75 Favored 'General case' 0 CA--C 1.559 1.316 0 C-N-CA 127.363 2.265 . . . . 0.0 111.227 -166.263 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -109.73 -4.77 15.89 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 127.664 2.385 . . . . 0.0 112.538 -175.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -84.22 -113.11 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.251 1.42 . . . . 0.0 108.304 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 HG11 ' A' ' 103' ' ' VAL . 21.8 ttp180 91.68 119.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 127.475 2.31 . . . . 0.0 108.857 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m170 -57.03 159.23 4.37 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 121.498 -0.751 . . . . 0.0 109.692 168.174 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p -41.97 -33.22 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.374 1.47 . . . . 0.0 113.635 176.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -146.8 123.05 1.71 Allowed Glycine 0 CA--C 1.534 1.26 0 CA-C-O 122.415 1.008 . . . . 0.0 112.426 165.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -158.15 96.46 1.45 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 129.509 3.124 . . . . 0.0 107.42 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -96.07 52.37 1.29 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 122.028 0.918 . . . . 0.0 110.353 178.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.68 -114.55 0.94 Allowed Glycine 0 CA--C 1.526 0.76 0 C-N-CA 126.35 1.929 . . . . 0.0 113.467 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -133.37 138.46 46.32 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.78 1.232 . . . . 0.0 112.529 172.762 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.4 m -91.23 143.55 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 127.153 2.181 . . . . 0.0 109.723 171.204 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.6 m -122.39 123.59 41.69 Favored 'General case' 0 N--CA 1.474 0.742 0 O-C-N 120.848 -1.157 . . . . 0.0 110.424 -172.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.14 159.25 15.06 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 114.613 1.338 . . . . 0.0 114.613 -175.427 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.69 175.26 10.28 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.858 2.063 . . . . 0.0 112.381 169.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.672 ' H ' ' HE2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -71.44 -16.37 62.37 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.516 1.126 . . . . 0.0 113.795 172.336 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.59 -13.32 61.36 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 121.967 0.889 . . . . 0.0 109.92 166.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.18 -4.43 58.7 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 127.635 2.54 . . . . 0.0 114.473 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.9 p -91.59 127.75 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 120.946 2.373 . . . . 0.0 114.633 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.11 119.81 32.73 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 163.69 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -87.6 140.43 29.52 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 172.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.64 131.39 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 124.477 1.111 . . . . 0.0 112.328 -168.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.0 p -157.21 60.3 0.51 Allowed 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.39 1.476 . . . . 0.0 113.383 -176.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.0 mp -95.99 142.53 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 119.446 -2.033 . . . . 0.0 112.847 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -117.09 136.79 52.72 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 125.828 1.651 . . . . 0.0 108.424 168.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -153.82 146.16 23.92 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.896 1.279 . . . . 0.0 111.794 -169.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 32.5 t -118.69 55.01 0.93 Allowed 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.084 -0.962 . . . . 0.0 113.091 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.406 HG11 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -139.45 -31.37 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 166.484 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -97.18 159.53 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 122.451 1.119 . . . . 0.0 112.208 172.42 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 53.8 p -156.94 163.18 39.42 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 125.642 1.577 . . . . 0.0 110.062 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.3 mt -82.4 73.39 9.44 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 122.341 1.067 . . . . 0.0 108.874 171.081 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -132.85 157.74 44.27 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.091 2.156 . . . . 0.0 107.67 170.501 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -116.87 41.94 1.98 Allowed Glycine 0 N--CA 1.472 1.09 0 C-N-CA 124.847 1.213 . . . . 0.0 113.45 -170.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.17 -88.52 0.51 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 127.381 2.273 . . . . 0.0 106.858 -178.453 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.79 12.83 13.08 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 126.016 1.726 . . . . 0.0 110.99 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -92.09 -160.82 0.77 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 120.467 -1.396 . . . . 0.0 112.176 173.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.413 HG23 HH21 ' A' ' 115' ' ' ARG . 8.3 pt -94.08 -13.47 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 N-CA-C 117.017 2.228 . . . . 0.0 117.017 -168.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.3 mm -73.1 125.93 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 122.326 2.33 . . . . 0.0 110.482 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.76 -0.66 81.44 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 117.782 -1.565 . . . . 0.0 113.917 -173.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.413 HH21 HG23 ' A' ' 112' ' ' ILE . 30.9 ttp180 -92.18 167.61 11.92 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.435 1.894 . . . . 0.0 110.573 176.075 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -113.6 163.19 15.28 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 125.582 1.553 . . . . 0.0 112.639 -176.081 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 41.7 tp -137.29 126.18 24.15 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 127.426 2.29 . . . . 0.0 110.452 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.5 p -100.21 140.21 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 126.456 1.903 . . . . 0.0 110.987 173.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -107.27 143.05 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 CA-C-O 121.676 0.751 . . . . 0.0 109.313 165.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -122.27 162.85 20.7 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.985 1.714 . . . . 0.0 111.558 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 -27.41 44.84 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 120.264 -1.522 . . . . 0.0 114.848 -167.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 20.7 mmtm -130.5 -175.63 3.71 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.758 2.072 . . . . 0.0 114.357 -171.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.45 153.51 31.23 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.718 1.207 . . . . 0.0 111.79 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -102.38 131.53 48.96 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.405 1.082 . . . . 0.0 110.889 -174.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -78.82 -31.98 46.07 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.352 1.861 . . . . 0.0 113.479 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.498 HD23 ' HE3' ' A' ' 75' ' ' LYS . 2.7 mm? 56.0 63.48 2.01 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.353 1.861 . . . . 0.0 114.803 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.0 10.21 64.85 Favored Glycine 0 N--CA 1.467 0.764 0 N-CA-C 120.065 2.786 . . . . 0.0 120.065 161.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.3 pptp? -148.33 -5.6 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 119.468 3.136 . . . . 0.0 119.468 -165.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.06 27.96 0.79 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 120.881 1.673 . . . . 0.0 116.035 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.96 -23.68 2.57 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.566 1.555 . . . . 0.0 116.508 171.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -95.88 165.45 12.27 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 119.717 1.759 . . . . 0.0 111.777 -173.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -49.96 -57.88 6.61 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.993 1.317 . . . . 0.0 109.24 168.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -50.83 -38.77 50.79 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 126.297 1.839 . . . . 0.0 112.803 177.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 20.1 m -62.51 -32.09 72.96 Favored 'General case' 0 N--CA 1.464 0.259 0 O-C-N 121.081 -1.012 . . . . 0.0 113.432 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.273 1.6 t -118.17 -10.62 10.25 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 117.324 -1.322 . . . . 0.0 113.988 -175.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . 0.256 0.6 OUTLIER -90.81 -34.1 15.44 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 120.469 1.486 . . . . 0.0 113.306 168.72 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.78 -17.58 4.0 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 126.042 1.737 . . . . 0.0 114.993 -176.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.424 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 96.61 12.64 50.16 Favored Glycine 0 N--CA 1.466 0.655 0 CA-C-N 120.454 1.479 . . . . 0.0 114.644 -178.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 61.72 7.73 2.07 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 119.711 1.756 . . . . 0.0 113.832 177.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.19 10.5 0.02 OUTLIER 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 118.816 2.895 . . . . 0.0 118.816 -164.585 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.48 -160.4 32.98 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 126.31 1.909 . . . . 0.0 113.588 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.5 t -55.04 148.83 12.98 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.954 -0.733 . . . . 0.0 111.584 176.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.86 128.95 37.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 170.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.421 HD12 ' H ' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -111.91 -119.23 0.3 Allowed 'General case' 0 C--O 1.238 0.497 0 O-C-N 124.382 1.051 . . . . 0.0 109.728 173.575 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.421 ' H ' HD12 ' A' ' 144' ' ' LEU . . . -68.27 151.91 46.23 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-O 122.425 1.107 . . . . 0.0 112.02 -172.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.6 t -154.24 143.28 21.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.334 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.93 151.59 23.09 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 -169.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.479 ' CG1' ' HB ' ' B' ' 148' ' ' VAL . 2.7 p -79.52 156.2 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.126 0.97 . . . . 0.0 111.885 172.48 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.4 mm -103.22 111.08 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.59 1.156 . . . . 0.0 111.872 170.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.07 159.96 13.47 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.965 1.269 . . . . 0.0 112.576 175.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.53 139.19 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.147 -1.208 . . . . 0.0 112.231 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.21 -141.34 0.23 Allowed 'General case' 0 CA--C 1.549 0.933 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 161.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.471 0.59 0 C-N-CA 124.835 1.254 . . . . 0.0 111.595 168.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.557 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 88.6 m -77.55 99.87 5.88 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.046 1.339 . . . . 0.0 107.754 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 33.9 mtmm -117.05 132.63 56.64 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 123.954 0.902 . . . . 0.0 113.363 -170.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.67 157.69 46.0 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 129.931 3.292 . . . . 0.0 109.67 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 33.5 t -136.32 114.13 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.577 1.18 . . . . 0.0 110.853 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.58 96.05 6.05 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 113.823 -1.535 . . . . 0.0 107.628 167.235 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 53' ' ' ASN . 34.4 m -86.03 115.55 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 165.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.4 mp -98.08 136.13 38.77 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.688 -174.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -157.97 121.8 4.08 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 119.741 1.155 . . . . 0.0 113.894 165.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -84.74 -115.41 0.72 Allowed Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 168.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -143.08 128.97 19.48 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.813 2.845 . . . . 0.0 106.011 -168.081 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.06 179.42 50.98 Favored Glycine 0 CA--C 1.537 1.421 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -167.058 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.45 49.56 2.68 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 125.293 3.995 . . . . 0.0 112.209 -176.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.65 112.65 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 126.334 1.853 . . . . 0.0 108.655 174.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 pm0 -158.71 166.53 31.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.651 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.96 171.92 35.05 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-O 122.133 0.851 . . . . 0.0 112.456 168.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 pp -121.63 122.76 67.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 166.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mm -131.36 101.9 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -75.38 148.32 39.29 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.249 1.02 . . . . 0.0 110.162 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.4 m-85 -126.61 116.37 20.91 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.171 1.789 . . . . 0.0 108.762 169.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -116.45 120.84 40.06 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 126.301 1.84 . . . . 0.0 112.537 177.436 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -113.92 130.01 56.55 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 122.127 0.965 . . . . 0.0 112.273 169.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.48 ' HE2' ' N ' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -87.17 -28.73 22.26 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.077 0.951 . . . . 0.0 112.474 -172.122 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -158.36 136.07 10.4 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 128.046 2.538 . . . . 0.0 107.71 168.381 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.8 t -47.62 -42.35 24.0 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 129.048 2.939 . . . . 0.0 113.495 -176.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -84.92 -7.67 59.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.057 1.343 . . . . 0.0 113.25 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.3 -167.71 42.13 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 125.521 1.534 . . . . 0.0 112.148 173.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' PRO . . . . . 0.406 ' O ' ' HE3' ' B' ' 23' ' ' LYS . 20.7 Cg_endo -84.51 176.66 6.21 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.305 2.67 . . . . 0.0 111.669 178.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.82 143.46 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 125.817 1.647 . . . . 0.0 109.4 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 14.9 tttp -107.78 130.58 54.96 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.352 1.061 . . . . 0.0 109.567 168.292 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.57 126.5 74.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 126.025 1.73 . . . . 0.0 108.495 -177.004 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -148.28 160.5 42.91 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -177.179 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.91 -149.26 21.26 Favored Glycine 0 C--N 1.333 0.397 0 C-N-CA 124.077 0.846 . . . . 0.0 111.868 170.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -150.82 128.78 11.76 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -171.157 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 mp -96.33 136.52 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.646 1.179 . . . . 0.0 109.213 169.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.4 mtpt -130.52 154.4 47.84 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 112.521 -178.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.11 -0.19 57.31 Favored Glycine 0 N--CA 1.475 1.235 0 C-N-CA 124.942 1.258 . . . . 0.0 113.332 -170.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 91.1 mt -78.49 149.01 33.25 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 124.738 1.215 . . . . 0.0 112.017 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -78.17 149.28 33.78 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 165.403 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' GLU . . . . . 0.404 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 1.5 pm0 -54.63 141.34 32.2 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 126.614 1.966 . . . . 0.0 113.064 -178.19 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.87 -168.24 18.0 Favored Glycine 0 N--CA 1.472 1.06 0 O-C-N 120.89 -1.131 . . . . 0.0 113.817 -177.121 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.432 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -82.02 138.93 34.77 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 128.011 2.525 . . . . 0.0 115.966 -167.837 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -137.04 131.73 33.21 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 128.58 2.752 . . . . 0.0 109.728 -174.004 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.43 161.6 54.27 Favored Glycine 0 N--CA 1.47 0.96 0 C-N-CA 124.672 1.129 . . . . 0.0 114.632 -172.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -153.38 118.94 5.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.651 1.225 . . . . 0.0 113.128 -168.198 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -157.33 150.02 23.21 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 119.893 -1.754 . . . . 0.0 115.248 177.187 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -104.93 117.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.406 1.483 . . . . 0.0 110.097 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -98.36 146.67 25.46 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.853 2.061 . . . . 0.0 109.799 -173.281 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -70.32 148.38 48.55 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.494 -171.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 77.83 156.66 0.17 Allowed 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 127.65 2.38 . . . . 0.0 112.498 -173.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.5 -1.3 81.94 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.724 168.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.451 ' CA ' HG11 ' A' ' 5' ' ' VAL . 13.6 t0 -76.92 115.89 17.11 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 118.782 1.291 . . . . 0.0 110.823 -174.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.506 HD22 HG22 ' B' ' 148' ' ' VAL 0.413 2.6 p-10 -144.21 43.64 1.43 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 123.502 1.62 . . . . 0.0 113.992 164.293 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.407 HG22 HG22 ' A' ' 7' ' ' VAL 0.3 0.5 OUTLIER . . . . . 0 N--CA 1.455 -0.217 0 CA-C-N 112.58 -2.1 . . . . 0.0 111.936 174.493 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.745 0 N-CA-C 112.543 0.571 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.84 -63.93 3.56 Favored Glycine 0 CA--C 1.539 1.549 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.491 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -89.77 -180.0 1.99 Allowed 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 124.916 3.744 . . . . 0.0 111.959 169.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -79.67 128.74 33.78 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-O 123.201 1.477 . . . . 0.0 111.925 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -63.41 127.72 32.58 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 113.116 -1.857 . . . . 0.0 108.329 163.309 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 -121.19 58.48 7.53 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 123.675 0.79 . . . . 0.0 112.158 -171.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.31 -11.72 29.44 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.426 2.084 . . . . 0.0 113.873 -178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.3 mp -92.97 -8.27 43.57 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 114.121 1.156 . . . . 0.0 114.121 173.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.8 t 61.68 74.81 0.43 Allowed 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 119.957 1.253 . . . . 0.0 113.432 175.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -167.35 179.14 5.16 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.33 1.452 . . . . 0.0 112.562 -171.158 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mppt? -85.55 171.43 11.73 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.995 1.718 . . . . 0.0 112.767 177.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -86.26 146.54 26.48 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.921 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.82 -108.21 0.49 Allowed Glycine 0 C--N 1.336 0.534 0 CA-C-O 119.063 -0.854 . . . . 0.0 114.875 165.531 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.59 -42.16 2.01 Favored Glycine 0 CA--C 1.555 2.589 0 CA-C-O 118.182 -1.343 . . . . 0.0 114.127 -168.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -84.32 15.38 2.18 Favored 'Trans proline' 0 CA--C 1.553 1.474 0 C-N-CA 124.241 3.294 . . . . 0.0 116.712 171.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -39.42 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 128.143 2.577 . . . . 0.0 110.376 165.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.44 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 1.0 OUTLIER -66.1 137.01 56.75 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 161.561 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -99.82 -16.58 18.02 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.298 1.439 . . . . 0.0 111.258 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -79.4 -60.18 2.47 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.56 -0.712 . . . . 0.0 110.464 -171.592 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.2 ttt-85 71.91 127.47 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.528 1.931 . . . . 0.0 112.374 168.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -76.62 173.02 12.08 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 119.237 -2.164 . . . . 0.0 111.669 168.04 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.7 p -76.85 134.86 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.597 -1.314 . . . . 0.0 109.376 167.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.23 9.13 86.93 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 126.447 1.975 . . . . 0.0 115.801 -174.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 61.5 m-20 -78.25 114.96 17.62 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-N 119.902 1.851 . . . . 0.0 111.924 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 56.8 mt -99.57 179.06 4.67 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.812 0.845 . . . . 0.0 110.086 168.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -109.9 165.2 12.32 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 125.074 1.321 . . . . 0.0 112.445 174.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -74.63 150.84 39.44 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 -168.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.4 m -114.67 128.66 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 128.373 2.669 . . . . 0.0 111.097 -172.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.33 128.16 45.42 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.739 -1.225 . . . . 0.0 111.724 -178.31 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.05 135.06 35.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 169.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.06 154.47 23.2 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.626 1.97 . . . . 0.0 109.438 167.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -45.63 -21.8 0.13 Allowed 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 129.037 2.935 . . . . 0.0 116.847 176.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.76 9.62 2.72 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.356 1.062 . . . . 0.0 111.408 172.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.2 35.54 42.97 Favored Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.338 2.399 . . . . 0.0 112.324 175.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 1.8 p -142.93 126.99 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 119.017 1.408 . . . . 0.0 114.65 -172.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.46 119.46 32.58 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 165.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.7 t0 -79.64 154.23 28.82 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.592 1.157 . . . . 0.0 109.724 169.523 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.3 144.2 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 168.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.7 p -156.24 58.5 0.58 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.635 1.574 . . . . 0.0 112.177 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 28.9 mt -80.35 148.68 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 120.237 -1.539 . . . . 0.0 111.334 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -128.84 137.5 51.52 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.908 2.083 . . . . 0.0 105.591 166.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -154.78 136.79 14.65 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.476 1.111 . . . . 0.0 111.604 -169.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.95 49.06 1.02 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 123.518 0.727 . . . . 0.0 112.932 178.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 t -149.46 20.15 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 124.858 1.263 . . . . 0.0 111.731 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -148.62 169.91 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 128.787 2.835 . . . . 0.0 107.944 169.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -156.88 157.3 34.64 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.837 -1.164 . . . . 0.0 110.129 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -99.2 60.79 1.2 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.121 1.369 . . . . 0.0 108.837 -178.223 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.8 m -84.88 -94.21 0.08 Allowed 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.995 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 163.62 60.66 0.02 OUTLIER Glycine 0 N--CA 1.473 1.139 0 O-C-N 120.836 -1.165 . . . . 0.0 113.263 -172.231 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 109' ' ' ASP . . . . . 0.436 ' CG ' ' H ' ' B' ' 110' ' ' HIS . 9.2 p-10 -161.24 -108.95 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 123.136 1.446 . . . . 0.0 108.978 -164.111 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 110' ' ' HIS . . . . . 0.436 ' H ' ' CG ' ' B' ' 109' ' ' ASP . 14.6 m-70 -107.57 -28.92 9.48 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 130.001 3.32 . . . . 0.0 110.821 173.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 79.9 p -48.44 -65.28 0.59 Allowed 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 128.222 2.609 . . . . 0.0 116.759 -167.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 33.8 mm -150.06 -51.46 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 128.003 2.521 . . . . 0.0 109.513 169.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 49.8 mm -65.3 120.69 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 169.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.78 10.86 69.08 Favored Glycine 0 CA--C 1.534 1.266 0 N-CA-C 114.585 0.594 . . . . 0.0 114.585 -170.029 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 20.2 ttt85 -108.79 -179.86 3.98 Favored 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.94 2.496 . . . . 0.0 109.672 171.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -148.11 130.35 15.56 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.132 -1.605 . . . . 0.0 112.938 179.073 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -101.53 134.09 45.19 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 119.294 0.952 . . . . 0.0 110.931 -175.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -118.74 137.09 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.204 1.402 . . . . 0.0 109.52 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.42 130.03 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-O 122.646 1.212 . . . . 0.0 108.142 168.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -107.22 152.98 23.36 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.642 1.977 . . . . 0.0 110.108 -172.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.77 -45.34 44.46 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 119.751 -1.843 . . . . 0.0 114.67 -166.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.11 171.55 7.32 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 120.949 1.704 . . . . 0.0 112.061 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.59 149.74 7.75 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 124.037 0.935 . . . . 0.0 112.538 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -75.87 134.44 40.31 Favored 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 168.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -41.18 68.77 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 175.486 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.3 mt 67.87 37.56 3.1 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 125.867 1.667 . . . . 0.0 111.44 170.026 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -171.2 -75.16 0.04 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.211 0.91 . . . . 0.0 113.441 169.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.8 ttpt -162.04 98.1 1.05 Allowed 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 126.85 2.06 . . . . 0.0 113.605 173.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 129' ' ' GLY . . . . . 0.473 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -76.87 -135.98 0.71 Allowed Glycine 0 CA--C 1.537 1.413 0 CA-C-O 122.247 0.915 . . . . 0.0 113.417 169.043 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.89 -9.35 52.52 Favored Glycine 0 N--CA 1.474 1.172 0 N-CA-C 118.448 2.139 . . . . 0.0 118.448 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -164.8 175.47 9.61 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 120.514 2.157 . . . . 0.0 111.59 -169.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -48.07 -54.74 12.1 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 113.396 0.887 . . . . 0.0 113.396 -170.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -57.58 -10.52 1.55 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 114.476 1.287 . . . . 0.0 114.476 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.473 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 90.9 p -58.05 -49.96 75.1 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.884 1.674 . . . . 0.0 112.964 167.829 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 19.0 p -93.24 -18.1 22.9 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 178.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -85.12 -35.68 21.62 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.669 0.788 . . . . 0.0 112.867 176.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 59.8 p -115.33 -112.17 0.34 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.981 1.312 . . . . 0.0 107.479 167.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -142.6 21.45 2.37 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.875 2.179 . . . . 0.0 112.187 169.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.71 13.79 3.68 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.517 1.927 . . . . 0.0 113.466 -171.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.34 33.18 0.02 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 128.951 2.901 . . . . 0.0 118.559 -165.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.86 -54.8 3.01 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 126.905 2.193 . . . . 0.0 115.568 169.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -173.51 175.91 2.91 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 125.848 1.659 . . . . 0.0 111.97 -170.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -127.2 115.08 18.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.249 1.419 . . . . 0.0 110.461 -169.757 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.8 pp -110.53 -37.17 5.56 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -170.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.57 158.34 33.74 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 119.558 1.072 . . . . 0.0 113.136 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 20.3 p -156.45 163.78 39.03 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.471 2.309 . . . . 0.0 110.24 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.92 142.43 8.69 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 127.075 2.274 . . . . 0.0 110.246 171.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.506 HG22 HD22 ' B' ' 53' ' ' ASN . 1.6 t -88.17 146.8 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 CA-C-N 118.967 1.383 . . . . 0.0 108.68 -174.344 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.5 mm -77.33 120.56 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.013 -1.054 . . . . 0.0 112.94 -169.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.47 -172.4 18.77 Favored Glycine 0 N--CA 1.47 0.958 0 C-N-CA 125.824 1.678 . . . . 0.0 113.567 175.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -133.43 160.39 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 173.075 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.88 -39.31 0.09 Allowed 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 125.902 1.681 . . . . 0.0 111.368 168.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 . . . . . 0 C--O 1.241 0.612 0 C-N-CA 126.31 1.844 . . . . 0.0 112.824 169.937 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.2 t . . . . . 0 N--CA 1.467 0.407 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.2 102.71 14.16 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.929 -0.482 . . . . 0.0 112.022 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.01 166.67 22.54 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.784 0.72 . . . . 0.0 109.339 167.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.1 t -138.69 140.69 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 122.309 1.052 . . . . 0.0 112.798 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.85 113.15 19.24 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 114.089 -1.414 . . . . 0.0 109.12 165.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.03 80.63 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 127.276 2.23 . . . . 0.0 108.476 167.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -73.84 157.76 35.76 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.007 0.923 . . . . 0.0 111.238 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -148.66 158.51 44.19 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.39 162.68 13.65 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 127.549 2.5 . . . . 0.0 107.54 166.002 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -76.33 57.66 1.2 Allowed 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 126.837 2.055 . . . . 0.0 111.85 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.13 -167.53 40.0 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 128.436 2.922 . . . . 0.0 109.553 -175.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -80.1 42.55 1.34 Allowed 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 125.224 3.949 . . . . 0.0 112.306 -172.788 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -131.42 129.63 62.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 124.44 1.096 . . . . 0.0 109.165 -175.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -158.66 169.36 24.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.42 1.888 . . . . 0.0 109.074 -172.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 135.79 4.55 Favored Glycine 0 C--O 1.224 -0.469 0 C-N-CA 121.321 -0.466 . . . . 0.0 112.577 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.08 132.11 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 168.375 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.442 HD12 HG11 ' A' ' 97' ' ' VAL . 15.2 mm -139.09 112.77 6.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 C-N-CA 123.835 0.854 . . . . 0.0 110.838 173.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 31.4 m-20 -78.49 144.32 35.83 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.976 0.91 . . . . 0.0 110.453 165.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -123.56 99.12 6.15 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.744 1.618 . . . . 0.0 109.886 172.671 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.88 105.34 11.09 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.664 1.186 . . . . 0.0 110.742 -179.629 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -79.29 83.1 5.37 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 120.926 -1.109 . . . . 0.0 108.537 169.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.51 -50.71 72.85 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 118.708 -0.663 . . . . 0.0 111.169 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.3 mp0 -132.38 136.48 46.84 Favored 'General case' 0 C--O 1.224 -0.241 0 C-N-CA 124.271 1.028 . . . . 0.0 108.876 168.05 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.1 p -67.08 -4.73 10.7 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 126.163 1.785 . . . . 0.0 114.954 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.46 1.93 9.6 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 126.743 2.017 . . . . 0.0 112.06 173.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.45 -153.2 12.52 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.664 1.602 . . . . 0.0 111.192 -176.173 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -86.24 173.06 6.9 Favored 'Trans proline' 0 N--CA 1.451 -1.01 0 C-N-CA 122.788 2.325 . . . . 0.0 111.761 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.95 134.06 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.759 1.624 . . . . 0.0 108.498 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.4 tttp -101.24 121.78 42.48 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 169.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.4 t -121.14 118.82 57.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 125.924 1.689 . . . . 0.0 109.095 -168.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -140.65 161.9 36.65 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -178.214 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.65 -150.73 22.97 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 124.783 1.182 . . . . 0.0 112.415 -179.323 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 43.1 p -158.09 136.04 10.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -171.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -109.7 112.93 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.668 1.187 . . . . 0.0 108.494 178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -120.79 135.86 55.04 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.955 1.302 . . . . 0.0 111.446 -168.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.67 -2.08 15.47 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 127.191 2.329 . . . . 0.0 113.559 -173.305 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.431 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -69.0 -178.27 1.21 Allowed 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 125.829 1.651 . . . . 0.0 110.992 169.587 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -115.11 156.22 25.62 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 127.962 2.505 . . . . 0.0 105.266 164.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -48.37 146.15 3.0 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 127.032 2.133 . . . . 0.0 114.118 -175.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.83 -177.4 32.86 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 122.084 0.824 . . . . 0.0 113.393 -178.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.491 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -70.13 150.26 46.71 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.449 2.3 . . . . 0.0 112.068 -169.489 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.431 ' CD2' HD23 ' A' ' 38' ' ' LEU . 92.8 m-70 -147.28 124.03 11.21 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.021 1.728 . . . . 0.0 110.32 175.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.43 155.43 32.44 Favored Glycine 0 N--CA 1.491 2.316 0 CA-C-N 120.281 1.4 . . . . 0.0 114.398 -174.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.635 ' CE1' HD11 ' A' ' 117' ' ' LEU . 2.0 t80 -146.1 102.11 3.59 Favored 'General case' 0 CA--C 1.552 1.051 0 CA-C-O 122.76 1.267 . . . . 0.0 113.77 -167.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -127.34 133.16 50.11 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.89 94.71 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 126.408 1.883 . . . . 0.0 110.355 174.171 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -73.75 108.84 6.82 Favored 'General case' 0 CA--C 1.557 1.242 0 O-C-N 120.604 -1.31 . . . . 0.0 114.36 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -31.03 106.23 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 127.408 2.283 . . . . 0.0 113.208 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 148.44 173.86 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 129.792 3.237 . . . . 0.0 109.758 -169.193 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.578 ' HA3' ' H ' ' B' ' 151' ' ' ILE . . . -116.85 -2.63 18.78 Favored Glycine 0 CA--C 1.549 2.201 0 C-N-CA 126.292 1.901 . . . . 0.0 109.859 160.627 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' C ' HD22 ' A' ' 53' ' ' ASN . 0.8 OUTLIER -75.69 147.22 39.57 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 128.008 2.523 . . . . 0.0 111.75 170.271 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.51 HD22 ' C ' ' A' ' 52' ' ' ASP 0.312 0.1 OUTLIER -173.53 17.47 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 119.041 2.978 . . . . 0.0 119.041 166.627 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.416 HG22 HG22 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -92.35 -12.52 32.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 120.083 -1.636 . . . . 0.0 114.315 -165.359 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.34 18.14 22.47 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.772 1.229 . . . . 0.0 112.678 172.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.66 -123.43 24.72 Favored Glycine 0 CA--C 1.529 0.933 0 O-C-N 120.697 -1.252 . . . . 0.0 112.243 174.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.3 m -72.5 -9.33 58.43 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 175.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -14.92 52.55 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 125.184 1.394 . . . . 0.0 111.407 169.188 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.7 m -95.28 -159.51 0.72 Allowed 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 127.41 2.284 . . . . 0.0 109.52 168.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.13 104.69 0.03 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 128.212 2.605 . . . . 0.0 116.374 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -63.07 166.72 23.77 Favored Glycine 0 CA--C 1.545 1.92 0 C-N-CA 125.869 1.699 . . . . 0.0 114.805 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -62.11 96.89 0.15 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 125.07 3.847 . . . . 0.0 113.173 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.0 p-80 47.82 64.49 1.61 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 126.124 1.769 . . . . 0.0 113.24 169.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -32.11 137.83 0.05 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.383 1.873 . . . . 0.0 115.439 -178.102 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -106.01 63.66 0.16 Allowed Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 126.559 1.944 . . . . 0.0 113.084 177.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -62.78 -35.77 66.27 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.612 2.208 . . . . 0.0 111.898 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.1 tp -77.76 -5.18 49.79 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 124.727 1.211 . . . . 0.0 112.869 173.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t 71.27 51.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.945 2.098 . . . . 0.0 112.497 172.008 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 78' ' ' GLU . 8.5 mtp180 -108.19 171.71 7.25 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -169.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.7 mttp -81.09 162.71 23.6 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.468 1.507 . . . . 0.0 109.521 165.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -72.36 151.72 42.51 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 121.012 -1.055 . . . . 0.0 112.151 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.73 -138.45 6.39 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 116.137 1.215 . . . . 0.0 116.137 169.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.457 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 139.77 -108.88 0.6 Allowed Glycine 0 CA--C 1.544 1.856 0 CA-C-O 116.835 -2.092 . . . . 0.0 114.934 -168.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -52.33 -3.65 0.11 Allowed 'Trans proline' 0 CA--C 1.546 1.103 1 C-N-CA 126.443 4.762 . . . . 0.0 120.068 -169.333 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.48 2.89 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 127.693 2.397 . . . . 0.0 112.594 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.457 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.3 OUTLIER -123.91 175.81 6.7 Favored 'General case' 0 CA--C 1.557 1.249 0 C-N-CA 129.091 2.957 . . . . 0.0 109.02 -174.912 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -116.55 -13.71 10.9 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.671 2.388 . . . . 0.0 111.143 -175.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 69' ' ' ARG . 3.8 mm-40 -91.59 -65.3 1.02 Allowed 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.769 1.228 . . . . 0.0 112.555 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 ' CG ' ' A' ' 101' ' ' ASP . 1.4 ttt-85 52.91 77.07 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 120.088 1.313 . . . . 0.0 111.48 171.232 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -46.91 153.32 0.42 Allowed 'General case' 0 N--CA 1.478 0.971 0 O-C-N 120.264 -1.523 . . . . 0.0 112.298 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 p -43.95 -40.62 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 120.125 1.33 . . . . 0.0 113.715 -176.216 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -97.08 34.2 5.24 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 126.863 2.173 . . . . 0.0 117.21 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -114.68 128.17 56.16 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.992 1.717 . . . . 0.0 110.426 176.221 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.1 mt -122.41 53.75 1.23 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-O 122.031 0.92 . . . . 0.0 108.555 168.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 62.2 -132.53 45.49 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.411 1.482 . . . . 0.0 114.229 175.242 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -143.45 154.86 44.11 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.573 1.149 . . . . 0.0 110.591 175.15 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.94 104.04 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.618 1.567 . . . . 0.0 109.733 -175.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -91.68 125.46 36.41 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 124.01 0.924 . . . . 0.0 109.222 -175.18 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.97 156.05 17.78 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -173.484 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -82.85 166.35 19.03 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.037 1.735 . . . . 0.0 110.206 167.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.6 pttt -51.28 -24.03 4.12 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 127.521 2.328 . . . . 0.0 113.274 167.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -76.78 -0.73 24.91 Favored 'General case' 0 CA--C 1.55 0.954 0 C-N-CA 125.929 1.691 . . . . 0.0 112.016 172.497 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.21 7.32 84.59 Favored Glycine 0 CA--C 1.52 0.404 0 O-C-N 120.183 -1.573 . . . . 0.0 113.523 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -95.18 123.69 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 125.405 1.482 . . . . 0.0 112.142 174.104 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.85 134.49 36.16 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 163.482 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -79.29 150.62 31.46 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 168.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.442 HG11 HD12 ' A' ' 18' ' ' ILE . 1.3 t -131.2 123.24 53.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 113.287 -1.779 . . . . 0.0 109.855 168.655 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.1 m -147.12 70.94 1.2 Allowed 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.865 2.066 . . . . 0.0 109.198 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 31.3 mt -116.4 152.37 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 125.502 1.521 . . . . 0.0 111.711 -168.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -145.48 137.28 25.37 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 127.172 2.189 . . . . 0.0 107.064 174.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.406 ' CG ' HH21 ' A' ' 79' ' ' ARG . 22.7 t70 -154.26 139.4 17.44 Favored 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -167.787 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -116.59 51.57 0.98 Allowed 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.6 t -128.62 -47.93 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -100.43 176.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.16 0.984 . . . . 0.0 112.005 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -157.94 176.03 13.07 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 120.693 -1.254 . . . . 0.0 110.696 172.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.4 mp -109.69 52.2 0.73 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.803 1.641 . . . . 0.0 109.46 -177.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.3 t -91.24 14.33 14.68 Favored 'General case' 0 CA--C 1.542 0.669 0 O-C-N 120.57 -1.331 . . . . 0.0 114.417 -174.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 102.47 -122.32 7.48 Favored Glycine 0 C--N 1.339 0.698 0 O-C-N 121.527 -0.733 . . . . 0.0 111.652 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -59.09 -52.7 64.59 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 126.934 2.094 . . . . 0.0 114.27 -163.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -88.48 9.43 23.72 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.737 1.615 . . . . 0.0 112.602 -174.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.21 -161.23 0.82 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 125.407 1.483 . . . . 0.0 113.937 -165.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.283 7.4 pt -88.96 1.16 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 175.283 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 38.8 mm -69.72 132.68 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 163.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.24 -12.11 55.79 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.763 -1.576 . . . . 0.0 115.631 -171.086 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.716 ' NE ' ' H ' ' A' ' 116' ' ' THR . 1.3 tpm_? -71.51 177.86 3.8 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.699 2.249 . . . . 0.0 108.486 178.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.716 ' H ' ' NE ' ' A' ' 115' ' ' ARG . 1.5 m -140.53 131.58 26.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 126.932 2.093 . . . . 0.0 106.717 175.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.635 HD11 ' CE1' ' A' ' 45' ' ' PHE . 2.3 tm? -87.22 137.8 32.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 125.542 1.776 . . . . 0.0 106.791 166.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 5.2 p -117.45 124.54 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.624 1.17 . . . . 0.0 108.427 168.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.42 145.18 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 O-C-N 124.94 1.4 . . . . 0.0 109.083 169.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 23.2 m-70 -117.34 161.76 19.01 Favored 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 125.16 1.384 . . . . 0.0 113.134 -170.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.54 -34.25 69.86 Favored 'General case' 0 N--CA 1.478 0.935 0 O-C-N 120.597 -1.314 . . . . 0.0 114.071 179.564 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.426 ' HE3' ' O ' ' A' ' 139' ' ' ASN . 17.9 ttpp -94.49 156.02 16.66 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 123.064 1.412 . . . . 0.0 113.766 -173.69 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.58 142.59 17.74 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.744 165.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -93.43 128.6 39.57 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 124.465 1.103 . . . . 0.0 110.641 -178.224 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.81 -21.65 59.17 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.697 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 72.3 mt 47.86 56.52 7.09 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 127.912 2.485 . . . . 0.0 111.219 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.16 -58.9 0.38 Allowed Glycine 0 N--CA 1.472 1.055 0 C-N-CA 125.864 1.697 . . . . 0.0 113.732 173.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp -126.05 77.55 1.69 Allowed 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 115.226 1.565 . . . . 0.0 115.226 -169.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.607 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -80.57 -95.23 0.4 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 107.196 -2.362 . . . . 0.0 107.196 165.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -150.03 8.58 0.81 Allowed Glycine 0 N--CA 1.474 1.173 0 N-CA-C 117.728 1.851 . . . . 0.0 117.728 -174.483 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.7 p30 -161.2 -177.7 6.23 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 120.4 2.1 . . . . 0.0 111.111 -176.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -55.77 -51.89 65.85 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.207 0.912 . . . . 0.0 112.727 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -59.38 -23.84 62.93 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -170.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.607 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 27.3 m -57.15 -29.31 63.51 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 172.233 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -100.25 -15.14 18.18 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 118.067 -0.968 . . . . 0.0 113.473 173.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.55 -85.37 0.16 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 119.968 1.258 . . . . 0.0 110.77 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 62.5 p -73.24 -11.47 60.52 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.48 9.06 79.74 Favored Glycine 0 N--CA 1.467 0.705 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 -165.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.426 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 4.8 t-20 52.53 21.92 1.97 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.501 1.92 . . . . 0.0 109.135 -166.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.97 -11.78 21.13 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 114.726 1.38 . . . . 0.0 114.726 -166.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.93 -156.12 24.22 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 124.698 1.142 . . . . 0.0 113.072 169.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -67.98 154.83 40.79 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 126.55 1.94 . . . . 0.0 111.609 -175.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.425 ' H ' ' HD2' ' A' ' 143' ' ' ARG . 0.3 OUTLIER -81.62 129.85 34.84 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.581 0.752 . . . . 0.0 109.192 -179.218 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.11 -64.19 1.1 Allowed 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.124 1.77 . . . . 0.0 110.276 -170.376 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.7 149.33 45.0 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 125.071 1.348 . . . . 0.0 110.531 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 63.7 m -139.08 146.63 40.98 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.047 1.739 . . . . 0.0 111.249 -176.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.08 142.93 8.72 Favored Glycine 0 N--CA 1.474 1.183 0 C-N-CA 124.804 1.192 . . . . 0.0 112.11 169.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.4 t -92.69 135.34 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 125.043 1.337 . . . . 0.0 109.312 -175.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.6 mm -77.55 115.77 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.718 -169.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.09 158.1 14.63 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.818 1.199 . . . . 0.0 113.426 -177.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -75.14 134.98 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.135 0.974 . . . . 0.0 113.326 -178.318 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.62 -177.35 6.53 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.711 2.404 . . . . 0.0 108.544 -170.592 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 . . . . . 0 N--CA 1.471 0.577 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 167.89 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.427 0 N-CA-C 113.013 0.745 . . . . 0.0 113.013 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.8 p -97.76 114.85 26.95 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.137 1.446 . . . . 0.0 108.879 171.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -113.07 125.37 54.31 Favored 'General case' 0 C--O 1.24 0.602 0 C-N-CA 125.098 1.359 . . . . 0.0 112.083 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -79.99 168.89 18.61 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 176.218 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.415 ' CG2' HG23 ' A' ' 54' ' ' THR . 1.9 p -156.12 101.94 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 127.771 2.429 . . . . 0.0 107.836 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.69 114.39 26.03 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.913 1.285 . . . . 0.0 111.403 -172.178 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.416 HG22 HG22 ' A' ' 54' ' ' THR . 2.1 t -83.97 72.61 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 125.17 1.388 . . . . 0.0 109.585 -172.299 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.3 mp -77.92 115.71 17.87 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 121.437 -0.79 . . . . 0.0 109.838 178.497 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.1 ttpp -161.79 120.13 2.31 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.197 1.799 . . . . 0.0 111.021 164.281 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -137.07 -69.53 0.05 OUTLIER Glycine 0 N--CA 1.467 0.708 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 169.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.95 76.99 2.84 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 127.703 2.401 . . . . 0.0 110.594 -169.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.94 -102.06 0.05 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.424 1.964 . . . . 0.0 112.403 174.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -85.65 0.55 8.46 Favored 'Trans proline' 0 C--N 1.353 0.807 1 C-N-CA 125.783 4.322 . . . . 0.0 115.469 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.33 120.82 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-N 121.753 2.07 . . . . 0.0 109.486 169.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.99 166.36 24.27 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.132 1.373 . . . . 0.0 110.827 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.11 174.92 33.97 Favored Glycine 0 N--CA 1.466 0.634 0 CA-C-O 123.082 1.379 . . . . 0.0 116.115 173.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.482 HG13 ' H ' ' B' ' 34' ' ' SER . 3.3 pt -143.08 50.86 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 CA-C-N 112.833 -1.684 . . . . 0.0 112.013 -166.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 13.1 mm -81.46 119.36 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 O-C-N 120.033 -1.667 . . . . 0.0 110.957 -169.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -88.0 154.96 20.08 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.498 1.519 . . . . 0.0 110.414 169.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.425 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 23.4 m-85 -143.54 108.05 4.83 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 169.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -98.38 117.82 33.65 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.994 1.109 . . . . 0.0 113.994 -173.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLN . . . . . 0.539 ' HB2' HD13 ' B' ' 106' ' ' LEU . 4.3 tp-100 -96.17 139.55 32.16 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.794 1.238 . . . . 0.0 111.165 169.453 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.592 ' H ' ' HD2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -92.2 -36.15 13.43 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.408 2.283 . . . . 0.0 113.59 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -159.47 136.71 9.69 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 126.961 2.104 . . . . 0.0 109.034 169.011 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 60.3 p -19.43 -57.13 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 129.109 2.964 . . . . 0.0 116.935 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -95.24 2.91 55.0 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 127.342 2.257 . . . . 0.0 115.531 -172.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.24 168.16 54.44 Favored Glycine 0 CA--C 1.544 1.904 0 O-C-N 120.781 -1.199 . . . . 0.0 113.164 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -67.02 163.66 33.04 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.677 2.918 . . . . 0.0 110.297 170.271 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 77.4 t -131.26 138.74 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 CA-C-N 119.476 1.034 . . . . 0.0 111.642 -169.077 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 72.9 mttt -92.48 112.15 23.99 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.23 174.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.51 131.94 32.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 125.214 1.406 . . . . 0.0 109.119 170.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -154.27 165.72 35.42 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 168.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.05 175.92 21.47 Favored Glycine 0 N--CA 1.468 0.798 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -174.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' SER . . . . . 0.482 ' H ' HG13 ' B' ' 17' ' ' ILE . 77.7 p -132.55 165.52 24.19 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -166.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -116.82 126.61 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.915 1.686 . . . . 0.0 107.895 168.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -126.17 132.93 51.7 Favored 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 124.905 1.282 . . . . 0.0 111.073 -177.235 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.44 -3.04 13.87 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.297 2.38 . . . . 0.0 112.801 -171.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.3 mt -66.93 162.73 21.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.051 0.925 . . . . 0.0 109.483 168.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -77.54 150.9 34.75 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 162.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -50.68 147.02 5.06 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 123.733 0.813 . . . . 0.0 110.306 168.175 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 104.06 -179.59 25.04 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.75 1.167 . . . . 0.0 113.486 -173.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.752 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.9 pt? -84.99 145.28 27.79 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.374 2.67 . . . . 0.0 113.401 -169.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 43' ' ' HIS . . . . . 0.401 ' HB2' HG23 ' B' ' 87' ' ' VAL . 93.1 m-70 -147.36 147.3 30.17 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 128.88 2.872 . . . . 0.0 111.228 -167.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.11 156.1 49.88 Favored Glycine 0 N--CA 1.479 1.526 0 CA-C-O 117.991 -1.45 . . . . 0.0 113.618 174.069 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -154.43 98.07 2.07 Favored 'General case' 0 CA--C 1.553 1.07 0 C-N-CA 125.808 1.643 . . . . 0.0 111.623 -173.218 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -121.36 128.22 52.03 Favored 'General case' 0 N--CA 1.472 0.665 0 O-C-N 120.248 -1.532 . . . . 0.0 113.773 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -80.24 100.43 4.59 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 171.421 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -68.59 130.27 42.35 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 119.41 -2.056 . . . . 0.0 108.836 -170.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.05 48.67 0.12 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 128.699 2.8 . . . . 0.0 114.179 -165.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 178.66 138.73 0.09 Allowed 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 129.1 2.96 . . . . 0.0 107.054 178.764 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.09 -5.8 88.96 Favored Glycine 0 N--CA 1.469 0.891 0 CA-C-N 115.214 -0.903 . . . . 0.0 114.912 174.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -79.19 52.43 1.31 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.961 1.704 . . . . 0.0 112.408 -170.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.252 23.0 p-10 175.89 64.98 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 116.686 2.106 . . . . 0.0 116.686 -169.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.7 t . . . . . 0 N--CA 1.48 1.029 0 O-C-N 120.425 -1.422 . . . . 0.0 113.282 167.155 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.405 0 CA-C-O 121.564 0.697 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -84.88 -139.83 4.75 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-O 118.54 -1.145 . . . . 0.0 111.268 169.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -72.41 176.32 8.84 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.015 3.143 . . . . 0.0 110.959 173.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.664 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -57.11 100.18 0.04 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 128.556 2.742 . . . . 0.0 109.559 170.052 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -49.62 146.34 4.3 Favored 'General case' 0 CA--C 1.538 0.485 0 O-C-N 124.148 0.905 . . . . 0.0 111.629 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -106.12 60.82 0.16 Allowed Pre-proline 0 CA--C 1.56 1.344 0 C-N-CA 126.334 1.853 . . . . 0.0 115.625 -171.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -61.42 -35.17 84.47 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.913 3.076 . . . . 0.0 113.457 -174.261 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 63.6 mt -79.65 -1.51 38.56 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.453 1.101 . . . . 0.0 113.542 176.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.3 t 58.37 58.03 3.61 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.597 1.159 . . . . 0.0 113.114 169.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -153.88 179.02 9.27 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -169.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 mtmp? -61.75 173.13 1.07 Allowed 'General case' 0 CA--C 1.541 0.622 0 CA-C-O 122.186 0.993 . . . . 0.0 111.98 174.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.507 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 63.6 t60 -123.09 148.73 45.32 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 116.35 1.982 . . . . 0.0 116.35 -166.656 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 121.65 -63.72 0.51 Allowed Glycine 0 C--N 1.339 0.709 0 C-N-CA 124.458 1.028 . . . . 0.0 115.278 162.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.61 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 88.14 -9.85 73.26 Favored Glycine 0 CA--C 1.548 2.14 1 N-CA-C 123.294 4.078 . . . . 0.0 123.294 168.296 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -89.26 -5.01 5.76 Favored 'Trans proline' 0 C--N 1.358 1.044 1 CA-C-N 124.605 4.202 . . . . 0.0 112.23 168.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.42 -25.18 0.11 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.319 1.847 . . . . 0.0 110.861 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.61 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -71.08 139.9 50.52 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 122.87 1.319 . . . . 0.0 109.433 164.972 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -90.44 -22.47 21.4 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 129.527 3.131 . . . . 0.0 113.009 -168.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -98.17 -79.92 0.46 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.21 1.404 . . . . 0.0 109.901 -172.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 87.92 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 127.45 2.3 . . . . 0.0 116.498 164.627 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -63.99 147.44 52.03 Favored 'General case' 0 N--CA 1.484 1.233 0 O-C-N 119.678 -1.889 . . . . 0.0 108.471 164.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.9 -10.03 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 CA-C-N 122.094 2.224 . . . . 0.0 112.372 -174.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.97 5.46 75.88 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.764 1.65 . . . . 0.0 114.695 169.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -97.9 132.26 43.64 Favored 'General case' 0 C--N 1.322 -0.623 0 O-C-N 119.666 -2.079 . . . . 0.0 111.758 -173.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 81.4 mt -130.35 176.62 7.98 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.697 1.999 . . . . 0.0 106.738 165.136 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.27 -138.87 6.34 Favored Glycine 0 N--CA 1.471 1.003 0 C-N-CA 123.863 0.744 . . . . 0.0 114.369 -171.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -102.47 151.1 22.69 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.36 1.064 . . . . 0.0 113.369 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.401 HG23 ' HB2' ' B' ' 43' ' ' HIS . 16.2 m -113.51 145.57 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 127.797 2.439 . . . . 0.0 110.728 169.49 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 54.8 m -134.23 122.54 22.9 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.215 0.916 . . . . 0.0 109.544 -174.102 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.12 151.56 22.14 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.61 160.25 14.86 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 130.189 3.395 . . . . 0.0 109.5 168.104 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -40.48 -26.66 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 128.616 2.766 . . . . 0.0 117.884 175.3 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -77.45 7.67 5.15 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.104 1.32 . . . . 0.0 112.029 173.13 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.9 8.87 87.25 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 127.247 2.356 . . . . 0.0 113.748 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 11.5 p -104.28 121.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 125.103 1.361 . . . . 0.0 112.684 -170.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.34 113.41 25.36 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 164.361 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -104.18 141.83 35.57 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.831 0.824 . . . . 0.0 111.314 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -117.65 147.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 CA-C-N 113.606 -1.634 . . . . 0.0 113.46 -170.575 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 17.4 p -161.17 60.0 0.29 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 125.258 1.423 . . . . 0.0 113.75 -175.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 24.4 mt -118.61 145.21 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 O-C-N 119.771 -1.83 . . . . 0.0 112.297 -172.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 100' ' ' GLU . . . . . 0.434 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 10.7 tt0 -104.03 121.53 43.37 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 165.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -112.44 134.87 53.73 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.679 1.192 . . . . 0.0 109.866 174.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.0 p -109.42 50.73 0.77 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.002 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 57.7 t -133.8 -39.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.863 1.665 . . . . 0.0 110.208 169.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.59 163.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-O 123.18 1.467 . . . . 0.0 113.393 176.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.539 ' H ' ' HB3' ' B' ' 111' ' ' SER . 58.1 m -159.43 147.67 17.61 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 127.14 2.176 . . . . 0.0 108.863 -172.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 106' ' ' LEU . . . . . 0.539 HD13 ' HB2' ' B' ' 22' ' ' GLN . 4.1 mp -79.58 97.42 6.48 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 119.013 0.824 . . . . 0.0 109.05 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.8 m -114.07 -33.71 5.62 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.178 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.15 -29.39 10.73 Favored Glycine 0 N--CA 1.469 0.858 0 CA-C-O 118.91 -0.939 . . . . 0.0 111.822 -168.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -154.25 -46.66 0.09 Allowed 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 115.577 1.695 . . . . 0.0 115.577 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -82.61 0.96 40.55 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 126.142 1.777 . . . . 0.0 112.755 -168.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 111' ' ' SER . . . . . 0.539 ' HB3' ' H ' ' B' ' 105' ' ' SER . 4.9 m -163.85 -78.11 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 177.016 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.4 pt -129.17 167.3 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 O-C-N 120.749 -1.22 . . . . 0.0 109.797 167.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.2 mm 77.93 146.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 C-N-CA 129.452 3.101 . . . . 0.0 106.84 -162.306 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.95 -45.76 2.29 Favored Glycine 0 N--CA 1.468 0.8 0 CA-C-O 118.985 -0.897 . . . . 0.0 113.698 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.8 mtp85 -75.85 176.62 7.64 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.961 1.304 . . . . 0.0 111.117 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 116' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 5.9 t -124.5 164.95 18.67 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 117.529 -1.224 . . . . 0.0 110.931 -173.759 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.421 ' C ' HD13 ' B' ' 117' ' ' LEU . 0.3 OUTLIER -127.11 140.56 52.18 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 119.619 1.1 . . . . 0.0 108.886 167.597 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 p -122.8 136.2 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.345 1.458 . . . . 0.0 110.101 172.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.07 158.73 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.486 1.114 . . . . 0.0 110.233 175.476 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -131.76 140.3 49.19 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.42 1.088 . . . . 0.0 111.729 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -63.3 -27.92 69.66 Favored 'General case' 0 N--CA 1.475 0.792 0 O-C-N 120.042 -1.661 . . . . 0.0 115.119 -174.149 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.93 165.19 14.0 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 120.071 -1.643 . . . . 0.0 109.957 166.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.21 152.0 34.93 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 124.307 1.043 . . . . 0.0 111.42 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.514 ' CG ' ' HB2' ' B' ' 140' ' ' ALA . 16.7 m-20 -86.55 159.95 19.11 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.302 1.841 . . . . 0.0 113.034 174.383 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.7 -49.7 17.51 Favored 'General case' 0 N--CA 1.485 1.304 0 CA-C-N 112.728 -2.033 . . . . 0.0 111.104 166.156 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.6 mm? 68.32 62.73 0.37 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 127.355 2.262 . . . . 0.0 110.167 -176.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 178.22 -111.61 0.33 Allowed Glycine 0 N--CA 1.47 0.901 0 O-C-N 121.583 -0.698 . . . . 0.0 111.748 -173.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -151.63 7.94 0.5 Allowed 'General case' 0 CA--C 1.566 1.584 0 C-N-CA 126.906 2.083 . . . . 0.0 112.551 169.087 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 34.86 -106.5 0.03 OUTLIER Glycine 0 C--N 1.35 1.324 0 C-N-CA 126.877 2.179 . . . . 0.0 114.071 169.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -129.71 21.83 4.98 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-O 117.958 -1.468 . . . . 0.0 114.16 169.275 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -165.37 168.57 16.65 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 120.393 2.096 . . . . 0.0 111.249 -171.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -61.85 -53.03 61.46 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.855 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -40.84 -37.74 0.82 Allowed 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.676 1.99 . . . . 0.0 114.637 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 54.9 m -56.02 -35.67 67.1 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 171.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -94.85 -23.56 17.42 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.935 1.243 . . . . 0.0 112.527 167.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -78.9 -33.62 45.43 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-N 119.981 1.264 . . . . 0.0 113.094 -171.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.2 m -135.71 -31.32 0.95 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 126.898 2.079 . . . . 0.0 110.616 -169.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 138' ' ' GLY . . . . . 0.507 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 125.49 -25.41 5.67 Favored Glycine 0 C--O 1.222 -0.599 0 C-N-CA 127.996 2.712 . . . . 0.0 111.714 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 58.2 t30 113.14 -8.63 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.856 1 C-N-CA 131.995 4.118 . . . . 0.0 112.291 176.397 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 140' ' ' ALA . . . . . 0.514 ' HB2' ' CG ' ' B' ' 124' ' ' ASP . . . -57.24 -7.35 0.53 Allowed 'General case' 0 CA--C 1.56 1.349 0 N-CA-C 118.466 2.765 . . . . 0.0 118.466 -163.023 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.76 -31.32 1.96 Allowed Glycine 0 N--CA 1.47 0.943 0 O-C-N 119.597 -1.939 . . . . 0.0 114.512 170.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -133.64 -173.39 3.22 Favored 'General case' 0 CA--C 1.544 0.743 0 O-C-N 121.752 -0.852 . . . . 0.0 112.717 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.24 -174.44 2.72 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 127.981 2.512 . . . . 0.0 108.837 172.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.527 HD23 ' H ' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -174.72 -160.1 0.09 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 130.156 3.382 . . . . 0.0 107.038 171.908 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.527 ' H ' HD23 ' B' ' 144' ' ' LEU . . . -69.86 171.98 8.44 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 127.503 2.321 . . . . 0.0 113.781 -176.182 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -155.92 153.31 29.43 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.817 -168.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.96 141.15 7.66 Favored Glycine 0 N--CA 1.469 0.881 0 C-N-CA 125.347 1.451 . . . . 0.0 113.975 172.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 2.3 t -77.58 147.83 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.835 0.854 . . . . 0.0 110.164 171.741 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.7 mm -91.91 98.29 8.21 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 126.535 1.934 . . . . 0.0 110.836 -171.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.75 -171.6 30.31 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 124.564 1.078 . . . . 0.0 114.058 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.578 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 3.4 mp -119.21 128.82 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.186 0 C-N-CA 126.042 1.737 . . . . 0.0 114.367 -169.591 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -100.69 -24.34 14.44 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.35 1.06 . . . . 0.0 112.18 169.04 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 CA--C 1.534 0.345 0 C-N-CA 126.974 2.109 . . . . 0.0 111.618 -175.097 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.465 0.301 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.297 6.3 ptpt -127.24 129.78 48.39 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 176.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.27 153.38 28.51 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 126.659 1.984 . . . . 0.0 109.376 174.152 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -122.65 142.67 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.106 1.363 . . . . 0.0 108.976 177.355 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -105.19 133.32 50.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 121.092 1.769 . . . . 0.0 110.33 166.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' B' ' 54' ' ' THR . 57.5 t -118.22 109.24 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.576 1.15 . . . . 0.0 109.574 -175.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.63 140.83 48.5 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.544 1.538 . . . . 0.0 112.187 -172.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -160.8 164.25 31.57 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 168.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.492 ' HA3' ' HE3' ' B' ' 9' ' ' LYS . . . 82.23 73.22 1.23 Allowed Glycine 0 C--N 1.335 0.48 0 N-CA-C 120.706 3.043 . . . . 0.0 120.706 161.668 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -160.04 60.96 0.35 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 108.212 164.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.76 -172.41 21.8 Favored Glycine 0 CA--C 1.541 1.671 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -164.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -73.58 58.7 3.91 Favored 'Trans proline' 0 CA--C 1.534 0.493 1 C-N-CA 125.749 4.299 . . . . 0.0 110.044 173.225 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.95 133.76 53.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 125.728 1.611 . . . . 0.0 110.263 -168.526 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.8 163.65 38.72 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 126.353 1.861 . . . . 0.0 109.85 -169.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.29 148.26 17.98 Favored Glycine 0 C--N 1.33 0.196 0 CA-C-O 122.407 1.004 . . . . 0.0 115.556 176.553 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -123.25 138.54 52.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 126.318 1.847 . . . . 0.0 109.888 167.814 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.9 mm -140.57 127.09 21.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 C-N-CA 125.496 1.518 . . . . 0.0 108.235 166.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -85.79 141.2 29.84 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.906 1.682 . . . . 0.0 109.839 166.175 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -124.28 97.82 5.49 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.727 2.011 . . . . 0.0 107.29 176.674 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.62 116.43 28.73 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-O 123.436 1.588 . . . . 0.0 111.636 -172.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.45 HE22 ' C ' ' A' ' 25' ' ' SER . 22.1 tt0 -108.67 148.85 29.8 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.954 178.643 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.437 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -89.45 -26.15 21.11 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.637 1.175 . . . . 0.0 112.912 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -131.71 -151.58 0.47 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.389 1.876 . . . . 0.0 110.401 167.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.45 ' C ' HE22 ' A' ' 22' ' ' GLN . 30.6 t -111.41 -17.53 13.09 Favored 'General case' 0 CA--C 1.555 1.169 0 C-N-CA 125.315 1.446 . . . . 0.0 110.754 167.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -90.67 -24.32 20.5 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 127.661 2.384 . . . . 0.0 115.466 170.014 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.2 175.64 52.41 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 119.462 1.028 . . . . 0.0 114.79 -173.25 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.56 151.91 47.83 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.855 2.37 . . . . 0.0 110.718 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.86 128.73 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 177.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -88.97 119.41 29.47 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 169.293 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.24 133.29 59.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 125.69 1.596 . . . . 0.0 110.141 -176.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -156.08 156.54 34.52 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.543 0.737 . . . . 0.0 111.886 177.097 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.1 -149.74 16.71 Favored Glycine 0 C--N 1.333 0.394 0 O-C-N 121.924 -0.485 . . . . 0.0 112.963 171.108 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 53.6 p -155.39 115.11 3.68 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 122.976 0.511 . . . . 0.0 112.056 -169.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.06 125.41 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-O 117.299 -1.334 . . . . 0.0 107.593 170.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.8 tttp -124.75 140.67 52.72 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 121.891 2.132 . . . . 0.0 111.552 -176.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.88 -0.25 13.45 Favored Glycine 0 N--CA 1.476 1.343 0 C-N-CA 127.243 2.354 . . . . 0.0 114.661 -176.457 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.459 ' H ' HD22 ' A' ' 38' ' ' LEU . 2.3 mm? -69.15 -178.82 1.37 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.603 1.561 . . . . 0.0 110.985 170.005 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.59 -42.42 5.93 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 117.209 -1.377 . . . . 0.0 113.511 169.36 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 176.48 -107.67 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.267 0 C-N-CA 128.773 2.829 . . . . 0.0 109.628 -178.528 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -39.54 148.38 0.15 Allowed Glycine 0 N--CA 1.479 1.511 0 C-N-CA 129.533 3.444 . . . . 0.0 119.885 -168.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.446 HD23 ' H ' ' A' ' 42' ' ' LEU . 1.0 OUTLIER -31.3 136.67 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 130.1 3.36 . . . . 0.0 117.796 -169.084 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.0 m-70 -130.32 140.5 50.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 128.94 2.896 . . . . 0.0 108.764 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.57 156.52 53.33 Favored Glycine 0 N--CA 1.474 1.22 0 C-N-CA 124.08 0.848 . . . . 0.0 111.981 175.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -155.44 105.65 2.48 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.157 0.983 . . . . 0.0 112.374 -168.109 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.03 140.04 32.51 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 119.936 -1.728 . . . . 0.0 115.185 -172.577 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -78.11 134.99 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 166.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m170 -112.9 176.74 4.89 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 126.889 2.075 . . . . 0.0 110.901 -174.695 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -74.55 132.55 41.91 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.566 1.147 . . . . 0.0 112.297 170.611 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -77.78 -178.49 5.43 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 127.798 2.439 . . . . 0.0 115.216 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.505 ' HA2' ' CA ' ' B' ' 152' ' ' ALA . . . 119.78 -118.26 3.86 Favored Glycine 0 CA--C 1.502 -0.774 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.288 -172.017 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -87.83 63.45 7.44 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 125.229 2.442 . . . . 0.0 108.015 177.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -77.18 56.92 1.35 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 113.297 -1.774 . . . . 0.0 110.794 176.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.438 HG21 HD13 ' B' ' 17' ' ' ILE . 13.5 p -124.81 -44.88 1.92 Allowed 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.394 1.478 . . . . 0.0 113.943 -168.331 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.22 10.58 0.74 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.587 1.155 . . . . 0.0 113.093 170.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.78 -150.59 51.48 Favored Glycine 0 CA--C 1.528 0.869 0 O-C-N 120.493 -1.38 . . . . 0.0 111.294 -173.706 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 27.9 p -61.39 -7.29 2.87 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 117.196 2.295 . . . . 0.0 117.196 -169.149 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -88.44 -12.98 41.56 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 119.547 1.067 . . . . 0.0 113.784 170.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.3 t -124.09 -36.33 2.71 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.465 1.03 . . . . 0.0 111.853 173.146 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -69.07 86.94 0.38 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 166.194 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -47.68 120.95 6.33 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 126.736 2.112 . . . . 0.0 114.353 -166.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -67.46 126.42 14.85 Favored 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.625 2.217 . . . . 0.0 111.598 -173.167 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 59.65 60.96 2.08 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 164.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -45.22 109.95 0.21 Allowed 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.667 1.587 . . . . 0.0 112.746 -178.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.4 p-10 -135.5 55.33 12.56 Favored Pre-proline 0 CA--C 1.546 0.795 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -169.317 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -62.56 -16.16 50.59 Favored 'Trans proline' 0 C--N 1.354 0.836 0 C-N-CA 122.447 2.098 . . . . 0.0 112.495 170.245 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.7 mt -78.04 -7.18 56.58 Favored 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 169.183 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.3 t 64.98 56.18 1.08 Allowed 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.995 1.718 . . . . 0.0 112.412 170.117 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtm-85 -120.45 172.41 7.84 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 116.061 1.874 . . . . 0.0 116.061 -167.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.61 153.2 37.43 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 128.561 2.744 . . . . 0.0 109.944 168.471 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -74.42 151.24 39.67 Favored 'General case' 0 CA--C 1.541 0.598 0 O-C-N 120.807 -1.183 . . . . 0.0 113.551 171.741 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.421 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.96 -123.64 2.07 Favored Glycine 0 C--N 1.34 0.77 0 CA-C-O 118.728 -1.04 . . . . 0.0 113.499 166.623 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.417 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 119.9 -48.79 0.92 Allowed Glycine 0 CA--C 1.546 1.985 0 N-CA-C 117.758 1.863 . . . . 0.0 117.758 179.201 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -87.29 9.36 3.94 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.508 2.805 . . . . 0.0 114.131 178.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.6 pttt -165.15 -27.05 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 126.256 1.822 . . . . 0.0 112.263 179.006 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.421 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.1 OUTLIER -83.57 161.09 21.29 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 128.618 2.767 . . . . 0.0 109.406 166.104 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -95.64 -17.98 20.9 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 125.591 1.556 . . . . 0.0 112.334 -172.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -95.19 -68.34 0.81 Allowed 'General case' 0 C--O 1.231 0.105 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -167.036 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.521 HH22 HG23 ' A' ' 104' ' ' ILE . 63.4 ttt-85 68.36 125.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 123.191 1.472 . . . . 0.0 111.24 -176.754 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -66.09 169.96 6.29 Favored 'General case' 0 CA--C 1.554 1.098 0 O-C-N 119.1 -2.25 . . . . 0.0 111.86 167.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.3 t -68.17 -50.47 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 O-C-N 120.684 -1.26 . . . . 0.0 108.665 176.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.33 92.76 1.83 Allowed Glycine 0 CA--C 1.529 0.918 0 N-CA-C 107.651 -2.179 . . . . 0.0 107.651 165.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -157.42 143.72 17.84 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.471 1.509 . . . . 0.0 112.558 171.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.99 177.63 7.75 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 127.489 2.316 . . . . 0.0 107.243 168.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.2 -126.34 1.11 Allowed Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.331 1.443 . . . . 0.0 113.908 -173.176 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 38.2 p-10 -144.61 164.31 31.31 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -175.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 26.8 m -136.44 123.39 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.491 1.117 . . . . 0.0 111.703 -169.273 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 m -98.53 141.34 31.5 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.305 1.042 . . . . 0.0 108.706 171.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 95' ' ' ALA . . . -97.29 156.03 16.61 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 172.395 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.58 158.58 24.34 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.306 1.842 . . . . 0.0 107.876 165.68 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -50.06 -21.7 1.35 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.208 2.203 . . . . 0.0 116.605 177.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -78.09 4.21 12.98 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 125.199 1.4 . . . . 0.0 111.963 172.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.08 12.22 82.75 Favored Glycine 0 C--O 1.225 -0.441 0 C-N-CA 126.847 2.165 . . . . 0.0 114.24 176.262 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -105.73 122.66 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 CA-C-N 119.114 1.457 . . . . 0.0 112.357 -178.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 89' ' ' ALA . . . -91.91 95.85 10.05 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 125.277 1.431 . . . . 0.0 109.948 169.108 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -79.48 127.32 31.98 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.62 1.568 . . . . 0.0 109.673 175.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.1 p -134.68 144.69 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -171.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.2 t -156.69 115.88 3.42 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.656 1.182 . . . . 0.0 111.556 173.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.6 mt -139.56 158.5 27.69 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 128.918 2.887 . . . . 0.0 109.986 -173.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -135.47 136.2 41.1 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 124.975 1.31 . . . . 0.0 108.114 167.252 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -148.69 134.12 18.57 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.566 1.146 . . . . 0.0 110.628 -167.027 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.6 p -106.91 45.81 0.96 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.93 18.13 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.782 1.233 . . . . 0.0 110.919 -175.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.521 HG23 HH22 ' A' ' 79' ' ' ARG . 0.2 OUTLIER -146.91 154.95 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 128.433 2.693 . . . . 0.0 106.334 164.996 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.566 ' H ' ' HB3' ' A' ' 111' ' ' SER . 76.5 p -157.67 161.7 38.6 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.775 1.23 . . . . 0.0 110.839 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -88.05 86.19 7.08 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.0 t -113.74 -4.16 13.43 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.898 1.279 . . . . 0.0 113.75 -172.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.2 -47.33 1.49 Allowed Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.046 -0.864 . . . . 0.0 113.588 -177.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 36.2 p-10 -142.09 -51.24 0.4 Allowed 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.913 1.82 . . . . 0.0 115.913 -169.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.97 -8.82 59.24 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 126.069 1.747 . . . . 0.0 112.922 -166.787 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.566 ' HB3' ' H ' ' A' ' 105' ' ' SER . 69.0 m -134.03 -109.67 0.22 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.623 1.169 . . . . 0.0 109.343 -174.318 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.4 pt -117.35 169.79 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 122.033 0.921 . . . . 0.0 108.754 166.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 108.4 132.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.071 1 C-N-CA 134.974 5.31 . . . . 0.0 106.384 -165.148 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.95 -3.23 1.63 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 116.174 1.229 . . . . 0.0 116.174 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.436 ' HB3' HD12 ' A' ' 149' ' ' ILE . 46.7 ttm-85 -78.95 171.63 14.94 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.744 1.218 . . . . 0.0 110.316 -172.167 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.5 t -116.53 162.38 17.68 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.113 1.365 . . . . 0.0 110.275 -178.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.93 131.52 18.82 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.694 1.598 . . . . 0.0 109.239 178.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 82.4 t -116.21 133.97 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 125.138 1.375 . . . . 0.0 108.693 175.085 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.411 HG23 ' HB3' ' A' ' 144' ' ' LEU . 30.8 m -103.2 155.09 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 168.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.37 130.92 41.32 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.655 1.182 . . . . 0.0 109.917 -168.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -58.48 -18.44 28.9 Favored 'General case' 0 CA--C 1.549 0.935 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.1 mmtm -128.73 168.06 16.37 Favored 'General case' 0 N--CA 1.479 0.99 0 O-C-N 118.66 -2.525 . . . . 0.0 115.063 -171.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -48.64 136.18 13.67 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 126.379 1.872 . . . . 0.0 111.68 173.19 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -122.72 146.95 47.03 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 124.664 2.174 . . . . 0.0 113.47 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.84 -29.24 55.81 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 112.563 -2.108 . . . . 0.0 113.673 -166.045 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.4 mt 35.13 58.45 0.77 Allowed 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 128.376 2.67 . . . . 0.0 111.274 176.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 145.15 -101.31 0.24 Allowed Glycine 0 C--N 1.334 0.431 0 C-N-CA 125.117 1.341 . . . . 0.0 110.869 -172.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -156.7 121.97 4.68 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 126.65 1.98 . . . . 0.0 112.042 -167.297 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.83 -90.38 1.8 Allowed Glycine 0 N--CA 1.467 0.734 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 176.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.3 2.89 2.64 Favored Glycine 0 N--CA 1.472 1.098 0 C-N-CA 125.362 1.458 . . . . 0.0 115.306 179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -120.95 161.93 20.75 Favored 'General case' 0 N--CA 1.463 0.187 0 C-N-CA 124.454 1.102 . . . . 0.0 113.116 -169.295 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -60.23 -55.87 28.42 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.527 1.156 . . . . 0.0 108.807 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -57.74 -7.33 0.67 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.453 1.901 . . . . 0.0 114.579 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.7 p -68.01 -48.52 65.49 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.917 1.235 . . . . 0.0 112.342 171.21 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 64.7 p -83.51 -26.87 29.81 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.344 0.658 . . . . 0.0 112.311 176.617 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 mtpm? -75.55 -60.56 2.25 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 178.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.1 p -104.35 -45.23 4.73 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 119.983 1.265 . . . . 0.0 113.706 178.185 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 125.26 7.99 5.65 Favored Glycine 0 CA--C 1.524 0.653 0 C-N-CA 126.214 1.864 . . . . 0.0 113.103 -168.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 56.97 21.66 6.45 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 170.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.47 26.42 0.02 OUTLIER 'General case' 0 CA--C 1.568 1.646 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -169.636 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.97 -40.79 2.13 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 128.581 2.991 . . . . 0.0 115.894 169.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.4 m -171.23 -150.13 0.06 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 126.028 1.731 . . . . 0.0 110.61 -175.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.468 ' HD3' ' H ' ' A' ' 143' ' ' ARG . 0.0 OUTLIER -114.3 -163.44 0.87 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.815 1.646 . . . . 0.0 109.878 170.458 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.411 ' HB3' HG23 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -171.67 -155.27 0.1 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 128.112 2.565 . . . . 0.0 107.92 179.395 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.93 145.98 28.24 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.302 1.441 . . . . 0.0 111.189 174.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.6 p -128.11 147.58 50.55 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.317 179.093 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.27 174.72 32.65 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 116.043 1.177 . . . . 0.0 116.043 -172.004 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.0 t -143.26 154.38 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 C-N-CA 124.575 1.15 . . . . 0.0 110.827 -170.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' A' ' 115' ' ' ARG . 41.8 mt -89.53 116.68 31.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 126.217 1.807 . . . . 0.0 115.086 -170.064 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' B' ' 114' ' ' GLY . . . -98.99 -179.01 31.81 Favored Glycine 0 CA--C 1.531 1.094 0 C-N-CA 127.393 2.425 . . . . 0.0 112.937 167.618 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -144.8 138.67 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 CA-C-N 119.059 1.43 . . . . 0.0 114.258 -174.39 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.457 ' HB2' ' HA2' ' B' ' 51' ' ' GLY . . . -105.06 -35.5 7.61 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.083 1.142 . . . . 0.0 114.083 171.421 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 CA--C 1.546 0.823 0 CA-C-O 122.725 1.25 . . . . 0.0 111.409 -170.376 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.802 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 40.0 p -74.38 110.96 9.09 Favored 'General case' 0 CA--C 1.512 -0.492 0 C-N-CA 125.731 1.612 . . . . 0.0 108.222 -172.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.1 mtmm -100.7 140.91 34.31 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -171.294 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.86 170.04 9.86 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.489 2.316 . . . . 0.0 111.485 173.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.38 145.79 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.393 1.877 . . . . 0.0 111.839 -175.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.36 139.09 33.0 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 123.846 0.858 . . . . 0.0 109.0 165.454 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.3 79.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 121.44 0.638 . . . . 0.0 109.967 169.116 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.8 mp -82.87 139.66 33.33 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 9' ' ' LYS . . . . . 0.492 ' HE3' ' HA3' ' A' ' 10' ' ' GLY . 5.7 ttpt -154.7 157.98 38.89 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 171.615 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.59 173.8 19.72 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 107.256 -2.337 . . . . 0.0 107.256 164.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -79.27 55.45 1.87 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.616 1.966 . . . . 0.0 111.047 172.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.9 -164.02 32.53 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.433 1.492 . . . . 0.0 112.454 -168.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.44 45.31 1.82 Allowed 'Trans proline' 0 CA--C 1.539 0.736 1 C-N-CA 125.933 4.422 . . . . 0.0 114.497 -168.193 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.453 HG11 HD23 ' B' ' 144' ' ' LEU . 3.4 t -133.75 132.75 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 177.709 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -156.48 164.19 38.53 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 124.747 1.219 . . . . 0.0 110.811 -169.691 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -149.39 106.2 0.32 Allowed Glycine 0 N--CA 1.462 0.399 0 C-N-CA 125.326 1.441 . . . . 0.0 110.757 176.167 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 54' ' ' THR 0.262 0.1 OUTLIER -118.03 103.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -170.031 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 21.6 mm -121.48 120.97 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.168 0.987 . . . . 0.0 110.324 -168.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.79 138.92 38.43 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.716 0.807 . . . . 0.0 111.65 169.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -120.56 119.03 31.73 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.299 1.44 . . . . 0.0 108.312 169.186 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -107.68 119.67 40.08 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.128 0.971 . . . . 0.0 111.439 174.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -79.01 95.75 5.58 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 168.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.27 -20.17 62.26 Favored 'General case' 0 N--CA 1.475 0.816 0 O-C-N 120.551 -1.343 . . . . 0.0 112.927 175.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -156.41 127.23 6.81 Favored 'General case' 0 C--O 1.216 -0.666 0 C-N-CA 124.328 1.051 . . . . 0.0 112.635 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 7.4 m -60.91 -21.34 63.27 Favored 'General case' 0 N--CA 1.48 1.056 0 N-CA-C 116.232 1.938 . . . . 0.0 116.232 -169.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -115.09 1.24 13.86 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.161 2.184 . . . . 0.0 112.191 175.605 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.2 -157.53 10.81 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.541 2.02 . . . . 0.0 111.927 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.87 165.89 25.9 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.942 2.428 . . . . 0.0 113.283 -170.12 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.5 t -116.55 137.92 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 126.349 1.86 . . . . 0.0 108.897 174.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -92.51 129.12 38.54 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 123.82 0.848 . . . . 0.0 109.225 167.636 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -114.99 125.57 72.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 C-N-CA 125.669 1.588 . . . . 0.0 109.093 175.497 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -151.7 154.63 36.7 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.872 0.869 . . . . 0.0 110.985 174.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.96 178.5 18.88 Favored Glycine 0 N--CA 1.462 0.395 0 CA-C-O 122.439 1.022 . . . . 0.0 113.7 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 34' ' ' SER . . . . . 0.4 ' HB2' ' CG2' ' B' ' 94' ' ' VAL . 23.5 p -114.13 140.18 48.72 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 115.821 1.785 . . . . 0.0 115.821 -164.55 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.16 108.1 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 125.701 1.6 . . . . 0.0 108.869 169.543 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -119.26 147.61 44.07 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 124.31 1.044 . . . . 0.0 109.994 -171.142 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.8 19.36 29.45 Favored Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.563 1.554 . . . . 0.0 111.531 -170.351 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 71.5 mt -92.35 -171.49 2.81 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.513 1.925 . . . . 0.0 108.717 167.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.48 150.99 48.38 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 130.404 3.482 . . . . 0.0 105.178 167.802 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -50.21 -9.6 0.05 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 129.61 3.164 . . . . 0.0 116.785 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -63.88 163.26 33.58 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.385 -1.447 . . . . 0.0 112.233 168.203 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -57.74 142.94 43.71 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 126.0 1.72 . . . . 0.0 111.18 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -131.32 128.39 39.65 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.356 1.062 . . . . 0.0 110.419 169.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.417 ' HA3' ' HB2' ' B' ' 124' ' ' ASP . . . -69.76 154.86 53.13 Favored Glycine 0 N--CA 1.47 0.965 0 CA-C-O 118.333 -1.26 . . . . 0.0 112.439 177.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -149.06 124.08 10.04 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 119.466 1.633 . . . . 0.0 112.033 -169.396 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -156.44 158.81 37.94 Favored 'General case' 0 C--O 1.238 0.474 0 O-C-N 120.415 -1.428 . . . . 0.0 112.773 178.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.9 m -101.15 126.79 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.012 1.325 . . . . 0.0 108.746 177.312 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.9 m-70 -76.8 177.7 7.42 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 122.73 1.253 . . . . 0.0 110.991 -178.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -62.91 154.75 29.29 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 162.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.54 -135.74 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 122.05 0.928 . . . . 0.0 112.011 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.457 ' HA2' ' HB2' ' A' ' 152' ' ' ALA . . . 91.65 -109.43 3.73 Favored Glycine 0 CA--C 1.495 -1.167 0 C-N-CA 123.889 0.757 . . . . 0.0 111.966 168.322 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.32 58.76 0.86 Allowed 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 127.081 2.152 . . . . 0.0 105.666 -174.257 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -62.15 -2.86 1.06 Allowed 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 116.376 1.991 . . . . 0.0 116.376 -165.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.524 ' HA ' HG13 ' A' ' 7' ' ' VAL 0.343 0.6 OUTLIER . . . . . 0 N--CA 1.468 0.427 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -164.2 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.579 0 CA-C-O 120.826 0.346 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.75 131.44 27.26 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 123.955 0.788 . . . . 0.0 112.5 175.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.0 114.05 2.84 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.759 2.306 . . . . 0.0 107.125 169.1 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.507 ' CD2' ' ND1' ' B' ' 71' ' ' HIS 0.27 0.0 OUTLIER 48.04 78.34 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.57 1.948 . . . . 0.0 114.125 -178.336 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -39.65 116.3 0.61 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.861 1.264 . . . . 0.0 110.559 169.153 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . 0.265 0.1 OUTLIER -122.41 73.37 40.32 Favored Pre-proline 0 CA--C 1.544 0.719 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -170.046 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -64.99 -24.78 59.84 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.821 2.347 . . . . 0.0 114.122 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.17 -6.43 56.54 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.077 0.951 . . . . 0.0 113.114 174.425 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.9 t 56.96 52.84 8.72 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.265 1.426 . . . . 0.0 113.508 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 mtp180 -109.34 179.1 4.25 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.662 1.185 . . . . 0.0 114.047 -169.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.97 175.44 9.07 Favored 'General case' 0 CA--C 1.548 0.885 0 O-C-N 120.591 -1.318 . . . . 0.0 108.633 162.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.507 ' ND1' ' CD2' ' B' ' 63' ' ' HIS . 83.6 t60 -110.85 152.47 26.64 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -167.785 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.488 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.35 -128.89 3.52 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-O 118.663 -1.076 . . . . 0.0 113.881 165.688 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 153.5 -40.05 0.69 Allowed Glycine 0 CA--C 1.546 1.969 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 176.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -112.23 29.99 0.03 OUTLIER 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 125.041 3.827 . . . . 0.0 111.608 169.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -158.93 -53.03 0.06 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 127.745 2.418 . . . . 0.0 106.332 -178.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 8.8 t0 -85.3 155.46 21.34 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.917 1.687 . . . . 0.0 108.865 163.11 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -103.93 -17.25 15.08 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.467 1.507 . . . . 0.0 112.34 172.173 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -74.44 -39.52 62.52 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 120.807 -1.183 . . . . 0.0 112.334 -170.594 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt85 33.28 90.92 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 127.33 2.252 . . . . 0.0 114.79 168.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.3 m80 -47.62 159.03 0.17 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.031 1.333 . . . . 0.0 112.511 178.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.8 m -71.08 87.29 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 119.063 0.847 . . . . 0.0 110.235 172.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.87 39.15 0.18 Allowed Glycine 0 CA--C 1.529 0.967 0 C-N-CA 126.361 1.934 . . . . 0.0 114.553 -173.463 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -134.33 118.08 17.09 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 125.466 1.506 . . . . 0.0 109.913 -173.578 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -105.66 -179.24 3.88 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.936 0.894 . . . . 0.0 109.44 169.032 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.41 -134.75 3.35 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 122.214 0.897 . . . . 0.0 112.455 179.244 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 86' ' ' ASN . . . . . 0.474 HD22 HD11 ' B' ' 126' ' ' LEU . 2.2 m-80 -112.75 142.2 45.67 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.723 0.809 . . . . 0.0 110.611 170.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 17.9 m -109.02 92.79 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 126.69 1.996 . . . . 0.0 109.104 173.3 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.5 m -82.53 132.29 35.2 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 173.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.37 171.62 8.93 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.259 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -83.83 162.72 20.48 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.118 1.367 . . . . 0.0 107.351 164.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.434 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -57.14 -14.84 4.44 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 172.217 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -72.3 -13.66 61.55 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 125.763 1.625 . . . . 0.0 111.71 172.272 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.51 4.53 67.94 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.015 1.769 . . . . 0.0 113.294 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 94' ' ' VAL . . . . . 0.4 ' CG2' ' HB2' ' B' ' 34' ' ' SER . 7.1 p -102.73 130.23 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 125.565 1.546 . . . . 0.0 113.788 177.087 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.82 108.41 19.9 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 165.347 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -98.61 113.66 25.8 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.102 0.953 . . . . 0.0 110.76 175.245 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -93.47 156.23 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 125.33 1.452 . . . . 0.0 113.807 -169.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.0 p -156.87 117.83 3.68 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.935 1.294 . . . . 0.0 111.098 173.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.7 mt -146.1 150.81 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 C-N-CA 128.78 2.832 . . . . 0.0 109.906 -176.225 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 -137.57 131.11 31.18 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.371 1.468 . . . . 0.0 107.57 168.101 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -155.4 152.19 28.76 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.901 1.074 . . . . 0.0 113.901 -168.559 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 86.3 p -116.49 59.34 0.74 Allowed 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 125.977 1.711 . . . . 0.0 114.184 -167.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 p -147.26 -2.61 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 116.357 1.984 . . . . 0.0 116.357 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.36 168.65 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 125.5 1.52 . . . . 0.0 110.785 177.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.439 ' H ' ' HB3' ' B' ' 111' ' ' SER . 57.9 p -147.97 170.42 17.75 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 115.571 1.693 . . . . 0.0 115.571 178.217 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mp -102.92 48.03 0.87 Allowed 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 168.258 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.3 m -85.27 33.66 0.56 Allowed 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.569 -1.332 . . . . 0.0 112.405 -176.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 87.97 65.77 1.33 Allowed Glycine 0 N--CA 1.469 0.862 0 C-N-CA 124.158 0.885 . . . . 0.0 112.767 176.209 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.315 0.0 OUTLIER 76.78 -21.74 0.31 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 127.673 2.389 . . . . 0.0 114.334 170.176 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -77.52 11.66 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 127.322 2.249 . . . . 0.0 112.886 -173.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 111' ' ' SER . . . . . 0.439 ' HB3' ' H ' ' B' ' 105' ' ' SER . 0.6 OUTLIER -142.02 -72.2 0.33 Allowed 'General case' 0 CA--C 1.544 0.743 0 N-CA-C 116.512 2.041 . . . . 0.0 116.512 170.471 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.94 0.7 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 116.016 1.858 . . . . 0.0 116.016 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.6 mm -89.12 149.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 168.432 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 114' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' A' ' 150' ' ' GLY . . . 77.72 6.78 87.19 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 114.561 0.585 . . . . 0.0 114.561 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.8 ttt180 -115.31 179.28 4.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.989 2.116 . . . . 0.0 111.462 -168.176 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.83 151.39 37.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 C-N-CA 124.034 0.934 . . . . 0.0 111.124 177.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 19.5 tp -128.31 140.91 51.61 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 127.13 2.172 . . . . 0.0 106.572 167.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.37 156.38 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 124.362 1.065 . . . . 0.0 110.592 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -125.87 134.04 67.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-O 122.514 1.149 . . . . 0.0 110.697 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -92.34 145.85 24.15 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.426 1.49 . . . . 0.0 112.258 -168.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -67.62 -39.92 84.69 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 121.086 -1.009 . . . . 0.0 111.996 -174.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -98.69 -179.99 4.49 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.582 1.153 . . . . 0.0 109.962 167.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.59 165.49 0.83 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.697 1.199 . . . . 0.0 111.541 168.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.417 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 26.0 t70 -107.87 148.25 29.84 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.739 0.78 . . . . 0.0 110.662 165.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.73 -20.81 45.54 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.595 1.958 . . . . 0.0 114.807 -169.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.474 HD11 HD22 ' B' ' 86' ' ' ASN . 8.9 mt 41.61 49.02 3.65 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 126.238 1.815 . . . . 0.0 113.993 169.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 135.71 -78.56 0.34 Allowed Glycine 0 N--CA 1.469 0.839 0 C-N-CA 124.894 1.235 . . . . 0.0 111.288 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.86 148.4 22.42 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 117.585 2.439 . . . . 0.0 117.585 170.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -157.67 -79.5 0.03 OUTLIER Glycine 0 C--N 1.332 0.315 0 C-N-CA 130.287 3.803 . . . . 0.0 106.901 171.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.6 -92.87 0.02 OUTLIER Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.056 1.789 . . . . 0.0 115.955 -169.559 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -131.03 -127.54 0.2 Allowed 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.169 -1.195 . . . . 0.0 113.03 -166.441 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.32 -53.78 4.08 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.292 3.037 . . . . 0.0 109.949 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -43.46 -33.64 1.14 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 128.3 2.64 . . . . 0.0 114.03 169.199 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.8 m -45.33 -36.43 4.15 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 126.639 1.975 . . . . 0.0 113.702 168.038 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -103.3 -20.27 14.16 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 126.126 1.77 . . . . 0.0 113.886 -173.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 41.9 mtpt -80.6 -36.5 32.67 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.053 0.941 . . . . 0.0 110.745 170.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 20.0 p -135.95 -108.88 0.2 Allowed 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 127.324 2.249 . . . . 0.0 107.953 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -165.94 148.18 13.35 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 127.597 2.522 . . . . 0.0 108.151 169.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -75.42 45.56 0.3 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.54 1.536 . . . . 0.0 112.572 -172.611 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.51 6.24 24.38 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -167.015 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.61 -47.29 0.42 Allowed Glycine 0 CA--C 1.536 1.39 0 N-CA-C 118.948 2.339 . . . . 0.0 118.948 168.244 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -175.31 -176.93 0.97 Allowed 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.547 1.674 . . . . 0.0 112.406 -169.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.29 142.43 19.29 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.978 1.311 . . . . 0.0 111.591 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.453 HD23 HG11 ' B' ' 14' ' ' VAL . 0.0 OUTLIER -103.74 -20.7 13.86 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.706 1.203 . . . . 0.0 114.123 -176.218 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.449 ' N ' HD22 ' B' ' 144' ' ' LEU . . . -155.56 147.05 22.87 Favored 'General case' 0 C--O 1.244 0.775 0 C-N-CA 124.486 1.114 . . . . 0.0 109.195 -178.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 63.3 m -138.99 149.18 44.4 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 127.936 2.494 . . . . 0.0 108.774 -179.015 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.71 160.03 29.98 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 115.421 0.929 . . . . 0.0 115.421 -174.188 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 5.2 t -109.56 152.15 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.189 1.396 . . . . 0.0 109.789 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.3 mm -94.72 116.78 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 126.081 1.753 . . . . 0.0 112.07 -174.371 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.16 165.48 15.13 Favored Glycine 0 C--N 1.348 1.237 0 C-N-CA 124.358 0.98 . . . . 0.0 112.503 177.023 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -117.7 124.89 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.505 ' CA ' ' HA2' ' A' ' 51' ' ' GLY . . . -79.76 -25.06 41.12 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 121.596 0.712 . . . . 0.0 110.265 165.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 70.0 mt-30 . . . . . 0 CA--C 1.531 0.229 0 C-N-CA 125.74 1.616 . . . . 0.0 109.023 178.347 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 34.7 p . . . . . 0 CA--C 1.507 -0.699 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.4 ttmm -101.89 125.95 48.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.014 -1.903 . . . . 0.0 106.315 168.05 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.57 159.85 41.21 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 125.116 1.367 . . . . 0.0 111.325 -169.761 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.6 t -139.65 143.42 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.438 1.113 . . . . 0.0 112.907 -169.001 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.2 111.72 14.92 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 164.468 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.614 ' CG2' ' H ' ' B' ' 54' ' ' THR . 6.8 m -97.27 112.29 28.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 168.193 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.7 mp -96.87 107.61 20.14 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.529 1.132 . . . . 0.0 111.021 -168.078 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -155.29 124.4 6.23 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 121.782 0.801 . . . . 0.0 112.865 173.226 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.63 -41.34 0.02 OUTLIER Glycine 0 CA--C 1.53 0.985 0 C-N-CA 127.898 2.666 . . . . 0.0 109.478 167.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -79.26 59.37 2.79 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 128.337 2.655 . . . . 0.0 112.55 -174.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.96 -104.25 0.06 OUTLIER Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.867 2.175 . . . . 0.0 114.232 171.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.04 -9.6 14.13 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 124.656 3.571 . . . . 0.0 114.621 -175.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.6 t -90.41 138.69 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-N 120.448 1.476 . . . . 0.0 108.325 171.076 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -156.82 164.81 37.66 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.018 1.327 . . . . 0.0 109.944 169.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.04 174.02 34.64 Favored Glycine 0 CA--C 1.507 -0.42 0 C-N-CA 124.329 0.966 . . . . 0.0 111.432 167.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 pp -127.52 142.15 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 C-N-CA 124.533 1.133 . . . . 0.0 108.356 168.37 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -130.19 133.83 63.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.708 . . . . 0.0 109.201 170.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -103.23 141.58 35.65 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 110.095 169.053 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -124.87 119.68 29.52 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.612 1.565 . . . . 0.0 108.24 171.486 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -115.85 119.33 35.64 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.346 1.459 . . . . 0.0 110.561 -175.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -129.62 141.83 50.86 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 123.506 1.622 . . . . 0.0 113.802 -174.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HE2' ' OE2' ' A' ' 24' ' ' GLU . 15.0 ptmt -82.93 -62.7 1.53 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.742 2.017 . . . . 0.0 114.189 -171.552 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.478 ' OE2' ' HE2' ' A' ' 23' ' ' LYS . 3.7 pm0 -133.48 172.81 12.22 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 126.215 1.806 . . . . 0.0 110.668 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 p -45.06 -54.03 7.17 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.37 1.868 . . . . 0.0 115.434 -168.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -96.2 7.75 45.63 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.795 1.638 . . . . 0.0 111.73 -178.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.24 150.46 37.11 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 125.27 1.414 . . . . 0.0 113.627 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -63.66 162.85 26.48 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 123.996 3.131 . . . . 0.0 110.373 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -129.86 130.76 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 C-N-CA 123.346 0.658 . . . . 0.0 110.046 -169.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -91.15 131.81 36.47 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 167.368 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.7 t -124.24 137.79 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 125.567 1.547 . . . . 0.0 109.132 -173.014 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.4 p90 -157.29 168.66 26.74 Favored 'General case' 0 N--CA 1.471 0.624 0 O-C-N 121.276 -0.89 . . . . 0.0 113.286 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.34 -157.68 27.35 Favored Glycine 0 C--N 1.335 0.498 0 C-N-CA 125.173 1.368 . . . . 0.0 111.204 170.507 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.5 p -155.5 147.5 23.44 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -122.07 122.19 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 -177.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 59.8 tttt -120.81 133.44 55.32 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.317 1.047 . . . . 0.0 110.579 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.26 4.29 16.14 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.931 2.205 . . . . 0.0 112.645 -168.617 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 98.0 mt -82.89 163.38 21.16 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 118.201 1.0 . . . . 0.0 111.467 169.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.9 t -96.81 145.65 25.64 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 126.038 1.735 . . . . 0.0 107.475 165.409 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.486 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.8 pm0 -51.19 143.35 11.14 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.196 2.598 . . . . 0.0 114.739 -173.654 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.76 -179.81 34.42 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 125.012 1.292 . . . . 0.0 113.464 -172.159 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -56.73 151.28 14.39 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 128.058 2.543 . . . . 0.0 113.555 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -147.96 138.82 23.22 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.905 1.682 . . . . 0.0 109.411 167.524 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.67 154.91 20.9 Favored Glycine 0 N--CA 1.48 1.604 0 C-N-CA 124.051 0.834 . . . . 0.0 113.115 172.088 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -158.58 95.37 1.32 Allowed 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 124.423 1.089 . . . . 0.0 112.262 -170.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -146.14 148.92 33.09 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.262 1.579 . . . . 0.0 115.262 -169.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -82.76 110.97 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.95 1.7 . . . . 0.0 110.186 171.517 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -82.65 165.97 19.56 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.795 2.038 . . . . 0.0 110.793 176.526 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -59.96 145.11 47.26 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 122.35 1.071 . . . . 0.0 111.469 -176.184 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -82.53 -114.93 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.709 1.604 . . . . 0.0 111.739 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.5 -96.06 1.73 Allowed Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -143.92 54.68 1.31 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 -172.2 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.29 5.3 p30 -73.39 27.98 0.07 Allowed 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.627 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.774 HG22 ' HA ' ' B' ' 7' ' ' VAL . 8.4 p -90.36 -7.37 53.42 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.352 1.461 . . . . 0.0 113.772 -168.015 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.19 -4.23 35.93 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.057 1.743 . . . . 0.0 112.97 168.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.92 -101.52 0.27 Allowed Glycine 0 C--N 1.343 0.941 0 CA-C-N 120.056 1.298 . . . . 0.0 112.519 170.193 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.4 m -54.83 -17.88 4.12 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 175.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.03 7.07 23.5 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.297 1.439 . . . . 0.0 113.521 175.267 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.4 t -171.85 98.0 0.17 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.94 1.696 . . . . 0.0 108.342 178.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 149.6 58.86 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 130.559 3.544 . . . . 0.0 111.687 -169.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -61.84 147.96 48.08 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 126.279 1.895 . . . . 0.0 114.123 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.77 95.17 0.54 Allowed 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 124.796 3.664 . . . . 0.0 113.765 -168.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 42.95 68.2 0.53 Allowed 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 126.517 1.927 . . . . 0.0 112.485 166.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -39.28 142.87 0.22 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-O 124.009 1.861 . . . . 0.0 115.085 -167.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 38.9 p-10 -104.41 48.95 0.08 OUTLIER Pre-proline 0 CA--C 1.554 1.121 0 C-N-CA 127.11 2.164 . . . . 0.0 114.352 -177.168 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -69.77 -15.81 37.22 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 121.941 1.729 . . . . 0.0 112.473 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.68 -3.16 42.72 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.769 1.628 . . . . 0.0 112.325 169.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.1 t 69.97 57.72 0.29 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.662 1.585 . . . . 0.0 113.029 168.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 ptm85 -152.6 176.41 11.75 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -169.023 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -91.24 168.17 11.79 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.35 1.46 . . . . 0.0 112.705 -179.001 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.6 t60 -75.95 160.56 29.76 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.427 1.091 . . . . 0.0 113.512 179.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.419 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 136.41 -113.64 1.08 Allowed Glycine 0 C--N 1.339 0.713 0 C-N-CA 125.392 1.472 . . . . 0.0 112.315 166.34 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.488 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 116.93 -56.52 0.54 Allowed Glycine 0 CA--C 1.537 1.449 0 N-CA-C 117.742 1.857 . . . . 0.0 117.742 171.344 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -81.24 -16.69 9.52 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 CA-C-N 121.54 2.67 . . . . 0.0 112.505 178.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.51 -5.73 4.2 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.804 1.242 . . . . 0.0 112.893 173.104 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.5 169.3 8.75 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.462 1.505 . . . . 0.0 110.377 178.072 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -101.08 -7.07 23.54 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 127.083 2.153 . . . . 0.0 112.729 -167.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -127.35 -82.94 0.61 Allowed 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 119.597 1.09 . . . . 0.0 113.583 -171.039 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 79.12 140.55 0.07 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 126.289 1.836 . . . . 0.0 113.546 170.65 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -82.95 -177.77 6.88 Favored 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 116.361 1.986 . . . . 0.0 116.361 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -66.97 -12.13 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 174.826 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -134.81 14.03 4.43 Favored Glycine 0 CA--C 1.531 1.085 0 CA-C-O 118.161 -1.355 . . . . 0.0 116.31 -171.014 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -92.84 112.6 24.62 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.654 1.727 . . . . 0.0 111.275 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.4 48.72 1.38 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 120.101 1.319 . . . . 0.0 111.874 177.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.94 -143.98 24.65 Favored Glycine 0 CA--C 1.536 1.367 0 O-C-N 121.211 -0.931 . . . . 0.0 114.93 172.161 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -131.95 158.07 42.38 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 126.184 1.793 . . . . 0.0 112.883 -179.385 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.7 m -114.17 106.74 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.165 1.786 . . . . 0.0 111.001 169.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.4 m -106.49 115.61 30.5 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.599 1.56 . . . . 0.0 110.229 -169.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.13 147.79 24.74 Favored 'General case' 0 CA--C 1.539 0.558 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -172.197 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -93.96 160.65 14.63 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 128.978 2.911 . . . . 0.0 109.685 168.239 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.83 -14.9 2.65 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 126.169 1.788 . . . . 0.0 115.698 -175.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.27 -5.3 26.75 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.757 -1.215 . . . . 0.0 112.11 171.318 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.82 15.53 65.28 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 127.008 2.242 . . . . 0.0 112.878 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.0 p -121.33 128.87 76.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.544 1.172 . . . . 0.0 113.699 -170.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.64 110.56 22.66 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 164.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -91.9 137.27 32.5 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 169.104 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -135.68 149.65 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 N-CA-C 116.801 2.148 . . . . 0.0 116.801 -168.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.9 m -155.21 127.37 7.7 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 126.052 1.741 . . . . 0.0 110.367 169.373 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 10.1 mm -140.82 166.44 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 129.026 2.93 . . . . 0.0 109.794 -173.535 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -155.29 154.61 32.38 Favored 'General case' 0 C--N 1.316 -0.87 0 C-N-CA 128.108 2.563 . . . . 0.0 107.825 170.217 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -155.79 150.99 26.7 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.938 1.295 . . . . 0.0 111.577 170.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -119.03 53.05 1.02 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.521 -1.218 . . . . 0.0 112.225 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 48.9 t -137.81 -43.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.3 1.44 . . . . 0.0 107.928 168.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.87 160.11 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 123.027 1.394 . . . . 0.0 110.93 167.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.53 ' H ' ' HB3' ' A' ' 111' ' ' SER . 3.6 p -156.29 168.87 25.97 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 128.762 2.825 . . . . 0.0 106.969 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -93.25 102.3 14.58 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -152.83 -6.91 0.19 Allowed 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -167.282 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.13 -95.83 2.13 Favored Glycine 0 C--N 1.336 0.546 0 O-C-N 120.927 -1.108 . . . . 0.0 111.613 173.191 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -69.97 -51.99 28.07 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.851 0.685 . . . . 0.0 112.851 -166.475 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -78.92 -27.81 43.78 Favored 'General case' 0 CA--C 1.539 0.547 0 O-C-N 120.271 -1.518 . . . . 0.0 112.358 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.53 ' HB3' ' H ' ' A' ' 105' ' ' SER . 8.2 m -118.88 -127.16 0.28 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.857 1.799 . . . . 0.0 115.857 -164.617 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.29 39.3 pt -111.03 173.69 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 O-C-N 119.769 -1.832 . . . . 0.0 108.682 166.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mm 90.49 136.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.843 1 C-N-CA 132.757 4.423 . . . . 0.0 107.25 -163.344 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 58.35 25.2 57.29 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.556 1.074 . . . . 0.0 114.687 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.1 ttm180 -122.17 156.29 34.0 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 126.614 1.965 . . . . 0.0 107.515 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.9 t -113.07 107.62 16.21 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 122.352 2.342 . . . . 0.0 115.694 -165.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 57.0 tp -76.99 128.92 35.39 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.72 0.808 . . . . 0.0 110.266 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -118.04 136.56 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.252 1.021 . . . . 0.0 109.127 169.352 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 m -93.04 144.74 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.384 -1.709 . . . . 0.0 106.384 168.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.7 m-70 -101.98 158.93 15.79 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-O 122.369 1.08 . . . . 0.0 112.987 -170.008 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -74.71 -35.64 62.71 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 -168.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -125.85 179.98 4.94 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 125.29 1.436 . . . . 0.0 112.597 173.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.25 140.47 38.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 126.683 1.993 . . . . 0.0 112.463 173.706 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -91.58 131.03 37.28 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.115 0.966 . . . . 0.0 111.057 178.731 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.419 ' OD1' ' HE3' ' A' ' 128' ' ' LYS . 0.3 OUTLIER -77.09 -18.93 57.65 Favored 'General case' 0 CA--C 1.554 1.118 0 N-CA-C 112.889 0.699 . . . . 0.0 112.889 174.998 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 41.3 mt 62.08 54.39 2.74 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.946 2.098 . . . . 0.0 113.686 173.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 118.62 -11.23 12.37 Favored Glycine 0 N--CA 1.475 1.246 0 N-CA-C 121.297 3.279 . . . . 0.0 121.297 164.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.541 ' HE3' ' H ' ' A' ' 128' ' ' LYS 0.252 0.0 OUTLIER -167.08 62.11 0.08 Allowed 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 118.192 2.664 . . . . 0.0 118.192 -173.626 . . . . . . . . 4 4 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -106.25 45.68 1.27 Allowed Glycine 0 N--CA 1.471 0.975 0 C-N-CA 127.041 2.257 . . . . 0.0 113.349 -172.342 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.21 -27.53 1.47 Allowed Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.62 1.105 . . . . 0.0 115.749 172.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -89.77 154.55 19.83 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 118.983 1.391 . . . . 0.0 110.381 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -55.33 -54.14 47.31 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-O 122.751 1.262 . . . . 0.0 109.108 167.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.4 tm-20 -51.89 -34.89 43.26 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 128.447 2.699 . . . . 0.0 112.593 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.0 p -60.03 -34.39 73.3 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.7 p -77.13 -14.37 59.81 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.61 1.164 . . . . 0.0 111.991 179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.3 mtpt -100.15 -53.76 3.05 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.516 1.926 . . . . 0.0 111.891 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.8 p -100.08 -34.42 10.07 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 117.659 -1.162 . . . . 0.0 113.781 -172.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.98 -3.2 28.64 Favored Glycine 0 CA--C 1.533 1.196 0 O-C-N 125.448 1.717 . . . . 0.0 113.715 -168.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.69 25.04 11.28 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 126.193 1.797 . . . . 0.0 112.738 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.82 46.39 0.29 Allowed 'General case' 0 CA--C 1.552 1.049 0 C-N-CA 126.799 2.04 . . . . 0.0 113.755 -168.157 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.04 -59.4 3.54 Favored Glycine 0 N--CA 1.467 0.728 0 C-N-CA 127.987 2.708 . . . . 0.0 113.692 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t 178.09 179.03 0.34 Allowed 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.11 2.164 . . . . 0.0 109.494 -169.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.64 153.66 35.02 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.03 -1.044 . . . . 0.0 111.018 169.75 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -135.14 -150.77 0.4 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.375 1.47 . . . . 0.0 108.63 169.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -52.93 141.96 20.64 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.274 1.43 . . . . 0.0 114.151 -173.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -134.72 154.67 51.46 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.983 1.313 . . . . 0.0 114.361 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.24 125.03 1.55 Allowed Glycine 0 CA--C 1.539 1.562 0 C-N-CA 124.646 1.117 . . . . 0.0 114.557 173.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -78.14 126.58 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 173.209 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 59.9 mt -78.41 124.51 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -167.166 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.76 167.97 13.96 Favored Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.847 1.213 . . . . 0.0 115.413 175.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.57 162.82 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 126.438 1.895 . . . . 0.0 113.416 -171.016 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.416 ' HB1' ' CD2' ' B' ' 50' ' ' PHE . . . -158.18 -40.97 0.06 Allowed 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.01 1.324 . . . . 0.0 112.032 169.062 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.47 0.538 0 C-N-CA 124.226 1.01 . . . . 0.0 112.159 169.096 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 70.9 p -134.08 125.43 28.02 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 166.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.3 mtmt -119.57 158.54 26.13 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -179.273 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.492 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -144.58 151.99 39.87 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.98 1.312 . . . . 0.0 112.534 169.589 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 p -111.08 133.53 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 125.987 1.715 . . . . 0.0 110.673 177.298 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.54 110.94 21.3 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.774 -1.204 . . . . 0.0 110.088 167.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 54' ' ' THR . 15.0 t -86.52 68.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 124.36 1.064 . . . . 0.0 112.063 -170.396 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -79.77 110.56 15.24 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 113.426 0.898 . . . . 0.0 113.426 -175.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mttm -157.62 129.55 7.03 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.71 1.204 . . . . 0.0 112.195 167.508 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.68 -56.9 0.01 OUTLIER Glycine 0 N--CA 1.468 0.772 0 C-N-CA 126.233 1.873 . . . . 0.0 109.885 169.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.58 72.29 3.24 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 125.989 1.715 . . . . 0.0 110.953 -176.777 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.64 -94.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.377 0 C-N-CA 127.844 2.64 . . . . 0.0 114.746 173.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -71.08 -20.98 28.03 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 123.964 3.109 . . . . 0.0 114.797 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.1 t -74.15 147.65 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 CA-C-N 121.483 1.947 . . . . 0.0 110.491 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.32 167.75 21.2 Favored 'General case' 0 CA--C 1.519 -0.228 0 C-N-CA 124.48 1.112 . . . . 0.0 109.651 167.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.8 59.58 0.4 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.874 169.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -75.41 127.42 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 117.776 0.788 . . . . 0.0 108.987 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.18 119.55 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 O-C-N 125.277 1.61 . . . . 0.0 109.741 176.51 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.2 121.27 23.41 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 124.915 1.286 . . . . 0.0 110.65 165.829 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -99.67 94.17 6.22 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.26 1.824 . . . . 0.0 106.135 167.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -98.25 113.66 25.67 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 124.311 1.044 . . . . 0.0 110.349 178.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -113.13 139.01 49.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 122.678 1.228 . . . . 0.0 110.464 179.431 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.71 -5.05 54.43 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.1 1.36 . . . . 0.0 114.237 -171.599 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 mp0 -155.75 -168.24 2.73 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 130.078 3.351 . . . . 0.0 106.603 175.499 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.8 t -89.2 -21.13 23.43 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-N 119.957 1.253 . . . . 0.0 110.135 163.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -109.6 11.32 24.8 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 126.191 1.796 . . . . 0.0 115.232 -176.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.77 -179.75 38.85 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 124.423 1.011 . . . . 0.0 112.834 -177.779 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.23 161.47 20.23 Favored 'Trans proline' 0 CA--C 1.537 0.654 0 C-N-CA 123.346 2.697 . . . . 0.0 109.421 168.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.01 134.94 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.89 0.876 . . . . 0.0 111.734 -169.239 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.6 mttp -87.84 126.14 34.86 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 165.531 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -123.75 89.03 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 127.362 2.265 . . . . 0.0 108.23 -169.218 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -119.09 156.24 30.08 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.799 0.84 . . . . 0.0 111.815 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.84 176.82 41.71 Favored Glycine 0 C--O 1.225 -0.439 0 O-C-N 121.479 -0.763 . . . . 0.0 113.437 -174.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -127.75 118.78 24.41 Favored 'General case' 0 C--O 1.239 0.543 0 O-C-N 122.054 -0.674 . . . . 0.0 111.948 -178.842 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.1 mm -92.08 117.8 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 169.777 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.3 pttt -139.41 137.34 35.58 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 123.185 0.594 . . . . 0.0 110.328 -168.721 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.29 0.68 54.01 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.871 1.7 . . . . 0.0 114.787 -173.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.464 HD11 ' HB2' ' B' ' 89' ' ' ALA . 0.5 OUTLIER -91.3 -160.35 0.72 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 118.412 1.106 . . . . 0.0 111.304 169.676 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.6 t -112.19 155.99 23.06 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.293 1.837 . . . . 0.0 110.976 178.774 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -47.65 149.85 1.13 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.625 1.97 . . . . 0.0 111.879 169.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.75 38.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 124.009 0.814 . . . . 0.0 113.726 -178.56 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -65.87 144.51 56.77 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 128.921 2.888 . . . . 0.0 113.157 -171.284 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -140.53 124.05 16.97 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 126.608 1.963 . . . . 0.0 110.508 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.5 149.85 35.45 Favored Glycine 0 N--CA 1.476 1.334 0 C-N-CA 124.744 1.164 . . . . 0.0 112.391 176.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -146.52 102.2 3.55 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-O 121.861 0.838 . . . . 0.0 112.404 -164.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -129.45 126.23 38.26 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 120.855 -1.153 . . . . 0.0 110.427 -169.233 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.79 116.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.296 1.439 . . . . 0.0 108.984 171.556 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.458 ' C ' ' H ' ' B' ' 50' ' ' PHE . 21.8 m170 -78.86 122.25 25.85 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 121.307 -0.871 . . . . 0.0 110.381 -179.493 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.65 2.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 127.053 2.141 . . . . 0.0 115.426 170.03 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 50' ' ' PHE . . . . . 0.458 ' H ' ' C ' ' B' ' 48' ' ' HIS . 2.5 m-85 -137.16 81.51 1.88 Allowed 'General case' 0 N--CA 1.442 -0.839 1 C-N-CA 133.776 4.83 . . . . 0.0 100.94 -176.011 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.05 20.07 35.04 Favored Glycine 0 N--CA 1.467 0.73 0 O-C-N 121.655 -0.653 . . . . 0.0 113.225 173.602 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -68.99 49.06 0.07 Allowed 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.042 2.537 . . . . 0.0 113.085 171.002 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -178.74 131.45 0.12 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.414 1.486 . . . . 0.0 111.047 -168.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.614 ' H ' ' CG2' ' A' ' 7' ' ' VAL . 6.6 t . . . . . 0 N--CA 1.478 0.951 0 N-CA-C 116.236 1.939 . . . . 0.0 116.236 175.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.558 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.52 -82.19 0.51 Allowed Glycine 0 CA--C 1.54 1.616 0 C-N-CA 126.842 2.163 . . . . 0.0 112.059 178.567 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.44 ' HA ' HG22 ' B' ' 137' ' ' THR . 66.9 Cg_endo -85.83 178.14 4.43 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 125.15 3.9 . . . . 0.0 115.139 -172.005 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -103.4 123.8 47.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.203 1.401 . . . . 0.0 110.796 179.386 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -58.26 146.9 32.47 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 120.789 0.328 . . . . 0.0 110.418 167.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.21 107.73 21.56 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.597 0.759 . . . . 0.0 112.515 -178.179 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -68.81 -30.85 26.4 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.135 1.89 . . . . 0.0 111.844 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -76.98 -7.81 56.28 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.096 0.959 . . . . 0.0 112.709 175.492 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.7 m 57.76 56.46 4.8 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.627 1.171 . . . . 0.0 111.743 172.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.89 172.69 15.64 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.394 1.478 . . . . 0.0 110.704 -168.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -72.5 176.68 5.19 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 -171.715 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -49.23 155.09 0.73 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.447 2.017 . . . . 0.0 116.447 -167.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' B' ' 79' ' ' ARG . . . -75.61 69.33 2.07 Favored Glycine 0 N--CA 1.473 1.144 0 C-N-CA 128.892 3.139 . . . . 0.0 114.212 -169.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.46 135.84 13.62 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 114.608 0.603 . . . . 0.0 114.608 -173.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -84.58 -0.95 9.52 Favored 'Trans proline' 0 CA--C 1.548 1.207 0 C-N-CA 123.87 3.047 . . . . 0.0 109.597 163.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.472 ' HE2' ' O ' ' B' ' 125' ' ' ASP . 0.1 OUTLIER -118.37 -10.61 10.15 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.642 1.977 . . . . 0.0 114.167 177.613 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -110.7 149.48 30.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.362 1.065 . . . . 0.0 109.022 -167.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -67.35 -25.53 66.03 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.535 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -88.65 146.22 25.21 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-O 125.07 2.367 . . . . 0.0 109.319 169.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.49 ' HA ' ' HA2' ' B' ' 72' ' ' GLY . 52.9 ttt-85 -167.03 106.67 0.6 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 112.545 -2.116 . . . . 0.0 113.293 -174.175 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -61.59 149.33 39.47 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.401 1.081 . . . . 0.0 109.157 162.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.3 -13.66 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 CA-C-N 120.891 1.678 . . . . 0.0 110.323 166.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.28 18.82 9.37 Favored Glycine 0 C--N 1.336 0.548 0 C-N-CA 127.235 2.35 . . . . 0.0 118.879 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.99 149.43 32.15 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 122.608 3.204 . . . . 0.0 112.917 168.672 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -107.64 174.95 5.66 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.575 1.55 . . . . 0.0 108.561 168.26 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.48 155.31 49.79 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 171.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -74.4 146.61 42.8 Favored 'General case' 0 CA--C 1.549 0.941 0 CA-C-O 121.658 0.742 . . . . 0.0 111.825 -170.324 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -101.21 119.56 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.996 1.719 . . . . 0.0 112.48 -168.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -98.58 126.88 44.3 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.331 1.052 . . . . 0.0 110.283 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.464 ' HB2' HD11 ' B' ' 38' ' ' LEU . . . -92.95 162.13 14.19 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 171.51 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -85.97 168.99 13.66 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.889 2.075 . . . . 0.0 113.123 170.216 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.24 61.93 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.644 1.978 . . . . 0.0 114.963 -177.329 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.35 2.35 18.89 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 125.643 1.577 . . . . 0.0 112.146 177.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.16 21.75 56.32 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 124.936 1.255 . . . . 0.0 113.458 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.13 134.39 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -179.091 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.09 130.3 54.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 124.828 1.251 . . . . 0.0 110.445 166.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -88.27 105.62 17.67 Favored 'General case' 0 C--O 1.232 0.165 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 163.126 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.93 129.9 36.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 114.954 -1.021 . . . . 0.0 108.631 169.432 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.1 m -146.38 94.21 2.42 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.387 1.075 . . . . 0.0 109.305 -176.492 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -130.9 159.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 126.346 1.858 . . . . 0.0 110.281 -174.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -139.77 142.2 36.77 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 128.077 2.551 . . . . 0.0 106.584 167.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -151.12 138.15 19.13 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.293 1.037 . . . . 0.0 111.876 -168.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 46.3 p -118.0 50.3 1.16 Allowed 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 177.068 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 p -147.26 4.64 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 171.602 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -122.71 160.89 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.576 1.551 . . . . 0.0 107.409 167.022 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 96.8 p -156.24 168.36 27.55 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 119.49 1.041 . . . . 0.0 113.626 -174.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -92.59 69.07 4.83 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.521 1.528 . . . . 0.0 110.055 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 5.7 m -117.56 160.02 21.92 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.775 1.63 . . . . 0.0 110.727 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 44.98 1.82 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 125.146 1.355 . . . . 0.0 114.468 -168.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -135.54 -84.63 0.39 Allowed 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.872 1.269 . . . . 0.0 110.449 -168.691 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -150.35 -2.82 0.37 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 127.74 2.416 . . . . 0.0 111.773 -176.427 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 95.0 p -61.09 -44.4 97.42 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.131 1.373 . . . . 0.0 114.11 -169.341 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 5.3 pt -154.16 -34.35 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 127.678 2.391 . . . . 0.0 111.223 166.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 45.1 mm -60.56 125.37 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 123.866 0.867 . . . . 0.0 108.765 -175.034 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.56 16.23 67.3 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 116.994 -2.003 . . . . 0.0 115.061 -178.544 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.4 mtm180 -79.62 168.21 19.68 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.841 1.82 . . . . 0.0 109.478 168.298 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 22.6 m -123.64 117.04 24.1 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.806 0.842 . . . . 0.0 110.31 175.416 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 37.6 tp -82.23 132.12 35.23 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 169.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -110.91 137.43 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.534 1.534 . . . . 0.0 108.751 165.62 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 p -109.77 130.36 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.968 0.89 . . . . 0.0 109.417 168.594 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.539 ' CE1' HH11 ' B' ' 143' ' ' ARG . 21.7 m-70 -99.91 161.12 13.8 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.527 1.131 . . . . 0.0 113.669 -172.167 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -76.42 -25.49 54.52 Favored 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.701 1.371 . . . . 0.0 114.701 -174.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -118.85 176.68 5.16 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 119.667 1.121 . . . . 0.0 112.415 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.71 164.3 2.14 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.151 1.38 . . . . 0.0 111.967 168.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -113.97 145.08 42.03 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.949 1.7 . . . . 0.0 110.546 -178.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 125' ' ' ASP . . . . . 0.472 ' O ' ' HE2' ' B' ' 75' ' ' LYS . 0.0 OUTLIER -73.95 -35.46 64.55 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-O 118.775 -0.631 . . . . 0.0 111.214 172.38 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 11.6 mt 77.54 24.61 0.77 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.015 2.126 . . . . 0.0 113.481 177.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.83 -78.9 0.06 OUTLIER Glycine 0 N--CA 1.474 1.182 0 CA-C-N 120.47 1.486 . . . . 0.0 116.657 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -156.22 87.67 1.06 Allowed 'General case' 0 N--CA 1.44 -0.925 0 C-N-CA 126.38 1.872 . . . . 0.0 110.93 173.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 129' ' ' GLY . . . . . 0.566 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -65.64 -10.99 52.24 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 126.836 2.16 . . . . 0.0 114.081 174.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.16 -33.8 2.47 Favored Glycine 0 N--CA 1.47 0.948 0 C-N-CA 124.366 0.984 . . . . 0.0 114.942 168.55 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.6 p30 -92.79 -177.78 4.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.498 1.519 . . . . 0.0 110.366 -177.459 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -61.5 -62.66 1.66 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 122.773 0.429 . . . . 0.0 110.351 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 133' ' ' GLU . . . . . 0.427 ' HB3' HD22 ' B' ' 139' ' ' ASN . 0.8 OUTLIER -42.06 -30.75 0.3 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 129.278 3.031 . . . . 0.0 115.572 -176.039 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.566 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 97.1 p -63.07 -41.84 99.53 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.373 1.469 . . . . 0.0 113.333 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 72.7 p -81.93 -30.57 31.72 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 123.834 0.854 . . . . 0.0 113.208 173.183 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -70.85 -53.15 16.31 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.704 2.002 . . . . 0.0 110.226 -177.309 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.44 HG22 ' HA ' ' B' ' 62' ' ' PRO . 74.6 p -111.54 -113.63 0.32 Allowed 'General case' 0 C--N 1.342 0.253 0 C-N-CA 128.207 2.603 . . . . 0.0 106.33 172.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -144.19 12.2 2.07 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 130.191 3.758 . . . . 0.0 111.874 169.155 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 139' ' ' ASN . . . . . 0.427 HD22 ' HB3' ' B' ' 133' ' ' GLU . 5.3 t-20 56.64 14.89 1.9 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.889 1.675 . . . . 0.0 113.814 -172.344 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.42 22.21 0.03 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 116.563 2.061 . . . . 0.0 116.563 -168.368 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.11 -169.81 52.12 Favored Glycine 0 CA--C 1.529 0.963 0 O-C-N 120.136 -1.603 . . . . 0.0 113.295 -171.506 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.06 -169.85 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.279 1.432 . . . . 0.0 110.906 174.266 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.539 HH11 ' CE1' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -137.3 146.5 44.72 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 115.622 1.712 . . . . 0.0 115.622 175.241 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.7 -121.96 0.06 Allowed 'General case' 0 CA--C 1.536 0.406 0 O-C-N 127.182 2.801 . . . . 0.0 106.451 164.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.35 154.86 41.37 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 122.932 1.349 . . . . 0.0 114.467 -166.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -139.16 152.02 47.09 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 126.381 1.872 . . . . 0.0 109.246 169.369 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.58 141.88 7.73 Favored Glycine 0 C--N 1.333 0.414 0 N-CA-C 114.369 0.508 . . . . 0.0 114.369 176.068 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -79.74 153.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.891 1.276 . . . . 0.0 110.464 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.19 109.73 20.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 124.878 1.271 . . . . 0.0 112.409 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.53 164.37 15.52 Favored Glycine 0 C--N 1.35 1.339 0 C-N-CA 125.204 1.383 . . . . 0.0 112.761 174.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.59 HG22 ' H ' ' B' ' 153' ' ' GLN . 2.6 mp -87.36 113.37 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 O-C-N 121.548 -0.972 . . . . 0.0 112.193 -168.677 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.492 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -82.42 16.57 2.03 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 128.112 2.565 . . . . 0.0 112.658 169.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 153' ' ' GLN . . . . . 0.59 ' H ' HG22 ' B' ' 151' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.436 0 C-N-CA 128.804 2.842 . . . . 0.0 111.991 170.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.518 -0.283 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -94.5 145.83 24.52 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.496 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -94.33 164.44 13.02 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 121.109 -0.994 . . . . 0.0 111.789 168.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.56 HG11 ' H ' ' B' ' 53' ' ' ASN . 1.2 p -112.45 164.22 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 172.149 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.77 81.25 1.5 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.993 1.317 . . . . 0.0 108.007 160.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.0 t -77.45 89.14 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.16 141.5 37.17 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.381 1.072 . . . . 0.0 112.167 -172.169 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -155.59 175.96 13.23 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 169.418 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 160.12 -95.08 0.14 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 127.283 2.373 . . . . 0.0 109.706 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -78.33 87.16 4.38 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 126.629 1.972 . . . . 0.0 112.406 -169.259 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.08 -98.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.991 2.234 . . . . 0.0 114.003 168.025 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -78.4 -2.35 12.42 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 125.191 3.927 . . . . 0.0 115.284 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.5 t -79.0 139.1 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 120.312 1.415 . . . . 0.0 110.389 171.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -148.6 170.45 18.09 Favored 'General case' 0 N--CA 1.462 0.169 0 C-N-CA 125.617 1.567 . . . . 0.0 110.494 169.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.57 162.76 28.73 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 114.877 -1.056 . . . . 0.0 111.559 165.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.3 tp -156.87 80.71 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 126.609 1.964 . . . . 0.0 107.737 -177.366 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mm -98.42 143.97 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.123 0.569 . . . . 0.0 110.1 175.306 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -114.7 148.99 37.49 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 128.93 2.892 . . . . 0.0 109.42 175.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.496 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 57.8 m-85 -141.78 82.11 1.79 Allowed 'General case' 0 CA--C 1.557 1.216 0 C-N-CA 123.983 0.913 . . . . 0.0 112.757 -178.428 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.446 ' HG2' ' CZ3' ' A' ' 32' ' ' TRP . 1.2 pt-20 -78.97 130.54 35.67 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 121.367 1.894 . . . . 0.0 114.755 -174.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -116.87 155.29 29.29 Favored 'General case' 0 CA--C 1.535 0.377 0 O-C-N 120.459 -1.4 . . . . 0.0 111.976 173.059 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -56.06 2.39 Favored 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.29 1.436 . . . . 0.0 112.64 -169.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -138.89 153.3 48.27 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 128.82 2.848 . . . . 0.0 107.739 169.406 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -48.45 -17.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 118.545 2.795 . . . . 0.0 118.545 -166.324 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -118.94 0.61 11.38 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.528 1.931 . . . . 0.0 113.405 -176.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.25 177.41 54.26 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.936 0.779 . . . . 0.0 112.829 176.496 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.91 177.52 8.62 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.293 3.329 . . . . 0.0 110.907 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 87.8 t -128.96 132.65 67.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 123.066 0.546 . . . . 0.0 110.128 178.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.43 122.39 34.83 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.9 t -103.47 128.02 56.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 126.002 1.721 . . . . 0.0 108.662 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.446 ' CZ3' ' HG2' ' A' ' 21' ' ' GLU . 3.1 p90 -144.83 157.71 44.06 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 122.84 0.456 . . . . 0.0 111.608 170.508 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.38 178.87 15.52 Favored Glycine 0 N--CA 1.463 0.465 0 O-C-N 121.259 -0.9 . . . . 0.0 112.427 -178.26 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 m -127.57 159.21 35.3 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 117.009 2.226 . . . . 0.0 117.009 -164.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.5 mm -123.73 124.5 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 127.2 2.2 . . . . 0.0 108.131 167.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -130.81 136.21 48.47 Favored 'General case' 0 CA--C 1.54 0.573 0 O-C-N 120.872 -1.142 . . . . 0.0 111.054 -169.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.41 -11.94 11.28 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.238 1.875 . . . . 0.0 113.557 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.9 mp -62.1 141.92 57.86 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 127.161 2.184 . . . . 0.0 109.062 169.264 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.6 t -71.59 -41.74 68.58 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -176.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 176.03 -160.62 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.743 1 C-N-CA 133.21 4.604 . . . . 0.0 105.168 178.469 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 74.24 173.42 29.28 Favored Glycine 0 N--CA 1.473 1.112 0 N-CA-C 117.165 1.626 . . . . 0.0 117.165 165.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.19 152.41 30.7 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.002 1.321 . . . . 0.0 109.61 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.458 ' HD1' ' HA ' ' A' ' 121' ' ' GLU . 93.3 m-70 -153.1 142.15 21.33 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.872 1.669 . . . . 0.0 112.82 -171.695 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 119' ' ' VAL . . . -57.22 163.23 7.18 Favored Glycine 0 N--CA 1.478 1.457 0 C-N-CA 124.867 1.223 . . . . 0.0 115.141 -174.639 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -160.45 84.55 0.71 Allowed 'General case' 0 CA--C 1.548 0.875 0 CA-C-O 122.672 1.225 . . . . 0.0 113.502 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -133.18 142.37 48.59 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 120.036 -1.665 . . . . 0.0 110.961 -171.299 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.562 HG23 ' HA2' ' A' ' 82' ' ' GLY . 11.4 m -109.23 128.71 64.96 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.167 0 CA-C-O 121.957 0.884 . . . . 0.0 109.046 176.432 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.8 m170 -76.09 156.8 33.54 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.762 -174.178 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -74.95 130.85 40.1 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 71.12 169.34 0.32 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-O 124.848 2.261 . . . . 0.0 113.862 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.68 11.01 56.29 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 129.589 3.471 . . . . 0.0 114.078 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.643 ' HA ' HG21 ' B' ' 5' ' ' VAL . 1.9 p30 -78.95 47.29 0.75 Allowed 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.27 2.535 . . . . 0.0 109.97 168.671 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.31 1.3 p30 -90.13 45.62 1.28 Allowed 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 115.533 1.679 . . . . 0.0 115.533 -165.661 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.521 HG22 ' HA ' ' B' ' 7' ' ' VAL . 19.4 p -119.91 -38.06 3.01 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -163.533 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.26 13.13 24.4 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 126.206 1.802 . . . . 0.0 112.9 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.48 -123.87 34.16 Favored Glycine 0 C--N 1.341 0.852 0 C-N-CA 125.112 1.339 . . . . 0.0 111.512 175.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 70.2 m -58.82 -13.77 7.06 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.827 1.417 . . . . 0.0 114.827 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.57 1.43 29.68 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.004 1.322 . . . . 0.0 112.081 173.135 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.2 m -158.54 -131.21 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 127.253 2.221 . . . . 0.0 108.209 -174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.34 95.35 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 128.002 2.521 . . . . 0.0 114.638 -173.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.6 162.24 53.92 Favored Glycine 0 CA--C 1.531 1.04 0 N-CA-C 115.301 0.88 . . . . 0.0 115.301 -167.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -69.24 84.57 0.57 Allowed 'Trans proline' 0 C--N 1.354 0.855 1 C-N-CA 125.963 4.442 . . . . 0.0 111.104 -173.539 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.5 p80 51.65 59.29 4.67 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 127.971 2.509 . . . . 0.0 110.808 169.049 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -56.05 167.05 0.66 Allowed 'General case' 0 N--CA 1.445 -0.723 0 CA-C-O 126.043 2.83 . . . . 0.0 112.443 -173.698 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.525 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.4 p-10 -118.88 73.67 12.3 Favored Pre-proline 0 C--N 1.314 -0.938 0 CA-C-N 110.837 -2.892 . . . . 0.0 112.275 -169.087 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.45 -23.72 75.14 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.018 2.479 . . . . 0.0 113.44 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 27.7 tp -86.64 -3.63 59.06 Favored 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.477 1.511 . . . . 0.0 113.191 170.43 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.7 t 68.15 49.69 0.83 Allowed 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.609 2.364 . . . . 0.0 112.578 176.377 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.525 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 7.9 mtp180 -106.67 170.91 7.65 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 115.224 1.564 . . . . 0.0 115.224 -168.636 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.5 mtmt -74.04 162.06 29.41 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.35 1.46 . . . . 0.0 109.247 164.434 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -86.83 142.63 27.94 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 172.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.415 ' HA2' ' HB3' ' A' ' 126' ' ' LEU . . . 147.4 -123.71 1.8 Allowed Glycine 0 C--N 1.341 0.815 0 N-CA-C 117.059 1.584 . . . . 0.0 117.059 164.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.47 -38.96 2.32 Favored Glycine 0 CA--C 1.546 1.998 0 N-CA-C 118.207 2.043 . . . . 0.0 118.207 -169.445 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -99.61 11.82 0.64 Allowed 'Trans proline' 0 CA--C 1.546 1.123 0 C-N-CA 123.955 3.104 . . . . 0.0 113.684 -176.438 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.67 -30.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 128.275 2.63 . . . . 0.0 109.893 167.635 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 5.3 t70 -75.31 152.89 38.13 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.153 0.978 . . . . 0.0 109.232 163.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -89.59 -26.13 20.96 Favored 'General case' 0 C--N 1.321 -0.664 1 C-N-CA 131.708 4.003 . . . . 0.0 111.679 -173.202 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -92.04 -71.29 0.65 Allowed 'General case' 0 C--N 1.34 0.164 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -169.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.4 ttt180 69.95 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.779 1.632 . . . . 0.0 112.861 -175.621 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -57.79 163.01 2.81 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 119.388 -2.07 . . . . 0.0 113.902 171.159 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.25 -38.16 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 119.353 0.979 . . . . 0.0 111.738 170.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.562 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -88.43 45.12 3.23 Favored Glycine 0 CA--C 1.533 1.158 0 N-CA-C 114.992 0.757 . . . . 0.0 114.992 177.579 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -137.44 134.46 35.87 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 120.824 -1.398 . . . . 0.0 111.154 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -127.6 53.49 1.75 Allowed 'General case' 0 CA--C 1.546 0.817 0 CA-C-O 122.111 0.958 . . . . 0.0 109.107 165.722 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.54 -138.26 42.76 Favored Glycine 0 C--N 1.342 0.882 0 C-N-CA 125.577 1.56 . . . . 0.0 113.129 172.579 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -141.71 150.86 42.39 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.031 0.933 . . . . 0.0 110.137 168.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.76 178.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 C-N-CA 127.659 2.384 . . . . 0.0 110.651 -174.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 83.1 m -149.96 138.2 20.47 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 124.973 1.309 . . . . 0.0 110.056 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.15 140.45 38.29 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.105 1.362 . . . . 0.0 114.641 -176.139 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -77.79 146.03 36.06 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.761 1.624 . . . . 0.0 109.775 166.455 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.93 -16.35 0.13 Allowed 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 130.066 3.346 . . . . 0.0 118.08 175.513 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -75.26 1.23 14.09 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-N 119.762 1.164 . . . . 0.0 110.776 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.25 43.52 4.95 Favored Glycine 0 C--N 1.336 0.551 0 C-N-CA 128.054 2.74 . . . . 0.0 112.408 171.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.8 p -155.38 132.22 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 119.562 1.681 . . . . 0.0 115.14 -175.252 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.75 107.64 20.13 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 165.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -98.37 144.59 27.6 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.658 0.742 . . . . 0.0 110.088 169.731 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -121.92 146.11 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 N-CA-C 115.07 1.507 . . . . 0.0 115.07 -174.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.8 t -159.47 81.34 0.75 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 126.712 2.005 . . . . 0.0 111.837 175.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -127.95 158.08 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 127.152 2.181 . . . . 0.0 110.917 -174.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -126.15 138.63 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 167.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -134.45 145.8 49.19 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.273 1.029 . . . . 0.0 112.718 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 12.4 p -120.5 48.58 1.57 Allowed 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 114.575 1.324 . . . . 0.0 114.575 -179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.0 m -139.35 3.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.35 139.18 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.819 1.248 . . . . 0.0 109.043 168.339 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 46.6 p -112.04 176.69 4.92 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 118.718 0.69 . . . . 0.0 111.123 169.031 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.8 mt -82.31 107.64 15.14 Favored 'General case' 0 C--N 1.345 0.4 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 167.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -136.98 -13.24 1.65 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.47 31.97 71.34 Favored Glycine 0 C--N 1.342 0.879 0 CA-C-N 119.884 1.22 . . . . 0.0 115.155 172.394 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -170.44 -103.32 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.802 1.241 . . . . 0.0 108.026 -169.398 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -79.43 8.74 5.7 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.34 2.256 . . . . 0.0 112.329 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 55.5 m -149.85 -161.53 1.36 Allowed 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.241 1.416 . . . . 0.0 109.438 165.372 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 15.3 pt -82.41 161.37 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 O-C-N 120.171 -1.581 . . . . 0.0 113.835 -168.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.445 HD11 ' HB2' ' A' ' 4' ' ' ALA . 2.3 mm 106.44 147.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 1 C-N-CA 135.023 5.329 . . . . 0.0 110.118 -167.155 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.47 2.73 56.02 Favored Glycine 0 C--O 1.219 -0.803 0 CA-C-O 117.319 -1.823 . . . . 0.0 114.838 174.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 34.8 mtt-85 -106.22 -176.14 2.99 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.898 2.479 . . . . 0.0 110.338 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.0 t -120.29 145.43 47.08 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 119.554 1.07 . . . . 0.0 110.934 169.565 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.0 tp -101.32 133.52 45.78 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 127.086 2.154 . . . . 0.0 109.723 170.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.46 147.8 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.512 1.525 . . . . 0.0 110.576 168.346 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.57 HG12 HD21 ' A' ' 144' ' ' LEU . 91.7 t -129.03 151.15 35.36 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 C-N-CA 126.067 1.747 . . . . 0.0 107.035 173.826 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 74.3 m-70 -124.25 133.8 53.41 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.365 1.066 . . . . 0.0 113.17 -168.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.458 ' HA ' ' HD1' ' A' ' 43' ' ' HIS 0.267 24.2 tp10 -84.81 39.07 0.73 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 -167.634 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -154.15 160.48 41.92 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.44 1.896 . . . . 0.0 109.5 169.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.57 118.36 8.08 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 169.393 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.5 157.93 20.3 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.477 1.132 . . . . 0.0 112.208 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -90.81 -9.49 46.27 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 128.587 2.755 . . . . 0.0 113.076 -169.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.415 ' HB3' ' HA2' ' A' ' 72' ' ' GLY . 2.3 mp 1.54 79.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 130.911 3.684 . . . . 0.0 116.194 -173.142 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.21 -66.68 0.57 Allowed Glycine 0 N--CA 1.467 0.753 0 C-N-CA 125.068 1.318 . . . . 0.0 114.287 170.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.7 ttpp -157.49 93.28 1.28 Allowed 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.436 1.273 . . . . 0.0 114.436 -170.256 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.88 -113.74 2.18 Favored Glycine 0 C--O 1.235 0.216 0 N-CA-C 108.336 -1.906 . . . . 0.0 108.336 165.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -131.32 33.66 2.74 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.151 1.834 . . . . 0.0 113.328 177.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -159.58 159.83 33.7 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 118.78 1.29 . . . . 0.0 108.766 -171.229 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -68.73 -48.97 62.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.29 0.566 . . . . 0.0 110.093 -176.19 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.1 mp0 -38.63 -33.97 0.13 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.636 3.174 . . . . 0.0 113.591 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.9 p -59.88 -44.97 93.9 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.281 1.432 . . . . 0.0 114.021 175.413 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.8 t -81.7 -36.38 28.76 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 118.96 0.8 . . . . 0.0 111.283 168.216 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 16.6 tttt -56.88 -48.14 78.86 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.117 1.367 . . . . 0.0 111.991 -175.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -147.48 -10.79 0.41 Allowed 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 126.818 2.047 . . . . 0.0 115.009 -168.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.65 3.56 57.25 Favored Glycine 0 C--O 1.223 -0.575 0 CA-C-O 117.374 -1.792 . . . . 0.0 113.128 -173.432 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 67.54 -60.33 0.39 Allowed 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.043 2.137 . . . . 0.0 111.333 -172.103 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 68.41 -21.39 0.14 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 129.795 3.238 . . . . 0.0 115.571 168.585 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.61 -20.26 0.14 Allowed Glycine 0 CA--C 1.537 1.418 0 C-N-CA 126.904 2.192 . . . . 0.0 118.447 166.798 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.7 t -161.65 -173.11 3.6 Favored 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 127.626 2.371 . . . . 0.0 110.819 176.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.05 154.22 43.01 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.473 -1.392 . . . . 0.0 110.029 169.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.57 HD21 HG12 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -128.94 -129.11 0.22 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 123.43 0.692 . . . . 0.0 110.292 169.664 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.43 158.87 32.75 Favored 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 126.667 1.987 . . . . 0.0 113.113 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -140.79 161.58 37.46 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.922 2.089 . . . . 0.0 110.062 169.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.32 148.21 16.7 Favored Glycine 0 N--CA 1.472 1.038 0 O-C-N 121.272 -0.892 . . . . 0.0 112.918 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -78.56 161.78 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 C-N-CA 123.95 0.9 . . . . 0.0 109.773 177.496 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 36.8 mt -110.71 98.51 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 120.356 -1.465 . . . . 0.0 112.207 -175.217 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.45 167.07 22.14 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.712 1.625 . . . . 0.0 115.402 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.99 80.07 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 C-N-CA 127.91 2.484 . . . . 0.0 113.387 -175.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.36 26.24 0.22 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.657 1.583 . . . . 0.0 115.16 -175.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 . . . . . 0 N--CA 1.469 0.518 0 C-N-CA 129.413 3.085 . . . . 0.0 114.346 176.549 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 119.418 -0.325 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.9 m -79.78 108.69 13.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 125.333 1.453 . . . . 0.0 108.088 -171.762 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 27.6 mttt -99.43 118.59 36.39 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -171.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -83.35 169.25 15.83 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 127.71 2.404 . . . . 0.0 114.874 178.24 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.643 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -156.07 125.43 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 129.412 3.085 . . . . 0.0 107.55 175.608 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.07 139.38 47.64 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.088 0.955 . . . . 0.0 113.173 179.496 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.521 ' HA ' HG22 ' A' ' 54' ' ' THR . 3.2 t -85.88 68.07 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.189 -0.914 . . . . 0.0 112.401 -168.65 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.12 103.13 5.17 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 122.208 1.004 . . . . 0.0 108.337 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -161.91 133.09 5.21 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 125.331 1.453 . . . . 0.0 109.713 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.25 -118.06 3.76 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -127.3 57.48 1.49 Allowed 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 126.046 1.738 . . . . 0.0 111.706 -164.071 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.5 -168.07 41.17 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 121.074 -1.016 . . . . 0.0 112.901 -171.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.55 -5.94 12.58 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 124.354 3.369 . . . . 0.0 115.444 -168.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.16 129.19 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 CA-C-N 120.258 1.39 . . . . 0.0 110.371 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -123.13 178.55 5.04 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 122.518 1.151 . . . . 0.0 110.29 168.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.2 163.01 31.29 Favored Glycine 0 CA--C 1.499 -0.942 0 CA-C-N 113.888 -1.506 . . . . 0.0 113.129 165.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pt -133.6 82.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 112.162 -2.019 . . . . 0.0 106.688 170.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.343 2.7 pp -89.49 109.87 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.043 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -112.74 133.54 54.71 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.523 2.329 . . . . 0.0 108.577 -170.058 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -124.48 147.06 48.58 Favored 'General case' 0 N--CA 1.474 0.766 0 O-C-N 121.028 -1.045 . . . . 0.0 111.178 -174.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -108.66 112.22 24.43 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.522 1.129 . . . . 0.0 111.717 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.3 99.04 10.87 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.114 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.43 ' HE2' ' HB2' ' B' ' 24' ' ' GLU . 0.2 OUTLIER -70.72 -28.8 65.0 Favored 'General case' 0 CA--C 1.539 0.53 0 O-C-N 121.415 -0.803 . . . . 0.0 113.108 170.276 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 24' ' ' GLU . . . . . 0.43 ' HB2' ' HE2' ' B' ' 23' ' ' LYS . 43.1 tt0 -163.61 124.54 2.29 Favored 'General case' 0 C--O 1.222 -0.355 0 C-N-CA 124.689 1.196 . . . . 0.0 110.446 -166.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.0 p -60.86 -10.16 5.2 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 127.977 2.511 . . . . 0.0 114.8 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -132.93 15.16 4.28 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.239 1.816 . . . . 0.0 111.841 -171.527 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.42 -153.09 7.42 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 126.628 2.061 . . . . 0.0 111.724 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -85.29 167.05 10.69 Favored 'Trans proline' 0 N--CA 1.456 -0.733 0 C-N-CA 122.642 2.228 . . . . 0.0 112.202 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -119.78 140.22 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 124.993 1.317 . . . . 0.0 108.859 170.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -94.89 121.94 37.01 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 168.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.17 131.95 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 128.04 2.536 . . . . 0.0 109.071 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -156.05 -176.77 6.13 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 119.49 168.25 13.89 Favored Glycine 0 C--N 1.335 0.518 0 CA-C-O 122.079 0.822 . . . . 0.0 114.478 166.566 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 4.9 p -99.08 123.37 43.33 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -167.522 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 mp -98.5 118.08 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 166.464 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -129.01 132.29 47.5 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.551 1.54 . . . . 0.0 110.788 -166.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.26 -2.59 29.68 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 128.228 2.823 . . . . 0.0 111.939 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 22.4 mt -69.91 148.11 49.41 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 118.94 1.37 . . . . 0.0 112.598 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 26.8 m -76.37 143.97 40.39 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 125.614 1.565 . . . . 0.0 107.211 165.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -59.24 156.4 12.48 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.81 -179.45 35.55 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.668 0.652 . . . . 0.0 112.281 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.477 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -83.25 142.39 31.17 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 127.267 2.227 . . . . 0.0 113.846 -169.56 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 80.5 m-70 -134.01 125.78 28.85 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 129.093 2.957 . . . . 0.0 108.602 -176.747 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.09 148.64 28.15 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 125.492 1.52 . . . . 0.0 112.594 178.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -142.26 103.52 4.29 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.999 1.399 . . . . 0.0 111.528 -168.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.56 139.0 33.07 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 120.223 -1.548 . . . . 0.0 111.226 -175.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.88 115.52 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 176.154 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -71.86 -178.52 2.34 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 128.119 2.567 . . . . 0.0 111.172 -169.116 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.7 145.02 46.45 Favored 'General case' 0 CA--C 1.547 0.828 0 O-C-N 121.317 -0.864 . . . . 0.0 111.008 168.612 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -92.54 -170.95 2.62 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.28 1.832 . . . . 0.0 113.06 -169.303 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.17 -108.36 3.0 Favored Glycine 0 C--N 1.334 0.447 0 N-CA-C 115.694 1.037 . . . . 0.0 115.694 163.369 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -77.92 65.04 3.27 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.252 1.421 . . . . 0.0 110.567 -169.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.56 ' H ' HG11 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -165.52 162.59 19.27 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.714 1.376 . . . . 0.0 114.714 -168.598 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 39.5 p . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 116.65 2.093 . . . . 0.0 116.65 179.526 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.354 0 CA-C-O 121.43 0.633 . . . . 0.0 112.352 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.46 171.17 25.56 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.194 1.378 . . . . 0.0 113.765 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -65.34 169.41 12.48 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 124.493 3.462 . . . . 0.0 112.264 -173.276 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -20.19 86.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 128.504 2.722 . . . . 0.0 117.733 175.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -50.57 126.63 15.9 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 123.54 1.638 . . . . 0.0 114.053 -172.076 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.46 59.81 0.46 Allowed Pre-proline 0 CA--C 1.558 1.261 0 CA-C-N 112.194 -2.276 . . . . 0.0 115.851 -168.726 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -65.28 -27.53 55.8 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 123.355 2.704 . . . . 0.0 114.232 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -76.28 -3.99 39.58 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.195 0.998 . . . . 0.0 112.244 175.575 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t 63.54 50.58 2.76 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 126.002 1.721 . . . . 0.0 111.114 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -103.14 168.45 9.17 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.551 1.14 . . . . 0.0 111.757 -174.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.452 ' HE3' ' HD2' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -96.39 173.1 7.54 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.456 1.502 . . . . 0.0 107.287 164.433 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.476 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 29.5 t60 -63.88 164.5 10.12 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 119.981 -1.699 . . . . 0.0 113.715 -178.028 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 166.67 -174.44 42.07 Favored Glycine 0 N--CA 1.469 0.863 0 O-C-N 120.921 -1.112 . . . . 0.0 113.929 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.28 -154.26 25.38 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 -167.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -62.77 -1.75 2.94 Favored 'Trans proline' 0 CA--C 1.54 0.807 1 C-N-CA 125.849 4.366 . . . . 0.0 116.379 -172.623 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -120.89 -1.98 9.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.021 1.329 . . . . 0.0 113.641 170.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -131.04 176.79 7.96 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 126.746 2.018 . . . . 0.0 110.259 -168.303 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -100.15 -17.07 17.58 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 127.13 2.172 . . . . 0.0 113.803 -169.504 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -95.2 -100.34 0.16 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 118.565 0.621 . . . . 0.0 112.673 -176.199 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.2 ttp-105 85.77 97.28 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 126.825 2.05 . . . . 0.0 110.024 -175.382 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -49.67 156.83 0.63 Allowed 'General case' 0 N--CA 1.475 0.799 0 O-C-N 119.936 -1.727 . . . . 0.0 111.788 168.021 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 46.4 t -53.38 -21.5 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 119.266 0.939 . . . . 0.0 113.265 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.29 61.4 0.55 Allowed Glycine 0 CA--C 1.531 1.036 0 CA-C-O 118.573 -1.126 . . . . 0.0 114.105 169.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -123.52 124.68 43.37 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 119.642 1.721 . . . . 0.0 109.099 168.143 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.9 mt -132.18 49.22 2.34 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 119.268 0.94 . . . . 0.0 112.381 -176.446 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.94 -148.29 47.71 Favored Glycine 0 CA--C 1.534 1.277 0 O-C-N 121.101 -1.0 . . . . 0.0 113.49 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -129.76 137.27 50.44 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.781 1.233 . . . . 0.0 109.837 168.639 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -96.15 133.32 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 125.861 1.664 . . . . 0.0 110.227 179.397 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 32.1 m -108.94 136.81 47.87 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 124.222 1.009 . . . . 0.0 108.803 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.35 145.09 26.47 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 174.088 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -77.18 146.91 36.76 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.118 1.767 . . . . 0.0 110.499 167.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -63.91 -14.3 52.46 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.925 1.824 . . . . 0.0 115.925 -169.634 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -76.16 3.32 10.86 Favored 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 125.471 1.508 . . . . 0.0 111.481 171.399 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 100.36 29.41 6.71 Favored Glycine 0 C--N 1.342 0.892 0 C-N-CA 126.327 1.918 . . . . 0.0 114.719 168.107 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.1 139.51 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 120.227 2.014 . . . . 0.0 115.215 -169.048 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.49 99.29 7.07 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 124.401 1.08 . . . . 0.0 110.187 169.114 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -87.74 91.24 8.68 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-O 122.591 1.186 . . . . 0.0 109.169 172.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -75.85 158.64 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 CA-C-N 114.109 -1.405 . . . . 0.0 114.133 -167.235 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 82.4 p -155.0 105.93 2.59 Favored 'General case' 0 N--CA 1.471 0.584 0 O-C-N 120.61 -1.306 . . . . 0.0 111.782 -175.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.3 mt -137.43 153.19 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 126.708 2.003 . . . . 0.0 110.639 -176.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -139.01 136.14 35.02 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.26 1.824 . . . . 0.0 107.92 168.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -149.18 143.97 26.28 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 125.873 1.669 . . . . 0.0 111.013 -172.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -107.89 53.19 0.69 Allowed 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 113.29 0.848 . . . . 0.0 113.29 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.1 t -144.3 -42.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 124.29 1.036 . . . . 0.0 112.92 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.63 163.08 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 O-C-N 121.14 -0.975 . . . . 0.0 113.447 -176.061 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -156.57 154.24 29.93 Favored 'General case' 0 N--CA 1.476 0.838 0 O-C-N 119.91 -1.744 . . . . 0.0 113.341 174.033 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mp -84.85 46.43 1.26 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.008 1.323 . . . . 0.0 108.65 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.0 m -75.59 -34.63 60.66 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 116.091 1.886 . . . . 0.0 116.091 -166.019 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.62 18.41 Favored Glycine 0 CA--C 1.536 1.352 0 N-CA-C 115.578 0.991 . . . . 0.0 115.578 -174.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 p30 -116.74 -83.23 0.63 Allowed 'General case' 0 CA--C 1.549 0.905 0 C-N-CA 125.65 1.58 . . . . 0.0 111.003 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -143.42 -1.59 1.02 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 129.399 3.079 . . . . 0.0 111.922 -178.098 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 52.5 m -73.46 -91.54 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 126.488 1.915 . . . . 0.0 112.003 -169.438 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.7 pt -136.04 -26.34 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 175.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 mm -66.04 136.68 26.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 CA-C-N 122.826 2.557 . . . . 0.0 108.621 168.238 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.52 -16.53 6.22 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.018 0.818 . . . . 0.0 114.594 -172.2 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -79.07 178.39 8.08 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.528 1.131 . . . . 0.0 109.361 169.235 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.57 124.26 12.56 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.479 1.036 . . . . 0.0 111.902 -170.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 tp -89.27 120.36 30.57 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.393 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.0 p -99.89 130.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 124.14 0.976 . . . . 0.0 110.802 171.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.8 m -93.38 133.71 33.58 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 165.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -96.39 177.75 5.59 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 125.355 1.462 . . . . 0.0 111.155 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -84.76 -58.04 2.87 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 120.912 -1.118 . . . . 0.0 110.648 -173.228 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -95.34 177.99 5.66 Favored 'General case' 0 N--CA 1.471 0.593 0 O-C-N 120.746 -1.221 . . . . 0.0 110.537 169.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.03 146.09 28.36 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 168.785 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -86.89 163.09 17.37 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 123.145 1.45 . . . . 0.0 111.368 169.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.47 -8.83 57.98 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.105 1.762 . . . . 0.0 112.25 -170.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 95.6 mt 33.6 50.24 0.28 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 128.511 2.724 . . . . 0.0 113.276 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 159.84 -93.62 0.12 Allowed Glycine 0 C--N 1.333 0.41 0 O-C-N 121.678 -0.639 . . . . 0.0 114.336 -178.279 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 128' ' ' LYS . . . . . 0.452 ' HD2' ' HE3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -159.16 127.38 5.08 Favored 'General case' 0 CA--C 1.55 0.978 0 C-N-CA 125.422 1.489 . . . . 0.0 112.422 -173.711 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -123.87 -19.05 2.8 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.593 1.092 . . . . 0.0 115.095 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 119.69 -14.49 10.65 Favored Glycine 0 N--CA 1.474 1.217 0 CA-C-O 118.34 -1.255 . . . . 0.0 116.227 171.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -98.11 165.12 12.04 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.875 1.838 . . . . 0.0 110.175 168.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -51.8 -55.83 17.51 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.328 1.051 . . . . 0.0 110.035 178.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -51.6 -33.29 32.3 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 128.041 2.536 . . . . 0.0 113.313 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -54.86 -46.37 74.67 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 121.137 1.789 . . . . 0.0 113.861 176.077 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -91.24 -31.67 16.05 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 172.578 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -74.11 -28.17 61.23 Favored 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.514 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.7 m -128.82 -44.68 1.32 Allowed 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.352 1.461 . . . . 0.0 111.672 -179.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 138' ' ' GLY . . . . . 0.476 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 122.16 7.92 7.49 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 127.781 2.61 . . . . 0.0 112.269 -167.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 61.08 -77.39 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 126.213 1.805 . . . . 0.0 109.382 -169.243 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 64.94 3.61 2.16 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 127.889 2.476 . . . . 0.0 117.482 164.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.49 -46.63 1.97 Allowed Glycine 0 N--CA 1.471 1.014 0 C-N-CA 125.398 1.475 . . . . 0.0 113.803 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.9 m -178.27 176.71 1.06 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 126.933 2.093 . . . . 0.0 112.002 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -79.43 173.63 12.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.586 0.754 . . . . 0.0 110.846 168.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -140.74 -79.55 0.27 Allowed 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.755 0.822 . . . . 0.0 109.964 169.339 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.47 43.89 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 126.4 1.88 . . . . 0.0 109.686 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -156.81 151.74 26.02 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.966 1.706 . . . . 0.0 111.833 -171.293 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.79 148.74 17.18 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 116.415 1.326 . . . . 0.0 116.415 176.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -74.56 140.68 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 117.627 0.713 . . . . 0.0 110.671 175.177 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.9 mm -81.24 118.4 28.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 C-N-CA 125.303 1.441 . . . . 0.0 111.566 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.6 -167.16 14.58 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 126.227 1.87 . . . . 0.0 112.613 169.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.425 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.0 OUTLIER -134.28 138.37 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.265 1.426 . . . . 0.0 114.34 -169.028 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.68 -141.26 0.27 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.703 1.201 . . . . 0.0 110.337 174.528 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.464 0 C-N-CA 124.272 1.029 . . . . 0.0 110.279 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.471 0.603 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -168.37 157.38 9.03 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 115.403 1.631 . . . . 0.0 115.403 163.557 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.1 179.02 8.06 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 130.231 3.413 . . . . 0.0 107.181 169.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.503 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.3 p -155.66 108.29 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 122.645 1.212 . . . . 0.0 111.619 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -101.5 96.64 7.27 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 167.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.1 t -76.91 136.06 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 165.425 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mp -128.39 104.29 7.63 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.155 -0.966 . . . . 0.0 109.562 -178.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -160.43 151.39 18.92 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 124.24 1.016 . . . . 0.0 111.865 -178.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.17 -116.94 1.02 Allowed Glycine 0 CA--C 1.524 0.624 0 CA-C-O 123.089 1.383 . . . . 0.0 111.618 166.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -92.7 56.32 2.63 Favored 'General case' 0 C--N 1.312 -1.035 1 C-N-CA 132.635 4.374 . . . . 0.0 115.034 -164.8 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.4 -168.19 35.25 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.296 -1.32 . . . . 0.0 114.074 176.218 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -86.02 17.88 1.67 Allowed 'Trans proline' 0 CA--C 1.539 0.767 1 C-N-CA 125.686 4.257 . . . . 0.0 113.553 -171.117 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 t -111.08 120.84 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.87 1.213 . . . . 0.0 108.975 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 pm0 -160.25 162.31 33.66 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.52 173.65 33.64 Favored Glycine 0 N--CA 1.462 0.377 0 C-N-CA 124.368 0.985 . . . . 0.0 113.296 168.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -126.24 134.13 67.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 124.386 1.074 . . . . 0.0 108.86 170.443 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.8 mm -137.6 105.24 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 118.274 0.488 . . . . 0.0 110.231 -172.605 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -77.67 161.74 27.55 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.597 0.713 . . . . 0.0 111.662 172.148 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.414 ' CD2' HG22 ' A' ' 31' ' ' VAL . 3.4 m-85 -137.17 111.22 8.32 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.897 1.679 . . . . 0.0 106.806 169.762 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -91.65 135.51 33.82 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 120.765 1.62 . . . . 0.0 109.794 172.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -132.1 145.99 51.75 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.825 0.821 . . . . 0.0 111.532 175.131 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -92.53 -34.74 13.94 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 124.624 1.169 . . . . 0.0 114.1 179.399 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.95 -154.42 0.55 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-N 120.66 1.573 . . . . 0.0 112.791 178.568 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 65.7 p -93.35 -0.23 56.68 Favored 'General case' 0 CA--C 1.538 0.518 0 O-C-N 119.228 -2.17 . . . . 0.0 115.469 -172.051 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -153.49 -8.71 0.16 Allowed 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 115.875 1.806 . . . . 0.0 115.875 -169.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.91 173.89 55.31 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 128.664 3.031 . . . . 0.0 114.023 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -78.22 139.36 16.75 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.046 2.497 . . . . 0.0 111.758 -175.498 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -108.84 132.9 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.418 1.087 . . . . 0.0 109.353 -170.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -99.07 113.21 25.3 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 122.172 0.987 . . . . 0.0 110.34 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.414 HG22 ' CD2' ' A' ' 20' ' ' PHE . 9.3 t -95.5 130.99 43.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 127.984 2.514 . . . . 0.0 109.14 -178.17 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.0 p90 -148.81 159.32 44.26 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.92 -157.12 27.21 Favored Glycine 0 C--O 1.225 -0.424 0 C-N-CA 126.058 1.79 . . . . 0.0 110.178 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.5 p -157.11 154.72 29.86 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 121.577 -0.955 . . . . 0.0 112.417 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 mp -121.67 130.91 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 125.599 1.56 . . . . 0.0 108.346 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.4 140.5 49.67 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.316 1.446 . . . . 0.0 111.012 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.52 11.6 11.51 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 126.17 1.843 . . . . 0.0 112.54 -168.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.7 mt -86.96 171.24 10.92 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.532 0.733 . . . . 0.0 109.54 169.393 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -80.53 -141.09 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 164.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.49 -154.13 0.37 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.939 1.296 . . . . 0.0 108.535 166.285 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 69.28 179.74 22.96 Favored Glycine 0 CA--C 1.532 1.147 0 O-C-N 120.398 -1.439 . . . . 0.0 115.331 168.24 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mp -87.52 154.77 20.36 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.973 1.709 . . . . 0.0 110.611 -176.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -150.67 103.52 3.11 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 127.323 2.249 . . . . 0.0 109.908 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.05 160.61 20.86 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 124.558 1.075 . . . . 0.0 114.185 -175.282 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -142.78 92.38 2.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 125.933 1.693 . . . . 0.0 109.186 -173.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -109.35 130.4 55.5 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.298 -1.501 . . . . 0.0 109.8 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -77.97 158.33 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 175.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -119.9 123.44 43.57 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 pm0 -57.47 147.16 27.33 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.774 0.797 . . . . 0.0 109.872 177.791 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 68.95 166.72 0.27 Allowed 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 126.111 2.862 . . . . 0.0 112.353 -176.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.81 10.8 18.4 Favored Glycine 0 N--CA 1.467 0.718 0 C-N-CA 128.198 2.809 . . . . 0.0 112.186 178.363 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -83.7 42.99 0.88 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 128.509 2.723 . . . . 0.0 114.055 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -179.88 -26.85 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 112.723 -2.035 . . . . 0.0 114.925 -166.369 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.389 43.4 p 27.74 -18.35 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 2 N-CA-C 123.535 4.643 . . . . 0.0 123.535 -167.625 . . . . . . . . 3 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.44 -0.37 57.36 Favored 'General case' 0 CA--C 1.549 0.91 0 CA-C-N 122.48 2.4 . . . . 0.0 114.278 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.9 -128.4 37.31 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 125.721 1.629 . . . . 0.0 111.396 177.523 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -51.62 -2.75 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.235 0 N-CA-C 117.215 2.302 . . . . 0.0 117.215 -176.665 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 85.7 m -110.63 11.37 22.82 Favored 'General case' 0 N--CA 1.481 1.108 0 O-C-N 119.795 -1.816 . . . . 0.0 113.782 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 t -155.79 -27.45 0.1 Allowed 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 115.92 1.822 . . . . 0.0 115.92 168.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.2 177.02 4.79 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.797 2.039 . . . . 0.0 108.912 166.298 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.79 -107.92 2.47 Favored Glycine 0 CA--C 1.541 1.719 0 CA-C-O 117.755 -1.58 . . . . 0.0 114.443 -169.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -101.69 -167.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.543 0.956 1 C-N-CA 127.23 5.287 . . . . 0.0 112.144 -174.623 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.742 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.6 OUTLIER -100.11 119.83 38.91 Favored 'General case' 0 CA--C 1.554 1.111 1 C-N-CA 132.292 4.237 . . . . 0.0 115.243 -178.274 . . . . . . . . 4 4 . 1 . 014 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -39.74 126.93 2.0 Allowed 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 130.074 3.35 . . . . 0.0 116.123 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 51.0 p-10 -121.6 32.72 0.21 Allowed Pre-proline 0 CA--C 1.557 1.212 0 N-CA-C 115.304 1.594 . . . . 0.0 115.304 -173.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -62.8 -20.66 71.8 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.959 3.106 . . . . 0.0 114.978 -167.351 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 60.5 mt -78.46 -1.78 35.34 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.09 1.356 . . . . 0.0 112.685 174.13 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.76 52.8 0.93 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 127.269 2.227 . . . . 0.0 111.765 173.661 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.4 ptt180 -156.97 -179.98 8.73 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -166.824 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.26 177.53 8.9 Favored 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.434 1.494 . . . . 0.0 113.983 -171.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -50.87 157.8 0.76 Allowed 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -169.608 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -80.85 67.75 3.52 Favored Glycine 0 N--CA 1.474 1.177 0 C-N-CA 125.601 1.572 . . . . 0.0 114.354 -167.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -97.06 128.37 9.53 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-O 118.913 -0.937 . . . . 0.0 114.583 -168.22 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -76.84 4.68 5.48 Favored 'Trans proline' 0 CA--C 1.545 1.071 0 C-N-CA 123.632 2.888 . . . . 0.0 111.713 167.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.56 -10.52 18.4 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.963 0.905 . . . . 0.0 111.863 168.501 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -123.37 139.73 53.74 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.155 0.982 . . . . 0.0 110.809 -166.691 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -66.81 -28.62 68.52 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.496 172.357 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -91.76 105.04 17.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 125.969 1.708 . . . . 0.0 106.946 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -140.11 112.69 7.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 129.065 2.946 . . . . 0.0 109.56 -170.201 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -58.71 152.29 19.15 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.094 1.357 . . . . 0.0 111.405 167.199 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 p -65.0 -13.75 15.43 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 171.233 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.02 43.64 1.36 Allowed Glycine 0 C--N 1.347 1.158 0 N-CA-C 118.26 2.064 . . . . 0.0 118.26 -168.469 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -147.68 143.6 27.75 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 119.891 1.845 . . . . 0.0 109.484 167.009 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.0 mt -108.67 54.37 0.66 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.638 0.732 . . . . 0.0 109.345 -175.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.09 -120.07 6.75 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 124.84 1.209 . . . . 0.0 112.239 -172.118 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -142.28 160.4 40.32 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.709 1.204 . . . . 0.0 109.717 170.468 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.681 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.7 OUTLIER -99.17 151.4 4.73 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.763 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 164.887 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.9 m -134.55 120.86 20.17 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 124.736 1.214 . . . . 0.0 108.738 -177.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.46 140.2 29.71 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -175.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -81.9 160.07 23.5 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 128.155 2.582 . . . . 0.0 110.151 169.013 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.47 -22.08 7.32 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 126.382 1.873 . . . . 0.0 114.944 -173.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -76.79 -3.9 40.69 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.445 2.298 . . . . 0.0 112.289 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.78 10.01 73.51 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 126.929 2.204 . . . . 0.0 114.477 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.83 137.54 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.583 1.553 . . . . 0.0 111.963 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.681 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -107.73 130.54 54.94 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.471 -0.936 . . . . 0.0 108.471 166.128 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -82.29 151.64 26.67 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 122.277 1.037 . . . . 0.0 109.499 170.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -134.08 129.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 112.81 -1.995 . . . . 0.0 111.867 164.463 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.2 p -157.85 54.05 0.47 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 124.4 1.08 . . . . 0.0 111.978 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.81 153.86 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 O-C-N 120.277 -1.515 . . . . 0.0 112.352 -171.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -129.28 139.9 51.63 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 125.845 1.658 . . . . 0.0 108.457 168.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -150.07 148.53 29.12 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.4 1.095 . . . . 0.0 111.662 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -107.5 55.61 0.65 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.082 1.753 . . . . 0.0 110.35 -171.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.6 p -152.47 11.32 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -169.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -153.58 163.09 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 127.158 2.183 . . . . 0.0 107.904 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.0 m -155.14 161.62 41.2 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 122.435 1.112 . . . . 0.0 112.56 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.5 tt -90.03 77.65 6.82 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 120.897 -1.127 . . . . 0.0 109.218 -169.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.7 t -83.3 -146.68 0.08 Allowed 'General case' 0 CA--C 1.547 0.841 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.704 167.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -137.73 23.06 3.11 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.105 1.812 . . . . 0.0 112.751 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -173.35 -70.09 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -163.127 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -94.01 11.15 30.75 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.576 2.35 . . . . 0.0 114.788 -164.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . 0.25 3.9 m -140.85 -100.6 0.15 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -178.368 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.5 pt -89.89 -57.32 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 CA-C-N 121.545 1.975 . . . . 0.0 111.345 169.014 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.0 mm -61.89 145.69 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 170.508 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 96.35 -38.92 2.94 Favored Glycine 0 CA--C 1.524 0.597 0 CA-C-O 118.09 -1.395 . . . . 0.0 113.606 176.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.7 ptt180 -83.31 170.07 14.99 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 119.212 1.506 . . . . 0.0 112.539 175.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.2 t -119.01 176.92 5.06 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.226 1.01 . . . . 0.0 113.457 174.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 22.2 tp -156.92 136.57 12.33 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 126.273 1.829 . . . . 0.0 113.536 -168.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.4 t -112.03 135.38 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.988 1.315 . . . . 0.0 110.478 170.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 m -93.31 151.85 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 168.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 65.8 m-70 -119.38 144.12 47.07 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.684 1.194 . . . . 0.0 113.007 -172.287 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -83.75 -16.67 43.93 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 120.956 -1.09 . . . . 0.0 113.25 -179.45 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -98.03 164.0 12.53 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 169.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.09 164.21 1.76 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.997 1.319 . . . . 0.0 112.041 170.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -124.16 141.01 52.42 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.103 1.761 . . . . 0.0 110.209 -177.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -73.39 -34.38 65.5 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 125.73 1.612 . . . . 0.0 110.862 177.816 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.6 mt 78.74 -24.19 0.22 Allowed 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 130.026 3.331 . . . . 0.0 113.272 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -137.23 -81.99 0.11 Allowed Glycine 0 N--CA 1.475 1.279 0 CA-C-N 121.379 1.9 . . . . 0.0 114.271 -175.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -158.23 139.21 13.13 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 128.29 2.636 . . . . 0.0 107.518 174.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -127.25 -119.87 2.29 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 126.708 2.099 . . . . 0.0 109.946 167.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -92.27 -33.57 7.58 Favored Glycine 0 N--CA 1.474 1.219 0 N-CA-C 117.629 1.811 . . . . 0.0 117.629 -167.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 32.6 p30 -114.44 172.09 7.23 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.384 1.473 . . . . 0.0 113.156 -168.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -48.58 -61.72 1.88 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 126.29 1.836 . . . . 0.0 110.506 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -41.1 -42.05 1.89 Allowed 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 128.509 2.724 . . . . 0.0 114.383 175.196 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.426 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 85.7 p -55.27 -28.83 56.07 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 121.499 1.954 . . . . 0.0 113.456 177.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -97.82 -32.65 11.6 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 113.806 1.039 . . . . 0.0 113.806 169.471 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -91.13 -15.12 29.93 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.547 1.939 . . . . 0.0 115.006 -169.143 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 77.2 p -137.3 -16.03 1.42 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 128.444 2.698 . . . . 0.0 112.81 170.211 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.04 12.24 60.47 Favored Glycine 0 C--N 1.341 0.861 0 C-N-CA 124.062 0.839 . . . . 0.0 112.284 -167.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.426 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 7.9 t-20 53.4 26.61 5.54 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.158 1.383 . . . . 0.0 111.563 -168.145 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.7 6.96 0.56 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.652 1.181 . . . . 0.0 113.732 -169.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.03 -37.14 0.15 Allowed Glycine 0 CA--C 1.531 1.073 1 C-N-CA 131.128 4.204 . . . . 0.0 117.753 168.551 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 46.3 t -175.92 140.64 0.43 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.291 1.437 . . . . 0.0 111.428 -168.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.7 ptt-85 -77.42 174.6 10.64 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 123.702 0.801 . . . . 0.0 113.158 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.52 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -152.52 -143.02 0.13 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.417 1.887 . . . . 0.0 107.426 177.355 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.52 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -68.4 167.42 14.69 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.312 1.845 . . . . 0.0 112.727 177.426 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -140.18 153.24 46.55 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 125.004 1.322 . . . . 0.0 111.122 -169.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.54 141.18 7.32 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 124.193 0.901 . . . . 0.0 113.381 171.042 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' B' ' 148' ' ' VAL . 6.3 p -75.8 163.24 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 166.797 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.2 mm -93.09 94.37 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 121.37 -0.831 . . . . 0.0 110.032 170.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.3 -178.79 48.46 Favored Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.047 1.784 . . . . 0.0 113.759 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -113.99 130.58 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 124.659 1.183 . . . . 0.0 112.809 -170.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.52 -3.48 58.33 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.266 1.826 . . . . 0.0 112.472 176.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 . . . . . 0 CA--C 1.533 0.294 0 C-N-CA 125.149 1.38 . . . . 0.0 110.183 175.524 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.29 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -77.45 111.65 13.38 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 123.003 1.382 . . . . 0.0 108.675 -168.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mtmm -101.05 113.34 26.25 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 113.949 -1.478 . . . . 0.0 114.479 -171.526 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -95.89 175.47 6.49 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 127.036 2.134 . . . . 0.0 110.636 167.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -159.65 137.87 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 126.283 1.833 . . . . 0.0 110.677 -169.149 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.13 134.03 55.22 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 124.107 0.963 . . . . 0.0 109.016 165.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.58 114.76 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.157 0.983 . . . . 0.0 108.455 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.432 ' CD2' HG23 ' B' ' 119' ' ' VAL . 5.8 mp -98.14 130.91 44.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 126.29 1.836 . . . . 0.0 110.396 -167.635 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttt -150.57 175.63 11.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.485 1.114 . . . . 0.0 112.458 -177.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 139.97 -71.57 0.43 Allowed Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.868 2.651 . . . . 0.0 109.059 -172.357 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.71 69.79 1.81 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.813 2.045 . . . . 0.0 113.18 -169.208 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.6 -97.64 0.01 OUTLIER Glycine 0 CA--C 1.536 1.376 0 C-N-CA 127.607 2.527 . . . . 0.0 114.747 169.682 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -80.85 -16.41 10.17 Favored 'Trans proline' 0 C--N 1.352 0.727 0 C-N-CA 124.074 3.182 . . . . 0.0 114.304 -179.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 t -79.51 139.33 18.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 CA-C-N 120.561 1.528 . . . . 0.0 109.359 175.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 pm0 -155.1 152.58 29.68 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 113.567 -1.651 . . . . 0.0 108.117 167.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.72 152.47 17.11 Favored Glycine 0 CA--C 1.488 -1.594 0 O-C-N 123.818 0.699 . . . . 0.0 111.817 172.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -126.7 130.87 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 166.081 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 11.1 mm -129.17 118.09 45.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 173.122 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -82.88 157.73 22.97 Favored 'General case' 0 N--CA 1.47 0.543 0 O-C-N 120.927 -1.108 . . . . 0.0 109.48 169.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.405 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 70.3 m-85 -139.54 87.26 2.17 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.76 1.224 . . . . 0.0 108.139 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -86.91 124.15 32.81 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 121.299 -0.875 . . . . 0.0 112.034 174.006 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -113.82 134.84 54.54 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.869 0.842 . . . . 0.0 110.822 165.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.33 -32.05 15.84 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 124.64 1.176 . . . . 0.0 112.552 179.188 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -99.14 -169.24 1.74 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.042 2.137 . . . . 0.0 109.836 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.9 m -118.28 -6.15 10.83 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 120.634 -1.291 . . . . 0.0 113.277 167.822 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 61.0 m-80 -141.67 19.89 2.18 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 126.36 1.864 . . . . 0.0 112.379 175.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.0 -158.17 14.22 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.596 2.046 . . . . 0.0 113.193 175.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.84 154.02 29.83 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.228 2.619 . . . . 0.0 113.776 -172.278 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.86 133.34 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 126.364 1.866 . . . . 0.0 110.377 178.465 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -89.81 122.62 33.05 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.456 1.103 . . . . 0.0 110.607 171.315 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.19 84.66 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 128.081 2.553 . . . . 0.0 109.787 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 5.9 p90 -106.81 153.57 22.27 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 123.717 0.807 . . . . 0.0 111.234 169.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.01 -158.39 30.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 124.349 0.976 . . . . 0.0 112.141 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 91.8 p -159.41 136.04 9.26 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 -172.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.469 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.5 mp -112.51 111.7 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 124.536 1.134 . . . . 0.0 109.77 173.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -116.43 133.63 55.8 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 123.829 0.852 . . . . 0.0 111.371 -169.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.66 -2.23 26.14 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 125.827 1.68 . . . . 0.0 114.792 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.3 pp -83.8 178.5 7.89 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 118.858 1.329 . . . . 0.0 109.59 169.1 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.72 163.33 22.52 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 124.052 0.941 . . . . 0.0 109.415 169.19 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 40' ' ' GLU . . . . . 0.437 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 0.7 OUTLIER -52.56 178.54 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 177.724 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.31 -166.97 54.86 Favored Glycine 0 CA--C 1.527 0.827 0 O-C-N 120.274 -1.516 . . . . 0.0 112.958 172.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 77.3 mt -73.84 148.98 41.89 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.8 1.64 . . . . 0.0 111.764 -173.145 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -149.0 126.65 11.7 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 127.349 2.26 . . . . 0.0 110.437 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.55 157.1 25.67 Favored Glycine 0 N--CA 1.49 2.283 0 CA-C-O 117.625 -1.653 . . . . 0.0 112.756 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -157.58 110.84 2.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.469 2.308 . . . . 0.0 112.449 171.328 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.6 m80 -138.08 144.02 40.73 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 119.905 -1.747 . . . . 0.0 111.389 -175.714 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 132.63 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 C-N-CA 123.978 0.911 . . . . 0.0 110.118 177.342 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -75.37 117.42 17.15 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 168.184 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -73.37 60.46 0.62 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.469 1.908 . . . . 0.0 114.217 -168.339 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -179.4 164.25 1.31 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 128.983 2.913 . . . . 0.0 109.461 170.303 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.43 -10.29 55.87 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.245 0.926 . . . . 0.0 114.66 169.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.503 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -82.03 51.37 1.74 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 126.942 2.097 . . . . 0.0 110.439 -176.021 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' C ' ' B' ' 53' ' ' ASN . 0.4 OUTLIER 171.26 33.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 0.997 0 N-CA-C 115.805 1.779 . . . . 0.0 115.805 -164.958 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 118.184 2.661 . . . . 0.0 118.184 -168.971 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.619 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.27 158.91 20.55 Favored Glycine 0 CA--C 1.534 1.263 0 CA-C-O 117.672 -1.627 . . . . 0.0 110.728 169.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -55.04 103.52 0.1 Allowed 'Trans proline' 0 C--N 1.355 0.92 1 C-N-CA 125.663 4.242 . . . . 0.0 109.936 178.538 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 46.12 62.02 2.44 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 113.679 -1.601 . . . . 0.0 111.131 -175.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -37.62 134.19 0.71 Allowed 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.398 1.479 . . . . 0.0 112.183 -175.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -117.26 80.15 11.99 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -165.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.92 -13.32 34.12 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 123.101 2.534 . . . . 0.0 114.119 177.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -90.0 -6.69 55.34 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.85 1.26 . . . . 0.0 112.679 177.242 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.3 t 50.77 50.59 18.69 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 127.514 2.325 . . . . 0.0 114.703 -177.279 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -108.65 177.34 4.81 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 124.85 1.26 . . . . 0.0 113.065 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.11 164.69 22.22 Favored 'General case' 0 N--CA 1.47 0.555 0 O-C-N 121.342 -0.849 . . . . 0.0 110.73 167.146 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.477 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 63.8 t60 -68.1 -176.33 0.7 Allowed 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 122.095 0.95 . . . . 0.0 113.111 -176.108 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.477 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 111.07 -154.52 16.61 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 124.513 1.054 . . . . 0.0 115.492 165.063 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 166.13 -89.38 0.1 Allowed Glycine 0 CA--C 1.528 0.864 0 CA-C-O 118.205 -1.331 . . . . 0.0 114.725 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -67.9 -1.12 6.35 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 123.049 2.5 . . . . 0.0 114.15 -175.522 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -129.24 -4.14 4.95 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 125.613 1.565 . . . . 0.0 112.631 168.288 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -153.19 112.84 3.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.932 1.293 . . . . 0.0 110.347 -169.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -64.13 -12.2 37.42 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.324 1.85 . . . . 0.0 114.572 -175.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -75.44 -22.67 57.16 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 120.235 1.379 . . . . 0.0 113.651 -170.267 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 12.4 ttp85 14.57 100.97 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 130.564 3.546 . . . . 0.0 115.325 164.614 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.1 m170 -51.49 155.75 1.45 Allowed 'General case' 0 CA--C 1.558 1.258 0 CA-C-O 117.272 -1.347 . . . . 0.0 109.834 168.004 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.316 85.3 t -74.57 -17.49 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-N 123.865 3.029 . . . . 0.0 110.231 -175.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.47 7.52 64.55 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 127.423 2.44 . . . . 0.0 114.404 166.616 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -98.93 119.25 37.4 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.838 1.819 . . . . 0.0 113.401 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 63.3 mt -102.27 -176.06 3.01 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 126.73 2.012 . . . . 0.0 106.015 164.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.23 -144.91 5.09 Favored Glycine 0 CA--C 1.534 1.275 0 O-C-N 120.891 -1.13 . . . . 0.0 114.114 -178.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.65 152.16 49.46 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 123.983 0.913 . . . . 0.0 109.818 168.677 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 9.8 p -113.72 142.18 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.57 1.948 . . . . 0.0 112.207 -168.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -115.08 120.01 38.36 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.047 1.129 . . . . 0.0 114.047 -169.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.49 155.34 17.89 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 119.043 2.979 . . . . 0.0 119.043 175.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -84.51 164.89 18.51 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-N 111.631 -2.532 . . . . 0.0 109.808 167.583 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.16 -12.45 5.17 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 115.129 1.529 . . . . 0.0 115.129 171.399 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.66 -27.32 61.18 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.837 1.655 . . . . 0.0 111.2 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.24 -2.27 54.46 Favored Glycine 0 CA--C 1.523 0.544 0 CA-C-O 117.661 -1.633 . . . . 0.0 114.355 -177.526 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 9.5 p -79.48 118.49 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 119.572 1.686 . . . . 0.0 112.352 168.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -89.02 119.56 29.65 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.454 1.502 . . . . 0.0 108.587 166.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -80.46 140.27 36.02 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 118.492 0.587 . . . . 0.0 110.593 174.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -128.75 134.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.267 -1.333 . . . . 0.0 110.437 166.617 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.3 p -156.61 56.67 0.55 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 122.762 1.267 . . . . 0.0 109.628 -169.313 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 54.8 mt -114.78 160.68 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 125.044 1.337 . . . . 0.0 111.285 -169.033 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -133.47 146.15 50.87 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.837 2.055 . . . . 0.0 108.467 169.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -140.35 125.75 18.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 124.702 1.201 . . . . 0.0 110.442 -169.287 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 79.4 p -107.04 57.72 0.63 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.745 1.218 . . . . 0.0 112.308 -172.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -154.56 -41.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.93 173.67 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.232 -0.918 . . . . 0.0 112.026 177.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 25.8 m -158.25 162.99 37.86 Favored 'General case' 0 N--CA 1.481 1.081 0 O-C-N 119.579 -1.95 . . . . 0.0 115.028 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.35 59.24 1.8 Allowed 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.611 2.364 . . . . 0.0 108.484 175.415 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.9 t -89.82 1.3 56.32 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.242 1.017 . . . . 0.0 113.276 -175.21 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.17 -32.46 1.11 Allowed Glycine 0 N--CA 1.474 1.179 0 C-N-CA 125.029 1.3 . . . . 0.0 114.818 177.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -123.51 -95.06 0.48 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.985 1.314 . . . . 0.0 112.76 -169.357 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -75.92 3.07 10.9 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 119.678 -1.889 . . . . 0.0 114.344 -164.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.9 t -107.2 -128.85 0.27 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.677 -175.109 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 pt -84.0 -18.64 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 121.516 1.962 . . . . 0.0 115.981 -179.142 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mm -69.4 134.3 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.389 0.995 . . . . 0.0 111.017 -171.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.22 -2.75 75.12 Favored Glycine 0 CA--C 1.533 1.213 0 CA-C-O 117.836 -1.535 . . . . 0.0 114.038 -178.691 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.6 mtm180 -86.58 158.33 19.53 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 119.476 1.638 . . . . 0.0 109.998 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.5 t -115.98 119.85 37.23 Favored 'General case' 0 N--CA 1.486 1.346 0 CA-C-N 120.41 1.459 . . . . 0.0 112.942 -168.487 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 36.6 tp -94.93 121.33 36.43 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 126.511 1.924 . . . . 0.0 110.476 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 p -107.39 126.32 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.6 1.16 . . . . 0.0 110.194 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.432 HG23 ' CD2' ' B' ' 8' ' ' LEU . 67.5 t -89.15 163.57 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 168.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.9 m-70 -123.8 138.21 54.54 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.964 1.306 . . . . 0.0 111.286 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.1 pp20? -70.94 -11.23 60.85 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.177 -1.577 . . . . 0.0 114.549 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -115.62 167.03 11.27 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.107 1.363 . . . . 0.0 112.707 168.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.07 150.54 7.97 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.773 1.629 . . . . 0.0 110.434 166.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -112.53 144.68 41.6 Favored 'General case' 0 C--O 1.243 0.735 0 CA-C-O 121.717 0.77 . . . . 0.0 112.762 -178.172 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -76.45 -25.29 54.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.571 1.548 . . . . 0.0 111.748 -177.064 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt 48.61 51.93 14.69 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 126.949 2.099 . . . . 0.0 111.473 170.655 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 170.21 -94.44 0.1 Allowed Glycine 0 C--N 1.334 0.43 0 N-CA-C 117.11 1.604 . . . . 0.0 117.11 173.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 ptpp? -163.27 30.46 0.09 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -164.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -51.64 -22.06 7.77 Favored Glycine 0 N--CA 1.477 1.404 0 N-CA-C 119.388 2.515 . . . . 0.0 119.388 -168.519 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 175.77 -18.68 0.04 OUTLIER Glycine 0 N--CA 1.474 1.182 0 N-CA-C 117.565 1.786 . . . . 0.0 117.565 174.682 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -144.68 179.37 7.34 Favored 'General case' 0 CA--C 1.545 0.782 0 CA-C-N 119.291 1.546 . . . . 0.0 113.56 -173.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . 0.262 0.0 OUTLIER -49.84 -63.91 0.97 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.848 2.059 . . . . 0.0 111.435 172.232 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -54.11 -33.7 58.37 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 121.593 1.997 . . . . 0.0 113.373 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.15 -32.81 62.41 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 121.083 1.765 . . . . 0.0 114.193 172.111 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -105.32 -12.53 16.02 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.435 1.094 . . . . 0.0 113.499 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.7 tttt -96.54 -35.82 10.97 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.381 1.873 . . . . 0.0 112.705 -178.441 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.2 p -126.78 -20.65 4.22 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 125.139 1.376 . . . . 0.0 114.689 175.19 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.58 13.83 42.95 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.554 1.073 . . . . 0.0 110.534 -166.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 66.43 -68.08 0.14 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.769 3.228 . . . . 0.0 110.111 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 57.69 -66.7 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 131.445 3.898 . . . . 0.0 113.243 177.41 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.35 -28.71 4.98 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 127.523 2.487 . . . . 0.0 111.977 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.2 t -166.49 -161.63 0.47 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 124.605 1.162 . . . . 0.0 112.108 173.02 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -119.53 -156.49 0.66 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 128.328 2.651 . . . . 0.0 109.558 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -179.82 -164.55 0.06 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.867 2.467 . . . . 0.0 107.275 -171.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.89 144.25 23.43 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 127.243 2.217 . . . . 0.0 111.532 176.829 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -144.36 147.84 33.95 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -175.619 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.04 150.01 19.92 Favored Glycine 0 N--CA 1.476 1.355 0 C-N-CA 124.693 1.14 . . . . 0.0 114.651 -174.63 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' A' ' 148' ' ' VAL . 5.0 t -82.37 150.25 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.67 -0.9 . . . . 0.0 113.059 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -77.26 78.9 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 C-N-CA 126.562 1.945 . . . . 0.0 110.94 171.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -97.02 -158.96 31.3 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.243 1.878 . . . . 0.0 112.644 173.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -136.69 148.87 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -95.91 -120.07 0.11 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 103.058 -2.941 . . . . 0.0 103.058 163.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.471 0.597 0 C-N-CA 123.787 0.835 . . . . 0.0 112.674 166.051 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.446 -0.672 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -146.06 138.94 25.7 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 116.413 2.005 . . . . 0.0 116.413 177.035 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 169.63 9.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 127.258 2.223 . . . . 0.0 111.439 171.358 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.556 HG22 HG21 ' B' ' 54' ' ' THR . 14.7 p -158.6 110.51 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.772 1.629 . . . . 0.0 111.739 173.177 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.79 116.29 12.0 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.755 1.222 . . . . 0.0 112.442 -167.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 p -81.42 84.51 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.69 100.69 8.83 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 173.304 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -159.68 80.12 0.72 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 123.482 0.713 . . . . 0.0 112.172 -172.598 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.03 8.02 3.53 Favored Glycine 0 N--CA 1.472 1.056 0 C-N-CA 125.813 1.673 . . . . 0.0 113.658 169.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -133.46 54.88 1.93 Allowed 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 125.761 1.624 . . . . 0.0 108.74 -168.221 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 29.51 -98.23 0.01 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 129.381 3.372 . . . . 0.0 115.735 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.3 -15.22 47.42 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 124.2 3.266 . . . . 0.0 115.001 -176.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 t -111.34 128.86 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 125.058 1.343 . . . . 0.0 108.515 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.98 162.68 40.32 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.82 -174.028 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.45 170.07 29.0 Favored Glycine 0 CA--C 1.505 -0.592 0 CA-C-O 122.571 1.095 . . . . 0.0 114.206 174.629 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -130.76 128.27 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 C-N-CA 126.618 1.967 . . . . 0.0 106.356 173.498 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -137.94 112.53 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 121.312 -0.867 . . . . 0.0 109.72 172.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 28.1 m-80 -75.75 157.78 33.09 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.032 0.933 . . . . 0.0 111.091 178.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -141.58 127.93 19.93 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.812 1.245 . . . . 0.0 107.823 168.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -91.66 120.19 32.21 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.017 0.826 . . . . 0.0 112.138 174.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp-100 -88.49 78.45 7.86 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 118.658 -2.526 . . . . 0.0 105.701 167.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.7 ptmt -58.19 -41.52 84.12 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 120.909 -1.119 . . . . 0.0 110.669 175.018 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -155.19 142.46 19.43 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 129.41 3.084 . . . . 0.0 108.088 -166.025 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 m -48.23 -44.42 33.18 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 116.175 1.917 . . . . 0.0 116.175 -167.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -126.12 23.38 7.1 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.783 1.233 . . . . 0.0 112.0 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.75 167.82 53.58 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.134 -0.815 . . . . 0.0 112.481 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -65.73 151.36 84.67 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.37 2.047 . . . . 0.0 109.496 169.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -135.62 134.63 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-O 122.63 1.205 . . . . 0.0 110.702 -175.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 ttmm -81.03 128.26 33.51 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 114.056 -1.429 . . . . 0.0 108.212 167.496 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 64.0 t -124.91 111.17 26.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 126.846 2.058 . . . . 0.0 110.599 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.2 p90 -144.81 154.85 43.11 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -168.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 162.11 -138.94 5.66 Favored Glycine 0 C--N 1.335 0.496 0 O-C-N 120.903 -1.123 . . . . 0.0 112.895 172.692 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -154.08 131.61 11.37 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -169.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mm -117.34 126.6 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 123.944 0.898 . . . . 0.0 109.322 173.169 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -123.7 142.23 51.27 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.305 1.842 . . . . 0.0 110.763 -168.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.49 -16.41 57.87 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 125.946 1.736 . . . . 0.0 111.774 -169.44 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -65.01 113.02 3.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 167.071 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -60.13 -41.54 92.91 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.97 0.804 . . . . 0.0 111.627 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.3 -178.16 1.98 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.381 1.073 . . . . 0.0 113.017 -168.499 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 65.96 176.27 6.53 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.961 1.267 . . . . 0.0 115.544 166.6 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.39 142.88 46.96 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 169.348 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -127.03 127.72 45.2 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 127.493 2.317 . . . . 0.0 107.145 174.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.84 156.43 40.35 Favored Glycine 0 N--CA 1.467 0.766 0 CA-C-O 119.016 -0.88 . . . . 0.0 111.13 -176.213 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.41 130.61 17.48 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 118.037 0.919 . . . . 0.0 109.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -154.89 161.97 41.26 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 120.337 -1.477 . . . . 0.0 111.1 173.7 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' CA ' ' A' ' 82' ' ' GLY . 0.8 OUTLIER -104.37 135.83 40.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-O 122.629 1.204 . . . . 0.0 110.92 176.11 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -73.53 176.69 5.9 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 126.562 1.945 . . . . 0.0 110.526 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -72.18 -14.36 61.79 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.608 1.706 . . . . 0.0 115.608 174.187 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.461 ' C ' ' HA ' ' A' ' 115' ' ' ARG . 22.3 m-85 -157.03 172.97 17.73 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 129.757 3.223 . . . . 0.0 107.609 -167.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.17 30.28 4.44 Favored Glycine 0 C--O 1.223 -0.581 0 N-CA-C 108.677 -1.769 . . . . 0.0 108.677 165.724 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -82.24 109.53 16.61 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 119.408 1.604 . . . . 0.0 111.027 -166.659 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.459 HD22 HG22 ' A' ' 148' ' ' VAL 0.299 12.4 p-10 -159.18 32.54 0.2 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 117.915 2.561 . . . . 0.0 117.915 179.284 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.735 HG22 HG23 ' B' ' 5' ' ' VAL . 0.1 OUTLIER -84.84 -35.54 22.19 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 126.078 1.751 . . . . 0.0 112.883 -167.816 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -115.06 -13.68 11.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.021 1.729 . . . . 0.0 113.429 177.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.58 -75.68 0.84 Allowed Glycine 0 CA--C 1.529 0.939 0 C-N-CA 124.49 1.043 . . . . 0.0 111.524 -174.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.8 m -65.65 -17.62 64.73 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.9 p -127.51 33.43 4.84 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.333 1.453 . . . . 0.0 112.103 171.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 97.7 p -179.42 106.67 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.334 1.853 . . . . 0.0 110.56 177.402 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 166.53 73.43 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 131.183 3.793 . . . . 0.0 109.097 175.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.62 107.87 2.38 Favored Glycine 0 CA--C 1.542 1.725 0 C-N-CA 125.194 1.378 . . . . 0.0 114.665 -169.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -86.56 101.09 0.58 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 124.041 3.161 . . . . 0.0 112.008 -168.626 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 55.44 39.73 31.19 Favored 'General case' 0 C--O 1.242 0.7 0 C-N-CA 127.495 2.318 . . . . 0.0 113.221 170.231 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -77.05 124.69 28.15 Favored 'General case' 0 C--O 1.234 0.269 0 O-C-N 120.365 -1.46 . . . . 0.0 108.148 169.272 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.79 135.09 8.98 Favored Pre-proline 0 CA--C 1.539 0.554 0 CA-C-N 114.048 -1.433 . . . . 0.0 112.252 -173.709 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -71.43 -2.42 11.24 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.051 2.501 . . . . 0.0 114.214 -172.087 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 26.8 mt -79.51 -20.01 48.27 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 118.947 0.794 . . . . 0.0 112.038 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t 49.07 50.98 17.05 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 125.247 1.419 . . . . 0.0 113.371 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.0 mtm-85 -112.53 178.51 4.27 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 125.251 1.42 . . . . 0.0 112.666 -173.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.77 161.14 27.91 Favored 'General case' 0 CA--C 1.553 1.093 0 CA-C-N 118.504 0.593 . . . . 0.0 109.811 164.669 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.444 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 82.1 t60 -66.51 -175.91 0.41 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.503 1.521 . . . . 0.0 112.542 -177.215 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.444 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 107.26 -138.27 14.41 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 115.549 0.98 . . . . 0.0 115.549 165.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.89 -64.54 0.6 Allowed Glycine 0 CA--C 1.541 1.68 0 N-CA-C 116.941 1.536 . . . . 0.0 116.941 -174.322 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.95 -4.55 15.31 Favored 'Trans proline' 0 CA--C 1.544 1.011 0 CA-C-N 121.11 2.455 . . . . 0.0 114.427 -178.295 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.59 -1.47 0.52 Allowed 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 126.154 1.782 . . . . 0.0 114.207 172.101 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -124.19 148.34 47.34 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.395 2.278 . . . . 0.0 107.405 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.04 -20.68 30.07 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 127.3 2.24 . . . . 0.0 112.735 -168.732 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -83.68 -64.96 1.07 Allowed 'General case' 0 C--O 1.232 0.149 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -169.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 34.7 ttt-85 66.19 120.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.285 1.434 . . . . 0.0 111.724 -177.694 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -65.53 172.56 3.24 Favored 'General case' 0 CA--C 1.544 0.716 0 O-C-N 119.567 -1.958 . . . . 0.0 109.355 165.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -35.29 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.313 -1.492 . . . . 0.0 112.644 168.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.503 ' CA ' HG23 ' A' ' 47' ' ' VAL . . . -107.71 50.65 0.77 Allowed Glycine 0 CA--C 1.534 1.277 0 N-CA-C 117.007 1.563 . . . . 0.0 117.007 -169.395 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -124.45 119.17 28.41 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.56 -0.965 . . . . 0.0 113.291 -169.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -97.35 175.5 6.23 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.944 1.298 . . . . 0.0 108.586 167.737 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.59 170.18 29.4 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.676 1.132 . . . . 0.0 111.214 169.034 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -76.79 145.85 38.24 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.56 1.318 . . . . 0.0 114.56 -176.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.21 122.71 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 127.23 2.212 . . . . 0.0 109.27 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 99.0 m -110.73 121.59 45.71 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -169.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.53 142.02 32.59 Favored 'General case' 0 N--CA 1.445 -0.702 0 C-N-CA 125.582 1.553 . . . . 0.0 113.328 -172.638 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.439 ' OD1' ' HE3' ' A' ' 91' ' ' LYS . 29.1 t0 -91.91 148.33 22.3 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.127 -1.397 . . . . 0.0 110.906 168.554 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.439 ' HE3' ' OD1' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -47.26 -21.23 0.25 Allowed 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 128.61 2.764 . . . . 0.0 117.38 -170.336 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -74.97 -0.71 19.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 127.492 2.317 . . . . 0.0 111.818 177.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.06 32.16 6.27 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 117.365 -1.797 . . . . 0.0 114.059 170.322 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -152.85 132.53 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 N-CA-C 117.152 2.279 . . . . 0.0 117.152 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.52 109.71 22.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.96 164.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -91.5 133.3 35.63 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.377 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -141.0 145.94 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 118.515 2.783 . . . . 0.0 118.515 -168.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 93.8 p -142.81 105.52 4.5 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.39 1.876 . . . . 0.0 110.018 168.27 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.3 mt -107.17 150.85 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 C-N-CA 125.916 1.686 . . . . 0.0 108.929 169.644 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -144.45 138.29 27.57 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.954 1.702 . . . . 0.0 107.631 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -157.05 152.25 26.26 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.162 0.985 . . . . 0.0 112.252 -168.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.3 p -119.17 55.2 0.95 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.469 1.108 . . . . 0.0 113.609 -168.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.6 p -158.56 -27.34 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 124.756 1.222 . . . . 0.0 112.776 171.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.56 150.02 5.51 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.327 0 O-C-N 121.062 -1.024 . . . . 0.0 111.029 175.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 p -158.05 162.92 38.13 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 121.057 -1.027 . . . . 0.0 109.174 171.173 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mp -85.83 47.82 1.5 Allowed 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.413 -1.429 . . . . 0.0 110.923 -172.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.6 t -82.18 -0.48 45.22 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -172.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.48 -7.02 74.58 Favored Glycine 0 N--CA 1.477 1.368 0 N-CA-C 118.216 2.046 . . . . 0.0 118.216 169.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -121.15 -94.81 0.49 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.637 1.575 . . . . 0.0 110.46 -167.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m170 -91.49 5.76 48.21 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -168.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.3 p -107.43 -70.71 0.78 Allowed 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 117.532 2.419 . . . . 0.0 117.532 -166.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pt -159.28 -51.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 125.747 1.619 . . . . 0.0 113.324 -167.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.43 145.62 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 125.89 1.676 . . . . 0.0 108.347 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.83 -22.08 2.99 Favored Glycine 0 N--CA 1.47 0.92 0 C-N-CA 124.585 1.088 . . . . 0.0 112.125 -167.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.461 ' HA ' ' C ' ' A' ' 50' ' ' PHE . 41.8 mtt180 -85.38 176.81 8.06 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.851 2.06 . . . . 0.0 110.948 169.162 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -108.76 133.66 52.52 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 127.471 2.309 . . . . 0.0 108.032 171.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.405 ' HB3' HD11 ' A' ' 149' ' ' ILE . 26.5 tp -102.41 118.05 36.04 Favored 'General case' 0 CA--C 1.535 0.365 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 168.349 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -112.15 129.81 66.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 CA-C-N 119.253 0.933 . . . . 0.0 110.815 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' A' ' 144' ' ' LEU . 2.4 p -88.92 145.99 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 121.394 0.616 . . . . 0.0 109.837 169.8 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -102.92 161.55 13.66 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.817 1.647 . . . . 0.0 111.83 -175.357 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.13 -31.91 62.95 Favored 'General case' 0 N--CA 1.473 0.704 0 O-C-N 121.081 -1.012 . . . . 0.0 112.086 -173.643 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 27.6 mmtm -131.86 -178.92 5.1 Favored 'General case' 0 C--O 1.237 0.4 0 O-C-N 119.234 -2.166 . . . . 0.0 110.974 169.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.72 129.02 39.38 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 125.077 1.351 . . . . 0.0 109.298 -176.305 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.18 152.62 30.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 166.212 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.27 -17.92 61.27 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.945 178.782 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 13.4 mt 61.77 41.96 11.2 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.037 1.335 . . . . 0.0 110.227 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 175.28 -97.08 0.11 Allowed Glycine 0 N--CA 1.471 0.999 0 N-CA-C 118.969 2.348 . . . . 0.0 118.969 177.351 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.0 pttt -162.69 37.26 0.11 Allowed 'General case' 0 CA--C 1.555 1.139 0 C-N-CA 127.99 2.516 . . . . 0.0 113.631 -167.68 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -55.07 -12.7 4.13 Favored Glycine 0 CA--C 1.539 1.535 0 N-CA-C 120.132 2.813 . . . . 0.0 120.132 -168.394 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.47 -28.8 0.5 Allowed Glycine 0 N--CA 1.477 1.379 0 CA-C-N 121.085 2.442 . . . . 0.0 118.038 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 22.1 p-10 -107.13 166.62 10.48 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 119.404 1.602 . . . . 0.0 109.656 174.143 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -57.05 -48.58 78.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 119.932 1.242 . . . . 0.0 109.67 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -48.54 -34.56 11.59 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.722 2.809 . . . . 0.0 113.046 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.6 p -57.7 -28.22 63.64 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 173.345 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.09 -23.82 10.68 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 169.674 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -59.18 -28.07 66.28 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.484 1.038 . . . . 0.0 111.467 172.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.9 p -133.87 -93.04 0.33 Allowed 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 166.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -158.12 24.81 0.4 Allowed Glycine 0 CA--C 1.537 1.428 0 C-N-CA 130.194 3.759 . . . . 0.0 109.224 168.368 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.11 -84.0 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.367 1.867 . . . . 0.0 107.787 -166.679 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 66.52 2.15 2.38 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 127.821 2.448 . . . . 0.0 116.711 166.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.71 -57.81 3.01 Favored Glycine 0 CA--C 1.53 1.004 0 C-N-CA 125.683 1.611 . . . . 0.0 113.681 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.5 t -171.83 -177.4 1.95 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.166 1.387 . . . . 0.0 111.306 -171.602 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.8 164.88 13.18 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 121.151 -0.968 . . . . 0.0 111.926 172.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.476 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -150.94 -152.57 0.44 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 127.568 2.347 . . . . 0.0 106.577 174.817 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.476 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -37.47 112.15 0.19 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.8 2.04 . . . . 0.0 114.296 -170.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.5 t -109.29 138.96 44.86 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.065 2.146 . . . . 0.0 110.538 -175.325 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.5 -178.57 21.13 Favored Glycine 0 N--CA 1.469 0.899 0 C-N-CA 124.588 1.09 . . . . 0.0 114.32 -175.118 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.459 HG22 HD22 ' A' ' 53' ' ' ASN . 0.2 OUTLIER -127.97 160.41 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 104.893 -2.262 . . . . 0.0 104.893 165.723 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.405 HD11 ' HB3' ' A' ' 117' ' ' LEU . 2.6 mm -135.04 130.56 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 CA-C-N 120.069 1.304 . . . . 0.0 112.434 -168.279 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.27 -114.04 1.37 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.668 1.604 . . . . 0.0 115.025 -175.122 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -158.38 129.25 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 118.877 1.338 . . . . 0.0 109.756 -177.23 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 -35.55 14.95 Favored 'General case' 0 N--CA 1.47 0.531 0 O-C-N 120.929 -1.107 . . . . 0.0 112.42 177.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 . . . . . 0 C--O 1.235 0.294 0 C-N-CA 127.264 2.226 . . . . 0.0 110.005 -171.524 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.549 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 99.2 m -79.17 105.21 10.34 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 169.27 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.496 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -97.66 122.52 40.84 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.709 1.203 . . . . 0.0 113.366 -168.409 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.52 178.12 8.37 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 120.911 -1.118 . . . . 0.0 114.005 -177.308 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.735 HG23 HG22 ' A' ' 54' ' ' THR . 0.2 OUTLIER -147.86 110.03 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 128.053 2.541 . . . . 0.0 106.784 169.314 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -99.3 133.28 43.82 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.951 0.9 . . . . 0.0 108.631 166.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -131.36 99.42 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 123.256 0.622 . . . . 0.0 110.965 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.8 mp -88.21 141.69 28.36 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 124.067 0.854 . . . . 0.0 109.867 169.148 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -156.07 168.16 28.13 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.913 1.685 . . . . 0.0 112.073 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.48 -101.95 0.19 Allowed Glycine 0 C--O 1.226 -0.398 0 N-CA-C 107.583 -2.207 . . . . 0.0 107.583 166.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -149.42 124.84 10.26 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 129.014 2.926 . . . . 0.0 106.095 -169.466 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.07 -177.69 44.61 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 124.544 1.069 . . . . 0.0 112.81 -174.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -71.92 30.22 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.093 1 C-N-CA 126.157 4.571 . . . . 0.0 115.11 -170.342 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.11 123.78 63.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.558 1.543 . . . . 0.0 109.441 -177.067 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.65 163.71 36.48 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 124.272 1.029 . . . . 0.0 109.585 176.05 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.67 108.78 0.79 Allowed Glycine 0 N--CA 1.461 0.302 0 CA-C-N 114.106 -1.406 . . . . 0.0 110.373 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.46 128.88 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 123.956 0.902 . . . . 0.0 109.401 169.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mm -134.82 124.51 43.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 123.864 0.866 . . . . 0.0 109.231 168.324 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -79.9 149.63 30.84 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 126.697 1.999 . . . . 0.0 109.924 165.302 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -143.97 101.97 3.82 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.496 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.4 OUTLIER -108.83 116.86 32.78 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.367 1.067 . . . . 0.0 109.831 -169.572 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -116.96 142.28 47.15 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 122.652 1.215 . . . . 0.0 112.917 -172.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.562 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -90.74 -7.57 52.13 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.337 1.455 . . . . 0.0 114.61 -173.656 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 24' ' ' GLU . . . . . 0.562 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 48.9 mp0 -150.22 -173.99 4.6 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 127.368 2.267 . . . . 0.0 108.24 173.024 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.6 p -75.4 -26.71 58.65 Favored 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.47 -0.769 . . . . 0.0 111.215 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -135.25 9.99 3.49 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.274 1.429 . . . . 0.0 114.101 -171.715 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.54 174.02 55.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.236 0.922 . . . . 0.0 111.555 169.559 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.11 166.13 30.85 Favored 'Trans proline' 0 CA--C 1.536 0.578 0 C-N-CA 122.712 2.274 . . . . 0.0 111.116 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.58 132.58 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 C-N-CA 124.876 1.27 . . . . 0.0 110.661 -168.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -88.52 127.81 35.54 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 168.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.8 t -116.91 124.19 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 126.011 1.724 . . . . 0.0 109.058 -171.05 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -155.41 157.29 36.8 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.152 -0.968 . . . . 0.0 113.269 177.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.13 -160.74 30.67 Favored Glycine 0 CA--C 1.52 0.364 0 O-C-N 121.553 -0.717 . . . . 0.0 113.706 -177.077 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 53.3 p -149.24 133.19 17.11 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 113.276 0.843 . . . . 0.0 113.276 -168.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -106.01 113.43 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 O-C-N 121.724 -0.61 . . . . 0.0 109.794 171.612 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.7 ptpt -110.78 157.96 19.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.164 1.385 . . . . 0.0 110.613 -170.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.28 8.29 75.09 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 123.861 0.743 . . . . 0.0 113.997 -173.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -81.15 -152.4 0.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 127.19 2.196 . . . . 0.0 107.865 168.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 39' ' ' THR . . . . . 0.499 HG23 ' H ' ' B' ' 40' ' ' GLU 0.282 7.9 t -137.14 -91.78 0.24 Allowed 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.996 1.318 . . . . 0.0 108.353 169.702 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 40' ' ' GLU . . . . . 0.499 ' H ' HG23 ' B' ' 39' ' ' THR . 0.0 OUTLIER -127.98 -56.55 1.27 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.438 1.495 . . . . 0.0 113.719 173.085 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.39 147.76 44.87 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 119.856 -1.778 . . . . 0.0 113.558 -169.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.442 ' H ' HD12 ' B' ' 42' ' ' LEU . 1.2 mp -44.9 141.91 2.0 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.84 2.056 . . . . 0.0 112.619 -173.233 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -126.09 130.64 51.49 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.689 1.596 . . . . 0.0 109.276 170.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.76 163.01 41.08 Favored Glycine 0 N--CA 1.482 1.717 0 CA-C-N 120.292 1.406 . . . . 0.0 111.516 172.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -152.46 130.31 11.7 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 120.673 2.237 . . . . 0.0 112.513 168.783 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.28 146.36 21.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.473 1.109 . . . . 0.0 111.999 -168.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 p -82.63 135.1 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 O-C-N 121.632 -0.667 . . . . 0.0 110.653 168.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.493 ' HB2' HG23 ' B' ' 116' ' ' THR . 7.5 m-70 -78.19 159.01 28.81 Favored 'General case' 0 CA--C 1.559 1.304 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.141 165.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -67.32 110.89 3.73 Favored 'General case' 0 N--CA 1.469 0.497 0 O-C-N 119.473 -2.017 . . . . 0.0 110.258 171.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 50' ' ' PHE . . . . . 0.432 ' O ' HG22 ' B' ' 116' ' ' THR . 4.3 m-30 142.31 167.37 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 1 C-N-CA 132.927 4.491 . . . . 0.0 110.176 175.717 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -131.13 14.83 5.39 Favored Glycine 0 C--O 1.222 -0.613 0 C-N-CA 126.42 1.962 . . . . 0.0 114.051 172.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -170.53 113.97 0.45 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.431 2.692 . . . . 0.0 103.972 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' B' ' 54' ' ' THR . 10.4 p-10 -116.04 -64.49 1.3 Allowed 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 114.354 1.242 . . . . 0.0 114.354 -164.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.556 HG21 HG22 ' A' ' 5' ' ' VAL . 2.8 p . . . . . 0 N--CA 1.462 0.139 0 C-N-CA 128.919 2.888 . . . . 0.0 113.275 170.018 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.542 0.664 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -69.62 -178.57 21.51 Favored Glycine 0 CA--C 1.538 1.476 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.553 173.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -62.72 168.34 10.32 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.647 2.231 . . . . 0.0 110.849 171.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -45.08 115.36 0.89 Allowed 'General case' 0 C--O 1.236 0.35 0 N-CA-C 115.575 1.695 . . . . 0.0 115.575 -178.434 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -45.58 117.46 1.45 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.832 166.31 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -120.84 65.82 13.24 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 115.103 -0.953 . . . . 0.0 113.152 -167.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.81 -4.87 14.18 Favored 'Trans proline' 0 CA--C 1.539 0.766 0 C-N-CA 123.304 2.669 . . . . 0.0 114.561 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 67' ' ' LEU . . . . . 0.411 ' HB3' ' HD3' ' B' ' 69' ' ' ARG . 3.3 mm? -106.73 -6.11 18.05 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.198 0.999 . . . . 0.0 112.71 175.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 18.9 t 66.4 57.92 0.7 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.884 1.674 . . . . 0.0 114.722 171.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 69' ' ' ARG . . . . . 0.411 ' HD3' ' HB3' ' B' ' 67' ' ' LEU . 0.2 OUTLIER -154.06 -176.58 5.93 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 116.226 1.935 . . . . 0.0 116.226 -169.279 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -80.62 178.15 8.54 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.953 1.301 . . . . 0.0 112.194 -170.046 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -108.73 144.36 36.63 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.287 -1.324 . . . . 0.0 114.168 176.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 154.33 -102.2 0.22 Allowed Glycine 0 C--N 1.336 0.543 0 C-N-CA 126.37 1.938 . . . . 0.0 110.108 167.297 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -41.22 2.01 Favored Glycine 0 CA--C 1.542 1.774 0 CA-C-O 118.013 -1.437 . . . . 0.0 115.653 172.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_exo -79.62 -25.83 5.17 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 124.206 3.271 . . . . 0.0 112.12 168.295 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.79 -53.52 2.64 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.901 0.88 . . . . 0.0 110.49 168.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -63.84 106.16 0.96 Allowed 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.311 1.414 . . . . 0.0 111.88 172.611 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.8 mp0 -59.76 -9.75 3.12 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 129.259 3.023 . . . . 0.0 113.485 175.445 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -85.1 -98.02 0.06 Allowed 'General case' 0 N--CA 1.453 -0.321 0 O-C-N 121.411 -0.806 . . . . 0.0 110.684 174.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 94.09 133.37 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.169 1.787 . . . . 0.0 110.845 173.125 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -70.23 154.54 41.79 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 168.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.2 t -80.44 87.94 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 166.124 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.47 4.35 0.18 Allowed Glycine 0 CA--C 1.537 1.452 0 N-CA-C 117.672 1.829 . . . . 0.0 117.672 -169.634 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -150.65 150.51 31.22 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 119.828 1.814 . . . . 0.0 112.511 174.773 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.7 mt -124.16 49.05 1.82 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.116 169.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.97 -102.99 0.91 Allowed Glycine 0 CA--C 1.532 1.154 0 O-C-N 120.64 -1.287 . . . . 0.0 115.37 176.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -144.71 163.25 34.57 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.024 1.33 . . . . 0.0 113.505 -175.404 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.2 m -114.45 165.49 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 127.502 2.321 . . . . 0.0 110.115 170.691 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 62.6 m -146.43 141.31 27.01 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.903 1.281 . . . . 0.0 108.007 174.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -97.49 164.35 12.48 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -173.097 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.0 -52.09 9.35 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.457 1.503 . . . . 0.0 113.248 -171.087 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttp 151.62 -37.94 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.991 1 C-N-CA 133.775 4.83 . . . . 0.0 109.637 -168.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -84.66 25.79 0.87 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.897 1.679 . . . . 0.0 111.021 -178.083 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.34 3.67 77.57 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.815 1.674 . . . . 0.0 115.56 174.521 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -109.34 129.41 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 119.011 1.406 . . . . 0.0 113.425 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -95.3 129.77 42.31 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 125.165 1.386 . . . . 0.0 107.766 165.095 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -116.93 130.62 56.82 Favored 'General case' 0 C--O 1.233 0.188 0 C-N-CA 125.012 1.325 . . . . 0.0 109.037 -172.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 45.5 t -130.26 137.19 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-N 114.16 -1.382 . . . . 0.0 114.239 -166.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.4 p -151.61 105.23 3.13 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 125.462 1.505 . . . . 0.0 111.635 177.379 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 22.3 mt -135.99 163.28 34.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 128.239 2.615 . . . . 0.0 110.45 -172.478 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -139.22 140.14 37.67 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 126.465 1.906 . . . . 0.0 107.089 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -146.01 143.18 29.28 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.491 1.116 . . . . 0.0 111.641 -169.453 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 9.0 p -118.4 46.04 1.89 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.039 -0.982 . . . . 0.0 112.57 -176.123 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . 0.272 4.4 p -156.12 20.32 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 174.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -131.45 160.52 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 120.65 -1.281 . . . . 0.0 108.344 167.121 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 51.4 m -158.03 168.87 25.92 Favored 'General case' 0 N--CA 1.47 0.573 0 O-C-N 120.691 -1.256 . . . . 0.0 112.192 175.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.29 64.23 1.6 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 125.974 1.709 . . . . 0.0 109.345 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.6 t -155.3 84.07 1.06 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.453 -1.405 . . . . 0.0 113.357 -169.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.29 -159.0 28.26 Favored Glycine 0 C--N 1.336 0.563 0 CA-C-O 122.997 1.332 . . . . 0.0 112.471 170.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -69.1 -19.7 64.06 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 127.57 2.348 . . . . 0.0 113.769 -167.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 64.7 m170 -97.3 7.9 45.63 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.112 1.365 . . . . 0.0 113.221 -175.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 73.2 m -81.98 176.79 9.26 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -165.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.02 -18.95 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 120.786 -1.196 . . . . 0.0 110.798 163.811 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mm -75.78 124.92 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 165.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.28 68.8 1.54 Allowed Glycine 0 CA--C 1.527 0.839 0 O-C-N 123.614 0.571 . . . . 0.0 113.462 -169.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -143.17 136.04 27.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.206 1.002 . . . . 0.0 109.579 168.037 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 116' ' ' THR . . . . . 0.493 HG23 ' HB2' ' B' ' 48' ' ' HIS . 3.6 t -96.42 77.8 2.99 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 124.864 1.266 . . . . 0.0 110.369 -173.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 54.5 tp -77.94 135.49 37.85 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.0 1.32 . . . . 0.0 109.881 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -129.64 146.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 126.067 1.747 . . . . 0.0 108.989 172.429 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 79.3 t -104.09 140.61 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 122.605 1.193 . . . . 0.0 107.897 168.43 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -95.6 160.02 14.71 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.625 2.37 . . . . 0.0 112.303 -170.363 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -80.97 -34.31 33.22 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 120.806 -1.184 . . . . 0.0 114.015 -167.552 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.4 mmmt -113.42 -176.52 2.92 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 120.176 -1.578 . . . . 0.0 112.428 173.656 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.29 143.64 27.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.64 1.176 . . . . 0.0 109.921 169.327 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.23 146.04 24.55 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.957 1.303 . . . . 0.0 109.041 172.018 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.41 -27.75 56.4 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 178.633 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 63.97 20.96 12.44 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.14 2.176 . . . . 0.0 114.34 174.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -150.68 -94.22 0.11 Allowed Glycine 0 N--CA 1.465 0.581 0 CA-C-N 120.583 1.538 . . . . 0.0 113.165 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 49.2 tttp -163.05 82.39 0.49 Allowed 'General case' 0 N--CA 1.432 -1.364 0 C-N-CA 127.172 2.189 . . . . 0.0 108.608 168.581 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.97 48.04 0.64 Allowed Glycine 0 CA--C 1.531 1.078 0 C-N-CA 126.778 2.133 . . . . 0.0 114.192 172.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 79.99 -10.97 37.67 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 118.084 1.994 . . . . 0.0 118.084 169.107 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 28.8 m-80 -115.28 177.78 4.53 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.765 2.282 . . . . 0.0 112.418 -169.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -59.11 -64.39 0.96 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.401 1.88 . . . . 0.0 108.992 165.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 48.7 mm-40 -47.8 -34.77 9.07 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.82 1.648 . . . . 0.0 113.37 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 8.8 m -55.97 -14.64 2.65 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 175.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 37.5 p -129.29 -24.56 2.82 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 168.255 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . 0.253 17.8 pttt -83.81 -6.0 59.33 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 115.764 1.765 . . . . 0.0 115.764 175.2 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 10.8 m -140.07 -44.64 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 124.948 1.299 . . . . 0.0 112.467 171.728 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.33 12.27 6.35 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.885 2.183 . . . . 0.0 114.151 -168.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 67.08 8.04 5.87 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 120.673 -1.487 . . . . 0.0 114.798 175.701 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.58 30.46 0.03 OUTLIER 'General case' 0 CA--C 1.564 1.506 0 N-CA-C 118.206 2.669 . . . . 0.0 118.206 -166.516 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.6 -51.4 3.37 Favored Glycine 0 N--CA 1.471 1.013 0 C-N-CA 127.218 2.342 . . . . 0.0 115.766 170.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 9.3 t -176.49 -163.1 0.09 Allowed 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.734 2.014 . . . . 0.0 110.545 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.21 142.27 17.03 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 119.77 -1.831 . . . . 0.0 115.739 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.74 -115.62 0.1 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 128.508 2.723 . . . . 0.0 111.266 -177.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.13 138.87 36.99 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 128.454 2.702 . . . . 0.0 111.114 -169.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -126.41 151.76 47.25 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 126.413 1.885 . . . . 0.0 112.274 -175.427 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.58 169.91 32.9 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 116.434 1.334 . . . . 0.0 116.434 -172.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . 0.273 0.4 OUTLIER -126.62 162.31 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 123.521 0.728 . . . . 0.0 109.753 170.066 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -120.95 127.64 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 124.412 1.085 . . . . 0.0 113.365 -166.177 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -123.89 -159.31 10.42 Favored Glycine 0 C--N 1.349 1.282 0 C-N-CA 125.039 1.304 . . . . 0.0 113.631 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -110.06 143.22 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 125.946 1.698 . . . . 0.0 111.959 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.448 ' HA ' ' CG ' ' A' ' 50' ' ' PHE . . . -124.49 37.98 4.29 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.456 1.902 . . . . 0.0 111.291 171.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.326 -0.429 0 C-N-CA 125.708 1.603 . . . . 0.0 109.829 -178.235 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 94.3 m . . . . . 0 N--CA 1.469 0.475 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.16 138.89 33.47 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -175.012 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.81 169.74 8.85 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 126.534 1.934 . . . . 0.0 112.18 173.035 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.3 t -147.48 153.89 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 127.95 2.5 . . . . 0.0 110.51 172.327 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.4 112.64 15.87 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 125.351 1.461 . . . . 0.0 107.168 165.252 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.6 m -82.66 90.95 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 173.369 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 25.0 mt -76.28 130.01 37.52 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.574 -172.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.1 mttm -152.29 -179.02 7.17 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.59 1.156 . . . . 0.0 113.152 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 134.84 -58.62 0.68 Allowed Glycine 0 N--CA 1.467 0.763 0 C-N-CA 125.968 1.747 . . . . 0.0 110.058 -178.31 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -78.44 69.04 4.57 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 122.087 0.946 . . . . 0.0 113.22 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 39.25 -100.38 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 C-N-CA 127.863 2.649 . . . . 0.0 115.71 169.083 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.98 -9.88 18.03 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 124.783 3.655 . . . . 0.0 114.56 -177.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 t -86.07 143.57 11.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-N 119.679 1.127 . . . . 0.0 110.008 172.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -156.36 158.24 37.04 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.51 168.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -117.18 126.83 7.12 Favored Glycine 0 C--O 1.22 -0.758 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.55 99.19 6.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 174.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -132.49 133.31 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 125.07 1.348 . . . . 0.0 109.525 -171.613 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -108.08 150.72 26.81 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.298 2.239 . . . . 0.0 111.208 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -122.22 134.75 54.7 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.567 1.947 . . . . 0.0 109.353 170.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -103.22 113.96 27.87 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 120.935 1.698 . . . . 0.0 110.904 172.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 37.1 tp60 -101.31 116.05 31.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 123.191 0.596 . . . . 0.0 109.488 172.547 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.1 pttp -102.9 -31.81 10.07 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 114.61 1.337 . . . . 0.0 114.61 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.7 mp0 -130.03 156.68 44.08 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 126.213 1.805 . . . . 0.0 108.766 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.0 m -55.68 -39.88 71.57 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 122.386 2.357 . . . . 0.0 116.244 -168.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.04 34.55 5.17 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.03 1.732 . . . . 0.0 110.422 167.043 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.89 153.47 51.35 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-O 118.129 -1.373 . . . . 0.0 111.021 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -66.38 142.7 67.01 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.123 2.549 . . . . 0.0 109.957 174.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.1 t -112.53 144.86 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.937 0.895 . . . . 0.0 110.879 -168.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.0 tttp -113.59 131.08 56.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.583 1.153 . . . . 0.0 108.804 167.012 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.96 144.49 16.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 127.872 2.469 . . . . 0.0 109.536 175.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -158.56 161.02 37.25 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.399 1.079 . . . . 0.0 113.185 172.118 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.63 -149.22 21.29 Favored Glycine 0 N--CA 1.469 0.865 0 C-N-CA 124.249 0.928 . . . . 0.0 112.693 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -153.57 148.75 26.9 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.4 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 16.9 mt -126.0 117.76 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 121.032 -1.043 . . . . 0.0 108.914 175.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.1 tttt -123.34 137.87 54.74 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 119.787 1.176 . . . . 0.0 112.168 -172.43 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.0 3.77 9.71 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 128.413 2.911 . . . . 0.0 113.886 -174.277 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.12 163.85 22.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 128.431 2.692 . . . . 0.0 112.074 176.302 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -95.07 158.4 15.48 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 166.01 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -64.07 145.22 56.29 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.99 -171.69 22.81 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.703 1.144 . . . . 0.0 114.591 -173.9 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 47.2 mt -66.23 146.94 54.04 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 125.532 1.533 . . . . 0.0 113.535 -169.437 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -144.99 128.59 17.11 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 127.01 2.124 . . . . 0.0 109.514 173.488 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.15 165.23 54.87 Favored Glycine 0 N--CA 1.473 1.137 0 CA-C-N 119.493 1.042 . . . . 0.0 112.292 -179.151 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.6 p90 -157.55 137.38 12.33 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.328 1.851 . . . . 0.0 113.706 167.001 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -148.58 163.87 35.94 Favored 'General case' 0 N--CA 1.451 -0.415 0 O-C-N 119.695 -1.878 . . . . 0.0 112.074 169.567 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -96.04 134.08 34.88 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-O 121.795 0.807 . . . . 0.0 110.266 173.159 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -71.51 116.06 11.42 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 103.66 -2.719 . . . . 0.0 103.66 168.679 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.647 ' H ' ' HA ' ' A' ' 63' ' ' HIS 0.305 3.6 tt0 -70.68 21.33 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.897 0 N-CA-C 115.988 1.847 . . . . 0.0 115.988 -168.513 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -132.82 148.94 52.31 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 126.872 2.069 . . . . 0.0 111.204 179.239 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.14 -17.77 42.08 Favored Glycine 0 N--CA 1.465 0.591 0 CA-C-O 117.129 -1.928 . . . . 0.0 115.155 169.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -72.39 88.78 1.2 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.053 1.927 . . . . 0.0 106.945 168.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.417 ' HA ' HG21 ' B' ' 7' ' ' VAL . 19.5 p-10 168.07 -34.39 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.469 2.308 . . . . 0.0 116.766 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 18.6 p 27.62 -40.55 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.042 2 C-N-CA 133.615 4.766 . . . . 0.0 122.91 179.24 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.2 13.72 2.22 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 127.53 2.332 . . . . 0.0 113.469 -173.744 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -148.04 34.33 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 124.657 1.122 . . . . 0.0 114.585 169.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.5 m -49.02 -19.99 0.48 Allowed 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -169.675 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.8 t -79.47 -4.49 51.47 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.454 1.101 . . . . 0.0 113.096 175.124 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 71.5 m -136.97 147.13 46.13 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.548 1.539 . . . . 0.0 110.739 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 63.51 -94.16 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.237 1.815 . . . . 0.0 113.126 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.54 -41.99 2.07 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 126.499 2.0 . . . . 0.0 116.413 -175.192 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -109.59 174.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.357 1.009 0 C-N-CA 123.194 2.596 . . . . 0.0 114.75 -175.395 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.727 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -97.16 134.68 40.16 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 129.99 3.316 . . . . 0.0 114.719 169.839 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -71.1 152.28 43.63 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 162.584 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 40.2 p-10 -125.75 60.11 31.22 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 124.252 1.021 . . . . 0.0 111.737 -177.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -61.79 -29.9 83.77 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.943 3.095 . . . . 0.0 115.057 -167.47 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 73.2 mt -75.9 -5.42 46.03 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 175.77 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t 66.83 110.02 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 130.027 3.331 . . . . 0.0 111.471 -177.424 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 171.92 172.03 0.1 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -169.487 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.49 ' H ' ' HD2' ' A' ' 70' ' ' LYS . 10.8 mptt -64.17 169.57 4.38 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.699 2.4 . . . . 0.0 111.68 168.505 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -96.23 138.99 33.02 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.839 1.256 . . . . 0.0 113.981 170.492 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.14 -110.05 0.44 Allowed Glycine 0 C--N 1.336 0.533 0 C-N-CA 124.007 0.813 . . . . 0.0 112.79 167.224 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.92 -20.2 24.52 Favored Glycine 0 CA--C 1.535 1.289 0 CA-C-O 115.237 -2.98 . . . . 0.0 118.396 -172.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.67 -11.81 3.23 Favored 'Trans proline' 0 C--N 1.357 0.982 0 CA-C-N 123.192 3.496 . . . . 0.0 112.282 168.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -152.51 -25.25 0.17 Allowed 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.078 1.351 . . . . 0.0 113.14 169.351 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -72.59 93.06 1.56 Allowed 'General case' 0 C--N 1.342 0.282 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 166.415 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -66.77 -6.51 16.24 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 114.674 -1.148 . . . . 0.0 113.87 -179.365 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -78.74 -64.84 1.08 Allowed 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 125.657 1.583 . . . . 0.0 109.567 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 59.98 127.72 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 129.833 3.253 . . . . 0.0 117.881 167.367 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -56.93 154.04 10.13 Favored 'General case' 0 CA--C 1.55 0.961 0 O-C-N 120.391 -1.443 . . . . 0.0 111.857 171.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 p -68.47 -28.87 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 120.229 1.377 . . . . 0.0 111.287 -174.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.17 105.58 2.1 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 107.081 -2.407 . . . . 0.0 107.081 165.005 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -160.52 142.91 12.92 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 117.956 0.878 . . . . 0.0 113.309 177.62 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -120.91 175.43 6.05 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 126.196 1.798 . . . . 0.0 112.129 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -95.1 -153.68 30.37 Favored Glycine 0 CA--C 1.535 1.307 0 C-N-CA 125.905 1.717 . . . . 0.0 114.114 178.293 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.0 p30 -108.0 156.97 18.65 Favored 'General case' 0 N--CA 1.467 0.379 0 O-C-N 121.777 -0.837 . . . . 0.0 110.956 168.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -106.53 173.92 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 127.217 2.207 . . . . 0.0 109.749 176.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -138.16 143.72 40.43 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 125.177 1.391 . . . . 0.0 108.871 169.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.64 152.56 25.4 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 124.105 0.962 . . . . 0.0 112.879 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -88.85 164.52 15.16 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.745 1.618 . . . . 0.0 111.203 168.186 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -63.53 -10.83 19.89 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.536 1.534 . . . . 0.0 114.828 170.433 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.12 -18.07 63.22 Favored 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 118.852 0.751 . . . . 0.0 109.805 169.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 105.09 -7.49 44.21 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 127.83 2.633 . . . . 0.0 112.808 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.57 139.47 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 125.603 1.561 . . . . 0.0 113.485 -173.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.39 129.93 52.29 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 164.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -79.52 142.09 36.1 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 167.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -122.16 140.34 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 CA-C-O 122.22 1.01 . . . . 0.0 113.472 171.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.6 p -156.33 122.38 4.97 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.452 1.501 . . . . 0.0 109.814 168.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.2 mp -128.98 156.09 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 C-N-CA 125.739 1.616 . . . . 0.0 108.843 173.199 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -157.37 135.84 11.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 126.574 1.95 . . . . 0.0 108.418 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -160.93 159.19 29.31 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 124.763 1.225 . . . . 0.0 112.431 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -121.16 48.19 1.7 Allowed 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.378 1.251 . . . . 0.0 114.378 172.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 57.3 t -137.95 -40.22 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.672 1.989 . . . . 0.0 109.961 169.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 pp -78.85 149.92 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 123.488 1.613 . . . . 0.0 114.474 172.394 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 94.6 p -155.26 169.53 23.97 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 126.635 1.974 . . . . 0.0 108.907 -176.306 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mp -96.36 48.26 1.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 172.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.3 t -103.06 -13.31 16.89 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 116.923 2.194 . . . . 0.0 116.923 -169.506 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 146.39 -88.05 0.16 Allowed Glycine 0 C--N 1.348 1.231 0 N-CA-C 120.124 2.809 . . . . 0.0 120.124 167.439 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -59.8 -61.01 2.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 C-N-CA 126.167 1.787 . . . . 0.0 115.215 -160.531 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 -125.3 1.3 7.77 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.177 1.391 . . . . 0.0 112.956 -174.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.7 p -78.45 -169.75 1.79 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.418 0.687 . . . . 0.0 112.35 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 3.3 pt -69.99 -30.16 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 O-C-N 118.954 -2.341 . . . . 0.0 114.105 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.9 mm -60.4 137.76 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-N 120.293 1.406 . . . . 0.0 110.493 171.66 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.98 -11.2 6.39 Favored Glycine 0 CA--C 1.527 0.797 0 CA-C-O 118.223 -1.321 . . . . 0.0 113.719 -177.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.17 139.38 39.9 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 120.035 1.917 . . . . 0.0 108.969 177.261 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 57.7 m -98.99 104.32 16.36 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -175.026 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 23.6 tp -80.26 120.08 23.87 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.108 1.363 . . . . 0.0 111.048 -177.162 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.87 138.87 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.62 1.568 . . . . 0.0 109.912 169.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.3 t -103.79 159.59 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 166.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -125.09 133.35 52.91 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.285 1.434 . . . . 0.0 111.24 -168.459 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -46.39 -35.62 5.67 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 127.569 2.348 . . . . 0.0 114.704 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -113.68 170.02 8.56 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.708 1.603 . . . . 0.0 112.512 -169.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.84 158.8 6.01 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.365 1.066 . . . . 0.0 110.642 167.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -138.29 142.53 39.81 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.272 1.029 . . . . 0.0 110.809 -168.161 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -85.91 -59.23 2.36 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 122.977 0.511 . . . . 0.0 111.891 176.534 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mp 65.93 84.95 0.15 Allowed 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 128.001 2.521 . . . . 0.0 113.9 -174.021 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 131.02 -29.97 3.43 Favored Glycine 0 N--CA 1.479 1.524 0 N-CA-C 118.888 2.315 . . . . 0.0 118.888 166.349 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -155.97 -58.92 0.1 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 119.474 1.637 . . . . 0.0 113.515 -169.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 44.22 -115.31 1.23 Allowed Glycine 0 C--N 1.34 0.754 0 C-N-CA 125.55 1.547 . . . . 0.0 111.55 -170.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.86 14.46 3.84 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-O 118.256 -1.302 . . . . 0.0 114.54 169.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -161.63 168.08 24.06 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 120.146 1.973 . . . . 0.0 112.853 -167.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -47.98 -58.75 4.02 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.137 1.375 . . . . 0.0 112.082 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -46.75 -31.89 3.28 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -179.078 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -65.7 -23.21 66.71 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.432 -1.418 . . . . 0.0 113.716 178.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.0 t -99.84 -29.56 12.53 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.931 0.892 . . . . 0.0 111.917 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -71.19 -41.45 70.29 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.25 1.42 . . . . 0.0 113.503 -176.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.5 p -124.48 -30.73 3.34 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.112 1.765 . . . . 0.0 112.801 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.98 -14.41 11.24 Favored Glycine 0 C--O 1.222 -0.648 0 C-N-CA 126.416 1.96 . . . . 0.0 111.184 -167.221 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 90.6 1.68 0.17 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.11 2.964 . . . . 0.0 112.346 178.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.54 -7.76 0.3 Allowed 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -168.615 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 64.96 7.91 32.49 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 120.327 2.891 . . . . 0.0 120.327 164.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.19 178.3 1.74 Allowed 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 121.166 2.483 . . . . 0.0 115.129 172.024 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 18.9 ptt-85 -76.4 -174.37 2.84 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.402 1.881 . . . . 0.0 109.883 165.746 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -177.76 -148.84 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 128.7 2.8 . . . . 0.0 107.504 165.111 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.28 144.24 55.86 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.079 0.952 . . . . 0.0 110.632 168.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.6 t -157.61 145.05 18.51 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.799 1.24 . . . . 0.0 112.312 -173.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.53 162.96 34.3 Favored Glycine 0 N--CA 1.474 1.176 0 C-N-CA 125.144 1.354 . . . . 0.0 112.46 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.8 p -78.87 153.29 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 118.795 1.298 . . . . 0.0 110.543 169.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mm -87.12 111.64 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 120.87 -1.144 . . . . 0.0 109.969 168.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.32 -155.8 23.55 Favored Glycine 0 CA--C 1.534 1.249 0 C-N-CA 125.659 1.6 . . . . 0.0 112.018 175.58 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.93 167.99 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-N 119.226 1.513 . . . . 0.0 113.616 177.546 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.96 -36.87 0.08 Allowed 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.979 1.712 . . . . 0.0 113.449 167.072 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . 0.299 27.6 pt20 . . . . . 0 C--O 1.235 0.31 0 C-N-CA 125.292 1.437 . . . . 0.0 114.307 -170.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.618 0 N-CA-C 112.632 0.604 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.7 m -79.79 105.85 11.39 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.354 1.462 . . . . 0.0 110.544 -167.441 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 24.3 mtmm -96.19 106.79 19.04 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 115.67 1.73 . . . . 0.0 115.67 -175.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.84 167.16 11.6 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.634 1.974 . . . . 0.0 111.034 167.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -158.44 151.65 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 C-N-CA 124.321 1.048 . . . . 0.0 113.554 -170.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.51 147.74 38.27 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.325 1.05 . . . . 0.0 109.471 162.757 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 53' ' ' ASN . 84.1 t -106.19 121.54 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.382 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 168.594 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.9 mp -92.34 107.62 19.35 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 126.683 1.993 . . . . 0.0 107.829 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 35.9 tttt -131.47 149.17 52.63 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 120.032 1.287 . . . . 0.0 114.006 175.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.08 151.72 16.87 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 128.799 3.095 . . . . 0.0 107.092 166.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -72.07 88.95 1.11 Allowed 'General case' 0 C--N 1.318 -0.767 0 C-N-CA 126.71 2.004 . . . . 0.0 112.038 -167.534 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.97 -129.47 3.29 Favored Glycine 0 CA--C 1.536 1.374 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.888 -177.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -93.24 -10.73 1.75 Allowed 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 124.143 3.229 . . . . 0.0 115.368 -169.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.1 t -91.82 113.49 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 120.458 1.481 . . . . 0.0 110.382 -176.705 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -159.13 161.54 36.32 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.619 -1.173 . . . . 0.0 113.547 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' B' ' 35' ' ' ILE . . . -150.67 167.23 30.38 Favored Glycine 0 CA--C 1.502 -0.765 0 CA-C-N 115.264 -0.88 . . . . 0.0 113.072 166.696 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.71 135.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.781 -1.562 . . . . 0.0 106.781 167.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.73 128.25 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.609 0.718 . . . . 0.0 109.774 169.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -96.11 136.51 36.47 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 125.587 1.555 . . . . 0.0 110.555 177.46 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -109.39 94.12 4.87 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 127.534 2.334 . . . . 0.0 109.583 173.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -95.68 109.42 21.7 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 121.041 -1.037 . . . . 0.0 111.567 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -98.37 140.45 32.63 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 121.231 -0.918 . . . . 0.0 111.438 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -78.67 -27.59 45.21 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -175.185 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -161.04 156.87 25.27 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 128.274 2.63 . . . . 0.0 107.318 168.068 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -46.7 -22.06 0.26 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 130.168 3.387 . . . . 0.0 116.698 -170.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -124.83 -4.42 7.59 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 128.536 2.735 . . . . 0.0 112.31 -174.233 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.41 160.03 27.71 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 125.876 1.703 . . . . 0.0 110.99 172.526 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.13 159.62 51.25 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.197 2.598 . . . . 0.0 112.626 -170.093 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.0 t -108.68 128.06 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.793 1.237 . . . . 0.0 110.036 -172.422 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -81.96 125.16 30.44 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 171.135 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.65 116.82 53.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.611 1.164 . . . . 0.0 108.845 170.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -137.35 158.64 43.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.006 0.922 . . . . 0.0 110.807 169.348 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.42 164.12 9.85 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-O 121.643 0.579 . . . . 0.0 112.688 174.226 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -113.62 116.52 29.61 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -165.004 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.428 ' HA ' ' HA3' ' B' ' 16' ' ' GLY . 4.0 mm -94.96 116.74 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 172.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -124.32 146.97 48.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.508 1.523 . . . . 0.0 111.196 -167.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -31.04 7.79 Favored Glycine 0 N--CA 1.471 0.986 0 C-N-CA 126.946 2.212 . . . . 0.0 112.143 -175.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.512 HD13 ' CD2' ' B' ' 43' ' ' HIS . 3.1 pp -76.0 128.24 34.62 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.511 1.124 . . . . 0.0 108.308 169.13 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -73.49 175.72 6.77 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.164 0.986 . . . . 0.0 111.888 -173.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -61.09 154.3 23.33 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -168.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.23 -175.02 29.18 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.399 1.0 . . . . 0.0 112.477 -175.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.3 mp -77.82 124.69 28.29 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 127.375 2.27 . . . . 0.0 112.078 -169.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 43' ' ' HIS . . . . . 0.512 ' CD2' HD13 ' B' ' 38' ' ' LEU . 60.0 m-70 -122.51 130.09 52.67 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.766 1.226 . . . . 0.0 107.976 171.138 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.32 165.84 38.87 Favored Glycine 0 N--CA 1.473 1.104 0 C-N-CA 126.443 1.973 . . . . 0.0 115.15 -169.244 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -156.58 99.96 1.91 Allowed 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 120.002 1.901 . . . . 0.0 112.764 -167.174 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -124.2 135.61 53.58 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 121.059 -1.025 . . . . 0.0 112.173 -169.564 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . 0.263 1.0 OUTLIER -102.84 141.14 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 119.077 0.853 . . . . 0.0 109.369 173.099 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.619 ' CG ' HG23 ' B' ' 116' ' ' THR . 0.3 OUTLIER -133.75 154.53 50.91 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.194 1.398 . . . . 0.0 112.732 -168.437 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -76.93 128.69 35.0 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -170.074 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.252 29.6 m-85 99.88 157.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 1 C-N-CA 132.732 4.413 . . . . 0.0 115.551 169.457 . . . . . . . . 3 2 . 1 . 016 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.92 -19.32 5.66 Favored Glycine 0 N--CA 1.471 1.014 0 C-N-CA 126.158 1.837 . . . . 0.0 113.176 177.3 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.46 51.94 0.07 Allowed 'General case' 0 CA--C 1.551 1.008 0 C-N-CA 127.558 2.343 . . . . 0.0 111.597 169.722 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -178.4 35.18 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -165.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 33.2 p . . . . . 0 CA--C 1.543 0.709 0 C-N-CA 128.608 2.763 . . . . 0.0 116.182 177.102 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.386 0 N-CA-C 113.476 0.917 . . . . 0.0 113.476 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.43 -175.15 48.72 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 124.638 1.113 . . . . 0.0 114.498 -177.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -83.31 -179.11 4.1 Favored 'Trans proline' 0 CA--C 1.539 0.752 1 C-N-CA 126.188 4.592 . . . . 0.0 111.774 175.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.488 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.7 p80 -80.7 107.37 13.45 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 122.452 1.12 . . . . 0.0 112.79 -174.336 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 136.81 5.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.57 1.948 . . . . 0.0 114.501 176.218 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.9 p-10 -116.81 47.4 0.62 Allowed Pre-proline 0 CA--C 1.55 0.965 0 CA-C-N 114.595 -1.184 . . . . 0.0 113.476 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -56.62 -30.47 83.49 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.819 3.012 . . . . 0.0 115.946 -168.351 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.4 mp -79.29 -4.94 53.14 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 124.468 1.107 . . . . 0.0 113.595 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 68.62 47.83 0.85 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 128.865 2.866 . . . . 0.0 111.115 -176.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.8 mmm180 -110.29 162.28 14.78 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 126.217 1.807 . . . . 0.0 111.011 -168.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 13.1 mmtm -74.43 173.26 10.55 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 167.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 30.1 t60 -50.88 158.22 0.71 Allowed 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -173.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.36 71.2 2.07 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.634 1.111 . . . . 0.0 113.634 -169.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -84.23 125.06 6.93 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -72.59 -11.89 26.52 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.001 1.801 . . . . 0.0 111.581 170.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.76 -5.91 13.29 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.168 0.987 . . . . 0.0 113.653 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -114.06 148.6 36.8 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.519 1.528 . . . . 0.0 108.281 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -74.68 -14.94 60.81 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 124.582 1.153 . . . . 0.0 111.82 -171.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -102.99 121.59 42.85 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.514 1.526 . . . . 0.0 107.678 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 -144.97 124.05 12.84 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 126.966 2.106 . . . . 0.0 110.788 -175.323 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 61.4 m170 -65.09 155.02 36.14 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.314 1.845 . . . . 0.0 110.842 164.724 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -55.95 -33.69 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.21 103.25 0.31 Allowed Glycine 0 C--N 1.345 1.061 0 N-CA-C 115.163 0.825 . . . . 0.0 115.163 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -159.53 146.88 16.94 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 130.329 3.452 . . . . 0.0 105.217 164.145 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 76.3 mt -128.96 56.34 1.68 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.779 0.799 . . . . 0.0 111.156 -168.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 59.91 -122.16 29.05 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.467 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -148.06 126.96 12.7 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.466 1.106 . . . . 0.0 110.785 -176.678 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -76.86 97.15 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.825 1.65 . . . . 0.0 109.314 177.203 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 92.0 m -97.6 120.91 38.83 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 113.338 -1.756 . . . . 0.0 109.253 -169.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.26 158.65 16.03 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -168.002 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -81.04 171.74 14.59 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.086 2.155 . . . . 0.0 112.158 168.711 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.791 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -67.26 -17.34 64.75 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.735 1.614 . . . . 0.0 114.017 174.28 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -71.6 -6.97 44.78 Favored 'General case' 0 CA--C 1.555 1.151 0 CA-C-O 122.433 1.111 . . . . 0.0 109.608 167.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.28 44.48 9.61 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 125.614 1.578 . . . . 0.0 109.895 173.203 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 13.3 p -142.54 130.31 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.523 1.129 . . . . 0.0 112.528 -177.64 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.21 94.91 5.77 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 124.512 1.125 . . . . 0.0 109.619 168.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -83.77 104.08 13.58 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 122.241 1.019 . . . . 0.0 109.834 168.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -80.34 154.22 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-N 113.961 -1.472 . . . . 0.0 111.741 -173.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 60.0 p -156.9 93.84 1.38 Allowed 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.182 -0.949 . . . . 0.0 112.719 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 21.2 mt -134.53 153.02 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 126.955 2.102 . . . . 0.0 111.394 -177.486 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -133.05 135.7 45.52 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 164.654 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -151.22 141.25 22.09 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 114.912 1.449 . . . . 0.0 114.912 -168.056 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.0 p -112.03 49.06 0.93 Allowed 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.6 t -123.13 4.99 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 C-N-CA 124.038 0.935 . . . . 0.0 111.158 174.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.24 170.75 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 C-N-CA 126.95 2.1 . . . . 0.0 110.509 -177.094 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -157.88 175.54 13.72 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.878 1.271 . . . . 0.0 110.817 169.305 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.6 mt -84.7 50.11 1.84 Allowed 'General case' 0 CA--C 1.548 0.893 0 O-C-N 120.204 -1.56 . . . . 0.0 109.609 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.4 t -81.79 25.22 0.56 Allowed 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 115.606 1.706 . . . . 0.0 115.606 -168.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.0 -51.59 3.86 Favored Glycine 0 C--N 1.336 0.542 0 C-N-CA 125.54 1.543 . . . . 0.0 115.087 168.085 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -101.2 -93.72 0.29 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 117.796 0.798 . . . . 0.0 111.137 -165.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 83.3 m-70 -84.05 2.56 38.58 Favored 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 1.1 t -95.42 -125.93 0.12 Allowed 'General case' 0 CA--C 1.551 0.994 0 O-C-N 119.793 -1.817 . . . . 0.0 113.066 -170.556 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 mm -80.08 -47.09 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-N 123.594 2.906 . . . . 0.0 113.222 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.1 mm -60.24 133.92 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 119.328 0.967 . . . . 0.0 108.936 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.53 6.18 65.49 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-O 118.574 -1.125 . . . . 0.0 115.037 178.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.65 164.08 19.91 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 119.115 1.458 . . . . 0.0 110.017 171.656 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 116' ' ' THR . . . . . 0.619 HG23 ' CG ' ' B' ' 48' ' ' HIS . 3.9 t -115.17 157.65 23.35 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.279 1.032 . . . . 0.0 110.046 175.528 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 17.9 tp -151.28 126.24 9.77 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.025 1.33 . . . . 0.0 112.22 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.9 p -116.46 134.99 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 126.152 1.781 . . . . 0.0 111.258 170.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -84.46 139.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.681 1.193 . . . . 0.0 108.865 169.074 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 66.2 m-70 -108.25 149.71 28.25 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.616 1.566 . . . . 0.0 112.705 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -73.65 -37.17 65.4 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -171.611 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -92.12 164.62 13.52 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 120.482 -1.386 . . . . 0.0 109.914 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.16 140.51 5.13 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.419 1.087 . . . . 0.0 111.216 169.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.65 129.29 37.46 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -73.57 0.7 11.86 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.892 2.077 . . . . 0.0 111.564 178.03 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 79.17 -37.65 0.19 Allowed 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.283 2.633 . . . . 0.0 114.07 168.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 143.22 47.77 0.04 OUTLIER Glycine 0 N--CA 1.477 1.378 0 CA-C-N 120.4 1.454 . . . . 0.0 114.975 -176.428 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.3 pttp -157.18 -113.46 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 -168.515 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 66.16 -3.84 2.98 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.652 2.072 . . . . 0.0 117.433 169.411 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.0 4.26 54.77 Favored Glycine 0 CA--C 1.536 1.392 0 CA-C-N 119.073 1.436 . . . . 0.0 114.053 -174.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 m-80 -119.12 156.8 29.12 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 125.722 1.609 . . . . 0.0 111.517 -176.122 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -54.11 -59.41 4.68 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.145 0.978 . . . . 0.0 109.238 166.536 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -54.7 -36.88 65.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.739 1.216 . . . . 0.0 113.169 -172.136 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.0 m -66.05 -13.28 59.7 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.695 1.998 . . . . 0.0 115.563 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -122.37 -20.04 6.24 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.882 0.873 . . . . 0.0 112.928 168.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -72.53 -46.66 53.5 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.121 1.368 . . . . 0.0 111.779 174.487 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.3 p -117.75 -34.21 4.28 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.221 1.008 . . . . 0.0 112.977 173.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.38 11.24 20.3 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 126.708 2.099 . . . . 0.0 111.972 -168.189 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t30 55.52 17.56 2.31 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 120.602 2.201 . . . . 0.0 113.29 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.33 25.07 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.073 0 C-N-CA 127.573 2.349 . . . . 0.0 116.145 -165.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.26 -51.63 3.93 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 127.558 2.504 . . . . 0.0 114.454 169.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 2.9 m 179.76 166.67 1.19 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.782 2.433 . . . . 0.0 111.906 -179.024 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.12 150.97 31.62 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.401 0.681 . . . . 0.0 110.887 173.442 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.31 -130.6 0.24 Allowed 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 126.739 2.016 . . . . 0.0 108.794 173.086 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.83 157.39 33.42 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 127.065 2.146 . . . . 0.0 114.437 -175.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -151.22 159.68 44.25 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -172.053 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.71 168.48 34.37 Favored Glycine 0 CA--C 1.543 1.825 0 C-N-CA 127.485 2.469 . . . . 0.0 113.842 175.202 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 54.2 t -124.83 138.2 54.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 C-N-CA 124.742 1.217 . . . . 0.0 108.563 174.489 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mm -79.04 122.6 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -166.354 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.62 -156.51 9.88 Favored Glycine 0 CA--C 1.542 1.773 0 C-N-CA 128.362 2.887 . . . . 0.0 113.141 169.547 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -142.08 147.39 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 C-N-CA 125.276 1.431 . . . . 0.0 114.702 -168.835 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.07 -22.43 10.56 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 125.499 1.519 . . . . 0.0 114.407 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 . . . . . 0 N--CA 1.471 0.606 0 C-N-CA 125.673 1.589 . . . . 0.0 112.453 -178.186 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.472 0.627 0 CA-C-O 121.657 0.741 . . . . 0.0 110.707 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.487 ' HE3' ' OE1' ' A' ' 153' ' ' GLN . 0.0 OUTLIER -77.98 117.71 19.57 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-N 114.741 -1.118 . . . . 0.0 112.053 169.289 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.4 178.59 6.44 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.429 1.091 . . . . 0.0 110.179 167.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -155.41 90.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 125.664 1.586 . . . . 0.0 109.981 -168.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.93 121.93 32.49 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.229 1.412 . . . . 0.0 110.573 174.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.0 p -95.75 126.68 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-N 118.9 0.773 . . . . 0.0 109.105 173.393 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mp -109.14 133.95 52.35 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.59 1.156 . . . . 0.0 108.627 169.42 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mtmt -157.77 133.12 8.9 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.267 1.427 . . . . 0.0 110.276 173.822 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.73 -81.08 0.63 Allowed Glycine 0 C--N 1.334 0.45 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -170.038 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -139.42 116.56 11.09 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 124.559 1.144 . . . . 0.0 108.987 -166.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.04 -101.41 0.03 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 128.988 3.185 . . . . 0.0 112.613 175.044 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -77.99 -9.46 16.74 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.275 2.65 . . . . 0.0 114.014 -174.047 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.8 t -88.46 126.19 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 121.33 1.877 . . . . 0.0 111.818 -176.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.87 159.11 43.13 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 125.162 1.385 . . . . 0.0 111.792 171.165 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.87 164.4 27.85 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 122.444 1.025 . . . . 0.0 113.811 169.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.79 133.93 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 125.127 1.371 . . . . 0.0 109.066 -179.596 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.6 mm -137.7 121.92 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 CA-C-N 119.74 1.155 . . . . 0.0 110.683 169.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -88.57 145.84 25.48 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.981 167.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -121.62 109.62 14.99 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 168.286 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.78 112.59 24.31 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.85 0.75 . . . . 0.0 111.529 -176.643 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -93.49 135.31 34.86 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -114.52 -45.54 3.01 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.612 1.565 . . . . 0.0 114.688 -175.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -118.9 -179.76 3.91 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.25 1.42 . . . . 0.0 109.204 167.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.8 p -67.66 -25.91 65.94 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 119.162 -2.211 . . . . 0.0 114.221 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -141.04 9.5 2.12 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 126.407 1.883 . . . . 0.0 112.598 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.8 151.94 52.31 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.795 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -61.91 137.63 68.77 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 124.169 3.246 . . . . 0.0 110.36 -172.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 79.3 t -102.59 135.53 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 123.525 0.73 . . . . 0.0 109.889 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -91.1 116.69 29.01 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 167.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.3 t -104.2 110.91 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 126.677 1.991 . . . . 0.0 108.7 -173.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -132.78 168.69 17.9 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 122.216 1.008 . . . . 0.0 113.143 -176.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.86 -155.48 26.15 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 124.87 1.224 . . . . 0.0 111.488 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -159.71 152.12 21.09 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -123.91 134.24 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 125.712 1.605 . . . . 0.0 107.865 -178.106 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.8 ptpt -149.58 152.03 34.81 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -172.141 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.1 12.12 52.94 Favored Glycine 0 CA--C 1.535 1.302 0 C-N-CA 125.256 1.407 . . . . 0.0 113.231 -168.587 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -111.86 164.7 12.79 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.005 2.122 . . . . 0.0 111.1 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.23 166.11 24.0 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.081 1.352 . . . . 0.0 111.438 176.583 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.31 -166.48 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 128.541 2.736 . . . . 0.0 113.661 -177.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.73 -178.38 42.78 Favored Glycine 0 CA--C 1.531 1.063 0 O-C-N 120.295 -1.503 . . . . 0.0 113.136 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.691 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -74.58 144.48 43.95 Favored 'General case' 0 CA--C 1.542 0.652 0 O-C-N 120.692 -1.476 . . . . 0.0 112.045 -178.065 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -136.8 151.29 49.0 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 128.789 2.836 . . . . 0.0 109.274 -177.151 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.29 173.83 26.69 Favored Glycine 0 N--CA 1.475 1.286 0 C-N-CA 125.317 1.437 . . . . 0.0 114.043 -174.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -159.93 122.46 3.4 Favored 'General case' 0 CA--C 1.554 1.122 0 C-N-CA 125.502 1.521 . . . . 0.0 112.754 -168.365 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 10.8 p-80 -152.07 134.14 15.01 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 118.705 -2.497 . . . . 0.0 113.607 167.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.6 m -84.99 146.0 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 CA-C-O 122.213 1.006 . . . . 0.0 108.948 170.327 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -107.13 176.09 5.28 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 124.021 1.867 . . . . 0.0 114.592 -168.034 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.2 pm0 -72.95 132.87 44.0 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 158.774 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.419 ' HB3' ' H ' ' A' ' 52' ' ' ASP . 6.8 m-85 75.77 167.59 0.27 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 124.422 2.058 . . . . 0.0 115.148 169.119 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.34 0.28 57.05 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 111.41 -2.632 . . . . 0.0 109.96 163.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.419 ' H ' ' HB3' ' A' ' 50' ' ' PHE . 6.7 t0 -69.92 138.08 52.11 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 165.136 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.479 HD22 HG11 ' B' ' 7' ' ' VAL . 13.5 p-10 -177.08 21.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 168.057 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.4 p -79.57 -14.33 58.92 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -163.554 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -108.1 10.05 28.18 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 124.5 1.12 . . . . 0.0 110.972 167.462 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.56 -138.06 35.46 Favored Glycine 0 CA--C 1.528 0.865 0 O-C-N 121.019 -1.05 . . . . 0.0 111.035 -171.352 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.2 m -57.17 -6.06 0.35 Allowed 'General case' 0 CA--C 1.549 0.928 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -174.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.5 t -103.13 0.71 32.24 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-N 119.966 1.257 . . . . 0.0 113.998 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.9 p -128.57 -18.37 3.95 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 168.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.37 153.98 35.73 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.326 1.851 . . . . 0.0 110.763 168.055 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.16 -173.78 28.81 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.239 0.923 . . . . 0.0 114.753 -170.252 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.41 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 40.9 Cg_endo -91.24 72.11 0.94 Allowed 'Trans proline' 0 CA--C 1.538 0.721 1 C-N-CA 125.401 4.068 . . . . 0.0 108.276 169.556 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.437 ' ND1' ' ND1' ' A' ' 71' ' ' HIS . 5.1 p80 43.9 70.04 0.36 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.958 1.703 . . . . 0.0 114.657 164.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -32.59 134.3 0.1 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 128.848 2.859 . . . . 0.0 117.901 -168.061 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 30.0 p-10 -103.75 34.25 0.05 OUTLIER Pre-proline 0 CA--C 1.559 1.302 0 N-CA-C 117.365 2.357 . . . . 0.0 117.365 -174.596 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -66.36 -15.17 47.15 Favored 'Trans proline' 0 C--N 1.357 1.003 0 CA-C-N 123.328 2.224 . . . . 0.0 115.068 -169.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -77.1 -0.84 26.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.099 1.359 . . . . 0.0 112.844 169.299 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.4 t 77.98 59.48 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.988 2.115 . . . . 0.0 112.3 168.601 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 ptm85 -149.72 169.35 21.24 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -67.57 156.7 36.14 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 127.889 2.476 . . . . 0.0 111.091 172.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.437 ' ND1' ' ND1' ' A' ' 63' ' ' HIS . 78.1 t60 -75.33 149.97 38.59 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.152 165.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.13 -145.36 12.76 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 116.508 -0.315 . . . . 0.0 113.052 166.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 165.32 -98.15 0.15 Allowed Glycine 0 CA--C 1.535 1.286 0 CA-C-O 117.166 -1.908 . . . . 0.0 114.771 168.606 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -65.43 0.42 2.85 Favored 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 124.821 3.681 . . . . 0.0 116.397 -169.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.34 1.73 1.41 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 127.124 2.17 . . . . 0.0 112.486 175.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.461 ' CG ' ' H ' ' A' ' 77' ' ' GLU . 19.9 t0 -95.96 -178.96 4.53 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 128.321 2.648 . . . . 0.0 111.131 178.439 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.461 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 20.1 tt0 -98.43 -31.26 12.09 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 129.635 3.174 . . . . 0.0 112.04 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -127.51 -70.62 0.7 Allowed 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -166.374 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.416 HH22 ' HB ' ' A' ' 103' ' ' VAL . 1.1 ttt-85 83.69 128.88 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 127.038 2.135 . . . . 0.0 111.436 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -66.25 169.63 6.94 Favored 'General case' 0 CA--C 1.55 0.953 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.245 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 m -85.11 65.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 CA-C-O 122.707 1.242 . . . . 0.0 109.68 173.147 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.76 88.73 0.3 Allowed Glycine 0 C--O 1.223 -0.555 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -168.512 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -158.0 150.5 22.41 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 128.132 2.573 . . . . 0.0 109.597 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 77.5 mt -129.8 178.04 6.81 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 126.08 1.752 . . . . 0.0 109.3 169.442 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -84.55 -129.04 1.82 Allowed Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.376 0.989 . . . . 0.0 113.184 -176.641 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -147.7 169.73 19.06 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.437 1.095 . . . . 0.0 110.53 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.63 170.73 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.173 0.989 . . . . 0.0 110.765 -170.418 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.5 m -140.78 138.52 34.17 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 125.727 1.611 . . . . 0.0 108.301 172.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.71 138.79 34.56 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.821 0.848 . . . . 0.0 110.563 176.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -87.43 162.8 17.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.64 1.176 . . . . 0.0 112.147 172.41 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -53.46 -19.06 3.17 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 127.783 2.433 . . . . 0.0 115.017 -170.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.68 4.07 48.49 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 128.241 2.616 . . . . 0.0 110.918 -173.132 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.68 26.84 21.54 Favored Glycine 0 C--N 1.341 0.829 0 C-N-CA 126.065 1.793 . . . . 0.0 113.907 172.332 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.18 132.3 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.4 129.21 43.8 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 126.159 1.783 . . . . 0.0 106.258 164.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -117.09 135.64 53.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 -178.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 51.3 t -125.24 129.81 73.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 114.114 -1.403 . . . . 0.0 114.381 -164.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.7 p -144.72 74.47 1.41 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.235 1.414 . . . . 0.0 112.52 176.296 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -101.09 159.39 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 120.604 -1.31 . . . . 0.0 111.481 -177.701 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -138.87 141.77 38.6 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.768 2.027 . . . . 0.0 107.941 172.405 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -145.42 141.2 28.19 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.229 1.411 . . . . 0.0 110.259 177.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.2 p -111.54 50.82 0.81 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -173.353 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.416 ' HB ' HH22 ' A' ' 79' ' ' ARG . 23.4 t -144.32 -42.97 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.207 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 168.468 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.43 155.52 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 CA-C-N 119.564 1.074 . . . . 0.0 112.095 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.9 p -156.98 167.67 29.77 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.565 -1.334 . . . . 0.0 113.351 177.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.12 56.8 1.31 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.956 1.36 . . . . 0.0 109.378 170.113 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.08 33.02 0.88 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.723 2.009 . . . . 0.0 111.428 168.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.4 -137.21 13.14 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 124.731 1.158 . . . . 0.0 111.928 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -93.65 -32.82 13.92 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 128.073 2.549 . . . . 0.0 115.766 -165.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -83.95 -8.23 59.22 Favored 'General case' 0 CA--C 1.545 0.758 0 O-C-N 120.305 -1.497 . . . . 0.0 111.607 -178.339 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 69.9 m -102.19 -40.6 6.72 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 115.416 1.636 . . . . 0.0 115.416 -170.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -169.49 -42.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.104 1.762 . . . . 0.0 114.134 171.599 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.85 141.51 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 168.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.68 8.85 61.05 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 116.31 -2.384 . . . . 0.0 113.896 -174.497 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -100.17 177.48 5.06 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 121.146 2.473 . . . . 0.0 109.62 169.061 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 27.2 m -120.91 146.72 46.32 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.855 1.662 . . . . 0.0 110.243 -175.011 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -127.33 143.36 51.24 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.858 1.663 . . . . 0.0 109.276 166.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.8 m -114.24 129.47 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 125.598 1.559 . . . . 0.0 109.569 169.392 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -98.56 120.53 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 168.232 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 2.1 m-70 -96.81 153.71 17.72 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.333 1.453 . . . . 0.0 113.337 -168.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.26 -62.63 1.57 Allowed 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 124.427 1.091 . . . . 0.0 111.305 -172.741 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.44 176.47 6.28 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.86 -1.15 . . . . 0.0 111.437 170.88 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.37 146.25 44.96 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.23 1.012 . . . . 0.0 113.428 -169.435 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.66 112.8 17.27 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 166.226 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -78.72 -8.0 58.29 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.661 1.985 . . . . 0.0 114.922 -167.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 34.28 89.28 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 129.385 3.074 . . . . 0.0 114.915 177.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.41 -55.36 4.9 Favored Glycine 0 N--CA 1.469 0.851 0 C-N-CA 125.456 1.503 . . . . 0.0 112.54 168.483 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -153.91 110.22 3.3 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -174.214 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.97 -95.48 2.21 Favored Glycine 0 CA--C 1.513 -0.079 0 N-CA-C 104.116 -3.593 . . . . 0.0 104.116 163.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.55 14.81 3.91 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 117.938 -1.479 . . . . 0.0 114.321 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -121.63 173.66 7.3 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 119.993 1.896 . . . . 0.0 112.215 -169.162 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -75.56 -48.17 23.55 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 113.067 -1.879 . . . . 0.0 109.04 167.065 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -61.59 -19.2 61.95 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 176.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 21.1 m -51.34 -39.33 56.81 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 119.955 1.252 . . . . 0.0 112.776 171.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -94.78 -33.18 12.98 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 174.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 mtpt -75.27 -29.23 60.09 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 120.618 1.554 . . . . 0.0 114.823 -178.387 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.0 p -136.85 -23.33 1.18 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.36 8.15 55.21 Favored Glycine 0 C--O 1.221 -0.718 0 C-N-CA 124.733 1.158 . . . . 0.0 110.686 -167.189 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 62.05 -4.04 0.22 Allowed 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.344 1.858 . . . . 0.0 114.153 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -58.41 -3.7 0.31 Allowed 'General case' 0 CA--C 1.555 1.159 0 C-N-CA 129.058 2.943 . . . . 0.0 117.151 -165.753 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.81 -81.6 1.38 Allowed Glycine 0 CA--C 1.532 1.144 0 C-N-CA 125.764 1.65 . . . . 0.0 113.337 172.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.7 m -172.27 166.66 5.9 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.021 1.729 . . . . 0.0 112.255 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.412 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -100.38 144.4 29.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 116.698 2.11 . . . . 0.0 116.698 -173.073 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.448 HD13 ' H ' ' A' ' 144' ' ' LEU . 0.0 OUTLIER -90.53 -21.97 21.54 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 113.652 -1.613 . . . . 0.0 111.375 166.3 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.14 142.65 23.53 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 122.185 0.993 . . . . 0.0 111.004 173.459 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.1 p -136.94 147.78 46.58 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 127.887 2.475 . . . . 0.0 109.082 178.348 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.63 160.44 31.86 Favored Glycine 0 N--CA 1.469 0.874 0 N-CA-C 115.478 0.951 . . . . 0.0 115.478 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 99.3 t -104.74 143.71 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.527 1.131 . . . . 0.0 110.704 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 68.7 mt -84.89 95.41 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 126.383 1.873 . . . . 0.0 111.836 -169.451 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -91.62 177.75 40.71 Favored Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.0 1.285 . . . . 0.0 113.622 177.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -132.83 158.05 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.727 2.011 . . . . 0.0 112.206 -178.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -153.67 -25.76 0.14 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 174.187 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' GLN . . . . . 0.487 ' OE1' ' HE3' ' A' ' 3' ' ' LYS . 34.3 tt0 . . . . . 0 CA--C 1.537 0.458 0 O-C-N 121.009 -1.057 . . . . 0.0 110.802 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.419 0 CA-C-O 120.933 0.397 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.3 m -84.1 99.97 10.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -174.289 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.271 0.0 OUTLIER -94.8 113.96 25.78 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-O 123.321 1.534 . . . . 0.0 112.963 178.295 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.05 164.21 25.94 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 125.709 1.604 . . . . 0.0 111.166 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.03 140.53 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 125.767 1.627 . . . . 0.0 108.027 178.299 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.5 124.15 21.03 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.479 HG11 HD22 ' A' ' 53' ' ' ASN . 4.1 p -79.95 120.62 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 169.763 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -112.31 110.71 21.1 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 125.125 1.37 . . . . 0.0 108.427 169.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 tttt -157.06 160.28 38.77 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-O 121.499 0.666 . . . . 0.0 111.629 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.0 -35.83 0.84 Allowed Glycine 0 N--CA 1.468 0.802 0 C-N-CA 127.154 2.311 . . . . 0.0 110.005 174.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.41 58.19 2.56 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.867 2.067 . . . . 0.0 110.859 177.289 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 36.8 -98.31 0.01 OUTLIER Glycine 0 CA--C 1.535 1.334 0 C-N-CA 128.104 2.764 . . . . 0.0 114.288 -176.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.06 -13.2 15.76 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 123.869 3.046 . . . . 0.0 114.785 -176.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.21 137.51 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 121.262 1.846 . . . . 0.0 111.675 -176.094 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -126.49 162.12 26.36 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 124.357 1.063 . . . . 0.0 110.375 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -128.19 62.99 0.62 Allowed Glycine 0 N--CA 1.469 0.853 0 C-N-CA 125.262 1.41 . . . . 0.0 111.836 172.027 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.464 ' C ' HD12 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -79.44 109.08 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 CA-C-N 118.358 1.079 . . . . 0.0 110.923 -168.686 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.459 ' N ' HD12 ' B' ' 17' ' ' ILE . 2.4 pp -110.8 150.88 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 169.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -129.46 129.15 44.25 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.054 2.142 . . . . 0.0 107.364 167.796 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -115.93 125.02 52.03 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 119.203 0.91 . . . . 0.0 109.834 178.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.65 127.39 52.38 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 123.726 0.81 . . . . 0.0 110.242 -178.619 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 22' ' ' GLN . . . . . 0.529 ' HG2' ' H ' ' B' ' 24' ' ' GLU . 52.4 tt0 -121.14 134.27 55.23 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 123.069 1.414 . . . . 0.0 112.57 170.15 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -82.89 0.4 44.39 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 126.485 1.914 . . . . 0.0 113.617 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 24' ' ' GLU . . . . . 0.529 ' H ' ' HG2' ' B' ' 22' ' ' GLN . 43.4 mt-10 -157.64 -164.64 1.59 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 130.333 3.453 . . . . 0.0 108.495 -169.168 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -120.47 -6.6 9.77 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.895 1.278 . . . . 0.0 111.868 165.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -116.84 -45.95 2.76 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.745 1.618 . . . . 0.0 113.685 -171.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.38 -162.83 11.31 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 125.184 1.373 . . . . 0.0 114.133 -176.569 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.18 161.45 38.22 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.524 2.149 . . . . 0.0 112.69 -171.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 13.9 t -133.71 136.42 54.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.834 1.654 . . . . 0.0 109.833 -173.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HD2' ' H ' ' B' ' 30' ' ' LYS . 5.2 mptt -80.85 130.99 35.34 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.253 0.549 . . . . 0.0 110.049 171.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.36 105.44 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 127.735 2.414 . . . . 0.0 108.227 178.673 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -138.49 162.16 35.22 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.85 173.11 13.06 Favored Glycine 0 N--CA 1.467 0.737 0 C-N-CA 124.668 1.128 . . . . 0.0 114.261 171.331 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.3 p -110.65 120.59 42.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 114.86 1.43 . . . . 0.0 114.86 -167.341 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.629 HD13 HG21 ' B' ' 87' ' ' VAL . 0.6 OUTLIER -92.01 117.12 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 167.499 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 pttt -137.81 136.61 37.37 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.511 0.725 . . . . 0.0 111.349 -167.673 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.57 -18.26 22.77 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 127.491 2.472 . . . . 0.0 113.636 -172.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.4 156.35 25.45 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.371 1.069 . . . . 0.0 111.705 172.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -69.25 166.13 19.08 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.258 1.423 . . . . 0.0 110.262 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -61.39 -176.36 0.07 Allowed 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 126.673 1.989 . . . . 0.0 115.197 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.42 177.28 51.83 Favored Glycine 0 N--CA 1.469 0.867 0 C-N-CA 124.905 1.24 . . . . 0.0 112.187 -179.179 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.829 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -71.23 141.99 50.6 Favored 'General case' 0 CA--C 1.541 0.614 0 O-C-N 120.824 -1.398 . . . . 0.0 110.092 177.381 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -134.21 141.29 46.99 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 127.317 2.247 . . . . 0.0 107.957 176.409 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.98 155.94 48.53 Favored Glycine 0 N--CA 1.479 1.562 0 CA-C-N 120.494 1.497 . . . . 0.0 113.217 -174.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -147.27 105.5 3.76 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.91 1.355 . . . . 0.0 110.465 -171.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.476 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -145.4 145.22 31.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 120.804 -1.185 . . . . 0.0 110.4 -167.965 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.564 HG23 ' HA2' ' B' ' 82' ' ' GLY . 34.5 m -115.03 120.7 65.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.278 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -176.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.476 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 3.7 m170 -74.93 152.1 38.84 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -173.533 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -73.05 94.05 1.85 Allowed 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 169.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 150.54 156.82 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 1 C-N-CA 132.351 4.26 . . . . 0.0 111.669 170.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.3 -21.19 42.28 Favored Glycine 0 C--N 1.337 0.621 0 C-N-CA 126.187 1.851 . . . . 0.0 111.294 164.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -58.05 157.42 8.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 165.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 162.65 31.26 0.0 OUTLIER 'General case' 0 C--O 1.241 0.62 0 C-N-CA 129.075 2.95 . . . . 0.0 111.496 165.691 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 18.2 p . . . . . 0 N--CA 1.455 -0.19 0 O-C-N 121.132 -0.98 . . . . 0.0 110.364 -168.423 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.249 0 CA-C-O 121.682 0.753 . . . . 0.0 112.017 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.08 -161.86 29.49 Favored Glycine 0 CA--C 1.54 1.602 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.568 173.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -78.03 -171.43 1.2 Allowed 'Trans proline' 0 CA--C 1.54 0.777 1 C-N-CA 126.257 4.638 . . . . 0.0 110.087 169.167 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.428 ' CD2' ' ND1' ' B' ' 71' ' ' HIS . 5.0 p-80 -73.76 80.32 1.57 Allowed 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.303 2.641 . . . . 0.0 107.084 168.05 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -56.0 169.88 0.35 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 123.826 1.774 . . . . 0.0 110.889 174.66 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -104.13 51.94 0.08 OUTLIER Pre-proline 0 CA--C 1.555 1.142 0 CA-C-N 113.392 -1.731 . . . . 0.0 115.165 -167.76 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.45 -25.72 48.2 Favored 'Trans proline' 0 C--N 1.354 0.865 0 C-N-CA 122.33 2.02 . . . . 0.0 111.469 -177.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 39.5 mt -81.6 -6.49 59.05 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 172.015 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.9 t 69.34 59.86 0.32 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 125.652 1.581 . . . . 0.0 113.84 174.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.9 ptt180 -162.01 176.26 10.94 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 115.449 1.648 . . . . 0.0 115.449 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.2 170.95 11.94 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.888 1.275 . . . . 0.0 114.116 177.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.428 ' ND1' ' CD2' ' B' ' 63' ' ' HIS . 77.0 t60 -83.76 162.26 20.71 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.378 0.671 . . . . 0.0 111.501 167.636 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.412 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 137.97 -102.39 0.37 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.377 1.941 . . . . 0.0 111.739 166.106 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.75 -53.44 0.71 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 116.958 -2.024 . . . . 0.0 117.498 172.226 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -87.86 -8.17 6.02 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.502 2.801 . . . . 0.0 111.25 176.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.49 ' HE2' ' HA ' ' B' ' 75' ' ' LYS . 0.1 OUTLIER -145.98 -16.64 0.46 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 176.248 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.412 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 13.7 t70 -101.67 92.45 4.87 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 103.181 -2.896 . . . . 0.0 103.181 159.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 56.2 mp0 -65.04 -4.88 5.2 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.676 1.191 . . . . 0.0 113.508 -176.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -74.61 -63.31 1.27 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.597 1.959 . . . . 0.0 107.711 178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 32.4 ttp180 67.83 119.79 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.959 2.207 . . . . 0.0 116.959 162.388 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -62.61 156.1 24.25 Favored 'General case' 0 N--CA 1.472 0.659 0 O-C-N 119.467 -2.021 . . . . 0.0 112.102 169.001 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -52.71 -32.75 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.564 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -96.33 39.05 2.91 Favored Glycine 0 CA--C 1.534 1.26 0 N-CA-C 116.708 1.443 . . . . 0.0 116.708 -174.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -129.96 108.39 10.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.281 -1.129 . . . . 0.0 111.715 -172.385 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -109.79 47.41 0.95 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 122.467 1.127 . . . . 0.0 110.153 168.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.5 -101.67 0.03 OUTLIER Glycine 0 CA--C 1.528 0.879 0 C-N-CA 127.984 2.707 . . . . 0.0 114.103 174.709 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.8 p30 -154.86 161.74 41.34 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.592 1.557 . . . . 0.0 111.553 -175.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.629 HG21 HD13 ' B' ' 35' ' ' ILE . 8.9 p -137.85 124.81 28.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 C-N-CA 126.916 2.086 . . . . 0.0 109.605 -171.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 55.5 m -107.73 123.89 49.2 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 114.707 -1.133 . . . . 0.0 111.19 -167.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.08 148.9 21.61 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 124.398 1.079 . . . . 0.0 112.509 -176.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -97.22 157.07 16.13 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.111 1.765 . . . . 0.0 112.236 169.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -24.94 24.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 127.246 2.219 . . . . 0.0 115.336 -169.067 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -79.65 5.75 12.42 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.984 1.714 . . . . 0.0 111.597 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.19 36.81 6.15 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 126.049 1.785 . . . . 0.0 113.2 171.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.27 138.39 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 117.31 2.337 . . . . 0.0 117.31 -172.177 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -118.93 93.07 3.97 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.72 2.008 . . . . 0.0 110.696 168.354 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -85.59 95.44 9.33 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-O 122.491 1.139 . . . . 0.0 110.665 172.271 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.75 152.89 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.513 -170.543 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.2 p -155.14 109.83 2.98 Favored 'General case' 0 CA--C 1.541 0.634 0 O-C-N 120.963 -1.086 . . . . 0.0 112.21 175.115 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.83 160.31 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 127.722 2.409 . . . . 0.0 110.12 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -134.32 141.14 46.82 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 164.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -144.59 152.38 40.43 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.528 1.131 . . . . 0.0 112.116 178.519 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.7 p -117.42 59.32 0.78 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.546 1.538 . . . . 0.0 111.654 -169.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -157.24 -42.09 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 174.034 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -79.21 154.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 O-C-N 121.883 -0.511 . . . . 0.0 110.628 169.353 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 9.2 p -155.26 170.37 22.03 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.329 1.052 . . . . 0.0 111.05 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 106' ' ' LEU . . . . . 0.456 HD13 ' HB2' ' B' ' 22' ' ' GLN . 10.1 mp -86.56 55.53 3.59 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.092 -1.005 . . . . 0.0 111.649 -173.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.1 t -90.47 12.81 17.43 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 116.876 2.176 . . . . 0.0 116.876 -169.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.22 -38.65 3.19 Favored Glycine 0 N--CA 1.475 1.235 0 N-CA-C 118.695 2.238 . . . . 0.0 118.695 167.232 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -107.16 -105.46 0.34 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.541 1.136 . . . . 0.0 110.572 -166.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -76.23 11.77 1.41 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 126.187 1.795 . . . . 0.0 113.363 175.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 9.7 p -84.12 -158.35 0.32 Allowed 'General case' 0 CA--C 1.553 1.086 0 C-N-CA 127.013 2.125 . . . . 0.0 114.13 -175.788 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' B' ' 115' ' ' ARG 0.39 8.1 pt -83.23 -9.39 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 O-C-N 119.666 -1.896 . . . . 0.0 114.234 168.284 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.5 mm -98.36 151.18 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 161.283 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 95.1 -41.12 2.56 Favored Glycine 0 N--CA 1.468 0.811 0 C-N-CA 124.342 0.973 . . . . 0.0 113.033 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 115' ' ' ARG . . . . . 0.512 HH21 ' HB2' ' B' ' 117' ' ' LEU . 0.2 OUTLIER -75.13 -179.56 4.45 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 127.49 2.316 . . . . 0.0 115.604 -169.579 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.1 t -103.43 176.18 5.23 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 127.437 2.295 . . . . 0.0 113.065 169.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.512 ' HB2' HH21 ' B' ' 115' ' ' ARG . 33.9 tp -152.95 144.99 23.76 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.157 2.183 . . . . 0.0 110.363 170.071 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.45 150.2 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 O-C-N 123.284 0.365 . . . . 0.0 110.796 167.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.89 128.42 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 168.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -90.16 148.84 22.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.93 0.892 . . . . 0.0 112.518 -169.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.297 2.4 pp20? -77.51 -32.55 54.17 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.3 -0.875 . . . . 0.0 112.661 -174.689 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -90.54 169.07 11.34 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.322 -0.861 . . . . 0.0 110.061 165.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.72 149.65 34.8 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.125 0.97 . . . . 0.0 109.628 164.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -78.9 131.89 36.57 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 168.372 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -78.58 -11.05 59.94 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.178 0.991 . . . . 0.0 112.523 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mm? 70.25 -66.33 0.28 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 129.998 3.319 . . . . 0.0 111.339 -176.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 176.09 29.38 0.04 OUTLIER Glycine 0 N--CA 1.463 0.491 0 N-CA-C 116.171 1.228 . . . . 0.0 116.171 -169.19 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -126.12 -20.34 4.54 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 117.088 2.255 . . . . 0.0 117.088 -167.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.89 129.92 47.16 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 106.506 -2.638 . . . . 0.0 106.506 168.519 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -74.12 46.39 1.52 Allowed Glycine 0 N--CA 1.473 1.102 0 C-N-CA 126.387 1.946 . . . . 0.0 112.865 -171.224 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -103.23 -89.86 0.38 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.653 1.181 . . . . 0.0 110.947 -169.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 170.4 -76.66 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 131.213 3.805 . . . . 0.0 102.474 -167.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -35.66 -52.85 0.7 Allowed 'General case' 0 CA--C 1.54 0.584 1 C-N-CA 132.147 4.179 . . . . 0.0 112.92 171.628 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.6 m -47.37 -31.1 3.71 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 176.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.3 t -112.72 -8.03 13.79 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 119.449 1.022 . . . . 0.0 112.264 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 22.4 mmtp -84.25 -47.42 10.81 Favored 'General case' 0 CA--C 1.537 0.469 0 O-C-N 120.75 -1.219 . . . . 0.0 110.853 168.623 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 74.6 p -117.01 -34.17 4.49 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.786 1.634 . . . . 0.0 113.079 -173.271 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.13 2.89 31.59 Favored Glycine 0 N--CA 1.47 0.922 0 CA-C-O 118.353 -1.248 . . . . 0.0 113.805 -177.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 51.48 24.16 2.11 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 119.55 1.675 . . . . 0.0 114.168 177.145 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.09 20.08 0.08 Allowed 'General case' 0 CA--C 1.553 1.067 0 N-CA-C 115.748 1.759 . . . . 0.0 115.748 -166.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.8 -66.76 2.4 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 126.459 1.981 . . . . 0.0 114.288 173.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -175.69 -163.56 0.12 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.803 1.641 . . . . 0.0 109.532 -169.44 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.26 145.73 33.0 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 174.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -90.58 -103.84 0.1 Allowed 'General case' 0 CA--C 1.537 0.462 0 O-C-N 124.98 1.425 . . . . 0.0 107.557 170.398 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.03 147.22 50.35 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.443 0.697 . . . . 0.0 111.901 -177.505 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.33 151.76 51.71 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 127.093 2.157 . . . . 0.0 110.17 173.753 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.87 174.82 37.55 Favored Glycine 0 C--O 1.221 -0.678 0 N-CA-C 116.461 1.344 . . . . 0.0 116.461 -174.22 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -142.37 143.47 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.408 1.483 . . . . 0.0 109.502 -168.264 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.2 129.82 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -165.481 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.71 -155.66 7.12 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 125.232 1.396 . . . . 0.0 111.023 167.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.43 157.23 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.033 1.333 . . . . 0.0 113.285 -169.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.9 -41.1 14.25 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 161.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 . . . . . 0 CA--C 1.536 0.432 1 C-N-CA 132.764 4.425 . . . . 0.0 107.194 168.437 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.511 -0.536 0 CA-C-O 123.028 1.394 . . . . 0.0 111.345 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -87.8 107.1 18.5 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 166.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.02 167.48 12.06 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.537 1.535 . . . . 0.0 111.893 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' B' ' 52' ' ' ASP . 2.0 p -159.35 149.23 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.395 1.078 . . . . 0.0 112.013 -168.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.33 121.22 14.53 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.073 1.749 . . . . 0.0 108.918 167.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -103.71 99.16 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 167.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.2 mp -81.03 116.29 20.91 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -176.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 mtpt -144.77 157.55 44.13 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-N 119.272 0.942 . . . . 0.0 111.818 -172.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.45 -47.87 0.43 Allowed Glycine 0 N--CA 1.47 0.904 0 C-N-CA 126.505 2.002 . . . . 0.0 111.252 169.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.62 61.42 2.94 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 128.64 2.776 . . . . 0.0 112.344 -168.774 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.4 -99.81 0.02 OUTLIER Glycine 0 CA--C 1.534 1.266 0 C-N-CA 126.974 2.226 . . . . 0.0 112.904 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -82.11 -7.39 12.09 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.202 3.268 . . . . 0.0 114.867 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -86.42 136.07 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 121.244 1.838 . . . . 0.0 110.889 175.796 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.38 151.44 35.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 114.066 -1.424 . . . . 0.0 110.833 167.542 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -118.77 98.79 0.75 Allowed Glycine 0 C--O 1.22 -0.779 0 C-N-CA 125.485 1.517 . . . . 0.0 110.259 174.511 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -91.38 110.84 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 108.382 -0.969 . . . . 0.0 108.382 171.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.431 HD13 ' CE1' ' A' ' 20' ' ' PHE . 1.8 pp -127.09 155.19 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-O 122.037 0.922 . . . . 0.0 110.713 168.091 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -130.96 156.2 45.51 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.476 1.51 . . . . 0.0 109.849 169.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' CE1' HD13 ' A' ' 18' ' ' ILE . 7.8 m-85 -123.8 120.51 32.85 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.001 1.32 . . . . 0.0 108.651 168.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -98.44 119.86 37.86 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.246 1.018 . . . . 0.0 110.118 172.819 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.95 170.47 16.05 Favored 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 166.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.93 -46.88 0.53 Allowed 'General case' 0 CA--C 1.558 1.253 0 C-N-CA 128.135 2.574 . . . . 0.0 110.166 168.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.6 mp0 -81.68 116.1 21.24 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 120.456 1.48 . . . . 0.0 111.964 173.514 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -68.6 -9.69 51.22 Favored 'General case' 0 CA--C 1.552 1.047 0 O-C-N 119.223 -2.173 . . . . 0.0 114.439 -174.402 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -110.78 -2.94 15.97 Favored 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 127.22 2.208 . . . . 0.0 114.542 174.004 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.27 175.99 38.32 Favored Glycine 0 CA--C 1.542 1.734 0 CA-C-O 118.848 -0.973 . . . . 0.0 113.756 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -77.77 163.17 29.2 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 124.731 3.62 . . . . 0.0 110.739 175.374 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.2 t -138.08 145.57 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.672 0.789 . . . . 0.0 112.165 -165.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.79 121.28 27.47 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.74 1.216 . . . . 0.0 111.425 169.766 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 94.6 t -101.16 133.47 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.852 2.061 . . . . 0.0 108.112 169.588 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -153.67 167.61 29.0 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.572 0.701 . . . . 0.0 112.658 171.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.51 -161.35 28.36 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 124.253 0.93 . . . . 0.0 113.432 172.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.8 p -154.35 118.98 4.87 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.519 0.727 . . . . 0.0 110.776 -169.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.496 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 2.2 mp -108.01 103.0 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.915 0.886 . . . . 0.0 109.019 -177.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -115.88 133.42 56.04 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.223 1.809 . . . . 0.0 111.934 -166.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.59 0.86 27.65 Favored Glycine 0 CA--C 1.536 1.399 0 C-N-CA 127.458 2.456 . . . . 0.0 113.26 -174.828 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 97.5 mt -70.57 162.74 28.31 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 118.508 1.154 . . . . 0.0 111.116 172.093 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.6 m -83.14 140.64 32.49 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 166.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -58.76 152.15 19.64 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.42 -172.67 29.17 Favored Glycine 0 CA--C 1.532 1.125 0 C-N-CA 124.241 0.924 . . . . 0.0 112.818 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -72.4 149.29 44.42 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.817 2.047 . . . . 0.0 112.329 -169.567 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -145.81 121.72 10.64 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.962 1.705 . . . . 0.0 110.14 173.288 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.62 147.76 23.46 Favored Glycine 0 N--CA 1.486 1.982 0 CA-C-N 119.992 1.269 . . . . 0.0 112.606 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -148.32 102.01 3.31 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 119.208 1.504 . . . . 0.0 112.408 -167.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m80 -150.27 169.86 20.35 Favored 'General case' 0 CA--C 1.52 -0.199 0 O-C-N 120.658 -1.276 . . . . 0.0 114.331 -168.489 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.6 m -75.73 129.93 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 113.608 -1.633 . . . . 0.0 109.871 166.105 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -80.86 137.71 36.18 Favored 'General case' 0 CA--C 1.551 0.986 0 N-CA-C 102.472 -3.159 . . . . 0.0 102.472 157.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -65.18 142.44 58.33 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -168.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 56.83 -169.05 0.1 Allowed 'General case' 0 C--O 1.241 0.623 0 C-N-CA 127.242 2.217 . . . . 0.0 113.898 175.802 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 54' ' ' THR . . . -136.69 5.71 3.76 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-O 116.78 -2.122 . . . . 0.0 113.525 -178.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG21 ' B' ' 5' ' ' VAL . 21.3 p-10 -77.91 48.6 0.72 Allowed 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 121.336 2.568 . . . . 0.0 110.404 169.324 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.574 ' HA ' HG21 ' B' ' 7' ' ' VAL . 0.2 OUTLIER 172.65 5.87 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 118.359 2.726 . . . . 0.0 118.359 -169.35 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 51' ' ' GLY . 43.4 p -31.37 -10.02 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.213 1 N-CA-C 124.607 5.04 . . . . 0.0 124.607 -167.497 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.02 35.67 0.06 Allowed 'General case' 0 CA--C 1.555 1.147 0 CA-C-N 123.504 2.865 . . . . 0.0 116.643 -169.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.1 -148.96 46.85 Favored Glycine 0 CA--C 1.526 0.734 0 O-C-N 120.784 -1.197 . . . . 0.0 111.617 172.301 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.3 p -64.42 -12.01 38.94 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 114.914 1.45 . . . . 0.0 114.914 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 p -80.01 -0.3 34.84 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.898 2.079 . . . . 0.0 112.833 178.763 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.1 m -155.87 177.49 11.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 127.655 2.382 . . . . 0.0 109.215 -176.55 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 77.1 -156.48 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 126.448 1.899 . . . . 0.0 113.96 172.563 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.2 -169.8 16.14 Favored Glycine 0 CA--C 1.541 1.674 0 C-N-CA 126.823 2.154 . . . . 0.0 114.931 -167.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -66.8 -177.03 0.83 Allowed 'Trans proline' 0 CA--C 1.539 0.761 1 C-N-CA 126.353 4.702 . . . . 0.0 113.588 177.709 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 114.26 21.88 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.625 1.17 . . . . 0.0 112.932 -170.514 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.424 ' CD2' ' HD3' ' A' ' 66' ' ' PRO . 8.8 t80 -41.43 128.44 3.07 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 127.385 2.274 . . . . 0.0 115.089 -169.616 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -112.0 45.92 0.27 Allowed Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 125.653 1.581 . . . . 0.0 114.281 -173.428 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.424 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 62.4 Cg_endo -69.15 -17.69 40.22 Favored 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 123.236 2.624 . . . . 0.0 111.722 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.5 mt -76.46 -7.14 54.49 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.201 1.4 . . . . 0.0 111.417 171.225 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.3 t 73.48 56.89 0.11 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 127.167 2.187 . . . . 0.0 112.267 171.754 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.16 172.45 16.92 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 116.52 2.044 . . . . 0.0 116.52 -167.588 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 15.2 mmtp -82.57 173.81 11.62 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 127.149 2.18 . . . . 0.0 112.167 171.081 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.4 t60 -72.58 165.07 25.41 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.034 1.733 . . . . 0.0 113.616 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.46 -140.53 8.59 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 124.984 1.278 . . . . 0.0 114.499 167.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.566 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.87 -86.14 0.29 Allowed Glycine 0 CA--C 1.533 1.205 0 C-N-CA 126.287 1.898 . . . . 0.0 115.617 174.026 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -61.21 -9.77 13.58 Favored 'Trans proline' 0 CA--C 1.539 0.728 0 C-N-CA 124.748 3.632 . . . . 0.0 116.001 -169.593 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.34 -7.98 2.58 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.936 0.894 . . . . 0.0 112.767 167.562 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.566 ' HB3' ' H ' ' A' ' 73' ' ' GLY 0.314 0.0 OUTLIER -93.04 175.19 6.88 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -164.699 . . . . . . . . 4 4 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 56.0 mp0 -103.21 -22.95 13.66 Favored 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 131.391 3.876 . . . . 0.0 111.46 -168.391 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.418 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 2.9 mm-40 -105.94 -114.93 0.25 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 127.464 2.306 . . . . 0.0 110.132 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 103.27 119.18 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 130.892 3.677 . . . . 0.0 112.856 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.4 m170 -65.44 -176.87 0.36 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 126.388 1.875 . . . . 0.0 114.451 169.787 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.5 p -84.58 143.79 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 120.762 -1.212 . . . . 0.0 108.636 166.091 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.2 -2.52 9.25 Favored Glycine 0 CA--C 1.54 1.607 0 N-CA-C 117.455 1.742 . . . . 0.0 117.455 172.669 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -77.35 85.43 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-N 120.486 2.143 . . . . 0.0 109.553 167.163 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.0 mt -82.55 54.83 2.75 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.29 -176.736 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.47 -135.95 29.54 Favored Glycine 0 CA--C 1.528 0.859 0 C-N-CA 125.172 1.368 . . . . 0.0 114.386 170.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -136.86 145.0 43.88 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.058 0.943 . . . . 0.0 111.325 175.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -93.51 107.1 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 126.333 1.853 . . . . 0.0 109.579 176.469 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.2 m -99.9 113.89 26.75 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.677 1.191 . . . . 0.0 109.187 -175.444 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.03 158.26 15.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.896 1.679 . . . . 0.0 114.05 -171.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.39 -173.09 3.67 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.265 1.426 . . . . 0.0 112.597 169.229 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -83.7 -13.55 53.82 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 116.615 2.08 . . . . 0.0 116.615 176.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -75.36 -7.73 54.78 Favored 'General case' 0 CA--C 1.561 1.388 0 CA-C-O 122.845 1.307 . . . . 0.0 108.005 163.174 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.02 8.94 56.5 Favored Glycine 0 C--N 1.339 0.733 0 C-N-CA 128.26 2.838 . . . . 0.0 113.258 168.637 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 125.43 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 119.058 1.429 . . . . 0.0 113.839 -169.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 100.21 12.14 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 166.123 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -89.89 134.01 34.44 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.415 1.486 . . . . 0.0 109.099 177.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -141.31 137.42 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -167.277 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.3 p -153.59 119.5 5.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 125.757 1.623 . . . . 0.0 110.413 169.33 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.8 mt -147.15 147.47 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 C-N-CA 128.646 2.779 . . . . 0.0 110.358 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -118.02 130.81 56.4 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.895 2.078 . . . . 0.0 105.98 167.057 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -139.36 134.38 32.41 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.853 0.861 . . . . 0.0 112.186 -172.236 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -114.69 46.46 1.4 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.175 1.176 . . . . 0.0 114.175 -179.164 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.57 7.11 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 C-N-CA 123.672 0.789 . . . . 0.0 112.865 167.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -133.33 161.37 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 C-N-CA 124.821 1.248 . . . . 0.0 109.056 168.614 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.3 p -148.61 162.32 39.92 Favored 'General case' 0 C--O 1.239 0.53 0 O-C-N 121.495 -0.753 . . . . 0.0 109.726 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -90.08 70.25 7.34 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 122.887 1.327 . . . . 0.0 109.39 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.6 t -106.69 142.85 35.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 114.296 -1.32 . . . . 0.0 109.343 168.219 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.21 10.93 52.14 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 127.573 2.511 . . . . 0.0 118.796 -165.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -129.31 -74.75 0.56 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.833 1.816 . . . . 0.0 110.292 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -95.26 -9.54 32.88 Favored 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.292 1.96 . . . . 0.0 116.292 -169.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 65.2 m -92.39 -123.54 0.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 CA-C-N 120.064 1.302 . . . . 0.0 113.66 -171.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.0 pt -115.95 14.86 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 119.61 -1.931 . . . . 0.0 115.727 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.8 mm -83.52 145.07 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 O-C-N 120.775 -1.203 . . . . 0.0 108.301 167.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 62.81 27.48 70.16 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 114.936 0.734 . . . . 0.0 114.936 168.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -106.3 153.8 21.66 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.471 1.108 . . . . 0.0 109.27 179.199 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 49.7 m -95.77 86.96 4.52 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.334 -0.854 . . . . 0.0 111.16 -167.237 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.8 tp -76.3 145.59 39.49 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-N 122.193 2.27 . . . . 0.0 113.457 -168.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.8 p -133.45 152.58 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 C-N-CA 126.751 2.021 . . . . 0.0 112.686 177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -112.85 133.05 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 124.33 1.052 . . . . 0.0 108.216 164.521 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -89.61 152.75 21.23 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-O 122.292 1.044 . . . . 0.0 113.075 -176.092 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -68.01 -29.35 68.34 Favored 'General case' 0 N--CA 1.473 0.707 0 O-C-N 120.46 -1.4 . . . . 0.0 114.754 -174.387 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -119.8 169.56 10.02 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.976 1.31 . . . . 0.0 112.285 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -49.37 148.07 2.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.58 1.152 . . . . 0.0 110.555 169.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -96.45 133.45 40.86 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 123.647 0.592 . . . . 0.0 109.77 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -84.78 -13.89 49.83 Favored 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 125.44 1.496 . . . . 0.0 113.464 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 65.1 -38.34 0.25 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 130.817 3.647 . . . . 0.0 114.327 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.96 -32.6 0.05 OUTLIER Glycine 0 CA--C 1.519 0.281 0 CA-C-N 119.579 1.081 . . . . 0.0 115.343 170.131 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.78 69.69 0.99 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 117.379 2.363 . . . . 0.0 117.379 -172.47 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -79.55 -68.29 1.5 Allowed Glycine 0 N--CA 1.461 0.346 0 N-CA-C 106.27 -2.732 . . . . 0.0 106.27 164.732 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 174.65 21.31 0.02 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 124.819 1.199 . . . . 0.0 115.068 -178.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -149.23 161.79 41.32 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 119.374 1.587 . . . . 0.0 110.095 -179.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 35.1 tp10 -69.34 -45.9 68.35 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.905 1.282 . . . . 0.0 111.786 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -45.39 -35.25 3.51 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.775 1.23 . . . . 0.0 113.417 176.16 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 33.4 t -58.7 -56.81 17.44 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 169.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.292 0.0 OUTLIER -66.53 -9.72 37.66 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 123.98 0.912 . . . . 0.0 111.184 -178.013 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 48.7 mtmt -93.41 -50.45 5.44 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 119.333 0.969 . . . . 0.0 113.285 167.67 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 68.6 p -113.36 -24.38 9.36 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 -166.245 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.14 -3.08 47.55 Favored Glycine 0 C--O 1.22 -0.729 0 C-N-CA 125.203 1.383 . . . . 0.0 112.545 -168.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 54.66 16.04 1.25 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.898 1.679 . . . . 0.0 113.279 -177.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.59 27.27 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.763 2.025 . . . . 0.0 115.735 -165.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.7 -75.05 2.42 Favored Glycine 0 C--N 1.338 0.694 0 C-N-CA 127.254 2.359 . . . . 0.0 113.361 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.4 t -170.21 -150.31 0.08 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.546 1.138 . . . . 0.0 110.442 -171.184 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.89 123.5 47.18 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.366 1.067 . . . . 0.0 110.891 -173.478 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.489 HD23 ' H ' ' A' ' 145' ' ' ALA . 1.7 tt -96.2 -137.4 0.25 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.86 2.064 . . . . 0.0 106.257 168.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.489 ' H ' HD23 ' A' ' 144' ' ' LEU . . . -61.15 151.03 32.38 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 125.049 1.34 . . . . 0.0 112.375 -176.537 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -148.04 142.95 26.86 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 114.836 -1.074 . . . . 0.0 113.846 -172.336 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.23 114.88 0.63 Allowed Glycine 0 CA--C 1.528 0.9 0 C-N-CA 125.386 1.469 . . . . 0.0 113.039 -176.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 0.5 OUTLIER -74.41 135.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.387 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 37.9 mt -74.98 124.35 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.055 0.542 . . . . 0.0 111.885 -167.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.08 -175.28 17.38 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 124.834 1.207 . . . . 0.0 113.27 173.087 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -124.83 152.12 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 126.581 1.953 . . . . 0.0 111.997 173.351 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.13 -8.19 2.31 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -178.237 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tm0? . . . . . 0 C--O 1.236 0.349 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 169.17 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.556 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -84.62 74.08 10.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 105.604 -1.998 . . . . 0.0 105.604 168.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ptpm? -76.01 121.58 22.96 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.39 -0.819 . . . . 0.0 110.328 -170.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.59 152.71 22.1 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.203 1.001 . . . . 0.0 110.939 -177.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.511 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -145.87 129.91 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.082 0.944 . . . . 0.0 111.288 -167.503 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.421 ' HB2' HG13 ' B' ' 149' ' ' ILE . . . -104.44 134.84 46.96 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.306 -1.315 . . . . 0.0 107.863 168.414 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.574 HG21 ' HA ' ' A' ' 53' ' ' ASN . 93.2 t -116.88 115.64 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 167.099 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -95.8 96.7 9.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 126.222 1.809 . . . . 0.0 108.942 -169.352 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -158.21 124.58 4.74 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.736 0.814 . . . . 0.0 110.233 175.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.25 -101.62 2.59 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 105.876 -2.89 . . . . 0.0 105.876 165.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -144.35 109.25 4.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 125.274 1.43 . . . . 0.0 109.702 -169.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.6 167.38 11.44 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 125.446 1.498 . . . . 0.0 111.648 -175.098 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -73.67 25.57 0.32 Allowed 'Trans proline' 0 CA--C 1.544 1.019 1 C-N-CA 125.361 4.041 . . . . 0.0 114.963 -170.126 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -122.68 119.83 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 119.605 1.093 . . . . 0.0 109.096 -178.677 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -158.66 158.15 33.22 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 114.684 -1.144 . . . . 0.0 112.357 -178.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.2 177.02 36.82 Favored Glycine 0 CA--C 1.506 -0.479 0 C-N-CA 124.843 1.211 . . . . 0.0 114.069 176.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -120.61 148.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 112.993 -1.603 . . . . 0.0 109.742 168.382 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.0 mm -128.81 130.84 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 166.301 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -100.41 141.84 32.71 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 126.31 1.844 . . . . 0.0 110.809 168.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -120.93 104.92 10.2 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.262 2.225 . . . . 0.0 108.845 171.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -99.78 103.18 14.79 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.842 0.857 . . . . 0.0 110.905 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -105.62 136.68 44.76 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 122.145 0.974 . . . . 0.0 109.27 169.208 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 16.6 pttp -98.71 -24.52 15.01 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 124.992 1.317 . . . . 0.0 113.692 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -163.93 134.84 4.47 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.061 2.144 . . . . 0.0 107.957 -164.294 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.5 p -51.83 -28.62 16.36 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 126.01 1.724 . . . . 0.0 114.873 -170.195 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -109.26 -6.18 15.63 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.558 1.543 . . . . 0.0 113.381 -176.052 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -88.22 165.97 34.69 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.86 1.219 . . . . 0.0 111.726 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.32 168.82 21.18 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.041 2.494 . . . . 0.0 111.902 -176.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.27 124.36 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 C-N-CA 123.828 0.851 . . . . 0.0 109.262 176.7 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -81.54 128.59 34.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.625 -0.672 . . . . 0.0 109.427 169.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 63.2 t -108.81 127.09 65.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 126.093 1.757 . . . . 0.0 109.261 179.595 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -151.37 163.07 39.77 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 121.573 -0.705 . . . . 0.0 112.266 170.282 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.84 -166.24 33.37 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 123.702 0.668 . . . . 0.0 112.657 174.229 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.4 p -152.9 128.01 9.73 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 122.97 0.508 . . . . 0.0 111.665 -169.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 31.3 mt -118.72 124.77 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 125.019 1.328 . . . . 0.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -122.37 139.93 53.26 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 120.769 1.622 . . . . 0.0 111.595 -176.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.88 -0.51 9.17 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 127.863 2.649 . . . . 0.0 113.502 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 92.3 mt -75.73 170.3 16.45 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.16 1.384 . . . . 0.0 111.24 174.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.5 t -90.02 151.07 21.84 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 166.043 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -49.22 143.56 6.01 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.601 0.761 . . . . 0.0 111.513 171.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.32 -178.88 22.8 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 124.713 1.149 . . . . 0.0 113.239 -176.081 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.732 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.7 pt? -80.59 149.54 29.87 Favored 'General case' 0 CA--C 1.553 1.066 0 C-N-CA 128.739 2.816 . . . . 0.0 113.732 -172.132 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -154.17 126.3 7.84 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 128.594 2.758 . . . . 0.0 110.685 -170.136 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.06 160.85 41.93 Favored Glycine 0 N--CA 1.482 1.766 0 CA-C-N 121.162 1.801 . . . . 0.0 113.914 -177.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.476 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.285 0.2 OUTLIER -159.38 138.21 10.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 128.182 2.593 . . . . 0.0 114.867 168.68 . . . . . . . . 4 4 . 1 . 018 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 16.6 m80 -149.1 141.64 24.35 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 120.659 -1.276 . . . . 0.0 114.087 -169.112 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.02 106.94 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 126.768 2.027 . . . . 0.0 111.166 178.155 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.409 ' C ' ' H ' ' B' ' 50' ' ' PHE . 8.1 m170 -79.22 135.7 36.86 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.486 1.115 . . . . 0.0 110.732 -176.677 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -70.24 17.64 0.06 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.537 1.935 . . . . 0.0 112.513 171.205 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 50' ' ' PHE . . . . . 0.409 ' H ' ' C ' ' B' ' 48' ' ' HIS . 23.0 m-85 -144.07 92.66 2.35 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 126.427 1.891 . . . . 0.0 107.942 -167.507 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.29 7.73 66.78 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 116.967 -2.018 . . . . 0.0 111.012 167.442 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.691 ' HA ' HG21 ' A' ' 5' ' ' VAL . 4.9 m-20 -77.1 49.79 0.7 Allowed 'General case' 0 N--CA 1.481 1.094 0 CA-C-O 124.779 2.228 . . . . 0.0 110.357 -176.112 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 20.0 p30 170.84 27.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 128.201 2.601 . . . . 0.0 113.574 -165.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 35.4 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 120.184 3.402 . . . . 0.0 120.184 -170.527 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.85 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -116.72 -99.79 2.13 Favored Glycine 0 CA--C 1.545 1.923 0 C-N-CA 125.315 1.436 . . . . 0.0 114.243 -174.159 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -92.0 177.26 1.76 Allowed 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.856 3.704 . . . . 0.0 113.429 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -115.26 126.02 54.01 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.862 2.465 . . . . 0.0 110.919 -175.491 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -48.84 149.33 1.84 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 129.253 3.021 . . . . 0.0 116.571 -169.653 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -111.65 44.11 0.23 Allowed Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 127.305 2.242 . . . . 0.0 113.695 -172.289 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -63.05 -30.54 76.1 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.705 2.27 . . . . 0.0 113.825 -169.378 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.66 -3.95 43.6 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.012 0.925 . . . . 0.0 112.582 173.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.0 t 77.27 58.91 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 127.368 2.267 . . . . 0.0 111.616 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 ptt180 -163.4 177.52 8.84 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 117.341 2.349 . . . . 0.0 117.341 -167.624 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -64.99 169.91 4.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.202 3.001 . . . . 0.0 114.276 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 19.8 t-80 -107.2 146.68 31.08 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.712 2.005 . . . . 0.0 114.236 -169.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 126.92 -104.26 0.7 Allowed Glycine 0 N--CA 1.472 1.092 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 163.769 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.44 -35.62 3.55 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-O 116.367 -2.351 . . . . 0.0 118.271 167.594 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 14.43 0.85 Allowed 'Trans proline' 0 CA--C 1.549 1.251 0 CA-C-N 123.349 3.574 . . . . 0.0 113.153 168.183 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.49 -26.92 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 127.531 2.332 . . . . 0.0 110.847 169.662 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.32 0.0 OUTLIER -64.47 151.79 43.37 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 123.225 1.488 . . . . 0.0 113.774 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 60.4 mp0 -88.42 -10.36 49.47 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 111.241 -2.709 . . . . 0.0 114.358 -166.063 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -143.98 -53.57 0.34 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.411 1.005 . . . . 0.0 112.58 -169.185 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 80.52 125.18 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 127.446 2.299 . . . . 0.0 114.362 166.53 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.5 m170 -67.08 148.23 52.15 Favored 'General case' 0 CA--C 1.541 0.608 0 O-C-N 121.018 -1.051 . . . . 0.0 110.856 167.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -72.4 26.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 125.311 1.444 . . . . 0.0 113.781 171.591 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -154.03 23.45 0.69 Allowed Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.636 1.589 . . . . 0.0 114.864 -169.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -125.54 129.31 49.47 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 119.071 1.435 . . . . 0.0 110.048 -178.533 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 86.6 mt -107.77 41.9 1.44 Allowed 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.042 0.837 . . . . 0.0 110.711 168.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.97 -117.68 5.02 Favored Glycine 0 CA--C 1.537 1.439 0 O-C-N 120.476 -1.39 . . . . 0.0 113.436 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -140.27 146.98 39.29 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.46 1.504 . . . . 0.0 113.394 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.476 HG13 ' CE1' ' B' ' 45' ' ' PHE . 28.2 m -93.39 145.49 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 127.237 2.215 . . . . 0.0 110.247 169.446 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 2.7 m -110.55 125.53 53.45 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 119.466 1.03 . . . . 0.0 109.618 171.011 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.39 163.9 15.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.447 0.699 . . . . 0.0 112.546 169.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.29 178.72 4.97 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.851 1.661 . . . . 0.0 112.713 173.277 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.595 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -58.22 -29.49 65.75 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.646 1.978 . . . . 0.0 116.314 171.955 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.18 -10.87 59.83 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 119.731 1.15 . . . . 0.0 111.099 171.195 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.54 11.82 46.5 Favored Glycine 0 C--N 1.334 0.464 0 CA-C-O 116.88 -2.067 . . . . 0.0 113.865 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.0 p -98.4 125.52 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 119.476 1.638 . . . . 0.0 113.357 179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.0 100.35 12.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.43 1.492 . . . . 0.0 108.04 165.617 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -87.37 143.25 27.34 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.242 1.017 . . . . 0.0 109.506 170.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.45 144.21 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 116.445 2.017 . . . . 0.0 116.445 -176.604 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.4 m -156.24 111.97 2.99 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.567 1.947 . . . . 0.0 111.161 174.208 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 13.2 mt -143.54 163.97 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 130.011 3.324 . . . . 0.0 109.571 -169.446 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -145.3 146.15 31.52 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 126.478 1.911 . . . . 0.0 107.757 168.523 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -144.69 132.05 20.76 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.935 0.894 . . . . 0.0 110.112 -175.661 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.8 p -113.54 46.04 1.34 Allowed 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.889 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.11 1.83 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 124.025 0.93 . . . . 0.0 111.687 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.46 171.42 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 126.35 1.86 . . . . 0.0 109.953 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 42.1 m -158.0 174.26 15.51 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 120.837 -1.164 . . . . 0.0 111.222 176.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 93.2 mt -109.54 54.03 0.67 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 127.407 2.283 . . . . 0.0 109.415 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.7 t -112.78 34.97 4.08 Favored 'General case' 0 CA--C 1.551 1.011 0 N-CA-C 115.626 1.714 . . . . 0.0 115.626 -168.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.92 -29.2 3.08 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 119.237 2.455 . . . . 0.0 119.237 165.345 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.251 17.7 t70 -99.41 -109.29 0.19 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 118.522 1.161 . . . . 0.0 108.448 -167.668 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -81.76 10.3 6.45 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.569 2.347 . . . . 0.0 112.703 175.614 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 m -60.76 -175.39 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.175 2.59 . . . . 0.0 115.081 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.282 11.6 pt -88.63 -3.91 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 119.941 -1.724 . . . . 0.0 114.424 172.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.7 mm -64.84 131.14 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 166.735 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.18 10.52 62.45 Favored Glycine 0 CA--C 1.524 0.653 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.281 -178.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -78.99 170.17 17.1 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 119.918 1.859 . . . . 0.0 109.836 173.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 91.8 m -112.33 112.5 24.12 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 48.5 tp -92.6 103.95 16.29 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 124.42 1.075 . . . . 0.0 109.459 177.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 13.7 p -86.4 149.53 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 167.61 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 37.9 t -128.41 143.76 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 167.597 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -106.0 163.08 13.04 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 125.665 1.586 . . . . 0.0 113.115 -168.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -76.28 -42.34 45.83 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.225 -175.101 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -110.56 176.07 5.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.822 1.649 . . . . 0.0 109.956 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.4 -176.59 6.29 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.252 0.549 . . . . 0.0 109.599 165.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -110.26 159.04 17.75 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.83 2.052 . . . . 0.0 113.032 -166.309 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -73.47 -14.21 61.2 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.904 1.282 . . . . 0.0 111.205 170.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 70.5 mt 54.08 61.45 3.05 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.124 1.77 . . . . 0.0 111.948 172.02 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.48 -54.15 3.47 Favored Glycine 0 N--CA 1.462 0.431 0 C-N-CA 125.688 1.613 . . . . 0.0 111.474 170.485 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.4 ttpt -126.9 72.9 1.37 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.676 1.19 . . . . 0.0 113.238 -168.828 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 129' ' ' GLY . . . . . 0.437 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -83.56 -30.46 29.9 Favored Glycine 0 CA--C 1.534 1.274 0 C-N-CA 124.579 1.085 . . . . 0.0 112.429 169.677 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 120.8 32.36 1.11 Allowed Glycine 0 N--CA 1.472 1.08 0 C-N-CA 125.167 1.365 . . . . 0.0 113.561 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -153.4 -156.21 0.67 Allowed 'General case' 0 CA--C 1.554 1.121 0 C-N-CA 124.571 1.148 . . . . 0.0 109.644 -169.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -95.9 -52.47 4.05 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 120.765 1.621 . . . . 0.0 110.727 171.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -54.29 -28.53 42.61 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 127.774 2.43 . . . . 0.0 113.176 -172.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.437 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 88.9 p -57.56 -30.78 65.51 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 125.016 1.327 . . . . 0.0 112.453 174.583 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -107.07 -27.48 10.6 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 117.519 -1.229 . . . . 0.0 114.188 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.7 tptm -71.88 -24.14 61.62 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 120.994 1.725 . . . . 0.0 113.056 -176.076 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -133.54 -46.6 0.82 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 126.287 1.835 . . . . 0.0 110.78 167.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.81 -9.0 8.1 Favored Glycine 0 C--O 1.221 -0.701 0 C-N-CA 125.477 1.513 . . . . 0.0 110.479 -163.253 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 57.63 37.32 27.4 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 124.992 1.317 . . . . 0.0 112.166 176.527 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.04 30.06 0.11 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 115.069 1.507 . . . . 0.0 115.069 -169.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.58 -57.27 2.52 Favored Glycine 0 N--CA 1.47 0.962 0 C-N-CA 127.539 2.495 . . . . 0.0 114.44 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.1 t -174.79 172.05 3.04 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.3 1.84 . . . . 0.0 110.479 -174.202 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.431 ' HD3' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -82.67 157.28 23.42 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 121.173 -0.954 . . . . 0.0 111.599 170.631 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -128.84 -97.58 0.38 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 124.546 1.138 . . . . 0.0 108.402 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -95.65 162.26 13.69 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.355 1.062 . . . . 0.0 111.242 174.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 p -158.5 155.9 29.3 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.788 1.235 . . . . 0.0 113.277 173.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.52 176.12 35.5 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 126.176 1.846 . . . . 0.0 112.362 171.246 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 76.7 t -107.3 157.29 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-N 118.247 1.024 . . . . 0.0 108.318 168.45 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.421 HG13 ' HB2' ' B' ' 6' ' ' ALA . 3.3 mt -87.24 110.85 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 123.886 0.874 . . . . 0.0 110.964 176.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -105.54 -165.47 23.56 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.554 1.549 . . . . 0.0 111.686 168.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -136.74 158.65 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 114.358 1.244 . . . . 0.0 114.358 -169.438 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -142.41 -19.61 0.69 Allowed 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 170.679 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.48 1.038 0 C-N-CA 125.317 1.447 . . . . 0.0 111.965 176.946 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 CA--C 1.512 -0.517 0 CA-C-O 122.772 1.272 . . . . 0.0 108.158 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.2 mtmm -98.91 132.66 44.07 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 112.616 -2.084 . . . . 0.0 113.924 171.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.62 168.7 13.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.029 0.932 . . . . 0.0 111.989 171.292 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.41 97.9 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 168.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -94.6 136.95 34.32 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 121.354 -0.842 . . . . 0.0 110.377 173.16 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.418 ' HB ' HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -134.38 130.48 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 C-N-CA 124.164 0.986 . . . . 0.0 110.44 -176.891 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -116.31 145.45 43.18 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.589 2.356 . . . . 0.0 110.6 172.452 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.74 160.17 40.32 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.292 1.037 . . . . 0.0 113.158 168.598 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.3 161.86 25.0 Favored Glycine 0 CA--C 1.525 0.708 0 C-N-CA 127.246 2.355 . . . . 0.0 107.901 168.187 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -76.62 59.46 1.52 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.298 1.439 . . . . 0.0 113.629 -177.381 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.58 -163.17 35.79 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 126.732 2.111 . . . . 0.0 110.194 -176.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -77.27 32.52 0.43 Allowed 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 125.041 3.827 . . . . 0.0 112.698 -173.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 t -114.24 124.09 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 C-N-CA 125.525 1.53 . . . . 0.0 108.58 -174.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mp0 -141.44 156.7 45.75 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 124.283 1.033 . . . . 0.0 110.284 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.56 139.93 10.87 Favored Glycine 0 CA--C 1.503 -0.695 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.133 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.8 125.76 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 117.354 0.577 . . . . 0.0 109.613 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.1 mm -133.74 122.72 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -111.41 101.18 9.65 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-O 122.537 1.16 . . . . 0.0 109.614 169.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -77.58 138.58 39.23 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.823 1.649 . . . . 0.0 108.574 176.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -110.21 121.65 45.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 119.845 1.202 . . . . 0.0 111.168 166.1 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.477 ' HB2' HD13 ' A' ' 106' ' ' LEU . 19.3 tp60 -82.48 128.59 34.42 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 163.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.59 -38.7 62.56 Favored 'General case' 0 CA--C 1.544 0.735 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 179.275 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -104.19 -129.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 129.653 3.181 . . . . 0.0 111.675 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.9 t -143.51 14.67 1.79 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.824 2.45 . . . . 0.0 110.209 167.693 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -168.07 -0.17 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 126.014 1.726 . . . . 0.0 115.426 -166.572 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.28 -151.58 11.49 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 125.849 1.69 . . . . 0.0 112.152 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -71.61 173.26 12.82 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 124.24 3.293 . . . . 0.0 113.616 -175.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -142.9 141.84 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.463 1.105 . . . . 0.0 110.872 -174.171 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.2 tttp -101.7 121.8 42.73 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 167.569 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.2 t -104.01 114.52 43.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 125.574 1.549 . . . . 0.0 108.581 -177.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.6 p90 -138.55 156.32 47.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 122.308 1.051 . . . . 0.0 113.035 177.243 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.02 -164.49 27.53 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.465 1.507 . . . . 0.0 111.361 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 88.7 p -158.1 160.22 37.1 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.049 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.1 mm -120.14 120.54 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 C-N-CA 124.597 1.159 . . . . 0.0 112.023 176.029 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.0 mmtt -104.95 152.13 23.06 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.386 1.474 . . . . 0.0 111.684 -174.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.35 -0.35 53.79 Favored Glycine 0 N--CA 1.475 1.288 0 C-N-CA 125.243 1.402 . . . . 0.0 114.435 174.098 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -83.85 173.5 11.19 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 126.467 1.907 . . . . 0.0 112.612 178.227 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.3 t -81.8 175.59 10.3 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 160.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.53 -175.8 0.14 Allowed 'General case' 0 CA--C 1.557 1.249 0 CA-C-O 122.44 1.114 . . . . 0.0 113.497 175.075 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.32 -179.69 45.44 Favored Glycine 0 CA--C 1.533 1.202 0 O-C-N 120.478 -1.389 . . . . 0.0 114.478 173.415 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.415 ' H ' HD12 ' A' ' 42' ' ' LEU . 5.8 mp -61.96 142.37 57.49 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 127.46 2.304 . . . . 0.0 111.359 -178.53 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -143.53 117.8 9.59 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 126.864 2.066 . . . . 0.0 109.442 176.042 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.14 141.87 47.71 Favored Glycine 0 N--CA 1.478 1.491 0 CA-C-N 120.038 1.29 . . . . 0.0 111.484 -179.07 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.277 0.1 OUTLIER -150.95 130.52 13.03 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 118.966 1.383 . . . . 0.0 111.839 174.403 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.87 143.65 26.4 Favored 'General case' 0 CA--C 1.535 0.366 0 O-C-N 121.278 -0.889 . . . . 0.0 111.917 -164.863 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -98.0 105.81 17.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.874 1.669 . . . . 0.0 108.5 -178.549 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -74.45 144.86 44.05 Favored 'General case' 0 C--N 1.322 -0.617 0 O-C-N 121.548 -0.72 . . . . 0.0 109.325 175.372 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -46.89 132.56 11.52 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 167.011 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.51 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 77.35 146.02 0.09 Allowed 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 124.729 2.204 . . . . 0.0 114.14 174.006 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.14 6.69 11.93 Favored Glycine 0 N--CA 1.466 0.69 0 C-N-CA 126.714 2.102 . . . . 0.0 111.788 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -76.89 42.89 0.32 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.648 1.579 . . . . 0.0 109.658 168.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 168.95 42.45 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 125.314 1.446 . . . . 0.0 113.638 -164.567 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -63.38 -4.69 2.84 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 116.23 1.937 . . . . 0.0 116.23 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.85 30.26 1.62 Allowed 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 120.381 1.446 . . . . 0.0 112.527 -171.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.37 -139.75 45.94 Favored Glycine 0 N--CA 1.466 0.642 0 O-C-N 120.828 -1.17 . . . . 0.0 111.509 171.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.6 p -52.57 -31.77 37.71 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 176.787 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.2 t -87.16 43.43 1.1 Allowed 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.415 1.462 . . . . 0.0 112.225 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.5 p -179.87 -32.64 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 127.411 2.285 . . . . 0.0 113.755 172.596 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -143.46 139.5 29.92 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 120.151 1.341 . . . . 0.0 113.62 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.35 -115.61 0.93 Allowed Glycine 0 CA--C 1.544 1.864 0 CA-C-O 117.952 -1.471 . . . . 0.0 113.559 -175.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.12 -179.69 5.48 Favored 'Trans proline' 0 C--N 1.348 0.532 1 C-N-CA 125.634 4.223 . . . . 0.0 112.689 -178.615 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -81.57 71.73 8.59 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.429 1.092 . . . . 0.0 109.97 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -43.71 140.52 1.82 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.519 1.528 . . . . 0.0 111.469 170.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -158.18 155.11 25.4 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 117.774 -1.108 . . . . 0.0 112.668 170.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -73.04 -10.94 25.08 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.082 1.855 . . . . 0.0 114.341 -172.435 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -87.68 -10.14 52.14 Favored 'General case' 0 CA--C 1.542 0.658 0 CA-C-N 119.834 1.197 . . . . 0.0 113.464 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.2 t 49.55 49.46 19.89 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.804 1.641 . . . . 0.0 114.166 175.272 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.1 mtm-85 -99.03 176.45 5.57 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 126.071 1.749 . . . . 0.0 113.435 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -76.89 168.38 20.19 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 126.59 1.956 . . . . 0.0 109.428 165.149 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -84.05 159.71 21.11 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 124.001 0.921 . . . . 0.0 113.386 -173.868 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.15 -134.67 5.84 Favored Glycine 0 C--N 1.341 0.816 0 N-CA-C 114.697 0.639 . . . . 0.0 114.697 167.544 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 124.33 -92.02 0.43 Allowed Glycine 0 CA--C 1.541 1.689 0 CA-C-O 118.59 -1.117 . . . . 0.0 113.94 -169.366 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.88 6.63 0.15 Allowed 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 123.8 3.0 . . . . 0.0 117.453 -175.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.257 0.0 OUTLIER -155.93 7.39 0.22 Allowed 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 127.344 2.258 . . . . 0.0 113.379 169.443 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.21 167.79 18.58 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.775 2.43 . . . . 0.0 110.153 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -111.19 -15.51 13.64 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.498 1.919 . . . . 0.0 112.542 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -78.22 -69.49 0.55 Allowed 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.241 1.016 . . . . 0.0 111.014 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 59.25 109.49 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.701 1.6 . . . . 0.0 112.31 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 27.1 m170 -59.03 148.37 31.11 Favored 'General case' 0 CA--C 1.544 0.717 0 O-C-N 119.205 -2.184 . . . . 0.0 110.348 167.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.5 t -79.22 54.33 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-O 123.769 1.747 . . . . 0.0 109.099 166.79 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.09 20.05 0.09 OUTLIER Glycine 0 CA--C 1.542 1.752 0 C-N-CA 128.87 3.129 . . . . 0.0 114.306 -179.088 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -122.29 130.13 52.86 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.006 2.403 . . . . 0.0 113.854 -175.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 74.4 mt -113.52 45.47 1.42 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.491 0.716 . . . . 0.0 110.78 168.734 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.45 -124.85 6.89 Favored Glycine 0 CA--C 1.534 1.269 0 O-C-N 121.41 -0.806 . . . . 0.0 113.17 -176.48 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -129.19 144.07 51.08 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.067 0.947 . . . . 0.0 111.545 173.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 95' ' ' ALA . 7.1 p -95.27 130.92 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 C-N-CA 125.602 1.561 . . . . 0.0 108.988 173.516 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.0 m -113.23 138.14 50.43 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 123.683 0.793 . . . . 0.0 112.175 -167.594 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.61 145.11 40.96 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 118.354 2.724 . . . . 0.0 118.354 -166.408 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -86.35 157.01 19.98 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 128.958 2.903 . . . . 0.0 111.314 169.241 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -47.42 -23.29 0.57 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 128.215 2.606 . . . . 0.0 117.155 176.314 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -76.45 3.65 10.76 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 119.844 1.202 . . . . 0.0 111.579 175.301 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.66 37.53 52.03 Favored Glycine 0 C--N 1.337 0.6 0 C-N-CA 125.23 1.395 . . . . 0.0 111.843 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -124.27 122.48 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.409 1.084 . . . . 0.0 110.621 176.282 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -84.3 118.11 23.99 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.427 1.491 . . . . 0.0 109.311 169.509 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.08 145.14 25.19 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.951 0.9 . . . . 0.0 112.079 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.82 138.17 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-N 114.001 -1.454 . . . . 0.0 114.823 169.423 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 m -155.27 62.27 0.63 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 127.058 2.143 . . . . 0.0 110.002 179.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.1 mt -95.58 154.56 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.346 1.858 . . . . 0.0 111.386 -176.178 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -133.35 143.25 48.86 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 125.437 1.495 . . . . 0.0 108.461 168.706 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -156.25 149.66 24.59 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.487 1.115 . . . . 0.0 112.572 -169.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.1 p -119.26 53.55 1.02 Allowed 'General case' 0 CA--C 1.542 0.65 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.639 178.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.0 t -138.84 -42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.154 0.982 . . . . 0.0 111.686 174.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -85.88 156.07 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 119.301 0.955 . . . . 0.0 112.099 174.382 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -151.45 147.49 26.92 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 124.409 1.084 . . . . 0.0 111.052 177.616 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.479 HD12 HD11 ' A' ' 112' ' ' ILE . 7.3 mp -78.39 57.21 1.88 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 120.836 -1.165 . . . . 0.0 109.308 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.6 m -130.31 15.96 5.55 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.887 1.275 . . . . 0.0 113.749 -168.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.7 -170.17 28.45 Favored Glycine 0 N--CA 1.44 -1.042 0 CA-C-O 124.853 2.363 . . . . 0.0 116.28 167.233 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.29 -51.74 64.85 Favored 'General case' 0 C--N 1.311 -1.083 1 CA-C-N 108.143 -4.029 . . . . 0.0 111.239 -168.72 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -79.76 4.14 17.25 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.419 1.087 . . . . 0.0 112.977 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.7 t -108.62 -93.29 0.41 Allowed 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.13 0.972 . . . . 0.0 111.476 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.479 HD11 HD12 ' A' ' 106' ' ' LEU . 10.9 pt -141.66 5.76 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 40.3 mm -84.13 119.5 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.404 -1.435 . . . . 0.0 107.733 171.239 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.97 30.54 72.25 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 117.915 -1.492 . . . . 0.0 113.664 -178.129 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.9 mmt-85 -86.88 145.85 26.42 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 120.527 2.163 . . . . 0.0 111.268 173.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 39.1 m -89.95 104.91 17.43 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 119.539 1.063 . . . . 0.0 111.499 177.715 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 15.5 tp -85.64 112.49 21.04 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.626 0.771 . . . . 0.0 110.642 173.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 9.9 p -92.46 148.18 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 118.953 -0.546 . . . . 0.0 109.714 169.054 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.48 134.08 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 122.262 1.029 . . . . 0.0 109.346 166.193 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.7 ' CE1' ' HE ' ' A' ' 143' ' ' ARG . 18.5 m-70 -109.84 152.57 25.58 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 126.111 1.764 . . . . 0.0 111.617 -169.431 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -79.48 -17.47 54.09 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 116.768 2.136 . . . . 0.0 116.768 -164.454 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.27 173.38 8.84 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 120.079 -1.638 . . . . 0.0 113.432 173.004 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.87 157.52 1.21 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.323 1.849 . . . . 0.0 112.439 172.251 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -97.79 131.35 44.38 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.974 0.892 . . . . 0.0 111.073 -176.273 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -26.6 62.38 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.53 1.932 . . . . 0.0 112.788 177.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.1 mt 54.09 53.63 10.81 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.917 1.687 . . . . 0.0 113.028 171.3 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.23 -25.37 27.33 Favored Glycine 0 N--CA 1.468 0.803 0 CA-C-O 118.218 -1.324 . . . . 0.0 114.99 170.795 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.354 6.4 mtmt -167.24 121.29 1.0 Allowed 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 164.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -143.53 -56.27 0.03 OUTLIER Glycine 0 CA--C 1.532 1.104 1 C-N-CA 131.177 4.227 . . . . 0.0 108.16 167.377 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -85.42 -93.18 0.8 Allowed Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.904 1.716 . . . . 0.0 114.032 177.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.541 ' CG ' ' H ' ' A' ' 132' ' ' GLU 0.27 0.8 OUTLIER -147.3 -96.69 0.09 Allowed 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 117.076 -1.44 . . . . 0.0 112.703 -169.3 . . . . . . . . 4 4 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.541 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 11.0 tt0 -111.97 -30.56 7.22 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 121.565 1.984 . . . . 0.0 114.396 170.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -61.36 -21.6 64.17 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.468 -2.02 . . . . 0.0 112.216 177.357 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.2 p -56.6 -25.55 53.14 Favored 'General case' 0 CA--C 1.54 0.583 1 C-N-CA 131.946 4.098 . . . . 0.0 113.376 164.502 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 p -116.23 -29.25 6.3 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 128.732 2.813 . . . . 0.0 112.974 -175.163 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 42.1 mttt -70.57 -56.71 5.88 Favored 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 169.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.7 p -99.08 -125.85 0.16 Allowed 'General case' 0 C--O 1.221 -0.42 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 167.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.14 28.88 1.53 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 129.006 3.193 . . . . 0.0 110.074 173.566 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 52.58 7.81 0.07 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 127.015 2.126 . . . . 0.0 115.168 -177.058 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.1 20.81 0.02 OUTLIER 'General case' 0 CA--C 1.56 1.358 0 C-N-CA 127.309 2.244 . . . . 0.0 116.681 -165.194 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.44 -144.83 34.91 Favored Glycine 0 CA--C 1.532 1.136 0 O-C-N 119.794 -1.816 . . . . 0.0 114.079 175.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.1 t -67.19 179.8 1.13 Allowed 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.392 1.077 . . . . 0.0 113.904 -174.543 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.7 ' HE ' ' CE1' ' A' ' 120' ' ' HIS . 95.4 mtt180 -124.7 114.53 19.43 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.911 1.684 . . . . 0.0 109.789 177.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -102.7 -24.76 13.72 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 125.772 1.629 . . . . 0.0 114.706 -171.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.78 158.81 35.96 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 124.497 1.119 . . . . 0.0 110.332 170.236 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.0 p -149.79 142.25 24.35 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.171 1.388 . . . . 0.0 109.503 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.57 175.77 34.84 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 115.388 0.915 . . . . 0.0 115.388 -170.183 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -133.1 152.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.018 1.327 . . . . 0.0 111.554 174.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 16.9 mt -83.82 115.51 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 127.646 2.378 . . . . 0.0 112.664 177.706 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' B' ' 51' ' ' GLY . . . -108.59 169.5 14.17 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 126.964 2.221 . . . . 0.0 114.532 -179.345 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -104.95 88.52 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 117.489 2.403 . . . . 0.0 117.489 -168.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.34 -25.49 51.13 Favored 'General case' 0 N--CA 1.477 0.902 0 O-C-N 120.07 -1.644 . . . . 0.0 113.08 173.184 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 . . . . . 0 C--O 1.236 0.363 0 C-N-CA 126.931 2.092 . . . . 0.0 110.459 176.377 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.304 0 CA-C-O 121.283 0.563 . . . . 0.0 111.894 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.8 t -157.35 125.5 5.52 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 126.846 2.058 . . . . 0.0 107.683 167.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.51 143.29 32.41 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-O 122.686 1.231 . . . . 0.0 113.651 174.775 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 169.64 17.35 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.366 1.866 . . . . 0.0 110.128 175.487 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -153.36 150.14 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 119.88 1.218 . . . . 0.0 111.892 -169.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.34 117.54 18.27 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 127.336 2.254 . . . . 0.0 109.126 169.113 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 8.4 m -101.93 116.89 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.363 1.465 . . . . 0.0 108.546 168.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.51 123.59 43.91 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.957 1.303 . . . . 0.0 113.323 -168.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . 0.26 0.2 OUTLIER -160.44 171.07 19.71 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 117.741 2.497 . . . . 0.0 117.741 165.366 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.97 36.64 0.27 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 129.606 3.479 . . . . 0.0 108.728 -174.547 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -159.23 55.29 0.4 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.045 1.338 . . . . 0.0 111.056 -167.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.85 -99.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 C-N-CA 127.266 2.365 . . . . 0.0 115.467 173.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -79.09 -14.33 13.52 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 123.949 3.099 . . . . 0.0 114.21 -176.179 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.4 HG21 HD21 ' B' ' 144' ' ' LEU . 2.1 t -98.86 141.37 16.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 120.398 1.454 . . . . 0.0 109.677 -179.725 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 pm0 -150.81 163.77 37.83 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.892 2.077 . . . . 0.0 107.237 169.456 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -147.94 134.06 4.93 Favored Glycine 0 CA--C 1.5 -0.904 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.379 175.072 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -97.03 130.1 46.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.337 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -133.64 116.29 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 C-N-CA 125.18 1.392 . . . . 0.0 109.045 168.33 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 65.7 m-20 -100.0 146.4 26.77 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.422 1.089 . . . . 0.0 110.855 171.146 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -121.73 135.51 54.94 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 126.852 2.061 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -128.37 122.0 30.43 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.695 1.198 . . . . 0.0 110.762 169.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.8 tt0 -109.4 140.34 43.23 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 168.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -103.5 6.2 37.32 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -174.416 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 37.1 mp0 -152.5 -178.45 6.85 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 129.341 3.056 . . . . 0.0 108.102 170.001 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.6 p -82.15 -25.35 34.42 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.675 -1.266 . . . . 0.0 112.784 168.301 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -132.31 19.4 4.4 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 125.343 1.457 . . . . 0.0 113.179 -177.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.1 -168.88 42.05 Favored Glycine 0 CA--C 1.541 1.713 0 C-N-CA 125.482 1.515 . . . . 0.0 113.688 172.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.3 169.0 14.53 Favored 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 124.096 3.198 . . . . 0.0 112.376 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 71.3 t -128.56 138.42 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.171 1.388 . . . . 0.0 111.387 -177.535 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -93.01 123.82 36.54 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 165.715 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.45 126.79 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.163 0.985 . . . . 0.0 110.8 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.8 p90 -146.74 164.32 33.13 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.959 0.885 . . . . 0.0 112.63 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.44 -153.58 25.42 Favored Glycine 0 C--N 1.334 0.452 0 C-N-CA 123.778 0.704 . . . . 0.0 112.47 176.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 60.6 p -153.16 119.52 5.54 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -168.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.3 mp -99.93 114.15 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 CA-C-O 118.265 -0.874 . . . . 0.0 109.941 173.254 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -122.18 133.84 54.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.929 1.241 . . . . 0.0 111.941 -175.441 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 132.05 -3.78 5.26 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 127.357 2.408 . . . . 0.0 114.271 176.008 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.447 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.8 OUTLIER -103.9 178.58 4.52 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 126.565 1.946 . . . . 0.0 112.22 -171.766 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -70.16 156.4 39.27 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.647 1.579 . . . . 0.0 110.227 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.06 156.28 28.67 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 168.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.35 -170.48 35.68 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.426 1.012 . . . . 0.0 113.285 178.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.708 HD22 ' H ' ' B' ' 42' ' ' LEU . 0.4 OUTLIER -65.19 152.57 43.3 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.415 1.886 . . . . 0.0 113.594 -174.095 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -149.18 125.58 10.9 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 127.781 2.433 . . . . 0.0 109.457 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.17 147.43 21.91 Favored Glycine 0 N--CA 1.481 1.646 0 CA-C-N 120.502 1.501 . . . . 0.0 111.551 173.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -154.19 87.88 1.21 Allowed 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.064 1.745 . . . . 0.0 109.321 -167.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -127.16 153.7 45.72 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 121.229 -0.919 . . . . 0.0 112.474 -166.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.1 97.99 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.069 0.85 . . . . 0.0 110.902 -175.288 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -79.47 134.92 36.54 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.195 -170.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -72.34 174.34 7.45 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.354 1.862 . . . . 0.0 113.028 -167.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 63.12 4.73 1.66 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.934 1.694 . . . . 0.0 114.974 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' A' ' 150' ' ' GLY . . . 52.71 16.22 3.72 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 120.267 -1.52 . . . . 0.0 113.584 -163.369 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -89.45 115.4 26.86 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 125.824 1.649 . . . . 0.0 110.322 -168.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -165.14 34.98 0.06 Allowed 'General case' 0 C--O 1.239 0.514 0 CA-C-O 124.149 1.928 . . . . 0.0 116.177 -178.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.418 HG22 ' HB ' ' A' ' 7' ' ' VAL 0.27 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.582 0 CA-C-N 114.261 -1.336 . . . . 0.0 112.959 -166.313 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.796 0 N-CA-C 118.111 2.634 . . . . 0.0 118.111 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -41.19 -46.41 4.23 Favored Glycine 0 CA--C 1.537 1.466 0 CA-C-O 116.459 -2.3 . . . . 0.0 115.497 -169.743 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -126.35 46.16 0.0 OUTLIER 'Trans proline' 0 C--N 1.356 0.925 0 CA-C-N 120.983 2.392 . . . . 0.0 115.52 -176.277 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.1 m170 78.6 78.34 0.06 Allowed 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.663 1.585 . . . . 0.0 112.916 167.02 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -48.06 138.75 8.88 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 161.306 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -157.18 116.66 2.0 Favored Pre-proline 0 N--CA 1.472 0.67 0 N-CA-C 116.746 2.128 . . . . 0.0 116.746 171.019 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.57 -5.58 15.6 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 N-CA-C 116.65 1.75 . . . . 0.0 116.65 -179.184 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -91.25 -7.51 51.0 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 119.526 1.057 . . . . 0.0 112.387 173.814 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t 54.66 54.26 9.46 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 125.571 1.548 . . . . 0.0 114.82 170.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.72 176.59 5.45 Favored 'General case' 0 N--CA 1.477 0.924 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -171.053 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.4 ptpp? -79.14 155.55 28.65 Favored 'General case' 0 CA--C 1.545 0.756 0 O-C-N 121.218 -0.926 . . . . 0.0 112.34 176.147 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -79.31 152.67 30.36 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.149 0.98 . . . . 0.0 113.187 -177.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.36 -117.43 1.04 Allowed Glycine 0 C--N 1.339 0.746 0 C-N-CA 123.195 0.426 . . . . 0.0 113.986 167.167 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.67 -28.17 6.87 Favored Glycine 0 CA--C 1.542 1.741 0 N-CA-C 120.12 2.808 . . . . 0.0 120.12 168.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -93.02 -13.83 1.24 Allowed 'Trans proline' 0 CA--C 1.544 1.025 0 CA-C-N 123.203 3.502 . . . . 0.0 112.879 173.067 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.404 ' HE3' ' HB2' ' B' ' 126' ' ' LEU . 0.0 OUTLIER -147.16 -1.39 0.65 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.576 1.55 . . . . 0.0 112.792 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.44 177.19 5.77 Favored 'General case' 0 CA--C 1.548 0.898 0 O-C-N 120.735 -1.228 . . . . 0.0 110.508 174.706 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -90.01 -23.63 21.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 129.324 3.05 . . . . 0.0 111.579 -172.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -129.63 -98.09 0.35 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.243 1.017 . . . . 0.0 112.881 -171.03 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 96.36 137.6 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 129.778 3.231 . . . . 0.0 110.577 -170.149 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -57.21 162.06 2.87 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.267 -1.521 . . . . 0.0 112.072 168.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 53.1 t -61.35 -37.6 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-N 120.403 1.456 . . . . 0.0 110.577 170.806 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.59 24.03 4.57 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.212 1.387 . . . . 0.0 115.933 170.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -109.39 127.72 54.58 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 116.523 2.046 . . . . 0.0 116.523 174.851 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.4 mt -115.31 169.26 9.27 Favored 'General case' 0 CA--C 1.56 1.35 0 N-CA-C 103.633 -2.728 . . . . 0.0 103.633 156.453 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.48 -126.22 1.95 Allowed Glycine 0 N--CA 1.48 1.605 0 C-N-CA 124.482 1.039 . . . . 0.0 114.265 -171.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -126.54 154.07 44.34 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.8 m -111.26 129.71 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.927 2.091 . . . . 0.0 110.568 -176.593 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -89.41 132.08 35.16 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.271 0.487 . . . . 0.0 110.181 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.58 162.11 13.45 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 124.849 1.26 . . . . 0.0 111.451 168.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.3 -174.77 3.16 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.085 1.354 . . . . 0.0 111.736 169.004 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.65 -10.02 47.43 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.73 -15.31 61.22 Favored 'General case' 0 CA--C 1.554 1.122 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 162.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.72 30.24 6.93 Favored Glycine 0 C--N 1.34 0.768 0 C-N-CA 127.272 2.368 . . . . 0.0 112.736 168.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -116.14 128.92 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 CA-C-N 119.854 1.827 . . . . 0.0 113.543 178.814 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 80.52 3.73 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 125.236 1.414 . . . . 0.0 110.215 167.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -77.85 123.7 27.07 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.682 1.593 . . . . 0.0 108.808 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.9 t -147.37 150.51 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -168.052 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 71.3 m -140.18 128.42 22.47 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 127.419 2.288 . . . . 0.0 108.367 166.068 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 34.7 mt -136.78 124.83 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 127.771 2.429 . . . . 0.0 108.928 -179.387 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 mp0 -117.4 115.69 25.72 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 126.307 1.843 . . . . 0.0 107.866 -175.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -140.46 144.32 36.01 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.933 0.873 . . . . 0.0 113.32 -168.327 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.2 p -110.89 51.1 0.78 Allowed 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 13.9 p -152.06 -38.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 167.59 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.288 0.1 OUTLIER -79.77 94.15 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 120.677 1.58 . . . . 0.0 110.888 172.549 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 38.4 p -102.14 153.21 20.15 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.148 1.779 . . . . 0.0 113.378 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.34 54.73 1.45 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.379 1.472 . . . . 0.0 110.851 -177.697 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.1 m -94.85 39.58 1.1 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 126.189 1.796 . . . . 0.0 112.128 -170.705 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 73.95 -39.46 0.97 Allowed Glycine 0 N--CA 1.475 1.271 0 C-N-CA 127.396 2.426 . . . . 0.0 115.83 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -161.65 -34.95 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.133 1.773 . . . . 0.0 111.962 -168.037 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 63.9 m-70 -75.85 -19.44 58.89 Favored 'General case' 0 C--O 1.226 -0.17 0 O-C-N 120.438 -1.413 . . . . 0.0 112.463 -167.521 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -142.62 -71.37 0.32 Allowed 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 122.793 0.437 . . . . 0.0 111.57 -172.128 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.25 2.3 pt -137.16 166.45 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 C-N-CA 125.252 1.421 . . . . 0.0 107.941 166.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.2 mm 86.72 144.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 131.308 3.843 . . . . 0.0 107.139 -163.06 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.43 3.45 25.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.133 0.873 . . . . 0.0 114.746 177.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 31.2 mtt180 -108.45 -172.45 2.06 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 128.785 2.834 . . . . 0.0 108.574 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 12.0 t -124.05 161.94 24.51 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 120.559 1.527 . . . . 0.0 109.423 166.761 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 tt -118.61 130.71 56.03 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 164.135 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 40.7 t -113.19 128.05 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 C-N-CA 125.098 1.359 . . . . 0.0 108.038 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -92.53 156.89 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 166.303 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.62 127.51 35.09 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.266 1.426 . . . . 0.0 108.752 -175.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -58.93 -14.52 9.38 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 118.122 2.638 . . . . 0.0 118.122 -166.032 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.8 mttp -137.45 177.33 7.95 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 124.042 3.11 . . . . 0.0 115.255 175.435 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.92 129.87 31.68 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 125.749 1.62 . . . . 0.0 110.888 -177.135 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -99.81 136.88 39.06 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 124.071 0.857 . . . . 0.0 110.327 171.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -81.49 -6.3 58.82 Favored 'General case' 0 CA--C 1.551 0.991 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.044 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.404 ' HB2' ' HE3' ' B' ' 75' ' ' LYS . 32.8 mt 60.69 67.89 0.79 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.314 1.846 . . . . 0.0 111.645 169.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.5 20.09 28.09 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 117.037 1.575 . . . . 0.0 117.037 168.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.4 mtmp? -146.88 -57.86 0.27 Allowed 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 120.092 3.367 . . . . 0.0 120.092 -165.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -78.82 37.72 1.91 Allowed Glycine 0 N--CA 1.475 1.299 0 C-N-CA 128.64 3.019 . . . . 0.0 110.618 -169.177 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 130' ' ' GLY . . . . . 0.479 ' HA3' ' H ' ' B' ' 134' ' ' SER . . . 173.82 84.0 0.06 OUTLIER Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 -168.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -40.01 -24.96 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.935 0 C-N-CA 130.632 3.573 . . . . 0.0 114.827 167.215 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -116.98 -78.49 0.58 Allowed 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 127.177 2.191 . . . . 0.0 107.517 167.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -63.97 -36.47 84.09 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.066 1.135 . . . . 0.0 114.066 -166.725 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.479 ' H ' ' HA3' ' B' ' 130' ' ' GLY . 13.8 t -71.31 -27.75 63.62 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 119.583 -1.948 . . . . 0.0 112.605 -177.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.316 8.9 t -83.41 -5.82 59.27 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 118.56 -0.733 . . . . 0.0 111.728 170.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -105.16 -68.2 0.87 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 124.882 1.273 . . . . 0.0 113.702 173.497 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.6 p -88.17 -32.28 18.7 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 125.347 1.459 . . . . 0.0 113.435 178.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 116.65 -23.92 9.95 Favored Glycine 0 N--CA 1.472 1.078 0 C-N-CA 125.32 1.438 . . . . 0.0 112.448 -168.2 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 10.2 t30 69.43 48.06 0.65 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 127.719 2.408 . . . . 0.0 110.014 178.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.87 31.3 0.06 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 127.402 2.281 . . . . 0.0 114.672 -169.183 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.49 -33.95 0.12 Allowed Glycine 0 CA--C 1.535 1.337 0 C-N-CA 128.614 3.007 . . . . 0.0 115.265 -172.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.7 t -160.16 -152.21 0.28 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.794 1.238 . . . . 0.0 112.398 178.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.52 -170.66 2.27 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 129.508 3.123 . . . . 0.0 107.706 174.624 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.4 HD21 HG21 ' B' ' 14' ' ' VAL . 0.4 OUTLIER -174.41 -168.7 0.4 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.467 1.907 . . . . 0.0 107.372 -169.852 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.68 153.95 1.53 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.67 2.788 . . . . 0.0 113.45 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -144.9 160.92 40.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.187 1.795 . . . . 0.0 112.821 -178.636 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.56 131.25 3.21 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 124.555 1.074 . . . . 0.0 111.98 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 128.18 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -176.842 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 35.4 mt -84.95 112.85 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.591 1.956 . . . . 0.0 111.228 -168.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.52 -144.44 10.96 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.416 -0.673 . . . . 0.0 111.416 168.497 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.17 163.61 26.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 124.507 1.123 . . . . 0.0 112.714 -168.524 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.51 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.35 -34.14 0.3 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 129.174 2.989 . . . . 0.0 109.789 166.67 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.469 0.491 0 C-N-CA 126.387 1.875 . . . . 0.0 111.813 167.368 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.5 p . . . . . 0 C--O 1.221 -0.435 0 N-CA-C 115.684 1.735 . . . . 0.0 115.684 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 mttp -161.94 87.46 0.65 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.003 1.721 . . . . 0.0 110.685 166.781 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.98 152.35 28.02 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 123.83 0.852 . . . . 0.0 109.227 167.073 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.438 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -160.04 147.58 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.856 0.862 . . . . 0.0 111.85 -168.086 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.69 139.21 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 165.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.513 HG21 ' HA ' ' B' ' 53' ' ' ASN . 88.9 t -98.29 88.9 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 167.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.72 123.74 30.15 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 127.049 2.14 . . . . 0.0 108.914 -170.177 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -135.62 144.15 45.95 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 122.38 1.086 . . . . 0.0 113.676 -170.352 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -109.08 160.94 13.3 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 107.36 -2.296 . . . . 0.0 107.36 166.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.08 58.16 1.5 Allowed 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 127.001 2.121 . . . . 0.0 111.935 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.4 -160.92 34.72 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.965 2.221 . . . . 0.0 110.565 -172.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.85 41.73 1.17 Allowed 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 125.152 3.901 . . . . 0.0 112.104 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.14 111.94 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 127.086 2.154 . . . . 0.0 108.726 -169.717 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -159.69 168.7 25.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.448 179.376 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.18 137.43 5.39 Favored Glycine 0 CA--C 1.506 -0.495 0 CA-C-N 115.659 -0.701 . . . . 0.0 112.065 168.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.0 134.04 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 166.326 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 pp -130.98 129.87 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.539 1.136 . . . . 0.0 109.231 165.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -103.2 153.75 20.04 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.537 1.935 . . . . 0.0 112.392 168.667 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -138.13 111.12 7.77 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 126.436 1.894 . . . . 0.0 109.123 169.41 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -96.33 84.78 3.8 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.315 -1.491 . . . . 0.0 112.54 176.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.424 ' HB3' HD13 ' A' ' 106' ' ' LEU . 3.5 tp60 -105.84 147.51 28.6 Favored 'General case' 0 C--O 1.222 -0.361 0 O-C-N 121.111 -0.993 . . . . 0.0 110.733 174.22 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.41 -15.14 9.11 Favored 'General case' 0 CA--C 1.551 1.005 0 C-N-CA 128.432 2.693 . . . . 0.0 112.49 -179.005 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -126.54 171.71 10.85 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 127.121 2.169 . . . . 0.0 110.594 -171.49 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 75.1 m -95.57 -26.5 15.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -126.58 -18.99 4.67 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 120.717 1.599 . . . . 0.0 114.904 -174.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.85 173.52 47.63 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.641 1.115 . . . . 0.0 112.973 176.655 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -80.95 171.04 14.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.847 3.031 . . . . 0.0 112.773 -176.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 t -140.48 136.1 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.34 1.456 . . . . 0.0 111.256 -170.568 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.9 tmtm? -80.77 128.89 34.16 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 168.203 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 38.1 t -121.91 143.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.669 1.987 . . . . 0.0 108.664 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.5 p90 -156.59 161.55 39.93 Favored 'General case' 0 C--N 1.326 -0.426 0 O-C-N 121.06 -1.025 . . . . 0.0 111.292 173.232 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.68 151.4 9.83 Favored Glycine 0 N--CA 1.452 -0.281 0 N-CA-C 114.879 0.711 . . . . 0.0 114.879 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -109.7 108.53 18.95 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.081 -0.56 . . . . 0.0 110.182 170.687 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -85.21 141.38 14.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 126.273 1.829 . . . . 0.0 107.789 167.704 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -149.38 132.4 16.23 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.216 1.806 . . . . 0.0 109.133 -178.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 -19.26 37.18 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 126.084 1.802 . . . . 0.0 114.179 -171.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.46 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -62.96 130.94 46.97 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 119.55 1.675 . . . . 0.0 111.956 169.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -67.5 152.84 44.97 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.634 1.974 . . . . 0.0 109.268 168.355 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -53.61 153.6 4.23 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.7 1.6 . . . . 0.0 115.111 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.99 -176.63 40.93 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.723 1.154 . . . . 0.0 112.668 -177.824 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mt -63.76 153.83 35.18 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.521 1.528 . . . . 0.0 112.18 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.46 ' CD2' HD23 ' A' ' 38' ' ' LEU . 78.6 m-70 -151.57 132.98 14.63 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 127.995 2.518 . . . . 0.0 108.701 169.086 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.91 142.77 46.86 Favored Glycine 0 N--CA 1.475 1.239 0 CA-C-O 118.905 -0.941 . . . . 0.0 112.263 178.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -132.93 102.83 5.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.939 1.696 . . . . 0.0 108.214 -175.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CD2' ' HB3' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -139.65 136.92 34.8 Favored 'General case' 0 CA--C 1.537 0.464 0 O-C-N 120.736 -1.228 . . . . 0.0 110.946 -167.372 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -93.89 124.58 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.201 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 116' ' ' THR . 14.6 m-70 -72.06 -177.86 2.2 Favored 'General case' 0 CA--C 1.55 0.966 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 169.298 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -64.89 167.24 7.91 Favored 'General case' 0 CA--C 1.549 0.923 0 O-C-N 119.97 -1.706 . . . . 0.0 111.767 169.478 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -90.36 -144.53 0.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -173.648 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.62 -147.36 26.65 Favored Glycine 0 N--CA 1.428 -1.835 0 CA-C-O 124.97 2.428 . . . . 0.0 111.441 169.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.749 ' HA ' HG21 ' B' ' 5' ' ' VAL . 19.5 p-10 -88.0 54.03 2.95 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 109.453 -3.374 . . . . 0.0 109.674 -168.565 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.643 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.369 4.1 p30 -75.19 18.57 0.19 Allowed 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 121.221 3.785 . . . . 0.0 121.221 -157.27 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.477 HG22 ' HA ' ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -76.3 -23.37 54.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 117.588 2.44 . . . . 0.0 117.588 -162.704 . . . . . . . . 4 4 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.71 -4.07 29.0 Favored 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 169.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.51 -111.31 4.02 Favored Glycine 0 C--N 1.342 0.881 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.567 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 31.0 p -47.84 -28.69 2.73 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.42 -19.48 29.59 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.727 1.211 . . . . 0.0 113.755 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 49.6 m -119.85 -43.73 2.55 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.208 0.913 . . . . 0.0 113.273 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.5 80.76 3.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.418 1.087 . . . . 0.0 111.289 -170.191 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.42 123.33 9.83 Favored Glycine 0 CA--C 1.536 1.389 0 C-N-CA 125.001 1.286 . . . . 0.0 112.245 -177.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -63.34 119.84 7.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.142 2.561 . . . . 0.0 109.372 -174.03 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.426 ' HB3' ' CD2' ' A' ' 46' ' ' HIS . 0.1 OUTLIER 34.27 66.93 0.24 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.155 1.782 . . . . 0.0 115.057 178.034 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -14.63 113.93 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 129.217 3.007 . . . . 0.0 114.505 174.609 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -114.53 38.6 0.22 Allowed Pre-proline 0 CA--C 1.555 1.138 0 C-N-CA 126.716 2.006 . . . . 0.0 115.448 -168.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -67.99 -14.6 41.57 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 122.668 2.246 . . . . 0.0 112.799 -177.331 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 64.3 mt -76.72 -6.73 53.39 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.169 1.388 . . . . 0.0 112.791 172.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.3 t 70.93 53.63 0.26 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 127.101 2.16 . . . . 0.0 113.009 174.129 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 20.6 mtm-85 -131.72 174.41 10.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -171.272 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mmtt -97.11 177.66 5.51 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 128.62 2.768 . . . . 0.0 110.193 166.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -81.62 154.13 26.31 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.807 1.41 . . . . 0.0 114.807 -169.656 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 158.38 -169.92 34.98 Favored Glycine 0 C--N 1.335 0.489 0 CA-C-N 115.277 -0.874 . . . . 0.0 113.93 166.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.13 -85.24 0.08 OUTLIER Glycine 0 CA--C 1.544 1.889 0 CA-C-O 117.9 -1.5 . . . . 0.0 114.192 168.688 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.05 19.04 0.16 Allowed 'Trans proline' 0 CA--C 1.553 1.459 1 C-N-CA 125.637 4.225 . . . . 0.0 116.635 -172.574 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.81 5.23 0.13 Allowed 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 128.144 2.578 . . . . 0.0 111.731 177.311 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -126.09 175.63 7.61 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 128.938 2.895 . . . . 0.0 112.922 -164.54 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 -129.88 -15.43 3.86 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 129.534 3.134 . . . . 0.0 111.833 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -85.89 -83.97 0.17 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.079 1.352 . . . . 0.0 112.486 177.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 72.35 112.43 0.06 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 126.488 1.915 . . . . 0.0 111.986 175.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -69.05 168.76 13.18 Favored 'General case' 0 CA--C 1.546 0.825 0 O-C-N 120.075 -1.641 . . . . 0.0 113.029 169.402 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -80.75 11.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 O-C-N 120.672 -1.268 . . . . 0.0 113.279 -178.619 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.95 10.21 7.48 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 126.766 2.127 . . . . 0.0 114.246 176.106 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -99.95 81.02 2.38 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 121.641 -0.917 . . . . 0.0 111.161 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.9 mt -79.17 48.71 0.89 Allowed 'General case' 0 CA--C 1.549 0.905 0 O-C-N 121.039 -1.038 . . . . 0.0 110.771 169.615 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.82 -118.7 9.31 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.541 1.543 . . . . 0.0 113.423 177.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.0 p30 -157.15 172.69 18.2 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.622 1.569 . . . . 0.0 112.64 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.9 p -133.63 125.11 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 C-N-CA 126.213 1.805 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 m -98.22 139.23 34.31 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.236 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.6 159.08 18.51 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.091 0.956 . . . . 0.0 113.418 172.52 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -89.4 154.66 19.88 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 126.83 2.052 . . . . 0.0 111.942 169.395 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.42 -14.6 12.82 Favored 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.818 2.447 . . . . 0.0 115.553 178.2 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -79.36 5.75 11.78 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 125.254 1.422 . . . . 0.0 112.941 168.367 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.26 40.59 9.05 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 125.708 1.623 . . . . 0.0 113.39 169.608 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.4 p -155.78 146.82 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 115.302 1.593 . . . . 0.0 115.302 -168.02 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.93 101.15 4.8 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 123.44 1.59 . . . . 0.0 109.604 167.083 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.54 79.29 1.8 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.249 2.219 . . . . 0.0 108.698 -173.701 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 70.9 t -93.23 147.81 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 127.31 2.244 . . . . 0.0 114.211 -167.376 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.6 t -150.51 116.51 5.6 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.23 1.412 . . . . 0.0 111.056 170.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.7 mt -140.11 168.97 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 128.296 2.638 . . . . 0.0 112.029 -168.625 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -136.28 136.42 39.78 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 127.909 2.484 . . . . 0.0 107.825 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -147.13 153.14 39.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 122.284 1.04 . . . . 0.0 113.373 -168.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 81.9 p -126.29 69.47 1.22 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.884 2.074 . . . . 0.0 110.898 -169.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.53 -35.71 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 124.211 1.004 . . . . 0.0 112.225 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.402 ' CD1' ' H ' ' A' ' 104' ' ' ILE . 0.1 OUTLIER -94.98 161.68 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.928 1.291 . . . . 0.0 112.225 174.772 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.1 p -158.07 177.64 11.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.233 1.013 . . . . 0.0 111.207 174.245 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.424 HD13 ' HB3' ' A' ' 22' ' ' GLN . 5.9 mp -111.53 80.3 1.3 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.474 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.7 t -147.34 -171.0 3.69 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -127.69 87.83 0.33 Allowed Glycine 0 C--O 1.219 -0.824 0 O-C-N 120.444 -1.41 . . . . 0.0 113.046 -177.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -177.26 -54.19 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 129.057 2.943 . . . . 0.0 108.615 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -140.02 8.04 2.27 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 114.647 1.351 . . . . 0.0 114.647 -173.451 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.474 ' CB ' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -73.08 -161.4 0.09 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 126.334 1.853 . . . . 0.0 113.9 -172.768 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 36.9 pt -109.47 1.08 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.5 mm -62.25 126.38 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 CA-C-N 119.981 1.264 . . . . 0.0 107.633 168.462 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.76 16.84 76.35 Favored Glycine 0 CA--C 1.522 0.469 0 CA-C-O 117.953 -1.471 . . . . 0.0 115.118 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 -102.25 169.82 8.47 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 119.267 1.533 . . . . 0.0 109.741 -175.424 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.404 HG23 ' HB2' ' A' ' 48' ' ' HIS . 10.2 t -123.54 121.85 36.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 120.614 1.552 . . . . 0.0 112.067 -173.477 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.427 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.3 OUTLIER -93.02 137.23 32.56 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 174.9 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.427 ' N ' HD13 ' A' ' 117' ' ' LEU . 98.3 t -129.71 131.22 66.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 126.065 1.746 . . . . 0.0 107.741 172.767 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 34.5 m -106.27 138.8 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 172.008 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -95.26 148.34 22.51 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.602 0.761 . . . . 0.0 112.739 -169.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.316 2.7 pp20? -74.47 -21.48 59.57 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -171.28 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -113.32 169.42 8.96 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.236 1.015 . . . . 0.0 112.593 171.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.73 154.14 9.53 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.533 1.533 . . . . 0.0 109.547 166.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -119.17 155.99 30.64 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 114.498 1.295 . . . . 0.0 114.498 -169.083 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.452 ' CG ' ' H ' ' A' ' 129' ' ' GLY . 2.9 t0 -89.83 -38.17 13.94 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 117.471 2.397 . . . . 0.0 117.471 -167.388 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 63.8 42.78 5.88 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.516 1.927 . . . . 0.0 113.322 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 134.8 -77.38 0.37 Allowed Glycine 0 C--N 1.337 0.586 0 C-N-CA 124.466 1.031 . . . . 0.0 112.716 169.397 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.17 62.16 1.17 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 118.853 2.909 . . . . 0.0 118.853 -174.508 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.452 ' H ' ' CG ' ' A' ' 125' ' ' ASP . . . -71.72 -71.5 1.04 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 106.899 -2.48 . . . . 0.0 106.899 163.325 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -77.79 -91.35 0.3 Allowed Glycine 0 CA--C 1.528 0.88 0 C-N-CA 126.177 1.846 . . . . 0.0 114.487 -173.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -144.02 -145.31 0.17 Allowed 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 124.822 1.249 . . . . 0.0 111.876 -165.729 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -69.66 -49.93 48.99 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.751 1.16 . . . . 0.0 112.367 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -47.13 -27.34 1.38 Allowed 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 116.15 1.907 . . . . 0.0 116.15 171.499 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 48.7 m -51.77 -23.68 4.95 Favored 'General case' 0 CA--C 1.543 0.699 0 O-C-N 120.195 -1.565 . . . . 0.0 113.719 167.103 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.5 p -99.54 -26.9 13.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.749 1.619 . . . . 0.0 115.033 173.582 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 31.6 mtpt -91.75 -24.82 19.32 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 124.103 0.961 . . . . 0.0 113.429 -176.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 39.6 p -123.31 -42.05 2.27 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.727 1.611 . . . . 0.0 112.83 169.455 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 105.81 18.99 10.7 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-O 118.864 -0.964 . . . . 0.0 111.091 -166.5 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 59.04 -1.7 0.11 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.58 2.352 . . . . 0.0 115.723 176.579 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.9 16.44 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.24 0 C-N-CA 128.822 2.849 . . . . 0.0 116.802 -165.327 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.27 -128.97 9.29 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 127.084 2.278 . . . . 0.0 111.658 -173.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.2 t -104.01 -168.22 1.47 Allowed 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.048 1.339 . . . . 0.0 113.122 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.65 151.41 36.18 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 120.629 -1.294 . . . . 0.0 110.925 168.445 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.3 tt -111.42 -66.81 1.04 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.699 2.0 . . . . 0.0 107.465 169.473 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -131.72 158.87 40.01 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.276 1.83 . . . . 0.0 110.31 177.521 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.0 p -156.38 151.74 26.69 Favored 'General case' 0 CA--C 1.553 1.062 0 C-N-CA 125.803 1.641 . . . . 0.0 113.171 -171.319 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.07 163.42 34.29 Favored Glycine 0 CA--C 1.542 1.762 0 C-N-CA 125.724 1.631 . . . . 0.0 114.205 172.608 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.8 t -107.54 137.59 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.455 1.127 . . . . 0.0 108.371 168.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.0 mt -81.31 126.88 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 127.513 2.325 . . . . 0.0 113.698 -169.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.0 -154.43 9.43 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 126.043 1.782 . . . . 0.0 112.412 168.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -131.17 146.15 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.607 1.163 . . . . 0.0 112.605 -178.005 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.04 15.82 Favored 'General case' 0 C--O 1.22 -0.476 0 C-N-CA 124.239 1.016 . . . . 0.0 109.472 174.811 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 . . . . . 0 C--O 1.239 0.524 0 C-N-CA 125.085 1.354 . . . . 0.0 108.746 173.441 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.401 0 CA-C-O 120.834 0.35 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.3 p -82.77 107.18 15.2 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.77 118.92 27.62 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 115.245 1.572 . . . . 0.0 115.245 -172.398 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -94.96 161.38 14.17 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.043 1.337 . . . . 0.0 111.957 169.252 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.749 HG21 ' HA ' ' A' ' 52' ' ' ASP . 2.2 p -148.73 116.04 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.784 2.034 . . . . 0.0 111.188 -169.781 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 6' ' ' ALA . . . . . 0.463 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -78.75 125.61 29.6 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.161 -0.962 . . . . 0.0 110.106 168.34 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.643 HG21 ' ND2' ' A' ' 53' ' ' ASN . 87.8 t -107.5 71.61 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.712 0.805 . . . . 0.0 111.291 -170.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.47 HD21 ' CD1' ' B' ' 117' ' ' LEU . 1.2 mp -83.56 130.42 35.0 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -169.733 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.6 mtpp -155.24 178.26 10.41 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.119 1.368 . . . . 0.0 113.119 172.774 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.73 -55.55 0.47 Allowed Glycine 0 C--O 1.224 -0.48 0 C-N-CA 127.175 2.322 . . . . 0.0 109.794 170.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -83.78 73.73 10.26 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.883 1.273 . . . . 0.0 110.481 -168.452 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.66 -103.58 0.06 OUTLIER Glycine 0 CA--C 1.538 1.471 0 C-N-CA 126.751 2.119 . . . . 0.0 113.136 176.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -79.87 -3.04 12.56 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 125.192 3.928 . . . . 0.0 114.724 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 42.0 t -77.53 128.37 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-N 120.025 1.284 . . . . 0.0 110.523 176.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -126.4 158.31 36.27 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 126.278 1.831 . . . . 0.0 109.181 167.115 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.01 101.91 0.28 Allowed Glycine 0 C--O 1.225 -0.415 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 168.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -102.43 106.02 19.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 C-N-CA 125.721 1.608 . . . . 0.0 106.676 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 4.2 mm -120.68 101.75 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.01 0.524 . . . . 0.0 109.964 -177.135 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -74.93 161.57 29.39 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 118.915 0.779 . . . . 0.0 110.523 172.28 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -146.73 100.47 3.33 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.947 2.099 . . . . 0.0 107.818 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 116.8 29.24 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.853 0.861 . . . . 0.0 112.017 -178.342 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -102.26 126.45 49.25 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.088 0.955 . . . . 0.0 110.767 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -49.78 20.71 Favored 'General case' 0 CA--C 1.55 0.963 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 171.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -151.5 134.56 15.86 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 128.757 2.823 . . . . 0.0 107.108 169.062 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 67.5 m -64.01 93.37 0.09 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.327 1.051 . . . . 0.0 112.268 178.329 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 p30 160.08 -32.66 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 131.081 3.753 . . . . 0.0 110.998 -174.667 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.6 173.18 45.41 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-O 119.241 -0.755 . . . . 0.0 111.936 172.597 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.04 166.9 19.34 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.422 2.748 . . . . 0.0 111.378 177.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 66.1 t -121.22 130.19 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 124.968 1.307 . . . . 0.0 109.017 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -86.87 119.24 26.88 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.73 0.776 . . . . 0.0 109.739 170.376 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.4 t -104.97 121.08 56.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 127.441 2.296 . . . . 0.0 108.813 -172.555 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -155.14 157.21 37.08 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.95 -135.64 4.87 Favored Glycine 0 N--CA 1.461 0.331 0 C-N-CA 124.709 1.147 . . . . 0.0 111.053 177.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.5 p -157.7 158.5 35.51 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 116.222 1.934 . . . . 0.0 116.222 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.491 HG12 HG11 ' B' ' 119' ' ' VAL . 1.3 mp -121.24 104.72 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.561 1.144 . . . . 0.0 108.483 170.3 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -106.27 124.47 49.64 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.3 3.1 3.53 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.269 1.89 . . . . 0.0 113.916 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.517 HD13 ' CD2' ' B' ' 43' ' ' HIS . 55.6 mt -79.76 -172.03 3.13 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 124.194 0.998 . . . . 0.0 108.409 167.397 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -119.58 -29.08 5.16 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 171.469 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 175.9 -176.65 0.12 Allowed 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 130.462 3.505 . . . . 0.0 106.327 -178.491 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.38 160.71 35.44 Favored Glycine 0 N--CA 1.461 0.354 0 C-N-CA 125.677 1.608 . . . . 0.0 114.072 166.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.426 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.1 mp -76.59 157.91 31.57 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 167.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 43' ' ' HIS . . . . . 0.517 ' CD2' HD13 ' B' ' 38' ' ' LEU . 95.5 m-70 -149.38 130.01 14.04 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 126.606 1.963 . . . . 0.0 108.681 -174.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.75 147.68 37.19 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 172.011 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.296 0.0 OUTLIER -138.32 133.56 33.17 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 123.947 1.832 . . . . 0.0 114.65 169.464 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.585 ' O ' HD22 ' B' ' 117' ' ' LEU . 2.3 m-70 -130.3 145.61 51.79 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.958 1.703 . . . . 0.0 111.63 -168.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -96.55 115.51 36.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 168.162 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -73.38 132.53 43.12 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 170.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -65.21 135.97 56.07 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 124.333 1.053 . . . . 0.0 112.037 -165.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 66.09 -169.93 0.2 Allowed 'General case' 0 CA--C 1.544 0.747 0 CA-C-O 123.274 1.511 . . . . 0.0 111.907 -175.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.55 2.85 3.85 Favored Glycine 0 C--O 1.225 -0.437 0 C-N-CA 126.602 2.049 . . . . 0.0 113.589 -175.171 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.438 ' HA ' HG21 ' A' ' 5' ' ' VAL . 11.6 p-10 -79.63 49.62 1.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 121.246 2.523 . . . . 0.0 111.262 169.662 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.513 ' HA ' HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER 176.42 28.26 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 112.079 -2.328 . . . . 0.0 115.293 -169.4 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.492 1.658 0 N-CA-C 120.687 3.588 . . . . 0.0 120.687 -168.51 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.376 0 N-CA-C 116.243 1.942 . . . . 0.0 116.243 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.76 126.79 32.82 Favored Glycine 0 CA--C 1.537 1.465 0 C-N-CA 125.448 1.499 . . . . 0.0 111.862 178.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -63.28 169.79 8.88 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 124.278 3.318 . . . . 0.0 112.484 -173.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 1.4 p-80 -61.57 108.17 0.93 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.902 1.681 . . . . 0.0 112.722 -169.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -53.22 135.67 37.83 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 126.207 1.803 . . . . 0.0 115.729 -167.666 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -116.72 42.38 0.36 Allowed Pre-proline 0 CA--C 1.559 1.327 0 C-N-CA 128.131 2.572 . . . . 0.0 114.746 -175.494 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -65.9 -20.48 58.05 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.092 1.862 . . . . 0.0 112.38 177.504 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 6.5 mp -77.9 -3.93 44.21 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 126.72 2.008 . . . . 0.0 113.666 170.798 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.3 t 52.41 59.14 4.72 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 125.778 1.631 . . . . 0.0 114.726 169.414 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.0 ptt180 -163.1 179.24 7.64 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.109 0.964 . . . . 0.0 111.914 -168.733 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.16 169.92 2.51 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 -179.174 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CD2' ' HA3' ' B' ' 138' ' ' GLY . 51.7 t60 -55.64 158.32 3.56 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.979 1.711 . . . . 0.0 114.456 -173.171 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -64.68 45.04 0.11 Allowed Glycine 0 N--CA 1.47 0.937 0 N-CA-C 120.915 3.126 . . . . 0.0 120.915 -164.187 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -75.95 124.44 7.4 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-N 119.835 1.818 . . . . 0.0 113.903 -169.341 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -74.71 -3.01 13.23 Favored 'Trans proline' 0 CA--C 1.546 1.094 0 CA-C-N 120.125 1.962 . . . . 0.0 110.319 166.309 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.418 ' HE2' ' OD2' ' B' ' 76' ' ' ASP . 3.1 ptmt -106.07 -3.58 21.4 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 127.94 2.496 . . . . 0.0 112.98 176.62 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.418 ' OD2' ' HE2' ' B' ' 75' ' ' LYS . 0.2 OUTLIER -130.88 142.47 50.38 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.199 1.4 . . . . 0.0 109.351 -172.492 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -70.45 -18.09 62.99 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.984 -0.448 . . . . 0.0 111.79 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -98.48 122.16 41.33 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 125.292 1.437 . . . . 0.0 107.828 169.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.3 ttt85 -150.27 115.45 5.39 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.3 1.84 . . . . 0.0 109.466 -171.738 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -60.15 163.6 4.76 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 127.091 2.156 . . . . 0.0 112.2 166.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.23 -30.76 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 C-N-CA 124.775 1.23 . . . . 0.0 113.451 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.01 33.91 3.07 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 121.14 -0.975 . . . . 0.0 113.405 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 34.4 m-20 -144.36 155.12 43.65 Favored 'General case' 0 CA--C 1.529 0.173 0 N-CA-C 117.645 2.461 . . . . 0.0 117.645 -169.219 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.6 mt -113.1 -178.61 3.42 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 127.719 2.408 . . . . 0.0 107.796 164.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.39 -129.07 1.47 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.128 0.871 . . . . 0.0 113.369 176.421 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -103.09 162.58 12.83 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.064 0.946 . . . . 0.0 112.284 172.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.477 HG21 HD13 ' B' ' 35' ' ' ILE . 7.6 p -136.36 140.51 43.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 127.555 2.342 . . . . 0.0 108.179 166.229 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 91.1 m -127.76 124.23 37.23 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -165.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -82.95 144.06 30.26 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 179.514 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -82.37 163.13 21.91 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 126.679 1.992 . . . . 0.0 109.924 167.264 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -51.58 -17.93 0.98 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 126.777 2.031 . . . . 0.0 116.074 170.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.41 -23.49 57.01 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 126.753 2.021 . . . . 0.0 112.387 172.69 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.09 -3.94 60.5 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 125.603 1.573 . . . . 0.0 114.946 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.6 129.02 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 118.923 1.362 . . . . 0.0 112.232 168.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -97.95 126.65 43.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 164.654 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -79.91 142.36 35.22 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.9 p -124.33 130.78 73.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-N 114.086 -1.416 . . . . 0.0 111.152 165.329 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.1 p -155.91 69.87 0.68 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.539 1.936 . . . . 0.0 109.997 -169.592 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 14.9 mt -127.57 162.2 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.124 1.769 . . . . 0.0 113.285 -167.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -138.66 148.74 44.4 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 127.821 2.448 . . . . 0.0 106.916 166.275 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -148.48 143.13 26.5 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 125.254 1.422 . . . . 0.0 109.106 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.3 p -108.86 55.02 0.64 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.606 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.61 -40.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.707 1.603 . . . . 0.0 109.76 170.008 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -82.32 155.27 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 CA-C-O 122.549 1.166 . . . . 0.0 113.997 179.187 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 35.6 m -158.1 156.11 30.4 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.888 1.675 . . . . 0.0 111.37 172.3 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.3 mp -76.74 79.85 3.36 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 126.678 1.991 . . . . 0.0 107.934 176.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.95 -19.27 20.37 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 113.233 0.827 . . . . 0.0 113.233 -172.401 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 83.65 9.96 82.27 Favored Glycine 0 N--CA 1.472 1.095 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.663 -174.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -165.26 -37.22 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.861 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -169.277 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -131.84 7.29 4.38 Favored 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 116.934 2.198 . . . . 0.0 116.934 -165.234 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.0 m -161.07 -55.95 0.05 Allowed 'General case' 0 N--CA 1.479 0.977 0 O-C-N 119.368 -2.083 . . . . 0.0 115.766 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.653 HG23 HG21 ' B' ' 149' ' ' ILE . 68.2 mt -137.75 158.18 33.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 173.463 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm 83.32 102.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.267 1 C-N-CA 131.847 4.059 . . . . 0.0 106.498 -166.387 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.08 13.61 83.48 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-O 115.504 -2.831 . . . . 0.0 116.91 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -92.92 152.46 19.35 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 121.314 2.557 . . . . 0.0 109.05 175.032 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.6 t -107.68 109.72 21.4 Favored 'General case' 0 N--CA 1.487 1.398 0 CA-C-N 121.393 1.906 . . . . 0.0 112.962 -167.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.585 HD22 ' O ' ' B' ' 46' ' ' HIS . 3.1 tm? -91.17 136.29 33.19 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.785 1.234 . . . . 0.0 110.42 -176.593 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 p -121.06 142.3 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 C-N-CA 125.702 1.601 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.491 HG11 HG12 ' B' ' 35' ' ' ILE . 6.0 m -107.47 140.27 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 123.61 0.764 . . . . 0.0 110.371 171.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -111.93 160.22 17.64 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-O 122.373 1.083 . . . . 0.0 113.029 -170.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -84.36 -33.21 23.87 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -99.11 167.72 10.52 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.57 1.077 . . . . 0.0 111.093 177.375 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.93 150.54 16.44 Favored 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 165.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -112.28 137.5 50.32 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.239 0.616 . . . . 0.0 109.723 173.392 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -79.91 -38.01 33.41 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 120.577 -0.449 . . . . 0.0 111.454 169.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . 0.269 1.8 mm? 86.1 63.6 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.759 2.423 . . . . 0.0 111.868 -169.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.0 -15.55 36.78 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 117.077 1.591 . . . . 0.0 117.077 166.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.81 -153.95 0.6 Allowed 'General case' 0 CA--C 1.552 1.026 0 CA-C-N 119.565 1.683 . . . . 0.0 109.885 169.379 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 122.41 -36.78 3.05 Favored Glycine 0 N--CA 1.471 1.02 0 O-C-N 120.688 -1.257 . . . . 0.0 113.149 -176.041 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.61 -16.18 0.32 Allowed Glycine 0 N--CA 1.475 1.272 0 N-CA-C 118.719 2.248 . . . . 0.0 118.719 169.394 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -122.01 169.13 11.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.21 2.005 . . . . 0.0 111.513 -174.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -62.66 -51.78 65.91 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.894 1.278 . . . . 0.0 109.711 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -49.29 -30.88 8.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.561 2.344 . . . . 0.0 113.548 174.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 92.1 p -60.2 -33.67 72.55 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 122.354 2.343 . . . . 0.0 113.957 171.491 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 33.0 p -62.66 -34.97 78.18 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.529 0.604 . . . . 0.0 111.461 177.437 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 38.7 mtpt -90.86 -39.1 12.52 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.997 1.719 . . . . 0.0 113.273 -174.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 53.8 p -104.93 -28.34 11.16 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 127.212 2.205 . . . . 0.0 114.181 -173.062 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 138' ' ' GLY . . . . . 0.415 ' HA3' ' CD2' ' B' ' 71' ' ' HIS . . . 103.57 -28.98 13.23 Favored Glycine 0 N--CA 1.465 0.6 0 C-N-CA 125.857 1.694 . . . . 0.0 113.924 -168.604 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 96.98 -11.35 0.08 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 130.787 3.635 . . . . 0.0 109.736 -167.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.2 -17.48 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 131.334 3.853 . . . . 0.0 119.71 -168.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 96.96 176.33 35.0 Favored Glycine 0 CA--C 1.534 1.264 0 C-N-CA 127.058 2.266 . . . . 0.0 113.09 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 81.5 p -62.63 -74.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -168.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 170.21 158.16 0.06 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 127.44 2.296 . . . . 0.0 114.594 176.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.98 -128.8 0.19 Allowed 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 126.934 2.094 . . . . 0.0 106.639 163.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.14 150.08 43.7 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 119.347 0.976 . . . . 0.0 112.293 -171.557 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 36.4 t -143.37 147.74 35.14 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.994 0.918 . . . . 0.0 110.454 173.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.0 160.81 31.48 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 123.889 0.757 . . . . 0.0 114.599 177.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -78.49 152.27 5.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 121.816 -0.814 . . . . 0.0 111.971 174.762 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.653 HG21 HG23 ' B' ' 112' ' ' ILE . 44.8 mt -83.53 91.8 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 123.82 0.848 . . . . 0.0 111.772 169.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -80.14 -163.09 27.4 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.573 1.082 . . . . 0.0 113.181 169.133 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.3 pp -139.1 141.01 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 125.351 1.46 . . . . 0.0 112.308 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -99.68 -7.09 26.12 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 124.175 0.99 . . . . 0.0 111.974 168.447 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.473 0.715 0 C-N-CA 127.922 2.489 . . . . 0.0 110.677 169.556 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.1 p . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 mtmm -86.98 122.29 30.63 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 174.181 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.13 162.6 12.97 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.394 1.878 . . . . 0.0 108.625 165.86 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.681 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.5 OUTLIER -160.05 134.78 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.499 1.12 . . . . 0.0 109.68 -168.604 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.6 137.91 54.54 Favored 'General case' 0 C--N 1.334 -0.095 0 CA-C-N 118.657 0.662 . . . . 0.0 112.311 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -95.19 115.54 34.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 167.996 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mp -95.01 117.02 29.43 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 169.505 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' B' ' 10' ' ' GLY . 13.1 ttpt -156.26 144.93 20.13 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 121.332 -0.855 . . . . 0.0 113.068 174.81 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.93 -33.04 0.47 Allowed Glycine 0 C--N 1.335 0.482 0 N-CA-C 116.768 1.467 . . . . 0.0 116.768 166.847 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -90.27 70.3 7.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 122.808 1.289 . . . . 0.0 109.657 -166.256 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.02 -106.66 0.14 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 128.724 3.059 . . . . 0.0 111.479 -174.941 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -76.1 -4.0 14.56 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 124.045 3.163 . . . . 0.0 113.886 -177.4 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 t -91.27 133.88 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 120.162 1.346 . . . . 0.0 111.897 176.431 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.21 159.08 44.6 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 127.211 2.204 . . . . 0.0 107.79 176.678 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -151.3 133.94 4.45 Favored Glycine 0 C--O 1.229 -0.166 0 CA-C-O 122.023 0.791 . . . . 0.0 111.84 177.129 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.19 130.44 56.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 169.822 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.55 122.99 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 124.326 1.017 . . . . 0.0 110.118 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -97.83 150.25 21.48 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.952 1.301 . . . . 0.0 110.194 167.042 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -124.83 111.25 15.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.322 1.849 . . . . 0.0 108.043 168.946 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -93.64 122.59 36.24 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 169.534 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -100.05 116.23 31.59 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.854 168.268 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . 0.263 0.0 OUTLIER -57.01 -50.35 73.0 Favored 'General case' 0 C--N 1.34 0.186 0 CA-C-O 119.095 -0.479 . . . . 0.0 112.044 175.893 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -158.42 145.66 17.83 Favored 'General case' 0 C--O 1.225 -0.213 0 CA-C-O 118.514 -0.755 . . . . 0.0 110.171 163.284 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.7 t -32.1 -51.52 0.25 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.985 2.114 . . . . 0.0 115.715 -167.989 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -78.34 -1.85 35.27 Favored 'General case' 0 CA--C 1.552 1.048 0 N-CA-C 115.559 1.688 . . . . 0.0 115.559 -175.9 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.45 -179.48 39.44 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.198 1.38 . . . . 0.0 113.756 -178.355 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -81.43 134.57 8.95 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 122.694 2.262 . . . . 0.0 111.354 175.218 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 t -86.69 128.76 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 O-C-N 121.779 -0.576 . . . . 0.0 110.393 -175.493 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 tmtt? -87.06 123.32 32.01 Favored 'General case' 0 CA--C 1.541 0.607 0 O-C-N 121.782 -0.574 . . . . 0.0 109.806 174.001 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -99.43 140.98 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.714 0.806 . . . . 0.0 110.343 169.866 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -145.05 156.64 44.04 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.37 0.668 . . . . 0.0 111.549 168.192 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.54 -160.4 29.23 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 123.346 0.498 . . . . 0.0 112.887 176.76 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.1 p -155.99 138.47 14.94 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 122.538 -0.39 . . . . 0.0 111.984 -175.615 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.91 110.42 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -179.191 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -112.91 142.93 45.01 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 127.685 2.394 . . . . 0.0 110.828 -167.287 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.01 0.81 54.9 Favored Glycine 0 CA--C 1.53 0.991 0 C-N-CA 126.457 1.98 . . . . 0.0 113.312 -177.982 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.7 mt -73.49 159.37 33.3 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 118.031 0.916 . . . . 0.0 110.573 176.275 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.4 t -82.75 160.23 22.36 Favored 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 162.374 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -53.6 160.15 1.36 Allowed 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -179.794 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.11 -170.71 34.72 Favored Glycine 0 CA--C 1.526 0.766 0 C-N-CA 124.128 0.87 . . . . 0.0 113.001 178.608 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.8 OUTLIER -79.18 153.13 30.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.827 1.251 . . . . 0.0 110.446 -175.249 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -147.03 114.29 6.26 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.539 2.336 . . . . 0.0 106.808 -177.088 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.87 154.09 28.58 Favored Glycine 0 N--CA 1.476 1.323 0 CA-C-N 119.887 1.221 . . . . 0.0 111.828 -176.717 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -157.4 135.11 10.69 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.629 1.214 . . . . 0.0 112.21 170.696 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.46 143.82 25.0 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 121.003 -1.061 . . . . 0.0 111.325 -170.03 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 15.9 m -85.08 136.84 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 167.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -104.72 179.22 4.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.91 1.684 . . . . 0.0 108.8 175.535 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.71 158.59 35.87 Favored 'General case' 0 N--CA 1.478 0.952 0 O-C-N 119.303 -2.123 . . . . 0.0 110.401 166.77 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 67.71 172.91 0.27 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.947 1.299 . . . . 0.0 112.298 174.648 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.04 10.33 63.84 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 126.588 2.042 . . . . 0.0 112.045 165.794 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.437 ' HA ' HG21 ' B' ' 5' ' ' VAL . 14.9 m-20 -74.07 100.76 3.69 Favored 'General case' 0 N--CA 1.453 -0.286 0 O-C-N 121.848 -0.795 . . . . 0.0 109.381 -173.331 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.444 1.5 p30 -145.61 35.69 1.06 Allowed 'General case' 0 C--N 1.341 0.224 0 N-CA-C 119.427 3.121 . . . . 0.0 119.427 173.872 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' B' ' 7' ' ' VAL . 0.2 OUTLIER -112.74 -36.74 5.08 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 117.548 -1.215 . . . . 0.0 112.66 -179.628 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.84 23.19 0.25 Allowed 'General case' 0 CA--C 1.554 1.133 0 CA-C-N 120.321 1.419 . . . . 0.0 113.518 169.919 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.06 -126.48 42.17 Favored Glycine 0 CA--C 1.528 0.863 0 O-C-N 120.523 -1.361 . . . . 0.0 112.105 176.777 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 77.2 m -68.85 -15.89 63.62 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 176.127 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.4 m -86.5 -19.96 28.77 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.272 1.429 . . . . 0.0 111.731 171.309 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.87 -50.46 12.21 Favored 'General case' 0 N--CA 1.476 0.835 0 O-C-N 121.37 -0.831 . . . . 0.0 110.87 169.146 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -148.62 131.26 15.9 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.029 0.919 . . . . 0.0 112.742 -177.499 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.09 -131.37 0.61 Allowed Glycine 0 CA--C 1.536 1.348 0 C-N-CA 126.69 2.09 . . . . 0.0 111.499 177.386 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -79.0 178.74 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 124.13 3.22 . . . . 0.0 111.001 174.892 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.06 83.39 4.36 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.062 1.345 . . . . 0.0 108.66 172.448 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -48.25 150.13 1.33 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.326 1.85 . . . . 0.0 113.225 -179.448 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.468 HD22 ' H ' ' A' ' 69' ' ' ARG . 63.6 t30 -146.97 114.21 4.26 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 174.855 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.76 -17.21 33.2 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.502 2.135 . . . . 0.0 113.008 175.677 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.74 -11.57 59.99 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 119.163 0.892 . . . . 0.0 113.044 175.701 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 t 53.23 46.9 25.55 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 126.008 1.723 . . . . 0.0 113.718 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.468 ' H ' HD22 ' A' ' 65' ' ' ASN . 52.6 mtp85 -104.44 168.14 9.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 127.612 2.365 . . . . 0.0 111.857 -177.747 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.59 151.46 44.63 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 122.129 0.966 . . . . 0.0 110.682 168.555 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.514 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 85.7 t60 -66.64 179.0 1.13 Allowed 'General case' 0 CA--C 1.545 0.754 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.105 164.334 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.448 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 113.16 -125.45 7.01 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 168.447 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.67 -50.68 0.8 Allowed Glycine 0 CA--C 1.539 1.566 0 CA-C-O 118.411 -1.216 . . . . 0.0 114.449 -178.0 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -80.01 -27.2 3.92 Favored 'Trans proline' 0 C--N 1.353 0.814 0 C-N-CA 122.884 2.389 . . . . 0.0 115.032 173.509 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptpt -121.75 -14.26 8.15 Favored 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 120.506 1.503 . . . . 0.0 113.904 169.094 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -105.84 153.47 21.88 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.866 1.266 . . . . 0.0 110.613 170.514 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -79.91 -14.6 58.51 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 125.995 1.718 . . . . 0.0 112.977 -169.584 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -103.83 -87.13 0.44 Allowed 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -166.771 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 84.82 133.24 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.287 1.835 . . . . 0.0 110.991 -173.403 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -59.82 156.69 13.68 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 125.776 1.63 . . . . 0.0 113.717 168.421 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.3 p -62.47 -36.54 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 CA-C-N 119.41 1.004 . . . . 0.0 112.925 179.634 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.8 102.1 1.92 Allowed Glycine 0 C--N 1.342 0.889 0 N-CA-C 106.027 -2.829 . . . . 0.0 106.027 167.596 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -162.34 147.89 12.75 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.012 1.115 . . . . 0.0 114.012 173.574 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 98.2 mt -121.7 173.47 7.43 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.558 1.943 . . . . 0.0 106.266 162.817 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.19 -107.88 1.31 Allowed Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.028 0.823 . . . . 0.0 112.758 -174.863 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -138.44 157.59 45.92 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.606 0.762 . . . . 0.0 111.432 169.182 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.567 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.5 OUTLIER -96.67 159.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 C-N-CA 125.233 1.413 . . . . 0.0 108.362 167.048 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.0 m -148.37 118.74 7.35 Favored 'General case' 0 N--CA 1.476 0.869 0 O-C-N 121.392 -0.817 . . . . 0.0 110.141 -174.977 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.33 142.61 28.25 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 125.587 1.555 . . . . 0.0 114.891 -169.747 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -78.09 148.63 34.13 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 113.189 -1.823 . . . . 0.0 109.005 166.118 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.468 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 7.0 pttp -39.08 -32.25 0.09 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 127.536 2.334 . . . . 0.0 115.768 169.663 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.468 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 28.2 m-20 -80.01 4.53 16.73 Favored 'General case' 0 CA--C 1.55 0.968 0 CA-C-N 119.978 1.263 . . . . 0.0 111.911 -178.776 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.45 -0.16 53.45 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 127.18 2.324 . . . . 0.0 115.434 168.581 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -113.79 131.89 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 119.273 1.536 . . . . 0.0 113.591 -174.382 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -98.86 132.42 44.22 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.405 164.65 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -77.9 152.2 33.41 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.243 1.021 . . . . 0.0 108.492 168.645 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.252 0.4 OUTLIER -128.43 126.65 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-N 113.78 -1.555 . . . . 0.0 112.277 165.997 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.7 t -157.81 89.07 1.0 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.226 1.011 . . . . 0.0 112.767 -177.01 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 4.2 mp -126.18 161.52 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 125.725 1.61 . . . . 0.0 110.811 176.382 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -140.3 137.72 34.38 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.493 2.717 . . . . 0.0 106.359 167.525 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -151.98 133.1 14.34 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 118.722 0.692 . . . . 0.0 112.48 -171.077 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.7 p -101.39 51.19 0.85 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.702 0.801 . . . . 0.0 112.261 175.976 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 41.0 t -130.98 -48.23 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.376 1.07 . . . . 0.0 108.511 169.207 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.53 155.12 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 122.839 1.304 . . . . 0.0 111.998 170.299 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.7 p -155.76 155.2 32.64 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 125.559 1.544 . . . . 0.0 109.968 -174.782 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -82.23 55.2 2.77 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 120.699 -1.25 . . . . 0.0 110.365 177.744 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.3 t -108.2 37.55 2.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.098 1.759 . . . . 0.0 113.282 -172.088 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 88.79 -143.93 17.9 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-O 122.426 1.014 . . . . 0.0 111.833 169.34 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -66.8 -44.64 80.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 123.881 1.8 . . . . 0.0 112.039 -166.988 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -85.19 -7.38 59.07 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 112.886 -1.961 . . . . 0.0 110.884 -170.705 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.4 t -118.82 -122.18 0.29 Allowed 'General case' 0 CA--C 1.547 0.86 0 CA-C-O 116.233 -1.842 . . . . 0.0 110.268 173.945 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.259 7.1 pt -124.49 67.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 CA-C-N 124.233 3.197 . . . . 0.0 116.911 178.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.4 mm -127.42 132.29 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 165.578 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.72 5.33 50.84 Favored Glycine 0 N--CA 1.472 1.082 0 CA-C-N 119.724 1.147 . . . . 0.0 115.772 177.228 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -80.78 178.21 8.53 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 118.535 1.168 . . . . 0.0 113.173 -170.105 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 36.5 m -101.37 138.67 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 127.351 2.26 . . . . 0.0 110.285 -177.593 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -138.18 135.27 35.48 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 124.242 0.964 . . . . 0.0 109.097 165.764 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 p -120.35 136.6 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 126.571 1.948 . . . . 0.0 108.911 176.972 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 16.6 m -101.97 149.52 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 166.027 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.5 m-70 -117.89 155.58 29.91 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.092 1.357 . . . . 0.0 111.928 -171.404 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -81.32 -33.99 32.18 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.815 1.246 . . . . 0.0 111.465 -171.036 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mmmt -92.58 165.05 13.19 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-N 119.375 0.989 . . . . 0.0 113.059 173.427 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.98 149.68 22.52 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.25 1.02 . . . . 0.0 109.354 165.043 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -99.88 135.29 41.52 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 169.108 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -77.91 -8.88 58.7 Favored 'General case' 0 N--CA 1.48 1.047 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 171.807 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.4 mt 62.73 48.66 4.1 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 124.97 1.308 . . . . 0.0 109.843 173.485 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.26 8.35 78.31 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 115.997 -2.557 . . . . 0.0 118.002 167.153 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -121.34 4.88 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 120.64 3.57 . . . . 0.0 120.64 -168.304 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.75 112.32 4.37 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 165.064 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -71.45 43.41 0.71 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 126.337 1.922 . . . . 0.0 114.55 -175.156 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -103.53 -77.05 0.57 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.828 1.651 . . . . 0.0 110.567 -174.446 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 174.49 -80.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 130.73 3.612 . . . . 0.0 105.494 -170.808 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -34.28 -54.47 0.51 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 128.528 2.731 . . . . 0.0 113.878 175.213 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -65.11 -5.44 6.62 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -169.565 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.8 t -126.09 -25.48 3.55 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 123.989 0.916 . . . . 0.0 111.984 165.356 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.0 tttt -54.21 -33.26 57.84 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.348 1.859 . . . . 0.0 111.531 168.604 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.0 p -110.99 -67.76 0.98 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 162.36 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 152.72 -23.67 0.82 Allowed Glycine 0 CA--C 1.534 1.23 0 C-N-CA 129.803 3.573 . . . . 0.0 112.746 -168.294 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 110.83 -8.6 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.646 1 C-N-CA 131.768 4.027 . . . . 0.0 113.057 176.183 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.59 -17.45 2.14 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 116.526 2.046 . . . . 0.0 116.526 -169.914 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.96 -135.37 28.03 Favored Glycine 0 CA--C 1.526 0.72 0 C-N-CA 124.529 1.062 . . . . 0.0 113.604 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.09 131.97 23.37 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 124.868 1.267 . . . . 0.0 111.677 -176.226 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -65.71 173.56 2.77 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-O 121.371 0.605 . . . . 0.0 109.438 169.243 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.457 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -150.08 -146.63 0.2 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.808 1.643 . . . . 0.0 107.268 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.457 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -50.59 150.66 2.64 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 123.018 1.39 . . . . 0.0 110.843 171.203 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 4.8 t -146.37 152.75 39.6 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 124.602 1.161 . . . . 0.0 109.3 -174.636 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.68 158.14 28.29 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 125.388 1.471 . . . . 0.0 114.028 -178.323 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -109.79 141.85 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.252 1.021 . . . . 0.0 109.335 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 15.0 mm -78.69 92.67 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 123.791 0.836 . . . . 0.0 111.493 -175.365 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -81.19 -175.83 50.37 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 125.003 1.287 . . . . 0.0 113.011 168.702 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 4.8 mp -136.19 138.7 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 O-C-N 121.015 -1.285 . . . . 0.0 110.412 -172.325 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -122.2 3.58 9.81 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.212 1.005 . . . . 0.0 113.331 171.281 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 . . . . . 0 C--O 1.238 0.45 0 C-N-CA 126.75 2.02 . . . . 0.0 112.402 176.557 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-O 121.272 0.558 . . . . 0.0 112.187 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 18.7 p -78.64 113.28 16.55 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.483 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.456 ' HE2' ' HB1' ' B' ' 152' ' ' ALA . 5.6 ptmm? -76.31 156.26 33.54 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.776 1.751 . . . . 0.0 112.081 172.042 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.491 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -149.17 165.03 33.03 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.047 2.539 . . . . 0.0 110.416 172.318 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.437 HG21 ' HA ' ' A' ' 52' ' ' ASP . 5.6 p -148.81 151.82 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.579 1.552 . . . . 0.0 110.764 -165.461 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.08 138.92 27.0 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.419 1.088 . . . . 0.0 110.515 168.1 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 54' ' ' THR . 46.9 t -105.65 84.74 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.911 0.884 . . . . 0.0 110.393 -169.842 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.272 0.9 OUTLIER -85.14 67.27 10.12 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 122.573 1.178 . . . . 0.0 113.075 -178.103 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt -97.95 111.73 23.92 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.053 173.367 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 10' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 9' ' ' LYS . . . -78.39 -103.24 0.2 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 171.831 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -139.38 109.67 6.52 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -167.856 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 51.07 -116.75 4.78 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.913 2.197 . . . . 0.0 112.01 -173.517 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.09 -11.39 27.1 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 124.997 3.798 . . . . 0.0 115.543 -167.606 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.7 t -92.14 94.94 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 123.049 1.404 . . . . 0.0 108.248 169.119 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.09 160.95 43.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.598 174.669 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.15 179.04 29.02 Favored Glycine 0 C--O 1.235 0.2 0 CA-C-O 123.034 1.352 . . . . 0.0 114.213 179.256 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -119.04 139.76 45.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.95 -1.625 . . . . 0.0 110.063 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -127.86 135.65 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 166.989 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -122.91 143.77 49.66 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 125.44 1.496 . . . . 0.0 110.067 169.936 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 87.8 m-85 -124.06 130.26 52.26 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.283 1.433 . . . . 0.0 108.262 170.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.98 120.47 41.49 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 124.333 1.053 . . . . 0.0 108.556 169.543 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -122.42 137.11 54.98 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 122.406 1.098 . . . . 0.0 108.896 168.546 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -105.89 -21.15 13.23 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.741 1.216 . . . . 0.0 113.063 -175.949 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -160.84 121.93 2.93 Favored 'General case' 0 C--O 1.222 -0.367 0 C-N-CA 127.692 2.397 . . . . 0.0 108.667 -164.126 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.1 m -59.25 -41.89 89.83 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.816 2.046 . . . . 0.0 113.179 -171.325 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -82.77 -4.5 58.03 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.502 1.921 . . . . 0.0 113.594 176.338 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.69 -175.94 33.89 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.742 1.639 . . . . 0.0 112.049 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.9 166.65 24.84 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.83 2.353 . . . . 0.0 112.117 178.896 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -115.42 137.79 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 169.441 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.43 129.06 39.72 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.739 0.816 . . . . 0.0 110.555 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -111.46 137.17 45.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 127.211 2.204 . . . . 0.0 109.832 -176.146 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 31.3 p90 -156.27 155.86 33.04 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 124.599 1.16 . . . . 0.0 110.972 168.619 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.32 140.47 3.06 Favored Glycine 0 C--N 1.332 0.351 0 CA-C-O 121.396 0.442 . . . . 0.0 114.1 -169.786 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 51.5 p -118.19 134.05 55.35 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.201 1.0 . . . . 0.0 110.178 -177.338 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -124.85 116.97 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 124.44 1.096 . . . . 0.0 110.435 -176.895 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 25.1 tptt -95.19 152.52 18.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.609 1.164 . . . . 0.0 109.393 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.87 -17.81 58.61 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.485 1.517 . . . . 0.0 113.722 -179.267 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 10.5 mp -69.89 119.33 13.95 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 118.457 1.128 . . . . 0.0 109.041 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -67.54 159.01 30.63 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 166.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -49.66 145.43 5.11 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.659 1.984 . . . . 0.0 114.591 -174.998 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 115.69 171.44 16.45 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 122.5 1.056 . . . . 0.0 113.864 -178.454 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.63 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.5 pt? -80.12 133.32 36.07 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.325 1.85 . . . . 0.0 111.522 -175.828 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -135.55 165.09 26.34 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 128.214 2.606 . . . . 0.0 108.964 -172.757 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.17 157.56 20.03 Favored Glycine 0 N--CA 1.482 1.713 0 C-N-CA 125.455 1.502 . . . . 0.0 114.705 -173.052 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -151.13 118.64 6.06 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.137 1.375 . . . . 0.0 113.243 -168.752 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.403 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -154.97 144.22 21.11 Favored 'General case' 0 CA--C 1.555 1.172 0 O-C-N 119.778 -1.826 . . . . 0.0 113.189 178.886 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -94.21 125.56 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 126.035 1.734 . . . . 0.0 110.154 171.076 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.403 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 7.6 m-70 -75.76 166.55 23.36 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.585 1.954 . . . . 0.0 111.042 179.174 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -75.63 133.54 40.84 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 167.321 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 74.57 167.74 0.29 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 128.015 2.526 . . . . 0.0 115.536 -178.58 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.21 -2.08 38.56 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 127.57 2.51 . . . . 0.0 114.269 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.681 ' HA ' HG21 ' A' ' 5' ' ' VAL 0.255 10.9 t0 -76.79 111.38 12.25 Favored 'General case' 0 CA--C 1.491 -1.303 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 165.023 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.3 0.1 OUTLIER -144.73 38.3 1.22 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-O 124.225 1.964 . . . . 0.0 113.264 168.738 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.0 p . . . . . 0 N--CA 1.446 -0.66 0 CA-C-N 112.093 -2.322 . . . . 0.0 111.852 -166.257 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.444 0 CA-C-O 121.238 0.542 . . . . 0.0 112.204 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.37 162.01 11.53 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 126.84 2.162 . . . . 0.0 110.015 -167.353 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 161.42 42.35 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 123.166 2.577 . . . . 0.0 112.164 -174.484 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.4 ' HB3' ' CD2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -23.89 100.14 0.02 OUTLIER 'General case' 0 C--O 1.237 0.433 0 C-N-CA 129.436 3.094 . . . . 0.0 113.827 167.587 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 64' ' ' PHE . . . . . 0.415 ' CG ' ' HD3' ' B' ' 66' ' ' PRO . 3.1 t80 -55.5 127.52 30.07 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 123.681 1.705 . . . . 0.0 111.482 177.267 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 24.3 p-10 -103.07 39.38 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.42 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 -177.868 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 66' ' ' PRO . . . . . 0.415 ' HD3' ' CG ' ' B' ' 64' ' ' PHE . 75.4 Cg_endo -67.02 -14.01 42.02 Favored 'Trans proline' 0 C--N 1.36 1.133 0 C-N-CA 123.277 2.651 . . . . 0.0 112.666 -176.827 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.6 mt -75.23 -1.24 22.49 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.841 1.656 . . . . 0.0 112.189 175.807 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.5 t 62.3 58.91 1.67 Allowed 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.794 1.238 . . . . 0.0 113.132 167.495 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -152.82 175.1 13.26 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 114.799 1.407 . . . . 0.0 114.799 -167.793 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.407 ' HE3' ' HG3' ' B' ' 78' ' ' GLU . 0.0 OUTLIER -78.53 168.66 19.45 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.108 0.956 . . . . 0.0 109.968 166.747 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 42.3 t60 -61.04 165.03 4.48 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 118.356 -0.831 . . . . 0.0 110.334 172.275 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 168.65 -169.67 41.83 Favored Glycine 0 N--CA 1.476 1.316 0 N-CA-C 117.533 1.773 . . . . 0.0 117.533 -172.947 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.432 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 134.78 -87.0 0.25 Allowed Glycine 0 CA--C 1.545 1.931 0 N-CA-C 121.112 3.205 . . . . 0.0 121.112 167.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -72.49 4.75 3.21 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 124.288 3.326 . . . . 0.0 114.459 -167.849 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . 0.27 0.0 OUTLIER -167.05 4.76 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 130.03 3.332 . . . . 0.0 112.804 175.398 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.432 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 2.4 t0 -128.16 138.54 52.53 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 126.79 2.036 . . . . 0.0 105.649 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 77' ' ' GLU . . . . . 0.456 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -90.82 -9.33 46.86 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 126.764 2.026 . . . . 0.0 114.844 -166.643 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 78' ' ' GLU . . . . . 0.407 ' HG3' ' HE3' ' B' ' 70' ' ' LYS . 6.9 mm-40 -84.38 -84.61 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.911 0.778 . . . . 0.0 109.995 -175.667 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.562 HH22 HG23 ' B' ' 104' ' ' ILE . 33.3 ttp85 78.84 102.45 0.07 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.77 2.028 . . . . 0.0 113.474 167.33 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 13.6 m170 -54.57 155.0 4.33 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 119.829 -1.794 . . . . 0.0 110.165 166.882 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -60.09 -30.41 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 119.708 1.14 . . . . 0.0 113.393 -169.612 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.38 -6.41 74.19 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-O 118.126 -1.375 . . . . 0.0 116.111 179.243 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -79.54 122.37 26.39 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 121.064 2.432 . . . . 0.0 109.902 -176.873 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -126.9 42.17 3.37 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 120.984 1.72 . . . . 0.0 113.455 177.186 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 60.25 -122.84 31.18 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.691 2.236 . . . . 0.0 118.691 166.007 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 86' ' ' ASN . . . . . 0.518 HD21 ' CD1' ' B' ' 126' ' ' LEU . 9.7 m120 -126.82 154.06 44.82 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 113.781 -1.209 . . . . 0.0 113.859 -169.091 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.2 m -130.77 125.55 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.432 1.493 . . . . 0.0 109.107 167.292 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 46.5 m -109.87 127.84 54.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.568 0.747 . . . . 0.0 109.045 -175.784 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.91 148.23 22.18 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.291 1.437 . . . . 0.0 114.078 -177.789 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -104.76 159.31 15.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.904 2.081 . . . . 0.0 110.154 167.145 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -71.35 8.44 1.04 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.583 2.068 . . . . 0.0 116.583 -168.679 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -76.7 -12.58 60.02 Favored 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 122.404 1.097 . . . . 0.0 108.9 164.221 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.93 40.42 7.1 Favored Glycine 0 C--N 1.337 0.601 0 C-N-CA 125.571 1.557 . . . . 0.0 110.412 -174.676 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.01 134.59 31.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.337 1.068 . . . . 0.0 113.384 177.857 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -102.04 120.35 40.29 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 162.728 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -115.43 140.39 49.18 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 122.365 1.079 . . . . 0.0 110.197 169.714 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.43 150.5 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-N 112.324 -2.216 . . . . 0.0 115.092 -169.395 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 p -153.01 119.47 5.59 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.28 1.032 . . . . 0.0 111.349 171.963 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.1 mt -145.07 159.35 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 128.321 2.649 . . . . 0.0 110.565 -170.186 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -140.67 140.96 35.06 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.162 1.785 . . . . 0.0 108.172 168.085 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.98 140.08 26.62 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.182 1.393 . . . . 0.0 111.253 -172.878 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.4 p -110.47 48.65 0.9 Allowed 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.664 0.987 . . . . 0.0 113.664 -175.442 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 33.0 m -148.84 -29.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 CA-C-O 117.997 -1.001 . . . . 0.0 113.144 167.132 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 104' ' ' ILE . . . . . 0.562 HG23 HH22 ' B' ' 79' ' ' ARG . 0.1 OUTLIER -76.88 154.11 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-N 121.164 1.802 . . . . 0.0 108.114 165.841 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 105' ' ' SER . . . . . 0.458 ' H ' ' HB3' ' B' ' 111' ' ' SER . 2.9 p -162.46 158.29 23.54 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 125.352 1.461 . . . . 0.0 109.116 -174.238 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -79.67 55.5 2.03 Favored 'General case' 0 CA--C 1.542 0.673 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 171.666 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 58.0 m -93.48 52.56 1.75 Allowed 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 124.245 1.018 . . . . 0.0 110.074 -173.24 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.87 -96.86 0.54 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 124.688 1.137 . . . . 0.0 111.413 -177.028 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -134.97 7.0 3.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 128.298 2.639 . . . . 0.0 110.596 179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -79.43 -11.84 59.9 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.623 -1.298 . . . . 0.0 111.947 173.528 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 111' ' ' SER . . . . . 0.458 ' HB3' ' H ' ' B' ' 105' ' ' SER . 18.4 m -141.75 -98.69 0.13 Allowed 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 113.372 0.878 . . . . 0.0 113.372 -170.003 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.5 pt -119.56 164.19 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 120.744 -1.223 . . . . 0.0 109.376 168.257 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.9 mm 94.43 137.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 131.149 3.78 . . . . 0.0 105.772 -163.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.26 -15.0 12.94 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 117.809 -1.55 . . . . 0.0 116.569 177.57 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.5 mtt85 -87.01 -175.4 5.34 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 125.642 1.577 . . . . 0.0 110.147 177.334 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -140.31 126.9 20.27 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 119.382 0.992 . . . . 0.0 111.718 -174.114 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -95.08 141.64 28.48 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.937 1.295 . . . . 0.0 110.056 -177.516 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.43 136.0 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.235 1.014 . . . . 0.0 109.146 177.237 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -93.55 140.95 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-O 122.438 1.113 . . . . 0.0 110.454 170.208 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -130.97 165.51 23.0 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.147 1.779 . . . . 0.0 111.223 -170.706 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -84.07 -37.86 21.53 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -170.215 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 87.3 mttt -102.35 144.13 31.22 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 119.172 0.896 . . . . 0.0 112.369 -174.231 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 123' ' ' ALA . . . . . 0.429 ' O ' HD11 ' B' ' 126' ' ' LEU . . . -77.66 54.86 1.26 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.004 1.321 . . . . 0.0 112.33 168.853 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.29 -12.06 17.52 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.742 2.017 . . . . 0.0 114.524 -177.853 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -65.25 -7.11 11.58 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 125.435 1.494 . . . . 0.0 114.637 -171.551 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.599 ' H ' HD13 ' B' ' 126' ' ' LEU . 0.0 OUTLIER -84.83 42.54 0.93 Allowed 'General case' 0 C--N 1.32 -0.685 0 O-C-N 119.383 -2.073 . . . . 0.0 114.789 179.168 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 63.14 8.41 23.45 Favored Glycine 0 N--CA 1.473 1.152 0 N-CA-C 117.401 1.72 . . . . 0.0 117.401 166.818 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 53.2 tttp -154.86 -59.25 0.11 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.54 1.136 . . . . 0.0 112.178 -167.889 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 37.99 -119.45 0.77 Allowed Glycine 0 CA--C 1.529 0.91 0 C-N-CA 126.071 1.796 . . . . 0.0 113.487 177.356 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -107.66 -22.81 7.15 Favored Glycine 0 CA--C 1.534 1.231 0 CA-C-O 117.75 -1.583 . . . . 0.0 116.9 -177.562 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -161.44 -178.08 6.4 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 121.22 2.51 . . . . 0.0 112.582 -172.073 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -47.49 -58.32 4.35 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 127.119 2.167 . . . . 0.0 113.128 -172.863 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -52.33 -21.01 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 115.37 1.618 . . . . 0.0 115.37 177.737 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 m -70.11 -27.33 64.5 Favored 'General case' 0 CA--C 1.549 0.905 0 O-C-N 119.644 -1.91 . . . . 0.0 112.526 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.5 t -79.67 -14.85 58.48 Favored 'General case' 0 N--CA 1.491 1.591 0 CA-C-N 119.853 1.206 . . . . 0.0 112.529 168.362 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mtpt -102.04 -91.44 0.33 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.285 1.834 . . . . 0.0 111.998 -177.853 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.2 p -74.88 -22.16 58.81 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 119.887 1.221 . . . . 0.0 113.986 178.532 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.96 3.46 62.02 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-O 115.497 -2.835 . . . . 0.0 111.145 -167.961 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 63.75 -68.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.167 2.587 . . . . 0.0 110.12 172.267 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 70.26 -15.56 0.34 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.689 2.796 . . . . 0.0 115.109 162.138 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.59 -53.34 4.51 Favored Glycine 0 N--CA 1.473 1.117 0 C-N-CA 126.936 2.207 . . . . 0.0 115.417 174.239 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.5 t -161.65 -166.1 1.42 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.685 0.794 . . . . 0.0 111.058 175.139 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.461 ' HE ' ' N ' ' B' ' 143' ' ' ARG . 0.1 OUTLIER -132.22 142.87 49.59 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.376 1.87 . . . . 0.0 107.35 176.639 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -127.23 -105.37 0.32 Allowed 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.789 1.236 . . . . 0.0 109.663 175.667 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.87 161.85 26.45 Favored 'General case' 0 CA--C 1.544 0.718 0 CA-C-N 120.295 1.407 . . . . 0.0 113.9 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.5 p -152.83 142.74 22.15 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.699 1.6 . . . . 0.0 111.116 -169.141 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.04 126.61 1.78 Allowed Glycine 0 C--N 1.338 0.692 0 N-CA-C 115.86 1.104 . . . . 0.0 115.86 -169.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -79.01 144.97 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 123.81 0.844 . . . . 0.0 109.243 -179.735 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 26.4 mt -92.25 126.15 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 C-N-CA 124.622 1.169 . . . . 0.0 112.214 -179.507 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.92 171.99 14.04 Favored Glycine 0 CA--C 1.538 1.505 0 N-CA-C 117.214 1.646 . . . . 0.0 117.214 172.131 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -87.43 107.83 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.019 1.328 . . . . 0.0 112.564 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.491 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -79.69 -5.03 54.35 Favored 'General case' 0 CA--C 1.554 1.111 0 O-C-N 121.133 -0.979 . . . . 0.0 111.122 166.757 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 . . . . . 0 N--CA 1.47 0.529 0 C-N-CA 131.259 3.824 . . . . 0.0 111.103 172.05 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.7 p . . . . . 0 CA--C 1.54 0.562 0 N-CA-C 116.414 2.005 . . . . 0.0 116.414 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.279 0.0 OUTLIER -155.7 117.85 4.1 Favored 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 117.573 2.435 . . . . 0.0 117.573 168.072 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.1 156.77 36.02 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.062 2.545 . . . . 0.0 106.403 164.077 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 32.3 t -154.7 155.07 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 120.148 1.34 . . . . 0.0 114.248 -164.891 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.87 128.13 33.99 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 125.892 1.677 . . . . 0.0 110.285 168.045 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.05 92.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 127.154 2.181 . . . . 0.0 108.59 176.822 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -77.01 149.18 35.9 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 125.936 1.694 . . . . 0.0 112.624 -167.509 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -155.35 153.58 30.7 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.127 0.971 . . . . 0.0 111.84 171.012 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.4 -110.61 3.18 Favored Glycine 0 N--CA 1.466 0.684 1 N-CA-C 101.753 -4.539 . . . . 0.0 101.753 162.73 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . 0.276 0.3 OUTLIER -155.62 148.46 24.29 Favored 'General case' 0 N--CA 1.442 -0.86 0 C-N-CA 124.886 1.275 . . . . 0.0 108.959 162.143 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.23 -170.83 36.25 Favored Glycine 0 CA--C 1.54 1.624 0 N-CA-C 107.666 -2.173 . . . . 0.0 107.666 -163.993 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.74 37.68 0.43 Allowed 'Trans proline' 0 CA--C 1.545 1.063 1 C-N-CA 125.459 4.106 . . . . 0.0 114.308 -171.802 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -108.61 122.44 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.062 1.745 . . . . 0.0 108.433 172.672 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 20.6 mp0 -145.92 166.49 25.84 Favored 'General case' 0 CA--C 1.519 -0.25 0 C-N-CA 125.52 1.528 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 131.81 3.0 Favored Glycine 0 C--O 1.224 -0.521 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.986 167.732 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.63 131.23 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 O-C-N 121.511 -0.994 . . . . 0.0 109.266 168.416 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.2 mm -131.06 122.62 52.1 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 167.81 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 40.8 m-20 -112.25 141.4 46.01 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 125.481 1.512 . . . . 0.0 111.813 169.054 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -116.93 108.76 16.19 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.906 1.682 . . . . 0.0 110.357 176.836 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HB2' ' CH2' ' A' ' 32' ' ' TRP . 0.0 OUTLIER -87.76 118.94 27.61 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 127.073 2.149 . . . . 0.0 109.978 169.62 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.568 ' HB3' HD11 ' A' ' 106' ' ' LEU . 19.5 tp60 -148.69 140.29 23.53 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.678 0.791 . . . . 0.0 109.321 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.82 -28.25 14.34 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -169.727 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.75 -139.86 0.1 Allowed 'General case' 0 CA--C 1.556 1.181 0 C-N-CA 125.494 1.518 . . . . 0.0 111.41 170.765 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.0 p -113.16 -11.73 13.24 Favored 'General case' 0 N--CA 1.482 1.14 0 O-C-N 118.987 -2.321 . . . . 0.0 115.758 -170.371 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -128.2 -16.67 4.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.453 1.901 . . . . 0.0 112.882 -177.579 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 171.08 48.05 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.548 1.547 . . . . 0.0 112.446 177.741 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -85.13 140.42 7.66 Favored 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 122.268 1.979 . . . . 0.0 111.856 -169.26 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -101.6 132.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.703 1.201 . . . . 0.0 109.487 -173.137 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.427 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 4.5 ttmp? -92.37 126.21 37.35 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.832 1.253 . . . . 0.0 109.178 169.344 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.8 t -110.19 127.78 66.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 126.069 1.748 . . . . 0.0 109.581 177.753 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.468 ' CH2' ' HB2' ' A' ' 21' ' ' GLU . 6.0 p90 -135.92 159.51 41.46 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.172 0.989 . . . . 0.0 111.434 170.342 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.64 -176.72 27.31 Favored Glycine 0 C--O 1.222 -0.651 0 O-C-N 121.718 -0.614 . . . . 0.0 114.041 -173.192 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.69 141.69 13.25 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.752 0.821 . . . . 0.0 111.543 -172.774 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mp -113.7 118.54 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 126.462 1.905 . . . . 0.0 109.315 -178.503 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -115.81 128.63 55.98 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 110.244 -171.606 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.23 6.34 9.02 Favored Glycine 0 N--CA 1.477 1.433 0 C-N-CA 125.568 1.556 . . . . 0.0 114.964 -177.89 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.574 HD23 HD11 ' A' ' 144' ' ' LEU . 31.6 mt -80.95 157.84 25.42 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.58 1.552 . . . . 0.0 111.609 173.599 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.9 t -75.41 151.95 38.07 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 163.398 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.58 147.05 23.26 Favored 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.593 1.088 . . . . 0.0 112.242 170.768 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 111.65 -175.74 17.67 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.854 1.216 . . . . 0.0 113.453 -174.791 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.5 mt -77.27 154.39 33.0 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.595 1.158 . . . . 0.0 112.144 -174.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.425 ' CG ' HD22 ' A' ' 38' ' ' LEU . 91.7 m-70 -153.11 123.45 7.11 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 127.077 2.151 . . . . 0.0 110.13 -171.851 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.85 151.72 47.96 Favored Glycine 0 N--CA 1.474 1.218 0 CA-C-N 120.167 1.349 . . . . 0.0 112.439 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.32 0.0 OUTLIER -146.19 140.2 26.44 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 166.119 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.51 153.54 38.59 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 120.998 -1.064 . . . . 0.0 112.031 -166.63 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 m -80.0 152.54 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 122.698 0.399 . . . . 0.0 110.526 168.109 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -93.98 167.98 11.25 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.052 1.741 . . . . 0.0 113.297 175.374 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -65.96 87.77 0.1 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.511 3.124 . . . . 0.0 109.596 170.115 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 74.2 177.96 0.22 Allowed 'General case' 0 C--N 1.347 0.491 0 CA-C-O 123.072 1.415 . . . . 0.0 112.848 168.884 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -95.23 -4.28 61.22 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 125.435 1.493 . . . . 0.0 111.143 168.128 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -66.98 64.79 0.06 Allowed 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 128.844 2.858 . . . . 0.0 109.817 169.261 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 167.53 -39.02 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.505 2.722 . . . . 0.0 114.714 179.364 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.36 0.5 OUTLIER 55.02 -58.48 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 130.303 3.441 . . . . 0.0 116.327 -174.829 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -68.47 4.22 1.45 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.264 1.426 . . . . 0.0 113.916 179.746 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.436 ' HA3' HG21 ' A' ' 116' ' ' THR . . . 62.89 -126.36 36.71 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 124.91 1.243 . . . . 0.0 111.394 171.023 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.66 -8.48 0.39 Allowed 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 117.302 2.334 . . . . 0.0 117.302 -171.753 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.9 t -107.31 -2.13 20.99 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.544 1.52 . . . . 0.0 114.815 171.522 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.6 m -119.01 -37.83 3.16 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.641 1.576 . . . . 0.0 112.699 173.212 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.57 170.87 15.35 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.2 1.8 . . . . 0.0 110.869 175.396 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -109.8 -69.81 0.63 Allowed Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.549 1.38 . . . . 0.0 116.549 -168.637 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -87.07 -174.16 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.47 1 C-N-CA 125.473 4.115 . . . . 0.0 114.234 -169.407 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -104.01 132.38 50.32 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 127.666 2.386 . . . . 0.0 111.781 -175.831 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -46.9 114.11 0.78 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.579 1.552 . . . . 0.0 111.484 168.97 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 54.0 p30 -112.3 32.04 0.11 Allowed Pre-proline 0 CA--C 1.555 1.148 0 N-CA-C 116.734 2.124 . . . . 0.0 116.734 -167.944 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -56.63 -23.12 47.22 Favored 'Trans proline' 0 C--N 1.354 0.86 0 C-N-CA 124.915 3.743 . . . . 0.0 117.319 -164.957 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.478 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 4.5 mm? -78.39 -0.41 29.02 Favored 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 174.711 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.7 t 66.58 55.5 0.79 Allowed 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 126.886 2.074 . . . . 0.0 110.318 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.478 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.5 ptp180 -143.36 170.99 14.74 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -165.93 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.31 0.0 OUTLIER -85.43 -178.64 6.76 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.365 1.866 . . . . 0.0 113.514 172.79 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.477 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 78.2 t60 -99.42 139.78 34.58 Favored 'General case' 0 C--O 1.22 -0.487 0 C-N-CA 125.876 1.67 . . . . 0.0 112.747 -170.806 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.89 -143.95 11.38 Favored Glycine 0 C--N 1.34 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 113.902 173.808 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.06 -75.93 0.21 Allowed Glycine 0 CA--C 1.535 1.293 0 N-CA-C 118.594 2.198 . . . . 0.0 118.594 -175.989 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -70.85 -11.73 29.82 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.954 2.436 . . . . 0.0 113.054 -171.089 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -130.05 -0.78 4.67 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.684 1.593 . . . . 0.0 111.238 168.25 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.73 122.97 25.37 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 124.053 1.882 . . . . 0.0 111.801 -167.564 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.1 -27.77 69.62 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 129.815 3.246 . . . . 0.0 111.717 169.115 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -88.31 76.35 8.38 Favored 'General case' 0 C--O 1.214 -0.776 0 C-N-CA 126.319 1.848 . . . . 0.0 108.192 177.613 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.6 ttt180 -111.51 110.64 21.17 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 129.599 3.16 . . . . 0.0 109.022 -178.464 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -59.95 159.9 8.57 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 119.385 0.993 . . . . 0.0 112.597 169.925 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 m -43.1 -57.37 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -173.161 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.2 31.53 8.54 Favored Glycine 0 N--CA 1.472 1.067 0 C-N-CA 125.064 1.316 . . . . 0.0 113.298 172.963 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -76.94 121.97 24.21 Favored 'General case' 0 C--O 1.237 0.408 0 O-C-N 120.942 -1.328 . . . . 0.0 108.253 169.744 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -95.76 176.82 5.99 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 112.854 -1.975 . . . . 0.0 109.149 167.525 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.73 23.99 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 124.305 0.955 . . . . 0.0 113.371 -175.341 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -83.9 126.19 32.74 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 121.675 -0.897 . . . . 0.0 108.91 167.843 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.98 170.59 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 164.235 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 t -145.02 127.73 16.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 124.683 1.193 . . . . 0.0 109.751 174.941 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.2 144.85 26.64 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 113.183 0.809 . . . . 0.0 113.183 174.417 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -67.47 170.96 6.65 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.191 1.796 . . . . 0.0 110.946 168.528 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.76 -32.15 29.61 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.753 1.221 . . . . 0.0 112.854 168.527 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -73.41 -15.49 61.35 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.938 1.695 . . . . 0.0 112.283 177.123 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.22 14.47 64.13 Favored Glycine 0 CA--C 1.527 0.808 0 O-C-N 120.832 -1.167 . . . . 0.0 113.43 179.167 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.6 p -96.71 125.22 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 124.226 1.011 . . . . 0.0 109.916 168.209 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.69 122.0 43.09 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 168.229 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -88.99 145.29 25.59 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 123.089 1.423 . . . . 0.0 110.145 -179.314 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.77 125.69 74.56 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.002 172.954 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.4 m -155.13 85.77 1.09 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.126 1.77 . . . . 0.0 108.67 -173.121 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 12.9 mt -140.13 154.64 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 127.308 2.243 . . . . 0.0 111.53 -169.208 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.427 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 15.7 tt0 -140.91 144.86 35.44 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.593 1.557 . . . . 0.0 108.233 168.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.98 144.84 21.59 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.624 1.169 . . . . 0.0 113.386 -166.821 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 55.2 p -116.7 49.37 1.17 Allowed 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -179.687 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.2 m -149.06 16.23 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 176.055 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.35 168.69 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 120.49 -1.381 . . . . 0.0 111.037 171.295 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.568 ' H ' ' HB3' ' A' ' 111' ' ' SER . 86.3 p -154.91 161.24 41.49 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.265 -0.897 . . . . 0.0 112.602 169.144 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.568 HD11 ' HB3' ' A' ' 22' ' ' GLN . 0.0 OUTLIER -92.53 50.89 1.66 Allowed 'General case' 0 CA--C 1.542 0.636 0 O-C-N 121.15 -0.969 . . . . 0.0 111.44 175.732 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.1 t -87.85 -40.91 13.62 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.436 1.094 . . . . 0.0 112.925 178.725 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.46 12.27 38.95 Favored Glycine 0 N--CA 1.478 1.494 0 N-CA-C 115.535 0.974 . . . . 0.0 115.535 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -89.54 -92.71 0.12 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.581 2.352 . . . . 0.0 111.006 -179.672 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -96.65 -24.96 15.75 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 126.585 1.954 . . . . 0.0 109.291 174.283 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.568 ' HB3' ' H ' ' A' ' 105' ' ' SER . 53.4 m -79.16 -142.14 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.07 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -168.001 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.7 pt -94.98 -21.46 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -166.414 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mm -63.75 141.97 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.811 1.187 . . . . 0.0 109.666 170.844 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.13 28.08 62.93 Favored Glycine 0 CA--C 1.503 -0.663 0 CA-C-O 116.701 -2.166 . . . . 0.0 113.446 177.475 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 84.7 mtt-85 -129.78 178.31 6.61 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.532 1.666 . . . . 0.0 108.515 171.741 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.436 HG21 ' HA3' ' A' ' 56' ' ' GLY . 89.4 m -117.19 145.36 43.91 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 119.328 0.967 . . . . 0.0 110.02 179.179 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.1 tp -108.31 134.14 51.55 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 119.074 0.852 . . . . 0.0 109.511 169.408 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -110.33 144.62 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.822 1.649 . . . . 0.0 110.643 172.619 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.99 142.24 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.903 1.281 . . . . 0.0 110.226 170.969 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -119.2 147.14 44.56 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.656 1.583 . . . . 0.0 114.563 -166.523 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -85.34 -17.29 37.23 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -166.73 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.9 169.48 8.89 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 120.087 -1.633 . . . . 0.0 111.082 172.718 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.6 133.6 55.84 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 168.727 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 40.2 t0 -83.36 154.03 24.26 Favored 'General case' 0 CA--C 1.54 0.571 0 O-C-N 123.272 0.357 . . . . 0.0 110.293 169.435 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -75.58 -50.9 14.16 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 165.973 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.2 mt 94.79 63.08 0.0 OUTLIER 'General case' 0 C--O 1.222 -0.358 0 C-N-CA 129.296 3.039 . . . . 0.0 109.299 -178.952 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.7 -25.63 16.58 Favored Glycine 0 N--CA 1.481 1.635 0 N-CA-C 117.069 1.588 . . . . 0.0 117.069 167.636 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -118.35 -144.96 0.37 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.181 1.792 . . . . 0.0 110.897 172.148 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.08 7.97 60.62 Favored Glycine 0 CA--C 1.536 1.352 0 O-C-N 120.356 -1.465 . . . . 0.0 113.23 -168.636 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.47 31.41 68.32 Favored Glycine 0 N--CA 1.472 1.057 0 N-CA-C 116.996 1.558 . . . . 0.0 116.996 167.802 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -150.1 172.6 15.01 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 119.856 1.828 . . . . 0.0 113.108 -173.514 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -47.91 -58.69 4.07 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.953 1.701 . . . . 0.0 112.938 176.599 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -65.1 -17.01 64.1 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.165 0.986 . . . . 0.0 113.433 -173.246 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.5 p -53.52 -45.74 69.85 Favored 'General case' 0 N--CA 1.469 0.494 0 O-C-N 120.824 -1.173 . . . . 0.0 113.089 174.245 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -96.31 -6.86 36.79 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.875 0.87 . . . . 0.0 112.018 -178.861 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.93 -48.2 5.52 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.708 1.14 . . . . 0.0 112.618 176.605 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 19.9 p -114.61 -25.14 8.44 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 174.867 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.477 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 121.97 -30.73 5.18 Favored Glycine 0 C--O 1.228 -0.226 0 C-N-CA 126.09 1.805 . . . . 0.0 112.356 -168.061 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.6 t30 114.08 2.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 131.601 3.96 . . . . 0.0 112.645 -174.566 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.5 1.27 0.02 OUTLIER 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 120.251 3.426 . . . . 0.0 120.251 -168.692 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.59 -32.68 0.17 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 120.985 3.154 . . . . 0.0 120.985 165.82 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.0 m -167.4 141.36 3.64 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 120.272 2.036 . . . . 0.0 111.581 -172.227 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.53 134.68 54.83 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.741 1.155 . . . . 0.0 112.214 178.319 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.574 HD11 HD23 ' A' ' 38' ' ' LEU . 2.3 pt? -110.36 -22.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.08 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.71 161.19 13.25 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 119.95 1.25 . . . . 0.0 112.46 -177.934 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.9 p -155.47 166.76 32.55 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.332 1.453 . . . . 0.0 112.763 172.926 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.44 136.84 4.83 Favored Glycine 0 N--CA 1.48 1.579 0 C-N-CA 125.287 1.422 . . . . 0.0 113.583 177.168 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -83.6 133.48 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.469 1.108 . . . . 0.0 110.641 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.49 110.13 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.023 0.929 . . . . 0.0 111.301 -172.016 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.74 170.14 13.31 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 122.76 1.2 . . . . 0.0 113.916 173.268 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.0 pp -91.25 164.03 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.672 1.189 . . . . 0.0 112.137 -174.258 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.483 ' HA ' ' CD1' ' B' ' 50' ' ' PHE . . . -155.53 -20.61 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 167.072 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.476 0.832 0 C-N-CA 124.521 1.128 . . . . 0.0 110.166 170.366 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.7 t -80.26 118.78 22.23 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 167.507 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.87 121.37 45.09 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -178.885 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.03 166.2 11.38 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.861 1.264 . . . . 0.0 110.794 168.101 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.74 146.07 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 125.477 1.511 . . . . 0.0 111.903 -166.722 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.0 101.2 3.99 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 123.756 0.822 . . . . 0.0 111.269 169.621 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -84.02 95.5 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 168.031 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.4 mt -81.34 140.25 34.88 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 122.784 0.434 . . . . 0.0 110.78 -177.043 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 9.0 mtpp -149.24 179.26 8.05 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 121.166 -0.959 . . . . 0.0 112.81 170.913 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.43 -70.79 0.29 Allowed Glycine 0 C--N 1.335 0.505 0 C-N-CA 126.393 1.949 . . . . 0.0 111.238 178.98 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -87.09 78.83 8.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.78 0.8 . . . . 0.0 112.715 -165.373 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 49.09 -104.22 0.09 OUTLIER Glycine 0 CA--C 1.534 1.249 0 C-N-CA 126.565 2.031 . . . . 0.0 112.623 171.514 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -80.01 -1.2 11.24 Favored 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 125.181 3.921 . . . . 0.0 114.176 -179.24 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.49 134.62 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 119.715 1.143 . . . . 0.0 110.8 171.84 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -135.51 161.92 34.13 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 125.843 1.657 . . . . 0.0 109.939 168.231 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.5 144.8 16.44 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 167.205 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -142.18 102.04 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.624 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -122.4 137.6 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 C-N-CA 123.957 0.903 . . . . 0.0 109.394 -179.76 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.36 152.41 34.99 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.058 2.143 . . . . 0.0 109.147 172.131 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -138.89 89.29 2.35 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.215 1.806 . . . . 0.0 107.66 -174.81 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.8 120.31 33.9 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 118.084 0.402 . . . . 0.0 110.07 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -112.52 141.46 46.25 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 122.578 1.18 . . . . 0.0 112.18 174.41 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.36 -26.8 24.64 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 126.571 1.949 . . . . 0.0 114.18 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 5.8 mp0 -122.94 -174.11 2.86 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.235 2.214 . . . . 0.0 109.885 174.506 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.2 m -98.52 -14.5 19.97 Favored 'General case' 0 N--CA 1.481 1.099 0 O-C-N 120.54 -1.35 . . . . 0.0 111.639 167.08 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -139.47 105.55 5.22 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.198 2.599 . . . . 0.0 107.181 169.34 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.61 -168.42 41.49 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 126.066 1.794 . . . . 0.0 110.637 -170.784 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -85.57 150.61 10.19 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.529 2.153 . . . . 0.0 111.848 -179.268 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 10.2 t -119.36 129.32 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.135 1.374 . . . . 0.0 110.111 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.6 ttmm -93.53 120.89 34.35 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.091 0.948 . . . . 0.0 110.514 174.47 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.3 t -106.25 112.54 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 C-N-CA 126.321 1.848 . . . . 0.0 108.046 -171.713 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -137.74 161.18 37.22 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -177.57 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 136.62 -139.72 10.87 Favored Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.533 1.539 . . . . 0.0 111.351 175.62 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 47.3 p -156.47 156.73 34.24 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 114.711 1.375 . . . . 0.0 114.711 -174.862 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 24.7 mm -123.43 126.64 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 168.692 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . 0.282 3.5 ptmt -140.33 157.21 45.91 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 115.313 1.597 . . . . 0.0 115.313 -177.534 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.23 6.4 33.9 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 127.103 2.287 . . . . 0.0 111.916 -167.872 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 144' ' ' LEU . 1.5 mt -94.79 172.27 8.27 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.992 1.317 . . . . 0.0 111.769 -172.751 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.27 150.65 36.95 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 165.427 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -53.3 -0.27 0.02 OUTLIER 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 129.796 3.238 . . . . 0.0 115.86 170.63 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -69.46 177.28 29.96 Favored Glycine 0 CA--C 1.537 1.43 0 O-C-N 120.149 -1.594 . . . . 0.0 113.605 169.587 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.456 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.0 mp -78.37 160.0 28.04 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.381 1.472 . . . . 0.0 108.727 168.452 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -149.64 109.72 4.13 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.761 2.424 . . . . 0.0 109.857 -170.155 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.56 130.22 17.69 Favored Glycine 0 N--CA 1.477 1.37 0 CA-C-N 119.938 1.244 . . . . 0.0 111.864 176.955 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.493 ' CB ' HG22 ' B' ' 119' ' ' VAL . 35.3 p90 -125.62 137.73 53.89 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 120.151 1.976 . . . . 0.0 113.419 174.095 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.86 144.49 29.33 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.201 -0.937 . . . . 0.0 113.325 -176.021 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -81.27 136.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 166.075 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -74.74 168.4 19.92 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.826 1.25 . . . . 0.0 110.833 175.619 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.1 pm0 -59.61 -14.83 15.07 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -169.921 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 50' ' ' PHE . . . . . 0.483 ' CD1' ' HA ' ' A' ' 152' ' ' ALA . 31.3 m-85 -169.83 -179.26 3.21 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 129.147 2.979 . . . . 0.0 108.216 -168.849 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -125.92 11.32 7.39 Favored Glycine 0 N--CA 1.475 1.291 0 C-N-CA 125.505 1.526 . . . . 0.0 113.89 179.714 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -73.5 45.02 0.17 Allowed 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.755 1.222 . . . . 0.0 110.347 167.076 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -173.55 55.72 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 123.693 1.711 . . . . 0.0 114.726 -162.765 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 1.1 t . . . . . 0 CA--C 1.547 0.832 0 C-N-CA 126.592 1.957 . . . . 0.0 114.492 -179.647 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.535 0 CA-C-O 120.982 0.42 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -62.92 123.17 29.64 Favored Glycine 0 CA--C 1.543 1.843 0 CA-C-O 116.943 -2.032 . . . . 0.0 111.785 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.48 59.67 7.54 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 124.631 3.554 . . . . 0.0 116.632 -165.057 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.296 11.9 p80 52.7 59.01 4.78 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.19 2.596 . . . . 0.0 113.821 177.021 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 64' ' ' PHE . . . . . 0.413 ' CG ' ' N ' ' B' ' 65' ' ' ASN . 22.9 t80 -50.25 165.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 128.243 2.617 . . . . 0.0 114.938 177.553 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 65' ' ' ASN . . . . . 0.413 ' N ' ' CG ' ' B' ' 64' ' ' PHE . 1.0 OUTLIER -100.19 60.12 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.425 0 C-N-CA 131.296 3.838 . . . . 0.0 114.058 -170.078 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.02 -26.59 66.01 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.747 2.298 . . . . 0.0 113.764 -176.949 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.34 -2.49 58.63 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 126.627 1.971 . . . . 0.0 113.165 172.696 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.5 t 59.43 49.75 8.36 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.564 1.946 . . . . 0.0 112.447 -173.201 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -117.17 170.41 8.69 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.264 1.209 . . . . 0.0 114.264 -179.607 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.404 ' HZ3' ' CG ' ' B' ' 76' ' ' ASP . 0.1 OUTLIER -73.18 164.82 26.13 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-O 122.75 1.262 . . . . 0.0 109.325 166.29 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.443 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 83.4 t60 -67.36 -176.17 0.56 Allowed 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.223 167.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.443 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 115.17 -128.93 8.32 Favored Glycine 0 CA--C 1.502 -0.723 0 N-CA-C 115.252 0.861 . . . . 0.0 115.252 164.305 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.05 -76.32 0.34 Allowed Glycine 0 CA--C 1.531 1.061 0 CA-C-O 118.002 -1.443 . . . . 0.0 111.749 -169.586 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.64 10.07 0.23 Allowed 'Trans proline' 0 CA--C 1.547 1.134 0 C-N-CA 124.302 3.335 . . . . 0.0 116.614 -178.766 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.5 tptm -166.07 -30.61 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.264 1.426 . . . . 0.0 112.48 -168.427 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.404 ' CG ' ' HZ3' ' B' ' 70' ' ' LYS . 8.6 t70 -125.03 119.12 27.79 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.579 1.552 . . . . 0.0 108.148 167.926 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -46.31 -17.86 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 130.156 3.383 . . . . 0.0 116.418 -174.319 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -85.36 -79.61 0.23 Allowed 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -169.587 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.505 ' HB3' HH11 ' B' ' 79' ' ' ARG . 1.1 ttp-105 78.42 110.71 0.07 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.734 1.614 . . . . 0.0 109.731 177.199 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -50.08 152.17 1.76 Allowed 'General case' 0 CA--C 1.549 0.937 0 O-C-N 120.566 -1.334 . . . . 0.0 113.494 172.224 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.7 t -52.82 -37.74 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 123.966 0.906 . . . . 0.0 112.434 176.958 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.78 96.79 1.21 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 108.264 -1.934 . . . . 0.0 108.264 167.345 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -156.2 146.29 21.36 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.96 1.304 . . . . 0.0 113.446 171.249 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 48.2 mt -130.82 167.06 19.52 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.203 1.801 . . . . 0.0 106.981 166.802 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -104.99 -161.82 23.8 Favored Glycine 0 N--CA 1.475 1.247 0 C-N-CA 124.67 1.128 . . . . 0.0 112.593 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -79.37 164.63 23.89 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 -177.283 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.467 HG22 ' HB1' ' B' ' 95' ' ' ALA . 2.9 p -125.99 157.29 36.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 C-N-CA 129.0 2.92 . . . . 0.0 108.524 166.235 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -135.15 133.72 39.44 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.068 0.947 . . . . 0.0 109.799 -177.205 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.05 158.49 15.41 Favored 'General case' 0 C--O 1.222 -0.347 0 N-CA-C 114.065 1.135 . . . . 0.0 114.065 -172.966 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -97.63 155.47 16.97 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.645 1.578 . . . . 0.0 108.718 166.406 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 6.2 pttm -47.2 -25.32 0.89 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 128.936 2.894 . . . . 0.0 115.249 -177.5 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.67 3.23 10.07 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.319 1.448 . . . . 0.0 110.986 178.294 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.18 2.42 60.68 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 129.765 3.555 . . . . 0.0 113.726 172.936 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.2 p -114.64 131.92 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-N 119.937 1.869 . . . . 0.0 114.889 -168.36 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.467 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -98.37 128.8 44.94 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.003 -1.453 . . . . 0.0 108.728 166.236 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -82.27 146.33 29.51 Favored 'General case' 0 N--CA 1.46 0.073 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 168.005 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.263 0.3 OUTLIER -129.36 135.62 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 114.289 -1.323 . . . . 0.0 114.252 166.285 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 2.9 p -157.2 57.13 0.52 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 125.591 1.556 . . . . 0.0 110.759 -169.984 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.3 mt -109.04 166.55 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 127.654 2.381 . . . . 0.0 111.593 -169.746 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -148.39 149.82 32.43 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 127.753 2.421 . . . . 0.0 109.081 171.881 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -146.63 145.46 30.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.36 1.464 . . . . 0.0 110.108 172.051 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.8 p -118.61 58.6 0.83 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.94 2.096 . . . . 0.0 113.041 -168.477 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 5.9 p -159.34 -37.18 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 113.27 0.841 . . . . 0.0 113.27 172.987 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.69 166.79 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-O 121.327 0.584 . . . . 0.0 110.773 171.444 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 36.8 m -156.57 175.8 13.55 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 120.752 -1.218 . . . . 0.0 112.615 178.983 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 106' ' ' LEU . . . . . 0.409 ' HA ' HG12 ' B' ' 113' ' ' ILE . 9.6 mp -92.61 76.35 5.02 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.664 1.586 . . . . 0.0 107.448 175.458 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.27 122.7 32.3 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.359 1.463 . . . . 0.0 108.077 -176.409 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.99 59.68 4.97 Favored Glycine 0 N--CA 1.471 1.021 0 C-N-CA 125.152 1.358 . . . . 0.0 112.976 -169.721 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -156.26 -76.62 0.09 Allowed 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 124.467 1.107 . . . . 0.0 110.347 -168.704 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -129.66 4.88 5.06 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 126.979 2.111 . . . . 0.0 112.559 -167.625 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.6 -151.92 0.47 Allowed 'General case' 0 CA--C 1.555 1.173 0 C-N-CA 127.651 2.381 . . . . 0.0 112.835 -166.999 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.8 pt -95.88 -5.35 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 118.718 -2.488 . . . . 0.0 115.657 -177.714 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 113' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' B' ' 106' ' ' LEU . 4.2 mm -67.4 129.28 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 165.095 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 66.41 51.25 44.33 Favored Glycine 0 C--O 1.225 -0.439 0 CA-C-O 117.854 -1.526 . . . . 0.0 112.541 178.043 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 25.7 mtt180 -129.19 145.61 51.28 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 118.346 1.073 . . . . 0.0 110.095 167.332 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 116' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 24.6 m -86.86 108.91 18.97 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 124.378 1.071 . . . . 0.0 109.628 -171.886 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 14.6 tp -91.6 125.07 36.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 120.441 1.473 . . . . 0.0 110.854 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -110.82 142.27 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.584 1.553 . . . . 0.0 110.315 170.424 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.493 HG22 ' CB ' ' B' ' 45' ' ' PHE . 59.0 t -112.74 144.07 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 165.338 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -109.76 160.9 15.93 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 126.584 1.953 . . . . 0.0 112.182 -172.235 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.265 1.8 pp20? -82.43 -17.77 44.2 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -172.09 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -113.97 172.87 6.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 176.713 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.16 164.31 1.77 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 124.475 1.11 . . . . 0.0 109.899 166.789 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.2 p30 -113.66 147.12 38.7 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 123.237 1.494 . . . . 0.0 112.531 170.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -86.86 -22.69 25.62 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.134 1.374 . . . . 0.0 111.077 171.749 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 54.9 mt 71.41 -29.63 0.2 Allowed 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 128.765 2.826 . . . . 0.0 114.503 169.506 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -159.52 -47.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.701 0 CA-C-N 120.844 1.657 . . . . 0.0 114.594 174.052 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.08 100.21 2.9 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 117.254 2.316 . . . . 0.0 117.254 -168.465 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.17 -76.84 1.34 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 107.131 -2.388 . . . . 0.0 107.131 166.687 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -179.52 27.83 0.05 OUTLIER Glycine 0 CA--C 1.532 1.103 0 C-N-CA 126.382 1.944 . . . . 0.0 112.956 175.946 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -146.34 172.84 12.89 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.998 1.719 . . . . 0.0 111.08 -167.309 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -64.58 -63.06 1.22 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 110.814 -170.453 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 133' ' ' GLU . . . . . 0.423 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 0.8 OUTLIER -56.18 -23.64 36.39 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 128.935 2.894 . . . . 0.0 111.916 -173.558 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 52.2 m -53.58 -49.82 66.93 Favored 'General case' 0 N--CA 1.462 0.14 0 C-N-CA 123.721 0.808 . . . . 0.0 112.425 168.383 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 44.2 p -91.21 -34.5 14.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.158 1.383 . . . . 0.0 110.699 -174.375 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -81.9 -31.74 31.29 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.143 2.177 . . . . 0.0 113.085 -171.275 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.8 p -125.24 -93.3 0.5 Allowed 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 169.281 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -174.0 22.22 0.06 OUTLIER Glycine 0 CA--C 1.53 1.019 0 C-N-CA 128.647 3.022 . . . . 0.0 111.58 169.688 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 56.67 4.04 0.14 Allowed 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 127.83 2.452 . . . . 0.0 116.545 -169.307 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.98 -5.88 0.03 OUTLIER 'General case' 0 CA--C 1.557 1.226 0 N-CA-C 119.865 3.284 . . . . 0.0 119.865 -168.337 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 88.12 -165.95 34.85 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.718 1.628 . . . . 0.0 113.661 -176.966 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 18.7 t -66.86 160.61 25.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 122.14 0.971 . . . . 0.0 111.284 173.598 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.7 ptt85 -67.38 164.16 19.19 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 122.356 1.074 . . . . 0.0 111.684 169.765 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 38' ' ' LEU 0.316 2.9 pp -135.55 -134.7 0.15 Allowed 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 104.229 -2.508 . . . . 0.0 104.229 160.175 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.75 154.88 8.41 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-N 120.536 1.516 . . . . 0.0 114.678 -178.697 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.1 t -151.0 143.94 24.58 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.658 1.983 . . . . 0.0 111.212 -172.677 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.29 144.25 9.51 Favored Glycine 0 N--CA 1.477 1.39 0 C-N-CA 125.507 1.527 . . . . 0.0 113.465 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 20.5 t -83.47 141.57 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 CA-C-N 119.268 1.534 . . . . 0.0 110.592 177.451 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 73.8 mt -75.32 106.76 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 121.473 0.654 . . . . 0.0 109.65 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.7 -172.87 19.36 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 124.387 0.994 . . . . 0.0 111.793 168.174 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -100.01 149.24 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.87 0.843 . . . . 0.0 112.726 -176.952 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -103.22 -135.21 0.33 Allowed 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 166.62 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 N--CA 1.473 0.701 0 C-N-CA 126.001 1.72 . . . . 0.0 110.983 168.881 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.475 0.82 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 42.8 pttt -83.12 139.49 33.16 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.933 1.349 . . . . 0.0 114.212 -172.042 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.458 ' CB ' HD11 ' A' ' 113' ' ' ILE . . . -99.08 146.03 26.51 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 127.369 2.268 . . . . 0.0 107.753 167.409 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 33.0 t -154.95 143.54 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 119.567 1.076 . . . . 0.0 110.993 -175.2 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.87 95.63 2.88 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 123.767 0.827 . . . . 0.0 110.504 169.116 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.8 m -76.15 92.7 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-O 122.127 0.965 . . . . 0.0 109.618 170.934 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.2 mt -76.52 139.01 40.59 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.006 0.922 . . . . 0.0 109.553 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.6 ttmm -155.45 177.62 11.16 Favored 'General case' 0 CA--C 1.542 0.672 0 O-C-N 120.753 -1.217 . . . . 0.0 109.765 179.648 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.03 -33.83 3.91 Favored Glycine 0 N--CA 1.472 1.076 0 C-N-CA 124.279 0.942 . . . . 0.0 114.341 169.16 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.85 65.7 5.09 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 122.299 1.047 . . . . 0.0 110.146 175.905 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.06 -101.94 0.03 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.081 2.753 . . . . 0.0 113.146 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -83.24 -2.84 10.79 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 124.66 3.573 . . . . 0.0 114.441 -178.346 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -95.28 137.42 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 CA-C-N 120.697 1.59 . . . . 0.0 111.156 176.987 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -144.56 161.86 38.05 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 125.918 1.687 . . . . 0.0 109.697 172.321 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -134.63 106.18 0.59 Allowed Glycine 0 CA--C 1.502 -0.723 0 C-N-CA 124.34 0.971 . . . . 0.0 111.314 177.779 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.2 117.47 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 167.862 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -135.9 106.94 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-O 121.616 0.722 . . . . 0.0 109.369 169.293 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 -100.22 139.7 35.52 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.687 1.595 . . . . 0.0 110.885 -179.585 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -120.46 135.56 55.02 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 119.091 0.86 . . . . 0.0 110.85 179.206 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -115.1 114.86 25.88 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 127.078 2.151 . . . . 0.0 109.852 -172.942 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.8 tp60 -125.92 130.9 52.21 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 113.51 -1.677 . . . . 0.0 109.828 -170.398 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.594 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -99.33 -11.74 20.94 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 128.147 2.579 . . . . 0.0 114.129 -168.771 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.413 ' CD ' ' H ' ' A' ' 25' ' ' SER . 5.3 tm-20 -149.25 -172.02 4.03 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 127.918 2.487 . . . . 0.0 108.681 -172.376 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.413 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 0.8 OUTLIER -72.34 -57.18 4.41 Favored 'General case' 0 N--CA 1.474 0.726 0 O-C-N 118.778 -2.451 . . . . 0.0 111.601 169.677 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -123.37 -3.16 8.43 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.73 1.612 . . . . 0.0 114.918 -169.271 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.36 161.48 6.98 Favored Glycine 0 CA--C 1.537 1.446 0 CA-C-N 119.224 0.92 . . . . 0.0 110.955 168.372 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -66.85 143.94 68.94 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.327 2.018 . . . . 0.0 110.61 -170.035 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 37.3 t -107.62 129.87 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 123.262 0.625 . . . . 0.0 110.158 -173.159 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -79.64 125.77 30.05 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 49.9 t -112.42 130.73 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 128.456 2.703 . . . . 0.0 108.154 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -155.41 165.79 35.54 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 119.577 1.081 . . . . 0.0 113.249 175.644 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.27 -155.95 26.76 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 123.902 0.763 . . . . 0.0 113.655 172.726 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.9 p -149.53 128.36 12.53 Favored 'General case' 0 C--O 1.239 0.528 0 C-N-CA 123.319 0.648 . . . . 0.0 112.367 -169.483 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.0 mp -104.52 106.6 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 123.697 0.799 . . . . 0.0 109.599 175.371 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 tttp -117.14 133.64 55.75 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.38 1.072 . . . . 0.0 112.894 -168.903 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.56 9.37 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 128.318 2.866 . . . . 0.0 113.623 -177.621 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.8 mt -77.86 174.71 10.74 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.097 2.159 . . . . 0.0 113.37 -175.862 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.36 148.71 22.13 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 162.284 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.589 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.0 OUTLIER -53.79 -2.01 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 129.222 3.009 . . . . 0.0 115.825 176.065 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.31 174.34 17.46 Favored Glycine 0 CA--C 1.536 1.404 0 O-C-N 120.251 -1.531 . . . . 0.0 113.29 169.212 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.718 HD23 ' H ' ' A' ' 42' ' ' LEU . 2.0 pt? -88.31 138.17 31.67 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.778 2.031 . . . . 0.0 109.997 171.053 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -130.87 149.23 52.6 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 129.018 2.927 . . . . 0.0 108.615 -171.723 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -112.09 135.09 12.48 Favored Glycine 0 N--CA 1.486 1.991 0 CA-C-O 116.861 -2.077 . . . . 0.0 111.405 -172.554 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -135.74 133.28 37.85 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 121.165 2.482 . . . . 0.0 114.956 179.073 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.42 26.77 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.027 1.331 . . . . 0.0 109.801 -170.781 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 116' ' ' THR . 0.3 OUTLIER -86.33 118.35 32.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.263 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.742 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.0 m170 -77.71 163.03 26.53 Favored 'General case' 0 CA--C 1.549 0.931 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 176.157 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.18 133.97 55.93 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.816 -0.553 . . . . 0.0 110.745 -176.83 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.465 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 43.0 m-85 71.02 165.32 0.29 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.612 2.365 . . . . 0.0 115.348 170.123 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.21 -3.55 19.16 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 126.434 1.969 . . . . 0.0 113.654 177.684 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.0 m-20 -72.91 46.79 0.17 Allowed 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.076 1.35 . . . . 0.0 110.59 170.015 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 174.45 40.1 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.635 2.374 . . . . 0.0 112.747 -167.541 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.0 t -53.71 19.97 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 129.78 3.232 . . . . 0.0 116.375 172.285 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.63 16.41 8.8 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 126.699 2.0 . . . . 0.0 112.715 -178.293 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.6 -144.02 41.42 Favored Glycine 0 N--CA 1.467 0.752 0 O-C-N 121.087 -1.008 . . . . 0.0 112.097 171.12 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 p -58.69 -23.24 59.12 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.748 1.018 . . . . 0.0 113.748 -178.011 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 13.0 t -90.52 42.64 1.11 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.364 1.066 . . . . 0.0 112.019 175.935 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 m 178.57 -35.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 129.577 3.151 . . . . 0.0 115.091 169.606 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.53 158.98 15.36 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -168.917 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.97 -153.93 17.76 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 126.004 1.764 . . . . 0.0 114.223 173.999 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -88.58 178.39 2.88 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 125.281 3.987 . . . . 0.0 112.107 -179.496 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -79.91 83.55 5.81 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 167.062 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -50.94 166.03 0.1 Allowed 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.34 2.256 . . . . 0.0 113.993 -174.153 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -108.11 57.84 0.23 Allowed Pre-proline 0 CA--C 1.552 1.031 0 C-N-CA 127.202 2.201 . . . . 0.0 112.25 -169.712 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -64.32 -28.82 63.52 Favored 'Trans proline' 0 C--N 1.354 0.838 0 CA-C-N 122.602 1.965 . . . . 0.0 113.272 -175.382 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.8 mp -82.13 -4.9 57.9 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.077 1.351 . . . . 0.0 113.171 170.533 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.8 t 65.37 54.15 1.2 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 127.242 2.217 . . . . 0.0 112.894 -175.916 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -121.51 174.37 6.82 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -170.912 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.7 mtmt -81.04 165.92 21.23 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.494 0.718 . . . . 0.0 110.719 167.18 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.445 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 73.8 t60 -71.02 175.21 5.35 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.643 0.735 . . . . 0.0 111.645 167.758 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.15 -138.16 9.92 Favored Glycine 0 CA--C 1.504 -0.599 0 C-N-CA 124.295 0.95 . . . . 0.0 112.173 167.629 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.78 -99.95 0.26 Allowed Glycine 0 CA--C 1.533 1.202 0 CA-C-O 115.811 -2.661 . . . . 0.0 109.845 -178.652 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -56.69 0.45 0.19 Allowed 'Trans proline' 0 CA--C 1.549 1.255 0 C-N-CA 124.126 3.218 . . . . 0.0 117.983 -178.742 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.0 pttt -134.86 -4.32 2.49 Favored 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.332 1.424 . . . . 0.0 114.276 167.339 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -155.82 112.11 3.11 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 126.051 1.74 . . . . 0.0 109.985 -175.555 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -62.21 -7.58 4.39 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -173.881 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -80.36 -9.02 59.74 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -173.048 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -17.36 118.53 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 129.446 3.098 . . . . 0.0 112.963 168.407 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.8 m80 -62.05 166.04 5.07 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.697 1.199 . . . . 0.0 111.61 177.916 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 32.5 m -76.33 29.58 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -178.469 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.402 ' CA ' HG12 ' A' ' 47' ' ' VAL . . . -148.28 9.99 1.13 Allowed Glycine 0 CA--C 1.532 1.096 0 C-N-CA 125.583 1.563 . . . . 0.0 115.166 -178.686 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -105.64 115.99 31.19 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.881 1.273 . . . . 0.0 113.209 -168.611 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.8 mp -91.2 170.7 9.79 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 163.459 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -79.79 -172.37 43.65 Favored Glycine 0 CA--C 1.529 0.941 0 O-C-N 121.372 -0.83 . . . . 0.0 112.238 171.751 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -78.42 144.11 36.15 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.422 -1.046 . . . . 0.0 112.512 172.6 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.443 HG22 ' HB1' ' A' ' 95' ' ' ALA . 2.3 p -114.51 139.43 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 128.003 2.521 . . . . 0.0 110.308 177.528 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.5 m -128.65 133.47 48.25 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.785 1.234 . . . . 0.0 110.586 -169.306 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.64 163.11 13.51 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 -176.2 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -83.32 169.8 15.26 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.106 1.362 . . . . 0.0 108.422 165.125 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.435 ' HD3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -62.02 -18.7 61.42 Favored 'General case' 0 N--CA 1.482 1.167 0 O-C-N 120.66 -1.275 . . . . 0.0 113.893 172.277 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -73.62 -3.03 25.52 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.59 1.556 . . . . 0.0 111.426 168.931 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.88 6.69 89.27 Favored Glycine 0 C--N 1.332 0.33 0 C-N-CA 126.155 1.836 . . . . 0.0 113.462 170.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -94.33 121.51 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 126.079 1.751 . . . . 0.0 111.541 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -97.89 99.12 10.42 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 167.148 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -79.9 143.86 33.9 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.543 1.537 . . . . 0.0 109.936 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.26 142.75 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 -176.503 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 p -149.89 109.98 4.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.417 1.487 . . . . 0.0 111.294 174.106 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.2 mt -138.08 158.73 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 127.295 2.238 . . . . 0.0 110.988 -171.157 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -145.39 144.33 30.6 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 126.353 1.861 . . . . 0.0 106.851 164.975 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -145.12 148.17 33.33 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 125.021 1.328 . . . . 0.0 110.597 179.373 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.32 49.69 0.95 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.674 0.789 . . . . 0.0 112.2 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.2 t -139.89 -47.7 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.211 1.404 . . . . 0.0 109.893 175.933 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -84.6 158.14 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-O 122.307 1.051 . . . . 0.0 113.201 175.592 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.9 p -157.03 171.51 20.33 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 115.316 1.599 . . . . 0.0 115.316 -171.614 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.01 80.25 9.1 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.41 1.484 . . . . 0.0 108.587 176.662 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 60.5 p -90.2 -170.95 2.94 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.564 0.697 . . . . 0.0 112.57 173.836 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.51 -43.77 5.12 Favored Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.363 0.982 . . . . 0.0 111.425 167.563 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 34.9 t0 -172.3 45.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.694 1.597 . . . . 0.0 111.787 -173.119 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -140.85 -40.53 0.4 Allowed 'General case' 0 N--CA 1.47 0.525 0 O-C-N 120.139 -1.601 . . . . 0.0 111.097 -172.16 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.9 m -90.67 -125.34 0.07 Allowed 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 127.988 2.515 . . . . 0.0 110.499 172.047 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.7 pt -102.7 -27.24 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 114.947 1.462 . . . . 0.0 114.947 -175.399 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.458 HD11 ' CB ' ' A' ' 4' ' ' ALA . 33.8 mm -60.46 138.23 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 168.374 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.67 8.25 73.84 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 117.366 -1.797 . . . . 0.0 113.631 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -122.17 174.12 7.16 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 119.913 1.856 . . . . 0.0 111.126 -174.17 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.45 ' N ' HG22 ' A' ' 47' ' ' VAL . 39.0 m -116.22 109.37 17.33 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.269 -1.519 . . . . 0.0 111.239 -163.328 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 33.9 tp -96.38 122.24 39.05 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.464 1.105 . . . . 0.0 110.64 -172.766 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 p -121.07 133.99 65.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.025 1.33 . . . . 0.0 108.839 175.203 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.3 t -90.67 152.64 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.225 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 165.053 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.03 138.55 54.43 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.745 2.018 . . . . 0.0 107.365 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.09 -46.3 79.08 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -167.256 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt -101.87 143.16 32.11 Favored 'General case' 0 C--N 1.329 -0.312 0 O-C-N 121.375 -0.828 . . . . 0.0 110.486 169.903 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.44 158.9 1.58 Allowed 'General case' 0 C--O 1.231 0.126 0 C-N-CA 125.027 1.331 . . . . 0.0 114.098 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -75.43 146.5 40.68 Favored 'General case' 0 N--CA 1.443 -0.823 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 165.599 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -68.54 -21.13 64.57 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.961 171.013 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.7 mt 85.33 -64.5 0.05 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 131.075 3.75 . . . . 0.0 108.582 -174.67 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.94 -75.75 0.98 Allowed Glycine 0 N--CA 1.464 0.559 0 C-N-CA 124.695 1.141 . . . . 0.0 110.887 -171.125 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -163.43 109.28 1.11 Allowed 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 168.583 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.44 21.74 0.69 Allowed Glycine 0 CA--C 1.545 1.965 0 C-N-CA 125.208 1.385 . . . . 0.0 116.509 172.669 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.25 10.94 73.43 Favored Glycine 0 N--CA 1.479 1.508 0 N-CA-C 118.551 2.18 . . . . 0.0 118.551 168.518 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.634 ' H ' ' HB3' ' A' ' 134' ' ' SER . 32.4 m-80 -127.24 179.47 5.43 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 119.872 1.836 . . . . 0.0 111.659 -173.559 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.31 -56.71 18.62 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 166.799 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -35.28 -31.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 128.839 2.855 . . . . 0.0 115.71 167.249 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.634 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 66.8 p -57.83 -24.44 57.44 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 117.435 2.383 . . . . 0.0 117.435 -166.842 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.282 3.4 t -133.02 -14.07 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 -179.203 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.2 ptmt -70.86 -47.37 59.69 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 120.297 1.408 . . . . 0.0 110.17 167.543 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -105.24 -18.85 13.99 Favored 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.943 -177.326 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.445 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 91.23 5.86 67.14 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 124.144 0.878 . . . . 0.0 112.311 -168.426 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 74.72 2.42 4.04 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.451 2.301 . . . . 0.0 114.442 -170.296 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.66 106.26 0.76 Allowed 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 119.43 1.014 . . . . 0.0 111.398 -169.284 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -36.58 -7.44 0.0 OUTLIER Glycine 0 N--CA 1.493 2.439 1 C-N-CA 131.255 4.264 . . . . 0.0 122.836 -165.862 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 18.4 p 104.86 156.73 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 131.06 3.744 . . . . 0.0 113.315 166.556 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 61.85 131.32 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 117.826 2.528 . . . . 0.0 117.826 166.03 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 179.94 -165.83 0.07 Allowed 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 128.571 2.748 . . . . 0.0 108.451 168.171 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -55.98 151.47 11.77 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.975 1.31 . . . . 0.0 112.429 170.17 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.5 t -153.0 152.06 30.97 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.749 2.02 . . . . 0.0 112.573 -172.848 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.46 167.52 36.34 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 127.731 2.586 . . . . 0.0 110.716 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.9 p -98.5 141.78 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 CA-C-N 119.771 1.785 . . . . 0.0 109.382 169.632 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.3 mt -78.92 102.27 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 O-C-N 121.635 -0.666 . . . . 0.0 111.473 -175.266 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.32 177.2 29.65 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-O 122.601 1.112 . . . . 0.0 112.506 171.744 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -111.41 158.53 11.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 126.364 1.866 . . . . 0.0 110.993 175.135 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.484 ' HB2' ' CG ' ' B' ' 52' ' ' ASP . . . -107.29 -14.79 14.8 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.212 1.005 . . . . 0.0 112.228 167.153 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 . . . . . 0 C--O 1.237 0.419 0 C-N-CA 126.863 2.065 . . . . 0.0 108.377 -164.819 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.389 0 CA-C-O 121.842 0.83 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.4 t -118.53 130.28 55.83 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 124.357 1.063 . . . . 0.0 110.113 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -91.29 148.82 22.07 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 168.182 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.04 141.77 31.39 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 114.339 -1.3 . . . . 0.0 107.891 166.612 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 49.0 t -137.95 142.88 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 CA-C-O 121.675 0.75 . . . . 0.0 111.815 -169.068 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.1 132.29 55.99 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 122.437 1.113 . . . . 0.0 112.169 169.822 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -115.83 86.07 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 127.065 2.146 . . . . 0.0 107.027 169.642 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.61 117.32 17.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -158.03 134.24 9.42 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 119.279 0.945 . . . . 0.0 113.249 -170.297 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.07 -38.7 0.05 OUTLIER Glycine 0 N--CA 1.471 0.992 0 C-N-CA 125.659 1.6 . . . . 0.0 111.443 172.453 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.13 66.6 2.96 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 128.393 2.677 . . . . 0.0 112.188 -176.282 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.33 -102.48 0.05 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 127.111 2.291 . . . . 0.0 113.613 174.321 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -82.55 -11.85 10.34 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.907 3.072 . . . . 0.0 114.257 -176.845 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -91.13 136.08 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 CA-C-N 120.013 1.278 . . . . 0.0 110.124 -177.518 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.76 156.73 35.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.747 168.397 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.45 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -125.83 123.58 4.92 Favored Glycine 0 CA--C 1.503 -0.675 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.045 173.714 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.37 128.44 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 164.567 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.7 pp -136.34 134.77 49.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 164.279 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -106.25 151.48 24.74 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.107 1.363 . . . . 0.0 112.111 172.392 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -120.91 128.24 52.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.409 1.884 . . . . 0.0 112.165 169.772 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -104.08 112.42 25.41 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 128.885 2.874 . . . . 0.0 110.742 173.635 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -108.26 124.73 50.76 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.464 -0.773 . . . . 0.0 109.679 174.809 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.92 -42.06 21.96 Favored 'General case' 0 CA--C 1.551 0.996 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 176.045 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -134.56 133.72 40.57 Favored 'General case' 0 C--O 1.22 -0.485 0 C-N-CA 126.098 1.759 . . . . 0.0 109.989 170.269 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 97.9 p -70.48 79.17 0.56 Allowed 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 120.523 1.51 . . . . 0.0 113.278 -178.174 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.9 p30 158.47 -30.1 0.0 OUTLIER 'General case' 0 CA--C 1.548 0.871 1 C-N-CA 132.877 4.471 . . . . 0.0 111.176 -176.506 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.03 -172.92 43.06 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 126.099 1.809 . . . . 0.0 113.993 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -78.75 170.92 17.41 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 124.14 3.227 . . . . 0.0 112.444 -170.093 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 32.1 t -139.59 131.77 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 CA-C-O 121.482 0.658 . . . . 0.0 112.333 -167.753 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -87.48 129.06 35.21 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 167.594 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 t -110.5 138.84 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 126.322 1.849 . . . . 0.0 109.665 173.736 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 19.5 p90 -152.91 168.74 24.78 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.706 -0.621 . . . . 0.0 112.032 170.487 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.4 -161.94 29.36 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 114.757 0.663 . . . . 0.0 114.757 174.031 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 46.2 p -153.96 123.99 6.85 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.003 0.921 . . . . 0.0 111.631 -170.027 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.45 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 2.7 mp -106.4 113.17 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 CA-C-O 117.709 -1.138 . . . . 0.0 111.388 177.169 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.0 mmmt -102.38 144.93 30.23 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 120.407 1.458 . . . . 0.0 109.374 -178.234 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.69 -4.23 14.81 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.232 1.396 . . . . 0.0 114.235 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -67.87 179.83 1.35 Allowed 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.367 1.067 . . . . 0.0 110.124 168.566 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -106.98 -32.27 7.95 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 117.763 -1.113 . . . . 0.0 113.892 172.108 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 173.39 -168.49 0.03 OUTLIER 'General case' 0 CA--C 1.556 1.207 1 C-N-CA 132.975 4.51 . . . . 0.0 105.174 178.876 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.5 161.96 28.43 Favored Glycine 0 CA--C 1.525 0.666 0 C-N-CA 126.1 1.809 . . . . 0.0 115.671 167.809 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.889 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -66.33 150.29 49.08 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.261 2.625 . . . . 0.0 108.968 168.658 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -143.88 121.87 12.08 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.589 1.156 . . . . 0.0 111.945 179.518 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.02 147.13 41.88 Favored Glycine 0 N--CA 1.482 1.759 0 CA-C-N 119.934 1.243 . . . . 0.0 112.559 -179.971 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -150.25 111.06 4.3 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.071 1.349 . . . . 0.0 110.115 -173.812 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.89 152.78 35.61 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 119.8 -1.812 . . . . 0.0 114.587 -165.071 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.02 126.81 53.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-O 121.447 0.642 . . . . 0.0 111.336 -177.322 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -78.21 -179.31 6.13 Favored 'General case' 0 CA--C 1.544 0.717 1 C-N-CA 131.837 4.055 . . . . 0.0 114.444 -175.128 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 49' ' ' GLU . . . . . 0.439 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 1.2 pm0 -59.99 135.26 57.65 Favored 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 163.208 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.274 42.7 m-85 -0.29 -130.45 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.621 1 C-N-CA 132.105 4.162 . . . . 0.0 116.865 -169.254 . . . . . . . . 3 2 . 1 . 023 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -130.44 -2.9 4.84 Favored Glycine 0 N--CA 1.472 1.034 0 C-N-CA 124.524 1.059 . . . . 0.0 114.079 -169.676 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.484 ' CG ' ' HB2' ' A' ' 152' ' ' ALA . 12.6 p-10 -81.83 48.32 1.2 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.333 1.853 . . . . 0.0 111.697 177.289 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.263 0.4 OUTLIER -176.89 43.9 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.489 1.516 . . . . 0.0 112.187 -168.937 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.482 1.129 0 C-N-CA 128.735 2.814 . . . . 0.0 115.969 171.768 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.097 0 N-CA-C 115.473 1.657 . . . . 0.0 115.473 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 61' ' ' GLY . . . . . 0.439 ' H ' ' CD ' ' B' ' 49' ' ' GLU . . . -99.3 -121.31 4.54 Favored Glycine 0 CA--C 1.544 1.902 0 C-N-CA 126.485 1.993 . . . . 0.0 115.082 -169.263 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -99.19 179.16 0.3 Allowed 'Trans proline' 0 C--N 1.35 0.618 1 C-N-CA 125.415 4.076 . . . . 0.0 111.566 -175.79 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -76.5 110.87 11.41 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.009 177.479 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -48.05 128.82 14.31 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.633 1.973 . . . . 0.0 113.78 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -121.57 64.96 16.69 Favored Pre-proline 0 CA--C 1.548 0.886 0 C-N-CA 124.721 1.208 . . . . 0.0 112.596 -172.312 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -63.58 -22.51 70.5 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 123.679 2.919 . . . . 0.0 113.465 -175.782 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.9 mt -79.51 -4.95 53.66 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.502 1.521 . . . . 0.0 112.916 172.606 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.7 p 62.15 52.07 3.34 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 127.891 2.476 . . . . 0.0 111.448 177.569 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -126.41 174.15 8.82 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 114.419 1.266 . . . . 0.0 114.419 -169.252 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 45.7 pttt -78.88 169.01 18.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 128.051 2.541 . . . . 0.0 111.192 171.235 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.419 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 78.6 t60 -90.28 174.85 7.36 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 176.221 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 72' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' B' ' 126' ' ' LEU . . . 129.24 -115.1 1.87 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 125.166 1.365 . . . . 0.0 113.48 166.57 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.03 -50.03 0.81 Allowed Glycine 0 CA--C 1.547 2.089 0 CA-C-O 117.859 -1.523 . . . . 0.0 116.196 173.044 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 74' ' ' PRO . . . . . 0.493 ' HD2' HD12 ' B' ' 126' ' ' LEU . 69.6 Cg_endo -88.64 -4.64 6.37 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 CA-C-N 121.425 2.613 . . . . 0.0 113.599 172.077 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 26.5 pttt -141.83 -1.35 1.27 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 124.256 1.022 . . . . 0.0 113.468 168.29 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -119.43 159.74 23.66 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.642 1.577 . . . . 0.0 110.099 169.496 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -81.96 -29.84 31.99 Favored 'General case' 0 CA--C 1.541 0.619 1 C-N-CA 132.486 4.314 . . . . 0.0 114.83 -171.321 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -98.51 -85.63 0.37 Allowed 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.714 -0.616 . . . . 0.0 111.165 -168.326 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ttp-105 80.93 121.22 0.05 OUTLIER 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.924 2.09 . . . . 0.0 111.16 176.979 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m80 -54.19 151.51 7.12 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 120.481 -1.387 . . . . 0.0 113.006 173.794 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -45.94 -48.38 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-O 119.048 -0.501 . . . . 0.0 112.104 -176.648 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.29 112.12 2.62 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-O 123.182 1.435 . . . . 0.0 113.117 169.411 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -155.56 107.14 2.58 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 130.659 3.584 . . . . 0.0 106.872 174.473 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 97.0 mt -89.09 54.06 2.87 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.558 0.743 . . . . 0.0 109.74 174.58 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.9 -107.56 0.14 Allowed Glycine 0 CA--C 1.532 1.107 0 C-N-CA 125.959 1.743 . . . . 0.0 113.652 177.449 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -153.74 146.16 24.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.367 1.467 . . . . 0.0 110.947 169.922 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.97 113.52 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 126.791 2.036 . . . . 0.0 110.359 -176.806 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -95.59 125.06 39.92 Favored 'General case' 0 N--CA 1.471 0.598 0 O-C-N 121.628 -0.67 . . . . 0.0 110.365 -175.189 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.38 148.62 24.01 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.738 1.215 . . . . 0.0 113.181 -175.595 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -76.71 174.91 9.88 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.49 1.516 . . . . 0.0 111.496 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.472 ' HB3' ' HZ3' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -68.59 -13.38 62.3 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 121.101 -1.0 . . . . 0.0 113.109 173.018 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -74.62 -23.7 58.74 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.101 1.36 . . . . 0.0 110.588 171.217 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.12 -2.71 59.8 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 116.655 -2.192 . . . . 0.0 114.47 -177.75 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.33 133.18 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 119.959 1.88 . . . . 0.0 113.818 169.856 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.44 113.93 27.8 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 164.783 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -99.67 133.34 44.16 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.066 1.347 . . . . 0.0 108.978 -176.596 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -135.26 135.7 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.495 1.118 . . . . 0.0 112.825 -167.393 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 27.6 p -156.11 113.69 3.27 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.312 1.445 . . . . 0.0 111.304 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 6.6 mt -145.14 152.57 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 127.85 2.46 . . . . 0.0 110.606 -169.333 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -134.98 137.78 43.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.846 0.858 . . . . 0.0 108.737 167.376 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -145.12 153.21 41.16 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 125.385 1.474 . . . . 0.0 112.327 -172.163 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 37.4 p -125.67 45.26 2.64 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 178.603 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.4 22.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.891 1.276 . . . . 0.0 112.669 169.427 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.15 158.86 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 127.119 2.168 . . . . 0.0 108.025 164.685 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 60.4 p -156.03 156.84 35.12 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.657 0.783 . . . . 0.0 109.758 -177.572 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -83.25 63.41 7.2 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.681 -1.262 . . . . 0.0 110.243 -177.322 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 11.1 t -93.5 154.59 17.81 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 165.703 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.0 -28.41 72.02 Favored Glycine 0 N--CA 1.47 0.909 0 C-N-CA 127.047 2.261 . . . . 0.0 118.322 -164.943 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 p30 -148.13 -46.67 0.16 Allowed 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -168.79 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -82.73 -18.89 39.18 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.782 -1.199 . . . . 0.0 111.994 -171.971 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 74.7 m -99.14 -92.85 0.26 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.093 0.957 . . . . 0.0 111.097 -176.174 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.74 -18.49 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 176.584 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 40.2 mm -68.64 153.0 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 122.089 2.222 . . . . 0.0 107.263 167.238 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.48 66.0 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 119.297 -0.724 . . . . 0.0 112.97 175.687 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 15.8 mtp85 -114.54 133.19 55.98 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 176.719 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.5 m -80.29 140.69 36.06 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.352 1.861 . . . . 0.0 107.003 179.258 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.3 tp -129.83 128.53 42.49 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.028 0.931 . . . . 0.0 109.786 -174.566 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.62 133.19 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.103 0.961 . . . . 0.0 110.628 177.736 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -98.24 149.25 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 165.969 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.2 m-70 -120.76 138.16 54.15 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.274 1.43 . . . . 0.0 113.199 -169.655 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -73.61 -24.79 60.09 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 120.163 -1.585 . . . . 0.0 114.013 -173.338 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -93.22 164.8 13.1 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 122.192 0.996 . . . . 0.0 112.355 169.808 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.87 158.97 20.7 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.008 1.323 . . . . 0.0 111.625 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -103.45 151.95 22.21 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.84 0.856 . . . . 0.0 112.185 179.124 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -102.36 -3.24 27.42 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 127.378 2.271 . . . . 0.0 112.878 -177.993 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.493 HD12 ' HD2' ' B' ' 74' ' ' PRO . 0.8 OUTLIER 45.85 56.45 5.97 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.132 1.773 . . . . 0.0 113.257 172.036 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.77 -54.1 1.68 Allowed Glycine 0 N--CA 1.471 1.033 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.014 173.023 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 134.55 18.86 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 172.314 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -160.21 -67.58 0.02 OUTLIER Glycine 0 CA--C 1.52 0.382 1 C-N-CA 130.723 4.011 . . . . 0.0 107.254 168.22 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -83.67 -111.14 0.56 Allowed Glycine 0 CA--C 1.533 1.188 0 C-N-CA 126.309 1.909 . . . . 0.0 117.039 -171.046 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -118.0 -159.13 0.74 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.431 2.292 . . . . 0.0 112.646 -163.307 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -49.34 -64.67 0.74 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.479 1.112 . . . . 0.0 112.033 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . 0.298 2.9 mt-10 -53.65 -10.37 0.27 Allowed 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 177.998 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 67.2 m -60.9 -47.76 84.92 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 122.133 2.242 . . . . 0.0 111.18 166.796 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 39.0 p -81.31 -38.14 27.25 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-O 119.102 -0.475 . . . . 0.0 111.347 176.493 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.9 tttt -68.63 -38.97 80.96 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.552 1.541 . . . . 0.0 113.88 -173.906 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 33.9 p -121.78 -68.72 0.88 Allowed 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 116.974 -1.488 . . . . 0.0 109.696 172.742 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 163.71 17.37 0.02 OUTLIER Glycine 0 CA--C 1.536 1.375 0 C-N-CA 130.476 3.894 . . . . 0.0 113.621 -176.286 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . 0.257 2.3 t-20 41.98 35.34 0.54 Allowed 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 128.017 2.527 . . . . 0.0 114.819 -166.522 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.56 3.45 0.13 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.784 1.633 . . . . 0.0 115.232 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.9 -43.86 0.51 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 129.324 3.345 . . . . 0.0 117.257 168.664 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 32.5 t -173.09 168.55 4.77 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.768 1.627 . . . . 0.0 110.062 -168.316 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 28.5 mtt180 -111.07 -177.69 3.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 -169.85 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.425 HD22 ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -171.31 -157.88 0.13 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 128.417 2.687 . . . . 0.0 107.138 -169.695 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 145' ' ' ALA . . . . . 0.425 ' H ' HD22 ' B' ' 144' ' ' LEU . . . -58.69 153.97 15.53 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -169.142 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -141.98 153.77 44.54 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 113.949 -1.478 . . . . 0.0 113.82 -172.109 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.99 -177.65 37.68 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 127.49 2.472 . . . . 0.0 111.485 176.627 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.61 152.69 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 166.896 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.0 mm -75.7 102.31 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 174.595 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.18 -179.51 35.54 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 125.835 1.683 . . . . 0.0 111.14 169.932 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.24 154.55 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 117.602 0.701 . . . . 0.0 112.796 -167.604 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.465 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.23 -2.74 0.68 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 115.008 1.484 . . . . 0.0 115.008 165.959 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.234 0.262 0 C-N-CA 124.671 1.189 . . . . 0.0 111.071 168.78 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p . . . . . 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 111.365 0.135 . . . . 0.0 111.365 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 024 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p . . . . . 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 111.365 0.135 . . . . 0.0 111.365 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 025 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.5 p . . . . . 0 N--CA 1.465 0.283 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 0.8 OUTLIER -163.43 129.75 3.26 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 164.361 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.44 154.03 44.21 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.326 2.25 . . . . 0.0 108.289 167.682 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 69.4 t -154.97 146.62 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 118.916 0.78 . . . . 0.0 112.778 -167.005 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.76 128.45 51.75 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.592 1.157 . . . . 0.0 109.321 165.006 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 29.0 m -113.71 127.1 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.597 1.159 . . . . 0.0 108.289 167.59 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.07 130.45 55.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.14 1.376 . . . . 0.0 109.913 -172.068 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -153.9 70.76 0.83 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.741 0.816 . . . . 0.0 110.869 170.222 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.1 -1.41 22.3 Favored Glycine 0 N--CA 1.469 0.851 0 CA-C-O 117.481 -1.733 . . . . 0.0 115.078 -173.958 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -156.08 110.32 2.81 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 119.151 1.476 . . . . 0.0 111.979 -169.74 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 31.66 -111.37 0.05 OUTLIER Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.168 2.318 . . . . 0.0 114.906 169.569 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -84.42 -2.05 9.85 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.597 2.865 . . . . 0.0 114.034 -175.778 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.0 t -102.05 135.37 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 120.445 1.475 . . . . 0.0 111.578 -168.609 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -127.24 171.93 11.03 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 122.87 1.319 . . . . 0.0 110.258 169.072 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.36 150.87 23.17 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 112.781 -2.008 . . . . 0.0 112.152 167.892 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -133.15 126.4 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 167.352 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mm -132.67 103.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -177.29 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -99.3 124.71 44.61 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.221 1.008 . . . . 0.0 112.151 177.107 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -104.69 156.45 17.97 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 127.303 2.241 . . . . 0.0 111.769 169.996 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -132.46 128.97 38.59 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.613 1.565 . . . . 0.0 108.597 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.467 ' CB ' HD13 ' A' ' 106' ' ' LEU . 0.0 OUTLIER -139.56 145.49 38.69 Favored 'General case' 0 CA--C 1.532 0.287 0 O-C-N 120.822 -1.174 . . . . 0.0 111.151 -174.224 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.469 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -113.4 -31.37 6.58 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -167.39 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -157.94 154.66 28.16 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.683 1.593 . . . . 0.0 107.908 172.438 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 m -47.44 -40.53 18.32 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 128.302 2.641 . . . . 0.0 113.156 173.018 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -84.1 -0.55 52.34 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.984 1.714 . . . . 0.0 112.771 174.681 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.58 139.65 14.57 Favored Glycine 0 CA--C 1.538 1.526 0 O-C-N 120.427 -1.421 . . . . 0.0 112.985 -172.694 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -69.74 163.71 37.26 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 123.933 3.089 . . . . 0.0 111.339 178.925 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t -132.75 136.56 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.177 0.591 . . . . 0.0 112.164 -167.024 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -95.49 124.54 39.57 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.093 1.357 . . . . 0.0 109.548 172.153 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 99' ' ' ILE . 0.3 OUTLIER -107.7 153.0 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 C-N-CA 125.672 1.589 . . . . 0.0 111.415 168.991 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 42.6 p90 -156.72 164.05 38.58 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.291 1.437 . . . . 0.0 111.834 168.779 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.94 -154.21 24.74 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 124.139 0.876 . . . . 0.0 112.597 175.656 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 78.1 p -156.58 150.85 25.32 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.009 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.15 116.26 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 171.783 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -136.12 140.18 43.5 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.111 0.964 . . . . 0.0 112.566 -165.982 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.57 -16.22 37.62 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 126.809 2.147 . . . . 0.0 112.275 -168.789 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.453 HD13 ' CD2' ' A' ' 43' ' ' HIS . 2.2 pp -84.39 155.05 22.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-N 118.473 1.137 . . . . 0.0 112.01 172.879 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.7 m -62.02 154.15 27.54 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 127.371 2.269 . . . . 0.0 112.012 176.674 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.8 pm0 -51.0 169.61 0.04 OUTLIER 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.258 1.423 . . . . 0.0 114.57 168.674 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.43 -176.32 46.51 Favored Glycine 0 N--CA 1.472 1.086 0 O-C-N 120.792 -1.192 . . . . 0.0 112.358 -177.485 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.3 mp -75.92 148.36 38.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.456 -1.026 . . . . 0.0 110.019 -176.56 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.453 ' CD2' HD13 ' A' ' 38' ' ' LEU . 85.4 m-70 -142.1 134.0 27.24 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.849 1.26 . . . . 0.0 109.2 173.836 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.2 152.13 49.52 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 177.75 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -150.5 118.0 6.1 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.806 2.042 . . . . 0.0 107.97 -169.141 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -153.89 145.2 23.01 Favored 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.116 -1.615 . . . . 0.0 111.221 -172.956 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.16 127.3 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.173 0.987 . . . . 0.0 110.647 170.248 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -72.83 -173.62 1.26 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 129.218 3.007 . . . . 0.0 110.349 177.414 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.55 ' H ' ' CD ' ' A' ' 49' ' ' GLU 0.268 1.9 pm0 -63.65 -120.31 0.0 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.081 1.752 . . . . 0.0 114.831 177.692 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -82.12 -168.03 1.79 Allowed 'General case' 0 CA--C 1.545 0.754 0 O-C-N 119.807 -1.808 . . . . 0.0 114.403 -167.129 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.58 9.45 60.59 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.067 1.794 . . . . 0.0 113.978 -179.354 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -108.98 38.79 2.18 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.986 1.714 . . . . 0.0 113.961 -173.769 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.4 ' OD1' ' HB2' ' A' ' 60' ' ' ALA . 2.1 p30 -172.43 22.27 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.858 1.313 . . . . 0.0 112.408 -165.082 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.411 ' H ' HG23 ' A' ' 54' ' ' THR . 3.1 p -44.33 5.8 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.613 1 C-N-CA 134.641 5.176 . . . . 0.0 118.784 -176.453 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.75 1.34 56.54 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.515 1.926 . . . . 0.0 112.87 172.579 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.84 -151.68 43.05 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 -179.135 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.1 t -51.26 -7.41 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.197 0 C-N-CA 127.206 2.203 . . . . 0.0 116.289 -176.42 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 58.5 p -87.95 18.51 4.14 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 120.162 -1.586 . . . . 0.0 113.318 169.2 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.9 m -169.81 -47.14 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 127.221 2.209 . . . . 0.0 109.761 -176.268 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.4 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . . . -70.61 151.31 45.13 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.45 1.9 . . . . 0.0 112.128 172.526 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -98.01 -170.28 32.35 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 125.803 1.668 . . . . 0.0 112.505 -176.188 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -83.79 60.87 6.69 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.501 2.801 . . . . 0.0 109.885 178.185 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.449 ' CE1' ' HA ' ' A' ' 137' ' ' THR . 0.5 OUTLIER 51.19 63.81 2.1 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.551 1.54 . . . . 0.0 112.773 168.272 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -28.29 113.57 0.07 Allowed 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 127.507 2.323 . . . . 0.0 111.854 175.679 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -78.11 103.59 1.45 Allowed Pre-proline 0 CA--C 1.545 0.773 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.795 -166.547 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -70.11 -21.12 32.3 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 121.899 1.733 . . . . 0.0 112.186 -174.516 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.89 -3.74 21.49 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.31 1.844 . . . . 0.0 112.677 175.996 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 t 54.18 44.24 29.44 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 125.25 1.42 . . . . 0.0 112.283 -169.623 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtm180 -92.2 171.19 9.24 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 120.994 -1.066 . . . . 0.0 111.37 174.378 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.75 164.64 18.41 Favored 'General case' 0 CA--C 1.547 0.858 0 O-C-N 121.23 -0.919 . . . . 0.0 109.762 167.792 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -80.31 142.54 34.42 Favored 'General case' 0 CA--C 1.536 0.414 0 O-C-N 120.265 -1.522 . . . . 0.0 111.718 -178.495 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 165.36 -131.5 2.41 Favored Glycine 0 N--CA 1.468 0.804 0 N-CA-C 115.859 1.104 . . . . 0.0 115.859 168.843 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.55 -41.7 1.72 Allowed Glycine 0 CA--C 1.543 1.822 0 N-CA-C 119.005 2.362 . . . . 0.0 119.005 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -95.39 -22.31 0.2 Allowed 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 121.885 2.843 . . . . 0.0 113.725 -175.798 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.5 pttt -132.26 -0.09 3.7 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.976 1.71 . . . . 0.0 112.21 175.348 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -138.72 155.49 48.19 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 130.869 3.668 . . . . 0.0 108.832 -176.428 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -107.07 -8.05 16.67 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 126.169 1.788 . . . . 0.0 112.911 -174.638 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.5 mm-40 -78.2 -20.21 52.31 Favored 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -172.994 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.481 HH21 HG12 ' A' ' 103' ' ' VAL . 4.8 ttp180 4.52 102.14 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 130.445 3.498 . . . . 0.0 115.374 166.493 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -59.58 162.35 5.13 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.654 0.782 . . . . 0.0 112.03 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 92.2 t -49.62 -41.18 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 124.366 1.066 . . . . 0.0 113.722 171.125 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.8 8.39 66.21 Favored Glycine 0 CA--C 1.539 1.583 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 177.266 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -99.25 97.49 8.56 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-N 119.635 1.718 . . . . 0.0 111.866 -175.184 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 87.0 mt -108.81 54.54 0.65 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.455 1.102 . . . . 0.0 111.954 -175.436 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.42 -151.48 43.43 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 125.023 1.296 . . . . 0.0 114.248 177.186 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.7 p30 -135.16 169.28 17.69 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 125.509 1.524 . . . . 0.0 109.568 169.864 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -128.58 113.88 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.536 1.134 . . . . 0.0 109.832 -171.147 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.4 m -109.15 124.37 50.7 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 123.913 0.885 . . . . 0.0 108.939 -170.102 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.94 151.17 21.64 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 -172.87 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -88.06 151.89 22.42 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 127.758 2.423 . . . . 0.0 110.381 167.952 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -49.94 -17.71 0.42 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 129.2 3.0 . . . . 0.0 116.994 175.557 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -75.65 0.75 16.54 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 124.266 1.026 . . . . 0.0 111.388 171.56 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.13 35.13 7.21 Favored Glycine 0 C--N 1.34 0.783 0 C-N-CA 125.996 1.76 . . . . 0.0 112.781 172.888 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.7 p -152.76 131.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.048 1.869 . . . . 0.0 116.048 -170.919 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.86 120.97 37.07 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 164.468 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -104.1 132.6 50.19 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.224 1.41 . . . . 0.0 107.747 177.118 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 49.1 t -134.41 141.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -165.608 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.9 t -157.46 119.27 3.73 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.333 1.853 . . . . 0.0 111.021 170.614 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.453 ' HB ' HG12 ' A' ' 31' ' ' VAL . 46.4 mt -135.47 145.59 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 126.233 1.813 . . . . 0.0 110.467 179.707 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.98 126.43 53.83 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 125.641 1.576 . . . . 0.0 106.945 166.269 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.82 144.46 50.24 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.925 0.89 . . . . 0.0 112.924 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 10.8 p -119.97 50.74 1.25 Allowed 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -177.381 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.481 HG12 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -154.72 6.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 N-CA-C 115.382 1.623 . . . . 0.0 115.382 168.642 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.64 152.79 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 120.77 -1.206 . . . . 0.0 109.851 177.726 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.485 ' H ' ' HB3' ' A' ' 111' ' ' SER . 52.4 p -155.43 179.3 9.31 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 120.982 -1.074 . . . . 0.0 112.691 -178.341 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.467 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.4 mp -81.72 48.35 1.19 Allowed 'General case' 0 CA--C 1.551 1.002 0 O-C-N 120.415 -1.428 . . . . 0.0 110.234 -174.571 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.9 t -88.16 43.92 1.16 Allowed 'General case' 0 CA--C 1.545 0.764 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 -168.454 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.19 -64.63 2.02 Favored Glycine 0 N--CA 1.475 1.248 0 C-N-CA 125.736 1.636 . . . . 0.0 116.072 168.249 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -149.41 16.67 0.92 Allowed 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 124.059 1.885 . . . . 0.0 110.595 -175.725 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 39.4 m-70 -126.31 5.7 7.02 Favored 'General case' 0 CA--C 1.545 0.771 0 O-C-N 120.004 -1.685 . . . . 0.0 112.873 -167.431 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB3' ' H ' ' A' ' 105' ' ' SER . 3.1 m -166.39 -103.12 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.74 1.216 . . . . 0.0 113.111 177.749 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.6 pt -117.72 28.13 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 CA-C-N 120.37 1.441 . . . . 0.0 113.679 -170.276 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -133.48 146.58 31.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 127.725 2.41 . . . . 0.0 105.578 164.084 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.12 30.38 75.68 Favored Glycine 0 C--O 1.22 -0.748 0 CA-C-O 118.869 -0.962 . . . . 0.0 113.101 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.7 mtt-85 -135.28 176.9 8.25 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.835 1.254 . . . . 0.0 109.351 176.345 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.4 m -132.52 116.11 16.32 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 119.689 1.131 . . . . 0.0 110.94 -170.885 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.7 tp -89.83 132.86 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.629 1.172 . . . . 0.0 110.308 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 146' ' ' CYS . 4.9 p -124.23 150.26 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.027 1.331 . . . . 0.0 110.326 172.302 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -105.33 167.56 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-O 121.418 0.628 . . . . 0.0 110.823 167.06 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.72 127.69 37.35 Favored 'General case' 0 CA--C 1.547 0.849 0 O-C-N 120.942 -1.099 . . . . 0.0 110.697 -173.823 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? -69.87 -10.13 57.38 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -169.55 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -107.93 162.1 14.33 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 114.442 1.275 . . . . 0.0 114.442 171.496 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.79 139.4 58.76 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.507 1.923 . . . . 0.0 109.792 167.081 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -111.3 148.84 32.05 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.849 2.059 . . . . 0.0 113.8 -171.815 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.342 13.3 t0 -101.93 -15.83 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 115.556 1.687 . . . . 0.0 115.556 -179.725 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt 56.26 81.0 0.13 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.724 1.609 . . . . 0.0 114.061 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.9 -43.74 1.91 Allowed Glycine 0 N--CA 1.471 1.009 0 C-N-CA 125.275 1.417 . . . . 0.0 111.935 168.921 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -99.42 175.03 5.99 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.219 1.408 . . . . 0.0 110.204 167.604 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 131.02 -9.92 5.68 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 126.311 1.91 . . . . 0.0 114.116 -169.312 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.54 11.04 85.85 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 116.272 1.269 . . . . 0.0 116.272 168.394 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 13.9 p30 -138.82 174.52 10.43 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.891 1.276 . . . . 0.0 110.077 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -65.69 -54.82 22.19 Favored 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 115.012 1.486 . . . . 0.0 115.012 -171.577 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.41 -26.54 42.32 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.661 -0.649 . . . . 0.0 111.883 176.291 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -54.38 -35.97 63.4 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.29 -1.506 . . . . 0.0 114.634 177.253 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.9 -28.16 15.33 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 124.423 1.089 . . . . 0.0 112.49 178.504 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.19 -65.25 0.98 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.018 0.827 . . . . 0.0 111.922 178.823 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.449 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 52.9 p -92.25 -24.31 19.04 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 126.56 1.944 . . . . 0.0 112.168 -171.868 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.58 16.51 24.23 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 124.533 1.063 . . . . 0.0 112.494 -168.964 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 73.09 4.54 4.96 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.566 1.946 . . . . 0.0 113.768 178.294 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.8 -10.96 4.36 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 -169.447 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.06 -30.07 0.53 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 128.507 2.956 . . . . 0.0 117.779 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.5 t -142.45 178.11 7.82 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.225 1.01 . . . . 0.0 110.469 -173.42 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.9 -175.58 2.81 Favored 'General case' 0 N--CA 1.473 0.725 0 O-C-N 120.59 -1.319 . . . . 0.0 110.102 -174.893 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.576 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -170.1 -158.96 0.18 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.76 2.024 . . . . 0.0 107.779 -176.07 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.576 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.26 159.7 30.75 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 127.057 2.143 . . . . 0.0 113.321 178.347 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.421 ' HB3' HG23 ' A' ' 118' ' ' VAL . 31.4 p -147.58 162.52 38.94 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.269 1.427 . . . . 0.0 112.985 -177.975 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.28 161.0 31.35 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 126.614 2.054 . . . . 0.0 112.228 169.333 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.1 t -78.54 160.83 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 CA-C-N 119.25 1.525 . . . . 0.0 110.869 170.403 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -103.1 113.12 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 CA-C-N 118.834 0.743 . . . . 0.0 110.643 167.838 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.2 -178.61 15.7 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 125.604 1.573 . . . . 0.0 113.23 -178.435 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.95 123.05 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 113.958 1.096 . . . . 0.0 113.958 -170.704 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.464 ' HB3' ' HB3' ' A' ' 3' ' ' LYS . . . -75.12 -31.05 61.0 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 122.921 1.343 . . . . 0.0 107.787 163.033 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.438 0 C-N-CA 125.481 1.512 . . . . 0.0 112.27 166.937 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.2 m -80.73 109.61 15.43 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 105.724 -1.954 . . . . 0.0 105.724 168.973 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.451 ' HE3' ' HB1' ' B' ' 152' ' ' ALA . 0.2 OUTLIER -116.27 152.87 32.97 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 117.894 2.553 . . . . 0.0 117.894 -172.711 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.75 147.49 37.46 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 126.255 1.822 . . . . 0.0 108.886 168.571 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.05 157.29 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 123.459 0.704 . . . . 0.0 111.037 -166.918 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.54 139.61 46.7 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.658 1.183 . . . . 0.0 111.438 169.648 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.4 m -108.62 122.41 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 167.094 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 8' ' ' LEU . . . . . 0.521 ' CD2' HD12 ' B' ' 117' ' ' LEU . 4.7 mp -99.98 75.86 1.89 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -164.453 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -105.61 100.74 10.29 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.257 1.423 . . . . 0.0 110.364 173.076 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.47 15.69 0.48 Allowed Glycine 0 N--CA 1.477 1.412 0 N-CA-C 115.68 1.032 . . . . 0.0 115.68 -178.11 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -159.61 136.78 9.6 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.625 2.37 . . . . 0.0 107.457 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -23.28 -80.26 0.01 OUTLIER Glycine 0 CA--C 1.537 1.451 0 C-N-CA 128.487 2.946 . . . . 0.0 116.083 -168.747 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -86.72 4.27 6.36 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 124.192 3.261 . . . . 0.0 113.949 -177.557 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 36.0 t -105.38 129.83 57.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 CA-C-O 122.872 1.32 . . . . 0.0 109.721 -172.446 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.2 168.29 19.13 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.777 1.631 . . . . 0.0 107.911 171.869 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.17 176.42 33.6 Favored Glycine 0 N--CA 1.464 0.543 0 O-C-N 120.432 -1.417 . . . . 0.0 113.546 176.488 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -158.31 103.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 126.687 1.995 . . . . 0.0 108.81 172.971 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.49 146.41 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 124.922 1.289 . . . . 0.0 111.594 176.636 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -119.12 168.99 10.32 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 127.268 2.227 . . . . 0.0 112.196 -171.034 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.38 98.86 3.21 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 127.263 2.225 . . . . 0.0 108.105 172.219 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -102.41 114.08 27.96 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 118.71 0.686 . . . . 0.0 111.581 -175.476 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -91.64 132.48 36.31 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.221 1.008 . . . . 0.0 110.948 176.227 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.4 ptmt -84.02 -30.79 25.83 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 179.349 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -162.17 144.73 11.37 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.19 2.196 . . . . 0.0 109.847 169.586 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 1.5 m -43.77 24.77 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 1 C-N-CA 137.957 6.503 . . . . 0.0 119.037 -174.767 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.6 p30 179.76 -24.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 128.371 2.668 . . . . 0.0 112.081 -170.194 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.6 165.11 54.3 Favored Glycine 0 CA--C 1.541 1.659 0 O-C-N 121.168 -0.958 . . . . 0.0 112.425 169.965 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -70.15 169.7 18.79 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 124.305 3.336 . . . . 0.0 113.12 -171.288 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 31.7 t -131.02 129.43 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.942 1.697 . . . . 0.0 110.503 -169.111 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -93.77 125.82 38.6 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-O 122.319 1.057 . . . . 0.0 109.902 170.56 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.06 128.16 39.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 127.585 2.354 . . . . 0.0 108.071 169.44 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -153.39 158.26 41.19 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 171.646 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.83 -141.99 12.79 Favored Glycine 0 N--CA 1.463 0.456 0 C-N-CA 125.08 1.324 . . . . 0.0 111.51 176.888 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 99.0 p -155.02 162.13 41.16 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 117.987 2.588 . . . . 0.0 117.987 -167.964 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 19.4 mm -130.4 123.93 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 C-N-CA 126.567 1.947 . . . . 0.0 107.445 168.067 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 tttp -122.24 136.49 54.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 122.854 2.57 . . . . 0.0 110.731 -178.63 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.26 -8.77 5.65 Favored Glycine 0 N--CA 1.474 1.202 0 C-N-CA 126.47 1.986 . . . . 0.0 114.094 -178.934 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.435 HD22 ' CE1' ' B' ' 43' ' ' HIS . 33.4 mt -70.22 172.97 7.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.096 1.358 . . . . 0.0 111.638 170.625 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 11.8 t -110.77 157.73 19.46 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 162.687 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -59.03 162.04 4.59 Favored 'General case' 0 CA--C 1.537 0.442 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -167.213 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.79 -179.15 34.07 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.671 -174.841 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.636 ' H ' HD23 ' B' ' 42' ' ' LEU . 2.2 pt? -75.64 144.21 41.81 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.533 1.533 . . . . 0.0 113.0 -169.975 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 43' ' ' HIS . . . . . 0.435 ' CE1' HD22 ' B' ' 38' ' ' LEU . 91.9 m-70 -140.37 170.14 16.37 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 126.948 2.099 . . . . 0.0 109.567 176.462 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -124.93 166.06 17.79 Favored Glycine 0 N--CA 1.478 1.486 0 C-N-CA 125.132 1.349 . . . . 0.0 113.148 -174.196 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -156.46 162.32 39.99 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.951 2.1 . . . . 0.0 112.82 172.921 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 46' ' ' HIS . . . . . 0.587 ' O ' HD22 ' B' ' 117' ' ' LEU . 46.7 p-80 -156.14 163.91 39.04 Favored 'General case' 0 C--N 1.347 0.468 0 O-C-N 120.583 -1.323 . . . . 0.0 108.835 168.797 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.483 HG22 ' CA ' ' B' ' 82' ' ' GLY . 0.5 OUTLIER -110.84 162.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 125.015 1.326 . . . . 0.0 108.857 -178.244 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 p-80 -136.67 126.18 25.18 Favored 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 120.984 -1.072 . . . . 0.0 109.789 176.606 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -71.75 136.47 47.16 Favored 'General case' 0 N--CA 1.452 -0.357 0 O-C-N 123.932 0.77 . . . . 0.0 109.913 179.443 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 121.22 133.05 0.0 OUTLIER 'General case' 0 C--O 1.233 0.209 1 C-N-CA 133.958 4.903 . . . . 0.0 108.449 -176.149 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.42 2.89 61.15 Favored Glycine 0 C--O 1.222 -0.615 0 CA-C-O 118.211 -1.327 . . . . 0.0 114.019 178.717 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -103.13 51.58 0.79 Allowed 'General case' 0 CA--C 1.536 0.423 0 CA-C-N 120.24 2.02 . . . . 0.0 112.934 -179.15 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -172.1 37.73 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 126.669 1.987 . . . . 0.0 110.995 -171.472 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.3 p . . . . . 0 N--CA 1.469 0.504 1 C-N-CA 133.688 4.795 . . . . 0.0 115.948 -171.614 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.604 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.99 163.57 26.9 Favored Glycine 0 CA--C 1.544 1.897 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -173.201 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -66.09 125.29 13.86 Favored 'Trans proline' 0 C--N 1.352 0.716 0 C-N-CA 124.977 3.785 . . . . 0.0 111.322 178.378 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.318 1.9 p80 28.32 59.23 0.12 Allowed 'General case' 0 C--O 1.239 0.551 0 C-N-CA 130.278 3.431 . . . . 0.0 116.858 177.935 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -58.8 121.1 10.28 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 105.153 -2.166 . . . . 0.0 105.153 162.836 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -125.47 142.4 41.65 Favored Pre-proline 0 CA--C 1.543 0.683 0 C-N-CA 124.365 1.066 . . . . 0.0 113.799 -169.068 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -83.38 -15.08 7.8 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.323 2.682 . . . . 0.0 113.587 175.172 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 79.8 mt -93.88 -10.63 33.28 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 115.03 1.492 . . . . 0.0 115.03 -171.486 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t 46.12 58.69 4.26 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 169.474 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 4.6 ptt180 -143.88 -174.96 4.4 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 127.899 2.48 . . . . 0.0 111.06 -175.611 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.25 3.1 pttp -65.19 160.48 21.28 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 120.231 1.378 . . . . 0.0 112.706 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -96.95 138.62 34.21 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.777 -1.556 . . . . 0.0 113.326 -177.086 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.92 -151.33 20.19 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 127.075 2.274 . . . . 0.0 109.456 170.49 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 169.25 -32.99 0.18 Allowed Glycine 0 CA--C 1.528 0.87 0 N-CA-C 119.722 2.649 . . . . 0.0 119.722 169.004 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.3 24.18 0.22 Allowed 'Trans proline' 0 CA--C 1.554 1.52 0 CA-C-N 122.97 3.385 . . . . 0.0 113.013 167.787 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 75' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -168.59 -41.39 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 129.865 3.266 . . . . 0.0 107.245 166.427 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.255 4.9 t70 -62.69 117.97 7.02 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 123.932 1.825 . . . . 0.0 109.599 -171.055 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.3 mp0 -72.48 -19.57 61.52 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 129.416 3.086 . . . . 0.0 114.471 -161.616 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -105.71 -65.21 1.08 Allowed 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.022 0.529 . . . . 0.0 111.197 176.798 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 76.77 126.72 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 125.181 1.393 . . . . 0.0 114.352 165.973 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -73.78 159.54 32.78 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 124.608 1.163 . . . . 0.0 113.015 168.106 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -61.86 -47.75 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 120.931 -1.106 . . . . 0.0 110.142 173.529 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 82' ' ' GLY . . . . . 0.483 ' CA ' HG22 ' B' ' 47' ' ' VAL . . . -77.56 31.38 1.67 Allowed Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.865 1.221 . . . . 0.0 115.369 176.587 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -115.71 117.39 30.14 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 121.368 -1.078 . . . . 0.0 108.941 170.291 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 87.1 mt -140.72 131.68 26.1 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 102.455 -3.165 . . . . 0.0 102.455 168.743 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.69 -144.77 16.07 Favored Glycine 0 N--CA 1.47 0.941 0 N-CA-C 119.698 2.639 . . . . 0.0 119.698 -163.534 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 86' ' ' ASN . . . . . 0.425 HD21 ' HA ' ' B' ' 124' ' ' ASP . 93.4 m-20 -72.96 159.86 33.02 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -165.979 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.3 p -133.05 177.28 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 130.387 3.475 . . . . 0.0 110.093 -171.185 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -155.76 132.79 10.67 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 119.666 1.121 . . . . 0.0 111.356 174.998 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.46 160.5 15.41 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.342 1.057 . . . . 0.0 113.776 176.283 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -92.08 177.2 6.24 Favored 'General case' 0 CA--C 1.552 1.041 0 C-N-CA 127.186 2.194 . . . . 0.0 112.663 170.293 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.74 -17.58 64.94 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 120.913 -1.117 . . . . 0.0 112.958 169.606 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.81 -27.26 63.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.081 0.952 . . . . 0.0 110.449 168.838 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.97 -4.5 65.52 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 117.96 -1.467 . . . . 0.0 114.439 -177.009 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.99 131.06 35.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 118.736 1.268 . . . . 0.0 110.917 168.782 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.16 124.63 44.35 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 165.892 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -79.16 143.51 35.37 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.706 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.09 130.53 72.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.686 166.625 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 8.6 m -150.77 82.97 1.34 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.857 1.263 . . . . 0.0 110.537 -175.142 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.6 mt -130.91 142.48 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.605 1.562 . . . . 0.0 111.007 -172.671 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -100.69 145.14 28.82 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.356 1.862 . . . . 0.0 107.176 168.653 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.973 0.909 . . . . 0.0 109.432 169.609 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.6 p -131.31 51.96 2.1 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.225 1.01 . . . . 0.0 112.263 179.868 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -152.47 34.82 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 122.736 1.255 . . . . 0.0 111.43 169.847 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.1 172.17 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 126.688 1.995 . . . . 0.0 111.329 -169.655 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -159.78 153.76 23.2 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 120.817 -1.177 . . . . 0.0 112.685 169.275 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.7 mp -82.72 58.91 4.48 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.641 -1.287 . . . . 0.0 110.345 176.377 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.9 t -89.11 141.1 28.8 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.071 171.417 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -77.1 47.83 2.66 Favored Glycine 0 N--CA 1.474 1.217 0 C-N-CA 126.23 1.871 . . . . 0.0 115.584 -168.443 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -139.15 -90.98 0.19 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.847 2.459 . . . . 0.0 107.784 -170.398 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -150.45 -4.88 0.33 Allowed 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 127.878 2.471 . . . . 0.0 112.275 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.5 t -69.34 -0.39 6.23 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.162 -1.586 . . . . 0.0 114.6 -174.979 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.5 7.5 pt 149.36 8.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 1 C-N-CA 135.667 5.587 . . . . 0.0 115.365 168.092 . . . . . . . . 3 2 . 1 . 026 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 48.9 mm -87.12 168.94 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 O-C-N 120.56 -1.337 . . . . 0.0 109.232 165.696 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.32 -33.39 2.02 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 117.849 1.899 . . . . 0.0 117.849 166.109 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 ptt85 -74.8 174.12 9.62 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 125.77 1.628 . . . . 0.0 112.043 -169.898 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -130.12 154.12 47.81 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.166 0.986 . . . . 0.0 109.699 -174.311 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' B' ' 46' ' ' HIS . 2.7 tm? -133.26 145.51 50.57 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 125.376 1.47 . . . . 0.0 111.505 -169.668 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.494 ' N ' HD13 ' B' ' 117' ' ' LEU . 6.7 p -128.14 135.76 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 126.194 1.797 . . . . 0.0 110.88 174.141 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 t -101.91 158.24 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 125.521 1.528 . . . . 0.0 108.392 169.858 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -128.21 153.25 47.12 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 127.799 2.44 . . . . 0.0 111.296 -173.115 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -75.32 -24.93 57.47 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.491 -178.819 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -100.54 171.16 7.9 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 119.704 1.138 . . . . 0.0 110.114 167.507 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -112.08 94.57 5.01 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 125.283 1.433 . . . . 0.0 111.925 -179.371 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.425 ' HA ' HD21 ' B' ' 86' ' ' ASN 0.267 25.5 t0 -152.97 146.92 25.36 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-O 123.561 1.648 . . . . 0.0 109.25 168.032 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -169.3 -52.27 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 130.467 3.507 . . . . 0.0 110.893 -178.245 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.585 ' H ' HD13 ' B' ' 126' ' ' LEU 0.338 0.0 OUTLIER -86.07 59.32 5.56 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 116.575 2.065 . . . . 0.0 116.575 -163.094 . . . . . . . . 4 4 . 1 . 026 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.44 -9.12 0.88 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 117.839 1.896 . . . . 0.0 117.839 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.3 ptmt -160.21 21.62 0.16 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 116.763 2.134 . . . . 0.0 116.763 -169.218 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.5 -19.38 78.95 Favored Glycine 0 N--CA 1.472 1.079 0 CA-C-N 120.26 1.391 . . . . 0.0 113.489 178.938 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -151.24 -42.24 0.02 OUTLIER Glycine 0 N--CA 1.468 0.83 0 N-CA-C 116.665 1.426 . . . . 0.0 116.665 -178.996 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -163.08 -165.31 1.08 Allowed 'General case' 0 CA--C 1.546 0.815 0 CA-C-N 120.201 2.0 . . . . 0.0 113.514 -173.448 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -49.27 -56.07 10.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.382 1.473 . . . . 0.0 110.876 169.043 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.23 -16.22 31.6 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.277 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 20.8 m -55.0 -31.79 61.28 Favored 'General case' 0 N--CA 1.471 0.594 0 O-C-N 120.091 -1.631 . . . . 0.0 112.702 168.527 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.264 2.8 t -97.44 -8.49 29.23 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 174.08 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -87.68 -60.95 1.83 Allowed 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.289 -1.507 . . . . 0.0 111.202 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 28.5 p -102.87 -24.92 13.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 126.018 1.727 . . . . 0.0 114.413 -177.223 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.55 -22.87 35.95 Favored Glycine 0 C--O 1.213 -1.159 0 CA-C-O 117.93 -1.483 . . . . 0.0 110.075 -166.26 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 33.2 t30 56.83 19.11 4.22 Favored 'General case' 0 CA--C 1.548 0.875 0 CA-C-N 119.351 1.576 . . . . 0.0 112.387 173.705 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.76 -23.16 2.51 Favored 'General case' 0 CA--C 1.557 1.226 0 C-N-CA 129.079 2.952 . . . . 0.0 115.057 -171.664 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 93.94 -153.19 21.07 Favored Glycine 0 C--N 1.343 0.924 0 C-N-CA 126.692 2.091 . . . . 0.0 114.414 174.765 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.03 151.88 2.45 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.711 2.004 . . . . 0.0 113.481 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 15.1 mtp-105 -66.24 166.88 11.2 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.9 -1.125 . . . . 0.0 113.474 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tp -150.01 -152.6 0.45 Allowed 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 128.727 2.811 . . . . 0.0 106.911 166.888 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.29 178.3 7.23 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -178.668 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.5 p -158.16 159.18 35.89 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.107 1.363 . . . . 0.0 111.459 -173.28 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.38 170.52 34.53 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.696 1.617 . . . . 0.0 113.416 176.086 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.54 147.41 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.639 1.176 . . . . 0.0 110.007 179.346 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.2 mm -93.47 76.68 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.324 0.65 . . . . 0.0 110.042 -178.71 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.57 161.88 32.7 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 123.652 0.644 . . . . 0.0 112.225 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.48 ' N ' HD12 ' B' ' 151' ' ' ILE . 1.1 mp -75.05 134.87 28.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -175.452 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.451 ' HB1' ' HE3' ' B' ' 3' ' ' LYS . . . -108.82 35.13 3.34 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.461 1.504 . . . . 0.0 113.485 -168.735 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 . . . . . 0 C--N 1.324 -0.518 0 C-N-CA 126.633 1.973 . . . . 0.0 110.691 -177.31 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m . . . . . 0 C--O 1.217 -0.648 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 ttmm -120.09 128.11 53.16 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -169.415 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -108.2 171.77 7.22 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.927 0.891 . . . . 0.0 112.921 169.407 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.417 HG11 ' HA ' ' B' ' 52' ' ' ASP . 0.3 OUTLIER -131.43 155.01 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 129.72 3.208 . . . . 0.0 106.908 165.97 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.25 114.81 19.45 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.738 1.154 . . . . 0.0 109.559 166.742 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' HG22 ' B' ' 54' ' ' THR . 8.7 t -88.57 76.42 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 125.185 1.394 . . . . 0.0 108.938 -171.91 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.47 103.96 9.75 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.034 -175.018 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 ttpp -160.92 132.16 5.53 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 123.274 0.63 . . . . 0.0 112.369 166.08 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.15 -95.5 1.94 Allowed Glycine 0 C--N 1.333 0.384 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 168.074 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.31 -177.1 3.41 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.013 1.725 . . . . 0.0 107.974 174.007 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 61.69 -173.55 7.32 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.732 2.11 . . . . 0.0 117.05 168.977 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.54 4.41 7.1 Favored 'Trans proline' 0 CA--C 1.543 0.941 1 C-N-CA 126.347 4.698 . . . . 0.0 113.836 178.593 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 m -79.43 138.03 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 126.848 2.059 . . . . 0.0 111.045 175.595 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.77 169.23 19.5 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 122.238 1.018 . . . . 0.0 109.801 165.707 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -141.17 149.01 20.71 Favored Glycine 0 CA--C 1.499 -0.92 0 CA-C-N 113.379 -1.737 . . . . 0.0 110.078 164.245 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -130.27 112.01 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 172.189 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 mm -135.61 102.44 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 121.469 -0.77 . . . . 0.0 111.077 -174.118 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -72.34 157.28 37.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.165 170.204 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.515 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 58.1 m-85 -137.22 98.71 3.8 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 168.867 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -89.93 108.02 19.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 122.12 0.962 . . . . 0.0 109.75 172.291 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -101.58 149.03 24.53 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 166.104 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -13.53 10.57 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.3 1.44 . . . . 0.0 112.253 -175.36 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.37 -146.06 0.37 Allowed 'General case' 0 CA--C 1.556 1.203 0 C-N-CA 128.919 2.887 . . . . 0.0 108.017 173.236 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.2 p -139.68 -45.84 0.44 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 126.009 1.723 . . . . 0.0 108.294 166.647 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.9 m-80 -85.76 32.45 0.59 Allowed 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.057 1.743 . . . . 0.0 112.722 172.969 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.91 -175.06 13.91 Favored Glycine 0 CA--C 1.538 1.499 0 C-N-CA 125.726 1.632 . . . . 0.0 113.002 177.404 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -76.54 170.99 18.87 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 123.82 3.013 . . . . 0.0 111.507 177.909 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.8 t -132.99 123.62 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.971 0.908 . . . . 0.0 110.31 -170.669 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.0 tttm -87.13 114.33 23.65 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 122.909 1.338 . . . . 0.0 112.621 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 t -95.25 131.1 42.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 125.941 1.696 . . . . 0.0 108.628 -176.646 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -153.38 160.3 42.61 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 173.653 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.08 -149.37 18.85 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 125.151 1.358 . . . . 0.0 111.521 -173.047 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 83.8 p -157.62 159.09 36.66 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 114.318 1.229 . . . . 0.0 114.318 -173.661 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -121.56 117.5 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.461 1.505 . . . . 0.0 107.331 171.863 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -128.88 151.82 49.2 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 126.146 1.779 . . . . 0.0 112.052 -165.165 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.58 10.88 82.73 Favored Glycine 0 CA--C 1.531 1.063 0 CA-C-O 118.773 -1.015 . . . . 0.0 113.785 -178.693 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.26 169.08 10.02 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.94 1.296 . . . . 0.0 111.0 173.332 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 t -69.83 160.13 32.33 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.77 1.228 . . . . 0.0 110.257 173.603 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.94 168.76 0.6 Allowed 'General case' 0 CA--C 1.55 0.961 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 178.611 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.6 -175.26 50.68 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.693 1.14 . . . . 0.0 113.472 170.141 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.465 ' H ' ' CD1' ' A' ' 42' ' ' LEU . 5.2 mp -56.14 147.04 21.37 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.728 2.411 . . . . 0.0 111.324 178.628 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -142.98 116.01 8.86 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 126.206 1.802 . . . . 0.0 110.187 176.004 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.53 151.45 14.35 Favored Glycine 0 N--CA 1.483 1.814 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.89 173.913 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -151.02 105.53 3.25 Favored 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 118.984 1.392 . . . . 0.0 111.089 -165.519 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.4 ' O ' HD12 ' A' ' 117' ' ' LEU . 11.8 m80 -145.57 160.18 42.03 Favored 'General case' 0 N--CA 1.471 0.597 0 O-C-N 119.431 -2.043 . . . . 0.0 113.909 -164.584 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . 0.288 0.4 OUTLIER -129.64 120.71 51.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 122.635 1.207 . . . . 0.0 111.489 -171.854 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -79.29 137.19 37.26 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.91 2.084 . . . . 0.0 109.785 175.829 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.0 pm0 -70.44 16.09 0.08 Allowed 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -178.232 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -126.75 144.23 51.01 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 124.425 1.09 . . . . 0.0 108.572 168.846 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.26 27.57 5.05 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.295 1.426 . . . . 0.0 111.539 168.38 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -86.94 173.1 9.55 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.432 1.493 . . . . 0.0 109.911 173.793 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.64 9.15 4.11 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 118.01 2.596 . . . . 0.0 118.01 164.561 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.4 t -61.3 71.32 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.244 2.217 . . . . 0.0 116.504 -168.57 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -141.84 -63.5 0.44 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 125.483 1.513 . . . . 0.0 112.804 168.068 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 166.59 -153.77 23.77 Favored Glycine 0 N--CA 1.47 0.911 0 O-C-N 120.761 -1.212 . . . . 0.0 112.52 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -56.11 -9.52 0.65 Allowed 'General case' 0 CA--C 1.552 1.022 0 N-CA-C 116.474 2.027 . . . . 0.0 116.474 -172.415 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 t -81.46 0.52 37.36 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.927 1.691 . . . . 0.0 113.256 173.725 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 60.9 m -159.39 178.42 9.94 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.564 1.945 . . . . 0.0 110.218 179.176 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 85.68 -125.73 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.502 1.921 . . . . 0.0 113.007 172.601 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 170.73 -153.9 21.83 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 125.677 1.608 . . . . 0.0 111.765 -169.962 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -109.32 57.58 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 123.619 2.879 . . . . 0.0 112.453 -174.547 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 61.95 87.83 0.09 Allowed 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.229 1.411 . . . . 0.0 108.338 -177.415 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -46.36 152.05 0.47 Allowed 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 113.15 -1.841 . . . . 0.0 111.447 -178.686 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.47 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.8 p-10 -136.47 101.06 10.06 Favored Pre-proline 0 CA--C 1.551 1.018 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -164.94 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.93 -27.78 3.64 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.25 1.967 . . . . 0.0 111.072 -176.171 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.25 -6.04 55.73 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.526 1.53 . . . . 0.0 111.683 167.761 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.7 t 62.69 48.16 4.4 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.98 2.112 . . . . 0.0 111.487 178.252 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.47 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 11.9 mtp180 -99.02 170.63 8.58 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 124.475 1.11 . . . . 0.0 112.922 -172.54 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.6 mmtt -84.92 174.17 10.01 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.89 1.676 . . . . 0.0 108.614 163.55 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 62.8 t60 -70.6 149.87 46.63 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 120.782 -1.199 . . . . 0.0 112.066 170.301 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -174.51 -165.2 30.61 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 124.071 0.843 . . . . 0.0 114.035 176.963 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.481 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.92 -100.45 0.43 Allowed Glycine 0 CA--C 1.537 1.425 0 CA-C-O 117.571 -1.683 . . . . 0.0 116.811 170.001 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.51 -19.53 23.44 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 CA-C-N 122.093 2.947 . . . . 0.0 116.377 -168.928 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.9 3.16 4.88 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.24 2.216 . . . . 0.0 112.594 176.06 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.481 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 10.3 t70 -145.88 155.7 43.06 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -164.986 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.57 -7.87 49.01 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 128.363 2.665 . . . . 0.0 113.402 -168.943 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -78.04 -106.39 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 118.696 0.68 . . . . 0.0 109.847 172.769 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.9 ttt180 71.58 101.01 0.07 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.166 1.386 . . . . 0.0 110.359 -172.392 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -51.8 152.67 2.82 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.789 -1.194 . . . . 0.0 111.298 166.527 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 19.3 m -52.88 -33.89 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-N 120.571 1.532 . . . . 0.0 112.785 -175.166 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.75 102.24 1.56 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 124.696 1.141 . . . . 0.0 110.639 166.015 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -160.06 116.22 2.43 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.258 2.223 . . . . 0.0 108.775 177.524 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 92.0 mt -103.01 176.32 5.19 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.577 1.08 . . . . 0.0 108.973 168.148 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.15 173.81 54.97 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 167.342 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -74.65 151.49 39.3 Favored 'General case' 0 CA--C 1.55 0.973 0 N-CA-C 115.09 1.515 . . . . 0.0 115.09 -171.544 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.2 m -102.88 117.23 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 127.974 2.51 . . . . 0.0 109.732 179.07 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.9 m -96.82 119.45 35.31 Favored 'General case' 0 N--CA 1.478 0.948 0 O-C-N 120.531 -1.356 . . . . 0.0 111.234 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.39 140.13 37.52 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -76.37 168.66 19.67 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.076 1.751 . . . . 0.0 111.798 170.62 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.8 pttm -45.74 -28.35 1.02 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.136 2.574 . . . . 0.0 115.135 170.822 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.73 -1.56 56.41 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.4 1.48 . . . . 0.0 111.818 -177.505 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.9 24.87 39.88 Favored Glycine 0 C--N 1.342 0.901 0 C-N-CA 125.274 1.416 . . . . 0.0 114.024 177.636 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.6 p -129.91 129.11 65.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 CA-C-N 118.497 1.148 . . . . 0.0 113.902 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.67 129.54 39.94 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.426 1.09 . . . . 0.0 108.129 166.076 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -79.16 151.02 31.53 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 167.935 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.6 t -135.04 123.87 41.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 CA-C-N 112.444 -2.162 . . . . 0.0 109.199 167.623 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.9 p -155.51 50.2 0.55 Allowed 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 124.025 1.869 . . . . 0.0 111.357 -177.311 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -103.45 170.44 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 127.603 2.361 . . . . 0.0 112.324 -166.48 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.94 121.48 20.57 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 165.622 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -98.17 137.17 37.32 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.478 0.656 . . . . 0.0 109.251 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.4 p -118.24 53.47 0.97 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.932 -1.031 . . . . 0.0 112.253 -178.709 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 13.8 p -155.18 -36.78 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.06 0.944 . . . . 0.0 112.629 168.71 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.71 168.97 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 120.115 1.325 . . . . 0.0 110.573 169.016 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 26.5 p -153.6 162.21 41.47 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 124.381 1.072 . . . . 0.0 111.335 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -83.94 66.39 9.13 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-O 122.185 0.993 . . . . 0.0 109.077 173.971 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 73.5 m -112.45 6.32 18.54 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.737 1.615 . . . . 0.0 113.713 -172.523 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.03 -110.91 3.19 Favored Glycine 0 C--N 1.342 0.871 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 175.4 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -62.49 -35.88 80.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 123.16 1.457 . . . . 0.0 112.776 -176.087 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -89.06 -1.79 58.26 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 114.389 -1.278 . . . . 0.0 111.603 -171.081 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.0 m -168.16 -103.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.218 1.807 . . . . 0.0 113.783 170.137 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.2 pt -124.09 164.35 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 120.972 1.714 . . . . 0.0 112.311 -176.78 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 105.64 121.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.234 1 C-N-CA 133.859 4.864 . . . . 0.0 108.305 -167.832 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.17 32.86 85.59 Favored Glycine 0 CA--C 1.527 0.826 0 CA-C-O 119.057 -0.857 . . . . 0.0 113.179 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.63 179.5 3.95 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 127.317 2.247 . . . . 0.0 108.323 173.577 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 21.1 m -130.6 119.35 22.36 Favored 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 121.944 2.157 . . . . 0.0 111.592 -179.078 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.4 HD12 ' O ' ' A' ' 46' ' ' HIS . 22.6 tp -92.35 119.25 31.73 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.554 1.542 . . . . 0.0 110.671 177.146 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.9 p -96.42 141.07 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.503 1.921 . . . . 0.0 111.111 174.647 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.9 p -118.08 137.34 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 122.046 0.927 . . . . 0.0 111.635 171.06 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 87.5 m-70 -99.72 161.95 13.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 125.231 1.412 . . . . 0.0 113.23 -170.128 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -83.7 -23.81 31.53 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -169.596 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -142.65 -174.85 4.27 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.737 0.815 . . . . 0.0 113.032 176.297 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.66 143.7 9.17 Favored 'General case' 0 C--N 1.341 0.206 0 C-N-CA 126.013 1.725 . . . . 0.0 111.215 172.163 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.99 149.6 24.07 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.789 1.636 . . . . 0.0 112.225 173.717 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -76.24 -10.05 59.11 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.762 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.2 mt 48.01 32.95 3.13 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 128.229 2.612 . . . . 0.0 113.235 177.175 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 165.63 -61.49 0.23 Allowed Glycine 0 N--CA 1.467 0.702 0 CA-C-N 120.492 1.496 . . . . 0.0 115.165 175.3 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -157.95 98.49 1.62 Allowed 'General case' 0 N--CA 1.428 -1.542 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 177.688 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.572 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -76.56 -115.12 0.14 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 126.222 1.868 . . . . 0.0 109.505 165.084 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -142.86 9.0 2.28 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 119.585 2.594 . . . . 0.0 119.585 -168.795 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -145.22 -169.38 3.19 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 120.651 2.226 . . . . 0.0 112.308 176.515 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -62.18 -49.87 74.07 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 121.173 1.806 . . . . 0.0 112.271 178.24 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.38 -22.85 63.8 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 123.439 0.696 . . . . 0.0 112.007 -177.65 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.572 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 25.2 m -64.37 -5.4 5.14 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.954 1.465 . . . . 0.0 114.954 168.193 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -122.35 -20.11 6.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.342 1.457 . . . . 0.0 112.029 172.634 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 85.7 mttt -84.2 -69.85 0.61 Allowed 'General case' 0 CA--C 1.547 0.839 0 O-C-N 120.983 -1.073 . . . . 0.0 111.752 172.939 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -92.11 -13.45 30.74 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 177.646 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 83.5 21.72 57.71 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 119.454 1.024 . . . . 0.0 110.855 -165.716 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 52.15 36.23 18.62 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.596 1.958 . . . . 0.0 113.7 176.848 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.1 40.61 0.08 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 116.136 1.902 . . . . 0.0 116.136 -168.799 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.91 -64.06 1.95 Allowed Glycine 0 CA--C 1.528 0.865 0 C-N-CA 126.53 2.014 . . . . 0.0 112.469 -171.543 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 29.9 t -177.07 -150.45 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 C-N-CA 126.809 2.044 . . . . 0.0 109.547 -171.262 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.439 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -156.83 104.57 2.14 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.959 2.104 . . . . 0.0 112.479 -176.77 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.2 pp -72.85 -35.57 67.25 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.222 1.409 . . . . 0.0 114.653 -176.613 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.39 172.85 9.3 Favored 'General case' 0 C--O 1.239 0.54 0 C-N-CA 124.904 1.282 . . . . 0.0 111.767 -175.77 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.0 p -156.43 165.72 35.51 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 127.225 2.21 . . . . 0.0 111.048 175.15 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.45 147.28 15.56 Favored Glycine 0 C--N 1.337 0.617 0 C-N-CA 124.58 1.086 . . . . 0.0 114.036 -175.042 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -73.12 141.37 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.051 0.541 . . . . 0.0 110.124 175.017 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.5 mp -77.78 80.0 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.535 1.134 . . . . 0.0 109.506 169.384 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -79.36 171.34 54.83 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.084 1.325 . . . . 0.0 112.485 172.472 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.464 ' H ' ' HA3' ' B' ' 51' ' ' GLY . 2.4 mp -102.05 131.25 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 126.142 1.777 . . . . 0.0 111.435 -169.478 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.62 37.84 4.25 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.975 2.11 . . . . 0.0 110.706 -179.662 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.549 0 C-N-CA 129.353 3.061 . . . . 0.0 115.072 -167.525 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 121.786 0.803 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.93 106.22 4.05 Favored 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 124.428 1.091 . . . . 0.0 109.359 169.778 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 118.22 21.39 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 170.058 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.04 168.85 18.66 Favored 'General case' 0 CA--C 1.54 0.568 0 O-C-N 120.641 -1.287 . . . . 0.0 108.51 163.576 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.67 155.35 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.8 0.81 . . . . 0.0 113.026 -166.388 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.24 143.49 25.0 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.389 2.276 . . . . 0.0 107.386 165.757 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.1 m -113.05 117.79 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 168.098 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.89 125.99 33.74 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.064 0.946 . . . . 0.0 109.863 -168.848 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -146.2 177.08 9.26 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.354 1.062 . . . . 0.0 113.507 170.651 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.12 -65.97 0.25 Allowed Glycine 0 C--N 1.33 0.201 0 C-N-CA 126.497 1.999 . . . . 0.0 109.024 -176.666 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -103.09 85.01 2.43 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.966 2.106 . . . . 0.0 112.797 -167.165 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.06 -98.43 0.01 OUTLIER Glycine 0 CA--C 1.537 1.467 0 C-N-CA 127.071 2.272 . . . . 0.0 115.98 167.785 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -77.06 -8.69 17.77 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.617 2.878 . . . . 0.0 115.433 -173.549 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -98.31 138.82 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 CA-C-N 121.061 1.755 . . . . 0.0 110.866 176.14 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.5 pm0 -160.16 166.07 30.43 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 125.43 1.492 . . . . 0.0 110.801 171.255 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.31 175.61 33.94 Favored Glycine 0 CA--C 1.507 -0.422 0 C-N-CA 123.283 0.468 . . . . 0.0 113.398 169.227 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.02 146.62 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 123.445 0.698 . . . . 0.0 110.114 169.561 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.17 155.2 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 123.807 0.843 . . . . 0.0 110.108 167.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -127.67 148.32 50.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.8 1.24 . . . . 0.0 109.669 167.735 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -128.16 97.79 4.88 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.369 1.468 . . . . 0.0 110.395 178.563 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -81.36 106.53 13.4 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.367 1.067 . . . . 0.0 113.62 -176.148 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -101.7 140.57 35.82 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 165.298 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.33 -13.47 9.28 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 125.933 1.693 . . . . 0.0 112.361 169.782 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -97.45 -145.01 0.3 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 131.019 3.728 . . . . 0.0 109.772 173.089 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 57.7 m -163.61 40.57 0.09 Allowed 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 127.883 2.473 . . . . 0.0 107.772 168.714 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 p30 178.02 -42.51 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 126.682 1.993 . . . . 0.0 112.436 -167.133 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.86 -168.46 21.74 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 125.333 1.444 . . . . 0.0 113.435 178.986 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.42 172.43 9.07 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 124.381 3.387 . . . . 0.0 114.554 -169.741 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 65.2 t -140.95 133.59 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 123.994 0.918 . . . . 0.0 111.391 177.954 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 mttp -80.18 116.95 20.56 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.285 0.564 . . . . 0.0 110.449 169.601 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.1 t -98.95 114.49 36.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 125.547 1.539 . . . . 0.0 109.099 170.057 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.3 p90 -137.28 154.87 50.01 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 123.529 0.731 . . . . 0.0 111.676 169.887 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 159.92 166.8 19.51 Favored Glycine 0 C--N 1.336 0.576 0 N-CA-C 114.82 0.688 . . . . 0.0 114.82 177.806 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 13.0 p -132.52 126.69 33.5 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.278 1.031 . . . . 0.0 111.3 -170.072 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.0 mm -112.77 125.38 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 124.984 1.314 . . . . 0.0 111.14 174.772 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -130.53 135.62 48.11 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 120.575 1.534 . . . . 0.0 112.737 -169.096 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.74 -4.48 10.79 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 126.197 1.856 . . . . 0.0 114.058 -176.494 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.516 HD13 ' H ' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -95.16 168.8 10.53 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.866 1.667 . . . . 0.0 111.724 170.464 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 m -69.36 152.77 44.55 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 127.18 2.192 . . . . 0.0 111.859 177.064 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 40' ' ' GLU . . . . . 0.422 ' HA ' ' HB3' ' B' ' 89' ' ' ALA . 9.6 pm0 -51.95 157.07 1.34 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.867 1.667 . . . . 0.0 113.52 169.257 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.73 177.56 43.96 Favored Glycine 0 CA--C 1.539 1.555 0 O-C-N 120.653 -1.279 . . . . 0.0 114.567 -176.614 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 147.58 21.32 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 128.035 2.534 . . . . 0.0 114.635 -176.071 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -144.51 130.45 19.35 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 127.068 2.147 . . . . 0.0 109.737 175.643 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.39 156.31 31.93 Favored Glycine 0 N--CA 1.476 1.305 0 C-N-CA 125.001 1.286 . . . . 0.0 113.694 -175.986 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -150.4 141.09 22.66 Favored 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 -170.025 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -145.43 115.9 7.6 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 118.234 -0.889 . . . . 0.0 113.303 -170.136 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 47' ' ' VAL . . . . . 0.578 HG12 ' HB3' ' B' ' 115' ' ' ARG . 0.3 OUTLIER -87.85 98.24 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 167.794 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.419 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 45.4 m170 -73.83 151.43 40.54 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 121.657 -0.652 . . . . 0.0 111.703 -170.982 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -49.93 126.19 13.64 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.017 1.727 . . . . 0.0 113.005 174.181 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 93.24 147.28 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 130.54 3.536 . . . . 0.0 114.443 172.128 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.464 ' HA3' ' H ' ' A' ' 151' ' ' ILE . . . -77.55 -7.5 87.14 Favored Glycine 0 CA--C 1.533 1.201 0 CA-C-O 117.558 -1.69 . . . . 0.0 113.096 168.257 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.417 ' HA ' HG11 ' A' ' 5' ' ' VAL . 14.4 t0 -86.39 132.1 34.04 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 120.313 2.056 . . . . 0.0 109.506 167.774 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' N ' ' B' ' 53' ' ' ASN 0.317 0.0 OUTLIER -157.85 28.33 0.27 Allowed 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 114.981 1.475 . . . . 0.0 114.981 179.243 . . . . . . . . 4 4 . 1 . 027 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 7' ' ' VAL . 17.9 p . . . . . 0 N--CA 1.464 0.268 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -168.4 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.549 0.936 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.07 167.23 27.09 Favored Glycine 0 CA--C 1.542 1.722 0 C-N-CA 125.174 1.369 . . . . 0.0 113.758 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 62' ' ' PRO . . . . . 0.419 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 59.9 Cg_endo -64.74 89.95 0.18 Allowed 'Trans proline' 0 C--N 1.354 0.824 1 C-N-CA 125.881 4.387 . . . . 0.0 112.248 -170.097 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 63' ' ' HIS . . . . . 0.401 ' CD2' ' O ' ' B' ' 137' ' ' THR 0.379 3.9 p-80 47.94 59.67 4.06 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 127.167 2.187 . . . . 0.0 113.79 175.85 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -47.72 129.88 14.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 111.884 -2.417 . . . . 0.0 109.541 168.034 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -110.21 66.33 0.44 Allowed Pre-proline 0 CA--C 1.549 0.931 0 C-N-CA 125.964 1.706 . . . . 0.0 114.823 -167.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -64.16 -21.04 67.84 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.002 2.468 . . . . 0.0 116.045 -169.417 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.38 -4.44 48.19 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.795 0.838 . . . . 0.0 112.703 172.488 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.0 t 67.36 46.99 1.34 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 128.691 2.797 . . . . 0.0 110.513 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.8 mtm-85 -109.5 167.1 10.38 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.059 -177.658 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -85.85 176.84 7.87 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 127.657 2.383 . . . . 0.0 108.175 167.016 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -62.63 175.21 0.84 Allowed 'General case' 0 CA--C 1.544 0.745 0 O-C-N 121.336 -0.852 . . . . 0.0 112.812 173.963 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.68 -149.79 20.75 Favored Glycine 0 C--N 1.339 0.718 0 N-CA-C 115.641 1.016 . . . . 0.0 115.641 170.386 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.86 -117.3 2.17 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 125.727 1.632 . . . . 0.0 112.755 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -65.01 -11.37 29.5 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.786 2.991 . . . . 0.0 116.075 -169.305 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.53 -3.13 10.92 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 119.534 1.061 . . . . 0.0 113.145 168.737 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -152.17 98.03 2.37 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -166.783 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 63.9 mm-40 -39.72 -4.99 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 131.32 3.848 . . . . 0.0 118.47 171.316 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -74.0 -75.95 0.14 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 121.021 1.737 . . . . 0.0 110.116 170.522 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.254 0.0 OUTLIER 52.76 107.02 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 127.326 2.251 . . . . 0.0 113.869 -177.595 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -54.53 143.79 23.3 Favored 'General case' 0 CA--C 1.552 1.028 0 O-C-N 119.631 -1.918 . . . . 0.0 110.525 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 96.9 t -35.36 -59.26 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -168.123 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.78 18.71 16.68 Favored Glycine 0 N--CA 1.468 0.801 0 CA-C-O 119.335 -0.703 . . . . 0.0 112.989 176.831 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.46 89.68 2.88 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-N 119.526 1.663 . . . . 0.0 111.775 -167.633 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.11 163.35 37.71 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 114.634 -1.166 . . . . 0.0 113.578 -167.86 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 78.25 170.37 36.47 Favored Glycine 0 N--CA 1.472 1.044 0 N-CA-C 115.274 0.87 . . . . 0.0 115.274 168.46 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 86' ' ' ASN . . . . . 0.446 HD21 ' HB2' ' B' ' 124' ' ' ASP . 1.3 m-80 -134.48 149.54 50.73 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.908 1.283 . . . . 0.0 109.969 174.827 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.5 m -112.53 129.31 68.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.884 1.674 . . . . 0.0 109.204 169.505 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.7 m -113.15 133.81 54.86 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 121.24 -0.913 . . . . 0.0 109.903 -170.119 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.422 ' HB3' ' HA ' ' B' ' 40' ' ' GLU . . . -88.15 137.3 32.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.711 1.204 . . . . 0.0 113.522 -178.212 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.86 -59.25 2.86 Favored 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -168.212 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 172.81 -40.88 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 128.405 2.682 . . . . 0.0 110.731 -166.047 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -78.25 13.2 1.58 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 125.877 1.671 . . . . 0.0 112.281 174.154 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.77 25.56 70.57 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-O 118.932 -0.927 . . . . 0.0 113.38 -177.242 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 94' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' B' ' 89' ' ' ALA . 7.4 p -105.96 109.52 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 126.338 1.855 . . . . 0.0 110.991 176.155 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -79.28 108.84 13.08 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 168.175 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -110.53 159.04 17.88 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 122.313 1.054 . . . . 0.0 112.273 -176.412 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -149.6 148.0 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 CA-C-N 113.62 -1.627 . . . . 0.0 115.302 176.91 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -157.77 98.61 1.65 Allowed 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 124.2 1.0 . . . . 0.0 112.306 169.687 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 15.2 mt -139.7 152.3 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 127.522 2.329 . . . . 0.0 110.876 -172.746 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -117.53 127.23 53.78 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 165.855 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -117.28 146.49 43.28 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.517 1.527 . . . . 0.0 111.049 176.097 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 51.31 0.95 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.495 0.718 . . . . 0.0 112.913 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 47.2 t -136.39 -50.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.252 1.421 . . . . 0.0 109.635 175.336 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.84 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 CA-C-N 119.128 0.877 . . . . 0.0 111.747 174.656 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.88 161.66 39.67 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 119.888 -1.758 . . . . 0.0 111.251 -178.453 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.83 58.46 1.89 Allowed 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.88 1.324 . . . . 0.0 110.602 177.257 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.31 160.6 20.67 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 124.544 1.137 . . . . 0.0 108.8 168.128 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.25 -59.0 10.15 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 119.612 2.605 . . . . 0.0 119.612 -163.21 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -148.94 34.87 0.75 Allowed 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 122.862 1.315 . . . . 0.0 110.745 -172.142 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -158.01 4.08 0.12 Allowed 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 114.957 1.466 . . . . 0.0 114.957 -168.759 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 10.6 t -133.28 -91.21 0.37 Allowed 'General case' 0 N--CA 1.48 1.031 0 O-C-N 119.984 -1.698 . . . . 0.0 109.634 -178.313 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.283 5.4 pt -120.26 -14.66 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-N 121.185 1.811 . . . . 0.0 115.696 166.861 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm -82.75 152.64 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 161.122 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.05 41.71 86.58 Favored Glycine 0 N--CA 1.467 0.703 0 C-N-CA 124.103 0.858 . . . . 0.0 112.401 -176.446 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 115' ' ' ARG . . . . . 0.578 ' HB3' HG12 ' B' ' 47' ' ' VAL . 1.3 mpt_? -144.88 171.16 14.82 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 127.242 2.217 . . . . 0.0 109.004 172.17 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.5 t -139.42 122.66 16.98 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.873 -1.142 . . . . 0.0 110.979 -177.694 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 39.8 tp -92.07 108.87 20.25 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -169.464 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.8 p -90.62 142.35 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 125.32 1.448 . . . . 0.0 110.117 168.136 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -120.66 146.09 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.458 0.646 . . . . 0.0 111.316 172.012 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 120' ' ' HIS . . . . . 0.41 ' HA ' ' HA ' ' B' ' 143' ' ' ARG . 92.0 m-70 -105.63 141.37 37.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.56 1.544 . . . . 0.0 114.369 -168.728 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.317 0.2 OUTLIER -72.03 -18.39 61.96 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 120.841 -1.162 . . . . 0.0 112.037 178.24 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mttp -104.29 162.92 12.79 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 124.466 1.106 . . . . 0.0 112.759 168.067 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.0 165.08 9.44 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.308 1.843 . . . . 0.0 110.789 167.046 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 124' ' ' ASP . . . . . 0.54 ' HB3' ' H ' ' B' ' 126' ' ' LEU . 12.4 m-20 -95.2 158.9 15.26 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 122.126 0.965 . . . . 0.0 113.177 169.712 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.34 -7.9 50.2 Favored 'General case' 0 CA--C 1.557 1.22 0 CA-C-N 113.715 -1.584 . . . . 0.0 112.561 167.026 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.54 ' H ' ' HB3' ' B' ' 124' ' ' ASP . 96.3 mt 33.11 44.91 0.06 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 129.543 3.137 . . . . 0.0 114.068 -174.737 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.67 -52.38 0.83 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 115.854 1.101 . . . . 0.0 115.854 168.773 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -155.99 80.94 1.0 Allowed 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 117.046 2.239 . . . . 0.0 117.046 -169.22 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB3' ' B' ' 134' ' ' SER . . . -80.2 -115.02 0.29 Allowed Glycine 0 CA--C 1.524 0.625 0 C-N-CA 124.076 0.846 . . . . 0.0 111.009 166.389 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -137.9 11.72 3.65 Favored Glycine 0 N--CA 1.472 1.071 0 N-CA-C 116.893 1.517 . . . . 0.0 116.893 -169.338 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -144.12 174.84 10.52 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 119.819 1.81 . . . . 0.0 111.765 177.65 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 132' ' ' GLU . . . . . 0.526 ' CG ' ' HE3' ' B' ' 136' ' ' LYS . 3.2 tp10 -51.59 -64.27 0.87 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.463 1.505 . . . . 0.0 112.574 173.08 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -53.18 -31.15 41.29 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -179.638 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 134' ' ' SER . . . . . 0.593 ' HB3' ' H ' ' B' ' 129' ' ' GLY . 26.1 m -49.69 -39.23 36.09 Favored 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.832 1.651 . . . . 0.0 113.969 170.773 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.76 -58.32 2.14 Favored 'General case' 0 CA--C 1.52 -0.205 0 C-N-CA 127.191 2.196 . . . . 0.0 110.294 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.526 ' HE3' ' CG ' ' B' ' 132' ' ' GLU . 22.2 ttpp -61.98 -39.62 92.81 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.1 1.36 . . . . 0.0 113.47 -172.197 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.401 ' O ' ' CD2' ' B' ' 63' ' ' HIS . 1.2 p -109.4 -79.04 0.58 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 119.523 1.056 . . . . 0.0 110.179 174.079 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 170.71 11.9 0.02 OUTLIER Glycine 0 CA--C 1.54 1.65 1 C-N-CA 131.625 4.44 . . . . 0.0 115.389 -179.006 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 20.8 t30 58.97 -35.67 0.06 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 128.831 2.852 . . . . 0.0 117.257 -170.688 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.79 -44.19 1.0 Allowed 'General case' 0 CA--C 1.554 1.113 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -165.33 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.57 -82.05 1.53 Allowed Glycine 0 C--N 1.341 0.829 0 N-CA-C 117.108 1.603 . . . . 0.0 117.108 164.264 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.3 t -80.78 151.62 28.69 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 123.817 0.847 . . . . 0.0 111.143 -169.083 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 143' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -144.49 159.53 42.62 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.728 1.149 . . . . 0.0 113.966 -168.539 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.22 -9.07 2.0 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 125.574 1.796 . . . . 0.0 115.524 -171.39 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -173.3 149.42 1.75 Allowed 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.354 1.062 . . . . 0.0 111.12 -177.657 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.0 t -148.31 150.83 34.32 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.673 1.589 . . . . 0.0 111.413 177.712 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.9 138.03 5.71 Favored Glycine 0 N--CA 1.474 1.191 0 CA-C-N 119.367 0.985 . . . . 0.0 114.55 175.192 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -74.28 144.54 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.351 0.66 . . . . 0.0 111.264 -179.644 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 13.3 mm -84.65 105.97 14.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 CA-C-O 121.635 0.731 . . . . 0.0 111.764 179.291 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.87 -175.73 19.06 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 125.07 1.319 . . . . 0.0 111.456 168.235 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 3.9 mp -122.32 132.49 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 O-C-N 121.105 -1.233 . . . . 0.0 110.772 -169.732 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 -7.93 16.21 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.056 1.343 . . . . 0.0 113.071 171.145 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.305 0.7 OUTLIER . . . . . 0 C--O 1.238 0.451 0 C-N-CA 126.358 1.863 . . . . 0.0 112.734 -179.443 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.107 0.956 . . . . 0.0 111.646 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -75.91 161.66 28.77 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -167.655 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.44 164.2 28.32 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.996 1.318 . . . . 0.0 110.255 168.873 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.547 ' CG1' ' HA ' ' B' ' 52' ' ' ASP . 7.3 p -132.61 129.56 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 124.612 1.165 . . . . 0.0 109.265 -179.027 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.81 110.72 15.44 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 120.994 -1.066 . . . . 0.0 109.179 177.869 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' B' ' 54' ' ' THR . 3.8 t -81.17 60.26 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 123.997 0.919 . . . . 0.0 111.563 -169.087 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.2 mp -76.72 116.87 17.78 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -167.779 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.422 ' CE ' HG12 ' A' ' 7' ' ' VAL . 34.4 mtmt -145.95 175.09 10.7 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 125.453 1.501 . . . . 0.0 111.896 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.92 -3.56 7.96 Favored Glycine 0 N--CA 1.474 1.233 0 N-CA-C 119.902 2.721 . . . . 0.0 119.902 166.832 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -137.29 83.11 1.97 Allowed 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 121.607 2.704 . . . . 0.0 110.163 178.827 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 38.44 -105.99 0.05 OUTLIER Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.522 2.011 . . . . 0.0 114.032 179.482 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -73.66 -5.84 17.73 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 124.279 3.32 . . . . 0.0 113.954 -176.25 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.4 ' C ' HE21 ' A' ' 15' ' ' GLN . 16.1 t -94.06 126.65 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 125.066 1.346 . . . . 0.0 111.699 -177.347 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.4 HE21 ' C ' ' A' ' 14' ' ' VAL . 1.2 mp0 -146.61 168.32 21.58 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 126.818 2.047 . . . . 0.0 108.01 169.457 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.23 170.91 24.82 Favored Glycine 0 CA--C 1.507 -0.413 0 CA-C-N 115.224 -0.898 . . . . 0.0 112.606 168.317 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 pt -150.34 53.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 114.195 -1.002 . . . . 0.0 111.169 -167.657 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.6 mm -80.35 112.23 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 O-C-N 120.984 -1.072 . . . . 0.0 110.348 -169.447 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.09 149.23 33.93 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 125.18 1.392 . . . . 0.0 111.491 175.969 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -134.51 116.24 14.85 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.299 1.84 . . . . 0.0 108.641 178.099 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -97.97 112.38 24.34 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.919 1.288 . . . . 0.0 112.255 175.329 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.4 tp60 -107.4 129.32 54.94 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 125.338 1.455 . . . . 0.0 109.226 177.968 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.53 -48.99 6.94 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.85 0.86 . . . . 0.0 111.447 178.784 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.63 136.46 51.67 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 127.302 2.241 . . . . 0.0 108.933 174.695 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 m -62.55 0.62 0.46 Allowed 'General case' 0 N--CA 1.48 1.05 0 N-CA-C 117.594 2.442 . . . . 0.0 117.594 -168.919 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.6 m-80 -114.22 -9.89 12.81 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 127.727 2.411 . . . . 0.0 113.9 178.033 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.6 -178.09 33.9 Favored Glycine 0 CA--C 1.537 1.424 0 CA-C-N 119.491 1.041 . . . . 0.0 115.053 -169.372 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -70.82 160.09 50.51 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.592 3.528 . . . . 0.0 110.898 -178.486 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.9 t -129.81 138.04 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.929 -0.482 . . . . 0.0 111.083 -170.68 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 100' ' ' GLU . 78.2 mttt -86.37 121.11 28.47 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 168.745 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.4 t -109.87 121.46 62.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.969 2.107 . . . . 0.0 108.692 -177.571 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -148.25 165.04 32.18 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 177.541 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.84 -173.37 14.67 Favored Glycine 0 N--CA 1.468 0.828 0 O-C-N 121.431 -0.793 . . . . 0.0 112.333 -178.741 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.85 167.32 21.98 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 -164.916 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -125.11 129.67 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 127.408 2.283 . . . . 0.0 108.421 171.709 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 44.8 pttt -115.33 159.01 21.59 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 120.316 1.416 . . . . 0.0 111.796 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.94 -6.97 73.4 Favored Glycine 0 N--CA 1.475 1.253 0 C-N-CA 125.371 1.462 . . . . 0.0 114.517 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 8.2 mp -62.86 153.17 34.07 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.872 2.069 . . . . 0.0 111.583 173.066 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -78.75 158.6 28.23 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 166.858 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -55.21 143.49 27.54 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.472 0.709 . . . . 0.0 112.87 175.607 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.09 -176.14 21.74 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 123.992 0.806 . . . . 0.0 114.84 177.44 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -68.29 139.19 55.93 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 127.775 2.43 . . . . 0.0 113.247 -171.124 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -145.45 120.37 9.99 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 128.565 2.746 . . . . 0.0 110.349 -174.711 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.98 22.88 Favored Glycine 0 N--CA 1.482 1.73 0 CA-C-O 117.095 -1.947 . . . . 0.0 112.716 -175.84 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.449 ' CB ' HG22 ' A' ' 119' ' ' VAL . 11.3 p90 -130.41 120.78 24.76 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.742 1.771 . . . . 0.0 113.478 177.522 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.414 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -154.3 156.11 36.37 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 115.195 -0.912 . . . . 0.0 112.843 -168.737 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 p -77.01 135.51 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 122.992 0.517 . . . . 0.0 109.844 171.305 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -112.48 171.97 7.2 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.895 1.678 . . . . 0.0 111.459 172.19 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -40.69 119.77 1.17 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.093 1.757 . . . . 0.0 113.178 -176.072 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -88.63 -164.43 1.13 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.846 2.458 . . . . 0.0 111.045 -177.328 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.71 -79.11 0.9 Allowed Glycine 0 C--N 1.334 0.464 0 N-CA-C 115.327 0.891 . . . . 0.0 115.327 167.076 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.517 ' HA ' HG11 ' B' ' 5' ' ' VAL . 44.9 p-10 -128.99 47.88 2.42 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 126.805 2.042 . . . . 0.0 115.19 -164.029 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 11.6 p30 -154.75 -30.73 0.11 Allowed 'General case' 0 N--CA 1.478 0.97 0 O-C-N 120.577 -1.327 . . . . 0.0 114.48 -172.68 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.342 12.4 t 21.15 35.88 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.6 1 C-N-CA 133.235 4.614 . . . . 0.0 120.408 173.251 . . . . . . . . 3 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -146.57 -2.78 0.64 Allowed 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 128.35 2.66 . . . . 0.0 111.101 169.652 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.42 -154.79 24.49 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.244 1.402 . . . . 0.0 114.0 175.67 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.2 t -46.86 -27.39 1.22 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.117 1.767 . . . . 0.0 115.263 -172.861 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 t -56.16 -14.51 2.77 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 126.715 2.006 . . . . 0.0 114.528 169.006 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.9 t -150.28 9.37 0.65 Allowed 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 127.044 2.138 . . . . 0.0 113.74 174.857 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -129.22 172.97 10.92 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 -168.167 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -97.95 -150.54 26.42 Favored Glycine 0 CA--C 1.546 2.021 0 C-N-CA 125.367 1.46 . . . . 0.0 115.383 -176.276 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -78.75 -170.03 0.91 Allowed 'Trans proline' 0 C--N 1.352 0.761 1 C-N-CA 127.831 5.688 . . . . 0.0 111.385 -179.651 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.417 ' CD2' ' HA ' ' A' ' 137' ' ' THR . 12.2 m170 -62.69 116.51 5.26 Favored 'General case' 0 N--CA 1.451 -0.412 0 O-C-N 121.97 -0.456 . . . . 0.0 111.029 177.743 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 146.94 44.46 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -174.383 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -110.32 79.69 1.72 Allowed Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.656 1.354 . . . . 0.0 114.656 -176.117 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.81 -12.55 14.83 Favored 'Trans proline' 0 CA--C 1.54 0.778 0 C-N-CA 123.14 2.56 . . . . 0.0 112.071 168.12 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.591 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 85.1 mt -137.61 2.82 2.48 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.163 1.785 . . . . 0.0 112.797 -168.394 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 25.2 m 58.96 70.18 0.67 Allowed 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 124.824 1.249 . . . . 0.0 113.092 168.689 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.591 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.2 ptp180 -155.48 177.42 11.39 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 119.874 3.287 . . . . 0.0 119.874 -163.99 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.416 ' HE2' ' N ' ' A' ' 70' ' ' LYS . 0.7 OUTLIER -78.81 178.03 8.24 Favored 'General case' 0 CA--C 1.549 0.907 0 CA-C-N 113.992 -1.458 . . . . 0.0 111.499 168.057 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.441 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 83.7 t60 -115.85 159.81 21.01 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -168.701 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.441 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 136.37 -102.81 0.42 Allowed Glycine 0 C--N 1.333 0.378 0 C-N-CA 125.586 1.565 . . . . 0.0 109.829 166.54 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.434 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 105.55 -36.92 4.08 Favored Glycine 0 CA--C 1.549 2.17 0 CA-C-O 117.448 -1.751 . . . . 0.0 116.558 -177.034 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -73.45 -19.98 21.3 Favored 'Trans proline' 0 C--N 1.358 1.043 0 CA-C-N 122.156 2.978 . . . . 0.0 113.863 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.19 -1.42 0.74 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 125.488 1.515 . . . . 0.0 112.267 -175.011 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.434 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -122.37 139.92 53.27 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 128.701 2.8 . . . . 0.0 107.192 -178.15 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -97.43 -9.24 27.66 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 128.052 2.541 . . . . 0.0 112.647 -174.456 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -82.57 -82.49 0.14 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.087 0.858 . . . . 0.0 109.196 -178.708 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 79.95 110.92 0.07 Allowed 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 126.604 1.961 . . . . 0.0 114.213 164.74 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 8.4 m80 -62.43 128.52 36.4 Favored 'General case' 0 CA--C 1.546 0.811 0 O-C-N 119.784 -1.823 . . . . 0.0 107.247 167.098 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.2 p -39.83 -36.6 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.215 0 N-CA-C 118.556 2.798 . . . . 0.0 118.556 -167.185 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.65 19.51 36.04 Favored Glycine 0 N--CA 1.477 1.386 0 CA-C-N 120.283 1.401 . . . . 0.0 115.39 178.687 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -78.31 140.35 38.81 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 119.223 1.512 . . . . 0.0 112.315 174.798 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.3 -176.36 3.12 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 163.224 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.52 -137.21 2.65 Favored Glycine 0 N--CA 1.468 0.831 0 O-C-N 121.322 -0.861 . . . . 0.0 111.861 174.808 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.6 p30 -100.59 147.39 26.0 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 122.006 -0.702 . . . . 0.0 112.008 168.119 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.47 149.84 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 127.572 2.349 . . . . 0.0 107.328 169.183 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.4 m -107.94 140.29 41.29 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.774 -0.579 . . . . 0.0 110.058 179.204 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.43 138.7 31.34 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.725 0.81 . . . . 0.0 111.944 171.984 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -80.37 147.61 30.97 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.468 1.507 . . . . 0.0 109.991 168.168 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -46.69 -22.18 0.27 Allowed 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 128.605 2.762 . . . . 0.0 116.641 174.329 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.13 0.27 19.48 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.177 1.391 . . . . 0.0 112.186 172.599 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.39 28.97 8.64 Favored Glycine 0 C--N 1.342 0.885 0 C-N-CA 125.987 1.756 . . . . 0.0 114.568 169.545 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.74 134.66 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 119.83 1.815 . . . . 0.0 115.282 -175.225 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.07 110.64 22.69 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 124.597 1.159 . . . . 0.0 107.907 166.334 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -106.71 137.9 43.88 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 122.356 1.074 . . . . 0.0 111.387 175.928 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -116.65 147.09 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-N 112.555 -2.111 . . . . 0.0 114.464 -168.649 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 82.8 p -158.93 90.1 0.97 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 178.655 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.3 mp -132.46 154.87 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 125.847 1.659 . . . . 0.0 112.968 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 30' ' ' LYS . 14.0 tt0 -117.76 115.99 26.13 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 164.039 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -117.57 114.54 23.57 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.327 1.061 . . . . 0.0 111.451 -171.375 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.6 p -84.03 54.91 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.472 -0.767 . . . . 0.0 111.686 -175.035 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.7 p -142.7 -17.55 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 114.75 1.389 . . . . 0.0 114.75 -169.813 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 pp -142.69 161.91 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.914 1.234 . . . . 0.0 112.622 -176.603 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.633 ' H ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -145.1 155.36 43.28 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 125.528 1.531 . . . . 0.0 113.601 -179.721 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.4 mp -83.67 56.94 3.83 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.781 1.632 . . . . 0.0 111.14 -175.449 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.03 -56.05 2.41 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.38 1.472 . . . . 0.0 110.543 178.365 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 143.38 -102.6 0.29 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 115.637 1.015 . . . . 0.0 115.637 169.572 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.81 -33.98 72.45 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 125.02 1.328 . . . . 0.0 111.873 175.002 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -80.02 1.0 29.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.036 1.734 . . . . 0.0 113.245 170.817 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.633 ' HB3' ' H ' ' A' ' 105' ' ' SER . 1.6 m -166.51 -90.42 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 169.846 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.385 7.6 pt -119.16 -99.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -179.015 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . 0.274 24.2 mm 37.11 -88.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 127.37 2.268 . . . . 0.0 113.794 -169.024 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.18 2.4 9.44 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-N 119.911 1.232 . . . . 0.0 115.091 175.612 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -79.38 152.1 30.58 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.571 1.685 . . . . 0.0 107.399 168.465 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.6 t -125.61 119.65 28.66 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 122.237 -0.289 . . . . 0.0 111.126 -168.871 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.72 130.3 34.71 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 124.461 1.104 . . . . 0.0 108.506 176.29 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.5 p -125.69 138.17 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.409 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.464 ' HB ' HD11 ' A' ' 144' ' ' LEU . 32.1 t -101.88 157.01 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 169.196 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.402 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 35.0 m-70 -130.22 146.68 51.86 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.619 1.568 . . . . 0.0 111.886 -167.372 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -71.56 -4.22 25.71 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.852 1.261 . . . . 0.0 114.044 -170.633 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 21.7 mmmt -127.68 160.36 31.91 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.061 1.345 . . . . 0.0 111.953 176.044 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.46 162.81 0.72 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.381 1.472 . . . . 0.0 112.505 169.719 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -111.27 130.18 55.74 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.302 1.841 . . . . 0.0 109.847 -175.336 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.265 1.0 OUTLIER -84.38 -8.15 59.08 Favored 'General case' 0 N--CA 1.48 1.04 0 N-CA-C 116.007 1.854 . . . . 0.0 116.007 -178.931 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 31.6 mt 63.73 42.18 6.43 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.576 1.95 . . . . 0.0 114.71 167.532 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 113.36 -38.11 3.34 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.447 1.022 . . . . 0.0 114.901 167.785 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.52 88.78 1.08 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 119.138 3.014 . . . . 0.0 119.138 169.62 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.4 -69.28 0.88 Allowed Glycine 0 CA--C 1.522 0.487 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 161.833 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.55 -107.94 3.25 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 117.714 1.846 . . . . 0.0 117.714 -168.557 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -102.56 -158.48 0.67 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.126 1.77 . . . . 0.0 113.861 -161.102 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.63 -47.68 49.63 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.133 0.573 . . . . 0.0 111.468 170.176 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -57.0 -34.28 67.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.007 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.456 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 24.0 p -52.43 -30.04 27.46 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 120.315 1.416 . . . . 0.0 112.04 170.109 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.2 p -97.55 -34.1 11.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 117.454 -1.26 . . . . 0.0 113.812 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -92.26 -46.23 7.82 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 114.651 1.352 . . . . 0.0 114.651 -176.835 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.417 ' HA ' ' CD2' ' A' ' 63' ' ' HIS . 17.9 p -90.81 -95.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.538 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 170.199 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -171.74 26.07 0.09 OUTLIER Glycine 0 CA--C 1.536 1.344 1 C-N-CA 132.568 4.89 . . . . 0.0 110.418 176.645 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.456 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 0.1 OUTLIER 56.59 -7.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 129.488 3.115 . . . . 0.0 116.714 -168.989 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.44 -38.36 43.02 Favored 'General case' 0 CA--C 1.55 0.98 0 CA-C-N 119.958 1.254 . . . . 0.0 113.939 -169.401 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.0 -116.03 4.22 Favored Glycine 0 N--CA 1.47 0.906 0 O-C-N 121.024 -1.048 . . . . 0.0 112.577 172.482 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 20.7 m -44.88 115.52 0.9 Allowed 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.524 1.53 . . . . 0.0 114.69 -169.924 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.63 160.5 31.46 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 121.41 -0.806 . . . . 0.0 112.482 172.985 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.464 HD11 ' HB ' ' A' ' 119' ' ' VAL 0.277 3.9 pp -142.28 -153.38 0.46 Allowed 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 126.829 2.052 . . . . 0.0 107.474 165.414 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.85 132.58 46.66 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 119.817 1.19 . . . . 0.0 113.269 -171.38 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.6 p -130.89 146.01 52.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 126.655 1.982 . . . . 0.0 111.63 -174.525 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.17 159.63 30.94 Favored Glycine 0 N--CA 1.472 1.038 0 N-CA-C 114.61 0.604 . . . . 0.0 114.61 179.362 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.59 161.85 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 C-N-CA 123.632 0.773 . . . . 0.0 109.676 168.409 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 27.8 mm -88.52 64.54 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 125.169 1.388 . . . . 0.0 110.096 178.773 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -68.82 139.49 33.08 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -174.06 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -77.76 144.78 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 O-C-N 121.719 -0.871 . . . . 0.0 111.16 -174.33 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.6 -17.16 10.03 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.162 2.185 . . . . 0.0 112.138 175.851 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 N--CA 1.468 0.468 0 C-N-CA 128.594 2.758 . . . . 0.0 113.428 175.27 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.502 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.2 m -78.14 106.09 9.8 Favored 'General case' 0 CA--C 1.51 -0.585 0 C-N-CA 124.766 1.226 . . . . 0.0 110.078 -172.763 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtmm -92.92 124.57 36.99 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 123.624 1.678 . . . . 0.0 113.305 178.667 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -115.66 175.37 5.56 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 127.256 2.222 . . . . 0.0 108.951 166.653 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.517 HG11 ' HA ' ' A' ' 52' ' ' ASP . 1.0 OUTLIER -148.16 146.74 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -177.611 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.13 119.89 36.1 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 163.98 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -124.78 115.25 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 175.848 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -103.91 147.12 27.71 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.041 1.336 . . . . 0.0 111.052 -179.025 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -140.3 142.88 35.64 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.095 1.358 . . . . 0.0 109.442 164.884 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.36 -117.17 3.52 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-O 122.96 1.311 . . . . 0.0 111.348 173.116 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.74 49.68 1.85 Allowed 'General case' 0 C--N 1.314 -0.974 0 C-N-CA 126.715 2.006 . . . . 0.0 113.529 -163.146 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -81.25 0.71 Allowed Glycine 0 CA--C 1.538 1.502 0 CA-C-O 117.289 -1.839 . . . . 0.0 113.115 -175.78 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -98.29 -2.3 1.13 Allowed 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 123.818 3.012 . . . . 0.0 115.183 -169.726 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -89.88 125.88 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-N 121.049 1.749 . . . . 0.0 110.08 178.174 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -130.61 166.99 19.47 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 124.039 0.935 . . . . 0.0 112.713 174.93 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -144.93 104.26 0.31 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 114.118 -1.401 . . . . 0.0 111.176 169.046 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.33 127.43 47.33 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.114 0 CA-C-N 118.781 1.291 . . . . 0.0 109.278 169.749 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 mm -131.85 112.44 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 126.46 1.904 . . . . 0.0 108.662 170.882 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -82.87 139.39 33.47 Favored 'General case' 0 CA--C 1.542 0.667 0 O-C-N 120.988 -1.07 . . . . 0.0 111.553 169.302 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -115.84 103.82 11.02 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.545 1.538 . . . . 0.0 110.541 179.308 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -108.51 108.13 18.93 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.592 1.157 . . . . 0.0 113.31 179.186 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -97.93 160.91 14.01 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.816 1.246 . . . . 0.0 110.603 171.304 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.78 -21.19 8.55 Favored 'General case' 0 CA--C 1.544 0.729 0 N-CA-C 114.214 1.19 . . . . 0.0 114.214 178.934 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.48 -165.72 1.08 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 127.739 2.416 . . . . 0.0 108.788 168.21 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.2 m -110.79 -11.28 14.4 Favored 'General case' 0 N--CA 1.48 1.026 0 O-C-N 120.612 -1.305 . . . . 0.0 112.118 167.001 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 m-80 -138.05 101.1 4.33 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.743 2.017 . . . . 0.0 107.893 168.712 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.73 -175.1 37.46 Favored Glycine 0 CA--C 1.539 1.565 0 C-N-CA 125.325 1.441 . . . . 0.0 111.77 -175.464 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.41 149.6 80.53 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 123.197 2.598 . . . . 0.0 115.853 -168.497 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 t -124.31 133.83 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.454 1.501 . . . . 0.0 109.749 -177.536 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -78.8 125.07 28.87 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.628 0.771 . . . . 0.0 109.507 170.086 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.65 77.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 C-N-CA 127.414 2.286 . . . . 0.0 106.201 -178.541 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -102.02 154.91 18.54 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.957 170.819 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 170.2 -177.37 43.52 Favored Glycine 0 C--O 1.227 -0.335 0 O-C-N 121.361 -0.837 . . . . 0.0 113.806 -176.72 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 76.7 p -155.41 127.99 7.91 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 124.129 0.972 . . . . 0.0 111.192 -179.691 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.443 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.7 mp -79.6 163.63 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 168.28 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 48.5 tttp -156.56 122.46 4.89 Favored 'General case' 0 N--CA 1.444 -0.739 0 O-C-N 120.851 -1.156 . . . . 0.0 108.588 165.247 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.52 1.03 12.32 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.277 1.894 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 62.0 mt -71.29 171.52 10.97 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 120.266 2.033 . . . . 0.0 110.046 168.648 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.0 t -91.42 158.04 16.73 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 163.761 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -58.88 147.07 35.25 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.412 1.085 . . . . 0.0 111.886 -178.75 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.04 -173.75 20.92 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 124.58 1.086 . . . . 0.0 112.266 -177.51 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.677 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.4 pt? -87.38 140.57 29.4 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.781 2.032 . . . . 0.0 112.016 -172.308 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -143.03 138.34 29.9 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.506 2.322 . . . . 0.0 108.141 -177.21 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -89.07 139.41 15.24 Favored Glycine 0 N--CA 1.473 1.139 0 CA-C-N 121.709 2.049 . . . . 0.0 111.031 -175.019 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -137.1 140.14 41.74 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.013 1.906 . . . . 0.0 111.963 170.407 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -149.9 154.99 39.24 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 121.126 -0.984 . . . . 0.0 111.843 -174.344 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.71 151.09 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 124.683 1.193 . . . . 0.0 109.67 -179.052 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -86.94 176.13 7.81 Favored 'General case' 0 CA--C 1.546 0.815 0 CA-C-O 122.556 1.169 . . . . 0.0 112.911 178.603 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -74.68 112.29 10.73 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 160.499 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.77 -162.71 0.16 Allowed 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.502 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -118.85 33.85 4.59 Favored Glycine 0 C--N 1.342 0.865 0 C-N-CA 128.019 2.723 . . . . 0.0 111.549 178.852 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.547 ' HA ' ' CG1' ' A' ' 5' ' ' VAL . 45.7 p-10 -116.91 69.29 0.75 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 124.048 1.88 . . . . 0.0 112.768 -169.953 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 53' ' ' ASN . . . . . 0.618 ' ND2' HG11 ' A' ' 7' ' ' VAL . 7.8 p-10 -124.22 57.94 1.21 Allowed 'General case' 0 C--O 1.244 0.813 0 N-CA-C 116.62 2.081 . . . . 0.0 116.62 -160.939 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 54' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 7' ' ' VAL 0.278 13.2 p . . . . . 0 C--N 1.32 -0.712 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.603 -163.122 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.239 0.514 0 CA-C-O 121.08 0.467 . . . . 0.0 111.583 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.55 -115.57 2.37 Favored Glycine 0 CA--C 1.541 1.663 0 C-N-CA 127.21 2.338 . . . . 0.0 113.27 -178.213 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.72 157.21 62.78 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.983 3.789 . . . . 0.0 116.152 -164.716 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -38.59 101.28 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 127.011 2.124 . . . . 0.0 116.033 169.675 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -58.95 119.4 7.15 Favored 'General case' 0 CA--C 1.544 0.722 0 O-C-N 121.574 -0.704 . . . . 0.0 109.63 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -104.23 75.8 0.25 Allowed Pre-proline 0 CA--C 1.549 0.91 0 C-N-CA 127.335 2.254 . . . . 0.0 112.588 -172.445 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -56.61 -33.01 92.19 Favored 'Trans proline' 0 C--N 1.355 0.879 0 C-N-CA 123.532 2.822 . . . . 0.0 115.843 -168.934 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 97.3 mt -79.76 -3.35 47.24 Favored 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 175.413 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.9 t 65.73 52.23 1.33 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.734 2.014 . . . . 0.0 112.912 178.705 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 11.4 mtp180 -105.57 172.33 6.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 -169.313 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -81.09 172.69 13.39 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 122.769 0.428 . . . . 0.0 110.518 165.025 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -104.49 146.5 28.78 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -170.791 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.15 -140.6 11.95 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 113.641 -1.618 . . . . 0.0 113.323 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 149.91 -29.46 1.13 Allowed Glycine 0 CA--C 1.545 1.932 0 N-CA-C 118.399 2.12 . . . . 0.0 118.399 -179.432 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 74' ' ' PRO . . . . . 0.429 ' HG3' ' H ' ' B' ' 86' ' ' ASN . 60.0 Cg_endo -69.83 -4.56 14.32 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 122.766 3.283 . . . . 0.0 112.998 168.535 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.93 -37.18 0.15 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.976 1.31 . . . . 0.0 109.752 165.853 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -61.39 109.26 1.1 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 123.621 1.676 . . . . 0.0 112.49 -176.95 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 77' ' ' GLU . . . . . 0.444 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 4.0 pm0 -44.03 -30.71 0.77 Allowed 'General case' 0 C--N 1.318 -0.794 1 C-N-CA 134.058 4.943 . . . . 0.0 115.689 169.198 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -90.85 -62.96 1.34 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.936 0.789 . . . . 0.0 111.123 -176.962 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.269 32.1 ptt180 55.34 121.26 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 129.114 2.966 . . . . 0.0 115.346 -175.507 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -56.7 151.33 14.19 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 119.141 -2.224 . . . . 0.0 112.65 173.581 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 80.5 t -49.96 -56.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 CA-C-N 118.753 0.706 . . . . 0.0 110.603 -176.926 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.69 115.25 5.17 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 105.132 -3.187 . . . . 0.0 105.132 164.333 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -158.35 158.26 33.97 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.9 0.85 . . . . 0.0 112.675 172.69 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 83.1 mt -144.19 153.07 41.71 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.99 2.116 . . . . 0.0 106.439 168.335 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -113.06 -124.1 4.17 Favored Glycine 0 N--CA 1.471 1.026 0 C-N-CA 124.459 1.028 . . . . 0.0 111.046 172.443 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 86' ' ' ASN . . . . . 0.429 ' H ' ' HG3' ' B' ' 74' ' ' PRO . 6.7 m-80 -78.54 135.11 37.23 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -175.65 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.74 121.07 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 C-N-CA 131.082 3.753 . . . . 0.0 108.84 167.053 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.1 m -119.22 119.27 33.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.102 0.961 . . . . 0.0 110.963 -170.257 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.58 160.3 14.69 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.947 1.299 . . . . 0.0 113.972 -174.758 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -84.69 178.12 7.79 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 128.593 2.757 . . . . 0.0 112.633 170.87 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -20.85 65.81 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 120.865 -1.147 . . . . 0.0 113.2 169.387 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -73.77 -11.7 60.47 Favored 'General case' 0 CA--C 1.55 0.969 0 CA-C-O 121.791 0.805 . . . . 0.0 110.145 171.603 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.84 2.75 88.42 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.843 1.687 . . . . 0.0 113.462 176.499 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -84.11 134.67 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 125.491 1.517 . . . . 0.0 111.839 170.751 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.15 135.19 52.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 164.251 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -90.37 143.69 26.52 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.806 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 t -132.7 129.05 58.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 113.822 -1.535 . . . . 0.0 108.139 171.54 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.6 p -157.28 59.91 0.5 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 122.466 1.127 . . . . 0.0 112.506 -166.772 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.4 mt -120.2 158.03 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 124.991 1.316 . . . . 0.0 111.836 -171.264 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -138.56 127.7 24.14 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 166.598 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -144.48 145.29 31.79 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -167.637 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 72.2 p -104.47 52.37 0.75 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.06 1.344 . . . . 0.0 112.449 -168.85 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 31.3 m -149.74 6.31 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 115.434 1.642 . . . . 0.0 115.434 -169.508 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.03 172.01 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 125.518 1.527 . . . . 0.0 110.645 -176.288 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 88.0 p -157.26 160.73 38.92 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.717 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.02 51.7 1.13 Allowed 'General case' 0 CA--C 1.54 0.586 0 O-C-N 121.631 -0.668 . . . . 0.0 111.587 174.486 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.5 m -81.38 -52.43 7.28 Favored 'General case' 0 N--CA 1.474 0.754 0 O-C-N 121.689 -0.632 . . . . 0.0 112.692 -176.836 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.5 -30.19 4.31 Favored Glycine 0 N--CA 1.471 0.988 0 C-N-CA 124.425 1.012 . . . . 0.0 114.697 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -82.91 -53.18 6.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 122.108 0.956 . . . . 0.0 112.544 -168.867 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -139.05 4.73 2.28 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -166.082 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.0 m -113.59 -112.11 0.34 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 123.894 0.878 . . . . 0.0 113.331 -168.92 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 45.5 mm -106.29 -59.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.794 1.237 . . . . 0.0 111.573 -174.89 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.6 mm -58.16 138.32 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 106.069 -1.826 . . . . 0.0 106.069 166.289 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.7 59.13 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.758 -1.023 . . . . 0.0 114.023 -174.978 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mtt85 -127.43 176.68 7.27 Favored 'General case' 0 C--N 1.347 0.492 0 CA-C-N 119.292 1.546 . . . . 0.0 112.765 171.025 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 2.2 m -126.29 153.07 45.32 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 128.016 2.527 . . . . 0.0 109.183 169.029 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 13.1 tp -130.1 133.04 46.4 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.763 1.625 . . . . 0.0 109.167 176.446 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.73 139.15 44.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 C-N-CA 126.499 1.92 . . . . 0.0 110.767 176.403 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -106.11 140.78 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.129 1.372 . . . . 0.0 109.927 167.439 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -97.6 156.9 16.31 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.807 2.043 . . . . 0.0 111.147 177.917 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 8.2 tm-20 -77.11 -27.77 54.18 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.498 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -103.45 175.0 5.62 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.465 1.106 . . . . 0.0 111.845 168.685 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.85 152.68 42.44 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.174 1.79 . . . . 0.0 113.976 173.809 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -89.87 145.53 25.08 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 122.546 1.165 . . . . 0.0 113.168 169.792 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -76.8 -39.4 51.55 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -168.936 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 84.32 24.68 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 126.433 1.893 . . . . 0.0 113.812 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 127' ' ' GLY . . . . . 0.403 ' HA2' ' HB ' ' B' ' 135' ' ' THR . . . 84.34 57.77 2.3 Favored Glycine 0 C--N 1.343 0.959 0 C-N-CA 125.749 1.643 . . . . 0.0 114.906 168.06 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -158.68 -17.09 0.07 Allowed 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -168.203 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.08 16.35 2.8 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.612 1.577 . . . . 0.0 115.114 178.696 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.57 -2.17 24.4 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.316 1.436 . . . . 0.0 116.459 169.416 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -102.4 162.41 12.94 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 118.837 1.318 . . . . 0.0 109.551 -178.797 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -50.44 -62.83 1.35 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 122.175 0.988 . . . . 0.0 109.485 167.733 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -46.36 -31.14 2.42 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 128.898 2.879 . . . . 0.0 114.601 173.794 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 15.3 p -56.67 -30.31 63.25 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 120.556 -1.34 . . . . 0.0 113.927 178.066 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 135' ' ' THR . . . . . 0.403 ' HB ' ' HA2' ' B' ' 127' ' ' GLY . 8.9 t -121.57 -13.54 8.35 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 170.111 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.5 tttt -74.79 -15.22 60.76 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.633 1.173 . . . . 0.0 113.263 169.635 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.2 p -148.31 -25.46 0.34 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 126.623 1.969 . . . . 0.0 114.67 167.421 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.13 53.83 Favored Glycine 0 CA--C 1.536 1.4 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -163.228 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 16.5 t30 51.67 18.07 0.68 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.618 1.967 . . . . 0.0 113.923 179.009 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.36 -0.04 0.22 Allowed 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 127.806 2.442 . . . . 0.0 116.667 -167.764 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.84 -129.71 10.48 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.14 1.353 . . . . 0.0 115.886 168.236 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.42 134.34 28.69 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 127.735 2.414 . . . . 0.0 112.493 -178.967 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.92 146.98 33.22 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 121.265 -0.897 . . . . 0.0 109.887 171.093 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.3 tt -120.66 -134.83 0.32 Allowed 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 168.97 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.75 156.72 32.23 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 -176.854 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -146.48 161.84 39.57 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.706 1.202 . . . . 0.0 111.099 170.002 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.47 146.75 13.33 Favored Glycine 0 N--CA 1.468 0.831 0 C-N-CA 125.141 1.353 . . . . 0.0 112.525 -174.541 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.46 HG12 ' H ' ' B' ' 149' ' ' ILE . 2.5 t -85.77 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 175.267 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 149' ' ' ILE . . . . . 0.46 ' H ' HG12 ' B' ' 148' ' ' VAL . 37.3 mt -123.19 114.14 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 120.097 -1.627 . . . . 0.0 111.878 -177.124 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.64 175.12 15.56 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 126.593 2.044 . . . . 0.0 115.037 -172.476 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -102.46 102.9 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.381 1.472 . . . . 0.0 112.65 -171.049 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.55 49.7 1.04 Allowed 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.535 1.934 . . . . 0.0 112.239 171.868 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 . . . . . 0 C--N 1.327 -0.378 0 C-N-CA 126.001 1.72 . . . . 0.0 111.387 177.738 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p . . . . . 0 N--CA 1.465 0.309 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.5 148.48 12.74 Favored 'General case' 0 C--O 1.238 0.469 0 C-N-CA 125.002 1.321 . . . . 0.0 112.413 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.65 161.23 39.89 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 126.293 1.837 . . . . 0.0 108.896 166.842 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.414 ' HB ' ' CG ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -156.29 150.6 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 124.487 1.115 . . . . 0.0 109.333 -178.056 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.07 93.37 2.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.463 1.105 . . . . 0.0 108.841 167.526 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -76.88 87.94 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.89 1.276 . . . . 0.0 107.793 170.355 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -76.75 127.42 32.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 125.874 1.67 . . . . 0.0 109.637 -173.606 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -144.04 169.8 17.15 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.318 1.047 . . . . 0.0 112.174 -174.176 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.19 -48.7 0.64 Allowed Glycine 0 N--CA 1.467 0.739 0 C-N-CA 125.329 1.442 . . . . 0.0 112.739 171.399 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.89 64.0 6.21 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 122.219 1.009 . . . . 0.0 110.694 -169.158 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.15 -101.75 0.04 OUTLIER Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.236 2.35 . . . . 0.0 113.132 179.102 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.07 -14.28 21.03 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.852 3.035 . . . . 0.0 113.635 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -76.89 136.24 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 119.849 1.204 . . . . 0.0 109.618 179.079 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.45 159.1 35.33 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 125.997 2.808 . . . . 0.0 113.377 167.163 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -111.16 142.53 16.92 Favored Glycine 0 C--N 1.313 -0.739 1 CA-C-N 108.188 -4.097 . . . . 0.0 109.438 172.968 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 86.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 122.641 1.21 . . . . 0.0 108.417 175.19 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -106.91 143.94 16.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.705 167.541 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -119.67 135.73 54.7 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 127.762 2.425 . . . . 0.0 110.573 -178.374 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-30 -119.93 157.86 27.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.462 1.505 . . . . 0.0 110.862 178.247 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.84 146.29 37.35 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 130.489 3.516 . . . . 0.0 104.598 171.265 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -146.0 -174.24 4.37 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.149 1.78 . . . . 0.0 106.721 172.125 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 -24.01 0.47 Allowed 'General case' 0 CA--C 1.55 0.943 0 O-C-N 118.962 -2.336 . . . . 0.0 114.463 167.402 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.403 ' HB2' ' H ' ' A' ' 27' ' ' GLY . 1.0 OUTLIER -98.72 -172.81 2.38 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.673 1.989 . . . . 0.0 109.571 170.578 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.61 -1.84 29.5 Favored 'General case' 0 CA--C 1.547 0.851 0 O-C-N 121.328 -0.857 . . . . 0.0 112.049 168.341 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -145.63 -7.98 0.58 Allowed 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -170.054 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' A' ' 24' ' ' GLU . . . -85.06 -163.75 37.56 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 118.873 -0.96 . . . . 0.0 111.771 177.057 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -84.11 161.17 13.53 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 121.964 1.776 . . . . 0.0 112.429 -171.153 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.11 152.87 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.963 1.705 . . . . 0.0 109.606 -170.064 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -94.17 151.15 19.69 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 170.755 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 96.0 t -130.93 97.7 3.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 127.161 2.184 . . . . 0.0 107.096 166.849 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.3 p90 -124.98 160.02 29.92 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.681 0.792 . . . . 0.0 111.52 172.56 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.44 -155.2 16.37 Favored Glycine 0 N--CA 1.469 0.867 0 O-C-N 120.983 -1.073 . . . . 0.0 112.052 -179.179 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.8 p -149.44 151.9 34.77 Favored 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 117.962 2.579 . . . . 0.0 117.962 -167.421 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.8 mm -118.0 133.17 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 126.16 1.784 . . . . 0.0 108.358 169.999 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.13 160.24 43.45 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 120.049 1.295 . . . . 0.0 114.144 -172.482 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.42 3.55 61.3 Favored Glycine 0 CA--C 1.538 1.486 0 C-N-CA 126.9 2.19 . . . . 0.0 112.293 -167.956 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.8 mt -85.23 173.26 10.52 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.305 1.842 . . . . 0.0 112.926 -173.985 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 m -74.19 175.97 7.04 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.642 1.177 . . . . 0.0 108.057 164.291 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.29 -93.51 0.03 OUTLIER 'General case' 0 CA--C 1.558 1.252 0 O-C-N 119.958 -1.714 . . . . 0.0 113.04 179.263 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -61.51 97.47 0.14 Allowed Glycine 0 CA--C 1.529 0.965 0 C-N-CA 126.733 2.111 . . . . 0.0 117.667 -167.486 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 65.4 mt 62.85 131.75 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 129.185 2.994 . . . . 0.0 116.606 168.482 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.01 141.58 46.24 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 129.4 3.08 . . . . 0.0 107.486 179.752 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.78 155.14 51.81 Favored Glycine 0 N--CA 1.468 0.794 0 C-N-CA 124.659 1.123 . . . . 0.0 111.715 173.846 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -150.38 98.48 2.66 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -167.475 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.66 145.99 30.22 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 120.955 -1.091 . . . . 0.0 111.69 -168.461 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 0.3 OUTLIER -102.2 119.68 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 126.149 1.78 . . . . 0.0 107.802 179.412 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -72.51 142.93 48.53 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.632 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -63.36 136.66 57.79 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -172.718 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 68.36 166.67 0.26 Allowed 'General case' 0 CA--C 1.543 0.68 0 CA-C-O 123.818 1.771 . . . . 0.0 113.995 175.338 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.31 -14.53 12.95 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 126.477 1.989 . . . . 0.0 114.413 -178.035 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -75.42 53.54 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 121.187 2.493 . . . . 0.0 112.757 -177.83 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 172.03 21.99 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.29 0 C-N-CA 128.318 2.647 . . . . 0.0 113.914 -167.065 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.604 HG22 HG21 ' A' ' 148' ' ' VAL . 76.5 p -36.1 -15.24 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 1 N-CA-C 122.332 4.197 . . . . 0.0 122.332 -170.463 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.41 15.37 4.49 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 122.097 2.226 . . . . 0.0 113.229 -174.052 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.92 -133.48 43.55 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 124.415 1.007 . . . . 0.0 111.908 174.952 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.9 t -58.46 -22.74 55.71 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 114.341 1.237 . . . . 0.0 114.341 -175.98 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . 0.256 15.0 t -90.95 42.6 1.11 Allowed 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 122.864 1.316 . . . . 0.0 112.291 171.974 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -179.87 -27.8 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.64 1.976 . . . . 0.0 115.659 172.095 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -134.93 142.69 46.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.529 1.532 . . . . 0.0 111.375 -168.702 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.31 -58.36 0.74 Allowed Glycine 0 CA--C 1.538 1.473 0 CA-C-O 117.636 -1.646 . . . . 0.0 115.053 -170.489 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -124.79 -177.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 124.151 3.234 . . . . 0.0 114.033 -169.31 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.462 ' HE1' ' HA ' ' A' ' 137' ' ' THR . 4.2 p-80 -115.13 125.3 53.3 Favored 'General case' 0 C--N 1.328 -0.358 1 C-N-CA 131.839 4.056 . . . . 0.0 106.7 175.087 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -85.76 175.45 8.69 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 123.571 1.653 . . . . 0.0 110.56 -171.328 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -107.48 48.68 0.17 Allowed Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 126.129 1.772 . . . . 0.0 113.444 177.081 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -64.52 -26.01 62.42 Favored 'Trans proline' 0 C--N 1.359 1.125 0 CA-C-N 122.044 1.766 . . . . 0.0 112.609 -179.354 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 76.2 mt -79.21 0.32 28.95 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.588 1.555 . . . . 0.0 112.993 171.041 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.28 58.29 0.7 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.893 2.077 . . . . 0.0 112.464 173.598 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -157.55 176.55 12.48 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 117.704 2.483 . . . . 0.0 117.704 -167.234 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.77 177.53 8.83 Favored 'General case' 0 CA--C 1.56 1.332 0 C-N-CA 126.822 2.049 . . . . 0.0 112.57 173.269 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -105.67 143.82 33.29 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -177.77 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.76 -115.84 0.7 Allowed Glycine 0 C--N 1.336 0.559 0 CA-C-N 114.336 -1.302 . . . . 0.0 113.675 166.607 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.23 -67.41 0.51 Allowed Glycine 0 CA--C 1.545 1.966 0 CA-C-O 118.933 -0.926 . . . . 0.0 114.614 179.027 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -65.77 -2.65 6.79 Favored 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 125.374 4.049 . . . . 0.0 116.459 173.109 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.82 -29.37 0.24 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.407 1.483 . . . . 0.0 111.466 170.402 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.9 t0 -87.01 104.1 15.98 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.588 0.755 . . . . 0.0 110.53 166.422 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -63.12 -13.45 36.76 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.165 2.186 . . . . 0.0 114.072 176.815 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -76.89 -72.29 0.35 Allowed 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 119.303 0.956 . . . . 0.0 110.536 -179.804 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.405 HH12 ' CG2' ' A' ' 103' ' ' VAL . 17.0 ttp180 77.45 114.09 0.07 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 126.901 2.081 . . . . 0.0 113.538 166.182 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -60.55 162.53 6.31 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 118.685 -2.509 . . . . 0.0 112.758 171.751 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -63.2 -29.93 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 O-C-N 121.231 -0.918 . . . . 0.0 112.52 172.691 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.12 12.32 54.61 Favored Glycine 0 CA--C 1.53 0.999 0 C-N-CA 124.696 1.141 . . . . 0.0 115.468 175.081 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -112.71 113.57 25.75 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-N 119.774 1.787 . . . . 0.0 114.439 -173.91 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.15 -173.76 4.9 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 163.164 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.46 -134.34 2.02 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 120.792 -1.193 . . . . 0.0 113.625 172.227 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.5 p30 -127.34 163.39 24.11 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.163 0.985 . . . . 0.0 108.95 168.535 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 136.4 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.131 0.972 . . . . 0.0 110.61 -171.686 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -110.6 135.87 50.57 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 175.292 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.12 156.26 18.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.524 0.678 . . . . 0.0 110.584 169.298 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -77.16 155.22 32.45 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.056 1.342 . . . . 0.0 108.497 166.861 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.92 -25.36 19.98 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.999 1.72 . . . . 0.0 115.23 -169.305 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -76.65 -2.37 32.38 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.499 2.32 . . . . 0.0 112.273 179.101 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.65 30.18 7.37 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-O 117.937 -1.48 . . . . 0.0 114.12 172.334 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -144.81 131.54 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -178.188 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.27 112.72 24.4 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 164.799 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.0 t0 -106.33 128.65 54.17 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 170.803 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.46 145.18 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-N 113.429 -1.714 . . . . 0.0 114.4 -164.176 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 86.1 p -147.94 89.62 1.76 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.16 1.384 . . . . 0.0 112.087 179.566 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.06 149.31 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.505 1.522 . . . . 0.0 111.499 -174.96 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -135.68 138.29 42.64 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.842 2.057 . . . . 0.0 106.421 166.961 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -146.99 153.97 40.69 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 124.912 1.285 . . . . 0.0 112.241 -167.567 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -118.17 52.91 0.99 Allowed 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.382 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.405 ' CG2' HH12 ' A' ' 79' ' ' ARG . 1.0 OUTLIER -154.66 16.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 115.889 1.811 . . . . 0.0 115.889 -178.781 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -139.63 176.37 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 125.937 1.695 . . . . 0.0 109.741 169.605 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 28.8 p -160.08 175.54 12.85 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 177.11 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.437 ' HA ' ' CG1' ' A' ' 113' ' ' ILE . 8.5 mp -103.94 56.6 0.73 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.047 1.739 . . . . 0.0 110.409 176.953 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.5 t -107.91 -16.51 14.28 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 121.699 3.963 . . . . 0.0 121.699 -169.449 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 77.44 103.84 0.17 Allowed Glycine 0 CA--C 1.529 0.912 0 CA-C-N 121.233 1.833 . . . . 0.0 111.177 -171.011 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 85.77 -44.88 0.06 Allowed 'General case' 0 C--N 1.318 -0.777 1 C-N-CA 131.925 4.09 . . . . 0.0 111.376 166.909 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -85.78 3.03 43.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.862 1.265 . . . . 0.0 112.669 -176.573 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 p -138.22 -152.56 0.43 Allowed 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -166.951 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.8 pt -96.58 -17.35 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 120.382 -1.449 . . . . 0.0 112.516 168.298 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.437 ' CG1' ' HA ' ' A' ' 106' ' ' LEU . 7.1 mm -72.37 133.37 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 166.202 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.52 ' HA3' HD11 ' B' ' 151' ' ' ILE . . . 67.76 42.29 87.24 Favored Glycine 0 CA--C 1.532 1.134 0 O-C-N 124.36 1.037 . . . . 0.0 110.528 -168.994 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.99 148.86 35.85 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 127.04 2.136 . . . . 0.0 105.263 170.256 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 11.6 m -114.85 109.99 19.0 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.005 -1.059 . . . . 0.0 112.994 -165.038 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 11.2 tp -86.14 139.8 30.77 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 120.005 1.275 . . . . 0.0 114.224 -169.633 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.486 HG11 ' HE ' ' A' ' 143' ' ' ARG . 1.0 OUTLIER -132.68 149.3 31.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.284 168.232 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.64 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 164.762 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -127.3 131.92 50.4 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.144 1.378 . . . . 0.0 109.543 -176.62 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -60.63 -40.81 93.3 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.491 1.663 . . . . 0.0 115.491 -166.888 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -86.53 147.44 25.96 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 121.018 1.735 . . . . 0.0 110.898 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -33.58 125.58 0.41 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.568 1.947 . . . . 0.0 111.102 166.236 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 35.5 t0 -75.57 134.7 40.64 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 169.751 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.96 -34.67 66.64 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.889 0.876 . . . . 0.0 111.88 178.451 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.1 mt 62.74 33.18 15.65 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.621 1.568 . . . . 0.0 112.533 173.586 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -174.04 -72.75 0.05 OUTLIER Glycine 0 N--CA 1.468 0.815 0 N-CA-C 116.399 1.32 . . . . 0.0 116.399 174.845 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -164.85 67.74 0.14 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.548 1.139 . . . . 0.0 114.073 178.252 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.3 68.03 0.7 Allowed Glycine 0 CA--C 1.531 1.061 0 C-N-CA 127.001 2.239 . . . . 0.0 113.416 176.175 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.26 -14.9 31.43 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 125.944 1.735 . . . . 0.0 115.226 172.714 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -141.23 177.08 8.33 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 118.982 1.391 . . . . 0.0 112.039 -171.409 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -77.62 -43.06 32.73 Favored 'General case' 0 C--O 1.217 -0.627 0 CA-C-N 114.625 -1.171 . . . . 0.0 109.978 165.476 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -44.57 -40.32 5.63 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 173.121 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.82 -33.36 23.27 Favored 'General case' 0 N--CA 1.472 0.635 0 O-C-N 120.858 -1.151 . . . . 0.0 114.034 171.54 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.4 -24.05 20.88 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 125.565 1.546 . . . . 0.0 112.527 177.772 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -87.24 -13.66 43.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 176.907 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.462 ' HA ' ' HE1' ' A' ' 63' ' ' HIS . 20.8 p -129.8 -45.93 1.16 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.386 1.074 . . . . 0.0 113.385 176.508 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.8 -0.77 15.34 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 125.777 1.923 . . . . 0.0 111.793 -166.465 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 56.74 21.19 5.7 Favored 'General case' 0 N--CA 1.478 0.965 0 O-C-N 119.808 -1.995 . . . . 0.0 111.974 -175.754 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.92 30.02 0.08 Allowed 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -167.098 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.23 -35.24 0.42 Allowed Glycine 0 N--CA 1.476 1.358 0 C-N-CA 129.673 3.511 . . . . 0.0 117.588 168.893 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.0 t -171.3 -144.59 0.04 OUTLIER 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.476 1.11 . . . . 0.0 110.108 -169.293 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.486 ' HE ' HG11 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -142.37 -174.88 4.25 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 127.515 2.326 . . . . 0.0 110.447 172.929 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -174.42 -141.04 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 129.568 3.147 . . . . 0.0 109.008 168.18 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -51.24 138.71 20.2 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 128.341 2.656 . . . . 0.0 114.377 -168.479 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 87.3 m -126.06 134.83 51.29 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 127.942 2.497 . . . . 0.0 112.606 -169.613 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.32 153.56 23.94 Favored Glycine 0 N--CA 1.482 1.751 0 C-N-CA 125.29 1.424 . . . . 0.0 114.252 169.023 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.604 HG21 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -78.31 149.95 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 CA-C-N 120.278 2.039 . . . . 0.0 110.301 170.185 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 10.0 mm -83.13 104.39 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 106.733 -1.581 . . . . 0.0 106.733 166.049 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -106.15 146.79 16.12 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 124.348 0.975 . . . . 0.0 111.134 176.587 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.5 pp -79.86 173.7 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 122.908 0.483 . . . . 0.0 111.346 175.255 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.45 ' HB2' ' CB ' ' B' ' 52' ' ' ASP . . . -155.95 -126.86 0.03 OUTLIER 'General case' 0 C--O 1.224 -0.269 0 C-N-CA 125.823 1.649 . . . . 0.0 111.156 163.894 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.858 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -164.244 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 p -115.91 115.51 26.34 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.133 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 3' ' ' LYS . . . . . 0.477 ' HZ3' ' HB2' ' B' ' 3' ' ' LYS . 0.0 OUTLIER -98.77 142.56 30.15 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 116.605 2.076 . . . . 0.0 116.605 169.966 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.24 132.25 42.89 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.841 2.456 . . . . 0.0 110.087 172.999 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 59.6 t -144.77 142.82 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 119.943 1.247 . . . . 0.0 111.786 -168.657 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -114.18 141.38 47.6 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.79 1.236 . . . . 0.0 113.853 171.929 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 15.0 m -104.06 99.62 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 167.383 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -78.91 130.35 35.52 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.722 1.209 . . . . 0.0 108.085 -175.63 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -156.18 174.47 15.33 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 -172.644 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.96 -43.03 1.35 Allowed Glycine 0 N--CA 1.471 1.002 0 C-N-CA 127.955 2.693 . . . . 0.0 111.32 172.792 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -82.96 59.17 4.74 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 127.932 2.493 . . . . 0.0 113.319 -168.633 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.41 -104.0 0.06 OUTLIER Glycine 0 CA--C 1.532 1.14 0 C-N-CA 127.537 2.494 . . . . 0.0 112.6 176.975 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.45 -14.62 16.11 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 123.618 2.878 . . . . 0.0 113.614 -177.564 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.496 HG21 HD11 ' B' ' 144' ' ' LEU . 2.8 t -90.05 128.79 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-N 120.096 1.317 . . . . 0.0 109.921 -178.542 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.513 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -146.06 155.12 42.56 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.848 173.121 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.27 153.14 20.64 Favored Glycine 0 C--O 1.227 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.229 177.569 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.4 HD11 ' ND2' ' B' ' 19' ' ' ASN . 0.0 OUTLIER -118.04 117.21 54.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 C-N-CA 126.234 1.814 . . . . 0.0 106.514 168.715 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.3 mm -128.19 104.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 O-C-N 123.64 0.587 . . . . 0.0 110.049 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 19' ' ' ASN . . . . . 0.4 ' ND2' HD11 ' B' ' 17' ' ' ILE . 0.8 OUTLIER -79.53 156.13 27.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.111 1.764 . . . . 0.0 111.981 167.961 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -139.82 108.21 5.84 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 130.655 3.582 . . . . 0.0 107.339 170.071 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.27 130.85 53.31 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.194 1.398 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -126.12 154.68 42.8 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 122.277 1.037 . . . . 0.0 111.35 -176.6 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.419 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 9.9 ptmm? -115.92 -24.35 8.17 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 128.298 2.639 . . . . 0.0 114.105 -177.512 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 24' ' ' GLU . . . . . 0.419 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 6.7 mp0 -135.79 162.25 33.32 Favored 'General case' 0 C--O 1.219 -0.502 0 CA-C-N 121.006 1.73 . . . . 0.0 112.877 173.649 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 p -64.94 -2.94 2.95 Favored 'General case' 0 N--CA 1.483 1.217 0 O-C-N 119.141 -2.224 . . . . 0.0 113.434 167.226 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.79 64.12 0.16 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 128.383 2.673 . . . . 0.0 109.754 -168.214 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.1 172.75 31.37 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.58 1.562 . . . . 0.0 113.411 -170.747 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.53 142.53 23.48 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.39 2.727 . . . . 0.0 110.683 178.634 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.05 132.6 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.158 0.983 . . . . 0.0 109.327 -172.606 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -95.96 115.6 27.67 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 121.626 0.726 . . . . 0.0 111.226 179.061 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.6 t -93.55 121.35 44.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 127.105 2.162 . . . . 0.0 108.807 -179.123 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -148.25 164.88 32.65 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 177.859 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.02 -147.67 19.4 Favored Glycine 0 C--N 1.334 0.448 0 C-N-CA 125.111 1.339 . . . . 0.0 111.356 176.795 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -157.94 156.61 31.56 Favored 'General case' 0 C--O 1.237 0.407 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -175.783 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.591 HG21 HG11 ' B' ' 119' ' ' VAL . 3.1 mp -124.39 133.67 68.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 125.284 1.433 . . . . 0.0 108.319 170.636 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -138.3 155.5 48.53 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -172.791 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.87 76.95 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.031 1.3 . . . . 0.0 114.022 -175.515 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.459 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.1 pt? -96.43 162.58 13.42 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 126.559 1.944 . . . . 0.0 112.11 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.23 154.24 1.26 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.458 2.703 . . . . 0.0 110.822 169.15 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -64.77 -60.34 3.2 Favored 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 120.717 1.599 . . . . 0.0 112.654 174.245 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -51.52 141.7 21.84 Favored Glycine 0 N--CA 1.472 1.075 0 C-N-CA 126.218 1.866 . . . . 0.0 114.733 -169.811 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 42' ' ' LEU . . . . . 0.631 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -40.74 136.88 1.29 Allowed 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 128.315 2.646 . . . . 0.0 115.243 -168.311 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -121.12 142.47 49.83 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 129.816 3.247 . . . . 0.0 109.173 -170.306 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.18 169.51 35.79 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.552 1.072 . . . . 0.0 111.879 172.436 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.2 t80 -160.43 57.95 0.34 Allowed 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.649 1.58 . . . . 0.0 110.728 -169.621 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -117.44 145.81 43.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.305 1.042 . . . . 0.0 113.401 -169.592 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -105.86 115.78 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.773 0.797 . . . . 0.0 109.189 -172.102 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 48' ' ' HIS . . . . . 0.478 ' HB2' HG23 ' B' ' 116' ' ' THR . 12.1 m-70 -76.42 174.16 10.59 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 124.974 1.31 . . . . 0.0 110.119 179.537 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 49' ' ' GLU . . . . . 0.532 ' H ' ' CD ' ' B' ' 49' ' ' GLU . 1.9 pm0 -61.15 85.58 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 127.127 2.171 . . . . 0.0 115.074 -168.242 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 67.95 -157.99 0.21 Allowed 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.089 2.156 . . . . 0.0 111.865 168.974 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.75 -14.88 18.29 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.461 1.505 . . . . 0.0 112.077 -177.871 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.45 ' CB ' ' HB2' ' A' ' 152' ' ' ALA . 7.5 t70 -62.57 56.52 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.023 1 C-N-CA 132.623 4.369 . . . . 0.0 110.6 169.555 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 16.3 p30 176.39 -11.01 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 128.079 2.552 . . . . 0.0 116.287 -174.388 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.315 8.4 t . . . . . 0 N--CA 1.498 1.952 2 N-CA-C 123.685 4.698 . . . . 0.0 123.685 176.268 . . . . . . . . 2 1 . 1 . 029 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 122.245 1.021 . . . . 0.0 113.173 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.79 -152.65 23.0 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 126.846 2.165 . . . . 0.0 111.312 178.796 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -109.08 49.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.596 2.864 . . . . 0.0 111.457 -178.326 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 56.77 82.69 0.11 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.932 1.293 . . . . 0.0 112.498 -179.2 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -40.49 131.62 2.21 Favored 'General case' 0 CA--C 1.542 0.673 0 CA-C-O 122.54 1.162 . . . . 0.0 113.089 169.557 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.7 p-10 -114.29 79.86 5.44 Favored Pre-proline 0 CA--C 1.547 0.838 0 C-N-CA 126.407 1.883 . . . . 0.0 112.457 -171.246 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -62.23 -14.52 38.73 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 123.114 2.543 . . . . 0.0 114.685 179.547 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -92.78 -4.0 53.79 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.111 1.364 . . . . 0.0 113.302 171.387 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 28.0 t 65.7 53.39 1.19 Allowed 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.366 1.866 . . . . 0.0 112.367 171.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -142.64 177.27 8.42 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -169.559 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.528 ' H ' ' HD2' ' B' ' 70' ' ' LYS . 1.3 mptt -79.41 175.4 10.63 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 126.441 1.897 . . . . 0.0 112.904 -178.228 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -97.49 136.61 37.67 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -176.805 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 139.83 -132.27 5.5 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 124.268 0.937 . . . . 0.0 113.596 167.421 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 146.04 -34.44 1.43 Allowed Glycine 0 CA--C 1.547 2.087 0 N-CA-C 118.234 2.054 . . . . 0.0 118.234 -177.037 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -78.4 -19.53 11.65 Favored 'Trans proline' 0 C--N 1.356 0.94 0 CA-C-N 122.263 3.032 . . . . 0.0 113.609 172.22 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -46.42 0.93 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 124.437 1.095 . . . . 0.0 109.917 167.93 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -56.14 126.04 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.976 0.893 . . . . 0.0 109.319 169.209 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -90.61 -5.86 55.35 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 128.973 2.909 . . . . 0.0 112.717 -168.341 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -100.58 -76.48 0.56 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 126.945 2.098 . . . . 0.0 110.773 -169.809 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 84.66 113.7 0.05 Allowed 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 126.519 1.928 . . . . 0.0 113.268 165.812 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -59.2 152.66 20.06 Favored 'General case' 0 CA--C 1.549 0.911 0 O-C-N 119.669 -1.894 . . . . 0.0 110.36 170.04 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -58.39 -30.98 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.891 -1.13 . . . . 0.0 112.681 178.223 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.35 37.47 3.42 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 126.619 2.057 . . . . 0.0 113.58 171.211 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -116.85 146.87 42.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 119.988 1.894 . . . . 0.0 115.737 173.892 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 79.1 mt -144.42 163.3 34.2 Favored 'General case' 0 CA--C 1.545 0.784 1 C-N-CA 132.102 4.161 . . . . 0.0 102.702 163.156 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.91 -87.06 0.99 Allowed Glycine 0 N--CA 1.468 0.829 0 O-C-N 121.926 -0.484 . . . . 0.0 113.428 -170.643 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -153.32 168.44 26.03 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 124.674 1.19 . . . . 0.0 113.479 -166.521 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.56 147.59 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 129.233 3.013 . . . . 0.0 110.214 -176.407 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 25.7 m -120.84 145.6 47.43 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 119.437 1.017 . . . . 0.0 109.991 -176.979 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.65 144.48 26.65 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.895 0.855 . . . . 0.0 111.666 175.95 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 90' ' ' ASP . . . . . 0.452 ' OD1' ' HE2' ' B' ' 91' ' ' LYS . 39.7 t0 -73.19 158.95 34.26 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.762 1.225 . . . . 0.0 109.813 168.921 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 91' ' ' LYS . . . . . 0.452 ' HE2' ' OD1' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -52.33 -28.2 18.34 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 115.42 1.637 . . . . 0.0 115.42 -168.292 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.85 -2.25 29.19 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.544 1.538 . . . . 0.0 112.283 -178.51 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.08 39.16 7.54 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 125.221 1.391 . . . . 0.0 113.154 177.843 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 3.2 p -132.62 126.37 54.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 CA-C-N 118.629 1.215 . . . . 0.0 113.811 170.018 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.58 119.23 31.31 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.518 1.527 . . . . 0.0 107.929 165.9 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.46 151.15 31.0 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 167.419 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.29 0.5 OUTLIER -134.53 131.59 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 114.593 -1.185 . . . . 0.0 112.899 165.477 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 9.6 p -157.69 59.96 0.48 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.151 1.38 . . . . 0.0 113.164 -168.65 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -115.39 156.08 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 C-N-CA 126.787 2.035 . . . . 0.0 112.715 -171.582 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -128.67 146.49 50.86 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.733 1.613 . . . . 0.0 108.288 166.997 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -141.02 134.83 30.41 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.243 1.417 . . . . 0.0 110.222 -179.03 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -112.75 59.27 0.64 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.315 1.446 . . . . 0.0 112.234 -167.578 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.4 p -158.12 -36.5 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.132 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.13 170.97 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 123.332 0.653 . . . . 0.0 111.349 172.712 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.8 m -157.51 159.44 37.21 Favored 'General case' 0 N--CA 1.469 0.506 0 O-C-N 120.12 -1.612 . . . . 0.0 111.335 176.316 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 106' ' ' LEU . . . . . 0.464 ' HG ' HD11 ' B' ' 113' ' ' ILE . 4.8 tt -81.12 75.02 8.1 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.056 0.942 . . . . 0.0 109.523 -173.627 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -138.97 152.18 47.47 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.761 1.625 . . . . 0.0 111.391 -174.088 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -101.91 68.54 0.39 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 126.968 2.223 . . . . 0.0 113.427 -169.29 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -154.43 -91.53 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.78 1.632 . . . . 0.0 110.362 -168.819 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -127.79 -4.43 5.81 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.742 2.017 . . . . 0.0 110.461 -170.048 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 16.4 m -92.6 -91.31 0.17 Allowed 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.523 1.929 . . . . 0.0 114.651 -166.066 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pt -135.36 -14.69 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 118.112 2.634 . . . . 0.0 118.112 176.724 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 113' ' ' ILE . . . . . 0.526 HD12 HG23 ' B' ' 151' ' ' ILE . 22.0 mm -86.58 105.8 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 CA-C-N 122.113 2.233 . . . . 0.0 108.747 179.283 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.59 61.45 1.17 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.573 0.606 . . . . 0.0 112.944 -171.908 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 23.4 ptt180 -140.36 144.95 36.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.981 1.312 . . . . 0.0 109.239 167.305 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 116' ' ' THR . . . . . 0.478 HG23 ' HB2' ' B' ' 48' ' ' HIS . 2.3 t -109.39 102.09 11.01 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 124.243 1.017 . . . . 0.0 111.067 -166.665 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 29.2 tp -86.33 129.67 34.77 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 124.152 0.981 . . . . 0.0 109.774 -173.245 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 t -107.82 118.09 54.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 169.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.591 HG11 HG21 ' B' ' 35' ' ' ILE . 13.9 p -78.85 120.03 29.18 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.37 0 N-CA-C 100.483 -3.895 . . . . 0.0 100.483 161.166 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -106.45 142.52 35.97 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 117.766 -1.111 . . . . 0.0 109.38 -168.189 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.92 -42.94 80.87 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 122.154 2.252 . . . . 0.0 113.915 -166.718 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.473 ' HE3' ' HA ' ' B' ' 122' ' ' LYS . 0.0 OUTLIER -111.7 152.35 27.83 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 171.624 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.12 161.02 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.853 1.661 . . . . 0.0 112.258 171.68 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -94.47 151.35 19.44 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 177.833 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -71.8 -16.66 62.19 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.572 1.949 . . . . 0.0 112.875 176.482 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.3 mt 57.96 84.29 0.1 Allowed 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 127.028 2.131 . . . . 0.0 114.464 169.764 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.74 -47.48 3.42 Favored Glycine 0 N--CA 1.465 0.622 0 C-N-CA 125.502 1.525 . . . . 0.0 111.015 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -158.84 137.91 11.33 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.609 1.564 . . . . 0.0 110.448 168.646 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -141.37 -101.15 0.43 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 169.164 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.57 -24.49 10.96 Favored Glycine 0 N--CA 1.471 0.972 0 N-CA-C 116.705 1.442 . . . . 0.0 116.705 -168.576 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -165.46 174.18 10.26 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.882 1.341 . . . . 0.0 111.83 -169.225 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -49.86 -50.84 44.19 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 126.062 1.745 . . . . 0.0 113.449 -170.313 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 133' ' ' GLU . . . . . 0.471 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 13.7 mp0 -45.76 -25.79 0.55 Allowed 'General case' 0 C--N 1.318 -0.794 0 C-N-CA 128.27 2.628 . . . . 0.0 113.705 175.305 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.6 p -64.95 -45.06 87.32 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 120.119 1.327 . . . . 0.0 112.716 178.823 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -79.91 -39.72 29.76 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.18 0.592 . . . . 0.0 111.523 173.151 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.29 -18.64 52.25 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -173.033 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.9 p -152.71 -15.11 0.16 Allowed 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 177.956 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.04 -7.56 58.85 Favored Glycine 0 C--O 1.214 -1.155 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.313 -168.652 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 51.3 t30 55.57 35.49 25.28 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-N 120.613 2.206 . . . . 0.0 112.157 178.184 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.9 38.88 0.08 Allowed 'General case' 0 CA--C 1.563 1.451 0 N-CA-C 115.759 1.763 . . . . 0.0 115.759 -166.998 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.16 -84.46 0.41 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 127.109 2.29 . . . . 0.0 113.767 175.488 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t -160.52 172.8 16.55 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.155 0.982 . . . . 0.0 112.978 -178.041 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 154.83 25.62 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.126 1.37 . . . . 0.0 113.624 -171.488 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.496 HD11 HG21 ' B' ' 14' ' ' VAL . 19.5 tp -159.79 -177.55 6.43 Favored 'General case' 0 CA--C 1.56 1.342 0 C-N-CA 129.795 3.238 . . . . 0.0 104.878 169.836 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.73 129.91 20.36 Favored 'General case' 0 CA--C 1.556 1.185 0 N-CA-C 115.838 1.792 . . . . 0.0 115.838 -165.146 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.9 m -114.91 134.19 55.36 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 126.712 2.005 . . . . 0.0 112.645 -176.687 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.9 144.12 10.17 Favored Glycine 0 N--CA 1.486 2.006 0 CA-C-N 120.994 1.724 . . . . 0.0 117.172 177.297 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.518 ' O ' HG21 ' A' ' 54' ' ' THR . 84.6 t -81.12 140.74 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 118.169 0.985 . . . . 0.0 109.893 176.022 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.4 mm -77.68 107.33 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 170.584 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.16 36.45 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.555 1.55 . . . . 0.0 111.951 169.635 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 151' ' ' ILE . . . . . 0.526 HG23 HD12 ' B' ' 113' ' ' ILE . 1.1 pp -138.91 160.65 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 125.04 1.336 . . . . 0.0 112.89 177.822 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.58 1.3 0.44 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.644 1.978 . . . . 0.0 112.554 164.603 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tm0? . . . . . 0 N--CA 1.472 0.648 0 C-N-CA 126.636 1.975 . . . . 0.0 110.876 169.699 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 67.4 p . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.1 ttpt -161.55 126.18 3.44 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 118.529 2.789 . . . . 0.0 118.529 166.085 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.52 177.5 4.9 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 129.489 3.116 . . . . 0.0 107.006 164.346 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.574 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.5 p -157.54 151.15 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 -164.227 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.07 115.21 7.92 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 110.627 166.252 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 68.9 t -101.41 95.59 4.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.667 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.9 mp -79.34 152.51 30.42 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.13 1.372 . . . . 0.0 108.68 173.612 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -153.24 158.56 41.88 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -130.11 158.33 22.31 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.308 2.385 . . . . 0.0 107.957 166.151 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -71.94 83.59 0.95 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 126.817 2.047 . . . . 0.0 110.941 -177.446 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.09 -147.64 18.78 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 127.041 2.258 . . . . 0.0 110.158 -169.403 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -94.64 9.51 1.93 Allowed 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 124.794 3.663 . . . . 0.0 114.87 -169.841 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.63 134.16 34.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 CA-C-N 120.025 1.284 . . . . 0.0 110.393 -177.369 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.39 164.67 34.28 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.517 1.127 . . . . 0.0 111.486 178.865 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.447 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -129.52 97.79 0.42 Allowed Glycine 0 C--O 1.215 -1.042 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 169.042 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -96.41 106.61 18.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 118.519 1.159 . . . . 0.0 108.012 175.892 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 pt -133.59 150.13 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 122.241 1.019 . . . . 0.0 111.62 177.09 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -122.74 145.29 48.54 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.637 1.575 . . . . 0.0 110.329 179.416 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -120.94 105.07 10.32 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.936 1.694 . . . . 0.0 109.635 -173.895 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.1 121.16 28.31 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 177.369 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.584 ' CB ' HD13 ' A' ' 106' ' ' LEU . 11.0 tp60 -147.76 137.94 22.91 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.251 0.548 . . . . 0.0 111.186 175.507 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.497 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -91.96 -24.28 19.31 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -175.735 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.66 -155.65 0.61 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-N 120.136 1.335 . . . . 0.0 113.038 176.489 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 66.6 m -107.25 10.25 29.91 Favored 'General case' 0 CA--C 1.543 0.677 0 O-C-N 119.377 -2.077 . . . . 0.0 113.634 -179.095 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -131.27 -10.29 3.7 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 126.021 1.728 . . . . 0.0 114.746 -172.437 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.13 160.74 20.75 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 128.926 3.155 . . . . 0.0 112.657 -168.615 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.75 151.57 32.02 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 123.028 2.486 . . . . 0.0 109.718 175.568 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 67.4 t -119.71 137.65 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.166 1.387 . . . . 0.0 110.004 -168.166 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -84.41 127.09 33.8 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.512 0.596 . . . . 0.0 110.1 170.19 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 t -107.82 130.09 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 125.632 1.573 . . . . 0.0 108.346 171.99 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -151.14 165.9 32.48 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 123.342 0.657 . . . . 0.0 111.54 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 131.16 -148.9 19.07 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 124.993 1.283 . . . . 0.0 111.754 175.928 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 54.1 p -142.6 127.22 17.98 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -169.815 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.447 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 10.2 mm -101.3 112.77 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 124.676 1.19 . . . . 0.0 108.279 170.987 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.9 pttt -129.58 152.07 49.5 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.835 1.198 . . . . 0.0 112.698 -166.514 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.01 5.52 64.05 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.38 0.99 . . . . 0.0 112.599 -169.061 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -75.44 -161.63 0.16 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 127.405 2.282 . . . . 0.0 109.662 168.766 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -151.98 171.24 18.13 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 126.627 1.971 . . . . 0.0 108.183 169.331 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -49.04 136.84 13.96 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.851 1.66 . . . . 0.0 113.439 -168.876 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.51 -173.13 28.21 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-O 122.597 1.11 . . . . 0.0 112.511 173.202 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.5 OUTLIER -73.01 160.45 32.07 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.1 0.96 . . . . 0.0 111.373 -171.339 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.402 ' HB2' HG13 ' A' ' 87' ' ' VAL . 81.6 m-70 -149.09 136.21 19.94 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 127.653 2.381 . . . . 0.0 108.867 176.62 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.17 148.71 32.48 Favored Glycine 0 N--CA 1.478 1.463 0 CA-C-O 119.261 -0.744 . . . . 0.0 111.964 171.226 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -153.15 78.71 1.17 Allowed 'General case' 0 CA--C 1.544 0.741 0 CA-C-O 122.88 1.324 . . . . 0.0 110.768 -168.556 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -124.73 157.86 34.66 Favored 'General case' 0 CA--C 1.516 -0.338 0 O-C-N 120.803 -1.186 . . . . 0.0 111.396 -169.428 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.618 HG11 HH11 ' A' ' 115' ' ' ARG . 1.7 m -87.65 151.52 3.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.24 176.628 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 8.4 m170 -113.88 168.79 9.5 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 104.102 -2.555 . . . . 0.0 104.102 160.175 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.75 -172.69 0.09 Allowed 'General case' 0 CA--C 1.554 1.11 0 N-CA-C 117.257 2.317 . . . . 0.0 117.257 -167.83 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -119.43 -36.58 3.32 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 128.203 2.601 . . . . 0.0 112.305 -175.739 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.19 -29.52 62.9 Favored Glycine 0 N--CA 1.47 0.93 1 C-N-CA 131.667 4.461 . . . . 0.0 114.588 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -123.97 151.23 43.9 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 163.045 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.576 ' HB2' HG13 ' B' ' 5' ' ' VAL . 0.5 OUTLIER -148.98 101.55 3.18 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 119.11 3.004 . . . . 0.0 119.11 -166.493 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.555 HG23 ' O ' ' A' ' 53' ' ' ASN 0.549 0.1 OUTLIER 112.48 -145.75 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.695 1 C-N-CA 133.673 4.789 . . . . 0.0 113.576 160.044 . . . . . . . . 5 4 . 1 . 030 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 49.05 -10.13 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 131.033 3.733 . . . . 0.0 117.91 -172.348 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.34 -132.12 11.11 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.968 2.223 . . . . 0.0 111.211 -176.915 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.9 m -62.78 -8.47 6.89 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 177.726 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.1 m -79.9 -24.07 41.38 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.922 1.289 . . . . 0.0 112.457 171.672 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.514 ' HB3' HG11 ' B' ' 7' ' ' VAL . 4.1 m -158.43 45.57 0.31 Allowed 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 116.193 1.923 . . . . 0.0 116.193 -169.2 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 176.96 125.45 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 127.807 2.443 . . . . 0.0 110.452 168.429 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -72.16 149.14 43.73 Favored Glycine 0 CA--C 1.541 1.667 0 O-C-N 120.736 -1.228 . . . . 0.0 114.372 -175.772 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -64.69 106.94 0.8 Allowed 'Trans proline' 0 C--N 1.354 0.822 1 C-N-CA 125.488 4.125 . . . . 0.0 111.604 -178.896 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.442 ' CE1' ' HA ' ' A' ' 137' ' ' THR 0.274 0.0 OUTLIER 36.04 57.18 1.0 Allowed 'General case' 0 C--O 1.234 0.247 0 C-N-CA 127.377 2.271 . . . . 0.0 112.468 170.458 . . . . . . . . 4 4 . 1 . 030 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -27.05 122.79 0.09 Allowed 'General case' 0 C--N 1.342 0.259 0 C-N-CA 128.285 2.634 . . . . 0.0 111.26 179.328 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 62.8 m-20 -71.84 101.26 0.37 Allowed Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -168.426 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -84.67 -12.46 7.49 Favored 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.157 2.571 . . . . 0.0 112.956 -167.963 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 92.0 mt -139.75 2.91 2.02 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 128.62 2.768 . . . . 0.0 110.717 -172.117 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 16.0 t 66.44 53.43 0.98 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.706 1.603 . . . . 0.0 114.022 175.675 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.79 179.57 4.94 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.978 1.711 . . . . 0.0 113.161 179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.1 mmtt -73.57 173.61 9.46 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 121.654 0.74 . . . . 0.0 111.667 169.356 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 48.9 t60 -72.15 157.77 37.14 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 168.489 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.413 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.78 -126.19 2.69 Favored Glycine 0 C--N 1.339 0.72 0 N-CA-C 116.576 1.39 . . . . 0.0 116.576 165.725 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.85 -90.24 0.36 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 116.58 1.392 . . . . 0.0 116.58 -171.105 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.5 -2.21 4.84 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.946 3.097 . . . . 0.0 115.184 -173.325 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.312 3.3 ptmm? -144.08 4.13 1.24 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 126.433 1.893 . . . . 0.0 112.677 168.346 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.0 OUTLIER -131.77 113.77 13.92 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 127.082 2.153 . . . . 0.0 109.168 177.038 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -71.16 -14.07 62.15 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 127.968 2.507 . . . . 0.0 114.082 -176.371 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -78.02 -62.06 1.8 Allowed 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.908 1.231 . . . . 0.0 109.295 175.361 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 74.6 ttt180 70.71 120.44 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 123.477 1.608 . . . . 0.0 112.831 169.592 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.8 m170 -66.98 136.58 55.53 Favored 'General case' 0 CA--C 1.543 0.694 0 O-C-N 118.96 -2.337 . . . . 0.0 109.217 164.832 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.0 t -53.74 -19.11 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 122.464 1.126 . . . . 0.0 111.636 166.281 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.489 ' HA3' HG22 ' A' ' 47' ' ' VAL . . . -92.16 41.09 2.82 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.255 2.36 . . . . 0.0 116.878 172.454 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -144.56 122.57 12.08 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 119.751 1.775 . . . . 0.0 111.865 -179.06 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.86 48.75 0.94 Allowed 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 123.811 1.767 . . . . 0.0 110.359 173.762 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.89 -133.48 52.71 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 126.122 1.82 . . . . 0.0 114.257 175.289 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.82 138.73 48.03 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.672 1.589 . . . . 0.0 110.11 171.495 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.402 HG13 ' HB2' ' A' ' 43' ' ' HIS . 8.0 p -92.95 127.45 45.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 166.327 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 24.4 m -115.39 119.48 36.4 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -176.27 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.99 156.96 17.31 Favored 'General case' 0 C--N 1.328 -0.353 0 O-C-N 123.667 0.604 . . . . 0.0 112.588 -177.21 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.73 168.54 19.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 126.403 1.881 . . . . 0.0 113.67 173.21 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.1 pptp? -60.11 -20.09 56.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.789 1.636 . . . . 0.0 113.79 168.723 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -80.95 0.04 37.25 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.006 1.322 . . . . 0.0 112.306 170.791 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 19.92 60.41 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 125.178 1.37 . . . . 0.0 114.099 174.633 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -134.16 138.85 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 119.04 1.42 . . . . 0.0 113.527 -176.54 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.79 123.31 40.45 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 165.655 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -97.74 118.8 35.09 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.581 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.12 140.08 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 CA-C-N 114.159 -1.382 . . . . 0.0 113.935 -165.733 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 77.4 p -155.65 123.2 5.57 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.594 1.558 . . . . 0.0 110.103 168.834 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -155.17 148.81 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 127.703 2.401 . . . . 0.0 109.992 -169.85 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -125.77 125.22 42.61 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 165.749 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -121.72 141.81 50.81 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.038 0.935 . . . . 0.0 110.994 -173.753 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -115.63 48.66 1.17 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.959 0.904 . . . . 0.0 112.863 -178.377 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.26 -4.81 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.459 1.104 . . . . 0.0 112.23 170.732 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.54 164.88 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 C-N-CA 125.951 1.7 . . . . 0.0 110.727 176.672 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 99.5 p -149.54 175.28 11.66 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 128.285 2.634 . . . . 0.0 109.072 178.098 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.584 HD13 ' CB ' ' A' ' 22' ' ' GLN . 6.8 mp -86.16 93.4 9.02 Favored 'General case' 0 CA--C 1.543 0.684 0 O-C-N 120.809 -1.182 . . . . 0.0 109.33 173.249 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.2 t -152.45 153.88 34.42 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.753 1.221 . . . . 0.0 110.119 169.04 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -103.08 29.23 12.88 Favored Glycine 0 N--CA 1.472 1.041 0 C-N-CA 126.142 1.829 . . . . 0.0 113.27 -178.147 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -86.81 -96.55 0.08 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 126.022 1.729 . . . . 0.0 106.691 169.655 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m170 -107.39 -7.75 16.54 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.458 1.503 . . . . 0.0 111.806 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -76.15 -157.77 0.08 Allowed 'General case' 0 CA--C 1.558 1.259 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -174.999 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.271 10.9 pt -97.14 44.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 118.455 -2.653 . . . . 0.0 116.06 -172.006 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.9 mm -115.73 126.96 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 166.321 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.18 -4.2 34.06 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 117.208 -1.885 . . . . 0.0 115.077 173.309 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.618 HH11 HG11 ' A' ' 47' ' ' VAL . 3.1 ptp180 -78.82 153.47 30.64 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 120.795 2.297 . . . . 0.0 110.889 170.218 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 6.3 t -101.29 162.75 12.67 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 119.676 1.125 . . . . 0.0 112.917 177.466 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.471 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -130.44 137.98 50.09 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.788 2.035 . . . . 0.0 107.921 174.52 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.471 ' N ' HD13 ' A' ' 117' ' ' LEU . 7.4 p -122.2 125.44 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.291 1.436 . . . . 0.0 109.969 175.24 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -90.2 143.08 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 171.84 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -106.64 158.35 17.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 122.009 0.909 . . . . 0.0 112.909 -174.567 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -71.56 -40.8 69.74 Favored 'General case' 0 CA--C 1.538 0.483 0 O-C-N 121.334 -0.854 . . . . 0.0 111.237 -169.07 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -116.82 174.73 5.92 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 124.706 1.202 . . . . 0.0 112.664 172.594 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.4 148.16 1.43 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.813 2.445 . . . . 0.0 112.252 172.422 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -110.29 142.57 41.73 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.282 1.033 . . . . 0.0 112.185 172.609 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -93.93 -8.3 40.56 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 176.888 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 77.09 -73.33 0.09 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 128.94 2.896 . . . . 0.0 111.516 169.301 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -95.8 -5.26 59.99 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 125.262 1.411 . . . . 0.0 113.539 -174.389 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt -158.23 -146.08 0.15 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 128.088 2.555 . . . . 0.0 112.539 173.15 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 133.31 -29.13 3.21 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 128.7 3.048 . . . . 0.0 110.617 -168.393 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 126.73 -17.03 6.47 Favored Glycine 0 N--CA 1.473 1.12 0 C-N-CA 126.282 1.896 . . . . 0.0 114.986 169.588 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -110.57 174.6 5.79 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.09 1.356 . . . . 0.0 113.683 -171.988 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -52.22 -59.67 4.12 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.319 1.848 . . . . 0.0 110.615 167.52 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -46.57 -36.01 6.42 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.735 1.214 . . . . 0.0 112.51 169.433 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -66.47 -3.74 6.85 Favored 'General case' 0 N--CA 1.476 0.86 0 O-C-N 120.132 -1.605 . . . . 0.0 113.909 -175.936 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.1 p -119.96 -12.96 9.08 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 175.896 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 ptpt -113.25 -26.1 8.56 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 176.952 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.442 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 0.5 OUTLIER -127.96 -17.94 4.31 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 127.049 2.14 . . . . 0.0 113.809 179.497 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.03 -21.49 41.62 Favored Glycine 0 N--CA 1.467 0.724 0 C-N-CA 126.537 2.018 . . . . 0.0 111.969 177.361 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 71.46 36.65 1.26 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.94 1.696 . . . . 0.0 112.421 168.492 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.32 44.69 0.01 OUTLIER 'General case' 0 CA--C 1.575 1.941 0 C-N-CA 128.414 2.686 . . . . 0.0 117.41 -169.268 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.8 -57.21 2.62 Favored Glycine 0 N--CA 1.473 1.157 0 C-N-CA 127.84 2.638 . . . . 0.0 114.483 -177.986 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.9 t -168.17 171.11 9.7 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.727 1.211 . . . . 0.0 111.572 -178.584 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -85.04 148.29 26.23 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 120.726 -1.233 . . . . 0.0 110.608 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -128.01 -146.28 0.32 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.521 1.929 . . . . 0.0 109.26 175.935 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.79 155.37 30.54 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 127.146 2.178 . . . . 0.0 114.596 179.748 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.3 p -151.96 153.74 34.67 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.086 1.355 . . . . 0.0 114.084 -173.304 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.04 159.87 31.5 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 125.042 1.306 . . . . 0.0 113.407 178.057 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 3.6 t -106.45 142.91 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-N 118.717 1.259 . . . . 0.0 109.422 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mm -77.48 93.74 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 CA-C-O 122.232 1.015 . . . . 0.0 110.156 -178.676 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -92.27 174.94 37.38 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 125.884 1.707 . . . . 0.0 112.706 173.581 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.07 149.64 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -173.372 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.98 -17.58 4.37 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.552 1.941 . . . . 0.0 115.006 177.561 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 . . . . . 0 N--CA 1.472 0.627 0 C-N-CA 125.689 1.595 . . . . 0.0 112.592 176.864 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.279 0.561 . . . . 0.0 112.235 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.7 t -156.63 112.17 2.92 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 125.814 1.646 . . . . 0.0 108.458 167.878 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 10.1 pttt -111.93 171.72 7.33 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 116.45 2.019 . . . . 0.0 116.45 -173.315 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -125.87 168.32 14.02 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 128.457 2.703 . . . . 0.0 110.957 174.492 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 5' ' ' VAL . . . . . 0.576 HG13 ' HB2' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -131.5 139.46 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 126.331 1.852 . . . . 0.0 111.861 -178.202 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.06 105.05 4.77 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.092 0.957 . . . . 0.0 109.477 165.041 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.514 HG11 ' HB3' ' A' ' 59' ' ' SER . 1.0 OUTLIER -92.13 130.81 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 166.358 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mp -92.07 143.41 26.48 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 123.554 0.742 . . . . 0.0 111.284 -178.728 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 tttm -156.14 175.93 13.33 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 168.903 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 148.8 -77.93 0.23 Allowed Glycine 0 CA--C 1.523 0.552 0 C-N-CA 128.463 2.935 . . . . 0.0 108.164 -172.936 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.74 75.49 3.39 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.021 1.728 . . . . 0.0 112.735 -168.251 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.73 -97.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.37 0 C-N-CA 127.503 2.478 . . . . 0.0 114.314 169.518 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -82.81 -1.34 10.46 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.958 3.772 . . . . 0.0 114.945 179.162 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.81 140.34 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 120.54 1.518 . . . . 0.0 110.047 170.749 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -139.71 168.03 20.76 Favored 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 125.684 1.594 . . . . 0.0 109.31 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -158.83 92.98 0.12 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.034 -1.426 . . . . 0.0 116.126 165.229 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.404 ' O ' HD13 ' B' ' 18' ' ' ILE . 0.0 OUTLIER -78.22 126.5 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-N 119.296 1.548 . . . . 0.0 110.723 175.931 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.469 HD12 HG11 ' B' ' 97' ' ' VAL . 26.7 mm -135.98 111.08 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 124.901 1.28 . . . . 0.0 110.977 176.113 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -74.8 146.62 41.91 Favored 'General case' 0 CA--C 1.546 0.819 0 O-C-N 121.328 -0.857 . . . . 0.0 110.009 166.963 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -128.76 100.64 5.79 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.707 1.603 . . . . 0.0 108.571 172.914 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -101.83 130.37 48.27 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -174.549 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -100.81 120.51 40.22 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.136 0.493 . . . . 0.0 111.41 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 23' ' ' LYS . . . . . 0.422 ' HG2' ' H ' ' B' ' 23' ' ' LYS . 7.9 ptmm? -75.06 -41.7 58.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 123.048 0.539 . . . . 0.0 111.204 168.678 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -156.58 133.58 10.42 Favored 'General case' 0 C--O 1.219 -0.52 0 C-N-CA 126.429 1.892 . . . . 0.0 110.321 168.309 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -60.42 -19.72 57.23 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 114.703 1.372 . . . . 0.0 114.703 -172.664 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -80.56 -6.26 57.98 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.655 1.182 . . . . 0.0 113.218 173.753 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.86 -164.34 11.22 Favored Glycine 0 CA--C 1.537 1.459 0 C-N-CA 126.546 2.022 . . . . 0.0 113.383 -172.935 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.37 155.52 25.06 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.271 2.647 . . . . 0.0 114.012 -169.25 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 84.5 t -102.6 137.35 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.766 1.626 . . . . 0.0 110.17 172.739 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -96.09 122.62 39.12 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 167.145 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.31 129.2 74.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 126.166 1.786 . . . . 0.0 107.856 -169.664 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.5 p90 -155.41 153.16 29.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 -178.679 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.64 -152.73 24.77 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 125.417 1.484 . . . . 0.0 109.92 179.717 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 69.0 p -159.04 147.42 18.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -175.074 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 6.0 mm -105.62 109.55 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.558 1.543 . . . . 0.0 109.078 177.812 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 44.9 tttp -120.75 133.43 55.33 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 119.463 1.029 . . . . 0.0 110.94 -168.887 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.66 -6.43 9.73 Favored Glycine 0 CA--C 1.541 1.681 0 C-N-CA 127.964 2.697 . . . . 0.0 113.839 -169.663 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.489 HD12 ' CE1' ' B' ' 43' ' ' HIS . 4.6 mm? -75.08 -179.89 4.61 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 126.373 1.869 . . . . 0.0 113.346 177.169 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -103.95 157.73 16.9 Favored 'General case' 0 C--O 1.239 0.553 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 162.521 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -64.86 168.94 5.65 Favored 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.741 1.385 . . . . 0.0 114.741 -170.84 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.59 -177.54 51.38 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.261 0.934 . . . . 0.0 114.161 -173.021 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.8 mp -66.97 149.33 50.78 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 127.298 2.239 . . . . 0.0 113.648 -174.156 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 43' ' ' HIS . . . . . 0.489 ' CE1' HD12 ' B' ' 38' ' ' LEU . 96.9 m-70 -140.5 133.42 29.19 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.726 1.61 . . . . 0.0 110.235 176.816 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.59 146.67 48.47 Favored Glycine 0 N--CA 1.475 1.257 0 CA-C-O 119.055 -0.858 . . . . 0.0 110.987 175.574 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -152.94 111.79 3.76 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.592 0.757 . . . . 0.0 111.852 -166.06 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -147.73 152.2 37.36 Favored 'General case' 0 N--CA 1.471 0.617 0 O-C-N 120.032 -1.667 . . . . 0.0 111.256 -169.852 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.41 131.41 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-O 123.719 1.724 . . . . 0.0 110.117 169.527 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 18.1 m-70 -76.08 108.69 9.16 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 165.448 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -68.75 21.62 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.238 2.215 . . . . 0.0 113.554 -169.288 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -153.81 131.74 11.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.976 1.71 . . . . 0.0 108.005 -171.158 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.28 -14.54 76.39 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 115.124 0.81 . . . . 0.0 115.124 178.427 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 52' ' ' ASP . . . . . 0.574 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -69.91 74.07 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 127.023 2.129 . . . . 0.0 111.149 178.257 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 5.4 p30 164.02 -36.54 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 128.697 2.799 . . . . 0.0 115.237 -178.85 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.401 0.1 OUTLIER . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 130.457 3.503 . . . . 0.0 118.667 -173.625 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.684 0 CA-C-O 121.22 0.533 . . . . 0.0 111.381 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.05 178.39 49.08 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 118.774 -1.014 . . . . 0.0 113.713 173.555 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -64.71 -176.3 0.42 Allowed 'Trans proline' 0 C--N 1.356 0.928 1 C-N-CA 128.171 5.914 . . . . 0.0 113.097 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 2.7 p-80 -53.48 111.82 0.78 Allowed 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.215 1.406 . . . . 0.0 108.53 169.338 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -57.49 157.9 6.36 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 114.434 -1.257 . . . . 0.0 111.174 -178.854 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.26 49.78 0.01 OUTLIER Pre-proline 0 CA--C 1.566 1.59 0 N-CA-C 114.909 1.448 . . . . 0.0 114.909 172.497 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -65.74 -28.98 51.45 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.366 2.238 . . . . 0.0 114.247 -171.553 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 65.7 mt -75.79 -4.0 38.14 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 173.4 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 64.95 55.16 1.19 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.524 1.529 . . . . 0.0 112.827 170.231 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.33 178.92 8.73 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 124.899 1.279 . . . . 0.0 112.709 -171.274 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HZ1' ' CD ' ' B' ' 77' ' ' GLU . 22.4 pttm -72.7 161.24 31.0 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.138 0.575 . . . . 0.0 111.173 -175.757 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -82.41 155.17 24.82 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 179.426 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 141.26 -108.93 0.57 Allowed Glycine 0 C--N 1.339 0.72 0 N-CA-C 114.246 0.458 . . . . 0.0 114.246 166.896 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.438 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 107.2 -19.61 34.38 Favored Glycine 0 CA--C 1.546 1.988 0 N-CA-C 119.145 2.418 . . . . 0.0 119.145 169.936 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 74' ' ' PRO . . . . . 0.43 ' HG2' HD13 ' B' ' 126' ' ' LEU . 0.5 OUTLIER -110.15 24.9 0.05 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 0 C-N-CA 124.248 3.299 . . . . 0.0 111.718 169.01 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 ptpt -165.85 -31.67 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 127.301 2.24 . . . . 0.0 110.646 170.967 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 76' ' ' ASP . . . . . 0.438 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.0 OUTLIER -84.2 136.72 33.85 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 128.469 2.708 . . . . 0.0 107.155 166.865 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 77' ' ' GLU . . . . . 0.487 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -87.63 -12.82 44.43 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 127.209 2.204 . . . . 0.0 113.523 -176.993 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -91.65 -98.65 0.12 Allowed 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.112 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 87.58 141.32 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 128.391 2.676 . . . . 0.0 113.573 174.599 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -69.67 154.99 41.2 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 116.938 -1.506 . . . . 0.0 107.872 162.73 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.326 7.1 p -76.5 -21.97 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-N 122.467 2.394 . . . . 0.0 111.104 177.173 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -69.11 20.81 0.4 Allowed Glycine 0 CA--C 1.537 1.436 0 C-N-CA 125.693 1.616 . . . . 0.0 115.327 169.202 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -124.63 118.16 25.88 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 120.785 2.292 . . . . 0.0 111.71 -176.736 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -97.75 170.81 8.73 Favored 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 166.378 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -76.04 175.5 52.27 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 166.899 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -70.65 145.93 50.32 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.559 -0.377 . . . . 0.0 111.104 -169.821 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.417 HG22 ' HB1' ' B' ' 95' ' ' ALA . 6.6 p -85.0 166.0 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 165.853 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -152.49 140.2 19.89 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.159 1.345 . . . . 0.0 112.688 -177.532 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 89' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -116.94 152.33 34.78 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -167.988 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -97.25 155.46 16.85 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 129.245 3.018 . . . . 0.0 110.943 170.573 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -43.01 -24.02 0.06 Allowed 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 129.487 3.115 . . . . 0.0 117.27 175.479 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.41 6.28 5.91 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 120.503 -1.373 . . . . 0.0 111.595 172.982 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.0 27.91 67.71 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 126.06 1.791 . . . . 0.0 112.801 178.564 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.5 p -115.71 120.28 64.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.09 0.956 . . . . 0.0 110.63 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -83.6 120.99 26.64 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.521 1.128 . . . . 0.0 108.728 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.42 146.3 28.51 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.852 0.834 . . . . 0.0 110.302 172.549 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 97' ' ' VAL . . . . . 0.469 HG11 HD12 ' B' ' 18' ' ' ILE . 0.4 OUTLIER -132.37 127.96 57.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.52 165.333 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -150.68 53.59 0.88 Allowed 'General case' 0 CA--C 1.545 0.757 0 CA-C-O 123.583 1.658 . . . . 0.0 109.204 -172.746 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.5 mp -105.03 160.85 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.241 1.816 . . . . 0.0 112.512 -166.587 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -140.23 142.12 35.84 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 128.153 2.581 . . . . 0.0 106.304 168.691 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -150.98 138.29 19.39 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 119.084 0.856 . . . . 0.0 111.393 -179.949 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.2 p -107.84 52.75 0.71 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.393 1.077 . . . . 0.0 111.815 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.63 -42.1 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.864 1.666 . . . . 0.0 108.967 177.172 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -87.9 144.64 8.78 Favored 'Isoleucine or valine' 0 C--N 1.344 0.338 0 CA-C-O 122.32 1.057 . . . . 0.0 110.463 167.468 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 10.3 p -148.86 168.41 23.08 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 124.201 1.001 . . . . 0.0 111.125 170.215 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -79.72 63.49 4.3 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 124.754 1.221 . . . . 0.0 108.628 174.737 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.0 t -84.55 -175.67 5.89 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.082 1.353 . . . . 0.0 110.342 169.086 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.06 -46.92 2.33 Favored Glycine 0 N--CA 1.475 1.265 0 O-C-N 120.924 -1.11 . . . . 0.0 113.832 177.016 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -125.27 -24.74 3.91 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -169.398 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 73.0 m-70 -97.71 7.98 45.48 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.558 1.543 . . . . 0.0 113.421 -171.554 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.62 -133.83 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -171.916 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.321 36.0 pt -81.28 -143.18 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 CA-C-N 119.431 1.014 . . . . 0.0 113.011 170.822 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm 59.49 124.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 127.597 2.359 . . . . 0.0 111.873 -165.56 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.05 19.68 61.69 Favored Glycine 0 N--CA 1.474 1.212 0 O-C-N 120.409 -1.432 . . . . 0.0 113.981 179.007 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? -99.93 172.45 7.22 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 127.157 2.183 . . . . 0.0 109.496 174.56 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.9 t -130.67 127.0 37.99 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-N 119.371 0.987 . . . . 0.0 112.287 177.977 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 16.7 tp -93.0 130.36 38.59 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 125.677 1.591 . . . . 0.0 110.322 -175.648 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.53 146.5 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 125.781 1.632 . . . . 0.0 111.323 175.514 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.3 p -121.78 142.14 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 123.48 0.712 . . . . 0.0 111.215 170.553 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -115.25 156.06 26.08 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 113.607 -168.728 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -73.67 -28.53 61.81 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -169.251 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -117.82 173.97 6.45 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.562 1.145 . . . . 0.0 112.228 176.721 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.8 134.06 56.25 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.368 1.467 . . . . 0.0 110.828 169.8 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -81.78 119.67 24.18 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.411 1.084 . . . . 0.0 111.277 173.6 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . 0.369 30.3 t0 -75.71 -4.88 42.86 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 170.47 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 126' ' ' LEU . . . . . 0.43 HD13 ' HG2' ' B' ' 74' ' ' PRO . 5.4 mt 61.03 76.03 0.39 Allowed 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 126.221 1.808 . . . . 0.0 112.123 165.125 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.13 -12.71 48.78 Favored Glycine 0 N--CA 1.476 1.303 0 C-N-CA 123.174 0.416 . . . . 0.0 112.875 176.913 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mtpm? -115.38 179.0 4.09 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.883 2.473 . . . . 0.0 109.223 170.033 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 126.39 -28.81 4.68 Favored Glycine 0 N--CA 1.469 0.861 0 C-N-CA 125.681 1.61 . . . . 0.0 111.351 -168.931 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 104.43 -6.29 45.52 Favored Glycine 0 N--CA 1.474 1.185 0 N-CA-C 117.253 1.661 . . . . 0.0 117.253 166.609 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.0 p-10 -110.74 170.24 8.23 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.771 1.628 . . . . 0.0 110.258 176.159 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 132' ' ' GLU . . . . . 0.415 ' OE2' ' HE2' ' B' ' 136' ' ' LYS . 24.2 tt0 -63.0 -41.65 99.63 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.514 -1.366 . . . . 0.0 110.412 -179.843 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -56.23 -27.88 56.49 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.369 2.267 . . . . 0.0 112.569 176.317 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.26 -23.04 54.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.566 1.076 . . . . 0.0 113.573 171.224 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.6 t -121.23 -13.05 8.56 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.373 1.619 . . . . 0.0 115.373 169.646 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.415 ' HE2' ' OE2' ' B' ' 132' ' ' GLU . 30.6 mttm -76.48 -23.96 53.82 Favored 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 121.009 1.732 . . . . 0.0 111.449 166.501 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 75.6 p -117.97 -114.21 0.33 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 104.3 -2.481 . . . . 0.0 104.3 165.386 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.24 -10.76 0.19 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 116.262 1.265 . . . . 0.0 116.262 169.136 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 114.85 -14.15 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 131.123 3.769 . . . . 0.0 112.737 177.819 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.08 4.9 0.11 Allowed 'General case' 0 CA--C 1.56 1.344 0 N-CA-C 117.497 2.406 . . . . 0.0 117.497 -174.34 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.8 -141.68 18.8 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.542 1.544 . . . . 0.0 113.466 174.808 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.0 t -68.64 -167.44 0.1 Allowed 'General case' 0 CA--C 1.544 0.732 0 CA-C-O 122.294 1.045 . . . . 0.0 111.965 175.909 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.88 155.79 44.69 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 124.428 1.091 . . . . 0.0 110.578 177.943 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.72 -123.19 0.29 Allowed 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 126.256 2.222 . . . . 0.0 105.034 164.003 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -66.91 160.71 25.65 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -166.394 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.8 t -147.88 152.08 37.0 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.445 1.898 . . . . 0.0 112.078 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.65 135.79 4.3 Favored Glycine 0 N--CA 1.483 1.829 0 CA-C-N 120.317 1.417 . . . . 0.0 115.667 -177.087 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 12.2 t -81.65 154.89 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 125.336 1.454 . . . . 0.0 111.779 -177.204 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 39.3 mt -95.46 93.82 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 126.455 1.902 . . . . 0.0 111.99 -176.358 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.24 173.63 30.35 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 125.614 1.578 . . . . 0.0 113.487 174.606 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.8 mp -95.49 85.98 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.095 1.887 . . . . 0.0 116.095 -167.943 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -73.78 18.92 0.12 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.961 1.704 . . . . 0.0 115.478 -179.801 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 . . . . . 0 N--CA 1.466 0.364 0 C-N-CA 130.845 3.658 . . . . 0.0 114.712 -169.279 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.812 0 CA-C-O 119.813 -0.137 . . . . 0.0 111.107 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -77.2 115.79 17.28 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 152' ' ' ALA . 14.4 pttm -89.13 129.96 35.64 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.375 168.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -90.56 173.52 8.02 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 164.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.582 HG23 HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -138.2 119.56 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.524 1.53 . . . . 0.0 108.475 -173.784 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.96 118.77 37.65 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 166.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 HG22 ' B' ' 54' ' ' THR . 22.0 t -110.99 99.66 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.705 0.802 . . . . 0.0 109.397 177.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.95 132.56 35.89 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.564 168.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -135.5 132.51 37.4 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.048 1.339 . . . . 0.0 110.643 168.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.95 -97.95 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 171.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.87 119.77 9.95 Favored 'General case' 0 N--CA 1.44 -0.94 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 -166.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 41.02 -99.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 128.743 3.068 . . . . 0.0 113.358 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.88 -11.88 33.52 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 123.311 2.674 . . . . 0.0 113.828 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.89 115.05 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 120.32 1.418 . . . . 0.0 112.44 179.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -139.9 169.9 16.86 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 122.265 1.031 . . . . 0.0 111.005 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.96 110.29 0.55 Allowed Glycine 0 C--O 1.224 -0.476 0 CA-C-N 113.984 -1.462 . . . . 0.0 111.639 168.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.62 134.65 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.106 0.953 . . . . 0.0 109.339 169.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.1 mm -139.38 124.45 21.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 C-N-CA 125.996 1.718 . . . . 0.0 109.888 168.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -90.81 141.32 28.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 124.867 1.267 . . . . 0.0 110.571 166.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.633 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 71.4 m-85 -113.94 101.53 9.34 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.686 1.194 . . . . 0.0 109.779 172.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -83.91 110.68 18.59 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 125.965 1.706 . . . . 0.0 111.172 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.498 ' HB2' HD13 ' A' ' 106' ' ' LEU . 6.7 tp60 -123.13 139.17 54.34 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.378 1.071 . . . . 0.0 110.989 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.94 -28.17 15.3 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 -168.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.277 0.0 OUTLIER -128.68 -106.76 0.3 Allowed 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.953 1.301 . . . . 0.0 109.508 166.628 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 88.4 p -152.96 -10.37 0.16 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 122.13 2.241 . . . . 0.0 116.358 -177.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -128.94 -13.91 4.52 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.377 1.471 . . . . 0.0 112.672 176.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 174.53 42.58 Favored Glycine 0 CA--C 1.543 1.812 0 C-N-CA 127.938 2.685 . . . . 0.0 113.885 175.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -79.91 157.32 23.99 Favored 'Trans proline' 0 CA--C 1.534 0.498 0 C-N-CA 123.546 2.831 . . . . 0.0 112.427 -168.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.2 t -118.21 136.89 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.97 0.908 . . . . 0.0 112.427 -166.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -93.57 124.31 37.47 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.597 1.159 . . . . 0.0 108.151 170.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.25 133.34 69.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.924 0.89 . . . . 0.0 110.29 -168.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -157.36 158.83 36.69 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.25 178.6 29.67 Favored Glycine 0 CA--C 1.528 0.849 0 C-N-CA 123.881 0.753 . . . . 0.0 114.799 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.0 p -115.69 125.35 52.72 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -167.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 9.7 mm -109.74 102.24 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 C-N-CA 125.224 1.41 . . . . 0.0 108.068 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -116.2 157.61 24.59 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.315 0.646 . . . . 0.0 112.194 -168.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.94 9.6 63.72 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 124.941 1.258 . . . . 0.0 112.448 -168.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 99.0 mt -83.33 167.93 17.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.688 1.195 . . . . 0.0 110.563 172.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -100.37 156.64 17.14 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 106.322 -1.732 . . . . 0.0 106.322 163.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -61.96 157.23 19.08 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-O 122.509 1.147 . . . . 0.0 113.429 -170.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.02 -176.83 36.37 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 122.147 0.859 . . . . 0.0 112.685 -173.056 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.504 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.2 mp -72.52 150.35 43.29 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.695 1.998 . . . . 0.0 111.895 -169.12 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -144.31 124.82 13.96 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.847 1.659 . . . . 0.0 110.462 174.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.04 148.33 36.38 Favored Glycine 0 N--CA 1.487 2.054 0 CA-C-O 118.723 -1.043 . . . . 0.0 112.869 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.508 ' CE1' HD11 ' A' ' 117' ' ' LEU . 7.4 t80 -149.84 97.53 2.61 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-N 118.325 1.062 . . . . 0.0 113.613 -166.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.504 ' O ' HD22 ' A' ' 117' ' ' LEU . 9.9 m80 -130.25 134.29 47.13 Favored 'General case' 0 N--CA 1.483 1.196 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -166.308 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.792 HG23 ' HA2' ' A' ' 82' ' ' GLY . 0.0 OUTLIER -85.36 113.94 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 122.015 0.912 . . . . 0.0 110.896 170.17 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -81.74 173.07 12.65 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 125.419 1.487 . . . . 0.0 114.109 -175.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.449 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.6 pm0 -65.06 133.41 51.58 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 126.062 1.745 . . . . 0.0 106.54 165.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 67.83 -176.91 0.2 Allowed 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 124.275 1.988 . . . . 0.0 112.992 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.34 3.65 29.68 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 130.618 3.961 . . . . 0.0 111.52 168.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -73.85 126.51 30.57 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 120.385 2.093 . . . . 0.0 109.51 172.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.532 ' CG ' HG21 ' B' ' 7' ' ' VAL 0.279 7.6 p-10 -156.12 42.62 0.4 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 123.289 1.518 . . . . 0.0 112.708 168.46 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.753 ' CG2' HG22 ' B' ' 7' ' ' VAL . 38.8 p -116.3 -25.7 7.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 112.737 -2.029 . . . . 0.0 113.905 -165.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 25.6 0.59 Allowed 'General case' 0 CA--C 1.552 1.039 0 CA-C-N 119.374 0.988 . . . . 0.0 112.109 168.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.69 -121.35 12.34 Favored Glycine 0 C--N 1.341 0.827 0 C-N-CA 125.573 1.558 . . . . 0.0 110.561 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -74.14 -13.68 60.85 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.17 39.44 0.45 Allowed 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 126.072 1.749 . . . . 0.0 111.72 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 69.8 m -148.29 -116.16 0.06 Allowed 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.306 2.243 . . . . 0.0 106.636 -169.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.59 109.98 0.71 Allowed 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 124.781 1.232 . . . . 0.0 112.23 169.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.57 -113.02 0.47 Allowed Glycine 0 CA--C 1.538 1.485 0 CA-C-O 117.928 -1.485 . . . . 0.0 109.574 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -82.67 -179.86 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 124.415 3.41 . . . . 0.0 108.102 165.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.29 123.07 32.52 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.673 0.789 . . . . 0.0 111.518 -172.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -26.03 131.77 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 129.419 3.088 . . . . 0.0 116.956 174.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -106.15 52.69 0.15 Allowed Pre-proline 0 CA--C 1.557 1.235 0 C-N-CA 124.883 1.273 . . . . 0.0 113.425 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -63.05 -25.3 73.57 Favored 'Trans proline' 0 C--N 1.355 0.896 0 CA-C-N 122.691 1.997 . . . . 0.0 112.937 -173.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 69.0 mt -99.5 -0.49 40.56 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.802 1.241 . . . . 0.0 113.797 172.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.4 t 70.57 58.87 0.23 Allowed 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 120.452 1.478 . . . . 0.0 114.073 168.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.06 176.01 10.04 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.446 1.498 . . . . 0.0 111.478 172.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -70.8 173.29 7.49 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 129.497 3.119 . . . . 0.0 113.225 178.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -69.02 149.29 48.95 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.481 167.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 171.45 -157.45 27.95 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 116.884 1.513 . . . . 0.0 116.884 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.81 -70.29 0.43 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 118.013 1.965 . . . . 0.0 118.013 168.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -75.98 0.03 9.76 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 123.327 2.685 . . . . 0.0 114.506 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.98 -31.48 0.21 Allowed 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 119.301 0.955 . . . . 0.0 111.415 171.094 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -89.92 153.23 20.77 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.464 1.506 . . . . 0.0 111.26 167.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.7 tt0 -98.68 -27.82 13.81 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 126.356 1.863 . . . . 0.0 112.722 -170.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -78.8 -53.02 7.54 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 121.412 -0.805 . . . . 0.0 110.704 -169.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.7 ttt180 58.17 119.75 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 117.789 2.515 . . . . 0.0 117.789 163.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.8 m170 -58.5 143.08 46.94 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 118.458 -2.652 . . . . 0.0 112.942 169.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 91.2 t -58.26 -24.18 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.334 -0.854 . . . . 0.0 110.432 167.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.792 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -80.89 23.38 4.39 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 117.157 -1.913 . . . . 0.0 116.44 172.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -127.4 109.62 11.95 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 120.577 2.189 . . . . 0.0 111.533 -178.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.437 HD21 HD23 ' A' ' 117' ' ' LEU . 0.9 OUTLIER -110.92 59.56 0.61 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.156 0.982 . . . . 0.0 110.742 172.502 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.79 -151.78 39.8 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.916 173.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.82 149.47 47.75 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.805 1.242 . . . . 0.0 108.619 169.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.26 106.47 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 124.559 1.144 . . . . 0.0 109.579 -174.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 38.7 m -96.14 114.67 26.39 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 124.451 1.1 . . . . 0.0 108.772 -174.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.73 154.11 19.18 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.666 1.187 . . . . 0.0 113.421 -172.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.6 176.84 6.13 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.513 1.125 . . . . 0.0 112.278 168.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.434 ' HZ3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -73.57 -18.9 61.01 Favored 'General case' 0 N--CA 1.473 0.718 0 O-C-N 121.113 -0.992 . . . . 0.0 113.003 -176.587 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.37 15.23 0.48 Allowed 'General case' 0 CA--C 1.56 1.328 0 CA-C-O 122.974 1.369 . . . . 0.0 110.799 170.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.29 12.74 80.18 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 128.131 2.776 . . . . 0.0 114.726 168.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.26 134.4 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 116.77 2.137 . . . . 0.0 116.77 -166.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.0 103.84 13.97 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.734 1.214 . . . . 0.0 107.822 166.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -94.89 109.36 21.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.944 0.878 . . . . 0.0 109.635 172.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -93.67 153.84 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 C-N-CA 124.825 1.25 . . . . 0.0 112.977 -169.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.2 p -149.6 125.74 10.69 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.933 0.893 . . . . 0.0 110.635 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.4 mt -144.98 157.99 13.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 128.548 2.739 . . . . 0.0 110.492 -169.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -147.04 135.89 22.23 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.456 1.902 . . . . 0.0 107.055 167.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -155.79 144.92 20.69 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -166.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.0 p -122.15 49.25 1.6 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.326 1.05 . . . . 0.0 113.742 176.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.03 -3.63 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 124.769 1.227 . . . . 0.0 112.478 171.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.61 163.74 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 127.023 2.129 . . . . 0.0 110.004 174.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.0 t -157.13 163.84 38.49 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.524 1.529 . . . . 0.0 110.53 170.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.498 HD13 ' HB2' ' A' ' 22' ' ' GLN . 7.5 mp -77.3 66.36 3.06 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 120.195 1.361 . . . . 0.0 110.923 -171.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.89 104.0 9.24 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 125.431 1.492 . . . . 0.0 114.185 -167.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.49 -145.37 32.88 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.269 167.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -109.24 11.28 25.5 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.609 1.564 . . . . 0.0 112.086 -167.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -141.78 -9.77 0.92 Allowed 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -167.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.2 t -90.22 -87.85 0.18 Allowed 'General case' 0 N--CA 1.471 0.596 0 O-C-N 120.774 -1.204 . . . . 0.0 110.951 -171.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.294 0.1 OUTLIER -134.33 16.01 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 120.708 1.595 . . . . 0.0 112.505 167.356 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.39 141.04 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.25 3.97 83.0 Favored Glycine 0 N--CA 1.468 0.82 0 C-N-CA 124.451 1.024 . . . . 0.0 114.575 -175.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 44.2 ttt180 -100.38 176.36 5.38 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.286 1.434 . . . . 0.0 111.903 -167.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 18.8 m -118.62 143.05 47.07 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.942 1.697 . . . . 0.0 108.987 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.508 HD11 ' CE1' ' A' ' 45' ' ' PHE . 3.2 tm? -117.62 141.89 47.85 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.581 1.152 . . . . 0.0 108.648 167.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.2 p -118.05 139.04 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.881 0.872 . . . . 0.0 111.52 172.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 4.7 p -110.81 133.64 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 O-C-N 124.293 0.996 . . . . 0.0 109.623 167.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 -99.94 159.45 15.07 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -60.6 -44.83 95.84 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.601 2.76 . . . . 0.0 114.714 -175.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 3.4 mppt? -127.35 -180.0 5.18 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.987 1.715 . . . . 0.0 113.163 -176.192 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.23 147.02 17.45 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.514 1.526 . . . . 0.0 112.428 173.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -102.53 137.04 41.3 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.821 1.648 . . . . 0.0 109.967 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -72.54 -43.31 63.68 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.964 -0.541 . . . . 0.0 111.673 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.0 mt 71.74 53.48 0.21 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.688 1.995 . . . . 0.0 111.967 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 158.43 -90.11 0.11 Allowed Glycine 0 N--CA 1.474 1.224 0 CA-C-N 119.598 1.09 . . . . 0.0 115.128 176.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.6 ttpm? -146.44 98.9 3.14 Favored 'General case' 0 N--CA 1.424 -1.76 0 C-N-CA 128.649 2.78 . . . . 0.0 107.745 177.068 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.5 -138.74 0.69 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 169.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -89.74 6.26 83.08 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.08 -175.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -157.99 168.92 25.77 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 120.372 2.086 . . . . 0.0 109.789 -169.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.91 -57.7 11.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.425 1.09 . . . . 0.0 110.836 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -41.24 -40.47 1.62 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 127.663 2.385 . . . . 0.0 114.562 178.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 64.1 p -55.12 -27.59 46.41 Favored 'General case' 0 N--CA 1.469 0.505 0 O-C-N 120.595 -1.315 . . . . 0.0 113.768 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 27.1 p -71.63 -28.02 63.49 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.557 1.143 . . . . 0.0 112.681 173.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -79.4 -56.98 3.93 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.771 1.628 . . . . 0.0 112.471 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.8 p -115.29 -14.84 11.65 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.525 1.306 . . . . 0.0 114.525 -170.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.49 -1.88 69.86 Favored Glycine 0 N--CA 1.466 0.65 0 O-C-N 123.902 0.751 . . . . 0.0 112.277 -169.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 66.16 17.56 10.77 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.671 1.188 . . . . 0.0 111.021 -176.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.6 -9.81 15.39 Favored 'General case' 0 CA--C 1.554 1.127 0 C-N-CA 123.898 0.879 . . . . 0.0 113.175 -168.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.67 -164.03 21.79 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.831 1.681 . . . . 0.0 112.937 178.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -63.68 175.67 1.05 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.797 1.239 . . . . 0.0 112.246 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.29 143.96 38.08 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 120.761 -1.212 . . . . 0.0 112.066 169.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -104.04 -94.72 0.33 Allowed 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.105 1.762 . . . . 0.0 109.052 173.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.34 149.18 38.78 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 122.379 1.085 . . . . 0.0 110.793 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.47 ' HB3' HD21 ' A' ' 53' ' ' ASN . 84.5 m -131.67 151.76 51.39 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 112.768 -2.014 . . . . 0.0 108.005 173.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.94 163.04 33.52 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 123.404 0.526 . . . . 0.0 113.899 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 25.1 t -113.5 160.87 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 125.358 1.463 . . . . 0.0 110.589 177.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.2 mt -114.65 123.26 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 124.222 1.009 . . . . 0.0 113.362 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -126.74 -168.73 12.62 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 126.144 1.83 . . . . 0.0 113.093 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 151' ' ' ILE . 2.2 mp -104.63 131.78 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 121.57 -0.959 . . . . 0.0 111.033 -169.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.542 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -118.71 22.6 11.92 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.719 1.608 . . . . 0.0 113.61 -174.242 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.332 -0.188 0 C-N-CA 124.368 1.067 . . . . 0.0 110.47 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.825 0.345 . . . . 0.0 111.845 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -107.98 122.49 46.95 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.726 0.81 . . . . 0.0 109.411 175.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -99.18 131.17 45.41 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 174.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.86 169.52 8.54 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.652 1.181 . . . . 0.0 114.08 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -161.63 88.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 C-N-CA 128.114 2.566 . . . . 0.0 109.218 -169.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.72 142.73 35.18 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 120.415 -1.428 . . . . 0.0 111.005 176.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.753 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.2 t -126.7 106.23 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 3.1 mp -100.0 139.33 35.82 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.603 1.161 . . . . 0.0 108.21 169.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -155.95 175.18 14.29 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.126 1.37 . . . . 0.0 110.307 170.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 143.62 -46.3 0.84 Allowed Glycine 0 N--CA 1.474 1.201 0 C-N-CA 124.54 1.067 . . . . 0.0 113.68 169.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -78.01 67.2 3.8 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.535 1.534 . . . . 0.0 109.23 175.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.24 -111.34 0.38 Allowed Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.649 2.547 . . . . 0.0 112.625 -175.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -76.51 1.14 8.76 Favored 'Trans proline' 0 CA--C 1.536 0.603 0 C-N-CA 124.906 3.737 . . . . 0.0 114.168 -176.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 31.1 t -79.49 131.39 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 120.155 1.343 . . . . 0.0 111.283 171.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -130.13 160.84 32.56 Favored 'General case' 0 CA--C 1.516 -0.363 0 C-N-CA 125.127 1.371 . . . . 0.0 109.381 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.68 107.68 0.69 Allowed Glycine 0 CA--C 1.499 -0.926 0 CA-C-N 113.956 -1.474 . . . . 0.0 109.491 169.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.73 120.71 65.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.252 2.9 pp -130.53 139.49 51.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 122.376 1.084 . . . . 0.0 110.715 172.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -107.54 172.98 6.53 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 125.921 1.688 . . . . 0.0 110.523 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -152.66 165.74 34.32 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.773 0.829 . . . . 0.0 109.528 170.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -136.02 138.12 41.88 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.175 1.39 . . . . 0.0 109.584 166.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 59.4 tp60 -102.97 102.28 12.32 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.554 0.742 . . . . 0.0 110.749 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.497 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -67.25 -45.0 78.0 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 120.51 -1.369 . . . . 0.0 113.703 176.158 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.497 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 40.0 mp0 -147.7 138.98 23.62 Favored 'General case' 0 C--O 1.222 -0.379 0 C-N-CA 126.858 2.063 . . . . 0.0 108.394 168.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 76.0 p -50.33 -20.44 1.08 Allowed 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -169.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -112.98 0.46 15.06 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.141 1.376 . . . . 0.0 113.248 -173.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.72 -170.3 43.18 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.664 1.126 . . . . 0.0 113.624 -173.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -81.2 162.52 20.14 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.761 2.307 . . . . 0.0 109.923 168.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -135.47 143.24 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.481 1.112 . . . . 0.0 110.999 -174.142 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HZ3' ' CD ' ' B' ' 100' ' ' GLU . 41.7 tttp -94.88 115.78 27.89 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.795 0.807 . . . . 0.0 110.153 167.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.94 144.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 166.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -144.56 -168.39 2.89 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 167.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.45 -153.82 17.22 Favored Glycine 0 N--CA 1.469 0.843 0 C-N-CA 124.84 1.21 . . . . 0.0 112.684 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 94.7 p -156.67 137.87 13.72 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 114.062 1.134 . . . . 0.0 114.062 -172.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.8 mm -104.96 119.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 169.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -131.91 144.62 50.98 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 121.192 1.814 . . . . 0.0 111.816 -171.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.7 -8.16 21.99 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 128.547 2.975 . . . . 0.0 113.374 -173.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.41 HD23 ' CD2' ' B' ' 43' ' ' HIS . 5.5 mp -71.44 156.48 39.41 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 129.327 3.051 . . . . 0.0 112.732 -176.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.6 t -74.48 168.32 19.95 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 164.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -75.52 146.1 40.81 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.167 -0.958 . . . . 0.0 112.976 177.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.72 -168.04 13.79 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 124.142 0.877 . . . . 0.0 113.017 -172.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.0 mt -76.12 147.43 38.58 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.896 2.078 . . . . 0.0 112.966 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CD2' HD23 ' B' ' 38' ' ' LEU . 87.2 m-70 -146.54 120.75 9.53 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.929 2.092 . . . . 0.0 110.501 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.06 145.86 37.05 Favored Glycine 0 N--CA 1.484 1.876 0 CA-C-O 117.536 -1.702 . . . . 0.0 112.333 -177.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.64 ' HB2' HG22 ' B' ' 119' ' ' VAL . 0.4 OUTLIER -141.49 125.89 17.64 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 121.173 2.486 . . . . 0.0 113.074 -178.546 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 28.7 m80 -137.2 128.21 27.59 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -171.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -80.59 137.51 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 165.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -113.81 171.27 7.69 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 118.715 0.689 . . . . 0.0 111.466 173.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -72.63 138.72 46.92 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 125.184 1.394 . . . . 0.0 110.707 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 72.0 168.36 0.31 Allowed 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.6 1.96 . . . . 0.0 111.37 -168.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.405 ' C ' HG11 ' A' ' 5' ' ' VAL . . . -93.32 16.62 60.19 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 164.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.409 ' HA ' HG21 ' A' ' 5' ' ' VAL . 15.5 t0 -87.35 110.45 20.25 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 125.9 1.68 . . . . 0.0 109.444 -168.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 13.0 p-10 -159.23 34.48 0.2 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 116.132 1.901 . . . . 0.0 116.132 -174.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.582 HG22 HG23 ' A' ' 5' ' ' VAL 0.321 1.3 p -71.16 -72.31 0.22 Allowed 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -164.622 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -88.57 -19.31 26.5 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.718 1.377 . . . . 0.0 114.718 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.84 -139.89 12.04 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 125.901 1.715 . . . . 0.0 110.275 -169.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 24.3 p -45.56 -33.26 2.68 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 118.304 2.705 . . . . 0.0 118.304 -168.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.2 m -68.58 -25.29 64.81 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 124.432 1.093 . . . . 0.0 112.421 175.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.3 m -107.96 67.99 0.69 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 128.504 2.722 . . . . 0.0 107.597 169.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 79.54 139.95 0.07 Allowed 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.776 2.43 . . . . 0.0 114.413 175.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.15 -115.81 4.04 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.502 1.525 . . . . 0.0 111.773 176.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.58 175.52 10.96 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.968 3.112 . . . . 0.0 110.978 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.63 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -69.57 113.76 7.16 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.94 1.696 . . . . 0.0 109.192 176.878 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -55.15 145.43 21.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.832 1.301 . . . . 0.0 114.503 -168.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -111.05 66.77 0.55 Allowed Pre-proline 0 CA--C 1.55 0.977 0 C-N-CA 126.87 2.068 . . . . 0.0 112.16 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -60.64 -35.64 88.78 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.076 2.518 . . . . 0.0 113.329 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 72.9 mt -80.85 -1.32 42.76 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.728 1.211 . . . . 0.0 114.177 171.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t 71.22 47.02 0.41 Allowed 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 127.835 2.454 . . . . 0.0 111.073 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.7 mtp180 -103.02 171.99 7.07 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -169.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mpmm? -83.45 167.07 17.81 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 125.665 1.586 . . . . 0.0 109.449 162.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -78.32 168.46 19.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.357 1.063 . . . . 0.0 112.087 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.6 -134.95 7.65 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 124.719 1.152 . . . . 0.0 113.495 168.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.81 -80.77 0.33 Allowed Glycine 0 CA--C 1.541 1.657 0 CA-C-N 118.278 1.039 . . . . 0.0 115.335 -174.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.19 7.5 0.63 Allowed 'Trans proline' 0 CA--C 1.547 1.175 0 CA-C-N 120.846 2.323 . . . . 0.0 115.328 -177.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.35 6.57 0.29 Allowed 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 126.986 2.115 . . . . 0.0 113.366 169.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.6 156.71 45.66 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.406 2.282 . . . . 0.0 110.336 -170.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -97.43 -9.22 27.71 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.648 1.979 . . . . 0.0 112.126 -173.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -83.86 -95.81 0.06 Allowed 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.443 -0.786 . . . . 0.0 110.482 177.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 48.8 ttt180 68.49 115.98 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.513 1.925 . . . . 0.0 112.274 -170.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -55.21 154.31 5.96 Favored 'General case' 0 CA--C 1.552 1.022 0 O-C-N 119.505 -1.997 . . . . 0.0 114.813 171.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -84.91 58.18 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 C-N-CA 124.573 1.149 . . . . 0.0 109.492 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.61 67.75 0.02 OUTLIER Glycine 0 N--CA 1.469 0.852 0 C-N-CA 127.569 2.509 . . . . 0.0 109.59 -169.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -163.9 165.45 22.75 Favored 'General case' 0 CA--C 1.553 1.065 0 C-N-CA 128.78 2.832 . . . . 0.0 110.027 166.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 92.9 mt -131.39 -178.38 4.82 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.386 2.274 . . . . 0.0 107.331 168.473 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.46 -112.4 0.86 Allowed Glycine 0 N--CA 1.47 0.95 0 CA-C-N 118.309 0.504 . . . . 0.0 112.689 -179.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -137.11 164.17 29.06 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-O 121.643 0.735 . . . . 0.0 112.813 176.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.5 m -108.61 175.59 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 127.342 2.257 . . . . 0.0 109.354 171.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 m -141.34 140.25 33.72 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.525 1.53 . . . . 0.0 107.633 169.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.42 139.58 40.68 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.439 1.096 . . . . 0.0 112.814 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -82.62 154.35 24.98 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.717 2.007 . . . . 0.0 110.603 168.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.22 1.25 0.51 Allowed 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 117.621 2.452 . . . . 0.0 117.621 -169.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -76.24 -7.37 54.71 Favored 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 125.138 1.375 . . . . 0.0 109.783 164.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 93.77 20.67 30.73 Favored Glycine 0 C--N 1.337 0.594 0 C-N-CA 128.719 3.057 . . . . 0.0 112.482 177.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.7 p -127.68 133.51 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 119.09 1.445 . . . . 0.0 114.224 -168.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.93 131.24 41.07 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 165.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -81.77 142.46 32.59 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 104.105 -2.554 . . . . 0.0 104.105 166.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 t -125.9 127.02 70.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 CA-C-N 113.349 -1.751 . . . . 0.0 107.541 169.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.8 p -158.77 51.4 0.39 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.723 1.609 . . . . 0.0 110.105 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 mt -103.56 148.76 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.874 1.67 . . . . 0.0 113.317 -167.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 100' ' ' GLU . . . . . 0.434 ' CD ' ' HZ3' ' B' ' 30' ' ' LYS . 5.6 mp0 -99.31 152.92 19.39 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 125.87 1.668 . . . . 0.0 109.457 174.054 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -153.81 148.49 26.36 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.787 -1.097 . . . . 0.0 111.039 167.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.6 p -118.55 53.65 0.97 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.279 1.032 . . . . 0.0 111.749 178.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.43 -35.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.958 168.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.92 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 CA-C-N 121.024 1.738 . . . . 0.0 111.151 167.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.0 m -160.92 162.43 32.03 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.474 1.509 . . . . 0.0 109.875 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -87.38 76.69 9.04 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.262 1.425 . . . . 0.0 109.172 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.3 t -158.21 104.82 1.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.468 0.651 . . . . 0.0 111.396 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.61 157.22 26.52 Favored Glycine 0 CA--C 1.526 0.763 0 CA-C-O 122.908 1.282 . . . . 0.0 112.445 -172.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -67.12 -21.26 65.85 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 131.391 3.876 . . . . 0.0 114.266 -169.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -107.56 14.88 25.32 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 128.58 2.752 . . . . 0.0 111.806 -175.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 81.0 p -101.67 -54.04 2.83 Favored 'General case' 0 CA--C 1.548 0.875 0 O-C-N 119.428 -2.045 . . . . 0.0 114.233 -174.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pt 178.51 -39.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 1 C-N-CA 133.941 4.897 . . . . 0.0 106.563 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm -57.71 131.08 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 N-CA-C 103.194 -2.891 . . . . 0.0 103.194 159.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.99 -18.97 8.24 Favored Glycine 0 CA--C 1.535 1.297 0 N-CA-C 117.046 1.578 . . . . 0.0 117.046 175.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.8 mtt180 -79.09 -178.09 5.96 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 126.408 1.883 . . . . 0.0 114.081 -177.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 8.8 t -120.19 170.03 9.7 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 127.929 2.492 . . . . 0.0 110.931 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tp -153.54 146.83 24.77 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.396 1.478 . . . . 0.0 111.358 171.065 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.43 137.34 56.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.622 1.569 . . . . 0.0 110.126 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.64 HG22 ' HB2' ' B' ' 45' ' ' PHE . 45.6 t -106.77 156.99 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 169.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -122.55 138.7 54.49 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.709 2.404 . . . . 0.0 111.905 -166.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -78.24 3.91 14.12 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -174.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -122.72 168.3 12.39 Favored 'General case' 0 CA--C 1.545 0.76 0 O-C-N 120.22 -1.55 . . . . 0.0 111.166 169.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.57 160.83 1.65 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.403 1.081 . . . . 0.0 111.223 169.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -107.72 149.13 28.53 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 122.732 0.413 . . . . 0.0 110.503 169.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -100.53 -8.84 22.66 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.794 2.038 . . . . 0.0 114.072 -171.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 54.09 70.35 0.62 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.81 1.644 . . . . 0.0 113.832 169.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.16 -51.99 4.47 Favored Glycine 0 N--CA 1.466 0.669 0 O-C-N 121.281 -0.887 . . . . 0.0 112.628 169.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.59 124.3 6.03 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 117.569 2.433 . . . . 0.0 117.569 173.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.24 0.62 Allowed Glycine 0 C--N 1.331 0.289 0 C-N-CA 129.67 3.509 . . . . 0.0 106.256 163.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -111.25 -57.72 0.48 Allowed Glycine 0 CA--C 1.53 0.991 0 N-CA-C 117.227 1.651 . . . . 0.0 117.227 -171.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 47.7 p30 -123.93 -175.62 3.27 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -161.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.02 -59.75 3.13 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 126.557 1.943 . . . . 0.0 111.452 171.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -50.56 -20.54 1.21 Allowed 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.81 1.781 . . . . 0.0 115.81 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.6 m -67.25 -40.73 86.31 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 119.838 -1.789 . . . . 0.0 112.302 170.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 22.1 p -82.75 -10.15 59.02 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 126.094 1.758 . . . . 0.0 113.674 -177.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.5 tttt -104.16 -77.18 0.58 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 128.42 2.688 . . . . 0.0 110.505 -168.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 22.2 p -79.2 -85.92 0.08 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 166.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 176.06 23.58 0.03 OUTLIER Glycine 0 CA--C 1.534 1.276 1 C-N-CA 131.431 4.348 . . . . 0.0 110.808 -177.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.3 t30 56.98 17.46 3.37 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.005 1.722 . . . . 0.0 114.907 -174.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.96 6.37 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.174 0 N-CA-C 119.384 3.105 . . . . 0.0 119.384 -167.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 62.16 -23.93 0.06 OUTLIER Glycine 0 N--CA 1.475 1.252 0 C-N-CA 130.089 3.709 . . . . 0.0 120.442 166.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.7 t -165.38 159.99 17.65 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.535 1.667 . . . . 0.0 111.111 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.16 179.7 6.6 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.095 0.958 . . . . 0.0 109.892 167.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.5 HD11 ' HB ' ' B' ' 119' ' ' VAL 0.33 3.8 pp -166.45 -154.02 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 129.49 3.116 . . . . 0.0 106.637 162.804 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.98 134.26 26.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.274 1.43 . . . . 0.0 112.811 -175.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.77 153.32 45.71 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.149 0.979 . . . . 0.0 111.01 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 176.81 37.44 Favored Glycine 0 N--CA 1.469 0.879 0 N-CA-C 116.186 1.235 . . . . 0.0 116.186 -170.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -111.0 149.36 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.481 1.112 . . . . 0.0 109.181 174.155 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 30.7 mm -80.88 125.57 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 CA-C-N 119.788 1.176 . . . . 0.0 112.051 -175.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.96 164.98 12.46 Favored Glycine 0 N--CA 1.477 1.403 0 O-C-N 121.23 -0.919 . . . . 0.0 113.392 -176.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 4.7 mp -128.33 131.76 68.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.603 0.716 . . . . 0.0 112.018 -176.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.24 -3.77 18.16 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.084 0.953 . . . . 0.0 112.689 168.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 . . . . . 0 N--CA 1.465 0.319 0 C-N-CA 127.987 2.515 . . . . 0.0 111.179 -173.656 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.045 0 CA-C-O 116.674 -1.631 . . . . 0.0 108.931 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p -76.71 54.64 0.99 Allowed 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.888 1.675 . . . . 0.0 114.922 -168.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.489 HG21 ' ND2' ' B' ' 53' ' ' ASN . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.623 ' OD1' HG21 ' B' ' 7' ' ' VAL 0.307 14.9 p-10 -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.645 HG22 ' CG2' ' A' ' 54' ' ' THR . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.489 ' ND2' HG21 ' A' ' 7' ' ' VAL 0.29 0.6 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t -78.67 -16.8 56.87 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.25 11.83 7.63 Favored 'General case' 0 CA--C 1.55 0.959 0 O-C-N 121.157 -0.965 . . . . 0.0 111.508 167.219 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.12 -142.03 40.58 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.082 1.325 . . . . 0.0 111.684 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 4.6 t -60.32 -11.29 6.15 Favored 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 39.5 m -91.9 -21.24 20.71 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 126.619 1.968 . . . . 0.0 113.101 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.28 -47.03 15.18 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 119.356 0.98 . . . . 0.0 111.005 169.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.84 169.94 11.14 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.716 2.006 . . . . 0.0 109.361 173.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.045 0 CA-C-O 116.674 -1.631 . . . . 0.0 108.931 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p -76.71 54.64 0.99 Allowed 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.888 1.675 . . . . 0.0 114.922 -168.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.489 HG21 ' ND2' ' B' ' 53' ' ' ASN . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.623 ' OD1' HG21 ' B' ' 7' ' ' VAL 0.307 14.9 p-10 -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.645 HG22 ' CG2' ' A' ' 54' ' ' THR . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.489 ' ND2' HG21 ' A' ' 7' ' ' VAL 0.29 0.6 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t -78.67 -16.8 56.87 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.25 11.83 7.63 Favored 'General case' 0 CA--C 1.55 0.959 0 O-C-N 121.157 -0.965 . . . . 0.0 111.508 167.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.12 -142.03 40.58 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.082 1.325 . . . . 0.0 111.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 4.6 t -60.32 -11.29 6.15 Favored 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 39.5 m -91.9 -21.24 20.71 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 126.619 1.968 . . . . 0.0 113.101 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.28 -47.03 15.18 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 119.356 0.98 . . . . 0.0 111.005 169.218 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.84 169.94 11.14 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.716 2.006 . . . . 0.0 109.361 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -156.86 121.92 4.59 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 124.353 1.061 . . . . 0.0 109.606 176.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.83 104.54 14.88 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 122.046 0.927 . . . . 0.0 108.699 168.086 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -89.48 169.23 11.55 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.263 -0.898 . . . . 0.0 111.296 173.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.487 HG21 ' HA ' ' B' ' 52' ' ' ASP . 3.1 p -151.97 142.78 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.676 1.19 . . . . 0.0 110.741 -170.213 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.13 120.5 12.36 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.509 1.123 . . . . 0.0 109.526 168.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.5 t -105.31 97.16 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 174.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -78.12 111.47 14.07 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 123.83 0.852 . . . . 0.0 109.544 -172.106 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -152.04 155.15 37.39 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 116.604 2.075 . . . . 0.0 116.604 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.43 -39.76 0.24 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 129.891 3.615 . . . . 0.0 108.814 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.44 57.64 4.12 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 129.699 3.2 . . . . 0.0 112.933 -168.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.95 -103.72 0.05 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.358 2.409 . . . . 0.0 114.054 173.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -83.87 -8.05 10.22 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 124.893 3.729 . . . . 0.0 114.555 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.03 141.87 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 120.377 1.444 . . . . 0.0 109.92 173.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -157.81 161.76 38.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.227 -1.351 . . . . 0.0 110.513 167.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.01 119.25 2.92 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 113.658 -1.61 . . . . 0.0 109.576 169.244 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.07 133.23 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 166.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.439 HD13 ' CE1' ' A' ' 20' ' ' PHE . 2.1 pp -136.14 143.19 36.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 122.703 1.24 . . . . 0.0 110.687 162.158 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.95 130.0 55.47 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 164.707 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.439 ' CE1' HD13 ' A' ' 18' ' ' ILE . 18.6 m-30 -114.2 132.43 56.11 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.205 1.002 . . . . 0.0 110.629 -179.056 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -108.56 117.11 33.32 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.02 1.328 . . . . 0.0 110.97 178.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.525 HE22 ' HA ' ' A' ' 25' ' ' SER . 1.3 tm0? -118.58 140.0 50.59 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 123.028 1.394 . . . . 0.0 113.27 173.502 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.518 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -87.01 -47.98 8.48 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 129.46 3.104 . . . . 0.0 113.739 -175.717 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -147.63 137.71 22.94 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 126.895 2.078 . . . . 0.0 110.44 -168.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.525 ' HA ' HE22 ' A' ' 22' ' ' GLN . 8.3 m -38.65 -57.65 1.16 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.939 1.696 . . . . 0.0 115.308 -169.245 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 -102.31 15.47 29.06 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 123.995 0.918 . . . . 0.0 111.765 -173.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.83 -170.85 30.06 Favored Glycine 0 CA--C 1.534 1.263 0 C-N-CA 124.776 1.179 . . . . 0.0 112.485 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -78.34 177.91 8.2 Favored 'Trans proline' 0 CA--C 1.536 0.588 0 C-N-CA 124.149 3.232 . . . . 0.0 112.818 -170.355 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.4 t -142.0 141.01 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 123.913 0.885 . . . . 0.0 111.173 -177.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -93.22 125.21 37.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.035 0.934 . . . . 0.0 109.56 169.573 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -117.5 125.25 73.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 127.674 2.389 . . . . 0.0 108.565 -169.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 7.0 p90 -153.87 162.39 41.27 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.611 0.72 . . . . 0.0 112.661 175.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.18 -158.21 27.15 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 125.145 1.355 . . . . 0.0 112.063 177.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.9 p -153.54 139.79 18.49 Favored 'General case' 0 C--O 1.237 0.403 0 O-C-N 122.396 -0.473 . . . . 0.0 112.07 -172.07 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -111.98 106.88 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.885 0.874 . . . . 0.0 108.668 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.02 128.13 54.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.758 2.423 . . . . 0.0 109.557 -165.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.4 -4.38 31.27 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.502 1.525 . . . . 0.0 112.109 -167.649 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.5 mt -65.53 162.45 18.05 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.593 1.197 . . . . 0.0 110.531 168.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -93.45 161.83 14.22 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 163.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -54.95 150.43 10.18 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.242 1.417 . . . . 0.0 113.352 -174.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.23 -177.57 36.59 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 124.758 1.17 . . . . 0.0 113.46 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.98 149.6 18.56 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 127.56 2.344 . . . . 0.0 112.588 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -145.65 134.0 21.83 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 126.125 1.77 . . . . 0.0 110.166 170.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.44 147.72 31.36 Favored Glycine 0 N--CA 1.481 1.664 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.142 173.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -156.85 106.27 2.24 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 119.03 1.415 . . . . 0.0 113.276 -172.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.04 153.12 30.47 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.801 1.408 . . . . 0.0 114.801 -168.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -82.2 138.37 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 165.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -87.18 157.99 19.24 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.386 1.875 . . . . 0.0 113.907 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 21.8 tt0 -71.57 90.07 1.0 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 125.182 1.393 . . . . 0.0 109.231 178.216 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 94.6 142.35 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 128.64 2.776 . . . . 0.0 108.809 178.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.09 13.24 9.69 Favored Glycine 0 C--O 1.221 -0.715 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.627 169.098 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' B' ' 5' ' ' VAL . 8.8 p-10 -88.44 47.67 1.53 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 124.578 2.132 . . . . 0.0 109.131 168.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -171.91 42.39 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 123.696 1.712 . . . . 0.0 110.104 -167.215 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.8 p -69.32 43.78 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 128.312 2.645 . . . . 0.0 117.455 -168.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -107.69 5.5 26.83 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.726 1.21 . . . . 0.0 109.345 164.396 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 51.56 -110.56 1.09 Allowed Glycine 0 C--N 1.347 1.178 0 C-N-CA 126.527 2.013 . . . . 0.0 112.938 168.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 69.5 m -53.32 -9.36 0.16 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 116.516 2.043 . . . . 0.0 116.516 178.214 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.4 t -124.99 19.02 8.45 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.455 1.65 . . . . 0.0 115.455 171.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.9 m -156.74 -40.51 0.07 Allowed 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 171.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.42 123.57 26.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.705 1.593 . . . . 0.0 112.191 -170.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -66.75 168.78 35.47 Favored Glycine 0 CA--C 1.538 1.48 0 CA-C-O 118.224 -1.32 . . . . 0.0 113.33 -175.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -56.48 176.21 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 125.007 3.805 . . . . 0.0 112.456 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.423 ' CD2' ' H ' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -68.06 114.22 6.39 Favored 'General case' 0 C--N 1.321 -0.644 0 O-C-N 121.484 -0.76 . . . . 0.0 112.615 -166.823 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -28.25 113.07 0.07 Allowed 'General case' 0 C--O 1.24 0.557 0 C-N-CA 127.489 2.316 . . . . 0.0 114.209 -172.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -111.61 50.59 0.33 Allowed Pre-proline 0 CA--C 1.551 0.997 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -174.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.11 -16.83 45.31 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 122.352 2.035 . . . . 0.0 112.51 177.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -79.42 -7.51 58.45 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.722 1.609 . . . . 0.0 112.456 168.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.9 t 64.26 49.74 2.51 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 128.437 2.695 . . . . 0.0 112.409 176.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.402 ' HD2' ' OE1' ' A' ' 78' ' ' GLU . 15.8 ptt180 -128.92 178.5 6.34 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.01 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.524 ' HE2' ' HA ' ' A' ' 70' ' ' LYS . 4.8 mmpt? -88.17 174.26 8.33 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.164 2.185 . . . . 0.0 112.375 -179.263 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -95.12 134.9 37.32 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.416 ' HA2' HD12 ' A' ' 126' ' ' LEU . . . 161.2 -123.17 1.18 Allowed Glycine 0 C--N 1.336 0.576 0 CA-C-O 119.72 -0.489 . . . . 0.0 113.682 168.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.66 -33.94 4.58 Favored Glycine 0 CA--C 1.545 1.952 0 CA-C-O 117.216 -1.88 . . . . 0.0 117.791 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -105.45 17.14 0.15 Allowed 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.619 2.879 . . . . 0.0 114.215 174.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.9 ptmm? -167.73 -22.02 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 127.389 2.276 . . . . 0.0 112.458 169.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -97.41 147.05 24.6 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 163.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -98.86 -6.58 28.78 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.445 1.898 . . . . 0.0 111.859 -171.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.402 ' OE1' ' HD2' ' A' ' 69' ' ' ARG . 3.7 mm-40 -77.4 -99.65 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.343 1.057 . . . . 0.0 110.035 -177.445 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 94.2 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 127.323 2.249 . . . . 0.0 111.179 174.104 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -58.31 156.96 9.18 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.569 1.147 . . . . 0.0 112.639 172.315 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.0 p -70.59 106.12 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.86 171.428 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.03 8.69 21.66 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 117.383 -1.787 . . . . 0.0 116.831 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.16 124.5 27.91 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 120.71 2.255 . . . . 0.0 109.545 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 97.5 mt -113.89 53.63 0.77 Allowed 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 120.575 1.534 . . . . 0.0 112.196 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.01 -141.99 42.49 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 121.56 -0.713 . . . . 0.0 111.659 174.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.67 127.43 45.16 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.482 0.713 . . . . 0.0 111.431 169.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.8 m -78.21 98.22 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.891 1.276 . . . . 0.0 108.985 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -93.3 117.41 30.04 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.822 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.49 139.88 30.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.806 1.242 . . . . 0.0 113.841 -174.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -72.32 156.74 38.77 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.146 2.178 . . . . 0.0 109.99 167.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -46.33 -25.38 0.63 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 128.294 2.638 . . . . 0.0 116.137 175.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -76.42 -0.48 22.98 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.632 1.173 . . . . 0.0 111.525 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.36 41.79 11.2 Favored Glycine 0 C--N 1.335 0.526 0 C-N-CA 126.535 2.017 . . . . 0.0 112.783 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.5 p -143.21 129.0 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 N-CA-C 114.737 1.384 . . . . 0.0 114.737 176.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.57 124.15 35.52 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 165.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -111.55 135.64 51.86 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 124.496 1.118 . . . . 0.0 108.91 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.5 t -139.15 136.71 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -166.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.2 t -155.43 116.36 3.9 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.553 1.541 . . . . 0.0 110.579 168.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -145.51 155.4 13.3 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 128.965 2.906 . . . . 0.0 110.806 -169.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -128.23 132.23 48.77 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 167.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -145.51 138.1 25.88 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 124.486 1.114 . . . . 0.0 111.954 -168.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -116.94 51.38 1.0 Allowed 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 178.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.19 3.48 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.197 0 C-N-CA 123.831 0.853 . . . . 0.0 111.983 167.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.2 168.0 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 126.671 1.988 . . . . 0.0 110.376 177.278 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.0 m -154.4 156.09 36.19 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.001 0.92 . . . . 0.0 111.086 -173.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.7 mt -93.5 73.01 4.42 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.689 0.757 . . . . 0.0 110.681 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.406 ' H ' ' HB2' ' A' ' 111' ' ' SER . 0.3 OUTLIER -117.84 144.91 44.97 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.384 1.474 . . . . 0.0 108.987 171.996 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -78.48 16.23 8.17 Favored Glycine 0 N--CA 1.479 1.539 0 N-CA-C 117.97 1.948 . . . . 0.0 117.97 -166.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -134.88 -89.26 0.35 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 125.794 1.638 . . . . 0.0 111.2 -169.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -87.39 4.81 41.6 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 120.595 -1.316 . . . . 0.0 113.168 -174.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.406 ' HB2' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -119.41 -141.7 0.35 Allowed 'General case' 0 CA--C 1.545 0.756 0 O-C-N 120.875 -1.141 . . . . 0.0 112.955 -168.629 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 51.5 mm -94.63 -28.87 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 O-C-N 120.595 -1.315 . . . . 0.0 114.389 -169.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.1 mm -55.06 133.05 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 119.191 0.905 . . . . 0.0 109.849 175.378 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.14 14.62 59.52 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.433 -1.204 . . . . 0.0 114.575 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -91.19 -169.99 2.51 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.408 1.604 . . . . 0.0 108.911 168.077 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 6.4 m -145.63 114.37 6.85 Favored 'General case' 0 N--CA 1.484 1.227 0 O-C-N 119.599 -1.938 . . . . 0.0 108.02 -171.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 50.5 tp -89.74 132.73 35.05 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 124.943 1.297 . . . . 0.0 109.638 -175.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.4 m -118.84 153.79 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 C-N-CA 123.275 0.63 . . . . 0.0 110.628 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.76 152.13 15.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 163.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -115.21 147.36 40.44 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.094 1.357 . . . . 0.0 111.183 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -66.09 -22.52 66.41 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 119.838 -1.789 . . . . 0.0 113.601 -174.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.7 mmtm -131.62 176.98 7.86 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 119.772 -1.83 . . . . 0.0 113.998 173.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.22 145.04 27.69 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 112.977 -1.919 . . . . 0.0 110.9 169.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.48 ' OD1' ' HB2' ' A' ' 140' ' ' ALA . 46.7 m-20 -79.03 169.2 18.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 122.188 0.994 . . . . 0.0 111.154 167.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.79 -38.49 53.91 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.203 164.04 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.416 HD12 ' HA2' ' A' ' 72' ' ' GLY . 1.8 mm? 63.35 60.32 1.16 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.957 2.503 . . . . 0.0 112.031 -171.465 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.59 -83.4 0.13 Allowed Glycine 0 N--CA 1.469 0.879 0 O-C-N 121.008 -1.058 . . . . 0.0 112.747 168.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -150.53 97.73 2.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.631 1.681 . . . . 0.0 110.921 169.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -74.09 176.07 47.3 Favored Glycine 0 CA--C 1.526 0.781 0 CA-C-N 112.086 -2.325 . . . . 0.0 107.651 163.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.09 29.79 0.15 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 127.599 2.523 . . . . 0.0 118.677 -167.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -148.03 -103.97 0.09 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 120.652 2.226 . . . . 0.0 111.528 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -163.22 -51.9 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 127.312 2.245 . . . . 0.0 108.58 -169.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 19.2 tp10 -50.17 -32.16 15.51 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 127.416 2.286 . . . . 0.0 112.351 169.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.593 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 77.6 p -53.24 -36.84 61.5 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 120.565 -1.334 . . . . 0.0 113.173 168.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 2.8 p -79.08 -20.99 47.39 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 172.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -79.79 -64.56 1.16 Allowed 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.5 1.046 . . . . 0.0 112.572 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 28.7 p -108.62 -9.52 15.29 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.842 1.657 . . . . 0.0 114.559 -174.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.2 -9.57 74.61 Favored Glycine 0 N--CA 1.471 1.031 0 CA-C-N 119.918 1.235 . . . . 0.0 111.781 -167.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 79.26 -44.1 0.32 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 129.245 3.018 . . . . 0.0 110.136 -179.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.48 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . . . 56.62 11.77 0.96 Allowed 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 128.433 2.693 . . . . 0.0 116.649 167.145 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.43 -36.25 0.45 Allowed Glycine 0 CA--C 1.537 1.445 0 C-N-CA 125.951 1.739 . . . . 0.0 113.673 -167.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -173.88 -156.59 0.08 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.149 1.779 . . . . 0.0 111.551 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.05 -166.22 1.15 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.798 2.039 . . . . 0.0 108.197 165.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -176.96 -151.79 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.661 2.384 . . . . 0.0 107.378 -175.586 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.72 148.99 23.05 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 125.709 1.604 . . . . 0.0 112.568 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.8 p -148.45 148.71 30.59 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.092 0.957 . . . . 0.0 113.459 -176.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.2 136.61 5.1 Favored Glycine 0 N--CA 1.465 0.604 0 C-N-CA 124.299 0.952 . . . . 0.0 113.543 -170.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -76.24 148.58 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 124.676 1.19 . . . . 0.0 109.333 -178.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -83.63 103.68 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 171.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -101.46 175.41 25.68 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.861 1.696 . . . . 0.0 112.064 169.068 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -114.51 140.84 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.307 1.043 . . . . 0.0 112.495 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.05 51.29 0.79 Allowed 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 124.027 1.87 . . . . 0.0 112.765 -176.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 38.9 tt0 . . . . . 0 C--N 1.326 -0.445 0 CA-C-N 111.487 -2.597 . . . . 0.0 110.006 167.672 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 p -78.76 107.07 11.21 Favored 'General case' 0 CA--C 1.512 -0.515 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 169.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.433 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -99.68 156.06 17.28 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 169.497 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.59 178.29 8.57 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 130.138 3.375 . . . . 0.0 107.19 167.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.403 ' H ' ' HB2' ' A' ' 52' ' ' ASP . 59.3 t -156.54 170.85 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.191 0 C-N-CA 127.03 2.132 . . . . 0.0 109.894 -169.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.36 142.69 19.44 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 127.28 2.232 . . . . 0.0 109.299 166.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.13 126.53 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.582 0.753 . . . . 0.0 110.085 173.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mp -97.26 140.25 32.02 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 125.287 1.435 . . . . 0.0 110.264 -172.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.8 ttpp -143.53 140.57 30.33 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.386 1.074 . . . . 0.0 111.535 170.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.39 -114.15 1.87 Allowed Glycine 0 CA--C 1.524 0.612 1 N-CA-C 102.471 -4.252 . . . . 0.0 102.471 163.203 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -157.7 127.15 5.93 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.406 1.882 . . . . 0.0 107.964 164.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.3 -141.96 17.31 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -167.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -84.72 -26.04 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.312 2.675 . . . . 0.0 113.938 -169.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -78.1 123.82 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.44 1.018 . . . . 0.0 110.873 -169.133 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.2 160.98 41.28 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.602 -175.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -139.85 160.15 26.11 Favored Glycine 0 C--O 1.224 -0.522 0 O-C-N 121.686 -0.634 . . . . 0.0 113.22 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -128.42 134.93 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 125.613 1.565 . . . . 0.0 107.852 168.413 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -137.82 112.93 9.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 C-N-CA 124.255 1.022 . . . . 0.0 109.792 172.125 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -76.59 153.25 35.49 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.391 1.076 . . . . 0.0 110.475 165.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.77 100.01 5.14 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 127.901 2.48 . . . . 0.0 108.762 172.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.433 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.8 OUTLIER -102.83 126.87 50.13 Favored 'General case' 0 N--CA 1.466 0.356 0 O-C-N 121.534 -0.729 . . . . 0.0 109.663 175.743 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLN . . . . . 0.465 HE22 ' CB ' ' B' ' 105' ' ' SER . 55.2 tt0 -126.87 141.22 51.87 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.133 0.973 . . . . 0.0 112.159 -176.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.479 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -78.71 -50.43 11.41 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.479 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 27.1 mp0 -146.29 150.54 35.96 Favored 'General case' 0 C--O 1.222 -0.374 0 C-N-CA 125.798 1.639 . . . . 0.0 109.778 173.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.9 m -58.62 10.8 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 128.72 2.808 . . . . 0.0 117.543 -171.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -144.7 -9.44 0.62 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 127.772 2.429 . . . . 0.0 113.886 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.44 -179.89 49.84 Favored Glycine 0 CA--C 1.541 1.657 0 CA-C-N 119.946 1.248 . . . . 0.0 110.6 168.087 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -75.67 160.8 37.58 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.611 2.208 . . . . 0.0 113.155 -171.068 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -120.56 129.67 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 124.802 1.241 . . . . 0.0 109.228 176.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -95.9 128.38 42.74 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.405 1.098 . . . . 0.0 110.176 170.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 t -90.92 129.05 42.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 128.936 2.894 . . . . 0.0 108.666 172.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.5 p90 -152.87 156.85 39.78 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 170.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.02 -154.67 24.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 124.778 1.18 . . . . 0.0 111.521 -169.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 85.2 p -162.59 150.85 14.33 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -172.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -113.61 123.92 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 125.277 1.431 . . . . 0.0 108.279 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -114.64 153.8 29.53 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 126.097 1.759 . . . . 0.0 111.359 -174.16 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.37 60.3 Favored Glycine 0 N--CA 1.475 1.294 0 C-N-CA 125.33 1.443 . . . . 0.0 114.507 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.01 166.43 17.76 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.494 1.518 . . . . 0.0 112.25 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -75.08 146.85 41.11 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 163.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' GLU . . . . . 0.503 ' CD ' ' HZ2' ' B' ' 91' ' ' LYS . 73.6 tt0 -49.27 143.21 6.45 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 124.904 1.282 . . . . 0.0 110.958 169.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.66 -175.44 23.42 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 124.222 0.915 . . . . 0.0 114.015 -177.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.5 OUTLIER -87.39 145.87 26.12 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 127.56 2.344 . . . . 0.0 112.358 -169.85 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -139.19 138.96 37.37 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 127.936 2.494 . . . . 0.0 111.61 -169.066 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.36 156.83 53.15 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 125.08 1.324 . . . . 0.0 112.415 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -157.25 99.51 1.79 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 118.17 0.985 . . . . 0.0 110.849 -168.299 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.415 ' HB2' ' CE1' ' B' ' 71' ' ' HIS . 3.0 p-80 -126.6 146.12 50.28 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-O 122.675 1.226 . . . . 0.0 113.133 -175.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.6 HG12 ' HB2' ' B' ' 117' ' ' LEU . 0.5 OUTLIER -111.42 151.14 13.58 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.293 175.809 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -119.08 119.36 33.98 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.313 -170.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -74.27 57.58 0.68 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.808 0.731 . . . . 0.0 109.557 166.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -161.6 106.94 1.31 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 125.088 1.355 . . . . 0.0 109.987 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -94.77 -5.21 61.42 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 117.144 -1.92 . . . . 0.0 115.026 -176.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.487 ' HA ' HG21 ' A' ' 5' ' ' VAL . 0.2 OUTLIER -76.84 52.7 0.86 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 120.735 2.268 . . . . 0.0 111.847 -170.209 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 176.58 35.28 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 116.733 2.123 . . . . 0.0 116.733 -167.454 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 13.8 p -73.71 36.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 119.488 -2.007 . . . . 0.0 115.469 -172.22 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.4 -1.96 58.24 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.622 1.969 . . . . 0.0 113.916 -169.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.21 -149.58 34.26 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -169.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 31.7 p -64.01 -7.89 9.97 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 113.981 1.104 . . . . 0.0 113.981 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 30.9 p -77.57 6.51 7.05 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.856 1.262 . . . . 0.0 114.086 174.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.6 t -162.45 -155.12 0.34 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 126.433 1.893 . . . . 0.0 109.54 169.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 72.07 71.25 0.15 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.81 2.044 . . . . 0.0 113.383 169.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.62 -54.66 4.9 Favored Glycine 0 CA--C 1.544 1.888 0 CA-C-O 116.747 -2.141 . . . . 0.0 114.929 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -130.52 168.95 0.0 OUTLIER 'Trans proline' 0 C--N 1.355 0.918 0 C-N-CA 123.22 2.613 . . . . 0.0 116.346 -172.745 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.614 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -85.03 141.57 30.19 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.991 2.117 . . . . 0.0 112.874 166.031 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -70.17 144.97 51.81 Favored 'General case' 0 CA--C 1.545 0.76 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.911 164.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 43.2 m-20 -106.83 75.09 0.39 Allowed Pre-proline 0 CA--C 1.555 1.17 0 C-N-CA 125.554 1.541 . . . . 0.0 112.714 -177.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -56.79 -47.9 21.16 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 124.123 3.215 . . . . 0.0 113.141 -174.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.1 mp -78.93 2.02 21.67 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.034 1.734 . . . . 0.0 113.14 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 59.7 p 68.29 45.04 1.27 Allowed 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 128.736 2.814 . . . . 0.0 111.513 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 69' ' ' ARG . . . . . 0.454 ' HD2' ' OE1' ' B' ' 78' ' ' GLU 0.298 23.7 ptt180 -130.7 171.45 13.08 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -169.136 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.4 169.26 14.76 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 113.625 -1.625 . . . . 0.0 107.345 -172.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CE1' ' HB2' ' B' ' 46' ' ' HIS . 46.9 t60 -63.51 164.11 9.93 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.989 168.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.62 -139.51 7.04 Favored Glycine 0 C--N 1.336 0.567 0 CA-C-O 119.532 -0.593 . . . . 0.0 112.303 169.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.87 -43.22 1.69 Allowed Glycine 0 CA--C 1.545 1.939 0 N-CA-C 119.186 2.434 . . . . 0.0 119.186 169.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -85.45 -12.34 6.67 Favored 'Trans proline' 0 C--N 1.356 0.959 0 CA-C-N 123.497 3.649 . . . . 0.0 113.519 173.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.29 1.92 0.97 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 126.829 2.051 . . . . 0.0 112.326 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.73 152.95 51.62 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 127.773 2.429 . . . . 0.0 108.632 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.94 -2.35 18.37 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.975 2.51 . . . . 0.0 113.072 -176.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 78' ' ' GLU . . . . . 0.454 ' OE1' ' HD2' ' B' ' 69' ' ' ARG . 4.4 mm-40 -75.05 -102.74 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 169.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 73.72 141.48 0.06 Allowed 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 125.705 2.669 . . . . 0.0 111.927 172.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -78.77 148.11 33.08 Favored 'General case' 0 CA--C 1.551 1.018 0 CA-C-N 113.065 -1.879 . . . . 0.0 111.615 171.11 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 19.8 m -46.96 -41.5 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 CA-C-N 120.559 1.527 . . . . 0.0 111.366 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.511 ' C ' HG23 ' B' ' 47' ' ' VAL . . . -99.29 104.84 2.94 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 164.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -157.01 129.95 7.74 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 125.634 1.574 . . . . 0.0 112.839 166.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -110.46 179.17 4.16 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 126.501 1.92 . . . . 0.0 110.392 170.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.82 -106.91 3.0 Favored Glycine 0 C--N 1.339 0.722 0 C-N-CA 124.774 1.178 . . . . 0.0 113.972 -171.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -127.11 158.64 36.48 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 123.919 0.888 . . . . 0.0 112.944 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.2 m -118.43 137.54 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 126.772 2.029 . . . . 0.0 109.216 168.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 90.5 m -125.12 115.69 20.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 121.195 1.816 . . . . 0.0 110.745 -173.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.06 137.33 36.76 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 124.751 1.22 . . . . 0.0 112.546 -176.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -73.62 178.49 4.69 Favored 'General case' 0 CA--C 1.541 0.629 0 O-C-N 124.148 0.905 . . . . 0.0 111.008 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.503 ' HZ2' ' CD ' ' B' ' 40' ' ' GLU . 3.3 ttmp? -76.96 66.46 2.8 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 123.45 1.595 . . . . 0.0 111.312 169.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -156.31 -45.29 0.07 Allowed 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 127.198 2.199 . . . . 0.0 108.807 175.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.85 -12.21 7.76 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 117.606 -1.664 . . . . 0.0 113.904 -172.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.6 p -81.21 121.76 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.555 1.677 . . . . 0.0 114.355 170.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.76 135.59 34.91 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.12 0.968 . . . . 0.0 108.478 164.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -77.0 148.0 36.5 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 123.0 1.381 . . . . 0.0 107.586 168.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.37 123.26 52.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 112.331 -2.213 . . . . 0.0 109.221 171.487 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.0 p -156.94 59.53 0.52 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.251 1.42 . . . . 0.0 112.546 -168.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.04 159.89 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 O-C-N 120.259 -1.526 . . . . 0.0 112.095 -173.119 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -145.3 155.06 42.98 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.044 2.138 . . . . 0.0 109.487 174.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -155.16 144.44 21.07 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.461 1.905 . . . . 0.0 110.328 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.0 p -113.92 49.32 1.0 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.7 t -151.3 14.57 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 123.617 0.767 . . . . 0.0 112.782 -170.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.25 166.64 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 O-C-N 119.66 -1.9 . . . . 0.0 110.723 -171.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.465 ' CB ' HE22 ' B' ' 22' ' ' GLN . 83.8 p -157.56 161.95 38.77 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 117.922 2.564 . . . . 0.0 117.922 171.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -78.78 72.91 5.32 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 126.831 2.052 . . . . 0.0 107.482 170.49 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 10.8 t -130.24 15.03 5.64 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -176.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 -63.74 0.33 Allowed Glycine 0 N--CA 1.474 1.219 0 N-CA-C 116.089 1.196 . . . . 0.0 116.089 169.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -119.44 -112.56 0.33 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 118.867 1.334 . . . . 0.0 109.53 -168.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -73.05 0.6 10.96 Favored 'General case' 0 CA--C 1.543 0.7 0 O-C-N 120.263 -1.523 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 54.0 p -71.08 -19.75 62.43 Favored 'General case' 0 CA--C 1.541 0.611 0 CA-C-O 116.587 -1.673 . . . . 0.0 114.305 169.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.305 3.9 pt 143.97 -11.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.114 1 C-N-CA 132.735 4.414 . . . . 0.0 116.227 168.831 . . . . . . . . 3 2 . 1 . 004 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.8 mm -76.08 148.15 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 120.266 1.394 . . . . 0.0 109.683 173.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 70.57 5.15 55.14 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 120.586 -1.321 . . . . 0.0 114.437 -175.123 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.9 ptt180 -79.31 156.1 28.19 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.135 1.374 . . . . 0.0 109.979 168.745 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.5 m -100.43 163.8 12.21 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.928 1.291 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.6 ' HB2' HG12 ' B' ' 47' ' ' VAL . 12.5 tp -148.85 126.5 11.74 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.032 1.733 . . . . 0.0 111.074 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 29.1 m -120.76 147.63 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.071 0.948 . . . . 0.0 110.906 167.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.4 p -104.58 154.68 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 124.434 1.094 . . . . 0.0 108.207 167.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 -120.35 159.76 24.4 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.252 1.421 . . . . 0.0 112.54 -173.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -84.8 -26.77 27.27 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 119.894 -1.754 . . . . 0.0 114.909 -168.571 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.31 179.84 3.92 Favored 'General case' 0 CA--C 1.545 0.785 0 O-C-N 119.606 -1.934 . . . . 0.0 108.702 166.611 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.39 151.4 47.21 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.105 0.962 . . . . 0.0 112.869 -176.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -75.65 143.37 42.25 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.215 0.531 . . . . 0.0 110.345 175.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -73.47 -20.05 60.79 Favored 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 123.714 0.806 . . . . 0.0 111.71 169.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 51.32 60.0 4.19 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.773 2.029 . . . . 0.0 112.191 -174.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.86 -26.26 25.11 Favored Glycine 0 N--CA 1.469 0.855 0 CA-C-O 117.797 -1.557 . . . . 0.0 116.539 168.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -159.51 100.87 1.5 Allowed 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 120.413 2.106 . . . . 0.0 112.424 176.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 129' ' ' GLY . . . . . 0.494 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -102.89 -132.46 7.67 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 166.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.88 12.07 49.5 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.462 1.505 . . . . 0.0 114.57 173.155 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -130.9 162.91 28.61 Favored 'General case' 0 C--N 1.344 0.345 0 CA-C-N 119.236 1.518 . . . . 0.0 114.387 -168.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -57.06 -59.64 4.77 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.301 1.441 . . . . 0.0 110.02 167.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -59.77 -14.59 15.25 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.689 1.596 . . . . 0.0 113.358 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.494 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 24.3 p -66.39 -28.0 68.29 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.883 1.219 . . . . 0.0 112.892 172.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 p -95.22 -31.31 13.55 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 127.135 2.174 . . . . 0.0 112.261 178.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 45.7 mttp -92.86 -23.66 18.73 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.652 1.581 . . . . 0.0 113.598 -173.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.431 HG21 HH21 ' B' ' 143' ' ' ARG . 41.7 p -138.69 -124.11 0.13 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 127.408 2.283 . . . . 0.0 105.034 164.627 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -126.86 8.37 7.24 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 125.466 1.507 . . . . 0.0 111.267 168.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 62.18 -79.74 0.02 OUTLIER 'General case' 0 C--N 1.347 0.492 0 C-N-CA 127.335 2.254 . . . . 0.0 110.066 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 60.64 29.92 19.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 126.397 1.879 . . . . 0.0 114.616 167.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.62 -42.4 1.27 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 125.768 1.652 . . . . 0.0 113.684 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.5 t -178.09 163.15 1.68 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.018 2.127 . . . . 0.0 111.315 175.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.431 HH21 HG21 ' B' ' 137' ' ' THR . 80.4 mtt85 -73.26 177.04 5.39 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 125.159 1.384 . . . . 0.0 110.322 168.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.57 -128.57 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 124.306 1.042 . . . . 0.0 111.245 -172.028 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.82 153.88 39.74 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.947 1.299 . . . . 0.0 112.447 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -137.41 152.01 49.16 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.109 1.364 . . . . 0.0 111.887 -169.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.92 171.24 33.8 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.201 1.381 . . . . 0.0 112.15 169.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 79.7 t -119.35 147.42 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 169.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.8 mm -86.5 88.6 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 O-C-N 121.626 -0.671 . . . . 0.0 110.526 -179.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.16 -168.3 42.66 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 123.431 0.538 . . . . 0.0 113.405 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.44 161.2 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -170.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.4 -56.43 0.4 Allowed 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.134 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 N--CA 1.464 0.241 0 C-N-CA 126.04 1.736 . . . . 0.0 110.129 -169.766 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.681 0 CA-C-O 118.448 -0.786 . . . . 0.0 112.888 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.505 HG23 HE22 ' A' ' 153' ' ' GLN . 40.0 m -75.06 121.43 22.01 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 -174.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.419 ' HE3' ' CG2' ' A' ' 5' ' ' VAL . 17.4 pttt -132.1 133.47 44.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 115.888 1.81 . . . . 0.0 115.888 -176.135 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 149' ' ' ILE . . . -86.95 167.57 14.15 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 163.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.419 ' CG2' ' HE3' ' A' ' 3' ' ' LYS . 15.2 t -147.43 118.21 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 119.207 0.912 . . . . 0.0 112.158 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.26 84.53 5.19 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 168.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.2 t -76.4 79.42 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 105.025 -2.213 . . . . 0.0 105.025 176.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.2 mt -67.09 127.68 33.5 Favored 'General case' 0 C--O 1.224 -0.239 0 CA-C-O 122.205 1.002 . . . . 0.0 111.177 -162.423 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.1 tttm -159.67 -174.6 4.7 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.342 1.457 . . . . 0.0 111.672 174.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.24 -6.44 21.34 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 124.778 1.18 . . . . 0.0 113.008 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -116.96 145.62 43.52 Favored 'General case' 0 N--CA 1.433 -1.276 1 C-N-CA 133.291 4.636 . . . . 0.0 103.4 168.478 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.66 -70.87 0.99 Allowed Glycine 0 CA--C 1.535 1.298 0 C-N-CA 126.011 1.767 . . . . 0.0 112.966 -177.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -69.16 -32.31 21.32 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 123.715 2.943 . . . . 0.0 114.537 -170.124 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -95.71 144.39 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 119.707 1.14 . . . . 0.0 111.304 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -139.83 173.66 11.3 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.523 1.129 . . . . 0.0 109.174 168.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.52 178.5 33.83 Favored Glycine 0 N--CA 1.468 0.784 0 C-N-CA 124.465 1.031 . . . . 0.0 114.954 169.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.3 pt -153.45 56.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 C-N-CA 124.943 1.297 . . . . 0.0 111.992 -170.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 mm -87.03 98.64 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 O-C-N 120.566 -1.334 . . . . 0.0 110.66 -173.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.02 147.31 34.88 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.782 1.233 . . . . 0.0 110.253 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -128.25 79.08 1.88 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.045 1.338 . . . . 0.0 109.544 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -81.7 112.31 18.76 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.086 1.354 . . . . 0.0 112.188 -175.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -101.02 131.83 46.72 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.449 1.5 . . . . 0.0 109.199 171.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.46 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -96.53 -22.95 16.78 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 124.438 1.095 . . . . 0.0 113.453 174.805 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -103.26 -138.35 0.35 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.668 3.187 . . . . 0.0 110.405 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.2 p -151.29 34.0 0.57 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 127.533 2.333 . . . . 0.0 109.33 169.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -178.88 -28.77 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.369 1.467 . . . . 0.0 114.44 -167.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.63 -169.21 40.29 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 125.165 1.364 . . . . 0.0 113.248 177.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -68.0 138.63 44.59 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.313 2.675 . . . . 0.0 112.834 -171.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.4 t -96.43 132.87 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 124.37 1.068 . . . . 0.0 110.062 173.175 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -81.23 118.61 22.74 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 169.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.12 79.11 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 127.687 2.395 . . . . 0.0 108.702 -174.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -103.28 164.99 11.29 Favored 'General case' 0 CA--C 1.541 0.607 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.418 172.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.36 -164.32 28.37 Favored Glycine 0 C--O 1.224 -0.491 0 C-N-CA 125.383 1.468 . . . . 0.0 111.506 174.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.6 p -155.38 168.47 26.97 Favored 'General case' 0 C--N 1.319 -0.722 0 O-C-N 121.686 -0.89 . . . . 0.0 110.597 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.67 HG21 HG11 ' A' ' 119' ' ' VAL . 4.3 mp -128.24 126.55 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 C-N-CA 126.283 1.833 . . . . 0.0 107.27 174.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.68 143.76 45.6 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 122.888 2.585 . . . . 0.0 113.032 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.42 -1.94 16.1 Favored Glycine 0 CA--C 1.54 1.636 0 C-N-CA 128.146 2.784 . . . . 0.0 113.561 -169.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.9 mt -79.01 161.95 26.26 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.059 1.344 . . . . 0.0 113.203 -177.205 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.1 t -85.53 155.64 21.11 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 164.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.4 pt-20 -57.6 172.59 0.35 Allowed 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 115.782 1.771 . . . . 0.0 115.782 -174.423 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.32 -178.6 53.84 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.621 1.105 . . . . 0.0 113.228 174.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -62.36 142.52 57.77 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.09 1.756 . . . . 0.0 112.606 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -142.72 124.08 14.72 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 127.84 2.456 . . . . 0.0 108.507 177.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.97 149.28 51.71 Favored Glycine 0 N--CA 1.477 1.396 0 CA-C-N 120.585 1.539 . . . . 0.0 110.919 178.011 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -147.7 117.88 7.31 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.907 1.854 . . . . 0.0 111.566 172.764 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -157.48 173.61 16.64 Favored 'General case' 0 C--O 1.236 0.367 0 O-C-N 121.104 -0.997 . . . . 0.0 109.741 -168.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.59 135.96 50.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 C-N-CA 124.214 1.006 . . . . 0.0 110.479 -166.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -77.18 176.18 8.97 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 122.849 0.46 . . . . 0.0 110.622 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 64' ' ' PHE . 1.2 pm0 -71.56 137.67 48.22 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.411 -0.806 . . . . 0.0 108.896 165.373 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 56.07 -169.05 0.09 Allowed 'General case' 0 CA--C 1.542 0.661 0 CA-C-O 123.665 1.698 . . . . 0.0 114.166 173.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.92 17.66 48.37 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-O 116.357 -2.357 . . . . 0.0 111.476 167.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.695 ' HA ' HG21 ' B' ' 5' ' ' VAL . 2.3 p30 -82.36 45.54 0.96 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.754 2.777 . . . . 0.0 112.454 -172.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.553 ' ND2' HG11 ' B' ' 7' ' ' VAL . 8.9 p-10 -91.69 34.39 0.98 Allowed 'General case' 0 C--O 1.235 0.301 0 N-CA-C 115.546 1.684 . . . . 0.0 115.546 -166.285 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.565 HG22 ' HA ' ' B' ' 7' ' ' VAL . 28.6 p -114.45 -18.86 11.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -160.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.69 21.2 4.89 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-N 119.214 0.915 . . . . 0.0 110.902 165.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.4 -112.7 3.63 Favored Glycine 0 C--N 1.342 0.878 0 C-N-CA 125.646 1.594 . . . . 0.0 111.476 173.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.5 t -80.87 -16.7 52.93 Favored 'General case' 0 CA--C 1.545 0.766 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 168.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.1 40.02 0.53 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.633 1.573 . . . . 0.0 108.8 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -172.16 167.07 6.01 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 127.46 2.304 . . . . 0.0 110.003 -162.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -1.31 106.71 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 129.522 3.129 . . . . 0.0 116.947 168.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.76 -84.39 0.74 Allowed Glycine 0 CA--C 1.54 1.609 0 C-N-CA 126.861 2.172 . . . . 0.0 113.165 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.9 173.74 13.94 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 124.39 3.393 . . . . 0.0 112.708 -171.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -92.96 115.39 28.08 Favored 'General case' 0 CA--C 1.536 0.404 0 O-C-N 121.156 -0.965 . . . . 0.0 113.533 -168.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 49' ' ' GLU . 40.2 t80 -43.89 130.4 5.75 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.135 1.374 . . . . 0.0 113.638 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 35.6 p-10 -145.27 68.49 13.67 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -168.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -61.11 -19.66 64.35 Favored 'Trans proline' 0 CA--C 1.54 0.784 0 C-N-CA 122.501 2.134 . . . . 0.0 112.058 169.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -76.88 -6.29 51.84 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.147 1.379 . . . . 0.0 113.608 171.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t 57.71 47.48 15.58 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 127.224 2.21 . . . . 0.0 112.233 174.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -111.24 173.01 6.54 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 114.657 1.354 . . . . 0.0 114.657 -175.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -89.04 176.14 7.11 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.187 2.195 . . . . 0.0 108.989 175.119 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.9 t60 -91.56 157.25 17.11 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.418 1.087 . . . . 0.0 113.674 -172.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 138.63 -129.73 4.62 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 124.021 0.82 . . . . 0.0 113.028 167.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 129.34 -30.05 3.73 Favored Glycine 0 CA--C 1.55 2.224 0 N-CA-C 119.763 2.665 . . . . 0.0 119.763 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -108.97 17.45 0.09 OUTLIER 'Trans proline' 0 CA--C 1.551 1.355 0 C-N-CA 124.933 3.756 . . . . 0.0 113.115 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.96 -26.17 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 128.286 2.634 . . . . 0.0 111.421 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.5 OUTLIER -94.78 148.07 22.68 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.864 2.066 . . . . 0.0 106.157 162.064 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -100.67 -8.98 22.32 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 126.901 2.08 . . . . 0.0 113.08 -178.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.64 -82.03 0.09 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.076 0.95 . . . . 0.0 110.553 -176.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.292 37.6 ptt180 66.67 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 127.063 2.145 . . . . 0.0 113.393 175.253 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -59.49 165.19 2.98 Favored 'General case' 0 CA--C 1.551 0.986 0 O-C-N 119.596 -1.94 . . . . 0.0 113.337 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 74.3 t -57.27 -25.26 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.457 -1.402 . . . . 0.0 112.697 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.67 31.19 7.41 Favored Glycine 0 CA--C 1.539 1.558 0 CA-C-O 118.222 -1.321 . . . . 0.0 115.993 173.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -112.25 139.73 47.55 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 117.387 2.365 . . . . 0.0 117.387 -172.06 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 79.9 mt -144.9 166.01 26.5 Favored 'General case' 0 CA--C 1.555 1.15 1 C-N-CA 133.704 4.802 . . . . 0.0 104.031 165.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.71 -129.32 5.3 Favored Glycine 0 N--CA 1.473 1.147 0 C-N-CA 123.664 0.65 . . . . 0.0 113.606 -169.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -113.06 147.33 37.48 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 121.974 0.892 . . . . 0.0 113.085 169.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.66 174.19 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.682 1.993 . . . . 0.0 108.372 167.187 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -140.57 124.02 16.91 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 168.418 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.1 139.81 34.19 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 118.239 0.472 . . . . 0.0 111.913 169.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.65 157.27 37.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.712 1.605 . . . . 0.0 110.386 167.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.83 -0.59 0.69 Allowed 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 114.684 1.365 . . . . 0.0 114.684 170.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -99.64 5.59 45.81 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.816 2.046 . . . . 0.0 112.482 170.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.08 0.54 65.75 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 126.27 1.89 . . . . 0.0 116.49 168.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.12 136.2 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 CA-C-N 119.497 1.649 . . . . 0.0 112.9 -177.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.3 129.85 50.41 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 124.948 1.299 . . . . 0.0 107.745 166.202 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -92.31 148.97 21.72 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 122.577 1.179 . . . . 0.0 108.835 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.07 124.58 37.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.451 -1.704 . . . . 0.0 109.232 173.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.1 p -155.31 76.04 0.96 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.962 1.363 . . . . 0.0 111.491 -169.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.72 159.57 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.484 1.513 . . . . 0.0 110.221 -169.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -147.17 121.43 9.57 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 104.777 -2.305 . . . . 0.0 104.777 166.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -126.29 131.79 51.8 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.641 1.21 . . . . 0.0 113.061 -168.516 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.1 p -82.98 58.73 4.53 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.393 1.077 . . . . 0.0 110.162 177.19 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -152.25 -44.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 170.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.45 143.14 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 118.938 0.79 . . . . 0.0 110.876 -179.189 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.518 ' H ' ' CB ' ' A' ' 111' ' ' SER . 35.8 p -132.22 161.02 34.45 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 126.556 1.942 . . . . 0.0 112.075 173.044 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 31.0 mt -79.71 94.54 5.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 168.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -131.97 -15.46 2.99 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -169.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.05 -68.67 3.39 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 120.347 1.43 . . . . 0.0 111.622 -170.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -92.04 -60.77 1.77 Allowed 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.705 1.24 . . . . 0.0 113.824 -173.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 28.7 m-70 -80.64 1.56 29.39 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.84 1.656 . . . . 0.0 112.903 -164.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' H ' ' A' ' 105' ' ' SER . 18.9 m -162.42 -88.88 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.264 0 N-CA-C 115.71 1.744 . . . . 0.0 115.71 177.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.41 162.75 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.093 -1.004 . . . . 0.0 111.093 -173.012 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 114.54 140.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 1 C-N-CA 135.521 5.528 . . . . 0.0 107.374 -169.421 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.63 -25.62 1.71 Allowed Glycine 0 CA--C 1.535 1.317 0 CA-C-O 118.26 -1.3 . . . . 0.0 115.836 177.11 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 10.6 ptt180 -74.73 163.64 27.46 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 126.253 1.821 . . . . 0.0 111.466 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.3 m -121.37 110.81 16.54 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 124.635 1.174 . . . . 0.0 113.042 -169.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.6 tp -99.66 122.87 43.31 Favored 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 121.124 1.784 . . . . 0.0 111.346 -173.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 143' ' ' ARG . 13.2 p -121.13 151.59 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 125.471 1.509 . . . . 0.0 113.315 179.119 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.678 HG13 ' CD2' ' A' ' 144' ' ' LEU . 7.4 p -103.9 143.28 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.035 0 C-N-CA 124.547 1.139 . . . . 0.0 110.344 166.493 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 40.6 m-70 -115.34 169.2 9.32 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 126.94 2.096 . . . . 0.0 115.123 -168.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -83.58 -30.17 27.21 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 116.075 1.88 . . . . 0.0 116.075 -173.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -107.0 170.18 8.1 Favored 'General case' 0 CA--C 1.546 0.805 0 CA-C-N 120.668 1.576 . . . . 0.0 111.881 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.57 163.89 6.51 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.022 1.329 . . . . 0.0 111.443 169.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -103.9 131.49 51.07 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.023 0.929 . . . . 0.0 110.422 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.88 -28.5 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 120.747 0.308 . . . . 0.0 111.656 177.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.0 mt 58.09 40.46 25.21 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.387 1.875 . . . . 0.0 112.446 173.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.27 -74.39 0.07 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 117.495 1.758 . . . . 0.0 117.495 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -139.06 -42.03 0.47 Allowed 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -164.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 54.64 -113.43 3.48 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 120.178 1.354 . . . . 0.0 110.47 -166.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -153.56 29.55 0.76 Allowed Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.222 1.867 . . . . 0.0 112.008 168.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -166.48 171.3 12.0 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.773 1.629 . . . . 0.0 111.669 -164.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -67.62 -54.65 17.95 Favored 'General case' 0 N--CA 1.469 0.478 0 O-C-N 121.32 -0.862 . . . . 0.0 113.185 -169.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.429 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 0.3 OUTLIER -65.09 -19.51 66.02 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.043 0.937 . . . . 0.0 111.25 -171.864 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.4 m -67.67 -33.35 74.76 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.897 -1.127 . . . . 0.0 111.729 168.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.4 p -83.29 -18.94 37.29 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 124.783 1.233 . . . . 0.0 114.241 174.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -105.99 -45.56 4.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.303 1.041 . . . . 0.0 113.57 -176.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.71 -26.33 12.33 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 116.829 -1.558 . . . . 0.0 113.87 177.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.63 12.44 47.56 Favored Glycine 0 N--CA 1.472 1.062 0 CA-C-N 119.327 0.967 . . . . 0.0 114.8 -173.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 60.38 8.95 1.78 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 118.975 1.387 . . . . 0.0 113.508 -174.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.84 -3.41 0.74 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -166.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.21 -160.04 25.67 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 126.694 2.092 . . . . 0.0 112.797 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 91.7 p -65.82 177.54 1.27 Allowed 'General case' 0 CA--C 1.547 0.828 0 O-C-N 122.026 -0.691 . . . . 0.0 112.139 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.463 ' HB2' HG21 ' A' ' 118' ' ' VAL . 27.5 ptt180 -136.2 132.37 35.8 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.923 -1.111 . . . . 0.0 112.749 -166.033 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.678 ' CD2' HG13 ' A' ' 119' ' ' VAL 0.335 0.0 OUTLIER -103.35 -106.76 0.27 Allowed 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.154 1.381 . . . . 0.0 111.723 -175.677 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.473 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -77.23 135.18 38.45 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 119.635 1.107 . . . . 0.0 111.216 -173.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.435 ' HB3' HG23 ' A' ' 118' ' ' VAL . 13.9 p -141.88 154.86 45.43 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 126.107 1.763 . . . . 0.0 111.69 -172.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.7 130.01 3.5 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 123.818 0.723 . . . . 0.0 111.915 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -72.47 170.53 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 167.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 4' ' ' ALA . 35.2 mm -129.56 126.39 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 O-C-N 120.738 -1.226 . . . . 0.0 113.331 -167.326 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -146.05 -126.24 1.77 Allowed Glycine 0 CA--C 1.539 1.591 0 C-N-CA 127.442 2.449 . . . . 0.0 114.617 -177.514 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 pp -147.46 68.67 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 120.642 -1.505 . . . . 0.0 113.932 -168.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.43 -20.43 54.54 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 120.567 -1.333 . . . . 0.0 114.462 -171.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLN . . . . . 0.505 HE22 HG23 ' A' ' 2' ' ' THR . 4.9 mm-40 . . . . . 0 N--CA 1.472 0.633 0 C-N-CA 124.497 1.119 . . . . 0.0 112.699 175.187 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.442 0 CA-C-O 121.12 0.486 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.4 m -83.24 99.87 10.24 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -96.36 165.18 12.32 Favored 'General case' 0 CA--C 1.548 0.899 0 CA-C-O 122.864 1.316 . . . . 0.0 113.251 -176.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.34 172.73 13.43 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -168.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.695 HG21 ' HA ' ' A' ' 52' ' ' ASP . 1.1 p -157.43 103.44 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 C-N-CA 127.25 2.22 . . . . 0.0 107.786 -169.051 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.27 130.42 35.02 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 120.472 -1.392 . . . . 0.0 111.699 171.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.565 ' HA ' HG22 ' A' ' 54' ' ' THR . 20.6 t -93.48 71.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.179 0.992 . . . . 0.0 111.136 -173.18 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -80.48 114.72 19.58 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.469 0.652 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 13.2 ttpp -144.97 151.18 38.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.84 0.829 . . . . 0.0 112.428 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.45 149.96 18.76 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 166.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -79.1 64.88 4.13 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 123.408 1.575 . . . . 0.0 110.372 169.102 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.52 -175.45 46.24 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 129.101 3.239 . . . . 0.0 108.685 -171.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.18 22.21 0.38 Allowed 'Trans proline' 0 CA--C 1.547 1.153 0 C-N-CA 124.65 3.566 . . . . 0.0 114.916 -169.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.454 HG11 HD13 ' B' ' 144' ' ' LEU . 1.3 t -118.97 130.31 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 C-N-CA 126.993 2.117 . . . . 0.0 109.002 -170.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.434 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -160.71 160.88 31.97 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 124.099 0.96 . . . . 0.0 110.999 -170.982 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.01 169.05 33.58 Favored Glycine 0 CA--C 1.51 -0.262 0 C-N-CA 124.779 1.18 . . . . 0.0 112.23 168.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.402 HG22 ' HB ' ' A' ' 54' ' ' THR . 1.0 OUTLIER -132.35 133.18 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 171.8 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.438 HD12 HG11 ' B' ' 97' ' ' VAL . 5.0 mm -135.09 109.58 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 19' ' ' ASN . . . . . 0.407 ' HB2' ' CE2' ' B' ' 32' ' ' TRP . 36.2 m120 -79.85 155.52 27.78 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 123.914 0.886 . . . . 0.0 111.959 175.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.439 ' CD2' HG22 ' B' ' 31' ' ' VAL . 5.5 m-85 -139.27 152.65 47.44 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 167.546 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -146.88 132.57 18.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 119.133 0.879 . . . . 0.0 109.951 167.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -84.84 137.86 32.91 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 122.721 0.408 . . . . 0.0 111.117 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.464 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -93.48 -91.64 0.18 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.179 0.992 . . . . 0.0 110.618 169.27 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.464 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 31.9 mp0 -82.37 169.25 16.67 Favored 'General case' 0 C--O 1.217 -0.607 0 O-C-N 120.538 -1.351 . . . . 0.0 110.544 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -51.02 -45.25 61.17 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 114.298 1.222 . . . . 0.0 114.298 -172.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 22.0 m-80 -127.01 40.27 3.75 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.632 1.973 . . . . 0.0 110.294 166.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.66 162.76 53.61 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-O 118.717 -1.046 . . . . 0.0 111.461 173.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -66.4 161.72 39.66 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.503 2.802 . . . . 0.0 110.005 174.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.0 t -136.55 133.36 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 122.973 0.509 . . . . 0.0 110.967 -169.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -79.84 132.16 36.04 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 168.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.439 HG22 ' CD2' ' B' ' 20' ' ' PHE . 21.3 t -120.85 111.54 32.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 126.578 1.951 . . . . 0.0 108.739 176.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 32' ' ' TRP . . . . . 0.407 ' CE2' ' HB2' ' B' ' 19' ' ' ASN . 17.5 p90 -140.11 153.27 46.66 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.366 0.603 . . . . 0.0 112.213 -173.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.49 -153.41 24.63 Favored Glycine 0 C--O 1.225 -0.433 0 C-N-CA 124.13 0.872 . . . . 0.0 111.507 178.065 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 12.6 p -157.1 158.66 36.79 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 114.045 1.128 . . . . 0.0 114.045 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -128.1 131.46 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 125.715 1.606 . . . . 0.0 107.912 -179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.1 ttpt -133.95 140.12 46.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 126.172 1.789 . . . . 0.0 110.617 -168.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.11 20.73 13.09 Favored Glycine 0 N--CA 1.481 1.638 0 C-N-CA 124.994 1.283 . . . . 0.0 114.373 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.2 pt? -117.91 165.9 13.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.756 2.822 . . . . 0.0 110.622 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.95 167.46 21.86 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.316 0.646 . . . . 0.0 110.205 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -64.65 -175.3 0.17 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 126.967 2.107 . . . . 0.0 114.549 171.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.33 -170.59 46.98 Favored Glycine 0 N--CA 1.47 0.944 0 O-C-N 120.388 -1.445 . . . . 0.0 112.432 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mt -77.01 155.16 32.79 Favored 'General case' 0 CA--C 1.545 0.757 0 O-C-N 121.172 -1.193 . . . . 0.0 110.02 177.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -147.63 123.57 10.68 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 127.931 2.493 . . . . 0.0 109.641 -172.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.34 151.16 36.2 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-N 120.926 1.694 . . . . 0.0 113.526 176.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -151.13 96.58 2.33 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.213 1.405 . . . . 0.0 112.171 -170.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.38 147.07 48.93 Favored 'General case' 0 N--CA 1.47 0.561 0 O-C-N 120.085 -1.634 . . . . 0.0 111.742 -167.512 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.526 HG23 ' HA2' ' B' ' 82' ' ' GLY . 27.5 m -108.66 120.19 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 122.484 1.135 . . . . 0.0 110.959 177.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -77.83 101.61 6.83 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -173.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -64.16 95.27 0.12 Allowed 'General case' 0 C--N 1.344 0.349 0 CA-C-O 123.116 1.436 . . . . 0.0 108.602 175.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 t80 177.55 -166.95 0.05 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 130.472 3.509 . . . . 0.0 104.349 -164.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.35 -122.02 3.5 Favored Glycine 0 CA--C 1.507 -0.43 0 CA-C-O 121.772 0.651 . . . . 0.0 112.477 171.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.07 152.83 39.85 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.684 1.594 . . . . 0.0 113.459 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 17.4 p-10 173.13 32.68 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 128.815 2.846 . . . . 0.0 108.843 -171.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 82.8 p -68.25 12.27 0.13 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.439 2.295 . . . . 0.0 116.382 -165.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.07 -2.83 28.68 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 125.162 1.385 . . . . 0.0 113.254 169.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.6 -150.57 19.93 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.559 1.552 . . . . 0.0 112.432 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 p -54.75 -5.79 0.1 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 116.82 2.156 . . . . 0.0 116.82 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.9 t -76.18 7.18 4.44 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.721 1.609 . . . . 0.0 111.619 166.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.1 m -154.86 158.82 39.94 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 127.92 2.488 . . . . 0.0 109.739 172.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 61.49 -76.81 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 127.354 2.262 . . . . 0.0 113.997 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.82 -91.75 0.94 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.296 1.903 . . . . 0.0 112.223 -174.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -100.33 -177.32 0.17 Allowed 'Trans proline' 0 CA--C 1.535 0.561 1 C-N-CA 125.939 4.426 . . . . 0.0 111.728 176.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.487 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -79.98 130.36 35.21 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 168.741 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -58.97 147.09 35.67 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.855 1.262 . . . . 0.0 112.56 171.281 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 50.3 m-20 -108.81 77.87 0.86 Allowed Pre-proline 0 CA--C 1.554 1.097 0 C-N-CA 125.276 1.43 . . . . 0.0 111.843 -176.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -58.21 -49.18 13.15 Favored 'Trans proline' 0 C--N 1.353 0.81 0 C-N-CA 123.975 3.116 . . . . 0.0 113.216 -174.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 75.1 mt -78.83 -0.44 30.62 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 126.144 1.778 . . . . 0.0 112.871 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.2 t 58.77 43.82 17.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 127.518 2.327 . . . . 0.0 112.151 -173.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.1 mtp180 -92.31 176.43 6.48 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 120.878 -1.139 . . . . 0.0 112.489 -176.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.513 ' HE2' ' OE1' ' B' ' 78' ' ' GLU . 0.3 OUTLIER -97.24 170.26 9.22 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 126.18 1.792 . . . . 0.0 108.829 165.312 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -96.66 151.64 19.42 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -167.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.44 -106.03 0.34 Allowed Glycine 0 C--N 1.345 1.053 0 C-N-CA 124.796 1.189 . . . . 0.0 114.809 166.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.85 -29.2 8.69 Favored Glycine 0 CA--C 1.543 1.811 0 N-CA-C 119.85 2.7 . . . . 0.0 119.85 174.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -104.03 6.47 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.049 0 C-N-CA 123.657 2.904 . . . . 0.0 112.578 172.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.01 -31.25 0.13 Allowed 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.908 1.283 . . . . 0.0 110.893 169.447 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.05 150.13 27.71 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 162.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -96.19 -17.99 20.41 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.519 1.927 . . . . 0.0 112.138 -176.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 78' ' ' GLU . . . . . 0.513 ' OE1' ' HE2' ' B' ' 70' ' ' LYS . 3.7 mt-10 -78.05 -50.66 11.65 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 121.049 -1.032 . . . . 0.0 113.023 -172.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 45.75 97.88 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.127 1.371 . . . . 0.0 114.059 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.6 m80 -50.79 144.78 7.86 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 119.729 -1.857 . . . . 0.0 110.262 169.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 m -55.41 -29.99 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 CA-C-N 120.239 1.381 . . . . 0.0 112.12 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.526 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -89.26 49.24 3.48 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 125.025 1.298 . . . . 0.0 116.053 171.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -139.46 123.17 17.48 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.353 1.461 . . . . 0.0 110.071 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -113.55 50.29 0.92 Allowed 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 168.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 55.73 -112.13 2.91 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 125.343 1.449 . . . . 0.0 114.445 177.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -155.7 159.07 39.23 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 126.196 1.798 . . . . 0.0 110.563 -175.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.8 p -117.37 175.75 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 127.517 2.327 . . . . 0.0 109.685 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -133.92 150.17 51.31 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.98 1.712 . . . . 0.0 108.326 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -117.7 149.03 41.42 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.443 1.497 . . . . 0.0 112.779 173.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -83.52 150.05 26.23 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 128.229 2.612 . . . . 0.0 112.281 169.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.82 -2.48 1.85 Allowed 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.884 1.673 . . . . 0.0 115.143 177.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -90.93 7.96 37.53 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.485 1.514 . . . . 0.0 112.069 169.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.82 28.81 22.73 Favored Glycine 0 C--N 1.341 0.821 0 CA-C-O 117.361 -1.799 . . . . 0.0 114.656 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -141.64 139.26 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.138 1.469 . . . . 0.0 114.521 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.14 122.04 44.5 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.558 1.543 . . . . 0.0 108.685 165.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -79.21 140.0 37.8 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 165.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 97' ' ' VAL . . . . . 0.438 HG11 HD12 ' B' ' 18' ' ' ILE 0.262 0.3 OUTLIER -119.71 129.04 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-O 122.557 1.17 . . . . 0.0 112.576 166.96 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 28.8 m -147.8 78.63 1.46 Allowed 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.362 1.465 . . . . 0.0 109.729 -172.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -122.44 154.14 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.484 1.513 . . . . 0.0 111.614 -173.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.8 tt0 -142.14 148.39 38.22 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.989 1.715 . . . . 0.0 107.346 167.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -149.83 150.48 32.04 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 125.117 1.367 . . . . 0.0 111.934 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.2 p -116.78 51.86 0.97 Allowed 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.7 -48.64 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 124.4 1.08 . . . . 0.0 110.819 169.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.96 157.31 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 119.327 0.967 . . . . 0.0 112.785 177.502 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 95.0 p -156.54 150.89 25.41 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.164 1.786 . . . . 0.0 109.023 -170.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mp -80.95 54.06 2.11 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 122.128 0.965 . . . . 0.0 108.745 172.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -84.93 62.61 7.58 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.121 -0.987 . . . . 0.0 109.968 -177.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.92 -111.11 4.06 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 124.784 1.183 . . . . 0.0 112.837 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -127.99 -14.8 4.92 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 127.67 2.388 . . . . 0.0 114.518 -167.542 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.0 -32.14 8.44 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 114.49 1.292 . . . . 0.0 114.49 -169.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -85.98 -15.14 42.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.258 0.7 OUTLIER -177.37 -47.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 C-N-CA 127.564 2.346 . . . . 0.0 109.109 168.536 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -58.86 143.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 105.61 -1.996 . . . . 0.0 105.61 162.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.65 -16.4 1.4 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 126.769 2.128 . . . . 0.0 113.628 -175.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 115' ' ' ARG . . . . . 0.52 HH11 ' HG3' ' B' ' 115' ' ' ARG . 4.5 ttm-85 -80.15 171.37 15.17 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.863 1.665 . . . . 0.0 111.854 176.145 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -113.14 154.52 26.5 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 125.379 1.471 . . . . 0.0 112.466 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 25.2 tp -121.15 138.25 54.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 128.246 2.619 . . . . 0.0 109.217 168.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -114.84 139.39 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 124.949 1.3 . . . . 0.0 109.872 168.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -119.57 133.99 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 171.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -110.94 151.06 28.35 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.767 1.227 . . . . 0.0 112.033 -168.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -79.2 -18.22 53.39 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -167.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 48.0 mttp -138.73 178.23 7.3 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 120.163 1.347 . . . . 0.0 113.569 177.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.91 130.51 37.61 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.282 1.433 . . . . 0.0 110.176 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -81.33 158.78 24.6 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 124.029 0.831 . . . . 0.0 109.221 170.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 125' ' ' ASP . . . . . 0.452 ' OD1' ' HE3' ' B' ' 128' ' ' LYS . 7.5 t70 -73.45 -43.29 60.63 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 119.306 -0.957 . . . . 0.0 109.3 168.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 2.0 mm? 70.15 53.14 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 127.123 2.169 . . . . 0.0 107.734 -168.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 161.22 -82.29 0.13 Allowed Glycine 0 N--CA 1.465 0.617 0 O-C-N 121.317 -0.864 . . . . 0.0 114.1 -175.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.537 ' H ' ' HE3' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -156.69 72.4 0.73 Allowed 'General case' 0 CA--C 1.549 0.938 0 N-CA-C 115.701 1.741 . . . . 0.0 115.701 -170.237 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -57.6 -24.81 54.03 Favored Glycine 0 CA--C 1.542 1.753 0 O-C-N 120.708 -1.245 . . . . 0.0 115.128 176.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.48 -28.38 0.49 Allowed Glycine 0 CA--C 1.534 1.24 0 N-CA-C 116.675 1.43 . . . . 0.0 116.675 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 131' ' ' ASN . . . . . 0.418 ' H ' ' HB3' ' B' ' 134' ' ' SER . 22.1 m120 -106.33 175.81 5.37 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 118.968 1.384 . . . . 0.0 113.098 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.1 tm-20 -51.64 -57.55 8.84 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.603 1.161 . . . . 0.0 108.904 166.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -41.33 -34.53 0.52 Allowed 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 126.236 1.814 . . . . 0.0 115.036 168.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' B' ' 131' ' ' ASN . 4.5 p -71.18 -9.96 58.97 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 119.318 -2.114 . . . . 0.0 115.836 -177.339 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.2 t -111.16 -7.98 14.43 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.166 1.387 . . . . 0.0 110.379 164.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -85.82 -50.33 7.22 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.737 1.615 . . . . 0.0 110.763 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 80.7 p -102.35 -35.52 8.79 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 128.686 2.794 . . . . 0.0 110.972 175.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.76 -9.63 52.05 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.045 1.783 . . . . 0.0 112.028 -169.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 75.96 30.93 0.71 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 129.446 3.098 . . . . 0.0 112.317 176.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.68 33.33 0.01 OUTLIER 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 178.444 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.55 -51.86 3.75 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 127.69 2.567 . . . . 0.0 114.79 175.006 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 170.9 157.39 0.07 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.862 1.665 . . . . 0.0 113.741 -174.328 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.33 134.0 34.52 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.413 1.085 . . . . 0.0 113.715 173.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.454 HD13 HG11 ' B' ' 14' ' ' VAL . 3.3 pp -104.7 -30.17 10.11 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.331 1.453 . . . . 0.0 113.469 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.81 161.55 36.94 Favored 'General case' 0 C--O 1.245 0.831 0 C-N-CA 125.705 1.602 . . . . 0.0 107.174 174.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.3 p -152.32 151.86 31.41 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 126.254 1.822 . . . . 0.0 108.525 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.46 145.69 11.77 Favored Glycine 0 C--O 1.224 -0.504 0 N-CA-C 115.632 1.013 . . . . 0.0 115.632 179.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 16.3 t -78.17 145.9 9.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.283 1.033 . . . . 0.0 108.244 167.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.6 mm -89.53 101.17 11.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.914 0.886 . . . . 0.0 109.979 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.62 164.46 30.39 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 173.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -93.78 141.14 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 123.902 0.881 . . . . 0.0 111.354 172.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -141.91 166.19 25.39 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.956 1.703 . . . . 0.0 111.154 168.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.466 0.351 0 C-N-CA 123.265 0.626 . . . . 0.0 111.133 -167.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.946 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -157.68 123.87 4.78 Favored 'General case' 0 CA--C 1.508 -0.635 0 O-C-N 125.6 1.812 . . . . 0.0 107.884 -168.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.0 ttpt -99.0 106.74 19.03 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 122.641 1.21 . . . . 0.0 112.967 169.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.65 173.23 7.99 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 126.078 1.751 . . . . 0.0 109.041 167.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.868 HG11 ' HA ' ' B' ' 52' ' ' ASP . 12.8 p -161.78 162.66 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.353 0.661 . . . . 0.0 111.996 -173.032 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.52 134.01 19.75 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.566 1.146 . . . . 0.0 109.899 163.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.26 94.29 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.525 1.93 . . . . 0.0 107.058 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -79.3 134.58 36.62 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 126.708 2.003 . . . . 0.0 110.206 -173.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.4 mtpt -155.87 179.71 8.94 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.313 1.045 . . . . 0.0 113.687 178.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.5 -60.47 0.42 Allowed Glycine 0 C--N 1.334 0.445 0 C-N-CA 128.083 2.754 . . . . 0.0 108.721 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -82.1 69.69 8.86 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.101 1.761 . . . . 0.0 111.52 -168.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.44 -100.67 0.03 OUTLIER Glycine 0 CA--C 1.54 1.643 0 C-N-CA 126.957 2.218 . . . . 0.0 114.132 171.695 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -80.38 -7.66 13.86 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 125.04 3.827 . . . . 0.0 114.331 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.3 t -77.22 142.17 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 CA-C-N 119.983 1.265 . . . . 0.0 109.105 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.45 158.04 39.35 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 124.95 1.3 . . . . 0.0 109.414 169.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -140.51 108.64 0.57 Allowed Glycine 0 C--O 1.22 -0.777 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.94 131.41 37.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 118.676 1.238 . . . . 0.0 108.392 168.632 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.3 pp -149.41 126.61 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-O 122.764 1.269 . . . . 0.0 111.413 166.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -74.82 166.3 23.84 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.78 1.232 . . . . 0.0 111.329 169.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -141.49 93.25 2.55 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.734 2.014 . . . . 0.0 107.879 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.447 ' OE2' ' HE3' ' A' ' 23' ' ' LYS . 4.6 tm-20 -92.55 122.9 35.44 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.588 1.555 . . . . 0.0 110.121 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -120.01 132.24 55.41 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.869 0.842 . . . . 0.0 112.333 169.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.554 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -75.13 -42.01 57.17 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.269 1.827 . . . . 0.0 112.584 -177.017 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.329 0.0 OUTLIER -110.01 -122.46 0.27 Allowed 'General case' 0 CA--C 1.544 0.729 0 CA-C-O 116.887 -1.53 . . . . 0.0 110.215 169.068 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 48.9 m -144.07 -25.31 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-N 120.847 1.658 . . . . 0.0 114.752 -172.126 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.47 -17.8 6.9 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 120.45 -1.406 . . . . 0.0 114.108 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -150.69 4.86 Favored Glycine 0 CA--C 1.542 1.755 1 C-N-CA 131.0 4.143 . . . . 0.0 114.104 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -88.41 156.71 6.62 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.296 2.664 . . . . 0.0 114.365 -168.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.14 134.48 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.763 1.225 . . . . 0.0 109.632 -173.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -97.58 126.0 42.63 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.229 1.411 . . . . 0.0 109.902 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.6 t -123.8 122.39 64.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 C-N-CA 126.587 1.955 . . . . 0.0 109.146 -170.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -146.9 150.27 34.89 Favored 'General case' 0 C--O 1.24 0.57 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -178.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.59 -153.13 23.43 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.834 1.683 . . . . 0.0 111.039 -169.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.1 p -158.57 143.35 16.09 Favored 'General case' 0 C--O 1.238 0.485 0 O-C-N 121.794 -0.827 . . . . 0.0 113.097 -169.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.44 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -109.13 106.2 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 125.251 1.42 . . . . 0.0 109.616 173.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -111.29 144.59 40.23 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.704 2.002 . . . . 0.0 110.549 -167.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.01 -24.04 24.08 Favored Glycine 0 N--CA 1.475 1.241 0 C-N-CA 126.566 2.031 . . . . 0.0 112.108 -171.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.4 mp -68.13 111.45 4.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.254 1.822 . . . . 0.0 107.644 168.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.4 t -68.78 -27.32 65.78 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.259 1.577 . . . . 0.0 115.259 -169.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 178.58 -175.4 0.19 Allowed 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 130.744 3.617 . . . . 0.0 106.549 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.54 159.81 35.41 Favored Glycine 0 N--CA 1.469 0.845 0 C-N-CA 126.263 1.887 . . . . 0.0 116.038 167.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.8 mt -70.45 132.61 45.84 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.827 1.251 . . . . 0.0 109.008 168.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -129.52 120.08 24.78 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.409 1.483 . . . . 0.0 107.253 177.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.13 164.47 36.48 Favored Glycine 0 N--CA 1.475 1.245 0 CA-C-O 117.619 -1.656 . . . . 0.0 111.563 176.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.25 1.6 p90 -156.06 111.32 2.94 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 120.989 2.394 . . . . 0.0 113.569 169.23 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -122.14 147.08 46.59 Favored 'General case' 0 CA--C 1.551 0.991 0 O-C-N 119.979 -1.701 . . . . 0.0 111.082 -172.124 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -82.31 120.63 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -71.12 111.85 6.81 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.43 -2.433 . . . . 0.0 104.43 168.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.478 ' H ' ' HA ' ' A' ' 63' ' ' HIS . 16.8 tt0 -64.39 116.86 6.5 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.148 -174.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.353 50.3 m-85 101.31 160.57 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 131.567 3.947 . . . . 0.0 113.708 -178.089 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.18 -14.7 55.63 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 114.746 -1.115 . . . . 0.0 114.48 -172.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG11 ' B' ' 5' ' ' VAL . 5.0 m-20 -71.93 54.9 0.28 Allowed 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 128.887 2.875 . . . . 0.0 113.134 -169.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -170.33 -42.34 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 119.539 3.163 . . . . 0.0 119.539 -168.728 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.298 0.9 OUTLIER 49.75 -58.99 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 129.115 2.966 . . . . 0.0 117.339 -169.775 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 22.44 0.82 Allowed 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 127.748 2.419 . . . . 0.0 114.596 -171.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.41 -127.82 44.4 Favored Glycine 0 C--N 1.336 0.553 0 C-N-CA 125.49 1.519 . . . . 0.0 110.878 172.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.5 m -56.56 -10.37 0.96 Allowed 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.08 1.85 22.73 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 125.251 1.42 . . . . 0.0 112.623 171.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 9.0 t -164.94 -156.52 0.31 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 129.532 3.133 . . . . 0.0 106.361 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 74.88 -169.09 0.1 Allowed 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 123.761 1.743 . . . . 0.0 115.147 166.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.68 155.43 16.08 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 127.151 2.31 . . . . 0.0 108.735 166.59 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.417 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 96.6 Cg_endo -75.61 76.43 3.63 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 123.924 3.083 . . . . 0.0 108.293 171.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.478 ' HA ' ' H ' ' A' ' 49' ' ' GLU . 5.1 p80 47.27 72.39 0.25 Allowed 'General case' 0 C--O 1.236 0.351 0 C-N-CA 127.261 2.225 . . . . 0.0 112.674 167.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -40.84 141.22 0.61 Allowed 'General case' 0 C--O 1.221 -0.395 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.603 -174.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -101.3 67.48 0.06 OUTLIER Pre-proline 0 CA--C 1.549 0.938 0 CA-C-N 114.195 -1.366 . . . . 0.0 113.527 175.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -65.13 -18.47 61.57 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 121.829 1.686 . . . . 0.0 112.593 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -77.97 -5.11 50.18 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.188 1.395 . . . . 0.0 113.523 170.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.6 t 60.78 53.41 3.92 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 127.01 2.124 . . . . 0.0 112.177 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 -139.3 175.35 9.63 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 -167.111 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.546 ' H ' ' HE3' ' A' ' 70' ' ' LYS . 0.5 OUTLIER -76.68 158.89 30.67 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.353 1.461 . . . . 0.0 112.017 173.179 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -79.4 147.92 32.18 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.481 -0.781 . . . . 0.0 112.469 168.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.467 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 155.64 -111.93 0.5 Allowed Glycine 0 C--N 1.339 0.701 0 CA-C-O 118.029 -1.429 . . . . 0.0 114.09 167.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.11 -85.88 0.39 Allowed Glycine 0 CA--C 1.537 1.446 0 CA-C-O 117.486 -1.73 . . . . 0.0 114.6 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -55.54 -6.88 1.1 Allowed 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 124.458 3.438 . . . . 0.0 116.869 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -155.89 9.97 0.27 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 128.585 2.754 . . . . 0.0 112.238 -176.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.467 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.6 OUTLIER -146.74 109.9 4.75 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 128.533 2.733 . . . . 0.0 109.624 179.106 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -64.35 -9.26 16.73 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 127.848 2.459 . . . . 0.0 114.719 -175.001 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -81.44 -91.83 0.06 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.76 0.824 . . . . 0.0 110.402 177.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.8 ttp-105 78.72 118.45 0.06 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.164 1.785 . . . . 0.0 111.141 171.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m80 -55.79 160.83 2.44 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.278 -1.514 . . . . 0.0 113.831 175.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.8 t -53.16 -50.74 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 121.047 1.749 . . . . 0.0 112.229 -170.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.7 3.06 Favored Glycine 0 C--N 1.341 0.833 0 N-CA-C 108.491 -1.844 . . . . 0.0 108.491 169.072 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -157.45 118.56 3.6 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.529 1.531 . . . . 0.0 109.512 179.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -105.16 165.57 11.0 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 126.099 1.76 . . . . 0.0 109.726 169.001 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.81 -136.77 8.57 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 125.249 1.404 . . . . 0.0 112.792 177.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.64 158.17 20.33 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 117.025 2.231 . . . . 0.0 117.025 -174.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.3 m -106.97 173.9 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 128.705 2.802 . . . . 0.0 110.188 167.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 t -141.74 141.27 33.25 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 125.552 1.541 . . . . 0.0 108.383 169.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.69 150.67 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 125.221 1.408 . . . . 0.0 111.589 178.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -100.64 158.79 15.68 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.884 1.673 . . . . 0.0 112.128 173.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -50.28 -21.93 1.58 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 129.099 2.959 . . . . 0.0 115.815 -169.302 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.26 0.94 54.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 128.58 2.752 . . . . 0.0 110.716 -172.277 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.32 32.05 6.24 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-O 117.477 -1.735 . . . . 0.0 114.052 173.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.2 p -155.66 133.53 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 117.512 2.412 . . . . 0.0 117.512 -171.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.65 129.22 40.02 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 163.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -88.59 145.49 25.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 168.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.7 t -131.85 122.27 49.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 113.251 -1.795 . . . . 0.0 107.934 167.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -146.35 58.81 1.21 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 127.687 2.395 . . . . 0.0 107.582 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 29.7 mt -116.77 155.65 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.498 1.519 . . . . 0.0 112.125 -166.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -135.99 130.24 33.3 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 167.362 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -132.69 144.71 50.5 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 125.353 1.461 . . . . 0.0 110.256 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.6 p -125.28 59.42 1.25 Allowed 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.276 1.431 . . . . 0.0 112.752 -167.59 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -156.31 -48.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 C-N-CA 123.008 0.523 . . . . 0.0 110.683 -174.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -82.32 158.79 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 164.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.2 p -160.24 168.85 24.46 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.064 1.345 . . . . 0.0 109.355 -175.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.3 mp -100.64 54.06 0.87 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.0 t -76.09 4.32 8.73 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 114.98 1.474 . . . . 0.0 114.98 -167.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 138.18 -86.83 0.22 Allowed Glycine 0 N--CA 1.462 0.39 0 N-CA-C 106.592 -2.603 . . . . 0.0 106.592 -169.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.99 -6.11 0.77 Allowed 'General case' 0 C--O 1.219 -0.526 0 C-N-CA 123.761 0.824 . . . . 0.0 113.199 168.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -73.03 -33.17 65.56 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 120.29 -1.506 . . . . 0.0 110.617 -165.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.0 p -105.78 -8.56 17.71 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 117.448 2.388 . . . . 0.0 117.448 -169.112 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.273 3.7 pt 176.69 -39.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 C-N-CA 127.698 2.399 . . . . 0.0 115.582 167.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.3 mm -49.47 125.03 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-N 121.605 2.002 . . . . 0.0 111.024 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.67 -7.01 66.87 Favored Glycine 0 CA--C 1.534 1.241 0 C-N-CA 125.766 1.65 . . . . 0.0 116.092 176.074 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.5 176.03 10.14 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.814 1.646 . . . . 0.0 110.622 170.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.1 t -132.97 129.03 37.69 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 120.185 1.357 . . . . 0.0 113.078 -174.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.2 tp -101.96 125.48 48.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.771 2.029 . . . . 0.0 109.523 -170.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -110.98 135.19 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 124.526 1.131 . . . . 0.0 109.595 174.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.581 HG13 HD22 ' A' ' 144' ' ' LEU . 2.2 p -92.63 141.51 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 C-N-CA 124.991 1.316 . . . . 0.0 109.088 168.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -112.95 168.42 9.71 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.097 2.559 . . . . 0.0 113.112 -168.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -86.61 -46.71 9.85 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 -168.183 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -99.9 -176.33 3.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 120.091 -1.631 . . . . 0.0 110.198 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.71 154.16 7.22 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 165.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 p30 -99.25 140.78 32.91 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.68 1.229 . . . . 0.0 110.792 167.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -78.62 -36.57 43.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 127.422 2.289 . . . . 0.0 112.213 -169.046 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 23.1 mt 55.82 47.83 19.44 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.717 1.207 . . . . 0.0 110.596 173.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 138.52 -62.25 0.57 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.415 -1.214 . . . . 0.0 115.9 171.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.39 87.39 1.31 Allowed 'General case' 0 CA--C 1.552 1.021 1 N-CA-C 122.417 4.229 . . . . 0.0 122.417 -166.5 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.71 -86.99 0.61 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 105.948 -2.861 . . . . 0.0 105.948 163.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -167.31 34.08 0.21 Allowed Glycine 0 N--CA 1.47 0.935 0 CA-C-O 119.03 -0.872 . . . . 0.0 114.827 171.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -164.05 150.34 11.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 119.513 1.657 . . . . 0.0 108.899 -167.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -48.3 -46.99 36.88 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.607 0.763 . . . . 0.0 112.275 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -50.51 -27.84 7.37 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 116.04 1.867 . . . . 0.0 116.04 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.1 p -53.25 -28.06 25.54 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-N 120.857 1.662 . . . . 0.0 112.656 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.9 t -113.51 -29.16 7.27 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 115.195 1.554 . . . . 0.0 115.195 170.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -67.65 -23.32 65.32 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 119.986 1.266 . . . . 0.0 113.355 178.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.9 p -141.11 -32.91 0.54 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.228 1.411 . . . . 0.0 114.236 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.39 5.16 49.39 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.587 1.565 . . . . 0.0 110.466 -164.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 51.53 30.99 6.96 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 127.311 2.244 . . . . 0.0 114.632 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.05 19.47 0.04 OUTLIER 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 118.06 2.615 . . . . 0.0 118.06 -166.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.62 8.05 37.64 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 119.437 2.535 . . . . 0.0 119.437 167.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 28.9 t 139.2 -178.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 1 C-N-CA 131.952 4.101 . . . . 0.0 111.183 170.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.08 154.22 37.62 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 126.18 1.792 . . . . 0.0 112.836 173.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.581 HD22 HG13 ' A' ' 119' ' ' VAL 0.349 0.0 OUTLIER -133.31 -127.2 0.17 Allowed 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.972 2.109 . . . . 0.0 107.868 167.104 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.05 147.77 46.2 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.068 1.304 . . . . 0.0 114.472 -166.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.7 p -137.42 147.63 45.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.612 1.565 . . . . 0.0 113.952 176.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.61 142.43 8.41 Favored Glycine 0 N--CA 1.473 1.165 0 C-N-CA 124.621 1.105 . . . . 0.0 114.238 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 87.6 t -76.27 150.43 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 C-N-CA 124.725 1.21 . . . . 0.0 110.246 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.9 mm -81.31 83.69 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 O-C-N 121.562 -0.711 . . . . 0.0 109.721 173.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.72 -169.01 43.59 Favored Glycine 0 N--CA 1.474 1.231 0 C-N-CA 126.849 2.166 . . . . 0.0 112.912 175.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -142.74 155.39 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 115.324 1.602 . . . . 0.0 115.324 -168.329 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.84 -15.11 14.46 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.567 1.547 . . . . 0.0 112.844 169.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.476 0.85 0 C-N-CA 130.057 3.343 . . . . 0.0 109.117 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.775 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 17.2 m -78.19 77.03 4.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.713 1.205 . . . . 0.0 111.425 -168.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.259 17.3 pttm -81.13 130.49 35.05 Favored 'General case' 0 CA--C 1.547 0.85 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -174.107 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.38 172.42 12.76 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 127.744 2.417 . . . . 0.0 111.288 -176.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.511 HG11 ' HA ' ' A' ' 52' ' ' ASP . 7.0 p -148.38 146.81 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.41 1.084 . . . . 0.0 112.734 -166.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.16 96.56 2.9 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-O 122.516 1.151 . . . . 0.0 108.799 168.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 53.1 t -79.64 96.82 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 104.878 -2.267 . . . . 0.0 104.878 166.071 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.65 114.94 17.0 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 77.0 tttt -160.76 131.34 5.31 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.465 1.484 . . . . 0.0 114.747 -175.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -162.04 -35.16 0.02 OUTLIER Glycine 0 N--CA 1.474 1.204 0 C-N-CA 125.232 1.396 . . . . 0.0 111.519 168.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -77.26 58.38 1.61 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 130.98 3.712 . . . . 0.0 113.075 175.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.91 -96.39 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 C-N-CA 129.184 3.278 . . . . 0.0 115.569 169.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.94 -16.45 14.32 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.134 3.223 . . . . 0.0 113.91 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -86.37 141.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-N 119.698 1.135 . . . . 0.0 109.105 174.235 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -157.12 161.03 39.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.758 1.223 . . . . 0.0 110.629 167.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.05 99.92 0.79 Allowed Glycine 0 C--O 1.222 -0.632 0 C-N-CA 126.073 1.797 . . . . 0.0 110.694 173.419 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -87.64 93.61 4.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 118.983 1.391 . . . . 0.0 108.425 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 pp -113.88 152.73 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.96 1.362 . . . . 0.0 111.821 171.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -123.29 175.79 6.49 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.761 1.224 . . . . 0.0 110.262 175.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -140.1 139.77 35.92 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.249 1.019 . . . . 0.0 109.371 168.516 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -134.28 131.73 38.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 168.382 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -125.71 141.09 52.19 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 122.069 0.938 . . . . 0.0 109.962 174.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 6.6 mtmm -84.51 -31.16 24.62 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 125.686 1.594 . . . . 0.0 110.774 -174.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -123.28 -164.56 1.22 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 128.938 2.895 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 36.7 p -106.97 -37.17 6.41 Favored 'General case' 0 N--CA 1.472 0.674 0 O-C-N 120.719 -1.238 . . . . 0.0 110.617 166.403 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -112.79 5.07 17.36 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.391 1.476 . . . . 0.0 114.023 -175.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.46 -178.01 37.05 Favored Glycine 0 CA--C 1.54 1.649 0 CA-C-O 118.692 -1.06 . . . . 0.0 112.448 172.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.81 157.7 54.62 Favored 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 123.026 2.484 . . . . 0.0 113.552 -176.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 94.2 t -120.37 136.03 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 126.555 1.942 . . . . 0.0 110.93 -170.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.3 mptt -79.23 118.84 21.54 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.417 0.627 . . . . 0.0 111.733 169.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.3 124.92 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 125.549 1.54 . . . . 0.0 107.252 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -151.28 160.83 43.6 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 123.156 0.582 . . . . 0.0 112.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.32 175.58 13.91 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 123.846 0.736 . . . . 0.0 113.65 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 43.7 p -119.77 124.05 45.22 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 115.068 1.507 . . . . 0.0 115.068 -166.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.556 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.0 mm -90.65 123.37 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 CA-C-O 116.878 -1.534 . . . . 0.0 109.973 168.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.2 tttt -132.82 132.64 42.39 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 122.219 2.282 . . . . 0.0 111.677 175.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.75 -9.76 6.07 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 127.42 2.438 . . . . 0.0 114.293 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.426 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.7 OUTLIER -91.3 168.2 11.75 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.62 1.568 . . . . 0.0 112.535 173.332 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.8 t -77.28 166.93 22.55 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.811 0.844 . . . . 0.0 111.241 169.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -67.41 -172.84 0.25 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 125.742 1.617 . . . . 0.0 115.204 -173.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.14 -172.75 54.25 Favored Glycine 0 N--CA 1.477 1.378 0 C-N-CA 124.568 1.08 . . . . 0.0 114.009 176.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 54.2 mt -66.95 144.16 56.39 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 120.67 -1.488 . . . . 0.0 110.202 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -133.25 130.42 38.99 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.679 1.192 . . . . 0.0 109.905 170.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.99 152.01 51.2 Favored Glycine 0 N--CA 1.468 0.828 0 C-N-CA 124.644 1.116 . . . . 0.0 112.21 179.403 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.514 ' CE1' HD21 ' B' ' 117' ' ' LEU . 2.8 t80 -148.73 105.29 3.55 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 117.508 0.654 . . . . 0.0 109.979 -169.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.433 ' CD2' ' CD2' ' B' ' 63' ' ' HIS . 0.5 OUTLIER -143.84 158.3 43.78 Favored 'General case' 0 CA--C 1.54 0.57 0 O-C-N 120.538 -1.351 . . . . 0.0 109.847 -175.836 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.84 126.89 64.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 C-N-CA 126.051 1.74 . . . . 0.0 108.715 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 14.3 m-70 -77.18 116.85 18.16 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 168.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.86 162.21 29.77 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -168.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.4 t80 68.72 177.01 0.26 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 125.647 1.579 . . . . 0.0 111.879 -173.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.96 0.43 9.86 Favored Glycine 0 N--CA 1.469 0.878 0 CA-C-O 118.881 -0.955 . . . . 0.0 114.177 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.868 ' HA ' HG11 ' A' ' 5' ' ' VAL . 4.1 t0 -86.72 51.21 2.17 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.018 1.327 . . . . 0.0 108.725 -177.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 179.63 34.84 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.109 0 N-CA-C 116.186 1.921 . . . . 0.0 116.186 -166.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.44 ' H ' HG23 ' B' ' 54' ' ' THR . 5.5 p -54.12 32.52 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 131.518 3.927 . . . . 0.0 120.591 -170.678 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -142.11 -3.31 1.09 Allowed 'General case' 0 CA--C 1.558 1.252 0 C-N-CA 127.94 2.496 . . . . 0.0 113.113 168.484 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.42 -121.52 5.68 Favored Glycine 0 C--N 1.343 0.948 0 C-N-CA 124.808 1.194 . . . . 0.0 113.175 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 27.1 p -57.67 -24.47 56.88 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 -170.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.0 t -91.94 21.54 4.87 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.356 1.462 . . . . 0.0 113.48 174.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 71.2 m -151.54 -37.64 0.12 Allowed 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.802 1.641 . . . . 0.0 114.974 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.27 170.78 19.19 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 120.982 1.719 . . . . 0.0 113.954 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.61 -158.97 32.54 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 125.871 1.7 . . . . 0.0 115.985 -169.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -74.56 -174.84 1.99 Allowed 'Trans proline' 0 CA--C 1.537 0.67 1 C-N-CA 126.239 4.626 . . . . 0.0 114.35 -169.074 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.785 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -65.14 96.58 0.21 Allowed 'General case' 0 N--CA 1.445 -0.689 1 C-N-CA 132.648 4.379 . . . . 0.0 109.166 -176.651 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -56.5 146.86 23.45 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 123.953 1.835 . . . . 0.0 109.998 174.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 48.8 p-10 -107.72 57.81 0.22 Allowed Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 -176.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.57 -20.23 53.8 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.285 1.99 . . . . 0.0 111.74 169.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.0 mp -77.02 -3.88 41.31 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.925 1.29 . . . . 0.0 112.392 169.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t 57.61 87.73 0.06 Allowed 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 127.995 2.518 . . . . 0.0 113.027 174.172 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 69' ' ' ARG . . . . . 0.404 ' HD3' ' C ' ' B' ' 78' ' ' GLU . 13.0 ptp180 179.17 176.62 0.58 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -169.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -84.14 176.93 8.45 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 128.111 2.565 . . . . 0.0 107.869 166.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 12.8 t60 -57.78 174.03 0.27 Allowed 'General case' 0 CA--C 1.546 0.791 0 O-C-N 120.39 -1.443 . . . . 0.0 111.813 169.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.83 -175.31 32.18 Favored Glycine 0 N--CA 1.465 0.599 0 O-C-N 121.272 -0.893 . . . . 0.0 113.427 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 136.37 -128.24 4.44 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 117.961 -1.466 . . . . 0.0 112.316 -170.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -48.0 -11.32 0.11 Allowed 'Trans proline' 0 CA--C 1.542 0.895 1 C-N-CA 126.009 4.473 . . . . 0.0 119.793 -172.042 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.65 -5.67 5.2 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 120.759 1.618 . . . . 0.0 114.157 169.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -126.48 178.19 6.02 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 127.401 2.28 . . . . 0.0 109.819 -168.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -106.72 -20.31 13.39 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.548 1.539 . . . . 0.0 111.989 -177.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 78' ' ' GLU . . . . . 0.404 ' C ' ' HD3' ' B' ' 69' ' ' ARG . 25.9 mt-10 -78.15 -92.32 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.695 0 O-C-N 121.06 -1.025 . . . . 0.0 113.204 -167.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 54.7 ttt180 78.38 93.61 0.06 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 126.328 1.851 . . . . 0.0 113.744 169.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -51.94 160.75 0.67 Allowed 'General case' 0 N--CA 1.481 1.101 0 O-C-N 119.974 -1.704 . . . . 0.0 112.594 166.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 p -68.04 -27.97 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 CA-C-N 121.229 1.831 . . . . 0.0 111.483 176.205 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -70.8 18.26 0.82 Allowed Glycine 0 CA--C 1.538 1.491 0 CA-C-O 117.109 -1.94 . . . . 0.0 116.277 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -121.04 110.51 16.33 Favored 'General case' 0 CA--C 1.55 0.951 0 CA-C-N 121.891 2.845 . . . . 0.0 112.312 -178.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -113.08 46.17 1.27 Allowed 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 123.361 1.553 . . . . 0.0 112.289 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.93 -141.24 45.32 Favored Glycine 0 CA--C 1.536 1.347 0 CA-C-N 114.054 -1.43 . . . . 0.0 115.499 169.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -116.15 140.16 49.58 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.722 1.209 . . . . 0.0 111.021 172.331 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -91.34 172.87 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 162.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -140.53 142.96 35.15 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 120.85 -1.156 . . . . 0.0 109.796 173.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 95' ' ' ALA . . . -118.95 157.87 26.86 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.555 1.542 . . . . 0.0 113.187 -169.255 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -107.55 162.46 13.93 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 127.439 2.295 . . . . 0.0 112.543 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.768 ' HE2' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -63.66 -12.81 37.0 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.31 1.444 . . . . 0.0 114.333 173.757 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -70.45 -14.94 62.74 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-O 121.707 0.765 . . . . 0.0 109.93 171.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.16 9.23 55.98 Favored Glycine 0 C--N 1.337 0.625 0 C-N-CA 126.593 2.044 . . . . 0.0 112.848 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.2 p -110.39 138.62 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 125.164 1.385 . . . . 0.0 114.39 -178.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 89' ' ' ALA . . . -111.65 97.13 6.5 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.598 1.959 . . . . 0.0 106.284 165.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -98.74 154.61 17.85 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.677 0.751 . . . . 0.0 111.089 174.25 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -150.66 150.95 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 116.231 1.938 . . . . 0.0 116.231 -173.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 51.6 p -157.46 105.83 2.09 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 124.226 1.01 . . . . 0.0 112.276 169.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 16.3 mt -136.85 151.56 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 126.969 2.108 . . . . 0.0 111.116 -178.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -109.43 107.29 17.38 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 167.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -96.87 138.16 34.85 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 127.285 2.234 . . . . 0.0 112.97 -176.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 82.5 p -108.05 49.93 0.79 Allowed 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 66.8 t -145.35 -44.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-O 118.585 -0.721 . . . . 0.0 112.231 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.94 162.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 120.148 1.34 . . . . 0.0 111.534 170.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.54 ' H ' ' HB3' ' B' ' 111' ' ' SER . 90.2 p -157.4 149.63 22.69 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 125.678 1.591 . . . . 0.0 109.776 -175.053 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 60.01 4.22 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.436 . . . . 0.0 107.496 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.3 t -115.89 8.52 14.75 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -168.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.02 -49.65 4.01 Favored Glycine 0 N--CA 1.472 1.08 0 O-C-N 120.768 -1.207 . . . . 0.0 114.937 168.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -116.67 -58.68 2.05 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 119.074 1.437 . . . . 0.0 112.331 -170.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -83.21 5.26 23.5 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 125.433 1.493 . . . . 0.0 112.506 -171.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 111' ' ' SER . . . . . 0.54 ' HB3' ' H ' ' B' ' 105' ' ' SER . 61.3 m -158.27 -115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.08 0.952 . . . . 0.0 112.668 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 38.6 pt -112.26 169.14 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 120.493 1.497 . . . . 0.0 112.408 -178.02 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.2 mm 91.24 117.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 1 C-N-CA 132.259 4.224 . . . . 0.0 105.641 -162.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.35 12.3 72.61 Favored Glycine 0 CA--C 1.534 1.238 0 CA-C-O 117.611 -1.661 . . . . 0.0 115.502 -176.599 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.82 169.03 10.78 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.585 2.193 . . . . 0.0 109.135 169.105 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . 0.261 13.3 t -131.7 113.5 13.64 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 123.417 2.826 . . . . 0.0 114.698 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.514 HD21 ' CE1' ' B' ' 45' ' ' PHE . 22.4 tp -88.49 140.67 29.23 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.474 1.91 . . . . 0.0 110.91 -169.464 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -127.07 142.62 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 124.065 0.946 . . . . 0.0 111.301 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.31 140.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 122.322 1.058 . . . . 0.0 110.097 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -102.96 148.59 25.48 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.834 -172.247 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.262 2.9 pp20? -80.05 -7.45 58.86 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 121.028 -1.045 . . . . 0.0 113.24 -170.267 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 58.2 mttp -126.66 176.44 7.22 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.824 2.05 . . . . 0.0 110.926 168.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -59.29 148.15 33.16 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.383 1.473 . . . . 0.0 111.278 169.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -91.41 138.08 31.86 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 167.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.68 -32.25 65.67 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 177.267 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.9 mt 66.62 66.24 0.45 Allowed 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.58 1.952 . . . . 0.0 111.284 169.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 149.13 -96.65 0.17 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 123.837 0.732 . . . . 0.0 111.311 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.465 ' HA ' ' HB3' ' B' ' 134' ' ' SER . 31.4 tttt -157.49 119.61 3.78 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.876 2.07 . . . . 0.0 110.906 167.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.14 -75.68 0.62 Allowed Glycine 0 CA--C 1.527 0.834 0 C-N-CA 126.382 1.944 . . . . 0.0 109.594 168.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -154.89 -12.22 0.06 OUTLIER Glycine 0 N--CA 1.47 0.954 0 N-CA-C 116.344 1.297 . . . . 0.0 116.344 175.136 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -109.53 -141.85 0.38 Allowed 'General case' 0 CA--C 1.548 0.881 0 CA-C-N 119.317 1.558 . . . . 0.0 110.03 -167.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -117.73 -48.74 2.56 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 120.619 1.554 . . . . 0.0 111.369 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -46.62 -32.3 3.4 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.412 1.885 . . . . 0.0 112.411 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' B' ' 128' ' ' LYS . 0.4 OUTLIER -49.21 -44.35 43.22 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 127.602 2.361 . . . . 0.0 113.041 169.723 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -95.15 -34.12 12.38 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 173.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -31.81 73.09 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.782 -1.199 . . . . 0.0 113.486 176.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.517 ' HA ' ' HE2' ' B' ' 63' ' ' HIS . 82.7 p -137.03 -27.1 1.0 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 116.759 -1.591 . . . . 0.0 114.612 -173.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.19 -2.79 31.31 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.668 1.127 . . . . 0.0 113.861 -168.331 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 12.9 t-20 55.89 9.96 0.51 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 126.279 1.831 . . . . 0.0 113.179 -169.219 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.36 24.96 0.02 OUTLIER 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 127.938 2.495 . . . . 0.0 116.826 -167.05 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.16 -139.17 19.52 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 126.555 2.026 . . . . 0.0 113.905 178.643 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.4 t -80.93 -148.16 0.06 Allowed 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.979 1.712 . . . . 0.0 109.6 168.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -140.71 155.81 46.37 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 120.353 -1.467 . . . . 0.0 110.098 172.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.501 HD12 ' H ' ' B' ' 145' ' ' ALA . 0.7 OUTLIER -109.72 -129.9 0.3 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 165.935 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.501 ' H ' HD12 ' B' ' 144' ' ' LEU . . . -61.68 144.97 53.73 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.552 1.541 . . . . 0.0 113.823 -170.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.8 p -138.42 151.32 47.35 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 126.194 1.797 . . . . 0.0 113.135 176.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.0 139.53 6.02 Favored Glycine 0 N--CA 1.471 0.997 0 O-C-N 120.989 -1.069 . . . . 0.0 114.239 -176.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.4 t -77.98 145.96 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.045 0.938 . . . . 0.0 109.605 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 54.6 mt -81.36 90.47 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.293 1.037 . . . . 0.0 109.781 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.18 -171.45 45.55 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 126.39 1.948 . . . . 0.0 111.952 171.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.48 ' H ' HD12 ' B' ' 151' ' ' ILE . 0.8 OUTLIER -127.58 124.46 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 115.737 1.755 . . . . 0.0 115.737 -167.641 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.19 0.08 47.01 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.965 2.106 . . . . 0.0 112.593 167.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 131.019 3.728 . . . . 0.0 115.692 -169.314 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 118.735 -0.65 . . . . 0.0 111.603 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.4 p -76.06 42.53 0.26 Allowed 'General case' 0 C--N 1.346 0.451 0 C-N-CA 128.958 2.903 . . . . 0.0 117.725 -164.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -165.43 101.94 0.72 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.783 1.633 . . . . 0.0 108.855 168.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.501 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -75.3 176.05 7.78 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 119.864 1.211 . . . . 0.0 111.482 173.446 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.654 HG21 ' HA ' ' B' ' 52' ' ' ASP . 1.4 p -153.63 117.49 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 127.225 2.21 . . . . 0.0 106.897 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.24 107.29 18.29 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.349 1.06 . . . . 0.0 109.74 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.0 t -76.09 79.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.226 1.01 . . . . 0.0 108.406 174.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -76.99 92.41 3.7 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 173.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 ttpp -157.91 119.68 3.64 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.897 0.879 . . . . 0.0 110.814 171.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.57 -102.28 0.54 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 106.663 -2.575 . . . . 0.0 106.663 166.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.98 109.86 5.07 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 125.938 1.695 . . . . 0.0 107.282 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.38 177.03 14.69 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 123.844 0.735 . . . . 0.0 114.209 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -68.37 20.76 0.13 Allowed 'Trans proline' 0 CA--C 1.542 0.89 1 C-N-CA 126.15 4.567 . . . . 0.0 116.696 -169.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 144' ' ' LEU . 1.4 t -128.34 128.46 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 CA-C-N 120.447 1.476 . . . . 0.0 109.508 -174.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -144.19 172.74 12.49 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.829 0.823 . . . . 0.0 112.657 -176.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.16 165.79 31.36 Favored Glycine 0 CA--C 1.509 -0.282 0 CA-C-N 112.828 -1.987 . . . . 0.0 112.947 167.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.469 HG13 ' H ' ' A' ' 34' ' ' SER . 7.8 pt -139.83 52.98 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 113.22 -1.49 . . . . 0.0 112.024 -167.007 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -80.47 105.7 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 O-C-N 120.418 -1.426 . . . . 0.0 111.079 -169.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -83.0 156.28 23.5 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.506 1.522 . . . . 0.0 110.613 173.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.501 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 66.1 m-85 -143.43 97.92 3.16 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.462 1.505 . . . . 0.0 109.677 175.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.72 136.32 37.38 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 119.884 -1.76 . . . . 0.0 107.202 173.393 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -152.91 -175.81 5.48 Favored 'General case' 0 CA--C 1.553 1.075 0 C-N-CA 127.78 2.432 . . . . 0.0 105.887 176.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.52 -15.29 0.49 Allowed 'General case' 0 CA--C 1.549 0.94 0 O-C-N 118.452 -2.655 . . . . 0.0 116.225 167.144 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -108.76 -174.27 2.47 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 127.869 2.468 . . . . 0.0 111.346 -174.095 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.3 p -81.33 -21.89 38.86 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 120.528 -1.358 . . . . 0.0 112.888 167.461 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -161.67 46.38 0.18 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.629 1.171 . . . . 0.0 113.399 -168.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.73 175.69 16.04 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 125.243 1.401 . . . . 0.0 110.637 169.429 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -74.67 157.95 43.78 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.032 1.821 . . . . 0.0 111.511 -169.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.5 t -131.3 149.4 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 125.097 1.359 . . . . 0.0 111.482 -167.202 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -116.51 103.74 10.72 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 123.641 0.776 . . . . 0.0 110.575 -175.175 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.5 t -80.22 119.85 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 126.834 2.054 . . . . 0.0 107.63 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 1.7 p90 -153.9 167.87 28.25 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.0 -155.75 15.93 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -170.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.469 ' H ' HG13 ' A' ' 17' ' ' ILE . 63.8 p -155.96 170.5 21.99 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 122.029 0.918 . . . . 0.0 113.345 -169.368 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.68 134.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 126.497 1.919 . . . . 0.0 107.256 169.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.18 150.23 33.39 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 121.63 2.013 . . . . 0.0 113.913 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.27 5.08 46.78 Favored Glycine 0 CA--C 1.539 1.581 0 C-N-CA 126.437 1.97 . . . . 0.0 112.285 -168.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -71.86 163.89 27.02 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.906 2.082 . . . . 0.0 111.055 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.5 t -81.32 155.81 25.83 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 164.313 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 74.7 tt0 -53.03 145.22 13.46 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.37 1.068 . . . . 0.0 111.349 169.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.09 -175.3 26.0 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 124.787 1.184 . . . . 0.0 114.146 -177.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -76.12 146.96 38.9 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 128.321 2.648 . . . . 0.0 114.464 -169.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -148.11 123.89 10.56 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.193 2.597 . . . . 0.0 109.911 -174.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.56 155.87 51.55 Favored Glycine 0 N--CA 1.479 1.512 0 CA-C-O 118.028 -1.429 . . . . 0.0 113.169 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.79 139.91 16.49 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 119.957 1.879 . . . . 0.0 114.375 172.285 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.415 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 9.0 p-80 -153.34 153.8 33.29 Favored 'General case' 0 CA--C 1.547 0.862 0 O-C-N 121.5 -0.75 . . . . 0.0 111.936 -179.594 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -98.36 112.44 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 123.946 0.899 . . . . 0.0 109.119 174.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -82.43 149.78 27.44 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 174.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -66.84 10.74 0.12 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 126.329 1.851 . . . . 0.0 114.304 -178.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -119.55 97.54 5.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 106.949 -1.501 . . . . 0.0 106.949 -169.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.24 -10.36 74.04 Favored Glycine 0 C--N 1.331 0.291 0 CA-C-O 117.885 -1.508 . . . . 0.0 111.17 166.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.595 ' HA ' HG21 ' B' ' 5' ' ' VAL . 12.8 t0 -73.7 123.25 23.73 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 104.381 -2.451 . . . . 0.0 104.381 164.166 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.487 ' H ' HG23 ' A' ' 54' ' ' THR 0.312 5.7 p-10 -147.35 51.09 1.07 Allowed 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 123.782 1.753 . . . . 0.0 112.724 168.486 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.487 HG23 ' H ' ' A' ' 53' ' ' ASN . 11.4 p -120.29 -23.89 6.08 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 112.173 -2.285 . . . . 0.0 112.755 -164.442 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -95.95 22.79 7.01 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.887 0.875 . . . . 0.0 111.603 168.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.76 -123.24 21.8 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 125.537 1.541 . . . . 0.0 111.913 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.7 p -67.49 -12.7 60.95 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 113.868 1.062 . . . . 0.0 113.868 173.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.69 39.24 0.61 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.412 1.485 . . . . 0.0 110.878 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 172.09 -55.37 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.39 2.276 . . . . 0.0 111.596 -169.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -97.54 153.39 18.2 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.73 -31.38 8.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 116.424 -2.32 . . . . 0.0 117.44 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -103.34 163.38 0.25 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 CA-C-N 122.124 2.962 . . . . 0.0 111.523 171.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.447 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.1 OUTLIER -137.24 107.78 6.53 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.558 1.143 . . . . 0.0 112.4 -166.678 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -58.97 154.66 14.93 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 114.141 -1.391 . . . . 0.0 111.998 169.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -119.7 77.68 21.29 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 127.712 2.405 . . . . 0.0 113.713 -170.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -63.64 -20.34 69.02 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.998 2.466 . . . . 0.0 113.445 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 53.6 mt -82.81 -2.49 54.7 Favored 'General case' 0 CA--C 1.543 0.685 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 170.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t 62.77 59.29 1.44 Allowed 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.611 1.564 . . . . 0.0 113.343 175.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.0 ptt180 -161.54 178.44 9.08 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -174.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.88 164.4 23.83 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 127.032 2.133 . . . . 0.0 110.006 173.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -62.88 168.23 4.08 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.735 0.814 . . . . 0.0 110.874 167.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 140.69 -156.0 25.12 Favored Glycine 0 N--CA 1.464 0.528 0 CA-C-O 119.11 -0.828 . . . . 0.0 113.808 171.198 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 -64.51 0.53 Allowed Glycine 0 CA--C 1.542 1.728 0 N-CA-C 117.924 1.93 . . . . 0.0 117.924 176.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -69.47 -19.46 37.47 Favored 'Trans proline' 0 C--N 1.349 0.6 0 CA-C-N 121.197 2.499 . . . . 0.0 114.722 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -134.66 -3.53 2.61 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 124.057 0.943 . . . . 0.0 112.758 179.319 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.56 147.81 50.73 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 128.344 2.658 . . . . 0.0 107.867 -173.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.427 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 0.0 OUTLIER -100.66 -11.99 19.55 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 130.77 3.628 . . . . 0.0 112.67 -167.631 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -81.47 -94.04 0.05 OUTLIER 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.996 1.718 . . . . 0.0 106.992 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.615 HH12 HG11 ' A' ' 103' ' ' VAL . 47.5 ttt180 80.02 121.1 0.05 OUTLIER 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.539 1.536 . . . . 0.0 111.617 168.597 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -71.52 140.77 50.06 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 120.899 -1.126 . . . . 0.0 108.946 165.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -50.88 -28.81 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.57 8.78 79.13 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 119.362 0.983 . . . . 0.0 115.537 175.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -88.84 129.95 35.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 120.103 1.951 . . . . 0.0 112.028 -175.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.99 -179.7 4.02 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 128.288 2.635 . . . . 0.0 107.518 170.159 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -92.39 -120.19 2.7 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 122.761 1.201 . . . . 0.0 114.032 -172.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -140.58 152.96 45.89 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.887 1.275 . . . . 0.0 110.777 169.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -116.01 137.1 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 127.581 2.352 . . . . 0.0 109.894 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -102.93 132.24 49.3 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 119.322 0.964 . . . . 0.0 108.797 169.47 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.75 144.36 27.81 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-O 120.881 0.372 . . . . 0.0 111.068 168.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -60.7 169.88 1.67 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 126.077 1.751 . . . . 0.0 111.753 170.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.32 -15.16 9.26 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.204 1.402 . . . . 0.0 114.143 168.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.05 3.17 55.15 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 125.894 1.678 . . . . 0.0 114.026 169.534 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.9 13.87 76.64 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 120.082 -1.637 . . . . 0.0 115.287 169.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.44 134.72 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 125.846 1.659 . . . . 0.0 112.875 171.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.59 112.12 25.08 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 165.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -104.81 139.42 39.6 Favored 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 124.694 1.198 . . . . 0.0 109.568 -177.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.3 t -137.27 140.28 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 114.962 1.467 . . . . 0.0 114.962 -166.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 89.3 p -154.76 104.39 2.51 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.995 1.318 . . . . 0.0 111.73 173.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.0 mt -136.85 141.84 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.784 2.034 . . . . 0.0 110.431 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -110.22 134.93 51.73 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 166.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -139.03 140.54 38.15 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 125.919 1.687 . . . . 0.0 111.648 -167.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 13.3 p -121.4 52.04 1.25 Allowed 'General case' 0 CA--C 1.543 0.699 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 177.137 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.615 HG11 HH12 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -147.03 1.81 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -177.469 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.11 176.07 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.858 1.663 . . . . 0.0 110.206 169.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.653 ' H ' ' HB3' ' A' ' 111' ' ' SER . 90.4 p -154.84 164.28 39.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 126.647 1.979 . . . . 0.0 112.066 171.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.9 mp -78.58 67.85 4.43 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.17 2.188 . . . . 0.0 108.534 177.214 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -128.23 -5.8 5.44 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 -168.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.68 -24.88 3.57 Favored Glycine 0 N--CA 1.472 1.046 0 CA-C-N 120.492 1.496 . . . . 0.0 116.427 169.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -94.22 -100.82 0.15 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 126.286 1.834 . . . . 0.0 107.711 -169.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -83.67 2.27 38.42 Favored 'General case' 0 C--N 1.323 -0.568 0 O-C-N 120.009 -1.682 . . . . 0.0 112.321 -174.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.653 ' HB3' ' H ' ' A' ' 105' ' ' SER . 39.4 m -125.11 -120.08 0.27 Allowed 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 115.864 1.801 . . . . 0.0 115.864 -169.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 42.2 pt -125.05 172.41 12.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 O-C-N 119.953 -1.717 . . . . 0.0 109.027 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.424 HD11 HG23 ' A' ' 151' ' ' ILE . 3.1 mm 76.68 147.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 128.657 2.783 . . . . 0.0 105.951 -162.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.48 -51.6 4.23 Favored Glycine 0 C--O 1.222 -0.626 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.62 -177.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 40.2 mtt180 -71.41 178.33 3.49 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 127.541 2.336 . . . . 0.0 110.191 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.9 m -138.91 124.99 20.02 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.862 0.865 . . . . 0.0 111.609 -169.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 47.4 tp -92.24 115.1 27.79 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 125.367 1.467 . . . . 0.0 110.103 178.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 15.0 p -102.45 140.36 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 124.597 1.159 . . . . 0.0 109.549 171.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -113.86 142.91 24.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.977 1.711 . . . . 0.0 107.681 171.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -118.72 148.2 43.02 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.91 2.084 . . . . 0.0 111.105 -168.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -74.6 -20.16 60.03 Favored 'General case' 0 CA--C 1.541 0.624 0 O-C-N 120.518 -1.364 . . . . 0.0 114.67 -168.29 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -125.38 171.19 10.65 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 119.82 -1.8 . . . . 0.0 112.283 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.2 139.9 51.25 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 124.714 1.205 . . . . 0.0 111.951 -175.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -87.76 136.83 32.79 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 123.869 0.867 . . . . 0.0 109.747 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.85 -37.23 76.06 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.726 1.211 . . . . 0.0 110.102 173.074 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 63.16 69.81 0.56 Allowed 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 124.999 1.32 . . . . 0.0 108.399 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.31 -109.87 0.42 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 117.055 1.582 . . . . 0.0 117.055 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.16 36.06 0.14 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 128.545 2.738 . . . . 0.0 111.754 -167.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -48.9 -31.39 10.24 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.482 1.991 . . . . 0.0 117.976 -168.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 167.35 2.78 0.03 OUTLIER Glycine 0 N--CA 1.476 1.322 0 N-CA-C 118.249 2.06 . . . . 0.0 118.249 178.042 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -146.22 -170.43 3.49 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 119.088 1.444 . . . . 0.0 111.747 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -70.58 -56.91 5.41 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.411 1.085 . . . . 0.0 109.57 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.496 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 1.2 mp0 -57.42 -28.12 62.99 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.876 1.67 . . . . 0.0 111.675 -174.268 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 42.8 m -46.25 -37.66 7.52 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 126.124 1.769 . . . . 0.0 112.789 171.465 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -111.92 -33.88 6.16 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -66.81 -24.22 66.15 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.0 0.92 . . . . 0.0 113.076 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.447 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 27.7 p -130.36 -32.68 1.74 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.885 1.674 . . . . 0.0 114.673 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.29 10.0 40.2 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -163.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 63.85 11.7 6.17 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.981 2.112 . . . . 0.0 114.483 177.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.0 19.07 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 117.326 2.343 . . . . 0.0 117.326 -167.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.76 -43.48 2.16 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 128.473 2.94 . . . . 0.0 115.266 168.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.5 t -168.69 169.34 10.17 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 118.512 1.156 . . . . 0.0 113.901 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.7 ptt-85 -71.5 158.96 35.33 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.168 1.387 . . . . 0.0 111.01 168.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.63 HD11 HG11 ' A' ' 14' ' ' VAL . 2.1 tm? -142.09 -103.31 0.14 Allowed 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 169.113 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.416 ' N ' HD13 ' A' ' 144' ' ' LEU . . . -103.68 160.46 14.74 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.248 1.019 . . . . 0.0 111.471 172.146 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.7 p -142.35 140.43 32.09 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.165 2.186 . . . . 0.0 108.898 -177.637 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.25 135.64 4.62 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 118.048 1.979 . . . . 0.0 118.048 -175.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -75.02 139.52 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.513 1.125 . . . . 0.0 109.416 -178.612 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.9 mm -87.88 107.55 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 122.572 0.349 . . . . 0.0 110.919 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.71 -171.79 14.15 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.71 1.148 . . . . 0.0 113.23 173.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.2 pp -133.01 129.49 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 N-CA-C 114.989 1.477 . . . . 0.0 114.989 -173.493 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.5 -161.64 0.89 Allowed 'General case' 0 CA--C 1.545 0.75 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 165.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 . . . . . 0 N--CA 1.475 0.804 0 C-N-CA 131.6 3.96 . . . . 0.0 108.565 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.415 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -86.84 108.72 18.88 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 172.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttmm -97.16 123.34 40.9 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.024 -173.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -93.63 175.65 6.66 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.634 1.346 . . . . 0.0 114.634 179.057 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.595 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -155.92 103.65 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 128.621 2.769 . . . . 0.0 106.427 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.13 122.06 24.46 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.533 -0.729 . . . . 0.0 109.746 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.408 ' HA ' HG22 ' A' ' 54' ' ' THR . 22.8 t -88.49 63.14 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 124.171 0.988 . . . . 0.0 108.802 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.465 ' HA ' ' HA3' ' B' ' 147' ' ' GLY 0.335 1.3 pt? -82.85 79.04 9.35 Favored 'General case' 0 N--CA 1.477 0.907 0 O-C-N 121.272 -0.892 . . . . 0.0 113.075 -171.824 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 tttm -117.47 129.76 56.02 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 -173.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.12 158.08 19.01 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 165.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -72.1 92.45 1.33 Allowed 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 128.637 2.775 . . . . 0.0 109.246 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.19 -153.61 21.95 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 127.102 2.286 . . . . 0.0 111.474 -176.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -86.1 7.66 4.88 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 125.0 3.8 . . . . 0.0 114.249 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -105.62 108.92 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 C-N-CA 125.146 1.378 . . . . 0.0 108.509 -177.253 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -159.7 166.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.668 1.187 . . . . 0.0 111.421 176.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.46 178.25 29.75 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 124.205 0.907 . . . . 0.0 113.862 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.434 HG13 ' H ' ' B' ' 34' ' ' SER . 3.0 pt -123.8 137.33 57.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 128.449 2.699 . . . . 0.0 109.726 171.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mm -136.98 113.12 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.534 1.061 . . . . 0.0 109.457 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -113.24 108.65 17.56 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.757 1.623 . . . . 0.0 112.501 -164.1 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.433 ' H ' ' HB3' ' B' ' 4' ' ' ALA . 30.4 m-85 -92.44 104.01 16.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.539 1.935 . . . . 0.0 110.281 -176.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -84.25 103.28 13.31 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.6 1.56 . . . . 0.0 110.781 172.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLN . . . . . 0.46 HE22 ' CB ' ' B' ' 105' ' ' SER . 3.1 tt0 -97.69 119.09 35.64 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 121.814 0.816 . . . . 0.0 110.931 173.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -64.13 -42.85 96.66 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.09 1.756 . . . . 0.0 113.268 175.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -157.17 155.37 30.83 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 126.016 1.726 . . . . 0.0 111.596 168.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.7 p -45.05 -3.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 1 C-N-CA 131.739 4.016 . . . . 0.0 118.567 -171.235 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -157.72 20.9 0.27 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.661 1.985 . . . . 0.0 111.444 -168.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.24 173.67 15.64 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.312 1.91 . . . . 0.0 112.563 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -67.03 168.67 16.72 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.578 2.852 . . . . 0.0 111.401 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -138.88 133.5 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 122.744 0.418 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.8 mttp -92.41 124.22 36.3 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.28 0.562 . . . . 0.0 109.832 169.167 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.5 t -120.56 86.58 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 127.995 2.518 . . . . 0.0 108.472 -170.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -110.07 168.7 9.24 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 121.2 -0.938 . . . . 0.0 112.281 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.46 -159.5 28.44 Favored Glycine 0 N--CA 1.462 0.432 0 O-C-N 120.973 -1.079 . . . . 0.0 111.869 174.304 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' SER . . . . . 0.434 ' H ' HG13 ' B' ' 17' ' ' ILE . 79.8 p -156.33 154.1 30.05 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -176.092 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.25 124.77 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.122 0.969 . . . . 0.0 109.997 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -119.39 146.58 45.23 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.841 1.257 . . . . 0.0 109.652 -178.048 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.38 10.66 38.16 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 124.916 1.246 . . . . 0.0 113.469 -169.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 76.8 mt -84.98 167.16 16.12 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.105 1.362 . . . . 0.0 111.651 168.444 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -94.78 156.5 16.35 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 164.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -59.98 148.62 34.69 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 123.727 0.811 . . . . 0.0 112.27 -177.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.67 -178.54 33.85 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 124.234 0.921 . . . . 0.0 113.506 -175.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -60.7 144.92 51.14 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 127.648 2.379 . . . . 0.0 114.013 -173.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -145.65 127.88 15.75 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 127.692 2.397 . . . . 0.0 109.985 175.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.26 158.09 52.35 Favored Glycine 0 N--CA 1.474 1.175 0 CA-C-N 119.239 0.927 . . . . 0.0 112.156 173.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -158.37 139.8 13.46 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.201 2.2 . . . . 0.0 112.061 166.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 19.1 p-80 -149.83 146.53 27.19 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 120.905 -1.122 . . . . 0.0 111.825 -176.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -91.4 138.51 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 124.568 1.147 . . . . 0.0 109.175 178.01 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -105.83 153.04 22.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 110.079 -178.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 49' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' B' ' 115' ' ' ARG . 24.0 tt0 -67.68 12.04 0.12 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.732 1.151 . . . . 0.0 113.479 178.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -140.59 125.04 17.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 O-C-N 120.031 -1.668 . . . . 0.0 108.932 -168.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.56 -3.18 61.96 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 124.616 1.103 . . . . 0.0 114.33 170.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.654 ' HA ' HG21 ' A' ' 5' ' ' VAL . 28.0 t0 -75.5 123.09 24.87 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 118.135 0.968 . . . . 0.0 109.93 -169.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.87 20.48 3.83 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 114.787 1.402 . . . . 0.0 114.787 164.452 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.311 14.9 t -127.04 -21.41 3.98 Favored 'General case' 0 C--N 1.324 -0.543 0 C-N-CA 123.227 0.611 . . . . 0.0 112.004 -166.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.2 9.43 3.78 Favored 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 122.206 1.003 . . . . 0.0 110.313 162.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 55.21 -105.17 0.35 Allowed Glycine 0 C--N 1.341 0.857 0 C-N-CA 127.406 2.431 . . . . 0.0 113.528 168.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.2 m -72.09 -11.06 60.58 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -111.95 28.24 8.93 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.676 1.19 . . . . 0.0 111.729 168.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.3 p -120.99 -161.3 0.89 Allowed 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.847 1.659 . . . . 0.0 112.734 175.08 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 62.79 -82.92 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 128.824 2.85 . . . . 0.0 112.803 -175.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.39 176.78 47.51 Favored Glycine 0 CA--C 1.545 1.947 0 C-N-CA 125.094 1.33 . . . . 0.0 114.582 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -102.42 179.46 0.15 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 124.722 3.614 . . . . 0.0 113.576 -177.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.646 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -72.75 74.7 1.12 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.649 3.18 . . . . 0.0 111.985 172.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -30.21 132.96 0.07 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 129.137 2.975 . . . . 0.0 115.312 169.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -122.86 59.27 12.9 Favored Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -172.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -62.85 -16.69 55.3 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 122.755 2.303 . . . . 0.0 113.911 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.81 -5.76 54.24 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.034 1.334 . . . . 0.0 113.324 169.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t 65.16 50.27 1.85 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 127.966 2.507 . . . . 0.0 112.885 178.29 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.6 mtp180 -118.02 176.21 5.31 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 124.94 1.296 . . . . 0.0 112.86 -172.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.3 mptm? -95.41 175.93 6.38 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.698 2.399 . . . . 0.0 109.441 164.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -62.7 157.75 20.19 Favored 'General case' 0 CA--C 1.539 0.531 0 O-C-N 120.918 -1.114 . . . . 0.0 111.009 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' B' ' 79' ' ' ARG . . . -176.52 -175.79 44.15 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 114.914 0.726 . . . . 0.0 114.914 174.51 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.65 -120.89 0.98 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 125.27 1.414 . . . . 0.0 113.988 169.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -62.52 -16.35 51.64 Favored 'Trans proline' 0 CA--C 1.54 0.793 0 C-N-CA 123.855 3.037 . . . . 0.0 115.259 -173.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.75 -4.15 19.7 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.578 1.151 . . . . 0.0 112.988 169.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -159.15 110.47 2.08 Favored 'General case' 0 CA--C 1.543 0.706 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 -167.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -40.88 -10.7 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 131.241 3.816 . . . . 0.0 116.76 168.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.69 -77.44 0.09 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 120.067 1.303 . . . . 0.0 109.315 -177.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.402 ' H ' ' HA3' ' B' ' 72' ' ' GLY . 15.2 ttp-105 56.53 77.25 0.26 Allowed 'General case' 0 N--CA 1.475 0.818 0 O-C-N 120.79 -1.194 . . . . 0.0 113.141 164.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.3 m170 -48.32 164.46 0.05 Allowed 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.709 -1.244 . . . . 0.0 114.019 172.134 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.85 -14.16 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.23 13.59 31.03 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.957 1.742 . . . . 0.0 116.75 176.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -100.81 103.86 15.09 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 120.801 2.3 . . . . 0.0 113.414 -171.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 42.9 mt -96.64 41.22 1.11 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.528 -1.358 . . . . 0.0 112.417 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.12 -129.74 43.14 Favored Glycine 0 CA--C 1.537 1.412 0 O-C-N 119.713 -1.867 . . . . 0.0 112.361 -174.214 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -147.98 161.01 42.21 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.877 0.871 . . . . 0.0 112.142 175.383 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.4 124.07 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 127.778 2.431 . . . . 0.0 110.906 -172.289 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.2 m -95.78 129.86 42.88 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.386 0.674 . . . . 0.0 109.666 174.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.32 148.47 25.05 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.56 162.53 15.62 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 128.677 2.791 . . . . 0.0 110.01 169.058 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -40.79 -21.23 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 129.421 3.088 . . . . 0.0 117.609 177.048 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -75.73 0.16 18.82 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.54 -1.35 . . . . 0.0 112.166 171.577 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.51 24.41 76.83 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 125.895 1.712 . . . . 0.0 112.602 -170.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.2 p -116.8 128.14 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 CA-C-N 118.785 1.293 . . . . 0.0 113.156 -177.244 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.1 117.05 29.62 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 166.117 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -98.25 130.93 44.95 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 123.793 0.837 . . . . 0.0 109.009 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.69 143.0 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 117.011 2.226 . . . . 0.0 117.011 -174.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 77.8 p -143.94 82.36 1.71 Allowed 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 126.352 1.861 . . . . 0.0 111.533 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.8 mt -97.69 157.61 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 120.594 -1.316 . . . . 0.0 110.071 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -144.69 145.59 31.8 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 127.642 2.377 . . . . 0.0 107.463 168.143 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.34 159.95 40.34 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.836 1.255 . . . . 0.0 111.336 173.206 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 35.7 p -127.37 46.08 2.6 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.472 1.509 . . . . 0.0 112.955 -168.163 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 23.1 m -145.87 15.12 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.226 1.011 . . . . 0.0 113.574 -176.075 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -148.78 165.99 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.107 2.163 . . . . 0.0 109.386 -173.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.46 ' CB ' HE22 ' B' ' 22' ' ' GLN . 18.1 m -157.39 168.0 28.63 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 125.066 1.346 . . . . 0.0 109.983 175.006 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 106' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' B' ' 22' ' ' GLN . 1.1 mm? -98.73 80.03 2.5 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.99 1.716 . . . . 0.0 107.723 -171.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -122.14 -18.91 6.74 Favored 'General case' 0 CA--C 1.567 1.628 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -175.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.06 0.71 89.26 Favored Glycine 0 N--CA 1.492 2.408 0 O-C-N 118.554 -2.591 . . . . 0.0 117.778 166.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.66 -88.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.918 2.487 . . . . 0.0 108.569 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 86.8 m-70 -115.15 -9.06 12.34 Favored 'General case' 0 CA--C 1.559 1.299 1 C-N-CA 132.715 4.406 . . . . 0.0 111.113 168.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 48.8 m -82.46 -166.05 1.18 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.63 1.972 . . . . 0.0 110.992 -174.188 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.452 HG22 ' H ' ' B' ' 113' ' ' ILE . 8.2 mm -71.28 162.3 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.834 0 O-C-N 118.603 -2.56 . . . . 0.0 108.637 169.151 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 113' ' ' ILE . . . . . 0.452 ' H ' HG22 ' B' ' 112' ' ' ILE . 1.4 mm 97.29 132.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.278 1 C-N-CA 133.75 4.82 . . . . 0.0 108.291 -168.632 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.22 5.51 34.88 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-O 117.565 -1.686 . . . . 0.0 115.815 176.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 115' ' ' ARG . . . . . 0.458 ' HD2' ' HA ' ' B' ' 49' ' ' GLU . 62.2 mmt-85 -77.61 -177.08 4.6 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 127.138 2.175 . . . . 0.0 110.797 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 39.5 m -128.26 141.12 51.55 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 116.446 -1.74 . . . . 0.0 109.945 173.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.7 tp -113.19 111.22 21.71 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.846 1.259 . . . . 0.0 111.208 171.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.9 p -88.56 149.33 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 124.264 1.026 . . . . 0.0 109.563 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 33.2 t -121.77 142.23 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 168.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -99.26 136.85 38.61 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.324 2.25 . . . . 0.0 111.379 -173.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -75.97 -10.86 59.77 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 120.419 -1.426 . . . . 0.0 113.796 -171.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 50.8 mttp -114.95 172.95 6.74 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 126.26 1.824 . . . . 0.0 111.959 169.204 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.99 163.59 1.94 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.809 1.244 . . . . 0.0 112.188 169.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -121.03 135.07 55.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 127.299 2.24 . . . . 0.0 107.209 175.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -73.03 -33.24 65.6 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 118.223 0.465 . . . . 0.0 112.216 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 29.3 mt 69.19 50.39 0.57 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.872 1.669 . . . . 0.0 114.223 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.21 -26.83 8.47 Favored Glycine 0 N--CA 1.474 1.211 0 N-CA-C 119.924 2.73 . . . . 0.0 119.924 163.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 8.4 pttm -163.93 99.41 0.87 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 120.1 1.95 . . . . 0.0 114.826 176.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.69 -7.71 56.45 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.938 1.732 . . . . 0.0 114.042 170.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 101.11 -8.64 57.54 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 125.497 1.522 . . . . 0.0 113.736 -170.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 p-10 -117.98 153.21 34.04 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 128.443 2.697 . . . . 0.0 109.611 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -66.41 -48.67 69.33 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 114.108 1.151 . . . . 0.0 114.108 -167.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.08 -33.1 72.81 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.837 1.255 . . . . 0.0 111.943 -175.395 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 61.8 m -53.45 -31.23 44.54 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 119.724 1.147 . . . . 0.0 112.574 168.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 1.1 p -85.03 -46.99 10.66 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.94 1.296 . . . . 0.0 112.513 172.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -70.49 -35.63 73.36 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.807 1.243 . . . . 0.0 113.523 -173.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 37.1 p -135.1 -28.78 1.15 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.265 1.426 . . . . 0.0 113.471 -175.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 108.95 0.54 31.83 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 118.44 -1.2 . . . . 0.0 113.538 -171.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 66.9 -4.39 0.79 Allowed 'General case' 0 N--CA 1.482 1.14 0 CA-C-N 119.492 1.646 . . . . 0.0 113.78 175.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -46.88 5.11 0.0 OUTLIER 'General case' 0 CA--C 1.565 1.545 1 C-N-CA 132.551 4.34 . . . . 0.0 121.497 -165.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.11 -69.9 3.21 Favored Glycine 0 CA--C 1.526 0.735 0 O-C-N 120.083 -1.636 . . . . 0.0 115.288 168.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.4 t -164.71 -152.4 0.17 Allowed 'General case' 0 N--CA 1.477 0.92 0 O-C-N 121.253 -1.145 . . . . 0.0 112.157 -171.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.65 148.87 29.81 Favored 'General case' 0 N--CA 1.47 0.557 0 O-C-N 120.427 -1.421 . . . . 0.0 113.991 176.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.402 ' CG ' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -97.85 -101.45 0.2 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.095 1.758 . . . . 0.0 110.099 169.54 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.402 ' H ' ' CG ' ' B' ' 144' ' ' LEU . . . -91.3 166.73 12.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.986 1.714 . . . . 0.0 111.05 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -157.08 143.19 17.91 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 127.181 2.192 . . . . 0.0 108.545 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 147' ' ' GLY . . . . . 0.465 ' HA3' ' HA ' ' B' ' 8' ' ' LEU . . . -164.76 171.08 40.1 Favored Glycine 0 N--CA 1.47 0.937 0 N-CA-C 117.354 1.702 . . . . 0.0 117.354 169.77 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -84.85 146.72 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.106 2.163 . . . . 0.0 110.577 -169.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 46.6 mm -86.43 103.09 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 125.649 1.58 . . . . 0.0 111.35 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.82 175.82 22.57 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.737 1.637 . . . . 0.0 113.134 171.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.455 ' HA ' ' HA ' ' B' ' 4' ' ' ALA 0.296 1.3 pp -114.78 139.21 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 177.762 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.4 159.66 30.27 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-O 122.951 1.358 . . . . 0.0 108.457 172.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 113.966 -1.47 . . . . 0.0 110.098 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.529 -0.748 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.5 p -75.76 109.97 9.79 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 128.501 2.721 . . . . 0.0 108.888 -171.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptpp? -105.25 135.87 45.81 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -87.18 161.83 17.83 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 164.247 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 t -145.1 149.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 CA-C-N 119.705 1.139 . . . . 0.0 110.045 173.612 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.16 109.16 12.53 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.452 1.501 . . . . 0.0 108.187 166.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -82.61 112.07 19.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 168.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -79.36 99.35 7.1 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -156.13 127.18 6.97 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.586 0.754 . . . . 0.0 111.904 177.275 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.67 -104.81 1.28 Allowed Glycine 0 CA--C 1.527 0.821 0 N-CA-C 105.277 -3.129 . . . . 0.0 105.277 164.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -156.33 129.64 8.13 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.628 1.571 . . . . 0.0 108.352 167.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 124.22 168.87 12.98 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.61 2.052 . . . . 0.0 110.519 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 23.27 0.19 Allowed 'Trans proline' 0 CA--C 1.546 1.089 1 C-N-CA 125.745 4.297 . . . . 0.0 116.39 -169.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -117.26 111.87 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -157.27 158.24 35.74 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.324 -174.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.68 179.18 37.23 Favored Glycine 0 CA--C 1.508 -0.371 0 C-N-CA 126.129 1.823 . . . . 0.0 113.494 176.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -134.04 142.02 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.295 1.438 . . . . 0.0 109.054 168.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.0 mm -133.23 111.23 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 168.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -77.68 150.49 34.51 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.075 1.75 . . . . 0.0 110.934 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -135.43 78.52 1.73 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.765 2.026 . . . . 0.0 108.542 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -81.74 117.64 22.21 Favored 'General case' 0 C--N 1.34 0.182 0 CA-C-O 121.863 0.839 . . . . 0.0 113.157 -177.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp60 -105.57 167.68 9.6 Favored 'General case' 0 CA--C 1.549 0.942 0 CA-C-O 122.951 1.358 . . . . 0.0 109.424 169.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.89 -28.09 1.6 Allowed 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 130.088 3.355 . . . . 0.0 111.725 -177.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -101.97 -132.13 0.27 Allowed 'General case' 0 CA--C 1.556 1.201 0 C-N-CA 124.621 1.168 . . . . 0.0 108.497 166.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 t -136.37 -82.04 0.39 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 120.249 -1.532 . . . . 0.0 107.681 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -76.24 72.16 3.0 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.069 0.85 . . . . 0.0 112.356 169.288 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.46 15.93 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 127.057 2.265 . . . . 0.0 111.16 171.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.3 158.4 56.37 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 123.395 2.73 . . . . 0.0 111.567 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.7 t -129.14 136.16 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.24 0.616 . . . . 0.0 110.67 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.0 mttm -87.02 119.75 27.56 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 122.394 1.092 . . . . 0.0 110.827 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.9 t -103.1 125.3 57.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 128.82 2.848 . . . . 0.0 109.332 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.7 p90 -157.14 161.85 39.37 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 169.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.77 171.99 13.03 Favored Glycine 0 N--CA 1.466 0.669 0 C-N-CA 124.833 1.206 . . . . 0.0 112.11 -176.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.3 p -132.33 143.33 49.79 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 -167.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mm -116.73 126.37 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 124.869 1.268 . . . . 0.0 111.404 171.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 54.3 tttt -127.79 146.2 50.67 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.695 1.598 . . . . 0.0 111.755 -173.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.02 -34.57 3.82 Favored Glycine 0 N--CA 1.477 1.423 0 C-N-CA 126.347 1.927 . . . . 0.0 111.197 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.466 HD23 ' H ' ' A' ' 38' ' ' LEU . 0.2 OUTLIER -66.58 129.06 38.59 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 165.658 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -69.33 169.54 12.07 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 118.615 0.643 . . . . 0.0 110.998 171.33 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -54.02 158.79 2.0 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.325 1.85 . . . . 0.0 115.475 -171.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.27 179.11 35.61 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.333 0.968 . . . . 0.0 112.783 -173.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.8 mt -64.05 137.23 57.89 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 126.981 2.112 . . . . 0.0 111.935 -174.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -133.54 131.63 39.98 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.613 1.165 . . . . 0.0 108.472 168.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.36 157.31 46.13 Favored Glycine 0 N--CA 1.46 0.248 0 CA-C-O 118.994 -0.892 . . . . 0.0 111.277 -174.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -155.46 141.91 18.64 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.804 0.811 . . . . 0.0 112.763 169.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.9 p-80 -152.58 168.2 26.36 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 123.171 0.588 . . . . 0.0 109.838 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.27 135.57 41.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 123.964 0.905 . . . . 0.0 108.735 175.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -71.73 134.31 46.16 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 170.316 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -76.4 47.76 0.49 Allowed 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.225 1.194 . . . . 0.0 114.225 -170.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 173.8 156.99 0.13 Allowed 'General case' 0 C--O 1.237 0.425 0 C-N-CA 129.649 3.18 . . . . 0.0 108.35 177.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.25 0.46 20.76 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 117.823 1.889 . . . . 0.0 117.823 -178.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -67.67 42.86 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.535 1.934 . . . . 0.0 115.248 171.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -166.54 22.16 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -163.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.4 t -29.14 74.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 129.678 3.191 . . . . 0.0 117.407 173.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 159.35 -14.54 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.05 0 C-N-CA 130.775 3.63 . . . . 0.0 111.749 -169.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.77 -127.78 25.75 Favored Glycine 0 C--N 1.345 1.034 0 C-N-CA 124.858 1.218 . . . . 0.0 112.15 167.37 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 12.4 t -57.69 -10.86 1.77 Allowed 'General case' 0 CA--C 1.552 1.028 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.4 t -108.11 23.13 14.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.229 1.412 . . . . 0.0 113.576 171.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.0 m -152.05 -20.31 0.18 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 116.819 2.155 . . . . 0.0 116.819 169.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -153.41 162.93 40.78 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 120.644 1.565 . . . . 0.0 111.799 169.249 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.89 160.86 52.07 Favored Glycine 0 CA--C 1.539 1.586 0 CA-C-O 119.359 -0.69 . . . . 0.0 112.579 176.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -70.08 172.41 13.0 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 124.152 3.235 . . . . 0.0 111.177 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -15.86 89.18 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 118.865 2.913 . . . . 0.0 118.865 176.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -67.41 98.45 0.65 Allowed 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -75.63 102.42 0.72 Allowed Pre-proline 0 CA--C 1.548 0.871 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -165.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -72.13 -33.3 9.63 Favored 'Trans proline' 0 C--N 1.355 0.915 0 C-N-CA 123.252 2.635 . . . . 0.0 113.086 -168.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.98 -4.27 49.15 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.655 1.182 . . . . 0.0 112.656 175.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.4 t 56.5 49.12 15.41 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.014 1.726 . . . . 0.0 112.823 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 -103.72 174.45 5.86 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.789 1.236 . . . . 0.0 113.365 -173.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 ptmm? -74.22 164.59 26.43 Favored 'General case' 0 CA--C 1.547 0.837 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 161.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -80.14 168.76 18.72 Favored 'General case' 0 CA--C 1.543 0.682 0 O-C-N 121.086 -1.009 . . . . 0.0 112.365 173.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 131.51 -154.95 21.12 Favored Glycine 0 C--N 1.338 0.692 0 C-N-CA 125.818 1.675 . . . . 0.0 113.022 167.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.25 -15.2 0.4 Allowed Glycine 0 CA--C 1.539 1.558 0 N-CA-C 121.331 3.293 . . . . 0.0 121.331 166.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -112.43 -12.11 0.03 OUTLIER 'Trans proline' 0 CA--C 1.545 1.03 0 CA-C-N 121.87 2.835 . . . . 0.0 112.939 168.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.553 ' HE3' ' HB2' ' A' ' 128' ' ' LYS . 0.0 OUTLIER -126.56 -3.43 6.67 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 125.569 1.548 . . . . 0.0 112.666 175.625 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -108.51 175.06 5.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 128.53 2.732 . . . . 0.0 109.548 -175.723 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -116.85 -9.65 11.16 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.769 2.028 . . . . 0.0 112.629 -168.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -122.98 -59.16 1.61 Allowed 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -165.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 46.33 118.55 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 117.881 2.548 . . . . 0.0 117.881 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -58.4 165.57 2.04 Favored 'General case' 0 N--CA 1.48 1.071 0 O-C-N 119.37 -2.081 . . . . 0.0 111.583 169.691 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.313 7.1 p -77.19 -18.97 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 CA-C-N 120.116 1.326 . . . . 0.0 113.078 -176.489 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -94.16 27.78 12.4 Favored Glycine 0 CA--C 1.542 1.75 0 C-N-CA 125.458 1.504 . . . . 0.0 114.937 167.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -107.28 131.58 54.05 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 120.417 2.108 . . . . 0.0 115.088 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 65.2 mt -115.05 178.81 4.15 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.241 1.816 . . . . 0.0 109.818 167.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -89.53 -121.68 2.1 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.435 1.493 . . . . 0.0 114.511 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.436 HD22 HD11 ' A' ' 126' ' ' LEU . 11.8 m-80 -127.04 154.25 44.9 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.071 1.348 . . . . 0.0 111.65 172.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.03 102.85 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 127.347 2.259 . . . . 0.0 109.709 168.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 m -89.63 126.84 35.78 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 124.744 1.218 . . . . 0.0 110.018 -179.077 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.21 150.47 21.97 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -80.9 160.0 24.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 127.301 2.24 . . . . 0.0 109.73 167.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.3 pttp -47.98 -19.35 0.24 Allowed 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 128.185 2.594 . . . . 0.0 115.811 169.365 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -74.64 -11.68 60.25 Favored 'General case' 0 CA--C 1.547 0.863 0 O-C-N 120.753 -1.217 . . . . 0.0 111.784 171.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.07 15.09 55.08 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.015 2.245 . . . . 0.0 113.281 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.8 p -117.38 130.48 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.092 1.446 . . . . 0.0 113.322 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.36 97.34 7.84 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 165.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -89.68 148.93 23.01 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.961 0.886 . . . . 0.0 110.289 168.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.53 146.17 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.105 -1.407 . . . . 0.0 114.433 -169.073 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 76.7 p -160.23 90.43 0.89 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.384 1.074 . . . . 0.0 112.623 -176.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 175.77 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 C-N-CA 125.918 1.687 . . . . 0.0 113.236 -174.042 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -144.75 146.9 32.38 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 128.302 2.641 . . . . 0.0 106.693 168.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -143.05 155.94 44.73 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 122.053 0.93 . . . . 0.0 111.052 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.6 p -121.08 64.71 0.87 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 127.069 2.148 . . . . 0.0 114.158 -166.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -156.83 -46.82 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 O-C-N 121.033 -1.042 . . . . 0.0 109.717 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.39 150.43 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 168.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -148.43 161.15 42.18 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.486 1.514 . . . . 0.0 111.259 -169.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 9.4 mt -78.04 97.85 5.53 Favored 'General case' 0 C--N 1.345 0.387 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 170.074 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.5 t -155.98 6.4 0.2 Allowed 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 -170.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.3 -119.88 5.04 Favored Glycine 0 C--N 1.342 0.865 0 CA-C-N 120.625 1.557 . . . . 0.0 109.713 168.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -62.41 -26.59 68.56 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 125.532 1.533 . . . . 0.0 111.209 -171.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.2 m170 -79.45 -24.25 42.56 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.302 1.041 . . . . 0.0 113.446 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.6 m -166.92 -110.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.6 mm -88.8 142.3 13.07 Favored 'Isoleucine or valine' 0 C--N 1.34 0.171 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 -176.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 92.19 133.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 131.526 3.93 . . . . 0.0 106.73 -164.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.28 15.27 81.69 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 117.211 -1.883 . . . . 0.0 115.823 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 26.5 mtt85 -117.05 176.92 4.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-N 120.426 2.113 . . . . 0.0 110.777 171.027 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -119.75 110.32 16.66 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 120.212 1.369 . . . . 0.0 112.104 -175.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 14.4 tp -90.1 127.41 36.08 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.601 1.161 . . . . 0.0 111.137 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.3 p -116.58 139.55 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.122 1.369 . . . . 0.0 110.491 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.4 m -101.44 152.88 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 123.509 0.724 . . . . 0.0 109.436 167.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -119.45 145.68 46.06 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.665 1.586 . . . . 0.0 112.08 -170.113 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -71.22 -24.46 62.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.674 -1.266 . . . . 0.0 114.147 -171.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.5 mptt -112.78 177.16 4.73 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.321 1.449 . . . . 0.0 110.344 168.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.06 146.8 10.58 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.535 1.934 . . . . 0.0 111.45 168.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -83.86 140.86 31.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 161.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.1 -49.79 33.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 174.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.436 HD11 HD22 ' A' ' 86' ' ' ASN . 14.5 mt 90.64 38.38 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 129.413 3.085 . . . . 0.0 113.292 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.82 26.68 8.34 Favored Glycine 0 N--CA 1.468 0.799 0 N-CA-C 117.73 1.852 . . . . 0.0 117.73 167.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.553 ' HB2' ' HE3' ' A' ' 75' ' ' LYS . 3.7 tttt -155.74 10.09 0.28 Allowed 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 117.131 2.271 . . . . 0.0 117.131 -175.328 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -67.74 117.55 8.87 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 107.051 -2.42 . . . . 0.0 107.051 167.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -69.89 43.14 0.49 Allowed Glycine 0 N--CA 1.477 1.375 0 C-N-CA 126.561 2.029 . . . . 0.0 115.473 -174.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -102.85 -82.62 0.49 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.302 1.841 . . . . 0.0 110.418 176.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 177.17 -69.31 0.01 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 131.154 3.781 . . . . 0.0 106.329 -173.019 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.66 -37.16 62.88 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.731 1.612 . . . . 0.0 114.675 -177.244 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.56 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 0.7 OUTLIER -62.78 -18.6 62.94 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 119.119 -2.238 . . . . 0.0 114.542 179.549 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -99.34 -10.18 22.62 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 124.0 0.92 . . . . 0.0 113.073 170.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.2 mtpt -81.54 -75.55 0.28 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.5 1.52 . . . . 0.0 111.499 169.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 58.5 p -94.03 -28.16 15.9 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 120.121 1.328 . . . . 0.0 113.571 -177.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.45 -14.26 30.3 Favored Glycine 0 N--CA 1.468 0.813 0 CA-C-N 119.44 1.018 . . . . 0.0 110.925 -166.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.56 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 8.3 t-20 61.04 30.69 19.68 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 118.196 0.998 . . . . 0.0 112.714 165.391 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.9 28.36 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 128.582 2.753 . . . . 0.0 117.969 -167.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 67.38 -13.44 0.57 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 119.884 2.713 . . . . 0.0 119.884 167.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . 0.265 16.7 t 146.31 -171.56 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 130.268 3.427 . . . . 0.0 113.23 169.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.59 178.1 6.95 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 128.228 2.611 . . . . 0.0 114.587 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 17.9 tp -162.74 -115.6 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.653 1.581 . . . . 0.0 109.657 168.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -99.24 169.98 8.99 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 125.895 1.678 . . . . 0.0 111.506 172.303 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.3 t -156.64 152.07 26.69 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.782 1.233 . . . . 0.0 111.872 -171.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.05 142.31 8.41 Favored Glycine 0 N--CA 1.473 1.138 0 C-N-CA 125.43 1.491 . . . . 0.0 113.189 178.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 72.1 t -80.73 150.05 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 CA-C-N 118.602 1.201 . . . . 0.0 111.282 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.6 mt -88.1 103.25 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 O-C-N 120.14 -1.6 . . . . 0.0 109.951 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.75 168.84 14.06 Favored Glycine 0 N--CA 1.473 1.142 0 C-N-CA 124.239 0.923 . . . . 0.0 113.242 176.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.58 124.04 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 118.847 1.323 . . . . 0.0 113.78 176.281 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.22 -32.57 13.63 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-O 121.726 0.774 . . . . 0.0 108.927 163.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 . . . . . 0 C--O 1.233 0.2 0 C-N-CA 128.903 2.881 . . . . 0.0 111.174 168.742 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.742 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 76.4 p -92.92 51.57 1.71 Allowed 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -166.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 58.1 mttp -78.12 131.84 37.42 Favored 'General case' 0 N--CA 1.473 0.678 0 O-C-N 119.193 -2.192 . . . . 0.0 114.004 -170.215 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -123.58 156.42 35.77 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.45 1.5 . . . . 0.0 109.015 169.139 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 38.1 t -140.75 146.85 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 123.495 0.718 . . . . 0.0 110.626 -171.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.63 116.04 19.69 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.057 0.943 . . . . 0.0 112.044 169.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -78.92 103.98 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 168.489 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.06 114.58 17.07 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtpm? -141.6 172.45 12.67 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 124.584 1.154 . . . . 0.0 111.766 -174.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.45 -59.85 0.68 Allowed Glycine 0 N--CA 1.465 0.626 0 C-N-CA 126.779 2.133 . . . . 0.0 110.059 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.41 59.49 5.45 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.809 1.244 . . . . 0.0 112.844 -168.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.57 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.973 2.702 . . . . 0.0 114.247 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.75 -17.1 37.81 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 123.661 2.907 . . . . 0.0 113.216 -178.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 t -87.61 124.29 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 119.487 1.04 . . . . 0.0 110.314 171.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.27 165.36 35.02 Favored 'General case' 0 C--O 1.224 -0.239 0 C-N-CA 123.871 0.868 . . . . 0.0 111.772 169.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.98 -179.22 31.76 Favored Glycine 0 N--CA 1.464 0.531 0 N-CA-C 115.664 1.026 . . . . 0.0 115.664 -176.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 10.1 pt -135.15 116.39 19.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 126.827 2.051 . . . . 0.0 107.858 166.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.98 117.86 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 169.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 62.2 m-20 -113.55 130.08 56.43 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.85 1.66 . . . . 0.0 110.852 -173.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -114.4 130.7 56.71 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.466 1.507 . . . . 0.0 110.198 -171.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -122.02 131.37 53.96 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.916 1.687 . . . . 0.0 110.178 172.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -124.62 140.5 52.88 Favored 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.344 -0.847 . . . . 0.0 109.063 167.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -99.57 -24.22 14.82 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 115.128 1.529 . . . . 0.0 115.128 -168.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 46.2 mp0 -143.16 146.96 34.19 Favored 'General case' 0 CA--C 1.512 -0.518 0 C-N-CA 127.911 2.484 . . . . 0.0 106.672 168.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.4 m -61.96 -21.18 64.59 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.452 1.278 . . . . 0.0 114.452 -172.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -107.11 0.17 23.27 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.949 1.7 . . . . 0.0 113.839 170.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.16 170.13 54.38 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.779 1.18 . . . . 0.0 111.358 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -71.66 157.88 54.72 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.267 1.978 . . . . 0.0 110.613 177.339 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -107.52 134.18 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 125.366 1.467 . . . . 0.0 108.116 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -96.84 126.3 41.9 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 167.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 42.3 t -108.01 124.31 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 125.941 1.697 . . . . 0.0 107.081 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -143.05 170.82 15.0 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.4 -153.5 19.17 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 124.596 1.093 . . . . 0.0 112.337 174.096 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 58.3 p -153.98 153.63 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 114.805 1.409 . . . . 0.0 114.805 -172.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.4 mp -124.83 133.47 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.808 1.643 . . . . 0.0 107.072 169.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -132.37 146.15 51.76 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.921 0.888 . . . . 0.0 112.778 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.58 -3.74 19.75 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 126.75 2.119 . . . . 0.0 114.582 -173.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.0 mt -74.28 173.5 10.11 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.546 1.138 . . . . 0.0 111.866 177.335 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.7 t -86.43 154.6 21.04 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 164.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -56.41 142.39 38.64 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 167.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.59 176.63 17.34 Favored Glycine 0 N--CA 1.472 1.038 0 C-N-CA 124.294 0.949 . . . . 0.0 113.451 -175.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.712 HD23 ' H ' ' B' ' 42' ' ' LEU . 1.8 pt? -89.14 126.01 35.28 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.951 1.7 . . . . 0.0 113.422 -169.398 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -123.18 146.23 47.96 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 127.818 2.447 . . . . 0.0 109.624 -178.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.07 155.97 33.6 Favored Glycine 0 N--CA 1.478 1.45 0 CA-C-N 121.133 1.788 . . . . 0.0 111.252 -177.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -153.81 135.59 14.5 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.658 1.729 . . . . 0.0 113.958 171.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -158.4 159.8 36.16 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.132 0.973 . . . . 0.0 112.867 -178.222 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.68 117.37 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.211 1.404 . . . . 0.0 110.158 -175.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -74.83 -173.54 1.91 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 128.43 2.692 . . . . 0.0 113.649 -169.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -63.29 152.05 38.91 Favored 'General case' 0 CA--C 1.541 0.6 0 O-C-N 120.245 -1.534 . . . . 0.0 112.055 171.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.23 161.23 13.85 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 115.071 1.508 . . . . 0.0 115.071 -168.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 67.37 -79.62 0.16 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.545 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -85.79 54.03 2.98 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 123.789 1.757 . . . . 0.0 110.557 -169.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -173.57 8.04 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.836 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 175.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 27.4 p -66.36 44.61 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 119.619 3.192 . . . . 0.0 119.619 -165.549 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.71 -2.99 31.09 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 125.048 1.339 . . . . 0.0 110.73 165.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.96 -166.19 19.02 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.481 1.991 . . . . 0.0 111.957 -172.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.4 t -61.59 -14.15 27.9 Favored 'General case' 0 N--CA 1.472 0.662 0 O-C-N 120.673 -1.486 . . . . 0.0 114.122 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 t -76.46 36.81 0.16 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 126.052 1.741 . . . . 0.0 112.54 169.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 26.4 m 178.07 -53.02 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.972 1 C-N-CA 131.761 4.024 . . . . 0.0 111.807 -176.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.3 123.08 16.17 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 116.938 2.199 . . . . 0.0 116.938 -168.243 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -73.02 -179.77 37.3 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 123.788 0.708 . . . . 0.0 112.009 169.322 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -60.9 167.65 8.42 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 124.484 3.456 . . . . 0.0 115.072 -165.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.721 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -57.05 86.36 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 127.53 2.332 . . . . 0.0 111.415 175.854 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -52.69 127.23 22.4 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.805 -1.088 . . . . 0.0 112.79 -167.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -117.78 65.77 5.15 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 125.964 1.706 . . . . 0.0 112.953 -168.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -64.05 -15.22 48.03 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.035 2.49 . . . . 0.0 113.618 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -79.32 -7.3 58.22 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.442 1.097 . . . . 0.0 113.118 170.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t 65.46 55.67 1.02 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.881 2.072 . . . . 0.0 112.194 175.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 mtm180 -121.4 178.36 4.83 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 -166.359 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 mttp -89.81 173.91 8.0 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 127.917 2.487 . . . . 0.0 112.468 169.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -109.14 146.38 34.18 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 117.283 2.327 . . . . 0.0 117.283 -168.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 129.82 -91.7 0.31 Allowed Glycine 0 C--N 1.343 0.967 0 C-N-CA 124.795 1.188 . . . . 0.0 112.468 166.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.62 -28.6 11.19 Favored Glycine 0 CA--C 1.551 2.302 0 N-CA-C 118.635 2.214 . . . . 0.0 118.635 174.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -87.36 -15.18 3.62 Favored 'Trans proline' 0 C--N 1.356 0.966 0 CA-C-N 122.797 3.298 . . . . 0.0 113.176 171.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.21 -48.62 1.45 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.247 1.419 . . . . 0.0 108.994 166.379 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -55.09 138.41 44.33 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.975 0.893 . . . . 0.0 110.884 171.198 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -87.93 -6.23 58.15 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 127.464 2.306 . . . . 0.0 113.0 -169.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -119.24 -56.57 2.07 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 115.543 1.683 . . . . 0.0 115.543 -174.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.537 HH21 ' CG1' ' B' ' 103' ' ' VAL 0.278 3.4 ptt180 57.93 136.61 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.906 2.483 . . . . 0.0 115.346 -173.176 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -73.35 166.78 22.54 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 118.725 -2.484 . . . . 0.0 111.107 169.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.46 -31.92 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 120.311 -1.493 . . . . 0.0 113.997 -177.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -100.66 22.24 40.56 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 118.789 -1.006 . . . . 0.0 115.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -96.32 114.21 25.87 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -169.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.0 mt -101.56 171.88 7.3 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 104.425 -2.435 . . . . 0.0 104.425 158.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.63 -98.84 1.18 Allowed Glycine 0 N--CA 1.474 1.169 0 CA-C-N 119.026 0.83 . . . . 0.0 111.858 175.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -142.13 164.09 31.09 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -177.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.43 129.14 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 129.264 3.026 . . . . 0.0 111.147 -168.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.5 m -100.84 140.55 34.97 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.043 0.937 . . . . 0.0 110.072 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.44 157.86 16.32 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.931 0.892 . . . . 0.0 111.344 167.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -82.11 178.45 8.27 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.14 1.376 . . . . 0.0 112.154 171.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.12 -28.25 68.96 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.594 1.558 . . . . 0.0 113.365 172.048 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -76.42 2.71 12.85 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.336 1.054 . . . . 0.0 110.616 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.27 -0.59 83.83 Favored Glycine 0 C--N 1.342 0.883 0 C-N-CA 127.179 2.323 . . . . 0.0 114.19 172.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.69 132.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 126.107 1.763 . . . . 0.0 113.464 178.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.03 133.9 41.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.786 1.235 . . . . 0.0 108.703 165.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -98.38 118.27 34.66 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 7.5 t -98.43 124.01 51.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.2 173.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -155.1 87.8 1.14 Allowed 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.284 1.434 . . . . 0.0 110.95 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.87 148.64 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 126.441 1.896 . . . . 0.0 112.609 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -112.54 133.1 54.77 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.041 2.536 . . . . 0.0 106.008 168.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.74 130.05 27.12 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 125.238 1.415 . . . . 0.0 111.161 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 25.3 p -113.17 44.26 1.57 Allowed 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -174.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 103' ' ' VAL . . . . . 0.537 ' CG1' HH21 ' B' ' 79' ' ' ARG 0.315 9.8 p -161.16 -21.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 116.275 1.954 . . . . 0.0 116.275 166.851 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.56 164.45 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 122.189 2.268 . . . . 0.0 109.754 168.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 76.8 p -157.71 159.48 36.93 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 -173.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -92.51 57.13 2.88 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 127.651 2.38 . . . . 0.0 105.484 172.027 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -116.16 21.17 13.88 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -167.34 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.48 -53.21 4.65 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-O 117.932 -1.482 . . . . 0.0 115.356 167.391 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -99.41 -103.07 0.22 Allowed 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.282 1.515 . . . . 0.0 110.738 -167.222 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 20.3 m170 -76.32 8.62 3.22 Favored 'General case' 0 CA--C 1.551 1.016 0 O-C-N 119.357 -2.089 . . . . 0.0 114.418 -167.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 69.8 p -93.81 -131.03 0.14 Allowed 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 129.084 2.954 . . . . 0.0 114.202 -167.428 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 14.9 pt -113.76 -15.52 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 121.344 1.884 . . . . 0.0 115.919 175.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.7 mm -54.46 129.79 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 CA-C-N 120.607 1.549 . . . . 0.0 108.299 168.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.15 -2.32 52.06 Favored Glycine 0 CA--C 1.534 1.273 0 CA-C-N 120.199 1.363 . . . . 0.0 115.529 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -87.54 176.5 7.44 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.432 1.893 . . . . 0.0 109.972 169.587 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.55 109.97 6.6 Favored 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 120.45 1.477 . . . . 0.0 113.319 -169.52 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 27.4 tp -83.16 120.27 25.57 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 124.051 0.94 . . . . 0.0 109.67 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 p -121.85 139.58 48.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 125.998 1.719 . . . . 0.0 110.024 176.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 t -95.81 166.99 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 124.927 1.291 . . . . 0.0 107.672 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -150.12 130.54 13.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.198 1.799 . . . . 0.0 107.877 -169.077 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 -53.76 -40.07 65.88 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 121.569 1.986 . . . . 0.0 115.691 -169.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.42 136.37 33.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 120.278 1.399 . . . . 0.0 109.674 175.294 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.82 159.71 1.6 Allowed 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.187 0.595 . . . . 0.0 110.935 165.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -82.75 146.89 28.75 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-O 123.217 1.484 . . . . 0.0 112.946 -171.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.31 -7.57 53.27 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 114.05 -1.432 . . . . 0.0 113.019 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.1 mt 57.75 55.26 5.6 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 127.163 2.185 . . . . 0.0 113.681 168.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.76 -67.09 0.93 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 175.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 103.85 6.74 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 124.963 1.305 . . . . 0.0 113.659 174.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -103.56 -71.9 0.88 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 107.03 -2.428 . . . . 0.0 107.03 164.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -130.28 -29.5 0.65 Allowed Glycine 0 CA--C 1.536 1.406 0 N-CA-C 119.15 2.42 . . . . 0.0 119.15 -173.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -166.41 173.81 9.6 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 122.036 2.918 . . . . 0.0 111.722 -167.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -42.82 -60.13 1.7 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.335 1.454 . . . . 0.0 113.878 -169.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 26.4 tp10 -35.96 -29.22 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 126.128 1.771 . . . . 0.0 114.395 172.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 83.9 p -63.61 -30.1 71.26 Favored 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 123.355 2.798 . . . . 0.0 115.824 174.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -108.08 -19.9 13.35 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 118.372 -0.823 . . . . 0.0 112.903 169.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -74.09 -49.3 24.61 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.633 1.173 . . . . 0.0 112.078 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 56.4 p -111.38 -95.35 0.43 Allowed 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 164.326 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.28 16.22 0.2 Allowed Glycine 0 CA--C 1.535 1.29 1 C-N-CA 131.2 4.238 . . . . 0.0 112.1 175.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 50.99 34.03 9.96 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.352 1.861 . . . . 0.0 113.019 -174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.34 24.98 0.08 Allowed 'General case' 0 CA--C 1.565 1.531 0 CA-C-O 121.929 0.871 . . . . 0.0 112.727 -169.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.09 -42.85 0.8 Allowed Glycine 0 N--CA 1.471 0.996 0 C-N-CA 129.924 3.63 . . . . 0.0 114.972 175.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 t -161.41 -156.39 0.44 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.541 1.537 . . . . 0.0 109.461 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -166.75 1.11 Allowed 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 127.105 2.162 . . . . 0.0 108.23 168.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -179.54 -173.6 0.26 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 128.328 2.651 . . . . 0.0 107.766 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.51 142.39 8.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.751 2.02 . . . . 0.0 112.154 174.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.2 p -151.9 159.57 43.78 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.908 1.683 . . . . 0.0 114.826 -167.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.78 142.53 8.32 Favored Glycine 0 CA--C 1.534 1.233 0 CA-C-O 118.795 -1.003 . . . . 0.0 114.837 173.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 26.5 t -79.51 135.42 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 125.222 1.409 . . . . 0.0 110.675 170.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.58 115.82 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 O-C-N 121.222 -0.924 . . . . 0.0 110.806 -174.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.76 174.94 15.7 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.942 1.258 . . . . 0.0 111.858 172.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -93.57 156.6 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 N-CA-C 115.337 1.606 . . . . 0.0 115.337 -168.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.51 -16.66 0.17 Allowed 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 126.914 2.085 . . . . 0.0 114.308 171.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 CA--C 1.533 0.311 0 C-N-CA 125.361 1.464 . . . . 0.0 112.911 168.168 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.525 ' HA ' ' H ' ' A' ' 22' ' ' GLN . 74.0 p -79.5 38.03 0.36 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -159.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.9 mttp -169.4 135.12 1.56 Allowed 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 127.322 2.249 . . . . 0.0 114.726 165.372 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.38 177.82 7.46 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 128.864 2.866 . . . . 0.0 110.188 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.451 HG11 ' CA ' ' B' ' 52' ' ' ASP . 1.6 p -155.26 127.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 C-N-CA 126.642 1.977 . . . . 0.0 108.903 -167.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.5 129.68 55.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.804 0.842 . . . . 0.0 111.495 170.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.407 HG22 HG22 ' B' ' 54' ' ' THR . 44.3 t -102.13 95.39 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.666 1.186 . . . . 0.0 107.876 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -89.06 124.28 34.15 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.1 mtpt -143.45 175.36 9.99 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 121.958 0.885 . . . . 0.0 112.416 168.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.29 -65.2 0.16 Allowed Glycine 0 C--N 1.33 0.234 0 C-N-CA 125.571 1.558 . . . . 0.0 110.629 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.85 69.51 3.35 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.51 1.124 . . . . 0.0 111.27 -164.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 40.88 -102.61 0.03 OUTLIER Glycine 0 CA--C 1.536 1.361 0 C-N-CA 127.104 2.288 . . . . 0.0 113.373 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -68.93 -5.98 17.0 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 124.209 3.273 . . . . 0.0 114.459 -178.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.4 t -76.36 135.43 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 CA-C-N 120.151 1.342 . . . . 0.0 110.037 169.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.79 156.79 45.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.212 -1.358 . . . . 0.0 108.642 166.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.89 105.48 0.59 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 169.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.2 127.23 46.37 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 CA-C-N 117.824 0.812 . . . . 0.0 109.778 171.157 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 pp -137.42 121.73 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 122.435 1.112 . . . . 0.0 110.823 166.268 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -83.5 161.07 21.36 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.963 1.305 . . . . 0.0 109.048 164.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -138.29 130.14 28.22 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.526 0.731 . . . . 0.0 109.62 167.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.89 153.66 22.07 Favored 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 165.424 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.525 ' H ' ' HA ' ' A' ' 2' ' ' THR . 1.3 tm0? -157.9 140.85 14.96 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 124.726 1.21 . . . . 0.0 110.781 168.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HZ2' ' CD ' ' A' ' 24' ' ' GLU 0.256 0.0 OUTLIER -82.3 -68.47 0.7 Allowed 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 175.434 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 20.7 mp0 -132.66 165.07 25.32 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.944 1.698 . . . . 0.0 110.77 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 m -56.01 -28.71 58.45 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -98.38 5.21 48.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.817 1.247 . . . . 0.0 112.729 172.376 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.59 149.57 19.27 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 125.014 1.292 . . . . 0.0 111.861 -176.07 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -69.75 174.79 8.97 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.836 3.024 . . . . 0.0 111.83 -178.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -133.54 153.42 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.811 1.244 . . . . 0.0 112.486 -168.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.3 mttm -120.75 112.48 18.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.459 1.104 . . . . 0.0 109.178 167.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -80.86 148.07 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 O-C-N 121.418 -0.801 . . . . 0.0 109.402 167.553 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.2 p90 -156.64 157.62 35.57 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.528 0.731 . . . . 0.0 112.182 165.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.88 -158.81 27.83 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.116 0.807 . . . . 0.0 115.116 -176.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.0 p -153.64 129.12 9.91 Favored 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -168.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mm -111.66 113.94 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.419 178.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . 0.26 0.0 OUTLIER -133.3 172.17 13.05 Favored 'General case' 0 C--N 1.345 0.37 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -178.582 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.54 1.09 59.11 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 126.928 2.204 . . . . 0.0 110.753 -166.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mt -87.21 173.55 9.15 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.869 1.268 . . . . 0.0 110.589 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.4 t -84.77 162.88 19.44 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 163.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -60.79 161.03 8.53 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-O 121.529 0.68 . . . . 0.0 112.205 169.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.48 -175.16 31.48 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.64 1.114 . . . . 0.0 112.812 -178.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.828 ' H ' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -71.92 151.04 43.62 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 128.272 2.629 . . . . 0.0 112.398 -171.933 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -152.36 115.45 4.66 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 127.831 2.452 . . . . 0.0 110.087 -173.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.65 152.49 30.85 Favored Glycine 0 N--CA 1.487 2.065 0 CA-C-N 120.854 1.661 . . . . 0.0 113.368 -178.518 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -149.64 103.46 3.26 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.631 1.572 . . . . 0.0 111.054 -169.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -141.85 145.96 35.27 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 119.849 -1.782 . . . . 0.0 114.986 -164.12 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -96.76 142.76 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-N 118.618 0.645 . . . . 0.0 110.958 -174.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -115.19 125.15 53.05 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.838 1.255 . . . . 0.0 109.511 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -62.42 25.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 128.013 2.525 . . . . 0.0 115.318 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -149.48 126.62 11.33 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 127.843 2.457 . . . . 0.0 107.507 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.95 -19.82 66.64 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 126.513 2.006 . . . . 0.0 115.048 173.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -76.23 51.62 0.7 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 127.313 2.245 . . . . 0.0 113.55 -168.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.433 ' HA ' HG21 ' B' ' 7' ' ' VAL . 1.4 p30 -176.32 22.32 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.211 0 C-N-CA 126.599 1.959 . . . . 0.0 115.399 -167.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.8 t -66.85 44.45 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 128.319 2.648 . . . . 0.0 116.697 178.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.67 -11.06 9.09 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -174.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.17 -166.63 14.6 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 125.268 1.413 . . . . 0.0 112.762 -169.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 37.7 t -51.79 -20.67 2.3 Favored 'General case' 0 CA--C 1.551 0.987 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 -177.259 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -68.66 -6.77 27.94 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 115.088 1.514 . . . . 0.0 115.088 175.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.6 t -149.76 -26.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -90.58 112.41 24.1 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.972 -1.08 . . . . 0.0 111.273 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.28 -119.48 1.11 Allowed Glycine 0 CA--C 1.545 1.935 0 C-N-CA 124.652 1.12 . . . . 0.0 113.568 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.35 173.73 2.19 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 124.205 3.27 . . . . 0.0 110.81 169.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -94.9 114.56 26.43 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.5 0.72 . . . . 0.0 110.352 -172.437 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -58.59 146.25 36.59 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.281 1.032 . . . . 0.0 112.64 177.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -126.83 85.58 60.53 Favored Pre-proline 0 CA--C 1.551 1.01 0 C-N-CA 125.885 1.674 . . . . 0.0 112.96 -168.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -61.74 -34.37 83.39 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 123.341 2.694 . . . . 0.0 113.519 -176.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.16 -4.96 47.21 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.602 0.761 . . . . 0.0 112.809 174.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.8 t 62.85 47.23 4.6 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 127.125 2.17 . . . . 0.0 112.179 178.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.7 ptt180 -117.9 176.56 5.14 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 114.544 1.313 . . . . 0.0 114.544 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -70.67 159.67 34.01 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.763 1.225 . . . . 0.0 111.704 174.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.424 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 84.6 t60 -68.12 120.68 14.71 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 164.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.4 -168.83 18.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 115.209 0.844 . . . . 0.0 115.209 -166.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -93.69 0.55 Allowed Glycine 0 CA--C 1.536 1.371 0 CA-C-O 117.004 -1.998 . . . . 0.0 114.933 176.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -74.56 47.06 1.55 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 124.777 3.651 . . . . 0.0 115.318 -170.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.498 ' HE3' HD23 ' A' ' 126' ' ' LEU . 6.4 ptpt 179.79 -5.7 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.065 1 C-N-CA 133.212 4.605 . . . . 0.0 113.852 165.195 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.421 ' H ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -134.47 177.46 7.75 Favored 'General case' 0 CA--C 1.559 1.316 0 C-N-CA 127.363 2.265 . . . . 0.0 111.227 -166.263 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -109.73 -4.77 15.89 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 127.664 2.385 . . . . 0.0 112.538 -175.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -84.22 -113.11 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.251 1.42 . . . . 0.0 108.304 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 HG11 ' A' ' 103' ' ' VAL . 21.8 ttp180 91.68 119.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 127.475 2.31 . . . . 0.0 108.857 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m170 -57.03 159.23 4.37 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 121.498 -0.751 . . . . 0.0 109.692 168.174 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p -41.97 -33.22 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.374 1.47 . . . . 0.0 113.635 176.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -146.8 123.05 1.71 Allowed Glycine 0 CA--C 1.534 1.26 0 CA-C-O 122.415 1.008 . . . . 0.0 112.426 165.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -158.15 96.46 1.45 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 129.509 3.124 . . . . 0.0 107.42 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -96.07 52.37 1.29 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 122.028 0.918 . . . . 0.0 110.353 178.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.68 -114.55 0.94 Allowed Glycine 0 CA--C 1.526 0.76 0 C-N-CA 126.35 1.929 . . . . 0.0 113.467 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -133.37 138.46 46.32 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.78 1.232 . . . . 0.0 112.529 172.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.4 m -91.23 143.55 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 127.153 2.181 . . . . 0.0 109.723 171.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.6 m -122.39 123.59 41.69 Favored 'General case' 0 N--CA 1.474 0.742 0 O-C-N 120.848 -1.157 . . . . 0.0 110.424 -172.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.14 159.25 15.06 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 114.613 1.338 . . . . 0.0 114.613 -175.427 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.69 175.26 10.28 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.858 2.063 . . . . 0.0 112.381 169.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.672 ' H ' ' HE2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -71.44 -16.37 62.37 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.516 1.126 . . . . 0.0 113.795 172.336 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.59 -13.32 61.36 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 121.967 0.889 . . . . 0.0 109.92 166.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.18 -4.43 58.7 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 127.635 2.54 . . . . 0.0 114.473 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.9 p -91.59 127.75 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 120.946 2.373 . . . . 0.0 114.633 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.11 119.81 32.73 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 163.69 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -87.6 140.43 29.52 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 172.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.64 131.39 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 124.477 1.111 . . . . 0.0 112.328 -168.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.0 p -157.21 60.3 0.51 Allowed 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.39 1.476 . . . . 0.0 113.383 -176.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.0 mp -95.99 142.53 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 119.446 -2.033 . . . . 0.0 112.847 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -117.09 136.79 52.72 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 125.828 1.651 . . . . 0.0 108.424 168.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -153.82 146.16 23.92 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.896 1.279 . . . . 0.0 111.794 -169.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 32.5 t -118.69 55.01 0.93 Allowed 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.084 -0.962 . . . . 0.0 113.091 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.406 HG11 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -139.45 -31.37 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 166.484 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -97.18 159.53 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 122.451 1.119 . . . . 0.0 112.208 172.42 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.507 ' HB2' HE21 ' A' ' 22' ' ' GLN . 53.8 p -156.94 163.18 39.42 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 125.642 1.577 . . . . 0.0 110.062 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.3 mt -82.4 73.39 9.44 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 122.341 1.067 . . . . 0.0 108.874 171.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -132.85 157.74 44.27 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.091 2.156 . . . . 0.0 107.67 170.501 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -116.87 41.94 1.98 Allowed Glycine 0 N--CA 1.472 1.09 0 C-N-CA 124.847 1.213 . . . . 0.0 113.45 -170.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.17 -88.52 0.51 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 127.381 2.273 . . . . 0.0 106.858 -178.453 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.79 12.83 13.08 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 126.016 1.726 . . . . 0.0 110.99 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -92.09 -160.82 0.77 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 120.467 -1.396 . . . . 0.0 112.176 173.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.413 HG23 HH21 ' A' ' 115' ' ' ARG . 8.3 pt -94.08 -13.47 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 N-CA-C 117.017 2.228 . . . . 0.0 117.017 -168.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.3 mm -73.1 125.93 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 122.326 2.33 . . . . 0.0 110.482 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.76 -0.66 81.44 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 117.782 -1.565 . . . . 0.0 113.917 -173.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.413 HH21 HG23 ' A' ' 112' ' ' ILE . 30.9 ttp180 -92.18 167.61 11.92 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.435 1.894 . . . . 0.0 110.573 176.075 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -113.6 163.19 15.28 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 125.582 1.553 . . . . 0.0 112.639 -176.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 41.7 tp -137.29 126.18 24.15 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 127.426 2.29 . . . . 0.0 110.452 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.5 p -100.21 140.21 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 126.456 1.903 . . . . 0.0 110.987 173.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -107.27 143.05 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 CA-C-O 121.676 0.751 . . . . 0.0 109.313 165.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -122.27 162.85 20.7 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.985 1.714 . . . . 0.0 111.558 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 -27.41 44.84 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 120.264 -1.522 . . . . 0.0 114.848 -167.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 20.7 mmtm -130.5 -175.63 3.71 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.758 2.072 . . . . 0.0 114.357 -171.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.45 153.51 31.23 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.718 1.207 . . . . 0.0 111.79 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -102.38 131.53 48.96 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.405 1.082 . . . . 0.0 110.889 -174.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -78.82 -31.98 46.07 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.352 1.861 . . . . 0.0 113.479 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.498 HD23 ' HE3' ' A' ' 75' ' ' LYS . 2.7 mm? 56.0 63.48 2.01 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.353 1.861 . . . . 0.0 114.803 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.0 10.21 64.85 Favored Glycine 0 N--CA 1.467 0.764 0 N-CA-C 120.065 2.786 . . . . 0.0 120.065 161.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.3 pptp? -148.33 -5.6 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 119.468 3.136 . . . . 0.0 119.468 -165.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.06 27.96 0.79 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 120.881 1.673 . . . . 0.0 116.035 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.96 -23.68 2.57 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.566 1.555 . . . . 0.0 116.508 171.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -95.88 165.45 12.27 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 119.717 1.759 . . . . 0.0 111.777 -173.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -49.96 -57.88 6.61 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.993 1.317 . . . . 0.0 109.24 168.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -50.83 -38.77 50.79 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 126.297 1.839 . . . . 0.0 112.803 177.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 20.1 m -62.51 -32.09 72.96 Favored 'General case' 0 N--CA 1.464 0.259 0 O-C-N 121.081 -1.012 . . . . 0.0 113.432 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.273 1.6 t -118.17 -10.62 10.25 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 117.324 -1.322 . . . . 0.0 113.988 -175.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . 0.256 0.6 OUTLIER -90.81 -34.1 15.44 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 120.469 1.486 . . . . 0.0 113.306 168.72 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.78 -17.58 4.0 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 126.042 1.737 . . . . 0.0 114.993 -176.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.424 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 96.61 12.64 50.16 Favored Glycine 0 N--CA 1.466 0.655 0 CA-C-N 120.454 1.479 . . . . 0.0 114.644 -178.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 61.72 7.73 2.07 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 119.711 1.756 . . . . 0.0 113.832 177.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.19 10.5 0.02 OUTLIER 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 118.816 2.895 . . . . 0.0 118.816 -164.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.48 -160.4 32.98 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 126.31 1.909 . . . . 0.0 113.588 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.5 t -55.04 148.83 12.98 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.954 -0.733 . . . . 0.0 111.584 176.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.86 128.95 37.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 170.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.421 HD12 ' H ' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -111.91 -119.23 0.3 Allowed 'General case' 0 C--O 1.238 0.497 0 O-C-N 124.382 1.051 . . . . 0.0 109.728 173.575 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.421 ' H ' HD12 ' A' ' 144' ' ' LEU . . . -68.27 151.91 46.23 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-O 122.425 1.107 . . . . 0.0 112.02 -172.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.6 t -154.24 143.28 21.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.334 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.93 151.59 23.09 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 -169.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.479 ' CG1' ' HB ' ' B' ' 148' ' ' VAL . 2.7 p -79.52 156.2 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.126 0.97 . . . . 0.0 111.885 172.48 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.4 mm -103.22 111.08 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.59 1.156 . . . . 0.0 111.872 170.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.07 159.96 13.47 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.965 1.269 . . . . 0.0 112.576 175.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.53 139.19 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.147 -1.208 . . . . 0.0 112.231 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.21 -141.34 0.23 Allowed 'General case' 0 CA--C 1.549 0.933 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 161.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.471 0.59 0 C-N-CA 124.835 1.254 . . . . 0.0 111.595 168.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.557 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 88.6 m -77.55 99.87 5.88 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.046 1.339 . . . . 0.0 107.754 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 33.9 mtmm -117.05 132.63 56.64 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 123.954 0.902 . . . . 0.0 113.363 -170.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.67 157.69 46.0 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 129.931 3.292 . . . . 0.0 109.67 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 33.5 t -136.32 114.13 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.577 1.18 . . . . 0.0 110.853 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.58 96.05 6.05 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 113.823 -1.535 . . . . 0.0 107.628 167.235 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 53' ' ' ASN . 34.4 m -86.03 115.55 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 165.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.4 mp -98.08 136.13 38.77 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.688 -174.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -157.97 121.8 4.08 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 119.741 1.155 . . . . 0.0 113.894 165.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -84.74 -115.41 0.72 Allowed Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 168.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -143.08 128.97 19.48 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.813 2.845 . . . . 0.0 106.011 -168.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.06 179.42 50.98 Favored Glycine 0 CA--C 1.537 1.421 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -167.058 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.45 49.56 2.68 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 125.293 3.995 . . . . 0.0 112.209 -176.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.65 112.65 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 126.334 1.853 . . . . 0.0 108.655 174.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 pm0 -158.71 166.53 31.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.651 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.96 171.92 35.05 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-O 122.133 0.851 . . . . 0.0 112.456 168.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 pp -121.63 122.76 67.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 166.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mm -131.36 101.9 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -75.38 148.32 39.29 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.249 1.02 . . . . 0.0 110.162 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.4 m-85 -126.61 116.37 20.91 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.171 1.789 . . . . 0.0 108.762 169.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -116.45 120.84 40.06 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 126.301 1.84 . . . . 0.0 112.537 177.436 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -113.92 130.01 56.55 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 122.127 0.965 . . . . 0.0 112.273 169.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.48 ' HE2' ' N ' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -87.17 -28.73 22.26 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.077 0.951 . . . . 0.0 112.474 -172.122 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -158.36 136.07 10.4 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 128.046 2.538 . . . . 0.0 107.71 168.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.8 t -47.62 -42.35 24.0 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 129.048 2.939 . . . . 0.0 113.495 -176.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -84.92 -7.67 59.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.057 1.343 . . . . 0.0 113.25 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.3 -167.71 42.13 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 125.521 1.534 . . . . 0.0 112.148 173.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' PRO . . . . . 0.406 ' O ' ' HE3' ' B' ' 23' ' ' LYS . 20.7 Cg_endo -84.51 176.66 6.21 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.305 2.67 . . . . 0.0 111.669 178.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.82 143.46 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 125.817 1.647 . . . . 0.0 109.4 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 14.9 tttp -107.78 130.58 54.96 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.352 1.061 . . . . 0.0 109.567 168.292 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.57 126.5 74.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 126.025 1.73 . . . . 0.0 108.495 -177.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -148.28 160.5 42.91 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -177.179 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.91 -149.26 21.26 Favored Glycine 0 C--N 1.333 0.397 0 C-N-CA 124.077 0.846 . . . . 0.0 111.868 170.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -150.82 128.78 11.76 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -171.157 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 mp -96.33 136.52 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.646 1.179 . . . . 0.0 109.213 169.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.4 mtpt -130.52 154.4 47.84 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 112.521 -178.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.11 -0.19 57.31 Favored Glycine 0 N--CA 1.475 1.235 0 C-N-CA 124.942 1.258 . . . . 0.0 113.332 -170.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 91.1 mt -78.49 149.01 33.25 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 124.738 1.215 . . . . 0.0 112.017 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -78.17 149.28 33.78 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 165.403 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' GLU . . . . . 0.404 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 1.5 pm0 -54.63 141.34 32.2 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 126.614 1.966 . . . . 0.0 113.064 -178.19 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.87 -168.24 18.0 Favored Glycine 0 N--CA 1.472 1.06 0 O-C-N 120.89 -1.131 . . . . 0.0 113.817 -177.121 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.432 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -82.02 138.93 34.77 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 128.011 2.525 . . . . 0.0 115.966 -167.837 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -137.04 131.73 33.21 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 128.58 2.752 . . . . 0.0 109.728 -174.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.43 161.6 54.27 Favored Glycine 0 N--CA 1.47 0.96 0 C-N-CA 124.672 1.129 . . . . 0.0 114.632 -172.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -153.38 118.94 5.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.651 1.225 . . . . 0.0 113.128 -168.198 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -157.33 150.02 23.21 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 119.893 -1.754 . . . . 0.0 115.248 177.187 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -104.93 117.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.406 1.483 . . . . 0.0 110.097 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -98.36 146.67 25.46 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.853 2.061 . . . . 0.0 109.799 -173.281 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -70.32 148.38 48.55 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.494 -171.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 77.83 156.66 0.17 Allowed 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 127.65 2.38 . . . . 0.0 112.498 -173.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.5 -1.3 81.94 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.724 168.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.451 ' CA ' HG11 ' A' ' 5' ' ' VAL . 13.6 t0 -76.92 115.89 17.11 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 118.782 1.291 . . . . 0.0 110.823 -174.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.506 HD22 HG22 ' B' ' 148' ' ' VAL 0.413 2.6 p-10 -144.21 43.64 1.43 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 123.502 1.62 . . . . 0.0 113.992 164.293 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.407 HG22 HG22 ' A' ' 7' ' ' VAL 0.3 0.5 OUTLIER -128.06 -28.02 2.68 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 112.58 -2.1 . . . . 0.0 111.936 174.493 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.41 -22.4 54.78 Favored 'General case' 0 CA--C 1.561 1.394 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 158.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.55 -101.34 0.38 Allowed Glycine 0 C--N 1.345 1.038 0 C-N-CA 128.132 2.777 . . . . 0.0 116.23 164.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.4 t -64.58 -31.44 72.65 Favored 'General case' 0 CA--C 1.545 0.759 0 O-C-N 121.146 -1.208 . . . . 0.0 112.359 -170.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.2 t -94.47 0.09 55.1 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.53 1.532 . . . . 0.0 113.78 171.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 12.9 p -94.15 -53.98 3.75 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 123.64 0.776 . . . . 0.0 112.472 173.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.52 28.51 0.19 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.599 1.559 . . . . 0.0 112.543 -168.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.84 -63.93 3.56 Favored Glycine 0 CA--C 1.539 1.549 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.491 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -89.77 -180.0 1.99 Allowed 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 124.916 3.744 . . . . 0.0 111.959 169.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -79.67 128.74 33.78 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-O 123.201 1.477 . . . . 0.0 111.925 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -63.41 127.72 32.58 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 113.116 -1.857 . . . . 0.0 108.329 163.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 -121.19 58.48 7.53 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 123.675 0.79 . . . . 0.0 112.158 -171.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.31 -11.72 29.44 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.426 2.084 . . . . 0.0 113.873 -178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.3 mp -92.97 -8.27 43.57 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 114.121 1.156 . . . . 0.0 114.121 173.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.8 t 61.68 74.81 0.43 Allowed 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 119.957 1.253 . . . . 0.0 113.432 175.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -167.35 179.14 5.16 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.33 1.452 . . . . 0.0 112.562 -171.158 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mppt? -85.55 171.43 11.73 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.995 1.718 . . . . 0.0 112.767 177.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -86.26 146.54 26.48 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.921 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.82 -108.21 0.49 Allowed Glycine 0 C--N 1.336 0.534 0 CA-C-O 119.063 -0.854 . . . . 0.0 114.875 165.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.59 -42.16 2.01 Favored Glycine 0 CA--C 1.555 2.589 0 CA-C-O 118.182 -1.343 . . . . 0.0 114.127 -168.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -84.32 15.38 2.18 Favored 'Trans proline' 0 CA--C 1.553 1.474 0 C-N-CA 124.241 3.294 . . . . 0.0 116.712 171.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -39.42 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 128.143 2.577 . . . . 0.0 110.376 165.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.44 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 1.0 OUTLIER -66.1 137.01 56.75 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 161.561 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -99.82 -16.58 18.02 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.298 1.439 . . . . 0.0 111.258 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -79.4 -60.18 2.47 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.56 -0.712 . . . . 0.0 110.464 -171.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.2 ttt-85 71.91 127.47 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.528 1.931 . . . . 0.0 112.374 168.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -76.62 173.02 12.08 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 119.237 -2.164 . . . . 0.0 111.669 168.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.7 p -76.85 134.86 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.597 -1.314 . . . . 0.0 109.376 167.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.23 9.13 86.93 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 126.447 1.975 . . . . 0.0 115.801 -174.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 61.5 m-20 -78.25 114.96 17.62 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-N 119.902 1.851 . . . . 0.0 111.924 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 56.8 mt -99.57 179.06 4.67 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.812 0.845 . . . . 0.0 110.086 168.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -109.9 165.2 12.32 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 125.074 1.321 . . . . 0.0 112.445 174.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -74.63 150.84 39.44 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 -168.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.4 m -114.67 128.66 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 128.373 2.669 . . . . 0.0 111.097 -172.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.33 128.16 45.42 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.739 -1.225 . . . . 0.0 111.724 -178.31 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.05 135.06 35.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 169.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.06 154.47 23.2 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.626 1.97 . . . . 0.0 109.438 167.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -45.63 -21.8 0.13 Allowed 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 129.037 2.935 . . . . 0.0 116.847 176.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.76 9.62 2.72 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.356 1.062 . . . . 0.0 111.408 172.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.2 35.54 42.97 Favored Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.338 2.399 . . . . 0.0 112.324 175.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 1.8 p -142.93 126.99 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 119.017 1.408 . . . . 0.0 114.65 -172.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.46 119.46 32.58 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 165.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.7 t0 -79.64 154.23 28.82 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.592 1.157 . . . . 0.0 109.724 169.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.3 144.2 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 168.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.7 p -156.24 58.5 0.58 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.635 1.574 . . . . 0.0 112.177 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 28.9 mt -80.35 148.68 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 120.237 -1.539 . . . . 0.0 111.334 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -128.84 137.5 51.52 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.908 2.083 . . . . 0.0 105.591 166.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -154.78 136.79 14.65 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.476 1.111 . . . . 0.0 111.604 -169.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.95 49.06 1.02 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 123.518 0.727 . . . . 0.0 112.932 178.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 t -149.46 20.15 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 124.858 1.263 . . . . 0.0 111.731 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -148.62 169.91 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 128.787 2.835 . . . . 0.0 107.944 169.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -156.88 157.3 34.64 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.837 -1.164 . . . . 0.0 110.129 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -99.2 60.79 1.2 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.121 1.369 . . . . 0.0 108.837 -178.223 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.8 m -84.88 -94.21 0.08 Allowed 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.995 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 163.62 60.66 0.02 OUTLIER Glycine 0 N--CA 1.473 1.139 0 O-C-N 120.836 -1.165 . . . . 0.0 113.263 -172.231 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 109' ' ' ASP . . . . . 0.436 ' CG ' ' H ' ' B' ' 110' ' ' HIS . 9.2 p-10 -161.24 -108.95 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 123.136 1.446 . . . . 0.0 108.978 -164.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 110' ' ' HIS . . . . . 0.436 ' H ' ' CG ' ' B' ' 109' ' ' ASP . 14.6 m-70 -107.57 -28.92 9.48 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 130.001 3.32 . . . . 0.0 110.821 173.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 79.9 p -48.44 -65.28 0.59 Allowed 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 128.222 2.609 . . . . 0.0 116.759 -167.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 33.8 mm -150.06 -51.46 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 128.003 2.521 . . . . 0.0 109.513 169.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 49.8 mm -65.3 120.69 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 169.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.78 10.86 69.08 Favored Glycine 0 CA--C 1.534 1.266 0 N-CA-C 114.585 0.594 . . . . 0.0 114.585 -170.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 20.2 ttt85 -108.79 -179.86 3.98 Favored 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.94 2.496 . . . . 0.0 109.672 171.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -148.11 130.35 15.56 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.132 -1.605 . . . . 0.0 112.938 179.073 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -101.53 134.09 45.19 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 119.294 0.952 . . . . 0.0 110.931 -175.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -118.74 137.09 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.204 1.402 . . . . 0.0 109.52 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.42 130.03 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-O 122.646 1.212 . . . . 0.0 108.142 168.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -107.22 152.98 23.36 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.642 1.977 . . . . 0.0 110.108 -172.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.77 -45.34 44.46 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 119.751 -1.843 . . . . 0.0 114.67 -166.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.11 171.55 7.32 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 120.949 1.704 . . . . 0.0 112.061 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.59 149.74 7.75 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 124.037 0.935 . . . . 0.0 112.538 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -75.87 134.44 40.31 Favored 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 168.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -41.18 68.77 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 175.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.3 mt 67.87 37.56 3.1 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 125.867 1.667 . . . . 0.0 111.44 170.026 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -171.2 -75.16 0.04 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.211 0.91 . . . . 0.0 113.441 169.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.8 ttpt -162.04 98.1 1.05 Allowed 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 126.85 2.06 . . . . 0.0 113.605 173.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 129' ' ' GLY . . . . . 0.473 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -76.87 -135.98 0.71 Allowed Glycine 0 CA--C 1.537 1.413 0 CA-C-O 122.247 0.915 . . . . 0.0 113.417 169.043 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.89 -9.35 52.52 Favored Glycine 0 N--CA 1.474 1.172 0 N-CA-C 118.448 2.139 . . . . 0.0 118.448 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -164.8 175.47 9.61 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 120.514 2.157 . . . . 0.0 111.59 -169.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -48.07 -54.74 12.1 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 113.396 0.887 . . . . 0.0 113.396 -170.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -57.58 -10.52 1.55 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 114.476 1.287 . . . . 0.0 114.476 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.473 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 90.9 p -58.05 -49.96 75.1 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.884 1.674 . . . . 0.0 112.964 167.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 19.0 p -93.24 -18.1 22.9 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 178.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -85.12 -35.68 21.62 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.669 0.788 . . . . 0.0 112.867 176.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 59.8 p -115.33 -112.17 0.34 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.981 1.312 . . . . 0.0 107.479 167.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -142.6 21.45 2.37 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.875 2.179 . . . . 0.0 112.187 169.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.71 13.79 3.68 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.517 1.927 . . . . 0.0 113.466 -171.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.34 33.18 0.02 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 128.951 2.901 . . . . 0.0 118.559 -165.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.86 -54.8 3.01 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 126.905 2.193 . . . . 0.0 115.568 169.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -173.51 175.91 2.91 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 125.848 1.659 . . . . 0.0 111.97 -170.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -127.2 115.08 18.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.249 1.419 . . . . 0.0 110.461 -169.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.8 pp -110.53 -37.17 5.56 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -170.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.57 158.34 33.74 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 119.558 1.072 . . . . 0.0 113.136 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 20.3 p -156.45 163.78 39.03 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.471 2.309 . . . . 0.0 110.24 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.92 142.43 8.69 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 127.075 2.274 . . . . 0.0 110.246 171.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.506 HG22 HD22 ' B' ' 53' ' ' ASN . 1.6 t -88.17 146.8 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 CA-C-N 118.967 1.383 . . . . 0.0 108.68 -174.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.5 mm -77.33 120.56 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.013 -1.054 . . . . 0.0 112.94 -169.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.47 -172.4 18.77 Favored Glycine 0 N--CA 1.47 0.958 0 C-N-CA 125.824 1.678 . . . . 0.0 113.567 175.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -133.43 160.39 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 173.075 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.88 -39.31 0.09 Allowed 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 125.902 1.681 . . . . 0.0 111.368 168.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 . . . . . 0 C--O 1.241 0.612 0 C-N-CA 126.31 1.844 . . . . 0.0 112.824 169.937 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.404 ' HA ' ' OE2' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.469 0.477 0 CA-C-O 119.111 -0.471 . . . . 0.0 110.099 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.2 t -161.04 116.81 2.19 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.29 2.636 . . . . 0.0 106.868 166.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.2 102.71 14.16 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.929 -0.482 . . . . 0.0 112.022 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.01 166.67 22.54 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.784 0.72 . . . . 0.0 109.339 167.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.1 t -138.69 140.69 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 122.309 1.052 . . . . 0.0 112.798 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.85 113.15 19.24 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 114.089 -1.414 . . . . 0.0 109.12 165.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.03 80.63 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 127.276 2.23 . . . . 0.0 108.476 167.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -73.84 157.76 35.76 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.007 0.923 . . . . 0.0 111.238 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -148.66 158.51 44.19 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.39 162.68 13.65 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 127.549 2.5 . . . . 0.0 107.54 166.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -76.33 57.66 1.2 Allowed 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 126.837 2.055 . . . . 0.0 111.85 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.13 -167.53 40.0 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 128.436 2.922 . . . . 0.0 109.553 -175.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -80.1 42.55 1.34 Allowed 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 125.224 3.949 . . . . 0.0 112.306 -172.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -131.42 129.63 62.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 124.44 1.096 . . . . 0.0 109.165 -175.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -158.66 169.36 24.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.42 1.888 . . . . 0.0 109.074 -172.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 135.79 4.55 Favored Glycine 0 C--O 1.224 -0.469 0 C-N-CA 121.321 -0.466 . . . . 0.0 112.577 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.08 132.11 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 168.375 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.442 HD12 HG11 ' A' ' 97' ' ' VAL . 15.2 mm -139.09 112.77 6.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 C-N-CA 123.835 0.854 . . . . 0.0 110.838 173.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 31.4 m-20 -78.49 144.32 35.83 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.976 0.91 . . . . 0.0 110.453 165.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -123.56 99.12 6.15 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.744 1.618 . . . . 0.0 109.886 172.671 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.404 ' OE2' ' HA ' ' A' ' 1' ' ' ALA . 0.0 OUTLIER -79.88 105.34 11.09 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.664 1.186 . . . . 0.0 110.742 -179.629 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -79.29 83.1 5.37 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 120.926 -1.109 . . . . 0.0 108.537 169.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.51 -50.71 72.85 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 118.708 -0.663 . . . . 0.0 111.169 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.3 mp0 -132.38 136.48 46.84 Favored 'General case' 0 C--O 1.224 -0.241 0 C-N-CA 124.271 1.028 . . . . 0.0 108.876 168.05 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.1 p -67.08 -4.73 10.7 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 126.163 1.785 . . . . 0.0 114.954 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.46 1.93 9.6 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 126.743 2.017 . . . . 0.0 112.06 173.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.45 -153.2 12.52 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.664 1.602 . . . . 0.0 111.192 -176.173 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -86.24 173.06 6.9 Favored 'Trans proline' 0 N--CA 1.451 -1.01 0 C-N-CA 122.788 2.325 . . . . 0.0 111.761 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.95 134.06 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.759 1.624 . . . . 0.0 108.498 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.4 tttp -101.24 121.78 42.48 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 169.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.4 t -121.14 118.82 57.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 125.924 1.689 . . . . 0.0 109.095 -168.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -140.65 161.9 36.65 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -178.214 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.65 -150.73 22.97 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 124.783 1.182 . . . . 0.0 112.415 -179.323 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 43.1 p -158.09 136.04 10.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -171.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -109.7 112.93 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.668 1.187 . . . . 0.0 108.494 178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -120.79 135.86 55.04 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.955 1.302 . . . . 0.0 111.446 -168.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.67 -2.08 15.47 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 127.191 2.329 . . . . 0.0 113.559 -173.305 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.431 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -69.0 -178.27 1.21 Allowed 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 125.829 1.651 . . . . 0.0 110.992 169.587 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -115.11 156.22 25.62 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 127.962 2.505 . . . . 0.0 105.266 164.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -48.37 146.15 3.0 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 127.032 2.133 . . . . 0.0 114.118 -175.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.83 -177.4 32.86 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 122.084 0.824 . . . . 0.0 113.393 -178.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.491 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -70.13 150.26 46.71 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.449 2.3 . . . . 0.0 112.068 -169.489 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.431 ' CD2' HD23 ' A' ' 38' ' ' LEU . 92.8 m-70 -147.28 124.03 11.21 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.021 1.728 . . . . 0.0 110.32 175.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.43 155.43 32.44 Favored Glycine 0 N--CA 1.491 2.316 0 CA-C-N 120.281 1.4 . . . . 0.0 114.398 -174.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.635 ' CE1' HD11 ' A' ' 117' ' ' LEU . 2.0 t80 -146.1 102.11 3.59 Favored 'General case' 0 CA--C 1.552 1.051 0 CA-C-O 122.76 1.267 . . . . 0.0 113.77 -167.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -127.34 133.16 50.11 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.89 94.71 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 126.408 1.883 . . . . 0.0 110.355 174.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -73.75 108.84 6.82 Favored 'General case' 0 CA--C 1.557 1.242 0 O-C-N 120.604 -1.31 . . . . 0.0 114.36 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -31.03 106.23 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 127.408 2.283 . . . . 0.0 113.208 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 148.44 173.86 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 129.792 3.237 . . . . 0.0 109.758 -169.193 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.578 ' HA3' ' H ' ' B' ' 151' ' ' ILE . . . -116.85 -2.63 18.78 Favored Glycine 0 CA--C 1.549 2.201 0 C-N-CA 126.292 1.901 . . . . 0.0 109.859 160.627 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' C ' HD22 ' A' ' 53' ' ' ASN . 0.8 OUTLIER -75.69 147.22 39.57 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 128.008 2.523 . . . . 0.0 111.75 170.271 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.51 HD22 ' C ' ' A' ' 52' ' ' ASP 0.312 0.1 OUTLIER -173.53 17.47 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 119.041 2.978 . . . . 0.0 119.041 166.627 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.416 HG22 HG22 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -92.35 -12.52 32.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 120.083 -1.636 . . . . 0.0 114.315 -165.359 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.34 18.14 22.47 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.772 1.229 . . . . 0.0 112.678 172.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.66 -123.43 24.72 Favored Glycine 0 CA--C 1.529 0.933 0 O-C-N 120.697 -1.252 . . . . 0.0 112.243 174.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.3 m -72.5 -9.33 58.43 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 175.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -14.92 52.55 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 125.184 1.394 . . . . 0.0 111.407 169.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.7 m -95.28 -159.51 0.72 Allowed 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 127.41 2.284 . . . . 0.0 109.52 168.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.13 104.69 0.03 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 128.212 2.605 . . . . 0.0 116.374 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -63.07 166.72 23.77 Favored Glycine 0 CA--C 1.545 1.92 0 C-N-CA 125.869 1.699 . . . . 0.0 114.805 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -62.11 96.89 0.15 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 125.07 3.847 . . . . 0.0 113.173 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.1 p80 47.82 64.49 1.61 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 126.124 1.769 . . . . 0.0 113.24 169.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -32.11 137.83 0.05 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.383 1.873 . . . . 0.0 115.439 -178.102 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -106.01 63.66 0.16 Allowed Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 126.559 1.944 . . . . 0.0 113.084 177.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -62.78 -35.77 66.27 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.612 2.208 . . . . 0.0 111.898 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.1 tp -77.76 -5.18 49.79 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 124.727 1.211 . . . . 0.0 112.869 173.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t 71.27 51.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.945 2.098 . . . . 0.0 112.497 172.008 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 78' ' ' GLU . 8.5 mtp180 -108.19 171.71 7.25 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -169.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.7 mttp -81.09 162.71 23.6 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.468 1.507 . . . . 0.0 109.521 165.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -72.36 151.72 42.51 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 121.012 -1.055 . . . . 0.0 112.151 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.73 -138.45 6.39 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 116.137 1.215 . . . . 0.0 116.137 169.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.457 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 139.77 -108.88 0.6 Allowed Glycine 0 CA--C 1.544 1.856 0 CA-C-O 116.835 -2.092 . . . . 0.0 114.934 -168.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -52.33 -3.65 0.11 Allowed 'Trans proline' 0 CA--C 1.546 1.103 1 C-N-CA 126.443 4.762 . . . . 0.0 120.068 -169.333 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.48 2.89 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 127.693 2.397 . . . . 0.0 112.594 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.457 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.3 OUTLIER -123.91 175.81 6.7 Favored 'General case' 0 CA--C 1.557 1.249 0 C-N-CA 129.091 2.957 . . . . 0.0 109.02 -174.912 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -116.55 -13.71 10.9 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.671 2.388 . . . . 0.0 111.143 -175.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 69' ' ' ARG . 3.8 mm-40 -91.59 -65.3 1.02 Allowed 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.769 1.228 . . . . 0.0 112.555 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 ' CG ' ' A' ' 101' ' ' ASP . 1.4 ttt-85 52.91 77.07 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 120.088 1.313 . . . . 0.0 111.48 171.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -46.91 153.32 0.42 Allowed 'General case' 0 N--CA 1.478 0.971 0 O-C-N 120.264 -1.523 . . . . 0.0 112.298 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 p -43.95 -40.62 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 120.125 1.33 . . . . 0.0 113.715 -176.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -97.08 34.2 5.24 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 126.863 2.173 . . . . 0.0 117.21 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -114.68 128.17 56.16 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.992 1.717 . . . . 0.0 110.426 176.221 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.1 mt -122.41 53.75 1.23 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-O 122.031 0.92 . . . . 0.0 108.555 168.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 62.2 -132.53 45.49 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.411 1.482 . . . . 0.0 114.229 175.242 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -143.45 154.86 44.11 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.573 1.149 . . . . 0.0 110.591 175.15 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.94 104.04 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.618 1.567 . . . . 0.0 109.733 -175.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -91.68 125.46 36.41 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 124.01 0.924 . . . . 0.0 109.222 -175.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.97 156.05 17.78 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -173.484 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -82.85 166.35 19.03 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.037 1.735 . . . . 0.0 110.206 167.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.6 pttt -51.28 -24.03 4.12 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 127.521 2.328 . . . . 0.0 113.274 167.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -76.78 -0.73 24.91 Favored 'General case' 0 CA--C 1.55 0.954 0 C-N-CA 125.929 1.691 . . . . 0.0 112.016 172.497 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.21 7.32 84.59 Favored Glycine 0 CA--C 1.52 0.404 0 O-C-N 120.183 -1.573 . . . . 0.0 113.523 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -95.18 123.69 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 125.405 1.482 . . . . 0.0 112.142 174.104 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.85 134.49 36.16 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 163.482 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -79.29 150.62 31.46 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 168.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.442 HG11 HD12 ' A' ' 18' ' ' ILE . 1.3 t -131.2 123.24 53.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 113.287 -1.779 . . . . 0.0 109.855 168.655 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.1 m -147.12 70.94 1.2 Allowed 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.865 2.066 . . . . 0.0 109.198 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 31.3 mt -116.4 152.37 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 125.502 1.521 . . . . 0.0 111.711 -168.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -145.48 137.28 25.37 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 127.172 2.189 . . . . 0.0 107.064 174.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.406 ' CG ' HH21 ' A' ' 79' ' ' ARG . 22.7 t70 -154.26 139.4 17.44 Favored 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -167.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -116.59 51.57 0.98 Allowed 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.6 t -128.62 -47.93 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -100.43 176.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.16 0.984 . . . . 0.0 112.005 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -157.94 176.03 13.07 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 120.693 -1.254 . . . . 0.0 110.696 172.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.4 mp -109.69 52.2 0.73 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.803 1.641 . . . . 0.0 109.46 -177.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.3 t -91.24 14.33 14.68 Favored 'General case' 0 CA--C 1.542 0.669 0 O-C-N 120.57 -1.331 . . . . 0.0 114.417 -174.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 102.47 -122.32 7.48 Favored Glycine 0 C--N 1.339 0.698 0 O-C-N 121.527 -0.733 . . . . 0.0 111.652 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -59.09 -52.7 64.59 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 126.934 2.094 . . . . 0.0 114.27 -163.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -88.48 9.43 23.72 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.737 1.615 . . . . 0.0 112.602 -174.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.21 -161.23 0.82 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 125.407 1.483 . . . . 0.0 113.937 -165.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.283 7.4 pt -88.96 1.16 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 175.283 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 38.8 mm -69.72 132.68 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 163.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.24 -12.11 55.79 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.763 -1.576 . . . . 0.0 115.631 -171.086 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.716 ' NE ' ' H ' ' A' ' 116' ' ' THR . 1.3 tpm_? -71.51 177.86 3.8 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.699 2.249 . . . . 0.0 108.486 178.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.716 ' H ' ' NE ' ' A' ' 115' ' ' ARG . 1.5 m -140.53 131.58 26.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 126.932 2.093 . . . . 0.0 106.717 175.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.635 HD11 ' CE1' ' A' ' 45' ' ' PHE . 2.3 tm? -87.22 137.8 32.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 125.542 1.776 . . . . 0.0 106.791 166.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 5.2 p -117.45 124.54 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.624 1.17 . . . . 0.0 108.427 168.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.42 145.18 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 O-C-N 124.94 1.4 . . . . 0.0 109.083 169.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 23.2 m-70 -117.34 161.76 19.01 Favored 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 125.16 1.384 . . . . 0.0 113.134 -170.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.54 -34.25 69.86 Favored 'General case' 0 N--CA 1.478 0.935 0 O-C-N 120.597 -1.314 . . . . 0.0 114.071 179.564 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.426 ' HE3' ' O ' ' A' ' 139' ' ' ASN . 17.9 ttpp -94.49 156.02 16.66 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 123.064 1.412 . . . . 0.0 113.766 -173.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.58 142.59 17.74 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.744 165.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -93.43 128.6 39.57 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 124.465 1.103 . . . . 0.0 110.641 -178.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.81 -21.65 59.17 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.697 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 72.3 mt 47.86 56.52 7.09 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 127.912 2.485 . . . . 0.0 111.219 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.16 -58.9 0.38 Allowed Glycine 0 N--CA 1.472 1.055 0 C-N-CA 125.864 1.697 . . . . 0.0 113.732 173.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp -126.05 77.55 1.69 Allowed 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 115.226 1.565 . . . . 0.0 115.226 -169.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.607 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -80.57 -95.23 0.4 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 107.196 -2.362 . . . . 0.0 107.196 165.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -150.03 8.58 0.81 Allowed Glycine 0 N--CA 1.474 1.173 0 N-CA-C 117.728 1.851 . . . . 0.0 117.728 -174.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.7 p30 -161.2 -177.7 6.23 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 120.4 2.1 . . . . 0.0 111.111 -176.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -55.77 -51.89 65.85 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.207 0.912 . . . . 0.0 112.727 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -59.38 -23.84 62.93 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -170.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.607 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 27.3 m -57.15 -29.31 63.51 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 172.233 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -100.25 -15.14 18.18 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 118.067 -0.968 . . . . 0.0 113.473 173.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.55 -85.37 0.16 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 119.968 1.258 . . . . 0.0 110.77 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 62.5 p -73.24 -11.47 60.52 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.48 9.06 79.74 Favored Glycine 0 N--CA 1.467 0.705 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 -165.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.426 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 4.8 t-20 52.53 21.92 1.97 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.501 1.92 . . . . 0.0 109.135 -166.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.97 -11.78 21.13 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 114.726 1.38 . . . . 0.0 114.726 -166.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.93 -156.12 24.22 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 124.698 1.142 . . . . 0.0 113.072 169.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -67.98 154.83 40.79 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 126.55 1.94 . . . . 0.0 111.609 -175.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.425 ' H ' ' HD2' ' A' ' 143' ' ' ARG . 0.3 OUTLIER -81.62 129.85 34.84 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.581 0.752 . . . . 0.0 109.192 -179.218 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.11 -64.19 1.1 Allowed 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.124 1.77 . . . . 0.0 110.276 -170.376 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.7 149.33 45.0 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 125.071 1.348 . . . . 0.0 110.531 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 63.7 m -139.08 146.63 40.98 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.047 1.739 . . . . 0.0 111.249 -176.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.08 142.93 8.72 Favored Glycine 0 N--CA 1.474 1.183 0 C-N-CA 124.804 1.192 . . . . 0.0 112.11 169.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.4 t -92.69 135.34 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 125.043 1.337 . . . . 0.0 109.312 -175.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.6 mm -77.55 115.77 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.718 -169.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.09 158.1 14.63 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.818 1.199 . . . . 0.0 113.426 -177.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -75.14 134.98 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.135 0.974 . . . . 0.0 113.326 -178.318 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.62 -177.35 6.53 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.711 2.404 . . . . 0.0 108.544 -170.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 . . . . . 0 N--CA 1.471 0.577 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 167.89 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.427 0 N-CA-C 113.013 0.745 . . . . 0.0 113.013 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.8 p -97.76 114.85 26.95 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.137 1.446 . . . . 0.0 108.879 171.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -113.07 125.37 54.31 Favored 'General case' 0 C--O 1.24 0.602 0 C-N-CA 125.098 1.359 . . . . 0.0 112.083 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -79.99 168.89 18.61 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 176.218 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.415 ' CG2' HG23 ' A' ' 54' ' ' THR . 1.9 p -156.12 101.94 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 127.771 2.429 . . . . 0.0 107.836 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.69 114.39 26.03 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.913 1.285 . . . . 0.0 111.403 -172.178 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.416 HG22 HG22 ' A' ' 54' ' ' THR . 2.1 t -83.97 72.61 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 125.17 1.388 . . . . 0.0 109.585 -172.299 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.3 mp -77.92 115.71 17.87 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 121.437 -0.79 . . . . 0.0 109.838 178.497 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.1 ttpp -161.79 120.13 2.31 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.197 1.799 . . . . 0.0 111.021 164.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -137.07 -69.53 0.05 OUTLIER Glycine 0 N--CA 1.467 0.708 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 169.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.95 76.99 2.84 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 127.703 2.401 . . . . 0.0 110.594 -169.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.94 -102.06 0.05 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.424 1.964 . . . . 0.0 112.403 174.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -85.65 0.55 8.46 Favored 'Trans proline' 0 C--N 1.353 0.807 1 C-N-CA 125.783 4.322 . . . . 0.0 115.469 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.33 120.82 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-N 121.753 2.07 . . . . 0.0 109.486 169.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.99 166.36 24.27 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.132 1.373 . . . . 0.0 110.827 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.11 174.92 33.97 Favored Glycine 0 N--CA 1.466 0.634 0 CA-C-O 123.082 1.379 . . . . 0.0 116.115 173.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.482 HG13 ' H ' ' B' ' 34' ' ' SER . 3.3 pt -143.08 50.86 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 CA-C-N 112.833 -1.684 . . . . 0.0 112.013 -166.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 13.1 mm -81.46 119.36 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 O-C-N 120.033 -1.667 . . . . 0.0 110.957 -169.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -88.0 154.96 20.08 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.498 1.519 . . . . 0.0 110.414 169.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.425 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 23.4 m-85 -143.54 108.05 4.83 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 169.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -98.38 117.82 33.65 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.994 1.109 . . . . 0.0 113.994 -173.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLN . . . . . 0.539 ' HB2' HD13 ' B' ' 106' ' ' LEU . 4.3 tp-100 -96.17 139.55 32.16 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.794 1.238 . . . . 0.0 111.165 169.453 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.592 ' H ' ' HD2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -92.2 -36.15 13.43 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.408 2.283 . . . . 0.0 113.59 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -159.47 136.71 9.69 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 126.961 2.104 . . . . 0.0 109.034 169.011 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 60.3 p -19.43 -57.13 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 129.109 2.964 . . . . 0.0 116.935 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.2 p-10 -95.24 2.91 55.0 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 127.342 2.257 . . . . 0.0 115.531 -172.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.24 168.16 54.44 Favored Glycine 0 CA--C 1.544 1.904 0 O-C-N 120.781 -1.199 . . . . 0.0 113.164 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -67.02 163.66 33.04 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.677 2.918 . . . . 0.0 110.297 170.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 77.4 t -131.26 138.74 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 CA-C-N 119.476 1.034 . . . . 0.0 111.642 -169.077 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 72.9 mttt -92.48 112.15 23.99 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.23 174.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.51 131.94 32.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 125.214 1.406 . . . . 0.0 109.119 170.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -154.27 165.72 35.42 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 168.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.05 175.92 21.47 Favored Glycine 0 N--CA 1.468 0.798 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -174.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' SER . . . . . 0.482 ' H ' HG13 ' B' ' 17' ' ' ILE . 77.7 p -132.55 165.52 24.19 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -166.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -116.82 126.61 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.915 1.686 . . . . 0.0 107.895 168.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -126.17 132.93 51.7 Favored 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 124.905 1.282 . . . . 0.0 111.073 -177.235 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.44 -3.04 13.87 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.297 2.38 . . . . 0.0 112.801 -171.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.3 mt -66.93 162.73 21.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.051 0.925 . . . . 0.0 109.483 168.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -77.54 150.9 34.75 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 162.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -50.68 147.02 5.06 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 123.733 0.813 . . . . 0.0 110.306 168.175 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 104.06 -179.59 25.04 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.75 1.167 . . . . 0.0 113.486 -173.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.752 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.9 pt? -84.99 145.28 27.79 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.374 2.67 . . . . 0.0 113.401 -169.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 43' ' ' HIS . . . . . 0.401 ' HB2' HG23 ' B' ' 87' ' ' VAL . 93.1 m-70 -147.36 147.3 30.17 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 128.88 2.872 . . . . 0.0 111.228 -167.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.11 156.1 49.88 Favored Glycine 0 N--CA 1.479 1.526 0 CA-C-O 117.991 -1.45 . . . . 0.0 113.618 174.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -154.43 98.07 2.07 Favored 'General case' 0 CA--C 1.553 1.07 0 C-N-CA 125.808 1.643 . . . . 0.0 111.623 -173.218 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -121.36 128.22 52.03 Favored 'General case' 0 N--CA 1.472 0.665 0 O-C-N 120.248 -1.532 . . . . 0.0 113.773 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -80.24 100.43 4.59 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 171.421 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -68.59 130.27 42.35 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 119.41 -2.056 . . . . 0.0 108.836 -170.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.05 48.67 0.12 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 128.699 2.8 . . . . 0.0 114.179 -165.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 178.66 138.73 0.09 Allowed 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 129.1 2.96 . . . . 0.0 107.054 178.764 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.09 -5.8 88.96 Favored Glycine 0 N--CA 1.469 0.891 0 CA-C-N 115.214 -0.903 . . . . 0.0 114.912 174.052 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -79.19 52.43 1.31 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.961 1.704 . . . . 0.0 112.408 -170.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.252 23.0 p-10 175.89 64.98 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 116.686 2.106 . . . . 0.0 116.686 -169.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.7 t -73.45 21.77 0.08 Allowed 'General case' 0 N--CA 1.48 1.029 0 O-C-N 120.425 -1.422 . . . . 0.0 113.282 167.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -132.37 9.65 4.39 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 126.151 1.781 . . . . 0.0 111.459 169.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 56.44 -124.93 36.48 Favored Glycine 0 C--N 1.345 1.034 0 O-C-N 121.135 -0.978 . . . . 0.0 112.229 174.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 74.2 m -60.21 -6.94 1.64 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 175.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.6 m -87.94 3.83 47.13 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 120.02 1.282 . . . . 0.0 111.456 168.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 74.8 m -151.64 -28.46 0.18 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 119.633 -1.917 . . . . 0.0 115.468 -177.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -123.16 168.92 11.79 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 120.301 1.409 . . . . 0.0 111.794 171.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -84.88 -139.83 4.75 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-O 118.54 -1.145 . . . . 0.0 111.268 169.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -72.41 176.32 8.84 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.015 3.143 . . . . 0.0 110.959 173.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.664 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -57.11 100.18 0.04 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 128.556 2.742 . . . . 0.0 109.559 170.052 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -49.62 146.34 4.3 Favored 'General case' 0 CA--C 1.538 0.485 0 O-C-N 124.148 0.905 . . . . 0.0 111.629 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -106.12 60.82 0.16 Allowed Pre-proline 0 CA--C 1.56 1.344 0 C-N-CA 126.334 1.853 . . . . 0.0 115.625 -171.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -61.42 -35.17 84.47 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.913 3.076 . . . . 0.0 113.457 -174.261 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 63.6 mt -79.65 -1.51 38.56 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.453 1.101 . . . . 0.0 113.542 176.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.3 t 58.37 58.03 3.61 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.597 1.159 . . . . 0.0 113.114 169.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -153.88 179.02 9.27 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -169.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 mtmp? -61.75 173.13 1.07 Allowed 'General case' 0 CA--C 1.541 0.622 0 CA-C-O 122.186 0.993 . . . . 0.0 111.98 174.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.507 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 63.6 t60 -123.09 148.73 45.32 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 116.35 1.982 . . . . 0.0 116.35 -166.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 121.65 -63.72 0.51 Allowed Glycine 0 C--N 1.339 0.709 0 C-N-CA 124.458 1.028 . . . . 0.0 115.278 162.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.61 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 88.14 -9.85 73.26 Favored Glycine 0 CA--C 1.548 2.14 1 N-CA-C 123.294 4.078 . . . . 0.0 123.294 168.296 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -89.26 -5.01 5.76 Favored 'Trans proline' 0 C--N 1.358 1.044 1 CA-C-N 124.605 4.202 . . . . 0.0 112.23 168.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.42 -25.18 0.11 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.319 1.847 . . . . 0.0 110.861 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.61 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -71.08 139.9 50.52 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 122.87 1.319 . . . . 0.0 109.433 164.972 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -90.44 -22.47 21.4 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 129.527 3.131 . . . . 0.0 113.009 -168.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -98.17 -79.92 0.46 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.21 1.404 . . . . 0.0 109.901 -172.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 87.92 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 127.45 2.3 . . . . 0.0 116.498 164.627 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -63.99 147.44 52.03 Favored 'General case' 0 N--CA 1.484 1.233 0 O-C-N 119.678 -1.889 . . . . 0.0 108.471 164.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.9 -10.03 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 CA-C-N 122.094 2.224 . . . . 0.0 112.372 -174.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.97 5.46 75.88 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.764 1.65 . . . . 0.0 114.695 169.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -97.9 132.26 43.64 Favored 'General case' 0 C--N 1.322 -0.623 0 O-C-N 119.666 -2.079 . . . . 0.0 111.758 -173.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 81.4 mt -130.35 176.62 7.98 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.697 1.999 . . . . 0.0 106.738 165.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.27 -138.87 6.34 Favored Glycine 0 N--CA 1.471 1.003 0 C-N-CA 123.863 0.744 . . . . 0.0 114.369 -171.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -102.47 151.1 22.69 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.36 1.064 . . . . 0.0 113.369 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.401 HG23 ' HB2' ' B' ' 43' ' ' HIS . 16.2 m -113.51 145.57 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 127.797 2.439 . . . . 0.0 110.728 169.49 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 54.8 m -134.23 122.54 22.9 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.215 0.916 . . . . 0.0 109.544 -174.102 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.12 151.56 22.14 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.61 160.25 14.86 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 130.189 3.395 . . . . 0.0 109.5 168.104 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -40.48 -26.66 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 128.616 2.766 . . . . 0.0 117.884 175.3 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -77.45 7.67 5.15 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.104 1.32 . . . . 0.0 112.029 173.13 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.9 8.87 87.25 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 127.247 2.356 . . . . 0.0 113.748 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 11.5 p -104.28 121.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 125.103 1.361 . . . . 0.0 112.684 -170.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.34 113.41 25.36 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 164.361 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -104.18 141.83 35.57 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.831 0.824 . . . . 0.0 111.314 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -117.65 147.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 CA-C-N 113.606 -1.634 . . . . 0.0 113.46 -170.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 17.4 p -161.17 60.0 0.29 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 125.258 1.423 . . . . 0.0 113.75 -175.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 24.4 mt -118.61 145.21 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 O-C-N 119.771 -1.83 . . . . 0.0 112.297 -172.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 100' ' ' GLU . . . . . 0.434 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 10.7 tt0 -104.03 121.53 43.37 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 165.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -112.44 134.87 53.73 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.679 1.192 . . . . 0.0 109.866 174.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.0 p -109.42 50.73 0.77 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.002 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 57.7 t -133.8 -39.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.863 1.665 . . . . 0.0 110.208 169.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.59 163.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-O 123.18 1.467 . . . . 0.0 113.393 176.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.539 ' H ' ' HB3' ' B' ' 111' ' ' SER . 58.1 m -159.43 147.67 17.61 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 127.14 2.176 . . . . 0.0 108.863 -172.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 106' ' ' LEU . . . . . 0.539 HD13 ' HB2' ' B' ' 22' ' ' GLN . 4.1 mp -79.58 97.42 6.48 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 119.013 0.824 . . . . 0.0 109.05 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.8 m -114.07 -33.71 5.62 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.178 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.15 -29.39 10.73 Favored Glycine 0 N--CA 1.469 0.858 0 CA-C-O 118.91 -0.939 . . . . 0.0 111.822 -168.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -154.25 -46.66 0.09 Allowed 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 115.577 1.695 . . . . 0.0 115.577 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -82.61 0.96 40.55 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 126.142 1.777 . . . . 0.0 112.755 -168.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 111' ' ' SER . . . . . 0.539 ' HB3' ' H ' ' B' ' 105' ' ' SER . 4.9 m -163.85 -78.11 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 177.016 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.4 pt -129.17 167.3 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 O-C-N 120.749 -1.22 . . . . 0.0 109.797 167.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.2 mm 77.93 146.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 C-N-CA 129.452 3.101 . . . . 0.0 106.84 -162.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.95 -45.76 2.29 Favored Glycine 0 N--CA 1.468 0.8 0 CA-C-O 118.985 -0.897 . . . . 0.0 113.698 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.8 mtp85 -75.85 176.62 7.64 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.961 1.304 . . . . 0.0 111.117 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 116' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 5.9 t -124.5 164.95 18.67 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 117.529 -1.224 . . . . 0.0 110.931 -173.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.421 ' C ' HD13 ' B' ' 117' ' ' LEU . 0.3 OUTLIER -127.11 140.56 52.18 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 119.619 1.1 . . . . 0.0 108.886 167.597 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 p -122.8 136.2 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.345 1.458 . . . . 0.0 110.101 172.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.07 158.73 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.486 1.114 . . . . 0.0 110.233 175.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -131.76 140.3 49.19 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.42 1.088 . . . . 0.0 111.729 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -63.3 -27.92 69.66 Favored 'General case' 0 N--CA 1.475 0.792 0 O-C-N 120.042 -1.661 . . . . 0.0 115.119 -174.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.93 165.19 14.0 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 120.071 -1.643 . . . . 0.0 109.957 166.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.21 152.0 34.93 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 124.307 1.043 . . . . 0.0 111.42 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.514 ' CG ' ' HB2' ' B' ' 140' ' ' ALA . 16.7 m-20 -86.55 159.95 19.11 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.302 1.841 . . . . 0.0 113.034 174.383 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.7 -49.7 17.51 Favored 'General case' 0 N--CA 1.485 1.304 0 CA-C-N 112.728 -2.033 . . . . 0.0 111.104 166.156 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.6 mm? 68.32 62.73 0.37 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 127.355 2.262 . . . . 0.0 110.167 -176.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 178.22 -111.61 0.33 Allowed Glycine 0 N--CA 1.47 0.901 0 O-C-N 121.583 -0.698 . . . . 0.0 111.748 -173.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -151.63 7.94 0.5 Allowed 'General case' 0 CA--C 1.566 1.584 0 C-N-CA 126.906 2.083 . . . . 0.0 112.551 169.087 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 34.86 -106.5 0.03 OUTLIER Glycine 0 C--N 1.35 1.324 0 C-N-CA 126.877 2.179 . . . . 0.0 114.071 169.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -129.71 21.83 4.98 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-O 117.958 -1.468 . . . . 0.0 114.16 169.275 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -165.37 168.57 16.65 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 120.393 2.096 . . . . 0.0 111.249 -171.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -61.85 -53.03 61.46 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.855 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -40.84 -37.74 0.82 Allowed 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.676 1.99 . . . . 0.0 114.637 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 54.9 m -56.02 -35.67 67.1 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 171.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -94.85 -23.56 17.42 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.935 1.243 . . . . 0.0 112.527 167.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -78.9 -33.62 45.43 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-N 119.981 1.264 . . . . 0.0 113.094 -171.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.2 m -135.71 -31.32 0.95 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 126.898 2.079 . . . . 0.0 110.616 -169.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 138' ' ' GLY . . . . . 0.507 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 125.49 -25.41 5.67 Favored Glycine 0 C--O 1.222 -0.599 0 C-N-CA 127.996 2.712 . . . . 0.0 111.714 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 58.2 t30 113.14 -8.63 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.856 1 C-N-CA 131.995 4.118 . . . . 0.0 112.291 176.397 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 140' ' ' ALA . . . . . 0.514 ' HB2' ' CG ' ' B' ' 124' ' ' ASP . . . -57.24 -7.35 0.53 Allowed 'General case' 0 CA--C 1.56 1.349 0 N-CA-C 118.466 2.765 . . . . 0.0 118.466 -163.023 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.76 -31.32 1.96 Allowed Glycine 0 N--CA 1.47 0.943 0 O-C-N 119.597 -1.939 . . . . 0.0 114.512 170.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -133.64 -173.39 3.22 Favored 'General case' 0 CA--C 1.544 0.743 0 O-C-N 121.752 -0.852 . . . . 0.0 112.717 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.24 -174.44 2.72 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 127.981 2.512 . . . . 0.0 108.837 172.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.527 HD23 ' H ' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -174.72 -160.1 0.09 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 130.156 3.382 . . . . 0.0 107.038 171.908 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.527 ' H ' HD23 ' B' ' 144' ' ' LEU . . . -69.86 171.98 8.44 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 127.503 2.321 . . . . 0.0 113.781 -176.182 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -155.92 153.31 29.43 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.817 -168.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.96 141.15 7.66 Favored Glycine 0 N--CA 1.469 0.881 0 C-N-CA 125.347 1.451 . . . . 0.0 113.975 172.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 2.3 t -77.58 147.83 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.835 0.854 . . . . 0.0 110.164 171.741 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.7 mm -91.91 98.29 8.21 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 126.535 1.934 . . . . 0.0 110.836 -171.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.75 -171.6 30.31 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 124.564 1.078 . . . . 0.0 114.058 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.578 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 3.4 mp -119.21 128.82 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.186 0 C-N-CA 126.042 1.737 . . . . 0.0 114.367 -169.591 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -100.69 -24.34 14.44 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.35 1.06 . . . . 0.0 112.18 169.04 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 CA--C 1.534 0.345 0 C-N-CA 126.974 2.109 . . . . 0.0 111.618 -175.097 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 118.07 -0.967 . . . . 0.0 108.553 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.41 98.73 11.94 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 166.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.297 6.3 ptpt -127.24 129.78 48.39 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 176.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.27 153.38 28.51 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 126.659 1.984 . . . . 0.0 109.376 174.152 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -122.65 142.67 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.106 1.363 . . . . 0.0 108.976 177.355 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -105.19 133.32 50.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 121.092 1.769 . . . . 0.0 110.33 166.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' B' ' 54' ' ' THR . 57.5 t -118.22 109.24 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.576 1.15 . . . . 0.0 109.574 -175.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.63 140.83 48.5 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.544 1.538 . . . . 0.0 112.187 -172.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -160.8 164.25 31.57 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 168.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.492 ' HA3' ' HE3' ' B' ' 9' ' ' LYS . . . 82.23 73.22 1.23 Allowed Glycine 0 C--N 1.335 0.48 0 N-CA-C 120.706 3.043 . . . . 0.0 120.706 161.668 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -160.04 60.96 0.35 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 108.212 164.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.76 -172.41 21.8 Favored Glycine 0 CA--C 1.541 1.671 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -164.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -73.58 58.7 3.91 Favored 'Trans proline' 0 CA--C 1.534 0.493 1 C-N-CA 125.749 4.299 . . . . 0.0 110.044 173.225 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.95 133.76 53.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 125.728 1.611 . . . . 0.0 110.263 -168.526 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.8 163.65 38.72 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 126.353 1.861 . . . . 0.0 109.85 -169.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.29 148.26 17.98 Favored Glycine 0 C--N 1.33 0.196 0 CA-C-O 122.407 1.004 . . . . 0.0 115.556 176.553 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -123.25 138.54 52.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 126.318 1.847 . . . . 0.0 109.888 167.814 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.9 mm -140.57 127.09 21.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 C-N-CA 125.496 1.518 . . . . 0.0 108.235 166.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -85.79 141.2 29.84 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.906 1.682 . . . . 0.0 109.839 166.175 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -124.28 97.82 5.49 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.727 2.011 . . . . 0.0 107.29 176.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.62 116.43 28.73 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-O 123.436 1.588 . . . . 0.0 111.636 -172.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.45 HE22 ' C ' ' A' ' 25' ' ' SER . 22.1 tt0 -108.67 148.85 29.8 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.954 178.643 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.437 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -89.45 -26.15 21.11 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.637 1.175 . . . . 0.0 112.912 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -131.71 -151.58 0.47 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.389 1.876 . . . . 0.0 110.401 167.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.45 ' C ' HE22 ' A' ' 22' ' ' GLN . 30.6 t -111.41 -17.53 13.09 Favored 'General case' 0 CA--C 1.555 1.169 0 C-N-CA 125.315 1.446 . . . . 0.0 110.754 167.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -90.67 -24.32 20.5 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 127.661 2.384 . . . . 0.0 115.466 170.014 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.2 175.64 52.41 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 119.462 1.028 . . . . 0.0 114.79 -173.25 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.56 151.91 47.83 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.855 2.37 . . . . 0.0 110.718 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.86 128.73 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 177.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -88.97 119.41 29.47 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 169.293 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.24 133.29 59.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 125.69 1.596 . . . . 0.0 110.141 -176.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -156.08 156.54 34.52 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.543 0.737 . . . . 0.0 111.886 177.097 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.1 -149.74 16.71 Favored Glycine 0 C--N 1.333 0.394 0 O-C-N 121.924 -0.485 . . . . 0.0 112.963 171.108 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 53.6 p -155.39 115.11 3.68 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 122.976 0.511 . . . . 0.0 112.056 -169.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.06 125.41 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-O 117.299 -1.334 . . . . 0.0 107.593 170.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.8 tttp -124.75 140.67 52.72 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 121.891 2.132 . . . . 0.0 111.552 -176.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.88 -0.25 13.45 Favored Glycine 0 N--CA 1.476 1.343 0 C-N-CA 127.243 2.354 . . . . 0.0 114.661 -176.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.459 ' H ' HD22 ' A' ' 38' ' ' LEU . 2.3 mm? -69.15 -178.82 1.37 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.603 1.561 . . . . 0.0 110.985 170.005 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.59 -42.42 5.93 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 117.209 -1.377 . . . . 0.0 113.511 169.36 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 176.48 -107.67 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.267 0 C-N-CA 128.773 2.829 . . . . 0.0 109.628 -178.528 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -39.54 148.38 0.15 Allowed Glycine 0 N--CA 1.479 1.511 0 C-N-CA 129.533 3.444 . . . . 0.0 119.885 -168.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.446 HD23 ' H ' ' A' ' 42' ' ' LEU . 1.0 OUTLIER -31.3 136.67 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 130.1 3.36 . . . . 0.0 117.796 -169.084 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.0 m-70 -130.32 140.5 50.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 128.94 2.896 . . . . 0.0 108.764 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.57 156.52 53.33 Favored Glycine 0 N--CA 1.474 1.22 0 C-N-CA 124.08 0.848 . . . . 0.0 111.981 175.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -155.44 105.65 2.48 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.157 0.983 . . . . 0.0 112.374 -168.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.03 140.04 32.51 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 119.936 -1.728 . . . . 0.0 115.185 -172.577 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -78.11 134.99 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 166.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m170 -112.9 176.74 4.89 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 126.889 2.075 . . . . 0.0 110.901 -174.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -74.55 132.55 41.91 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.566 1.147 . . . . 0.0 112.297 170.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -77.78 -178.49 5.43 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 127.798 2.439 . . . . 0.0 115.216 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.505 ' HA2' ' CA ' ' B' ' 152' ' ' ALA . . . 119.78 -118.26 3.86 Favored Glycine 0 CA--C 1.502 -0.774 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.288 -172.017 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -87.83 63.45 7.44 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 125.229 2.442 . . . . 0.0 108.015 177.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -77.18 56.92 1.35 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 113.297 -1.774 . . . . 0.0 110.794 176.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.438 HG21 HD13 ' B' ' 17' ' ' ILE . 13.5 p -124.81 -44.88 1.92 Allowed 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.394 1.478 . . . . 0.0 113.943 -168.331 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.22 10.58 0.74 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.587 1.155 . . . . 0.0 113.093 170.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.78 -150.59 51.48 Favored Glycine 0 CA--C 1.528 0.869 0 O-C-N 120.493 -1.38 . . . . 0.0 111.294 -173.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 27.9 p -61.39 -7.29 2.87 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 117.196 2.295 . . . . 0.0 117.196 -169.149 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -88.44 -12.98 41.56 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 119.547 1.067 . . . . 0.0 113.784 170.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.3 t -124.09 -36.33 2.71 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.465 1.03 . . . . 0.0 111.853 173.146 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -69.07 86.94 0.38 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 166.194 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -47.68 120.95 6.33 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 126.736 2.112 . . . . 0.0 114.353 -166.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -67.46 126.42 14.85 Favored 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.625 2.217 . . . . 0.0 111.598 -173.167 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 59.65 60.96 2.08 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 164.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -45.22 109.95 0.21 Allowed 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.667 1.587 . . . . 0.0 112.746 -178.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.4 p-10 -135.5 55.33 12.56 Favored Pre-proline 0 CA--C 1.546 0.795 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -169.317 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -62.56 -16.16 50.59 Favored 'Trans proline' 0 C--N 1.354 0.836 0 C-N-CA 122.447 2.098 . . . . 0.0 112.495 170.245 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.7 mt -78.04 -7.18 56.58 Favored 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 169.183 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.3 t 64.98 56.18 1.08 Allowed 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.995 1.718 . . . . 0.0 112.412 170.117 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtm-85 -120.45 172.41 7.84 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 116.061 1.874 . . . . 0.0 116.061 -167.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.61 153.2 37.43 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 128.561 2.744 . . . . 0.0 109.944 168.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -74.42 151.24 39.67 Favored 'General case' 0 CA--C 1.541 0.598 0 O-C-N 120.807 -1.183 . . . . 0.0 113.551 171.741 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.421 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.96 -123.64 2.07 Favored Glycine 0 C--N 1.34 0.77 0 CA-C-O 118.728 -1.04 . . . . 0.0 113.499 166.623 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.417 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 119.9 -48.79 0.92 Allowed Glycine 0 CA--C 1.546 1.985 0 N-CA-C 117.758 1.863 . . . . 0.0 117.758 179.201 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -87.29 9.36 3.94 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.508 2.805 . . . . 0.0 114.131 178.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.6 pttt -165.15 -27.05 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 126.256 1.822 . . . . 0.0 112.263 179.006 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.421 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.1 OUTLIER -83.57 161.09 21.29 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 128.618 2.767 . . . . 0.0 109.406 166.104 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -95.64 -17.98 20.9 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 125.591 1.556 . . . . 0.0 112.334 -172.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -95.19 -68.34 0.81 Allowed 'General case' 0 C--O 1.231 0.105 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -167.036 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.521 HH22 HG23 ' A' ' 104' ' ' ILE . 63.4 ttt-85 68.36 125.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 123.191 1.472 . . . . 0.0 111.24 -176.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -66.09 169.96 6.29 Favored 'General case' 0 CA--C 1.554 1.098 0 O-C-N 119.1 -2.25 . . . . 0.0 111.86 167.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.3 t -68.17 -50.47 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 O-C-N 120.684 -1.26 . . . . 0.0 108.665 176.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.33 92.76 1.83 Allowed Glycine 0 CA--C 1.529 0.918 0 N-CA-C 107.651 -2.179 . . . . 0.0 107.651 165.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -157.42 143.72 17.84 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.471 1.509 . . . . 0.0 112.558 171.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.99 177.63 7.75 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 127.489 2.316 . . . . 0.0 107.243 168.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.2 -126.34 1.11 Allowed Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.331 1.443 . . . . 0.0 113.908 -173.176 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 38.2 p-10 -144.61 164.31 31.31 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -175.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 26.8 m -136.44 123.39 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.491 1.117 . . . . 0.0 111.703 -169.273 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 m -98.53 141.34 31.5 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.305 1.042 . . . . 0.0 108.706 171.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 95' ' ' ALA . . . -97.29 156.03 16.61 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 172.395 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.58 158.58 24.34 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.306 1.842 . . . . 0.0 107.876 165.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -50.06 -21.7 1.35 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.208 2.203 . . . . 0.0 116.605 177.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -78.09 4.21 12.98 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 125.199 1.4 . . . . 0.0 111.963 172.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.08 12.22 82.75 Favored Glycine 0 C--O 1.225 -0.441 0 C-N-CA 126.847 2.165 . . . . 0.0 114.24 176.262 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -105.73 122.66 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 CA-C-N 119.114 1.457 . . . . 0.0 112.357 -178.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 89' ' ' ALA . . . -91.91 95.85 10.05 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 125.277 1.431 . . . . 0.0 109.948 169.108 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -79.48 127.32 31.98 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.62 1.568 . . . . 0.0 109.673 175.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.1 p -134.68 144.69 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -171.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.2 t -156.69 115.88 3.42 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.656 1.182 . . . . 0.0 111.556 173.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.6 mt -139.56 158.5 27.69 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 128.918 2.887 . . . . 0.0 109.986 -173.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -135.47 136.2 41.1 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 124.975 1.31 . . . . 0.0 108.114 167.252 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -148.69 134.12 18.57 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.566 1.146 . . . . 0.0 110.628 -167.027 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.6 p -106.91 45.81 0.96 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.93 18.13 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.782 1.233 . . . . 0.0 110.919 -175.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.521 HG23 HH22 ' A' ' 79' ' ' ARG . 0.2 OUTLIER -146.91 154.95 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 128.433 2.693 . . . . 0.0 106.334 164.996 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.566 ' H ' ' HB3' ' A' ' 111' ' ' SER . 76.5 p -157.67 161.7 38.6 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.775 1.23 . . . . 0.0 110.839 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -88.05 86.19 7.08 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.0 t -113.74 -4.16 13.43 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.898 1.279 . . . . 0.0 113.75 -172.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.2 -47.33 1.49 Allowed Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.046 -0.864 . . . . 0.0 113.588 -177.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 36.2 p-10 -142.09 -51.24 0.4 Allowed 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.913 1.82 . . . . 0.0 115.913 -169.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.97 -8.82 59.24 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 126.069 1.747 . . . . 0.0 112.922 -166.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.566 ' HB3' ' H ' ' A' ' 105' ' ' SER . 69.0 m -134.03 -109.67 0.22 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.623 1.169 . . . . 0.0 109.343 -174.318 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.4 pt -117.35 169.79 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 122.033 0.921 . . . . 0.0 108.754 166.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 108.4 132.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.071 1 C-N-CA 134.974 5.31 . . . . 0.0 106.384 -165.148 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.95 -3.23 1.63 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 116.174 1.229 . . . . 0.0 116.174 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.436 ' HB3' HD12 ' A' ' 149' ' ' ILE . 46.7 ttm-85 -78.95 171.63 14.94 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.744 1.218 . . . . 0.0 110.316 -172.167 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.5 t -116.53 162.38 17.68 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.113 1.365 . . . . 0.0 110.275 -178.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.93 131.52 18.82 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.694 1.598 . . . . 0.0 109.239 178.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 82.4 t -116.21 133.97 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 125.138 1.375 . . . . 0.0 108.693 175.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.411 HG23 ' HB3' ' A' ' 144' ' ' LEU . 30.8 m -103.2 155.09 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 168.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.37 130.92 41.32 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.655 1.182 . . . . 0.0 109.917 -168.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -58.48 -18.44 28.9 Favored 'General case' 0 CA--C 1.549 0.935 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.1 mmtm -128.73 168.06 16.37 Favored 'General case' 0 N--CA 1.479 0.99 0 O-C-N 118.66 -2.525 . . . . 0.0 115.063 -171.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -48.64 136.18 13.67 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 126.379 1.872 . . . . 0.0 111.68 173.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -122.72 146.95 47.03 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 124.664 2.174 . . . . 0.0 113.47 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.84 -29.24 55.81 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 112.563 -2.108 . . . . 0.0 113.673 -166.045 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.4 mt 35.13 58.45 0.77 Allowed 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 128.376 2.67 . . . . 0.0 111.274 176.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 145.15 -101.31 0.24 Allowed Glycine 0 C--N 1.334 0.431 0 C-N-CA 125.117 1.341 . . . . 0.0 110.869 -172.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -156.7 121.97 4.68 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 126.65 1.98 . . . . 0.0 112.042 -167.297 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.83 -90.38 1.8 Allowed Glycine 0 N--CA 1.467 0.734 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 176.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.3 2.89 2.64 Favored Glycine 0 N--CA 1.472 1.098 0 C-N-CA 125.362 1.458 . . . . 0.0 115.306 179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -120.95 161.93 20.75 Favored 'General case' 0 N--CA 1.463 0.187 0 C-N-CA 124.454 1.102 . . . . 0.0 113.116 -169.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -60.23 -55.87 28.42 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.527 1.156 . . . . 0.0 108.807 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -57.74 -7.33 0.67 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.453 1.901 . . . . 0.0 114.579 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.7 p -68.01 -48.52 65.49 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.917 1.235 . . . . 0.0 112.342 171.21 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 64.7 p -83.51 -26.87 29.81 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.344 0.658 . . . . 0.0 112.311 176.617 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 mtpm? -75.55 -60.56 2.25 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 178.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.1 p -104.35 -45.23 4.73 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 119.983 1.265 . . . . 0.0 113.706 178.185 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 125.26 7.99 5.65 Favored Glycine 0 CA--C 1.524 0.653 0 C-N-CA 126.214 1.864 . . . . 0.0 113.103 -168.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 56.97 21.66 6.45 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 170.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.47 26.42 0.02 OUTLIER 'General case' 0 CA--C 1.568 1.646 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -169.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.97 -40.79 2.13 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 128.581 2.991 . . . . 0.0 115.894 169.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.4 m -171.23 -150.13 0.06 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 126.028 1.731 . . . . 0.0 110.61 -175.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.468 ' HD3' ' H ' ' A' ' 143' ' ' ARG . 0.0 OUTLIER -114.3 -163.44 0.87 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.815 1.646 . . . . 0.0 109.878 170.458 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.411 ' HB3' HG23 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -171.67 -155.27 0.1 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 128.112 2.565 . . . . 0.0 107.92 179.395 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.93 145.98 28.24 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.302 1.441 . . . . 0.0 111.189 174.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.6 p -128.11 147.58 50.55 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.317 179.093 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.27 174.72 32.65 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 116.043 1.177 . . . . 0.0 116.043 -172.004 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.0 t -143.26 154.38 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 C-N-CA 124.575 1.15 . . . . 0.0 110.827 -170.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' A' ' 115' ' ' ARG . 41.8 mt -89.53 116.68 31.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 126.217 1.807 . . . . 0.0 115.086 -170.064 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' B' ' 114' ' ' GLY . . . -98.99 -179.01 31.81 Favored Glycine 0 CA--C 1.531 1.094 0 C-N-CA 127.393 2.425 . . . . 0.0 112.937 167.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -144.8 138.67 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 CA-C-N 119.059 1.43 . . . . 0.0 114.258 -174.39 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.457 ' HB2' ' HA2' ' B' ' 51' ' ' GLY . . . -105.06 -35.5 7.61 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.083 1.142 . . . . 0.0 114.083 171.421 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 CA--C 1.546 0.823 0 CA-C-O 122.725 1.25 . . . . 0.0 111.409 -170.376 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.802 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 40.0 p -74.38 110.96 9.09 Favored 'General case' 0 CA--C 1.512 -0.492 0 C-N-CA 125.731 1.612 . . . . 0.0 108.222 -172.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.1 mtmm -100.7 140.91 34.31 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -171.294 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.86 170.04 9.86 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.489 2.316 . . . . 0.0 111.485 173.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.38 145.79 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.393 1.877 . . . . 0.0 111.839 -175.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.36 139.09 33.0 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 123.846 0.858 . . . . 0.0 109.0 165.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.3 79.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 121.44 0.638 . . . . 0.0 109.967 169.116 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.8 mp -82.87 139.66 33.33 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 9' ' ' LYS . . . . . 0.492 ' HE3' ' HA3' ' A' ' 10' ' ' GLY . 5.7 ttpt -154.7 157.98 38.89 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 171.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.59 173.8 19.72 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 107.256 -2.337 . . . . 0.0 107.256 164.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -79.27 55.45 1.87 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.616 1.966 . . . . 0.0 111.047 172.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.9 -164.02 32.53 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.433 1.492 . . . . 0.0 112.454 -168.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.44 45.31 1.82 Allowed 'Trans proline' 0 CA--C 1.539 0.736 1 C-N-CA 125.933 4.422 . . . . 0.0 114.497 -168.193 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.453 HG11 HD23 ' B' ' 144' ' ' LEU . 3.4 t -133.75 132.75 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 177.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -156.48 164.19 38.53 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 124.747 1.219 . . . . 0.0 110.811 -169.691 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -149.39 106.2 0.32 Allowed Glycine 0 N--CA 1.462 0.399 0 C-N-CA 125.326 1.441 . . . . 0.0 110.757 176.167 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 54' ' ' THR 0.262 0.1 OUTLIER -118.03 103.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -170.031 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 21.6 mm -121.48 120.97 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.168 0.987 . . . . 0.0 110.324 -168.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.79 138.92 38.43 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.716 0.807 . . . . 0.0 111.65 169.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -120.56 119.03 31.73 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.299 1.44 . . . . 0.0 108.312 169.186 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -107.68 119.67 40.08 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.128 0.971 . . . . 0.0 111.439 174.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -79.01 95.75 5.58 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 168.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.27 -20.17 62.26 Favored 'General case' 0 N--CA 1.475 0.816 0 O-C-N 120.551 -1.343 . . . . 0.0 112.927 175.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -156.41 127.23 6.81 Favored 'General case' 0 C--O 1.216 -0.666 0 C-N-CA 124.328 1.051 . . . . 0.0 112.635 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 7.4 m -60.91 -21.34 63.27 Favored 'General case' 0 N--CA 1.48 1.056 0 N-CA-C 116.232 1.938 . . . . 0.0 116.232 -169.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -115.09 1.24 13.86 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.161 2.184 . . . . 0.0 112.191 175.605 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.2 -157.53 10.81 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.541 2.02 . . . . 0.0 111.927 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.87 165.89 25.9 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.942 2.428 . . . . 0.0 113.283 -170.12 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.5 t -116.55 137.92 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 126.349 1.86 . . . . 0.0 108.897 174.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -92.51 129.12 38.54 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 123.82 0.848 . . . . 0.0 109.225 167.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -114.99 125.57 72.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 C-N-CA 125.669 1.588 . . . . 0.0 109.093 175.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -151.7 154.63 36.7 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.872 0.869 . . . . 0.0 110.985 174.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.96 178.5 18.88 Favored Glycine 0 N--CA 1.462 0.395 0 CA-C-O 122.439 1.022 . . . . 0.0 113.7 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 34' ' ' SER . . . . . 0.4 ' HB2' ' CG2' ' B' ' 94' ' ' VAL . 23.5 p -114.13 140.18 48.72 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 115.821 1.785 . . . . 0.0 115.821 -164.55 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.16 108.1 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 125.701 1.6 . . . . 0.0 108.869 169.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -119.26 147.61 44.07 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 124.31 1.044 . . . . 0.0 109.994 -171.142 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.8 19.36 29.45 Favored Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.563 1.554 . . . . 0.0 111.531 -170.351 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 71.5 mt -92.35 -171.49 2.81 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.513 1.925 . . . . 0.0 108.717 167.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.48 150.99 48.38 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 130.404 3.482 . . . . 0.0 105.178 167.802 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -50.21 -9.6 0.05 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 129.61 3.164 . . . . 0.0 116.785 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -63.88 163.26 33.58 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.385 -1.447 . . . . 0.0 112.233 168.203 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -57.74 142.94 43.71 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 126.0 1.72 . . . . 0.0 111.18 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -131.32 128.39 39.65 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.356 1.062 . . . . 0.0 110.419 169.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.417 ' HA3' ' HB2' ' B' ' 124' ' ' ASP . . . -69.76 154.86 53.13 Favored Glycine 0 N--CA 1.47 0.965 0 CA-C-O 118.333 -1.26 . . . . 0.0 112.439 177.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -149.06 124.08 10.04 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 119.466 1.633 . . . . 0.0 112.033 -169.396 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -156.44 158.81 37.94 Favored 'General case' 0 C--O 1.238 0.474 0 O-C-N 120.415 -1.428 . . . . 0.0 112.773 178.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.9 m -101.15 126.79 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.012 1.325 . . . . 0.0 108.746 177.312 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.9 m-70 -76.8 177.7 7.42 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 122.73 1.253 . . . . 0.0 110.991 -178.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -62.91 154.75 29.29 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 162.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.54 -135.74 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 122.05 0.928 . . . . 0.0 112.011 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.457 ' HA2' ' HB2' ' A' ' 152' ' ' ALA . . . 91.65 -109.43 3.73 Favored Glycine 0 CA--C 1.495 -1.167 0 C-N-CA 123.889 0.757 . . . . 0.0 111.966 168.322 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.32 58.76 0.86 Allowed 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 127.081 2.152 . . . . 0.0 105.666 -174.257 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -62.15 -2.86 1.06 Allowed 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 116.376 1.991 . . . . 0.0 116.376 -165.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.524 ' HA ' HG13 ' A' ' 7' ' ' VAL 0.343 0.6 OUTLIER -66.12 -33.21 75.27 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -164.2 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.53 8.55 40.26 Favored 'General case' 0 CA--C 1.552 1.048 0 CA-C-N 119.525 1.057 . . . . 0.0 113.198 168.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 55.66 -124.07 32.44 Favored Glycine 0 C--N 1.342 0.906 0 C-N-CA 125.034 1.302 . . . . 0.0 111.791 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t -56.23 -7.1 0.32 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 127.364 2.266 . . . . 0.0 115.695 176.536 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 23.4 m -115.73 30.2 7.5 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.534 1.533 . . . . 0.0 110.397 176.06 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 40.2 t -159.41 -55.77 0.06 Allowed 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.656 1.182 . . . . 0.0 110.723 170.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -94.77 141.52 28.53 Favored 'General case' 0 C--O 1.24 0.579 0 C-N-CA 124.058 0.943 . . . . 0.0 111.063 177.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.75 131.44 27.26 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 123.955 0.788 . . . . 0.0 112.5 175.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.0 114.05 2.84 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.759 2.306 . . . . 0.0 107.125 169.1 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.417 ' CE1' ' ND1' ' B' ' 71' ' ' HIS 0.27 0.0 OUTLIER 48.04 78.34 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.57 1.948 . . . . 0.0 114.125 -178.336 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -39.65 116.3 0.61 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.861 1.264 . . . . 0.0 110.559 169.153 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . 0.265 0.1 OUTLIER -122.41 73.37 40.32 Favored Pre-proline 0 CA--C 1.544 0.719 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -170.046 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -64.99 -24.78 59.84 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.821 2.347 . . . . 0.0 114.122 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.17 -6.43 56.54 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.077 0.951 . . . . 0.0 113.114 174.425 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.9 t 56.96 52.84 8.72 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.265 1.426 . . . . 0.0 113.508 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 mtp180 -109.34 179.1 4.25 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.662 1.185 . . . . 0.0 114.047 -169.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.97 175.44 9.07 Favored 'General case' 0 CA--C 1.548 0.885 0 O-C-N 120.591 -1.318 . . . . 0.0 108.633 162.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.417 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 83.6 t60 -110.85 152.47 26.64 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -167.785 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.488 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.35 -128.89 3.52 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-O 118.663 -1.076 . . . . 0.0 113.881 165.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 153.5 -40.05 0.69 Allowed Glycine 0 CA--C 1.546 1.969 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 176.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -112.23 29.99 0.03 OUTLIER 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 125.041 3.827 . . . . 0.0 111.608 169.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -158.93 -53.03 0.06 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 127.745 2.418 . . . . 0.0 106.332 -178.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 8.8 t0 -85.3 155.46 21.34 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.917 1.687 . . . . 0.0 108.865 163.11 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -103.93 -17.25 15.08 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.467 1.507 . . . . 0.0 112.34 172.173 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -74.44 -39.52 62.52 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 120.807 -1.183 . . . . 0.0 112.334 -170.594 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt85 33.28 90.92 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 127.33 2.252 . . . . 0.0 114.79 168.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.3 m80 -47.62 159.03 0.17 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.031 1.333 . . . . 0.0 112.511 178.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.8 m -71.08 87.29 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 119.063 0.847 . . . . 0.0 110.235 172.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.87 39.15 0.18 Allowed Glycine 0 CA--C 1.529 0.967 0 C-N-CA 126.361 1.934 . . . . 0.0 114.553 -173.463 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -134.33 118.08 17.09 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 125.466 1.506 . . . . 0.0 109.913 -173.578 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -105.66 -179.24 3.88 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.936 0.894 . . . . 0.0 109.44 169.032 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.41 -134.75 3.35 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 122.214 0.897 . . . . 0.0 112.455 179.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 86' ' ' ASN . . . . . 0.474 HD22 HD11 ' B' ' 126' ' ' LEU . 2.2 m-80 -112.75 142.2 45.67 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.723 0.809 . . . . 0.0 110.611 170.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 17.9 m -109.02 92.79 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 126.69 1.996 . . . . 0.0 109.104 173.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.5 m -82.53 132.29 35.2 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 173.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.37 171.62 8.93 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -83.83 162.72 20.48 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.118 1.367 . . . . 0.0 107.351 164.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.434 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -57.14 -14.84 4.44 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 172.217 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -72.3 -13.66 61.55 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 125.763 1.625 . . . . 0.0 111.71 172.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.51 4.53 67.94 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.015 1.769 . . . . 0.0 113.294 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 94' ' ' VAL . . . . . 0.4 ' CG2' ' HB2' ' B' ' 34' ' ' SER . 7.1 p -102.73 130.23 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 125.565 1.546 . . . . 0.0 113.788 177.087 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.82 108.41 19.9 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 165.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -98.61 113.66 25.8 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.102 0.953 . . . . 0.0 110.76 175.245 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -93.47 156.23 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 125.33 1.452 . . . . 0.0 113.807 -169.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.0 p -156.87 117.83 3.68 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.935 1.294 . . . . 0.0 111.098 173.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.7 mt -146.1 150.81 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 C-N-CA 128.78 2.832 . . . . 0.0 109.906 -176.225 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 -137.57 131.11 31.18 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.371 1.468 . . . . 0.0 107.57 168.101 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -155.4 152.19 28.76 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.901 1.074 . . . . 0.0 113.901 -168.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 86.3 p -116.49 59.34 0.74 Allowed 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 125.977 1.711 . . . . 0.0 114.184 -167.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 p -147.26 -2.61 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 116.357 1.984 . . . . 0.0 116.357 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.36 168.65 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 125.5 1.52 . . . . 0.0 110.785 177.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.439 ' H ' ' HB3' ' B' ' 111' ' ' SER . 57.9 p -147.97 170.42 17.75 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 115.571 1.693 . . . . 0.0 115.571 178.217 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mp -102.92 48.03 0.87 Allowed 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 168.258 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.3 m -85.27 33.66 0.56 Allowed 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.569 -1.332 . . . . 0.0 112.405 -176.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 87.97 65.77 1.33 Allowed Glycine 0 N--CA 1.469 0.862 0 C-N-CA 124.158 0.885 . . . . 0.0 112.767 176.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.315 0.0 OUTLIER 76.78 -21.74 0.31 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 127.673 2.389 . . . . 0.0 114.334 170.176 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -77.52 11.66 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 127.322 2.249 . . . . 0.0 112.886 -173.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 111' ' ' SER . . . . . 0.439 ' HB3' ' H ' ' B' ' 105' ' ' SER . 0.6 OUTLIER -142.02 -72.2 0.33 Allowed 'General case' 0 CA--C 1.544 0.743 0 N-CA-C 116.512 2.041 . . . . 0.0 116.512 170.471 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.94 0.7 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 116.016 1.858 . . . . 0.0 116.016 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.6 mm -89.12 149.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 168.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 114' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' A' ' 150' ' ' GLY . . . 77.72 6.78 87.19 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 114.561 0.585 . . . . 0.0 114.561 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.8 ttt180 -115.31 179.28 4.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.989 2.116 . . . . 0.0 111.462 -168.176 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.83 151.39 37.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 C-N-CA 124.034 0.934 . . . . 0.0 111.124 177.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 19.5 tp -128.31 140.91 51.61 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 127.13 2.172 . . . . 0.0 106.572 167.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.37 156.38 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 124.362 1.065 . . . . 0.0 110.592 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -125.87 134.04 67.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-O 122.514 1.149 . . . . 0.0 110.697 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -92.34 145.85 24.15 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.426 1.49 . . . . 0.0 112.258 -168.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -67.62 -39.92 84.69 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 121.086 -1.009 . . . . 0.0 111.996 -174.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -98.69 -179.99 4.49 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.582 1.153 . . . . 0.0 109.962 167.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.59 165.49 0.83 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.697 1.199 . . . . 0.0 111.541 168.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.417 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 26.0 t70 -107.87 148.25 29.84 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.739 0.78 . . . . 0.0 110.662 165.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.73 -20.81 45.54 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.595 1.958 . . . . 0.0 114.807 -169.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.474 HD11 HD22 ' B' ' 86' ' ' ASN . 8.9 mt 41.61 49.02 3.65 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 126.238 1.815 . . . . 0.0 113.993 169.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 135.71 -78.56 0.34 Allowed Glycine 0 N--CA 1.469 0.839 0 C-N-CA 124.894 1.235 . . . . 0.0 111.288 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.86 148.4 22.42 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 117.585 2.439 . . . . 0.0 117.585 170.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -157.67 -79.5 0.03 OUTLIER Glycine 0 C--N 1.332 0.315 0 C-N-CA 130.287 3.803 . . . . 0.0 106.901 171.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.6 -92.87 0.02 OUTLIER Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.056 1.789 . . . . 0.0 115.955 -169.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -131.03 -127.54 0.2 Allowed 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.169 -1.195 . . . . 0.0 113.03 -166.441 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.32 -53.78 4.08 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.292 3.037 . . . . 0.0 109.949 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -43.46 -33.64 1.14 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 128.3 2.64 . . . . 0.0 114.03 169.199 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.8 m -45.33 -36.43 4.15 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 126.639 1.975 . . . . 0.0 113.702 168.038 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -103.3 -20.27 14.16 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 126.126 1.77 . . . . 0.0 113.886 -173.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 41.9 mtpt -80.6 -36.5 32.67 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.053 0.941 . . . . 0.0 110.745 170.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 20.0 p -135.95 -108.88 0.2 Allowed 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 127.324 2.249 . . . . 0.0 107.953 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -165.94 148.18 13.35 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 127.597 2.522 . . . . 0.0 108.151 169.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -75.42 45.56 0.3 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.54 1.536 . . . . 0.0 112.572 -172.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.51 6.24 24.38 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -167.015 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.61 -47.29 0.42 Allowed Glycine 0 CA--C 1.536 1.39 0 N-CA-C 118.948 2.339 . . . . 0.0 118.948 168.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -175.31 -176.93 0.97 Allowed 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.547 1.674 . . . . 0.0 112.406 -169.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.29 142.43 19.29 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.978 1.311 . . . . 0.0 111.591 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.453 HD23 HG11 ' B' ' 14' ' ' VAL . 0.0 OUTLIER -103.74 -20.7 13.86 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.706 1.203 . . . . 0.0 114.123 -176.218 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.449 ' N ' HD22 ' B' ' 144' ' ' LEU . . . -155.56 147.05 22.87 Favored 'General case' 0 C--O 1.244 0.775 0 C-N-CA 124.486 1.114 . . . . 0.0 109.195 -178.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 63.3 m -138.99 149.18 44.4 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 127.936 2.494 . . . . 0.0 108.774 -179.015 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.71 160.03 29.98 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 115.421 0.929 . . . . 0.0 115.421 -174.188 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 5.2 t -109.56 152.15 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.189 1.396 . . . . 0.0 109.789 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.3 mm -94.72 116.78 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 126.081 1.753 . . . . 0.0 112.07 -174.371 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.16 165.48 15.13 Favored Glycine 0 C--N 1.348 1.237 0 C-N-CA 124.358 0.98 . . . . 0.0 112.503 177.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -117.7 124.89 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.505 ' CA ' ' HA2' ' A' ' 51' ' ' GLY . . . -79.76 -25.06 41.12 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 121.596 0.712 . . . . 0.0 110.265 165.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 70.0 mt-30 . . . . . 0 CA--C 1.531 0.229 0 C-N-CA 125.74 1.616 . . . . 0.0 109.023 178.347 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.802 0 CA-C-O 120.336 0.112 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 34.7 p -84.24 118.4 24.14 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -171.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.4 ttmm -101.89 125.95 48.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.014 -1.903 . . . . 0.0 106.315 168.05 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.57 159.85 41.21 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 125.116 1.367 . . . . 0.0 111.325 -169.761 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.6 t -139.65 143.42 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.438 1.113 . . . . 0.0 112.907 -169.001 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.2 111.72 14.92 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 164.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.614 ' CG2' ' H ' ' B' ' 54' ' ' THR . 6.8 m -97.27 112.29 28.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 168.193 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.7 mp -96.87 107.61 20.14 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.529 1.132 . . . . 0.0 111.021 -168.078 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -155.29 124.4 6.23 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 121.782 0.801 . . . . 0.0 112.865 173.226 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.63 -41.34 0.02 OUTLIER Glycine 0 CA--C 1.53 0.985 0 C-N-CA 127.898 2.666 . . . . 0.0 109.478 167.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -79.26 59.37 2.79 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 128.337 2.655 . . . . 0.0 112.55 -174.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.96 -104.25 0.06 OUTLIER Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.867 2.175 . . . . 0.0 114.232 171.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.04 -9.6 14.13 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 124.656 3.571 . . . . 0.0 114.621 -175.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.6 t -90.41 138.69 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-N 120.448 1.476 . . . . 0.0 108.325 171.076 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -156.82 164.81 37.66 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.018 1.327 . . . . 0.0 109.944 169.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.04 174.02 34.64 Favored Glycine 0 CA--C 1.507 -0.42 0 C-N-CA 124.329 0.966 . . . . 0.0 111.432 167.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 pp -127.52 142.15 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 C-N-CA 124.533 1.133 . . . . 0.0 108.356 168.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -130.19 133.83 63.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.708 . . . . 0.0 109.201 170.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -103.23 141.58 35.65 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 110.095 169.053 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -124.87 119.68 29.52 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.612 1.565 . . . . 0.0 108.24 171.486 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -115.85 119.33 35.64 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.346 1.459 . . . . 0.0 110.561 -175.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -129.62 141.83 50.86 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 123.506 1.622 . . . . 0.0 113.802 -174.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HE2' ' OE2' ' A' ' 24' ' ' GLU . 15.0 ptmt -82.93 -62.7 1.53 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.742 2.017 . . . . 0.0 114.189 -171.552 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.478 ' OE2' ' HE2' ' A' ' 23' ' ' LYS . 3.7 pm0 -133.48 172.81 12.22 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 126.215 1.806 . . . . 0.0 110.668 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 p -45.06 -54.03 7.17 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.37 1.868 . . . . 0.0 115.434 -168.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -96.2 7.75 45.63 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.795 1.638 . . . . 0.0 111.73 -178.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.24 150.46 37.11 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 125.27 1.414 . . . . 0.0 113.627 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -63.66 162.85 26.48 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 123.996 3.131 . . . . 0.0 110.373 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -129.86 130.76 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 C-N-CA 123.346 0.658 . . . . 0.0 110.046 -169.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -91.15 131.81 36.47 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 167.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.7 t -124.24 137.79 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 125.567 1.547 . . . . 0.0 109.132 -173.014 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.4 p90 -157.29 168.66 26.74 Favored 'General case' 0 N--CA 1.471 0.624 0 O-C-N 121.276 -0.89 . . . . 0.0 113.286 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.34 -157.68 27.35 Favored Glycine 0 C--N 1.335 0.498 0 C-N-CA 125.173 1.368 . . . . 0.0 111.204 170.507 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.5 p -155.5 147.5 23.44 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -122.07 122.19 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 -177.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 59.8 tttt -120.81 133.44 55.32 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.317 1.047 . . . . 0.0 110.579 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.26 4.29 16.14 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.931 2.205 . . . . 0.0 112.645 -168.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 98.0 mt -82.89 163.38 21.16 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 118.201 1.0 . . . . 0.0 111.467 169.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.9 t -96.81 145.65 25.64 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 126.038 1.735 . . . . 0.0 107.475 165.409 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.486 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.8 pm0 -51.19 143.35 11.14 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.196 2.598 . . . . 0.0 114.739 -173.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.76 -179.81 34.42 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 125.012 1.292 . . . . 0.0 113.464 -172.159 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -56.73 151.28 14.39 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 128.058 2.543 . . . . 0.0 113.555 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -147.96 138.82 23.22 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.905 1.682 . . . . 0.0 109.411 167.524 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.67 154.91 20.9 Favored Glycine 0 N--CA 1.48 1.604 0 C-N-CA 124.051 0.834 . . . . 0.0 113.115 172.088 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -158.58 95.37 1.32 Allowed 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 124.423 1.089 . . . . 0.0 112.262 -170.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -146.14 148.92 33.09 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.262 1.579 . . . . 0.0 115.262 -169.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -82.76 110.97 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.95 1.7 . . . . 0.0 110.186 171.517 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -82.65 165.97 19.56 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.795 2.038 . . . . 0.0 110.793 176.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -59.96 145.11 47.26 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 122.35 1.071 . . . . 0.0 111.469 -176.184 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -82.53 -114.93 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.709 1.604 . . . . 0.0 111.739 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.5 -96.06 1.73 Allowed Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -143.92 54.68 1.31 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 -172.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.29 5.3 p30 -73.39 27.98 0.07 Allowed 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.627 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.774 HG22 ' HA ' ' B' ' 7' ' ' VAL . 8.4 p -90.36 -7.37 53.42 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.352 1.461 . . . . 0.0 113.772 -168.015 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.19 -4.23 35.93 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.057 1.743 . . . . 0.0 112.97 168.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.92 -101.52 0.27 Allowed Glycine 0 C--N 1.343 0.941 0 CA-C-N 120.056 1.298 . . . . 0.0 112.519 170.193 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.4 m -54.83 -17.88 4.12 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 175.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.03 7.07 23.5 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.297 1.439 . . . . 0.0 113.521 175.267 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.4 t -171.85 98.0 0.17 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.94 1.696 . . . . 0.0 108.342 178.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 149.6 58.86 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 130.559 3.544 . . . . 0.0 111.687 -169.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -61.84 147.96 48.08 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 126.279 1.895 . . . . 0.0 114.123 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.77 95.17 0.54 Allowed 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 124.796 3.664 . . . . 0.0 113.765 -168.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 p80 42.95 68.2 0.53 Allowed 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 126.517 1.927 . . . . 0.0 112.485 166.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -39.28 142.87 0.22 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-O 124.009 1.861 . . . . 0.0 115.085 -167.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 38.9 p-10 -104.41 48.95 0.08 OUTLIER Pre-proline 0 CA--C 1.554 1.121 0 C-N-CA 127.11 2.164 . . . . 0.0 114.352 -177.168 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -69.77 -15.81 37.22 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 121.941 1.729 . . . . 0.0 112.473 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.68 -3.16 42.72 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.769 1.628 . . . . 0.0 112.325 169.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.1 t 69.97 57.72 0.29 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.662 1.585 . . . . 0.0 113.029 168.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 ptm85 -152.6 176.41 11.75 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -169.023 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -91.24 168.17 11.79 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.35 1.46 . . . . 0.0 112.705 -179.001 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.6 t60 -75.95 160.56 29.76 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.427 1.091 . . . . 0.0 113.512 179.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.419 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 136.41 -113.64 1.08 Allowed Glycine 0 C--N 1.339 0.713 0 C-N-CA 125.392 1.472 . . . . 0.0 112.315 166.34 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.488 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 116.93 -56.52 0.54 Allowed Glycine 0 CA--C 1.537 1.449 0 N-CA-C 117.742 1.857 . . . . 0.0 117.742 171.344 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -81.24 -16.69 9.52 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 CA-C-N 121.54 2.67 . . . . 0.0 112.505 178.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.51 -5.73 4.2 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.804 1.242 . . . . 0.0 112.893 173.104 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.5 169.3 8.75 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.462 1.505 . . . . 0.0 110.377 178.072 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -101.08 -7.07 23.54 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 127.083 2.153 . . . . 0.0 112.729 -167.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -127.35 -82.94 0.61 Allowed 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 119.597 1.09 . . . . 0.0 113.583 -171.039 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 79.12 140.55 0.07 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 126.289 1.836 . . . . 0.0 113.546 170.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -82.95 -177.77 6.88 Favored 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 116.361 1.986 . . . . 0.0 116.361 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -66.97 -12.13 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 174.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -134.81 14.03 4.43 Favored Glycine 0 CA--C 1.531 1.085 0 CA-C-O 118.161 -1.355 . . . . 0.0 116.31 -171.014 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -92.84 112.6 24.62 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.654 1.727 . . . . 0.0 111.275 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.4 48.72 1.38 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 120.101 1.319 . . . . 0.0 111.874 177.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.94 -143.98 24.65 Favored Glycine 0 CA--C 1.536 1.367 0 O-C-N 121.211 -0.931 . . . . 0.0 114.93 172.161 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -131.95 158.07 42.38 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 126.184 1.793 . . . . 0.0 112.883 -179.385 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.7 m -114.17 106.74 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.165 1.786 . . . . 0.0 111.001 169.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.4 m -106.49 115.61 30.5 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.599 1.56 . . . . 0.0 110.229 -169.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.13 147.79 24.74 Favored 'General case' 0 CA--C 1.539 0.558 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -172.197 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -93.96 160.65 14.63 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 128.978 2.911 . . . . 0.0 109.685 168.239 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.83 -14.9 2.65 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 126.169 1.788 . . . . 0.0 115.698 -175.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.27 -5.3 26.75 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.757 -1.215 . . . . 0.0 112.11 171.318 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.82 15.53 65.28 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 127.008 2.242 . . . . 0.0 112.878 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.0 p -121.33 128.87 76.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.544 1.172 . . . . 0.0 113.699 -170.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.64 110.56 22.66 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 164.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -91.9 137.27 32.5 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 169.104 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -135.68 149.65 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 N-CA-C 116.801 2.148 . . . . 0.0 116.801 -168.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.9 m -155.21 127.37 7.7 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 126.052 1.741 . . . . 0.0 110.367 169.373 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 10.1 mm -140.82 166.44 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 129.026 2.93 . . . . 0.0 109.794 -173.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -155.29 154.61 32.38 Favored 'General case' 0 C--N 1.316 -0.87 0 C-N-CA 128.108 2.563 . . . . 0.0 107.825 170.217 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -155.79 150.99 26.7 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.938 1.295 . . . . 0.0 111.577 170.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -119.03 53.05 1.02 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.521 -1.218 . . . . 0.0 112.225 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 48.9 t -137.81 -43.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.3 1.44 . . . . 0.0 107.928 168.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.87 160.11 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 123.027 1.394 . . . . 0.0 110.93 167.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.53 ' H ' ' HB3' ' A' ' 111' ' ' SER . 3.6 p -156.29 168.87 25.97 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 128.762 2.825 . . . . 0.0 106.969 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -93.25 102.3 14.58 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -152.83 -6.91 0.19 Allowed 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -167.282 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.13 -95.83 2.13 Favored Glycine 0 C--N 1.336 0.546 0 O-C-N 120.927 -1.108 . . . . 0.0 111.613 173.191 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -69.97 -51.99 28.07 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.851 0.685 . . . . 0.0 112.851 -166.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -78.92 -27.81 43.78 Favored 'General case' 0 CA--C 1.539 0.547 0 O-C-N 120.271 -1.518 . . . . 0.0 112.358 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.53 ' HB3' ' H ' ' A' ' 105' ' ' SER . 8.2 m -118.88 -127.16 0.28 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.857 1.799 . . . . 0.0 115.857 -164.617 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.29 39.3 pt -111.03 173.69 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 O-C-N 119.769 -1.832 . . . . 0.0 108.682 166.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mm 90.49 136.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.843 1 C-N-CA 132.757 4.423 . . . . 0.0 107.25 -163.344 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 58.35 25.2 57.29 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.556 1.074 . . . . 0.0 114.687 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.1 ttm180 -122.17 156.29 34.0 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 126.614 1.965 . . . . 0.0 107.515 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.9 t -113.07 107.62 16.21 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 122.352 2.342 . . . . 0.0 115.694 -165.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 57.0 tp -76.99 128.92 35.39 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.72 0.808 . . . . 0.0 110.266 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -118.04 136.56 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.252 1.021 . . . . 0.0 109.127 169.352 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 m -93.04 144.74 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.384 -1.709 . . . . 0.0 106.384 168.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.7 m-70 -101.98 158.93 15.79 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-O 122.369 1.08 . . . . 0.0 112.987 -170.008 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -74.71 -35.64 62.71 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 -168.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -125.85 179.98 4.94 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 125.29 1.436 . . . . 0.0 112.597 173.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.25 140.47 38.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 126.683 1.993 . . . . 0.0 112.463 173.706 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -91.58 131.03 37.28 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.115 0.966 . . . . 0.0 111.057 178.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.419 ' OD1' ' HE3' ' A' ' 128' ' ' LYS . 0.3 OUTLIER -77.09 -18.93 57.65 Favored 'General case' 0 CA--C 1.554 1.118 0 N-CA-C 112.889 0.699 . . . . 0.0 112.889 174.998 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 41.3 mt 62.08 54.39 2.74 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.946 2.098 . . . . 0.0 113.686 173.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 118.62 -11.23 12.37 Favored Glycine 0 N--CA 1.475 1.246 0 N-CA-C 121.297 3.279 . . . . 0.0 121.297 164.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.541 ' HE3' ' H ' ' A' ' 128' ' ' LYS 0.252 0.0 OUTLIER -167.08 62.11 0.08 Allowed 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 118.192 2.664 . . . . 0.0 118.192 -173.626 . . . . . . . . 4 4 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -106.25 45.68 1.27 Allowed Glycine 0 N--CA 1.471 0.975 0 C-N-CA 127.041 2.257 . . . . 0.0 113.349 -172.342 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.21 -27.53 1.47 Allowed Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.62 1.105 . . . . 0.0 115.749 172.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -89.77 154.55 19.83 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 118.983 1.391 . . . . 0.0 110.381 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -55.33 -54.14 47.31 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-O 122.751 1.262 . . . . 0.0 109.108 167.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.4 tm-20 -51.89 -34.89 43.26 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 128.447 2.699 . . . . 0.0 112.593 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.0 p -60.03 -34.39 73.3 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.7 p -77.13 -14.37 59.81 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.61 1.164 . . . . 0.0 111.991 179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.3 mtpt -100.15 -53.76 3.05 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.516 1.926 . . . . 0.0 111.891 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.8 p -100.08 -34.42 10.07 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 117.659 -1.162 . . . . 0.0 113.781 -172.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.98 -3.2 28.64 Favored Glycine 0 CA--C 1.533 1.196 0 O-C-N 125.448 1.717 . . . . 0.0 113.715 -168.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.69 25.04 11.28 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 126.193 1.797 . . . . 0.0 112.738 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.82 46.39 0.29 Allowed 'General case' 0 CA--C 1.552 1.049 0 C-N-CA 126.799 2.04 . . . . 0.0 113.755 -168.157 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.04 -59.4 3.54 Favored Glycine 0 N--CA 1.467 0.728 0 C-N-CA 127.987 2.708 . . . . 0.0 113.692 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t 178.09 179.03 0.34 Allowed 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.11 2.164 . . . . 0.0 109.494 -169.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.64 153.66 35.02 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.03 -1.044 . . . . 0.0 111.018 169.75 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -135.14 -150.77 0.4 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.375 1.47 . . . . 0.0 108.63 169.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -52.93 141.96 20.64 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.274 1.43 . . . . 0.0 114.151 -173.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -134.72 154.67 51.46 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.983 1.313 . . . . 0.0 114.361 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.24 125.03 1.55 Allowed Glycine 0 CA--C 1.539 1.562 0 C-N-CA 124.646 1.117 . . . . 0.0 114.557 173.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -78.14 126.58 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 173.209 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 59.9 mt -78.41 124.51 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -167.166 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.76 167.97 13.96 Favored Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.847 1.213 . . . . 0.0 115.413 175.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.57 162.82 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 126.438 1.895 . . . . 0.0 113.416 -171.016 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.416 ' HB1' ' CD2' ' B' ' 50' ' ' PHE . . . -158.18 -40.97 0.06 Allowed 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.01 1.324 . . . . 0.0 112.032 169.062 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.47 0.538 0 C-N-CA 124.226 1.01 . . . . 0.0 112.159 169.096 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 70.9 p -134.08 125.43 28.02 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 166.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.3 mtmt -119.57 158.54 26.13 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -179.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.492 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -144.58 151.99 39.87 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.98 1.312 . . . . 0.0 112.534 169.589 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 p -111.08 133.53 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 125.987 1.715 . . . . 0.0 110.673 177.298 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.54 110.94 21.3 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.774 -1.204 . . . . 0.0 110.088 167.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 54' ' ' THR . 15.0 t -86.52 68.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 124.36 1.064 . . . . 0.0 112.063 -170.396 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -79.77 110.56 15.24 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 113.426 0.898 . . . . 0.0 113.426 -175.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mttm -157.62 129.55 7.03 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.71 1.204 . . . . 0.0 112.195 167.508 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.68 -56.9 0.01 OUTLIER Glycine 0 N--CA 1.468 0.772 0 C-N-CA 126.233 1.873 . . . . 0.0 109.885 169.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.58 72.29 3.24 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 125.989 1.715 . . . . 0.0 110.953 -176.777 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.64 -94.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.377 0 C-N-CA 127.844 2.64 . . . . 0.0 114.746 173.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -71.08 -20.98 28.03 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 123.964 3.109 . . . . 0.0 114.797 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.1 t -74.15 147.65 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 CA-C-N 121.483 1.947 . . . . 0.0 110.491 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.32 167.75 21.2 Favored 'General case' 0 CA--C 1.519 -0.228 0 C-N-CA 124.48 1.112 . . . . 0.0 109.651 167.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.8 59.58 0.4 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.874 169.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -75.41 127.42 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 117.776 0.788 . . . . 0.0 108.987 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.18 119.55 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 O-C-N 125.277 1.61 . . . . 0.0 109.741 176.51 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.2 121.27 23.41 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 124.915 1.286 . . . . 0.0 110.65 165.829 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -99.67 94.17 6.22 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.26 1.824 . . . . 0.0 106.135 167.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -98.25 113.66 25.67 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 124.311 1.044 . . . . 0.0 110.349 178.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -113.13 139.01 49.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 122.678 1.228 . . . . 0.0 110.464 179.431 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.71 -5.05 54.43 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.1 1.36 . . . . 0.0 114.237 -171.599 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 mp0 -155.75 -168.24 2.73 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 130.078 3.351 . . . . 0.0 106.603 175.499 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.8 t -89.2 -21.13 23.43 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-N 119.957 1.253 . . . . 0.0 110.135 163.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -109.6 11.32 24.8 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 126.191 1.796 . . . . 0.0 115.232 -176.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.77 -179.75 38.85 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 124.423 1.011 . . . . 0.0 112.834 -177.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.23 161.47 20.23 Favored 'Trans proline' 0 CA--C 1.537 0.654 0 C-N-CA 123.346 2.697 . . . . 0.0 109.421 168.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.01 134.94 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.89 0.876 . . . . 0.0 111.734 -169.239 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.6 mttp -87.84 126.14 34.86 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 165.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -123.75 89.03 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 127.362 2.265 . . . . 0.0 108.23 -169.218 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -119.09 156.24 30.08 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.799 0.84 . . . . 0.0 111.815 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.84 176.82 41.71 Favored Glycine 0 C--O 1.225 -0.439 0 O-C-N 121.479 -0.763 . . . . 0.0 113.437 -174.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -127.75 118.78 24.41 Favored 'General case' 0 C--O 1.239 0.543 0 O-C-N 122.054 -0.674 . . . . 0.0 111.948 -178.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.1 mm -92.08 117.8 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 169.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.3 pttt -139.41 137.34 35.58 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 123.185 0.594 . . . . 0.0 110.328 -168.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.29 0.68 54.01 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.871 1.7 . . . . 0.0 114.787 -173.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.464 HD11 ' HB2' ' B' ' 89' ' ' ALA . 0.5 OUTLIER -91.3 -160.35 0.72 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 118.412 1.106 . . . . 0.0 111.304 169.676 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.6 t -112.19 155.99 23.06 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.293 1.837 . . . . 0.0 110.976 178.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -47.65 149.85 1.13 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.625 1.97 . . . . 0.0 111.879 169.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.75 38.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 124.009 0.814 . . . . 0.0 113.726 -178.56 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -65.87 144.51 56.77 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 128.921 2.888 . . . . 0.0 113.157 -171.284 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -140.53 124.05 16.97 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 126.608 1.963 . . . . 0.0 110.508 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.5 149.85 35.45 Favored Glycine 0 N--CA 1.476 1.334 0 C-N-CA 124.744 1.164 . . . . 0.0 112.391 176.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -146.52 102.2 3.55 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-O 121.861 0.838 . . . . 0.0 112.404 -164.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -129.45 126.23 38.26 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 120.855 -1.153 . . . . 0.0 110.427 -169.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.79 116.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.296 1.439 . . . . 0.0 108.984 171.556 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.458 ' C ' ' H ' ' B' ' 50' ' ' PHE . 21.8 m170 -78.86 122.25 25.85 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 121.307 -0.871 . . . . 0.0 110.381 -179.493 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.65 2.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 127.053 2.141 . . . . 0.0 115.426 170.03 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 50' ' ' PHE . . . . . 0.458 ' H ' ' C ' ' B' ' 48' ' ' HIS . 2.5 m-85 -137.16 81.51 1.88 Allowed 'General case' 0 N--CA 1.442 -0.839 1 C-N-CA 133.776 4.83 . . . . 0.0 100.94 -176.011 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.05 20.07 35.04 Favored Glycine 0 N--CA 1.467 0.73 0 O-C-N 121.655 -0.653 . . . . 0.0 113.225 173.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -68.99 49.06 0.07 Allowed 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.042 2.537 . . . . 0.0 113.085 171.002 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.6 p-10 -178.74 131.45 0.12 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.414 1.486 . . . . 0.0 111.047 -168.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.614 ' H ' ' CG2' ' A' ' 7' ' ' VAL . 6.6 t -152.31 14.7 0.6 Allowed 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 116.236 1.939 . . . . 0.0 116.236 175.51 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.44 25.58 10.52 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 119.293 0.951 . . . . 0.0 110.901 167.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.25 -119.63 15.17 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 124.634 1.111 . . . . 0.0 112.148 170.359 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 20.7 m -68.34 -24.28 64.8 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 118.161 -0.923 . . . . 0.0 113.395 174.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.5 m -81.54 45.83 0.91 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 120.287 1.403 . . . . 0.0 109.258 171.571 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -170.97 -59.71 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.922 1.689 . . . . 0.0 111.633 -176.002 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.05 172.93 15.54 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 -168.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.52 -82.19 0.51 Allowed Glycine 0 CA--C 1.54 1.616 0 C-N-CA 126.842 2.163 . . . . 0.0 112.059 178.567 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.44 ' HA ' HG22 ' B' ' 137' ' ' THR . 66.9 Cg_endo -85.83 178.14 4.43 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 125.15 3.9 . . . . 0.0 115.139 -172.005 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -103.4 123.8 47.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.203 1.401 . . . . 0.0 110.796 179.386 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -58.26 146.9 32.47 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 120.789 0.328 . . . . 0.0 110.418 167.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.21 107.73 21.56 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.597 0.759 . . . . 0.0 112.515 -178.179 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -68.81 -30.85 26.4 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.135 1.89 . . . . 0.0 111.844 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -76.98 -7.81 56.28 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.096 0.959 . . . . 0.0 112.709 175.492 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.7 m 57.76 56.46 4.8 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.627 1.171 . . . . 0.0 111.743 172.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.89 172.69 15.64 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.394 1.478 . . . . 0.0 110.704 -168.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -72.5 176.68 5.19 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 -171.715 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -49.23 155.09 0.73 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.447 2.017 . . . . 0.0 116.447 -167.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' B' ' 79' ' ' ARG . . . -75.61 69.33 2.07 Favored Glycine 0 N--CA 1.473 1.144 0 C-N-CA 128.892 3.139 . . . . 0.0 114.212 -169.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.46 135.84 13.62 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 114.608 0.603 . . . . 0.0 114.608 -173.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -84.58 -0.95 9.52 Favored 'Trans proline' 0 CA--C 1.548 1.207 0 C-N-CA 123.87 3.047 . . . . 0.0 109.597 163.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.472 ' HE2' ' O ' ' B' ' 125' ' ' ASP . 0.1 OUTLIER -118.37 -10.61 10.15 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.642 1.977 . . . . 0.0 114.167 177.613 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -110.7 149.48 30.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.362 1.065 . . . . 0.0 109.022 -167.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -67.35 -25.53 66.03 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -88.65 146.22 25.21 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-O 125.07 2.367 . . . . 0.0 109.319 169.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.49 ' HA ' ' HA2' ' B' ' 72' ' ' GLY . 52.9 ttt-85 -167.03 106.67 0.6 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 112.545 -2.116 . . . . 0.0 113.293 -174.175 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -61.59 149.33 39.47 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.401 1.081 . . . . 0.0 109.157 162.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.3 -13.66 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 CA-C-N 120.891 1.678 . . . . 0.0 110.323 166.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.28 18.82 9.37 Favored Glycine 0 C--N 1.336 0.548 0 C-N-CA 127.235 2.35 . . . . 0.0 118.879 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.99 149.43 32.15 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 122.608 3.204 . . . . 0.0 112.917 168.672 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -107.64 174.95 5.66 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.575 1.55 . . . . 0.0 108.561 168.26 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.48 155.31 49.79 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 171.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -74.4 146.61 42.8 Favored 'General case' 0 CA--C 1.549 0.941 0 CA-C-O 121.658 0.742 . . . . 0.0 111.825 -170.324 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -101.21 119.56 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.996 1.719 . . . . 0.0 112.48 -168.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -98.58 126.88 44.3 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.331 1.052 . . . . 0.0 110.283 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.464 ' HB2' HD11 ' B' ' 38' ' ' LEU . . . -92.95 162.13 14.19 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 171.51 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -85.97 168.99 13.66 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.889 2.075 . . . . 0.0 113.123 170.216 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.24 61.93 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.644 1.978 . . . . 0.0 114.963 -177.329 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.35 2.35 18.89 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 125.643 1.577 . . . . 0.0 112.146 177.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.16 21.75 56.32 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 124.936 1.255 . . . . 0.0 113.458 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.13 134.39 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -179.091 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.09 130.3 54.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 124.828 1.251 . . . . 0.0 110.445 166.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -88.27 105.62 17.67 Favored 'General case' 0 C--O 1.232 0.165 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 163.126 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.93 129.9 36.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 114.954 -1.021 . . . . 0.0 108.631 169.432 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.1 m -146.38 94.21 2.42 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.387 1.075 . . . . 0.0 109.305 -176.492 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -130.9 159.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 126.346 1.858 . . . . 0.0 110.281 -174.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -139.77 142.2 36.77 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 128.077 2.551 . . . . 0.0 106.584 167.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -151.12 138.15 19.13 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.293 1.037 . . . . 0.0 111.876 -168.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 46.3 p -118.0 50.3 1.16 Allowed 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 177.068 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 p -147.26 4.64 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 171.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -122.71 160.89 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.576 1.551 . . . . 0.0 107.409 167.022 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 96.8 p -156.24 168.36 27.55 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 119.49 1.041 . . . . 0.0 113.626 -174.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -92.59 69.07 4.83 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.521 1.528 . . . . 0.0 110.055 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 5.7 m -117.56 160.02 21.92 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.775 1.63 . . . . 0.0 110.727 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 44.98 1.82 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 125.146 1.355 . . . . 0.0 114.468 -168.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -135.54 -84.63 0.39 Allowed 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.872 1.269 . . . . 0.0 110.449 -168.691 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -150.35 -2.82 0.37 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 127.74 2.416 . . . . 0.0 111.773 -176.427 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 95.0 p -61.09 -44.4 97.42 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.131 1.373 . . . . 0.0 114.11 -169.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 5.3 pt -154.16 -34.35 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 127.678 2.391 . . . . 0.0 111.223 166.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 45.1 mm -60.56 125.37 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 123.866 0.867 . . . . 0.0 108.765 -175.034 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.56 16.23 67.3 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 116.994 -2.003 . . . . 0.0 115.061 -178.544 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.4 mtm180 -79.62 168.21 19.68 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.841 1.82 . . . . 0.0 109.478 168.298 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 22.6 m -123.64 117.04 24.1 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.806 0.842 . . . . 0.0 110.31 175.416 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 37.6 tp -82.23 132.12 35.23 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 169.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -110.91 137.43 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.534 1.534 . . . . 0.0 108.751 165.62 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 p -109.77 130.36 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.968 0.89 . . . . 0.0 109.417 168.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.539 ' CE1' HH11 ' B' ' 143' ' ' ARG . 21.7 m-70 -99.91 161.12 13.8 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.527 1.131 . . . . 0.0 113.669 -172.167 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -76.42 -25.49 54.52 Favored 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.701 1.371 . . . . 0.0 114.701 -174.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -118.85 176.68 5.16 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 119.667 1.121 . . . . 0.0 112.415 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.71 164.3 2.14 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.151 1.38 . . . . 0.0 111.967 168.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -113.97 145.08 42.03 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.949 1.7 . . . . 0.0 110.546 -178.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 125' ' ' ASP . . . . . 0.472 ' O ' ' HE2' ' B' ' 75' ' ' LYS . 0.0 OUTLIER -73.95 -35.46 64.55 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-O 118.775 -0.631 . . . . 0.0 111.214 172.38 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 11.6 mt 77.54 24.61 0.77 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.015 2.126 . . . . 0.0 113.481 177.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.83 -78.9 0.06 OUTLIER Glycine 0 N--CA 1.474 1.182 0 CA-C-N 120.47 1.486 . . . . 0.0 116.657 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -156.22 87.67 1.06 Allowed 'General case' 0 N--CA 1.44 -0.925 0 C-N-CA 126.38 1.872 . . . . 0.0 110.93 173.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 129' ' ' GLY . . . . . 0.566 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -65.64 -10.99 52.24 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 126.836 2.16 . . . . 0.0 114.081 174.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.16 -33.8 2.47 Favored Glycine 0 N--CA 1.47 0.948 0 C-N-CA 124.366 0.984 . . . . 0.0 114.942 168.55 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.6 p30 -92.79 -177.78 4.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.498 1.519 . . . . 0.0 110.366 -177.459 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -61.5 -62.66 1.66 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 122.773 0.429 . . . . 0.0 110.351 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 133' ' ' GLU . . . . . 0.427 ' HB3' HD22 ' B' ' 139' ' ' ASN . 0.8 OUTLIER -42.06 -30.75 0.3 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 129.278 3.031 . . . . 0.0 115.572 -176.039 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.566 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 97.1 p -63.07 -41.84 99.53 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.373 1.469 . . . . 0.0 113.333 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 72.7 p -81.93 -30.57 31.72 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 123.834 0.854 . . . . 0.0 113.208 173.183 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -70.85 -53.15 16.31 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.704 2.002 . . . . 0.0 110.226 -177.309 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.44 HG22 ' HA ' ' B' ' 62' ' ' PRO . 74.6 p -111.54 -113.63 0.32 Allowed 'General case' 0 C--N 1.342 0.253 0 C-N-CA 128.207 2.603 . . . . 0.0 106.33 172.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -144.19 12.2 2.07 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 130.191 3.758 . . . . 0.0 111.874 169.155 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 139' ' ' ASN . . . . . 0.427 HD22 ' HB3' ' B' ' 133' ' ' GLU . 5.3 t-20 56.64 14.89 1.9 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.889 1.675 . . . . 0.0 113.814 -172.344 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.42 22.21 0.03 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 116.563 2.061 . . . . 0.0 116.563 -168.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.11 -169.81 52.12 Favored Glycine 0 CA--C 1.529 0.963 0 O-C-N 120.136 -1.603 . . . . 0.0 113.295 -171.506 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.06 -169.85 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.279 1.432 . . . . 0.0 110.906 174.266 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.539 HH11 ' CE1' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -137.3 146.5 44.72 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 115.622 1.712 . . . . 0.0 115.622 175.241 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.7 -121.96 0.06 Allowed 'General case' 0 CA--C 1.536 0.406 0 O-C-N 127.182 2.801 . . . . 0.0 106.451 164.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.35 154.86 41.37 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 122.932 1.349 . . . . 0.0 114.467 -166.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -139.16 152.02 47.09 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 126.381 1.872 . . . . 0.0 109.246 169.369 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.58 141.88 7.73 Favored Glycine 0 C--N 1.333 0.414 0 N-CA-C 114.369 0.508 . . . . 0.0 114.369 176.068 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -79.74 153.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.891 1.276 . . . . 0.0 110.464 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.19 109.73 20.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 124.878 1.271 . . . . 0.0 112.409 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.53 164.37 15.52 Favored Glycine 0 C--N 1.35 1.339 0 C-N-CA 125.204 1.383 . . . . 0.0 112.761 174.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.59 HG22 ' H ' ' B' ' 153' ' ' GLN . 2.6 mp -87.36 113.37 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 O-C-N 121.548 -0.972 . . . . 0.0 112.193 -168.677 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.492 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -82.42 16.57 2.03 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 128.112 2.565 . . . . 0.0 112.658 169.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 153' ' ' GLN . . . . . 0.59 ' H ' HG22 ' B' ' 151' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.436 0 C-N-CA 128.804 2.842 . . . . 0.0 111.991 170.557 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.925 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.5 t -159.64 132.52 6.8 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 124.981 1.312 . . . . 0.0 108.956 172.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -94.5 145.83 24.52 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.496 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -94.33 164.44 13.02 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 121.109 -0.994 . . . . 0.0 111.789 168.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.56 HG11 ' H ' ' B' ' 53' ' ' ASN . 1.2 p -112.45 164.22 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 172.149 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.77 81.25 1.5 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.993 1.317 . . . . 0.0 108.007 160.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.0 t -77.45 89.14 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.16 141.5 37.17 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.381 1.072 . . . . 0.0 112.167 -172.169 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -155.59 175.96 13.23 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 169.418 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 160.12 -95.08 0.14 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 127.283 2.373 . . . . 0.0 109.706 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -78.33 87.16 4.38 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 126.629 1.972 . . . . 0.0 112.406 -169.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.08 -98.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.991 2.234 . . . . 0.0 114.003 168.025 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -78.4 -2.35 12.42 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 125.191 3.927 . . . . 0.0 115.284 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.5 t -79.0 139.1 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 120.312 1.415 . . . . 0.0 110.389 171.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -148.6 170.45 18.09 Favored 'General case' 0 N--CA 1.462 0.169 0 C-N-CA 125.617 1.567 . . . . 0.0 110.494 169.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.57 162.76 28.73 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 114.877 -1.056 . . . . 0.0 111.559 165.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.3 tp -156.87 80.71 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 126.609 1.964 . . . . 0.0 107.737 -177.366 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mm -98.42 143.97 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.123 0.569 . . . . 0.0 110.1 175.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -114.7 148.99 37.49 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 128.93 2.892 . . . . 0.0 109.42 175.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.496 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 57.8 m-85 -141.78 82.11 1.79 Allowed 'General case' 0 CA--C 1.557 1.216 0 C-N-CA 123.983 0.913 . . . . 0.0 112.757 -178.428 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.446 ' HG2' ' CZ3' ' A' ' 32' ' ' TRP . 1.2 pt-20 -78.97 130.54 35.67 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 121.367 1.894 . . . . 0.0 114.755 -174.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.547 HE22 ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -116.87 155.29 29.29 Favored 'General case' 0 CA--C 1.535 0.377 0 O-C-N 120.459 -1.4 . . . . 0.0 111.976 173.059 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -56.06 2.39 Favored 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.29 1.436 . . . . 0.0 112.64 -169.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.547 ' C ' HE22 ' A' ' 22' ' ' GLN . 0.4 OUTLIER -138.89 153.3 48.27 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 128.82 2.848 . . . . 0.0 107.739 169.406 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -48.45 -17.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 118.545 2.795 . . . . 0.0 118.545 -166.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -118.94 0.61 11.38 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.528 1.931 . . . . 0.0 113.405 -176.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.25 177.41 54.26 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.936 0.779 . . . . 0.0 112.829 176.496 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.91 177.52 8.62 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.293 3.329 . . . . 0.0 110.907 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 87.8 t -128.96 132.65 67.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 123.066 0.546 . . . . 0.0 110.128 178.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.43 122.39 34.83 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.9 t -103.47 128.02 56.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 126.002 1.721 . . . . 0.0 108.662 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.446 ' CZ3' ' HG2' ' A' ' 21' ' ' GLU . 3.1 p90 -144.83 157.71 44.06 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 122.84 0.456 . . . . 0.0 111.608 170.508 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.38 178.87 15.52 Favored Glycine 0 N--CA 1.463 0.465 0 O-C-N 121.259 -0.9 . . . . 0.0 112.427 -178.26 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 m -127.57 159.21 35.3 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 117.009 2.226 . . . . 0.0 117.009 -164.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.5 mm -123.73 124.5 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 127.2 2.2 . . . . 0.0 108.131 167.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -130.81 136.21 48.47 Favored 'General case' 0 CA--C 1.54 0.573 0 O-C-N 120.872 -1.142 . . . . 0.0 111.054 -169.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.41 -11.94 11.28 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.238 1.875 . . . . 0.0 113.557 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.9 mp -62.1 141.92 57.86 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 127.161 2.184 . . . . 0.0 109.062 169.264 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.6 t -71.59 -41.74 68.58 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -176.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 176.03 -160.62 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.743 1 C-N-CA 133.21 4.604 . . . . 0.0 105.168 178.469 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 74.24 173.42 29.28 Favored Glycine 0 N--CA 1.473 1.112 0 N-CA-C 117.165 1.626 . . . . 0.0 117.165 165.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.19 152.41 30.7 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.002 1.321 . . . . 0.0 109.61 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.458 ' HD1' ' HA ' ' A' ' 121' ' ' GLU . 93.3 m-70 -153.1 142.15 21.33 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.872 1.669 . . . . 0.0 112.82 -171.695 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 119' ' ' VAL . . . -57.22 163.23 7.18 Favored Glycine 0 N--CA 1.478 1.457 0 C-N-CA 124.867 1.223 . . . . 0.0 115.141 -174.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -160.45 84.55 0.71 Allowed 'General case' 0 CA--C 1.548 0.875 0 CA-C-O 122.672 1.225 . . . . 0.0 113.502 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -133.18 142.37 48.59 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 120.036 -1.665 . . . . 0.0 110.961 -171.299 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.562 HG23 ' HA2' ' A' ' 82' ' ' GLY . 11.4 m -109.23 128.71 64.96 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.167 0 CA-C-O 121.957 0.884 . . . . 0.0 109.046 176.432 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.8 m170 -76.09 156.8 33.54 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.762 -174.178 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -74.95 130.85 40.1 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 71.12 169.34 0.32 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-O 124.848 2.261 . . . . 0.0 113.862 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.68 11.01 56.29 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 129.589 3.471 . . . . 0.0 114.078 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.643 ' HA ' HG21 ' B' ' 5' ' ' VAL . 1.9 p30 -78.95 47.29 0.75 Allowed 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.27 2.535 . . . . 0.0 109.97 168.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.31 1.3 p30 -90.13 45.62 1.28 Allowed 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 115.533 1.679 . . . . 0.0 115.533 -165.661 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.521 HG22 ' HA ' ' B' ' 7' ' ' VAL . 19.4 p -119.91 -38.06 3.01 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -163.533 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.26 13.13 24.4 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 126.206 1.802 . . . . 0.0 112.9 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.48 -123.87 34.16 Favored Glycine 0 C--N 1.341 0.852 0 C-N-CA 125.112 1.339 . . . . 0.0 111.512 175.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 70.2 m -58.82 -13.77 7.06 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.827 1.417 . . . . 0.0 114.827 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.57 1.43 29.68 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.004 1.322 . . . . 0.0 112.081 173.135 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.2 m -158.54 -131.21 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 127.253 2.221 . . . . 0.0 108.209 -174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.34 95.35 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 128.002 2.521 . . . . 0.0 114.638 -173.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.6 162.24 53.92 Favored Glycine 0 CA--C 1.531 1.04 0 N-CA-C 115.301 0.88 . . . . 0.0 115.301 -167.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -69.24 84.57 0.57 Allowed 'Trans proline' 0 C--N 1.354 0.855 1 C-N-CA 125.963 4.442 . . . . 0.0 111.104 -173.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.5 p80 51.65 59.29 4.67 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 127.971 2.509 . . . . 0.0 110.808 169.049 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -56.05 167.05 0.66 Allowed 'General case' 0 N--CA 1.445 -0.723 0 CA-C-O 126.043 2.83 . . . . 0.0 112.443 -173.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.525 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.4 p-10 -118.88 73.67 12.3 Favored Pre-proline 0 C--N 1.314 -0.938 0 CA-C-N 110.837 -2.892 . . . . 0.0 112.275 -169.087 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.45 -23.72 75.14 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.018 2.479 . . . . 0.0 113.44 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 27.7 tp -86.64 -3.63 59.06 Favored 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.477 1.511 . . . . 0.0 113.191 170.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.7 t 68.15 49.69 0.83 Allowed 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.609 2.364 . . . . 0.0 112.578 176.377 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.525 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 7.9 mtp180 -106.67 170.91 7.65 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 115.224 1.564 . . . . 0.0 115.224 -168.636 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.5 mtmt -74.04 162.06 29.41 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.35 1.46 . . . . 0.0 109.247 164.434 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -86.83 142.63 27.94 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 172.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.415 ' HA2' ' HB3' ' A' ' 126' ' ' LEU . . . 147.4 -123.71 1.8 Allowed Glycine 0 C--N 1.341 0.815 0 N-CA-C 117.059 1.584 . . . . 0.0 117.059 164.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.47 -38.96 2.32 Favored Glycine 0 CA--C 1.546 1.998 0 N-CA-C 118.207 2.043 . . . . 0.0 118.207 -169.445 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -99.61 11.82 0.64 Allowed 'Trans proline' 0 CA--C 1.546 1.123 0 C-N-CA 123.955 3.104 . . . . 0.0 113.684 -176.438 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.67 -30.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 128.275 2.63 . . . . 0.0 109.893 167.635 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 5.3 t70 -75.31 152.89 38.13 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.153 0.978 . . . . 0.0 109.232 163.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -89.59 -26.13 20.96 Favored 'General case' 0 C--N 1.321 -0.664 1 C-N-CA 131.708 4.003 . . . . 0.0 111.679 -173.202 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -92.04 -71.29 0.65 Allowed 'General case' 0 C--N 1.34 0.164 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -169.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.4 ttt180 69.95 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.779 1.632 . . . . 0.0 112.861 -175.621 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -57.79 163.01 2.81 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 119.388 -2.07 . . . . 0.0 113.902 171.159 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.25 -38.16 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 119.353 0.979 . . . . 0.0 111.738 170.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.562 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -88.43 45.12 3.23 Favored Glycine 0 CA--C 1.533 1.158 0 N-CA-C 114.992 0.757 . . . . 0.0 114.992 177.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -137.44 134.46 35.87 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 120.824 -1.398 . . . . 0.0 111.154 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -127.6 53.49 1.75 Allowed 'General case' 0 CA--C 1.546 0.817 0 CA-C-O 122.111 0.958 . . . . 0.0 109.107 165.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.54 -138.26 42.76 Favored Glycine 0 C--N 1.342 0.882 0 C-N-CA 125.577 1.56 . . . . 0.0 113.129 172.579 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -141.71 150.86 42.39 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.031 0.933 . . . . 0.0 110.137 168.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.76 178.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 C-N-CA 127.659 2.384 . . . . 0.0 110.651 -174.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 83.1 m -149.96 138.2 20.47 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 124.973 1.309 . . . . 0.0 110.056 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.15 140.45 38.29 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.105 1.362 . . . . 0.0 114.641 -176.139 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -77.79 146.03 36.06 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.761 1.624 . . . . 0.0 109.775 166.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.93 -16.35 0.13 Allowed 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 130.066 3.346 . . . . 0.0 118.08 175.513 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -75.26 1.23 14.09 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-N 119.762 1.164 . . . . 0.0 110.776 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.25 43.52 4.95 Favored Glycine 0 C--N 1.336 0.551 0 C-N-CA 128.054 2.74 . . . . 0.0 112.408 171.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.8 p -155.38 132.22 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 119.562 1.681 . . . . 0.0 115.14 -175.252 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.75 107.64 20.13 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 165.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -98.37 144.59 27.6 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.658 0.742 . . . . 0.0 110.088 169.731 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -121.92 146.11 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 N-CA-C 115.07 1.507 . . . . 0.0 115.07 -174.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.8 t -159.47 81.34 0.75 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 126.712 2.005 . . . . 0.0 111.837 175.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -127.95 158.08 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 127.152 2.181 . . . . 0.0 110.917 -174.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -126.15 138.63 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 167.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -134.45 145.8 49.19 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.273 1.029 . . . . 0.0 112.718 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 12.4 p -120.5 48.58 1.57 Allowed 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 114.575 1.324 . . . . 0.0 114.575 -179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.0 m -139.35 3.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.35 139.18 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.819 1.248 . . . . 0.0 109.043 168.339 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 46.6 p -112.04 176.69 4.92 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 118.718 0.69 . . . . 0.0 111.123 169.031 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.8 mt -82.31 107.64 15.14 Favored 'General case' 0 C--N 1.345 0.4 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 167.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -136.98 -13.24 1.65 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.47 31.97 71.34 Favored Glycine 0 C--N 1.342 0.879 0 CA-C-N 119.884 1.22 . . . . 0.0 115.155 172.394 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -170.44 -103.32 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.802 1.241 . . . . 0.0 108.026 -169.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -79.43 8.74 5.7 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.34 2.256 . . . . 0.0 112.329 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 55.5 m -149.85 -161.53 1.36 Allowed 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.241 1.416 . . . . 0.0 109.438 165.372 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 15.3 pt -82.41 161.37 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 O-C-N 120.171 -1.581 . . . . 0.0 113.835 -168.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.445 HD11 ' HB2' ' A' ' 4' ' ' ALA . 2.3 mm 106.44 147.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 1 C-N-CA 135.023 5.329 . . . . 0.0 110.118 -167.155 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.47 2.73 56.02 Favored Glycine 0 C--O 1.219 -0.803 0 CA-C-O 117.319 -1.823 . . . . 0.0 114.838 174.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 34.8 mtt-85 -106.22 -176.14 2.99 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.898 2.479 . . . . 0.0 110.338 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.0 t -120.29 145.43 47.08 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 119.554 1.07 . . . . 0.0 110.934 169.565 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.0 tp -101.32 133.52 45.78 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 127.086 2.154 . . . . 0.0 109.723 170.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.46 147.8 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.512 1.525 . . . . 0.0 110.576 168.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.57 HG12 HD21 ' A' ' 144' ' ' LEU . 91.7 t -129.03 151.15 35.36 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 C-N-CA 126.067 1.747 . . . . 0.0 107.035 173.826 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 74.3 m-70 -124.25 133.8 53.41 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.365 1.066 . . . . 0.0 113.17 -168.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.458 ' HA ' ' HD1' ' A' ' 43' ' ' HIS 0.267 24.2 tp10 -84.81 39.07 0.73 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 -167.634 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -154.15 160.48 41.92 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.44 1.896 . . . . 0.0 109.5 169.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.57 118.36 8.08 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 169.393 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.5 157.93 20.3 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.477 1.132 . . . . 0.0 112.208 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -90.81 -9.49 46.27 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 128.587 2.755 . . . . 0.0 113.076 -169.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.415 ' HB3' ' HA2' ' A' ' 72' ' ' GLY . 2.3 mp 1.54 79.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 130.911 3.684 . . . . 0.0 116.194 -173.142 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.21 -66.68 0.57 Allowed Glycine 0 N--CA 1.467 0.753 0 C-N-CA 125.068 1.318 . . . . 0.0 114.287 170.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.7 ttpp -157.49 93.28 1.28 Allowed 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.436 1.273 . . . . 0.0 114.436 -170.256 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.88 -113.74 2.18 Favored Glycine 0 C--O 1.235 0.216 0 N-CA-C 108.336 -1.906 . . . . 0.0 108.336 165.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -131.32 33.66 2.74 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.151 1.834 . . . . 0.0 113.328 177.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -159.58 159.83 33.7 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 118.78 1.29 . . . . 0.0 108.766 -171.229 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -68.73 -48.97 62.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.29 0.566 . . . . 0.0 110.093 -176.19 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.1 mp0 -38.63 -33.97 0.13 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.636 3.174 . . . . 0.0 113.591 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.9 p -59.88 -44.97 93.9 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.281 1.432 . . . . 0.0 114.021 175.413 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.8 t -81.7 -36.38 28.76 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 118.96 0.8 . . . . 0.0 111.283 168.216 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 16.6 tttt -56.88 -48.14 78.86 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.117 1.367 . . . . 0.0 111.991 -175.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -147.48 -10.79 0.41 Allowed 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 126.818 2.047 . . . . 0.0 115.009 -168.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.65 3.56 57.25 Favored Glycine 0 C--O 1.223 -0.575 0 CA-C-O 117.374 -1.792 . . . . 0.0 113.128 -173.432 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 67.54 -60.33 0.39 Allowed 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.043 2.137 . . . . 0.0 111.333 -172.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 68.41 -21.39 0.14 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 129.795 3.238 . . . . 0.0 115.571 168.585 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.61 -20.26 0.14 Allowed Glycine 0 CA--C 1.537 1.418 0 C-N-CA 126.904 2.192 . . . . 0.0 118.447 166.798 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.7 t -161.65 -173.11 3.6 Favored 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 127.626 2.371 . . . . 0.0 110.819 176.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.05 154.22 43.01 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.473 -1.392 . . . . 0.0 110.029 169.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.57 HD21 HG12 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -128.94 -129.11 0.22 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 123.43 0.692 . . . . 0.0 110.292 169.664 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.43 158.87 32.75 Favored 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 126.667 1.987 . . . . 0.0 113.113 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -140.79 161.58 37.46 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.922 2.089 . . . . 0.0 110.062 169.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.32 148.21 16.7 Favored Glycine 0 N--CA 1.472 1.038 0 O-C-N 121.272 -0.892 . . . . 0.0 112.918 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -78.56 161.78 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 C-N-CA 123.95 0.9 . . . . 0.0 109.773 177.496 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 36.8 mt -110.71 98.51 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 120.356 -1.465 . . . . 0.0 112.207 -175.217 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.45 167.07 22.14 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.712 1.625 . . . . 0.0 115.402 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.99 80.07 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 C-N-CA 127.91 2.484 . . . . 0.0 113.387 -175.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.36 26.24 0.22 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.657 1.583 . . . . 0.0 115.16 -175.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 . . . . . 0 N--CA 1.469 0.518 0 C-N-CA 129.413 3.085 . . . . 0.0 114.346 176.549 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 119.418 -0.325 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.9 m -79.78 108.69 13.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 125.333 1.453 . . . . 0.0 108.088 -171.762 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 27.6 mttt -99.43 118.59 36.39 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -171.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -83.35 169.25 15.83 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 127.71 2.404 . . . . 0.0 114.874 178.24 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.643 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -156.07 125.43 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 129.412 3.085 . . . . 0.0 107.55 175.608 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.07 139.38 47.64 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.088 0.955 . . . . 0.0 113.173 179.496 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.521 ' HA ' HG22 ' A' ' 54' ' ' THR . 3.2 t -85.88 68.07 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.189 -0.914 . . . . 0.0 112.401 -168.65 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.12 103.13 5.17 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 122.208 1.004 . . . . 0.0 108.337 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -161.91 133.09 5.21 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 125.331 1.453 . . . . 0.0 109.713 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.25 -118.06 3.76 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -127.3 57.48 1.49 Allowed 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 126.046 1.738 . . . . 0.0 111.706 -164.071 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.5 -168.07 41.17 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 121.074 -1.016 . . . . 0.0 112.901 -171.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.55 -5.94 12.58 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 124.354 3.369 . . . . 0.0 115.444 -168.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.16 129.19 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 CA-C-N 120.258 1.39 . . . . 0.0 110.371 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -123.13 178.55 5.04 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 122.518 1.151 . . . . 0.0 110.29 168.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.2 163.01 31.29 Favored Glycine 0 CA--C 1.499 -0.942 0 CA-C-N 113.888 -1.506 . . . . 0.0 113.129 165.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pt -133.6 82.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 112.162 -2.019 . . . . 0.0 106.688 170.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.343 2.7 pp -89.49 109.87 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.043 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -112.74 133.54 54.71 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.523 2.329 . . . . 0.0 108.577 -170.058 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -124.48 147.06 48.58 Favored 'General case' 0 N--CA 1.474 0.766 0 O-C-N 121.028 -1.045 . . . . 0.0 111.178 -174.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -108.66 112.22 24.43 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.522 1.129 . . . . 0.0 111.717 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.3 99.04 10.87 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.114 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.43 ' HE2' ' HB2' ' B' ' 24' ' ' GLU . 0.2 OUTLIER -70.72 -28.8 65.0 Favored 'General case' 0 CA--C 1.539 0.53 0 O-C-N 121.415 -0.803 . . . . 0.0 113.108 170.276 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.43 ' HB2' ' HE2' ' B' ' 23' ' ' LYS . 43.1 tt0 -163.61 124.54 2.29 Favored 'General case' 0 C--O 1.222 -0.355 0 C-N-CA 124.689 1.196 . . . . 0.0 110.446 -166.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.0 p -60.86 -10.16 5.2 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 127.977 2.511 . . . . 0.0 114.8 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -132.93 15.16 4.28 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.239 1.816 . . . . 0.0 111.841 -171.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.42 -153.09 7.42 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 126.628 2.061 . . . . 0.0 111.724 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -85.29 167.05 10.69 Favored 'Trans proline' 0 N--CA 1.456 -0.733 0 C-N-CA 122.642 2.228 . . . . 0.0 112.202 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -119.78 140.22 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 124.993 1.317 . . . . 0.0 108.859 170.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -94.89 121.94 37.01 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 168.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.17 131.95 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 128.04 2.536 . . . . 0.0 109.071 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -156.05 -176.77 6.13 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 119.49 168.25 13.89 Favored Glycine 0 C--N 1.335 0.518 0 CA-C-O 122.079 0.822 . . . . 0.0 114.478 166.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 4.9 p -99.08 123.37 43.33 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -167.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 mp -98.5 118.08 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 166.464 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -129.01 132.29 47.5 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.551 1.54 . . . . 0.0 110.788 -166.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.26 -2.59 29.68 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 128.228 2.823 . . . . 0.0 111.939 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 22.4 mt -69.91 148.11 49.41 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 118.94 1.37 . . . . 0.0 112.598 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 26.8 m -76.37 143.97 40.39 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 125.614 1.565 . . . . 0.0 107.211 165.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -59.24 156.4 12.48 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.81 -179.45 35.55 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.668 0.652 . . . . 0.0 112.281 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.477 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -83.25 142.39 31.17 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 127.267 2.227 . . . . 0.0 113.846 -169.56 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 80.5 m-70 -134.01 125.78 28.85 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 129.093 2.957 . . . . 0.0 108.602 -176.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.09 148.64 28.15 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 125.492 1.52 . . . . 0.0 112.594 178.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -142.26 103.52 4.29 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.999 1.399 . . . . 0.0 111.528 -168.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.56 139.0 33.07 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 120.223 -1.548 . . . . 0.0 111.226 -175.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.88 115.52 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 176.154 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -71.86 -178.52 2.34 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 128.119 2.567 . . . . 0.0 111.172 -169.116 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.7 145.02 46.45 Favored 'General case' 0 CA--C 1.547 0.828 0 O-C-N 121.317 -0.864 . . . . 0.0 111.008 168.612 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -92.54 -170.95 2.62 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.28 1.832 . . . . 0.0 113.06 -169.303 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.17 -108.36 3.0 Favored Glycine 0 C--N 1.334 0.447 0 N-CA-C 115.694 1.037 . . . . 0.0 115.694 163.369 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -77.92 65.04 3.27 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.252 1.421 . . . . 0.0 110.567 -169.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.56 ' H ' HG11 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -165.52 162.59 19.27 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.714 1.376 . . . . 0.0 114.714 -168.598 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 39.5 p -137.17 -45.77 0.57 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.65 2.093 . . . . 0.0 116.65 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -87.04 -57.12 3.08 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.077 0.853 . . . . 0.0 110.959 177.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.96 -82.64 0.32 Allowed Glycine 0 N--CA 1.466 0.691 0 C-N-CA 124.69 1.138 . . . . 0.0 110.97 -175.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.3 t -64.25 -9.8 19.63 Favored 'General case' 0 CA--C 1.554 1.1 0 CA-C-N 119.021 1.41 . . . . 0.0 114.02 178.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -126.84 34.93 4.69 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.861 2.465 . . . . 0.0 110.07 170.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 7.4 m -156.83 -55.58 0.08 Allowed 'General case' 0 N--CA 1.482 1.154 0 O-C-N 119.769 -1.832 . . . . 0.0 114.938 176.232 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.31 160.16 24.55 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.596 1.159 . . . . 0.0 112.352 -172.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.46 171.17 25.56 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.194 1.378 . . . . 0.0 113.765 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -65.34 169.41 12.48 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 124.493 3.462 . . . . 0.0 112.264 -173.276 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -20.19 86.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 128.504 2.722 . . . . 0.0 117.733 175.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -50.57 126.63 15.9 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 123.54 1.638 . . . . 0.0 114.053 -172.076 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.46 59.81 0.46 Allowed Pre-proline 0 CA--C 1.558 1.261 0 CA-C-N 112.194 -2.276 . . . . 0.0 115.851 -168.726 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -65.28 -27.53 55.8 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 123.355 2.704 . . . . 0.0 114.232 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -76.28 -3.99 39.58 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.195 0.998 . . . . 0.0 112.244 175.575 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t 63.54 50.58 2.76 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 126.002 1.721 . . . . 0.0 111.114 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -103.14 168.45 9.17 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.551 1.14 . . . . 0.0 111.757 -174.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.452 ' HE3' ' HD2' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -96.39 173.1 7.54 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.456 1.502 . . . . 0.0 107.287 164.433 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.476 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 29.5 t60 -63.88 164.5 10.12 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 119.981 -1.699 . . . . 0.0 113.715 -178.028 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 166.67 -174.44 42.07 Favored Glycine 0 N--CA 1.469 0.863 0 O-C-N 120.921 -1.112 . . . . 0.0 113.929 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.28 -154.26 25.38 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 -167.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -62.77 -1.75 2.94 Favored 'Trans proline' 0 CA--C 1.54 0.807 1 C-N-CA 125.849 4.366 . . . . 0.0 116.379 -172.623 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -120.89 -1.98 9.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.021 1.329 . . . . 0.0 113.641 170.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -131.04 176.79 7.96 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 126.746 2.018 . . . . 0.0 110.259 -168.303 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -100.15 -17.07 17.58 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 127.13 2.172 . . . . 0.0 113.803 -169.504 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -95.2 -100.34 0.16 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 118.565 0.621 . . . . 0.0 112.673 -176.199 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.2 ttp-105 85.77 97.28 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 126.825 2.05 . . . . 0.0 110.024 -175.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -49.67 156.83 0.63 Allowed 'General case' 0 N--CA 1.475 0.799 0 O-C-N 119.936 -1.727 . . . . 0.0 111.788 168.021 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 46.4 t -53.38 -21.5 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 119.266 0.939 . . . . 0.0 113.265 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.29 61.4 0.55 Allowed Glycine 0 CA--C 1.531 1.036 0 CA-C-O 118.573 -1.126 . . . . 0.0 114.105 169.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -123.52 124.68 43.37 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 119.642 1.721 . . . . 0.0 109.099 168.143 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.9 mt -132.18 49.22 2.34 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 119.268 0.94 . . . . 0.0 112.381 -176.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.94 -148.29 47.71 Favored Glycine 0 CA--C 1.534 1.277 0 O-C-N 121.101 -1.0 . . . . 0.0 113.49 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -129.76 137.27 50.44 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.781 1.233 . . . . 0.0 109.837 168.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -96.15 133.32 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 125.861 1.664 . . . . 0.0 110.227 179.397 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 32.1 m -108.94 136.81 47.87 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 124.222 1.009 . . . . 0.0 108.803 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.35 145.09 26.47 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 174.088 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -77.18 146.91 36.76 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.118 1.767 . . . . 0.0 110.499 167.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -63.91 -14.3 52.46 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.925 1.824 . . . . 0.0 115.925 -169.634 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -76.16 3.32 10.86 Favored 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 125.471 1.508 . . . . 0.0 111.481 171.399 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 100.36 29.41 6.71 Favored Glycine 0 C--N 1.342 0.892 0 C-N-CA 126.327 1.918 . . . . 0.0 114.719 168.107 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.1 139.51 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 120.227 2.014 . . . . 0.0 115.215 -169.048 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.49 99.29 7.07 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 124.401 1.08 . . . . 0.0 110.187 169.114 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -87.74 91.24 8.68 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-O 122.591 1.186 . . . . 0.0 109.169 172.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -75.85 158.64 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 CA-C-N 114.109 -1.405 . . . . 0.0 114.133 -167.235 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 82.4 p -155.0 105.93 2.59 Favored 'General case' 0 N--CA 1.471 0.584 0 O-C-N 120.61 -1.306 . . . . 0.0 111.782 -175.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.3 mt -137.43 153.19 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 126.708 2.003 . . . . 0.0 110.639 -176.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -139.01 136.14 35.02 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.26 1.824 . . . . 0.0 107.92 168.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -149.18 143.97 26.28 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 125.873 1.669 . . . . 0.0 111.013 -172.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -107.89 53.19 0.69 Allowed 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 113.29 0.848 . . . . 0.0 113.29 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.1 t -144.3 -42.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 124.29 1.036 . . . . 0.0 112.92 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.63 163.08 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 O-C-N 121.14 -0.975 . . . . 0.0 113.447 -176.061 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -156.57 154.24 29.93 Favored 'General case' 0 N--CA 1.476 0.838 0 O-C-N 119.91 -1.744 . . . . 0.0 113.341 174.033 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mp -84.85 46.43 1.26 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.008 1.323 . . . . 0.0 108.65 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.0 m -75.59 -34.63 60.66 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 116.091 1.886 . . . . 0.0 116.091 -166.019 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.62 18.41 Favored Glycine 0 CA--C 1.536 1.352 0 N-CA-C 115.578 0.991 . . . . 0.0 115.578 -174.168 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 p30 -116.74 -83.23 0.63 Allowed 'General case' 0 CA--C 1.549 0.905 0 C-N-CA 125.65 1.58 . . . . 0.0 111.003 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -143.42 -1.59 1.02 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 129.399 3.079 . . . . 0.0 111.922 -178.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 52.5 m -73.46 -91.54 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 126.488 1.915 . . . . 0.0 112.003 -169.438 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.7 pt -136.04 -26.34 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 175.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 mm -66.04 136.68 26.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 CA-C-N 122.826 2.557 . . . . 0.0 108.621 168.238 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.52 -16.53 6.22 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.018 0.818 . . . . 0.0 114.594 -172.2 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -79.07 178.39 8.08 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.528 1.131 . . . . 0.0 109.361 169.235 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.57 124.26 12.56 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.479 1.036 . . . . 0.0 111.902 -170.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 tp -89.27 120.36 30.57 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.393 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.0 p -99.89 130.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 124.14 0.976 . . . . 0.0 110.802 171.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.8 m -93.38 133.71 33.58 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 165.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -96.39 177.75 5.59 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 125.355 1.462 . . . . 0.0 111.155 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -84.76 -58.04 2.87 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 120.912 -1.118 . . . . 0.0 110.648 -173.228 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -95.34 177.99 5.66 Favored 'General case' 0 N--CA 1.471 0.593 0 O-C-N 120.746 -1.221 . . . . 0.0 110.537 169.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.03 146.09 28.36 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 168.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -86.89 163.09 17.37 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 123.145 1.45 . . . . 0.0 111.368 169.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.47 -8.83 57.98 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.105 1.762 . . . . 0.0 112.25 -170.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 95.6 mt 33.6 50.24 0.28 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 128.511 2.724 . . . . 0.0 113.276 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 159.84 -93.62 0.12 Allowed Glycine 0 C--N 1.333 0.41 0 O-C-N 121.678 -0.639 . . . . 0.0 114.336 -178.279 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 128' ' ' LYS . . . . . 0.452 ' HD2' ' HE3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -159.16 127.38 5.08 Favored 'General case' 0 CA--C 1.55 0.978 0 C-N-CA 125.422 1.489 . . . . 0.0 112.422 -173.711 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -123.87 -19.05 2.8 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.593 1.092 . . . . 0.0 115.095 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 119.69 -14.49 10.65 Favored Glycine 0 N--CA 1.474 1.217 0 CA-C-O 118.34 -1.255 . . . . 0.0 116.227 171.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -98.11 165.12 12.04 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.875 1.838 . . . . 0.0 110.175 168.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -51.8 -55.83 17.51 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.328 1.051 . . . . 0.0 110.035 178.304 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -51.6 -33.29 32.3 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 128.041 2.536 . . . . 0.0 113.313 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -54.86 -46.37 74.67 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 121.137 1.789 . . . . 0.0 113.861 176.077 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -91.24 -31.67 16.05 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 172.578 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -74.11 -28.17 61.23 Favored 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.514 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.7 m -128.82 -44.68 1.32 Allowed 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.352 1.461 . . . . 0.0 111.672 -179.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 138' ' ' GLY . . . . . 0.476 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 122.16 7.92 7.49 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 127.781 2.61 . . . . 0.0 112.269 -167.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 61.08 -77.39 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 126.213 1.805 . . . . 0.0 109.382 -169.243 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 64.94 3.61 2.16 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 127.889 2.476 . . . . 0.0 117.482 164.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.49 -46.63 1.97 Allowed Glycine 0 N--CA 1.471 1.014 0 C-N-CA 125.398 1.475 . . . . 0.0 113.803 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.9 m -178.27 176.71 1.06 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 126.933 2.093 . . . . 0.0 112.002 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -79.43 173.63 12.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.586 0.754 . . . . 0.0 110.846 168.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -140.74 -79.55 0.27 Allowed 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.755 0.822 . . . . 0.0 109.964 169.339 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.47 43.89 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 126.4 1.88 . . . . 0.0 109.686 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -156.81 151.74 26.02 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.966 1.706 . . . . 0.0 111.833 -171.293 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.79 148.74 17.18 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 116.415 1.326 . . . . 0.0 116.415 176.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -74.56 140.68 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 117.627 0.713 . . . . 0.0 110.671 175.177 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.9 mm -81.24 118.4 28.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 C-N-CA 125.303 1.441 . . . . 0.0 111.566 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.6 -167.16 14.58 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 126.227 1.87 . . . . 0.0 112.613 169.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.425 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.0 OUTLIER -134.28 138.37 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.265 1.426 . . . . 0.0 114.34 -169.028 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.68 -141.26 0.27 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.703 1.201 . . . . 0.0 110.337 174.528 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.464 0 C-N-CA 124.272 1.029 . . . . 0.0 110.279 -176.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.905 0 CA-C-O 117.458 -1.258 . . . . 0.0 108.674 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 p -79.16 48.27 0.85 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -167.049 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -168.37 157.38 9.03 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 115.403 1.631 . . . . 0.0 115.403 163.557 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.1 179.02 8.06 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 130.231 3.413 . . . . 0.0 107.181 169.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.503 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.3 p -155.66 108.29 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 122.645 1.212 . . . . 0.0 111.619 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -101.5 96.64 7.27 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 167.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.1 t -76.91 136.06 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 165.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mp -128.39 104.29 7.63 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.155 -0.966 . . . . 0.0 109.562 -178.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -160.43 151.39 18.92 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 124.24 1.016 . . . . 0.0 111.865 -178.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.17 -116.94 1.02 Allowed Glycine 0 CA--C 1.524 0.624 0 CA-C-O 123.089 1.383 . . . . 0.0 111.618 166.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -92.7 56.32 2.63 Favored 'General case' 0 C--N 1.312 -1.035 1 C-N-CA 132.635 4.374 . . . . 0.0 115.034 -164.8 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.4 -168.19 35.25 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.296 -1.32 . . . . 0.0 114.074 176.218 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -86.02 17.88 1.67 Allowed 'Trans proline' 0 CA--C 1.539 0.767 1 C-N-CA 125.686 4.257 . . . . 0.0 113.553 -171.117 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 t -111.08 120.84 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.87 1.213 . . . . 0.0 108.975 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 pm0 -160.25 162.31 33.66 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.52 173.65 33.64 Favored Glycine 0 N--CA 1.462 0.377 0 C-N-CA 124.368 0.985 . . . . 0.0 113.296 168.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -126.24 134.13 67.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 124.386 1.074 . . . . 0.0 108.86 170.443 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.8 mm -137.6 105.24 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 118.274 0.488 . . . . 0.0 110.231 -172.605 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -77.67 161.74 27.55 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.597 0.713 . . . . 0.0 111.662 172.148 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.414 ' CD2' HG22 ' A' ' 31' ' ' VAL . 3.4 m-85 -137.17 111.22 8.32 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.897 1.679 . . . . 0.0 106.806 169.762 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -91.65 135.51 33.82 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 120.765 1.62 . . . . 0.0 109.794 172.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -132.1 145.99 51.75 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.825 0.821 . . . . 0.0 111.532 175.131 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -92.53 -34.74 13.94 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 124.624 1.169 . . . . 0.0 114.1 179.399 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.95 -154.42 0.55 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-N 120.66 1.573 . . . . 0.0 112.791 178.568 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 65.7 p -93.35 -0.23 56.68 Favored 'General case' 0 CA--C 1.538 0.518 0 O-C-N 119.228 -2.17 . . . . 0.0 115.469 -172.051 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -153.49 -8.71 0.16 Allowed 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 115.875 1.806 . . . . 0.0 115.875 -169.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.91 173.89 55.31 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 128.664 3.031 . . . . 0.0 114.023 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -78.22 139.36 16.75 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.046 2.497 . . . . 0.0 111.758 -175.498 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -108.84 132.9 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.418 1.087 . . . . 0.0 109.353 -170.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -99.07 113.21 25.3 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 122.172 0.987 . . . . 0.0 110.34 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.414 HG22 ' CD2' ' A' ' 20' ' ' PHE . 9.3 t -95.5 130.99 43.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 127.984 2.514 . . . . 0.0 109.14 -178.17 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.0 p90 -148.81 159.32 44.26 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.92 -157.12 27.21 Favored Glycine 0 C--O 1.225 -0.424 0 C-N-CA 126.058 1.79 . . . . 0.0 110.178 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.5 p -157.11 154.72 29.86 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 121.577 -0.955 . . . . 0.0 112.417 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 mp -121.67 130.91 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 125.599 1.56 . . . . 0.0 108.346 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.4 140.5 49.67 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.316 1.446 . . . . 0.0 111.012 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.52 11.6 11.51 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 126.17 1.843 . . . . 0.0 112.54 -168.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.7 mt -86.96 171.24 10.92 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.532 0.733 . . . . 0.0 109.54 169.393 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -80.53 -141.09 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 164.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.49 -154.13 0.37 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.939 1.296 . . . . 0.0 108.535 166.285 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 69.28 179.74 22.96 Favored Glycine 0 CA--C 1.532 1.147 0 O-C-N 120.398 -1.439 . . . . 0.0 115.331 168.24 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mp -87.52 154.77 20.36 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.973 1.709 . . . . 0.0 110.611 -176.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -150.67 103.52 3.11 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 127.323 2.249 . . . . 0.0 109.908 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.05 160.61 20.86 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 124.558 1.075 . . . . 0.0 114.185 -175.282 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -142.78 92.38 2.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 125.933 1.693 . . . . 0.0 109.186 -173.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -109.35 130.4 55.5 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.298 -1.501 . . . . 0.0 109.8 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -77.97 158.33 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 175.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -119.9 123.44 43.57 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 pm0 -57.47 147.16 27.33 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.774 0.797 . . . . 0.0 109.872 177.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 68.95 166.72 0.27 Allowed 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 126.111 2.862 . . . . 0.0 112.353 -176.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.81 10.8 18.4 Favored Glycine 0 N--CA 1.467 0.718 0 C-N-CA 128.198 2.809 . . . . 0.0 112.186 178.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -83.7 42.99 0.88 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 128.509 2.723 . . . . 0.0 114.055 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -179.88 -26.85 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 112.723 -2.035 . . . . 0.0 114.925 -166.369 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.389 43.4 p 27.74 -18.35 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 2 N-CA-C 123.535 4.643 . . . . 0.0 123.535 -167.625 . . . . . . . . 3 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.44 -0.37 57.36 Favored 'General case' 0 CA--C 1.549 0.91 0 CA-C-N 122.48 2.4 . . . . 0.0 114.278 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.9 -128.4 37.31 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 125.721 1.629 . . . . 0.0 111.396 177.523 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -51.62 -2.75 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.235 0 N-CA-C 117.215 2.302 . . . . 0.0 117.215 -176.665 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 85.7 m -110.63 11.37 22.82 Favored 'General case' 0 N--CA 1.481 1.108 0 O-C-N 119.795 -1.816 . . . . 0.0 113.782 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 t -155.79 -27.45 0.1 Allowed 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 115.92 1.822 . . . . 0.0 115.92 168.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.2 177.02 4.79 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.797 2.039 . . . . 0.0 108.912 166.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.79 -107.92 2.47 Favored Glycine 0 CA--C 1.541 1.719 0 CA-C-O 117.755 -1.58 . . . . 0.0 114.443 -169.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -101.69 -167.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.543 0.956 1 C-N-CA 127.23 5.287 . . . . 0.0 112.144 -174.623 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.742 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.6 OUTLIER -100.11 119.83 38.91 Favored 'General case' 0 CA--C 1.554 1.111 1 C-N-CA 132.292 4.237 . . . . 0.0 115.243 -178.274 . . . . . . . . 4 4 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -39.74 126.93 2.0 Allowed 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 130.074 3.35 . . . . 0.0 116.123 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 51.0 p-10 -121.6 32.72 0.21 Allowed Pre-proline 0 CA--C 1.557 1.212 0 N-CA-C 115.304 1.594 . . . . 0.0 115.304 -173.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -62.8 -20.66 71.8 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.959 3.106 . . . . 0.0 114.978 -167.351 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 60.5 mt -78.46 -1.78 35.34 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.09 1.356 . . . . 0.0 112.685 174.13 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.76 52.8 0.93 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 127.269 2.227 . . . . 0.0 111.765 173.661 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.4 ptt180 -156.97 -179.98 8.73 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -166.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.26 177.53 8.9 Favored 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.434 1.494 . . . . 0.0 113.983 -171.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -50.87 157.8 0.76 Allowed 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -169.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -80.85 67.75 3.52 Favored Glycine 0 N--CA 1.474 1.177 0 C-N-CA 125.601 1.572 . . . . 0.0 114.354 -167.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -97.06 128.37 9.53 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-O 118.913 -0.937 . . . . 0.0 114.583 -168.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -76.84 4.68 5.48 Favored 'Trans proline' 0 CA--C 1.545 1.071 0 C-N-CA 123.632 2.888 . . . . 0.0 111.713 167.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.56 -10.52 18.4 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.963 0.905 . . . . 0.0 111.863 168.501 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -123.37 139.73 53.74 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.155 0.982 . . . . 0.0 110.809 -166.691 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -66.81 -28.62 68.52 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.496 172.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -91.76 105.04 17.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 125.969 1.708 . . . . 0.0 106.946 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -140.11 112.69 7.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 129.065 2.946 . . . . 0.0 109.56 -170.201 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -58.71 152.29 19.15 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.094 1.357 . . . . 0.0 111.405 167.199 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 p -65.0 -13.75 15.43 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 171.233 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.02 43.64 1.36 Allowed Glycine 0 C--N 1.347 1.158 0 N-CA-C 118.26 2.064 . . . . 0.0 118.26 -168.469 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -147.68 143.6 27.75 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 119.891 1.845 . . . . 0.0 109.484 167.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.0 mt -108.67 54.37 0.66 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.638 0.732 . . . . 0.0 109.345 -175.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.09 -120.07 6.75 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 124.84 1.209 . . . . 0.0 112.239 -172.118 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -142.28 160.4 40.32 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.709 1.204 . . . . 0.0 109.717 170.468 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.681 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.7 OUTLIER -99.17 151.4 4.73 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.763 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 164.887 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.9 m -134.55 120.86 20.17 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 124.736 1.214 . . . . 0.0 108.738 -177.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.46 140.2 29.71 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -175.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -81.9 160.07 23.5 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 128.155 2.582 . . . . 0.0 110.151 169.013 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.47 -22.08 7.32 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 126.382 1.873 . . . . 0.0 114.944 -173.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -76.79 -3.9 40.69 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.445 2.298 . . . . 0.0 112.289 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.78 10.01 73.51 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 126.929 2.204 . . . . 0.0 114.477 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.83 137.54 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.583 1.553 . . . . 0.0 111.963 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.681 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -107.73 130.54 54.94 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.471 -0.936 . . . . 0.0 108.471 166.128 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -82.29 151.64 26.67 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 122.277 1.037 . . . . 0.0 109.499 170.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -134.08 129.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 112.81 -1.995 . . . . 0.0 111.867 164.463 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.2 p -157.85 54.05 0.47 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 124.4 1.08 . . . . 0.0 111.978 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.81 153.86 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 O-C-N 120.277 -1.515 . . . . 0.0 112.352 -171.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -129.28 139.9 51.63 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 125.845 1.658 . . . . 0.0 108.457 168.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -150.07 148.53 29.12 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.4 1.095 . . . . 0.0 111.662 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -107.5 55.61 0.65 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.082 1.753 . . . . 0.0 110.35 -171.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.6 p -152.47 11.32 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -169.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -153.58 163.09 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 127.158 2.183 . . . . 0.0 107.904 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.0 m -155.14 161.62 41.2 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 122.435 1.112 . . . . 0.0 112.56 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.5 tt -90.03 77.65 6.82 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 120.897 -1.127 . . . . 0.0 109.218 -169.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.7 t -83.3 -146.68 0.08 Allowed 'General case' 0 CA--C 1.547 0.841 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.704 167.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -137.73 23.06 3.11 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.105 1.812 . . . . 0.0 112.751 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -173.35 -70.09 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -163.127 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -94.01 11.15 30.75 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.576 2.35 . . . . 0.0 114.788 -164.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . 0.25 3.9 m -140.85 -100.6 0.15 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -178.368 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.5 pt -89.89 -57.32 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 CA-C-N 121.545 1.975 . . . . 0.0 111.345 169.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.0 mm -61.89 145.69 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 170.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 96.35 -38.92 2.94 Favored Glycine 0 CA--C 1.524 0.597 0 CA-C-O 118.09 -1.395 . . . . 0.0 113.606 176.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.7 ptt180 -83.31 170.07 14.99 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 119.212 1.506 . . . . 0.0 112.539 175.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.2 t -119.01 176.92 5.06 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.226 1.01 . . . . 0.0 113.457 174.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 22.2 tp -156.92 136.57 12.33 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 126.273 1.829 . . . . 0.0 113.536 -168.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.4 t -112.03 135.38 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.988 1.315 . . . . 0.0 110.478 170.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 m -93.31 151.85 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 168.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 65.8 m-70 -119.38 144.12 47.07 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.684 1.194 . . . . 0.0 113.007 -172.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -83.75 -16.67 43.93 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 120.956 -1.09 . . . . 0.0 113.25 -179.45 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -98.03 164.0 12.53 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 169.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.09 164.21 1.76 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.997 1.319 . . . . 0.0 112.041 170.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -124.16 141.01 52.42 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.103 1.761 . . . . 0.0 110.209 -177.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -73.39 -34.38 65.5 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 125.73 1.612 . . . . 0.0 110.862 177.816 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 42.6 mt 78.74 -24.19 0.22 Allowed 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 130.026 3.331 . . . . 0.0 113.272 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -137.23 -81.99 0.11 Allowed Glycine 0 N--CA 1.475 1.279 0 CA-C-N 121.379 1.9 . . . . 0.0 114.271 -175.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -158.23 139.21 13.13 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 128.29 2.636 . . . . 0.0 107.518 174.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -127.25 -119.87 2.29 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 126.708 2.099 . . . . 0.0 109.946 167.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -92.27 -33.57 7.58 Favored Glycine 0 N--CA 1.474 1.219 0 N-CA-C 117.629 1.811 . . . . 0.0 117.629 -167.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 32.6 p30 -114.44 172.09 7.23 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.384 1.473 . . . . 0.0 113.156 -168.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -48.58 -61.72 1.88 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 126.29 1.836 . . . . 0.0 110.506 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -41.1 -42.05 1.89 Allowed 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 128.509 2.724 . . . . 0.0 114.383 175.196 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.426 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 85.7 p -55.27 -28.83 56.07 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 121.499 1.954 . . . . 0.0 113.456 177.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -97.82 -32.65 11.6 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 113.806 1.039 . . . . 0.0 113.806 169.471 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.419 ' C ' ' HE2' ' A' ' 63' ' ' HIS . 86.6 tttt -91.13 -15.12 29.93 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.547 1.939 . . . . 0.0 115.006 -169.143 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.428 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 77.2 p -137.3 -16.03 1.42 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 128.444 2.698 . . . . 0.0 112.81 170.211 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.04 12.24 60.47 Favored Glycine 0 C--N 1.341 0.861 0 C-N-CA 124.062 0.839 . . . . 0.0 112.284 -167.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.426 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 7.9 t-20 53.4 26.61 5.54 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.158 1.383 . . . . 0.0 111.563 -168.145 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.7 6.96 0.56 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.652 1.181 . . . . 0.0 113.732 -169.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.03 -37.14 0.15 Allowed Glycine 0 CA--C 1.531 1.073 1 C-N-CA 131.128 4.204 . . . . 0.0 117.753 168.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 46.3 t -175.92 140.64 0.43 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.291 1.437 . . . . 0.0 111.428 -168.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.7 ptt-85 -77.42 174.6 10.64 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 123.702 0.801 . . . . 0.0 113.158 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.52 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -152.52 -143.02 0.13 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.417 1.887 . . . . 0.0 107.426 177.355 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.52 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -68.4 167.42 14.69 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.312 1.845 . . . . 0.0 112.727 177.426 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -140.18 153.24 46.55 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 125.004 1.322 . . . . 0.0 111.122 -169.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.54 141.18 7.32 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 124.193 0.901 . . . . 0.0 113.381 171.042 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' B' ' 148' ' ' VAL . 6.3 p -75.8 163.24 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 166.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.2 mm -93.09 94.37 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 121.37 -0.831 . . . . 0.0 110.032 170.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.3 -178.79 48.46 Favored Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.047 1.784 . . . . 0.0 113.759 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -113.99 130.58 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 124.659 1.183 . . . . 0.0 112.809 -170.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.52 -3.48 58.33 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.266 1.826 . . . . 0.0 112.472 176.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 . . . . . 0 CA--C 1.533 0.294 0 C-N-CA 125.149 1.38 . . . . 0.0 110.183 175.524 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.29 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -77.45 111.65 13.38 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 123.003 1.382 . . . . 0.0 108.675 -168.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mtmm -101.05 113.34 26.25 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 113.949 -1.478 . . . . 0.0 114.479 -171.526 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -95.89 175.47 6.49 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 127.036 2.134 . . . . 0.0 110.636 167.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -159.65 137.87 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 126.283 1.833 . . . . 0.0 110.677 -169.149 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.13 134.03 55.22 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 124.107 0.963 . . . . 0.0 109.016 165.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.58 114.76 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.157 0.983 . . . . 0.0 108.455 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.432 ' CD2' HG23 ' B' ' 119' ' ' VAL . 5.8 mp -98.14 130.91 44.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 126.29 1.836 . . . . 0.0 110.396 -167.635 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttt -150.57 175.63 11.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.485 1.114 . . . . 0.0 112.458 -177.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 139.97 -71.57 0.43 Allowed Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.868 2.651 . . . . 0.0 109.059 -172.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.71 69.79 1.81 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.813 2.045 . . . . 0.0 113.18 -169.208 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.6 -97.64 0.01 OUTLIER Glycine 0 CA--C 1.536 1.376 0 C-N-CA 127.607 2.527 . . . . 0.0 114.747 169.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -80.85 -16.41 10.17 Favored 'Trans proline' 0 C--N 1.352 0.727 0 C-N-CA 124.074 3.182 . . . . 0.0 114.304 -179.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 t -79.51 139.33 18.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 CA-C-N 120.561 1.528 . . . . 0.0 109.359 175.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 pm0 -155.1 152.58 29.68 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 113.567 -1.651 . . . . 0.0 108.117 167.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.72 152.47 17.11 Favored Glycine 0 CA--C 1.488 -1.594 0 O-C-N 123.818 0.699 . . . . 0.0 111.817 172.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -126.7 130.87 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 166.081 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 11.1 mm -129.17 118.09 45.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 173.122 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -82.88 157.73 22.97 Favored 'General case' 0 N--CA 1.47 0.543 0 O-C-N 120.927 -1.108 . . . . 0.0 109.48 169.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.405 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 70.3 m-85 -139.54 87.26 2.17 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.76 1.224 . . . . 0.0 108.139 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -86.91 124.15 32.81 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 121.299 -0.875 . . . . 0.0 112.034 174.006 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -113.82 134.84 54.54 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.869 0.842 . . . . 0.0 110.822 165.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.33 -32.05 15.84 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 124.64 1.176 . . . . 0.0 112.552 179.188 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -99.14 -169.24 1.74 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.042 2.137 . . . . 0.0 109.836 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.9 m -118.28 -6.15 10.83 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 120.634 -1.291 . . . . 0.0 113.277 167.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 61.0 m-80 -141.67 19.89 2.18 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 126.36 1.864 . . . . 0.0 112.379 175.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.0 -158.17 14.22 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.596 2.046 . . . . 0.0 113.193 175.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.84 154.02 29.83 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.228 2.619 . . . . 0.0 113.776 -172.278 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.86 133.34 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 126.364 1.866 . . . . 0.0 110.377 178.465 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -89.81 122.62 33.05 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.456 1.103 . . . . 0.0 110.607 171.315 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.19 84.66 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 128.081 2.553 . . . . 0.0 109.787 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 5.9 p90 -106.81 153.57 22.27 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 123.717 0.807 . . . . 0.0 111.234 169.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.01 -158.39 30.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 124.349 0.976 . . . . 0.0 112.141 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 91.8 p -159.41 136.04 9.26 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 -172.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.469 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.5 mp -112.51 111.7 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 124.536 1.134 . . . . 0.0 109.77 173.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -116.43 133.63 55.8 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 123.829 0.852 . . . . 0.0 111.371 -169.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.66 -2.23 26.14 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 125.827 1.68 . . . . 0.0 114.792 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.3 pp -83.8 178.5 7.89 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 118.858 1.329 . . . . 0.0 109.59 169.1 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.72 163.33 22.52 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 124.052 0.941 . . . . 0.0 109.415 169.19 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 40' ' ' GLU . . . . . 0.437 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 0.7 OUTLIER -52.56 178.54 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 177.724 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.31 -166.97 54.86 Favored Glycine 0 CA--C 1.527 0.827 0 O-C-N 120.274 -1.516 . . . . 0.0 112.958 172.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 77.3 mt -73.84 148.98 41.89 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.8 1.64 . . . . 0.0 111.764 -173.145 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -149.0 126.65 11.7 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 127.349 2.26 . . . . 0.0 110.437 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.55 157.1 25.67 Favored Glycine 0 N--CA 1.49 2.283 0 CA-C-O 117.625 -1.653 . . . . 0.0 112.756 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -157.58 110.84 2.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.469 2.308 . . . . 0.0 112.449 171.328 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.6 m80 -138.08 144.02 40.73 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 119.905 -1.747 . . . . 0.0 111.389 -175.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 132.63 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 C-N-CA 123.978 0.911 . . . . 0.0 110.118 177.342 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -75.37 117.42 17.15 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 168.184 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -73.37 60.46 0.62 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.469 1.908 . . . . 0.0 114.217 -168.339 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -179.4 164.25 1.31 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 128.983 2.913 . . . . 0.0 109.461 170.303 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.43 -10.29 55.87 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.245 0.926 . . . . 0.0 114.66 169.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.503 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -82.03 51.37 1.74 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 126.942 2.097 . . . . 0.0 110.439 -176.021 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' C ' ' B' ' 53' ' ' ASN . 0.4 OUTLIER 171.26 33.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 0.997 0 N-CA-C 115.805 1.779 . . . . 0.0 115.805 -164.958 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 37.4 p -40.26 -34.49 0.32 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 118.184 2.661 . . . . 0.0 118.184 -168.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 18.16 1.84 Allowed 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 -167.148 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 -141.3 20.29 Favored Glycine 0 CA--C 1.526 0.725 0 O-C-N 120.71 -1.244 . . . . 0.0 113.12 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.8 t -62.08 -5.96 2.62 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 115.399 1.629 . . . . 0.0 115.399 -174.344 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 11.2 t -80.15 -4.23 52.14 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.419 1.088 . . . . 0.0 112.293 170.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -149.04 159.49 44.18 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 119.993 1.269 . . . . 0.0 113.65 -177.156 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 61.0 -138.07 0.57 Allowed 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.883 2.073 . . . . 0.0 110.052 -168.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.27 158.91 20.55 Favored Glycine 0 CA--C 1.534 1.263 0 CA-C-O 117.672 -1.627 . . . . 0.0 110.728 169.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -55.04 103.52 0.1 Allowed 'Trans proline' 0 C--N 1.355 0.92 1 C-N-CA 125.663 4.242 . . . . 0.0 109.936 178.538 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 46.12 62.02 2.44 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 113.679 -1.601 . . . . 0.0 111.131 -175.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -37.62 134.19 0.71 Allowed 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.398 1.479 . . . . 0.0 112.183 -175.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -117.26 80.15 11.99 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -165.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.92 -13.32 34.12 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 123.101 2.534 . . . . 0.0 114.119 177.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -90.0 -6.69 55.34 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.85 1.26 . . . . 0.0 112.679 177.242 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.3 t 50.77 50.59 18.69 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 127.514 2.325 . . . . 0.0 114.703 -177.279 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -108.65 177.34 4.81 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 124.85 1.26 . . . . 0.0 113.065 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.11 164.69 22.22 Favored 'General case' 0 N--CA 1.47 0.555 0 O-C-N 121.342 -0.849 . . . . 0.0 110.73 167.146 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.477 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 63.8 t60 -68.1 -176.33 0.7 Allowed 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 122.095 0.95 . . . . 0.0 113.111 -176.108 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.477 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 111.07 -154.52 16.61 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 124.513 1.054 . . . . 0.0 115.492 165.063 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 166.13 -89.38 0.1 Allowed Glycine 0 CA--C 1.528 0.864 0 CA-C-O 118.205 -1.331 . . . . 0.0 114.725 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -67.9 -1.12 6.35 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 123.049 2.5 . . . . 0.0 114.15 -175.522 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -129.24 -4.14 4.95 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 125.613 1.565 . . . . 0.0 112.631 168.288 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -153.19 112.84 3.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.932 1.293 . . . . 0.0 110.347 -169.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -64.13 -12.2 37.42 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.324 1.85 . . . . 0.0 114.572 -175.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -75.44 -22.67 57.16 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 120.235 1.379 . . . . 0.0 113.651 -170.267 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 12.4 ttp85 14.57 100.97 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 130.564 3.546 . . . . 0.0 115.325 164.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.1 m170 -51.49 155.75 1.45 Allowed 'General case' 0 CA--C 1.558 1.258 0 CA-C-O 117.272 -1.347 . . . . 0.0 109.834 168.004 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.316 85.3 t -74.57 -17.49 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-N 123.865 3.029 . . . . 0.0 110.231 -175.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.47 7.52 64.55 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 127.423 2.44 . . . . 0.0 114.404 166.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -98.93 119.25 37.4 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.838 1.819 . . . . 0.0 113.401 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 63.3 mt -102.27 -176.06 3.01 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 126.73 2.012 . . . . 0.0 106.015 164.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.23 -144.91 5.09 Favored Glycine 0 CA--C 1.534 1.275 0 O-C-N 120.891 -1.13 . . . . 0.0 114.114 -178.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.65 152.16 49.46 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 123.983 0.913 . . . . 0.0 109.818 168.677 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 9.8 p -113.72 142.18 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.57 1.948 . . . . 0.0 112.207 -168.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -115.08 120.01 38.36 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.047 1.129 . . . . 0.0 114.047 -169.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.49 155.34 17.89 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 119.043 2.979 . . . . 0.0 119.043 175.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -84.51 164.89 18.51 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-N 111.631 -2.532 . . . . 0.0 109.808 167.583 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.16 -12.45 5.17 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 115.129 1.529 . . . . 0.0 115.129 171.399 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.66 -27.32 61.18 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.837 1.655 . . . . 0.0 111.2 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.24 -2.27 54.46 Favored Glycine 0 CA--C 1.523 0.544 0 CA-C-O 117.661 -1.633 . . . . 0.0 114.355 -177.526 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 9.5 p -79.48 118.49 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 119.572 1.686 . . . . 0.0 112.352 168.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -89.02 119.56 29.65 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.454 1.502 . . . . 0.0 108.587 166.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -80.46 140.27 36.02 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 118.492 0.587 . . . . 0.0 110.593 174.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -128.75 134.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.267 -1.333 . . . . 0.0 110.437 166.617 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.3 p -156.61 56.67 0.55 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 122.762 1.267 . . . . 0.0 109.628 -169.313 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 54.8 mt -114.78 160.68 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 125.044 1.337 . . . . 0.0 111.285 -169.033 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -133.47 146.15 50.87 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.837 2.055 . . . . 0.0 108.467 169.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -140.35 125.75 18.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 124.702 1.201 . . . . 0.0 110.442 -169.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 79.4 p -107.04 57.72 0.63 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.745 1.218 . . . . 0.0 112.308 -172.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -154.56 -41.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.93 173.67 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.232 -0.918 . . . . 0.0 112.026 177.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 25.8 m -158.25 162.99 37.86 Favored 'General case' 0 N--CA 1.481 1.081 0 O-C-N 119.579 -1.95 . . . . 0.0 115.028 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.35 59.24 1.8 Allowed 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.611 2.364 . . . . 0.0 108.484 175.415 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.9 t -89.82 1.3 56.32 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.242 1.017 . . . . 0.0 113.276 -175.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.17 -32.46 1.11 Allowed Glycine 0 N--CA 1.474 1.179 0 C-N-CA 125.029 1.3 . . . . 0.0 114.818 177.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -123.51 -95.06 0.48 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.985 1.314 . . . . 0.0 112.76 -169.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -75.92 3.07 10.9 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 119.678 -1.889 . . . . 0.0 114.344 -164.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.9 t -107.2 -128.85 0.27 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.677 -175.109 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 pt -84.0 -18.64 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 121.516 1.962 . . . . 0.0 115.981 -179.142 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mm -69.4 134.3 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.389 0.995 . . . . 0.0 111.017 -171.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.22 -2.75 75.12 Favored Glycine 0 CA--C 1.533 1.213 0 CA-C-O 117.836 -1.535 . . . . 0.0 114.038 -178.691 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.6 mtm180 -86.58 158.33 19.53 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 119.476 1.638 . . . . 0.0 109.998 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.5 t -115.98 119.85 37.23 Favored 'General case' 0 N--CA 1.486 1.346 0 CA-C-N 120.41 1.459 . . . . 0.0 112.942 -168.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 36.6 tp -94.93 121.33 36.43 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 126.511 1.924 . . . . 0.0 110.476 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 p -107.39 126.32 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.6 1.16 . . . . 0.0 110.194 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.432 HG23 ' CD2' ' B' ' 8' ' ' LEU . 67.5 t -89.15 163.57 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 168.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.9 m-70 -123.8 138.21 54.54 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.964 1.306 . . . . 0.0 111.286 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.1 pp20? -70.94 -11.23 60.85 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.177 -1.577 . . . . 0.0 114.549 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -115.62 167.03 11.27 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.107 1.363 . . . . 0.0 112.707 168.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.07 150.54 7.97 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.773 1.629 . . . . 0.0 110.434 166.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -112.53 144.68 41.6 Favored 'General case' 0 C--O 1.243 0.735 0 CA-C-O 121.717 0.77 . . . . 0.0 112.762 -178.172 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -76.45 -25.29 54.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.571 1.548 . . . . 0.0 111.748 -177.064 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt 48.61 51.93 14.69 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 126.949 2.099 . . . . 0.0 111.473 170.655 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 170.21 -94.44 0.1 Allowed Glycine 0 C--N 1.334 0.43 0 N-CA-C 117.11 1.604 . . . . 0.0 117.11 173.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 ptpp? -163.27 30.46 0.09 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -164.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -51.64 -22.06 7.77 Favored Glycine 0 N--CA 1.477 1.404 0 N-CA-C 119.388 2.515 . . . . 0.0 119.388 -168.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 175.77 -18.68 0.04 OUTLIER Glycine 0 N--CA 1.474 1.182 0 N-CA-C 117.565 1.786 . . . . 0.0 117.565 174.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -144.68 179.37 7.34 Favored 'General case' 0 CA--C 1.545 0.782 0 CA-C-N 119.291 1.546 . . . . 0.0 113.56 -173.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . 0.262 0.0 OUTLIER -49.84 -63.91 0.97 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.848 2.059 . . . . 0.0 111.435 172.232 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -54.11 -33.7 58.37 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 121.593 1.997 . . . . 0.0 113.373 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.15 -32.81 62.41 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 121.083 1.765 . . . . 0.0 114.193 172.111 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -105.32 -12.53 16.02 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.435 1.094 . . . . 0.0 113.499 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.7 tttt -96.54 -35.82 10.97 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.381 1.873 . . . . 0.0 112.705 -178.441 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.2 p -126.78 -20.65 4.22 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 125.139 1.376 . . . . 0.0 114.689 175.19 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.58 13.83 42.95 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.554 1.073 . . . . 0.0 110.534 -166.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 66.43 -68.08 0.14 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.769 3.228 . . . . 0.0 110.111 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 57.69 -66.7 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 131.445 3.898 . . . . 0.0 113.243 177.41 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.35 -28.71 4.98 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 127.523 2.487 . . . . 0.0 111.977 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.2 t -166.49 -161.63 0.47 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 124.605 1.162 . . . . 0.0 112.108 173.02 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -119.53 -156.49 0.66 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 128.328 2.651 . . . . 0.0 109.558 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -179.82 -164.55 0.06 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.867 2.467 . . . . 0.0 107.275 -171.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.89 144.25 23.43 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 127.243 2.217 . . . . 0.0 111.532 176.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -144.36 147.84 33.95 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -175.619 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.04 150.01 19.92 Favored Glycine 0 N--CA 1.476 1.355 0 C-N-CA 124.693 1.14 . . . . 0.0 114.651 -174.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' A' ' 148' ' ' VAL . 5.0 t -82.37 150.25 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.67 -0.9 . . . . 0.0 113.059 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -77.26 78.9 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 C-N-CA 126.562 1.945 . . . . 0.0 110.94 171.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -97.02 -158.96 31.3 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.243 1.878 . . . . 0.0 112.644 173.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -136.69 148.87 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -95.91 -120.07 0.11 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 103.058 -2.941 . . . . 0.0 103.058 163.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.471 0.597 0 C-N-CA 123.787 0.835 . . . . 0.0 112.674 166.051 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 122.564 1.174 . . . . 0.0 111.849 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.3 t -157.37 171.09 21.01 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 130.276 3.43 . . . . 0.0 104.26 164.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -146.06 138.94 25.7 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 116.413 2.005 . . . . 0.0 116.413 177.035 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 169.63 9.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 127.258 2.223 . . . . 0.0 111.439 171.358 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.556 HG22 HG21 ' B' ' 54' ' ' THR . 14.7 p -158.6 110.51 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.772 1.629 . . . . 0.0 111.739 173.177 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.79 116.29 12.0 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.755 1.222 . . . . 0.0 112.442 -167.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 p -81.42 84.51 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.69 100.69 8.83 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 173.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -159.68 80.12 0.72 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 123.482 0.713 . . . . 0.0 112.172 -172.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.03 8.02 3.53 Favored Glycine 0 N--CA 1.472 1.056 0 C-N-CA 125.813 1.673 . . . . 0.0 113.658 169.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -133.46 54.88 1.93 Allowed 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 125.761 1.624 . . . . 0.0 108.74 -168.221 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 29.51 -98.23 0.01 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 129.381 3.372 . . . . 0.0 115.735 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.3 -15.22 47.42 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 124.2 3.266 . . . . 0.0 115.001 -176.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 t -111.34 128.86 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 125.058 1.343 . . . . 0.0 108.515 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.98 162.68 40.32 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.82 -174.028 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.45 170.07 29.0 Favored Glycine 0 CA--C 1.505 -0.592 0 CA-C-O 122.571 1.095 . . . . 0.0 114.206 174.629 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -130.76 128.27 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 C-N-CA 126.618 1.967 . . . . 0.0 106.356 173.498 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -137.94 112.53 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 121.312 -0.867 . . . . 0.0 109.72 172.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 28.1 m-80 -75.75 157.78 33.09 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.032 0.933 . . . . 0.0 111.091 178.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -141.58 127.93 19.93 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.812 1.245 . . . . 0.0 107.823 168.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -91.66 120.19 32.21 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.017 0.826 . . . . 0.0 112.138 174.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp-100 -88.49 78.45 7.86 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 118.658 -2.526 . . . . 0.0 105.701 167.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.7 ptmt -58.19 -41.52 84.12 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 120.909 -1.119 . . . . 0.0 110.669 175.018 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -155.19 142.46 19.43 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 129.41 3.084 . . . . 0.0 108.088 -166.025 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 m -48.23 -44.42 33.18 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 116.175 1.917 . . . . 0.0 116.175 -167.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -126.12 23.38 7.1 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.783 1.233 . . . . 0.0 112.0 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.75 167.82 53.58 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.134 -0.815 . . . . 0.0 112.481 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -65.73 151.36 84.67 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.37 2.047 . . . . 0.0 109.496 169.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -135.62 134.63 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-O 122.63 1.205 . . . . 0.0 110.702 -175.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 ttmm -81.03 128.26 33.51 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 114.056 -1.429 . . . . 0.0 108.212 167.496 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 64.0 t -124.91 111.17 26.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 126.846 2.058 . . . . 0.0 110.599 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.2 p90 -144.81 154.85 43.11 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -168.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 162.11 -138.94 5.66 Favored Glycine 0 C--N 1.335 0.496 0 O-C-N 120.903 -1.123 . . . . 0.0 112.895 172.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -154.08 131.61 11.37 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -169.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mm -117.34 126.6 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 123.944 0.898 . . . . 0.0 109.322 173.169 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -123.7 142.23 51.27 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.305 1.842 . . . . 0.0 110.763 -168.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.49 -16.41 57.87 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 125.946 1.736 . . . . 0.0 111.774 -169.44 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -65.01 113.02 3.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 167.071 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -60.13 -41.54 92.91 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.97 0.804 . . . . 0.0 111.627 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.3 -178.16 1.98 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.381 1.073 . . . . 0.0 113.017 -168.499 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 65.96 176.27 6.53 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.961 1.267 . . . . 0.0 115.544 166.6 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.39 142.88 46.96 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 169.348 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -127.03 127.72 45.2 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 127.493 2.317 . . . . 0.0 107.145 174.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.84 156.43 40.35 Favored Glycine 0 N--CA 1.467 0.766 0 CA-C-O 119.016 -0.88 . . . . 0.0 111.13 -176.213 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.41 130.61 17.48 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 118.037 0.919 . . . . 0.0 109.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -154.89 161.97 41.26 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 120.337 -1.477 . . . . 0.0 111.1 173.7 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' CA ' ' A' ' 82' ' ' GLY . 0.8 OUTLIER -104.37 135.83 40.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-O 122.629 1.204 . . . . 0.0 110.92 176.11 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -73.53 176.69 5.9 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 126.562 1.945 . . . . 0.0 110.526 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -72.18 -14.36 61.79 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.608 1.706 . . . . 0.0 115.608 174.187 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.461 ' C ' ' HA ' ' A' ' 115' ' ' ARG . 22.3 m-85 -157.03 172.97 17.73 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 129.757 3.223 . . . . 0.0 107.609 -167.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.17 30.28 4.44 Favored Glycine 0 C--O 1.223 -0.581 0 N-CA-C 108.677 -1.769 . . . . 0.0 108.677 165.724 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -82.24 109.53 16.61 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 119.408 1.604 . . . . 0.0 111.027 -166.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.459 HD22 HG22 ' A' ' 148' ' ' VAL 0.299 12.4 p-10 -159.18 32.54 0.2 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 117.915 2.561 . . . . 0.0 117.915 179.284 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.735 HG22 HG23 ' B' ' 5' ' ' VAL . 0.1 OUTLIER -84.84 -35.54 22.19 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 126.078 1.751 . . . . 0.0 112.883 -167.816 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -115.06 -13.68 11.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.021 1.729 . . . . 0.0 113.429 177.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.58 -75.68 0.84 Allowed Glycine 0 CA--C 1.529 0.939 0 C-N-CA 124.49 1.043 . . . . 0.0 111.524 -174.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.8 m -65.65 -17.62 64.73 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.9 p -127.51 33.43 4.84 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.333 1.453 . . . . 0.0 112.103 171.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 97.7 p -179.42 106.67 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.334 1.853 . . . . 0.0 110.56 177.402 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 166.53 73.43 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 131.183 3.793 . . . . 0.0 109.097 175.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.62 107.87 2.38 Favored Glycine 0 CA--C 1.542 1.725 0 C-N-CA 125.194 1.378 . . . . 0.0 114.665 -169.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -86.56 101.09 0.58 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 124.041 3.161 . . . . 0.0 112.008 -168.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 55.44 39.73 31.19 Favored 'General case' 0 C--O 1.242 0.7 0 C-N-CA 127.495 2.318 . . . . 0.0 113.221 170.231 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -77.05 124.69 28.15 Favored 'General case' 0 C--O 1.234 0.269 0 O-C-N 120.365 -1.46 . . . . 0.0 108.148 169.272 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.79 135.09 8.98 Favored Pre-proline 0 CA--C 1.539 0.554 0 CA-C-N 114.048 -1.433 . . . . 0.0 112.252 -173.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -71.43 -2.42 11.24 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.051 2.501 . . . . 0.0 114.214 -172.087 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 26.8 mt -79.51 -20.01 48.27 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 118.947 0.794 . . . . 0.0 112.038 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t 49.07 50.98 17.05 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 125.247 1.419 . . . . 0.0 113.371 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.0 mtm-85 -112.53 178.51 4.27 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 125.251 1.42 . . . . 0.0 112.666 -173.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.77 161.14 27.91 Favored 'General case' 0 CA--C 1.553 1.093 0 CA-C-N 118.504 0.593 . . . . 0.0 109.811 164.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.444 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 82.1 t60 -66.51 -175.91 0.41 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.503 1.521 . . . . 0.0 112.542 -177.215 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.444 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 107.26 -138.27 14.41 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 115.549 0.98 . . . . 0.0 115.549 165.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.89 -64.54 0.6 Allowed Glycine 0 CA--C 1.541 1.68 0 N-CA-C 116.941 1.536 . . . . 0.0 116.941 -174.322 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.95 -4.55 15.31 Favored 'Trans proline' 0 CA--C 1.544 1.011 0 CA-C-N 121.11 2.455 . . . . 0.0 114.427 -178.295 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.59 -1.47 0.52 Allowed 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 126.154 1.782 . . . . 0.0 114.207 172.101 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -124.19 148.34 47.34 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.395 2.278 . . . . 0.0 107.405 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.04 -20.68 30.07 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 127.3 2.24 . . . . 0.0 112.735 -168.732 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -83.68 -64.96 1.07 Allowed 'General case' 0 C--O 1.232 0.149 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -169.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 34.7 ttt-85 66.19 120.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.285 1.434 . . . . 0.0 111.724 -177.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -65.53 172.56 3.24 Favored 'General case' 0 CA--C 1.544 0.716 0 O-C-N 119.567 -1.958 . . . . 0.0 109.355 165.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -35.29 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.313 -1.492 . . . . 0.0 112.644 168.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.503 ' CA ' HG23 ' A' ' 47' ' ' VAL . . . -107.71 50.65 0.77 Allowed Glycine 0 CA--C 1.534 1.277 0 N-CA-C 117.007 1.563 . . . . 0.0 117.007 -169.395 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -124.45 119.17 28.41 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.56 -0.965 . . . . 0.0 113.291 -169.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -97.35 175.5 6.23 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.944 1.298 . . . . 0.0 108.586 167.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.59 170.18 29.4 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.676 1.132 . . . . 0.0 111.214 169.034 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -76.79 145.85 38.24 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.56 1.318 . . . . 0.0 114.56 -176.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.21 122.71 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 127.23 2.212 . . . . 0.0 109.27 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 99.0 m -110.73 121.59 45.71 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -169.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.53 142.02 32.59 Favored 'General case' 0 N--CA 1.445 -0.702 0 C-N-CA 125.582 1.553 . . . . 0.0 113.328 -172.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.439 ' OD1' ' HE3' ' A' ' 91' ' ' LYS . 29.1 t0 -91.91 148.33 22.3 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.127 -1.397 . . . . 0.0 110.906 168.554 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.439 ' HE3' ' OD1' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -47.26 -21.23 0.25 Allowed 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 128.61 2.764 . . . . 0.0 117.38 -170.336 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -74.97 -0.71 19.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 127.492 2.317 . . . . 0.0 111.818 177.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.06 32.16 6.27 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 117.365 -1.797 . . . . 0.0 114.059 170.322 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -152.85 132.53 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 N-CA-C 117.152 2.279 . . . . 0.0 117.152 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.52 109.71 22.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.96 164.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -91.5 133.3 35.63 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.377 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -141.0 145.94 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 118.515 2.783 . . . . 0.0 118.515 -168.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 93.8 p -142.81 105.52 4.5 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.39 1.876 . . . . 0.0 110.018 168.27 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.3 mt -107.17 150.85 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 C-N-CA 125.916 1.686 . . . . 0.0 108.929 169.644 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -144.45 138.29 27.57 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.954 1.702 . . . . 0.0 107.631 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -157.05 152.25 26.26 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.162 0.985 . . . . 0.0 112.252 -168.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.3 p -119.17 55.2 0.95 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.469 1.108 . . . . 0.0 113.609 -168.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.6 p -158.56 -27.34 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 124.756 1.222 . . . . 0.0 112.776 171.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.56 150.02 5.51 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.327 0 O-C-N 121.062 -1.024 . . . . 0.0 111.029 175.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 p -158.05 162.92 38.13 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 121.057 -1.027 . . . . 0.0 109.174 171.173 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mp -85.83 47.82 1.5 Allowed 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.413 -1.429 . . . . 0.0 110.923 -172.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.6 t -82.18 -0.48 45.22 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -172.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.48 -7.02 74.58 Favored Glycine 0 N--CA 1.477 1.368 0 N-CA-C 118.216 2.046 . . . . 0.0 118.216 169.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -121.15 -94.81 0.49 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.637 1.575 . . . . 0.0 110.46 -167.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m170 -91.49 5.76 48.21 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -168.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.3 p -107.43 -70.71 0.78 Allowed 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 117.532 2.419 . . . . 0.0 117.532 -166.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pt -159.28 -51.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 125.747 1.619 . . . . 0.0 113.324 -167.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.43 145.62 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 125.89 1.676 . . . . 0.0 108.347 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.83 -22.08 2.99 Favored Glycine 0 N--CA 1.47 0.92 0 C-N-CA 124.585 1.088 . . . . 0.0 112.125 -167.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.461 ' HA ' ' C ' ' A' ' 50' ' ' PHE . 41.8 mtt180 -85.38 176.81 8.06 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.851 2.06 . . . . 0.0 110.948 169.162 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -108.76 133.66 52.52 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 127.471 2.309 . . . . 0.0 108.032 171.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.405 ' HB3' HD11 ' A' ' 149' ' ' ILE . 26.5 tp -102.41 118.05 36.04 Favored 'General case' 0 CA--C 1.535 0.365 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 168.349 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -112.15 129.81 66.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 CA-C-N 119.253 0.933 . . . . 0.0 110.815 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' A' ' 144' ' ' LEU . 2.4 p -88.92 145.99 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 121.394 0.616 . . . . 0.0 109.837 169.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -102.92 161.55 13.66 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.817 1.647 . . . . 0.0 111.83 -175.357 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.13 -31.91 62.95 Favored 'General case' 0 N--CA 1.473 0.704 0 O-C-N 121.081 -1.012 . . . . 0.0 112.086 -173.643 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 27.6 mmtm -131.86 -178.92 5.1 Favored 'General case' 0 C--O 1.237 0.4 0 O-C-N 119.234 -2.166 . . . . 0.0 110.974 169.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.72 129.02 39.38 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 125.077 1.351 . . . . 0.0 109.298 -176.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.18 152.62 30.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 166.212 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.27 -17.92 61.27 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.945 178.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 13.4 mt 61.77 41.96 11.2 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.037 1.335 . . . . 0.0 110.227 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 175.28 -97.08 0.11 Allowed Glycine 0 N--CA 1.471 0.999 0 N-CA-C 118.969 2.348 . . . . 0.0 118.969 177.351 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.0 pttt -162.69 37.26 0.11 Allowed 'General case' 0 CA--C 1.555 1.139 0 C-N-CA 127.99 2.516 . . . . 0.0 113.631 -167.68 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -55.07 -12.7 4.13 Favored Glycine 0 CA--C 1.539 1.535 0 N-CA-C 120.132 2.813 . . . . 0.0 120.132 -168.394 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.47 -28.8 0.5 Allowed Glycine 0 N--CA 1.477 1.379 0 CA-C-N 121.085 2.442 . . . . 0.0 118.038 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 22.1 p-10 -107.13 166.62 10.48 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 119.404 1.602 . . . . 0.0 109.656 174.143 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -57.05 -48.58 78.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 119.932 1.242 . . . . 0.0 109.67 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -48.54 -34.56 11.59 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.722 2.809 . . . . 0.0 113.046 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.6 p -57.7 -28.22 63.64 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 173.345 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.09 -23.82 10.68 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 169.674 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -59.18 -28.07 66.28 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.484 1.038 . . . . 0.0 111.467 172.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.9 p -133.87 -93.04 0.33 Allowed 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 166.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -158.12 24.81 0.4 Allowed Glycine 0 CA--C 1.537 1.428 0 C-N-CA 130.194 3.759 . . . . 0.0 109.224 168.368 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.11 -84.0 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.367 1.867 . . . . 0.0 107.787 -166.679 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 66.52 2.15 2.38 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 127.821 2.448 . . . . 0.0 116.711 166.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.71 -57.81 3.01 Favored Glycine 0 CA--C 1.53 1.004 0 C-N-CA 125.683 1.611 . . . . 0.0 113.681 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.5 t -171.83 -177.4 1.95 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.166 1.387 . . . . 0.0 111.306 -171.602 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.8 164.88 13.18 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 121.151 -0.968 . . . . 0.0 111.926 172.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.476 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -150.94 -152.57 0.44 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 127.568 2.347 . . . . 0.0 106.577 174.817 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.476 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -37.47 112.15 0.19 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.8 2.04 . . . . 0.0 114.296 -170.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.5 t -109.29 138.96 44.86 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.065 2.146 . . . . 0.0 110.538 -175.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.5 -178.57 21.13 Favored Glycine 0 N--CA 1.469 0.899 0 C-N-CA 124.588 1.09 . . . . 0.0 114.32 -175.118 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.459 HG22 HD22 ' A' ' 53' ' ' ASN . 0.2 OUTLIER -127.97 160.41 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 104.893 -2.262 . . . . 0.0 104.893 165.723 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.405 HD11 ' HB3' ' A' ' 117' ' ' LEU . 2.6 mm -135.04 130.56 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 CA-C-N 120.069 1.304 . . . . 0.0 112.434 -168.279 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.27 -114.04 1.37 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.668 1.604 . . . . 0.0 115.025 -175.122 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -158.38 129.25 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 118.877 1.338 . . . . 0.0 109.756 -177.23 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 -35.55 14.95 Favored 'General case' 0 N--CA 1.47 0.531 0 O-C-N 120.929 -1.107 . . . . 0.0 112.42 177.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 . . . . . 0 C--O 1.235 0.294 0 C-N-CA 127.264 2.226 . . . . 0.0 110.005 -171.524 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.549 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 99.2 m -79.17 105.21 10.34 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 169.27 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.496 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -97.66 122.52 40.84 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.709 1.203 . . . . 0.0 113.366 -168.409 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.52 178.12 8.37 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 120.911 -1.118 . . . . 0.0 114.005 -177.308 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.735 HG23 HG22 ' A' ' 54' ' ' THR . 0.2 OUTLIER -147.86 110.03 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 128.053 2.541 . . . . 0.0 106.784 169.314 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -99.3 133.28 43.82 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.951 0.9 . . . . 0.0 108.631 166.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -131.36 99.42 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 123.256 0.622 . . . . 0.0 110.965 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.8 mp -88.21 141.69 28.36 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 124.067 0.854 . . . . 0.0 109.867 169.148 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -156.07 168.16 28.13 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.913 1.685 . . . . 0.0 112.073 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.48 -101.95 0.19 Allowed Glycine 0 C--O 1.226 -0.398 0 N-CA-C 107.583 -2.207 . . . . 0.0 107.583 166.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -149.42 124.84 10.26 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 129.014 2.926 . . . . 0.0 106.095 -169.466 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.07 -177.69 44.61 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 124.544 1.069 . . . . 0.0 112.81 -174.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -71.92 30.22 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.093 1 C-N-CA 126.157 4.571 . . . . 0.0 115.11 -170.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.11 123.78 63.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.558 1.543 . . . . 0.0 109.441 -177.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.65 163.71 36.48 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 124.272 1.029 . . . . 0.0 109.585 176.05 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.67 108.78 0.79 Allowed Glycine 0 N--CA 1.461 0.302 0 CA-C-N 114.106 -1.406 . . . . 0.0 110.373 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.46 128.88 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 123.956 0.902 . . . . 0.0 109.401 169.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mm -134.82 124.51 43.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 123.864 0.866 . . . . 0.0 109.231 168.324 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -79.9 149.63 30.84 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 126.697 1.999 . . . . 0.0 109.924 165.302 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -143.97 101.97 3.82 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.496 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.4 OUTLIER -108.83 116.86 32.78 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.367 1.067 . . . . 0.0 109.831 -169.572 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -116.96 142.28 47.15 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 122.652 1.215 . . . . 0.0 112.917 -172.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.562 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -90.74 -7.57 52.13 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.337 1.455 . . . . 0.0 114.61 -173.656 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.562 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 48.9 mp0 -150.22 -173.99 4.6 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 127.368 2.267 . . . . 0.0 108.24 173.024 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.6 p -75.4 -26.71 58.65 Favored 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.47 -0.769 . . . . 0.0 111.215 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -135.25 9.99 3.49 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.274 1.429 . . . . 0.0 114.101 -171.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.54 174.02 55.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.236 0.922 . . . . 0.0 111.555 169.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.11 166.13 30.85 Favored 'Trans proline' 0 CA--C 1.536 0.578 0 C-N-CA 122.712 2.274 . . . . 0.0 111.116 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.58 132.58 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 C-N-CA 124.876 1.27 . . . . 0.0 110.661 -168.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -88.52 127.81 35.54 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 168.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.8 t -116.91 124.19 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 126.011 1.724 . . . . 0.0 109.058 -171.05 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -155.41 157.29 36.8 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.152 -0.968 . . . . 0.0 113.269 177.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.13 -160.74 30.67 Favored Glycine 0 CA--C 1.52 0.364 0 O-C-N 121.553 -0.717 . . . . 0.0 113.706 -177.077 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 53.3 p -149.24 133.19 17.11 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 113.276 0.843 . . . . 0.0 113.276 -168.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -106.01 113.43 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 O-C-N 121.724 -0.61 . . . . 0.0 109.794 171.612 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.7 ptpt -110.78 157.96 19.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.164 1.385 . . . . 0.0 110.613 -170.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.28 8.29 75.09 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 123.861 0.743 . . . . 0.0 113.997 -173.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -81.15 -152.4 0.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 127.19 2.196 . . . . 0.0 107.865 168.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 39' ' ' THR . . . . . 0.499 HG23 ' H ' ' B' ' 40' ' ' GLU 0.282 7.9 t -137.14 -91.78 0.24 Allowed 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.996 1.318 . . . . 0.0 108.353 169.702 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 40' ' ' GLU . . . . . 0.499 ' H ' HG23 ' B' ' 39' ' ' THR . 0.0 OUTLIER -127.98 -56.55 1.27 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.438 1.495 . . . . 0.0 113.719 173.085 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.39 147.76 44.87 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 119.856 -1.778 . . . . 0.0 113.558 -169.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.442 ' H ' HD12 ' B' ' 42' ' ' LEU . 1.2 mp -44.9 141.91 2.0 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.84 2.056 . . . . 0.0 112.619 -173.233 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -126.09 130.64 51.49 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.689 1.596 . . . . 0.0 109.276 170.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.76 163.01 41.08 Favored Glycine 0 N--CA 1.482 1.717 0 CA-C-N 120.292 1.406 . . . . 0.0 111.516 172.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -152.46 130.31 11.7 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 120.673 2.237 . . . . 0.0 112.513 168.783 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.28 146.36 21.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.473 1.109 . . . . 0.0 111.999 -168.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 p -82.63 135.1 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 O-C-N 121.632 -0.667 . . . . 0.0 110.653 168.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.493 ' HB2' HG23 ' B' ' 116' ' ' THR . 7.5 m-70 -78.19 159.01 28.81 Favored 'General case' 0 CA--C 1.559 1.304 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.141 165.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -67.32 110.89 3.73 Favored 'General case' 0 N--CA 1.469 0.497 0 O-C-N 119.473 -2.017 . . . . 0.0 110.258 171.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 50' ' ' PHE . . . . . 0.432 ' O ' HG22 ' B' ' 116' ' ' THR . 4.3 m-30 142.31 167.37 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 1 C-N-CA 132.927 4.491 . . . . 0.0 110.176 175.717 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -131.13 14.83 5.39 Favored Glycine 0 C--O 1.222 -0.613 0 C-N-CA 126.42 1.962 . . . . 0.0 114.051 172.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -170.53 113.97 0.45 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.431 2.692 . . . . 0.0 103.972 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' B' ' 54' ' ' THR . 10.4 p-10 -116.04 -64.49 1.3 Allowed 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 114.354 1.242 . . . . 0.0 114.354 -164.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.556 HG21 HG22 ' A' ' 5' ' ' VAL . 2.8 p 77.56 -55.86 0.52 Allowed 'General case' 0 N--CA 1.462 0.139 0 C-N-CA 128.919 2.888 . . . . 0.0 113.275 170.018 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 -52.28 11.17 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.236 1.014 . . . . 0.0 111.479 177.088 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.55 -139.56 11.02 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.789 1.662 . . . . 0.0 109.185 -169.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 45.2 m -49.95 -32.03 13.95 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -172.025 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 -8.27 0.99 Allowed 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 128.108 2.563 . . . . 0.0 114.363 173.089 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 38.7 m -159.03 42.12 0.23 Allowed 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 128.576 2.75 . . . . 0.0 107.41 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -170.22 72.59 0.07 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.282 2.233 . . . . 0.0 109.267 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -69.62 -178.57 21.51 Favored Glycine 0 CA--C 1.538 1.476 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.553 173.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -62.72 168.34 10.32 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.647 2.231 . . . . 0.0 110.849 171.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -45.08 115.36 0.89 Allowed 'General case' 0 C--O 1.236 0.35 0 N-CA-C 115.575 1.695 . . . . 0.0 115.575 -178.434 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -45.58 117.46 1.45 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.832 166.31 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -120.84 65.82 13.24 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 115.103 -0.953 . . . . 0.0 113.152 -167.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.81 -4.87 14.18 Favored 'Trans proline' 0 CA--C 1.539 0.766 0 C-N-CA 123.304 2.669 . . . . 0.0 114.561 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 67' ' ' LEU . . . . . 0.411 ' HB3' ' HD3' ' B' ' 69' ' ' ARG . 3.3 mm? -106.73 -6.11 18.05 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.198 0.999 . . . . 0.0 112.71 175.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 18.9 t 66.4 57.92 0.7 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.884 1.674 . . . . 0.0 114.722 171.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 69' ' ' ARG . . . . . 0.411 ' HD3' ' HB3' ' B' ' 67' ' ' LEU . 0.2 OUTLIER -154.06 -176.58 5.93 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 116.226 1.935 . . . . 0.0 116.226 -169.279 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -80.62 178.15 8.54 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.953 1.301 . . . . 0.0 112.194 -170.046 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -108.73 144.36 36.63 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.287 -1.324 . . . . 0.0 114.168 176.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 154.33 -102.2 0.22 Allowed Glycine 0 C--N 1.336 0.543 0 C-N-CA 126.37 1.938 . . . . 0.0 110.108 167.297 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -41.22 2.01 Favored Glycine 0 CA--C 1.542 1.774 0 CA-C-O 118.013 -1.437 . . . . 0.0 115.653 172.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_exo -79.62 -25.83 5.17 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 124.206 3.271 . . . . 0.0 112.12 168.295 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.79 -53.52 2.64 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.901 0.88 . . . . 0.0 110.49 168.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -63.84 106.16 0.96 Allowed 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.311 1.414 . . . . 0.0 111.88 172.611 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.8 mp0 -59.76 -9.75 3.12 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 129.259 3.023 . . . . 0.0 113.485 175.445 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -85.1 -98.02 0.06 Allowed 'General case' 0 N--CA 1.453 -0.321 0 O-C-N 121.411 -0.806 . . . . 0.0 110.684 174.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 94.09 133.37 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.169 1.787 . . . . 0.0 110.845 173.125 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -70.23 154.54 41.79 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 168.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.2 t -80.44 87.94 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 166.124 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.47 4.35 0.18 Allowed Glycine 0 CA--C 1.537 1.452 0 N-CA-C 117.672 1.829 . . . . 0.0 117.672 -169.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -150.65 150.51 31.22 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 119.828 1.814 . . . . 0.0 112.511 174.773 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.7 mt -124.16 49.05 1.82 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.116 169.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.97 -102.99 0.91 Allowed Glycine 0 CA--C 1.532 1.154 0 O-C-N 120.64 -1.287 . . . . 0.0 115.37 176.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -144.71 163.25 34.57 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.024 1.33 . . . . 0.0 113.505 -175.404 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.2 m -114.45 165.49 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 127.502 2.321 . . . . 0.0 110.115 170.691 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 62.6 m -146.43 141.31 27.01 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.903 1.281 . . . . 0.0 108.007 174.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -97.49 164.35 12.48 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -173.097 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.0 -52.09 9.35 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.457 1.503 . . . . 0.0 113.248 -171.087 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttp 151.62 -37.94 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.991 1 C-N-CA 133.775 4.83 . . . . 0.0 109.637 -168.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -84.66 25.79 0.87 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.897 1.679 . . . . 0.0 111.021 -178.083 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.34 3.67 77.57 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.815 1.674 . . . . 0.0 115.56 174.521 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -109.34 129.41 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 119.011 1.406 . . . . 0.0 113.425 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -95.3 129.77 42.31 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 125.165 1.386 . . . . 0.0 107.766 165.095 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -116.93 130.62 56.82 Favored 'General case' 0 C--O 1.233 0.188 0 C-N-CA 125.012 1.325 . . . . 0.0 109.037 -172.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 45.5 t -130.26 137.19 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-N 114.16 -1.382 . . . . 0.0 114.239 -166.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.4 p -151.61 105.23 3.13 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 125.462 1.505 . . . . 0.0 111.635 177.379 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 22.3 mt -135.99 163.28 34.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 128.239 2.615 . . . . 0.0 110.45 -172.478 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -139.22 140.14 37.67 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 126.465 1.906 . . . . 0.0 107.089 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -146.01 143.18 29.28 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.491 1.116 . . . . 0.0 111.641 -169.453 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 9.0 p -118.4 46.04 1.89 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.039 -0.982 . . . . 0.0 112.57 -176.123 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . 0.272 4.4 p -156.12 20.32 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 174.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -131.45 160.52 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 120.65 -1.281 . . . . 0.0 108.344 167.121 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 51.4 m -158.03 168.87 25.92 Favored 'General case' 0 N--CA 1.47 0.573 0 O-C-N 120.691 -1.256 . . . . 0.0 112.192 175.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.29 64.23 1.6 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 125.974 1.709 . . . . 0.0 109.345 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.6 t -155.3 84.07 1.06 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.453 -1.405 . . . . 0.0 113.357 -169.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.29 -159.0 28.26 Favored Glycine 0 C--N 1.336 0.563 0 CA-C-O 122.997 1.332 . . . . 0.0 112.471 170.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -69.1 -19.7 64.06 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 127.57 2.348 . . . . 0.0 113.769 -167.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 64.7 m170 -97.3 7.9 45.63 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.112 1.365 . . . . 0.0 113.221 -175.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 73.2 m -81.98 176.79 9.26 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -165.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.02 -18.95 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 120.786 -1.196 . . . . 0.0 110.798 163.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mm -75.78 124.92 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 165.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.28 68.8 1.54 Allowed Glycine 0 CA--C 1.527 0.839 0 O-C-N 123.614 0.571 . . . . 0.0 113.462 -169.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -143.17 136.04 27.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.206 1.002 . . . . 0.0 109.579 168.037 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 116' ' ' THR . . . . . 0.493 HG23 ' HB2' ' B' ' 48' ' ' HIS . 3.6 t -96.42 77.8 2.99 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 124.864 1.266 . . . . 0.0 110.369 -173.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 54.5 tp -77.94 135.49 37.85 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.0 1.32 . . . . 0.0 109.881 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -129.64 146.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 126.067 1.747 . . . . 0.0 108.989 172.429 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 79.3 t -104.09 140.61 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 122.605 1.193 . . . . 0.0 107.897 168.43 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -95.6 160.02 14.71 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.625 2.37 . . . . 0.0 112.303 -170.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -80.97 -34.31 33.22 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 120.806 -1.184 . . . . 0.0 114.015 -167.552 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.4 mmmt -113.42 -176.52 2.92 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 120.176 -1.578 . . . . 0.0 112.428 173.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.29 143.64 27.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.64 1.176 . . . . 0.0 109.921 169.327 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.23 146.04 24.55 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.957 1.303 . . . . 0.0 109.041 172.018 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.41 -27.75 56.4 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 178.633 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 63.97 20.96 12.44 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.14 2.176 . . . . 0.0 114.34 174.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -150.68 -94.22 0.11 Allowed Glycine 0 N--CA 1.465 0.581 0 CA-C-N 120.583 1.538 . . . . 0.0 113.165 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 49.2 tttp -163.05 82.39 0.49 Allowed 'General case' 0 N--CA 1.432 -1.364 0 C-N-CA 127.172 2.189 . . . . 0.0 108.608 168.581 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.97 48.04 0.64 Allowed Glycine 0 CA--C 1.531 1.078 0 C-N-CA 126.778 2.133 . . . . 0.0 114.192 172.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 79.99 -10.97 37.67 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 118.084 1.994 . . . . 0.0 118.084 169.107 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 28.8 m-80 -115.28 177.78 4.53 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.765 2.282 . . . . 0.0 112.418 -169.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -59.11 -64.39 0.96 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.401 1.88 . . . . 0.0 108.992 165.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 48.7 mm-40 -47.8 -34.77 9.07 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.82 1.648 . . . . 0.0 113.37 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 8.8 m -55.97 -14.64 2.65 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 175.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 37.5 p -129.29 -24.56 2.82 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 168.255 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . 0.253 17.8 pttt -83.81 -6.0 59.33 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 115.764 1.765 . . . . 0.0 115.764 175.2 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 10.8 m -140.07 -44.64 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 124.948 1.299 . . . . 0.0 112.467 171.728 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.33 12.27 6.35 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.885 2.183 . . . . 0.0 114.151 -168.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 67.08 8.04 5.87 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 120.673 -1.487 . . . . 0.0 114.798 175.701 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.58 30.46 0.03 OUTLIER 'General case' 0 CA--C 1.564 1.506 0 N-CA-C 118.206 2.669 . . . . 0.0 118.206 -166.516 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.6 -51.4 3.37 Favored Glycine 0 N--CA 1.471 1.013 0 C-N-CA 127.218 2.342 . . . . 0.0 115.766 170.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 9.3 t -176.49 -163.1 0.09 Allowed 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.734 2.014 . . . . 0.0 110.545 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.21 142.27 17.03 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 119.77 -1.831 . . . . 0.0 115.739 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.74 -115.62 0.1 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 128.508 2.723 . . . . 0.0 111.266 -177.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.13 138.87 36.99 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 128.454 2.702 . . . . 0.0 111.114 -169.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -126.41 151.76 47.25 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 126.413 1.885 . . . . 0.0 112.274 -175.427 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.58 169.91 32.9 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 116.434 1.334 . . . . 0.0 116.434 -172.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . 0.273 0.4 OUTLIER -126.62 162.31 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 123.521 0.728 . . . . 0.0 109.753 170.066 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -120.95 127.64 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 124.412 1.085 . . . . 0.0 113.365 -166.177 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -123.89 -159.31 10.42 Favored Glycine 0 C--N 1.349 1.282 0 C-N-CA 125.039 1.304 . . . . 0.0 113.631 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -110.06 143.22 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 125.946 1.698 . . . . 0.0 111.959 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.448 ' HA ' ' CG ' ' A' ' 50' ' ' PHE . . . -124.49 37.98 4.29 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.456 1.902 . . . . 0.0 111.291 171.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.326 -0.429 0 C-N-CA 125.708 1.603 . . . . 0.0 109.829 -178.235 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.566 0 CA-C-O 117.08 -1.438 . . . . 0.0 108.141 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 94.3 m -83.84 76.63 10.0 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 120.523 1.511 . . . . 0.0 108.802 -172.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.16 138.89 33.47 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -175.012 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.81 169.74 8.85 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 126.534 1.934 . . . . 0.0 112.18 173.035 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.3 t -147.48 153.89 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 127.95 2.5 . . . . 0.0 110.51 172.327 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.4 112.64 15.87 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 125.351 1.461 . . . . 0.0 107.168 165.252 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.6 m -82.66 90.95 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 173.369 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 25.0 mt -76.28 130.01 37.52 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.574 -172.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.1 mttm -152.29 -179.02 7.17 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.59 1.156 . . . . 0.0 113.152 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 134.84 -58.62 0.68 Allowed Glycine 0 N--CA 1.467 0.763 0 C-N-CA 125.968 1.747 . . . . 0.0 110.058 -178.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -78.44 69.04 4.57 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 122.087 0.946 . . . . 0.0 113.22 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 39.25 -100.38 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 C-N-CA 127.863 2.649 . . . . 0.0 115.71 169.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.98 -9.88 18.03 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 124.783 3.655 . . . . 0.0 114.56 -177.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 t -86.07 143.57 11.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-N 119.679 1.127 . . . . 0.0 110.008 172.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -156.36 158.24 37.04 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.51 168.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -117.18 126.83 7.12 Favored Glycine 0 C--O 1.22 -0.758 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.55 99.19 6.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 174.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -132.49 133.31 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 125.07 1.348 . . . . 0.0 109.525 -171.613 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -108.08 150.72 26.81 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.298 2.239 . . . . 0.0 111.208 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -122.22 134.75 54.7 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.567 1.947 . . . . 0.0 109.353 170.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -103.22 113.96 27.87 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 120.935 1.698 . . . . 0.0 110.904 172.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 37.1 tp60 -101.31 116.05 31.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 123.191 0.596 . . . . 0.0 109.488 172.547 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.1 pttp -102.9 -31.81 10.07 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 114.61 1.337 . . . . 0.0 114.61 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.7 mp0 -130.03 156.68 44.08 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 126.213 1.805 . . . . 0.0 108.766 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.0 m -55.68 -39.88 71.57 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 122.386 2.357 . . . . 0.0 116.244 -168.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.04 34.55 5.17 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.03 1.732 . . . . 0.0 110.422 167.043 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.89 153.47 51.35 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-O 118.129 -1.373 . . . . 0.0 111.021 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -66.38 142.7 67.01 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.123 2.549 . . . . 0.0 109.957 174.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.1 t -112.53 144.86 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.937 0.895 . . . . 0.0 110.879 -168.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.0 tttp -113.59 131.08 56.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.583 1.153 . . . . 0.0 108.804 167.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.96 144.49 16.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 127.872 2.469 . . . . 0.0 109.536 175.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -158.56 161.02 37.25 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.399 1.079 . . . . 0.0 113.185 172.118 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.63 -149.22 21.29 Favored Glycine 0 N--CA 1.469 0.865 0 C-N-CA 124.249 0.928 . . . . 0.0 112.693 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -153.57 148.75 26.9 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.4 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 16.9 mt -126.0 117.76 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 121.032 -1.043 . . . . 0.0 108.914 175.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.1 tttt -123.34 137.87 54.74 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 119.787 1.176 . . . . 0.0 112.168 -172.43 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.0 3.77 9.71 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 128.413 2.911 . . . . 0.0 113.886 -174.277 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.12 163.85 22.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 128.431 2.692 . . . . 0.0 112.074 176.302 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -95.07 158.4 15.48 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 166.01 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -64.07 145.22 56.29 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.99 -171.69 22.81 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.703 1.144 . . . . 0.0 114.591 -173.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 47.2 mt -66.23 146.94 54.04 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 125.532 1.533 . . . . 0.0 113.535 -169.437 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -144.99 128.59 17.11 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 127.01 2.124 . . . . 0.0 109.514 173.488 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.15 165.23 54.87 Favored Glycine 0 N--CA 1.473 1.137 0 CA-C-N 119.493 1.042 . . . . 0.0 112.292 -179.151 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.6 p90 -157.55 137.38 12.33 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.328 1.851 . . . . 0.0 113.706 167.001 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -148.58 163.87 35.94 Favored 'General case' 0 N--CA 1.451 -0.415 0 O-C-N 119.695 -1.878 . . . . 0.0 112.074 169.567 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -96.04 134.08 34.88 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-O 121.795 0.807 . . . . 0.0 110.266 173.159 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -71.51 116.06 11.42 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 103.66 -2.719 . . . . 0.0 103.66 168.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.647 ' H ' ' HA ' ' A' ' 63' ' ' HIS 0.305 3.6 tt0 -70.68 21.33 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.897 0 N-CA-C 115.988 1.847 . . . . 0.0 115.988 -168.513 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -132.82 148.94 52.31 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 126.872 2.069 . . . . 0.0 111.204 179.239 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.14 -17.77 42.08 Favored Glycine 0 N--CA 1.465 0.591 0 CA-C-O 117.129 -1.928 . . . . 0.0 115.155 169.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -72.39 88.78 1.2 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.053 1.927 . . . . 0.0 106.945 168.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.417 ' HA ' HG21 ' B' ' 7' ' ' VAL . 19.5 p-10 168.07 -34.39 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.469 2.308 . . . . 0.0 116.766 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 18.6 p 27.62 -40.55 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.042 2 C-N-CA 133.615 4.766 . . . . 0.0 122.91 179.24 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.2 13.72 2.22 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 127.53 2.332 . . . . 0.0 113.469 -173.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -148.04 34.33 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 124.657 1.122 . . . . 0.0 114.585 169.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.5 m -49.02 -19.99 0.48 Allowed 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -169.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.8 t -79.47 -4.49 51.47 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.454 1.101 . . . . 0.0 113.096 175.124 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 71.5 m -136.97 147.13 46.13 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.548 1.539 . . . . 0.0 110.739 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 63.51 -94.16 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.237 1.815 . . . . 0.0 113.126 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.54 -41.99 2.07 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 126.499 2.0 . . . . 0.0 116.413 -175.192 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -109.59 174.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.357 1.009 0 C-N-CA 123.194 2.596 . . . . 0.0 114.75 -175.395 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.727 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -97.16 134.68 40.16 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 129.99 3.316 . . . . 0.0 114.719 169.839 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -71.1 152.28 43.63 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 162.584 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 40.2 p-10 -125.75 60.11 31.22 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 124.252 1.021 . . . . 0.0 111.737 -177.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -61.79 -29.9 83.77 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.943 3.095 . . . . 0.0 115.057 -167.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 73.2 mt -75.9 -5.42 46.03 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 175.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t 66.83 110.02 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 130.027 3.331 . . . . 0.0 111.471 -177.424 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 171.92 172.03 0.1 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -169.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.49 ' H ' ' HD2' ' A' ' 70' ' ' LYS . 10.8 mptt -64.17 169.57 4.38 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.699 2.4 . . . . 0.0 111.68 168.505 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -96.23 138.99 33.02 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.839 1.256 . . . . 0.0 113.981 170.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.14 -110.05 0.44 Allowed Glycine 0 C--N 1.336 0.533 0 C-N-CA 124.007 0.813 . . . . 0.0 112.79 167.224 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.92 -20.2 24.52 Favored Glycine 0 CA--C 1.535 1.289 0 CA-C-O 115.237 -2.98 . . . . 0.0 118.396 -172.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.67 -11.81 3.23 Favored 'Trans proline' 0 C--N 1.357 0.982 0 CA-C-N 123.192 3.496 . . . . 0.0 112.282 168.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -152.51 -25.25 0.17 Allowed 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.078 1.351 . . . . 0.0 113.14 169.351 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -72.59 93.06 1.56 Allowed 'General case' 0 C--N 1.342 0.282 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 166.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -66.77 -6.51 16.24 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 114.674 -1.148 . . . . 0.0 113.87 -179.365 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -78.74 -64.84 1.08 Allowed 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 125.657 1.583 . . . . 0.0 109.567 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 59.98 127.72 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 129.833 3.253 . . . . 0.0 117.881 167.367 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -56.93 154.04 10.13 Favored 'General case' 0 CA--C 1.55 0.961 0 O-C-N 120.391 -1.443 . . . . 0.0 111.857 171.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 p -68.47 -28.87 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 120.229 1.377 . . . . 0.0 111.287 -174.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.17 105.58 2.1 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 107.081 -2.407 . . . . 0.0 107.081 165.005 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -160.52 142.91 12.92 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 117.956 0.878 . . . . 0.0 113.309 177.62 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -120.91 175.43 6.05 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 126.196 1.798 . . . . 0.0 112.129 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -95.1 -153.68 30.37 Favored Glycine 0 CA--C 1.535 1.307 0 C-N-CA 125.905 1.717 . . . . 0.0 114.114 178.293 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.0 p30 -108.0 156.97 18.65 Favored 'General case' 0 N--CA 1.467 0.379 0 O-C-N 121.777 -0.837 . . . . 0.0 110.956 168.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -106.53 173.92 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 127.217 2.207 . . . . 0.0 109.749 176.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -138.16 143.72 40.43 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 125.177 1.391 . . . . 0.0 108.871 169.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.64 152.56 25.4 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 124.105 0.962 . . . . 0.0 112.879 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -88.85 164.52 15.16 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.745 1.618 . . . . 0.0 111.203 168.186 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -63.53 -10.83 19.89 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.536 1.534 . . . . 0.0 114.828 170.433 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.12 -18.07 63.22 Favored 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 118.852 0.751 . . . . 0.0 109.805 169.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 105.09 -7.49 44.21 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 127.83 2.633 . . . . 0.0 112.808 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.57 139.47 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 125.603 1.561 . . . . 0.0 113.485 -173.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.39 129.93 52.29 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 164.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -79.52 142.09 36.1 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 167.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -122.16 140.34 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 CA-C-O 122.22 1.01 . . . . 0.0 113.472 171.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.6 p -156.33 122.38 4.97 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.452 1.501 . . . . 0.0 109.814 168.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.2 mp -128.98 156.09 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 C-N-CA 125.739 1.616 . . . . 0.0 108.843 173.199 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -157.37 135.84 11.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 126.574 1.95 . . . . 0.0 108.418 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -160.93 159.19 29.31 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 124.763 1.225 . . . . 0.0 112.431 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -121.16 48.19 1.7 Allowed 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.378 1.251 . . . . 0.0 114.378 172.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 57.3 t -137.95 -40.22 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.672 1.989 . . . . 0.0 109.961 169.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 pp -78.85 149.92 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 123.488 1.613 . . . . 0.0 114.474 172.394 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 94.6 p -155.26 169.53 23.97 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 126.635 1.974 . . . . 0.0 108.907 -176.306 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mp -96.36 48.26 1.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 172.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.3 t -103.06 -13.31 16.89 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 116.923 2.194 . . . . 0.0 116.923 -169.506 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 146.39 -88.05 0.16 Allowed Glycine 0 C--N 1.348 1.231 0 N-CA-C 120.124 2.809 . . . . 0.0 120.124 167.439 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -59.8 -61.01 2.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 C-N-CA 126.167 1.787 . . . . 0.0 115.215 -160.531 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 -125.3 1.3 7.77 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.177 1.391 . . . . 0.0 112.956 -174.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.7 p -78.45 -169.75 1.79 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.418 0.687 . . . . 0.0 112.35 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 3.3 pt -69.99 -30.16 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 O-C-N 118.954 -2.341 . . . . 0.0 114.105 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.9 mm -60.4 137.76 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-N 120.293 1.406 . . . . 0.0 110.493 171.66 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.98 -11.2 6.39 Favored Glycine 0 CA--C 1.527 0.797 0 CA-C-O 118.223 -1.321 . . . . 0.0 113.719 -177.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.17 139.38 39.9 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 120.035 1.917 . . . . 0.0 108.969 177.261 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 57.7 m -98.99 104.32 16.36 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -175.026 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 23.6 tp -80.26 120.08 23.87 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.108 1.363 . . . . 0.0 111.048 -177.162 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.87 138.87 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.62 1.568 . . . . 0.0 109.912 169.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.3 t -103.79 159.59 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 166.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -125.09 133.35 52.91 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.285 1.434 . . . . 0.0 111.24 -168.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -46.39 -35.62 5.67 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 127.569 2.348 . . . . 0.0 114.704 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -113.68 170.02 8.56 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.708 1.603 . . . . 0.0 112.512 -169.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.84 158.8 6.01 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.365 1.066 . . . . 0.0 110.642 167.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -138.29 142.53 39.81 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.272 1.029 . . . . 0.0 110.809 -168.161 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -85.91 -59.23 2.36 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 122.977 0.511 . . . . 0.0 111.891 176.534 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mp 65.93 84.95 0.15 Allowed 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 128.001 2.521 . . . . 0.0 113.9 -174.021 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 131.02 -29.97 3.43 Favored Glycine 0 N--CA 1.479 1.524 0 N-CA-C 118.888 2.315 . . . . 0.0 118.888 166.349 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -155.97 -58.92 0.1 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 119.474 1.637 . . . . 0.0 113.515 -169.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 44.22 -115.31 1.23 Allowed Glycine 0 C--N 1.34 0.754 0 C-N-CA 125.55 1.547 . . . . 0.0 111.55 -170.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.86 14.46 3.84 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-O 118.256 -1.302 . . . . 0.0 114.54 169.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -161.63 168.08 24.06 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 120.146 1.973 . . . . 0.0 112.853 -167.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -47.98 -58.75 4.02 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.137 1.375 . . . . 0.0 112.082 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -46.75 -31.89 3.28 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -179.078 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -65.7 -23.21 66.71 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.432 -1.418 . . . . 0.0 113.716 178.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.0 t -99.84 -29.56 12.53 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.931 0.892 . . . . 0.0 111.917 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -71.19 -41.45 70.29 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.25 1.42 . . . . 0.0 113.503 -176.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.5 p -124.48 -30.73 3.34 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.112 1.765 . . . . 0.0 112.801 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.98 -14.41 11.24 Favored Glycine 0 C--O 1.222 -0.648 0 C-N-CA 126.416 1.96 . . . . 0.0 111.184 -167.221 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 90.6 1.68 0.17 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.11 2.964 . . . . 0.0 112.346 178.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.54 -7.76 0.3 Allowed 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -168.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 64.96 7.91 32.49 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 120.327 2.891 . . . . 0.0 120.327 164.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.19 178.3 1.74 Allowed 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 121.166 2.483 . . . . 0.0 115.129 172.024 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 18.9 ptt-85 -76.4 -174.37 2.84 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.402 1.881 . . . . 0.0 109.883 165.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -177.76 -148.84 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 128.7 2.8 . . . . 0.0 107.504 165.111 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.28 144.24 55.86 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.079 0.952 . . . . 0.0 110.632 168.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.6 t -157.61 145.05 18.51 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.799 1.24 . . . . 0.0 112.312 -173.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.53 162.96 34.3 Favored Glycine 0 N--CA 1.474 1.176 0 C-N-CA 125.144 1.354 . . . . 0.0 112.46 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.8 p -78.87 153.29 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 118.795 1.298 . . . . 0.0 110.543 169.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mm -87.12 111.64 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 120.87 -1.144 . . . . 0.0 109.969 168.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.32 -155.8 23.55 Favored Glycine 0 CA--C 1.534 1.249 0 C-N-CA 125.659 1.6 . . . . 0.0 112.018 175.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.93 167.99 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-N 119.226 1.513 . . . . 0.0 113.616 177.546 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.96 -36.87 0.08 Allowed 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.979 1.712 . . . . 0.0 113.449 167.072 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . 0.299 27.6 pt20 . . . . . 0 C--O 1.235 0.31 0 C-N-CA 125.292 1.437 . . . . 0.0 114.307 -170.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.618 0 N-CA-C 112.632 0.604 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.7 m -79.79 105.85 11.39 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.354 1.462 . . . . 0.0 110.544 -167.441 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 24.3 mtmm -96.19 106.79 19.04 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 115.67 1.73 . . . . 0.0 115.67 -175.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.84 167.16 11.6 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.634 1.974 . . . . 0.0 111.034 167.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -158.44 151.65 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 C-N-CA 124.321 1.048 . . . . 0.0 113.554 -170.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.51 147.74 38.27 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.325 1.05 . . . . 0.0 109.471 162.757 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 53' ' ' ASN . 84.1 t -106.19 121.54 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.382 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 168.594 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.9 mp -92.34 107.62 19.35 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 126.683 1.993 . . . . 0.0 107.829 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 35.9 tttt -131.47 149.17 52.63 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 120.032 1.287 . . . . 0.0 114.006 175.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.08 151.72 16.87 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 128.799 3.095 . . . . 0.0 107.092 166.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -72.07 88.95 1.11 Allowed 'General case' 0 C--N 1.318 -0.767 0 C-N-CA 126.71 2.004 . . . . 0.0 112.038 -167.534 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.97 -129.47 3.29 Favored Glycine 0 CA--C 1.536 1.374 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.888 -177.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -93.24 -10.73 1.75 Allowed 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 124.143 3.229 . . . . 0.0 115.368 -169.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.1 t -91.82 113.49 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 120.458 1.481 . . . . 0.0 110.382 -176.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -159.13 161.54 36.32 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.619 -1.173 . . . . 0.0 113.547 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' B' ' 35' ' ' ILE . . . -150.67 167.23 30.38 Favored Glycine 0 CA--C 1.502 -0.765 0 CA-C-N 115.264 -0.88 . . . . 0.0 113.072 166.696 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.71 135.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.781 -1.562 . . . . 0.0 106.781 167.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.73 128.25 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.609 0.718 . . . . 0.0 109.774 169.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -96.11 136.51 36.47 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 125.587 1.555 . . . . 0.0 110.555 177.46 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -109.39 94.12 4.87 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 127.534 2.334 . . . . 0.0 109.583 173.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -95.68 109.42 21.7 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 121.041 -1.037 . . . . 0.0 111.567 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -98.37 140.45 32.63 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 121.231 -0.918 . . . . 0.0 111.438 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -78.67 -27.59 45.21 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -175.185 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -161.04 156.87 25.27 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 128.274 2.63 . . . . 0.0 107.318 168.068 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -46.7 -22.06 0.26 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 130.168 3.387 . . . . 0.0 116.698 -170.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -124.83 -4.42 7.59 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 128.536 2.735 . . . . 0.0 112.31 -174.233 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.41 160.03 27.71 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 125.876 1.703 . . . . 0.0 110.99 172.526 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.13 159.62 51.25 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.197 2.598 . . . . 0.0 112.626 -170.093 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.0 t -108.68 128.06 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.793 1.237 . . . . 0.0 110.036 -172.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -81.96 125.16 30.44 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 171.135 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.65 116.82 53.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.611 1.164 . . . . 0.0 108.845 170.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -137.35 158.64 43.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.006 0.922 . . . . 0.0 110.807 169.348 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.42 164.12 9.85 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-O 121.643 0.579 . . . . 0.0 112.688 174.226 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -113.62 116.52 29.61 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -165.004 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.428 ' HA ' ' HA3' ' B' ' 16' ' ' GLY . 4.0 mm -94.96 116.74 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 172.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -124.32 146.97 48.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.508 1.523 . . . . 0.0 111.196 -167.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -31.04 7.79 Favored Glycine 0 N--CA 1.471 0.986 0 C-N-CA 126.946 2.212 . . . . 0.0 112.143 -175.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.512 HD13 ' CD2' ' B' ' 43' ' ' HIS . 3.1 pp -76.0 128.24 34.62 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.511 1.124 . . . . 0.0 108.308 169.13 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -73.49 175.72 6.77 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.164 0.986 . . . . 0.0 111.888 -173.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -61.09 154.3 23.33 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -168.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.23 -175.02 29.18 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.399 1.0 . . . . 0.0 112.477 -175.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.3 mp -77.82 124.69 28.29 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 127.375 2.27 . . . . 0.0 112.078 -169.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 43' ' ' HIS . . . . . 0.512 ' CD2' HD13 ' B' ' 38' ' ' LEU . 60.0 m-70 -122.51 130.09 52.67 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.766 1.226 . . . . 0.0 107.976 171.138 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.32 165.84 38.87 Favored Glycine 0 N--CA 1.473 1.104 0 C-N-CA 126.443 1.973 . . . . 0.0 115.15 -169.244 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -156.58 99.96 1.91 Allowed 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 120.002 1.901 . . . . 0.0 112.764 -167.174 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -124.2 135.61 53.58 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 121.059 -1.025 . . . . 0.0 112.173 -169.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . 0.263 1.0 OUTLIER -102.84 141.14 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 119.077 0.853 . . . . 0.0 109.369 173.099 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.619 ' CG ' HG23 ' B' ' 116' ' ' THR . 0.3 OUTLIER -133.75 154.53 50.91 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.194 1.398 . . . . 0.0 112.732 -168.437 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -76.93 128.69 35.0 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -170.074 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.252 29.6 m-85 99.88 157.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 1 C-N-CA 132.732 4.413 . . . . 0.0 115.551 169.457 . . . . . . . . 3 2 . 1 . 016 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.92 -19.32 5.66 Favored Glycine 0 N--CA 1.471 1.014 0 C-N-CA 126.158 1.837 . . . . 0.0 113.176 177.3 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.46 51.94 0.07 Allowed 'General case' 0 CA--C 1.551 1.008 0 C-N-CA 127.558 2.343 . . . . 0.0 111.597 169.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -178.4 35.18 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -165.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 33.2 p -63.6 40.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.608 2.763 . . . . 0.0 116.182 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -128.49 7.31 5.8 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.957 1.303 . . . . 0.0 112.779 173.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.44 -154.52 50.35 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 120.878 -1.139 . . . . 0.0 110.956 -173.248 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 85.7 m -57.93 -6.69 0.6 Allowed 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 117.691 2.478 . . . . 0.0 117.691 -169.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.3 t -84.85 5.84 27.16 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 120.258 1.39 . . . . 0.0 112.695 168.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 33.8 m -154.1 -35.47 0.1 Allowed 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 126.44 1.896 . . . . 0.0 113.834 172.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -88.18 141.03 28.89 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 125.352 1.461 . . . . 0.0 113.476 -175.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.43 -175.15 48.72 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 124.638 1.113 . . . . 0.0 114.498 -177.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -83.31 -179.11 4.1 Favored 'Trans proline' 0 CA--C 1.539 0.752 1 C-N-CA 126.188 4.592 . . . . 0.0 111.774 175.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.488 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.7 p80 -80.7 107.37 13.45 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 122.452 1.12 . . . . 0.0 112.79 -174.336 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 136.81 5.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.57 1.948 . . . . 0.0 114.501 176.218 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.9 p-10 -116.81 47.4 0.62 Allowed Pre-proline 0 CA--C 1.55 0.965 0 CA-C-N 114.595 -1.184 . . . . 0.0 113.476 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -56.62 -30.47 83.49 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.819 3.012 . . . . 0.0 115.946 -168.351 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.4 mp -79.29 -4.94 53.14 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 124.468 1.107 . . . . 0.0 113.595 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 68.62 47.83 0.85 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 128.865 2.866 . . . . 0.0 111.115 -176.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.8 mmm180 -110.29 162.28 14.78 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 126.217 1.807 . . . . 0.0 111.011 -168.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 13.1 mmtm -74.43 173.26 10.55 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 167.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 30.1 t60 -50.88 158.22 0.71 Allowed 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -173.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.36 71.2 2.07 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.634 1.111 . . . . 0.0 113.634 -169.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -84.23 125.06 6.93 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -72.59 -11.89 26.52 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.001 1.801 . . . . 0.0 111.581 170.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.76 -5.91 13.29 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.168 0.987 . . . . 0.0 113.653 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -114.06 148.6 36.8 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.519 1.528 . . . . 0.0 108.281 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -74.68 -14.94 60.81 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 124.582 1.153 . . . . 0.0 111.82 -171.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -102.99 121.59 42.85 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.514 1.526 . . . . 0.0 107.678 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 -144.97 124.05 12.84 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 126.966 2.106 . . . . 0.0 110.788 -175.323 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 61.4 m170 -65.09 155.02 36.14 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.314 1.845 . . . . 0.0 110.842 164.724 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -55.95 -33.69 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.21 103.25 0.31 Allowed Glycine 0 C--N 1.345 1.061 0 N-CA-C 115.163 0.825 . . . . 0.0 115.163 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -159.53 146.88 16.94 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 130.329 3.452 . . . . 0.0 105.217 164.145 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 76.3 mt -128.96 56.34 1.68 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.779 0.799 . . . . 0.0 111.156 -168.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 59.91 -122.16 29.05 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.467 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -148.06 126.96 12.7 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.466 1.106 . . . . 0.0 110.785 -176.678 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -76.86 97.15 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.825 1.65 . . . . 0.0 109.314 177.203 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 92.0 m -97.6 120.91 38.83 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 113.338 -1.756 . . . . 0.0 109.253 -169.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.26 158.65 16.03 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -168.002 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -81.04 171.74 14.59 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.086 2.155 . . . . 0.0 112.158 168.711 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.791 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -67.26 -17.34 64.75 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.735 1.614 . . . . 0.0 114.017 174.28 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -71.6 -6.97 44.78 Favored 'General case' 0 CA--C 1.555 1.151 0 CA-C-O 122.433 1.111 . . . . 0.0 109.608 167.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.28 44.48 9.61 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 125.614 1.578 . . . . 0.0 109.895 173.203 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 13.3 p -142.54 130.31 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.523 1.129 . . . . 0.0 112.528 -177.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.21 94.91 5.77 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 124.512 1.125 . . . . 0.0 109.619 168.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -83.77 104.08 13.58 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 122.241 1.019 . . . . 0.0 109.834 168.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -80.34 154.22 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-N 113.961 -1.472 . . . . 0.0 111.741 -173.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 60.0 p -156.9 93.84 1.38 Allowed 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.182 -0.949 . . . . 0.0 112.719 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 21.2 mt -134.53 153.02 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 126.955 2.102 . . . . 0.0 111.394 -177.486 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -133.05 135.7 45.52 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 164.654 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -151.22 141.25 22.09 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 114.912 1.449 . . . . 0.0 114.912 -168.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.0 p -112.03 49.06 0.93 Allowed 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.6 t -123.13 4.99 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 C-N-CA 124.038 0.935 . . . . 0.0 111.158 174.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.24 170.75 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 C-N-CA 126.95 2.1 . . . . 0.0 110.509 -177.094 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -157.88 175.54 13.72 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.878 1.271 . . . . 0.0 110.817 169.305 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.6 mt -84.7 50.11 1.84 Allowed 'General case' 0 CA--C 1.548 0.893 0 O-C-N 120.204 -1.56 . . . . 0.0 109.609 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.4 t -81.79 25.22 0.56 Allowed 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 115.606 1.706 . . . . 0.0 115.606 -168.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.0 -51.59 3.86 Favored Glycine 0 C--N 1.336 0.542 0 C-N-CA 125.54 1.543 . . . . 0.0 115.087 168.085 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -101.2 -93.72 0.29 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 117.796 0.798 . . . . 0.0 111.137 -165.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 83.3 m-70 -84.05 2.56 38.58 Favored 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 1.1 t -95.42 -125.93 0.12 Allowed 'General case' 0 CA--C 1.551 0.994 0 O-C-N 119.793 -1.817 . . . . 0.0 113.066 -170.556 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 mm -80.08 -47.09 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-N 123.594 2.906 . . . . 0.0 113.222 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.1 mm -60.24 133.92 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 119.328 0.967 . . . . 0.0 108.936 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.53 6.18 65.49 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-O 118.574 -1.125 . . . . 0.0 115.037 178.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.65 164.08 19.91 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 119.115 1.458 . . . . 0.0 110.017 171.656 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 116' ' ' THR . . . . . 0.619 HG23 ' CG ' ' B' ' 48' ' ' HIS . 3.9 t -115.17 157.65 23.35 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.279 1.032 . . . . 0.0 110.046 175.528 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 17.9 tp -151.28 126.24 9.77 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.025 1.33 . . . . 0.0 112.22 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.9 p -116.46 134.99 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 126.152 1.781 . . . . 0.0 111.258 170.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -84.46 139.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.681 1.193 . . . . 0.0 108.865 169.074 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 66.2 m-70 -108.25 149.71 28.25 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.616 1.566 . . . . 0.0 112.705 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -73.65 -37.17 65.4 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -171.611 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -92.12 164.62 13.52 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 120.482 -1.386 . . . . 0.0 109.914 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.16 140.51 5.13 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.419 1.087 . . . . 0.0 111.216 169.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.65 129.29 37.46 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -73.57 0.7 11.86 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.892 2.077 . . . . 0.0 111.564 178.03 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 79.17 -37.65 0.19 Allowed 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.283 2.633 . . . . 0.0 114.07 168.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 143.22 47.77 0.04 OUTLIER Glycine 0 N--CA 1.477 1.378 0 CA-C-N 120.4 1.454 . . . . 0.0 114.975 -176.428 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.3 pttp -157.18 -113.46 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 -168.515 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 66.16 -3.84 2.98 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.652 2.072 . . . . 0.0 117.433 169.411 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.0 4.26 54.77 Favored Glycine 0 CA--C 1.536 1.392 0 CA-C-N 119.073 1.436 . . . . 0.0 114.053 -174.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 m-80 -119.12 156.8 29.12 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 125.722 1.609 . . . . 0.0 111.517 -176.122 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -54.11 -59.41 4.68 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.145 0.978 . . . . 0.0 109.238 166.536 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -54.7 -36.88 65.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.739 1.216 . . . . 0.0 113.169 -172.136 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.0 m -66.05 -13.28 59.7 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.695 1.998 . . . . 0.0 115.563 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -122.37 -20.04 6.24 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.882 0.873 . . . . 0.0 112.928 168.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -72.53 -46.66 53.5 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.121 1.368 . . . . 0.0 111.779 174.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.3 p -117.75 -34.21 4.28 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.221 1.008 . . . . 0.0 112.977 173.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.38 11.24 20.3 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 126.708 2.099 . . . . 0.0 111.972 -168.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t30 55.52 17.56 2.31 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 120.602 2.201 . . . . 0.0 113.29 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.33 25.07 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.073 0 C-N-CA 127.573 2.349 . . . . 0.0 116.145 -165.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.26 -51.63 3.93 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 127.558 2.504 . . . . 0.0 114.454 169.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 2.9 m 179.76 166.67 1.19 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.782 2.433 . . . . 0.0 111.906 -179.024 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.12 150.97 31.62 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.401 0.681 . . . . 0.0 110.887 173.442 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.31 -130.6 0.24 Allowed 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 126.739 2.016 . . . . 0.0 108.794 173.086 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.83 157.39 33.42 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 127.065 2.146 . . . . 0.0 114.437 -175.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -151.22 159.68 44.25 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -172.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.71 168.48 34.37 Favored Glycine 0 CA--C 1.543 1.825 0 C-N-CA 127.485 2.469 . . . . 0.0 113.842 175.202 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 54.2 t -124.83 138.2 54.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 C-N-CA 124.742 1.217 . . . . 0.0 108.563 174.489 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mm -79.04 122.6 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -166.354 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.62 -156.51 9.88 Favored Glycine 0 CA--C 1.542 1.773 0 C-N-CA 128.362 2.887 . . . . 0.0 113.141 169.547 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -142.08 147.39 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 C-N-CA 125.276 1.431 . . . . 0.0 114.702 -168.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.07 -22.43 10.56 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 125.499 1.519 . . . . 0.0 114.407 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 . . . . . 0 N--CA 1.471 0.606 0 C-N-CA 125.673 1.589 . . . . 0.0 112.453 -178.186 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.585 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -96.9 116.68 29.61 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.146 0.979 . . . . 0.0 110.707 -169.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.487 ' HE3' ' OE1' ' A' ' 153' ' ' GLN . 0.0 OUTLIER -77.98 117.71 19.57 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-N 114.741 -1.118 . . . . 0.0 112.053 169.289 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.4 178.59 6.44 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.429 1.091 . . . . 0.0 110.179 167.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -155.41 90.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 125.664 1.586 . . . . 0.0 109.981 -168.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.93 121.93 32.49 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.229 1.412 . . . . 0.0 110.573 174.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.0 p -95.75 126.68 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-N 118.9 0.773 . . . . 0.0 109.105 173.393 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mp -109.14 133.95 52.35 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.59 1.156 . . . . 0.0 108.627 169.42 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mtmt -157.77 133.12 8.9 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.267 1.427 . . . . 0.0 110.276 173.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.73 -81.08 0.63 Allowed Glycine 0 C--N 1.334 0.45 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -170.038 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -139.42 116.56 11.09 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 124.559 1.144 . . . . 0.0 108.987 -166.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.04 -101.41 0.03 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 128.988 3.185 . . . . 0.0 112.613 175.044 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -77.99 -9.46 16.74 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.275 2.65 . . . . 0.0 114.014 -174.047 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.8 t -88.46 126.19 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 121.33 1.877 . . . . 0.0 111.818 -176.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.87 159.11 43.13 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 125.162 1.385 . . . . 0.0 111.792 171.165 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.87 164.4 27.85 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 122.444 1.025 . . . . 0.0 113.811 169.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.79 133.93 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 125.127 1.371 . . . . 0.0 109.066 -179.596 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.6 mm -137.7 121.92 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 CA-C-N 119.74 1.155 . . . . 0.0 110.683 169.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -88.57 145.84 25.48 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.981 167.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -121.62 109.62 14.99 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 168.286 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.78 112.59 24.31 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.85 0.75 . . . . 0.0 111.529 -176.643 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -93.49 135.31 34.86 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -114.52 -45.54 3.01 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.612 1.565 . . . . 0.0 114.688 -175.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -118.9 -179.76 3.91 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.25 1.42 . . . . 0.0 109.204 167.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.8 p -67.66 -25.91 65.94 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 119.162 -2.211 . . . . 0.0 114.221 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -141.04 9.5 2.12 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 126.407 1.883 . . . . 0.0 112.598 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.8 151.94 52.31 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.795 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -61.91 137.63 68.77 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 124.169 3.246 . . . . 0.0 110.36 -172.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 79.3 t -102.59 135.53 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 123.525 0.73 . . . . 0.0 109.889 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -91.1 116.69 29.01 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 167.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.3 t -104.2 110.91 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 126.677 1.991 . . . . 0.0 108.7 -173.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -132.78 168.69 17.9 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 122.216 1.008 . . . . 0.0 113.143 -176.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.86 -155.48 26.15 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 124.87 1.224 . . . . 0.0 111.488 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -159.71 152.12 21.09 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -123.91 134.24 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 125.712 1.605 . . . . 0.0 107.865 -178.106 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.8 ptpt -149.58 152.03 34.81 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -172.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.1 12.12 52.94 Favored Glycine 0 CA--C 1.535 1.302 0 C-N-CA 125.256 1.407 . . . . 0.0 113.231 -168.587 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -111.86 164.7 12.79 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.005 2.122 . . . . 0.0 111.1 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.23 166.11 24.0 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.081 1.352 . . . . 0.0 111.438 176.583 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.31 -166.48 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 128.541 2.736 . . . . 0.0 113.661 -177.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.73 -178.38 42.78 Favored Glycine 0 CA--C 1.531 1.063 0 O-C-N 120.295 -1.503 . . . . 0.0 113.136 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.691 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -74.58 144.48 43.95 Favored 'General case' 0 CA--C 1.542 0.652 0 O-C-N 120.692 -1.476 . . . . 0.0 112.045 -178.065 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -136.8 151.29 49.0 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 128.789 2.836 . . . . 0.0 109.274 -177.151 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.29 173.83 26.69 Favored Glycine 0 N--CA 1.475 1.286 0 C-N-CA 125.317 1.437 . . . . 0.0 114.043 -174.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -159.93 122.46 3.4 Favored 'General case' 0 CA--C 1.554 1.122 0 C-N-CA 125.502 1.521 . . . . 0.0 112.754 -168.365 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 10.8 p-80 -152.07 134.14 15.01 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 118.705 -2.497 . . . . 0.0 113.607 167.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.6 m -84.99 146.0 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 CA-C-O 122.213 1.006 . . . . 0.0 108.948 170.327 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -107.13 176.09 5.28 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 124.021 1.867 . . . . 0.0 114.592 -168.034 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.2 pm0 -72.95 132.87 44.0 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 158.774 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.419 ' HB3' ' H ' ' A' ' 52' ' ' ASP . 6.8 m-85 75.77 167.59 0.27 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 124.422 2.058 . . . . 0.0 115.148 169.119 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.34 0.28 57.05 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 111.41 -2.632 . . . . 0.0 109.96 163.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.419 ' H ' ' HB3' ' A' ' 50' ' ' PHE . 6.7 t0 -69.92 138.08 52.11 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 165.136 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.479 HD22 HG11 ' B' ' 7' ' ' VAL . 13.5 p-10 -177.08 21.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 168.057 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.4 p -79.57 -14.33 58.92 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -163.554 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -108.1 10.05 28.18 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 124.5 1.12 . . . . 0.0 110.972 167.462 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.56 -138.06 35.46 Favored Glycine 0 CA--C 1.528 0.865 0 O-C-N 121.019 -1.05 . . . . 0.0 111.035 -171.352 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.2 m -57.17 -6.06 0.35 Allowed 'General case' 0 CA--C 1.549 0.928 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -174.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.5 t -103.13 0.71 32.24 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-N 119.966 1.257 . . . . 0.0 113.998 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.9 p -128.57 -18.37 3.95 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 168.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.37 153.98 35.73 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.326 1.851 . . . . 0.0 110.763 168.055 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.16 -173.78 28.81 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.239 0.923 . . . . 0.0 114.753 -170.252 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.41 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 40.9 Cg_endo -91.24 72.11 0.94 Allowed 'Trans proline' 0 CA--C 1.538 0.721 1 C-N-CA 125.401 4.068 . . . . 0.0 108.276 169.556 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.432 ' CE1' ' ND1' ' A' ' 71' ' ' HIS . 5.1 p80 43.9 70.04 0.36 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.958 1.703 . . . . 0.0 114.657 164.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -32.59 134.3 0.1 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 128.848 2.859 . . . . 0.0 117.901 -168.061 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 30.0 p-10 -103.75 34.25 0.05 OUTLIER Pre-proline 0 CA--C 1.559 1.302 0 N-CA-C 117.365 2.357 . . . . 0.0 117.365 -174.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -66.36 -15.17 47.15 Favored 'Trans proline' 0 C--N 1.357 1.003 0 CA-C-N 123.328 2.224 . . . . 0.0 115.068 -169.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -77.1 -0.84 26.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.099 1.359 . . . . 0.0 112.844 169.299 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.4 t 77.98 59.48 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.988 2.115 . . . . 0.0 112.3 168.601 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 ptm85 -149.72 169.35 21.24 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -67.57 156.7 36.14 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 127.889 2.476 . . . . 0.0 111.091 172.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.432 ' ND1' ' CE1' ' A' ' 63' ' ' HIS . 78.1 t60 -75.33 149.97 38.59 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.152 165.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.13 -145.36 12.76 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 116.508 -0.315 . . . . 0.0 113.052 166.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 165.32 -98.15 0.15 Allowed Glycine 0 CA--C 1.535 1.286 0 CA-C-O 117.166 -1.908 . . . . 0.0 114.771 168.606 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -65.43 0.42 2.85 Favored 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 124.821 3.681 . . . . 0.0 116.397 -169.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.34 1.73 1.41 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 127.124 2.17 . . . . 0.0 112.486 175.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.461 ' CG ' ' H ' ' A' ' 77' ' ' GLU . 19.9 t0 -95.96 -178.96 4.53 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 128.321 2.648 . . . . 0.0 111.131 178.439 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.461 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 20.1 tt0 -98.43 -31.26 12.09 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 129.635 3.174 . . . . 0.0 112.04 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -127.51 -70.62 0.7 Allowed 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -166.374 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.416 HH22 ' HB ' ' A' ' 103' ' ' VAL . 1.1 ttt-85 83.69 128.88 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 127.038 2.135 . . . . 0.0 111.436 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -66.25 169.63 6.94 Favored 'General case' 0 CA--C 1.55 0.953 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.245 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 m -85.11 65.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 CA-C-O 122.707 1.242 . . . . 0.0 109.68 173.147 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.76 88.73 0.3 Allowed Glycine 0 C--O 1.223 -0.555 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -168.512 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -158.0 150.5 22.41 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 128.132 2.573 . . . . 0.0 109.597 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 77.5 mt -129.8 178.04 6.81 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 126.08 1.752 . . . . 0.0 109.3 169.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -84.55 -129.04 1.82 Allowed Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.376 0.989 . . . . 0.0 113.184 -176.641 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -147.7 169.73 19.06 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.437 1.095 . . . . 0.0 110.53 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.63 170.73 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.173 0.989 . . . . 0.0 110.765 -170.418 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.5 m -140.78 138.52 34.17 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 125.727 1.611 . . . . 0.0 108.301 172.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.71 138.79 34.56 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.821 0.848 . . . . 0.0 110.563 176.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -87.43 162.8 17.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.64 1.176 . . . . 0.0 112.147 172.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -53.46 -19.06 3.17 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 127.783 2.433 . . . . 0.0 115.017 -170.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.68 4.07 48.49 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 128.241 2.616 . . . . 0.0 110.918 -173.132 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.68 26.84 21.54 Favored Glycine 0 C--N 1.341 0.829 0 C-N-CA 126.065 1.793 . . . . 0.0 113.907 172.332 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.18 132.3 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.4 129.21 43.8 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 126.159 1.783 . . . . 0.0 106.258 164.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -117.09 135.64 53.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 -178.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 51.3 t -125.24 129.81 73.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 114.114 -1.403 . . . . 0.0 114.381 -164.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.7 p -144.72 74.47 1.41 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.235 1.414 . . . . 0.0 112.52 176.296 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -101.09 159.39 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 120.604 -1.31 . . . . 0.0 111.481 -177.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -138.87 141.77 38.6 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.768 2.027 . . . . 0.0 107.941 172.405 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -145.42 141.2 28.19 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.229 1.411 . . . . 0.0 110.259 177.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.2 p -111.54 50.82 0.81 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -173.353 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.416 ' HB ' HH22 ' A' ' 79' ' ' ARG . 23.4 t -144.32 -42.97 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.207 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 168.468 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.43 155.52 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 CA-C-N 119.564 1.074 . . . . 0.0 112.095 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.9 p -156.98 167.67 29.77 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.565 -1.334 . . . . 0.0 113.351 177.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.12 56.8 1.31 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.956 1.36 . . . . 0.0 109.378 170.113 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.08 33.02 0.88 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.723 2.009 . . . . 0.0 111.428 168.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.4 -137.21 13.14 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 124.731 1.158 . . . . 0.0 111.928 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -93.65 -32.82 13.92 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 128.073 2.549 . . . . 0.0 115.766 -165.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -83.95 -8.23 59.22 Favored 'General case' 0 CA--C 1.545 0.758 0 O-C-N 120.305 -1.497 . . . . 0.0 111.607 -178.339 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 69.9 m -102.19 -40.6 6.72 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 115.416 1.636 . . . . 0.0 115.416 -170.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -169.49 -42.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.104 1.762 . . . . 0.0 114.134 171.599 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.85 141.51 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 168.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.68 8.85 61.05 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 116.31 -2.384 . . . . 0.0 113.896 -174.497 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -100.17 177.48 5.06 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 121.146 2.473 . . . . 0.0 109.62 169.061 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 27.2 m -120.91 146.72 46.32 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.855 1.662 . . . . 0.0 110.243 -175.011 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -127.33 143.36 51.24 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.858 1.663 . . . . 0.0 109.276 166.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.8 m -114.24 129.47 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 125.598 1.559 . . . . 0.0 109.569 169.392 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -98.56 120.53 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 168.232 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 2.1 m-70 -96.81 153.71 17.72 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.333 1.453 . . . . 0.0 113.337 -168.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.26 -62.63 1.57 Allowed 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 124.427 1.091 . . . . 0.0 111.305 -172.741 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.44 176.47 6.28 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.86 -1.15 . . . . 0.0 111.437 170.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.37 146.25 44.96 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.23 1.012 . . . . 0.0 113.428 -169.435 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.66 112.8 17.27 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 166.226 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -78.72 -8.0 58.29 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.661 1.985 . . . . 0.0 114.922 -167.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 34.28 89.28 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 129.385 3.074 . . . . 0.0 114.915 177.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.41 -55.36 4.9 Favored Glycine 0 N--CA 1.469 0.851 0 C-N-CA 125.456 1.503 . . . . 0.0 112.54 168.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -153.91 110.22 3.3 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -174.214 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.97 -95.48 2.21 Favored Glycine 0 CA--C 1.513 -0.079 0 N-CA-C 104.116 -3.593 . . . . 0.0 104.116 163.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.55 14.81 3.91 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 117.938 -1.479 . . . . 0.0 114.321 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -121.63 173.66 7.3 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 119.993 1.896 . . . . 0.0 112.215 -169.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -75.56 -48.17 23.55 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 113.067 -1.879 . . . . 0.0 109.04 167.065 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -61.59 -19.2 61.95 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 176.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 21.1 m -51.34 -39.33 56.81 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 119.955 1.252 . . . . 0.0 112.776 171.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -94.78 -33.18 12.98 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 174.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 mtpt -75.27 -29.23 60.09 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 120.618 1.554 . . . . 0.0 114.823 -178.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.0 p -136.85 -23.33 1.18 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.36 8.15 55.21 Favored Glycine 0 C--O 1.221 -0.718 0 C-N-CA 124.733 1.158 . . . . 0.0 110.686 -167.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 62.05 -4.04 0.22 Allowed 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.344 1.858 . . . . 0.0 114.153 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -58.41 -3.7 0.31 Allowed 'General case' 0 CA--C 1.555 1.159 0 C-N-CA 129.058 2.943 . . . . 0.0 117.151 -165.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.81 -81.6 1.38 Allowed Glycine 0 CA--C 1.532 1.144 0 C-N-CA 125.764 1.65 . . . . 0.0 113.337 172.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.7 m -172.27 166.66 5.9 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.021 1.729 . . . . 0.0 112.255 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.412 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -100.38 144.4 29.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 116.698 2.11 . . . . 0.0 116.698 -173.073 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.448 HD13 ' H ' ' A' ' 144' ' ' LEU . 0.0 OUTLIER -90.53 -21.97 21.54 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 113.652 -1.613 . . . . 0.0 111.375 166.3 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.14 142.65 23.53 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 122.185 0.993 . . . . 0.0 111.004 173.459 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.1 p -136.94 147.78 46.58 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 127.887 2.475 . . . . 0.0 109.082 178.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.63 160.44 31.86 Favored Glycine 0 N--CA 1.469 0.874 0 N-CA-C 115.478 0.951 . . . . 0.0 115.478 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 99.3 t -104.74 143.71 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.527 1.131 . . . . 0.0 110.704 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 68.7 mt -84.89 95.41 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 126.383 1.873 . . . . 0.0 111.836 -169.451 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -91.62 177.75 40.71 Favored Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.0 1.285 . . . . 0.0 113.622 177.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -132.83 158.05 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.727 2.011 . . . . 0.0 112.206 -178.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -153.67 -25.76 0.14 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 174.187 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLN . . . . . 0.487 ' OE1' ' HE3' ' A' ' 3' ' ' LYS . 34.3 tt0 . . . . . 0 CA--C 1.537 0.458 0 O-C-N 121.009 -1.057 . . . . 0.0 110.802 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.419 0 CA-C-O 120.933 0.397 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.3 m -84.1 99.97 10.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -174.289 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.271 0.0 OUTLIER -94.8 113.96 25.78 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-O 123.321 1.534 . . . . 0.0 112.963 178.295 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.05 164.21 25.94 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 125.709 1.604 . . . . 0.0 111.166 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.03 140.53 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 125.767 1.627 . . . . 0.0 108.027 178.299 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.5 124.15 21.03 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.479 HG11 HD22 ' A' ' 53' ' ' ASN . 4.1 p -79.95 120.62 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 169.763 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -112.31 110.71 21.1 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 125.125 1.37 . . . . 0.0 108.427 169.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 tttt -157.06 160.28 38.77 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-O 121.499 0.666 . . . . 0.0 111.629 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.0 -35.83 0.84 Allowed Glycine 0 N--CA 1.468 0.802 0 C-N-CA 127.154 2.311 . . . . 0.0 110.005 174.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.41 58.19 2.56 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.867 2.067 . . . . 0.0 110.859 177.289 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 36.8 -98.31 0.01 OUTLIER Glycine 0 CA--C 1.535 1.334 0 C-N-CA 128.104 2.764 . . . . 0.0 114.288 -176.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.06 -13.2 15.76 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 123.869 3.046 . . . . 0.0 114.785 -176.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.21 137.51 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 121.262 1.846 . . . . 0.0 111.675 -176.094 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -126.49 162.12 26.36 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 124.357 1.063 . . . . 0.0 110.375 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -128.19 62.99 0.62 Allowed Glycine 0 N--CA 1.469 0.853 0 C-N-CA 125.262 1.41 . . . . 0.0 111.836 172.027 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.464 ' C ' HD12 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -79.44 109.08 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 CA-C-N 118.358 1.079 . . . . 0.0 110.923 -168.686 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.459 ' N ' HD12 ' B' ' 17' ' ' ILE . 2.4 pp -110.8 150.88 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 169.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -129.46 129.15 44.25 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.054 2.142 . . . . 0.0 107.364 167.796 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -115.93 125.02 52.03 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 119.203 0.91 . . . . 0.0 109.834 178.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.65 127.39 52.38 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 123.726 0.81 . . . . 0.0 110.242 -178.619 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 22' ' ' GLN . . . . . 0.529 ' HG2' ' H ' ' B' ' 24' ' ' GLU . 52.4 tt0 -121.14 134.27 55.23 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 123.069 1.414 . . . . 0.0 112.57 170.15 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -82.89 0.4 44.39 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 126.485 1.914 . . . . 0.0 113.617 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.529 ' H ' ' HG2' ' B' ' 22' ' ' GLN . 43.4 mt-10 -157.64 -164.64 1.59 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 130.333 3.453 . . . . 0.0 108.495 -169.168 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -120.47 -6.6 9.77 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.895 1.278 . . . . 0.0 111.868 165.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -116.84 -45.95 2.76 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.745 1.618 . . . . 0.0 113.685 -171.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.38 -162.83 11.31 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 125.184 1.373 . . . . 0.0 114.133 -176.569 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.18 161.45 38.22 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.524 2.149 . . . . 0.0 112.69 -171.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 13.9 t -133.71 136.42 54.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.834 1.654 . . . . 0.0 109.833 -173.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HD2' ' H ' ' B' ' 30' ' ' LYS . 5.2 mptt -80.85 130.99 35.34 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.253 0.549 . . . . 0.0 110.049 171.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.36 105.44 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 127.735 2.414 . . . . 0.0 108.227 178.673 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -138.49 162.16 35.22 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.85 173.11 13.06 Favored Glycine 0 N--CA 1.467 0.737 0 C-N-CA 124.668 1.128 . . . . 0.0 114.261 171.331 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.3 p -110.65 120.59 42.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 114.86 1.43 . . . . 0.0 114.86 -167.341 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.629 HD13 HG21 ' B' ' 87' ' ' VAL . 0.6 OUTLIER -92.01 117.12 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 167.499 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 pttt -137.81 136.61 37.37 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.511 0.725 . . . . 0.0 111.349 -167.673 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.57 -18.26 22.77 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 127.491 2.472 . . . . 0.0 113.636 -172.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.4 156.35 25.45 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.371 1.069 . . . . 0.0 111.705 172.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -69.25 166.13 19.08 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.258 1.423 . . . . 0.0 110.262 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -61.39 -176.36 0.07 Allowed 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 126.673 1.989 . . . . 0.0 115.197 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.42 177.28 51.83 Favored Glycine 0 N--CA 1.469 0.867 0 C-N-CA 124.905 1.24 . . . . 0.0 112.187 -179.179 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.829 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -71.23 141.99 50.6 Favored 'General case' 0 CA--C 1.541 0.614 0 O-C-N 120.824 -1.398 . . . . 0.0 110.092 177.381 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -134.21 141.29 46.99 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 127.317 2.247 . . . . 0.0 107.957 176.409 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.98 155.94 48.53 Favored Glycine 0 N--CA 1.479 1.562 0 CA-C-N 120.494 1.497 . . . . 0.0 113.217 -174.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -147.27 105.5 3.76 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.91 1.355 . . . . 0.0 110.465 -171.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.476 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -145.4 145.22 31.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 120.804 -1.185 . . . . 0.0 110.4 -167.965 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.564 HG23 ' HA2' ' B' ' 82' ' ' GLY . 34.5 m -115.03 120.7 65.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.278 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -176.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.476 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 3.7 m170 -74.93 152.1 38.84 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -173.533 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -73.05 94.05 1.85 Allowed 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 169.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 150.54 156.82 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 1 C-N-CA 132.351 4.26 . . . . 0.0 111.669 170.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.3 -21.19 42.28 Favored Glycine 0 C--N 1.337 0.621 0 C-N-CA 126.187 1.851 . . . . 0.0 111.294 164.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -58.05 157.42 8.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 165.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 13.1 p-10 162.65 31.26 0.0 OUTLIER 'General case' 0 C--O 1.241 0.62 0 C-N-CA 129.075 2.95 . . . . 0.0 111.496 165.691 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 18.2 p -69.77 -41.64 74.89 Favored 'General case' 0 N--CA 1.455 -0.19 0 O-C-N 121.132 -0.98 . . . . 0.0 110.364 -168.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.9 25.32 3.71 Favored 'General case' 0 CA--C 1.556 1.182 0 C-N-CA 124.725 1.21 . . . . 0.0 111.892 166.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.79 -128.48 23.59 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 120.302 -1.499 . . . . 0.0 112.447 174.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 5.5 t -71.84 -12.31 61.22 Favored 'General case' 0 CA--C 1.547 0.835 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -98.69 50.22 0.98 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.842 1.257 . . . . 0.0 107.789 171.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -170.73 -81.3 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 -168.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -93.78 153.19 18.44 Favored 'General case' 0 C--O 1.234 0.249 0 O-C-N 121.455 -0.778 . . . . 0.0 112.017 173.093 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.08 -161.86 29.49 Favored Glycine 0 CA--C 1.54 1.602 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.568 173.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -78.03 -171.43 1.2 Allowed 'Trans proline' 0 CA--C 1.54 0.777 1 C-N-CA 126.257 4.638 . . . . 0.0 110.087 169.167 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.777 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 2.1 p80 -73.76 80.32 1.57 Allowed 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.303 2.641 . . . . 0.0 107.084 168.05 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -56.0 169.88 0.35 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 123.826 1.774 . . . . 0.0 110.889 174.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -104.13 51.94 0.08 OUTLIER Pre-proline 0 CA--C 1.555 1.142 0 CA-C-N 113.392 -1.731 . . . . 0.0 115.165 -167.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.45 -25.72 48.2 Favored 'Trans proline' 0 C--N 1.354 0.865 0 C-N-CA 122.33 2.02 . . . . 0.0 111.469 -177.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 39.5 mt -81.6 -6.49 59.05 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 172.015 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.9 t 69.34 59.86 0.32 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 125.652 1.581 . . . . 0.0 113.84 174.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.9 ptt180 -162.01 176.26 10.94 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 115.449 1.648 . . . . 0.0 115.449 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.2 170.95 11.94 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.888 1.275 . . . . 0.0 114.116 177.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.401 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 77.0 t60 -83.76 162.26 20.71 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.378 0.671 . . . . 0.0 111.501 167.636 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.412 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 137.97 -102.39 0.37 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.377 1.941 . . . . 0.0 111.739 166.106 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.75 -53.44 0.71 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 116.958 -2.024 . . . . 0.0 117.498 172.226 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -87.86 -8.17 6.02 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.502 2.801 . . . . 0.0 111.25 176.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.49 ' HE2' ' HA ' ' B' ' 75' ' ' LYS . 0.1 OUTLIER -145.98 -16.64 0.46 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 176.248 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.412 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 13.7 t70 -101.67 92.45 4.87 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 103.181 -2.896 . . . . 0.0 103.181 159.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 56.2 mp0 -65.04 -4.88 5.2 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.676 1.191 . . . . 0.0 113.508 -176.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -74.61 -63.31 1.27 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.597 1.959 . . . . 0.0 107.711 178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 32.4 ttp180 67.83 119.79 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.959 2.207 . . . . 0.0 116.959 162.388 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -62.61 156.1 24.25 Favored 'General case' 0 N--CA 1.472 0.659 0 O-C-N 119.467 -2.021 . . . . 0.0 112.102 169.001 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -52.71 -32.75 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.564 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -96.33 39.05 2.91 Favored Glycine 0 CA--C 1.534 1.26 0 N-CA-C 116.708 1.443 . . . . 0.0 116.708 -174.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -129.96 108.39 10.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.281 -1.129 . . . . 0.0 111.715 -172.385 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -109.79 47.41 0.95 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 122.467 1.127 . . . . 0.0 110.153 168.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.5 -101.67 0.03 OUTLIER Glycine 0 CA--C 1.528 0.879 0 C-N-CA 127.984 2.707 . . . . 0.0 114.103 174.709 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.8 p30 -154.86 161.74 41.34 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.592 1.557 . . . . 0.0 111.553 -175.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.629 HG21 HD13 ' B' ' 35' ' ' ILE . 8.9 p -137.85 124.81 28.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 C-N-CA 126.916 2.086 . . . . 0.0 109.605 -171.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 55.5 m -107.73 123.89 49.2 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 114.707 -1.133 . . . . 0.0 111.19 -167.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.08 148.9 21.61 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 124.398 1.079 . . . . 0.0 112.509 -176.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -97.22 157.07 16.13 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.111 1.765 . . . . 0.0 112.236 169.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -24.94 24.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 127.246 2.219 . . . . 0.0 115.336 -169.067 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -79.65 5.75 12.42 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.984 1.714 . . . . 0.0 111.597 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.19 36.81 6.15 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 126.049 1.785 . . . . 0.0 113.2 171.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.27 138.39 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 117.31 2.337 . . . . 0.0 117.31 -172.177 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -118.93 93.07 3.97 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.72 2.008 . . . . 0.0 110.696 168.354 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -85.59 95.44 9.33 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-O 122.491 1.139 . . . . 0.0 110.665 172.271 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.75 152.89 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.513 -170.543 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.2 p -155.14 109.83 2.98 Favored 'General case' 0 CA--C 1.541 0.634 0 O-C-N 120.963 -1.086 . . . . 0.0 112.21 175.115 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.83 160.31 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 127.722 2.409 . . . . 0.0 110.12 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -134.32 141.14 46.82 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 164.496 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -144.59 152.38 40.43 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.528 1.131 . . . . 0.0 112.116 178.519 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.7 p -117.42 59.32 0.78 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.546 1.538 . . . . 0.0 111.654 -169.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -157.24 -42.09 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 174.034 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -79.21 154.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 O-C-N 121.883 -0.511 . . . . 0.0 110.628 169.353 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 9.2 p -155.26 170.37 22.03 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.329 1.052 . . . . 0.0 111.05 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 106' ' ' LEU . . . . . 0.456 HD13 ' HB2' ' B' ' 22' ' ' GLN . 10.1 mp -86.56 55.53 3.59 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.092 -1.005 . . . . 0.0 111.649 -173.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.1 t -90.47 12.81 17.43 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 116.876 2.176 . . . . 0.0 116.876 -169.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.22 -38.65 3.19 Favored Glycine 0 N--CA 1.475 1.235 0 N-CA-C 118.695 2.238 . . . . 0.0 118.695 167.232 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -107.16 -105.46 0.34 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.541 1.136 . . . . 0.0 110.572 -166.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -76.23 11.77 1.41 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 126.187 1.795 . . . . 0.0 113.363 175.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 9.7 p -84.12 -158.35 0.32 Allowed 'General case' 0 CA--C 1.553 1.086 0 C-N-CA 127.013 2.125 . . . . 0.0 114.13 -175.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' B' ' 115' ' ' ARG 0.39 8.1 pt -83.23 -9.39 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 O-C-N 119.666 -1.896 . . . . 0.0 114.234 168.284 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.5 mm -98.36 151.18 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 161.283 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 95.1 -41.12 2.56 Favored Glycine 0 N--CA 1.468 0.811 0 C-N-CA 124.342 0.973 . . . . 0.0 113.033 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 115' ' ' ARG . . . . . 0.512 HH21 ' HB2' ' B' ' 117' ' ' LEU . 0.2 OUTLIER -75.13 -179.56 4.45 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 127.49 2.316 . . . . 0.0 115.604 -169.579 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.1 t -103.43 176.18 5.23 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 127.437 2.295 . . . . 0.0 113.065 169.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.512 ' HB2' HH21 ' B' ' 115' ' ' ARG . 33.9 tp -152.95 144.99 23.76 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.157 2.183 . . . . 0.0 110.363 170.071 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.45 150.2 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 O-C-N 123.284 0.365 . . . . 0.0 110.796 167.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.89 128.42 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 168.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -90.16 148.84 22.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.93 0.892 . . . . 0.0 112.518 -169.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.297 2.4 pp20? -77.51 -32.55 54.17 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.3 -0.875 . . . . 0.0 112.661 -174.689 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -90.54 169.07 11.34 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.322 -0.861 . . . . 0.0 110.061 165.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.72 149.65 34.8 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.125 0.97 . . . . 0.0 109.628 164.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -78.9 131.89 36.57 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 168.372 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -78.58 -11.05 59.94 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.178 0.991 . . . . 0.0 112.523 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mm? 70.25 -66.33 0.28 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 129.998 3.319 . . . . 0.0 111.339 -176.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 176.09 29.38 0.04 OUTLIER Glycine 0 N--CA 1.463 0.491 0 N-CA-C 116.171 1.228 . . . . 0.0 116.171 -169.19 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -126.12 -20.34 4.54 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 117.088 2.255 . . . . 0.0 117.088 -167.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.89 129.92 47.16 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 106.506 -2.638 . . . . 0.0 106.506 168.519 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -74.12 46.39 1.52 Allowed Glycine 0 N--CA 1.473 1.102 0 C-N-CA 126.387 1.946 . . . . 0.0 112.865 -171.224 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -103.23 -89.86 0.38 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.653 1.181 . . . . 0.0 110.947 -169.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 170.4 -76.66 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 131.213 3.805 . . . . 0.0 102.474 -167.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -35.66 -52.85 0.7 Allowed 'General case' 0 CA--C 1.54 0.584 1 C-N-CA 132.147 4.179 . . . . 0.0 112.92 171.628 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.6 m -47.37 -31.1 3.71 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 176.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.3 t -112.72 -8.03 13.79 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 119.449 1.022 . . . . 0.0 112.264 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 22.4 mmtp -84.25 -47.42 10.81 Favored 'General case' 0 CA--C 1.537 0.469 0 O-C-N 120.75 -1.219 . . . . 0.0 110.853 168.623 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 74.6 p -117.01 -34.17 4.49 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.786 1.634 . . . . 0.0 113.079 -173.271 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.13 2.89 31.59 Favored Glycine 0 N--CA 1.47 0.922 0 CA-C-O 118.353 -1.248 . . . . 0.0 113.805 -177.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 51.48 24.16 2.11 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 119.55 1.675 . . . . 0.0 114.168 177.145 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.09 20.08 0.08 Allowed 'General case' 0 CA--C 1.553 1.067 0 N-CA-C 115.748 1.759 . . . . 0.0 115.748 -166.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.8 -66.76 2.4 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 126.459 1.981 . . . . 0.0 114.288 173.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -175.69 -163.56 0.12 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.803 1.641 . . . . 0.0 109.532 -169.44 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.26 145.73 33.0 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 174.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -90.58 -103.84 0.1 Allowed 'General case' 0 CA--C 1.537 0.462 0 O-C-N 124.98 1.425 . . . . 0.0 107.557 170.398 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.03 147.22 50.35 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.443 0.697 . . . . 0.0 111.901 -177.505 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.33 151.76 51.71 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 127.093 2.157 . . . . 0.0 110.17 173.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.87 174.82 37.55 Favored Glycine 0 C--O 1.221 -0.678 0 N-CA-C 116.461 1.344 . . . . 0.0 116.461 -174.22 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -142.37 143.47 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.408 1.483 . . . . 0.0 109.502 -168.264 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.2 129.82 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -165.481 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.71 -155.66 7.12 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 125.232 1.396 . . . . 0.0 111.023 167.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.43 157.23 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.033 1.333 . . . . 0.0 113.285 -169.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.9 -41.1 14.25 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 161.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 . . . . . 0 CA--C 1.536 0.432 1 C-N-CA 132.764 4.425 . . . . 0.0 107.194 168.437 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 118.959 -0.543 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.03 55.22 1.8 Allowed 'General case' 0 CA--C 1.511 -0.536 0 CA-C-O 123.028 1.394 . . . . 0.0 111.345 -171.786 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -87.8 107.1 18.5 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 166.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.02 167.48 12.06 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.537 1.535 . . . . 0.0 111.893 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' B' ' 52' ' ' ASP . 2.0 p -159.35 149.23 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.395 1.078 . . . . 0.0 112.013 -168.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.33 121.22 14.53 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.073 1.749 . . . . 0.0 108.918 167.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -103.71 99.16 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 167.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.2 mp -81.03 116.29 20.91 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -176.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 mtpt -144.77 157.55 44.13 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-N 119.272 0.942 . . . . 0.0 111.818 -172.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.45 -47.87 0.43 Allowed Glycine 0 N--CA 1.47 0.904 0 C-N-CA 126.505 2.002 . . . . 0.0 111.252 169.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.62 61.42 2.94 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 128.64 2.776 . . . . 0.0 112.344 -168.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.4 -99.81 0.02 OUTLIER Glycine 0 CA--C 1.534 1.266 0 C-N-CA 126.974 2.226 . . . . 0.0 112.904 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -82.11 -7.39 12.09 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.202 3.268 . . . . 0.0 114.867 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -86.42 136.07 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 121.244 1.838 . . . . 0.0 110.889 175.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.38 151.44 35.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 114.066 -1.424 . . . . 0.0 110.833 167.542 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -118.77 98.79 0.75 Allowed Glycine 0 C--O 1.22 -0.779 0 C-N-CA 125.485 1.517 . . . . 0.0 110.259 174.511 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -91.38 110.84 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 108.382 -0.969 . . . . 0.0 108.382 171.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.431 HD13 ' CE1' ' A' ' 20' ' ' PHE . 1.8 pp -127.09 155.19 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-O 122.037 0.922 . . . . 0.0 110.713 168.091 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -130.96 156.2 45.51 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.476 1.51 . . . . 0.0 109.849 169.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' CE1' HD13 ' A' ' 18' ' ' ILE . 7.8 m-85 -123.8 120.51 32.85 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.001 1.32 . . . . 0.0 108.651 168.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -98.44 119.86 37.86 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.246 1.018 . . . . 0.0 110.118 172.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.95 170.47 16.05 Favored 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 166.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.93 -46.88 0.53 Allowed 'General case' 0 CA--C 1.558 1.253 0 C-N-CA 128.135 2.574 . . . . 0.0 110.166 168.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.6 mp0 -81.68 116.1 21.24 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 120.456 1.48 . . . . 0.0 111.964 173.514 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -68.6 -9.69 51.22 Favored 'General case' 0 CA--C 1.552 1.047 0 O-C-N 119.223 -2.173 . . . . 0.0 114.439 -174.402 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -110.78 -2.94 15.97 Favored 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 127.22 2.208 . . . . 0.0 114.542 174.004 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.27 175.99 38.32 Favored Glycine 0 CA--C 1.542 1.734 0 CA-C-O 118.848 -0.973 . . . . 0.0 113.756 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -77.77 163.17 29.2 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 124.731 3.62 . . . . 0.0 110.739 175.374 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.2 t -138.08 145.57 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.672 0.789 . . . . 0.0 112.165 -165.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.79 121.28 27.47 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.74 1.216 . . . . 0.0 111.425 169.766 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 94.6 t -101.16 133.47 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.852 2.061 . . . . 0.0 108.112 169.588 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -153.67 167.61 29.0 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.572 0.701 . . . . 0.0 112.658 171.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.51 -161.35 28.36 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 124.253 0.93 . . . . 0.0 113.432 172.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.8 p -154.35 118.98 4.87 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.519 0.727 . . . . 0.0 110.776 -169.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.496 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 2.2 mp -108.01 103.0 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.915 0.886 . . . . 0.0 109.019 -177.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -115.88 133.42 56.04 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.223 1.809 . . . . 0.0 111.934 -166.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.59 0.86 27.65 Favored Glycine 0 CA--C 1.536 1.399 0 C-N-CA 127.458 2.456 . . . . 0.0 113.26 -174.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 97.5 mt -70.57 162.74 28.31 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 118.508 1.154 . . . . 0.0 111.116 172.093 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.6 m -83.14 140.64 32.49 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 166.241 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -58.76 152.15 19.64 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.42 -172.67 29.17 Favored Glycine 0 CA--C 1.532 1.125 0 C-N-CA 124.241 0.924 . . . . 0.0 112.818 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -72.4 149.29 44.42 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.817 2.047 . . . . 0.0 112.329 -169.567 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -145.81 121.72 10.64 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.962 1.705 . . . . 0.0 110.14 173.288 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.62 147.76 23.46 Favored Glycine 0 N--CA 1.486 1.982 0 CA-C-N 119.992 1.269 . . . . 0.0 112.606 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -148.32 102.01 3.31 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 119.208 1.504 . . . . 0.0 112.408 -167.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m80 -150.27 169.86 20.35 Favored 'General case' 0 CA--C 1.52 -0.199 0 O-C-N 120.658 -1.276 . . . . 0.0 114.331 -168.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.6 m -75.73 129.93 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 113.608 -1.633 . . . . 0.0 109.871 166.105 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -80.86 137.71 36.18 Favored 'General case' 0 CA--C 1.551 0.986 0 N-CA-C 102.472 -3.159 . . . . 0.0 102.472 157.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -65.18 142.44 58.33 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -168.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 56.83 -169.05 0.1 Allowed 'General case' 0 C--O 1.241 0.623 0 C-N-CA 127.242 2.217 . . . . 0.0 113.898 175.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 54' ' ' THR . . . -136.69 5.71 3.76 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-O 116.78 -2.122 . . . . 0.0 113.525 -178.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG21 ' B' ' 5' ' ' VAL . 21.3 p-10 -77.91 48.6 0.72 Allowed 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 121.336 2.568 . . . . 0.0 110.404 169.324 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.574 ' HA ' HG21 ' B' ' 7' ' ' VAL . 0.2 OUTLIER 172.65 5.87 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 118.359 2.726 . . . . 0.0 118.359 -169.35 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 51' ' ' GLY . 43.4 p -31.37 -10.02 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.213 1 N-CA-C 124.607 5.04 . . . . 0.0 124.607 -167.497 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.02 35.67 0.06 Allowed 'General case' 0 CA--C 1.555 1.147 0 CA-C-N 123.504 2.865 . . . . 0.0 116.643 -169.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.1 -148.96 46.85 Favored Glycine 0 CA--C 1.526 0.734 0 O-C-N 120.784 -1.197 . . . . 0.0 111.617 172.301 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.3 p -64.42 -12.01 38.94 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 114.914 1.45 . . . . 0.0 114.914 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 p -80.01 -0.3 34.84 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.898 2.079 . . . . 0.0 112.833 178.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.1 m -155.87 177.49 11.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 127.655 2.382 . . . . 0.0 109.215 -176.55 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 77.1 -156.48 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 126.448 1.899 . . . . 0.0 113.96 172.563 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.2 -169.8 16.14 Favored Glycine 0 CA--C 1.541 1.674 0 C-N-CA 126.823 2.154 . . . . 0.0 114.931 -167.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -66.8 -177.03 0.83 Allowed 'Trans proline' 0 CA--C 1.539 0.761 1 C-N-CA 126.353 4.702 . . . . 0.0 113.588 177.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 114.26 21.88 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.625 1.17 . . . . 0.0 112.932 -170.514 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.424 ' CD2' ' HD3' ' A' ' 66' ' ' PRO . 8.8 t80 -41.43 128.44 3.07 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 127.385 2.274 . . . . 0.0 115.089 -169.616 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -112.0 45.92 0.27 Allowed Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 125.653 1.581 . . . . 0.0 114.281 -173.428 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.424 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 62.4 Cg_endo -69.15 -17.69 40.22 Favored 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 123.236 2.624 . . . . 0.0 111.722 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.5 mt -76.46 -7.14 54.49 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.201 1.4 . . . . 0.0 111.417 171.225 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.3 t 73.48 56.89 0.11 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 127.167 2.187 . . . . 0.0 112.267 171.754 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.16 172.45 16.92 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 116.52 2.044 . . . . 0.0 116.52 -167.588 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 15.2 mmtp -82.57 173.81 11.62 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 127.149 2.18 . . . . 0.0 112.167 171.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.4 t60 -72.58 165.07 25.41 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.034 1.733 . . . . 0.0 113.616 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.46 -140.53 8.59 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 124.984 1.278 . . . . 0.0 114.499 167.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.566 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.87 -86.14 0.29 Allowed Glycine 0 CA--C 1.533 1.205 0 C-N-CA 126.287 1.898 . . . . 0.0 115.617 174.026 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -61.21 -9.77 13.58 Favored 'Trans proline' 0 CA--C 1.539 0.728 0 C-N-CA 124.748 3.632 . . . . 0.0 116.001 -169.593 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.34 -7.98 2.58 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.936 0.894 . . . . 0.0 112.767 167.562 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.566 ' HB3' ' H ' ' A' ' 73' ' ' GLY 0.314 0.0 OUTLIER -93.04 175.19 6.88 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -164.699 . . . . . . . . 4 4 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 56.0 mp0 -103.21 -22.95 13.66 Favored 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 131.391 3.876 . . . . 0.0 111.46 -168.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.418 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 2.9 mm-40 -105.94 -114.93 0.25 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 127.464 2.306 . . . . 0.0 110.132 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 103.27 119.18 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 130.892 3.677 . . . . 0.0 112.856 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.4 m170 -65.44 -176.87 0.36 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 126.388 1.875 . . . . 0.0 114.451 169.787 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.5 p -84.58 143.79 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 120.762 -1.212 . . . . 0.0 108.636 166.091 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.2 -2.52 9.25 Favored Glycine 0 CA--C 1.54 1.607 0 N-CA-C 117.455 1.742 . . . . 0.0 117.455 172.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -77.35 85.43 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-N 120.486 2.143 . . . . 0.0 109.553 167.163 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.0 mt -82.55 54.83 2.75 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.29 -176.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.47 -135.95 29.54 Favored Glycine 0 CA--C 1.528 0.859 0 C-N-CA 125.172 1.368 . . . . 0.0 114.386 170.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -136.86 145.0 43.88 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.058 0.943 . . . . 0.0 111.325 175.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -93.51 107.1 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 126.333 1.853 . . . . 0.0 109.579 176.469 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.2 m -99.9 113.89 26.75 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.677 1.191 . . . . 0.0 109.187 -175.444 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.03 158.26 15.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.896 1.679 . . . . 0.0 114.05 -171.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.39 -173.09 3.67 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.265 1.426 . . . . 0.0 112.597 169.229 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -83.7 -13.55 53.82 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 116.615 2.08 . . . . 0.0 116.615 176.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -75.36 -7.73 54.78 Favored 'General case' 0 CA--C 1.561 1.388 0 CA-C-O 122.845 1.307 . . . . 0.0 108.005 163.174 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.02 8.94 56.5 Favored Glycine 0 C--N 1.339 0.733 0 C-N-CA 128.26 2.838 . . . . 0.0 113.258 168.637 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 125.43 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 119.058 1.429 . . . . 0.0 113.839 -169.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 100.21 12.14 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 166.123 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -89.89 134.01 34.44 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.415 1.486 . . . . 0.0 109.099 177.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -141.31 137.42 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -167.277 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.3 p -153.59 119.5 5.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 125.757 1.623 . . . . 0.0 110.413 169.33 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.8 mt -147.15 147.47 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 C-N-CA 128.646 2.779 . . . . 0.0 110.358 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -118.02 130.81 56.4 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.895 2.078 . . . . 0.0 105.98 167.057 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -139.36 134.38 32.41 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.853 0.861 . . . . 0.0 112.186 -172.236 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -114.69 46.46 1.4 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.175 1.176 . . . . 0.0 114.175 -179.164 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.57 7.11 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 C-N-CA 123.672 0.789 . . . . 0.0 112.865 167.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -133.33 161.37 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 C-N-CA 124.821 1.248 . . . . 0.0 109.056 168.614 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.3 p -148.61 162.32 39.92 Favored 'General case' 0 C--O 1.239 0.53 0 O-C-N 121.495 -0.753 . . . . 0.0 109.726 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -90.08 70.25 7.34 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 122.887 1.327 . . . . 0.0 109.39 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.6 t -106.69 142.85 35.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 114.296 -1.32 . . . . 0.0 109.343 168.219 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.21 10.93 52.14 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 127.573 2.511 . . . . 0.0 118.796 -165.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -129.31 -74.75 0.56 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.833 1.816 . . . . 0.0 110.292 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -95.26 -9.54 32.88 Favored 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.292 1.96 . . . . 0.0 116.292 -169.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 65.2 m -92.39 -123.54 0.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 CA-C-N 120.064 1.302 . . . . 0.0 113.66 -171.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.0 pt -115.95 14.86 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 119.61 -1.931 . . . . 0.0 115.727 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.8 mm -83.52 145.07 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 O-C-N 120.775 -1.203 . . . . 0.0 108.301 167.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 62.81 27.48 70.16 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 114.936 0.734 . . . . 0.0 114.936 168.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -106.3 153.8 21.66 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.471 1.108 . . . . 0.0 109.27 179.199 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 49.7 m -95.77 86.96 4.52 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.334 -0.854 . . . . 0.0 111.16 -167.237 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.8 tp -76.3 145.59 39.49 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-N 122.193 2.27 . . . . 0.0 113.457 -168.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.8 p -133.45 152.58 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 C-N-CA 126.751 2.021 . . . . 0.0 112.686 177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -112.85 133.05 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 124.33 1.052 . . . . 0.0 108.216 164.521 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -89.61 152.75 21.23 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-O 122.292 1.044 . . . . 0.0 113.075 -176.092 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -68.01 -29.35 68.34 Favored 'General case' 0 N--CA 1.473 0.707 0 O-C-N 120.46 -1.4 . . . . 0.0 114.754 -174.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -119.8 169.56 10.02 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.976 1.31 . . . . 0.0 112.285 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -49.37 148.07 2.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.58 1.152 . . . . 0.0 110.555 169.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -96.45 133.45 40.86 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 123.647 0.592 . . . . 0.0 109.77 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -84.78 -13.89 49.83 Favored 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 125.44 1.496 . . . . 0.0 113.464 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 65.1 -38.34 0.25 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 130.817 3.647 . . . . 0.0 114.327 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.96 -32.6 0.05 OUTLIER Glycine 0 CA--C 1.519 0.281 0 CA-C-N 119.579 1.081 . . . . 0.0 115.343 170.131 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.78 69.69 0.99 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 117.379 2.363 . . . . 0.0 117.379 -172.47 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -79.55 -68.29 1.5 Allowed Glycine 0 N--CA 1.461 0.346 0 N-CA-C 106.27 -2.732 . . . . 0.0 106.27 164.732 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 174.65 21.31 0.02 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 124.819 1.199 . . . . 0.0 115.068 -178.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -149.23 161.79 41.32 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 119.374 1.587 . . . . 0.0 110.095 -179.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 35.1 tp10 -69.34 -45.9 68.35 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.905 1.282 . . . . 0.0 111.786 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -45.39 -35.25 3.51 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.775 1.23 . . . . 0.0 113.417 176.16 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 33.4 t -58.7 -56.81 17.44 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 169.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.292 0.0 OUTLIER -66.53 -9.72 37.66 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 123.98 0.912 . . . . 0.0 111.184 -178.013 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 48.7 mtmt -93.41 -50.45 5.44 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 119.333 0.969 . . . . 0.0 113.285 167.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 68.6 p -113.36 -24.38 9.36 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 -166.245 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.14 -3.08 47.55 Favored Glycine 0 C--O 1.22 -0.729 0 C-N-CA 125.203 1.383 . . . . 0.0 112.545 -168.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 54.66 16.04 1.25 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.898 1.679 . . . . 0.0 113.279 -177.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.59 27.27 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.763 2.025 . . . . 0.0 115.735 -165.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.7 -75.05 2.42 Favored Glycine 0 C--N 1.338 0.694 0 C-N-CA 127.254 2.359 . . . . 0.0 113.361 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.4 t -170.21 -150.31 0.08 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.546 1.138 . . . . 0.0 110.442 -171.184 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.89 123.5 47.18 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.366 1.067 . . . . 0.0 110.891 -173.478 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.489 HD23 ' H ' ' A' ' 145' ' ' ALA . 1.7 tt -96.2 -137.4 0.25 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.86 2.064 . . . . 0.0 106.257 168.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.489 ' H ' HD23 ' A' ' 144' ' ' LEU . . . -61.15 151.03 32.38 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 125.049 1.34 . . . . 0.0 112.375 -176.537 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -148.04 142.95 26.86 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 114.836 -1.074 . . . . 0.0 113.846 -172.336 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.23 114.88 0.63 Allowed Glycine 0 CA--C 1.528 0.9 0 C-N-CA 125.386 1.469 . . . . 0.0 113.039 -176.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 0.5 OUTLIER -74.41 135.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.387 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 37.9 mt -74.98 124.35 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.055 0.542 . . . . 0.0 111.885 -167.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.08 -175.28 17.38 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 124.834 1.207 . . . . 0.0 113.27 173.087 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -124.83 152.12 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 126.581 1.953 . . . . 0.0 111.997 173.351 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.13 -8.19 2.31 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -178.237 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tm0? . . . . . 0 C--O 1.236 0.349 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 169.17 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.556 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -84.62 74.08 10.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 105.604 -1.998 . . . . 0.0 105.604 168.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ptpm? -76.01 121.58 22.96 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.39 -0.819 . . . . 0.0 110.328 -170.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.59 152.71 22.1 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.203 1.001 . . . . 0.0 110.939 -177.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.511 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -145.87 129.91 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.082 0.944 . . . . 0.0 111.288 -167.503 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.421 ' HB2' HG13 ' B' ' 149' ' ' ILE . . . -104.44 134.84 46.96 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.306 -1.315 . . . . 0.0 107.863 168.414 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.574 HG21 ' HA ' ' A' ' 53' ' ' ASN . 93.2 t -116.88 115.64 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 167.099 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -95.8 96.7 9.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 126.222 1.809 . . . . 0.0 108.942 -169.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -158.21 124.58 4.74 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.736 0.814 . . . . 0.0 110.233 175.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.25 -101.62 2.59 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 105.876 -2.89 . . . . 0.0 105.876 165.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -144.35 109.25 4.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 125.274 1.43 . . . . 0.0 109.702 -169.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.6 167.38 11.44 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 125.446 1.498 . . . . 0.0 111.648 -175.098 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -73.67 25.57 0.32 Allowed 'Trans proline' 0 CA--C 1.544 1.019 1 C-N-CA 125.361 4.041 . . . . 0.0 114.963 -170.126 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -122.68 119.83 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 119.605 1.093 . . . . 0.0 109.096 -178.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -158.66 158.15 33.22 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 114.684 -1.144 . . . . 0.0 112.357 -178.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.2 177.02 36.82 Favored Glycine 0 CA--C 1.506 -0.479 0 C-N-CA 124.843 1.211 . . . . 0.0 114.069 176.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -120.61 148.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 112.993 -1.603 . . . . 0.0 109.742 168.382 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.0 mm -128.81 130.84 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 166.301 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -100.41 141.84 32.71 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 126.31 1.844 . . . . 0.0 110.809 168.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -120.93 104.92 10.2 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.262 2.225 . . . . 0.0 108.845 171.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -99.78 103.18 14.79 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.842 0.857 . . . . 0.0 110.905 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -105.62 136.68 44.76 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 122.145 0.974 . . . . 0.0 109.27 169.208 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 16.6 pttp -98.71 -24.52 15.01 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 124.992 1.317 . . . . 0.0 113.692 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -163.93 134.84 4.47 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.061 2.144 . . . . 0.0 107.957 -164.294 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.5 p -51.83 -28.62 16.36 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 126.01 1.724 . . . . 0.0 114.873 -170.195 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -109.26 -6.18 15.63 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.558 1.543 . . . . 0.0 113.381 -176.052 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -88.22 165.97 34.69 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.86 1.219 . . . . 0.0 111.726 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.32 168.82 21.18 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.041 2.494 . . . . 0.0 111.902 -176.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.27 124.36 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 C-N-CA 123.828 0.851 . . . . 0.0 109.262 176.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -81.54 128.59 34.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.625 -0.672 . . . . 0.0 109.427 169.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 63.2 t -108.81 127.09 65.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 126.093 1.757 . . . . 0.0 109.261 179.595 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -151.37 163.07 39.77 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 121.573 -0.705 . . . . 0.0 112.266 170.282 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.84 -166.24 33.37 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 123.702 0.668 . . . . 0.0 112.657 174.229 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.4 p -152.9 128.01 9.73 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 122.97 0.508 . . . . 0.0 111.665 -169.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 31.3 mt -118.72 124.77 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 125.019 1.328 . . . . 0.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -122.37 139.93 53.26 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 120.769 1.622 . . . . 0.0 111.595 -176.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.88 -0.51 9.17 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 127.863 2.649 . . . . 0.0 113.502 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 92.3 mt -75.73 170.3 16.45 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.16 1.384 . . . . 0.0 111.24 174.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.5 t -90.02 151.07 21.84 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 166.043 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -49.22 143.56 6.01 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.601 0.761 . . . . 0.0 111.513 171.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.32 -178.88 22.8 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 124.713 1.149 . . . . 0.0 113.239 -176.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.732 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.7 pt? -80.59 149.54 29.87 Favored 'General case' 0 CA--C 1.553 1.066 0 C-N-CA 128.739 2.816 . . . . 0.0 113.732 -172.132 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -154.17 126.3 7.84 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 128.594 2.758 . . . . 0.0 110.685 -170.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.06 160.85 41.93 Favored Glycine 0 N--CA 1.482 1.766 0 CA-C-N 121.162 1.801 . . . . 0.0 113.914 -177.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.476 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.285 0.2 OUTLIER -159.38 138.21 10.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 128.182 2.593 . . . . 0.0 114.867 168.68 . . . . . . . . 4 4 . 1 . 018 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 16.6 m80 -149.1 141.64 24.35 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 120.659 -1.276 . . . . 0.0 114.087 -169.112 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.02 106.94 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 126.768 2.027 . . . . 0.0 111.166 178.155 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.409 ' C ' ' H ' ' B' ' 50' ' ' PHE . 8.1 m170 -79.22 135.7 36.86 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.486 1.115 . . . . 0.0 110.732 -176.677 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -70.24 17.64 0.06 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.537 1.935 . . . . 0.0 112.513 171.205 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 50' ' ' PHE . . . . . 0.409 ' H ' ' C ' ' B' ' 48' ' ' HIS . 23.0 m-85 -144.07 92.66 2.35 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 126.427 1.891 . . . . 0.0 107.942 -167.507 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.29 7.73 66.78 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 116.967 -2.018 . . . . 0.0 111.012 167.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.691 ' HA ' HG21 ' A' ' 5' ' ' VAL . 4.9 m-20 -77.1 49.79 0.7 Allowed 'General case' 0 N--CA 1.481 1.094 0 CA-C-O 124.779 2.228 . . . . 0.0 110.357 -176.112 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 20.0 p30 170.84 27.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 128.201 2.601 . . . . 0.0 113.574 -165.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 35.4 p -39.42 -22.73 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 120.184 3.402 . . . . 0.0 120.184 -170.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.98 2.81 0.66 Allowed 'General case' 0 CA--C 1.553 1.068 0 N-CA-C 114.925 1.454 . . . . 0.0 114.925 171.012 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.99 -149.23 26.4 Favored Glycine 0 CA--C 1.526 0.747 0 O-C-N 120.924 -1.11 . . . . 0.0 112.256 174.096 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.6 t -62.3 -15.66 49.14 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 178.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 10.0 m -62.56 -1.46 0.82 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.297 1.439 . . . . 0.0 111.382 166.253 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -155.29 14.0 0.38 Allowed 'General case' 0 CA--C 1.548 0.883 0 O-C-N 119.712 -1.868 . . . . 0.0 114.215 178.17 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.12 155.75 38.48 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.39 1.45 . . . . 0.0 113.545 -169.518 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -116.72 -99.79 2.13 Favored Glycine 0 CA--C 1.545 1.923 0 C-N-CA 125.315 1.436 . . . . 0.0 114.243 -174.159 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -92.0 177.26 1.76 Allowed 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.856 3.704 . . . . 0.0 113.429 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -115.26 126.02 54.01 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.862 2.465 . . . . 0.0 110.919 -175.491 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -48.84 149.33 1.84 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 129.253 3.021 . . . . 0.0 116.571 -169.653 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -111.65 44.11 0.23 Allowed Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 127.305 2.242 . . . . 0.0 113.695 -172.289 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -63.05 -30.54 76.1 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.705 2.27 . . . . 0.0 113.825 -169.378 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.66 -3.95 43.6 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.012 0.925 . . . . 0.0 112.582 173.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.0 t 77.27 58.91 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 127.368 2.267 . . . . 0.0 111.616 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 ptt180 -163.4 177.52 8.84 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 117.341 2.349 . . . . 0.0 117.341 -167.624 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -64.99 169.91 4.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.202 3.001 . . . . 0.0 114.276 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 52.7 t60 -107.2 146.68 31.08 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.712 2.005 . . . . 0.0 114.236 -169.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 126.92 -104.26 0.7 Allowed Glycine 0 N--CA 1.472 1.092 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 163.769 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.44 -35.62 3.55 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-O 116.367 -2.351 . . . . 0.0 118.271 167.594 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 14.43 0.85 Allowed 'Trans proline' 0 CA--C 1.549 1.251 0 CA-C-N 123.349 3.574 . . . . 0.0 113.153 168.183 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.49 -26.92 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 127.531 2.332 . . . . 0.0 110.847 169.662 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.32 0.0 OUTLIER -64.47 151.79 43.37 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 123.225 1.488 . . . . 0.0 113.774 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 60.4 mp0 -88.42 -10.36 49.47 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 111.241 -2.709 . . . . 0.0 114.358 -166.063 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -143.98 -53.57 0.34 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.411 1.005 . . . . 0.0 112.58 -169.185 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 80.52 125.18 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 127.446 2.299 . . . . 0.0 114.362 166.53 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.5 m170 -67.08 148.23 52.15 Favored 'General case' 0 CA--C 1.541 0.608 0 O-C-N 121.018 -1.051 . . . . 0.0 110.856 167.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -72.4 26.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 125.311 1.444 . . . . 0.0 113.781 171.591 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -154.03 23.45 0.69 Allowed Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.636 1.589 . . . . 0.0 114.864 -169.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -125.54 129.31 49.47 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 119.071 1.435 . . . . 0.0 110.048 -178.533 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 86.6 mt -107.77 41.9 1.44 Allowed 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.042 0.837 . . . . 0.0 110.711 168.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.97 -117.68 5.02 Favored Glycine 0 CA--C 1.537 1.439 0 O-C-N 120.476 -1.39 . . . . 0.0 113.436 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -140.27 146.98 39.29 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.46 1.504 . . . . 0.0 113.394 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.476 HG13 ' CE1' ' B' ' 45' ' ' PHE . 28.2 m -93.39 145.49 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 127.237 2.215 . . . . 0.0 110.247 169.446 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 2.7 m -110.55 125.53 53.45 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 119.466 1.03 . . . . 0.0 109.618 171.011 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.39 163.9 15.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.447 0.699 . . . . 0.0 112.546 169.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.29 178.72 4.97 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.851 1.661 . . . . 0.0 112.713 173.277 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.595 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -58.22 -29.49 65.75 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.646 1.978 . . . . 0.0 116.314 171.955 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.18 -10.87 59.83 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 119.731 1.15 . . . . 0.0 111.099 171.195 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.54 11.82 46.5 Favored Glycine 0 C--N 1.334 0.464 0 CA-C-O 116.88 -2.067 . . . . 0.0 113.865 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.0 p -98.4 125.52 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 119.476 1.638 . . . . 0.0 113.357 179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.0 100.35 12.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.43 1.492 . . . . 0.0 108.04 165.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -87.37 143.25 27.34 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.242 1.017 . . . . 0.0 109.506 170.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.45 144.21 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 116.445 2.017 . . . . 0.0 116.445 -176.604 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.4 m -156.24 111.97 2.99 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.567 1.947 . . . . 0.0 111.161 174.208 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 13.2 mt -143.54 163.97 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 130.011 3.324 . . . . 0.0 109.571 -169.446 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -145.3 146.15 31.52 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 126.478 1.911 . . . . 0.0 107.757 168.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -144.69 132.05 20.76 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.935 0.894 . . . . 0.0 110.112 -175.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.8 p -113.54 46.04 1.34 Allowed 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.889 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.11 1.83 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 124.025 0.93 . . . . 0.0 111.687 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.46 171.42 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 126.35 1.86 . . . . 0.0 109.953 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 42.1 m -158.0 174.26 15.51 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 120.837 -1.164 . . . . 0.0 111.222 176.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 93.2 mt -109.54 54.03 0.67 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 127.407 2.283 . . . . 0.0 109.415 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.7 t -112.78 34.97 4.08 Favored 'General case' 0 CA--C 1.551 1.011 0 N-CA-C 115.626 1.714 . . . . 0.0 115.626 -168.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.92 -29.2 3.08 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 119.237 2.455 . . . . 0.0 119.237 165.345 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.251 17.7 t70 -99.41 -109.29 0.19 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 118.522 1.161 . . . . 0.0 108.448 -167.668 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -81.76 10.3 6.45 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.569 2.347 . . . . 0.0 112.703 175.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 m -60.76 -175.39 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.175 2.59 . . . . 0.0 115.081 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.282 11.6 pt -88.63 -3.91 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 119.941 -1.724 . . . . 0.0 114.424 172.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.7 mm -64.84 131.14 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 166.735 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.18 10.52 62.45 Favored Glycine 0 CA--C 1.524 0.653 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.281 -178.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -78.99 170.17 17.1 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 119.918 1.859 . . . . 0.0 109.836 173.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 91.8 m -112.33 112.5 24.12 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 48.5 tp -92.6 103.95 16.29 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 124.42 1.075 . . . . 0.0 109.459 177.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 13.7 p -86.4 149.53 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 167.61 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 37.9 t -128.41 143.76 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 167.597 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -106.0 163.08 13.04 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 125.665 1.586 . . . . 0.0 113.115 -168.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -76.28 -42.34 45.83 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.225 -175.101 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -110.56 176.07 5.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.822 1.649 . . . . 0.0 109.956 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.4 -176.59 6.29 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.252 0.549 . . . . 0.0 109.599 165.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -110.26 159.04 17.75 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.83 2.052 . . . . 0.0 113.032 -166.309 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -73.47 -14.21 61.2 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.904 1.282 . . . . 0.0 111.205 170.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 70.5 mt 54.08 61.45 3.05 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.124 1.77 . . . . 0.0 111.948 172.02 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.48 -54.15 3.47 Favored Glycine 0 N--CA 1.462 0.431 0 C-N-CA 125.688 1.613 . . . . 0.0 111.474 170.485 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.4 ttpt -126.9 72.9 1.37 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.676 1.19 . . . . 0.0 113.238 -168.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 129' ' ' GLY . . . . . 0.437 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -83.56 -30.46 29.9 Favored Glycine 0 CA--C 1.534 1.274 0 C-N-CA 124.579 1.085 . . . . 0.0 112.429 169.677 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 120.8 32.36 1.11 Allowed Glycine 0 N--CA 1.472 1.08 0 C-N-CA 125.167 1.365 . . . . 0.0 113.561 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -153.4 -156.21 0.67 Allowed 'General case' 0 CA--C 1.554 1.121 0 C-N-CA 124.571 1.148 . . . . 0.0 109.644 -169.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -95.9 -52.47 4.05 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 120.765 1.621 . . . . 0.0 110.727 171.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -54.29 -28.53 42.61 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 127.774 2.43 . . . . 0.0 113.176 -172.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.437 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 88.9 p -57.56 -30.78 65.51 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 125.016 1.327 . . . . 0.0 112.453 174.583 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -107.07 -27.48 10.6 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 117.519 -1.229 . . . . 0.0 114.188 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.7 tptm -71.88 -24.14 61.62 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 120.994 1.725 . . . . 0.0 113.056 -176.076 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -133.54 -46.6 0.82 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 126.287 1.835 . . . . 0.0 110.78 167.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.81 -9.0 8.1 Favored Glycine 0 C--O 1.221 -0.701 0 C-N-CA 125.477 1.513 . . . . 0.0 110.479 -163.253 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 57.63 37.32 27.4 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 124.992 1.317 . . . . 0.0 112.166 176.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.04 30.06 0.11 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 115.069 1.507 . . . . 0.0 115.069 -169.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.58 -57.27 2.52 Favored Glycine 0 N--CA 1.47 0.962 0 C-N-CA 127.539 2.495 . . . . 0.0 114.44 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.1 t -174.79 172.05 3.04 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.3 1.84 . . . . 0.0 110.479 -174.202 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.431 ' HD3' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -82.67 157.28 23.42 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 121.173 -0.954 . . . . 0.0 111.599 170.631 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -128.84 -97.58 0.38 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 124.546 1.138 . . . . 0.0 108.402 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -95.65 162.26 13.69 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.355 1.062 . . . . 0.0 111.242 174.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 p -158.5 155.9 29.3 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.788 1.235 . . . . 0.0 113.277 173.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.52 176.12 35.5 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 126.176 1.846 . . . . 0.0 112.362 171.246 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 76.7 t -107.3 157.29 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-N 118.247 1.024 . . . . 0.0 108.318 168.45 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.421 HG13 ' HB2' ' B' ' 6' ' ' ALA . 3.3 mt -87.24 110.85 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 123.886 0.874 . . . . 0.0 110.964 176.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -105.54 -165.47 23.56 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.554 1.549 . . . . 0.0 111.686 168.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -136.74 158.65 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 114.358 1.244 . . . . 0.0 114.358 -169.438 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -142.41 -19.61 0.69 Allowed 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 170.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.48 1.038 0 C-N-CA 125.317 1.447 . . . . 0.0 111.965 176.946 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.775 0 CA-C-O 117.258 -1.353 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -75.22 123.6 25.57 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 122.772 1.272 . . . . 0.0 108.158 -172.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.2 mtmm -98.91 132.66 44.07 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 112.616 -2.084 . . . . 0.0 113.924 171.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.62 168.7 13.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.029 0.932 . . . . 0.0 111.989 171.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.41 97.9 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 168.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -94.6 136.95 34.32 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 121.354 -0.842 . . . . 0.0 110.377 173.16 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.418 ' HB ' HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -134.38 130.48 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 C-N-CA 124.164 0.986 . . . . 0.0 110.44 -176.891 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -116.31 145.45 43.18 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.589 2.356 . . . . 0.0 110.6 172.452 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.74 160.17 40.32 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.292 1.037 . . . . 0.0 113.158 168.598 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.3 161.86 25.0 Favored Glycine 0 CA--C 1.525 0.708 0 C-N-CA 127.246 2.355 . . . . 0.0 107.901 168.187 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -76.62 59.46 1.52 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.298 1.439 . . . . 0.0 113.629 -177.381 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.58 -163.17 35.79 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 126.732 2.111 . . . . 0.0 110.194 -176.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -77.27 32.52 0.43 Allowed 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 125.041 3.827 . . . . 0.0 112.698 -173.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 t -114.24 124.09 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 C-N-CA 125.525 1.53 . . . . 0.0 108.58 -174.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mp0 -141.44 156.7 45.75 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 124.283 1.033 . . . . 0.0 110.284 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.56 139.93 10.87 Favored Glycine 0 CA--C 1.503 -0.695 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.133 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.8 125.76 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 117.354 0.577 . . . . 0.0 109.613 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.1 mm -133.74 122.72 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -111.41 101.18 9.65 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-O 122.537 1.16 . . . . 0.0 109.614 169.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -77.58 138.58 39.23 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.823 1.649 . . . . 0.0 108.574 176.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -110.21 121.65 45.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 119.845 1.202 . . . . 0.0 111.168 166.1 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.477 ' HB2' HD13 ' A' ' 106' ' ' LEU . 19.3 tp60 -82.48 128.59 34.42 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 163.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.59 -38.7 62.56 Favored 'General case' 0 CA--C 1.544 0.735 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 179.275 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -104.19 -129.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 129.653 3.181 . . . . 0.0 111.675 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.9 t -143.51 14.67 1.79 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.824 2.45 . . . . 0.0 110.209 167.693 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -168.07 -0.17 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 126.014 1.726 . . . . 0.0 115.426 -166.572 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.28 -151.58 11.49 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 125.849 1.69 . . . . 0.0 112.152 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -71.61 173.26 12.82 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 124.24 3.293 . . . . 0.0 113.616 -175.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -142.9 141.84 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.463 1.105 . . . . 0.0 110.872 -174.171 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.2 tttp -101.7 121.8 42.73 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 167.569 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.2 t -104.01 114.52 43.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 125.574 1.549 . . . . 0.0 108.581 -177.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.6 p90 -138.55 156.32 47.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 122.308 1.051 . . . . 0.0 113.035 177.243 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.02 -164.49 27.53 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.465 1.507 . . . . 0.0 111.361 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 88.7 p -158.1 160.22 37.1 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.049 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.1 mm -120.14 120.54 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 C-N-CA 124.597 1.159 . . . . 0.0 112.023 176.029 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.0 mmtt -104.95 152.13 23.06 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.386 1.474 . . . . 0.0 111.684 -174.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.35 -0.35 53.79 Favored Glycine 0 N--CA 1.475 1.288 0 C-N-CA 125.243 1.402 . . . . 0.0 114.435 174.098 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -83.85 173.5 11.19 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 126.467 1.907 . . . . 0.0 112.612 178.227 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.3 t -81.8 175.59 10.3 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 160.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.53 -175.8 0.14 Allowed 'General case' 0 CA--C 1.557 1.249 0 CA-C-O 122.44 1.114 . . . . 0.0 113.497 175.075 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.32 -179.69 45.44 Favored Glycine 0 CA--C 1.533 1.202 0 O-C-N 120.478 -1.389 . . . . 0.0 114.478 173.415 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.415 ' H ' HD12 ' A' ' 42' ' ' LEU . 5.8 mp -61.96 142.37 57.49 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 127.46 2.304 . . . . 0.0 111.359 -178.53 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -143.53 117.8 9.59 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 126.864 2.066 . . . . 0.0 109.442 176.042 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.14 141.87 47.71 Favored Glycine 0 N--CA 1.478 1.491 0 CA-C-N 120.038 1.29 . . . . 0.0 111.484 -179.07 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.277 0.1 OUTLIER -150.95 130.52 13.03 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 118.966 1.383 . . . . 0.0 111.839 174.403 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.87 143.65 26.4 Favored 'General case' 0 CA--C 1.535 0.366 0 O-C-N 121.278 -0.889 . . . . 0.0 111.917 -164.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -98.0 105.81 17.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.874 1.669 . . . . 0.0 108.5 -178.549 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -74.45 144.86 44.05 Favored 'General case' 0 C--N 1.322 -0.617 0 O-C-N 121.548 -0.72 . . . . 0.0 109.325 175.372 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -46.89 132.56 11.52 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 167.011 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.51 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 77.35 146.02 0.09 Allowed 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 124.729 2.204 . . . . 0.0 114.14 174.006 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.14 6.69 11.93 Favored Glycine 0 N--CA 1.466 0.69 0 C-N-CA 126.714 2.102 . . . . 0.0 111.788 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -76.89 42.89 0.32 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.648 1.579 . . . . 0.0 109.658 168.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 168.95 42.45 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 125.314 1.446 . . . . 0.0 113.638 -164.567 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -63.38 -4.69 2.84 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 116.23 1.937 . . . . 0.0 116.23 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.85 30.26 1.62 Allowed 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 120.381 1.446 . . . . 0.0 112.527 -171.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.37 -139.75 45.94 Favored Glycine 0 N--CA 1.466 0.642 0 O-C-N 120.828 -1.17 . . . . 0.0 111.509 171.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.6 p -52.57 -31.77 37.71 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 176.787 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.2 t -87.16 43.43 1.1 Allowed 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.415 1.462 . . . . 0.0 112.225 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.5 p -179.87 -32.64 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 127.411 2.285 . . . . 0.0 113.755 172.596 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -143.46 139.5 29.92 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 120.151 1.341 . . . . 0.0 113.62 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.35 -115.61 0.93 Allowed Glycine 0 CA--C 1.544 1.864 0 CA-C-O 117.952 -1.471 . . . . 0.0 113.559 -175.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.12 -179.69 5.48 Favored 'Trans proline' 0 C--N 1.348 0.532 1 C-N-CA 125.634 4.223 . . . . 0.0 112.689 -178.615 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -81.57 71.73 8.59 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.429 1.092 . . . . 0.0 109.97 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -43.71 140.52 1.82 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.519 1.528 . . . . 0.0 111.469 170.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -158.18 155.11 25.4 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 117.774 -1.108 . . . . 0.0 112.668 170.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -73.04 -10.94 25.08 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.082 1.855 . . . . 0.0 114.341 -172.435 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -87.68 -10.14 52.14 Favored 'General case' 0 CA--C 1.542 0.658 0 CA-C-N 119.834 1.197 . . . . 0.0 113.464 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.2 t 49.55 49.46 19.89 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.804 1.641 . . . . 0.0 114.166 175.272 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.1 mtm-85 -99.03 176.45 5.57 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 126.071 1.749 . . . . 0.0 113.435 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -76.89 168.38 20.19 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 126.59 1.956 . . . . 0.0 109.428 165.149 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -84.05 159.71 21.11 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 124.001 0.921 . . . . 0.0 113.386 -173.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.15 -134.67 5.84 Favored Glycine 0 C--N 1.341 0.816 0 N-CA-C 114.697 0.639 . . . . 0.0 114.697 167.544 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 124.33 -92.02 0.43 Allowed Glycine 0 CA--C 1.541 1.689 0 CA-C-O 118.59 -1.117 . . . . 0.0 113.94 -169.366 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.88 6.63 0.15 Allowed 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 123.8 3.0 . . . . 0.0 117.453 -175.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.257 0.0 OUTLIER -155.93 7.39 0.22 Allowed 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 127.344 2.258 . . . . 0.0 113.379 169.443 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.21 167.79 18.58 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.775 2.43 . . . . 0.0 110.153 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -111.19 -15.51 13.64 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.498 1.919 . . . . 0.0 112.542 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -78.22 -69.49 0.55 Allowed 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.241 1.016 . . . . 0.0 111.014 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 59.25 109.49 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.701 1.6 . . . . 0.0 112.31 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 27.1 m170 -59.03 148.37 31.11 Favored 'General case' 0 CA--C 1.544 0.717 0 O-C-N 119.205 -2.184 . . . . 0.0 110.348 167.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.5 t -79.22 54.33 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-O 123.769 1.747 . . . . 0.0 109.099 166.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.09 20.05 0.09 OUTLIER Glycine 0 CA--C 1.542 1.752 0 C-N-CA 128.87 3.129 . . . . 0.0 114.306 -179.088 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -122.29 130.13 52.86 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.006 2.403 . . . . 0.0 113.854 -175.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 74.4 mt -113.52 45.47 1.42 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.491 0.716 . . . . 0.0 110.78 168.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.45 -124.85 6.89 Favored Glycine 0 CA--C 1.534 1.269 0 O-C-N 121.41 -0.806 . . . . 0.0 113.17 -176.48 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -129.19 144.07 51.08 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.067 0.947 . . . . 0.0 111.545 173.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 95' ' ' ALA . 7.1 p -95.27 130.92 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 C-N-CA 125.602 1.561 . . . . 0.0 108.988 173.516 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.0 m -113.23 138.14 50.43 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 123.683 0.793 . . . . 0.0 112.175 -167.594 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.61 145.11 40.96 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 118.354 2.724 . . . . 0.0 118.354 -166.408 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -86.35 157.01 19.98 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 128.958 2.903 . . . . 0.0 111.314 169.241 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -47.42 -23.29 0.57 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 128.215 2.606 . . . . 0.0 117.155 176.314 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -76.45 3.65 10.76 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 119.844 1.202 . . . . 0.0 111.579 175.301 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.66 37.53 52.03 Favored Glycine 0 C--N 1.337 0.6 0 C-N-CA 125.23 1.395 . . . . 0.0 111.843 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -124.27 122.48 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.409 1.084 . . . . 0.0 110.621 176.282 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -84.3 118.11 23.99 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.427 1.491 . . . . 0.0 109.311 169.509 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.08 145.14 25.19 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.951 0.9 . . . . 0.0 112.079 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.82 138.17 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-N 114.001 -1.454 . . . . 0.0 114.823 169.423 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 m -155.27 62.27 0.63 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 127.058 2.143 . . . . 0.0 110.002 179.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.1 mt -95.58 154.56 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.346 1.858 . . . . 0.0 111.386 -176.178 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -133.35 143.25 48.86 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 125.437 1.495 . . . . 0.0 108.461 168.706 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -156.25 149.66 24.59 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.487 1.115 . . . . 0.0 112.572 -169.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.1 p -119.26 53.55 1.02 Allowed 'General case' 0 CA--C 1.542 0.65 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.639 178.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.0 t -138.84 -42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.154 0.982 . . . . 0.0 111.686 174.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -85.88 156.07 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 119.301 0.955 . . . . 0.0 112.099 174.382 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -151.45 147.49 26.92 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 124.409 1.084 . . . . 0.0 111.052 177.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.479 HD12 HD11 ' A' ' 112' ' ' ILE . 7.3 mp -78.39 57.21 1.88 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 120.836 -1.165 . . . . 0.0 109.308 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.6 m -130.31 15.96 5.55 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.887 1.275 . . . . 0.0 113.749 -168.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.7 -170.17 28.45 Favored Glycine 0 N--CA 1.44 -1.042 0 CA-C-O 124.853 2.363 . . . . 0.0 116.28 167.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.29 -51.74 64.85 Favored 'General case' 0 C--N 1.311 -1.083 1 CA-C-N 108.143 -4.029 . . . . 0.0 111.239 -168.72 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -79.76 4.14 17.25 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.419 1.087 . . . . 0.0 112.977 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.7 t -108.62 -93.29 0.41 Allowed 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.13 0.972 . . . . 0.0 111.476 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.479 HD11 HD12 ' A' ' 106' ' ' LEU . 10.9 pt -141.66 5.76 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 40.3 mm -84.13 119.5 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.404 -1.435 . . . . 0.0 107.733 171.239 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.97 30.54 72.25 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 117.915 -1.492 . . . . 0.0 113.664 -178.129 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.9 mmt-85 -86.88 145.85 26.42 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 120.527 2.163 . . . . 0.0 111.268 173.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 39.1 m -89.95 104.91 17.43 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 119.539 1.063 . . . . 0.0 111.499 177.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 15.5 tp -85.64 112.49 21.04 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.626 0.771 . . . . 0.0 110.642 173.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 9.9 p -92.46 148.18 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 118.953 -0.546 . . . . 0.0 109.714 169.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.48 134.08 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 122.262 1.029 . . . . 0.0 109.346 166.193 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.7 ' CE1' ' HE ' ' A' ' 143' ' ' ARG . 18.5 m-70 -109.84 152.57 25.58 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 126.111 1.764 . . . . 0.0 111.617 -169.431 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -79.48 -17.47 54.09 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 116.768 2.136 . . . . 0.0 116.768 -164.454 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.27 173.38 8.84 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 120.079 -1.638 . . . . 0.0 113.432 173.004 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.87 157.52 1.21 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.323 1.849 . . . . 0.0 112.439 172.251 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -97.79 131.35 44.38 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.974 0.892 . . . . 0.0 111.073 -176.273 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -26.6 62.38 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.53 1.932 . . . . 0.0 112.788 177.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.1 mt 54.09 53.63 10.81 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.917 1.687 . . . . 0.0 113.028 171.3 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.23 -25.37 27.33 Favored Glycine 0 N--CA 1.468 0.803 0 CA-C-O 118.218 -1.324 . . . . 0.0 114.99 170.795 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.354 6.4 mtmt -167.24 121.29 1.0 Allowed 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 164.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -143.53 -56.27 0.03 OUTLIER Glycine 0 CA--C 1.532 1.104 1 C-N-CA 131.177 4.227 . . . . 0.0 108.16 167.377 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -85.42 -93.18 0.8 Allowed Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.904 1.716 . . . . 0.0 114.032 177.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.541 ' CG ' ' H ' ' A' ' 132' ' ' GLU 0.27 0.8 OUTLIER -147.3 -96.69 0.09 Allowed 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 117.076 -1.44 . . . . 0.0 112.703 -169.3 . . . . . . . . 4 4 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.541 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 11.0 tt0 -111.97 -30.56 7.22 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 121.565 1.984 . . . . 0.0 114.396 170.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -61.36 -21.6 64.17 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.468 -2.02 . . . . 0.0 112.216 177.357 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.2 p -56.6 -25.55 53.14 Favored 'General case' 0 CA--C 1.54 0.583 1 C-N-CA 131.946 4.098 . . . . 0.0 113.376 164.502 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 p -116.23 -29.25 6.3 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 128.732 2.813 . . . . 0.0 112.974 -175.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 42.1 mttt -70.57 -56.71 5.88 Favored 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 169.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.7 p -99.08 -125.85 0.16 Allowed 'General case' 0 C--O 1.221 -0.42 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 167.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.14 28.88 1.53 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 129.006 3.193 . . . . 0.0 110.074 173.566 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 52.58 7.81 0.07 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 127.015 2.126 . . . . 0.0 115.168 -177.058 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.1 20.81 0.02 OUTLIER 'General case' 0 CA--C 1.56 1.358 0 C-N-CA 127.309 2.244 . . . . 0.0 116.681 -165.194 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.44 -144.83 34.91 Favored Glycine 0 CA--C 1.532 1.136 0 O-C-N 119.794 -1.816 . . . . 0.0 114.079 175.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.1 t -67.19 179.8 1.13 Allowed 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.392 1.077 . . . . 0.0 113.904 -174.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.7 ' HE ' ' CE1' ' A' ' 120' ' ' HIS . 95.4 mtt180 -124.7 114.53 19.43 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.911 1.684 . . . . 0.0 109.789 177.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -102.7 -24.76 13.72 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 125.772 1.629 . . . . 0.0 114.706 -171.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.78 158.81 35.96 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 124.497 1.119 . . . . 0.0 110.332 170.236 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.0 p -149.79 142.25 24.35 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.171 1.388 . . . . 0.0 109.503 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.57 175.77 34.84 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 115.388 0.915 . . . . 0.0 115.388 -170.183 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -133.1 152.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.018 1.327 . . . . 0.0 111.554 174.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 16.9 mt -83.82 115.51 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 127.646 2.378 . . . . 0.0 112.664 177.706 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' B' ' 51' ' ' GLY . . . -108.59 169.5 14.17 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 126.964 2.221 . . . . 0.0 114.532 -179.345 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -104.95 88.52 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 117.489 2.403 . . . . 0.0 117.489 -168.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.34 -25.49 51.13 Favored 'General case' 0 N--CA 1.477 0.902 0 O-C-N 120.07 -1.644 . . . . 0.0 113.08 173.184 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 . . . . . 0 C--O 1.236 0.363 0 C-N-CA 126.931 2.092 . . . . 0.0 110.459 176.377 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.304 0 CA-C-O 121.283 0.563 . . . . 0.0 111.894 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.8 t -157.35 125.5 5.52 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 126.846 2.058 . . . . 0.0 107.683 167.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.51 143.29 32.41 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-O 122.686 1.231 . . . . 0.0 113.651 174.775 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 169.64 17.35 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.366 1.866 . . . . 0.0 110.128 175.487 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -153.36 150.14 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 119.88 1.218 . . . . 0.0 111.892 -169.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.34 117.54 18.27 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 127.336 2.254 . . . . 0.0 109.126 169.113 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 8.4 m -101.93 116.89 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.363 1.465 . . . . 0.0 108.546 168.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.51 123.59 43.91 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.957 1.303 . . . . 0.0 113.323 -168.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . 0.26 0.2 OUTLIER -160.44 171.07 19.71 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 117.741 2.497 . . . . 0.0 117.741 165.366 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.97 36.64 0.27 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 129.606 3.479 . . . . 0.0 108.728 -174.547 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -159.23 55.29 0.4 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.045 1.338 . . . . 0.0 111.056 -167.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.85 -99.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 C-N-CA 127.266 2.365 . . . . 0.0 115.467 173.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -79.09 -14.33 13.52 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 123.949 3.099 . . . . 0.0 114.21 -176.179 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.4 HG21 HD21 ' B' ' 144' ' ' LEU . 2.1 t -98.86 141.37 16.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 120.398 1.454 . . . . 0.0 109.677 -179.725 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 pm0 -150.81 163.77 37.83 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.892 2.077 . . . . 0.0 107.237 169.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -147.94 134.06 4.93 Favored Glycine 0 CA--C 1.5 -0.904 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.379 175.072 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -97.03 130.1 46.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.337 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -133.64 116.29 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 C-N-CA 125.18 1.392 . . . . 0.0 109.045 168.33 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 65.7 m-20 -100.0 146.4 26.77 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.422 1.089 . . . . 0.0 110.855 171.146 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -121.73 135.51 54.94 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 126.852 2.061 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -128.37 122.0 30.43 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.695 1.198 . . . . 0.0 110.762 169.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.8 tt0 -109.4 140.34 43.23 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 168.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -103.5 6.2 37.32 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -174.416 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 37.1 mp0 -152.5 -178.45 6.85 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 129.341 3.056 . . . . 0.0 108.102 170.001 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.6 p -82.15 -25.35 34.42 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.675 -1.266 . . . . 0.0 112.784 168.301 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -132.31 19.4 4.4 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 125.343 1.457 . . . . 0.0 113.179 -177.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.1 -168.88 42.05 Favored Glycine 0 CA--C 1.541 1.713 0 C-N-CA 125.482 1.515 . . . . 0.0 113.688 172.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.3 169.0 14.53 Favored 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 124.096 3.198 . . . . 0.0 112.376 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 71.3 t -128.56 138.42 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.171 1.388 . . . . 0.0 111.387 -177.535 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -93.01 123.82 36.54 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 165.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.45 126.79 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.163 0.985 . . . . 0.0 110.8 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.8 p90 -146.74 164.32 33.13 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.959 0.885 . . . . 0.0 112.63 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.44 -153.58 25.42 Favored Glycine 0 C--N 1.334 0.452 0 C-N-CA 123.778 0.704 . . . . 0.0 112.47 176.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 60.6 p -153.16 119.52 5.54 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -168.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.3 mp -99.93 114.15 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 CA-C-O 118.265 -0.874 . . . . 0.0 109.941 173.254 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -122.18 133.84 54.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.929 1.241 . . . . 0.0 111.941 -175.441 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 132.05 -3.78 5.26 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 127.357 2.408 . . . . 0.0 114.271 176.008 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.447 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.8 OUTLIER -103.9 178.58 4.52 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 126.565 1.946 . . . . 0.0 112.22 -171.766 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -70.16 156.4 39.27 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.647 1.579 . . . . 0.0 110.227 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.06 156.28 28.67 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 168.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.35 -170.48 35.68 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.426 1.012 . . . . 0.0 113.285 178.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.708 HD22 ' H ' ' B' ' 42' ' ' LEU . 0.4 OUTLIER -65.19 152.57 43.3 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.415 1.886 . . . . 0.0 113.594 -174.095 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -149.18 125.58 10.9 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 127.781 2.433 . . . . 0.0 109.457 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.17 147.43 21.91 Favored Glycine 0 N--CA 1.481 1.646 0 CA-C-N 120.502 1.501 . . . . 0.0 111.551 173.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -154.19 87.88 1.21 Allowed 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.064 1.745 . . . . 0.0 109.321 -167.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -127.16 153.7 45.72 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 121.229 -0.919 . . . . 0.0 112.474 -166.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.1 97.99 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.069 0.85 . . . . 0.0 110.902 -175.288 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -79.47 134.92 36.54 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.195 -170.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -72.34 174.34 7.45 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.354 1.862 . . . . 0.0 113.028 -167.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 63.12 4.73 1.66 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.934 1.694 . . . . 0.0 114.974 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' A' ' 150' ' ' GLY . . . 52.71 16.22 3.72 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 120.267 -1.52 . . . . 0.0 113.584 -163.369 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -89.45 115.4 26.86 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 125.824 1.649 . . . . 0.0 110.322 -168.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -165.14 34.98 0.06 Allowed 'General case' 0 C--O 1.239 0.514 0 CA-C-O 124.149 1.928 . . . . 0.0 116.177 -178.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.418 HG22 ' HB ' ' A' ' 7' ' ' VAL 0.27 0.1 OUTLIER -86.47 -43.0 13.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.261 -1.336 . . . . 0.0 112.959 -166.313 . . . . . . . . 4 4 . 1 . 019 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.26 31.49 6.56 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.909 1.284 . . . . 0.0 113.067 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.57 -109.1 2.7 Favored Glycine 0 N--CA 1.468 0.818 0 O-C-N 121.033 -1.042 . . . . 0.0 112.329 169.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 56.0 m -75.93 -17.07 59.89 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 171.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.9 m -86.6 52.85 2.62 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 168.014 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m 172.03 -170.53 0.03 OUTLIER 'General case' 0 CA--C 1.56 1.335 0 C-N-CA 130.378 3.471 . . . . 0.0 106.488 -165.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.5 27.39 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 129.026 2.93 . . . . 0.0 118.111 -179.271 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -41.19 -46.41 4.23 Favored Glycine 0 CA--C 1.537 1.466 0 CA-C-O 116.459 -2.3 . . . . 0.0 115.497 -169.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -126.35 46.16 0.0 OUTLIER 'Trans proline' 0 C--N 1.356 0.925 0 CA-C-N 120.983 2.392 . . . . 0.0 115.52 -176.277 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.1 m170 78.6 78.34 0.06 Allowed 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.663 1.585 . . . . 0.0 112.916 167.02 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -48.06 138.75 8.88 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 161.306 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -157.18 116.66 2.0 Favored Pre-proline 0 N--CA 1.472 0.67 0 N-CA-C 116.746 2.128 . . . . 0.0 116.746 171.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.57 -5.58 15.6 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 N-CA-C 116.65 1.75 . . . . 0.0 116.65 -179.184 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -91.25 -7.51 51.0 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 119.526 1.057 . . . . 0.0 112.387 173.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t 54.66 54.26 9.46 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 125.571 1.548 . . . . 0.0 114.82 170.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.72 176.59 5.45 Favored 'General case' 0 N--CA 1.477 0.924 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -171.053 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.4 ptpp? -79.14 155.55 28.65 Favored 'General case' 0 CA--C 1.545 0.756 0 O-C-N 121.218 -0.926 . . . . 0.0 112.34 176.147 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -79.31 152.67 30.36 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.149 0.98 . . . . 0.0 113.187 -177.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.36 -117.43 1.04 Allowed Glycine 0 C--N 1.339 0.746 0 C-N-CA 123.195 0.426 . . . . 0.0 113.986 167.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.67 -28.17 6.87 Favored Glycine 0 CA--C 1.542 1.741 0 N-CA-C 120.12 2.808 . . . . 0.0 120.12 168.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -93.02 -13.83 1.24 Allowed 'Trans proline' 0 CA--C 1.544 1.025 0 CA-C-N 123.203 3.502 . . . . 0.0 112.879 173.067 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.404 ' HE3' ' HB2' ' B' ' 126' ' ' LEU . 0.0 OUTLIER -147.16 -1.39 0.65 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.576 1.55 . . . . 0.0 112.792 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.44 177.19 5.77 Favored 'General case' 0 CA--C 1.548 0.898 0 O-C-N 120.735 -1.228 . . . . 0.0 110.508 174.706 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -90.01 -23.63 21.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 129.324 3.05 . . . . 0.0 111.579 -172.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -129.63 -98.09 0.35 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.243 1.017 . . . . 0.0 112.881 -171.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 96.36 137.6 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 129.778 3.231 . . . . 0.0 110.577 -170.149 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -57.21 162.06 2.87 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.267 -1.521 . . . . 0.0 112.072 168.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 53.1 t -61.35 -37.6 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-N 120.403 1.456 . . . . 0.0 110.577 170.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.59 24.03 4.57 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.212 1.387 . . . . 0.0 115.933 170.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -109.39 127.72 54.58 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 116.523 2.046 . . . . 0.0 116.523 174.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.4 mt -115.31 169.26 9.27 Favored 'General case' 0 CA--C 1.56 1.35 0 N-CA-C 103.633 -2.728 . . . . 0.0 103.633 156.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.48 -126.22 1.95 Allowed Glycine 0 N--CA 1.48 1.605 0 C-N-CA 124.482 1.039 . . . . 0.0 114.265 -171.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -126.54 154.07 44.34 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.8 m -111.26 129.71 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.927 2.091 . . . . 0.0 110.568 -176.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -89.41 132.08 35.16 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.271 0.487 . . . . 0.0 110.181 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.58 162.11 13.45 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 124.849 1.26 . . . . 0.0 111.451 168.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.3 -174.77 3.16 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.085 1.354 . . . . 0.0 111.736 169.004 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.65 -10.02 47.43 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.73 -15.31 61.22 Favored 'General case' 0 CA--C 1.554 1.122 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 162.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.72 30.24 6.93 Favored Glycine 0 C--N 1.34 0.768 0 C-N-CA 127.272 2.368 . . . . 0.0 112.736 168.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -116.14 128.92 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 CA-C-N 119.854 1.827 . . . . 0.0 113.543 178.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 80.52 3.73 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 125.236 1.414 . . . . 0.0 110.215 167.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -77.85 123.7 27.07 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.682 1.593 . . . . 0.0 108.808 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.9 t -147.37 150.51 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -168.052 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 71.3 m -140.18 128.42 22.47 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 127.419 2.288 . . . . 0.0 108.367 166.068 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 34.7 mt -136.78 124.83 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 127.771 2.429 . . . . 0.0 108.928 -179.387 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 mp0 -117.4 115.69 25.72 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 126.307 1.843 . . . . 0.0 107.866 -175.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -140.46 144.32 36.01 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.933 0.873 . . . . 0.0 113.32 -168.327 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.2 p -110.89 51.1 0.78 Allowed 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 13.9 p -152.06 -38.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 167.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.288 0.1 OUTLIER -79.77 94.15 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 120.677 1.58 . . . . 0.0 110.888 172.549 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 38.4 p -102.14 153.21 20.15 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.148 1.779 . . . . 0.0 113.378 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.34 54.73 1.45 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.379 1.472 . . . . 0.0 110.851 -177.697 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.1 m -94.85 39.58 1.1 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 126.189 1.796 . . . . 0.0 112.128 -170.705 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 73.95 -39.46 0.97 Allowed Glycine 0 N--CA 1.475 1.271 0 C-N-CA 127.396 2.426 . . . . 0.0 115.83 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -161.65 -34.95 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.133 1.773 . . . . 0.0 111.962 -168.037 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 63.9 m-70 -75.85 -19.44 58.89 Favored 'General case' 0 C--O 1.226 -0.17 0 O-C-N 120.438 -1.413 . . . . 0.0 112.463 -167.521 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -142.62 -71.37 0.32 Allowed 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 122.793 0.437 . . . . 0.0 111.57 -172.128 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.25 2.3 pt -137.16 166.45 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 C-N-CA 125.252 1.421 . . . . 0.0 107.941 166.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.2 mm 86.72 144.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 131.308 3.843 . . . . 0.0 107.139 -163.06 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.43 3.45 25.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.133 0.873 . . . . 0.0 114.746 177.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 31.2 mtt180 -108.45 -172.45 2.06 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 128.785 2.834 . . . . 0.0 108.574 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 12.0 t -124.05 161.94 24.51 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 120.559 1.527 . . . . 0.0 109.423 166.761 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 tt -118.61 130.71 56.03 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 164.135 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 40.7 t -113.19 128.05 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 C-N-CA 125.098 1.359 . . . . 0.0 108.038 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -92.53 156.89 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 166.303 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.62 127.51 35.09 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.266 1.426 . . . . 0.0 108.752 -175.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -58.93 -14.52 9.38 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 118.122 2.638 . . . . 0.0 118.122 -166.032 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.8 mttp -137.45 177.33 7.95 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 124.042 3.11 . . . . 0.0 115.255 175.435 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.92 129.87 31.68 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 125.749 1.62 . . . . 0.0 110.888 -177.135 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -99.81 136.88 39.06 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 124.071 0.857 . . . . 0.0 110.327 171.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -81.49 -6.3 58.82 Favored 'General case' 0 CA--C 1.551 0.991 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.044 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.404 ' HB2' ' HE3' ' B' ' 75' ' ' LYS . 32.8 mt 60.69 67.89 0.79 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.314 1.846 . . . . 0.0 111.645 169.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.5 20.09 28.09 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 117.037 1.575 . . . . 0.0 117.037 168.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.4 mtmp? -146.88 -57.86 0.27 Allowed 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 120.092 3.367 . . . . 0.0 120.092 -165.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -78.82 37.72 1.91 Allowed Glycine 0 N--CA 1.475 1.299 0 C-N-CA 128.64 3.019 . . . . 0.0 110.618 -169.177 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 130' ' ' GLY . . . . . 0.479 ' HA3' ' H ' ' B' ' 134' ' ' SER . . . 173.82 84.0 0.06 OUTLIER Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 -168.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -40.01 -24.96 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.935 0 C-N-CA 130.632 3.573 . . . . 0.0 114.827 167.215 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -116.98 -78.49 0.58 Allowed 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 127.177 2.191 . . . . 0.0 107.517 167.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -63.97 -36.47 84.09 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.066 1.135 . . . . 0.0 114.066 -166.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.479 ' H ' ' HA3' ' B' ' 130' ' ' GLY . 13.8 t -71.31 -27.75 63.62 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 119.583 -1.948 . . . . 0.0 112.605 -177.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.316 8.9 t -83.41 -5.82 59.27 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 118.56 -0.733 . . . . 0.0 111.728 170.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -105.16 -68.2 0.87 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 124.882 1.273 . . . . 0.0 113.702 173.497 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.6 p -88.17 -32.28 18.7 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 125.347 1.459 . . . . 0.0 113.435 178.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 116.65 -23.92 9.95 Favored Glycine 0 N--CA 1.472 1.078 0 C-N-CA 125.32 1.438 . . . . 0.0 112.448 -168.2 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 10.2 t30 69.43 48.06 0.65 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 127.719 2.408 . . . . 0.0 110.014 178.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.87 31.3 0.06 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 127.402 2.281 . . . . 0.0 114.672 -169.183 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.49 -33.95 0.12 Allowed Glycine 0 CA--C 1.535 1.337 0 C-N-CA 128.614 3.007 . . . . 0.0 115.265 -172.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.7 t -160.16 -152.21 0.28 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.794 1.238 . . . . 0.0 112.398 178.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.52 -170.66 2.27 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 129.508 3.123 . . . . 0.0 107.706 174.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.4 HD21 HG21 ' B' ' 14' ' ' VAL . 0.4 OUTLIER -174.41 -168.7 0.4 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.467 1.907 . . . . 0.0 107.372 -169.852 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.68 153.95 1.53 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.67 2.788 . . . . 0.0 113.45 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -144.9 160.92 40.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.187 1.795 . . . . 0.0 112.821 -178.636 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.56 131.25 3.21 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 124.555 1.074 . . . . 0.0 111.98 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 128.18 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -176.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 35.4 mt -84.95 112.85 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.591 1.956 . . . . 0.0 111.228 -168.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.52 -144.44 10.96 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.416 -0.673 . . . . 0.0 111.416 168.497 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.17 163.61 26.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 124.507 1.123 . . . . 0.0 112.714 -168.524 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.51 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.35 -34.14 0.3 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 129.174 2.989 . . . . 0.0 109.789 166.67 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.469 0.491 0 C-N-CA 126.387 1.875 . . . . 0.0 111.813 167.368 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 119.965 -0.064 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.5 p -78.51 53.76 1.35 Allowed 'General case' 0 C--O 1.221 -0.435 0 C-N-CA 127.582 2.353 . . . . 0.0 115.684 -164.555 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 mttp -161.94 87.46 0.65 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.003 1.721 . . . . 0.0 110.685 166.781 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.98 152.35 28.02 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 123.83 0.852 . . . . 0.0 109.227 167.073 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.438 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -160.04 147.58 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.856 0.862 . . . . 0.0 111.85 -168.086 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.69 139.21 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 165.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.513 HG21 ' HA ' ' B' ' 53' ' ' ASN . 88.9 t -98.29 88.9 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 167.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.72 123.74 30.15 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 127.049 2.14 . . . . 0.0 108.914 -170.177 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -135.62 144.15 45.95 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 122.38 1.086 . . . . 0.0 113.676 -170.352 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -109.08 160.94 13.3 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 107.36 -2.296 . . . . 0.0 107.36 166.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.08 58.16 1.5 Allowed 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 127.001 2.121 . . . . 0.0 111.935 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.4 -160.92 34.72 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.965 2.221 . . . . 0.0 110.565 -172.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.85 41.73 1.17 Allowed 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 125.152 3.901 . . . . 0.0 112.104 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.14 111.94 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 127.086 2.154 . . . . 0.0 108.726 -169.717 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -159.69 168.7 25.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.448 179.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.18 137.43 5.39 Favored Glycine 0 CA--C 1.506 -0.495 0 CA-C-N 115.659 -0.701 . . . . 0.0 112.065 168.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.0 134.04 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 166.326 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 pp -130.98 129.87 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.539 1.136 . . . . 0.0 109.231 165.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -103.2 153.75 20.04 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.537 1.935 . . . . 0.0 112.392 168.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -138.13 111.12 7.77 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 126.436 1.894 . . . . 0.0 109.123 169.41 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -96.33 84.78 3.8 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.315 -1.491 . . . . 0.0 112.54 176.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.424 ' HB3' HD13 ' A' ' 106' ' ' LEU . 3.5 tp60 -105.84 147.51 28.6 Favored 'General case' 0 C--O 1.222 -0.361 0 O-C-N 121.111 -0.993 . . . . 0.0 110.733 174.22 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.41 -15.14 9.11 Favored 'General case' 0 CA--C 1.551 1.005 0 C-N-CA 128.432 2.693 . . . . 0.0 112.49 -179.005 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -126.54 171.71 10.85 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 127.121 2.169 . . . . 0.0 110.594 -171.49 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 75.1 m -95.57 -26.5 15.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -126.58 -18.99 4.67 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 120.717 1.599 . . . . 0.0 114.904 -174.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.85 173.52 47.63 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.641 1.115 . . . . 0.0 112.973 176.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -80.95 171.04 14.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.847 3.031 . . . . 0.0 112.773 -176.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 t -140.48 136.1 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.34 1.456 . . . . 0.0 111.256 -170.568 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.9 tmtm? -80.77 128.89 34.16 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 168.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 38.1 t -121.91 143.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.669 1.987 . . . . 0.0 108.664 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.5 p90 -156.59 161.55 39.93 Favored 'General case' 0 C--N 1.326 -0.426 0 O-C-N 121.06 -1.025 . . . . 0.0 111.292 173.232 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.68 151.4 9.83 Favored Glycine 0 N--CA 1.452 -0.281 0 N-CA-C 114.879 0.711 . . . . 0.0 114.879 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -109.7 108.53 18.95 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.081 -0.56 . . . . 0.0 110.182 170.687 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -85.21 141.38 14.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 126.273 1.829 . . . . 0.0 107.789 167.704 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -149.38 132.4 16.23 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.216 1.806 . . . . 0.0 109.133 -178.685 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 -19.26 37.18 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 126.084 1.802 . . . . 0.0 114.179 -171.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.46 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -62.96 130.94 46.97 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 119.55 1.675 . . . . 0.0 111.956 169.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -67.5 152.84 44.97 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.634 1.974 . . . . 0.0 109.268 168.355 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -53.61 153.6 4.23 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.7 1.6 . . . . 0.0 115.111 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.99 -176.63 40.93 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.723 1.154 . . . . 0.0 112.668 -177.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mt -63.76 153.83 35.18 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.521 1.528 . . . . 0.0 112.18 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.46 ' CD2' HD23 ' A' ' 38' ' ' LEU . 78.6 m-70 -151.57 132.98 14.63 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 127.995 2.518 . . . . 0.0 108.701 169.086 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.91 142.77 46.86 Favored Glycine 0 N--CA 1.475 1.239 0 CA-C-O 118.905 -0.941 . . . . 0.0 112.263 178.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -132.93 102.83 5.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.939 1.696 . . . . 0.0 108.214 -175.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CD2' ' HB3' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -139.65 136.92 34.8 Favored 'General case' 0 CA--C 1.537 0.464 0 O-C-N 120.736 -1.228 . . . . 0.0 110.946 -167.372 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -93.89 124.58 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.201 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 116' ' ' THR . 14.6 m-70 -72.06 -177.86 2.2 Favored 'General case' 0 CA--C 1.55 0.966 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 169.298 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -64.89 167.24 7.91 Favored 'General case' 0 CA--C 1.549 0.923 0 O-C-N 119.97 -1.706 . . . . 0.0 111.767 169.478 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -90.36 -144.53 0.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -173.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.62 -147.36 26.65 Favored Glycine 0 N--CA 1.428 -1.835 0 CA-C-O 124.97 2.428 . . . . 0.0 111.441 169.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.749 ' HA ' HG21 ' B' ' 5' ' ' VAL . 19.5 p-10 -88.0 54.03 2.95 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 109.453 -3.374 . . . . 0.0 109.674 -168.565 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.643 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.369 4.1 p30 -75.19 18.57 0.19 Allowed 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 121.221 3.785 . . . . 0.0 121.221 -157.27 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.477 HG22 ' HA ' ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -76.3 -23.37 54.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 117.588 2.44 . . . . 0.0 117.588 -162.704 . . . . . . . . 4 4 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.71 -4.07 29.0 Favored 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 169.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.51 -111.31 4.02 Favored Glycine 0 C--N 1.342 0.881 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.567 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 31.0 p -47.84 -28.69 2.73 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.42 -19.48 29.59 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.727 1.211 . . . . 0.0 113.755 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 49.6 m -119.85 -43.73 2.55 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.208 0.913 . . . . 0.0 113.273 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.5 80.76 3.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.418 1.087 . . . . 0.0 111.289 -170.191 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.42 123.33 9.83 Favored Glycine 0 CA--C 1.536 1.389 0 C-N-CA 125.001 1.286 . . . . 0.0 112.245 -177.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -63.34 119.84 7.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.142 2.561 . . . . 0.0 109.372 -174.03 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.426 ' HB3' ' CD2' ' A' ' 46' ' ' HIS . 0.1 OUTLIER 34.27 66.93 0.24 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.155 1.782 . . . . 0.0 115.057 178.034 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -14.63 113.93 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 129.217 3.007 . . . . 0.0 114.505 174.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -114.53 38.6 0.22 Allowed Pre-proline 0 CA--C 1.555 1.138 0 C-N-CA 126.716 2.006 . . . . 0.0 115.448 -168.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -67.99 -14.6 41.57 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 122.668 2.246 . . . . 0.0 112.799 -177.331 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 64.3 mt -76.72 -6.73 53.39 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.169 1.388 . . . . 0.0 112.791 172.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.3 t 70.93 53.63 0.26 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 127.101 2.16 . . . . 0.0 113.009 174.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 20.6 mtm-85 -131.72 174.41 10.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -171.272 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mmtt -97.11 177.66 5.51 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 128.62 2.768 . . . . 0.0 110.193 166.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -81.62 154.13 26.31 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.807 1.41 . . . . 0.0 114.807 -169.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 158.38 -169.92 34.98 Favored Glycine 0 C--N 1.335 0.489 0 CA-C-N 115.277 -0.874 . . . . 0.0 113.93 166.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.13 -85.24 0.08 OUTLIER Glycine 0 CA--C 1.544 1.889 0 CA-C-O 117.9 -1.5 . . . . 0.0 114.192 168.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.05 19.04 0.16 Allowed 'Trans proline' 0 CA--C 1.553 1.459 1 C-N-CA 125.637 4.225 . . . . 0.0 116.635 -172.574 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.81 5.23 0.13 Allowed 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 128.144 2.578 . . . . 0.0 111.731 177.311 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -126.09 175.63 7.61 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 128.938 2.895 . . . . 0.0 112.922 -164.54 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 -129.88 -15.43 3.86 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 129.534 3.134 . . . . 0.0 111.833 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -85.89 -83.97 0.17 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.079 1.352 . . . . 0.0 112.486 177.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 72.35 112.43 0.06 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 126.488 1.915 . . . . 0.0 111.986 175.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -69.05 168.76 13.18 Favored 'General case' 0 CA--C 1.546 0.825 0 O-C-N 120.075 -1.641 . . . . 0.0 113.029 169.402 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -80.75 11.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 O-C-N 120.672 -1.268 . . . . 0.0 113.279 -178.619 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.95 10.21 7.48 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 126.766 2.127 . . . . 0.0 114.246 176.106 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -99.95 81.02 2.38 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 121.641 -0.917 . . . . 0.0 111.161 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.9 mt -79.17 48.71 0.89 Allowed 'General case' 0 CA--C 1.549 0.905 0 O-C-N 121.039 -1.038 . . . . 0.0 110.771 169.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.82 -118.7 9.31 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.541 1.543 . . . . 0.0 113.423 177.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.0 p30 -157.15 172.69 18.2 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.622 1.569 . . . . 0.0 112.64 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.9 p -133.63 125.11 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 C-N-CA 126.213 1.805 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 m -98.22 139.23 34.31 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.6 159.08 18.51 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.091 0.956 . . . . 0.0 113.418 172.52 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -89.4 154.66 19.88 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 126.83 2.052 . . . . 0.0 111.942 169.395 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.42 -14.6 12.82 Favored 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.818 2.447 . . . . 0.0 115.553 178.2 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -79.36 5.75 11.78 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 125.254 1.422 . . . . 0.0 112.941 168.367 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.26 40.59 9.05 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 125.708 1.623 . . . . 0.0 113.39 169.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.4 p -155.78 146.82 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 115.302 1.593 . . . . 0.0 115.302 -168.02 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.93 101.15 4.8 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 123.44 1.59 . . . . 0.0 109.604 167.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.54 79.29 1.8 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.249 2.219 . . . . 0.0 108.698 -173.701 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 70.9 t -93.23 147.81 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 127.31 2.244 . . . . 0.0 114.211 -167.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.6 t -150.51 116.51 5.6 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.23 1.412 . . . . 0.0 111.056 170.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.7 mt -140.11 168.97 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 128.296 2.638 . . . . 0.0 112.029 -168.625 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -136.28 136.42 39.78 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 127.909 2.484 . . . . 0.0 107.825 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -147.13 153.14 39.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 122.284 1.04 . . . . 0.0 113.373 -168.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 81.9 p -126.29 69.47 1.22 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.884 2.074 . . . . 0.0 110.898 -169.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.53 -35.71 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 124.211 1.004 . . . . 0.0 112.225 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.402 ' CD1' ' H ' ' A' ' 104' ' ' ILE . 0.1 OUTLIER -94.98 161.68 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.928 1.291 . . . . 0.0 112.225 174.772 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.1 p -158.07 177.64 11.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.233 1.013 . . . . 0.0 111.207 174.245 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.424 HD13 ' HB3' ' A' ' 22' ' ' GLN . 5.9 mp -111.53 80.3 1.3 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.474 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.7 t -147.34 -171.0 3.69 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -127.69 87.83 0.33 Allowed Glycine 0 C--O 1.219 -0.824 0 O-C-N 120.444 -1.41 . . . . 0.0 113.046 -177.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -177.26 -54.19 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 129.057 2.943 . . . . 0.0 108.615 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -140.02 8.04 2.27 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 114.647 1.351 . . . . 0.0 114.647 -173.451 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.474 ' CB ' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -73.08 -161.4 0.09 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 126.334 1.853 . . . . 0.0 113.9 -172.768 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 36.9 pt -109.47 1.08 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.5 mm -62.25 126.38 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 CA-C-N 119.981 1.264 . . . . 0.0 107.633 168.462 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.76 16.84 76.35 Favored Glycine 0 CA--C 1.522 0.469 0 CA-C-O 117.953 -1.471 . . . . 0.0 115.118 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 -102.25 169.82 8.47 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 119.267 1.533 . . . . 0.0 109.741 -175.424 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.404 HG23 ' HB2' ' A' ' 48' ' ' HIS . 10.2 t -123.54 121.85 36.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 120.614 1.552 . . . . 0.0 112.067 -173.477 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.427 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.3 OUTLIER -93.02 137.23 32.56 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 174.9 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.427 ' N ' HD13 ' A' ' 117' ' ' LEU . 98.3 t -129.71 131.22 66.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 126.065 1.746 . . . . 0.0 107.741 172.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 34.5 m -106.27 138.8 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 172.008 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -95.26 148.34 22.51 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.602 0.761 . . . . 0.0 112.739 -169.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.316 2.7 pp20? -74.47 -21.48 59.57 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -171.28 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -113.32 169.42 8.96 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.236 1.015 . . . . 0.0 112.593 171.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.73 154.14 9.53 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.533 1.533 . . . . 0.0 109.547 166.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -119.17 155.99 30.64 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 114.498 1.295 . . . . 0.0 114.498 -169.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.452 ' CG ' ' H ' ' A' ' 129' ' ' GLY . 2.9 t0 -89.83 -38.17 13.94 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 117.471 2.397 . . . . 0.0 117.471 -167.388 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 63.8 42.78 5.88 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.516 1.927 . . . . 0.0 113.322 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 134.8 -77.38 0.37 Allowed Glycine 0 C--N 1.337 0.586 0 C-N-CA 124.466 1.031 . . . . 0.0 112.716 169.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.17 62.16 1.17 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 118.853 2.909 . . . . 0.0 118.853 -174.508 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.452 ' H ' ' CG ' ' A' ' 125' ' ' ASP . . . -71.72 -71.5 1.04 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 106.899 -2.48 . . . . 0.0 106.899 163.325 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -77.79 -91.35 0.3 Allowed Glycine 0 CA--C 1.528 0.88 0 C-N-CA 126.177 1.846 . . . . 0.0 114.487 -173.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -144.02 -145.31 0.17 Allowed 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 124.822 1.249 . . . . 0.0 111.876 -165.729 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -69.66 -49.93 48.99 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.751 1.16 . . . . 0.0 112.367 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -47.13 -27.34 1.38 Allowed 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 116.15 1.907 . . . . 0.0 116.15 171.499 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 48.7 m -51.77 -23.68 4.95 Favored 'General case' 0 CA--C 1.543 0.699 0 O-C-N 120.195 -1.565 . . . . 0.0 113.719 167.103 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.5 p -99.54 -26.9 13.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.749 1.619 . . . . 0.0 115.033 173.582 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 31.6 mtpt -91.75 -24.82 19.32 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 124.103 0.961 . . . . 0.0 113.429 -176.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 39.6 p -123.31 -42.05 2.27 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.727 1.611 . . . . 0.0 112.83 169.455 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 105.81 18.99 10.7 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-O 118.864 -0.964 . . . . 0.0 111.091 -166.5 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 59.04 -1.7 0.11 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.58 2.352 . . . . 0.0 115.723 176.579 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.9 16.44 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.24 0 C-N-CA 128.822 2.849 . . . . 0.0 116.802 -165.327 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.27 -128.97 9.29 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 127.084 2.278 . . . . 0.0 111.658 -173.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.2 t -104.01 -168.22 1.47 Allowed 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.048 1.339 . . . . 0.0 113.122 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.65 151.41 36.18 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 120.629 -1.294 . . . . 0.0 110.925 168.445 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.3 tt -111.42 -66.81 1.04 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.699 2.0 . . . . 0.0 107.465 169.473 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -131.72 158.87 40.01 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.276 1.83 . . . . 0.0 110.31 177.521 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.0 p -156.38 151.74 26.69 Favored 'General case' 0 CA--C 1.553 1.062 0 C-N-CA 125.803 1.641 . . . . 0.0 113.171 -171.319 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.07 163.42 34.29 Favored Glycine 0 CA--C 1.542 1.762 0 C-N-CA 125.724 1.631 . . . . 0.0 114.205 172.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.8 t -107.54 137.59 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.455 1.127 . . . . 0.0 108.371 168.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.0 mt -81.31 126.88 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 127.513 2.325 . . . . 0.0 113.698 -169.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.0 -154.43 9.43 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 126.043 1.782 . . . . 0.0 112.412 168.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -131.17 146.15 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.607 1.163 . . . . 0.0 112.605 -178.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.04 15.82 Favored 'General case' 0 C--O 1.22 -0.476 0 C-N-CA 124.239 1.016 . . . . 0.0 109.472 174.811 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 . . . . . 0 C--O 1.239 0.524 0 C-N-CA 125.085 1.354 . . . . 0.0 108.746 173.441 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.401 0 CA-C-O 120.834 0.35 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.3 p -82.77 107.18 15.2 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.77 118.92 27.62 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 115.245 1.572 . . . . 0.0 115.245 -172.398 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -94.96 161.38 14.17 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.043 1.337 . . . . 0.0 111.957 169.252 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.749 HG21 ' HA ' ' A' ' 52' ' ' ASP . 2.2 p -148.73 116.04 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.784 2.034 . . . . 0.0 111.188 -169.781 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 6' ' ' ALA . . . . . 0.463 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -78.75 125.61 29.6 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.161 -0.962 . . . . 0.0 110.106 168.34 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.643 HG21 ' ND2' ' A' ' 53' ' ' ASN . 87.8 t -107.5 71.61 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.712 0.805 . . . . 0.0 111.291 -170.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.47 HD21 ' CD1' ' B' ' 117' ' ' LEU . 1.2 mp -83.56 130.42 35.0 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -169.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.6 mtpp -155.24 178.26 10.41 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.119 1.368 . . . . 0.0 113.119 172.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.73 -55.55 0.47 Allowed Glycine 0 C--O 1.224 -0.48 0 C-N-CA 127.175 2.322 . . . . 0.0 109.794 170.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -83.78 73.73 10.26 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.883 1.273 . . . . 0.0 110.481 -168.452 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.66 -103.58 0.06 OUTLIER Glycine 0 CA--C 1.538 1.471 0 C-N-CA 126.751 2.119 . . . . 0.0 113.136 176.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -79.87 -3.04 12.56 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 125.192 3.928 . . . . 0.0 114.724 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 42.0 t -77.53 128.37 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-N 120.025 1.284 . . . . 0.0 110.523 176.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -126.4 158.31 36.27 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 126.278 1.831 . . . . 0.0 109.181 167.115 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.01 101.91 0.28 Allowed Glycine 0 C--O 1.225 -0.415 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 168.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -102.43 106.02 19.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 C-N-CA 125.721 1.608 . . . . 0.0 106.676 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 4.2 mm -120.68 101.75 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.01 0.524 . . . . 0.0 109.964 -177.135 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -74.93 161.57 29.39 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 118.915 0.779 . . . . 0.0 110.523 172.28 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -146.73 100.47 3.33 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.947 2.099 . . . . 0.0 107.818 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 116.8 29.24 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.853 0.861 . . . . 0.0 112.017 -178.342 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -102.26 126.45 49.25 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.088 0.955 . . . . 0.0 110.767 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -49.78 20.71 Favored 'General case' 0 CA--C 1.55 0.963 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 171.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -151.5 134.56 15.86 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 128.757 2.823 . . . . 0.0 107.108 169.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 67.5 m -64.01 93.37 0.09 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.327 1.051 . . . . 0.0 112.268 178.329 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 p30 160.08 -32.66 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 131.081 3.753 . . . . 0.0 110.998 -174.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.6 173.18 45.41 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-O 119.241 -0.755 . . . . 0.0 111.936 172.597 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.04 166.9 19.34 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.422 2.748 . . . . 0.0 111.378 177.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 66.1 t -121.22 130.19 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 124.968 1.307 . . . . 0.0 109.017 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -86.87 119.24 26.88 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.73 0.776 . . . . 0.0 109.739 170.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.4 t -104.97 121.08 56.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 127.441 2.296 . . . . 0.0 108.813 -172.555 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -155.14 157.21 37.08 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.95 -135.64 4.87 Favored Glycine 0 N--CA 1.461 0.331 0 C-N-CA 124.709 1.147 . . . . 0.0 111.053 177.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.5 p -157.7 158.5 35.51 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 116.222 1.934 . . . . 0.0 116.222 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.491 HG12 HG11 ' B' ' 119' ' ' VAL . 1.3 mp -121.24 104.72 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.561 1.144 . . . . 0.0 108.483 170.3 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -106.27 124.47 49.64 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.3 3.1 3.53 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.269 1.89 . . . . 0.0 113.916 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.517 HD13 ' CD2' ' B' ' 43' ' ' HIS . 55.6 mt -79.76 -172.03 3.13 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 124.194 0.998 . . . . 0.0 108.409 167.397 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -119.58 -29.08 5.16 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 171.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 175.9 -176.65 0.12 Allowed 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 130.462 3.505 . . . . 0.0 106.327 -178.491 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.38 160.71 35.44 Favored Glycine 0 N--CA 1.461 0.354 0 C-N-CA 125.677 1.608 . . . . 0.0 114.072 166.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.426 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.1 mp -76.59 157.91 31.57 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 167.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 43' ' ' HIS . . . . . 0.517 ' CD2' HD13 ' B' ' 38' ' ' LEU . 95.5 m-70 -149.38 130.01 14.04 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 126.606 1.963 . . . . 0.0 108.681 -174.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.75 147.68 37.19 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 172.011 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.296 0.0 OUTLIER -138.32 133.56 33.17 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 123.947 1.832 . . . . 0.0 114.65 169.464 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.585 ' O ' HD22 ' B' ' 117' ' ' LEU . 2.3 m-70 -130.3 145.61 51.79 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.958 1.703 . . . . 0.0 111.63 -168.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -96.55 115.51 36.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 168.162 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -73.38 132.53 43.12 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 170.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -65.21 135.97 56.07 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 124.333 1.053 . . . . 0.0 112.037 -165.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 66.09 -169.93 0.2 Allowed 'General case' 0 CA--C 1.544 0.747 0 CA-C-O 123.274 1.511 . . . . 0.0 111.907 -175.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.55 2.85 3.85 Favored Glycine 0 C--O 1.225 -0.437 0 C-N-CA 126.602 2.049 . . . . 0.0 113.589 -175.171 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.438 ' HA ' HG21 ' A' ' 5' ' ' VAL . 11.6 p-10 -79.63 49.62 1.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 121.246 2.523 . . . . 0.0 111.262 169.662 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.513 ' HA ' HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER 176.42 28.26 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 112.079 -2.328 . . . . 0.0 115.293 -169.4 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 11.0 p -57.35 18.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 120.687 3.588 . . . . 0.0 120.687 -168.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.54 3.02 20.8 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-N 121.131 1.787 . . . . 0.0 113.955 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.04 -161.99 49.63 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 119.549 1.068 . . . . 0.0 113.156 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 18.6 t -52.3 -21.25 3.31 Favored 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 115.881 1.808 . . . . 0.0 115.881 -169.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.1 t -66.09 -10.6 42.09 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 125.835 1.654 . . . . 0.0 113.666 169.666 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.5 m -161.15 -4.42 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -171.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.04 144.32 47.62 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 116.243 1.942 . . . . 0.0 116.243 -166.151 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.76 126.79 32.82 Favored Glycine 0 CA--C 1.537 1.465 0 C-N-CA 125.448 1.499 . . . . 0.0 111.862 178.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -63.28 169.79 8.88 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 124.278 3.318 . . . . 0.0 112.484 -173.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.601 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -61.57 108.17 0.93 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.902 1.681 . . . . 0.0 112.722 -169.259 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -53.22 135.67 37.83 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 126.207 1.803 . . . . 0.0 115.729 -167.666 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -116.72 42.38 0.36 Allowed Pre-proline 0 CA--C 1.559 1.327 0 C-N-CA 128.131 2.572 . . . . 0.0 114.746 -175.494 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -65.9 -20.48 58.05 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.092 1.862 . . . . 0.0 112.38 177.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 6.5 mp -77.9 -3.93 44.21 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 126.72 2.008 . . . . 0.0 113.666 170.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.3 t 52.41 59.14 4.72 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 125.778 1.631 . . . . 0.0 114.726 169.414 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.0 ptt180 -163.1 179.24 7.64 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.109 0.964 . . . . 0.0 111.914 -168.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.16 169.92 2.51 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 -179.174 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CD2' ' HA3' ' B' ' 138' ' ' GLY . 51.7 t60 -55.64 158.32 3.56 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.979 1.711 . . . . 0.0 114.456 -173.171 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -64.68 45.04 0.11 Allowed Glycine 0 N--CA 1.47 0.937 0 N-CA-C 120.915 3.126 . . . . 0.0 120.915 -164.187 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -75.95 124.44 7.4 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-N 119.835 1.818 . . . . 0.0 113.903 -169.341 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -74.71 -3.01 13.23 Favored 'Trans proline' 0 CA--C 1.546 1.094 0 CA-C-N 120.125 1.962 . . . . 0.0 110.319 166.309 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.418 ' HE2' ' OD2' ' B' ' 76' ' ' ASP . 3.1 ptmt -106.07 -3.58 21.4 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 127.94 2.496 . . . . 0.0 112.98 176.62 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.418 ' OD2' ' HE2' ' B' ' 75' ' ' LYS . 0.2 OUTLIER -130.88 142.47 50.38 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.199 1.4 . . . . 0.0 109.351 -172.492 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -70.45 -18.09 62.99 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.984 -0.448 . . . . 0.0 111.79 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -98.48 122.16 41.33 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 125.292 1.437 . . . . 0.0 107.828 169.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.3 ttt85 -150.27 115.45 5.39 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.3 1.84 . . . . 0.0 109.466 -171.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -60.15 163.6 4.76 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 127.091 2.156 . . . . 0.0 112.2 166.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.23 -30.76 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 C-N-CA 124.775 1.23 . . . . 0.0 113.451 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.01 33.91 3.07 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 121.14 -0.975 . . . . 0.0 113.405 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 34.4 m-20 -144.36 155.12 43.65 Favored 'General case' 0 CA--C 1.529 0.173 0 N-CA-C 117.645 2.461 . . . . 0.0 117.645 -169.219 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.6 mt -113.1 -178.61 3.42 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 127.719 2.408 . . . . 0.0 107.796 164.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.39 -129.07 1.47 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.128 0.871 . . . . 0.0 113.369 176.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -103.09 162.58 12.83 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.064 0.946 . . . . 0.0 112.284 172.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.477 HG21 HD13 ' B' ' 35' ' ' ILE . 7.6 p -136.36 140.51 43.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 127.555 2.342 . . . . 0.0 108.179 166.229 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 91.1 m -127.76 124.23 37.23 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -165.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -82.95 144.06 30.26 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 179.514 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -82.37 163.13 21.91 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 126.679 1.992 . . . . 0.0 109.924 167.264 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -51.58 -17.93 0.98 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 126.777 2.031 . . . . 0.0 116.074 170.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.41 -23.49 57.01 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 126.753 2.021 . . . . 0.0 112.387 172.69 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.09 -3.94 60.5 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 125.603 1.573 . . . . 0.0 114.946 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.6 129.02 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 118.923 1.362 . . . . 0.0 112.232 168.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -97.95 126.65 43.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 164.654 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -79.91 142.36 35.22 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.9 p -124.33 130.78 73.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-N 114.086 -1.416 . . . . 0.0 111.152 165.329 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.1 p -155.91 69.87 0.68 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.539 1.936 . . . . 0.0 109.997 -169.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 14.9 mt -127.57 162.2 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.124 1.769 . . . . 0.0 113.285 -167.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -138.66 148.74 44.4 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 127.821 2.448 . . . . 0.0 106.916 166.275 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -148.48 143.13 26.5 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 125.254 1.422 . . . . 0.0 109.106 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.3 p -108.86 55.02 0.64 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.606 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.61 -40.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.707 1.603 . . . . 0.0 109.76 170.008 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -82.32 155.27 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 CA-C-O 122.549 1.166 . . . . 0.0 113.997 179.187 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 35.6 m -158.1 156.11 30.4 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.888 1.675 . . . . 0.0 111.37 172.3 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.3 mp -76.74 79.85 3.36 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 126.678 1.991 . . . . 0.0 107.934 176.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.95 -19.27 20.37 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 113.233 0.827 . . . . 0.0 113.233 -172.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 83.65 9.96 82.27 Favored Glycine 0 N--CA 1.472 1.095 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.663 -174.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -165.26 -37.22 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.861 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -169.277 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -131.84 7.29 4.38 Favored 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 116.934 2.198 . . . . 0.0 116.934 -165.234 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.0 m -161.07 -55.95 0.05 Allowed 'General case' 0 N--CA 1.479 0.977 0 O-C-N 119.368 -2.083 . . . . 0.0 115.766 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.653 HG23 HG21 ' B' ' 149' ' ' ILE . 68.2 mt -137.75 158.18 33.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 173.463 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm 83.32 102.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.267 1 C-N-CA 131.847 4.059 . . . . 0.0 106.498 -166.387 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.08 13.61 83.48 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-O 115.504 -2.831 . . . . 0.0 116.91 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -92.92 152.46 19.35 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 121.314 2.557 . . . . 0.0 109.05 175.032 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.6 t -107.68 109.72 21.4 Favored 'General case' 0 N--CA 1.487 1.398 0 CA-C-N 121.393 1.906 . . . . 0.0 112.962 -167.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.585 HD22 ' O ' ' B' ' 46' ' ' HIS . 3.1 tm? -91.17 136.29 33.19 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.785 1.234 . . . . 0.0 110.42 -176.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 p -121.06 142.3 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 C-N-CA 125.702 1.601 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.491 HG11 HG12 ' B' ' 35' ' ' ILE . 6.0 m -107.47 140.27 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 123.61 0.764 . . . . 0.0 110.371 171.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -111.93 160.22 17.64 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-O 122.373 1.083 . . . . 0.0 113.029 -170.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -84.36 -33.21 23.87 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -99.11 167.72 10.52 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.57 1.077 . . . . 0.0 111.093 177.375 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.93 150.54 16.44 Favored 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 165.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -112.28 137.5 50.32 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.239 0.616 . . . . 0.0 109.723 173.392 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -79.91 -38.01 33.41 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 120.577 -0.449 . . . . 0.0 111.454 169.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . 0.269 1.8 mm? 86.1 63.6 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.759 2.423 . . . . 0.0 111.868 -169.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.0 -15.55 36.78 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 117.077 1.591 . . . . 0.0 117.077 166.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.81 -153.95 0.6 Allowed 'General case' 0 CA--C 1.552 1.026 0 CA-C-N 119.565 1.683 . . . . 0.0 109.885 169.379 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 122.41 -36.78 3.05 Favored Glycine 0 N--CA 1.471 1.02 0 O-C-N 120.688 -1.257 . . . . 0.0 113.149 -176.041 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.61 -16.18 0.32 Allowed Glycine 0 N--CA 1.475 1.272 0 N-CA-C 118.719 2.248 . . . . 0.0 118.719 169.394 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -122.01 169.13 11.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.21 2.005 . . . . 0.0 111.513 -174.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -62.66 -51.78 65.91 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.894 1.278 . . . . 0.0 109.711 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -49.29 -30.88 8.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.561 2.344 . . . . 0.0 113.548 174.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 92.1 p -60.2 -33.67 72.55 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 122.354 2.343 . . . . 0.0 113.957 171.491 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 33.0 p -62.66 -34.97 78.18 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.529 0.604 . . . . 0.0 111.461 177.437 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 38.7 mtpt -90.86 -39.1 12.52 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.997 1.719 . . . . 0.0 113.273 -174.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 53.8 p -104.93 -28.34 11.16 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 127.212 2.205 . . . . 0.0 114.181 -173.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 138' ' ' GLY . . . . . 0.415 ' HA3' ' CD2' ' B' ' 71' ' ' HIS . . . 103.57 -28.98 13.23 Favored Glycine 0 N--CA 1.465 0.6 0 C-N-CA 125.857 1.694 . . . . 0.0 113.924 -168.604 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 96.98 -11.35 0.08 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 130.787 3.635 . . . . 0.0 109.736 -167.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.2 -17.48 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 131.334 3.853 . . . . 0.0 119.71 -168.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 96.96 176.33 35.0 Favored Glycine 0 CA--C 1.534 1.264 0 C-N-CA 127.058 2.266 . . . . 0.0 113.09 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 81.5 p -62.63 -74.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -168.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 170.21 158.16 0.06 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 127.44 2.296 . . . . 0.0 114.594 176.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.98 -128.8 0.19 Allowed 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 126.934 2.094 . . . . 0.0 106.639 163.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.14 150.08 43.7 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 119.347 0.976 . . . . 0.0 112.293 -171.557 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 36.4 t -143.37 147.74 35.14 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.994 0.918 . . . . 0.0 110.454 173.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.0 160.81 31.48 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 123.889 0.757 . . . . 0.0 114.599 177.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -78.49 152.27 5.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 121.816 -0.814 . . . . 0.0 111.971 174.762 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.653 HG21 HG23 ' B' ' 112' ' ' ILE . 44.8 mt -83.53 91.8 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 123.82 0.848 . . . . 0.0 111.772 169.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -80.14 -163.09 27.4 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.573 1.082 . . . . 0.0 113.181 169.133 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.3 pp -139.1 141.01 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 125.351 1.46 . . . . 0.0 112.308 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -99.68 -7.09 26.12 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 124.175 0.99 . . . . 0.0 111.974 168.447 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.473 0.715 0 C-N-CA 127.922 2.489 . . . . 0.0 110.677 169.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 CA-C-O 120.856 0.36 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.1 p -152.04 119.45 5.99 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 125.108 1.363 . . . . 0.0 108.742 -169.955 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 mtmm -86.98 122.29 30.63 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 174.181 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.13 162.6 12.97 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.394 1.878 . . . . 0.0 108.625 165.86 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.681 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.5 OUTLIER -160.05 134.78 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.499 1.12 . . . . 0.0 109.68 -168.604 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.6 137.91 54.54 Favored 'General case' 0 C--N 1.334 -0.095 0 CA-C-N 118.657 0.662 . . . . 0.0 112.311 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -95.19 115.54 34.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 167.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mp -95.01 117.02 29.43 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 169.505 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' B' ' 10' ' ' GLY . 13.1 ttpt -156.26 144.93 20.13 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 121.332 -0.855 . . . . 0.0 113.068 174.81 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.93 -33.04 0.47 Allowed Glycine 0 C--N 1.335 0.482 0 N-CA-C 116.768 1.467 . . . . 0.0 116.768 166.847 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -90.27 70.3 7.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 122.808 1.289 . . . . 0.0 109.657 -166.256 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.02 -106.66 0.14 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 128.724 3.059 . . . . 0.0 111.479 -174.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -76.1 -4.0 14.56 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 124.045 3.163 . . . . 0.0 113.886 -177.4 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 t -91.27 133.88 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 120.162 1.346 . . . . 0.0 111.897 176.431 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.21 159.08 44.6 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 127.211 2.204 . . . . 0.0 107.79 176.678 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -151.3 133.94 4.45 Favored Glycine 0 C--O 1.229 -0.166 0 CA-C-O 122.023 0.791 . . . . 0.0 111.84 177.129 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.19 130.44 56.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 169.822 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.55 122.99 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 124.326 1.017 . . . . 0.0 110.118 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -97.83 150.25 21.48 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.952 1.301 . . . . 0.0 110.194 167.042 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -124.83 111.25 15.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.322 1.849 . . . . 0.0 108.043 168.946 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -93.64 122.59 36.24 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 169.534 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -100.05 116.23 31.59 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.854 168.268 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . 0.263 0.0 OUTLIER -57.01 -50.35 73.0 Favored 'General case' 0 C--N 1.34 0.186 0 CA-C-O 119.095 -0.479 . . . . 0.0 112.044 175.893 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -158.42 145.66 17.83 Favored 'General case' 0 C--O 1.225 -0.213 0 CA-C-O 118.514 -0.755 . . . . 0.0 110.171 163.284 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.7 t -32.1 -51.52 0.25 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.985 2.114 . . . . 0.0 115.715 -167.989 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -78.34 -1.85 35.27 Favored 'General case' 0 CA--C 1.552 1.048 0 N-CA-C 115.559 1.688 . . . . 0.0 115.559 -175.9 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.45 -179.48 39.44 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.198 1.38 . . . . 0.0 113.756 -178.355 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -81.43 134.57 8.95 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 122.694 2.262 . . . . 0.0 111.354 175.218 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 t -86.69 128.76 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 O-C-N 121.779 -0.576 . . . . 0.0 110.393 -175.493 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 tmtt? -87.06 123.32 32.01 Favored 'General case' 0 CA--C 1.541 0.607 0 O-C-N 121.782 -0.574 . . . . 0.0 109.806 174.001 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -99.43 140.98 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.714 0.806 . . . . 0.0 110.343 169.866 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -145.05 156.64 44.04 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.37 0.668 . . . . 0.0 111.549 168.192 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.54 -160.4 29.23 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 123.346 0.498 . . . . 0.0 112.887 176.76 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.1 p -155.99 138.47 14.94 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 122.538 -0.39 . . . . 0.0 111.984 -175.615 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.91 110.42 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -179.191 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -112.91 142.93 45.01 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 127.685 2.394 . . . . 0.0 110.828 -167.287 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.01 0.81 54.9 Favored Glycine 0 CA--C 1.53 0.991 0 C-N-CA 126.457 1.98 . . . . 0.0 113.312 -177.982 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.7 mt -73.49 159.37 33.3 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 118.031 0.916 . . . . 0.0 110.573 176.275 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.4 t -82.75 160.23 22.36 Favored 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 162.374 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -53.6 160.15 1.36 Allowed 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -179.794 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.11 -170.71 34.72 Favored Glycine 0 CA--C 1.526 0.766 0 C-N-CA 124.128 0.87 . . . . 0.0 113.001 178.608 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.8 OUTLIER -79.18 153.13 30.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.827 1.251 . . . . 0.0 110.446 -175.249 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -147.03 114.29 6.26 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.539 2.336 . . . . 0.0 106.808 -177.088 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.87 154.09 28.58 Favored Glycine 0 N--CA 1.476 1.323 0 CA-C-N 119.887 1.221 . . . . 0.0 111.828 -176.717 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -157.4 135.11 10.69 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.629 1.214 . . . . 0.0 112.21 170.696 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.46 143.82 25.0 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 121.003 -1.061 . . . . 0.0 111.325 -170.03 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 15.9 m -85.08 136.84 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 167.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -104.72 179.22 4.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.91 1.684 . . . . 0.0 108.8 175.535 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.71 158.59 35.87 Favored 'General case' 0 N--CA 1.478 0.952 0 O-C-N 119.303 -2.123 . . . . 0.0 110.401 166.77 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 67.71 172.91 0.27 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.947 1.299 . . . . 0.0 112.298 174.648 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.04 10.33 63.84 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 126.588 2.042 . . . . 0.0 112.045 165.794 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.437 ' HA ' HG21 ' B' ' 5' ' ' VAL . 14.9 m-20 -74.07 100.76 3.69 Favored 'General case' 0 N--CA 1.453 -0.286 0 O-C-N 121.848 -0.795 . . . . 0.0 109.381 -173.331 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.444 1.5 p30 -145.61 35.69 1.06 Allowed 'General case' 0 C--N 1.341 0.224 0 N-CA-C 119.427 3.121 . . . . 0.0 119.427 173.872 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' B' ' 7' ' ' VAL . 0.2 OUTLIER -112.74 -36.74 5.08 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 117.548 -1.215 . . . . 0.0 112.66 -179.628 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.84 23.19 0.25 Allowed 'General case' 0 CA--C 1.554 1.133 0 CA-C-N 120.321 1.419 . . . . 0.0 113.518 169.919 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.06 -126.48 42.17 Favored Glycine 0 CA--C 1.528 0.863 0 O-C-N 120.523 -1.361 . . . . 0.0 112.105 176.777 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 77.2 m -68.85 -15.89 63.62 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 176.127 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.4 m -86.5 -19.96 28.77 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.272 1.429 . . . . 0.0 111.731 171.309 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.87 -50.46 12.21 Favored 'General case' 0 N--CA 1.476 0.835 0 O-C-N 121.37 -0.831 . . . . 0.0 110.87 169.146 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -148.62 131.26 15.9 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.029 0.919 . . . . 0.0 112.742 -177.499 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.09 -131.37 0.61 Allowed Glycine 0 CA--C 1.536 1.348 0 C-N-CA 126.69 2.09 . . . . 0.0 111.499 177.386 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -79.0 178.74 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 124.13 3.22 . . . . 0.0 111.001 174.892 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.561 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -78.06 83.39 4.36 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.062 1.345 . . . . 0.0 108.66 172.448 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -48.25 150.13 1.33 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.326 1.85 . . . . 0.0 113.225 -179.448 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.468 HD22 ' H ' ' A' ' 69' ' ' ARG . 63.6 t30 -146.97 114.21 4.26 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 174.855 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.76 -17.21 33.2 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.502 2.135 . . . . 0.0 113.008 175.677 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.74 -11.57 59.99 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 119.163 0.892 . . . . 0.0 113.044 175.701 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 t 53.23 46.9 25.55 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 126.008 1.723 . . . . 0.0 113.718 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.468 ' H ' HD22 ' A' ' 65' ' ' ASN . 52.6 mtp85 -104.44 168.14 9.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 127.612 2.365 . . . . 0.0 111.857 -177.747 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.59 151.46 44.63 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 122.129 0.966 . . . . 0.0 110.682 168.555 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.514 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 85.7 t60 -66.64 179.0 1.13 Allowed 'General case' 0 CA--C 1.545 0.754 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.105 164.334 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.448 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 113.16 -125.45 7.01 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 168.447 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.67 -50.68 0.8 Allowed Glycine 0 CA--C 1.539 1.566 0 CA-C-O 118.411 -1.216 . . . . 0.0 114.449 -178.0 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -80.01 -27.2 3.92 Favored 'Trans proline' 0 C--N 1.353 0.814 0 C-N-CA 122.884 2.389 . . . . 0.0 115.032 173.509 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptpt -121.75 -14.26 8.15 Favored 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 120.506 1.503 . . . . 0.0 113.904 169.094 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -105.84 153.47 21.88 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.866 1.266 . . . . 0.0 110.613 170.514 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -79.91 -14.6 58.51 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 125.995 1.718 . . . . 0.0 112.977 -169.584 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -103.83 -87.13 0.44 Allowed 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -166.771 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 84.82 133.24 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.287 1.835 . . . . 0.0 110.991 -173.403 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -59.82 156.69 13.68 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 125.776 1.63 . . . . 0.0 113.717 168.421 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.3 p -62.47 -36.54 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 CA-C-N 119.41 1.004 . . . . 0.0 112.925 179.634 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.8 102.1 1.92 Allowed Glycine 0 C--N 1.342 0.889 0 N-CA-C 106.027 -2.829 . . . . 0.0 106.027 167.596 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -162.34 147.89 12.75 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.012 1.115 . . . . 0.0 114.012 173.574 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 98.2 mt -121.7 173.47 7.43 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.558 1.943 . . . . 0.0 106.266 162.817 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.19 -107.88 1.31 Allowed Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.028 0.823 . . . . 0.0 112.758 -174.863 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -138.44 157.59 45.92 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.606 0.762 . . . . 0.0 111.432 169.182 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.567 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.5 OUTLIER -96.67 159.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 C-N-CA 125.233 1.413 . . . . 0.0 108.362 167.048 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.0 m -148.37 118.74 7.35 Favored 'General case' 0 N--CA 1.476 0.869 0 O-C-N 121.392 -0.817 . . . . 0.0 110.141 -174.977 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.33 142.61 28.25 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 125.587 1.555 . . . . 0.0 114.891 -169.747 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -78.09 148.63 34.13 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 113.189 -1.823 . . . . 0.0 109.005 166.118 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 7.0 pttp -39.08 -32.25 0.09 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 127.536 2.334 . . . . 0.0 115.768 169.663 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.468 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 28.2 m-20 -80.01 4.53 16.73 Favored 'General case' 0 CA--C 1.55 0.968 0 CA-C-N 119.978 1.263 . . . . 0.0 111.911 -178.776 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.45 -0.16 53.45 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 127.18 2.324 . . . . 0.0 115.434 168.581 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -113.79 131.89 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 119.273 1.536 . . . . 0.0 113.591 -174.382 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -98.86 132.42 44.22 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.405 164.65 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -77.9 152.2 33.41 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.243 1.021 . . . . 0.0 108.492 168.645 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.252 0.4 OUTLIER -128.43 126.65 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-N 113.78 -1.555 . . . . 0.0 112.277 165.997 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.7 t -157.81 89.07 1.0 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.226 1.011 . . . . 0.0 112.767 -177.01 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 4.2 mp -126.18 161.52 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 125.725 1.61 . . . . 0.0 110.811 176.382 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -140.3 137.72 34.38 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.493 2.717 . . . . 0.0 106.359 167.525 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -151.98 133.1 14.34 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 118.722 0.692 . . . . 0.0 112.48 -171.077 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.7 p -101.39 51.19 0.85 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.702 0.801 . . . . 0.0 112.261 175.976 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 41.0 t -130.98 -48.23 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.376 1.07 . . . . 0.0 108.511 169.207 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.53 155.12 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 122.839 1.304 . . . . 0.0 111.998 170.299 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.7 p -155.76 155.2 32.64 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 125.559 1.544 . . . . 0.0 109.968 -174.782 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -82.23 55.2 2.77 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 120.699 -1.25 . . . . 0.0 110.365 177.744 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.3 t -108.2 37.55 2.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.098 1.759 . . . . 0.0 113.282 -172.088 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 88.79 -143.93 17.9 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-O 122.426 1.014 . . . . 0.0 111.833 169.34 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -66.8 -44.64 80.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 123.881 1.8 . . . . 0.0 112.039 -166.988 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -85.19 -7.38 59.07 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 112.886 -1.961 . . . . 0.0 110.884 -170.705 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.4 t -118.82 -122.18 0.29 Allowed 'General case' 0 CA--C 1.547 0.86 0 CA-C-O 116.233 -1.842 . . . . 0.0 110.268 173.945 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.259 7.1 pt -124.49 67.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 CA-C-N 124.233 3.197 . . . . 0.0 116.911 178.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.4 mm -127.42 132.29 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 165.578 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.72 5.33 50.84 Favored Glycine 0 N--CA 1.472 1.082 0 CA-C-N 119.724 1.147 . . . . 0.0 115.772 177.228 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -80.78 178.21 8.53 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 118.535 1.168 . . . . 0.0 113.173 -170.105 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 36.5 m -101.37 138.67 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 127.351 2.26 . . . . 0.0 110.285 -177.593 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -138.18 135.27 35.48 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 124.242 0.964 . . . . 0.0 109.097 165.764 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 p -120.35 136.6 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 126.571 1.948 . . . . 0.0 108.911 176.972 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 16.6 m -101.97 149.52 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 166.027 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.5 m-70 -117.89 155.58 29.91 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.092 1.357 . . . . 0.0 111.928 -171.404 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -81.32 -33.99 32.18 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.815 1.246 . . . . 0.0 111.465 -171.036 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mmmt -92.58 165.05 13.19 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-N 119.375 0.989 . . . . 0.0 113.059 173.427 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.98 149.68 22.52 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.25 1.02 . . . . 0.0 109.354 165.043 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -99.88 135.29 41.52 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 169.108 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -77.91 -8.88 58.7 Favored 'General case' 0 N--CA 1.48 1.047 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 171.807 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.4 mt 62.73 48.66 4.1 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 124.97 1.308 . . . . 0.0 109.843 173.485 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.26 8.35 78.31 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 115.997 -2.557 . . . . 0.0 118.002 167.153 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -121.34 4.88 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 120.64 3.57 . . . . 0.0 120.64 -168.304 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.75 112.32 4.37 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 165.064 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -71.45 43.41 0.71 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 126.337 1.922 . . . . 0.0 114.55 -175.156 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -103.53 -77.05 0.57 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.828 1.651 . . . . 0.0 110.567 -174.446 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 174.49 -80.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 130.73 3.612 . . . . 0.0 105.494 -170.808 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -34.28 -54.47 0.51 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 128.528 2.731 . . . . 0.0 113.878 175.213 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -65.11 -5.44 6.62 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -169.565 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.8 t -126.09 -25.48 3.55 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 123.989 0.916 . . . . 0.0 111.984 165.356 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.0 tttt -54.21 -33.26 57.84 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.348 1.859 . . . . 0.0 111.531 168.604 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.0 p -110.99 -67.76 0.98 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 162.36 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 152.72 -23.67 0.82 Allowed Glycine 0 CA--C 1.534 1.23 0 C-N-CA 129.803 3.573 . . . . 0.0 112.746 -168.294 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 110.83 -8.6 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.646 1 C-N-CA 131.768 4.027 . . . . 0.0 113.057 176.183 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.59 -17.45 2.14 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 116.526 2.046 . . . . 0.0 116.526 -169.914 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.96 -135.37 28.03 Favored Glycine 0 CA--C 1.526 0.72 0 C-N-CA 124.529 1.062 . . . . 0.0 113.604 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.09 131.97 23.37 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 124.868 1.267 . . . . 0.0 111.677 -176.226 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -65.71 173.56 2.77 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-O 121.371 0.605 . . . . 0.0 109.438 169.243 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.457 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -150.08 -146.63 0.2 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.808 1.643 . . . . 0.0 107.268 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.457 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -50.59 150.66 2.64 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 123.018 1.39 . . . . 0.0 110.843 171.203 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 4.8 t -146.37 152.75 39.6 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 124.602 1.161 . . . . 0.0 109.3 -174.636 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.68 158.14 28.29 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 125.388 1.471 . . . . 0.0 114.028 -178.323 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -109.79 141.85 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.252 1.021 . . . . 0.0 109.335 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 15.0 mm -78.69 92.67 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 123.791 0.836 . . . . 0.0 111.493 -175.365 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -81.19 -175.83 50.37 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 125.003 1.287 . . . . 0.0 113.011 168.702 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 4.8 mp -136.19 138.7 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 O-C-N 121.015 -1.285 . . . . 0.0 110.412 -172.325 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -122.2 3.58 9.81 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.212 1.005 . . . . 0.0 113.331 171.281 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 . . . . . 0 C--O 1.238 0.45 0 C-N-CA 126.75 2.02 . . . . 0.0 112.402 176.557 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-O 121.272 0.558 . . . . 0.0 112.187 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 18.7 p -78.64 113.28 16.55 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.483 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.456 ' HE2' ' HB1' ' B' ' 152' ' ' ALA . 5.6 ptmm? -76.31 156.26 33.54 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.776 1.751 . . . . 0.0 112.081 172.042 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.491 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -149.17 165.03 33.03 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.047 2.539 . . . . 0.0 110.416 172.318 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.437 HG21 ' HA ' ' A' ' 52' ' ' ASP . 5.6 p -148.81 151.82 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.579 1.552 . . . . 0.0 110.764 -165.461 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.08 138.92 27.0 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.419 1.088 . . . . 0.0 110.515 168.1 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 54' ' ' THR . 46.9 t -105.65 84.74 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.911 0.884 . . . . 0.0 110.393 -169.842 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.272 0.9 OUTLIER -85.14 67.27 10.12 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 122.573 1.178 . . . . 0.0 113.075 -178.103 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt -97.95 111.73 23.92 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.053 173.367 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 10' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 9' ' ' LYS . . . -78.39 -103.24 0.2 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 171.831 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -139.38 109.67 6.52 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -167.856 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 51.07 -116.75 4.78 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.913 2.197 . . . . 0.0 112.01 -173.517 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.09 -11.39 27.1 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 124.997 3.798 . . . . 0.0 115.543 -167.606 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.7 t -92.14 94.94 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 123.049 1.404 . . . . 0.0 108.248 169.119 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.09 160.95 43.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.598 174.669 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.15 179.04 29.02 Favored Glycine 0 C--O 1.235 0.2 0 CA-C-O 123.034 1.352 . . . . 0.0 114.213 179.256 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -119.04 139.76 45.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.95 -1.625 . . . . 0.0 110.063 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -127.86 135.65 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 166.989 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -122.91 143.77 49.66 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 125.44 1.496 . . . . 0.0 110.067 169.936 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 87.8 m-85 -124.06 130.26 52.26 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.283 1.433 . . . . 0.0 108.262 170.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.98 120.47 41.49 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 124.333 1.053 . . . . 0.0 108.556 169.543 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -122.42 137.11 54.98 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 122.406 1.098 . . . . 0.0 108.896 168.546 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -105.89 -21.15 13.23 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.741 1.216 . . . . 0.0 113.063 -175.949 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -160.84 121.93 2.93 Favored 'General case' 0 C--O 1.222 -0.367 0 C-N-CA 127.692 2.397 . . . . 0.0 108.667 -164.126 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.1 m -59.25 -41.89 89.83 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.816 2.046 . . . . 0.0 113.179 -171.325 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -82.77 -4.5 58.03 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.502 1.921 . . . . 0.0 113.594 176.338 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.69 -175.94 33.89 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.742 1.639 . . . . 0.0 112.049 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.9 166.65 24.84 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.83 2.353 . . . . 0.0 112.117 178.896 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -115.42 137.79 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 169.441 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.43 129.06 39.72 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.739 0.816 . . . . 0.0 110.555 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -111.46 137.17 45.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 127.211 2.204 . . . . 0.0 109.832 -176.146 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 31.3 p90 -156.27 155.86 33.04 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 124.599 1.16 . . . . 0.0 110.972 168.619 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.32 140.47 3.06 Favored Glycine 0 C--N 1.332 0.351 0 CA-C-O 121.396 0.442 . . . . 0.0 114.1 -169.786 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 51.5 p -118.19 134.05 55.35 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.201 1.0 . . . . 0.0 110.178 -177.338 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -124.85 116.97 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 124.44 1.096 . . . . 0.0 110.435 -176.895 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 25.1 tptt -95.19 152.52 18.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.609 1.164 . . . . 0.0 109.393 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.87 -17.81 58.61 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.485 1.517 . . . . 0.0 113.722 -179.267 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 10.5 mp -69.89 119.33 13.95 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 118.457 1.128 . . . . 0.0 109.041 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -67.54 159.01 30.63 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 166.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -49.66 145.43 5.11 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.659 1.984 . . . . 0.0 114.591 -174.998 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 115.69 171.44 16.45 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 122.5 1.056 . . . . 0.0 113.864 -178.454 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.63 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.5 pt? -80.12 133.32 36.07 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.325 1.85 . . . . 0.0 111.522 -175.828 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -135.55 165.09 26.34 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 128.214 2.606 . . . . 0.0 108.964 -172.757 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.17 157.56 20.03 Favored Glycine 0 N--CA 1.482 1.713 0 C-N-CA 125.455 1.502 . . . . 0.0 114.705 -173.052 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -151.13 118.64 6.06 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.137 1.375 . . . . 0.0 113.243 -168.752 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.403 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -154.97 144.22 21.11 Favored 'General case' 0 CA--C 1.555 1.172 0 O-C-N 119.778 -1.826 . . . . 0.0 113.189 178.886 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -94.21 125.56 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 126.035 1.734 . . . . 0.0 110.154 171.076 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.403 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 7.6 m-70 -75.76 166.55 23.36 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.585 1.954 . . . . 0.0 111.042 179.174 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -75.63 133.54 40.84 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 167.321 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 74.57 167.74 0.29 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 128.015 2.526 . . . . 0.0 115.536 -178.58 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.21 -2.08 38.56 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 127.57 2.51 . . . . 0.0 114.269 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.681 ' HA ' HG21 ' A' ' 5' ' ' VAL 0.255 10.9 t0 -76.79 111.38 12.25 Favored 'General case' 0 CA--C 1.491 -1.303 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 165.023 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.3 0.1 OUTLIER -144.73 38.3 1.22 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-O 124.225 1.964 . . . . 0.0 113.264 168.738 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.0 p -79.89 -34.03 39.44 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 112.093 -2.322 . . . . 0.0 111.852 -166.257 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.3 20.49 0.68 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 124.503 1.121 . . . . 0.0 110.605 163.857 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.34 -134.6 50.21 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 125.679 1.609 . . . . 0.0 112.136 -176.771 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 7.1 t -60.13 -8.43 2.44 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.305 1.842 . . . . 0.0 114.837 179.772 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.7 m -89.51 -18.92 25.73 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 126.528 1.931 . . . . 0.0 112.348 174.858 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 m -94.77 -170.24 2.18 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 123.767 0.827 . . . . 0.0 110.63 168.954 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 66.69 -96.06 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.661 1.984 . . . . 0.0 112.204 177.137 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.37 162.01 11.53 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 126.84 2.162 . . . . 0.0 110.015 -167.353 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 161.42 42.35 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 123.166 2.577 . . . . 0.0 112.164 -174.484 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.4 ' HB3' ' CD2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -23.89 100.14 0.02 OUTLIER 'General case' 0 C--O 1.237 0.433 0 C-N-CA 129.436 3.094 . . . . 0.0 113.827 167.587 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 64' ' ' PHE . . . . . 0.415 ' CG ' ' HD3' ' B' ' 66' ' ' PRO . 3.1 t80 -55.5 127.52 30.07 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 123.681 1.705 . . . . 0.0 111.482 177.267 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 24.3 p-10 -103.07 39.38 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.42 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 -177.868 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 66' ' ' PRO . . . . . 0.415 ' HD3' ' CG ' ' B' ' 64' ' ' PHE . 75.4 Cg_endo -67.02 -14.01 42.02 Favored 'Trans proline' 0 C--N 1.36 1.133 0 C-N-CA 123.277 2.651 . . . . 0.0 112.666 -176.827 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.6 mt -75.23 -1.24 22.49 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.841 1.656 . . . . 0.0 112.189 175.807 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.5 t 62.3 58.91 1.67 Allowed 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.794 1.238 . . . . 0.0 113.132 167.495 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -152.82 175.1 13.26 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 114.799 1.407 . . . . 0.0 114.799 -167.793 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.407 ' HE3' ' HG3' ' B' ' 78' ' ' GLU . 0.0 OUTLIER -78.53 168.66 19.45 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.108 0.956 . . . . 0.0 109.968 166.747 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.455 ' HE2' ' HA ' ' B' ' 125' ' ' ASP . 42.3 t60 -61.04 165.03 4.48 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 118.356 -0.831 . . . . 0.0 110.334 172.275 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 168.65 -169.67 41.83 Favored Glycine 0 N--CA 1.476 1.316 0 N-CA-C 117.533 1.773 . . . . 0.0 117.533 -172.947 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.432 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 134.78 -87.0 0.25 Allowed Glycine 0 CA--C 1.545 1.931 0 N-CA-C 121.112 3.205 . . . . 0.0 121.112 167.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -72.49 4.75 3.21 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 124.288 3.326 . . . . 0.0 114.459 -167.849 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . 0.27 0.0 OUTLIER -167.05 4.76 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 130.03 3.332 . . . . 0.0 112.804 175.398 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.432 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 2.4 t0 -128.16 138.54 52.53 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 126.79 2.036 . . . . 0.0 105.649 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 77' ' ' GLU . . . . . 0.456 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -90.82 -9.33 46.86 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 126.764 2.026 . . . . 0.0 114.844 -166.643 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 78' ' ' GLU . . . . . 0.407 ' HG3' ' HE3' ' B' ' 70' ' ' LYS . 6.9 mm-40 -84.38 -84.61 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.911 0.778 . . . . 0.0 109.995 -175.667 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.562 HH22 HG23 ' B' ' 104' ' ' ILE . 33.3 ttp85 78.84 102.45 0.07 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.77 2.028 . . . . 0.0 113.474 167.33 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 13.6 m170 -54.57 155.0 4.33 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 119.829 -1.794 . . . . 0.0 110.165 166.882 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -60.09 -30.41 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 119.708 1.14 . . . . 0.0 113.393 -169.612 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.38 -6.41 74.19 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-O 118.126 -1.375 . . . . 0.0 116.111 179.243 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -79.54 122.37 26.39 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 121.064 2.432 . . . . 0.0 109.902 -176.873 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -126.9 42.17 3.37 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 120.984 1.72 . . . . 0.0 113.455 177.186 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 60.25 -122.84 31.18 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.691 2.236 . . . . 0.0 118.691 166.007 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 86' ' ' ASN . . . . . 0.518 HD21 ' CD1' ' B' ' 126' ' ' LEU . 9.7 m120 -126.82 154.06 44.82 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 113.781 -1.209 . . . . 0.0 113.859 -169.091 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.2 m -130.77 125.55 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.432 1.493 . . . . 0.0 109.107 167.292 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 46.5 m -109.87 127.84 54.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.568 0.747 . . . . 0.0 109.045 -175.784 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.91 148.23 22.18 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.291 1.437 . . . . 0.0 114.078 -177.789 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -104.76 159.31 15.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.904 2.081 . . . . 0.0 110.154 167.145 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -71.35 8.44 1.04 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.583 2.068 . . . . 0.0 116.583 -168.679 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -76.7 -12.58 60.02 Favored 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 122.404 1.097 . . . . 0.0 108.9 164.221 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.93 40.42 7.1 Favored Glycine 0 C--N 1.337 0.601 0 C-N-CA 125.571 1.557 . . . . 0.0 110.412 -174.676 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.01 134.59 31.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.337 1.068 . . . . 0.0 113.384 177.857 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -102.04 120.35 40.29 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 162.728 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -115.43 140.39 49.18 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 122.365 1.079 . . . . 0.0 110.197 169.714 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.43 150.5 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-N 112.324 -2.216 . . . . 0.0 115.092 -169.395 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 p -153.01 119.47 5.59 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.28 1.032 . . . . 0.0 111.349 171.963 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.1 mt -145.07 159.35 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 128.321 2.649 . . . . 0.0 110.565 -170.186 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -140.67 140.96 35.06 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.162 1.785 . . . . 0.0 108.172 168.085 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.98 140.08 26.62 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.182 1.393 . . . . 0.0 111.253 -172.878 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.4 p -110.47 48.65 0.9 Allowed 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.664 0.987 . . . . 0.0 113.664 -175.442 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 33.0 m -148.84 -29.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 CA-C-O 117.997 -1.001 . . . . 0.0 113.144 167.132 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 104' ' ' ILE . . . . . 0.562 HG23 HH22 ' B' ' 79' ' ' ARG . 0.1 OUTLIER -76.88 154.11 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-N 121.164 1.802 . . . . 0.0 108.114 165.841 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 105' ' ' SER . . . . . 0.458 ' H ' ' HB3' ' B' ' 111' ' ' SER . 2.9 p -162.46 158.29 23.54 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 125.352 1.461 . . . . 0.0 109.116 -174.238 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -79.67 55.5 2.03 Favored 'General case' 0 CA--C 1.542 0.673 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 171.666 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 58.0 m -93.48 52.56 1.75 Allowed 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 124.245 1.018 . . . . 0.0 110.074 -173.24 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.87 -96.86 0.54 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 124.688 1.137 . . . . 0.0 111.413 -177.028 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -134.97 7.0 3.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 128.298 2.639 . . . . 0.0 110.596 179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -79.43 -11.84 59.9 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.623 -1.298 . . . . 0.0 111.947 173.528 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 111' ' ' SER . . . . . 0.458 ' HB3' ' H ' ' B' ' 105' ' ' SER . 18.4 m -141.75 -98.69 0.13 Allowed 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 113.372 0.878 . . . . 0.0 113.372 -170.003 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.5 pt -119.56 164.19 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 120.744 -1.223 . . . . 0.0 109.376 168.257 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.9 mm 94.43 137.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 131.149 3.78 . . . . 0.0 105.772 -163.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.26 -15.0 12.94 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 117.809 -1.55 . . . . 0.0 116.569 177.57 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.5 mtt85 -87.01 -175.4 5.34 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 125.642 1.577 . . . . 0.0 110.147 177.334 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -140.31 126.9 20.27 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 119.382 0.992 . . . . 0.0 111.718 -174.114 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -95.08 141.64 28.48 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.937 1.295 . . . . 0.0 110.056 -177.516 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.43 136.0 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.235 1.014 . . . . 0.0 109.146 177.237 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -93.55 140.95 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-O 122.438 1.113 . . . . 0.0 110.454 170.208 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -130.97 165.51 23.0 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.147 1.779 . . . . 0.0 111.223 -170.706 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -84.07 -37.86 21.53 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -170.215 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 87.3 mttt -102.35 144.13 31.22 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 119.172 0.896 . . . . 0.0 112.369 -174.231 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 123' ' ' ALA . . . . . 0.429 ' O ' HD11 ' B' ' 126' ' ' LEU . . . -77.66 54.86 1.26 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.004 1.321 . . . . 0.0 112.33 168.853 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.29 -12.06 17.52 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.742 2.017 . . . . 0.0 114.524 -177.853 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 125' ' ' ASP . . . . . 0.455 ' HA ' ' HE2' ' B' ' 71' ' ' HIS . 20.9 t70 -65.25 -7.11 11.58 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 125.435 1.494 . . . . 0.0 114.637 -171.551 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.599 ' H ' HD13 ' B' ' 126' ' ' LEU . 0.0 OUTLIER -84.83 42.54 0.93 Allowed 'General case' 0 C--N 1.32 -0.685 0 O-C-N 119.383 -2.073 . . . . 0.0 114.789 179.168 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 63.14 8.41 23.45 Favored Glycine 0 N--CA 1.473 1.152 0 N-CA-C 117.401 1.72 . . . . 0.0 117.401 166.818 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 53.2 tttp -154.86 -59.25 0.11 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.54 1.136 . . . . 0.0 112.178 -167.889 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 37.99 -119.45 0.77 Allowed Glycine 0 CA--C 1.529 0.91 0 C-N-CA 126.071 1.796 . . . . 0.0 113.487 177.356 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -107.66 -22.81 7.15 Favored Glycine 0 CA--C 1.534 1.231 0 CA-C-O 117.75 -1.583 . . . . 0.0 116.9 -177.562 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -161.44 -178.08 6.4 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 121.22 2.51 . . . . 0.0 112.582 -172.073 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -47.49 -58.32 4.35 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 127.119 2.167 . . . . 0.0 113.128 -172.863 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -52.33 -21.01 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 115.37 1.618 . . . . 0.0 115.37 177.737 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 m -70.11 -27.33 64.5 Favored 'General case' 0 CA--C 1.549 0.905 0 O-C-N 119.644 -1.91 . . . . 0.0 112.526 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.5 t -79.67 -14.85 58.48 Favored 'General case' 0 N--CA 1.491 1.591 0 CA-C-N 119.853 1.206 . . . . 0.0 112.529 168.362 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mtpt -102.04 -91.44 0.33 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.285 1.834 . . . . 0.0 111.998 -177.853 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.2 p -74.88 -22.16 58.81 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 119.887 1.221 . . . . 0.0 113.986 178.532 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.96 3.46 62.02 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-O 115.497 -2.835 . . . . 0.0 111.145 -167.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 63.75 -68.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.167 2.587 . . . . 0.0 110.12 172.267 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 70.26 -15.56 0.34 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.689 2.796 . . . . 0.0 115.109 162.138 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.59 -53.34 4.51 Favored Glycine 0 N--CA 1.473 1.117 0 C-N-CA 126.936 2.207 . . . . 0.0 115.417 174.239 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.5 t -161.65 -166.1 1.42 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.685 0.794 . . . . 0.0 111.058 175.139 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.461 ' HE ' ' N ' ' B' ' 143' ' ' ARG . 0.1 OUTLIER -132.22 142.87 49.59 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.376 1.87 . . . . 0.0 107.35 176.639 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -127.23 -105.37 0.32 Allowed 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.789 1.236 . . . . 0.0 109.663 175.667 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.87 161.85 26.45 Favored 'General case' 0 CA--C 1.544 0.718 0 CA-C-N 120.295 1.407 . . . . 0.0 113.9 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.5 p -152.83 142.74 22.15 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.699 1.6 . . . . 0.0 111.116 -169.141 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.04 126.61 1.78 Allowed Glycine 0 C--N 1.338 0.692 0 N-CA-C 115.86 1.104 . . . . 0.0 115.86 -169.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -79.01 144.97 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 123.81 0.844 . . . . 0.0 109.243 -179.735 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 26.4 mt -92.25 126.15 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 C-N-CA 124.622 1.169 . . . . 0.0 112.214 -179.507 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.92 171.99 14.04 Favored Glycine 0 CA--C 1.538 1.505 0 N-CA-C 117.214 1.646 . . . . 0.0 117.214 172.131 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -87.43 107.83 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.019 1.328 . . . . 0.0 112.564 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.491 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -79.69 -5.03 54.35 Favored 'General case' 0 CA--C 1.554 1.111 0 O-C-N 121.133 -0.979 . . . . 0.0 111.122 166.757 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 . . . . . 0 N--CA 1.47 0.529 0 C-N-CA 131.259 3.824 . . . . 0.0 111.103 172.05 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 CA-C-O 120.314 0.102 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.7 p -77.08 65.16 2.66 Favored 'General case' 0 CA--C 1.54 0.562 0 N-CA-C 116.414 2.005 . . . . 0.0 116.414 -165.846 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.279 0.0 OUTLIER -155.7 117.85 4.1 Favored 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 117.573 2.435 . . . . 0.0 117.573 168.072 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.1 156.77 36.02 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.062 2.545 . . . . 0.0 106.403 164.077 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 32.3 t -154.7 155.07 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 120.148 1.34 . . . . 0.0 114.248 -164.891 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.87 128.13 33.99 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 125.892 1.677 . . . . 0.0 110.285 168.045 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.05 92.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 127.154 2.181 . . . . 0.0 108.59 176.822 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -77.01 149.18 35.9 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 125.936 1.694 . . . . 0.0 112.624 -167.509 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -155.35 153.58 30.7 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.127 0.971 . . . . 0.0 111.84 171.012 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.4 -110.61 3.18 Favored Glycine 0 N--CA 1.466 0.684 1 N-CA-C 101.753 -4.539 . . . . 0.0 101.753 162.73 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . 0.276 0.3 OUTLIER -155.62 148.46 24.29 Favored 'General case' 0 N--CA 1.442 -0.86 0 C-N-CA 124.886 1.275 . . . . 0.0 108.959 162.143 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.23 -170.83 36.25 Favored Glycine 0 CA--C 1.54 1.624 0 N-CA-C 107.666 -2.173 . . . . 0.0 107.666 -163.993 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.74 37.68 0.43 Allowed 'Trans proline' 0 CA--C 1.545 1.063 1 C-N-CA 125.459 4.106 . . . . 0.0 114.308 -171.802 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -108.61 122.44 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.062 1.745 . . . . 0.0 108.433 172.672 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 20.6 mp0 -145.92 166.49 25.84 Favored 'General case' 0 CA--C 1.519 -0.25 0 C-N-CA 125.52 1.528 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 131.81 3.0 Favored Glycine 0 C--O 1.224 -0.521 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.986 167.732 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.63 131.23 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 O-C-N 121.511 -0.994 . . . . 0.0 109.266 168.416 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.2 mm -131.06 122.62 52.1 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 167.81 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 40.8 m-20 -112.25 141.4 46.01 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 125.481 1.512 . . . . 0.0 111.813 169.054 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -116.93 108.76 16.19 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.906 1.682 . . . . 0.0 110.357 176.836 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HB2' ' CH2' ' A' ' 32' ' ' TRP . 0.0 OUTLIER -87.76 118.94 27.61 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 127.073 2.149 . . . . 0.0 109.978 169.62 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.568 ' HB3' HD11 ' A' ' 106' ' ' LEU . 19.5 tp60 -148.69 140.29 23.53 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.678 0.791 . . . . 0.0 109.321 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.82 -28.25 14.34 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -169.727 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.75 -139.86 0.1 Allowed 'General case' 0 CA--C 1.556 1.181 0 C-N-CA 125.494 1.518 . . . . 0.0 111.41 170.765 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.0 p -113.16 -11.73 13.24 Favored 'General case' 0 N--CA 1.482 1.14 0 O-C-N 118.987 -2.321 . . . . 0.0 115.758 -170.371 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -128.2 -16.67 4.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.453 1.901 . . . . 0.0 112.882 -177.579 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 171.08 48.05 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.548 1.547 . . . . 0.0 112.446 177.741 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -85.13 140.42 7.66 Favored 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 122.268 1.979 . . . . 0.0 111.856 -169.26 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -101.6 132.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.703 1.201 . . . . 0.0 109.487 -173.137 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.427 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 4.5 ttmp? -92.37 126.21 37.35 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.832 1.253 . . . . 0.0 109.178 169.344 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.8 t -110.19 127.78 66.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 126.069 1.748 . . . . 0.0 109.581 177.753 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.468 ' CH2' ' HB2' ' A' ' 21' ' ' GLU . 6.0 p90 -135.92 159.51 41.46 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.172 0.989 . . . . 0.0 111.434 170.342 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.64 -176.72 27.31 Favored Glycine 0 C--O 1.222 -0.651 0 O-C-N 121.718 -0.614 . . . . 0.0 114.041 -173.192 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.69 141.69 13.25 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.752 0.821 . . . . 0.0 111.543 -172.774 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mp -113.7 118.54 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 126.462 1.905 . . . . 0.0 109.315 -178.503 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -115.81 128.63 55.98 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 110.244 -171.606 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.23 6.34 9.02 Favored Glycine 0 N--CA 1.477 1.433 0 C-N-CA 125.568 1.556 . . . . 0.0 114.964 -177.89 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.574 HD23 HD11 ' A' ' 144' ' ' LEU . 31.6 mt -80.95 157.84 25.42 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.58 1.552 . . . . 0.0 111.609 173.599 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.9 t -75.41 151.95 38.07 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 163.398 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.58 147.05 23.26 Favored 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.593 1.088 . . . . 0.0 112.242 170.768 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 111.65 -175.74 17.67 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.854 1.216 . . . . 0.0 113.453 -174.791 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.5 mt -77.27 154.39 33.0 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.595 1.158 . . . . 0.0 112.144 -174.953 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.425 ' CG ' HD22 ' A' ' 38' ' ' LEU . 91.7 m-70 -153.11 123.45 7.11 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 127.077 2.151 . . . . 0.0 110.13 -171.851 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.85 151.72 47.96 Favored Glycine 0 N--CA 1.474 1.218 0 CA-C-N 120.167 1.349 . . . . 0.0 112.439 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.32 0.0 OUTLIER -146.19 140.2 26.44 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 166.119 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.51 153.54 38.59 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 120.998 -1.064 . . . . 0.0 112.031 -166.63 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 m -80.0 152.54 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 122.698 0.399 . . . . 0.0 110.526 168.109 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -93.98 167.98 11.25 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.052 1.741 . . . . 0.0 113.297 175.374 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -65.96 87.77 0.1 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.511 3.124 . . . . 0.0 109.596 170.115 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 74.2 177.96 0.22 Allowed 'General case' 0 C--N 1.347 0.491 0 CA-C-O 123.072 1.415 . . . . 0.0 112.848 168.884 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -95.23 -4.28 61.22 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 125.435 1.493 . . . . 0.0 111.143 168.128 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -66.98 64.79 0.06 Allowed 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 128.844 2.858 . . . . 0.0 109.817 169.261 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 167.53 -39.02 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.505 2.722 . . . . 0.0 114.714 179.364 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.36 0.5 OUTLIER 55.02 -58.48 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 130.303 3.441 . . . . 0.0 116.327 -174.829 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -68.47 4.22 1.45 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.264 1.426 . . . . 0.0 113.916 179.746 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.436 ' HA3' HG21 ' A' ' 116' ' ' THR . . . 62.89 -126.36 36.71 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 124.91 1.243 . . . . 0.0 111.394 171.023 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.66 -8.48 0.39 Allowed 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 117.302 2.334 . . . . 0.0 117.302 -171.753 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.9 t -107.31 -2.13 20.99 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.544 1.52 . . . . 0.0 114.815 171.522 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.6 m -119.01 -37.83 3.16 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.641 1.576 . . . . 0.0 112.699 173.212 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.57 170.87 15.35 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.2 1.8 . . . . 0.0 110.869 175.396 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -109.8 -69.81 0.63 Allowed Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.549 1.38 . . . . 0.0 116.549 -168.637 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -87.07 -174.16 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.47 1 C-N-CA 125.473 4.115 . . . . 0.0 114.234 -169.407 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -104.01 132.38 50.32 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 127.666 2.386 . . . . 0.0 111.781 -175.831 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -46.9 114.11 0.78 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.579 1.552 . . . . 0.0 111.484 168.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 54.0 p30 -112.3 32.04 0.11 Allowed Pre-proline 0 CA--C 1.555 1.148 0 N-CA-C 116.734 2.124 . . . . 0.0 116.734 -167.944 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -56.63 -23.12 47.22 Favored 'Trans proline' 0 C--N 1.354 0.86 0 C-N-CA 124.915 3.743 . . . . 0.0 117.319 -164.957 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.478 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 4.5 mm? -78.39 -0.41 29.02 Favored 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 174.711 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.7 t 66.58 55.5 0.79 Allowed 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 126.886 2.074 . . . . 0.0 110.318 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.478 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.5 ptp180 -143.36 170.99 14.74 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -165.93 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.31 0.0 OUTLIER -85.43 -178.64 6.76 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.365 1.866 . . . . 0.0 113.514 172.79 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.477 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 78.2 t60 -99.42 139.78 34.58 Favored 'General case' 0 C--O 1.22 -0.487 0 C-N-CA 125.876 1.67 . . . . 0.0 112.747 -170.806 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.89 -143.95 11.38 Favored Glycine 0 C--N 1.34 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 113.902 173.808 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.06 -75.93 0.21 Allowed Glycine 0 CA--C 1.535 1.293 0 N-CA-C 118.594 2.198 . . . . 0.0 118.594 -175.989 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -70.85 -11.73 29.82 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.954 2.436 . . . . 0.0 113.054 -171.089 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -130.05 -0.78 4.67 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.684 1.593 . . . . 0.0 111.238 168.25 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.73 122.97 25.37 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 124.053 1.882 . . . . 0.0 111.801 -167.564 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.1 -27.77 69.62 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 129.815 3.246 . . . . 0.0 111.717 169.115 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -88.31 76.35 8.38 Favored 'General case' 0 C--O 1.214 -0.776 0 C-N-CA 126.319 1.848 . . . . 0.0 108.192 177.613 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.6 ttt180 -111.51 110.64 21.17 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 129.599 3.16 . . . . 0.0 109.022 -178.464 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -59.95 159.9 8.57 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 119.385 0.993 . . . . 0.0 112.597 169.925 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 m -43.1 -57.37 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -173.161 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.2 31.53 8.54 Favored Glycine 0 N--CA 1.472 1.067 0 C-N-CA 125.064 1.316 . . . . 0.0 113.298 172.963 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -76.94 121.97 24.21 Favored 'General case' 0 C--O 1.237 0.408 0 O-C-N 120.942 -1.328 . . . . 0.0 108.253 169.744 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -95.76 176.82 5.99 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 112.854 -1.975 . . . . 0.0 109.149 167.525 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.73 23.99 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 124.305 0.955 . . . . 0.0 113.371 -175.341 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -83.9 126.19 32.74 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 121.675 -0.897 . . . . 0.0 108.91 167.843 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.98 170.59 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 164.235 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 t -145.02 127.73 16.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 124.683 1.193 . . . . 0.0 109.751 174.941 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.2 144.85 26.64 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 113.183 0.809 . . . . 0.0 113.183 174.417 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -67.47 170.96 6.65 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.191 1.796 . . . . 0.0 110.946 168.528 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.76 -32.15 29.61 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.753 1.221 . . . . 0.0 112.854 168.527 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -73.41 -15.49 61.35 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.938 1.695 . . . . 0.0 112.283 177.123 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.22 14.47 64.13 Favored Glycine 0 CA--C 1.527 0.808 0 O-C-N 120.832 -1.167 . . . . 0.0 113.43 179.167 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.6 p -96.71 125.22 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 124.226 1.011 . . . . 0.0 109.916 168.209 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.69 122.0 43.09 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 168.229 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -88.99 145.29 25.59 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 123.089 1.423 . . . . 0.0 110.145 -179.314 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.77 125.69 74.56 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.002 172.954 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.4 m -155.13 85.77 1.09 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.126 1.77 . . . . 0.0 108.67 -173.121 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 12.9 mt -140.13 154.64 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 127.308 2.243 . . . . 0.0 111.53 -169.208 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.427 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 15.7 tt0 -140.91 144.86 35.44 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.593 1.557 . . . . 0.0 108.233 168.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.98 144.84 21.59 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.624 1.169 . . . . 0.0 113.386 -166.821 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 55.2 p -116.7 49.37 1.17 Allowed 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -179.687 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.2 m -149.06 16.23 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 176.055 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.35 168.69 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 120.49 -1.381 . . . . 0.0 111.037 171.295 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.568 ' H ' ' HB3' ' A' ' 111' ' ' SER . 86.3 p -154.91 161.24 41.49 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.265 -0.897 . . . . 0.0 112.602 169.144 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.568 HD11 ' HB3' ' A' ' 22' ' ' GLN . 0.0 OUTLIER -92.53 50.89 1.66 Allowed 'General case' 0 CA--C 1.542 0.636 0 O-C-N 121.15 -0.969 . . . . 0.0 111.44 175.732 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.1 t -87.85 -40.91 13.62 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.436 1.094 . . . . 0.0 112.925 178.725 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.46 12.27 38.95 Favored Glycine 0 N--CA 1.478 1.494 0 N-CA-C 115.535 0.974 . . . . 0.0 115.535 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -89.54 -92.71 0.12 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.581 2.352 . . . . 0.0 111.006 -179.672 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -96.65 -24.96 15.75 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 126.585 1.954 . . . . 0.0 109.291 174.283 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.568 ' HB3' ' H ' ' A' ' 105' ' ' SER . 53.4 m -79.16 -142.14 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.07 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -168.001 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.7 pt -94.98 -21.46 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -166.414 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mm -63.75 141.97 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.811 1.187 . . . . 0.0 109.666 170.844 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.13 28.08 62.93 Favored Glycine 0 CA--C 1.503 -0.663 0 CA-C-O 116.701 -2.166 . . . . 0.0 113.446 177.475 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 84.7 mtt-85 -129.78 178.31 6.61 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.532 1.666 . . . . 0.0 108.515 171.741 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.436 HG21 ' HA3' ' A' ' 56' ' ' GLY . 89.4 m -117.19 145.36 43.91 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 119.328 0.967 . . . . 0.0 110.02 179.179 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.1 tp -108.31 134.14 51.55 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 119.074 0.852 . . . . 0.0 109.511 169.408 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -110.33 144.62 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.822 1.649 . . . . 0.0 110.643 172.619 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.99 142.24 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.903 1.281 . . . . 0.0 110.226 170.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -119.2 147.14 44.56 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.656 1.583 . . . . 0.0 114.563 -166.523 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -85.34 -17.29 37.23 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -166.73 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.9 169.48 8.89 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 120.087 -1.633 . . . . 0.0 111.082 172.718 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.6 133.6 55.84 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 168.727 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 40.2 t0 -83.36 154.03 24.26 Favored 'General case' 0 CA--C 1.54 0.571 0 O-C-N 123.272 0.357 . . . . 0.0 110.293 169.435 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -75.58 -50.9 14.16 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 165.973 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.2 mt 94.79 63.08 0.0 OUTLIER 'General case' 0 C--O 1.222 -0.358 0 C-N-CA 129.296 3.039 . . . . 0.0 109.299 -178.952 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.7 -25.63 16.58 Favored Glycine 0 N--CA 1.481 1.635 0 N-CA-C 117.069 1.588 . . . . 0.0 117.069 167.636 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -118.35 -144.96 0.37 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.181 1.792 . . . . 0.0 110.897 172.148 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.08 7.97 60.62 Favored Glycine 0 CA--C 1.536 1.352 0 O-C-N 120.356 -1.465 . . . . 0.0 113.23 -168.636 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.47 31.41 68.32 Favored Glycine 0 N--CA 1.472 1.057 0 N-CA-C 116.996 1.558 . . . . 0.0 116.996 167.802 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -150.1 172.6 15.01 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 119.856 1.828 . . . . 0.0 113.108 -173.514 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -47.91 -58.69 4.07 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.953 1.701 . . . . 0.0 112.938 176.599 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -65.1 -17.01 64.1 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.165 0.986 . . . . 0.0 113.433 -173.246 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.5 p -53.52 -45.74 69.85 Favored 'General case' 0 N--CA 1.469 0.494 0 O-C-N 120.824 -1.173 . . . . 0.0 113.089 174.245 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -96.31 -6.86 36.79 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.875 0.87 . . . . 0.0 112.018 -178.861 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.93 -48.2 5.52 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.708 1.14 . . . . 0.0 112.618 176.605 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 19.9 p -114.61 -25.14 8.44 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 174.867 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.477 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 121.97 -30.73 5.18 Favored Glycine 0 C--O 1.228 -0.226 0 C-N-CA 126.09 1.805 . . . . 0.0 112.356 -168.061 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 57.6 t30 114.08 2.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 131.601 3.96 . . . . 0.0 112.645 -174.566 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.5 1.27 0.02 OUTLIER 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 120.251 3.426 . . . . 0.0 120.251 -168.692 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.59 -32.68 0.17 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 120.985 3.154 . . . . 0.0 120.985 165.82 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.0 m -167.4 141.36 3.64 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 120.272 2.036 . . . . 0.0 111.581 -172.227 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.53 134.68 54.83 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.741 1.155 . . . . 0.0 112.214 178.319 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.574 HD11 HD23 ' A' ' 38' ' ' LEU . 2.3 pt? -110.36 -22.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.08 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.71 161.19 13.25 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 119.95 1.25 . . . . 0.0 112.46 -177.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.9 p -155.47 166.76 32.55 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.332 1.453 . . . . 0.0 112.763 172.926 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.44 136.84 4.83 Favored Glycine 0 N--CA 1.48 1.579 0 C-N-CA 125.287 1.422 . . . . 0.0 113.583 177.168 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -83.6 133.48 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.469 1.108 . . . . 0.0 110.641 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.49 110.13 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.023 0.929 . . . . 0.0 111.301 -172.016 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.74 170.14 13.31 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 122.76 1.2 . . . . 0.0 113.916 173.268 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.0 pp -91.25 164.03 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.672 1.189 . . . . 0.0 112.137 -174.258 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.483 ' HA ' ' CD1' ' B' ' 50' ' ' PHE . . . -155.53 -20.61 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 167.072 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.476 0.832 0 C-N-CA 124.521 1.128 . . . . 0.0 110.166 170.366 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.7 t -80.26 118.78 22.23 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 167.507 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.87 121.37 45.09 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -178.885 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.03 166.2 11.38 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.861 1.264 . . . . 0.0 110.794 168.101 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.74 146.07 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 125.477 1.511 . . . . 0.0 111.903 -166.722 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.0 101.2 3.99 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 123.756 0.822 . . . . 0.0 111.269 169.621 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -84.02 95.5 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 168.031 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.4 mt -81.34 140.25 34.88 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 122.784 0.434 . . . . 0.0 110.78 -177.043 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 9.0 mtpp -149.24 179.26 8.05 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 121.166 -0.959 . . . . 0.0 112.81 170.913 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.43 -70.79 0.29 Allowed Glycine 0 C--N 1.335 0.505 0 C-N-CA 126.393 1.949 . . . . 0.0 111.238 178.98 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -87.09 78.83 8.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.78 0.8 . . . . 0.0 112.715 -165.373 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 49.09 -104.22 0.09 OUTLIER Glycine 0 CA--C 1.534 1.249 0 C-N-CA 126.565 2.031 . . . . 0.0 112.623 171.514 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -80.01 -1.2 11.24 Favored 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 125.181 3.921 . . . . 0.0 114.176 -179.24 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.49 134.62 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 119.715 1.143 . . . . 0.0 110.8 171.84 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -135.51 161.92 34.13 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 125.843 1.657 . . . . 0.0 109.939 168.231 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.5 144.8 16.44 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 167.205 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -142.18 102.04 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.624 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -122.4 137.6 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 C-N-CA 123.957 0.903 . . . . 0.0 109.394 -179.76 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.36 152.41 34.99 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.058 2.143 . . . . 0.0 109.147 172.131 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -138.89 89.29 2.35 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.215 1.806 . . . . 0.0 107.66 -174.81 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.8 120.31 33.9 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 118.084 0.402 . . . . 0.0 110.07 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -112.52 141.46 46.25 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 122.578 1.18 . . . . 0.0 112.18 174.41 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.36 -26.8 24.64 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 126.571 1.949 . . . . 0.0 114.18 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 5.8 mp0 -122.94 -174.11 2.86 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.235 2.214 . . . . 0.0 109.885 174.506 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.2 m -98.52 -14.5 19.97 Favored 'General case' 0 N--CA 1.481 1.099 0 O-C-N 120.54 -1.35 . . . . 0.0 111.639 167.08 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -139.47 105.55 5.22 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.198 2.599 . . . . 0.0 107.181 169.34 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.61 -168.42 41.49 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 126.066 1.794 . . . . 0.0 110.637 -170.784 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -85.57 150.61 10.19 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.529 2.153 . . . . 0.0 111.848 -179.268 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 10.2 t -119.36 129.32 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.135 1.374 . . . . 0.0 110.111 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.6 ttmm -93.53 120.89 34.35 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.091 0.948 . . . . 0.0 110.514 174.47 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.3 t -106.25 112.54 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 C-N-CA 126.321 1.848 . . . . 0.0 108.046 -171.713 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -137.74 161.18 37.22 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -177.57 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 136.62 -139.72 10.87 Favored Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.533 1.539 . . . . 0.0 111.351 175.62 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 47.3 p -156.47 156.73 34.24 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 114.711 1.375 . . . . 0.0 114.711 -174.862 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 24.7 mm -123.43 126.64 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 168.692 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . 0.282 3.5 ptmt -140.33 157.21 45.91 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 115.313 1.597 . . . . 0.0 115.313 -177.534 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.23 6.4 33.9 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 127.103 2.287 . . . . 0.0 111.916 -167.872 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 144' ' ' LEU . 1.5 mt -94.79 172.27 8.27 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.992 1.317 . . . . 0.0 111.769 -172.751 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.27 150.65 36.95 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 165.427 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -53.3 -0.27 0.02 OUTLIER 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 129.796 3.238 . . . . 0.0 115.86 170.63 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -69.46 177.28 29.96 Favored Glycine 0 CA--C 1.537 1.43 0 O-C-N 120.149 -1.594 . . . . 0.0 113.605 169.587 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.456 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.0 mp -78.37 160.0 28.04 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.381 1.472 . . . . 0.0 108.727 168.452 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -149.64 109.72 4.13 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.761 2.424 . . . . 0.0 109.857 -170.155 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.56 130.22 17.69 Favored Glycine 0 N--CA 1.477 1.37 0 CA-C-N 119.938 1.244 . . . . 0.0 111.864 176.955 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.493 ' CB ' HG22 ' B' ' 119' ' ' VAL . 35.3 p90 -125.62 137.73 53.89 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 120.151 1.976 . . . . 0.0 113.419 174.095 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.86 144.49 29.33 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.201 -0.937 . . . . 0.0 113.325 -176.021 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -81.27 136.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 166.075 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -74.74 168.4 19.92 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.826 1.25 . . . . 0.0 110.833 175.619 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.1 pm0 -59.61 -14.83 15.07 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -169.921 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 50' ' ' PHE . . . . . 0.483 ' CD1' ' HA ' ' A' ' 152' ' ' ALA . 31.3 m-85 -169.83 -179.26 3.21 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 129.147 2.979 . . . . 0.0 108.216 -168.849 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -125.92 11.32 7.39 Favored Glycine 0 N--CA 1.475 1.291 0 C-N-CA 125.505 1.526 . . . . 0.0 113.89 179.714 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -73.5 45.02 0.17 Allowed 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.755 1.222 . . . . 0.0 110.347 167.076 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -173.55 55.72 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 123.693 1.711 . . . . 0.0 114.726 -162.765 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 1.1 t -76.62 13.59 0.96 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.592 1.957 . . . . 0.0 114.492 -179.647 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 55' ' ' ALA . . . . . 0.437 ' HB1' ' HB ' ' B' ' 58' ' ' THR . . . -113.8 3.16 15.39 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 115.223 1.564 . . . . 0.0 115.223 -170.905 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.33 -117.0 10.16 Favored Glycine 0 CA--C 1.527 0.838 0 O-C-N 121.343 -0.848 . . . . 0.0 111.495 174.733 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.7 p -51.46 -20.01 1.65 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.493 1.517 . . . . 0.0 115.043 174.334 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 58' ' ' THR . . . . . 0.437 ' HB ' ' HB1' ' B' ' 55' ' ' ALA . 60.0 m -104.02 -4.6 23.11 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.171 1.388 . . . . 0.0 112.693 -177.051 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m 168.08 106.37 0.01 OUTLIER 'General case' 0 C--O 1.235 0.299 0 C-N-CA 128.638 2.775 . . . . 0.0 106.401 177.033 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.48 98.49 0.19 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.815 2.046 . . . . 0.0 109.895 173.509 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -62.92 123.17 29.64 Favored Glycine 0 CA--C 1.543 1.843 0 CA-C-O 116.943 -2.032 . . . . 0.0 111.785 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.48 59.67 7.54 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 124.631 3.554 . . . . 0.0 116.632 -165.057 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.296 11.9 p80 52.7 59.01 4.78 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.19 2.596 . . . . 0.0 113.821 177.021 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 64' ' ' PHE . . . . . 0.413 ' CG ' ' N ' ' B' ' 65' ' ' ASN . 22.9 t80 -50.25 165.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 128.243 2.617 . . . . 0.0 114.938 177.553 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 65' ' ' ASN . . . . . 0.413 ' N ' ' CG ' ' B' ' 64' ' ' PHE . 1.0 OUTLIER -100.19 60.12 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.425 0 C-N-CA 131.296 3.838 . . . . 0.0 114.058 -170.078 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.02 -26.59 66.01 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.747 2.298 . . . . 0.0 113.764 -176.949 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.34 -2.49 58.63 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 126.627 1.971 . . . . 0.0 113.165 172.696 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.5 t 59.43 49.75 8.36 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.564 1.946 . . . . 0.0 112.447 -173.201 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -117.17 170.41 8.69 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.264 1.209 . . . . 0.0 114.264 -179.607 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.404 ' HZ3' ' CG ' ' B' ' 76' ' ' ASP . 0.1 OUTLIER -73.18 164.82 26.13 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-O 122.75 1.262 . . . . 0.0 109.325 166.29 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.443 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 83.4 t60 -67.36 -176.17 0.56 Allowed 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.223 167.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.443 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 115.17 -128.93 8.32 Favored Glycine 0 CA--C 1.502 -0.723 0 N-CA-C 115.252 0.861 . . . . 0.0 115.252 164.305 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.05 -76.32 0.34 Allowed Glycine 0 CA--C 1.531 1.061 0 CA-C-O 118.002 -1.443 . . . . 0.0 111.749 -169.586 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.64 10.07 0.23 Allowed 'Trans proline' 0 CA--C 1.547 1.134 0 C-N-CA 124.302 3.335 . . . . 0.0 116.614 -178.766 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.5 tptm -166.07 -30.61 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.264 1.426 . . . . 0.0 112.48 -168.427 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.404 ' CG ' ' HZ3' ' B' ' 70' ' ' LYS . 8.6 t70 -125.03 119.12 27.79 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.579 1.552 . . . . 0.0 108.148 167.926 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -46.31 -17.86 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 130.156 3.383 . . . . 0.0 116.418 -174.319 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -85.36 -79.61 0.23 Allowed 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -169.587 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.505 ' HB3' HH11 ' B' ' 79' ' ' ARG . 1.1 ttp-105 78.42 110.71 0.07 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.734 1.614 . . . . 0.0 109.731 177.199 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -50.08 152.17 1.76 Allowed 'General case' 0 CA--C 1.549 0.937 0 O-C-N 120.566 -1.334 . . . . 0.0 113.494 172.224 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.7 t -52.82 -37.74 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 123.966 0.906 . . . . 0.0 112.434 176.958 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.78 96.79 1.21 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 108.264 -1.934 . . . . 0.0 108.264 167.345 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -156.2 146.29 21.36 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.96 1.304 . . . . 0.0 113.446 171.249 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 48.2 mt -130.82 167.06 19.52 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.203 1.801 . . . . 0.0 106.981 166.802 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -104.99 -161.82 23.8 Favored Glycine 0 N--CA 1.475 1.247 0 C-N-CA 124.67 1.128 . . . . 0.0 112.593 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -79.37 164.63 23.89 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 -177.283 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.467 HG22 ' HB1' ' B' ' 95' ' ' ALA . 2.9 p -125.99 157.29 36.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 C-N-CA 129.0 2.92 . . . . 0.0 108.524 166.235 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -135.15 133.72 39.44 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.068 0.947 . . . . 0.0 109.799 -177.205 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.05 158.49 15.41 Favored 'General case' 0 C--O 1.222 -0.347 0 N-CA-C 114.065 1.135 . . . . 0.0 114.065 -172.966 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -97.63 155.47 16.97 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.645 1.578 . . . . 0.0 108.718 166.406 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 6.2 pttm -47.2 -25.32 0.89 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 128.936 2.894 . . . . 0.0 115.249 -177.5 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.67 3.23 10.07 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.319 1.448 . . . . 0.0 110.986 178.294 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.18 2.42 60.68 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 129.765 3.555 . . . . 0.0 113.726 172.936 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.2 p -114.64 131.92 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-N 119.937 1.869 . . . . 0.0 114.889 -168.36 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.467 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -98.37 128.8 44.94 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.003 -1.453 . . . . 0.0 108.728 166.236 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -82.27 146.33 29.51 Favored 'General case' 0 N--CA 1.46 0.073 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 168.005 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.263 0.3 OUTLIER -129.36 135.62 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 114.289 -1.323 . . . . 0.0 114.252 166.285 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 2.9 p -157.2 57.13 0.52 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 125.591 1.556 . . . . 0.0 110.759 -169.984 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.3 mt -109.04 166.55 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 127.654 2.381 . . . . 0.0 111.593 -169.746 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -148.39 149.82 32.43 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 127.753 2.421 . . . . 0.0 109.081 171.881 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -146.63 145.46 30.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.36 1.464 . . . . 0.0 110.108 172.051 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.8 p -118.61 58.6 0.83 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.94 2.096 . . . . 0.0 113.041 -168.477 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 5.9 p -159.34 -37.18 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 113.27 0.841 . . . . 0.0 113.27 172.987 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.69 166.79 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-O 121.327 0.584 . . . . 0.0 110.773 171.444 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 36.8 m -156.57 175.8 13.55 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 120.752 -1.218 . . . . 0.0 112.615 178.983 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 106' ' ' LEU . . . . . 0.409 ' HA ' HG12 ' B' ' 113' ' ' ILE . 9.6 mp -92.61 76.35 5.02 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.664 1.586 . . . . 0.0 107.448 175.458 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.27 122.7 32.3 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.359 1.463 . . . . 0.0 108.077 -176.409 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.99 59.68 4.97 Favored Glycine 0 N--CA 1.471 1.021 0 C-N-CA 125.152 1.358 . . . . 0.0 112.976 -169.721 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -156.26 -76.62 0.09 Allowed 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 124.467 1.107 . . . . 0.0 110.347 -168.704 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -129.66 4.88 5.06 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 126.979 2.111 . . . . 0.0 112.559 -167.625 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.6 -151.92 0.47 Allowed 'General case' 0 CA--C 1.555 1.173 0 C-N-CA 127.651 2.381 . . . . 0.0 112.835 -166.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.8 pt -95.88 -5.35 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 118.718 -2.488 . . . . 0.0 115.657 -177.714 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 113' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' B' ' 106' ' ' LEU . 4.2 mm -67.4 129.28 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 165.095 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 66.41 51.25 44.33 Favored Glycine 0 C--O 1.225 -0.439 0 CA-C-O 117.854 -1.526 . . . . 0.0 112.541 178.043 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 25.7 mtt180 -129.19 145.61 51.28 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 118.346 1.073 . . . . 0.0 110.095 167.332 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 116' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 24.6 m -86.86 108.91 18.97 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 124.378 1.071 . . . . 0.0 109.628 -171.886 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 14.6 tp -91.6 125.07 36.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 120.441 1.473 . . . . 0.0 110.854 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -110.82 142.27 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.584 1.553 . . . . 0.0 110.315 170.424 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.493 HG22 ' CB ' ' B' ' 45' ' ' PHE . 59.0 t -112.74 144.07 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 165.338 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -109.76 160.9 15.93 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 126.584 1.953 . . . . 0.0 112.182 -172.235 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.265 1.8 pp20? -82.43 -17.77 44.2 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -172.09 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -113.97 172.87 6.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 176.713 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.16 164.31 1.77 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 124.475 1.11 . . . . 0.0 109.899 166.789 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.2 p30 -113.66 147.12 38.7 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 123.237 1.494 . . . . 0.0 112.531 170.971 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -86.86 -22.69 25.62 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.134 1.374 . . . . 0.0 111.077 171.749 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 54.9 mt 71.41 -29.63 0.2 Allowed 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 128.765 2.826 . . . . 0.0 114.503 169.506 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -159.52 -47.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.701 0 CA-C-N 120.844 1.657 . . . . 0.0 114.594 174.052 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.08 100.21 2.9 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 117.254 2.316 . . . . 0.0 117.254 -168.465 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.17 -76.84 1.34 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 107.131 -2.388 . . . . 0.0 107.131 166.687 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -179.52 27.83 0.05 OUTLIER Glycine 0 CA--C 1.532 1.103 0 C-N-CA 126.382 1.944 . . . . 0.0 112.956 175.946 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -146.34 172.84 12.89 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.998 1.719 . . . . 0.0 111.08 -167.309 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -64.58 -63.06 1.22 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 110.814 -170.453 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 133' ' ' GLU . . . . . 0.423 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 0.8 OUTLIER -56.18 -23.64 36.39 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 128.935 2.894 . . . . 0.0 111.916 -173.558 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 52.2 m -53.58 -49.82 66.93 Favored 'General case' 0 N--CA 1.462 0.14 0 C-N-CA 123.721 0.808 . . . . 0.0 112.425 168.383 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 44.2 p -91.21 -34.5 14.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.158 1.383 . . . . 0.0 110.699 -174.375 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -81.9 -31.74 31.29 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.143 2.177 . . . . 0.0 113.085 -171.275 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.8 p -125.24 -93.3 0.5 Allowed 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 169.281 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -174.0 22.22 0.06 OUTLIER Glycine 0 CA--C 1.53 1.019 0 C-N-CA 128.647 3.022 . . . . 0.0 111.58 169.688 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 56.67 4.04 0.14 Allowed 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 127.83 2.452 . . . . 0.0 116.545 -169.307 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.98 -5.88 0.03 OUTLIER 'General case' 0 CA--C 1.557 1.226 0 N-CA-C 119.865 3.284 . . . . 0.0 119.865 -168.337 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 88.12 -165.95 34.85 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.718 1.628 . . . . 0.0 113.661 -176.966 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 18.7 t -66.86 160.61 25.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 122.14 0.971 . . . . 0.0 111.284 173.598 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.7 ptt85 -67.38 164.16 19.19 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 122.356 1.074 . . . . 0.0 111.684 169.765 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 38' ' ' LEU 0.316 2.9 pp -135.55 -134.7 0.15 Allowed 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 104.229 -2.508 . . . . 0.0 104.229 160.175 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.75 154.88 8.41 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-N 120.536 1.516 . . . . 0.0 114.678 -178.697 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.1 t -151.0 143.94 24.58 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.658 1.983 . . . . 0.0 111.212 -172.677 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.29 144.25 9.51 Favored Glycine 0 N--CA 1.477 1.39 0 C-N-CA 125.507 1.527 . . . . 0.0 113.465 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 20.5 t -83.47 141.57 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 CA-C-N 119.268 1.534 . . . . 0.0 110.592 177.451 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 73.8 mt -75.32 106.76 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 121.473 0.654 . . . . 0.0 109.65 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.7 -172.87 19.36 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 124.387 0.994 . . . . 0.0 111.793 168.174 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -100.01 149.24 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.87 0.843 . . . . 0.0 112.726 -176.952 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -103.22 -135.21 0.33 Allowed 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 166.62 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 N--CA 1.473 0.701 0 C-N-CA 126.001 1.72 . . . . 0.0 110.983 168.881 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 115.917 -1.992 . . . . 0.0 106.669 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m -90.74 97.14 11.0 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 122.12 2.236 . . . . 0.0 108.061 -179.472 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 42.8 pttt -83.12 139.49 33.16 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.933 1.349 . . . . 0.0 114.212 -172.042 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.458 ' CB ' HD11 ' A' ' 113' ' ' ILE . . . -99.08 146.03 26.51 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 127.369 2.268 . . . . 0.0 107.753 167.409 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 33.0 t -154.95 143.54 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 119.567 1.076 . . . . 0.0 110.993 -175.2 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.87 95.63 2.88 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 123.767 0.827 . . . . 0.0 110.504 169.116 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.8 m -76.15 92.7 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-O 122.127 0.965 . . . . 0.0 109.618 170.934 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.2 mt -76.52 139.01 40.59 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.006 0.922 . . . . 0.0 109.553 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.6 ttmm -155.45 177.62 11.16 Favored 'General case' 0 CA--C 1.542 0.672 0 O-C-N 120.753 -1.217 . . . . 0.0 109.765 179.648 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.03 -33.83 3.91 Favored Glycine 0 N--CA 1.472 1.076 0 C-N-CA 124.279 0.942 . . . . 0.0 114.341 169.16 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.85 65.7 5.09 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 122.299 1.047 . . . . 0.0 110.146 175.905 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.06 -101.94 0.03 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.081 2.753 . . . . 0.0 113.146 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -83.24 -2.84 10.79 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 124.66 3.573 . . . . 0.0 114.441 -178.346 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -95.28 137.42 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 CA-C-N 120.697 1.59 . . . . 0.0 111.156 176.987 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -144.56 161.86 38.05 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 125.918 1.687 . . . . 0.0 109.697 172.321 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -134.63 106.18 0.59 Allowed Glycine 0 CA--C 1.502 -0.723 0 C-N-CA 124.34 0.971 . . . . 0.0 111.314 177.779 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.2 117.47 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 167.862 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -135.9 106.94 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-O 121.616 0.722 . . . . 0.0 109.369 169.293 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 -100.22 139.7 35.52 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.687 1.595 . . . . 0.0 110.885 -179.585 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -120.46 135.56 55.02 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 119.091 0.86 . . . . 0.0 110.85 179.206 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -115.1 114.86 25.88 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 127.078 2.151 . . . . 0.0 109.852 -172.942 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.8 tp60 -125.92 130.9 52.21 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 113.51 -1.677 . . . . 0.0 109.828 -170.398 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.594 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -99.33 -11.74 20.94 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 128.147 2.579 . . . . 0.0 114.129 -168.771 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.413 ' CD ' ' H ' ' A' ' 25' ' ' SER . 5.3 tm-20 -149.25 -172.02 4.03 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 127.918 2.487 . . . . 0.0 108.681 -172.376 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.413 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 0.8 OUTLIER -72.34 -57.18 4.41 Favored 'General case' 0 N--CA 1.474 0.726 0 O-C-N 118.778 -2.451 . . . . 0.0 111.601 169.677 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -123.37 -3.16 8.43 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.73 1.612 . . . . 0.0 114.918 -169.271 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.36 161.48 6.98 Favored Glycine 0 CA--C 1.537 1.446 0 CA-C-N 119.224 0.92 . . . . 0.0 110.955 168.372 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -66.85 143.94 68.94 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.327 2.018 . . . . 0.0 110.61 -170.035 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 37.3 t -107.62 129.87 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 123.262 0.625 . . . . 0.0 110.158 -173.159 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -79.64 125.77 30.05 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 49.9 t -112.42 130.73 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 128.456 2.703 . . . . 0.0 108.154 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -155.41 165.79 35.54 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 119.577 1.081 . . . . 0.0 113.249 175.644 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.27 -155.95 26.76 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 123.902 0.763 . . . . 0.0 113.655 172.726 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.9 p -149.53 128.36 12.53 Favored 'General case' 0 C--O 1.239 0.528 0 C-N-CA 123.319 0.648 . . . . 0.0 112.367 -169.483 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.0 mp -104.52 106.6 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 123.697 0.799 . . . . 0.0 109.599 175.371 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 tttp -117.14 133.64 55.75 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.38 1.072 . . . . 0.0 112.894 -168.903 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.56 9.37 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 128.318 2.866 . . . . 0.0 113.623 -177.621 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.8 mt -77.86 174.71 10.74 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.097 2.159 . . . . 0.0 113.37 -175.862 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.36 148.71 22.13 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 162.284 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.589 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.0 OUTLIER -53.79 -2.01 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 129.222 3.009 . . . . 0.0 115.825 176.065 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.31 174.34 17.46 Favored Glycine 0 CA--C 1.536 1.404 0 O-C-N 120.251 -1.531 . . . . 0.0 113.29 169.212 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.718 HD23 ' H ' ' A' ' 42' ' ' LEU . 2.0 pt? -88.31 138.17 31.67 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.778 2.031 . . . . 0.0 109.997 171.053 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -130.87 149.23 52.6 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 129.018 2.927 . . . . 0.0 108.615 -171.723 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -112.09 135.09 12.48 Favored Glycine 0 N--CA 1.486 1.991 0 CA-C-O 116.861 -2.077 . . . . 0.0 111.405 -172.554 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -135.74 133.28 37.85 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 121.165 2.482 . . . . 0.0 114.956 179.073 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.42 26.77 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.027 1.331 . . . . 0.0 109.801 -170.781 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 116' ' ' THR . 0.3 OUTLIER -86.33 118.35 32.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.263 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.742 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.0 m170 -77.71 163.03 26.53 Favored 'General case' 0 CA--C 1.549 0.931 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 176.157 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.18 133.97 55.93 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.816 -0.553 . . . . 0.0 110.745 -176.83 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.465 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 43.0 m-85 71.02 165.32 0.29 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.612 2.365 . . . . 0.0 115.348 170.123 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.21 -3.55 19.16 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 126.434 1.969 . . . . 0.0 113.654 177.684 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.0 m-20 -72.91 46.79 0.17 Allowed 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.076 1.35 . . . . 0.0 110.59 170.015 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 174.45 40.1 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.635 2.374 . . . . 0.0 112.747 -167.541 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.0 t -53.71 19.97 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 129.78 3.232 . . . . 0.0 116.375 172.285 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.63 16.41 8.8 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 126.699 2.0 . . . . 0.0 112.715 -178.293 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.6 -144.02 41.42 Favored Glycine 0 N--CA 1.467 0.752 0 O-C-N 121.087 -1.008 . . . . 0.0 112.097 171.12 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 p -58.69 -23.24 59.12 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.748 1.018 . . . . 0.0 113.748 -178.011 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 13.0 t -90.52 42.64 1.11 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.364 1.066 . . . . 0.0 112.019 175.935 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 m 178.57 -35.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 129.577 3.151 . . . . 0.0 115.091 169.606 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.53 158.98 15.36 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -168.917 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.97 -153.93 17.76 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 126.004 1.764 . . . . 0.0 114.223 173.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -88.58 178.39 2.88 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 125.281 3.987 . . . . 0.0 112.107 -179.496 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.487 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 3.4 p80 -79.91 83.55 5.81 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 167.062 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -50.94 166.03 0.1 Allowed 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.34 2.256 . . . . 0.0 113.993 -174.153 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -108.11 57.84 0.23 Allowed Pre-proline 0 CA--C 1.552 1.031 0 C-N-CA 127.202 2.201 . . . . 0.0 112.25 -169.712 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -64.32 -28.82 63.52 Favored 'Trans proline' 0 C--N 1.354 0.838 0 CA-C-N 122.602 1.965 . . . . 0.0 113.272 -175.382 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.8 mp -82.13 -4.9 57.9 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.077 1.351 . . . . 0.0 113.171 170.533 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.8 t 65.37 54.15 1.2 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 127.242 2.217 . . . . 0.0 112.894 -175.916 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -121.51 174.37 6.82 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -170.912 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.7 mtmt -81.04 165.92 21.23 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.494 0.718 . . . . 0.0 110.719 167.18 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.445 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 73.8 t60 -71.02 175.21 5.35 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.643 0.735 . . . . 0.0 111.645 167.758 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.15 -138.16 9.92 Favored Glycine 0 CA--C 1.504 -0.599 0 C-N-CA 124.295 0.95 . . . . 0.0 112.173 167.629 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.78 -99.95 0.26 Allowed Glycine 0 CA--C 1.533 1.202 0 CA-C-O 115.811 -2.661 . . . . 0.0 109.845 -178.652 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -56.69 0.45 0.19 Allowed 'Trans proline' 0 CA--C 1.549 1.255 0 C-N-CA 124.126 3.218 . . . . 0.0 117.983 -178.742 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.0 pttt -134.86 -4.32 2.49 Favored 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.332 1.424 . . . . 0.0 114.276 167.339 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -155.82 112.11 3.11 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 126.051 1.74 . . . . 0.0 109.985 -175.555 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -62.21 -7.58 4.39 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -173.881 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -80.36 -9.02 59.74 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -173.048 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -17.36 118.53 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 129.446 3.098 . . . . 0.0 112.963 168.407 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.8 m80 -62.05 166.04 5.07 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.697 1.199 . . . . 0.0 111.61 177.916 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 32.5 m -76.33 29.58 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -178.469 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.402 ' CA ' HG12 ' A' ' 47' ' ' VAL . . . -148.28 9.99 1.13 Allowed Glycine 0 CA--C 1.532 1.096 0 C-N-CA 125.583 1.563 . . . . 0.0 115.166 -178.686 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -105.64 115.99 31.19 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.881 1.273 . . . . 0.0 113.209 -168.611 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.8 mp -91.2 170.7 9.79 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 163.459 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -79.79 -172.37 43.65 Favored Glycine 0 CA--C 1.529 0.941 0 O-C-N 121.372 -0.83 . . . . 0.0 112.238 171.751 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -78.42 144.11 36.15 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.422 -1.046 . . . . 0.0 112.512 172.6 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.443 HG22 ' HB1' ' A' ' 95' ' ' ALA . 2.3 p -114.51 139.43 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 128.003 2.521 . . . . 0.0 110.308 177.528 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.5 m -128.65 133.47 48.25 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.785 1.234 . . . . 0.0 110.586 -169.306 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.64 163.11 13.51 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 -176.2 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -83.32 169.8 15.26 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.106 1.362 . . . . 0.0 108.422 165.125 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.435 ' HD3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -62.02 -18.7 61.42 Favored 'General case' 0 N--CA 1.482 1.167 0 O-C-N 120.66 -1.275 . . . . 0.0 113.893 172.277 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -73.62 -3.03 25.52 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.59 1.556 . . . . 0.0 111.426 168.931 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.88 6.69 89.27 Favored Glycine 0 C--N 1.332 0.33 0 C-N-CA 126.155 1.836 . . . . 0.0 113.462 170.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -94.33 121.51 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 126.079 1.751 . . . . 0.0 111.541 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -97.89 99.12 10.42 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 167.148 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -79.9 143.86 33.9 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.543 1.537 . . . . 0.0 109.936 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.26 142.75 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 -176.503 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 p -149.89 109.98 4.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.417 1.487 . . . . 0.0 111.294 174.106 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.2 mt -138.08 158.73 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 127.295 2.238 . . . . 0.0 110.988 -171.157 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -145.39 144.33 30.6 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 126.353 1.861 . . . . 0.0 106.851 164.975 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -145.12 148.17 33.33 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 125.021 1.328 . . . . 0.0 110.597 179.373 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.32 49.69 0.95 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.674 0.789 . . . . 0.0 112.2 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.2 t -139.89 -47.7 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.211 1.404 . . . . 0.0 109.893 175.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -84.6 158.14 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-O 122.307 1.051 . . . . 0.0 113.201 175.592 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.9 p -157.03 171.51 20.33 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 115.316 1.599 . . . . 0.0 115.316 -171.614 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.01 80.25 9.1 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.41 1.484 . . . . 0.0 108.587 176.662 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 60.5 p -90.2 -170.95 2.94 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.564 0.697 . . . . 0.0 112.57 173.836 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.51 -43.77 5.12 Favored Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.363 0.982 . . . . 0.0 111.425 167.563 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 34.9 t0 -172.3 45.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.694 1.597 . . . . 0.0 111.787 -173.119 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -140.85 -40.53 0.4 Allowed 'General case' 0 N--CA 1.47 0.525 0 O-C-N 120.139 -1.601 . . . . 0.0 111.097 -172.16 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.9 m -90.67 -125.34 0.07 Allowed 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 127.988 2.515 . . . . 0.0 110.499 172.047 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.7 pt -102.7 -27.24 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 114.947 1.462 . . . . 0.0 114.947 -175.399 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.458 HD11 ' CB ' ' A' ' 4' ' ' ALA . 33.8 mm -60.46 138.23 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 168.374 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.67 8.25 73.84 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 117.366 -1.797 . . . . 0.0 113.631 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -122.17 174.12 7.16 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 119.913 1.856 . . . . 0.0 111.126 -174.17 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.45 ' N ' HG22 ' A' ' 47' ' ' VAL . 39.0 m -116.22 109.37 17.33 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.269 -1.519 . . . . 0.0 111.239 -163.328 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 33.9 tp -96.38 122.24 39.05 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.464 1.105 . . . . 0.0 110.64 -172.766 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 p -121.07 133.99 65.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.025 1.33 . . . . 0.0 108.839 175.203 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.3 t -90.67 152.64 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.225 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 165.053 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.03 138.55 54.43 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.745 2.018 . . . . 0.0 107.365 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.09 -46.3 79.08 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -167.256 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt -101.87 143.16 32.11 Favored 'General case' 0 C--N 1.329 -0.312 0 O-C-N 121.375 -0.828 . . . . 0.0 110.486 169.903 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.44 158.9 1.58 Allowed 'General case' 0 C--O 1.231 0.126 0 C-N-CA 125.027 1.331 . . . . 0.0 114.098 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -75.43 146.5 40.68 Favored 'General case' 0 N--CA 1.443 -0.823 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 165.599 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -68.54 -21.13 64.57 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.961 171.013 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.7 mt 85.33 -64.5 0.05 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 131.075 3.75 . . . . 0.0 108.582 -174.67 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.94 -75.75 0.98 Allowed Glycine 0 N--CA 1.464 0.559 0 C-N-CA 124.695 1.141 . . . . 0.0 110.887 -171.125 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -163.43 109.28 1.11 Allowed 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 168.583 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.44 21.74 0.69 Allowed Glycine 0 CA--C 1.545 1.965 0 C-N-CA 125.208 1.385 . . . . 0.0 116.509 172.669 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.25 10.94 73.43 Favored Glycine 0 N--CA 1.479 1.508 0 N-CA-C 118.551 2.18 . . . . 0.0 118.551 168.518 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.634 ' H ' ' HB3' ' A' ' 134' ' ' SER . 32.4 m-80 -127.24 179.47 5.43 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 119.872 1.836 . . . . 0.0 111.659 -173.559 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.31 -56.71 18.62 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 166.799 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -35.28 -31.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 128.839 2.855 . . . . 0.0 115.71 167.249 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.634 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 66.8 p -57.83 -24.44 57.44 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 117.435 2.383 . . . . 0.0 117.435 -166.842 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.282 3.4 t -133.02 -14.07 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 -179.203 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.2 ptmt -70.86 -47.37 59.69 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 120.297 1.408 . . . . 0.0 110.17 167.543 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -105.24 -18.85 13.99 Favored 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.943 -177.326 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.445 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 91.23 5.86 67.14 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 124.144 0.878 . . . . 0.0 112.311 -168.426 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 74.72 2.42 4.04 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.451 2.301 . . . . 0.0 114.442 -170.296 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.66 106.26 0.76 Allowed 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 119.43 1.014 . . . . 0.0 111.398 -169.284 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -36.58 -7.44 0.0 OUTLIER Glycine 0 N--CA 1.493 2.439 1 C-N-CA 131.255 4.264 . . . . 0.0 122.836 -165.862 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 18.4 p 104.86 156.73 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 131.06 3.744 . . . . 0.0 113.315 166.556 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 61.85 131.32 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 117.826 2.528 . . . . 0.0 117.826 166.03 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 179.94 -165.83 0.07 Allowed 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 128.571 2.748 . . . . 0.0 108.451 168.171 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -55.98 151.47 11.77 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.975 1.31 . . . . 0.0 112.429 170.17 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.5 t -153.0 152.06 30.97 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.749 2.02 . . . . 0.0 112.573 -172.848 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.46 167.52 36.34 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 127.731 2.586 . . . . 0.0 110.716 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.9 p -98.5 141.78 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 CA-C-N 119.771 1.785 . . . . 0.0 109.382 169.632 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.3 mt -78.92 102.27 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 O-C-N 121.635 -0.666 . . . . 0.0 111.473 -175.266 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.32 177.2 29.65 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-O 122.601 1.112 . . . . 0.0 112.506 171.744 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -111.41 158.53 11.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 126.364 1.866 . . . . 0.0 110.993 175.135 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.484 ' HB2' ' CG ' ' B' ' 52' ' ' ASP . . . -107.29 -14.79 14.8 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.212 1.005 . . . . 0.0 112.228 167.153 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 . . . . . 0 C--O 1.237 0.419 0 C-N-CA 126.863 2.065 . . . . 0.0 108.377 -164.819 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.389 0 CA-C-O 121.842 0.83 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.4 t -118.53 130.28 55.83 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 124.357 1.063 . . . . 0.0 110.113 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -91.29 148.82 22.07 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 168.182 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.04 141.77 31.39 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 114.339 -1.3 . . . . 0.0 107.891 166.612 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 49.0 t -137.95 142.88 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 CA-C-O 121.675 0.75 . . . . 0.0 111.815 -169.068 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.1 132.29 55.99 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 122.437 1.113 . . . . 0.0 112.169 169.822 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -115.83 86.07 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 127.065 2.146 . . . . 0.0 107.027 169.642 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.61 117.32 17.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -158.03 134.24 9.42 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 119.279 0.945 . . . . 0.0 113.249 -170.297 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.07 -38.7 0.05 OUTLIER Glycine 0 N--CA 1.471 0.992 0 C-N-CA 125.659 1.6 . . . . 0.0 111.443 172.453 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.13 66.6 2.96 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 128.393 2.677 . . . . 0.0 112.188 -176.282 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.33 -102.48 0.05 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 127.111 2.291 . . . . 0.0 113.613 174.321 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -82.55 -11.85 10.34 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.907 3.072 . . . . 0.0 114.257 -176.845 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -91.13 136.08 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 CA-C-N 120.013 1.278 . . . . 0.0 110.124 -177.518 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.76 156.73 35.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.747 168.397 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.45 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -125.83 123.58 4.92 Favored Glycine 0 CA--C 1.503 -0.675 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.045 173.714 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.37 128.44 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 164.567 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.7 pp -136.34 134.77 49.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 164.279 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -106.25 151.48 24.74 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.107 1.363 . . . . 0.0 112.111 172.392 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -120.91 128.24 52.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.409 1.884 . . . . 0.0 112.165 169.772 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -104.08 112.42 25.41 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 128.885 2.874 . . . . 0.0 110.742 173.635 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -108.26 124.73 50.76 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.464 -0.773 . . . . 0.0 109.679 174.809 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.92 -42.06 21.96 Favored 'General case' 0 CA--C 1.551 0.996 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 176.045 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -134.56 133.72 40.57 Favored 'General case' 0 C--O 1.22 -0.485 0 C-N-CA 126.098 1.759 . . . . 0.0 109.989 170.269 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 97.9 p -70.48 79.17 0.56 Allowed 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 120.523 1.51 . . . . 0.0 113.278 -178.174 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.9 p30 158.47 -30.1 0.0 OUTLIER 'General case' 0 CA--C 1.548 0.871 1 C-N-CA 132.877 4.471 . . . . 0.0 111.176 -176.506 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.03 -172.92 43.06 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 126.099 1.809 . . . . 0.0 113.993 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -78.75 170.92 17.41 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 124.14 3.227 . . . . 0.0 112.444 -170.093 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 32.1 t -139.59 131.77 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 CA-C-O 121.482 0.658 . . . . 0.0 112.333 -167.753 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -87.48 129.06 35.21 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 167.594 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 t -110.5 138.84 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 126.322 1.849 . . . . 0.0 109.665 173.736 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 19.5 p90 -152.91 168.74 24.78 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.706 -0.621 . . . . 0.0 112.032 170.487 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.4 -161.94 29.36 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 114.757 0.663 . . . . 0.0 114.757 174.031 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 46.2 p -153.96 123.99 6.85 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.003 0.921 . . . . 0.0 111.631 -170.027 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.45 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 2.7 mp -106.4 113.17 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 CA-C-O 117.709 -1.138 . . . . 0.0 111.388 177.169 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.0 mmmt -102.38 144.93 30.23 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 120.407 1.458 . . . . 0.0 109.374 -178.234 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.69 -4.23 14.81 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.232 1.396 . . . . 0.0 114.235 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -67.87 179.83 1.35 Allowed 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.367 1.067 . . . . 0.0 110.124 168.566 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -106.98 -32.27 7.95 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 117.763 -1.113 . . . . 0.0 113.892 172.108 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 173.39 -168.49 0.03 OUTLIER 'General case' 0 CA--C 1.556 1.207 1 C-N-CA 132.975 4.51 . . . . 0.0 105.174 178.876 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.5 161.96 28.43 Favored Glycine 0 CA--C 1.525 0.666 0 C-N-CA 126.1 1.809 . . . . 0.0 115.671 167.809 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.889 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -66.33 150.29 49.08 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.261 2.625 . . . . 0.0 108.968 168.658 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -143.88 121.87 12.08 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.589 1.156 . . . . 0.0 111.945 179.518 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.02 147.13 41.88 Favored Glycine 0 N--CA 1.482 1.759 0 CA-C-N 119.934 1.243 . . . . 0.0 112.559 -179.971 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -150.25 111.06 4.3 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.071 1.349 . . . . 0.0 110.115 -173.812 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -149.89 152.78 35.61 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 119.8 -1.812 . . . . 0.0 114.587 -165.071 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.02 126.81 53.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-O 121.447 0.642 . . . . 0.0 111.336 -177.322 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -78.21 -179.31 6.13 Favored 'General case' 0 CA--C 1.544 0.717 1 C-N-CA 131.837 4.055 . . . . 0.0 114.444 -175.128 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 49' ' ' GLU . . . . . 0.439 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 1.2 pm0 -59.99 135.26 57.65 Favored 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 163.208 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.274 42.7 m-85 -0.29 -130.45 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.621 1 C-N-CA 132.105 4.162 . . . . 0.0 116.865 -169.254 . . . . . . . . 3 2 . 1 . 023 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -130.44 -2.9 4.84 Favored Glycine 0 N--CA 1.472 1.034 0 C-N-CA 124.524 1.059 . . . . 0.0 114.079 -169.676 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.484 ' CG ' ' HB2' ' A' ' 152' ' ' ALA . 12.6 p-10 -81.83 48.32 1.2 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.333 1.853 . . . . 0.0 111.697 177.289 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.263 0.4 OUTLIER -176.89 43.9 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.489 1.516 . . . . 0.0 112.187 -168.937 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 9.1 t -59.69 19.74 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 128.735 2.814 . . . . 0.0 115.969 171.768 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -117.38 4.23 12.53 Favored 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.972 1.709 . . . . 0.0 113.248 169.244 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.81 -144.82 38.98 Favored Glycine 0 N--CA 1.471 1.029 0 O-C-N 120.998 -1.064 . . . . 0.0 111.477 -177.878 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 57' ' ' CYS . . . . . 0.44 ' C ' ' H ' ' B' ' 59' ' ' SER . 26.7 p -55.74 -26.24 44.54 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -177.638 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.7 m -71.79 30.68 0.05 Allowed 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 126.407 1.883 . . . . 0.0 112.085 171.578 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 59' ' ' SER . . . . . 0.44 ' H ' ' C ' ' B' ' 57' ' ' CYS . 13.4 t -179.81 5.53 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.191 0 C-N-CA 130.392 3.477 . . . . 0.0 114.36 175.862 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.45 165.61 23.64 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 121.831 2.105 . . . . 0.0 115.473 -168.414 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 61' ' ' GLY . . . . . 0.439 ' H ' ' CD ' ' B' ' 49' ' ' GLU . . . -99.3 -121.31 4.54 Favored Glycine 0 CA--C 1.544 1.902 0 C-N-CA 126.485 1.993 . . . . 0.0 115.082 -169.263 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -99.19 179.16 0.3 Allowed 'Trans proline' 0 C--N 1.35 0.618 1 C-N-CA 125.415 4.076 . . . . 0.0 111.566 -175.79 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.496 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -76.5 110.87 11.41 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.009 177.479 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -48.05 128.82 14.31 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.633 1.973 . . . . 0.0 113.78 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -121.57 64.96 16.69 Favored Pre-proline 0 CA--C 1.548 0.886 0 C-N-CA 124.721 1.208 . . . . 0.0 112.596 -172.312 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -63.58 -22.51 70.5 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 123.679 2.919 . . . . 0.0 113.465 -175.782 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.9 mt -79.51 -4.95 53.66 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.502 1.521 . . . . 0.0 112.916 172.606 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.7 p 62.15 52.07 3.34 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 127.891 2.476 . . . . 0.0 111.448 177.569 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -126.41 174.15 8.82 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 114.419 1.266 . . . . 0.0 114.419 -169.252 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 45.7 pttt -78.88 169.01 18.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 128.051 2.541 . . . . 0.0 111.192 171.235 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.419 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 78.6 t60 -90.28 174.85 7.36 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 176.221 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 72' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' B' ' 126' ' ' LEU . . . 129.24 -115.1 1.87 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 125.166 1.365 . . . . 0.0 113.48 166.57 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.03 -50.03 0.81 Allowed Glycine 0 CA--C 1.547 2.089 0 CA-C-O 117.859 -1.523 . . . . 0.0 116.196 173.044 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 74' ' ' PRO . . . . . 0.493 ' HD2' HD12 ' B' ' 126' ' ' LEU . 69.6 Cg_endo -88.64 -4.64 6.37 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 CA-C-N 121.425 2.613 . . . . 0.0 113.599 172.077 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 26.5 pttt -141.83 -1.35 1.27 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 124.256 1.022 . . . . 0.0 113.468 168.29 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -119.43 159.74 23.66 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.642 1.577 . . . . 0.0 110.099 169.496 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -81.96 -29.84 31.99 Favored 'General case' 0 CA--C 1.541 0.619 1 C-N-CA 132.486 4.314 . . . . 0.0 114.83 -171.321 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -98.51 -85.63 0.37 Allowed 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.714 -0.616 . . . . 0.0 111.165 -168.326 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ttp-105 80.93 121.22 0.05 OUTLIER 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.924 2.09 . . . . 0.0 111.16 176.979 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m80 -54.19 151.51 7.12 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 120.481 -1.387 . . . . 0.0 113.006 173.794 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -45.94 -48.38 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-O 119.048 -0.501 . . . . 0.0 112.104 -176.648 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.29 112.12 2.62 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-O 123.182 1.435 . . . . 0.0 113.117 169.411 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -155.56 107.14 2.58 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 130.659 3.584 . . . . 0.0 106.872 174.473 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 97.0 mt -89.09 54.06 2.87 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.558 0.743 . . . . 0.0 109.74 174.58 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.9 -107.56 0.14 Allowed Glycine 0 CA--C 1.532 1.107 0 C-N-CA 125.959 1.743 . . . . 0.0 113.652 177.449 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -153.74 146.16 24.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.367 1.467 . . . . 0.0 110.947 169.922 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.97 113.52 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 126.791 2.036 . . . . 0.0 110.359 -176.806 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -95.59 125.06 39.92 Favored 'General case' 0 N--CA 1.471 0.598 0 O-C-N 121.628 -0.67 . . . . 0.0 110.365 -175.189 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.38 148.62 24.01 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.738 1.215 . . . . 0.0 113.181 -175.595 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -76.71 174.91 9.88 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.49 1.516 . . . . 0.0 111.496 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.472 ' HB3' ' HZ3' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -68.59 -13.38 62.3 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 121.101 -1.0 . . . . 0.0 113.109 173.018 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -74.62 -23.7 58.74 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.101 1.36 . . . . 0.0 110.588 171.217 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.12 -2.71 59.8 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 116.655 -2.192 . . . . 0.0 114.47 -177.75 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.33 133.18 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 119.959 1.88 . . . . 0.0 113.818 169.856 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.44 113.93 27.8 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 164.783 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -99.67 133.34 44.16 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.066 1.347 . . . . 0.0 108.978 -176.596 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -135.26 135.7 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.495 1.118 . . . . 0.0 112.825 -167.393 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 27.6 p -156.11 113.69 3.27 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.312 1.445 . . . . 0.0 111.304 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 6.6 mt -145.14 152.57 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 127.85 2.46 . . . . 0.0 110.606 -169.333 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -134.98 137.78 43.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.846 0.858 . . . . 0.0 108.737 167.376 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -145.12 153.21 41.16 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 125.385 1.474 . . . . 0.0 112.327 -172.163 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 37.4 p -125.67 45.26 2.64 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 178.603 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.4 22.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.891 1.276 . . . . 0.0 112.669 169.427 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.15 158.86 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 127.119 2.168 . . . . 0.0 108.025 164.685 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 60.4 p -156.03 156.84 35.12 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.657 0.783 . . . . 0.0 109.758 -177.572 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -83.25 63.41 7.2 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.681 -1.262 . . . . 0.0 110.243 -177.322 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 11.1 t -93.5 154.59 17.81 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 165.703 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.0 -28.41 72.02 Favored Glycine 0 N--CA 1.47 0.909 0 C-N-CA 127.047 2.261 . . . . 0.0 118.322 -164.943 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 p30 -148.13 -46.67 0.16 Allowed 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -168.79 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -82.73 -18.89 39.18 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.782 -1.199 . . . . 0.0 111.994 -171.971 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 74.7 m -99.14 -92.85 0.26 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.093 0.957 . . . . 0.0 111.097 -176.174 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.74 -18.49 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 176.584 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 40.2 mm -68.64 153.0 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 122.089 2.222 . . . . 0.0 107.263 167.238 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.48 66.0 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 119.297 -0.724 . . . . 0.0 112.97 175.687 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 15.8 mtp85 -114.54 133.19 55.98 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 176.719 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.5 m -80.29 140.69 36.06 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.352 1.861 . . . . 0.0 107.003 179.258 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.3 tp -129.83 128.53 42.49 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.028 0.931 . . . . 0.0 109.786 -174.566 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.62 133.19 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.103 0.961 . . . . 0.0 110.628 177.736 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -98.24 149.25 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 165.969 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.2 m-70 -120.76 138.16 54.15 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.274 1.43 . . . . 0.0 113.199 -169.655 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -73.61 -24.79 60.09 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 120.163 -1.585 . . . . 0.0 114.013 -173.338 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -93.22 164.8 13.1 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 122.192 0.996 . . . . 0.0 112.355 169.808 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.87 158.97 20.7 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.008 1.323 . . . . 0.0 111.625 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -103.45 151.95 22.21 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.84 0.856 . . . . 0.0 112.185 179.124 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -102.36 -3.24 27.42 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 127.378 2.271 . . . . 0.0 112.878 -177.993 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.493 HD12 ' HD2' ' B' ' 74' ' ' PRO . 0.8 OUTLIER 45.85 56.45 5.97 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.132 1.773 . . . . 0.0 113.257 172.036 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.77 -54.1 1.68 Allowed Glycine 0 N--CA 1.471 1.033 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.014 173.023 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 134.55 18.86 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 172.314 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -160.21 -67.58 0.02 OUTLIER Glycine 0 CA--C 1.52 0.382 1 C-N-CA 130.723 4.011 . . . . 0.0 107.254 168.22 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -83.67 -111.14 0.56 Allowed Glycine 0 CA--C 1.533 1.188 0 C-N-CA 126.309 1.909 . . . . 0.0 117.039 -171.046 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -118.0 -159.13 0.74 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.431 2.292 . . . . 0.0 112.646 -163.307 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -49.34 -64.67 0.74 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.479 1.112 . . . . 0.0 112.033 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . 0.298 2.9 mt-10 -53.65 -10.37 0.27 Allowed 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 177.998 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 67.2 m -60.9 -47.76 84.92 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 122.133 2.242 . . . . 0.0 111.18 166.796 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 39.0 p -81.31 -38.14 27.25 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-O 119.102 -0.475 . . . . 0.0 111.347 176.493 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.9 tttt -68.63 -38.97 80.96 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.552 1.541 . . . . 0.0 113.88 -173.906 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.4 ' O ' ' CE1' ' B' ' 63' ' ' HIS . 33.9 p -121.78 -68.72 0.88 Allowed 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 116.974 -1.488 . . . . 0.0 109.696 172.742 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 163.71 17.37 0.02 OUTLIER Glycine 0 CA--C 1.536 1.375 0 C-N-CA 130.476 3.894 . . . . 0.0 113.621 -176.286 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . 0.257 2.3 t-20 41.98 35.34 0.54 Allowed 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 128.017 2.527 . . . . 0.0 114.819 -166.522 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.56 3.45 0.13 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.784 1.633 . . . . 0.0 115.232 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.9 -43.86 0.51 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 129.324 3.345 . . . . 0.0 117.257 168.664 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 32.5 t -173.09 168.55 4.77 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.768 1.627 . . . . 0.0 110.062 -168.316 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 28.5 mtt180 -111.07 -177.69 3.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 -169.85 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.425 HD22 ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -171.31 -157.88 0.13 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 128.417 2.687 . . . . 0.0 107.138 -169.695 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 145' ' ' ALA . . . . . 0.425 ' H ' HD22 ' B' ' 144' ' ' LEU . . . -58.69 153.97 15.53 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -169.142 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -141.98 153.77 44.54 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 113.949 -1.478 . . . . 0.0 113.82 -172.109 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.99 -177.65 37.68 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 127.49 2.472 . . . . 0.0 111.485 176.627 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.61 152.69 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 166.896 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.0 mm -75.7 102.31 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 174.595 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.18 -179.51 35.54 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 125.835 1.683 . . . . 0.0 111.14 169.932 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.24 154.55 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 117.602 0.701 . . . . 0.0 112.796 -167.604 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.465 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.23 -2.74 0.68 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 115.008 1.484 . . . . 0.0 115.008 165.959 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.234 0.262 0 C-N-CA 124.671 1.189 . . . . 0.0 111.071 168.78 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.514 0 CA-C-O 118.395 -0.812 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m -77.2 113.0 14.48 Favored 'General case' 0 CA--C 1.511 -0.539 0 C-N-CA 127.839 2.456 . . . . 0.0 107.146 -171.178 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p -92.91 -29.77 15.73 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.67 -51.24 36.47 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 118.192 0.451 . . . . 0.0 111.151 177.103 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.49 -134.95 7.55 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 126.195 1.855 . . . . 0.0 111.092 -173.24 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.8 t -54.42 -26.31 29.9 Favored 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -172.175 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 m -75.45 -34.36 60.96 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.866 1.267 . . . . 0.0 111.621 176.229 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 99.6 p -101.85 66.22 1.04 Allowed 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.183 1.793 . . . . 0.0 110.012 179.269 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.72 66.14 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.39 1.076 . . . . 0.0 111.365 -177.142 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 024 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.514 0 CA-C-O 118.395 -0.812 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m -77.2 113.0 14.48 Favored 'General case' 0 CA--C 1.511 -0.539 0 C-N-CA 127.839 2.456 . . . . 0.0 107.146 -171.178 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p -92.91 -29.77 15.73 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.67 -51.24 36.47 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 118.192 0.451 . . . . 0.0 111.151 177.103 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.49 -134.95 7.55 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 126.195 1.855 . . . . 0.0 111.092 -173.24 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.8 t -54.42 -26.31 29.9 Favored 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -172.175 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 m -75.45 -34.36 60.96 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.866 1.267 . . . . 0.0 111.621 176.229 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 99.6 p -101.85 66.22 1.04 Allowed 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.183 1.793 . . . . 0.0 110.012 179.269 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.72 66.14 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.39 1.076 . . . . 0.0 111.365 -177.142 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 025 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.922 0 CA-C-O 118.284 -0.865 . . . . 0.0 110.029 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.5 p -77.76 56.02 1.45 Allowed 'General case' 0 C--N 1.345 0.383 0 C-N-CA 127.385 2.274 . . . . 0.0 115.7 -166.296 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 0.8 OUTLIER -163.43 129.75 3.26 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 164.361 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.44 154.03 44.21 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.326 2.25 . . . . 0.0 108.289 167.682 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 69.4 t -154.97 146.62 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 118.916 0.78 . . . . 0.0 112.778 -167.005 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.76 128.45 51.75 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.592 1.157 . . . . 0.0 109.321 165.006 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 29.0 m -113.71 127.1 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.597 1.159 . . . . 0.0 108.289 167.59 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.07 130.45 55.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.14 1.376 . . . . 0.0 109.913 -172.068 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -153.9 70.76 0.83 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.741 0.816 . . . . 0.0 110.869 170.222 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.1 -1.41 22.3 Favored Glycine 0 N--CA 1.469 0.851 0 CA-C-O 117.481 -1.733 . . . . 0.0 115.078 -173.958 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -156.08 110.32 2.81 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 119.151 1.476 . . . . 0.0 111.979 -169.74 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 31.66 -111.37 0.05 OUTLIER Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.168 2.318 . . . . 0.0 114.906 169.569 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -84.42 -2.05 9.85 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.597 2.865 . . . . 0.0 114.034 -175.778 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.0 t -102.05 135.37 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 120.445 1.475 . . . . 0.0 111.578 -168.609 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -127.24 171.93 11.03 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 122.87 1.319 . . . . 0.0 110.258 169.072 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.36 150.87 23.17 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 112.781 -2.008 . . . . 0.0 112.152 167.892 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -133.15 126.4 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 167.352 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mm -132.67 103.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -177.29 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -99.3 124.71 44.61 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.221 1.008 . . . . 0.0 112.151 177.107 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -104.69 156.45 17.97 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 127.303 2.241 . . . . 0.0 111.769 169.996 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -132.46 128.97 38.59 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.613 1.565 . . . . 0.0 108.597 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.467 ' CB ' HD13 ' A' ' 106' ' ' LEU . 0.0 OUTLIER -139.56 145.49 38.69 Favored 'General case' 0 CA--C 1.532 0.287 0 O-C-N 120.822 -1.174 . . . . 0.0 111.151 -174.224 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.469 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -113.4 -31.37 6.58 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -167.39 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -157.94 154.66 28.16 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.683 1.593 . . . . 0.0 107.908 172.438 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 m -47.44 -40.53 18.32 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 128.302 2.641 . . . . 0.0 113.156 173.018 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -84.1 -0.55 52.34 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.984 1.714 . . . . 0.0 112.771 174.681 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.58 139.65 14.57 Favored Glycine 0 CA--C 1.538 1.526 0 O-C-N 120.427 -1.421 . . . . 0.0 112.985 -172.694 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -69.74 163.71 37.26 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 123.933 3.089 . . . . 0.0 111.339 178.925 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t -132.75 136.56 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.177 0.591 . . . . 0.0 112.164 -167.024 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -95.49 124.54 39.57 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.093 1.357 . . . . 0.0 109.548 172.153 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 99' ' ' ILE . 0.3 OUTLIER -107.7 153.0 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 C-N-CA 125.672 1.589 . . . . 0.0 111.415 168.991 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 42.6 p90 -156.72 164.05 38.58 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.291 1.437 . . . . 0.0 111.834 168.779 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.94 -154.21 24.74 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 124.139 0.876 . . . . 0.0 112.597 175.656 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 78.1 p -156.58 150.85 25.32 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.009 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.15 116.26 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 171.783 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -136.12 140.18 43.5 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.111 0.964 . . . . 0.0 112.566 -165.982 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.57 -16.22 37.62 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 126.809 2.147 . . . . 0.0 112.275 -168.789 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.453 HD13 ' CD2' ' A' ' 43' ' ' HIS . 2.2 pp -84.39 155.05 22.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-N 118.473 1.137 . . . . 0.0 112.01 172.879 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.7 m -62.02 154.15 27.54 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 127.371 2.269 . . . . 0.0 112.012 176.674 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.8 pm0 -51.0 169.61 0.04 OUTLIER 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.258 1.423 . . . . 0.0 114.57 168.674 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.43 -176.32 46.51 Favored Glycine 0 N--CA 1.472 1.086 0 O-C-N 120.792 -1.192 . . . . 0.0 112.358 -177.485 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.3 mp -75.92 148.36 38.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.456 -1.026 . . . . 0.0 110.019 -176.56 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.453 ' CD2' HD13 ' A' ' 38' ' ' LEU . 85.4 m-70 -142.1 134.0 27.24 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.849 1.26 . . . . 0.0 109.2 173.836 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.2 152.13 49.52 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 177.75 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -150.5 118.0 6.1 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.806 2.042 . . . . 0.0 107.97 -169.141 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.474 ' NE2' ' CD2' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -153.89 145.2 23.01 Favored 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.116 -1.615 . . . . 0.0 111.221 -172.956 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.16 127.3 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.173 0.987 . . . . 0.0 110.647 170.248 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -72.83 -173.62 1.26 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 129.218 3.007 . . . . 0.0 110.349 177.414 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.55 ' H ' ' CD ' ' A' ' 49' ' ' GLU 0.268 1.9 pm0 -63.65 -120.31 0.0 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.081 1.752 . . . . 0.0 114.831 177.692 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -82.12 -168.03 1.79 Allowed 'General case' 0 CA--C 1.545 0.754 0 O-C-N 119.807 -1.808 . . . . 0.0 114.403 -167.129 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.58 9.45 60.59 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.067 1.794 . . . . 0.0 113.978 -179.354 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -108.98 38.79 2.18 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.986 1.714 . . . . 0.0 113.961 -173.769 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.4 ' OD1' ' HB2' ' A' ' 60' ' ' ALA . 2.1 p30 -172.43 22.27 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.858 1.313 . . . . 0.0 112.408 -165.082 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.411 ' H ' HG23 ' A' ' 54' ' ' THR . 3.1 p -44.33 5.8 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.613 1 C-N-CA 134.641 5.176 . . . . 0.0 118.784 -176.453 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.75 1.34 56.54 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.515 1.926 . . . . 0.0 112.87 172.579 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.84 -151.68 43.05 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 -179.135 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.1 t -51.26 -7.41 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.197 0 C-N-CA 127.206 2.203 . . . . 0.0 116.289 -176.42 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 58.5 p -87.95 18.51 4.14 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 120.162 -1.586 . . . . 0.0 113.318 169.2 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.9 m -169.81 -47.14 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 127.221 2.209 . . . . 0.0 109.761 -176.268 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.4 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . . . -70.61 151.31 45.13 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.45 1.9 . . . . 0.0 112.128 172.526 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -98.01 -170.28 32.35 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 125.803 1.668 . . . . 0.0 112.505 -176.188 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -83.79 60.87 6.69 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.501 2.801 . . . . 0.0 109.885 178.185 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' ' NE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER 51.19 63.81 2.1 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.551 1.54 . . . . 0.0 112.773 168.272 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -28.29 113.57 0.07 Allowed 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 127.507 2.323 . . . . 0.0 111.854 175.679 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -78.11 103.59 1.45 Allowed Pre-proline 0 CA--C 1.545 0.773 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.795 -166.547 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -70.11 -21.12 32.3 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 121.899 1.733 . . . . 0.0 112.186 -174.516 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.89 -3.74 21.49 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.31 1.844 . . . . 0.0 112.677 175.996 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 t 54.18 44.24 29.44 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 125.25 1.42 . . . . 0.0 112.283 -169.623 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtm180 -92.2 171.19 9.24 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 120.994 -1.066 . . . . 0.0 111.37 174.378 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.75 164.64 18.41 Favored 'General case' 0 CA--C 1.547 0.858 0 O-C-N 121.23 -0.919 . . . . 0.0 109.762 167.792 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -80.31 142.54 34.42 Favored 'General case' 0 CA--C 1.536 0.414 0 O-C-N 120.265 -1.522 . . . . 0.0 111.718 -178.495 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 165.36 -131.5 2.41 Favored Glycine 0 N--CA 1.468 0.804 0 N-CA-C 115.859 1.104 . . . . 0.0 115.859 168.843 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.55 -41.7 1.72 Allowed Glycine 0 CA--C 1.543 1.822 0 N-CA-C 119.005 2.362 . . . . 0.0 119.005 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -95.39 -22.31 0.2 Allowed 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 121.885 2.843 . . . . 0.0 113.725 -175.798 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.5 pttt -132.26 -0.09 3.7 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.976 1.71 . . . . 0.0 112.21 175.348 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -138.72 155.49 48.19 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 130.869 3.668 . . . . 0.0 108.832 -176.428 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -107.07 -8.05 16.67 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 126.169 1.788 . . . . 0.0 112.911 -174.638 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.5 mm-40 -78.2 -20.21 52.31 Favored 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -172.994 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.481 HH21 HG12 ' A' ' 103' ' ' VAL . 4.8 ttp180 4.52 102.14 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 130.445 3.498 . . . . 0.0 115.374 166.493 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -59.58 162.35 5.13 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.654 0.782 . . . . 0.0 112.03 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 92.2 t -49.62 -41.18 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 124.366 1.066 . . . . 0.0 113.722 171.125 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.8 8.39 66.21 Favored Glycine 0 CA--C 1.539 1.583 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 177.266 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -99.25 97.49 8.56 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-N 119.635 1.718 . . . . 0.0 111.866 -175.184 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 87.0 mt -108.81 54.54 0.65 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.455 1.102 . . . . 0.0 111.954 -175.436 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.42 -151.48 43.43 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 125.023 1.296 . . . . 0.0 114.248 177.186 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.7 p30 -135.16 169.28 17.69 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 125.509 1.524 . . . . 0.0 109.568 169.864 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -128.58 113.88 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.536 1.134 . . . . 0.0 109.832 -171.147 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.4 m -109.15 124.37 50.7 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 123.913 0.885 . . . . 0.0 108.939 -170.102 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.94 151.17 21.64 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 -172.87 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -88.06 151.89 22.42 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 127.758 2.423 . . . . 0.0 110.381 167.952 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -49.94 -17.71 0.42 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 129.2 3.0 . . . . 0.0 116.994 175.557 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -75.65 0.75 16.54 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 124.266 1.026 . . . . 0.0 111.388 171.56 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.13 35.13 7.21 Favored Glycine 0 C--N 1.34 0.783 0 C-N-CA 125.996 1.76 . . . . 0.0 112.781 172.888 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.7 p -152.76 131.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.048 1.869 . . . . 0.0 116.048 -170.919 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.86 120.97 37.07 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 164.468 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -104.1 132.6 50.19 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.224 1.41 . . . . 0.0 107.747 177.118 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 49.1 t -134.41 141.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -165.608 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.9 t -157.46 119.27 3.73 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.333 1.853 . . . . 0.0 111.021 170.614 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.453 ' HB ' HG12 ' A' ' 31' ' ' VAL . 46.4 mt -135.47 145.59 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 126.233 1.813 . . . . 0.0 110.467 179.707 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.98 126.43 53.83 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 125.641 1.576 . . . . 0.0 106.945 166.269 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.82 144.46 50.24 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.925 0.89 . . . . 0.0 112.924 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 10.8 p -119.97 50.74 1.25 Allowed 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -177.381 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.481 HG12 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -154.72 6.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 N-CA-C 115.382 1.623 . . . . 0.0 115.382 168.642 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.64 152.79 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 120.77 -1.206 . . . . 0.0 109.851 177.726 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.485 ' H ' ' HB3' ' A' ' 111' ' ' SER . 52.4 p -155.43 179.3 9.31 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 120.982 -1.074 . . . . 0.0 112.691 -178.341 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.467 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.4 mp -81.72 48.35 1.19 Allowed 'General case' 0 CA--C 1.551 1.002 0 O-C-N 120.415 -1.428 . . . . 0.0 110.234 -174.571 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.9 t -88.16 43.92 1.16 Allowed 'General case' 0 CA--C 1.545 0.764 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 -168.454 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.19 -64.63 2.02 Favored Glycine 0 N--CA 1.475 1.248 0 C-N-CA 125.736 1.636 . . . . 0.0 116.072 168.249 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -149.41 16.67 0.92 Allowed 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 124.059 1.885 . . . . 0.0 110.595 -175.725 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 39.4 m-70 -126.31 5.7 7.02 Favored 'General case' 0 CA--C 1.545 0.771 0 O-C-N 120.004 -1.685 . . . . 0.0 112.873 -167.431 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB3' ' H ' ' A' ' 105' ' ' SER . 3.1 m -166.39 -103.12 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.74 1.216 . . . . 0.0 113.111 177.749 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.6 pt -117.72 28.13 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 CA-C-N 120.37 1.441 . . . . 0.0 113.679 -170.276 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -133.48 146.58 31.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 127.725 2.41 . . . . 0.0 105.578 164.084 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.12 30.38 75.68 Favored Glycine 0 C--O 1.22 -0.748 0 CA-C-O 118.869 -0.962 . . . . 0.0 113.101 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.7 mtt-85 -135.28 176.9 8.25 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.835 1.254 . . . . 0.0 109.351 176.345 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.4 m -132.52 116.11 16.32 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 119.689 1.131 . . . . 0.0 110.94 -170.885 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.7 tp -89.83 132.86 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.629 1.172 . . . . 0.0 110.308 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 146' ' ' CYS . 4.9 p -124.23 150.26 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.027 1.331 . . . . 0.0 110.326 172.302 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -105.33 167.56 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-O 121.418 0.628 . . . . 0.0 110.823 167.06 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.72 127.69 37.35 Favored 'General case' 0 CA--C 1.547 0.849 0 O-C-N 120.942 -1.099 . . . . 0.0 110.697 -173.823 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? -69.87 -10.13 57.38 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -169.55 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -107.93 162.1 14.33 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 114.442 1.275 . . . . 0.0 114.442 171.496 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.79 139.4 58.76 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.507 1.923 . . . . 0.0 109.792 167.081 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -111.3 148.84 32.05 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.849 2.059 . . . . 0.0 113.8 -171.815 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.342 13.3 t0 -101.93 -15.83 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 115.556 1.687 . . . . 0.0 115.556 -179.725 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt 56.26 81.0 0.13 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.724 1.609 . . . . 0.0 114.061 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.9 -43.74 1.91 Allowed Glycine 0 N--CA 1.471 1.009 0 C-N-CA 125.275 1.417 . . . . 0.0 111.935 168.921 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -99.42 175.03 5.99 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.219 1.408 . . . . 0.0 110.204 167.604 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 131.02 -9.92 5.68 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 126.311 1.91 . . . . 0.0 114.116 -169.312 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.54 11.04 85.85 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 116.272 1.269 . . . . 0.0 116.272 168.394 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 13.9 p30 -138.82 174.52 10.43 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.891 1.276 . . . . 0.0 110.077 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -65.69 -54.82 22.19 Favored 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 115.012 1.486 . . . . 0.0 115.012 -171.577 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.41 -26.54 42.32 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.661 -0.649 . . . . 0.0 111.883 176.291 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -54.38 -35.97 63.4 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.29 -1.506 . . . . 0.0 114.634 177.253 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.9 -28.16 15.33 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 124.423 1.089 . . . . 0.0 112.49 178.504 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.19 -65.25 0.98 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.018 0.827 . . . . 0.0 111.922 178.823 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.9 p -92.25 -24.31 19.04 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 126.56 1.944 . . . . 0.0 112.168 -171.868 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.58 16.51 24.23 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 124.533 1.063 . . . . 0.0 112.494 -168.964 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 73.09 4.54 4.96 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.566 1.946 . . . . 0.0 113.768 178.294 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.8 -10.96 4.36 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 -169.447 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.06 -30.07 0.53 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 128.507 2.956 . . . . 0.0 117.779 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.5 t -142.45 178.11 7.82 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.225 1.01 . . . . 0.0 110.469 -173.42 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.9 -175.58 2.81 Favored 'General case' 0 N--CA 1.473 0.725 0 O-C-N 120.59 -1.319 . . . . 0.0 110.102 -174.893 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.576 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -170.1 -158.96 0.18 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.76 2.024 . . . . 0.0 107.779 -176.07 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.576 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.26 159.7 30.75 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 127.057 2.143 . . . . 0.0 113.321 178.347 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.421 ' HB3' HG23 ' A' ' 118' ' ' VAL . 31.4 p -147.58 162.52 38.94 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.269 1.427 . . . . 0.0 112.985 -177.975 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.28 161.0 31.35 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 126.614 2.054 . . . . 0.0 112.228 169.333 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.1 t -78.54 160.83 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 CA-C-N 119.25 1.525 . . . . 0.0 110.869 170.403 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -103.1 113.12 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 CA-C-N 118.834 0.743 . . . . 0.0 110.643 167.838 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.2 -178.61 15.7 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 125.604 1.573 . . . . 0.0 113.23 -178.435 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.95 123.05 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 113.958 1.096 . . . . 0.0 113.958 -170.704 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.464 ' HB3' ' HB3' ' A' ' 3' ' ' LYS . . . -75.12 -31.05 61.0 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 122.921 1.343 . . . . 0.0 107.787 163.033 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.438 0 C-N-CA 125.481 1.512 . . . . 0.0 112.27 166.937 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.2 m -80.73 109.61 15.43 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 105.724 -1.954 . . . . 0.0 105.724 168.973 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.451 ' HE3' ' HB1' ' B' ' 152' ' ' ALA . 0.2 OUTLIER -116.27 152.87 32.97 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 117.894 2.553 . . . . 0.0 117.894 -172.711 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.75 147.49 37.46 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 126.255 1.822 . . . . 0.0 108.886 168.571 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.05 157.29 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 123.459 0.704 . . . . 0.0 111.037 -166.918 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.54 139.61 46.7 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.658 1.183 . . . . 0.0 111.438 169.648 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.4 m -108.62 122.41 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 167.094 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 8' ' ' LEU . . . . . 0.521 ' CD2' HD12 ' B' ' 117' ' ' LEU . 4.7 mp -99.98 75.86 1.89 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -164.453 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -105.61 100.74 10.29 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.257 1.423 . . . . 0.0 110.364 173.076 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.47 15.69 0.48 Allowed Glycine 0 N--CA 1.477 1.412 0 N-CA-C 115.68 1.032 . . . . 0.0 115.68 -178.11 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -159.61 136.78 9.6 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.625 2.37 . . . . 0.0 107.457 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -23.28 -80.26 0.01 OUTLIER Glycine 0 CA--C 1.537 1.451 0 C-N-CA 128.487 2.946 . . . . 0.0 116.083 -168.747 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -86.72 4.27 6.36 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 124.192 3.261 . . . . 0.0 113.949 -177.557 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 36.0 t -105.38 129.83 57.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 CA-C-O 122.872 1.32 . . . . 0.0 109.721 -172.446 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.2 168.29 19.13 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.777 1.631 . . . . 0.0 107.911 171.869 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.17 176.42 33.6 Favored Glycine 0 N--CA 1.464 0.543 0 O-C-N 120.432 -1.417 . . . . 0.0 113.546 176.488 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -158.31 103.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 126.687 1.995 . . . . 0.0 108.81 172.971 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.49 146.41 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 124.922 1.289 . . . . 0.0 111.594 176.636 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -119.12 168.99 10.32 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 127.268 2.227 . . . . 0.0 112.196 -171.034 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.38 98.86 3.21 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 127.263 2.225 . . . . 0.0 108.105 172.219 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -102.41 114.08 27.96 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 118.71 0.686 . . . . 0.0 111.581 -175.476 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -91.64 132.48 36.31 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.221 1.008 . . . . 0.0 110.948 176.227 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.4 ptmt -84.02 -30.79 25.83 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 179.349 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -162.17 144.73 11.37 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.19 2.196 . . . . 0.0 109.847 169.586 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 1.5 m -43.77 24.77 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 1 C-N-CA 137.957 6.503 . . . . 0.0 119.037 -174.767 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.6 p30 179.76 -24.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 128.371 2.668 . . . . 0.0 112.081 -170.194 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.6 165.11 54.3 Favored Glycine 0 CA--C 1.541 1.659 0 O-C-N 121.168 -0.958 . . . . 0.0 112.425 169.965 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -70.15 169.7 18.79 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 124.305 3.336 . . . . 0.0 113.12 -171.288 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 31.7 t -131.02 129.43 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.942 1.697 . . . . 0.0 110.503 -169.111 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -93.77 125.82 38.6 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-O 122.319 1.057 . . . . 0.0 109.902 170.56 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.06 128.16 39.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 127.585 2.354 . . . . 0.0 108.071 169.44 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -153.39 158.26 41.19 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 171.646 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.83 -141.99 12.79 Favored Glycine 0 N--CA 1.463 0.456 0 C-N-CA 125.08 1.324 . . . . 0.0 111.51 176.888 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 99.0 p -155.02 162.13 41.16 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 117.987 2.588 . . . . 0.0 117.987 -167.964 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 19.4 mm -130.4 123.93 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 C-N-CA 126.567 1.947 . . . . 0.0 107.445 168.067 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 tttp -122.24 136.49 54.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 122.854 2.57 . . . . 0.0 110.731 -178.63 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.26 -8.77 5.65 Favored Glycine 0 N--CA 1.474 1.202 0 C-N-CA 126.47 1.986 . . . . 0.0 114.094 -178.934 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.435 HD22 ' CE1' ' B' ' 43' ' ' HIS . 33.4 mt -70.22 172.97 7.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.096 1.358 . . . . 0.0 111.638 170.625 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 11.8 t -110.77 157.73 19.46 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 162.687 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -59.03 162.04 4.59 Favored 'General case' 0 CA--C 1.537 0.442 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -167.213 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.79 -179.15 34.07 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.671 -174.841 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.636 ' H ' HD23 ' B' ' 42' ' ' LEU . 2.2 pt? -75.64 144.21 41.81 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.533 1.533 . . . . 0.0 113.0 -169.975 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 43' ' ' HIS . . . . . 0.435 ' CE1' HD22 ' B' ' 38' ' ' LEU . 91.9 m-70 -140.37 170.14 16.37 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 126.948 2.099 . . . . 0.0 109.567 176.462 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -124.93 166.06 17.79 Favored Glycine 0 N--CA 1.478 1.486 0 C-N-CA 125.132 1.349 . . . . 0.0 113.148 -174.196 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -156.46 162.32 39.99 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.951 2.1 . . . . 0.0 112.82 172.921 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 46' ' ' HIS . . . . . 0.587 ' O ' HD22 ' B' ' 117' ' ' LEU . 46.7 p-80 -156.14 163.91 39.04 Favored 'General case' 0 C--N 1.347 0.468 0 O-C-N 120.583 -1.323 . . . . 0.0 108.835 168.797 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.483 HG22 ' CA ' ' B' ' 82' ' ' GLY . 0.5 OUTLIER -110.84 162.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 125.015 1.326 . . . . 0.0 108.857 -178.244 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.3 p80 -136.67 126.18 25.18 Favored 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 120.984 -1.072 . . . . 0.0 109.789 176.606 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -71.75 136.47 47.16 Favored 'General case' 0 N--CA 1.452 -0.357 0 O-C-N 123.932 0.77 . . . . 0.0 109.913 179.443 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 121.22 133.05 0.0 OUTLIER 'General case' 0 C--O 1.233 0.209 1 C-N-CA 133.958 4.903 . . . . 0.0 108.449 -176.149 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.42 2.89 61.15 Favored Glycine 0 C--O 1.222 -0.615 0 CA-C-O 118.211 -1.327 . . . . 0.0 114.019 178.717 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -103.13 51.58 0.79 Allowed 'General case' 0 CA--C 1.536 0.423 0 CA-C-N 120.24 2.02 . . . . 0.0 112.934 -179.15 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -172.1 37.73 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 126.669 1.987 . . . . 0.0 110.995 -171.472 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.3 p -61.8 47.02 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.504 1 C-N-CA 133.688 4.795 . . . . 0.0 115.948 -171.614 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -152.28 -21.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.882 2.073 . . . . 0.0 112.53 178.481 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.48 -161.89 12.69 Favored Glycine 0 C--N 1.344 0.992 0 CA-C-N 119.464 1.029 . . . . 0.0 113.298 170.623 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -52.78 1.17 0.01 OUTLIER 'General case' 0 CA--C 1.56 1.356 0 C-N-CA 128.213 2.605 . . . . 0.0 115.094 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.5 t -94.32 -11.85 29.21 Favored 'General case' 0 N--CA 1.481 1.088 0 O-C-N 119.193 -2.192 . . . . 0.0 112.896 168.051 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 75.0 m -132.86 0.26 3.5 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 125.023 1.329 . . . . 0.0 113.687 178.915 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -155.52 -176.49 5.97 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.343 1.857 . . . . 0.0 110.142 173.493 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.99 163.57 26.9 Favored Glycine 0 CA--C 1.544 1.897 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -173.201 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -66.09 125.29 13.86 Favored 'Trans proline' 0 C--N 1.352 0.716 0 C-N-CA 124.977 3.785 . . . . 0.0 111.322 178.378 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.318 1.9 p80 28.32 59.23 0.12 Allowed 'General case' 0 C--O 1.239 0.551 0 C-N-CA 130.278 3.431 . . . . 0.0 116.858 177.935 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -58.8 121.1 10.28 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 105.153 -2.166 . . . . 0.0 105.153 162.836 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -125.47 142.4 41.65 Favored Pre-proline 0 CA--C 1.543 0.683 0 C-N-CA 124.365 1.066 . . . . 0.0 113.799 -169.068 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -83.38 -15.08 7.8 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.323 2.682 . . . . 0.0 113.587 175.172 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 79.8 mt -93.88 -10.63 33.28 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 115.03 1.492 . . . . 0.0 115.03 -171.486 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t 46.12 58.69 4.26 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 169.474 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 4.6 ptt180 -143.88 -174.96 4.4 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 127.899 2.48 . . . . 0.0 111.06 -175.611 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.25 3.1 pttp -65.19 160.48 21.28 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 120.231 1.378 . . . . 0.0 112.706 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -96.95 138.62 34.21 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.777 -1.556 . . . . 0.0 113.326 -177.086 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.92 -151.33 20.19 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 127.075 2.274 . . . . 0.0 109.456 170.49 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 169.25 -32.99 0.18 Allowed Glycine 0 CA--C 1.528 0.87 0 N-CA-C 119.722 2.649 . . . . 0.0 119.722 169.004 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.3 24.18 0.22 Allowed 'Trans proline' 0 CA--C 1.554 1.52 0 CA-C-N 122.97 3.385 . . . . 0.0 113.013 167.787 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 75' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -168.59 -41.39 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 129.865 3.266 . . . . 0.0 107.245 166.427 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.255 4.9 t70 -62.69 117.97 7.02 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 123.932 1.825 . . . . 0.0 109.599 -171.055 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.3 mp0 -72.48 -19.57 61.52 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 129.416 3.086 . . . . 0.0 114.471 -161.616 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -105.71 -65.21 1.08 Allowed 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.022 0.529 . . . . 0.0 111.197 176.798 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 76.77 126.72 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 125.181 1.393 . . . . 0.0 114.352 165.973 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -73.78 159.54 32.78 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 124.608 1.163 . . . . 0.0 113.015 168.106 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -61.86 -47.75 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 120.931 -1.106 . . . . 0.0 110.142 173.529 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 82' ' ' GLY . . . . . 0.483 ' CA ' HG22 ' B' ' 47' ' ' VAL . . . -77.56 31.38 1.67 Allowed Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.865 1.221 . . . . 0.0 115.369 176.587 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -115.71 117.39 30.14 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 121.368 -1.078 . . . . 0.0 108.941 170.291 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 87.1 mt -140.72 131.68 26.1 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 102.455 -3.165 . . . . 0.0 102.455 168.743 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.69 -144.77 16.07 Favored Glycine 0 N--CA 1.47 0.941 0 N-CA-C 119.698 2.639 . . . . 0.0 119.698 -163.534 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 86' ' ' ASN . . . . . 0.425 HD21 ' HA ' ' B' ' 124' ' ' ASP . 93.4 m-20 -72.96 159.86 33.02 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -165.979 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.3 p -133.05 177.28 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 130.387 3.475 . . . . 0.0 110.093 -171.185 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -155.76 132.79 10.67 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 119.666 1.121 . . . . 0.0 111.356 174.998 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.46 160.5 15.41 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.342 1.057 . . . . 0.0 113.776 176.283 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -92.08 177.2 6.24 Favored 'General case' 0 CA--C 1.552 1.041 0 C-N-CA 127.186 2.194 . . . . 0.0 112.663 170.293 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.74 -17.58 64.94 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 120.913 -1.117 . . . . 0.0 112.958 169.606 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.81 -27.26 63.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.081 0.952 . . . . 0.0 110.449 168.838 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.97 -4.5 65.52 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 117.96 -1.467 . . . . 0.0 114.439 -177.009 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.99 131.06 35.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 118.736 1.268 . . . . 0.0 110.917 168.782 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.16 124.63 44.35 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 165.892 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -79.16 143.51 35.37 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.706 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.09 130.53 72.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.686 166.625 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 8.6 m -150.77 82.97 1.34 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.857 1.263 . . . . 0.0 110.537 -175.142 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.6 mt -130.91 142.48 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.605 1.562 . . . . 0.0 111.007 -172.671 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -100.69 145.14 28.82 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.356 1.862 . . . . 0.0 107.176 168.653 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.973 0.909 . . . . 0.0 109.432 169.609 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.6 p -131.31 51.96 2.1 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.225 1.01 . . . . 0.0 112.263 179.868 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -152.47 34.82 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 122.736 1.255 . . . . 0.0 111.43 169.847 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.1 172.17 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 126.688 1.995 . . . . 0.0 111.329 -169.655 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -159.78 153.76 23.2 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 120.817 -1.177 . . . . 0.0 112.685 169.275 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.7 mp -82.72 58.91 4.48 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.641 -1.287 . . . . 0.0 110.345 176.377 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.9 t -89.11 141.1 28.8 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.071 171.417 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -77.1 47.83 2.66 Favored Glycine 0 N--CA 1.474 1.217 0 C-N-CA 126.23 1.871 . . . . 0.0 115.584 -168.443 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -139.15 -90.98 0.19 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.847 2.459 . . . . 0.0 107.784 -170.398 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -150.45 -4.88 0.33 Allowed 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 127.878 2.471 . . . . 0.0 112.275 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.5 t -69.34 -0.39 6.23 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.162 -1.586 . . . . 0.0 114.6 -174.979 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.5 7.5 pt 149.36 8.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 1 C-N-CA 135.667 5.587 . . . . 0.0 115.365 168.092 . . . . . . . . 3 2 . 1 . 026 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 48.9 mm -87.12 168.94 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 O-C-N 120.56 -1.337 . . . . 0.0 109.232 165.696 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.32 -33.39 2.02 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 117.849 1.899 . . . . 0.0 117.849 166.109 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 ptt85 -74.8 174.12 9.62 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 125.77 1.628 . . . . 0.0 112.043 -169.898 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -130.12 154.12 47.81 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.166 0.986 . . . . 0.0 109.699 -174.311 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' B' ' 46' ' ' HIS . 2.7 tm? -133.26 145.51 50.57 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 125.376 1.47 . . . . 0.0 111.505 -169.668 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.494 ' N ' HD13 ' B' ' 117' ' ' LEU . 6.7 p -128.14 135.76 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 126.194 1.797 . . . . 0.0 110.88 174.141 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 t -101.91 158.24 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 125.521 1.528 . . . . 0.0 108.392 169.858 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -128.21 153.25 47.12 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 127.799 2.44 . . . . 0.0 111.296 -173.115 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -75.32 -24.93 57.47 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.491 -178.819 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -100.54 171.16 7.9 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 119.704 1.138 . . . . 0.0 110.114 167.507 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -112.08 94.57 5.01 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 125.283 1.433 . . . . 0.0 111.925 -179.371 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.425 ' HA ' HD21 ' B' ' 86' ' ' ASN 0.267 25.5 t0 -152.97 146.92 25.36 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-O 123.561 1.648 . . . . 0.0 109.25 168.032 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -169.3 -52.27 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 130.467 3.507 . . . . 0.0 110.893 -178.245 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.585 ' H ' HD13 ' B' ' 126' ' ' LEU 0.338 0.0 OUTLIER -86.07 59.32 5.56 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 116.575 2.065 . . . . 0.0 116.575 -163.094 . . . . . . . . 4 4 . 1 . 026 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.44 -9.12 0.88 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 117.839 1.896 . . . . 0.0 117.839 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.3 ptmt -160.21 21.62 0.16 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 116.763 2.134 . . . . 0.0 116.763 -169.218 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.5 -19.38 78.95 Favored Glycine 0 N--CA 1.472 1.079 0 CA-C-N 120.26 1.391 . . . . 0.0 113.489 178.938 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -151.24 -42.24 0.02 OUTLIER Glycine 0 N--CA 1.468 0.83 0 N-CA-C 116.665 1.426 . . . . 0.0 116.665 -178.996 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -163.08 -165.31 1.08 Allowed 'General case' 0 CA--C 1.546 0.815 0 CA-C-N 120.201 2.0 . . . . 0.0 113.514 -173.448 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -49.27 -56.07 10.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.382 1.473 . . . . 0.0 110.876 169.043 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.23 -16.22 31.6 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.277 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 20.8 m -55.0 -31.79 61.28 Favored 'General case' 0 N--CA 1.471 0.594 0 O-C-N 120.091 -1.631 . . . . 0.0 112.702 168.527 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.264 2.8 t -97.44 -8.49 29.23 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 174.08 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -87.68 -60.95 1.83 Allowed 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.289 -1.507 . . . . 0.0 111.202 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 28.5 p -102.87 -24.92 13.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 126.018 1.727 . . . . 0.0 114.413 -177.223 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.55 -22.87 35.95 Favored Glycine 0 C--O 1.213 -1.159 0 CA-C-O 117.93 -1.483 . . . . 0.0 110.075 -166.26 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 33.2 t30 56.83 19.11 4.22 Favored 'General case' 0 CA--C 1.548 0.875 0 CA-C-N 119.351 1.576 . . . . 0.0 112.387 173.705 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.76 -23.16 2.51 Favored 'General case' 0 CA--C 1.557 1.226 0 C-N-CA 129.079 2.952 . . . . 0.0 115.057 -171.664 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 93.94 -153.19 21.07 Favored Glycine 0 C--N 1.343 0.924 0 C-N-CA 126.692 2.091 . . . . 0.0 114.414 174.765 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.03 151.88 2.45 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.711 2.004 . . . . 0.0 113.481 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 15.1 mtp-105 -66.24 166.88 11.2 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.9 -1.125 . . . . 0.0 113.474 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tp -150.01 -152.6 0.45 Allowed 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 128.727 2.811 . . . . 0.0 106.911 166.888 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.29 178.3 7.23 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -178.668 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.5 p -158.16 159.18 35.89 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.107 1.363 . . . . 0.0 111.459 -173.28 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.38 170.52 34.53 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.696 1.617 . . . . 0.0 113.416 176.086 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.54 147.41 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.639 1.176 . . . . 0.0 110.007 179.346 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.2 mm -93.47 76.68 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.324 0.65 . . . . 0.0 110.042 -178.71 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.57 161.88 32.7 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 123.652 0.644 . . . . 0.0 112.225 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.48 ' N ' HD12 ' B' ' 151' ' ' ILE . 1.1 mp -75.05 134.87 28.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -175.452 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.451 ' HB1' ' HE3' ' B' ' 3' ' ' LYS . . . -108.82 35.13 3.34 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.461 1.504 . . . . 0.0 113.485 -168.735 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 . . . . . 0 C--N 1.324 -0.518 0 C-N-CA 126.633 1.973 . . . . 0.0 110.691 -177.31 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 118.221 -0.895 . . . . 0.0 108.826 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m -79.71 79.6 6.19 Favored 'General case' 0 C--O 1.217 -0.648 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.294 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 ttmm -120.09 128.11 53.16 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -169.415 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -108.2 171.77 7.22 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.927 0.891 . . . . 0.0 112.921 169.407 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.417 HG11 ' HA ' ' B' ' 52' ' ' ASP . 0.3 OUTLIER -131.43 155.01 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 129.72 3.208 . . . . 0.0 106.908 165.97 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.25 114.81 19.45 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.738 1.154 . . . . 0.0 109.559 166.742 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' HG22 ' B' ' 54' ' ' THR . 8.7 t -88.57 76.42 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 125.185 1.394 . . . . 0.0 108.938 -171.91 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.47 103.96 9.75 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.034 -175.018 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 ttpp -160.92 132.16 5.53 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 123.274 0.63 . . . . 0.0 112.369 166.08 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.15 -95.5 1.94 Allowed Glycine 0 C--N 1.333 0.384 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 168.074 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.31 -177.1 3.41 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.013 1.725 . . . . 0.0 107.974 174.007 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 61.69 -173.55 7.32 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.732 2.11 . . . . 0.0 117.05 168.977 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.54 4.41 7.1 Favored 'Trans proline' 0 CA--C 1.543 0.941 1 C-N-CA 126.347 4.698 . . . . 0.0 113.836 178.593 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 m -79.43 138.03 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 126.848 2.059 . . . . 0.0 111.045 175.595 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.77 169.23 19.5 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 122.238 1.018 . . . . 0.0 109.801 165.707 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -141.17 149.01 20.71 Favored Glycine 0 CA--C 1.499 -0.92 0 CA-C-N 113.379 -1.737 . . . . 0.0 110.078 164.245 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -130.27 112.01 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 172.189 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 mm -135.61 102.44 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 121.469 -0.77 . . . . 0.0 111.077 -174.118 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -72.34 157.28 37.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.165 170.204 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.515 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 58.1 m-85 -137.22 98.71 3.8 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 168.867 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -89.93 108.02 19.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 122.12 0.962 . . . . 0.0 109.75 172.291 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -101.58 149.03 24.53 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 166.104 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -13.53 10.57 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.3 1.44 . . . . 0.0 112.253 -175.36 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.37 -146.06 0.37 Allowed 'General case' 0 CA--C 1.556 1.203 0 C-N-CA 128.919 2.887 . . . . 0.0 108.017 173.236 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.2 p -139.68 -45.84 0.44 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 126.009 1.723 . . . . 0.0 108.294 166.647 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.9 m-80 -85.76 32.45 0.59 Allowed 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.057 1.743 . . . . 0.0 112.722 172.969 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.91 -175.06 13.91 Favored Glycine 0 CA--C 1.538 1.499 0 C-N-CA 125.726 1.632 . . . . 0.0 113.002 177.404 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -76.54 170.99 18.87 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 123.82 3.013 . . . . 0.0 111.507 177.909 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.8 t -132.99 123.62 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.971 0.908 . . . . 0.0 110.31 -170.669 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.0 tttm -87.13 114.33 23.65 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 122.909 1.338 . . . . 0.0 112.621 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 t -95.25 131.1 42.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 125.941 1.696 . . . . 0.0 108.628 -176.646 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -153.38 160.3 42.61 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 173.653 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.08 -149.37 18.85 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 125.151 1.358 . . . . 0.0 111.521 -173.047 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 83.8 p -157.62 159.09 36.66 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 114.318 1.229 . . . . 0.0 114.318 -173.661 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -121.56 117.5 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.461 1.505 . . . . 0.0 107.331 171.863 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -128.88 151.82 49.2 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 126.146 1.779 . . . . 0.0 112.052 -165.165 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.58 10.88 82.73 Favored Glycine 0 CA--C 1.531 1.063 0 CA-C-O 118.773 -1.015 . . . . 0.0 113.785 -178.693 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.26 169.08 10.02 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.94 1.296 . . . . 0.0 111.0 173.332 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 t -69.83 160.13 32.33 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.77 1.228 . . . . 0.0 110.257 173.603 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.94 168.76 0.6 Allowed 'General case' 0 CA--C 1.55 0.961 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 178.611 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.6 -175.26 50.68 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.693 1.14 . . . . 0.0 113.472 170.141 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.465 ' H ' ' CD1' ' A' ' 42' ' ' LEU . 5.2 mp -56.14 147.04 21.37 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.728 2.411 . . . . 0.0 111.324 178.628 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -142.98 116.01 8.86 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 126.206 1.802 . . . . 0.0 110.187 176.004 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.53 151.45 14.35 Favored Glycine 0 N--CA 1.483 1.814 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.89 173.913 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -151.02 105.53 3.25 Favored 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 118.984 1.392 . . . . 0.0 111.089 -165.519 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.4 ' O ' HD12 ' A' ' 117' ' ' LEU . 11.8 m80 -145.57 160.18 42.03 Favored 'General case' 0 N--CA 1.471 0.597 0 O-C-N 119.431 -2.043 . . . . 0.0 113.909 -164.584 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . 0.288 0.4 OUTLIER -129.64 120.71 51.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 122.635 1.207 . . . . 0.0 111.489 -171.854 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -79.29 137.19 37.26 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.91 2.084 . . . . 0.0 109.785 175.829 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.0 pm0 -70.44 16.09 0.08 Allowed 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -178.232 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -126.75 144.23 51.01 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 124.425 1.09 . . . . 0.0 108.572 168.846 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.26 27.57 5.05 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.295 1.426 . . . . 0.0 111.539 168.38 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -86.94 173.1 9.55 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.432 1.493 . . . . 0.0 109.911 173.793 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.64 9.15 4.11 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 118.01 2.596 . . . . 0.0 118.01 164.561 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.4 t -61.3 71.32 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.244 2.217 . . . . 0.0 116.504 -168.57 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -141.84 -63.5 0.44 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 125.483 1.513 . . . . 0.0 112.804 168.068 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 166.59 -153.77 23.77 Favored Glycine 0 N--CA 1.47 0.911 0 O-C-N 120.761 -1.212 . . . . 0.0 112.52 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -56.11 -9.52 0.65 Allowed 'General case' 0 CA--C 1.552 1.022 0 N-CA-C 116.474 2.027 . . . . 0.0 116.474 -172.415 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 t -81.46 0.52 37.36 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.927 1.691 . . . . 0.0 113.256 173.725 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 60.9 m -159.39 178.42 9.94 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.564 1.945 . . . . 0.0 110.218 179.176 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 85.68 -125.73 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.502 1.921 . . . . 0.0 113.007 172.601 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 170.73 -153.9 21.83 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 125.677 1.608 . . . . 0.0 111.765 -169.962 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -109.32 57.58 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 123.619 2.879 . . . . 0.0 112.453 -174.547 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 61.95 87.83 0.09 Allowed 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.229 1.411 . . . . 0.0 108.338 -177.415 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -46.36 152.05 0.47 Allowed 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 113.15 -1.841 . . . . 0.0 111.447 -178.686 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.47 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.8 p-10 -136.47 101.06 10.06 Favored Pre-proline 0 CA--C 1.551 1.018 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -164.94 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.93 -27.78 3.64 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.25 1.967 . . . . 0.0 111.072 -176.171 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.25 -6.04 55.73 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.526 1.53 . . . . 0.0 111.683 167.761 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.7 t 62.69 48.16 4.4 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.98 2.112 . . . . 0.0 111.487 178.252 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.47 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 11.9 mtp180 -99.02 170.63 8.58 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 124.475 1.11 . . . . 0.0 112.922 -172.54 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.6 mmtt -84.92 174.17 10.01 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.89 1.676 . . . . 0.0 108.614 163.55 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 62.8 t60 -70.6 149.87 46.63 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 120.782 -1.199 . . . . 0.0 112.066 170.301 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -174.51 -165.2 30.61 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 124.071 0.843 . . . . 0.0 114.035 176.963 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.481 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.92 -100.45 0.43 Allowed Glycine 0 CA--C 1.537 1.425 0 CA-C-O 117.571 -1.683 . . . . 0.0 116.811 170.001 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.51 -19.53 23.44 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 CA-C-N 122.093 2.947 . . . . 0.0 116.377 -168.928 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.9 3.16 4.88 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.24 2.216 . . . . 0.0 112.594 176.06 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.481 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 10.3 t70 -145.88 155.7 43.06 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -164.986 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.57 -7.87 49.01 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 128.363 2.665 . . . . 0.0 113.402 -168.943 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -78.04 -106.39 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 118.696 0.68 . . . . 0.0 109.847 172.769 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.9 ttt180 71.58 101.01 0.07 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.166 1.386 . . . . 0.0 110.359 -172.392 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -51.8 152.67 2.82 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.789 -1.194 . . . . 0.0 111.298 166.527 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 19.3 m -52.88 -33.89 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-N 120.571 1.532 . . . . 0.0 112.785 -175.166 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.75 102.24 1.56 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 124.696 1.141 . . . . 0.0 110.639 166.015 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -160.06 116.22 2.43 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.258 2.223 . . . . 0.0 108.775 177.524 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 92.0 mt -103.01 176.32 5.19 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.577 1.08 . . . . 0.0 108.973 168.148 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.15 173.81 54.97 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 167.342 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -74.65 151.49 39.3 Favored 'General case' 0 CA--C 1.55 0.973 0 N-CA-C 115.09 1.515 . . . . 0.0 115.09 -171.544 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.2 m -102.88 117.23 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 127.974 2.51 . . . . 0.0 109.732 179.07 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.9 m -96.82 119.45 35.31 Favored 'General case' 0 N--CA 1.478 0.948 0 O-C-N 120.531 -1.356 . . . . 0.0 111.234 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.39 140.13 37.52 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -76.37 168.66 19.67 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.076 1.751 . . . . 0.0 111.798 170.62 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.8 pttm -45.74 -28.35 1.02 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.136 2.574 . . . . 0.0 115.135 170.822 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.73 -1.56 56.41 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.4 1.48 . . . . 0.0 111.818 -177.505 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.9 24.87 39.88 Favored Glycine 0 C--N 1.342 0.901 0 C-N-CA 125.274 1.416 . . . . 0.0 114.024 177.636 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.6 p -129.91 129.11 65.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 CA-C-N 118.497 1.148 . . . . 0.0 113.902 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.67 129.54 39.94 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.426 1.09 . . . . 0.0 108.129 166.076 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -79.16 151.02 31.53 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 167.935 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.6 t -135.04 123.87 41.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 CA-C-N 112.444 -2.162 . . . . 0.0 109.199 167.623 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.9 p -155.51 50.2 0.55 Allowed 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 124.025 1.869 . . . . 0.0 111.357 -177.311 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -103.45 170.44 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 127.603 2.361 . . . . 0.0 112.324 -166.48 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.94 121.48 20.57 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 165.622 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -98.17 137.17 37.32 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.478 0.656 . . . . 0.0 109.251 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.4 p -118.24 53.47 0.97 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.932 -1.031 . . . . 0.0 112.253 -178.709 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 13.8 p -155.18 -36.78 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.06 0.944 . . . . 0.0 112.629 168.71 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.71 168.97 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 120.115 1.325 . . . . 0.0 110.573 169.016 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 26.5 p -153.6 162.21 41.47 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 124.381 1.072 . . . . 0.0 111.335 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -83.94 66.39 9.13 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-O 122.185 0.993 . . . . 0.0 109.077 173.971 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 73.5 m -112.45 6.32 18.54 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.737 1.615 . . . . 0.0 113.713 -172.523 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.03 -110.91 3.19 Favored Glycine 0 C--N 1.342 0.871 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 175.4 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -62.49 -35.88 80.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 123.16 1.457 . . . . 0.0 112.776 -176.087 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -89.06 -1.79 58.26 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 114.389 -1.278 . . . . 0.0 111.603 -171.081 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.0 m -168.16 -103.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.218 1.807 . . . . 0.0 113.783 170.137 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.2 pt -124.09 164.35 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 120.972 1.714 . . . . 0.0 112.311 -176.78 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 105.64 121.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.234 1 C-N-CA 133.859 4.864 . . . . 0.0 108.305 -167.832 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.17 32.86 85.59 Favored Glycine 0 CA--C 1.527 0.826 0 CA-C-O 119.057 -0.857 . . . . 0.0 113.179 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.63 179.5 3.95 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 127.317 2.247 . . . . 0.0 108.323 173.577 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 21.1 m -130.6 119.35 22.36 Favored 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 121.944 2.157 . . . . 0.0 111.592 -179.078 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.4 HD12 ' O ' ' A' ' 46' ' ' HIS . 22.6 tp -92.35 119.25 31.73 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.554 1.542 . . . . 0.0 110.671 177.146 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.9 p -96.42 141.07 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.503 1.921 . . . . 0.0 111.111 174.647 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.9 p -118.08 137.34 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 122.046 0.927 . . . . 0.0 111.635 171.06 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 87.5 m-70 -99.72 161.95 13.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 125.231 1.412 . . . . 0.0 113.23 -170.128 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -83.7 -23.81 31.53 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -169.596 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -142.65 -174.85 4.27 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.737 0.815 . . . . 0.0 113.032 176.297 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.66 143.7 9.17 Favored 'General case' 0 C--N 1.341 0.206 0 C-N-CA 126.013 1.725 . . . . 0.0 111.215 172.163 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.99 149.6 24.07 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.789 1.636 . . . . 0.0 112.225 173.717 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -76.24 -10.05 59.11 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.762 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.2 mt 48.01 32.95 3.13 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 128.229 2.612 . . . . 0.0 113.235 177.175 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 165.63 -61.49 0.23 Allowed Glycine 0 N--CA 1.467 0.702 0 CA-C-N 120.492 1.496 . . . . 0.0 115.165 175.3 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -157.95 98.49 1.62 Allowed 'General case' 0 N--CA 1.428 -1.542 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 177.688 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.572 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -76.56 -115.12 0.14 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 126.222 1.868 . . . . 0.0 109.505 165.084 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -142.86 9.0 2.28 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 119.585 2.594 . . . . 0.0 119.585 -168.795 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -145.22 -169.38 3.19 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 120.651 2.226 . . . . 0.0 112.308 176.515 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -62.18 -49.87 74.07 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 121.173 1.806 . . . . 0.0 112.271 178.24 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.38 -22.85 63.8 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 123.439 0.696 . . . . 0.0 112.007 -177.65 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.572 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 25.2 m -64.37 -5.4 5.14 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.954 1.465 . . . . 0.0 114.954 168.193 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -122.35 -20.11 6.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.342 1.457 . . . . 0.0 112.029 172.634 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 85.7 mttt -84.2 -69.85 0.61 Allowed 'General case' 0 CA--C 1.547 0.839 0 O-C-N 120.983 -1.073 . . . . 0.0 111.752 172.939 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -92.11 -13.45 30.74 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 177.646 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 83.5 21.72 57.71 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 119.454 1.024 . . . . 0.0 110.855 -165.716 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 52.15 36.23 18.62 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.596 1.958 . . . . 0.0 113.7 176.848 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.1 40.61 0.08 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 116.136 1.902 . . . . 0.0 116.136 -168.799 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.91 -64.06 1.95 Allowed Glycine 0 CA--C 1.528 0.865 0 C-N-CA 126.53 2.014 . . . . 0.0 112.469 -171.543 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 29.9 t -177.07 -150.45 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 C-N-CA 126.809 2.044 . . . . 0.0 109.547 -171.262 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.439 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -156.83 104.57 2.14 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.959 2.104 . . . . 0.0 112.479 -176.77 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.2 pp -72.85 -35.57 67.25 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.222 1.409 . . . . 0.0 114.653 -176.613 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.39 172.85 9.3 Favored 'General case' 0 C--O 1.239 0.54 0 C-N-CA 124.904 1.282 . . . . 0.0 111.767 -175.77 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.0 p -156.43 165.72 35.51 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 127.225 2.21 . . . . 0.0 111.048 175.15 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.45 147.28 15.56 Favored Glycine 0 C--N 1.337 0.617 0 C-N-CA 124.58 1.086 . . . . 0.0 114.036 -175.042 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -73.12 141.37 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.051 0.541 . . . . 0.0 110.124 175.017 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.5 mp -77.78 80.0 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.535 1.134 . . . . 0.0 109.506 169.384 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -79.36 171.34 54.83 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.084 1.325 . . . . 0.0 112.485 172.472 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.464 ' H ' ' HA3' ' B' ' 51' ' ' GLY . 2.4 mp -102.05 131.25 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 126.142 1.777 . . . . 0.0 111.435 -169.478 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.62 37.84 4.25 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.975 2.11 . . . . 0.0 110.706 -179.662 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.549 0 C-N-CA 129.353 3.061 . . . . 0.0 115.072 -167.525 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 121.786 0.803 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.93 106.22 4.05 Favored 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 124.428 1.091 . . . . 0.0 109.359 169.778 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 118.22 21.39 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 170.058 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.04 168.85 18.66 Favored 'General case' 0 CA--C 1.54 0.568 0 O-C-N 120.641 -1.287 . . . . 0.0 108.51 163.576 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.67 155.35 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.8 0.81 . . . . 0.0 113.026 -166.388 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.24 143.49 25.0 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.389 2.276 . . . . 0.0 107.386 165.757 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.1 m -113.05 117.79 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 168.098 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.89 125.99 33.74 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.064 0.946 . . . . 0.0 109.863 -168.848 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -146.2 177.08 9.26 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.354 1.062 . . . . 0.0 113.507 170.651 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.12 -65.97 0.25 Allowed Glycine 0 C--N 1.33 0.201 0 C-N-CA 126.497 1.999 . . . . 0.0 109.024 -176.666 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -103.09 85.01 2.43 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.966 2.106 . . . . 0.0 112.797 -167.165 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.06 -98.43 0.01 OUTLIER Glycine 0 CA--C 1.537 1.467 0 C-N-CA 127.071 2.272 . . . . 0.0 115.98 167.785 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -77.06 -8.69 17.77 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.617 2.878 . . . . 0.0 115.433 -173.549 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -98.31 138.82 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 CA-C-N 121.061 1.755 . . . . 0.0 110.866 176.14 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.5 pm0 -160.16 166.07 30.43 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 125.43 1.492 . . . . 0.0 110.801 171.255 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.31 175.61 33.94 Favored Glycine 0 CA--C 1.507 -0.422 0 C-N-CA 123.283 0.468 . . . . 0.0 113.398 169.227 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.02 146.62 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 123.445 0.698 . . . . 0.0 110.114 169.561 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.17 155.2 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 123.807 0.843 . . . . 0.0 110.108 167.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -127.67 148.32 50.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.8 1.24 . . . . 0.0 109.669 167.735 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -128.16 97.79 4.88 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.369 1.468 . . . . 0.0 110.395 178.563 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -81.36 106.53 13.4 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.367 1.067 . . . . 0.0 113.62 -176.148 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -101.7 140.57 35.82 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 165.298 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.33 -13.47 9.28 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 125.933 1.693 . . . . 0.0 112.361 169.782 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -97.45 -145.01 0.3 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 131.019 3.728 . . . . 0.0 109.772 173.089 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 57.7 m -163.61 40.57 0.09 Allowed 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 127.883 2.473 . . . . 0.0 107.772 168.714 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 p30 178.02 -42.51 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 126.682 1.993 . . . . 0.0 112.436 -167.133 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.86 -168.46 21.74 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 125.333 1.444 . . . . 0.0 113.435 178.986 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.42 172.43 9.07 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 124.381 3.387 . . . . 0.0 114.554 -169.741 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 65.2 t -140.95 133.59 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 123.994 0.918 . . . . 0.0 111.391 177.954 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 mttp -80.18 116.95 20.56 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.285 0.564 . . . . 0.0 110.449 169.601 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.1 t -98.95 114.49 36.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 125.547 1.539 . . . . 0.0 109.099 170.057 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.3 p90 -137.28 154.87 50.01 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 123.529 0.731 . . . . 0.0 111.676 169.887 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 159.92 166.8 19.51 Favored Glycine 0 C--N 1.336 0.576 0 N-CA-C 114.82 0.688 . . . . 0.0 114.82 177.806 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 13.0 p -132.52 126.69 33.5 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.278 1.031 . . . . 0.0 111.3 -170.072 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.0 mm -112.77 125.38 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 124.984 1.314 . . . . 0.0 111.14 174.772 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -130.53 135.62 48.11 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 120.575 1.534 . . . . 0.0 112.737 -169.096 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.74 -4.48 10.79 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 126.197 1.856 . . . . 0.0 114.058 -176.494 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.516 HD13 ' H ' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -95.16 168.8 10.53 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.866 1.667 . . . . 0.0 111.724 170.464 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 m -69.36 152.77 44.55 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 127.18 2.192 . . . . 0.0 111.859 177.064 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 40' ' ' GLU . . . . . 0.422 ' HA ' ' HB3' ' B' ' 89' ' ' ALA . 9.6 pm0 -51.95 157.07 1.34 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.867 1.667 . . . . 0.0 113.52 169.257 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.73 177.56 43.96 Favored Glycine 0 CA--C 1.539 1.555 0 O-C-N 120.653 -1.279 . . . . 0.0 114.567 -176.614 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 147.58 21.32 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 128.035 2.534 . . . . 0.0 114.635 -176.071 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -144.51 130.45 19.35 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 127.068 2.147 . . . . 0.0 109.737 175.643 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.39 156.31 31.93 Favored Glycine 0 N--CA 1.476 1.305 0 C-N-CA 125.001 1.286 . . . . 0.0 113.694 -175.986 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -150.4 141.09 22.66 Favored 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 -170.025 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -145.43 115.9 7.6 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 118.234 -0.889 . . . . 0.0 113.303 -170.136 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 47' ' ' VAL . . . . . 0.578 HG12 ' HB3' ' B' ' 115' ' ' ARG . 0.3 OUTLIER -87.85 98.24 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 167.794 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.419 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 45.4 m170 -73.83 151.43 40.54 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 121.657 -0.652 . . . . 0.0 111.703 -170.982 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -49.93 126.19 13.64 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.017 1.727 . . . . 0.0 113.005 174.181 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 93.24 147.28 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 130.54 3.536 . . . . 0.0 114.443 172.128 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.464 ' HA3' ' H ' ' A' ' 151' ' ' ILE . . . -77.55 -7.5 87.14 Favored Glycine 0 CA--C 1.533 1.201 0 CA-C-O 117.558 -1.69 . . . . 0.0 113.096 168.257 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.417 ' HA ' HG11 ' A' ' 5' ' ' VAL . 14.4 t0 -86.39 132.1 34.04 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 120.313 2.056 . . . . 0.0 109.506 167.774 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' N ' ' B' ' 53' ' ' ASN 0.317 0.0 OUTLIER -157.85 28.33 0.27 Allowed 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 114.981 1.475 . . . . 0.0 114.981 179.243 . . . . . . . . 4 4 . 1 . 027 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 7' ' ' VAL . 17.9 p -102.13 -22.71 14.16 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -168.4 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.73 6.45 47.46 Favored 'General case' 0 CA--C 1.551 0.992 0 C-N-CA 123.853 0.861 . . . . 0.0 110.694 165.885 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.57 -110.81 3.59 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 125.038 1.304 . . . . 0.0 111.775 171.578 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 72.1 m -71.03 -11.44 60.97 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -171.287 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -102.06 1.62 36.63 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.569 1.147 . . . . 0.0 113.101 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 68.6 m -99.9 -125.72 0.17 Allowed 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 124.846 1.258 . . . . 0.0 108.098 168.176 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.86 83.31 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.744 1.618 . . . . 0.0 114.297 171.743 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.07 167.23 27.09 Favored Glycine 0 CA--C 1.542 1.722 0 C-N-CA 125.174 1.369 . . . . 0.0 113.758 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 62' ' ' PRO . . . . . 0.419 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 59.9 Cg_endo -64.74 89.95 0.18 Allowed 'Trans proline' 0 C--N 1.354 0.824 1 C-N-CA 125.881 4.387 . . . . 0.0 112.248 -170.097 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.379 0.1 OUTLIER 47.94 59.67 4.06 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 127.167 2.187 . . . . 0.0 113.79 175.85 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -47.72 129.88 14.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 111.884 -2.417 . . . . 0.0 109.541 168.034 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -110.21 66.33 0.44 Allowed Pre-proline 0 CA--C 1.549 0.931 0 C-N-CA 125.964 1.706 . . . . 0.0 114.823 -167.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -64.16 -21.04 67.84 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.002 2.468 . . . . 0.0 116.045 -169.417 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.38 -4.44 48.19 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.795 0.838 . . . . 0.0 112.703 172.488 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.0 t 67.36 46.99 1.34 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 128.691 2.797 . . . . 0.0 110.513 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.8 mtm-85 -109.5 167.1 10.38 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.059 -177.658 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -85.85 176.84 7.87 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 127.657 2.383 . . . . 0.0 108.175 167.016 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -62.63 175.21 0.84 Allowed 'General case' 0 CA--C 1.544 0.745 0 O-C-N 121.336 -0.852 . . . . 0.0 112.812 173.963 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.68 -149.79 20.75 Favored Glycine 0 C--N 1.339 0.718 0 N-CA-C 115.641 1.016 . . . . 0.0 115.641 170.386 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.86 -117.3 2.17 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 125.727 1.632 . . . . 0.0 112.755 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -65.01 -11.37 29.5 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.786 2.991 . . . . 0.0 116.075 -169.305 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.53 -3.13 10.92 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 119.534 1.061 . . . . 0.0 113.145 168.737 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -152.17 98.03 2.37 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -166.783 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 63.9 mm-40 -39.72 -4.99 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 131.32 3.848 . . . . 0.0 118.47 171.316 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -74.0 -75.95 0.14 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 121.021 1.737 . . . . 0.0 110.116 170.522 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.254 0.0 OUTLIER 52.76 107.02 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 127.326 2.251 . . . . 0.0 113.869 -177.595 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -54.53 143.79 23.3 Favored 'General case' 0 CA--C 1.552 1.028 0 O-C-N 119.631 -1.918 . . . . 0.0 110.525 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 96.9 t -35.36 -59.26 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -168.123 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.78 18.71 16.68 Favored Glycine 0 N--CA 1.468 0.801 0 CA-C-O 119.335 -0.703 . . . . 0.0 112.989 176.831 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.46 89.68 2.88 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-N 119.526 1.663 . . . . 0.0 111.775 -167.633 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.11 163.35 37.71 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 114.634 -1.166 . . . . 0.0 113.578 -167.86 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 78.25 170.37 36.47 Favored Glycine 0 N--CA 1.472 1.044 0 N-CA-C 115.274 0.87 . . . . 0.0 115.274 168.46 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 86' ' ' ASN . . . . . 0.446 HD21 ' HB2' ' B' ' 124' ' ' ASP . 1.3 m-80 -134.48 149.54 50.73 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.908 1.283 . . . . 0.0 109.969 174.827 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.5 m -112.53 129.31 68.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.884 1.674 . . . . 0.0 109.204 169.505 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.7 m -113.15 133.81 54.86 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 121.24 -0.913 . . . . 0.0 109.903 -170.119 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.422 ' HB3' ' HA ' ' B' ' 40' ' ' GLU . . . -88.15 137.3 32.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.711 1.204 . . . . 0.0 113.522 -178.212 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.86 -59.25 2.86 Favored 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -168.212 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 172.81 -40.88 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 128.405 2.682 . . . . 0.0 110.731 -166.047 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -78.25 13.2 1.58 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 125.877 1.671 . . . . 0.0 112.281 174.154 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.77 25.56 70.57 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-O 118.932 -0.927 . . . . 0.0 113.38 -177.242 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 94' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' B' ' 89' ' ' ALA . 7.4 p -105.96 109.52 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 126.338 1.855 . . . . 0.0 110.991 176.155 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -79.28 108.84 13.08 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 168.175 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -110.53 159.04 17.88 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 122.313 1.054 . . . . 0.0 112.273 -176.412 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -149.6 148.0 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 CA-C-N 113.62 -1.627 . . . . 0.0 115.302 176.91 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -157.77 98.61 1.65 Allowed 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 124.2 1.0 . . . . 0.0 112.306 169.687 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 15.2 mt -139.7 152.3 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 127.522 2.329 . . . . 0.0 110.876 -172.746 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -117.53 127.23 53.78 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 165.855 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -117.28 146.49 43.28 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.517 1.527 . . . . 0.0 111.049 176.097 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 51.31 0.95 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.495 0.718 . . . . 0.0 112.913 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 47.2 t -136.39 -50.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.252 1.421 . . . . 0.0 109.635 175.336 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.84 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 CA-C-N 119.128 0.877 . . . . 0.0 111.747 174.656 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.88 161.66 39.67 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 119.888 -1.758 . . . . 0.0 111.251 -178.453 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.83 58.46 1.89 Allowed 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.88 1.324 . . . . 0.0 110.602 177.257 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.31 160.6 20.67 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 124.544 1.137 . . . . 0.0 108.8 168.128 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.25 -59.0 10.15 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 119.612 2.605 . . . . 0.0 119.612 -163.21 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -148.94 34.87 0.75 Allowed 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 122.862 1.315 . . . . 0.0 110.745 -172.142 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -158.01 4.08 0.12 Allowed 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 114.957 1.466 . . . . 0.0 114.957 -168.759 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 10.6 t -133.28 -91.21 0.37 Allowed 'General case' 0 N--CA 1.48 1.031 0 O-C-N 119.984 -1.698 . . . . 0.0 109.634 -178.313 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.283 5.4 pt -120.26 -14.66 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-N 121.185 1.811 . . . . 0.0 115.696 166.861 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm -82.75 152.64 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 161.122 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.05 41.71 86.58 Favored Glycine 0 N--CA 1.467 0.703 0 C-N-CA 124.103 0.858 . . . . 0.0 112.401 -176.446 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 115' ' ' ARG . . . . . 0.578 ' HB3' HG12 ' B' ' 47' ' ' VAL . 1.3 mpt_? -144.88 171.16 14.82 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 127.242 2.217 . . . . 0.0 109.004 172.17 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.5 t -139.42 122.66 16.98 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.873 -1.142 . . . . 0.0 110.979 -177.694 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 39.8 tp -92.07 108.87 20.25 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -169.464 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.8 p -90.62 142.35 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 125.32 1.448 . . . . 0.0 110.117 168.136 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -120.66 146.09 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.458 0.646 . . . . 0.0 111.316 172.012 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 120' ' ' HIS . . . . . 0.41 ' HA ' ' HA ' ' B' ' 143' ' ' ARG . 92.0 m-70 -105.63 141.37 37.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.56 1.544 . . . . 0.0 114.369 -168.728 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.317 0.2 OUTLIER -72.03 -18.39 61.96 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 120.841 -1.162 . . . . 0.0 112.037 178.24 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mttp -104.29 162.92 12.79 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 124.466 1.106 . . . . 0.0 112.759 168.067 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.0 165.08 9.44 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.308 1.843 . . . . 0.0 110.789 167.046 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 124' ' ' ASP . . . . . 0.54 ' HB3' ' H ' ' B' ' 126' ' ' LEU . 12.4 m-20 -95.2 158.9 15.26 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 122.126 0.965 . . . . 0.0 113.177 169.712 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.34 -7.9 50.2 Favored 'General case' 0 CA--C 1.557 1.22 0 CA-C-N 113.715 -1.584 . . . . 0.0 112.561 167.026 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.54 ' H ' ' HB3' ' B' ' 124' ' ' ASP . 96.3 mt 33.11 44.91 0.06 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 129.543 3.137 . . . . 0.0 114.068 -174.737 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.67 -52.38 0.83 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 115.854 1.101 . . . . 0.0 115.854 168.773 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -155.99 80.94 1.0 Allowed 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 117.046 2.239 . . . . 0.0 117.046 -169.22 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB3' ' B' ' 134' ' ' SER . . . -80.2 -115.02 0.29 Allowed Glycine 0 CA--C 1.524 0.625 0 C-N-CA 124.076 0.846 . . . . 0.0 111.009 166.389 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -137.9 11.72 3.65 Favored Glycine 0 N--CA 1.472 1.071 0 N-CA-C 116.893 1.517 . . . . 0.0 116.893 -169.338 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -144.12 174.84 10.52 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 119.819 1.81 . . . . 0.0 111.765 177.65 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 132' ' ' GLU . . . . . 0.526 ' CG ' ' HE3' ' B' ' 136' ' ' LYS . 3.2 tp10 -51.59 -64.27 0.87 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.463 1.505 . . . . 0.0 112.574 173.08 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -53.18 -31.15 41.29 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -179.638 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 134' ' ' SER . . . . . 0.593 ' HB3' ' H ' ' B' ' 129' ' ' GLY . 26.1 m -49.69 -39.23 36.09 Favored 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.832 1.651 . . . . 0.0 113.969 170.773 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.76 -58.32 2.14 Favored 'General case' 0 CA--C 1.52 -0.205 0 C-N-CA 127.191 2.196 . . . . 0.0 110.294 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.526 ' HE3' ' CG ' ' B' ' 132' ' ' GLU . 22.2 ttpp -61.98 -39.62 92.81 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.1 1.36 . . . . 0.0 113.47 -172.197 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 p -109.4 -79.04 0.58 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 119.523 1.056 . . . . 0.0 110.179 174.079 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 170.71 11.9 0.02 OUTLIER Glycine 0 CA--C 1.54 1.65 1 C-N-CA 131.625 4.44 . . . . 0.0 115.389 -179.006 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 20.8 t30 58.97 -35.67 0.06 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 128.831 2.852 . . . . 0.0 117.257 -170.688 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.79 -44.19 1.0 Allowed 'General case' 0 CA--C 1.554 1.113 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -165.33 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.57 -82.05 1.53 Allowed Glycine 0 C--N 1.341 0.829 0 N-CA-C 117.108 1.603 . . . . 0.0 117.108 164.264 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.3 t -80.78 151.62 28.69 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 123.817 0.847 . . . . 0.0 111.143 -169.083 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -144.49 159.53 42.62 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.728 1.149 . . . . 0.0 113.966 -168.539 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.22 -9.07 2.0 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 125.574 1.796 . . . . 0.0 115.524 -171.39 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -173.3 149.42 1.75 Allowed 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.354 1.062 . . . . 0.0 111.12 -177.657 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.0 t -148.31 150.83 34.32 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.673 1.589 . . . . 0.0 111.413 177.712 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.9 138.03 5.71 Favored Glycine 0 N--CA 1.474 1.191 0 CA-C-N 119.367 0.985 . . . . 0.0 114.55 175.192 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -74.28 144.54 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.351 0.66 . . . . 0.0 111.264 -179.644 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 13.3 mm -84.65 105.97 14.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 CA-C-O 121.635 0.731 . . . . 0.0 111.764 179.291 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.87 -175.73 19.06 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 125.07 1.319 . . . . 0.0 111.456 168.235 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 3.9 mp -122.32 132.49 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 O-C-N 121.105 -1.233 . . . . 0.0 110.772 -169.732 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 -7.93 16.21 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.056 1.343 . . . . 0.0 113.071 171.145 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.305 0.7 OUTLIER . . . . . 0 C--O 1.238 0.451 0 C-N-CA 126.358 1.863 . . . . 0.0 112.734 -179.443 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.69 0 CA-C-O 116.0 -1.952 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -91.94 77.56 5.42 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 122.671 2.487 . . . . 0.0 111.646 -169.677 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -75.91 161.66 28.77 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -167.655 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.44 164.2 28.32 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.996 1.318 . . . . 0.0 110.255 168.873 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.547 ' CG1' ' HA ' ' B' ' 52' ' ' ASP . 7.3 p -132.61 129.56 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 124.612 1.165 . . . . 0.0 109.265 -179.027 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.81 110.72 15.44 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 120.994 -1.066 . . . . 0.0 109.179 177.869 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' B' ' 54' ' ' THR . 3.8 t -81.17 60.26 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 123.997 0.919 . . . . 0.0 111.563 -169.087 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.2 mp -76.72 116.87 17.78 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -167.779 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.422 ' CE ' HG12 ' A' ' 7' ' ' VAL . 34.4 mtmt -145.95 175.09 10.7 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 125.453 1.501 . . . . 0.0 111.896 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.92 -3.56 7.96 Favored Glycine 0 N--CA 1.474 1.233 0 N-CA-C 119.902 2.721 . . . . 0.0 119.902 166.832 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -137.29 83.11 1.97 Allowed 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 121.607 2.704 . . . . 0.0 110.163 178.827 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 38.44 -105.99 0.05 OUTLIER Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.522 2.011 . . . . 0.0 114.032 179.482 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -73.66 -5.84 17.73 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 124.279 3.32 . . . . 0.0 113.954 -176.25 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.4 ' C ' HE21 ' A' ' 15' ' ' GLN . 16.1 t -94.06 126.65 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 125.066 1.346 . . . . 0.0 111.699 -177.347 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.4 HE21 ' C ' ' A' ' 14' ' ' VAL . 1.2 mp0 -146.61 168.32 21.58 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 126.818 2.047 . . . . 0.0 108.01 169.457 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.23 170.91 24.82 Favored Glycine 0 CA--C 1.507 -0.413 0 CA-C-N 115.224 -0.898 . . . . 0.0 112.606 168.317 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 pt -150.34 53.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 114.195 -1.002 . . . . 0.0 111.169 -167.657 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.6 mm -80.35 112.23 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 O-C-N 120.984 -1.072 . . . . 0.0 110.348 -169.447 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.09 149.23 33.93 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 125.18 1.392 . . . . 0.0 111.491 175.969 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -134.51 116.24 14.85 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.299 1.84 . . . . 0.0 108.641 178.099 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -97.97 112.38 24.34 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.919 1.288 . . . . 0.0 112.255 175.329 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.4 tp60 -107.4 129.32 54.94 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 125.338 1.455 . . . . 0.0 109.226 177.968 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.53 -48.99 6.94 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.85 0.86 . . . . 0.0 111.447 178.784 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.63 136.46 51.67 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 127.302 2.241 . . . . 0.0 108.933 174.695 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 m -62.55 0.62 0.46 Allowed 'General case' 0 N--CA 1.48 1.05 0 N-CA-C 117.594 2.442 . . . . 0.0 117.594 -168.919 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.6 m-80 -114.22 -9.89 12.81 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 127.727 2.411 . . . . 0.0 113.9 178.033 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.6 -178.09 33.9 Favored Glycine 0 CA--C 1.537 1.424 0 CA-C-N 119.491 1.041 . . . . 0.0 115.053 -169.372 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -70.82 160.09 50.51 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.592 3.528 . . . . 0.0 110.898 -178.486 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.9 t -129.81 138.04 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.929 -0.482 . . . . 0.0 111.083 -170.68 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 100' ' ' GLU . 78.2 mttt -86.37 121.11 28.47 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 168.745 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.4 t -109.87 121.46 62.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.969 2.107 . . . . 0.0 108.692 -177.571 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -148.25 165.04 32.18 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 177.541 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.84 -173.37 14.67 Favored Glycine 0 N--CA 1.468 0.828 0 O-C-N 121.431 -0.793 . . . . 0.0 112.333 -178.741 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.85 167.32 21.98 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 -164.916 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -125.11 129.67 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 127.408 2.283 . . . . 0.0 108.421 171.709 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 44.8 pttt -115.33 159.01 21.59 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 120.316 1.416 . . . . 0.0 111.796 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.94 -6.97 73.4 Favored Glycine 0 N--CA 1.475 1.253 0 C-N-CA 125.371 1.462 . . . . 0.0 114.517 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 8.2 mp -62.86 153.17 34.07 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.872 2.069 . . . . 0.0 111.583 173.066 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -78.75 158.6 28.23 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 166.858 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -55.21 143.49 27.54 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.472 0.709 . . . . 0.0 112.87 175.607 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.09 -176.14 21.74 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 123.992 0.806 . . . . 0.0 114.84 177.44 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -68.29 139.19 55.93 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 127.775 2.43 . . . . 0.0 113.247 -171.124 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -145.45 120.37 9.99 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 128.565 2.746 . . . . 0.0 110.349 -174.711 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.98 22.88 Favored Glycine 0 N--CA 1.482 1.73 0 CA-C-O 117.095 -1.947 . . . . 0.0 112.716 -175.84 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.449 ' CB ' HG22 ' A' ' 119' ' ' VAL . 11.3 p90 -130.41 120.78 24.76 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.742 1.771 . . . . 0.0 113.478 177.522 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.414 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -154.3 156.11 36.37 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 115.195 -0.912 . . . . 0.0 112.843 -168.737 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 p -77.01 135.51 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 122.992 0.517 . . . . 0.0 109.844 171.305 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -112.48 171.97 7.2 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.895 1.678 . . . . 0.0 111.459 172.19 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -40.69 119.77 1.17 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.093 1.757 . . . . 0.0 113.178 -176.072 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -88.63 -164.43 1.13 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.846 2.458 . . . . 0.0 111.045 -177.328 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.71 -79.11 0.9 Allowed Glycine 0 C--N 1.334 0.464 0 N-CA-C 115.327 0.891 . . . . 0.0 115.327 167.076 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.517 ' HA ' HG11 ' B' ' 5' ' ' VAL . 44.9 p-10 -128.99 47.88 2.42 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 126.805 2.042 . . . . 0.0 115.19 -164.029 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 11.6 p30 -154.75 -30.73 0.11 Allowed 'General case' 0 N--CA 1.478 0.97 0 O-C-N 120.577 -1.327 . . . . 0.0 114.48 -172.68 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.342 12.4 t 21.15 35.88 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.6 1 C-N-CA 133.235 4.614 . . . . 0.0 120.408 173.251 . . . . . . . . 3 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -146.57 -2.78 0.64 Allowed 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 128.35 2.66 . . . . 0.0 111.101 169.652 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.42 -154.79 24.49 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.244 1.402 . . . . 0.0 114.0 175.67 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.2 t -46.86 -27.39 1.22 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.117 1.767 . . . . 0.0 115.263 -172.861 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 t -56.16 -14.51 2.77 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 126.715 2.006 . . . . 0.0 114.528 169.006 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.9 t -150.28 9.37 0.65 Allowed 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 127.044 2.138 . . . . 0.0 113.74 174.857 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -129.22 172.97 10.92 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 -168.167 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -97.95 -150.54 26.42 Favored Glycine 0 CA--C 1.546 2.021 0 C-N-CA 125.367 1.46 . . . . 0.0 115.383 -176.276 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -78.75 -170.03 0.91 Allowed 'Trans proline' 0 C--N 1.352 0.761 1 C-N-CA 127.831 5.688 . . . . 0.0 111.385 -179.651 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.417 ' CD2' ' HA ' ' A' ' 137' ' ' THR . 12.2 m170 -62.69 116.51 5.26 Favored 'General case' 0 N--CA 1.451 -0.412 0 O-C-N 121.97 -0.456 . . . . 0.0 111.029 177.743 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 146.94 44.46 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -174.383 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -110.32 79.69 1.72 Allowed Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.656 1.354 . . . . 0.0 114.656 -176.117 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.81 -12.55 14.83 Favored 'Trans proline' 0 CA--C 1.54 0.778 0 C-N-CA 123.14 2.56 . . . . 0.0 112.071 168.12 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.591 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 85.1 mt -137.61 2.82 2.48 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.163 1.785 . . . . 0.0 112.797 -168.394 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 25.2 m 58.96 70.18 0.67 Allowed 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 124.824 1.249 . . . . 0.0 113.092 168.689 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.591 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.2 ptp180 -155.48 177.42 11.39 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 119.874 3.287 . . . . 0.0 119.874 -163.99 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.416 ' HE2' ' N ' ' A' ' 70' ' ' LYS . 0.7 OUTLIER -78.81 178.03 8.24 Favored 'General case' 0 CA--C 1.549 0.907 0 CA-C-N 113.992 -1.458 . . . . 0.0 111.499 168.057 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.441 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 83.7 t60 -115.85 159.81 21.01 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -168.701 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.441 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 136.37 -102.81 0.42 Allowed Glycine 0 C--N 1.333 0.378 0 C-N-CA 125.586 1.565 . . . . 0.0 109.829 166.54 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.434 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 105.55 -36.92 4.08 Favored Glycine 0 CA--C 1.549 2.17 0 CA-C-O 117.448 -1.751 . . . . 0.0 116.558 -177.034 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -73.45 -19.98 21.3 Favored 'Trans proline' 0 C--N 1.358 1.043 0 CA-C-N 122.156 2.978 . . . . 0.0 113.863 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.19 -1.42 0.74 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 125.488 1.515 . . . . 0.0 112.267 -175.011 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.434 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -122.37 139.92 53.27 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 128.701 2.8 . . . . 0.0 107.192 -178.15 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -97.43 -9.24 27.66 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 128.052 2.541 . . . . 0.0 112.647 -174.456 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -82.57 -82.49 0.14 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.087 0.858 . . . . 0.0 109.196 -178.708 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 79.95 110.92 0.07 Allowed 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 126.604 1.961 . . . . 0.0 114.213 164.74 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 8.4 m80 -62.43 128.52 36.4 Favored 'General case' 0 CA--C 1.546 0.811 0 O-C-N 119.784 -1.823 . . . . 0.0 107.247 167.098 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.2 p -39.83 -36.6 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.215 0 N-CA-C 118.556 2.798 . . . . 0.0 118.556 -167.185 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.65 19.51 36.04 Favored Glycine 0 N--CA 1.477 1.386 0 CA-C-N 120.283 1.401 . . . . 0.0 115.39 178.687 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -78.31 140.35 38.81 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 119.223 1.512 . . . . 0.0 112.315 174.798 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.3 -176.36 3.12 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 163.224 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.52 -137.21 2.65 Favored Glycine 0 N--CA 1.468 0.831 0 O-C-N 121.322 -0.861 . . . . 0.0 111.861 174.808 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.6 p30 -100.59 147.39 26.0 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 122.006 -0.702 . . . . 0.0 112.008 168.119 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.47 149.84 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 127.572 2.349 . . . . 0.0 107.328 169.183 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.4 m -107.94 140.29 41.29 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.774 -0.579 . . . . 0.0 110.058 179.204 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.43 138.7 31.34 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.725 0.81 . . . . 0.0 111.944 171.984 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -80.37 147.61 30.97 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.468 1.507 . . . . 0.0 109.991 168.168 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -46.69 -22.18 0.27 Allowed 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 128.605 2.762 . . . . 0.0 116.641 174.329 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.13 0.27 19.48 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.177 1.391 . . . . 0.0 112.186 172.599 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.39 28.97 8.64 Favored Glycine 0 C--N 1.342 0.885 0 C-N-CA 125.987 1.756 . . . . 0.0 114.568 169.545 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.74 134.66 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 119.83 1.815 . . . . 0.0 115.282 -175.225 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.07 110.64 22.69 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 124.597 1.159 . . . . 0.0 107.907 166.334 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -106.71 137.9 43.88 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 122.356 1.074 . . . . 0.0 111.387 175.928 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -116.65 147.09 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-N 112.555 -2.111 . . . . 0.0 114.464 -168.649 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 82.8 p -158.93 90.1 0.97 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 178.655 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.3 mp -132.46 154.87 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 125.847 1.659 . . . . 0.0 112.968 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 30' ' ' LYS . 14.0 tt0 -117.76 115.99 26.13 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 164.039 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -117.57 114.54 23.57 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.327 1.061 . . . . 0.0 111.451 -171.375 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.6 p -84.03 54.91 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.472 -0.767 . . . . 0.0 111.686 -175.035 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.7 p -142.7 -17.55 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 114.75 1.389 . . . . 0.0 114.75 -169.813 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 pp -142.69 161.91 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.914 1.234 . . . . 0.0 112.622 -176.603 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.633 ' H ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -145.1 155.36 43.28 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 125.528 1.531 . . . . 0.0 113.601 -179.721 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.4 mp -83.67 56.94 3.83 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.781 1.632 . . . . 0.0 111.14 -175.449 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.03 -56.05 2.41 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.38 1.472 . . . . 0.0 110.543 178.365 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 143.38 -102.6 0.29 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 115.637 1.015 . . . . 0.0 115.637 169.572 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.81 -33.98 72.45 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 125.02 1.328 . . . . 0.0 111.873 175.002 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -80.02 1.0 29.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.036 1.734 . . . . 0.0 113.245 170.817 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.633 ' HB3' ' H ' ' A' ' 105' ' ' SER . 1.6 m -166.51 -90.42 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 169.846 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.385 7.6 pt -119.16 -99.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -179.015 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . 0.274 24.2 mm 37.11 -88.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 127.37 2.268 . . . . 0.0 113.794 -169.024 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.18 2.4 9.44 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-N 119.911 1.232 . . . . 0.0 115.091 175.612 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -79.38 152.1 30.58 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.571 1.685 . . . . 0.0 107.399 168.465 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.6 t -125.61 119.65 28.66 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 122.237 -0.289 . . . . 0.0 111.126 -168.871 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.72 130.3 34.71 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 124.461 1.104 . . . . 0.0 108.506 176.29 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.5 p -125.69 138.17 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.409 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.464 ' HB ' HD11 ' A' ' 144' ' ' LEU . 32.1 t -101.88 157.01 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 169.196 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.402 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 35.0 m-70 -130.22 146.68 51.86 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.619 1.568 . . . . 0.0 111.886 -167.372 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -71.56 -4.22 25.71 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.852 1.261 . . . . 0.0 114.044 -170.633 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 21.7 mmmt -127.68 160.36 31.91 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.061 1.345 . . . . 0.0 111.953 176.044 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.46 162.81 0.72 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.381 1.472 . . . . 0.0 112.505 169.719 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -111.27 130.18 55.74 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.302 1.841 . . . . 0.0 109.847 -175.336 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.265 1.0 OUTLIER -84.38 -8.15 59.08 Favored 'General case' 0 N--CA 1.48 1.04 0 N-CA-C 116.007 1.854 . . . . 0.0 116.007 -178.931 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 31.6 mt 63.73 42.18 6.43 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.576 1.95 . . . . 0.0 114.71 167.532 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 113.36 -38.11 3.34 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.447 1.022 . . . . 0.0 114.901 167.785 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.52 88.78 1.08 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 119.138 3.014 . . . . 0.0 119.138 169.62 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.4 -69.28 0.88 Allowed Glycine 0 CA--C 1.522 0.487 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 161.833 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.55 -107.94 3.25 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 117.714 1.846 . . . . 0.0 117.714 -168.557 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -102.56 -158.48 0.67 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.126 1.77 . . . . 0.0 113.861 -161.102 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.63 -47.68 49.63 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.133 0.573 . . . . 0.0 111.468 170.176 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -57.0 -34.28 67.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.007 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.456 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 24.0 p -52.43 -30.04 27.46 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 120.315 1.416 . . . . 0.0 112.04 170.109 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.2 p -97.55 -34.1 11.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 117.454 -1.26 . . . . 0.0 113.812 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -92.26 -46.23 7.82 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 114.651 1.352 . . . . 0.0 114.651 -176.835 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.417 ' HA ' ' CD2' ' A' ' 63' ' ' HIS . 17.9 p -90.81 -95.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.538 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 170.199 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -171.74 26.07 0.09 OUTLIER Glycine 0 CA--C 1.536 1.344 1 C-N-CA 132.568 4.89 . . . . 0.0 110.418 176.645 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.456 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 0.1 OUTLIER 56.59 -7.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 129.488 3.115 . . . . 0.0 116.714 -168.989 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.44 -38.36 43.02 Favored 'General case' 0 CA--C 1.55 0.98 0 CA-C-N 119.958 1.254 . . . . 0.0 113.939 -169.401 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.0 -116.03 4.22 Favored Glycine 0 N--CA 1.47 0.906 0 O-C-N 121.024 -1.048 . . . . 0.0 112.577 172.482 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 20.7 m -44.88 115.52 0.9 Allowed 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.524 1.53 . . . . 0.0 114.69 -169.924 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.63 160.5 31.46 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 121.41 -0.806 . . . . 0.0 112.482 172.985 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.464 HD11 ' HB ' ' A' ' 119' ' ' VAL 0.277 3.9 pp -142.28 -153.38 0.46 Allowed 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 126.829 2.052 . . . . 0.0 107.474 165.414 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.85 132.58 46.66 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 119.817 1.19 . . . . 0.0 113.269 -171.38 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.6 p -130.89 146.01 52.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 126.655 1.982 . . . . 0.0 111.63 -174.525 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.17 159.63 30.94 Favored Glycine 0 N--CA 1.472 1.038 0 N-CA-C 114.61 0.604 . . . . 0.0 114.61 179.362 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.59 161.85 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 C-N-CA 123.632 0.773 . . . . 0.0 109.676 168.409 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 27.8 mm -88.52 64.54 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 125.169 1.388 . . . . 0.0 110.096 178.773 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -68.82 139.49 33.08 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -174.06 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -77.76 144.78 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 O-C-N 121.719 -0.871 . . . . 0.0 111.16 -174.33 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.6 -17.16 10.03 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.162 2.185 . . . . 0.0 112.138 175.851 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 N--CA 1.468 0.468 0 C-N-CA 128.594 2.758 . . . . 0.0 113.428 175.27 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.502 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.2 m -78.14 106.09 9.8 Favored 'General case' 0 CA--C 1.51 -0.585 0 C-N-CA 124.766 1.226 . . . . 0.0 110.078 -172.763 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtmm -92.92 124.57 36.99 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 123.624 1.678 . . . . 0.0 113.305 178.667 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -115.66 175.37 5.56 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 127.256 2.222 . . . . 0.0 108.951 166.653 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.517 HG11 ' HA ' ' A' ' 52' ' ' ASP . 1.0 OUTLIER -148.16 146.74 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -177.611 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.13 119.89 36.1 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 163.98 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -124.78 115.25 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 175.848 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -103.91 147.12 27.71 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.041 1.336 . . . . 0.0 111.052 -179.025 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -140.3 142.88 35.64 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.095 1.358 . . . . 0.0 109.442 164.884 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.36 -117.17 3.52 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-O 122.96 1.311 . . . . 0.0 111.348 173.116 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.74 49.68 1.85 Allowed 'General case' 0 C--N 1.314 -0.974 0 C-N-CA 126.715 2.006 . . . . 0.0 113.529 -163.146 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -81.25 0.71 Allowed Glycine 0 CA--C 1.538 1.502 0 CA-C-O 117.289 -1.839 . . . . 0.0 113.115 -175.78 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -98.29 -2.3 1.13 Allowed 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 123.818 3.012 . . . . 0.0 115.183 -169.726 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -89.88 125.88 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-N 121.049 1.749 . . . . 0.0 110.08 178.174 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -130.61 166.99 19.47 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 124.039 0.935 . . . . 0.0 112.713 174.93 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -144.93 104.26 0.31 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 114.118 -1.401 . . . . 0.0 111.176 169.046 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.33 127.43 47.33 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.114 0 CA-C-N 118.781 1.291 . . . . 0.0 109.278 169.749 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 mm -131.85 112.44 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 126.46 1.904 . . . . 0.0 108.662 170.882 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -82.87 139.39 33.47 Favored 'General case' 0 CA--C 1.542 0.667 0 O-C-N 120.988 -1.07 . . . . 0.0 111.553 169.302 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -115.84 103.82 11.02 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.545 1.538 . . . . 0.0 110.541 179.308 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -108.51 108.13 18.93 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.592 1.157 . . . . 0.0 113.31 179.186 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -97.93 160.91 14.01 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.816 1.246 . . . . 0.0 110.603 171.304 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.78 -21.19 8.55 Favored 'General case' 0 CA--C 1.544 0.729 0 N-CA-C 114.214 1.19 . . . . 0.0 114.214 178.934 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.48 -165.72 1.08 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 127.739 2.416 . . . . 0.0 108.788 168.21 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.2 m -110.79 -11.28 14.4 Favored 'General case' 0 N--CA 1.48 1.026 0 O-C-N 120.612 -1.305 . . . . 0.0 112.118 167.001 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 m-80 -138.05 101.1 4.33 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.743 2.017 . . . . 0.0 107.893 168.712 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.73 -175.1 37.46 Favored Glycine 0 CA--C 1.539 1.565 0 C-N-CA 125.325 1.441 . . . . 0.0 111.77 -175.464 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.41 149.6 80.53 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 123.197 2.598 . . . . 0.0 115.853 -168.497 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 t -124.31 133.83 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.454 1.501 . . . . 0.0 109.749 -177.536 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -78.8 125.07 28.87 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.628 0.771 . . . . 0.0 109.507 170.086 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.65 77.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 C-N-CA 127.414 2.286 . . . . 0.0 106.201 -178.541 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -102.02 154.91 18.54 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.957 170.819 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 170.2 -177.37 43.52 Favored Glycine 0 C--O 1.227 -0.335 0 O-C-N 121.361 -0.837 . . . . 0.0 113.806 -176.72 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 76.7 p -155.41 127.99 7.91 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 124.129 0.972 . . . . 0.0 111.192 -179.691 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.443 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.7 mp -79.6 163.63 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 168.28 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 48.5 tttp -156.56 122.46 4.89 Favored 'General case' 0 N--CA 1.444 -0.739 0 O-C-N 120.851 -1.156 . . . . 0.0 108.588 165.247 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.52 1.03 12.32 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.277 1.894 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 62.0 mt -71.29 171.52 10.97 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 120.266 2.033 . . . . 0.0 110.046 168.648 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.0 t -91.42 158.04 16.73 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 163.761 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -58.88 147.07 35.25 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.412 1.085 . . . . 0.0 111.886 -178.75 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.04 -173.75 20.92 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 124.58 1.086 . . . . 0.0 112.266 -177.51 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.677 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.4 pt? -87.38 140.57 29.4 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.781 2.032 . . . . 0.0 112.016 -172.308 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -143.03 138.34 29.9 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.506 2.322 . . . . 0.0 108.141 -177.21 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -89.07 139.41 15.24 Favored Glycine 0 N--CA 1.473 1.139 0 CA-C-N 121.709 2.049 . . . . 0.0 111.031 -175.019 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -137.1 140.14 41.74 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.013 1.906 . . . . 0.0 111.963 170.407 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -149.9 154.99 39.24 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 121.126 -0.984 . . . . 0.0 111.843 -174.344 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.71 151.09 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 124.683 1.193 . . . . 0.0 109.67 -179.052 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -86.94 176.13 7.81 Favored 'General case' 0 CA--C 1.546 0.815 0 CA-C-O 122.556 1.169 . . . . 0.0 112.911 178.603 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -74.68 112.29 10.73 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 160.499 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.77 -162.71 0.16 Allowed 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.502 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -118.85 33.85 4.59 Favored Glycine 0 C--N 1.342 0.865 0 C-N-CA 128.019 2.723 . . . . 0.0 111.549 178.852 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.547 ' HA ' ' CG1' ' A' ' 5' ' ' VAL . 45.7 p-10 -116.91 69.29 0.75 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 124.048 1.88 . . . . 0.0 112.768 -169.953 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 53' ' ' ASN . . . . . 0.618 ' ND2' HG11 ' A' ' 7' ' ' VAL . 7.8 p-10 -124.22 57.94 1.21 Allowed 'General case' 0 C--O 1.244 0.813 0 N-CA-C 116.62 2.081 . . . . 0.0 116.62 -160.939 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 54' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 7' ' ' VAL 0.278 13.2 p -110.02 -54.89 2.52 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.603 -163.122 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.45 31.23 0.12 Allowed 'General case' 0 CA--C 1.557 1.215 0 C-N-CA 124.909 1.284 . . . . 0.0 113.079 167.684 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.25 -131.56 52.11 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 120.693 -1.254 . . . . 0.0 113.364 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 3.8 t -69.34 -7.54 38.22 Favored 'General case' 0 CA--C 1.548 0.894 0 N-CA-C 115.002 1.482 . . . . 0.0 115.002 -174.7 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 13.2 t -108.19 14.1 25.29 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.72 1.208 . . . . 0.0 112.341 169.528 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.7 t -107.39 -63.93 1.25 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.857 1.663 . . . . 0.0 109.098 169.574 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -166.52 134.05 2.66 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 124.816 1.246 . . . . 0.0 111.583 -178.499 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.55 -115.57 2.37 Favored Glycine 0 CA--C 1.541 1.663 0 C-N-CA 127.21 2.338 . . . . 0.0 113.27 -178.213 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.72 157.21 62.78 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.983 3.789 . . . . 0.0 116.152 -164.716 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -38.59 101.28 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 127.011 2.124 . . . . 0.0 116.033 169.675 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -58.95 119.4 7.15 Favored 'General case' 0 CA--C 1.544 0.722 0 O-C-N 121.574 -0.704 . . . . 0.0 109.63 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -104.23 75.8 0.25 Allowed Pre-proline 0 CA--C 1.549 0.91 0 C-N-CA 127.335 2.254 . . . . 0.0 112.588 -172.445 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -56.61 -33.01 92.19 Favored 'Trans proline' 0 C--N 1.355 0.879 0 C-N-CA 123.532 2.822 . . . . 0.0 115.843 -168.934 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 97.3 mt -79.76 -3.35 47.24 Favored 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 175.413 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.9 t 65.73 52.23 1.33 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.734 2.014 . . . . 0.0 112.912 178.705 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 11.4 mtp180 -105.57 172.33 6.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 -169.313 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -81.09 172.69 13.39 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 122.769 0.428 . . . . 0.0 110.518 165.025 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -104.49 146.5 28.78 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -170.791 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.15 -140.6 11.95 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 113.641 -1.618 . . . . 0.0 113.323 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 149.91 -29.46 1.13 Allowed Glycine 0 CA--C 1.545 1.932 0 N-CA-C 118.399 2.12 . . . . 0.0 118.399 -179.432 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 74' ' ' PRO . . . . . 0.429 ' HG3' ' H ' ' B' ' 86' ' ' ASN . 60.0 Cg_endo -69.83 -4.56 14.32 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 122.766 3.283 . . . . 0.0 112.998 168.535 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.93 -37.18 0.15 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.976 1.31 . . . . 0.0 109.752 165.853 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -61.39 109.26 1.1 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 123.621 1.676 . . . . 0.0 112.49 -176.95 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 77' ' ' GLU . . . . . 0.444 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 4.0 pm0 -44.03 -30.71 0.77 Allowed 'General case' 0 C--N 1.318 -0.794 1 C-N-CA 134.058 4.943 . . . . 0.0 115.689 169.198 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -90.85 -62.96 1.34 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.936 0.789 . . . . 0.0 111.123 -176.962 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.269 32.1 ptt180 55.34 121.26 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 129.114 2.966 . . . . 0.0 115.346 -175.507 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -56.7 151.33 14.19 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 119.141 -2.224 . . . . 0.0 112.65 173.581 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 80.5 t -49.96 -56.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 CA-C-N 118.753 0.706 . . . . 0.0 110.603 -176.926 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.69 115.25 5.17 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 105.132 -3.187 . . . . 0.0 105.132 164.333 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -158.35 158.26 33.97 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.9 0.85 . . . . 0.0 112.675 172.69 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 83.1 mt -144.19 153.07 41.71 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.99 2.116 . . . . 0.0 106.439 168.335 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -113.06 -124.1 4.17 Favored Glycine 0 N--CA 1.471 1.026 0 C-N-CA 124.459 1.028 . . . . 0.0 111.046 172.443 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 86' ' ' ASN . . . . . 0.429 ' H ' ' HG3' ' B' ' 74' ' ' PRO . 6.7 m-80 -78.54 135.11 37.23 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -175.65 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.74 121.07 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 C-N-CA 131.082 3.753 . . . . 0.0 108.84 167.053 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.1 m -119.22 119.27 33.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.102 0.961 . . . . 0.0 110.963 -170.257 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.58 160.3 14.69 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.947 1.299 . . . . 0.0 113.972 -174.758 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -84.69 178.12 7.79 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 128.593 2.757 . . . . 0.0 112.633 170.87 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -20.85 65.81 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 120.865 -1.147 . . . . 0.0 113.2 169.387 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -73.77 -11.7 60.47 Favored 'General case' 0 CA--C 1.55 0.969 0 CA-C-O 121.791 0.805 . . . . 0.0 110.145 171.603 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.84 2.75 88.42 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.843 1.687 . . . . 0.0 113.462 176.499 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -84.11 134.67 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 125.491 1.517 . . . . 0.0 111.839 170.751 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.15 135.19 52.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 164.251 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -90.37 143.69 26.52 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.806 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 t -132.7 129.05 58.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 113.822 -1.535 . . . . 0.0 108.139 171.54 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.6 p -157.28 59.91 0.5 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 122.466 1.127 . . . . 0.0 112.506 -166.772 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.4 mt -120.2 158.03 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 124.991 1.316 . . . . 0.0 111.836 -171.264 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -138.56 127.7 24.14 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 166.598 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -144.48 145.29 31.79 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -167.637 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 72.2 p -104.47 52.37 0.75 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.06 1.344 . . . . 0.0 112.449 -168.85 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 31.3 m -149.74 6.31 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 115.434 1.642 . . . . 0.0 115.434 -169.508 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.03 172.01 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 125.518 1.527 . . . . 0.0 110.645 -176.288 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 88.0 p -157.26 160.73 38.92 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.717 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.02 51.7 1.13 Allowed 'General case' 0 CA--C 1.54 0.586 0 O-C-N 121.631 -0.668 . . . . 0.0 111.587 174.486 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.5 m -81.38 -52.43 7.28 Favored 'General case' 0 N--CA 1.474 0.754 0 O-C-N 121.689 -0.632 . . . . 0.0 112.692 -176.836 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.5 -30.19 4.31 Favored Glycine 0 N--CA 1.471 0.988 0 C-N-CA 124.425 1.012 . . . . 0.0 114.697 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -82.91 -53.18 6.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 122.108 0.956 . . . . 0.0 112.544 -168.867 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -139.05 4.73 2.28 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -166.082 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.0 m -113.59 -112.11 0.34 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 123.894 0.878 . . . . 0.0 113.331 -168.92 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 45.5 mm -106.29 -59.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.794 1.237 . . . . 0.0 111.573 -174.89 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.6 mm -58.16 138.32 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 106.069 -1.826 . . . . 0.0 106.069 166.289 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.7 59.13 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.758 -1.023 . . . . 0.0 114.023 -174.978 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mtt85 -127.43 176.68 7.27 Favored 'General case' 0 C--N 1.347 0.492 0 CA-C-N 119.292 1.546 . . . . 0.0 112.765 171.025 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 2.2 m -126.29 153.07 45.32 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 128.016 2.527 . . . . 0.0 109.183 169.029 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 13.1 tp -130.1 133.04 46.4 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.763 1.625 . . . . 0.0 109.167 176.446 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.73 139.15 44.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 C-N-CA 126.499 1.92 . . . . 0.0 110.767 176.403 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -106.11 140.78 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.129 1.372 . . . . 0.0 109.927 167.439 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -97.6 156.9 16.31 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.807 2.043 . . . . 0.0 111.147 177.917 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 8.2 tm-20 -77.11 -27.77 54.18 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.498 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -103.45 175.0 5.62 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.465 1.106 . . . . 0.0 111.845 168.685 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.85 152.68 42.44 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.174 1.79 . . . . 0.0 113.976 173.809 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -89.87 145.53 25.08 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 122.546 1.165 . . . . 0.0 113.168 169.792 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -76.8 -39.4 51.55 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -168.936 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 84.32 24.68 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 126.433 1.893 . . . . 0.0 113.812 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 127' ' ' GLY . . . . . 0.403 ' HA2' ' HB ' ' B' ' 135' ' ' THR . . . 84.34 57.77 2.3 Favored Glycine 0 C--N 1.343 0.959 0 C-N-CA 125.749 1.643 . . . . 0.0 114.906 168.06 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -158.68 -17.09 0.07 Allowed 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -168.203 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.08 16.35 2.8 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.612 1.577 . . . . 0.0 115.114 178.696 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.57 -2.17 24.4 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.316 1.436 . . . . 0.0 116.459 169.416 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -102.4 162.41 12.94 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 118.837 1.318 . . . . 0.0 109.551 -178.797 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -50.44 -62.83 1.35 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 122.175 0.988 . . . . 0.0 109.485 167.733 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -46.36 -31.14 2.42 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 128.898 2.879 . . . . 0.0 114.601 173.794 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 15.3 p -56.67 -30.31 63.25 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 120.556 -1.34 . . . . 0.0 113.927 178.066 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 135' ' ' THR . . . . . 0.403 ' HB ' ' HA2' ' B' ' 127' ' ' GLY . 8.9 t -121.57 -13.54 8.35 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 170.111 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.5 tttt -74.79 -15.22 60.76 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.633 1.173 . . . . 0.0 113.263 169.635 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.2 p -148.31 -25.46 0.34 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 126.623 1.969 . . . . 0.0 114.67 167.421 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.13 53.83 Favored Glycine 0 CA--C 1.536 1.4 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -163.228 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 16.5 t30 51.67 18.07 0.68 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.618 1.967 . . . . 0.0 113.923 179.009 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.36 -0.04 0.22 Allowed 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 127.806 2.442 . . . . 0.0 116.667 -167.764 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.84 -129.71 10.48 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.14 1.353 . . . . 0.0 115.886 168.236 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.42 134.34 28.69 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 127.735 2.414 . . . . 0.0 112.493 -178.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.92 146.98 33.22 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 121.265 -0.897 . . . . 0.0 109.887 171.093 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.3 tt -120.66 -134.83 0.32 Allowed 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 168.97 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.75 156.72 32.23 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 -176.854 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -146.48 161.84 39.57 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.706 1.202 . . . . 0.0 111.099 170.002 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.47 146.75 13.33 Favored Glycine 0 N--CA 1.468 0.831 0 C-N-CA 125.141 1.353 . . . . 0.0 112.525 -174.541 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.46 HG12 ' H ' ' B' ' 149' ' ' ILE . 2.5 t -85.77 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 175.267 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 149' ' ' ILE . . . . . 0.46 ' H ' HG12 ' B' ' 148' ' ' VAL . 37.3 mt -123.19 114.14 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 120.097 -1.627 . . . . 0.0 111.878 -177.124 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.64 175.12 15.56 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 126.593 2.044 . . . . 0.0 115.037 -172.476 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -102.46 102.9 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.381 1.472 . . . . 0.0 112.65 -171.049 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.55 49.7 1.04 Allowed 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.535 1.934 . . . . 0.0 112.239 171.868 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 . . . . . 0 C--N 1.327 -0.378 0 C-N-CA 126.001 1.72 . . . . 0.0 111.387 177.738 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.527 ' HB2' ' HA ' ' B' ' 109' ' ' ASP . . . . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 118.161 -0.923 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p -84.23 43.61 0.96 Allowed 'General case' 0 C--N 1.348 0.531 0 C-N-CA 125.519 1.528 . . . . 0.0 112.92 -168.886 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.5 148.48 12.74 Favored 'General case' 0 C--O 1.238 0.469 0 C-N-CA 125.002 1.321 . . . . 0.0 112.413 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.65 161.23 39.89 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 126.293 1.837 . . . . 0.0 108.896 166.842 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.414 ' HB ' ' CG ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -156.29 150.6 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 124.487 1.115 . . . . 0.0 109.333 -178.056 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.07 93.37 2.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.463 1.105 . . . . 0.0 108.841 167.526 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -76.88 87.94 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.89 1.276 . . . . 0.0 107.793 170.355 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -76.75 127.42 32.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 125.874 1.67 . . . . 0.0 109.637 -173.606 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -144.04 169.8 17.15 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.318 1.047 . . . . 0.0 112.174 -174.176 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.19 -48.7 0.64 Allowed Glycine 0 N--CA 1.467 0.739 0 C-N-CA 125.329 1.442 . . . . 0.0 112.739 171.399 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.89 64.0 6.21 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 122.219 1.009 . . . . 0.0 110.694 -169.158 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.15 -101.75 0.04 OUTLIER Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.236 2.35 . . . . 0.0 113.132 179.102 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.07 -14.28 21.03 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.852 3.035 . . . . 0.0 113.635 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -76.89 136.24 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 119.849 1.204 . . . . 0.0 109.618 179.079 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.45 159.1 35.33 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 125.997 2.808 . . . . 0.0 113.377 167.163 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -111.16 142.53 16.92 Favored Glycine 0 C--N 1.313 -0.739 1 CA-C-N 108.188 -4.097 . . . . 0.0 109.438 172.968 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 86.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 122.641 1.21 . . . . 0.0 108.417 175.19 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -106.91 143.94 16.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.705 167.541 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -119.67 135.73 54.7 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 127.762 2.425 . . . . 0.0 110.573 -178.374 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-30 -119.93 157.86 27.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.462 1.505 . . . . 0.0 110.862 178.247 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.84 146.29 37.35 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 130.489 3.516 . . . . 0.0 104.598 171.265 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -146.0 -174.24 4.37 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.149 1.78 . . . . 0.0 106.721 172.125 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 -24.01 0.47 Allowed 'General case' 0 CA--C 1.55 0.943 0 O-C-N 118.962 -2.336 . . . . 0.0 114.463 167.402 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.403 ' HB2' ' H ' ' A' ' 27' ' ' GLY . 1.0 OUTLIER -98.72 -172.81 2.38 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.673 1.989 . . . . 0.0 109.571 170.578 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.61 -1.84 29.5 Favored 'General case' 0 CA--C 1.547 0.851 0 O-C-N 121.328 -0.857 . . . . 0.0 112.049 168.341 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -145.63 -7.98 0.58 Allowed 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -170.054 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' A' ' 24' ' ' GLU . . . -85.06 -163.75 37.56 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 118.873 -0.96 . . . . 0.0 111.771 177.057 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -84.11 161.17 13.53 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 121.964 1.776 . . . . 0.0 112.429 -171.153 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.11 152.87 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.963 1.705 . . . . 0.0 109.606 -170.064 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -94.17 151.15 19.69 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 170.755 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 96.0 t -130.93 97.7 3.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 127.161 2.184 . . . . 0.0 107.096 166.849 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.3 p90 -124.98 160.02 29.92 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.681 0.792 . . . . 0.0 111.52 172.56 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.44 -155.2 16.37 Favored Glycine 0 N--CA 1.469 0.867 0 O-C-N 120.983 -1.073 . . . . 0.0 112.052 -179.179 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.8 p -149.44 151.9 34.77 Favored 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 117.962 2.579 . . . . 0.0 117.962 -167.421 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.8 mm -118.0 133.17 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 126.16 1.784 . . . . 0.0 108.358 169.999 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.13 160.24 43.45 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 120.049 1.295 . . . . 0.0 114.144 -172.482 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.42 3.55 61.3 Favored Glycine 0 CA--C 1.538 1.486 0 C-N-CA 126.9 2.19 . . . . 0.0 112.293 -167.956 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.8 mt -85.23 173.26 10.52 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.305 1.842 . . . . 0.0 112.926 -173.985 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 m -74.19 175.97 7.04 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.642 1.177 . . . . 0.0 108.057 164.291 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.29 -93.51 0.03 OUTLIER 'General case' 0 CA--C 1.558 1.252 0 O-C-N 119.958 -1.714 . . . . 0.0 113.04 179.263 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -61.51 97.47 0.14 Allowed Glycine 0 CA--C 1.529 0.965 0 C-N-CA 126.733 2.111 . . . . 0.0 117.667 -167.486 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 65.4 mt 62.85 131.75 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 129.185 2.994 . . . . 0.0 116.606 168.482 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.01 141.58 46.24 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 129.4 3.08 . . . . 0.0 107.486 179.752 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.78 155.14 51.81 Favored Glycine 0 N--CA 1.468 0.794 0 C-N-CA 124.659 1.123 . . . . 0.0 111.715 173.846 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -150.38 98.48 2.66 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -167.475 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.66 145.99 30.22 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 120.955 -1.091 . . . . 0.0 111.69 -168.461 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 0.3 OUTLIER -102.2 119.68 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 126.149 1.78 . . . . 0.0 107.802 179.412 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -72.51 142.93 48.53 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.632 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -63.36 136.66 57.79 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -172.718 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 68.36 166.67 0.26 Allowed 'General case' 0 CA--C 1.543 0.68 0 CA-C-O 123.818 1.771 . . . . 0.0 113.995 175.338 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.31 -14.53 12.95 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 126.477 1.989 . . . . 0.0 114.413 -178.035 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -75.42 53.54 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 121.187 2.493 . . . . 0.0 112.757 -177.83 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 172.03 21.99 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.29 0 C-N-CA 128.318 2.647 . . . . 0.0 113.914 -167.065 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.604 HG22 HG21 ' A' ' 148' ' ' VAL . 76.5 p -36.1 -15.24 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 1 N-CA-C 122.332 4.197 . . . . 0.0 122.332 -170.463 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.41 15.37 4.49 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 122.097 2.226 . . . . 0.0 113.229 -174.052 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.92 -133.48 43.55 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 124.415 1.007 . . . . 0.0 111.908 174.952 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.9 t -58.46 -22.74 55.71 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 114.341 1.237 . . . . 0.0 114.341 -175.98 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . 0.256 15.0 t -90.95 42.6 1.11 Allowed 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 122.864 1.316 . . . . 0.0 112.291 171.974 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -179.87 -27.8 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.64 1.976 . . . . 0.0 115.659 172.095 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -134.93 142.69 46.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.529 1.532 . . . . 0.0 111.375 -168.702 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.31 -58.36 0.74 Allowed Glycine 0 CA--C 1.538 1.473 0 CA-C-O 117.636 -1.646 . . . . 0.0 115.053 -170.489 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -124.79 -177.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 124.151 3.234 . . . . 0.0 114.033 -169.31 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.515 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 1.4 p80 -115.13 125.3 53.3 Favored 'General case' 0 C--N 1.328 -0.358 1 C-N-CA 131.839 4.056 . . . . 0.0 106.7 175.087 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -85.76 175.45 8.69 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 123.571 1.653 . . . . 0.0 110.56 -171.328 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -107.48 48.68 0.17 Allowed Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 126.129 1.772 . . . . 0.0 113.444 177.081 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -64.52 -26.01 62.42 Favored 'Trans proline' 0 C--N 1.359 1.125 0 CA-C-N 122.044 1.766 . . . . 0.0 112.609 -179.354 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 76.2 mt -79.21 0.32 28.95 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.588 1.555 . . . . 0.0 112.993 171.041 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.28 58.29 0.7 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.893 2.077 . . . . 0.0 112.464 173.598 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -157.55 176.55 12.48 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 117.704 2.483 . . . . 0.0 117.704 -167.234 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.77 177.53 8.83 Favored 'General case' 0 CA--C 1.56 1.332 0 C-N-CA 126.822 2.049 . . . . 0.0 112.57 173.269 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -105.67 143.82 33.29 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -177.77 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.76 -115.84 0.7 Allowed Glycine 0 C--N 1.336 0.559 0 CA-C-N 114.336 -1.302 . . . . 0.0 113.675 166.607 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.23 -67.41 0.51 Allowed Glycine 0 CA--C 1.545 1.966 0 CA-C-O 118.933 -0.926 . . . . 0.0 114.614 179.027 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -65.77 -2.65 6.79 Favored 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 125.374 4.049 . . . . 0.0 116.459 173.109 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.82 -29.37 0.24 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.407 1.483 . . . . 0.0 111.466 170.402 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.9 t0 -87.01 104.1 15.98 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.588 0.755 . . . . 0.0 110.53 166.422 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -63.12 -13.45 36.76 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.165 2.186 . . . . 0.0 114.072 176.815 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -76.89 -72.29 0.35 Allowed 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 119.303 0.956 . . . . 0.0 110.536 -179.804 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.405 HH12 ' CG2' ' A' ' 103' ' ' VAL . 17.0 ttp180 77.45 114.09 0.07 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 126.901 2.081 . . . . 0.0 113.538 166.182 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -60.55 162.53 6.31 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 118.685 -2.509 . . . . 0.0 112.758 171.751 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -63.2 -29.93 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 O-C-N 121.231 -0.918 . . . . 0.0 112.52 172.691 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.12 12.32 54.61 Favored Glycine 0 CA--C 1.53 0.999 0 C-N-CA 124.696 1.141 . . . . 0.0 115.468 175.081 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -112.71 113.57 25.75 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-N 119.774 1.787 . . . . 0.0 114.439 -173.91 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.15 -173.76 4.9 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 163.164 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.46 -134.34 2.02 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 120.792 -1.193 . . . . 0.0 113.625 172.227 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.5 p30 -127.34 163.39 24.11 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.163 0.985 . . . . 0.0 108.95 168.535 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 136.4 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.131 0.972 . . . . 0.0 110.61 -171.686 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -110.6 135.87 50.57 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 175.292 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.12 156.26 18.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.524 0.678 . . . . 0.0 110.584 169.298 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -77.16 155.22 32.45 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.056 1.342 . . . . 0.0 108.497 166.861 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.92 -25.36 19.98 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.999 1.72 . . . . 0.0 115.23 -169.305 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -76.65 -2.37 32.38 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.499 2.32 . . . . 0.0 112.273 179.101 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.65 30.18 7.37 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-O 117.937 -1.48 . . . . 0.0 114.12 172.334 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -144.81 131.54 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -178.188 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.27 112.72 24.4 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 164.799 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.0 t0 -106.33 128.65 54.17 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 170.803 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.46 145.18 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-N 113.429 -1.714 . . . . 0.0 114.4 -164.176 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 86.1 p -147.94 89.62 1.76 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.16 1.384 . . . . 0.0 112.087 179.566 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.06 149.31 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.505 1.522 . . . . 0.0 111.499 -174.96 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -135.68 138.29 42.64 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.842 2.057 . . . . 0.0 106.421 166.961 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -146.99 153.97 40.69 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 124.912 1.285 . . . . 0.0 112.241 -167.567 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -118.17 52.91 0.99 Allowed 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.382 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.405 ' CG2' HH12 ' A' ' 79' ' ' ARG . 1.0 OUTLIER -154.66 16.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 115.889 1.811 . . . . 0.0 115.889 -178.781 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -139.63 176.37 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 125.937 1.695 . . . . 0.0 109.741 169.605 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 28.8 p -160.08 175.54 12.85 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 177.11 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.437 ' HA ' ' CG1' ' A' ' 113' ' ' ILE . 8.5 mp -103.94 56.6 0.73 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.047 1.739 . . . . 0.0 110.409 176.953 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.5 t -107.91 -16.51 14.28 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 121.699 3.963 . . . . 0.0 121.699 -169.449 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 77.44 103.84 0.17 Allowed Glycine 0 CA--C 1.529 0.912 0 CA-C-N 121.233 1.833 . . . . 0.0 111.177 -171.011 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 85.77 -44.88 0.06 Allowed 'General case' 0 C--N 1.318 -0.777 1 C-N-CA 131.925 4.09 . . . . 0.0 111.376 166.909 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -85.78 3.03 43.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.862 1.265 . . . . 0.0 112.669 -176.573 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 p -138.22 -152.56 0.43 Allowed 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -166.951 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.8 pt -96.58 -17.35 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 120.382 -1.449 . . . . 0.0 112.516 168.298 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.437 ' CG1' ' HA ' ' A' ' 106' ' ' LEU . 7.1 mm -72.37 133.37 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 166.202 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.52 ' HA3' HD11 ' B' ' 151' ' ' ILE . . . 67.76 42.29 87.24 Favored Glycine 0 CA--C 1.532 1.134 0 O-C-N 124.36 1.037 . . . . 0.0 110.528 -168.994 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.99 148.86 35.85 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 127.04 2.136 . . . . 0.0 105.263 170.256 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 11.6 m -114.85 109.99 19.0 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.005 -1.059 . . . . 0.0 112.994 -165.038 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 11.2 tp -86.14 139.8 30.77 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 120.005 1.275 . . . . 0.0 114.224 -169.633 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.486 HG11 ' HE ' ' A' ' 143' ' ' ARG . 1.0 OUTLIER -132.68 149.3 31.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.284 168.232 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.64 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 164.762 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -127.3 131.92 50.4 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.144 1.378 . . . . 0.0 109.543 -176.62 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -60.63 -40.81 93.3 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.491 1.663 . . . . 0.0 115.491 -166.888 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -86.53 147.44 25.96 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 121.018 1.735 . . . . 0.0 110.898 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -33.58 125.58 0.41 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.568 1.947 . . . . 0.0 111.102 166.236 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 35.5 t0 -75.57 134.7 40.64 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 169.751 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.96 -34.67 66.64 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.889 0.876 . . . . 0.0 111.88 178.451 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.1 mt 62.74 33.18 15.65 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.621 1.568 . . . . 0.0 112.533 173.586 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -174.04 -72.75 0.05 OUTLIER Glycine 0 N--CA 1.468 0.815 0 N-CA-C 116.399 1.32 . . . . 0.0 116.399 174.845 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -164.85 67.74 0.14 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.548 1.139 . . . . 0.0 114.073 178.252 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.3 68.03 0.7 Allowed Glycine 0 CA--C 1.531 1.061 0 C-N-CA 127.001 2.239 . . . . 0.0 113.416 176.175 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.26 -14.9 31.43 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 125.944 1.735 . . . . 0.0 115.226 172.714 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -141.23 177.08 8.33 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 118.982 1.391 . . . . 0.0 112.039 -171.409 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -77.62 -43.06 32.73 Favored 'General case' 0 C--O 1.217 -0.627 0 CA-C-N 114.625 -1.171 . . . . 0.0 109.978 165.476 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -44.57 -40.32 5.63 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 173.121 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.82 -33.36 23.27 Favored 'General case' 0 N--CA 1.472 0.635 0 O-C-N 120.858 -1.151 . . . . 0.0 114.034 171.54 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.4 -24.05 20.88 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 125.565 1.546 . . . . 0.0 112.527 177.772 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -87.24 -13.66 43.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 176.907 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.416 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 20.8 p -129.8 -45.93 1.16 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.386 1.074 . . . . 0.0 113.385 176.508 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.8 -0.77 15.34 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 125.777 1.923 . . . . 0.0 111.793 -166.465 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 56.74 21.19 5.7 Favored 'General case' 0 N--CA 1.478 0.965 0 O-C-N 119.808 -1.995 . . . . 0.0 111.974 -175.754 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.92 30.02 0.08 Allowed 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -167.098 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.23 -35.24 0.42 Allowed Glycine 0 N--CA 1.476 1.358 0 C-N-CA 129.673 3.511 . . . . 0.0 117.588 168.893 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.0 t -171.3 -144.59 0.04 OUTLIER 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.476 1.11 . . . . 0.0 110.108 -169.293 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.486 ' HE ' HG11 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -142.37 -174.88 4.25 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 127.515 2.326 . . . . 0.0 110.447 172.929 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -174.42 -141.04 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 129.568 3.147 . . . . 0.0 109.008 168.18 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -51.24 138.71 20.2 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 128.341 2.656 . . . . 0.0 114.377 -168.479 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 87.3 m -126.06 134.83 51.29 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 127.942 2.497 . . . . 0.0 112.606 -169.613 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.32 153.56 23.94 Favored Glycine 0 N--CA 1.482 1.751 0 C-N-CA 125.29 1.424 . . . . 0.0 114.252 169.023 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.604 HG21 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -78.31 149.95 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 CA-C-N 120.278 2.039 . . . . 0.0 110.301 170.185 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 10.0 mm -83.13 104.39 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 106.733 -1.581 . . . . 0.0 106.733 166.049 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -106.15 146.79 16.12 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 124.348 0.975 . . . . 0.0 111.134 176.587 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.5 pp -79.86 173.7 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 122.908 0.483 . . . . 0.0 111.346 175.255 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.45 ' HB2' ' CB ' ' B' ' 52' ' ' ASP . . . -155.95 -126.86 0.03 OUTLIER 'General case' 0 C--O 1.224 -0.269 0 C-N-CA 125.823 1.649 . . . . 0.0 111.156 163.894 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.858 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -164.244 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 p -115.91 115.51 26.34 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.133 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 3' ' ' LYS . . . . . 0.477 ' HZ3' ' HB2' ' B' ' 3' ' ' LYS . 0.0 OUTLIER -98.77 142.56 30.15 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 116.605 2.076 . . . . 0.0 116.605 169.966 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.24 132.25 42.89 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.841 2.456 . . . . 0.0 110.087 172.999 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 59.6 t -144.77 142.82 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 119.943 1.247 . . . . 0.0 111.786 -168.657 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -114.18 141.38 47.6 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.79 1.236 . . . . 0.0 113.853 171.929 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 15.0 m -104.06 99.62 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 167.383 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -78.91 130.35 35.52 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.722 1.209 . . . . 0.0 108.085 -175.63 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -156.18 174.47 15.33 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 -172.644 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.96 -43.03 1.35 Allowed Glycine 0 N--CA 1.471 1.002 0 C-N-CA 127.955 2.693 . . . . 0.0 111.32 172.792 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -82.96 59.17 4.74 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 127.932 2.493 . . . . 0.0 113.319 -168.633 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.41 -104.0 0.06 OUTLIER Glycine 0 CA--C 1.532 1.14 0 C-N-CA 127.537 2.494 . . . . 0.0 112.6 176.975 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.45 -14.62 16.11 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 123.618 2.878 . . . . 0.0 113.614 -177.564 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.496 HG21 HD11 ' B' ' 144' ' ' LEU . 2.8 t -90.05 128.79 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-N 120.096 1.317 . . . . 0.0 109.921 -178.542 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.513 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -146.06 155.12 42.56 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.848 173.121 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.27 153.14 20.64 Favored Glycine 0 C--O 1.227 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.229 177.569 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.4 HD11 ' ND2' ' B' ' 19' ' ' ASN . 0.0 OUTLIER -118.04 117.21 54.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 C-N-CA 126.234 1.814 . . . . 0.0 106.514 168.715 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.3 mm -128.19 104.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 O-C-N 123.64 0.587 . . . . 0.0 110.049 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 19' ' ' ASN . . . . . 0.4 ' ND2' HD11 ' B' ' 17' ' ' ILE . 0.8 OUTLIER -79.53 156.13 27.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.111 1.764 . . . . 0.0 111.981 167.961 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -139.82 108.21 5.84 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 130.655 3.582 . . . . 0.0 107.339 170.071 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.27 130.85 53.31 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.194 1.398 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -126.12 154.68 42.8 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 122.277 1.037 . . . . 0.0 111.35 -176.6 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.419 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 9.9 ptmm? -115.92 -24.35 8.17 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 128.298 2.639 . . . . 0.0 114.105 -177.512 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 24' ' ' GLU . . . . . 0.419 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 6.7 mp0 -135.79 162.25 33.32 Favored 'General case' 0 C--O 1.219 -0.502 0 CA-C-N 121.006 1.73 . . . . 0.0 112.877 173.649 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 p -64.94 -2.94 2.95 Favored 'General case' 0 N--CA 1.483 1.217 0 O-C-N 119.141 -2.224 . . . . 0.0 113.434 167.226 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.79 64.12 0.16 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 128.383 2.673 . . . . 0.0 109.754 -168.214 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.1 172.75 31.37 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.58 1.562 . . . . 0.0 113.411 -170.747 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.53 142.53 23.48 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.39 2.727 . . . . 0.0 110.683 178.634 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.05 132.6 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.158 0.983 . . . . 0.0 109.327 -172.606 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -95.96 115.6 27.67 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 121.626 0.726 . . . . 0.0 111.226 179.061 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.6 t -93.55 121.35 44.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 127.105 2.162 . . . . 0.0 108.807 -179.123 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -148.25 164.88 32.65 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 177.859 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.02 -147.67 19.4 Favored Glycine 0 C--N 1.334 0.448 0 C-N-CA 125.111 1.339 . . . . 0.0 111.356 176.795 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -157.94 156.61 31.56 Favored 'General case' 0 C--O 1.237 0.407 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -175.783 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.591 HG21 HG11 ' B' ' 119' ' ' VAL . 3.1 mp -124.39 133.67 68.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 125.284 1.433 . . . . 0.0 108.319 170.636 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -138.3 155.5 48.53 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -172.791 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.87 76.95 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.031 1.3 . . . . 0.0 114.022 -175.515 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.459 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.1 pt? -96.43 162.58 13.42 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 126.559 1.944 . . . . 0.0 112.11 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.23 154.24 1.26 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.458 2.703 . . . . 0.0 110.822 169.15 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -64.77 -60.34 3.2 Favored 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 120.717 1.599 . . . . 0.0 112.654 174.245 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -51.52 141.7 21.84 Favored Glycine 0 N--CA 1.472 1.075 0 C-N-CA 126.218 1.866 . . . . 0.0 114.733 -169.811 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 42' ' ' LEU . . . . . 0.631 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -40.74 136.88 1.29 Allowed 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 128.315 2.646 . . . . 0.0 115.243 -168.311 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -121.12 142.47 49.83 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 129.816 3.247 . . . . 0.0 109.173 -170.306 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.18 169.51 35.79 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.552 1.072 . . . . 0.0 111.879 172.436 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.2 t80 -160.43 57.95 0.34 Allowed 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.649 1.58 . . . . 0.0 110.728 -169.621 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -117.44 145.81 43.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.305 1.042 . . . . 0.0 113.401 -169.592 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -105.86 115.78 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.773 0.797 . . . . 0.0 109.189 -172.102 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 48' ' ' HIS . . . . . 0.478 ' HB2' HG23 ' B' ' 116' ' ' THR . 12.1 m-70 -76.42 174.16 10.59 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 124.974 1.31 . . . . 0.0 110.119 179.537 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 49' ' ' GLU . . . . . 0.532 ' H ' ' CD ' ' B' ' 49' ' ' GLU . 1.9 pm0 -61.15 85.58 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 127.127 2.171 . . . . 0.0 115.074 -168.242 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 67.95 -157.99 0.21 Allowed 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.089 2.156 . . . . 0.0 111.865 168.974 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.75 -14.88 18.29 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.461 1.505 . . . . 0.0 112.077 -177.871 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.45 ' CB ' ' HB2' ' A' ' 152' ' ' ALA . 7.5 t70 -62.57 56.52 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.023 1 C-N-CA 132.623 4.369 . . . . 0.0 110.6 169.555 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 16.3 p30 176.39 -11.01 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 128.079 2.552 . . . . 0.0 116.287 -174.388 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.315 8.4 t 7.21 30.1 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.952 2 N-CA-C 123.685 4.698 . . . . 0.0 123.685 176.268 . . . . . . . . 3 2 . 1 . 029 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -162.2 10.93 0.07 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 119.874 -1.766 . . . . 0.0 112.162 -176.973 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.86 -130.82 50.09 Favored Glycine 0 CA--C 1.523 0.585 0 C-N-CA 124.965 1.269 . . . . 0.0 114.048 172.296 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.2 t -57.9 -17.31 15.82 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 117.023 2.231 . . . . 0.0 117.023 -167.3 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 10.1 t -81.61 -6.57 59.13 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 120.253 1.388 . . . . 0.0 113.321 171.067 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 28.0 m -144.29 2.99 1.16 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -171.253 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.18 167.85 11.82 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 119.455 1.025 . . . . 0.0 113.173 -169.59 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.79 -152.65 23.0 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 126.846 2.165 . . . . 0.0 111.312 178.796 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -109.08 49.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.596 2.864 . . . . 0.0 111.457 -178.326 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 56.77 82.69 0.11 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.932 1.293 . . . . 0.0 112.498 -179.2 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -40.49 131.62 2.21 Favored 'General case' 0 CA--C 1.542 0.673 0 CA-C-O 122.54 1.162 . . . . 0.0 113.089 169.557 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.7 p-10 -114.29 79.86 5.44 Favored Pre-proline 0 CA--C 1.547 0.838 0 C-N-CA 126.407 1.883 . . . . 0.0 112.457 -171.246 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -62.23 -14.52 38.73 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 123.114 2.543 . . . . 0.0 114.685 179.547 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -92.78 -4.0 53.79 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.111 1.364 . . . . 0.0 113.302 171.387 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 28.0 t 65.7 53.39 1.19 Allowed 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.366 1.866 . . . . 0.0 112.367 171.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -142.64 177.27 8.42 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -169.559 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.528 ' H ' ' HD2' ' B' ' 70' ' ' LYS . 1.3 mptt -79.41 175.4 10.63 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 126.441 1.897 . . . . 0.0 112.904 -178.228 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -97.49 136.61 37.67 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -176.805 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 139.83 -132.27 5.5 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 124.268 0.937 . . . . 0.0 113.596 167.421 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 146.04 -34.44 1.43 Allowed Glycine 0 CA--C 1.547 2.087 0 N-CA-C 118.234 2.054 . . . . 0.0 118.234 -177.037 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -78.4 -19.53 11.65 Favored 'Trans proline' 0 C--N 1.356 0.94 0 CA-C-N 122.263 3.032 . . . . 0.0 113.609 172.22 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -46.42 0.93 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 124.437 1.095 . . . . 0.0 109.917 167.93 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -56.14 126.04 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.976 0.893 . . . . 0.0 109.319 169.209 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -90.61 -5.86 55.35 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 128.973 2.909 . . . . 0.0 112.717 -168.341 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -100.58 -76.48 0.56 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 126.945 2.098 . . . . 0.0 110.773 -169.809 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 84.66 113.7 0.05 Allowed 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 126.519 1.928 . . . . 0.0 113.268 165.812 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -59.2 152.66 20.06 Favored 'General case' 0 CA--C 1.549 0.911 0 O-C-N 119.669 -1.894 . . . . 0.0 110.36 170.04 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -58.39 -30.98 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.891 -1.13 . . . . 0.0 112.681 178.223 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.35 37.47 3.42 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 126.619 2.057 . . . . 0.0 113.58 171.211 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -116.85 146.87 42.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 119.988 1.894 . . . . 0.0 115.737 173.892 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 79.1 mt -144.42 163.3 34.2 Favored 'General case' 0 CA--C 1.545 0.784 1 C-N-CA 132.102 4.161 . . . . 0.0 102.702 163.156 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.91 -87.06 0.99 Allowed Glycine 0 N--CA 1.468 0.829 0 O-C-N 121.926 -0.484 . . . . 0.0 113.428 -170.643 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -153.32 168.44 26.03 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 124.674 1.19 . . . . 0.0 113.479 -166.521 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.56 147.59 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 129.233 3.013 . . . . 0.0 110.214 -176.407 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 25.7 m -120.84 145.6 47.43 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 119.437 1.017 . . . . 0.0 109.991 -176.979 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.65 144.48 26.65 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.895 0.855 . . . . 0.0 111.666 175.95 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 90' ' ' ASP . . . . . 0.452 ' OD1' ' HE2' ' B' ' 91' ' ' LYS . 39.7 t0 -73.19 158.95 34.26 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.762 1.225 . . . . 0.0 109.813 168.921 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 91' ' ' LYS . . . . . 0.452 ' HE2' ' OD1' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -52.33 -28.2 18.34 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 115.42 1.637 . . . . 0.0 115.42 -168.292 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.85 -2.25 29.19 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.544 1.538 . . . . 0.0 112.283 -178.51 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.08 39.16 7.54 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 125.221 1.391 . . . . 0.0 113.154 177.843 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 3.2 p -132.62 126.37 54.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 CA-C-N 118.629 1.215 . . . . 0.0 113.811 170.018 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.58 119.23 31.31 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.518 1.527 . . . . 0.0 107.929 165.9 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.46 151.15 31.0 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 167.419 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.29 0.5 OUTLIER -134.53 131.59 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 114.593 -1.185 . . . . 0.0 112.899 165.477 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 9.6 p -157.69 59.96 0.48 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.151 1.38 . . . . 0.0 113.164 -168.65 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -115.39 156.08 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 C-N-CA 126.787 2.035 . . . . 0.0 112.715 -171.582 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -128.67 146.49 50.86 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.733 1.613 . . . . 0.0 108.288 166.997 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -141.02 134.83 30.41 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.243 1.417 . . . . 0.0 110.222 -179.03 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -112.75 59.27 0.64 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.315 1.446 . . . . 0.0 112.234 -167.578 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.4 p -158.12 -36.5 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.132 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.13 170.97 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 123.332 0.653 . . . . 0.0 111.349 172.712 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.8 m -157.51 159.44 37.21 Favored 'General case' 0 N--CA 1.469 0.506 0 O-C-N 120.12 -1.612 . . . . 0.0 111.335 176.316 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 106' ' ' LEU . . . . . 0.464 ' HG ' HD11 ' B' ' 113' ' ' ILE . 4.8 tt -81.12 75.02 8.1 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.056 0.942 . . . . 0.0 109.523 -173.627 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -138.97 152.18 47.47 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.761 1.625 . . . . 0.0 111.391 -174.088 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -101.91 68.54 0.39 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 126.968 2.223 . . . . 0.0 113.427 -169.29 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 109' ' ' ASP . . . . . 0.527 ' HA ' ' HB2' ' A' ' 1' ' ' ALA . 0.6 OUTLIER -154.43 -91.53 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.78 1.632 . . . . 0.0 110.362 -168.819 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -127.79 -4.43 5.81 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.742 2.017 . . . . 0.0 110.461 -170.048 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 16.4 m -92.6 -91.31 0.17 Allowed 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.523 1.929 . . . . 0.0 114.651 -166.066 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pt -135.36 -14.69 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 118.112 2.634 . . . . 0.0 118.112 176.724 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 113' ' ' ILE . . . . . 0.526 HD12 HG23 ' B' ' 151' ' ' ILE . 22.0 mm -86.58 105.8 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 CA-C-N 122.113 2.233 . . . . 0.0 108.747 179.283 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.59 61.45 1.17 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.573 0.606 . . . . 0.0 112.944 -171.908 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 23.4 ptt180 -140.36 144.95 36.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.981 1.312 . . . . 0.0 109.239 167.305 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 116' ' ' THR . . . . . 0.478 HG23 ' HB2' ' B' ' 48' ' ' HIS . 2.3 t -109.39 102.09 11.01 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 124.243 1.017 . . . . 0.0 111.067 -166.665 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 29.2 tp -86.33 129.67 34.77 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 124.152 0.981 . . . . 0.0 109.774 -173.245 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 t -107.82 118.09 54.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 169.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.591 HG11 HG21 ' B' ' 35' ' ' ILE . 13.9 p -78.85 120.03 29.18 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.37 0 N-CA-C 100.483 -3.895 . . . . 0.0 100.483 161.166 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -106.45 142.52 35.97 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 117.766 -1.111 . . . . 0.0 109.38 -168.189 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.92 -42.94 80.87 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 122.154 2.252 . . . . 0.0 113.915 -166.718 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.473 ' HE3' ' HA ' ' B' ' 122' ' ' LYS . 0.0 OUTLIER -111.7 152.35 27.83 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 171.624 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.12 161.02 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.853 1.661 . . . . 0.0 112.258 171.68 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -94.47 151.35 19.44 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 177.833 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -71.8 -16.66 62.19 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.572 1.949 . . . . 0.0 112.875 176.482 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.3 mt 57.96 84.29 0.1 Allowed 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 127.028 2.131 . . . . 0.0 114.464 169.764 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.74 -47.48 3.42 Favored Glycine 0 N--CA 1.465 0.622 0 C-N-CA 125.502 1.525 . . . . 0.0 111.015 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -158.84 137.91 11.33 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.609 1.564 . . . . 0.0 110.448 168.646 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -141.37 -101.15 0.43 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 169.164 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.57 -24.49 10.96 Favored Glycine 0 N--CA 1.471 0.972 0 N-CA-C 116.705 1.442 . . . . 0.0 116.705 -168.576 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -165.46 174.18 10.26 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.882 1.341 . . . . 0.0 111.83 -169.225 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -49.86 -50.84 44.19 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 126.062 1.745 . . . . 0.0 113.449 -170.313 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 133' ' ' GLU . . . . . 0.471 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 13.7 mp0 -45.76 -25.79 0.55 Allowed 'General case' 0 C--N 1.318 -0.794 0 C-N-CA 128.27 2.628 . . . . 0.0 113.705 175.305 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.6 p -64.95 -45.06 87.32 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 120.119 1.327 . . . . 0.0 112.716 178.823 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -79.91 -39.72 29.76 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.18 0.592 . . . . 0.0 111.523 173.151 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.29 -18.64 52.25 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -173.033 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.9 p -152.71 -15.11 0.16 Allowed 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 177.956 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.04 -7.56 58.85 Favored Glycine 0 C--O 1.214 -1.155 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.313 -168.652 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 51.3 t30 55.57 35.49 25.28 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-N 120.613 2.206 . . . . 0.0 112.157 178.184 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.9 38.88 0.08 Allowed 'General case' 0 CA--C 1.563 1.451 0 N-CA-C 115.759 1.763 . . . . 0.0 115.759 -166.998 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.16 -84.46 0.41 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 127.109 2.29 . . . . 0.0 113.767 175.488 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t -160.52 172.8 16.55 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.155 0.982 . . . . 0.0 112.978 -178.041 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 154.83 25.62 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.126 1.37 . . . . 0.0 113.624 -171.488 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.496 HD11 HG21 ' B' ' 14' ' ' VAL . 19.5 tp -159.79 -177.55 6.43 Favored 'General case' 0 CA--C 1.56 1.342 0 C-N-CA 129.795 3.238 . . . . 0.0 104.878 169.836 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.73 129.91 20.36 Favored 'General case' 0 CA--C 1.556 1.185 0 N-CA-C 115.838 1.792 . . . . 0.0 115.838 -165.146 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.9 m -114.91 134.19 55.36 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 126.712 2.005 . . . . 0.0 112.645 -176.687 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.9 144.12 10.17 Favored Glycine 0 N--CA 1.486 2.006 0 CA-C-N 120.994 1.724 . . . . 0.0 117.172 177.297 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.518 ' O ' HG21 ' A' ' 54' ' ' THR . 84.6 t -81.12 140.74 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 118.169 0.985 . . . . 0.0 109.893 176.022 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.4 mm -77.68 107.33 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 170.584 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.16 36.45 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.555 1.55 . . . . 0.0 111.951 169.635 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 151' ' ' ILE . . . . . 0.526 HG23 HD12 ' B' ' 113' ' ' ILE . 1.1 pp -138.91 160.65 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 125.04 1.336 . . . . 0.0 112.89 177.822 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.58 1.3 0.44 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.644 1.978 . . . . 0.0 112.554 164.603 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tm0? . . . . . 0 N--CA 1.472 0.648 0 C-N-CA 126.636 1.975 . . . . 0.0 110.876 169.699 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.758 0 CA-C-O 118.973 -0.537 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 67.4 p -78.82 64.66 3.85 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 127.132 2.173 . . . . 0.0 114.881 -166.241 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.1 ttpt -161.55 126.18 3.44 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 118.529 2.789 . . . . 0.0 118.529 166.085 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.52 177.5 4.9 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 129.489 3.116 . . . . 0.0 107.006 164.346 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.574 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.5 p -157.54 151.15 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 -164.227 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.07 115.21 7.92 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 110.627 166.252 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 68.9 t -101.41 95.59 4.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.667 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.9 mp -79.34 152.51 30.42 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.13 1.372 . . . . 0.0 108.68 173.612 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -153.24 158.56 41.88 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -130.11 158.33 22.31 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.308 2.385 . . . . 0.0 107.957 166.151 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -71.94 83.59 0.95 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 126.817 2.047 . . . . 0.0 110.941 -177.446 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.09 -147.64 18.78 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 127.041 2.258 . . . . 0.0 110.158 -169.403 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -94.64 9.51 1.93 Allowed 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 124.794 3.663 . . . . 0.0 114.87 -169.841 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.63 134.16 34.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 CA-C-N 120.025 1.284 . . . . 0.0 110.393 -177.369 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.39 164.67 34.28 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.517 1.127 . . . . 0.0 111.486 178.865 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.447 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -129.52 97.79 0.42 Allowed Glycine 0 C--O 1.215 -1.042 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 169.042 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -96.41 106.61 18.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 118.519 1.159 . . . . 0.0 108.012 175.892 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 pt -133.59 150.13 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 122.241 1.019 . . . . 0.0 111.62 177.09 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -122.74 145.29 48.54 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.637 1.575 . . . . 0.0 110.329 179.416 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -120.94 105.07 10.32 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.936 1.694 . . . . 0.0 109.635 -173.895 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.1 121.16 28.31 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 177.369 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.584 ' CB ' HD13 ' A' ' 106' ' ' LEU . 11.0 tp60 -147.76 137.94 22.91 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.251 0.548 . . . . 0.0 111.186 175.507 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.497 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -91.96 -24.28 19.31 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -175.735 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.66 -155.65 0.61 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-N 120.136 1.335 . . . . 0.0 113.038 176.489 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 66.6 m -107.25 10.25 29.91 Favored 'General case' 0 CA--C 1.543 0.677 0 O-C-N 119.377 -2.077 . . . . 0.0 113.634 -179.095 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -131.27 -10.29 3.7 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 126.021 1.728 . . . . 0.0 114.746 -172.437 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.13 160.74 20.75 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 128.926 3.155 . . . . 0.0 112.657 -168.615 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.75 151.57 32.02 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 123.028 2.486 . . . . 0.0 109.718 175.568 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 67.4 t -119.71 137.65 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.166 1.387 . . . . 0.0 110.004 -168.166 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -84.41 127.09 33.8 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.512 0.596 . . . . 0.0 110.1 170.19 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 t -107.82 130.09 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 125.632 1.573 . . . . 0.0 108.346 171.99 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -151.14 165.9 32.48 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 123.342 0.657 . . . . 0.0 111.54 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 131.16 -148.9 19.07 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 124.993 1.283 . . . . 0.0 111.754 175.928 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 54.1 p -142.6 127.22 17.98 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -169.815 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.447 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 10.2 mm -101.3 112.77 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 124.676 1.19 . . . . 0.0 108.279 170.987 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.9 pttt -129.58 152.07 49.5 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.835 1.198 . . . . 0.0 112.698 -166.514 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.01 5.52 64.05 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.38 0.99 . . . . 0.0 112.599 -169.061 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -75.44 -161.63 0.16 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 127.405 2.282 . . . . 0.0 109.662 168.766 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -151.98 171.24 18.13 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 126.627 1.971 . . . . 0.0 108.183 169.331 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -49.04 136.84 13.96 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.851 1.66 . . . . 0.0 113.439 -168.876 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.51 -173.13 28.21 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-O 122.597 1.11 . . . . 0.0 112.511 173.202 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.5 OUTLIER -73.01 160.45 32.07 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.1 0.96 . . . . 0.0 111.373 -171.339 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.402 ' HB2' HG13 ' A' ' 87' ' ' VAL . 81.6 m-70 -149.09 136.21 19.94 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 127.653 2.381 . . . . 0.0 108.867 176.62 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.17 148.71 32.48 Favored Glycine 0 N--CA 1.478 1.463 0 CA-C-O 119.261 -0.744 . . . . 0.0 111.964 171.226 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -153.15 78.71 1.17 Allowed 'General case' 0 CA--C 1.544 0.741 0 CA-C-O 122.88 1.324 . . . . 0.0 110.768 -168.556 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -124.73 157.86 34.66 Favored 'General case' 0 CA--C 1.516 -0.338 0 O-C-N 120.803 -1.186 . . . . 0.0 111.396 -169.428 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.618 HG11 HH11 ' A' ' 115' ' ' ARG . 1.7 m -87.65 151.52 3.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.24 176.628 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 8.4 m170 -113.88 168.79 9.5 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 104.102 -2.555 . . . . 0.0 104.102 160.175 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.75 -172.69 0.09 Allowed 'General case' 0 CA--C 1.554 1.11 0 N-CA-C 117.257 2.317 . . . . 0.0 117.257 -167.83 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -119.43 -36.58 3.32 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 128.203 2.601 . . . . 0.0 112.305 -175.739 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.19 -29.52 62.9 Favored Glycine 0 N--CA 1.47 0.93 1 C-N-CA 131.667 4.461 . . . . 0.0 114.588 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -123.97 151.23 43.9 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 163.045 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.576 ' HB2' HG13 ' B' ' 5' ' ' VAL . 0.5 OUTLIER -148.98 101.55 3.18 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 119.11 3.004 . . . . 0.0 119.11 -166.493 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.555 HG23 ' O ' ' A' ' 53' ' ' ASN 0.549 0.1 OUTLIER 112.48 -145.75 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.695 1 C-N-CA 133.673 4.789 . . . . 0.0 113.576 160.044 . . . . . . . . 5 4 . 1 . 030 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 49.05 -10.13 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 131.033 3.733 . . . . 0.0 117.91 -172.348 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.34 -132.12 11.11 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.968 2.223 . . . . 0.0 111.211 -176.915 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.9 m -62.78 -8.47 6.89 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 177.726 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.1 m -79.9 -24.07 41.38 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.922 1.289 . . . . 0.0 112.457 171.672 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.514 ' HB3' HG11 ' B' ' 7' ' ' VAL . 4.1 m -158.43 45.57 0.31 Allowed 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 116.193 1.923 . . . . 0.0 116.193 -169.2 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 176.96 125.45 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 127.807 2.443 . . . . 0.0 110.452 168.429 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -72.16 149.14 43.73 Favored Glycine 0 CA--C 1.541 1.667 0 O-C-N 120.736 -1.228 . . . . 0.0 114.372 -175.772 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -64.69 106.94 0.8 Allowed 'Trans proline' 0 C--N 1.354 0.822 1 C-N-CA 125.488 4.125 . . . . 0.0 111.604 -178.896 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.442 ' CE1' ' HA ' ' A' ' 137' ' ' THR 0.274 0.0 OUTLIER 36.04 57.18 1.0 Allowed 'General case' 0 C--O 1.234 0.247 0 C-N-CA 127.377 2.271 . . . . 0.0 112.468 170.458 . . . . . . . . 4 4 . 1 . 030 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -27.05 122.79 0.09 Allowed 'General case' 0 C--N 1.342 0.259 0 C-N-CA 128.285 2.634 . . . . 0.0 111.26 179.328 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 62.8 m-20 -71.84 101.26 0.37 Allowed Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -168.426 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -84.67 -12.46 7.49 Favored 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.157 2.571 . . . . 0.0 112.956 -167.963 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 92.0 mt -139.75 2.91 2.02 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 128.62 2.768 . . . . 0.0 110.717 -172.117 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 16.0 t 66.44 53.43 0.98 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.706 1.603 . . . . 0.0 114.022 175.675 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.79 179.57 4.94 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.978 1.711 . . . . 0.0 113.161 179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.1 mmtt -73.57 173.61 9.46 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 121.654 0.74 . . . . 0.0 111.667 169.356 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 48.9 t60 -72.15 157.77 37.14 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 168.489 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.413 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.78 -126.19 2.69 Favored Glycine 0 C--N 1.339 0.72 0 N-CA-C 116.576 1.39 . . . . 0.0 116.576 165.725 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.85 -90.24 0.36 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 116.58 1.392 . . . . 0.0 116.58 -171.105 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.5 -2.21 4.84 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.946 3.097 . . . . 0.0 115.184 -173.325 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.312 3.3 ptmm? -144.08 4.13 1.24 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 126.433 1.893 . . . . 0.0 112.677 168.346 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.0 OUTLIER -131.77 113.77 13.92 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 127.082 2.153 . . . . 0.0 109.168 177.038 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -71.16 -14.07 62.15 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 127.968 2.507 . . . . 0.0 114.082 -176.371 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -78.02 -62.06 1.8 Allowed 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.908 1.231 . . . . 0.0 109.295 175.361 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 74.6 ttt180 70.71 120.44 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 123.477 1.608 . . . . 0.0 112.831 169.592 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.8 m170 -66.98 136.58 55.53 Favored 'General case' 0 CA--C 1.543 0.694 0 O-C-N 118.96 -2.337 . . . . 0.0 109.217 164.832 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.0 t -53.74 -19.11 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 122.464 1.126 . . . . 0.0 111.636 166.281 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.489 ' HA3' HG22 ' A' ' 47' ' ' VAL . . . -92.16 41.09 2.82 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.255 2.36 . . . . 0.0 116.878 172.454 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -144.56 122.57 12.08 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 119.751 1.775 . . . . 0.0 111.865 -179.06 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.86 48.75 0.94 Allowed 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 123.811 1.767 . . . . 0.0 110.359 173.762 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.89 -133.48 52.71 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 126.122 1.82 . . . . 0.0 114.257 175.289 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.82 138.73 48.03 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.672 1.589 . . . . 0.0 110.11 171.495 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.402 HG13 ' HB2' ' A' ' 43' ' ' HIS . 8.0 p -92.95 127.45 45.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 166.327 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 24.4 m -115.39 119.48 36.4 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -176.27 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.99 156.96 17.31 Favored 'General case' 0 C--N 1.328 -0.353 0 O-C-N 123.667 0.604 . . . . 0.0 112.588 -177.21 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.73 168.54 19.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 126.403 1.881 . . . . 0.0 113.67 173.21 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.1 pptp? -60.11 -20.09 56.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.789 1.636 . . . . 0.0 113.79 168.723 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -80.95 0.04 37.25 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.006 1.322 . . . . 0.0 112.306 170.791 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 19.92 60.41 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 125.178 1.37 . . . . 0.0 114.099 174.633 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -134.16 138.85 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 119.04 1.42 . . . . 0.0 113.527 -176.54 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.79 123.31 40.45 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 165.655 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -97.74 118.8 35.09 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.581 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.12 140.08 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 CA-C-N 114.159 -1.382 . . . . 0.0 113.935 -165.733 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 77.4 p -155.65 123.2 5.57 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.594 1.558 . . . . 0.0 110.103 168.834 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -155.17 148.81 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 127.703 2.401 . . . . 0.0 109.992 -169.85 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -125.77 125.22 42.61 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 165.749 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -121.72 141.81 50.81 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.038 0.935 . . . . 0.0 110.994 -173.753 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -115.63 48.66 1.17 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.959 0.904 . . . . 0.0 112.863 -178.377 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.26 -4.81 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.459 1.104 . . . . 0.0 112.23 170.732 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.54 164.88 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 C-N-CA 125.951 1.7 . . . . 0.0 110.727 176.672 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 99.5 p -149.54 175.28 11.66 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 128.285 2.634 . . . . 0.0 109.072 178.098 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.584 HD13 ' CB ' ' A' ' 22' ' ' GLN . 6.8 mp -86.16 93.4 9.02 Favored 'General case' 0 CA--C 1.543 0.684 0 O-C-N 120.809 -1.182 . . . . 0.0 109.33 173.249 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.2 t -152.45 153.88 34.42 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.753 1.221 . . . . 0.0 110.119 169.04 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -103.08 29.23 12.88 Favored Glycine 0 N--CA 1.472 1.041 0 C-N-CA 126.142 1.829 . . . . 0.0 113.27 -178.147 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -86.81 -96.55 0.08 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 126.022 1.729 . . . . 0.0 106.691 169.655 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m170 -107.39 -7.75 16.54 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.458 1.503 . . . . 0.0 111.806 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -76.15 -157.77 0.08 Allowed 'General case' 0 CA--C 1.558 1.259 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -174.999 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.271 10.9 pt -97.14 44.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 118.455 -2.653 . . . . 0.0 116.06 -172.006 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.9 mm -115.73 126.96 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 166.321 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.18 -4.2 34.06 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 117.208 -1.885 . . . . 0.0 115.077 173.309 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.618 HH11 HG11 ' A' ' 47' ' ' VAL . 3.1 ptp180 -78.82 153.47 30.64 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 120.795 2.297 . . . . 0.0 110.889 170.218 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 6.3 t -101.29 162.75 12.67 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 119.676 1.125 . . . . 0.0 112.917 177.466 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.471 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -130.44 137.98 50.09 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.788 2.035 . . . . 0.0 107.921 174.52 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.471 ' N ' HD13 ' A' ' 117' ' ' LEU . 7.4 p -122.2 125.44 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.291 1.436 . . . . 0.0 109.969 175.24 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -90.2 143.08 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 171.84 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -106.64 158.35 17.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 122.009 0.909 . . . . 0.0 112.909 -174.567 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -71.56 -40.8 69.74 Favored 'General case' 0 CA--C 1.538 0.483 0 O-C-N 121.334 -0.854 . . . . 0.0 111.237 -169.07 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -116.82 174.73 5.92 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 124.706 1.202 . . . . 0.0 112.664 172.594 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.4 148.16 1.43 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.813 2.445 . . . . 0.0 112.252 172.422 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -110.29 142.57 41.73 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.282 1.033 . . . . 0.0 112.185 172.609 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -93.93 -8.3 40.56 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 176.888 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 77.09 -73.33 0.09 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 128.94 2.896 . . . . 0.0 111.516 169.301 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -95.8 -5.26 59.99 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 125.262 1.411 . . . . 0.0 113.539 -174.389 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt -158.23 -146.08 0.15 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 128.088 2.555 . . . . 0.0 112.539 173.15 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 133.31 -29.13 3.21 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 128.7 3.048 . . . . 0.0 110.617 -168.393 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 126.73 -17.03 6.47 Favored Glycine 0 N--CA 1.473 1.12 0 C-N-CA 126.282 1.896 . . . . 0.0 114.986 169.588 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -110.57 174.6 5.79 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.09 1.356 . . . . 0.0 113.683 -171.988 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -52.22 -59.67 4.12 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.319 1.848 . . . . 0.0 110.615 167.52 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -46.57 -36.01 6.42 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.735 1.214 . . . . 0.0 112.51 169.433 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -66.47 -3.74 6.85 Favored 'General case' 0 N--CA 1.476 0.86 0 O-C-N 120.132 -1.605 . . . . 0.0 113.909 -175.936 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.1 p -119.96 -12.96 9.08 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 175.896 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 ptpt -113.25 -26.1 8.56 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 176.952 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.442 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 0.5 OUTLIER -127.96 -17.94 4.31 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 127.049 2.14 . . . . 0.0 113.809 179.497 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.03 -21.49 41.62 Favored Glycine 0 N--CA 1.467 0.724 0 C-N-CA 126.537 2.018 . . . . 0.0 111.969 177.361 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 71.46 36.65 1.26 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.94 1.696 . . . . 0.0 112.421 168.492 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.32 44.69 0.01 OUTLIER 'General case' 0 CA--C 1.575 1.941 0 C-N-CA 128.414 2.686 . . . . 0.0 117.41 -169.268 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.8 -57.21 2.62 Favored Glycine 0 N--CA 1.473 1.157 0 C-N-CA 127.84 2.638 . . . . 0.0 114.483 -177.986 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.9 t -168.17 171.11 9.7 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.727 1.211 . . . . 0.0 111.572 -178.584 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -85.04 148.29 26.23 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 120.726 -1.233 . . . . 0.0 110.608 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -128.01 -146.28 0.32 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.521 1.929 . . . . 0.0 109.26 175.935 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.79 155.37 30.54 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 127.146 2.178 . . . . 0.0 114.596 179.748 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.3 p -151.96 153.74 34.67 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.086 1.355 . . . . 0.0 114.084 -173.304 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.04 159.87 31.5 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 125.042 1.306 . . . . 0.0 113.407 178.057 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 3.6 t -106.45 142.91 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-N 118.717 1.259 . . . . 0.0 109.422 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mm -77.48 93.74 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 CA-C-O 122.232 1.015 . . . . 0.0 110.156 -178.676 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -92.27 174.94 37.38 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 125.884 1.707 . . . . 0.0 112.706 173.581 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.07 149.64 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -173.372 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.98 -17.58 4.37 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.552 1.941 . . . . 0.0 115.006 177.561 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 . . . . . 0 N--CA 1.472 0.627 0 C-N-CA 125.689 1.595 . . . . 0.0 112.592 176.864 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.279 0.561 . . . . 0.0 112.235 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.7 t -156.63 112.17 2.92 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 125.814 1.646 . . . . 0.0 108.458 167.878 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 10.1 pttt -111.93 171.72 7.33 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 116.45 2.019 . . . . 0.0 116.45 -173.315 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -125.87 168.32 14.02 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 128.457 2.703 . . . . 0.0 110.957 174.492 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 5' ' ' VAL . . . . . 0.576 HG13 ' HB2' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -131.5 139.46 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 126.331 1.852 . . . . 0.0 111.861 -178.202 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.06 105.05 4.77 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.092 0.957 . . . . 0.0 109.477 165.041 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.514 HG11 ' HB3' ' A' ' 59' ' ' SER . 1.0 OUTLIER -92.13 130.81 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 166.358 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mp -92.07 143.41 26.48 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 123.554 0.742 . . . . 0.0 111.284 -178.728 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 tttm -156.14 175.93 13.33 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 168.903 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 148.8 -77.93 0.23 Allowed Glycine 0 CA--C 1.523 0.552 0 C-N-CA 128.463 2.935 . . . . 0.0 108.164 -172.936 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.74 75.49 3.39 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.021 1.728 . . . . 0.0 112.735 -168.251 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.73 -97.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.37 0 C-N-CA 127.503 2.478 . . . . 0.0 114.314 169.518 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -82.81 -1.34 10.46 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.958 3.772 . . . . 0.0 114.945 179.162 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.81 140.34 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 120.54 1.518 . . . . 0.0 110.047 170.749 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -139.71 168.03 20.76 Favored 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 125.684 1.594 . . . . 0.0 109.31 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -158.83 92.98 0.12 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.034 -1.426 . . . . 0.0 116.126 165.229 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.404 ' O ' HD13 ' B' ' 18' ' ' ILE . 0.0 OUTLIER -78.22 126.5 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-N 119.296 1.548 . . . . 0.0 110.723 175.931 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.469 HD12 HG11 ' B' ' 97' ' ' VAL . 26.7 mm -135.98 111.08 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 124.901 1.28 . . . . 0.0 110.977 176.113 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -74.8 146.62 41.91 Favored 'General case' 0 CA--C 1.546 0.819 0 O-C-N 121.328 -0.857 . . . . 0.0 110.009 166.963 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -128.76 100.64 5.79 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.707 1.603 . . . . 0.0 108.571 172.914 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -101.83 130.37 48.27 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -174.549 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -100.81 120.51 40.22 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.136 0.493 . . . . 0.0 111.41 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 23' ' ' LYS . . . . . 0.422 ' HG2' ' H ' ' B' ' 23' ' ' LYS . 7.9 ptmm? -75.06 -41.7 58.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 123.048 0.539 . . . . 0.0 111.204 168.678 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -156.58 133.58 10.42 Favored 'General case' 0 C--O 1.219 -0.52 0 C-N-CA 126.429 1.892 . . . . 0.0 110.321 168.309 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -60.42 -19.72 57.23 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 114.703 1.372 . . . . 0.0 114.703 -172.664 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -80.56 -6.26 57.98 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.655 1.182 . . . . 0.0 113.218 173.753 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.86 -164.34 11.22 Favored Glycine 0 CA--C 1.537 1.459 0 C-N-CA 126.546 2.022 . . . . 0.0 113.383 -172.935 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.37 155.52 25.06 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.271 2.647 . . . . 0.0 114.012 -169.25 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 84.5 t -102.6 137.35 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.766 1.626 . . . . 0.0 110.17 172.739 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -96.09 122.62 39.12 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 167.145 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.31 129.2 74.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 126.166 1.786 . . . . 0.0 107.856 -169.664 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.5 p90 -155.41 153.16 29.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 -178.679 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.64 -152.73 24.77 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 125.417 1.484 . . . . 0.0 109.92 179.717 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 69.0 p -159.04 147.42 18.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -175.074 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 6.0 mm -105.62 109.55 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.558 1.543 . . . . 0.0 109.078 177.812 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 44.9 tttp -120.75 133.43 55.33 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 119.463 1.029 . . . . 0.0 110.94 -168.887 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.66 -6.43 9.73 Favored Glycine 0 CA--C 1.541 1.681 0 C-N-CA 127.964 2.697 . . . . 0.0 113.839 -169.663 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.489 HD12 ' CE1' ' B' ' 43' ' ' HIS . 4.6 mm? -75.08 -179.89 4.61 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 126.373 1.869 . . . . 0.0 113.346 177.169 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -103.95 157.73 16.9 Favored 'General case' 0 C--O 1.239 0.553 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 162.521 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -64.86 168.94 5.65 Favored 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.741 1.385 . . . . 0.0 114.741 -170.84 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.59 -177.54 51.38 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.261 0.934 . . . . 0.0 114.161 -173.021 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.8 mp -66.97 149.33 50.78 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 127.298 2.239 . . . . 0.0 113.648 -174.156 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 43' ' ' HIS . . . . . 0.489 ' CE1' HD12 ' B' ' 38' ' ' LEU . 96.9 m-70 -140.5 133.42 29.19 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.726 1.61 . . . . 0.0 110.235 176.816 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.59 146.67 48.47 Favored Glycine 0 N--CA 1.475 1.257 0 CA-C-O 119.055 -0.858 . . . . 0.0 110.987 175.574 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -152.94 111.79 3.76 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.592 0.757 . . . . 0.0 111.852 -166.06 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -147.73 152.2 37.36 Favored 'General case' 0 N--CA 1.471 0.617 0 O-C-N 120.032 -1.667 . . . . 0.0 111.256 -169.852 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.41 131.41 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-O 123.719 1.724 . . . . 0.0 110.117 169.527 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 18.1 m-70 -76.08 108.69 9.16 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 165.448 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -68.75 21.62 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.238 2.215 . . . . 0.0 113.554 -169.288 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -153.81 131.74 11.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.976 1.71 . . . . 0.0 108.005 -171.158 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.28 -14.54 76.39 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 115.124 0.81 . . . . 0.0 115.124 178.427 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 52' ' ' ASP . . . . . 0.574 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -69.91 74.07 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 127.023 2.129 . . . . 0.0 111.149 178.257 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 5.4 p30 164.02 -36.54 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 128.697 2.799 . . . . 0.0 115.237 -178.85 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.401 0.1 OUTLIER 54.13 -47.4 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 130.457 3.503 . . . . 0.0 118.667 -173.625 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.98 21.23 6.9 Favored 'General case' 0 CA--C 1.549 0.906 0 CA-C-N 120.37 1.441 . . . . 0.0 113.643 -178.497 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 53.62 -128.67 39.88 Favored Glycine 0 C--N 1.34 0.782 0 C-N-CA 126.028 1.775 . . . . 0.0 112.919 169.248 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.1 m -58.16 -7.79 0.92 Allowed 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 115.856 1.798 . . . . 0.0 115.856 178.245 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 34.5 m -103.89 -0.11 29.49 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 126.084 1.753 . . . . 0.0 111.61 177.213 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 74.4 m -146.31 7.08 1.0 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 171.753 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.68 -172.71 1.96 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.845 2.058 . . . . 0.0 111.381 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.05 178.39 49.08 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 118.774 -1.014 . . . . 0.0 113.713 173.555 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -64.71 -176.3 0.42 Allowed 'Trans proline' 0 C--N 1.356 0.928 1 C-N-CA 128.171 5.914 . . . . 0.0 113.097 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 63' ' ' HIS . . . . . 0.623 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.6 p80 -53.48 111.82 0.78 Allowed 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.215 1.406 . . . . 0.0 108.53 169.338 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -57.49 157.9 6.36 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 114.434 -1.257 . . . . 0.0 111.174 -178.854 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.26 49.78 0.01 OUTLIER Pre-proline 0 CA--C 1.566 1.59 0 N-CA-C 114.909 1.448 . . . . 0.0 114.909 172.497 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -65.74 -28.98 51.45 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.366 2.238 . . . . 0.0 114.247 -171.553 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 65.7 mt -75.79 -4.0 38.14 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 173.4 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 64.95 55.16 1.19 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.524 1.529 . . . . 0.0 112.827 170.231 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.33 178.92 8.73 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 124.899 1.279 . . . . 0.0 112.709 -171.274 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HZ1' ' CD ' ' B' ' 77' ' ' GLU . 22.4 pttm -72.7 161.24 31.0 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.138 0.575 . . . . 0.0 111.173 -175.757 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -82.41 155.17 24.82 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 179.426 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 141.26 -108.93 0.57 Allowed Glycine 0 C--N 1.339 0.72 0 N-CA-C 114.246 0.458 . . . . 0.0 114.246 166.896 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.438 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 107.2 -19.61 34.38 Favored Glycine 0 CA--C 1.546 1.988 0 N-CA-C 119.145 2.418 . . . . 0.0 119.145 169.936 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 74' ' ' PRO . . . . . 0.43 ' HG2' HD13 ' B' ' 126' ' ' LEU . 0.5 OUTLIER -110.15 24.9 0.05 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 0 C-N-CA 124.248 3.299 . . . . 0.0 111.718 169.01 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 ptpt -165.85 -31.67 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 127.301 2.24 . . . . 0.0 110.646 170.967 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 76' ' ' ASP . . . . . 0.438 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.0 OUTLIER -84.2 136.72 33.85 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 128.469 2.708 . . . . 0.0 107.155 166.865 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 77' ' ' GLU . . . . . 0.487 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -87.63 -12.82 44.43 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 127.209 2.204 . . . . 0.0 113.523 -176.993 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -91.65 -98.65 0.12 Allowed 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.112 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 87.58 141.32 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 128.391 2.676 . . . . 0.0 113.573 174.599 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -69.67 154.99 41.2 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 116.938 -1.506 . . . . 0.0 107.872 162.73 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.326 7.1 p -76.5 -21.97 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-N 122.467 2.394 . . . . 0.0 111.104 177.173 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -69.11 20.81 0.4 Allowed Glycine 0 CA--C 1.537 1.436 0 C-N-CA 125.693 1.616 . . . . 0.0 115.327 169.202 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -124.63 118.16 25.88 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 120.785 2.292 . . . . 0.0 111.71 -176.736 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -97.75 170.81 8.73 Favored 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 166.378 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -76.04 175.5 52.27 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 166.899 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -70.65 145.93 50.32 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.559 -0.377 . . . . 0.0 111.104 -169.821 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.417 HG22 ' HB1' ' B' ' 95' ' ' ALA . 6.6 p -85.0 166.0 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 165.853 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -152.49 140.2 19.89 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.159 1.345 . . . . 0.0 112.688 -177.532 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 89' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -116.94 152.33 34.78 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -167.988 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -97.25 155.46 16.85 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 129.245 3.018 . . . . 0.0 110.943 170.573 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -43.01 -24.02 0.06 Allowed 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 129.487 3.115 . . . . 0.0 117.27 175.479 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.41 6.28 5.91 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 120.503 -1.373 . . . . 0.0 111.595 172.982 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.0 27.91 67.71 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 126.06 1.791 . . . . 0.0 112.801 178.564 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.5 p -115.71 120.28 64.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.09 0.956 . . . . 0.0 110.63 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -83.6 120.99 26.64 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.521 1.128 . . . . 0.0 108.728 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.42 146.3 28.51 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.852 0.834 . . . . 0.0 110.302 172.549 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 97' ' ' VAL . . . . . 0.469 HG11 HD12 ' B' ' 18' ' ' ILE . 0.4 OUTLIER -132.37 127.96 57.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.52 165.333 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -150.68 53.59 0.88 Allowed 'General case' 0 CA--C 1.545 0.757 0 CA-C-O 123.583 1.658 . . . . 0.0 109.204 -172.746 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.5 mp -105.03 160.85 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.241 1.816 . . . . 0.0 112.512 -166.587 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -140.23 142.12 35.84 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 128.153 2.581 . . . . 0.0 106.304 168.691 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -150.98 138.29 19.39 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 119.084 0.856 . . . . 0.0 111.393 -179.949 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.2 p -107.84 52.75 0.71 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.393 1.077 . . . . 0.0 111.815 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.63 -42.1 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.864 1.666 . . . . 0.0 108.967 177.172 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -87.9 144.64 8.78 Favored 'Isoleucine or valine' 0 C--N 1.344 0.338 0 CA-C-O 122.32 1.057 . . . . 0.0 110.463 167.468 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 10.3 p -148.86 168.41 23.08 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 124.201 1.001 . . . . 0.0 111.125 170.215 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -79.72 63.49 4.3 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 124.754 1.221 . . . . 0.0 108.628 174.737 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.0 t -84.55 -175.67 5.89 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.082 1.353 . . . . 0.0 110.342 169.086 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.06 -46.92 2.33 Favored Glycine 0 N--CA 1.475 1.265 0 O-C-N 120.924 -1.11 . . . . 0.0 113.832 177.016 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -125.27 -24.74 3.91 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -169.398 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 73.0 m-70 -97.71 7.98 45.48 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.558 1.543 . . . . 0.0 113.421 -171.554 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.62 -133.83 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -171.916 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.321 36.0 pt -81.28 -143.18 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 CA-C-N 119.431 1.014 . . . . 0.0 113.011 170.822 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm 59.49 124.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 127.597 2.359 . . . . 0.0 111.873 -165.56 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.05 19.68 61.69 Favored Glycine 0 N--CA 1.474 1.212 0 O-C-N 120.409 -1.432 . . . . 0.0 113.981 179.007 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? -99.93 172.45 7.22 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 127.157 2.183 . . . . 0.0 109.496 174.56 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.9 t -130.67 127.0 37.99 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-N 119.371 0.987 . . . . 0.0 112.287 177.977 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 16.7 tp -93.0 130.36 38.59 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 125.677 1.591 . . . . 0.0 110.322 -175.648 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.53 146.5 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 125.781 1.632 . . . . 0.0 111.323 175.514 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.3 p -121.78 142.14 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 123.48 0.712 . . . . 0.0 111.215 170.553 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -115.25 156.06 26.08 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 113.607 -168.728 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -73.67 -28.53 61.81 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -169.251 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -117.82 173.97 6.45 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.562 1.145 . . . . 0.0 112.228 176.721 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.8 134.06 56.25 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.368 1.467 . . . . 0.0 110.828 169.8 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -81.78 119.67 24.18 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.411 1.084 . . . . 0.0 111.277 173.6 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . 0.369 30.3 t0 -75.71 -4.88 42.86 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 170.47 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 126' ' ' LEU . . . . . 0.43 HD13 ' HG2' ' B' ' 74' ' ' PRO . 5.4 mt 61.03 76.03 0.39 Allowed 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 126.221 1.808 . . . . 0.0 112.123 165.125 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.13 -12.71 48.78 Favored Glycine 0 N--CA 1.476 1.303 0 C-N-CA 123.174 0.416 . . . . 0.0 112.875 176.913 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mtpm? -115.38 179.0 4.09 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.883 2.473 . . . . 0.0 109.223 170.033 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 126.39 -28.81 4.68 Favored Glycine 0 N--CA 1.469 0.861 0 C-N-CA 125.681 1.61 . . . . 0.0 111.351 -168.931 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 104.43 -6.29 45.52 Favored Glycine 0 N--CA 1.474 1.185 0 N-CA-C 117.253 1.661 . . . . 0.0 117.253 166.609 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.0 p-10 -110.74 170.24 8.23 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.771 1.628 . . . . 0.0 110.258 176.159 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 132' ' ' GLU . . . . . 0.415 ' OE2' ' HE2' ' B' ' 136' ' ' LYS . 24.2 tt0 -63.0 -41.65 99.63 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.514 -1.366 . . . . 0.0 110.412 -179.843 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -56.23 -27.88 56.49 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.369 2.267 . . . . 0.0 112.569 176.317 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.26 -23.04 54.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.566 1.076 . . . . 0.0 113.573 171.224 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.6 t -121.23 -13.05 8.56 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.373 1.619 . . . . 0.0 115.373 169.646 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.415 ' HE2' ' OE2' ' B' ' 132' ' ' GLU . 30.6 mttm -76.48 -23.96 53.82 Favored 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 121.009 1.732 . . . . 0.0 111.449 166.501 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 75.6 p -117.97 -114.21 0.33 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 104.3 -2.481 . . . . 0.0 104.3 165.386 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.24 -10.76 0.19 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 116.262 1.265 . . . . 0.0 116.262 169.136 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 114.85 -14.15 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 131.123 3.769 . . . . 0.0 112.737 177.819 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.08 4.9 0.11 Allowed 'General case' 0 CA--C 1.56 1.344 0 N-CA-C 117.497 2.406 . . . . 0.0 117.497 -174.34 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.8 -141.68 18.8 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.542 1.544 . . . . 0.0 113.466 174.808 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.0 t -68.64 -167.44 0.1 Allowed 'General case' 0 CA--C 1.544 0.732 0 CA-C-O 122.294 1.045 . . . . 0.0 111.965 175.909 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.88 155.79 44.69 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 124.428 1.091 . . . . 0.0 110.578 177.943 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.72 -123.19 0.29 Allowed 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 126.256 2.222 . . . . 0.0 105.034 164.003 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -66.91 160.71 25.65 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -166.394 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.8 t -147.88 152.08 37.0 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.445 1.898 . . . . 0.0 112.078 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.65 135.79 4.3 Favored Glycine 0 N--CA 1.483 1.829 0 CA-C-N 120.317 1.417 . . . . 0.0 115.667 -177.087 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 12.2 t -81.65 154.89 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 125.336 1.454 . . . . 0.0 111.779 -177.204 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 39.3 mt -95.46 93.82 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 126.455 1.902 . . . . 0.0 111.99 -176.358 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.24 173.63 30.35 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 125.614 1.578 . . . . 0.0 113.487 174.606 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.8 mp -95.49 85.98 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.095 1.887 . . . . 0.0 116.095 -167.943 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -73.78 18.92 0.12 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.961 1.704 . . . . 0.0 115.478 -179.801 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 . . . . . 0 N--CA 1.466 0.364 0 C-N-CA 130.845 3.658 . . . . 0.0 114.712 -169.279 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.511 -0.541 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 152' ' ' ALA . 14.4 pttm -89.13 129.96 35.64 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.375 168.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -90.56 173.52 8.02 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 164.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.582 HG23 HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -138.2 119.56 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.524 1.53 . . . . 0.0 108.475 -173.784 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.96 118.77 37.65 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 166.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 HG22 ' B' ' 54' ' ' THR . 22.0 t -110.99 99.66 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.705 0.802 . . . . 0.0 109.397 177.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.95 132.56 35.89 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.564 168.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -135.5 132.51 37.4 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.048 1.339 . . . . 0.0 110.643 168.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.95 -97.95 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 171.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.87 119.77 9.95 Favored 'General case' 0 N--CA 1.44 -0.94 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 -166.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 41.02 -99.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 128.743 3.068 . . . . 0.0 113.358 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.88 -11.88 33.52 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 123.311 2.674 . . . . 0.0 113.828 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.89 115.05 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 120.32 1.418 . . . . 0.0 112.44 179.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -139.9 169.9 16.86 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 122.265 1.031 . . . . 0.0 111.005 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.96 110.29 0.55 Allowed Glycine 0 C--O 1.224 -0.476 0 CA-C-N 113.984 -1.462 . . . . 0.0 111.639 168.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.62 134.65 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.106 0.953 . . . . 0.0 109.339 169.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.1 mm -139.38 124.45 21.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 C-N-CA 125.996 1.718 . . . . 0.0 109.888 168.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -90.81 141.32 28.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 124.867 1.267 . . . . 0.0 110.571 166.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.633 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 71.4 m-85 -113.94 101.53 9.34 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.686 1.194 . . . . 0.0 109.779 172.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -83.91 110.68 18.59 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 125.965 1.706 . . . . 0.0 111.172 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.498 ' HB2' HD13 ' A' ' 106' ' ' LEU . 6.7 tp60 -123.13 139.17 54.34 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.378 1.071 . . . . 0.0 110.989 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.94 -28.17 15.3 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 -168.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.277 0.0 OUTLIER -128.68 -106.76 0.3 Allowed 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.953 1.301 . . . . 0.0 109.508 166.628 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 88.4 p -152.96 -10.37 0.16 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 122.13 2.241 . . . . 0.0 116.358 -177.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -128.94 -13.91 4.52 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.377 1.471 . . . . 0.0 112.672 176.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 174.53 42.58 Favored Glycine 0 CA--C 1.543 1.812 0 C-N-CA 127.938 2.685 . . . . 0.0 113.885 175.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -79.91 157.32 23.99 Favored 'Trans proline' 0 CA--C 1.534 0.498 0 C-N-CA 123.546 2.831 . . . . 0.0 112.427 -168.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.2 t -118.21 136.89 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.97 0.908 . . . . 0.0 112.427 -166.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -93.57 124.31 37.47 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.597 1.159 . . . . 0.0 108.151 170.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.25 133.34 69.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.924 0.89 . . . . 0.0 110.29 -168.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -157.36 158.83 36.69 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.25 178.6 29.67 Favored Glycine 0 CA--C 1.528 0.849 0 C-N-CA 123.881 0.753 . . . . 0.0 114.799 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.0 p -115.69 125.35 52.72 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -167.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 9.7 mm -109.74 102.24 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 C-N-CA 125.224 1.41 . . . . 0.0 108.068 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -116.2 157.61 24.59 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.315 0.646 . . . . 0.0 112.194 -168.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.94 9.6 63.72 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 124.941 1.258 . . . . 0.0 112.448 -168.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 99.0 mt -83.33 167.93 17.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.688 1.195 . . . . 0.0 110.563 172.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -100.37 156.64 17.14 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 106.322 -1.732 . . . . 0.0 106.322 163.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -61.96 157.23 19.08 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-O 122.509 1.147 . . . . 0.0 113.429 -170.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.02 -176.83 36.37 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 122.147 0.859 . . . . 0.0 112.685 -173.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.504 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.2 mp -72.52 150.35 43.29 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.695 1.998 . . . . 0.0 111.895 -169.12 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -144.31 124.82 13.96 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.847 1.659 . . . . 0.0 110.462 174.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.04 148.33 36.38 Favored Glycine 0 N--CA 1.487 2.054 0 CA-C-O 118.723 -1.043 . . . . 0.0 112.869 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.508 ' CE1' HD11 ' A' ' 117' ' ' LEU . 7.4 t80 -149.84 97.53 2.61 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-N 118.325 1.062 . . . . 0.0 113.613 -166.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.504 ' O ' HD22 ' A' ' 117' ' ' LEU . 9.9 m80 -130.25 134.29 47.13 Favored 'General case' 0 N--CA 1.483 1.196 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -166.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.792 HG23 ' HA2' ' A' ' 82' ' ' GLY . 0.0 OUTLIER -85.36 113.94 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 122.015 0.912 . . . . 0.0 110.896 170.17 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -81.74 173.07 12.65 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 125.419 1.487 . . . . 0.0 114.109 -175.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.449 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.6 pm0 -65.06 133.41 51.58 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 126.062 1.745 . . . . 0.0 106.54 165.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 67.83 -176.91 0.2 Allowed 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 124.275 1.988 . . . . 0.0 112.992 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.34 3.65 29.68 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 130.618 3.961 . . . . 0.0 111.52 168.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.411 ' C ' HD22 ' A' ' 53' ' ' ASN . 14.9 t0 -73.85 126.51 30.57 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 120.385 2.093 . . . . 0.0 109.51 172.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.532 ' CG ' HG21 ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -156.12 42.62 0.4 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 123.289 1.518 . . . . 0.0 112.708 168.46 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.753 ' CG2' HG22 ' B' ' 7' ' ' VAL . 38.8 p -116.3 -25.7 7.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 112.737 -2.029 . . . . 0.0 113.905 -165.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 25.6 0.59 Allowed 'General case' 0 CA--C 1.552 1.039 0 CA-C-N 119.374 0.988 . . . . 0.0 112.109 168.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.69 -121.35 12.34 Favored Glycine 0 C--N 1.341 0.827 0 C-N-CA 125.573 1.558 . . . . 0.0 110.561 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -74.14 -13.68 60.85 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.17 39.44 0.45 Allowed 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 126.072 1.749 . . . . 0.0 111.72 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 69.8 m -148.29 -116.16 0.06 Allowed 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.306 2.243 . . . . 0.0 106.636 -169.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.59 109.98 0.71 Allowed 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 124.781 1.232 . . . . 0.0 112.23 169.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.57 -113.02 0.47 Allowed Glycine 0 CA--C 1.538 1.485 0 CA-C-O 117.928 -1.485 . . . . 0.0 109.574 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -82.67 -179.86 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 124.415 3.41 . . . . 0.0 108.102 165.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.29 123.07 32.52 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.673 0.789 . . . . 0.0 111.518 -172.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -26.03 131.77 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 129.419 3.088 . . . . 0.0 116.956 174.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -106.15 52.69 0.15 Allowed Pre-proline 0 CA--C 1.557 1.235 0 C-N-CA 124.883 1.273 . . . . 0.0 113.425 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -63.05 -25.3 73.57 Favored 'Trans proline' 0 C--N 1.355 0.896 0 CA-C-N 122.691 1.997 . . . . 0.0 112.937 -173.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 69.0 mt -99.5 -0.49 40.56 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.802 1.241 . . . . 0.0 113.797 172.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.4 t 70.57 58.87 0.23 Allowed 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 120.452 1.478 . . . . 0.0 114.073 168.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.06 176.01 10.04 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.446 1.498 . . . . 0.0 111.478 172.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -70.8 173.29 7.49 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 129.497 3.119 . . . . 0.0 113.225 178.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -69.02 149.29 48.95 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.481 167.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 171.45 -157.45 27.95 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 116.884 1.513 . . . . 0.0 116.884 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.81 -70.29 0.43 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 118.013 1.965 . . . . 0.0 118.013 168.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -75.98 0.03 9.76 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 123.327 2.685 . . . . 0.0 114.506 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.98 -31.48 0.21 Allowed 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 119.301 0.955 . . . . 0.0 111.415 171.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -89.92 153.23 20.77 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.464 1.506 . . . . 0.0 111.26 167.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.7 tt0 -98.68 -27.82 13.81 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 126.356 1.863 . . . . 0.0 112.722 -170.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -78.8 -53.02 7.54 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 121.412 -0.805 . . . . 0.0 110.704 -169.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.7 ttt180 58.17 119.75 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 117.789 2.515 . . . . 0.0 117.789 163.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.8 m170 -58.5 143.08 46.94 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 118.458 -2.652 . . . . 0.0 112.942 169.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 91.2 t -58.26 -24.18 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.334 -0.854 . . . . 0.0 110.432 167.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.792 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -80.89 23.38 4.39 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 117.157 -1.913 . . . . 0.0 116.44 172.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -127.4 109.62 11.95 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 120.577 2.189 . . . . 0.0 111.533 -178.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.437 HD21 HD23 ' A' ' 117' ' ' LEU . 0.9 OUTLIER -110.92 59.56 0.61 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.156 0.982 . . . . 0.0 110.742 172.502 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.79 -151.78 39.8 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.916 173.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.82 149.47 47.75 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.805 1.242 . . . . 0.0 108.619 169.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.26 106.47 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 124.559 1.144 . . . . 0.0 109.579 -174.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 38.7 m -96.14 114.67 26.39 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 124.451 1.1 . . . . 0.0 108.772 -174.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.73 154.11 19.18 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.666 1.187 . . . . 0.0 113.421 -172.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.6 176.84 6.13 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.513 1.125 . . . . 0.0 112.278 168.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.434 ' HZ3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -73.57 -18.9 61.01 Favored 'General case' 0 N--CA 1.473 0.718 0 O-C-N 121.113 -0.992 . . . . 0.0 113.003 -176.587 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.37 15.23 0.48 Allowed 'General case' 0 CA--C 1.56 1.328 0 CA-C-O 122.974 1.369 . . . . 0.0 110.799 170.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.29 12.74 80.18 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 128.131 2.776 . . . . 0.0 114.726 168.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.26 134.4 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 116.77 2.137 . . . . 0.0 116.77 -166.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.0 103.84 13.97 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.734 1.214 . . . . 0.0 107.822 166.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -94.89 109.36 21.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.944 0.878 . . . . 0.0 109.635 172.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -93.67 153.84 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 C-N-CA 124.825 1.25 . . . . 0.0 112.977 -169.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.2 p -149.6 125.74 10.69 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.933 0.893 . . . . 0.0 110.635 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.4 mt -144.98 157.99 13.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 128.548 2.739 . . . . 0.0 110.492 -169.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -147.04 135.89 22.23 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.456 1.902 . . . . 0.0 107.055 167.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -155.79 144.92 20.69 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -166.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.0 p -122.15 49.25 1.6 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.326 1.05 . . . . 0.0 113.742 176.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.03 -3.63 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 124.769 1.227 . . . . 0.0 112.478 171.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.61 163.74 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 127.023 2.129 . . . . 0.0 110.004 174.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.0 t -157.13 163.84 38.49 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.524 1.529 . . . . 0.0 110.53 170.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.498 HD13 ' HB2' ' A' ' 22' ' ' GLN . 7.5 mp -77.3 66.36 3.06 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 120.195 1.361 . . . . 0.0 110.923 -171.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.89 104.0 9.24 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 125.431 1.492 . . . . 0.0 114.185 -167.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.49 -145.37 32.88 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.269 167.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -109.24 11.28 25.5 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.609 1.564 . . . . 0.0 112.086 -167.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -141.78 -9.77 0.92 Allowed 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -167.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.2 t -90.22 -87.85 0.18 Allowed 'General case' 0 N--CA 1.471 0.596 0 O-C-N 120.774 -1.204 . . . . 0.0 110.951 -171.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.294 0.1 OUTLIER -134.33 16.01 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 120.708 1.595 . . . . 0.0 112.505 167.356 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.39 141.04 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.25 3.97 83.0 Favored Glycine 0 N--CA 1.468 0.82 0 C-N-CA 124.451 1.024 . . . . 0.0 114.575 -175.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 44.2 ttt180 -100.38 176.36 5.38 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.286 1.434 . . . . 0.0 111.903 -167.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 18.8 m -118.62 143.05 47.07 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.942 1.697 . . . . 0.0 108.987 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.508 HD11 ' CE1' ' A' ' 45' ' ' PHE . 3.2 tm? -117.62 141.89 47.85 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.581 1.152 . . . . 0.0 108.648 167.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.2 p -118.05 139.04 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.881 0.872 . . . . 0.0 111.52 172.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 4.7 p -110.81 133.64 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 O-C-N 124.293 0.996 . . . . 0.0 109.623 167.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 -99.94 159.45 15.07 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -60.6 -44.83 95.84 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.601 2.76 . . . . 0.0 114.714 -175.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 3.4 mppt? -127.35 -180.0 5.18 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.987 1.715 . . . . 0.0 113.163 -176.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.23 147.02 17.45 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.514 1.526 . . . . 0.0 112.428 173.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -102.53 137.04 41.3 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.821 1.648 . . . . 0.0 109.967 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -72.54 -43.31 63.68 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.964 -0.541 . . . . 0.0 111.673 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.0 mt 71.74 53.48 0.21 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.688 1.995 . . . . 0.0 111.967 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 158.43 -90.11 0.11 Allowed Glycine 0 N--CA 1.474 1.224 0 CA-C-N 119.598 1.09 . . . . 0.0 115.128 176.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.6 ttpm? -146.44 98.9 3.14 Favored 'General case' 0 N--CA 1.424 -1.76 0 C-N-CA 128.649 2.78 . . . . 0.0 107.745 177.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.5 -138.74 0.69 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 169.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -89.74 6.26 83.08 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.08 -175.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -157.99 168.92 25.77 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 120.372 2.086 . . . . 0.0 109.789 -169.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.91 -57.7 11.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.425 1.09 . . . . 0.0 110.836 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -41.24 -40.47 1.62 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 127.663 2.385 . . . . 0.0 114.562 178.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 64.1 p -55.12 -27.59 46.41 Favored 'General case' 0 N--CA 1.469 0.505 0 O-C-N 120.595 -1.315 . . . . 0.0 113.768 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 27.1 p -71.63 -28.02 63.49 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.557 1.143 . . . . 0.0 112.681 173.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -79.4 -56.98 3.93 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.771 1.628 . . . . 0.0 112.471 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.8 p -115.29 -14.84 11.65 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.525 1.306 . . . . 0.0 114.525 -170.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.49 -1.88 69.86 Favored Glycine 0 N--CA 1.466 0.65 0 O-C-N 123.902 0.751 . . . . 0.0 112.277 -169.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 66.16 17.56 10.77 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.671 1.188 . . . . 0.0 111.021 -176.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.6 -9.81 15.39 Favored 'General case' 0 CA--C 1.554 1.127 0 C-N-CA 123.898 0.879 . . . . 0.0 113.175 -168.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.67 -164.03 21.79 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.831 1.681 . . . . 0.0 112.937 178.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -63.68 175.67 1.05 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.797 1.239 . . . . 0.0 112.246 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.29 143.96 38.08 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 120.761 -1.212 . . . . 0.0 112.066 169.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -104.04 -94.72 0.33 Allowed 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.105 1.762 . . . . 0.0 109.052 173.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.34 149.18 38.78 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 122.379 1.085 . . . . 0.0 110.793 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 84.5 m -131.67 151.76 51.39 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 112.768 -2.014 . . . . 0.0 108.005 173.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.94 163.04 33.52 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 123.404 0.526 . . . . 0.0 113.899 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 25.1 t -113.5 160.87 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 125.358 1.463 . . . . 0.0 110.589 177.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.2 mt -114.65 123.26 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 124.222 1.009 . . . . 0.0 113.362 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -126.74 -168.73 12.62 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 126.144 1.83 . . . . 0.0 113.093 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 151' ' ' ILE . 2.2 mp -104.63 131.78 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 121.57 -0.959 . . . . 0.0 111.033 -169.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.542 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -118.71 22.6 11.92 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.719 1.608 . . . . 0.0 113.61 -174.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.332 -0.188 0 C-N-CA 124.368 1.067 . . . . 0.0 110.47 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.825 0.345 . . . . 0.0 111.845 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -107.98 122.49 46.95 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.726 0.81 . . . . 0.0 109.411 175.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -99.18 131.17 45.41 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 174.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.86 169.52 8.54 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.652 1.181 . . . . 0.0 114.08 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -161.63 88.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 C-N-CA 128.114 2.566 . . . . 0.0 109.218 -169.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.72 142.73 35.18 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 120.415 -1.428 . . . . 0.0 111.005 176.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.753 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.2 t -126.7 106.23 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 3.1 mp -100.0 139.33 35.82 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.603 1.161 . . . . 0.0 108.21 169.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -155.95 175.18 14.29 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.126 1.37 . . . . 0.0 110.307 170.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 143.62 -46.3 0.84 Allowed Glycine 0 N--CA 1.474 1.201 0 C-N-CA 124.54 1.067 . . . . 0.0 113.68 169.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -78.01 67.2 3.8 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.535 1.534 . . . . 0.0 109.23 175.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.24 -111.34 0.38 Allowed Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.649 2.547 . . . . 0.0 112.625 -175.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -76.51 1.14 8.76 Favored 'Trans proline' 0 CA--C 1.536 0.603 0 C-N-CA 124.906 3.737 . . . . 0.0 114.168 -176.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 31.1 t -79.49 131.39 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 120.155 1.343 . . . . 0.0 111.283 171.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -130.13 160.84 32.56 Favored 'General case' 0 CA--C 1.516 -0.363 0 C-N-CA 125.127 1.371 . . . . 0.0 109.381 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.68 107.68 0.69 Allowed Glycine 0 CA--C 1.499 -0.926 0 CA-C-N 113.956 -1.474 . . . . 0.0 109.491 169.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.73 120.71 65.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.252 2.9 pp -130.53 139.49 51.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 122.376 1.084 . . . . 0.0 110.715 172.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -107.54 172.98 6.53 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 125.921 1.688 . . . . 0.0 110.523 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -152.66 165.74 34.32 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.773 0.829 . . . . 0.0 109.528 170.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -136.02 138.12 41.88 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.175 1.39 . . . . 0.0 109.584 166.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 59.4 tp60 -102.97 102.28 12.32 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.554 0.742 . . . . 0.0 110.749 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.497 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -67.25 -45.0 78.0 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 120.51 -1.369 . . . . 0.0 113.703 176.158 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . 0.497 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 40.0 mp0 -147.7 138.98 23.62 Favored 'General case' 0 C--O 1.222 -0.379 0 C-N-CA 126.858 2.063 . . . . 0.0 108.394 168.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 76.0 p -50.33 -20.44 1.08 Allowed 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -169.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -112.98 0.46 15.06 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.141 1.376 . . . . 0.0 113.248 -173.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.72 -170.3 43.18 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.664 1.126 . . . . 0.0 113.624 -173.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -81.2 162.52 20.14 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.761 2.307 . . . . 0.0 109.923 168.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -135.47 143.24 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.481 1.112 . . . . 0.0 110.999 -174.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HZ3' ' CD ' ' B' ' 100' ' ' GLU . 41.7 tttp -94.88 115.78 27.89 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.795 0.807 . . . . 0.0 110.153 167.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.94 144.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 166.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -144.56 -168.39 2.89 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 167.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.45 -153.82 17.22 Favored Glycine 0 N--CA 1.469 0.843 0 C-N-CA 124.84 1.21 . . . . 0.0 112.684 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 94.7 p -156.67 137.87 13.72 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 114.062 1.134 . . . . 0.0 114.062 -172.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.8 mm -104.96 119.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 169.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -131.91 144.62 50.98 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 121.192 1.814 . . . . 0.0 111.816 -171.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.7 -8.16 21.99 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 128.547 2.975 . . . . 0.0 113.374 -173.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.41 HD23 ' CD2' ' B' ' 43' ' ' HIS . 5.5 mp -71.44 156.48 39.41 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 129.327 3.051 . . . . 0.0 112.732 -176.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.6 t -74.48 168.32 19.95 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 164.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -75.52 146.1 40.81 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.167 -0.958 . . . . 0.0 112.976 177.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.72 -168.04 13.79 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 124.142 0.877 . . . . 0.0 113.017 -172.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.0 mt -76.12 147.43 38.58 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.896 2.078 . . . . 0.0 112.966 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CD2' HD23 ' B' ' 38' ' ' LEU . 87.2 m-70 -146.54 120.75 9.53 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.929 2.092 . . . . 0.0 110.501 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.06 145.86 37.05 Favored Glycine 0 N--CA 1.484 1.876 0 CA-C-O 117.536 -1.702 . . . . 0.0 112.333 -177.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.64 ' HB2' HG22 ' B' ' 119' ' ' VAL . 0.4 OUTLIER -141.49 125.89 17.64 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 121.173 2.486 . . . . 0.0 113.074 -178.546 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 28.7 m80 -137.2 128.21 27.59 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -171.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -80.59 137.51 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 165.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -113.81 171.27 7.69 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 118.715 0.689 . . . . 0.0 111.466 173.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -72.63 138.72 46.92 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 125.184 1.394 . . . . 0.0 110.707 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 72.0 168.36 0.31 Allowed 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.6 1.96 . . . . 0.0 111.37 -168.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.405 ' C ' HG11 ' A' ' 5' ' ' VAL . . . -93.32 16.62 60.19 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 164.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.409 ' HA ' HG21 ' A' ' 5' ' ' VAL . 15.5 t0 -87.35 110.45 20.25 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 125.9 1.68 . . . . 0.0 109.444 -168.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.618 HD21 HG22 ' B' ' 148' ' ' VAL . 2.2 p30 -159.23 34.48 0.2 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 116.132 1.901 . . . . 0.0 116.132 -174.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.582 HG22 HG23 ' A' ' 5' ' ' VAL 0.321 1.3 p . . . . . 0 CA--C 1.536 0.426 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -164.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.797 0 CA-C-O 123.011 1.386 . . . . 0.0 114.413 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.15 -115.81 4.04 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.502 1.525 . . . . 0.0 111.773 176.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.58 175.52 10.96 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.968 3.112 . . . . 0.0 110.978 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.63 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -69.57 113.76 7.16 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.94 1.696 . . . . 0.0 109.192 176.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -55.15 145.43 21.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.832 1.301 . . . . 0.0 114.503 -168.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -111.05 66.77 0.55 Allowed Pre-proline 0 CA--C 1.55 0.977 0 C-N-CA 126.87 2.068 . . . . 0.0 112.16 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -60.64 -35.64 88.78 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.076 2.518 . . . . 0.0 113.329 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 72.9 mt -80.85 -1.32 42.76 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.728 1.211 . . . . 0.0 114.177 171.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t 71.22 47.02 0.41 Allowed 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 127.835 2.454 . . . . 0.0 111.073 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.7 mtp180 -103.02 171.99 7.07 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -169.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mpmm? -83.45 167.07 17.81 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 125.665 1.586 . . . . 0.0 109.449 162.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -78.32 168.46 19.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.357 1.063 . . . . 0.0 112.087 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.6 -134.95 7.65 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 124.719 1.152 . . . . 0.0 113.495 168.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.81 -80.77 0.33 Allowed Glycine 0 CA--C 1.541 1.657 0 CA-C-N 118.278 1.039 . . . . 0.0 115.335 -174.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.19 7.5 0.63 Allowed 'Trans proline' 0 CA--C 1.547 1.175 0 CA-C-N 120.846 2.323 . . . . 0.0 115.328 -177.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.35 6.57 0.29 Allowed 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 126.986 2.115 . . . . 0.0 113.366 169.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.6 156.71 45.66 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.406 2.282 . . . . 0.0 110.336 -170.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -97.43 -9.22 27.71 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.648 1.979 . . . . 0.0 112.126 -173.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -83.86 -95.81 0.06 Allowed 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.443 -0.786 . . . . 0.0 110.482 177.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 48.8 ttt180 68.49 115.98 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.513 1.925 . . . . 0.0 112.274 -170.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -55.21 154.31 5.96 Favored 'General case' 0 CA--C 1.552 1.022 0 O-C-N 119.505 -1.997 . . . . 0.0 114.813 171.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -84.91 58.18 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 C-N-CA 124.573 1.149 . . . . 0.0 109.492 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.61 67.75 0.02 OUTLIER Glycine 0 N--CA 1.469 0.852 0 C-N-CA 127.569 2.509 . . . . 0.0 109.59 -169.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -163.9 165.45 22.75 Favored 'General case' 0 CA--C 1.553 1.065 0 C-N-CA 128.78 2.832 . . . . 0.0 110.027 166.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 92.9 mt -131.39 -178.38 4.82 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.386 2.274 . . . . 0.0 107.331 168.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.46 -112.4 0.86 Allowed Glycine 0 N--CA 1.47 0.95 0 CA-C-N 118.309 0.504 . . . . 0.0 112.689 -179.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -137.11 164.17 29.06 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-O 121.643 0.735 . . . . 0.0 112.813 176.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.5 m -108.61 175.59 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 127.342 2.257 . . . . 0.0 109.354 171.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 m -141.34 140.25 33.72 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.525 1.53 . . . . 0.0 107.633 169.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.42 139.58 40.68 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.439 1.096 . . . . 0.0 112.814 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -82.62 154.35 24.98 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.717 2.007 . . . . 0.0 110.603 168.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.22 1.25 0.51 Allowed 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 117.621 2.452 . . . . 0.0 117.621 -169.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -76.24 -7.37 54.71 Favored 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 125.138 1.375 . . . . 0.0 109.783 164.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 93.77 20.67 30.73 Favored Glycine 0 C--N 1.337 0.594 0 C-N-CA 128.719 3.057 . . . . 0.0 112.482 177.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.7 p -127.68 133.51 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 119.09 1.445 . . . . 0.0 114.224 -168.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.93 131.24 41.07 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 165.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -81.77 142.46 32.59 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 104.105 -2.554 . . . . 0.0 104.105 166.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 t -125.9 127.02 70.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 CA-C-N 113.349 -1.751 . . . . 0.0 107.541 169.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.8 p -158.77 51.4 0.39 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.723 1.609 . . . . 0.0 110.105 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 mt -103.56 148.76 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.874 1.67 . . . . 0.0 113.317 -167.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . 0.434 ' CD ' ' HZ3' ' B' ' 30' ' ' LYS . 5.6 mp0 -99.31 152.92 19.39 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 125.87 1.668 . . . . 0.0 109.457 174.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -153.81 148.49 26.36 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.787 -1.097 . . . . 0.0 111.039 167.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.6 p -118.55 53.65 0.97 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.279 1.032 . . . . 0.0 111.749 178.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.43 -35.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.958 168.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.92 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 CA-C-N 121.024 1.738 . . . . 0.0 111.151 167.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.0 m -160.92 162.43 32.03 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.474 1.509 . . . . 0.0 109.875 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -87.38 76.69 9.04 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.262 1.425 . . . . 0.0 109.172 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.3 t -158.21 104.82 1.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.468 0.651 . . . . 0.0 111.396 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.61 157.22 26.52 Favored Glycine 0 CA--C 1.526 0.763 0 CA-C-O 122.908 1.282 . . . . 0.0 112.445 -172.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -67.12 -21.26 65.85 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 131.391 3.876 . . . . 0.0 114.266 -169.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -107.56 14.88 25.32 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 128.58 2.752 . . . . 0.0 111.806 -175.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 81.0 p -101.67 -54.04 2.83 Favored 'General case' 0 CA--C 1.548 0.875 0 O-C-N 119.428 -2.045 . . . . 0.0 114.233 -174.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pt 178.51 -39.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 1 C-N-CA 133.941 4.897 . . . . 0.0 106.563 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm -57.71 131.08 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 N-CA-C 103.194 -2.891 . . . . 0.0 103.194 159.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.99 -18.97 8.24 Favored Glycine 0 CA--C 1.535 1.297 0 N-CA-C 117.046 1.578 . . . . 0.0 117.046 175.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.8 mtt180 -79.09 -178.09 5.96 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 126.408 1.883 . . . . 0.0 114.081 -177.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 8.8 t -120.19 170.03 9.7 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 127.929 2.492 . . . . 0.0 110.931 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tp -153.54 146.83 24.77 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.396 1.478 . . . . 0.0 111.358 171.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.43 137.34 56.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.622 1.569 . . . . 0.0 110.126 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.64 HG22 ' HB2' ' B' ' 45' ' ' PHE . 45.6 t -106.77 156.99 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 169.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -122.55 138.7 54.49 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.709 2.404 . . . . 0.0 111.905 -166.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -78.24 3.91 14.12 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -174.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -122.72 168.3 12.39 Favored 'General case' 0 CA--C 1.545 0.76 0 O-C-N 120.22 -1.55 . . . . 0.0 111.166 169.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.57 160.83 1.65 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.403 1.081 . . . . 0.0 111.223 169.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -107.72 149.13 28.53 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 122.732 0.413 . . . . 0.0 110.503 169.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -100.53 -8.84 22.66 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.794 2.038 . . . . 0.0 114.072 -171.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 54.09 70.35 0.62 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.81 1.644 . . . . 0.0 113.832 169.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.16 -51.99 4.47 Favored Glycine 0 N--CA 1.466 0.669 0 O-C-N 121.281 -0.887 . . . . 0.0 112.628 169.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.59 124.3 6.03 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 117.569 2.433 . . . . 0.0 117.569 173.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.24 0.62 Allowed Glycine 0 C--N 1.331 0.289 0 C-N-CA 129.67 3.509 . . . . 0.0 106.256 163.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -111.25 -57.72 0.48 Allowed Glycine 0 CA--C 1.53 0.991 0 N-CA-C 117.227 1.651 . . . . 0.0 117.227 -171.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . 0.564 HD21 ' ND2' ' B' ' 139' ' ' ASN . 0.1 OUTLIER -123.93 -175.62 3.27 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -161.545 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.02 -59.75 3.13 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 126.557 1.943 . . . . 0.0 111.452 171.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -50.56 -20.54 1.21 Allowed 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.81 1.781 . . . . 0.0 115.81 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.6 m -67.25 -40.73 86.31 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 119.838 -1.789 . . . . 0.0 112.302 170.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 22.1 p -82.75 -10.15 59.02 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 126.094 1.758 . . . . 0.0 113.674 -177.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.5 tttt -104.16 -77.18 0.58 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 128.42 2.688 . . . . 0.0 110.505 -168.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 22.2 p -79.2 -85.92 0.08 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 166.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 176.06 23.58 0.03 OUTLIER Glycine 0 CA--C 1.534 1.276 1 C-N-CA 131.431 4.348 . . . . 0.0 110.808 -177.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . 0.564 ' ND2' HD21 ' B' ' 131' ' ' ASN . 0.7 OUTLIER 56.98 17.46 3.37 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.005 1.722 . . . . 0.0 114.907 -174.918 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.96 6.37 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.174 0 N-CA-C 119.384 3.105 . . . . 0.0 119.384 -167.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 62.16 -23.93 0.06 OUTLIER Glycine 0 N--CA 1.475 1.252 0 C-N-CA 130.089 3.709 . . . . 0.0 120.442 166.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.7 t -165.38 159.99 17.65 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.535 1.667 . . . . 0.0 111.111 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.16 179.7 6.6 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.095 0.958 . . . . 0.0 109.892 167.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.5 HD11 ' HB ' ' B' ' 119' ' ' VAL 0.33 3.8 pp -166.45 -154.02 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 129.49 3.116 . . . . 0.0 106.637 162.804 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.98 134.26 26.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.274 1.43 . . . . 0.0 112.811 -175.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.77 153.32 45.71 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.149 0.979 . . . . 0.0 111.01 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 176.81 37.44 Favored Glycine 0 N--CA 1.469 0.879 0 N-CA-C 116.186 1.235 . . . . 0.0 116.186 -170.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.618 HG22 HD21 ' B' ' 53' ' ' ASN . 0.5 OUTLIER -111.0 149.36 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.481 1.112 . . . . 0.0 109.181 174.155 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 30.7 mm -80.88 125.57 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 CA-C-N 119.788 1.176 . . . . 0.0 112.051 -175.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.96 164.98 12.46 Favored Glycine 0 N--CA 1.477 1.403 0 O-C-N 121.23 -0.919 . . . . 0.0 113.392 -176.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 4.7 mp -128.33 131.76 68.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.603 0.716 . . . . 0.0 112.018 -176.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.24 -3.77 18.16 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.084 0.953 . . . . 0.0 112.689 168.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 . . . . . 0 N--CA 1.465 0.319 0 C-N-CA 127.987 2.515 . . . . 0.0 111.179 -173.656 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.471 HG13 ' HB ' ' B' ' 54' ' ' THR . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.773 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.673 ' CG2' HD21 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.773 HG21 ' ND2' ' A' ' 53' ' ' ASN . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t . . . . . 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.348 0 CA-C-O 122.073 0.939 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.471 HG13 ' HB ' ' B' ' 54' ' ' THR . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.773 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.673 ' CG2' HD21 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.773 HG21 ' ND2' ' A' ' 53' ' ' ASN . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t . . . . . 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.348 0 CA-C-O 122.073 0.939 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t . . . . . 0 N--CA 1.465 0.307 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.83 104.54 14.88 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 122.046 0.927 . . . . 0.0 108.699 168.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -89.48 169.23 11.55 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.263 -0.898 . . . . 0.0 111.296 173.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.487 HG21 ' HA ' ' B' ' 52' ' ' ASP . 3.1 p -151.97 142.78 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.676 1.19 . . . . 0.0 110.741 -170.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.13 120.5 12.36 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.509 1.123 . . . . 0.0 109.526 168.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.5 t -105.31 97.16 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 174.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -78.12 111.47 14.07 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 123.83 0.852 . . . . 0.0 109.544 -172.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -152.04 155.15 37.39 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 116.604 2.075 . . . . 0.0 116.604 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.43 -39.76 0.24 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 129.891 3.615 . . . . 0.0 108.814 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.44 57.64 4.12 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 129.699 3.2 . . . . 0.0 112.933 -168.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.95 -103.72 0.05 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.358 2.409 . . . . 0.0 114.054 173.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -83.87 -8.05 10.22 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 124.893 3.729 . . . . 0.0 114.555 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.03 141.87 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 120.377 1.444 . . . . 0.0 109.92 173.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -157.81 161.76 38.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.227 -1.351 . . . . 0.0 110.513 167.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.01 119.25 2.92 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 113.658 -1.61 . . . . 0.0 109.576 169.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.07 133.23 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 166.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.439 HD13 ' CE1' ' A' ' 20' ' ' PHE . 2.1 pp -136.14 143.19 36.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 122.703 1.24 . . . . 0.0 110.687 162.158 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.95 130.0 55.47 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 164.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.439 ' CE1' HD13 ' A' ' 18' ' ' ILE . 18.6 m-30 -114.2 132.43 56.11 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.205 1.002 . . . . 0.0 110.629 -179.056 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -108.56 117.11 33.32 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.02 1.328 . . . . 0.0 110.97 178.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.525 HE22 ' HA ' ' A' ' 25' ' ' SER . 1.3 tm0? -118.58 140.0 50.59 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 123.028 1.394 . . . . 0.0 113.27 173.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.518 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -87.01 -47.98 8.48 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 129.46 3.104 . . . . 0.0 113.739 -175.717 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -147.63 137.71 22.94 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 126.895 2.078 . . . . 0.0 110.44 -168.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.525 ' HA ' HE22 ' A' ' 22' ' ' GLN . 8.3 m -38.65 -57.65 1.16 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.939 1.696 . . . . 0.0 115.308 -169.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 -102.31 15.47 29.06 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 123.995 0.918 . . . . 0.0 111.765 -173.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.83 -170.85 30.06 Favored Glycine 0 CA--C 1.534 1.263 0 C-N-CA 124.776 1.179 . . . . 0.0 112.485 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -78.34 177.91 8.2 Favored 'Trans proline' 0 CA--C 1.536 0.588 0 C-N-CA 124.149 3.232 . . . . 0.0 112.818 -170.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.4 t -142.0 141.01 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 123.913 0.885 . . . . 0.0 111.173 -177.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -93.22 125.21 37.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.035 0.934 . . . . 0.0 109.56 169.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -117.5 125.25 73.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 127.674 2.389 . . . . 0.0 108.565 -169.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 7.0 p90 -153.87 162.39 41.27 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.611 0.72 . . . . 0.0 112.661 175.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.18 -158.21 27.15 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 125.145 1.355 . . . . 0.0 112.063 177.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.9 p -153.54 139.79 18.49 Favored 'General case' 0 C--O 1.237 0.403 0 O-C-N 122.396 -0.473 . . . . 0.0 112.07 -172.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -111.98 106.88 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.885 0.874 . . . . 0.0 108.668 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.02 128.13 54.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.758 2.423 . . . . 0.0 109.557 -165.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.4 -4.38 31.27 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.502 1.525 . . . . 0.0 112.109 -167.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.5 mt -65.53 162.45 18.05 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.593 1.197 . . . . 0.0 110.531 168.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -93.45 161.83 14.22 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 163.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -54.95 150.43 10.18 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.242 1.417 . . . . 0.0 113.352 -174.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.23 -177.57 36.59 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 124.758 1.17 . . . . 0.0 113.46 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.98 149.6 18.56 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 127.56 2.344 . . . . 0.0 112.588 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -145.65 134.0 21.83 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 126.125 1.77 . . . . 0.0 110.166 170.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.44 147.72 31.36 Favored Glycine 0 N--CA 1.481 1.664 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.142 173.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -156.85 106.27 2.24 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 119.03 1.415 . . . . 0.0 113.276 -172.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.04 153.12 30.47 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.801 1.408 . . . . 0.0 114.801 -168.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -82.2 138.37 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 165.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -87.18 157.99 19.24 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.386 1.875 . . . . 0.0 113.907 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 21.8 tt0 -71.57 90.07 1.0 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 125.182 1.393 . . . . 0.0 109.231 178.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 94.6 142.35 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 128.64 2.776 . . . . 0.0 108.809 178.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.09 13.24 9.69 Favored Glycine 0 C--O 1.221 -0.715 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.627 169.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' B' ' 5' ' ' VAL . 8.8 p-10 -88.44 47.67 1.53 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 124.578 2.132 . . . . 0.0 109.131 168.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -171.91 42.39 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 123.696 1.712 . . . . 0.0 110.104 -167.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.8 p -69.32 43.78 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 128.312 2.645 . . . . 0.0 117.455 -168.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -107.69 5.5 26.83 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.726 1.21 . . . . 0.0 109.345 164.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 51.56 -110.56 1.09 Allowed Glycine 0 C--N 1.347 1.178 0 C-N-CA 126.527 2.013 . . . . 0.0 112.938 168.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 69.5 m -53.32 -9.36 0.16 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 116.516 2.043 . . . . 0.0 116.516 178.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.4 t -124.99 19.02 8.45 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.455 1.65 . . . . 0.0 115.455 171.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.9 m -156.74 -40.51 0.07 Allowed 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 171.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.42 123.57 26.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.705 1.593 . . . . 0.0 112.191 -170.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -66.75 168.78 35.47 Favored Glycine 0 CA--C 1.538 1.48 0 CA-C-O 118.224 -1.32 . . . . 0.0 113.33 -175.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -56.48 176.21 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 125.007 3.805 . . . . 0.0 112.456 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.423 ' CD2' ' H ' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -68.06 114.22 6.39 Favored 'General case' 0 C--N 1.321 -0.644 0 O-C-N 121.484 -0.76 . . . . 0.0 112.615 -166.823 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -28.25 113.07 0.07 Allowed 'General case' 0 C--O 1.24 0.557 0 C-N-CA 127.489 2.316 . . . . 0.0 114.209 -172.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -111.61 50.59 0.33 Allowed Pre-proline 0 CA--C 1.551 0.997 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -174.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.11 -16.83 45.31 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 122.352 2.035 . . . . 0.0 112.51 177.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -79.42 -7.51 58.45 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.722 1.609 . . . . 0.0 112.456 168.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.9 t 64.26 49.74 2.51 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 128.437 2.695 . . . . 0.0 112.409 176.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.402 ' HD2' ' OE1' ' A' ' 78' ' ' GLU . 15.8 ptt180 -128.92 178.5 6.34 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.524 ' HE2' ' HA ' ' A' ' 70' ' ' LYS . 4.8 mmpt? -88.17 174.26 8.33 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.164 2.185 . . . . 0.0 112.375 -179.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -95.12 134.9 37.32 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.416 ' HA2' HD12 ' A' ' 126' ' ' LEU . . . 161.2 -123.17 1.18 Allowed Glycine 0 C--N 1.336 0.576 0 CA-C-O 119.72 -0.489 . . . . 0.0 113.682 168.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.66 -33.94 4.58 Favored Glycine 0 CA--C 1.545 1.952 0 CA-C-O 117.216 -1.88 . . . . 0.0 117.791 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -105.45 17.14 0.15 Allowed 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.619 2.879 . . . . 0.0 114.215 174.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.9 ptmm? -167.73 -22.02 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 127.389 2.276 . . . . 0.0 112.458 169.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -97.41 147.05 24.6 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 163.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -98.86 -6.58 28.78 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.445 1.898 . . . . 0.0 111.859 -171.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.402 ' OE1' ' HD2' ' A' ' 69' ' ' ARG . 3.7 mm-40 -77.4 -99.65 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.343 1.057 . . . . 0.0 110.035 -177.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 94.2 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 127.323 2.249 . . . . 0.0 111.179 174.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -58.31 156.96 9.18 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.569 1.147 . . . . 0.0 112.639 172.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.0 p -70.59 106.12 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.86 171.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.03 8.69 21.66 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 117.383 -1.787 . . . . 0.0 116.831 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.16 124.5 27.91 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 120.71 2.255 . . . . 0.0 109.545 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 97.5 mt -113.89 53.63 0.77 Allowed 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 120.575 1.534 . . . . 0.0 112.196 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.01 -141.99 42.49 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 121.56 -0.713 . . . . 0.0 111.659 174.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.67 127.43 45.16 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.482 0.713 . . . . 0.0 111.431 169.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.8 m -78.21 98.22 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.891 1.276 . . . . 0.0 108.985 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -93.3 117.41 30.04 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.822 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.49 139.88 30.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.806 1.242 . . . . 0.0 113.841 -174.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -72.32 156.74 38.77 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.146 2.178 . . . . 0.0 109.99 167.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -46.33 -25.38 0.63 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 128.294 2.638 . . . . 0.0 116.137 175.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -76.42 -0.48 22.98 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.632 1.173 . . . . 0.0 111.525 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.36 41.79 11.2 Favored Glycine 0 C--N 1.335 0.526 0 C-N-CA 126.535 2.017 . . . . 0.0 112.783 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.5 p -143.21 129.0 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 N-CA-C 114.737 1.384 . . . . 0.0 114.737 176.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.57 124.15 35.52 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 165.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -111.55 135.64 51.86 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 124.496 1.118 . . . . 0.0 108.91 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.5 t -139.15 136.71 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -166.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.2 t -155.43 116.36 3.9 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.553 1.541 . . . . 0.0 110.579 168.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -145.51 155.4 13.3 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 128.965 2.906 . . . . 0.0 110.806 -169.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -128.23 132.23 48.77 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 167.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -145.51 138.1 25.88 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 124.486 1.114 . . . . 0.0 111.954 -168.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -116.94 51.38 1.0 Allowed 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 178.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.19 3.48 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.197 0 C-N-CA 123.831 0.853 . . . . 0.0 111.983 167.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.2 168.0 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 126.671 1.988 . . . . 0.0 110.376 177.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.0 m -154.4 156.09 36.19 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.001 0.92 . . . . 0.0 111.086 -173.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.7 mt -93.5 73.01 4.42 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.689 0.757 . . . . 0.0 110.681 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.406 ' H ' ' HB2' ' A' ' 111' ' ' SER . 0.3 OUTLIER -117.84 144.91 44.97 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.384 1.474 . . . . 0.0 108.987 171.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -78.48 16.23 8.17 Favored Glycine 0 N--CA 1.479 1.539 0 N-CA-C 117.97 1.948 . . . . 0.0 117.97 -166.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -134.88 -89.26 0.35 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 125.794 1.638 . . . . 0.0 111.2 -169.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -87.39 4.81 41.6 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 120.595 -1.316 . . . . 0.0 113.168 -174.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.406 ' HB2' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -119.41 -141.7 0.35 Allowed 'General case' 0 CA--C 1.545 0.756 0 O-C-N 120.875 -1.141 . . . . 0.0 112.955 -168.629 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 51.5 mm -94.63 -28.87 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 O-C-N 120.595 -1.315 . . . . 0.0 114.389 -169.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.1 mm -55.06 133.05 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 119.191 0.905 . . . . 0.0 109.849 175.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.14 14.62 59.52 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.433 -1.204 . . . . 0.0 114.575 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -91.19 -169.99 2.51 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.408 1.604 . . . . 0.0 108.911 168.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 6.4 m -145.63 114.37 6.85 Favored 'General case' 0 N--CA 1.484 1.227 0 O-C-N 119.599 -1.938 . . . . 0.0 108.02 -171.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 50.5 tp -89.74 132.73 35.05 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 124.943 1.297 . . . . 0.0 109.638 -175.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.4 m -118.84 153.79 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 C-N-CA 123.275 0.63 . . . . 0.0 110.628 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.76 152.13 15.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 163.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -115.21 147.36 40.44 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.094 1.357 . . . . 0.0 111.183 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -66.09 -22.52 66.41 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 119.838 -1.789 . . . . 0.0 113.601 -174.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.7 mmtm -131.62 176.98 7.86 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 119.772 -1.83 . . . . 0.0 113.998 173.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.22 145.04 27.69 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 112.977 -1.919 . . . . 0.0 110.9 169.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.48 ' OD1' ' HB2' ' A' ' 140' ' ' ALA . 46.7 m-20 -79.03 169.2 18.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 122.188 0.994 . . . . 0.0 111.154 167.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.79 -38.49 53.91 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.203 164.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.416 HD12 ' HA2' ' A' ' 72' ' ' GLY . 1.8 mm? 63.35 60.32 1.16 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.957 2.503 . . . . 0.0 112.031 -171.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.59 -83.4 0.13 Allowed Glycine 0 N--CA 1.469 0.879 0 O-C-N 121.008 -1.058 . . . . 0.0 112.747 168.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -150.53 97.73 2.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.631 1.681 . . . . 0.0 110.921 169.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -74.09 176.07 47.3 Favored Glycine 0 CA--C 1.526 0.781 0 CA-C-N 112.086 -2.325 . . . . 0.0 107.651 163.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.09 29.79 0.15 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 127.599 2.523 . . . . 0.0 118.677 -167.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -148.03 -103.97 0.09 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 120.652 2.226 . . . . 0.0 111.528 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -163.22 -51.9 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 127.312 2.245 . . . . 0.0 108.58 -169.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 19.2 tp10 -50.17 -32.16 15.51 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 127.416 2.286 . . . . 0.0 112.351 169.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.593 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 77.6 p -53.24 -36.84 61.5 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 120.565 -1.334 . . . . 0.0 113.173 168.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 2.8 p -79.08 -20.99 47.39 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 172.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -79.79 -64.56 1.16 Allowed 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.5 1.046 . . . . 0.0 112.572 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 28.7 p -108.62 -9.52 15.29 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.842 1.657 . . . . 0.0 114.559 -174.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.2 -9.57 74.61 Favored Glycine 0 N--CA 1.471 1.031 0 CA-C-N 119.918 1.235 . . . . 0.0 111.781 -167.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 79.26 -44.1 0.32 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 129.245 3.018 . . . . 0.0 110.136 -179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.48 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . . . 56.62 11.77 0.96 Allowed 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 128.433 2.693 . . . . 0.0 116.649 167.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.43 -36.25 0.45 Allowed Glycine 0 CA--C 1.537 1.445 0 C-N-CA 125.951 1.739 . . . . 0.0 113.673 -167.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -173.88 -156.59 0.08 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.149 1.779 . . . . 0.0 111.551 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.05 -166.22 1.15 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.798 2.039 . . . . 0.0 108.197 165.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -176.96 -151.79 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.661 2.384 . . . . 0.0 107.378 -175.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.72 148.99 23.05 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 125.709 1.604 . . . . 0.0 112.568 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.8 p -148.45 148.71 30.59 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.092 0.957 . . . . 0.0 113.459 -176.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.2 136.61 5.1 Favored Glycine 0 N--CA 1.465 0.604 0 C-N-CA 124.299 0.952 . . . . 0.0 113.543 -170.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -76.24 148.58 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 124.676 1.19 . . . . 0.0 109.333 -178.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -83.63 103.68 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 171.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -101.46 175.41 25.68 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.861 1.696 . . . . 0.0 112.064 169.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -114.51 140.84 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.307 1.043 . . . . 0.0 112.495 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.05 51.29 0.79 Allowed 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 124.027 1.87 . . . . 0.0 112.765 -176.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 38.9 tt0 . . . . . 0 C--N 1.326 -0.445 0 CA-C-N 111.487 -2.597 . . . . 0.0 110.006 167.672 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 p -78.76 107.07 11.21 Favored 'General case' 0 CA--C 1.512 -0.515 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 169.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.433 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -99.68 156.06 17.28 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 169.497 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.59 178.29 8.57 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 130.138 3.375 . . . . 0.0 107.19 167.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.403 ' H ' ' HB2' ' A' ' 52' ' ' ASP . 59.3 t -156.54 170.85 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.191 0 C-N-CA 127.03 2.132 . . . . 0.0 109.894 -169.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.36 142.69 19.44 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 127.28 2.232 . . . . 0.0 109.299 166.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.13 126.53 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.582 0.753 . . . . 0.0 110.085 173.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mp -97.26 140.25 32.02 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 125.287 1.435 . . . . 0.0 110.264 -172.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.8 ttpp -143.53 140.57 30.33 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.386 1.074 . . . . 0.0 111.535 170.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.39 -114.15 1.87 Allowed Glycine 0 CA--C 1.524 0.612 1 N-CA-C 102.471 -4.252 . . . . 0.0 102.471 163.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -157.7 127.15 5.93 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.406 1.882 . . . . 0.0 107.964 164.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.3 -141.96 17.31 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -167.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -84.72 -26.04 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.312 2.675 . . . . 0.0 113.938 -169.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -78.1 123.82 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.44 1.018 . . . . 0.0 110.873 -169.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.2 160.98 41.28 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.602 -175.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -139.85 160.15 26.11 Favored Glycine 0 C--O 1.224 -0.522 0 O-C-N 121.686 -0.634 . . . . 0.0 113.22 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -128.42 134.93 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 125.613 1.565 . . . . 0.0 107.852 168.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -137.82 112.93 9.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 C-N-CA 124.255 1.022 . . . . 0.0 109.792 172.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -76.59 153.25 35.49 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.391 1.076 . . . . 0.0 110.475 165.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.77 100.01 5.14 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 127.901 2.48 . . . . 0.0 108.762 172.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.433 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.8 OUTLIER -102.83 126.87 50.13 Favored 'General case' 0 N--CA 1.466 0.356 0 O-C-N 121.534 -0.729 . . . . 0.0 109.663 175.743 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . 0.465 HE22 ' CB ' ' B' ' 105' ' ' SER . 55.2 tt0 -126.87 141.22 51.87 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.133 0.973 . . . . 0.0 112.159 -176.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.479 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -78.71 -50.43 11.41 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . 0.479 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 27.1 mp0 -146.29 150.54 35.96 Favored 'General case' 0 C--O 1.222 -0.374 0 C-N-CA 125.798 1.639 . . . . 0.0 109.778 173.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.9 m -58.62 10.8 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 128.72 2.808 . . . . 0.0 117.543 -171.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -144.7 -9.44 0.62 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 127.772 2.429 . . . . 0.0 113.886 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.44 -179.89 49.84 Favored Glycine 0 CA--C 1.541 1.657 0 CA-C-N 119.946 1.248 . . . . 0.0 110.6 168.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -75.67 160.8 37.58 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.611 2.208 . . . . 0.0 113.155 -171.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -120.56 129.67 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 124.802 1.241 . . . . 0.0 109.228 176.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -95.9 128.38 42.74 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.405 1.098 . . . . 0.0 110.176 170.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 t -90.92 129.05 42.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 128.936 2.894 . . . . 0.0 108.666 172.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.5 p90 -152.87 156.85 39.78 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 170.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.02 -154.67 24.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 124.778 1.18 . . . . 0.0 111.521 -169.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 85.2 p -162.59 150.85 14.33 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -172.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -113.61 123.92 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 125.277 1.431 . . . . 0.0 108.279 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -114.64 153.8 29.53 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 126.097 1.759 . . . . 0.0 111.359 -174.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.37 60.3 Favored Glycine 0 N--CA 1.475 1.294 0 C-N-CA 125.33 1.443 . . . . 0.0 114.507 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.01 166.43 17.76 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.494 1.518 . . . . 0.0 112.25 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -75.08 146.85 41.11 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 163.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . 0.503 ' CD ' ' HZ2' ' B' ' 91' ' ' LYS . 73.6 tt0 -49.27 143.21 6.45 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 124.904 1.282 . . . . 0.0 110.958 169.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.66 -175.44 23.42 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 124.222 0.915 . . . . 0.0 114.015 -177.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.5 OUTLIER -87.39 145.87 26.12 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 127.56 2.344 . . . . 0.0 112.358 -169.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -139.19 138.96 37.37 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 127.936 2.494 . . . . 0.0 111.61 -169.066 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.36 156.83 53.15 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 125.08 1.324 . . . . 0.0 112.415 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -157.25 99.51 1.79 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 118.17 0.985 . . . . 0.0 110.849 -168.299 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.415 ' HB2' ' CE1' ' B' ' 71' ' ' HIS . 3.0 p-80 -126.6 146.12 50.28 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-O 122.675 1.226 . . . . 0.0 113.133 -175.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.6 HG12 ' HB2' ' B' ' 117' ' ' LEU . 0.5 OUTLIER -111.42 151.14 13.58 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.293 175.809 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -119.08 119.36 33.98 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.313 -170.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -74.27 57.58 0.68 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.808 0.731 . . . . 0.0 109.557 166.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -161.6 106.94 1.31 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 125.088 1.355 . . . . 0.0 109.987 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -94.77 -5.21 61.42 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 117.144 -1.92 . . . . 0.0 115.026 -176.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.487 ' HA ' HG21 ' A' ' 5' ' ' VAL . 0.2 OUTLIER -76.84 52.7 0.86 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 120.735 2.268 . . . . 0.0 111.847 -170.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 176.58 35.28 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 116.733 2.123 . . . . 0.0 116.733 -167.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.49 1.55 0 O-C-N 119.488 -2.007 . . . . 0.0 115.469 -172.22 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.75 0 CA-C-O 122.49 1.138 . . . . 0.0 113.383 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.62 -54.66 4.9 Favored Glycine 0 CA--C 1.544 1.888 0 CA-C-O 116.747 -2.141 . . . . 0.0 114.929 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -130.52 168.95 0.0 OUTLIER 'Trans proline' 0 C--N 1.355 0.918 0 C-N-CA 123.22 2.613 . . . . 0.0 116.346 -172.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.614 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -85.03 141.57 30.19 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.991 2.117 . . . . 0.0 112.874 166.031 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -70.17 144.97 51.81 Favored 'General case' 0 CA--C 1.545 0.76 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.911 164.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 43.2 m-20 -106.83 75.09 0.39 Allowed Pre-proline 0 CA--C 1.555 1.17 0 C-N-CA 125.554 1.541 . . . . 0.0 112.714 -177.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -56.79 -47.9 21.16 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 124.123 3.215 . . . . 0.0 113.141 -174.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.1 mp -78.93 2.02 21.67 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.034 1.734 . . . . 0.0 113.14 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 59.7 p 68.29 45.04 1.27 Allowed 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 128.736 2.814 . . . . 0.0 111.513 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . 0.454 ' HD2' ' OE1' ' B' ' 78' ' ' GLU 0.298 23.7 ptt180 -130.7 171.45 13.08 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -169.136 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.4 169.26 14.76 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 113.625 -1.625 . . . . 0.0 107.345 -172.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CE1' ' HB2' ' B' ' 46' ' ' HIS . 46.9 t60 -63.51 164.11 9.93 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.989 168.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.62 -139.51 7.04 Favored Glycine 0 C--N 1.336 0.567 0 CA-C-O 119.532 -0.593 . . . . 0.0 112.303 169.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.87 -43.22 1.69 Allowed Glycine 0 CA--C 1.545 1.939 0 N-CA-C 119.186 2.434 . . . . 0.0 119.186 169.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -85.45 -12.34 6.67 Favored 'Trans proline' 0 C--N 1.356 0.959 0 CA-C-N 123.497 3.649 . . . . 0.0 113.519 173.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.29 1.92 0.97 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 126.829 2.051 . . . . 0.0 112.326 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.73 152.95 51.62 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 127.773 2.429 . . . . 0.0 108.632 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.94 -2.35 18.37 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.975 2.51 . . . . 0.0 113.072 -176.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . 0.454 ' OE1' ' HD2' ' B' ' 69' ' ' ARG . 4.4 mm-40 -75.05 -102.74 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 169.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 73.72 141.48 0.06 Allowed 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 125.705 2.669 . . . . 0.0 111.927 172.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -78.77 148.11 33.08 Favored 'General case' 0 CA--C 1.551 1.018 0 CA-C-N 113.065 -1.879 . . . . 0.0 111.615 171.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 19.8 m -46.96 -41.5 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 CA-C-N 120.559 1.527 . . . . 0.0 111.366 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.511 ' C ' HG23 ' B' ' 47' ' ' VAL . . . -99.29 104.84 2.94 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 164.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -157.01 129.95 7.74 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 125.634 1.574 . . . . 0.0 112.839 166.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -110.46 179.17 4.16 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 126.501 1.92 . . . . 0.0 110.392 170.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.82 -106.91 3.0 Favored Glycine 0 C--N 1.339 0.722 0 C-N-CA 124.774 1.178 . . . . 0.0 113.972 -171.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -127.11 158.64 36.48 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 123.919 0.888 . . . . 0.0 112.944 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.2 m -118.43 137.54 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 126.772 2.029 . . . . 0.0 109.216 168.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 90.5 m -125.12 115.69 20.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 121.195 1.816 . . . . 0.0 110.745 -173.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.06 137.33 36.76 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 124.751 1.22 . . . . 0.0 112.546 -176.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -73.62 178.49 4.69 Favored 'General case' 0 CA--C 1.541 0.629 0 O-C-N 124.148 0.905 . . . . 0.0 111.008 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.503 ' HZ2' ' CD ' ' B' ' 40' ' ' GLU . 3.3 ttmp? -76.96 66.46 2.8 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 123.45 1.595 . . . . 0.0 111.312 169.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -156.31 -45.29 0.07 Allowed 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 127.198 2.199 . . . . 0.0 108.807 175.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.85 -12.21 7.76 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 117.606 -1.664 . . . . 0.0 113.904 -172.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.6 p -81.21 121.76 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.555 1.677 . . . . 0.0 114.355 170.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.76 135.59 34.91 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.12 0.968 . . . . 0.0 108.478 164.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -77.0 148.0 36.5 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 123.0 1.381 . . . . 0.0 107.586 168.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.37 123.26 52.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 112.331 -2.213 . . . . 0.0 109.221 171.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.0 p -156.94 59.53 0.52 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.251 1.42 . . . . 0.0 112.546 -168.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.04 159.89 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 O-C-N 120.259 -1.526 . . . . 0.0 112.095 -173.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -145.3 155.06 42.98 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.044 2.138 . . . . 0.0 109.487 174.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -155.16 144.44 21.07 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.461 1.905 . . . . 0.0 110.328 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.0 p -113.92 49.32 1.0 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.7 t -151.3 14.57 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 123.617 0.767 . . . . 0.0 112.782 -170.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.25 166.64 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 O-C-N 119.66 -1.9 . . . . 0.0 110.723 -171.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.465 ' CB ' HE22 ' B' ' 22' ' ' GLN . 83.8 p -157.56 161.95 38.77 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 117.922 2.564 . . . . 0.0 117.922 171.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -78.78 72.91 5.32 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 126.831 2.052 . . . . 0.0 107.482 170.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 10.8 t -130.24 15.03 5.64 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -176.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 -63.74 0.33 Allowed Glycine 0 N--CA 1.474 1.219 0 N-CA-C 116.089 1.196 . . . . 0.0 116.089 169.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -119.44 -112.56 0.33 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 118.867 1.334 . . . . 0.0 109.53 -168.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -73.05 0.6 10.96 Favored 'General case' 0 CA--C 1.543 0.7 0 O-C-N 120.263 -1.523 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 54.0 p -71.08 -19.75 62.43 Favored 'General case' 0 CA--C 1.541 0.611 0 CA-C-O 116.587 -1.673 . . . . 0.0 114.305 169.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.305 3.9 pt 143.97 -11.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.114 1 C-N-CA 132.735 4.414 . . . . 0.0 116.227 168.831 . . . . . . . . 3 2 . 1 . 004 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.8 mm -76.08 148.15 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 120.266 1.394 . . . . 0.0 109.683 173.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 70.57 5.15 55.14 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 120.586 -1.321 . . . . 0.0 114.437 -175.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.9 ptt180 -79.31 156.1 28.19 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.135 1.374 . . . . 0.0 109.979 168.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.5 m -100.43 163.8 12.21 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.928 1.291 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.6 ' HB2' HG12 ' B' ' 47' ' ' VAL . 12.5 tp -148.85 126.5 11.74 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.032 1.733 . . . . 0.0 111.074 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 29.1 m -120.76 147.63 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.071 0.948 . . . . 0.0 110.906 167.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.4 p -104.58 154.68 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 124.434 1.094 . . . . 0.0 108.207 167.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 -120.35 159.76 24.4 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.252 1.421 . . . . 0.0 112.54 -173.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -84.8 -26.77 27.27 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 119.894 -1.754 . . . . 0.0 114.909 -168.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.31 179.84 3.92 Favored 'General case' 0 CA--C 1.545 0.785 0 O-C-N 119.606 -1.934 . . . . 0.0 108.702 166.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.39 151.4 47.21 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.105 0.962 . . . . 0.0 112.869 -176.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -75.65 143.37 42.25 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.215 0.531 . . . . 0.0 110.345 175.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -73.47 -20.05 60.79 Favored 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 123.714 0.806 . . . . 0.0 111.71 169.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 51.32 60.0 4.19 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.773 2.029 . . . . 0.0 112.191 -174.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.86 -26.26 25.11 Favored Glycine 0 N--CA 1.469 0.855 0 CA-C-O 117.797 -1.557 . . . . 0.0 116.539 168.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -159.51 100.87 1.5 Allowed 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 120.413 2.106 . . . . 0.0 112.424 176.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . 0.494 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -102.89 -132.46 7.67 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 166.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.88 12.07 49.5 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.462 1.505 . . . . 0.0 114.57 173.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -130.9 162.91 28.61 Favored 'General case' 0 C--N 1.344 0.345 0 CA-C-N 119.236 1.518 . . . . 0.0 114.387 -168.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -57.06 -59.64 4.77 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.301 1.441 . . . . 0.0 110.02 167.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -59.77 -14.59 15.25 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.689 1.596 . . . . 0.0 113.358 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.494 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 24.3 p -66.39 -28.0 68.29 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.883 1.219 . . . . 0.0 112.892 172.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 p -95.22 -31.31 13.55 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 127.135 2.174 . . . . 0.0 112.261 178.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 45.7 mttp -92.86 -23.66 18.73 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.652 1.581 . . . . 0.0 113.598 -173.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.431 HG21 HH21 ' B' ' 143' ' ' ARG . 41.7 p -138.69 -124.11 0.13 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 127.408 2.283 . . . . 0.0 105.034 164.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -126.86 8.37 7.24 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 125.466 1.507 . . . . 0.0 111.267 168.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 62.18 -79.74 0.02 OUTLIER 'General case' 0 C--N 1.347 0.492 0 C-N-CA 127.335 2.254 . . . . 0.0 110.066 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 60.64 29.92 19.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 126.397 1.879 . . . . 0.0 114.616 167.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.62 -42.4 1.27 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 125.768 1.652 . . . . 0.0 113.684 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.5 t -178.09 163.15 1.68 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.018 2.127 . . . . 0.0 111.315 175.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.431 HH21 HG21 ' B' ' 137' ' ' THR . 80.4 mtt85 -73.26 177.04 5.39 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 125.159 1.384 . . . . 0.0 110.322 168.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.57 -128.57 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 124.306 1.042 . . . . 0.0 111.245 -172.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.82 153.88 39.74 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.947 1.299 . . . . 0.0 112.447 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -137.41 152.01 49.16 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.109 1.364 . . . . 0.0 111.887 -169.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.92 171.24 33.8 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.201 1.381 . . . . 0.0 112.15 169.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 79.7 t -119.35 147.42 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 169.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.8 mm -86.5 88.6 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 O-C-N 121.626 -0.671 . . . . 0.0 110.526 -179.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.16 -168.3 42.66 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 123.431 0.538 . . . . 0.0 113.405 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.44 161.2 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -170.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.4 -56.43 0.4 Allowed 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.134 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 N--CA 1.464 0.241 0 C-N-CA 126.04 1.736 . . . . 0.0 110.129 -169.766 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.505 HG23 HE22 ' A' ' 153' ' ' GLN . 40.0 m . . . . . 0 CA--C 1.508 -0.648 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.419 ' HE3' ' CG2' ' A' ' 5' ' ' VAL . 17.4 pttt -132.1 133.47 44.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 115.888 1.81 . . . . 0.0 115.888 -176.135 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 149' ' ' ILE . . . -86.95 167.57 14.15 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 163.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.419 ' CG2' ' HE3' ' A' ' 3' ' ' LYS . 15.2 t -147.43 118.21 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 119.207 0.912 . . . . 0.0 112.158 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.26 84.53 5.19 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 168.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.2 t -76.4 79.42 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 105.025 -2.213 . . . . 0.0 105.025 176.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.2 mt -67.09 127.68 33.5 Favored 'General case' 0 C--O 1.224 -0.239 0 CA-C-O 122.205 1.002 . . . . 0.0 111.177 -162.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.1 tttm -159.67 -174.6 4.7 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.342 1.457 . . . . 0.0 111.672 174.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.24 -6.44 21.34 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 124.778 1.18 . . . . 0.0 113.008 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -116.96 145.62 43.52 Favored 'General case' 0 N--CA 1.433 -1.276 1 C-N-CA 133.291 4.636 . . . . 0.0 103.4 168.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.66 -70.87 0.99 Allowed Glycine 0 CA--C 1.535 1.298 0 C-N-CA 126.011 1.767 . . . . 0.0 112.966 -177.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -69.16 -32.31 21.32 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 123.715 2.943 . . . . 0.0 114.537 -170.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -95.71 144.39 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 119.707 1.14 . . . . 0.0 111.304 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -139.83 173.66 11.3 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.523 1.129 . . . . 0.0 109.174 168.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.52 178.5 33.83 Favored Glycine 0 N--CA 1.468 0.784 0 C-N-CA 124.465 1.031 . . . . 0.0 114.954 169.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.3 pt -153.45 56.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 C-N-CA 124.943 1.297 . . . . 0.0 111.992 -170.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 mm -87.03 98.64 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 O-C-N 120.566 -1.334 . . . . 0.0 110.66 -173.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.02 147.31 34.88 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.782 1.233 . . . . 0.0 110.253 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -128.25 79.08 1.88 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.045 1.338 . . . . 0.0 109.544 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -81.7 112.31 18.76 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.086 1.354 . . . . 0.0 112.188 -175.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -101.02 131.83 46.72 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.449 1.5 . . . . 0.0 109.199 171.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.46 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -96.53 -22.95 16.78 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 124.438 1.095 . . . . 0.0 113.453 174.805 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -103.26 -138.35 0.35 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.668 3.187 . . . . 0.0 110.405 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.2 p -151.29 34.0 0.57 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 127.533 2.333 . . . . 0.0 109.33 169.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -178.88 -28.77 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.369 1.467 . . . . 0.0 114.44 -167.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.63 -169.21 40.29 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 125.165 1.364 . . . . 0.0 113.248 177.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -68.0 138.63 44.59 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.313 2.675 . . . . 0.0 112.834 -171.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.4 t -96.43 132.87 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 124.37 1.068 . . . . 0.0 110.062 173.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -81.23 118.61 22.74 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 169.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.12 79.11 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 127.687 2.395 . . . . 0.0 108.702 -174.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -103.28 164.99 11.29 Favored 'General case' 0 CA--C 1.541 0.607 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.418 172.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.36 -164.32 28.37 Favored Glycine 0 C--O 1.224 -0.491 0 C-N-CA 125.383 1.468 . . . . 0.0 111.506 174.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.6 p -155.38 168.47 26.97 Favored 'General case' 0 C--N 1.319 -0.722 0 O-C-N 121.686 -0.89 . . . . 0.0 110.597 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.67 HG21 HG11 ' A' ' 119' ' ' VAL . 4.3 mp -128.24 126.55 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 C-N-CA 126.283 1.833 . . . . 0.0 107.27 174.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.68 143.76 45.6 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 122.888 2.585 . . . . 0.0 113.032 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.42 -1.94 16.1 Favored Glycine 0 CA--C 1.54 1.636 0 C-N-CA 128.146 2.784 . . . . 0.0 113.561 -169.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.9 mt -79.01 161.95 26.26 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.059 1.344 . . . . 0.0 113.203 -177.205 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.1 t -85.53 155.64 21.11 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 164.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.4 pt-20 -57.6 172.59 0.35 Allowed 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 115.782 1.771 . . . . 0.0 115.782 -174.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.32 -178.6 53.84 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.621 1.105 . . . . 0.0 113.228 174.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -62.36 142.52 57.77 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.09 1.756 . . . . 0.0 112.606 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -142.72 124.08 14.72 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 127.84 2.456 . . . . 0.0 108.507 177.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.97 149.28 51.71 Favored Glycine 0 N--CA 1.477 1.396 0 CA-C-N 120.585 1.539 . . . . 0.0 110.919 178.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -147.7 117.88 7.31 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.907 1.854 . . . . 0.0 111.566 172.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.4 OUTLIER -157.48 173.61 16.64 Favored 'General case' 0 C--O 1.236 0.367 0 O-C-N 121.104 -0.997 . . . . 0.0 109.741 -168.324 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.59 135.96 50.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 C-N-CA 124.214 1.006 . . . . 0.0 110.479 -166.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -77.18 176.18 8.97 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 122.849 0.46 . . . . 0.0 110.622 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 64' ' ' PHE . 1.2 pm0 -71.56 137.67 48.22 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.411 -0.806 . . . . 0.0 108.896 165.373 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 56.07 -169.05 0.09 Allowed 'General case' 0 CA--C 1.542 0.661 0 CA-C-O 123.665 1.698 . . . . 0.0 114.166 173.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.92 17.66 48.37 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-O 116.357 -2.357 . . . . 0.0 111.476 167.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.695 ' HA ' HG21 ' B' ' 5' ' ' VAL . 2.3 p30 -82.36 45.54 0.96 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.754 2.777 . . . . 0.0 112.454 -172.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.408 ' H ' ' ND2' ' A' ' 53' ' ' ASN . 0.3 OUTLIER -91.69 34.39 0.98 Allowed 'General case' 0 C--O 1.235 0.301 0 N-CA-C 115.546 1.684 . . . . 0.0 115.546 -166.285 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.565 HG22 ' HA ' ' B' ' 7' ' ' VAL . 28.6 p -114.45 -18.86 11.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -160.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.69 21.2 4.89 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-N 119.214 0.915 . . . . 0.0 110.902 165.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.4 -112.7 3.63 Favored Glycine 0 C--N 1.342 0.878 0 C-N-CA 125.646 1.594 . . . . 0.0 111.476 173.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.5 t -80.87 -16.7 52.93 Favored 'General case' 0 CA--C 1.545 0.766 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 168.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.1 40.02 0.53 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.633 1.573 . . . . 0.0 108.8 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -172.16 167.07 6.01 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 127.46 2.304 . . . . 0.0 110.003 -162.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -1.31 106.71 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 129.522 3.129 . . . . 0.0 116.947 168.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.76 -84.39 0.74 Allowed Glycine 0 CA--C 1.54 1.609 0 C-N-CA 126.861 2.172 . . . . 0.0 113.165 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.9 173.74 13.94 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 124.39 3.393 . . . . 0.0 112.708 -171.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -92.96 115.39 28.08 Favored 'General case' 0 CA--C 1.536 0.404 0 O-C-N 121.156 -0.965 . . . . 0.0 113.533 -168.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 49' ' ' GLU . 40.2 t80 -43.89 130.4 5.75 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.135 1.374 . . . . 0.0 113.638 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 35.6 p-10 -145.27 68.49 13.67 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -168.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -61.11 -19.66 64.35 Favored 'Trans proline' 0 CA--C 1.54 0.784 0 C-N-CA 122.501 2.134 . . . . 0.0 112.058 169.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -76.88 -6.29 51.84 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.147 1.379 . . . . 0.0 113.608 171.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t 57.71 47.48 15.58 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 127.224 2.21 . . . . 0.0 112.233 174.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -111.24 173.01 6.54 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 114.657 1.354 . . . . 0.0 114.657 -175.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -89.04 176.14 7.11 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.187 2.195 . . . . 0.0 108.989 175.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.9 t60 -91.56 157.25 17.11 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.418 1.087 . . . . 0.0 113.674 -172.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 138.63 -129.73 4.62 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 124.021 0.82 . . . . 0.0 113.028 167.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 129.34 -30.05 3.73 Favored Glycine 0 CA--C 1.55 2.224 0 N-CA-C 119.763 2.665 . . . . 0.0 119.763 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -108.97 17.45 0.09 OUTLIER 'Trans proline' 0 CA--C 1.551 1.355 0 C-N-CA 124.933 3.756 . . . . 0.0 113.115 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.96 -26.17 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 128.286 2.634 . . . . 0.0 111.421 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.5 OUTLIER -94.78 148.07 22.68 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.864 2.066 . . . . 0.0 106.157 162.064 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -100.67 -8.98 22.32 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 126.901 2.08 . . . . 0.0 113.08 -178.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.64 -82.03 0.09 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.076 0.95 . . . . 0.0 110.553 -176.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.292 37.6 ptt180 66.67 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 127.063 2.145 . . . . 0.0 113.393 175.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -59.49 165.19 2.98 Favored 'General case' 0 CA--C 1.551 0.986 0 O-C-N 119.596 -1.94 . . . . 0.0 113.337 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 74.3 t -57.27 -25.26 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.457 -1.402 . . . . 0.0 112.697 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.67 31.19 7.41 Favored Glycine 0 CA--C 1.539 1.558 0 CA-C-O 118.222 -1.321 . . . . 0.0 115.993 173.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -112.25 139.73 47.55 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 117.387 2.365 . . . . 0.0 117.387 -172.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 79.9 mt -144.9 166.01 26.5 Favored 'General case' 0 CA--C 1.555 1.15 1 C-N-CA 133.704 4.802 . . . . 0.0 104.031 165.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.71 -129.32 5.3 Favored Glycine 0 N--CA 1.473 1.147 0 C-N-CA 123.664 0.65 . . . . 0.0 113.606 -169.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -113.06 147.33 37.48 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 121.974 0.892 . . . . 0.0 113.085 169.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.66 174.19 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.682 1.993 . . . . 0.0 108.372 167.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -140.57 124.02 16.91 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 168.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.1 139.81 34.19 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 118.239 0.472 . . . . 0.0 111.913 169.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.65 157.27 37.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.712 1.605 . . . . 0.0 110.386 167.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.83 -0.59 0.69 Allowed 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 114.684 1.365 . . . . 0.0 114.684 170.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -99.64 5.59 45.81 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.816 2.046 . . . . 0.0 112.482 170.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.08 0.54 65.75 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 126.27 1.89 . . . . 0.0 116.49 168.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.12 136.2 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 CA-C-N 119.497 1.649 . . . . 0.0 112.9 -177.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.3 129.85 50.41 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 124.948 1.299 . . . . 0.0 107.745 166.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -92.31 148.97 21.72 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 122.577 1.179 . . . . 0.0 108.835 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.07 124.58 37.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.451 -1.704 . . . . 0.0 109.232 173.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.1 p -155.31 76.04 0.96 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.962 1.363 . . . . 0.0 111.491 -169.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.72 159.57 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.484 1.513 . . . . 0.0 110.221 -169.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -147.17 121.43 9.57 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 104.777 -2.305 . . . . 0.0 104.777 166.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -126.29 131.79 51.8 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.641 1.21 . . . . 0.0 113.061 -168.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.1 p -82.98 58.73 4.53 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.393 1.077 . . . . 0.0 110.162 177.19 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -152.25 -44.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 170.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.45 143.14 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 118.938 0.79 . . . . 0.0 110.876 -179.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.518 ' H ' ' CB ' ' A' ' 111' ' ' SER . 35.8 p -132.22 161.02 34.45 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 126.556 1.942 . . . . 0.0 112.075 173.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 31.0 mt -79.71 94.54 5.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 168.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -131.97 -15.46 2.99 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -169.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.05 -68.67 3.39 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 120.347 1.43 . . . . 0.0 111.622 -170.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -92.04 -60.77 1.77 Allowed 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.705 1.24 . . . . 0.0 113.824 -173.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 28.7 m-70 -80.64 1.56 29.39 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.84 1.656 . . . . 0.0 112.903 -164.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' H ' ' A' ' 105' ' ' SER . 18.9 m -162.42 -88.88 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.264 0 N-CA-C 115.71 1.744 . . . . 0.0 115.71 177.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.41 162.75 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.093 -1.004 . . . . 0.0 111.093 -173.012 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 114.54 140.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 1 C-N-CA 135.521 5.528 . . . . 0.0 107.374 -169.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.63 -25.62 1.71 Allowed Glycine 0 CA--C 1.535 1.317 0 CA-C-O 118.26 -1.3 . . . . 0.0 115.836 177.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 10.6 ptt180 -74.73 163.64 27.46 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 126.253 1.821 . . . . 0.0 111.466 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.3 m -121.37 110.81 16.54 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 124.635 1.174 . . . . 0.0 113.042 -169.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.6 tp -99.66 122.87 43.31 Favored 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 121.124 1.784 . . . . 0.0 111.346 -173.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 143' ' ' ARG . 13.2 p -121.13 151.59 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 125.471 1.509 . . . . 0.0 113.315 179.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.678 HG13 ' CD2' ' A' ' 144' ' ' LEU . 7.4 p -103.9 143.28 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.035 0 C-N-CA 124.547 1.139 . . . . 0.0 110.344 166.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 40.6 m-70 -115.34 169.2 9.32 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 126.94 2.096 . . . . 0.0 115.123 -168.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -83.58 -30.17 27.21 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 116.075 1.88 . . . . 0.0 116.075 -173.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -107.0 170.18 8.1 Favored 'General case' 0 CA--C 1.546 0.805 0 CA-C-N 120.668 1.576 . . . . 0.0 111.881 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.57 163.89 6.51 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.022 1.329 . . . . 0.0 111.443 169.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -103.9 131.49 51.07 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.023 0.929 . . . . 0.0 110.422 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.88 -28.5 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 120.747 0.308 . . . . 0.0 111.656 177.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.0 mt 58.09 40.46 25.21 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.387 1.875 . . . . 0.0 112.446 173.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.27 -74.39 0.07 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 117.495 1.758 . . . . 0.0 117.495 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -139.06 -42.03 0.47 Allowed 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -164.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 54.64 -113.43 3.48 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 120.178 1.354 . . . . 0.0 110.47 -166.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -153.56 29.55 0.76 Allowed Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.222 1.867 . . . . 0.0 112.008 168.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -166.48 171.3 12.0 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.773 1.629 . . . . 0.0 111.669 -164.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -67.62 -54.65 17.95 Favored 'General case' 0 N--CA 1.469 0.478 0 O-C-N 121.32 -0.862 . . . . 0.0 113.185 -169.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.429 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 0.3 OUTLIER -65.09 -19.51 66.02 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.043 0.937 . . . . 0.0 111.25 -171.864 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.4 m -67.67 -33.35 74.76 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.897 -1.127 . . . . 0.0 111.729 168.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.4 p -83.29 -18.94 37.29 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 124.783 1.233 . . . . 0.0 114.241 174.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -105.99 -45.56 4.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.303 1.041 . . . . 0.0 113.57 -176.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.71 -26.33 12.33 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 116.829 -1.558 . . . . 0.0 113.87 177.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.63 12.44 47.56 Favored Glycine 0 N--CA 1.472 1.062 0 CA-C-N 119.327 0.967 . . . . 0.0 114.8 -173.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 60.38 8.95 1.78 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 118.975 1.387 . . . . 0.0 113.508 -174.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.84 -3.41 0.74 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -166.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.21 -160.04 25.67 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 126.694 2.092 . . . . 0.0 112.797 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 91.7 p -65.82 177.54 1.27 Allowed 'General case' 0 CA--C 1.547 0.828 0 O-C-N 122.026 -0.691 . . . . 0.0 112.139 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.463 ' HB2' HG21 ' A' ' 118' ' ' VAL . 27.5 ptt180 -136.2 132.37 35.8 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.923 -1.111 . . . . 0.0 112.749 -166.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.678 ' CD2' HG13 ' A' ' 119' ' ' VAL 0.335 0.0 OUTLIER -103.35 -106.76 0.27 Allowed 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.154 1.381 . . . . 0.0 111.723 -175.677 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.473 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -77.23 135.18 38.45 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 119.635 1.107 . . . . 0.0 111.216 -173.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.435 ' HB3' HG23 ' A' ' 118' ' ' VAL . 13.9 p -141.88 154.86 45.43 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 126.107 1.763 . . . . 0.0 111.69 -172.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.7 130.01 3.5 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 123.818 0.723 . . . . 0.0 111.915 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -72.47 170.53 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 167.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 4' ' ' ALA . 35.2 mm -129.56 126.39 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 O-C-N 120.738 -1.226 . . . . 0.0 113.331 -167.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -146.05 -126.24 1.77 Allowed Glycine 0 CA--C 1.539 1.591 0 C-N-CA 127.442 2.449 . . . . 0.0 114.617 -177.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 pp -147.46 68.67 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 120.642 -1.505 . . . . 0.0 113.932 -168.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.43 -20.43 54.54 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 120.567 -1.333 . . . . 0.0 114.462 -171.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . 0.505 HE22 HG23 ' A' ' 2' ' ' THR . 4.9 mm-40 . . . . . 0 N--CA 1.472 0.633 0 C-N-CA 124.497 1.119 . . . . 0.0 112.699 175.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.442 0 CA-C-O 121.12 0.486 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.4 m -83.24 99.87 10.24 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -96.36 165.18 12.32 Favored 'General case' 0 CA--C 1.548 0.899 0 CA-C-O 122.864 1.316 . . . . 0.0 113.251 -176.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.34 172.73 13.43 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -168.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.695 HG21 ' HA ' ' A' ' 52' ' ' ASP . 1.1 p -157.43 103.44 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 C-N-CA 127.25 2.22 . . . . 0.0 107.786 -169.051 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.27 130.42 35.02 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 120.472 -1.392 . . . . 0.0 111.699 171.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.565 ' HA ' HG22 ' A' ' 54' ' ' THR . 20.6 t -93.48 71.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.179 0.992 . . . . 0.0 111.136 -173.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -80.48 114.72 19.58 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.469 0.652 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 13.2 ttpp -144.97 151.18 38.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.84 0.829 . . . . 0.0 112.428 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.45 149.96 18.76 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 166.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -79.1 64.88 4.13 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 123.408 1.575 . . . . 0.0 110.372 169.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.52 -175.45 46.24 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 129.101 3.239 . . . . 0.0 108.685 -171.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.18 22.21 0.38 Allowed 'Trans proline' 0 CA--C 1.547 1.153 0 C-N-CA 124.65 3.566 . . . . 0.0 114.916 -169.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.454 HG11 HD13 ' B' ' 144' ' ' LEU . 1.3 t -118.97 130.31 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 C-N-CA 126.993 2.117 . . . . 0.0 109.002 -170.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.434 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -160.71 160.88 31.97 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 124.099 0.96 . . . . 0.0 110.999 -170.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.01 169.05 33.58 Favored Glycine 0 CA--C 1.51 -0.262 0 C-N-CA 124.779 1.18 . . . . 0.0 112.23 168.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.402 HG22 ' HB ' ' A' ' 54' ' ' THR . 1.0 OUTLIER -132.35 133.18 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 171.8 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.438 HD12 HG11 ' B' ' 97' ' ' VAL . 5.0 mm -135.09 109.58 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . 0.407 ' HB2' ' CE2' ' B' ' 32' ' ' TRP . 36.2 m120 -79.85 155.52 27.78 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 123.914 0.886 . . . . 0.0 111.959 175.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.439 ' CD2' HG22 ' B' ' 31' ' ' VAL . 5.5 m-85 -139.27 152.65 47.44 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 167.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -146.88 132.57 18.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 119.133 0.879 . . . . 0.0 109.951 167.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -84.84 137.86 32.91 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 122.721 0.408 . . . . 0.0 111.117 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.464 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -93.48 -91.64 0.18 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.179 0.992 . . . . 0.0 110.618 169.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . 0.464 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 31.9 mp0 -82.37 169.25 16.67 Favored 'General case' 0 C--O 1.217 -0.607 0 O-C-N 120.538 -1.351 . . . . 0.0 110.544 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -51.02 -45.25 61.17 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 114.298 1.222 . . . . 0.0 114.298 -172.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 22.0 m-80 -127.01 40.27 3.75 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.632 1.973 . . . . 0.0 110.294 166.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.66 162.76 53.61 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-O 118.717 -1.046 . . . . 0.0 111.461 173.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -66.4 161.72 39.66 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.503 2.802 . . . . 0.0 110.005 174.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.0 t -136.55 133.36 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 122.973 0.509 . . . . 0.0 110.967 -169.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -79.84 132.16 36.04 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 168.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.439 HG22 ' CD2' ' B' ' 20' ' ' PHE . 21.3 t -120.85 111.54 32.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 126.578 1.951 . . . . 0.0 108.739 176.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . 0.407 ' CE2' ' HB2' ' B' ' 19' ' ' ASN . 17.5 p90 -140.11 153.27 46.66 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.366 0.603 . . . . 0.0 112.213 -173.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.49 -153.41 24.63 Favored Glycine 0 C--O 1.225 -0.433 0 C-N-CA 124.13 0.872 . . . . 0.0 111.507 178.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 12.6 p -157.1 158.66 36.79 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 114.045 1.128 . . . . 0.0 114.045 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -128.1 131.46 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 125.715 1.606 . . . . 0.0 107.912 -179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.1 ttpt -133.95 140.12 46.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 126.172 1.789 . . . . 0.0 110.617 -168.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.11 20.73 13.09 Favored Glycine 0 N--CA 1.481 1.638 0 C-N-CA 124.994 1.283 . . . . 0.0 114.373 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.2 pt? -117.91 165.9 13.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.756 2.822 . . . . 0.0 110.622 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.95 167.46 21.86 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.316 0.646 . . . . 0.0 110.205 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -64.65 -175.3 0.17 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 126.967 2.107 . . . . 0.0 114.549 171.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.33 -170.59 46.98 Favored Glycine 0 N--CA 1.47 0.944 0 O-C-N 120.388 -1.445 . . . . 0.0 112.432 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mt -77.01 155.16 32.79 Favored 'General case' 0 CA--C 1.545 0.757 0 O-C-N 121.172 -1.193 . . . . 0.0 110.02 177.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -147.63 123.57 10.68 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 127.931 2.493 . . . . 0.0 109.641 -172.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.34 151.16 36.2 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-N 120.926 1.694 . . . . 0.0 113.526 176.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -151.13 96.58 2.33 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.213 1.405 . . . . 0.0 112.171 -170.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.38 147.07 48.93 Favored 'General case' 0 N--CA 1.47 0.561 0 O-C-N 120.085 -1.634 . . . . 0.0 111.742 -167.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.526 HG23 ' HA2' ' B' ' 82' ' ' GLY . 27.5 m -108.66 120.19 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 122.484 1.135 . . . . 0.0 110.959 177.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -77.83 101.61 6.83 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -173.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -64.16 95.27 0.12 Allowed 'General case' 0 C--N 1.344 0.349 0 CA-C-O 123.116 1.436 . . . . 0.0 108.602 175.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 t80 177.55 -166.95 0.05 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 130.472 3.509 . . . . 0.0 104.349 -164.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.35 -122.02 3.5 Favored Glycine 0 CA--C 1.507 -0.43 0 CA-C-O 121.772 0.651 . . . . 0.0 112.477 171.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.07 152.83 39.85 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.684 1.594 . . . . 0.0 113.459 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 173.13 32.68 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 128.815 2.846 . . . . 0.0 108.843 -171.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 82.8 p . . . . . 0 CA--C 1.534 0.343 0 C-N-CA 127.439 2.295 . . . . 0.0 116.382 -165.806 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.871 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.82 -91.75 0.94 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.296 1.903 . . . . 0.0 112.223 -174.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -100.33 -177.32 0.17 Allowed 'Trans proline' 0 CA--C 1.535 0.561 1 C-N-CA 125.939 4.426 . . . . 0.0 111.728 176.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.487 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -79.98 130.36 35.21 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 168.741 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -58.97 147.09 35.67 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.855 1.262 . . . . 0.0 112.56 171.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 50.3 m-20 -108.81 77.87 0.86 Allowed Pre-proline 0 CA--C 1.554 1.097 0 C-N-CA 125.276 1.43 . . . . 0.0 111.843 -176.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -58.21 -49.18 13.15 Favored 'Trans proline' 0 C--N 1.353 0.81 0 C-N-CA 123.975 3.116 . . . . 0.0 113.216 -174.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 75.1 mt -78.83 -0.44 30.62 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 126.144 1.778 . . . . 0.0 112.871 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.2 t 58.77 43.82 17.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 127.518 2.327 . . . . 0.0 112.151 -173.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.1 mtp180 -92.31 176.43 6.48 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 120.878 -1.139 . . . . 0.0 112.489 -176.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.513 ' HE2' ' OE1' ' B' ' 78' ' ' GLU . 0.3 OUTLIER -97.24 170.26 9.22 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 126.18 1.792 . . . . 0.0 108.829 165.312 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -96.66 151.64 19.42 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -167.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.44 -106.03 0.34 Allowed Glycine 0 C--N 1.345 1.053 0 C-N-CA 124.796 1.189 . . . . 0.0 114.809 166.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.85 -29.2 8.69 Favored Glycine 0 CA--C 1.543 1.811 0 N-CA-C 119.85 2.7 . . . . 0.0 119.85 174.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -104.03 6.47 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.049 0 C-N-CA 123.657 2.904 . . . . 0.0 112.578 172.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.01 -31.25 0.13 Allowed 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.908 1.283 . . . . 0.0 110.893 169.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.05 150.13 27.71 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 162.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -96.19 -17.99 20.41 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.519 1.927 . . . . 0.0 112.138 -176.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . 0.513 ' OE1' ' HE2' ' B' ' 70' ' ' LYS . 3.7 mt-10 -78.05 -50.66 11.65 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 121.049 -1.032 . . . . 0.0 113.023 -172.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 45.75 97.88 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.127 1.371 . . . . 0.0 114.059 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.6 m80 -50.79 144.78 7.86 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 119.729 -1.857 . . . . 0.0 110.262 169.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 m -55.41 -29.99 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 CA-C-N 120.239 1.381 . . . . 0.0 112.12 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.526 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -89.26 49.24 3.48 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 125.025 1.298 . . . . 0.0 116.053 171.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -139.46 123.17 17.48 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.353 1.461 . . . . 0.0 110.071 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -113.55 50.29 0.92 Allowed 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 168.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 55.73 -112.13 2.91 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 125.343 1.449 . . . . 0.0 114.445 177.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -155.7 159.07 39.23 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 126.196 1.798 . . . . 0.0 110.563 -175.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.8 p -117.37 175.75 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 127.517 2.327 . . . . 0.0 109.685 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -133.92 150.17 51.31 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.98 1.712 . . . . 0.0 108.326 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -117.7 149.03 41.42 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.443 1.497 . . . . 0.0 112.779 173.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -83.52 150.05 26.23 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 128.229 2.612 . . . . 0.0 112.281 169.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.82 -2.48 1.85 Allowed 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.884 1.673 . . . . 0.0 115.143 177.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -90.93 7.96 37.53 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.485 1.514 . . . . 0.0 112.069 169.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.82 28.81 22.73 Favored Glycine 0 C--N 1.341 0.821 0 CA-C-O 117.361 -1.799 . . . . 0.0 114.656 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -141.64 139.26 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.138 1.469 . . . . 0.0 114.521 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.14 122.04 44.5 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.558 1.543 . . . . 0.0 108.685 165.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -79.21 140.0 37.8 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 165.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . 0.438 HG11 HD12 ' B' ' 18' ' ' ILE 0.262 0.3 OUTLIER -119.71 129.04 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-O 122.557 1.17 . . . . 0.0 112.576 166.96 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 28.8 m -147.8 78.63 1.46 Allowed 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.362 1.465 . . . . 0.0 109.729 -172.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -122.44 154.14 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.484 1.513 . . . . 0.0 111.614 -173.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.8 tt0 -142.14 148.39 38.22 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.989 1.715 . . . . 0.0 107.346 167.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -149.83 150.48 32.04 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 125.117 1.367 . . . . 0.0 111.934 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.2 p -116.78 51.86 0.97 Allowed 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.7 -48.64 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 124.4 1.08 . . . . 0.0 110.819 169.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.96 157.31 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 119.327 0.967 . . . . 0.0 112.785 177.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 95.0 p -156.54 150.89 25.41 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.164 1.786 . . . . 0.0 109.023 -170.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mp -80.95 54.06 2.11 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 122.128 0.965 . . . . 0.0 108.745 172.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -84.93 62.61 7.58 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.121 -0.987 . . . . 0.0 109.968 -177.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.92 -111.11 4.06 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 124.784 1.183 . . . . 0.0 112.837 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -127.99 -14.8 4.92 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 127.67 2.388 . . . . 0.0 114.518 -167.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.0 -32.14 8.44 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 114.49 1.292 . . . . 0.0 114.49 -169.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -85.98 -15.14 42.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.258 0.7 OUTLIER -177.37 -47.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 C-N-CA 127.564 2.346 . . . . 0.0 109.109 168.536 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -58.86 143.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 105.61 -1.996 . . . . 0.0 105.61 162.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.65 -16.4 1.4 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 126.769 2.128 . . . . 0.0 113.628 -175.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . 0.52 HH11 ' HG3' ' B' ' 115' ' ' ARG . 4.5 ttm-85 -80.15 171.37 15.17 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.863 1.665 . . . . 0.0 111.854 176.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -113.14 154.52 26.5 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 125.379 1.471 . . . . 0.0 112.466 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 25.2 tp -121.15 138.25 54.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 128.246 2.619 . . . . 0.0 109.217 168.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -114.84 139.39 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 124.949 1.3 . . . . 0.0 109.872 168.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -119.57 133.99 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 171.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -110.94 151.06 28.35 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.767 1.227 . . . . 0.0 112.033 -168.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -79.2 -18.22 53.39 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -167.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 48.0 mttp -138.73 178.23 7.3 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 120.163 1.347 . . . . 0.0 113.569 177.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.91 130.51 37.61 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.282 1.433 . . . . 0.0 110.176 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -81.33 158.78 24.6 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 124.029 0.831 . . . . 0.0 109.221 170.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . 0.452 ' OD1' ' HE3' ' B' ' 128' ' ' LYS . 7.5 t70 -73.45 -43.29 60.63 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 119.306 -0.957 . . . . 0.0 109.3 168.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 2.0 mm? 70.15 53.14 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 127.123 2.169 . . . . 0.0 107.734 -168.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 161.22 -82.29 0.13 Allowed Glycine 0 N--CA 1.465 0.617 0 O-C-N 121.317 -0.864 . . . . 0.0 114.1 -175.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.537 ' H ' ' HE3' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -156.69 72.4 0.73 Allowed 'General case' 0 CA--C 1.549 0.938 0 N-CA-C 115.701 1.741 . . . . 0.0 115.701 -170.237 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -57.6 -24.81 54.03 Favored Glycine 0 CA--C 1.542 1.753 0 O-C-N 120.708 -1.245 . . . . 0.0 115.128 176.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.48 -28.38 0.49 Allowed Glycine 0 CA--C 1.534 1.24 0 N-CA-C 116.675 1.43 . . . . 0.0 116.675 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . 0.418 ' H ' ' HB3' ' B' ' 134' ' ' SER . 62.2 m-80 -106.33 175.81 5.37 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 118.968 1.384 . . . . 0.0 113.098 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.1 tm-20 -51.64 -57.55 8.84 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.603 1.161 . . . . 0.0 108.904 166.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -41.33 -34.53 0.52 Allowed 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 126.236 1.814 . . . . 0.0 115.036 168.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' B' ' 131' ' ' ASN . 4.5 p -71.18 -9.96 58.97 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 119.318 -2.114 . . . . 0.0 115.836 -177.339 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.2 t -111.16 -7.98 14.43 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.166 1.387 . . . . 0.0 110.379 164.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -85.82 -50.33 7.22 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.737 1.615 . . . . 0.0 110.763 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 80.7 p -102.35 -35.52 8.79 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 128.686 2.794 . . . . 0.0 110.972 175.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.76 -9.63 52.05 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.045 1.783 . . . . 0.0 112.028 -169.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . 0.447 HD22 ' HA ' ' B' ' 139' ' ' ASN . 0.1 OUTLIER 75.96 30.93 0.71 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 129.446 3.098 . . . . 0.0 112.317 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.68 33.33 0.01 OUTLIER 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 178.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.55 -51.86 3.75 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 127.69 2.567 . . . . 0.0 114.79 175.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 170.9 157.39 0.07 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.862 1.665 . . . . 0.0 113.741 -174.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.33 134.0 34.52 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.413 1.085 . . . . 0.0 113.715 173.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.454 HD13 HG11 ' B' ' 14' ' ' VAL . 3.3 pp -104.7 -30.17 10.11 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.331 1.453 . . . . 0.0 113.469 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.81 161.55 36.94 Favored 'General case' 0 C--O 1.245 0.831 0 C-N-CA 125.705 1.602 . . . . 0.0 107.174 174.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.3 p -152.32 151.86 31.41 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 126.254 1.822 . . . . 0.0 108.525 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.46 145.69 11.77 Favored Glycine 0 C--O 1.224 -0.504 0 N-CA-C 115.632 1.013 . . . . 0.0 115.632 179.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 16.3 t -78.17 145.9 9.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.283 1.033 . . . . 0.0 108.244 167.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.6 mm -89.53 101.17 11.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.914 0.886 . . . . 0.0 109.979 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.62 164.46 30.39 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 173.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -93.78 141.14 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 123.902 0.881 . . . . 0.0 111.354 172.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -141.91 166.19 25.39 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.956 1.703 . . . . 0.0 111.154 168.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.466 0.351 0 C-N-CA 123.265 0.626 . . . . 0.0 111.133 -167.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.508 -0.635 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.0 ttpt -99.0 106.74 19.03 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 122.641 1.21 . . . . 0.0 112.967 169.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.65 173.23 7.99 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 126.078 1.751 . . . . 0.0 109.041 167.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.868 HG11 ' HA ' ' B' ' 52' ' ' ASP . 12.8 p -161.78 162.66 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.353 0.661 . . . . 0.0 111.996 -173.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.52 134.01 19.75 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.566 1.146 . . . . 0.0 109.899 163.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.26 94.29 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.525 1.93 . . . . 0.0 107.058 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -79.3 134.58 36.62 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 126.708 2.003 . . . . 0.0 110.206 -173.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.4 mtpt -155.87 179.71 8.94 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.313 1.045 . . . . 0.0 113.687 178.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.5 -60.47 0.42 Allowed Glycine 0 C--N 1.334 0.445 0 C-N-CA 128.083 2.754 . . . . 0.0 108.721 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -82.1 69.69 8.86 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.101 1.761 . . . . 0.0 111.52 -168.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.44 -100.67 0.03 OUTLIER Glycine 0 CA--C 1.54 1.643 0 C-N-CA 126.957 2.218 . . . . 0.0 114.132 171.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -80.38 -7.66 13.86 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 125.04 3.827 . . . . 0.0 114.331 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.3 t -77.22 142.17 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 CA-C-N 119.983 1.265 . . . . 0.0 109.105 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.45 158.04 39.35 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 124.95 1.3 . . . . 0.0 109.414 169.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -140.51 108.64 0.57 Allowed Glycine 0 C--O 1.22 -0.777 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.94 131.41 37.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 118.676 1.238 . . . . 0.0 108.392 168.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.3 pp -149.41 126.61 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-O 122.764 1.269 . . . . 0.0 111.413 166.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -74.82 166.3 23.84 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.78 1.232 . . . . 0.0 111.329 169.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -141.49 93.25 2.55 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.734 2.014 . . . . 0.0 107.879 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.447 ' OE2' ' HE3' ' A' ' 23' ' ' LYS . 4.6 tm-20 -92.55 122.9 35.44 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.588 1.555 . . . . 0.0 110.121 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -120.01 132.24 55.41 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.869 0.842 . . . . 0.0 112.333 169.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.554 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -75.13 -42.01 57.17 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.269 1.827 . . . . 0.0 112.584 -177.017 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.329 0.0 OUTLIER -110.01 -122.46 0.27 Allowed 'General case' 0 CA--C 1.544 0.729 0 CA-C-O 116.887 -1.53 . . . . 0.0 110.215 169.068 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 48.9 m -144.07 -25.31 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-N 120.847 1.658 . . . . 0.0 114.752 -172.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.47 -17.8 6.9 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 120.45 -1.406 . . . . 0.0 114.108 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -150.69 4.86 Favored Glycine 0 CA--C 1.542 1.755 1 C-N-CA 131.0 4.143 . . . . 0.0 114.104 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -88.41 156.71 6.62 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.296 2.664 . . . . 0.0 114.365 -168.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.14 134.48 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.763 1.225 . . . . 0.0 109.632 -173.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -97.58 126.0 42.63 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.229 1.411 . . . . 0.0 109.902 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.6 t -123.8 122.39 64.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 C-N-CA 126.587 1.955 . . . . 0.0 109.146 -170.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -146.9 150.27 34.89 Favored 'General case' 0 C--O 1.24 0.57 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -178.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.59 -153.13 23.43 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.834 1.683 . . . . 0.0 111.039 -169.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.1 p -158.57 143.35 16.09 Favored 'General case' 0 C--O 1.238 0.485 0 O-C-N 121.794 -0.827 . . . . 0.0 113.097 -169.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.44 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -109.13 106.2 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 125.251 1.42 . . . . 0.0 109.616 173.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -111.29 144.59 40.23 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.704 2.002 . . . . 0.0 110.549 -167.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.01 -24.04 24.08 Favored Glycine 0 N--CA 1.475 1.241 0 C-N-CA 126.566 2.031 . . . . 0.0 112.108 -171.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.4 mp -68.13 111.45 4.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.254 1.822 . . . . 0.0 107.644 168.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.4 t -68.78 -27.32 65.78 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.259 1.577 . . . . 0.0 115.259 -169.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 178.58 -175.4 0.19 Allowed 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 130.744 3.617 . . . . 0.0 106.549 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.54 159.81 35.41 Favored Glycine 0 N--CA 1.469 0.845 0 C-N-CA 126.263 1.887 . . . . 0.0 116.038 167.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.8 mt -70.45 132.61 45.84 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.827 1.251 . . . . 0.0 109.008 168.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -129.52 120.08 24.78 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.409 1.483 . . . . 0.0 107.253 177.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.13 164.47 36.48 Favored Glycine 0 N--CA 1.475 1.245 0 CA-C-O 117.619 -1.656 . . . . 0.0 111.563 176.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.25 1.6 p90 -156.06 111.32 2.94 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 120.989 2.394 . . . . 0.0 113.569 169.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -122.14 147.08 46.59 Favored 'General case' 0 CA--C 1.551 0.991 0 O-C-N 119.979 -1.701 . . . . 0.0 111.082 -172.124 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -82.31 120.63 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -71.12 111.85 6.81 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.43 -2.433 . . . . 0.0 104.43 168.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.478 ' H ' ' HA ' ' A' ' 63' ' ' HIS . 16.8 tt0 -64.39 116.86 6.5 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.148 -174.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.353 50.3 m-85 101.31 160.57 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 131.567 3.947 . . . . 0.0 113.708 -178.089 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.18 -14.7 55.63 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 114.746 -1.115 . . . . 0.0 114.48 -172.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG11 ' B' ' 5' ' ' VAL . 5.0 m-20 -71.93 54.9 0.28 Allowed 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 128.887 2.875 . . . . 0.0 113.134 -169.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -170.33 -42.34 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 119.539 3.163 . . . . 0.0 119.539 -168.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.298 0.9 OUTLIER 49.75 -58.99 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 129.115 2.966 . . . . 0.0 117.339 -169.775 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 22.44 0.82 Allowed 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 127.748 2.419 . . . . 0.0 114.596 -171.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.41 -127.82 44.4 Favored Glycine 0 C--N 1.336 0.553 0 C-N-CA 125.49 1.519 . . . . 0.0 110.878 172.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.5 m -56.56 -10.37 0.96 Allowed 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.08 1.85 22.73 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 125.251 1.42 . . . . 0.0 112.623 171.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 9.0 t -164.94 -156.52 0.31 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 129.532 3.133 . . . . 0.0 106.361 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 74.88 -169.09 0.1 Allowed 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 123.761 1.743 . . . . 0.0 115.147 166.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.68 155.43 16.08 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 127.151 2.31 . . . . 0.0 108.735 166.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.417 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 96.6 Cg_endo -75.61 76.43 3.63 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 123.924 3.083 . . . . 0.0 108.293 171.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.478 ' HA ' ' H ' ' A' ' 49' ' ' GLU . 5.1 p80 47.27 72.39 0.25 Allowed 'General case' 0 C--O 1.236 0.351 0 C-N-CA 127.261 2.225 . . . . 0.0 112.674 167.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -40.84 141.22 0.61 Allowed 'General case' 0 C--O 1.221 -0.395 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.603 -174.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -101.3 67.48 0.06 OUTLIER Pre-proline 0 CA--C 1.549 0.938 0 CA-C-N 114.195 -1.366 . . . . 0.0 113.527 175.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -65.13 -18.47 61.57 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 121.829 1.686 . . . . 0.0 112.593 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -77.97 -5.11 50.18 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.188 1.395 . . . . 0.0 113.523 170.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.6 t 60.78 53.41 3.92 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 127.01 2.124 . . . . 0.0 112.177 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 -139.3 175.35 9.63 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 -167.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.546 ' H ' ' HE3' ' A' ' 70' ' ' LYS . 0.5 OUTLIER -76.68 158.89 30.67 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.353 1.461 . . . . 0.0 112.017 173.179 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.416 ' ND1' ' CE1' ' A' ' 63' ' ' HIS . 86.0 t60 -79.4 147.92 32.18 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.481 -0.781 . . . . 0.0 112.469 168.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.467 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 155.64 -111.93 0.5 Allowed Glycine 0 C--N 1.339 0.701 0 CA-C-O 118.029 -1.429 . . . . 0.0 114.09 167.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.11 -85.88 0.39 Allowed Glycine 0 CA--C 1.537 1.446 0 CA-C-O 117.486 -1.73 . . . . 0.0 114.6 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -55.54 -6.88 1.1 Allowed 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 124.458 3.438 . . . . 0.0 116.869 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -155.89 9.97 0.27 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 128.585 2.754 . . . . 0.0 112.238 -176.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.467 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.6 OUTLIER -146.74 109.9 4.75 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 128.533 2.733 . . . . 0.0 109.624 179.106 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -64.35 -9.26 16.73 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 127.848 2.459 . . . . 0.0 114.719 -175.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -81.44 -91.83 0.06 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.76 0.824 . . . . 0.0 110.402 177.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.8 ttp-105 78.72 118.45 0.06 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.164 1.785 . . . . 0.0 111.141 171.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m80 -55.79 160.83 2.44 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.278 -1.514 . . . . 0.0 113.831 175.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.8 t -53.16 -50.74 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 121.047 1.749 . . . . 0.0 112.229 -170.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.7 3.06 Favored Glycine 0 C--N 1.341 0.833 0 N-CA-C 108.491 -1.844 . . . . 0.0 108.491 169.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -157.45 118.56 3.6 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.529 1.531 . . . . 0.0 109.512 179.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -105.16 165.57 11.0 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 126.099 1.76 . . . . 0.0 109.726 169.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.81 -136.77 8.57 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 125.249 1.404 . . . . 0.0 112.792 177.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.64 158.17 20.33 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 117.025 2.231 . . . . 0.0 117.025 -174.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.3 m -106.97 173.9 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 128.705 2.802 . . . . 0.0 110.188 167.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 t -141.74 141.27 33.25 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 125.552 1.541 . . . . 0.0 108.383 169.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.69 150.67 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 125.221 1.408 . . . . 0.0 111.589 178.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -100.64 158.79 15.68 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.884 1.673 . . . . 0.0 112.128 173.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -50.28 -21.93 1.58 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 129.099 2.959 . . . . 0.0 115.815 -169.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.26 0.94 54.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 128.58 2.752 . . . . 0.0 110.716 -172.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.32 32.05 6.24 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-O 117.477 -1.735 . . . . 0.0 114.052 173.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.2 p -155.66 133.53 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 117.512 2.412 . . . . 0.0 117.512 -171.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.65 129.22 40.02 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 163.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -88.59 145.49 25.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 168.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.7 t -131.85 122.27 49.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 113.251 -1.795 . . . . 0.0 107.934 167.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -146.35 58.81 1.21 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 127.687 2.395 . . . . 0.0 107.582 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 29.7 mt -116.77 155.65 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.498 1.519 . . . . 0.0 112.125 -166.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -135.99 130.24 33.3 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 167.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -132.69 144.71 50.5 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 125.353 1.461 . . . . 0.0 110.256 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.6 p -125.28 59.42 1.25 Allowed 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.276 1.431 . . . . 0.0 112.752 -167.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -156.31 -48.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 C-N-CA 123.008 0.523 . . . . 0.0 110.683 -174.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -82.32 158.79 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 164.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.2 p -160.24 168.85 24.46 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.064 1.345 . . . . 0.0 109.355 -175.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.3 mp -100.64 54.06 0.87 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.0 t -76.09 4.32 8.73 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 114.98 1.474 . . . . 0.0 114.98 -167.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 138.18 -86.83 0.22 Allowed Glycine 0 N--CA 1.462 0.39 0 N-CA-C 106.592 -2.603 . . . . 0.0 106.592 -169.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.99 -6.11 0.77 Allowed 'General case' 0 C--O 1.219 -0.526 0 C-N-CA 123.761 0.824 . . . . 0.0 113.199 168.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.03 -33.17 65.56 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 120.29 -1.506 . . . . 0.0 110.617 -165.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.0 p -105.78 -8.56 17.71 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 117.448 2.388 . . . . 0.0 117.448 -169.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.273 3.7 pt 176.69 -39.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 C-N-CA 127.698 2.399 . . . . 0.0 115.582 167.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.3 mm -49.47 125.03 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-N 121.605 2.002 . . . . 0.0 111.024 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.67 -7.01 66.87 Favored Glycine 0 CA--C 1.534 1.241 0 C-N-CA 125.766 1.65 . . . . 0.0 116.092 176.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.5 176.03 10.14 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.814 1.646 . . . . 0.0 110.622 170.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.1 t -132.97 129.03 37.69 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 120.185 1.357 . . . . 0.0 113.078 -174.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.2 tp -101.96 125.48 48.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.771 2.029 . . . . 0.0 109.523 -170.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -110.98 135.19 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 124.526 1.131 . . . . 0.0 109.595 174.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.581 HG13 HD22 ' A' ' 144' ' ' LEU . 2.2 p -92.63 141.51 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 C-N-CA 124.991 1.316 . . . . 0.0 109.088 168.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -112.95 168.42 9.71 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.097 2.559 . . . . 0.0 113.112 -168.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -86.61 -46.71 9.85 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 -168.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -99.9 -176.33 3.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 120.091 -1.631 . . . . 0.0 110.198 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.71 154.16 7.22 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 165.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 p30 -99.25 140.78 32.91 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.68 1.229 . . . . 0.0 110.792 167.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -78.62 -36.57 43.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 127.422 2.289 . . . . 0.0 112.213 -169.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 23.1 mt 55.82 47.83 19.44 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.717 1.207 . . . . 0.0 110.596 173.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 138.52 -62.25 0.57 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.415 -1.214 . . . . 0.0 115.9 171.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.39 87.39 1.31 Allowed 'General case' 0 CA--C 1.552 1.021 1 N-CA-C 122.417 4.229 . . . . 0.0 122.417 -166.5 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.71 -86.99 0.61 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 105.948 -2.861 . . . . 0.0 105.948 163.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -167.31 34.08 0.21 Allowed Glycine 0 N--CA 1.47 0.935 0 CA-C-O 119.03 -0.872 . . . . 0.0 114.827 171.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -164.05 150.34 11.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 119.513 1.657 . . . . 0.0 108.899 -167.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -48.3 -46.99 36.88 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.607 0.763 . . . . 0.0 112.275 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -50.51 -27.84 7.37 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 116.04 1.867 . . . . 0.0 116.04 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.1 p -53.25 -28.06 25.54 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-N 120.857 1.662 . . . . 0.0 112.656 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.9 t -113.51 -29.16 7.27 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 115.195 1.554 . . . . 0.0 115.195 170.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -67.65 -23.32 65.32 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 119.986 1.266 . . . . 0.0 113.355 178.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.9 p -141.11 -32.91 0.54 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.228 1.411 . . . . 0.0 114.236 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.39 5.16 49.39 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.587 1.565 . . . . 0.0 110.466 -164.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 51.53 30.99 6.96 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 127.311 2.244 . . . . 0.0 114.632 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.05 19.47 0.04 OUTLIER 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 118.06 2.615 . . . . 0.0 118.06 -166.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.62 8.05 37.64 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 119.437 2.535 . . . . 0.0 119.437 167.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 28.9 t 139.2 -178.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 1 C-N-CA 131.952 4.101 . . . . 0.0 111.183 170.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.08 154.22 37.62 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 126.18 1.792 . . . . 0.0 112.836 173.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.581 HD22 HG13 ' A' ' 119' ' ' VAL 0.349 0.0 OUTLIER -133.31 -127.2 0.17 Allowed 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.972 2.109 . . . . 0.0 107.868 167.104 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.05 147.77 46.2 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.068 1.304 . . . . 0.0 114.472 -166.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.7 p -137.42 147.63 45.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.612 1.565 . . . . 0.0 113.952 176.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.61 142.43 8.41 Favored Glycine 0 N--CA 1.473 1.165 0 C-N-CA 124.621 1.105 . . . . 0.0 114.238 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 87.6 t -76.27 150.43 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 C-N-CA 124.725 1.21 . . . . 0.0 110.246 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.9 mm -81.31 83.69 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 O-C-N 121.562 -0.711 . . . . 0.0 109.721 173.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.72 -169.01 43.59 Favored Glycine 0 N--CA 1.474 1.231 0 C-N-CA 126.849 2.166 . . . . 0.0 112.912 175.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -142.74 155.39 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 115.324 1.602 . . . . 0.0 115.324 -168.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.84 -15.11 14.46 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.567 1.547 . . . . 0.0 112.844 169.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.476 0.85 0 C-N-CA 130.057 3.343 . . . . 0.0 109.117 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.775 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 17.2 m -78.19 77.03 4.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.713 1.205 . . . . 0.0 111.425 -168.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.259 17.3 pttm -81.13 130.49 35.05 Favored 'General case' 0 CA--C 1.547 0.85 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -174.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.38 172.42 12.76 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 127.744 2.417 . . . . 0.0 111.288 -176.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.511 HG11 ' HA ' ' A' ' 52' ' ' ASP . 7.0 p -148.38 146.81 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.41 1.084 . . . . 0.0 112.734 -166.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.16 96.56 2.9 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-O 122.516 1.151 . . . . 0.0 108.799 168.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 53.1 t -79.64 96.82 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 104.878 -2.267 . . . . 0.0 104.878 166.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.65 114.94 17.0 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 77.0 tttt -160.76 131.34 5.31 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.465 1.484 . . . . 0.0 114.747 -175.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -162.04 -35.16 0.02 OUTLIER Glycine 0 N--CA 1.474 1.204 0 C-N-CA 125.232 1.396 . . . . 0.0 111.519 168.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -77.26 58.38 1.61 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 130.98 3.712 . . . . 0.0 113.075 175.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.91 -96.39 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 C-N-CA 129.184 3.278 . . . . 0.0 115.569 169.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.94 -16.45 14.32 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.134 3.223 . . . . 0.0 113.91 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -86.37 141.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-N 119.698 1.135 . . . . 0.0 109.105 174.235 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -157.12 161.03 39.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.758 1.223 . . . . 0.0 110.629 167.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.05 99.92 0.79 Allowed Glycine 0 C--O 1.222 -0.632 0 C-N-CA 126.073 1.797 . . . . 0.0 110.694 173.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -87.64 93.61 4.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 118.983 1.391 . . . . 0.0 108.425 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 pp -113.88 152.73 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.96 1.362 . . . . 0.0 111.821 171.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -123.29 175.79 6.49 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.761 1.224 . . . . 0.0 110.262 175.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -140.1 139.77 35.92 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.249 1.019 . . . . 0.0 109.371 168.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -134.28 131.73 38.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 168.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -125.71 141.09 52.19 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 122.069 0.938 . . . . 0.0 109.962 174.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 6.6 mtmm -84.51 -31.16 24.62 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 125.686 1.594 . . . . 0.0 110.774 -174.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -123.28 -164.56 1.22 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 128.938 2.895 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 36.7 p -106.97 -37.17 6.41 Favored 'General case' 0 N--CA 1.472 0.674 0 O-C-N 120.719 -1.238 . . . . 0.0 110.617 166.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -112.79 5.07 17.36 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.391 1.476 . . . . 0.0 114.023 -175.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.46 -178.01 37.05 Favored Glycine 0 CA--C 1.54 1.649 0 CA-C-O 118.692 -1.06 . . . . 0.0 112.448 172.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.81 157.7 54.62 Favored 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 123.026 2.484 . . . . 0.0 113.552 -176.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 94.2 t -120.37 136.03 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 126.555 1.942 . . . . 0.0 110.93 -170.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.3 mptt -79.23 118.84 21.54 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.417 0.627 . . . . 0.0 111.733 169.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.3 124.92 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 125.549 1.54 . . . . 0.0 107.252 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -151.28 160.83 43.6 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 123.156 0.582 . . . . 0.0 112.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.32 175.58 13.91 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 123.846 0.736 . . . . 0.0 113.65 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 43.7 p -119.77 124.05 45.22 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 115.068 1.507 . . . . 0.0 115.068 -166.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.556 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.0 mm -90.65 123.37 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 CA-C-O 116.878 -1.534 . . . . 0.0 109.973 168.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.2 tttt -132.82 132.64 42.39 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 122.219 2.282 . . . . 0.0 111.677 175.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.75 -9.76 6.07 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 127.42 2.438 . . . . 0.0 114.293 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.426 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.7 OUTLIER -91.3 168.2 11.75 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.62 1.568 . . . . 0.0 112.535 173.332 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.8 t -77.28 166.93 22.55 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.811 0.844 . . . . 0.0 111.241 169.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -67.41 -172.84 0.25 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 125.742 1.617 . . . . 0.0 115.204 -173.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.14 -172.75 54.25 Favored Glycine 0 N--CA 1.477 1.378 0 C-N-CA 124.568 1.08 . . . . 0.0 114.009 176.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 54.2 mt -66.95 144.16 56.39 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 120.67 -1.488 . . . . 0.0 110.202 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -133.25 130.42 38.99 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.679 1.192 . . . . 0.0 109.905 170.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.99 152.01 51.2 Favored Glycine 0 N--CA 1.468 0.828 0 C-N-CA 124.644 1.116 . . . . 0.0 112.21 179.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.514 ' CE1' HD21 ' B' ' 117' ' ' LEU . 2.8 t80 -148.73 105.29 3.55 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 117.508 0.654 . . . . 0.0 109.979 -169.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.433 ' CD2' ' CD2' ' B' ' 63' ' ' HIS . 0.5 OUTLIER -143.84 158.3 43.78 Favored 'General case' 0 CA--C 1.54 0.57 0 O-C-N 120.538 -1.351 . . . . 0.0 109.847 -175.836 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.84 126.89 64.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 C-N-CA 126.051 1.74 . . . . 0.0 108.715 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 14.3 m-70 -77.18 116.85 18.16 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 168.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.86 162.21 29.77 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -168.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.4 t80 68.72 177.01 0.26 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 125.647 1.579 . . . . 0.0 111.879 -173.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.96 0.43 9.86 Favored Glycine 0 N--CA 1.469 0.878 0 CA-C-O 118.881 -0.955 . . . . 0.0 114.177 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.868 ' HA ' HG11 ' A' ' 5' ' ' VAL . 4.1 t0 -86.72 51.21 2.17 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.018 1.327 . . . . 0.0 108.725 -177.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 179.63 34.84 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.109 0 N-CA-C 116.186 1.921 . . . . 0.0 116.186 -166.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.44 ' H ' HG23 ' B' ' 54' ' ' THR . 5.5 p . . . . . 0 CA--C 1.551 1.015 0 C-N-CA 131.518 3.927 . . . . 0.0 120.591 -170.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.575 0 CA-C-O 122.631 1.205 . . . . 0.0 113.954 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.61 -158.97 32.54 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 125.871 1.7 . . . . 0.0 115.985 -169.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -74.56 -174.84 1.99 Allowed 'Trans proline' 0 CA--C 1.537 0.67 1 C-N-CA 126.239 4.626 . . . . 0.0 114.35 -169.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.785 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -65.14 96.58 0.21 Allowed 'General case' 0 N--CA 1.445 -0.689 1 C-N-CA 132.648 4.379 . . . . 0.0 109.166 -176.651 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -56.5 146.86 23.45 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 123.953 1.835 . . . . 0.0 109.998 174.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 48.8 p-10 -107.72 57.81 0.22 Allowed Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 -176.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.57 -20.23 53.8 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.285 1.99 . . . . 0.0 111.74 169.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.0 mp -77.02 -3.88 41.31 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.925 1.29 . . . . 0.0 112.392 169.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t 57.61 87.73 0.06 Allowed 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 127.995 2.518 . . . . 0.0 113.027 174.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . 0.404 ' HD3' ' C ' ' B' ' 78' ' ' GLU . 13.0 ptp180 179.17 176.62 0.58 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -169.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -84.14 176.93 8.45 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 128.111 2.565 . . . . 0.0 107.869 166.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.412 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 12.8 t60 -57.78 174.03 0.27 Allowed 'General case' 0 CA--C 1.546 0.791 0 O-C-N 120.39 -1.443 . . . . 0.0 111.813 169.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.83 -175.31 32.18 Favored Glycine 0 N--CA 1.465 0.599 0 O-C-N 121.272 -0.893 . . . . 0.0 113.427 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 136.37 -128.24 4.44 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 117.961 -1.466 . . . . 0.0 112.316 -170.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -48.0 -11.32 0.11 Allowed 'Trans proline' 0 CA--C 1.542 0.895 1 C-N-CA 126.009 4.473 . . . . 0.0 119.793 -172.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.65 -5.67 5.2 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 120.759 1.618 . . . . 0.0 114.157 169.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -126.48 178.19 6.02 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 127.401 2.28 . . . . 0.0 109.819 -168.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -106.72 -20.31 13.39 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.548 1.539 . . . . 0.0 111.989 -177.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . 0.404 ' C ' ' HD3' ' B' ' 69' ' ' ARG . 25.9 mt-10 -78.15 -92.32 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.695 0 O-C-N 121.06 -1.025 . . . . 0.0 113.204 -167.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 54.7 ttt180 78.38 93.61 0.06 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 126.328 1.851 . . . . 0.0 113.744 169.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -51.94 160.75 0.67 Allowed 'General case' 0 N--CA 1.481 1.101 0 O-C-N 119.974 -1.704 . . . . 0.0 112.594 166.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 p -68.04 -27.97 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 CA-C-N 121.229 1.831 . . . . 0.0 111.483 176.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -70.8 18.26 0.82 Allowed Glycine 0 CA--C 1.538 1.491 0 CA-C-O 117.109 -1.94 . . . . 0.0 116.277 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -121.04 110.51 16.33 Favored 'General case' 0 CA--C 1.55 0.951 0 CA-C-N 121.891 2.845 . . . . 0.0 112.312 -178.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -113.08 46.17 1.27 Allowed 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 123.361 1.553 . . . . 0.0 112.289 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.93 -141.24 45.32 Favored Glycine 0 CA--C 1.536 1.347 0 CA-C-N 114.054 -1.43 . . . . 0.0 115.499 169.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -116.15 140.16 49.58 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.722 1.209 . . . . 0.0 111.021 172.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -91.34 172.87 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 162.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -140.53 142.96 35.15 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 120.85 -1.156 . . . . 0.0 109.796 173.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 95' ' ' ALA . . . -118.95 157.87 26.86 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.555 1.542 . . . . 0.0 113.187 -169.255 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -107.55 162.46 13.93 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 127.439 2.295 . . . . 0.0 112.543 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.768 ' HE2' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -63.66 -12.81 37.0 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.31 1.444 . . . . 0.0 114.333 173.757 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -70.45 -14.94 62.74 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-O 121.707 0.765 . . . . 0.0 109.93 171.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.16 9.23 55.98 Favored Glycine 0 C--N 1.337 0.625 0 C-N-CA 126.593 2.044 . . . . 0.0 112.848 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.2 p -110.39 138.62 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 125.164 1.385 . . . . 0.0 114.39 -178.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 89' ' ' ALA . . . -111.65 97.13 6.5 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.598 1.959 . . . . 0.0 106.284 165.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -98.74 154.61 17.85 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.677 0.751 . . . . 0.0 111.089 174.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -150.66 150.95 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 116.231 1.938 . . . . 0.0 116.231 -173.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 51.6 p -157.46 105.83 2.09 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 124.226 1.01 . . . . 0.0 112.276 169.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 16.3 mt -136.85 151.56 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 126.969 2.108 . . . . 0.0 111.116 -178.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -109.43 107.29 17.38 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 167.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -96.87 138.16 34.85 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 127.285 2.234 . . . . 0.0 112.97 -176.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 82.5 p -108.05 49.93 0.79 Allowed 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 66.8 t -145.35 -44.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-O 118.585 -0.721 . . . . 0.0 112.231 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.94 162.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 120.148 1.34 . . . . 0.0 111.534 170.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.54 ' H ' ' HB3' ' B' ' 111' ' ' SER . 90.2 p -157.4 149.63 22.69 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 125.678 1.591 . . . . 0.0 109.776 -175.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 60.01 4.22 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.436 . . . . 0.0 107.496 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.3 t -115.89 8.52 14.75 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -168.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.02 -49.65 4.01 Favored Glycine 0 N--CA 1.472 1.08 0 O-C-N 120.768 -1.207 . . . . 0.0 114.937 168.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -116.67 -58.68 2.05 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 119.074 1.437 . . . . 0.0 112.331 -170.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -83.21 5.26 23.5 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 125.433 1.493 . . . . 0.0 112.506 -171.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . 0.54 ' HB3' ' H ' ' B' ' 105' ' ' SER . 61.3 m -158.27 -115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.08 0.952 . . . . 0.0 112.668 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 38.6 pt -112.26 169.14 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 120.493 1.497 . . . . 0.0 112.408 -178.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.2 mm 91.24 117.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 1 C-N-CA 132.259 4.224 . . . . 0.0 105.641 -162.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.35 12.3 72.61 Favored Glycine 0 CA--C 1.534 1.238 0 CA-C-O 117.611 -1.661 . . . . 0.0 115.502 -176.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.82 169.03 10.78 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.585 2.193 . . . . 0.0 109.135 169.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . 0.261 13.3 t -131.7 113.5 13.64 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 123.417 2.826 . . . . 0.0 114.698 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.514 HD21 ' CE1' ' B' ' 45' ' ' PHE . 22.4 tp -88.49 140.67 29.23 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.474 1.91 . . . . 0.0 110.91 -169.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -127.07 142.62 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 124.065 0.946 . . . . 0.0 111.301 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.31 140.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 122.322 1.058 . . . . 0.0 110.097 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -102.96 148.59 25.48 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.834 -172.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.262 2.9 pp20? -80.05 -7.45 58.86 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 121.028 -1.045 . . . . 0.0 113.24 -170.267 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 58.2 mttp -126.66 176.44 7.22 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.824 2.05 . . . . 0.0 110.926 168.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -59.29 148.15 33.16 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.383 1.473 . . . . 0.0 111.278 169.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -91.41 138.08 31.86 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 167.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.68 -32.25 65.67 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 177.267 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.9 mt 66.62 66.24 0.45 Allowed 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.58 1.952 . . . . 0.0 111.284 169.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 149.13 -96.65 0.17 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 123.837 0.732 . . . . 0.0 111.311 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.465 ' HA ' ' HB3' ' B' ' 134' ' ' SER . 31.4 tttt -157.49 119.61 3.78 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.876 2.07 . . . . 0.0 110.906 167.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.14 -75.68 0.62 Allowed Glycine 0 CA--C 1.527 0.834 0 C-N-CA 126.382 1.944 . . . . 0.0 109.594 168.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -154.89 -12.22 0.06 OUTLIER Glycine 0 N--CA 1.47 0.954 0 N-CA-C 116.344 1.297 . . . . 0.0 116.344 175.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -109.53 -141.85 0.38 Allowed 'General case' 0 CA--C 1.548 0.881 0 CA-C-N 119.317 1.558 . . . . 0.0 110.03 -167.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -117.73 -48.74 2.56 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 120.619 1.554 . . . . 0.0 111.369 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -46.62 -32.3 3.4 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.412 1.885 . . . . 0.0 112.411 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' B' ' 128' ' ' LYS . 0.4 OUTLIER -49.21 -44.35 43.22 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 127.602 2.361 . . . . 0.0 113.041 169.723 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -95.15 -34.12 12.38 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 173.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -31.81 73.09 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.782 -1.199 . . . . 0.0 113.486 176.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 82.7 p -137.03 -27.1 1.0 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 116.759 -1.591 . . . . 0.0 114.612 -173.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.19 -2.79 31.31 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.668 1.127 . . . . 0.0 113.861 -168.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 12.9 t-20 55.89 9.96 0.51 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 126.279 1.831 . . . . 0.0 113.179 -169.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.36 24.96 0.02 OUTLIER 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 127.938 2.495 . . . . 0.0 116.826 -167.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.16 -139.17 19.52 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 126.555 2.026 . . . . 0.0 113.905 178.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.4 t -80.93 -148.16 0.06 Allowed 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.979 1.712 . . . . 0.0 109.6 168.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -140.71 155.81 46.37 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 120.353 -1.467 . . . . 0.0 110.098 172.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.501 HD12 ' H ' ' B' ' 145' ' ' ALA . 0.7 OUTLIER -109.72 -129.9 0.3 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 165.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.501 ' H ' HD12 ' B' ' 144' ' ' LEU . . . -61.68 144.97 53.73 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.552 1.541 . . . . 0.0 113.823 -170.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.8 p -138.42 151.32 47.35 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 126.194 1.797 . . . . 0.0 113.135 176.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.0 139.53 6.02 Favored Glycine 0 N--CA 1.471 0.997 0 O-C-N 120.989 -1.069 . . . . 0.0 114.239 -176.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.4 t -77.98 145.96 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.045 0.938 . . . . 0.0 109.605 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 54.6 mt -81.36 90.47 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.293 1.037 . . . . 0.0 109.781 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.18 -171.45 45.55 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 126.39 1.948 . . . . 0.0 111.952 171.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.48 ' H ' HD12 ' B' ' 151' ' ' ILE . 0.8 OUTLIER -127.58 124.46 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 115.737 1.755 . . . . 0.0 115.737 -167.641 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.19 0.08 47.01 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.965 2.106 . . . . 0.0 112.593 167.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 131.019 3.728 . . . . 0.0 115.692 -169.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.4 p . . . . . 0 N--CA 1.468 0.425 0 N-CA-C 117.725 2.491 . . . . 0.0 117.725 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -165.43 101.94 0.72 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.783 1.633 . . . . 0.0 108.855 168.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.501 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -75.3 176.05 7.78 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 119.864 1.211 . . . . 0.0 111.482 173.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.654 HG21 ' HA ' ' B' ' 52' ' ' ASP . 1.4 p -153.63 117.49 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 127.225 2.21 . . . . 0.0 106.897 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.24 107.29 18.29 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.349 1.06 . . . . 0.0 109.74 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.0 t -76.09 79.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.226 1.01 . . . . 0.0 108.406 174.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -76.99 92.41 3.7 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 173.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 ttpp -157.91 119.68 3.64 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.897 0.879 . . . . 0.0 110.814 171.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.57 -102.28 0.54 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 106.663 -2.575 . . . . 0.0 106.663 166.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.98 109.86 5.07 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 125.938 1.695 . . . . 0.0 107.282 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.38 177.03 14.69 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 123.844 0.735 . . . . 0.0 114.209 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -68.37 20.76 0.13 Allowed 'Trans proline' 0 CA--C 1.542 0.89 1 C-N-CA 126.15 4.567 . . . . 0.0 116.696 -169.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 144' ' ' LEU . 1.4 t -128.34 128.46 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 CA-C-N 120.447 1.476 . . . . 0.0 109.508 -174.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -144.19 172.74 12.49 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.829 0.823 . . . . 0.0 112.657 -176.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.16 165.79 31.36 Favored Glycine 0 CA--C 1.509 -0.282 0 CA-C-N 112.828 -1.987 . . . . 0.0 112.947 167.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.469 HG13 ' H ' ' A' ' 34' ' ' SER . 7.8 pt -139.83 52.98 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 113.22 -1.49 . . . . 0.0 112.024 -167.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -80.47 105.7 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 O-C-N 120.418 -1.426 . . . . 0.0 111.079 -169.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -83.0 156.28 23.5 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.506 1.522 . . . . 0.0 110.613 173.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.501 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 66.1 m-85 -143.43 97.92 3.16 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.462 1.505 . . . . 0.0 109.677 175.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.72 136.32 37.38 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 119.884 -1.76 . . . . 0.0 107.202 173.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -152.91 -175.81 5.48 Favored 'General case' 0 CA--C 1.553 1.075 0 C-N-CA 127.78 2.432 . . . . 0.0 105.887 176.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.52 -15.29 0.49 Allowed 'General case' 0 CA--C 1.549 0.94 0 O-C-N 118.452 -2.655 . . . . 0.0 116.225 167.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -108.76 -174.27 2.47 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 127.869 2.468 . . . . 0.0 111.346 -174.095 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.3 p -81.33 -21.89 38.86 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 120.528 -1.358 . . . . 0.0 112.888 167.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -161.67 46.38 0.18 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.629 1.171 . . . . 0.0 113.399 -168.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.73 175.69 16.04 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 125.243 1.401 . . . . 0.0 110.637 169.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -74.67 157.95 43.78 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.032 1.821 . . . . 0.0 111.511 -169.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.5 t -131.3 149.4 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 125.097 1.359 . . . . 0.0 111.482 -167.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -116.51 103.74 10.72 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 123.641 0.776 . . . . 0.0 110.575 -175.175 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.5 t -80.22 119.85 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 126.834 2.054 . . . . 0.0 107.63 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 1.7 p90 -153.9 167.87 28.25 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.0 -155.75 15.93 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -170.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.469 ' H ' HG13 ' A' ' 17' ' ' ILE . 63.8 p -155.96 170.5 21.99 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 122.029 0.918 . . . . 0.0 113.345 -169.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.68 134.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 126.497 1.919 . . . . 0.0 107.256 169.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.18 150.23 33.39 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 121.63 2.013 . . . . 0.0 113.913 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.27 5.08 46.78 Favored Glycine 0 CA--C 1.539 1.581 0 C-N-CA 126.437 1.97 . . . . 0.0 112.285 -168.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -71.86 163.89 27.02 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.906 2.082 . . . . 0.0 111.055 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.5 t -81.32 155.81 25.83 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 164.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 74.7 tt0 -53.03 145.22 13.46 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.37 1.068 . . . . 0.0 111.349 169.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.09 -175.3 26.0 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 124.787 1.184 . . . . 0.0 114.146 -177.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -76.12 146.96 38.9 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 128.321 2.648 . . . . 0.0 114.464 -169.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -148.11 123.89 10.56 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.193 2.597 . . . . 0.0 109.911 -174.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.56 155.87 51.55 Favored Glycine 0 N--CA 1.479 1.512 0 CA-C-O 118.028 -1.429 . . . . 0.0 113.169 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.79 139.91 16.49 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 119.957 1.879 . . . . 0.0 114.375 172.285 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.415 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 9.0 p-80 -153.34 153.8 33.29 Favored 'General case' 0 CA--C 1.547 0.862 0 O-C-N 121.5 -0.75 . . . . 0.0 111.936 -179.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -98.36 112.44 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 123.946 0.899 . . . . 0.0 109.119 174.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -82.43 149.78 27.44 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 174.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -66.84 10.74 0.12 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 126.329 1.851 . . . . 0.0 114.304 -178.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -119.55 97.54 5.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 106.949 -1.501 . . . . 0.0 106.949 -169.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.24 -10.36 74.04 Favored Glycine 0 C--N 1.331 0.291 0 CA-C-O 117.885 -1.508 . . . . 0.0 111.17 166.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.595 ' HA ' HG21 ' B' ' 5' ' ' VAL . 12.8 t0 -73.7 123.25 23.73 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 104.381 -2.451 . . . . 0.0 104.381 164.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.563 HD21 HG13 ' A' ' 148' ' ' VAL 0.312 0.0 OUTLIER -147.35 51.09 1.07 Allowed 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 123.782 1.753 . . . . 0.0 112.724 168.486 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.487 HG23 ' H ' ' A' ' 53' ' ' ASN . 11.4 p -120.29 -23.89 6.08 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 112.173 -2.285 . . . . 0.0 112.755 -164.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -95.95 22.79 7.01 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.887 0.875 . . . . 0.0 111.603 168.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.76 -123.24 21.8 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 125.537 1.541 . . . . 0.0 111.913 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.7 p -67.49 -12.7 60.95 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 113.868 1.062 . . . . 0.0 113.868 173.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.69 39.24 0.61 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.412 1.485 . . . . 0.0 110.878 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 172.09 -55.37 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.39 2.276 . . . . 0.0 111.596 -169.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -97.54 153.39 18.2 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.73 -31.38 8.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 116.424 -2.32 . . . . 0.0 117.44 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -103.34 163.38 0.25 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 CA-C-N 122.124 2.962 . . . . 0.0 111.523 171.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.426 ' CD2' ' N ' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -137.24 107.78 6.53 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.558 1.143 . . . . 0.0 112.4 -166.678 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -58.97 154.66 14.93 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 114.141 -1.391 . . . . 0.0 111.998 169.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -119.7 77.68 21.29 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 127.712 2.405 . . . . 0.0 113.713 -170.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -63.64 -20.34 69.02 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.998 2.466 . . . . 0.0 113.445 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 53.6 mt -82.81 -2.49 54.7 Favored 'General case' 0 CA--C 1.543 0.685 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 170.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t 62.77 59.29 1.44 Allowed 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.611 1.564 . . . . 0.0 113.343 175.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.0 ptt180 -161.54 178.44 9.08 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -174.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.88 164.4 23.83 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 127.032 2.133 . . . . 0.0 110.006 173.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -62.88 168.23 4.08 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.735 0.814 . . . . 0.0 110.874 167.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 140.69 -156.0 25.12 Favored Glycine 0 N--CA 1.464 0.528 0 CA-C-O 119.11 -0.828 . . . . 0.0 113.808 171.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 -64.51 0.53 Allowed Glycine 0 CA--C 1.542 1.728 0 N-CA-C 117.924 1.93 . . . . 0.0 117.924 176.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -69.47 -19.46 37.47 Favored 'Trans proline' 0 C--N 1.349 0.6 0 CA-C-N 121.197 2.499 . . . . 0.0 114.722 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -134.66 -3.53 2.61 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 124.057 0.943 . . . . 0.0 112.758 179.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.56 147.81 50.73 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 128.344 2.658 . . . . 0.0 107.867 -173.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.427 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 0.0 OUTLIER -100.66 -11.99 19.55 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 130.77 3.628 . . . . 0.0 112.67 -167.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -81.47 -94.04 0.05 OUTLIER 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.996 1.718 . . . . 0.0 106.992 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.615 HH12 HG11 ' A' ' 103' ' ' VAL . 47.5 ttt180 80.02 121.1 0.05 OUTLIER 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.539 1.536 . . . . 0.0 111.617 168.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -71.52 140.77 50.06 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 120.899 -1.126 . . . . 0.0 108.946 165.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -50.88 -28.81 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.57 8.78 79.13 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 119.362 0.983 . . . . 0.0 115.537 175.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -88.84 129.95 35.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 120.103 1.951 . . . . 0.0 112.028 -175.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.99 -179.7 4.02 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 128.288 2.635 . . . . 0.0 107.518 170.159 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -92.39 -120.19 2.7 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 122.761 1.201 . . . . 0.0 114.032 -172.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -140.58 152.96 45.89 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.887 1.275 . . . . 0.0 110.777 169.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -116.01 137.1 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 127.581 2.352 . . . . 0.0 109.894 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -102.93 132.24 49.3 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 119.322 0.964 . . . . 0.0 108.797 169.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.75 144.36 27.81 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-O 120.881 0.372 . . . . 0.0 111.068 168.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -60.7 169.88 1.67 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 126.077 1.751 . . . . 0.0 111.753 170.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.32 -15.16 9.26 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.204 1.402 . . . . 0.0 114.143 168.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.05 3.17 55.15 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 125.894 1.678 . . . . 0.0 114.026 169.534 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.9 13.87 76.64 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 120.082 -1.637 . . . . 0.0 115.287 169.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.44 134.72 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 125.846 1.659 . . . . 0.0 112.875 171.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.59 112.12 25.08 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 165.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -104.81 139.42 39.6 Favored 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 124.694 1.198 . . . . 0.0 109.568 -177.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.3 t -137.27 140.28 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 114.962 1.467 . . . . 0.0 114.962 -166.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 89.3 p -154.76 104.39 2.51 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.995 1.318 . . . . 0.0 111.73 173.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.0 mt -136.85 141.84 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.784 2.034 . . . . 0.0 110.431 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -110.22 134.93 51.73 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 166.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -139.03 140.54 38.15 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 125.919 1.687 . . . . 0.0 111.648 -167.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 13.3 p -121.4 52.04 1.25 Allowed 'General case' 0 CA--C 1.543 0.699 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 177.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.615 HG11 HH12 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -147.03 1.81 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -177.469 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.11 176.07 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.858 1.663 . . . . 0.0 110.206 169.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.653 ' H ' ' HB3' ' A' ' 111' ' ' SER . 90.4 p -154.84 164.28 39.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 126.647 1.979 . . . . 0.0 112.066 171.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.9 mp -78.58 67.85 4.43 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.17 2.188 . . . . 0.0 108.534 177.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -128.23 -5.8 5.44 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 -168.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.68 -24.88 3.57 Favored Glycine 0 N--CA 1.472 1.046 0 CA-C-N 120.492 1.496 . . . . 0.0 116.427 169.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -94.22 -100.82 0.15 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 126.286 1.834 . . . . 0.0 107.711 -169.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -83.67 2.27 38.42 Favored 'General case' 0 C--N 1.323 -0.568 0 O-C-N 120.009 -1.682 . . . . 0.0 112.321 -174.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.653 ' HB3' ' H ' ' A' ' 105' ' ' SER . 39.4 m -125.11 -120.08 0.27 Allowed 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 115.864 1.801 . . . . 0.0 115.864 -169.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 42.2 pt -125.05 172.41 12.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 O-C-N 119.953 -1.717 . . . . 0.0 109.027 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.424 HD11 HG23 ' A' ' 151' ' ' ILE . 3.1 mm 76.68 147.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 128.657 2.783 . . . . 0.0 105.951 -162.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.48 -51.6 4.23 Favored Glycine 0 C--O 1.222 -0.626 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.62 -177.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 40.2 mtt180 -71.41 178.33 3.49 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 127.541 2.336 . . . . 0.0 110.191 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.9 m -138.91 124.99 20.02 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.862 0.865 . . . . 0.0 111.609 -169.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 47.4 tp -92.24 115.1 27.79 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 125.367 1.467 . . . . 0.0 110.103 178.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 15.0 p -102.45 140.36 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 124.597 1.159 . . . . 0.0 109.549 171.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -113.86 142.91 24.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.977 1.711 . . . . 0.0 107.681 171.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -118.72 148.2 43.02 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.91 2.084 . . . . 0.0 111.105 -168.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -74.6 -20.16 60.03 Favored 'General case' 0 CA--C 1.541 0.624 0 O-C-N 120.518 -1.364 . . . . 0.0 114.67 -168.29 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -125.38 171.19 10.65 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 119.82 -1.8 . . . . 0.0 112.283 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.2 139.9 51.25 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 124.714 1.205 . . . . 0.0 111.951 -175.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -87.76 136.83 32.79 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 123.869 0.867 . . . . 0.0 109.747 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.85 -37.23 76.06 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.726 1.211 . . . . 0.0 110.102 173.074 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 63.16 69.81 0.56 Allowed 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 124.999 1.32 . . . . 0.0 108.399 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.31 -109.87 0.42 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 117.055 1.582 . . . . 0.0 117.055 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.16 36.06 0.14 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 128.545 2.738 . . . . 0.0 111.754 -167.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -48.9 -31.39 10.24 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.482 1.991 . . . . 0.0 117.976 -168.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 167.35 2.78 0.03 OUTLIER Glycine 0 N--CA 1.476 1.322 0 N-CA-C 118.249 2.06 . . . . 0.0 118.249 178.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -146.22 -170.43 3.49 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 119.088 1.444 . . . . 0.0 111.747 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -70.58 -56.91 5.41 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.411 1.085 . . . . 0.0 109.57 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.496 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 1.2 mp0 -57.42 -28.12 62.99 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.876 1.67 . . . . 0.0 111.675 -174.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 42.8 m -46.25 -37.66 7.52 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 126.124 1.769 . . . . 0.0 112.789 171.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -111.92 -33.88 6.16 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -66.81 -24.22 66.15 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.0 0.92 . . . . 0.0 113.076 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 27.7 p -130.36 -32.68 1.74 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.885 1.674 . . . . 0.0 114.673 173.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.29 10.0 40.2 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -163.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 63.85 11.7 6.17 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.981 2.112 . . . . 0.0 114.483 177.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.0 19.07 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 117.326 2.343 . . . . 0.0 117.326 -167.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.76 -43.48 2.16 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 128.473 2.94 . . . . 0.0 115.266 168.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.5 t -168.69 169.34 10.17 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 118.512 1.156 . . . . 0.0 113.901 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.7 ptt-85 -71.5 158.96 35.33 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.168 1.387 . . . . 0.0 111.01 168.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.63 HD11 HG11 ' A' ' 14' ' ' VAL . 2.1 tm? -142.09 -103.31 0.14 Allowed 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 169.113 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.416 ' N ' HD13 ' A' ' 144' ' ' LEU . . . -103.68 160.46 14.74 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.248 1.019 . . . . 0.0 111.471 172.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.7 p -142.35 140.43 32.09 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.165 2.186 . . . . 0.0 108.898 -177.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.25 135.64 4.62 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 118.048 1.979 . . . . 0.0 118.048 -175.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.563 HG13 HD21 ' A' ' 53' ' ' ASN . 0.0 OUTLIER -75.02 139.52 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.513 1.125 . . . . 0.0 109.416 -178.612 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.9 mm -87.88 107.55 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 122.572 0.349 . . . . 0.0 110.919 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.71 -171.79 14.15 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.71 1.148 . . . . 0.0 113.23 173.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.2 pp -133.01 129.49 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 N-CA-C 114.989 1.477 . . . . 0.0 114.989 -173.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.5 -161.64 0.89 Allowed 'General case' 0 CA--C 1.545 0.75 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 165.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 . . . . . 0 N--CA 1.475 0.804 0 C-N-CA 131.6 3.96 . . . . 0.0 108.565 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.415 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -86.84 108.72 18.88 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 172.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttmm -97.16 123.34 40.9 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.024 -173.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -93.63 175.65 6.66 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.634 1.346 . . . . 0.0 114.634 179.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.595 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -155.92 103.65 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 128.621 2.769 . . . . 0.0 106.427 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.13 122.06 24.46 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.533 -0.729 . . . . 0.0 109.746 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.408 ' HA ' HG22 ' A' ' 54' ' ' THR . 22.8 t -88.49 63.14 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 124.171 0.988 . . . . 0.0 108.802 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.465 ' HA ' ' HA3' ' B' ' 147' ' ' GLY 0.335 1.3 pt? -82.85 79.04 9.35 Favored 'General case' 0 N--CA 1.477 0.907 0 O-C-N 121.272 -0.892 . . . . 0.0 113.075 -171.824 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 tttm -117.47 129.76 56.02 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 -173.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.12 158.08 19.01 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 165.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -72.1 92.45 1.33 Allowed 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 128.637 2.775 . . . . 0.0 109.246 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.19 -153.61 21.95 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 127.102 2.286 . . . . 0.0 111.474 -176.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -86.1 7.66 4.88 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 125.0 3.8 . . . . 0.0 114.249 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -105.62 108.92 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 C-N-CA 125.146 1.378 . . . . 0.0 108.509 -177.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -159.7 166.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.668 1.187 . . . . 0.0 111.421 176.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.46 178.25 29.75 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 124.205 0.907 . . . . 0.0 113.862 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.434 HG13 ' H ' ' B' ' 34' ' ' SER . 3.0 pt -123.8 137.33 57.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 128.449 2.699 . . . . 0.0 109.726 171.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mm -136.98 113.12 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.534 1.061 . . . . 0.0 109.457 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -113.24 108.65 17.56 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.757 1.623 . . . . 0.0 112.501 -164.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.433 ' H ' ' HB3' ' B' ' 4' ' ' ALA . 30.4 m-85 -92.44 104.01 16.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.539 1.935 . . . . 0.0 110.281 -176.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -84.25 103.28 13.31 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.6 1.56 . . . . 0.0 110.781 172.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . 0.46 HE22 ' CB ' ' B' ' 105' ' ' SER . 3.1 tt0 -97.69 119.09 35.64 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 121.814 0.816 . . . . 0.0 110.931 173.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -64.13 -42.85 96.66 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.09 1.756 . . . . 0.0 113.268 175.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -157.17 155.37 30.83 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 126.016 1.726 . . . . 0.0 111.596 168.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.7 p -45.05 -3.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 1 C-N-CA 131.739 4.016 . . . . 0.0 118.567 -171.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -157.72 20.9 0.27 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.661 1.985 . . . . 0.0 111.444 -168.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.24 173.67 15.64 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.312 1.91 . . . . 0.0 112.563 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -67.03 168.67 16.72 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.578 2.852 . . . . 0.0 111.401 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -138.88 133.5 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 122.744 0.418 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.8 mttp -92.41 124.22 36.3 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.28 0.562 . . . . 0.0 109.832 169.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.5 t -120.56 86.58 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 127.995 2.518 . . . . 0.0 108.472 -170.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -110.07 168.7 9.24 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 121.2 -0.938 . . . . 0.0 112.281 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.46 -159.5 28.44 Favored Glycine 0 N--CA 1.462 0.432 0 O-C-N 120.973 -1.079 . . . . 0.0 111.869 174.304 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . 0.434 ' H ' HG13 ' B' ' 17' ' ' ILE . 79.8 p -156.33 154.1 30.05 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -176.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.25 124.77 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.122 0.969 . . . . 0.0 109.997 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -119.39 146.58 45.23 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.841 1.257 . . . . 0.0 109.652 -178.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.38 10.66 38.16 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 124.916 1.246 . . . . 0.0 113.469 -169.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 76.8 mt -84.98 167.16 16.12 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.105 1.362 . . . . 0.0 111.651 168.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -94.78 156.5 16.35 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 164.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -59.98 148.62 34.69 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 123.727 0.811 . . . . 0.0 112.27 -177.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.67 -178.54 33.85 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 124.234 0.921 . . . . 0.0 113.506 -175.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -60.7 144.92 51.14 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 127.648 2.379 . . . . 0.0 114.013 -173.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -145.65 127.88 15.75 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 127.692 2.397 . . . . 0.0 109.985 175.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.26 158.09 52.35 Favored Glycine 0 N--CA 1.474 1.175 0 CA-C-N 119.239 0.927 . . . . 0.0 112.156 173.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -158.37 139.8 13.46 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.201 2.2 . . . . 0.0 112.061 166.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 19.1 p-80 -149.83 146.53 27.19 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 120.905 -1.122 . . . . 0.0 111.825 -176.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -91.4 138.51 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 124.568 1.147 . . . . 0.0 109.175 178.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -105.83 153.04 22.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 110.079 -178.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' B' ' 115' ' ' ARG . 24.0 tt0 -67.68 12.04 0.12 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.732 1.151 . . . . 0.0 113.479 178.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -140.59 125.04 17.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 O-C-N 120.031 -1.668 . . . . 0.0 108.932 -168.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.56 -3.18 61.96 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 124.616 1.103 . . . . 0.0 114.33 170.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.654 ' HA ' HG21 ' A' ' 5' ' ' VAL . 28.0 t0 -75.5 123.09 24.87 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 118.135 0.968 . . . . 0.0 109.93 -169.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.87 20.48 3.83 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 114.787 1.402 . . . . 0.0 114.787 164.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.311 14.9 t . . . . . 0 C--N 1.324 -0.543 0 C-N-CA 123.227 0.611 . . . . 0.0 112.004 -166.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.596 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.39 176.78 47.51 Favored Glycine 0 CA--C 1.545 1.947 0 C-N-CA 125.094 1.33 . . . . 0.0 114.582 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -102.42 179.46 0.15 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 124.722 3.614 . . . . 0.0 113.576 -177.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.646 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -72.75 74.7 1.12 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.649 3.18 . . . . 0.0 111.985 172.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -30.21 132.96 0.07 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 129.137 2.975 . . . . 0.0 115.312 169.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -122.86 59.27 12.9 Favored Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -172.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -62.85 -16.69 55.3 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 122.755 2.303 . . . . 0.0 113.911 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.81 -5.76 54.24 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.034 1.334 . . . . 0.0 113.324 169.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t 65.16 50.27 1.85 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 127.966 2.507 . . . . 0.0 112.885 178.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.6 mtp180 -118.02 176.21 5.31 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 124.94 1.296 . . . . 0.0 112.86 -172.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.3 mptm? -95.41 175.93 6.38 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.698 2.399 . . . . 0.0 109.441 164.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -62.7 157.75 20.19 Favored 'General case' 0 CA--C 1.539 0.531 0 O-C-N 120.918 -1.114 . . . . 0.0 111.009 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' B' ' 79' ' ' ARG . . . -176.52 -175.79 44.15 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 114.914 0.726 . . . . 0.0 114.914 174.51 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.65 -120.89 0.98 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 125.27 1.414 . . . . 0.0 113.988 169.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -62.52 -16.35 51.64 Favored 'Trans proline' 0 CA--C 1.54 0.793 0 C-N-CA 123.855 3.037 . . . . 0.0 115.259 -173.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.75 -4.15 19.7 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.578 1.151 . . . . 0.0 112.988 169.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -159.15 110.47 2.08 Favored 'General case' 0 CA--C 1.543 0.706 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 -167.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -40.88 -10.7 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 131.241 3.816 . . . . 0.0 116.76 168.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.69 -77.44 0.09 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 120.067 1.303 . . . . 0.0 109.315 -177.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.402 ' H ' ' HA3' ' B' ' 72' ' ' GLY . 15.2 ttp-105 56.53 77.25 0.26 Allowed 'General case' 0 N--CA 1.475 0.818 0 O-C-N 120.79 -1.194 . . . . 0.0 113.141 164.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.3 m170 -48.32 164.46 0.05 Allowed 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.709 -1.244 . . . . 0.0 114.019 172.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.85 -14.16 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.23 13.59 31.03 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.957 1.742 . . . . 0.0 116.75 176.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -100.81 103.86 15.09 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 120.801 2.3 . . . . 0.0 113.414 -171.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 42.9 mt -96.64 41.22 1.11 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.528 -1.358 . . . . 0.0 112.417 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.12 -129.74 43.14 Favored Glycine 0 CA--C 1.537 1.412 0 O-C-N 119.713 -1.867 . . . . 0.0 112.361 -174.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -147.98 161.01 42.21 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.877 0.871 . . . . 0.0 112.142 175.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.4 124.07 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 127.778 2.431 . . . . 0.0 110.906 -172.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.2 m -95.78 129.86 42.88 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.386 0.674 . . . . 0.0 109.666 174.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.32 148.47 25.05 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.56 162.53 15.62 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 128.677 2.791 . . . . 0.0 110.01 169.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -40.79 -21.23 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 129.421 3.088 . . . . 0.0 117.609 177.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -75.73 0.16 18.82 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.54 -1.35 . . . . 0.0 112.166 171.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.51 24.41 76.83 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 125.895 1.712 . . . . 0.0 112.602 -170.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.2 p -116.8 128.14 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 CA-C-N 118.785 1.293 . . . . 0.0 113.156 -177.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.1 117.05 29.62 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 166.117 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -98.25 130.93 44.95 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 123.793 0.837 . . . . 0.0 109.009 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.69 143.0 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 117.011 2.226 . . . . 0.0 117.011 -174.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 77.8 p -143.94 82.36 1.71 Allowed 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 126.352 1.861 . . . . 0.0 111.533 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.8 mt -97.69 157.61 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 120.594 -1.316 . . . . 0.0 110.071 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -144.69 145.59 31.8 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 127.642 2.377 . . . . 0.0 107.463 168.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.34 159.95 40.34 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.836 1.255 . . . . 0.0 111.336 173.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 35.7 p -127.37 46.08 2.6 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.472 1.509 . . . . 0.0 112.955 -168.163 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 23.1 m -145.87 15.12 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.226 1.011 . . . . 0.0 113.574 -176.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -148.78 165.99 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.107 2.163 . . . . 0.0 109.386 -173.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.46 ' CB ' HE22 ' B' ' 22' ' ' GLN . 18.1 m -157.39 168.0 28.63 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 125.066 1.346 . . . . 0.0 109.983 175.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' B' ' 22' ' ' GLN . 1.1 mm? -98.73 80.03 2.5 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.99 1.716 . . . . 0.0 107.723 -171.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -122.14 -18.91 6.74 Favored 'General case' 0 CA--C 1.567 1.628 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -175.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.06 0.71 89.26 Favored Glycine 0 N--CA 1.492 2.408 0 O-C-N 118.554 -2.591 . . . . 0.0 117.778 166.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.66 -88.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.918 2.487 . . . . 0.0 108.569 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 86.8 m-70 -115.15 -9.06 12.34 Favored 'General case' 0 CA--C 1.559 1.299 1 C-N-CA 132.715 4.406 . . . . 0.0 111.113 168.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 48.8 m -82.46 -166.05 1.18 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.63 1.972 . . . . 0.0 110.992 -174.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.452 HG22 ' H ' ' B' ' 113' ' ' ILE . 8.2 mm -71.28 162.3 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.834 0 O-C-N 118.603 -2.56 . . . . 0.0 108.637 169.151 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . 0.452 ' H ' HG22 ' B' ' 112' ' ' ILE . 1.4 mm 97.29 132.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.278 1 C-N-CA 133.75 4.82 . . . . 0.0 108.291 -168.632 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.22 5.51 34.88 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-O 117.565 -1.686 . . . . 0.0 115.815 176.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . 0.458 ' HD2' ' HA ' ' B' ' 49' ' ' GLU . 62.2 mmt-85 -77.61 -177.08 4.6 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 127.138 2.175 . . . . 0.0 110.797 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 39.5 m -128.26 141.12 51.55 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 116.446 -1.74 . . . . 0.0 109.945 173.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.7 tp -113.19 111.22 21.71 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.846 1.259 . . . . 0.0 111.208 171.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.9 p -88.56 149.33 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 124.264 1.026 . . . . 0.0 109.563 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 33.2 t -121.77 142.23 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 168.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -99.26 136.85 38.61 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.324 2.25 . . . . 0.0 111.379 -173.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -75.97 -10.86 59.77 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 120.419 -1.426 . . . . 0.0 113.796 -171.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 50.8 mttp -114.95 172.95 6.74 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 126.26 1.824 . . . . 0.0 111.959 169.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.99 163.59 1.94 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.809 1.244 . . . . 0.0 112.188 169.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -121.03 135.07 55.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 127.299 2.24 . . . . 0.0 107.209 175.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -73.03 -33.24 65.6 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 118.223 0.465 . . . . 0.0 112.216 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 29.3 mt 69.19 50.39 0.57 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.872 1.669 . . . . 0.0 114.223 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.21 -26.83 8.47 Favored Glycine 0 N--CA 1.474 1.211 0 N-CA-C 119.924 2.73 . . . . 0.0 119.924 163.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 8.4 pttm -163.93 99.41 0.87 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 120.1 1.95 . . . . 0.0 114.826 176.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.69 -7.71 56.45 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.938 1.732 . . . . 0.0 114.042 170.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 101.11 -8.64 57.54 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 125.497 1.522 . . . . 0.0 113.736 -170.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 p-10 -117.98 153.21 34.04 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 128.443 2.697 . . . . 0.0 109.611 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -66.41 -48.67 69.33 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 114.108 1.151 . . . . 0.0 114.108 -167.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.08 -33.1 72.81 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.837 1.255 . . . . 0.0 111.943 -175.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 61.8 m -53.45 -31.23 44.54 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 119.724 1.147 . . . . 0.0 112.574 168.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 1.1 p -85.03 -46.99 10.66 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.94 1.296 . . . . 0.0 112.513 172.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -70.49 -35.63 73.36 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.807 1.243 . . . . 0.0 113.523 -173.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 37.1 p -135.1 -28.78 1.15 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.265 1.426 . . . . 0.0 113.471 -175.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 108.95 0.54 31.83 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 118.44 -1.2 . . . . 0.0 113.538 -171.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 66.9 -4.39 0.79 Allowed 'General case' 0 N--CA 1.482 1.14 0 CA-C-N 119.492 1.646 . . . . 0.0 113.78 175.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -46.88 5.11 0.0 OUTLIER 'General case' 0 CA--C 1.565 1.545 1 C-N-CA 132.551 4.34 . . . . 0.0 121.497 -165.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.11 -69.9 3.21 Favored Glycine 0 CA--C 1.526 0.735 0 O-C-N 120.083 -1.636 . . . . 0.0 115.288 168.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.4 t -164.71 -152.4 0.17 Allowed 'General case' 0 N--CA 1.477 0.92 0 O-C-N 121.253 -1.145 . . . . 0.0 112.157 -171.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.65 148.87 29.81 Favored 'General case' 0 N--CA 1.47 0.557 0 O-C-N 120.427 -1.421 . . . . 0.0 113.991 176.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.402 ' CG ' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -97.85 -101.45 0.2 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.095 1.758 . . . . 0.0 110.099 169.54 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.402 ' H ' ' CG ' ' B' ' 144' ' ' LEU . . . -91.3 166.73 12.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.986 1.714 . . . . 0.0 111.05 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -157.08 143.19 17.91 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 127.181 2.192 . . . . 0.0 108.545 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . 0.465 ' HA3' ' HA ' ' B' ' 8' ' ' LEU . . . -164.76 171.08 40.1 Favored Glycine 0 N--CA 1.47 0.937 0 N-CA-C 117.354 1.702 . . . . 0.0 117.354 169.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -84.85 146.72 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.106 2.163 . . . . 0.0 110.577 -169.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 46.6 mm -86.43 103.09 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 125.649 1.58 . . . . 0.0 111.35 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.82 175.82 22.57 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.737 1.637 . . . . 0.0 113.134 171.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.455 ' HA ' ' HA ' ' B' ' 4' ' ' ALA 0.296 1.3 pp -114.78 139.21 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 177.762 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.4 159.66 30.27 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-O 122.951 1.358 . . . . 0.0 108.457 172.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 113.966 -1.47 . . . . 0.0 110.098 -177.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.5 p . . . . . 0 CA--C 1.517 -0.304 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptpp? -105.25 135.87 45.81 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -87.18 161.83 17.83 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 164.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 t -145.1 149.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 CA-C-N 119.705 1.139 . . . . 0.0 110.045 173.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.16 109.16 12.53 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.452 1.501 . . . . 0.0 108.187 166.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -82.61 112.07 19.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 168.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -79.36 99.35 7.1 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -156.13 127.18 6.97 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.586 0.754 . . . . 0.0 111.904 177.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.67 -104.81 1.28 Allowed Glycine 0 CA--C 1.527 0.821 0 N-CA-C 105.277 -3.129 . . . . 0.0 105.277 164.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -156.33 129.64 8.13 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.628 1.571 . . . . 0.0 108.352 167.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 124.22 168.87 12.98 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.61 2.052 . . . . 0.0 110.519 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 23.27 0.19 Allowed 'Trans proline' 0 CA--C 1.546 1.089 1 C-N-CA 125.745 4.297 . . . . 0.0 116.39 -169.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -117.26 111.87 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -157.27 158.24 35.74 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.324 -174.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.68 179.18 37.23 Favored Glycine 0 CA--C 1.508 -0.371 0 C-N-CA 126.129 1.823 . . . . 0.0 113.494 176.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -134.04 142.02 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.295 1.438 . . . . 0.0 109.054 168.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.0 mm -133.23 111.23 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 168.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -77.68 150.49 34.51 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.075 1.75 . . . . 0.0 110.934 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -135.43 78.52 1.73 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.765 2.026 . . . . 0.0 108.542 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -81.74 117.64 22.21 Favored 'General case' 0 C--N 1.34 0.182 0 CA-C-O 121.863 0.839 . . . . 0.0 113.157 -177.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp60 -105.57 167.68 9.6 Favored 'General case' 0 CA--C 1.549 0.942 0 CA-C-O 122.951 1.358 . . . . 0.0 109.424 169.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.89 -28.09 1.6 Allowed 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 130.088 3.355 . . . . 0.0 111.725 -177.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -101.97 -132.13 0.27 Allowed 'General case' 0 CA--C 1.556 1.201 0 C-N-CA 124.621 1.168 . . . . 0.0 108.497 166.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 t -136.37 -82.04 0.39 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 120.249 -1.532 . . . . 0.0 107.681 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -76.24 72.16 3.0 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.069 0.85 . . . . 0.0 112.356 169.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.46 15.93 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 127.057 2.265 . . . . 0.0 111.16 171.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.3 158.4 56.37 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 123.395 2.73 . . . . 0.0 111.567 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.7 t -129.14 136.16 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.24 0.616 . . . . 0.0 110.67 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.0 mttm -87.02 119.75 27.56 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 122.394 1.092 . . . . 0.0 110.827 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.9 t -103.1 125.3 57.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 128.82 2.848 . . . . 0.0 109.332 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.7 p90 -157.14 161.85 39.37 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 169.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.77 171.99 13.03 Favored Glycine 0 N--CA 1.466 0.669 0 C-N-CA 124.833 1.206 . . . . 0.0 112.11 -176.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.3 p -132.33 143.33 49.79 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 -167.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mm -116.73 126.37 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 124.869 1.268 . . . . 0.0 111.404 171.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 54.3 tttt -127.79 146.2 50.67 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.695 1.598 . . . . 0.0 111.755 -173.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.02 -34.57 3.82 Favored Glycine 0 N--CA 1.477 1.423 0 C-N-CA 126.347 1.927 . . . . 0.0 111.197 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.466 HD23 ' H ' ' A' ' 38' ' ' LEU . 0.2 OUTLIER -66.58 129.06 38.59 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 165.658 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -69.33 169.54 12.07 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 118.615 0.643 . . . . 0.0 110.998 171.33 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -54.02 158.79 2.0 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.325 1.85 . . . . 0.0 115.475 -171.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.27 179.11 35.61 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.333 0.968 . . . . 0.0 112.783 -173.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.8 mt -64.05 137.23 57.89 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 126.981 2.112 . . . . 0.0 111.935 -174.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -133.54 131.63 39.98 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.613 1.165 . . . . 0.0 108.472 168.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.36 157.31 46.13 Favored Glycine 0 N--CA 1.46 0.248 0 CA-C-O 118.994 -0.892 . . . . 0.0 111.277 -174.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -155.46 141.91 18.64 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.804 0.811 . . . . 0.0 112.763 169.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.9 p-80 -152.58 168.2 26.36 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 123.171 0.588 . . . . 0.0 109.838 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.27 135.57 41.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 123.964 0.905 . . . . 0.0 108.735 175.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -71.73 134.31 46.16 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 170.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -76.4 47.76 0.49 Allowed 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.225 1.194 . . . . 0.0 114.225 -170.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 173.8 156.99 0.13 Allowed 'General case' 0 C--O 1.237 0.425 0 C-N-CA 129.649 3.18 . . . . 0.0 108.35 177.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.25 0.46 20.76 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 117.823 1.889 . . . . 0.0 117.823 -178.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -67.67 42.86 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.535 1.934 . . . . 0.0 115.248 171.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -166.54 22.16 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -163.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.4 t -29.14 74.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 129.678 3.191 . . . . 0.0 117.407 173.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 159.35 -14.54 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.05 0 C-N-CA 130.775 3.63 . . . . 0.0 111.749 -169.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.77 -127.78 25.75 Favored Glycine 0 C--N 1.345 1.034 0 C-N-CA 124.858 1.218 . . . . 0.0 112.15 167.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 12.4 t -57.69 -10.86 1.77 Allowed 'General case' 0 CA--C 1.552 1.028 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.4 t -108.11 23.13 14.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.229 1.412 . . . . 0.0 113.576 171.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.0 m -152.05 -20.31 0.18 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 116.819 2.155 . . . . 0.0 116.819 169.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -153.41 162.93 40.78 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 120.644 1.565 . . . . 0.0 111.799 169.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.89 160.86 52.07 Favored Glycine 0 CA--C 1.539 1.586 0 CA-C-O 119.359 -0.69 . . . . 0.0 112.579 176.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -70.08 172.41 13.0 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 124.152 3.235 . . . . 0.0 111.177 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -15.86 89.18 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 118.865 2.913 . . . . 0.0 118.865 176.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -67.41 98.45 0.65 Allowed 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -75.63 102.42 0.72 Allowed Pre-proline 0 CA--C 1.548 0.871 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -165.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -72.13 -33.3 9.63 Favored 'Trans proline' 0 C--N 1.355 0.915 0 C-N-CA 123.252 2.635 . . . . 0.0 113.086 -168.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.98 -4.27 49.15 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.655 1.182 . . . . 0.0 112.656 175.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.4 t 56.5 49.12 15.41 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.014 1.726 . . . . 0.0 112.823 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 -103.72 174.45 5.86 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.789 1.236 . . . . 0.0 113.365 -173.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 ptmm? -74.22 164.59 26.43 Favored 'General case' 0 CA--C 1.547 0.837 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 161.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -80.14 168.76 18.72 Favored 'General case' 0 CA--C 1.543 0.682 0 O-C-N 121.086 -1.009 . . . . 0.0 112.365 173.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 131.51 -154.95 21.12 Favored Glycine 0 C--N 1.338 0.692 0 C-N-CA 125.818 1.675 . . . . 0.0 113.022 167.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.25 -15.2 0.4 Allowed Glycine 0 CA--C 1.539 1.558 0 N-CA-C 121.331 3.293 . . . . 0.0 121.331 166.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -112.43 -12.11 0.03 OUTLIER 'Trans proline' 0 CA--C 1.545 1.03 0 CA-C-N 121.87 2.835 . . . . 0.0 112.939 168.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.553 ' HE3' ' HB2' ' A' ' 128' ' ' LYS . 0.0 OUTLIER -126.56 -3.43 6.67 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 125.569 1.548 . . . . 0.0 112.666 175.625 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -108.51 175.06 5.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 128.53 2.732 . . . . 0.0 109.548 -175.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -116.85 -9.65 11.16 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.769 2.028 . . . . 0.0 112.629 -168.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -122.98 -59.16 1.61 Allowed 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -165.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 46.33 118.55 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 117.881 2.548 . . . . 0.0 117.881 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -58.4 165.57 2.04 Favored 'General case' 0 N--CA 1.48 1.071 0 O-C-N 119.37 -2.081 . . . . 0.0 111.583 169.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.313 7.1 p -77.19 -18.97 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 CA-C-N 120.116 1.326 . . . . 0.0 113.078 -176.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -94.16 27.78 12.4 Favored Glycine 0 CA--C 1.542 1.75 0 C-N-CA 125.458 1.504 . . . . 0.0 114.937 167.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -107.28 131.58 54.05 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 120.417 2.108 . . . . 0.0 115.088 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 65.2 mt -115.05 178.81 4.15 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.241 1.816 . . . . 0.0 109.818 167.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -89.53 -121.68 2.1 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.435 1.493 . . . . 0.0 114.511 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.436 HD22 HD11 ' A' ' 126' ' ' LEU . 11.8 m-80 -127.04 154.25 44.9 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.071 1.348 . . . . 0.0 111.65 172.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.03 102.85 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 127.347 2.259 . . . . 0.0 109.709 168.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 m -89.63 126.84 35.78 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 124.744 1.218 . . . . 0.0 110.018 -179.077 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.21 150.47 21.97 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -80.9 160.0 24.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 127.301 2.24 . . . . 0.0 109.73 167.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.3 pttp -47.98 -19.35 0.24 Allowed 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 128.185 2.594 . . . . 0.0 115.811 169.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -74.64 -11.68 60.25 Favored 'General case' 0 CA--C 1.547 0.863 0 O-C-N 120.753 -1.217 . . . . 0.0 111.784 171.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.07 15.09 55.08 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.015 2.245 . . . . 0.0 113.281 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.8 p -117.38 130.48 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.092 1.446 . . . . 0.0 113.322 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.36 97.34 7.84 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 165.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -89.68 148.93 23.01 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.961 0.886 . . . . 0.0 110.289 168.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.53 146.17 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.105 -1.407 . . . . 0.0 114.433 -169.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 76.7 p -160.23 90.43 0.89 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.384 1.074 . . . . 0.0 112.623 -176.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 175.77 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 C-N-CA 125.918 1.687 . . . . 0.0 113.236 -174.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -144.75 146.9 32.38 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 128.302 2.641 . . . . 0.0 106.693 168.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -143.05 155.94 44.73 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 122.053 0.93 . . . . 0.0 111.052 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.6 p -121.08 64.71 0.87 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 127.069 2.148 . . . . 0.0 114.158 -166.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -156.83 -46.82 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 O-C-N 121.033 -1.042 . . . . 0.0 109.717 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.39 150.43 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 168.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -148.43 161.15 42.18 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.486 1.514 . . . . 0.0 111.259 -169.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 9.4 mt -78.04 97.85 5.53 Favored 'General case' 0 C--N 1.345 0.387 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 170.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.5 t -155.98 6.4 0.2 Allowed 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 -170.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.3 -119.88 5.04 Favored Glycine 0 C--N 1.342 0.865 0 CA-C-N 120.625 1.557 . . . . 0.0 109.713 168.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -62.41 -26.59 68.56 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 125.532 1.533 . . . . 0.0 111.209 -171.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.2 m170 -79.45 -24.25 42.56 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.302 1.041 . . . . 0.0 113.446 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.6 m -166.92 -110.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.6 mm -88.8 142.3 13.07 Favored 'Isoleucine or valine' 0 C--N 1.34 0.171 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 -176.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 92.19 133.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 131.526 3.93 . . . . 0.0 106.73 -164.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.28 15.27 81.69 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 117.211 -1.883 . . . . 0.0 115.823 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 26.5 mtt85 -117.05 176.92 4.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-N 120.426 2.113 . . . . 0.0 110.777 171.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -119.75 110.32 16.66 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 120.212 1.369 . . . . 0.0 112.104 -175.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 14.4 tp -90.1 127.41 36.08 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.601 1.161 . . . . 0.0 111.137 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.3 p -116.58 139.55 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.122 1.369 . . . . 0.0 110.491 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.4 m -101.44 152.88 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 123.509 0.724 . . . . 0.0 109.436 167.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -119.45 145.68 46.06 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.665 1.586 . . . . 0.0 112.08 -170.113 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -71.22 -24.46 62.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.674 -1.266 . . . . 0.0 114.147 -171.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.5 mptt -112.78 177.16 4.73 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.321 1.449 . . . . 0.0 110.344 168.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.06 146.8 10.58 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.535 1.934 . . . . 0.0 111.45 168.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -83.86 140.86 31.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 161.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.1 -49.79 33.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 174.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.436 HD11 HD22 ' A' ' 86' ' ' ASN . 14.5 mt 90.64 38.38 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 129.413 3.085 . . . . 0.0 113.292 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.82 26.68 8.34 Favored Glycine 0 N--CA 1.468 0.799 0 N-CA-C 117.73 1.852 . . . . 0.0 117.73 167.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.553 ' HB2' ' HE3' ' A' ' 75' ' ' LYS . 3.7 tttt -155.74 10.09 0.28 Allowed 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 117.131 2.271 . . . . 0.0 117.131 -175.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -67.74 117.55 8.87 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 107.051 -2.42 . . . . 0.0 107.051 167.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -69.89 43.14 0.49 Allowed Glycine 0 N--CA 1.477 1.375 0 C-N-CA 126.561 2.029 . . . . 0.0 115.473 -174.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -102.85 -82.62 0.49 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.302 1.841 . . . . 0.0 110.418 176.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 177.17 -69.31 0.01 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 131.154 3.781 . . . . 0.0 106.329 -173.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.66 -37.16 62.88 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.731 1.612 . . . . 0.0 114.675 -177.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.56 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 0.7 OUTLIER -62.78 -18.6 62.94 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 119.119 -2.238 . . . . 0.0 114.542 179.549 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -99.34 -10.18 22.62 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 124.0 0.92 . . . . 0.0 113.073 170.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.2 mtpt -81.54 -75.55 0.28 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.5 1.52 . . . . 0.0 111.499 169.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 58.5 p -94.03 -28.16 15.9 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 120.121 1.328 . . . . 0.0 113.571 -177.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.45 -14.26 30.3 Favored Glycine 0 N--CA 1.468 0.813 0 CA-C-N 119.44 1.018 . . . . 0.0 110.925 -166.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.56 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 8.3 t-20 61.04 30.69 19.68 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 118.196 0.998 . . . . 0.0 112.714 165.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.9 28.36 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 128.582 2.753 . . . . 0.0 117.969 -167.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 67.38 -13.44 0.57 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 119.884 2.713 . . . . 0.0 119.884 167.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . 0.265 16.7 t 146.31 -171.56 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 130.268 3.427 . . . . 0.0 113.23 169.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.59 178.1 6.95 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 128.228 2.611 . . . . 0.0 114.587 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 17.9 tp -162.74 -115.6 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.653 1.581 . . . . 0.0 109.657 168.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -99.24 169.98 8.99 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 125.895 1.678 . . . . 0.0 111.506 172.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.3 t -156.64 152.07 26.69 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.782 1.233 . . . . 0.0 111.872 -171.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.05 142.31 8.41 Favored Glycine 0 N--CA 1.473 1.138 0 C-N-CA 125.43 1.491 . . . . 0.0 113.189 178.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 72.1 t -80.73 150.05 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 CA-C-N 118.602 1.201 . . . . 0.0 111.282 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.6 mt -88.1 103.25 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 O-C-N 120.14 -1.6 . . . . 0.0 109.951 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.75 168.84 14.06 Favored Glycine 0 N--CA 1.473 1.142 0 C-N-CA 124.239 0.923 . . . . 0.0 113.242 176.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.58 124.04 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 118.847 1.323 . . . . 0.0 113.78 176.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.22 -32.57 13.63 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-O 121.726 0.774 . . . . 0.0 108.927 163.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 . . . . . 0 C--O 1.233 0.2 0 C-N-CA 128.903 2.881 . . . . 0.0 111.174 168.742 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.742 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 76.4 p -92.92 51.57 1.71 Allowed 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -166.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 58.1 mttp -78.12 131.84 37.42 Favored 'General case' 0 N--CA 1.473 0.678 0 O-C-N 119.193 -2.192 . . . . 0.0 114.004 -170.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -123.58 156.42 35.77 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.45 1.5 . . . . 0.0 109.015 169.139 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 38.1 t -140.75 146.85 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 123.495 0.718 . . . . 0.0 110.626 -171.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.63 116.04 19.69 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.057 0.943 . . . . 0.0 112.044 169.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -78.92 103.98 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 168.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.06 114.58 17.07 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtpm? -141.6 172.45 12.67 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 124.584 1.154 . . . . 0.0 111.766 -174.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.45 -59.85 0.68 Allowed Glycine 0 N--CA 1.465 0.626 0 C-N-CA 126.779 2.133 . . . . 0.0 110.059 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.41 59.49 5.45 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.809 1.244 . . . . 0.0 112.844 -168.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.57 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.973 2.702 . . . . 0.0 114.247 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.75 -17.1 37.81 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 123.661 2.907 . . . . 0.0 113.216 -178.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 t -87.61 124.29 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 119.487 1.04 . . . . 0.0 110.314 171.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.27 165.36 35.02 Favored 'General case' 0 C--O 1.224 -0.239 0 C-N-CA 123.871 0.868 . . . . 0.0 111.772 169.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.98 -179.22 31.76 Favored Glycine 0 N--CA 1.464 0.531 0 N-CA-C 115.664 1.026 . . . . 0.0 115.664 -176.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 10.1 pt -135.15 116.39 19.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 126.827 2.051 . . . . 0.0 107.858 166.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.98 117.86 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 169.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 62.2 m-20 -113.55 130.08 56.43 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.85 1.66 . . . . 0.0 110.852 -173.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -114.4 130.7 56.71 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.466 1.507 . . . . 0.0 110.198 -171.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -122.02 131.37 53.96 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.916 1.687 . . . . 0.0 110.178 172.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -124.62 140.5 52.88 Favored 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.344 -0.847 . . . . 0.0 109.063 167.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -99.57 -24.22 14.82 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 115.128 1.529 . . . . 0.0 115.128 -168.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 46.2 mp0 -143.16 146.96 34.19 Favored 'General case' 0 CA--C 1.512 -0.518 0 C-N-CA 127.911 2.484 . . . . 0.0 106.672 168.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.4 m -61.96 -21.18 64.59 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.452 1.278 . . . . 0.0 114.452 -172.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -107.11 0.17 23.27 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.949 1.7 . . . . 0.0 113.839 170.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.16 170.13 54.38 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.779 1.18 . . . . 0.0 111.358 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -71.66 157.88 54.72 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.267 1.978 . . . . 0.0 110.613 177.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -107.52 134.18 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 125.366 1.467 . . . . 0.0 108.116 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -96.84 126.3 41.9 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 167.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 42.3 t -108.01 124.31 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 125.941 1.697 . . . . 0.0 107.081 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -143.05 170.82 15.0 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.4 -153.5 19.17 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 124.596 1.093 . . . . 0.0 112.337 174.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 58.3 p -153.98 153.63 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 114.805 1.409 . . . . 0.0 114.805 -172.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.4 mp -124.83 133.47 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.808 1.643 . . . . 0.0 107.072 169.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -132.37 146.15 51.76 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.921 0.888 . . . . 0.0 112.778 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.58 -3.74 19.75 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 126.75 2.119 . . . . 0.0 114.582 -173.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.0 mt -74.28 173.5 10.11 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.546 1.138 . . . . 0.0 111.866 177.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.7 t -86.43 154.6 21.04 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 164.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -56.41 142.39 38.64 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 167.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.59 176.63 17.34 Favored Glycine 0 N--CA 1.472 1.038 0 C-N-CA 124.294 0.949 . . . . 0.0 113.451 -175.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.712 HD23 ' H ' ' B' ' 42' ' ' LEU . 1.8 pt? -89.14 126.01 35.28 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.951 1.7 . . . . 0.0 113.422 -169.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -123.18 146.23 47.96 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 127.818 2.447 . . . . 0.0 109.624 -178.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.07 155.97 33.6 Favored Glycine 0 N--CA 1.478 1.45 0 CA-C-N 121.133 1.788 . . . . 0.0 111.252 -177.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -153.81 135.59 14.5 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.658 1.729 . . . . 0.0 113.958 171.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' B' ' 120' ' ' HIS . 0.1 OUTLIER -158.4 159.8 36.16 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.132 0.973 . . . . 0.0 112.867 -178.222 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.68 117.37 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.211 1.404 . . . . 0.0 110.158 -175.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -74.83 -173.54 1.91 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 128.43 2.692 . . . . 0.0 113.649 -169.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -63.29 152.05 38.91 Favored 'General case' 0 CA--C 1.541 0.6 0 O-C-N 120.245 -1.534 . . . . 0.0 112.055 171.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.23 161.23 13.85 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 115.071 1.508 . . . . 0.0 115.071 -168.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 67.37 -79.62 0.16 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -85.79 54.03 2.98 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 123.789 1.757 . . . . 0.0 110.557 -169.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -173.57 8.04 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.836 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 175.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 27.4 p . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 119.619 3.192 . . . . 0.0 119.619 -165.549 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.592 0 N-CA-C 116.938 2.199 . . . . 0.0 116.938 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -73.02 -179.77 37.3 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 123.788 0.708 . . . . 0.0 112.009 169.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -60.9 167.65 8.42 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 124.484 3.456 . . . . 0.0 115.072 -165.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.721 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -57.05 86.36 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 127.53 2.332 . . . . 0.0 111.415 175.854 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -52.69 127.23 22.4 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.805 -1.088 . . . . 0.0 112.79 -167.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -117.78 65.77 5.15 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 125.964 1.706 . . . . 0.0 112.953 -168.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -64.05 -15.22 48.03 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.035 2.49 . . . . 0.0 113.618 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -79.32 -7.3 58.22 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.442 1.097 . . . . 0.0 113.118 170.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t 65.46 55.67 1.02 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.881 2.072 . . . . 0.0 112.194 175.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 mtm180 -121.4 178.36 4.83 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 -166.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 mttp -89.81 173.91 8.0 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 127.917 2.487 . . . . 0.0 112.468 169.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -109.14 146.38 34.18 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 117.283 2.327 . . . . 0.0 117.283 -168.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 129.82 -91.7 0.31 Allowed Glycine 0 C--N 1.343 0.967 0 C-N-CA 124.795 1.188 . . . . 0.0 112.468 166.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.62 -28.6 11.19 Favored Glycine 0 CA--C 1.551 2.302 0 N-CA-C 118.635 2.214 . . . . 0.0 118.635 174.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -87.36 -15.18 3.62 Favored 'Trans proline' 0 C--N 1.356 0.966 0 CA-C-N 122.797 3.298 . . . . 0.0 113.176 171.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.21 -48.62 1.45 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.247 1.419 . . . . 0.0 108.994 166.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -55.09 138.41 44.33 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.975 0.893 . . . . 0.0 110.884 171.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -87.93 -6.23 58.15 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 127.464 2.306 . . . . 0.0 113.0 -169.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -119.24 -56.57 2.07 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 115.543 1.683 . . . . 0.0 115.543 -174.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.537 HH21 ' CG1' ' B' ' 103' ' ' VAL 0.278 3.4 ptt180 57.93 136.61 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.906 2.483 . . . . 0.0 115.346 -173.176 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -73.35 166.78 22.54 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 118.725 -2.484 . . . . 0.0 111.107 169.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.46 -31.92 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 120.311 -1.493 . . . . 0.0 113.997 -177.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -100.66 22.24 40.56 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 118.789 -1.006 . . . . 0.0 115.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -96.32 114.21 25.87 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -169.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.0 mt -101.56 171.88 7.3 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 104.425 -2.435 . . . . 0.0 104.425 158.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.63 -98.84 1.18 Allowed Glycine 0 N--CA 1.474 1.169 0 CA-C-N 119.026 0.83 . . . . 0.0 111.858 175.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -142.13 164.09 31.09 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -177.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.43 129.14 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 129.264 3.026 . . . . 0.0 111.147 -168.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.5 m -100.84 140.55 34.97 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.043 0.937 . . . . 0.0 110.072 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.44 157.86 16.32 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.931 0.892 . . . . 0.0 111.344 167.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -82.11 178.45 8.27 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.14 1.376 . . . . 0.0 112.154 171.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.12 -28.25 68.96 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.594 1.558 . . . . 0.0 113.365 172.048 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -76.42 2.71 12.85 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.336 1.054 . . . . 0.0 110.616 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.27 -0.59 83.83 Favored Glycine 0 C--N 1.342 0.883 0 C-N-CA 127.179 2.323 . . . . 0.0 114.19 172.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.69 132.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 126.107 1.763 . . . . 0.0 113.464 178.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.03 133.9 41.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.786 1.235 . . . . 0.0 108.703 165.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -98.38 118.27 34.66 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 7.5 t -98.43 124.01 51.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.2 173.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -155.1 87.8 1.14 Allowed 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.284 1.434 . . . . 0.0 110.95 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.87 148.64 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 126.441 1.896 . . . . 0.0 112.609 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -112.54 133.1 54.77 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.041 2.536 . . . . 0.0 106.008 168.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.74 130.05 27.12 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 125.238 1.415 . . . . 0.0 111.161 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 25.3 p -113.17 44.26 1.57 Allowed 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -174.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . 0.537 ' CG1' HH21 ' B' ' 79' ' ' ARG 0.315 9.8 p -161.16 -21.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 116.275 1.954 . . . . 0.0 116.275 166.851 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.56 164.45 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 122.189 2.268 . . . . 0.0 109.754 168.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 76.8 p -157.71 159.48 36.93 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 -173.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -92.51 57.13 2.88 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 127.651 2.38 . . . . 0.0 105.484 172.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -116.16 21.17 13.88 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -167.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.48 -53.21 4.65 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-O 117.932 -1.482 . . . . 0.0 115.356 167.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -99.41 -103.07 0.22 Allowed 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.282 1.515 . . . . 0.0 110.738 -167.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 20.3 m170 -76.32 8.62 3.22 Favored 'General case' 0 CA--C 1.551 1.016 0 O-C-N 119.357 -2.089 . . . . 0.0 114.418 -167.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 69.8 p -93.81 -131.03 0.14 Allowed 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 129.084 2.954 . . . . 0.0 114.202 -167.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 14.9 pt -113.76 -15.52 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 121.344 1.884 . . . . 0.0 115.919 175.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.7 mm -54.46 129.79 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 CA-C-N 120.607 1.549 . . . . 0.0 108.299 168.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.15 -2.32 52.06 Favored Glycine 0 CA--C 1.534 1.273 0 CA-C-N 120.199 1.363 . . . . 0.0 115.529 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -87.54 176.5 7.44 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.432 1.893 . . . . 0.0 109.972 169.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.55 109.97 6.6 Favored 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 120.45 1.477 . . . . 0.0 113.319 -169.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 27.4 tp -83.16 120.27 25.57 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 124.051 0.94 . . . . 0.0 109.67 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 p -121.85 139.58 48.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 125.998 1.719 . . . . 0.0 110.024 176.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 t -95.81 166.99 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 124.927 1.291 . . . . 0.0 107.672 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 73.4 m-70 -150.12 130.54 13.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.198 1.799 . . . . 0.0 107.877 -169.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 -53.76 -40.07 65.88 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 121.569 1.986 . . . . 0.0 115.691 -169.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.42 136.37 33.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 120.278 1.399 . . . . 0.0 109.674 175.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.82 159.71 1.6 Allowed 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.187 0.595 . . . . 0.0 110.935 165.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -82.75 146.89 28.75 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-O 123.217 1.484 . . . . 0.0 112.946 -171.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.31 -7.57 53.27 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 114.05 -1.432 . . . . 0.0 113.019 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.1 mt 57.75 55.26 5.6 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 127.163 2.185 . . . . 0.0 113.681 168.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.76 -67.09 0.93 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 175.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 103.85 6.74 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 124.963 1.305 . . . . 0.0 113.659 174.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -103.56 -71.9 0.88 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 107.03 -2.428 . . . . 0.0 107.03 164.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -130.28 -29.5 0.65 Allowed Glycine 0 CA--C 1.536 1.406 0 N-CA-C 119.15 2.42 . . . . 0.0 119.15 -173.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -166.41 173.81 9.6 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 122.036 2.918 . . . . 0.0 111.722 -167.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -42.82 -60.13 1.7 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.335 1.454 . . . . 0.0 113.878 -169.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 26.4 tp10 -35.96 -29.22 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 126.128 1.771 . . . . 0.0 114.395 172.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 83.9 p -63.61 -30.1 71.26 Favored 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 123.355 2.798 . . . . 0.0 115.824 174.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -108.08 -19.9 13.35 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 118.372 -0.823 . . . . 0.0 112.903 169.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -74.09 -49.3 24.61 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.633 1.173 . . . . 0.0 112.078 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 56.4 p -111.38 -95.35 0.43 Allowed 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 164.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.28 16.22 0.2 Allowed Glycine 0 CA--C 1.535 1.29 1 C-N-CA 131.2 4.238 . . . . 0.0 112.1 175.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 50.99 34.03 9.96 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.352 1.861 . . . . 0.0 113.019 -174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.34 24.98 0.08 Allowed 'General case' 0 CA--C 1.565 1.531 0 CA-C-O 121.929 0.871 . . . . 0.0 112.727 -169.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.09 -42.85 0.8 Allowed Glycine 0 N--CA 1.471 0.996 0 C-N-CA 129.924 3.63 . . . . 0.0 114.972 175.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 t -161.41 -156.39 0.44 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.541 1.537 . . . . 0.0 109.461 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -166.75 1.11 Allowed 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 127.105 2.162 . . . . 0.0 108.23 168.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -179.54 -173.6 0.26 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 128.328 2.651 . . . . 0.0 107.766 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.51 142.39 8.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.751 2.02 . . . . 0.0 112.154 174.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.2 p -151.9 159.57 43.78 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.908 1.683 . . . . 0.0 114.826 -167.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.78 142.53 8.32 Favored Glycine 0 CA--C 1.534 1.233 0 CA-C-O 118.795 -1.003 . . . . 0.0 114.837 173.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 26.5 t -79.51 135.42 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 125.222 1.409 . . . . 0.0 110.675 170.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.58 115.82 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 O-C-N 121.222 -0.924 . . . . 0.0 110.806 -174.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.76 174.94 15.7 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.942 1.258 . . . . 0.0 111.858 172.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -93.57 156.6 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 N-CA-C 115.337 1.606 . . . . 0.0 115.337 -168.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.51 -16.66 0.17 Allowed 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 126.914 2.085 . . . . 0.0 114.308 171.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 CA--C 1.533 0.311 0 C-N-CA 125.361 1.464 . . . . 0.0 112.911 168.168 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.525 ' HA ' ' H ' ' A' ' 22' ' ' GLN . 74.0 p . . . . . 0 N--CA 1.468 0.472 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.9 mttp -169.4 135.12 1.56 Allowed 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 127.322 2.249 . . . . 0.0 114.726 165.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.38 177.82 7.46 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 128.864 2.866 . . . . 0.0 110.188 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.451 HG11 ' CA ' ' B' ' 52' ' ' ASP . 1.6 p -155.26 127.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 C-N-CA 126.642 1.977 . . . . 0.0 108.903 -167.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.5 129.68 55.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.804 0.842 . . . . 0.0 111.495 170.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.407 HG22 HG22 ' B' ' 54' ' ' THR . 44.3 t -102.13 95.39 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.666 1.186 . . . . 0.0 107.876 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -89.06 124.28 34.15 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.1 mtpt -143.45 175.36 9.99 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 121.958 0.885 . . . . 0.0 112.416 168.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.29 -65.2 0.16 Allowed Glycine 0 C--N 1.33 0.234 0 C-N-CA 125.571 1.558 . . . . 0.0 110.629 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.85 69.51 3.35 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.51 1.124 . . . . 0.0 111.27 -164.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 40.88 -102.61 0.03 OUTLIER Glycine 0 CA--C 1.536 1.361 0 C-N-CA 127.104 2.288 . . . . 0.0 113.373 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -68.93 -5.98 17.0 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 124.209 3.273 . . . . 0.0 114.459 -178.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.4 t -76.36 135.43 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 CA-C-N 120.151 1.342 . . . . 0.0 110.037 169.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.79 156.79 45.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.212 -1.358 . . . . 0.0 108.642 166.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.89 105.48 0.59 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 169.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.2 127.23 46.37 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 CA-C-N 117.824 0.812 . . . . 0.0 109.778 171.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 pp -137.42 121.73 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 122.435 1.112 . . . . 0.0 110.823 166.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -83.5 161.07 21.36 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.963 1.305 . . . . 0.0 109.048 164.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -138.29 130.14 28.22 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.526 0.731 . . . . 0.0 109.62 167.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.89 153.66 22.07 Favored 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 165.424 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.525 ' H ' ' HA ' ' A' ' 2' ' ' THR . 1.3 tm0? -157.9 140.85 14.96 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 124.726 1.21 . . . . 0.0 110.781 168.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HZ2' ' CD ' ' A' ' 24' ' ' GLU 0.256 0.0 OUTLIER -82.3 -68.47 0.7 Allowed 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 175.434 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 20.7 mp0 -132.66 165.07 25.32 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.944 1.698 . . . . 0.0 110.77 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 m -56.01 -28.71 58.45 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -98.38 5.21 48.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.817 1.247 . . . . 0.0 112.729 172.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.59 149.57 19.27 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 125.014 1.292 . . . . 0.0 111.861 -176.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -69.75 174.79 8.97 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.836 3.024 . . . . 0.0 111.83 -178.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -133.54 153.42 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.811 1.244 . . . . 0.0 112.486 -168.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.3 mttm -120.75 112.48 18.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.459 1.104 . . . . 0.0 109.178 167.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -80.86 148.07 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 O-C-N 121.418 -0.801 . . . . 0.0 109.402 167.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.2 p90 -156.64 157.62 35.57 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.528 0.731 . . . . 0.0 112.182 165.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.88 -158.81 27.83 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.116 0.807 . . . . 0.0 115.116 -176.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.0 p -153.64 129.12 9.91 Favored 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -168.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mm -111.66 113.94 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.419 178.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . 0.26 0.0 OUTLIER -133.3 172.17 13.05 Favored 'General case' 0 C--N 1.345 0.37 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -178.582 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.54 1.09 59.11 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 126.928 2.204 . . . . 0.0 110.753 -166.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mt -87.21 173.55 9.15 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.869 1.268 . . . . 0.0 110.589 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.4 t -84.77 162.88 19.44 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 163.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -60.79 161.03 8.53 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-O 121.529 0.68 . . . . 0.0 112.205 169.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.48 -175.16 31.48 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.64 1.114 . . . . 0.0 112.812 -178.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.828 ' H ' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -71.92 151.04 43.62 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 128.272 2.629 . . . . 0.0 112.398 -171.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -152.36 115.45 4.66 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 127.831 2.452 . . . . 0.0 110.087 -173.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.65 152.49 30.85 Favored Glycine 0 N--CA 1.487 2.065 0 CA-C-N 120.854 1.661 . . . . 0.0 113.368 -178.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -149.64 103.46 3.26 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.631 1.572 . . . . 0.0 111.054 -169.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -141.85 145.96 35.27 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 119.849 -1.782 . . . . 0.0 114.986 -164.12 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -96.76 142.76 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-N 118.618 0.645 . . . . 0.0 110.958 -174.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -115.19 125.15 53.05 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.838 1.255 . . . . 0.0 109.511 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -62.42 25.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 128.013 2.525 . . . . 0.0 115.318 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -149.48 126.62 11.33 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 127.843 2.457 . . . . 0.0 107.507 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.95 -19.82 66.64 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 126.513 2.006 . . . . 0.0 115.048 173.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -76.23 51.62 0.7 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 127.313 2.245 . . . . 0.0 113.55 -168.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.433 ' HA ' HG21 ' B' ' 7' ' ' VAL . 1.4 p30 -176.32 22.32 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.211 0 C-N-CA 126.599 1.959 . . . . 0.0 115.399 -167.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.8 t -66.85 44.45 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 128.319 2.648 . . . . 0.0 116.697 178.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.67 -11.06 9.09 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -174.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.17 -166.63 14.6 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 125.268 1.413 . . . . 0.0 112.762 -169.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 37.7 t -51.79 -20.67 2.3 Favored 'General case' 0 CA--C 1.551 0.987 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 -177.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -68.66 -6.77 27.94 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 115.088 1.514 . . . . 0.0 115.088 175.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.6 t -149.76 -26.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -90.58 112.41 24.1 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.972 -1.08 . . . . 0.0 111.273 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.28 -119.48 1.11 Allowed Glycine 0 CA--C 1.545 1.935 0 C-N-CA 124.652 1.12 . . . . 0.0 113.568 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.35 173.73 2.19 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 124.205 3.27 . . . . 0.0 110.81 169.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -94.9 114.56 26.43 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.5 0.72 . . . . 0.0 110.352 -172.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -58.59 146.25 36.59 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.281 1.032 . . . . 0.0 112.64 177.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -126.83 85.58 60.53 Favored Pre-proline 0 CA--C 1.551 1.01 0 C-N-CA 125.885 1.674 . . . . 0.0 112.96 -168.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -61.74 -34.37 83.39 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 123.341 2.694 . . . . 0.0 113.519 -176.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.16 -4.96 47.21 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.602 0.761 . . . . 0.0 112.809 174.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.8 t 62.85 47.23 4.6 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 127.125 2.17 . . . . 0.0 112.179 178.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.7 ptt180 -117.9 176.56 5.14 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 114.544 1.313 . . . . 0.0 114.544 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -70.67 159.67 34.01 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.763 1.225 . . . . 0.0 111.704 174.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.424 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 84.6 t60 -68.12 120.68 14.71 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 164.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.4 -168.83 18.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 115.209 0.844 . . . . 0.0 115.209 -166.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -93.69 0.55 Allowed Glycine 0 CA--C 1.536 1.371 0 CA-C-O 117.004 -1.998 . . . . 0.0 114.933 176.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -74.56 47.06 1.55 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 124.777 3.651 . . . . 0.0 115.318 -170.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.498 ' HE3' HD23 ' A' ' 126' ' ' LEU . 6.4 ptpt 179.79 -5.7 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.065 1 C-N-CA 133.212 4.605 . . . . 0.0 113.852 165.195 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.421 ' H ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -134.47 177.46 7.75 Favored 'General case' 0 CA--C 1.559 1.316 0 C-N-CA 127.363 2.265 . . . . 0.0 111.227 -166.263 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -109.73 -4.77 15.89 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 127.664 2.385 . . . . 0.0 112.538 -175.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -84.22 -113.11 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.251 1.42 . . . . 0.0 108.304 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 HG11 ' A' ' 103' ' ' VAL . 21.8 ttp180 91.68 119.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 127.475 2.31 . . . . 0.0 108.857 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m170 -57.03 159.23 4.37 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 121.498 -0.751 . . . . 0.0 109.692 168.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p -41.97 -33.22 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.374 1.47 . . . . 0.0 113.635 176.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -146.8 123.05 1.71 Allowed Glycine 0 CA--C 1.534 1.26 0 CA-C-O 122.415 1.008 . . . . 0.0 112.426 165.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -158.15 96.46 1.45 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 129.509 3.124 . . . . 0.0 107.42 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -96.07 52.37 1.29 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 122.028 0.918 . . . . 0.0 110.353 178.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.68 -114.55 0.94 Allowed Glycine 0 CA--C 1.526 0.76 0 C-N-CA 126.35 1.929 . . . . 0.0 113.467 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -133.37 138.46 46.32 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.78 1.232 . . . . 0.0 112.529 172.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.4 m -91.23 143.55 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 127.153 2.181 . . . . 0.0 109.723 171.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.6 m -122.39 123.59 41.69 Favored 'General case' 0 N--CA 1.474 0.742 0 O-C-N 120.848 -1.157 . . . . 0.0 110.424 -172.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.14 159.25 15.06 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 114.613 1.338 . . . . 0.0 114.613 -175.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.69 175.26 10.28 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.858 2.063 . . . . 0.0 112.381 169.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.672 ' H ' ' HE2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -71.44 -16.37 62.37 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.516 1.126 . . . . 0.0 113.795 172.336 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.59 -13.32 61.36 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 121.967 0.889 . . . . 0.0 109.92 166.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.18 -4.43 58.7 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 127.635 2.54 . . . . 0.0 114.473 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.9 p -91.59 127.75 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 120.946 2.373 . . . . 0.0 114.633 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.11 119.81 32.73 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 163.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -87.6 140.43 29.52 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 172.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.64 131.39 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 124.477 1.111 . . . . 0.0 112.328 -168.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.0 p -157.21 60.3 0.51 Allowed 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.39 1.476 . . . . 0.0 113.383 -176.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.0 mp -95.99 142.53 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 119.446 -2.033 . . . . 0.0 112.847 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -117.09 136.79 52.72 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 125.828 1.651 . . . . 0.0 108.424 168.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -153.82 146.16 23.92 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.896 1.279 . . . . 0.0 111.794 -169.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 32.5 t -118.69 55.01 0.93 Allowed 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.084 -0.962 . . . . 0.0 113.091 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.406 HG11 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -139.45 -31.37 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 166.484 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -97.18 159.53 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 122.451 1.119 . . . . 0.0 112.208 172.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.507 ' HB2' HE21 ' A' ' 22' ' ' GLN . 53.8 p -156.94 163.18 39.42 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 125.642 1.577 . . . . 0.0 110.062 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.3 mt -82.4 73.39 9.44 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 122.341 1.067 . . . . 0.0 108.874 171.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -132.85 157.74 44.27 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.091 2.156 . . . . 0.0 107.67 170.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -116.87 41.94 1.98 Allowed Glycine 0 N--CA 1.472 1.09 0 C-N-CA 124.847 1.213 . . . . 0.0 113.45 -170.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.17 -88.52 0.51 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 127.381 2.273 . . . . 0.0 106.858 -178.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.79 12.83 13.08 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 126.016 1.726 . . . . 0.0 110.99 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -92.09 -160.82 0.77 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 120.467 -1.396 . . . . 0.0 112.176 173.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.413 HG23 HH21 ' A' ' 115' ' ' ARG . 8.3 pt -94.08 -13.47 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 N-CA-C 117.017 2.228 . . . . 0.0 117.017 -168.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.3 mm -73.1 125.93 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 122.326 2.33 . . . . 0.0 110.482 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.76 -0.66 81.44 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 117.782 -1.565 . . . . 0.0 113.917 -173.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.413 HH21 HG23 ' A' ' 112' ' ' ILE . 30.9 ttp180 -92.18 167.61 11.92 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.435 1.894 . . . . 0.0 110.573 176.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -113.6 163.19 15.28 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 125.582 1.553 . . . . 0.0 112.639 -176.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 41.7 tp -137.29 126.18 24.15 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 127.426 2.29 . . . . 0.0 110.452 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.5 p -100.21 140.21 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 126.456 1.903 . . . . 0.0 110.987 173.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -107.27 143.05 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 CA-C-O 121.676 0.751 . . . . 0.0 109.313 165.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -122.27 162.85 20.7 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.985 1.714 . . . . 0.0 111.558 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 -27.41 44.84 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 120.264 -1.522 . . . . 0.0 114.848 -167.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 20.7 mmtm -130.5 -175.63 3.71 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.758 2.072 . . . . 0.0 114.357 -171.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.45 153.51 31.23 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.718 1.207 . . . . 0.0 111.79 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -102.38 131.53 48.96 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.405 1.082 . . . . 0.0 110.889 -174.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -78.82 -31.98 46.07 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.352 1.861 . . . . 0.0 113.479 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.498 HD23 ' HE3' ' A' ' 75' ' ' LYS . 2.7 mm? 56.0 63.48 2.01 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.353 1.861 . . . . 0.0 114.803 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.0 10.21 64.85 Favored Glycine 0 N--CA 1.467 0.764 0 N-CA-C 120.065 2.786 . . . . 0.0 120.065 161.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.3 pptp? -148.33 -5.6 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 119.468 3.136 . . . . 0.0 119.468 -165.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.06 27.96 0.79 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 120.881 1.673 . . . . 0.0 116.035 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.96 -23.68 2.57 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.566 1.555 . . . . 0.0 116.508 171.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -95.88 165.45 12.27 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 119.717 1.759 . . . . 0.0 111.777 -173.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -49.96 -57.88 6.61 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.993 1.317 . . . . 0.0 109.24 168.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -50.83 -38.77 50.79 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 126.297 1.839 . . . . 0.0 112.803 177.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 20.1 m -62.51 -32.09 72.96 Favored 'General case' 0 N--CA 1.464 0.259 0 O-C-N 121.081 -1.012 . . . . 0.0 113.432 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.273 1.6 t -118.17 -10.62 10.25 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 117.324 -1.322 . . . . 0.0 113.988 -175.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . 0.256 0.6 OUTLIER -90.81 -34.1 15.44 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 120.469 1.486 . . . . 0.0 113.306 168.72 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.78 -17.58 4.0 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 126.042 1.737 . . . . 0.0 114.993 -176.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.424 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 96.61 12.64 50.16 Favored Glycine 0 N--CA 1.466 0.655 0 CA-C-N 120.454 1.479 . . . . 0.0 114.644 -178.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 61.72 7.73 2.07 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 119.711 1.756 . . . . 0.0 113.832 177.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.19 10.5 0.02 OUTLIER 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 118.816 2.895 . . . . 0.0 118.816 -164.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.48 -160.4 32.98 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 126.31 1.909 . . . . 0.0 113.588 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.5 t -55.04 148.83 12.98 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.954 -0.733 . . . . 0.0 111.584 176.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.86 128.95 37.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 170.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.421 HD12 ' H ' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -111.91 -119.23 0.3 Allowed 'General case' 0 C--O 1.238 0.497 0 O-C-N 124.382 1.051 . . . . 0.0 109.728 173.575 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.421 ' H ' HD12 ' A' ' 144' ' ' LEU . . . -68.27 151.91 46.23 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-O 122.425 1.107 . . . . 0.0 112.02 -172.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.6 t -154.24 143.28 21.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.334 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.93 151.59 23.09 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 -169.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.479 ' CG1' ' HB ' ' B' ' 148' ' ' VAL . 2.7 p -79.52 156.2 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.126 0.97 . . . . 0.0 111.885 172.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.4 mm -103.22 111.08 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.59 1.156 . . . . 0.0 111.872 170.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.07 159.96 13.47 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.965 1.269 . . . . 0.0 112.576 175.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.53 139.19 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.147 -1.208 . . . . 0.0 112.231 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.21 -141.34 0.23 Allowed 'General case' 0 CA--C 1.549 0.933 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 161.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.471 0.59 0 C-N-CA 124.835 1.254 . . . . 0.0 111.595 168.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.557 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 88.6 m -77.55 99.87 5.88 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.046 1.339 . . . . 0.0 107.754 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 33.9 mtmm -117.05 132.63 56.64 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 123.954 0.902 . . . . 0.0 113.363 -170.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.67 157.69 46.0 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 129.931 3.292 . . . . 0.0 109.67 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 33.5 t -136.32 114.13 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.577 1.18 . . . . 0.0 110.853 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.58 96.05 6.05 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 113.823 -1.535 . . . . 0.0 107.628 167.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 53' ' ' ASN . 34.4 m -86.03 115.55 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 165.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.4 mp -98.08 136.13 38.77 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.688 -174.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -157.97 121.8 4.08 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 119.741 1.155 . . . . 0.0 113.894 165.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -84.74 -115.41 0.72 Allowed Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 168.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -143.08 128.97 19.48 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.813 2.845 . . . . 0.0 106.011 -168.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.06 179.42 50.98 Favored Glycine 0 CA--C 1.537 1.421 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -167.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.45 49.56 2.68 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 125.293 3.995 . . . . 0.0 112.209 -176.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.65 112.65 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 126.334 1.853 . . . . 0.0 108.655 174.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 pm0 -158.71 166.53 31.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.651 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.96 171.92 35.05 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-O 122.133 0.851 . . . . 0.0 112.456 168.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 pp -121.63 122.76 67.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 166.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mm -131.36 101.9 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.38 148.32 39.29 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.249 1.02 . . . . 0.0 110.162 175.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.4 m-85 -126.61 116.37 20.91 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.171 1.789 . . . . 0.0 108.762 169.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -116.45 120.84 40.06 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 126.301 1.84 . . . . 0.0 112.537 177.436 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -113.92 130.01 56.55 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 122.127 0.965 . . . . 0.0 112.273 169.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.48 ' HE2' ' N ' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -87.17 -28.73 22.26 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.077 0.951 . . . . 0.0 112.474 -172.122 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -158.36 136.07 10.4 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 128.046 2.538 . . . . 0.0 107.71 168.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.8 t -47.62 -42.35 24.0 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 129.048 2.939 . . . . 0.0 113.495 -176.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -84.92 -7.67 59.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.057 1.343 . . . . 0.0 113.25 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.3 -167.71 42.13 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 125.521 1.534 . . . . 0.0 112.148 173.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . 0.406 ' O ' ' HE3' ' B' ' 23' ' ' LYS . 20.7 Cg_endo -84.51 176.66 6.21 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.305 2.67 . . . . 0.0 111.669 178.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.82 143.46 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 125.817 1.647 . . . . 0.0 109.4 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 14.9 tttp -107.78 130.58 54.96 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.352 1.061 . . . . 0.0 109.567 168.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.57 126.5 74.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 126.025 1.73 . . . . 0.0 108.495 -177.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -148.28 160.5 42.91 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -177.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.91 -149.26 21.26 Favored Glycine 0 C--N 1.333 0.397 0 C-N-CA 124.077 0.846 . . . . 0.0 111.868 170.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -150.82 128.78 11.76 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -171.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 mp -96.33 136.52 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.646 1.179 . . . . 0.0 109.213 169.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.4 mtpt -130.52 154.4 47.84 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 112.521 -178.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.11 -0.19 57.31 Favored Glycine 0 N--CA 1.475 1.235 0 C-N-CA 124.942 1.258 . . . . 0.0 113.332 -170.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 91.1 mt -78.49 149.01 33.25 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 124.738 1.215 . . . . 0.0 112.017 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -78.17 149.28 33.78 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 165.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . 0.404 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 1.5 pm0 -54.63 141.34 32.2 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 126.614 1.966 . . . . 0.0 113.064 -178.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.87 -168.24 18.0 Favored Glycine 0 N--CA 1.472 1.06 0 O-C-N 120.89 -1.131 . . . . 0.0 113.817 -177.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.432 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -82.02 138.93 34.77 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 128.011 2.525 . . . . 0.0 115.966 -167.837 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -137.04 131.73 33.21 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 128.58 2.752 . . . . 0.0 109.728 -174.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.43 161.6 54.27 Favored Glycine 0 N--CA 1.47 0.96 0 C-N-CA 124.672 1.129 . . . . 0.0 114.632 -172.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -153.38 118.94 5.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.651 1.225 . . . . 0.0 113.128 -168.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -157.33 150.02 23.21 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 119.893 -1.754 . . . . 0.0 115.248 177.187 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -104.93 117.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.406 1.483 . . . . 0.0 110.097 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -98.36 146.67 25.46 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.853 2.061 . . . . 0.0 109.799 -173.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -70.32 148.38 48.55 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.494 -171.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 77.83 156.66 0.17 Allowed 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 127.65 2.38 . . . . 0.0 112.498 -173.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.5 -1.3 81.94 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.724 168.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.451 ' CA ' HG11 ' A' ' 5' ' ' VAL . 13.6 t0 -76.92 115.89 17.11 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 118.782 1.291 . . . . 0.0 110.823 -174.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.413 0.0 OUTLIER -144.21 43.64 1.43 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 123.502 1.62 . . . . 0.0 113.992 164.293 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.407 HG22 HG22 ' A' ' 7' ' ' VAL 0.3 0.5 OUTLIER . . . . . 0 N--CA 1.455 -0.217 0 CA-C-N 112.58 -2.1 . . . . 0.0 111.936 174.493 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.745 0 N-CA-C 112.543 0.571 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.84 -63.93 3.56 Favored Glycine 0 CA--C 1.539 1.549 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.491 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -89.77 -180.0 1.99 Allowed 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 124.916 3.744 . . . . 0.0 111.959 169.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -79.67 128.74 33.78 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-O 123.201 1.477 . . . . 0.0 111.925 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -63.41 127.72 32.58 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 113.116 -1.857 . . . . 0.0 108.329 163.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 -121.19 58.48 7.53 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 123.675 0.79 . . . . 0.0 112.158 -171.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.31 -11.72 29.44 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.426 2.084 . . . . 0.0 113.873 -178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.3 mp -92.97 -8.27 43.57 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 114.121 1.156 . . . . 0.0 114.121 173.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.8 t 61.68 74.81 0.43 Allowed 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 119.957 1.253 . . . . 0.0 113.432 175.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -167.35 179.14 5.16 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.33 1.452 . . . . 0.0 112.562 -171.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mppt? -85.55 171.43 11.73 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.995 1.718 . . . . 0.0 112.767 177.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -86.26 146.54 26.48 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.921 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.44 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.82 -108.21 0.49 Allowed Glycine 0 C--N 1.336 0.534 0 CA-C-O 119.063 -0.854 . . . . 0.0 114.875 165.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.59 -42.16 2.01 Favored Glycine 0 CA--C 1.555 2.589 0 CA-C-O 118.182 -1.343 . . . . 0.0 114.127 -168.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -84.32 15.38 2.18 Favored 'Trans proline' 0 CA--C 1.553 1.474 0 C-N-CA 124.241 3.294 . . . . 0.0 116.712 171.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -39.42 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 128.143 2.577 . . . . 0.0 110.376 165.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.44 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 1.0 OUTLIER -66.1 137.01 56.75 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 161.561 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -99.82 -16.58 18.02 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.298 1.439 . . . . 0.0 111.258 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -79.4 -60.18 2.47 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.56 -0.712 . . . . 0.0 110.464 -171.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.2 ttt-85 71.91 127.47 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.528 1.931 . . . . 0.0 112.374 168.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -76.62 173.02 12.08 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 119.237 -2.164 . . . . 0.0 111.669 168.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.7 p -76.85 134.86 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.597 -1.314 . . . . 0.0 109.376 167.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.23 9.13 86.93 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 126.447 1.975 . . . . 0.0 115.801 -174.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 61.5 m-20 -78.25 114.96 17.62 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-N 119.902 1.851 . . . . 0.0 111.924 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 56.8 mt -99.57 179.06 4.67 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.812 0.845 . . . . 0.0 110.086 168.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -109.9 165.2 12.32 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 125.074 1.321 . . . . 0.0 112.445 174.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -74.63 150.84 39.44 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 -168.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.4 m -114.67 128.66 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 128.373 2.669 . . . . 0.0 111.097 -172.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.33 128.16 45.42 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.739 -1.225 . . . . 0.0 111.724 -178.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.05 135.06 35.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 169.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.06 154.47 23.2 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.626 1.97 . . . . 0.0 109.438 167.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -45.63 -21.8 0.13 Allowed 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 129.037 2.935 . . . . 0.0 116.847 176.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.76 9.62 2.72 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.356 1.062 . . . . 0.0 111.408 172.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.2 35.54 42.97 Favored Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.338 2.399 . . . . 0.0 112.324 175.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 1.8 p -142.93 126.99 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 119.017 1.408 . . . . 0.0 114.65 -172.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.46 119.46 32.58 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 165.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.7 t0 -79.64 154.23 28.82 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.592 1.157 . . . . 0.0 109.724 169.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.3 144.2 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 168.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.7 p -156.24 58.5 0.58 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.635 1.574 . . . . 0.0 112.177 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 28.9 mt -80.35 148.68 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 120.237 -1.539 . . . . 0.0 111.334 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -128.84 137.5 51.52 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.908 2.083 . . . . 0.0 105.591 166.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -154.78 136.79 14.65 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.476 1.111 . . . . 0.0 111.604 -169.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.95 49.06 1.02 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 123.518 0.727 . . . . 0.0 112.932 178.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 t -149.46 20.15 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 124.858 1.263 . . . . 0.0 111.731 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -148.62 169.91 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 128.787 2.835 . . . . 0.0 107.944 169.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -156.88 157.3 34.64 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.837 -1.164 . . . . 0.0 110.129 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -99.2 60.79 1.2 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.121 1.369 . . . . 0.0 108.837 -178.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.8 m -84.88 -94.21 0.08 Allowed 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.995 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 163.62 60.66 0.02 OUTLIER Glycine 0 N--CA 1.473 1.139 0 O-C-N 120.836 -1.165 . . . . 0.0 113.263 -172.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . 0.436 ' CG ' ' H ' ' B' ' 110' ' ' HIS . 9.2 p-10 -161.24 -108.95 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 123.136 1.446 . . . . 0.0 108.978 -164.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . 0.436 ' H ' ' CG ' ' B' ' 109' ' ' ASP . 14.6 m-70 -107.57 -28.92 9.48 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 130.001 3.32 . . . . 0.0 110.821 173.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 79.9 p -48.44 -65.28 0.59 Allowed 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 128.222 2.609 . . . . 0.0 116.759 -167.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 33.8 mm -150.06 -51.46 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 128.003 2.521 . . . . 0.0 109.513 169.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 49.8 mm -65.3 120.69 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 169.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.78 10.86 69.08 Favored Glycine 0 CA--C 1.534 1.266 0 N-CA-C 114.585 0.594 . . . . 0.0 114.585 -170.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 20.2 ttt85 -108.79 -179.86 3.98 Favored 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.94 2.496 . . . . 0.0 109.672 171.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -148.11 130.35 15.56 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.132 -1.605 . . . . 0.0 112.938 179.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -101.53 134.09 45.19 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 119.294 0.952 . . . . 0.0 110.931 -175.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -118.74 137.09 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.204 1.402 . . . . 0.0 109.52 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.42 130.03 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-O 122.646 1.212 . . . . 0.0 108.142 168.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -107.22 152.98 23.36 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.642 1.977 . . . . 0.0 110.108 -172.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.77 -45.34 44.46 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 119.751 -1.843 . . . . 0.0 114.67 -166.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.11 171.55 7.32 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 120.949 1.704 . . . . 0.0 112.061 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.59 149.74 7.75 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 124.037 0.935 . . . . 0.0 112.538 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -75.87 134.44 40.31 Favored 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 168.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -41.18 68.77 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 175.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.3 mt 67.87 37.56 3.1 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 125.867 1.667 . . . . 0.0 111.44 170.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -171.2 -75.16 0.04 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.211 0.91 . . . . 0.0 113.441 169.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.8 ttpt -162.04 98.1 1.05 Allowed 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 126.85 2.06 . . . . 0.0 113.605 173.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . 0.473 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -76.87 -135.98 0.71 Allowed Glycine 0 CA--C 1.537 1.413 0 CA-C-O 122.247 0.915 . . . . 0.0 113.417 169.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.89 -9.35 52.52 Favored Glycine 0 N--CA 1.474 1.172 0 N-CA-C 118.448 2.139 . . . . 0.0 118.448 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -164.8 175.47 9.61 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 120.514 2.157 . . . . 0.0 111.59 -169.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -48.07 -54.74 12.1 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 113.396 0.887 . . . . 0.0 113.396 -170.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -57.58 -10.52 1.55 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 114.476 1.287 . . . . 0.0 114.476 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.473 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 90.9 p -58.05 -49.96 75.1 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.884 1.674 . . . . 0.0 112.964 167.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 19.0 p -93.24 -18.1 22.9 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 178.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -85.12 -35.68 21.62 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.669 0.788 . . . . 0.0 112.867 176.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 59.8 p -115.33 -112.17 0.34 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.981 1.312 . . . . 0.0 107.479 167.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -142.6 21.45 2.37 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.875 2.179 . . . . 0.0 112.187 169.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.71 13.79 3.68 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.517 1.927 . . . . 0.0 113.466 -171.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.34 33.18 0.02 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 128.951 2.901 . . . . 0.0 118.559 -165.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.86 -54.8 3.01 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 126.905 2.193 . . . . 0.0 115.568 169.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -173.51 175.91 2.91 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 125.848 1.659 . . . . 0.0 111.97 -170.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -127.2 115.08 18.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.249 1.419 . . . . 0.0 110.461 -169.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.8 pp -110.53 -37.17 5.56 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -170.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.57 158.34 33.74 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 119.558 1.072 . . . . 0.0 113.136 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 20.3 p -156.45 163.78 39.03 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.471 2.309 . . . . 0.0 110.24 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.92 142.43 8.69 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 127.075 2.274 . . . . 0.0 110.246 171.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.479 ' HB ' ' CG1' ' A' ' 148' ' ' VAL . 1.6 t -88.17 146.8 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 CA-C-N 118.967 1.383 . . . . 0.0 108.68 -174.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.5 mm -77.33 120.56 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.013 -1.054 . . . . 0.0 112.94 -169.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.47 -172.4 18.77 Favored Glycine 0 N--CA 1.47 0.958 0 C-N-CA 125.824 1.678 . . . . 0.0 113.567 175.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -133.43 160.39 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 173.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.88 -39.31 0.09 Allowed 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 125.902 1.681 . . . . 0.0 111.368 168.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 . . . . . 0 C--O 1.241 0.612 0 C-N-CA 126.31 1.844 . . . . 0.0 112.824 169.937 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.2 t . . . . . 0 N--CA 1.467 0.407 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.2 102.71 14.16 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.929 -0.482 . . . . 0.0 112.022 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.01 166.67 22.54 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.784 0.72 . . . . 0.0 109.339 167.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.1 t -138.69 140.69 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 122.309 1.052 . . . . 0.0 112.798 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.85 113.15 19.24 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 114.089 -1.414 . . . . 0.0 109.12 165.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.03 80.63 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 127.276 2.23 . . . . 0.0 108.476 167.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -73.84 157.76 35.76 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.007 0.923 . . . . 0.0 111.238 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -148.66 158.51 44.19 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.39 162.68 13.65 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 127.549 2.5 . . . . 0.0 107.54 166.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -76.33 57.66 1.2 Allowed 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 126.837 2.055 . . . . 0.0 111.85 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.13 -167.53 40.0 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 128.436 2.922 . . . . 0.0 109.553 -175.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -80.1 42.55 1.34 Allowed 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 125.224 3.949 . . . . 0.0 112.306 -172.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -131.42 129.63 62.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 124.44 1.096 . . . . 0.0 109.165 -175.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -158.66 169.36 24.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.42 1.888 . . . . 0.0 109.074 -172.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 135.79 4.55 Favored Glycine 0 C--O 1.224 -0.469 0 C-N-CA 121.321 -0.466 . . . . 0.0 112.577 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.08 132.11 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 168.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.442 HD12 HG11 ' A' ' 97' ' ' VAL . 15.2 mm -139.09 112.77 6.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 C-N-CA 123.835 0.854 . . . . 0.0 110.838 173.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -78.49 144.32 35.83 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.976 0.91 . . . . 0.0 110.453 165.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -123.56 99.12 6.15 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.744 1.618 . . . . 0.0 109.886 172.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.88 105.34 11.09 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.664 1.186 . . . . 0.0 110.742 -179.629 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -79.29 83.1 5.37 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 120.926 -1.109 . . . . 0.0 108.537 169.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.51 -50.71 72.85 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 118.708 -0.663 . . . . 0.0 111.169 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.3 mp0 -132.38 136.48 46.84 Favored 'General case' 0 C--O 1.224 -0.241 0 C-N-CA 124.271 1.028 . . . . 0.0 108.876 168.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.1 p -67.08 -4.73 10.7 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 126.163 1.785 . . . . 0.0 114.954 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.46 1.93 9.6 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 126.743 2.017 . . . . 0.0 112.06 173.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.45 -153.2 12.52 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.664 1.602 . . . . 0.0 111.192 -176.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -86.24 173.06 6.9 Favored 'Trans proline' 0 N--CA 1.451 -1.01 0 C-N-CA 122.788 2.325 . . . . 0.0 111.761 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.95 134.06 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.759 1.624 . . . . 0.0 108.498 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.4 tttp -101.24 121.78 42.48 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 169.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.4 t -121.14 118.82 57.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 125.924 1.689 . . . . 0.0 109.095 -168.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -140.65 161.9 36.65 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -178.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.65 -150.73 22.97 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 124.783 1.182 . . . . 0.0 112.415 -179.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 43.1 p -158.09 136.04 10.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -171.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -109.7 112.93 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.668 1.187 . . . . 0.0 108.494 178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -120.79 135.86 55.04 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.955 1.302 . . . . 0.0 111.446 -168.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.67 -2.08 15.47 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 127.191 2.329 . . . . 0.0 113.559 -173.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.431 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -69.0 -178.27 1.21 Allowed 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 125.829 1.651 . . . . 0.0 110.992 169.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -115.11 156.22 25.62 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 127.962 2.505 . . . . 0.0 105.266 164.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -48.37 146.15 3.0 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 127.032 2.133 . . . . 0.0 114.118 -175.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.83 -177.4 32.86 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 122.084 0.824 . . . . 0.0 113.393 -178.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.491 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -70.13 150.26 46.71 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.449 2.3 . . . . 0.0 112.068 -169.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.431 ' CD2' HD23 ' A' ' 38' ' ' LEU . 92.8 m-70 -147.28 124.03 11.21 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.021 1.728 . . . . 0.0 110.32 175.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.43 155.43 32.44 Favored Glycine 0 N--CA 1.491 2.316 0 CA-C-N 120.281 1.4 . . . . 0.0 114.398 -174.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.635 ' CE1' HD11 ' A' ' 117' ' ' LEU . 2.0 t80 -146.1 102.11 3.59 Favored 'General case' 0 CA--C 1.552 1.051 0 CA-C-O 122.76 1.267 . . . . 0.0 113.77 -167.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -127.34 133.16 50.11 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.89 94.71 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 126.408 1.883 . . . . 0.0 110.355 174.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -73.75 108.84 6.82 Favored 'General case' 0 CA--C 1.557 1.242 0 O-C-N 120.604 -1.31 . . . . 0.0 114.36 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -31.03 106.23 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 127.408 2.283 . . . . 0.0 113.208 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 148.44 173.86 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 129.792 3.237 . . . . 0.0 109.758 -169.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.578 ' HA3' ' H ' ' B' ' 151' ' ' ILE . . . -116.85 -2.63 18.78 Favored Glycine 0 CA--C 1.549 2.201 0 C-N-CA 126.292 1.901 . . . . 0.0 109.859 160.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.51 ' C ' HD22 ' A' ' 53' ' ' ASN . 0.8 OUTLIER -75.69 147.22 39.57 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 128.008 2.523 . . . . 0.0 111.75 170.271 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.51 HD22 ' C ' ' A' ' 52' ' ' ASP 0.312 0.1 OUTLIER -173.53 17.47 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 119.041 2.978 . . . . 0.0 119.041 166.627 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.416 HG22 HG22 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -92.35 -12.52 32.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 120.083 -1.636 . . . . 0.0 114.315 -165.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.34 18.14 22.47 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.772 1.229 . . . . 0.0 112.678 172.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.66 -123.43 24.72 Favored Glycine 0 CA--C 1.529 0.933 0 O-C-N 120.697 -1.252 . . . . 0.0 112.243 174.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.3 m -72.5 -9.33 58.43 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 175.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -14.92 52.55 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 125.184 1.394 . . . . 0.0 111.407 169.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.7 m -95.28 -159.51 0.72 Allowed 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 127.41 2.284 . . . . 0.0 109.52 168.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.13 104.69 0.03 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 128.212 2.605 . . . . 0.0 116.374 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -63.07 166.72 23.77 Favored Glycine 0 CA--C 1.545 1.92 0 C-N-CA 125.869 1.699 . . . . 0.0 114.805 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -62.11 96.89 0.15 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 125.07 3.847 . . . . 0.0 113.173 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.1 p80 47.82 64.49 1.61 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 126.124 1.769 . . . . 0.0 113.24 169.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -32.11 137.83 0.05 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.383 1.873 . . . . 0.0 115.439 -178.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -106.01 63.66 0.16 Allowed Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 126.559 1.944 . . . . 0.0 113.084 177.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -62.78 -35.77 66.27 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.612 2.208 . . . . 0.0 111.898 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.1 tp -77.76 -5.18 49.79 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 124.727 1.211 . . . . 0.0 112.869 173.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t 71.27 51.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.945 2.098 . . . . 0.0 112.497 172.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 78' ' ' GLU . 8.5 mtp180 -108.19 171.71 7.25 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -169.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.7 mttp -81.09 162.71 23.6 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.468 1.507 . . . . 0.0 109.521 165.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -72.36 151.72 42.51 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 121.012 -1.055 . . . . 0.0 112.151 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.73 -138.45 6.39 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 116.137 1.215 . . . . 0.0 116.137 169.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.457 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 139.77 -108.88 0.6 Allowed Glycine 0 CA--C 1.544 1.856 0 CA-C-O 116.835 -2.092 . . . . 0.0 114.934 -168.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -52.33 -3.65 0.11 Allowed 'Trans proline' 0 CA--C 1.546 1.103 1 C-N-CA 126.443 4.762 . . . . 0.0 120.068 -169.333 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.48 2.89 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 127.693 2.397 . . . . 0.0 112.594 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.457 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.3 OUTLIER -123.91 175.81 6.7 Favored 'General case' 0 CA--C 1.557 1.249 0 C-N-CA 129.091 2.957 . . . . 0.0 109.02 -174.912 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -116.55 -13.71 10.9 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.671 2.388 . . . . 0.0 111.143 -175.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 69' ' ' ARG . 3.8 mm-40 -91.59 -65.3 1.02 Allowed 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.769 1.228 . . . . 0.0 112.555 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 ' CG ' ' A' ' 101' ' ' ASP . 1.4 ttt-85 52.91 77.07 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 120.088 1.313 . . . . 0.0 111.48 171.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -46.91 153.32 0.42 Allowed 'General case' 0 N--CA 1.478 0.971 0 O-C-N 120.264 -1.523 . . . . 0.0 112.298 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 p -43.95 -40.62 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 120.125 1.33 . . . . 0.0 113.715 -176.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -97.08 34.2 5.24 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 126.863 2.173 . . . . 0.0 117.21 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -114.68 128.17 56.16 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.992 1.717 . . . . 0.0 110.426 176.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.1 mt -122.41 53.75 1.23 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-O 122.031 0.92 . . . . 0.0 108.555 168.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 62.2 -132.53 45.49 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.411 1.482 . . . . 0.0 114.229 175.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -143.45 154.86 44.11 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.573 1.149 . . . . 0.0 110.591 175.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.94 104.04 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.618 1.567 . . . . 0.0 109.733 -175.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -91.68 125.46 36.41 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 124.01 0.924 . . . . 0.0 109.222 -175.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.97 156.05 17.78 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -173.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -82.85 166.35 19.03 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.037 1.735 . . . . 0.0 110.206 167.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.6 pttt -51.28 -24.03 4.12 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 127.521 2.328 . . . . 0.0 113.274 167.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -76.78 -0.73 24.91 Favored 'General case' 0 CA--C 1.55 0.954 0 C-N-CA 125.929 1.691 . . . . 0.0 112.016 172.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.21 7.32 84.59 Favored Glycine 0 CA--C 1.52 0.404 0 O-C-N 120.183 -1.573 . . . . 0.0 113.523 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -95.18 123.69 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 125.405 1.482 . . . . 0.0 112.142 174.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.85 134.49 36.16 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 163.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -79.29 150.62 31.46 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 168.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.442 HG11 HD12 ' A' ' 18' ' ' ILE . 1.3 t -131.2 123.24 53.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 113.287 -1.779 . . . . 0.0 109.855 168.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.1 m -147.12 70.94 1.2 Allowed 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.865 2.066 . . . . 0.0 109.198 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 31.3 mt -116.4 152.37 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 125.502 1.521 . . . . 0.0 111.711 -168.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -145.48 137.28 25.37 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 127.172 2.189 . . . . 0.0 107.064 174.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.406 ' CG ' HH21 ' A' ' 79' ' ' ARG . 22.7 t70 -154.26 139.4 17.44 Favored 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -167.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -116.59 51.57 0.98 Allowed 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.6 t -128.62 -47.93 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -100.43 176.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.16 0.984 . . . . 0.0 112.005 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -157.94 176.03 13.07 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 120.693 -1.254 . . . . 0.0 110.696 172.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.4 mp -109.69 52.2 0.73 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.803 1.641 . . . . 0.0 109.46 -177.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.3 t -91.24 14.33 14.68 Favored 'General case' 0 CA--C 1.542 0.669 0 O-C-N 120.57 -1.331 . . . . 0.0 114.417 -174.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 102.47 -122.32 7.48 Favored Glycine 0 C--N 1.339 0.698 0 O-C-N 121.527 -0.733 . . . . 0.0 111.652 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -59.09 -52.7 64.59 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 126.934 2.094 . . . . 0.0 114.27 -163.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -88.48 9.43 23.72 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.737 1.615 . . . . 0.0 112.602 -174.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.21 -161.23 0.82 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 125.407 1.483 . . . . 0.0 113.937 -165.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.283 7.4 pt -88.96 1.16 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 175.283 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 38.8 mm -69.72 132.68 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 163.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.24 -12.11 55.79 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.763 -1.576 . . . . 0.0 115.631 -171.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.716 ' NE ' ' H ' ' A' ' 116' ' ' THR . 1.3 tpm_? -71.51 177.86 3.8 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.699 2.249 . . . . 0.0 108.486 178.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.716 ' H ' ' NE ' ' A' ' 115' ' ' ARG . 1.5 m -140.53 131.58 26.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 126.932 2.093 . . . . 0.0 106.717 175.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.635 HD11 ' CE1' ' A' ' 45' ' ' PHE . 2.3 tm? -87.22 137.8 32.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 125.542 1.776 . . . . 0.0 106.791 166.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 5.2 p -117.45 124.54 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.624 1.17 . . . . 0.0 108.427 168.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.42 145.18 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 O-C-N 124.94 1.4 . . . . 0.0 109.083 169.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 23.2 m-70 -117.34 161.76 19.01 Favored 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 125.16 1.384 . . . . 0.0 113.134 -170.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.54 -34.25 69.86 Favored 'General case' 0 N--CA 1.478 0.935 0 O-C-N 120.597 -1.314 . . . . 0.0 114.071 179.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.426 ' HE3' ' O ' ' A' ' 139' ' ' ASN . 17.9 ttpp -94.49 156.02 16.66 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 123.064 1.412 . . . . 0.0 113.766 -173.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.58 142.59 17.74 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.744 165.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -93.43 128.6 39.57 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 124.465 1.103 . . . . 0.0 110.641 -178.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.81 -21.65 59.17 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.697 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 72.3 mt 47.86 56.52 7.09 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 127.912 2.485 . . . . 0.0 111.219 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.16 -58.9 0.38 Allowed Glycine 0 N--CA 1.472 1.055 0 C-N-CA 125.864 1.697 . . . . 0.0 113.732 173.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp -126.05 77.55 1.69 Allowed 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 115.226 1.565 . . . . 0.0 115.226 -169.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.607 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -80.57 -95.23 0.4 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 107.196 -2.362 . . . . 0.0 107.196 165.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -150.03 8.58 0.81 Allowed Glycine 0 N--CA 1.474 1.173 0 N-CA-C 117.728 1.851 . . . . 0.0 117.728 -174.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.7 p30 -161.2 -177.7 6.23 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 120.4 2.1 . . . . 0.0 111.111 -176.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -55.77 -51.89 65.85 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.207 0.912 . . . . 0.0 112.727 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -59.38 -23.84 62.93 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -170.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.607 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 27.3 m -57.15 -29.31 63.51 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 172.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -100.25 -15.14 18.18 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 118.067 -0.968 . . . . 0.0 113.473 173.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.55 -85.37 0.16 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 119.968 1.258 . . . . 0.0 110.77 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 62.5 p -73.24 -11.47 60.52 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.48 9.06 79.74 Favored Glycine 0 N--CA 1.467 0.705 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 -165.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.426 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 4.8 t-20 52.53 21.92 1.97 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.501 1.92 . . . . 0.0 109.135 -166.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.97 -11.78 21.13 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 114.726 1.38 . . . . 0.0 114.726 -166.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.93 -156.12 24.22 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 124.698 1.142 . . . . 0.0 113.072 169.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -67.98 154.83 40.79 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 126.55 1.94 . . . . 0.0 111.609 -175.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.425 ' H ' ' HD2' ' A' ' 143' ' ' ARG . 0.3 OUTLIER -81.62 129.85 34.84 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.581 0.752 . . . . 0.0 109.192 -179.218 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.11 -64.19 1.1 Allowed 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.124 1.77 . . . . 0.0 110.276 -170.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.7 149.33 45.0 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 125.071 1.348 . . . . 0.0 110.531 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 63.7 m -139.08 146.63 40.98 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.047 1.739 . . . . 0.0 111.249 -176.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.08 142.93 8.72 Favored Glycine 0 N--CA 1.474 1.183 0 C-N-CA 124.804 1.192 . . . . 0.0 112.11 169.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.4 t -92.69 135.34 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 125.043 1.337 . . . . 0.0 109.312 -175.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.6 mm -77.55 115.77 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.718 -169.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.09 158.1 14.63 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.818 1.199 . . . . 0.0 113.426 -177.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -75.14 134.98 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.135 0.974 . . . . 0.0 113.326 -178.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.62 -177.35 6.53 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.711 2.404 . . . . 0.0 108.544 -170.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 . . . . . 0 N--CA 1.471 0.577 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 167.89 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.427 0 N-CA-C 113.013 0.745 . . . . 0.0 113.013 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.8 p -97.76 114.85 26.95 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.137 1.446 . . . . 0.0 108.879 171.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -113.07 125.37 54.31 Favored 'General case' 0 C--O 1.24 0.602 0 C-N-CA 125.098 1.359 . . . . 0.0 112.083 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -79.99 168.89 18.61 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 176.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.415 ' CG2' HG23 ' A' ' 54' ' ' THR . 1.9 p -156.12 101.94 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 127.771 2.429 . . . . 0.0 107.836 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.69 114.39 26.03 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.913 1.285 . . . . 0.0 111.403 -172.178 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.416 HG22 HG22 ' A' ' 54' ' ' THR . 2.1 t -83.97 72.61 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 125.17 1.388 . . . . 0.0 109.585 -172.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.3 mp -77.92 115.71 17.87 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 121.437 -0.79 . . . . 0.0 109.838 178.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.1 ttpp -161.79 120.13 2.31 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.197 1.799 . . . . 0.0 111.021 164.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -137.07 -69.53 0.05 OUTLIER Glycine 0 N--CA 1.467 0.708 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 169.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.95 76.99 2.84 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 127.703 2.401 . . . . 0.0 110.594 -169.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.94 -102.06 0.05 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.424 1.964 . . . . 0.0 112.403 174.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -85.65 0.55 8.46 Favored 'Trans proline' 0 C--N 1.353 0.807 1 C-N-CA 125.783 4.322 . . . . 0.0 115.469 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.33 120.82 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-N 121.753 2.07 . . . . 0.0 109.486 169.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.99 166.36 24.27 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.132 1.373 . . . . 0.0 110.827 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.11 174.92 33.97 Favored Glycine 0 N--CA 1.466 0.634 0 CA-C-O 123.082 1.379 . . . . 0.0 116.115 173.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.482 HG13 ' H ' ' B' ' 34' ' ' SER . 3.3 pt -143.08 50.86 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 CA-C-N 112.833 -1.684 . . . . 0.0 112.013 -166.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 13.1 mm -81.46 119.36 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 O-C-N 120.033 -1.667 . . . . 0.0 110.957 -169.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -88.0 154.96 20.08 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.498 1.519 . . . . 0.0 110.414 169.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.425 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 23.4 m-85 -143.54 108.05 4.83 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 169.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -98.38 117.82 33.65 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.994 1.109 . . . . 0.0 113.994 -173.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . 0.539 ' HB2' HD13 ' B' ' 106' ' ' LEU . 4.3 tp-100 -96.17 139.55 32.16 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.794 1.238 . . . . 0.0 111.165 169.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.592 ' H ' ' HD2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -92.2 -36.15 13.43 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.408 2.283 . . . . 0.0 113.59 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -159.47 136.71 9.69 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 126.961 2.104 . . . . 0.0 109.034 169.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 60.3 p -19.43 -57.13 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 129.109 2.964 . . . . 0.0 116.935 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . 0.421 ' H ' ' ND2' ' B' ' 26' ' ' ASN . 4.3 p30 -95.24 2.91 55.0 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 127.342 2.257 . . . . 0.0 115.531 -172.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.24 168.16 54.44 Favored Glycine 0 CA--C 1.544 1.904 0 O-C-N 120.781 -1.199 . . . . 0.0 113.164 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -67.02 163.66 33.04 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.677 2.918 . . . . 0.0 110.297 170.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 77.4 t -131.26 138.74 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 CA-C-N 119.476 1.034 . . . . 0.0 111.642 -169.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 72.9 mttt -92.48 112.15 23.99 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.23 174.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.51 131.94 32.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 125.214 1.406 . . . . 0.0 109.119 170.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -154.27 165.72 35.42 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 168.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.05 175.92 21.47 Favored Glycine 0 N--CA 1.468 0.798 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -174.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . 0.482 ' H ' HG13 ' B' ' 17' ' ' ILE . 77.7 p -132.55 165.52 24.19 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -166.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -116.82 126.61 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.915 1.686 . . . . 0.0 107.895 168.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -126.17 132.93 51.7 Favored 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 124.905 1.282 . . . . 0.0 111.073 -177.235 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.44 -3.04 13.87 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.297 2.38 . . . . 0.0 112.801 -171.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.3 mt -66.93 162.73 21.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.051 0.925 . . . . 0.0 109.483 168.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -77.54 150.9 34.75 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 162.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -50.68 147.02 5.06 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 123.733 0.813 . . . . 0.0 110.306 168.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 104.06 -179.59 25.04 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.75 1.167 . . . . 0.0 113.486 -173.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.752 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.9 pt? -84.99 145.28 27.79 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.374 2.67 . . . . 0.0 113.401 -169.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . 0.401 ' HB2' HG23 ' B' ' 87' ' ' VAL . 93.1 m-70 -147.36 147.3 30.17 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 128.88 2.872 . . . . 0.0 111.228 -167.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.11 156.1 49.88 Favored Glycine 0 N--CA 1.479 1.526 0 CA-C-O 117.991 -1.45 . . . . 0.0 113.618 174.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -154.43 98.07 2.07 Favored 'General case' 0 CA--C 1.553 1.07 0 C-N-CA 125.808 1.643 . . . . 0.0 111.623 -173.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -121.36 128.22 52.03 Favored 'General case' 0 N--CA 1.472 0.665 0 O-C-N 120.248 -1.532 . . . . 0.0 113.773 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -80.24 100.43 4.59 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 171.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -68.59 130.27 42.35 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 119.41 -2.056 . . . . 0.0 108.836 -170.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.05 48.67 0.12 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 128.699 2.8 . . . . 0.0 114.179 -165.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 178.66 138.73 0.09 Allowed 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 129.1 2.96 . . . . 0.0 107.054 178.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.09 -5.8 88.96 Favored Glycine 0 N--CA 1.469 0.891 0 CA-C-N 115.214 -0.903 . . . . 0.0 114.912 174.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -79.19 52.43 1.31 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.961 1.704 . . . . 0.0 112.408 -170.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.412 HD22 ' N ' ' B' ' 53' ' ' ASN 0.252 0.0 OUTLIER 175.89 64.98 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 116.686 2.106 . . . . 0.0 116.686 -169.64 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.7 t . . . . . 0 N--CA 1.48 1.029 0 O-C-N 120.425 -1.422 . . . . 0.0 113.282 167.155 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.405 0 CA-C-O 121.564 0.697 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -84.88 -139.83 4.75 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-O 118.54 -1.145 . . . . 0.0 111.268 169.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -72.41 176.32 8.84 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.015 3.143 . . . . 0.0 110.959 173.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.664 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -57.11 100.18 0.04 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 128.556 2.742 . . . . 0.0 109.559 170.052 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -49.62 146.34 4.3 Favored 'General case' 0 CA--C 1.538 0.485 0 O-C-N 124.148 0.905 . . . . 0.0 111.629 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -106.12 60.82 0.16 Allowed Pre-proline 0 CA--C 1.56 1.344 0 C-N-CA 126.334 1.853 . . . . 0.0 115.625 -171.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -61.42 -35.17 84.47 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.913 3.076 . . . . 0.0 113.457 -174.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 63.6 mt -79.65 -1.51 38.56 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.453 1.101 . . . . 0.0 113.542 176.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.3 t 58.37 58.03 3.61 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.597 1.159 . . . . 0.0 113.114 169.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -153.88 179.02 9.27 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -169.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 mtmp? -61.75 173.13 1.07 Allowed 'General case' 0 CA--C 1.541 0.622 0 CA-C-O 122.186 0.993 . . . . 0.0 111.98 174.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.507 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 63.6 t60 -123.09 148.73 45.32 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 116.35 1.982 . . . . 0.0 116.35 -166.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 121.65 -63.72 0.51 Allowed Glycine 0 C--N 1.339 0.709 0 C-N-CA 124.458 1.028 . . . . 0.0 115.278 162.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.61 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 88.14 -9.85 73.26 Favored Glycine 0 CA--C 1.548 2.14 1 N-CA-C 123.294 4.078 . . . . 0.0 123.294 168.296 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -89.26 -5.01 5.76 Favored 'Trans proline' 0 C--N 1.358 1.044 1 CA-C-N 124.605 4.202 . . . . 0.0 112.23 168.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.42 -25.18 0.11 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.319 1.847 . . . . 0.0 110.861 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.61 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -71.08 139.9 50.52 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 122.87 1.319 . . . . 0.0 109.433 164.972 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -90.44 -22.47 21.4 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 129.527 3.131 . . . . 0.0 113.009 -168.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -98.17 -79.92 0.46 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.21 1.404 . . . . 0.0 109.901 -172.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 87.92 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 127.45 2.3 . . . . 0.0 116.498 164.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -63.99 147.44 52.03 Favored 'General case' 0 N--CA 1.484 1.233 0 O-C-N 119.678 -1.889 . . . . 0.0 108.471 164.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.9 -10.03 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 CA-C-N 122.094 2.224 . . . . 0.0 112.372 -174.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.97 5.46 75.88 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.764 1.65 . . . . 0.0 114.695 169.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -97.9 132.26 43.64 Favored 'General case' 0 C--N 1.322 -0.623 0 O-C-N 119.666 -2.079 . . . . 0.0 111.758 -173.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 81.4 mt -130.35 176.62 7.98 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.697 1.999 . . . . 0.0 106.738 165.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.27 -138.87 6.34 Favored Glycine 0 N--CA 1.471 1.003 0 C-N-CA 123.863 0.744 . . . . 0.0 114.369 -171.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -102.47 151.1 22.69 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.36 1.064 . . . . 0.0 113.369 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.401 HG23 ' HB2' ' B' ' 43' ' ' HIS . 16.2 m -113.51 145.57 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 127.797 2.439 . . . . 0.0 110.728 169.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 54.8 m -134.23 122.54 22.9 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.215 0.916 . . . . 0.0 109.544 -174.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.12 151.56 22.14 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.61 160.25 14.86 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 130.189 3.395 . . . . 0.0 109.5 168.104 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -40.48 -26.66 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 128.616 2.766 . . . . 0.0 117.884 175.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -77.45 7.67 5.15 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.104 1.32 . . . . 0.0 112.029 173.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.9 8.87 87.25 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 127.247 2.356 . . . . 0.0 113.748 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 11.5 p -104.28 121.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 125.103 1.361 . . . . 0.0 112.684 -170.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.34 113.41 25.36 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 164.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -104.18 141.83 35.57 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.831 0.824 . . . . 0.0 111.314 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -117.65 147.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 CA-C-N 113.606 -1.634 . . . . 0.0 113.46 -170.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 17.4 p -161.17 60.0 0.29 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 125.258 1.423 . . . . 0.0 113.75 -175.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 24.4 mt -118.61 145.21 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 O-C-N 119.771 -1.83 . . . . 0.0 112.297 -172.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . 0.434 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 10.7 tt0 -104.03 121.53 43.37 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 165.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -112.44 134.87 53.73 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.679 1.192 . . . . 0.0 109.866 174.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.0 p -109.42 50.73 0.77 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.002 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 57.7 t -133.8 -39.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.863 1.665 . . . . 0.0 110.208 169.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.59 163.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-O 123.18 1.467 . . . . 0.0 113.393 176.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.539 ' H ' ' HB3' ' B' ' 111' ' ' SER . 58.1 m -159.43 147.67 17.61 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 127.14 2.176 . . . . 0.0 108.863 -172.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . 0.539 HD13 ' HB2' ' B' ' 22' ' ' GLN . 4.1 mp -79.58 97.42 6.48 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 119.013 0.824 . . . . 0.0 109.05 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.8 m -114.07 -33.71 5.62 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.178 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.15 -29.39 10.73 Favored Glycine 0 N--CA 1.469 0.858 0 CA-C-O 118.91 -0.939 . . . . 0.0 111.822 -168.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -154.25 -46.66 0.09 Allowed 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 115.577 1.695 . . . . 0.0 115.577 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -82.61 0.96 40.55 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 126.142 1.777 . . . . 0.0 112.755 -168.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . 0.539 ' HB3' ' H ' ' B' ' 105' ' ' SER . 4.9 m -163.85 -78.11 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 177.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.4 pt -129.17 167.3 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 O-C-N 120.749 -1.22 . . . . 0.0 109.797 167.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.2 mm 77.93 146.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 C-N-CA 129.452 3.101 . . . . 0.0 106.84 -162.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.95 -45.76 2.29 Favored Glycine 0 N--CA 1.468 0.8 0 CA-C-O 118.985 -0.897 . . . . 0.0 113.698 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.8 mtp85 -75.85 176.62 7.64 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.961 1.304 . . . . 0.0 111.117 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 5.9 t -124.5 164.95 18.67 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 117.529 -1.224 . . . . 0.0 110.931 -173.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.421 ' C ' HD13 ' B' ' 117' ' ' LEU . 0.3 OUTLIER -127.11 140.56 52.18 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 119.619 1.1 . . . . 0.0 108.886 167.597 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 p -122.8 136.2 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.345 1.458 . . . . 0.0 110.101 172.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.07 158.73 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.486 1.114 . . . . 0.0 110.233 175.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -131.76 140.3 49.19 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.42 1.088 . . . . 0.0 111.729 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -63.3 -27.92 69.66 Favored 'General case' 0 N--CA 1.475 0.792 0 O-C-N 120.042 -1.661 . . . . 0.0 115.119 -174.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.93 165.19 14.0 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 120.071 -1.643 . . . . 0.0 109.957 166.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.21 152.0 34.93 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 124.307 1.043 . . . . 0.0 111.42 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.514 ' CG ' ' HB2' ' B' ' 140' ' ' ALA . 16.7 m-20 -86.55 159.95 19.11 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.302 1.841 . . . . 0.0 113.034 174.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.7 -49.7 17.51 Favored 'General case' 0 N--CA 1.485 1.304 0 CA-C-N 112.728 -2.033 . . . . 0.0 111.104 166.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.6 mm? 68.32 62.73 0.37 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 127.355 2.262 . . . . 0.0 110.167 -176.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 178.22 -111.61 0.33 Allowed Glycine 0 N--CA 1.47 0.901 0 O-C-N 121.583 -0.698 . . . . 0.0 111.748 -173.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -151.63 7.94 0.5 Allowed 'General case' 0 CA--C 1.566 1.584 0 C-N-CA 126.906 2.083 . . . . 0.0 112.551 169.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 34.86 -106.5 0.03 OUTLIER Glycine 0 C--N 1.35 1.324 0 C-N-CA 126.877 2.179 . . . . 0.0 114.071 169.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -129.71 21.83 4.98 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-O 117.958 -1.468 . . . . 0.0 114.16 169.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -165.37 168.57 16.65 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 120.393 2.096 . . . . 0.0 111.249 -171.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -61.85 -53.03 61.46 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.855 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -40.84 -37.74 0.82 Allowed 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.676 1.99 . . . . 0.0 114.637 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 54.9 m -56.02 -35.67 67.1 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 171.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -94.85 -23.56 17.42 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.935 1.243 . . . . 0.0 112.527 167.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -78.9 -33.62 45.43 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-N 119.981 1.264 . . . . 0.0 113.094 -171.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.2 m -135.71 -31.32 0.95 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 126.898 2.079 . . . . 0.0 110.616 -169.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . 0.507 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 125.49 -25.41 5.67 Favored Glycine 0 C--O 1.222 -0.599 0 C-N-CA 127.996 2.712 . . . . 0.0 111.714 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 113.14 -8.63 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.856 1 C-N-CA 131.995 4.118 . . . . 0.0 112.291 176.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . 0.514 ' HB2' ' CG ' ' B' ' 124' ' ' ASP . . . -57.24 -7.35 0.53 Allowed 'General case' 0 CA--C 1.56 1.349 0 N-CA-C 118.466 2.765 . . . . 0.0 118.466 -163.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.76 -31.32 1.96 Allowed Glycine 0 N--CA 1.47 0.943 0 O-C-N 119.597 -1.939 . . . . 0.0 114.512 170.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -133.64 -173.39 3.22 Favored 'General case' 0 CA--C 1.544 0.743 0 O-C-N 121.752 -0.852 . . . . 0.0 112.717 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.24 -174.44 2.72 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 127.981 2.512 . . . . 0.0 108.837 172.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.527 HD23 ' H ' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -174.72 -160.1 0.09 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 130.156 3.382 . . . . 0.0 107.038 171.908 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.527 ' H ' HD23 ' B' ' 144' ' ' LEU . . . -69.86 171.98 8.44 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 127.503 2.321 . . . . 0.0 113.781 -176.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -155.92 153.31 29.43 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.817 -168.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.96 141.15 7.66 Favored Glycine 0 N--CA 1.469 0.881 0 C-N-CA 125.347 1.451 . . . . 0.0 113.975 172.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 2.3 t -77.58 147.83 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.835 0.854 . . . . 0.0 110.164 171.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.7 mm -91.91 98.29 8.21 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 126.535 1.934 . . . . 0.0 110.836 -171.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.75 -171.6 30.31 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 124.564 1.078 . . . . 0.0 114.058 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.578 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 3.4 mp -119.21 128.82 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.186 0 C-N-CA 126.042 1.737 . . . . 0.0 114.367 -169.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -100.69 -24.34 14.44 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.35 1.06 . . . . 0.0 112.18 169.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 CA--C 1.534 0.345 0 C-N-CA 126.974 2.109 . . . . 0.0 111.618 -175.097 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.465 0.301 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.297 6.3 ptpt -127.24 129.78 48.39 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 176.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.27 153.38 28.51 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 126.659 1.984 . . . . 0.0 109.376 174.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -122.65 142.67 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.106 1.363 . . . . 0.0 108.976 177.355 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -105.19 133.32 50.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 121.092 1.769 . . . . 0.0 110.33 166.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' B' ' 54' ' ' THR . 57.5 t -118.22 109.24 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.576 1.15 . . . . 0.0 109.574 -175.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.63 140.83 48.5 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.544 1.538 . . . . 0.0 112.187 -172.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -160.8 164.25 31.57 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 168.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.492 ' HA3' ' HE3' ' B' ' 9' ' ' LYS . . . 82.23 73.22 1.23 Allowed Glycine 0 C--N 1.335 0.48 0 N-CA-C 120.706 3.043 . . . . 0.0 120.706 161.668 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -160.04 60.96 0.35 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 108.212 164.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.76 -172.41 21.8 Favored Glycine 0 CA--C 1.541 1.671 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -164.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -73.58 58.7 3.91 Favored 'Trans proline' 0 CA--C 1.534 0.493 1 C-N-CA 125.749 4.299 . . . . 0.0 110.044 173.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.95 133.76 53.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 125.728 1.611 . . . . 0.0 110.263 -168.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.8 163.65 38.72 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 126.353 1.861 . . . . 0.0 109.85 -169.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.29 148.26 17.98 Favored Glycine 0 C--N 1.33 0.196 0 CA-C-O 122.407 1.004 . . . . 0.0 115.556 176.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -123.25 138.54 52.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 126.318 1.847 . . . . 0.0 109.888 167.814 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.9 mm -140.57 127.09 21.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 C-N-CA 125.496 1.518 . . . . 0.0 108.235 166.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -85.79 141.2 29.84 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.906 1.682 . . . . 0.0 109.839 166.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -124.28 97.82 5.49 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.727 2.011 . . . . 0.0 107.29 176.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.62 116.43 28.73 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-O 123.436 1.588 . . . . 0.0 111.636 -172.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.45 HE22 ' C ' ' A' ' 25' ' ' SER . 22.1 tt0 -108.67 148.85 29.8 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.954 178.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.437 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -89.45 -26.15 21.11 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.637 1.175 . . . . 0.0 112.912 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -131.71 -151.58 0.47 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.389 1.876 . . . . 0.0 110.401 167.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.45 ' C ' HE22 ' A' ' 22' ' ' GLN . 30.6 t -111.41 -17.53 13.09 Favored 'General case' 0 CA--C 1.555 1.169 0 C-N-CA 125.315 1.446 . . . . 0.0 110.754 167.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -90.67 -24.32 20.5 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 127.661 2.384 . . . . 0.0 115.466 170.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.2 175.64 52.41 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 119.462 1.028 . . . . 0.0 114.79 -173.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.56 151.91 47.83 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.855 2.37 . . . . 0.0 110.718 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.86 128.73 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 177.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -88.97 119.41 29.47 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 169.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.24 133.29 59.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 125.69 1.596 . . . . 0.0 110.141 -176.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -156.08 156.54 34.52 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.543 0.737 . . . . 0.0 111.886 177.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.1 -149.74 16.71 Favored Glycine 0 C--N 1.333 0.394 0 O-C-N 121.924 -0.485 . . . . 0.0 112.963 171.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 53.6 p -155.39 115.11 3.68 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 122.976 0.511 . . . . 0.0 112.056 -169.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.06 125.41 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-O 117.299 -1.334 . . . . 0.0 107.593 170.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.8 tttp -124.75 140.67 52.72 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 121.891 2.132 . . . . 0.0 111.552 -176.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.88 -0.25 13.45 Favored Glycine 0 N--CA 1.476 1.343 0 C-N-CA 127.243 2.354 . . . . 0.0 114.661 -176.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.459 ' H ' HD22 ' A' ' 38' ' ' LEU . 2.3 mm? -69.15 -178.82 1.37 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.603 1.561 . . . . 0.0 110.985 170.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.59 -42.42 5.93 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 117.209 -1.377 . . . . 0.0 113.511 169.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 176.48 -107.67 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.267 0 C-N-CA 128.773 2.829 . . . . 0.0 109.628 -178.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -39.54 148.38 0.15 Allowed Glycine 0 N--CA 1.479 1.511 0 C-N-CA 129.533 3.444 . . . . 0.0 119.885 -168.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.446 HD23 ' H ' ' A' ' 42' ' ' LEU . 1.0 OUTLIER -31.3 136.67 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 130.1 3.36 . . . . 0.0 117.796 -169.084 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.0 m-70 -130.32 140.5 50.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 128.94 2.896 . . . . 0.0 108.764 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.57 156.52 53.33 Favored Glycine 0 N--CA 1.474 1.22 0 C-N-CA 124.08 0.848 . . . . 0.0 111.981 175.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -155.44 105.65 2.48 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.157 0.983 . . . . 0.0 112.374 -168.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.03 140.04 32.51 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 119.936 -1.728 . . . . 0.0 115.185 -172.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -78.11 134.99 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 166.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m170 -112.9 176.74 4.89 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 126.889 2.075 . . . . 0.0 110.901 -174.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -74.55 132.55 41.91 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.566 1.147 . . . . 0.0 112.297 170.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -77.78 -178.49 5.43 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 127.798 2.439 . . . . 0.0 115.216 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.505 ' HA2' ' CA ' ' B' ' 152' ' ' ALA . . . 119.78 -118.26 3.86 Favored Glycine 0 CA--C 1.502 -0.774 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.288 -172.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -87.83 63.45 7.44 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 125.229 2.442 . . . . 0.0 108.015 177.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -77.18 56.92 1.35 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 113.297 -1.774 . . . . 0.0 110.794 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.438 HG21 HD13 ' B' ' 17' ' ' ILE . 13.5 p -124.81 -44.88 1.92 Allowed 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.394 1.478 . . . . 0.0 113.943 -168.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.22 10.58 0.74 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.587 1.155 . . . . 0.0 113.093 170.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.78 -150.59 51.48 Favored Glycine 0 CA--C 1.528 0.869 0 O-C-N 120.493 -1.38 . . . . 0.0 111.294 -173.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 27.9 p -61.39 -7.29 2.87 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 117.196 2.295 . . . . 0.0 117.196 -169.149 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -88.44 -12.98 41.56 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 119.547 1.067 . . . . 0.0 113.784 170.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.3 t -124.09 -36.33 2.71 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.465 1.03 . . . . 0.0 111.853 173.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -69.07 86.94 0.38 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 166.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -47.68 120.95 6.33 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 126.736 2.112 . . . . 0.0 114.353 -166.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -67.46 126.42 14.85 Favored 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.625 2.217 . . . . 0.0 111.598 -173.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 59.65 60.96 2.08 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 164.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -45.22 109.95 0.21 Allowed 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.667 1.587 . . . . 0.0 112.746 -178.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.4 p-10 -135.5 55.33 12.56 Favored Pre-proline 0 CA--C 1.546 0.795 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -169.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -62.56 -16.16 50.59 Favored 'Trans proline' 0 C--N 1.354 0.836 0 C-N-CA 122.447 2.098 . . . . 0.0 112.495 170.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.7 mt -78.04 -7.18 56.58 Favored 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 169.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.3 t 64.98 56.18 1.08 Allowed 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.995 1.718 . . . . 0.0 112.412 170.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtm-85 -120.45 172.41 7.84 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 116.061 1.874 . . . . 0.0 116.061 -167.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.61 153.2 37.43 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 128.561 2.744 . . . . 0.0 109.944 168.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -74.42 151.24 39.67 Favored 'General case' 0 CA--C 1.541 0.598 0 O-C-N 120.807 -1.183 . . . . 0.0 113.551 171.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.421 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.96 -123.64 2.07 Favored Glycine 0 C--N 1.34 0.77 0 CA-C-O 118.728 -1.04 . . . . 0.0 113.499 166.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.417 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 119.9 -48.79 0.92 Allowed Glycine 0 CA--C 1.546 1.985 0 N-CA-C 117.758 1.863 . . . . 0.0 117.758 179.201 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -87.29 9.36 3.94 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.508 2.805 . . . . 0.0 114.131 178.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.6 pttt -165.15 -27.05 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 126.256 1.822 . . . . 0.0 112.263 179.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.421 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.1 OUTLIER -83.57 161.09 21.29 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 128.618 2.767 . . . . 0.0 109.406 166.104 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -95.64 -17.98 20.9 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 125.591 1.556 . . . . 0.0 112.334 -172.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -95.19 -68.34 0.81 Allowed 'General case' 0 C--O 1.231 0.105 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -167.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.521 HH22 HG23 ' A' ' 104' ' ' ILE . 63.4 ttt-85 68.36 125.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 123.191 1.472 . . . . 0.0 111.24 -176.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -66.09 169.96 6.29 Favored 'General case' 0 CA--C 1.554 1.098 0 O-C-N 119.1 -2.25 . . . . 0.0 111.86 167.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.3 t -68.17 -50.47 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 O-C-N 120.684 -1.26 . . . . 0.0 108.665 176.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.33 92.76 1.83 Allowed Glycine 0 CA--C 1.529 0.918 0 N-CA-C 107.651 -2.179 . . . . 0.0 107.651 165.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -157.42 143.72 17.84 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.471 1.509 . . . . 0.0 112.558 171.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.99 177.63 7.75 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 127.489 2.316 . . . . 0.0 107.243 168.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.2 -126.34 1.11 Allowed Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.331 1.443 . . . . 0.0 113.908 -173.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 38.2 p-10 -144.61 164.31 31.31 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -175.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 26.8 m -136.44 123.39 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.491 1.117 . . . . 0.0 111.703 -169.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 m -98.53 141.34 31.5 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.305 1.042 . . . . 0.0 108.706 171.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 95' ' ' ALA . . . -97.29 156.03 16.61 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 172.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.58 158.58 24.34 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.306 1.842 . . . . 0.0 107.876 165.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -50.06 -21.7 1.35 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.208 2.203 . . . . 0.0 116.605 177.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -78.09 4.21 12.98 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 125.199 1.4 . . . . 0.0 111.963 172.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.08 12.22 82.75 Favored Glycine 0 C--O 1.225 -0.441 0 C-N-CA 126.847 2.165 . . . . 0.0 114.24 176.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -105.73 122.66 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 CA-C-N 119.114 1.457 . . . . 0.0 112.357 -178.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 89' ' ' ALA . . . -91.91 95.85 10.05 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 125.277 1.431 . . . . 0.0 109.948 169.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -79.48 127.32 31.98 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.62 1.568 . . . . 0.0 109.673 175.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.1 p -134.68 144.69 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -171.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.2 t -156.69 115.88 3.42 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.656 1.182 . . . . 0.0 111.556 173.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.6 mt -139.56 158.5 27.69 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 128.918 2.887 . . . . 0.0 109.986 -173.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -135.47 136.2 41.1 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 124.975 1.31 . . . . 0.0 108.114 167.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -148.69 134.12 18.57 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.566 1.146 . . . . 0.0 110.628 -167.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.6 p -106.91 45.81 0.96 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.93 18.13 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.782 1.233 . . . . 0.0 110.919 -175.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.521 HG23 HH22 ' A' ' 79' ' ' ARG . 0.2 OUTLIER -146.91 154.95 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 128.433 2.693 . . . . 0.0 106.334 164.996 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.566 ' H ' ' HB3' ' A' ' 111' ' ' SER . 76.5 p -157.67 161.7 38.6 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.775 1.23 . . . . 0.0 110.839 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -88.05 86.19 7.08 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.0 t -113.74 -4.16 13.43 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.898 1.279 . . . . 0.0 113.75 -172.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.2 -47.33 1.49 Allowed Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.046 -0.864 . . . . 0.0 113.588 -177.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 36.2 p-10 -142.09 -51.24 0.4 Allowed 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.913 1.82 . . . . 0.0 115.913 -169.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.97 -8.82 59.24 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 126.069 1.747 . . . . 0.0 112.922 -166.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.566 ' HB3' ' H ' ' A' ' 105' ' ' SER . 69.0 m -134.03 -109.67 0.22 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.623 1.169 . . . . 0.0 109.343 -174.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.4 pt -117.35 169.79 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 122.033 0.921 . . . . 0.0 108.754 166.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 108.4 132.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.071 1 C-N-CA 134.974 5.31 . . . . 0.0 106.384 -165.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.95 -3.23 1.63 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 116.174 1.229 . . . . 0.0 116.174 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.436 ' HB3' HD12 ' A' ' 149' ' ' ILE . 46.7 ttm-85 -78.95 171.63 14.94 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.744 1.218 . . . . 0.0 110.316 -172.167 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.5 t -116.53 162.38 17.68 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.113 1.365 . . . . 0.0 110.275 -178.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.93 131.52 18.82 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.694 1.598 . . . . 0.0 109.239 178.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 82.4 t -116.21 133.97 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 125.138 1.375 . . . . 0.0 108.693 175.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.411 HG23 ' HB3' ' A' ' 144' ' ' LEU . 30.8 m -103.2 155.09 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 168.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.37 130.92 41.32 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.655 1.182 . . . . 0.0 109.917 -168.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -58.48 -18.44 28.9 Favored 'General case' 0 CA--C 1.549 0.935 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.1 mmtm -128.73 168.06 16.37 Favored 'General case' 0 N--CA 1.479 0.99 0 O-C-N 118.66 -2.525 . . . . 0.0 115.063 -171.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -48.64 136.18 13.67 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 126.379 1.872 . . . . 0.0 111.68 173.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -122.72 146.95 47.03 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 124.664 2.174 . . . . 0.0 113.47 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.84 -29.24 55.81 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 112.563 -2.108 . . . . 0.0 113.673 -166.045 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.4 mt 35.13 58.45 0.77 Allowed 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 128.376 2.67 . . . . 0.0 111.274 176.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 145.15 -101.31 0.24 Allowed Glycine 0 C--N 1.334 0.431 0 C-N-CA 125.117 1.341 . . . . 0.0 110.869 -172.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -156.7 121.97 4.68 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 126.65 1.98 . . . . 0.0 112.042 -167.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.83 -90.38 1.8 Allowed Glycine 0 N--CA 1.467 0.734 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 176.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.3 2.89 2.64 Favored Glycine 0 N--CA 1.472 1.098 0 C-N-CA 125.362 1.458 . . . . 0.0 115.306 179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -120.95 161.93 20.75 Favored 'General case' 0 N--CA 1.463 0.187 0 C-N-CA 124.454 1.102 . . . . 0.0 113.116 -169.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -60.23 -55.87 28.42 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.527 1.156 . . . . 0.0 108.807 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -57.74 -7.33 0.67 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.453 1.901 . . . . 0.0 114.579 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.7 p -68.01 -48.52 65.49 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.917 1.235 . . . . 0.0 112.342 171.21 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 64.7 p -83.51 -26.87 29.81 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.344 0.658 . . . . 0.0 112.311 176.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 mtpm? -75.55 -60.56 2.25 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 178.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.1 p -104.35 -45.23 4.73 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 119.983 1.265 . . . . 0.0 113.706 178.185 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 125.26 7.99 5.65 Favored Glycine 0 CA--C 1.524 0.653 0 C-N-CA 126.214 1.864 . . . . 0.0 113.103 -168.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 56.97 21.66 6.45 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 170.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.47 26.42 0.02 OUTLIER 'General case' 0 CA--C 1.568 1.646 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -169.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.97 -40.79 2.13 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 128.581 2.991 . . . . 0.0 115.894 169.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.4 m -171.23 -150.13 0.06 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 126.028 1.731 . . . . 0.0 110.61 -175.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.468 ' HD3' ' H ' ' A' ' 143' ' ' ARG . 0.0 OUTLIER -114.3 -163.44 0.87 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.815 1.646 . . . . 0.0 109.878 170.458 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.411 ' HB3' HG23 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -171.67 -155.27 0.1 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 128.112 2.565 . . . . 0.0 107.92 179.395 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.93 145.98 28.24 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.302 1.441 . . . . 0.0 111.189 174.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.6 p -128.11 147.58 50.55 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.317 179.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.27 174.72 32.65 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 116.043 1.177 . . . . 0.0 116.043 -172.004 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.0 t -143.26 154.38 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 C-N-CA 124.575 1.15 . . . . 0.0 110.827 -170.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' A' ' 115' ' ' ARG . 41.8 mt -89.53 116.68 31.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 126.217 1.807 . . . . 0.0 115.086 -170.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' B' ' 114' ' ' GLY . . . -98.99 -179.01 31.81 Favored Glycine 0 CA--C 1.531 1.094 0 C-N-CA 127.393 2.425 . . . . 0.0 112.937 167.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -144.8 138.67 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 CA-C-N 119.059 1.43 . . . . 0.0 114.258 -174.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.457 ' HB2' ' HA2' ' B' ' 51' ' ' GLY . . . -105.06 -35.5 7.61 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.083 1.142 . . . . 0.0 114.083 171.421 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 CA--C 1.546 0.823 0 CA-C-O 122.725 1.25 . . . . 0.0 111.409 -170.376 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.802 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 40.0 p -74.38 110.96 9.09 Favored 'General case' 0 CA--C 1.512 -0.492 0 C-N-CA 125.731 1.612 . . . . 0.0 108.222 -172.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.1 mtmm -100.7 140.91 34.31 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -171.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.86 170.04 9.86 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.489 2.316 . . . . 0.0 111.485 173.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.38 145.79 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.393 1.877 . . . . 0.0 111.839 -175.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.36 139.09 33.0 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 123.846 0.858 . . . . 0.0 109.0 165.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.3 79.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 121.44 0.638 . . . . 0.0 109.967 169.116 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.8 mp -82.87 139.66 33.33 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . 0.492 ' HE3' ' HA3' ' A' ' 10' ' ' GLY . 5.7 ttpt -154.7 157.98 38.89 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 171.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.59 173.8 19.72 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 107.256 -2.337 . . . . 0.0 107.256 164.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -79.27 55.45 1.87 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.616 1.966 . . . . 0.0 111.047 172.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.9 -164.02 32.53 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.433 1.492 . . . . 0.0 112.454 -168.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.44 45.31 1.82 Allowed 'Trans proline' 0 CA--C 1.539 0.736 1 C-N-CA 125.933 4.422 . . . . 0.0 114.497 -168.193 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.453 HG11 HD23 ' B' ' 144' ' ' LEU . 3.4 t -133.75 132.75 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 177.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -156.48 164.19 38.53 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 124.747 1.219 . . . . 0.0 110.811 -169.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -149.39 106.2 0.32 Allowed Glycine 0 N--CA 1.462 0.399 0 C-N-CA 125.326 1.441 . . . . 0.0 110.757 176.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 54' ' ' THR 0.262 0.1 OUTLIER -118.03 103.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -170.031 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 21.6 mm -121.48 120.97 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.168 0.987 . . . . 0.0 110.324 -168.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.79 138.92 38.43 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.716 0.807 . . . . 0.0 111.65 169.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -120.56 119.03 31.73 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.299 1.44 . . . . 0.0 108.312 169.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -107.68 119.67 40.08 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.128 0.971 . . . . 0.0 111.439 174.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -79.01 95.75 5.58 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 168.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.27 -20.17 62.26 Favored 'General case' 0 N--CA 1.475 0.816 0 O-C-N 120.551 -1.343 . . . . 0.0 112.927 175.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -156.41 127.23 6.81 Favored 'General case' 0 C--O 1.216 -0.666 0 C-N-CA 124.328 1.051 . . . . 0.0 112.635 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 7.4 m -60.91 -21.34 63.27 Favored 'General case' 0 N--CA 1.48 1.056 0 N-CA-C 116.232 1.938 . . . . 0.0 116.232 -169.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -115.09 1.24 13.86 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.161 2.184 . . . . 0.0 112.191 175.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.2 -157.53 10.81 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.541 2.02 . . . . 0.0 111.927 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.87 165.89 25.9 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.942 2.428 . . . . 0.0 113.283 -170.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.5 t -116.55 137.92 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 126.349 1.86 . . . . 0.0 108.897 174.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -92.51 129.12 38.54 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 123.82 0.848 . . . . 0.0 109.225 167.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -114.99 125.57 72.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 C-N-CA 125.669 1.588 . . . . 0.0 109.093 175.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -151.7 154.63 36.7 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.872 0.869 . . . . 0.0 110.985 174.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.96 178.5 18.88 Favored Glycine 0 N--CA 1.462 0.395 0 CA-C-O 122.439 1.022 . . . . 0.0 113.7 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . 0.4 ' HB2' ' CG2' ' B' ' 94' ' ' VAL . 23.5 p -114.13 140.18 48.72 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 115.821 1.785 . . . . 0.0 115.821 -164.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.16 108.1 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 125.701 1.6 . . . . 0.0 108.869 169.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -119.26 147.61 44.07 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 124.31 1.044 . . . . 0.0 109.994 -171.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.8 19.36 29.45 Favored Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.563 1.554 . . . . 0.0 111.531 -170.351 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 71.5 mt -92.35 -171.49 2.81 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.513 1.925 . . . . 0.0 108.717 167.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.48 150.99 48.38 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 130.404 3.482 . . . . 0.0 105.178 167.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -50.21 -9.6 0.05 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 129.61 3.164 . . . . 0.0 116.785 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -63.88 163.26 33.58 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.385 -1.447 . . . . 0.0 112.233 168.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -57.74 142.94 43.71 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 126.0 1.72 . . . . 0.0 111.18 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -131.32 128.39 39.65 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.356 1.062 . . . . 0.0 110.419 169.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.417 ' HA3' ' HB2' ' B' ' 124' ' ' ASP . . . -69.76 154.86 53.13 Favored Glycine 0 N--CA 1.47 0.965 0 CA-C-O 118.333 -1.26 . . . . 0.0 112.439 177.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -149.06 124.08 10.04 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 119.466 1.633 . . . . 0.0 112.033 -169.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -156.44 158.81 37.94 Favored 'General case' 0 C--O 1.238 0.474 0 O-C-N 120.415 -1.428 . . . . 0.0 112.773 178.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.9 m -101.15 126.79 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.012 1.325 . . . . 0.0 108.746 177.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.9 m-70 -76.8 177.7 7.42 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 122.73 1.253 . . . . 0.0 110.991 -178.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -62.91 154.75 29.29 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 162.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.54 -135.74 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 122.05 0.928 . . . . 0.0 112.011 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.457 ' HA2' ' HB2' ' A' ' 152' ' ' ALA . . . 91.65 -109.43 3.73 Favored Glycine 0 CA--C 1.495 -1.167 0 C-N-CA 123.889 0.757 . . . . 0.0 111.966 168.322 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.32 58.76 0.86 Allowed 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 127.081 2.152 . . . . 0.0 105.666 -174.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.489 ' ND2' ' H ' ' B' ' 53' ' ' ASN . 0.0 OUTLIER -62.15 -2.86 1.06 Allowed 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 116.376 1.991 . . . . 0.0 116.376 -165.902 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.524 ' HA ' HG13 ' A' ' 7' ' ' VAL 0.343 0.6 OUTLIER . . . . . 0 N--CA 1.468 0.427 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -164.2 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.579 0 CA-C-O 120.826 0.346 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.75 131.44 27.26 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 123.955 0.788 . . . . 0.0 112.5 175.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.0 114.05 2.84 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.759 2.306 . . . . 0.0 107.125 169.1 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.417 ' CE1' ' ND1' ' B' ' 71' ' ' HIS 0.27 0.0 OUTLIER 48.04 78.34 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.57 1.948 . . . . 0.0 114.125 -178.336 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -39.65 116.3 0.61 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.861 1.264 . . . . 0.0 110.559 169.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . 0.265 0.1 OUTLIER -122.41 73.37 40.32 Favored Pre-proline 0 CA--C 1.544 0.719 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -170.046 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -64.99 -24.78 59.84 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.821 2.347 . . . . 0.0 114.122 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.17 -6.43 56.54 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.077 0.951 . . . . 0.0 113.114 174.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.9 t 56.96 52.84 8.72 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.265 1.426 . . . . 0.0 113.508 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 mtp180 -109.34 179.1 4.25 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.662 1.185 . . . . 0.0 114.047 -169.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.97 175.44 9.07 Favored 'General case' 0 CA--C 1.548 0.885 0 O-C-N 120.591 -1.318 . . . . 0.0 108.633 162.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.417 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 83.6 t60 -110.85 152.47 26.64 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -167.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.488 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.35 -128.89 3.52 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-O 118.663 -1.076 . . . . 0.0 113.881 165.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 153.5 -40.05 0.69 Allowed Glycine 0 CA--C 1.546 1.969 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 176.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -112.23 29.99 0.03 OUTLIER 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 125.041 3.827 . . . . 0.0 111.608 169.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -158.93 -53.03 0.06 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 127.745 2.418 . . . . 0.0 106.332 -178.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 8.8 t0 -85.3 155.46 21.34 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.917 1.687 . . . . 0.0 108.865 163.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -103.93 -17.25 15.08 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.467 1.507 . . . . 0.0 112.34 172.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -74.44 -39.52 62.52 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 120.807 -1.183 . . . . 0.0 112.334 -170.594 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt85 33.28 90.92 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 127.33 2.252 . . . . 0.0 114.79 168.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.3 m80 -47.62 159.03 0.17 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.031 1.333 . . . . 0.0 112.511 178.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.8 m -71.08 87.29 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 119.063 0.847 . . . . 0.0 110.235 172.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.87 39.15 0.18 Allowed Glycine 0 CA--C 1.529 0.967 0 C-N-CA 126.361 1.934 . . . . 0.0 114.553 -173.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -134.33 118.08 17.09 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 125.466 1.506 . . . . 0.0 109.913 -173.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -105.66 -179.24 3.88 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.936 0.894 . . . . 0.0 109.44 169.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.41 -134.75 3.35 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 122.214 0.897 . . . . 0.0 112.455 179.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . 0.474 HD22 HD11 ' B' ' 126' ' ' LEU . 2.2 m-80 -112.75 142.2 45.67 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.723 0.809 . . . . 0.0 110.611 170.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 17.9 m -109.02 92.79 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 126.69 1.996 . . . . 0.0 109.104 173.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.5 m -82.53 132.29 35.2 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 173.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.37 171.62 8.93 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -83.83 162.72 20.48 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.118 1.367 . . . . 0.0 107.351 164.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.434 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -57.14 -14.84 4.44 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 172.217 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -72.3 -13.66 61.55 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 125.763 1.625 . . . . 0.0 111.71 172.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.51 4.53 67.94 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.015 1.769 . . . . 0.0 113.294 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . 0.4 ' CG2' ' HB2' ' B' ' 34' ' ' SER . 7.1 p -102.73 130.23 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 125.565 1.546 . . . . 0.0 113.788 177.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.82 108.41 19.9 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 165.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -98.61 113.66 25.8 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.102 0.953 . . . . 0.0 110.76 175.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -93.47 156.23 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 125.33 1.452 . . . . 0.0 113.807 -169.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.0 p -156.87 117.83 3.68 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.935 1.294 . . . . 0.0 111.098 173.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.7 mt -146.1 150.81 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 C-N-CA 128.78 2.832 . . . . 0.0 109.906 -176.225 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 -137.57 131.11 31.18 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.371 1.468 . . . . 0.0 107.57 168.101 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -155.4 152.19 28.76 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.901 1.074 . . . . 0.0 113.901 -168.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 86.3 p -116.49 59.34 0.74 Allowed 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 125.977 1.711 . . . . 0.0 114.184 -167.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 p -147.26 -2.61 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 116.357 1.984 . . . . 0.0 116.357 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.36 168.65 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 125.5 1.52 . . . . 0.0 110.785 177.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.439 ' H ' ' HB3' ' B' ' 111' ' ' SER . 57.9 p -147.97 170.42 17.75 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 115.571 1.693 . . . . 0.0 115.571 178.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mp -102.92 48.03 0.87 Allowed 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 168.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.3 m -85.27 33.66 0.56 Allowed 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.569 -1.332 . . . . 0.0 112.405 -176.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 87.97 65.77 1.33 Allowed Glycine 0 N--CA 1.469 0.862 0 C-N-CA 124.158 0.885 . . . . 0.0 112.767 176.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.315 0.0 OUTLIER 76.78 -21.74 0.31 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 127.673 2.389 . . . . 0.0 114.334 170.176 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -77.52 11.66 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 127.322 2.249 . . . . 0.0 112.886 -173.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . 0.439 ' HB3' ' H ' ' B' ' 105' ' ' SER . 0.6 OUTLIER -142.02 -72.2 0.33 Allowed 'General case' 0 CA--C 1.544 0.743 0 N-CA-C 116.512 2.041 . . . . 0.0 116.512 170.471 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.94 0.7 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 116.016 1.858 . . . . 0.0 116.016 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.6 mm -89.12 149.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 168.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' A' ' 150' ' ' GLY . . . 77.72 6.78 87.19 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 114.561 0.585 . . . . 0.0 114.561 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.8 ttt180 -115.31 179.28 4.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.989 2.116 . . . . 0.0 111.462 -168.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.83 151.39 37.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 C-N-CA 124.034 0.934 . . . . 0.0 111.124 177.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 19.5 tp -128.31 140.91 51.61 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 127.13 2.172 . . . . 0.0 106.572 167.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.37 156.38 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 124.362 1.065 . . . . 0.0 110.592 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -125.87 134.04 67.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-O 122.514 1.149 . . . . 0.0 110.697 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -92.34 145.85 24.15 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.426 1.49 . . . . 0.0 112.258 -168.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -67.62 -39.92 84.69 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 121.086 -1.009 . . . . 0.0 111.996 -174.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -98.69 -179.99 4.49 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.582 1.153 . . . . 0.0 109.962 167.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.59 165.49 0.83 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.697 1.199 . . . . 0.0 111.541 168.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.417 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 26.0 t70 -107.87 148.25 29.84 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.739 0.78 . . . . 0.0 110.662 165.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.73 -20.81 45.54 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.595 1.958 . . . . 0.0 114.807 -169.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.474 HD11 HD22 ' B' ' 86' ' ' ASN . 8.9 mt 41.61 49.02 3.65 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 126.238 1.815 . . . . 0.0 113.993 169.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 135.71 -78.56 0.34 Allowed Glycine 0 N--CA 1.469 0.839 0 C-N-CA 124.894 1.235 . . . . 0.0 111.288 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.86 148.4 22.42 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 117.585 2.439 . . . . 0.0 117.585 170.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -157.67 -79.5 0.03 OUTLIER Glycine 0 C--N 1.332 0.315 0 C-N-CA 130.287 3.803 . . . . 0.0 106.901 171.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.6 -92.87 0.02 OUTLIER Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.056 1.789 . . . . 0.0 115.955 -169.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -131.03 -127.54 0.2 Allowed 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.169 -1.195 . . . . 0.0 113.03 -166.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.32 -53.78 4.08 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.292 3.037 . . . . 0.0 109.949 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -43.46 -33.64 1.14 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 128.3 2.64 . . . . 0.0 114.03 169.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.8 m -45.33 -36.43 4.15 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 126.639 1.975 . . . . 0.0 113.702 168.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -103.3 -20.27 14.16 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 126.126 1.77 . . . . 0.0 113.886 -173.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 41.9 mtpt -80.6 -36.5 32.67 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.053 0.941 . . . . 0.0 110.745 170.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 20.0 p -135.95 -108.88 0.2 Allowed 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 127.324 2.249 . . . . 0.0 107.953 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -165.94 148.18 13.35 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 127.597 2.522 . . . . 0.0 108.151 169.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -75.42 45.56 0.3 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.54 1.536 . . . . 0.0 112.572 -172.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.51 6.24 24.38 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -167.015 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.61 -47.29 0.42 Allowed Glycine 0 CA--C 1.536 1.39 0 N-CA-C 118.948 2.339 . . . . 0.0 118.948 168.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -175.31 -176.93 0.97 Allowed 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.547 1.674 . . . . 0.0 112.406 -169.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.29 142.43 19.29 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.978 1.311 . . . . 0.0 111.591 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.453 HD23 HG11 ' B' ' 14' ' ' VAL . 0.0 OUTLIER -103.74 -20.7 13.86 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.706 1.203 . . . . 0.0 114.123 -176.218 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.449 ' N ' HD22 ' B' ' 144' ' ' LEU . . . -155.56 147.05 22.87 Favored 'General case' 0 C--O 1.244 0.775 0 C-N-CA 124.486 1.114 . . . . 0.0 109.195 -178.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 63.3 m -138.99 149.18 44.4 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 127.936 2.494 . . . . 0.0 108.774 -179.015 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.71 160.03 29.98 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 115.421 0.929 . . . . 0.0 115.421 -174.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 5.2 t -109.56 152.15 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.189 1.396 . . . . 0.0 109.789 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.3 mm -94.72 116.78 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 126.081 1.753 . . . . 0.0 112.07 -174.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.16 165.48 15.13 Favored Glycine 0 C--N 1.348 1.237 0 C-N-CA 124.358 0.98 . . . . 0.0 112.503 177.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -117.7 124.89 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.505 ' CA ' ' HA2' ' A' ' 51' ' ' GLY . . . -79.76 -25.06 41.12 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 121.596 0.712 . . . . 0.0 110.265 165.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 70.0 mt-30 . . . . . 0 CA--C 1.531 0.229 0 C-N-CA 125.74 1.616 . . . . 0.0 109.023 178.347 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 34.7 p . . . . . 0 CA--C 1.507 -0.699 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.4 ttmm -101.89 125.95 48.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.014 -1.903 . . . . 0.0 106.315 168.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.57 159.85 41.21 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 125.116 1.367 . . . . 0.0 111.325 -169.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.6 t -139.65 143.42 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.438 1.113 . . . . 0.0 112.907 -169.001 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.2 111.72 14.92 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 164.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.614 ' CG2' ' H ' ' B' ' 54' ' ' THR . 6.8 m -97.27 112.29 28.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 168.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.7 mp -96.87 107.61 20.14 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.529 1.132 . . . . 0.0 111.021 -168.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -155.29 124.4 6.23 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 121.782 0.801 . . . . 0.0 112.865 173.226 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.63 -41.34 0.02 OUTLIER Glycine 0 CA--C 1.53 0.985 0 C-N-CA 127.898 2.666 . . . . 0.0 109.478 167.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -79.26 59.37 2.79 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 128.337 2.655 . . . . 0.0 112.55 -174.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.96 -104.25 0.06 OUTLIER Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.867 2.175 . . . . 0.0 114.232 171.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.04 -9.6 14.13 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 124.656 3.571 . . . . 0.0 114.621 -175.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.6 t -90.41 138.69 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-N 120.448 1.476 . . . . 0.0 108.325 171.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -156.82 164.81 37.66 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.018 1.327 . . . . 0.0 109.944 169.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.04 174.02 34.64 Favored Glycine 0 CA--C 1.507 -0.42 0 C-N-CA 124.329 0.966 . . . . 0.0 111.432 167.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 pp -127.52 142.15 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 C-N-CA 124.533 1.133 . . . . 0.0 108.356 168.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -130.19 133.83 63.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.708 . . . . 0.0 109.201 170.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -103.23 141.58 35.65 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 110.095 169.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -124.87 119.68 29.52 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.612 1.565 . . . . 0.0 108.24 171.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -115.85 119.33 35.64 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.346 1.459 . . . . 0.0 110.561 -175.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -129.62 141.83 50.86 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 123.506 1.622 . . . . 0.0 113.802 -174.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HE2' ' OE2' ' A' ' 24' ' ' GLU . 15.0 ptmt -82.93 -62.7 1.53 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.742 2.017 . . . . 0.0 114.189 -171.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.478 ' OE2' ' HE2' ' A' ' 23' ' ' LYS . 3.7 pm0 -133.48 172.81 12.22 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 126.215 1.806 . . . . 0.0 110.668 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 p -45.06 -54.03 7.17 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.37 1.868 . . . . 0.0 115.434 -168.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -96.2 7.75 45.63 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.795 1.638 . . . . 0.0 111.73 -178.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.24 150.46 37.11 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 125.27 1.414 . . . . 0.0 113.627 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -63.66 162.85 26.48 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 123.996 3.131 . . . . 0.0 110.373 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -129.86 130.76 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 C-N-CA 123.346 0.658 . . . . 0.0 110.046 -169.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -91.15 131.81 36.47 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 167.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.7 t -124.24 137.79 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 125.567 1.547 . . . . 0.0 109.132 -173.014 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.4 p90 -157.29 168.66 26.74 Favored 'General case' 0 N--CA 1.471 0.624 0 O-C-N 121.276 -0.89 . . . . 0.0 113.286 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.34 -157.68 27.35 Favored Glycine 0 C--N 1.335 0.498 0 C-N-CA 125.173 1.368 . . . . 0.0 111.204 170.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.5 p -155.5 147.5 23.44 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -122.07 122.19 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 -177.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 59.8 tttt -120.81 133.44 55.32 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.317 1.047 . . . . 0.0 110.579 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.26 4.29 16.14 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.931 2.205 . . . . 0.0 112.645 -168.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 98.0 mt -82.89 163.38 21.16 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 118.201 1.0 . . . . 0.0 111.467 169.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.9 t -96.81 145.65 25.64 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 126.038 1.735 . . . . 0.0 107.475 165.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.486 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.8 pm0 -51.19 143.35 11.14 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.196 2.598 . . . . 0.0 114.739 -173.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.76 -179.81 34.42 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 125.012 1.292 . . . . 0.0 113.464 -172.159 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -56.73 151.28 14.39 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 128.058 2.543 . . . . 0.0 113.555 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -147.96 138.82 23.22 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.905 1.682 . . . . 0.0 109.411 167.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.67 154.91 20.9 Favored Glycine 0 N--CA 1.48 1.604 0 C-N-CA 124.051 0.834 . . . . 0.0 113.115 172.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -158.58 95.37 1.32 Allowed 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 124.423 1.089 . . . . 0.0 112.262 -170.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -146.14 148.92 33.09 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.262 1.579 . . . . 0.0 115.262 -169.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -82.76 110.97 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.95 1.7 . . . . 0.0 110.186 171.517 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -82.65 165.97 19.56 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.795 2.038 . . . . 0.0 110.793 176.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -59.96 145.11 47.26 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 122.35 1.071 . . . . 0.0 111.469 -176.184 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -82.53 -114.93 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.709 1.604 . . . . 0.0 111.739 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.5 -96.06 1.73 Allowed Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -143.92 54.68 1.31 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 -172.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.407 HD21 ' CG2' ' A' ' 148' ' ' VAL 0.29 7.3 p-10 -73.39 27.98 0.07 Allowed 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.627 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.774 HG22 ' HA ' ' B' ' 7' ' ' VAL . 8.4 p -90.36 -7.37 53.42 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.352 1.461 . . . . 0.0 113.772 -168.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.19 -4.23 35.93 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.057 1.743 . . . . 0.0 112.97 168.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.92 -101.52 0.27 Allowed Glycine 0 C--N 1.343 0.941 0 CA-C-N 120.056 1.298 . . . . 0.0 112.519 170.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.4 m -54.83 -17.88 4.12 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 175.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.03 7.07 23.5 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.297 1.439 . . . . 0.0 113.521 175.267 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.4 t -171.85 98.0 0.17 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.94 1.696 . . . . 0.0 108.342 178.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 149.6 58.86 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 130.559 3.544 . . . . 0.0 111.687 -169.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -61.84 147.96 48.08 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 126.279 1.895 . . . . 0.0 114.123 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.77 95.17 0.54 Allowed 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 124.796 3.664 . . . . 0.0 113.765 -168.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 p80 42.95 68.2 0.53 Allowed 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 126.517 1.927 . . . . 0.0 112.485 166.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -39.28 142.87 0.22 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-O 124.009 1.861 . . . . 0.0 115.085 -167.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 38.9 p-10 -104.41 48.95 0.08 OUTLIER Pre-proline 0 CA--C 1.554 1.121 0 C-N-CA 127.11 2.164 . . . . 0.0 114.352 -177.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -69.77 -15.81 37.22 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 121.941 1.729 . . . . 0.0 112.473 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.68 -3.16 42.72 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.769 1.628 . . . . 0.0 112.325 169.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.1 t 69.97 57.72 0.29 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.662 1.585 . . . . 0.0 113.029 168.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 ptm85 -152.6 176.41 11.75 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -169.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -91.24 168.17 11.79 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.35 1.46 . . . . 0.0 112.705 -179.001 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.6 t60 -75.95 160.56 29.76 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.427 1.091 . . . . 0.0 113.512 179.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.419 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 136.41 -113.64 1.08 Allowed Glycine 0 C--N 1.339 0.713 0 C-N-CA 125.392 1.472 . . . . 0.0 112.315 166.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.488 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 116.93 -56.52 0.54 Allowed Glycine 0 CA--C 1.537 1.449 0 N-CA-C 117.742 1.857 . . . . 0.0 117.742 171.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -81.24 -16.69 9.52 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 CA-C-N 121.54 2.67 . . . . 0.0 112.505 178.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.51 -5.73 4.2 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.804 1.242 . . . . 0.0 112.893 173.104 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.5 169.3 8.75 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.462 1.505 . . . . 0.0 110.377 178.072 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -101.08 -7.07 23.54 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 127.083 2.153 . . . . 0.0 112.729 -167.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -127.35 -82.94 0.61 Allowed 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 119.597 1.09 . . . . 0.0 113.583 -171.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 79.12 140.55 0.07 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 126.289 1.836 . . . . 0.0 113.546 170.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -82.95 -177.77 6.88 Favored 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 116.361 1.986 . . . . 0.0 116.361 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -66.97 -12.13 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 174.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -134.81 14.03 4.43 Favored Glycine 0 CA--C 1.531 1.085 0 CA-C-O 118.161 -1.355 . . . . 0.0 116.31 -171.014 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -92.84 112.6 24.62 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.654 1.727 . . . . 0.0 111.275 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.4 48.72 1.38 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 120.101 1.319 . . . . 0.0 111.874 177.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.94 -143.98 24.65 Favored Glycine 0 CA--C 1.536 1.367 0 O-C-N 121.211 -0.931 . . . . 0.0 114.93 172.161 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -131.95 158.07 42.38 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 126.184 1.793 . . . . 0.0 112.883 -179.385 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.7 m -114.17 106.74 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.165 1.786 . . . . 0.0 111.001 169.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.4 m -106.49 115.61 30.5 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.599 1.56 . . . . 0.0 110.229 -169.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.13 147.79 24.74 Favored 'General case' 0 CA--C 1.539 0.558 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -172.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -93.96 160.65 14.63 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 128.978 2.911 . . . . 0.0 109.685 168.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.83 -14.9 2.65 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 126.169 1.788 . . . . 0.0 115.698 -175.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.27 -5.3 26.75 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.757 -1.215 . . . . 0.0 112.11 171.318 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.82 15.53 65.28 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 127.008 2.242 . . . . 0.0 112.878 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.0 p -121.33 128.87 76.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.544 1.172 . . . . 0.0 113.699 -170.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.64 110.56 22.66 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 164.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -91.9 137.27 32.5 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 169.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -135.68 149.65 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 N-CA-C 116.801 2.148 . . . . 0.0 116.801 -168.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.9 m -155.21 127.37 7.7 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 126.052 1.741 . . . . 0.0 110.367 169.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 10.1 mm -140.82 166.44 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 129.026 2.93 . . . . 0.0 109.794 -173.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -155.29 154.61 32.38 Favored 'General case' 0 C--N 1.316 -0.87 0 C-N-CA 128.108 2.563 . . . . 0.0 107.825 170.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -155.79 150.99 26.7 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.938 1.295 . . . . 0.0 111.577 170.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -119.03 53.05 1.02 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.521 -1.218 . . . . 0.0 112.225 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 48.9 t -137.81 -43.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.3 1.44 . . . . 0.0 107.928 168.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.87 160.11 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 123.027 1.394 . . . . 0.0 110.93 167.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.53 ' H ' ' HB3' ' A' ' 111' ' ' SER . 3.6 p -156.29 168.87 25.97 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 128.762 2.825 . . . . 0.0 106.969 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -93.25 102.3 14.58 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -152.83 -6.91 0.19 Allowed 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -167.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.13 -95.83 2.13 Favored Glycine 0 C--N 1.336 0.546 0 O-C-N 120.927 -1.108 . . . . 0.0 111.613 173.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -69.97 -51.99 28.07 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.851 0.685 . . . . 0.0 112.851 -166.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -78.92 -27.81 43.78 Favored 'General case' 0 CA--C 1.539 0.547 0 O-C-N 120.271 -1.518 . . . . 0.0 112.358 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.53 ' HB3' ' H ' ' A' ' 105' ' ' SER . 8.2 m -118.88 -127.16 0.28 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.857 1.799 . . . . 0.0 115.857 -164.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.29 39.3 pt -111.03 173.69 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 O-C-N 119.769 -1.832 . . . . 0.0 108.682 166.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mm 90.49 136.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.843 1 C-N-CA 132.757 4.423 . . . . 0.0 107.25 -163.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 58.35 25.2 57.29 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.556 1.074 . . . . 0.0 114.687 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.1 ttm180 -122.17 156.29 34.0 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 126.614 1.965 . . . . 0.0 107.515 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.9 t -113.07 107.62 16.21 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 122.352 2.342 . . . . 0.0 115.694 -165.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 57.0 tp -76.99 128.92 35.39 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.72 0.808 . . . . 0.0 110.266 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -118.04 136.56 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.252 1.021 . . . . 0.0 109.127 169.352 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 m -93.04 144.74 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.384 -1.709 . . . . 0.0 106.384 168.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.7 m-70 -101.98 158.93 15.79 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-O 122.369 1.08 . . . . 0.0 112.987 -170.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -74.71 -35.64 62.71 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 -168.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -125.85 179.98 4.94 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 125.29 1.436 . . . . 0.0 112.597 173.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.25 140.47 38.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 126.683 1.993 . . . . 0.0 112.463 173.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -91.58 131.03 37.28 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.115 0.966 . . . . 0.0 111.057 178.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.419 ' OD1' ' HE3' ' A' ' 128' ' ' LYS . 0.3 OUTLIER -77.09 -18.93 57.65 Favored 'General case' 0 CA--C 1.554 1.118 0 N-CA-C 112.889 0.699 . . . . 0.0 112.889 174.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 41.3 mt 62.08 54.39 2.74 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.946 2.098 . . . . 0.0 113.686 173.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 118.62 -11.23 12.37 Favored Glycine 0 N--CA 1.475 1.246 0 N-CA-C 121.297 3.279 . . . . 0.0 121.297 164.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.541 ' HE3' ' H ' ' A' ' 128' ' ' LYS 0.252 0.0 OUTLIER -167.08 62.11 0.08 Allowed 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 118.192 2.664 . . . . 0.0 118.192 -173.626 . . . . . . . . 4 4 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -106.25 45.68 1.27 Allowed Glycine 0 N--CA 1.471 0.975 0 C-N-CA 127.041 2.257 . . . . 0.0 113.349 -172.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.21 -27.53 1.47 Allowed Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.62 1.105 . . . . 0.0 115.749 172.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -89.77 154.55 19.83 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 118.983 1.391 . . . . 0.0 110.381 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -55.33 -54.14 47.31 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-O 122.751 1.262 . . . . 0.0 109.108 167.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.4 tm-20 -51.89 -34.89 43.26 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 128.447 2.699 . . . . 0.0 112.593 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.0 p -60.03 -34.39 73.3 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.7 p -77.13 -14.37 59.81 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.61 1.164 . . . . 0.0 111.991 179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.3 mtpt -100.15 -53.76 3.05 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.516 1.926 . . . . 0.0 111.891 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.8 p -100.08 -34.42 10.07 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 117.659 -1.162 . . . . 0.0 113.781 -172.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.98 -3.2 28.64 Favored Glycine 0 CA--C 1.533 1.196 0 O-C-N 125.448 1.717 . . . . 0.0 113.715 -168.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.69 25.04 11.28 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 126.193 1.797 . . . . 0.0 112.738 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.82 46.39 0.29 Allowed 'General case' 0 CA--C 1.552 1.049 0 C-N-CA 126.799 2.04 . . . . 0.0 113.755 -168.157 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.04 -59.4 3.54 Favored Glycine 0 N--CA 1.467 0.728 0 C-N-CA 127.987 2.708 . . . . 0.0 113.692 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t 178.09 179.03 0.34 Allowed 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.11 2.164 . . . . 0.0 109.494 -169.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.64 153.66 35.02 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.03 -1.044 . . . . 0.0 111.018 169.75 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -135.14 -150.77 0.4 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.375 1.47 . . . . 0.0 108.63 169.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -52.93 141.96 20.64 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.274 1.43 . . . . 0.0 114.151 -173.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -134.72 154.67 51.46 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.983 1.313 . . . . 0.0 114.361 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.24 125.03 1.55 Allowed Glycine 0 CA--C 1.539 1.562 0 C-N-CA 124.646 1.117 . . . . 0.0 114.557 173.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.407 ' CG2' HD21 ' A' ' 53' ' ' ASN . 2.8 t -78.14 126.58 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 173.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 59.9 mt -78.41 124.51 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -167.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.76 167.97 13.96 Favored Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.847 1.213 . . . . 0.0 115.413 175.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.57 162.82 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 126.438 1.895 . . . . 0.0 113.416 -171.016 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.416 ' HB1' ' CD2' ' B' ' 50' ' ' PHE . . . -158.18 -40.97 0.06 Allowed 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.01 1.324 . . . . 0.0 112.032 169.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.47 0.538 0 C-N-CA 124.226 1.01 . . . . 0.0 112.159 169.096 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 70.9 p -134.08 125.43 28.02 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 166.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.3 mtmt -119.57 158.54 26.13 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -179.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.492 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -144.58 151.99 39.87 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.98 1.312 . . . . 0.0 112.534 169.589 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 p -111.08 133.53 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 125.987 1.715 . . . . 0.0 110.673 177.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.54 110.94 21.3 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.774 -1.204 . . . . 0.0 110.088 167.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 54' ' ' THR . 15.0 t -86.52 68.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 124.36 1.064 . . . . 0.0 112.063 -170.396 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -79.77 110.56 15.24 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 113.426 0.898 . . . . 0.0 113.426 -175.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mttm -157.62 129.55 7.03 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.71 1.204 . . . . 0.0 112.195 167.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.68 -56.9 0.01 OUTLIER Glycine 0 N--CA 1.468 0.772 0 C-N-CA 126.233 1.873 . . . . 0.0 109.885 169.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.58 72.29 3.24 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 125.989 1.715 . . . . 0.0 110.953 -176.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.64 -94.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.377 0 C-N-CA 127.844 2.64 . . . . 0.0 114.746 173.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -71.08 -20.98 28.03 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 123.964 3.109 . . . . 0.0 114.797 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.1 t -74.15 147.65 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 CA-C-N 121.483 1.947 . . . . 0.0 110.491 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.32 167.75 21.2 Favored 'General case' 0 CA--C 1.519 -0.228 0 C-N-CA 124.48 1.112 . . . . 0.0 109.651 167.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.8 59.58 0.4 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.874 169.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -75.41 127.42 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 117.776 0.788 . . . . 0.0 108.987 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.18 119.55 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 O-C-N 125.277 1.61 . . . . 0.0 109.741 176.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.2 121.27 23.41 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 124.915 1.286 . . . . 0.0 110.65 165.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -99.67 94.17 6.22 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.26 1.824 . . . . 0.0 106.135 167.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -98.25 113.66 25.67 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 124.311 1.044 . . . . 0.0 110.349 178.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -113.13 139.01 49.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 122.678 1.228 . . . . 0.0 110.464 179.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.71 -5.05 54.43 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.1 1.36 . . . . 0.0 114.237 -171.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 mp0 -155.75 -168.24 2.73 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 130.078 3.351 . . . . 0.0 106.603 175.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.8 t -89.2 -21.13 23.43 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-N 119.957 1.253 . . . . 0.0 110.135 163.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -109.6 11.32 24.8 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 126.191 1.796 . . . . 0.0 115.232 -176.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.77 -179.75 38.85 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 124.423 1.011 . . . . 0.0 112.834 -177.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.23 161.47 20.23 Favored 'Trans proline' 0 CA--C 1.537 0.654 0 C-N-CA 123.346 2.697 . . . . 0.0 109.421 168.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.01 134.94 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.89 0.876 . . . . 0.0 111.734 -169.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.6 mttp -87.84 126.14 34.86 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 165.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -123.75 89.03 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 127.362 2.265 . . . . 0.0 108.23 -169.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -119.09 156.24 30.08 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.799 0.84 . . . . 0.0 111.815 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.84 176.82 41.71 Favored Glycine 0 C--O 1.225 -0.439 0 O-C-N 121.479 -0.763 . . . . 0.0 113.437 -174.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -127.75 118.78 24.41 Favored 'General case' 0 C--O 1.239 0.543 0 O-C-N 122.054 -0.674 . . . . 0.0 111.948 -178.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.1 mm -92.08 117.8 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 169.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.3 pttt -139.41 137.34 35.58 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 123.185 0.594 . . . . 0.0 110.328 -168.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.29 0.68 54.01 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.871 1.7 . . . . 0.0 114.787 -173.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.464 HD11 ' HB2' ' B' ' 89' ' ' ALA . 0.5 OUTLIER -91.3 -160.35 0.72 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 118.412 1.106 . . . . 0.0 111.304 169.676 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.6 t -112.19 155.99 23.06 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.293 1.837 . . . . 0.0 110.976 178.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -47.65 149.85 1.13 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.625 1.97 . . . . 0.0 111.879 169.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.75 38.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 124.009 0.814 . . . . 0.0 113.726 -178.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -65.87 144.51 56.77 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 128.921 2.888 . . . . 0.0 113.157 -171.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -140.53 124.05 16.97 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 126.608 1.963 . . . . 0.0 110.508 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.5 149.85 35.45 Favored Glycine 0 N--CA 1.476 1.334 0 C-N-CA 124.744 1.164 . . . . 0.0 112.391 176.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -146.52 102.2 3.55 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-O 121.861 0.838 . . . . 0.0 112.404 -164.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -129.45 126.23 38.26 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 120.855 -1.153 . . . . 0.0 110.427 -169.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.79 116.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.296 1.439 . . . . 0.0 108.984 171.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.458 ' C ' ' H ' ' B' ' 50' ' ' PHE . 21.8 m170 -78.86 122.25 25.85 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 121.307 -0.871 . . . . 0.0 110.381 -179.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.65 2.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 127.053 2.141 . . . . 0.0 115.426 170.03 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . 0.458 ' H ' ' C ' ' B' ' 48' ' ' HIS . 2.5 m-85 -137.16 81.51 1.88 Allowed 'General case' 0 N--CA 1.442 -0.839 1 C-N-CA 133.776 4.83 . . . . 0.0 100.94 -176.011 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.05 20.07 35.04 Favored Glycine 0 N--CA 1.467 0.73 0 O-C-N 121.655 -0.653 . . . . 0.0 113.225 173.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -68.99 49.06 0.07 Allowed 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.042 2.537 . . . . 0.0 113.085 171.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -178.74 131.45 0.12 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.414 1.486 . . . . 0.0 111.047 -168.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.614 ' H ' ' CG2' ' A' ' 7' ' ' VAL . 6.6 t . . . . . 0 N--CA 1.478 0.951 0 N-CA-C 116.236 1.939 . . . . 0.0 116.236 175.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.558 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.52 -82.19 0.51 Allowed Glycine 0 CA--C 1.54 1.616 0 C-N-CA 126.842 2.163 . . . . 0.0 112.059 178.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.44 ' HA ' HG22 ' B' ' 137' ' ' THR . 66.9 Cg_endo -85.83 178.14 4.43 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 125.15 3.9 . . . . 0.0 115.139 -172.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -103.4 123.8 47.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.203 1.401 . . . . 0.0 110.796 179.386 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -58.26 146.9 32.47 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 120.789 0.328 . . . . 0.0 110.418 167.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.21 107.73 21.56 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.597 0.759 . . . . 0.0 112.515 -178.179 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -68.81 -30.85 26.4 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.135 1.89 . . . . 0.0 111.844 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -76.98 -7.81 56.28 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.096 0.959 . . . . 0.0 112.709 175.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.7 m 57.76 56.46 4.8 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.627 1.171 . . . . 0.0 111.743 172.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.89 172.69 15.64 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.394 1.478 . . . . 0.0 110.704 -168.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -72.5 176.68 5.19 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 -171.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -49.23 155.09 0.73 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.447 2.017 . . . . 0.0 116.447 -167.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' B' ' 79' ' ' ARG . . . -75.61 69.33 2.07 Favored Glycine 0 N--CA 1.473 1.144 0 C-N-CA 128.892 3.139 . . . . 0.0 114.212 -169.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.46 135.84 13.62 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 114.608 0.603 . . . . 0.0 114.608 -173.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -84.58 -0.95 9.52 Favored 'Trans proline' 0 CA--C 1.548 1.207 0 C-N-CA 123.87 3.047 . . . . 0.0 109.597 163.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.472 ' HE2' ' O ' ' B' ' 125' ' ' ASP . 0.1 OUTLIER -118.37 -10.61 10.15 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.642 1.977 . . . . 0.0 114.167 177.613 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -110.7 149.48 30.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.362 1.065 . . . . 0.0 109.022 -167.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -67.35 -25.53 66.03 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -88.65 146.22 25.21 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-O 125.07 2.367 . . . . 0.0 109.319 169.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.49 ' HA ' ' HA2' ' B' ' 72' ' ' GLY . 52.9 ttt-85 -167.03 106.67 0.6 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 112.545 -2.116 . . . . 0.0 113.293 -174.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -61.59 149.33 39.47 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.401 1.081 . . . . 0.0 109.157 162.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.3 -13.66 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 CA-C-N 120.891 1.678 . . . . 0.0 110.323 166.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.28 18.82 9.37 Favored Glycine 0 C--N 1.336 0.548 0 C-N-CA 127.235 2.35 . . . . 0.0 118.879 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.99 149.43 32.15 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 122.608 3.204 . . . . 0.0 112.917 168.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -107.64 174.95 5.66 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.575 1.55 . . . . 0.0 108.561 168.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.48 155.31 49.79 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 171.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -74.4 146.61 42.8 Favored 'General case' 0 CA--C 1.549 0.941 0 CA-C-O 121.658 0.742 . . . . 0.0 111.825 -170.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -101.21 119.56 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.996 1.719 . . . . 0.0 112.48 -168.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -98.58 126.88 44.3 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.331 1.052 . . . . 0.0 110.283 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.464 ' HB2' HD11 ' B' ' 38' ' ' LEU . . . -92.95 162.13 14.19 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 171.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -85.97 168.99 13.66 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.889 2.075 . . . . 0.0 113.123 170.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.24 61.93 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.644 1.978 . . . . 0.0 114.963 -177.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.35 2.35 18.89 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 125.643 1.577 . . . . 0.0 112.146 177.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.16 21.75 56.32 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 124.936 1.255 . . . . 0.0 113.458 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.13 134.39 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -179.091 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.09 130.3 54.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 124.828 1.251 . . . . 0.0 110.445 166.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -88.27 105.62 17.67 Favored 'General case' 0 C--O 1.232 0.165 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 163.126 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.93 129.9 36.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 114.954 -1.021 . . . . 0.0 108.631 169.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.1 m -146.38 94.21 2.42 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.387 1.075 . . . . 0.0 109.305 -176.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -130.9 159.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 126.346 1.858 . . . . 0.0 110.281 -174.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -139.77 142.2 36.77 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 128.077 2.551 . . . . 0.0 106.584 167.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -151.12 138.15 19.13 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.293 1.037 . . . . 0.0 111.876 -168.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 46.3 p -118.0 50.3 1.16 Allowed 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 177.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 p -147.26 4.64 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 171.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -122.71 160.89 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.576 1.551 . . . . 0.0 107.409 167.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 96.8 p -156.24 168.36 27.55 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 119.49 1.041 . . . . 0.0 113.626 -174.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -92.59 69.07 4.83 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.521 1.528 . . . . 0.0 110.055 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 5.7 m -117.56 160.02 21.92 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.775 1.63 . . . . 0.0 110.727 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 44.98 1.82 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 125.146 1.355 . . . . 0.0 114.468 -168.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -135.54 -84.63 0.39 Allowed 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.872 1.269 . . . . 0.0 110.449 -168.691 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -150.35 -2.82 0.37 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 127.74 2.416 . . . . 0.0 111.773 -176.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 95.0 p -61.09 -44.4 97.42 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.131 1.373 . . . . 0.0 114.11 -169.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 5.3 pt -154.16 -34.35 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 127.678 2.391 . . . . 0.0 111.223 166.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 45.1 mm -60.56 125.37 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 123.866 0.867 . . . . 0.0 108.765 -175.034 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.56 16.23 67.3 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 116.994 -2.003 . . . . 0.0 115.061 -178.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.4 mtm180 -79.62 168.21 19.68 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.841 1.82 . . . . 0.0 109.478 168.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 22.6 m -123.64 117.04 24.1 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.806 0.842 . . . . 0.0 110.31 175.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 37.6 tp -82.23 132.12 35.23 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 169.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -110.91 137.43 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.534 1.534 . . . . 0.0 108.751 165.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 p -109.77 130.36 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.968 0.89 . . . . 0.0 109.417 168.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.539 ' CE1' HH11 ' B' ' 143' ' ' ARG . 21.7 m-70 -99.91 161.12 13.8 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.527 1.131 . . . . 0.0 113.669 -172.167 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -76.42 -25.49 54.52 Favored 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.701 1.371 . . . . 0.0 114.701 -174.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -118.85 176.68 5.16 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 119.667 1.121 . . . . 0.0 112.415 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.71 164.3 2.14 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.151 1.38 . . . . 0.0 111.967 168.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -113.97 145.08 42.03 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.949 1.7 . . . . 0.0 110.546 -178.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . 0.472 ' O ' ' HE2' ' B' ' 75' ' ' LYS . 0.0 OUTLIER -73.95 -35.46 64.55 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-O 118.775 -0.631 . . . . 0.0 111.214 172.38 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 11.6 mt 77.54 24.61 0.77 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.015 2.126 . . . . 0.0 113.481 177.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.83 -78.9 0.06 OUTLIER Glycine 0 N--CA 1.474 1.182 0 CA-C-N 120.47 1.486 . . . . 0.0 116.657 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -156.22 87.67 1.06 Allowed 'General case' 0 N--CA 1.44 -0.925 0 C-N-CA 126.38 1.872 . . . . 0.0 110.93 173.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . 0.566 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -65.64 -10.99 52.24 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 126.836 2.16 . . . . 0.0 114.081 174.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.16 -33.8 2.47 Favored Glycine 0 N--CA 1.47 0.948 0 C-N-CA 124.366 0.984 . . . . 0.0 114.942 168.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.6 p30 -92.79 -177.78 4.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.498 1.519 . . . . 0.0 110.366 -177.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -61.5 -62.66 1.66 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 122.773 0.429 . . . . 0.0 110.351 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . 0.427 ' HB3' HD22 ' B' ' 139' ' ' ASN . 0.8 OUTLIER -42.06 -30.75 0.3 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 129.278 3.031 . . . . 0.0 115.572 -176.039 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.566 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 97.1 p -63.07 -41.84 99.53 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.373 1.469 . . . . 0.0 113.333 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 72.7 p -81.93 -30.57 31.72 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 123.834 0.854 . . . . 0.0 113.208 173.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -70.85 -53.15 16.31 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.704 2.002 . . . . 0.0 110.226 -177.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.44 HG22 ' HA ' ' B' ' 62' ' ' PRO . 74.6 p -111.54 -113.63 0.32 Allowed 'General case' 0 C--N 1.342 0.253 0 C-N-CA 128.207 2.603 . . . . 0.0 106.33 172.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -144.19 12.2 2.07 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 130.191 3.758 . . . . 0.0 111.874 169.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . 0.427 HD22 ' HB3' ' B' ' 133' ' ' GLU . 5.3 t-20 56.64 14.89 1.9 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.889 1.675 . . . . 0.0 113.814 -172.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.42 22.21 0.03 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 116.563 2.061 . . . . 0.0 116.563 -168.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.11 -169.81 52.12 Favored Glycine 0 CA--C 1.529 0.963 0 O-C-N 120.136 -1.603 . . . . 0.0 113.295 -171.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.06 -169.85 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.279 1.432 . . . . 0.0 110.906 174.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.539 HH11 ' CE1' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -137.3 146.5 44.72 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 115.622 1.712 . . . . 0.0 115.622 175.241 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.7 -121.96 0.06 Allowed 'General case' 0 CA--C 1.536 0.406 0 O-C-N 127.182 2.801 . . . . 0.0 106.451 164.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.35 154.86 41.37 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 122.932 1.349 . . . . 0.0 114.467 -166.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -139.16 152.02 47.09 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 126.381 1.872 . . . . 0.0 109.246 169.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.58 141.88 7.73 Favored Glycine 0 C--N 1.333 0.414 0 N-CA-C 114.369 0.508 . . . . 0.0 114.369 176.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -79.74 153.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.891 1.276 . . . . 0.0 110.464 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.19 109.73 20.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 124.878 1.271 . . . . 0.0 112.409 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.53 164.37 15.52 Favored Glycine 0 C--N 1.35 1.339 0 C-N-CA 125.204 1.383 . . . . 0.0 112.761 174.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.59 HG22 ' H ' ' B' ' 153' ' ' GLN . 2.6 mp -87.36 113.37 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 O-C-N 121.548 -0.972 . . . . 0.0 112.193 -168.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.492 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -82.42 16.57 2.03 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 128.112 2.565 . . . . 0.0 112.658 169.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . 0.59 ' H ' HG22 ' B' ' 151' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.436 0 C-N-CA 128.804 2.842 . . . . 0.0 111.991 170.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.518 -0.283 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -94.5 145.83 24.52 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.496 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -94.33 164.44 13.02 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 121.109 -0.994 . . . . 0.0 111.789 168.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.56 HG11 ' H ' ' B' ' 53' ' ' ASN . 1.2 p -112.45 164.22 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 172.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.77 81.25 1.5 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.993 1.317 . . . . 0.0 108.007 160.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.0 t -77.45 89.14 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.16 141.5 37.17 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.381 1.072 . . . . 0.0 112.167 -172.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -155.59 175.96 13.23 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 169.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 160.12 -95.08 0.14 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 127.283 2.373 . . . . 0.0 109.706 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -78.33 87.16 4.38 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 126.629 1.972 . . . . 0.0 112.406 -169.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.08 -98.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.991 2.234 . . . . 0.0 114.003 168.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -78.4 -2.35 12.42 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 125.191 3.927 . . . . 0.0 115.284 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.5 t -79.0 139.1 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 120.312 1.415 . . . . 0.0 110.389 171.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -148.6 170.45 18.09 Favored 'General case' 0 N--CA 1.462 0.169 0 C-N-CA 125.617 1.567 . . . . 0.0 110.494 169.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.57 162.76 28.73 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 114.877 -1.056 . . . . 0.0 111.559 165.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.3 tp -156.87 80.71 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 126.609 1.964 . . . . 0.0 107.737 -177.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mm -98.42 143.97 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.123 0.569 . . . . 0.0 110.1 175.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -114.7 148.99 37.49 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 128.93 2.892 . . . . 0.0 109.42 175.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.496 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 57.8 m-85 -141.78 82.11 1.79 Allowed 'General case' 0 CA--C 1.557 1.216 0 C-N-CA 123.983 0.913 . . . . 0.0 112.757 -178.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.446 ' HG2' ' CZ3' ' A' ' 32' ' ' TRP . 1.2 pt-20 -78.97 130.54 35.67 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 121.367 1.894 . . . . 0.0 114.755 -174.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.547 HE22 ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -116.87 155.29 29.29 Favored 'General case' 0 CA--C 1.535 0.377 0 O-C-N 120.459 -1.4 . . . . 0.0 111.976 173.059 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -56.06 2.39 Favored 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.29 1.436 . . . . 0.0 112.64 -169.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.547 ' C ' HE22 ' A' ' 22' ' ' GLN . 0.4 OUTLIER -138.89 153.3 48.27 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 128.82 2.848 . . . . 0.0 107.739 169.406 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -48.45 -17.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 118.545 2.795 . . . . 0.0 118.545 -166.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -118.94 0.61 11.38 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.528 1.931 . . . . 0.0 113.405 -176.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.25 177.41 54.26 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.936 0.779 . . . . 0.0 112.829 176.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.91 177.52 8.62 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.293 3.329 . . . . 0.0 110.907 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 87.8 t -128.96 132.65 67.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 123.066 0.546 . . . . 0.0 110.128 178.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.43 122.39 34.83 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.9 t -103.47 128.02 56.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 126.002 1.721 . . . . 0.0 108.662 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.446 ' CZ3' ' HG2' ' A' ' 21' ' ' GLU . 3.1 p90 -144.83 157.71 44.06 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 122.84 0.456 . . . . 0.0 111.608 170.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.38 178.87 15.52 Favored Glycine 0 N--CA 1.463 0.465 0 O-C-N 121.259 -0.9 . . . . 0.0 112.427 -178.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 m -127.57 159.21 35.3 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 117.009 2.226 . . . . 0.0 117.009 -164.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.5 mm -123.73 124.5 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 127.2 2.2 . . . . 0.0 108.131 167.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -130.81 136.21 48.47 Favored 'General case' 0 CA--C 1.54 0.573 0 O-C-N 120.872 -1.142 . . . . 0.0 111.054 -169.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.41 -11.94 11.28 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.238 1.875 . . . . 0.0 113.557 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.9 mp -62.1 141.92 57.86 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 127.161 2.184 . . . . 0.0 109.062 169.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.6 t -71.59 -41.74 68.58 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -176.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 176.03 -160.62 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.743 1 C-N-CA 133.21 4.604 . . . . 0.0 105.168 178.469 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 74.24 173.42 29.28 Favored Glycine 0 N--CA 1.473 1.112 0 N-CA-C 117.165 1.626 . . . . 0.0 117.165 165.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.19 152.41 30.7 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.002 1.321 . . . . 0.0 109.61 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -153.1 142.15 21.33 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.872 1.669 . . . . 0.0 112.82 -171.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 119' ' ' VAL . . . -57.22 163.23 7.18 Favored Glycine 0 N--CA 1.478 1.457 0 C-N-CA 124.867 1.223 . . . . 0.0 115.141 -174.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -160.45 84.55 0.71 Allowed 'General case' 0 CA--C 1.548 0.875 0 CA-C-O 122.672 1.225 . . . . 0.0 113.502 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -133.18 142.37 48.59 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 120.036 -1.665 . . . . 0.0 110.961 -171.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.562 HG23 ' HA2' ' A' ' 82' ' ' GLY . 11.4 m -109.23 128.71 64.96 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.167 0 CA-C-O 121.957 0.884 . . . . 0.0 109.046 176.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.8 m170 -76.09 156.8 33.54 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.762 -174.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -74.95 130.85 40.1 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 71.12 169.34 0.32 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-O 124.848 2.261 . . . . 0.0 113.862 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.68 11.01 56.29 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 129.589 3.471 . . . . 0.0 114.078 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.643 ' HA ' HG21 ' B' ' 5' ' ' VAL . 1.9 p30 -78.95 47.29 0.75 Allowed 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.27 2.535 . . . . 0.0 109.97 168.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.468 ' H ' ' ND2' ' A' ' 53' ' ' ASN 0.31 0.1 OUTLIER -90.13 45.62 1.28 Allowed 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 115.533 1.679 . . . . 0.0 115.533 -165.661 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.521 HG22 ' HA ' ' B' ' 7' ' ' VAL . 19.4 p -119.91 -38.06 3.01 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -163.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.26 13.13 24.4 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 126.206 1.802 . . . . 0.0 112.9 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.48 -123.87 34.16 Favored Glycine 0 C--N 1.341 0.852 0 C-N-CA 125.112 1.339 . . . . 0.0 111.512 175.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 70.2 m -58.82 -13.77 7.06 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.827 1.417 . . . . 0.0 114.827 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.57 1.43 29.68 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.004 1.322 . . . . 0.0 112.081 173.135 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.2 m -158.54 -131.21 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 127.253 2.221 . . . . 0.0 108.209 -174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.34 95.35 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 128.002 2.521 . . . . 0.0 114.638 -173.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.6 162.24 53.92 Favored Glycine 0 CA--C 1.531 1.04 0 N-CA-C 115.301 0.88 . . . . 0.0 115.301 -167.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -69.24 84.57 0.57 Allowed 'Trans proline' 0 C--N 1.354 0.855 1 C-N-CA 125.963 4.442 . . . . 0.0 111.104 -173.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.5 p80 51.65 59.29 4.67 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 127.971 2.509 . . . . 0.0 110.808 169.049 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -56.05 167.05 0.66 Allowed 'General case' 0 N--CA 1.445 -0.723 0 CA-C-O 126.043 2.83 . . . . 0.0 112.443 -173.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.525 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.4 p-10 -118.88 73.67 12.3 Favored Pre-proline 0 C--N 1.314 -0.938 0 CA-C-N 110.837 -2.892 . . . . 0.0 112.275 -169.087 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.45 -23.72 75.14 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.018 2.479 . . . . 0.0 113.44 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 27.7 tp -86.64 -3.63 59.06 Favored 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.477 1.511 . . . . 0.0 113.191 170.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.7 t 68.15 49.69 0.83 Allowed 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.609 2.364 . . . . 0.0 112.578 176.377 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.525 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 7.9 mtp180 -106.67 170.91 7.65 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 115.224 1.564 . . . . 0.0 115.224 -168.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.5 mtmt -74.04 162.06 29.41 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.35 1.46 . . . . 0.0 109.247 164.434 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -86.83 142.63 27.94 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 172.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.415 ' HA2' ' HB3' ' A' ' 126' ' ' LEU . . . 147.4 -123.71 1.8 Allowed Glycine 0 C--N 1.341 0.815 0 N-CA-C 117.059 1.584 . . . . 0.0 117.059 164.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.47 -38.96 2.32 Favored Glycine 0 CA--C 1.546 1.998 0 N-CA-C 118.207 2.043 . . . . 0.0 118.207 -169.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -99.61 11.82 0.64 Allowed 'Trans proline' 0 CA--C 1.546 1.123 0 C-N-CA 123.955 3.104 . . . . 0.0 113.684 -176.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.67 -30.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 128.275 2.63 . . . . 0.0 109.893 167.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 5.3 t70 -75.31 152.89 38.13 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.153 0.978 . . . . 0.0 109.232 163.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -89.59 -26.13 20.96 Favored 'General case' 0 C--N 1.321 -0.664 1 C-N-CA 131.708 4.003 . . . . 0.0 111.679 -173.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -92.04 -71.29 0.65 Allowed 'General case' 0 C--N 1.34 0.164 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -169.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.4 ttt180 69.95 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.779 1.632 . . . . 0.0 112.861 -175.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -57.79 163.01 2.81 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 119.388 -2.07 . . . . 0.0 113.902 171.159 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.25 -38.16 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 119.353 0.979 . . . . 0.0 111.738 170.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.562 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -88.43 45.12 3.23 Favored Glycine 0 CA--C 1.533 1.158 0 N-CA-C 114.992 0.757 . . . . 0.0 114.992 177.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -137.44 134.46 35.87 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 120.824 -1.398 . . . . 0.0 111.154 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -127.6 53.49 1.75 Allowed 'General case' 0 CA--C 1.546 0.817 0 CA-C-O 122.111 0.958 . . . . 0.0 109.107 165.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.54 -138.26 42.76 Favored Glycine 0 C--N 1.342 0.882 0 C-N-CA 125.577 1.56 . . . . 0.0 113.129 172.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -141.71 150.86 42.39 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.031 0.933 . . . . 0.0 110.137 168.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.76 178.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 C-N-CA 127.659 2.384 . . . . 0.0 110.651 -174.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 83.1 m -149.96 138.2 20.47 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 124.973 1.309 . . . . 0.0 110.056 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.15 140.45 38.29 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.105 1.362 . . . . 0.0 114.641 -176.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -77.79 146.03 36.06 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.761 1.624 . . . . 0.0 109.775 166.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.93 -16.35 0.13 Allowed 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 130.066 3.346 . . . . 0.0 118.08 175.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -75.26 1.23 14.09 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-N 119.762 1.164 . . . . 0.0 110.776 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.25 43.52 4.95 Favored Glycine 0 C--N 1.336 0.551 0 C-N-CA 128.054 2.74 . . . . 0.0 112.408 171.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.8 p -155.38 132.22 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 119.562 1.681 . . . . 0.0 115.14 -175.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.75 107.64 20.13 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 165.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -98.37 144.59 27.6 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.658 0.742 . . . . 0.0 110.088 169.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -121.92 146.11 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 N-CA-C 115.07 1.507 . . . . 0.0 115.07 -174.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.8 t -159.47 81.34 0.75 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 126.712 2.005 . . . . 0.0 111.837 175.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -127.95 158.08 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 127.152 2.181 . . . . 0.0 110.917 -174.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -126.15 138.63 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 167.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -134.45 145.8 49.19 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.273 1.029 . . . . 0.0 112.718 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 12.4 p -120.5 48.58 1.57 Allowed 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 114.575 1.324 . . . . 0.0 114.575 -179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.0 m -139.35 3.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.35 139.18 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.819 1.248 . . . . 0.0 109.043 168.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 46.6 p -112.04 176.69 4.92 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 118.718 0.69 . . . . 0.0 111.123 169.031 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.8 mt -82.31 107.64 15.14 Favored 'General case' 0 C--N 1.345 0.4 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 167.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -136.98 -13.24 1.65 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.47 31.97 71.34 Favored Glycine 0 C--N 1.342 0.879 0 CA-C-N 119.884 1.22 . . . . 0.0 115.155 172.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -170.44 -103.32 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.802 1.241 . . . . 0.0 108.026 -169.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -79.43 8.74 5.7 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.34 2.256 . . . . 0.0 112.329 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 55.5 m -149.85 -161.53 1.36 Allowed 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.241 1.416 . . . . 0.0 109.438 165.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 15.3 pt -82.41 161.37 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 O-C-N 120.171 -1.581 . . . . 0.0 113.835 -168.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.445 HD11 ' HB2' ' A' ' 4' ' ' ALA . 2.3 mm 106.44 147.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 1 C-N-CA 135.023 5.329 . . . . 0.0 110.118 -167.155 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.47 2.73 56.02 Favored Glycine 0 C--O 1.219 -0.803 0 CA-C-O 117.319 -1.823 . . . . 0.0 114.838 174.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 34.8 mtt-85 -106.22 -176.14 2.99 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.898 2.479 . . . . 0.0 110.338 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.0 t -120.29 145.43 47.08 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 119.554 1.07 . . . . 0.0 110.934 169.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.0 tp -101.32 133.52 45.78 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 127.086 2.154 . . . . 0.0 109.723 170.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.46 147.8 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.512 1.525 . . . . 0.0 110.576 168.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.57 HG12 HD21 ' A' ' 144' ' ' LEU . 91.7 t -129.03 151.15 35.36 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 C-N-CA 126.067 1.747 . . . . 0.0 107.035 173.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 74.3 m-70 -124.25 133.8 53.41 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.365 1.066 . . . . 0.0 113.17 -168.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.267 24.2 tp10 -84.81 39.07 0.73 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 -167.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -154.15 160.48 41.92 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.44 1.896 . . . . 0.0 109.5 169.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.57 118.36 8.08 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 169.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.5 157.93 20.3 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.477 1.132 . . . . 0.0 112.208 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -90.81 -9.49 46.27 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 128.587 2.755 . . . . 0.0 113.076 -169.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.415 ' HB3' ' HA2' ' A' ' 72' ' ' GLY . 2.3 mp 1.54 79.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 130.911 3.684 . . . . 0.0 116.194 -173.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.21 -66.68 0.57 Allowed Glycine 0 N--CA 1.467 0.753 0 C-N-CA 125.068 1.318 . . . . 0.0 114.287 170.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.7 ttpp -157.49 93.28 1.28 Allowed 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.436 1.273 . . . . 0.0 114.436 -170.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.88 -113.74 2.18 Favored Glycine 0 C--O 1.235 0.216 0 N-CA-C 108.336 -1.906 . . . . 0.0 108.336 165.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -131.32 33.66 2.74 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.151 1.834 . . . . 0.0 113.328 177.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -159.58 159.83 33.7 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 118.78 1.29 . . . . 0.0 108.766 -171.229 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -68.73 -48.97 62.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.29 0.566 . . . . 0.0 110.093 -176.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.1 mp0 -38.63 -33.97 0.13 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.636 3.174 . . . . 0.0 113.591 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.9 p -59.88 -44.97 93.9 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.281 1.432 . . . . 0.0 114.021 175.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.8 t -81.7 -36.38 28.76 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 118.96 0.8 . . . . 0.0 111.283 168.216 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 16.6 tttt -56.88 -48.14 78.86 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.117 1.367 . . . . 0.0 111.991 -175.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -147.48 -10.79 0.41 Allowed 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 126.818 2.047 . . . . 0.0 115.009 -168.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.65 3.56 57.25 Favored Glycine 0 C--O 1.223 -0.575 0 CA-C-O 117.374 -1.792 . . . . 0.0 113.128 -173.432 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 67.54 -60.33 0.39 Allowed 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.043 2.137 . . . . 0.0 111.333 -172.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 68.41 -21.39 0.14 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 129.795 3.238 . . . . 0.0 115.571 168.585 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.61 -20.26 0.14 Allowed Glycine 0 CA--C 1.537 1.418 0 C-N-CA 126.904 2.192 . . . . 0.0 118.447 166.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.7 t -161.65 -173.11 3.6 Favored 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 127.626 2.371 . . . . 0.0 110.819 176.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.05 154.22 43.01 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.473 -1.392 . . . . 0.0 110.029 169.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.57 HD21 HG12 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -128.94 -129.11 0.22 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 123.43 0.692 . . . . 0.0 110.292 169.664 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.43 158.87 32.75 Favored 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 126.667 1.987 . . . . 0.0 113.113 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -140.79 161.58 37.46 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.922 2.089 . . . . 0.0 110.062 169.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.32 148.21 16.7 Favored Glycine 0 N--CA 1.472 1.038 0 O-C-N 121.272 -0.892 . . . . 0.0 112.918 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -78.56 161.78 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 C-N-CA 123.95 0.9 . . . . 0.0 109.773 177.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 36.8 mt -110.71 98.51 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 120.356 -1.465 . . . . 0.0 112.207 -175.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.45 167.07 22.14 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.712 1.625 . . . . 0.0 115.402 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.99 80.07 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 C-N-CA 127.91 2.484 . . . . 0.0 113.387 -175.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.36 26.24 0.22 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.657 1.583 . . . . 0.0 115.16 -175.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 . . . . . 0 N--CA 1.469 0.518 0 C-N-CA 129.413 3.085 . . . . 0.0 114.346 176.549 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 119.418 -0.325 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.9 m -79.78 108.69 13.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 125.333 1.453 . . . . 0.0 108.088 -171.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 27.6 mttt -99.43 118.59 36.39 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -171.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -83.35 169.25 15.83 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 127.71 2.404 . . . . 0.0 114.874 178.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.643 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -156.07 125.43 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 129.412 3.085 . . . . 0.0 107.55 175.608 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.07 139.38 47.64 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.088 0.955 . . . . 0.0 113.173 179.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.521 ' HA ' HG22 ' A' ' 54' ' ' THR . 3.2 t -85.88 68.07 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.189 -0.914 . . . . 0.0 112.401 -168.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.12 103.13 5.17 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 122.208 1.004 . . . . 0.0 108.337 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -161.91 133.09 5.21 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 125.331 1.453 . . . . 0.0 109.713 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.25 -118.06 3.76 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -127.3 57.48 1.49 Allowed 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 126.046 1.738 . . . . 0.0 111.706 -164.071 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.5 -168.07 41.17 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 121.074 -1.016 . . . . 0.0 112.901 -171.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.55 -5.94 12.58 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 124.354 3.369 . . . . 0.0 115.444 -168.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.16 129.19 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 CA-C-N 120.258 1.39 . . . . 0.0 110.371 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -123.13 178.55 5.04 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 122.518 1.151 . . . . 0.0 110.29 168.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.2 163.01 31.29 Favored Glycine 0 CA--C 1.499 -0.942 0 CA-C-N 113.888 -1.506 . . . . 0.0 113.129 165.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pt -133.6 82.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 112.162 -2.019 . . . . 0.0 106.688 170.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.343 2.7 pp -89.49 109.87 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -112.74 133.54 54.71 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.523 2.329 . . . . 0.0 108.577 -170.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -124.48 147.06 48.58 Favored 'General case' 0 N--CA 1.474 0.766 0 O-C-N 121.028 -1.045 . . . . 0.0 111.178 -174.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -108.66 112.22 24.43 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.522 1.129 . . . . 0.0 111.717 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.3 99.04 10.87 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.43 ' HE2' ' HB2' ' B' ' 24' ' ' GLU . 0.2 OUTLIER -70.72 -28.8 65.0 Favored 'General case' 0 CA--C 1.539 0.53 0 O-C-N 121.415 -0.803 . . . . 0.0 113.108 170.276 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . 0.43 ' HB2' ' HE2' ' B' ' 23' ' ' LYS . 43.1 tt0 -163.61 124.54 2.29 Favored 'General case' 0 C--O 1.222 -0.355 0 C-N-CA 124.689 1.196 . . . . 0.0 110.446 -166.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.0 p -60.86 -10.16 5.2 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 127.977 2.511 . . . . 0.0 114.8 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -132.93 15.16 4.28 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.239 1.816 . . . . 0.0 111.841 -171.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.42 -153.09 7.42 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 126.628 2.061 . . . . 0.0 111.724 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -85.29 167.05 10.69 Favored 'Trans proline' 0 N--CA 1.456 -0.733 0 C-N-CA 122.642 2.228 . . . . 0.0 112.202 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -119.78 140.22 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 124.993 1.317 . . . . 0.0 108.859 170.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -94.89 121.94 37.01 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 168.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.17 131.95 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 128.04 2.536 . . . . 0.0 109.071 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -156.05 -176.77 6.13 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 119.49 168.25 13.89 Favored Glycine 0 C--N 1.335 0.518 0 CA-C-O 122.079 0.822 . . . . 0.0 114.478 166.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 4.9 p -99.08 123.37 43.33 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -167.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 mp -98.5 118.08 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 166.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -129.01 132.29 47.5 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.551 1.54 . . . . 0.0 110.788 -166.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.26 -2.59 29.68 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 128.228 2.823 . . . . 0.0 111.939 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 22.4 mt -69.91 148.11 49.41 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 118.94 1.37 . . . . 0.0 112.598 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 26.8 m -76.37 143.97 40.39 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 125.614 1.565 . . . . 0.0 107.211 165.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -59.24 156.4 12.48 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.81 -179.45 35.55 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.668 0.652 . . . . 0.0 112.281 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.477 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -83.25 142.39 31.17 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 127.267 2.227 . . . . 0.0 113.846 -169.56 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 80.5 m-70 -134.01 125.78 28.85 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 129.093 2.957 . . . . 0.0 108.602 -176.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.09 148.64 28.15 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 125.492 1.52 . . . . 0.0 112.594 178.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -142.26 103.52 4.29 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.999 1.399 . . . . 0.0 111.528 -168.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.56 139.0 33.07 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 120.223 -1.548 . . . . 0.0 111.226 -175.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.88 115.52 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 176.154 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -71.86 -178.52 2.34 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 128.119 2.567 . . . . 0.0 111.172 -169.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.7 145.02 46.45 Favored 'General case' 0 CA--C 1.547 0.828 0 O-C-N 121.317 -0.864 . . . . 0.0 111.008 168.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -92.54 -170.95 2.62 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.28 1.832 . . . . 0.0 113.06 -169.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.17 -108.36 3.0 Favored Glycine 0 C--N 1.334 0.447 0 N-CA-C 115.694 1.037 . . . . 0.0 115.694 163.369 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -77.92 65.04 3.27 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.252 1.421 . . . . 0.0 110.567 -169.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.56 ' H ' HG11 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -165.52 162.59 19.27 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.714 1.376 . . . . 0.0 114.714 -168.598 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 39.5 p . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 116.65 2.093 . . . . 0.0 116.65 179.526 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.354 0 CA-C-O 121.43 0.633 . . . . 0.0 112.352 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.46 171.17 25.56 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.194 1.378 . . . . 0.0 113.765 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -65.34 169.41 12.48 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 124.493 3.462 . . . . 0.0 112.264 -173.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -20.19 86.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 128.504 2.722 . . . . 0.0 117.733 175.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -50.57 126.63 15.9 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 123.54 1.638 . . . . 0.0 114.053 -172.076 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.46 59.81 0.46 Allowed Pre-proline 0 CA--C 1.558 1.261 0 CA-C-N 112.194 -2.276 . . . . 0.0 115.851 -168.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -65.28 -27.53 55.8 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 123.355 2.704 . . . . 0.0 114.232 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -76.28 -3.99 39.58 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.195 0.998 . . . . 0.0 112.244 175.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t 63.54 50.58 2.76 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 126.002 1.721 . . . . 0.0 111.114 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -103.14 168.45 9.17 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.551 1.14 . . . . 0.0 111.757 -174.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.452 ' HE3' ' HD2' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -96.39 173.1 7.54 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.456 1.502 . . . . 0.0 107.287 164.433 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.476 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 29.5 t60 -63.88 164.5 10.12 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 119.981 -1.699 . . . . 0.0 113.715 -178.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 166.67 -174.44 42.07 Favored Glycine 0 N--CA 1.469 0.863 0 O-C-N 120.921 -1.112 . . . . 0.0 113.929 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.28 -154.26 25.38 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 -167.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -62.77 -1.75 2.94 Favored 'Trans proline' 0 CA--C 1.54 0.807 1 C-N-CA 125.849 4.366 . . . . 0.0 116.379 -172.623 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -120.89 -1.98 9.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.021 1.329 . . . . 0.0 113.641 170.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -131.04 176.79 7.96 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 126.746 2.018 . . . . 0.0 110.259 -168.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -100.15 -17.07 17.58 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 127.13 2.172 . . . . 0.0 113.803 -169.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -95.2 -100.34 0.16 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 118.565 0.621 . . . . 0.0 112.673 -176.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.2 ttp-105 85.77 97.28 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 126.825 2.05 . . . . 0.0 110.024 -175.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -49.67 156.83 0.63 Allowed 'General case' 0 N--CA 1.475 0.799 0 O-C-N 119.936 -1.727 . . . . 0.0 111.788 168.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 46.4 t -53.38 -21.5 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 119.266 0.939 . . . . 0.0 113.265 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.29 61.4 0.55 Allowed Glycine 0 CA--C 1.531 1.036 0 CA-C-O 118.573 -1.126 . . . . 0.0 114.105 169.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -123.52 124.68 43.37 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 119.642 1.721 . . . . 0.0 109.099 168.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.9 mt -132.18 49.22 2.34 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 119.268 0.94 . . . . 0.0 112.381 -176.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.94 -148.29 47.71 Favored Glycine 0 CA--C 1.534 1.277 0 O-C-N 121.101 -1.0 . . . . 0.0 113.49 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -129.76 137.27 50.44 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.781 1.233 . . . . 0.0 109.837 168.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -96.15 133.32 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 125.861 1.664 . . . . 0.0 110.227 179.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 32.1 m -108.94 136.81 47.87 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 124.222 1.009 . . . . 0.0 108.803 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.35 145.09 26.47 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 174.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -77.18 146.91 36.76 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.118 1.767 . . . . 0.0 110.499 167.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -63.91 -14.3 52.46 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.925 1.824 . . . . 0.0 115.925 -169.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -76.16 3.32 10.86 Favored 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 125.471 1.508 . . . . 0.0 111.481 171.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 100.36 29.41 6.71 Favored Glycine 0 C--N 1.342 0.892 0 C-N-CA 126.327 1.918 . . . . 0.0 114.719 168.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.1 139.51 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 120.227 2.014 . . . . 0.0 115.215 -169.048 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.49 99.29 7.07 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 124.401 1.08 . . . . 0.0 110.187 169.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -87.74 91.24 8.68 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-O 122.591 1.186 . . . . 0.0 109.169 172.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -75.85 158.64 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 CA-C-N 114.109 -1.405 . . . . 0.0 114.133 -167.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 82.4 p -155.0 105.93 2.59 Favored 'General case' 0 N--CA 1.471 0.584 0 O-C-N 120.61 -1.306 . . . . 0.0 111.782 -175.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.3 mt -137.43 153.19 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 126.708 2.003 . . . . 0.0 110.639 -176.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -139.01 136.14 35.02 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.26 1.824 . . . . 0.0 107.92 168.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -149.18 143.97 26.28 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 125.873 1.669 . . . . 0.0 111.013 -172.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -107.89 53.19 0.69 Allowed 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 113.29 0.848 . . . . 0.0 113.29 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.1 t -144.3 -42.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 124.29 1.036 . . . . 0.0 112.92 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.63 163.08 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 O-C-N 121.14 -0.975 . . . . 0.0 113.447 -176.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -156.57 154.24 29.93 Favored 'General case' 0 N--CA 1.476 0.838 0 O-C-N 119.91 -1.744 . . . . 0.0 113.341 174.033 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mp -84.85 46.43 1.26 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.008 1.323 . . . . 0.0 108.65 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.0 m -75.59 -34.63 60.66 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 116.091 1.886 . . . . 0.0 116.091 -166.019 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.62 18.41 Favored Glycine 0 CA--C 1.536 1.352 0 N-CA-C 115.578 0.991 . . . . 0.0 115.578 -174.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 p30 -116.74 -83.23 0.63 Allowed 'General case' 0 CA--C 1.549 0.905 0 C-N-CA 125.65 1.58 . . . . 0.0 111.003 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -143.42 -1.59 1.02 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 129.399 3.079 . . . . 0.0 111.922 -178.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 52.5 m -73.46 -91.54 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 126.488 1.915 . . . . 0.0 112.003 -169.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.7 pt -136.04 -26.34 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 175.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 mm -66.04 136.68 26.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 CA-C-N 122.826 2.557 . . . . 0.0 108.621 168.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.52 -16.53 6.22 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.018 0.818 . . . . 0.0 114.594 -172.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -79.07 178.39 8.08 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.528 1.131 . . . . 0.0 109.361 169.235 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.57 124.26 12.56 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.479 1.036 . . . . 0.0 111.902 -170.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 tp -89.27 120.36 30.57 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.0 p -99.89 130.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 124.14 0.976 . . . . 0.0 110.802 171.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.8 m -93.38 133.71 33.58 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 165.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -96.39 177.75 5.59 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 125.355 1.462 . . . . 0.0 111.155 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -84.76 -58.04 2.87 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 120.912 -1.118 . . . . 0.0 110.648 -173.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -95.34 177.99 5.66 Favored 'General case' 0 N--CA 1.471 0.593 0 O-C-N 120.746 -1.221 . . . . 0.0 110.537 169.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.03 146.09 28.36 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 168.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -86.89 163.09 17.37 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 123.145 1.45 . . . . 0.0 111.368 169.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.47 -8.83 57.98 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.105 1.762 . . . . 0.0 112.25 -170.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 95.6 mt 33.6 50.24 0.28 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 128.511 2.724 . . . . 0.0 113.276 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 159.84 -93.62 0.12 Allowed Glycine 0 C--N 1.333 0.41 0 O-C-N 121.678 -0.639 . . . . 0.0 114.336 -178.279 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . 0.452 ' HD2' ' HE3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -159.16 127.38 5.08 Favored 'General case' 0 CA--C 1.55 0.978 0 C-N-CA 125.422 1.489 . . . . 0.0 112.422 -173.711 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -123.87 -19.05 2.8 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.593 1.092 . . . . 0.0 115.095 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 119.69 -14.49 10.65 Favored Glycine 0 N--CA 1.474 1.217 0 CA-C-O 118.34 -1.255 . . . . 0.0 116.227 171.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -98.11 165.12 12.04 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.875 1.838 . . . . 0.0 110.175 168.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -51.8 -55.83 17.51 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.328 1.051 . . . . 0.0 110.035 178.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -51.6 -33.29 32.3 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 128.041 2.536 . . . . 0.0 113.313 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -54.86 -46.37 74.67 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 121.137 1.789 . . . . 0.0 113.861 176.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -91.24 -31.67 16.05 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 172.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -74.11 -28.17 61.23 Favored 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.7 m -128.82 -44.68 1.32 Allowed 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.352 1.461 . . . . 0.0 111.672 -179.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . 0.476 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 122.16 7.92 7.49 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 127.781 2.61 . . . . 0.0 112.269 -167.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 61.08 -77.39 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 126.213 1.805 . . . . 0.0 109.382 -169.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 64.94 3.61 2.16 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 127.889 2.476 . . . . 0.0 117.482 164.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.49 -46.63 1.97 Allowed Glycine 0 N--CA 1.471 1.014 0 C-N-CA 125.398 1.475 . . . . 0.0 113.803 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.9 m -178.27 176.71 1.06 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 126.933 2.093 . . . . 0.0 112.002 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -79.43 173.63 12.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.586 0.754 . . . . 0.0 110.846 168.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -140.74 -79.55 0.27 Allowed 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.755 0.822 . . . . 0.0 109.964 169.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.47 43.89 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 126.4 1.88 . . . . 0.0 109.686 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -156.81 151.74 26.02 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.966 1.706 . . . . 0.0 111.833 -171.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.79 148.74 17.18 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 116.415 1.326 . . . . 0.0 116.415 176.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -74.56 140.68 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 117.627 0.713 . . . . 0.0 110.671 175.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.9 mm -81.24 118.4 28.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 C-N-CA 125.303 1.441 . . . . 0.0 111.566 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.6 -167.16 14.58 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 126.227 1.87 . . . . 0.0 112.613 169.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.425 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.0 OUTLIER -134.28 138.37 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.265 1.426 . . . . 0.0 114.34 -169.028 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.68 -141.26 0.27 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.703 1.201 . . . . 0.0 110.337 174.528 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.464 0 C-N-CA 124.272 1.029 . . . . 0.0 110.279 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.471 0.603 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -168.37 157.38 9.03 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 115.403 1.631 . . . . 0.0 115.403 163.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.1 179.02 8.06 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 130.231 3.413 . . . . 0.0 107.181 169.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.503 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.3 p -155.66 108.29 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 122.645 1.212 . . . . 0.0 111.619 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -101.5 96.64 7.27 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 167.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.1 t -76.91 136.06 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 165.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mp -128.39 104.29 7.63 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.155 -0.966 . . . . 0.0 109.562 -178.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -160.43 151.39 18.92 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 124.24 1.016 . . . . 0.0 111.865 -178.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.17 -116.94 1.02 Allowed Glycine 0 CA--C 1.524 0.624 0 CA-C-O 123.089 1.383 . . . . 0.0 111.618 166.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -92.7 56.32 2.63 Favored 'General case' 0 C--N 1.312 -1.035 1 C-N-CA 132.635 4.374 . . . . 0.0 115.034 -164.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.4 -168.19 35.25 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.296 -1.32 . . . . 0.0 114.074 176.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -86.02 17.88 1.67 Allowed 'Trans proline' 0 CA--C 1.539 0.767 1 C-N-CA 125.686 4.257 . . . . 0.0 113.553 -171.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 t -111.08 120.84 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.87 1.213 . . . . 0.0 108.975 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 pm0 -160.25 162.31 33.66 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.52 173.65 33.64 Favored Glycine 0 N--CA 1.462 0.377 0 C-N-CA 124.368 0.985 . . . . 0.0 113.296 168.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -126.24 134.13 67.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 124.386 1.074 . . . . 0.0 108.86 170.443 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.8 mm -137.6 105.24 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 118.274 0.488 . . . . 0.0 110.231 -172.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -77.67 161.74 27.55 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.597 0.713 . . . . 0.0 111.662 172.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.414 ' CD2' HG22 ' A' ' 31' ' ' VAL . 3.4 m-85 -137.17 111.22 8.32 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.897 1.679 . . . . 0.0 106.806 169.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -91.65 135.51 33.82 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 120.765 1.62 . . . . 0.0 109.794 172.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -132.1 145.99 51.75 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.825 0.821 . . . . 0.0 111.532 175.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -92.53 -34.74 13.94 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 124.624 1.169 . . . . 0.0 114.1 179.399 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.95 -154.42 0.55 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-N 120.66 1.573 . . . . 0.0 112.791 178.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 65.7 p -93.35 -0.23 56.68 Favored 'General case' 0 CA--C 1.538 0.518 0 O-C-N 119.228 -2.17 . . . . 0.0 115.469 -172.051 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -153.49 -8.71 0.16 Allowed 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 115.875 1.806 . . . . 0.0 115.875 -169.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.91 173.89 55.31 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 128.664 3.031 . . . . 0.0 114.023 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -78.22 139.36 16.75 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.046 2.497 . . . . 0.0 111.758 -175.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -108.84 132.9 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.418 1.087 . . . . 0.0 109.353 -170.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -99.07 113.21 25.3 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 122.172 0.987 . . . . 0.0 110.34 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.414 HG22 ' CD2' ' A' ' 20' ' ' PHE . 9.3 t -95.5 130.99 43.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 127.984 2.514 . . . . 0.0 109.14 -178.17 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.0 p90 -148.81 159.32 44.26 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.92 -157.12 27.21 Favored Glycine 0 C--O 1.225 -0.424 0 C-N-CA 126.058 1.79 . . . . 0.0 110.178 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.5 p -157.11 154.72 29.86 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 121.577 -0.955 . . . . 0.0 112.417 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 mp -121.67 130.91 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 125.599 1.56 . . . . 0.0 108.346 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.4 140.5 49.67 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.316 1.446 . . . . 0.0 111.012 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.52 11.6 11.51 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 126.17 1.843 . . . . 0.0 112.54 -168.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.7 mt -86.96 171.24 10.92 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.532 0.733 . . . . 0.0 109.54 169.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -80.53 -141.09 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 164.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.49 -154.13 0.37 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.939 1.296 . . . . 0.0 108.535 166.285 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 69.28 179.74 22.96 Favored Glycine 0 CA--C 1.532 1.147 0 O-C-N 120.398 -1.439 . . . . 0.0 115.331 168.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mp -87.52 154.77 20.36 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.973 1.709 . . . . 0.0 110.611 -176.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -150.67 103.52 3.11 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 127.323 2.249 . . . . 0.0 109.908 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.05 160.61 20.86 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 124.558 1.075 . . . . 0.0 114.185 -175.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -142.78 92.38 2.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 125.933 1.693 . . . . 0.0 109.186 -173.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -109.35 130.4 55.5 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.298 -1.501 . . . . 0.0 109.8 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -77.97 158.33 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 175.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -119.9 123.44 43.57 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 pm0 -57.47 147.16 27.33 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.774 0.797 . . . . 0.0 109.872 177.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 68.95 166.72 0.27 Allowed 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 126.111 2.862 . . . . 0.0 112.353 -176.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.81 10.8 18.4 Favored Glycine 0 N--CA 1.467 0.718 0 C-N-CA 128.198 2.809 . . . . 0.0 112.186 178.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -83.7 42.99 0.88 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 128.509 2.723 . . . . 0.0 114.055 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -179.88 -26.85 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 112.723 -2.035 . . . . 0.0 114.925 -166.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.389 43.4 p 27.74 -18.35 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 2 N-CA-C 123.535 4.643 . . . . 0.0 123.535 -167.625 . . . . . . . . 3 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.44 -0.37 57.36 Favored 'General case' 0 CA--C 1.549 0.91 0 CA-C-N 122.48 2.4 . . . . 0.0 114.278 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.9 -128.4 37.31 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 125.721 1.629 . . . . 0.0 111.396 177.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -51.62 -2.75 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.235 0 N-CA-C 117.215 2.302 . . . . 0.0 117.215 -176.665 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 85.7 m -110.63 11.37 22.82 Favored 'General case' 0 N--CA 1.481 1.108 0 O-C-N 119.795 -1.816 . . . . 0.0 113.782 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 t -155.79 -27.45 0.1 Allowed 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 115.92 1.822 . . . . 0.0 115.92 168.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.2 177.02 4.79 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.797 2.039 . . . . 0.0 108.912 166.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.79 -107.92 2.47 Favored Glycine 0 CA--C 1.541 1.719 0 CA-C-O 117.755 -1.58 . . . . 0.0 114.443 -169.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -101.69 -167.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.543 0.956 1 C-N-CA 127.23 5.287 . . . . 0.0 112.144 -174.623 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.742 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.6 OUTLIER -100.11 119.83 38.91 Favored 'General case' 0 CA--C 1.554 1.111 1 C-N-CA 132.292 4.237 . . . . 0.0 115.243 -178.274 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -39.74 126.93 2.0 Allowed 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 130.074 3.35 . . . . 0.0 116.123 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 51.0 p-10 -121.6 32.72 0.21 Allowed Pre-proline 0 CA--C 1.557 1.212 0 N-CA-C 115.304 1.594 . . . . 0.0 115.304 -173.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -62.8 -20.66 71.8 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.959 3.106 . . . . 0.0 114.978 -167.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 60.5 mt -78.46 -1.78 35.34 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.09 1.356 . . . . 0.0 112.685 174.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.76 52.8 0.93 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 127.269 2.227 . . . . 0.0 111.765 173.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.4 ptt180 -156.97 -179.98 8.73 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -166.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.26 177.53 8.9 Favored 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.434 1.494 . . . . 0.0 113.983 -171.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -50.87 157.8 0.76 Allowed 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -169.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -80.85 67.75 3.52 Favored Glycine 0 N--CA 1.474 1.177 0 C-N-CA 125.601 1.572 . . . . 0.0 114.354 -167.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -97.06 128.37 9.53 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-O 118.913 -0.937 . . . . 0.0 114.583 -168.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -76.84 4.68 5.48 Favored 'Trans proline' 0 CA--C 1.545 1.071 0 C-N-CA 123.632 2.888 . . . . 0.0 111.713 167.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.56 -10.52 18.4 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.963 0.905 . . . . 0.0 111.863 168.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -123.37 139.73 53.74 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.155 0.982 . . . . 0.0 110.809 -166.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -66.81 -28.62 68.52 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.496 172.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -91.76 105.04 17.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 125.969 1.708 . . . . 0.0 106.946 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -140.11 112.69 7.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 129.065 2.946 . . . . 0.0 109.56 -170.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -58.71 152.29 19.15 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.094 1.357 . . . . 0.0 111.405 167.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 p -65.0 -13.75 15.43 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 171.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.02 43.64 1.36 Allowed Glycine 0 C--N 1.347 1.158 0 N-CA-C 118.26 2.064 . . . . 0.0 118.26 -168.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -147.68 143.6 27.75 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 119.891 1.845 . . . . 0.0 109.484 167.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.0 mt -108.67 54.37 0.66 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.638 0.732 . . . . 0.0 109.345 -175.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.09 -120.07 6.75 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 124.84 1.209 . . . . 0.0 112.239 -172.118 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.439 HD22 HD21 ' A' ' 126' ' ' LEU . 6.5 p30 -142.28 160.4 40.32 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.709 1.204 . . . . 0.0 109.717 170.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.681 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.7 OUTLIER -99.17 151.4 4.73 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.763 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 164.887 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.9 m -134.55 120.86 20.17 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 124.736 1.214 . . . . 0.0 108.738 -177.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.46 140.2 29.71 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -175.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -81.9 160.07 23.5 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 128.155 2.582 . . . . 0.0 110.151 169.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.47 -22.08 7.32 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 126.382 1.873 . . . . 0.0 114.944 -173.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -76.79 -3.9 40.69 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.445 2.298 . . . . 0.0 112.289 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.78 10.01 73.51 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 126.929 2.204 . . . . 0.0 114.477 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.83 137.54 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.583 1.553 . . . . 0.0 111.963 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.681 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -107.73 130.54 54.94 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.471 -0.936 . . . . 0.0 108.471 166.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -82.29 151.64 26.67 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 122.277 1.037 . . . . 0.0 109.499 170.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -134.08 129.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 112.81 -1.995 . . . . 0.0 111.867 164.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.2 p -157.85 54.05 0.47 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 124.4 1.08 . . . . 0.0 111.978 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.81 153.86 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 O-C-N 120.277 -1.515 . . . . 0.0 112.352 -171.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -129.28 139.9 51.63 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 125.845 1.658 . . . . 0.0 108.457 168.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -150.07 148.53 29.12 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.4 1.095 . . . . 0.0 111.662 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -107.5 55.61 0.65 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.082 1.753 . . . . 0.0 110.35 -171.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.6 p -152.47 11.32 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -169.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -153.58 163.09 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 127.158 2.183 . . . . 0.0 107.904 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.0 m -155.14 161.62 41.2 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 122.435 1.112 . . . . 0.0 112.56 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.5 tt -90.03 77.65 6.82 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 120.897 -1.127 . . . . 0.0 109.218 -169.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.7 t -83.3 -146.68 0.08 Allowed 'General case' 0 CA--C 1.547 0.841 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.704 167.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -137.73 23.06 3.11 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.105 1.812 . . . . 0.0 112.751 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -173.35 -70.09 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -163.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -94.01 11.15 30.75 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.576 2.35 . . . . 0.0 114.788 -164.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . 0.25 3.9 m -140.85 -100.6 0.15 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -178.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.5 pt -89.89 -57.32 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 CA-C-N 121.545 1.975 . . . . 0.0 111.345 169.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.0 mm -61.89 145.69 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 170.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 96.35 -38.92 2.94 Favored Glycine 0 CA--C 1.524 0.597 0 CA-C-O 118.09 -1.395 . . . . 0.0 113.606 176.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.7 ptt180 -83.31 170.07 14.99 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 119.212 1.506 . . . . 0.0 112.539 175.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.2 t -119.01 176.92 5.06 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.226 1.01 . . . . 0.0 113.457 174.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 22.2 tp -156.92 136.57 12.33 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 126.273 1.829 . . . . 0.0 113.536 -168.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.4 t -112.03 135.38 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.988 1.315 . . . . 0.0 110.478 170.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 m -93.31 151.85 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 168.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 65.8 m-70 -119.38 144.12 47.07 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.684 1.194 . . . . 0.0 113.007 -172.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -83.75 -16.67 43.93 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 120.956 -1.09 . . . . 0.0 113.25 -179.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -98.03 164.0 12.53 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 169.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.09 164.21 1.76 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.997 1.319 . . . . 0.0 112.041 170.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -124.16 141.01 52.42 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.103 1.761 . . . . 0.0 110.209 -177.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -73.39 -34.38 65.5 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 125.73 1.612 . . . . 0.0 110.862 177.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.439 HD21 HD22 ' A' ' 86' ' ' ASN . 42.6 mt 78.74 -24.19 0.22 Allowed 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 130.026 3.331 . . . . 0.0 113.272 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -137.23 -81.99 0.11 Allowed Glycine 0 N--CA 1.475 1.279 0 CA-C-N 121.379 1.9 . . . . 0.0 114.271 -175.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -158.23 139.21 13.13 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 128.29 2.636 . . . . 0.0 107.518 174.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -127.25 -119.87 2.29 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 126.708 2.099 . . . . 0.0 109.946 167.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -92.27 -33.57 7.58 Favored Glycine 0 N--CA 1.474 1.219 0 N-CA-C 117.629 1.811 . . . . 0.0 117.629 -167.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 32.6 p30 -114.44 172.09 7.23 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.384 1.473 . . . . 0.0 113.156 -168.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -48.58 -61.72 1.88 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 126.29 1.836 . . . . 0.0 110.506 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -41.1 -42.05 1.89 Allowed 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 128.509 2.724 . . . . 0.0 114.383 175.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.426 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 85.7 p -55.27 -28.83 56.07 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 121.499 1.954 . . . . 0.0 113.456 177.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -97.82 -32.65 11.6 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 113.806 1.039 . . . . 0.0 113.806 169.471 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -91.13 -15.12 29.93 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.547 1.939 . . . . 0.0 115.006 -169.143 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 77.2 p -137.3 -16.03 1.42 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 128.444 2.698 . . . . 0.0 112.81 170.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.04 12.24 60.47 Favored Glycine 0 C--N 1.341 0.861 0 C-N-CA 124.062 0.839 . . . . 0.0 112.284 -167.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.426 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 7.9 t-20 53.4 26.61 5.54 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.158 1.383 . . . . 0.0 111.563 -168.145 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.7 6.96 0.56 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.652 1.181 . . . . 0.0 113.732 -169.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.03 -37.14 0.15 Allowed Glycine 0 CA--C 1.531 1.073 1 C-N-CA 131.128 4.204 . . . . 0.0 117.753 168.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 46.3 t -175.92 140.64 0.43 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.291 1.437 . . . . 0.0 111.428 -168.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.7 ptt-85 -77.42 174.6 10.64 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 123.702 0.801 . . . . 0.0 113.158 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.52 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -152.52 -143.02 0.13 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.417 1.887 . . . . 0.0 107.426 177.355 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.52 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -68.4 167.42 14.69 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.312 1.845 . . . . 0.0 112.727 177.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -140.18 153.24 46.55 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 125.004 1.322 . . . . 0.0 111.122 -169.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.54 141.18 7.32 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 124.193 0.901 . . . . 0.0 113.381 171.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' B' ' 148' ' ' VAL . 6.3 p -75.8 163.24 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 166.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.2 mm -93.09 94.37 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 121.37 -0.831 . . . . 0.0 110.032 170.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.3 -178.79 48.46 Favored Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.047 1.784 . . . . 0.0 113.759 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -113.99 130.58 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 124.659 1.183 . . . . 0.0 112.809 -170.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.52 -3.48 58.33 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.266 1.826 . . . . 0.0 112.472 176.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 . . . . . 0 CA--C 1.533 0.294 0 C-N-CA 125.149 1.38 . . . . 0.0 110.183 175.524 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.29 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -77.45 111.65 13.38 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 123.003 1.382 . . . . 0.0 108.675 -168.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mtmm -101.05 113.34 26.25 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 113.949 -1.478 . . . . 0.0 114.479 -171.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -95.89 175.47 6.49 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 127.036 2.134 . . . . 0.0 110.636 167.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -159.65 137.87 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 126.283 1.833 . . . . 0.0 110.677 -169.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.13 134.03 55.22 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 124.107 0.963 . . . . 0.0 109.016 165.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.58 114.76 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.157 0.983 . . . . 0.0 108.455 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.432 ' CD2' HG23 ' B' ' 119' ' ' VAL . 5.8 mp -98.14 130.91 44.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 126.29 1.836 . . . . 0.0 110.396 -167.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttt -150.57 175.63 11.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.485 1.114 . . . . 0.0 112.458 -177.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 139.97 -71.57 0.43 Allowed Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.868 2.651 . . . . 0.0 109.059 -172.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.71 69.79 1.81 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.813 2.045 . . . . 0.0 113.18 -169.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.6 -97.64 0.01 OUTLIER Glycine 0 CA--C 1.536 1.376 0 C-N-CA 127.607 2.527 . . . . 0.0 114.747 169.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -80.85 -16.41 10.17 Favored 'Trans proline' 0 C--N 1.352 0.727 0 C-N-CA 124.074 3.182 . . . . 0.0 114.304 -179.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 t -79.51 139.33 18.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 CA-C-N 120.561 1.528 . . . . 0.0 109.359 175.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.1 152.58 29.68 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 113.567 -1.651 . . . . 0.0 108.117 167.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.72 152.47 17.11 Favored Glycine 0 CA--C 1.488 -1.594 0 O-C-N 123.818 0.699 . . . . 0.0 111.817 172.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -126.7 130.87 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 166.081 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 11.1 mm -129.17 118.09 45.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 173.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -82.88 157.73 22.97 Favored 'General case' 0 N--CA 1.47 0.543 0 O-C-N 120.927 -1.108 . . . . 0.0 109.48 169.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.405 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 70.3 m-85 -139.54 87.26 2.17 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.76 1.224 . . . . 0.0 108.139 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -86.91 124.15 32.81 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 121.299 -0.875 . . . . 0.0 112.034 174.006 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -113.82 134.84 54.54 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.869 0.842 . . . . 0.0 110.822 165.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.33 -32.05 15.84 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 124.64 1.176 . . . . 0.0 112.552 179.188 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -99.14 -169.24 1.74 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.042 2.137 . . . . 0.0 109.836 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.9 m -118.28 -6.15 10.83 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 120.634 -1.291 . . . . 0.0 113.277 167.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 61.0 m-80 -141.67 19.89 2.18 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 126.36 1.864 . . . . 0.0 112.379 175.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.0 -158.17 14.22 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.596 2.046 . . . . 0.0 113.193 175.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.84 154.02 29.83 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.228 2.619 . . . . 0.0 113.776 -172.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.86 133.34 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 126.364 1.866 . . . . 0.0 110.377 178.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -89.81 122.62 33.05 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.456 1.103 . . . . 0.0 110.607 171.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.19 84.66 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 128.081 2.553 . . . . 0.0 109.787 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 5.9 p90 -106.81 153.57 22.27 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 123.717 0.807 . . . . 0.0 111.234 169.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.01 -158.39 30.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 124.349 0.976 . . . . 0.0 112.141 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 91.8 p -159.41 136.04 9.26 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 -172.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.469 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.5 mp -112.51 111.7 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 124.536 1.134 . . . . 0.0 109.77 173.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -116.43 133.63 55.8 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 123.829 0.852 . . . . 0.0 111.371 -169.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.66 -2.23 26.14 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 125.827 1.68 . . . . 0.0 114.792 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.3 pp -83.8 178.5 7.89 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 118.858 1.329 . . . . 0.0 109.59 169.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.72 163.33 22.52 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 124.052 0.941 . . . . 0.0 109.415 169.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . 0.437 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 0.7 OUTLIER -52.56 178.54 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 177.724 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.31 -166.97 54.86 Favored Glycine 0 CA--C 1.527 0.827 0 O-C-N 120.274 -1.516 . . . . 0.0 112.958 172.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 77.3 mt -73.84 148.98 41.89 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.8 1.64 . . . . 0.0 111.764 -173.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -149.0 126.65 11.7 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 127.349 2.26 . . . . 0.0 110.437 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.55 157.1 25.67 Favored Glycine 0 N--CA 1.49 2.283 0 CA-C-O 117.625 -1.653 . . . . 0.0 112.756 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -157.58 110.84 2.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.469 2.308 . . . . 0.0 112.449 171.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.6 m80 -138.08 144.02 40.73 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 119.905 -1.747 . . . . 0.0 111.389 -175.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 132.63 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 C-N-CA 123.978 0.911 . . . . 0.0 110.118 177.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -75.37 117.42 17.15 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 168.184 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -73.37 60.46 0.62 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.469 1.908 . . . . 0.0 114.217 -168.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -179.4 164.25 1.31 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 128.983 2.913 . . . . 0.0 109.461 170.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.43 -10.29 55.87 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.245 0.926 . . . . 0.0 114.66 169.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.503 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -82.03 51.37 1.74 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 126.942 2.097 . . . . 0.0 110.439 -176.021 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' C ' ' B' ' 53' ' ' ASN . 0.4 OUTLIER 171.26 33.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 0.997 0 N-CA-C 115.805 1.779 . . . . 0.0 115.805 -164.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 118.184 2.661 . . . . 0.0 118.184 -168.971 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.619 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.27 158.91 20.55 Favored Glycine 0 CA--C 1.534 1.263 0 CA-C-O 117.672 -1.627 . . . . 0.0 110.728 169.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -55.04 103.52 0.1 Allowed 'Trans proline' 0 C--N 1.355 0.92 1 C-N-CA 125.663 4.242 . . . . 0.0 109.936 178.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 46.12 62.02 2.44 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 113.679 -1.601 . . . . 0.0 111.131 -175.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -37.62 134.19 0.71 Allowed 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.398 1.479 . . . . 0.0 112.183 -175.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -117.26 80.15 11.99 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -165.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.92 -13.32 34.12 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 123.101 2.534 . . . . 0.0 114.119 177.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -90.0 -6.69 55.34 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.85 1.26 . . . . 0.0 112.679 177.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.3 t 50.77 50.59 18.69 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 127.514 2.325 . . . . 0.0 114.703 -177.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -108.65 177.34 4.81 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 124.85 1.26 . . . . 0.0 113.065 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.11 164.69 22.22 Favored 'General case' 0 N--CA 1.47 0.555 0 O-C-N 121.342 -0.849 . . . . 0.0 110.73 167.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.477 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 63.8 t60 -68.1 -176.33 0.7 Allowed 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 122.095 0.95 . . . . 0.0 113.111 -176.108 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.477 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 111.07 -154.52 16.61 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 124.513 1.054 . . . . 0.0 115.492 165.063 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 166.13 -89.38 0.1 Allowed Glycine 0 CA--C 1.528 0.864 0 CA-C-O 118.205 -1.331 . . . . 0.0 114.725 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -67.9 -1.12 6.35 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 123.049 2.5 . . . . 0.0 114.15 -175.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -129.24 -4.14 4.95 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 125.613 1.565 . . . . 0.0 112.631 168.288 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -153.19 112.84 3.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.932 1.293 . . . . 0.0 110.347 -169.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -64.13 -12.2 37.42 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.324 1.85 . . . . 0.0 114.572 -175.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -75.44 -22.67 57.16 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 120.235 1.379 . . . . 0.0 113.651 -170.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 12.4 ttp85 14.57 100.97 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 130.564 3.546 . . . . 0.0 115.325 164.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.1 m170 -51.49 155.75 1.45 Allowed 'General case' 0 CA--C 1.558 1.258 0 CA-C-O 117.272 -1.347 . . . . 0.0 109.834 168.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.316 85.3 t -74.57 -17.49 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-N 123.865 3.029 . . . . 0.0 110.231 -175.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.47 7.52 64.55 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 127.423 2.44 . . . . 0.0 114.404 166.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -98.93 119.25 37.4 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.838 1.819 . . . . 0.0 113.401 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 63.3 mt -102.27 -176.06 3.01 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 126.73 2.012 . . . . 0.0 106.015 164.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.23 -144.91 5.09 Favored Glycine 0 CA--C 1.534 1.275 0 O-C-N 120.891 -1.13 . . . . 0.0 114.114 -178.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.65 152.16 49.46 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 123.983 0.913 . . . . 0.0 109.818 168.677 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 9.8 p -113.72 142.18 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.57 1.948 . . . . 0.0 112.207 -168.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -115.08 120.01 38.36 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.047 1.129 . . . . 0.0 114.047 -169.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.49 155.34 17.89 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 119.043 2.979 . . . . 0.0 119.043 175.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -84.51 164.89 18.51 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-N 111.631 -2.532 . . . . 0.0 109.808 167.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.16 -12.45 5.17 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 115.129 1.529 . . . . 0.0 115.129 171.399 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.66 -27.32 61.18 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.837 1.655 . . . . 0.0 111.2 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.24 -2.27 54.46 Favored Glycine 0 CA--C 1.523 0.544 0 CA-C-O 117.661 -1.633 . . . . 0.0 114.355 -177.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 9.5 p -79.48 118.49 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 119.572 1.686 . . . . 0.0 112.352 168.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -89.02 119.56 29.65 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.454 1.502 . . . . 0.0 108.587 166.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -80.46 140.27 36.02 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 118.492 0.587 . . . . 0.0 110.593 174.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -128.75 134.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.267 -1.333 . . . . 0.0 110.437 166.617 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.3 p -156.61 56.67 0.55 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 122.762 1.267 . . . . 0.0 109.628 -169.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 54.8 mt -114.78 160.68 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 125.044 1.337 . . . . 0.0 111.285 -169.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -133.47 146.15 50.87 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.837 2.055 . . . . 0.0 108.467 169.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -140.35 125.75 18.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 124.702 1.201 . . . . 0.0 110.442 -169.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 79.4 p -107.04 57.72 0.63 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.745 1.218 . . . . 0.0 112.308 -172.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -154.56 -41.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.93 173.67 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.232 -0.918 . . . . 0.0 112.026 177.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 25.8 m -158.25 162.99 37.86 Favored 'General case' 0 N--CA 1.481 1.081 0 O-C-N 119.579 -1.95 . . . . 0.0 115.028 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.35 59.24 1.8 Allowed 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.611 2.364 . . . . 0.0 108.484 175.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.9 t -89.82 1.3 56.32 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.242 1.017 . . . . 0.0 113.276 -175.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.17 -32.46 1.11 Allowed Glycine 0 N--CA 1.474 1.179 0 C-N-CA 125.029 1.3 . . . . 0.0 114.818 177.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -123.51 -95.06 0.48 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.985 1.314 . . . . 0.0 112.76 -169.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -75.92 3.07 10.9 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 119.678 -1.889 . . . . 0.0 114.344 -164.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.9 t -107.2 -128.85 0.27 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.677 -175.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 pt -84.0 -18.64 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 121.516 1.962 . . . . 0.0 115.981 -179.142 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mm -69.4 134.3 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.389 0.995 . . . . 0.0 111.017 -171.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.22 -2.75 75.12 Favored Glycine 0 CA--C 1.533 1.213 0 CA-C-O 117.836 -1.535 . . . . 0.0 114.038 -178.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.6 mtm180 -86.58 158.33 19.53 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 119.476 1.638 . . . . 0.0 109.998 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.5 t -115.98 119.85 37.23 Favored 'General case' 0 N--CA 1.486 1.346 0 CA-C-N 120.41 1.459 . . . . 0.0 112.942 -168.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 36.6 tp -94.93 121.33 36.43 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 126.511 1.924 . . . . 0.0 110.476 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 p -107.39 126.32 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.6 1.16 . . . . 0.0 110.194 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.432 HG23 ' CD2' ' B' ' 8' ' ' LEU . 67.5 t -89.15 163.57 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 168.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.9 m-70 -123.8 138.21 54.54 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.964 1.306 . . . . 0.0 111.286 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.1 pp20? -70.94 -11.23 60.85 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.177 -1.577 . . . . 0.0 114.549 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -115.62 167.03 11.27 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.107 1.363 . . . . 0.0 112.707 168.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.07 150.54 7.97 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.773 1.629 . . . . 0.0 110.434 166.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -112.53 144.68 41.6 Favored 'General case' 0 C--O 1.243 0.735 0 CA-C-O 121.717 0.77 . . . . 0.0 112.762 -178.172 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -76.45 -25.29 54.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.571 1.548 . . . . 0.0 111.748 -177.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt 48.61 51.93 14.69 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 126.949 2.099 . . . . 0.0 111.473 170.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 170.21 -94.44 0.1 Allowed Glycine 0 C--N 1.334 0.43 0 N-CA-C 117.11 1.604 . . . . 0.0 117.11 173.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 ptpp? -163.27 30.46 0.09 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -164.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -51.64 -22.06 7.77 Favored Glycine 0 N--CA 1.477 1.404 0 N-CA-C 119.388 2.515 . . . . 0.0 119.388 -168.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 175.77 -18.68 0.04 OUTLIER Glycine 0 N--CA 1.474 1.182 0 N-CA-C 117.565 1.786 . . . . 0.0 117.565 174.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -144.68 179.37 7.34 Favored 'General case' 0 CA--C 1.545 0.782 0 CA-C-N 119.291 1.546 . . . . 0.0 113.56 -173.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . 0.262 0.0 OUTLIER -49.84 -63.91 0.97 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.848 2.059 . . . . 0.0 111.435 172.232 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -54.11 -33.7 58.37 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 121.593 1.997 . . . . 0.0 113.373 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.15 -32.81 62.41 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 121.083 1.765 . . . . 0.0 114.193 172.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -105.32 -12.53 16.02 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.435 1.094 . . . . 0.0 113.499 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.7 tttt -96.54 -35.82 10.97 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.381 1.873 . . . . 0.0 112.705 -178.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.2 p -126.78 -20.65 4.22 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 125.139 1.376 . . . . 0.0 114.689 175.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.58 13.83 42.95 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.554 1.073 . . . . 0.0 110.534 -166.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 66.43 -68.08 0.14 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.769 3.228 . . . . 0.0 110.111 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 57.69 -66.7 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 131.445 3.898 . . . . 0.0 113.243 177.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.35 -28.71 4.98 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 127.523 2.487 . . . . 0.0 111.977 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.2 t -166.49 -161.63 0.47 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 124.605 1.162 . . . . 0.0 112.108 173.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -119.53 -156.49 0.66 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 128.328 2.651 . . . . 0.0 109.558 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -179.82 -164.55 0.06 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.867 2.467 . . . . 0.0 107.275 -171.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.89 144.25 23.43 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 127.243 2.217 . . . . 0.0 111.532 176.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -144.36 147.84 33.95 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -175.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.04 150.01 19.92 Favored Glycine 0 N--CA 1.476 1.355 0 C-N-CA 124.693 1.14 . . . . 0.0 114.651 -174.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' A' ' 148' ' ' VAL . 5.0 t -82.37 150.25 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.67 -0.9 . . . . 0.0 113.059 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -77.26 78.9 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 C-N-CA 126.562 1.945 . . . . 0.0 110.94 171.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -97.02 -158.96 31.3 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.243 1.878 . . . . 0.0 112.644 173.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -136.69 148.87 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -95.91 -120.07 0.11 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 103.058 -2.941 . . . . 0.0 103.058 163.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.471 0.597 0 C-N-CA 123.787 0.835 . . . . 0.0 112.674 166.051 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.446 -0.672 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -146.06 138.94 25.7 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 116.413 2.005 . . . . 0.0 116.413 177.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 169.63 9.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 127.258 2.223 . . . . 0.0 111.439 171.358 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.556 HG22 HG21 ' B' ' 54' ' ' THR . 14.7 p -158.6 110.51 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.772 1.629 . . . . 0.0 111.739 173.177 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.79 116.29 12.0 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.755 1.222 . . . . 0.0 112.442 -167.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 p -81.42 84.51 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.69 100.69 8.83 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 173.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -159.68 80.12 0.72 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 123.482 0.713 . . . . 0.0 112.172 -172.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.03 8.02 3.53 Favored Glycine 0 N--CA 1.472 1.056 0 C-N-CA 125.813 1.673 . . . . 0.0 113.658 169.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -133.46 54.88 1.93 Allowed 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 125.761 1.624 . . . . 0.0 108.74 -168.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 29.51 -98.23 0.01 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 129.381 3.372 . . . . 0.0 115.735 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.3 -15.22 47.42 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 124.2 3.266 . . . . 0.0 115.001 -176.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 t -111.34 128.86 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 125.058 1.343 . . . . 0.0 108.515 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.98 162.68 40.32 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.82 -174.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.45 170.07 29.0 Favored Glycine 0 CA--C 1.505 -0.592 0 CA-C-O 122.571 1.095 . . . . 0.0 114.206 174.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -130.76 128.27 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 C-N-CA 126.618 1.967 . . . . 0.0 106.356 173.498 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -137.94 112.53 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 121.312 -0.867 . . . . 0.0 109.72 172.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 28.1 m-80 -75.75 157.78 33.09 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.032 0.933 . . . . 0.0 111.091 178.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -141.58 127.93 19.93 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.812 1.245 . . . . 0.0 107.823 168.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -91.66 120.19 32.21 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.017 0.826 . . . . 0.0 112.138 174.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.469 HE22 ' HB2' ' A' ' 105' ' ' SER . 9.8 tp60 -88.49 78.45 7.86 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 118.658 -2.526 . . . . 0.0 105.701 167.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.7 ptmt -58.19 -41.52 84.12 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 120.909 -1.119 . . . . 0.0 110.669 175.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -155.19 142.46 19.43 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 129.41 3.084 . . . . 0.0 108.088 -166.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 m -48.23 -44.42 33.18 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 116.175 1.917 . . . . 0.0 116.175 -167.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -126.12 23.38 7.1 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.783 1.233 . . . . 0.0 112.0 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.75 167.82 53.58 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.134 -0.815 . . . . 0.0 112.481 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -65.73 151.36 84.67 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.37 2.047 . . . . 0.0 109.496 169.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -135.62 134.63 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-O 122.63 1.205 . . . . 0.0 110.702 -175.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 ttmm -81.03 128.26 33.51 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 114.056 -1.429 . . . . 0.0 108.212 167.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 64.0 t -124.91 111.17 26.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 126.846 2.058 . . . . 0.0 110.599 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.2 p90 -144.81 154.85 43.11 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -168.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 162.11 -138.94 5.66 Favored Glycine 0 C--N 1.335 0.496 0 O-C-N 120.903 -1.123 . . . . 0.0 112.895 172.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -154.08 131.61 11.37 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -169.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mm -117.34 126.6 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 123.944 0.898 . . . . 0.0 109.322 173.169 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -123.7 142.23 51.27 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.305 1.842 . . . . 0.0 110.763 -168.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.49 -16.41 57.87 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 125.946 1.736 . . . . 0.0 111.774 -169.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -65.01 113.02 3.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 167.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -60.13 -41.54 92.91 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.97 0.804 . . . . 0.0 111.627 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.3 -178.16 1.98 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.381 1.073 . . . . 0.0 113.017 -168.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 65.96 176.27 6.53 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.961 1.267 . . . . 0.0 115.544 166.6 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.39 142.88 46.96 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 169.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -127.03 127.72 45.2 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 127.493 2.317 . . . . 0.0 107.145 174.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.84 156.43 40.35 Favored Glycine 0 N--CA 1.467 0.766 0 CA-C-O 119.016 -0.88 . . . . 0.0 111.13 -176.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.41 130.61 17.48 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 118.037 0.919 . . . . 0.0 109.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -154.89 161.97 41.26 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 120.337 -1.477 . . . . 0.0 111.1 173.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' CA ' ' A' ' 82' ' ' GLY . 0.8 OUTLIER -104.37 135.83 40.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-O 122.629 1.204 . . . . 0.0 110.92 176.11 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -73.53 176.69 5.9 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 126.562 1.945 . . . . 0.0 110.526 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -72.18 -14.36 61.79 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.608 1.706 . . . . 0.0 115.608 174.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.461 ' C ' ' HA ' ' A' ' 115' ' ' ARG . 22.3 m-85 -157.03 172.97 17.73 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 129.757 3.223 . . . . 0.0 107.609 -167.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.17 30.28 4.44 Favored Glycine 0 C--O 1.223 -0.581 0 N-CA-C 108.677 -1.769 . . . . 0.0 108.677 165.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -82.24 109.53 16.61 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 119.408 1.604 . . . . 0.0 111.027 -166.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.438 HD21 HG22 ' A' ' 148' ' ' VAL 0.299 1.9 p30 -159.18 32.54 0.2 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 117.915 2.561 . . . . 0.0 117.915 179.284 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.735 HG22 HG23 ' B' ' 5' ' ' VAL . 0.1 OUTLIER -84.84 -35.54 22.19 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 126.078 1.751 . . . . 0.0 112.883 -167.816 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -115.06 -13.68 11.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.021 1.729 . . . . 0.0 113.429 177.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.58 -75.68 0.84 Allowed Glycine 0 CA--C 1.529 0.939 0 C-N-CA 124.49 1.043 . . . . 0.0 111.524 -174.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.8 m -65.65 -17.62 64.73 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.9 p -127.51 33.43 4.84 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.333 1.453 . . . . 0.0 112.103 171.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 97.7 p -179.42 106.67 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.334 1.853 . . . . 0.0 110.56 177.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 166.53 73.43 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 131.183 3.793 . . . . 0.0 109.097 175.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.62 107.87 2.38 Favored Glycine 0 CA--C 1.542 1.725 0 C-N-CA 125.194 1.378 . . . . 0.0 114.665 -169.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -86.56 101.09 0.58 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 124.041 3.161 . . . . 0.0 112.008 -168.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 55.44 39.73 31.19 Favored 'General case' 0 C--O 1.242 0.7 0 C-N-CA 127.495 2.318 . . . . 0.0 113.221 170.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -77.05 124.69 28.15 Favored 'General case' 0 C--O 1.234 0.269 0 O-C-N 120.365 -1.46 . . . . 0.0 108.148 169.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.79 135.09 8.98 Favored Pre-proline 0 CA--C 1.539 0.554 0 CA-C-N 114.048 -1.433 . . . . 0.0 112.252 -173.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -71.43 -2.42 11.24 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.051 2.501 . . . . 0.0 114.214 -172.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 26.8 mt -79.51 -20.01 48.27 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 118.947 0.794 . . . . 0.0 112.038 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t 49.07 50.98 17.05 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 125.247 1.419 . . . . 0.0 113.371 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.0 mtm-85 -112.53 178.51 4.27 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 125.251 1.42 . . . . 0.0 112.666 -173.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.77 161.14 27.91 Favored 'General case' 0 CA--C 1.553 1.093 0 CA-C-N 118.504 0.593 . . . . 0.0 109.811 164.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.444 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 82.1 t60 -66.51 -175.91 0.41 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.503 1.521 . . . . 0.0 112.542 -177.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.444 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 107.26 -138.27 14.41 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 115.549 0.98 . . . . 0.0 115.549 165.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.89 -64.54 0.6 Allowed Glycine 0 CA--C 1.541 1.68 0 N-CA-C 116.941 1.536 . . . . 0.0 116.941 -174.322 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.95 -4.55 15.31 Favored 'Trans proline' 0 CA--C 1.544 1.011 0 CA-C-N 121.11 2.455 . . . . 0.0 114.427 -178.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.59 -1.47 0.52 Allowed 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 126.154 1.782 . . . . 0.0 114.207 172.101 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -124.19 148.34 47.34 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.395 2.278 . . . . 0.0 107.405 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.04 -20.68 30.07 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 127.3 2.24 . . . . 0.0 112.735 -168.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -83.68 -64.96 1.07 Allowed 'General case' 0 C--O 1.232 0.149 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -169.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 34.7 ttt-85 66.19 120.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.285 1.434 . . . . 0.0 111.724 -177.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -65.53 172.56 3.24 Favored 'General case' 0 CA--C 1.544 0.716 0 O-C-N 119.567 -1.958 . . . . 0.0 109.355 165.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -35.29 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.313 -1.492 . . . . 0.0 112.644 168.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.503 ' CA ' HG23 ' A' ' 47' ' ' VAL . . . -107.71 50.65 0.77 Allowed Glycine 0 CA--C 1.534 1.277 0 N-CA-C 117.007 1.563 . . . . 0.0 117.007 -169.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -124.45 119.17 28.41 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.56 -0.965 . . . . 0.0 113.291 -169.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -97.35 175.5 6.23 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.944 1.298 . . . . 0.0 108.586 167.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.59 170.18 29.4 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.676 1.132 . . . . 0.0 111.214 169.034 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -76.79 145.85 38.24 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.56 1.318 . . . . 0.0 114.56 -176.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.21 122.71 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 127.23 2.212 . . . . 0.0 109.27 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 99.0 m -110.73 121.59 45.71 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -169.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.53 142.02 32.59 Favored 'General case' 0 N--CA 1.445 -0.702 0 C-N-CA 125.582 1.553 . . . . 0.0 113.328 -172.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.439 ' OD1' ' HE3' ' A' ' 91' ' ' LYS . 29.1 t0 -91.91 148.33 22.3 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.127 -1.397 . . . . 0.0 110.906 168.554 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.439 ' HE3' ' OD1' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -47.26 -21.23 0.25 Allowed 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 128.61 2.764 . . . . 0.0 117.38 -170.336 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -74.97 -0.71 19.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 127.492 2.317 . . . . 0.0 111.818 177.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.06 32.16 6.27 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 117.365 -1.797 . . . . 0.0 114.059 170.322 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -152.85 132.53 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 N-CA-C 117.152 2.279 . . . . 0.0 117.152 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.52 109.71 22.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.96 164.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -91.5 133.3 35.63 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -141.0 145.94 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 118.515 2.783 . . . . 0.0 118.515 -168.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 93.8 p -142.81 105.52 4.5 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.39 1.876 . . . . 0.0 110.018 168.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.3 mt -107.17 150.85 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 C-N-CA 125.916 1.686 . . . . 0.0 108.929 169.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -144.45 138.29 27.57 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.954 1.702 . . . . 0.0 107.631 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -157.05 152.25 26.26 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.162 0.985 . . . . 0.0 112.252 -168.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.3 p -119.17 55.2 0.95 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.469 1.108 . . . . 0.0 113.609 -168.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.6 p -158.56 -27.34 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 124.756 1.222 . . . . 0.0 112.776 171.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.56 150.02 5.51 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.327 0 O-C-N 121.062 -1.024 . . . . 0.0 111.029 175.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.469 ' HB2' HE22 ' A' ' 22' ' ' GLN . 2.9 p -158.05 162.92 38.13 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 121.057 -1.027 . . . . 0.0 109.174 171.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mp -85.83 47.82 1.5 Allowed 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.413 -1.429 . . . . 0.0 110.923 -172.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.6 t -82.18 -0.48 45.22 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -172.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.48 -7.02 74.58 Favored Glycine 0 N--CA 1.477 1.368 0 N-CA-C 118.216 2.046 . . . . 0.0 118.216 169.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -121.15 -94.81 0.49 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.637 1.575 . . . . 0.0 110.46 -167.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m170 -91.49 5.76 48.21 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -168.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.3 p -107.43 -70.71 0.78 Allowed 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 117.532 2.419 . . . . 0.0 117.532 -166.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pt -159.28 -51.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 125.747 1.619 . . . . 0.0 113.324 -167.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.43 145.62 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 125.89 1.676 . . . . 0.0 108.347 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.83 -22.08 2.99 Favored Glycine 0 N--CA 1.47 0.92 0 C-N-CA 124.585 1.088 . . . . 0.0 112.125 -167.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.461 ' HA ' ' C ' ' A' ' 50' ' ' PHE . 41.8 mtt180 -85.38 176.81 8.06 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.851 2.06 . . . . 0.0 110.948 169.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -108.76 133.66 52.52 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 127.471 2.309 . . . . 0.0 108.032 171.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.405 ' HB3' HD11 ' A' ' 149' ' ' ILE . 26.5 tp -102.41 118.05 36.04 Favored 'General case' 0 CA--C 1.535 0.365 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 168.349 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -112.15 129.81 66.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 CA-C-N 119.253 0.933 . . . . 0.0 110.815 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' A' ' 144' ' ' LEU . 2.4 p -88.92 145.99 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 121.394 0.616 . . . . 0.0 109.837 169.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -102.92 161.55 13.66 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.817 1.647 . . . . 0.0 111.83 -175.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.13 -31.91 62.95 Favored 'General case' 0 N--CA 1.473 0.704 0 O-C-N 121.081 -1.012 . . . . 0.0 112.086 -173.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 27.6 mmtm -131.86 -178.92 5.1 Favored 'General case' 0 C--O 1.237 0.4 0 O-C-N 119.234 -2.166 . . . . 0.0 110.974 169.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.72 129.02 39.38 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 125.077 1.351 . . . . 0.0 109.298 -176.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.18 152.62 30.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 166.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.27 -17.92 61.27 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.945 178.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 13.4 mt 61.77 41.96 11.2 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.037 1.335 . . . . 0.0 110.227 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 175.28 -97.08 0.11 Allowed Glycine 0 N--CA 1.471 0.999 0 N-CA-C 118.969 2.348 . . . . 0.0 118.969 177.351 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.0 pttt -162.69 37.26 0.11 Allowed 'General case' 0 CA--C 1.555 1.139 0 C-N-CA 127.99 2.516 . . . . 0.0 113.631 -167.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -55.07 -12.7 4.13 Favored Glycine 0 CA--C 1.539 1.535 0 N-CA-C 120.132 2.813 . . . . 0.0 120.132 -168.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.47 -28.8 0.5 Allowed Glycine 0 N--CA 1.477 1.379 0 CA-C-N 121.085 2.442 . . . . 0.0 118.038 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.407 HD21 ' ND2' ' A' ' 139' ' ' ASN . 22.1 p-10 -107.13 166.62 10.48 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 119.404 1.602 . . . . 0.0 109.656 174.143 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -57.05 -48.58 78.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 119.932 1.242 . . . . 0.0 109.67 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -48.54 -34.56 11.59 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.722 2.809 . . . . 0.0 113.046 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.6 p -57.7 -28.22 63.64 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 173.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.09 -23.82 10.68 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 169.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -59.18 -28.07 66.28 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.484 1.038 . . . . 0.0 111.467 172.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.9 p -133.87 -93.04 0.33 Allowed 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 166.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -158.12 24.81 0.4 Allowed Glycine 0 CA--C 1.537 1.428 0 C-N-CA 130.194 3.759 . . . . 0.0 109.224 168.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.407 ' ND2' HD21 ' A' ' 131' ' ' ASN . 23.8 t-20 67.11 -84.0 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.367 1.867 . . . . 0.0 107.787 -166.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 66.52 2.15 2.38 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 127.821 2.448 . . . . 0.0 116.711 166.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.71 -57.81 3.01 Favored Glycine 0 CA--C 1.53 1.004 0 C-N-CA 125.683 1.611 . . . . 0.0 113.681 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.5 t -171.83 -177.4 1.95 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.166 1.387 . . . . 0.0 111.306 -171.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.8 164.88 13.18 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 121.151 -0.968 . . . . 0.0 111.926 172.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.476 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -150.94 -152.57 0.44 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 127.568 2.347 . . . . 0.0 106.577 174.817 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.476 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -37.47 112.15 0.19 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.8 2.04 . . . . 0.0 114.296 -170.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.5 t -109.29 138.96 44.86 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.065 2.146 . . . . 0.0 110.538 -175.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.5 -178.57 21.13 Favored Glycine 0 N--CA 1.469 0.899 0 C-N-CA 124.588 1.09 . . . . 0.0 114.32 -175.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.438 HG22 HD21 ' A' ' 53' ' ' ASN . 0.2 OUTLIER -127.97 160.41 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 104.893 -2.262 . . . . 0.0 104.893 165.723 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.405 HD11 ' HB3' ' A' ' 117' ' ' LEU . 2.6 mm -135.04 130.56 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 CA-C-N 120.069 1.304 . . . . 0.0 112.434 -168.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.27 -114.04 1.37 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.668 1.604 . . . . 0.0 115.025 -175.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -158.38 129.25 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 118.877 1.338 . . . . 0.0 109.756 -177.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 -35.55 14.95 Favored 'General case' 0 N--CA 1.47 0.531 0 O-C-N 120.929 -1.107 . . . . 0.0 112.42 177.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 . . . . . 0 C--O 1.235 0.294 0 C-N-CA 127.264 2.226 . . . . 0.0 110.005 -171.524 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.549 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 99.2 m -79.17 105.21 10.34 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 169.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.496 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -97.66 122.52 40.84 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.709 1.203 . . . . 0.0 113.366 -168.409 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.52 178.12 8.37 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 120.911 -1.118 . . . . 0.0 114.005 -177.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.735 HG23 HG22 ' A' ' 54' ' ' THR . 0.2 OUTLIER -147.86 110.03 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 128.053 2.541 . . . . 0.0 106.784 169.314 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -99.3 133.28 43.82 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.951 0.9 . . . . 0.0 108.631 166.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -131.36 99.42 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 123.256 0.622 . . . . 0.0 110.965 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.8 mp -88.21 141.69 28.36 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 124.067 0.854 . . . . 0.0 109.867 169.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -156.07 168.16 28.13 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.913 1.685 . . . . 0.0 112.073 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.48 -101.95 0.19 Allowed Glycine 0 C--O 1.226 -0.398 0 N-CA-C 107.583 -2.207 . . . . 0.0 107.583 166.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -149.42 124.84 10.26 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 129.014 2.926 . . . . 0.0 106.095 -169.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.07 -177.69 44.61 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 124.544 1.069 . . . . 0.0 112.81 -174.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -71.92 30.22 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.093 1 C-N-CA 126.157 4.571 . . . . 0.0 115.11 -170.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.11 123.78 63.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.558 1.543 . . . . 0.0 109.441 -177.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.65 163.71 36.48 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 124.272 1.029 . . . . 0.0 109.585 176.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.67 108.78 0.79 Allowed Glycine 0 N--CA 1.461 0.302 0 CA-C-N 114.106 -1.406 . . . . 0.0 110.373 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.46 128.88 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 123.956 0.902 . . . . 0.0 109.401 169.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mm -134.82 124.51 43.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 123.864 0.866 . . . . 0.0 109.231 168.324 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -79.9 149.63 30.84 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 126.697 1.999 . . . . 0.0 109.924 165.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -143.97 101.97 3.82 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.496 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.4 OUTLIER -108.83 116.86 32.78 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.367 1.067 . . . . 0.0 109.831 -169.572 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -116.96 142.28 47.15 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 122.652 1.215 . . . . 0.0 112.917 -172.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.562 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -90.74 -7.57 52.13 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.337 1.455 . . . . 0.0 114.61 -173.656 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . 0.562 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 48.9 mp0 -150.22 -173.99 4.6 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 127.368 2.267 . . . . 0.0 108.24 173.024 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.6 p -75.4 -26.71 58.65 Favored 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.47 -0.769 . . . . 0.0 111.215 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -135.25 9.99 3.49 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.274 1.429 . . . . 0.0 114.101 -171.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.54 174.02 55.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.236 0.922 . . . . 0.0 111.555 169.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.11 166.13 30.85 Favored 'Trans proline' 0 CA--C 1.536 0.578 0 C-N-CA 122.712 2.274 . . . . 0.0 111.116 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.58 132.58 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 C-N-CA 124.876 1.27 . . . . 0.0 110.661 -168.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -88.52 127.81 35.54 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 168.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.8 t -116.91 124.19 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 126.011 1.724 . . . . 0.0 109.058 -171.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -155.41 157.29 36.8 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.152 -0.968 . . . . 0.0 113.269 177.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.13 -160.74 30.67 Favored Glycine 0 CA--C 1.52 0.364 0 O-C-N 121.553 -0.717 . . . . 0.0 113.706 -177.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 53.3 p -149.24 133.19 17.11 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 113.276 0.843 . . . . 0.0 113.276 -168.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -106.01 113.43 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 O-C-N 121.724 -0.61 . . . . 0.0 109.794 171.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.7 ptpt -110.78 157.96 19.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.164 1.385 . . . . 0.0 110.613 -170.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.28 8.29 75.09 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 123.861 0.743 . . . . 0.0 113.997 -173.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -81.15 -152.4 0.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 127.19 2.196 . . . . 0.0 107.865 168.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . 0.499 HG23 ' H ' ' B' ' 40' ' ' GLU 0.282 7.9 t -137.14 -91.78 0.24 Allowed 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.996 1.318 . . . . 0.0 108.353 169.702 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . 0.499 ' H ' HG23 ' B' ' 39' ' ' THR . 0.0 OUTLIER -127.98 -56.55 1.27 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.438 1.495 . . . . 0.0 113.719 173.085 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.39 147.76 44.87 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 119.856 -1.778 . . . . 0.0 113.558 -169.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.442 ' H ' HD12 ' B' ' 42' ' ' LEU . 1.2 mp -44.9 141.91 2.0 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.84 2.056 . . . . 0.0 112.619 -173.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -126.09 130.64 51.49 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.689 1.596 . . . . 0.0 109.276 170.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.76 163.01 41.08 Favored Glycine 0 N--CA 1.482 1.717 0 CA-C-N 120.292 1.406 . . . . 0.0 111.516 172.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -152.46 130.31 11.7 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 120.673 2.237 . . . . 0.0 112.513 168.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.28 146.36 21.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.473 1.109 . . . . 0.0 111.999 -168.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 p -82.63 135.1 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 O-C-N 121.632 -0.667 . . . . 0.0 110.653 168.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.493 ' HB2' HG23 ' B' ' 116' ' ' THR . 7.5 m-70 -78.19 159.01 28.81 Favored 'General case' 0 CA--C 1.559 1.304 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.141 165.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -67.32 110.89 3.73 Favored 'General case' 0 N--CA 1.469 0.497 0 O-C-N 119.473 -2.017 . . . . 0.0 110.258 171.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . 0.432 ' O ' HG22 ' B' ' 116' ' ' THR . 4.3 m-30 142.31 167.37 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 1 C-N-CA 132.927 4.491 . . . . 0.0 110.176 175.717 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -131.13 14.83 5.39 Favored Glycine 0 C--O 1.222 -0.613 0 C-N-CA 126.42 1.962 . . . . 0.0 114.051 172.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -170.53 113.97 0.45 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.431 2.692 . . . . 0.0 103.972 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' B' ' 54' ' ' THR . 2.6 p30 -116.04 -64.49 1.3 Allowed 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 114.354 1.242 . . . . 0.0 114.354 -164.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.556 HG21 HG22 ' A' ' 5' ' ' VAL . 2.8 p . . . . . 0 N--CA 1.462 0.139 0 C-N-CA 128.919 2.888 . . . . 0.0 113.275 170.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.542 0.664 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -69.62 -178.57 21.51 Favored Glycine 0 CA--C 1.538 1.476 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.553 173.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -62.72 168.34 10.32 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.647 2.231 . . . . 0.0 110.849 171.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -45.08 115.36 0.89 Allowed 'General case' 0 C--O 1.236 0.35 0 N-CA-C 115.575 1.695 . . . . 0.0 115.575 -178.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -45.58 117.46 1.45 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.832 166.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -120.84 65.82 13.24 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 115.103 -0.953 . . . . 0.0 113.152 -167.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.81 -4.87 14.18 Favored 'Trans proline' 0 CA--C 1.539 0.766 0 C-N-CA 123.304 2.669 . . . . 0.0 114.561 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . 0.411 ' HB3' ' HD3' ' B' ' 69' ' ' ARG . 3.3 mm? -106.73 -6.11 18.05 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.198 0.999 . . . . 0.0 112.71 175.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 18.9 t 66.4 57.92 0.7 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.884 1.674 . . . . 0.0 114.722 171.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . 0.411 ' HD3' ' HB3' ' B' ' 67' ' ' LEU . 0.2 OUTLIER -154.06 -176.58 5.93 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 116.226 1.935 . . . . 0.0 116.226 -169.279 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -80.62 178.15 8.54 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.953 1.301 . . . . 0.0 112.194 -170.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -108.73 144.36 36.63 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.287 -1.324 . . . . 0.0 114.168 176.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 154.33 -102.2 0.22 Allowed Glycine 0 C--N 1.336 0.543 0 C-N-CA 126.37 1.938 . . . . 0.0 110.108 167.297 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -41.22 2.01 Favored Glycine 0 CA--C 1.542 1.774 0 CA-C-O 118.013 -1.437 . . . . 0.0 115.653 172.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_exo -79.62 -25.83 5.17 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 124.206 3.271 . . . . 0.0 112.12 168.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.79 -53.52 2.64 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.901 0.88 . . . . 0.0 110.49 168.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -63.84 106.16 0.96 Allowed 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.311 1.414 . . . . 0.0 111.88 172.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.8 mp0 -59.76 -9.75 3.12 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 129.259 3.023 . . . . 0.0 113.485 175.445 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -85.1 -98.02 0.06 Allowed 'General case' 0 N--CA 1.453 -0.321 0 O-C-N 121.411 -0.806 . . . . 0.0 110.684 174.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 94.09 133.37 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.169 1.787 . . . . 0.0 110.845 173.125 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -70.23 154.54 41.79 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 168.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.2 t -80.44 87.94 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 166.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.47 4.35 0.18 Allowed Glycine 0 CA--C 1.537 1.452 0 N-CA-C 117.672 1.829 . . . . 0.0 117.672 -169.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -150.65 150.51 31.22 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 119.828 1.814 . . . . 0.0 112.511 174.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.7 mt -124.16 49.05 1.82 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.116 169.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.97 -102.99 0.91 Allowed Glycine 0 CA--C 1.532 1.154 0 O-C-N 120.64 -1.287 . . . . 0.0 115.37 176.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -144.71 163.25 34.57 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.024 1.33 . . . . 0.0 113.505 -175.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.2 m -114.45 165.49 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 127.502 2.321 . . . . 0.0 110.115 170.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 62.6 m -146.43 141.31 27.01 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.903 1.281 . . . . 0.0 108.007 174.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -97.49 164.35 12.48 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -173.097 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.0 -52.09 9.35 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.457 1.503 . . . . 0.0 113.248 -171.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttp 151.62 -37.94 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.991 1 C-N-CA 133.775 4.83 . . . . 0.0 109.637 -168.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -84.66 25.79 0.87 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.897 1.679 . . . . 0.0 111.021 -178.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.34 3.67 77.57 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.815 1.674 . . . . 0.0 115.56 174.521 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -109.34 129.41 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 119.011 1.406 . . . . 0.0 113.425 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -95.3 129.77 42.31 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 125.165 1.386 . . . . 0.0 107.766 165.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -116.93 130.62 56.82 Favored 'General case' 0 C--O 1.233 0.188 0 C-N-CA 125.012 1.325 . . . . 0.0 109.037 -172.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 45.5 t -130.26 137.19 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-N 114.16 -1.382 . . . . 0.0 114.239 -166.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.4 p -151.61 105.23 3.13 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 125.462 1.505 . . . . 0.0 111.635 177.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 22.3 mt -135.99 163.28 34.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 128.239 2.615 . . . . 0.0 110.45 -172.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -139.22 140.14 37.67 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 126.465 1.906 . . . . 0.0 107.089 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -146.01 143.18 29.28 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.491 1.116 . . . . 0.0 111.641 -169.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 9.0 p -118.4 46.04 1.89 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.039 -0.982 . . . . 0.0 112.57 -176.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . 0.272 4.4 p -156.12 20.32 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 174.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -131.45 160.52 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 120.65 -1.281 . . . . 0.0 108.344 167.121 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 51.4 m -158.03 168.87 25.92 Favored 'General case' 0 N--CA 1.47 0.573 0 O-C-N 120.691 -1.256 . . . . 0.0 112.192 175.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.29 64.23 1.6 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 125.974 1.709 . . . . 0.0 109.345 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.6 t -155.3 84.07 1.06 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.453 -1.405 . . . . 0.0 113.357 -169.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.29 -159.0 28.26 Favored Glycine 0 C--N 1.336 0.563 0 CA-C-O 122.997 1.332 . . . . 0.0 112.471 170.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -69.1 -19.7 64.06 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 127.57 2.348 . . . . 0.0 113.769 -167.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 64.7 m170 -97.3 7.9 45.63 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.112 1.365 . . . . 0.0 113.221 -175.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 73.2 m -81.98 176.79 9.26 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -165.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.02 -18.95 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 120.786 -1.196 . . . . 0.0 110.798 163.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mm -75.78 124.92 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 165.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.28 68.8 1.54 Allowed Glycine 0 CA--C 1.527 0.839 0 O-C-N 123.614 0.571 . . . . 0.0 113.462 -169.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -143.17 136.04 27.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.206 1.002 . . . . 0.0 109.579 168.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . 0.493 HG23 ' HB2' ' B' ' 48' ' ' HIS . 3.6 t -96.42 77.8 2.99 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 124.864 1.266 . . . . 0.0 110.369 -173.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 54.5 tp -77.94 135.49 37.85 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.0 1.32 . . . . 0.0 109.881 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -129.64 146.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 126.067 1.747 . . . . 0.0 108.989 172.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 79.3 t -104.09 140.61 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 122.605 1.193 . . . . 0.0 107.897 168.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -95.6 160.02 14.71 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.625 2.37 . . . . 0.0 112.303 -170.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -80.97 -34.31 33.22 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 120.806 -1.184 . . . . 0.0 114.015 -167.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.4 mmmt -113.42 -176.52 2.92 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 120.176 -1.578 . . . . 0.0 112.428 173.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.29 143.64 27.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.64 1.176 . . . . 0.0 109.921 169.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.23 146.04 24.55 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.957 1.303 . . . . 0.0 109.041 172.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.41 -27.75 56.4 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 178.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 63.97 20.96 12.44 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.14 2.176 . . . . 0.0 114.34 174.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -150.68 -94.22 0.11 Allowed Glycine 0 N--CA 1.465 0.581 0 CA-C-N 120.583 1.538 . . . . 0.0 113.165 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 49.2 tttp -163.05 82.39 0.49 Allowed 'General case' 0 N--CA 1.432 -1.364 0 C-N-CA 127.172 2.189 . . . . 0.0 108.608 168.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.97 48.04 0.64 Allowed Glycine 0 CA--C 1.531 1.078 0 C-N-CA 126.778 2.133 . . . . 0.0 114.192 172.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 79.99 -10.97 37.67 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 118.084 1.994 . . . . 0.0 118.084 169.107 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 28.8 m-80 -115.28 177.78 4.53 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.765 2.282 . . . . 0.0 112.418 -169.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -59.11 -64.39 0.96 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.401 1.88 . . . . 0.0 108.992 165.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 48.7 mm-40 -47.8 -34.77 9.07 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.82 1.648 . . . . 0.0 113.37 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 8.8 m -55.97 -14.64 2.65 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 175.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 37.5 p -129.29 -24.56 2.82 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 168.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . 0.253 17.8 pttt -83.81 -6.0 59.33 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 115.764 1.765 . . . . 0.0 115.764 175.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 10.8 m -140.07 -44.64 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 124.948 1.299 . . . . 0.0 112.467 171.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.33 12.27 6.35 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.885 2.183 . . . . 0.0 114.151 -168.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 67.08 8.04 5.87 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 120.673 -1.487 . . . . 0.0 114.798 175.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.58 30.46 0.03 OUTLIER 'General case' 0 CA--C 1.564 1.506 0 N-CA-C 118.206 2.669 . . . . 0.0 118.206 -166.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.6 -51.4 3.37 Favored Glycine 0 N--CA 1.471 1.013 0 C-N-CA 127.218 2.342 . . . . 0.0 115.766 170.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 9.3 t -176.49 -163.1 0.09 Allowed 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.734 2.014 . . . . 0.0 110.545 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.21 142.27 17.03 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 119.77 -1.831 . . . . 0.0 115.739 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.74 -115.62 0.1 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 128.508 2.723 . . . . 0.0 111.266 -177.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.13 138.87 36.99 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 128.454 2.702 . . . . 0.0 111.114 -169.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -126.41 151.76 47.25 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 126.413 1.885 . . . . 0.0 112.274 -175.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.58 169.91 32.9 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 116.434 1.334 . . . . 0.0 116.434 -172.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . 0.273 0.4 OUTLIER -126.62 162.31 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 123.521 0.728 . . . . 0.0 109.753 170.066 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -120.95 127.64 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 124.412 1.085 . . . . 0.0 113.365 -166.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -123.89 -159.31 10.42 Favored Glycine 0 C--N 1.349 1.282 0 C-N-CA 125.039 1.304 . . . . 0.0 113.631 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -110.06 143.22 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 125.946 1.698 . . . . 0.0 111.959 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.448 ' HA ' ' CG ' ' A' ' 50' ' ' PHE . . . -124.49 37.98 4.29 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.456 1.902 . . . . 0.0 111.291 171.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.326 -0.429 0 C-N-CA 125.708 1.603 . . . . 0.0 109.829 -178.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 94.3 m . . . . . 0 N--CA 1.469 0.475 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.16 138.89 33.47 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -175.012 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.81 169.74 8.85 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 126.534 1.934 . . . . 0.0 112.18 173.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.3 t -147.48 153.89 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 127.95 2.5 . . . . 0.0 110.51 172.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.4 112.64 15.87 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 125.351 1.461 . . . . 0.0 107.168 165.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.6 m -82.66 90.95 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 173.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 25.0 mt -76.28 130.01 37.52 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.574 -172.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.1 mttm -152.29 -179.02 7.17 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.59 1.156 . . . . 0.0 113.152 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 134.84 -58.62 0.68 Allowed Glycine 0 N--CA 1.467 0.763 0 C-N-CA 125.968 1.747 . . . . 0.0 110.058 -178.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -78.44 69.04 4.57 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 122.087 0.946 . . . . 0.0 113.22 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 39.25 -100.38 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 C-N-CA 127.863 2.649 . . . . 0.0 115.71 169.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.98 -9.88 18.03 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 124.783 3.655 . . . . 0.0 114.56 -177.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 t -86.07 143.57 11.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-N 119.679 1.127 . . . . 0.0 110.008 172.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -156.36 158.24 37.04 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.51 168.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -117.18 126.83 7.12 Favored Glycine 0 C--O 1.22 -0.758 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.55 99.19 6.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 174.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -132.49 133.31 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 125.07 1.348 . . . . 0.0 109.525 -171.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -108.08 150.72 26.81 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.298 2.239 . . . . 0.0 111.208 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -122.22 134.75 54.7 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.567 1.947 . . . . 0.0 109.353 170.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -103.22 113.96 27.87 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 120.935 1.698 . . . . 0.0 110.904 172.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 37.1 tp60 -101.31 116.05 31.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 123.191 0.596 . . . . 0.0 109.488 172.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.1 pttp -102.9 -31.81 10.07 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 114.61 1.337 . . . . 0.0 114.61 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.7 mp0 -130.03 156.68 44.08 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 126.213 1.805 . . . . 0.0 108.766 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.0 m -55.68 -39.88 71.57 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 122.386 2.357 . . . . 0.0 116.244 -168.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.04 34.55 5.17 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.03 1.732 . . . . 0.0 110.422 167.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.89 153.47 51.35 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-O 118.129 -1.373 . . . . 0.0 111.021 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -66.38 142.7 67.01 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.123 2.549 . . . . 0.0 109.957 174.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.1 t -112.53 144.86 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.937 0.895 . . . . 0.0 110.879 -168.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.0 tttp -113.59 131.08 56.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.583 1.153 . . . . 0.0 108.804 167.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.96 144.49 16.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 127.872 2.469 . . . . 0.0 109.536 175.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -158.56 161.02 37.25 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.399 1.079 . . . . 0.0 113.185 172.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.63 -149.22 21.29 Favored Glycine 0 N--CA 1.469 0.865 0 C-N-CA 124.249 0.928 . . . . 0.0 112.693 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -153.57 148.75 26.9 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.4 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 16.9 mt -126.0 117.76 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 121.032 -1.043 . . . . 0.0 108.914 175.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.1 tttt -123.34 137.87 54.74 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 119.787 1.176 . . . . 0.0 112.168 -172.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.0 3.77 9.71 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 128.413 2.911 . . . . 0.0 113.886 -174.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.12 163.85 22.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 128.431 2.692 . . . . 0.0 112.074 176.302 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -95.07 158.4 15.48 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 166.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -64.07 145.22 56.29 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.99 -171.69 22.81 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.703 1.144 . . . . 0.0 114.591 -173.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 47.2 mt -66.23 146.94 54.04 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 125.532 1.533 . . . . 0.0 113.535 -169.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -144.99 128.59 17.11 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 127.01 2.124 . . . . 0.0 109.514 173.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.15 165.23 54.87 Favored Glycine 0 N--CA 1.473 1.137 0 CA-C-N 119.493 1.042 . . . . 0.0 112.292 -179.151 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.6 p90 -157.55 137.38 12.33 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.328 1.851 . . . . 0.0 113.706 167.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -148.58 163.87 35.94 Favored 'General case' 0 N--CA 1.451 -0.415 0 O-C-N 119.695 -1.878 . . . . 0.0 112.074 169.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -96.04 134.08 34.88 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-O 121.795 0.807 . . . . 0.0 110.266 173.159 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -71.51 116.06 11.42 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 103.66 -2.719 . . . . 0.0 103.66 168.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.647 ' H ' ' HA ' ' A' ' 63' ' ' HIS 0.305 3.6 tt0 -70.68 21.33 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.897 0 N-CA-C 115.988 1.847 . . . . 0.0 115.988 -168.513 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -132.82 148.94 52.31 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 126.872 2.069 . . . . 0.0 111.204 179.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.14 -17.77 42.08 Favored Glycine 0 N--CA 1.465 0.591 0 CA-C-O 117.129 -1.928 . . . . 0.0 115.155 169.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.467 ' C ' HD22 ' A' ' 53' ' ' ASN . 15.4 t0 -72.39 88.78 1.2 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.053 1.927 . . . . 0.0 106.945 168.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.467 HD22 ' C ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER 168.07 -34.39 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.469 2.308 . . . . 0.0 116.766 169.456 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 18.6 p 27.62 -40.55 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.042 2 C-N-CA 133.615 4.766 . . . . 0.0 122.91 179.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.2 13.72 2.22 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 127.53 2.332 . . . . 0.0 113.469 -173.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -148.04 34.33 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 124.657 1.122 . . . . 0.0 114.585 169.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.5 m -49.02 -19.99 0.48 Allowed 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -169.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.8 t -79.47 -4.49 51.47 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.454 1.101 . . . . 0.0 113.096 175.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 71.5 m -136.97 147.13 46.13 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.548 1.539 . . . . 0.0 110.739 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 63.51 -94.16 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.237 1.815 . . . . 0.0 113.126 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.54 -41.99 2.07 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 126.499 2.0 . . . . 0.0 116.413 -175.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -109.59 174.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.357 1.009 0 C-N-CA 123.194 2.596 . . . . 0.0 114.75 -175.395 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.727 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -97.16 134.68 40.16 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 129.99 3.316 . . . . 0.0 114.719 169.839 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -71.1 152.28 43.63 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 162.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 40.2 p-10 -125.75 60.11 31.22 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 124.252 1.021 . . . . 0.0 111.737 -177.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -61.79 -29.9 83.77 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.943 3.095 . . . . 0.0 115.057 -167.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 73.2 mt -75.9 -5.42 46.03 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 175.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t 66.83 110.02 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 130.027 3.331 . . . . 0.0 111.471 -177.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 171.92 172.03 0.1 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -169.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.49 ' H ' ' HD2' ' A' ' 70' ' ' LYS . 10.8 mptt -64.17 169.57 4.38 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.699 2.4 . . . . 0.0 111.68 168.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -96.23 138.99 33.02 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.839 1.256 . . . . 0.0 113.981 170.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.14 -110.05 0.44 Allowed Glycine 0 C--N 1.336 0.533 0 C-N-CA 124.007 0.813 . . . . 0.0 112.79 167.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.92 -20.2 24.52 Favored Glycine 0 CA--C 1.535 1.289 0 CA-C-O 115.237 -2.98 . . . . 0.0 118.396 -172.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.67 -11.81 3.23 Favored 'Trans proline' 0 C--N 1.357 0.982 0 CA-C-N 123.192 3.496 . . . . 0.0 112.282 168.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -152.51 -25.25 0.17 Allowed 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.078 1.351 . . . . 0.0 113.14 169.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -72.59 93.06 1.56 Allowed 'General case' 0 C--N 1.342 0.282 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 166.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -66.77 -6.51 16.24 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 114.674 -1.148 . . . . 0.0 113.87 -179.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -78.74 -64.84 1.08 Allowed 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 125.657 1.583 . . . . 0.0 109.567 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 59.98 127.72 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 129.833 3.253 . . . . 0.0 117.881 167.367 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -56.93 154.04 10.13 Favored 'General case' 0 CA--C 1.55 0.961 0 O-C-N 120.391 -1.443 . . . . 0.0 111.857 171.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 p -68.47 -28.87 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 120.229 1.377 . . . . 0.0 111.287 -174.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.17 105.58 2.1 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 107.081 -2.407 . . . . 0.0 107.081 165.005 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -160.52 142.91 12.92 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 117.956 0.878 . . . . 0.0 113.309 177.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -120.91 175.43 6.05 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 126.196 1.798 . . . . 0.0 112.129 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -95.1 -153.68 30.37 Favored Glycine 0 CA--C 1.535 1.307 0 C-N-CA 125.905 1.717 . . . . 0.0 114.114 178.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.0 p30 -108.0 156.97 18.65 Favored 'General case' 0 N--CA 1.467 0.379 0 O-C-N 121.777 -0.837 . . . . 0.0 110.956 168.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -106.53 173.92 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 127.217 2.207 . . . . 0.0 109.749 176.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -138.16 143.72 40.43 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 125.177 1.391 . . . . 0.0 108.871 169.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.64 152.56 25.4 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 124.105 0.962 . . . . 0.0 112.879 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -88.85 164.52 15.16 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.745 1.618 . . . . 0.0 111.203 168.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -63.53 -10.83 19.89 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.536 1.534 . . . . 0.0 114.828 170.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.12 -18.07 63.22 Favored 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 118.852 0.751 . . . . 0.0 109.805 169.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 105.09 -7.49 44.21 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 127.83 2.633 . . . . 0.0 112.808 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.57 139.47 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 125.603 1.561 . . . . 0.0 113.485 -173.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.39 129.93 52.29 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 164.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -79.52 142.09 36.1 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 167.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -122.16 140.34 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 CA-C-O 122.22 1.01 . . . . 0.0 113.472 171.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.6 p -156.33 122.38 4.97 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.452 1.501 . . . . 0.0 109.814 168.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.2 mp -128.98 156.09 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 C-N-CA 125.739 1.616 . . . . 0.0 108.843 173.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -157.37 135.84 11.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 126.574 1.95 . . . . 0.0 108.418 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -160.93 159.19 29.31 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 124.763 1.225 . . . . 0.0 112.431 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -121.16 48.19 1.7 Allowed 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.378 1.251 . . . . 0.0 114.378 172.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 57.3 t -137.95 -40.22 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.672 1.989 . . . . 0.0 109.961 169.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 pp -78.85 149.92 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 123.488 1.613 . . . . 0.0 114.474 172.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 94.6 p -155.26 169.53 23.97 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 126.635 1.974 . . . . 0.0 108.907 -176.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mp -96.36 48.26 1.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 172.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.3 t -103.06 -13.31 16.89 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 116.923 2.194 . . . . 0.0 116.923 -169.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 146.39 -88.05 0.16 Allowed Glycine 0 C--N 1.348 1.231 0 N-CA-C 120.124 2.809 . . . . 0.0 120.124 167.439 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -59.8 -61.01 2.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 C-N-CA 126.167 1.787 . . . . 0.0 115.215 -160.531 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 -125.3 1.3 7.77 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.177 1.391 . . . . 0.0 112.956 -174.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.7 p -78.45 -169.75 1.79 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.418 0.687 . . . . 0.0 112.35 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 3.3 pt -69.99 -30.16 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 O-C-N 118.954 -2.341 . . . . 0.0 114.105 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.9 mm -60.4 137.76 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-N 120.293 1.406 . . . . 0.0 110.493 171.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.98 -11.2 6.39 Favored Glycine 0 CA--C 1.527 0.797 0 CA-C-O 118.223 -1.321 . . . . 0.0 113.719 -177.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.17 139.38 39.9 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 120.035 1.917 . . . . 0.0 108.969 177.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 57.7 m -98.99 104.32 16.36 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -175.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 23.6 tp -80.26 120.08 23.87 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.108 1.363 . . . . 0.0 111.048 -177.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.87 138.87 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.62 1.568 . . . . 0.0 109.912 169.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.3 t -103.79 159.59 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 166.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -125.09 133.35 52.91 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.285 1.434 . . . . 0.0 111.24 -168.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -46.39 -35.62 5.67 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 127.569 2.348 . . . . 0.0 114.704 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -113.68 170.02 8.56 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.708 1.603 . . . . 0.0 112.512 -169.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.84 158.8 6.01 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.365 1.066 . . . . 0.0 110.642 167.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -138.29 142.53 39.81 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.272 1.029 . . . . 0.0 110.809 -168.161 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -85.91 -59.23 2.36 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 122.977 0.511 . . . . 0.0 111.891 176.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mp 65.93 84.95 0.15 Allowed 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 128.001 2.521 . . . . 0.0 113.9 -174.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 131.02 -29.97 3.43 Favored Glycine 0 N--CA 1.479 1.524 0 N-CA-C 118.888 2.315 . . . . 0.0 118.888 166.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -155.97 -58.92 0.1 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 119.474 1.637 . . . . 0.0 113.515 -169.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 44.22 -115.31 1.23 Allowed Glycine 0 C--N 1.34 0.754 0 C-N-CA 125.55 1.547 . . . . 0.0 111.55 -170.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.86 14.46 3.84 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-O 118.256 -1.302 . . . . 0.0 114.54 169.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -161.63 168.08 24.06 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 120.146 1.973 . . . . 0.0 112.853 -167.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -47.98 -58.75 4.02 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.137 1.375 . . . . 0.0 112.082 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -46.75 -31.89 3.28 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -179.078 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -65.7 -23.21 66.71 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.432 -1.418 . . . . 0.0 113.716 178.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.0 t -99.84 -29.56 12.53 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.931 0.892 . . . . 0.0 111.917 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -71.19 -41.45 70.29 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.25 1.42 . . . . 0.0 113.503 -176.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.5 p -124.48 -30.73 3.34 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.112 1.765 . . . . 0.0 112.801 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.98 -14.41 11.24 Favored Glycine 0 C--O 1.222 -0.648 0 C-N-CA 126.416 1.96 . . . . 0.0 111.184 -167.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 90.6 1.68 0.17 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.11 2.964 . . . . 0.0 112.346 178.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.54 -7.76 0.3 Allowed 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -168.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 64.96 7.91 32.49 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 120.327 2.891 . . . . 0.0 120.327 164.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.19 178.3 1.74 Allowed 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 121.166 2.483 . . . . 0.0 115.129 172.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 18.9 ptt-85 -76.4 -174.37 2.84 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.402 1.881 . . . . 0.0 109.883 165.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -177.76 -148.84 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 128.7 2.8 . . . . 0.0 107.504 165.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.28 144.24 55.86 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.079 0.952 . . . . 0.0 110.632 168.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.6 t -157.61 145.05 18.51 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.799 1.24 . . . . 0.0 112.312 -173.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.53 162.96 34.3 Favored Glycine 0 N--CA 1.474 1.176 0 C-N-CA 125.144 1.354 . . . . 0.0 112.46 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.8 p -78.87 153.29 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 118.795 1.298 . . . . 0.0 110.543 169.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mm -87.12 111.64 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 120.87 -1.144 . . . . 0.0 109.969 168.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.32 -155.8 23.55 Favored Glycine 0 CA--C 1.534 1.249 0 C-N-CA 125.659 1.6 . . . . 0.0 112.018 175.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.93 167.99 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-N 119.226 1.513 . . . . 0.0 113.616 177.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.96 -36.87 0.08 Allowed 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.979 1.712 . . . . 0.0 113.449 167.072 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . 0.299 27.6 pt20 . . . . . 0 C--O 1.235 0.31 0 C-N-CA 125.292 1.437 . . . . 0.0 114.307 -170.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.618 0 N-CA-C 112.632 0.604 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.7 m -79.79 105.85 11.39 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.354 1.462 . . . . 0.0 110.544 -167.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 24.3 mtmm -96.19 106.79 19.04 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 115.67 1.73 . . . . 0.0 115.67 -175.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.84 167.16 11.6 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.634 1.974 . . . . 0.0 111.034 167.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -158.44 151.65 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 C-N-CA 124.321 1.048 . . . . 0.0 113.554 -170.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.51 147.74 38.27 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.325 1.05 . . . . 0.0 109.471 162.757 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 53' ' ' ASN . 84.1 t -106.19 121.54 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.382 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 168.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.9 mp -92.34 107.62 19.35 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 126.683 1.993 . . . . 0.0 107.829 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 35.9 tttt -131.47 149.17 52.63 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 120.032 1.287 . . . . 0.0 114.006 175.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.08 151.72 16.87 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 128.799 3.095 . . . . 0.0 107.092 166.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -72.07 88.95 1.11 Allowed 'General case' 0 C--N 1.318 -0.767 0 C-N-CA 126.71 2.004 . . . . 0.0 112.038 -167.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.97 -129.47 3.29 Favored Glycine 0 CA--C 1.536 1.374 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.888 -177.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -93.24 -10.73 1.75 Allowed 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 124.143 3.229 . . . . 0.0 115.368 -169.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.1 t -91.82 113.49 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 120.458 1.481 . . . . 0.0 110.382 -176.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -159.13 161.54 36.32 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.619 -1.173 . . . . 0.0 113.547 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' B' ' 35' ' ' ILE . . . -150.67 167.23 30.38 Favored Glycine 0 CA--C 1.502 -0.765 0 CA-C-N 115.264 -0.88 . . . . 0.0 113.072 166.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.71 135.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.781 -1.562 . . . . 0.0 106.781 167.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.73 128.25 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.609 0.718 . . . . 0.0 109.774 169.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -96.11 136.51 36.47 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 125.587 1.555 . . . . 0.0 110.555 177.46 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -109.39 94.12 4.87 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 127.534 2.334 . . . . 0.0 109.583 173.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -95.68 109.42 21.7 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 121.041 -1.037 . . . . 0.0 111.567 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -98.37 140.45 32.63 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 121.231 -0.918 . . . . 0.0 111.438 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -78.67 -27.59 45.21 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -175.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -161.04 156.87 25.27 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 128.274 2.63 . . . . 0.0 107.318 168.068 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -46.7 -22.06 0.26 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 130.168 3.387 . . . . 0.0 116.698 -170.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -124.83 -4.42 7.59 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 128.536 2.735 . . . . 0.0 112.31 -174.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.41 160.03 27.71 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 125.876 1.703 . . . . 0.0 110.99 172.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.13 159.62 51.25 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.197 2.598 . . . . 0.0 112.626 -170.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.0 t -108.68 128.06 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.793 1.237 . . . . 0.0 110.036 -172.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -81.96 125.16 30.44 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 171.135 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.65 116.82 53.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.611 1.164 . . . . 0.0 108.845 170.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -137.35 158.64 43.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.006 0.922 . . . . 0.0 110.807 169.348 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.42 164.12 9.85 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-O 121.643 0.579 . . . . 0.0 112.688 174.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -113.62 116.52 29.61 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -165.004 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.428 ' HA ' ' HA3' ' B' ' 16' ' ' GLY . 4.0 mm -94.96 116.74 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 172.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -124.32 146.97 48.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.508 1.523 . . . . 0.0 111.196 -167.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -31.04 7.79 Favored Glycine 0 N--CA 1.471 0.986 0 C-N-CA 126.946 2.212 . . . . 0.0 112.143 -175.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.512 HD13 ' CD2' ' B' ' 43' ' ' HIS . 3.1 pp -76.0 128.24 34.62 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.511 1.124 . . . . 0.0 108.308 169.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -73.49 175.72 6.77 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.164 0.986 . . . . 0.0 111.888 -173.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -61.09 154.3 23.33 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -168.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.23 -175.02 29.18 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.399 1.0 . . . . 0.0 112.477 -175.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.3 mp -77.82 124.69 28.29 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 127.375 2.27 . . . . 0.0 112.078 -169.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . 0.512 ' CD2' HD13 ' B' ' 38' ' ' LEU . 60.0 m-70 -122.51 130.09 52.67 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.766 1.226 . . . . 0.0 107.976 171.138 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.32 165.84 38.87 Favored Glycine 0 N--CA 1.473 1.104 0 C-N-CA 126.443 1.973 . . . . 0.0 115.15 -169.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -156.58 99.96 1.91 Allowed 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 120.002 1.901 . . . . 0.0 112.764 -167.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -124.2 135.61 53.58 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 121.059 -1.025 . . . . 0.0 112.173 -169.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . 0.263 1.0 OUTLIER -102.84 141.14 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 119.077 0.853 . . . . 0.0 109.369 173.099 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.619 ' CG ' HG23 ' B' ' 116' ' ' THR . 0.3 OUTLIER -133.75 154.53 50.91 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.194 1.398 . . . . 0.0 112.732 -168.437 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -76.93 128.69 35.0 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -170.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.252 29.6 m-85 99.88 157.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 1 C-N-CA 132.732 4.413 . . . . 0.0 115.551 169.457 . . . . . . . . 3 2 . 1 . 016 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.92 -19.32 5.66 Favored Glycine 0 N--CA 1.471 1.014 0 C-N-CA 126.158 1.837 . . . . 0.0 113.176 177.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.46 51.94 0.07 Allowed 'General case' 0 CA--C 1.551 1.008 0 C-N-CA 127.558 2.343 . . . . 0.0 111.597 169.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -178.4 35.18 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -165.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 33.2 p . . . . . 0 CA--C 1.543 0.709 0 C-N-CA 128.608 2.763 . . . . 0.0 116.182 177.102 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.386 0 N-CA-C 113.476 0.917 . . . . 0.0 113.476 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.43 -175.15 48.72 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 124.638 1.113 . . . . 0.0 114.498 -177.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -83.31 -179.11 4.1 Favored 'Trans proline' 0 CA--C 1.539 0.752 1 C-N-CA 126.188 4.592 . . . . 0.0 111.774 175.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.488 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.7 p80 -80.7 107.37 13.45 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 122.452 1.12 . . . . 0.0 112.79 -174.336 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 136.81 5.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.57 1.948 . . . . 0.0 114.501 176.218 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.9 p-10 -116.81 47.4 0.62 Allowed Pre-proline 0 CA--C 1.55 0.965 0 CA-C-N 114.595 -1.184 . . . . 0.0 113.476 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -56.62 -30.47 83.49 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.819 3.012 . . . . 0.0 115.946 -168.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.4 mp -79.29 -4.94 53.14 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 124.468 1.107 . . . . 0.0 113.595 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 68.62 47.83 0.85 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 128.865 2.866 . . . . 0.0 111.115 -176.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.8 mmm180 -110.29 162.28 14.78 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 126.217 1.807 . . . . 0.0 111.011 -168.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 13.1 mmtm -74.43 173.26 10.55 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 167.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 30.1 t60 -50.88 158.22 0.71 Allowed 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -173.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.36 71.2 2.07 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.634 1.111 . . . . 0.0 113.634 -169.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -84.23 125.06 6.93 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -72.59 -11.89 26.52 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.001 1.801 . . . . 0.0 111.581 170.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.76 -5.91 13.29 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.168 0.987 . . . . 0.0 113.653 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -114.06 148.6 36.8 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.519 1.528 . . . . 0.0 108.281 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -74.68 -14.94 60.81 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 124.582 1.153 . . . . 0.0 111.82 -171.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -102.99 121.59 42.85 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.514 1.526 . . . . 0.0 107.678 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 -144.97 124.05 12.84 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 126.966 2.106 . . . . 0.0 110.788 -175.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 61.4 m170 -65.09 155.02 36.14 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.314 1.845 . . . . 0.0 110.842 164.724 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -55.95 -33.69 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.21 103.25 0.31 Allowed Glycine 0 C--N 1.345 1.061 0 N-CA-C 115.163 0.825 . . . . 0.0 115.163 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -159.53 146.88 16.94 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 130.329 3.452 . . . . 0.0 105.217 164.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 76.3 mt -128.96 56.34 1.68 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.779 0.799 . . . . 0.0 111.156 -168.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 59.91 -122.16 29.05 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.467 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -148.06 126.96 12.7 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.466 1.106 . . . . 0.0 110.785 -176.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -76.86 97.15 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.825 1.65 . . . . 0.0 109.314 177.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 92.0 m -97.6 120.91 38.83 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 113.338 -1.756 . . . . 0.0 109.253 -169.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.26 158.65 16.03 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -168.002 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -81.04 171.74 14.59 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.086 2.155 . . . . 0.0 112.158 168.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.791 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -67.26 -17.34 64.75 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.735 1.614 . . . . 0.0 114.017 174.28 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -71.6 -6.97 44.78 Favored 'General case' 0 CA--C 1.555 1.151 0 CA-C-O 122.433 1.111 . . . . 0.0 109.608 167.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.28 44.48 9.61 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 125.614 1.578 . . . . 0.0 109.895 173.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 13.3 p -142.54 130.31 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.523 1.129 . . . . 0.0 112.528 -177.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.21 94.91 5.77 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 124.512 1.125 . . . . 0.0 109.619 168.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -83.77 104.08 13.58 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 122.241 1.019 . . . . 0.0 109.834 168.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -80.34 154.22 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-N 113.961 -1.472 . . . . 0.0 111.741 -173.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 60.0 p -156.9 93.84 1.38 Allowed 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.182 -0.949 . . . . 0.0 112.719 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 21.2 mt -134.53 153.02 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 126.955 2.102 . . . . 0.0 111.394 -177.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -133.05 135.7 45.52 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 164.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -151.22 141.25 22.09 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 114.912 1.449 . . . . 0.0 114.912 -168.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.0 p -112.03 49.06 0.93 Allowed 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.6 t -123.13 4.99 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 C-N-CA 124.038 0.935 . . . . 0.0 111.158 174.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.24 170.75 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 C-N-CA 126.95 2.1 . . . . 0.0 110.509 -177.094 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -157.88 175.54 13.72 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.878 1.271 . . . . 0.0 110.817 169.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.6 mt -84.7 50.11 1.84 Allowed 'General case' 0 CA--C 1.548 0.893 0 O-C-N 120.204 -1.56 . . . . 0.0 109.609 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.4 t -81.79 25.22 0.56 Allowed 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 115.606 1.706 . . . . 0.0 115.606 -168.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.0 -51.59 3.86 Favored Glycine 0 C--N 1.336 0.542 0 C-N-CA 125.54 1.543 . . . . 0.0 115.087 168.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -101.2 -93.72 0.29 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 117.796 0.798 . . . . 0.0 111.137 -165.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 83.3 m-70 -84.05 2.56 38.58 Favored 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 1.1 t -95.42 -125.93 0.12 Allowed 'General case' 0 CA--C 1.551 0.994 0 O-C-N 119.793 -1.817 . . . . 0.0 113.066 -170.556 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 mm -80.08 -47.09 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-N 123.594 2.906 . . . . 0.0 113.222 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.1 mm -60.24 133.92 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 119.328 0.967 . . . . 0.0 108.936 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.53 6.18 65.49 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-O 118.574 -1.125 . . . . 0.0 115.037 178.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.65 164.08 19.91 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 119.115 1.458 . . . . 0.0 110.017 171.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . 0.619 HG23 ' CG ' ' B' ' 48' ' ' HIS . 3.9 t -115.17 157.65 23.35 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.279 1.032 . . . . 0.0 110.046 175.528 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 17.9 tp -151.28 126.24 9.77 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.025 1.33 . . . . 0.0 112.22 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.9 p -116.46 134.99 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 126.152 1.781 . . . . 0.0 111.258 170.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -84.46 139.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.681 1.193 . . . . 0.0 108.865 169.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 66.2 m-70 -108.25 149.71 28.25 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.616 1.566 . . . . 0.0 112.705 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -73.65 -37.17 65.4 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -171.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -92.12 164.62 13.52 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 120.482 -1.386 . . . . 0.0 109.914 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.16 140.51 5.13 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.419 1.087 . . . . 0.0 111.216 169.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.65 129.29 37.46 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -73.57 0.7 11.86 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.892 2.077 . . . . 0.0 111.564 178.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 79.17 -37.65 0.19 Allowed 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.283 2.633 . . . . 0.0 114.07 168.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 143.22 47.77 0.04 OUTLIER Glycine 0 N--CA 1.477 1.378 0 CA-C-N 120.4 1.454 . . . . 0.0 114.975 -176.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.3 pttp -157.18 -113.46 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 -168.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 66.16 -3.84 2.98 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.652 2.072 . . . . 0.0 117.433 169.411 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.0 4.26 54.77 Favored Glycine 0 CA--C 1.536 1.392 0 CA-C-N 119.073 1.436 . . . . 0.0 114.053 -174.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 m-80 -119.12 156.8 29.12 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 125.722 1.609 . . . . 0.0 111.517 -176.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -54.11 -59.41 4.68 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.145 0.978 . . . . 0.0 109.238 166.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -54.7 -36.88 65.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.739 1.216 . . . . 0.0 113.169 -172.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.0 m -66.05 -13.28 59.7 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.695 1.998 . . . . 0.0 115.563 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -122.37 -20.04 6.24 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.882 0.873 . . . . 0.0 112.928 168.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -72.53 -46.66 53.5 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.121 1.368 . . . . 0.0 111.779 174.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.3 p -117.75 -34.21 4.28 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.221 1.008 . . . . 0.0 112.977 173.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.38 11.24 20.3 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 126.708 2.099 . . . . 0.0 111.972 -168.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 55.52 17.56 2.31 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 120.602 2.201 . . . . 0.0 113.29 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.33 25.07 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.073 0 C-N-CA 127.573 2.349 . . . . 0.0 116.145 -165.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.26 -51.63 3.93 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 127.558 2.504 . . . . 0.0 114.454 169.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 2.9 m 179.76 166.67 1.19 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.782 2.433 . . . . 0.0 111.906 -179.024 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.12 150.97 31.62 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.401 0.681 . . . . 0.0 110.887 173.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.31 -130.6 0.24 Allowed 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 126.739 2.016 . . . . 0.0 108.794 173.086 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.83 157.39 33.42 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 127.065 2.146 . . . . 0.0 114.437 -175.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -151.22 159.68 44.25 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -172.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.71 168.48 34.37 Favored Glycine 0 CA--C 1.543 1.825 0 C-N-CA 127.485 2.469 . . . . 0.0 113.842 175.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 54.2 t -124.83 138.2 54.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 C-N-CA 124.742 1.217 . . . . 0.0 108.563 174.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mm -79.04 122.6 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -166.354 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.62 -156.51 9.88 Favored Glycine 0 CA--C 1.542 1.773 0 C-N-CA 128.362 2.887 . . . . 0.0 113.141 169.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -142.08 147.39 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 C-N-CA 125.276 1.431 . . . . 0.0 114.702 -168.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.07 -22.43 10.56 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 125.499 1.519 . . . . 0.0 114.407 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 . . . . . 0 N--CA 1.471 0.606 0 C-N-CA 125.673 1.589 . . . . 0.0 112.453 -178.186 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.472 0.627 0 CA-C-O 121.657 0.741 . . . . 0.0 110.707 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.487 ' HE3' ' OE1' ' A' ' 153' ' ' GLN . 0.0 OUTLIER -77.98 117.71 19.57 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-N 114.741 -1.118 . . . . 0.0 112.053 169.289 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.4 178.59 6.44 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.429 1.091 . . . . 0.0 110.179 167.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -155.41 90.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 125.664 1.586 . . . . 0.0 109.981 -168.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.93 121.93 32.49 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.229 1.412 . . . . 0.0 110.573 174.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.0 p -95.75 126.68 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-N 118.9 0.773 . . . . 0.0 109.105 173.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mp -109.14 133.95 52.35 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.59 1.156 . . . . 0.0 108.627 169.42 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mtmt -157.77 133.12 8.9 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.267 1.427 . . . . 0.0 110.276 173.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.73 -81.08 0.63 Allowed Glycine 0 C--N 1.334 0.45 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -170.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -139.42 116.56 11.09 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 124.559 1.144 . . . . 0.0 108.987 -166.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.04 -101.41 0.03 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 128.988 3.185 . . . . 0.0 112.613 175.044 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -77.99 -9.46 16.74 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.275 2.65 . . . . 0.0 114.014 -174.047 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.8 t -88.46 126.19 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 121.33 1.877 . . . . 0.0 111.818 -176.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.87 159.11 43.13 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 125.162 1.385 . . . . 0.0 111.792 171.165 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.87 164.4 27.85 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 122.444 1.025 . . . . 0.0 113.811 169.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.79 133.93 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 125.127 1.371 . . . . 0.0 109.066 -179.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.6 mm -137.7 121.92 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 CA-C-N 119.74 1.155 . . . . 0.0 110.683 169.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -88.57 145.84 25.48 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.981 167.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -121.62 109.62 14.99 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 168.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.78 112.59 24.31 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.85 0.75 . . . . 0.0 111.529 -176.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -93.49 135.31 34.86 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -114.52 -45.54 3.01 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.612 1.565 . . . . 0.0 114.688 -175.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -118.9 -179.76 3.91 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.25 1.42 . . . . 0.0 109.204 167.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.8 p -67.66 -25.91 65.94 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 119.162 -2.211 . . . . 0.0 114.221 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -141.04 9.5 2.12 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 126.407 1.883 . . . . 0.0 112.598 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.8 151.94 52.31 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.795 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -61.91 137.63 68.77 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 124.169 3.246 . . . . 0.0 110.36 -172.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 79.3 t -102.59 135.53 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 123.525 0.73 . . . . 0.0 109.889 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -91.1 116.69 29.01 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 167.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.3 t -104.2 110.91 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 126.677 1.991 . . . . 0.0 108.7 -173.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -132.78 168.69 17.9 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 122.216 1.008 . . . . 0.0 113.143 -176.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.86 -155.48 26.15 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 124.87 1.224 . . . . 0.0 111.488 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -159.71 152.12 21.09 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -123.91 134.24 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 125.712 1.605 . . . . 0.0 107.865 -178.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.8 ptpt -149.58 152.03 34.81 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -172.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.1 12.12 52.94 Favored Glycine 0 CA--C 1.535 1.302 0 C-N-CA 125.256 1.407 . . . . 0.0 113.231 -168.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -111.86 164.7 12.79 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.005 2.122 . . . . 0.0 111.1 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.23 166.11 24.0 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.081 1.352 . . . . 0.0 111.438 176.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.31 -166.48 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 128.541 2.736 . . . . 0.0 113.661 -177.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.73 -178.38 42.78 Favored Glycine 0 CA--C 1.531 1.063 0 O-C-N 120.295 -1.503 . . . . 0.0 113.136 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.691 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -74.58 144.48 43.95 Favored 'General case' 0 CA--C 1.542 0.652 0 O-C-N 120.692 -1.476 . . . . 0.0 112.045 -178.065 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -136.8 151.29 49.0 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 128.789 2.836 . . . . 0.0 109.274 -177.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.29 173.83 26.69 Favored Glycine 0 N--CA 1.475 1.286 0 C-N-CA 125.317 1.437 . . . . 0.0 114.043 -174.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -159.93 122.46 3.4 Favored 'General case' 0 CA--C 1.554 1.122 0 C-N-CA 125.502 1.521 . . . . 0.0 112.754 -168.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 10.8 p-80 -152.07 134.14 15.01 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 118.705 -2.497 . . . . 0.0 113.607 167.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.6 m -84.99 146.0 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 CA-C-O 122.213 1.006 . . . . 0.0 108.948 170.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -107.13 176.09 5.28 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 124.021 1.867 . . . . 0.0 114.592 -168.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.2 pm0 -72.95 132.87 44.0 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 158.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.419 ' HB3' ' H ' ' A' ' 52' ' ' ASP . 6.8 m-85 75.77 167.59 0.27 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 124.422 2.058 . . . . 0.0 115.148 169.119 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.34 0.28 57.05 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 111.41 -2.632 . . . . 0.0 109.96 163.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.419 ' H ' ' HB3' ' A' ' 50' ' ' PHE . 6.7 t0 -69.92 138.08 52.11 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 165.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.403 HD21 ' CG2' ' A' ' 148' ' ' VAL . 0.8 OUTLIER -177.08 21.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 168.057 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.4 p -79.57 -14.33 58.92 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -163.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -108.1 10.05 28.18 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 124.5 1.12 . . . . 0.0 110.972 167.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.56 -138.06 35.46 Favored Glycine 0 CA--C 1.528 0.865 0 O-C-N 121.019 -1.05 . . . . 0.0 111.035 -171.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.2 m -57.17 -6.06 0.35 Allowed 'General case' 0 CA--C 1.549 0.928 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -174.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.5 t -103.13 0.71 32.24 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-N 119.966 1.257 . . . . 0.0 113.998 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.9 p -128.57 -18.37 3.95 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 168.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.37 153.98 35.73 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.326 1.851 . . . . 0.0 110.763 168.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.16 -173.78 28.81 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.239 0.923 . . . . 0.0 114.753 -170.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.41 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 40.9 Cg_endo -91.24 72.11 0.94 Allowed 'Trans proline' 0 CA--C 1.538 0.721 1 C-N-CA 125.401 4.068 . . . . 0.0 108.276 169.556 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.437 ' ND1' ' ND1' ' A' ' 71' ' ' HIS . 5.1 p80 43.9 70.04 0.36 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.958 1.703 . . . . 0.0 114.657 164.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -32.59 134.3 0.1 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 128.848 2.859 . . . . 0.0 117.901 -168.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 30.0 p-10 -103.75 34.25 0.05 OUTLIER Pre-proline 0 CA--C 1.559 1.302 0 N-CA-C 117.365 2.357 . . . . 0.0 117.365 -174.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -66.36 -15.17 47.15 Favored 'Trans proline' 0 C--N 1.357 1.003 0 CA-C-N 123.328 2.224 . . . . 0.0 115.068 -169.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -77.1 -0.84 26.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.099 1.359 . . . . 0.0 112.844 169.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.4 t 77.98 59.48 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.988 2.115 . . . . 0.0 112.3 168.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 ptm85 -149.72 169.35 21.24 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -67.57 156.7 36.14 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 127.889 2.476 . . . . 0.0 111.091 172.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.437 ' ND1' ' ND1' ' A' ' 63' ' ' HIS . 78.1 t60 -75.33 149.97 38.59 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.152 165.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.13 -145.36 12.76 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 116.508 -0.315 . . . . 0.0 113.052 166.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 165.32 -98.15 0.15 Allowed Glycine 0 CA--C 1.535 1.286 0 CA-C-O 117.166 -1.908 . . . . 0.0 114.771 168.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -65.43 0.42 2.85 Favored 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 124.821 3.681 . . . . 0.0 116.397 -169.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.34 1.73 1.41 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 127.124 2.17 . . . . 0.0 112.486 175.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.461 ' CG ' ' H ' ' A' ' 77' ' ' GLU . 19.9 t0 -95.96 -178.96 4.53 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 128.321 2.648 . . . . 0.0 111.131 178.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.461 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 20.1 tt0 -98.43 -31.26 12.09 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 129.635 3.174 . . . . 0.0 112.04 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -127.51 -70.62 0.7 Allowed 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -166.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.416 HH22 ' HB ' ' A' ' 103' ' ' VAL . 1.1 ttt-85 83.69 128.88 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 127.038 2.135 . . . . 0.0 111.436 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -66.25 169.63 6.94 Favored 'General case' 0 CA--C 1.55 0.953 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 m -85.11 65.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 CA-C-O 122.707 1.242 . . . . 0.0 109.68 173.147 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.76 88.73 0.3 Allowed Glycine 0 C--O 1.223 -0.555 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -168.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -158.0 150.5 22.41 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 128.132 2.573 . . . . 0.0 109.597 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 77.5 mt -129.8 178.04 6.81 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 126.08 1.752 . . . . 0.0 109.3 169.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -84.55 -129.04 1.82 Allowed Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.376 0.989 . . . . 0.0 113.184 -176.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -147.7 169.73 19.06 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.437 1.095 . . . . 0.0 110.53 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.63 170.73 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.173 0.989 . . . . 0.0 110.765 -170.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.5 m -140.78 138.52 34.17 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 125.727 1.611 . . . . 0.0 108.301 172.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.71 138.79 34.56 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.821 0.848 . . . . 0.0 110.563 176.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -87.43 162.8 17.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.64 1.176 . . . . 0.0 112.147 172.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -53.46 -19.06 3.17 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 127.783 2.433 . . . . 0.0 115.017 -170.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.68 4.07 48.49 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 128.241 2.616 . . . . 0.0 110.918 -173.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.68 26.84 21.54 Favored Glycine 0 C--N 1.341 0.829 0 C-N-CA 126.065 1.793 . . . . 0.0 113.907 172.332 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.18 132.3 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.4 129.21 43.8 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 126.159 1.783 . . . . 0.0 106.258 164.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -117.09 135.64 53.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 -178.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 51.3 t -125.24 129.81 73.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 114.114 -1.403 . . . . 0.0 114.381 -164.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.7 p -144.72 74.47 1.41 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.235 1.414 . . . . 0.0 112.52 176.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -101.09 159.39 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 120.604 -1.31 . . . . 0.0 111.481 -177.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -138.87 141.77 38.6 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.768 2.027 . . . . 0.0 107.941 172.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -145.42 141.2 28.19 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.229 1.411 . . . . 0.0 110.259 177.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.2 p -111.54 50.82 0.81 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -173.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.416 ' HB ' HH22 ' A' ' 79' ' ' ARG . 23.4 t -144.32 -42.97 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.207 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 168.468 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.43 155.52 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 CA-C-N 119.564 1.074 . . . . 0.0 112.095 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.9 p -156.98 167.67 29.77 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.565 -1.334 . . . . 0.0 113.351 177.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.12 56.8 1.31 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.956 1.36 . . . . 0.0 109.378 170.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.08 33.02 0.88 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.723 2.009 . . . . 0.0 111.428 168.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.4 -137.21 13.14 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 124.731 1.158 . . . . 0.0 111.928 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -93.65 -32.82 13.92 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 128.073 2.549 . . . . 0.0 115.766 -165.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -83.95 -8.23 59.22 Favored 'General case' 0 CA--C 1.545 0.758 0 O-C-N 120.305 -1.497 . . . . 0.0 111.607 -178.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 69.9 m -102.19 -40.6 6.72 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 115.416 1.636 . . . . 0.0 115.416 -170.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -169.49 -42.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.104 1.762 . . . . 0.0 114.134 171.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.85 141.51 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 168.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.68 8.85 61.05 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 116.31 -2.384 . . . . 0.0 113.896 -174.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -100.17 177.48 5.06 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 121.146 2.473 . . . . 0.0 109.62 169.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 27.2 m -120.91 146.72 46.32 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.855 1.662 . . . . 0.0 110.243 -175.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -127.33 143.36 51.24 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.858 1.663 . . . . 0.0 109.276 166.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.8 m -114.24 129.47 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 125.598 1.559 . . . . 0.0 109.569 169.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -98.56 120.53 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 168.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 2.1 m-70 -96.81 153.71 17.72 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.333 1.453 . . . . 0.0 113.337 -168.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.26 -62.63 1.57 Allowed 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 124.427 1.091 . . . . 0.0 111.305 -172.741 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.44 176.47 6.28 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.86 -1.15 . . . . 0.0 111.437 170.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.37 146.25 44.96 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.23 1.012 . . . . 0.0 113.428 -169.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.66 112.8 17.27 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 166.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -78.72 -8.0 58.29 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.661 1.985 . . . . 0.0 114.922 -167.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 34.28 89.28 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 129.385 3.074 . . . . 0.0 114.915 177.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.41 -55.36 4.9 Favored Glycine 0 N--CA 1.469 0.851 0 C-N-CA 125.456 1.503 . . . . 0.0 112.54 168.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -153.91 110.22 3.3 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -174.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.97 -95.48 2.21 Favored Glycine 0 CA--C 1.513 -0.079 0 N-CA-C 104.116 -3.593 . . . . 0.0 104.116 163.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.55 14.81 3.91 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 117.938 -1.479 . . . . 0.0 114.321 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -121.63 173.66 7.3 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 119.993 1.896 . . . . 0.0 112.215 -169.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -75.56 -48.17 23.55 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 113.067 -1.879 . . . . 0.0 109.04 167.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -61.59 -19.2 61.95 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 176.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 21.1 m -51.34 -39.33 56.81 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 119.955 1.252 . . . . 0.0 112.776 171.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -94.78 -33.18 12.98 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 174.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 mtpt -75.27 -29.23 60.09 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 120.618 1.554 . . . . 0.0 114.823 -178.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.0 p -136.85 -23.33 1.18 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.36 8.15 55.21 Favored Glycine 0 C--O 1.221 -0.718 0 C-N-CA 124.733 1.158 . . . . 0.0 110.686 -167.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 62.05 -4.04 0.22 Allowed 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.344 1.858 . . . . 0.0 114.153 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -58.41 -3.7 0.31 Allowed 'General case' 0 CA--C 1.555 1.159 0 C-N-CA 129.058 2.943 . . . . 0.0 117.151 -165.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.81 -81.6 1.38 Allowed Glycine 0 CA--C 1.532 1.144 0 C-N-CA 125.764 1.65 . . . . 0.0 113.337 172.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.7 m -172.27 166.66 5.9 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.021 1.729 . . . . 0.0 112.255 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.412 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -100.38 144.4 29.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 116.698 2.11 . . . . 0.0 116.698 -173.073 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.448 HD13 ' H ' ' A' ' 144' ' ' LEU . 0.0 OUTLIER -90.53 -21.97 21.54 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 113.652 -1.613 . . . . 0.0 111.375 166.3 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.14 142.65 23.53 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 122.185 0.993 . . . . 0.0 111.004 173.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.1 p -136.94 147.78 46.58 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 127.887 2.475 . . . . 0.0 109.082 178.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.63 160.44 31.86 Favored Glycine 0 N--CA 1.469 0.874 0 N-CA-C 115.478 0.951 . . . . 0.0 115.478 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.403 ' CG2' HD21 ' A' ' 53' ' ' ASN . 99.3 t -104.74 143.71 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.527 1.131 . . . . 0.0 110.704 174.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 68.7 mt -84.89 95.41 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 126.383 1.873 . . . . 0.0 111.836 -169.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -91.62 177.75 40.71 Favored Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.0 1.285 . . . . 0.0 113.622 177.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -132.83 158.05 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.727 2.011 . . . . 0.0 112.206 -178.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -153.67 -25.76 0.14 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 174.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . 0.487 ' OE1' ' HE3' ' A' ' 3' ' ' LYS . 34.3 tt0 . . . . . 0 CA--C 1.537 0.458 0 O-C-N 121.009 -1.057 . . . . 0.0 110.802 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.419 0 CA-C-O 120.933 0.397 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.3 m -84.1 99.97 10.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -174.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.271 0.0 OUTLIER -94.8 113.96 25.78 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-O 123.321 1.534 . . . . 0.0 112.963 178.295 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.05 164.21 25.94 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 125.709 1.604 . . . . 0.0 111.166 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.03 140.53 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 125.767 1.627 . . . . 0.0 108.027 178.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.5 124.15 21.03 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 4.1 p -79.95 120.62 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 169.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -112.31 110.71 21.1 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 125.125 1.37 . . . . 0.0 108.427 169.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 tttt -157.06 160.28 38.77 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-O 121.499 0.666 . . . . 0.0 111.629 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.0 -35.83 0.84 Allowed Glycine 0 N--CA 1.468 0.802 0 C-N-CA 127.154 2.311 . . . . 0.0 110.005 174.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.41 58.19 2.56 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.867 2.067 . . . . 0.0 110.859 177.289 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 36.8 -98.31 0.01 OUTLIER Glycine 0 CA--C 1.535 1.334 0 C-N-CA 128.104 2.764 . . . . 0.0 114.288 -176.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.06 -13.2 15.76 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 123.869 3.046 . . . . 0.0 114.785 -176.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.21 137.51 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 121.262 1.846 . . . . 0.0 111.675 -176.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -126.49 162.12 26.36 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 124.357 1.063 . . . . 0.0 110.375 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -128.19 62.99 0.62 Allowed Glycine 0 N--CA 1.469 0.853 0 C-N-CA 125.262 1.41 . . . . 0.0 111.836 172.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.464 ' C ' HD12 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -79.44 109.08 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 CA-C-N 118.358 1.079 . . . . 0.0 110.923 -168.686 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.459 ' N ' HD12 ' B' ' 17' ' ' ILE . 2.4 pp -110.8 150.88 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 169.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -129.46 129.15 44.25 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.054 2.142 . . . . 0.0 107.364 167.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -115.93 125.02 52.03 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 119.203 0.91 . . . . 0.0 109.834 178.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.65 127.39 52.38 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 123.726 0.81 . . . . 0.0 110.242 -178.619 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . 0.529 ' HG2' ' H ' ' B' ' 24' ' ' GLU . 52.4 tt0 -121.14 134.27 55.23 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 123.069 1.414 . . . . 0.0 112.57 170.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -82.89 0.4 44.39 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 126.485 1.914 . . . . 0.0 113.617 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . 0.529 ' H ' ' HG2' ' B' ' 22' ' ' GLN . 43.4 mt-10 -157.64 -164.64 1.59 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 130.333 3.453 . . . . 0.0 108.495 -169.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -120.47 -6.6 9.77 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.895 1.278 . . . . 0.0 111.868 165.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -116.84 -45.95 2.76 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.745 1.618 . . . . 0.0 113.685 -171.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.38 -162.83 11.31 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 125.184 1.373 . . . . 0.0 114.133 -176.569 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.18 161.45 38.22 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.524 2.149 . . . . 0.0 112.69 -171.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 13.9 t -133.71 136.42 54.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.834 1.654 . . . . 0.0 109.833 -173.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HD2' ' H ' ' B' ' 30' ' ' LYS . 5.2 mptt -80.85 130.99 35.34 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.253 0.549 . . . . 0.0 110.049 171.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.36 105.44 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 127.735 2.414 . . . . 0.0 108.227 178.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -138.49 162.16 35.22 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.85 173.11 13.06 Favored Glycine 0 N--CA 1.467 0.737 0 C-N-CA 124.668 1.128 . . . . 0.0 114.261 171.331 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.3 p -110.65 120.59 42.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 114.86 1.43 . . . . 0.0 114.86 -167.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.629 HD13 HG21 ' B' ' 87' ' ' VAL . 0.6 OUTLIER -92.01 117.12 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 167.499 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 pttt -137.81 136.61 37.37 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.511 0.725 . . . . 0.0 111.349 -167.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.57 -18.26 22.77 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 127.491 2.472 . . . . 0.0 113.636 -172.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.4 156.35 25.45 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.371 1.069 . . . . 0.0 111.705 172.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -69.25 166.13 19.08 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.258 1.423 . . . . 0.0 110.262 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -61.39 -176.36 0.07 Allowed 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 126.673 1.989 . . . . 0.0 115.197 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.42 177.28 51.83 Favored Glycine 0 N--CA 1.469 0.867 0 C-N-CA 124.905 1.24 . . . . 0.0 112.187 -179.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.829 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -71.23 141.99 50.6 Favored 'General case' 0 CA--C 1.541 0.614 0 O-C-N 120.824 -1.398 . . . . 0.0 110.092 177.381 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -134.21 141.29 46.99 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 127.317 2.247 . . . . 0.0 107.957 176.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.98 155.94 48.53 Favored Glycine 0 N--CA 1.479 1.562 0 CA-C-N 120.494 1.497 . . . . 0.0 113.217 -174.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -147.27 105.5 3.76 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.91 1.355 . . . . 0.0 110.465 -171.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.476 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -145.4 145.22 31.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 120.804 -1.185 . . . . 0.0 110.4 -167.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.564 HG23 ' HA2' ' B' ' 82' ' ' GLY . 34.5 m -115.03 120.7 65.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.278 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -176.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.476 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 3.7 m170 -74.93 152.1 38.84 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -173.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -73.05 94.05 1.85 Allowed 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 169.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 150.54 156.82 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 1 C-N-CA 132.351 4.26 . . . . 0.0 111.669 170.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.3 -21.19 42.28 Favored Glycine 0 C--N 1.337 0.621 0 C-N-CA 126.187 1.851 . . . . 0.0 111.294 164.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.422 ' C ' HD22 ' B' ' 53' ' ' ASN . 29.9 t0 -58.05 157.42 8.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 165.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.422 HD22 ' C ' ' B' ' 52' ' ' ASP . 1.3 p30 162.65 31.26 0.0 OUTLIER 'General case' 0 C--O 1.241 0.62 0 C-N-CA 129.075 2.95 . . . . 0.0 111.496 165.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 18.2 p . . . . . 0 N--CA 1.455 -0.19 0 O-C-N 121.132 -0.98 . . . . 0.0 110.364 -168.423 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.249 0 CA-C-O 121.682 0.753 . . . . 0.0 112.017 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.08 -161.86 29.49 Favored Glycine 0 CA--C 1.54 1.602 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.568 173.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -78.03 -171.43 1.2 Allowed 'Trans proline' 0 CA--C 1.54 0.777 1 C-N-CA 126.257 4.638 . . . . 0.0 110.087 169.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.777 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 2.1 p80 -73.76 80.32 1.57 Allowed 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.303 2.641 . . . . 0.0 107.084 168.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -56.0 169.88 0.35 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 123.826 1.774 . . . . 0.0 110.889 174.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -104.13 51.94 0.08 OUTLIER Pre-proline 0 CA--C 1.555 1.142 0 CA-C-N 113.392 -1.731 . . . . 0.0 115.165 -167.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.45 -25.72 48.2 Favored 'Trans proline' 0 C--N 1.354 0.865 0 C-N-CA 122.33 2.02 . . . . 0.0 111.469 -177.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 39.5 mt -81.6 -6.49 59.05 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 172.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.9 t 69.34 59.86 0.32 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 125.652 1.581 . . . . 0.0 113.84 174.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.9 ptt180 -162.01 176.26 10.94 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 115.449 1.648 . . . . 0.0 115.449 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.2 170.95 11.94 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.888 1.275 . . . . 0.0 114.116 177.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.434 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 77.0 t60 -83.76 162.26 20.71 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.378 0.671 . . . . 0.0 111.501 167.636 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.412 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 137.97 -102.39 0.37 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.377 1.941 . . . . 0.0 111.739 166.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.75 -53.44 0.71 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 116.958 -2.024 . . . . 0.0 117.498 172.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -87.86 -8.17 6.02 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.502 2.801 . . . . 0.0 111.25 176.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.49 ' HE2' ' HA ' ' B' ' 75' ' ' LYS . 0.1 OUTLIER -145.98 -16.64 0.46 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 176.248 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.412 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 13.7 t70 -101.67 92.45 4.87 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 103.181 -2.896 . . . . 0.0 103.181 159.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 56.2 mp0 -65.04 -4.88 5.2 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.676 1.191 . . . . 0.0 113.508 -176.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -74.61 -63.31 1.27 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.597 1.959 . . . . 0.0 107.711 178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 32.4 ttp180 67.83 119.79 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.959 2.207 . . . . 0.0 116.959 162.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -62.61 156.1 24.25 Favored 'General case' 0 N--CA 1.472 0.659 0 O-C-N 119.467 -2.021 . . . . 0.0 112.102 169.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -52.71 -32.75 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.564 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -96.33 39.05 2.91 Favored Glycine 0 CA--C 1.534 1.26 0 N-CA-C 116.708 1.443 . . . . 0.0 116.708 -174.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -129.96 108.39 10.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.281 -1.129 . . . . 0.0 111.715 -172.385 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -109.79 47.41 0.95 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 122.467 1.127 . . . . 0.0 110.153 168.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.5 -101.67 0.03 OUTLIER Glycine 0 CA--C 1.528 0.879 0 C-N-CA 127.984 2.707 . . . . 0.0 114.103 174.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.8 p30 -154.86 161.74 41.34 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.592 1.557 . . . . 0.0 111.553 -175.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.629 HG21 HD13 ' B' ' 35' ' ' ILE . 8.9 p -137.85 124.81 28.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 C-N-CA 126.916 2.086 . . . . 0.0 109.605 -171.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 55.5 m -107.73 123.89 49.2 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 114.707 -1.133 . . . . 0.0 111.19 -167.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.08 148.9 21.61 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 124.398 1.079 . . . . 0.0 112.509 -176.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -97.22 157.07 16.13 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.111 1.765 . . . . 0.0 112.236 169.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -24.94 24.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 127.246 2.219 . . . . 0.0 115.336 -169.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -79.65 5.75 12.42 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.984 1.714 . . . . 0.0 111.597 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.19 36.81 6.15 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 126.049 1.785 . . . . 0.0 113.2 171.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.27 138.39 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 117.31 2.337 . . . . 0.0 117.31 -172.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -118.93 93.07 3.97 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.72 2.008 . . . . 0.0 110.696 168.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -85.59 95.44 9.33 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-O 122.491 1.139 . . . . 0.0 110.665 172.271 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.75 152.89 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.513 -170.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.2 p -155.14 109.83 2.98 Favored 'General case' 0 CA--C 1.541 0.634 0 O-C-N 120.963 -1.086 . . . . 0.0 112.21 175.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.83 160.31 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 127.722 2.409 . . . . 0.0 110.12 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -134.32 141.14 46.82 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 164.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -144.59 152.38 40.43 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.528 1.131 . . . . 0.0 112.116 178.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.7 p -117.42 59.32 0.78 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.546 1.538 . . . . 0.0 111.654 -169.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -157.24 -42.09 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 174.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -79.21 154.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 O-C-N 121.883 -0.511 . . . . 0.0 110.628 169.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 9.2 p -155.26 170.37 22.03 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.329 1.052 . . . . 0.0 111.05 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . 0.456 HD13 ' HB2' ' B' ' 22' ' ' GLN . 10.1 mp -86.56 55.53 3.59 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.092 -1.005 . . . . 0.0 111.649 -173.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.1 t -90.47 12.81 17.43 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 116.876 2.176 . . . . 0.0 116.876 -169.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.22 -38.65 3.19 Favored Glycine 0 N--CA 1.475 1.235 0 N-CA-C 118.695 2.238 . . . . 0.0 118.695 167.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -107.16 -105.46 0.34 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.541 1.136 . . . . 0.0 110.572 -166.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -76.23 11.77 1.41 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 126.187 1.795 . . . . 0.0 113.363 175.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 9.7 p -84.12 -158.35 0.32 Allowed 'General case' 0 CA--C 1.553 1.086 0 C-N-CA 127.013 2.125 . . . . 0.0 114.13 -175.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' B' ' 115' ' ' ARG 0.39 8.1 pt -83.23 -9.39 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 O-C-N 119.666 -1.896 . . . . 0.0 114.234 168.284 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.5 mm -98.36 151.18 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 161.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 95.1 -41.12 2.56 Favored Glycine 0 N--CA 1.468 0.811 0 C-N-CA 124.342 0.973 . . . . 0.0 113.033 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . 0.512 HH21 ' HB2' ' B' ' 117' ' ' LEU . 0.2 OUTLIER -75.13 -179.56 4.45 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 127.49 2.316 . . . . 0.0 115.604 -169.579 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.1 t -103.43 176.18 5.23 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 127.437 2.295 . . . . 0.0 113.065 169.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.512 ' HB2' HH21 ' B' ' 115' ' ' ARG . 33.9 tp -152.95 144.99 23.76 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.157 2.183 . . . . 0.0 110.363 170.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.45 150.2 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 O-C-N 123.284 0.365 . . . . 0.0 110.796 167.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.89 128.42 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 168.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -90.16 148.84 22.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.93 0.892 . . . . 0.0 112.518 -169.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.297 2.4 pp20? -77.51 -32.55 54.17 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.3 -0.875 . . . . 0.0 112.661 -174.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -90.54 169.07 11.34 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.322 -0.861 . . . . 0.0 110.061 165.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.72 149.65 34.8 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.125 0.97 . . . . 0.0 109.628 164.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -78.9 131.89 36.57 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 168.372 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -78.58 -11.05 59.94 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.178 0.991 . . . . 0.0 112.523 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mm? 70.25 -66.33 0.28 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 129.998 3.319 . . . . 0.0 111.339 -176.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 176.09 29.38 0.04 OUTLIER Glycine 0 N--CA 1.463 0.491 0 N-CA-C 116.171 1.228 . . . . 0.0 116.171 -169.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -126.12 -20.34 4.54 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 117.088 2.255 . . . . 0.0 117.088 -167.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.89 129.92 47.16 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 106.506 -2.638 . . . . 0.0 106.506 168.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -74.12 46.39 1.52 Allowed Glycine 0 N--CA 1.473 1.102 0 C-N-CA 126.387 1.946 . . . . 0.0 112.865 -171.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -103.23 -89.86 0.38 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.653 1.181 . . . . 0.0 110.947 -169.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 170.4 -76.66 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 131.213 3.805 . . . . 0.0 102.474 -167.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -35.66 -52.85 0.7 Allowed 'General case' 0 CA--C 1.54 0.584 1 C-N-CA 132.147 4.179 . . . . 0.0 112.92 171.628 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.6 m -47.37 -31.1 3.71 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 176.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.3 t -112.72 -8.03 13.79 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 119.449 1.022 . . . . 0.0 112.264 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 22.4 mmtp -84.25 -47.42 10.81 Favored 'General case' 0 CA--C 1.537 0.469 0 O-C-N 120.75 -1.219 . . . . 0.0 110.853 168.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 74.6 p -117.01 -34.17 4.49 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.786 1.634 . . . . 0.0 113.079 -173.271 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.13 2.89 31.59 Favored Glycine 0 N--CA 1.47 0.922 0 CA-C-O 118.353 -1.248 . . . . 0.0 113.805 -177.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 51.48 24.16 2.11 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 119.55 1.675 . . . . 0.0 114.168 177.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.09 20.08 0.08 Allowed 'General case' 0 CA--C 1.553 1.067 0 N-CA-C 115.748 1.759 . . . . 0.0 115.748 -166.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.8 -66.76 2.4 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 126.459 1.981 . . . . 0.0 114.288 173.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -175.69 -163.56 0.12 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.803 1.641 . . . . 0.0 109.532 -169.44 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.26 145.73 33.0 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 174.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -90.58 -103.84 0.1 Allowed 'General case' 0 CA--C 1.537 0.462 0 O-C-N 124.98 1.425 . . . . 0.0 107.557 170.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.03 147.22 50.35 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.443 0.697 . . . . 0.0 111.901 -177.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.33 151.76 51.71 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 127.093 2.157 . . . . 0.0 110.17 173.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.87 174.82 37.55 Favored Glycine 0 C--O 1.221 -0.678 0 N-CA-C 116.461 1.344 . . . . 0.0 116.461 -174.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -142.37 143.47 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.408 1.483 . . . . 0.0 109.502 -168.264 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.2 129.82 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -165.481 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.71 -155.66 7.12 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 125.232 1.396 . . . . 0.0 111.023 167.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.43 157.23 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.033 1.333 . . . . 0.0 113.285 -169.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.9 -41.1 14.25 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 161.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 . . . . . 0 CA--C 1.536 0.432 1 C-N-CA 132.764 4.425 . . . . 0.0 107.194 168.437 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.511 -0.536 0 CA-C-O 123.028 1.394 . . . . 0.0 111.345 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -87.8 107.1 18.5 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 166.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.02 167.48 12.06 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.537 1.535 . . . . 0.0 111.893 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' B' ' 52' ' ' ASP . 2.0 p -159.35 149.23 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.395 1.078 . . . . 0.0 112.013 -168.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.33 121.22 14.53 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.073 1.749 . . . . 0.0 108.918 167.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -103.71 99.16 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 167.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.2 mp -81.03 116.29 20.91 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -176.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 mtpt -144.77 157.55 44.13 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-N 119.272 0.942 . . . . 0.0 111.818 -172.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.45 -47.87 0.43 Allowed Glycine 0 N--CA 1.47 0.904 0 C-N-CA 126.505 2.002 . . . . 0.0 111.252 169.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.62 61.42 2.94 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 128.64 2.776 . . . . 0.0 112.344 -168.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.4 -99.81 0.02 OUTLIER Glycine 0 CA--C 1.534 1.266 0 C-N-CA 126.974 2.226 . . . . 0.0 112.904 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -82.11 -7.39 12.09 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.202 3.268 . . . . 0.0 114.867 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -86.42 136.07 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 121.244 1.838 . . . . 0.0 110.889 175.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.38 151.44 35.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 114.066 -1.424 . . . . 0.0 110.833 167.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -118.77 98.79 0.75 Allowed Glycine 0 C--O 1.22 -0.779 0 C-N-CA 125.485 1.517 . . . . 0.0 110.259 174.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -91.38 110.84 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 108.382 -0.969 . . . . 0.0 108.382 171.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.431 HD13 ' CE1' ' A' ' 20' ' ' PHE . 1.8 pp -127.09 155.19 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-O 122.037 0.922 . . . . 0.0 110.713 168.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -130.96 156.2 45.51 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.476 1.51 . . . . 0.0 109.849 169.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' CE1' HD13 ' A' ' 18' ' ' ILE . 7.8 m-85 -123.8 120.51 32.85 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.001 1.32 . . . . 0.0 108.651 168.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -98.44 119.86 37.86 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.246 1.018 . . . . 0.0 110.118 172.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.95 170.47 16.05 Favored 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 166.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.93 -46.88 0.53 Allowed 'General case' 0 CA--C 1.558 1.253 0 C-N-CA 128.135 2.574 . . . . 0.0 110.166 168.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.6 mp0 -81.68 116.1 21.24 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 120.456 1.48 . . . . 0.0 111.964 173.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -68.6 -9.69 51.22 Favored 'General case' 0 CA--C 1.552 1.047 0 O-C-N 119.223 -2.173 . . . . 0.0 114.439 -174.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -110.78 -2.94 15.97 Favored 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 127.22 2.208 . . . . 0.0 114.542 174.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.27 175.99 38.32 Favored Glycine 0 CA--C 1.542 1.734 0 CA-C-O 118.848 -0.973 . . . . 0.0 113.756 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -77.77 163.17 29.2 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 124.731 3.62 . . . . 0.0 110.739 175.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.2 t -138.08 145.57 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.672 0.789 . . . . 0.0 112.165 -165.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.79 121.28 27.47 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.74 1.216 . . . . 0.0 111.425 169.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 94.6 t -101.16 133.47 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.852 2.061 . . . . 0.0 108.112 169.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -153.67 167.61 29.0 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.572 0.701 . . . . 0.0 112.658 171.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.51 -161.35 28.36 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 124.253 0.93 . . . . 0.0 113.432 172.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.8 p -154.35 118.98 4.87 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.519 0.727 . . . . 0.0 110.776 -169.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.496 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 2.2 mp -108.01 103.0 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.915 0.886 . . . . 0.0 109.019 -177.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -115.88 133.42 56.04 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.223 1.809 . . . . 0.0 111.934 -166.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.59 0.86 27.65 Favored Glycine 0 CA--C 1.536 1.399 0 C-N-CA 127.458 2.456 . . . . 0.0 113.26 -174.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 97.5 mt -70.57 162.74 28.31 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 118.508 1.154 . . . . 0.0 111.116 172.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.6 m -83.14 140.64 32.49 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 166.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -58.76 152.15 19.64 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.42 -172.67 29.17 Favored Glycine 0 CA--C 1.532 1.125 0 C-N-CA 124.241 0.924 . . . . 0.0 112.818 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -72.4 149.29 44.42 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.817 2.047 . . . . 0.0 112.329 -169.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -145.81 121.72 10.64 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.962 1.705 . . . . 0.0 110.14 173.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.62 147.76 23.46 Favored Glycine 0 N--CA 1.486 1.982 0 CA-C-N 119.992 1.269 . . . . 0.0 112.606 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -148.32 102.01 3.31 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 119.208 1.504 . . . . 0.0 112.408 -167.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m80 -150.27 169.86 20.35 Favored 'General case' 0 CA--C 1.52 -0.199 0 O-C-N 120.658 -1.276 . . . . 0.0 114.331 -168.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.6 m -75.73 129.93 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 113.608 -1.633 . . . . 0.0 109.871 166.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -80.86 137.71 36.18 Favored 'General case' 0 CA--C 1.551 0.986 0 N-CA-C 102.472 -3.159 . . . . 0.0 102.472 157.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -65.18 142.44 58.33 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -168.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 56.83 -169.05 0.1 Allowed 'General case' 0 C--O 1.241 0.623 0 C-N-CA 127.242 2.217 . . . . 0.0 113.898 175.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 54' ' ' THR . . . -136.69 5.71 3.76 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-O 116.78 -2.122 . . . . 0.0 113.525 -178.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG21 ' B' ' 5' ' ' VAL . 21.3 p-10 -77.91 48.6 0.72 Allowed 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 121.336 2.568 . . . . 0.0 110.404 169.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.574 ' HA ' HG21 ' B' ' 7' ' ' VAL . 0.2 OUTLIER 172.65 5.87 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 118.359 2.726 . . . . 0.0 118.359 -169.35 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 51' ' ' GLY . 43.4 p -31.37 -10.02 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.213 1 N-CA-C 124.607 5.04 . . . . 0.0 124.607 -167.497 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.02 35.67 0.06 Allowed 'General case' 0 CA--C 1.555 1.147 0 CA-C-N 123.504 2.865 . . . . 0.0 116.643 -169.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.1 -148.96 46.85 Favored Glycine 0 CA--C 1.526 0.734 0 O-C-N 120.784 -1.197 . . . . 0.0 111.617 172.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.3 p -64.42 -12.01 38.94 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 114.914 1.45 . . . . 0.0 114.914 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 p -80.01 -0.3 34.84 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.898 2.079 . . . . 0.0 112.833 178.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.1 m -155.87 177.49 11.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 127.655 2.382 . . . . 0.0 109.215 -176.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 77.1 -156.48 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 126.448 1.899 . . . . 0.0 113.96 172.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.2 -169.8 16.14 Favored Glycine 0 CA--C 1.541 1.674 0 C-N-CA 126.823 2.154 . . . . 0.0 114.931 -167.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -66.8 -177.03 0.83 Allowed 'Trans proline' 0 CA--C 1.539 0.761 1 C-N-CA 126.353 4.702 . . . . 0.0 113.588 177.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 114.26 21.88 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.625 1.17 . . . . 0.0 112.932 -170.514 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.424 ' CD2' ' HD3' ' A' ' 66' ' ' PRO . 8.8 t80 -41.43 128.44 3.07 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 127.385 2.274 . . . . 0.0 115.089 -169.616 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -112.0 45.92 0.27 Allowed Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 125.653 1.581 . . . . 0.0 114.281 -173.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.424 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 62.4 Cg_endo -69.15 -17.69 40.22 Favored 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 123.236 2.624 . . . . 0.0 111.722 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.5 mt -76.46 -7.14 54.49 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.201 1.4 . . . . 0.0 111.417 171.225 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.3 t 73.48 56.89 0.11 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 127.167 2.187 . . . . 0.0 112.267 171.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.16 172.45 16.92 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 116.52 2.044 . . . . 0.0 116.52 -167.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 15.2 mmtp -82.57 173.81 11.62 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 127.149 2.18 . . . . 0.0 112.167 171.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.4 t60 -72.58 165.07 25.41 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.034 1.733 . . . . 0.0 113.616 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.46 -140.53 8.59 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 124.984 1.278 . . . . 0.0 114.499 167.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.566 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.87 -86.14 0.29 Allowed Glycine 0 CA--C 1.533 1.205 0 C-N-CA 126.287 1.898 . . . . 0.0 115.617 174.026 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -61.21 -9.77 13.58 Favored 'Trans proline' 0 CA--C 1.539 0.728 0 C-N-CA 124.748 3.632 . . . . 0.0 116.001 -169.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.34 -7.98 2.58 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.936 0.894 . . . . 0.0 112.767 167.562 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.566 ' HB3' ' H ' ' A' ' 73' ' ' GLY 0.314 0.0 OUTLIER -93.04 175.19 6.88 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -164.699 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 56.0 mp0 -103.21 -22.95 13.66 Favored 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 131.391 3.876 . . . . 0.0 111.46 -168.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.418 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 2.9 mm-40 -105.94 -114.93 0.25 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 127.464 2.306 . . . . 0.0 110.132 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 103.27 119.18 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 130.892 3.677 . . . . 0.0 112.856 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.4 m170 -65.44 -176.87 0.36 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 126.388 1.875 . . . . 0.0 114.451 169.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.5 p -84.58 143.79 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 120.762 -1.212 . . . . 0.0 108.636 166.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.2 -2.52 9.25 Favored Glycine 0 CA--C 1.54 1.607 0 N-CA-C 117.455 1.742 . . . . 0.0 117.455 172.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -77.35 85.43 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-N 120.486 2.143 . . . . 0.0 109.553 167.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.0 mt -82.55 54.83 2.75 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.29 -176.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.47 -135.95 29.54 Favored Glycine 0 CA--C 1.528 0.859 0 C-N-CA 125.172 1.368 . . . . 0.0 114.386 170.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -136.86 145.0 43.88 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.058 0.943 . . . . 0.0 111.325 175.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -93.51 107.1 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 126.333 1.853 . . . . 0.0 109.579 176.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.2 m -99.9 113.89 26.75 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.677 1.191 . . . . 0.0 109.187 -175.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.03 158.26 15.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.896 1.679 . . . . 0.0 114.05 -171.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.39 -173.09 3.67 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.265 1.426 . . . . 0.0 112.597 169.229 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -83.7 -13.55 53.82 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 116.615 2.08 . . . . 0.0 116.615 176.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -75.36 -7.73 54.78 Favored 'General case' 0 CA--C 1.561 1.388 0 CA-C-O 122.845 1.307 . . . . 0.0 108.005 163.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.02 8.94 56.5 Favored Glycine 0 C--N 1.339 0.733 0 C-N-CA 128.26 2.838 . . . . 0.0 113.258 168.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 125.43 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 119.058 1.429 . . . . 0.0 113.839 -169.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 100.21 12.14 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 166.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -89.89 134.01 34.44 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.415 1.486 . . . . 0.0 109.099 177.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -141.31 137.42 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -167.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.3 p -153.59 119.5 5.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 125.757 1.623 . . . . 0.0 110.413 169.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.8 mt -147.15 147.47 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 C-N-CA 128.646 2.779 . . . . 0.0 110.358 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -118.02 130.81 56.4 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.895 2.078 . . . . 0.0 105.98 167.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -139.36 134.38 32.41 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.853 0.861 . . . . 0.0 112.186 -172.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -114.69 46.46 1.4 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.175 1.176 . . . . 0.0 114.175 -179.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.57 7.11 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 C-N-CA 123.672 0.789 . . . . 0.0 112.865 167.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -133.33 161.37 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 C-N-CA 124.821 1.248 . . . . 0.0 109.056 168.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.3 p -148.61 162.32 39.92 Favored 'General case' 0 C--O 1.239 0.53 0 O-C-N 121.495 -0.753 . . . . 0.0 109.726 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -90.08 70.25 7.34 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 122.887 1.327 . . . . 0.0 109.39 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.6 t -106.69 142.85 35.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 114.296 -1.32 . . . . 0.0 109.343 168.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.21 10.93 52.14 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 127.573 2.511 . . . . 0.0 118.796 -165.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -129.31 -74.75 0.56 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.833 1.816 . . . . 0.0 110.292 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -95.26 -9.54 32.88 Favored 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.292 1.96 . . . . 0.0 116.292 -169.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 65.2 m -92.39 -123.54 0.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 CA-C-N 120.064 1.302 . . . . 0.0 113.66 -171.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.0 pt -115.95 14.86 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 119.61 -1.931 . . . . 0.0 115.727 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.8 mm -83.52 145.07 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 O-C-N 120.775 -1.203 . . . . 0.0 108.301 167.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 62.81 27.48 70.16 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 114.936 0.734 . . . . 0.0 114.936 168.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -106.3 153.8 21.66 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.471 1.108 . . . . 0.0 109.27 179.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 49.7 m -95.77 86.96 4.52 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.334 -0.854 . . . . 0.0 111.16 -167.237 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.8 tp -76.3 145.59 39.49 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-N 122.193 2.27 . . . . 0.0 113.457 -168.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.8 p -133.45 152.58 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 C-N-CA 126.751 2.021 . . . . 0.0 112.686 177.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -112.85 133.05 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 124.33 1.052 . . . . 0.0 108.216 164.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -89.61 152.75 21.23 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-O 122.292 1.044 . . . . 0.0 113.075 -176.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -68.01 -29.35 68.34 Favored 'General case' 0 N--CA 1.473 0.707 0 O-C-N 120.46 -1.4 . . . . 0.0 114.754 -174.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -119.8 169.56 10.02 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.976 1.31 . . . . 0.0 112.285 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -49.37 148.07 2.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.58 1.152 . . . . 0.0 110.555 169.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -96.45 133.45 40.86 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 123.647 0.592 . . . . 0.0 109.77 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -84.78 -13.89 49.83 Favored 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 125.44 1.496 . . . . 0.0 113.464 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 65.1 -38.34 0.25 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 130.817 3.647 . . . . 0.0 114.327 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.96 -32.6 0.05 OUTLIER Glycine 0 CA--C 1.519 0.281 0 CA-C-N 119.579 1.081 . . . . 0.0 115.343 170.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.78 69.69 0.99 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 117.379 2.363 . . . . 0.0 117.379 -172.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -79.55 -68.29 1.5 Allowed Glycine 0 N--CA 1.461 0.346 0 N-CA-C 106.27 -2.732 . . . . 0.0 106.27 164.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 174.65 21.31 0.02 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 124.819 1.199 . . . . 0.0 115.068 -178.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -149.23 161.79 41.32 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 119.374 1.587 . . . . 0.0 110.095 -179.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 35.1 tp10 -69.34 -45.9 68.35 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.905 1.282 . . . . 0.0 111.786 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -45.39 -35.25 3.51 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.775 1.23 . . . . 0.0 113.417 176.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 33.4 t -58.7 -56.81 17.44 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 169.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.292 0.0 OUTLIER -66.53 -9.72 37.66 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 123.98 0.912 . . . . 0.0 111.184 -178.013 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 48.7 mtmt -93.41 -50.45 5.44 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 119.333 0.969 . . . . 0.0 113.285 167.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 68.6 p -113.36 -24.38 9.36 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 -166.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.14 -3.08 47.55 Favored Glycine 0 C--O 1.22 -0.729 0 C-N-CA 125.203 1.383 . . . . 0.0 112.545 -168.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 54.66 16.04 1.25 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.898 1.679 . . . . 0.0 113.279 -177.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.59 27.27 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.763 2.025 . . . . 0.0 115.735 -165.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.7 -75.05 2.42 Favored Glycine 0 C--N 1.338 0.694 0 C-N-CA 127.254 2.359 . . . . 0.0 113.361 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.4 t -170.21 -150.31 0.08 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.546 1.138 . . . . 0.0 110.442 -171.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.89 123.5 47.18 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.366 1.067 . . . . 0.0 110.891 -173.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.489 HD23 ' H ' ' A' ' 145' ' ' ALA . 1.7 tt -96.2 -137.4 0.25 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.86 2.064 . . . . 0.0 106.257 168.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.489 ' H ' HD23 ' A' ' 144' ' ' LEU . . . -61.15 151.03 32.38 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 125.049 1.34 . . . . 0.0 112.375 -176.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -148.04 142.95 26.86 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 114.836 -1.074 . . . . 0.0 113.846 -172.336 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.23 114.88 0.63 Allowed Glycine 0 CA--C 1.528 0.9 0 C-N-CA 125.386 1.469 . . . . 0.0 113.039 -176.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 0.5 OUTLIER -74.41 135.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.387 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 37.9 mt -74.98 124.35 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.055 0.542 . . . . 0.0 111.885 -167.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.08 -175.28 17.38 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 124.834 1.207 . . . . 0.0 113.27 173.087 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -124.83 152.12 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 126.581 1.953 . . . . 0.0 111.997 173.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.13 -8.19 2.31 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -178.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tm0? . . . . . 0 C--O 1.236 0.349 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 169.17 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.556 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -84.62 74.08 10.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 105.604 -1.998 . . . . 0.0 105.604 168.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ptpm? -76.01 121.58 22.96 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.39 -0.819 . . . . 0.0 110.328 -170.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.59 152.71 22.1 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.203 1.001 . . . . 0.0 110.939 -177.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.511 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -145.87 129.91 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.082 0.944 . . . . 0.0 111.288 -167.503 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.421 ' HB2' HG13 ' B' ' 149' ' ' ILE . . . -104.44 134.84 46.96 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.306 -1.315 . . . . 0.0 107.863 168.414 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.574 HG21 ' HA ' ' A' ' 53' ' ' ASN . 93.2 t -116.88 115.64 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 167.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -95.8 96.7 9.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 126.222 1.809 . . . . 0.0 108.942 -169.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -158.21 124.58 4.74 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.736 0.814 . . . . 0.0 110.233 175.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.25 -101.62 2.59 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 105.876 -2.89 . . . . 0.0 105.876 165.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -144.35 109.25 4.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 125.274 1.43 . . . . 0.0 109.702 -169.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.6 167.38 11.44 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 125.446 1.498 . . . . 0.0 111.648 -175.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -73.67 25.57 0.32 Allowed 'Trans proline' 0 CA--C 1.544 1.019 1 C-N-CA 125.361 4.041 . . . . 0.0 114.963 -170.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -122.68 119.83 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 119.605 1.093 . . . . 0.0 109.096 -178.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -158.66 158.15 33.22 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 114.684 -1.144 . . . . 0.0 112.357 -178.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.2 177.02 36.82 Favored Glycine 0 CA--C 1.506 -0.479 0 C-N-CA 124.843 1.211 . . . . 0.0 114.069 176.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -120.61 148.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 112.993 -1.603 . . . . 0.0 109.742 168.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.0 mm -128.81 130.84 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 166.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -100.41 141.84 32.71 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 126.31 1.844 . . . . 0.0 110.809 168.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -120.93 104.92 10.2 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.262 2.225 . . . . 0.0 108.845 171.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -99.78 103.18 14.79 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.842 0.857 . . . . 0.0 110.905 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -105.62 136.68 44.76 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 122.145 0.974 . . . . 0.0 109.27 169.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 16.6 pttp -98.71 -24.52 15.01 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 124.992 1.317 . . . . 0.0 113.692 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -163.93 134.84 4.47 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.061 2.144 . . . . 0.0 107.957 -164.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.5 p -51.83 -28.62 16.36 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 126.01 1.724 . . . . 0.0 114.873 -170.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -109.26 -6.18 15.63 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.558 1.543 . . . . 0.0 113.381 -176.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -88.22 165.97 34.69 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.86 1.219 . . . . 0.0 111.726 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.32 168.82 21.18 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.041 2.494 . . . . 0.0 111.902 -176.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.27 124.36 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 C-N-CA 123.828 0.851 . . . . 0.0 109.262 176.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -81.54 128.59 34.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.625 -0.672 . . . . 0.0 109.427 169.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 63.2 t -108.81 127.09 65.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 126.093 1.757 . . . . 0.0 109.261 179.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -151.37 163.07 39.77 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 121.573 -0.705 . . . . 0.0 112.266 170.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.84 -166.24 33.37 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 123.702 0.668 . . . . 0.0 112.657 174.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.4 p -152.9 128.01 9.73 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 122.97 0.508 . . . . 0.0 111.665 -169.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 31.3 mt -118.72 124.77 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 125.019 1.328 . . . . 0.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -122.37 139.93 53.26 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 120.769 1.622 . . . . 0.0 111.595 -176.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.88 -0.51 9.17 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 127.863 2.649 . . . . 0.0 113.502 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 92.3 mt -75.73 170.3 16.45 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.16 1.384 . . . . 0.0 111.24 174.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.5 t -90.02 151.07 21.84 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 166.043 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -49.22 143.56 6.01 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.601 0.761 . . . . 0.0 111.513 171.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.32 -178.88 22.8 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 124.713 1.149 . . . . 0.0 113.239 -176.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.732 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.7 pt? -80.59 149.54 29.87 Favored 'General case' 0 CA--C 1.553 1.066 0 C-N-CA 128.739 2.816 . . . . 0.0 113.732 -172.132 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -154.17 126.3 7.84 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 128.594 2.758 . . . . 0.0 110.685 -170.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.06 160.85 41.93 Favored Glycine 0 N--CA 1.482 1.766 0 CA-C-N 121.162 1.801 . . . . 0.0 113.914 -177.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.476 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.285 0.2 OUTLIER -159.38 138.21 10.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 128.182 2.593 . . . . 0.0 114.867 168.68 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 16.6 m80 -149.1 141.64 24.35 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 120.659 -1.276 . . . . 0.0 114.087 -169.112 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.02 106.94 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 126.768 2.027 . . . . 0.0 111.166 178.155 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.409 ' C ' ' H ' ' B' ' 50' ' ' PHE . 8.1 m170 -79.22 135.7 36.86 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.486 1.115 . . . . 0.0 110.732 -176.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -70.24 17.64 0.06 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.537 1.935 . . . . 0.0 112.513 171.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . 0.409 ' H ' ' C ' ' B' ' 48' ' ' HIS . 23.0 m-85 -144.07 92.66 2.35 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 126.427 1.891 . . . . 0.0 107.942 -167.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.29 7.73 66.78 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 116.967 -2.018 . . . . 0.0 111.012 167.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.691 ' HA ' HG21 ' A' ' 5' ' ' VAL . 4.9 m-20 -77.1 49.79 0.7 Allowed 'General case' 0 N--CA 1.481 1.094 0 CA-C-O 124.779 2.228 . . . . 0.0 110.357 -176.112 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 170.84 27.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 128.201 2.601 . . . . 0.0 113.574 -165.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 35.4 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 120.184 3.402 . . . . 0.0 120.184 -170.527 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.85 0 N-CA-C 113.545 0.942 . . . . 0.0 113.545 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -116.72 -99.79 2.13 Favored Glycine 0 CA--C 1.545 1.923 0 C-N-CA 125.315 1.436 . . . . 0.0 114.243 -174.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -92.0 177.26 1.76 Allowed 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.856 3.704 . . . . 0.0 113.429 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -115.26 126.02 54.01 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.862 2.465 . . . . 0.0 110.919 -175.491 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -48.84 149.33 1.84 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 129.253 3.021 . . . . 0.0 116.571 -169.653 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -111.65 44.11 0.23 Allowed Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 127.305 2.242 . . . . 0.0 113.695 -172.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -63.05 -30.54 76.1 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.705 2.27 . . . . 0.0 113.825 -169.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.66 -3.95 43.6 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.012 0.925 . . . . 0.0 112.582 173.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.0 t 77.27 58.91 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 127.368 2.267 . . . . 0.0 111.616 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 ptt180 -163.4 177.52 8.84 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 117.341 2.349 . . . . 0.0 117.341 -167.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -64.99 169.91 4.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.202 3.001 . . . . 0.0 114.276 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 52.7 t60 -107.2 146.68 31.08 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.712 2.005 . . . . 0.0 114.236 -169.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 126.92 -104.26 0.7 Allowed Glycine 0 N--CA 1.472 1.092 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 163.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.44 -35.62 3.55 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-O 116.367 -2.351 . . . . 0.0 118.271 167.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 14.43 0.85 Allowed 'Trans proline' 0 CA--C 1.549 1.251 0 CA-C-N 123.349 3.574 . . . . 0.0 113.153 168.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.49 -26.92 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 127.531 2.332 . . . . 0.0 110.847 169.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.32 0.0 OUTLIER -64.47 151.79 43.37 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 123.225 1.488 . . . . 0.0 113.774 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 60.4 mp0 -88.42 -10.36 49.47 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 111.241 -2.709 . . . . 0.0 114.358 -166.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -143.98 -53.57 0.34 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.411 1.005 . . . . 0.0 112.58 -169.185 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 80.52 125.18 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 127.446 2.299 . . . . 0.0 114.362 166.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.5 m170 -67.08 148.23 52.15 Favored 'General case' 0 CA--C 1.541 0.608 0 O-C-N 121.018 -1.051 . . . . 0.0 110.856 167.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -72.4 26.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 125.311 1.444 . . . . 0.0 113.781 171.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -154.03 23.45 0.69 Allowed Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.636 1.589 . . . . 0.0 114.864 -169.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -125.54 129.31 49.47 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 119.071 1.435 . . . . 0.0 110.048 -178.533 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 86.6 mt -107.77 41.9 1.44 Allowed 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.042 0.837 . . . . 0.0 110.711 168.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.97 -117.68 5.02 Favored Glycine 0 CA--C 1.537 1.439 0 O-C-N 120.476 -1.39 . . . . 0.0 113.436 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -140.27 146.98 39.29 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.46 1.504 . . . . 0.0 113.394 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.476 HG13 ' CE1' ' B' ' 45' ' ' PHE . 28.2 m -93.39 145.49 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 127.237 2.215 . . . . 0.0 110.247 169.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 2.7 m -110.55 125.53 53.45 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 119.466 1.03 . . . . 0.0 109.618 171.011 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.39 163.9 15.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.447 0.699 . . . . 0.0 112.546 169.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.29 178.72 4.97 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.851 1.661 . . . . 0.0 112.713 173.277 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.595 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -58.22 -29.49 65.75 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.646 1.978 . . . . 0.0 116.314 171.955 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.18 -10.87 59.83 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 119.731 1.15 . . . . 0.0 111.099 171.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.54 11.82 46.5 Favored Glycine 0 C--N 1.334 0.464 0 CA-C-O 116.88 -2.067 . . . . 0.0 113.865 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.0 p -98.4 125.52 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 119.476 1.638 . . . . 0.0 113.357 179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.0 100.35 12.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.43 1.492 . . . . 0.0 108.04 165.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -87.37 143.25 27.34 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.242 1.017 . . . . 0.0 109.506 170.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.45 144.21 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 116.445 2.017 . . . . 0.0 116.445 -176.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.4 m -156.24 111.97 2.99 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.567 1.947 . . . . 0.0 111.161 174.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 13.2 mt -143.54 163.97 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 130.011 3.324 . . . . 0.0 109.571 -169.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -145.3 146.15 31.52 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 126.478 1.911 . . . . 0.0 107.757 168.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -144.69 132.05 20.76 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.935 0.894 . . . . 0.0 110.112 -175.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.8 p -113.54 46.04 1.34 Allowed 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.889 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.11 1.83 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 124.025 0.93 . . . . 0.0 111.687 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.46 171.42 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 126.35 1.86 . . . . 0.0 109.953 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 42.1 m -158.0 174.26 15.51 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 120.837 -1.164 . . . . 0.0 111.222 176.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 93.2 mt -109.54 54.03 0.67 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 127.407 2.283 . . . . 0.0 109.415 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.7 t -112.78 34.97 4.08 Favored 'General case' 0 CA--C 1.551 1.011 0 N-CA-C 115.626 1.714 . . . . 0.0 115.626 -168.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.92 -29.2 3.08 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 119.237 2.455 . . . . 0.0 119.237 165.345 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.251 17.7 t70 -99.41 -109.29 0.19 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 118.522 1.161 . . . . 0.0 108.448 -167.668 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -81.76 10.3 6.45 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.569 2.347 . . . . 0.0 112.703 175.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 m -60.76 -175.39 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.175 2.59 . . . . 0.0 115.081 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.282 11.6 pt -88.63 -3.91 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 119.941 -1.724 . . . . 0.0 114.424 172.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.7 mm -64.84 131.14 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 166.735 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.18 10.52 62.45 Favored Glycine 0 CA--C 1.524 0.653 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.281 -178.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -78.99 170.17 17.1 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 119.918 1.859 . . . . 0.0 109.836 173.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 91.8 m -112.33 112.5 24.12 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 48.5 tp -92.6 103.95 16.29 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 124.42 1.075 . . . . 0.0 109.459 177.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 13.7 p -86.4 149.53 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 167.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 37.9 t -128.41 143.76 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 167.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -106.0 163.08 13.04 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 125.665 1.586 . . . . 0.0 113.115 -168.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -76.28 -42.34 45.83 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.225 -175.101 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -110.56 176.07 5.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.822 1.649 . . . . 0.0 109.956 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.4 -176.59 6.29 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.252 0.549 . . . . 0.0 109.599 165.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -110.26 159.04 17.75 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.83 2.052 . . . . 0.0 113.032 -166.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -73.47 -14.21 61.2 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.904 1.282 . . . . 0.0 111.205 170.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 70.5 mt 54.08 61.45 3.05 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.124 1.77 . . . . 0.0 111.948 172.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.48 -54.15 3.47 Favored Glycine 0 N--CA 1.462 0.431 0 C-N-CA 125.688 1.613 . . . . 0.0 111.474 170.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.4 ttpt -126.9 72.9 1.37 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.676 1.19 . . . . 0.0 113.238 -168.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . 0.437 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -83.56 -30.46 29.9 Favored Glycine 0 CA--C 1.534 1.274 0 C-N-CA 124.579 1.085 . . . . 0.0 112.429 169.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 120.8 32.36 1.11 Allowed Glycine 0 N--CA 1.472 1.08 0 C-N-CA 125.167 1.365 . . . . 0.0 113.561 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -153.4 -156.21 0.67 Allowed 'General case' 0 CA--C 1.554 1.121 0 C-N-CA 124.571 1.148 . . . . 0.0 109.644 -169.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -95.9 -52.47 4.05 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 120.765 1.621 . . . . 0.0 110.727 171.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -54.29 -28.53 42.61 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 127.774 2.43 . . . . 0.0 113.176 -172.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.437 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 88.9 p -57.56 -30.78 65.51 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 125.016 1.327 . . . . 0.0 112.453 174.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -107.07 -27.48 10.6 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 117.519 -1.229 . . . . 0.0 114.188 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.7 tptm -71.88 -24.14 61.62 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 120.994 1.725 . . . . 0.0 113.056 -176.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -133.54 -46.6 0.82 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 126.287 1.835 . . . . 0.0 110.78 167.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.81 -9.0 8.1 Favored Glycine 0 C--O 1.221 -0.701 0 C-N-CA 125.477 1.513 . . . . 0.0 110.479 -163.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 57.63 37.32 27.4 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 124.992 1.317 . . . . 0.0 112.166 176.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.04 30.06 0.11 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 115.069 1.507 . . . . 0.0 115.069 -169.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.58 -57.27 2.52 Favored Glycine 0 N--CA 1.47 0.962 0 C-N-CA 127.539 2.495 . . . . 0.0 114.44 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.1 t -174.79 172.05 3.04 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.3 1.84 . . . . 0.0 110.479 -174.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.431 ' HD3' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -82.67 157.28 23.42 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 121.173 -0.954 . . . . 0.0 111.599 170.631 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -128.84 -97.58 0.38 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 124.546 1.138 . . . . 0.0 108.402 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -95.65 162.26 13.69 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.355 1.062 . . . . 0.0 111.242 174.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 p -158.5 155.9 29.3 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.788 1.235 . . . . 0.0 113.277 173.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.52 176.12 35.5 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 126.176 1.846 . . . . 0.0 112.362 171.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 76.7 t -107.3 157.29 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-N 118.247 1.024 . . . . 0.0 108.318 168.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.421 HG13 ' HB2' ' B' ' 6' ' ' ALA . 3.3 mt -87.24 110.85 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 123.886 0.874 . . . . 0.0 110.964 176.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -105.54 -165.47 23.56 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.554 1.549 . . . . 0.0 111.686 168.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -136.74 158.65 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 114.358 1.244 . . . . 0.0 114.358 -169.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -142.41 -19.61 0.69 Allowed 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 170.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.48 1.038 0 C-N-CA 125.317 1.447 . . . . 0.0 111.965 176.946 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 CA--C 1.512 -0.517 0 CA-C-O 122.772 1.272 . . . . 0.0 108.158 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.2 mtmm -98.91 132.66 44.07 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 112.616 -2.084 . . . . 0.0 113.924 171.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.62 168.7 13.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.029 0.932 . . . . 0.0 111.989 171.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.41 97.9 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 168.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -94.6 136.95 34.32 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 121.354 -0.842 . . . . 0.0 110.377 173.16 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.418 ' HB ' HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -134.38 130.48 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 C-N-CA 124.164 0.986 . . . . 0.0 110.44 -176.891 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -116.31 145.45 43.18 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.589 2.356 . . . . 0.0 110.6 172.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.74 160.17 40.32 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.292 1.037 . . . . 0.0 113.158 168.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.3 161.86 25.0 Favored Glycine 0 CA--C 1.525 0.708 0 C-N-CA 127.246 2.355 . . . . 0.0 107.901 168.187 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -76.62 59.46 1.52 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.298 1.439 . . . . 0.0 113.629 -177.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.58 -163.17 35.79 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 126.732 2.111 . . . . 0.0 110.194 -176.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -77.27 32.52 0.43 Allowed 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 125.041 3.827 . . . . 0.0 112.698 -173.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 t -114.24 124.09 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 C-N-CA 125.525 1.53 . . . . 0.0 108.58 -174.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -141.44 156.7 45.75 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 124.283 1.033 . . . . 0.0 110.284 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.56 139.93 10.87 Favored Glycine 0 CA--C 1.503 -0.695 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.133 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.8 125.76 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 117.354 0.577 . . . . 0.0 109.613 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.1 mm -133.74 122.72 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -111.41 101.18 9.65 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-O 122.537 1.16 . . . . 0.0 109.614 169.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -77.58 138.58 39.23 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.823 1.649 . . . . 0.0 108.574 176.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -110.21 121.65 45.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 119.845 1.202 . . . . 0.0 111.168 166.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.477 ' HB2' HD13 ' A' ' 106' ' ' LEU . 19.3 tp60 -82.48 128.59 34.42 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 163.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.59 -38.7 62.56 Favored 'General case' 0 CA--C 1.544 0.735 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 179.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -104.19 -129.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 129.653 3.181 . . . . 0.0 111.675 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.9 t -143.51 14.67 1.79 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.824 2.45 . . . . 0.0 110.209 167.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -168.07 -0.17 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 126.014 1.726 . . . . 0.0 115.426 -166.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.28 -151.58 11.49 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 125.849 1.69 . . . . 0.0 112.152 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -71.61 173.26 12.82 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 124.24 3.293 . . . . 0.0 113.616 -175.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -142.9 141.84 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.463 1.105 . . . . 0.0 110.872 -174.171 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.2 tttp -101.7 121.8 42.73 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 167.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.2 t -104.01 114.52 43.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 125.574 1.549 . . . . 0.0 108.581 -177.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.6 p90 -138.55 156.32 47.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 122.308 1.051 . . . . 0.0 113.035 177.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.02 -164.49 27.53 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.465 1.507 . . . . 0.0 111.361 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 88.7 p -158.1 160.22 37.1 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.049 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.1 mm -120.14 120.54 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 C-N-CA 124.597 1.159 . . . . 0.0 112.023 176.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.0 mmtt -104.95 152.13 23.06 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.386 1.474 . . . . 0.0 111.684 -174.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.35 -0.35 53.79 Favored Glycine 0 N--CA 1.475 1.288 0 C-N-CA 125.243 1.402 . . . . 0.0 114.435 174.098 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -83.85 173.5 11.19 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 126.467 1.907 . . . . 0.0 112.612 178.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.3 t -81.8 175.59 10.3 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 160.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.53 -175.8 0.14 Allowed 'General case' 0 CA--C 1.557 1.249 0 CA-C-O 122.44 1.114 . . . . 0.0 113.497 175.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.32 -179.69 45.44 Favored Glycine 0 CA--C 1.533 1.202 0 O-C-N 120.478 -1.389 . . . . 0.0 114.478 173.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.415 ' H ' HD12 ' A' ' 42' ' ' LEU . 5.8 mp -61.96 142.37 57.49 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 127.46 2.304 . . . . 0.0 111.359 -178.53 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -143.53 117.8 9.59 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 126.864 2.066 . . . . 0.0 109.442 176.042 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.14 141.87 47.71 Favored Glycine 0 N--CA 1.478 1.491 0 CA-C-N 120.038 1.29 . . . . 0.0 111.484 -179.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.277 0.1 OUTLIER -150.95 130.52 13.03 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 118.966 1.383 . . . . 0.0 111.839 174.403 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.87 143.65 26.4 Favored 'General case' 0 CA--C 1.535 0.366 0 O-C-N 121.278 -0.889 . . . . 0.0 111.917 -164.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -98.0 105.81 17.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.874 1.669 . . . . 0.0 108.5 -178.549 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -74.45 144.86 44.05 Favored 'General case' 0 C--N 1.322 -0.617 0 O-C-N 121.548 -0.72 . . . . 0.0 109.325 175.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -46.89 132.56 11.52 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 167.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.51 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 77.35 146.02 0.09 Allowed 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 124.729 2.204 . . . . 0.0 114.14 174.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.14 6.69 11.93 Favored Glycine 0 N--CA 1.466 0.69 0 C-N-CA 126.714 2.102 . . . . 0.0 111.788 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -76.89 42.89 0.32 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.648 1.579 . . . . 0.0 109.658 168.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 168.95 42.45 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 125.314 1.446 . . . . 0.0 113.638 -164.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -63.38 -4.69 2.84 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 116.23 1.937 . . . . 0.0 116.23 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.85 30.26 1.62 Allowed 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 120.381 1.446 . . . . 0.0 112.527 -171.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.37 -139.75 45.94 Favored Glycine 0 N--CA 1.466 0.642 0 O-C-N 120.828 -1.17 . . . . 0.0 111.509 171.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.6 p -52.57 -31.77 37.71 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 176.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.2 t -87.16 43.43 1.1 Allowed 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.415 1.462 . . . . 0.0 112.225 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.5 p -179.87 -32.64 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 127.411 2.285 . . . . 0.0 113.755 172.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -143.46 139.5 29.92 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 120.151 1.341 . . . . 0.0 113.62 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.35 -115.61 0.93 Allowed Glycine 0 CA--C 1.544 1.864 0 CA-C-O 117.952 -1.471 . . . . 0.0 113.559 -175.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.12 -179.69 5.48 Favored 'Trans proline' 0 C--N 1.348 0.532 1 C-N-CA 125.634 4.223 . . . . 0.0 112.689 -178.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -81.57 71.73 8.59 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.429 1.092 . . . . 0.0 109.97 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -43.71 140.52 1.82 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.519 1.528 . . . . 0.0 111.469 170.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -158.18 155.11 25.4 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 117.774 -1.108 . . . . 0.0 112.668 170.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -73.04 -10.94 25.08 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.082 1.855 . . . . 0.0 114.341 -172.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -87.68 -10.14 52.14 Favored 'General case' 0 CA--C 1.542 0.658 0 CA-C-N 119.834 1.197 . . . . 0.0 113.464 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.2 t 49.55 49.46 19.89 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.804 1.641 . . . . 0.0 114.166 175.272 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.1 mtm-85 -99.03 176.45 5.57 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 126.071 1.749 . . . . 0.0 113.435 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -76.89 168.38 20.19 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 126.59 1.956 . . . . 0.0 109.428 165.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -84.05 159.71 21.11 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 124.001 0.921 . . . . 0.0 113.386 -173.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.15 -134.67 5.84 Favored Glycine 0 C--N 1.341 0.816 0 N-CA-C 114.697 0.639 . . . . 0.0 114.697 167.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 124.33 -92.02 0.43 Allowed Glycine 0 CA--C 1.541 1.689 0 CA-C-O 118.59 -1.117 . . . . 0.0 113.94 -169.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.88 6.63 0.15 Allowed 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 123.8 3.0 . . . . 0.0 117.453 -175.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.257 0.0 OUTLIER -155.93 7.39 0.22 Allowed 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 127.344 2.258 . . . . 0.0 113.379 169.443 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.21 167.79 18.58 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.775 2.43 . . . . 0.0 110.153 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -111.19 -15.51 13.64 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.498 1.919 . . . . 0.0 112.542 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -78.22 -69.49 0.55 Allowed 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.241 1.016 . . . . 0.0 111.014 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 59.25 109.49 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.701 1.6 . . . . 0.0 112.31 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 27.1 m170 -59.03 148.37 31.11 Favored 'General case' 0 CA--C 1.544 0.717 0 O-C-N 119.205 -2.184 . . . . 0.0 110.348 167.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.5 t -79.22 54.33 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-O 123.769 1.747 . . . . 0.0 109.099 166.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.09 20.05 0.09 OUTLIER Glycine 0 CA--C 1.542 1.752 0 C-N-CA 128.87 3.129 . . . . 0.0 114.306 -179.088 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -122.29 130.13 52.86 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.006 2.403 . . . . 0.0 113.854 -175.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 74.4 mt -113.52 45.47 1.42 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.491 0.716 . . . . 0.0 110.78 168.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.45 -124.85 6.89 Favored Glycine 0 CA--C 1.534 1.269 0 O-C-N 121.41 -0.806 . . . . 0.0 113.17 -176.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -129.19 144.07 51.08 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.067 0.947 . . . . 0.0 111.545 173.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 95' ' ' ALA . 7.1 p -95.27 130.92 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 C-N-CA 125.602 1.561 . . . . 0.0 108.988 173.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.0 m -113.23 138.14 50.43 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 123.683 0.793 . . . . 0.0 112.175 -167.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.61 145.11 40.96 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 118.354 2.724 . . . . 0.0 118.354 -166.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -86.35 157.01 19.98 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 128.958 2.903 . . . . 0.0 111.314 169.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -47.42 -23.29 0.57 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 128.215 2.606 . . . . 0.0 117.155 176.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -76.45 3.65 10.76 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 119.844 1.202 . . . . 0.0 111.579 175.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.66 37.53 52.03 Favored Glycine 0 C--N 1.337 0.6 0 C-N-CA 125.23 1.395 . . . . 0.0 111.843 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -124.27 122.48 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.409 1.084 . . . . 0.0 110.621 176.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -84.3 118.11 23.99 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.427 1.491 . . . . 0.0 109.311 169.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.08 145.14 25.19 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.951 0.9 . . . . 0.0 112.079 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.82 138.17 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-N 114.001 -1.454 . . . . 0.0 114.823 169.423 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 m -155.27 62.27 0.63 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 127.058 2.143 . . . . 0.0 110.002 179.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.1 mt -95.58 154.56 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.346 1.858 . . . . 0.0 111.386 -176.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -133.35 143.25 48.86 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 125.437 1.495 . . . . 0.0 108.461 168.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -156.25 149.66 24.59 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.487 1.115 . . . . 0.0 112.572 -169.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.1 p -119.26 53.55 1.02 Allowed 'General case' 0 CA--C 1.542 0.65 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.639 178.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.0 t -138.84 -42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.154 0.982 . . . . 0.0 111.686 174.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -85.88 156.07 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 119.301 0.955 . . . . 0.0 112.099 174.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -151.45 147.49 26.92 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 124.409 1.084 . . . . 0.0 111.052 177.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.479 HD12 HD11 ' A' ' 112' ' ' ILE . 7.3 mp -78.39 57.21 1.88 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 120.836 -1.165 . . . . 0.0 109.308 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.6 m -130.31 15.96 5.55 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.887 1.275 . . . . 0.0 113.749 -168.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.7 -170.17 28.45 Favored Glycine 0 N--CA 1.44 -1.042 0 CA-C-O 124.853 2.363 . . . . 0.0 116.28 167.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.29 -51.74 64.85 Favored 'General case' 0 C--N 1.311 -1.083 1 CA-C-N 108.143 -4.029 . . . . 0.0 111.239 -168.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -79.76 4.14 17.25 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.419 1.087 . . . . 0.0 112.977 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.7 t -108.62 -93.29 0.41 Allowed 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.13 0.972 . . . . 0.0 111.476 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.479 HD11 HD12 ' A' ' 106' ' ' LEU . 10.9 pt -141.66 5.76 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 40.3 mm -84.13 119.5 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.404 -1.435 . . . . 0.0 107.733 171.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.97 30.54 72.25 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 117.915 -1.492 . . . . 0.0 113.664 -178.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.9 mmt-85 -86.88 145.85 26.42 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 120.527 2.163 . . . . 0.0 111.268 173.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 39.1 m -89.95 104.91 17.43 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 119.539 1.063 . . . . 0.0 111.499 177.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 15.5 tp -85.64 112.49 21.04 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.626 0.771 . . . . 0.0 110.642 173.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 9.9 p -92.46 148.18 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 118.953 -0.546 . . . . 0.0 109.714 169.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.48 134.08 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 122.262 1.029 . . . . 0.0 109.346 166.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.7 ' CE1' ' HE ' ' A' ' 143' ' ' ARG . 18.5 m-70 -109.84 152.57 25.58 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 126.111 1.764 . . . . 0.0 111.617 -169.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -79.48 -17.47 54.09 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 116.768 2.136 . . . . 0.0 116.768 -164.454 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.27 173.38 8.84 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 120.079 -1.638 . . . . 0.0 113.432 173.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.87 157.52 1.21 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.323 1.849 . . . . 0.0 112.439 172.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -97.79 131.35 44.38 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.974 0.892 . . . . 0.0 111.073 -176.273 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -26.6 62.38 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.53 1.932 . . . . 0.0 112.788 177.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.1 mt 54.09 53.63 10.81 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.917 1.687 . . . . 0.0 113.028 171.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.23 -25.37 27.33 Favored Glycine 0 N--CA 1.468 0.803 0 CA-C-O 118.218 -1.324 . . . . 0.0 114.99 170.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.354 6.4 mtmt -167.24 121.29 1.0 Allowed 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 164.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -143.53 -56.27 0.03 OUTLIER Glycine 0 CA--C 1.532 1.104 1 C-N-CA 131.177 4.227 . . . . 0.0 108.16 167.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -85.42 -93.18 0.8 Allowed Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.904 1.716 . . . . 0.0 114.032 177.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.541 ' CG ' ' H ' ' A' ' 132' ' ' GLU 0.27 0.8 OUTLIER -147.3 -96.69 0.09 Allowed 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 117.076 -1.44 . . . . 0.0 112.703 -169.3 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.541 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 11.0 tt0 -111.97 -30.56 7.22 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 121.565 1.984 . . . . 0.0 114.396 170.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -61.36 -21.6 64.17 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.468 -2.02 . . . . 0.0 112.216 177.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.2 p -56.6 -25.55 53.14 Favored 'General case' 0 CA--C 1.54 0.583 1 C-N-CA 131.946 4.098 . . . . 0.0 113.376 164.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 p -116.23 -29.25 6.3 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 128.732 2.813 . . . . 0.0 112.974 -175.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 42.1 mttt -70.57 -56.71 5.88 Favored 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 169.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.7 p -99.08 -125.85 0.16 Allowed 'General case' 0 C--O 1.221 -0.42 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 167.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.14 28.88 1.53 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 129.006 3.193 . . . . 0.0 110.074 173.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 52.58 7.81 0.07 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 127.015 2.126 . . . . 0.0 115.168 -177.058 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.1 20.81 0.02 OUTLIER 'General case' 0 CA--C 1.56 1.358 0 C-N-CA 127.309 2.244 . . . . 0.0 116.681 -165.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.44 -144.83 34.91 Favored Glycine 0 CA--C 1.532 1.136 0 O-C-N 119.794 -1.816 . . . . 0.0 114.079 175.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.1 t -67.19 179.8 1.13 Allowed 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.392 1.077 . . . . 0.0 113.904 -174.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.7 ' HE ' ' CE1' ' A' ' 120' ' ' HIS . 95.4 mtt180 -124.7 114.53 19.43 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.911 1.684 . . . . 0.0 109.789 177.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -102.7 -24.76 13.72 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 125.772 1.629 . . . . 0.0 114.706 -171.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.78 158.81 35.96 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 124.497 1.119 . . . . 0.0 110.332 170.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.0 p -149.79 142.25 24.35 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.171 1.388 . . . . 0.0 109.503 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.57 175.77 34.84 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 115.388 0.915 . . . . 0.0 115.388 -170.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -133.1 152.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.018 1.327 . . . . 0.0 111.554 174.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 16.9 mt -83.82 115.51 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 127.646 2.378 . . . . 0.0 112.664 177.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' B' ' 51' ' ' GLY . . . -108.59 169.5 14.17 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 126.964 2.221 . . . . 0.0 114.532 -179.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -104.95 88.52 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 117.489 2.403 . . . . 0.0 117.489 -168.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.34 -25.49 51.13 Favored 'General case' 0 N--CA 1.477 0.902 0 O-C-N 120.07 -1.644 . . . . 0.0 113.08 173.184 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 . . . . . 0 C--O 1.236 0.363 0 C-N-CA 126.931 2.092 . . . . 0.0 110.459 176.377 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.304 0 CA-C-O 121.283 0.563 . . . . 0.0 111.894 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.8 t -157.35 125.5 5.52 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 126.846 2.058 . . . . 0.0 107.683 167.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.51 143.29 32.41 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-O 122.686 1.231 . . . . 0.0 113.651 174.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 169.64 17.35 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.366 1.866 . . . . 0.0 110.128 175.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -153.36 150.14 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 119.88 1.218 . . . . 0.0 111.892 -169.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.34 117.54 18.27 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 127.336 2.254 . . . . 0.0 109.126 169.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 8.4 m -101.93 116.89 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.363 1.465 . . . . 0.0 108.546 168.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.51 123.59 43.91 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.957 1.303 . . . . 0.0 113.323 -168.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . 0.26 0.2 OUTLIER -160.44 171.07 19.71 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 117.741 2.497 . . . . 0.0 117.741 165.366 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.97 36.64 0.27 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 129.606 3.479 . . . . 0.0 108.728 -174.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -159.23 55.29 0.4 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.045 1.338 . . . . 0.0 111.056 -167.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.85 -99.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 C-N-CA 127.266 2.365 . . . . 0.0 115.467 173.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -79.09 -14.33 13.52 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 123.949 3.099 . . . . 0.0 114.21 -176.179 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.4 HG21 HD21 ' B' ' 144' ' ' LEU . 2.1 t -98.86 141.37 16.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 120.398 1.454 . . . . 0.0 109.677 -179.725 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 pm0 -150.81 163.77 37.83 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.892 2.077 . . . . 0.0 107.237 169.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -147.94 134.06 4.93 Favored Glycine 0 CA--C 1.5 -0.904 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.379 175.072 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -97.03 130.1 46.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -133.64 116.29 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 C-N-CA 125.18 1.392 . . . . 0.0 109.045 168.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 65.7 m-20 -100.0 146.4 26.77 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.422 1.089 . . . . 0.0 110.855 171.146 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -121.73 135.51 54.94 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 126.852 2.061 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -128.37 122.0 30.43 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.695 1.198 . . . . 0.0 110.762 169.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.8 tt0 -109.4 140.34 43.23 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 168.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -103.5 6.2 37.32 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -174.416 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 37.1 mp0 -152.5 -178.45 6.85 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 129.341 3.056 . . . . 0.0 108.102 170.001 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.6 p -82.15 -25.35 34.42 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.675 -1.266 . . . . 0.0 112.784 168.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -132.31 19.4 4.4 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 125.343 1.457 . . . . 0.0 113.179 -177.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.1 -168.88 42.05 Favored Glycine 0 CA--C 1.541 1.713 0 C-N-CA 125.482 1.515 . . . . 0.0 113.688 172.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.3 169.0 14.53 Favored 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 124.096 3.198 . . . . 0.0 112.376 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 71.3 t -128.56 138.42 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.171 1.388 . . . . 0.0 111.387 -177.535 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -93.01 123.82 36.54 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 165.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.45 126.79 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.163 0.985 . . . . 0.0 110.8 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.8 p90 -146.74 164.32 33.13 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.959 0.885 . . . . 0.0 112.63 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.44 -153.58 25.42 Favored Glycine 0 C--N 1.334 0.452 0 C-N-CA 123.778 0.704 . . . . 0.0 112.47 176.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 60.6 p -153.16 119.52 5.54 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -168.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.3 mp -99.93 114.15 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 CA-C-O 118.265 -0.874 . . . . 0.0 109.941 173.254 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -122.18 133.84 54.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.929 1.241 . . . . 0.0 111.941 -175.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 132.05 -3.78 5.26 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 127.357 2.408 . . . . 0.0 114.271 176.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.447 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.8 OUTLIER -103.9 178.58 4.52 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 126.565 1.946 . . . . 0.0 112.22 -171.766 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -70.16 156.4 39.27 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.647 1.579 . . . . 0.0 110.227 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.06 156.28 28.67 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 168.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.35 -170.48 35.68 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.426 1.012 . . . . 0.0 113.285 178.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.708 HD22 ' H ' ' B' ' 42' ' ' LEU . 0.4 OUTLIER -65.19 152.57 43.3 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.415 1.886 . . . . 0.0 113.594 -174.095 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -149.18 125.58 10.9 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 127.781 2.433 . . . . 0.0 109.457 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.17 147.43 21.91 Favored Glycine 0 N--CA 1.481 1.646 0 CA-C-N 120.502 1.501 . . . . 0.0 111.551 173.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -154.19 87.88 1.21 Allowed 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.064 1.745 . . . . 0.0 109.321 -167.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -127.16 153.7 45.72 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 121.229 -0.919 . . . . 0.0 112.474 -166.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.1 97.99 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.069 0.85 . . . . 0.0 110.902 -175.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -79.47 134.92 36.54 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.195 -170.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -72.34 174.34 7.45 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.354 1.862 . . . . 0.0 113.028 -167.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 63.12 4.73 1.66 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.934 1.694 . . . . 0.0 114.974 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' A' ' 150' ' ' GLY . . . 52.71 16.22 3.72 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 120.267 -1.52 . . . . 0.0 113.584 -163.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.492 ' C ' HD22 ' B' ' 53' ' ' ASN . 5.9 t0 -89.45 115.4 26.86 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 125.824 1.649 . . . . 0.0 110.322 -168.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.492 HD22 ' C ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -165.14 34.98 0.06 Allowed 'General case' 0 C--O 1.239 0.514 0 CA-C-O 124.149 1.928 . . . . 0.0 116.177 -178.912 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.418 HG22 ' HB ' ' A' ' 7' ' ' VAL 0.27 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.582 0 CA-C-N 114.261 -1.336 . . . . 0.0 112.959 -166.313 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.796 0 N-CA-C 118.111 2.634 . . . . 0.0 118.111 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -41.19 -46.41 4.23 Favored Glycine 0 CA--C 1.537 1.466 0 CA-C-O 116.459 -2.3 . . . . 0.0 115.497 -169.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -126.35 46.16 0.0 OUTLIER 'Trans proline' 0 C--N 1.356 0.925 0 CA-C-N 120.983 2.392 . . . . 0.0 115.52 -176.277 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.1 m170 78.6 78.34 0.06 Allowed 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.663 1.585 . . . . 0.0 112.916 167.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -48.06 138.75 8.88 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 161.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.608 ' ND2' ' H ' ' B' ' 81' ' ' VAL . 9.3 t-20 -157.18 116.66 2.0 Favored Pre-proline 0 N--CA 1.472 0.67 0 N-CA-C 116.746 2.128 . . . . 0.0 116.746 171.019 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.57 -5.58 15.6 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 N-CA-C 116.65 1.75 . . . . 0.0 116.65 -179.184 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -91.25 -7.51 51.0 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 119.526 1.057 . . . . 0.0 112.387 173.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t 54.66 54.26 9.46 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 125.571 1.548 . . . . 0.0 114.82 170.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.72 176.59 5.45 Favored 'General case' 0 N--CA 1.477 0.924 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -171.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.4 ptpp? -79.14 155.55 28.65 Favored 'General case' 0 CA--C 1.545 0.756 0 O-C-N 121.218 -0.926 . . . . 0.0 112.34 176.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -79.31 152.67 30.36 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.149 0.98 . . . . 0.0 113.187 -177.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.36 -117.43 1.04 Allowed Glycine 0 C--N 1.339 0.746 0 C-N-CA 123.195 0.426 . . . . 0.0 113.986 167.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.67 -28.17 6.87 Favored Glycine 0 CA--C 1.542 1.741 0 N-CA-C 120.12 2.808 . . . . 0.0 120.12 168.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -93.02 -13.83 1.24 Allowed 'Trans proline' 0 CA--C 1.544 1.025 0 CA-C-N 123.203 3.502 . . . . 0.0 112.879 173.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.404 ' HE3' ' HB2' ' B' ' 126' ' ' LEU . 0.0 OUTLIER -147.16 -1.39 0.65 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.576 1.55 . . . . 0.0 112.792 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.44 177.19 5.77 Favored 'General case' 0 CA--C 1.548 0.898 0 O-C-N 120.735 -1.228 . . . . 0.0 110.508 174.706 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -90.01 -23.63 21.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 129.324 3.05 . . . . 0.0 111.579 -172.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -129.63 -98.09 0.35 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.243 1.017 . . . . 0.0 112.881 -171.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 96.36 137.6 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 129.778 3.231 . . . . 0.0 110.577 -170.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -57.21 162.06 2.87 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.267 -1.521 . . . . 0.0 112.072 168.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.608 ' H ' ' ND2' ' B' ' 65' ' ' ASN . 53.1 t -61.35 -37.6 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-N 120.403 1.456 . . . . 0.0 110.577 170.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.59 24.03 4.57 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.212 1.387 . . . . 0.0 115.933 170.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -109.39 127.72 54.58 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 116.523 2.046 . . . . 0.0 116.523 174.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.4 mt -115.31 169.26 9.27 Favored 'General case' 0 CA--C 1.56 1.35 0 N-CA-C 103.633 -2.728 . . . . 0.0 103.633 156.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.48 -126.22 1.95 Allowed Glycine 0 N--CA 1.48 1.605 0 C-N-CA 124.482 1.039 . . . . 0.0 114.265 -171.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -126.54 154.07 44.34 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.8 m -111.26 129.71 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.927 2.091 . . . . 0.0 110.568 -176.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -89.41 132.08 35.16 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.271 0.487 . . . . 0.0 110.181 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.58 162.11 13.45 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 124.849 1.26 . . . . 0.0 111.451 168.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.3 -174.77 3.16 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.085 1.354 . . . . 0.0 111.736 169.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.65 -10.02 47.43 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.73 -15.31 61.22 Favored 'General case' 0 CA--C 1.554 1.122 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 162.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.72 30.24 6.93 Favored Glycine 0 C--N 1.34 0.768 0 C-N-CA 127.272 2.368 . . . . 0.0 112.736 168.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -116.14 128.92 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 CA-C-N 119.854 1.827 . . . . 0.0 113.543 178.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 80.52 3.73 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 125.236 1.414 . . . . 0.0 110.215 167.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -77.85 123.7 27.07 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.682 1.593 . . . . 0.0 108.808 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.9 t -147.37 150.51 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -168.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 71.3 m -140.18 128.42 22.47 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 127.419 2.288 . . . . 0.0 108.367 166.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 34.7 mt -136.78 124.83 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 127.771 2.429 . . . . 0.0 108.928 -179.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 mp0 -117.4 115.69 25.72 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 126.307 1.843 . . . . 0.0 107.866 -175.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -140.46 144.32 36.01 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.933 0.873 . . . . 0.0 113.32 -168.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.2 p -110.89 51.1 0.78 Allowed 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 13.9 p -152.06 -38.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 167.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.288 0.1 OUTLIER -79.77 94.15 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 120.677 1.58 . . . . 0.0 110.888 172.549 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 38.4 p -102.14 153.21 20.15 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.148 1.779 . . . . 0.0 113.378 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.34 54.73 1.45 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.379 1.472 . . . . 0.0 110.851 -177.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.1 m -94.85 39.58 1.1 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 126.189 1.796 . . . . 0.0 112.128 -170.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 73.95 -39.46 0.97 Allowed Glycine 0 N--CA 1.475 1.271 0 C-N-CA 127.396 2.426 . . . . 0.0 115.83 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -161.65 -34.95 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.133 1.773 . . . . 0.0 111.962 -168.037 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 63.9 m-70 -75.85 -19.44 58.89 Favored 'General case' 0 C--O 1.226 -0.17 0 O-C-N 120.438 -1.413 . . . . 0.0 112.463 -167.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -142.62 -71.37 0.32 Allowed 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 122.793 0.437 . . . . 0.0 111.57 -172.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.25 2.3 pt -137.16 166.45 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 C-N-CA 125.252 1.421 . . . . 0.0 107.941 166.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.2 mm 86.72 144.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 131.308 3.843 . . . . 0.0 107.139 -163.06 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.43 3.45 25.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.133 0.873 . . . . 0.0 114.746 177.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 31.2 mtt180 -108.45 -172.45 2.06 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 128.785 2.834 . . . . 0.0 108.574 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 12.0 t -124.05 161.94 24.51 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 120.559 1.527 . . . . 0.0 109.423 166.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 tt -118.61 130.71 56.03 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 164.135 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 40.7 t -113.19 128.05 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 C-N-CA 125.098 1.359 . . . . 0.0 108.038 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -92.53 156.89 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 166.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.62 127.51 35.09 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.266 1.426 . . . . 0.0 108.752 -175.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -58.93 -14.52 9.38 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 118.122 2.638 . . . . 0.0 118.122 -166.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.8 mttp -137.45 177.33 7.95 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 124.042 3.11 . . . . 0.0 115.255 175.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.92 129.87 31.68 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 125.749 1.62 . . . . 0.0 110.888 -177.135 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -99.81 136.88 39.06 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 124.071 0.857 . . . . 0.0 110.327 171.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -81.49 -6.3 58.82 Favored 'General case' 0 CA--C 1.551 0.991 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.044 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.404 ' HB2' ' HE3' ' B' ' 75' ' ' LYS . 32.8 mt 60.69 67.89 0.79 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.314 1.846 . . . . 0.0 111.645 169.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.5 20.09 28.09 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 117.037 1.575 . . . . 0.0 117.037 168.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.4 mtmp? -146.88 -57.86 0.27 Allowed 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 120.092 3.367 . . . . 0.0 120.092 -165.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -78.82 37.72 1.91 Allowed Glycine 0 N--CA 1.475 1.299 0 C-N-CA 128.64 3.019 . . . . 0.0 110.618 -169.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . 0.479 ' HA3' ' H ' ' B' ' 134' ' ' SER . . . 173.82 84.0 0.06 OUTLIER Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 -168.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -40.01 -24.96 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.935 0 C-N-CA 130.632 3.573 . . . . 0.0 114.827 167.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -116.98 -78.49 0.58 Allowed 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 127.177 2.191 . . . . 0.0 107.517 167.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -63.97 -36.47 84.09 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.066 1.135 . . . . 0.0 114.066 -166.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.479 ' H ' ' HA3' ' B' ' 130' ' ' GLY . 13.8 t -71.31 -27.75 63.62 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 119.583 -1.948 . . . . 0.0 112.605 -177.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.316 8.9 t -83.41 -5.82 59.27 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 118.56 -0.733 . . . . 0.0 111.728 170.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -105.16 -68.2 0.87 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 124.882 1.273 . . . . 0.0 113.702 173.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.6 p -88.17 -32.28 18.7 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 125.347 1.459 . . . . 0.0 113.435 178.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 116.65 -23.92 9.95 Favored Glycine 0 N--CA 1.472 1.078 0 C-N-CA 125.32 1.438 . . . . 0.0 112.448 -168.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 10.2 t30 69.43 48.06 0.65 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 127.719 2.408 . . . . 0.0 110.014 178.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.87 31.3 0.06 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 127.402 2.281 . . . . 0.0 114.672 -169.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.49 -33.95 0.12 Allowed Glycine 0 CA--C 1.535 1.337 0 C-N-CA 128.614 3.007 . . . . 0.0 115.265 -172.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.7 t -160.16 -152.21 0.28 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.794 1.238 . . . . 0.0 112.398 178.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.52 -170.66 2.27 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 129.508 3.123 . . . . 0.0 107.706 174.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.4 HD21 HG21 ' B' ' 14' ' ' VAL . 0.4 OUTLIER -174.41 -168.7 0.4 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.467 1.907 . . . . 0.0 107.372 -169.852 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.68 153.95 1.53 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.67 2.788 . . . . 0.0 113.45 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -144.9 160.92 40.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.187 1.795 . . . . 0.0 112.821 -178.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.56 131.25 3.21 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 124.555 1.074 . . . . 0.0 111.98 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 128.18 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -176.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 35.4 mt -84.95 112.85 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.591 1.956 . . . . 0.0 111.228 -168.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.52 -144.44 10.96 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.416 -0.673 . . . . 0.0 111.416 168.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.17 163.61 26.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 124.507 1.123 . . . . 0.0 112.714 -168.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.51 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.35 -34.14 0.3 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 129.174 2.989 . . . . 0.0 109.789 166.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.469 0.491 0 C-N-CA 126.387 1.875 . . . . 0.0 111.813 167.368 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.5 p . . . . . 0 C--O 1.221 -0.435 0 N-CA-C 115.684 1.735 . . . . 0.0 115.684 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 mttp -161.94 87.46 0.65 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.003 1.721 . . . . 0.0 110.685 166.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.98 152.35 28.02 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 123.83 0.852 . . . . 0.0 109.227 167.073 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.438 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -160.04 147.58 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.856 0.862 . . . . 0.0 111.85 -168.086 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.69 139.21 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 165.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.513 HG21 ' HA ' ' B' ' 53' ' ' ASN . 88.9 t -98.29 88.9 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 167.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.72 123.74 30.15 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 127.049 2.14 . . . . 0.0 108.914 -170.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -135.62 144.15 45.95 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 122.38 1.086 . . . . 0.0 113.676 -170.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -109.08 160.94 13.3 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 107.36 -2.296 . . . . 0.0 107.36 166.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.08 58.16 1.5 Allowed 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 127.001 2.121 . . . . 0.0 111.935 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.4 -160.92 34.72 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.965 2.221 . . . . 0.0 110.565 -172.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.85 41.73 1.17 Allowed 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 125.152 3.901 . . . . 0.0 112.104 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.14 111.94 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 127.086 2.154 . . . . 0.0 108.726 -169.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -159.69 168.7 25.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.448 179.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.18 137.43 5.39 Favored Glycine 0 CA--C 1.506 -0.495 0 CA-C-N 115.659 -0.701 . . . . 0.0 112.065 168.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.0 134.04 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 166.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 pp -130.98 129.87 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.539 1.136 . . . . 0.0 109.231 165.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -103.2 153.75 20.04 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.537 1.935 . . . . 0.0 112.392 168.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -138.13 111.12 7.77 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 126.436 1.894 . . . . 0.0 109.123 169.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -96.33 84.78 3.8 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.315 -1.491 . . . . 0.0 112.54 176.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.424 ' HB3' HD13 ' A' ' 106' ' ' LEU . 3.5 tp60 -105.84 147.51 28.6 Favored 'General case' 0 C--O 1.222 -0.361 0 O-C-N 121.111 -0.993 . . . . 0.0 110.733 174.22 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.41 -15.14 9.11 Favored 'General case' 0 CA--C 1.551 1.005 0 C-N-CA 128.432 2.693 . . . . 0.0 112.49 -179.005 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -126.54 171.71 10.85 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 127.121 2.169 . . . . 0.0 110.594 -171.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 75.1 m -95.57 -26.5 15.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -126.58 -18.99 4.67 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 120.717 1.599 . . . . 0.0 114.904 -174.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.85 173.52 47.63 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.641 1.115 . . . . 0.0 112.973 176.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -80.95 171.04 14.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.847 3.031 . . . . 0.0 112.773 -176.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 t -140.48 136.1 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.34 1.456 . . . . 0.0 111.256 -170.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.9 tmtm? -80.77 128.89 34.16 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 168.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 38.1 t -121.91 143.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.669 1.987 . . . . 0.0 108.664 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.5 p90 -156.59 161.55 39.93 Favored 'General case' 0 C--N 1.326 -0.426 0 O-C-N 121.06 -1.025 . . . . 0.0 111.292 173.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.68 151.4 9.83 Favored Glycine 0 N--CA 1.452 -0.281 0 N-CA-C 114.879 0.711 . . . . 0.0 114.879 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -109.7 108.53 18.95 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.081 -0.56 . . . . 0.0 110.182 170.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -85.21 141.38 14.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 126.273 1.829 . . . . 0.0 107.789 167.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -149.38 132.4 16.23 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.216 1.806 . . . . 0.0 109.133 -178.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 -19.26 37.18 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 126.084 1.802 . . . . 0.0 114.179 -171.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.46 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -62.96 130.94 46.97 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 119.55 1.675 . . . . 0.0 111.956 169.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -67.5 152.84 44.97 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.634 1.974 . . . . 0.0 109.268 168.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -53.61 153.6 4.23 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.7 1.6 . . . . 0.0 115.111 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.99 -176.63 40.93 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.723 1.154 . . . . 0.0 112.668 -177.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mt -63.76 153.83 35.18 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.521 1.528 . . . . 0.0 112.18 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.46 ' CD2' HD23 ' A' ' 38' ' ' LEU . 78.6 m-70 -151.57 132.98 14.63 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 127.995 2.518 . . . . 0.0 108.701 169.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.91 142.77 46.86 Favored Glycine 0 N--CA 1.475 1.239 0 CA-C-O 118.905 -0.941 . . . . 0.0 112.263 178.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -132.93 102.83 5.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.939 1.696 . . . . 0.0 108.214 -175.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CD2' ' HB3' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -139.65 136.92 34.8 Favored 'General case' 0 CA--C 1.537 0.464 0 O-C-N 120.736 -1.228 . . . . 0.0 110.946 -167.372 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -93.89 124.58 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 116' ' ' THR . 14.6 m-70 -72.06 -177.86 2.2 Favored 'General case' 0 CA--C 1.55 0.966 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 169.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -64.89 167.24 7.91 Favored 'General case' 0 CA--C 1.549 0.923 0 O-C-N 119.97 -1.706 . . . . 0.0 111.767 169.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -90.36 -144.53 0.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -173.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.62 -147.36 26.65 Favored Glycine 0 N--CA 1.428 -1.835 0 CA-C-O 124.97 2.428 . . . . 0.0 111.441 169.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.749 ' HA ' HG21 ' B' ' 5' ' ' VAL . 19.5 p-10 -88.0 54.03 2.95 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 109.453 -3.374 . . . . 0.0 109.674 -168.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.643 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.369 4.1 p30 -75.19 18.57 0.19 Allowed 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 121.221 3.785 . . . . 0.0 121.221 -157.27 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.477 HG22 ' HA ' ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -76.3 -23.37 54.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 117.588 2.44 . . . . 0.0 117.588 -162.704 . . . . . . . . 4 4 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.71 -4.07 29.0 Favored 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 169.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.51 -111.31 4.02 Favored Glycine 0 C--N 1.342 0.881 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 31.0 p -47.84 -28.69 2.73 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.42 -19.48 29.59 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.727 1.211 . . . . 0.0 113.755 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 49.6 m -119.85 -43.73 2.55 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.208 0.913 . . . . 0.0 113.273 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.5 80.76 3.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.418 1.087 . . . . 0.0 111.289 -170.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.42 123.33 9.83 Favored Glycine 0 CA--C 1.536 1.389 0 C-N-CA 125.001 1.286 . . . . 0.0 112.245 -177.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -63.34 119.84 7.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.142 2.561 . . . . 0.0 109.372 -174.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.426 ' HB3' ' CD2' ' A' ' 46' ' ' HIS . 0.1 OUTLIER 34.27 66.93 0.24 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.155 1.782 . . . . 0.0 115.057 178.034 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -14.63 113.93 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 129.217 3.007 . . . . 0.0 114.505 174.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -114.53 38.6 0.22 Allowed Pre-proline 0 CA--C 1.555 1.138 0 C-N-CA 126.716 2.006 . . . . 0.0 115.448 -168.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -67.99 -14.6 41.57 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 122.668 2.246 . . . . 0.0 112.799 -177.331 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 64.3 mt -76.72 -6.73 53.39 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.169 1.388 . . . . 0.0 112.791 172.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.3 t 70.93 53.63 0.26 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 127.101 2.16 . . . . 0.0 113.009 174.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 20.6 mtm-85 -131.72 174.41 10.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -171.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mmtt -97.11 177.66 5.51 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 128.62 2.768 . . . . 0.0 110.193 166.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -81.62 154.13 26.31 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.807 1.41 . . . . 0.0 114.807 -169.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 158.38 -169.92 34.98 Favored Glycine 0 C--N 1.335 0.489 0 CA-C-N 115.277 -0.874 . . . . 0.0 113.93 166.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.13 -85.24 0.08 OUTLIER Glycine 0 CA--C 1.544 1.889 0 CA-C-O 117.9 -1.5 . . . . 0.0 114.192 168.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.05 19.04 0.16 Allowed 'Trans proline' 0 CA--C 1.553 1.459 1 C-N-CA 125.637 4.225 . . . . 0.0 116.635 -172.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.81 5.23 0.13 Allowed 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 128.144 2.578 . . . . 0.0 111.731 177.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -126.09 175.63 7.61 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 128.938 2.895 . . . . 0.0 112.922 -164.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 -129.88 -15.43 3.86 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 129.534 3.134 . . . . 0.0 111.833 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -85.89 -83.97 0.17 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.079 1.352 . . . . 0.0 112.486 177.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 72.35 112.43 0.06 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 126.488 1.915 . . . . 0.0 111.986 175.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -69.05 168.76 13.18 Favored 'General case' 0 CA--C 1.546 0.825 0 O-C-N 120.075 -1.641 . . . . 0.0 113.029 169.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -80.75 11.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 O-C-N 120.672 -1.268 . . . . 0.0 113.279 -178.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.95 10.21 7.48 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 126.766 2.127 . . . . 0.0 114.246 176.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -99.95 81.02 2.38 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 121.641 -0.917 . . . . 0.0 111.161 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.9 mt -79.17 48.71 0.89 Allowed 'General case' 0 CA--C 1.549 0.905 0 O-C-N 121.039 -1.038 . . . . 0.0 110.771 169.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.82 -118.7 9.31 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.541 1.543 . . . . 0.0 113.423 177.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.0 p30 -157.15 172.69 18.2 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.622 1.569 . . . . 0.0 112.64 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.9 p -133.63 125.11 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 C-N-CA 126.213 1.805 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 m -98.22 139.23 34.31 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.6 159.08 18.51 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.091 0.956 . . . . 0.0 113.418 172.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -89.4 154.66 19.88 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 126.83 2.052 . . . . 0.0 111.942 169.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.42 -14.6 12.82 Favored 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.818 2.447 . . . . 0.0 115.553 178.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -79.36 5.75 11.78 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 125.254 1.422 . . . . 0.0 112.941 168.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.26 40.59 9.05 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 125.708 1.623 . . . . 0.0 113.39 169.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.4 p -155.78 146.82 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 115.302 1.593 . . . . 0.0 115.302 -168.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.93 101.15 4.8 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 123.44 1.59 . . . . 0.0 109.604 167.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.54 79.29 1.8 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.249 2.219 . . . . 0.0 108.698 -173.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 70.9 t -93.23 147.81 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 127.31 2.244 . . . . 0.0 114.211 -167.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.6 t -150.51 116.51 5.6 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.23 1.412 . . . . 0.0 111.056 170.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.7 mt -140.11 168.97 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 128.296 2.638 . . . . 0.0 112.029 -168.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -136.28 136.42 39.78 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 127.909 2.484 . . . . 0.0 107.825 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -147.13 153.14 39.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 122.284 1.04 . . . . 0.0 113.373 -168.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 81.9 p -126.29 69.47 1.22 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.884 2.074 . . . . 0.0 110.898 -169.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.53 -35.71 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 124.211 1.004 . . . . 0.0 112.225 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.402 ' CD1' ' H ' ' A' ' 104' ' ' ILE . 0.1 OUTLIER -94.98 161.68 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.928 1.291 . . . . 0.0 112.225 174.772 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.1 p -158.07 177.64 11.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.233 1.013 . . . . 0.0 111.207 174.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.424 HD13 ' HB3' ' A' ' 22' ' ' GLN . 5.9 mp -111.53 80.3 1.3 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.474 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.7 t -147.34 -171.0 3.69 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -127.69 87.83 0.33 Allowed Glycine 0 C--O 1.219 -0.824 0 O-C-N 120.444 -1.41 . . . . 0.0 113.046 -177.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -177.26 -54.19 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 129.057 2.943 . . . . 0.0 108.615 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -140.02 8.04 2.27 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 114.647 1.351 . . . . 0.0 114.647 -173.451 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.474 ' CB ' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -73.08 -161.4 0.09 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 126.334 1.853 . . . . 0.0 113.9 -172.768 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 36.9 pt -109.47 1.08 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.5 mm -62.25 126.38 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 CA-C-N 119.981 1.264 . . . . 0.0 107.633 168.462 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.76 16.84 76.35 Favored Glycine 0 CA--C 1.522 0.469 0 CA-C-O 117.953 -1.471 . . . . 0.0 115.118 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 -102.25 169.82 8.47 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 119.267 1.533 . . . . 0.0 109.741 -175.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.404 HG23 ' HB2' ' A' ' 48' ' ' HIS . 10.2 t -123.54 121.85 36.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 120.614 1.552 . . . . 0.0 112.067 -173.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.427 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.3 OUTLIER -93.02 137.23 32.56 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 174.9 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.427 ' N ' HD13 ' A' ' 117' ' ' LEU . 98.3 t -129.71 131.22 66.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 126.065 1.746 . . . . 0.0 107.741 172.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 34.5 m -106.27 138.8 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 172.008 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -95.26 148.34 22.51 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.602 0.761 . . . . 0.0 112.739 -169.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.316 2.7 pp20? -74.47 -21.48 59.57 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -171.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -113.32 169.42 8.96 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.236 1.015 . . . . 0.0 112.593 171.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.73 154.14 9.53 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.533 1.533 . . . . 0.0 109.547 166.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -119.17 155.99 30.64 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 114.498 1.295 . . . . 0.0 114.498 -169.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.452 ' CG ' ' H ' ' A' ' 129' ' ' GLY . 2.9 t0 -89.83 -38.17 13.94 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 117.471 2.397 . . . . 0.0 117.471 -167.388 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 63.8 42.78 5.88 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.516 1.927 . . . . 0.0 113.322 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 134.8 -77.38 0.37 Allowed Glycine 0 C--N 1.337 0.586 0 C-N-CA 124.466 1.031 . . . . 0.0 112.716 169.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.17 62.16 1.17 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 118.853 2.909 . . . . 0.0 118.853 -174.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.452 ' H ' ' CG ' ' A' ' 125' ' ' ASP . . . -71.72 -71.5 1.04 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 106.899 -2.48 . . . . 0.0 106.899 163.325 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -77.79 -91.35 0.3 Allowed Glycine 0 CA--C 1.528 0.88 0 C-N-CA 126.177 1.846 . . . . 0.0 114.487 -173.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -144.02 -145.31 0.17 Allowed 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 124.822 1.249 . . . . 0.0 111.876 -165.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -69.66 -49.93 48.99 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.751 1.16 . . . . 0.0 112.367 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -47.13 -27.34 1.38 Allowed 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 116.15 1.907 . . . . 0.0 116.15 171.499 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 48.7 m -51.77 -23.68 4.95 Favored 'General case' 0 CA--C 1.543 0.699 0 O-C-N 120.195 -1.565 . . . . 0.0 113.719 167.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.5 p -99.54 -26.9 13.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.749 1.619 . . . . 0.0 115.033 173.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 31.6 mtpt -91.75 -24.82 19.32 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 124.103 0.961 . . . . 0.0 113.429 -176.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 39.6 p -123.31 -42.05 2.27 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.727 1.611 . . . . 0.0 112.83 169.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 105.81 18.99 10.7 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-O 118.864 -0.964 . . . . 0.0 111.091 -166.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 59.04 -1.7 0.11 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.58 2.352 . . . . 0.0 115.723 176.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.9 16.44 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.24 0 C-N-CA 128.822 2.849 . . . . 0.0 116.802 -165.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.27 -128.97 9.29 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 127.084 2.278 . . . . 0.0 111.658 -173.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.2 t -104.01 -168.22 1.47 Allowed 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.048 1.339 . . . . 0.0 113.122 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.65 151.41 36.18 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 120.629 -1.294 . . . . 0.0 110.925 168.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.3 tt -111.42 -66.81 1.04 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.699 2.0 . . . . 0.0 107.465 169.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -131.72 158.87 40.01 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.276 1.83 . . . . 0.0 110.31 177.521 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.0 p -156.38 151.74 26.69 Favored 'General case' 0 CA--C 1.553 1.062 0 C-N-CA 125.803 1.641 . . . . 0.0 113.171 -171.319 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.07 163.42 34.29 Favored Glycine 0 CA--C 1.542 1.762 0 C-N-CA 125.724 1.631 . . . . 0.0 114.205 172.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.8 t -107.54 137.59 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.455 1.127 . . . . 0.0 108.371 168.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.0 mt -81.31 126.88 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 127.513 2.325 . . . . 0.0 113.698 -169.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.0 -154.43 9.43 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 126.043 1.782 . . . . 0.0 112.412 168.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -131.17 146.15 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.607 1.163 . . . . 0.0 112.605 -178.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.04 15.82 Favored 'General case' 0 C--O 1.22 -0.476 0 C-N-CA 124.239 1.016 . . . . 0.0 109.472 174.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 . . . . . 0 C--O 1.239 0.524 0 C-N-CA 125.085 1.354 . . . . 0.0 108.746 173.441 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.401 0 CA-C-O 120.834 0.35 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.3 p -82.77 107.18 15.2 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.77 118.92 27.62 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 115.245 1.572 . . . . 0.0 115.245 -172.398 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -94.96 161.38 14.17 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.043 1.337 . . . . 0.0 111.957 169.252 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.749 HG21 ' HA ' ' A' ' 52' ' ' ASP . 2.2 p -148.73 116.04 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.784 2.034 . . . . 0.0 111.188 -169.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . 0.463 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -78.75 125.61 29.6 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.161 -0.962 . . . . 0.0 110.106 168.34 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.643 HG21 ' ND2' ' A' ' 53' ' ' ASN . 87.8 t -107.5 71.61 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.712 0.805 . . . . 0.0 111.291 -170.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.47 HD21 ' CD1' ' B' ' 117' ' ' LEU . 1.2 mp -83.56 130.42 35.0 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -169.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.6 mtpp -155.24 178.26 10.41 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.119 1.368 . . . . 0.0 113.119 172.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.73 -55.55 0.47 Allowed Glycine 0 C--O 1.224 -0.48 0 C-N-CA 127.175 2.322 . . . . 0.0 109.794 170.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -83.78 73.73 10.26 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.883 1.273 . . . . 0.0 110.481 -168.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.66 -103.58 0.06 OUTLIER Glycine 0 CA--C 1.538 1.471 0 C-N-CA 126.751 2.119 . . . . 0.0 113.136 176.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -79.87 -3.04 12.56 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 125.192 3.928 . . . . 0.0 114.724 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 42.0 t -77.53 128.37 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-N 120.025 1.284 . . . . 0.0 110.523 176.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -126.4 158.31 36.27 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 126.278 1.831 . . . . 0.0 109.181 167.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.01 101.91 0.28 Allowed Glycine 0 C--O 1.225 -0.415 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 168.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -102.43 106.02 19.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 C-N-CA 125.721 1.608 . . . . 0.0 106.676 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 4.2 mm -120.68 101.75 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.01 0.524 . . . . 0.0 109.964 -177.135 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -74.93 161.57 29.39 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 118.915 0.779 . . . . 0.0 110.523 172.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -146.73 100.47 3.33 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.947 2.099 . . . . 0.0 107.818 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 116.8 29.24 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.853 0.861 . . . . 0.0 112.017 -178.342 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -102.26 126.45 49.25 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.088 0.955 . . . . 0.0 110.767 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -49.78 20.71 Favored 'General case' 0 CA--C 1.55 0.963 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 171.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -151.5 134.56 15.86 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 128.757 2.823 . . . . 0.0 107.108 169.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 67.5 m -64.01 93.37 0.09 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.327 1.051 . . . . 0.0 112.268 178.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 p30 160.08 -32.66 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 131.081 3.753 . . . . 0.0 110.998 -174.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.6 173.18 45.41 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-O 119.241 -0.755 . . . . 0.0 111.936 172.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.04 166.9 19.34 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.422 2.748 . . . . 0.0 111.378 177.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 66.1 t -121.22 130.19 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 124.968 1.307 . . . . 0.0 109.017 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -86.87 119.24 26.88 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.73 0.776 . . . . 0.0 109.739 170.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.4 t -104.97 121.08 56.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 127.441 2.296 . . . . 0.0 108.813 -172.555 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -155.14 157.21 37.08 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.95 -135.64 4.87 Favored Glycine 0 N--CA 1.461 0.331 0 C-N-CA 124.709 1.147 . . . . 0.0 111.053 177.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.5 p -157.7 158.5 35.51 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 116.222 1.934 . . . . 0.0 116.222 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.491 HG12 HG11 ' B' ' 119' ' ' VAL . 1.3 mp -121.24 104.72 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.561 1.144 . . . . 0.0 108.483 170.3 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -106.27 124.47 49.64 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.3 3.1 3.53 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.269 1.89 . . . . 0.0 113.916 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.517 HD13 ' CD2' ' B' ' 43' ' ' HIS . 55.6 mt -79.76 -172.03 3.13 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 124.194 0.998 . . . . 0.0 108.409 167.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -119.58 -29.08 5.16 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 171.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 175.9 -176.65 0.12 Allowed 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 130.462 3.505 . . . . 0.0 106.327 -178.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.38 160.71 35.44 Favored Glycine 0 N--CA 1.461 0.354 0 C-N-CA 125.677 1.608 . . . . 0.0 114.072 166.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.426 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.1 mp -76.59 157.91 31.57 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 167.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . 0.517 ' CD2' HD13 ' B' ' 38' ' ' LEU . 95.5 m-70 -149.38 130.01 14.04 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 126.606 1.963 . . . . 0.0 108.681 -174.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.75 147.68 37.19 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 172.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.296 0.0 OUTLIER -138.32 133.56 33.17 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 123.947 1.832 . . . . 0.0 114.65 169.464 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.585 ' O ' HD22 ' B' ' 117' ' ' LEU . 1.5 m80 -130.3 145.61 51.79 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.958 1.703 . . . . 0.0 111.63 -168.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -96.55 115.51 36.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 168.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -73.38 132.53 43.12 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 170.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -65.21 135.97 56.07 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 124.333 1.053 . . . . 0.0 112.037 -165.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 66.09 -169.93 0.2 Allowed 'General case' 0 CA--C 1.544 0.747 0 CA-C-O 123.274 1.511 . . . . 0.0 111.907 -175.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.55 2.85 3.85 Favored Glycine 0 C--O 1.225 -0.437 0 C-N-CA 126.602 2.049 . . . . 0.0 113.589 -175.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.438 ' HA ' HG21 ' A' ' 5' ' ' VAL . 11.6 p-10 -79.63 49.62 1.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 121.246 2.523 . . . . 0.0 111.262 169.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.513 ' HA ' HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER 176.42 28.26 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 112.079 -2.328 . . . . 0.0 115.293 -169.4 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.492 1.658 0 N-CA-C 120.687 3.588 . . . . 0.0 120.687 -168.51 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.376 0 N-CA-C 116.243 1.942 . . . . 0.0 116.243 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.76 126.79 32.82 Favored Glycine 0 CA--C 1.537 1.465 0 C-N-CA 125.448 1.499 . . . . 0.0 111.862 178.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -63.28 169.79 8.88 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 124.278 3.318 . . . . 0.0 112.484 -173.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.601 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -61.57 108.17 0.93 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.902 1.681 . . . . 0.0 112.722 -169.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -53.22 135.67 37.83 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 126.207 1.803 . . . . 0.0 115.729 -167.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -116.72 42.38 0.36 Allowed Pre-proline 0 CA--C 1.559 1.327 0 C-N-CA 128.131 2.572 . . . . 0.0 114.746 -175.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -65.9 -20.48 58.05 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.092 1.862 . . . . 0.0 112.38 177.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 6.5 mp -77.9 -3.93 44.21 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 126.72 2.008 . . . . 0.0 113.666 170.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.3 t 52.41 59.14 4.72 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 125.778 1.631 . . . . 0.0 114.726 169.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.0 ptt180 -163.1 179.24 7.64 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.109 0.964 . . . . 0.0 111.914 -168.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.16 169.92 2.51 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 -179.174 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CD2' ' HA3' ' B' ' 138' ' ' GLY . 51.7 t60 -55.64 158.32 3.56 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.979 1.711 . . . . 0.0 114.456 -173.171 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -64.68 45.04 0.11 Allowed Glycine 0 N--CA 1.47 0.937 0 N-CA-C 120.915 3.126 . . . . 0.0 120.915 -164.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -75.95 124.44 7.4 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-N 119.835 1.818 . . . . 0.0 113.903 -169.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -74.71 -3.01 13.23 Favored 'Trans proline' 0 CA--C 1.546 1.094 0 CA-C-N 120.125 1.962 . . . . 0.0 110.319 166.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.418 ' HE2' ' OD2' ' B' ' 76' ' ' ASP . 3.1 ptmt -106.07 -3.58 21.4 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 127.94 2.496 . . . . 0.0 112.98 176.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.418 ' OD2' ' HE2' ' B' ' 75' ' ' LYS . 0.2 OUTLIER -130.88 142.47 50.38 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.199 1.4 . . . . 0.0 109.351 -172.492 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -70.45 -18.09 62.99 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.984 -0.448 . . . . 0.0 111.79 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -98.48 122.16 41.33 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 125.292 1.437 . . . . 0.0 107.828 169.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.3 ttt85 -150.27 115.45 5.39 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.3 1.84 . . . . 0.0 109.466 -171.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -60.15 163.6 4.76 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 127.091 2.156 . . . . 0.0 112.2 166.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.23 -30.76 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 C-N-CA 124.775 1.23 . . . . 0.0 113.451 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.01 33.91 3.07 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 121.14 -0.975 . . . . 0.0 113.405 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 34.4 m-20 -144.36 155.12 43.65 Favored 'General case' 0 CA--C 1.529 0.173 0 N-CA-C 117.645 2.461 . . . . 0.0 117.645 -169.219 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.6 mt -113.1 -178.61 3.42 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 127.719 2.408 . . . . 0.0 107.796 164.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.39 -129.07 1.47 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.128 0.871 . . . . 0.0 113.369 176.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -103.09 162.58 12.83 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.064 0.946 . . . . 0.0 112.284 172.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.477 HG21 HD13 ' B' ' 35' ' ' ILE . 7.6 p -136.36 140.51 43.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 127.555 2.342 . . . . 0.0 108.179 166.229 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 91.1 m -127.76 124.23 37.23 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -165.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -82.95 144.06 30.26 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 179.514 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -82.37 163.13 21.91 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 126.679 1.992 . . . . 0.0 109.924 167.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -51.58 -17.93 0.98 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 126.777 2.031 . . . . 0.0 116.074 170.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.41 -23.49 57.01 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 126.753 2.021 . . . . 0.0 112.387 172.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.09 -3.94 60.5 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 125.603 1.573 . . . . 0.0 114.946 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.6 129.02 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 118.923 1.362 . . . . 0.0 112.232 168.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -97.95 126.65 43.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 164.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -79.91 142.36 35.22 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.9 p -124.33 130.78 73.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-N 114.086 -1.416 . . . . 0.0 111.152 165.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.1 p -155.91 69.87 0.68 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.539 1.936 . . . . 0.0 109.997 -169.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 14.9 mt -127.57 162.2 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.124 1.769 . . . . 0.0 113.285 -167.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -138.66 148.74 44.4 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 127.821 2.448 . . . . 0.0 106.916 166.275 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -148.48 143.13 26.5 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 125.254 1.422 . . . . 0.0 109.106 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.3 p -108.86 55.02 0.64 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.606 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.61 -40.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.707 1.603 . . . . 0.0 109.76 170.008 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -82.32 155.27 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 CA-C-O 122.549 1.166 . . . . 0.0 113.997 179.187 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 35.6 m -158.1 156.11 30.4 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.888 1.675 . . . . 0.0 111.37 172.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.3 mp -76.74 79.85 3.36 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 126.678 1.991 . . . . 0.0 107.934 176.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.95 -19.27 20.37 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 113.233 0.827 . . . . 0.0 113.233 -172.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 83.65 9.96 82.27 Favored Glycine 0 N--CA 1.472 1.095 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.663 -174.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -165.26 -37.22 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.861 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -169.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -131.84 7.29 4.38 Favored 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 116.934 2.198 . . . . 0.0 116.934 -165.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.0 m -161.07 -55.95 0.05 Allowed 'General case' 0 N--CA 1.479 0.977 0 O-C-N 119.368 -2.083 . . . . 0.0 115.766 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.653 HG23 HG21 ' B' ' 149' ' ' ILE . 68.2 mt -137.75 158.18 33.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 173.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm 83.32 102.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.267 1 C-N-CA 131.847 4.059 . . . . 0.0 106.498 -166.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.08 13.61 83.48 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-O 115.504 -2.831 . . . . 0.0 116.91 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -92.92 152.46 19.35 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 121.314 2.557 . . . . 0.0 109.05 175.032 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.6 t -107.68 109.72 21.4 Favored 'General case' 0 N--CA 1.487 1.398 0 CA-C-N 121.393 1.906 . . . . 0.0 112.962 -167.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.585 HD22 ' O ' ' B' ' 46' ' ' HIS . 3.1 tm? -91.17 136.29 33.19 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.785 1.234 . . . . 0.0 110.42 -176.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 p -121.06 142.3 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 C-N-CA 125.702 1.601 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.491 HG11 HG12 ' B' ' 35' ' ' ILE . 6.0 m -107.47 140.27 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 123.61 0.764 . . . . 0.0 110.371 171.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -111.93 160.22 17.64 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-O 122.373 1.083 . . . . 0.0 113.029 -170.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -84.36 -33.21 23.87 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -99.11 167.72 10.52 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.57 1.077 . . . . 0.0 111.093 177.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.93 150.54 16.44 Favored 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 165.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -112.28 137.5 50.32 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.239 0.616 . . . . 0.0 109.723 173.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -79.91 -38.01 33.41 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 120.577 -0.449 . . . . 0.0 111.454 169.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . 0.269 1.8 mm? 86.1 63.6 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.759 2.423 . . . . 0.0 111.868 -169.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.0 -15.55 36.78 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 117.077 1.591 . . . . 0.0 117.077 166.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.81 -153.95 0.6 Allowed 'General case' 0 CA--C 1.552 1.026 0 CA-C-N 119.565 1.683 . . . . 0.0 109.885 169.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 122.41 -36.78 3.05 Favored Glycine 0 N--CA 1.471 1.02 0 O-C-N 120.688 -1.257 . . . . 0.0 113.149 -176.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.61 -16.18 0.32 Allowed Glycine 0 N--CA 1.475 1.272 0 N-CA-C 118.719 2.248 . . . . 0.0 118.719 169.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -122.01 169.13 11.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.21 2.005 . . . . 0.0 111.513 -174.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -62.66 -51.78 65.91 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.894 1.278 . . . . 0.0 109.711 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -49.29 -30.88 8.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.561 2.344 . . . . 0.0 113.548 174.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 92.1 p -60.2 -33.67 72.55 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 122.354 2.343 . . . . 0.0 113.957 171.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 33.0 p -62.66 -34.97 78.18 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.529 0.604 . . . . 0.0 111.461 177.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 38.7 mtpt -90.86 -39.1 12.52 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.997 1.719 . . . . 0.0 113.273 -174.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 53.8 p -104.93 -28.34 11.16 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 127.212 2.205 . . . . 0.0 114.181 -173.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . 0.415 ' HA3' ' CD2' ' B' ' 71' ' ' HIS . . . 103.57 -28.98 13.23 Favored Glycine 0 N--CA 1.465 0.6 0 C-N-CA 125.857 1.694 . . . . 0.0 113.924 -168.604 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 96.98 -11.35 0.08 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 130.787 3.635 . . . . 0.0 109.736 -167.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.2 -17.48 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 131.334 3.853 . . . . 0.0 119.71 -168.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 96.96 176.33 35.0 Favored Glycine 0 CA--C 1.534 1.264 0 C-N-CA 127.058 2.266 . . . . 0.0 113.09 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 81.5 p -62.63 -74.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -168.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 170.21 158.16 0.06 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 127.44 2.296 . . . . 0.0 114.594 176.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.98 -128.8 0.19 Allowed 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 126.934 2.094 . . . . 0.0 106.639 163.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.14 150.08 43.7 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 119.347 0.976 . . . . 0.0 112.293 -171.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 36.4 t -143.37 147.74 35.14 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.994 0.918 . . . . 0.0 110.454 173.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.0 160.81 31.48 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 123.889 0.757 . . . . 0.0 114.599 177.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -78.49 152.27 5.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 121.816 -0.814 . . . . 0.0 111.971 174.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.653 HG21 HG23 ' B' ' 112' ' ' ILE . 44.8 mt -83.53 91.8 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 123.82 0.848 . . . . 0.0 111.772 169.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -80.14 -163.09 27.4 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.573 1.082 . . . . 0.0 113.181 169.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.3 pp -139.1 141.01 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 125.351 1.46 . . . . 0.0 112.308 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -99.68 -7.09 26.12 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 124.175 0.99 . . . . 0.0 111.974 168.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.473 0.715 0 C-N-CA 127.922 2.489 . . . . 0.0 110.677 169.556 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.1 p . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 mtmm -86.98 122.29 30.63 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 174.181 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.13 162.6 12.97 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.394 1.878 . . . . 0.0 108.625 165.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.681 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.5 OUTLIER -160.05 134.78 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.499 1.12 . . . . 0.0 109.68 -168.604 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.6 137.91 54.54 Favored 'General case' 0 C--N 1.334 -0.095 0 CA-C-N 118.657 0.662 . . . . 0.0 112.311 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -95.19 115.54 34.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 167.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mp -95.01 117.02 29.43 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 169.505 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' B' ' 10' ' ' GLY . 13.1 ttpt -156.26 144.93 20.13 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 121.332 -0.855 . . . . 0.0 113.068 174.81 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.93 -33.04 0.47 Allowed Glycine 0 C--N 1.335 0.482 0 N-CA-C 116.768 1.467 . . . . 0.0 116.768 166.847 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -90.27 70.3 7.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 122.808 1.289 . . . . 0.0 109.657 -166.256 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.02 -106.66 0.14 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 128.724 3.059 . . . . 0.0 111.479 -174.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -76.1 -4.0 14.56 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 124.045 3.163 . . . . 0.0 113.886 -177.4 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 t -91.27 133.88 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 120.162 1.346 . . . . 0.0 111.897 176.431 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.21 159.08 44.6 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 127.211 2.204 . . . . 0.0 107.79 176.678 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -151.3 133.94 4.45 Favored Glycine 0 C--O 1.229 -0.166 0 CA-C-O 122.023 0.791 . . . . 0.0 111.84 177.129 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.19 130.44 56.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 169.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.55 122.99 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 124.326 1.017 . . . . 0.0 110.118 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -97.83 150.25 21.48 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.952 1.301 . . . . 0.0 110.194 167.042 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -124.83 111.25 15.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.322 1.849 . . . . 0.0 108.043 168.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -93.64 122.59 36.24 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 169.534 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -100.05 116.23 31.59 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.854 168.268 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . 0.263 0.0 OUTLIER -57.01 -50.35 73.0 Favored 'General case' 0 C--N 1.34 0.186 0 CA-C-O 119.095 -0.479 . . . . 0.0 112.044 175.893 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -158.42 145.66 17.83 Favored 'General case' 0 C--O 1.225 -0.213 0 CA-C-O 118.514 -0.755 . . . . 0.0 110.171 163.284 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.7 t -32.1 -51.52 0.25 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.985 2.114 . . . . 0.0 115.715 -167.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -78.34 -1.85 35.27 Favored 'General case' 0 CA--C 1.552 1.048 0 N-CA-C 115.559 1.688 . . . . 0.0 115.559 -175.9 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.45 -179.48 39.44 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.198 1.38 . . . . 0.0 113.756 -178.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -81.43 134.57 8.95 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 122.694 2.262 . . . . 0.0 111.354 175.218 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 t -86.69 128.76 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 O-C-N 121.779 -0.576 . . . . 0.0 110.393 -175.493 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 tmtt? -87.06 123.32 32.01 Favored 'General case' 0 CA--C 1.541 0.607 0 O-C-N 121.782 -0.574 . . . . 0.0 109.806 174.001 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -99.43 140.98 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.714 0.806 . . . . 0.0 110.343 169.866 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -145.05 156.64 44.04 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.37 0.668 . . . . 0.0 111.549 168.192 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.54 -160.4 29.23 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 123.346 0.498 . . . . 0.0 112.887 176.76 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.1 p -155.99 138.47 14.94 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 122.538 -0.39 . . . . 0.0 111.984 -175.615 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.91 110.42 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -179.191 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -112.91 142.93 45.01 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 127.685 2.394 . . . . 0.0 110.828 -167.287 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.01 0.81 54.9 Favored Glycine 0 CA--C 1.53 0.991 0 C-N-CA 126.457 1.98 . . . . 0.0 113.312 -177.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.7 mt -73.49 159.37 33.3 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 118.031 0.916 . . . . 0.0 110.573 176.275 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.4 t -82.75 160.23 22.36 Favored 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 162.374 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -53.6 160.15 1.36 Allowed 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -179.794 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.11 -170.71 34.72 Favored Glycine 0 CA--C 1.526 0.766 0 C-N-CA 124.128 0.87 . . . . 0.0 113.001 178.608 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.8 OUTLIER -79.18 153.13 30.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.827 1.251 . . . . 0.0 110.446 -175.249 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -147.03 114.29 6.26 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.539 2.336 . . . . 0.0 106.808 -177.088 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.87 154.09 28.58 Favored Glycine 0 N--CA 1.476 1.323 0 CA-C-N 119.887 1.221 . . . . 0.0 111.828 -176.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -157.4 135.11 10.69 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.629 1.214 . . . . 0.0 112.21 170.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.46 143.82 25.0 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 121.003 -1.061 . . . . 0.0 111.325 -170.03 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 15.9 m -85.08 136.84 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 167.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -104.72 179.22 4.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.91 1.684 . . . . 0.0 108.8 175.535 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.71 158.59 35.87 Favored 'General case' 0 N--CA 1.478 0.952 0 O-C-N 119.303 -2.123 . . . . 0.0 110.401 166.77 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 67.71 172.91 0.27 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.947 1.299 . . . . 0.0 112.298 174.648 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.04 10.33 63.84 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 126.588 2.042 . . . . 0.0 112.045 165.794 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.437 ' HA ' HG21 ' B' ' 5' ' ' VAL . 14.9 m-20 -74.07 100.76 3.69 Favored 'General case' 0 N--CA 1.453 -0.286 0 O-C-N 121.848 -0.795 . . . . 0.0 109.381 -173.331 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.444 1.5 p30 -145.61 35.69 1.06 Allowed 'General case' 0 C--N 1.341 0.224 0 N-CA-C 119.427 3.121 . . . . 0.0 119.427 173.872 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' B' ' 7' ' ' VAL . 0.2 OUTLIER -112.74 -36.74 5.08 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 117.548 -1.215 . . . . 0.0 112.66 -179.628 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.84 23.19 0.25 Allowed 'General case' 0 CA--C 1.554 1.133 0 CA-C-N 120.321 1.419 . . . . 0.0 113.518 169.919 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.06 -126.48 42.17 Favored Glycine 0 CA--C 1.528 0.863 0 O-C-N 120.523 -1.361 . . . . 0.0 112.105 176.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 77.2 m -68.85 -15.89 63.62 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 176.127 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.4 m -86.5 -19.96 28.77 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.272 1.429 . . . . 0.0 111.731 171.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.87 -50.46 12.21 Favored 'General case' 0 N--CA 1.476 0.835 0 O-C-N 121.37 -0.831 . . . . 0.0 110.87 169.146 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -148.62 131.26 15.9 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.029 0.919 . . . . 0.0 112.742 -177.499 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.09 -131.37 0.61 Allowed Glycine 0 CA--C 1.536 1.348 0 C-N-CA 126.69 2.09 . . . . 0.0 111.499 177.386 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -79.0 178.74 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 124.13 3.22 . . . . 0.0 111.001 174.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.561 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -78.06 83.39 4.36 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.062 1.345 . . . . 0.0 108.66 172.448 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -48.25 150.13 1.33 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.326 1.85 . . . . 0.0 113.225 -179.448 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.468 HD22 ' H ' ' A' ' 69' ' ' ARG . 63.6 t30 -146.97 114.21 4.26 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 174.855 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.76 -17.21 33.2 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.502 2.135 . . . . 0.0 113.008 175.677 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.74 -11.57 59.99 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 119.163 0.892 . . . . 0.0 113.044 175.701 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 t 53.23 46.9 25.55 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 126.008 1.723 . . . . 0.0 113.718 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.468 ' H ' HD22 ' A' ' 65' ' ' ASN . 52.6 mtp85 -104.44 168.14 9.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 127.612 2.365 . . . . 0.0 111.857 -177.747 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.59 151.46 44.63 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 122.129 0.966 . . . . 0.0 110.682 168.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.514 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 85.7 t60 -66.64 179.0 1.13 Allowed 'General case' 0 CA--C 1.545 0.754 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.105 164.334 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.448 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 113.16 -125.45 7.01 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 168.447 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.67 -50.68 0.8 Allowed Glycine 0 CA--C 1.539 1.566 0 CA-C-O 118.411 -1.216 . . . . 0.0 114.449 -178.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -80.01 -27.2 3.92 Favored 'Trans proline' 0 C--N 1.353 0.814 0 C-N-CA 122.884 2.389 . . . . 0.0 115.032 173.509 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptpt -121.75 -14.26 8.15 Favored 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 120.506 1.503 . . . . 0.0 113.904 169.094 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -105.84 153.47 21.88 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.866 1.266 . . . . 0.0 110.613 170.514 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -79.91 -14.6 58.51 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 125.995 1.718 . . . . 0.0 112.977 -169.584 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -103.83 -87.13 0.44 Allowed 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -166.771 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 84.82 133.24 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.287 1.835 . . . . 0.0 110.991 -173.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -59.82 156.69 13.68 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 125.776 1.63 . . . . 0.0 113.717 168.421 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.3 p -62.47 -36.54 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 CA-C-N 119.41 1.004 . . . . 0.0 112.925 179.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.8 102.1 1.92 Allowed Glycine 0 C--N 1.342 0.889 0 N-CA-C 106.027 -2.829 . . . . 0.0 106.027 167.596 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -162.34 147.89 12.75 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.012 1.115 . . . . 0.0 114.012 173.574 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 98.2 mt -121.7 173.47 7.43 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.558 1.943 . . . . 0.0 106.266 162.817 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.19 -107.88 1.31 Allowed Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.028 0.823 . . . . 0.0 112.758 -174.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -138.44 157.59 45.92 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.606 0.762 . . . . 0.0 111.432 169.182 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.567 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.5 OUTLIER -96.67 159.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 C-N-CA 125.233 1.413 . . . . 0.0 108.362 167.048 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.0 m -148.37 118.74 7.35 Favored 'General case' 0 N--CA 1.476 0.869 0 O-C-N 121.392 -0.817 . . . . 0.0 110.141 -174.977 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.33 142.61 28.25 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 125.587 1.555 . . . . 0.0 114.891 -169.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -78.09 148.63 34.13 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 113.189 -1.823 . . . . 0.0 109.005 166.118 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.468 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 7.0 pttp -39.08 -32.25 0.09 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 127.536 2.334 . . . . 0.0 115.768 169.663 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.468 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 28.2 m-20 -80.01 4.53 16.73 Favored 'General case' 0 CA--C 1.55 0.968 0 CA-C-N 119.978 1.263 . . . . 0.0 111.911 -178.776 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.45 -0.16 53.45 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 127.18 2.324 . . . . 0.0 115.434 168.581 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -113.79 131.89 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 119.273 1.536 . . . . 0.0 113.591 -174.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -98.86 132.42 44.22 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.405 164.65 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -77.9 152.2 33.41 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.243 1.021 . . . . 0.0 108.492 168.645 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.252 0.4 OUTLIER -128.43 126.65 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-N 113.78 -1.555 . . . . 0.0 112.277 165.997 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.7 t -157.81 89.07 1.0 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.226 1.011 . . . . 0.0 112.767 -177.01 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 4.2 mp -126.18 161.52 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 125.725 1.61 . . . . 0.0 110.811 176.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -140.3 137.72 34.38 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.493 2.717 . . . . 0.0 106.359 167.525 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -151.98 133.1 14.34 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 118.722 0.692 . . . . 0.0 112.48 -171.077 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.7 p -101.39 51.19 0.85 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.702 0.801 . . . . 0.0 112.261 175.976 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 41.0 t -130.98 -48.23 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.376 1.07 . . . . 0.0 108.511 169.207 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.53 155.12 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 122.839 1.304 . . . . 0.0 111.998 170.299 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.7 p -155.76 155.2 32.64 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 125.559 1.544 . . . . 0.0 109.968 -174.782 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -82.23 55.2 2.77 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 120.699 -1.25 . . . . 0.0 110.365 177.744 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.3 t -108.2 37.55 2.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.098 1.759 . . . . 0.0 113.282 -172.088 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 88.79 -143.93 17.9 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-O 122.426 1.014 . . . . 0.0 111.833 169.34 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -66.8 -44.64 80.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 123.881 1.8 . . . . 0.0 112.039 -166.988 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -85.19 -7.38 59.07 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 112.886 -1.961 . . . . 0.0 110.884 -170.705 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.4 t -118.82 -122.18 0.29 Allowed 'General case' 0 CA--C 1.547 0.86 0 CA-C-O 116.233 -1.842 . . . . 0.0 110.268 173.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.259 7.1 pt -124.49 67.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 CA-C-N 124.233 3.197 . . . . 0.0 116.911 178.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.4 mm -127.42 132.29 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 165.578 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.72 5.33 50.84 Favored Glycine 0 N--CA 1.472 1.082 0 CA-C-N 119.724 1.147 . . . . 0.0 115.772 177.228 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -80.78 178.21 8.53 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 118.535 1.168 . . . . 0.0 113.173 -170.105 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 36.5 m -101.37 138.67 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 127.351 2.26 . . . . 0.0 110.285 -177.593 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -138.18 135.27 35.48 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 124.242 0.964 . . . . 0.0 109.097 165.764 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 p -120.35 136.6 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 126.571 1.948 . . . . 0.0 108.911 176.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 16.6 m -101.97 149.52 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 166.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.5 m-70 -117.89 155.58 29.91 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.092 1.357 . . . . 0.0 111.928 -171.404 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -81.32 -33.99 32.18 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.815 1.246 . . . . 0.0 111.465 -171.036 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mmmt -92.58 165.05 13.19 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-N 119.375 0.989 . . . . 0.0 113.059 173.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.98 149.68 22.52 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.25 1.02 . . . . 0.0 109.354 165.043 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -99.88 135.29 41.52 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 169.108 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -77.91 -8.88 58.7 Favored 'General case' 0 N--CA 1.48 1.047 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 171.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.4 mt 62.73 48.66 4.1 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 124.97 1.308 . . . . 0.0 109.843 173.485 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.26 8.35 78.31 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 115.997 -2.557 . . . . 0.0 118.002 167.153 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -121.34 4.88 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 120.64 3.57 . . . . 0.0 120.64 -168.304 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.75 112.32 4.37 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 165.064 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -71.45 43.41 0.71 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 126.337 1.922 . . . . 0.0 114.55 -175.156 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -103.53 -77.05 0.57 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.828 1.651 . . . . 0.0 110.567 -174.446 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 174.49 -80.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 130.73 3.612 . . . . 0.0 105.494 -170.808 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -34.28 -54.47 0.51 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 128.528 2.731 . . . . 0.0 113.878 175.213 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -65.11 -5.44 6.62 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -169.565 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.8 t -126.09 -25.48 3.55 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 123.989 0.916 . . . . 0.0 111.984 165.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.0 tttt -54.21 -33.26 57.84 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.348 1.859 . . . . 0.0 111.531 168.604 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.0 p -110.99 -67.76 0.98 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 162.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 152.72 -23.67 0.82 Allowed Glycine 0 CA--C 1.534 1.23 0 C-N-CA 129.803 3.573 . . . . 0.0 112.746 -168.294 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 110.83 -8.6 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.646 1 C-N-CA 131.768 4.027 . . . . 0.0 113.057 176.183 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.59 -17.45 2.14 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 116.526 2.046 . . . . 0.0 116.526 -169.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.96 -135.37 28.03 Favored Glycine 0 CA--C 1.526 0.72 0 C-N-CA 124.529 1.062 . . . . 0.0 113.604 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.09 131.97 23.37 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 124.868 1.267 . . . . 0.0 111.677 -176.226 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -65.71 173.56 2.77 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-O 121.371 0.605 . . . . 0.0 109.438 169.243 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.457 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -150.08 -146.63 0.2 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.808 1.643 . . . . 0.0 107.268 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.457 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -50.59 150.66 2.64 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 123.018 1.39 . . . . 0.0 110.843 171.203 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 4.8 t -146.37 152.75 39.6 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 124.602 1.161 . . . . 0.0 109.3 -174.636 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.68 158.14 28.29 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 125.388 1.471 . . . . 0.0 114.028 -178.323 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -109.79 141.85 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.252 1.021 . . . . 0.0 109.335 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 15.0 mm -78.69 92.67 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 123.791 0.836 . . . . 0.0 111.493 -175.365 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -81.19 -175.83 50.37 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 125.003 1.287 . . . . 0.0 113.011 168.702 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 4.8 mp -136.19 138.7 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 O-C-N 121.015 -1.285 . . . . 0.0 110.412 -172.325 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -122.2 3.58 9.81 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.212 1.005 . . . . 0.0 113.331 171.281 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 . . . . . 0 C--O 1.238 0.45 0 C-N-CA 126.75 2.02 . . . . 0.0 112.402 176.557 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-O 121.272 0.558 . . . . 0.0 112.187 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 18.7 p -78.64 113.28 16.55 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.483 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.456 ' HE2' ' HB1' ' B' ' 152' ' ' ALA . 5.6 ptmm? -76.31 156.26 33.54 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.776 1.751 . . . . 0.0 112.081 172.042 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.491 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -149.17 165.03 33.03 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.047 2.539 . . . . 0.0 110.416 172.318 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.437 HG21 ' HA ' ' A' ' 52' ' ' ASP . 5.6 p -148.81 151.82 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.579 1.552 . . . . 0.0 110.764 -165.461 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.08 138.92 27.0 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.419 1.088 . . . . 0.0 110.515 168.1 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 54' ' ' THR . 46.9 t -105.65 84.74 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.911 0.884 . . . . 0.0 110.393 -169.842 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.272 0.9 OUTLIER -85.14 67.27 10.12 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 122.573 1.178 . . . . 0.0 113.075 -178.103 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt -97.95 111.73 23.92 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.053 173.367 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 9' ' ' LYS . . . -78.39 -103.24 0.2 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 171.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -139.38 109.67 6.52 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -167.856 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 51.07 -116.75 4.78 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.913 2.197 . . . . 0.0 112.01 -173.517 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.09 -11.39 27.1 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 124.997 3.798 . . . . 0.0 115.543 -167.606 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.7 t -92.14 94.94 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 123.049 1.404 . . . . 0.0 108.248 169.119 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.09 160.95 43.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.598 174.669 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.15 179.04 29.02 Favored Glycine 0 C--O 1.235 0.2 0 CA-C-O 123.034 1.352 . . . . 0.0 114.213 179.256 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -119.04 139.76 45.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.95 -1.625 . . . . 0.0 110.063 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -127.86 135.65 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 166.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -122.91 143.77 49.66 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 125.44 1.496 . . . . 0.0 110.067 169.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 87.8 m-85 -124.06 130.26 52.26 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.283 1.433 . . . . 0.0 108.262 170.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.98 120.47 41.49 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 124.333 1.053 . . . . 0.0 108.556 169.543 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -122.42 137.11 54.98 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 122.406 1.098 . . . . 0.0 108.896 168.546 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -105.89 -21.15 13.23 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.741 1.216 . . . . 0.0 113.063 -175.949 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -160.84 121.93 2.93 Favored 'General case' 0 C--O 1.222 -0.367 0 C-N-CA 127.692 2.397 . . . . 0.0 108.667 -164.126 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.1 m -59.25 -41.89 89.83 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.816 2.046 . . . . 0.0 113.179 -171.325 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -82.77 -4.5 58.03 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.502 1.921 . . . . 0.0 113.594 176.338 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.69 -175.94 33.89 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.742 1.639 . . . . 0.0 112.049 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.9 166.65 24.84 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.83 2.353 . . . . 0.0 112.117 178.896 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -115.42 137.79 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 169.441 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.43 129.06 39.72 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.739 0.816 . . . . 0.0 110.555 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -111.46 137.17 45.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 127.211 2.204 . . . . 0.0 109.832 -176.146 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 31.3 p90 -156.27 155.86 33.04 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 124.599 1.16 . . . . 0.0 110.972 168.619 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.32 140.47 3.06 Favored Glycine 0 C--N 1.332 0.351 0 CA-C-O 121.396 0.442 . . . . 0.0 114.1 -169.786 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 51.5 p -118.19 134.05 55.35 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.201 1.0 . . . . 0.0 110.178 -177.338 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -124.85 116.97 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 124.44 1.096 . . . . 0.0 110.435 -176.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 25.1 tptt -95.19 152.52 18.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.609 1.164 . . . . 0.0 109.393 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.87 -17.81 58.61 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.485 1.517 . . . . 0.0 113.722 -179.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 10.5 mp -69.89 119.33 13.95 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 118.457 1.128 . . . . 0.0 109.041 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -67.54 159.01 30.63 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 166.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -49.66 145.43 5.11 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.659 1.984 . . . . 0.0 114.591 -174.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 115.69 171.44 16.45 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 122.5 1.056 . . . . 0.0 113.864 -178.454 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.63 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.5 pt? -80.12 133.32 36.07 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.325 1.85 . . . . 0.0 111.522 -175.828 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -135.55 165.09 26.34 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 128.214 2.606 . . . . 0.0 108.964 -172.757 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.17 157.56 20.03 Favored Glycine 0 N--CA 1.482 1.713 0 C-N-CA 125.455 1.502 . . . . 0.0 114.705 -173.052 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -151.13 118.64 6.06 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.137 1.375 . . . . 0.0 113.243 -168.752 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.403 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -154.97 144.22 21.11 Favored 'General case' 0 CA--C 1.555 1.172 0 O-C-N 119.778 -1.826 . . . . 0.0 113.189 178.886 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -94.21 125.56 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 126.035 1.734 . . . . 0.0 110.154 171.076 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.403 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 7.6 m-70 -75.76 166.55 23.36 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.585 1.954 . . . . 0.0 111.042 179.174 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -75.63 133.54 40.84 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 167.321 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 74.57 167.74 0.29 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 128.015 2.526 . . . . 0.0 115.536 -178.58 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.21 -2.08 38.56 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 127.57 2.51 . . . . 0.0 114.269 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.681 ' HA ' HG21 ' A' ' 5' ' ' VAL 0.255 10.9 t0 -76.79 111.38 12.25 Favored 'General case' 0 CA--C 1.491 -1.303 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 165.023 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.3 0.1 OUTLIER -144.73 38.3 1.22 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-O 124.225 1.964 . . . . 0.0 113.264 168.738 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.0 p . . . . . 0 N--CA 1.446 -0.66 0 CA-C-N 112.093 -2.322 . . . . 0.0 111.852 -166.257 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.444 0 CA-C-O 121.238 0.542 . . . . 0.0 112.204 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.37 162.01 11.53 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 126.84 2.162 . . . . 0.0 110.015 -167.353 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 161.42 42.35 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 123.166 2.577 . . . . 0.0 112.164 -174.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.4 ' HB3' ' CD2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -23.89 100.14 0.02 OUTLIER 'General case' 0 C--O 1.237 0.433 0 C-N-CA 129.436 3.094 . . . . 0.0 113.827 167.587 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . 0.415 ' CG ' ' HD3' ' B' ' 66' ' ' PRO . 3.1 t80 -55.5 127.52 30.07 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 123.681 1.705 . . . . 0.0 111.482 177.267 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 24.3 p-10 -103.07 39.38 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.42 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 -177.868 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . 0.415 ' HD3' ' CG ' ' B' ' 64' ' ' PHE . 75.4 Cg_endo -67.02 -14.01 42.02 Favored 'Trans proline' 0 C--N 1.36 1.133 0 C-N-CA 123.277 2.651 . . . . 0.0 112.666 -176.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.6 mt -75.23 -1.24 22.49 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.841 1.656 . . . . 0.0 112.189 175.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.5 t 62.3 58.91 1.67 Allowed 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.794 1.238 . . . . 0.0 113.132 167.495 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -152.82 175.1 13.26 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 114.799 1.407 . . . . 0.0 114.799 -167.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.407 ' HE3' ' HG3' ' B' ' 78' ' ' GLU . 0.0 OUTLIER -78.53 168.66 19.45 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.108 0.956 . . . . 0.0 109.968 166.747 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 42.3 t60 -61.04 165.03 4.48 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 118.356 -0.831 . . . . 0.0 110.334 172.275 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 168.65 -169.67 41.83 Favored Glycine 0 N--CA 1.476 1.316 0 N-CA-C 117.533 1.773 . . . . 0.0 117.533 -172.947 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.432 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 134.78 -87.0 0.25 Allowed Glycine 0 CA--C 1.545 1.931 0 N-CA-C 121.112 3.205 . . . . 0.0 121.112 167.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -72.49 4.75 3.21 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 124.288 3.326 . . . . 0.0 114.459 -167.849 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . 0.27 0.0 OUTLIER -167.05 4.76 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 130.03 3.332 . . . . 0.0 112.804 175.398 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.432 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 2.4 t0 -128.16 138.54 52.53 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 126.79 2.036 . . . . 0.0 105.649 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . 0.456 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -90.82 -9.33 46.86 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 126.764 2.026 . . . . 0.0 114.844 -166.643 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . 0.407 ' HG3' ' HE3' ' B' ' 70' ' ' LYS . 6.9 mm-40 -84.38 -84.61 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.911 0.778 . . . . 0.0 109.995 -175.667 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.562 HH22 HG23 ' B' ' 104' ' ' ILE . 33.3 ttp85 78.84 102.45 0.07 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.77 2.028 . . . . 0.0 113.474 167.33 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 13.6 m170 -54.57 155.0 4.33 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 119.829 -1.794 . . . . 0.0 110.165 166.882 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -60.09 -30.41 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 119.708 1.14 . . . . 0.0 113.393 -169.612 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.38 -6.41 74.19 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-O 118.126 -1.375 . . . . 0.0 116.111 179.243 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -79.54 122.37 26.39 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 121.064 2.432 . . . . 0.0 109.902 -176.873 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -126.9 42.17 3.37 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 120.984 1.72 . . . . 0.0 113.455 177.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 60.25 -122.84 31.18 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.691 2.236 . . . . 0.0 118.691 166.007 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . 0.518 HD21 ' CD1' ' B' ' 126' ' ' LEU . 9.7 m120 -126.82 154.06 44.82 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 113.781 -1.209 . . . . 0.0 113.859 -169.091 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.2 m -130.77 125.55 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.432 1.493 . . . . 0.0 109.107 167.292 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 46.5 m -109.87 127.84 54.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.568 0.747 . . . . 0.0 109.045 -175.784 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.91 148.23 22.18 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.291 1.437 . . . . 0.0 114.078 -177.789 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -104.76 159.31 15.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.904 2.081 . . . . 0.0 110.154 167.145 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -71.35 8.44 1.04 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.583 2.068 . . . . 0.0 116.583 -168.679 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -76.7 -12.58 60.02 Favored 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 122.404 1.097 . . . . 0.0 108.9 164.221 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.93 40.42 7.1 Favored Glycine 0 C--N 1.337 0.601 0 C-N-CA 125.571 1.557 . . . . 0.0 110.412 -174.676 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.01 134.59 31.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.337 1.068 . . . . 0.0 113.384 177.857 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -102.04 120.35 40.29 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 162.728 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -115.43 140.39 49.18 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 122.365 1.079 . . . . 0.0 110.197 169.714 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.43 150.5 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-N 112.324 -2.216 . . . . 0.0 115.092 -169.395 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 p -153.01 119.47 5.59 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.28 1.032 . . . . 0.0 111.349 171.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.1 mt -145.07 159.35 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 128.321 2.649 . . . . 0.0 110.565 -170.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -140.67 140.96 35.06 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.162 1.785 . . . . 0.0 108.172 168.085 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.98 140.08 26.62 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.182 1.393 . . . . 0.0 111.253 -172.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.4 p -110.47 48.65 0.9 Allowed 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.664 0.987 . . . . 0.0 113.664 -175.442 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 33.0 m -148.84 -29.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 CA-C-O 117.997 -1.001 . . . . 0.0 113.144 167.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . 0.562 HG23 HH22 ' B' ' 79' ' ' ARG . 0.1 OUTLIER -76.88 154.11 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-N 121.164 1.802 . . . . 0.0 108.114 165.841 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . 0.458 ' H ' ' HB3' ' B' ' 111' ' ' SER . 2.9 p -162.46 158.29 23.54 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 125.352 1.461 . . . . 0.0 109.116 -174.238 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -79.67 55.5 2.03 Favored 'General case' 0 CA--C 1.542 0.673 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 171.666 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 58.0 m -93.48 52.56 1.75 Allowed 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 124.245 1.018 . . . . 0.0 110.074 -173.24 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.87 -96.86 0.54 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 124.688 1.137 . . . . 0.0 111.413 -177.028 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -134.97 7.0 3.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 128.298 2.639 . . . . 0.0 110.596 179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -79.43 -11.84 59.9 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.623 -1.298 . . . . 0.0 111.947 173.528 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . 0.458 ' HB3' ' H ' ' B' ' 105' ' ' SER . 18.4 m -141.75 -98.69 0.13 Allowed 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 113.372 0.878 . . . . 0.0 113.372 -170.003 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.5 pt -119.56 164.19 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 120.744 -1.223 . . . . 0.0 109.376 168.257 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.9 mm 94.43 137.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 131.149 3.78 . . . . 0.0 105.772 -163.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.26 -15.0 12.94 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 117.809 -1.55 . . . . 0.0 116.569 177.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.5 mtt85 -87.01 -175.4 5.34 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 125.642 1.577 . . . . 0.0 110.147 177.334 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -140.31 126.9 20.27 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 119.382 0.992 . . . . 0.0 111.718 -174.114 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -95.08 141.64 28.48 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.937 1.295 . . . . 0.0 110.056 -177.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.43 136.0 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.235 1.014 . . . . 0.0 109.146 177.237 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -93.55 140.95 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-O 122.438 1.113 . . . . 0.0 110.454 170.208 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -130.97 165.51 23.0 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.147 1.779 . . . . 0.0 111.223 -170.706 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -84.07 -37.86 21.53 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -170.215 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 87.3 mttt -102.35 144.13 31.22 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 119.172 0.896 . . . . 0.0 112.369 -174.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . 0.429 ' O ' HD11 ' B' ' 126' ' ' LEU . . . -77.66 54.86 1.26 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.004 1.321 . . . . 0.0 112.33 168.853 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.29 -12.06 17.52 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.742 2.017 . . . . 0.0 114.524 -177.853 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -65.25 -7.11 11.58 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 125.435 1.494 . . . . 0.0 114.637 -171.551 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.599 ' H ' HD13 ' B' ' 126' ' ' LEU . 0.0 OUTLIER -84.83 42.54 0.93 Allowed 'General case' 0 C--N 1.32 -0.685 0 O-C-N 119.383 -2.073 . . . . 0.0 114.789 179.168 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 63.14 8.41 23.45 Favored Glycine 0 N--CA 1.473 1.152 0 N-CA-C 117.401 1.72 . . . . 0.0 117.401 166.818 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 53.2 tttp -154.86 -59.25 0.11 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.54 1.136 . . . . 0.0 112.178 -167.889 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 37.99 -119.45 0.77 Allowed Glycine 0 CA--C 1.529 0.91 0 C-N-CA 126.071 1.796 . . . . 0.0 113.487 177.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -107.66 -22.81 7.15 Favored Glycine 0 CA--C 1.534 1.231 0 CA-C-O 117.75 -1.583 . . . . 0.0 116.9 -177.562 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -161.44 -178.08 6.4 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 121.22 2.51 . . . . 0.0 112.582 -172.073 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -47.49 -58.32 4.35 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 127.119 2.167 . . . . 0.0 113.128 -172.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -52.33 -21.01 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 115.37 1.618 . . . . 0.0 115.37 177.737 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 m -70.11 -27.33 64.5 Favored 'General case' 0 CA--C 1.549 0.905 0 O-C-N 119.644 -1.91 . . . . 0.0 112.526 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.5 t -79.67 -14.85 58.48 Favored 'General case' 0 N--CA 1.491 1.591 0 CA-C-N 119.853 1.206 . . . . 0.0 112.529 168.362 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mtpt -102.04 -91.44 0.33 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.285 1.834 . . . . 0.0 111.998 -177.853 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.2 p -74.88 -22.16 58.81 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 119.887 1.221 . . . . 0.0 113.986 178.532 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.96 3.46 62.02 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-O 115.497 -2.835 . . . . 0.0 111.145 -167.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 63.75 -68.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.167 2.587 . . . . 0.0 110.12 172.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 70.26 -15.56 0.34 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.689 2.796 . . . . 0.0 115.109 162.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.59 -53.34 4.51 Favored Glycine 0 N--CA 1.473 1.117 0 C-N-CA 126.936 2.207 . . . . 0.0 115.417 174.239 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.5 t -161.65 -166.1 1.42 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.685 0.794 . . . . 0.0 111.058 175.139 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.461 ' HE ' ' N ' ' B' ' 143' ' ' ARG . 0.1 OUTLIER -132.22 142.87 49.59 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.376 1.87 . . . . 0.0 107.35 176.639 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -127.23 -105.37 0.32 Allowed 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.789 1.236 . . . . 0.0 109.663 175.667 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.87 161.85 26.45 Favored 'General case' 0 CA--C 1.544 0.718 0 CA-C-N 120.295 1.407 . . . . 0.0 113.9 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.5 p -152.83 142.74 22.15 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.699 1.6 . . . . 0.0 111.116 -169.141 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.04 126.61 1.78 Allowed Glycine 0 C--N 1.338 0.692 0 N-CA-C 115.86 1.104 . . . . 0.0 115.86 -169.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -79.01 144.97 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 123.81 0.844 . . . . 0.0 109.243 -179.735 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 26.4 mt -92.25 126.15 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 C-N-CA 124.622 1.169 . . . . 0.0 112.214 -179.507 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.92 171.99 14.04 Favored Glycine 0 CA--C 1.538 1.505 0 N-CA-C 117.214 1.646 . . . . 0.0 117.214 172.131 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -87.43 107.83 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.019 1.328 . . . . 0.0 112.564 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.491 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -79.69 -5.03 54.35 Favored 'General case' 0 CA--C 1.554 1.111 0 O-C-N 121.133 -0.979 . . . . 0.0 111.122 166.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 . . . . . 0 N--CA 1.47 0.529 0 C-N-CA 131.259 3.824 . . . . 0.0 111.103 172.05 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.7 p . . . . . 0 CA--C 1.54 0.562 0 N-CA-C 116.414 2.005 . . . . 0.0 116.414 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.279 0.0 OUTLIER -155.7 117.85 4.1 Favored 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 117.573 2.435 . . . . 0.0 117.573 168.072 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.1 156.77 36.02 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.062 2.545 . . . . 0.0 106.403 164.077 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 32.3 t -154.7 155.07 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 120.148 1.34 . . . . 0.0 114.248 -164.891 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.87 128.13 33.99 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 125.892 1.677 . . . . 0.0 110.285 168.045 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.05 92.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 127.154 2.181 . . . . 0.0 108.59 176.822 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -77.01 149.18 35.9 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 125.936 1.694 . . . . 0.0 112.624 -167.509 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -155.35 153.58 30.7 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.127 0.971 . . . . 0.0 111.84 171.012 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.4 -110.61 3.18 Favored Glycine 0 N--CA 1.466 0.684 1 N-CA-C 101.753 -4.539 . . . . 0.0 101.753 162.73 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . 0.276 0.3 OUTLIER -155.62 148.46 24.29 Favored 'General case' 0 N--CA 1.442 -0.86 0 C-N-CA 124.886 1.275 . . . . 0.0 108.959 162.143 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.23 -170.83 36.25 Favored Glycine 0 CA--C 1.54 1.624 0 N-CA-C 107.666 -2.173 . . . . 0.0 107.666 -163.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.74 37.68 0.43 Allowed 'Trans proline' 0 CA--C 1.545 1.063 1 C-N-CA 125.459 4.106 . . . . 0.0 114.308 -171.802 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -108.61 122.44 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.062 1.745 . . . . 0.0 108.433 172.672 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.92 166.49 25.84 Favored 'General case' 0 CA--C 1.519 -0.25 0 C-N-CA 125.52 1.528 . . . . 0.0 110.262 179.222 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 131.81 3.0 Favored Glycine 0 C--O 1.224 -0.521 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.986 167.732 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.63 131.23 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 O-C-N 121.511 -0.994 . . . . 0.0 109.266 168.416 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.2 mm -131.06 122.62 52.1 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 167.81 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -112.25 141.4 46.01 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 125.481 1.512 . . . . 0.0 111.813 169.054 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -116.93 108.76 16.19 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.906 1.682 . . . . 0.0 110.357 176.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HB2' ' CH2' ' A' ' 32' ' ' TRP . 0.0 OUTLIER -87.76 118.94 27.61 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 127.073 2.149 . . . . 0.0 109.978 169.62 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.568 ' HB3' HD11 ' A' ' 106' ' ' LEU . 19.5 tp60 -148.69 140.29 23.53 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.678 0.791 . . . . 0.0 109.321 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.82 -28.25 14.34 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -169.727 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.75 -139.86 0.1 Allowed 'General case' 0 CA--C 1.556 1.181 0 C-N-CA 125.494 1.518 . . . . 0.0 111.41 170.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.0 p -113.16 -11.73 13.24 Favored 'General case' 0 N--CA 1.482 1.14 0 O-C-N 118.987 -2.321 . . . . 0.0 115.758 -170.371 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -128.2 -16.67 4.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.453 1.901 . . . . 0.0 112.882 -177.579 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 171.08 48.05 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.548 1.547 . . . . 0.0 112.446 177.741 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -85.13 140.42 7.66 Favored 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 122.268 1.979 . . . . 0.0 111.856 -169.26 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -101.6 132.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.703 1.201 . . . . 0.0 109.487 -173.137 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.427 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 4.5 ttmp? -92.37 126.21 37.35 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.832 1.253 . . . . 0.0 109.178 169.344 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.8 t -110.19 127.78 66.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 126.069 1.748 . . . . 0.0 109.581 177.753 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.468 ' CH2' ' HB2' ' A' ' 21' ' ' GLU . 6.0 p90 -135.92 159.51 41.46 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.172 0.989 . . . . 0.0 111.434 170.342 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.64 -176.72 27.31 Favored Glycine 0 C--O 1.222 -0.651 0 O-C-N 121.718 -0.614 . . . . 0.0 114.041 -173.192 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.69 141.69 13.25 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.752 0.821 . . . . 0.0 111.543 -172.774 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mp -113.7 118.54 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 126.462 1.905 . . . . 0.0 109.315 -178.503 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -115.81 128.63 55.98 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 110.244 -171.606 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.23 6.34 9.02 Favored Glycine 0 N--CA 1.477 1.433 0 C-N-CA 125.568 1.556 . . . . 0.0 114.964 -177.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.574 HD23 HD11 ' A' ' 144' ' ' LEU . 31.6 mt -80.95 157.84 25.42 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.58 1.552 . . . . 0.0 111.609 173.599 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.9 t -75.41 151.95 38.07 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 163.398 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.58 147.05 23.26 Favored 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.593 1.088 . . . . 0.0 112.242 170.768 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 111.65 -175.74 17.67 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.854 1.216 . . . . 0.0 113.453 -174.791 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.5 mt -77.27 154.39 33.0 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.595 1.158 . . . . 0.0 112.144 -174.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.425 ' CG ' HD22 ' A' ' 38' ' ' LEU . 91.7 m-70 -153.11 123.45 7.11 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 127.077 2.151 . . . . 0.0 110.13 -171.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.85 151.72 47.96 Favored Glycine 0 N--CA 1.474 1.218 0 CA-C-N 120.167 1.349 . . . . 0.0 112.439 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.32 0.0 OUTLIER -146.19 140.2 26.44 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 166.119 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.401 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -148.51 153.54 38.59 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 120.998 -1.064 . . . . 0.0 112.031 -166.63 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 m -80.0 152.54 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 122.698 0.399 . . . . 0.0 110.526 168.109 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -93.98 167.98 11.25 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.052 1.741 . . . . 0.0 113.297 175.374 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -65.96 87.77 0.1 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.511 3.124 . . . . 0.0 109.596 170.115 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 74.2 177.96 0.22 Allowed 'General case' 0 C--N 1.347 0.491 0 CA-C-O 123.072 1.415 . . . . 0.0 112.848 168.884 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -95.23 -4.28 61.22 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 125.435 1.493 . . . . 0.0 111.143 168.128 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -66.98 64.79 0.06 Allowed 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 128.844 2.858 . . . . 0.0 109.817 169.261 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 167.53 -39.02 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.505 2.722 . . . . 0.0 114.714 179.364 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.36 0.5 OUTLIER 55.02 -58.48 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 130.303 3.441 . . . . 0.0 116.327 -174.829 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -68.47 4.22 1.45 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.264 1.426 . . . . 0.0 113.916 179.746 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.436 ' HA3' HG21 ' A' ' 116' ' ' THR . . . 62.89 -126.36 36.71 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 124.91 1.243 . . . . 0.0 111.394 171.023 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.66 -8.48 0.39 Allowed 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 117.302 2.334 . . . . 0.0 117.302 -171.753 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.9 t -107.31 -2.13 20.99 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.544 1.52 . . . . 0.0 114.815 171.522 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.6 m -119.01 -37.83 3.16 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.641 1.576 . . . . 0.0 112.699 173.212 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.57 170.87 15.35 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.2 1.8 . . . . 0.0 110.869 175.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -109.8 -69.81 0.63 Allowed Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.549 1.38 . . . . 0.0 116.549 -168.637 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -87.07 -174.16 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.47 1 C-N-CA 125.473 4.115 . . . . 0.0 114.234 -169.407 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -104.01 132.38 50.32 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 127.666 2.386 . . . . 0.0 111.781 -175.831 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -46.9 114.11 0.78 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.579 1.552 . . . . 0.0 111.484 168.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 54.0 p30 -112.3 32.04 0.11 Allowed Pre-proline 0 CA--C 1.555 1.148 0 N-CA-C 116.734 2.124 . . . . 0.0 116.734 -167.944 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -56.63 -23.12 47.22 Favored 'Trans proline' 0 C--N 1.354 0.86 0 C-N-CA 124.915 3.743 . . . . 0.0 117.319 -164.957 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.478 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 4.5 mm? -78.39 -0.41 29.02 Favored 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 174.711 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.7 t 66.58 55.5 0.79 Allowed 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 126.886 2.074 . . . . 0.0 110.318 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.478 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.5 ptp180 -143.36 170.99 14.74 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -165.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.31 0.0 OUTLIER -85.43 -178.64 6.76 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.365 1.866 . . . . 0.0 113.514 172.79 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.477 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 78.2 t60 -99.42 139.78 34.58 Favored 'General case' 0 C--O 1.22 -0.487 0 C-N-CA 125.876 1.67 . . . . 0.0 112.747 -170.806 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.89 -143.95 11.38 Favored Glycine 0 C--N 1.34 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 113.902 173.808 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.06 -75.93 0.21 Allowed Glycine 0 CA--C 1.535 1.293 0 N-CA-C 118.594 2.198 . . . . 0.0 118.594 -175.989 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -70.85 -11.73 29.82 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.954 2.436 . . . . 0.0 113.054 -171.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -130.05 -0.78 4.67 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.684 1.593 . . . . 0.0 111.238 168.25 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.73 122.97 25.37 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 124.053 1.882 . . . . 0.0 111.801 -167.564 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.1 -27.77 69.62 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 129.815 3.246 . . . . 0.0 111.717 169.115 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -88.31 76.35 8.38 Favored 'General case' 0 C--O 1.214 -0.776 0 C-N-CA 126.319 1.848 . . . . 0.0 108.192 177.613 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.6 ttt180 -111.51 110.64 21.17 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 129.599 3.16 . . . . 0.0 109.022 -178.464 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -59.95 159.9 8.57 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 119.385 0.993 . . . . 0.0 112.597 169.925 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 m -43.1 -57.37 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -173.161 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.2 31.53 8.54 Favored Glycine 0 N--CA 1.472 1.067 0 C-N-CA 125.064 1.316 . . . . 0.0 113.298 172.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -76.94 121.97 24.21 Favored 'General case' 0 C--O 1.237 0.408 0 O-C-N 120.942 -1.328 . . . . 0.0 108.253 169.744 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -95.76 176.82 5.99 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 112.854 -1.975 . . . . 0.0 109.149 167.525 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.73 23.99 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 124.305 0.955 . . . . 0.0 113.371 -175.341 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -83.9 126.19 32.74 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 121.675 -0.897 . . . . 0.0 108.91 167.843 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.98 170.59 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 164.235 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 t -145.02 127.73 16.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 124.683 1.193 . . . . 0.0 109.751 174.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.2 144.85 26.64 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 113.183 0.809 . . . . 0.0 113.183 174.417 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -67.47 170.96 6.65 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.191 1.796 . . . . 0.0 110.946 168.528 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.76 -32.15 29.61 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.753 1.221 . . . . 0.0 112.854 168.527 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -73.41 -15.49 61.35 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.938 1.695 . . . . 0.0 112.283 177.123 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.22 14.47 64.13 Favored Glycine 0 CA--C 1.527 0.808 0 O-C-N 120.832 -1.167 . . . . 0.0 113.43 179.167 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.6 p -96.71 125.22 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 124.226 1.011 . . . . 0.0 109.916 168.209 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.69 122.0 43.09 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 168.229 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -88.99 145.29 25.59 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 123.089 1.423 . . . . 0.0 110.145 -179.314 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.77 125.69 74.56 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.002 172.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.4 m -155.13 85.77 1.09 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.126 1.77 . . . . 0.0 108.67 -173.121 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 12.9 mt -140.13 154.64 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 127.308 2.243 . . . . 0.0 111.53 -169.208 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.427 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 15.7 tt0 -140.91 144.86 35.44 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.593 1.557 . . . . 0.0 108.233 168.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.98 144.84 21.59 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.624 1.169 . . . . 0.0 113.386 -166.821 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 55.2 p -116.7 49.37 1.17 Allowed 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -179.687 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.2 m -149.06 16.23 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 176.055 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.35 168.69 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 120.49 -1.381 . . . . 0.0 111.037 171.295 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.568 ' H ' ' HB3' ' A' ' 111' ' ' SER . 86.3 p -154.91 161.24 41.49 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.265 -0.897 . . . . 0.0 112.602 169.144 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.568 HD11 ' HB3' ' A' ' 22' ' ' GLN . 0.0 OUTLIER -92.53 50.89 1.66 Allowed 'General case' 0 CA--C 1.542 0.636 0 O-C-N 121.15 -0.969 . . . . 0.0 111.44 175.732 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.1 t -87.85 -40.91 13.62 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.436 1.094 . . . . 0.0 112.925 178.725 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.46 12.27 38.95 Favored Glycine 0 N--CA 1.478 1.494 0 N-CA-C 115.535 0.974 . . . . 0.0 115.535 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -89.54 -92.71 0.12 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.581 2.352 . . . . 0.0 111.006 -179.672 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.3 m170 -96.65 -24.96 15.75 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 126.585 1.954 . . . . 0.0 109.291 174.283 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.568 ' HB3' ' H ' ' A' ' 105' ' ' SER . 53.4 m -79.16 -142.14 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.07 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -168.001 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.7 pt -94.98 -21.46 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -166.414 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mm -63.75 141.97 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.811 1.187 . . . . 0.0 109.666 170.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.13 28.08 62.93 Favored Glycine 0 CA--C 1.503 -0.663 0 CA-C-O 116.701 -2.166 . . . . 0.0 113.446 177.475 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 84.7 mtt-85 -129.78 178.31 6.61 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.532 1.666 . . . . 0.0 108.515 171.741 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.436 HG21 ' HA3' ' A' ' 56' ' ' GLY . 89.4 m -117.19 145.36 43.91 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 119.328 0.967 . . . . 0.0 110.02 179.179 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.1 tp -108.31 134.14 51.55 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 119.074 0.852 . . . . 0.0 109.511 169.408 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -110.33 144.62 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.822 1.649 . . . . 0.0 110.643 172.619 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.99 142.24 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.903 1.281 . . . . 0.0 110.226 170.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.401 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 44.9 m-70 -119.2 147.14 44.56 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.656 1.583 . . . . 0.0 114.563 -166.523 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -85.34 -17.29 37.23 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -166.73 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.9 169.48 8.89 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 120.087 -1.633 . . . . 0.0 111.082 172.718 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.6 133.6 55.84 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 168.727 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 40.2 t0 -83.36 154.03 24.26 Favored 'General case' 0 CA--C 1.54 0.571 0 O-C-N 123.272 0.357 . . . . 0.0 110.293 169.435 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -75.58 -50.9 14.16 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 165.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.2 mt 94.79 63.08 0.0 OUTLIER 'General case' 0 C--O 1.222 -0.358 0 C-N-CA 129.296 3.039 . . . . 0.0 109.299 -178.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.7 -25.63 16.58 Favored Glycine 0 N--CA 1.481 1.635 0 N-CA-C 117.069 1.588 . . . . 0.0 117.069 167.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -118.35 -144.96 0.37 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.181 1.792 . . . . 0.0 110.897 172.148 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.08 7.97 60.62 Favored Glycine 0 CA--C 1.536 1.352 0 O-C-N 120.356 -1.465 . . . . 0.0 113.23 -168.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.47 31.41 68.32 Favored Glycine 0 N--CA 1.472 1.057 0 N-CA-C 116.996 1.558 . . . . 0.0 116.996 167.802 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -150.1 172.6 15.01 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 119.856 1.828 . . . . 0.0 113.108 -173.514 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -47.91 -58.69 4.07 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.953 1.701 . . . . 0.0 112.938 176.599 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -65.1 -17.01 64.1 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.165 0.986 . . . . 0.0 113.433 -173.246 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.5 p -53.52 -45.74 69.85 Favored 'General case' 0 N--CA 1.469 0.494 0 O-C-N 120.824 -1.173 . . . . 0.0 113.089 174.245 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -96.31 -6.86 36.79 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.875 0.87 . . . . 0.0 112.018 -178.861 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.93 -48.2 5.52 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.708 1.14 . . . . 0.0 112.618 176.605 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 19.9 p -114.61 -25.14 8.44 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 174.867 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.477 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 121.97 -30.73 5.18 Favored Glycine 0 C--O 1.228 -0.226 0 C-N-CA 126.09 1.805 . . . . 0.0 112.356 -168.061 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 114.08 2.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 131.601 3.96 . . . . 0.0 112.645 -174.566 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.5 1.27 0.02 OUTLIER 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 120.251 3.426 . . . . 0.0 120.251 -168.692 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.59 -32.68 0.17 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 120.985 3.154 . . . . 0.0 120.985 165.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.0 m -167.4 141.36 3.64 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 120.272 2.036 . . . . 0.0 111.581 -172.227 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.53 134.68 54.83 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.741 1.155 . . . . 0.0 112.214 178.319 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.574 HD11 HD23 ' A' ' 38' ' ' LEU . 2.3 pt? -110.36 -22.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.08 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.71 161.19 13.25 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 119.95 1.25 . . . . 0.0 112.46 -177.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.9 p -155.47 166.76 32.55 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.332 1.453 . . . . 0.0 112.763 172.926 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.44 136.84 4.83 Favored Glycine 0 N--CA 1.48 1.579 0 C-N-CA 125.287 1.422 . . . . 0.0 113.583 177.168 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -83.6 133.48 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.469 1.108 . . . . 0.0 110.641 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.49 110.13 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.023 0.929 . . . . 0.0 111.301 -172.016 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.74 170.14 13.31 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 122.76 1.2 . . . . 0.0 113.916 173.268 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.0 pp -91.25 164.03 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.672 1.189 . . . . 0.0 112.137 -174.258 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.483 ' HA ' ' CD1' ' B' ' 50' ' ' PHE . . . -155.53 -20.61 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 167.072 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.476 0.832 0 C-N-CA 124.521 1.128 . . . . 0.0 110.166 170.366 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.7 t -80.26 118.78 22.23 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 167.507 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.87 121.37 45.09 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -178.885 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.03 166.2 11.38 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.861 1.264 . . . . 0.0 110.794 168.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.74 146.07 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 125.477 1.511 . . . . 0.0 111.903 -166.722 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.0 101.2 3.99 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 123.756 0.822 . . . . 0.0 111.269 169.621 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -84.02 95.5 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 168.031 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.4 mt -81.34 140.25 34.88 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 122.784 0.434 . . . . 0.0 110.78 -177.043 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 9.0 mtpp -149.24 179.26 8.05 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 121.166 -0.959 . . . . 0.0 112.81 170.913 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.43 -70.79 0.29 Allowed Glycine 0 C--N 1.335 0.505 0 C-N-CA 126.393 1.949 . . . . 0.0 111.238 178.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -87.09 78.83 8.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.78 0.8 . . . . 0.0 112.715 -165.373 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 49.09 -104.22 0.09 OUTLIER Glycine 0 CA--C 1.534 1.249 0 C-N-CA 126.565 2.031 . . . . 0.0 112.623 171.514 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -80.01 -1.2 11.24 Favored 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 125.181 3.921 . . . . 0.0 114.176 -179.24 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.49 134.62 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 119.715 1.143 . . . . 0.0 110.8 171.84 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -135.51 161.92 34.13 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 125.843 1.657 . . . . 0.0 109.939 168.231 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.5 144.8 16.44 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 167.205 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -142.18 102.04 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -122.4 137.6 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 C-N-CA 123.957 0.903 . . . . 0.0 109.394 -179.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.36 152.41 34.99 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.058 2.143 . . . . 0.0 109.147 172.131 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -138.89 89.29 2.35 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.215 1.806 . . . . 0.0 107.66 -174.81 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.8 120.31 33.9 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 118.084 0.402 . . . . 0.0 110.07 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -112.52 141.46 46.25 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 122.578 1.18 . . . . 0.0 112.18 174.41 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.36 -26.8 24.64 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 126.571 1.949 . . . . 0.0 114.18 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 5.8 mp0 -122.94 -174.11 2.86 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.235 2.214 . . . . 0.0 109.885 174.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.2 m -98.52 -14.5 19.97 Favored 'General case' 0 N--CA 1.481 1.099 0 O-C-N 120.54 -1.35 . . . . 0.0 111.639 167.08 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -139.47 105.55 5.22 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.198 2.599 . . . . 0.0 107.181 169.34 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.61 -168.42 41.49 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 126.066 1.794 . . . . 0.0 110.637 -170.784 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -85.57 150.61 10.19 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.529 2.153 . . . . 0.0 111.848 -179.268 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 10.2 t -119.36 129.32 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.135 1.374 . . . . 0.0 110.111 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.6 ttmm -93.53 120.89 34.35 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.091 0.948 . . . . 0.0 110.514 174.47 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.3 t -106.25 112.54 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 C-N-CA 126.321 1.848 . . . . 0.0 108.046 -171.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -137.74 161.18 37.22 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -177.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 136.62 -139.72 10.87 Favored Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.533 1.539 . . . . 0.0 111.351 175.62 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 47.3 p -156.47 156.73 34.24 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 114.711 1.375 . . . . 0.0 114.711 -174.862 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 24.7 mm -123.43 126.64 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 168.692 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . 0.282 3.5 ptmt -140.33 157.21 45.91 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 115.313 1.597 . . . . 0.0 115.313 -177.534 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.23 6.4 33.9 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 127.103 2.287 . . . . 0.0 111.916 -167.872 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 144' ' ' LEU . 1.5 mt -94.79 172.27 8.27 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.992 1.317 . . . . 0.0 111.769 -172.751 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.27 150.65 36.95 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 165.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -53.3 -0.27 0.02 OUTLIER 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 129.796 3.238 . . . . 0.0 115.86 170.63 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -69.46 177.28 29.96 Favored Glycine 0 CA--C 1.537 1.43 0 O-C-N 120.149 -1.594 . . . . 0.0 113.605 169.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.456 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.0 mp -78.37 160.0 28.04 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.381 1.472 . . . . 0.0 108.727 168.452 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -149.64 109.72 4.13 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.761 2.424 . . . . 0.0 109.857 -170.155 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.56 130.22 17.69 Favored Glycine 0 N--CA 1.477 1.37 0 CA-C-N 119.938 1.244 . . . . 0.0 111.864 176.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.493 ' CB ' HG22 ' B' ' 119' ' ' VAL . 35.3 p90 -125.62 137.73 53.89 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 120.151 1.976 . . . . 0.0 113.419 174.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.86 144.49 29.33 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.201 -0.937 . . . . 0.0 113.325 -176.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -81.27 136.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 166.075 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -74.74 168.4 19.92 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.826 1.25 . . . . 0.0 110.833 175.619 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.1 pm0 -59.61 -14.83 15.07 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -169.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . 0.483 ' CD1' ' HA ' ' A' ' 152' ' ' ALA . 31.3 m-85 -169.83 -179.26 3.21 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 129.147 2.979 . . . . 0.0 108.216 -168.849 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -125.92 11.32 7.39 Favored Glycine 0 N--CA 1.475 1.291 0 C-N-CA 125.505 1.526 . . . . 0.0 113.89 179.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -73.5 45.02 0.17 Allowed 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.755 1.222 . . . . 0.0 110.347 167.076 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -173.55 55.72 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 123.693 1.711 . . . . 0.0 114.726 -162.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 1.1 t . . . . . 0 CA--C 1.547 0.832 0 C-N-CA 126.592 1.957 . . . . 0.0 114.492 -179.647 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.535 0 CA-C-O 120.982 0.42 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -62.92 123.17 29.64 Favored Glycine 0 CA--C 1.543 1.843 0 CA-C-O 116.943 -2.032 . . . . 0.0 111.785 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.48 59.67 7.54 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 124.631 3.554 . . . . 0.0 116.632 -165.057 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.296 11.9 p80 52.7 59.01 4.78 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.19 2.596 . . . . 0.0 113.821 177.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . 0.413 ' CG ' ' N ' ' B' ' 65' ' ' ASN . 22.9 t80 -50.25 165.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 128.243 2.617 . . . . 0.0 114.938 177.553 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . 0.413 ' N ' ' CG ' ' B' ' 64' ' ' PHE . 1.0 OUTLIER -100.19 60.12 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.425 0 C-N-CA 131.296 3.838 . . . . 0.0 114.058 -170.078 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.02 -26.59 66.01 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.747 2.298 . . . . 0.0 113.764 -176.949 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.34 -2.49 58.63 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 126.627 1.971 . . . . 0.0 113.165 172.696 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.5 t 59.43 49.75 8.36 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.564 1.946 . . . . 0.0 112.447 -173.201 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -117.17 170.41 8.69 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.264 1.209 . . . . 0.0 114.264 -179.607 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.404 ' HZ3' ' CG ' ' B' ' 76' ' ' ASP . 0.1 OUTLIER -73.18 164.82 26.13 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-O 122.75 1.262 . . . . 0.0 109.325 166.29 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.443 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 83.4 t60 -67.36 -176.17 0.56 Allowed 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.223 167.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.443 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 115.17 -128.93 8.32 Favored Glycine 0 CA--C 1.502 -0.723 0 N-CA-C 115.252 0.861 . . . . 0.0 115.252 164.305 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.05 -76.32 0.34 Allowed Glycine 0 CA--C 1.531 1.061 0 CA-C-O 118.002 -1.443 . . . . 0.0 111.749 -169.586 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.64 10.07 0.23 Allowed 'Trans proline' 0 CA--C 1.547 1.134 0 C-N-CA 124.302 3.335 . . . . 0.0 116.614 -178.766 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.5 tptm -166.07 -30.61 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.264 1.426 . . . . 0.0 112.48 -168.427 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.404 ' CG ' ' HZ3' ' B' ' 70' ' ' LYS . 8.6 t70 -125.03 119.12 27.79 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.579 1.552 . . . . 0.0 108.148 167.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -46.31 -17.86 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 130.156 3.383 . . . . 0.0 116.418 -174.319 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -85.36 -79.61 0.23 Allowed 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -169.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.505 ' HB3' HH11 ' B' ' 79' ' ' ARG . 1.1 ttp-105 78.42 110.71 0.07 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.734 1.614 . . . . 0.0 109.731 177.199 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -50.08 152.17 1.76 Allowed 'General case' 0 CA--C 1.549 0.937 0 O-C-N 120.566 -1.334 . . . . 0.0 113.494 172.224 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.7 t -52.82 -37.74 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 123.966 0.906 . . . . 0.0 112.434 176.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.78 96.79 1.21 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 108.264 -1.934 . . . . 0.0 108.264 167.345 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -156.2 146.29 21.36 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.96 1.304 . . . . 0.0 113.446 171.249 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 48.2 mt -130.82 167.06 19.52 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.203 1.801 . . . . 0.0 106.981 166.802 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -104.99 -161.82 23.8 Favored Glycine 0 N--CA 1.475 1.247 0 C-N-CA 124.67 1.128 . . . . 0.0 112.593 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -79.37 164.63 23.89 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 -177.283 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.467 HG22 ' HB1' ' B' ' 95' ' ' ALA . 2.9 p -125.99 157.29 36.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 C-N-CA 129.0 2.92 . . . . 0.0 108.524 166.235 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -135.15 133.72 39.44 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.068 0.947 . . . . 0.0 109.799 -177.205 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.05 158.49 15.41 Favored 'General case' 0 C--O 1.222 -0.347 0 N-CA-C 114.065 1.135 . . . . 0.0 114.065 -172.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -97.63 155.47 16.97 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.645 1.578 . . . . 0.0 108.718 166.406 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 6.2 pttm -47.2 -25.32 0.89 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 128.936 2.894 . . . . 0.0 115.249 -177.5 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.67 3.23 10.07 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.319 1.448 . . . . 0.0 110.986 178.294 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.18 2.42 60.68 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 129.765 3.555 . . . . 0.0 113.726 172.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.2 p -114.64 131.92 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-N 119.937 1.869 . . . . 0.0 114.889 -168.36 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.467 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -98.37 128.8 44.94 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.003 -1.453 . . . . 0.0 108.728 166.236 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -82.27 146.33 29.51 Favored 'General case' 0 N--CA 1.46 0.073 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 168.005 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.263 0.3 OUTLIER -129.36 135.62 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 114.289 -1.323 . . . . 0.0 114.252 166.285 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 2.9 p -157.2 57.13 0.52 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 125.591 1.556 . . . . 0.0 110.759 -169.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.3 mt -109.04 166.55 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 127.654 2.381 . . . . 0.0 111.593 -169.746 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -148.39 149.82 32.43 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 127.753 2.421 . . . . 0.0 109.081 171.881 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -146.63 145.46 30.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.36 1.464 . . . . 0.0 110.108 172.051 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.8 p -118.61 58.6 0.83 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.94 2.096 . . . . 0.0 113.041 -168.477 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 5.9 p -159.34 -37.18 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 113.27 0.841 . . . . 0.0 113.27 172.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.69 166.79 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-O 121.327 0.584 . . . . 0.0 110.773 171.444 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 36.8 m -156.57 175.8 13.55 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 120.752 -1.218 . . . . 0.0 112.615 178.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . 0.409 ' HA ' HG12 ' B' ' 113' ' ' ILE . 9.6 mp -92.61 76.35 5.02 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.664 1.586 . . . . 0.0 107.448 175.458 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.27 122.7 32.3 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.359 1.463 . . . . 0.0 108.077 -176.409 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.99 59.68 4.97 Favored Glycine 0 N--CA 1.471 1.021 0 C-N-CA 125.152 1.358 . . . . 0.0 112.976 -169.721 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -156.26 -76.62 0.09 Allowed 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 124.467 1.107 . . . . 0.0 110.347 -168.704 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 m170 -129.66 4.88 5.06 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 126.979 2.111 . . . . 0.0 112.559 -167.625 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.6 -151.92 0.47 Allowed 'General case' 0 CA--C 1.555 1.173 0 C-N-CA 127.651 2.381 . . . . 0.0 112.835 -166.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.8 pt -95.88 -5.35 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 118.718 -2.488 . . . . 0.0 115.657 -177.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' B' ' 106' ' ' LEU . 4.2 mm -67.4 129.28 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 165.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 66.41 51.25 44.33 Favored Glycine 0 C--O 1.225 -0.439 0 CA-C-O 117.854 -1.526 . . . . 0.0 112.541 178.043 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 25.7 mtt180 -129.19 145.61 51.28 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 118.346 1.073 . . . . 0.0 110.095 167.332 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 24.6 m -86.86 108.91 18.97 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 124.378 1.071 . . . . 0.0 109.628 -171.886 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 14.6 tp -91.6 125.07 36.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 120.441 1.473 . . . . 0.0 110.854 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -110.82 142.27 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.584 1.553 . . . . 0.0 110.315 170.424 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.493 HG22 ' CB ' ' B' ' 45' ' ' PHE . 59.0 t -112.74 144.07 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 165.338 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -109.76 160.9 15.93 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 126.584 1.953 . . . . 0.0 112.182 -172.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.265 1.8 pp20? -82.43 -17.77 44.2 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -172.09 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -113.97 172.87 6.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 176.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.16 164.31 1.77 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 124.475 1.11 . . . . 0.0 109.899 166.789 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.2 p30 -113.66 147.12 38.7 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 123.237 1.494 . . . . 0.0 112.531 170.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -86.86 -22.69 25.62 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.134 1.374 . . . . 0.0 111.077 171.749 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 54.9 mt 71.41 -29.63 0.2 Allowed 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 128.765 2.826 . . . . 0.0 114.503 169.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -159.52 -47.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.701 0 CA-C-N 120.844 1.657 . . . . 0.0 114.594 174.052 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.08 100.21 2.9 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 117.254 2.316 . . . . 0.0 117.254 -168.465 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.17 -76.84 1.34 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 107.131 -2.388 . . . . 0.0 107.131 166.687 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -179.52 27.83 0.05 OUTLIER Glycine 0 CA--C 1.532 1.103 0 C-N-CA 126.382 1.944 . . . . 0.0 112.956 175.946 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -146.34 172.84 12.89 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.998 1.719 . . . . 0.0 111.08 -167.309 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -64.58 -63.06 1.22 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 110.814 -170.453 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . 0.423 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 0.8 OUTLIER -56.18 -23.64 36.39 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 128.935 2.894 . . . . 0.0 111.916 -173.558 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 52.2 m -53.58 -49.82 66.93 Favored 'General case' 0 N--CA 1.462 0.14 0 C-N-CA 123.721 0.808 . . . . 0.0 112.425 168.383 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 44.2 p -91.21 -34.5 14.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.158 1.383 . . . . 0.0 110.699 -174.375 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -81.9 -31.74 31.29 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.143 2.177 . . . . 0.0 113.085 -171.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.8 p -125.24 -93.3 0.5 Allowed 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 169.281 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -174.0 22.22 0.06 OUTLIER Glycine 0 CA--C 1.53 1.019 0 C-N-CA 128.647 3.022 . . . . 0.0 111.58 169.688 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 56.67 4.04 0.14 Allowed 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 127.83 2.452 . . . . 0.0 116.545 -169.307 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.98 -5.88 0.03 OUTLIER 'General case' 0 CA--C 1.557 1.226 0 N-CA-C 119.865 3.284 . . . . 0.0 119.865 -168.337 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 88.12 -165.95 34.85 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.718 1.628 . . . . 0.0 113.661 -176.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 18.7 t -66.86 160.61 25.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 122.14 0.971 . . . . 0.0 111.284 173.598 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.7 ptt85 -67.38 164.16 19.19 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 122.356 1.074 . . . . 0.0 111.684 169.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 38' ' ' LEU 0.316 2.9 pp -135.55 -134.7 0.15 Allowed 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 104.229 -2.508 . . . . 0.0 104.229 160.175 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.75 154.88 8.41 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-N 120.536 1.516 . . . . 0.0 114.678 -178.697 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.1 t -151.0 143.94 24.58 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.658 1.983 . . . . 0.0 111.212 -172.677 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.29 144.25 9.51 Favored Glycine 0 N--CA 1.477 1.39 0 C-N-CA 125.507 1.527 . . . . 0.0 113.465 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 20.5 t -83.47 141.57 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 CA-C-N 119.268 1.534 . . . . 0.0 110.592 177.451 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 73.8 mt -75.32 106.76 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 121.473 0.654 . . . . 0.0 109.65 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.7 -172.87 19.36 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 124.387 0.994 . . . . 0.0 111.793 168.174 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -100.01 149.24 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.87 0.843 . . . . 0.0 112.726 -176.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -103.22 -135.21 0.33 Allowed 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 166.62 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 N--CA 1.473 0.701 0 C-N-CA 126.001 1.72 . . . . 0.0 110.983 168.881 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.475 0.82 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 42.8 pttt -83.12 139.49 33.16 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.933 1.349 . . . . 0.0 114.212 -172.042 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.458 ' CB ' HD11 ' A' ' 113' ' ' ILE . . . -99.08 146.03 26.51 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 127.369 2.268 . . . . 0.0 107.753 167.409 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 33.0 t -154.95 143.54 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 119.567 1.076 . . . . 0.0 110.993 -175.2 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.87 95.63 2.88 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 123.767 0.827 . . . . 0.0 110.504 169.116 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.8 m -76.15 92.7 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-O 122.127 0.965 . . . . 0.0 109.618 170.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.2 mt -76.52 139.01 40.59 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.006 0.922 . . . . 0.0 109.553 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.6 ttmm -155.45 177.62 11.16 Favored 'General case' 0 CA--C 1.542 0.672 0 O-C-N 120.753 -1.217 . . . . 0.0 109.765 179.648 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.03 -33.83 3.91 Favored Glycine 0 N--CA 1.472 1.076 0 C-N-CA 124.279 0.942 . . . . 0.0 114.341 169.16 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.85 65.7 5.09 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 122.299 1.047 . . . . 0.0 110.146 175.905 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.06 -101.94 0.03 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.081 2.753 . . . . 0.0 113.146 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -83.24 -2.84 10.79 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 124.66 3.573 . . . . 0.0 114.441 -178.346 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -95.28 137.42 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 CA-C-N 120.697 1.59 . . . . 0.0 111.156 176.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -144.56 161.86 38.05 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 125.918 1.687 . . . . 0.0 109.697 172.321 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -134.63 106.18 0.59 Allowed Glycine 0 CA--C 1.502 -0.723 0 C-N-CA 124.34 0.971 . . . . 0.0 111.314 177.779 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.2 117.47 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 167.862 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -135.9 106.94 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-O 121.616 0.722 . . . . 0.0 109.369 169.293 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 -100.22 139.7 35.52 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.687 1.595 . . . . 0.0 110.885 -179.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -120.46 135.56 55.02 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 119.091 0.86 . . . . 0.0 110.85 179.206 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -115.1 114.86 25.88 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 127.078 2.151 . . . . 0.0 109.852 -172.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.8 tp60 -125.92 130.9 52.21 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 113.51 -1.677 . . . . 0.0 109.828 -170.398 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.594 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -99.33 -11.74 20.94 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 128.147 2.579 . . . . 0.0 114.129 -168.771 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.413 ' CD ' ' H ' ' A' ' 25' ' ' SER . 5.3 tm-20 -149.25 -172.02 4.03 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 127.918 2.487 . . . . 0.0 108.681 -172.376 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.413 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 0.8 OUTLIER -72.34 -57.18 4.41 Favored 'General case' 0 N--CA 1.474 0.726 0 O-C-N 118.778 -2.451 . . . . 0.0 111.601 169.677 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -123.37 -3.16 8.43 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.73 1.612 . . . . 0.0 114.918 -169.271 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.36 161.48 6.98 Favored Glycine 0 CA--C 1.537 1.446 0 CA-C-N 119.224 0.92 . . . . 0.0 110.955 168.372 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -66.85 143.94 68.94 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.327 2.018 . . . . 0.0 110.61 -170.035 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 37.3 t -107.62 129.87 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 123.262 0.625 . . . . 0.0 110.158 -173.159 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -79.64 125.77 30.05 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 49.9 t -112.42 130.73 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 128.456 2.703 . . . . 0.0 108.154 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -155.41 165.79 35.54 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 119.577 1.081 . . . . 0.0 113.249 175.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.27 -155.95 26.76 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 123.902 0.763 . . . . 0.0 113.655 172.726 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.9 p -149.53 128.36 12.53 Favored 'General case' 0 C--O 1.239 0.528 0 C-N-CA 123.319 0.648 . . . . 0.0 112.367 -169.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.0 mp -104.52 106.6 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 123.697 0.799 . . . . 0.0 109.599 175.371 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 tttp -117.14 133.64 55.75 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.38 1.072 . . . . 0.0 112.894 -168.903 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.56 9.37 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 128.318 2.866 . . . . 0.0 113.623 -177.621 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.8 mt -77.86 174.71 10.74 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.097 2.159 . . . . 0.0 113.37 -175.862 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.36 148.71 22.13 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 162.284 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.589 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.0 OUTLIER -53.79 -2.01 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 129.222 3.009 . . . . 0.0 115.825 176.065 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.31 174.34 17.46 Favored Glycine 0 CA--C 1.536 1.404 0 O-C-N 120.251 -1.531 . . . . 0.0 113.29 169.212 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.718 HD23 ' H ' ' A' ' 42' ' ' LEU . 2.0 pt? -88.31 138.17 31.67 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.778 2.031 . . . . 0.0 109.997 171.053 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -130.87 149.23 52.6 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 129.018 2.927 . . . . 0.0 108.615 -171.723 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -112.09 135.09 12.48 Favored Glycine 0 N--CA 1.486 1.991 0 CA-C-O 116.861 -2.077 . . . . 0.0 111.405 -172.554 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -135.74 133.28 37.85 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 121.165 2.482 . . . . 0.0 114.956 179.073 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.42 26.77 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.027 1.331 . . . . 0.0 109.801 -170.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 116' ' ' THR . 0.3 OUTLIER -86.33 118.35 32.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.263 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.742 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.0 m170 -77.71 163.03 26.53 Favored 'General case' 0 CA--C 1.549 0.931 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 176.157 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.18 133.97 55.93 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.816 -0.553 . . . . 0.0 110.745 -176.83 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.465 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 43.0 m-85 71.02 165.32 0.29 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.612 2.365 . . . . 0.0 115.348 170.123 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.21 -3.55 19.16 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 126.434 1.969 . . . . 0.0 113.654 177.684 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.0 m-20 -72.91 46.79 0.17 Allowed 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.076 1.35 . . . . 0.0 110.59 170.015 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 174.45 40.1 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.635 2.374 . . . . 0.0 112.747 -167.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.0 t -53.71 19.97 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 129.78 3.232 . . . . 0.0 116.375 172.285 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.63 16.41 8.8 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 126.699 2.0 . . . . 0.0 112.715 -178.293 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.6 -144.02 41.42 Favored Glycine 0 N--CA 1.467 0.752 0 O-C-N 121.087 -1.008 . . . . 0.0 112.097 171.12 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 p -58.69 -23.24 59.12 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.748 1.018 . . . . 0.0 113.748 -178.011 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 13.0 t -90.52 42.64 1.11 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.364 1.066 . . . . 0.0 112.019 175.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 m 178.57 -35.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 129.577 3.151 . . . . 0.0 115.091 169.606 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.53 158.98 15.36 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -168.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.97 -153.93 17.76 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 126.004 1.764 . . . . 0.0 114.223 173.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -88.58 178.39 2.88 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 125.281 3.987 . . . . 0.0 112.107 -179.496 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.487 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 3.4 p80 -79.91 83.55 5.81 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 167.062 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -50.94 166.03 0.1 Allowed 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.34 2.256 . . . . 0.0 113.993 -174.153 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -108.11 57.84 0.23 Allowed Pre-proline 0 CA--C 1.552 1.031 0 C-N-CA 127.202 2.201 . . . . 0.0 112.25 -169.712 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -64.32 -28.82 63.52 Favored 'Trans proline' 0 C--N 1.354 0.838 0 CA-C-N 122.602 1.965 . . . . 0.0 113.272 -175.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.8 mp -82.13 -4.9 57.9 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.077 1.351 . . . . 0.0 113.171 170.533 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.8 t 65.37 54.15 1.2 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 127.242 2.217 . . . . 0.0 112.894 -175.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -121.51 174.37 6.82 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -170.912 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.7 mtmt -81.04 165.92 21.23 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.494 0.718 . . . . 0.0 110.719 167.18 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.445 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 73.8 t60 -71.02 175.21 5.35 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.643 0.735 . . . . 0.0 111.645 167.758 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.15 -138.16 9.92 Favored Glycine 0 CA--C 1.504 -0.599 0 C-N-CA 124.295 0.95 . . . . 0.0 112.173 167.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.78 -99.95 0.26 Allowed Glycine 0 CA--C 1.533 1.202 0 CA-C-O 115.811 -2.661 . . . . 0.0 109.845 -178.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -56.69 0.45 0.19 Allowed 'Trans proline' 0 CA--C 1.549 1.255 0 C-N-CA 124.126 3.218 . . . . 0.0 117.983 -178.742 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.0 pttt -134.86 -4.32 2.49 Favored 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.332 1.424 . . . . 0.0 114.276 167.339 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -155.82 112.11 3.11 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 126.051 1.74 . . . . 0.0 109.985 -175.555 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -62.21 -7.58 4.39 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -173.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -80.36 -9.02 59.74 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -173.048 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -17.36 118.53 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 129.446 3.098 . . . . 0.0 112.963 168.407 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.8 m80 -62.05 166.04 5.07 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.697 1.199 . . . . 0.0 111.61 177.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 32.5 m -76.33 29.58 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -178.469 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.402 ' CA ' HG12 ' A' ' 47' ' ' VAL . . . -148.28 9.99 1.13 Allowed Glycine 0 CA--C 1.532 1.096 0 C-N-CA 125.583 1.563 . . . . 0.0 115.166 -178.686 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -105.64 115.99 31.19 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.881 1.273 . . . . 0.0 113.209 -168.611 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.8 mp -91.2 170.7 9.79 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 163.459 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -79.79 -172.37 43.65 Favored Glycine 0 CA--C 1.529 0.941 0 O-C-N 121.372 -0.83 . . . . 0.0 112.238 171.751 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -78.42 144.11 36.15 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.422 -1.046 . . . . 0.0 112.512 172.6 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.443 HG22 ' HB1' ' A' ' 95' ' ' ALA . 2.3 p -114.51 139.43 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 128.003 2.521 . . . . 0.0 110.308 177.528 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.5 m -128.65 133.47 48.25 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.785 1.234 . . . . 0.0 110.586 -169.306 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.64 163.11 13.51 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 -176.2 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -83.32 169.8 15.26 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.106 1.362 . . . . 0.0 108.422 165.125 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.435 ' HD3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -62.02 -18.7 61.42 Favored 'General case' 0 N--CA 1.482 1.167 0 O-C-N 120.66 -1.275 . . . . 0.0 113.893 172.277 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -73.62 -3.03 25.52 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.59 1.556 . . . . 0.0 111.426 168.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.88 6.69 89.27 Favored Glycine 0 C--N 1.332 0.33 0 C-N-CA 126.155 1.836 . . . . 0.0 113.462 170.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -94.33 121.51 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 126.079 1.751 . . . . 0.0 111.541 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -97.89 99.12 10.42 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 167.148 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -79.9 143.86 33.9 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.543 1.537 . . . . 0.0 109.936 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.26 142.75 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 -176.503 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 p -149.89 109.98 4.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.417 1.487 . . . . 0.0 111.294 174.106 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.2 mt -138.08 158.73 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 127.295 2.238 . . . . 0.0 110.988 -171.157 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -145.39 144.33 30.6 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 126.353 1.861 . . . . 0.0 106.851 164.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -145.12 148.17 33.33 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 125.021 1.328 . . . . 0.0 110.597 179.373 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.32 49.69 0.95 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.674 0.789 . . . . 0.0 112.2 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.2 t -139.89 -47.7 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.211 1.404 . . . . 0.0 109.893 175.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -84.6 158.14 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-O 122.307 1.051 . . . . 0.0 113.201 175.592 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.9 p -157.03 171.51 20.33 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 115.316 1.599 . . . . 0.0 115.316 -171.614 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.01 80.25 9.1 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.41 1.484 . . . . 0.0 108.587 176.662 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 60.5 p -90.2 -170.95 2.94 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.564 0.697 . . . . 0.0 112.57 173.836 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.51 -43.77 5.12 Favored Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.363 0.982 . . . . 0.0 111.425 167.563 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 34.9 t0 -172.3 45.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.694 1.597 . . . . 0.0 111.787 -173.119 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -140.85 -40.53 0.4 Allowed 'General case' 0 N--CA 1.47 0.525 0 O-C-N 120.139 -1.601 . . . . 0.0 111.097 -172.16 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.9 m -90.67 -125.34 0.07 Allowed 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 127.988 2.515 . . . . 0.0 110.499 172.047 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.7 pt -102.7 -27.24 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 114.947 1.462 . . . . 0.0 114.947 -175.399 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.458 HD11 ' CB ' ' A' ' 4' ' ' ALA . 33.8 mm -60.46 138.23 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 168.374 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.67 8.25 73.84 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 117.366 -1.797 . . . . 0.0 113.631 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -122.17 174.12 7.16 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 119.913 1.856 . . . . 0.0 111.126 -174.17 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.45 ' N ' HG22 ' A' ' 47' ' ' VAL . 39.0 m -116.22 109.37 17.33 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.269 -1.519 . . . . 0.0 111.239 -163.328 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 33.9 tp -96.38 122.24 39.05 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.464 1.105 . . . . 0.0 110.64 -172.766 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 p -121.07 133.99 65.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.025 1.33 . . . . 0.0 108.839 175.203 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.3 t -90.67 152.64 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.225 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 165.053 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.03 138.55 54.43 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.745 2.018 . . . . 0.0 107.365 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.09 -46.3 79.08 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -167.256 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt -101.87 143.16 32.11 Favored 'General case' 0 C--N 1.329 -0.312 0 O-C-N 121.375 -0.828 . . . . 0.0 110.486 169.903 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.44 158.9 1.58 Allowed 'General case' 0 C--O 1.231 0.126 0 C-N-CA 125.027 1.331 . . . . 0.0 114.098 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -75.43 146.5 40.68 Favored 'General case' 0 N--CA 1.443 -0.823 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 165.599 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -68.54 -21.13 64.57 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.961 171.013 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.7 mt 85.33 -64.5 0.05 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 131.075 3.75 . . . . 0.0 108.582 -174.67 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.94 -75.75 0.98 Allowed Glycine 0 N--CA 1.464 0.559 0 C-N-CA 124.695 1.141 . . . . 0.0 110.887 -171.125 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -163.43 109.28 1.11 Allowed 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 168.583 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.44 21.74 0.69 Allowed Glycine 0 CA--C 1.545 1.965 0 C-N-CA 125.208 1.385 . . . . 0.0 116.509 172.669 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.25 10.94 73.43 Favored Glycine 0 N--CA 1.479 1.508 0 N-CA-C 118.551 2.18 . . . . 0.0 118.551 168.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.634 ' H ' ' HB3' ' A' ' 134' ' ' SER . 32.4 m-80 -127.24 179.47 5.43 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 119.872 1.836 . . . . 0.0 111.659 -173.559 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.31 -56.71 18.62 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 166.799 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -35.28 -31.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 128.839 2.855 . . . . 0.0 115.71 167.249 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.634 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 66.8 p -57.83 -24.44 57.44 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 117.435 2.383 . . . . 0.0 117.435 -166.842 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.282 3.4 t -133.02 -14.07 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 -179.203 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.2 ptmt -70.86 -47.37 59.69 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 120.297 1.408 . . . . 0.0 110.17 167.543 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -105.24 -18.85 13.99 Favored 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.943 -177.326 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.445 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 91.23 5.86 67.14 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 124.144 0.878 . . . . 0.0 112.311 -168.426 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 74.72 2.42 4.04 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.451 2.301 . . . . 0.0 114.442 -170.296 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.66 106.26 0.76 Allowed 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 119.43 1.014 . . . . 0.0 111.398 -169.284 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -36.58 -7.44 0.0 OUTLIER Glycine 0 N--CA 1.493 2.439 1 C-N-CA 131.255 4.264 . . . . 0.0 122.836 -165.862 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 18.4 p 104.86 156.73 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 131.06 3.744 . . . . 0.0 113.315 166.556 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 61.85 131.32 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 117.826 2.528 . . . . 0.0 117.826 166.03 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 179.94 -165.83 0.07 Allowed 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 128.571 2.748 . . . . 0.0 108.451 168.171 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -55.98 151.47 11.77 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.975 1.31 . . . . 0.0 112.429 170.17 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.5 t -153.0 152.06 30.97 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.749 2.02 . . . . 0.0 112.573 -172.848 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.46 167.52 36.34 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 127.731 2.586 . . . . 0.0 110.716 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.9 p -98.5 141.78 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 CA-C-N 119.771 1.785 . . . . 0.0 109.382 169.632 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.3 mt -78.92 102.27 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 O-C-N 121.635 -0.666 . . . . 0.0 111.473 -175.266 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.32 177.2 29.65 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-O 122.601 1.112 . . . . 0.0 112.506 171.744 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -111.41 158.53 11.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 126.364 1.866 . . . . 0.0 110.993 175.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.484 ' HB2' ' CG ' ' B' ' 52' ' ' ASP . . . -107.29 -14.79 14.8 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.212 1.005 . . . . 0.0 112.228 167.153 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 . . . . . 0 C--O 1.237 0.419 0 C-N-CA 126.863 2.065 . . . . 0.0 108.377 -164.819 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.389 0 CA-C-O 121.842 0.83 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.4 t -118.53 130.28 55.83 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 124.357 1.063 . . . . 0.0 110.113 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -91.29 148.82 22.07 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 168.182 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.04 141.77 31.39 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 114.339 -1.3 . . . . 0.0 107.891 166.612 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 49.0 t -137.95 142.88 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 CA-C-O 121.675 0.75 . . . . 0.0 111.815 -169.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.1 132.29 55.99 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 122.437 1.113 . . . . 0.0 112.169 169.822 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -115.83 86.07 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 127.065 2.146 . . . . 0.0 107.027 169.642 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.61 117.32 17.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -158.03 134.24 9.42 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 119.279 0.945 . . . . 0.0 113.249 -170.297 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.07 -38.7 0.05 OUTLIER Glycine 0 N--CA 1.471 0.992 0 C-N-CA 125.659 1.6 . . . . 0.0 111.443 172.453 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.13 66.6 2.96 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 128.393 2.677 . . . . 0.0 112.188 -176.282 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.33 -102.48 0.05 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 127.111 2.291 . . . . 0.0 113.613 174.321 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -82.55 -11.85 10.34 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.907 3.072 . . . . 0.0 114.257 -176.845 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -91.13 136.08 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 CA-C-N 120.013 1.278 . . . . 0.0 110.124 -177.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.76 156.73 35.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.747 168.397 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.45 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -125.83 123.58 4.92 Favored Glycine 0 CA--C 1.503 -0.675 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.045 173.714 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.37 128.44 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 164.567 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.7 pp -136.34 134.77 49.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 164.279 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -106.25 151.48 24.74 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.107 1.363 . . . . 0.0 112.111 172.392 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -120.91 128.24 52.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.409 1.884 . . . . 0.0 112.165 169.772 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -104.08 112.42 25.41 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 128.885 2.874 . . . . 0.0 110.742 173.635 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -108.26 124.73 50.76 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.464 -0.773 . . . . 0.0 109.679 174.809 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.92 -42.06 21.96 Favored 'General case' 0 CA--C 1.551 0.996 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 176.045 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -134.56 133.72 40.57 Favored 'General case' 0 C--O 1.22 -0.485 0 C-N-CA 126.098 1.759 . . . . 0.0 109.989 170.269 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 97.9 p -70.48 79.17 0.56 Allowed 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 120.523 1.51 . . . . 0.0 113.278 -178.174 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.9 p30 158.47 -30.1 0.0 OUTLIER 'General case' 0 CA--C 1.548 0.871 1 C-N-CA 132.877 4.471 . . . . 0.0 111.176 -176.506 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.03 -172.92 43.06 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 126.099 1.809 . . . . 0.0 113.993 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -78.75 170.92 17.41 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 124.14 3.227 . . . . 0.0 112.444 -170.093 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 32.1 t -139.59 131.77 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 CA-C-O 121.482 0.658 . . . . 0.0 112.333 -167.753 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -87.48 129.06 35.21 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 167.594 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 t -110.5 138.84 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 126.322 1.849 . . . . 0.0 109.665 173.736 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 19.5 p90 -152.91 168.74 24.78 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.706 -0.621 . . . . 0.0 112.032 170.487 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.4 -161.94 29.36 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 114.757 0.663 . . . . 0.0 114.757 174.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 46.2 p -153.96 123.99 6.85 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.003 0.921 . . . . 0.0 111.631 -170.027 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.45 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 2.7 mp -106.4 113.17 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 CA-C-O 117.709 -1.138 . . . . 0.0 111.388 177.169 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.0 mmmt -102.38 144.93 30.23 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 120.407 1.458 . . . . 0.0 109.374 -178.234 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.69 -4.23 14.81 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.232 1.396 . . . . 0.0 114.235 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -67.87 179.83 1.35 Allowed 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.367 1.067 . . . . 0.0 110.124 168.566 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -106.98 -32.27 7.95 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 117.763 -1.113 . . . . 0.0 113.892 172.108 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 173.39 -168.49 0.03 OUTLIER 'General case' 0 CA--C 1.556 1.207 1 C-N-CA 132.975 4.51 . . . . 0.0 105.174 178.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.5 161.96 28.43 Favored Glycine 0 CA--C 1.525 0.666 0 C-N-CA 126.1 1.809 . . . . 0.0 115.671 167.809 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.889 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -66.33 150.29 49.08 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.261 2.625 . . . . 0.0 108.968 168.658 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -143.88 121.87 12.08 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.589 1.156 . . . . 0.0 111.945 179.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.02 147.13 41.88 Favored Glycine 0 N--CA 1.482 1.759 0 CA-C-N 119.934 1.243 . . . . 0.0 112.559 -179.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -150.25 111.06 4.3 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.071 1.349 . . . . 0.0 110.115 -173.812 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.89 152.78 35.61 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 119.8 -1.812 . . . . 0.0 114.587 -165.071 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.02 126.81 53.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-O 121.447 0.642 . . . . 0.0 111.336 -177.322 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -78.21 -179.31 6.13 Favored 'General case' 0 CA--C 1.544 0.717 1 C-N-CA 131.837 4.055 . . . . 0.0 114.444 -175.128 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . 0.439 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 1.2 pm0 -59.99 135.26 57.65 Favored 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 163.208 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.274 42.7 m-85 -0.29 -130.45 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.621 1 C-N-CA 132.105 4.162 . . . . 0.0 116.865 -169.254 . . . . . . . . 3 2 . 1 . 023 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -130.44 -2.9 4.84 Favored Glycine 0 N--CA 1.472 1.034 0 C-N-CA 124.524 1.059 . . . . 0.0 114.079 -169.676 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.484 ' CG ' ' HB2' ' A' ' 152' ' ' ALA . 12.6 p-10 -81.83 48.32 1.2 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.333 1.853 . . . . 0.0 111.697 177.289 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.263 0.4 OUTLIER -176.89 43.9 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.489 1.516 . . . . 0.0 112.187 -168.937 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.482 1.129 0 C-N-CA 128.735 2.814 . . . . 0.0 115.969 171.768 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.097 0 N-CA-C 115.473 1.657 . . . . 0.0 115.473 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . 0.439 ' H ' ' CD ' ' B' ' 49' ' ' GLU . . . -99.3 -121.31 4.54 Favored Glycine 0 CA--C 1.544 1.902 0 C-N-CA 126.485 1.993 . . . . 0.0 115.082 -169.263 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -99.19 179.16 0.3 Allowed 'Trans proline' 0 C--N 1.35 0.618 1 C-N-CA 125.415 4.076 . . . . 0.0 111.566 -175.79 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.496 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -76.5 110.87 11.41 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.009 177.479 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -48.05 128.82 14.31 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.633 1.973 . . . . 0.0 113.78 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -121.57 64.96 16.69 Favored Pre-proline 0 CA--C 1.548 0.886 0 C-N-CA 124.721 1.208 . . . . 0.0 112.596 -172.312 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -63.58 -22.51 70.5 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 123.679 2.919 . . . . 0.0 113.465 -175.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.9 mt -79.51 -4.95 53.66 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.502 1.521 . . . . 0.0 112.916 172.606 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.7 p 62.15 52.07 3.34 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 127.891 2.476 . . . . 0.0 111.448 177.569 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -126.41 174.15 8.82 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 114.419 1.266 . . . . 0.0 114.419 -169.252 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 45.7 pttt -78.88 169.01 18.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 128.051 2.541 . . . . 0.0 111.192 171.235 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.419 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 78.6 t60 -90.28 174.85 7.36 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 176.221 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' B' ' 126' ' ' LEU . . . 129.24 -115.1 1.87 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 125.166 1.365 . . . . 0.0 113.48 166.57 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.03 -50.03 0.81 Allowed Glycine 0 CA--C 1.547 2.089 0 CA-C-O 117.859 -1.523 . . . . 0.0 116.196 173.044 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . 0.493 ' HD2' HD12 ' B' ' 126' ' ' LEU . 69.6 Cg_endo -88.64 -4.64 6.37 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 CA-C-N 121.425 2.613 . . . . 0.0 113.599 172.077 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 26.5 pttt -141.83 -1.35 1.27 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 124.256 1.022 . . . . 0.0 113.468 168.29 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -119.43 159.74 23.66 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.642 1.577 . . . . 0.0 110.099 169.496 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -81.96 -29.84 31.99 Favored 'General case' 0 CA--C 1.541 0.619 1 C-N-CA 132.486 4.314 . . . . 0.0 114.83 -171.321 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -98.51 -85.63 0.37 Allowed 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.714 -0.616 . . . . 0.0 111.165 -168.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ttp-105 80.93 121.22 0.05 OUTLIER 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.924 2.09 . . . . 0.0 111.16 176.979 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m80 -54.19 151.51 7.12 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 120.481 -1.387 . . . . 0.0 113.006 173.794 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -45.94 -48.38 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-O 119.048 -0.501 . . . . 0.0 112.104 -176.648 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.29 112.12 2.62 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-O 123.182 1.435 . . . . 0.0 113.117 169.411 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -155.56 107.14 2.58 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 130.659 3.584 . . . . 0.0 106.872 174.473 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 97.0 mt -89.09 54.06 2.87 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.558 0.743 . . . . 0.0 109.74 174.58 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.9 -107.56 0.14 Allowed Glycine 0 CA--C 1.532 1.107 0 C-N-CA 125.959 1.743 . . . . 0.0 113.652 177.449 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.74 146.16 24.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.367 1.467 . . . . 0.0 110.947 169.922 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.97 113.52 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 126.791 2.036 . . . . 0.0 110.359 -176.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -95.59 125.06 39.92 Favored 'General case' 0 N--CA 1.471 0.598 0 O-C-N 121.628 -0.67 . . . . 0.0 110.365 -175.189 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.38 148.62 24.01 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.738 1.215 . . . . 0.0 113.181 -175.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -76.71 174.91 9.88 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.49 1.516 . . . . 0.0 111.496 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.472 ' HB3' ' HZ3' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -68.59 -13.38 62.3 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 121.101 -1.0 . . . . 0.0 113.109 173.018 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -74.62 -23.7 58.74 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.101 1.36 . . . . 0.0 110.588 171.217 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.12 -2.71 59.8 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 116.655 -2.192 . . . . 0.0 114.47 -177.75 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.33 133.18 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 119.959 1.88 . . . . 0.0 113.818 169.856 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.44 113.93 27.8 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 164.783 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -99.67 133.34 44.16 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.066 1.347 . . . . 0.0 108.978 -176.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -135.26 135.7 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.495 1.118 . . . . 0.0 112.825 -167.393 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 27.6 p -156.11 113.69 3.27 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.312 1.445 . . . . 0.0 111.304 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 6.6 mt -145.14 152.57 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 127.85 2.46 . . . . 0.0 110.606 -169.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -134.98 137.78 43.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.846 0.858 . . . . 0.0 108.737 167.376 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -145.12 153.21 41.16 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 125.385 1.474 . . . . 0.0 112.327 -172.163 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 37.4 p -125.67 45.26 2.64 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 178.603 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.4 22.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.891 1.276 . . . . 0.0 112.669 169.427 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.15 158.86 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 127.119 2.168 . . . . 0.0 108.025 164.685 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 60.4 p -156.03 156.84 35.12 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.657 0.783 . . . . 0.0 109.758 -177.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -83.25 63.41 7.2 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.681 -1.262 . . . . 0.0 110.243 -177.322 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 11.1 t -93.5 154.59 17.81 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 165.703 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.0 -28.41 72.02 Favored Glycine 0 N--CA 1.47 0.909 0 C-N-CA 127.047 2.261 . . . . 0.0 118.322 -164.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 p30 -148.13 -46.67 0.16 Allowed 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -168.79 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -82.73 -18.89 39.18 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.782 -1.199 . . . . 0.0 111.994 -171.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 74.7 m -99.14 -92.85 0.26 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.093 0.957 . . . . 0.0 111.097 -176.174 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.74 -18.49 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 176.584 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 40.2 mm -68.64 153.0 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 122.089 2.222 . . . . 0.0 107.263 167.238 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.48 66.0 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 119.297 -0.724 . . . . 0.0 112.97 175.687 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 15.8 mtp85 -114.54 133.19 55.98 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 176.719 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.5 m -80.29 140.69 36.06 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.352 1.861 . . . . 0.0 107.003 179.258 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.3 tp -129.83 128.53 42.49 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.028 0.931 . . . . 0.0 109.786 -174.566 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.62 133.19 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.103 0.961 . . . . 0.0 110.628 177.736 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -98.24 149.25 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 165.969 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.2 m-70 -120.76 138.16 54.15 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.274 1.43 . . . . 0.0 113.199 -169.655 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -73.61 -24.79 60.09 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 120.163 -1.585 . . . . 0.0 114.013 -173.338 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -93.22 164.8 13.1 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 122.192 0.996 . . . . 0.0 112.355 169.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.87 158.97 20.7 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.008 1.323 . . . . 0.0 111.625 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -103.45 151.95 22.21 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.84 0.856 . . . . 0.0 112.185 179.124 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -102.36 -3.24 27.42 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 127.378 2.271 . . . . 0.0 112.878 -177.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.493 HD12 ' HD2' ' B' ' 74' ' ' PRO . 0.8 OUTLIER 45.85 56.45 5.97 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.132 1.773 . . . . 0.0 113.257 172.036 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.77 -54.1 1.68 Allowed Glycine 0 N--CA 1.471 1.033 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.014 173.023 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 134.55 18.86 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 172.314 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -160.21 -67.58 0.02 OUTLIER Glycine 0 CA--C 1.52 0.382 1 C-N-CA 130.723 4.011 . . . . 0.0 107.254 168.22 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -83.67 -111.14 0.56 Allowed Glycine 0 CA--C 1.533 1.188 0 C-N-CA 126.309 1.909 . . . . 0.0 117.039 -171.046 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -118.0 -159.13 0.74 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.431 2.292 . . . . 0.0 112.646 -163.307 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -49.34 -64.67 0.74 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.479 1.112 . . . . 0.0 112.033 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . 0.298 2.9 mt-10 -53.65 -10.37 0.27 Allowed 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 177.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 67.2 m -60.9 -47.76 84.92 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 122.133 2.242 . . . . 0.0 111.18 166.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 39.0 p -81.31 -38.14 27.25 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-O 119.102 -0.475 . . . . 0.0 111.347 176.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.9 tttt -68.63 -38.97 80.96 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.552 1.541 . . . . 0.0 113.88 -173.906 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.4 ' O ' ' CE1' ' B' ' 63' ' ' HIS . 33.9 p -121.78 -68.72 0.88 Allowed 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 116.974 -1.488 . . . . 0.0 109.696 172.742 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 163.71 17.37 0.02 OUTLIER Glycine 0 CA--C 1.536 1.375 0 C-N-CA 130.476 3.894 . . . . 0.0 113.621 -176.286 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . 0.257 2.3 t-20 41.98 35.34 0.54 Allowed 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 128.017 2.527 . . . . 0.0 114.819 -166.522 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.56 3.45 0.13 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.784 1.633 . . . . 0.0 115.232 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.9 -43.86 0.51 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 129.324 3.345 . . . . 0.0 117.257 168.664 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 32.5 t -173.09 168.55 4.77 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.768 1.627 . . . . 0.0 110.062 -168.316 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 28.5 mtt180 -111.07 -177.69 3.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 -169.85 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.425 HD22 ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -171.31 -157.88 0.13 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 128.417 2.687 . . . . 0.0 107.138 -169.695 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . 0.425 ' H ' HD22 ' B' ' 144' ' ' LEU . . . -58.69 153.97 15.53 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -169.142 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -141.98 153.77 44.54 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 113.949 -1.478 . . . . 0.0 113.82 -172.109 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.99 -177.65 37.68 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 127.49 2.472 . . . . 0.0 111.485 176.627 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.61 152.69 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 166.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.0 mm -75.7 102.31 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 174.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.18 -179.51 35.54 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 125.835 1.683 . . . . 0.0 111.14 169.932 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.24 154.55 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 117.602 0.701 . . . . 0.0 112.796 -167.604 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.465 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.23 -2.74 0.68 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 115.008 1.484 . . . . 0.0 115.008 165.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.234 0.262 0 C-N-CA 124.671 1.189 . . . . 0.0 111.071 168.78 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p . . . . . 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 111.365 0.135 . . . . 0.0 111.365 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 024 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p . . . . . 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 111.365 0.135 . . . . 0.0 111.365 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 025 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.5 p . . . . . 0 N--CA 1.465 0.283 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 0.8 OUTLIER -163.43 129.75 3.26 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 164.361 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.44 154.03 44.21 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.326 2.25 . . . . 0.0 108.289 167.682 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 69.4 t -154.97 146.62 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 118.916 0.78 . . . . 0.0 112.778 -167.005 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.76 128.45 51.75 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.592 1.157 . . . . 0.0 109.321 165.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 29.0 m -113.71 127.1 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.597 1.159 . . . . 0.0 108.289 167.59 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.07 130.45 55.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.14 1.376 . . . . 0.0 109.913 -172.068 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -153.9 70.76 0.83 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.741 0.816 . . . . 0.0 110.869 170.222 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.1 -1.41 22.3 Favored Glycine 0 N--CA 1.469 0.851 0 CA-C-O 117.481 -1.733 . . . . 0.0 115.078 -173.958 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -156.08 110.32 2.81 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 119.151 1.476 . . . . 0.0 111.979 -169.74 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 31.66 -111.37 0.05 OUTLIER Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.168 2.318 . . . . 0.0 114.906 169.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -84.42 -2.05 9.85 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.597 2.865 . . . . 0.0 114.034 -175.778 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.0 t -102.05 135.37 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 120.445 1.475 . . . . 0.0 111.578 -168.609 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -127.24 171.93 11.03 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 122.87 1.319 . . . . 0.0 110.258 169.072 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.36 150.87 23.17 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 112.781 -2.008 . . . . 0.0 112.152 167.892 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -133.15 126.4 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 167.352 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mm -132.67 103.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -177.29 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -99.3 124.71 44.61 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.221 1.008 . . . . 0.0 112.151 177.107 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -104.69 156.45 17.97 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 127.303 2.241 . . . . 0.0 111.769 169.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -132.46 128.97 38.59 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.613 1.565 . . . . 0.0 108.597 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.565 HE21 ' HB2' ' A' ' 105' ' ' SER . 2.4 tm0? -139.56 145.49 38.69 Favored 'General case' 0 CA--C 1.532 0.287 0 O-C-N 120.822 -1.174 . . . . 0.0 111.151 -174.224 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.469 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -113.4 -31.37 6.58 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -167.39 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -157.94 154.66 28.16 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.683 1.593 . . . . 0.0 107.908 172.438 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 m -47.44 -40.53 18.32 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 128.302 2.641 . . . . 0.0 113.156 173.018 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -84.1 -0.55 52.34 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.984 1.714 . . . . 0.0 112.771 174.681 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.58 139.65 14.57 Favored Glycine 0 CA--C 1.538 1.526 0 O-C-N 120.427 -1.421 . . . . 0.0 112.985 -172.694 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -69.74 163.71 37.26 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 123.933 3.089 . . . . 0.0 111.339 178.925 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t -132.75 136.56 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.177 0.591 . . . . 0.0 112.164 -167.024 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -95.49 124.54 39.57 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.093 1.357 . . . . 0.0 109.548 172.153 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 99' ' ' ILE . 0.3 OUTLIER -107.7 153.0 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 C-N-CA 125.672 1.589 . . . . 0.0 111.415 168.991 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 42.6 p90 -156.72 164.05 38.58 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.291 1.437 . . . . 0.0 111.834 168.779 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.94 -154.21 24.74 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 124.139 0.876 . . . . 0.0 112.597 175.656 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 78.1 p -156.58 150.85 25.32 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.15 116.26 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 171.783 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -136.12 140.18 43.5 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.111 0.964 . . . . 0.0 112.566 -165.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.57 -16.22 37.62 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 126.809 2.147 . . . . 0.0 112.275 -168.789 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.453 HD13 ' CD2' ' A' ' 43' ' ' HIS . 2.2 pp -84.39 155.05 22.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-N 118.473 1.137 . . . . 0.0 112.01 172.879 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.7 m -62.02 154.15 27.54 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 127.371 2.269 . . . . 0.0 112.012 176.674 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.8 pm0 -51.0 169.61 0.04 OUTLIER 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.258 1.423 . . . . 0.0 114.57 168.674 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.43 -176.32 46.51 Favored Glycine 0 N--CA 1.472 1.086 0 O-C-N 120.792 -1.192 . . . . 0.0 112.358 -177.485 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.3 mp -75.92 148.36 38.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.456 -1.026 . . . . 0.0 110.019 -176.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.453 ' CD2' HD13 ' A' ' 38' ' ' LEU . 85.4 m-70 -142.1 134.0 27.24 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.849 1.26 . . . . 0.0 109.2 173.836 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.2 152.13 49.52 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 177.75 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -150.5 118.0 6.1 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.806 2.042 . . . . 0.0 107.97 -169.141 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.474 ' NE2' ' CD2' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -153.89 145.2 23.01 Favored 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.116 -1.615 . . . . 0.0 111.221 -172.956 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.16 127.3 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.173 0.987 . . . . 0.0 110.647 170.248 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -72.83 -173.62 1.26 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 129.218 3.007 . . . . 0.0 110.349 177.414 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.55 ' H ' ' CD ' ' A' ' 49' ' ' GLU 0.268 1.9 pm0 -63.65 -120.31 0.0 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.081 1.752 . . . . 0.0 114.831 177.692 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -82.12 -168.03 1.79 Allowed 'General case' 0 CA--C 1.545 0.754 0 O-C-N 119.807 -1.808 . . . . 0.0 114.403 -167.129 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.58 9.45 60.59 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.067 1.794 . . . . 0.0 113.978 -179.354 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -108.98 38.79 2.18 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.986 1.714 . . . . 0.0 113.961 -173.769 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.4 ' OD1' ' HB2' ' A' ' 60' ' ' ALA . 2.1 p30 -172.43 22.27 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.858 1.313 . . . . 0.0 112.408 -165.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.411 ' H ' HG23 ' A' ' 54' ' ' THR . 3.1 p -44.33 5.8 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.613 1 C-N-CA 134.641 5.176 . . . . 0.0 118.784 -176.453 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.75 1.34 56.54 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.515 1.926 . . . . 0.0 112.87 172.579 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.84 -151.68 43.05 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 -179.135 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.1 t -51.26 -7.41 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.197 0 C-N-CA 127.206 2.203 . . . . 0.0 116.289 -176.42 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 58.5 p -87.95 18.51 4.14 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 120.162 -1.586 . . . . 0.0 113.318 169.2 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.9 m -169.81 -47.14 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 127.221 2.209 . . . . 0.0 109.761 -176.268 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.4 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . . . -70.61 151.31 45.13 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.45 1.9 . . . . 0.0 112.128 172.526 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -98.01 -170.28 32.35 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 125.803 1.668 . . . . 0.0 112.505 -176.188 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -83.79 60.87 6.69 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.501 2.801 . . . . 0.0 109.885 178.185 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' ' NE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER 51.19 63.81 2.1 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.551 1.54 . . . . 0.0 112.773 168.272 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -28.29 113.57 0.07 Allowed 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 127.507 2.323 . . . . 0.0 111.854 175.679 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -78.11 103.59 1.45 Allowed Pre-proline 0 CA--C 1.545 0.773 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.795 -166.547 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -70.11 -21.12 32.3 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 121.899 1.733 . . . . 0.0 112.186 -174.516 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.89 -3.74 21.49 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.31 1.844 . . . . 0.0 112.677 175.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 t 54.18 44.24 29.44 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 125.25 1.42 . . . . 0.0 112.283 -169.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtm180 -92.2 171.19 9.24 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 120.994 -1.066 . . . . 0.0 111.37 174.378 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.75 164.64 18.41 Favored 'General case' 0 CA--C 1.547 0.858 0 O-C-N 121.23 -0.919 . . . . 0.0 109.762 167.792 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -80.31 142.54 34.42 Favored 'General case' 0 CA--C 1.536 0.414 0 O-C-N 120.265 -1.522 . . . . 0.0 111.718 -178.495 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 165.36 -131.5 2.41 Favored Glycine 0 N--CA 1.468 0.804 0 N-CA-C 115.859 1.104 . . . . 0.0 115.859 168.843 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.55 -41.7 1.72 Allowed Glycine 0 CA--C 1.543 1.822 0 N-CA-C 119.005 2.362 . . . . 0.0 119.005 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -95.39 -22.31 0.2 Allowed 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 121.885 2.843 . . . . 0.0 113.725 -175.798 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.5 pttt -132.26 -0.09 3.7 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.976 1.71 . . . . 0.0 112.21 175.348 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -138.72 155.49 48.19 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 130.869 3.668 . . . . 0.0 108.832 -176.428 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -107.07 -8.05 16.67 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 126.169 1.788 . . . . 0.0 112.911 -174.638 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.5 mm-40 -78.2 -20.21 52.31 Favored 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -172.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.481 HH21 HG12 ' A' ' 103' ' ' VAL . 4.8 ttp180 4.52 102.14 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 130.445 3.498 . . . . 0.0 115.374 166.493 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -59.58 162.35 5.13 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.654 0.782 . . . . 0.0 112.03 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 92.2 t -49.62 -41.18 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 124.366 1.066 . . . . 0.0 113.722 171.125 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.8 8.39 66.21 Favored Glycine 0 CA--C 1.539 1.583 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 177.266 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -99.25 97.49 8.56 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-N 119.635 1.718 . . . . 0.0 111.866 -175.184 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 87.0 mt -108.81 54.54 0.65 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.455 1.102 . . . . 0.0 111.954 -175.436 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.42 -151.48 43.43 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 125.023 1.296 . . . . 0.0 114.248 177.186 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.7 p30 -135.16 169.28 17.69 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 125.509 1.524 . . . . 0.0 109.568 169.864 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -128.58 113.88 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.536 1.134 . . . . 0.0 109.832 -171.147 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.4 m -109.15 124.37 50.7 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 123.913 0.885 . . . . 0.0 108.939 -170.102 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.94 151.17 21.64 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 -172.87 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -88.06 151.89 22.42 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 127.758 2.423 . . . . 0.0 110.381 167.952 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -49.94 -17.71 0.42 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 129.2 3.0 . . . . 0.0 116.994 175.557 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -75.65 0.75 16.54 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 124.266 1.026 . . . . 0.0 111.388 171.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.13 35.13 7.21 Favored Glycine 0 C--N 1.34 0.783 0 C-N-CA 125.996 1.76 . . . . 0.0 112.781 172.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.7 p -152.76 131.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.048 1.869 . . . . 0.0 116.048 -170.919 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.86 120.97 37.07 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 164.468 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -104.1 132.6 50.19 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.224 1.41 . . . . 0.0 107.747 177.118 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 49.1 t -134.41 141.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -165.608 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.9 t -157.46 119.27 3.73 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.333 1.853 . . . . 0.0 111.021 170.614 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.453 ' HB ' HG12 ' A' ' 31' ' ' VAL . 46.4 mt -135.47 145.59 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 126.233 1.813 . . . . 0.0 110.467 179.707 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.98 126.43 53.83 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 125.641 1.576 . . . . 0.0 106.945 166.269 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.82 144.46 50.24 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.925 0.89 . . . . 0.0 112.924 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 10.8 p -119.97 50.74 1.25 Allowed 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -177.381 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.481 HG12 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -154.72 6.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 N-CA-C 115.382 1.623 . . . . 0.0 115.382 168.642 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.64 152.79 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 120.77 -1.206 . . . . 0.0 109.851 177.726 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.565 ' HB2' HE21 ' A' ' 22' ' ' GLN . 52.4 p -155.43 179.3 9.31 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 120.982 -1.074 . . . . 0.0 112.691 -178.341 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.467 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.4 mp -81.72 48.35 1.19 Allowed 'General case' 0 CA--C 1.551 1.002 0 O-C-N 120.415 -1.428 . . . . 0.0 110.234 -174.571 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.9 t -88.16 43.92 1.16 Allowed 'General case' 0 CA--C 1.545 0.764 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 -168.454 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.19 -64.63 2.02 Favored Glycine 0 N--CA 1.475 1.248 0 C-N-CA 125.736 1.636 . . . . 0.0 116.072 168.249 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -149.41 16.67 0.92 Allowed 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 124.059 1.885 . . . . 0.0 110.595 -175.725 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 39.4 m-70 -126.31 5.7 7.02 Favored 'General case' 0 CA--C 1.545 0.771 0 O-C-N 120.004 -1.685 . . . . 0.0 112.873 -167.431 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB3' ' H ' ' A' ' 105' ' ' SER . 3.1 m -166.39 -103.12 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.74 1.216 . . . . 0.0 113.111 177.749 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.6 pt -117.72 28.13 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 CA-C-N 120.37 1.441 . . . . 0.0 113.679 -170.276 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -133.48 146.58 31.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 127.725 2.41 . . . . 0.0 105.578 164.084 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.12 30.38 75.68 Favored Glycine 0 C--O 1.22 -0.748 0 CA-C-O 118.869 -0.962 . . . . 0.0 113.101 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.7 mtt-85 -135.28 176.9 8.25 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.835 1.254 . . . . 0.0 109.351 176.345 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.4 m -132.52 116.11 16.32 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 119.689 1.131 . . . . 0.0 110.94 -170.885 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.7 tp -89.83 132.86 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.629 1.172 . . . . 0.0 110.308 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 146' ' ' CYS . 4.9 p -124.23 150.26 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.027 1.331 . . . . 0.0 110.326 172.302 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -105.33 167.56 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-O 121.418 0.628 . . . . 0.0 110.823 167.06 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.72 127.69 37.35 Favored 'General case' 0 CA--C 1.547 0.849 0 O-C-N 120.942 -1.099 . . . . 0.0 110.697 -173.823 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? -69.87 -10.13 57.38 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -169.55 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -107.93 162.1 14.33 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 114.442 1.275 . . . . 0.0 114.442 171.496 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.79 139.4 58.76 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.507 1.923 . . . . 0.0 109.792 167.081 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -111.3 148.84 32.05 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.849 2.059 . . . . 0.0 113.8 -171.815 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.342 13.3 t0 -101.93 -15.83 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 115.556 1.687 . . . . 0.0 115.556 -179.725 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt 56.26 81.0 0.13 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.724 1.609 . . . . 0.0 114.061 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.9 -43.74 1.91 Allowed Glycine 0 N--CA 1.471 1.009 0 C-N-CA 125.275 1.417 . . . . 0.0 111.935 168.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -99.42 175.03 5.99 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.219 1.408 . . . . 0.0 110.204 167.604 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 131.02 -9.92 5.68 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 126.311 1.91 . . . . 0.0 114.116 -169.312 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.54 11.04 85.85 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 116.272 1.269 . . . . 0.0 116.272 168.394 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 13.9 p30 -138.82 174.52 10.43 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.891 1.276 . . . . 0.0 110.077 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -65.69 -54.82 22.19 Favored 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 115.012 1.486 . . . . 0.0 115.012 -171.577 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.41 -26.54 42.32 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.661 -0.649 . . . . 0.0 111.883 176.291 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -54.38 -35.97 63.4 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.29 -1.506 . . . . 0.0 114.634 177.253 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.9 -28.16 15.33 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 124.423 1.089 . . . . 0.0 112.49 178.504 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.19 -65.25 0.98 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.018 0.827 . . . . 0.0 111.922 178.823 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.9 p -92.25 -24.31 19.04 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 126.56 1.944 . . . . 0.0 112.168 -171.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.58 16.51 24.23 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 124.533 1.063 . . . . 0.0 112.494 -168.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 73.09 4.54 4.96 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.566 1.946 . . . . 0.0 113.768 178.294 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.8 -10.96 4.36 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 -169.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.06 -30.07 0.53 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 128.507 2.956 . . . . 0.0 117.779 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.5 t -142.45 178.11 7.82 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.225 1.01 . . . . 0.0 110.469 -173.42 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.9 -175.58 2.81 Favored 'General case' 0 N--CA 1.473 0.725 0 O-C-N 120.59 -1.319 . . . . 0.0 110.102 -174.893 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.576 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -170.1 -158.96 0.18 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.76 2.024 . . . . 0.0 107.779 -176.07 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.576 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.26 159.7 30.75 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 127.057 2.143 . . . . 0.0 113.321 178.347 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.421 ' HB3' HG23 ' A' ' 118' ' ' VAL . 31.4 p -147.58 162.52 38.94 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.269 1.427 . . . . 0.0 112.985 -177.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.28 161.0 31.35 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 126.614 2.054 . . . . 0.0 112.228 169.333 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.1 t -78.54 160.83 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 CA-C-N 119.25 1.525 . . . . 0.0 110.869 170.403 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -103.1 113.12 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 CA-C-N 118.834 0.743 . . . . 0.0 110.643 167.838 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.2 -178.61 15.7 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 125.604 1.573 . . . . 0.0 113.23 -178.435 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.95 123.05 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 113.958 1.096 . . . . 0.0 113.958 -170.704 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.464 ' HB3' ' HB3' ' A' ' 3' ' ' LYS . . . -75.12 -31.05 61.0 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 122.921 1.343 . . . . 0.0 107.787 163.033 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.438 0 C-N-CA 125.481 1.512 . . . . 0.0 112.27 166.937 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.2 m -80.73 109.61 15.43 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 105.724 -1.954 . . . . 0.0 105.724 168.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.451 ' HE3' ' HB1' ' B' ' 152' ' ' ALA . 0.2 OUTLIER -116.27 152.87 32.97 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 117.894 2.553 . . . . 0.0 117.894 -172.711 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.75 147.49 37.46 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 126.255 1.822 . . . . 0.0 108.886 168.571 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.05 157.29 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 123.459 0.704 . . . . 0.0 111.037 -166.918 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.54 139.61 46.7 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.658 1.183 . . . . 0.0 111.438 169.648 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.4 m -108.62 122.41 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 167.094 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . 0.521 ' CD2' HD12 ' B' ' 117' ' ' LEU . 4.7 mp -99.98 75.86 1.89 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -164.453 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -105.61 100.74 10.29 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.257 1.423 . . . . 0.0 110.364 173.076 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.47 15.69 0.48 Allowed Glycine 0 N--CA 1.477 1.412 0 N-CA-C 115.68 1.032 . . . . 0.0 115.68 -178.11 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -159.61 136.78 9.6 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.625 2.37 . . . . 0.0 107.457 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -23.28 -80.26 0.01 OUTLIER Glycine 0 CA--C 1.537 1.451 0 C-N-CA 128.487 2.946 . . . . 0.0 116.083 -168.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -86.72 4.27 6.36 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 124.192 3.261 . . . . 0.0 113.949 -177.557 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 36.0 t -105.38 129.83 57.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 CA-C-O 122.872 1.32 . . . . 0.0 109.721 -172.446 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.2 168.29 19.13 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.777 1.631 . . . . 0.0 107.911 171.869 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.17 176.42 33.6 Favored Glycine 0 N--CA 1.464 0.543 0 O-C-N 120.432 -1.417 . . . . 0.0 113.546 176.488 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -158.31 103.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 126.687 1.995 . . . . 0.0 108.81 172.971 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.49 146.41 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 124.922 1.289 . . . . 0.0 111.594 176.636 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -119.12 168.99 10.32 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 127.268 2.227 . . . . 0.0 112.196 -171.034 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.38 98.86 3.21 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 127.263 2.225 . . . . 0.0 108.105 172.219 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -102.41 114.08 27.96 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 118.71 0.686 . . . . 0.0 111.581 -175.476 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -91.64 132.48 36.31 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.221 1.008 . . . . 0.0 110.948 176.227 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.4 ptmt -84.02 -30.79 25.83 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 179.349 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -162.17 144.73 11.37 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.19 2.196 . . . . 0.0 109.847 169.586 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 1.5 m -43.77 24.77 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 1 C-N-CA 137.957 6.503 . . . . 0.0 119.037 -174.767 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.6 p30 179.76 -24.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 128.371 2.668 . . . . 0.0 112.081 -170.194 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.6 165.11 54.3 Favored Glycine 0 CA--C 1.541 1.659 0 O-C-N 121.168 -0.958 . . . . 0.0 112.425 169.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -70.15 169.7 18.79 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 124.305 3.336 . . . . 0.0 113.12 -171.288 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 31.7 t -131.02 129.43 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.942 1.697 . . . . 0.0 110.503 -169.111 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -93.77 125.82 38.6 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-O 122.319 1.057 . . . . 0.0 109.902 170.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.06 128.16 39.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 127.585 2.354 . . . . 0.0 108.071 169.44 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -153.39 158.26 41.19 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 171.646 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.83 -141.99 12.79 Favored Glycine 0 N--CA 1.463 0.456 0 C-N-CA 125.08 1.324 . . . . 0.0 111.51 176.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 99.0 p -155.02 162.13 41.16 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 117.987 2.588 . . . . 0.0 117.987 -167.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 19.4 mm -130.4 123.93 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 C-N-CA 126.567 1.947 . . . . 0.0 107.445 168.067 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 tttp -122.24 136.49 54.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 122.854 2.57 . . . . 0.0 110.731 -178.63 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.26 -8.77 5.65 Favored Glycine 0 N--CA 1.474 1.202 0 C-N-CA 126.47 1.986 . . . . 0.0 114.094 -178.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.435 HD22 ' CE1' ' B' ' 43' ' ' HIS . 33.4 mt -70.22 172.97 7.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.096 1.358 . . . . 0.0 111.638 170.625 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 11.8 t -110.77 157.73 19.46 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 162.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -59.03 162.04 4.59 Favored 'General case' 0 CA--C 1.537 0.442 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -167.213 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.79 -179.15 34.07 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.671 -174.841 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.636 ' H ' HD23 ' B' ' 42' ' ' LEU . 2.2 pt? -75.64 144.21 41.81 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.533 1.533 . . . . 0.0 113.0 -169.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . 0.435 ' CE1' HD22 ' B' ' 38' ' ' LEU . 91.9 m-70 -140.37 170.14 16.37 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 126.948 2.099 . . . . 0.0 109.567 176.462 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -124.93 166.06 17.79 Favored Glycine 0 N--CA 1.478 1.486 0 C-N-CA 125.132 1.349 . . . . 0.0 113.148 -174.196 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -156.46 162.32 39.99 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.951 2.1 . . . . 0.0 112.82 172.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . 0.587 ' O ' HD22 ' B' ' 117' ' ' LEU . 46.7 p-80 -156.14 163.91 39.04 Favored 'General case' 0 C--N 1.347 0.468 0 O-C-N 120.583 -1.323 . . . . 0.0 108.835 168.797 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.483 HG22 ' CA ' ' B' ' 82' ' ' GLY . 0.5 OUTLIER -110.84 162.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 125.015 1.326 . . . . 0.0 108.857 -178.244 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.3 p80 -136.67 126.18 25.18 Favored 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 120.984 -1.072 . . . . 0.0 109.789 176.606 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -71.75 136.47 47.16 Favored 'General case' 0 N--CA 1.452 -0.357 0 O-C-N 123.932 0.77 . . . . 0.0 109.913 179.443 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 121.22 133.05 0.0 OUTLIER 'General case' 0 C--O 1.233 0.209 1 C-N-CA 133.958 4.903 . . . . 0.0 108.449 -176.149 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.42 2.89 61.15 Favored Glycine 0 C--O 1.222 -0.615 0 CA-C-O 118.211 -1.327 . . . . 0.0 114.019 178.717 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -103.13 51.58 0.79 Allowed 'General case' 0 CA--C 1.536 0.423 0 CA-C-N 120.24 2.02 . . . . 0.0 112.934 -179.15 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.1 37.73 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 126.669 1.987 . . . . 0.0 110.995 -171.472 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.3 p . . . . . 0 N--CA 1.469 0.504 1 C-N-CA 133.688 4.795 . . . . 0.0 115.948 -171.614 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.604 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.99 163.57 26.9 Favored Glycine 0 CA--C 1.544 1.897 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -173.201 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -66.09 125.29 13.86 Favored 'Trans proline' 0 C--N 1.352 0.716 0 C-N-CA 124.977 3.785 . . . . 0.0 111.322 178.378 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.318 1.9 p80 28.32 59.23 0.12 Allowed 'General case' 0 C--O 1.239 0.551 0 C-N-CA 130.278 3.431 . . . . 0.0 116.858 177.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -58.8 121.1 10.28 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 105.153 -2.166 . . . . 0.0 105.153 162.836 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -125.47 142.4 41.65 Favored Pre-proline 0 CA--C 1.543 0.683 0 C-N-CA 124.365 1.066 . . . . 0.0 113.799 -169.068 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -83.38 -15.08 7.8 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.323 2.682 . . . . 0.0 113.587 175.172 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 79.8 mt -93.88 -10.63 33.28 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 115.03 1.492 . . . . 0.0 115.03 -171.486 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t 46.12 58.69 4.26 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 169.474 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 4.6 ptt180 -143.88 -174.96 4.4 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 127.899 2.48 . . . . 0.0 111.06 -175.611 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.25 3.1 pttp -65.19 160.48 21.28 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 120.231 1.378 . . . . 0.0 112.706 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -96.95 138.62 34.21 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.777 -1.556 . . . . 0.0 113.326 -177.086 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.92 -151.33 20.19 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 127.075 2.274 . . . . 0.0 109.456 170.49 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 169.25 -32.99 0.18 Allowed Glycine 0 CA--C 1.528 0.87 0 N-CA-C 119.722 2.649 . . . . 0.0 119.722 169.004 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.3 24.18 0.22 Allowed 'Trans proline' 0 CA--C 1.554 1.52 0 CA-C-N 122.97 3.385 . . . . 0.0 113.013 167.787 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -168.59 -41.39 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 129.865 3.266 . . . . 0.0 107.245 166.427 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.255 4.9 t70 -62.69 117.97 7.02 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 123.932 1.825 . . . . 0.0 109.599 -171.055 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.3 mp0 -72.48 -19.57 61.52 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 129.416 3.086 . . . . 0.0 114.471 -161.616 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -105.71 -65.21 1.08 Allowed 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.022 0.529 . . . . 0.0 111.197 176.798 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 76.77 126.72 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 125.181 1.393 . . . . 0.0 114.352 165.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -73.78 159.54 32.78 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 124.608 1.163 . . . . 0.0 113.015 168.106 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -61.86 -47.75 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 120.931 -1.106 . . . . 0.0 110.142 173.529 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . 0.483 ' CA ' HG22 ' B' ' 47' ' ' VAL . . . -77.56 31.38 1.67 Allowed Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.865 1.221 . . . . 0.0 115.369 176.587 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -115.71 117.39 30.14 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 121.368 -1.078 . . . . 0.0 108.941 170.291 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 87.1 mt -140.72 131.68 26.1 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 102.455 -3.165 . . . . 0.0 102.455 168.743 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.69 -144.77 16.07 Favored Glycine 0 N--CA 1.47 0.941 0 N-CA-C 119.698 2.639 . . . . 0.0 119.698 -163.534 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . 0.425 HD21 ' HA ' ' B' ' 124' ' ' ASP . 93.4 m-20 -72.96 159.86 33.02 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -165.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.3 p -133.05 177.28 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 130.387 3.475 . . . . 0.0 110.093 -171.185 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -155.76 132.79 10.67 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 119.666 1.121 . . . . 0.0 111.356 174.998 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.46 160.5 15.41 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.342 1.057 . . . . 0.0 113.776 176.283 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -92.08 177.2 6.24 Favored 'General case' 0 CA--C 1.552 1.041 0 C-N-CA 127.186 2.194 . . . . 0.0 112.663 170.293 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.74 -17.58 64.94 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 120.913 -1.117 . . . . 0.0 112.958 169.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.81 -27.26 63.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.081 0.952 . . . . 0.0 110.449 168.838 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.97 -4.5 65.52 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 117.96 -1.467 . . . . 0.0 114.439 -177.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.99 131.06 35.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 118.736 1.268 . . . . 0.0 110.917 168.782 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.16 124.63 44.35 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 165.892 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -79.16 143.51 35.37 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.706 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.09 130.53 72.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.686 166.625 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 8.6 m -150.77 82.97 1.34 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.857 1.263 . . . . 0.0 110.537 -175.142 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.6 mt -130.91 142.48 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.605 1.562 . . . . 0.0 111.007 -172.671 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -100.69 145.14 28.82 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.356 1.862 . . . . 0.0 107.176 168.653 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.973 0.909 . . . . 0.0 109.432 169.609 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.6 p -131.31 51.96 2.1 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.225 1.01 . . . . 0.0 112.263 179.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -152.47 34.82 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 122.736 1.255 . . . . 0.0 111.43 169.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.1 172.17 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 126.688 1.995 . . . . 0.0 111.329 -169.655 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -159.78 153.76 23.2 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 120.817 -1.177 . . . . 0.0 112.685 169.275 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.7 mp -82.72 58.91 4.48 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.641 -1.287 . . . . 0.0 110.345 176.377 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.9 t -89.11 141.1 28.8 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.071 171.417 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -77.1 47.83 2.66 Favored Glycine 0 N--CA 1.474 1.217 0 C-N-CA 126.23 1.871 . . . . 0.0 115.584 -168.443 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -139.15 -90.98 0.19 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.847 2.459 . . . . 0.0 107.784 -170.398 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -150.45 -4.88 0.33 Allowed 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 127.878 2.471 . . . . 0.0 112.275 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.5 t -69.34 -0.39 6.23 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.162 -1.586 . . . . 0.0 114.6 -174.979 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.5 7.5 pt 149.36 8.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 1 C-N-CA 135.667 5.587 . . . . 0.0 115.365 168.092 . . . . . . . . 3 2 . 1 . 026 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 48.9 mm -87.12 168.94 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 O-C-N 120.56 -1.337 . . . . 0.0 109.232 165.696 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.32 -33.39 2.02 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 117.849 1.899 . . . . 0.0 117.849 166.109 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 ptt85 -74.8 174.12 9.62 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 125.77 1.628 . . . . 0.0 112.043 -169.898 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -130.12 154.12 47.81 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.166 0.986 . . . . 0.0 109.699 -174.311 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' B' ' 46' ' ' HIS . 2.7 tm? -133.26 145.51 50.57 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 125.376 1.47 . . . . 0.0 111.505 -169.668 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.494 ' N ' HD13 ' B' ' 117' ' ' LEU . 6.7 p -128.14 135.76 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 126.194 1.797 . . . . 0.0 110.88 174.141 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 t -101.91 158.24 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 125.521 1.528 . . . . 0.0 108.392 169.858 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -128.21 153.25 47.12 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 127.799 2.44 . . . . 0.0 111.296 -173.115 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -75.32 -24.93 57.47 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.491 -178.819 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -100.54 171.16 7.9 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 119.704 1.138 . . . . 0.0 110.114 167.507 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -112.08 94.57 5.01 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 125.283 1.433 . . . . 0.0 111.925 -179.371 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.425 ' HA ' HD21 ' B' ' 86' ' ' ASN 0.267 25.5 t0 -152.97 146.92 25.36 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-O 123.561 1.648 . . . . 0.0 109.25 168.032 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -169.3 -52.27 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 130.467 3.507 . . . . 0.0 110.893 -178.245 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.585 ' H ' HD13 ' B' ' 126' ' ' LEU 0.338 0.0 OUTLIER -86.07 59.32 5.56 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 116.575 2.065 . . . . 0.0 116.575 -163.094 . . . . . . . . 4 4 . 1 . 026 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.44 -9.12 0.88 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 117.839 1.896 . . . . 0.0 117.839 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.3 ptmt -160.21 21.62 0.16 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 116.763 2.134 . . . . 0.0 116.763 -169.218 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.5 -19.38 78.95 Favored Glycine 0 N--CA 1.472 1.079 0 CA-C-N 120.26 1.391 . . . . 0.0 113.489 178.938 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -151.24 -42.24 0.02 OUTLIER Glycine 0 N--CA 1.468 0.83 0 N-CA-C 116.665 1.426 . . . . 0.0 116.665 -178.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -163.08 -165.31 1.08 Allowed 'General case' 0 CA--C 1.546 0.815 0 CA-C-N 120.201 2.0 . . . . 0.0 113.514 -173.448 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -49.27 -56.07 10.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.382 1.473 . . . . 0.0 110.876 169.043 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.23 -16.22 31.6 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 20.8 m -55.0 -31.79 61.28 Favored 'General case' 0 N--CA 1.471 0.594 0 O-C-N 120.091 -1.631 . . . . 0.0 112.702 168.527 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.264 2.8 t -97.44 -8.49 29.23 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 174.08 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -87.68 -60.95 1.83 Allowed 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.289 -1.507 . . . . 0.0 111.202 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 28.5 p -102.87 -24.92 13.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 126.018 1.727 . . . . 0.0 114.413 -177.223 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.55 -22.87 35.95 Favored Glycine 0 C--O 1.213 -1.159 0 CA-C-O 117.93 -1.483 . . . . 0.0 110.075 -166.26 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 33.2 t30 56.83 19.11 4.22 Favored 'General case' 0 CA--C 1.548 0.875 0 CA-C-N 119.351 1.576 . . . . 0.0 112.387 173.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.76 -23.16 2.51 Favored 'General case' 0 CA--C 1.557 1.226 0 C-N-CA 129.079 2.952 . . . . 0.0 115.057 -171.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 93.94 -153.19 21.07 Favored Glycine 0 C--N 1.343 0.924 0 C-N-CA 126.692 2.091 . . . . 0.0 114.414 174.765 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.03 151.88 2.45 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.711 2.004 . . . . 0.0 113.481 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 15.1 mtp-105 -66.24 166.88 11.2 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.9 -1.125 . . . . 0.0 113.474 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tp -150.01 -152.6 0.45 Allowed 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 128.727 2.811 . . . . 0.0 106.911 166.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.29 178.3 7.23 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -178.668 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.5 p -158.16 159.18 35.89 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.107 1.363 . . . . 0.0 111.459 -173.28 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.38 170.52 34.53 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.696 1.617 . . . . 0.0 113.416 176.086 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.54 147.41 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.639 1.176 . . . . 0.0 110.007 179.346 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.2 mm -93.47 76.68 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.324 0.65 . . . . 0.0 110.042 -178.71 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.57 161.88 32.7 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 123.652 0.644 . . . . 0.0 112.225 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.48 ' N ' HD12 ' B' ' 151' ' ' ILE . 1.1 mp -75.05 134.87 28.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -175.452 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.451 ' HB1' ' HE3' ' B' ' 3' ' ' LYS . . . -108.82 35.13 3.34 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.461 1.504 . . . . 0.0 113.485 -168.735 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 . . . . . 0 C--N 1.324 -0.518 0 C-N-CA 126.633 1.973 . . . . 0.0 110.691 -177.31 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m . . . . . 0 C--O 1.217 -0.648 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 ttmm -120.09 128.11 53.16 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -169.415 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -108.2 171.77 7.22 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.927 0.891 . . . . 0.0 112.921 169.407 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.417 HG11 ' HA ' ' B' ' 52' ' ' ASP . 0.3 OUTLIER -131.43 155.01 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 129.72 3.208 . . . . 0.0 106.908 165.97 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.25 114.81 19.45 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.738 1.154 . . . . 0.0 109.559 166.742 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' HG22 ' B' ' 54' ' ' THR . 8.7 t -88.57 76.42 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 125.185 1.394 . . . . 0.0 108.938 -171.91 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.47 103.96 9.75 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.034 -175.018 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 ttpp -160.92 132.16 5.53 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 123.274 0.63 . . . . 0.0 112.369 166.08 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.15 -95.5 1.94 Allowed Glycine 0 C--N 1.333 0.384 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 168.074 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.31 -177.1 3.41 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.013 1.725 . . . . 0.0 107.974 174.007 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 61.69 -173.55 7.32 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.732 2.11 . . . . 0.0 117.05 168.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.54 4.41 7.1 Favored 'Trans proline' 0 CA--C 1.543 0.941 1 C-N-CA 126.347 4.698 . . . . 0.0 113.836 178.593 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 m -79.43 138.03 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 126.848 2.059 . . . . 0.0 111.045 175.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.77 169.23 19.5 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 122.238 1.018 . . . . 0.0 109.801 165.707 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -141.17 149.01 20.71 Favored Glycine 0 CA--C 1.499 -0.92 0 CA-C-N 113.379 -1.737 . . . . 0.0 110.078 164.245 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -130.27 112.01 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 172.189 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 mm -135.61 102.44 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 121.469 -0.77 . . . . 0.0 111.077 -174.118 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -72.34 157.28 37.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.165 170.204 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.515 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 58.1 m-85 -137.22 98.71 3.8 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 168.867 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -89.93 108.02 19.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 122.12 0.962 . . . . 0.0 109.75 172.291 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -101.58 149.03 24.53 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 166.104 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -13.53 10.57 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.3 1.44 . . . . 0.0 112.253 -175.36 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.37 -146.06 0.37 Allowed 'General case' 0 CA--C 1.556 1.203 0 C-N-CA 128.919 2.887 . . . . 0.0 108.017 173.236 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.2 p -139.68 -45.84 0.44 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 126.009 1.723 . . . . 0.0 108.294 166.647 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.9 m-80 -85.76 32.45 0.59 Allowed 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.057 1.743 . . . . 0.0 112.722 172.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.91 -175.06 13.91 Favored Glycine 0 CA--C 1.538 1.499 0 C-N-CA 125.726 1.632 . . . . 0.0 113.002 177.404 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -76.54 170.99 18.87 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 123.82 3.013 . . . . 0.0 111.507 177.909 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.8 t -132.99 123.62 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.971 0.908 . . . . 0.0 110.31 -170.669 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.0 tttm -87.13 114.33 23.65 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 122.909 1.338 . . . . 0.0 112.621 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 t -95.25 131.1 42.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 125.941 1.696 . . . . 0.0 108.628 -176.646 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -153.38 160.3 42.61 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 173.653 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.08 -149.37 18.85 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 125.151 1.358 . . . . 0.0 111.521 -173.047 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 83.8 p -157.62 159.09 36.66 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 114.318 1.229 . . . . 0.0 114.318 -173.661 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -121.56 117.5 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.461 1.505 . . . . 0.0 107.331 171.863 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -128.88 151.82 49.2 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 126.146 1.779 . . . . 0.0 112.052 -165.165 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.58 10.88 82.73 Favored Glycine 0 CA--C 1.531 1.063 0 CA-C-O 118.773 -1.015 . . . . 0.0 113.785 -178.693 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.26 169.08 10.02 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.94 1.296 . . . . 0.0 111.0 173.332 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 t -69.83 160.13 32.33 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.77 1.228 . . . . 0.0 110.257 173.603 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.94 168.76 0.6 Allowed 'General case' 0 CA--C 1.55 0.961 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 178.611 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.6 -175.26 50.68 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.693 1.14 . . . . 0.0 113.472 170.141 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.465 ' H ' ' CD1' ' A' ' 42' ' ' LEU . 5.2 mp -56.14 147.04 21.37 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.728 2.411 . . . . 0.0 111.324 178.628 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -142.98 116.01 8.86 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 126.206 1.802 . . . . 0.0 110.187 176.004 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.53 151.45 14.35 Favored Glycine 0 N--CA 1.483 1.814 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.89 173.913 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -151.02 105.53 3.25 Favored 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 118.984 1.392 . . . . 0.0 111.089 -165.519 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.4 ' O ' HD12 ' A' ' 117' ' ' LEU . 11.8 m80 -145.57 160.18 42.03 Favored 'General case' 0 N--CA 1.471 0.597 0 O-C-N 119.431 -2.043 . . . . 0.0 113.909 -164.584 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . 0.288 0.4 OUTLIER -129.64 120.71 51.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 122.635 1.207 . . . . 0.0 111.489 -171.854 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -79.29 137.19 37.26 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.91 2.084 . . . . 0.0 109.785 175.829 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.0 pm0 -70.44 16.09 0.08 Allowed 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -178.232 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -126.75 144.23 51.01 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 124.425 1.09 . . . . 0.0 108.572 168.846 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.26 27.57 5.05 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.295 1.426 . . . . 0.0 111.539 168.38 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -86.94 173.1 9.55 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.432 1.493 . . . . 0.0 109.911 173.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.64 9.15 4.11 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 118.01 2.596 . . . . 0.0 118.01 164.561 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.4 t -61.3 71.32 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.244 2.217 . . . . 0.0 116.504 -168.57 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -141.84 -63.5 0.44 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 125.483 1.513 . . . . 0.0 112.804 168.068 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 166.59 -153.77 23.77 Favored Glycine 0 N--CA 1.47 0.911 0 O-C-N 120.761 -1.212 . . . . 0.0 112.52 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -56.11 -9.52 0.65 Allowed 'General case' 0 CA--C 1.552 1.022 0 N-CA-C 116.474 2.027 . . . . 0.0 116.474 -172.415 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 t -81.46 0.52 37.36 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.927 1.691 . . . . 0.0 113.256 173.725 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 60.9 m -159.39 178.42 9.94 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.564 1.945 . . . . 0.0 110.218 179.176 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 85.68 -125.73 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.502 1.921 . . . . 0.0 113.007 172.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 170.73 -153.9 21.83 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 125.677 1.608 . . . . 0.0 111.765 -169.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -109.32 57.58 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 123.619 2.879 . . . . 0.0 112.453 -174.547 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 61.95 87.83 0.09 Allowed 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.229 1.411 . . . . 0.0 108.338 -177.415 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -46.36 152.05 0.47 Allowed 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 113.15 -1.841 . . . . 0.0 111.447 -178.686 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.47 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.8 p-10 -136.47 101.06 10.06 Favored Pre-proline 0 CA--C 1.551 1.018 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -164.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.93 -27.78 3.64 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.25 1.967 . . . . 0.0 111.072 -176.171 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.25 -6.04 55.73 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.526 1.53 . . . . 0.0 111.683 167.761 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.7 t 62.69 48.16 4.4 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.98 2.112 . . . . 0.0 111.487 178.252 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.47 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 11.9 mtp180 -99.02 170.63 8.58 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 124.475 1.11 . . . . 0.0 112.922 -172.54 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.6 mmtt -84.92 174.17 10.01 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.89 1.676 . . . . 0.0 108.614 163.55 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 62.8 t60 -70.6 149.87 46.63 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 120.782 -1.199 . . . . 0.0 112.066 170.301 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -174.51 -165.2 30.61 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 124.071 0.843 . . . . 0.0 114.035 176.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.481 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.92 -100.45 0.43 Allowed Glycine 0 CA--C 1.537 1.425 0 CA-C-O 117.571 -1.683 . . . . 0.0 116.811 170.001 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.51 -19.53 23.44 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 CA-C-N 122.093 2.947 . . . . 0.0 116.377 -168.928 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.9 3.16 4.88 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.24 2.216 . . . . 0.0 112.594 176.06 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.481 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 10.3 t70 -145.88 155.7 43.06 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -164.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.57 -7.87 49.01 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 128.363 2.665 . . . . 0.0 113.402 -168.943 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -78.04 -106.39 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 118.696 0.68 . . . . 0.0 109.847 172.769 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.9 ttt180 71.58 101.01 0.07 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.166 1.386 . . . . 0.0 110.359 -172.392 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -51.8 152.67 2.82 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.789 -1.194 . . . . 0.0 111.298 166.527 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 19.3 m -52.88 -33.89 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-N 120.571 1.532 . . . . 0.0 112.785 -175.166 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.75 102.24 1.56 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 124.696 1.141 . . . . 0.0 110.639 166.015 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -160.06 116.22 2.43 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.258 2.223 . . . . 0.0 108.775 177.524 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 92.0 mt -103.01 176.32 5.19 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.577 1.08 . . . . 0.0 108.973 168.148 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.15 173.81 54.97 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 167.342 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -74.65 151.49 39.3 Favored 'General case' 0 CA--C 1.55 0.973 0 N-CA-C 115.09 1.515 . . . . 0.0 115.09 -171.544 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.2 m -102.88 117.23 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 127.974 2.51 . . . . 0.0 109.732 179.07 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.9 m -96.82 119.45 35.31 Favored 'General case' 0 N--CA 1.478 0.948 0 O-C-N 120.531 -1.356 . . . . 0.0 111.234 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.39 140.13 37.52 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -76.37 168.66 19.67 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.076 1.751 . . . . 0.0 111.798 170.62 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.8 pttm -45.74 -28.35 1.02 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.136 2.574 . . . . 0.0 115.135 170.822 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.73 -1.56 56.41 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.4 1.48 . . . . 0.0 111.818 -177.505 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.9 24.87 39.88 Favored Glycine 0 C--N 1.342 0.901 0 C-N-CA 125.274 1.416 . . . . 0.0 114.024 177.636 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.6 p -129.91 129.11 65.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 CA-C-N 118.497 1.148 . . . . 0.0 113.902 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.67 129.54 39.94 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.426 1.09 . . . . 0.0 108.129 166.076 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -79.16 151.02 31.53 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 167.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.6 t -135.04 123.87 41.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 CA-C-N 112.444 -2.162 . . . . 0.0 109.199 167.623 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.9 p -155.51 50.2 0.55 Allowed 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 124.025 1.869 . . . . 0.0 111.357 -177.311 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -103.45 170.44 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 127.603 2.361 . . . . 0.0 112.324 -166.48 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.94 121.48 20.57 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 165.622 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -98.17 137.17 37.32 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.478 0.656 . . . . 0.0 109.251 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.4 p -118.24 53.47 0.97 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.932 -1.031 . . . . 0.0 112.253 -178.709 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 13.8 p -155.18 -36.78 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.06 0.944 . . . . 0.0 112.629 168.71 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.71 168.97 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 120.115 1.325 . . . . 0.0 110.573 169.016 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 26.5 p -153.6 162.21 41.47 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 124.381 1.072 . . . . 0.0 111.335 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -83.94 66.39 9.13 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-O 122.185 0.993 . . . . 0.0 109.077 173.971 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 73.5 m -112.45 6.32 18.54 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.737 1.615 . . . . 0.0 113.713 -172.523 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.03 -110.91 3.19 Favored Glycine 0 C--N 1.342 0.871 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 175.4 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -62.49 -35.88 80.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 123.16 1.457 . . . . 0.0 112.776 -176.087 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -89.06 -1.79 58.26 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 114.389 -1.278 . . . . 0.0 111.603 -171.081 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.0 m -168.16 -103.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.218 1.807 . . . . 0.0 113.783 170.137 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.2 pt -124.09 164.35 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 120.972 1.714 . . . . 0.0 112.311 -176.78 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 105.64 121.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.234 1 C-N-CA 133.859 4.864 . . . . 0.0 108.305 -167.832 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.17 32.86 85.59 Favored Glycine 0 CA--C 1.527 0.826 0 CA-C-O 119.057 -0.857 . . . . 0.0 113.179 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.63 179.5 3.95 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 127.317 2.247 . . . . 0.0 108.323 173.577 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 21.1 m -130.6 119.35 22.36 Favored 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 121.944 2.157 . . . . 0.0 111.592 -179.078 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.4 HD12 ' O ' ' A' ' 46' ' ' HIS . 22.6 tp -92.35 119.25 31.73 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.554 1.542 . . . . 0.0 110.671 177.146 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.9 p -96.42 141.07 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.503 1.921 . . . . 0.0 111.111 174.647 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.9 p -118.08 137.34 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 122.046 0.927 . . . . 0.0 111.635 171.06 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 87.5 m-70 -99.72 161.95 13.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 125.231 1.412 . . . . 0.0 113.23 -170.128 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -83.7 -23.81 31.53 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -169.596 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -142.65 -174.85 4.27 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.737 0.815 . . . . 0.0 113.032 176.297 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.66 143.7 9.17 Favored 'General case' 0 C--N 1.341 0.206 0 C-N-CA 126.013 1.725 . . . . 0.0 111.215 172.163 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.99 149.6 24.07 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.789 1.636 . . . . 0.0 112.225 173.717 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -76.24 -10.05 59.11 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.762 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.2 mt 48.01 32.95 3.13 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 128.229 2.612 . . . . 0.0 113.235 177.175 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 165.63 -61.49 0.23 Allowed Glycine 0 N--CA 1.467 0.702 0 CA-C-N 120.492 1.496 . . . . 0.0 115.165 175.3 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -157.95 98.49 1.62 Allowed 'General case' 0 N--CA 1.428 -1.542 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 177.688 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.572 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -76.56 -115.12 0.14 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 126.222 1.868 . . . . 0.0 109.505 165.084 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -142.86 9.0 2.28 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 119.585 2.594 . . . . 0.0 119.585 -168.795 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -145.22 -169.38 3.19 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 120.651 2.226 . . . . 0.0 112.308 176.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -62.18 -49.87 74.07 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 121.173 1.806 . . . . 0.0 112.271 178.24 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.38 -22.85 63.8 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 123.439 0.696 . . . . 0.0 112.007 -177.65 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.572 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 25.2 m -64.37 -5.4 5.14 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.954 1.465 . . . . 0.0 114.954 168.193 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -122.35 -20.11 6.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.342 1.457 . . . . 0.0 112.029 172.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 85.7 mttt -84.2 -69.85 0.61 Allowed 'General case' 0 CA--C 1.547 0.839 0 O-C-N 120.983 -1.073 . . . . 0.0 111.752 172.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -92.11 -13.45 30.74 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 177.646 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 83.5 21.72 57.71 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 119.454 1.024 . . . . 0.0 110.855 -165.716 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 52.15 36.23 18.62 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.596 1.958 . . . . 0.0 113.7 176.848 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.1 40.61 0.08 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 116.136 1.902 . . . . 0.0 116.136 -168.799 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.91 -64.06 1.95 Allowed Glycine 0 CA--C 1.528 0.865 0 C-N-CA 126.53 2.014 . . . . 0.0 112.469 -171.543 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 29.9 t -177.07 -150.45 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 C-N-CA 126.809 2.044 . . . . 0.0 109.547 -171.262 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.439 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -156.83 104.57 2.14 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.959 2.104 . . . . 0.0 112.479 -176.77 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.2 pp -72.85 -35.57 67.25 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.222 1.409 . . . . 0.0 114.653 -176.613 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.39 172.85 9.3 Favored 'General case' 0 C--O 1.239 0.54 0 C-N-CA 124.904 1.282 . . . . 0.0 111.767 -175.77 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.0 p -156.43 165.72 35.51 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 127.225 2.21 . . . . 0.0 111.048 175.15 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.45 147.28 15.56 Favored Glycine 0 C--N 1.337 0.617 0 C-N-CA 124.58 1.086 . . . . 0.0 114.036 -175.042 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -73.12 141.37 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.051 0.541 . . . . 0.0 110.124 175.017 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.5 mp -77.78 80.0 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.535 1.134 . . . . 0.0 109.506 169.384 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -79.36 171.34 54.83 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.084 1.325 . . . . 0.0 112.485 172.472 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.464 ' H ' ' HA3' ' B' ' 51' ' ' GLY . 2.4 mp -102.05 131.25 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 126.142 1.777 . . . . 0.0 111.435 -169.478 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.62 37.84 4.25 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.975 2.11 . . . . 0.0 110.706 -179.662 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.549 0 C-N-CA 129.353 3.061 . . . . 0.0 115.072 -167.525 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 121.786 0.803 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.93 106.22 4.05 Favored 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 124.428 1.091 . . . . 0.0 109.359 169.778 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 118.22 21.39 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 170.058 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.04 168.85 18.66 Favored 'General case' 0 CA--C 1.54 0.568 0 O-C-N 120.641 -1.287 . . . . 0.0 108.51 163.576 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.67 155.35 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.8 0.81 . . . . 0.0 113.026 -166.388 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.24 143.49 25.0 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.389 2.276 . . . . 0.0 107.386 165.757 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.1 m -113.05 117.79 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 168.098 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.89 125.99 33.74 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.064 0.946 . . . . 0.0 109.863 -168.848 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -146.2 177.08 9.26 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.354 1.062 . . . . 0.0 113.507 170.651 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.12 -65.97 0.25 Allowed Glycine 0 C--N 1.33 0.201 0 C-N-CA 126.497 1.999 . . . . 0.0 109.024 -176.666 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -103.09 85.01 2.43 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.966 2.106 . . . . 0.0 112.797 -167.165 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.06 -98.43 0.01 OUTLIER Glycine 0 CA--C 1.537 1.467 0 C-N-CA 127.071 2.272 . . . . 0.0 115.98 167.785 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -77.06 -8.69 17.77 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.617 2.878 . . . . 0.0 115.433 -173.549 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -98.31 138.82 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 CA-C-N 121.061 1.755 . . . . 0.0 110.866 176.14 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.5 pm0 -160.16 166.07 30.43 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 125.43 1.492 . . . . 0.0 110.801 171.255 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.31 175.61 33.94 Favored Glycine 0 CA--C 1.507 -0.422 0 C-N-CA 123.283 0.468 . . . . 0.0 113.398 169.227 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.02 146.62 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 123.445 0.698 . . . . 0.0 110.114 169.561 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.17 155.2 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 123.807 0.843 . . . . 0.0 110.108 167.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -127.67 148.32 50.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.8 1.24 . . . . 0.0 109.669 167.735 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -128.16 97.79 4.88 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.369 1.468 . . . . 0.0 110.395 178.563 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -81.36 106.53 13.4 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.367 1.067 . . . . 0.0 113.62 -176.148 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -101.7 140.57 35.82 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 165.298 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.33 -13.47 9.28 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 125.933 1.693 . . . . 0.0 112.361 169.782 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -97.45 -145.01 0.3 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 131.019 3.728 . . . . 0.0 109.772 173.089 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 57.7 m -163.61 40.57 0.09 Allowed 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 127.883 2.473 . . . . 0.0 107.772 168.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 p30 178.02 -42.51 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 126.682 1.993 . . . . 0.0 112.436 -167.133 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.86 -168.46 21.74 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 125.333 1.444 . . . . 0.0 113.435 178.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.42 172.43 9.07 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 124.381 3.387 . . . . 0.0 114.554 -169.741 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 65.2 t -140.95 133.59 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 123.994 0.918 . . . . 0.0 111.391 177.954 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 mttp -80.18 116.95 20.56 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.285 0.564 . . . . 0.0 110.449 169.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.1 t -98.95 114.49 36.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 125.547 1.539 . . . . 0.0 109.099 170.057 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.3 p90 -137.28 154.87 50.01 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 123.529 0.731 . . . . 0.0 111.676 169.887 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 159.92 166.8 19.51 Favored Glycine 0 C--N 1.336 0.576 0 N-CA-C 114.82 0.688 . . . . 0.0 114.82 177.806 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 13.0 p -132.52 126.69 33.5 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.278 1.031 . . . . 0.0 111.3 -170.072 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.0 mm -112.77 125.38 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 124.984 1.314 . . . . 0.0 111.14 174.772 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -130.53 135.62 48.11 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 120.575 1.534 . . . . 0.0 112.737 -169.096 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.74 -4.48 10.79 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 126.197 1.856 . . . . 0.0 114.058 -176.494 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.516 HD13 ' H ' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -95.16 168.8 10.53 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.866 1.667 . . . . 0.0 111.724 170.464 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 m -69.36 152.77 44.55 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 127.18 2.192 . . . . 0.0 111.859 177.064 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . 0.422 ' HA ' ' HB3' ' B' ' 89' ' ' ALA . 9.6 pm0 -51.95 157.07 1.34 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.867 1.667 . . . . 0.0 113.52 169.257 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.73 177.56 43.96 Favored Glycine 0 CA--C 1.539 1.555 0 O-C-N 120.653 -1.279 . . . . 0.0 114.567 -176.614 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 147.58 21.32 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 128.035 2.534 . . . . 0.0 114.635 -176.071 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -144.51 130.45 19.35 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 127.068 2.147 . . . . 0.0 109.737 175.643 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.39 156.31 31.93 Favored Glycine 0 N--CA 1.476 1.305 0 C-N-CA 125.001 1.286 . . . . 0.0 113.694 -175.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -150.4 141.09 22.66 Favored 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 -170.025 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -145.43 115.9 7.6 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 118.234 -0.889 . . . . 0.0 113.303 -170.136 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . 0.578 HG12 ' HB3' ' B' ' 115' ' ' ARG . 0.3 OUTLIER -87.85 98.24 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 167.794 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.419 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 45.4 m170 -73.83 151.43 40.54 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 121.657 -0.652 . . . . 0.0 111.703 -170.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -49.93 126.19 13.64 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.017 1.727 . . . . 0.0 113.005 174.181 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 93.24 147.28 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 130.54 3.536 . . . . 0.0 114.443 172.128 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.464 ' HA3' ' H ' ' A' ' 151' ' ' ILE . . . -77.55 -7.5 87.14 Favored Glycine 0 CA--C 1.533 1.201 0 CA-C-O 117.558 -1.69 . . . . 0.0 113.096 168.257 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.417 ' HA ' HG11 ' A' ' 5' ' ' VAL . 14.4 t0 -86.39 132.1 34.04 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 120.313 2.056 . . . . 0.0 109.506 167.774 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' N ' ' B' ' 53' ' ' ASN 0.317 0.0 OUTLIER -157.85 28.33 0.27 Allowed 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 114.981 1.475 . . . . 0.0 114.981 179.243 . . . . . . . . 4 4 . 1 . 027 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 7' ' ' VAL . 17.9 p . . . . . 0 N--CA 1.464 0.268 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -168.4 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.549 0.936 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.07 167.23 27.09 Favored Glycine 0 CA--C 1.542 1.722 0 C-N-CA 125.174 1.369 . . . . 0.0 113.758 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . 0.419 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 59.9 Cg_endo -64.74 89.95 0.18 Allowed 'Trans proline' 0 C--N 1.354 0.824 1 C-N-CA 125.881 4.387 . . . . 0.0 112.248 -170.097 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.379 0.1 OUTLIER 47.94 59.67 4.06 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 127.167 2.187 . . . . 0.0 113.79 175.85 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -47.72 129.88 14.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 111.884 -2.417 . . . . 0.0 109.541 168.034 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -110.21 66.33 0.44 Allowed Pre-proline 0 CA--C 1.549 0.931 0 C-N-CA 125.964 1.706 . . . . 0.0 114.823 -167.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -64.16 -21.04 67.84 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.002 2.468 . . . . 0.0 116.045 -169.417 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.38 -4.44 48.19 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.795 0.838 . . . . 0.0 112.703 172.488 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.0 t 67.36 46.99 1.34 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 128.691 2.797 . . . . 0.0 110.513 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.8 mtm-85 -109.5 167.1 10.38 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.059 -177.658 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -85.85 176.84 7.87 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 127.657 2.383 . . . . 0.0 108.175 167.016 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -62.63 175.21 0.84 Allowed 'General case' 0 CA--C 1.544 0.745 0 O-C-N 121.336 -0.852 . . . . 0.0 112.812 173.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.68 -149.79 20.75 Favored Glycine 0 C--N 1.339 0.718 0 N-CA-C 115.641 1.016 . . . . 0.0 115.641 170.386 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.86 -117.3 2.17 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 125.727 1.632 . . . . 0.0 112.755 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -65.01 -11.37 29.5 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.786 2.991 . . . . 0.0 116.075 -169.305 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.53 -3.13 10.92 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 119.534 1.061 . . . . 0.0 113.145 168.737 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -152.17 98.03 2.37 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -166.783 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 63.9 mm-40 -39.72 -4.99 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 131.32 3.848 . . . . 0.0 118.47 171.316 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -74.0 -75.95 0.14 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 121.021 1.737 . . . . 0.0 110.116 170.522 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.254 0.0 OUTLIER 52.76 107.02 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 127.326 2.251 . . . . 0.0 113.869 -177.595 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -54.53 143.79 23.3 Favored 'General case' 0 CA--C 1.552 1.028 0 O-C-N 119.631 -1.918 . . . . 0.0 110.525 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 96.9 t -35.36 -59.26 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -168.123 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.78 18.71 16.68 Favored Glycine 0 N--CA 1.468 0.801 0 CA-C-O 119.335 -0.703 . . . . 0.0 112.989 176.831 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.46 89.68 2.88 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-N 119.526 1.663 . . . . 0.0 111.775 -167.633 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.11 163.35 37.71 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 114.634 -1.166 . . . . 0.0 113.578 -167.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 78.25 170.37 36.47 Favored Glycine 0 N--CA 1.472 1.044 0 N-CA-C 115.274 0.87 . . . . 0.0 115.274 168.46 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . 0.446 HD21 ' HB2' ' B' ' 124' ' ' ASP . 1.3 m-80 -134.48 149.54 50.73 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.908 1.283 . . . . 0.0 109.969 174.827 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.5 m -112.53 129.31 68.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.884 1.674 . . . . 0.0 109.204 169.505 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.7 m -113.15 133.81 54.86 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 121.24 -0.913 . . . . 0.0 109.903 -170.119 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.422 ' HB3' ' HA ' ' B' ' 40' ' ' GLU . . . -88.15 137.3 32.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.711 1.204 . . . . 0.0 113.522 -178.212 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.86 -59.25 2.86 Favored 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -168.212 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 172.81 -40.88 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 128.405 2.682 . . . . 0.0 110.731 -166.047 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -78.25 13.2 1.58 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 125.877 1.671 . . . . 0.0 112.281 174.154 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.77 25.56 70.57 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-O 118.932 -0.927 . . . . 0.0 113.38 -177.242 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' B' ' 89' ' ' ALA . 7.4 p -105.96 109.52 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 126.338 1.855 . . . . 0.0 110.991 176.155 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -79.28 108.84 13.08 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 168.175 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -110.53 159.04 17.88 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 122.313 1.054 . . . . 0.0 112.273 -176.412 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -149.6 148.0 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 CA-C-N 113.62 -1.627 . . . . 0.0 115.302 176.91 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -157.77 98.61 1.65 Allowed 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 124.2 1.0 . . . . 0.0 112.306 169.687 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 15.2 mt -139.7 152.3 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 127.522 2.329 . . . . 0.0 110.876 -172.746 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -117.53 127.23 53.78 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 165.855 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -117.28 146.49 43.28 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.517 1.527 . . . . 0.0 111.049 176.097 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 51.31 0.95 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.495 0.718 . . . . 0.0 112.913 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 47.2 t -136.39 -50.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.252 1.421 . . . . 0.0 109.635 175.336 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.84 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 CA-C-N 119.128 0.877 . . . . 0.0 111.747 174.656 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.88 161.66 39.67 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 119.888 -1.758 . . . . 0.0 111.251 -178.453 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.83 58.46 1.89 Allowed 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.88 1.324 . . . . 0.0 110.602 177.257 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.31 160.6 20.67 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 124.544 1.137 . . . . 0.0 108.8 168.128 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.25 -59.0 10.15 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 119.612 2.605 . . . . 0.0 119.612 -163.21 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -148.94 34.87 0.75 Allowed 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 122.862 1.315 . . . . 0.0 110.745 -172.142 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -158.01 4.08 0.12 Allowed 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 114.957 1.466 . . . . 0.0 114.957 -168.759 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 10.6 t -133.28 -91.21 0.37 Allowed 'General case' 0 N--CA 1.48 1.031 0 O-C-N 119.984 -1.698 . . . . 0.0 109.634 -178.313 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.283 5.4 pt -120.26 -14.66 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-N 121.185 1.811 . . . . 0.0 115.696 166.861 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm -82.75 152.64 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 161.122 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.05 41.71 86.58 Favored Glycine 0 N--CA 1.467 0.703 0 C-N-CA 124.103 0.858 . . . . 0.0 112.401 -176.446 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . 0.578 ' HB3' HG12 ' B' ' 47' ' ' VAL . 1.3 mpt_? -144.88 171.16 14.82 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 127.242 2.217 . . . . 0.0 109.004 172.17 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.5 t -139.42 122.66 16.98 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.873 -1.142 . . . . 0.0 110.979 -177.694 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 39.8 tp -92.07 108.87 20.25 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -169.464 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.8 p -90.62 142.35 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 125.32 1.448 . . . . 0.0 110.117 168.136 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -120.66 146.09 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.458 0.646 . . . . 0.0 111.316 172.012 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . 0.41 ' HA ' ' HA ' ' B' ' 143' ' ' ARG . 92.0 m-70 -105.63 141.37 37.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.56 1.544 . . . . 0.0 114.369 -168.728 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.317 0.2 OUTLIER -72.03 -18.39 61.96 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 120.841 -1.162 . . . . 0.0 112.037 178.24 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mttp -104.29 162.92 12.79 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 124.466 1.106 . . . . 0.0 112.759 168.067 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.0 165.08 9.44 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.308 1.843 . . . . 0.0 110.789 167.046 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . 0.54 ' HB3' ' H ' ' B' ' 126' ' ' LEU . 12.4 m-20 -95.2 158.9 15.26 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 122.126 0.965 . . . . 0.0 113.177 169.712 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.34 -7.9 50.2 Favored 'General case' 0 CA--C 1.557 1.22 0 CA-C-N 113.715 -1.584 . . . . 0.0 112.561 167.026 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.54 ' H ' ' HB3' ' B' ' 124' ' ' ASP . 96.3 mt 33.11 44.91 0.06 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 129.543 3.137 . . . . 0.0 114.068 -174.737 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.67 -52.38 0.83 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 115.854 1.101 . . . . 0.0 115.854 168.773 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -155.99 80.94 1.0 Allowed 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 117.046 2.239 . . . . 0.0 117.046 -169.22 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB3' ' B' ' 134' ' ' SER . . . -80.2 -115.02 0.29 Allowed Glycine 0 CA--C 1.524 0.625 0 C-N-CA 124.076 0.846 . . . . 0.0 111.009 166.389 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -137.9 11.72 3.65 Favored Glycine 0 N--CA 1.472 1.071 0 N-CA-C 116.893 1.517 . . . . 0.0 116.893 -169.338 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -144.12 174.84 10.52 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 119.819 1.81 . . . . 0.0 111.765 177.65 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . 0.526 ' CG ' ' HE3' ' B' ' 136' ' ' LYS . 3.2 tp10 -51.59 -64.27 0.87 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.463 1.505 . . . . 0.0 112.574 173.08 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -53.18 -31.15 41.29 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -179.638 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . 0.593 ' HB3' ' H ' ' B' ' 129' ' ' GLY . 26.1 m -49.69 -39.23 36.09 Favored 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.832 1.651 . . . . 0.0 113.969 170.773 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.76 -58.32 2.14 Favored 'General case' 0 CA--C 1.52 -0.205 0 C-N-CA 127.191 2.196 . . . . 0.0 110.294 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.526 ' HE3' ' CG ' ' B' ' 132' ' ' GLU . 22.2 ttpp -61.98 -39.62 92.81 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.1 1.36 . . . . 0.0 113.47 -172.197 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 p -109.4 -79.04 0.58 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 119.523 1.056 . . . . 0.0 110.179 174.079 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 170.71 11.9 0.02 OUTLIER Glycine 0 CA--C 1.54 1.65 1 C-N-CA 131.625 4.44 . . . . 0.0 115.389 -179.006 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 58.97 -35.67 0.06 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 128.831 2.852 . . . . 0.0 117.257 -170.688 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.79 -44.19 1.0 Allowed 'General case' 0 CA--C 1.554 1.113 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -165.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.57 -82.05 1.53 Allowed Glycine 0 C--N 1.341 0.829 0 N-CA-C 117.108 1.603 . . . . 0.0 117.108 164.264 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.3 t -80.78 151.62 28.69 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 123.817 0.847 . . . . 0.0 111.143 -169.083 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -144.49 159.53 42.62 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.728 1.149 . . . . 0.0 113.966 -168.539 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.22 -9.07 2.0 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 125.574 1.796 . . . . 0.0 115.524 -171.39 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -173.3 149.42 1.75 Allowed 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.354 1.062 . . . . 0.0 111.12 -177.657 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.0 t -148.31 150.83 34.32 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.673 1.589 . . . . 0.0 111.413 177.712 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.9 138.03 5.71 Favored Glycine 0 N--CA 1.474 1.191 0 CA-C-N 119.367 0.985 . . . . 0.0 114.55 175.192 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -74.28 144.54 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.351 0.66 . . . . 0.0 111.264 -179.644 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 13.3 mm -84.65 105.97 14.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 CA-C-O 121.635 0.731 . . . . 0.0 111.764 179.291 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.87 -175.73 19.06 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 125.07 1.319 . . . . 0.0 111.456 168.235 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 3.9 mp -122.32 132.49 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 O-C-N 121.105 -1.233 . . . . 0.0 110.772 -169.732 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 -7.93 16.21 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.056 1.343 . . . . 0.0 113.071 171.145 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.305 0.7 OUTLIER . . . . . 0 C--O 1.238 0.451 0 C-N-CA 126.358 1.863 . . . . 0.0 112.734 -179.443 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.107 0.956 . . . . 0.0 111.646 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -75.91 161.66 28.77 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -167.655 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.44 164.2 28.32 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.996 1.318 . . . . 0.0 110.255 168.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.547 ' CG1' ' HA ' ' B' ' 52' ' ' ASP . 7.3 p -132.61 129.56 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 124.612 1.165 . . . . 0.0 109.265 -179.027 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.81 110.72 15.44 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 120.994 -1.066 . . . . 0.0 109.179 177.869 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' B' ' 54' ' ' THR . 3.8 t -81.17 60.26 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 123.997 0.919 . . . . 0.0 111.563 -169.087 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.2 mp -76.72 116.87 17.78 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -167.779 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.422 ' CE ' HG12 ' A' ' 7' ' ' VAL . 34.4 mtmt -145.95 175.09 10.7 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 125.453 1.501 . . . . 0.0 111.896 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.92 -3.56 7.96 Favored Glycine 0 N--CA 1.474 1.233 0 N-CA-C 119.902 2.721 . . . . 0.0 119.902 166.832 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -137.29 83.11 1.97 Allowed 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 121.607 2.704 . . . . 0.0 110.163 178.827 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 38.44 -105.99 0.05 OUTLIER Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.522 2.011 . . . . 0.0 114.032 179.482 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -73.66 -5.84 17.73 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 124.279 3.32 . . . . 0.0 113.954 -176.25 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.4 ' C ' HE21 ' A' ' 15' ' ' GLN . 16.1 t -94.06 126.65 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 125.066 1.346 . . . . 0.0 111.699 -177.347 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.4 HE21 ' C ' ' A' ' 14' ' ' VAL . 1.2 mp0 -146.61 168.32 21.58 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 126.818 2.047 . . . . 0.0 108.01 169.457 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.23 170.91 24.82 Favored Glycine 0 CA--C 1.507 -0.413 0 CA-C-N 115.224 -0.898 . . . . 0.0 112.606 168.317 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 pt -150.34 53.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 114.195 -1.002 . . . . 0.0 111.169 -167.657 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.6 mm -80.35 112.23 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 O-C-N 120.984 -1.072 . . . . 0.0 110.348 -169.447 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.09 149.23 33.93 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 125.18 1.392 . . . . 0.0 111.491 175.969 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -134.51 116.24 14.85 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.299 1.84 . . . . 0.0 108.641 178.099 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -97.97 112.38 24.34 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.919 1.288 . . . . 0.0 112.255 175.329 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.4 tp60 -107.4 129.32 54.94 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 125.338 1.455 . . . . 0.0 109.226 177.968 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.53 -48.99 6.94 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.85 0.86 . . . . 0.0 111.447 178.784 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.63 136.46 51.67 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 127.302 2.241 . . . . 0.0 108.933 174.695 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 m -62.55 0.62 0.46 Allowed 'General case' 0 N--CA 1.48 1.05 0 N-CA-C 117.594 2.442 . . . . 0.0 117.594 -168.919 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.6 m-80 -114.22 -9.89 12.81 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 127.727 2.411 . . . . 0.0 113.9 178.033 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.6 -178.09 33.9 Favored Glycine 0 CA--C 1.537 1.424 0 CA-C-N 119.491 1.041 . . . . 0.0 115.053 -169.372 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -70.82 160.09 50.51 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.592 3.528 . . . . 0.0 110.898 -178.486 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.9 t -129.81 138.04 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.929 -0.482 . . . . 0.0 111.083 -170.68 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 100' ' ' GLU . 78.2 mttt -86.37 121.11 28.47 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 168.745 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.4 t -109.87 121.46 62.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.969 2.107 . . . . 0.0 108.692 -177.571 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -148.25 165.04 32.18 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 177.541 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.84 -173.37 14.67 Favored Glycine 0 N--CA 1.468 0.828 0 O-C-N 121.431 -0.793 . . . . 0.0 112.333 -178.741 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.85 167.32 21.98 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 -164.916 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -125.11 129.67 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 127.408 2.283 . . . . 0.0 108.421 171.709 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 44.8 pttt -115.33 159.01 21.59 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 120.316 1.416 . . . . 0.0 111.796 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.94 -6.97 73.4 Favored Glycine 0 N--CA 1.475 1.253 0 C-N-CA 125.371 1.462 . . . . 0.0 114.517 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 8.2 mp -62.86 153.17 34.07 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.872 2.069 . . . . 0.0 111.583 173.066 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -78.75 158.6 28.23 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 166.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -55.21 143.49 27.54 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.472 0.709 . . . . 0.0 112.87 175.607 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.09 -176.14 21.74 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 123.992 0.806 . . . . 0.0 114.84 177.44 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -68.29 139.19 55.93 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 127.775 2.43 . . . . 0.0 113.247 -171.124 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -145.45 120.37 9.99 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 128.565 2.746 . . . . 0.0 110.349 -174.711 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.98 22.88 Favored Glycine 0 N--CA 1.482 1.73 0 CA-C-O 117.095 -1.947 . . . . 0.0 112.716 -175.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.449 ' CB ' HG22 ' A' ' 119' ' ' VAL . 11.3 p90 -130.41 120.78 24.76 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.742 1.771 . . . . 0.0 113.478 177.522 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.414 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -154.3 156.11 36.37 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 115.195 -0.912 . . . . 0.0 112.843 -168.737 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 p -77.01 135.51 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 122.992 0.517 . . . . 0.0 109.844 171.305 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -112.48 171.97 7.2 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.895 1.678 . . . . 0.0 111.459 172.19 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -40.69 119.77 1.17 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.093 1.757 . . . . 0.0 113.178 -176.072 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -88.63 -164.43 1.13 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.846 2.458 . . . . 0.0 111.045 -177.328 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.71 -79.11 0.9 Allowed Glycine 0 C--N 1.334 0.464 0 N-CA-C 115.327 0.891 . . . . 0.0 115.327 167.076 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.517 ' HA ' HG11 ' B' ' 5' ' ' VAL . 44.9 p-10 -128.99 47.88 2.42 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 126.805 2.042 . . . . 0.0 115.19 -164.029 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 11.6 p30 -154.75 -30.73 0.11 Allowed 'General case' 0 N--CA 1.478 0.97 0 O-C-N 120.577 -1.327 . . . . 0.0 114.48 -172.68 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.342 12.4 t 21.15 35.88 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.6 1 C-N-CA 133.235 4.614 . . . . 0.0 120.408 173.251 . . . . . . . . 3 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -146.57 -2.78 0.64 Allowed 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 128.35 2.66 . . . . 0.0 111.101 169.652 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.42 -154.79 24.49 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.244 1.402 . . . . 0.0 114.0 175.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.2 t -46.86 -27.39 1.22 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.117 1.767 . . . . 0.0 115.263 -172.861 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 t -56.16 -14.51 2.77 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 126.715 2.006 . . . . 0.0 114.528 169.006 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.9 t -150.28 9.37 0.65 Allowed 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 127.044 2.138 . . . . 0.0 113.74 174.857 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -129.22 172.97 10.92 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 -168.167 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -97.95 -150.54 26.42 Favored Glycine 0 CA--C 1.546 2.021 0 C-N-CA 125.367 1.46 . . . . 0.0 115.383 -176.276 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -78.75 -170.03 0.91 Allowed 'Trans proline' 0 C--N 1.352 0.761 1 C-N-CA 127.831 5.688 . . . . 0.0 111.385 -179.651 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.417 ' CD2' ' HA ' ' A' ' 137' ' ' THR . 12.2 m170 -62.69 116.51 5.26 Favored 'General case' 0 N--CA 1.451 -0.412 0 O-C-N 121.97 -0.456 . . . . 0.0 111.029 177.743 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 146.94 44.46 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -174.383 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -110.32 79.69 1.72 Allowed Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.656 1.354 . . . . 0.0 114.656 -176.117 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.81 -12.55 14.83 Favored 'Trans proline' 0 CA--C 1.54 0.778 0 C-N-CA 123.14 2.56 . . . . 0.0 112.071 168.12 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.591 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 85.1 mt -137.61 2.82 2.48 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.163 1.785 . . . . 0.0 112.797 -168.394 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 25.2 m 58.96 70.18 0.67 Allowed 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 124.824 1.249 . . . . 0.0 113.092 168.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.591 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.2 ptp180 -155.48 177.42 11.39 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 119.874 3.287 . . . . 0.0 119.874 -163.99 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.416 ' HE2' ' N ' ' A' ' 70' ' ' LYS . 0.7 OUTLIER -78.81 178.03 8.24 Favored 'General case' 0 CA--C 1.549 0.907 0 CA-C-N 113.992 -1.458 . . . . 0.0 111.499 168.057 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.441 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 83.7 t60 -115.85 159.81 21.01 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -168.701 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.441 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 136.37 -102.81 0.42 Allowed Glycine 0 C--N 1.333 0.378 0 C-N-CA 125.586 1.565 . . . . 0.0 109.829 166.54 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.434 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 105.55 -36.92 4.08 Favored Glycine 0 CA--C 1.549 2.17 0 CA-C-O 117.448 -1.751 . . . . 0.0 116.558 -177.034 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -73.45 -19.98 21.3 Favored 'Trans proline' 0 C--N 1.358 1.043 0 CA-C-N 122.156 2.978 . . . . 0.0 113.863 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.19 -1.42 0.74 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 125.488 1.515 . . . . 0.0 112.267 -175.011 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.434 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -122.37 139.92 53.27 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 128.701 2.8 . . . . 0.0 107.192 -178.15 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -97.43 -9.24 27.66 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 128.052 2.541 . . . . 0.0 112.647 -174.456 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -82.57 -82.49 0.14 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.087 0.858 . . . . 0.0 109.196 -178.708 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 79.95 110.92 0.07 Allowed 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 126.604 1.961 . . . . 0.0 114.213 164.74 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 8.4 m80 -62.43 128.52 36.4 Favored 'General case' 0 CA--C 1.546 0.811 0 O-C-N 119.784 -1.823 . . . . 0.0 107.247 167.098 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.2 p -39.83 -36.6 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.215 0 N-CA-C 118.556 2.798 . . . . 0.0 118.556 -167.185 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.65 19.51 36.04 Favored Glycine 0 N--CA 1.477 1.386 0 CA-C-N 120.283 1.401 . . . . 0.0 115.39 178.687 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -78.31 140.35 38.81 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 119.223 1.512 . . . . 0.0 112.315 174.798 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.3 -176.36 3.12 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 163.224 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.52 -137.21 2.65 Favored Glycine 0 N--CA 1.468 0.831 0 O-C-N 121.322 -0.861 . . . . 0.0 111.861 174.808 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.6 p30 -100.59 147.39 26.0 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 122.006 -0.702 . . . . 0.0 112.008 168.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.47 149.84 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 127.572 2.349 . . . . 0.0 107.328 169.183 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.4 m -107.94 140.29 41.29 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.774 -0.579 . . . . 0.0 110.058 179.204 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.43 138.7 31.34 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.725 0.81 . . . . 0.0 111.944 171.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -80.37 147.61 30.97 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.468 1.507 . . . . 0.0 109.991 168.168 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -46.69 -22.18 0.27 Allowed 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 128.605 2.762 . . . . 0.0 116.641 174.329 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.13 0.27 19.48 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.177 1.391 . . . . 0.0 112.186 172.599 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.39 28.97 8.64 Favored Glycine 0 C--N 1.342 0.885 0 C-N-CA 125.987 1.756 . . . . 0.0 114.568 169.545 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.74 134.66 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 119.83 1.815 . . . . 0.0 115.282 -175.225 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.07 110.64 22.69 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 124.597 1.159 . . . . 0.0 107.907 166.334 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -106.71 137.9 43.88 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 122.356 1.074 . . . . 0.0 111.387 175.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -116.65 147.09 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-N 112.555 -2.111 . . . . 0.0 114.464 -168.649 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 82.8 p -158.93 90.1 0.97 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 178.655 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.3 mp -132.46 154.87 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 125.847 1.659 . . . . 0.0 112.968 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 30' ' ' LYS . 14.0 tt0 -117.76 115.99 26.13 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 164.039 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -117.57 114.54 23.57 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.327 1.061 . . . . 0.0 111.451 -171.375 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.6 p -84.03 54.91 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.472 -0.767 . . . . 0.0 111.686 -175.035 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.7 p -142.7 -17.55 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 114.75 1.389 . . . . 0.0 114.75 -169.813 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 pp -142.69 161.91 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.914 1.234 . . . . 0.0 112.622 -176.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.633 ' H ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -145.1 155.36 43.28 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 125.528 1.531 . . . . 0.0 113.601 -179.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.4 mp -83.67 56.94 3.83 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.781 1.632 . . . . 0.0 111.14 -175.449 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.03 -56.05 2.41 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.38 1.472 . . . . 0.0 110.543 178.365 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 143.38 -102.6 0.29 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 115.637 1.015 . . . . 0.0 115.637 169.572 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.81 -33.98 72.45 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 125.02 1.328 . . . . 0.0 111.873 175.002 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -80.02 1.0 29.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.036 1.734 . . . . 0.0 113.245 170.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.633 ' HB3' ' H ' ' A' ' 105' ' ' SER . 1.6 m -166.51 -90.42 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 169.846 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.385 7.6 pt -119.16 -99.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -179.015 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . 0.274 24.2 mm 37.11 -88.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 127.37 2.268 . . . . 0.0 113.794 -169.024 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.18 2.4 9.44 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-N 119.911 1.232 . . . . 0.0 115.091 175.612 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -79.38 152.1 30.58 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.571 1.685 . . . . 0.0 107.399 168.465 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.6 t -125.61 119.65 28.66 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 122.237 -0.289 . . . . 0.0 111.126 -168.871 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.72 130.3 34.71 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 124.461 1.104 . . . . 0.0 108.506 176.29 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.5 p -125.69 138.17 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.409 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.464 ' HB ' HD11 ' A' ' 144' ' ' LEU . 32.1 t -101.88 157.01 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 169.196 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.402 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 35.0 m-70 -130.22 146.68 51.86 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.619 1.568 . . . . 0.0 111.886 -167.372 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -71.56 -4.22 25.71 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.852 1.261 . . . . 0.0 114.044 -170.633 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 21.7 mmmt -127.68 160.36 31.91 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.061 1.345 . . . . 0.0 111.953 176.044 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.46 162.81 0.72 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.381 1.472 . . . . 0.0 112.505 169.719 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -111.27 130.18 55.74 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.302 1.841 . . . . 0.0 109.847 -175.336 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.265 1.0 OUTLIER -84.38 -8.15 59.08 Favored 'General case' 0 N--CA 1.48 1.04 0 N-CA-C 116.007 1.854 . . . . 0.0 116.007 -178.931 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 31.6 mt 63.73 42.18 6.43 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.576 1.95 . . . . 0.0 114.71 167.532 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 113.36 -38.11 3.34 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.447 1.022 . . . . 0.0 114.901 167.785 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.52 88.78 1.08 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 119.138 3.014 . . . . 0.0 119.138 169.62 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.4 -69.28 0.88 Allowed Glycine 0 CA--C 1.522 0.487 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 161.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.55 -107.94 3.25 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 117.714 1.846 . . . . 0.0 117.714 -168.557 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -102.56 -158.48 0.67 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.126 1.77 . . . . 0.0 113.861 -161.102 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.63 -47.68 49.63 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.133 0.573 . . . . 0.0 111.468 170.176 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -57.0 -34.28 67.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.007 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.456 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 24.0 p -52.43 -30.04 27.46 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 120.315 1.416 . . . . 0.0 112.04 170.109 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.2 p -97.55 -34.1 11.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 117.454 -1.26 . . . . 0.0 113.812 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -92.26 -46.23 7.82 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 114.651 1.352 . . . . 0.0 114.651 -176.835 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.417 ' HA ' ' CD2' ' A' ' 63' ' ' HIS . 17.9 p -90.81 -95.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.538 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 170.199 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -171.74 26.07 0.09 OUTLIER Glycine 0 CA--C 1.536 1.344 1 C-N-CA 132.568 4.89 . . . . 0.0 110.418 176.645 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.456 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 0.1 OUTLIER 56.59 -7.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 129.488 3.115 . . . . 0.0 116.714 -168.989 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.44 -38.36 43.02 Favored 'General case' 0 CA--C 1.55 0.98 0 CA-C-N 119.958 1.254 . . . . 0.0 113.939 -169.401 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.0 -116.03 4.22 Favored Glycine 0 N--CA 1.47 0.906 0 O-C-N 121.024 -1.048 . . . . 0.0 112.577 172.482 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 20.7 m -44.88 115.52 0.9 Allowed 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.524 1.53 . . . . 0.0 114.69 -169.924 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.63 160.5 31.46 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 121.41 -0.806 . . . . 0.0 112.482 172.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.464 HD11 ' HB ' ' A' ' 119' ' ' VAL 0.277 3.9 pp -142.28 -153.38 0.46 Allowed 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 126.829 2.052 . . . . 0.0 107.474 165.414 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.85 132.58 46.66 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 119.817 1.19 . . . . 0.0 113.269 -171.38 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.6 p -130.89 146.01 52.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 126.655 1.982 . . . . 0.0 111.63 -174.525 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.17 159.63 30.94 Favored Glycine 0 N--CA 1.472 1.038 0 N-CA-C 114.61 0.604 . . . . 0.0 114.61 179.362 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.59 161.85 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 C-N-CA 123.632 0.773 . . . . 0.0 109.676 168.409 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 27.8 mm -88.52 64.54 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 125.169 1.388 . . . . 0.0 110.096 178.773 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -68.82 139.49 33.08 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -174.06 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -77.76 144.78 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 O-C-N 121.719 -0.871 . . . . 0.0 111.16 -174.33 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.6 -17.16 10.03 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.162 2.185 . . . . 0.0 112.138 175.851 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 N--CA 1.468 0.468 0 C-N-CA 128.594 2.758 . . . . 0.0 113.428 175.27 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.502 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.2 m -78.14 106.09 9.8 Favored 'General case' 0 CA--C 1.51 -0.585 0 C-N-CA 124.766 1.226 . . . . 0.0 110.078 -172.763 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtmm -92.92 124.57 36.99 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 123.624 1.678 . . . . 0.0 113.305 178.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -115.66 175.37 5.56 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 127.256 2.222 . . . . 0.0 108.951 166.653 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.517 HG11 ' HA ' ' A' ' 52' ' ' ASP . 1.0 OUTLIER -148.16 146.74 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -177.611 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.13 119.89 36.1 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 163.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -124.78 115.25 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 175.848 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -103.91 147.12 27.71 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.041 1.336 . . . . 0.0 111.052 -179.025 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -140.3 142.88 35.64 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.095 1.358 . . . . 0.0 109.442 164.884 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.36 -117.17 3.52 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-O 122.96 1.311 . . . . 0.0 111.348 173.116 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.74 49.68 1.85 Allowed 'General case' 0 C--N 1.314 -0.974 0 C-N-CA 126.715 2.006 . . . . 0.0 113.529 -163.146 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -81.25 0.71 Allowed Glycine 0 CA--C 1.538 1.502 0 CA-C-O 117.289 -1.839 . . . . 0.0 113.115 -175.78 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -98.29 -2.3 1.13 Allowed 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 123.818 3.012 . . . . 0.0 115.183 -169.726 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -89.88 125.88 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-N 121.049 1.749 . . . . 0.0 110.08 178.174 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -130.61 166.99 19.47 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 124.039 0.935 . . . . 0.0 112.713 174.93 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -144.93 104.26 0.31 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 114.118 -1.401 . . . . 0.0 111.176 169.046 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.33 127.43 47.33 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.114 0 CA-C-N 118.781 1.291 . . . . 0.0 109.278 169.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 mm -131.85 112.44 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 126.46 1.904 . . . . 0.0 108.662 170.882 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -82.87 139.39 33.47 Favored 'General case' 0 CA--C 1.542 0.667 0 O-C-N 120.988 -1.07 . . . . 0.0 111.553 169.302 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -115.84 103.82 11.02 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.545 1.538 . . . . 0.0 110.541 179.308 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -108.51 108.13 18.93 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.592 1.157 . . . . 0.0 113.31 179.186 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -97.93 160.91 14.01 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.816 1.246 . . . . 0.0 110.603 171.304 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.78 -21.19 8.55 Favored 'General case' 0 CA--C 1.544 0.729 0 N-CA-C 114.214 1.19 . . . . 0.0 114.214 178.934 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.48 -165.72 1.08 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 127.739 2.416 . . . . 0.0 108.788 168.21 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.2 m -110.79 -11.28 14.4 Favored 'General case' 0 N--CA 1.48 1.026 0 O-C-N 120.612 -1.305 . . . . 0.0 112.118 167.001 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 m-80 -138.05 101.1 4.33 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.743 2.017 . . . . 0.0 107.893 168.712 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.73 -175.1 37.46 Favored Glycine 0 CA--C 1.539 1.565 0 C-N-CA 125.325 1.441 . . . . 0.0 111.77 -175.464 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.41 149.6 80.53 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 123.197 2.598 . . . . 0.0 115.853 -168.497 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 t -124.31 133.83 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.454 1.501 . . . . 0.0 109.749 -177.536 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -78.8 125.07 28.87 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.628 0.771 . . . . 0.0 109.507 170.086 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.65 77.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 C-N-CA 127.414 2.286 . . . . 0.0 106.201 -178.541 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -102.02 154.91 18.54 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.957 170.819 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 170.2 -177.37 43.52 Favored Glycine 0 C--O 1.227 -0.335 0 O-C-N 121.361 -0.837 . . . . 0.0 113.806 -176.72 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 76.7 p -155.41 127.99 7.91 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 124.129 0.972 . . . . 0.0 111.192 -179.691 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.443 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.7 mp -79.6 163.63 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 168.28 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 48.5 tttp -156.56 122.46 4.89 Favored 'General case' 0 N--CA 1.444 -0.739 0 O-C-N 120.851 -1.156 . . . . 0.0 108.588 165.247 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.52 1.03 12.32 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.277 1.894 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 62.0 mt -71.29 171.52 10.97 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 120.266 2.033 . . . . 0.0 110.046 168.648 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.0 t -91.42 158.04 16.73 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 163.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -58.88 147.07 35.25 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.412 1.085 . . . . 0.0 111.886 -178.75 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.04 -173.75 20.92 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 124.58 1.086 . . . . 0.0 112.266 -177.51 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.677 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.4 pt? -87.38 140.57 29.4 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.781 2.032 . . . . 0.0 112.016 -172.308 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -143.03 138.34 29.9 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.506 2.322 . . . . 0.0 108.141 -177.21 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -89.07 139.41 15.24 Favored Glycine 0 N--CA 1.473 1.139 0 CA-C-N 121.709 2.049 . . . . 0.0 111.031 -175.019 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -137.1 140.14 41.74 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.013 1.906 . . . . 0.0 111.963 170.407 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -149.9 154.99 39.24 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 121.126 -0.984 . . . . 0.0 111.843 -174.344 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.71 151.09 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 124.683 1.193 . . . . 0.0 109.67 -179.052 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -86.94 176.13 7.81 Favored 'General case' 0 CA--C 1.546 0.815 0 CA-C-O 122.556 1.169 . . . . 0.0 112.911 178.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -74.68 112.29 10.73 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 160.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.77 -162.71 0.16 Allowed 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.502 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -118.85 33.85 4.59 Favored Glycine 0 C--N 1.342 0.865 0 C-N-CA 128.019 2.723 . . . . 0.0 111.549 178.852 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.547 ' HA ' ' CG1' ' A' ' 5' ' ' VAL . 45.7 p-10 -116.91 69.29 0.75 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 124.048 1.88 . . . . 0.0 112.768 -169.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . 0.468 ' OD1' HG11 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -124.22 57.94 1.21 Allowed 'General case' 0 C--O 1.244 0.813 0 N-CA-C 116.62 2.081 . . . . 0.0 116.62 -160.939 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 7' ' ' VAL 0.278 13.2 p . . . . . 0 C--N 1.32 -0.712 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.603 -163.122 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.239 0.514 0 CA-C-O 121.08 0.467 . . . . 0.0 111.583 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.55 -115.57 2.37 Favored Glycine 0 CA--C 1.541 1.663 0 C-N-CA 127.21 2.338 . . . . 0.0 113.27 -178.213 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.72 157.21 62.78 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.983 3.789 . . . . 0.0 116.152 -164.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -38.59 101.28 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 127.011 2.124 . . . . 0.0 116.033 169.675 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -58.95 119.4 7.15 Favored 'General case' 0 CA--C 1.544 0.722 0 O-C-N 121.574 -0.704 . . . . 0.0 109.63 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -104.23 75.8 0.25 Allowed Pre-proline 0 CA--C 1.549 0.91 0 C-N-CA 127.335 2.254 . . . . 0.0 112.588 -172.445 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -56.61 -33.01 92.19 Favored 'Trans proline' 0 C--N 1.355 0.879 0 C-N-CA 123.532 2.822 . . . . 0.0 115.843 -168.934 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 97.3 mt -79.76 -3.35 47.24 Favored 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 175.413 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.9 t 65.73 52.23 1.33 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.734 2.014 . . . . 0.0 112.912 178.705 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 11.4 mtp180 -105.57 172.33 6.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 -169.313 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -81.09 172.69 13.39 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 122.769 0.428 . . . . 0.0 110.518 165.025 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -104.49 146.5 28.78 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -170.791 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.15 -140.6 11.95 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 113.641 -1.618 . . . . 0.0 113.323 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 149.91 -29.46 1.13 Allowed Glycine 0 CA--C 1.545 1.932 0 N-CA-C 118.399 2.12 . . . . 0.0 118.399 -179.432 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . 0.429 ' HG3' ' H ' ' B' ' 86' ' ' ASN . 60.0 Cg_endo -69.83 -4.56 14.32 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 122.766 3.283 . . . . 0.0 112.998 168.535 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.93 -37.18 0.15 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.976 1.31 . . . . 0.0 109.752 165.853 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -61.39 109.26 1.1 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 123.621 1.676 . . . . 0.0 112.49 -176.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . 0.444 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 4.0 pm0 -44.03 -30.71 0.77 Allowed 'General case' 0 C--N 1.318 -0.794 1 C-N-CA 134.058 4.943 . . . . 0.0 115.689 169.198 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -90.85 -62.96 1.34 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.936 0.789 . . . . 0.0 111.123 -176.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.269 32.1 ptt180 55.34 121.26 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 129.114 2.966 . . . . 0.0 115.346 -175.507 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -56.7 151.33 14.19 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 119.141 -2.224 . . . . 0.0 112.65 173.581 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 80.5 t -49.96 -56.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 CA-C-N 118.753 0.706 . . . . 0.0 110.603 -176.926 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.69 115.25 5.17 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 105.132 -3.187 . . . . 0.0 105.132 164.333 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -158.35 158.26 33.97 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.9 0.85 . . . . 0.0 112.675 172.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 83.1 mt -144.19 153.07 41.71 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.99 2.116 . . . . 0.0 106.439 168.335 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -113.06 -124.1 4.17 Favored Glycine 0 N--CA 1.471 1.026 0 C-N-CA 124.459 1.028 . . . . 0.0 111.046 172.443 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . 0.429 ' H ' ' HG3' ' B' ' 74' ' ' PRO . 6.7 m-80 -78.54 135.11 37.23 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -175.65 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.74 121.07 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 C-N-CA 131.082 3.753 . . . . 0.0 108.84 167.053 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.1 m -119.22 119.27 33.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.102 0.961 . . . . 0.0 110.963 -170.257 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.58 160.3 14.69 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.947 1.299 . . . . 0.0 113.972 -174.758 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -84.69 178.12 7.79 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 128.593 2.757 . . . . 0.0 112.633 170.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -20.85 65.81 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 120.865 -1.147 . . . . 0.0 113.2 169.387 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -73.77 -11.7 60.47 Favored 'General case' 0 CA--C 1.55 0.969 0 CA-C-O 121.791 0.805 . . . . 0.0 110.145 171.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.84 2.75 88.42 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.843 1.687 . . . . 0.0 113.462 176.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -84.11 134.67 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 125.491 1.517 . . . . 0.0 111.839 170.751 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.15 135.19 52.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 164.251 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -90.37 143.69 26.52 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.806 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 t -132.7 129.05 58.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 113.822 -1.535 . . . . 0.0 108.139 171.54 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.6 p -157.28 59.91 0.5 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 122.466 1.127 . . . . 0.0 112.506 -166.772 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.4 mt -120.2 158.03 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 124.991 1.316 . . . . 0.0 111.836 -171.264 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -138.56 127.7 24.14 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 166.598 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -144.48 145.29 31.79 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -167.637 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 72.2 p -104.47 52.37 0.75 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.06 1.344 . . . . 0.0 112.449 -168.85 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 31.3 m -149.74 6.31 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 115.434 1.642 . . . . 0.0 115.434 -169.508 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.03 172.01 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 125.518 1.527 . . . . 0.0 110.645 -176.288 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 88.0 p -157.26 160.73 38.92 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.717 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.02 51.7 1.13 Allowed 'General case' 0 CA--C 1.54 0.586 0 O-C-N 121.631 -0.668 . . . . 0.0 111.587 174.486 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.5 m -81.38 -52.43 7.28 Favored 'General case' 0 N--CA 1.474 0.754 0 O-C-N 121.689 -0.632 . . . . 0.0 112.692 -176.836 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.5 -30.19 4.31 Favored Glycine 0 N--CA 1.471 0.988 0 C-N-CA 124.425 1.012 . . . . 0.0 114.697 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -82.91 -53.18 6.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 122.108 0.956 . . . . 0.0 112.544 -168.867 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -139.05 4.73 2.28 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -166.082 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.0 m -113.59 -112.11 0.34 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 123.894 0.878 . . . . 0.0 113.331 -168.92 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 45.5 mm -106.29 -59.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.794 1.237 . . . . 0.0 111.573 -174.89 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.6 mm -58.16 138.32 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 106.069 -1.826 . . . . 0.0 106.069 166.289 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.7 59.13 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.758 -1.023 . . . . 0.0 114.023 -174.978 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mtt85 -127.43 176.68 7.27 Favored 'General case' 0 C--N 1.347 0.492 0 CA-C-N 119.292 1.546 . . . . 0.0 112.765 171.025 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 2.2 m -126.29 153.07 45.32 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 128.016 2.527 . . . . 0.0 109.183 169.029 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 13.1 tp -130.1 133.04 46.4 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.763 1.625 . . . . 0.0 109.167 176.446 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.73 139.15 44.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 C-N-CA 126.499 1.92 . . . . 0.0 110.767 176.403 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -106.11 140.78 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.129 1.372 . . . . 0.0 109.927 167.439 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -97.6 156.9 16.31 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.807 2.043 . . . . 0.0 111.147 177.917 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 8.2 tm-20 -77.11 -27.77 54.18 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.498 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -103.45 175.0 5.62 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.465 1.106 . . . . 0.0 111.845 168.685 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.85 152.68 42.44 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.174 1.79 . . . . 0.0 113.976 173.809 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -89.87 145.53 25.08 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 122.546 1.165 . . . . 0.0 113.168 169.792 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -76.8 -39.4 51.55 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -168.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 84.32 24.68 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 126.433 1.893 . . . . 0.0 113.812 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . 0.403 ' HA2' ' HB ' ' B' ' 135' ' ' THR . . . 84.34 57.77 2.3 Favored Glycine 0 C--N 1.343 0.959 0 C-N-CA 125.749 1.643 . . . . 0.0 114.906 168.06 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -158.68 -17.09 0.07 Allowed 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -168.203 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.08 16.35 2.8 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.612 1.577 . . . . 0.0 115.114 178.696 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.57 -2.17 24.4 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.316 1.436 . . . . 0.0 116.459 169.416 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -102.4 162.41 12.94 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 118.837 1.318 . . . . 0.0 109.551 -178.797 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -50.44 -62.83 1.35 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 122.175 0.988 . . . . 0.0 109.485 167.733 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . 0.55 ' HB3' HD22 ' B' ' 139' ' ' ASN . 0.4 OUTLIER -46.36 -31.14 2.42 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 128.898 2.879 . . . . 0.0 114.601 173.794 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 15.3 p -56.67 -30.31 63.25 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 120.556 -1.34 . . . . 0.0 113.927 178.066 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . 0.403 ' HB ' ' HA2' ' B' ' 127' ' ' GLY . 8.9 t -121.57 -13.54 8.35 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 170.111 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.5 tttt -74.79 -15.22 60.76 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.633 1.173 . . . . 0.0 113.263 169.635 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.2 p -148.31 -25.46 0.34 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 126.623 1.969 . . . . 0.0 114.67 167.421 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.13 53.83 Favored Glycine 0 CA--C 1.536 1.4 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -163.228 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . 0.55 HD22 ' HB3' ' B' ' 133' ' ' GLU . 8.1 t-20 51.67 18.07 0.68 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.618 1.967 . . . . 0.0 113.923 179.009 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.36 -0.04 0.22 Allowed 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 127.806 2.442 . . . . 0.0 116.667 -167.764 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.84 -129.71 10.48 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.14 1.353 . . . . 0.0 115.886 168.236 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.42 134.34 28.69 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 127.735 2.414 . . . . 0.0 112.493 -178.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.92 146.98 33.22 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 121.265 -0.897 . . . . 0.0 109.887 171.093 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.3 tt -120.66 -134.83 0.32 Allowed 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 168.97 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.75 156.72 32.23 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 -176.854 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -146.48 161.84 39.57 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.706 1.202 . . . . 0.0 111.099 170.002 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.47 146.75 13.33 Favored Glycine 0 N--CA 1.468 0.831 0 C-N-CA 125.141 1.353 . . . . 0.0 112.525 -174.541 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.46 HG12 ' H ' ' B' ' 149' ' ' ILE . 2.5 t -85.77 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 175.267 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . 0.46 ' H ' HG12 ' B' ' 148' ' ' VAL . 37.3 mt -123.19 114.14 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 120.097 -1.627 . . . . 0.0 111.878 -177.124 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.64 175.12 15.56 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 126.593 2.044 . . . . 0.0 115.037 -172.476 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -102.46 102.9 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.381 1.472 . . . . 0.0 112.65 -171.049 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.55 49.7 1.04 Allowed 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.535 1.934 . . . . 0.0 112.239 171.868 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 . . . . . 0 C--N 1.327 -0.378 0 C-N-CA 126.001 1.72 . . . . 0.0 111.387 177.738 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p . . . . . 0 N--CA 1.465 0.309 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.5 148.48 12.74 Favored 'General case' 0 C--O 1.238 0.469 0 C-N-CA 125.002 1.321 . . . . 0.0 112.413 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.65 161.23 39.89 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 126.293 1.837 . . . . 0.0 108.896 166.842 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.414 ' HB ' ' CG ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -156.29 150.6 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 124.487 1.115 . . . . 0.0 109.333 -178.056 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.07 93.37 2.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.463 1.105 . . . . 0.0 108.841 167.526 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -76.88 87.94 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.89 1.276 . . . . 0.0 107.793 170.355 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -76.75 127.42 32.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 125.874 1.67 . . . . 0.0 109.637 -173.606 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -144.04 169.8 17.15 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.318 1.047 . . . . 0.0 112.174 -174.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.19 -48.7 0.64 Allowed Glycine 0 N--CA 1.467 0.739 0 C-N-CA 125.329 1.442 . . . . 0.0 112.739 171.399 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.89 64.0 6.21 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 122.219 1.009 . . . . 0.0 110.694 -169.158 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.15 -101.75 0.04 OUTLIER Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.236 2.35 . . . . 0.0 113.132 179.102 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.07 -14.28 21.03 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.852 3.035 . . . . 0.0 113.635 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -76.89 136.24 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 119.849 1.204 . . . . 0.0 109.618 179.079 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.45 159.1 35.33 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 125.997 2.808 . . . . 0.0 113.377 167.163 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -111.16 142.53 16.92 Favored Glycine 0 C--N 1.313 -0.739 1 CA-C-N 108.188 -4.097 . . . . 0.0 109.438 172.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 86.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 122.641 1.21 . . . . 0.0 108.417 175.19 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -106.91 143.94 16.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.705 167.541 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -119.67 135.73 54.7 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 127.762 2.425 . . . . 0.0 110.573 -178.374 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-30 -119.93 157.86 27.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.462 1.505 . . . . 0.0 110.862 178.247 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.84 146.29 37.35 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 130.489 3.516 . . . . 0.0 104.598 171.265 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -146.0 -174.24 4.37 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.149 1.78 . . . . 0.0 106.721 172.125 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 -24.01 0.47 Allowed 'General case' 0 CA--C 1.55 0.943 0 O-C-N 118.962 -2.336 . . . . 0.0 114.463 167.402 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.403 ' HB2' ' H ' ' A' ' 27' ' ' GLY . 1.0 OUTLIER -98.72 -172.81 2.38 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.673 1.989 . . . . 0.0 109.571 170.578 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.61 -1.84 29.5 Favored 'General case' 0 CA--C 1.547 0.851 0 O-C-N 121.328 -0.857 . . . . 0.0 112.049 168.341 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -145.63 -7.98 0.58 Allowed 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -170.054 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' A' ' 24' ' ' GLU . . . -85.06 -163.75 37.56 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 118.873 -0.96 . . . . 0.0 111.771 177.057 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -84.11 161.17 13.53 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 121.964 1.776 . . . . 0.0 112.429 -171.153 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.11 152.87 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.963 1.705 . . . . 0.0 109.606 -170.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -94.17 151.15 19.69 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 170.755 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 96.0 t -130.93 97.7 3.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 127.161 2.184 . . . . 0.0 107.096 166.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.3 p90 -124.98 160.02 29.92 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.681 0.792 . . . . 0.0 111.52 172.56 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.44 -155.2 16.37 Favored Glycine 0 N--CA 1.469 0.867 0 O-C-N 120.983 -1.073 . . . . 0.0 112.052 -179.179 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.8 p -149.44 151.9 34.77 Favored 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 117.962 2.579 . . . . 0.0 117.962 -167.421 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.8 mm -118.0 133.17 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 126.16 1.784 . . . . 0.0 108.358 169.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.13 160.24 43.45 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 120.049 1.295 . . . . 0.0 114.144 -172.482 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.42 3.55 61.3 Favored Glycine 0 CA--C 1.538 1.486 0 C-N-CA 126.9 2.19 . . . . 0.0 112.293 -167.956 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.8 mt -85.23 173.26 10.52 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.305 1.842 . . . . 0.0 112.926 -173.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 m -74.19 175.97 7.04 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.642 1.177 . . . . 0.0 108.057 164.291 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.29 -93.51 0.03 OUTLIER 'General case' 0 CA--C 1.558 1.252 0 O-C-N 119.958 -1.714 . . . . 0.0 113.04 179.263 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -61.51 97.47 0.14 Allowed Glycine 0 CA--C 1.529 0.965 0 C-N-CA 126.733 2.111 . . . . 0.0 117.667 -167.486 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 65.4 mt 62.85 131.75 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 129.185 2.994 . . . . 0.0 116.606 168.482 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.01 141.58 46.24 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 129.4 3.08 . . . . 0.0 107.486 179.752 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.78 155.14 51.81 Favored Glycine 0 N--CA 1.468 0.794 0 C-N-CA 124.659 1.123 . . . . 0.0 111.715 173.846 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -150.38 98.48 2.66 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -167.475 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.66 145.99 30.22 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 120.955 -1.091 . . . . 0.0 111.69 -168.461 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 0.3 OUTLIER -102.2 119.68 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 126.149 1.78 . . . . 0.0 107.802 179.412 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -72.51 142.93 48.53 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.632 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -63.36 136.66 57.79 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -172.718 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 68.36 166.67 0.26 Allowed 'General case' 0 CA--C 1.543 0.68 0 CA-C-O 123.818 1.771 . . . . 0.0 113.995 175.338 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.31 -14.53 12.95 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 126.477 1.989 . . . . 0.0 114.413 -178.035 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -75.42 53.54 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 121.187 2.493 . . . . 0.0 112.757 -177.83 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 172.03 21.99 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.29 0 C-N-CA 128.318 2.647 . . . . 0.0 113.914 -167.065 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.604 HG22 HG21 ' A' ' 148' ' ' VAL . 76.5 p -36.1 -15.24 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 1 N-CA-C 122.332 4.197 . . . . 0.0 122.332 -170.463 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.41 15.37 4.49 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 122.097 2.226 . . . . 0.0 113.229 -174.052 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.92 -133.48 43.55 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 124.415 1.007 . . . . 0.0 111.908 174.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.9 t -58.46 -22.74 55.71 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 114.341 1.237 . . . . 0.0 114.341 -175.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . 0.256 15.0 t -90.95 42.6 1.11 Allowed 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 122.864 1.316 . . . . 0.0 112.291 171.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -179.87 -27.8 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.64 1.976 . . . . 0.0 115.659 172.095 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -134.93 142.69 46.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.529 1.532 . . . . 0.0 111.375 -168.702 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.31 -58.36 0.74 Allowed Glycine 0 CA--C 1.538 1.473 0 CA-C-O 117.636 -1.646 . . . . 0.0 115.053 -170.489 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -124.79 -177.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 124.151 3.234 . . . . 0.0 114.033 -169.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.515 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 1.4 p80 -115.13 125.3 53.3 Favored 'General case' 0 C--N 1.328 -0.358 1 C-N-CA 131.839 4.056 . . . . 0.0 106.7 175.087 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -85.76 175.45 8.69 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 123.571 1.653 . . . . 0.0 110.56 -171.328 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -107.48 48.68 0.17 Allowed Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 126.129 1.772 . . . . 0.0 113.444 177.081 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -64.52 -26.01 62.42 Favored 'Trans proline' 0 C--N 1.359 1.125 0 CA-C-N 122.044 1.766 . . . . 0.0 112.609 -179.354 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 76.2 mt -79.21 0.32 28.95 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.588 1.555 . . . . 0.0 112.993 171.041 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.28 58.29 0.7 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.893 2.077 . . . . 0.0 112.464 173.598 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -157.55 176.55 12.48 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 117.704 2.483 . . . . 0.0 117.704 -167.234 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.77 177.53 8.83 Favored 'General case' 0 CA--C 1.56 1.332 0 C-N-CA 126.822 2.049 . . . . 0.0 112.57 173.269 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -105.67 143.82 33.29 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -177.77 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.76 -115.84 0.7 Allowed Glycine 0 C--N 1.336 0.559 0 CA-C-N 114.336 -1.302 . . . . 0.0 113.675 166.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.23 -67.41 0.51 Allowed Glycine 0 CA--C 1.545 1.966 0 CA-C-O 118.933 -0.926 . . . . 0.0 114.614 179.027 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -65.77 -2.65 6.79 Favored 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 125.374 4.049 . . . . 0.0 116.459 173.109 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.82 -29.37 0.24 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.407 1.483 . . . . 0.0 111.466 170.402 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.9 t0 -87.01 104.1 15.98 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.588 0.755 . . . . 0.0 110.53 166.422 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -63.12 -13.45 36.76 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.165 2.186 . . . . 0.0 114.072 176.815 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -76.89 -72.29 0.35 Allowed 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 119.303 0.956 . . . . 0.0 110.536 -179.804 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.405 HH12 ' CG2' ' A' ' 103' ' ' VAL . 17.0 ttp180 77.45 114.09 0.07 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 126.901 2.081 . . . . 0.0 113.538 166.182 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -60.55 162.53 6.31 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 118.685 -2.509 . . . . 0.0 112.758 171.751 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -63.2 -29.93 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 O-C-N 121.231 -0.918 . . . . 0.0 112.52 172.691 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.12 12.32 54.61 Favored Glycine 0 CA--C 1.53 0.999 0 C-N-CA 124.696 1.141 . . . . 0.0 115.468 175.081 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -112.71 113.57 25.75 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-N 119.774 1.787 . . . . 0.0 114.439 -173.91 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.15 -173.76 4.9 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 163.164 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.46 -134.34 2.02 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 120.792 -1.193 . . . . 0.0 113.625 172.227 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.5 p30 -127.34 163.39 24.11 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.163 0.985 . . . . 0.0 108.95 168.535 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 136.4 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.131 0.972 . . . . 0.0 110.61 -171.686 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -110.6 135.87 50.57 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 175.292 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.12 156.26 18.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.524 0.678 . . . . 0.0 110.584 169.298 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -77.16 155.22 32.45 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.056 1.342 . . . . 0.0 108.497 166.861 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.92 -25.36 19.98 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.999 1.72 . . . . 0.0 115.23 -169.305 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -76.65 -2.37 32.38 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.499 2.32 . . . . 0.0 112.273 179.101 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.65 30.18 7.37 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-O 117.937 -1.48 . . . . 0.0 114.12 172.334 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -144.81 131.54 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -178.188 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.27 112.72 24.4 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 164.799 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.0 t0 -106.33 128.65 54.17 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 170.803 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.46 145.18 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-N 113.429 -1.714 . . . . 0.0 114.4 -164.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 86.1 p -147.94 89.62 1.76 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.16 1.384 . . . . 0.0 112.087 179.566 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.06 149.31 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.505 1.522 . . . . 0.0 111.499 -174.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -135.68 138.29 42.64 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.842 2.057 . . . . 0.0 106.421 166.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -146.99 153.97 40.69 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 124.912 1.285 . . . . 0.0 112.241 -167.567 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -118.17 52.91 0.99 Allowed 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.382 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.405 ' CG2' HH12 ' A' ' 79' ' ' ARG . 1.0 OUTLIER -154.66 16.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 115.889 1.811 . . . . 0.0 115.889 -178.781 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -139.63 176.37 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 125.937 1.695 . . . . 0.0 109.741 169.605 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 28.8 p -160.08 175.54 12.85 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 177.11 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.437 ' HA ' ' CG1' ' A' ' 113' ' ' ILE . 8.5 mp -103.94 56.6 0.73 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.047 1.739 . . . . 0.0 110.409 176.953 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.5 t -107.91 -16.51 14.28 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 121.699 3.963 . . . . 0.0 121.699 -169.449 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 77.44 103.84 0.17 Allowed Glycine 0 CA--C 1.529 0.912 0 CA-C-N 121.233 1.833 . . . . 0.0 111.177 -171.011 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 85.77 -44.88 0.06 Allowed 'General case' 0 C--N 1.318 -0.777 1 C-N-CA 131.925 4.09 . . . . 0.0 111.376 166.909 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -85.78 3.03 43.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.862 1.265 . . . . 0.0 112.669 -176.573 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 p -138.22 -152.56 0.43 Allowed 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -166.951 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.8 pt -96.58 -17.35 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 120.382 -1.449 . . . . 0.0 112.516 168.298 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.437 ' CG1' ' HA ' ' A' ' 106' ' ' LEU . 7.1 mm -72.37 133.37 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 166.202 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.52 ' HA3' HD11 ' B' ' 151' ' ' ILE . . . 67.76 42.29 87.24 Favored Glycine 0 CA--C 1.532 1.134 0 O-C-N 124.36 1.037 . . . . 0.0 110.528 -168.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.99 148.86 35.85 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 127.04 2.136 . . . . 0.0 105.263 170.256 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 11.6 m -114.85 109.99 19.0 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.005 -1.059 . . . . 0.0 112.994 -165.038 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 11.2 tp -86.14 139.8 30.77 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 120.005 1.275 . . . . 0.0 114.224 -169.633 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.486 HG11 ' HE ' ' A' ' 143' ' ' ARG . 1.0 OUTLIER -132.68 149.3 31.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.284 168.232 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.64 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 164.762 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -127.3 131.92 50.4 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.144 1.378 . . . . 0.0 109.543 -176.62 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -60.63 -40.81 93.3 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.491 1.663 . . . . 0.0 115.491 -166.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -86.53 147.44 25.96 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 121.018 1.735 . . . . 0.0 110.898 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -33.58 125.58 0.41 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.568 1.947 . . . . 0.0 111.102 166.236 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 35.5 t0 -75.57 134.7 40.64 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 169.751 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.96 -34.67 66.64 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.889 0.876 . . . . 0.0 111.88 178.451 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.1 mt 62.74 33.18 15.65 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.621 1.568 . . . . 0.0 112.533 173.586 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -174.04 -72.75 0.05 OUTLIER Glycine 0 N--CA 1.468 0.815 0 N-CA-C 116.399 1.32 . . . . 0.0 116.399 174.845 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -164.85 67.74 0.14 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.548 1.139 . . . . 0.0 114.073 178.252 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.3 68.03 0.7 Allowed Glycine 0 CA--C 1.531 1.061 0 C-N-CA 127.001 2.239 . . . . 0.0 113.416 176.175 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.26 -14.9 31.43 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 125.944 1.735 . . . . 0.0 115.226 172.714 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -141.23 177.08 8.33 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 118.982 1.391 . . . . 0.0 112.039 -171.409 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -77.62 -43.06 32.73 Favored 'General case' 0 C--O 1.217 -0.627 0 CA-C-N 114.625 -1.171 . . . . 0.0 109.978 165.476 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -44.57 -40.32 5.63 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 173.121 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.82 -33.36 23.27 Favored 'General case' 0 N--CA 1.472 0.635 0 O-C-N 120.858 -1.151 . . . . 0.0 114.034 171.54 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.4 -24.05 20.88 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 125.565 1.546 . . . . 0.0 112.527 177.772 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -87.24 -13.66 43.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 176.907 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.8 p -129.8 -45.93 1.16 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.386 1.074 . . . . 0.0 113.385 176.508 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.8 -0.77 15.34 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 125.777 1.923 . . . . 0.0 111.793 -166.465 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 56.74 21.19 5.7 Favored 'General case' 0 N--CA 1.478 0.965 0 O-C-N 119.808 -1.995 . . . . 0.0 111.974 -175.754 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.92 30.02 0.08 Allowed 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -167.098 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.23 -35.24 0.42 Allowed Glycine 0 N--CA 1.476 1.358 0 C-N-CA 129.673 3.511 . . . . 0.0 117.588 168.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.0 t -171.3 -144.59 0.04 OUTLIER 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.476 1.11 . . . . 0.0 110.108 -169.293 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.486 ' HE ' HG11 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -142.37 -174.88 4.25 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 127.515 2.326 . . . . 0.0 110.447 172.929 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -174.42 -141.04 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 129.568 3.147 . . . . 0.0 109.008 168.18 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -51.24 138.71 20.2 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 128.341 2.656 . . . . 0.0 114.377 -168.479 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 87.3 m -126.06 134.83 51.29 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 127.942 2.497 . . . . 0.0 112.606 -169.613 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.32 153.56 23.94 Favored Glycine 0 N--CA 1.482 1.751 0 C-N-CA 125.29 1.424 . . . . 0.0 114.252 169.023 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.604 HG21 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -78.31 149.95 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 CA-C-N 120.278 2.039 . . . . 0.0 110.301 170.185 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 10.0 mm -83.13 104.39 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 106.733 -1.581 . . . . 0.0 106.733 166.049 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -106.15 146.79 16.12 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 124.348 0.975 . . . . 0.0 111.134 176.587 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.5 pp -79.86 173.7 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 122.908 0.483 . . . . 0.0 111.346 175.255 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.45 ' HB2' ' CB ' ' B' ' 52' ' ' ASP . . . -155.95 -126.86 0.03 OUTLIER 'General case' 0 C--O 1.224 -0.269 0 C-N-CA 125.823 1.649 . . . . 0.0 111.156 163.894 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.858 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -164.244 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 p -115.91 115.51 26.34 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.133 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . 0.477 ' HZ3' ' HB2' ' B' ' 3' ' ' LYS . 0.0 OUTLIER -98.77 142.56 30.15 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 116.605 2.076 . . . . 0.0 116.605 169.966 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.24 132.25 42.89 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.841 2.456 . . . . 0.0 110.087 172.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 59.6 t -144.77 142.82 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 119.943 1.247 . . . . 0.0 111.786 -168.657 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -114.18 141.38 47.6 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.79 1.236 . . . . 0.0 113.853 171.929 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 15.0 m -104.06 99.62 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 167.383 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -78.91 130.35 35.52 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.722 1.209 . . . . 0.0 108.085 -175.63 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -156.18 174.47 15.33 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 -172.644 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.96 -43.03 1.35 Allowed Glycine 0 N--CA 1.471 1.002 0 C-N-CA 127.955 2.693 . . . . 0.0 111.32 172.792 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -82.96 59.17 4.74 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 127.932 2.493 . . . . 0.0 113.319 -168.633 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.41 -104.0 0.06 OUTLIER Glycine 0 CA--C 1.532 1.14 0 C-N-CA 127.537 2.494 . . . . 0.0 112.6 176.975 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.45 -14.62 16.11 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 123.618 2.878 . . . . 0.0 113.614 -177.564 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.496 HG21 HD11 ' B' ' 144' ' ' LEU . 2.8 t -90.05 128.79 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-N 120.096 1.317 . . . . 0.0 109.921 -178.542 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.513 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -146.06 155.12 42.56 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.848 173.121 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.27 153.14 20.64 Favored Glycine 0 C--O 1.227 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.229 177.569 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.4 HD11 ' ND2' ' B' ' 19' ' ' ASN . 0.0 OUTLIER -118.04 117.21 54.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 C-N-CA 126.234 1.814 . . . . 0.0 106.514 168.715 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.3 mm -128.19 104.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 O-C-N 123.64 0.587 . . . . 0.0 110.049 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . 0.4 ' ND2' HD11 ' B' ' 17' ' ' ILE . 0.8 OUTLIER -79.53 156.13 27.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.111 1.764 . . . . 0.0 111.981 167.961 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -139.82 108.21 5.84 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 130.655 3.582 . . . . 0.0 107.339 170.071 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.27 130.85 53.31 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.194 1.398 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -126.12 154.68 42.8 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 122.277 1.037 . . . . 0.0 111.35 -176.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.419 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 9.9 ptmm? -115.92 -24.35 8.17 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 128.298 2.639 . . . . 0.0 114.105 -177.512 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . 0.419 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 6.7 mp0 -135.79 162.25 33.32 Favored 'General case' 0 C--O 1.219 -0.502 0 CA-C-N 121.006 1.73 . . . . 0.0 112.877 173.649 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 p -64.94 -2.94 2.95 Favored 'General case' 0 N--CA 1.483 1.217 0 O-C-N 119.141 -2.224 . . . . 0.0 113.434 167.226 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.79 64.12 0.16 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 128.383 2.673 . . . . 0.0 109.754 -168.214 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.1 172.75 31.37 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.58 1.562 . . . . 0.0 113.411 -170.747 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.53 142.53 23.48 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.39 2.727 . . . . 0.0 110.683 178.634 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.05 132.6 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.158 0.983 . . . . 0.0 109.327 -172.606 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -95.96 115.6 27.67 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 121.626 0.726 . . . . 0.0 111.226 179.061 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.6 t -93.55 121.35 44.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 127.105 2.162 . . . . 0.0 108.807 -179.123 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -148.25 164.88 32.65 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 177.859 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.02 -147.67 19.4 Favored Glycine 0 C--N 1.334 0.448 0 C-N-CA 125.111 1.339 . . . . 0.0 111.356 176.795 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -157.94 156.61 31.56 Favored 'General case' 0 C--O 1.237 0.407 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -175.783 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.591 HG21 HG11 ' B' ' 119' ' ' VAL . 3.1 mp -124.39 133.67 68.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 125.284 1.433 . . . . 0.0 108.319 170.636 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -138.3 155.5 48.53 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -172.791 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.87 76.95 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.031 1.3 . . . . 0.0 114.022 -175.515 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.459 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.1 pt? -96.43 162.58 13.42 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 126.559 1.944 . . . . 0.0 112.11 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.23 154.24 1.26 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.458 2.703 . . . . 0.0 110.822 169.15 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -64.77 -60.34 3.2 Favored 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 120.717 1.599 . . . . 0.0 112.654 174.245 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -51.52 141.7 21.84 Favored Glycine 0 N--CA 1.472 1.075 0 C-N-CA 126.218 1.866 . . . . 0.0 114.733 -169.811 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . 0.631 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -40.74 136.88 1.29 Allowed 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 128.315 2.646 . . . . 0.0 115.243 -168.311 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -121.12 142.47 49.83 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 129.816 3.247 . . . . 0.0 109.173 -170.306 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.18 169.51 35.79 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.552 1.072 . . . . 0.0 111.879 172.436 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.2 t80 -160.43 57.95 0.34 Allowed 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.649 1.58 . . . . 0.0 110.728 -169.621 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -117.44 145.81 43.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.305 1.042 . . . . 0.0 113.401 -169.592 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -105.86 115.78 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.773 0.797 . . . . 0.0 109.189 -172.102 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . 0.478 ' HB2' HG23 ' B' ' 116' ' ' THR . 12.1 m-70 -76.42 174.16 10.59 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 124.974 1.31 . . . . 0.0 110.119 179.537 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . 0.532 ' H ' ' CD ' ' B' ' 49' ' ' GLU . 1.9 pm0 -61.15 85.58 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 127.127 2.171 . . . . 0.0 115.074 -168.242 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 67.95 -157.99 0.21 Allowed 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.089 2.156 . . . . 0.0 111.865 168.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.75 -14.88 18.29 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.461 1.505 . . . . 0.0 112.077 -177.871 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.45 ' CB ' ' HB2' ' A' ' 152' ' ' ALA . 7.5 t70 -62.57 56.52 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.023 1 C-N-CA 132.623 4.369 . . . . 0.0 110.6 169.555 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 16.3 p30 176.39 -11.01 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 128.079 2.552 . . . . 0.0 116.287 -174.388 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.315 8.4 t . . . . . 0 N--CA 1.498 1.952 2 N-CA-C 123.685 4.698 . . . . 0.0 123.685 176.268 . . . . . . . . 2 1 . 1 . 029 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 122.245 1.021 . . . . 0.0 113.173 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.79 -152.65 23.0 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 126.846 2.165 . . . . 0.0 111.312 178.796 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -109.08 49.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.596 2.864 . . . . 0.0 111.457 -178.326 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 56.77 82.69 0.11 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.932 1.293 . . . . 0.0 112.498 -179.2 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -40.49 131.62 2.21 Favored 'General case' 0 CA--C 1.542 0.673 0 CA-C-O 122.54 1.162 . . . . 0.0 113.089 169.557 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.7 p-10 -114.29 79.86 5.44 Favored Pre-proline 0 CA--C 1.547 0.838 0 C-N-CA 126.407 1.883 . . . . 0.0 112.457 -171.246 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -62.23 -14.52 38.73 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 123.114 2.543 . . . . 0.0 114.685 179.547 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -92.78 -4.0 53.79 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.111 1.364 . . . . 0.0 113.302 171.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 28.0 t 65.7 53.39 1.19 Allowed 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.366 1.866 . . . . 0.0 112.367 171.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -142.64 177.27 8.42 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -169.559 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.528 ' H ' ' HD2' ' B' ' 70' ' ' LYS . 1.3 mptt -79.41 175.4 10.63 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 126.441 1.897 . . . . 0.0 112.904 -178.228 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -97.49 136.61 37.67 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -176.805 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 139.83 -132.27 5.5 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 124.268 0.937 . . . . 0.0 113.596 167.421 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 146.04 -34.44 1.43 Allowed Glycine 0 CA--C 1.547 2.087 0 N-CA-C 118.234 2.054 . . . . 0.0 118.234 -177.037 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -78.4 -19.53 11.65 Favored 'Trans proline' 0 C--N 1.356 0.94 0 CA-C-N 122.263 3.032 . . . . 0.0 113.609 172.22 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -46.42 0.93 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 124.437 1.095 . . . . 0.0 109.917 167.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -56.14 126.04 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.976 0.893 . . . . 0.0 109.319 169.209 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -90.61 -5.86 55.35 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 128.973 2.909 . . . . 0.0 112.717 -168.341 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -100.58 -76.48 0.56 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 126.945 2.098 . . . . 0.0 110.773 -169.809 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 84.66 113.7 0.05 Allowed 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 126.519 1.928 . . . . 0.0 113.268 165.812 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -59.2 152.66 20.06 Favored 'General case' 0 CA--C 1.549 0.911 0 O-C-N 119.669 -1.894 . . . . 0.0 110.36 170.04 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -58.39 -30.98 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.891 -1.13 . . . . 0.0 112.681 178.223 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.35 37.47 3.42 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 126.619 2.057 . . . . 0.0 113.58 171.211 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -116.85 146.87 42.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 119.988 1.894 . . . . 0.0 115.737 173.892 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 79.1 mt -144.42 163.3 34.2 Favored 'General case' 0 CA--C 1.545 0.784 1 C-N-CA 132.102 4.161 . . . . 0.0 102.702 163.156 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.91 -87.06 0.99 Allowed Glycine 0 N--CA 1.468 0.829 0 O-C-N 121.926 -0.484 . . . . 0.0 113.428 -170.643 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -153.32 168.44 26.03 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 124.674 1.19 . . . . 0.0 113.479 -166.521 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.56 147.59 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 129.233 3.013 . . . . 0.0 110.214 -176.407 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 25.7 m -120.84 145.6 47.43 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 119.437 1.017 . . . . 0.0 109.991 -176.979 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.65 144.48 26.65 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.895 0.855 . . . . 0.0 111.666 175.95 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . 0.452 ' OD1' ' HE2' ' B' ' 91' ' ' LYS . 39.7 t0 -73.19 158.95 34.26 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.762 1.225 . . . . 0.0 109.813 168.921 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . 0.452 ' HE2' ' OD1' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -52.33 -28.2 18.34 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 115.42 1.637 . . . . 0.0 115.42 -168.292 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.85 -2.25 29.19 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.544 1.538 . . . . 0.0 112.283 -178.51 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.08 39.16 7.54 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 125.221 1.391 . . . . 0.0 113.154 177.843 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 3.2 p -132.62 126.37 54.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 CA-C-N 118.629 1.215 . . . . 0.0 113.811 170.018 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.58 119.23 31.31 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.518 1.527 . . . . 0.0 107.929 165.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.46 151.15 31.0 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 167.419 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.29 0.5 OUTLIER -134.53 131.59 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 114.593 -1.185 . . . . 0.0 112.899 165.477 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 9.6 p -157.69 59.96 0.48 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.151 1.38 . . . . 0.0 113.164 -168.65 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -115.39 156.08 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 C-N-CA 126.787 2.035 . . . . 0.0 112.715 -171.582 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -128.67 146.49 50.86 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.733 1.613 . . . . 0.0 108.288 166.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -141.02 134.83 30.41 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.243 1.417 . . . . 0.0 110.222 -179.03 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -112.75 59.27 0.64 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.315 1.446 . . . . 0.0 112.234 -167.578 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.4 p -158.12 -36.5 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.132 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.13 170.97 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 123.332 0.653 . . . . 0.0 111.349 172.712 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.8 m -157.51 159.44 37.21 Favored 'General case' 0 N--CA 1.469 0.506 0 O-C-N 120.12 -1.612 . . . . 0.0 111.335 176.316 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . 0.464 ' HG ' HD11 ' B' ' 113' ' ' ILE . 4.8 tt -81.12 75.02 8.1 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.056 0.942 . . . . 0.0 109.523 -173.627 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -138.97 152.18 47.47 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.761 1.625 . . . . 0.0 111.391 -174.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -101.91 68.54 0.39 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 126.968 2.223 . . . . 0.0 113.427 -169.29 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -154.43 -91.53 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.78 1.632 . . . . 0.0 110.362 -168.819 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -127.79 -4.43 5.81 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.742 2.017 . . . . 0.0 110.461 -170.048 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 16.4 m -92.6 -91.31 0.17 Allowed 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.523 1.929 . . . . 0.0 114.651 -166.066 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pt -135.36 -14.69 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 118.112 2.634 . . . . 0.0 118.112 176.724 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . 0.526 HD12 HG23 ' B' ' 151' ' ' ILE . 22.0 mm -86.58 105.8 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 CA-C-N 122.113 2.233 . . . . 0.0 108.747 179.283 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.59 61.45 1.17 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.573 0.606 . . . . 0.0 112.944 -171.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 23.4 ptt180 -140.36 144.95 36.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.981 1.312 . . . . 0.0 109.239 167.305 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . 0.478 HG23 ' HB2' ' B' ' 48' ' ' HIS . 2.3 t -109.39 102.09 11.01 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 124.243 1.017 . . . . 0.0 111.067 -166.665 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 29.2 tp -86.33 129.67 34.77 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 124.152 0.981 . . . . 0.0 109.774 -173.245 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 t -107.82 118.09 54.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 169.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.591 HG11 HG21 ' B' ' 35' ' ' ILE . 13.9 p -78.85 120.03 29.18 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.37 0 N-CA-C 100.483 -3.895 . . . . 0.0 100.483 161.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -106.45 142.52 35.97 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 117.766 -1.111 . . . . 0.0 109.38 -168.189 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.92 -42.94 80.87 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 122.154 2.252 . . . . 0.0 113.915 -166.718 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.473 ' HE3' ' HA ' ' B' ' 122' ' ' LYS . 0.0 OUTLIER -111.7 152.35 27.83 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 171.624 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.12 161.02 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.853 1.661 . . . . 0.0 112.258 171.68 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -94.47 151.35 19.44 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 177.833 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -71.8 -16.66 62.19 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.572 1.949 . . . . 0.0 112.875 176.482 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.3 mt 57.96 84.29 0.1 Allowed 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 127.028 2.131 . . . . 0.0 114.464 169.764 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.74 -47.48 3.42 Favored Glycine 0 N--CA 1.465 0.622 0 C-N-CA 125.502 1.525 . . . . 0.0 111.015 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -158.84 137.91 11.33 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.609 1.564 . . . . 0.0 110.448 168.646 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -141.37 -101.15 0.43 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 169.164 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.57 -24.49 10.96 Favored Glycine 0 N--CA 1.471 0.972 0 N-CA-C 116.705 1.442 . . . . 0.0 116.705 -168.576 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -165.46 174.18 10.26 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.882 1.341 . . . . 0.0 111.83 -169.225 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -49.86 -50.84 44.19 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 126.062 1.745 . . . . 0.0 113.449 -170.313 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . 0.471 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 13.7 mp0 -45.76 -25.79 0.55 Allowed 'General case' 0 C--N 1.318 -0.794 0 C-N-CA 128.27 2.628 . . . . 0.0 113.705 175.305 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.6 p -64.95 -45.06 87.32 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 120.119 1.327 . . . . 0.0 112.716 178.823 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -79.91 -39.72 29.76 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.18 0.592 . . . . 0.0 111.523 173.151 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.29 -18.64 52.25 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -173.033 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.9 p -152.71 -15.11 0.16 Allowed 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 177.956 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.04 -7.56 58.85 Favored Glycine 0 C--O 1.214 -1.155 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.313 -168.652 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 51.3 t30 55.57 35.49 25.28 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-N 120.613 2.206 . . . . 0.0 112.157 178.184 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.9 38.88 0.08 Allowed 'General case' 0 CA--C 1.563 1.451 0 N-CA-C 115.759 1.763 . . . . 0.0 115.759 -166.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.16 -84.46 0.41 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 127.109 2.29 . . . . 0.0 113.767 175.488 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t -160.52 172.8 16.55 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.155 0.982 . . . . 0.0 112.978 -178.041 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 154.83 25.62 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.126 1.37 . . . . 0.0 113.624 -171.488 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.496 HD11 HG21 ' B' ' 14' ' ' VAL . 19.5 tp -159.79 -177.55 6.43 Favored 'General case' 0 CA--C 1.56 1.342 0 C-N-CA 129.795 3.238 . . . . 0.0 104.878 169.836 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.73 129.91 20.36 Favored 'General case' 0 CA--C 1.556 1.185 0 N-CA-C 115.838 1.792 . . . . 0.0 115.838 -165.146 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.9 m -114.91 134.19 55.36 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 126.712 2.005 . . . . 0.0 112.645 -176.687 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.9 144.12 10.17 Favored Glycine 0 N--CA 1.486 2.006 0 CA-C-N 120.994 1.724 . . . . 0.0 117.172 177.297 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.518 ' O ' HG21 ' A' ' 54' ' ' THR . 84.6 t -81.12 140.74 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 118.169 0.985 . . . . 0.0 109.893 176.022 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.4 mm -77.68 107.33 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 170.584 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.16 36.45 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.555 1.55 . . . . 0.0 111.951 169.635 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . 0.526 HG23 HD12 ' B' ' 113' ' ' ILE . 1.1 pp -138.91 160.65 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 125.04 1.336 . . . . 0.0 112.89 177.822 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.58 1.3 0.44 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.644 1.978 . . . . 0.0 112.554 164.603 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tm0? . . . . . 0 N--CA 1.472 0.648 0 C-N-CA 126.636 1.975 . . . . 0.0 110.876 169.699 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 67.4 p . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.1 ttpt -161.55 126.18 3.44 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 118.529 2.789 . . . . 0.0 118.529 166.085 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.52 177.5 4.9 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 129.489 3.116 . . . . 0.0 107.006 164.346 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.574 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.5 p -157.54 151.15 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 -164.227 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.07 115.21 7.92 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 110.627 166.252 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 68.9 t -101.41 95.59 4.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.667 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.9 mp -79.34 152.51 30.42 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.13 1.372 . . . . 0.0 108.68 173.612 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -153.24 158.56 41.88 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -130.11 158.33 22.31 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.308 2.385 . . . . 0.0 107.957 166.151 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -71.94 83.59 0.95 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 126.817 2.047 . . . . 0.0 110.941 -177.446 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.09 -147.64 18.78 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 127.041 2.258 . . . . 0.0 110.158 -169.403 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -94.64 9.51 1.93 Allowed 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 124.794 3.663 . . . . 0.0 114.87 -169.841 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.63 134.16 34.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 CA-C-N 120.025 1.284 . . . . 0.0 110.393 -177.369 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.39 164.67 34.28 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.517 1.127 . . . . 0.0 111.486 178.865 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.447 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -129.52 97.79 0.42 Allowed Glycine 0 C--O 1.215 -1.042 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 169.042 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -96.41 106.61 18.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 118.519 1.159 . . . . 0.0 108.012 175.892 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 pt -133.59 150.13 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 122.241 1.019 . . . . 0.0 111.62 177.09 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -122.74 145.29 48.54 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.637 1.575 . . . . 0.0 110.329 179.416 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -120.94 105.07 10.32 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.936 1.694 . . . . 0.0 109.635 -173.895 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.1 121.16 28.31 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 177.369 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.584 ' CB ' HD13 ' A' ' 106' ' ' LEU . 11.0 tp60 -147.76 137.94 22.91 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.251 0.548 . . . . 0.0 111.186 175.507 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.497 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -91.96 -24.28 19.31 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -175.735 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.66 -155.65 0.61 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-N 120.136 1.335 . . . . 0.0 113.038 176.489 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 66.6 m -107.25 10.25 29.91 Favored 'General case' 0 CA--C 1.543 0.677 0 O-C-N 119.377 -2.077 . . . . 0.0 113.634 -179.095 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -131.27 -10.29 3.7 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 126.021 1.728 . . . . 0.0 114.746 -172.437 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.13 160.74 20.75 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 128.926 3.155 . . . . 0.0 112.657 -168.615 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.75 151.57 32.02 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 123.028 2.486 . . . . 0.0 109.718 175.568 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 67.4 t -119.71 137.65 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.166 1.387 . . . . 0.0 110.004 -168.166 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -84.41 127.09 33.8 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.512 0.596 . . . . 0.0 110.1 170.19 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 t -107.82 130.09 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 125.632 1.573 . . . . 0.0 108.346 171.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -151.14 165.9 32.48 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 123.342 0.657 . . . . 0.0 111.54 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 131.16 -148.9 19.07 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 124.993 1.283 . . . . 0.0 111.754 175.928 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 54.1 p -142.6 127.22 17.98 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -169.815 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.447 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 10.2 mm -101.3 112.77 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 124.676 1.19 . . . . 0.0 108.279 170.987 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.9 pttt -129.58 152.07 49.5 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.835 1.198 . . . . 0.0 112.698 -166.514 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.01 5.52 64.05 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.38 0.99 . . . . 0.0 112.599 -169.061 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -75.44 -161.63 0.16 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 127.405 2.282 . . . . 0.0 109.662 168.766 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -151.98 171.24 18.13 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 126.627 1.971 . . . . 0.0 108.183 169.331 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -49.04 136.84 13.96 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.851 1.66 . . . . 0.0 113.439 -168.876 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.51 -173.13 28.21 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-O 122.597 1.11 . . . . 0.0 112.511 173.202 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.5 OUTLIER -73.01 160.45 32.07 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.1 0.96 . . . . 0.0 111.373 -171.339 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.402 ' HB2' HG13 ' A' ' 87' ' ' VAL . 81.6 m-70 -149.09 136.21 19.94 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 127.653 2.381 . . . . 0.0 108.867 176.62 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.17 148.71 32.48 Favored Glycine 0 N--CA 1.478 1.463 0 CA-C-O 119.261 -0.744 . . . . 0.0 111.964 171.226 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -153.15 78.71 1.17 Allowed 'General case' 0 CA--C 1.544 0.741 0 CA-C-O 122.88 1.324 . . . . 0.0 110.768 -168.556 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -124.73 157.86 34.66 Favored 'General case' 0 CA--C 1.516 -0.338 0 O-C-N 120.803 -1.186 . . . . 0.0 111.396 -169.428 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.618 HG11 HH11 ' A' ' 115' ' ' ARG . 1.7 m -87.65 151.52 3.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.24 176.628 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 8.4 m170 -113.88 168.79 9.5 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 104.102 -2.555 . . . . 0.0 104.102 160.175 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.75 -172.69 0.09 Allowed 'General case' 0 CA--C 1.554 1.11 0 N-CA-C 117.257 2.317 . . . . 0.0 117.257 -167.83 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -119.43 -36.58 3.32 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 128.203 2.601 . . . . 0.0 112.305 -175.739 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.19 -29.52 62.9 Favored Glycine 0 N--CA 1.47 0.93 1 C-N-CA 131.667 4.461 . . . . 0.0 114.588 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -123.97 151.23 43.9 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 163.045 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.576 ' HB2' HG13 ' B' ' 5' ' ' VAL . 0.5 OUTLIER -148.98 101.55 3.18 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 119.11 3.004 . . . . 0.0 119.11 -166.493 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.555 HG23 ' O ' ' A' ' 53' ' ' ASN 0.549 0.1 OUTLIER 112.48 -145.75 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.695 1 C-N-CA 133.673 4.789 . . . . 0.0 113.576 160.044 . . . . . . . . 5 4 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 49.05 -10.13 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 131.033 3.733 . . . . 0.0 117.91 -172.348 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.34 -132.12 11.11 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.968 2.223 . . . . 0.0 111.211 -176.915 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.9 m -62.78 -8.47 6.89 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 177.726 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.1 m -79.9 -24.07 41.38 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.922 1.289 . . . . 0.0 112.457 171.672 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.514 ' HB3' HG11 ' B' ' 7' ' ' VAL . 4.1 m -158.43 45.57 0.31 Allowed 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 116.193 1.923 . . . . 0.0 116.193 -169.2 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 176.96 125.45 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 127.807 2.443 . . . . 0.0 110.452 168.429 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -72.16 149.14 43.73 Favored Glycine 0 CA--C 1.541 1.667 0 O-C-N 120.736 -1.228 . . . . 0.0 114.372 -175.772 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -64.69 106.94 0.8 Allowed 'Trans proline' 0 C--N 1.354 0.822 1 C-N-CA 125.488 4.125 . . . . 0.0 111.604 -178.896 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.442 ' CE1' ' HA ' ' A' ' 137' ' ' THR 0.274 0.0 OUTLIER 36.04 57.18 1.0 Allowed 'General case' 0 C--O 1.234 0.247 0 C-N-CA 127.377 2.271 . . . . 0.0 112.468 170.458 . . . . . . . . 4 4 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -27.05 122.79 0.09 Allowed 'General case' 0 C--N 1.342 0.259 0 C-N-CA 128.285 2.634 . . . . 0.0 111.26 179.328 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 62.8 m-20 -71.84 101.26 0.37 Allowed Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -168.426 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -84.67 -12.46 7.49 Favored 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.157 2.571 . . . . 0.0 112.956 -167.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 92.0 mt -139.75 2.91 2.02 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 128.62 2.768 . . . . 0.0 110.717 -172.117 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 16.0 t 66.44 53.43 0.98 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.706 1.603 . . . . 0.0 114.022 175.675 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.79 179.57 4.94 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.978 1.711 . . . . 0.0 113.161 179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.1 mmtt -73.57 173.61 9.46 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 121.654 0.74 . . . . 0.0 111.667 169.356 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 48.9 t60 -72.15 157.77 37.14 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 168.489 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.413 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.78 -126.19 2.69 Favored Glycine 0 C--N 1.339 0.72 0 N-CA-C 116.576 1.39 . . . . 0.0 116.576 165.725 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.85 -90.24 0.36 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 116.58 1.392 . . . . 0.0 116.58 -171.105 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.5 -2.21 4.84 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.946 3.097 . . . . 0.0 115.184 -173.325 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.312 3.3 ptmm? -144.08 4.13 1.24 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 126.433 1.893 . . . . 0.0 112.677 168.346 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.0 OUTLIER -131.77 113.77 13.92 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 127.082 2.153 . . . . 0.0 109.168 177.038 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -71.16 -14.07 62.15 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 127.968 2.507 . . . . 0.0 114.082 -176.371 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -78.02 -62.06 1.8 Allowed 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.908 1.231 . . . . 0.0 109.295 175.361 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 74.6 ttt180 70.71 120.44 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 123.477 1.608 . . . . 0.0 112.831 169.592 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.8 m170 -66.98 136.58 55.53 Favored 'General case' 0 CA--C 1.543 0.694 0 O-C-N 118.96 -2.337 . . . . 0.0 109.217 164.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.0 t -53.74 -19.11 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 122.464 1.126 . . . . 0.0 111.636 166.281 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.489 ' HA3' HG22 ' A' ' 47' ' ' VAL . . . -92.16 41.09 2.82 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.255 2.36 . . . . 0.0 116.878 172.454 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -144.56 122.57 12.08 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 119.751 1.775 . . . . 0.0 111.865 -179.06 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.86 48.75 0.94 Allowed 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 123.811 1.767 . . . . 0.0 110.359 173.762 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.89 -133.48 52.71 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 126.122 1.82 . . . . 0.0 114.257 175.289 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.82 138.73 48.03 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.672 1.589 . . . . 0.0 110.11 171.495 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.402 HG13 ' HB2' ' A' ' 43' ' ' HIS . 8.0 p -92.95 127.45 45.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 166.327 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 24.4 m -115.39 119.48 36.4 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -176.27 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.99 156.96 17.31 Favored 'General case' 0 C--N 1.328 -0.353 0 O-C-N 123.667 0.604 . . . . 0.0 112.588 -177.21 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.73 168.54 19.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 126.403 1.881 . . . . 0.0 113.67 173.21 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.1 pptp? -60.11 -20.09 56.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.789 1.636 . . . . 0.0 113.79 168.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -80.95 0.04 37.25 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.006 1.322 . . . . 0.0 112.306 170.791 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 19.92 60.41 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 125.178 1.37 . . . . 0.0 114.099 174.633 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -134.16 138.85 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 119.04 1.42 . . . . 0.0 113.527 -176.54 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.79 123.31 40.45 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 165.655 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -97.74 118.8 35.09 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.581 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.12 140.08 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 CA-C-N 114.159 -1.382 . . . . 0.0 113.935 -165.733 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 77.4 p -155.65 123.2 5.57 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.594 1.558 . . . . 0.0 110.103 168.834 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -155.17 148.81 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 127.703 2.401 . . . . 0.0 109.992 -169.85 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -125.77 125.22 42.61 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 165.749 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -121.72 141.81 50.81 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.038 0.935 . . . . 0.0 110.994 -173.753 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -115.63 48.66 1.17 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.959 0.904 . . . . 0.0 112.863 -178.377 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.26 -4.81 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.459 1.104 . . . . 0.0 112.23 170.732 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.54 164.88 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 C-N-CA 125.951 1.7 . . . . 0.0 110.727 176.672 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 99.5 p -149.54 175.28 11.66 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 128.285 2.634 . . . . 0.0 109.072 178.098 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.584 HD13 ' CB ' ' A' ' 22' ' ' GLN . 6.8 mp -86.16 93.4 9.02 Favored 'General case' 0 CA--C 1.543 0.684 0 O-C-N 120.809 -1.182 . . . . 0.0 109.33 173.249 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.2 t -152.45 153.88 34.42 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.753 1.221 . . . . 0.0 110.119 169.04 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -103.08 29.23 12.88 Favored Glycine 0 N--CA 1.472 1.041 0 C-N-CA 126.142 1.829 . . . . 0.0 113.27 -178.147 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -86.81 -96.55 0.08 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 126.022 1.729 . . . . 0.0 106.691 169.655 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m170 -107.39 -7.75 16.54 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.458 1.503 . . . . 0.0 111.806 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -76.15 -157.77 0.08 Allowed 'General case' 0 CA--C 1.558 1.259 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -174.999 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.271 10.9 pt -97.14 44.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 118.455 -2.653 . . . . 0.0 116.06 -172.006 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.9 mm -115.73 126.96 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 166.321 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.18 -4.2 34.06 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 117.208 -1.885 . . . . 0.0 115.077 173.309 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.618 HH11 HG11 ' A' ' 47' ' ' VAL . 3.1 ptp180 -78.82 153.47 30.64 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 120.795 2.297 . . . . 0.0 110.889 170.218 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 6.3 t -101.29 162.75 12.67 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 119.676 1.125 . . . . 0.0 112.917 177.466 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.471 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -130.44 137.98 50.09 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.788 2.035 . . . . 0.0 107.921 174.52 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.471 ' N ' HD13 ' A' ' 117' ' ' LEU . 7.4 p -122.2 125.44 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.291 1.436 . . . . 0.0 109.969 175.24 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -90.2 143.08 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 171.84 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -106.64 158.35 17.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 122.009 0.909 . . . . 0.0 112.909 -174.567 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -71.56 -40.8 69.74 Favored 'General case' 0 CA--C 1.538 0.483 0 O-C-N 121.334 -0.854 . . . . 0.0 111.237 -169.07 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -116.82 174.73 5.92 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 124.706 1.202 . . . . 0.0 112.664 172.594 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.4 148.16 1.43 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.813 2.445 . . . . 0.0 112.252 172.422 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -110.29 142.57 41.73 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.282 1.033 . . . . 0.0 112.185 172.609 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -93.93 -8.3 40.56 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 176.888 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 77.09 -73.33 0.09 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 128.94 2.896 . . . . 0.0 111.516 169.301 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -95.8 -5.26 59.99 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 125.262 1.411 . . . . 0.0 113.539 -174.389 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt -158.23 -146.08 0.15 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 128.088 2.555 . . . . 0.0 112.539 173.15 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 133.31 -29.13 3.21 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 128.7 3.048 . . . . 0.0 110.617 -168.393 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 126.73 -17.03 6.47 Favored Glycine 0 N--CA 1.473 1.12 0 C-N-CA 126.282 1.896 . . . . 0.0 114.986 169.588 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -110.57 174.6 5.79 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.09 1.356 . . . . 0.0 113.683 -171.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -52.22 -59.67 4.12 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.319 1.848 . . . . 0.0 110.615 167.52 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -46.57 -36.01 6.42 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.735 1.214 . . . . 0.0 112.51 169.433 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -66.47 -3.74 6.85 Favored 'General case' 0 N--CA 1.476 0.86 0 O-C-N 120.132 -1.605 . . . . 0.0 113.909 -175.936 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.1 p -119.96 -12.96 9.08 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 175.896 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 ptpt -113.25 -26.1 8.56 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 176.952 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.442 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 0.5 OUTLIER -127.96 -17.94 4.31 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 127.049 2.14 . . . . 0.0 113.809 179.497 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.03 -21.49 41.62 Favored Glycine 0 N--CA 1.467 0.724 0 C-N-CA 126.537 2.018 . . . . 0.0 111.969 177.361 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 71.46 36.65 1.26 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.94 1.696 . . . . 0.0 112.421 168.492 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.32 44.69 0.01 OUTLIER 'General case' 0 CA--C 1.575 1.941 0 C-N-CA 128.414 2.686 . . . . 0.0 117.41 -169.268 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.8 -57.21 2.62 Favored Glycine 0 N--CA 1.473 1.157 0 C-N-CA 127.84 2.638 . . . . 0.0 114.483 -177.986 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.9 t -168.17 171.11 9.7 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.727 1.211 . . . . 0.0 111.572 -178.584 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -85.04 148.29 26.23 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 120.726 -1.233 . . . . 0.0 110.608 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -128.01 -146.28 0.32 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.521 1.929 . . . . 0.0 109.26 175.935 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.79 155.37 30.54 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 127.146 2.178 . . . . 0.0 114.596 179.748 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.3 p -151.96 153.74 34.67 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.086 1.355 . . . . 0.0 114.084 -173.304 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.04 159.87 31.5 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 125.042 1.306 . . . . 0.0 113.407 178.057 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 3.6 t -106.45 142.91 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-N 118.717 1.259 . . . . 0.0 109.422 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mm -77.48 93.74 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 CA-C-O 122.232 1.015 . . . . 0.0 110.156 -178.676 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -92.27 174.94 37.38 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 125.884 1.707 . . . . 0.0 112.706 173.581 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.07 149.64 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -173.372 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.98 -17.58 4.37 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.552 1.941 . . . . 0.0 115.006 177.561 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 . . . . . 0 N--CA 1.472 0.627 0 C-N-CA 125.689 1.595 . . . . 0.0 112.592 176.864 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.279 0.561 . . . . 0.0 112.235 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.7 t -156.63 112.17 2.92 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 125.814 1.646 . . . . 0.0 108.458 167.878 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 10.1 pttt -111.93 171.72 7.33 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 116.45 2.019 . . . . 0.0 116.45 -173.315 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -125.87 168.32 14.02 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 128.457 2.703 . . . . 0.0 110.957 174.492 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 5' ' ' VAL . . . . . 0.576 HG13 ' HB2' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -131.5 139.46 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 126.331 1.852 . . . . 0.0 111.861 -178.202 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.06 105.05 4.77 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.092 0.957 . . . . 0.0 109.477 165.041 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.514 HG11 ' HB3' ' A' ' 59' ' ' SER . 1.0 OUTLIER -92.13 130.81 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 166.358 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mp -92.07 143.41 26.48 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 123.554 0.742 . . . . 0.0 111.284 -178.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 tttm -156.14 175.93 13.33 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 168.903 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 148.8 -77.93 0.23 Allowed Glycine 0 CA--C 1.523 0.552 0 C-N-CA 128.463 2.935 . . . . 0.0 108.164 -172.936 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.74 75.49 3.39 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.021 1.728 . . . . 0.0 112.735 -168.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.73 -97.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.37 0 C-N-CA 127.503 2.478 . . . . 0.0 114.314 169.518 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -82.81 -1.34 10.46 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.958 3.772 . . . . 0.0 114.945 179.162 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.81 140.34 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 120.54 1.518 . . . . 0.0 110.047 170.749 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -139.71 168.03 20.76 Favored 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 125.684 1.594 . . . . 0.0 109.31 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -158.83 92.98 0.12 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.034 -1.426 . . . . 0.0 116.126 165.229 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.404 ' O ' HD13 ' B' ' 18' ' ' ILE . 0.0 OUTLIER -78.22 126.5 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-N 119.296 1.548 . . . . 0.0 110.723 175.931 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.469 HD12 HG11 ' B' ' 97' ' ' VAL . 26.7 mm -135.98 111.08 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 124.901 1.28 . . . . 0.0 110.977 176.113 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -74.8 146.62 41.91 Favored 'General case' 0 CA--C 1.546 0.819 0 O-C-N 121.328 -0.857 . . . . 0.0 110.009 166.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -128.76 100.64 5.79 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.707 1.603 . . . . 0.0 108.571 172.914 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -101.83 130.37 48.27 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -174.549 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -100.81 120.51 40.22 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.136 0.493 . . . . 0.0 111.41 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 23' ' ' LYS . . . . . 0.422 ' HG2' ' H ' ' B' ' 23' ' ' LYS . 7.9 ptmm? -75.06 -41.7 58.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 123.048 0.539 . . . . 0.0 111.204 168.678 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -156.58 133.58 10.42 Favored 'General case' 0 C--O 1.219 -0.52 0 C-N-CA 126.429 1.892 . . . . 0.0 110.321 168.309 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -60.42 -19.72 57.23 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 114.703 1.372 . . . . 0.0 114.703 -172.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -80.56 -6.26 57.98 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.655 1.182 . . . . 0.0 113.218 173.753 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.86 -164.34 11.22 Favored Glycine 0 CA--C 1.537 1.459 0 C-N-CA 126.546 2.022 . . . . 0.0 113.383 -172.935 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.37 155.52 25.06 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.271 2.647 . . . . 0.0 114.012 -169.25 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 84.5 t -102.6 137.35 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.766 1.626 . . . . 0.0 110.17 172.739 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -96.09 122.62 39.12 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 167.145 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.31 129.2 74.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 126.166 1.786 . . . . 0.0 107.856 -169.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.5 p90 -155.41 153.16 29.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 -178.679 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.64 -152.73 24.77 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 125.417 1.484 . . . . 0.0 109.92 179.717 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 69.0 p -159.04 147.42 18.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -175.074 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 6.0 mm -105.62 109.55 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.558 1.543 . . . . 0.0 109.078 177.812 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 44.9 tttp -120.75 133.43 55.33 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 119.463 1.029 . . . . 0.0 110.94 -168.887 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.66 -6.43 9.73 Favored Glycine 0 CA--C 1.541 1.681 0 C-N-CA 127.964 2.697 . . . . 0.0 113.839 -169.663 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.489 HD12 ' CE1' ' B' ' 43' ' ' HIS . 4.6 mm? -75.08 -179.89 4.61 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 126.373 1.869 . . . . 0.0 113.346 177.169 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -103.95 157.73 16.9 Favored 'General case' 0 C--O 1.239 0.553 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 162.521 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -64.86 168.94 5.65 Favored 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.741 1.385 . . . . 0.0 114.741 -170.84 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.59 -177.54 51.38 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.261 0.934 . . . . 0.0 114.161 -173.021 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.8 mp -66.97 149.33 50.78 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 127.298 2.239 . . . . 0.0 113.648 -174.156 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 43' ' ' HIS . . . . . 0.489 ' CE1' HD12 ' B' ' 38' ' ' LEU . 96.9 m-70 -140.5 133.42 29.19 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.726 1.61 . . . . 0.0 110.235 176.816 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.59 146.67 48.47 Favored Glycine 0 N--CA 1.475 1.257 0 CA-C-O 119.055 -0.858 . . . . 0.0 110.987 175.574 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -152.94 111.79 3.76 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.592 0.757 . . . . 0.0 111.852 -166.06 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -147.73 152.2 37.36 Favored 'General case' 0 N--CA 1.471 0.617 0 O-C-N 120.032 -1.667 . . . . 0.0 111.256 -169.852 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.41 131.41 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-O 123.719 1.724 . . . . 0.0 110.117 169.527 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 18.1 m-70 -76.08 108.69 9.16 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 165.448 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -68.75 21.62 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.238 2.215 . . . . 0.0 113.554 -169.288 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -153.81 131.74 11.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.976 1.71 . . . . 0.0 108.005 -171.158 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.28 -14.54 76.39 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 115.124 0.81 . . . . 0.0 115.124 178.427 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 52' ' ' ASP . . . . . 0.574 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -69.91 74.07 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 127.023 2.129 . . . . 0.0 111.149 178.257 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 5.4 p30 164.02 -36.54 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 128.697 2.799 . . . . 0.0 115.237 -178.85 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.401 0.1 OUTLIER . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 130.457 3.503 . . . . 0.0 118.667 -173.625 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.684 0 CA-C-O 121.22 0.533 . . . . 0.0 111.381 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.05 178.39 49.08 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 118.774 -1.014 . . . . 0.0 113.713 173.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -64.71 -176.3 0.42 Allowed 'Trans proline' 0 C--N 1.356 0.928 1 C-N-CA 128.171 5.914 . . . . 0.0 113.097 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 63' ' ' HIS . . . . . 0.623 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.6 p80 -53.48 111.82 0.78 Allowed 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.215 1.406 . . . . 0.0 108.53 169.338 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -57.49 157.9 6.36 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 114.434 -1.257 . . . . 0.0 111.174 -178.854 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.26 49.78 0.01 OUTLIER Pre-proline 0 CA--C 1.566 1.59 0 N-CA-C 114.909 1.448 . . . . 0.0 114.909 172.497 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -65.74 -28.98 51.45 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.366 2.238 . . . . 0.0 114.247 -171.553 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 65.7 mt -75.79 -4.0 38.14 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 173.4 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 64.95 55.16 1.19 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.524 1.529 . . . . 0.0 112.827 170.231 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.33 178.92 8.73 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 124.899 1.279 . . . . 0.0 112.709 -171.274 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HZ1' ' CD ' ' B' ' 77' ' ' GLU . 22.4 pttm -72.7 161.24 31.0 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.138 0.575 . . . . 0.0 111.173 -175.757 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -82.41 155.17 24.82 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 179.426 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 141.26 -108.93 0.57 Allowed Glycine 0 C--N 1.339 0.72 0 N-CA-C 114.246 0.458 . . . . 0.0 114.246 166.896 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.438 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 107.2 -19.61 34.38 Favored Glycine 0 CA--C 1.546 1.988 0 N-CA-C 119.145 2.418 . . . . 0.0 119.145 169.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 74' ' ' PRO . . . . . 0.43 ' HG2' HD13 ' B' ' 126' ' ' LEU . 0.5 OUTLIER -110.15 24.9 0.05 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 0 C-N-CA 124.248 3.299 . . . . 0.0 111.718 169.01 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 ptpt -165.85 -31.67 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 127.301 2.24 . . . . 0.0 110.646 170.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 76' ' ' ASP . . . . . 0.438 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.0 OUTLIER -84.2 136.72 33.85 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 128.469 2.708 . . . . 0.0 107.155 166.865 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 77' ' ' GLU . . . . . 0.487 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -87.63 -12.82 44.43 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 127.209 2.204 . . . . 0.0 113.523 -176.993 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -91.65 -98.65 0.12 Allowed 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.112 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 87.58 141.32 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 128.391 2.676 . . . . 0.0 113.573 174.599 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -69.67 154.99 41.2 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 116.938 -1.506 . . . . 0.0 107.872 162.73 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.326 7.1 p -76.5 -21.97 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-N 122.467 2.394 . . . . 0.0 111.104 177.173 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -69.11 20.81 0.4 Allowed Glycine 0 CA--C 1.537 1.436 0 C-N-CA 125.693 1.616 . . . . 0.0 115.327 169.202 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -124.63 118.16 25.88 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 120.785 2.292 . . . . 0.0 111.71 -176.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -97.75 170.81 8.73 Favored 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 166.378 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -76.04 175.5 52.27 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 166.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -70.65 145.93 50.32 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.559 -0.377 . . . . 0.0 111.104 -169.821 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.417 HG22 ' HB1' ' B' ' 95' ' ' ALA . 6.6 p -85.0 166.0 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 165.853 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -152.49 140.2 19.89 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.159 1.345 . . . . 0.0 112.688 -177.532 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 89' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -116.94 152.33 34.78 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -167.988 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -97.25 155.46 16.85 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 129.245 3.018 . . . . 0.0 110.943 170.573 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -43.01 -24.02 0.06 Allowed 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 129.487 3.115 . . . . 0.0 117.27 175.479 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.41 6.28 5.91 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 120.503 -1.373 . . . . 0.0 111.595 172.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.0 27.91 67.71 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 126.06 1.791 . . . . 0.0 112.801 178.564 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.5 p -115.71 120.28 64.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.09 0.956 . . . . 0.0 110.63 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -83.6 120.99 26.64 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.521 1.128 . . . . 0.0 108.728 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.42 146.3 28.51 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.852 0.834 . . . . 0.0 110.302 172.549 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . 0.469 HG11 HD12 ' B' ' 18' ' ' ILE . 0.4 OUTLIER -132.37 127.96 57.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.52 165.333 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -150.68 53.59 0.88 Allowed 'General case' 0 CA--C 1.545 0.757 0 CA-C-O 123.583 1.658 . . . . 0.0 109.204 -172.746 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.5 mp -105.03 160.85 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.241 1.816 . . . . 0.0 112.512 -166.587 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -140.23 142.12 35.84 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 128.153 2.581 . . . . 0.0 106.304 168.691 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -150.98 138.29 19.39 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 119.084 0.856 . . . . 0.0 111.393 -179.949 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.2 p -107.84 52.75 0.71 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.393 1.077 . . . . 0.0 111.815 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.63 -42.1 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.864 1.666 . . . . 0.0 108.967 177.172 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -87.9 144.64 8.78 Favored 'Isoleucine or valine' 0 C--N 1.344 0.338 0 CA-C-O 122.32 1.057 . . . . 0.0 110.463 167.468 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 10.3 p -148.86 168.41 23.08 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 124.201 1.001 . . . . 0.0 111.125 170.215 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -79.72 63.49 4.3 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 124.754 1.221 . . . . 0.0 108.628 174.737 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.0 t -84.55 -175.67 5.89 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.082 1.353 . . . . 0.0 110.342 169.086 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.06 -46.92 2.33 Favored Glycine 0 N--CA 1.475 1.265 0 O-C-N 120.924 -1.11 . . . . 0.0 113.832 177.016 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -125.27 -24.74 3.91 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -169.398 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 73.0 m-70 -97.71 7.98 45.48 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.558 1.543 . . . . 0.0 113.421 -171.554 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.62 -133.83 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -171.916 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.321 36.0 pt -81.28 -143.18 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 CA-C-N 119.431 1.014 . . . . 0.0 113.011 170.822 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm 59.49 124.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 127.597 2.359 . . . . 0.0 111.873 -165.56 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.05 19.68 61.69 Favored Glycine 0 N--CA 1.474 1.212 0 O-C-N 120.409 -1.432 . . . . 0.0 113.981 179.007 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? -99.93 172.45 7.22 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 127.157 2.183 . . . . 0.0 109.496 174.56 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.9 t -130.67 127.0 37.99 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-N 119.371 0.987 . . . . 0.0 112.287 177.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 16.7 tp -93.0 130.36 38.59 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 125.677 1.591 . . . . 0.0 110.322 -175.648 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.53 146.5 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 125.781 1.632 . . . . 0.0 111.323 175.514 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.3 p -121.78 142.14 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 123.48 0.712 . . . . 0.0 111.215 170.553 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -115.25 156.06 26.08 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 113.607 -168.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -73.67 -28.53 61.81 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -169.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -117.82 173.97 6.45 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.562 1.145 . . . . 0.0 112.228 176.721 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.8 134.06 56.25 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.368 1.467 . . . . 0.0 110.828 169.8 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -81.78 119.67 24.18 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.411 1.084 . . . . 0.0 111.277 173.6 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 125' ' ' ASP . . . . . . . . . . . . 0.369 30.3 t0 -75.71 -4.88 42.86 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 170.47 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 126' ' ' LEU . . . . . 0.43 HD13 ' HG2' ' B' ' 74' ' ' PRO . 5.4 mt 61.03 76.03 0.39 Allowed 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 126.221 1.808 . . . . 0.0 112.123 165.125 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.13 -12.71 48.78 Favored Glycine 0 N--CA 1.476 1.303 0 C-N-CA 123.174 0.416 . . . . 0.0 112.875 176.913 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mtpm? -115.38 179.0 4.09 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.883 2.473 . . . . 0.0 109.223 170.033 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 126.39 -28.81 4.68 Favored Glycine 0 N--CA 1.469 0.861 0 C-N-CA 125.681 1.61 . . . . 0.0 111.351 -168.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 104.43 -6.29 45.52 Favored Glycine 0 N--CA 1.474 1.185 0 N-CA-C 117.253 1.661 . . . . 0.0 117.253 166.609 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.0 p-10 -110.74 170.24 8.23 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.771 1.628 . . . . 0.0 110.258 176.159 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 132' ' ' GLU . . . . . 0.415 ' OE2' ' HE2' ' B' ' 136' ' ' LYS . 24.2 tt0 -63.0 -41.65 99.63 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.514 -1.366 . . . . 0.0 110.412 -179.843 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -56.23 -27.88 56.49 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.369 2.267 . . . . 0.0 112.569 176.317 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.26 -23.04 54.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.566 1.076 . . . . 0.0 113.573 171.224 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.6 t -121.23 -13.05 8.56 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.373 1.619 . . . . 0.0 115.373 169.646 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.415 ' HE2' ' OE2' ' B' ' 132' ' ' GLU . 30.6 mttm -76.48 -23.96 53.82 Favored 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 121.009 1.732 . . . . 0.0 111.449 166.501 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 75.6 p -117.97 -114.21 0.33 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 104.3 -2.481 . . . . 0.0 104.3 165.386 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.24 -10.76 0.19 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 116.262 1.265 . . . . 0.0 116.262 169.136 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 114.85 -14.15 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 131.123 3.769 . . . . 0.0 112.737 177.819 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.08 4.9 0.11 Allowed 'General case' 0 CA--C 1.56 1.344 0 N-CA-C 117.497 2.406 . . . . 0.0 117.497 -174.34 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.8 -141.68 18.8 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.542 1.544 . . . . 0.0 113.466 174.808 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.0 t -68.64 -167.44 0.1 Allowed 'General case' 0 CA--C 1.544 0.732 0 CA-C-O 122.294 1.045 . . . . 0.0 111.965 175.909 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.88 155.79 44.69 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 124.428 1.091 . . . . 0.0 110.578 177.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.72 -123.19 0.29 Allowed 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 126.256 2.222 . . . . 0.0 105.034 164.003 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -66.91 160.71 25.65 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -166.394 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.8 t -147.88 152.08 37.0 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.445 1.898 . . . . 0.0 112.078 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.65 135.79 4.3 Favored Glycine 0 N--CA 1.483 1.829 0 CA-C-N 120.317 1.417 . . . . 0.0 115.667 -177.087 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 12.2 t -81.65 154.89 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 125.336 1.454 . . . . 0.0 111.779 -177.204 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 39.3 mt -95.46 93.82 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 126.455 1.902 . . . . 0.0 111.99 -176.358 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.24 173.63 30.35 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 125.614 1.578 . . . . 0.0 113.487 174.606 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.8 mp -95.49 85.98 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.095 1.887 . . . . 0.0 116.095 -167.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -73.78 18.92 0.12 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.961 1.704 . . . . 0.0 115.478 -179.801 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 . . . . . 0 N--CA 1.466 0.364 0 C-N-CA 130.845 3.658 . . . . 0.0 114.712 -169.279 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.812 0 CA-C-O 119.813 -0.137 . . . . 0.0 111.107 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 t -77.2 115.79 17.28 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 152' ' ' ALA . 14.4 pttm -89.13 129.96 35.64 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.598 -1.183 . . . . 0.0 110.375 168.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.633 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -90.56 173.52 8.02 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 164.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.582 HG23 HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -138.2 119.56 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.524 1.53 . . . . 0.0 108.475 -173.784 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.96 118.77 37.65 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 166.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 HG22 ' B' ' 54' ' ' THR . 22.0 t -110.99 99.66 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.705 0.802 . . . . 0.0 109.397 177.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.95 132.56 35.89 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.564 168.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -135.5 132.51 37.4 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.048 1.339 . . . . 0.0 110.643 168.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.95 -97.95 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 171.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.87 119.77 9.95 Favored 'General case' 0 N--CA 1.44 -0.94 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 -166.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 41.02 -99.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 128.743 3.068 . . . . 0.0 113.358 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.88 -11.88 33.52 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 123.311 2.674 . . . . 0.0 113.828 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.89 115.05 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 120.32 1.418 . . . . 0.0 112.44 179.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -139.9 169.9 16.86 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 122.265 1.031 . . . . 0.0 111.005 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.96 110.29 0.55 Allowed Glycine 0 C--O 1.224 -0.476 0 CA-C-N 113.984 -1.462 . . . . 0.0 111.639 168.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.62 134.65 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 CA-C-N 118.106 0.953 . . . . 0.0 109.339 169.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.1 mm -139.38 124.45 21.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 C-N-CA 125.996 1.718 . . . . 0.0 109.888 168.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -90.81 141.32 28.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 124.867 1.267 . . . . 0.0 110.571 166.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.633 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 71.4 m-85 -113.94 101.53 9.34 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.686 1.194 . . . . 0.0 109.779 172.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -83.91 110.68 18.59 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 125.965 1.706 . . . . 0.0 111.172 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.498 ' HB2' HD13 ' A' ' 106' ' ' LEU . 6.7 tp60 -123.13 139.17 54.34 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.378 1.071 . . . . 0.0 110.989 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.94 -28.17 15.3 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 -168.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.277 0.0 OUTLIER -128.68 -106.76 0.3 Allowed 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.953 1.301 . . . . 0.0 109.508 166.628 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 88.4 p -152.96 -10.37 0.16 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 122.13 2.241 . . . . 0.0 116.358 -177.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -128.94 -13.91 4.52 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.377 1.471 . . . . 0.0 112.672 176.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 174.53 42.58 Favored Glycine 0 CA--C 1.543 1.812 0 C-N-CA 127.938 2.685 . . . . 0.0 113.885 175.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -79.91 157.32 23.99 Favored 'Trans proline' 0 CA--C 1.534 0.498 0 C-N-CA 123.546 2.831 . . . . 0.0 112.427 -168.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.2 t -118.21 136.89 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.97 0.908 . . . . 0.0 112.427 -166.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -93.57 124.31 37.47 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.597 1.159 . . . . 0.0 108.151 170.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.25 133.34 69.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.924 0.89 . . . . 0.0 110.29 -168.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -157.36 158.83 36.69 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.25 178.6 29.67 Favored Glycine 0 CA--C 1.528 0.849 0 C-N-CA 123.881 0.753 . . . . 0.0 114.799 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.0 p -115.69 125.35 52.72 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -167.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 9.7 mm -109.74 102.24 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 C-N-CA 125.224 1.41 . . . . 0.0 108.068 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -116.2 157.61 24.59 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.315 0.646 . . . . 0.0 112.194 -168.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.94 9.6 63.72 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 124.941 1.258 . . . . 0.0 112.448 -168.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 99.0 mt -83.33 167.93 17.13 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.688 1.195 . . . . 0.0 110.563 172.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -100.37 156.64 17.14 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 106.322 -1.732 . . . . 0.0 106.322 163.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -61.96 157.23 19.08 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-O 122.509 1.147 . . . . 0.0 113.429 -170.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.02 -176.83 36.37 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 122.147 0.859 . . . . 0.0 112.685 -173.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.504 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.2 mp -72.52 150.35 43.29 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.695 1.998 . . . . 0.0 111.895 -169.12 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -144.31 124.82 13.96 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 125.847 1.659 . . . . 0.0 110.462 174.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.04 148.33 36.38 Favored Glycine 0 N--CA 1.487 2.054 0 CA-C-O 118.723 -1.043 . . . . 0.0 112.869 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.508 ' CE1' HD11 ' A' ' 117' ' ' LEU . 7.4 t80 -149.84 97.53 2.61 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-N 118.325 1.062 . . . . 0.0 113.613 -166.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.504 ' O ' HD22 ' A' ' 117' ' ' LEU . 9.9 m80 -130.25 134.29 47.13 Favored 'General case' 0 N--CA 1.483 1.196 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -166.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.792 HG23 ' HA2' ' A' ' 82' ' ' GLY . 0.0 OUTLIER -85.36 113.94 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 122.015 0.912 . . . . 0.0 110.896 170.17 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -81.74 173.07 12.65 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 125.419 1.487 . . . . 0.0 114.109 -175.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.449 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.6 pm0 -65.06 133.41 51.58 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 126.062 1.745 . . . . 0.0 106.54 165.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 67.83 -176.91 0.2 Allowed 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 124.275 1.988 . . . . 0.0 112.992 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.34 3.65 29.68 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 130.618 3.961 . . . . 0.0 111.52 168.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.411 ' C ' HD22 ' A' ' 53' ' ' ASN . 14.9 t0 -73.85 126.51 30.57 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 120.385 2.093 . . . . 0.0 109.51 172.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.532 ' CG ' HG21 ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -156.12 42.62 0.4 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 123.289 1.518 . . . . 0.0 112.708 168.46 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.753 ' CG2' HG22 ' B' ' 7' ' ' VAL . 38.8 p -116.3 -25.7 7.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 112.737 -2.029 . . . . 0.0 113.905 -165.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 25.6 0.59 Allowed 'General case' 0 CA--C 1.552 1.039 0 CA-C-N 119.374 0.988 . . . . 0.0 112.109 168.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.69 -121.35 12.34 Favored Glycine 0 C--N 1.341 0.827 0 C-N-CA 125.573 1.558 . . . . 0.0 110.561 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -74.14 -13.68 60.85 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.17 39.44 0.45 Allowed 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 126.072 1.749 . . . . 0.0 111.72 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 69.8 m -148.29 -116.16 0.06 Allowed 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.306 2.243 . . . . 0.0 106.636 -169.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.59 109.98 0.71 Allowed 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 124.781 1.232 . . . . 0.0 112.23 169.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.57 -113.02 0.47 Allowed Glycine 0 CA--C 1.538 1.485 0 CA-C-O 117.928 -1.485 . . . . 0.0 109.574 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -82.67 -179.86 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 124.415 3.41 . . . . 0.0 108.102 165.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.29 123.07 32.52 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.673 0.789 . . . . 0.0 111.518 -172.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -26.03 131.77 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 129.419 3.088 . . . . 0.0 116.956 174.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -106.15 52.69 0.15 Allowed Pre-proline 0 CA--C 1.557 1.235 0 C-N-CA 124.883 1.273 . . . . 0.0 113.425 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -63.05 -25.3 73.57 Favored 'Trans proline' 0 C--N 1.355 0.896 0 CA-C-N 122.691 1.997 . . . . 0.0 112.937 -173.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 69.0 mt -99.5 -0.49 40.56 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.802 1.241 . . . . 0.0 113.797 172.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.4 t 70.57 58.87 0.23 Allowed 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 120.452 1.478 . . . . 0.0 114.073 168.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.06 176.01 10.04 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.446 1.498 . . . . 0.0 111.478 172.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -70.8 173.29 7.49 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 129.497 3.119 . . . . 0.0 113.225 178.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.2 t60 -69.02 149.29 48.95 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.481 167.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 171.45 -157.45 27.95 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 116.884 1.513 . . . . 0.0 116.884 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.81 -70.29 0.43 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 118.013 1.965 . . . . 0.0 118.013 168.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -75.98 0.03 9.76 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 123.327 2.685 . . . . 0.0 114.506 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.98 -31.48 0.21 Allowed 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 119.301 0.955 . . . . 0.0 111.415 171.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -89.92 153.23 20.77 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.464 1.506 . . . . 0.0 111.26 167.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.7 tt0 -98.68 -27.82 13.81 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 126.356 1.863 . . . . 0.0 112.722 -170.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -78.8 -53.02 7.54 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 121.412 -0.805 . . . . 0.0 110.704 -169.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.7 ttt180 58.17 119.75 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 117.789 2.515 . . . . 0.0 117.789 163.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 21.8 m170 -58.5 143.08 46.94 Favored 'General case' 0 CA--C 1.544 0.725 0 O-C-N 118.458 -2.652 . . . . 0.0 112.942 169.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 91.2 t -58.26 -24.18 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.334 -0.854 . . . . 0.0 110.432 167.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.792 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -80.89 23.38 4.39 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 117.157 -1.913 . . . . 0.0 116.44 172.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -127.4 109.62 11.95 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 120.577 2.189 . . . . 0.0 111.533 -178.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.437 HD21 HD23 ' A' ' 117' ' ' LEU . 0.9 OUTLIER -110.92 59.56 0.61 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.156 0.982 . . . . 0.0 110.742 172.502 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.79 -151.78 39.8 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.916 173.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.82 149.47 47.75 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.805 1.242 . . . . 0.0 108.619 169.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 19.5 m -103.26 106.47 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 124.559 1.144 . . . . 0.0 109.579 -174.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 38.7 m -96.14 114.67 26.39 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 124.451 1.1 . . . . 0.0 108.772 -174.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.73 154.11 19.18 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.666 1.187 . . . . 0.0 113.421 -172.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.6 176.84 6.13 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.513 1.125 . . . . 0.0 112.278 168.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.434 ' HZ3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -73.57 -18.9 61.01 Favored 'General case' 0 N--CA 1.473 0.718 0 O-C-N 121.113 -0.992 . . . . 0.0 113.003 -176.587 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.37 15.23 0.48 Allowed 'General case' 0 CA--C 1.56 1.328 0 CA-C-O 122.974 1.369 . . . . 0.0 110.799 170.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.29 12.74 80.18 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 128.131 2.776 . . . . 0.0 114.726 168.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.26 134.4 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 116.77 2.137 . . . . 0.0 116.77 -166.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.0 103.84 13.97 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 124.734 1.214 . . . . 0.0 107.822 166.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -94.89 109.36 21.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.944 0.878 . . . . 0.0 109.635 172.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -93.67 153.84 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 C-N-CA 124.825 1.25 . . . . 0.0 112.977 -169.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.2 p -149.6 125.74 10.69 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.933 0.893 . . . . 0.0 110.635 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.4 mt -144.98 157.99 13.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 128.548 2.739 . . . . 0.0 110.492 -169.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -147.04 135.89 22.23 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.456 1.902 . . . . 0.0 107.055 167.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -155.79 144.92 20.69 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -166.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.0 p -122.15 49.25 1.6 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.326 1.05 . . . . 0.0 113.742 176.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.03 -3.63 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 124.769 1.227 . . . . 0.0 112.478 171.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.61 163.74 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 127.023 2.129 . . . . 0.0 110.004 174.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 10.0 t -157.13 163.84 38.49 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.524 1.529 . . . . 0.0 110.53 170.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.498 HD13 ' HB2' ' A' ' 22' ' ' GLN . 7.5 mp -77.3 66.36 3.06 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 120.195 1.361 . . . . 0.0 110.923 -171.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.89 104.0 9.24 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 125.431 1.492 . . . . 0.0 114.185 -167.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.49 -145.37 32.88 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.269 167.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -109.24 11.28 25.5 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.609 1.564 . . . . 0.0 112.086 -167.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -141.78 -9.77 0.92 Allowed 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -167.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 23.2 t -90.22 -87.85 0.18 Allowed 'General case' 0 N--CA 1.471 0.596 0 O-C-N 120.774 -1.204 . . . . 0.0 110.951 -171.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.294 0.1 OUTLIER -134.33 16.01 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 120.708 1.595 . . . . 0.0 112.505 167.356 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.39 141.04 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.25 3.97 83.0 Favored Glycine 0 N--CA 1.468 0.82 0 C-N-CA 124.451 1.024 . . . . 0.0 114.575 -175.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 44.2 ttt180 -100.38 176.36 5.38 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.286 1.434 . . . . 0.0 111.903 -167.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 18.8 m -118.62 143.05 47.07 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.942 1.697 . . . . 0.0 108.987 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.508 HD11 ' CE1' ' A' ' 45' ' ' PHE . 3.2 tm? -117.62 141.89 47.85 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.581 1.152 . . . . 0.0 108.648 167.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.2 p -118.05 139.04 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.881 0.872 . . . . 0.0 111.52 172.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 4.7 p -110.81 133.64 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 O-C-N 124.293 0.996 . . . . 0.0 109.623 167.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 -99.94 159.45 15.07 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -60.6 -44.83 95.84 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.601 2.76 . . . . 0.0 114.714 -175.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 3.4 mppt? -127.35 -180.0 5.18 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.987 1.715 . . . . 0.0 113.163 -176.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.23 147.02 17.45 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 125.514 1.526 . . . . 0.0 112.428 173.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -102.53 137.04 41.3 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.821 1.648 . . . . 0.0 109.967 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -72.54 -43.31 63.68 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.964 -0.541 . . . . 0.0 111.673 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.0 mt 71.74 53.48 0.21 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.688 1.995 . . . . 0.0 111.967 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 158.43 -90.11 0.11 Allowed Glycine 0 N--CA 1.474 1.224 0 CA-C-N 119.598 1.09 . . . . 0.0 115.128 176.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.6 ttpm? -146.44 98.9 3.14 Favored 'General case' 0 N--CA 1.424 -1.76 0 C-N-CA 128.649 2.78 . . . . 0.0 107.745 177.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.5 -138.74 0.69 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 169.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -89.74 6.26 83.08 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.08 -175.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -157.99 168.92 25.77 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 120.372 2.086 . . . . 0.0 109.789 -169.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.91 -57.7 11.54 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.425 1.09 . . . . 0.0 110.836 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -41.24 -40.47 1.62 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 127.663 2.385 . . . . 0.0 114.562 178.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 64.1 p -55.12 -27.59 46.41 Favored 'General case' 0 N--CA 1.469 0.505 0 O-C-N 120.595 -1.315 . . . . 0.0 113.768 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 27.1 p -71.63 -28.02 63.49 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.557 1.143 . . . . 0.0 112.681 173.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -79.4 -56.98 3.93 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.771 1.628 . . . . 0.0 112.471 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.8 p -115.29 -14.84 11.65 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.525 1.306 . . . . 0.0 114.525 -170.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.49 -1.88 69.86 Favored Glycine 0 N--CA 1.466 0.65 0 O-C-N 123.902 0.751 . . . . 0.0 112.277 -169.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 66.16 17.56 10.77 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.671 1.188 . . . . 0.0 111.021 -176.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.6 -9.81 15.39 Favored 'General case' 0 CA--C 1.554 1.127 0 C-N-CA 123.898 0.879 . . . . 0.0 113.175 -168.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.67 -164.03 21.79 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.831 1.681 . . . . 0.0 112.937 178.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 m -63.68 175.67 1.05 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.797 1.239 . . . . 0.0 112.246 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.29 143.96 38.08 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 120.761 -1.212 . . . . 0.0 112.066 169.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -104.04 -94.72 0.33 Allowed 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.105 1.762 . . . . 0.0 109.052 173.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.34 149.18 38.78 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 122.379 1.085 . . . . 0.0 110.793 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 84.5 m -131.67 151.76 51.39 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 112.768 -2.014 . . . . 0.0 108.005 173.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.94 163.04 33.52 Favored Glycine 0 C--N 1.332 0.31 0 C-N-CA 123.404 0.526 . . . . 0.0 113.899 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 25.1 t -113.5 160.87 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 125.358 1.463 . . . . 0.0 110.589 177.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.2 mt -114.65 123.26 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 124.222 1.009 . . . . 0.0 113.362 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -126.74 -168.73 12.62 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 126.144 1.83 . . . . 0.0 113.093 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 151' ' ' ILE . 2.2 mp -104.63 131.78 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 121.57 -0.959 . . . . 0.0 111.033 -169.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.542 ' HB2' ' CG1' ' A' ' 5' ' ' VAL . . . -118.71 22.6 11.92 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.719 1.608 . . . . 0.0 113.61 -174.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.332 -0.188 0 C-N-CA 124.368 1.067 . . . . 0.0 110.47 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.825 0.345 . . . . 0.0 111.845 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 9.9 t -107.98 122.49 46.95 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.726 0.81 . . . . 0.0 109.411 175.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -99.18 131.17 45.41 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 174.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.86 169.52 8.54 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.652 1.181 . . . . 0.0 114.08 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -161.63 88.07 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 C-N-CA 128.114 2.566 . . . . 0.0 109.218 -169.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.72 142.73 35.18 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 120.415 -1.428 . . . . 0.0 111.005 176.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.753 HG22 ' CG2' ' A' ' 54' ' ' THR . 4.2 t -126.7 106.23 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 3.1 mp -100.0 139.33 35.82 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.603 1.161 . . . . 0.0 108.21 169.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -155.95 175.18 14.29 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.126 1.37 . . . . 0.0 110.307 170.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 143.62 -46.3 0.84 Allowed Glycine 0 N--CA 1.474 1.201 0 C-N-CA 124.54 1.067 . . . . 0.0 113.68 169.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -78.01 67.2 3.8 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.535 1.534 . . . . 0.0 109.23 175.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.24 -111.34 0.38 Allowed Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.649 2.547 . . . . 0.0 112.625 -175.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -76.51 1.14 8.76 Favored 'Trans proline' 0 CA--C 1.536 0.603 0 C-N-CA 124.906 3.737 . . . . 0.0 114.168 -176.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 31.1 t -79.49 131.39 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 120.155 1.343 . . . . 0.0 111.283 171.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -130.13 160.84 32.56 Favored 'General case' 0 CA--C 1.516 -0.363 0 C-N-CA 125.127 1.371 . . . . 0.0 109.381 167.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.68 107.68 0.69 Allowed Glycine 0 CA--C 1.499 -0.926 0 CA-C-N 113.956 -1.474 . . . . 0.0 109.491 169.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.73 120.71 65.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.252 2.9 pp -130.53 139.49 51.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 122.376 1.084 . . . . 0.0 110.715 172.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -107.54 172.98 6.53 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 125.921 1.688 . . . . 0.0 110.523 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -152.66 165.74 34.32 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.773 0.829 . . . . 0.0 109.528 170.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -136.02 138.12 41.88 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.175 1.39 . . . . 0.0 109.584 166.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 59.4 tp60 -102.97 102.28 12.32 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 123.554 0.742 . . . . 0.0 110.749 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.497 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -67.25 -45.0 78.0 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 120.51 -1.369 . . . . 0.0 113.703 176.158 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.497 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 40.0 mp0 -147.7 138.98 23.62 Favored 'General case' 0 C--O 1.222 -0.379 0 C-N-CA 126.858 2.063 . . . . 0.0 108.394 168.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 76.0 p -50.33 -20.44 1.08 Allowed 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -169.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -112.98 0.46 15.06 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 125.141 1.376 . . . . 0.0 113.248 -173.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.72 -170.3 43.18 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.664 1.126 . . . . 0.0 113.624 -173.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -81.2 162.52 20.14 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.761 2.307 . . . . 0.0 109.923 168.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -135.47 143.24 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 124.481 1.112 . . . . 0.0 110.999 -174.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HZ3' ' CD ' ' B' ' 100' ' ' GLU . 41.7 tttp -94.88 115.78 27.89 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.795 0.807 . . . . 0.0 110.153 167.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.94 144.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 166.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -144.56 -168.39 2.89 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 167.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.45 -153.82 17.22 Favored Glycine 0 N--CA 1.469 0.843 0 C-N-CA 124.84 1.21 . . . . 0.0 112.684 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 94.7 p -156.67 137.87 13.72 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 114.062 1.134 . . . . 0.0 114.062 -172.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 7.8 mm -104.96 119.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 169.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -131.91 144.62 50.98 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 121.192 1.814 . . . . 0.0 111.816 -171.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.7 -8.16 21.99 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 128.547 2.975 . . . . 0.0 113.374 -173.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.41 HD23 ' CD2' ' B' ' 43' ' ' HIS . 5.5 mp -71.44 156.48 39.41 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 129.327 3.051 . . . . 0.0 112.732 -176.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.6 t -74.48 168.32 19.95 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 164.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -75.52 146.1 40.81 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.167 -0.958 . . . . 0.0 112.976 177.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 107.72 -168.04 13.79 Favored Glycine 0 CA--C 1.532 1.096 0 C-N-CA 124.142 0.877 . . . . 0.0 113.017 -172.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.0 mt -76.12 147.43 38.58 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 126.896 2.078 . . . . 0.0 112.966 -169.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . 0.41 ' CD2' HD23 ' B' ' 38' ' ' LEU . 87.2 m-70 -146.54 120.75 9.53 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.929 2.092 . . . . 0.0 110.501 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.06 145.86 37.05 Favored Glycine 0 N--CA 1.484 1.876 0 CA-C-O 117.536 -1.702 . . . . 0.0 112.333 -177.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.64 ' HB2' HG22 ' B' ' 119' ' ' VAL . 0.4 OUTLIER -141.49 125.89 17.64 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 121.173 2.486 . . . . 0.0 113.074 -178.546 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 28.7 m80 -137.2 128.21 27.59 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -171.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.0 m -80.59 137.51 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 165.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -113.81 171.27 7.69 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 118.715 0.689 . . . . 0.0 111.466 173.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -72.63 138.72 46.92 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 125.184 1.394 . . . . 0.0 110.707 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 72.0 168.36 0.31 Allowed 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.6 1.96 . . . . 0.0 111.37 -168.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.405 ' C ' HG11 ' A' ' 5' ' ' VAL . . . -93.32 16.62 60.19 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 164.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.409 ' HA ' HG21 ' A' ' 5' ' ' VAL . 15.5 t0 -87.35 110.45 20.25 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 125.9 1.68 . . . . 0.0 109.444 -168.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.618 HD21 HG22 ' B' ' 148' ' ' VAL . 2.2 p30 -159.23 34.48 0.2 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 116.132 1.901 . . . . 0.0 116.132 -174.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.582 HG22 HG23 ' A' ' 5' ' ' VAL 0.321 1.3 p -71.16 -72.31 0.22 Allowed 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -164.622 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -88.57 -19.31 26.5 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.718 1.377 . . . . 0.0 114.718 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.84 -139.89 12.04 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 125.901 1.715 . . . . 0.0 110.275 -169.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 24.3 p -45.56 -33.26 2.68 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 118.304 2.705 . . . . 0.0 118.304 -168.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.2 m -68.58 -25.29 64.81 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 124.432 1.093 . . . . 0.0 112.421 175.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.3 m -107.96 67.99 0.69 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 128.504 2.722 . . . . 0.0 107.597 169.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 79.54 139.95 0.07 Allowed 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.776 2.43 . . . . 0.0 114.413 175.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.15 -115.81 4.04 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.502 1.525 . . . . 0.0 111.773 176.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.58 175.52 10.96 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.968 3.112 . . . . 0.0 110.978 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.63 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -69.57 113.76 7.16 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.94 1.696 . . . . 0.0 109.192 176.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 19.5 t80 -55.15 145.43 21.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 122.832 1.301 . . . . 0.0 114.503 -168.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -111.05 66.77 0.55 Allowed Pre-proline 0 CA--C 1.55 0.977 0 C-N-CA 126.87 2.068 . . . . 0.0 112.16 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -60.64 -35.64 88.78 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.076 2.518 . . . . 0.0 113.329 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 72.9 mt -80.85 -1.32 42.76 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.728 1.211 . . . . 0.0 114.177 171.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t 71.22 47.02 0.41 Allowed 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 127.835 2.454 . . . . 0.0 111.073 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.7 mtp180 -103.02 171.99 7.07 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -169.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mpmm? -83.45 167.07 17.81 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 125.665 1.586 . . . . 0.0 109.449 162.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -78.32 168.46 19.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.357 1.063 . . . . 0.0 112.087 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 134.6 -134.95 7.65 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 124.719 1.152 . . . . 0.0 113.495 168.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.81 -80.77 0.33 Allowed Glycine 0 CA--C 1.541 1.657 0 CA-C-N 118.278 1.039 . . . . 0.0 115.335 -174.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.19 7.5 0.63 Allowed 'Trans proline' 0 CA--C 1.547 1.175 0 CA-C-N 120.846 2.323 . . . . 0.0 115.328 -177.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.35 6.57 0.29 Allowed 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 126.986 2.115 . . . . 0.0 113.366 169.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.6 156.71 45.66 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.406 2.282 . . . . 0.0 110.336 -170.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -97.43 -9.22 27.71 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.648 1.979 . . . . 0.0 112.126 -173.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -83.86 -95.81 0.06 Allowed 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.443 -0.786 . . . . 0.0 110.482 177.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 48.8 ttt180 68.49 115.98 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.513 1.925 . . . . 0.0 112.274 -170.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -55.21 154.31 5.96 Favored 'General case' 0 CA--C 1.552 1.022 0 O-C-N 119.505 -1.997 . . . . 0.0 114.813 171.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -84.91 58.18 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 C-N-CA 124.573 1.149 . . . . 0.0 109.492 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 144.61 67.75 0.02 OUTLIER Glycine 0 N--CA 1.469 0.852 0 C-N-CA 127.569 2.509 . . . . 0.0 109.59 -169.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -163.9 165.45 22.75 Favored 'General case' 0 CA--C 1.553 1.065 0 C-N-CA 128.78 2.832 . . . . 0.0 110.027 166.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 92.9 mt -131.39 -178.38 4.82 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.386 2.274 . . . . 0.0 107.331 168.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.46 -112.4 0.86 Allowed Glycine 0 N--CA 1.47 0.95 0 CA-C-N 118.309 0.504 . . . . 0.0 112.689 -179.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -137.11 164.17 29.06 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-O 121.643 0.735 . . . . 0.0 112.813 176.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.5 m -108.61 175.59 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 127.342 2.257 . . . . 0.0 109.354 171.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 3.2 m -141.34 140.25 33.72 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.525 1.53 . . . . 0.0 107.633 169.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.42 139.58 40.68 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 124.439 1.096 . . . . 0.0 112.814 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -82.62 154.35 24.98 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 126.717 2.007 . . . . 0.0 110.603 168.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.22 1.25 0.51 Allowed 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 117.621 2.452 . . . . 0.0 117.621 -169.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -76.24 -7.37 54.71 Favored 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 125.138 1.375 . . . . 0.0 109.783 164.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 93.77 20.67 30.73 Favored Glycine 0 C--N 1.337 0.594 0 C-N-CA 128.719 3.057 . . . . 0.0 112.482 177.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.7 p -127.68 133.51 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 119.09 1.445 . . . . 0.0 114.224 -168.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.93 131.24 41.07 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 165.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -81.77 142.46 32.59 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 104.105 -2.554 . . . . 0.0 104.105 166.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 t -125.9 127.02 70.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 CA-C-N 113.349 -1.751 . . . . 0.0 107.541 169.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 26.8 p -158.77 51.4 0.39 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.723 1.609 . . . . 0.0 110.105 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 mt -103.56 148.76 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.874 1.67 . . . . 0.0 113.317 -167.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . 0.434 ' CD ' ' HZ3' ' B' ' 30' ' ' LYS . 5.6 mp0 -99.31 152.92 19.39 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 125.87 1.668 . . . . 0.0 109.457 174.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -153.81 148.49 26.36 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 114.787 -1.097 . . . . 0.0 111.039 167.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.6 p -118.55 53.65 0.97 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.279 1.032 . . . . 0.0 111.749 178.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.43 -35.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.958 168.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.92 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 CA-C-N 121.024 1.738 . . . . 0.0 111.151 167.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.0 m -160.92 162.43 32.03 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.474 1.509 . . . . 0.0 109.875 171.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -87.38 76.69 9.04 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.262 1.425 . . . . 0.0 109.172 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 20.3 t -158.21 104.82 1.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.468 0.651 . . . . 0.0 111.396 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.61 157.22 26.52 Favored Glycine 0 CA--C 1.526 0.763 0 CA-C-O 122.908 1.282 . . . . 0.0 112.445 -172.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -67.12 -21.26 65.85 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 131.391 3.876 . . . . 0.0 114.266 -169.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -107.56 14.88 25.32 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 128.58 2.752 . . . . 0.0 111.806 -175.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 81.0 p -101.67 -54.04 2.83 Favored 'General case' 0 CA--C 1.548 0.875 0 O-C-N 119.428 -2.045 . . . . 0.0 114.233 -174.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.0 pt 178.51 -39.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 1 C-N-CA 133.941 4.897 . . . . 0.0 106.563 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mm -57.71 131.08 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 N-CA-C 103.194 -2.891 . . . . 0.0 103.194 159.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.99 -18.97 8.24 Favored Glycine 0 CA--C 1.535 1.297 0 N-CA-C 117.046 1.578 . . . . 0.0 117.046 175.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 72.8 mtt180 -79.09 -178.09 5.96 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 126.408 1.883 . . . . 0.0 114.081 -177.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 8.8 t -120.19 170.03 9.7 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 127.929 2.492 . . . . 0.0 110.931 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tp -153.54 146.83 24.77 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.396 1.478 . . . . 0.0 111.358 171.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.43 137.34 56.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.622 1.569 . . . . 0.0 110.126 169.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.64 HG22 ' HB2' ' B' ' 45' ' ' PHE . 45.6 t -106.77 156.99 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 169.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -122.55 138.7 54.49 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.709 2.404 . . . . 0.0 111.905 -166.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -78.24 3.91 14.12 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -174.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -122.72 168.3 12.39 Favored 'General case' 0 CA--C 1.545 0.76 0 O-C-N 120.22 -1.55 . . . . 0.0 111.166 169.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.57 160.83 1.65 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.403 1.081 . . . . 0.0 111.223 169.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -107.72 149.13 28.53 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 122.732 0.413 . . . . 0.0 110.503 169.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -100.53 -8.84 22.66 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.794 2.038 . . . . 0.0 114.072 -171.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 54.09 70.35 0.62 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.81 1.644 . . . . 0.0 113.832 169.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.16 -51.99 4.47 Favored Glycine 0 N--CA 1.466 0.669 0 O-C-N 121.281 -0.887 . . . . 0.0 112.628 169.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.59 124.3 6.03 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 117.569 2.433 . . . . 0.0 117.569 173.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.24 0.62 Allowed Glycine 0 C--N 1.331 0.289 0 C-N-CA 129.67 3.509 . . . . 0.0 106.256 163.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -111.25 -57.72 0.48 Allowed Glycine 0 CA--C 1.53 0.991 0 N-CA-C 117.227 1.651 . . . . 0.0 117.227 -171.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . 0.564 HD21 ' ND2' ' B' ' 139' ' ' ASN . 0.1 OUTLIER -123.93 -175.62 3.27 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -161.545 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -48.02 -59.75 3.13 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 126.557 1.943 . . . . 0.0 111.452 171.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -50.56 -20.54 1.21 Allowed 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.81 1.781 . . . . 0.0 115.81 178.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 13.6 m -67.25 -40.73 86.31 Favored 'General case' 0 N--CA 1.476 0.831 0 O-C-N 119.838 -1.789 . . . . 0.0 112.302 170.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 22.1 p -82.75 -10.15 59.02 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 126.094 1.758 . . . . 0.0 113.674 -177.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.5 tttt -104.16 -77.18 0.58 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 128.42 2.688 . . . . 0.0 110.505 -168.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 22.2 p -79.2 -85.92 0.08 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 166.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 176.06 23.58 0.03 OUTLIER Glycine 0 CA--C 1.534 1.276 1 C-N-CA 131.431 4.348 . . . . 0.0 110.808 -177.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . 0.564 ' ND2' HD21 ' B' ' 131' ' ' ASN . 0.7 OUTLIER 56.98 17.46 3.37 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.005 1.722 . . . . 0.0 114.907 -174.918 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.96 6.37 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.174 0 N-CA-C 119.384 3.105 . . . . 0.0 119.384 -167.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 62.16 -23.93 0.06 OUTLIER Glycine 0 N--CA 1.475 1.252 0 C-N-CA 130.089 3.709 . . . . 0.0 120.442 166.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.7 t -165.38 159.99 17.65 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.535 1.667 . . . . 0.0 111.111 177.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.16 179.7 6.6 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.095 0.958 . . . . 0.0 109.892 167.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.5 HD11 ' HB ' ' B' ' 119' ' ' VAL 0.33 3.8 pp -166.45 -154.02 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 129.49 3.116 . . . . 0.0 106.637 162.804 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.98 134.26 26.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.274 1.43 . . . . 0.0 112.811 -175.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.77 153.32 45.71 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.149 0.979 . . . . 0.0 111.01 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.86 176.81 37.44 Favored Glycine 0 N--CA 1.469 0.879 0 N-CA-C 116.186 1.235 . . . . 0.0 116.186 -170.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.618 HG22 HD21 ' B' ' 53' ' ' ASN . 0.5 OUTLIER -111.0 149.36 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.481 1.112 . . . . 0.0 109.181 174.155 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 30.7 mm -80.88 125.57 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 CA-C-N 119.788 1.176 . . . . 0.0 112.051 -175.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.96 164.98 12.46 Favored Glycine 0 N--CA 1.477 1.403 0 O-C-N 121.23 -0.919 . . . . 0.0 113.392 -176.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 4.7 mp -128.33 131.76 68.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.603 0.716 . . . . 0.0 112.018 -176.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.24 -3.77 18.16 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.084 0.953 . . . . 0.0 112.689 168.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 . . . . . 0 N--CA 1.465 0.319 0 C-N-CA 127.987 2.515 . . . . 0.0 111.179 -173.656 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.045 0 CA-C-O 116.674 -1.631 . . . . 0.0 108.931 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p -76.71 54.64 0.99 Allowed 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.888 1.675 . . . . 0.0 114.922 -168.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.471 HG13 ' HB ' ' B' ' 54' ' ' THR . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.773 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.673 ' CG2' HD21 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.773 HG21 ' ND2' ' A' ' 53' ' ' ASN . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t -78.67 -16.8 56.87 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.25 11.83 7.63 Favored 'General case' 0 CA--C 1.55 0.959 0 O-C-N 121.157 -0.965 . . . . 0.0 111.508 167.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.12 -142.03 40.58 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.082 1.325 . . . . 0.0 111.684 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 4.6 t -60.32 -11.29 6.15 Favored 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 39.5 m -91.9 -21.24 20.71 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 126.619 1.968 . . . . 0.0 113.101 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.28 -47.03 15.18 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 119.356 0.98 . . . . 0.0 111.005 169.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.84 169.94 11.14 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.716 2.006 . . . . 0.0 109.361 173.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.045 0 CA-C-O 116.674 -1.631 . . . . 0.0 108.931 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.1 p -76.71 54.64 0.99 Allowed 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 125.888 1.675 . . . . 0.0 114.922 -168.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -166.72 144.6 5.1 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 125.551 1.54 . . . . 0.0 111.928 166.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -161.43 158.84 27.36 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 129.179 2.992 . . . . 0.0 107.792 172.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 19' ' ' ASN . 60.9 t -139.98 132.1 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 123.165 0.586 . . . . 0.0 110.181 -170.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.52 ' O ' HG21 ' B' ' 54' ' ' THR . . . -103.32 121.16 42.17 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 125.487 1.515 . . . . 0.0 110.037 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.471 HG13 ' HB ' ' B' ' 54' ' ' THR . 97.8 t -107.4 89.07 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 C-N-CA 124.531 1.132 . . . . 0.0 108.092 -171.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mp -102.2 112.83 25.66 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-O 121.967 0.889 . . . . 0.0 112.892 -174.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.482 ' HE2' ' HG2' ' A' ' 15' ' ' GLN . 30.6 mttm -152.27 141.15 21.08 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.853 2.061 . . . . 0.0 108.735 169.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.35 26.28 0.04 OUTLIER Glycine 0 N--CA 1.474 1.218 0 CA-C-O 118.838 -0.979 . . . . 0.0 114.6 176.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.8 t70 -156.87 114.19 3.13 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.949 2.1 . . . . 0.0 108.607 -170.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 21.76 -115.99 0.01 OUTLIER Glycine 0 CA--C 1.541 1.707 0 C-N-CA 128.266 2.841 . . . . 0.0 115.85 -176.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -91.18 9.66 2.95 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 124.993 3.795 . . . . 0.0 113.072 178.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 30.0 t -92.46 138.63 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 122.847 1.308 . . . . 0.0 111.551 -168.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.482 ' HG2' ' HE2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -130.77 142.53 50.41 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-N 113.833 -1.531 . . . . 0.0 110.521 169.263 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.93 128.44 7.54 Favored Glycine 0 C--N 1.322 -0.209 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 168.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.656 HD13 HG23 ' B' ' 54' ' ' THR . 0.1 OUTLIER -136.17 106.43 5.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.4 mm -135.06 131.17 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 C-N-CA 124.966 1.306 . . . . 0.0 108.07 -169.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 5' ' ' VAL . 10.0 m120 -99.85 154.3 18.46 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.8 0.84 . . . . 0.0 110.849 169.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -132.86 121.44 22.92 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.739 1.616 . . . . 0.0 107.941 171.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -103.8 135.31 45.59 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.707 2.049 . . . . 0.0 107.44 167.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.437 ' CB ' HD13 ' A' ' 106' ' ' LEU . 7.2 tp60 -135.57 144.38 46.17 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 170.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 -41.17 16.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.08 1.352 . . . . 0.0 111.913 -172.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -141.81 174.47 10.55 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.895 1.278 . . . . 0.0 112.24 -168.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.3 p -63.95 -21.0 66.29 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 125.069 1.348 . . . . 0.0 111.586 165.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -137.33 92.89 2.75 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 127.0 2.12 . . . . 0.0 110.178 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.76 -179.98 48.1 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 125.309 1.433 . . . . 0.0 113.53 172.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -81.22 140.38 12.27 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.001 2.467 . . . . 0.0 111.609 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.91 130.83 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-N 118.87 0.759 . . . . 0.0 110.389 -177.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.1 ttmp? -96.39 120.39 36.62 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.44 0.696 . . . . 0.0 110.081 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.8 t -104.52 133.31 48.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 127.073 2.149 . . . . 0.0 110.079 178.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -146.29 161.67 39.8 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.285 0.634 . . . . 0.0 112.48 169.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.4 -153.09 23.3 Favored Glycine 0 N--CA 1.47 0.926 0 O-C-N 121.147 -0.97 . . . . 0.0 113.571 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 89.8 p -149.8 156.72 42.3 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -169.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -128.13 113.71 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 121.428 -0.795 . . . . 0.0 109.318 171.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.23 129.17 52.03 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.848 2.059 . . . . 0.0 109.055 -176.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.24 -0.85 5.69 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 126.815 2.15 . . . . 0.0 114.741 174.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 43' ' ' HIS . 7.4 mp -83.5 -178.65 7.12 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.445 1.898 . . . . 0.0 112.446 -175.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.5 t -112.94 155.52 24.61 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.951 2.5 . . . . 0.0 109.259 168.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -55.49 78.65 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 131.01 3.724 . . . . 0.0 113.588 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 175.09 47.23 Favored Glycine 0 N--CA 1.466 0.67 0 C-N-CA 124.629 1.109 . . . . 0.0 113.356 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.7 mp -78.12 146.15 35.31 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.618 1.567 . . . . 0.0 110.079 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.487 ' CD2' HD23 ' A' ' 38' ' ' LEU . 69.6 m-70 -146.12 129.43 16.74 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 126.263 1.825 . . . . 0.0 108.376 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.85 174.31 48.95 Favored Glycine 0 N--CA 1.487 2.079 0 CA-C-N 122.065 2.211 . . . . 0.0 113.567 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -161.15 135.14 6.88 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 126.893 2.077 . . . . 0.0 113.656 167.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.459 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -156.57 161.1 39.98 Favored 'General case' 0 CA--C 1.55 0.979 0 O-C-N 120.37 -1.456 . . . . 0.0 112.328 174.362 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.06 125.73 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.282 1.433 . . . . 0.0 110.832 -173.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -79.06 154.24 29.58 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.155 1.782 . . . . 0.0 110.961 168.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -72.81 -5.52 38.63 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 127.658 2.383 . . . . 0.0 116.18 -169.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -127.2 164.53 21.47 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.308 1.843 . . . . 0.0 112.216 -169.136 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -113.6 3.66 24.72 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 126.458 1.98 . . . . 0.0 115.287 170.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -78.42 122.54 25.94 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.113 1.456 . . . . 0.0 108.585 168.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.773 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.307 0.2 OUTLIER -165.14 -105.29 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 179.534 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.645 ' CG2' HG22 ' B' ' 7' ' ' VAL . 2.5 p 65.32 -31.47 0.14 Allowed 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 129.545 3.138 . . . . 0.0 116.167 -170.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.0 -8.24 58.76 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.633 1.573 . . . . 0.0 113.869 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 69.88 -108.52 2.5 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.249 1.404 . . . . 0.0 112.647 169.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 42.2 t -51.31 -33.83 30.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.266 1.426 . . . . 0.0 113.997 -174.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.4 t -95.66 -13.2 24.48 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.754 1.622 . . . . 0.0 115.242 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 58.9 p -96.73 -30.73 13.04 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 120.001 1.273 . . . . 0.0 112.755 176.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.91 116.62 14.74 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 121.122 -0.986 . . . . 0.0 109.396 169.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -88.04 -141.93 7.76 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.121 1.344 . . . . 0.0 113.455 -177.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -93.89 -179.22 0.76 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 124.879 3.72 . . . . 0.0 110.697 169.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.459 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 7.0 m170 -81.28 112.24 18.41 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.662 -174.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -63.67 133.69 54.07 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 121.464 0.649 . . . . 0.0 111.134 172.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.8 p-10 -125.95 49.18 3.43 Favored Pre-proline 0 CA--C 1.551 1.011 0 C-N-CA 124.71 1.204 . . . . 0.0 113.924 -169.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.37 -23.45 65.34 Favored 'Trans proline' 0 C--N 1.352 0.757 0 C-N-CA 123.424 2.749 . . . . 0.0 114.807 -172.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.54 -2.38 42.03 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.813 1.245 . . . . 0.0 112.782 171.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.7 t 67.9 54.98 0.6 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.112 2.165 . . . . 0.0 113.752 169.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -152.9 175.62 12.73 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -169.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 77' ' ' GLU . 2.7 mppt? -70.83 163.02 28.17 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.107 0.956 . . . . 0.0 112.255 -174.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 75.0 t60 -81.82 149.27 28.43 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.301 167.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 138.32 -99.91 0.29 Allowed Glycine 0 C--N 1.337 0.635 0 CA-C-O 119.695 -0.503 . . . . 0.0 114.198 165.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 111.42 -29.71 8.47 Favored Glycine 0 CA--C 1.547 2.09 0 N-CA-C 118.708 2.243 . . . . 0.0 118.708 172.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -99.25 -26.83 0.05 OUTLIER 'Trans proline' 0 CA--C 1.543 0.933 0 CA-C-N 122.172 2.986 . . . . 0.0 113.854 172.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.42 -8.85 10.98 Favored 'General case' 0 N--CA 1.486 1.353 0 CA-C-N 119.661 1.119 . . . . 0.0 113.074 168.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.472 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.42 140.47 36.65 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 127.987 2.515 . . . . 0.0 105.577 167.406 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -77.25 -20.86 54.6 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 123.46 0.704 . . . . 0.0 111.361 -174.138 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -99.64 -99.48 0.23 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 113.591 0.959 . . . . 0.0 113.591 -165.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.285 3.0 ptp180 97.84 129.61 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 127.979 2.512 . . . . 0.0 111.699 175.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -60.41 164.93 3.97 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.755 1.622 . . . . 0.0 112.35 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -72.54 94.29 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 167.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.93 19.39 2.45 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 125.36 1.457 . . . . 0.0 114.448 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -102.46 113.95 27.74 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 119.425 1.612 . . . . 0.0 113.84 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -107.06 166.63 10.47 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 124.776 1.23 . . . . 0.0 108.647 166.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.3 177.61 45.75 Favored Glycine 0 CA--C 1.535 1.331 0 C-N-CA 123.358 0.504 . . . . 0.0 112.942 175.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -77.27 167.72 21.25 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 176.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -109.39 173.89 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 C-N-CA 126.97 2.108 . . . . 0.0 110.562 169.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -144.99 137.92 26.43 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 126.179 1.792 . . . . 0.0 107.003 169.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.45 157.86 16.75 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 123.697 0.799 . . . . 0.0 112.29 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.13 -175.14 5.41 Favored 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 123.876 0.87 . . . . 0.0 112.9 171.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -18.96 63.32 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 115.972 1.841 . . . . 0.0 115.972 174.066 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.85 -9.94 59.72 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.09 -1.631 . . . . 0.0 109.197 166.493 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.54 25.81 60.24 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-O 116.759 -2.134 . . . . 0.0 111.874 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.59 122.62 49.37 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 119.484 1.642 . . . . 0.0 110.497 168.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -89.12 137.5 32.27 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 164.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -101.52 135.15 43.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 171.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.0 t -112.74 128.59 69.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 113.037 -1.892 . . . . 0.0 109.544 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 42.7 m -156.85 78.2 0.91 Allowed 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.642 1.577 . . . . 0.0 111.74 -174.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -138.41 153.61 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 126.755 2.022 . . . . 0.0 112.913 -169.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -147.69 142.01 26.27 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.876 2.07 . . . . 0.0 108.231 168.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.83 147.29 25.85 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.776 1.23 . . . . 0.0 111.557 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -105.58 52.14 0.74 Allowed 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -167.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.5 m -149.19 16.7 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.93 163.61 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.255 1.822 . . . . 0.0 109.913 177.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.492 ' H ' ' CB ' ' A' ' 111' ' ' SER . 32.2 m -156.3 166.31 33.82 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.405 -1.435 . . . . 0.0 112.227 175.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.437 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.9 mp -78.7 85.18 4.74 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 -179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.7 t -150.12 7.18 0.61 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 116.887 2.18 . . . . 0.0 116.887 -169.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.87 -113.42 4.19 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 121.137 1.789 . . . . 0.0 110.267 170.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -59.64 -52.29 66.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 122.327 1.06 . . . . 0.0 111.185 -174.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 25.8 m-70 -77.86 -1.02 29.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 113.896 -1.502 . . . . 0.0 111.315 -166.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.492 ' CB ' ' H ' ' A' ' 105' ' ' SER . 5.3 m -163.96 -99.06 0.02 OUTLIER 'General case' 0 C--N 1.343 0.294 0 N-CA-C 116.533 2.049 . . . . 0.0 116.533 169.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.8 pt -131.42 169.15 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.701 HD13 HG22 ' A' ' 149' ' ' ILE . 18.0 mm 94.76 135.89 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 1 C-N-CA 133.895 4.878 . . . . 0.0 110.101 -168.287 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.85 -0.0 16.79 Favored Glycine 0 N--CA 1.473 1.136 0 N-CA-C 115.538 0.975 . . . . 0.0 115.538 -172.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -91.72 178.07 6.02 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 128.255 2.622 . . . . 0.0 111.483 172.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.7 m -131.9 115.82 16.38 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 119.239 0.927 . . . . 0.0 111.663 -172.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 32.8 tp -84.93 124.88 32.16 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.94 0.896 . . . . 0.0 111.243 177.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 4.6 p -103.46 145.32 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.928 0.891 . . . . 0.0 109.546 168.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.78 132.35 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 168.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -97.37 151.87 19.5 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 125.343 1.457 . . . . 0.0 111.315 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -75.75 -47.26 26.72 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -165.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -87.36 179.91 6.51 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 119.662 1.119 . . . . 0.0 111.898 174.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.58 143.4 24.7 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 166.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.3 t0 -84.65 127.48 34.11 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 167.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -76.52 -30.39 57.14 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.646 1.978 . . . . 0.0 111.03 179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.6 mt 63.93 54.05 1.8 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.801 1.64 . . . . 0.0 111.788 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 124.02 -78.11 0.36 Allowed Glycine 0 N--CA 1.47 0.954 0 C-N-CA 123.735 0.683 . . . . 0.0 111.492 174.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.53 135.09 20.88 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 172.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -152.09 -75.02 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.433 1 C-N-CA 131.754 4.502 . . . . 0.0 105.331 169.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -72.95 -95.64 0.09 OUTLIER Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.533 1.54 . . . . 0.0 115.608 -172.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -130.33 -148.11 0.35 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.163 1.385 . . . . 0.0 111.508 -164.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -70.93 -46.96 61.54 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.344 1.429 . . . . 0.0 111.581 -178.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.46 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 5.8 mp0 -47.43 -24.51 0.82 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 130.26 3.424 . . . . 0.0 113.007 175.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 49.6 m -60.2 -45.84 91.77 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.357 1.463 . . . . 0.0 112.601 169.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.7 p -79.39 -39.51 32.35 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 124.827 1.251 . . . . 0.0 111.607 177.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -60.84 -49.14 78.7 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 128.245 2.618 . . . . 0.0 112.021 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 25.2 p -150.35 -4.15 0.35 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 116.541 2.052 . . . . 0.0 116.541 -167.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.66 17.71 37.76 Favored Glycine 0 C--O 1.22 -0.76 0 CA-C-N 120.009 1.277 . . . . 0.0 114.038 178.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.16 11.91 1.17 Allowed 'General case' 0 CA--C 1.55 0.96 0 CA-C-N 119.159 1.479 . . . . 0.0 113.849 172.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.33 13.75 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 120.018 3.34 . . . . 0.0 120.018 -161.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.39 -55.27 1.97 Allowed Glycine 0 N--CA 1.472 1.052 0 C-N-CA 127.13 2.3 . . . . 0.0 115.934 169.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.4 t -167.87 -157.79 0.23 Allowed 'General case' 0 CA--C 1.553 1.094 0 C-N-CA 125.391 1.476 . . . . 0.0 112.403 -174.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 65.2 mtt-85 -130.84 167.51 18.8 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.255 1.822 . . . . 0.0 113.198 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.61 -117.67 0.15 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.168 2.187 . . . . 0.0 105.845 165.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -71.77 162.37 29.56 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.404 1.481 . . . . 0.0 114.315 -173.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 50.9 t -156.0 134.1 11.36 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 128.28 2.632 . . . . 0.0 109.726 -172.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.92 155.55 26.61 Favored Glycine 0 N--CA 1.479 1.566 0 CA-C-N 120.54 1.518 . . . . 0.0 116.408 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.673 ' CG2' HD21 ' A' ' 53' ' ' ASN . 99.0 t -83.87 152.63 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.922 0.889 . . . . 0.0 111.161 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.701 HG22 HD13 ' A' ' 113' ' ' ILE . 33.0 mm -103.36 116.94 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 126.686 1.994 . . . . 0.0 112.378 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.42 156.98 15.25 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 125.61 1.576 . . . . 0.0 114.919 175.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.468 HG23 HD12 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -89.96 117.47 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.796 1.638 . . . . 0.0 111.42 -178.601 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.78 176.46 5.14 Favored 'General case' 0 CA--C 1.541 0.611 0 O-C-N 120.481 -1.387 . . . . 0.0 113.297 -173.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 N--CA 1.47 0.547 0 C-N-CA 124.875 1.27 . . . . 0.0 110.523 168.669 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.463 0 CA-C-O 121.916 0.865 . . . . 0.0 111.775 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 98.2 m -88.97 102.6 15.23 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 -175.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.265 24.2 pttt -116.78 149.25 40.26 Favored 'General case' 0 N--CA 1.479 0.978 0 N-CA-C 117.604 2.446 . . . . 0.0 117.604 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' B' ' 106' ' ' LEU . . . -119.85 166.21 13.58 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.487 2.315 . . . . 0.0 110.139 168.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.578 HG12 HG23 ' B' ' 7' ' ' VAL . 2.3 t -128.34 136.62 59.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 124.326 1.05 . . . . 0.0 109.467 168.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -100.12 111.1 23.39 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.348 1.059 . . . . 0.0 108.539 168.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.773 HG21 ' ND2' ' A' ' 53' ' ' ASN . 16.4 t -93.95 114.3 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 C-N-CA 123.683 0.793 . . . . 0.0 109.509 -177.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.52 HD21 HD22 ' B' ' 117' ' ' LEU . 10.2 mp -108.94 129.56 55.43 Favored 'General case' 0 N--CA 1.469 0.509 0 O-C-N 124.836 1.335 . . . . 0.0 112.254 179.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.414 ' HE3' ' CB ' ' B' ' 15' ' ' GLN . 14.1 mttt -161.73 123.03 2.77 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.62 1.568 . . . . 0.0 110.497 168.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -147.87 -69.56 0.01 OUTLIER Glycine 0 N--CA 1.467 0.735 0 C-N-CA 123.29 0.472 . . . . 0.0 113.025 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -82.83 74.3 9.81 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.258 2.223 . . . . 0.0 111.916 -167.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 48.82 -102.79 0.06 OUTLIER Glycine 0 CA--C 1.534 1.276 0 C-N-CA 127.105 2.288 . . . . 0.0 112.467 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.92 -3.02 12.53 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 124.518 3.479 . . . . 0.0 114.32 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -93.22 132.09 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 CA-C-N 120.583 1.538 . . . . 0.0 111.195 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.414 ' CB ' ' HE3' ' B' ' 9' ' ' LYS . 0.0 OUTLIER -144.09 169.89 16.99 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 127.016 2.126 . . . . 0.0 110.602 -176.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.94 156.2 26.74 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-O 122.583 1.102 . . . . 0.0 114.222 169.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 tp -136.99 106.85 4.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 127.225 2.21 . . . . 0.0 107.889 177.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.2 mm -117.82 131.75 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.108 0.963 . . . . 0.0 110.228 175.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -91.23 150.16 21.46 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 124.845 1.258 . . . . 0.0 111.699 170.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -130.98 111.75 12.33 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.591 1.156 . . . . 0.0 108.826 172.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -108.25 122.12 46.29 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 127.82 2.448 . . . . 0.0 112.642 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . 0.621 ' HB2' HD13 ' B' ' 106' ' ' LEU . 57.7 tp60 -119.04 146.57 44.95 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.832 1.653 . . . . 0.0 112.288 -168.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.04 -73.32 0.69 Allowed 'General case' 0 CA--C 1.554 1.134 0 C-N-CA 124.723 1.209 . . . . 0.0 112.046 174.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -87.06 -174.84 5.1 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-N 121.308 1.867 . . . . 0.0 110.638 175.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.1 p -65.77 -18.6 65.45 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.23 1.812 . . . . 0.0 114.064 169.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -154.65 27.6 0.44 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 126.79 2.036 . . . . 0.0 111.538 -169.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.81 155.69 39.37 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-O 117.573 -1.681 . . . . 0.0 112.271 172.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -61.84 135.26 54.78 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 123.366 2.711 . . . . 0.0 109.541 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 61.2 t -102.17 131.92 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.34 0.591 . . . . 0.0 110.117 -176.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -78.98 111.77 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 169.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 28.0 t -109.2 91.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 126.47 1.908 . . . . 0.0 106.863 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -110.51 166.0 11.35 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-O 121.677 0.751 . . . . 0.0 110.379 169.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.56 -154.59 25.89 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 124.021 0.82 . . . . 0.0 111.776 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 55.6 p -157.13 136.39 11.97 Favored 'General case' 0 CA--C 1.545 0.757 0 N-CA-C 117.539 2.422 . . . . 0.0 117.539 -169.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.631 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 18.1 mm -92.38 153.34 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.73 1.612 . . . . 0.0 107.378 166.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -147.14 139.45 24.63 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 122.323 2.329 . . . . 0.0 111.586 170.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.53 -7.42 5.9 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.742 2.115 . . . . 0.0 113.684 -177.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.97 176.47 2.07 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.096 0.959 . . . . 0.0 109.13 167.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -96.33 -38.98 9.85 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 118.07 -0.967 . . . . 0.0 112.017 168.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 175.01 -162.38 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 131.409 3.883 . . . . 0.0 104.682 -173.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.81 161.91 37.78 Favored Glycine 0 N--CA 1.466 0.657 0 C-N-CA 126.285 1.898 . . . . 0.0 115.145 166.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.643 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.9 OUTLIER -80.1 147.46 31.4 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 125.81 1.644 . . . . 0.0 109.584 169.332 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -148.04 153.22 38.66 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 127.776 2.431 . . . . 0.0 110.82 -169.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -106.38 152.46 17.02 Favored Glycine 0 N--CA 1.477 1.403 0 CA-C-O 118.104 -1.387 . . . . 0.0 113.765 179.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.98 145.31 29.7 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 116.198 1.925 . . . . 0.0 116.198 171.087 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -139.59 165.81 26.26 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.164 1.385 . . . . 0.0 111.603 171.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.454 HG23 ' CA ' ' B' ' 82' ' ' GLY . 28.9 m -121.49 126.99 75.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.371 1.069 . . . . 0.0 108.209 -177.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 1.1 m170 -91.95 131.93 36.89 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 118.756 -0.64 . . . . 0.0 109.924 -176.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.02 133.26 51.67 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 165.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 86.97 169.15 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 128.033 2.533 . . . . 0.0 112.066 -168.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.87 42.78 1.6 Allowed Glycine 0 CA--C 1.529 0.948 0 C-N-CA 127.377 2.417 . . . . 0.0 114.395 -177.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -103.49 120.12 40.23 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.354 1.862 . . . . 0.0 109.433 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.29 0.1 OUTLIER -161.01 -13.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 121.056 3.724 . . . . 0.0 121.056 -178.216 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.656 HG23 HD13 ' A' ' 17' ' ' ILE . 4.8 t -78.67 -16.8 56.87 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -173.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.25 11.83 7.63 Favored 'General case' 0 CA--C 1.55 0.959 0 O-C-N 121.157 -0.965 . . . . 0.0 111.508 167.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.12 -142.03 40.58 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.082 1.325 . . . . 0.0 111.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 4.6 t -60.32 -11.29 6.15 Favored 'General case' 0 CA--C 1.549 0.936 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 39.5 m -91.9 -21.24 20.71 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 126.619 1.968 . . . . 0.0 113.101 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.28 -47.03 15.18 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 119.356 0.98 . . . . 0.0 111.005 169.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.84 169.94 11.14 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 126.716 2.006 . . . . 0.0 109.361 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . 0.479 ' H ' ' CD ' ' B' ' 62' ' ' PRO . . . -167.51 -14.27 0.02 OUTLIER Glycine 0 CA--C 1.537 1.463 0 CA-C-O 116.321 -2.377 . . . . 0.0 116.176 178.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 3.1 Cg_endo -127.99 167.58 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 1.02 0 C-N-CA 123.168 2.579 . . . . 0.0 114.165 169.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.499 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -66.76 103.75 1.18 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 128.226 2.61 . . . . 0.0 114.677 167.664 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -62.91 125.43 23.97 Favored 'General case' 0 CA--C 1.54 0.594 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 164.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.404 ' HA ' ' HD2' ' B' ' 66' ' ' PRO . 0.4 OUTLIER -99.53 98.24 6.68 Favored Pre-proline 0 CA--C 1.549 0.924 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -169.406 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' B' ' 65' ' ' ASN . 37.2 Cg_endo -58.86 -30.54 93.22 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 122.952 2.435 . . . . 0.0 113.685 178.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -87.69 -6.68 58.11 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 42.8 t 64.18 57.97 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 120.324 1.42 . . . . 0.0 112.597 -178.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . 0.449 ' NH2' ' HA ' ' B' ' 78' ' ' GLU . 65.8 mtp85 -137.22 177.5 7.82 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.016 1.727 . . . . 0.0 111.598 -168.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.344 0.0 OUTLIER -106.01 175.32 5.54 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 119.27 0.941 . . . . 0.0 112.65 175.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.44 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 75.9 t60 -79.84 166.51 21.63 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.977 1.473 . . . . 0.0 114.977 -168.155 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 124.49 -128.91 6.93 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 126.153 1.835 . . . . 0.0 112.492 167.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 135.54 -63.57 0.59 Allowed Glycine 0 CA--C 1.534 1.268 0 CA-C-O 117.98 -1.456 . . . . 0.0 114.804 169.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -75.79 23.55 0.44 Allowed 'Trans proline' 0 CA--C 1.549 1.231 0 C-N-CA 123.584 2.856 . . . . 0.0 111.934 171.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.413 ' H ' ' C ' ' B' ' 73' ' ' GLY . 45.5 tttt -165.97 -7.27 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.198 0 C-N-CA 129.723 3.209 . . . . 0.0 112.568 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -140.32 140.45 35.65 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 120.174 -1.579 . . . . 0.0 111.431 -168.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 19.6 mp0 -76.5 -26.08 54.91 Favored 'General case' 0 C--N 1.319 -0.744 1 C-N-CA 132.036 4.135 . . . . 0.0 112.438 -167.544 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . 0.449 ' HA ' ' NH2' ' B' ' 69' ' ' ARG . 0.4 OUTLIER -88.81 -73.74 0.49 Allowed 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 123.152 0.581 . . . . 0.0 110.176 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 66.12 137.87 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 124.482 2.087 . . . . 0.0 113.133 -176.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 17.4 m80 -90.83 154.77 19.26 Favored 'General case' 0 CA--C 1.544 0.745 0 O-C-N 120.198 -1.564 . . . . 0.0 112.889 168.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.04 -5.69 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 124.233 1.013 . . . . 0.0 112.723 169.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.454 ' CA ' HG23 ' B' ' 47' ' ' VAL . . . -124.87 67.36 0.52 Allowed Glycine 0 CA--C 1.533 1.206 0 N-CA-C 118.145 2.018 . . . . 0.0 118.145 172.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -147.69 116.16 6.64 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 125.174 1.389 . . . . 0.0 112.707 -178.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 77.4 mt -111.27 43.65 1.45 Allowed 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.215 1.37 . . . . 0.0 114.498 179.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.38 -139.2 47.28 Favored Glycine 0 CA--C 1.538 1.512 0 O-C-N 119.917 -1.74 . . . . 0.0 114.479 169.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -114.44 157.98 22.18 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.47 1.508 . . . . 0.0 111.626 177.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.454 ' CG2' ' HB1' ' B' ' 95' ' ' ALA . 0.4 OUTLIER -143.5 132.26 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 129.132 2.973 . . . . 0.0 109.404 -172.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 93.9 m -113.86 153.12 29.72 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 119.02 0.827 . . . . 0.0 109.898 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.487 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -119.11 144.2 46.75 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 125.925 1.69 . . . . 0.0 113.145 -179.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -94.48 161.84 14.06 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.039 1.336 . . . . 0.0 111.528 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -50.05 -21.73 1.36 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 128.418 2.687 . . . . 0.0 116.714 -175.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.89 1.02 24.98 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 125.243 1.417 . . . . 0.0 112.118 174.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 89.46 8.71 67.75 Favored Glycine 0 C--N 1.337 0.589 0 C-N-CA 127.709 2.576 . . . . 0.0 115.114 174.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -101.14 128.74 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.378 1.471 . . . . 0.0 111.346 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -91.09 129.93 37.04 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 124.25 0.969 . . . . 0.0 110.111 169.212 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -94.41 135.41 35.87 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.935 1.294 . . . . 0.0 108.772 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.78 129.41 74.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 113.187 -1.824 . . . . 0.0 108.588 176.198 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 4.3 p -158.48 59.4 0.44 Allowed 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.609 1.195 . . . . 0.0 112.819 -167.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -118.85 151.69 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 125.534 1.534 . . . . 0.0 112.263 -174.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -138.38 132.48 31.53 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 165.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -152.84 143.39 22.68 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 122.177 0.989 . . . . 0.0 112.792 -168.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -93.08 53.93 2.06 Favored 'General case' 0 CA--C 1.538 0.51 0 O-C-N 121.072 -1.018 . . . . 0.0 111.464 -172.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.83 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 N-CA-C 114.284 1.216 . . . . 0.0 114.284 -171.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -154.64 158.57 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.399 1.48 . . . . 0.0 110.597 -177.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.502 ' H ' ' HB3' ' B' ' 111' ' ' SER . 93.8 p -156.15 171.03 20.87 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.332 1.053 . . . . 0.0 113.067 168.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' B' ' 22' ' ' GLN . 5.3 mp -76.17 58.71 1.27 Allowed 'General case' 0 CA--C 1.541 0.629 0 O-C-N 120.42 -1.425 . . . . 0.0 109.43 171.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 23.1 t -112.53 23.07 13.95 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.931 2.093 . . . . 0.0 112.265 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 92.64 -132.25 11.17 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 123.823 1.791 . . . . 0.0 114.548 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -32.83 74.61 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 127.523 2.329 . . . . 0.0 112.56 -164.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 -3.85 52.28 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 128.395 2.678 . . . . 0.0 111.614 178.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . 0.502 ' HB3' ' H ' ' B' ' 105' ' ' SER . 10.3 m -158.17 -70.83 0.09 Allowed 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 118.348 2.722 . . . . 0.0 118.348 -175.304 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 26.5 mt -151.26 140.31 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 N-CA-C 105.757 -1.942 . . . . 0.0 105.757 -172.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.4 mm 83.27 116.57 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 130.357 3.463 . . . . 0.0 108.813 -166.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 83.5 -14.56 40.22 Favored Glycine 0 CA--C 1.534 1.23 0 CA-C-O 116.977 -2.013 . . . . 0.0 115.724 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.2 ttp180 -84.67 177.38 8.07 Favored 'General case' 0 CA--C 1.556 1.179 0 CA-C-N 120.748 2.274 . . . . 0.0 112.413 -172.302 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 88.9 m -108.6 157.66 18.29 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 126.254 1.821 . . . . 0.0 111.848 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.52 HD22 HD21 ' B' ' 8' ' ' LEU . 9.8 tt -137.95 133.52 33.82 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.06 1.344 . . . . 0.0 109.246 165.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 p -121.95 143.81 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 124.251 1.02 . . . . 0.0 109.703 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.6 t -118.19 166.05 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 124.469 1.108 . . . . 0.0 108.896 169.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -123.44 137.69 54.75 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.49 1.916 . . . . 0.0 111.387 -173.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -68.9 -18.16 64.08 Favored 'General case' 0 CA--C 1.544 0.744 0 O-C-N 120.511 -1.368 . . . . 0.0 111.115 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.43 169.14 9.54 Favored 'General case' 0 CA--C 1.547 0.857 0 O-C-N 119.327 -2.108 . . . . 0.0 110.217 167.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.54 153.49 41.29 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 124.353 1.061 . . . . 0.0 112.283 -175.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -79.07 138.12 37.83 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.765 0.826 . . . . 0.0 111.703 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.21 -45.25 41.61 Favored 'General case' 0 C--O 1.225 -0.228 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.154 173.226 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.5 mt 88.93 63.58 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 128.189 2.596 . . . . 0.0 111.97 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.48 -20.93 46.33 Favored Glycine 0 N--CA 1.471 1.015 0 N-CA-C 119.886 2.714 . . . . 0.0 119.886 164.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . 0.271 13.4 pttm -158.25 37.15 0.24 Allowed 'General case' 0 N--CA 1.476 0.836 0 CA-C-N 120.648 2.224 . . . . 0.0 116.514 -166.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.03 19.84 1.21 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 126.662 2.077 . . . . 0.0 115.792 174.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -2.95 82.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.087 1.327 . . . . 0.0 115.9 170.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -116.76 177.98 4.51 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 119.208 1.504 . . . . 0.0 112.324 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.69 -57.26 9.5 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 113.99 -1.459 . . . . 0.0 108.287 166.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' B' ' 136' ' ' LYS . 13.4 tp10 -47.05 -33.75 5.16 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 126.251 1.82 . . . . 0.0 114.084 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.88 -26.53 68.21 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 115.859 1.8 . . . . 0.0 115.859 175.114 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.8 t -113.49 -23.19 9.95 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.749 0.82 . . . . 0.0 112.447 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.457 ' HB3' ' HA ' ' B' ' 133' ' ' GLU . 15.0 tttt -65.89 -50.17 65.44 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 127.74 2.416 . . . . 0.0 110.704 169.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 73.0 p -119.9 -117.18 0.31 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 127.215 2.206 . . . . 0.0 105.162 167.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -140.52 29.26 2.39 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 127.832 2.634 . . . . 0.0 111.734 174.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.93 3.27 1.59 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 126.167 1.787 . . . . 0.0 115.227 176.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.22 18.43 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 129.163 2.985 . . . . 0.0 118.994 -166.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.47 -56.31 2.89 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 127.642 2.544 . . . . 0.0 114.139 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 72.2 m -131.42 150.6 52.09 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.669 0.747 . . . . 0.0 111.786 -169.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 6.4 mpt_? -77.09 178.24 7.16 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 165.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.468 HD13 ' H ' ' B' ' 145' ' ' ALA . 0.1 OUTLIER -176.58 -173.1 0.49 Allowed 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 128.368 2.667 . . . . 0.0 105.852 -176.379 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.468 ' H ' HD13 ' B' ' 144' ' ' LEU . . . -48.04 125.94 9.91 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.087 1.355 . . . . 0.0 111.567 -170.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.9 t -118.76 152.27 36.48 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 125.751 1.62 . . . . 0.0 110.039 177.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.41 174.83 35.59 Favored Glycine 0 C--O 1.225 -0.458 0 N-CA-C 116.105 1.202 . . . . 0.0 116.105 -169.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -131.56 143.95 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 127.011 2.124 . . . . 0.0 109.409 -169.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 12.1 mt -100.29 132.07 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -173.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -141.74 175.97 22.22 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.494 1.357 . . . . 0.0 116.494 171.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.99 118.71 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 124.275 1.03 . . . . 0.0 111.965 -169.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.33 -0.64 43.44 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.665 0.786 . . . . 0.0 112.996 -177.302 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.539 0.549 0 C-N-CA 128.38 2.672 . . . . 0.0 107.352 -172.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.669 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.8 t -156.86 121.92 4.59 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 124.353 1.061 . . . . 0.0 109.606 176.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.83 104.54 14.88 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 122.046 0.927 . . . . 0.0 108.699 168.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -89.48 169.23 11.55 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.263 -0.898 . . . . 0.0 111.296 173.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.487 HG21 ' HA ' ' B' ' 52' ' ' ASP . 3.1 p -151.97 142.78 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.676 1.19 . . . . 0.0 110.741 -170.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -142.13 120.5 12.36 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.509 1.123 . . . . 0.0 109.526 168.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.5 t -105.31 97.16 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 174.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -78.12 111.47 14.07 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 123.83 0.852 . . . . 0.0 109.544 -172.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -152.04 155.15 37.39 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 116.604 2.075 . . . . 0.0 116.604 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 167.43 -39.76 0.24 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 129.891 3.615 . . . . 0.0 108.814 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.44 57.64 4.12 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 129.699 3.2 . . . . 0.0 112.933 -168.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.95 -103.72 0.05 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.358 2.409 . . . . 0.0 114.054 173.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -83.87 -8.05 10.22 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 124.893 3.729 . . . . 0.0 114.555 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -89.03 141.87 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 120.377 1.444 . . . . 0.0 109.92 173.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -157.81 161.76 38.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.227 -1.351 . . . . 0.0 110.513 167.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -129.01 119.25 2.92 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 113.658 -1.61 . . . . 0.0 109.576 169.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.07 133.23 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 166.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.439 HD13 ' CE1' ' A' ' 20' ' ' PHE . 2.1 pp -136.14 143.19 36.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 122.703 1.24 . . . . 0.0 110.687 162.158 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.95 130.0 55.47 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 164.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.439 ' CE1' HD13 ' A' ' 18' ' ' ILE . 18.6 m-30 -114.2 132.43 56.11 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.205 1.002 . . . . 0.0 110.629 -179.056 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -108.56 117.11 33.32 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.02 1.328 . . . . 0.0 110.97 178.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.525 HE22 ' HA ' ' A' ' 25' ' ' SER . 1.3 tm0? -118.58 140.0 50.59 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 123.028 1.394 . . . . 0.0 113.27 173.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.518 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -87.01 -47.98 8.48 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 129.46 3.104 . . . . 0.0 113.739 -175.717 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -147.63 137.71 22.94 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 126.895 2.078 . . . . 0.0 110.44 -168.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.525 ' HA ' HE22 ' A' ' 22' ' ' GLN . 8.3 m -38.65 -57.65 1.16 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.939 1.696 . . . . 0.0 115.308 -169.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 -102.31 15.47 29.06 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 123.995 0.918 . . . . 0.0 111.765 -173.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.83 -170.85 30.06 Favored Glycine 0 CA--C 1.534 1.263 0 C-N-CA 124.776 1.179 . . . . 0.0 112.485 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -78.34 177.91 8.2 Favored 'Trans proline' 0 CA--C 1.536 0.588 0 C-N-CA 124.149 3.232 . . . . 0.0 112.818 -170.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.4 t -142.0 141.01 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 123.913 0.885 . . . . 0.0 111.173 -177.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -93.22 125.21 37.7 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.035 0.934 . . . . 0.0 109.56 169.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 t -117.5 125.25 73.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 127.674 2.389 . . . . 0.0 108.565 -169.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 7.0 p90 -153.87 162.39 41.27 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.611 0.72 . . . . 0.0 112.661 175.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.18 -158.21 27.15 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 125.145 1.355 . . . . 0.0 112.063 177.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.9 p -153.54 139.79 18.49 Favored 'General case' 0 C--O 1.237 0.403 0 O-C-N 122.396 -0.473 . . . . 0.0 112.07 -172.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -111.98 106.88 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.885 0.874 . . . . 0.0 108.668 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.02 128.13 54.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.758 2.423 . . . . 0.0 109.557 -165.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.4 -4.38 31.27 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.502 1.525 . . . . 0.0 112.109 -167.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.5 mt -65.53 162.45 18.05 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.593 1.197 . . . . 0.0 110.531 168.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.2 t -93.45 161.83 14.22 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 163.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 54.3 tt0 -54.95 150.43 10.18 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.242 1.417 . . . . 0.0 113.352 -174.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.23 -177.57 36.59 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 124.758 1.17 . . . . 0.0 113.46 176.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.98 149.6 18.56 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 127.56 2.344 . . . . 0.0 112.588 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 70.1 m-70 -145.65 134.0 21.83 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 126.125 1.77 . . . . 0.0 110.166 170.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.44 147.72 31.36 Favored Glycine 0 N--CA 1.481 1.664 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.142 173.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -156.85 106.27 2.24 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 119.03 1.415 . . . . 0.0 113.276 -172.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.04 153.12 30.47 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.801 1.408 . . . . 0.0 114.801 -168.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -82.2 138.37 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 165.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -87.18 157.99 19.24 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.386 1.875 . . . . 0.0 113.907 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 21.8 tt0 -71.57 90.07 1.0 Allowed 'General case' 0 CA--C 1.518 -0.265 0 C-N-CA 125.182 1.393 . . . . 0.0 109.231 178.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 94.6 142.35 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.615 0 C-N-CA 128.64 2.776 . . . . 0.0 108.809 178.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.09 13.24 9.69 Favored Glycine 0 C--O 1.221 -0.715 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.627 169.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.403 ' HB2' ' H ' ' B' ' 5' ' ' VAL . 8.8 p-10 -88.44 47.67 1.53 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 124.578 2.132 . . . . 0.0 109.131 168.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -171.91 42.39 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 123.696 1.712 . . . . 0.0 110.104 -167.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.8 p -69.32 43.78 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 128.312 2.645 . . . . 0.0 117.455 -168.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -107.69 5.5 26.83 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.726 1.21 . . . . 0.0 109.345 164.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 51.56 -110.56 1.09 Allowed Glycine 0 C--N 1.347 1.178 0 C-N-CA 126.527 2.013 . . . . 0.0 112.938 168.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 69.5 m -53.32 -9.36 0.16 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 116.516 2.043 . . . . 0.0 116.516 178.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.4 t -124.99 19.02 8.45 Favored 'General case' 0 N--CA 1.481 1.106 0 N-CA-C 115.455 1.65 . . . . 0.0 115.455 171.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.9 m -156.74 -40.51 0.07 Allowed 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 171.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.42 123.57 26.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.705 1.593 . . . . 0.0 112.191 -170.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -66.75 168.78 35.47 Favored Glycine 0 CA--C 1.538 1.48 0 CA-C-O 118.224 -1.32 . . . . 0.0 113.33 -175.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -56.48 176.21 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 125.007 3.805 . . . . 0.0 112.456 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.423 ' CD2' ' H ' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -68.06 114.22 6.39 Favored 'General case' 0 C--N 1.321 -0.644 0 O-C-N 121.484 -0.76 . . . . 0.0 112.615 -166.823 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -28.25 113.07 0.07 Allowed 'General case' 0 C--O 1.24 0.557 0 C-N-CA 127.489 2.316 . . . . 0.0 114.209 -172.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -111.61 50.59 0.33 Allowed Pre-proline 0 CA--C 1.551 0.997 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -174.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -68.11 -16.83 45.31 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 122.352 2.035 . . . . 0.0 112.51 177.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -79.42 -7.51 58.45 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.722 1.609 . . . . 0.0 112.456 168.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.9 t 64.26 49.74 2.51 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 128.437 2.695 . . . . 0.0 112.409 176.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.402 ' HD2' ' OE1' ' A' ' 78' ' ' GLU . 15.8 ptt180 -128.92 178.5 6.34 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.524 ' HE2' ' HA ' ' A' ' 70' ' ' LYS . 4.8 mmpt? -88.17 174.26 8.33 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 127.164 2.185 . . . . 0.0 112.375 -179.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -95.12 134.9 37.32 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.416 ' HA2' HD12 ' A' ' 126' ' ' LEU . . . 161.2 -123.17 1.18 Allowed Glycine 0 C--N 1.336 0.576 0 CA-C-O 119.72 -0.489 . . . . 0.0 113.682 168.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.66 -33.94 4.58 Favored Glycine 0 CA--C 1.545 1.952 0 CA-C-O 117.216 -1.88 . . . . 0.0 117.791 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -105.45 17.14 0.15 Allowed 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.619 2.879 . . . . 0.0 114.215 174.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.9 ptmm? -167.73 -22.02 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 127.389 2.276 . . . . 0.0 112.458 169.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -97.41 147.05 24.6 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 163.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -98.86 -6.58 28.78 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.445 1.898 . . . . 0.0 111.859 -171.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.402 ' OE1' ' HD2' ' A' ' 69' ' ' ARG . 3.7 mm-40 -77.4 -99.65 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.343 1.057 . . . . 0.0 110.035 -177.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 94.2 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 127.323 2.249 . . . . 0.0 111.179 174.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -58.31 156.96 9.18 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.569 1.147 . . . . 0.0 112.639 172.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.0 p -70.59 106.12 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.86 171.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.03 8.69 21.66 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 117.383 -1.787 . . . . 0.0 116.831 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.16 124.5 27.91 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 120.71 2.255 . . . . 0.0 109.545 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 97.5 mt -113.89 53.63 0.77 Allowed 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 120.575 1.534 . . . . 0.0 112.196 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.01 -141.99 42.49 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 121.56 -0.713 . . . . 0.0 111.659 174.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -126.67 127.43 45.16 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.482 0.713 . . . . 0.0 111.431 169.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 18.8 m -78.21 98.22 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.891 1.276 . . . . 0.0 108.985 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -93.3 117.41 30.04 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.572 -1.195 . . . . 0.0 107.822 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.49 139.88 30.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.806 1.242 . . . . 0.0 113.841 -174.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -72.32 156.74 38.77 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 127.146 2.178 . . . . 0.0 109.99 167.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -46.33 -25.38 0.63 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 128.294 2.638 . . . . 0.0 116.137 175.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -76.42 -0.48 22.98 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.632 1.173 . . . . 0.0 111.525 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.36 41.79 11.2 Favored Glycine 0 C--N 1.335 0.526 0 C-N-CA 126.535 2.017 . . . . 0.0 112.783 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.5 p -143.21 129.0 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 N-CA-C 114.737 1.384 . . . . 0.0 114.737 176.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.57 124.15 35.52 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 165.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -111.55 135.64 51.86 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 124.496 1.118 . . . . 0.0 108.91 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.5 t -139.15 136.71 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -166.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.2 t -155.43 116.36 3.9 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.553 1.541 . . . . 0.0 110.579 168.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 11.8 mt -145.51 155.4 13.3 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 128.965 2.906 . . . . 0.0 110.806 -169.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -128.23 132.23 48.77 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 105.115 -2.18 . . . . 0.0 105.115 167.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -145.51 138.1 25.88 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 124.486 1.114 . . . . 0.0 111.954 -168.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -116.94 51.38 1.0 Allowed 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 178.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.19 3.48 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.197 0 C-N-CA 123.831 0.853 . . . . 0.0 111.983 167.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.2 168.0 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 126.671 1.988 . . . . 0.0 110.376 177.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.0 m -154.4 156.09 36.19 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.001 0.92 . . . . 0.0 111.086 -173.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 83.7 mt -93.5 73.01 4.42 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.689 0.757 . . . . 0.0 110.681 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.406 ' H ' ' HB2' ' A' ' 111' ' ' SER . 0.3 OUTLIER -117.84 144.91 44.97 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.384 1.474 . . . . 0.0 108.987 171.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -78.48 16.23 8.17 Favored Glycine 0 N--CA 1.479 1.539 0 N-CA-C 117.97 1.948 . . . . 0.0 117.97 -166.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -134.88 -89.26 0.35 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 125.794 1.638 . . . . 0.0 111.2 -169.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -87.39 4.81 41.6 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 120.595 -1.316 . . . . 0.0 113.168 -174.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.406 ' HB2' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -119.41 -141.7 0.35 Allowed 'General case' 0 CA--C 1.545 0.756 0 O-C-N 120.875 -1.141 . . . . 0.0 112.955 -168.629 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 51.5 mm -94.63 -28.87 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 O-C-N 120.595 -1.315 . . . . 0.0 114.389 -169.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.1 mm -55.06 133.05 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 119.191 0.905 . . . . 0.0 109.849 175.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.14 14.62 59.52 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.433 -1.204 . . . . 0.0 114.575 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -91.19 -169.99 2.51 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.408 1.604 . . . . 0.0 108.911 168.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 6.4 m -145.63 114.37 6.85 Favored 'General case' 0 N--CA 1.484 1.227 0 O-C-N 119.599 -1.938 . . . . 0.0 108.02 -171.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 50.5 tp -89.74 132.73 35.05 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 124.943 1.297 . . . . 0.0 109.638 -175.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.4 m -118.84 153.79 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 C-N-CA 123.275 0.63 . . . . 0.0 110.628 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.76 152.13 15.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 163.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -115.21 147.36 40.44 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.094 1.357 . . . . 0.0 111.183 -178.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -66.09 -22.52 66.41 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 119.838 -1.789 . . . . 0.0 113.601 -174.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.7 mmtm -131.62 176.98 7.86 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 119.772 -1.83 . . . . 0.0 113.998 173.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.22 145.04 27.69 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 112.977 -1.919 . . . . 0.0 110.9 169.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.48 ' OD1' ' HB2' ' A' ' 140' ' ' ALA . 46.7 m-20 -79.03 169.2 18.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 122.188 0.994 . . . . 0.0 111.154 167.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.79 -38.49 53.91 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.203 164.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.416 HD12 ' HA2' ' A' ' 72' ' ' GLY . 1.8 mm? 63.35 60.32 1.16 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.957 2.503 . . . . 0.0 112.031 -171.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.59 -83.4 0.13 Allowed Glycine 0 N--CA 1.469 0.879 0 O-C-N 121.008 -1.058 . . . . 0.0 112.747 168.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -150.53 97.73 2.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.631 1.681 . . . . 0.0 110.921 169.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -74.09 176.07 47.3 Favored Glycine 0 CA--C 1.526 0.781 0 CA-C-N 112.086 -2.325 . . . . 0.0 107.651 163.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.09 29.79 0.15 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 127.599 2.523 . . . . 0.0 118.677 -167.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -148.03 -103.97 0.09 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 120.652 2.226 . . . . 0.0 111.528 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -163.22 -51.9 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 127.312 2.245 . . . . 0.0 108.58 -169.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 19.2 tp10 -50.17 -32.16 15.51 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 127.416 2.286 . . . . 0.0 112.351 169.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.593 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 77.6 p -53.24 -36.84 61.5 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 120.565 -1.334 . . . . 0.0 113.173 168.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 2.8 p -79.08 -20.99 47.39 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 172.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -79.79 -64.56 1.16 Allowed 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.5 1.046 . . . . 0.0 112.572 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 28.7 p -108.62 -9.52 15.29 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.842 1.657 . . . . 0.0 114.559 -174.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 93.2 -9.57 74.61 Favored Glycine 0 N--CA 1.471 1.031 0 CA-C-N 119.918 1.235 . . . . 0.0 111.781 -167.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 79.26 -44.1 0.32 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 129.245 3.018 . . . . 0.0 110.136 -179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.48 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . . . 56.62 11.77 0.96 Allowed 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 128.433 2.693 . . . . 0.0 116.649 167.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.43 -36.25 0.45 Allowed Glycine 0 CA--C 1.537 1.445 0 C-N-CA 125.951 1.739 . . . . 0.0 113.673 -167.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -173.88 -156.59 0.08 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.149 1.779 . . . . 0.0 111.551 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.05 -166.22 1.15 Allowed 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.798 2.039 . . . . 0.0 108.197 165.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -176.96 -151.79 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.661 2.384 . . . . 0.0 107.378 -175.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.72 148.99 23.05 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 125.709 1.604 . . . . 0.0 112.568 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 26.8 p -148.45 148.71 30.59 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.092 0.957 . . . . 0.0 113.459 -176.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.2 136.61 5.1 Favored Glycine 0 N--CA 1.465 0.604 0 C-N-CA 124.299 0.952 . . . . 0.0 113.543 -170.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.2 t -76.24 148.58 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 124.676 1.19 . . . . 0.0 109.333 -178.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -83.63 103.68 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 171.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -101.46 175.41 25.68 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.861 1.696 . . . . 0.0 112.064 169.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -114.51 140.84 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.307 1.043 . . . . 0.0 112.495 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.05 51.29 0.79 Allowed 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 124.027 1.87 . . . . 0.0 112.765 -176.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 38.9 tt0 . . . . . 0 C--N 1.326 -0.445 0 CA-C-N 111.487 -2.597 . . . . 0.0 110.006 167.672 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.1 p -78.76 107.07 11.21 Favored 'General case' 0 CA--C 1.512 -0.515 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 169.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.433 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -99.68 156.06 17.28 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 169.497 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.59 178.29 8.57 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 130.138 3.375 . . . . 0.0 107.19 167.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.403 ' H ' ' HB2' ' A' ' 52' ' ' ASP . 59.3 t -156.54 170.85 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.191 0 C-N-CA 127.03 2.132 . . . . 0.0 109.894 -169.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.36 142.69 19.44 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 127.28 2.232 . . . . 0.0 109.299 166.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.13 126.53 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.582 0.753 . . . . 0.0 110.085 173.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.1 mp -97.26 140.25 32.02 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 125.287 1.435 . . . . 0.0 110.264 -172.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 20.8 ttpp -143.53 140.57 30.33 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.386 1.074 . . . . 0.0 111.535 170.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -91.39 -114.15 1.87 Allowed Glycine 0 CA--C 1.524 0.612 1 N-CA-C 102.471 -4.252 . . . . 0.0 102.471 163.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -157.7 127.15 5.93 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.406 1.882 . . . . 0.0 107.964 164.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 115.3 -141.96 17.31 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -167.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -84.72 -26.04 1.74 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 123.312 2.675 . . . . 0.0 113.938 -169.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -78.1 123.82 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.44 1.018 . . . . 0.0 110.873 -169.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.2 160.98 41.28 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.602 -175.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -139.85 160.15 26.11 Favored Glycine 0 C--O 1.224 -0.522 0 O-C-N 121.686 -0.634 . . . . 0.0 113.22 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -128.42 134.93 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 125.613 1.565 . . . . 0.0 107.852 168.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -137.82 112.93 9.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 C-N-CA 124.255 1.022 . . . . 0.0 109.792 172.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -76.59 153.25 35.49 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.391 1.076 . . . . 0.0 110.475 165.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -130.77 100.01 5.14 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 127.901 2.48 . . . . 0.0 108.762 172.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.433 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.8 OUTLIER -102.83 126.87 50.13 Favored 'General case' 0 N--CA 1.466 0.356 0 O-C-N 121.534 -0.729 . . . . 0.0 109.663 175.743 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . 0.465 HE22 ' CB ' ' B' ' 105' ' ' SER . 55.2 tt0 -126.87 141.22 51.87 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.133 0.973 . . . . 0.0 112.159 -176.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.479 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -78.71 -50.43 11.41 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.479 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 27.1 mp0 -146.29 150.54 35.96 Favored 'General case' 0 C--O 1.222 -0.374 0 C-N-CA 125.798 1.639 . . . . 0.0 109.778 173.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.9 m -58.62 10.8 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 128.72 2.808 . . . . 0.0 117.543 -171.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -144.7 -9.44 0.62 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 127.772 2.429 . . . . 0.0 113.886 169.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.44 -179.89 49.84 Favored Glycine 0 CA--C 1.541 1.657 0 CA-C-N 119.946 1.248 . . . . 0.0 110.6 168.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -75.67 160.8 37.58 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.611 2.208 . . . . 0.0 113.155 -171.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -120.56 129.67 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 124.802 1.241 . . . . 0.0 109.228 176.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? -95.9 128.38 42.74 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.405 1.098 . . . . 0.0 110.176 170.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 1.3 t -90.92 129.05 42.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 C-N-CA 128.936 2.894 . . . . 0.0 108.666 172.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.5 p90 -152.87 156.85 39.78 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 170.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.02 -154.67 24.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 124.778 1.18 . . . . 0.0 111.521 -169.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 85.2 p -162.59 150.85 14.33 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.899 1.444 . . . . 0.0 114.899 -172.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -113.61 123.92 69.74 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 125.277 1.431 . . . . 0.0 108.279 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -114.64 153.8 29.53 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 126.097 1.759 . . . . 0.0 111.359 -174.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.37 60.3 Favored Glycine 0 N--CA 1.475 1.294 0 C-N-CA 125.33 1.443 . . . . 0.0 114.507 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.01 166.43 17.76 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.494 1.518 . . . . 0.0 112.25 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -75.08 146.85 41.11 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 163.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . 0.503 ' CD ' ' HZ2' ' B' ' 91' ' ' LYS . 73.6 tt0 -49.27 143.21 6.45 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 124.904 1.282 . . . . 0.0 110.958 169.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 103.66 -175.44 23.42 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 124.222 0.915 . . . . 0.0 114.015 -177.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 42' ' ' LEU . 0.5 OUTLIER -87.39 145.87 26.12 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 127.56 2.344 . . . . 0.0 112.358 -169.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -139.19 138.96 37.37 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 127.936 2.494 . . . . 0.0 111.61 -169.066 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.36 156.83 53.15 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 125.08 1.324 . . . . 0.0 112.415 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -157.25 99.51 1.79 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 118.17 0.985 . . . . 0.0 110.849 -168.299 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.415 ' HB2' ' CE1' ' B' ' 71' ' ' HIS . 3.0 p-80 -126.6 146.12 50.28 Favored 'General case' 0 C--N 1.342 0.259 0 CA-C-O 122.675 1.226 . . . . 0.0 113.133 -175.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.6 HG12 ' HB2' ' B' ' 117' ' ' LEU . 0.5 OUTLIER -111.42 151.14 13.58 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.293 175.809 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -119.08 119.36 33.98 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.313 -170.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -74.27 57.58 0.68 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.808 0.731 . . . . 0.0 109.557 166.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -161.6 106.94 1.31 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 125.088 1.355 . . . . 0.0 109.987 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -94.77 -5.21 61.42 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-O 117.144 -1.92 . . . . 0.0 115.026 -176.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.487 ' HA ' HG21 ' A' ' 5' ' ' VAL . 0.2 OUTLIER -76.84 52.7 0.86 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 120.735 2.268 . . . . 0.0 111.847 -170.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 176.58 35.28 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 116.733 2.123 . . . . 0.0 116.733 -167.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 13.8 p -73.71 36.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 119.488 -2.007 . . . . 0.0 115.469 -172.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.4 -1.96 58.24 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.622 1.969 . . . . 0.0 113.916 -169.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.21 -149.58 34.26 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -169.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 31.7 p -64.01 -7.89 9.97 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 113.981 1.104 . . . . 0.0 113.981 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 30.9 p -77.57 6.51 7.05 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.856 1.262 . . . . 0.0 114.086 174.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 8.6 t -162.45 -155.12 0.34 Allowed 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 126.433 1.893 . . . . 0.0 109.54 169.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 72.07 71.25 0.15 Allowed 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.81 2.044 . . . . 0.0 113.383 169.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.62 -54.66 4.9 Favored Glycine 0 CA--C 1.544 1.888 0 CA-C-O 116.747 -2.141 . . . . 0.0 114.929 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -130.52 168.95 0.0 OUTLIER 'Trans proline' 0 C--N 1.355 0.918 0 C-N-CA 123.22 2.613 . . . . 0.0 116.346 -172.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.614 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.2 OUTLIER -85.03 141.57 30.19 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 126.991 2.117 . . . . 0.0 112.874 166.031 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -70.17 144.97 51.81 Favored 'General case' 0 CA--C 1.545 0.76 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.911 164.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 43.2 m-20 -106.83 75.09 0.39 Allowed Pre-proline 0 CA--C 1.555 1.17 0 C-N-CA 125.554 1.541 . . . . 0.0 112.714 -177.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -56.79 -47.9 21.16 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 124.123 3.215 . . . . 0.0 113.141 -174.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.1 mp -78.93 2.02 21.67 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.034 1.734 . . . . 0.0 113.14 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 59.7 p 68.29 45.04 1.27 Allowed 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 128.736 2.814 . . . . 0.0 111.513 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . 0.454 ' HD2' ' OE1' ' B' ' 78' ' ' GLU 0.298 23.7 ptt180 -130.7 171.45 13.08 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -169.136 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.4 169.26 14.76 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 113.625 -1.625 . . . . 0.0 107.345 -172.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CE1' ' HB2' ' B' ' 46' ' ' HIS . 46.9 t60 -63.51 164.11 9.93 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.989 168.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.62 -139.51 7.04 Favored Glycine 0 C--N 1.336 0.567 0 CA-C-O 119.532 -0.593 . . . . 0.0 112.303 169.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.87 -43.22 1.69 Allowed Glycine 0 CA--C 1.545 1.939 0 N-CA-C 119.186 2.434 . . . . 0.0 119.186 169.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -85.45 -12.34 6.67 Favored 'Trans proline' 0 C--N 1.356 0.959 0 CA-C-N 123.497 3.649 . . . . 0.0 113.519 173.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.29 1.92 0.97 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 126.829 2.051 . . . . 0.0 112.326 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.73 152.95 51.62 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 127.773 2.429 . . . . 0.0 108.632 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.94 -2.35 18.37 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.975 2.51 . . . . 0.0 113.072 -176.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . 0.454 ' OE1' ' HD2' ' B' ' 69' ' ' ARG . 4.4 mm-40 -75.05 -102.74 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 169.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 73.72 141.48 0.06 Allowed 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 125.705 2.669 . . . . 0.0 111.927 172.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -78.77 148.11 33.08 Favored 'General case' 0 CA--C 1.551 1.018 0 CA-C-N 113.065 -1.879 . . . . 0.0 111.615 171.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 19.8 m -46.96 -41.5 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 CA-C-N 120.559 1.527 . . . . 0.0 111.366 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.511 ' C ' HG23 ' B' ' 47' ' ' VAL . . . -99.29 104.84 2.94 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 164.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -157.01 129.95 7.74 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 125.634 1.574 . . . . 0.0 112.839 166.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 6.5 mp -110.46 179.17 4.16 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 126.501 1.92 . . . . 0.0 110.392 170.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.82 -106.91 3.0 Favored Glycine 0 C--N 1.339 0.722 0 C-N-CA 124.774 1.178 . . . . 0.0 113.972 -171.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -127.11 158.64 36.48 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 123.919 0.888 . . . . 0.0 112.944 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 4.2 m -118.43 137.54 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 126.772 2.029 . . . . 0.0 109.216 168.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 90.5 m -125.12 115.69 20.88 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 121.195 1.816 . . . . 0.0 110.745 -173.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.06 137.33 36.76 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 124.751 1.22 . . . . 0.0 112.546 -176.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -73.62 178.49 4.69 Favored 'General case' 0 CA--C 1.541 0.629 0 O-C-N 124.148 0.905 . . . . 0.0 111.008 170.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.503 ' HZ2' ' CD ' ' B' ' 40' ' ' GLU . 3.3 ttmp? -76.96 66.46 2.8 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 123.45 1.595 . . . . 0.0 111.312 169.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -156.31 -45.29 0.07 Allowed 'General case' 0 C--N 1.319 -0.721 0 C-N-CA 127.198 2.199 . . . . 0.0 108.807 175.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 124.85 -12.21 7.76 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 117.606 -1.664 . . . . 0.0 113.904 -172.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.6 p -81.21 121.76 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.555 1.677 . . . . 0.0 114.355 170.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.76 135.59 34.91 Favored 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.12 0.968 . . . . 0.0 108.478 164.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -77.0 148.0 36.5 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 123.0 1.381 . . . . 0.0 107.586 168.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -131.37 123.26 52.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 112.331 -2.213 . . . . 0.0 109.221 171.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 7.0 p -156.94 59.53 0.52 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.251 1.42 . . . . 0.0 112.546 -168.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 3.1 mp -109.04 159.89 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 O-C-N 120.259 -1.526 . . . . 0.0 112.095 -173.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -145.3 155.06 42.98 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.044 2.138 . . . . 0.0 109.487 174.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -155.16 144.44 21.07 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.461 1.905 . . . . 0.0 110.328 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.0 p -113.92 49.32 1.0 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.7 t -151.3 14.57 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 123.617 0.767 . . . . 0.0 112.782 -170.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.25 166.64 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.152 0 O-C-N 119.66 -1.9 . . . . 0.0 110.723 -171.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.465 ' CB ' HE22 ' B' ' 22' ' ' GLN . 83.8 p -157.56 161.95 38.77 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 117.922 2.564 . . . . 0.0 117.922 171.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.7 mp -78.78 72.91 5.32 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 126.831 2.052 . . . . 0.0 107.482 170.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 10.8 t -130.24 15.03 5.64 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -176.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.59 -63.74 0.33 Allowed Glycine 0 N--CA 1.474 1.219 0 N-CA-C 116.089 1.196 . . . . 0.0 116.089 169.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -119.44 -112.56 0.33 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 118.867 1.334 . . . . 0.0 109.53 -168.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 58.7 m-70 -73.05 0.6 10.96 Favored 'General case' 0 CA--C 1.543 0.7 0 O-C-N 120.263 -1.523 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 54.0 p -71.08 -19.75 62.43 Favored 'General case' 0 CA--C 1.541 0.611 0 CA-C-O 116.587 -1.673 . . . . 0.0 114.305 169.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.305 3.9 pt 143.97 -11.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.114 1 C-N-CA 132.735 4.414 . . . . 0.0 116.227 168.831 . . . . . . . . 3 2 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 29.8 mm -76.08 148.15 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 CA-C-N 120.266 1.394 . . . . 0.0 109.683 173.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 70.57 5.15 55.14 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 120.586 -1.321 . . . . 0.0 114.437 -175.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.9 ptt180 -79.31 156.1 28.19 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.135 1.374 . . . . 0.0 109.979 168.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.5 m -100.43 163.8 12.21 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.928 1.291 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.6 ' HB2' HG12 ' B' ' 47' ' ' VAL . 12.5 tp -148.85 126.5 11.74 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.032 1.733 . . . . 0.0 111.074 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 29.1 m -120.76 147.63 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.071 0.948 . . . . 0.0 110.906 167.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.4 p -104.58 154.68 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 124.434 1.094 . . . . 0.0 108.207 167.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 -120.35 159.76 24.4 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.252 1.421 . . . . 0.0 112.54 -173.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -84.8 -26.77 27.27 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 119.894 -1.754 . . . . 0.0 114.909 -168.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.31 179.84 3.92 Favored 'General case' 0 CA--C 1.545 0.785 0 O-C-N 119.606 -1.934 . . . . 0.0 108.702 166.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.39 151.4 47.21 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.105 0.962 . . . . 0.0 112.869 -176.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -75.65 143.37 42.25 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.215 0.531 . . . . 0.0 110.345 175.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -73.47 -20.05 60.79 Favored 'General case' 0 CA--C 1.555 1.141 0 C-N-CA 123.714 0.806 . . . . 0.0 111.71 169.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 51.32 60.0 4.19 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 126.773 2.029 . . . . 0.0 112.191 -174.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.86 -26.26 25.11 Favored Glycine 0 N--CA 1.469 0.855 0 CA-C-O 117.797 -1.557 . . . . 0.0 116.539 168.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.3 ttmt -159.51 100.87 1.5 Allowed 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 120.413 2.106 . . . . 0.0 112.424 176.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . 0.494 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -102.89 -132.46 7.67 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 166.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.88 12.07 49.5 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.462 1.505 . . . . 0.0 114.57 173.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -130.9 162.91 28.61 Favored 'General case' 0 C--N 1.344 0.345 0 CA-C-N 119.236 1.518 . . . . 0.0 114.387 -168.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -57.06 -59.64 4.77 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.301 1.441 . . . . 0.0 110.02 167.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -59.77 -14.59 15.25 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.689 1.596 . . . . 0.0 113.358 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.494 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 24.3 p -66.39 -28.0 68.29 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.883 1.219 . . . . 0.0 112.892 172.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 2.4 p -95.22 -31.31 13.55 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 127.135 2.174 . . . . 0.0 112.261 178.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 45.7 mttp -92.86 -23.66 18.73 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.652 1.581 . . . . 0.0 113.598 -173.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.431 HG21 HH21 ' B' ' 143' ' ' ARG . 41.7 p -138.69 -124.11 0.13 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 127.408 2.283 . . . . 0.0 105.034 164.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -126.86 8.37 7.24 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 125.466 1.507 . . . . 0.0 111.267 168.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 62.18 -79.74 0.02 OUTLIER 'General case' 0 C--N 1.347 0.492 0 C-N-CA 127.335 2.254 . . . . 0.0 110.066 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 60.64 29.92 19.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 126.397 1.879 . . . . 0.0 114.616 167.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.62 -42.4 1.27 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 125.768 1.652 . . . . 0.0 113.684 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 10.5 t -178.09 163.15 1.68 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.018 2.127 . . . . 0.0 111.315 175.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.431 HH21 HG21 ' B' ' 137' ' ' THR . 80.4 mtt85 -73.26 177.04 5.39 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 125.159 1.384 . . . . 0.0 110.322 168.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.57 -128.57 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 124.306 1.042 . . . . 0.0 111.245 -172.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.82 153.88 39.74 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 124.947 1.299 . . . . 0.0 112.447 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -137.41 152.01 49.16 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.109 1.364 . . . . 0.0 111.887 -169.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.92 171.24 33.8 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.201 1.381 . . . . 0.0 112.15 169.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 79.7 t -119.35 147.42 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 169.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 14.8 mm -86.5 88.6 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 O-C-N 121.626 -0.671 . . . . 0.0 110.526 -179.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.16 -168.3 42.66 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 123.431 0.538 . . . . 0.0 113.405 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.6 pp -135.44 161.2 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -170.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.4 -56.43 0.4 Allowed 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.134 169.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 N--CA 1.464 0.241 0 C-N-CA 126.04 1.736 . . . . 0.0 110.129 -169.766 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.681 0 CA-C-O 118.448 -0.786 . . . . 0.0 112.888 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.505 HG23 HE22 ' A' ' 153' ' ' GLN . 40.0 m -75.06 121.43 22.01 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 -174.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.419 ' HE3' ' CG2' ' A' ' 5' ' ' VAL . 17.4 pttt -132.1 133.47 44.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 115.888 1.81 . . . . 0.0 115.888 -176.135 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 149' ' ' ILE . . . -86.95 167.57 14.15 Favored 'General case' 0 CA--C 1.535 0.4 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 163.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.419 ' CG2' ' HE3' ' A' ' 3' ' ' LYS . 15.2 t -147.43 118.21 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 119.207 0.912 . . . . 0.0 112.158 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.26 84.53 5.19 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 168.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 54.2 t -76.4 79.42 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 105.025 -2.213 . . . . 0.0 105.025 176.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.2 mt -67.09 127.68 33.5 Favored 'General case' 0 C--O 1.224 -0.239 0 CA-C-O 122.205 1.002 . . . . 0.0 111.177 -162.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.1 tttm -159.67 -174.6 4.7 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.342 1.457 . . . . 0.0 111.672 174.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.24 -6.44 21.34 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 124.778 1.18 . . . . 0.0 113.008 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -116.96 145.62 43.52 Favored 'General case' 0 N--CA 1.433 -1.276 1 C-N-CA 133.291 4.636 . . . . 0.0 103.4 168.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.66 -70.87 0.99 Allowed Glycine 0 CA--C 1.535 1.298 0 C-N-CA 126.011 1.767 . . . . 0.0 112.966 -177.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -69.16 -32.31 21.32 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 123.715 2.943 . . . . 0.0 114.537 -170.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -95.71 144.39 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 119.707 1.14 . . . . 0.0 111.304 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -139.83 173.66 11.3 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.523 1.129 . . . . 0.0 109.174 168.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.52 178.5 33.83 Favored Glycine 0 N--CA 1.468 0.784 0 C-N-CA 124.465 1.031 . . . . 0.0 114.954 169.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.3 pt -153.45 56.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 C-N-CA 124.943 1.297 . . . . 0.0 111.992 -170.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.5 mm -87.03 98.64 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 O-C-N 120.566 -1.334 . . . . 0.0 110.66 -173.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.02 147.31 34.88 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.782 1.233 . . . . 0.0 110.253 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -128.25 79.08 1.88 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.045 1.338 . . . . 0.0 109.544 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -81.7 112.31 18.76 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 125.086 1.354 . . . . 0.0 112.188 -175.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -101.02 131.83 46.72 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.449 1.5 . . . . 0.0 109.199 171.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.46 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -96.53 -22.95 16.78 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 124.438 1.095 . . . . 0.0 113.453 174.805 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -103.26 -138.35 0.35 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.668 3.187 . . . . 0.0 110.405 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.2 p -151.29 34.0 0.57 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 127.533 2.333 . . . . 0.0 109.33 169.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -178.88 -28.77 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.369 1.467 . . . . 0.0 114.44 -167.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.63 -169.21 40.29 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 125.165 1.364 . . . . 0.0 113.248 177.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -68.0 138.63 44.59 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.313 2.675 . . . . 0.0 112.834 -171.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.4 t -96.43 132.87 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 124.37 1.068 . . . . 0.0 110.062 173.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 ttmm -81.23 118.61 22.74 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 169.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.12 79.11 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 127.687 2.395 . . . . 0.0 108.702 -174.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -103.28 164.99 11.29 Favored 'General case' 0 CA--C 1.541 0.607 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.418 172.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.36 -164.32 28.37 Favored Glycine 0 C--O 1.224 -0.491 0 C-N-CA 125.383 1.468 . . . . 0.0 111.506 174.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.6 p -155.38 168.47 26.97 Favored 'General case' 0 C--N 1.319 -0.722 0 O-C-N 121.686 -0.89 . . . . 0.0 110.597 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.67 HG21 HG11 ' A' ' 119' ' ' VAL . 4.3 mp -128.24 126.55 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 C-N-CA 126.283 1.833 . . . . 0.0 107.27 174.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.68 143.76 45.6 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 122.888 2.585 . . . . 0.0 113.032 -179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.42 -1.94 16.1 Favored Glycine 0 CA--C 1.54 1.636 0 C-N-CA 128.146 2.784 . . . . 0.0 113.561 -169.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.9 mt -79.01 161.95 26.26 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.059 1.344 . . . . 0.0 113.203 -177.205 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.1 t -85.53 155.64 21.11 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 164.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 26.4 pt-20 -57.6 172.59 0.35 Allowed 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 115.782 1.771 . . . . 0.0 115.782 -174.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.32 -178.6 53.84 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.621 1.105 . . . . 0.0 113.228 174.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.6 mp -62.36 142.52 57.77 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.09 1.756 . . . . 0.0 112.606 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -142.72 124.08 14.72 Favored 'General case' 0 N--CA 1.469 0.475 0 C-N-CA 127.84 2.456 . . . . 0.0 108.507 177.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.97 149.28 51.71 Favored Glycine 0 N--CA 1.477 1.396 0 CA-C-N 120.585 1.539 . . . . 0.0 110.919 178.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -147.7 117.88 7.31 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.907 1.854 . . . . 0.0 111.566 172.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.4 OUTLIER -157.48 173.61 16.64 Favored 'General case' 0 C--O 1.236 0.367 0 O-C-N 121.104 -0.997 . . . . 0.0 109.741 -168.324 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -112.59 135.96 50.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 C-N-CA 124.214 1.006 . . . . 0.0 110.479 -166.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -77.18 176.18 8.97 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 122.849 0.46 . . . . 0.0 110.622 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 64' ' ' PHE . 1.2 pm0 -71.56 137.67 48.22 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.411 -0.806 . . . . 0.0 108.896 165.373 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 56.07 -169.05 0.09 Allowed 'General case' 0 CA--C 1.542 0.661 0 CA-C-O 123.665 1.698 . . . . 0.0 114.166 173.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.92 17.66 48.37 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-O 116.357 -2.357 . . . . 0.0 111.476 167.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.695 ' HA ' HG21 ' B' ' 5' ' ' VAL . 2.3 p30 -82.36 45.54 0.96 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 121.754 2.777 . . . . 0.0 112.454 -172.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.408 ' H ' ' ND2' ' A' ' 53' ' ' ASN . 0.3 OUTLIER -91.69 34.39 0.98 Allowed 'General case' 0 C--O 1.235 0.301 0 N-CA-C 115.546 1.684 . . . . 0.0 115.546 -166.285 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.565 HG22 ' HA ' ' B' ' 7' ' ' VAL . 28.6 p -114.45 -18.86 11.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -160.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.69 21.2 4.89 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-N 119.214 0.915 . . . . 0.0 110.902 165.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.4 -112.7 3.63 Favored Glycine 0 C--N 1.342 0.878 0 C-N-CA 125.646 1.594 . . . . 0.0 111.476 173.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.5 t -80.87 -16.7 52.93 Favored 'General case' 0 CA--C 1.545 0.766 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 168.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.1 40.02 0.53 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.633 1.573 . . . . 0.0 108.8 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -172.16 167.07 6.01 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 127.46 2.304 . . . . 0.0 110.003 -162.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -1.31 106.71 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 129.522 3.129 . . . . 0.0 116.947 168.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.76 -84.39 0.74 Allowed Glycine 0 CA--C 1.54 1.609 0 C-N-CA 126.861 2.172 . . . . 0.0 113.165 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.9 173.74 13.94 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 124.39 3.393 . . . . 0.0 112.708 -171.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -92.96 115.39 28.08 Favored 'General case' 0 CA--C 1.536 0.404 0 O-C-N 121.156 -0.965 . . . . 0.0 113.533 -168.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 49' ' ' GLU . 40.2 t80 -43.89 130.4 5.75 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.135 1.374 . . . . 0.0 113.638 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 35.6 p-10 -145.27 68.49 13.67 Favored Pre-proline 0 CA--C 1.541 0.598 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -168.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -61.11 -19.66 64.35 Favored 'Trans proline' 0 CA--C 1.54 0.784 0 C-N-CA 122.501 2.134 . . . . 0.0 112.058 169.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 96.3 mt -76.88 -6.29 51.84 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.147 1.379 . . . . 0.0 113.608 171.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.1 t 57.71 47.48 15.58 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 127.224 2.21 . . . . 0.0 112.233 174.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.8 ptt180 -111.24 173.01 6.54 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 114.657 1.354 . . . . 0.0 114.657 -175.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -89.04 176.14 7.11 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.187 2.195 . . . . 0.0 108.989 175.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 53.9 t60 -91.56 157.25 17.11 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.418 1.087 . . . . 0.0 113.674 -172.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 138.63 -129.73 4.62 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 124.021 0.82 . . . . 0.0 113.028 167.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 129.34 -30.05 3.73 Favored Glycine 0 CA--C 1.55 2.224 0 N-CA-C 119.763 2.665 . . . . 0.0 119.763 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -108.97 17.45 0.09 OUTLIER 'Trans proline' 0 CA--C 1.551 1.355 0 C-N-CA 124.933 3.756 . . . . 0.0 113.115 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.96 -26.17 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 128.286 2.634 . . . . 0.0 111.421 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.5 OUTLIER -94.78 148.07 22.68 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.864 2.066 . . . . 0.0 106.157 162.064 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -100.67 -8.98 22.32 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 126.901 2.08 . . . . 0.0 113.08 -178.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.64 -82.03 0.09 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 124.076 0.95 . . . . 0.0 110.553 -176.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . 0.292 37.6 ptt180 66.67 111.95 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 127.063 2.145 . . . . 0.0 113.393 175.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -59.49 165.19 2.98 Favored 'General case' 0 CA--C 1.551 0.986 0 O-C-N 119.596 -1.94 . . . . 0.0 113.337 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 74.3 t -57.27 -25.26 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.457 -1.402 . . . . 0.0 112.697 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.67 31.19 7.41 Favored Glycine 0 CA--C 1.539 1.558 0 CA-C-O 118.222 -1.321 . . . . 0.0 115.993 173.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -112.25 139.73 47.55 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 117.387 2.365 . . . . 0.0 117.387 -172.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 79.9 mt -144.9 166.01 26.5 Favored 'General case' 0 CA--C 1.555 1.15 1 C-N-CA 133.704 4.802 . . . . 0.0 104.031 165.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.71 -129.32 5.3 Favored Glycine 0 N--CA 1.473 1.147 0 C-N-CA 123.664 0.65 . . . . 0.0 113.606 -169.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -113.06 147.33 37.48 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 121.974 0.892 . . . . 0.0 113.085 169.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -92.66 174.19 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.682 1.993 . . . . 0.0 108.372 167.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -140.57 124.02 16.91 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 168.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -82.1 139.81 34.19 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 118.239 0.472 . . . . 0.0 111.913 169.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -69.65 157.27 37.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 125.712 1.605 . . . . 0.0 110.386 167.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.83 -0.59 0.69 Allowed 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 114.684 1.365 . . . . 0.0 114.684 170.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -99.64 5.59 45.81 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.816 2.046 . . . . 0.0 112.482 170.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.08 0.54 65.75 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 126.27 1.89 . . . . 0.0 116.49 168.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.12 136.2 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 CA-C-N 119.497 1.649 . . . . 0.0 112.9 -177.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.3 129.85 50.41 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 124.948 1.299 . . . . 0.0 107.745 166.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -92.31 148.97 21.72 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-O 122.577 1.179 . . . . 0.0 108.835 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.07 124.58 37.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 113.451 -1.704 . . . . 0.0 109.232 173.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.1 p -155.31 76.04 0.96 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.962 1.363 . . . . 0.0 111.491 -169.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.72 159.57 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.484 1.513 . . . . 0.0 110.221 -169.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -147.17 121.43 9.57 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 104.777 -2.305 . . . . 0.0 104.777 166.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -126.29 131.79 51.8 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.641 1.21 . . . . 0.0 113.061 -168.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 90.1 p -82.98 58.73 4.53 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.393 1.077 . . . . 0.0 110.162 177.19 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -152.25 -44.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 170.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.45 143.14 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 118.938 0.79 . . . . 0.0 110.876 -179.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.518 ' H ' ' CB ' ' A' ' 111' ' ' SER . 35.8 p -132.22 161.02 34.45 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 126.556 1.942 . . . . 0.0 112.075 173.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 31.0 mt -79.71 94.54 5.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 168.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -131.97 -15.46 2.99 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 115.77 1.767 . . . . 0.0 115.77 -169.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.05 -68.67 3.39 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-N 120.347 1.43 . . . . 0.0 111.622 -170.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -92.04 -60.77 1.77 Allowed 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.705 1.24 . . . . 0.0 113.824 -173.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 28.7 m-70 -80.64 1.56 29.39 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.84 1.656 . . . . 0.0 112.903 -164.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' H ' ' A' ' 105' ' ' SER . 18.9 m -162.42 -88.88 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.264 0 N-CA-C 115.71 1.744 . . . . 0.0 115.71 177.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -135.41 162.75 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.093 -1.004 . . . . 0.0 111.093 -173.012 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 114.54 140.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 1 C-N-CA 135.521 5.528 . . . . 0.0 107.374 -169.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.63 -25.62 1.71 Allowed Glycine 0 CA--C 1.535 1.317 0 CA-C-O 118.26 -1.3 . . . . 0.0 115.836 177.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 10.6 ptt180 -74.73 163.64 27.46 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 126.253 1.821 . . . . 0.0 111.466 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.3 m -121.37 110.81 16.54 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 124.635 1.174 . . . . 0.0 113.042 -169.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.6 tp -99.66 122.87 43.31 Favored 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 121.124 1.784 . . . . 0.0 111.346 -173.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 143' ' ' ARG . 13.2 p -121.13 151.59 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 125.471 1.509 . . . . 0.0 113.315 179.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.678 HG13 ' CD2' ' A' ' 144' ' ' LEU . 7.4 p -103.9 143.28 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.035 0 C-N-CA 124.547 1.139 . . . . 0.0 110.344 166.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 40.6 m-70 -115.34 169.2 9.32 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 126.94 2.096 . . . . 0.0 115.123 -168.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -83.58 -30.17 27.21 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 116.075 1.88 . . . . 0.0 116.075 -173.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -107.0 170.18 8.1 Favored 'General case' 0 CA--C 1.546 0.805 0 CA-C-N 120.668 1.576 . . . . 0.0 111.881 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.57 163.89 6.51 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.022 1.329 . . . . 0.0 111.443 169.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -103.9 131.49 51.07 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.023 0.929 . . . . 0.0 110.422 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.88 -28.5 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 120.747 0.308 . . . . 0.0 111.656 177.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.0 mt 58.09 40.46 25.21 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.387 1.875 . . . . 0.0 112.446 173.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.27 -74.39 0.07 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 117.495 1.758 . . . . 0.0 117.495 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -139.06 -42.03 0.47 Allowed 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -164.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 54.64 -113.43 3.48 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 120.178 1.354 . . . . 0.0 110.47 -166.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -153.56 29.55 0.76 Allowed Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.222 1.867 . . . . 0.0 112.008 168.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 10.0 p-10 -166.48 171.3 12.0 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.773 1.629 . . . . 0.0 111.669 -164.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -67.62 -54.65 17.95 Favored 'General case' 0 N--CA 1.469 0.478 0 O-C-N 121.32 -0.862 . . . . 0.0 113.185 -169.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.429 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 0.3 OUTLIER -65.09 -19.51 66.02 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.043 0.937 . . . . 0.0 111.25 -171.864 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.4 m -67.67 -33.35 74.76 Favored 'General case' 0 CA--C 1.546 0.826 0 O-C-N 120.897 -1.127 . . . . 0.0 111.729 168.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.4 p -83.29 -18.94 37.29 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 124.783 1.233 . . . . 0.0 114.241 174.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -105.99 -45.56 4.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.303 1.041 . . . . 0.0 113.57 -176.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.71 -26.33 12.33 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 116.829 -1.558 . . . . 0.0 113.87 177.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.63 12.44 47.56 Favored Glycine 0 N--CA 1.472 1.062 0 CA-C-N 119.327 0.967 . . . . 0.0 114.8 -173.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 60.38 8.95 1.78 Allowed 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 118.975 1.387 . . . . 0.0 113.508 -174.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.84 -3.41 0.74 Allowed 'General case' 0 CA--C 1.57 1.723 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -166.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.21 -160.04 25.67 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 126.694 2.092 . . . . 0.0 112.797 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 91.7 p -65.82 177.54 1.27 Allowed 'General case' 0 CA--C 1.547 0.828 0 O-C-N 122.026 -0.691 . . . . 0.0 112.139 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.463 ' HB2' HG21 ' A' ' 118' ' ' VAL . 27.5 ptt180 -136.2 132.37 35.8 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.923 -1.111 . . . . 0.0 112.749 -166.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.678 ' CD2' HG13 ' A' ' 119' ' ' VAL 0.335 0.0 OUTLIER -103.35 -106.76 0.27 Allowed 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.154 1.381 . . . . 0.0 111.723 -175.677 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.473 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -77.23 135.18 38.45 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 119.635 1.107 . . . . 0.0 111.216 -173.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.435 ' HB3' HG23 ' A' ' 118' ' ' VAL . 13.9 p -141.88 154.86 45.43 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 126.107 1.763 . . . . 0.0 111.69 -172.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -146.7 130.01 3.5 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 123.818 0.723 . . . . 0.0 111.915 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -72.47 170.53 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 167.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 4' ' ' ALA . 35.2 mm -129.56 126.39 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 O-C-N 120.738 -1.226 . . . . 0.0 113.331 -167.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -146.05 -126.24 1.77 Allowed Glycine 0 CA--C 1.539 1.591 0 C-N-CA 127.442 2.449 . . . . 0.0 114.617 -177.514 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.1 pp -147.46 68.67 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 120.642 -1.505 . . . . 0.0 113.932 -168.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.43 -20.43 54.54 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 120.567 -1.333 . . . . 0.0 114.462 -171.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . 0.505 HE22 HG23 ' A' ' 2' ' ' THR . 4.9 mm-40 . . . . . 0 N--CA 1.472 0.633 0 C-N-CA 124.497 1.119 . . . . 0.0 112.699 175.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.442 0 CA-C-O 121.12 0.486 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.4 m -83.24 99.87 10.24 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -96.36 165.18 12.32 Favored 'General case' 0 CA--C 1.548 0.899 0 CA-C-O 122.864 1.316 . . . . 0.0 113.251 -176.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.34 172.73 13.43 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -168.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.695 HG21 ' HA ' ' A' ' 52' ' ' ASP . 1.1 p -157.43 103.44 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 C-N-CA 127.25 2.22 . . . . 0.0 107.786 -169.051 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.27 130.42 35.02 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 120.472 -1.392 . . . . 0.0 111.699 171.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.565 ' HA ' HG22 ' A' ' 54' ' ' THR . 20.6 t -93.48 71.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.179 0.992 . . . . 0.0 111.136 -173.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -80.48 114.72 19.58 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.469 0.652 . . . . 0.0 109.531 -178.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 13.2 ttpp -144.97 151.18 38.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.84 0.829 . . . . 0.0 112.428 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.45 149.96 18.76 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 106.322 -2.711 . . . . 0.0 106.322 166.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -79.1 64.88 4.13 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 123.408 1.575 . . . . 0.0 110.372 169.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.52 -175.45 46.24 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 129.101 3.239 . . . . 0.0 108.685 -171.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.18 22.21 0.38 Allowed 'Trans proline' 0 CA--C 1.547 1.153 0 C-N-CA 124.65 3.566 . . . . 0.0 114.916 -169.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.454 HG11 HD13 ' B' ' 144' ' ' LEU . 1.3 t -118.97 130.31 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 C-N-CA 126.993 2.117 . . . . 0.0 109.002 -170.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.434 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -160.71 160.88 31.97 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 124.099 0.96 . . . . 0.0 110.999 -170.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.01 169.05 33.58 Favored Glycine 0 CA--C 1.51 -0.262 0 C-N-CA 124.779 1.18 . . . . 0.0 112.23 168.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.402 HG22 ' HB ' ' A' ' 54' ' ' THR . 1.0 OUTLIER -132.35 133.18 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 171.8 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.438 HD12 HG11 ' B' ' 97' ' ' VAL . 5.0 mm -135.09 109.58 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . 0.407 ' HB2' ' CE2' ' B' ' 32' ' ' TRP . 36.2 m120 -79.85 155.52 27.78 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 123.914 0.886 . . . . 0.0 111.959 175.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.439 ' CD2' HG22 ' B' ' 31' ' ' VAL . 5.5 m-85 -139.27 152.65 47.44 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 167.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -146.88 132.57 18.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 119.133 0.879 . . . . 0.0 109.951 167.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -84.84 137.86 32.91 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 122.721 0.408 . . . . 0.0 111.117 -177.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.464 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -93.48 -91.64 0.18 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.179 0.992 . . . . 0.0 110.618 169.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.464 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 31.9 mp0 -82.37 169.25 16.67 Favored 'General case' 0 C--O 1.217 -0.607 0 O-C-N 120.538 -1.351 . . . . 0.0 110.544 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -51.02 -45.25 61.17 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 114.298 1.222 . . . . 0.0 114.298 -172.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 22.0 m-80 -127.01 40.27 3.75 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.632 1.973 . . . . 0.0 110.294 166.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.66 162.76 53.61 Favored Glycine 0 CA--C 1.536 1.378 0 CA-C-O 118.717 -1.046 . . . . 0.0 111.461 173.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -66.4 161.72 39.66 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.503 2.802 . . . . 0.0 110.005 174.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 53.0 t -136.55 133.36 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 122.973 0.509 . . . . 0.0 110.967 -169.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -79.84 132.16 36.04 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 168.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.439 HG22 ' CD2' ' B' ' 20' ' ' PHE . 21.3 t -120.85 111.54 32.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 126.578 1.951 . . . . 0.0 108.739 176.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . 0.407 ' CE2' ' HB2' ' B' ' 19' ' ' ASN . 17.5 p90 -140.11 153.27 46.66 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.366 0.603 . . . . 0.0 112.213 -173.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.49 -153.41 24.63 Favored Glycine 0 C--O 1.225 -0.433 0 C-N-CA 124.13 0.872 . . . . 0.0 111.507 178.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 12.6 p -157.1 158.66 36.79 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 114.045 1.128 . . . . 0.0 114.045 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -128.1 131.46 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 125.715 1.606 . . . . 0.0 107.912 -179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 23.1 ttpt -133.95 140.12 46.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 126.172 1.789 . . . . 0.0 110.617 -168.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.11 20.73 13.09 Favored Glycine 0 N--CA 1.481 1.638 0 C-N-CA 124.994 1.283 . . . . 0.0 114.373 178.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.543 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.2 pt? -117.91 165.9 13.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.756 2.822 . . . . 0.0 110.622 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.95 167.46 21.86 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.316 0.646 . . . . 0.0 110.205 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -64.65 -175.3 0.17 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 126.967 2.107 . . . . 0.0 114.549 171.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.33 -170.59 46.98 Favored Glycine 0 N--CA 1.47 0.944 0 O-C-N 120.388 -1.445 . . . . 0.0 112.432 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 2.7 mt -77.01 155.16 32.79 Favored 'General case' 0 CA--C 1.545 0.757 0 O-C-N 121.172 -1.193 . . . . 0.0 110.02 177.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -147.63 123.57 10.68 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 127.931 2.493 . . . . 0.0 109.641 -172.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.34 151.16 36.2 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-N 120.926 1.694 . . . . 0.0 113.526 176.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -151.13 96.58 2.33 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 125.213 1.405 . . . . 0.0 112.171 -170.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.38 147.07 48.93 Favored 'General case' 0 N--CA 1.47 0.561 0 O-C-N 120.085 -1.634 . . . . 0.0 111.742 -167.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.526 HG23 ' HA2' ' B' ' 82' ' ' GLY . 27.5 m -108.66 120.19 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 122.484 1.135 . . . . 0.0 110.959 177.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -77.83 101.61 6.83 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -173.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -64.16 95.27 0.12 Allowed 'General case' 0 C--N 1.344 0.349 0 CA-C-O 123.116 1.436 . . . . 0.0 108.602 175.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 t80 177.55 -166.95 0.05 Allowed 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 130.472 3.509 . . . . 0.0 104.349 -164.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.35 -122.02 3.5 Favored Glycine 0 CA--C 1.507 -0.43 0 CA-C-O 121.772 0.651 . . . . 0.0 112.477 171.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.07 152.83 39.85 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.684 1.594 . . . . 0.0 113.459 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 173.13 32.68 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 128.815 2.846 . . . . 0.0 108.843 -171.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 82.8 p -68.25 12.27 0.13 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.439 2.295 . . . . 0.0 116.382 -165.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.07 -2.83 28.68 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 125.162 1.385 . . . . 0.0 113.254 169.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.6 -150.57 19.93 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.559 1.552 . . . . 0.0 112.432 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 18.1 p -54.75 -5.79 0.1 Allowed 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 116.82 2.156 . . . . 0.0 116.82 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.9 t -76.18 7.18 4.44 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.721 1.609 . . . . 0.0 111.619 166.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 6.1 m -154.86 158.82 39.94 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 127.92 2.488 . . . . 0.0 109.739 172.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 61.49 -76.81 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 127.354 2.262 . . . . 0.0 113.997 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.82 -91.75 0.94 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.296 1.903 . . . . 0.0 112.223 -174.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -100.33 -177.32 0.17 Allowed 'Trans proline' 0 CA--C 1.535 0.561 1 C-N-CA 125.939 4.426 . . . . 0.0 111.728 176.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.487 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -79.98 130.36 35.21 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 168.741 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 41.7 t80 -58.97 147.09 35.67 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.855 1.262 . . . . 0.0 112.56 171.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 50.3 m-20 -108.81 77.87 0.86 Allowed Pre-proline 0 CA--C 1.554 1.097 0 C-N-CA 125.276 1.43 . . . . 0.0 111.843 -176.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -58.21 -49.18 13.15 Favored 'Trans proline' 0 C--N 1.353 0.81 0 C-N-CA 123.975 3.116 . . . . 0.0 113.216 -174.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 75.1 mt -78.83 -0.44 30.62 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 126.144 1.778 . . . . 0.0 112.871 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.2 t 58.77 43.82 17.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 127.518 2.327 . . . . 0.0 112.151 -173.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.1 mtp180 -92.31 176.43 6.48 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 120.878 -1.139 . . . . 0.0 112.489 -176.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.513 ' HE2' ' OE1' ' B' ' 78' ' ' GLU . 0.3 OUTLIER -97.24 170.26 9.22 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 126.18 1.792 . . . . 0.0 108.829 165.312 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -96.66 151.64 19.42 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -167.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.44 -106.03 0.34 Allowed Glycine 0 C--N 1.345 1.053 0 C-N-CA 124.796 1.189 . . . . 0.0 114.809 166.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.85 -29.2 8.69 Favored Glycine 0 CA--C 1.543 1.811 0 N-CA-C 119.85 2.7 . . . . 0.0 119.85 174.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -104.03 6.47 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.049 0 C-N-CA 123.657 2.904 . . . . 0.0 112.578 172.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.01 -31.25 0.13 Allowed 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.908 1.283 . . . . 0.0 110.893 169.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -82.05 150.13 27.71 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 162.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -96.19 -17.99 20.41 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.519 1.927 . . . . 0.0 112.138 -176.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . 0.513 ' OE1' ' HE2' ' B' ' 70' ' ' LYS . 3.7 mt-10 -78.05 -50.66 11.65 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 121.049 -1.032 . . . . 0.0 113.023 -172.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 45.75 97.88 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.127 1.371 . . . . 0.0 114.059 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.6 m80 -50.79 144.78 7.86 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 119.729 -1.857 . . . . 0.0 110.262 169.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 m -55.41 -29.99 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 CA-C-N 120.239 1.381 . . . . 0.0 112.12 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.526 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -89.26 49.24 3.48 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 125.025 1.298 . . . . 0.0 116.053 171.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -139.46 123.17 17.48 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.353 1.461 . . . . 0.0 110.071 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -113.55 50.29 0.92 Allowed 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 168.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 55.73 -112.13 2.91 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 125.343 1.449 . . . . 0.0 114.445 177.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -155.7 159.07 39.23 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 126.196 1.798 . . . . 0.0 110.563 -175.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 5.8 p -117.37 175.75 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 127.517 2.327 . . . . 0.0 109.685 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -133.92 150.17 51.31 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.98 1.712 . . . . 0.0 108.326 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -117.7 149.03 41.42 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.443 1.497 . . . . 0.0 112.779 173.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -83.52 150.05 26.23 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 128.229 2.612 . . . . 0.0 112.281 169.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.82 -2.48 1.85 Allowed 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.884 1.673 . . . . 0.0 115.143 177.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -90.93 7.96 37.53 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.485 1.514 . . . . 0.0 112.069 169.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.82 28.81 22.73 Favored Glycine 0 C--N 1.341 0.821 0 CA-C-O 117.361 -1.799 . . . . 0.0 114.656 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -141.64 139.26 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.138 1.469 . . . . 0.0 114.521 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.14 122.04 44.5 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.558 1.543 . . . . 0.0 108.685 165.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -79.21 140.0 37.8 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 165.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . 0.438 HG11 HD12 ' B' ' 18' ' ' ILE 0.262 0.3 OUTLIER -119.71 129.04 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-O 122.557 1.17 . . . . 0.0 112.576 166.96 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 28.8 m -147.8 78.63 1.46 Allowed 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.362 1.465 . . . . 0.0 109.729 -172.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -122.44 154.14 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.484 1.513 . . . . 0.0 111.614 -173.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.8 tt0 -142.14 148.39 38.22 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.989 1.715 . . . . 0.0 107.346 167.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -149.83 150.48 32.04 Favored 'General case' 0 N--CA 1.464 0.261 0 C-N-CA 125.117 1.367 . . . . 0.0 111.934 -175.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.2 p -116.78 51.86 0.97 Allowed 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.7 -48.64 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 124.4 1.08 . . . . 0.0 110.819 169.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.96 157.31 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 119.327 0.967 . . . . 0.0 112.785 177.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 95.0 p -156.54 150.89 25.41 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.164 1.786 . . . . 0.0 109.023 -170.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mp -80.95 54.06 2.11 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 122.128 0.965 . . . . 0.0 108.745 172.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -84.93 62.61 7.58 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.121 -0.987 . . . . 0.0 109.968 -177.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.92 -111.11 4.06 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 124.784 1.183 . . . . 0.0 112.837 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -127.99 -14.8 4.92 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 127.67 2.388 . . . . 0.0 114.518 -167.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.0 -32.14 8.44 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 114.49 1.292 . . . . 0.0 114.49 -169.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.7 m -85.98 -15.14 42.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.258 0.7 OUTLIER -177.37 -47.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 C-N-CA 127.564 2.346 . . . . 0.0 109.109 168.536 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 26.5 mm -58.86 143.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 105.61 -1.996 . . . . 0.0 105.61 162.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.65 -16.4 1.4 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 126.769 2.128 . . . . 0.0 113.628 -175.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . 0.52 HH11 ' HG3' ' B' ' 115' ' ' ARG . 4.5 ttm-85 -80.15 171.37 15.17 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.863 1.665 . . . . 0.0 111.854 176.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -113.14 154.52 26.5 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 125.379 1.471 . . . . 0.0 112.466 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 25.2 tp -121.15 138.25 54.29 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 128.246 2.619 . . . . 0.0 109.217 168.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -114.84 139.39 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 124.949 1.3 . . . . 0.0 109.872 168.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 p -119.57 133.99 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 171.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -110.94 151.06 28.35 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.767 1.227 . . . . 0.0 112.033 -168.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -79.2 -18.22 53.39 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -167.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 48.0 mttp -138.73 178.23 7.3 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 120.163 1.347 . . . . 0.0 113.569 177.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.91 130.51 37.61 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.282 1.433 . . . . 0.0 110.176 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -81.33 158.78 24.6 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 124.029 0.831 . . . . 0.0 109.221 170.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . 0.452 ' OD1' ' HE3' ' B' ' 128' ' ' LYS . 7.5 t70 -73.45 -43.29 60.63 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 119.306 -0.957 . . . . 0.0 109.3 168.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 2.0 mm? 70.15 53.14 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 127.123 2.169 . . . . 0.0 107.734 -168.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 161.22 -82.29 0.13 Allowed Glycine 0 N--CA 1.465 0.617 0 O-C-N 121.317 -0.864 . . . . 0.0 114.1 -175.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.537 ' H ' ' HE3' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -156.69 72.4 0.73 Allowed 'General case' 0 CA--C 1.549 0.938 0 N-CA-C 115.701 1.741 . . . . 0.0 115.701 -170.237 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -57.6 -24.81 54.03 Favored Glycine 0 CA--C 1.542 1.753 0 O-C-N 120.708 -1.245 . . . . 0.0 115.128 176.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.48 -28.38 0.49 Allowed Glycine 0 CA--C 1.534 1.24 0 N-CA-C 116.675 1.43 . . . . 0.0 116.675 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . 0.418 ' H ' ' HB3' ' B' ' 134' ' ' SER . 62.2 m-80 -106.33 175.81 5.37 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 118.968 1.384 . . . . 0.0 113.098 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 13.1 tm-20 -51.64 -57.55 8.84 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.603 1.161 . . . . 0.0 108.904 166.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -41.33 -34.53 0.52 Allowed 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 126.236 1.814 . . . . 0.0 115.036 168.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' B' ' 131' ' ' ASN . 4.5 p -71.18 -9.96 58.97 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 119.318 -2.114 . . . . 0.0 115.836 -177.339 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 3.2 t -111.16 -7.98 14.43 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.166 1.387 . . . . 0.0 110.379 164.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -85.82 -50.33 7.22 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.737 1.615 . . . . 0.0 110.763 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 80.7 p -102.35 -35.52 8.79 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 128.686 2.794 . . . . 0.0 110.972 175.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.76 -9.63 52.05 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.045 1.783 . . . . 0.0 112.028 -169.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . 0.447 HD22 ' HA ' ' B' ' 139' ' ' ASN . 0.1 OUTLIER 75.96 30.93 0.71 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 129.446 3.098 . . . . 0.0 112.317 176.413 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -63.68 33.33 0.01 OUTLIER 'General case' 0 CA--C 1.568 1.668 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 178.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.55 -51.86 3.75 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 127.69 2.567 . . . . 0.0 114.79 175.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 170.9 157.39 0.07 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.862 1.665 . . . . 0.0 113.741 -174.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.33 134.0 34.52 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.413 1.085 . . . . 0.0 113.715 173.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.454 HD13 HG11 ' B' ' 14' ' ' VAL . 3.3 pp -104.7 -30.17 10.11 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.331 1.453 . . . . 0.0 113.469 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.81 161.55 36.94 Favored 'General case' 0 C--O 1.245 0.831 0 C-N-CA 125.705 1.602 . . . . 0.0 107.174 174.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.3 p -152.32 151.86 31.41 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 126.254 1.822 . . . . 0.0 108.525 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.46 145.69 11.77 Favored Glycine 0 C--O 1.224 -0.504 0 N-CA-C 115.632 1.013 . . . . 0.0 115.632 179.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 16.3 t -78.17 145.9 9.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.283 1.033 . . . . 0.0 108.244 167.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.6 mm -89.53 101.17 11.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.914 0.886 . . . . 0.0 109.979 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -90.62 164.46 30.39 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 173.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -93.78 141.14 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 123.902 0.881 . . . . 0.0 111.354 172.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -141.91 166.19 25.39 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.956 1.703 . . . . 0.0 111.154 168.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.466 0.351 0 C-N-CA 123.265 0.626 . . . . 0.0 111.133 -167.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.946 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -157.68 123.87 4.78 Favored 'General case' 0 CA--C 1.508 -0.635 0 O-C-N 125.6 1.812 . . . . 0.0 107.884 -168.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.0 ttpt -99.0 106.74 19.03 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 122.641 1.21 . . . . 0.0 112.967 169.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.65 173.23 7.99 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 126.078 1.751 . . . . 0.0 109.041 167.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.868 HG11 ' HA ' ' B' ' 52' ' ' ASP . 12.8 p -161.78 162.66 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.353 0.661 . . . . 0.0 111.996 -173.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.52 134.01 19.75 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.566 1.146 . . . . 0.0 109.899 163.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.26 94.29 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 126.525 1.93 . . . . 0.0 107.058 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -79.3 134.58 36.62 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 126.708 2.003 . . . . 0.0 110.206 -173.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 13.4 mtpt -155.87 179.71 8.94 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.313 1.045 . . . . 0.0 113.687 178.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.5 -60.47 0.42 Allowed Glycine 0 C--N 1.334 0.445 0 C-N-CA 128.083 2.754 . . . . 0.0 108.721 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -82.1 69.69 8.86 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.101 1.761 . . . . 0.0 111.52 -168.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.44 -100.67 0.03 OUTLIER Glycine 0 CA--C 1.54 1.643 0 C-N-CA 126.957 2.218 . . . . 0.0 114.132 171.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -80.38 -7.66 13.86 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 125.04 3.827 . . . . 0.0 114.331 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 38.3 t -77.22 142.17 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 CA-C-N 119.983 1.265 . . . . 0.0 109.105 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.45 158.04 39.35 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 124.95 1.3 . . . . 0.0 109.414 169.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.44 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -140.51 108.64 0.57 Allowed Glycine 0 C--O 1.22 -0.777 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.94 131.41 37.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 118.676 1.238 . . . . 0.0 108.392 168.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.3 pp -149.41 126.61 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-O 122.764 1.269 . . . . 0.0 111.413 166.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -74.82 166.3 23.84 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.78 1.232 . . . . 0.0 111.329 169.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -141.49 93.25 2.55 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.734 2.014 . . . . 0.0 107.879 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.447 ' OE2' ' HE3' ' A' ' 23' ' ' LYS . 4.6 tm-20 -92.55 122.9 35.44 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.588 1.555 . . . . 0.0 110.121 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -120.01 132.24 55.41 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.869 0.842 . . . . 0.0 112.333 169.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.554 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -75.13 -42.01 57.17 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.269 1.827 . . . . 0.0 112.584 -177.017 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.329 0.0 OUTLIER -110.01 -122.46 0.27 Allowed 'General case' 0 CA--C 1.544 0.729 0 CA-C-O 116.887 -1.53 . . . . 0.0 110.215 169.068 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 48.9 m -144.07 -25.31 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-N 120.847 1.658 . . . . 0.0 114.752 -172.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.47 -17.8 6.9 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 120.45 -1.406 . . . . 0.0 114.108 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -150.69 4.86 Favored Glycine 0 CA--C 1.542 1.755 1 C-N-CA 131.0 4.143 . . . . 0.0 114.104 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -88.41 156.71 6.62 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.296 2.664 . . . . 0.0 114.365 -168.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.14 134.48 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.763 1.225 . . . . 0.0 109.632 -173.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -97.58 126.0 42.63 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.229 1.411 . . . . 0.0 109.902 178.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.6 t -123.8 122.39 64.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 C-N-CA 126.587 1.955 . . . . 0.0 109.146 -170.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -146.9 150.27 34.89 Favored 'General case' 0 C--O 1.24 0.57 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -178.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 140.59 -153.13 23.43 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.834 1.683 . . . . 0.0 111.039 -169.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.1 p -158.57 143.35 16.09 Favored 'General case' 0 C--O 1.238 0.485 0 O-C-N 121.794 -0.827 . . . . 0.0 113.097 -169.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.44 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -109.13 106.2 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 125.251 1.42 . . . . 0.0 109.616 173.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -111.29 144.59 40.23 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.704 2.002 . . . . 0.0 110.549 -167.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.01 -24.04 24.08 Favored Glycine 0 N--CA 1.475 1.241 0 C-N-CA 126.566 2.031 . . . . 0.0 112.108 -171.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.4 mp -68.13 111.45 4.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.254 1.822 . . . . 0.0 107.644 168.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 6.4 t -68.78 -27.32 65.78 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.259 1.577 . . . . 0.0 115.259 -169.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 178.58 -175.4 0.19 Allowed 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 130.744 3.617 . . . . 0.0 106.549 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.54 159.81 35.41 Favored Glycine 0 N--CA 1.469 0.845 0 C-N-CA 126.263 1.887 . . . . 0.0 116.038 167.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.8 mt -70.45 132.61 45.84 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.827 1.251 . . . . 0.0 109.008 168.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -129.52 120.08 24.78 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.409 1.483 . . . . 0.0 107.253 177.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.13 164.47 36.48 Favored Glycine 0 N--CA 1.475 1.245 0 CA-C-O 117.619 -1.656 . . . . 0.0 111.563 176.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.25 1.6 p90 -156.06 111.32 2.94 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 120.989 2.394 . . . . 0.0 113.569 169.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -122.14 147.08 46.59 Favored 'General case' 0 CA--C 1.551 0.991 0 O-C-N 119.979 -1.701 . . . . 0.0 111.082 -172.124 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -82.31 120.63 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -71.12 111.85 6.81 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.43 -2.433 . . . . 0.0 104.43 168.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.478 ' H ' ' HA ' ' A' ' 63' ' ' HIS . 16.8 tt0 -64.39 116.86 6.5 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.148 -174.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.353 50.3 m-85 101.31 160.57 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 131.567 3.947 . . . . 0.0 113.708 -178.089 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.18 -14.7 55.63 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 114.746 -1.115 . . . . 0.0 114.48 -172.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG11 ' B' ' 5' ' ' VAL . 5.0 m-20 -71.93 54.9 0.28 Allowed 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 128.887 2.875 . . . . 0.0 113.134 -169.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -170.33 -42.34 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 119.539 3.163 . . . . 0.0 119.539 -168.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.298 0.9 OUTLIER 49.75 -58.99 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 129.115 2.966 . . . . 0.0 117.339 -169.775 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -82.26 22.44 0.82 Allowed 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 127.748 2.419 . . . . 0.0 114.596 -171.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.41 -127.82 44.4 Favored Glycine 0 C--N 1.336 0.553 0 C-N-CA 125.49 1.519 . . . . 0.0 110.878 172.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.5 m -56.56 -10.37 0.96 Allowed 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 115.547 1.684 . . . . 0.0 115.547 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.08 1.85 22.73 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 125.251 1.42 . . . . 0.0 112.623 171.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 9.0 t -164.94 -156.52 0.31 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 129.532 3.133 . . . . 0.0 106.361 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 74.88 -169.09 0.1 Allowed 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 123.761 1.743 . . . . 0.0 115.147 166.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.68 155.43 16.08 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 127.151 2.31 . . . . 0.0 108.735 166.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.417 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 96.6 Cg_endo -75.61 76.43 3.63 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 123.924 3.083 . . . . 0.0 108.293 171.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.478 ' HA ' ' H ' ' A' ' 49' ' ' GLU . 5.1 p80 47.27 72.39 0.25 Allowed 'General case' 0 C--O 1.236 0.351 0 C-N-CA 127.261 2.225 . . . . 0.0 112.674 167.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -40.84 141.22 0.61 Allowed 'General case' 0 C--O 1.221 -0.395 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.603 -174.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -101.3 67.48 0.06 OUTLIER Pre-proline 0 CA--C 1.549 0.938 0 CA-C-N 114.195 -1.366 . . . . 0.0 113.527 175.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -65.13 -18.47 61.57 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 121.829 1.686 . . . . 0.0 112.593 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -77.97 -5.11 50.18 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.188 1.395 . . . . 0.0 113.523 170.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.6 t 60.78 53.41 3.92 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 127.01 2.124 . . . . 0.0 112.177 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 -139.3 175.35 9.63 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 -167.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.546 ' H ' ' HE3' ' A' ' 70' ' ' LYS . 0.5 OUTLIER -76.68 158.89 30.67 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.353 1.461 . . . . 0.0 112.017 173.179 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -79.4 147.92 32.18 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 115.481 -0.781 . . . . 0.0 112.469 168.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.467 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 155.64 -111.93 0.5 Allowed Glycine 0 C--N 1.339 0.701 0 CA-C-O 118.029 -1.429 . . . . 0.0 114.09 167.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.11 -85.88 0.39 Allowed Glycine 0 CA--C 1.537 1.446 0 CA-C-O 117.486 -1.73 . . . . 0.0 114.6 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -55.54 -6.88 1.1 Allowed 'Trans proline' 0 CA--C 1.543 0.973 0 C-N-CA 124.458 3.438 . . . . 0.0 116.869 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmm? -155.89 9.97 0.27 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 128.585 2.754 . . . . 0.0 112.238 -176.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.467 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.6 OUTLIER -146.74 109.9 4.75 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 128.533 2.733 . . . . 0.0 109.624 179.106 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -64.35 -9.26 16.73 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 127.848 2.459 . . . . 0.0 114.719 -175.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -81.44 -91.83 0.06 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.76 0.824 . . . . 0.0 110.402 177.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.8 ttp-105 78.72 118.45 0.06 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.164 1.785 . . . . 0.0 111.141 171.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 23.0 m80 -55.79 160.83 2.44 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.278 -1.514 . . . . 0.0 113.831 175.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.8 t -53.16 -50.74 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 121.047 1.749 . . . . 0.0 112.229 -170.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.7 3.06 Favored Glycine 0 C--N 1.341 0.833 0 N-CA-C 108.491 -1.844 . . . . 0.0 108.491 169.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -157.45 118.56 3.6 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.529 1.531 . . . . 0.0 109.512 179.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -105.16 165.57 11.0 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 126.099 1.76 . . . . 0.0 109.726 169.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.81 -136.77 8.57 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 125.249 1.404 . . . . 0.0 112.792 177.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.64 158.17 20.33 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 117.025 2.231 . . . . 0.0 117.025 -174.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.3 m -106.97 173.9 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 128.705 2.802 . . . . 0.0 110.188 167.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.1 t -141.74 141.27 33.25 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 125.552 1.541 . . . . 0.0 108.383 169.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.69 150.67 25.26 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 125.221 1.408 . . . . 0.0 111.589 178.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -100.64 158.79 15.68 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.884 1.673 . . . . 0.0 112.128 173.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -50.28 -21.93 1.58 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 129.099 2.959 . . . . 0.0 115.815 -169.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.26 0.94 54.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 128.58 2.752 . . . . 0.0 110.716 -172.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.32 32.05 6.24 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-O 117.477 -1.735 . . . . 0.0 114.052 173.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.2 p -155.66 133.53 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 117.512 2.412 . . . . 0.0 117.512 -171.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.65 129.22 40.02 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 163.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -88.59 145.49 25.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 168.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.7 t -131.85 122.27 49.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 113.251 -1.795 . . . . 0.0 107.934 167.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -146.35 58.81 1.21 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 127.687 2.395 . . . . 0.0 107.582 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 29.7 mt -116.77 155.65 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.498 1.519 . . . . 0.0 112.125 -166.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -135.99 130.24 33.3 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 167.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -132.69 144.71 50.5 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 125.353 1.461 . . . . 0.0 110.256 -169.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.6 p -125.28 59.42 1.25 Allowed 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.276 1.431 . . . . 0.0 112.752 -167.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.3 p -156.31 -48.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 C-N-CA 123.008 0.523 . . . . 0.0 110.683 -174.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -82.32 158.79 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 164.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.2 p -160.24 168.85 24.46 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.064 1.345 . . . . 0.0 109.355 -175.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.3 mp -100.64 54.06 0.87 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.0 t -76.09 4.32 8.73 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 114.98 1.474 . . . . 0.0 114.98 -167.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 138.18 -86.83 0.22 Allowed Glycine 0 N--CA 1.462 0.39 0 N-CA-C 106.592 -2.603 . . . . 0.0 106.592 -169.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -143.99 -6.11 0.77 Allowed 'General case' 0 C--O 1.219 -0.526 0 C-N-CA 123.761 0.824 . . . . 0.0 113.199 168.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -73.03 -33.17 65.56 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 120.29 -1.506 . . . . 0.0 110.617 -165.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.0 p -105.78 -8.56 17.71 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 117.448 2.388 . . . . 0.0 117.448 -169.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.273 3.7 pt 176.69 -39.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 C-N-CA 127.698 2.399 . . . . 0.0 115.582 167.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.3 mm -49.47 125.03 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-N 121.605 2.002 . . . . 0.0 111.024 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.67 -7.01 66.87 Favored Glycine 0 CA--C 1.534 1.241 0 C-N-CA 125.766 1.65 . . . . 0.0 116.092 176.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.5 176.03 10.14 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.814 1.646 . . . . 0.0 110.622 170.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 3.1 t -132.97 129.03 37.69 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 120.185 1.357 . . . . 0.0 113.078 -174.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 58.2 tp -101.96 125.48 48.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 126.771 2.029 . . . . 0.0 109.523 -170.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 14.9 p -110.98 135.19 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 124.526 1.131 . . . . 0.0 109.595 174.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.581 HG13 HD22 ' A' ' 144' ' ' LEU . 2.2 p -92.63 141.51 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 C-N-CA 124.991 1.316 . . . . 0.0 109.088 168.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -112.95 168.42 9.71 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.097 2.559 . . . . 0.0 113.112 -168.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -86.61 -46.71 9.85 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 -168.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -99.9 -176.33 3.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 120.091 -1.631 . . . . 0.0 110.198 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.71 154.16 7.22 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 165.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.3 p30 -99.25 140.78 32.91 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.68 1.229 . . . . 0.0 110.792 167.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -78.62 -36.57 43.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 127.422 2.289 . . . . 0.0 112.213 -169.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 23.1 mt 55.82 47.83 19.44 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.717 1.207 . . . . 0.0 110.596 173.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 138.52 -62.25 0.57 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.415 -1.214 . . . . 0.0 115.9 171.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.39 87.39 1.31 Allowed 'General case' 0 CA--C 1.552 1.021 1 N-CA-C 122.417 4.229 . . . . 0.0 122.417 -166.5 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.71 -86.99 0.61 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 105.948 -2.861 . . . . 0.0 105.948 163.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -167.31 34.08 0.21 Allowed Glycine 0 N--CA 1.47 0.935 0 CA-C-O 119.03 -0.872 . . . . 0.0 114.827 171.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -164.05 150.34 11.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 119.513 1.657 . . . . 0.0 108.899 -167.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -48.3 -46.99 36.88 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.607 0.763 . . . . 0.0 112.275 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -50.51 -27.84 7.37 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 116.04 1.867 . . . . 0.0 116.04 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.1 p -53.25 -28.06 25.54 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-N 120.857 1.662 . . . . 0.0 112.656 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 6.9 t -113.51 -29.16 7.27 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 115.195 1.554 . . . . 0.0 115.195 170.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -67.65 -23.32 65.32 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 119.986 1.266 . . . . 0.0 113.355 178.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.9 p -141.11 -32.91 0.54 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.228 1.411 . . . . 0.0 114.236 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.39 5.16 49.39 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.587 1.565 . . . . 0.0 110.466 -164.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 51.53 30.99 6.96 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 127.311 2.244 . . . . 0.0 114.632 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.05 19.47 0.04 OUTLIER 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 118.06 2.615 . . . . 0.0 118.06 -166.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.62 8.05 37.64 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 119.437 2.535 . . . . 0.0 119.437 167.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 28.9 t 139.2 -178.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 1 C-N-CA 131.952 4.101 . . . . 0.0 111.183 170.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.08 154.22 37.62 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 126.18 1.792 . . . . 0.0 112.836 173.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.581 HD22 HG13 ' A' ' 119' ' ' VAL 0.349 0.0 OUTLIER -133.31 -127.2 0.17 Allowed 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.972 2.109 . . . . 0.0 107.868 167.104 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.05 147.77 46.2 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.068 1.304 . . . . 0.0 114.472 -166.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 27.7 p -137.42 147.63 45.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.612 1.565 . . . . 0.0 113.952 176.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.61 142.43 8.41 Favored Glycine 0 N--CA 1.473 1.165 0 C-N-CA 124.621 1.105 . . . . 0.0 114.238 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 87.6 t -76.27 150.43 6.32 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 C-N-CA 124.725 1.21 . . . . 0.0 110.246 -177.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 17.9 mm -81.31 83.69 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 O-C-N 121.562 -0.711 . . . . 0.0 109.721 173.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.72 -169.01 43.59 Favored Glycine 0 N--CA 1.474 1.231 0 C-N-CA 126.849 2.166 . . . . 0.0 112.912 175.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -142.74 155.39 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 115.324 1.602 . . . . 0.0 115.324 -168.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -108.84 -15.11 14.46 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 125.567 1.547 . . . . 0.0 112.844 169.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.476 0.85 0 C-N-CA 130.057 3.343 . . . . 0.0 109.117 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.775 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 17.2 m -78.19 77.03 4.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.713 1.205 . . . . 0.0 111.425 -168.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.259 17.3 pttm -81.13 130.49 35.05 Favored 'General case' 0 CA--C 1.547 0.85 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -174.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.38 172.42 12.76 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 127.744 2.417 . . . . 0.0 111.288 -176.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.511 HG11 ' HA ' ' A' ' 52' ' ' ASP . 7.0 p -148.38 146.81 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.41 1.084 . . . . 0.0 112.734 -166.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.16 96.56 2.9 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-O 122.516 1.151 . . . . 0.0 108.799 168.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 53.1 t -79.64 96.82 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 104.878 -2.267 . . . . 0.0 104.878 166.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.65 114.94 17.0 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 77.0 tttt -160.76 131.34 5.31 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.465 1.484 . . . . 0.0 114.747 -175.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -162.04 -35.16 0.02 OUTLIER Glycine 0 N--CA 1.474 1.204 0 C-N-CA 125.232 1.396 . . . . 0.0 111.519 168.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -77.26 58.38 1.61 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 130.98 3.712 . . . . 0.0 113.075 175.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.91 -96.39 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 C-N-CA 129.184 3.278 . . . . 0.0 115.569 169.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.94 -16.45 14.32 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.134 3.223 . . . . 0.0 113.91 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -86.37 141.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-N 119.698 1.135 . . . . 0.0 109.105 174.235 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -157.12 161.03 39.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.758 1.223 . . . . 0.0 110.629 167.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.05 99.92 0.79 Allowed Glycine 0 C--O 1.222 -0.632 0 C-N-CA 126.073 1.797 . . . . 0.0 110.694 173.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -87.64 93.61 4.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 118.983 1.391 . . . . 0.0 108.425 175.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.5 pp -113.88 152.73 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.96 1.362 . . . . 0.0 111.821 171.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -123.29 175.79 6.49 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.761 1.224 . . . . 0.0 110.262 175.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -140.1 139.77 35.92 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 124.249 1.019 . . . . 0.0 109.371 168.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -134.28 131.73 38.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 168.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -125.71 141.09 52.19 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-O 122.069 0.938 . . . . 0.0 109.962 174.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 6.6 mtmm -84.51 -31.16 24.62 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 125.686 1.594 . . . . 0.0 110.774 -174.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -123.28 -164.56 1.22 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 128.938 2.895 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 36.7 p -106.97 -37.17 6.41 Favored 'General case' 0 N--CA 1.472 0.674 0 O-C-N 120.719 -1.238 . . . . 0.0 110.617 166.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -112.79 5.07 17.36 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.391 1.476 . . . . 0.0 114.023 -175.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.46 -178.01 37.05 Favored Glycine 0 CA--C 1.54 1.649 0 CA-C-O 118.692 -1.06 . . . . 0.0 112.448 172.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.81 157.7 54.62 Favored 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 123.026 2.484 . . . . 0.0 113.552 -176.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 94.2 t -120.37 136.03 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 126.555 1.942 . . . . 0.0 110.93 -170.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.3 mptt -79.23 118.84 21.54 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.417 0.627 . . . . 0.0 111.733 169.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -106.3 124.92 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 125.549 1.54 . . . . 0.0 107.252 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -151.28 160.83 43.6 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 123.156 0.582 . . . . 0.0 112.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.32 175.58 13.91 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 123.846 0.736 . . . . 0.0 113.65 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 43.7 p -119.77 124.05 45.22 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 115.068 1.507 . . . . 0.0 115.068 -166.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.556 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.0 mm -90.65 123.37 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 CA-C-O 116.878 -1.534 . . . . 0.0 109.973 168.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 56.2 tttt -132.82 132.64 42.39 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 122.219 2.282 . . . . 0.0 111.677 175.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 129.75 -9.76 6.07 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 127.42 2.438 . . . . 0.0 114.293 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.426 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.7 OUTLIER -91.3 168.2 11.75 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.62 1.568 . . . . 0.0 112.535 173.332 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.8 t -77.28 166.93 22.55 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.811 0.844 . . . . 0.0 111.241 169.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -67.41 -172.84 0.25 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 125.742 1.617 . . . . 0.0 115.204 -173.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.14 -172.75 54.25 Favored Glycine 0 N--CA 1.477 1.378 0 C-N-CA 124.568 1.08 . . . . 0.0 114.009 176.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 54.2 mt -66.95 144.16 56.39 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 120.67 -1.488 . . . . 0.0 110.202 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -133.25 130.42 38.99 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.679 1.192 . . . . 0.0 109.905 170.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.99 152.01 51.2 Favored Glycine 0 N--CA 1.468 0.828 0 C-N-CA 124.644 1.116 . . . . 0.0 112.21 179.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.514 ' CE1' HD21 ' B' ' 117' ' ' LEU . 2.8 t80 -148.73 105.29 3.55 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 117.508 0.654 . . . . 0.0 109.979 -169.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.433 ' CD2' ' CD2' ' B' ' 63' ' ' HIS . 0.5 OUTLIER -143.84 158.3 43.78 Favored 'General case' 0 CA--C 1.54 0.57 0 O-C-N 120.538 -1.351 . . . . 0.0 109.847 -175.836 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.84 126.89 64.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 C-N-CA 126.051 1.74 . . . . 0.0 108.715 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 14.3 m-70 -77.18 116.85 18.16 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 168.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.86 162.21 29.77 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -168.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 1.4 t80 68.72 177.01 0.26 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 125.647 1.579 . . . . 0.0 111.879 -173.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -122.96 0.43 9.86 Favored Glycine 0 N--CA 1.469 0.878 0 CA-C-O 118.881 -0.955 . . . . 0.0 114.177 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.868 ' HA ' HG11 ' A' ' 5' ' ' VAL . 4.1 t0 -86.72 51.21 2.17 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.018 1.327 . . . . 0.0 108.725 -177.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 179.63 34.84 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.109 0 N-CA-C 116.186 1.921 . . . . 0.0 116.186 -166.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.44 ' H ' HG23 ' B' ' 54' ' ' THR . 5.5 p -54.12 32.52 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 131.518 3.927 . . . . 0.0 120.591 -170.678 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -142.11 -3.31 1.09 Allowed 'General case' 0 CA--C 1.558 1.252 0 C-N-CA 127.94 2.496 . . . . 0.0 113.113 168.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.42 -121.52 5.68 Favored Glycine 0 C--N 1.343 0.948 0 C-N-CA 124.808 1.194 . . . . 0.0 113.175 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 27.1 p -57.67 -24.47 56.88 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 -170.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.0 t -91.94 21.54 4.87 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.356 1.462 . . . . 0.0 113.48 174.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 71.2 m -151.54 -37.64 0.12 Allowed 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.802 1.641 . . . . 0.0 114.974 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.27 170.78 19.19 Favored 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 120.982 1.719 . . . . 0.0 113.954 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.61 -158.97 32.54 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 125.871 1.7 . . . . 0.0 115.985 -169.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -74.56 -174.84 1.99 Allowed 'Trans proline' 0 CA--C 1.537 0.67 1 C-N-CA 126.239 4.626 . . . . 0.0 114.35 -169.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.785 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.1 OUTLIER -65.14 96.58 0.21 Allowed 'General case' 0 N--CA 1.445 -0.689 1 C-N-CA 132.648 4.379 . . . . 0.0 109.166 -176.651 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -56.5 146.86 23.45 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 123.953 1.835 . . . . 0.0 109.998 174.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 48.8 p-10 -107.72 57.81 0.22 Allowed Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 -176.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.57 -20.23 53.8 Favored 'Trans proline' 0 C--N 1.358 1.043 0 C-N-CA 122.285 1.99 . . . . 0.0 111.74 169.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 11.0 mp -77.02 -3.88 41.31 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.925 1.29 . . . . 0.0 112.392 169.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t 57.61 87.73 0.06 Allowed 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 127.995 2.518 . . . . 0.0 113.027 174.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . 0.404 ' HD3' ' C ' ' B' ' 78' ' ' GLU . 13.0 ptp180 179.17 176.62 0.58 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -169.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -84.14 176.93 8.45 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 128.111 2.565 . . . . 0.0 107.869 166.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 12.8 t60 -57.78 174.03 0.27 Allowed 'General case' 0 CA--C 1.546 0.791 0 O-C-N 120.39 -1.443 . . . . 0.0 111.813 169.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.83 -175.31 32.18 Favored Glycine 0 N--CA 1.465 0.599 0 O-C-N 121.272 -0.893 . . . . 0.0 113.427 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 136.37 -128.24 4.44 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 117.961 -1.466 . . . . 0.0 112.316 -170.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -48.0 -11.32 0.11 Allowed 'Trans proline' 0 CA--C 1.542 0.895 1 C-N-CA 126.009 4.473 . . . . 0.0 119.793 -172.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.65 -5.67 5.2 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 120.759 1.618 . . . . 0.0 114.157 169.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -126.48 178.19 6.02 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 127.401 2.28 . . . . 0.0 109.819 -168.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -106.72 -20.31 13.39 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.548 1.539 . . . . 0.0 111.989 -177.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . 0.404 ' C ' ' HD3' ' B' ' 69' ' ' ARG . 25.9 mt-10 -78.15 -92.32 0.03 OUTLIER 'General case' 0 CA--C 1.543 0.695 0 O-C-N 121.06 -1.025 . . . . 0.0 113.204 -167.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 54.7 ttt180 78.38 93.61 0.06 Allowed 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 126.328 1.851 . . . . 0.0 113.744 169.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -51.94 160.75 0.67 Allowed 'General case' 0 N--CA 1.481 1.101 0 O-C-N 119.974 -1.704 . . . . 0.0 112.594 166.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 p -68.04 -27.97 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 CA-C-N 121.229 1.831 . . . . 0.0 111.483 176.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -70.8 18.26 0.82 Allowed Glycine 0 CA--C 1.538 1.491 0 CA-C-O 117.109 -1.94 . . . . 0.0 116.277 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -121.04 110.51 16.33 Favored 'General case' 0 CA--C 1.55 0.951 0 CA-C-N 121.891 2.845 . . . . 0.0 112.312 -178.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -113.08 46.17 1.27 Allowed 'General case' 0 N--CA 1.48 1.063 0 CA-C-O 123.361 1.553 . . . . 0.0 112.289 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.93 -141.24 45.32 Favored Glycine 0 CA--C 1.536 1.347 0 CA-C-N 114.054 -1.43 . . . . 0.0 115.499 169.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -116.15 140.16 49.58 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.722 1.209 . . . . 0.0 111.021 172.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -91.34 172.87 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 162.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 5.2 t -140.53 142.96 35.15 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 120.85 -1.156 . . . . 0.0 109.796 173.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 95' ' ' ALA . . . -118.95 157.87 26.86 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.555 1.542 . . . . 0.0 113.187 -169.255 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -107.55 162.46 13.93 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 127.439 2.295 . . . . 0.0 112.543 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.768 ' HE2' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -63.66 -12.81 37.0 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.31 1.444 . . . . 0.0 114.333 173.757 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -70.45 -14.94 62.74 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-O 121.707 0.765 . . . . 0.0 109.93 171.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.16 9.23 55.98 Favored Glycine 0 C--N 1.337 0.625 0 C-N-CA 126.593 2.044 . . . . 0.0 112.848 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.2 p -110.39 138.62 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 125.164 1.385 . . . . 0.0 114.39 -178.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.642 ' HB2' ' HB2' ' B' ' 89' ' ' ALA . . . -111.65 97.13 6.5 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 126.598 1.959 . . . . 0.0 106.284 165.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -98.74 154.61 17.85 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.677 0.751 . . . . 0.0 111.089 174.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -150.66 150.95 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 116.231 1.938 . . . . 0.0 116.231 -173.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 51.6 p -157.46 105.83 2.09 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 124.226 1.01 . . . . 0.0 112.276 169.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 16.3 mt -136.85 151.56 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 126.969 2.108 . . . . 0.0 111.116 -178.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -109.43 107.29 17.38 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 167.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -96.87 138.16 34.85 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 127.285 2.234 . . . . 0.0 112.97 -176.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 82.5 p -108.05 49.93 0.79 Allowed 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 66.8 t -145.35 -44.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-O 118.585 -0.721 . . . . 0.0 112.231 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.94 162.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 120.148 1.34 . . . . 0.0 111.534 170.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.54 ' H ' ' HB3' ' B' ' 111' ' ' SER . 90.2 p -157.4 149.63 22.69 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 125.678 1.591 . . . . 0.0 109.776 -175.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 60.01 4.22 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.436 . . . . 0.0 107.496 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.3 t -115.89 8.52 14.75 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -168.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.02 -49.65 4.01 Favored Glycine 0 N--CA 1.472 1.08 0 O-C-N 120.768 -1.207 . . . . 0.0 114.937 168.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -116.67 -58.68 2.05 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 119.074 1.437 . . . . 0.0 112.331 -170.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -83.21 5.26 23.5 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 125.433 1.493 . . . . 0.0 112.506 -171.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . 0.54 ' HB3' ' H ' ' B' ' 105' ' ' SER . 61.3 m -158.27 -115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.08 0.952 . . . . 0.0 112.668 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 38.6 pt -112.26 169.14 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 120.493 1.497 . . . . 0.0 112.408 -178.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.2 mm 91.24 117.92 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.068 1 C-N-CA 132.259 4.224 . . . . 0.0 105.641 -162.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.35 12.3 72.61 Favored Glycine 0 CA--C 1.534 1.238 0 CA-C-O 117.611 -1.661 . . . . 0.0 115.502 -176.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.82 169.03 10.78 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.585 2.193 . . . . 0.0 109.135 169.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . 0.261 13.3 t -131.7 113.5 13.64 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 123.417 2.826 . . . . 0.0 114.698 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.514 HD21 ' CE1' ' B' ' 45' ' ' PHE . 22.4 tp -88.49 140.67 29.23 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.474 1.91 . . . . 0.0 110.91 -169.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -127.07 142.62 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 124.065 0.946 . . . . 0.0 111.301 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -103.31 140.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 122.322 1.058 . . . . 0.0 110.097 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -102.96 148.59 25.48 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.834 -172.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.262 2.9 pp20? -80.05 -7.45 58.86 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 121.028 -1.045 . . . . 0.0 113.24 -170.267 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 58.2 mttp -126.66 176.44 7.22 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.824 2.05 . . . . 0.0 110.926 168.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -59.29 148.15 33.16 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.383 1.473 . . . . 0.0 111.278 169.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -91.41 138.08 31.86 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 167.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.68 -32.25 65.67 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 177.267 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.9 mt 66.62 66.24 0.45 Allowed 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.58 1.952 . . . . 0.0 111.284 169.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 149.13 -96.65 0.17 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 123.837 0.732 . . . . 0.0 111.311 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.465 ' HA ' ' HB3' ' B' ' 134' ' ' SER . 31.4 tttt -157.49 119.61 3.78 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.876 2.07 . . . . 0.0 110.906 167.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.14 -75.68 0.62 Allowed Glycine 0 CA--C 1.527 0.834 0 C-N-CA 126.382 1.944 . . . . 0.0 109.594 168.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -154.89 -12.22 0.06 OUTLIER Glycine 0 N--CA 1.47 0.954 0 N-CA-C 116.344 1.297 . . . . 0.0 116.344 175.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -109.53 -141.85 0.38 Allowed 'General case' 0 CA--C 1.548 0.881 0 CA-C-N 119.317 1.558 . . . . 0.0 110.03 -167.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -117.73 -48.74 2.56 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 120.619 1.554 . . . . 0.0 111.369 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -46.62 -32.3 3.4 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.412 1.885 . . . . 0.0 112.411 169.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.465 ' HB3' ' HA ' ' B' ' 128' ' ' LYS . 0.4 OUTLIER -49.21 -44.35 43.22 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 127.602 2.361 . . . . 0.0 113.041 169.723 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -95.15 -34.12 12.38 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 173.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -31.81 73.09 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.782 -1.199 . . . . 0.0 113.486 176.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.517 ' HA ' ' HE2' ' B' ' 63' ' ' HIS . 82.7 p -137.03 -27.1 1.0 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 116.759 -1.591 . . . . 0.0 114.612 -173.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.19 -2.79 31.31 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.668 1.127 . . . . 0.0 113.861 -168.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 12.9 t-20 55.89 9.96 0.51 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 126.279 1.831 . . . . 0.0 113.179 -169.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.36 24.96 0.02 OUTLIER 'General case' 0 CA--C 1.566 1.572 0 C-N-CA 127.938 2.495 . . . . 0.0 116.826 -167.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.16 -139.17 19.52 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 126.555 2.026 . . . . 0.0 113.905 178.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 14.4 t -80.93 -148.16 0.06 Allowed 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.979 1.712 . . . . 0.0 109.6 168.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -140.71 155.81 46.37 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 120.353 -1.467 . . . . 0.0 110.098 172.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.501 HD12 ' H ' ' B' ' 145' ' ' ALA . 0.7 OUTLIER -109.72 -129.9 0.3 Allowed 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 165.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.501 ' H ' HD12 ' B' ' 144' ' ' LEU . . . -61.68 144.97 53.73 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.552 1.541 . . . . 0.0 113.823 -170.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.8 p -138.42 151.32 47.35 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 126.194 1.797 . . . . 0.0 113.135 176.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.0 139.53 6.02 Favored Glycine 0 N--CA 1.471 0.997 0 O-C-N 120.989 -1.069 . . . . 0.0 114.239 -176.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 6.4 t -77.98 145.96 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.045 0.938 . . . . 0.0 109.605 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 54.6 mt -81.36 90.47 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.293 1.037 . . . . 0.0 109.781 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -89.18 -171.45 45.55 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 126.39 1.948 . . . . 0.0 111.952 171.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.48 ' H ' HD12 ' B' ' 151' ' ' ILE . 0.8 OUTLIER -127.58 124.46 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 115.737 1.755 . . . . 0.0 115.737 -167.641 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.19 0.08 47.01 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 126.965 2.106 . . . . 0.0 112.593 167.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 131.019 3.728 . . . . 0.0 115.692 -169.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 118.735 -0.65 . . . . 0.0 111.603 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.4 p -76.06 42.53 0.26 Allowed 'General case' 0 C--N 1.346 0.451 0 C-N-CA 128.958 2.903 . . . . 0.0 117.725 -164.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -165.43 101.94 0.72 Allowed 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.783 1.633 . . . . 0.0 108.855 168.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.501 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -75.3 176.05 7.78 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 119.864 1.211 . . . . 0.0 111.482 173.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.654 HG21 ' HA ' ' B' ' 52' ' ' ASP . 1.4 p -153.63 117.49 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 127.225 2.21 . . . . 0.0 106.897 177.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.24 107.29 18.29 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.349 1.06 . . . . 0.0 109.74 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.0 t -76.09 79.97 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.226 1.01 . . . . 0.0 108.406 174.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 11.2 mp -76.99 92.41 3.7 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 173.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 ttpp -157.91 119.68 3.64 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.897 0.879 . . . . 0.0 110.814 171.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.57 -102.28 0.54 Allowed Glycine 0 CA--C 1.524 0.61 0 N-CA-C 106.663 -2.575 . . . . 0.0 106.663 166.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -144.98 109.86 5.07 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 125.938 1.695 . . . . 0.0 107.282 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 136.38 177.03 14.69 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 123.844 0.735 . . . . 0.0 114.209 178.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -68.37 20.76 0.13 Allowed 'Trans proline' 0 CA--C 1.542 0.89 1 C-N-CA 126.15 4.567 . . . . 0.0 116.696 -169.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 144' ' ' LEU . 1.4 t -128.34 128.46 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 CA-C-N 120.447 1.476 . . . . 0.0 109.508 -174.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -144.19 172.74 12.49 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.829 0.823 . . . . 0.0 112.657 -176.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.16 165.79 31.36 Favored Glycine 0 CA--C 1.509 -0.282 0 CA-C-N 112.828 -1.987 . . . . 0.0 112.947 167.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.469 HG13 ' H ' ' A' ' 34' ' ' SER . 7.8 pt -139.83 52.98 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 113.22 -1.49 . . . . 0.0 112.024 -167.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -80.47 105.7 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 O-C-N 120.418 -1.426 . . . . 0.0 111.079 -169.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -83.0 156.28 23.5 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.506 1.522 . . . . 0.0 110.613 173.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.501 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 66.1 m-85 -143.43 97.92 3.16 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.462 1.505 . . . . 0.0 109.677 175.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.72 136.32 37.38 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 119.884 -1.76 . . . . 0.0 107.202 173.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -152.91 -175.81 5.48 Favored 'General case' 0 CA--C 1.553 1.075 0 C-N-CA 127.78 2.432 . . . . 0.0 105.887 176.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.52 -15.29 0.49 Allowed 'General case' 0 CA--C 1.549 0.94 0 O-C-N 118.452 -2.655 . . . . 0.0 116.225 167.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -108.76 -174.27 2.47 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 127.869 2.468 . . . . 0.0 111.346 -174.095 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.3 p -81.33 -21.89 38.86 Favored 'General case' 0 N--CA 1.476 0.826 0 O-C-N 120.528 -1.358 . . . . 0.0 112.888 167.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -161.67 46.38 0.18 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.629 1.171 . . . . 0.0 113.399 -168.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.73 175.69 16.04 Favored Glycine 0 CA--C 1.534 1.266 0 C-N-CA 125.243 1.401 . . . . 0.0 110.637 169.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -74.67 157.95 43.78 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.032 1.821 . . . . 0.0 111.511 -169.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.5 t -131.3 149.4 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 C-N-CA 125.097 1.359 . . . . 0.0 111.482 -167.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -116.51 103.74 10.72 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 123.641 0.776 . . . . 0.0 110.575 -175.175 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.5 t -80.22 119.85 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 C-N-CA 126.834 2.054 . . . . 0.0 107.63 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 1.7 p90 -153.9 167.87 28.25 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 176.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.0 -155.75 15.93 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -170.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.469 ' H ' HG13 ' A' ' 17' ' ' ILE . 63.8 p -155.96 170.5 21.99 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 122.029 0.918 . . . . 0.0 113.345 -169.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.68 134.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 126.497 1.919 . . . . 0.0 107.256 169.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.18 150.23 33.39 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 121.63 2.013 . . . . 0.0 113.913 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.27 5.08 46.78 Favored Glycine 0 CA--C 1.539 1.581 0 C-N-CA 126.437 1.97 . . . . 0.0 112.285 -168.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -71.86 163.89 27.02 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.906 2.082 . . . . 0.0 111.055 170.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 5.5 t -81.32 155.81 25.83 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 164.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 74.7 tt0 -53.03 145.22 13.46 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.37 1.068 . . . . 0.0 111.349 169.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 101.09 -175.3 26.0 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 124.787 1.184 . . . . 0.0 114.146 -177.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -76.12 146.96 38.9 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 128.321 2.648 . . . . 0.0 114.464 -169.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -148.11 123.89 10.56 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.193 2.597 . . . . 0.0 109.911 -174.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.56 155.87 51.55 Favored Glycine 0 N--CA 1.479 1.512 0 CA-C-O 118.028 -1.429 . . . . 0.0 113.169 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.79 139.91 16.49 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 119.957 1.879 . . . . 0.0 114.375 172.285 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.415 ' CE1' ' CD2' ' A' ' 63' ' ' HIS . 9.0 p-80 -153.34 153.8 33.29 Favored 'General case' 0 CA--C 1.547 0.862 0 O-C-N 121.5 -0.75 . . . . 0.0 111.936 -179.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -98.36 112.44 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 123.946 0.899 . . . . 0.0 109.119 174.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -82.43 149.78 27.44 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 174.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -66.84 10.74 0.12 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 126.329 1.851 . . . . 0.0 114.304 -178.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -119.55 97.54 5.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 106.949 -1.501 . . . . 0.0 106.949 -169.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.24 -10.36 74.04 Favored Glycine 0 C--N 1.331 0.291 0 CA-C-O 117.885 -1.508 . . . . 0.0 111.17 166.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.595 ' HA ' HG21 ' B' ' 5' ' ' VAL . 12.8 t0 -73.7 123.25 23.73 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 104.381 -2.451 . . . . 0.0 104.381 164.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.563 HD21 HG13 ' A' ' 148' ' ' VAL 0.312 0.0 OUTLIER -147.35 51.09 1.07 Allowed 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 123.782 1.753 . . . . 0.0 112.724 168.486 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.487 HG23 ' H ' ' A' ' 53' ' ' ASN . 11.4 p -120.29 -23.89 6.08 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 112.173 -2.285 . . . . 0.0 112.755 -164.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -95.95 22.79 7.01 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.887 0.875 . . . . 0.0 111.603 168.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.76 -123.24 21.8 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 125.537 1.541 . . . . 0.0 111.913 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 9.7 p -67.49 -12.7 60.95 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 113.868 1.062 . . . . 0.0 113.868 173.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.69 39.24 0.61 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.412 1.485 . . . . 0.0 110.878 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 172.09 -55.37 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.39 2.276 . . . . 0.0 111.596 -169.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -97.54 153.39 18.2 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -175.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.73 -31.38 8.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 116.424 -2.32 . . . . 0.0 117.44 175.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -103.34 163.38 0.25 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 CA-C-N 122.124 2.962 . . . . 0.0 111.523 171.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.447 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.1 OUTLIER -137.24 107.78 6.53 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.558 1.143 . . . . 0.0 112.4 -166.678 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -58.97 154.66 14.93 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 114.141 -1.391 . . . . 0.0 111.998 169.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -119.7 77.68 21.29 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 127.712 2.405 . . . . 0.0 113.713 -170.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -63.64 -20.34 69.02 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.998 2.466 . . . . 0.0 113.445 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 53.6 mt -82.81 -2.49 54.7 Favored 'General case' 0 CA--C 1.543 0.685 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 170.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t 62.77 59.29 1.44 Allowed 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.611 1.564 . . . . 0.0 113.343 175.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.0 ptt180 -161.54 178.44 9.08 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -174.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.88 164.4 23.83 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 127.032 2.133 . . . . 0.0 110.006 173.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -62.88 168.23 4.08 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.735 0.814 . . . . 0.0 110.874 167.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 140.69 -156.0 25.12 Favored Glycine 0 N--CA 1.464 0.528 0 CA-C-O 119.11 -0.828 . . . . 0.0 113.808 171.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 -64.51 0.53 Allowed Glycine 0 CA--C 1.542 1.728 0 N-CA-C 117.924 1.93 . . . . 0.0 117.924 176.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -69.47 -19.46 37.47 Favored 'Trans proline' 0 C--N 1.349 0.6 0 CA-C-N 121.197 2.499 . . . . 0.0 114.722 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -134.66 -3.53 2.61 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 124.057 0.943 . . . . 0.0 112.758 179.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.56 147.81 50.73 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 128.344 2.658 . . . . 0.0 107.867 -173.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.427 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 0.0 OUTLIER -100.66 -11.99 19.55 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 130.77 3.628 . . . . 0.0 112.67 -167.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -81.47 -94.04 0.05 OUTLIER 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 125.996 1.718 . . . . 0.0 106.992 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.615 HH12 HG11 ' A' ' 103' ' ' VAL . 47.5 ttt180 80.02 121.1 0.05 OUTLIER 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.539 1.536 . . . . 0.0 111.617 168.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 10.2 m170 -71.52 140.77 50.06 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 120.899 -1.126 . . . . 0.0 108.946 165.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 p -50.88 -28.81 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -89.57 8.78 79.13 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 119.362 0.983 . . . . 0.0 115.537 175.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -88.84 129.95 35.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 120.103 1.951 . . . . 0.0 112.028 -175.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -105.99 -179.7 4.02 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 128.288 2.635 . . . . 0.0 107.518 170.159 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -92.39 -120.19 2.7 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 122.761 1.201 . . . . 0.0 114.032 -172.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 p30 -140.58 152.96 45.89 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.887 1.275 . . . . 0.0 110.777 169.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 30.0 m -116.01 137.1 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 127.581 2.352 . . . . 0.0 109.894 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -102.93 132.24 49.3 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 119.322 0.964 . . . . 0.0 108.797 169.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.75 144.36 27.81 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-O 120.881 0.372 . . . . 0.0 111.068 168.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -60.7 169.88 1.67 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 126.077 1.751 . . . . 0.0 111.753 170.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.32 -15.16 9.26 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.204 1.402 . . . . 0.0 114.143 168.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.05 3.17 55.15 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 125.894 1.678 . . . . 0.0 114.026 169.534 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.9 13.87 76.64 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 120.082 -1.637 . . . . 0.0 115.287 169.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.44 134.72 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 125.846 1.659 . . . . 0.0 112.875 171.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.59 112.12 25.08 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 165.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -104.81 139.42 39.6 Favored 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 124.694 1.198 . . . . 0.0 109.568 -177.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.3 t -137.27 140.28 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 114.962 1.467 . . . . 0.0 114.962 -166.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 89.3 p -154.76 104.39 2.51 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.995 1.318 . . . . 0.0 111.73 173.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.0 mt -136.85 141.84 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.784 2.034 . . . . 0.0 110.431 -178.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -110.22 134.93 51.73 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 166.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -139.03 140.54 38.15 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 125.919 1.687 . . . . 0.0 111.648 -167.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 13.3 p -121.4 52.04 1.25 Allowed 'General case' 0 CA--C 1.543 0.699 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 177.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.615 HG11 HH12 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -147.03 1.81 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 N-CA-C 115.514 1.672 . . . . 0.0 115.514 -177.469 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.11 176.07 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.858 1.663 . . . . 0.0 110.206 169.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.653 ' H ' ' HB3' ' A' ' 111' ' ' SER . 90.4 p -154.84 164.28 39.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 126.647 1.979 . . . . 0.0 112.066 171.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 7.9 mp -78.58 67.85 4.43 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.17 2.188 . . . . 0.0 108.534 177.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.0 t -128.23 -5.8 5.44 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 -168.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.68 -24.88 3.57 Favored Glycine 0 N--CA 1.472 1.046 0 CA-C-N 120.492 1.496 . . . . 0.0 116.427 169.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -94.22 -100.82 0.15 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 126.286 1.834 . . . . 0.0 107.711 -169.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -83.67 2.27 38.42 Favored 'General case' 0 C--N 1.323 -0.568 0 O-C-N 120.009 -1.682 . . . . 0.0 112.321 -174.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.653 ' HB3' ' H ' ' A' ' 105' ' ' SER . 39.4 m -125.11 -120.08 0.27 Allowed 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 115.864 1.801 . . . . 0.0 115.864 -169.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 42.2 pt -125.05 172.41 12.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 O-C-N 119.953 -1.717 . . . . 0.0 109.027 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.424 HD11 HG23 ' A' ' 151' ' ' ILE . 3.1 mm 76.68 147.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 128.657 2.783 . . . . 0.0 105.951 -162.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.48 -51.6 4.23 Favored Glycine 0 C--O 1.222 -0.626 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.62 -177.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 40.2 mtt180 -71.41 178.33 3.49 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 127.541 2.336 . . . . 0.0 110.191 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.9 m -138.91 124.99 20.02 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.862 0.865 . . . . 0.0 111.609 -169.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 47.4 tp -92.24 115.1 27.79 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 125.367 1.467 . . . . 0.0 110.103 178.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 15.0 p -102.45 140.36 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 124.597 1.159 . . . . 0.0 109.549 171.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -113.86 142.91 24.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.977 1.711 . . . . 0.0 107.681 171.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -118.72 148.2 43.02 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.91 2.084 . . . . 0.0 111.105 -168.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -74.6 -20.16 60.03 Favored 'General case' 0 CA--C 1.541 0.624 0 O-C-N 120.518 -1.364 . . . . 0.0 114.67 -168.29 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -125.38 171.19 10.65 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 119.82 -1.8 . . . . 0.0 112.283 177.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.2 139.9 51.25 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 124.714 1.205 . . . . 0.0 111.951 -175.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -87.76 136.83 32.79 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 123.869 0.867 . . . . 0.0 109.747 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.85 -37.23 76.06 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.726 1.211 . . . . 0.0 110.102 173.074 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 63.16 69.81 0.56 Allowed 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 124.999 1.32 . . . . 0.0 108.399 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 160.31 -109.87 0.42 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 117.055 1.582 . . . . 0.0 117.055 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.16 36.06 0.14 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 128.545 2.738 . . . . 0.0 111.754 -167.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -48.9 -31.39 10.24 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.482 1.991 . . . . 0.0 117.976 -168.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 167.35 2.78 0.03 OUTLIER Glycine 0 N--CA 1.476 1.322 0 N-CA-C 118.249 2.06 . . . . 0.0 118.249 178.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -146.22 -170.43 3.49 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 119.088 1.444 . . . . 0.0 111.747 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -70.58 -56.91 5.41 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.411 1.085 . . . . 0.0 109.57 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.496 ' CD ' ' H ' ' A' ' 133' ' ' GLU . 1.2 mp0 -57.42 -28.12 62.99 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.876 1.67 . . . . 0.0 111.675 -174.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 42.8 m -46.25 -37.66 7.52 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 126.124 1.769 . . . . 0.0 112.789 171.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -111.92 -33.88 6.16 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 69.8 tttt -66.81 -24.22 66.15 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.0 0.92 . . . . 0.0 113.076 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.447 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 27.7 p -130.36 -32.68 1.74 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.885 1.674 . . . . 0.0 114.673 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.29 10.0 40.2 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -163.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 63.85 11.7 6.17 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.981 2.112 . . . . 0.0 114.483 177.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.0 19.07 0.02 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 117.326 2.343 . . . . 0.0 117.326 -167.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.76 -43.48 2.16 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 128.473 2.94 . . . . 0.0 115.266 168.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.5 t -168.69 169.34 10.17 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 118.512 1.156 . . . . 0.0 113.901 -174.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.7 ptt-85 -71.5 158.96 35.33 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.168 1.387 . . . . 0.0 111.01 168.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.63 HD11 HG11 ' A' ' 14' ' ' VAL . 2.1 tm? -142.09 -103.31 0.14 Allowed 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 169.113 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.416 ' N ' HD13 ' A' ' 144' ' ' LEU . . . -103.68 160.46 14.74 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.248 1.019 . . . . 0.0 111.471 172.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.7 p -142.35 140.43 32.09 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.165 2.186 . . . . 0.0 108.898 -177.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.25 135.64 4.62 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 118.048 1.979 . . . . 0.0 118.048 -175.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.563 HG13 HD21 ' A' ' 53' ' ' ASN . 0.0 OUTLIER -75.02 139.52 18.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.513 1.125 . . . . 0.0 109.416 -178.612 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.9 mm -87.88 107.55 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 122.572 0.349 . . . . 0.0 110.919 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.71 -171.79 14.15 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.71 1.148 . . . . 0.0 113.23 173.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.2 pp -133.01 129.49 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 N-CA-C 114.989 1.477 . . . . 0.0 114.989 -173.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -98.5 -161.64 0.89 Allowed 'General case' 0 CA--C 1.545 0.75 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 165.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 . . . . . 0 N--CA 1.475 0.804 0 C-N-CA 131.6 3.96 . . . . 0.0 108.565 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.237 0.415 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.9 t -86.84 108.72 18.88 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 172.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttmm -97.16 123.34 40.9 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 113.649 -1.614 . . . . 0.0 111.024 -173.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -93.63 175.65 6.66 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.634 1.346 . . . . 0.0 114.634 179.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.595 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -155.92 103.65 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 128.621 2.769 . . . . 0.0 106.427 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.13 122.06 24.46 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.533 -0.729 . . . . 0.0 109.746 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.408 ' HA ' HG22 ' A' ' 54' ' ' THR . 22.8 t -88.49 63.14 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 124.171 0.988 . . . . 0.0 108.802 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.465 ' HA ' ' HA3' ' B' ' 147' ' ' GLY 0.335 1.3 pt? -82.85 79.04 9.35 Favored 'General case' 0 N--CA 1.477 0.907 0 O-C-N 121.272 -0.892 . . . . 0.0 113.075 -171.824 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 15.1 tttm -117.47 129.76 56.02 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 115.683 1.734 . . . . 0.0 115.683 -173.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.12 158.08 19.01 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 165.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -72.1 92.45 1.33 Allowed 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 128.637 2.775 . . . . 0.0 109.246 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.19 -153.61 21.95 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 127.102 2.286 . . . . 0.0 111.474 -176.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -86.1 7.66 4.88 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 125.0 3.8 . . . . 0.0 114.249 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -105.62 108.92 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 C-N-CA 125.146 1.378 . . . . 0.0 108.509 -177.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -159.7 166.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.668 1.187 . . . . 0.0 111.421 176.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.46 178.25 29.75 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 124.205 0.907 . . . . 0.0 113.862 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.434 HG13 ' H ' ' B' ' 34' ' ' SER . 3.0 pt -123.8 137.33 57.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 128.449 2.699 . . . . 0.0 109.726 171.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mm -136.98 113.12 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.534 1.061 . . . . 0.0 109.457 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -113.24 108.65 17.56 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.757 1.623 . . . . 0.0 112.501 -164.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.433 ' H ' ' HB3' ' B' ' 4' ' ' ALA . 30.4 m-85 -92.44 104.01 16.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.539 1.935 . . . . 0.0 110.281 -176.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -84.25 103.28 13.31 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.6 1.56 . . . . 0.0 110.781 172.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . 0.46 HE22 ' CB ' ' B' ' 105' ' ' SER . 3.1 tt0 -97.69 119.09 35.64 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 121.814 0.816 . . . . 0.0 110.931 173.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -64.13 -42.85 96.66 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.09 1.756 . . . . 0.0 113.268 175.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -157.17 155.37 30.83 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 126.016 1.726 . . . . 0.0 111.596 168.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.7 p -45.05 -3.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 1 C-N-CA 131.739 4.016 . . . . 0.0 118.567 -171.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -157.72 20.9 0.27 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.661 1.985 . . . . 0.0 111.444 -168.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.24 173.67 15.64 Favored Glycine 0 CA--C 1.536 1.385 0 C-N-CA 126.312 1.91 . . . . 0.0 112.563 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -67.03 168.67 16.72 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.578 2.852 . . . . 0.0 111.401 179.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -138.88 133.5 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 C-N-CA 122.744 0.418 . . . . 0.0 111.538 -168.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.8 mttp -92.41 124.22 36.3 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.28 0.562 . . . . 0.0 109.832 169.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.5 t -120.56 86.58 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 127.995 2.518 . . . . 0.0 108.472 -170.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -110.07 168.7 9.24 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 121.2 -0.938 . . . . 0.0 112.281 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.46 -159.5 28.44 Favored Glycine 0 N--CA 1.462 0.432 0 O-C-N 120.973 -1.079 . . . . 0.0 111.869 174.304 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . 0.434 ' H ' HG13 ' B' ' 17' ' ' ILE . 79.8 p -156.33 154.1 30.05 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 -176.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.25 124.77 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.122 0.969 . . . . 0.0 109.997 176.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 46.9 tttp -119.39 146.58 45.23 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.841 1.257 . . . . 0.0 109.652 -178.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.38 10.66 38.16 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 124.916 1.246 . . . . 0.0 113.469 -169.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 76.8 mt -84.98 167.16 16.12 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.105 1.362 . . . . 0.0 111.651 168.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 15.3 t -94.78 156.5 16.35 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 164.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -59.98 148.62 34.69 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 123.727 0.811 . . . . 0.0 112.27 -177.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.67 -178.54 33.85 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 124.234 0.921 . . . . 0.0 113.506 -175.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mp -60.7 144.92 51.14 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 127.648 2.379 . . . . 0.0 114.013 -173.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -145.65 127.88 15.75 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 127.692 2.397 . . . . 0.0 109.985 175.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.26 158.09 52.35 Favored Glycine 0 N--CA 1.474 1.175 0 CA-C-N 119.239 0.927 . . . . 0.0 112.156 173.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -158.37 139.8 13.46 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.201 2.2 . . . . 0.0 112.061 166.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 19.1 p-80 -149.83 146.53 27.19 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 120.905 -1.122 . . . . 0.0 111.825 -176.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -91.4 138.51 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 124.568 1.147 . . . . 0.0 109.175 178.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -105.83 153.04 22.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 110.079 -178.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' B' ' 115' ' ' ARG . 24.0 tt0 -67.68 12.04 0.12 Allowed 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 119.732 1.151 . . . . 0.0 113.479 178.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -140.59 125.04 17.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 O-C-N 120.031 -1.668 . . . . 0.0 108.932 -168.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -73.56 -3.18 61.96 Favored Glycine 0 N--CA 1.465 0.607 0 C-N-CA 124.616 1.103 . . . . 0.0 114.33 170.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.654 ' HA ' HG21 ' A' ' 5' ' ' VAL . 28.0 t0 -75.5 123.09 24.87 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 118.135 0.968 . . . . 0.0 109.93 -169.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.87 20.48 3.83 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 114.787 1.402 . . . . 0.0 114.787 164.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.311 14.9 t -127.04 -21.41 3.98 Favored 'General case' 0 C--N 1.324 -0.543 0 C-N-CA 123.227 0.611 . . . . 0.0 112.004 -166.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -78.2 9.43 3.78 Favored 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 122.206 1.003 . . . . 0.0 110.313 162.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 55.21 -105.17 0.35 Allowed Glycine 0 C--N 1.341 0.857 0 C-N-CA 127.406 2.431 . . . . 0.0 113.528 168.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 73.2 m -72.09 -11.06 60.58 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -111.95 28.24 8.93 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.676 1.19 . . . . 0.0 111.729 168.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.3 p -120.99 -161.3 0.89 Allowed 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.847 1.659 . . . . 0.0 112.734 175.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 62.79 -82.92 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.596 0 C-N-CA 128.824 2.85 . . . . 0.0 112.803 -175.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.39 176.78 47.51 Favored Glycine 0 CA--C 1.545 1.947 0 C-N-CA 125.094 1.33 . . . . 0.0 114.582 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -102.42 179.46 0.15 Allowed 'Trans proline' 0 CA--C 1.54 0.788 0 C-N-CA 124.722 3.614 . . . . 0.0 113.576 -177.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.646 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -72.75 74.7 1.12 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.649 3.18 . . . . 0.0 111.985 172.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -30.21 132.96 0.07 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 129.137 2.975 . . . . 0.0 115.312 169.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -122.86 59.27 12.9 Favored Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 -172.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -62.85 -16.69 55.3 Favored 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 122.755 2.303 . . . . 0.0 113.911 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.81 -5.76 54.24 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.034 1.334 . . . . 0.0 113.324 169.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t 65.16 50.27 1.85 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 127.966 2.507 . . . . 0.0 112.885 178.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.6 mtp180 -118.02 176.21 5.31 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 124.94 1.296 . . . . 0.0 112.86 -172.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.3 mptm? -95.41 175.93 6.38 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.698 2.399 . . . . 0.0 109.441 164.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -62.7 157.75 20.19 Favored 'General case' 0 CA--C 1.539 0.531 0 O-C-N 120.918 -1.114 . . . . 0.0 111.009 -179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' B' ' 79' ' ' ARG . . . -176.52 -175.79 44.15 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 114.914 0.726 . . . . 0.0 114.914 174.51 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 160.65 -120.89 0.98 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 125.27 1.414 . . . . 0.0 113.988 169.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -62.52 -16.35 51.64 Favored 'Trans proline' 0 CA--C 1.54 0.793 0 C-N-CA 123.855 3.037 . . . . 0.0 115.259 -173.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.75 -4.15 19.7 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.578 1.151 . . . . 0.0 112.988 169.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -159.15 110.47 2.08 Favored 'General case' 0 CA--C 1.543 0.706 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 -167.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -40.88 -10.7 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 131.241 3.816 . . . . 0.0 116.76 168.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.69 -77.44 0.09 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 120.067 1.303 . . . . 0.0 109.315 -177.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.402 ' H ' ' HA3' ' B' ' 72' ' ' GLY . 15.2 ttp-105 56.53 77.25 0.26 Allowed 'General case' 0 N--CA 1.475 0.818 0 O-C-N 120.79 -1.194 . . . . 0.0 113.141 164.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 22.3 m170 -48.32 164.46 0.05 Allowed 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.709 -1.244 . . . . 0.0 114.019 172.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.85 -14.16 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 113.265 0.839 . . . . 0.0 113.265 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.23 13.59 31.03 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.957 1.742 . . . . 0.0 116.75 176.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -100.81 103.86 15.09 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 120.801 2.3 . . . . 0.0 113.414 -171.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 42.9 mt -96.64 41.22 1.11 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.528 -1.358 . . . . 0.0 112.417 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.12 -129.74 43.14 Favored Glycine 0 CA--C 1.537 1.412 0 O-C-N 119.713 -1.867 . . . . 0.0 112.361 -174.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -147.98 161.01 42.21 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.877 0.871 . . . . 0.0 112.142 175.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.4 124.07 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 127.778 2.431 . . . . 0.0 110.906 -172.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.2 m -95.78 129.86 42.88 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.386 0.674 . . . . 0.0 109.666 174.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.32 148.47 25.05 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 169.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.56 162.53 15.62 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 128.677 2.791 . . . . 0.0 110.01 169.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -40.79 -21.23 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 129.421 3.088 . . . . 0.0 117.609 177.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -75.73 0.16 18.82 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.54 -1.35 . . . . 0.0 112.166 171.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.51 24.41 76.83 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 125.895 1.712 . . . . 0.0 112.602 -170.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 12.2 p -116.8 128.14 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 CA-C-N 118.785 1.293 . . . . 0.0 113.156 -177.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.1 117.05 29.62 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 166.117 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -98.25 130.93 44.95 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 123.793 0.837 . . . . 0.0 109.009 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.69 143.0 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 117.011 2.226 . . . . 0.0 117.011 -174.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 77.8 p -143.94 82.36 1.71 Allowed 'General case' 0 CA--C 1.55 0.968 0 C-N-CA 126.352 1.861 . . . . 0.0 111.533 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.8 mt -97.69 157.61 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 O-C-N 120.594 -1.316 . . . . 0.0 110.071 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -144.69 145.59 31.8 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 127.642 2.377 . . . . 0.0 107.463 168.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -155.34 159.95 40.34 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.836 1.255 . . . . 0.0 111.336 173.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 35.7 p -127.37 46.08 2.6 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.472 1.509 . . . . 0.0 112.955 -168.163 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 23.1 m -145.87 15.12 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.226 1.011 . . . . 0.0 113.574 -176.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -148.78 165.99 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.107 2.163 . . . . 0.0 109.386 -173.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.46 ' CB ' HE22 ' B' ' 22' ' ' GLN . 18.1 m -157.39 168.0 28.63 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 125.066 1.346 . . . . 0.0 109.983 175.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' B' ' 22' ' ' GLN . 1.1 mm? -98.73 80.03 2.5 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 125.99 1.716 . . . . 0.0 107.723 -171.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -122.14 -18.91 6.74 Favored 'General case' 0 CA--C 1.567 1.628 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -175.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.06 0.71 89.26 Favored Glycine 0 N--CA 1.492 2.408 0 O-C-N 118.554 -2.591 . . . . 0.0 117.778 166.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.66 -88.48 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 127.918 2.487 . . . . 0.0 108.569 173.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 86.8 m-70 -115.15 -9.06 12.34 Favored 'General case' 0 CA--C 1.559 1.299 1 C-N-CA 132.715 4.406 . . . . 0.0 111.113 168.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 48.8 m -82.46 -166.05 1.18 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.63 1.972 . . . . 0.0 110.992 -174.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.452 HG22 ' H ' ' B' ' 113' ' ' ILE . 8.2 mm -71.28 162.3 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.834 0 O-C-N 118.603 -2.56 . . . . 0.0 108.637 169.151 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . 0.452 ' H ' HG22 ' B' ' 112' ' ' ILE . 1.4 mm 97.29 132.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.278 1 C-N-CA 133.75 4.82 . . . . 0.0 108.291 -168.632 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.22 5.51 34.88 Favored Glycine 0 CA--C 1.525 0.667 0 CA-C-O 117.565 -1.686 . . . . 0.0 115.815 176.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . 0.458 ' HD2' ' HA ' ' B' ' 49' ' ' GLU . 62.2 mmt-85 -77.61 -177.08 4.6 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 127.138 2.175 . . . . 0.0 110.797 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 39.5 m -128.26 141.12 51.55 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-O 116.446 -1.74 . . . . 0.0 109.945 173.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.7 tp -113.19 111.22 21.71 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.846 1.259 . . . . 0.0 111.208 171.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.9 p -88.56 149.33 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 124.264 1.026 . . . . 0.0 109.563 168.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 33.2 t -121.77 142.23 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 168.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -99.26 136.85 38.61 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.324 2.25 . . . . 0.0 111.379 -173.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 pp20? -75.97 -10.86 59.77 Favored 'General case' 0 N--CA 1.475 0.799 0 O-C-N 120.419 -1.426 . . . . 0.0 113.796 -171.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 50.8 mttp -114.95 172.95 6.74 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 126.26 1.824 . . . . 0.0 111.959 169.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.99 163.59 1.94 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.809 1.244 . . . . 0.0 112.188 169.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 51.9 t0 -121.03 135.07 55.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 127.299 2.24 . . . . 0.0 107.209 175.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -73.03 -33.24 65.6 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 118.223 0.465 . . . . 0.0 112.216 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 29.3 mt 69.19 50.39 0.57 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.872 1.669 . . . . 0.0 114.223 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 116.21 -26.83 8.47 Favored Glycine 0 N--CA 1.474 1.211 0 N-CA-C 119.924 2.73 . . . . 0.0 119.924 163.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 8.4 pttm -163.93 99.41 0.87 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 120.1 1.95 . . . . 0.0 114.826 176.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -97.69 -7.71 56.45 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.938 1.732 . . . . 0.0 114.042 170.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 101.11 -8.64 57.54 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 125.497 1.522 . . . . 0.0 113.736 -170.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 p-10 -117.98 153.21 34.04 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 128.443 2.697 . . . . 0.0 109.611 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -66.41 -48.67 69.33 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 114.108 1.151 . . . . 0.0 114.108 -167.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.08 -33.1 72.81 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.837 1.255 . . . . 0.0 111.943 -175.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 61.8 m -53.45 -31.23 44.54 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 119.724 1.147 . . . . 0.0 112.574 168.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 1.1 p -85.03 -46.99 10.66 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.94 1.296 . . . . 0.0 112.513 172.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -70.49 -35.63 73.36 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.807 1.243 . . . . 0.0 113.523 -173.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 37.1 p -135.1 -28.78 1.15 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.265 1.426 . . . . 0.0 113.471 -175.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 108.95 0.54 31.83 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 118.44 -1.2 . . . . 0.0 113.538 -171.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 66.9 -4.39 0.79 Allowed 'General case' 0 N--CA 1.482 1.14 0 CA-C-N 119.492 1.646 . . . . 0.0 113.78 175.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -46.88 5.11 0.0 OUTLIER 'General case' 0 CA--C 1.565 1.545 1 C-N-CA 132.551 4.34 . . . . 0.0 121.497 -165.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.11 -69.9 3.21 Favored Glycine 0 CA--C 1.526 0.735 0 O-C-N 120.083 -1.636 . . . . 0.0 115.288 168.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.4 t -164.71 -152.4 0.17 Allowed 'General case' 0 N--CA 1.477 0.92 0 O-C-N 121.253 -1.145 . . . . 0.0 112.157 -171.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.65 148.87 29.81 Favored 'General case' 0 N--CA 1.47 0.557 0 O-C-N 120.427 -1.421 . . . . 0.0 113.991 176.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.402 ' CG ' ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -97.85 -101.45 0.2 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.095 1.758 . . . . 0.0 110.099 169.54 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.402 ' H ' ' CG ' ' B' ' 144' ' ' LEU . . . -91.3 166.73 12.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.986 1.714 . . . . 0.0 111.05 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 11.3 p -157.08 143.19 17.91 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 127.181 2.192 . . . . 0.0 108.545 -178.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . 0.465 ' HA3' ' HA ' ' B' ' 8' ' ' LEU . . . -164.76 171.08 40.1 Favored Glycine 0 N--CA 1.47 0.937 0 N-CA-C 117.354 1.702 . . . . 0.0 117.354 169.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.8 t -84.85 146.72 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.106 2.163 . . . . 0.0 110.577 -169.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 46.6 mm -86.43 103.09 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 125.649 1.58 . . . . 0.0 111.35 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.82 175.82 22.57 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.737 1.637 . . . . 0.0 113.134 171.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.455 ' HA ' ' HA ' ' B' ' 4' ' ' ALA 0.296 1.3 pp -114.78 139.21 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 177.762 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.4 159.66 30.27 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-O 122.951 1.358 . . . . 0.0 108.457 172.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.316 -0.855 0 CA-C-N 113.966 -1.47 . . . . 0.0 110.098 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.65 0 CA-C-O 118.529 -0.748 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.5 p -75.76 109.97 9.79 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 128.501 2.721 . . . . 0.0 108.888 -171.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.6 ptpp? -105.25 135.87 45.81 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -87.18 161.83 17.83 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 164.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 t -145.1 149.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 CA-C-N 119.705 1.139 . . . . 0.0 110.045 173.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.16 109.16 12.53 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.452 1.501 . . . . 0.0 108.187 166.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.1 m -82.61 112.07 19.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 168.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -79.36 99.35 7.1 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 38.3 tttm -156.13 127.18 6.97 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.586 0.754 . . . . 0.0 111.904 177.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -90.67 -104.81 1.28 Allowed Glycine 0 CA--C 1.527 0.821 0 N-CA-C 105.277 -3.129 . . . . 0.0 105.277 164.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -156.33 129.64 8.13 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.628 1.571 . . . . 0.0 108.352 167.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 124.22 168.87 12.98 Favored Glycine 0 CA--C 1.538 1.511 0 C-N-CA 126.61 2.052 . . . . 0.0 110.519 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 23.27 0.19 Allowed 'Trans proline' 0 CA--C 1.546 1.089 1 C-N-CA 125.745 4.297 . . . . 0.0 116.39 -169.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -117.26 111.87 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -157.27 158.24 35.74 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.324 -174.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.68 179.18 37.23 Favored Glycine 0 CA--C 1.508 -0.371 0 C-N-CA 126.129 1.823 . . . . 0.0 113.494 176.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -134.04 142.02 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 125.295 1.438 . . . . 0.0 109.054 168.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.0 mm -133.23 111.23 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 168.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -77.68 150.49 34.51 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.075 1.75 . . . . 0.0 110.934 169.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -135.43 78.52 1.73 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.765 2.026 . . . . 0.0 108.542 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -81.74 117.64 22.21 Favored 'General case' 0 C--N 1.34 0.182 0 CA-C-O 121.863 0.839 . . . . 0.0 113.157 -177.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp60 -105.57 167.68 9.6 Favored 'General case' 0 CA--C 1.549 0.942 0 CA-C-O 122.951 1.358 . . . . 0.0 109.424 169.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.89 -28.09 1.6 Allowed 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 130.088 3.355 . . . . 0.0 111.725 -177.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -101.97 -132.13 0.27 Allowed 'General case' 0 CA--C 1.556 1.201 0 C-N-CA 124.621 1.168 . . . . 0.0 108.497 166.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 t -136.37 -82.04 0.39 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 120.249 -1.532 . . . . 0.0 107.681 168.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -76.24 72.16 3.0 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 119.069 0.85 . . . . 0.0 112.356 169.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.46 15.93 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 127.057 2.265 . . . . 0.0 111.16 171.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.3 158.4 56.37 Favored 'Trans proline' 0 C--N 1.349 0.584 0 C-N-CA 123.395 2.73 . . . . 0.0 111.567 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.7 t -129.14 136.16 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.24 0.616 . . . . 0.0 110.67 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 62.0 mttm -87.02 119.75 27.56 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 122.394 1.092 . . . . 0.0 110.827 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.9 t -103.1 125.3 57.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 128.82 2.848 . . . . 0.0 109.332 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 6.7 p90 -157.14 161.85 39.37 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 169.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.77 171.99 13.03 Favored Glycine 0 N--CA 1.466 0.669 0 C-N-CA 124.833 1.206 . . . . 0.0 112.11 -176.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.3 p -132.33 143.33 49.79 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 -167.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mm -116.73 126.37 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 124.869 1.268 . . . . 0.0 111.404 171.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 54.3 tttt -127.79 146.2 50.67 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.695 1.598 . . . . 0.0 111.755 -173.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.02 -34.57 3.82 Favored Glycine 0 N--CA 1.477 1.423 0 C-N-CA 126.347 1.927 . . . . 0.0 111.197 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.466 HD23 ' H ' ' A' ' 38' ' ' LEU . 0.2 OUTLIER -66.58 129.06 38.59 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 165.658 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -69.33 169.54 12.07 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 118.615 0.643 . . . . 0.0 110.998 171.33 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -54.02 158.79 2.0 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.325 1.85 . . . . 0.0 115.475 -171.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.27 179.11 35.61 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.333 0.968 . . . . 0.0 112.783 -173.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.8 mt -64.05 137.23 57.89 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 126.981 2.112 . . . . 0.0 111.935 -174.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -133.54 131.63 39.98 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.613 1.165 . . . . 0.0 108.472 168.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.36 157.31 46.13 Favored Glycine 0 N--CA 1.46 0.248 0 CA-C-O 118.994 -0.892 . . . . 0.0 111.277 -174.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -155.46 141.91 18.64 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-O 121.804 0.811 . . . . 0.0 112.763 169.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.9 p-80 -152.58 168.2 26.36 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 123.171 0.588 . . . . 0.0 109.838 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.27 135.57 41.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 C-N-CA 123.964 0.905 . . . . 0.0 108.735 175.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -71.73 134.31 46.16 Favored 'General case' 0 CA--C 1.541 0.612 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 170.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -76.4 47.76 0.49 Allowed 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 114.225 1.194 . . . . 0.0 114.225 -170.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 173.8 156.99 0.13 Allowed 'General case' 0 C--O 1.237 0.425 0 C-N-CA 129.649 3.18 . . . . 0.0 108.35 177.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.25 0.46 20.76 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 117.823 1.889 . . . . 0.0 117.823 -178.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -67.67 42.86 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 126.535 1.934 . . . . 0.0 115.248 171.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -166.54 22.16 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -163.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.4 t -29.14 74.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 129.678 3.191 . . . . 0.0 117.407 173.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 159.35 -14.54 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.05 0 C-N-CA 130.775 3.63 . . . . 0.0 111.749 -169.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.77 -127.78 25.75 Favored Glycine 0 C--N 1.345 1.034 0 C-N-CA 124.858 1.218 . . . . 0.0 112.15 167.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 12.4 t -57.69 -10.86 1.77 Allowed 'General case' 0 CA--C 1.552 1.028 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.4 t -108.11 23.13 14.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.229 1.412 . . . . 0.0 113.576 171.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.0 m -152.05 -20.31 0.18 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 116.819 2.155 . . . . 0.0 116.819 169.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -153.41 162.93 40.78 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 120.644 1.565 . . . . 0.0 111.799 169.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.89 160.86 52.07 Favored Glycine 0 CA--C 1.539 1.586 0 CA-C-O 119.359 -0.69 . . . . 0.0 112.579 176.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -70.08 172.41 13.0 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 124.152 3.235 . . . . 0.0 111.177 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -15.86 89.18 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 118.865 2.913 . . . . 0.0 118.865 176.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -67.41 98.45 0.65 Allowed 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -75.63 102.42 0.72 Allowed Pre-proline 0 CA--C 1.548 0.871 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -165.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -72.13 -33.3 9.63 Favored 'Trans proline' 0 C--N 1.355 0.915 0 C-N-CA 123.252 2.635 . . . . 0.0 113.086 -168.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -78.98 -4.27 49.15 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.655 1.182 . . . . 0.0 112.656 175.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.4 t 56.5 49.12 15.41 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 126.014 1.726 . . . . 0.0 112.823 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 6.8 mtp180 -103.72 174.45 5.86 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.789 1.236 . . . . 0.0 113.365 -173.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 ptmm? -74.22 164.59 26.43 Favored 'General case' 0 CA--C 1.547 0.837 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 161.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -80.14 168.76 18.72 Favored 'General case' 0 CA--C 1.543 0.682 0 O-C-N 121.086 -1.009 . . . . 0.0 112.365 173.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 131.51 -154.95 21.12 Favored Glycine 0 C--N 1.338 0.692 0 C-N-CA 125.818 1.675 . . . . 0.0 113.022 167.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.25 -15.2 0.4 Allowed Glycine 0 CA--C 1.539 1.558 0 N-CA-C 121.331 3.293 . . . . 0.0 121.331 166.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -112.43 -12.11 0.03 OUTLIER 'Trans proline' 0 CA--C 1.545 1.03 0 CA-C-N 121.87 2.835 . . . . 0.0 112.939 168.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.553 ' HE3' ' HB2' ' A' ' 128' ' ' LYS . 0.0 OUTLIER -126.56 -3.43 6.67 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 125.569 1.548 . . . . 0.0 112.666 175.625 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -108.51 175.06 5.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 128.53 2.732 . . . . 0.0 109.548 -175.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -116.85 -9.65 11.16 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.769 2.028 . . . . 0.0 112.629 -168.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -122.98 -59.16 1.61 Allowed 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -165.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 46.33 118.55 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 117.881 2.548 . . . . 0.0 117.881 -178.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -58.4 165.57 2.04 Favored 'General case' 0 N--CA 1.48 1.071 0 O-C-N 119.37 -2.081 . . . . 0.0 111.583 169.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.313 7.1 p -77.19 -18.97 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 CA-C-N 120.116 1.326 . . . . 0.0 113.078 -176.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -94.16 27.78 12.4 Favored Glycine 0 CA--C 1.542 1.75 0 C-N-CA 125.458 1.504 . . . . 0.0 114.937 167.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -107.28 131.58 54.05 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 120.417 2.108 . . . . 0.0 115.088 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 65.2 mt -115.05 178.81 4.15 Favored 'General case' 0 CA--C 1.55 0.953 0 C-N-CA 126.241 1.816 . . . . 0.0 109.818 167.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -89.53 -121.68 2.1 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.435 1.493 . . . . 0.0 114.511 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.436 HD22 HD11 ' A' ' 126' ' ' LEU . 11.8 m-80 -127.04 154.25 44.9 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.071 1.348 . . . . 0.0 111.65 172.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -115.03 102.85 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 127.347 2.259 . . . . 0.0 109.709 168.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 m -89.63 126.84 35.78 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 124.744 1.218 . . . . 0.0 110.018 -179.077 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.21 150.47 21.97 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -80.9 160.0 24.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 127.301 2.24 . . . . 0.0 109.73 167.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.3 pttp -47.98 -19.35 0.24 Allowed 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 128.185 2.594 . . . . 0.0 115.811 169.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -74.64 -11.68 60.25 Favored 'General case' 0 CA--C 1.547 0.863 0 O-C-N 120.753 -1.217 . . . . 0.0 111.784 171.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.07 15.09 55.08 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.015 2.245 . . . . 0.0 113.281 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.8 p -117.38 130.48 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-N 119.092 1.446 . . . . 0.0 113.322 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.36 97.34 7.84 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 165.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -89.68 148.93 23.01 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.961 0.886 . . . . 0.0 110.289 168.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.53 146.17 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.105 -1.407 . . . . 0.0 114.433 -169.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 76.7 p -160.23 90.43 0.89 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.384 1.074 . . . . 0.0 112.623 -176.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 175.77 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 C-N-CA 125.918 1.687 . . . . 0.0 113.236 -174.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -144.75 146.9 32.38 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 128.302 2.641 . . . . 0.0 106.693 168.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -143.05 155.94 44.73 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 122.053 0.93 . . . . 0.0 111.052 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 8.6 p -121.08 64.71 0.87 Allowed 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 127.069 2.148 . . . . 0.0 114.158 -166.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -156.83 -46.82 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 O-C-N 121.033 -1.042 . . . . 0.0 109.717 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.39 150.43 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 168.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 93.1 p -148.43 161.15 42.18 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 125.486 1.514 . . . . 0.0 111.259 -169.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 9.4 mt -78.04 97.85 5.53 Favored 'General case' 0 C--N 1.345 0.387 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 170.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.5 t -155.98 6.4 0.2 Allowed 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 -170.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 80.3 -119.88 5.04 Favored Glycine 0 C--N 1.342 0.865 0 CA-C-N 120.625 1.557 . . . . 0.0 109.713 168.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -62.41 -26.59 68.56 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 125.532 1.533 . . . . 0.0 111.209 -171.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.2 m170 -79.45 -24.25 42.56 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.302 1.041 . . . . 0.0 113.446 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.6 m -166.92 -110.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -178.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.6 mm -88.8 142.3 13.07 Favored 'Isoleucine or valine' 0 C--N 1.34 0.171 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 -176.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 92.19 133.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 131.526 3.93 . . . . 0.0 106.73 -164.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.28 15.27 81.69 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-O 117.211 -1.883 . . . . 0.0 115.823 169.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 26.5 mtt85 -117.05 176.92 4.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-N 120.426 2.113 . . . . 0.0 110.777 171.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -119.75 110.32 16.66 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 120.212 1.369 . . . . 0.0 112.104 -175.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 14.4 tp -90.1 127.41 36.08 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.601 1.161 . . . . 0.0 111.137 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.3 p -116.58 139.55 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.122 1.369 . . . . 0.0 110.491 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.4 m -101.44 152.88 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 123.509 0.724 . . . . 0.0 109.436 167.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -119.45 145.68 46.06 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.665 1.586 . . . . 0.0 112.08 -170.113 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -71.22 -24.46 62.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.674 -1.266 . . . . 0.0 114.147 -171.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.5 mptt -112.78 177.16 4.73 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.321 1.449 . . . . 0.0 110.344 168.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.06 146.8 10.58 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.535 1.934 . . . . 0.0 111.45 168.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -83.86 140.86 31.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 104.411 -2.44 . . . . 0.0 104.411 161.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.1 -49.79 33.38 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 174.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.436 HD11 HD22 ' A' ' 86' ' ' ASN . 14.5 mt 90.64 38.38 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 129.413 3.085 . . . . 0.0 113.292 175.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 99.82 26.68 8.34 Favored Glycine 0 N--CA 1.468 0.799 0 N-CA-C 117.73 1.852 . . . . 0.0 117.73 167.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.553 ' HB2' ' HE3' ' A' ' 75' ' ' LYS . 3.7 tttt -155.74 10.09 0.28 Allowed 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 117.131 2.271 . . . . 0.0 117.131 -175.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -67.74 117.55 8.87 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 107.051 -2.42 . . . . 0.0 107.051 167.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -69.89 43.14 0.49 Allowed Glycine 0 N--CA 1.477 1.375 0 C-N-CA 126.561 2.029 . . . . 0.0 115.473 -174.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -102.85 -82.62 0.49 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.302 1.841 . . . . 0.0 110.418 176.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 177.17 -69.31 0.01 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 131.154 3.781 . . . . 0.0 106.329 -173.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.66 -37.16 62.88 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 125.731 1.612 . . . . 0.0 114.675 -177.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.56 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 0.7 OUTLIER -62.78 -18.6 62.94 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 119.119 -2.238 . . . . 0.0 114.542 179.549 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.0 t -99.34 -10.18 22.62 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 124.0 0.92 . . . . 0.0 113.073 170.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.2 mtpt -81.54 -75.55 0.28 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.5 1.52 . . . . 0.0 111.499 169.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 58.5 p -94.03 -28.16 15.9 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 120.121 1.328 . . . . 0.0 113.571 -177.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.45 -14.26 30.3 Favored Glycine 0 N--CA 1.468 0.813 0 CA-C-N 119.44 1.018 . . . . 0.0 110.925 -166.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.56 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 8.3 t-20 61.04 30.69 19.68 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 118.196 0.998 . . . . 0.0 112.714 165.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.9 28.36 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 128.582 2.753 . . . . 0.0 117.969 -167.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 67.38 -13.44 0.57 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 119.884 2.713 . . . . 0.0 119.884 167.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . 0.265 16.7 t 146.31 -171.56 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 130.268 3.427 . . . . 0.0 113.23 169.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.59 178.1 6.95 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 128.228 2.611 . . . . 0.0 114.587 -178.217 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 17.9 tp -162.74 -115.6 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.653 1.581 . . . . 0.0 109.657 168.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -99.24 169.98 8.99 Favored 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 125.895 1.678 . . . . 0.0 111.506 172.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 25.3 t -156.64 152.07 26.69 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.782 1.233 . . . . 0.0 111.872 -171.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.05 142.31 8.41 Favored Glycine 0 N--CA 1.473 1.138 0 C-N-CA 125.43 1.491 . . . . 0.0 113.189 178.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 72.1 t -80.73 150.05 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 CA-C-N 118.602 1.201 . . . . 0.0 111.282 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.6 mt -88.1 103.25 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 O-C-N 120.14 -1.6 . . . . 0.0 109.951 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.75 168.84 14.06 Favored Glycine 0 N--CA 1.473 1.142 0 C-N-CA 124.239 0.923 . . . . 0.0 113.242 176.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.58 124.04 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 118.847 1.323 . . . . 0.0 113.78 176.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.22 -32.57 13.63 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-O 121.726 0.774 . . . . 0.0 108.927 163.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 . . . . . 0 C--O 1.233 0.2 0 C-N-CA 128.903 2.881 . . . . 0.0 111.174 168.742 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.742 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 76.4 p -92.92 51.57 1.71 Allowed 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 114.426 1.269 . . . . 0.0 114.426 -166.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 58.1 mttp -78.12 131.84 37.42 Favored 'General case' 0 N--CA 1.473 0.678 0 O-C-N 119.193 -2.192 . . . . 0.0 114.004 -170.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -123.58 156.42 35.77 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.45 1.5 . . . . 0.0 109.015 169.139 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 38.1 t -140.75 146.85 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 123.495 0.718 . . . . 0.0 110.626 -171.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.63 116.04 19.69 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.057 0.943 . . . . 0.0 112.044 169.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -78.92 103.98 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 168.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.06 114.58 17.07 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtpm? -141.6 172.45 12.67 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 124.584 1.154 . . . . 0.0 111.766 -174.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.45 -59.85 0.68 Allowed Glycine 0 N--CA 1.465 0.626 0 C-N-CA 126.779 2.133 . . . . 0.0 110.059 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.41 59.49 5.45 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.809 1.244 . . . . 0.0 112.844 -168.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.57 -100.08 0.02 OUTLIER Glycine 0 CA--C 1.534 1.262 0 C-N-CA 127.973 2.702 . . . . 0.0 114.247 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.75 -17.1 37.81 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 123.661 2.907 . . . . 0.0 113.216 -178.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 t -87.61 124.29 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 119.487 1.04 . . . . 0.0 110.314 171.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.27 165.36 35.02 Favored 'General case' 0 C--O 1.224 -0.239 0 C-N-CA 123.871 0.868 . . . . 0.0 111.772 169.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.98 -179.22 31.76 Favored Glycine 0 N--CA 1.464 0.531 0 N-CA-C 115.664 1.026 . . . . 0.0 115.664 -176.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 10.1 pt -135.15 116.39 19.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 126.827 2.051 . . . . 0.0 107.858 166.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.98 117.86 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 169.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 62.2 m-20 -113.55 130.08 56.43 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 125.85 1.66 . . . . 0.0 110.852 -173.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -114.4 130.7 56.71 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.466 1.507 . . . . 0.0 110.198 -171.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -122.02 131.37 53.96 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.916 1.687 . . . . 0.0 110.178 172.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -124.62 140.5 52.88 Favored 'General case' 0 CA--C 1.54 0.566 0 O-C-N 121.344 -0.847 . . . . 0.0 109.063 167.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 4.5 ptmm? -99.57 -24.22 14.82 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 115.128 1.529 . . . . 0.0 115.128 -168.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 46.2 mp0 -143.16 146.96 34.19 Favored 'General case' 0 CA--C 1.512 -0.518 0 C-N-CA 127.911 2.484 . . . . 0.0 106.672 168.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 15.4 m -61.96 -21.18 64.59 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.452 1.278 . . . . 0.0 114.452 -172.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -107.11 0.17 23.27 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 125.949 1.7 . . . . 0.0 113.839 170.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.16 170.13 54.38 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.779 1.18 . . . . 0.0 111.358 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -71.66 157.88 54.72 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 122.267 1.978 . . . . 0.0 110.613 177.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -107.52 134.18 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 125.366 1.467 . . . . 0.0 108.116 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -96.84 126.3 41.9 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 167.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 42.3 t -108.01 124.31 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 125.941 1.697 . . . . 0.0 107.081 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -143.05 170.82 15.0 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 178.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.4 -153.5 19.17 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 124.596 1.093 . . . . 0.0 112.337 174.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 58.3 p -153.98 153.63 32.31 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 114.805 1.409 . . . . 0.0 114.805 -172.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.4 mp -124.83 133.47 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.808 1.643 . . . . 0.0 107.072 169.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -132.37 146.15 51.76 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.921 0.888 . . . . 0.0 112.778 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.58 -3.74 19.75 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 126.75 2.119 . . . . 0.0 114.582 -173.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.0 mt -74.28 173.5 10.11 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.546 1.138 . . . . 0.0 111.866 177.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.7 t -86.43 154.6 21.04 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 164.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -56.41 142.39 38.64 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 167.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.59 176.63 17.34 Favored Glycine 0 N--CA 1.472 1.038 0 C-N-CA 124.294 0.949 . . . . 0.0 113.451 -175.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.712 HD23 ' H ' ' B' ' 42' ' ' LEU . 1.8 pt? -89.14 126.01 35.28 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.951 1.7 . . . . 0.0 113.422 -169.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -123.18 146.23 47.96 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 127.818 2.447 . . . . 0.0 109.624 -178.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.07 155.97 33.6 Favored Glycine 0 N--CA 1.478 1.45 0 CA-C-N 121.133 1.788 . . . . 0.0 111.252 -177.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -153.81 135.59 14.5 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.658 1.729 . . . . 0.0 113.958 171.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.404 ' CE1' ' CD2' ' B' ' 120' ' ' HIS . 0.1 OUTLIER -158.4 159.8 36.16 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 124.132 0.973 . . . . 0.0 112.867 -178.222 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -99.68 117.37 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.211 1.404 . . . . 0.0 110.158 -175.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 3.5 m170 -74.83 -173.54 1.91 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 128.43 2.692 . . . . 0.0 113.649 -169.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -63.29 152.05 38.91 Favored 'General case' 0 CA--C 1.541 0.6 0 O-C-N 120.245 -1.534 . . . . 0.0 112.055 171.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.23 161.23 13.85 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 115.071 1.508 . . . . 0.0 115.071 -168.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 67.37 -79.62 0.16 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 117.025 1.57 . . . . 0.0 117.025 169.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -85.79 54.03 2.98 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 123.789 1.757 . . . . 0.0 110.557 -169.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -173.57 8.04 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.836 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 175.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 27.4 p -66.36 44.61 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 119.619 3.192 . . . . 0.0 119.619 -165.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.71 -2.99 31.09 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 125.048 1.339 . . . . 0.0 110.73 165.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.96 -166.19 19.02 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.481 1.991 . . . . 0.0 111.957 -172.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.4 t -61.59 -14.15 27.9 Favored 'General case' 0 N--CA 1.472 0.662 0 O-C-N 120.673 -1.486 . . . . 0.0 114.122 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 t -76.46 36.81 0.16 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 126.052 1.741 . . . . 0.0 112.54 169.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 26.4 m 178.07 -53.02 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.972 1 C-N-CA 131.761 4.024 . . . . 0.0 111.807 -176.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.3 123.08 16.17 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 116.938 2.199 . . . . 0.0 116.938 -168.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -73.02 -179.77 37.3 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 123.788 0.708 . . . . 0.0 112.009 169.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -60.9 167.65 8.42 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 124.484 3.456 . . . . 0.0 115.072 -165.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.721 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -57.05 86.36 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 127.53 2.332 . . . . 0.0 111.415 175.854 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -52.69 127.23 22.4 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.805 -1.088 . . . . 0.0 112.79 -167.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -117.78 65.77 5.15 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 125.964 1.706 . . . . 0.0 112.953 -168.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -64.05 -15.22 48.03 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.035 2.49 . . . . 0.0 113.618 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -79.32 -7.3 58.22 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.442 1.097 . . . . 0.0 113.118 170.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t 65.46 55.67 1.02 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 126.881 2.072 . . . . 0.0 112.194 175.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 mtm180 -121.4 178.36 4.83 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 -166.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 11.6 mttp -89.81 173.91 8.0 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 127.917 2.487 . . . . 0.0 112.468 169.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -109.14 146.38 34.18 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 117.283 2.327 . . . . 0.0 117.283 -168.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 129.82 -91.7 0.31 Allowed Glycine 0 C--N 1.343 0.967 0 C-N-CA 124.795 1.188 . . . . 0.0 112.468 166.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.62 -28.6 11.19 Favored Glycine 0 CA--C 1.551 2.302 0 N-CA-C 118.635 2.214 . . . . 0.0 118.635 174.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -87.36 -15.18 3.62 Favored 'Trans proline' 0 C--N 1.356 0.966 0 CA-C-N 122.797 3.298 . . . . 0.0 113.176 171.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.21 -48.62 1.45 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.247 1.419 . . . . 0.0 108.994 166.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -55.09 138.41 44.33 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.975 0.893 . . . . 0.0 110.884 171.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -87.93 -6.23 58.15 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 127.464 2.306 . . . . 0.0 113.0 -169.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -119.24 -56.57 2.07 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 115.543 1.683 . . . . 0.0 115.543 -174.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.537 HH21 ' CG1' ' B' ' 103' ' ' VAL 0.278 3.4 ptt180 57.93 136.61 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 127.906 2.483 . . . . 0.0 115.346 -173.176 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -73.35 166.78 22.54 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 118.725 -2.484 . . . . 0.0 111.107 169.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.46 -31.92 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 120.311 -1.493 . . . . 0.0 113.997 -177.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -100.66 22.24 40.56 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 118.789 -1.006 . . . . 0.0 115.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 36.1 m-20 -96.32 114.21 25.87 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -169.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.0 mt -101.56 171.88 7.3 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 104.425 -2.435 . . . . 0.0 104.425 158.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.63 -98.84 1.18 Allowed Glycine 0 N--CA 1.474 1.169 0 CA-C-N 119.026 0.83 . . . . 0.0 111.858 175.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -142.13 164.09 31.09 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -177.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.43 129.14 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 C-N-CA 129.264 3.026 . . . . 0.0 111.147 -168.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 8.5 m -100.84 140.55 34.97 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 124.043 0.937 . . . . 0.0 110.072 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.44 157.86 16.32 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.931 0.892 . . . . 0.0 111.344 167.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -82.11 178.45 8.27 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.14 1.376 . . . . 0.0 112.154 171.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.12 -28.25 68.96 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.594 1.558 . . . . 0.0 113.365 172.048 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -76.42 2.71 12.85 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.336 1.054 . . . . 0.0 110.616 175.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.27 -0.59 83.83 Favored Glycine 0 C--N 1.342 0.883 0 C-N-CA 127.179 2.323 . . . . 0.0 114.19 172.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.69 132.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 126.107 1.763 . . . . 0.0 113.464 178.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.03 133.9 41.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.786 1.235 . . . . 0.0 108.703 165.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -98.38 118.27 34.66 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 7.5 t -98.43 124.01 51.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.2 173.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 14.5 m -155.1 87.8 1.14 Allowed 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.284 1.434 . . . . 0.0 110.95 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.87 148.64 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 126.441 1.896 . . . . 0.0 112.609 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -112.54 133.1 54.77 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.041 2.536 . . . . 0.0 106.008 168.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -138.74 130.05 27.12 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 125.238 1.415 . . . . 0.0 111.161 -173.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 25.3 p -113.17 44.26 1.57 Allowed 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -174.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . 0.537 ' CG1' HH21 ' B' ' 79' ' ' ARG 0.315 9.8 p -161.16 -21.26 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 116.275 1.954 . . . . 0.0 116.275 166.851 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.56 164.45 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 122.189 2.268 . . . . 0.0 109.754 168.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 76.8 p -157.71 159.48 36.93 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 -173.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -92.51 57.13 2.88 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 127.651 2.38 . . . . 0.0 105.484 172.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -116.16 21.17 13.88 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -167.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.48 -53.21 4.65 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-O 117.932 -1.482 . . . . 0.0 115.356 167.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 m-20 -99.41 -103.07 0.22 Allowed 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.282 1.515 . . . . 0.0 110.738 -167.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 20.3 m170 -76.32 8.62 3.22 Favored 'General case' 0 CA--C 1.551 1.016 0 O-C-N 119.357 -2.089 . . . . 0.0 114.418 -167.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 69.8 p -93.81 -131.03 0.14 Allowed 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 129.084 2.954 . . . . 0.0 114.202 -167.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 14.9 pt -113.76 -15.52 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 121.344 1.884 . . . . 0.0 115.919 175.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.7 mm -54.46 129.79 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 CA-C-N 120.607 1.549 . . . . 0.0 108.299 168.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.15 -2.32 52.06 Favored Glycine 0 CA--C 1.534 1.273 0 CA-C-N 120.199 1.363 . . . . 0.0 115.529 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -87.54 176.5 7.44 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 126.432 1.893 . . . . 0.0 109.972 169.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.55 109.97 6.6 Favored 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 120.45 1.477 . . . . 0.0 113.319 -169.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 27.4 tp -83.16 120.27 25.57 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 124.051 0.94 . . . . 0.0 109.67 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 p -121.85 139.58 48.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 125.998 1.719 . . . . 0.0 110.024 176.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 t -95.81 166.99 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 124.927 1.291 . . . . 0.0 107.672 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.404 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 73.4 m-70 -150.12 130.54 13.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.198 1.799 . . . . 0.0 107.877 -169.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 -53.76 -40.07 65.88 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 121.569 1.986 . . . . 0.0 115.691 -169.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.42 136.37 33.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 120.278 1.399 . . . . 0.0 109.674 175.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.82 159.71 1.6 Allowed 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.187 0.595 . . . . 0.0 110.935 165.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -82.75 146.89 28.75 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-O 123.217 1.484 . . . . 0.0 112.946 -171.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.31 -7.57 53.27 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 114.05 -1.432 . . . . 0.0 113.019 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 6.1 mt 57.75 55.26 5.6 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 127.163 2.185 . . . . 0.0 113.681 168.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 96.76 -67.09 0.93 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 175.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 103.85 6.74 Favored 'General case' 0 N--CA 1.44 -0.973 0 C-N-CA 124.963 1.305 . . . . 0.0 113.659 174.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -103.56 -71.9 0.88 Allowed Glycine 0 CA--C 1.524 0.622 0 N-CA-C 107.03 -2.428 . . . . 0.0 107.03 164.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -130.28 -29.5 0.65 Allowed Glycine 0 CA--C 1.536 1.406 0 N-CA-C 119.15 2.42 . . . . 0.0 119.15 -173.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -166.41 173.81 9.6 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 122.036 2.918 . . . . 0.0 111.722 -167.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -42.82 -60.13 1.7 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.335 1.454 . . . . 0.0 113.878 -169.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 26.4 tp10 -35.96 -29.22 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 126.128 1.771 . . . . 0.0 114.395 172.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 83.9 p -63.61 -30.1 71.26 Favored 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 123.355 2.798 . . . . 0.0 115.824 174.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -108.08 -19.9 13.35 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 118.372 -0.823 . . . . 0.0 112.903 169.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -74.09 -49.3 24.61 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.633 1.173 . . . . 0.0 112.078 176.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 56.4 p -111.38 -95.35 0.43 Allowed 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 102.687 -3.079 . . . . 0.0 102.687 164.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.28 16.22 0.2 Allowed Glycine 0 CA--C 1.535 1.29 1 C-N-CA 131.2 4.238 . . . . 0.0 112.1 175.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 50.99 34.03 9.96 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 126.352 1.861 . . . . 0.0 113.019 -174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.34 24.98 0.08 Allowed 'General case' 0 CA--C 1.565 1.531 0 CA-C-O 121.929 0.871 . . . . 0.0 112.727 -169.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 72.09 -42.85 0.8 Allowed Glycine 0 N--CA 1.471 0.996 0 C-N-CA 129.924 3.63 . . . . 0.0 114.972 175.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 8.6 t -161.41 -156.39 0.44 Allowed 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 125.541 1.537 . . . . 0.0 109.461 -175.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -166.75 1.11 Allowed 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 127.105 2.162 . . . . 0.0 108.23 168.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -179.54 -173.6 0.26 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 128.328 2.651 . . . . 0.0 107.766 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.51 142.39 8.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.751 2.02 . . . . 0.0 112.154 174.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.2 p -151.9 159.57 43.78 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.908 1.683 . . . . 0.0 114.826 -167.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.78 142.53 8.32 Favored Glycine 0 CA--C 1.534 1.233 0 CA-C-O 118.795 -1.003 . . . . 0.0 114.837 173.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 26.5 t -79.51 135.42 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 125.222 1.409 . . . . 0.0 110.675 170.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -85.58 115.82 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 O-C-N 121.222 -0.924 . . . . 0.0 110.806 -174.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -119.76 174.94 15.7 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.942 1.258 . . . . 0.0 111.858 172.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -93.57 156.6 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 N-CA-C 115.337 1.606 . . . . 0.0 115.337 -168.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.51 -16.66 0.17 Allowed 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 126.914 2.085 . . . . 0.0 114.308 171.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 CA--C 1.533 0.311 0 C-N-CA 125.361 1.464 . . . . 0.0 112.911 168.168 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.525 ' HA ' ' H ' ' A' ' 22' ' ' GLN . 74.0 p -79.5 38.03 0.36 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 118.86 2.911 . . . . 0.0 118.86 -159.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 23.9 mttp -169.4 135.12 1.56 Allowed 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 127.322 2.249 . . . . 0.0 114.726 165.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.38 177.82 7.46 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 128.864 2.866 . . . . 0.0 110.188 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.451 HG11 ' CA ' ' B' ' 52' ' ' ASP . 1.6 p -155.26 127.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 C-N-CA 126.642 1.977 . . . . 0.0 108.903 -167.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.5 129.68 55.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.804 0.842 . . . . 0.0 111.495 170.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.407 HG22 HG22 ' B' ' 54' ' ' THR . 44.3 t -102.13 95.39 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.666 1.186 . . . . 0.0 107.876 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -89.06 124.28 34.15 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 20.1 mtpt -143.45 175.36 9.99 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 121.958 0.885 . . . . 0.0 112.416 168.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.29 -65.2 0.16 Allowed Glycine 0 C--N 1.33 0.234 0 C-N-CA 125.571 1.558 . . . . 0.0 110.629 178.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.85 69.51 3.35 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.51 1.124 . . . . 0.0 111.27 -164.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 40.88 -102.61 0.03 OUTLIER Glycine 0 CA--C 1.536 1.361 0 C-N-CA 127.104 2.288 . . . . 0.0 113.373 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -68.93 -5.98 17.0 Favored 'Trans proline' 0 CA--C 1.54 0.816 0 C-N-CA 124.209 3.273 . . . . 0.0 114.459 -178.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.4 t -76.36 135.43 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 CA-C-N 120.151 1.342 . . . . 0.0 110.037 169.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.79 156.79 45.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.212 -1.358 . . . . 0.0 108.642 166.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.89 105.48 0.59 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 169.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.2 127.23 46.37 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.635 0 CA-C-N 117.824 0.812 . . . . 0.0 109.778 171.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 pp -137.42 121.73 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 122.435 1.112 . . . . 0.0 110.823 166.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -83.5 161.07 21.36 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.963 1.305 . . . . 0.0 109.048 164.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -138.29 130.14 28.22 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.526 0.731 . . . . 0.0 109.62 167.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.89 153.66 22.07 Favored 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 165.424 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.525 ' H ' ' HA ' ' A' ' 2' ' ' THR . 1.3 tm0? -157.9 140.85 14.96 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 124.726 1.21 . . . . 0.0 110.781 168.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HZ2' ' CD ' ' A' ' 24' ' ' GLU 0.256 0.0 OUTLIER -82.3 -68.47 0.7 Allowed 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 175.434 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.48 ' CD ' ' HZ2' ' A' ' 23' ' ' LYS . 20.7 mp0 -132.66 165.07 25.32 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.944 1.698 . . . . 0.0 110.77 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 m -56.01 -28.71 58.45 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 115.118 1.525 . . . . 0.0 115.118 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -98.38 5.21 48.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 124.817 1.247 . . . . 0.0 112.729 172.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.59 149.57 19.27 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 125.014 1.292 . . . . 0.0 111.861 -176.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -69.75 174.79 8.97 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.836 3.024 . . . . 0.0 111.83 -178.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -133.54 153.42 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.811 1.244 . . . . 0.0 112.486 -168.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.3 mttm -120.75 112.48 18.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 124.459 1.104 . . . . 0.0 109.178 167.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 p -80.86 148.07 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 O-C-N 121.418 -0.801 . . . . 0.0 109.402 167.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.2 p90 -156.64 157.62 35.57 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.528 0.731 . . . . 0.0 112.182 165.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.88 -158.81 27.83 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.116 0.807 . . . . 0.0 115.116 -176.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.0 p -153.64 129.12 9.91 Favored 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -168.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mm -111.66 113.94 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.419 178.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . 0.26 0.0 OUTLIER -133.3 172.17 13.05 Favored 'General case' 0 C--N 1.345 0.37 0 N-CA-C 115.392 1.627 . . . . 0.0 115.392 -178.582 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.54 1.09 59.11 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 126.928 2.204 . . . . 0.0 110.753 -166.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 6.0 mt -87.21 173.55 9.15 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.869 1.268 . . . . 0.0 110.589 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.4 t -84.77 162.88 19.44 Favored 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 163.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -60.79 161.03 8.53 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-O 121.529 0.68 . . . . 0.0 112.205 169.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.48 -175.16 31.48 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.64 1.114 . . . . 0.0 112.812 -178.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.828 ' H ' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -71.92 151.04 43.62 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 128.272 2.629 . . . . 0.0 112.398 -171.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -152.36 115.45 4.66 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 127.831 2.452 . . . . 0.0 110.087 -173.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.65 152.49 30.85 Favored Glycine 0 N--CA 1.487 2.065 0 CA-C-N 120.854 1.661 . . . . 0.0 113.368 -178.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -149.64 103.46 3.26 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.631 1.572 . . . . 0.0 111.054 -169.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -141.85 145.96 35.27 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 119.849 -1.782 . . . . 0.0 114.986 -164.12 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.1 m -96.76 142.76 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-N 118.618 0.645 . . . . 0.0 110.958 -174.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -115.19 125.15 53.05 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.838 1.255 . . . . 0.0 109.511 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -62.42 25.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 128.013 2.525 . . . . 0.0 115.318 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -149.48 126.62 11.33 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 127.843 2.457 . . . . 0.0 107.507 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.95 -19.82 66.64 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 126.513 2.006 . . . . 0.0 115.048 173.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -76.23 51.62 0.7 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 127.313 2.245 . . . . 0.0 113.55 -168.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.433 ' HA ' HG21 ' B' ' 7' ' ' VAL . 1.4 p30 -176.32 22.32 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.211 0 C-N-CA 126.599 1.959 . . . . 0.0 115.399 -167.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.8 t -66.85 44.45 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 128.319 2.648 . . . . 0.0 116.697 178.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.67 -11.06 9.09 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -174.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.17 -166.63 14.6 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 125.268 1.413 . . . . 0.0 112.762 -169.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 37.7 t -51.79 -20.67 2.3 Favored 'General case' 0 CA--C 1.551 0.987 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 -177.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.8 t -68.66 -6.77 27.94 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 115.088 1.514 . . . . 0.0 115.088 175.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.6 t -149.76 -26.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -90.58 112.41 24.1 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.972 -1.08 . . . . 0.0 111.273 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.28 -119.48 1.11 Allowed Glycine 0 CA--C 1.545 1.935 0 C-N-CA 124.652 1.12 . . . . 0.0 113.568 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.35 173.73 2.19 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 124.205 3.27 . . . . 0.0 110.81 169.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -94.9 114.56 26.43 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.5 0.72 . . . . 0.0 110.352 -172.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -58.59 146.25 36.59 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.281 1.032 . . . . 0.0 112.64 177.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -126.83 85.58 60.53 Favored Pre-proline 0 CA--C 1.551 1.01 0 C-N-CA 125.885 1.674 . . . . 0.0 112.96 -168.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -61.74 -34.37 83.39 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 123.341 2.694 . . . . 0.0 113.519 -176.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.16 -4.96 47.21 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.602 0.761 . . . . 0.0 112.809 174.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.8 t 62.85 47.23 4.6 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 127.125 2.17 . . . . 0.0 112.179 178.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.7 ptt180 -117.9 176.56 5.14 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 114.544 1.313 . . . . 0.0 114.544 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.2 mttm -70.67 159.67 34.01 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.763 1.225 . . . . 0.0 111.704 174.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.424 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 84.6 t60 -68.12 120.68 14.71 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 164.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -154.4 -168.83 18.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 115.209 0.844 . . . . 0.0 115.209 -166.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -93.69 0.55 Allowed Glycine 0 CA--C 1.536 1.371 0 CA-C-O 117.004 -1.998 . . . . 0.0 114.933 176.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -74.56 47.06 1.55 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 124.777 3.651 . . . . 0.0 115.318 -170.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.498 ' HE3' HD23 ' A' ' 126' ' ' LEU . 6.4 ptpt 179.79 -5.7 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.065 1 C-N-CA 133.212 4.605 . . . . 0.0 113.852 165.195 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.421 ' H ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -134.47 177.46 7.75 Favored 'General case' 0 CA--C 1.559 1.316 0 C-N-CA 127.363 2.265 . . . . 0.0 111.227 -166.263 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -109.73 -4.77 15.89 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 127.664 2.385 . . . . 0.0 112.538 -175.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -84.22 -113.11 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.251 1.42 . . . . 0.0 108.304 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 HG11 ' A' ' 103' ' ' VAL . 21.8 ttp180 91.68 119.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 127.475 2.31 . . . . 0.0 108.857 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m170 -57.03 159.23 4.37 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 121.498 -0.751 . . . . 0.0 109.692 168.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.4 p -41.97 -33.22 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.374 1.47 . . . . 0.0 113.635 176.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -146.8 123.05 1.71 Allowed Glycine 0 CA--C 1.534 1.26 0 CA-C-O 122.415 1.008 . . . . 0.0 112.426 165.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -158.15 96.46 1.45 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 129.509 3.124 . . . . 0.0 107.42 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -96.07 52.37 1.29 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 122.028 0.918 . . . . 0.0 110.353 178.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.68 -114.55 0.94 Allowed Glycine 0 CA--C 1.526 0.76 0 C-N-CA 126.35 1.929 . . . . 0.0 113.467 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.3 p30 -133.37 138.46 46.32 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.78 1.232 . . . . 0.0 112.529 172.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 29.4 m -91.23 143.55 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 127.153 2.181 . . . . 0.0 109.723 171.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.6 m -122.39 123.59 41.69 Favored 'General case' 0 N--CA 1.474 0.742 0 O-C-N 120.848 -1.157 . . . . 0.0 110.424 -172.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.14 159.25 15.06 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 114.613 1.338 . . . . 0.0 114.613 -175.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.69 175.26 10.28 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.858 2.063 . . . . 0.0 112.381 169.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.672 ' H ' ' HE2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -71.44 -16.37 62.37 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.516 1.126 . . . . 0.0 113.795 172.336 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.59 -13.32 61.36 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 121.967 0.889 . . . . 0.0 109.92 166.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.18 -4.43 58.7 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 127.635 2.54 . . . . 0.0 114.473 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.9 p -91.59 127.75 43.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 120.946 2.373 . . . . 0.0 114.633 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.11 119.81 32.73 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 163.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -87.6 140.43 29.52 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 172.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.64 131.39 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 124.477 1.111 . . . . 0.0 112.328 -168.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 52.0 p -157.21 60.3 0.51 Allowed 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.39 1.476 . . . . 0.0 113.383 -176.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.0 mp -95.99 142.53 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 119.446 -2.033 . . . . 0.0 112.847 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -117.09 136.79 52.72 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 125.828 1.651 . . . . 0.0 108.424 168.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -153.82 146.16 23.92 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.896 1.279 . . . . 0.0 111.794 -169.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 32.5 t -118.69 55.01 0.93 Allowed 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.084 -0.962 . . . . 0.0 113.091 179.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.406 HG11 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -139.45 -31.37 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 166.484 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -97.18 159.53 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 122.451 1.119 . . . . 0.0 112.208 172.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.507 ' HB2' HE21 ' A' ' 22' ' ' GLN . 53.8 p -156.94 163.18 39.42 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 125.642 1.577 . . . . 0.0 110.062 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.3 mt -82.4 73.39 9.44 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 122.341 1.067 . . . . 0.0 108.874 171.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -132.85 157.74 44.27 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.091 2.156 . . . . 0.0 107.67 170.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -116.87 41.94 1.98 Allowed Glycine 0 N--CA 1.472 1.09 0 C-N-CA 124.847 1.213 . . . . 0.0 113.45 -170.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.17 -88.52 0.51 Allowed 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 127.381 2.273 . . . . 0.0 106.858 -178.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.79 12.83 13.08 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 126.016 1.726 . . . . 0.0 110.99 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -92.09 -160.82 0.77 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 120.467 -1.396 . . . . 0.0 112.176 173.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.413 HG23 HH21 ' A' ' 115' ' ' ARG . 8.3 pt -94.08 -13.47 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 N-CA-C 117.017 2.228 . . . . 0.0 117.017 -168.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.3 mm -73.1 125.93 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 122.326 2.33 . . . . 0.0 110.482 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.76 -0.66 81.44 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 117.782 -1.565 . . . . 0.0 113.917 -173.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.413 HH21 HG23 ' A' ' 112' ' ' ILE . 30.9 ttp180 -92.18 167.61 11.92 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.435 1.894 . . . . 0.0 110.573 176.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.5 m -113.6 163.19 15.28 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 125.582 1.553 . . . . 0.0 112.639 -176.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 41.7 tp -137.29 126.18 24.15 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 127.426 2.29 . . . . 0.0 110.452 172.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.5 p -100.21 140.21 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 126.456 1.903 . . . . 0.0 110.987 173.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 p -107.27 143.05 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 CA-C-O 121.676 0.751 . . . . 0.0 109.313 165.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -122.27 162.85 20.7 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.985 1.714 . . . . 0.0 111.558 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 -27.41 44.84 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 120.264 -1.522 . . . . 0.0 114.848 -167.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 20.7 mmtm -130.5 -175.63 3.71 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.758 2.072 . . . . 0.0 114.357 -171.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.45 153.51 31.23 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.718 1.207 . . . . 0.0 111.79 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -102.38 131.53 48.96 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 124.405 1.082 . . . . 0.0 110.889 -174.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -78.82 -31.98 46.07 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.352 1.861 . . . . 0.0 113.479 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.498 HD23 ' HE3' ' A' ' 75' ' ' LYS . 2.7 mm? 56.0 63.48 2.01 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.353 1.861 . . . . 0.0 114.803 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.0 10.21 64.85 Favored Glycine 0 N--CA 1.467 0.764 0 N-CA-C 120.065 2.786 . . . . 0.0 120.065 161.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.3 pptp? -148.33 -5.6 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 119.468 3.136 . . . . 0.0 119.468 -165.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.06 27.96 0.79 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 120.881 1.673 . . . . 0.0 116.035 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.96 -23.68 2.57 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.566 1.555 . . . . 0.0 116.508 171.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -95.88 165.45 12.27 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 119.717 1.759 . . . . 0.0 111.777 -173.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -49.96 -57.88 6.61 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.993 1.317 . . . . 0.0 109.24 168.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -50.83 -38.77 50.79 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 126.297 1.839 . . . . 0.0 112.803 177.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 20.1 m -62.51 -32.09 72.96 Favored 'General case' 0 N--CA 1.464 0.259 0 O-C-N 121.081 -1.012 . . . . 0.0 113.432 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.273 1.6 t -118.17 -10.62 10.25 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 117.324 -1.322 . . . . 0.0 113.988 -175.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . 0.256 0.6 OUTLIER -90.81 -34.1 15.44 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 120.469 1.486 . . . . 0.0 113.306 168.72 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.78 -17.58 4.0 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 126.042 1.737 . . . . 0.0 114.993 -176.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.424 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 96.61 12.64 50.16 Favored Glycine 0 N--CA 1.466 0.655 0 CA-C-N 120.454 1.479 . . . . 0.0 114.644 -178.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 61.72 7.73 2.07 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 119.711 1.756 . . . . 0.0 113.832 177.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.19 10.5 0.02 OUTLIER 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 118.816 2.895 . . . . 0.0 118.816 -164.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.48 -160.4 32.98 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 126.31 1.909 . . . . 0.0 113.588 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.5 t -55.04 148.83 12.98 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.954 -0.733 . . . . 0.0 111.584 176.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.86 128.95 37.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 170.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.421 HD12 ' H ' ' A' ' 145' ' ' ALA . 0.5 OUTLIER -111.91 -119.23 0.3 Allowed 'General case' 0 C--O 1.238 0.497 0 O-C-N 124.382 1.051 . . . . 0.0 109.728 173.575 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.421 ' H ' HD12 ' A' ' 144' ' ' LEU . . . -68.27 151.91 46.23 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-O 122.425 1.107 . . . . 0.0 112.02 -172.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.6 t -154.24 143.28 21.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.334 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.93 151.59 23.09 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 -169.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.479 ' CG1' ' HB ' ' B' ' 148' ' ' VAL . 2.7 p -79.52 156.2 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.126 0.97 . . . . 0.0 111.885 172.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.4 mm -103.22 111.08 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 124.59 1.156 . . . . 0.0 111.872 170.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -115.07 159.96 13.47 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.965 1.269 . . . . 0.0 112.576 175.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.53 139.19 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.147 -1.208 . . . . 0.0 112.231 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.21 -141.34 0.23 Allowed 'General case' 0 CA--C 1.549 0.933 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 161.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.471 0.59 0 C-N-CA 124.835 1.254 . . . . 0.0 111.595 168.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.557 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 88.6 m -77.55 99.87 5.88 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.046 1.339 . . . . 0.0 107.754 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 33.9 mtmm -117.05 132.63 56.64 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 123.954 0.902 . . . . 0.0 113.363 -170.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.67 157.69 46.0 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 129.931 3.292 . . . . 0.0 109.67 -177.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 33.5 t -136.32 114.13 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 CA-C-O 122.577 1.18 . . . . 0.0 110.853 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.58 96.05 6.05 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 113.823 -1.535 . . . . 0.0 107.628 167.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 53' ' ' ASN . 34.4 m -86.03 115.55 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 165.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.4 mp -98.08 136.13 38.77 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.688 -174.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -157.97 121.8 4.08 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 119.741 1.155 . . . . 0.0 113.894 165.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -84.74 -115.41 0.72 Allowed Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 168.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -143.08 128.97 19.48 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 128.813 2.845 . . . . 0.0 106.011 -168.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.06 179.42 50.98 Favored Glycine 0 CA--C 1.537 1.421 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -167.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -76.45 49.56 2.68 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 125.293 3.995 . . . . 0.0 112.209 -176.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.65 112.65 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 126.334 1.853 . . . . 0.0 108.655 174.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 pm0 -158.71 166.53 31.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.651 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.96 171.92 35.05 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-O 122.133 0.851 . . . . 0.0 112.456 168.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 pp -121.63 122.76 67.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 166.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mm -131.36 101.9 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.38 148.32 39.29 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.249 1.02 . . . . 0.0 110.162 175.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 43.4 m-85 -126.61 116.37 20.91 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.171 1.789 . . . . 0.0 108.762 169.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -116.45 120.84 40.06 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 126.301 1.84 . . . . 0.0 112.537 177.436 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -113.92 130.01 56.55 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 122.127 0.965 . . . . 0.0 112.273 169.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.48 ' HE2' ' N ' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -87.17 -28.73 22.26 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.077 0.951 . . . . 0.0 112.474 -172.122 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -158.36 136.07 10.4 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 128.046 2.538 . . . . 0.0 107.71 168.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 16.8 t -47.62 -42.35 24.0 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 129.048 2.939 . . . . 0.0 113.495 -176.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 37.6 m-80 -84.92 -7.67 59.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.057 1.343 . . . . 0.0 113.25 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.3 -167.71 42.13 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 125.521 1.534 . . . . 0.0 112.148 173.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . 0.406 ' O ' ' HE3' ' B' ' 23' ' ' LYS . 20.7 Cg_endo -84.51 176.66 6.21 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.305 2.67 . . . . 0.0 111.669 178.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 22.9 t -119.82 143.46 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 125.817 1.647 . . . . 0.0 109.4 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 14.9 tttp -107.78 130.58 54.96 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.352 1.061 . . . . 0.0 109.567 168.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.57 126.5 74.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 126.025 1.73 . . . . 0.0 108.495 -177.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -148.28 160.5 42.91 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -177.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.91 -149.26 21.26 Favored Glycine 0 C--N 1.333 0.397 0 C-N-CA 124.077 0.846 . . . . 0.0 111.868 170.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -150.82 128.78 11.76 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -171.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.9 mp -96.33 136.52 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.646 1.179 . . . . 0.0 109.213 169.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.4 mtpt -130.52 154.4 47.84 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 112.521 -178.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.11 -0.19 57.31 Favored Glycine 0 N--CA 1.475 1.235 0 C-N-CA 124.942 1.258 . . . . 0.0 113.332 -170.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 91.1 mt -78.49 149.01 33.25 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 124.738 1.215 . . . . 0.0 112.017 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -78.17 149.28 33.78 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 165.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . 0.404 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 1.5 pm0 -54.63 141.34 32.2 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 126.614 1.966 . . . . 0.0 113.064 -178.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 102.87 -168.24 18.0 Favored Glycine 0 N--CA 1.472 1.06 0 O-C-N 120.89 -1.131 . . . . 0.0 113.817 -177.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.432 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -82.02 138.93 34.77 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 128.011 2.525 . . . . 0.0 115.966 -167.837 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -137.04 131.73 33.21 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 128.58 2.752 . . . . 0.0 109.728 -174.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.43 161.6 54.27 Favored Glycine 0 N--CA 1.47 0.96 0 C-N-CA 124.672 1.129 . . . . 0.0 114.632 -172.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -153.38 118.94 5.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.651 1.225 . . . . 0.0 113.128 -168.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -157.33 150.02 23.21 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 119.893 -1.754 . . . . 0.0 115.248 177.187 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -104.93 117.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.406 1.483 . . . . 0.0 110.097 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -98.36 146.67 25.46 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.853 2.061 . . . . 0.0 109.799 -173.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -70.32 148.38 48.55 Favored 'General case' 0 N--CA 1.468 0.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.494 -171.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 77.83 156.66 0.17 Allowed 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 127.65 2.38 . . . . 0.0 112.498 -173.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -78.5 -1.3 81.94 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.724 168.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.451 ' CA ' HG11 ' A' ' 5' ' ' VAL . 13.6 t0 -76.92 115.89 17.11 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-N 118.782 1.291 . . . . 0.0 110.823 -174.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.413 0.0 OUTLIER -144.21 43.64 1.43 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 123.502 1.62 . . . . 0.0 113.992 164.293 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.407 HG22 HG22 ' A' ' 7' ' ' VAL 0.3 0.5 OUTLIER -128.06 -28.02 2.68 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 112.58 -2.1 . . . . 0.0 111.936 174.493 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.41 -22.4 54.78 Favored 'General case' 0 CA--C 1.561 1.394 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 158.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.55 -101.34 0.38 Allowed Glycine 0 C--N 1.345 1.038 0 C-N-CA 128.132 2.777 . . . . 0.0 116.23 164.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.4 t -64.58 -31.44 72.65 Favored 'General case' 0 CA--C 1.545 0.759 0 O-C-N 121.146 -1.208 . . . . 0.0 112.359 -170.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.2 t -94.47 0.09 55.1 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.53 1.532 . . . . 0.0 113.78 171.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 12.9 p -94.15 -53.98 3.75 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 123.64 0.776 . . . . 0.0 112.472 173.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.52 28.51 0.19 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 125.599 1.559 . . . . 0.0 112.543 -168.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.84 -63.93 3.56 Favored Glycine 0 CA--C 1.539 1.549 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.491 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -89.77 -180.0 1.99 Allowed 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 124.916 3.744 . . . . 0.0 111.959 169.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -79.67 128.74 33.78 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-O 123.201 1.477 . . . . 0.0 111.925 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -63.41 127.72 32.58 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 113.116 -1.857 . . . . 0.0 108.329 163.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 84.3 m-20 -121.19 58.48 7.53 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 123.675 0.79 . . . . 0.0 112.158 -171.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.31 -11.72 29.44 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.426 2.084 . . . . 0.0 113.873 -178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.3 mp -92.97 -8.27 43.57 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 114.121 1.156 . . . . 0.0 114.121 173.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.8 t 61.68 74.81 0.43 Allowed 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 119.957 1.253 . . . . 0.0 113.432 175.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -167.35 179.14 5.16 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.33 1.452 . . . . 0.0 112.562 -171.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mppt? -85.55 171.43 11.73 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.995 1.718 . . . . 0.0 112.767 177.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -86.26 146.54 26.48 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.921 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.44 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.82 -108.21 0.49 Allowed Glycine 0 C--N 1.336 0.534 0 CA-C-O 119.063 -0.854 . . . . 0.0 114.875 165.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.59 -42.16 2.01 Favored Glycine 0 CA--C 1.555 2.589 0 CA-C-O 118.182 -1.343 . . . . 0.0 114.127 -168.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -84.32 15.38 2.18 Favored 'Trans proline' 0 CA--C 1.553 1.474 0 C-N-CA 124.241 3.294 . . . . 0.0 116.712 171.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -39.42 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 128.143 2.577 . . . . 0.0 110.376 165.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.44 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 1.0 OUTLIER -66.1 137.01 56.75 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 161.561 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -99.82 -16.58 18.02 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.298 1.439 . . . . 0.0 111.258 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -79.4 -60.18 2.47 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.56 -0.712 . . . . 0.0 110.464 -171.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 57.2 ttt-85 71.91 127.47 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.528 1.931 . . . . 0.0 112.374 168.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -76.62 173.02 12.08 Favored 'General case' 0 N--CA 1.475 0.8 0 O-C-N 119.237 -2.164 . . . . 0.0 111.669 168.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 5.7 p -76.85 134.86 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.597 -1.314 . . . . 0.0 109.376 167.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.23 9.13 86.93 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 126.447 1.975 . . . . 0.0 115.801 -174.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 61.5 m-20 -78.25 114.96 17.62 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-N 119.902 1.851 . . . . 0.0 111.924 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 56.8 mt -99.57 179.06 4.67 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.812 0.845 . . . . 0.0 110.086 168.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -109.9 165.2 12.32 Favored Glycine 0 CA--C 1.527 0.83 0 C-N-CA 125.074 1.321 . . . . 0.0 112.445 174.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -74.63 150.84 39.44 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 -168.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 27.4 m -114.67 128.66 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 128.373 2.669 . . . . 0.0 111.097 -172.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -99.33 128.16 45.42 Favored 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.739 -1.225 . . . . 0.0 111.724 -178.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -81.05 135.06 35.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 169.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.06 154.47 23.2 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.626 1.97 . . . . 0.0 109.438 167.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -45.63 -21.8 0.13 Allowed 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 129.037 2.935 . . . . 0.0 116.847 176.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.76 9.62 2.72 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.356 1.062 . . . . 0.0 111.408 172.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.2 35.54 42.97 Favored Glycine 0 C--N 1.339 0.718 0 C-N-CA 127.338 2.399 . . . . 0.0 112.324 175.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 1.8 p -142.93 126.99 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 119.017 1.408 . . . . 0.0 114.65 -172.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.46 119.46 32.58 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 165.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.7 t0 -79.64 154.23 28.82 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 124.592 1.157 . . . . 0.0 109.724 169.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.3 144.2 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 N-CA-C 115.903 1.816 . . . . 0.0 115.903 168.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.7 p -156.24 58.5 0.58 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.635 1.574 . . . . 0.0 112.177 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 28.9 mt -80.35 148.68 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 O-C-N 120.237 -1.539 . . . . 0.0 111.334 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -128.84 137.5 51.52 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.908 2.083 . . . . 0.0 105.591 166.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -154.78 136.79 14.65 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.476 1.111 . . . . 0.0 111.604 -169.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.95 49.06 1.02 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 123.518 0.727 . . . . 0.0 112.932 178.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 t -149.46 20.15 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 124.858 1.263 . . . . 0.0 111.731 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -148.62 169.91 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 128.787 2.835 . . . . 0.0 107.944 169.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -156.88 157.3 34.64 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.837 -1.164 . . . . 0.0 110.129 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -99.2 60.79 1.2 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.121 1.369 . . . . 0.0 108.837 -178.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 2.8 m -84.88 -94.21 0.08 Allowed 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.995 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 163.62 60.66 0.02 OUTLIER Glycine 0 N--CA 1.473 1.139 0 O-C-N 120.836 -1.165 . . . . 0.0 113.263 -172.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . 0.436 ' CG ' ' H ' ' B' ' 110' ' ' HIS . 9.2 p-10 -161.24 -108.95 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 123.136 1.446 . . . . 0.0 108.978 -164.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . 0.436 ' H ' ' CG ' ' B' ' 109' ' ' ASP . 14.6 m-70 -107.57 -28.92 9.48 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 130.001 3.32 . . . . 0.0 110.821 173.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 79.9 p -48.44 -65.28 0.59 Allowed 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 128.222 2.609 . . . . 0.0 116.759 -167.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 33.8 mm -150.06 -51.46 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 128.003 2.521 . . . . 0.0 109.513 169.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 49.8 mm -65.3 120.69 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 169.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.78 10.86 69.08 Favored Glycine 0 CA--C 1.534 1.266 0 N-CA-C 114.585 0.594 . . . . 0.0 114.585 -170.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 20.2 ttt85 -108.79 -179.86 3.98 Favored 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.94 2.496 . . . . 0.0 109.672 171.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -148.11 130.35 15.56 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.132 -1.605 . . . . 0.0 112.938 179.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -101.53 134.09 45.19 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 119.294 0.952 . . . . 0.0 110.931 -175.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.9 p -118.74 137.09 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 125.204 1.402 . . . . 0.0 109.52 176.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.42 130.03 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-O 122.646 1.212 . . . . 0.0 108.142 168.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -107.22 152.98 23.36 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 126.642 1.977 . . . . 0.0 110.108 -172.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.77 -45.34 44.46 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 119.751 -1.843 . . . . 0.0 114.67 -166.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.11 171.55 7.32 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 120.949 1.704 . . . . 0.0 112.061 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.59 149.74 7.75 Favored 'General case' 0 N--CA 1.462 0.158 0 C-N-CA 124.037 0.935 . . . . 0.0 112.538 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -75.87 134.44 40.31 Favored 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 168.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -41.18 68.77 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 175.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 8.3 mt 67.87 37.56 3.1 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 125.867 1.667 . . . . 0.0 111.44 170.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -171.2 -75.16 0.04 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.211 0.91 . . . . 0.0 113.441 169.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 13.8 ttpt -162.04 98.1 1.05 Allowed 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 126.85 2.06 . . . . 0.0 113.605 173.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . 0.473 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -76.87 -135.98 0.71 Allowed Glycine 0 CA--C 1.537 1.413 0 CA-C-O 122.247 0.915 . . . . 0.0 113.417 169.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.89 -9.35 52.52 Favored Glycine 0 N--CA 1.474 1.172 0 N-CA-C 118.448 2.139 . . . . 0.0 118.448 -166.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -164.8 175.47 9.61 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 120.514 2.157 . . . . 0.0 111.59 -169.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -48.07 -54.74 12.1 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 113.396 0.887 . . . . 0.0 113.396 -170.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -57.58 -10.52 1.55 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 114.476 1.287 . . . . 0.0 114.476 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.473 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 90.9 p -58.05 -49.96 75.1 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.884 1.674 . . . . 0.0 112.964 167.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 19.0 p -93.24 -18.1 22.9 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 178.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 13.4 mttt -85.12 -35.68 21.62 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.669 0.788 . . . . 0.0 112.867 176.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 59.8 p -115.33 -112.17 0.34 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.981 1.312 . . . . 0.0 107.479 167.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -142.6 21.45 2.37 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 126.875 2.179 . . . . 0.0 112.187 169.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 59.71 13.79 3.68 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.517 1.927 . . . . 0.0 113.466 -171.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.34 33.18 0.02 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 128.951 2.901 . . . . 0.0 118.559 -165.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.86 -54.8 3.01 Favored Glycine 0 CA--C 1.527 0.817 0 C-N-CA 126.905 2.193 . . . . 0.0 115.568 169.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.0 m -173.51 175.91 2.91 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 125.848 1.659 . . . . 0.0 111.97 -170.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -127.2 115.08 18.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.249 1.419 . . . . 0.0 110.461 -169.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.8 pp -110.53 -37.17 5.56 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -170.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -158.57 158.34 33.74 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 119.558 1.072 . . . . 0.0 113.136 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 20.3 p -156.45 163.78 39.03 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 127.471 2.309 . . . . 0.0 110.24 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.92 142.43 8.69 Favored Glycine 0 CA--C 1.531 1.081 0 C-N-CA 127.075 2.274 . . . . 0.0 110.246 171.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.479 ' HB ' ' CG1' ' A' ' 148' ' ' VAL . 1.6 t -88.17 146.8 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 CA-C-N 118.967 1.383 . . . . 0.0 108.68 -174.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 41.5 mm -77.33 120.56 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 121.013 -1.054 . . . . 0.0 112.94 -169.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.47 -172.4 18.77 Favored Glycine 0 N--CA 1.47 0.958 0 C-N-CA 125.824 1.678 . . . . 0.0 113.567 175.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -133.43 160.39 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 173.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.88 -39.31 0.09 Allowed 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 125.902 1.681 . . . . 0.0 111.368 168.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 . . . . . 0 C--O 1.241 0.612 0 C-N-CA 126.31 1.844 . . . . 0.0 112.824 169.937 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.404 ' HA ' ' OE2' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.469 0.477 0 CA-C-O 119.111 -0.471 . . . . 0.0 110.099 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.2 t -161.04 116.81 2.19 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.29 2.636 . . . . 0.0 106.868 166.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.2 102.71 14.16 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 121.929 -0.482 . . . . 0.0 112.022 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.01 166.67 22.54 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.784 0.72 . . . . 0.0 109.339 167.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.1 t -138.69 140.69 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 122.309 1.052 . . . . 0.0 112.798 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.85 113.15 19.24 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 114.089 -1.414 . . . . 0.0 109.12 165.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.03 80.63 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 127.276 2.23 . . . . 0.0 108.476 167.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -73.84 157.76 35.76 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.007 0.923 . . . . 0.0 111.238 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -148.66 158.51 44.19 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 173.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -119.39 162.68 13.65 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 127.549 2.5 . . . . 0.0 107.54 166.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -76.33 57.66 1.2 Allowed 'General case' 0 C--N 1.31 -1.142 0 C-N-CA 126.837 2.055 . . . . 0.0 111.85 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.13 -167.53 40.0 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 128.436 2.922 . . . . 0.0 109.553 -175.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -80.1 42.55 1.34 Allowed 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 125.224 3.949 . . . . 0.0 112.306 -172.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -131.42 129.63 62.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 124.44 1.096 . . . . 0.0 109.165 -175.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -158.66 169.36 24.58 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.42 1.888 . . . . 0.0 109.074 -172.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 135.79 4.55 Favored Glycine 0 C--O 1.224 -0.469 0 C-N-CA 121.321 -0.466 . . . . 0.0 112.577 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.08 132.11 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 168.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.442 HD12 HG11 ' A' ' 97' ' ' VAL . 15.2 mm -139.09 112.77 6.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 C-N-CA 123.835 0.854 . . . . 0.0 110.838 173.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -78.49 144.32 35.83 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.976 0.91 . . . . 0.0 110.453 165.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -123.56 99.12 6.15 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.744 1.618 . . . . 0.0 109.886 172.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.404 ' OE2' ' HA ' ' A' ' 1' ' ' ALA . 0.0 OUTLIER -79.88 105.34 11.09 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.664 1.186 . . . . 0.0 110.742 -179.629 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -79.29 83.1 5.37 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 120.926 -1.109 . . . . 0.0 108.537 169.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.51 -50.71 72.85 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 118.708 -0.663 . . . . 0.0 111.169 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.3 mp0 -132.38 136.48 46.84 Favored 'General case' 0 C--O 1.224 -0.241 0 C-N-CA 124.271 1.028 . . . . 0.0 108.876 168.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.1 p -67.08 -4.73 10.7 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 126.163 1.785 . . . . 0.0 114.954 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.46 1.93 9.6 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 126.743 2.017 . . . . 0.0 112.06 173.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.45 -153.2 12.52 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.664 1.602 . . . . 0.0 111.192 -176.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -86.24 173.06 6.9 Favored 'Trans proline' 0 N--CA 1.451 -1.01 0 C-N-CA 122.788 2.325 . . . . 0.0 111.761 178.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.95 134.06 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.759 1.624 . . . . 0.0 108.498 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.4 tttp -101.24 121.78 42.48 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 169.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.4 t -121.14 118.82 57.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 125.924 1.689 . . . . 0.0 109.095 -168.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -140.65 161.9 36.65 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 -178.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.65 -150.73 22.97 Favored Glycine 0 CA--C 1.523 0.577 0 C-N-CA 124.783 1.182 . . . . 0.0 112.415 -179.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 43.1 p -158.09 136.04 10.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -171.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -109.7 112.93 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.668 1.187 . . . . 0.0 108.494 178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -120.79 135.86 55.04 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.955 1.302 . . . . 0.0 111.446 -168.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.67 -2.08 15.47 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 127.191 2.329 . . . . 0.0 113.559 -173.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.431 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -69.0 -178.27 1.21 Allowed 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 125.829 1.651 . . . . 0.0 110.992 169.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 t -115.11 156.22 25.62 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 127.962 2.505 . . . . 0.0 105.266 164.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -48.37 146.15 3.0 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 127.032 2.133 . . . . 0.0 114.118 -175.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.83 -177.4 32.86 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 122.084 0.824 . . . . 0.0 113.393 -178.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.491 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -70.13 150.26 46.71 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.449 2.3 . . . . 0.0 112.068 -169.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.431 ' CD2' HD23 ' A' ' 38' ' ' LEU . 92.8 m-70 -147.28 124.03 11.21 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.021 1.728 . . . . 0.0 110.32 175.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.43 155.43 32.44 Favored Glycine 0 N--CA 1.491 2.316 0 CA-C-N 120.281 1.4 . . . . 0.0 114.398 -174.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.635 ' CE1' HD11 ' A' ' 117' ' ' LEU . 2.0 t80 -146.1 102.11 3.59 Favored 'General case' 0 CA--C 1.552 1.051 0 CA-C-O 122.76 1.267 . . . . 0.0 113.77 -167.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -127.34 133.16 50.11 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.89 94.71 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 126.408 1.883 . . . . 0.0 110.355 174.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -73.75 108.84 6.82 Favored 'General case' 0 CA--C 1.557 1.242 0 O-C-N 120.604 -1.31 . . . . 0.0 114.36 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -31.03 106.23 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 127.408 2.283 . . . . 0.0 113.208 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 148.44 173.86 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 129.792 3.237 . . . . 0.0 109.758 -169.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.578 ' HA3' ' H ' ' B' ' 151' ' ' ILE . . . -116.85 -2.63 18.78 Favored Glycine 0 CA--C 1.549 2.201 0 C-N-CA 126.292 1.901 . . . . 0.0 109.859 160.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.51 ' C ' HD22 ' A' ' 53' ' ' ASN . 0.8 OUTLIER -75.69 147.22 39.57 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 128.008 2.523 . . . . 0.0 111.75 170.271 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.51 HD22 ' C ' ' A' ' 52' ' ' ASP 0.312 0.1 OUTLIER -173.53 17.47 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 119.041 2.978 . . . . 0.0 119.041 166.627 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.416 HG22 HG22 ' B' ' 7' ' ' VAL . 0.1 OUTLIER -92.35 -12.52 32.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 120.083 -1.636 . . . . 0.0 114.315 -165.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.34 18.14 22.47 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.772 1.229 . . . . 0.0 112.678 172.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.66 -123.43 24.72 Favored Glycine 0 CA--C 1.529 0.933 0 O-C-N 120.697 -1.252 . . . . 0.0 112.243 174.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 34.3 m -72.5 -9.33 58.43 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 114.725 1.38 . . . . 0.0 114.725 175.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -14.92 52.55 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 125.184 1.394 . . . . 0.0 111.407 169.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 3.7 m -95.28 -159.51 0.72 Allowed 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 127.41 2.284 . . . . 0.0 109.52 168.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -38.13 104.69 0.03 OUTLIER 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 128.212 2.605 . . . . 0.0 116.374 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -63.07 166.72 23.77 Favored Glycine 0 CA--C 1.545 1.92 0 C-N-CA 125.869 1.699 . . . . 0.0 114.805 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -62.11 96.89 0.15 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 125.07 3.847 . . . . 0.0 113.173 -168.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 2.1 p80 47.82 64.49 1.61 Allowed 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 126.124 1.769 . . . . 0.0 113.24 169.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -32.11 137.83 0.05 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 126.383 1.873 . . . . 0.0 115.439 -178.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -106.01 63.66 0.16 Allowed Pre-proline 0 CA--C 1.55 0.969 0 C-N-CA 126.559 1.944 . . . . 0.0 113.084 177.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -62.78 -35.77 66.27 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.612 2.208 . . . . 0.0 111.898 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.1 tp -77.76 -5.18 49.79 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 124.727 1.211 . . . . 0.0 112.869 173.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t 71.27 51.85 0.26 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.945 2.098 . . . . 0.0 112.497 172.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 78' ' ' GLU . 8.5 mtp180 -108.19 171.71 7.25 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -169.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.7 mttp -81.09 162.71 23.6 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 125.468 1.507 . . . . 0.0 109.521 165.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -72.36 151.72 42.51 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 121.012 -1.055 . . . . 0.0 112.151 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.73 -138.45 6.39 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 116.137 1.215 . . . . 0.0 116.137 169.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.457 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 139.77 -108.88 0.6 Allowed Glycine 0 CA--C 1.544 1.856 0 CA-C-O 116.835 -2.092 . . . . 0.0 114.934 -168.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -52.33 -3.65 0.11 Allowed 'Trans proline' 0 CA--C 1.546 1.103 1 C-N-CA 126.443 4.762 . . . . 0.0 120.068 -169.333 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.48 2.89 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 127.693 2.397 . . . . 0.0 112.594 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.457 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.3 OUTLIER -123.91 175.81 6.7 Favored 'General case' 0 CA--C 1.557 1.249 0 C-N-CA 129.091 2.957 . . . . 0.0 109.02 -174.912 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -116.55 -13.71 10.9 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.671 2.388 . . . . 0.0 111.143 -175.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 69' ' ' ARG . 3.8 mm-40 -91.59 -65.3 1.02 Allowed 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.769 1.228 . . . . 0.0 112.555 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.406 HH21 ' CG ' ' A' ' 101' ' ' ASP . 1.4 ttt-85 52.91 77.07 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 120.088 1.313 . . . . 0.0 111.48 171.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -46.91 153.32 0.42 Allowed 'General case' 0 N--CA 1.478 0.971 0 O-C-N 120.264 -1.523 . . . . 0.0 112.298 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 p -43.95 -40.62 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 120.125 1.33 . . . . 0.0 113.715 -176.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -97.08 34.2 5.24 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 126.863 2.173 . . . . 0.0 117.21 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -114.68 128.17 56.16 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.992 1.717 . . . . 0.0 110.426 176.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.1 mt -122.41 53.75 1.23 Allowed 'General case' 0 CA--C 1.54 0.559 0 CA-C-O 122.031 0.92 . . . . 0.0 108.555 168.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 62.2 -132.53 45.49 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 125.411 1.482 . . . . 0.0 114.229 175.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -143.45 154.86 44.11 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 124.573 1.149 . . . . 0.0 110.591 175.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 33.2 m -109.94 104.04 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.618 1.567 . . . . 0.0 109.733 -175.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.1 m -91.68 125.46 36.41 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 124.01 0.924 . . . . 0.0 109.222 -175.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -101.97 156.05 17.78 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -173.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -82.85 166.35 19.03 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.037 1.735 . . . . 0.0 110.206 167.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.6 pttt -51.28 -24.03 4.12 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 127.521 2.328 . . . . 0.0 113.274 167.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -76.78 -0.73 24.91 Favored 'General case' 0 CA--C 1.55 0.954 0 C-N-CA 125.929 1.691 . . . . 0.0 112.016 172.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.21 7.32 84.59 Favored Glycine 0 CA--C 1.52 0.404 0 O-C-N 120.183 -1.573 . . . . 0.0 113.523 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -95.18 123.69 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 125.405 1.482 . . . . 0.0 112.142 174.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.85 134.49 36.16 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 163.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -79.29 150.62 31.46 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 168.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.442 HG11 HD12 ' A' ' 18' ' ' ILE . 1.3 t -131.2 123.24 53.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 113.287 -1.779 . . . . 0.0 109.855 168.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.1 m -147.12 70.94 1.2 Allowed 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.865 2.066 . . . . 0.0 109.198 -172.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 31.3 mt -116.4 152.37 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 125.502 1.521 . . . . 0.0 111.711 -168.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -145.48 137.28 25.37 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 127.172 2.189 . . . . 0.0 107.064 174.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.406 ' CG ' HH21 ' A' ' 79' ' ' ARG . 22.7 t70 -154.26 139.4 17.44 Favored 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -167.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -116.59 51.57 0.98 Allowed 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 39.6 t -128.62 -47.93 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 178.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -100.43 176.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.16 0.984 . . . . 0.0 112.005 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.9 m -157.94 176.03 13.07 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 120.693 -1.254 . . . . 0.0 110.696 172.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.4 mp -109.69 52.2 0.73 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.803 1.641 . . . . 0.0 109.46 -177.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.3 t -91.24 14.33 14.68 Favored 'General case' 0 CA--C 1.542 0.669 0 O-C-N 120.57 -1.331 . . . . 0.0 114.417 -174.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 102.47 -122.32 7.48 Favored Glycine 0 C--N 1.339 0.698 0 O-C-N 121.527 -0.733 . . . . 0.0 111.652 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -59.09 -52.7 64.59 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 126.934 2.094 . . . . 0.0 114.27 -163.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -88.48 9.43 23.72 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.737 1.615 . . . . 0.0 112.602 -174.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.21 -161.23 0.82 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 125.407 1.483 . . . . 0.0 113.937 -165.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.283 7.4 pt -88.96 1.16 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 115.264 1.579 . . . . 0.0 115.264 175.283 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 38.8 mm -69.72 132.68 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 163.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.24 -12.11 55.79 Favored Glycine 0 C--O 1.224 -0.531 0 CA-C-O 117.763 -1.576 . . . . 0.0 115.631 -171.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.716 ' NE ' ' H ' ' A' ' 116' ' ' THR . 1.3 tpm_? -71.51 177.86 3.8 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.699 2.249 . . . . 0.0 108.486 178.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.716 ' H ' ' NE ' ' A' ' 115' ' ' ARG . 1.5 m -140.53 131.58 26.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 126.932 2.093 . . . . 0.0 106.717 175.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.635 HD11 ' CE1' ' A' ' 45' ' ' PHE . 2.3 tm? -87.22 137.8 32.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 125.542 1.776 . . . . 0.0 106.791 166.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 5.2 p -117.45 124.54 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.624 1.17 . . . . 0.0 108.427 168.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.42 145.18 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 O-C-N 124.94 1.4 . . . . 0.0 109.083 169.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 23.2 m-70 -117.34 161.76 19.01 Favored 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 125.16 1.384 . . . . 0.0 113.134 -170.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.54 -34.25 69.86 Favored 'General case' 0 N--CA 1.478 0.935 0 O-C-N 120.597 -1.314 . . . . 0.0 114.071 179.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.426 ' HE3' ' O ' ' A' ' 139' ' ' ASN . 17.9 ttpp -94.49 156.02 16.66 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 123.064 1.412 . . . . 0.0 113.766 -173.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.58 142.59 17.74 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.636 -1.62 . . . . 0.0 109.744 165.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -93.43 128.6 39.57 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 124.465 1.103 . . . . 0.0 110.641 -178.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -74.81 -21.65 59.17 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.697 -177.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 72.3 mt 47.86 56.52 7.09 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 127.912 2.485 . . . . 0.0 111.219 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.16 -58.9 0.38 Allowed Glycine 0 N--CA 1.472 1.055 0 C-N-CA 125.864 1.697 . . . . 0.0 113.732 173.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp -126.05 77.55 1.69 Allowed 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 115.226 1.565 . . . . 0.0 115.226 -169.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.607 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -80.57 -95.23 0.4 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 107.196 -2.362 . . . . 0.0 107.196 165.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -150.03 8.58 0.81 Allowed Glycine 0 N--CA 1.474 1.173 0 N-CA-C 117.728 1.851 . . . . 0.0 117.728 -174.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.7 p30 -161.2 -177.7 6.23 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 120.4 2.1 . . . . 0.0 111.111 -176.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -55.77 -51.89 65.85 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.207 0.912 . . . . 0.0 112.727 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -59.38 -23.84 62.93 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -170.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.607 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 27.3 m -57.15 -29.31 63.51 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 172.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -100.25 -15.14 18.18 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 118.067 -0.968 . . . . 0.0 113.473 173.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.55 -85.37 0.16 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 119.968 1.258 . . . . 0.0 110.77 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 62.5 p -73.24 -11.47 60.52 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.48 9.06 79.74 Favored Glycine 0 N--CA 1.467 0.705 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 -165.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.426 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 4.8 t-20 52.53 21.92 1.97 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.501 1.92 . . . . 0.0 109.135 -166.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.97 -11.78 21.13 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 114.726 1.38 . . . . 0.0 114.726 -166.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.93 -156.12 24.22 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 124.698 1.142 . . . . 0.0 113.072 169.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.7 m -67.98 154.83 40.79 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 126.55 1.94 . . . . 0.0 111.609 -175.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.425 ' H ' ' HD2' ' A' ' 143' ' ' ARG . 0.3 OUTLIER -81.62 129.85 34.84 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.581 0.752 . . . . 0.0 109.192 -179.218 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.11 -64.19 1.1 Allowed 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.124 1.77 . . . . 0.0 110.276 -170.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -138.7 149.33 45.0 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 125.071 1.348 . . . . 0.0 110.531 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 63.7 m -139.08 146.63 40.98 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.047 1.739 . . . . 0.0 111.249 -176.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.08 142.93 8.72 Favored Glycine 0 N--CA 1.474 1.183 0 C-N-CA 124.804 1.192 . . . . 0.0 112.11 169.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.4 t -92.69 135.34 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 125.043 1.337 . . . . 0.0 109.312 -175.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 3.6 mm -77.55 115.77 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.718 -169.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.09 158.1 14.63 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.818 1.199 . . . . 0.0 113.426 -177.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -75.14 134.98 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.135 0.974 . . . . 0.0 113.326 -178.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.62 -177.35 6.53 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.711 2.404 . . . . 0.0 108.544 -170.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 . . . . . 0 N--CA 1.471 0.577 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 167.89 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.427 0 N-CA-C 113.013 0.745 . . . . 0.0 113.013 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 23.8 p -97.76 114.85 26.95 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 123.137 1.446 . . . . 0.0 108.879 171.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -113.07 125.37 54.31 Favored 'General case' 0 C--O 1.24 0.602 0 C-N-CA 125.098 1.359 . . . . 0.0 112.083 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -79.99 168.89 18.61 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 176.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.415 ' CG2' HG23 ' A' ' 54' ' ' THR . 1.9 p -156.12 101.94 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 127.771 2.429 . . . . 0.0 107.836 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.69 114.39 26.03 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.913 1.285 . . . . 0.0 111.403 -172.178 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.416 HG22 HG22 ' A' ' 54' ' ' THR . 2.1 t -83.97 72.61 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 125.17 1.388 . . . . 0.0 109.585 -172.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.3 mp -77.92 115.71 17.87 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 121.437 -0.79 . . . . 0.0 109.838 178.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.1 ttpp -161.79 120.13 2.31 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 126.197 1.799 . . . . 0.0 111.021 164.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -137.07 -69.53 0.05 OUTLIER Glycine 0 N--CA 1.467 0.708 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 169.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -75.95 76.99 2.84 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 127.703 2.401 . . . . 0.0 110.594 -169.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.94 -102.06 0.05 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.424 1.964 . . . . 0.0 112.403 174.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -85.65 0.55 8.46 Favored 'Trans proline' 0 C--N 1.353 0.807 1 C-N-CA 125.783 4.322 . . . . 0.0 115.469 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.33 120.82 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-N 121.753 2.07 . . . . 0.0 109.486 169.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.99 166.36 24.27 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.132 1.373 . . . . 0.0 110.827 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.11 174.92 33.97 Favored Glycine 0 N--CA 1.466 0.634 0 CA-C-O 123.082 1.379 . . . . 0.0 116.115 173.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.482 HG13 ' H ' ' B' ' 34' ' ' SER . 3.3 pt -143.08 50.86 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 CA-C-N 112.833 -1.684 . . . . 0.0 112.013 -166.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 13.1 mm -81.46 119.36 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 O-C-N 120.033 -1.667 . . . . 0.0 110.957 -169.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -88.0 154.96 20.08 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.498 1.519 . . . . 0.0 110.414 169.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.425 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 23.4 m-85 -143.54 108.05 4.83 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 169.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -98.38 117.82 33.65 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 113.994 1.109 . . . . 0.0 113.994 -173.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . 0.539 ' HB2' HD13 ' B' ' 106' ' ' LEU . 4.3 tp-100 -96.17 139.55 32.16 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.794 1.238 . . . . 0.0 111.165 169.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.592 ' H ' ' HD2' ' B' ' 23' ' ' LYS . 0.0 OUTLIER -92.2 -36.15 13.43 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 127.408 2.283 . . . . 0.0 113.59 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -159.47 136.71 9.69 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 126.961 2.104 . . . . 0.0 109.034 169.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 60.3 p -19.43 -57.13 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 129.109 2.964 . . . . 0.0 116.935 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . 0.421 ' H ' ' ND2' ' B' ' 26' ' ' ASN . 4.3 p30 -95.24 2.91 55.0 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 127.342 2.257 . . . . 0.0 115.531 -172.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.24 168.16 54.44 Favored Glycine 0 CA--C 1.544 1.904 0 O-C-N 120.781 -1.199 . . . . 0.0 113.164 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -67.02 163.66 33.04 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.677 2.918 . . . . 0.0 110.297 170.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 77.4 t -131.26 138.74 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 CA-C-N 119.476 1.034 . . . . 0.0 111.642 -169.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.434 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 72.9 mttt -92.48 112.15 23.99 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.23 174.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -83.51 131.94 32.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 C-N-CA 125.214 1.406 . . . . 0.0 109.119 170.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -154.27 165.72 35.42 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 168.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 109.05 175.92 21.47 Favored Glycine 0 N--CA 1.468 0.798 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -174.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . 0.482 ' H ' HG13 ' B' ' 17' ' ' ILE . 77.7 p -132.55 165.52 24.19 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -166.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -116.82 126.61 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 125.915 1.686 . . . . 0.0 107.895 168.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -126.17 132.93 51.7 Favored 'General case' 0 N--CA 1.448 -0.541 0 C-N-CA 124.905 1.282 . . . . 0.0 111.073 -177.235 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.44 -3.04 13.87 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.297 2.38 . . . . 0.0 112.801 -171.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 72.3 mt -66.93 162.73 21.21 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 118.051 0.925 . . . . 0.0 109.483 168.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 t -77.54 150.9 34.75 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 162.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -50.68 147.02 5.06 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 123.733 0.813 . . . . 0.0 110.306 168.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 104.06 -179.59 25.04 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.75 1.167 . . . . 0.0 113.486 -173.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.752 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.9 pt? -84.99 145.28 27.79 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.374 2.67 . . . . 0.0 113.401 -169.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . 0.401 ' HB2' HG23 ' B' ' 87' ' ' VAL . 93.1 m-70 -147.36 147.3 30.17 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 128.88 2.872 . . . . 0.0 111.228 -167.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.11 156.1 49.88 Favored Glycine 0 N--CA 1.479 1.526 0 CA-C-O 117.991 -1.45 . . . . 0.0 113.618 174.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -154.43 98.07 2.07 Favored 'General case' 0 CA--C 1.553 1.07 0 C-N-CA 125.808 1.643 . . . . 0.0 111.623 -173.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -121.36 128.22 52.03 Favored 'General case' 0 N--CA 1.472 0.665 0 O-C-N 120.248 -1.532 . . . . 0.0 113.773 -176.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -80.24 100.43 4.59 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 171.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -68.59 130.27 42.35 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 119.41 -2.056 . . . . 0.0 108.836 -170.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.05 48.67 0.12 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 128.699 2.8 . . . . 0.0 114.179 -165.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 178.66 138.73 0.09 Allowed 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 129.1 2.96 . . . . 0.0 107.054 178.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -79.09 -5.8 88.96 Favored Glycine 0 N--CA 1.469 0.891 0 CA-C-N 115.214 -0.903 . . . . 0.0 114.912 174.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 29.1 t0 -79.19 52.43 1.31 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.961 1.704 . . . . 0.0 112.408 -170.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.412 HD22 ' N ' ' B' ' 53' ' ' ASN 0.252 0.0 OUTLIER 175.89 64.98 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 116.686 2.106 . . . . 0.0 116.686 -169.64 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 4.7 t -73.45 21.77 0.08 Allowed 'General case' 0 N--CA 1.48 1.029 0 O-C-N 120.425 -1.422 . . . . 0.0 113.282 167.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -132.37 9.65 4.39 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 126.151 1.781 . . . . 0.0 111.459 169.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 56.44 -124.93 36.48 Favored Glycine 0 C--N 1.345 1.034 0 O-C-N 121.135 -0.978 . . . . 0.0 112.229 174.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 74.2 m -60.21 -6.94 1.64 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 175.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.6 m -87.94 3.83 47.13 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-N 120.02 1.282 . . . . 0.0 111.456 168.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 74.8 m -151.64 -28.46 0.18 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 119.633 -1.917 . . . . 0.0 115.468 -177.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -123.16 168.92 11.79 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 120.301 1.409 . . . . 0.0 111.794 171.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -84.88 -139.83 4.75 Favored Glycine 0 CA--C 1.541 1.669 0 CA-C-O 118.54 -1.145 . . . . 0.0 111.268 169.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -72.41 176.32 8.84 Favored 'Trans proline' 0 CA--C 1.541 0.833 0 C-N-CA 124.015 3.143 . . . . 0.0 110.959 173.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.664 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -57.11 100.18 0.04 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 128.556 2.742 . . . . 0.0 109.559 170.052 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 49.6 m-85 -49.62 146.34 4.3 Favored 'General case' 0 CA--C 1.538 0.485 0 O-C-N 124.148 0.905 . . . . 0.0 111.629 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -106.12 60.82 0.16 Allowed Pre-proline 0 CA--C 1.56 1.344 0 C-N-CA 126.334 1.853 . . . . 0.0 115.625 -171.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -61.42 -35.17 84.47 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.913 3.076 . . . . 0.0 113.457 -174.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 63.6 mt -79.65 -1.51 38.56 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.453 1.101 . . . . 0.0 113.542 176.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.3 t 58.37 58.03 3.61 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.597 1.159 . . . . 0.0 113.114 169.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -153.88 179.02 9.27 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -169.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 mtmp? -61.75 173.13 1.07 Allowed 'General case' 0 CA--C 1.541 0.622 0 CA-C-O 122.186 0.993 . . . . 0.0 111.98 174.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.507 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 63.6 t60 -123.09 148.73 45.32 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 116.35 1.982 . . . . 0.0 116.35 -166.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 121.65 -63.72 0.51 Allowed Glycine 0 C--N 1.339 0.709 0 C-N-CA 124.458 1.028 . . . . 0.0 115.278 162.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.61 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 88.14 -9.85 73.26 Favored Glycine 0 CA--C 1.548 2.14 1 N-CA-C 123.294 4.078 . . . . 0.0 123.294 168.296 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -89.26 -5.01 5.76 Favored 'Trans proline' 0 C--N 1.358 1.044 1 CA-C-N 124.605 4.202 . . . . 0.0 112.23 168.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.42 -25.18 0.11 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 126.319 1.847 . . . . 0.0 110.861 177.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.61 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -71.08 139.9 50.52 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 122.87 1.319 . . . . 0.0 109.433 164.972 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -90.44 -22.47 21.4 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 129.527 3.131 . . . . 0.0 113.009 -168.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -98.17 -79.92 0.46 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 125.21 1.404 . . . . 0.0 109.901 -172.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 87.92 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 127.45 2.3 . . . . 0.0 116.498 164.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 4.7 m170 -63.99 147.44 52.03 Favored 'General case' 0 N--CA 1.484 1.233 0 O-C-N 119.678 -1.889 . . . . 0.0 108.471 164.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.9 -10.03 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 CA-C-N 122.094 2.224 . . . . 0.0 112.372 -174.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.97 5.46 75.88 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.764 1.65 . . . . 0.0 114.695 169.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -97.9 132.26 43.64 Favored 'General case' 0 C--N 1.322 -0.623 0 O-C-N 119.666 -2.079 . . . . 0.0 111.758 -173.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 81.4 mt -130.35 176.62 7.98 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.697 1.999 . . . . 0.0 106.738 165.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.27 -138.87 6.34 Favored Glycine 0 N--CA 1.471 1.003 0 C-N-CA 123.863 0.744 . . . . 0.0 114.369 -171.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -102.47 151.1 22.69 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.36 1.064 . . . . 0.0 113.369 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.401 HG23 ' HB2' ' B' ' 43' ' ' HIS . 16.2 m -113.51 145.57 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 127.797 2.439 . . . . 0.0 110.728 169.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 54.8 m -134.23 122.54 22.9 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.215 0.916 . . . . 0.0 109.544 -174.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -89.12 151.56 22.14 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 114.126 1.158 . . . . 0.0 114.126 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.61 160.25 14.86 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 130.189 3.395 . . . . 0.0 109.5 168.104 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -40.48 -26.66 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 128.616 2.766 . . . . 0.0 117.884 175.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -77.45 7.67 5.15 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 120.104 1.32 . . . . 0.0 112.029 173.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.9 8.87 87.25 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 127.247 2.356 . . . . 0.0 113.748 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 11.5 p -104.28 121.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 125.103 1.361 . . . . 0.0 112.684 -170.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.34 113.41 25.36 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 164.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -104.18 141.83 35.57 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.831 0.824 . . . . 0.0 111.314 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -117.65 147.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 CA-C-N 113.606 -1.634 . . . . 0.0 113.46 -170.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 17.4 p -161.17 60.0 0.29 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 125.258 1.423 . . . . 0.0 113.75 -175.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 24.4 mt -118.61 145.21 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 O-C-N 119.771 -1.83 . . . . 0.0 112.297 -172.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . 0.434 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 10.7 tt0 -104.03 121.53 43.37 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 165.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -112.44 134.87 53.73 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.679 1.192 . . . . 0.0 109.866 174.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 87.0 p -109.42 50.73 0.77 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.002 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 57.7 t -133.8 -39.11 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.863 1.665 . . . . 0.0 110.208 169.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.59 163.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-O 123.18 1.467 . . . . 0.0 113.393 176.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.539 ' H ' ' HB3' ' B' ' 111' ' ' SER . 58.1 m -159.43 147.67 17.61 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 127.14 2.176 . . . . 0.0 108.863 -172.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . 0.539 HD13 ' HB2' ' B' ' 22' ' ' GLN . 4.1 mp -79.58 97.42 6.48 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 119.013 0.824 . . . . 0.0 109.05 -179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 7.8 m -114.07 -33.71 5.62 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.178 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.15 -29.39 10.73 Favored Glycine 0 N--CA 1.469 0.858 0 CA-C-O 118.91 -0.939 . . . . 0.0 111.822 -168.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 10.2 p30 -154.25 -46.66 0.09 Allowed 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 115.577 1.695 . . . . 0.0 115.577 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -82.61 0.96 40.55 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 126.142 1.777 . . . . 0.0 112.755 -168.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . 0.539 ' HB3' ' H ' ' B' ' 105' ' ' SER . 4.9 m -163.85 -78.11 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 177.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.4 pt -129.17 167.3 24.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 O-C-N 120.749 -1.22 . . . . 0.0 109.797 167.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 35.2 mm 77.93 146.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 C-N-CA 129.452 3.101 . . . . 0.0 106.84 -162.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 76.95 -45.76 2.29 Favored Glycine 0 N--CA 1.468 0.8 0 CA-C-O 118.985 -0.897 . . . . 0.0 113.698 -172.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 10.8 mtp85 -75.85 176.62 7.64 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.961 1.304 . . . . 0.0 111.117 -174.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 5.9 t -124.5 164.95 18.67 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 117.529 -1.224 . . . . 0.0 110.931 -173.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.421 ' C ' HD13 ' B' ' 117' ' ' LEU . 0.3 OUTLIER -127.11 140.56 52.18 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 119.619 1.1 . . . . 0.0 108.886 167.597 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 p -122.8 136.2 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.345 1.458 . . . . 0.0 110.101 172.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.07 158.73 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.486 1.114 . . . . 0.0 110.233 175.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -131.76 140.3 49.19 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.42 1.088 . . . . 0.0 111.729 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -63.3 -27.92 69.66 Favored 'General case' 0 N--CA 1.475 0.792 0 O-C-N 120.042 -1.661 . . . . 0.0 115.119 -174.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.93 165.19 14.0 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 120.071 -1.643 . . . . 0.0 109.957 166.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -77.21 152.0 34.93 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 124.307 1.043 . . . . 0.0 111.42 177.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.514 ' CG ' ' HB2' ' B' ' 140' ' ' ALA . 16.7 m-20 -86.55 159.95 19.11 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.302 1.841 . . . . 0.0 113.034 174.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.7 -49.7 17.51 Favored 'General case' 0 N--CA 1.485 1.304 0 CA-C-N 112.728 -2.033 . . . . 0.0 111.104 166.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.6 mm? 68.32 62.73 0.37 Allowed 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 127.355 2.262 . . . . 0.0 110.167 -176.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 178.22 -111.61 0.33 Allowed Glycine 0 N--CA 1.47 0.901 0 O-C-N 121.583 -0.698 . . . . 0.0 111.748 -173.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -151.63 7.94 0.5 Allowed 'General case' 0 CA--C 1.566 1.584 0 C-N-CA 126.906 2.083 . . . . 0.0 112.551 169.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 34.86 -106.5 0.03 OUTLIER Glycine 0 C--N 1.35 1.324 0 C-N-CA 126.877 2.179 . . . . 0.0 114.071 169.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -129.71 21.83 4.98 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-O 117.958 -1.468 . . . . 0.0 114.16 169.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -165.37 168.57 16.65 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 120.393 2.096 . . . . 0.0 111.249 -171.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -61.85 -53.03 61.46 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.855 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -40.84 -37.74 0.82 Allowed 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 126.676 1.99 . . . . 0.0 114.637 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 54.9 m -56.02 -35.67 67.1 Favored 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 171.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.8 t -94.85 -23.56 17.42 Favored 'General case' 0 N--CA 1.486 1.328 0 CA-C-N 119.935 1.243 . . . . 0.0 112.527 167.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.9 ttpt -78.9 -33.62 45.43 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-N 119.981 1.264 . . . . 0.0 113.094 -171.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.2 m -135.71 -31.32 0.95 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 126.898 2.079 . . . . 0.0 110.616 -169.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . 0.507 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 125.49 -25.41 5.67 Favored Glycine 0 C--O 1.222 -0.599 0 C-N-CA 127.996 2.712 . . . . 0.0 111.714 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 113.14 -8.63 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.856 1 C-N-CA 131.995 4.118 . . . . 0.0 112.291 176.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . 0.514 ' HB2' ' CG ' ' B' ' 124' ' ' ASP . . . -57.24 -7.35 0.53 Allowed 'General case' 0 CA--C 1.56 1.349 0 N-CA-C 118.466 2.765 . . . . 0.0 118.466 -163.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.76 -31.32 1.96 Allowed Glycine 0 N--CA 1.47 0.943 0 O-C-N 119.597 -1.939 . . . . 0.0 114.512 170.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.9 t -133.64 -173.39 3.22 Favored 'General case' 0 CA--C 1.544 0.743 0 O-C-N 121.752 -0.852 . . . . 0.0 112.717 -170.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -119.24 -174.44 2.72 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 127.981 2.512 . . . . 0.0 108.837 172.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.527 HD23 ' H ' ' B' ' 145' ' ' ALA . 0.2 OUTLIER -174.72 -160.1 0.09 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 130.156 3.382 . . . . 0.0 107.038 171.908 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.527 ' H ' HD23 ' B' ' 144' ' ' LEU . . . -69.86 171.98 8.44 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 127.503 2.321 . . . . 0.0 113.781 -176.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -155.92 153.31 29.43 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.252 1.421 . . . . 0.0 111.817 -168.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.96 141.15 7.66 Favored Glycine 0 N--CA 1.469 0.881 0 C-N-CA 125.347 1.451 . . . . 0.0 113.975 172.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 2.3 t -77.58 147.83 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.835 0.854 . . . . 0.0 110.164 171.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 19.7 mm -91.91 98.29 8.21 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 126.535 1.934 . . . . 0.0 110.836 -171.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.75 -171.6 30.31 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 124.564 1.078 . . . . 0.0 114.058 176.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.578 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 3.4 mp -119.21 128.82 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.186 0 C-N-CA 126.042 1.737 . . . . 0.0 114.367 -169.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -100.69 -24.34 14.44 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.35 1.06 . . . . 0.0 112.18 169.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 CA--C 1.534 0.345 0 C-N-CA 126.974 2.109 . . . . 0.0 111.618 -175.097 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 118.07 -0.967 . . . . 0.0 108.553 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.41 98.73 11.94 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 166.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.297 6.3 ptpt -127.24 129.78 48.39 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 176.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.27 153.38 28.51 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 126.659 1.984 . . . . 0.0 109.376 174.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -122.65 142.67 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.106 1.363 . . . . 0.0 108.976 177.355 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -105.19 133.32 50.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 121.092 1.769 . . . . 0.0 110.33 166.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' B' ' 54' ' ' THR . 57.5 t -118.22 109.24 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.576 1.15 . . . . 0.0 109.574 -175.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.63 140.83 48.5 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 125.544 1.538 . . . . 0.0 112.187 -172.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -160.8 164.25 31.57 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 168.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.492 ' HA3' ' HE3' ' B' ' 9' ' ' LYS . . . 82.23 73.22 1.23 Allowed Glycine 0 C--N 1.335 0.48 0 N-CA-C 120.706 3.043 . . . . 0.0 120.706 161.668 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -160.04 60.96 0.35 Allowed 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 108.212 164.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.76 -172.41 21.8 Favored Glycine 0 CA--C 1.541 1.671 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -164.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -73.58 58.7 3.91 Favored 'Trans proline' 0 CA--C 1.534 0.493 1 C-N-CA 125.749 4.299 . . . . 0.0 110.044 173.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -134.95 133.76 53.6 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 C-N-CA 125.728 1.611 . . . . 0.0 110.263 -168.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.8 163.65 38.72 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 126.353 1.861 . . . . 0.0 109.85 -169.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.29 148.26 17.98 Favored Glycine 0 C--N 1.33 0.196 0 CA-C-O 122.407 1.004 . . . . 0.0 115.556 176.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -123.25 138.54 52.85 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.611 0 C-N-CA 126.318 1.847 . . . . 0.0 109.888 167.814 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.9 mm -140.57 127.09 21.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 C-N-CA 125.496 1.518 . . . . 0.0 108.235 166.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -85.79 141.2 29.84 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.906 1.682 . . . . 0.0 109.839 166.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -124.28 97.82 5.49 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.727 2.011 . . . . 0.0 107.29 176.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.62 116.43 28.73 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-O 123.436 1.588 . . . . 0.0 111.636 -172.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.45 HE22 ' C ' ' A' ' 25' ' ' SER . 22.1 tt0 -108.67 148.85 29.8 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.954 178.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.437 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -89.45 -26.15 21.11 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.637 1.175 . . . . 0.0 112.912 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -131.71 -151.58 0.47 Allowed 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 126.389 1.876 . . . . 0.0 110.401 167.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.45 ' C ' HE22 ' A' ' 22' ' ' GLN . 30.6 t -111.41 -17.53 13.09 Favored 'General case' 0 CA--C 1.555 1.169 0 C-N-CA 125.315 1.446 . . . . 0.0 110.754 167.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -90.67 -24.32 20.5 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 127.661 2.384 . . . . 0.0 115.466 170.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.2 175.64 52.41 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 119.462 1.028 . . . . 0.0 114.79 -173.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.56 151.91 47.83 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.855 2.37 . . . . 0.0 110.718 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.7 t -98.86 128.73 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 177.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -88.97 119.41 29.47 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 169.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.24 133.29 59.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 125.69 1.596 . . . . 0.0 110.141 -176.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -156.08 156.54 34.52 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.543 0.737 . . . . 0.0 111.886 177.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.1 -149.74 16.71 Favored Glycine 0 C--N 1.333 0.394 0 O-C-N 121.924 -0.485 . . . . 0.0 112.963 171.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 53.6 p -155.39 115.11 3.68 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 122.976 0.511 . . . . 0.0 112.056 -169.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.06 125.41 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-O 117.299 -1.334 . . . . 0.0 107.593 170.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.8 tttp -124.75 140.67 52.72 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 121.891 2.132 . . . . 0.0 111.552 -176.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.88 -0.25 13.45 Favored Glycine 0 N--CA 1.476 1.343 0 C-N-CA 127.243 2.354 . . . . 0.0 114.661 -176.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.459 ' H ' HD22 ' A' ' 38' ' ' LEU . 2.3 mm? -69.15 -178.82 1.37 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 125.603 1.561 . . . . 0.0 110.985 170.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.8 t -102.59 -42.42 5.93 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 117.209 -1.377 . . . . 0.0 113.511 169.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 176.48 -107.67 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.267 0 C-N-CA 128.773 2.829 . . . . 0.0 109.628 -178.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -39.54 148.38 0.15 Allowed Glycine 0 N--CA 1.479 1.511 0 C-N-CA 129.533 3.444 . . . . 0.0 119.885 -168.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.446 HD23 ' H ' ' A' ' 42' ' ' LEU . 1.0 OUTLIER -31.3 136.67 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 130.1 3.36 . . . . 0.0 117.796 -169.084 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.0 m-70 -130.32 140.5 50.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 128.94 2.896 . . . . 0.0 108.764 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.57 156.52 53.33 Favored Glycine 0 N--CA 1.474 1.22 0 C-N-CA 124.08 0.848 . . . . 0.0 111.981 175.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 50.7 t80 -155.44 105.65 2.48 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.157 0.983 . . . . 0.0 112.374 -168.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.03 140.04 32.51 Favored 'General case' 0 N--CA 1.475 0.788 0 O-C-N 119.936 -1.728 . . . . 0.0 115.185 -172.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -78.11 134.99 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 166.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m170 -112.9 176.74 4.89 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 126.889 2.075 . . . . 0.0 110.901 -174.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -74.55 132.55 41.91 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.566 1.147 . . . . 0.0 112.297 170.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -77.78 -178.49 5.43 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 127.798 2.439 . . . . 0.0 115.216 -177.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.505 ' HA2' ' CA ' ' B' ' 152' ' ' ALA . . . 119.78 -118.26 3.86 Favored Glycine 0 CA--C 1.502 -0.774 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.288 -172.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -87.83 63.45 7.44 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 125.229 2.442 . . . . 0.0 108.015 177.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -77.18 56.92 1.35 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 113.297 -1.774 . . . . 0.0 110.794 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.438 HG21 HD13 ' B' ' 17' ' ' ILE . 13.5 p -124.81 -44.88 1.92 Allowed 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.394 1.478 . . . . 0.0 113.943 -168.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.22 10.58 0.74 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.587 1.155 . . . . 0.0 113.093 170.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.78 -150.59 51.48 Favored Glycine 0 CA--C 1.528 0.869 0 O-C-N 120.493 -1.38 . . . . 0.0 111.294 -173.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 27.9 p -61.39 -7.29 2.87 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 117.196 2.295 . . . . 0.0 117.196 -169.149 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -88.44 -12.98 41.56 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 119.547 1.067 . . . . 0.0 113.784 170.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 5.3 t -124.09 -36.33 2.71 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 119.465 1.03 . . . . 0.0 111.853 173.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -69.07 86.94 0.38 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 166.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -47.68 120.95 6.33 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 126.736 2.112 . . . . 0.0 114.353 -166.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -67.46 126.42 14.85 Favored 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.625 2.217 . . . . 0.0 111.598 -173.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 78.9 m-70 59.65 60.96 2.08 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 164.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -45.22 109.95 0.21 Allowed 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.667 1.587 . . . . 0.0 112.746 -178.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.4 p-10 -135.5 55.33 12.56 Favored Pre-proline 0 CA--C 1.546 0.795 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -169.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -62.56 -16.16 50.59 Favored 'Trans proline' 0 C--N 1.354 0.836 0 C-N-CA 122.447 2.098 . . . . 0.0 112.495 170.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.7 mt -78.04 -7.18 56.58 Favored 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 169.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.3 t 64.98 56.18 1.08 Allowed 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.995 1.718 . . . . 0.0 112.412 170.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.5 mtm-85 -120.45 172.41 7.84 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 116.061 1.874 . . . . 0.0 116.061 -167.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.61 153.2 37.43 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 128.561 2.744 . . . . 0.0 109.944 168.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -74.42 151.24 39.67 Favored 'General case' 0 CA--C 1.541 0.598 0 O-C-N 120.807 -1.183 . . . . 0.0 113.551 171.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.421 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.96 -123.64 2.07 Favored Glycine 0 C--N 1.34 0.77 0 CA-C-O 118.728 -1.04 . . . . 0.0 113.499 166.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.417 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 119.9 -48.79 0.92 Allowed Glycine 0 CA--C 1.546 1.985 0 N-CA-C 117.758 1.863 . . . . 0.0 117.758 179.201 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -87.29 9.36 3.94 Favored 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.508 2.805 . . . . 0.0 114.131 178.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.6 pttt -165.15 -27.05 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 126.256 1.822 . . . . 0.0 112.263 179.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.421 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.1 OUTLIER -83.57 161.09 21.29 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 128.618 2.767 . . . . 0.0 109.406 166.104 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -95.64 -17.98 20.9 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 125.591 1.556 . . . . 0.0 112.334 -172.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -95.19 -68.34 0.81 Allowed 'General case' 0 C--O 1.231 0.105 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -167.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.521 HH22 HG23 ' A' ' 104' ' ' ILE . 63.4 ttt-85 68.36 125.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 123.191 1.472 . . . . 0.0 111.24 -176.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -66.09 169.96 6.29 Favored 'General case' 0 CA--C 1.554 1.098 0 O-C-N 119.1 -2.25 . . . . 0.0 111.86 167.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.3 t -68.17 -50.47 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 O-C-N 120.684 -1.26 . . . . 0.0 108.665 176.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.33 92.76 1.83 Allowed Glycine 0 CA--C 1.529 0.918 0 N-CA-C 107.651 -2.179 . . . . 0.0 107.651 165.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -157.42 143.72 17.84 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 125.471 1.509 . . . . 0.0 112.558 171.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.99 177.63 7.75 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 127.489 2.316 . . . . 0.0 107.243 168.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.2 -126.34 1.11 Allowed Glycine 0 CA--C 1.531 1.054 0 C-N-CA 125.331 1.443 . . . . 0.0 113.908 -173.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 38.2 p-10 -144.61 164.31 31.31 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -175.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 26.8 m -136.44 123.39 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.491 1.117 . . . . 0.0 111.703 -169.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 m -98.53 141.34 31.5 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.305 1.042 . . . . 0.0 108.706 171.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 95' ' ' ALA . . . -97.29 156.03 16.61 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 172.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.58 158.58 24.34 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.306 1.842 . . . . 0.0 107.876 165.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -50.06 -21.7 1.35 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 127.208 2.203 . . . . 0.0 116.605 177.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -78.09 4.21 12.98 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 125.199 1.4 . . . . 0.0 111.963 172.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.08 12.22 82.75 Favored Glycine 0 C--O 1.225 -0.441 0 C-N-CA 126.847 2.165 . . . . 0.0 114.24 176.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -105.73 122.66 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 CA-C-N 119.114 1.457 . . . . 0.0 112.357 -178.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 89' ' ' ALA . . . -91.91 95.85 10.05 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 125.277 1.431 . . . . 0.0 109.948 169.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -79.48 127.32 31.98 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.62 1.568 . . . . 0.0 109.673 175.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 4.1 p -134.68 144.69 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -171.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.2 t -156.69 115.88 3.42 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.656 1.182 . . . . 0.0 111.556 173.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.6 mt -139.56 158.5 27.69 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 128.918 2.887 . . . . 0.0 109.986 -173.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -135.47 136.2 41.1 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 124.975 1.31 . . . . 0.0 108.114 167.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -148.69 134.12 18.57 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.566 1.146 . . . . 0.0 110.628 -167.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.6 p -106.91 45.81 0.96 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.93 18.13 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.782 1.233 . . . . 0.0 110.919 -175.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.521 HG23 HH22 ' A' ' 79' ' ' ARG . 0.2 OUTLIER -146.91 154.95 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 128.433 2.693 . . . . 0.0 106.334 164.996 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.566 ' H ' ' HB3' ' A' ' 111' ' ' SER . 76.5 p -157.67 161.7 38.6 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.775 1.23 . . . . 0.0 110.839 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -88.05 86.19 7.08 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.0 t -113.74 -4.16 13.43 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.898 1.279 . . . . 0.0 113.75 -172.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.2 -47.33 1.49 Allowed Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.046 -0.864 . . . . 0.0 113.588 -177.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 36.2 p-10 -142.09 -51.24 0.4 Allowed 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.913 1.82 . . . . 0.0 115.913 -169.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -78.97 -8.82 59.24 Favored 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 126.069 1.747 . . . . 0.0 112.922 -166.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.566 ' HB3' ' H ' ' A' ' 105' ' ' SER . 69.0 m -134.03 -109.67 0.22 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.623 1.169 . . . . 0.0 109.343 -174.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 38.4 pt -117.35 169.79 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 122.033 0.921 . . . . 0.0 108.754 166.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.4 mm 108.4 132.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.071 1 C-N-CA 134.974 5.31 . . . . 0.0 106.384 -165.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.95 -3.23 1.63 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 116.174 1.229 . . . . 0.0 116.174 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.436 ' HB3' HD12 ' A' ' 149' ' ' ILE . 46.7 ttm-85 -78.95 171.63 14.94 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.744 1.218 . . . . 0.0 110.316 -172.167 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.5 t -116.53 162.38 17.68 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.113 1.365 . . . . 0.0 110.275 -178.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.93 131.52 18.82 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.694 1.598 . . . . 0.0 109.239 178.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 82.4 t -116.21 133.97 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 125.138 1.375 . . . . 0.0 108.693 175.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.411 HG23 ' HB3' ' A' ' 144' ' ' LEU . 30.8 m -103.2 155.09 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 168.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.37 130.92 41.32 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.655 1.182 . . . . 0.0 109.917 -168.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -58.48 -18.44 28.9 Favored 'General case' 0 CA--C 1.549 0.935 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.1 mmtm -128.73 168.06 16.37 Favored 'General case' 0 N--CA 1.479 0.99 0 O-C-N 118.66 -2.525 . . . . 0.0 115.063 -171.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -48.64 136.18 13.67 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 126.379 1.872 . . . . 0.0 111.68 173.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -122.72 146.95 47.03 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-O 124.664 2.174 . . . . 0.0 113.47 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.84 -29.24 55.81 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 112.563 -2.108 . . . . 0.0 113.673 -166.045 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.4 mt 35.13 58.45 0.77 Allowed 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 128.376 2.67 . . . . 0.0 111.274 176.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 145.15 -101.31 0.24 Allowed Glycine 0 C--N 1.334 0.431 0 C-N-CA 125.117 1.341 . . . . 0.0 110.869 -172.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -156.7 121.97 4.68 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 126.65 1.98 . . . . 0.0 112.042 -167.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -113.83 -90.38 1.8 Allowed Glycine 0 N--CA 1.467 0.734 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 176.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.3 2.89 2.64 Favored Glycine 0 N--CA 1.472 1.098 0 C-N-CA 125.362 1.458 . . . . 0.0 115.306 179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -120.95 161.93 20.75 Favored 'General case' 0 N--CA 1.463 0.187 0 C-N-CA 124.454 1.102 . . . . 0.0 113.116 -169.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -60.23 -55.87 28.42 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.527 1.156 . . . . 0.0 108.807 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -57.74 -7.33 0.67 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 126.453 1.901 . . . . 0.0 114.579 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 60.7 p -68.01 -48.52 65.49 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 119.917 1.235 . . . . 0.0 112.342 171.21 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 64.7 p -83.51 -26.87 29.81 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.344 0.658 . . . . 0.0 112.311 176.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 mtpm? -75.55 -60.56 2.25 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 178.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.1 p -104.35 -45.23 4.73 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 119.983 1.265 . . . . 0.0 113.706 178.185 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 125.26 7.99 5.65 Favored Glycine 0 CA--C 1.524 0.653 0 C-N-CA 126.214 1.864 . . . . 0.0 113.103 -168.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 56.97 21.66 6.45 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 115.7 1.741 . . . . 0.0 115.7 170.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.47 26.42 0.02 OUTLIER 'General case' 0 CA--C 1.568 1.646 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -169.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.97 -40.79 2.13 Favored Glycine 0 N--CA 1.47 0.952 0 C-N-CA 128.581 2.991 . . . . 0.0 115.894 169.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.4 m -171.23 -150.13 0.06 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 126.028 1.731 . . . . 0.0 110.61 -175.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.468 ' HD3' ' H ' ' A' ' 143' ' ' ARG . 0.0 OUTLIER -114.3 -163.44 0.87 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.815 1.646 . . . . 0.0 109.878 170.458 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.411 ' HB3' HG23 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -171.67 -155.27 0.1 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 128.112 2.565 . . . . 0.0 107.92 179.395 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.93 145.98 28.24 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.302 1.441 . . . . 0.0 111.189 174.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 8.6 p -128.11 147.58 50.55 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.317 179.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.27 174.72 32.65 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 116.043 1.177 . . . . 0.0 116.043 -172.004 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 97.0 t -143.26 154.38 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 C-N-CA 124.575 1.15 . . . . 0.0 110.827 -170.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' A' ' 115' ' ' ARG . 41.8 mt -89.53 116.68 31.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 126.217 1.807 . . . . 0.0 115.086 -170.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' B' ' 114' ' ' GLY . . . -98.99 -179.01 31.81 Favored Glycine 0 CA--C 1.531 1.094 0 C-N-CA 127.393 2.425 . . . . 0.0 112.937 167.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -144.8 138.67 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 CA-C-N 119.059 1.43 . . . . 0.0 114.258 -174.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.457 ' HB2' ' HA2' ' B' ' 51' ' ' GLY . . . -105.06 -35.5 7.61 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.083 1.142 . . . . 0.0 114.083 171.421 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 CA--C 1.546 0.823 0 CA-C-O 122.725 1.25 . . . . 0.0 111.409 -170.376 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.802 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 40.0 p -74.38 110.96 9.09 Favored 'General case' 0 CA--C 1.512 -0.492 0 C-N-CA 125.731 1.612 . . . . 0.0 108.222 -172.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.1 mtmm -100.7 140.91 34.31 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 -171.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.86 170.04 9.86 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 127.489 2.316 . . . . 0.0 111.485 173.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -132.38 145.79 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.393 1.877 . . . . 0.0 111.839 -175.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -96.36 139.09 33.0 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 123.846 0.858 . . . . 0.0 109.0 165.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.3 79.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 121.44 0.638 . . . . 0.0 109.967 169.116 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.8 mp -82.87 139.66 33.33 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . 0.492 ' HE3' ' HA3' ' A' ' 10' ' ' GLY . 5.7 ttpt -154.7 157.98 38.89 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 171.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -106.59 173.8 19.72 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 107.256 -2.337 . . . . 0.0 107.256 164.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -79.27 55.45 1.87 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.616 1.966 . . . . 0.0 111.047 172.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.9 -164.02 32.53 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.433 1.492 . . . . 0.0 112.454 -168.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.44 45.31 1.82 Allowed 'Trans proline' 0 CA--C 1.539 0.736 1 C-N-CA 125.933 4.422 . . . . 0.0 114.497 -168.193 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.453 HG11 HD23 ' B' ' 144' ' ' LEU . 3.4 t -133.75 132.75 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 177.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -156.48 164.19 38.53 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 124.747 1.219 . . . . 0.0 110.811 -169.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -149.39 106.2 0.32 Allowed Glycine 0 N--CA 1.462 0.399 0 C-N-CA 125.326 1.441 . . . . 0.0 110.757 176.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 54' ' ' THR 0.262 0.1 OUTLIER -118.03 103.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -170.031 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 21.6 mm -121.48 120.97 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.168 0.987 . . . . 0.0 110.324 -168.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -78.79 138.92 38.43 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.716 0.807 . . . . 0.0 111.65 169.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -120.56 119.03 31.73 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.299 1.44 . . . . 0.0 108.312 169.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -107.68 119.67 40.08 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 124.128 0.971 . . . . 0.0 111.439 174.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 46.8 tp60 -79.01 95.75 5.58 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 168.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.27 -20.17 62.26 Favored 'General case' 0 N--CA 1.475 0.816 0 O-C-N 120.551 -1.343 . . . . 0.0 112.927 175.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 49.5 tt0 -156.41 127.23 6.81 Favored 'General case' 0 C--O 1.216 -0.666 0 C-N-CA 124.328 1.051 . . . . 0.0 112.635 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 7.4 m -60.91 -21.34 63.27 Favored 'General case' 0 N--CA 1.48 1.056 0 N-CA-C 116.232 1.938 . . . . 0.0 116.232 -169.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -115.09 1.24 13.86 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.161 2.184 . . . . 0.0 112.191 175.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.2 -157.53 10.81 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.541 2.02 . . . . 0.0 111.927 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.87 165.89 25.9 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.942 2.428 . . . . 0.0 113.283 -170.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 59.5 t -116.55 137.92 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 126.349 1.86 . . . . 0.0 108.897 174.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.6 mttt -92.51 129.12 38.54 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 123.82 0.848 . . . . 0.0 109.225 167.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -114.99 125.57 72.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 C-N-CA 125.669 1.588 . . . . 0.0 109.093 175.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 8.5 p90 -151.7 154.63 36.7 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.872 0.869 . . . . 0.0 110.985 174.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.96 178.5 18.88 Favored Glycine 0 N--CA 1.462 0.395 0 CA-C-O 122.439 1.022 . . . . 0.0 113.7 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . 0.4 ' HB2' ' CG2' ' B' ' 94' ' ' VAL . 23.5 p -114.13 140.18 48.72 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 115.821 1.785 . . . . 0.0 115.821 -164.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.16 108.1 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 C-N-CA 125.701 1.6 . . . . 0.0 108.869 169.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -119.26 147.61 44.07 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 124.31 1.044 . . . . 0.0 109.994 -171.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.8 19.36 29.45 Favored Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.563 1.554 . . . . 0.0 111.531 -170.351 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 71.5 mt -92.35 -171.49 2.81 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.513 1.925 . . . . 0.0 108.717 167.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.48 150.99 48.38 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 130.404 3.482 . . . . 0.0 105.178 167.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -50.21 -9.6 0.05 OUTLIER 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 129.61 3.164 . . . . 0.0 116.785 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -63.88 163.26 33.58 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.385 -1.447 . . . . 0.0 112.233 168.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -57.74 142.94 43.71 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 126.0 1.72 . . . . 0.0 111.18 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -131.32 128.39 39.65 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.356 1.062 . . . . 0.0 110.419 169.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.417 ' HA3' ' HB2' ' B' ' 124' ' ' ASP . . . -69.76 154.86 53.13 Favored Glycine 0 N--CA 1.47 0.965 0 CA-C-O 118.333 -1.26 . . . . 0.0 112.439 177.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -149.06 124.08 10.04 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 119.466 1.633 . . . . 0.0 112.033 -169.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -156.44 158.81 37.94 Favored 'General case' 0 C--O 1.238 0.474 0 O-C-N 120.415 -1.428 . . . . 0.0 112.773 178.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.9 m -101.15 126.79 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 C-N-CA 125.012 1.325 . . . . 0.0 108.746 177.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.9 m-70 -76.8 177.7 7.42 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 122.73 1.253 . . . . 0.0 110.991 -178.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -62.91 154.75 29.29 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 162.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -75.54 -135.74 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 122.05 0.928 . . . . 0.0 112.011 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.457 ' HA2' ' HB2' ' A' ' 152' ' ' ALA . . . 91.65 -109.43 3.73 Favored Glycine 0 CA--C 1.495 -1.167 0 C-N-CA 123.889 0.757 . . . . 0.0 111.966 168.322 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.32 58.76 0.86 Allowed 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 127.081 2.152 . . . . 0.0 105.666 -174.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.489 ' ND2' ' H ' ' B' ' 53' ' ' ASN . 0.0 OUTLIER -62.15 -2.86 1.06 Allowed 'General case' 0 CA--C 1.544 0.73 0 N-CA-C 116.376 1.991 . . . . 0.0 116.376 -165.902 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.524 ' HA ' HG13 ' A' ' 7' ' ' VAL 0.343 0.6 OUTLIER -66.12 -33.21 75.27 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -164.2 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.53 8.55 40.26 Favored 'General case' 0 CA--C 1.552 1.048 0 CA-C-N 119.525 1.057 . . . . 0.0 113.198 168.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 55.66 -124.07 32.44 Favored Glycine 0 C--N 1.342 0.906 0 C-N-CA 125.034 1.302 . . . . 0.0 111.791 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.8 t -56.23 -7.1 0.32 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 127.364 2.266 . . . . 0.0 115.695 176.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 23.4 m -115.73 30.2 7.5 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.534 1.533 . . . . 0.0 110.397 176.06 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 40.2 t -159.41 -55.77 0.06 Allowed 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.656 1.182 . . . . 0.0 110.723 170.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -94.77 141.52 28.53 Favored 'General case' 0 C--O 1.24 0.579 0 C-N-CA 124.058 0.943 . . . . 0.0 111.063 177.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.75 131.44 27.26 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 123.955 0.788 . . . . 0.0 112.5 175.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.0 114.05 2.84 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.759 2.306 . . . . 0.0 107.125 169.1 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.417 ' CE1' ' ND1' ' B' ' 71' ' ' HIS 0.27 0.0 OUTLIER 48.04 78.34 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.57 1.948 . . . . 0.0 114.125 -178.336 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -39.65 116.3 0.61 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.861 1.264 . . . . 0.0 110.559 169.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . 0.265 0.1 OUTLIER -122.41 73.37 40.32 Favored Pre-proline 0 CA--C 1.544 0.719 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -170.046 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -64.99 -24.78 59.84 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.821 2.347 . . . . 0.0 114.122 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.17 -6.43 56.54 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.077 0.951 . . . . 0.0 113.114 174.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.9 t 56.96 52.84 8.72 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.265 1.426 . . . . 0.0 113.508 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 mtp180 -109.34 179.1 4.25 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.662 1.185 . . . . 0.0 114.047 -169.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.97 175.44 9.07 Favored 'General case' 0 CA--C 1.548 0.885 0 O-C-N 120.591 -1.318 . . . . 0.0 108.633 162.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.417 ' ND1' ' CE1' ' B' ' 63' ' ' HIS . 83.6 t60 -110.85 152.47 26.64 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -167.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.488 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 143.35 -128.89 3.52 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-O 118.663 -1.076 . . . . 0.0 113.881 165.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 153.5 -40.05 0.69 Allowed Glycine 0 CA--C 1.546 1.969 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 176.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -112.23 29.99 0.03 OUTLIER 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 125.041 3.827 . . . . 0.0 111.608 169.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -158.93 -53.03 0.06 Allowed 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 127.745 2.418 . . . . 0.0 106.332 -178.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 8.8 t0 -85.3 155.46 21.34 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.917 1.687 . . . . 0.0 108.865 163.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -103.93 -17.25 15.08 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.467 1.507 . . . . 0.0 112.34 172.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -74.44 -39.52 62.52 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 120.807 -1.183 . . . . 0.0 112.334 -170.594 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.8 ptt85 33.28 90.92 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 127.33 2.252 . . . . 0.0 114.79 168.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.3 m80 -47.62 159.03 0.17 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.031 1.333 . . . . 0.0 112.511 178.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 4.8 m -71.08 87.29 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 119.063 0.847 . . . . 0.0 110.235 172.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.87 39.15 0.18 Allowed Glycine 0 CA--C 1.529 0.967 0 C-N-CA 126.361 1.934 . . . . 0.0 114.553 -173.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -134.33 118.08 17.09 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 125.466 1.506 . . . . 0.0 109.913 -173.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 95.9 mt -105.66 -179.24 3.88 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.936 0.894 . . . . 0.0 109.44 169.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.41 -134.75 3.35 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 122.214 0.897 . . . . 0.0 112.455 179.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . 0.474 HD22 HD11 ' B' ' 126' ' ' LEU . 2.2 m-80 -112.75 142.2 45.67 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.723 0.809 . . . . 0.0 110.611 170.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 17.9 m -109.02 92.79 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 126.69 1.996 . . . . 0.0 109.104 173.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.5 m -82.53 132.29 35.2 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 173.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.37 171.62 8.93 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -83.83 162.72 20.48 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.118 1.367 . . . . 0.0 107.351 164.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.434 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -57.14 -14.84 4.44 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 172.217 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -72.3 -13.66 61.55 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 125.763 1.625 . . . . 0.0 111.71 172.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.51 4.53 67.94 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.015 1.769 . . . . 0.0 113.294 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . 0.4 ' CG2' ' HB2' ' B' ' 34' ' ' SER . 7.1 p -102.73 130.23 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 125.565 1.546 . . . . 0.0 113.788 177.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.82 108.41 19.9 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 165.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -98.61 113.66 25.8 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.102 0.953 . . . . 0.0 110.76 175.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -93.47 156.23 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 125.33 1.452 . . . . 0.0 113.807 -169.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.0 p -156.87 117.83 3.68 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.935 1.294 . . . . 0.0 111.098 173.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.7 mt -146.1 150.81 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 C-N-CA 128.78 2.832 . . . . 0.0 109.906 -176.225 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 -137.57 131.11 31.18 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 125.371 1.468 . . . . 0.0 107.57 168.101 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -155.4 152.19 28.76 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.901 1.074 . . . . 0.0 113.901 -168.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 86.3 p -116.49 59.34 0.74 Allowed 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 125.977 1.711 . . . . 0.0 114.184 -167.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.0 p -147.26 -2.61 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 N-CA-C 116.357 1.984 . . . . 0.0 116.357 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.36 168.65 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 125.5 1.52 . . . . 0.0 110.785 177.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.439 ' H ' ' HB3' ' B' ' 111' ' ' SER . 57.9 p -147.97 170.42 17.75 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 115.571 1.693 . . . . 0.0 115.571 178.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mp -102.92 48.03 0.87 Allowed 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 168.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.3 m -85.27 33.66 0.56 Allowed 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.569 -1.332 . . . . 0.0 112.405 -176.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 87.97 65.77 1.33 Allowed Glycine 0 N--CA 1.469 0.862 0 C-N-CA 124.158 0.885 . . . . 0.0 112.767 176.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.315 0.0 OUTLIER 76.78 -21.74 0.31 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 127.673 2.389 . . . . 0.0 114.334 170.176 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -77.52 11.66 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 127.322 2.249 . . . . 0.0 112.886 -173.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . 0.439 ' HB3' ' H ' ' B' ' 105' ' ' SER . 0.6 OUTLIER -142.02 -72.2 0.33 Allowed 'General case' 0 CA--C 1.544 0.743 0 N-CA-C 116.512 2.041 . . . . 0.0 116.512 170.471 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.94 0.7 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 116.016 1.858 . . . . 0.0 116.016 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.6 mm -89.12 149.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 168.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . 0.482 ' HA2' ' HA2' ' A' ' 150' ' ' GLY . . . 77.72 6.78 87.19 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 114.561 0.585 . . . . 0.0 114.561 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 21.8 ttt180 -115.31 179.28 4.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.989 2.116 . . . . 0.0 111.462 -168.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.83 151.39 37.44 Favored 'General case' 0 CA--C 1.505 -0.786 0 C-N-CA 124.034 0.934 . . . . 0.0 111.124 177.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 19.5 tp -128.31 140.91 51.61 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 127.13 2.172 . . . . 0.0 106.572 167.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.37 156.38 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 124.362 1.065 . . . . 0.0 110.592 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -125.87 134.04 67.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-O 122.514 1.149 . . . . 0.0 110.697 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -92.34 145.85 24.15 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.426 1.49 . . . . 0.0 112.258 -168.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -67.62 -39.92 84.69 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 121.086 -1.009 . . . . 0.0 111.996 -174.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -98.69 -179.99 4.49 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.582 1.153 . . . . 0.0 109.962 167.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.59 165.49 0.83 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.697 1.199 . . . . 0.0 111.541 168.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.417 ' HB2' ' HA3' ' B' ' 44' ' ' GLY . 26.0 t70 -107.87 148.25 29.84 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 121.739 0.78 . . . . 0.0 110.662 165.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -79.73 -20.81 45.54 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.595 1.958 . . . . 0.0 114.807 -169.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.474 HD11 HD22 ' B' ' 86' ' ' ASN . 8.9 mt 41.61 49.02 3.65 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 126.238 1.815 . . . . 0.0 113.993 169.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 135.71 -78.56 0.34 Allowed Glycine 0 N--CA 1.469 0.839 0 C-N-CA 124.894 1.235 . . . . 0.0 111.288 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.86 148.4 22.42 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 117.585 2.439 . . . . 0.0 117.585 170.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -157.67 -79.5 0.03 OUTLIER Glycine 0 C--N 1.332 0.315 0 C-N-CA 130.287 3.803 . . . . 0.0 106.901 171.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.6 -92.87 0.02 OUTLIER Glycine 0 CA--C 1.528 0.853 0 C-N-CA 126.056 1.789 . . . . 0.0 115.955 -169.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -131.03 -127.54 0.2 Allowed 'General case' 0 CA--C 1.547 0.84 0 O-C-N 121.169 -1.195 . . . . 0.0 113.03 -166.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.32 -53.78 4.08 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.292 3.037 . . . . 0.0 109.949 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -43.46 -33.64 1.14 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 128.3 2.64 . . . . 0.0 114.03 169.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 25.8 m -45.33 -36.43 4.15 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 126.639 1.975 . . . . 0.0 113.702 168.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -103.3 -20.27 14.16 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 126.126 1.77 . . . . 0.0 113.886 -173.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 41.9 mtpt -80.6 -36.5 32.67 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.053 0.941 . . . . 0.0 110.745 170.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 20.0 p -135.95 -108.88 0.2 Allowed 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 127.324 2.249 . . . . 0.0 107.953 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -165.94 148.18 13.35 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 127.597 2.522 . . . . 0.0 108.151 169.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -75.42 45.56 0.3 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.54 1.536 . . . . 0.0 112.572 -172.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.51 6.24 24.38 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 116.486 2.032 . . . . 0.0 116.486 -167.015 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.61 -47.29 0.42 Allowed Glycine 0 CA--C 1.536 1.39 0 N-CA-C 118.948 2.339 . . . . 0.0 118.948 168.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.6 m -175.31 -176.93 0.97 Allowed 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.547 1.674 . . . . 0.0 112.406 -169.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.29 142.43 19.29 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.978 1.311 . . . . 0.0 111.591 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.453 HD23 HG11 ' B' ' 14' ' ' VAL . 0.0 OUTLIER -103.74 -20.7 13.86 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.706 1.203 . . . . 0.0 114.123 -176.218 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.449 ' N ' HD22 ' B' ' 144' ' ' LEU . . . -155.56 147.05 22.87 Favored 'General case' 0 C--O 1.244 0.775 0 C-N-CA 124.486 1.114 . . . . 0.0 109.195 -178.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 63.3 m -138.99 149.18 44.4 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 127.936 2.494 . . . . 0.0 108.774 -179.015 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.71 160.03 29.98 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 115.421 0.929 . . . . 0.0 115.421 -174.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.41 HG21 HG21 ' A' ' 7' ' ' VAL . 5.2 t -109.56 152.15 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.189 1.396 . . . . 0.0 109.789 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.3 mm -94.72 116.78 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 126.081 1.753 . . . . 0.0 112.07 -174.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.16 165.48 15.13 Favored Glycine 0 C--N 1.348 1.237 0 C-N-CA 124.358 0.98 . . . . 0.0 112.503 177.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -117.7 124.89 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -173.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.505 ' CA ' ' HA2' ' A' ' 51' ' ' GLY . . . -79.76 -25.06 41.12 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 121.596 0.712 . . . . 0.0 110.265 165.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 70.0 mt-30 . . . . . 0 CA--C 1.531 0.229 0 C-N-CA 125.74 1.616 . . . . 0.0 109.023 178.347 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.802 0 CA-C-O 120.336 0.112 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 34.7 p -84.24 118.4 24.14 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -171.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.4 ttmm -101.89 125.95 48.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.014 -1.903 . . . . 0.0 106.315 168.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.57 159.85 41.21 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 125.116 1.367 . . . . 0.0 111.325 -169.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 53.6 t -139.65 143.42 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-O 122.438 1.113 . . . . 0.0 112.907 -169.001 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.2 111.72 14.92 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 164.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.614 ' CG2' ' H ' ' B' ' 54' ' ' THR . 6.8 m -97.27 112.29 28.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 168.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.7 mp -96.87 107.61 20.14 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.529 1.132 . . . . 0.0 111.021 -168.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -155.29 124.4 6.23 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 121.782 0.801 . . . . 0.0 112.865 173.226 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.63 -41.34 0.02 OUTLIER Glycine 0 CA--C 1.53 0.985 0 C-N-CA 127.898 2.666 . . . . 0.0 109.478 167.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -79.26 59.37 2.79 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 128.337 2.655 . . . . 0.0 112.55 -174.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.96 -104.25 0.06 OUTLIER Glycine 0 CA--C 1.537 1.431 0 C-N-CA 126.867 2.175 . . . . 0.0 114.232 171.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.04 -9.6 14.13 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 124.656 3.571 . . . . 0.0 114.621 -175.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.6 t -90.41 138.69 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-N 120.448 1.476 . . . . 0.0 108.325 171.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -156.82 164.81 37.66 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.018 1.327 . . . . 0.0 109.944 169.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.04 174.02 34.64 Favored Glycine 0 CA--C 1.507 -0.42 0 C-N-CA 124.329 0.966 . . . . 0.0 111.432 167.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.1 pp -127.52 142.15 44.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 C-N-CA 124.533 1.133 . . . . 0.0 108.356 168.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.9 mm -130.19 133.83 63.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.708 . . . . 0.0 109.201 170.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -103.23 141.58 35.65 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 110.095 169.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -124.87 119.68 29.52 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 125.612 1.565 . . . . 0.0 108.24 171.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -115.85 119.33 35.64 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.346 1.459 . . . . 0.0 110.561 -175.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -129.62 141.83 50.86 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 123.506 1.622 . . . . 0.0 113.802 -174.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.478 ' HE2' ' OE2' ' A' ' 24' ' ' GLU . 15.0 ptmt -82.93 -62.7 1.53 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.742 2.017 . . . . 0.0 114.189 -171.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.478 ' OE2' ' HE2' ' A' ' 23' ' ' LYS . 3.7 pm0 -133.48 172.81 12.22 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 126.215 1.806 . . . . 0.0 110.668 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.5 p -45.06 -54.03 7.17 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.37 1.868 . . . . 0.0 115.434 -168.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -96.2 7.75 45.63 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.795 1.638 . . . . 0.0 111.73 -178.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.24 150.46 37.11 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 125.27 1.414 . . . . 0.0 113.627 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -63.66 162.85 26.48 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 C-N-CA 123.996 3.131 . . . . 0.0 110.373 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -129.86 130.76 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 C-N-CA 123.346 0.658 . . . . 0.0 110.046 -169.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -91.15 131.81 36.47 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 167.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.7 t -124.24 137.79 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 125.567 1.547 . . . . 0.0 109.132 -173.014 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 27.4 p90 -157.29 168.66 26.74 Favored 'General case' 0 N--CA 1.471 0.624 0 O-C-N 121.276 -0.89 . . . . 0.0 113.286 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.34 -157.68 27.35 Favored Glycine 0 C--N 1.335 0.498 0 C-N-CA 125.173 1.368 . . . . 0.0 111.204 170.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.5 p -155.5 147.5 23.44 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.3 mp -122.07 122.19 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 -177.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 59.8 tttt -120.81 133.44 55.32 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.317 1.047 . . . . 0.0 110.579 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.26 4.29 16.14 Favored Glycine 0 CA--C 1.539 1.583 0 C-N-CA 126.931 2.205 . . . . 0.0 112.645 -168.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 98.0 mt -82.89 163.38 21.16 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 118.201 1.0 . . . . 0.0 111.467 169.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.9 t -96.81 145.65 25.64 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 126.038 1.735 . . . . 0.0 107.475 165.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.486 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.8 pm0 -51.19 143.35 11.14 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 128.196 2.598 . . . . 0.0 114.739 -173.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.76 -179.81 34.42 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 125.012 1.292 . . . . 0.0 113.464 -172.159 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.2 mp -56.73 151.28 14.39 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 128.058 2.543 . . . . 0.0 113.555 -174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -147.96 138.82 23.22 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.905 1.682 . . . . 0.0 109.411 167.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.67 154.91 20.9 Favored Glycine 0 N--CA 1.48 1.604 0 C-N-CA 124.051 0.834 . . . . 0.0 113.115 172.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -158.58 95.37 1.32 Allowed 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 124.423 1.089 . . . . 0.0 112.262 -170.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -146.14 148.92 33.09 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.262 1.579 . . . . 0.0 115.262 -169.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -82.76 110.97 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.95 1.7 . . . . 0.0 110.186 171.517 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -82.65 165.97 19.56 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.795 2.038 . . . . 0.0 110.793 176.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -59.96 145.11 47.26 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 122.35 1.071 . . . . 0.0 111.469 -176.184 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -82.53 -114.93 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 125.709 1.604 . . . . 0.0 111.739 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.5 -96.06 1.73 Allowed Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 178.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -143.92 54.68 1.31 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 -172.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.407 HD21 ' CG2' ' A' ' 148' ' ' VAL 0.29 7.3 p-10 -73.39 27.98 0.07 Allowed 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.627 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.774 HG22 ' HA ' ' B' ' 7' ' ' VAL . 8.4 p -90.36 -7.37 53.42 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.352 1.461 . . . . 0.0 113.772 -168.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.19 -4.23 35.93 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.057 1.743 . . . . 0.0 112.97 168.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.92 -101.52 0.27 Allowed Glycine 0 C--N 1.343 0.941 0 CA-C-N 120.056 1.298 . . . . 0.0 112.519 170.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.4 m -54.83 -17.88 4.12 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 175.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.03 7.07 23.5 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.297 1.439 . . . . 0.0 113.521 175.267 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.4 t -171.85 98.0 0.17 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.94 1.696 . . . . 0.0 108.342 178.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 149.6 58.86 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 130.559 3.544 . . . . 0.0 111.687 -169.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -61.84 147.96 48.08 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 126.279 1.895 . . . . 0.0 114.123 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.77 95.17 0.54 Allowed 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 124.796 3.664 . . . . 0.0 113.765 -168.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 p80 42.95 68.2 0.53 Allowed 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 126.517 1.927 . . . . 0.0 112.485 166.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -39.28 142.87 0.22 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-O 124.009 1.861 . . . . 0.0 115.085 -167.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 38.9 p-10 -104.41 48.95 0.08 OUTLIER Pre-proline 0 CA--C 1.554 1.121 0 C-N-CA 127.11 2.164 . . . . 0.0 114.352 -177.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -69.77 -15.81 37.22 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 121.941 1.729 . . . . 0.0 112.473 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -78.68 -3.16 42.72 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.769 1.628 . . . . 0.0 112.325 169.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.1 t 69.97 57.72 0.29 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.662 1.585 . . . . 0.0 113.029 168.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.6 ptm85 -152.6 176.41 11.75 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -169.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -91.24 168.17 11.79 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.35 1.46 . . . . 0.0 112.705 -179.001 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.6 t60 -75.95 160.56 29.76 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 124.427 1.091 . . . . 0.0 113.512 179.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.419 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 136.41 -113.64 1.08 Allowed Glycine 0 C--N 1.339 0.713 0 C-N-CA 125.392 1.472 . . . . 0.0 112.315 166.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.488 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 116.93 -56.52 0.54 Allowed Glycine 0 CA--C 1.537 1.449 0 N-CA-C 117.742 1.857 . . . . 0.0 117.742 171.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -81.24 -16.69 9.52 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 CA-C-N 121.54 2.67 . . . . 0.0 112.505 178.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.51 -5.73 4.2 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.804 1.242 . . . . 0.0 112.893 173.104 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -102.5 169.3 8.75 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.462 1.505 . . . . 0.0 110.377 178.072 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -101.08 -7.07 23.54 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 127.083 2.153 . . . . 0.0 112.729 -167.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -127.35 -82.94 0.61 Allowed 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 119.597 1.09 . . . . 0.0 113.583 -171.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 79.12 140.55 0.07 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 126.289 1.836 . . . . 0.0 113.546 170.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 25.3 m170 -82.95 -177.77 6.88 Favored 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 116.361 1.986 . . . . 0.0 116.361 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -66.97 -12.13 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 N-CA-C 115.336 1.606 . . . . 0.0 115.336 174.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -134.81 14.03 4.43 Favored Glycine 0 CA--C 1.531 1.085 0 CA-C-O 118.161 -1.355 . . . . 0.0 116.31 -171.014 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -92.84 112.6 24.62 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.654 1.727 . . . . 0.0 111.275 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.4 48.72 1.38 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 120.101 1.319 . . . . 0.0 111.874 177.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 80.94 -143.98 24.65 Favored Glycine 0 CA--C 1.536 1.367 0 O-C-N 121.211 -0.931 . . . . 0.0 114.93 172.161 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -131.95 158.07 42.38 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 126.184 1.793 . . . . 0.0 112.883 -179.385 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.7 m -114.17 106.74 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 126.165 1.786 . . . . 0.0 111.001 169.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.4 m -106.49 115.61 30.5 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.599 1.56 . . . . 0.0 110.229 -169.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.13 147.79 24.74 Favored 'General case' 0 CA--C 1.539 0.558 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -172.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -93.96 160.65 14.63 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 128.978 2.911 . . . . 0.0 109.685 168.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.83 -14.9 2.65 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 126.169 1.788 . . . . 0.0 115.698 -175.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.27 -5.3 26.75 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.757 -1.215 . . . . 0.0 112.11 171.318 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.82 15.53 65.28 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 127.008 2.242 . . . . 0.0 112.878 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.0 p -121.33 128.87 76.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.544 1.172 . . . . 0.0 113.699 -170.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.64 110.56 22.66 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 164.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -91.9 137.27 32.5 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 169.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -135.68 149.65 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 N-CA-C 116.801 2.148 . . . . 0.0 116.801 -168.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.9 m -155.21 127.37 7.7 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 126.052 1.741 . . . . 0.0 110.367 169.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 10.1 mm -140.82 166.44 18.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 129.026 2.93 . . . . 0.0 109.794 -173.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -155.29 154.61 32.38 Favored 'General case' 0 C--N 1.316 -0.87 0 C-N-CA 128.108 2.563 . . . . 0.0 107.825 170.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -155.79 150.99 26.7 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.938 1.295 . . . . 0.0 111.577 170.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.4 p -119.03 53.05 1.02 Allowed 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.521 -1.218 . . . . 0.0 112.225 177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 48.9 t -137.81 -43.47 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.3 1.44 . . . . 0.0 107.928 168.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.87 160.11 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 123.027 1.394 . . . . 0.0 110.93 167.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.53 ' H ' ' HB3' ' A' ' 111' ' ' SER . 3.6 p -156.29 168.87 25.97 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 128.762 2.825 . . . . 0.0 106.969 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -93.25 102.3 14.58 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 179.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -152.83 -6.91 0.19 Allowed 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 -167.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.13 -95.83 2.13 Favored Glycine 0 C--N 1.336 0.546 0 O-C-N 120.927 -1.108 . . . . 0.0 111.613 173.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -69.97 -51.99 28.07 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.851 0.685 . . . . 0.0 112.851 -166.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -78.92 -27.81 43.78 Favored 'General case' 0 CA--C 1.539 0.547 0 O-C-N 120.271 -1.518 . . . . 0.0 112.358 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.53 ' HB3' ' H ' ' A' ' 105' ' ' SER . 8.2 m -118.88 -127.16 0.28 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.857 1.799 . . . . 0.0 115.857 -164.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.29 39.3 pt -111.03 173.69 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 O-C-N 119.769 -1.832 . . . . 0.0 108.682 166.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mm 90.49 136.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.843 1 C-N-CA 132.757 4.423 . . . . 0.0 107.25 -163.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 58.35 25.2 57.29 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 124.556 1.074 . . . . 0.0 114.687 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.1 ttm180 -122.17 156.29 34.0 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 126.614 1.965 . . . . 0.0 107.515 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.9 t -113.07 107.62 16.21 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 122.352 2.342 . . . . 0.0 115.694 -165.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 57.0 tp -76.99 128.92 35.39 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.72 0.808 . . . . 0.0 110.266 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 m -118.04 136.56 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.252 1.021 . . . . 0.0 109.127 169.352 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.4 m -93.04 144.74 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.384 -1.709 . . . . 0.0 106.384 168.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.7 m-70 -101.98 158.93 15.79 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-O 122.369 1.08 . . . . 0.0 112.987 -170.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -74.71 -35.64 62.71 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 -168.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -125.85 179.98 4.94 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 125.29 1.436 . . . . 0.0 112.597 173.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.25 140.47 38.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 126.683 1.993 . . . . 0.0 112.463 173.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -91.58 131.03 37.28 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.115 0.966 . . . . 0.0 111.057 178.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.419 ' OD1' ' HE3' ' A' ' 128' ' ' LYS . 0.3 OUTLIER -77.09 -18.93 57.65 Favored 'General case' 0 CA--C 1.554 1.118 0 N-CA-C 112.889 0.699 . . . . 0.0 112.889 174.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 41.3 mt 62.08 54.39 2.74 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 126.946 2.098 . . . . 0.0 113.686 173.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 118.62 -11.23 12.37 Favored Glycine 0 N--CA 1.475 1.246 0 N-CA-C 121.297 3.279 . . . . 0.0 121.297 164.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.541 ' HE3' ' H ' ' A' ' 128' ' ' LYS 0.252 0.0 OUTLIER -167.08 62.11 0.08 Allowed 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 118.192 2.664 . . . . 0.0 118.192 -173.626 . . . . . . . . 4 4 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -106.25 45.68 1.27 Allowed Glycine 0 N--CA 1.471 0.975 0 C-N-CA 127.041 2.257 . . . . 0.0 113.349 -172.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 76.21 -27.53 1.47 Allowed Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.62 1.105 . . . . 0.0 115.749 172.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -89.77 154.55 19.83 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 118.983 1.391 . . . . 0.0 110.381 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -55.33 -54.14 47.31 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-O 122.751 1.262 . . . . 0.0 109.108 167.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.4 tm-20 -51.89 -34.89 43.26 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 128.447 2.699 . . . . 0.0 112.593 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 52.0 p -60.03 -34.39 73.3 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.7 p -77.13 -14.37 59.81 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.61 1.164 . . . . 0.0 111.991 179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.3 mtpt -100.15 -53.76 3.05 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 126.516 1.926 . . . . 0.0 111.891 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.8 p -100.08 -34.42 10.07 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 117.659 -1.162 . . . . 0.0 113.781 -172.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.98 -3.2 28.64 Favored Glycine 0 CA--C 1.533 1.196 0 O-C-N 125.448 1.717 . . . . 0.0 113.715 -168.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.69 25.04 11.28 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 126.193 1.797 . . . . 0.0 112.738 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.82 46.39 0.29 Allowed 'General case' 0 CA--C 1.552 1.049 0 C-N-CA 126.799 2.04 . . . . 0.0 113.755 -168.157 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.04 -59.4 3.54 Favored Glycine 0 N--CA 1.467 0.728 0 C-N-CA 127.987 2.708 . . . . 0.0 113.692 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t 178.09 179.03 0.34 Allowed 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.11 2.164 . . . . 0.0 109.494 -169.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.64 153.66 35.02 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 121.03 -1.044 . . . . 0.0 111.018 169.75 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -135.14 -150.77 0.4 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.375 1.47 . . . . 0.0 108.63 169.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -52.93 141.96 20.64 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.274 1.43 . . . . 0.0 114.151 -173.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -134.72 154.67 51.46 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.983 1.313 . . . . 0.0 114.361 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.24 125.03 1.55 Allowed Glycine 0 CA--C 1.539 1.562 0 C-N-CA 124.646 1.117 . . . . 0.0 114.557 173.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.407 ' CG2' HD21 ' A' ' 53' ' ' ASN . 2.8 t -78.14 126.58 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 173.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 59.9 mt -78.41 124.51 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -167.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.76 167.97 13.96 Favored Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.847 1.213 . . . . 0.0 115.413 175.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.57 162.82 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 126.438 1.895 . . . . 0.0 113.416 -171.016 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.416 ' HB1' ' CD2' ' B' ' 50' ' ' PHE . . . -158.18 -40.97 0.06 Allowed 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.01 1.324 . . . . 0.0 112.032 169.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.47 0.538 0 C-N-CA 124.226 1.01 . . . . 0.0 112.159 169.096 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 70.9 p -134.08 125.43 28.02 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 166.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 14.3 mtmt -119.57 158.54 26.13 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -179.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.492 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -144.58 151.99 39.87 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.98 1.312 . . . . 0.0 112.534 169.589 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 p -111.08 133.53 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 125.987 1.715 . . . . 0.0 110.673 177.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.54 110.94 21.3 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.774 -1.204 . . . . 0.0 110.088 167.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 54' ' ' THR . 15.0 t -86.52 68.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 124.36 1.064 . . . . 0.0 112.063 -170.396 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -79.77 110.56 15.24 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 113.426 0.898 . . . . 0.0 113.426 -175.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mttm -157.62 129.55 7.03 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.71 1.204 . . . . 0.0 112.195 167.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.68 -56.9 0.01 OUTLIER Glycine 0 N--CA 1.468 0.772 0 C-N-CA 126.233 1.873 . . . . 0.0 109.885 169.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.58 72.29 3.24 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 125.989 1.715 . . . . 0.0 110.953 -176.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.64 -94.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.377 0 C-N-CA 127.844 2.64 . . . . 0.0 114.746 173.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -71.08 -20.98 28.03 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 123.964 3.109 . . . . 0.0 114.797 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 62.1 t -74.15 147.65 8.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 CA-C-N 121.483 1.947 . . . . 0.0 110.491 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.32 167.75 21.2 Favored 'General case' 0 CA--C 1.519 -0.228 0 C-N-CA 124.48 1.112 . . . . 0.0 109.651 167.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.8 59.58 0.4 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.874 169.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -75.41 127.42 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 117.776 0.788 . . . . 0.0 108.987 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.18 119.55 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 O-C-N 125.277 1.61 . . . . 0.0 109.741 176.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.2 121.27 23.41 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 124.915 1.286 . . . . 0.0 110.65 165.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -99.67 94.17 6.22 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 126.26 1.824 . . . . 0.0 106.135 167.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -98.25 113.66 25.67 Favored 'General case' 0 C--O 1.233 0.217 0 C-N-CA 124.311 1.044 . . . . 0.0 110.349 178.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -113.13 139.01 49.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 122.678 1.228 . . . . 0.0 110.464 179.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.71 -5.05 54.43 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 125.1 1.36 . . . . 0.0 114.237 -171.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 mp0 -155.75 -168.24 2.73 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 130.078 3.351 . . . . 0.0 106.603 175.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 26.8 t -89.2 -21.13 23.43 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-N 119.957 1.253 . . . . 0.0 110.135 163.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -109.6 11.32 24.8 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 126.191 1.796 . . . . 0.0 115.232 -176.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.77 -179.75 38.85 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 124.423 1.011 . . . . 0.0 112.834 -177.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.23 161.47 20.23 Favored 'Trans proline' 0 CA--C 1.537 0.654 0 C-N-CA 123.346 2.697 . . . . 0.0 109.421 168.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 4.7 t -116.01 134.94 57.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.89 0.876 . . . . 0.0 111.734 -169.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.6 mttp -87.84 126.14 34.86 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 165.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 47.9 t -123.75 89.03 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 127.362 2.265 . . . . 0.0 108.23 -169.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -119.09 156.24 30.08 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.799 0.84 . . . . 0.0 111.815 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 172.84 176.82 41.71 Favored Glycine 0 C--O 1.225 -0.439 0 O-C-N 121.479 -0.763 . . . . 0.0 113.437 -174.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -127.75 118.78 24.41 Favored 'General case' 0 C--O 1.239 0.543 0 O-C-N 122.054 -0.674 . . . . 0.0 111.948 -178.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.1 mm -92.08 117.8 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 169.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.3 pttt -139.41 137.34 35.58 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 123.185 0.594 . . . . 0.0 110.328 -168.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.29 0.68 54.01 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.871 1.7 . . . . 0.0 114.787 -173.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.464 HD11 ' HB2' ' B' ' 89' ' ' ALA . 0.5 OUTLIER -91.3 -160.35 0.72 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 118.412 1.106 . . . . 0.0 111.304 169.676 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 5.6 t -112.19 155.99 23.06 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.293 1.837 . . . . 0.0 110.976 178.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -47.65 149.85 1.13 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.625 1.97 . . . . 0.0 111.879 169.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.75 38.8 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 124.009 0.814 . . . . 0.0 113.726 -178.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -65.87 144.51 56.77 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 128.921 2.888 . . . . 0.0 113.157 -171.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -140.53 124.05 16.97 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 126.608 1.963 . . . . 0.0 110.508 177.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.5 149.85 35.45 Favored Glycine 0 N--CA 1.476 1.334 0 C-N-CA 124.744 1.164 . . . . 0.0 112.391 176.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -146.52 102.2 3.55 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-O 121.861 0.838 . . . . 0.0 112.404 -164.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -129.45 126.23 38.26 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 120.855 -1.153 . . . . 0.0 110.427 -169.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.79 116.69 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.296 1.439 . . . . 0.0 108.984 171.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.458 ' C ' ' H ' ' B' ' 50' ' ' PHE . 21.8 m170 -78.86 122.25 25.85 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 121.307 -0.871 . . . . 0.0 110.381 -179.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.65 2.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 127.053 2.141 . . . . 0.0 115.426 170.03 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . 0.458 ' H ' ' C ' ' B' ' 48' ' ' HIS . 2.5 m-85 -137.16 81.51 1.88 Allowed 'General case' 0 N--CA 1.442 -0.839 1 C-N-CA 133.776 4.83 . . . . 0.0 100.94 -176.011 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.05 20.07 35.04 Favored Glycine 0 N--CA 1.467 0.73 0 O-C-N 121.655 -0.653 . . . . 0.0 113.225 173.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -68.99 49.06 0.07 Allowed 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.042 2.537 . . . . 0.0 113.085 171.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -178.74 131.45 0.12 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.414 1.486 . . . . 0.0 111.047 -168.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.614 ' H ' ' CG2' ' A' ' 7' ' ' VAL . 6.6 t -152.31 14.7 0.6 Allowed 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 116.236 1.939 . . . . 0.0 116.236 175.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.44 25.58 10.52 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-N 119.293 0.951 . . . . 0.0 110.901 167.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.25 -119.63 15.17 Favored Glycine 0 C--N 1.341 0.818 0 C-N-CA 124.634 1.111 . . . . 0.0 112.148 170.359 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 20.7 m -68.34 -24.28 64.8 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 118.161 -0.923 . . . . 0.0 113.395 174.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 8.5 m -81.54 45.83 0.91 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 120.287 1.403 . . . . 0.0 109.258 171.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 15.7 m -170.97 -59.71 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.922 1.689 . . . . 0.0 111.633 -176.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.05 172.93 15.54 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 -168.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.52 -82.19 0.51 Allowed Glycine 0 CA--C 1.54 1.616 0 C-N-CA 126.842 2.163 . . . . 0.0 112.059 178.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.44 ' HA ' HG22 ' B' ' 137' ' ' THR . 66.9 Cg_endo -85.83 178.14 4.43 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 125.15 3.9 . . . . 0.0 115.139 -172.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -103.4 123.8 47.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 125.203 1.401 . . . . 0.0 110.796 179.386 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -58.26 146.9 32.47 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 120.789 0.328 . . . . 0.0 110.418 167.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.21 107.73 21.56 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.597 0.759 . . . . 0.0 112.515 -178.179 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -68.81 -30.85 26.4 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.135 1.89 . . . . 0.0 111.844 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -76.98 -7.81 56.28 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.096 0.959 . . . . 0.0 112.709 175.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 33.7 m 57.76 56.46 4.8 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.627 1.171 . . . . 0.0 111.743 172.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.89 172.69 15.64 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.394 1.478 . . . . 0.0 110.704 -168.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -72.5 176.68 5.19 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 -171.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -49.23 155.09 0.73 Allowed 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 116.447 2.017 . . . . 0.0 116.447 -167.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' B' ' 79' ' ' ARG . . . -75.61 69.33 2.07 Favored Glycine 0 N--CA 1.473 1.144 0 C-N-CA 128.892 3.139 . . . . 0.0 114.212 -169.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.46 135.84 13.62 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 114.608 0.603 . . . . 0.0 114.608 -173.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -84.58 -0.95 9.52 Favored 'Trans proline' 0 CA--C 1.548 1.207 0 C-N-CA 123.87 3.047 . . . . 0.0 109.597 163.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.472 ' HE2' ' O ' ' B' ' 125' ' ' ASP . 0.1 OUTLIER -118.37 -10.61 10.15 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.642 1.977 . . . . 0.0 114.167 177.613 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -110.7 149.48 30.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.362 1.065 . . . . 0.0 109.022 -167.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -67.35 -25.53 66.03 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -88.65 146.22 25.21 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-O 125.07 2.367 . . . . 0.0 109.319 169.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.49 ' HA ' ' HA2' ' B' ' 72' ' ' GLY . 52.9 ttt-85 -167.03 106.67 0.6 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 112.545 -2.116 . . . . 0.0 113.293 -174.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -61.59 149.33 39.47 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.401 1.081 . . . . 0.0 109.157 162.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.3 -13.66 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 CA-C-N 120.891 1.678 . . . . 0.0 110.323 166.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.28 18.82 9.37 Favored Glycine 0 C--N 1.336 0.548 0 C-N-CA 127.235 2.35 . . . . 0.0 118.879 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.99 149.43 32.15 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 122.608 3.204 . . . . 0.0 112.917 168.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -107.64 174.95 5.66 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.575 1.55 . . . . 0.0 108.561 168.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.48 155.31 49.79 Favored Glycine 0 CA--C 1.529 0.949 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 171.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -74.4 146.61 42.8 Favored 'General case' 0 CA--C 1.549 0.941 0 CA-C-O 121.658 0.742 . . . . 0.0 111.825 -170.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -101.21 119.56 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 125.996 1.719 . . . . 0.0 112.48 -168.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -98.58 126.88 44.3 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.331 1.052 . . . . 0.0 110.283 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.464 ' HB2' HD11 ' B' ' 38' ' ' LEU . . . -92.95 162.13 14.19 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 171.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -85.97 168.99 13.66 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.889 2.075 . . . . 0.0 113.123 170.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.91 -26.24 61.93 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 126.644 1.978 . . . . 0.0 114.963 -177.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.35 2.35 18.89 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 125.643 1.577 . . . . 0.0 112.146 177.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.16 21.75 56.32 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 124.936 1.255 . . . . 0.0 113.458 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.13 134.39 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 114.561 1.319 . . . . 0.0 114.561 -179.091 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -106.09 130.3 54.02 Favored 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 124.828 1.251 . . . . 0.0 110.445 166.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -88.27 105.62 17.67 Favored 'General case' 0 C--O 1.232 0.165 0 N-CA-C 104.869 -2.271 . . . . 0.0 104.869 163.126 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.93 129.9 36.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 114.954 -1.021 . . . . 0.0 108.631 169.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.1 m -146.38 94.21 2.42 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.387 1.075 . . . . 0.0 109.305 -176.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.8 mt -130.9 159.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 126.346 1.858 . . . . 0.0 110.281 -174.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -139.77 142.2 36.77 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 128.077 2.551 . . . . 0.0 106.584 167.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -151.12 138.15 19.13 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.293 1.037 . . . . 0.0 111.876 -168.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 46.3 p -118.0 50.3 1.16 Allowed 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 177.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 1.1 p -147.26 4.64 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 171.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -122.71 160.89 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.576 1.551 . . . . 0.0 107.409 167.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 96.8 p -156.24 168.36 27.55 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 119.49 1.041 . . . . 0.0 113.626 -174.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -92.59 69.07 4.83 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.521 1.528 . . . . 0.0 110.055 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 5.7 m -117.56 160.02 21.92 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.775 1.63 . . . . 0.0 110.727 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 44.98 1.82 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 125.146 1.355 . . . . 0.0 114.468 -168.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -135.54 -84.63 0.39 Allowed 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.872 1.269 . . . . 0.0 110.449 -168.691 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -150.35 -2.82 0.37 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 127.74 2.416 . . . . 0.0 111.773 -176.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 95.0 p -61.09 -44.4 97.42 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 125.131 1.373 . . . . 0.0 114.11 -169.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 5.3 pt -154.16 -34.35 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 C-N-CA 127.678 2.391 . . . . 0.0 111.223 166.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 45.1 mm -60.56 125.37 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 123.866 0.867 . . . . 0.0 108.765 -175.034 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.56 16.23 67.3 Favored Glycine 0 CA--C 1.527 0.789 0 CA-C-O 116.994 -2.003 . . . . 0.0 115.061 -178.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 24.4 mtm180 -79.62 168.21 19.68 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-N 119.841 1.82 . . . . 0.0 109.478 168.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 22.6 m -123.64 117.04 24.1 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.806 0.842 . . . . 0.0 110.31 175.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 37.6 tp -82.23 132.12 35.23 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 169.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -110.91 137.43 43.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.534 1.534 . . . . 0.0 108.751 165.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 p -109.77 130.36 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.968 0.89 . . . . 0.0 109.417 168.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.539 ' CE1' HH11 ' B' ' 143' ' ' ARG . 21.7 m-70 -99.91 161.12 13.8 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.527 1.131 . . . . 0.0 113.669 -172.167 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -76.42 -25.49 54.52 Favored 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.701 1.371 . . . . 0.0 114.701 -174.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -118.85 176.68 5.16 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 119.667 1.121 . . . . 0.0 112.415 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.71 164.3 2.14 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.151 1.38 . . . . 0.0 111.967 168.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -113.97 145.08 42.03 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.949 1.7 . . . . 0.0 110.546 -178.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . 0.472 ' O ' ' HE2' ' B' ' 75' ' ' LYS . 0.0 OUTLIER -73.95 -35.46 64.55 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-O 118.775 -0.631 . . . . 0.0 111.214 172.38 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 11.6 mt 77.54 24.61 0.77 Allowed 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.015 2.126 . . . . 0.0 113.481 177.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 179.83 -78.9 0.06 OUTLIER Glycine 0 N--CA 1.474 1.182 0 CA-C-N 120.47 1.486 . . . . 0.0 116.657 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -156.22 87.67 1.06 Allowed 'General case' 0 N--CA 1.44 -0.925 0 C-N-CA 126.38 1.872 . . . . 0.0 110.93 173.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . 0.566 ' H ' ' HB2' ' B' ' 134' ' ' SER . . . -65.64 -10.99 52.24 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 126.836 2.16 . . . . 0.0 114.081 174.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.16 -33.8 2.47 Favored Glycine 0 N--CA 1.47 0.948 0 C-N-CA 124.366 0.984 . . . . 0.0 114.942 168.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.6 p30 -92.79 -177.78 4.64 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.498 1.519 . . . . 0.0 110.366 -177.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -61.5 -62.66 1.66 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 122.773 0.429 . . . . 0.0 110.351 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . 0.427 ' HB3' HD22 ' B' ' 139' ' ' ASN . 0.8 OUTLIER -42.06 -30.75 0.3 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 129.278 3.031 . . . . 0.0 115.572 -176.039 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.566 ' HB2' ' H ' ' B' ' 129' ' ' GLY . 97.1 p -63.07 -41.84 99.53 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.373 1.469 . . . . 0.0 113.333 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 72.7 p -81.93 -30.57 31.72 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 123.834 0.854 . . . . 0.0 113.208 173.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -70.85 -53.15 16.31 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.704 2.002 . . . . 0.0 110.226 -177.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.44 HG22 ' HA ' ' B' ' 62' ' ' PRO . 74.6 p -111.54 -113.63 0.32 Allowed 'General case' 0 C--N 1.342 0.253 0 C-N-CA 128.207 2.603 . . . . 0.0 106.33 172.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -144.19 12.2 2.07 Favored Glycine 0 CA--C 1.535 1.291 0 C-N-CA 130.191 3.758 . . . . 0.0 111.874 169.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . 0.427 HD22 ' HB3' ' B' ' 133' ' ' GLU . 5.3 t-20 56.64 14.89 1.9 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.889 1.675 . . . . 0.0 113.814 -172.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.42 22.21 0.03 OUTLIER 'General case' 0 CA--C 1.561 1.39 0 N-CA-C 116.563 2.061 . . . . 0.0 116.563 -168.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.11 -169.81 52.12 Favored Glycine 0 CA--C 1.529 0.963 0 O-C-N 120.136 -1.603 . . . . 0.0 113.295 -171.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.06 -169.85 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.279 1.432 . . . . 0.0 110.906 174.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.539 HH11 ' CE1' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -137.3 146.5 44.72 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 115.622 1.712 . . . . 0.0 115.622 175.241 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.7 -121.96 0.06 Allowed 'General case' 0 CA--C 1.536 0.406 0 O-C-N 127.182 2.801 . . . . 0.0 106.451 164.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.35 154.86 41.37 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 122.932 1.349 . . . . 0.0 114.467 -166.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -139.16 152.02 47.09 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 126.381 1.872 . . . . 0.0 109.246 169.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.58 141.88 7.73 Favored Glycine 0 C--N 1.333 0.414 0 N-CA-C 114.369 0.508 . . . . 0.0 114.369 176.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.7 t -79.74 153.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.891 1.276 . . . . 0.0 110.464 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.19 109.73 20.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 124.878 1.271 . . . . 0.0 112.409 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -103.53 164.37 15.52 Favored Glycine 0 C--N 1.35 1.339 0 C-N-CA 125.204 1.383 . . . . 0.0 112.761 174.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.59 HG22 ' H ' ' B' ' 153' ' ' GLN . 2.6 mp -87.36 113.37 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 O-C-N 121.548 -0.972 . . . . 0.0 112.193 -168.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.492 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -82.42 16.57 2.03 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 128.112 2.565 . . . . 0.0 112.658 169.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . 0.59 ' H ' HG22 ' B' ' 151' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.436 0 C-N-CA 128.804 2.842 . . . . 0.0 111.991 170.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.925 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.5 t -159.64 132.52 6.8 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 124.981 1.312 . . . . 0.0 108.956 172.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -94.5 145.83 24.52 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 173.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.496 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -94.33 164.44 13.02 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 121.109 -0.994 . . . . 0.0 111.789 168.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.56 HG11 ' H ' ' B' ' 53' ' ' ASN . 1.2 p -112.45 164.22 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 172.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -147.77 81.25 1.5 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.993 1.317 . . . . 0.0 108.007 160.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.0 t -77.45 89.14 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.16 141.5 37.17 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.381 1.072 . . . . 0.0 112.167 -172.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -155.59 175.96 13.23 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 169.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 160.12 -95.08 0.14 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 127.283 2.373 . . . . 0.0 109.706 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -78.33 87.16 4.38 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 126.629 1.972 . . . . 0.0 112.406 -169.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.08 -98.05 0.01 OUTLIER Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.991 2.234 . . . . 0.0 114.003 168.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -78.4 -2.35 12.42 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 125.191 3.927 . . . . 0.0 115.284 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.5 t -79.0 139.1 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 120.312 1.415 . . . . 0.0 110.389 171.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -148.6 170.45 18.09 Favored 'General case' 0 N--CA 1.462 0.169 0 C-N-CA 125.617 1.567 . . . . 0.0 110.494 169.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.57 162.76 28.73 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 114.877 -1.056 . . . . 0.0 111.559 165.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.3 tp -156.87 80.71 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 126.609 1.964 . . . . 0.0 107.737 -177.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mm -98.42 143.97 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.123 0.569 . . . . 0.0 110.1 175.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -114.7 148.99 37.49 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 128.93 2.892 . . . . 0.0 109.42 175.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.496 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 57.8 m-85 -141.78 82.11 1.79 Allowed 'General case' 0 CA--C 1.557 1.216 0 C-N-CA 123.983 0.913 . . . . 0.0 112.757 -178.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.446 ' HG2' ' CZ3' ' A' ' 32' ' ' TRP . 1.2 pt-20 -78.97 130.54 35.67 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 121.367 1.894 . . . . 0.0 114.755 -174.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.547 HE22 ' C ' ' A' ' 24' ' ' GLU . 0.0 OUTLIER -116.87 155.29 29.29 Favored 'General case' 0 CA--C 1.535 0.377 0 O-C-N 120.459 -1.4 . . . . 0.0 111.976 173.059 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -56.06 2.39 Favored 'General case' 0 CA--C 1.556 1.189 0 C-N-CA 125.29 1.436 . . . . 0.0 112.64 -169.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.547 ' C ' HE22 ' A' ' 22' ' ' GLN . 0.4 OUTLIER -138.89 153.3 48.27 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 128.82 2.848 . . . . 0.0 107.739 169.406 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -48.45 -17.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 118.545 2.795 . . . . 0.0 118.545 -166.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -118.94 0.61 11.38 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.528 1.931 . . . . 0.0 113.405 -176.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.25 177.41 54.26 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.936 0.779 . . . . 0.0 112.829 176.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.91 177.52 8.62 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.293 3.329 . . . . 0.0 110.907 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 87.8 t -128.96 132.65 67.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 123.066 0.546 . . . . 0.0 110.128 178.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.43 122.39 34.83 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.9 t -103.47 128.02 56.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 C-N-CA 126.002 1.721 . . . . 0.0 108.662 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.446 ' CZ3' ' HG2' ' A' ' 21' ' ' GLU . 3.1 p90 -144.83 157.71 44.06 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 122.84 0.456 . . . . 0.0 111.608 170.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 127.38 178.87 15.52 Favored Glycine 0 N--CA 1.463 0.465 0 O-C-N 121.259 -0.9 . . . . 0.0 112.427 -178.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 m -127.57 159.21 35.3 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 117.009 2.226 . . . . 0.0 117.009 -164.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 19.5 mm -123.73 124.5 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 127.2 2.2 . . . . 0.0 108.131 167.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -130.81 136.21 48.47 Favored 'General case' 0 CA--C 1.54 0.573 0 O-C-N 120.872 -1.142 . . . . 0.0 111.054 -169.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.41 -11.94 11.28 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 126.238 1.875 . . . . 0.0 113.557 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.9 mp -62.1 141.92 57.86 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 127.161 2.184 . . . . 0.0 109.062 169.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.6 t -71.59 -41.74 68.58 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -176.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 176.03 -160.62 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.743 1 C-N-CA 133.21 4.604 . . . . 0.0 105.168 178.469 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 74.24 173.42 29.28 Favored Glycine 0 N--CA 1.473 1.112 0 N-CA-C 117.165 1.626 . . . . 0.0 117.165 165.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 mp -79.19 152.41 30.7 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.002 1.321 . . . . 0.0 109.61 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -153.1 142.15 21.33 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.872 1.669 . . . . 0.0 112.82 -171.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 119' ' ' VAL . . . -57.22 163.23 7.18 Favored Glycine 0 N--CA 1.478 1.457 0 C-N-CA 124.867 1.223 . . . . 0.0 115.141 -174.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -160.45 84.55 0.71 Allowed 'General case' 0 CA--C 1.548 0.875 0 CA-C-O 122.672 1.225 . . . . 0.0 113.502 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -133.18 142.37 48.59 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 120.036 -1.665 . . . . 0.0 110.961 -171.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.562 HG23 ' HA2' ' A' ' 82' ' ' GLY . 11.4 m -109.23 128.71 64.96 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.167 0 CA-C-O 121.957 0.884 . . . . 0.0 109.046 176.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.8 m170 -76.09 156.8 33.54 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.762 -174.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -74.95 130.85 40.1 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 71.12 169.34 0.32 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-O 124.848 2.261 . . . . 0.0 113.862 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.68 11.01 56.29 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 129.589 3.471 . . . . 0.0 114.078 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.643 ' HA ' HG21 ' B' ' 5' ' ' VAL . 1.9 p30 -78.95 47.29 0.75 Allowed 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 121.27 2.535 . . . . 0.0 109.97 168.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.468 ' H ' ' ND2' ' A' ' 53' ' ' ASN 0.31 0.1 OUTLIER -90.13 45.62 1.28 Allowed 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 115.533 1.679 . . . . 0.0 115.533 -165.661 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.521 HG22 ' HA ' ' B' ' 7' ' ' VAL . 19.4 p -119.91 -38.06 3.01 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -163.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.26 13.13 24.4 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 126.206 1.802 . . . . 0.0 112.9 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.48 -123.87 34.16 Favored Glycine 0 C--N 1.341 0.852 0 C-N-CA 125.112 1.339 . . . . 0.0 111.512 175.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 70.2 m -58.82 -13.77 7.06 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.827 1.417 . . . . 0.0 114.827 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.57 1.43 29.68 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.004 1.322 . . . . 0.0 112.081 173.135 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.2 m -158.54 -131.21 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.994 0 C-N-CA 127.253 2.221 . . . . 0.0 108.209 -174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -32.34 95.35 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 128.002 2.521 . . . . 0.0 114.638 -173.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.6 162.24 53.92 Favored Glycine 0 CA--C 1.531 1.04 0 N-CA-C 115.301 0.88 . . . . 0.0 115.301 -167.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -69.24 84.57 0.57 Allowed 'Trans proline' 0 C--N 1.354 0.855 1 C-N-CA 125.963 4.442 . . . . 0.0 111.104 -173.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.5 p80 51.65 59.29 4.67 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 127.971 2.509 . . . . 0.0 110.808 169.049 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -56.05 167.05 0.66 Allowed 'General case' 0 N--CA 1.445 -0.723 0 CA-C-O 126.043 2.83 . . . . 0.0 112.443 -173.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.525 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.4 p-10 -118.88 73.67 12.3 Favored Pre-proline 0 C--N 1.314 -0.938 0 CA-C-N 110.837 -2.892 . . . . 0.0 112.275 -169.087 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -62.45 -23.72 75.14 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.018 2.479 . . . . 0.0 113.44 176.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 27.7 tp -86.64 -3.63 59.06 Favored 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.477 1.511 . . . . 0.0 113.191 170.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.7 t 68.15 49.69 0.83 Allowed 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 127.609 2.364 . . . . 0.0 112.578 176.377 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.525 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 7.9 mtp180 -106.67 170.91 7.65 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 115.224 1.564 . . . . 0.0 115.224 -168.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.5 mtmt -74.04 162.06 29.41 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.35 1.46 . . . . 0.0 109.247 164.434 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -86.83 142.63 27.94 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 172.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.415 ' HA2' ' HB3' ' A' ' 126' ' ' LEU . . . 147.4 -123.71 1.8 Allowed Glycine 0 C--N 1.341 0.815 0 N-CA-C 117.059 1.584 . . . . 0.0 117.059 164.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.47 -38.96 2.32 Favored Glycine 0 CA--C 1.546 1.998 0 N-CA-C 118.207 2.043 . . . . 0.0 118.207 -169.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -99.61 11.82 0.64 Allowed 'Trans proline' 0 CA--C 1.546 1.123 0 C-N-CA 123.955 3.104 . . . . 0.0 113.684 -176.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.67 -30.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 128.275 2.63 . . . . 0.0 109.893 167.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.411 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 5.3 t70 -75.31 152.89 38.13 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-O 122.153 0.978 . . . . 0.0 109.232 163.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -89.59 -26.13 20.96 Favored 'General case' 0 C--N 1.321 -0.664 1 C-N-CA 131.708 4.003 . . . . 0.0 111.679 -173.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -92.04 -71.29 0.65 Allowed 'General case' 0 C--N 1.34 0.164 0 N-CA-C 114.307 1.225 . . . . 0.0 114.307 -169.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 21.4 ttt180 69.95 116.99 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.779 1.632 . . . . 0.0 112.861 -175.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -57.79 163.01 2.81 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 119.388 -2.07 . . . . 0.0 113.902 171.159 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.25 -38.16 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 119.353 0.979 . . . . 0.0 111.738 170.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.562 ' HA2' HG23 ' A' ' 47' ' ' VAL . . . -88.43 45.12 3.23 Favored Glycine 0 CA--C 1.533 1.158 0 N-CA-C 114.992 0.757 . . . . 0.0 114.992 177.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -137.44 134.46 35.87 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 120.824 -1.398 . . . . 0.0 111.154 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 14.0 mt -127.6 53.49 1.75 Allowed 'General case' 0 CA--C 1.546 0.817 0 CA-C-O 122.111 0.958 . . . . 0.0 109.107 165.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.54 -138.26 42.76 Favored Glycine 0 C--N 1.342 0.882 0 C-N-CA 125.577 1.56 . . . . 0.0 113.129 172.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -141.71 150.86 42.39 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 124.031 0.933 . . . . 0.0 110.137 168.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 p -96.76 178.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 C-N-CA 127.659 2.384 . . . . 0.0 110.651 -174.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 83.1 m -149.96 138.2 20.47 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 124.973 1.309 . . . . 0.0 110.056 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -105.15 140.45 38.29 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.105 1.362 . . . . 0.0 114.641 -176.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -77.79 146.03 36.06 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.761 1.624 . . . . 0.0 109.775 166.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.93 -16.35 0.13 Allowed 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 130.066 3.346 . . . . 0.0 118.08 175.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -75.26 1.23 14.09 Favored 'General case' 0 N--CA 1.485 1.291 0 CA-C-N 119.762 1.164 . . . . 0.0 110.776 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.25 43.52 4.95 Favored Glycine 0 C--N 1.336 0.551 0 C-N-CA 128.054 2.74 . . . . 0.0 112.408 171.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.8 p -155.38 132.22 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-N 119.562 1.681 . . . . 0.0 115.14 -175.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.75 107.64 20.13 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 165.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -98.37 144.59 27.6 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.658 0.742 . . . . 0.0 110.088 169.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -121.92 146.11 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 N-CA-C 115.07 1.507 . . . . 0.0 115.07 -174.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.8 t -159.47 81.34 0.75 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 126.712 2.005 . . . . 0.0 111.837 175.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -127.95 158.08 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 127.152 2.181 . . . . 0.0 110.917 -174.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -126.15 138.63 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 167.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -134.45 145.8 49.19 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.273 1.029 . . . . 0.0 112.718 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 12.4 p -120.5 48.58 1.57 Allowed 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 114.575 1.324 . . . . 0.0 114.575 -179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 30.0 m -139.35 3.95 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 168.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.35 139.18 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.819 1.248 . . . . 0.0 109.043 168.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 46.6 p -112.04 176.69 4.92 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-N 118.718 0.69 . . . . 0.0 111.123 169.031 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.8 mt -82.31 107.64 15.14 Favored 'General case' 0 C--N 1.345 0.4 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 167.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -136.98 -13.24 1.65 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.47 31.97 71.34 Favored Glycine 0 C--N 1.342 0.879 0 CA-C-N 119.884 1.22 . . . . 0.0 115.155 172.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -170.44 -103.32 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.802 1.241 . . . . 0.0 108.026 -169.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -79.43 8.74 5.7 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.34 2.256 . . . . 0.0 112.329 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 55.5 m -149.85 -161.53 1.36 Allowed 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.241 1.416 . . . . 0.0 109.438 165.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 15.3 pt -82.41 161.37 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 O-C-N 120.171 -1.581 . . . . 0.0 113.835 -168.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.445 HD11 ' HB2' ' A' ' 4' ' ' ALA . 2.3 mm 106.44 147.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 1 C-N-CA 135.023 5.329 . . . . 0.0 110.118 -167.155 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.47 2.73 56.02 Favored Glycine 0 C--O 1.219 -0.803 0 CA-C-O 117.319 -1.823 . . . . 0.0 114.838 174.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 34.8 mtt-85 -106.22 -176.14 2.99 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.898 2.479 . . . . 0.0 110.338 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 9.0 t -120.29 145.43 47.08 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 119.554 1.07 . . . . 0.0 110.934 169.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.0 tp -101.32 133.52 45.78 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 127.086 2.154 . . . . 0.0 109.723 170.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.46 147.8 18.61 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.512 1.525 . . . . 0.0 110.576 168.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.57 HG12 HD21 ' A' ' 144' ' ' LEU . 91.7 t -129.03 151.15 35.36 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.676 0 C-N-CA 126.067 1.747 . . . . 0.0 107.035 173.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 74.3 m-70 -124.25 133.8 53.41 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.365 1.066 . . . . 0.0 113.17 -168.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.267 24.2 tp10 -84.81 39.07 0.73 Allowed 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 -167.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 30.6 mttt -154.15 160.48 41.92 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.44 1.896 . . . . 0.0 109.5 169.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.57 118.36 8.08 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 169.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.5 157.93 20.3 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-O 122.477 1.132 . . . . 0.0 112.208 -177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -90.81 -9.49 46.27 Favored 'General case' 0 CA--C 1.552 1.057 0 C-N-CA 128.587 2.755 . . . . 0.0 113.076 -169.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.415 ' HB3' ' HA2' ' A' ' 72' ' ' GLY . 2.3 mp 1.54 79.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 130.911 3.684 . . . . 0.0 116.194 -173.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.21 -66.68 0.57 Allowed Glycine 0 N--CA 1.467 0.753 0 C-N-CA 125.068 1.318 . . . . 0.0 114.287 170.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 6.7 ttpp -157.49 93.28 1.28 Allowed 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.436 1.273 . . . . 0.0 114.436 -170.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.88 -113.74 2.18 Favored Glycine 0 C--O 1.235 0.216 0 N-CA-C 108.336 -1.906 . . . . 0.0 108.336 165.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -131.32 33.66 2.74 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.151 1.834 . . . . 0.0 113.328 177.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -159.58 159.83 33.7 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 118.78 1.29 . . . . 0.0 108.766 -171.229 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -68.73 -48.97 62.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.29 0.566 . . . . 0.0 110.093 -176.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.1 mp0 -38.63 -33.97 0.13 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.636 3.174 . . . . 0.0 113.591 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.9 p -59.88 -44.97 93.9 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.281 1.432 . . . . 0.0 114.021 175.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.8 t -81.7 -36.38 28.76 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 118.96 0.8 . . . . 0.0 111.283 168.216 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 16.6 tttt -56.88 -48.14 78.86 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.117 1.367 . . . . 0.0 111.991 -175.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 11.4 p -147.48 -10.79 0.41 Allowed 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 126.818 2.047 . . . . 0.0 115.009 -168.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.65 3.56 57.25 Favored Glycine 0 C--O 1.223 -0.575 0 CA-C-O 117.374 -1.792 . . . . 0.0 113.128 -173.432 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 67.54 -60.33 0.39 Allowed 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 127.043 2.137 . . . . 0.0 111.333 -172.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 68.41 -21.39 0.14 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 129.795 3.238 . . . . 0.0 115.571 168.585 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.61 -20.26 0.14 Allowed Glycine 0 CA--C 1.537 1.418 0 C-N-CA 126.904 2.192 . . . . 0.0 118.447 166.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.7 t -161.65 -173.11 3.6 Favored 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 127.626 2.371 . . . . 0.0 110.819 176.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.05 154.22 43.01 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.473 -1.392 . . . . 0.0 110.029 169.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.57 HD21 HG12 ' A' ' 119' ' ' VAL . 0.5 OUTLIER -128.94 -129.11 0.22 Allowed 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 123.43 0.692 . . . . 0.0 110.292 169.664 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -68.43 158.87 32.75 Favored 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 126.667 1.987 . . . . 0.0 113.113 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.7 p -140.79 161.58 37.46 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.922 2.089 . . . . 0.0 110.062 169.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.32 148.21 16.7 Favored Glycine 0 N--CA 1.472 1.038 0 O-C-N 121.272 -0.892 . . . . 0.0 112.918 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -78.56 161.78 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 C-N-CA 123.95 0.9 . . . . 0.0 109.773 177.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 36.8 mt -110.71 98.51 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 120.356 -1.465 . . . . 0.0 112.207 -175.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.45 167.07 22.14 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.712 1.625 . . . . 0.0 115.402 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.99 80.07 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 C-N-CA 127.91 2.484 . . . . 0.0 113.387 -175.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.36 26.24 0.22 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.657 1.583 . . . . 0.0 115.16 -175.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 . . . . . 0 N--CA 1.469 0.518 0 C-N-CA 129.413 3.085 . . . . 0.0 114.346 176.549 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.298 0 CA-C-O 119.418 -0.325 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 6.9 m -79.78 108.69 13.53 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 125.333 1.453 . . . . 0.0 108.088 -171.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 27.6 mttt -99.43 118.59 36.39 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -171.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -83.35 169.25 15.83 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 127.71 2.404 . . . . 0.0 114.874 178.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.643 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -156.07 125.43 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 129.412 3.085 . . . . 0.0 107.55 175.608 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.07 139.38 47.64 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.088 0.955 . . . . 0.0 113.173 179.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.521 ' HA ' HG22 ' A' ' 54' ' ' THR . 3.2 t -85.88 68.07 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.189 -0.914 . . . . 0.0 112.401 -168.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.12 103.13 5.17 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 122.208 1.004 . . . . 0.0 108.337 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -161.91 133.09 5.21 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 125.331 1.453 . . . . 0.0 109.713 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.25 -118.06 3.76 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 168.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -127.3 57.48 1.49 Allowed 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 126.046 1.738 . . . . 0.0 111.706 -164.071 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.5 -168.07 41.17 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 121.074 -1.016 . . . . 0.0 112.901 -171.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.55 -5.94 12.58 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 124.354 3.369 . . . . 0.0 115.444 -168.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.16 129.19 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 CA-C-N 120.258 1.39 . . . . 0.0 110.371 -178.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -123.13 178.55 5.04 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 122.518 1.151 . . . . 0.0 110.29 168.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.2 163.01 31.29 Favored Glycine 0 CA--C 1.499 -0.942 0 CA-C-N 113.888 -1.506 . . . . 0.0 113.129 165.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pt -133.6 82.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 112.162 -2.019 . . . . 0.0 106.688 170.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . 0.343 2.7 pp -89.49 109.87 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -112.74 133.54 54.71 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.523 2.329 . . . . 0.0 108.577 -170.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -124.48 147.06 48.58 Favored 'General case' 0 N--CA 1.474 0.766 0 O-C-N 121.028 -1.045 . . . . 0.0 111.178 -174.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -108.66 112.22 24.43 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.522 1.129 . . . . 0.0 111.717 175.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.3 99.04 10.87 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.43 ' HE2' ' HB2' ' B' ' 24' ' ' GLU . 0.2 OUTLIER -70.72 -28.8 65.0 Favored 'General case' 0 CA--C 1.539 0.53 0 O-C-N 121.415 -0.803 . . . . 0.0 113.108 170.276 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.43 ' HB2' ' HE2' ' B' ' 23' ' ' LYS . 43.1 tt0 -163.61 124.54 2.29 Favored 'General case' 0 C--O 1.222 -0.355 0 C-N-CA 124.689 1.196 . . . . 0.0 110.446 -166.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.0 p -60.86 -10.16 5.2 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 127.977 2.511 . . . . 0.0 114.8 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -132.93 15.16 4.28 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 126.239 1.816 . . . . 0.0 111.841 -171.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.42 -153.09 7.42 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 126.628 2.061 . . . . 0.0 111.724 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -85.29 167.05 10.69 Favored 'Trans proline' 0 N--CA 1.456 -0.733 0 C-N-CA 122.642 2.228 . . . . 0.0 112.202 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 74.9 t -119.78 140.22 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 124.993 1.317 . . . . 0.0 108.859 170.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -94.89 121.94 37.01 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 168.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.17 131.95 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 128.04 2.536 . . . . 0.0 109.071 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.0 p90 -156.05 -176.77 6.13 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 119.49 168.25 13.89 Favored Glycine 0 C--N 1.335 0.518 0 CA-C-O 122.079 0.822 . . . . 0.0 114.478 166.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 4.9 p -99.08 123.37 43.33 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -167.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 4.6 mp -98.5 118.08 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 166.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -129.01 132.29 47.5 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.551 1.54 . . . . 0.0 110.788 -166.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.26 -2.59 29.68 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 128.228 2.823 . . . . 0.0 111.939 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 22.4 mt -69.91 148.11 49.41 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 118.94 1.37 . . . . 0.0 112.598 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 26.8 m -76.37 143.97 40.39 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 125.614 1.565 . . . . 0.0 107.211 165.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -59.24 156.4 12.48 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 95.81 -179.45 35.55 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 123.668 0.652 . . . . 0.0 112.281 -172.129 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.477 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -83.25 142.39 31.17 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 127.267 2.227 . . . . 0.0 113.846 -169.56 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 80.5 m-70 -134.01 125.78 28.85 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 129.093 2.957 . . . . 0.0 108.602 -176.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -56.09 148.64 28.15 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 125.492 1.52 . . . . 0.0 112.594 178.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -142.26 103.52 4.29 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.999 1.399 . . . . 0.0 111.528 -168.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.56 139.0 33.07 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 120.223 -1.548 . . . . 0.0 111.226 -175.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.88 115.52 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 176.154 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -71.86 -178.52 2.34 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 128.119 2.567 . . . . 0.0 111.172 -169.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.7 145.02 46.45 Favored 'General case' 0 CA--C 1.547 0.828 0 O-C-N 121.317 -0.864 . . . . 0.0 111.008 168.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 38.9 p90 -92.54 -170.95 2.62 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.28 1.832 . . . . 0.0 113.06 -169.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.17 -108.36 3.0 Favored Glycine 0 C--N 1.334 0.447 0 N-CA-C 115.694 1.037 . . . . 0.0 115.694 163.369 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -77.92 65.04 3.27 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.252 1.421 . . . . 0.0 110.567 -169.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.56 ' H ' HG11 ' A' ' 5' ' ' VAL . 0.0 OUTLIER -165.52 162.59 19.27 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 114.714 1.376 . . . . 0.0 114.714 -168.598 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 39.5 p -137.17 -45.77 0.57 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.65 2.093 . . . . 0.0 116.65 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -87.04 -57.12 3.08 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 119.077 0.853 . . . . 0.0 110.959 177.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 114.96 -82.64 0.32 Allowed Glycine 0 N--CA 1.466 0.691 0 C-N-CA 124.69 1.138 . . . . 0.0 110.97 -175.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 2.3 t -64.25 -9.8 19.63 Favored 'General case' 0 CA--C 1.554 1.1 0 CA-C-N 119.021 1.41 . . . . 0.0 114.02 178.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -126.84 34.93 4.69 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 127.861 2.465 . . . . 0.0 110.07 170.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 7.4 m -156.83 -55.58 0.08 Allowed 'General case' 0 N--CA 1.482 1.154 0 O-C-N 119.769 -1.832 . . . . 0.0 114.938 176.232 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.31 160.16 24.55 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 124.596 1.159 . . . . 0.0 112.352 -172.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.46 171.17 25.56 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.194 1.378 . . . . 0.0 113.765 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -65.34 169.41 12.48 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 124.493 3.462 . . . . 0.0 112.264 -173.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -20.19 86.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 128.504 2.722 . . . . 0.0 117.733 175.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -50.57 126.63 15.9 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 123.54 1.638 . . . . 0.0 114.053 -172.076 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.46 59.81 0.46 Allowed Pre-proline 0 CA--C 1.558 1.261 0 CA-C-N 112.194 -2.276 . . . . 0.0 115.851 -168.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -65.28 -27.53 55.8 Favored 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 123.355 2.704 . . . . 0.0 114.232 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.9 mp -76.28 -3.99 39.58 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.195 0.998 . . . . 0.0 112.244 175.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 32.3 t 63.54 50.58 2.76 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 126.002 1.721 . . . . 0.0 111.114 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -103.14 168.45 9.17 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.551 1.14 . . . . 0.0 111.757 -174.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.452 ' HE3' ' HD2' ' B' ' 128' ' ' LYS . 0.0 OUTLIER -96.39 173.1 7.54 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.456 1.502 . . . . 0.0 107.287 164.433 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.476 ' CD2' ' HA2' ' B' ' 138' ' ' GLY . 29.5 t60 -63.88 164.5 10.12 Favored 'General case' 0 CA--C 1.547 0.832 0 O-C-N 119.981 -1.699 . . . . 0.0 113.715 -178.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 166.67 -174.44 42.07 Favored Glycine 0 N--CA 1.469 0.863 0 O-C-N 120.921 -1.112 . . . . 0.0 113.929 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 157.28 -154.26 25.38 Favored Glycine 0 CA--C 1.531 1.07 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 -167.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -62.77 -1.75 2.94 Favored 'Trans proline' 0 CA--C 1.54 0.807 1 C-N-CA 125.849 4.366 . . . . 0.0 116.379 -172.623 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -120.89 -1.98 9.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.021 1.329 . . . . 0.0 113.641 170.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -131.04 176.79 7.96 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 126.746 2.018 . . . . 0.0 110.259 -168.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -100.15 -17.07 17.58 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 127.13 2.172 . . . . 0.0 113.803 -169.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -95.2 -100.34 0.16 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 118.565 0.621 . . . . 0.0 112.673 -176.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 17.2 ttp-105 85.77 97.28 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 126.825 2.05 . . . . 0.0 110.024 -175.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -49.67 156.83 0.63 Allowed 'General case' 0 N--CA 1.475 0.799 0 O-C-N 119.936 -1.727 . . . . 0.0 111.788 168.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 46.4 t -53.38 -21.5 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 119.266 0.939 . . . . 0.0 113.265 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -122.29 61.4 0.55 Allowed Glycine 0 CA--C 1.531 1.036 0 CA-C-O 118.573 -1.126 . . . . 0.0 114.105 169.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -123.52 124.68 43.37 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 119.642 1.721 . . . . 0.0 109.099 168.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 90.9 mt -132.18 49.22 2.34 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 119.268 0.94 . . . . 0.0 112.381 -176.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.94 -148.29 47.71 Favored Glycine 0 CA--C 1.534 1.277 0 O-C-N 121.101 -1.0 . . . . 0.0 113.49 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -129.76 137.27 50.44 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.781 1.233 . . . . 0.0 109.837 168.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.0 p -96.15 133.32 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 125.861 1.664 . . . . 0.0 110.227 179.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 32.1 m -108.94 136.81 47.87 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 124.222 1.009 . . . . 0.0 108.803 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.35 145.09 26.47 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 174.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -77.18 146.91 36.76 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.118 1.767 . . . . 0.0 110.499 167.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -63.91 -14.3 52.46 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.925 1.824 . . . . 0.0 115.925 -169.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -76.16 3.32 10.86 Favored 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 125.471 1.508 . . . . 0.0 111.481 171.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 100.36 29.41 6.71 Favored Glycine 0 C--N 1.342 0.892 0 C-N-CA 126.327 1.918 . . . . 0.0 114.719 168.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.1 139.51 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 120.227 2.014 . . . . 0.0 115.215 -169.048 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.49 99.29 7.07 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 124.401 1.08 . . . . 0.0 110.187 169.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -87.74 91.24 8.68 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-O 122.591 1.186 . . . . 0.0 109.169 172.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -75.85 158.64 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 CA-C-N 114.109 -1.405 . . . . 0.0 114.133 -167.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 82.4 p -155.0 105.93 2.59 Favored 'General case' 0 N--CA 1.471 0.584 0 O-C-N 120.61 -1.306 . . . . 0.0 111.782 -175.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.3 mt -137.43 153.19 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 126.708 2.003 . . . . 0.0 110.639 -176.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -139.01 136.14 35.02 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 126.26 1.824 . . . . 0.0 107.92 168.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -149.18 143.97 26.28 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 125.873 1.669 . . . . 0.0 111.013 -172.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 60.0 p -107.89 53.19 0.69 Allowed 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 113.29 0.848 . . . . 0.0 113.29 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 43.1 t -144.3 -42.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 124.29 1.036 . . . . 0.0 112.92 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -87.63 163.08 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 O-C-N 121.14 -0.975 . . . . 0.0 113.447 -176.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -156.57 154.24 29.93 Favored 'General case' 0 N--CA 1.476 0.838 0 O-C-N 119.91 -1.744 . . . . 0.0 113.341 174.033 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mp -84.85 46.43 1.26 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.008 1.323 . . . . 0.0 108.65 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.0 m -75.59 -34.63 60.66 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 116.091 1.886 . . . . 0.0 116.091 -166.019 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.62 18.41 Favored Glycine 0 CA--C 1.536 1.352 0 N-CA-C 115.578 0.991 . . . . 0.0 115.578 -174.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 6.9 p30 -116.74 -83.23 0.63 Allowed 'General case' 0 CA--C 1.549 0.905 0 C-N-CA 125.65 1.58 . . . . 0.0 111.003 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 87.1 m-70 -143.42 -1.59 1.02 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 129.399 3.079 . . . . 0.0 111.922 -178.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 52.5 m -73.46 -91.54 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 126.488 1.915 . . . . 0.0 112.003 -169.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.7 pt -136.04 -26.34 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 175.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 mm -66.04 136.68 26.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 CA-C-N 122.826 2.557 . . . . 0.0 108.621 168.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.52 -16.53 6.22 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.018 0.818 . . . . 0.0 114.594 -172.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -79.07 178.39 8.08 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.528 1.131 . . . . 0.0 109.361 169.235 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.57 124.26 12.56 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.479 1.036 . . . . 0.0 111.902 -170.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 9.4 tp -89.27 120.36 30.57 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.0 p -99.89 130.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 124.14 0.976 . . . . 0.0 110.802 171.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.8 m -93.38 133.71 33.58 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 165.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -96.39 177.75 5.59 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 125.355 1.462 . . . . 0.0 111.155 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -84.76 -58.04 2.87 Favored 'General case' 0 N--CA 1.467 0.395 0 O-C-N 120.912 -1.118 . . . . 0.0 110.648 -173.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -95.34 177.99 5.66 Favored 'General case' 0 N--CA 1.471 0.593 0 O-C-N 120.746 -1.221 . . . . 0.0 110.537 169.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.03 146.09 28.36 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 168.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -86.89 163.09 17.37 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 123.145 1.45 . . . . 0.0 111.368 169.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.47 -8.83 57.98 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 126.105 1.762 . . . . 0.0 112.25 -170.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 95.6 mt 33.6 50.24 0.28 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 128.511 2.724 . . . . 0.0 113.276 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 159.84 -93.62 0.12 Allowed Glycine 0 C--N 1.333 0.41 0 O-C-N 121.678 -0.639 . . . . 0.0 114.336 -178.279 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . 0.452 ' HD2' ' HE3' ' B' ' 70' ' ' LYS . 0.0 OUTLIER -159.16 127.38 5.08 Favored 'General case' 0 CA--C 1.55 0.978 0 C-N-CA 125.422 1.489 . . . . 0.0 112.422 -173.711 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -123.87 -19.05 2.8 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 124.593 1.092 . . . . 0.0 115.095 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 119.69 -14.49 10.65 Favored Glycine 0 N--CA 1.474 1.217 0 CA-C-O 118.34 -1.255 . . . . 0.0 116.227 171.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -98.11 165.12 12.04 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.875 1.838 . . . . 0.0 110.175 168.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -51.8 -55.83 17.51 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.328 1.051 . . . . 0.0 110.035 178.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -51.6 -33.29 32.3 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 128.041 2.536 . . . . 0.0 113.313 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -54.86 -46.37 74.67 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 121.137 1.789 . . . . 0.0 113.861 176.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.7 t -91.24 -31.67 16.05 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 172.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -74.11 -28.17 61.23 Favored 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.7 m -128.82 -44.68 1.32 Allowed 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.352 1.461 . . . . 0.0 111.672 -179.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . 0.476 ' HA2' ' CD2' ' B' ' 71' ' ' HIS . . . 122.16 7.92 7.49 Favored Glycine 0 CA--C 1.525 0.684 0 C-N-CA 127.781 2.61 . . . . 0.0 112.269 -167.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 61.08 -77.39 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 126.213 1.805 . . . . 0.0 109.382 -169.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 64.94 3.61 2.16 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 127.889 2.476 . . . . 0.0 117.482 164.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.49 -46.63 1.97 Allowed Glycine 0 N--CA 1.471 1.014 0 C-N-CA 125.398 1.475 . . . . 0.0 113.803 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 1.9 m -178.27 176.71 1.06 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 126.933 2.093 . . . . 0.0 112.002 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -79.43 173.63 12.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.586 0.754 . . . . 0.0 110.846 168.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -140.74 -79.55 0.27 Allowed 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.755 0.822 . . . . 0.0 109.964 169.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.47 43.89 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 126.4 1.88 . . . . 0.0 109.686 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -156.81 151.74 26.02 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.966 1.706 . . . . 0.0 111.833 -171.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.79 148.74 17.18 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 116.415 1.326 . . . . 0.0 116.415 176.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.9 t -74.56 140.68 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 117.627 0.713 . . . . 0.0 110.671 175.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.9 mm -81.24 118.4 28.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 C-N-CA 125.303 1.441 . . . . 0.0 111.566 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.6 -167.16 14.58 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 126.227 1.87 . . . . 0.0 112.613 169.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.425 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.0 OUTLIER -134.28 138.37 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.265 1.426 . . . . 0.0 114.34 -169.028 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.68 -141.26 0.27 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.703 1.201 . . . . 0.0 110.337 174.528 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.468 0.464 0 C-N-CA 124.272 1.029 . . . . 0.0 110.279 -176.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.905 0 CA-C-O 117.458 -1.258 . . . . 0.0 108.674 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 p -79.16 48.27 0.85 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -167.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -168.37 157.38 9.03 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 115.403 1.631 . . . . 0.0 115.403 163.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.1 179.02 8.06 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 130.231 3.413 . . . . 0.0 107.181 169.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.503 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.3 p -155.66 108.29 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 122.645 1.212 . . . . 0.0 111.619 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -101.5 96.64 7.27 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 167.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.1 t -76.91 136.06 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 165.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 mp -128.39 104.29 7.63 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.155 -0.966 . . . . 0.0 109.562 -178.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 58.1 tttp -160.43 151.39 18.92 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 124.24 1.016 . . . . 0.0 111.865 -178.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.17 -116.94 1.02 Allowed Glycine 0 CA--C 1.524 0.624 0 CA-C-O 123.089 1.383 . . . . 0.0 111.618 166.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -92.7 56.32 2.63 Favored 'General case' 0 C--N 1.312 -1.035 1 C-N-CA 132.635 4.374 . . . . 0.0 115.034 -164.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.4 -168.19 35.25 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.296 -1.32 . . . . 0.0 114.074 176.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -86.02 17.88 1.67 Allowed 'Trans proline' 0 CA--C 1.539 0.767 1 C-N-CA 125.686 4.257 . . . . 0.0 113.553 -171.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 t -111.08 120.84 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.87 1.213 . . . . 0.0 108.975 -178.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.3 pm0 -160.25 162.31 33.66 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 114.545 1.313 . . . . 0.0 114.545 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.52 173.65 33.64 Favored Glycine 0 N--CA 1.462 0.377 0 C-N-CA 124.368 0.985 . . . . 0.0 113.296 168.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -126.24 134.13 67.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 124.386 1.074 . . . . 0.0 108.86 170.443 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.8 mm -137.6 105.24 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 118.274 0.488 . . . . 0.0 110.231 -172.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -77.67 161.74 27.55 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.597 0.713 . . . . 0.0 111.662 172.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.414 ' CD2' HG22 ' A' ' 31' ' ' VAL . 3.4 m-85 -137.17 111.22 8.32 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.897 1.679 . . . . 0.0 106.806 169.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -91.65 135.51 33.82 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 120.765 1.62 . . . . 0.0 109.794 172.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.7 tp60 -132.1 145.99 51.75 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.825 0.821 . . . . 0.0 111.532 175.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.48 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -92.53 -34.74 13.94 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 124.624 1.169 . . . . 0.0 114.1 179.399 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.95 -154.42 0.55 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-N 120.66 1.573 . . . . 0.0 112.791 178.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 65.7 p -93.35 -0.23 56.68 Favored 'General case' 0 CA--C 1.538 0.518 0 O-C-N 119.228 -2.17 . . . . 0.0 115.469 -172.051 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -153.49 -8.71 0.16 Allowed 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 115.875 1.806 . . . . 0.0 115.875 -169.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.91 173.89 55.31 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 128.664 3.031 . . . . 0.0 114.023 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -78.22 139.36 16.75 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.046 2.497 . . . . 0.0 111.758 -175.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -108.84 132.9 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 124.418 1.087 . . . . 0.0 109.353 -170.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -99.07 113.21 25.3 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 122.172 0.987 . . . . 0.0 110.34 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.414 HG22 ' CD2' ' A' ' 20' ' ' PHE . 9.3 t -95.5 130.99 43.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 127.984 2.514 . . . . 0.0 109.14 -178.17 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.0 p90 -148.81 159.32 44.26 Favored 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.92 -157.12 27.21 Favored Glycine 0 C--O 1.225 -0.424 0 C-N-CA 126.058 1.79 . . . . 0.0 110.178 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.5 p -157.11 154.72 29.86 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 121.577 -0.955 . . . . 0.0 112.417 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.9 mp -121.67 130.91 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 125.599 1.56 . . . . 0.0 108.346 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -131.4 140.5 49.67 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.316 1.446 . . . . 0.0 111.012 -178.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.52 11.6 11.51 Favored Glycine 0 CA--C 1.536 1.405 0 C-N-CA 126.17 1.843 . . . . 0.0 112.54 -168.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.7 mt -86.96 171.24 10.92 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.532 0.733 . . . . 0.0 109.54 169.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -80.53 -141.09 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 164.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.49 -154.13 0.37 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.939 1.296 . . . . 0.0 108.535 166.285 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 69.28 179.74 22.96 Favored Glycine 0 CA--C 1.532 1.147 0 O-C-N 120.398 -1.439 . . . . 0.0 115.331 168.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 mp -87.52 154.77 20.36 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.973 1.709 . . . . 0.0 110.611 -176.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -150.67 103.52 3.11 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 127.323 2.249 . . . . 0.0 109.908 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.05 160.61 20.86 Favored Glycine 0 N--CA 1.476 1.313 0 C-N-CA 124.558 1.075 . . . . 0.0 114.185 -175.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -142.78 92.38 2.4 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 125.933 1.693 . . . . 0.0 109.186 -173.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -109.35 130.4 55.5 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.298 -1.501 . . . . 0.0 109.8 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 2.1 m -77.97 158.33 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 175.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -119.9 123.44 43.57 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 pm0 -57.47 147.16 27.33 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 121.774 0.797 . . . . 0.0 109.872 177.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 68.95 166.72 0.27 Allowed 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 126.111 2.862 . . . . 0.0 112.353 -176.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.81 10.8 18.4 Favored Glycine 0 N--CA 1.467 0.718 0 C-N-CA 128.198 2.809 . . . . 0.0 112.186 178.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -83.7 42.99 0.88 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 128.509 2.723 . . . . 0.0 114.055 -178.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -179.88 -26.85 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 112.723 -2.035 . . . . 0.0 114.925 -166.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.389 43.4 p 27.74 -18.35 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 2 N-CA-C 123.535 4.643 . . . . 0.0 123.535 -167.625 . . . . . . . . 3 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.44 -0.37 57.36 Favored 'General case' 0 CA--C 1.549 0.91 0 CA-C-N 122.48 2.4 . . . . 0.0 114.278 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.9 -128.4 37.31 Favored Glycine 0 C--N 1.339 0.721 0 C-N-CA 125.721 1.629 . . . . 0.0 111.396 177.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -51.62 -2.75 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.235 0 N-CA-C 117.215 2.302 . . . . 0.0 117.215 -176.665 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 85.7 m -110.63 11.37 22.82 Favored 'General case' 0 N--CA 1.481 1.108 0 O-C-N 119.795 -1.816 . . . . 0.0 113.782 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.8 t -155.79 -27.45 0.1 Allowed 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 115.92 1.822 . . . . 0.0 115.92 168.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.2 177.02 4.79 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 126.797 2.039 . . . . 0.0 108.912 166.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.79 -107.92 2.47 Favored Glycine 0 CA--C 1.541 1.719 0 CA-C-O 117.755 -1.58 . . . . 0.0 114.443 -169.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -101.69 -167.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.543 0.956 1 C-N-CA 127.23 5.287 . . . . 0.0 112.144 -174.623 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.742 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.6 OUTLIER -100.11 119.83 38.91 Favored 'General case' 0 CA--C 1.554 1.111 1 C-N-CA 132.292 4.237 . . . . 0.0 115.243 -178.274 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -39.74 126.93 2.0 Allowed 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 130.074 3.35 . . . . 0.0 116.123 178.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 51.0 p-10 -121.6 32.72 0.21 Allowed Pre-proline 0 CA--C 1.557 1.212 0 N-CA-C 115.304 1.594 . . . . 0.0 115.304 -173.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -62.8 -20.66 71.8 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.959 3.106 . . . . 0.0 114.978 -167.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 60.5 mt -78.46 -1.78 35.34 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.09 1.356 . . . . 0.0 112.685 174.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.76 52.8 0.93 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 127.269 2.227 . . . . 0.0 111.765 173.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.4 ptt180 -156.97 -179.98 8.73 Favored 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -166.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.26 177.53 8.9 Favored 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.434 1.494 . . . . 0.0 113.983 -171.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -50.87 157.8 0.76 Allowed 'General case' 0 CA--C 1.552 1.023 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -169.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -80.85 67.75 3.52 Favored Glycine 0 N--CA 1.474 1.177 0 C-N-CA 125.601 1.572 . . . . 0.0 114.354 -167.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -97.06 128.37 9.53 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-O 118.913 -0.937 . . . . 0.0 114.583 -168.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -76.84 4.68 5.48 Favored 'Trans proline' 0 CA--C 1.545 1.071 0 C-N-CA 123.632 2.888 . . . . 0.0 111.713 167.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.56 -10.52 18.4 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.963 0.905 . . . . 0.0 111.863 168.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -123.37 139.73 53.74 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.155 0.982 . . . . 0.0 110.809 -166.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -66.81 -28.62 68.52 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.496 172.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -91.76 105.04 17.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 125.969 1.708 . . . . 0.0 106.946 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -140.11 112.69 7.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 129.065 2.946 . . . . 0.0 109.56 -170.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -58.71 152.29 19.15 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.094 1.357 . . . . 0.0 111.405 167.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 p -65.0 -13.75 15.43 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 171.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.02 43.64 1.36 Allowed Glycine 0 C--N 1.347 1.158 0 N-CA-C 118.26 2.064 . . . . 0.0 118.26 -168.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -147.68 143.6 27.75 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 119.891 1.845 . . . . 0.0 109.484 167.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.0 mt -108.67 54.37 0.66 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.638 0.732 . . . . 0.0 109.345 -175.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.09 -120.07 6.75 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 124.84 1.209 . . . . 0.0 112.239 -172.118 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.439 HD22 HD21 ' A' ' 126' ' ' LEU . 6.5 p30 -142.28 160.4 40.32 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.709 1.204 . . . . 0.0 109.717 170.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.681 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.7 OUTLIER -99.17 151.4 4.73 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.763 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 164.887 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.9 m -134.55 120.86 20.17 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 124.736 1.214 . . . . 0.0 108.738 -177.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.46 140.2 29.71 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -175.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -81.9 160.07 23.5 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 128.155 2.582 . . . . 0.0 110.151 169.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.47 -22.08 7.32 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 126.382 1.873 . . . . 0.0 114.944 -173.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -76.79 -3.9 40.69 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 127.445 2.298 . . . . 0.0 112.289 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.78 10.01 73.51 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 126.929 2.204 . . . . 0.0 114.477 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.7 p -108.83 137.54 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 C-N-CA 125.583 1.553 . . . . 0.0 111.963 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.681 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -107.73 130.54 54.94 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.471 -0.936 . . . . 0.0 108.471 166.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -82.29 151.64 26.67 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 122.277 1.037 . . . . 0.0 109.499 170.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -134.08 129.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 112.81 -1.995 . . . . 0.0 111.867 164.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.2 p -157.85 54.05 0.47 Allowed 'General case' 0 CA--C 1.551 0.987 0 C-N-CA 124.4 1.08 . . . . 0.0 111.978 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.81 153.86 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 O-C-N 120.277 -1.515 . . . . 0.0 112.352 -171.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -129.28 139.9 51.63 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 125.845 1.658 . . . . 0.0 108.457 168.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -150.07 148.53 29.12 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.4 1.095 . . . . 0.0 111.662 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 83.5 p -107.5 55.61 0.65 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 126.082 1.753 . . . . 0.0 110.35 -171.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.6 p -152.47 11.32 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -169.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -153.58 163.09 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 127.158 2.183 . . . . 0.0 107.904 -179.044 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.0 m -155.14 161.62 41.2 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 122.435 1.112 . . . . 0.0 112.56 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 1.5 tt -90.03 77.65 6.82 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 120.897 -1.127 . . . . 0.0 109.218 -169.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 4.7 t -83.3 -146.68 0.08 Allowed 'General case' 0 CA--C 1.547 0.841 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.704 167.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -137.73 23.06 3.11 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.105 1.812 . . . . 0.0 112.751 173.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -173.35 -70.09 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -163.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -94.01 11.15 30.75 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.576 2.35 . . . . 0.0 114.788 -164.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . 0.25 3.9 m -140.85 -100.6 0.15 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 116.278 1.955 . . . . 0.0 116.278 -178.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 1.5 pt -89.89 -57.32 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 CA-C-N 121.545 1.975 . . . . 0.0 111.345 169.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.0 mm -61.89 145.69 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 170.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 96.35 -38.92 2.94 Favored Glycine 0 CA--C 1.524 0.597 0 CA-C-O 118.09 -1.395 . . . . 0.0 113.606 176.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.7 ptt180 -83.31 170.07 14.99 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 119.212 1.506 . . . . 0.0 112.539 175.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 5.2 t -119.01 176.92 5.06 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.226 1.01 . . . . 0.0 113.457 174.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 22.2 tp -156.92 136.57 12.33 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 126.273 1.829 . . . . 0.0 113.536 -168.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.4 t -112.03 135.38 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.988 1.315 . . . . 0.0 110.478 170.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.1 m -93.31 151.85 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 168.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 65.8 m-70 -119.38 144.12 47.07 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.684 1.194 . . . . 0.0 113.007 -172.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -83.75 -16.67 43.93 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 120.956 -1.09 . . . . 0.0 113.25 -179.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -98.03 164.0 12.53 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 169.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.09 164.21 1.76 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.997 1.319 . . . . 0.0 112.041 170.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -124.16 141.01 52.42 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.103 1.761 . . . . 0.0 110.209 -177.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -73.39 -34.38 65.5 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 125.73 1.612 . . . . 0.0 110.862 177.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.439 HD21 HD22 ' A' ' 86' ' ' ASN . 42.6 mt 78.74 -24.19 0.22 Allowed 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 130.026 3.331 . . . . 0.0 113.272 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -137.23 -81.99 0.11 Allowed Glycine 0 N--CA 1.475 1.279 0 CA-C-N 121.379 1.9 . . . . 0.0 114.271 -175.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 72.4 tttt -158.23 139.21 13.13 Favored 'General case' 0 N--CA 1.439 -0.993 0 C-N-CA 128.29 2.636 . . . . 0.0 107.518 174.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -127.25 -119.87 2.29 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 126.708 2.099 . . . . 0.0 109.946 167.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -92.27 -33.57 7.58 Favored Glycine 0 N--CA 1.474 1.219 0 N-CA-C 117.629 1.811 . . . . 0.0 117.629 -167.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 32.6 p30 -114.44 172.09 7.23 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.384 1.473 . . . . 0.0 113.156 -168.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -48.58 -61.72 1.88 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 126.29 1.836 . . . . 0.0 110.506 169.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -41.1 -42.05 1.89 Allowed 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 128.509 2.724 . . . . 0.0 114.383 175.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.426 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 85.7 p -55.27 -28.83 56.07 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 121.499 1.954 . . . . 0.0 113.456 177.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 23.3 p -97.82 -32.65 11.6 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 113.806 1.039 . . . . 0.0 113.806 169.471 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.419 ' C ' ' HE2' ' A' ' 63' ' ' HIS . 86.6 tttt -91.13 -15.12 29.93 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.547 1.939 . . . . 0.0 115.006 -169.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.428 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 77.2 p -137.3 -16.03 1.42 Allowed 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 128.444 2.698 . . . . 0.0 112.81 170.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 91.04 12.24 60.47 Favored Glycine 0 C--N 1.341 0.861 0 C-N-CA 124.062 0.839 . . . . 0.0 112.284 -167.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.426 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 7.9 t-20 53.4 26.61 5.54 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.158 1.383 . . . . 0.0 111.563 -168.145 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.7 6.96 0.56 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.652 1.181 . . . . 0.0 113.732 -169.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.03 -37.14 0.15 Allowed Glycine 0 CA--C 1.531 1.073 1 C-N-CA 131.128 4.204 . . . . 0.0 117.753 168.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 46.3 t -175.92 140.64 0.43 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.291 1.437 . . . . 0.0 111.428 -168.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.7 ptt-85 -77.42 174.6 10.64 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 123.702 0.801 . . . . 0.0 113.158 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.52 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -152.52 -143.02 0.13 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.417 1.887 . . . . 0.0 107.426 177.355 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.52 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -68.4 167.42 14.69 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.312 1.845 . . . . 0.0 112.727 177.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -140.18 153.24 46.55 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 125.004 1.322 . . . . 0.0 111.122 -169.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.54 141.18 7.32 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 124.193 0.901 . . . . 0.0 113.381 171.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' B' ' 148' ' ' VAL . 6.3 p -75.8 163.24 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 166.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.2 mm -93.09 94.37 4.68 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 121.37 -0.831 . . . . 0.0 110.032 170.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.3 -178.79 48.46 Favored Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.047 1.784 . . . . 0.0 113.759 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -113.99 130.58 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 124.659 1.183 . . . . 0.0 112.809 -170.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.52 -3.48 58.33 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.266 1.826 . . . . 0.0 112.472 176.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 . . . . . 0 CA--C 1.533 0.294 0 C-N-CA 125.149 1.38 . . . . 0.0 110.183 175.524 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.29 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 8.8 t -77.45 111.65 13.38 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 123.003 1.382 . . . . 0.0 108.675 -168.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 21.5 mtmm -101.05 113.34 26.25 Favored 'General case' 0 CA--C 1.544 0.744 0 CA-C-N 113.949 -1.478 . . . . 0.0 114.479 -171.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' B' ' 20' ' ' PHE . . . -95.89 175.47 6.49 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 127.036 2.134 . . . . 0.0 110.636 167.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -159.65 137.87 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 126.283 1.833 . . . . 0.0 110.677 -169.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.13 134.03 55.22 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 124.107 0.963 . . . . 0.0 109.016 165.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.58 114.76 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.157 0.983 . . . . 0.0 108.455 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.432 ' CD2' HG23 ' B' ' 119' ' ' VAL . 5.8 mp -98.14 130.91 44.89 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 126.29 1.836 . . . . 0.0 110.396 -167.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.1 mttt -150.57 175.63 11.73 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.485 1.114 . . . . 0.0 112.458 -177.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 139.97 -71.57 0.43 Allowed Glycine 0 CA--C 1.525 0.667 0 C-N-CA 127.868 2.651 . . . . 0.0 109.059 -172.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -74.71 69.79 1.81 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.813 2.045 . . . . 0.0 113.18 -169.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 43.6 -97.64 0.01 OUTLIER Glycine 0 CA--C 1.536 1.376 0 C-N-CA 127.607 2.527 . . . . 0.0 114.747 169.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -80.85 -16.41 10.17 Favored 'Trans proline' 0 C--N 1.352 0.727 0 C-N-CA 124.074 3.182 . . . . 0.0 114.304 -179.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 t -79.51 139.33 18.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 CA-C-N 120.561 1.528 . . . . 0.0 109.359 175.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.1 152.58 29.68 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 113.567 -1.651 . . . . 0.0 108.117 167.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -119.72 152.47 17.11 Favored Glycine 0 CA--C 1.488 -1.594 0 O-C-N 123.818 0.699 . . . . 0.0 111.817 172.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -126.7 130.87 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 166.081 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 11.1 mm -129.17 118.09 45.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 173.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -82.88 157.73 22.97 Favored 'General case' 0 N--CA 1.47 0.543 0 O-C-N 120.927 -1.108 . . . . 0.0 109.48 169.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.405 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 70.3 m-85 -139.54 87.26 2.17 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.76 1.224 . . . . 0.0 108.139 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -86.91 124.15 32.81 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 121.299 -0.875 . . . . 0.0 112.034 174.006 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -113.82 134.84 54.54 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.869 0.842 . . . . 0.0 110.822 165.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.33 -32.05 15.84 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 124.64 1.176 . . . . 0.0 112.552 179.188 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -99.14 -169.24 1.74 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.042 2.137 . . . . 0.0 109.836 170.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.9 m -118.28 -6.15 10.83 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 120.634 -1.291 . . . . 0.0 113.277 167.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 61.0 m-80 -141.67 19.89 2.18 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 126.36 1.864 . . . . 0.0 112.379 175.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.0 -158.17 14.22 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.596 2.046 . . . . 0.0 113.193 175.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.84 154.02 29.83 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.228 2.619 . . . . 0.0 113.776 -172.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 15.9 t -117.86 133.34 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 126.364 1.866 . . . . 0.0 110.377 178.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -89.81 122.62 33.05 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.456 1.103 . . . . 0.0 110.607 171.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.19 84.66 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 C-N-CA 128.081 2.553 . . . . 0.0 109.787 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 5.9 p90 -106.81 153.57 22.27 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 123.717 0.807 . . . . 0.0 111.234 169.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.01 -158.39 30.69 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 124.349 0.976 . . . . 0.0 112.141 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 91.8 p -159.41 136.04 9.26 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 -172.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.469 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.5 mp -112.51 111.7 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 124.536 1.134 . . . . 0.0 109.77 173.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -116.43 133.63 55.8 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 123.829 0.852 . . . . 0.0 111.371 -169.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.66 -2.23 26.14 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 125.827 1.68 . . . . 0.0 114.792 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 1.3 pp -83.8 178.5 7.89 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 118.858 1.329 . . . . 0.0 109.59 169.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.72 163.33 22.52 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 124.052 0.941 . . . . 0.0 109.415 169.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . 0.437 ' H ' ' CD ' ' B' ' 40' ' ' GLU . 0.7 OUTLIER -52.56 178.54 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 177.724 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.31 -166.97 54.86 Favored Glycine 0 CA--C 1.527 0.827 0 O-C-N 120.274 -1.516 . . . . 0.0 112.958 172.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 77.3 mt -73.84 148.98 41.89 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.8 1.64 . . . . 0.0 111.764 -173.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -149.0 126.65 11.7 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 127.349 2.26 . . . . 0.0 110.437 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.55 157.1 25.67 Favored Glycine 0 N--CA 1.49 2.283 0 CA-C-O 117.625 -1.653 . . . . 0.0 112.756 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 20.3 p90 -157.58 110.84 2.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 127.469 2.308 . . . . 0.0 112.449 171.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.6 m80 -138.08 144.02 40.73 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 119.905 -1.747 . . . . 0.0 111.389 -175.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -89.53 132.63 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 C-N-CA 123.978 0.911 . . . . 0.0 110.118 177.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -75.37 117.42 17.15 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 168.184 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -73.37 60.46 0.62 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.469 1.908 . . . . 0.0 114.217 -168.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -179.4 164.25 1.31 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 128.983 2.913 . . . . 0.0 109.461 170.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -96.43 -10.29 55.87 Favored Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.245 0.926 . . . . 0.0 114.66 169.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.503 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -82.03 51.37 1.74 Allowed 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 126.942 2.097 . . . . 0.0 110.439 -176.021 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' C ' ' B' ' 53' ' ' ASN . 0.4 OUTLIER 171.26 33.62 0.0 OUTLIER 'General case' 0 CA--C 1.551 0.997 0 N-CA-C 115.805 1.779 . . . . 0.0 115.805 -164.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 37.4 p -40.26 -34.49 0.32 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 118.184 2.661 . . . . 0.0 118.184 -168.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 18.16 1.84 Allowed 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 -167.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.58 -141.3 20.29 Favored Glycine 0 CA--C 1.526 0.725 0 O-C-N 120.71 -1.244 . . . . 0.0 113.12 169.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 9.8 t -62.08 -5.96 2.62 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 115.399 1.629 . . . . 0.0 115.399 -174.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 11.2 t -80.15 -4.23 52.14 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.419 1.088 . . . . 0.0 112.293 170.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 70.3 m -149.04 159.49 44.18 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 119.993 1.269 . . . . 0.0 113.65 -177.156 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 61.0 -138.07 0.57 Allowed 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.883 2.073 . . . . 0.0 110.052 -168.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.27 158.91 20.55 Favored Glycine 0 CA--C 1.534 1.263 0 CA-C-O 117.672 -1.627 . . . . 0.0 110.728 169.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -55.04 103.52 0.1 Allowed 'Trans proline' 0 C--N 1.355 0.92 1 C-N-CA 125.663 4.242 . . . . 0.0 109.936 178.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 46.12 62.02 2.44 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 113.679 -1.601 . . . . 0.0 111.131 -175.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -37.62 134.19 0.71 Allowed 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.398 1.479 . . . . 0.0 112.183 -175.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -117.26 80.15 11.99 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -165.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -69.92 -13.32 34.12 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 123.101 2.534 . . . . 0.0 114.119 177.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -90.0 -6.69 55.34 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.85 1.26 . . . . 0.0 112.679 177.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.3 t 50.77 50.59 18.69 Favored 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 127.514 2.325 . . . . 0.0 114.703 -177.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -108.65 177.34 4.81 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 124.85 1.26 . . . . 0.0 113.065 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.11 164.69 22.22 Favored 'General case' 0 N--CA 1.47 0.555 0 O-C-N 121.342 -0.849 . . . . 0.0 110.73 167.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.477 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 63.8 t60 -68.1 -176.33 0.7 Allowed 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 122.095 0.95 . . . . 0.0 113.111 -176.108 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.477 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 111.07 -154.52 16.61 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 124.513 1.054 . . . . 0.0 115.492 165.063 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 166.13 -89.38 0.1 Allowed Glycine 0 CA--C 1.528 0.864 0 CA-C-O 118.205 -1.331 . . . . 0.0 114.725 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -67.9 -1.12 6.35 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 123.049 2.5 . . . . 0.0 114.15 -175.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -129.24 -4.14 4.95 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 125.613 1.565 . . . . 0.0 112.631 168.288 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -153.19 112.84 3.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.932 1.293 . . . . 0.0 110.347 -169.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -64.13 -12.2 37.42 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.324 1.85 . . . . 0.0 114.572 -175.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -75.44 -22.67 57.16 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 120.235 1.379 . . . . 0.0 113.651 -170.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 12.4 ttp85 14.57 100.97 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 130.564 3.546 . . . . 0.0 115.325 164.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 16.1 m170 -51.49 155.75 1.45 Allowed 'General case' 0 CA--C 1.558 1.258 0 CA-C-O 117.272 -1.347 . . . . 0.0 109.834 168.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.316 85.3 t -74.57 -17.49 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-N 123.865 3.029 . . . . 0.0 110.231 -175.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -82.47 7.52 64.55 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 127.423 2.44 . . . . 0.0 114.404 166.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -98.93 119.25 37.4 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.838 1.819 . . . . 0.0 113.401 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 63.3 mt -102.27 -176.06 3.01 Favored 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 126.73 2.012 . . . . 0.0 106.015 164.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.23 -144.91 5.09 Favored Glycine 0 CA--C 1.534 1.275 0 O-C-N 120.891 -1.13 . . . . 0.0 114.114 -178.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.65 152.16 49.46 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 123.983 0.913 . . . . 0.0 109.818 168.677 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 9.8 p -113.72 142.18 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.57 1.948 . . . . 0.0 112.207 -168.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -115.08 120.01 38.36 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.047 1.129 . . . . 0.0 114.047 -169.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.49 155.34 17.89 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 119.043 2.979 . . . . 0.0 119.043 175.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -84.51 164.89 18.51 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-N 111.631 -2.532 . . . . 0.0 109.808 167.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.16 -12.45 5.17 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 115.129 1.529 . . . . 0.0 115.129 171.399 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.66 -27.32 61.18 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.837 1.655 . . . . 0.0 111.2 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.24 -2.27 54.46 Favored Glycine 0 CA--C 1.523 0.544 0 CA-C-O 117.661 -1.633 . . . . 0.0 114.355 -177.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 9.5 p -79.48 118.49 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 119.572 1.686 . . . . 0.0 112.352 168.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -89.02 119.56 29.65 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.454 1.502 . . . . 0.0 108.587 166.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -80.46 140.27 36.02 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 118.492 0.587 . . . . 0.0 110.593 174.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -128.75 134.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.267 -1.333 . . . . 0.0 110.437 166.617 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.3 p -156.61 56.67 0.55 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 122.762 1.267 . . . . 0.0 109.628 -169.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 54.8 mt -114.78 160.68 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 125.044 1.337 . . . . 0.0 111.285 -169.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 31.3 tt0 -133.47 146.15 50.87 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.837 2.055 . . . . 0.0 108.467 169.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -140.35 125.75 18.91 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 124.702 1.201 . . . . 0.0 110.442 -169.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 79.4 p -107.04 57.72 0.63 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 124.745 1.218 . . . . 0.0 112.308 -172.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 p -154.56 -41.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.93 173.67 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 O-C-N 121.232 -0.918 . . . . 0.0 112.026 177.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 25.8 m -158.25 162.99 37.86 Favored 'General case' 0 N--CA 1.481 1.081 0 O-C-N 119.579 -1.95 . . . . 0.0 115.028 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.35 59.24 1.8 Allowed 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 127.611 2.364 . . . . 0.0 108.484 175.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.9 t -89.82 1.3 56.32 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.242 1.017 . . . . 0.0 113.276 -175.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.17 -32.46 1.11 Allowed Glycine 0 N--CA 1.474 1.179 0 C-N-CA 125.029 1.3 . . . . 0.0 114.818 177.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.1 t0 -123.51 -95.06 0.48 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.985 1.314 . . . . 0.0 112.76 -169.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -75.92 3.07 10.9 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 119.678 -1.889 . . . . 0.0 114.344 -164.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.9 t -107.2 -128.85 0.27 Allowed 'General case' 0 CA--C 1.541 0.628 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.677 -175.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 pt -84.0 -18.64 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 121.516 1.962 . . . . 0.0 115.981 -179.142 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mm -69.4 134.3 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.389 0.995 . . . . 0.0 111.017 -171.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.22 -2.75 75.12 Favored Glycine 0 CA--C 1.533 1.213 0 CA-C-O 117.836 -1.535 . . . . 0.0 114.038 -178.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 18.6 mtm180 -86.58 158.33 19.53 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 119.476 1.638 . . . . 0.0 109.998 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.5 t -115.98 119.85 37.23 Favored 'General case' 0 N--CA 1.486 1.346 0 CA-C-N 120.41 1.459 . . . . 0.0 112.942 -168.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 36.6 tp -94.93 121.33 36.43 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 126.511 1.924 . . . . 0.0 110.476 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.4 p -107.39 126.32 63.62 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.6 1.16 . . . . 0.0 110.194 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.432 HG23 ' CD2' ' B' ' 8' ' ' LEU . 67.5 t -89.15 163.57 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 168.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 56.9 m-70 -123.8 138.21 54.54 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.964 1.306 . . . . 0.0 111.286 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 3.1 pp20? -70.94 -11.23 60.85 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 120.177 -1.577 . . . . 0.0 114.549 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -115.62 167.03 11.27 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.107 1.363 . . . . 0.0 112.707 168.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -54.07 150.54 7.97 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 125.773 1.629 . . . . 0.0 110.434 166.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -112.53 144.68 41.6 Favored 'General case' 0 C--O 1.243 0.735 0 CA-C-O 121.717 0.77 . . . . 0.0 112.762 -178.172 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -76.45 -25.29 54.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.571 1.548 . . . . 0.0 111.748 -177.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 47.9 mt 48.61 51.93 14.69 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 126.949 2.099 . . . . 0.0 111.473 170.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 170.21 -94.44 0.1 Allowed Glycine 0 C--N 1.334 0.43 0 N-CA-C 117.11 1.604 . . . . 0.0 117.11 173.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 ptpp? -163.27 30.46 0.09 Allowed 'General case' 0 CA--C 1.55 0.949 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -164.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -51.64 -22.06 7.77 Favored Glycine 0 N--CA 1.477 1.404 0 N-CA-C 119.388 2.515 . . . . 0.0 119.388 -168.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 175.77 -18.68 0.04 OUTLIER Glycine 0 N--CA 1.474 1.182 0 N-CA-C 117.565 1.786 . . . . 0.0 117.565 174.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -144.68 179.37 7.34 Favored 'General case' 0 CA--C 1.545 0.782 0 CA-C-N 119.291 1.546 . . . . 0.0 113.56 -173.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . 0.262 0.0 OUTLIER -49.84 -63.91 0.97 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.848 2.059 . . . . 0.0 111.435 172.232 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -54.11 -33.7 58.37 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 121.593 1.997 . . . . 0.0 113.373 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.15 -32.81 62.41 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 121.083 1.765 . . . . 0.0 114.193 172.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 9.3 t -105.32 -12.53 16.02 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.435 1.094 . . . . 0.0 113.499 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 28.7 tttt -96.54 -35.82 10.97 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.381 1.873 . . . . 0.0 112.705 -178.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 8.2 p -126.78 -20.65 4.22 Favored 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 125.139 1.376 . . . . 0.0 114.689 175.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 97.58 13.83 42.95 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.554 1.073 . . . . 0.0 110.534 -166.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 66.43 -68.08 0.14 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.769 3.228 . . . . 0.0 110.111 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 57.69 -66.7 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 131.445 3.898 . . . . 0.0 113.243 177.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.35 -28.71 4.98 Favored Glycine 0 CA--C 1.531 1.065 0 C-N-CA 127.523 2.487 . . . . 0.0 111.977 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.2 t -166.49 -161.63 0.47 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 124.605 1.162 . . . . 0.0 112.108 173.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -119.53 -156.49 0.66 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 128.328 2.651 . . . . 0.0 109.558 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -179.82 -164.55 0.06 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.867 2.467 . . . . 0.0 107.275 -171.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.89 144.25 23.43 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 127.243 2.217 . . . . 0.0 111.532 176.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.2 p -144.36 147.84 33.95 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -175.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.04 150.01 19.92 Favored Glycine 0 N--CA 1.476 1.355 0 C-N-CA 124.693 1.14 . . . . 0.0 114.651 -174.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.494 HG11 HG11 ' A' ' 148' ' ' VAL . 5.0 t -82.37 150.25 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.67 -0.9 . . . . 0.0 113.059 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mt -77.26 78.9 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 C-N-CA 126.562 1.945 . . . . 0.0 110.94 171.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -97.02 -158.96 31.3 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 126.243 1.878 . . . . 0.0 112.644 173.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -136.69 148.87 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -171.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -95.91 -120.07 0.11 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 103.058 -2.941 . . . . 0.0 103.058 163.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.471 0.597 0 C-N-CA 123.787 0.835 . . . . 0.0 112.674 166.051 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 122.564 1.174 . . . . 0.0 111.849 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.3 t -157.37 171.09 21.01 Favored 'General case' 0 N--CA 1.446 -0.672 0 C-N-CA 130.276 3.43 . . . . 0.0 104.26 164.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -146.06 138.94 25.7 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 116.413 2.005 . . . . 0.0 116.413 177.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 169.63 9.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 127.258 2.223 . . . . 0.0 111.439 171.358 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.556 HG22 HG21 ' B' ' 54' ' ' THR . 14.7 p -158.6 110.51 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.772 1.629 . . . . 0.0 111.739 173.177 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.79 116.29 12.0 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.755 1.222 . . . . 0.0 112.442 -167.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.4 p -81.42 84.51 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.69 100.69 8.83 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 173.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 35.0 ttmt -159.68 80.12 0.72 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 123.482 0.713 . . . . 0.0 112.172 -172.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.03 8.02 3.53 Favored Glycine 0 N--CA 1.472 1.056 0 C-N-CA 125.813 1.673 . . . . 0.0 113.658 169.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -133.46 54.88 1.93 Allowed 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 125.761 1.624 . . . . 0.0 108.74 -168.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 29.51 -98.23 0.01 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 129.381 3.372 . . . . 0.0 115.735 179.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.3 -15.22 47.42 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 124.2 3.266 . . . . 0.0 115.001 -176.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 t -111.34 128.86 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 125.058 1.343 . . . . 0.0 108.515 -175.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.98 162.68 40.32 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.82 -174.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.45 170.07 29.0 Favored Glycine 0 CA--C 1.505 -0.592 0 CA-C-O 122.571 1.095 . . . . 0.0 114.206 174.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -130.76 128.27 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 C-N-CA 126.618 1.967 . . . . 0.0 106.356 173.498 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.3 mm -137.94 112.53 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 121.312 -0.867 . . . . 0.0 109.72 172.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 28.1 m-80 -75.75 157.78 33.09 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.032 0.933 . . . . 0.0 111.091 178.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -141.58 127.93 19.93 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 124.812 1.245 . . . . 0.0 107.823 168.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -91.66 120.19 32.21 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 119.017 0.826 . . . . 0.0 112.138 174.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.469 HE22 ' HB2' ' A' ' 105' ' ' SER . 9.8 tp60 -88.49 78.45 7.86 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 118.658 -2.526 . . . . 0.0 105.701 167.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.7 ptmt -58.19 -41.52 84.12 Favored 'General case' 0 CA--C 1.543 0.695 0 O-C-N 120.909 -1.119 . . . . 0.0 110.669 175.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -155.19 142.46 19.43 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 129.41 3.084 . . . . 0.0 108.088 -166.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.2 m -48.23 -44.42 33.18 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 116.175 1.917 . . . . 0.0 116.175 -167.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -126.12 23.38 7.1 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.783 1.233 . . . . 0.0 112.0 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.75 167.82 53.58 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.134 -0.815 . . . . 0.0 112.481 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -65.73 151.36 84.67 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.37 2.047 . . . . 0.0 109.496 169.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 86.3 t -135.62 134.63 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-O 122.63 1.205 . . . . 0.0 110.702 -175.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.5 ttmm -81.03 128.26 33.51 Favored 'General case' 0 CA--C 1.539 0.557 0 CA-C-N 114.056 -1.429 . . . . 0.0 108.212 167.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 64.0 t -124.91 111.17 26.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 126.846 2.058 . . . . 0.0 110.599 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 17.2 p90 -144.81 154.85 43.11 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -168.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 162.11 -138.94 5.66 Favored Glycine 0 C--N 1.335 0.496 0 O-C-N 120.903 -1.123 . . . . 0.0 112.895 172.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -154.08 131.61 11.37 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 112.284 0.475 . . . . 0.0 112.284 -169.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mm -117.34 126.6 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 123.944 0.898 . . . . 0.0 109.322 173.169 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.3 ttpt -123.7 142.23 51.27 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.305 1.842 . . . . 0.0 110.763 -168.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.49 -16.41 57.87 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 125.946 1.736 . . . . 0.0 111.774 -169.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -65.01 113.02 3.6 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 167.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -60.13 -41.54 92.91 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 118.97 0.804 . . . . 0.0 111.627 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.3 -178.16 1.98 Allowed 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.381 1.073 . . . . 0.0 113.017 -168.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 65.96 176.27 6.53 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.961 1.267 . . . . 0.0 115.544 166.6 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -73.39 142.88 46.96 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 169.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -127.03 127.72 45.2 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 127.493 2.317 . . . . 0.0 107.145 174.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.84 156.43 40.35 Favored Glycine 0 N--CA 1.467 0.766 0 CA-C-O 119.016 -0.88 . . . . 0.0 111.13 -176.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.41 130.61 17.48 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 118.037 0.919 . . . . 0.0 109.297 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -154.89 161.97 41.26 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 120.337 -1.477 . . . . 0.0 111.1 173.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' CA ' ' A' ' 82' ' ' GLY . 0.8 OUTLIER -104.37 135.83 40.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-O 122.629 1.204 . . . . 0.0 110.92 176.11 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -73.53 176.69 5.9 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 126.562 1.945 . . . . 0.0 110.526 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -72.18 -14.36 61.79 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.608 1.706 . . . . 0.0 115.608 174.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.461 ' C ' ' HA ' ' A' ' 115' ' ' ARG . 22.3 m-85 -157.03 172.97 17.73 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 129.757 3.223 . . . . 0.0 107.609 -167.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.17 30.28 4.44 Favored Glycine 0 C--O 1.223 -0.581 0 N-CA-C 108.677 -1.769 . . . . 0.0 108.677 165.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -82.24 109.53 16.61 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 119.408 1.604 . . . . 0.0 111.027 -166.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.438 HD21 HG22 ' A' ' 148' ' ' VAL 0.299 1.9 p30 -159.18 32.54 0.2 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 117.915 2.561 . . . . 0.0 117.915 179.284 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.735 HG22 HG23 ' B' ' 5' ' ' VAL . 0.1 OUTLIER -84.84 -35.54 22.19 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 126.078 1.751 . . . . 0.0 112.883 -167.816 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -115.06 -13.68 11.85 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.021 1.729 . . . . 0.0 113.429 177.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.58 -75.68 0.84 Allowed Glycine 0 CA--C 1.529 0.939 0 C-N-CA 124.49 1.043 . . . . 0.0 111.524 -174.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.8 m -65.65 -17.62 64.73 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.9 p -127.51 33.43 4.84 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.333 1.453 . . . . 0.0 112.103 171.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 97.7 p -179.42 106.67 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.334 1.853 . . . . 0.0 110.56 177.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 166.53 73.43 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 131.183 3.793 . . . . 0.0 109.097 175.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -74.62 107.87 2.38 Favored Glycine 0 CA--C 1.542 1.725 0 C-N-CA 125.194 1.378 . . . . 0.0 114.665 -169.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -86.56 101.09 0.58 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 124.041 3.161 . . . . 0.0 112.008 -168.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 55.44 39.73 31.19 Favored 'General case' 0 C--O 1.242 0.7 0 C-N-CA 127.495 2.318 . . . . 0.0 113.221 170.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -77.05 124.69 28.15 Favored 'General case' 0 C--O 1.234 0.269 0 O-C-N 120.365 -1.46 . . . . 0.0 108.148 169.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -152.79 135.09 8.98 Favored Pre-proline 0 CA--C 1.539 0.554 0 CA-C-N 114.048 -1.433 . . . . 0.0 112.252 -173.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -71.43 -2.42 11.24 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.051 2.501 . . . . 0.0 114.214 -172.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 26.8 mt -79.51 -20.01 48.27 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 118.947 0.794 . . . . 0.0 112.038 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t 49.07 50.98 17.05 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 125.247 1.419 . . . . 0.0 113.371 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.0 mtm-85 -112.53 178.51 4.27 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 125.251 1.42 . . . . 0.0 112.666 -173.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.77 161.14 27.91 Favored 'General case' 0 CA--C 1.553 1.093 0 CA-C-N 118.504 0.593 . . . . 0.0 109.811 164.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.444 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 82.1 t60 -66.51 -175.91 0.41 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 125.503 1.521 . . . . 0.0 112.542 -177.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.444 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 107.26 -138.27 14.41 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 115.549 0.98 . . . . 0.0 115.549 165.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.89 -64.54 0.6 Allowed Glycine 0 CA--C 1.541 1.68 0 N-CA-C 116.941 1.536 . . . . 0.0 116.941 -174.322 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.95 -4.55 15.31 Favored 'Trans proline' 0 CA--C 1.544 1.011 0 CA-C-N 121.11 2.455 . . . . 0.0 114.427 -178.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.59 -1.47 0.52 Allowed 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 126.154 1.782 . . . . 0.0 114.207 172.101 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -124.19 148.34 47.34 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.395 2.278 . . . . 0.0 107.405 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.04 -20.68 30.07 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 127.3 2.24 . . . . 0.0 112.735 -168.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -83.68 -64.96 1.07 Allowed 'General case' 0 C--O 1.232 0.149 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -169.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 34.7 ttt-85 66.19 120.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.285 1.434 . . . . 0.0 111.724 -177.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -65.53 172.56 3.24 Favored 'General case' 0 CA--C 1.544 0.716 0 O-C-N 119.567 -1.958 . . . . 0.0 109.355 165.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -35.29 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.313 -1.492 . . . . 0.0 112.644 168.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.503 ' CA ' HG23 ' A' ' 47' ' ' VAL . . . -107.71 50.65 0.77 Allowed Glycine 0 CA--C 1.534 1.277 0 N-CA-C 117.007 1.563 . . . . 0.0 117.007 -169.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -124.45 119.17 28.41 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.56 -0.965 . . . . 0.0 113.291 -169.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -97.35 175.5 6.23 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.944 1.298 . . . . 0.0 108.586 167.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -94.59 170.18 29.4 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.676 1.132 . . . . 0.0 111.214 169.034 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -76.79 145.85 38.24 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.56 1.318 . . . . 0.0 114.56 -176.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.21 122.71 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 127.23 2.212 . . . . 0.0 109.27 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 99.0 m -110.73 121.59 45.71 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -169.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -100.53 142.02 32.59 Favored 'General case' 0 N--CA 1.445 -0.702 0 C-N-CA 125.582 1.553 . . . . 0.0 113.328 -172.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.439 ' OD1' ' HE3' ' A' ' 91' ' ' LYS . 29.1 t0 -91.91 148.33 22.3 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.127 -1.397 . . . . 0.0 110.906 168.554 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.439 ' HE3' ' OD1' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -47.26 -21.23 0.25 Allowed 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 128.61 2.764 . . . . 0.0 117.38 -170.336 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -74.97 -0.71 19.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 127.492 2.317 . . . . 0.0 111.818 177.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.06 32.16 6.27 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 117.365 -1.797 . . . . 0.0 114.059 170.322 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -152.85 132.53 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 N-CA-C 117.152 2.279 . . . . 0.0 117.152 -176.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.52 109.71 22.24 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.96 164.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -91.5 133.3 35.63 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -141.0 145.94 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 118.515 2.783 . . . . 0.0 118.515 -168.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 93.8 p -142.81 105.52 4.5 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.39 1.876 . . . . 0.0 110.018 168.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.3 mt -107.17 150.85 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 C-N-CA 125.916 1.686 . . . . 0.0 108.929 169.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -144.45 138.29 27.57 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.954 1.702 . . . . 0.0 107.631 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -157.05 152.25 26.26 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.162 0.985 . . . . 0.0 112.252 -168.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.3 p -119.17 55.2 0.95 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.469 1.108 . . . . 0.0 113.609 -168.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.6 p -158.56 -27.34 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 124.756 1.222 . . . . 0.0 112.776 171.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.56 150.02 5.51 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.327 0 O-C-N 121.062 -1.024 . . . . 0.0 111.029 175.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.469 ' HB2' HE22 ' A' ' 22' ' ' GLN . 2.9 p -158.05 162.92 38.13 Favored 'General case' 0 C--N 1.32 -0.695 0 O-C-N 121.057 -1.027 . . . . 0.0 109.174 171.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.2 mp -85.83 47.82 1.5 Allowed 'General case' 0 CA--C 1.547 0.836 0 O-C-N 120.413 -1.429 . . . . 0.0 110.923 -172.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.6 t -82.18 -0.48 45.22 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -172.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.48 -7.02 74.58 Favored Glycine 0 N--CA 1.477 1.368 0 N-CA-C 118.216 2.046 . . . . 0.0 118.216 169.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -121.15 -94.81 0.49 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 125.637 1.575 . . . . 0.0 110.46 -167.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 2.3 m170 -91.49 5.76 48.21 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 -168.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.3 p -107.43 -70.71 0.78 Allowed 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 117.532 2.419 . . . . 0.0 117.532 -166.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pt -159.28 -51.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 125.747 1.619 . . . . 0.0 113.324 -167.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.43 145.62 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 125.89 1.676 . . . . 0.0 108.347 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.83 -22.08 2.99 Favored Glycine 0 N--CA 1.47 0.92 0 C-N-CA 124.585 1.088 . . . . 0.0 112.125 -167.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.461 ' HA ' ' C ' ' A' ' 50' ' ' PHE . 41.8 mtt180 -85.38 176.81 8.06 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 126.851 2.06 . . . . 0.0 110.948 169.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 1.4 m -108.76 133.66 52.52 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 127.471 2.309 . . . . 0.0 108.032 171.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.405 ' HB3' HD11 ' A' ' 149' ' ' ILE . 26.5 tp -102.41 118.05 36.04 Favored 'General case' 0 CA--C 1.535 0.365 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 168.349 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -112.15 129.81 66.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 CA-C-N 119.253 0.933 . . . . 0.0 110.815 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.465 HG13 ' HB3' ' A' ' 144' ' ' LEU . 2.4 p -88.92 145.99 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 121.394 0.616 . . . . 0.0 109.837 169.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -102.92 161.55 13.66 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.817 1.647 . . . . 0.0 111.83 -175.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.13 -31.91 62.95 Favored 'General case' 0 N--CA 1.473 0.704 0 O-C-N 121.081 -1.012 . . . . 0.0 112.086 -173.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 27.6 mmtm -131.86 -178.92 5.1 Favored 'General case' 0 C--O 1.237 0.4 0 O-C-N 119.234 -2.166 . . . . 0.0 110.974 169.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.72 129.02 39.38 Favored 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 125.077 1.351 . . . . 0.0 109.298 -176.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -79.18 152.62 30.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 166.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -73.27 -17.92 61.27 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.945 178.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 13.4 mt 61.77 41.96 11.2 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.037 1.335 . . . . 0.0 110.227 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 175.28 -97.08 0.11 Allowed Glycine 0 N--CA 1.471 0.999 0 N-CA-C 118.969 2.348 . . . . 0.0 118.969 177.351 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.0 pttt -162.69 37.26 0.11 Allowed 'General case' 0 CA--C 1.555 1.139 0 C-N-CA 127.99 2.516 . . . . 0.0 113.631 -167.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -55.07 -12.7 4.13 Favored Glycine 0 CA--C 1.539 1.535 0 N-CA-C 120.132 2.813 . . . . 0.0 120.132 -168.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.47 -28.8 0.5 Allowed Glycine 0 N--CA 1.477 1.379 0 CA-C-N 121.085 2.442 . . . . 0.0 118.038 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.407 HD21 ' ND2' ' A' ' 139' ' ' ASN . 22.1 p-10 -107.13 166.62 10.48 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 119.404 1.602 . . . . 0.0 109.656 174.143 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -57.05 -48.58 78.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 119.932 1.242 . . . . 0.0 109.67 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -48.54 -34.56 11.59 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.722 2.809 . . . . 0.0 113.046 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 75.6 p -57.7 -28.22 63.64 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 173.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.09 -23.82 10.68 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 169.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -59.18 -28.07 66.28 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.484 1.038 . . . . 0.0 111.467 172.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.9 p -133.87 -93.04 0.33 Allowed 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 166.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -158.12 24.81 0.4 Allowed Glycine 0 CA--C 1.537 1.428 0 C-N-CA 130.194 3.759 . . . . 0.0 109.224 168.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.407 ' ND2' HD21 ' A' ' 131' ' ' ASN . 23.8 t-20 67.11 -84.0 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.367 1.867 . . . . 0.0 107.787 -166.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . 66.52 2.15 2.38 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 127.821 2.448 . . . . 0.0 116.711 166.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.71 -57.81 3.01 Favored Glycine 0 CA--C 1.53 1.004 0 C-N-CA 125.683 1.611 . . . . 0.0 113.681 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 19.5 t -171.83 -177.4 1.95 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.166 1.387 . . . . 0.0 111.306 -171.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.8 164.88 13.18 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 121.151 -0.968 . . . . 0.0 111.926 172.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.476 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -150.94 -152.57 0.44 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 127.568 2.347 . . . . 0.0 106.577 174.817 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.476 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -37.47 112.15 0.19 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.8 2.04 . . . . 0.0 114.296 -170.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.5 t -109.29 138.96 44.86 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.065 2.146 . . . . 0.0 110.538 -175.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.5 -178.57 21.13 Favored Glycine 0 N--CA 1.469 0.899 0 C-N-CA 124.588 1.09 . . . . 0.0 114.32 -175.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.438 HG22 HD21 ' A' ' 53' ' ' ASN . 0.2 OUTLIER -127.97 160.41 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 104.893 -2.262 . . . . 0.0 104.893 165.723 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.405 HD11 ' HB3' ' A' ' 117' ' ' LEU . 2.6 mm -135.04 130.56 52.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 CA-C-N 120.069 1.304 . . . . 0.0 112.434 -168.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -135.27 -114.04 1.37 Allowed Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.668 1.604 . . . . 0.0 115.025 -175.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -158.38 129.25 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 118.877 1.338 . . . . 0.0 109.756 -177.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 -35.55 14.95 Favored 'General case' 0 N--CA 1.47 0.531 0 O-C-N 120.929 -1.107 . . . . 0.0 112.42 177.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 . . . . . 0 C--O 1.235 0.294 0 C-N-CA 127.264 2.226 . . . . 0.0 110.005 -171.524 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.549 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 99.2 m -79.17 105.21 10.34 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 169.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.496 ' HZ3' ' CD ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -97.66 122.52 40.84 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.709 1.203 . . . . 0.0 113.366 -168.409 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.52 178.12 8.37 Favored 'General case' 0 CA--C 1.545 0.761 0 O-C-N 120.911 -1.118 . . . . 0.0 114.005 -177.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.735 HG23 HG22 ' A' ' 54' ' ' THR . 0.2 OUTLIER -147.86 110.03 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 128.053 2.541 . . . . 0.0 106.784 169.314 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -99.3 133.28 43.82 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.951 0.9 . . . . 0.0 108.631 166.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -131.36 99.42 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 123.256 0.622 . . . . 0.0 110.965 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 8.8 mp -88.21 141.69 28.36 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 124.067 0.854 . . . . 0.0 109.867 169.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -156.07 168.16 28.13 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 125.913 1.685 . . . . 0.0 112.073 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.48 -101.95 0.19 Allowed Glycine 0 C--O 1.226 -0.398 0 N-CA-C 107.583 -2.207 . . . . 0.0 107.583 166.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -149.42 124.84 10.26 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 129.014 2.926 . . . . 0.0 106.095 -169.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.07 -177.69 44.61 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 124.544 1.069 . . . . 0.0 112.81 -174.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -71.92 30.22 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.093 1 C-N-CA 126.157 4.571 . . . . 0.0 115.11 -170.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.11 123.78 63.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 125.558 1.543 . . . . 0.0 109.441 -177.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.65 163.71 36.48 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 124.272 1.029 . . . . 0.0 109.585 176.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -132.67 108.78 0.79 Allowed Glycine 0 N--CA 1.461 0.302 0 CA-C-N 114.106 -1.406 . . . . 0.0 110.373 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.46 128.88 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 123.956 0.902 . . . . 0.0 109.401 169.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mm -134.82 124.51 43.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 123.864 0.866 . . . . 0.0 109.231 168.324 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -79.9 149.63 30.84 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 126.697 1.999 . . . . 0.0 109.924 165.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -143.97 101.97 3.82 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.496 ' CD ' ' HZ3' ' B' ' 3' ' ' LYS . 0.4 OUTLIER -108.83 116.86 32.78 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.367 1.067 . . . . 0.0 109.831 -169.572 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 -116.96 142.28 47.15 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-O 122.652 1.215 . . . . 0.0 112.917 -172.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.562 ' HZ2' ' CD ' ' B' ' 24' ' ' GLU . 0.0 OUTLIER -90.74 -7.57 52.13 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.337 1.455 . . . . 0.0 114.61 -173.656 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.562 ' CD ' ' HZ2' ' B' ' 23' ' ' LYS . 48.9 mp0 -150.22 -173.99 4.6 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 127.368 2.267 . . . . 0.0 108.24 173.024 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.6 p -75.4 -26.71 58.65 Favored 'General case' 0 CA--C 1.537 0.476 0 O-C-N 121.47 -0.769 . . . . 0.0 111.215 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -135.25 9.99 3.49 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.274 1.429 . . . . 0.0 114.101 -171.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.54 174.02 55.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.236 0.922 . . . . 0.0 111.555 169.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.11 166.13 30.85 Favored 'Trans proline' 0 CA--C 1.536 0.578 0 C-N-CA 122.712 2.274 . . . . 0.0 111.116 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.58 132.58 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 C-N-CA 124.876 1.27 . . . . 0.0 110.661 -168.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -88.52 127.81 35.54 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 168.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.8 t -116.91 124.19 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 126.011 1.724 . . . . 0.0 109.058 -171.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -155.41 157.29 36.8 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.152 -0.968 . . . . 0.0 113.269 177.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.13 -160.74 30.67 Favored Glycine 0 CA--C 1.52 0.364 0 O-C-N 121.553 -0.717 . . . . 0.0 113.706 -177.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 53.3 p -149.24 133.19 17.11 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 113.276 0.843 . . . . 0.0 113.276 -168.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -106.01 113.43 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 O-C-N 121.724 -0.61 . . . . 0.0 109.794 171.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 3.7 ptpt -110.78 157.96 19.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.164 1.385 . . . . 0.0 110.613 -170.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.28 8.29 75.09 Favored Glycine 0 N--CA 1.476 1.308 0 C-N-CA 123.861 0.743 . . . . 0.0 113.997 -173.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 6.3 mp -81.15 -152.4 0.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 127.19 2.196 . . . . 0.0 107.865 168.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . 0.499 HG23 ' H ' ' B' ' 40' ' ' GLU 0.282 7.9 t -137.14 -91.78 0.24 Allowed 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 124.996 1.318 . . . . 0.0 108.353 169.702 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . 0.499 ' H ' HG23 ' B' ' 39' ' ' THR . 0.0 OUTLIER -127.98 -56.55 1.27 Allowed 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.438 1.495 . . . . 0.0 113.719 173.085 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -60.39 147.76 44.87 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 119.856 -1.778 . . . . 0.0 113.558 -169.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.442 ' H ' HD12 ' B' ' 42' ' ' LEU . 1.2 mp -44.9 141.91 2.0 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 126.84 2.056 . . . . 0.0 112.619 -173.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 73.1 m-70 -126.09 130.64 51.49 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.689 1.596 . . . . 0.0 109.276 170.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.76 163.01 41.08 Favored Glycine 0 N--CA 1.482 1.717 0 CA-C-N 120.292 1.406 . . . . 0.0 111.516 172.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -152.46 130.31 11.7 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 120.673 2.237 . . . . 0.0 112.513 168.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -156.28 146.36 21.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.473 1.109 . . . . 0.0 111.999 -168.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 p -82.63 135.1 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 O-C-N 121.632 -0.667 . . . . 0.0 110.653 168.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.493 ' HB2' HG23 ' B' ' 116' ' ' THR . 7.5 m-70 -78.19 159.01 28.81 Favored 'General case' 0 CA--C 1.559 1.304 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.141 165.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -67.32 110.89 3.73 Favored 'General case' 0 N--CA 1.469 0.497 0 O-C-N 119.473 -2.017 . . . . 0.0 110.258 171.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . 0.432 ' O ' HG22 ' B' ' 116' ' ' THR . 4.3 m-30 142.31 167.37 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 1 C-N-CA 132.927 4.491 . . . . 0.0 110.176 175.717 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -131.13 14.83 5.39 Favored Glycine 0 C--O 1.222 -0.613 0 C-N-CA 126.42 1.962 . . . . 0.0 114.051 172.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -170.53 113.97 0.45 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.431 2.692 . . . . 0.0 103.972 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' B' ' 54' ' ' THR . 2.6 p30 -116.04 -64.49 1.3 Allowed 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 114.354 1.242 . . . . 0.0 114.354 -164.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.556 HG21 HG22 ' A' ' 5' ' ' VAL . 2.8 p 77.56 -55.86 0.52 Allowed 'General case' 0 N--CA 1.462 0.139 0 C-N-CA 128.919 2.888 . . . . 0.0 113.275 170.018 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 -52.28 11.17 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.236 1.014 . . . . 0.0 111.479 177.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 133.55 -139.56 11.02 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.789 1.662 . . . . 0.0 109.185 -169.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 45.2 m -49.95 -32.03 13.95 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -172.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 -8.27 0.99 Allowed 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 128.108 2.563 . . . . 0.0 114.363 173.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 38.7 m -159.03 42.12 0.23 Allowed 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 128.576 2.75 . . . . 0.0 107.41 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -170.22 72.59 0.07 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.282 2.233 . . . . 0.0 109.267 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -69.62 -178.57 21.51 Favored Glycine 0 CA--C 1.538 1.476 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.553 173.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -62.72 168.34 10.32 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.647 2.231 . . . . 0.0 110.849 171.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -45.08 115.36 0.89 Allowed 'General case' 0 C--O 1.236 0.35 0 N-CA-C 115.575 1.695 . . . . 0.0 115.575 -178.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -45.58 117.46 1.45 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.832 166.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -120.84 65.82 13.24 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 115.103 -0.953 . . . . 0.0 113.152 -167.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.81 -4.87 14.18 Favored 'Trans proline' 0 CA--C 1.539 0.766 0 C-N-CA 123.304 2.669 . . . . 0.0 114.561 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . 0.411 ' HB3' ' HD3' ' B' ' 69' ' ' ARG . 3.3 mm? -106.73 -6.11 18.05 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 124.198 0.999 . . . . 0.0 112.71 175.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 18.9 t 66.4 57.92 0.7 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 125.884 1.674 . . . . 0.0 114.722 171.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . 0.411 ' HD3' ' HB3' ' B' ' 67' ' ' LEU . 0.2 OUTLIER -154.06 -176.58 5.93 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 116.226 1.935 . . . . 0.0 116.226 -169.279 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -80.62 178.15 8.54 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.953 1.301 . . . . 0.0 112.194 -170.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -108.73 144.36 36.63 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.287 -1.324 . . . . 0.0 114.168 176.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 154.33 -102.2 0.22 Allowed Glycine 0 C--N 1.336 0.543 0 C-N-CA 126.37 1.938 . . . . 0.0 110.108 167.297 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.89 -41.22 2.01 Favored Glycine 0 CA--C 1.542 1.774 0 CA-C-O 118.013 -1.437 . . . . 0.0 115.653 172.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_exo -79.62 -25.83 5.17 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 124.206 3.271 . . . . 0.0 112.12 168.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.79 -53.52 2.64 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.901 0.88 . . . . 0.0 110.49 168.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -63.84 106.16 0.96 Allowed 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.311 1.414 . . . . 0.0 111.88 172.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 42.8 mp0 -59.76 -9.75 3.12 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 129.259 3.023 . . . . 0.0 113.485 175.445 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -85.1 -98.02 0.06 Allowed 'General case' 0 N--CA 1.453 -0.321 0 O-C-N 121.411 -0.806 . . . . 0.0 110.684 174.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 94.09 133.37 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.169 1.787 . . . . 0.0 110.845 173.125 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -70.23 154.54 41.79 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 168.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.2 t -80.44 87.94 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 166.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.47 4.35 0.18 Allowed Glycine 0 CA--C 1.537 1.452 0 N-CA-C 117.672 1.829 . . . . 0.0 117.672 -169.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -150.65 150.51 31.22 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 119.828 1.814 . . . . 0.0 112.511 174.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.7 mt -124.16 49.05 1.82 Allowed 'General case' 0 CA--C 1.547 0.842 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.116 169.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.97 -102.99 0.91 Allowed Glycine 0 CA--C 1.532 1.154 0 O-C-N 120.64 -1.287 . . . . 0.0 115.37 176.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -144.71 163.25 34.57 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 125.024 1.33 . . . . 0.0 113.505 -175.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 8.2 m -114.45 165.49 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 127.502 2.321 . . . . 0.0 110.115 170.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 62.6 m -146.43 141.31 27.01 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.903 1.281 . . . . 0.0 108.007 174.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -97.49 164.35 12.48 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -173.097 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -78.0 -52.09 9.35 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.457 1.503 . . . . 0.0 113.248 -171.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 9.4 pttp 151.62 -37.94 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.991 1 C-N-CA 133.775 4.83 . . . . 0.0 109.637 -168.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -84.66 25.79 0.87 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.897 1.679 . . . . 0.0 111.021 -178.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.34 3.67 77.57 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.815 1.674 . . . . 0.0 115.56 174.521 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.3 p -109.34 129.41 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-N 119.011 1.406 . . . . 0.0 113.425 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -95.3 129.77 42.31 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 125.165 1.386 . . . . 0.0 107.766 165.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -116.93 130.62 56.82 Favored 'General case' 0 C--O 1.233 0.188 0 C-N-CA 125.012 1.325 . . . . 0.0 109.037 -172.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 45.5 t -130.26 137.19 56.96 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-N 114.16 -1.382 . . . . 0.0 114.239 -166.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 86.4 p -151.61 105.23 3.13 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 125.462 1.505 . . . . 0.0 111.635 177.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 22.3 mt -135.99 163.28 34.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 128.239 2.615 . . . . 0.0 110.45 -172.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -139.22 140.14 37.67 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 126.465 1.906 . . . . 0.0 107.089 167.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -146.01 143.18 29.28 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.491 1.116 . . . . 0.0 111.641 -169.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 9.0 p -118.4 46.04 1.89 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.039 -0.982 . . . . 0.0 112.57 -176.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . 0.272 4.4 p -156.12 20.32 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 174.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -131.45 160.52 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 120.65 -1.281 . . . . 0.0 108.344 167.121 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 51.4 m -158.03 168.87 25.92 Favored 'General case' 0 N--CA 1.47 0.573 0 O-C-N 120.691 -1.256 . . . . 0.0 112.192 175.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.29 64.23 1.6 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 125.974 1.709 . . . . 0.0 109.345 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 4.6 t -155.3 84.07 1.06 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.453 -1.405 . . . . 0.0 113.357 -169.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 89.29 -159.0 28.26 Favored Glycine 0 C--N 1.336 0.563 0 CA-C-O 122.997 1.332 . . . . 0.0 112.471 170.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -69.1 -19.7 64.06 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 127.57 2.348 . . . . 0.0 113.769 -167.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 64.7 m170 -97.3 7.9 45.63 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.112 1.365 . . . . 0.0 113.221 -175.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 73.2 m -81.98 176.79 9.26 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -165.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -80.02 -18.95 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 O-C-N 120.786 -1.196 . . . . 0.0 110.798 163.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mm -75.78 124.92 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 165.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.28 68.8 1.54 Allowed Glycine 0 CA--C 1.527 0.839 0 O-C-N 123.614 0.571 . . . . 0.0 113.462 -169.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -143.17 136.04 27.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 124.206 1.002 . . . . 0.0 109.579 168.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . 0.493 HG23 ' HB2' ' B' ' 48' ' ' HIS . 3.6 t -96.42 77.8 2.99 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 124.864 1.266 . . . . 0.0 110.369 -173.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 54.5 tp -77.94 135.49 37.85 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.0 1.32 . . . . 0.0 109.881 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -129.64 146.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 126.067 1.747 . . . . 0.0 108.989 172.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 79.3 t -104.09 140.61 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 122.605 1.193 . . . . 0.0 107.897 168.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -95.6 160.02 14.71 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.625 2.37 . . . . 0.0 112.303 -170.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -80.97 -34.31 33.22 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 120.806 -1.184 . . . . 0.0 114.015 -167.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 6.4 mmmt -113.42 -176.52 2.92 Favored 'General case' 0 N--CA 1.478 0.967 0 O-C-N 120.176 -1.578 . . . . 0.0 112.428 173.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -55.29 143.64 27.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.64 1.176 . . . . 0.0 109.921 169.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.23 146.04 24.55 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.957 1.303 . . . . 0.0 109.041 172.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -76.41 -27.75 56.4 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 178.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 9.7 mt 63.97 20.96 12.44 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.14 2.176 . . . . 0.0 114.34 174.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -150.68 -94.22 0.11 Allowed Glycine 0 N--CA 1.465 0.581 0 CA-C-N 120.583 1.538 . . . . 0.0 113.165 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 49.2 tttp -163.05 82.39 0.49 Allowed 'General case' 0 N--CA 1.432 -1.364 0 C-N-CA 127.172 2.189 . . . . 0.0 108.608 168.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.97 48.04 0.64 Allowed Glycine 0 CA--C 1.531 1.078 0 C-N-CA 126.778 2.133 . . . . 0.0 114.192 172.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 79.99 -10.97 37.67 Favored Glycine 0 CA--C 1.534 1.219 0 N-CA-C 118.084 1.994 . . . . 0.0 118.084 169.107 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 28.8 m-80 -115.28 177.78 4.53 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.765 2.282 . . . . 0.0 112.418 -169.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -59.11 -64.39 0.96 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.401 1.88 . . . . 0.0 108.992 165.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 48.7 mm-40 -47.8 -34.77 9.07 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.82 1.648 . . . . 0.0 113.37 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 8.8 m -55.97 -14.64 2.65 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 175.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 37.5 p -129.29 -24.56 2.82 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 168.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . 0.253 17.8 pttt -83.81 -6.0 59.33 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 115.764 1.765 . . . . 0.0 115.764 175.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 10.8 m -140.07 -44.64 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 124.948 1.299 . . . . 0.0 112.467 171.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.33 12.27 6.35 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 126.885 2.183 . . . . 0.0 114.151 -168.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 67.08 8.04 5.87 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 120.673 -1.487 . . . . 0.0 114.798 175.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.58 30.46 0.03 OUTLIER 'General case' 0 CA--C 1.564 1.506 0 N-CA-C 118.206 2.669 . . . . 0.0 118.206 -166.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.6 -51.4 3.37 Favored Glycine 0 N--CA 1.471 1.013 0 C-N-CA 127.218 2.342 . . . . 0.0 115.766 170.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 9.3 t -176.49 -163.1 0.09 Allowed 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.734 2.014 . . . . 0.0 110.545 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.21 142.27 17.03 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 119.77 -1.831 . . . . 0.0 115.739 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.74 -115.62 0.1 Allowed 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 128.508 2.723 . . . . 0.0 111.266 -177.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.13 138.87 36.99 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 128.454 2.702 . . . . 0.0 111.114 -169.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 28.4 p -126.41 151.76 47.25 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 126.413 1.885 . . . . 0.0 112.274 -175.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -154.58 169.91 32.9 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 116.434 1.334 . . . . 0.0 116.434 -172.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . 0.273 0.4 OUTLIER -126.62 162.31 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 123.521 0.728 . . . . 0.0 109.753 170.066 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 18.0 mt -120.95 127.64 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 C-N-CA 124.412 1.085 . . . . 0.0 113.365 -166.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -123.89 -159.31 10.42 Favored Glycine 0 C--N 1.349 1.282 0 C-N-CA 125.039 1.304 . . . . 0.0 113.631 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.1 pp -110.06 143.22 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 125.946 1.698 . . . . 0.0 111.959 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.448 ' HA ' ' CG ' ' A' ' 50' ' ' PHE . . . -124.49 37.98 4.29 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.456 1.902 . . . . 0.0 111.291 171.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.326 -0.429 0 C-N-CA 125.708 1.603 . . . . 0.0 109.829 -178.235 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.566 0 CA-C-O 117.08 -1.438 . . . . 0.0 108.141 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 94.3 m -83.84 76.63 10.0 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 120.523 1.511 . . . . 0.0 108.802 -172.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.16 138.89 33.47 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -175.012 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.81 169.74 8.85 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 126.534 1.934 . . . . 0.0 112.18 173.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 3.3 t -147.48 153.89 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 127.95 2.5 . . . . 0.0 110.51 172.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -126.4 112.64 15.87 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 125.351 1.461 . . . . 0.0 107.168 165.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.6 m -82.66 90.95 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 173.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 25.0 mt -76.28 130.01 37.52 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.574 -172.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.1 mttm -152.29 -179.02 7.17 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.59 1.156 . . . . 0.0 113.152 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 134.84 -58.62 0.68 Allowed Glycine 0 N--CA 1.467 0.763 0 C-N-CA 125.968 1.747 . . . . 0.0 110.058 -178.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -78.44 69.04 4.57 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 122.087 0.946 . . . . 0.0 113.22 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 39.25 -100.38 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 C-N-CA 127.863 2.649 . . . . 0.0 115.71 169.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.98 -9.88 18.03 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 124.783 3.655 . . . . 0.0 114.56 -177.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 t -86.07 143.57 11.22 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-N 119.679 1.127 . . . . 0.0 110.008 172.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -156.36 158.24 37.04 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.51 168.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -117.18 126.83 7.12 Favored Glycine 0 C--O 1.22 -0.758 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.55 99.19 6.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 174.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 pp -132.49 133.31 59.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 125.07 1.348 . . . . 0.0 109.525 -171.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -108.08 150.72 26.81 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 127.298 2.239 . . . . 0.0 111.208 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -122.22 134.75 54.7 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.567 1.947 . . . . 0.0 109.353 170.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -103.22 113.96 27.87 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 120.935 1.698 . . . . 0.0 110.904 172.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 37.1 tp60 -101.31 116.05 31.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 123.191 0.596 . . . . 0.0 109.488 172.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 12.1 pttp -102.9 -31.81 10.07 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 114.61 1.337 . . . . 0.0 114.61 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.7 mp0 -130.03 156.68 44.08 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 126.213 1.805 . . . . 0.0 108.766 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 5.0 m -55.68 -39.88 71.57 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 122.386 2.357 . . . . 0.0 116.244 -168.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -121.04 34.55 5.17 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.03 1.732 . . . . 0.0 110.422 167.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.89 153.47 51.35 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-O 118.129 -1.373 . . . . 0.0 111.021 171.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -66.38 142.7 67.01 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.123 2.549 . . . . 0.0 109.957 174.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.1 t -112.53 144.86 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.937 0.895 . . . . 0.0 110.879 -168.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.0 tttp -113.59 131.08 56.24 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.583 1.153 . . . . 0.0 108.804 167.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.9 t -107.96 144.49 16.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 127.872 2.469 . . . . 0.0 109.536 175.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 28.5 p90 -158.56 161.02 37.25 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.399 1.079 . . . . 0.0 113.185 172.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.63 -149.22 21.29 Favored Glycine 0 N--CA 1.469 0.865 0 C-N-CA 124.249 0.928 . . . . 0.0 112.693 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 79.8 p -153.57 148.75 26.9 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.4 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 16.9 mt -126.0 117.76 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 121.032 -1.043 . . . . 0.0 108.914 175.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 61.1 tttt -123.34 137.87 54.74 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 119.787 1.176 . . . . 0.0 112.168 -172.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.0 3.77 9.71 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 128.413 2.911 . . . . 0.0 113.886 -174.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.12 163.85 22.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 128.431 2.692 . . . . 0.0 112.074 176.302 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -95.07 158.4 15.48 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 166.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -64.07 145.22 56.29 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 113.399 0.888 . . . . 0.0 113.399 -172.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 100.99 -171.69 22.81 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 124.703 1.144 . . . . 0.0 114.591 -173.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 47.2 mt -66.23 146.94 54.04 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 125.532 1.533 . . . . 0.0 113.535 -169.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -144.99 128.59 17.11 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 127.01 2.124 . . . . 0.0 109.514 173.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.15 165.23 54.87 Favored Glycine 0 N--CA 1.473 1.137 0 CA-C-N 119.493 1.042 . . . . 0.0 112.292 -179.151 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.6 p90 -157.55 137.38 12.33 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.328 1.851 . . . . 0.0 113.706 167.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 p-80 -148.58 163.87 35.94 Favored 'General case' 0 N--CA 1.451 -0.415 0 O-C-N 119.695 -1.878 . . . . 0.0 112.074 169.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.1 m -96.04 134.08 34.88 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-O 121.795 0.807 . . . . 0.0 110.266 173.159 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 32.7 m170 -71.51 116.06 11.42 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 103.66 -2.719 . . . . 0.0 103.66 168.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.647 ' H ' ' HA ' ' A' ' 63' ' ' HIS 0.305 3.6 tt0 -70.68 21.33 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.897 0 N-CA-C 115.988 1.847 . . . . 0.0 115.988 -168.513 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -132.82 148.94 52.31 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 126.872 2.069 . . . . 0.0 111.204 179.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -93.14 -17.77 42.08 Favored Glycine 0 N--CA 1.465 0.591 0 CA-C-O 117.129 -1.928 . . . . 0.0 115.155 169.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.467 ' C ' HD22 ' A' ' 53' ' ' ASN . 15.4 t0 -72.39 88.78 1.2 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 120.053 1.927 . . . . 0.0 106.945 168.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.467 HD22 ' C ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER 168.07 -34.39 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 127.469 2.308 . . . . 0.0 116.766 169.456 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 18.6 p 27.62 -40.55 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.042 2 C-N-CA 133.615 4.766 . . . . 0.0 122.91 179.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.2 13.72 2.22 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 127.53 2.332 . . . . 0.0 113.469 -173.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -148.04 34.33 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 124.657 1.122 . . . . 0.0 114.585 169.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.5 m -49.02 -19.99 0.48 Allowed 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -169.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.8 t -79.47 -4.49 51.47 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.454 1.101 . . . . 0.0 113.096 175.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 71.5 m -136.97 147.13 46.13 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.548 1.539 . . . . 0.0 110.739 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 63.51 -94.16 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.237 1.815 . . . . 0.0 113.126 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.54 -41.99 2.07 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 126.499 2.0 . . . . 0.0 116.413 -175.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -109.59 174.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.357 1.009 0 C-N-CA 123.194 2.596 . . . . 0.0 114.75 -175.395 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.727 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -97.16 134.68 40.16 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 129.99 3.316 . . . . 0.0 114.719 169.839 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -71.1 152.28 43.63 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 162.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 40.2 p-10 -125.75 60.11 31.22 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 124.252 1.021 . . . . 0.0 111.737 -177.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -61.79 -29.9 83.77 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.943 3.095 . . . . 0.0 115.057 -167.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 73.2 mt -75.9 -5.42 46.03 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 175.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t 66.83 110.02 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 130.027 3.331 . . . . 0.0 111.471 -177.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 171.92 172.03 0.1 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -169.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.49 ' H ' ' HD2' ' A' ' 70' ' ' LYS . 10.8 mptt -64.17 169.57 4.38 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 127.699 2.4 . . . . 0.0 111.68 168.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 76.1 t60 -96.23 138.99 33.02 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.839 1.256 . . . . 0.0 113.981 170.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 152.14 -110.05 0.44 Allowed Glycine 0 C--N 1.336 0.533 0 C-N-CA 124.007 0.813 . . . . 0.0 112.79 167.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.92 -20.2 24.52 Favored Glycine 0 CA--C 1.535 1.289 0 CA-C-O 115.237 -2.98 . . . . 0.0 118.396 -172.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.67 -11.81 3.23 Favored 'Trans proline' 0 C--N 1.357 0.982 0 CA-C-N 123.192 3.496 . . . . 0.0 112.282 168.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -152.51 -25.25 0.17 Allowed 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.078 1.351 . . . . 0.0 113.14 169.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -72.59 93.06 1.56 Allowed 'General case' 0 C--N 1.342 0.282 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 166.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -66.77 -6.51 16.24 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-N 114.674 -1.148 . . . . 0.0 113.87 -179.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -78.74 -64.84 1.08 Allowed 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 125.657 1.583 . . . . 0.0 109.567 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 59.98 127.72 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 129.833 3.253 . . . . 0.0 117.881 167.367 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -56.93 154.04 10.13 Favored 'General case' 0 CA--C 1.55 0.961 0 O-C-N 120.391 -1.443 . . . . 0.0 111.857 171.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 p -68.47 -28.87 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 120.229 1.377 . . . . 0.0 111.287 -174.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.17 105.58 2.1 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 107.081 -2.407 . . . . 0.0 107.081 165.005 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -160.52 142.91 12.92 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 117.956 0.878 . . . . 0.0 113.309 177.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -120.91 175.43 6.05 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 126.196 1.798 . . . . 0.0 112.129 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -95.1 -153.68 30.37 Favored Glycine 0 CA--C 1.535 1.307 0 C-N-CA 125.905 1.717 . . . . 0.0 114.114 178.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.0 p30 -108.0 156.97 18.65 Favored 'General case' 0 N--CA 1.467 0.379 0 O-C-N 121.777 -0.837 . . . . 0.0 110.956 168.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -106.53 173.92 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 C-N-CA 127.217 2.207 . . . . 0.0 109.749 176.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -138.16 143.72 40.43 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 125.177 1.391 . . . . 0.0 108.871 169.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.64 152.56 25.4 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 124.105 0.962 . . . . 0.0 112.879 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -88.85 164.52 15.16 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.745 1.618 . . . . 0.0 111.203 168.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -63.53 -10.83 19.89 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.536 1.534 . . . . 0.0 114.828 170.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.12 -18.07 63.22 Favored 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 118.852 0.751 . . . . 0.0 109.805 169.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 105.09 -7.49 44.21 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 127.83 2.633 . . . . 0.0 112.808 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.57 139.47 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 125.603 1.561 . . . . 0.0 113.485 -173.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -104.39 129.93 52.29 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 164.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -79.52 142.09 36.1 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 167.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -122.16 140.34 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 CA-C-O 122.22 1.01 . . . . 0.0 113.472 171.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.6 p -156.33 122.38 4.97 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.452 1.501 . . . . 0.0 109.814 168.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.2 mp -128.98 156.09 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 C-N-CA 125.739 1.616 . . . . 0.0 108.843 173.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -157.37 135.84 11.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 126.574 1.95 . . . . 0.0 108.418 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -160.93 159.19 29.31 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 124.763 1.225 . . . . 0.0 112.431 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -121.16 48.19 1.7 Allowed 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.378 1.251 . . . . 0.0 114.378 172.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 57.3 t -137.95 -40.22 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.672 1.989 . . . . 0.0 109.961 169.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.2 pp -78.85 149.92 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-O 123.488 1.613 . . . . 0.0 114.474 172.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 94.6 p -155.26 169.53 23.97 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 126.635 1.974 . . . . 0.0 108.907 -176.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mp -96.36 48.26 1.09 Allowed 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 172.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.3 t -103.06 -13.31 16.89 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 116.923 2.194 . . . . 0.0 116.923 -169.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 146.39 -88.05 0.16 Allowed Glycine 0 C--N 1.348 1.231 0 N-CA-C 120.124 2.809 . . . . 0.0 120.124 167.439 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -59.8 -61.01 2.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 C-N-CA 126.167 1.787 . . . . 0.0 115.215 -160.531 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 -125.3 1.3 7.77 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 125.177 1.391 . . . . 0.0 112.956 -174.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.7 p -78.45 -169.75 1.79 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.418 0.687 . . . . 0.0 112.35 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 3.3 pt -69.99 -30.16 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 O-C-N 118.954 -2.341 . . . . 0.0 114.105 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.9 mm -60.4 137.76 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-N 120.293 1.406 . . . . 0.0 110.493 171.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 73.98 -11.2 6.39 Favored Glycine 0 CA--C 1.527 0.797 0 CA-C-O 118.223 -1.321 . . . . 0.0 113.719 -177.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.17 139.38 39.9 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 120.035 1.917 . . . . 0.0 108.969 177.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 57.7 m -98.99 104.32 16.36 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -175.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 23.6 tp -80.26 120.08 23.87 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.108 1.363 . . . . 0.0 111.048 -177.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.87 138.87 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.62 1.568 . . . . 0.0 109.912 169.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.3 t -103.79 159.59 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 166.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -125.09 133.35 52.91 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.285 1.434 . . . . 0.0 111.24 -168.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.8 tt0 -46.39 -35.62 5.67 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 127.569 2.348 . . . . 0.0 114.704 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -113.68 170.02 8.56 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.708 1.603 . . . . 0.0 112.512 -169.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.84 158.8 6.01 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.365 1.066 . . . . 0.0 110.642 167.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -138.29 142.53 39.81 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.272 1.029 . . . . 0.0 110.809 -168.161 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -85.91 -59.23 2.36 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 122.977 0.511 . . . . 0.0 111.891 176.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mp 65.93 84.95 0.15 Allowed 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 128.001 2.521 . . . . 0.0 113.9 -174.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 131.02 -29.97 3.43 Favored Glycine 0 N--CA 1.479 1.524 0 N-CA-C 118.888 2.315 . . . . 0.0 118.888 166.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -155.97 -58.92 0.1 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 119.474 1.637 . . . . 0.0 113.515 -169.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 44.22 -115.31 1.23 Allowed Glycine 0 C--N 1.34 0.754 0 C-N-CA 125.55 1.547 . . . . 0.0 111.55 -170.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.86 14.46 3.84 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-O 118.256 -1.302 . . . . 0.0 114.54 169.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -161.63 168.08 24.06 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 120.146 1.973 . . . . 0.0 112.853 -167.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -47.98 -58.75 4.02 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.137 1.375 . . . . 0.0 112.082 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -46.75 -31.89 3.28 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -179.078 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.1 m -65.7 -23.21 66.71 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 120.432 -1.418 . . . . 0.0 113.716 178.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.0 t -99.84 -29.56 12.53 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.931 0.892 . . . . 0.0 111.917 168.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -71.19 -41.45 70.29 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.25 1.42 . . . . 0.0 113.503 -176.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.5 p -124.48 -30.73 3.34 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.112 1.765 . . . . 0.0 112.801 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.98 -14.41 11.24 Favored Glycine 0 C--O 1.222 -0.648 0 C-N-CA 126.416 1.96 . . . . 0.0 111.184 -167.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 90.6 1.68 0.17 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.11 2.964 . . . . 0.0 112.346 178.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.54 -7.76 0.3 Allowed 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 117.407 2.373 . . . . 0.0 117.407 -168.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 64.96 7.91 32.49 Favored Glycine 0 CA--C 1.529 0.955 0 N-CA-C 120.327 2.891 . . . . 0.0 120.327 164.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.19 178.3 1.74 Allowed 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 121.166 2.483 . . . . 0.0 115.129 172.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 18.9 ptt-85 -76.4 -174.37 2.84 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 126.402 1.881 . . . . 0.0 109.883 165.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -177.76 -148.84 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 128.7 2.8 . . . . 0.0 107.504 165.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -62.28 144.24 55.86 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.079 0.952 . . . . 0.0 110.632 168.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.6 t -157.61 145.05 18.51 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.799 1.24 . . . . 0.0 112.312 -173.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.53 162.96 34.3 Favored Glycine 0 N--CA 1.474 1.176 0 C-N-CA 125.144 1.354 . . . . 0.0 112.46 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 5.8 p -78.87 153.29 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 118.795 1.298 . . . . 0.0 110.543 169.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mm -87.12 111.64 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 O-C-N 120.87 -1.144 . . . . 0.0 109.969 168.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -104.32 -155.8 23.55 Favored Glycine 0 CA--C 1.534 1.249 0 C-N-CA 125.659 1.6 . . . . 0.0 112.018 175.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.93 167.99 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-N 119.226 1.513 . . . . 0.0 113.616 177.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.96 -36.87 0.08 Allowed 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 125.979 1.712 . . . . 0.0 113.449 167.072 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . 0.299 27.6 pt20 . . . . . 0 C--O 1.235 0.31 0 C-N-CA 125.292 1.437 . . . . 0.0 114.307 -170.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.618 0 N-CA-C 112.632 0.604 . . . . 0.0 112.632 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.7 m -79.79 105.85 11.39 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.354 1.462 . . . . 0.0 110.544 -167.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 24.3 mtmm -96.19 106.79 19.04 Favored 'General case' 0 CA--C 1.547 0.858 0 N-CA-C 115.67 1.73 . . . . 0.0 115.67 -175.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -94.84 167.16 11.6 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.634 1.974 . . . . 0.0 111.034 167.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.5 p -158.44 151.65 7.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 C-N-CA 124.321 1.048 . . . . 0.0 113.554 -170.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.51 147.74 38.27 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.325 1.05 . . . . 0.0 109.471 162.757 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 53' ' ' ASN . 84.1 t -106.19 121.54 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.382 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 168.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.9 mp -92.34 107.62 19.35 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 126.683 1.993 . . . . 0.0 107.829 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 35.9 tttt -131.47 149.17 52.63 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 120.032 1.287 . . . . 0.0 114.006 175.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.08 151.72 16.87 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 128.799 3.095 . . . . 0.0 107.092 166.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -72.07 88.95 1.11 Allowed 'General case' 0 C--N 1.318 -0.767 0 C-N-CA 126.71 2.004 . . . . 0.0 112.038 -167.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.97 -129.47 3.29 Favored Glycine 0 CA--C 1.536 1.374 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.888 -177.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -93.24 -10.73 1.75 Allowed 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 124.143 3.229 . . . . 0.0 115.368 -169.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.1 t -91.82 113.49 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 120.458 1.481 . . . . 0.0 110.382 -176.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -159.13 161.54 36.32 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.619 -1.173 . . . . 0.0 113.547 169.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' B' ' 35' ' ' ILE . . . -150.67 167.23 30.38 Favored Glycine 0 CA--C 1.502 -0.765 0 CA-C-N 115.264 -0.88 . . . . 0.0 113.072 166.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.71 135.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.781 -1.562 . . . . 0.0 106.781 167.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 1.8 pp -127.73 128.25 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.609 0.718 . . . . 0.0 109.774 169.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -96.11 136.51 36.47 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 125.587 1.555 . . . . 0.0 110.555 177.46 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -109.39 94.12 4.87 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 127.534 2.334 . . . . 0.0 109.583 173.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -95.68 109.42 21.7 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 121.041 -1.037 . . . . 0.0 111.567 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -98.37 140.45 32.63 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 121.231 -0.918 . . . . 0.0 111.438 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -78.67 -27.59 45.21 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -175.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -161.04 156.87 25.27 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 128.274 2.63 . . . . 0.0 107.318 168.068 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.7 p -46.7 -22.06 0.26 Allowed 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 130.168 3.387 . . . . 0.0 116.698 -170.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -124.83 -4.42 7.59 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 128.536 2.735 . . . . 0.0 112.31 -174.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.41 160.03 27.71 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 125.876 1.703 . . . . 0.0 110.99 172.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.13 159.62 51.25 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.197 2.598 . . . . 0.0 112.626 -170.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 5.0 t -108.68 128.06 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.793 1.237 . . . . 0.0 110.036 -172.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 92.5 mttt -81.96 125.16 30.44 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 171.135 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.65 116.82 53.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.611 1.164 . . . . 0.0 108.845 170.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -137.35 158.64 43.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.006 0.922 . . . . 0.0 110.807 169.348 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.42 164.12 9.85 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-O 121.643 0.579 . . . . 0.0 112.688 174.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.9 p -113.62 116.52 29.61 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -165.004 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.428 ' HA ' ' HA3' ' B' ' 16' ' ' GLY . 4.0 mm -94.96 116.74 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 172.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -124.32 146.97 48.48 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.508 1.523 . . . . 0.0 111.196 -167.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.99 -31.04 7.79 Favored Glycine 0 N--CA 1.471 0.986 0 C-N-CA 126.946 2.212 . . . . 0.0 112.143 -175.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.512 HD13 ' CD2' ' B' ' 43' ' ' HIS . 3.1 pp -76.0 128.24 34.62 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.511 1.124 . . . . 0.0 108.308 169.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.1 t -73.49 175.72 6.77 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.164 0.986 . . . . 0.0 111.888 -173.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -61.09 154.3 23.33 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -168.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.23 -175.02 29.18 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.399 1.0 . . . . 0.0 112.477 -175.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 5.3 mp -77.82 124.69 28.29 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 127.375 2.27 . . . . 0.0 112.078 -169.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . 0.512 ' CD2' HD13 ' B' ' 38' ' ' LEU . 60.0 m-70 -122.51 130.09 52.67 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.766 1.226 . . . . 0.0 107.976 171.138 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.32 165.84 38.87 Favored Glycine 0 N--CA 1.473 1.104 0 C-N-CA 126.443 1.973 . . . . 0.0 115.15 -169.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -156.58 99.96 1.91 Allowed 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 120.002 1.901 . . . . 0.0 112.764 -167.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -124.2 135.61 53.58 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 121.059 -1.025 . . . . 0.0 112.173 -169.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . 0.263 1.0 OUTLIER -102.84 141.14 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 119.077 0.853 . . . . 0.0 109.369 173.099 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.619 ' CG ' HG23 ' B' ' 116' ' ' THR . 0.3 OUTLIER -133.75 154.53 50.91 Favored 'General case' 0 CA--C 1.544 0.735 0 C-N-CA 125.194 1.398 . . . . 0.0 112.732 -168.437 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -76.93 128.69 35.0 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -170.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.252 29.6 m-85 99.88 157.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.641 1 C-N-CA 132.732 4.413 . . . . 0.0 115.551 169.457 . . . . . . . . 3 2 . 1 . 016 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -115.92 -19.32 5.66 Favored Glycine 0 N--CA 1.471 1.014 0 C-N-CA 126.158 1.837 . . . . 0.0 113.176 177.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.46 51.94 0.07 Allowed 'General case' 0 CA--C 1.551 1.008 0 C-N-CA 127.558 2.343 . . . . 0.0 111.597 169.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -178.4 35.18 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.965 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -165.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 33.2 p -63.6 40.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.608 2.763 . . . . 0.0 116.182 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -128.49 7.31 5.8 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 124.957 1.303 . . . . 0.0 112.779 173.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 65.44 -154.52 50.35 Favored Glycine 0 CA--C 1.528 0.904 0 O-C-N 120.878 -1.139 . . . . 0.0 110.956 -173.248 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 85.7 m -57.93 -6.69 0.6 Allowed 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 117.691 2.478 . . . . 0.0 117.691 -169.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.3 t -84.85 5.84 27.16 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 120.258 1.39 . . . . 0.0 112.695 168.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 33.8 m -154.1 -35.47 0.1 Allowed 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 126.44 1.896 . . . . 0.0 113.834 172.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -88.18 141.03 28.89 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 125.352 1.461 . . . . 0.0 113.476 -175.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.43 -175.15 48.72 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 124.638 1.113 . . . . 0.0 114.498 -177.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -83.31 -179.11 4.1 Favored 'Trans proline' 0 CA--C 1.539 0.752 1 C-N-CA 126.188 4.592 . . . . 0.0 111.774 175.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.488 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.7 p80 -80.7 107.37 13.45 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 122.452 1.12 . . . . 0.0 112.79 -174.336 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 136.81 5.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.57 1.948 . . . . 0.0 114.501 176.218 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.9 p-10 -116.81 47.4 0.62 Allowed Pre-proline 0 CA--C 1.55 0.965 0 CA-C-N 114.595 -1.184 . . . . 0.0 113.476 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -56.62 -30.47 83.49 Favored 'Trans proline' 0 C--N 1.355 0.917 0 C-N-CA 123.819 3.012 . . . . 0.0 115.946 -168.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 10.4 mp -79.29 -4.94 53.14 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 124.468 1.107 . . . . 0.0 113.595 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 68.62 47.83 0.85 Allowed 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 128.865 2.866 . . . . 0.0 111.115 -176.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 13.8 mmm180 -110.29 162.28 14.78 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 126.217 1.807 . . . . 0.0 111.011 -168.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 13.1 mmtm -74.43 173.26 10.55 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 167.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 30.1 t60 -50.88 158.22 0.71 Allowed 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -173.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.36 71.2 2.07 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.634 1.111 . . . . 0.0 113.634 -169.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -84.23 125.06 6.93 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -72.59 -11.89 26.52 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.001 1.801 . . . . 0.0 111.581 170.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.76 -5.91 13.29 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.168 0.987 . . . . 0.0 113.653 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -114.06 148.6 36.8 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 125.519 1.528 . . . . 0.0 108.281 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -74.68 -14.94 60.81 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 124.582 1.153 . . . . 0.0 111.82 -171.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -102.99 121.59 42.85 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.514 1.526 . . . . 0.0 107.678 169.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 -144.97 124.05 12.84 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 126.966 2.106 . . . . 0.0 110.788 -175.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 61.4 m170 -65.09 155.02 36.14 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.314 1.845 . . . . 0.0 110.842 164.724 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -55.95 -33.69 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.205 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -143.21 103.25 0.31 Allowed Glycine 0 C--N 1.345 1.061 0 N-CA-C 115.163 0.825 . . . . 0.0 115.163 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -159.53 146.88 16.94 Favored 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 130.329 3.452 . . . . 0.0 105.217 164.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 76.3 mt -128.96 56.34 1.68 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.779 0.799 . . . . 0.0 111.156 -168.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 59.91 -122.16 29.05 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.467 174.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -148.06 126.96 12.7 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.466 1.106 . . . . 0.0 110.785 -176.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.7 m -76.86 97.15 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.825 1.65 . . . . 0.0 109.314 177.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 92.0 m -97.6 120.91 38.83 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 113.338 -1.756 . . . . 0.0 109.253 -169.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.26 158.65 16.03 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -168.002 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -81.04 171.74 14.59 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.086 2.155 . . . . 0.0 112.158 168.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.791 ' H ' ' HE2' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -67.26 -17.34 64.75 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.735 1.614 . . . . 0.0 114.017 174.28 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -71.6 -6.97 44.78 Favored 'General case' 0 CA--C 1.555 1.151 0 CA-C-O 122.433 1.111 . . . . 0.0 109.608 167.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 79.28 44.48 9.61 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 125.614 1.578 . . . . 0.0 109.895 173.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 13.3 p -142.54 130.31 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 C-N-CA 124.523 1.129 . . . . 0.0 112.528 -177.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -103.21 94.91 5.77 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 124.512 1.125 . . . . 0.0 109.619 168.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -83.77 104.08 13.58 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 122.241 1.019 . . . . 0.0 109.834 168.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -80.34 154.22 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 CA-C-N 113.961 -1.472 . . . . 0.0 111.741 -173.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 60.0 p -156.9 93.84 1.38 Allowed 'General case' 0 CA--C 1.546 0.807 0 O-C-N 121.182 -0.949 . . . . 0.0 112.719 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 21.2 mt -134.53 153.02 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 126.955 2.102 . . . . 0.0 111.394 -177.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -133.05 135.7 45.52 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 164.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -151.22 141.25 22.09 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 114.912 1.449 . . . . 0.0 114.912 -168.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.0 p -112.03 49.06 0.93 Allowed 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 113.852 1.056 . . . . 0.0 113.852 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.6 t -123.13 4.99 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 C-N-CA 124.038 0.935 . . . . 0.0 111.158 174.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.24 170.75 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 C-N-CA 126.95 2.1 . . . . 0.0 110.509 -177.094 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.4 m -157.88 175.54 13.72 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.878 1.271 . . . . 0.0 110.817 169.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 38.6 mt -84.7 50.11 1.84 Allowed 'General case' 0 CA--C 1.548 0.893 0 O-C-N 120.204 -1.56 . . . . 0.0 109.609 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 21.4 t -81.79 25.22 0.56 Allowed 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 115.606 1.706 . . . . 0.0 115.606 -168.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.0 -51.59 3.86 Favored Glycine 0 C--N 1.336 0.542 0 C-N-CA 125.54 1.543 . . . . 0.0 115.087 168.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -101.2 -93.72 0.29 Allowed 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 117.796 0.798 . . . . 0.0 111.137 -165.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 83.3 m-70 -84.05 2.56 38.58 Favored 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 1.1 t -95.42 -125.93 0.12 Allowed 'General case' 0 CA--C 1.551 0.994 0 O-C-N 119.793 -1.817 . . . . 0.0 113.066 -170.556 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 mm -80.08 -47.09 21.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-N 123.594 2.906 . . . . 0.0 113.222 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 50.1 mm -60.24 133.92 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 119.328 0.967 . . . . 0.0 108.936 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 72.53 6.18 65.49 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-O 118.574 -1.125 . . . . 0.0 115.037 178.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.65 164.08 19.91 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 119.115 1.458 . . . . 0.0 110.017 171.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . 0.619 HG23 ' CG ' ' B' ' 48' ' ' HIS . 3.9 t -115.17 157.65 23.35 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.279 1.032 . . . . 0.0 110.046 175.528 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 17.9 tp -151.28 126.24 9.77 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 125.025 1.33 . . . . 0.0 112.22 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.9 p -116.46 134.99 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 126.152 1.781 . . . . 0.0 111.258 170.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 1.3 p -84.46 139.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.681 1.193 . . . . 0.0 108.865 169.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 66.2 m-70 -108.25 149.71 28.25 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.616 1.566 . . . . 0.0 112.705 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -73.65 -37.17 65.4 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -171.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -92.12 164.62 13.52 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 120.482 -1.386 . . . . 0.0 109.914 167.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.16 140.51 5.13 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.419 1.087 . . . . 0.0 111.216 169.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.65 129.29 37.46 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 166.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -73.57 0.7 11.86 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 126.892 2.077 . . . . 0.0 111.564 178.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 79.17 -37.65 0.19 Allowed 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 128.283 2.633 . . . . 0.0 114.07 168.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 143.22 47.77 0.04 OUTLIER Glycine 0 N--CA 1.477 1.378 0 CA-C-N 120.4 1.454 . . . . 0.0 114.975 -176.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 16.3 pttp -157.18 -113.46 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 -168.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 66.16 -3.84 2.98 Favored Glycine 0 N--CA 1.474 1.216 0 C-N-CA 126.652 2.072 . . . . 0.0 117.433 169.411 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.0 4.26 54.77 Favored Glycine 0 CA--C 1.536 1.392 0 CA-C-N 119.073 1.436 . . . . 0.0 114.053 -174.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.5 m-80 -119.12 156.8 29.12 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 125.722 1.609 . . . . 0.0 111.517 -176.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -54.11 -59.41 4.68 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.145 0.978 . . . . 0.0 109.238 166.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -54.7 -36.88 65.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.739 1.216 . . . . 0.0 113.169 -172.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 58.0 m -66.05 -13.28 59.7 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.695 1.998 . . . . 0.0 115.563 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -122.37 -20.04 6.24 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.882 0.873 . . . . 0.0 112.928 168.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -72.53 -46.66 53.5 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.121 1.368 . . . . 0.0 111.779 174.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 41.3 p -117.75 -34.21 4.28 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.221 1.008 . . . . 0.0 112.977 173.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 110.38 11.24 20.3 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 126.708 2.099 . . . . 0.0 111.972 -168.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 55.52 17.56 2.31 Favored 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 120.602 2.201 . . . . 0.0 113.29 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -69.33 25.07 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.073 0 C-N-CA 127.573 2.349 . . . . 0.0 116.145 -165.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 79.26 -51.63 3.93 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 127.558 2.504 . . . . 0.0 114.454 169.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 2.9 m 179.76 166.67 1.19 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 127.782 2.433 . . . . 0.0 111.906 -179.024 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.12 150.97 31.62 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.401 0.681 . . . . 0.0 110.887 173.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.31 -130.6 0.24 Allowed 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 126.739 2.016 . . . . 0.0 108.794 173.086 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.83 157.39 33.42 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 127.065 2.146 . . . . 0.0 114.437 -175.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 14.9 p -151.22 159.68 44.25 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -172.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.71 168.48 34.37 Favored Glycine 0 CA--C 1.543 1.825 0 C-N-CA 127.485 2.469 . . . . 0.0 113.842 175.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 54.2 t -124.83 138.2 54.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 C-N-CA 124.742 1.217 . . . . 0.0 108.563 174.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.8 mm -79.04 122.6 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -166.354 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.62 -156.51 9.88 Favored Glycine 0 CA--C 1.542 1.773 0 C-N-CA 128.362 2.887 . . . . 0.0 113.141 169.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -142.08 147.39 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 C-N-CA 125.276 1.431 . . . . 0.0 114.702 -168.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -113.07 -22.43 10.56 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 125.499 1.519 . . . . 0.0 114.407 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 . . . . . 0 N--CA 1.471 0.606 0 C-N-CA 125.673 1.589 . . . . 0.0 112.453 -178.186 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.585 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.8 t -96.9 116.68 29.61 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 124.146 0.979 . . . . 0.0 110.707 -169.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.487 ' HE3' ' OE1' ' A' ' 153' ' ' GLN . 0.0 OUTLIER -77.98 117.71 19.57 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-N 114.741 -1.118 . . . . 0.0 112.053 169.289 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.4 178.59 6.44 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.429 1.091 . . . . 0.0 110.179 167.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -155.41 90.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 125.664 1.586 . . . . 0.0 109.981 -168.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.93 121.93 32.49 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.229 1.412 . . . . 0.0 110.573 174.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.0 p -95.75 126.68 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 CA-C-N 118.9 0.773 . . . . 0.0 109.105 173.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mp -109.14 133.95 52.35 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.59 1.156 . . . . 0.0 108.627 169.42 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mtmt -157.77 133.12 8.9 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.267 1.427 . . . . 0.0 110.276 173.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.73 -81.08 0.63 Allowed Glycine 0 C--N 1.334 0.45 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -170.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -139.42 116.56 11.09 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 124.559 1.144 . . . . 0.0 108.987 -166.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.04 -101.41 0.03 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 128.988 3.185 . . . . 0.0 112.613 175.044 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -77.99 -9.46 16.74 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.275 2.65 . . . . 0.0 114.014 -174.047 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.8 t -88.46 126.19 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 121.33 1.877 . . . . 0.0 111.818 -176.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.87 159.11 43.13 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 125.162 1.385 . . . . 0.0 111.792 171.165 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -144.87 164.4 27.85 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 122.444 1.025 . . . . 0.0 113.811 169.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.79 133.93 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 125.127 1.371 . . . . 0.0 109.066 -179.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.6 mm -137.7 121.92 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 CA-C-N 119.74 1.155 . . . . 0.0 110.683 169.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -88.57 145.84 25.48 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.981 167.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -121.62 109.62 14.99 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 168.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.78 112.59 24.31 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.85 0.75 . . . . 0.0 111.529 -176.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -93.49 135.31 34.86 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -114.52 -45.54 3.01 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.612 1.565 . . . . 0.0 114.688 -175.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -118.9 -179.76 3.91 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.25 1.42 . . . . 0.0 109.204 167.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.8 p -67.66 -25.91 65.94 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 119.162 -2.211 . . . . 0.0 114.221 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -141.04 9.5 2.12 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 126.407 1.883 . . . . 0.0 112.598 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.8 151.94 52.31 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.527 -1.152 . . . . 0.0 111.795 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -61.91 137.63 68.77 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 124.169 3.246 . . . . 0.0 110.36 -172.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 79.3 t -102.59 135.53 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 123.525 0.73 . . . . 0.0 109.889 -176.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.1 tttp -91.1 116.69 29.01 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 167.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.3 t -104.2 110.91 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 126.677 1.991 . . . . 0.0 108.7 -173.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -132.78 168.69 17.9 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 122.216 1.008 . . . . 0.0 113.143 -176.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.86 -155.48 26.15 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 124.87 1.224 . . . . 0.0 111.488 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -159.71 152.12 21.09 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.1 mp -123.91 134.24 67.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 125.712 1.605 . . . . 0.0 107.865 -178.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 5.8 ptpt -149.58 152.03 34.81 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -172.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.1 12.12 52.94 Favored Glycine 0 CA--C 1.535 1.302 0 C-N-CA 125.256 1.407 . . . . 0.0 113.231 -168.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -111.86 164.7 12.79 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 127.005 2.122 . . . . 0.0 111.1 175.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -74.23 166.11 24.0 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.081 1.352 . . . . 0.0 111.438 176.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.31 -166.48 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 128.541 2.736 . . . . 0.0 113.661 -177.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.73 -178.38 42.78 Favored Glycine 0 CA--C 1.531 1.063 0 O-C-N 120.295 -1.503 . . . . 0.0 113.136 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.691 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -74.58 144.48 43.95 Favored 'General case' 0 CA--C 1.542 0.652 0 O-C-N 120.692 -1.476 . . . . 0.0 112.045 -178.065 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -136.8 151.29 49.0 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 128.789 2.836 . . . . 0.0 109.274 -177.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.29 173.83 26.69 Favored Glycine 0 N--CA 1.475 1.286 0 C-N-CA 125.317 1.437 . . . . 0.0 114.043 -174.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -159.93 122.46 3.4 Favored 'General case' 0 CA--C 1.554 1.122 0 C-N-CA 125.502 1.521 . . . . 0.0 112.754 -168.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 10.8 p-80 -152.07 134.14 15.01 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 118.705 -2.497 . . . . 0.0 113.607 167.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 5.6 m -84.99 146.0 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 CA-C-O 122.213 1.006 . . . . 0.0 108.948 170.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -107.13 176.09 5.28 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 124.021 1.867 . . . . 0.0 114.592 -168.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 1.2 pm0 -72.95 132.87 44.0 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 104.705 -2.332 . . . . 0.0 104.705 158.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.419 ' HB3' ' H ' ' A' ' 52' ' ' ASP . 6.8 m-85 75.77 167.59 0.27 Allowed 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 124.422 2.058 . . . . 0.0 115.148 169.119 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.34 0.28 57.05 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 111.41 -2.632 . . . . 0.0 109.96 163.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.419 ' H ' ' HB3' ' A' ' 50' ' ' PHE . 6.7 t0 -69.92 138.08 52.11 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 165.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.403 HD21 ' CG2' ' A' ' 148' ' ' VAL . 0.8 OUTLIER -177.08 21.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 168.057 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.4 p -79.57 -14.33 58.92 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 115.234 1.568 . . . . 0.0 115.234 -163.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -108.1 10.05 28.18 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 124.5 1.12 . . . . 0.0 110.972 167.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 66.56 -138.06 35.46 Favored Glycine 0 CA--C 1.528 0.865 0 O-C-N 121.019 -1.05 . . . . 0.0 111.035 -171.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 72.2 m -57.17 -6.06 0.35 Allowed 'General case' 0 CA--C 1.549 0.928 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -174.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.5 t -103.13 0.71 32.24 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-N 119.966 1.257 . . . . 0.0 113.998 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 7.9 p -128.57 -18.37 3.95 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 113.539 0.94 . . . . 0.0 113.539 168.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.37 153.98 35.73 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.326 1.851 . . . . 0.0 110.763 168.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.16 -173.78 28.81 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.239 0.923 . . . . 0.0 114.753 -170.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.41 ' C ' ' CD2' ' A' ' 63' ' ' HIS . 40.9 Cg_endo -91.24 72.11 0.94 Allowed 'Trans proline' 0 CA--C 1.538 0.721 1 C-N-CA 125.401 4.068 . . . . 0.0 108.276 169.556 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.432 ' CE1' ' ND1' ' A' ' 71' ' ' HIS . 5.1 p80 43.9 70.04 0.36 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.958 1.703 . . . . 0.0 114.657 164.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -32.59 134.3 0.1 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 128.848 2.859 . . . . 0.0 117.901 -168.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 30.0 p-10 -103.75 34.25 0.05 OUTLIER Pre-proline 0 CA--C 1.559 1.302 0 N-CA-C 117.365 2.357 . . . . 0.0 117.365 -174.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -66.36 -15.17 47.15 Favored 'Trans proline' 0 C--N 1.357 1.003 0 CA-C-N 123.328 2.224 . . . . 0.0 115.068 -169.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -77.1 -0.84 26.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.099 1.359 . . . . 0.0 112.844 169.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.4 t 77.98 59.48 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.988 2.115 . . . . 0.0 112.3 168.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 ptm85 -149.72 169.35 21.24 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -168.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.4 mttp -67.57 156.7 36.14 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 127.889 2.476 . . . . 0.0 111.091 172.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.432 ' ND1' ' CE1' ' A' ' 63' ' ' HIS . 78.1 t60 -75.33 149.97 38.59 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.152 165.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.13 -145.36 12.76 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 116.508 -0.315 . . . . 0.0 113.052 166.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 165.32 -98.15 0.15 Allowed Glycine 0 CA--C 1.535 1.286 0 CA-C-O 117.166 -1.908 . . . . 0.0 114.771 168.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -65.43 0.42 2.85 Favored 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 124.821 3.681 . . . . 0.0 116.397 -169.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.34 1.73 1.41 Allowed 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 127.124 2.17 . . . . 0.0 112.486 175.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.461 ' CG ' ' H ' ' A' ' 77' ' ' GLU . 19.9 t0 -95.96 -178.96 4.53 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 128.321 2.648 . . . . 0.0 111.131 178.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.461 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 20.1 tt0 -98.43 -31.26 12.09 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 129.635 3.174 . . . . 0.0 112.04 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -127.51 -70.62 0.7 Allowed 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 116.814 2.153 . . . . 0.0 116.814 -166.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.416 HH22 ' HB ' ' A' ' 103' ' ' VAL . 1.1 ttt-85 83.69 128.88 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 127.038 2.135 . . . . 0.0 111.436 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -66.25 169.63 6.94 Favored 'General case' 0 CA--C 1.55 0.953 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 171.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.6 m -85.11 65.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 CA-C-O 122.707 1.242 . . . . 0.0 109.68 173.147 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.76 88.73 0.3 Allowed Glycine 0 C--O 1.223 -0.555 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -168.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -158.0 150.5 22.41 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 128.132 2.573 . . . . 0.0 109.597 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 77.5 mt -129.8 178.04 6.81 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 126.08 1.752 . . . . 0.0 109.3 169.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -84.55 -129.04 1.82 Allowed Glycine 0 CA--C 1.532 1.117 0 C-N-CA 124.376 0.989 . . . . 0.0 113.184 -176.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -147.7 169.73 19.06 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 124.437 1.095 . . . . 0.0 110.53 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.63 170.73 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.173 0.989 . . . . 0.0 110.765 -170.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.5 m -140.78 138.52 34.17 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 125.727 1.611 . . . . 0.0 108.301 172.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.71 138.79 34.56 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 123.821 0.848 . . . . 0.0 110.563 176.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -87.43 162.8 17.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.64 1.176 . . . . 0.0 112.147 172.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -53.46 -19.06 3.17 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 127.783 2.433 . . . . 0.0 115.017 -170.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.68 4.07 48.49 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 128.241 2.616 . . . . 0.0 110.918 -173.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.68 26.84 21.54 Favored Glycine 0 C--N 1.341 0.829 0 C-N-CA 126.065 1.793 . . . . 0.0 113.907 172.332 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.18 132.3 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -173.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.4 129.21 43.8 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 126.159 1.783 . . . . 0.0 106.258 164.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -117.09 135.64 53.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 -178.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 51.3 t -125.24 129.81 73.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 114.114 -1.403 . . . . 0.0 114.381 -164.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.7 p -144.72 74.47 1.41 Allowed 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 125.235 1.414 . . . . 0.0 112.52 176.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 mp -101.09 159.39 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 120.604 -1.31 . . . . 0.0 111.481 -177.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -138.87 141.77 38.6 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 126.768 2.027 . . . . 0.0 107.941 172.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -145.42 141.2 28.19 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.229 1.411 . . . . 0.0 110.259 177.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.2 p -111.54 50.82 0.81 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -173.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.416 ' HB ' HH22 ' A' ' 79' ' ' ARG . 23.4 t -144.32 -42.97 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.207 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 168.468 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.43 155.52 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 CA-C-N 119.564 1.074 . . . . 0.0 112.095 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.9 p -156.98 167.67 29.77 Favored 'General case' 0 N--CA 1.475 0.805 0 O-C-N 120.565 -1.334 . . . . 0.0 113.351 177.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.0 mp -77.12 56.8 1.31 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.956 1.36 . . . . 0.0 109.378 170.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.08 33.02 0.88 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.723 2.009 . . . . 0.0 111.428 168.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.4 -137.21 13.14 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 124.731 1.158 . . . . 0.0 111.928 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -93.65 -32.82 13.92 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 128.073 2.549 . . . . 0.0 115.766 -165.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -83.95 -8.23 59.22 Favored 'General case' 0 CA--C 1.545 0.758 0 O-C-N 120.305 -1.497 . . . . 0.0 111.607 -178.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 69.9 m -102.19 -40.6 6.72 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 115.416 1.636 . . . . 0.0 115.416 -170.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -169.49 -42.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.104 1.762 . . . . 0.0 114.134 171.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.85 141.51 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 168.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.68 8.85 61.05 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 116.31 -2.384 . . . . 0.0 113.896 -174.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -100.17 177.48 5.06 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 121.146 2.473 . . . . 0.0 109.62 169.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 27.2 m -120.91 146.72 46.32 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 125.855 1.662 . . . . 0.0 110.243 -175.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -127.33 143.36 51.24 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.858 1.663 . . . . 0.0 109.276 166.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.8 m -114.24 129.47 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 125.598 1.559 . . . . 0.0 109.569 169.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 1.6 p -98.56 120.53 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 168.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 2.1 m-70 -96.81 153.71 17.72 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 125.333 1.453 . . . . 0.0 113.337 -168.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.26 -62.63 1.57 Allowed 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 124.427 1.091 . . . . 0.0 111.305 -172.741 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.44 176.47 6.28 Favored 'General case' 0 N--CA 1.472 0.655 0 O-C-N 120.86 -1.15 . . . . 0.0 111.437 170.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.37 146.25 44.96 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.23 1.012 . . . . 0.0 113.428 -169.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.66 112.8 17.27 Favored 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 166.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -78.72 -8.0 58.29 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.661 1.985 . . . . 0.0 114.922 -167.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 34.28 89.28 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 129.385 3.074 . . . . 0.0 114.915 177.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 85.41 -55.36 4.9 Favored Glycine 0 N--CA 1.469 0.851 0 C-N-CA 125.456 1.503 . . . . 0.0 112.54 168.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -153.91 110.22 3.3 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -174.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.97 -95.48 2.21 Favored Glycine 0 CA--C 1.513 -0.079 0 N-CA-C 104.116 -3.593 . . . . 0.0 104.116 163.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -136.55 14.81 3.91 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 117.938 -1.479 . . . . 0.0 114.321 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -121.63 173.66 7.3 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 119.993 1.896 . . . . 0.0 112.215 -169.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -75.56 -48.17 23.55 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 113.067 -1.879 . . . . 0.0 109.04 167.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -61.59 -19.2 61.95 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 176.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 21.1 m -51.34 -39.33 56.81 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 119.955 1.252 . . . . 0.0 112.776 171.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 5.0 t -94.78 -33.18 12.98 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 174.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 mtpt -75.27 -29.23 60.09 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 120.618 1.554 . . . . 0.0 114.823 -178.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.0 p -136.85 -23.33 1.18 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 98.36 8.15 55.21 Favored Glycine 0 C--O 1.221 -0.718 0 C-N-CA 124.733 1.158 . . . . 0.0 110.686 -167.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 62.05 -4.04 0.22 Allowed 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 126.344 1.858 . . . . 0.0 114.153 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -58.41 -3.7 0.31 Allowed 'General case' 0 CA--C 1.555 1.159 0 C-N-CA 129.058 2.943 . . . . 0.0 117.151 -165.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.81 -81.6 1.38 Allowed Glycine 0 CA--C 1.532 1.144 0 C-N-CA 125.764 1.65 . . . . 0.0 113.337 172.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 2.7 m -172.27 166.66 5.9 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.021 1.729 . . . . 0.0 112.255 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.412 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -100.38 144.4 29.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 116.698 2.11 . . . . 0.0 116.698 -173.073 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.448 HD13 ' H ' ' A' ' 144' ' ' LEU . 0.0 OUTLIER -90.53 -21.97 21.54 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 113.652 -1.613 . . . . 0.0 111.375 166.3 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -151.14 142.65 23.53 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 122.185 0.993 . . . . 0.0 111.004 173.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.1 p -136.94 147.78 46.58 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 127.887 2.475 . . . . 0.0 109.082 178.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.63 160.44 31.86 Favored Glycine 0 N--CA 1.469 0.874 0 N-CA-C 115.478 0.951 . . . . 0.0 115.478 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.403 ' CG2' HD21 ' A' ' 53' ' ' ASN . 99.3 t -104.74 143.71 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.527 1.131 . . . . 0.0 110.704 174.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 68.7 mt -84.89 95.41 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 126.383 1.873 . . . . 0.0 111.836 -169.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -91.62 177.75 40.71 Favored Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.0 1.285 . . . . 0.0 113.622 177.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -132.83 158.05 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.727 2.011 . . . . 0.0 112.206 -178.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -153.67 -25.76 0.14 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 174.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . 0.487 ' OE1' ' HE3' ' A' ' 3' ' ' LYS . 34.3 tt0 . . . . . 0 CA--C 1.537 0.458 0 O-C-N 121.009 -1.057 . . . . 0.0 110.802 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 0.419 0 CA-C-O 120.933 0.397 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.3 m -84.1 99.97 10.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -174.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . 0.271 0.0 OUTLIER -94.8 113.96 25.78 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-O 123.321 1.534 . . . . 0.0 112.963 178.295 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.05 164.21 25.94 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 125.709 1.604 . . . . 0.0 111.166 168.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 1.3 p -156.03 140.53 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 125.767 1.627 . . . . 0.0 108.027 178.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -137.5 124.15 21.03 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 4.1 p -79.95 120.62 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 169.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.4 mp -112.31 110.71 21.1 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 125.125 1.37 . . . . 0.0 108.427 169.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 tttt -157.06 160.28 38.77 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-O 121.499 0.666 . . . . 0.0 111.629 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.0 -35.83 0.84 Allowed Glycine 0 N--CA 1.468 0.802 0 C-N-CA 127.154 2.311 . . . . 0.0 110.005 174.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.41 58.19 2.56 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 126.867 2.067 . . . . 0.0 110.859 177.289 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 36.8 -98.31 0.01 OUTLIER Glycine 0 CA--C 1.535 1.334 0 C-N-CA 128.104 2.764 . . . . 0.0 114.288 -176.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.06 -13.2 15.76 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 123.869 3.046 . . . . 0.0 114.785 -176.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.21 137.51 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 121.262 1.846 . . . . 0.0 111.675 -176.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -126.49 162.12 26.36 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 124.357 1.063 . . . . 0.0 110.375 168.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -128.19 62.99 0.62 Allowed Glycine 0 N--CA 1.469 0.853 0 C-N-CA 125.262 1.41 . . . . 0.0 111.836 172.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.464 ' C ' HD12 ' B' ' 17' ' ' ILE . 0.0 OUTLIER -79.44 109.08 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 CA-C-N 118.358 1.079 . . . . 0.0 110.923 -168.686 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.459 ' N ' HD12 ' B' ' 17' ' ' ILE . 2.4 pp -110.8 150.88 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 169.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -129.46 129.15 44.25 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.054 2.142 . . . . 0.0 107.364 167.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.7 m-30 -115.93 125.02 52.03 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 119.203 0.91 . . . . 0.0 109.834 178.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.65 127.39 52.38 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 123.726 0.81 . . . . 0.0 110.242 -178.619 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . 0.529 ' HG2' ' H ' ' B' ' 24' ' ' GLU . 52.4 tt0 -121.14 134.27 55.23 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 123.069 1.414 . . . . 0.0 112.57 170.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 5.0 ptmm? -82.89 0.4 44.39 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 126.485 1.914 . . . . 0.0 113.617 179.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.529 ' H ' ' HG2' ' B' ' 22' ' ' GLN . 43.4 mt-10 -157.64 -164.64 1.59 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 130.333 3.453 . . . . 0.0 108.495 -169.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -120.47 -6.6 9.77 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 124.895 1.278 . . . . 0.0 111.868 165.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -116.84 -45.95 2.76 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 125.745 1.618 . . . . 0.0 113.685 -171.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.38 -162.83 11.31 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 125.184 1.373 . . . . 0.0 114.133 -176.569 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.18 161.45 38.22 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.524 2.149 . . . . 0.0 112.69 -171.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 13.9 t -133.71 136.42 54.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 125.834 1.654 . . . . 0.0 109.833 -173.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HD2' ' H ' ' B' ' 30' ' ' LYS . 5.2 mptt -80.85 130.99 35.34 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.253 0.549 . . . . 0.0 110.049 171.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.36 105.44 18.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 127.735 2.414 . . . . 0.0 108.227 178.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -138.49 162.16 35.22 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.85 173.11 13.06 Favored Glycine 0 N--CA 1.467 0.737 0 C-N-CA 124.668 1.128 . . . . 0.0 114.261 171.331 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 24.3 p -110.65 120.59 42.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 114.86 1.43 . . . . 0.0 114.86 -167.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.629 HD13 HG21 ' B' ' 87' ' ' VAL . 0.6 OUTLIER -92.01 117.12 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 167.499 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 pttt -137.81 136.61 37.37 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.511 0.725 . . . . 0.0 111.349 -167.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.57 -18.26 22.77 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 127.491 2.472 . . . . 0.0 113.636 -172.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.4 156.35 25.45 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.371 1.069 . . . . 0.0 111.705 172.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -69.25 166.13 19.08 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.258 1.423 . . . . 0.0 110.262 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -61.39 -176.36 0.07 Allowed 'General case' 0 CA--C 1.551 1.019 0 C-N-CA 126.673 1.989 . . . . 0.0 115.197 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.42 177.28 51.83 Favored Glycine 0 N--CA 1.469 0.867 0 C-N-CA 124.905 1.24 . . . . 0.0 112.187 -179.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.829 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -71.23 141.99 50.6 Favored 'General case' 0 CA--C 1.541 0.614 0 O-C-N 120.824 -1.398 . . . . 0.0 110.092 177.381 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -134.21 141.29 46.99 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 127.317 2.247 . . . . 0.0 107.957 176.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.98 155.94 48.53 Favored Glycine 0 N--CA 1.479 1.562 0 CA-C-N 120.494 1.497 . . . . 0.0 113.217 -174.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -147.27 105.5 3.76 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.91 1.355 . . . . 0.0 110.465 -171.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.476 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -145.4 145.22 31.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 120.804 -1.185 . . . . 0.0 110.4 -167.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.564 HG23 ' HA2' ' B' ' 82' ' ' GLY . 34.5 m -115.03 120.7 65.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.278 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -176.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.476 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 3.7 m170 -74.93 152.1 38.84 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -173.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -73.05 94.05 1.85 Allowed 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 169.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 150.54 156.82 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.563 1 C-N-CA 132.351 4.26 . . . . 0.0 111.669 170.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -89.3 -21.19 42.28 Favored Glycine 0 C--N 1.337 0.621 0 C-N-CA 126.187 1.851 . . . . 0.0 111.294 164.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.422 ' C ' HD22 ' B' ' 53' ' ' ASN . 29.9 t0 -58.05 157.42 8.02 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 165.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.422 HD22 ' C ' ' B' ' 52' ' ' ASP . 1.3 p30 162.65 31.26 0.0 OUTLIER 'General case' 0 C--O 1.241 0.62 0 C-N-CA 129.075 2.95 . . . . 0.0 111.496 165.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 18.2 p -69.77 -41.64 74.89 Favored 'General case' 0 N--CA 1.455 -0.19 0 O-C-N 121.132 -0.98 . . . . 0.0 110.364 -168.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.9 25.32 3.71 Favored 'General case' 0 CA--C 1.556 1.182 0 C-N-CA 124.725 1.21 . . . . 0.0 111.892 166.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.79 -128.48 23.59 Favored Glycine 0 CA--C 1.529 0.925 0 O-C-N 120.302 -1.499 . . . . 0.0 112.447 174.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 5.5 t -71.84 -12.31 61.22 Favored 'General case' 0 CA--C 1.547 0.835 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -98.69 50.22 0.98 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.842 1.257 . . . . 0.0 107.789 171.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -170.73 -81.3 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 -168.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -93.78 153.19 18.44 Favored 'General case' 0 C--O 1.234 0.249 0 O-C-N 121.455 -0.778 . . . . 0.0 112.017 173.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.08 -161.86 29.49 Favored Glycine 0 CA--C 1.54 1.602 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.568 173.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -78.03 -171.43 1.2 Allowed 'Trans proline' 0 CA--C 1.54 0.777 1 C-N-CA 126.257 4.638 . . . . 0.0 110.087 169.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.777 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 2.1 p80 -73.76 80.32 1.57 Allowed 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 128.303 2.641 . . . . 0.0 107.084 168.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -56.0 169.88 0.35 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-O 123.826 1.774 . . . . 0.0 110.889 174.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -104.13 51.94 0.08 OUTLIER Pre-proline 0 CA--C 1.555 1.142 0 CA-C-N 113.392 -1.731 . . . . 0.0 115.165 -167.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.45 -25.72 48.2 Favored 'Trans proline' 0 C--N 1.354 0.865 0 C-N-CA 122.33 2.02 . . . . 0.0 111.469 -177.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 39.5 mt -81.6 -6.49 59.05 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 172.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 16.9 t 69.34 59.86 0.32 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 125.652 1.581 . . . . 0.0 113.84 174.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 1.9 ptt180 -162.01 176.26 10.94 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 115.449 1.648 . . . . 0.0 115.449 -170.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.2 170.95 11.94 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.888 1.275 . . . . 0.0 114.116 177.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.401 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 77.0 t60 -83.76 162.26 20.71 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.378 0.671 . . . . 0.0 111.501 167.636 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.412 ' HA3' ' HB3' ' B' ' 76' ' ' ASP . . . 137.97 -102.39 0.37 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.377 1.941 . . . . 0.0 111.739 166.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.75 -53.44 0.71 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 116.958 -2.024 . . . . 0.0 117.498 172.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -87.86 -8.17 6.02 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.502 2.801 . . . . 0.0 111.25 176.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.49 ' HE2' ' HA ' ' B' ' 75' ' ' LYS . 0.1 OUTLIER -145.98 -16.64 0.46 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 176.248 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.412 ' HB3' ' HA3' ' B' ' 72' ' ' GLY . 13.7 t70 -101.67 92.45 4.87 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 103.181 -2.896 . . . . 0.0 103.181 159.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 56.2 mp0 -65.04 -4.88 5.2 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.676 1.191 . . . . 0.0 113.508 -176.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -74.61 -63.31 1.27 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.597 1.959 . . . . 0.0 107.711 178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 32.4 ttp180 67.83 119.79 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.959 2.207 . . . . 0.0 116.959 162.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -62.61 156.1 24.25 Favored 'General case' 0 N--CA 1.472 0.659 0 O-C-N 119.467 -2.021 . . . . 0.0 112.102 169.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -52.71 -32.75 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.564 ' HA2' HG23 ' B' ' 47' ' ' VAL . . . -96.33 39.05 2.91 Favored Glycine 0 CA--C 1.534 1.26 0 N-CA-C 116.708 1.443 . . . . 0.0 116.708 -174.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -129.96 108.39 10.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.281 -1.129 . . . . 0.0 111.715 -172.385 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -109.79 47.41 0.95 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 122.467 1.127 . . . . 0.0 110.153 168.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.5 -101.67 0.03 OUTLIER Glycine 0 CA--C 1.528 0.879 0 C-N-CA 127.984 2.707 . . . . 0.0 114.103 174.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.8 p30 -154.86 161.74 41.34 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.592 1.557 . . . . 0.0 111.553 -175.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.629 HG21 HD13 ' B' ' 35' ' ' ILE . 8.9 p -137.85 124.81 28.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 C-N-CA 126.916 2.086 . . . . 0.0 109.605 -171.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 55.5 m -107.73 123.89 49.2 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 114.707 -1.133 . . . . 0.0 111.19 -167.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.08 148.9 21.61 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 124.398 1.079 . . . . 0.0 112.509 -176.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -97.22 157.07 16.13 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.111 1.765 . . . . 0.0 112.236 169.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -24.94 24.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 127.246 2.219 . . . . 0.0 115.336 -169.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -79.65 5.75 12.42 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.984 1.714 . . . . 0.0 111.597 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.19 36.81 6.15 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 126.049 1.785 . . . . 0.0 113.2 171.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.27 138.39 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 N-CA-C 117.31 2.337 . . . . 0.0 117.31 -172.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -118.93 93.07 3.97 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 126.72 2.008 . . . . 0.0 110.696 168.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -85.59 95.44 9.33 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-O 122.491 1.139 . . . . 0.0 110.665 172.271 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.75 152.89 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.513 -170.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 20.2 p -155.14 109.83 2.98 Favored 'General case' 0 CA--C 1.541 0.634 0 O-C-N 120.963 -1.086 . . . . 0.0 112.21 175.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.83 160.31 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 127.722 2.409 . . . . 0.0 110.12 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -134.32 141.14 46.82 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 164.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -144.59 152.38 40.43 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.528 1.131 . . . . 0.0 112.116 178.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.7 p -117.42 59.32 0.78 Allowed 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.546 1.538 . . . . 0.0 111.654 -169.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -157.24 -42.09 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 174.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -79.21 154.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 O-C-N 121.883 -0.511 . . . . 0.0 110.628 169.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 9.2 p -155.26 170.37 22.03 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.329 1.052 . . . . 0.0 111.05 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . 0.456 HD13 ' HB2' ' B' ' 22' ' ' GLN . 10.1 mp -86.56 55.53 3.59 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.092 -1.005 . . . . 0.0 111.649 -173.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 8.1 t -90.47 12.81 17.43 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 116.876 2.176 . . . . 0.0 116.876 -169.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 90.22 -38.65 3.19 Favored Glycine 0 N--CA 1.475 1.235 0 N-CA-C 118.695 2.238 . . . . 0.0 118.695 167.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -107.16 -105.46 0.34 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.541 1.136 . . . . 0.0 110.572 -166.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 7.2 m-70 -76.23 11.77 1.41 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 126.187 1.795 . . . . 0.0 113.363 175.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 9.7 p -84.12 -158.35 0.32 Allowed 'General case' 0 CA--C 1.553 1.086 0 C-N-CA 127.013 2.125 . . . . 0.0 114.13 -175.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' B' ' 115' ' ' ARG 0.39 8.1 pt -83.23 -9.39 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 O-C-N 119.666 -1.896 . . . . 0.0 114.234 168.284 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 46.5 mm -98.36 151.18 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 161.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 95.1 -41.12 2.56 Favored Glycine 0 N--CA 1.468 0.811 0 C-N-CA 124.342 0.973 . . . . 0.0 113.033 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . 0.512 HH21 ' HB2' ' B' ' 117' ' ' LEU . 0.2 OUTLIER -75.13 -179.56 4.45 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 127.49 2.316 . . . . 0.0 115.604 -169.579 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.1 t -103.43 176.18 5.23 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 127.437 2.295 . . . . 0.0 113.065 169.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.512 ' HB2' HH21 ' B' ' 115' ' ' ARG . 33.9 tp -152.95 144.99 23.76 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.157 2.183 . . . . 0.0 110.363 170.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.45 150.2 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 O-C-N 123.284 0.365 . . . . 0.0 110.796 167.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -110.89 128.42 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 168.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -90.16 148.84 22.72 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.93 0.892 . . . . 0.0 112.518 -169.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.297 2.4 pp20? -77.51 -32.55 54.17 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 121.3 -0.875 . . . . 0.0 112.661 -174.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -90.54 169.07 11.34 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.322 -0.861 . . . . 0.0 110.061 165.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -60.72 149.65 34.8 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.125 0.97 . . . . 0.0 109.628 164.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -78.9 131.89 36.57 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 168.372 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -78.58 -11.05 59.94 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.178 0.991 . . . . 0.0 112.523 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mm? 70.25 -66.33 0.28 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 129.998 3.319 . . . . 0.0 111.339 -176.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 176.09 29.38 0.04 OUTLIER Glycine 0 N--CA 1.463 0.491 0 N-CA-C 116.171 1.228 . . . . 0.0 116.171 -169.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.8 pttp -126.12 -20.34 4.54 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 117.088 2.255 . . . . 0.0 117.088 -167.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -60.89 129.92 47.16 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 106.506 -2.638 . . . . 0.0 106.506 168.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -74.12 46.39 1.52 Allowed Glycine 0 N--CA 1.473 1.102 0 C-N-CA 126.387 1.946 . . . . 0.0 112.865 -171.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -103.23 -89.86 0.38 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.653 1.181 . . . . 0.0 110.947 -169.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 170.4 -76.66 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 131.213 3.805 . . . . 0.0 102.474 -167.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -35.66 -52.85 0.7 Allowed 'General case' 0 CA--C 1.54 0.584 1 C-N-CA 132.147 4.179 . . . . 0.0 112.92 171.628 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 3.6 m -47.37 -31.1 3.71 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 176.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.3 t -112.72 -8.03 13.79 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 119.449 1.022 . . . . 0.0 112.264 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 22.4 mmtp -84.25 -47.42 10.81 Favored 'General case' 0 CA--C 1.537 0.469 0 O-C-N 120.75 -1.219 . . . . 0.0 110.853 168.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 74.6 p -117.01 -34.17 4.49 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.786 1.634 . . . . 0.0 113.079 -173.271 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 109.13 2.89 31.59 Favored Glycine 0 N--CA 1.47 0.922 0 CA-C-O 118.353 -1.248 . . . . 0.0 113.805 -177.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 51.48 24.16 2.11 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 119.55 1.675 . . . . 0.0 114.168 177.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.09 20.08 0.08 Allowed 'General case' 0 CA--C 1.553 1.067 0 N-CA-C 115.748 1.759 . . . . 0.0 115.748 -166.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.8 -66.76 2.4 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 126.459 1.981 . . . . 0.0 114.288 173.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -175.69 -163.56 0.12 Allowed 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.803 1.641 . . . . 0.0 109.532 -169.44 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.26 145.73 33.0 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 174.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -90.58 -103.84 0.1 Allowed 'General case' 0 CA--C 1.537 0.462 0 O-C-N 124.98 1.425 . . . . 0.0 107.557 170.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.03 147.22 50.35 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 123.443 0.697 . . . . 0.0 111.901 -177.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.33 151.76 51.71 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 127.093 2.157 . . . . 0.0 110.17 173.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.87 174.82 37.55 Favored Glycine 0 C--O 1.221 -0.678 0 N-CA-C 116.461 1.344 . . . . 0.0 116.461 -174.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -142.37 143.47 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 125.408 1.483 . . . . 0.0 109.502 -168.264 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -109.2 129.82 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -165.481 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -136.71 -155.66 7.12 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 125.232 1.396 . . . . 0.0 111.023 167.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.3 pp -139.43 157.23 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.033 1.333 . . . . 0.0 113.285 -169.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.9 -41.1 14.25 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 161.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 . . . . . 0 CA--C 1.536 0.432 1 C-N-CA 132.764 4.425 . . . . 0.0 107.194 168.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.152 0 CA-C-O 118.959 -0.543 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.03 55.22 1.8 Allowed 'General case' 0 CA--C 1.511 -0.536 0 CA-C-O 123.028 1.394 . . . . 0.0 111.345 -171.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -87.8 107.1 18.5 Favored 'General case' 0 C--O 1.242 0.675 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 166.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.02 167.48 12.06 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.537 1.535 . . . . 0.0 111.893 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.691 HG21 ' HA ' ' B' ' 52' ' ' ASP . 2.0 p -159.35 149.23 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.395 1.078 . . . . 0.0 112.013 -168.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.33 121.22 14.53 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.073 1.749 . . . . 0.0 108.918 167.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 m -103.71 99.16 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 167.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.2 mp -81.03 116.29 20.91 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -176.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 mtpt -144.77 157.55 44.13 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-N 119.272 0.942 . . . . 0.0 111.818 -172.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.45 -47.87 0.43 Allowed Glycine 0 N--CA 1.47 0.904 0 C-N-CA 126.505 2.002 . . . . 0.0 111.252 169.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.62 61.42 2.94 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 128.64 2.776 . . . . 0.0 112.344 -168.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.4 -99.81 0.02 OUTLIER Glycine 0 CA--C 1.534 1.266 0 C-N-CA 126.974 2.226 . . . . 0.0 112.904 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -82.11 -7.39 12.09 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.202 3.268 . . . . 0.0 114.867 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -86.42 136.07 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 121.244 1.838 . . . . 0.0 110.889 175.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.38 151.44 35.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 114.066 -1.424 . . . . 0.0 110.833 167.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -118.77 98.79 0.75 Allowed Glycine 0 C--O 1.22 -0.779 0 C-N-CA 125.485 1.517 . . . . 0.0 110.259 174.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -91.38 110.84 23.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 108.382 -0.969 . . . . 0.0 108.382 171.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.431 HD13 ' CE1' ' A' ' 20' ' ' PHE . 1.8 pp -127.09 155.19 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 CA-C-O 122.037 0.922 . . . . 0.0 110.713 168.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -130.96 156.2 45.51 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.476 1.51 . . . . 0.0 109.849 169.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' CE1' HD13 ' A' ' 18' ' ' ILE . 7.8 m-85 -123.8 120.51 32.85 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 125.001 1.32 . . . . 0.0 108.651 168.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -98.44 119.86 37.86 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.246 1.018 . . . . 0.0 110.118 172.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.95 170.47 16.05 Favored 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 166.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.93 -46.88 0.53 Allowed 'General case' 0 CA--C 1.558 1.253 0 C-N-CA 128.135 2.574 . . . . 0.0 110.166 168.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.6 mp0 -81.68 116.1 21.24 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 120.456 1.48 . . . . 0.0 111.964 173.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 t -68.6 -9.69 51.22 Favored 'General case' 0 CA--C 1.552 1.047 0 O-C-N 119.223 -2.173 . . . . 0.0 114.439 -174.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -110.78 -2.94 15.97 Favored 'General case' 0 CA--C 1.55 0.98 0 C-N-CA 127.22 2.208 . . . . 0.0 114.542 174.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.27 175.99 38.32 Favored Glycine 0 CA--C 1.542 1.734 0 CA-C-O 118.848 -0.973 . . . . 0.0 113.756 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -77.77 163.17 29.2 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 124.731 3.62 . . . . 0.0 110.739 175.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.2 t -138.08 145.57 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.672 0.789 . . . . 0.0 112.165 -165.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.79 121.28 27.47 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.74 1.216 . . . . 0.0 111.425 169.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 94.6 t -101.16 133.47 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.852 2.061 . . . . 0.0 108.112 169.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.4 p90 -153.67 167.61 29.0 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.572 0.701 . . . . 0.0 112.658 171.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.51 -161.35 28.36 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 124.253 0.93 . . . . 0.0 113.432 172.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.8 p -154.35 118.98 4.87 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.519 0.727 . . . . 0.0 110.776 -169.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.496 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 2.2 mp -108.01 103.0 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.915 0.886 . . . . 0.0 109.019 -177.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -115.88 133.42 56.04 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.223 1.809 . . . . 0.0 111.934 -166.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 111.59 0.86 27.65 Favored Glycine 0 CA--C 1.536 1.399 0 C-N-CA 127.458 2.456 . . . . 0.0 113.26 -174.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 97.5 mt -70.57 162.74 28.31 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 118.508 1.154 . . . . 0.0 111.116 172.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 4.6 m -83.14 140.64 32.49 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 166.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -58.76 152.15 19.64 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.42 -172.67 29.17 Favored Glycine 0 CA--C 1.532 1.125 0 C-N-CA 124.241 0.924 . . . . 0.0 112.818 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.506 ' H ' HD12 ' A' ' 42' ' ' LEU . 1.1 mp -72.4 149.29 44.42 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.817 2.047 . . . . 0.0 112.329 -169.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -145.81 121.72 10.64 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.962 1.705 . . . . 0.0 110.14 173.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.62 147.76 23.46 Favored Glycine 0 N--CA 1.486 1.982 0 CA-C-N 119.992 1.269 . . . . 0.0 112.606 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -148.32 102.01 3.31 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 119.208 1.504 . . . . 0.0 112.408 -167.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.4 m80 -150.27 169.86 20.35 Favored 'General case' 0 CA--C 1.52 -0.199 0 O-C-N 120.658 -1.276 . . . . 0.0 114.331 -168.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.6 m -75.73 129.93 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 113.608 -1.633 . . . . 0.0 109.871 166.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -80.86 137.71 36.18 Favored 'General case' 0 CA--C 1.551 0.986 0 N-CA-C 102.472 -3.159 . . . . 0.0 102.472 157.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -65.18 142.44 58.33 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -168.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 56.83 -169.05 0.1 Allowed 'General case' 0 C--O 1.241 0.623 0 C-N-CA 127.242 2.217 . . . . 0.0 113.898 175.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 54' ' ' THR . . . -136.69 5.71 3.76 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-O 116.78 -2.122 . . . . 0.0 113.525 -178.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' HA ' HG21 ' B' ' 5' ' ' VAL . 21.3 p-10 -77.91 48.6 0.72 Allowed 'General case' 0 N--CA 1.479 0.994 0 CA-C-N 121.336 2.568 . . . . 0.0 110.404 169.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.574 ' HA ' HG21 ' B' ' 7' ' ' VAL . 0.2 OUTLIER 172.65 5.87 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 118.359 2.726 . . . . 0.0 118.359 -169.35 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 51' ' ' GLY . 43.4 p -31.37 -10.02 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.213 1 N-CA-C 124.607 5.04 . . . . 0.0 124.607 -167.497 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.02 35.67 0.06 Allowed 'General case' 0 CA--C 1.555 1.147 0 CA-C-N 123.504 2.865 . . . . 0.0 116.643 -169.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.1 -148.96 46.85 Favored Glycine 0 CA--C 1.526 0.734 0 O-C-N 120.784 -1.197 . . . . 0.0 111.617 172.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 18.3 p -64.42 -12.01 38.94 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 114.914 1.45 . . . . 0.0 114.914 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 p -80.01 -0.3 34.84 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 126.898 2.079 . . . . 0.0 112.833 178.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.1 m -155.87 177.49 11.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 127.655 2.382 . . . . 0.0 109.215 -176.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 77.1 -156.48 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 126.448 1.899 . . . . 0.0 113.96 172.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -149.2 -169.8 16.14 Favored Glycine 0 CA--C 1.541 1.674 0 C-N-CA 126.823 2.154 . . . . 0.0 114.931 -167.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -66.8 -177.03 0.83 Allowed 'Trans proline' 0 CA--C 1.539 0.761 1 C-N-CA 126.353 4.702 . . . . 0.0 113.588 177.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -84.65 114.26 21.88 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.625 1.17 . . . . 0.0 112.932 -170.514 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.424 ' CD2' ' HD3' ' A' ' 66' ' ' PRO . 8.8 t80 -41.43 128.44 3.07 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 127.385 2.274 . . . . 0.0 115.089 -169.616 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -112.0 45.92 0.27 Allowed Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 125.653 1.581 . . . . 0.0 114.281 -173.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.424 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 62.4 Cg_endo -69.15 -17.69 40.22 Favored 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 123.236 2.624 . . . . 0.0 111.722 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.5 mt -76.46 -7.14 54.49 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 125.201 1.4 . . . . 0.0 111.417 171.225 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 36.3 t 73.48 56.89 0.11 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 127.167 2.187 . . . . 0.0 112.267 171.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.16 172.45 16.92 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 116.52 2.044 . . . . 0.0 116.52 -167.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 15.2 mmtp -82.57 173.81 11.62 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 127.149 2.18 . . . . 0.0 112.167 171.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.4 t60 -72.58 165.07 25.41 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.034 1.733 . . . . 0.0 113.616 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 147.46 -140.53 8.59 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 124.984 1.278 . . . . 0.0 114.499 167.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.566 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.87 -86.14 0.29 Allowed Glycine 0 CA--C 1.533 1.205 0 C-N-CA 126.287 1.898 . . . . 0.0 115.617 174.026 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -61.21 -9.77 13.58 Favored 'Trans proline' 0 CA--C 1.539 0.728 0 C-N-CA 124.748 3.632 . . . . 0.0 116.001 -169.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.34 -7.98 2.58 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.936 0.894 . . . . 0.0 112.767 167.562 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.566 ' HB3' ' H ' ' A' ' 73' ' ' GLY 0.314 0.0 OUTLIER -93.04 175.19 6.88 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 116.002 1.853 . . . . 0.0 116.002 -164.699 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 56.0 mp0 -103.21 -22.95 13.66 Favored 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 131.391 3.876 . . . . 0.0 111.46 -168.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.418 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 2.9 mm-40 -105.94 -114.93 0.25 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 127.464 2.306 . . . . 0.0 110.132 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 103.27 119.18 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 130.892 3.677 . . . . 0.0 112.856 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.4 m170 -65.44 -176.87 0.36 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 126.388 1.875 . . . . 0.0 114.451 169.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.5 p -84.58 143.79 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 120.762 -1.212 . . . . 0.0 108.636 166.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.2 -2.52 9.25 Favored Glycine 0 CA--C 1.54 1.607 0 N-CA-C 117.455 1.742 . . . . 0.0 117.455 172.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 45.6 p-10 -77.35 85.43 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-N 120.486 2.143 . . . . 0.0 109.553 167.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.0 mt -82.55 54.83 2.75 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.29 -176.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 68.47 -135.95 29.54 Favored Glycine 0 CA--C 1.528 0.859 0 C-N-CA 125.172 1.368 . . . . 0.0 114.386 170.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -136.86 145.0 43.88 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.058 0.943 . . . . 0.0 111.325 175.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.5 m -93.51 107.1 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 126.333 1.853 . . . . 0.0 109.579 176.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 30.2 m -99.9 113.89 26.75 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.677 1.191 . . . . 0.0 109.187 -175.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.03 158.26 15.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.896 1.679 . . . . 0.0 114.05 -171.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.39 -173.09 3.67 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.265 1.426 . . . . 0.0 112.597 169.229 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -83.7 -13.55 53.82 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 116.615 2.08 . . . . 0.0 116.615 176.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -75.36 -7.73 54.78 Favored 'General case' 0 CA--C 1.561 1.388 0 CA-C-O 122.845 1.307 . . . . 0.0 108.005 163.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.02 8.94 56.5 Favored Glycine 0 C--N 1.339 0.733 0 C-N-CA 128.26 2.838 . . . . 0.0 113.258 168.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.5 p -105.97 125.43 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 119.058 1.429 . . . . 0.0 113.839 -169.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 100.21 12.14 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 166.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -89.89 134.01 34.44 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.415 1.486 . . . . 0.0 109.099 177.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 24.9 t -141.31 137.42 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -167.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 59.3 p -153.59 119.5 5.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 125.757 1.623 . . . . 0.0 110.413 169.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.8 mt -147.15 147.47 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 C-N-CA 128.646 2.779 . . . . 0.0 110.358 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -118.02 130.81 56.4 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 126.895 2.078 . . . . 0.0 105.98 167.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -139.36 134.38 32.41 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.853 0.861 . . . . 0.0 112.186 -172.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.5 p -114.69 46.46 1.4 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 114.175 1.176 . . . . 0.0 114.175 -179.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.57 7.11 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 C-N-CA 123.672 0.789 . . . . 0.0 112.865 167.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -133.33 161.37 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 C-N-CA 124.821 1.248 . . . . 0.0 109.056 168.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.3 p -148.61 162.32 39.92 Favored 'General case' 0 C--O 1.239 0.53 0 O-C-N 121.495 -0.753 . . . . 0.0 109.726 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.2 mp -90.08 70.25 7.34 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-O 122.887 1.327 . . . . 0.0 109.39 173.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.6 t -106.69 142.85 35.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 114.296 -1.32 . . . . 0.0 109.343 168.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.21 10.93 52.14 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 127.573 2.511 . . . . 0.0 118.796 -165.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -129.31 -74.75 0.56 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 119.833 1.816 . . . . 0.0 110.292 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -95.26 -9.54 32.88 Favored 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.292 1.96 . . . . 0.0 116.292 -169.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 65.2 m -92.39 -123.54 0.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 CA-C-N 120.064 1.302 . . . . 0.0 113.66 -171.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.0 pt -115.95 14.86 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 119.61 -1.931 . . . . 0.0 115.727 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.8 mm -83.52 145.07 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 O-C-N 120.775 -1.203 . . . . 0.0 108.301 167.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 62.81 27.48 70.16 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 114.936 0.734 . . . . 0.0 114.936 168.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -106.3 153.8 21.66 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.471 1.108 . . . . 0.0 109.27 179.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 49.7 m -95.77 86.96 4.52 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.334 -0.854 . . . . 0.0 111.16 -167.237 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.8 tp -76.3 145.59 39.49 Favored 'General case' 0 N--CA 1.487 1.399 0 CA-C-N 122.193 2.27 . . . . 0.0 113.457 -168.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.8 p -133.45 152.58 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 C-N-CA 126.751 2.021 . . . . 0.0 112.686 177.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -112.85 133.05 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 124.33 1.052 . . . . 0.0 108.216 164.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -89.61 152.75 21.23 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-O 122.292 1.044 . . . . 0.0 113.075 -176.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -68.01 -29.35 68.34 Favored 'General case' 0 N--CA 1.473 0.707 0 O-C-N 120.46 -1.4 . . . . 0.0 114.754 -174.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -119.8 169.56 10.02 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.976 1.31 . . . . 0.0 112.285 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -49.37 148.07 2.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 124.58 1.152 . . . . 0.0 110.555 169.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -96.45 133.45 40.86 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 123.647 0.592 . . . . 0.0 109.77 179.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -84.78 -13.89 49.83 Favored 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 125.44 1.496 . . . . 0.0 113.464 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 65.1 -38.34 0.25 Allowed 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 130.817 3.647 . . . . 0.0 114.327 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.96 -32.6 0.05 OUTLIER Glycine 0 CA--C 1.519 0.281 0 CA-C-N 119.579 1.081 . . . . 0.0 115.343 170.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.78 69.69 0.99 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 117.379 2.363 . . . . 0.0 117.379 -172.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -79.55 -68.29 1.5 Allowed Glycine 0 N--CA 1.461 0.346 0 N-CA-C 106.27 -2.732 . . . . 0.0 106.27 164.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 174.65 21.31 0.02 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 124.819 1.199 . . . . 0.0 115.068 -178.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -149.23 161.79 41.32 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 119.374 1.587 . . . . 0.0 110.095 -179.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 35.1 tp10 -69.34 -45.9 68.35 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.905 1.282 . . . . 0.0 111.786 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -45.39 -35.25 3.51 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.775 1.23 . . . . 0.0 113.417 176.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 33.4 t -58.7 -56.81 17.44 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 169.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.292 0.0 OUTLIER -66.53 -9.72 37.66 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 123.98 0.912 . . . . 0.0 111.184 -178.013 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 48.7 mtmt -93.41 -50.45 5.44 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 119.333 0.969 . . . . 0.0 113.285 167.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 68.6 p -113.36 -24.38 9.36 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 -166.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 103.14 -3.08 47.55 Favored Glycine 0 C--O 1.22 -0.729 0 C-N-CA 125.203 1.383 . . . . 0.0 112.545 -168.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 54.66 16.04 1.25 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.898 1.679 . . . . 0.0 113.279 -177.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -71.59 27.27 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.763 2.025 . . . . 0.0 115.735 -165.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 82.7 -75.05 2.42 Favored Glycine 0 C--N 1.338 0.694 0 C-N-CA 127.254 2.359 . . . . 0.0 113.361 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.4 t -170.21 -150.31 0.08 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.546 1.138 . . . . 0.0 110.442 -171.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.89 123.5 47.18 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.366 1.067 . . . . 0.0 110.891 -173.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.489 HD23 ' H ' ' A' ' 145' ' ' ALA . 1.7 tt -96.2 -137.4 0.25 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.86 2.064 . . . . 0.0 106.257 168.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.489 ' H ' HD23 ' A' ' 144' ' ' LEU . . . -61.15 151.03 32.38 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 125.049 1.34 . . . . 0.0 112.375 -176.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.1 p -148.04 142.95 26.86 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 114.836 -1.074 . . . . 0.0 113.846 -172.336 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.23 114.88 0.63 Allowed Glycine 0 CA--C 1.528 0.9 0 C-N-CA 125.386 1.469 . . . . 0.0 113.039 -176.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 0.5 OUTLIER -74.41 135.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.387 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 37.9 mt -74.98 124.35 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.055 0.542 . . . . 0.0 111.885 -167.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.08 -175.28 17.38 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 124.834 1.207 . . . . 0.0 113.27 173.087 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -124.83 152.12 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 126.581 1.953 . . . . 0.0 111.997 173.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.13 -8.19 2.31 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -178.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 4.0 tm0? . . . . . 0 C--O 1.236 0.349 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 169.17 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.556 0 N-CA-C 111.739 0.274 . . . . 0.0 111.739 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -84.62 74.08 10.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 105.604 -1.998 . . . . 0.0 105.604 168.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ptpm? -76.01 121.58 22.96 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.39 -0.819 . . . . 0.0 110.328 -170.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.59 152.71 22.1 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.203 1.001 . . . . 0.0 110.939 -177.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.511 HG21 ' HA ' ' A' ' 52' ' ' ASP . 0.2 OUTLIER -145.87 129.91 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.082 0.944 . . . . 0.0 111.288 -167.503 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.421 ' HB2' HG13 ' B' ' 149' ' ' ILE . . . -104.44 134.84 46.96 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.306 -1.315 . . . . 0.0 107.863 168.414 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.574 HG21 ' HA ' ' A' ' 53' ' ' ASN . 93.2 t -116.88 115.64 49.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 167.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -95.8 96.7 9.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 126.222 1.809 . . . . 0.0 108.942 -169.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -158.21 124.58 4.74 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.736 0.814 . . . . 0.0 110.233 175.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.25 -101.62 2.59 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 105.876 -2.89 . . . . 0.0 105.876 165.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -144.35 109.25 4.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 125.274 1.43 . . . . 0.0 109.702 -169.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 134.6 167.38 11.44 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 125.446 1.498 . . . . 0.0 111.648 -175.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -73.67 25.57 0.32 Allowed 'Trans proline' 0 CA--C 1.544 1.019 1 C-N-CA 125.361 4.041 . . . . 0.0 114.963 -170.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -122.68 119.83 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 119.605 1.093 . . . . 0.0 109.096 -178.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -158.66 158.15 33.22 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 114.684 -1.144 . . . . 0.0 112.357 -178.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.2 177.02 36.82 Favored Glycine 0 CA--C 1.506 -0.479 0 C-N-CA 124.843 1.211 . . . . 0.0 114.069 176.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -120.61 148.2 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 112.993 -1.603 . . . . 0.0 109.742 168.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.0 mm -128.81 130.84 68.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 166.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -100.41 141.84 32.71 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 126.31 1.844 . . . . 0.0 110.809 168.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -120.93 104.92 10.2 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.262 2.225 . . . . 0.0 108.845 171.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -99.78 103.18 14.79 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.842 0.857 . . . . 0.0 110.905 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -105.62 136.68 44.76 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 122.145 0.974 . . . . 0.0 109.27 169.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 16.6 pttp -98.71 -24.52 15.01 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 124.992 1.317 . . . . 0.0 113.692 -170.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -163.93 134.84 4.47 Favored 'General case' 0 CA--C 1.513 -0.469 0 C-N-CA 127.061 2.144 . . . . 0.0 107.957 -164.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 5.5 p -51.83 -28.62 16.36 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 126.01 1.724 . . . . 0.0 114.873 -170.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -109.26 -6.18 15.63 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.558 1.543 . . . . 0.0 113.381 -176.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -88.22 165.97 34.69 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.86 1.219 . . . . 0.0 111.726 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.32 168.82 21.18 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.041 2.494 . . . . 0.0 111.902 -176.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.27 124.36 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 C-N-CA 123.828 0.851 . . . . 0.0 109.262 176.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -81.54 128.59 34.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.625 -0.672 . . . . 0.0 109.427 169.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 63.2 t -108.81 127.09 65.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 C-N-CA 126.093 1.757 . . . . 0.0 109.261 179.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -151.37 163.07 39.77 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 121.573 -0.705 . . . . 0.0 112.266 170.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 156.84 -166.24 33.37 Favored Glycine 0 C--N 1.334 0.418 0 C-N-CA 123.702 0.668 . . . . 0.0 112.657 174.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.4 p -152.9 128.01 9.73 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 122.97 0.508 . . . . 0.0 111.665 -169.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 31.3 mt -118.72 124.77 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 125.019 1.328 . . . . 0.0 110.273 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 73.9 tttt -122.37 139.93 53.26 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 120.769 1.622 . . . . 0.0 111.595 -176.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.88 -0.51 9.17 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 127.863 2.649 . . . . 0.0 113.502 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 92.3 mt -75.73 170.3 16.45 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 125.16 1.384 . . . . 0.0 111.24 174.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.5 t -90.02 151.07 21.84 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 166.043 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -49.22 143.56 6.01 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.601 0.761 . . . . 0.0 111.513 171.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.32 -178.88 22.8 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 124.713 1.149 . . . . 0.0 113.239 -176.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.732 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.7 pt? -80.59 149.54 29.87 Favored 'General case' 0 CA--C 1.553 1.066 0 C-N-CA 128.739 2.816 . . . . 0.0 113.732 -172.132 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -154.17 126.3 7.84 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 128.594 2.758 . . . . 0.0 110.685 -170.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.06 160.85 41.93 Favored Glycine 0 N--CA 1.482 1.766 0 CA-C-N 121.162 1.801 . . . . 0.0 113.914 -177.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.476 ' CE1' HG13 ' B' ' 87' ' ' VAL 0.285 0.2 OUTLIER -159.38 138.21 10.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 128.182 2.593 . . . . 0.0 114.867 168.68 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 16.6 m80 -149.1 141.64 24.35 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 120.659 -1.276 . . . . 0.0 114.087 -169.112 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.02 106.94 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 126.768 2.027 . . . . 0.0 111.166 178.155 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.409 ' C ' ' H ' ' B' ' 50' ' ' PHE . 8.1 m170 -79.22 135.7 36.86 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.486 1.115 . . . . 0.0 110.732 -176.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -70.24 17.64 0.06 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 126.537 1.935 . . . . 0.0 112.513 171.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . 0.409 ' H ' ' C ' ' B' ' 48' ' ' HIS . 23.0 m-85 -144.07 92.66 2.35 Favored 'General case' 0 N--CA 1.45 -0.426 0 C-N-CA 126.427 1.891 . . . . 0.0 107.942 -167.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.29 7.73 66.78 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 116.967 -2.018 . . . . 0.0 111.012 167.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.691 ' HA ' HG21 ' A' ' 5' ' ' VAL . 4.9 m-20 -77.1 49.79 0.7 Allowed 'General case' 0 N--CA 1.481 1.094 0 CA-C-O 124.779 2.228 . . . . 0.0 110.357 -176.112 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 170.84 27.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 128.201 2.601 . . . . 0.0 113.574 -165.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 35.4 p -39.42 -22.73 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 120.184 3.402 . . . . 0.0 120.184 -170.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.98 2.81 0.66 Allowed 'General case' 0 CA--C 1.553 1.068 0 N-CA-C 114.925 1.454 . . . . 0.0 114.925 171.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.99 -149.23 26.4 Favored Glycine 0 CA--C 1.526 0.747 0 O-C-N 120.924 -1.11 . . . . 0.0 112.256 174.096 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 17.6 t -62.3 -15.66 49.14 Favored 'General case' 0 CA--C 1.548 0.871 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 178.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 10.0 m -62.56 -1.46 0.82 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.297 1.439 . . . . 0.0 111.382 166.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.4 t -155.29 14.0 0.38 Allowed 'General case' 0 CA--C 1.548 0.883 0 O-C-N 119.712 -1.868 . . . . 0.0 114.215 178.17 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -152.12 155.75 38.48 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.39 1.45 . . . . 0.0 113.545 -169.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -116.72 -99.79 2.13 Favored Glycine 0 CA--C 1.545 1.923 0 C-N-CA 125.315 1.436 . . . . 0.0 114.243 -174.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -92.0 177.26 1.76 Allowed 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.856 3.704 . . . . 0.0 113.429 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -115.26 126.02 54.01 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 127.862 2.465 . . . . 0.0 110.919 -175.491 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -48.84 149.33 1.84 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 129.253 3.021 . . . . 0.0 116.571 -169.653 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -111.65 44.11 0.23 Allowed Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 127.305 2.242 . . . . 0.0 113.695 -172.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -63.05 -30.54 76.1 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 122.705 2.27 . . . . 0.0 113.825 -169.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -77.66 -3.95 43.6 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.012 0.925 . . . . 0.0 112.582 173.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 29.0 t 77.27 58.91 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 127.368 2.267 . . . . 0.0 111.616 169.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 6.4 ptt180 -163.4 177.52 8.84 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 117.341 2.349 . . . . 0.0 117.341 -167.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 31.5 mttp -64.99 169.91 4.87 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 129.202 3.001 . . . . 0.0 114.276 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 52.7 t60 -107.2 146.68 31.08 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 126.712 2.005 . . . . 0.0 114.236 -169.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 126.92 -104.26 0.7 Allowed Glycine 0 N--CA 1.472 1.092 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 163.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.44 -35.62 3.55 Favored Glycine 0 CA--C 1.541 1.707 0 CA-C-O 116.367 -2.351 . . . . 0.0 118.271 167.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 14.43 0.85 Allowed 'Trans proline' 0 CA--C 1.549 1.251 0 CA-C-N 123.349 3.574 . . . . 0.0 113.153 168.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.49 -26.92 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 127.531 2.332 . . . . 0.0 110.847 169.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.32 0.0 OUTLIER -64.47 151.79 43.37 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 123.225 1.488 . . . . 0.0 113.774 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 60.4 mp0 -88.42 -10.36 49.47 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 111.241 -2.709 . . . . 0.0 114.358 -166.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 80.8 mt-10 -143.98 -53.57 0.34 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.411 1.005 . . . . 0.0 112.58 -169.185 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 80.52 125.18 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 127.446 2.299 . . . . 0.0 114.362 166.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.5 m170 -67.08 148.23 52.15 Favored 'General case' 0 CA--C 1.541 0.608 0 O-C-N 121.018 -1.051 . . . . 0.0 110.856 167.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -72.4 26.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 C-N-CA 125.311 1.444 . . . . 0.0 113.781 171.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -154.03 23.45 0.69 Allowed Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.636 1.589 . . . . 0.0 114.864 -169.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -125.54 129.31 49.47 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 119.071 1.435 . . . . 0.0 110.048 -178.533 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 86.6 mt -107.77 41.9 1.44 Allowed 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.042 0.837 . . . . 0.0 110.711 168.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.97 -117.68 5.02 Favored Glycine 0 CA--C 1.537 1.439 0 O-C-N 120.476 -1.39 . . . . 0.0 113.436 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -140.27 146.98 39.29 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.46 1.504 . . . . 0.0 113.394 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.476 HG13 ' CE1' ' B' ' 45' ' ' PHE . 28.2 m -93.39 145.49 7.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 127.237 2.215 . . . . 0.0 110.247 169.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 2.7 m -110.55 125.53 53.45 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 119.466 1.03 . . . . 0.0 109.618 171.011 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -88.39 163.9 15.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.447 0.699 . . . . 0.0 112.546 169.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.29 178.72 4.97 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.851 1.661 . . . . 0.0 112.713 173.277 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.595 ' HD3' ' H ' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -58.22 -29.49 65.75 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 126.646 1.978 . . . . 0.0 116.314 171.955 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.18 -10.87 59.83 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 119.731 1.15 . . . . 0.0 111.099 171.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.54 11.82 46.5 Favored Glycine 0 C--N 1.334 0.464 0 CA-C-O 116.88 -2.067 . . . . 0.0 113.865 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.0 p -98.4 125.52 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 CA-C-N 119.476 1.638 . . . . 0.0 113.357 179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.0 100.35 12.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.43 1.492 . . . . 0.0 108.04 165.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -87.37 143.25 27.34 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.242 1.017 . . . . 0.0 109.506 170.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.45 144.21 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 116.445 2.017 . . . . 0.0 116.445 -176.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.4 m -156.24 111.97 2.99 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.567 1.947 . . . . 0.0 111.161 174.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 13.2 mt -143.54 163.97 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 130.011 3.324 . . . . 0.0 109.571 -169.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -145.3 146.15 31.52 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 126.478 1.911 . . . . 0.0 107.757 168.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -144.69 132.05 20.76 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.935 0.894 . . . . 0.0 110.112 -175.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 54.8 p -113.54 46.04 1.34 Allowed 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.889 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.11 1.83 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 124.025 0.93 . . . . 0.0 111.687 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -139.46 171.42 14.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 126.35 1.86 . . . . 0.0 109.953 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 42.1 m -158.0 174.26 15.51 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 120.837 -1.164 . . . . 0.0 111.222 176.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 93.2 mt -109.54 54.03 0.67 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 127.407 2.283 . . . . 0.0 109.415 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.7 t -112.78 34.97 4.08 Favored 'General case' 0 CA--C 1.551 1.011 0 N-CA-C 115.626 1.714 . . . . 0.0 115.626 -168.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.92 -29.2 3.08 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 119.237 2.455 . . . . 0.0 119.237 165.345 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . 0.251 17.7 t70 -99.41 -109.29 0.19 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 118.522 1.161 . . . . 0.0 108.448 -167.668 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -81.76 10.3 6.45 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.569 2.347 . . . . 0.0 112.703 175.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 m -60.76 -175.39 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 128.175 2.59 . . . . 0.0 115.081 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.282 11.6 pt -88.63 -3.91 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 119.941 -1.724 . . . . 0.0 114.424 172.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.7 mm -64.84 131.14 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 166.735 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.18 10.52 62.45 Favored Glycine 0 CA--C 1.524 0.653 0 CA-C-O 118.274 -1.292 . . . . 0.0 115.281 -178.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -78.99 170.17 17.1 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 119.918 1.859 . . . . 0.0 109.836 173.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 91.8 m -112.33 112.5 24.12 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 48.5 tp -92.6 103.95 16.29 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 124.42 1.075 . . . . 0.0 109.459 177.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 13.7 p -86.4 149.53 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 167.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 37.9 t -128.41 143.76 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 167.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -106.0 163.08 13.04 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 125.665 1.586 . . . . 0.0 113.115 -168.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -76.28 -42.34 45.83 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.225 -175.101 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -110.56 176.07 5.18 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.822 1.649 . . . . 0.0 109.956 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.4 -176.59 6.29 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.252 0.549 . . . . 0.0 109.599 165.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -110.26 159.04 17.75 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.83 2.052 . . . . 0.0 113.032 -166.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 -73.47 -14.21 61.2 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.904 1.282 . . . . 0.0 111.205 170.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 70.5 mt 54.08 61.45 3.05 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.124 1.77 . . . . 0.0 111.948 172.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 90.48 -54.15 3.47 Favored Glycine 0 N--CA 1.462 0.431 0 C-N-CA 125.688 1.613 . . . . 0.0 111.474 170.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 14.4 ttpt -126.9 72.9 1.37 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.676 1.19 . . . . 0.0 113.238 -168.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . 0.437 ' H ' ' CB ' ' B' ' 134' ' ' SER . . . -83.56 -30.46 29.9 Favored Glycine 0 CA--C 1.534 1.274 0 C-N-CA 124.579 1.085 . . . . 0.0 112.429 169.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 120.8 32.36 1.11 Allowed Glycine 0 N--CA 1.472 1.08 0 C-N-CA 125.167 1.365 . . . . 0.0 113.561 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -153.4 -156.21 0.67 Allowed 'General case' 0 CA--C 1.554 1.121 0 C-N-CA 124.571 1.148 . . . . 0.0 109.644 -169.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -95.9 -52.47 4.05 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 120.765 1.621 . . . . 0.0 110.727 171.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -54.29 -28.53 42.61 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 127.774 2.43 . . . . 0.0 113.176 -172.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.437 ' CB ' ' H ' ' B' ' 129' ' ' GLY . 88.9 p -57.56 -30.78 65.51 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 125.016 1.327 . . . . 0.0 112.453 174.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 10.2 t -107.07 -27.48 10.6 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 117.519 -1.229 . . . . 0.0 114.188 170.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 7.7 tptm -71.88 -24.14 61.62 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 120.994 1.725 . . . . 0.0 113.056 -176.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.5 p -133.54 -46.6 0.82 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 126.287 1.835 . . . . 0.0 110.78 167.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.81 -9.0 8.1 Favored Glycine 0 C--O 1.221 -0.701 0 C-N-CA 125.477 1.513 . . . . 0.0 110.479 -163.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 57.63 37.32 27.4 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 124.992 1.317 . . . . 0.0 112.166 176.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.04 30.06 0.11 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 115.069 1.507 . . . . 0.0 115.069 -169.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.58 -57.27 2.52 Favored Glycine 0 N--CA 1.47 0.962 0 C-N-CA 127.539 2.495 . . . . 0.0 114.44 176.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 33.1 t -174.79 172.05 3.04 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.3 1.84 . . . . 0.0 110.479 -174.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.431 ' HD3' ' H ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -82.67 157.28 23.42 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 121.173 -0.954 . . . . 0.0 111.599 170.631 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -128.84 -97.58 0.38 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 124.546 1.138 . . . . 0.0 108.402 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -95.65 162.26 13.69 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.355 1.062 . . . . 0.0 111.242 174.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 19.1 p -158.5 155.9 29.3 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.788 1.235 . . . . 0.0 113.277 173.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.52 176.12 35.5 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 126.176 1.846 . . . . 0.0 112.362 171.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 76.7 t -107.3 157.29 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-N 118.247 1.024 . . . . 0.0 108.318 168.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.421 HG13 ' HB2' ' B' ' 6' ' ' ALA . 3.3 mt -87.24 110.85 21.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 123.886 0.874 . . . . 0.0 110.964 176.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -105.54 -165.47 23.56 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 125.554 1.549 . . . . 0.0 111.686 168.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -136.74 158.65 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 114.358 1.244 . . . . 0.0 114.358 -169.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -142.41 -19.61 0.69 Allowed 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 170.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.48 1.038 0 C-N-CA 125.317 1.447 . . . . 0.0 111.965 176.946 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.775 0 CA-C-O 117.258 -1.353 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.7 t -75.22 123.6 25.57 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 122.772 1.272 . . . . 0.0 108.158 -172.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.2 mtmm -98.91 132.66 44.07 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 112.616 -2.084 . . . . 0.0 113.924 171.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.62 168.7 13.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.029 0.932 . . . . 0.0 111.989 171.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.2 p -134.41 97.9 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 168.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -94.6 136.95 34.32 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 121.354 -0.842 . . . . 0.0 110.377 173.16 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.418 ' HB ' HG22 ' B' ' 54' ' ' THR . 0.2 OUTLIER -134.38 130.48 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 C-N-CA 124.164 0.986 . . . . 0.0 110.44 -176.891 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -116.31 145.45 43.18 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.589 2.356 . . . . 0.0 110.6 172.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.74 160.17 40.32 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.292 1.037 . . . . 0.0 113.158 168.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.3 161.86 25.0 Favored Glycine 0 CA--C 1.525 0.708 0 C-N-CA 127.246 2.355 . . . . 0.0 107.901 168.187 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -76.62 59.46 1.52 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.298 1.439 . . . . 0.0 113.629 -177.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.58 -163.17 35.79 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 126.732 2.111 . . . . 0.0 110.194 -176.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -77.27 32.52 0.43 Allowed 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 125.041 3.827 . . . . 0.0 112.698 -173.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 t -114.24 124.09 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 C-N-CA 125.525 1.53 . . . . 0.0 108.58 -174.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -141.44 156.7 45.75 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 124.283 1.033 . . . . 0.0 110.284 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.56 139.93 10.87 Favored Glycine 0 CA--C 1.503 -0.695 0 CA-C-N 114.765 -1.107 . . . . 0.0 111.133 168.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.8 125.76 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 117.354 0.577 . . . . 0.0 109.613 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.1 mm -133.74 122.72 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 178.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -111.41 101.18 9.65 Favored 'General case' 0 CA--C 1.537 0.447 0 CA-C-O 122.537 1.16 . . . . 0.0 109.614 169.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -77.58 138.58 39.23 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.823 1.649 . . . . 0.0 108.574 176.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -110.21 121.65 45.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 119.845 1.202 . . . . 0.0 111.168 166.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.477 ' HB2' HD13 ' A' ' 106' ' ' LEU . 19.3 tp60 -82.48 128.59 34.42 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 163.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.59 -38.7 62.56 Favored 'General case' 0 CA--C 1.544 0.735 0 O-C-N 121.322 -0.861 . . . . 0.0 110.579 179.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -104.19 -129.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 129.653 3.181 . . . . 0.0 111.675 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.9 t -143.51 14.67 1.79 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.824 2.45 . . . . 0.0 110.209 167.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -168.07 -0.17 0.02 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 126.014 1.726 . . . . 0.0 115.426 -166.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.28 -151.58 11.49 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 125.849 1.69 . . . . 0.0 112.152 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -71.61 173.26 12.82 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 124.24 3.293 . . . . 0.0 113.616 -175.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -142.9 141.84 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.463 1.105 . . . . 0.0 110.872 -174.171 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.2 tttp -101.7 121.8 42.73 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 167.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.2 t -104.01 114.52 43.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 125.574 1.549 . . . . 0.0 108.581 -177.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 3.6 p90 -138.55 156.32 47.59 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 122.308 1.051 . . . . 0.0 113.035 177.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 144.02 -164.49 27.53 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.465 1.507 . . . . 0.0 111.361 -175.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 88.7 p -158.1 160.22 37.1 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.049 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.1 mm -120.14 120.54 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 C-N-CA 124.597 1.159 . . . . 0.0 112.023 176.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 12.0 mmtt -104.95 152.13 23.06 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.386 1.474 . . . . 0.0 111.684 -174.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.35 -0.35 53.79 Favored Glycine 0 N--CA 1.475 1.288 0 C-N-CA 125.243 1.402 . . . . 0.0 114.435 174.098 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -83.85 173.5 11.19 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 126.467 1.907 . . . . 0.0 112.612 178.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 2.3 t -81.8 175.59 10.3 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 160.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.53 -175.8 0.14 Allowed 'General case' 0 CA--C 1.557 1.249 0 CA-C-O 122.44 1.114 . . . . 0.0 113.497 175.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.32 -179.69 45.44 Favored Glycine 0 CA--C 1.533 1.202 0 O-C-N 120.478 -1.389 . . . . 0.0 114.478 173.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.415 ' H ' HD12 ' A' ' 42' ' ' LEU . 5.8 mp -61.96 142.37 57.49 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 127.46 2.304 . . . . 0.0 111.359 -178.53 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -143.53 117.8 9.59 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 126.864 2.066 . . . . 0.0 109.442 176.042 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.14 141.87 47.71 Favored Glycine 0 N--CA 1.478 1.491 0 CA-C-N 120.038 1.29 . . . . 0.0 111.484 -179.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.277 0.1 OUTLIER -150.95 130.52 13.03 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 118.966 1.383 . . . . 0.0 111.839 174.403 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.87 143.65 26.4 Favored 'General case' 0 CA--C 1.535 0.366 0 O-C-N 121.278 -0.889 . . . . 0.0 111.917 -164.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -98.0 105.81 17.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.874 1.669 . . . . 0.0 108.5 -178.549 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -74.45 144.86 44.05 Favored 'General case' 0 C--N 1.322 -0.617 0 O-C-N 121.548 -0.72 . . . . 0.0 109.325 175.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -46.89 132.56 11.52 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 167.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.51 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 22.3 m-85 77.35 146.02 0.09 Allowed 'General case' 0 CA--C 1.54 0.573 0 CA-C-O 124.729 2.204 . . . . 0.0 114.14 174.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.14 6.69 11.93 Favored Glycine 0 N--CA 1.466 0.69 0 C-N-CA 126.714 2.102 . . . . 0.0 111.788 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -76.89 42.89 0.32 Allowed 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.648 1.579 . . . . 0.0 109.658 168.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 168.95 42.45 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.081 0 C-N-CA 125.314 1.446 . . . . 0.0 113.638 -164.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -63.38 -4.69 2.84 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 116.23 1.937 . . . . 0.0 116.23 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.85 30.26 1.62 Allowed 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 120.381 1.446 . . . . 0.0 112.527 -171.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.37 -139.75 45.94 Favored Glycine 0 N--CA 1.466 0.642 0 O-C-N 120.828 -1.17 . . . . 0.0 111.509 171.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.6 p -52.57 -31.77 37.71 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 176.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.2 t -87.16 43.43 1.1 Allowed 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.415 1.462 . . . . 0.0 112.225 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 66.5 p -179.87 -32.64 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 127.411 2.285 . . . . 0.0 113.755 172.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -143.46 139.5 29.92 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 120.151 1.341 . . . . 0.0 113.62 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -86.35 -115.61 0.93 Allowed Glycine 0 CA--C 1.544 1.864 0 CA-C-O 117.952 -1.471 . . . . 0.0 113.559 -175.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.12 -179.69 5.48 Favored 'Trans proline' 0 C--N 1.348 0.532 1 C-N-CA 125.634 4.223 . . . . 0.0 112.689 -178.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -81.57 71.73 8.59 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.429 1.092 . . . . 0.0 109.97 179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -43.71 140.52 1.82 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 125.519 1.528 . . . . 0.0 111.469 170.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -158.18 155.11 25.4 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 117.774 -1.108 . . . . 0.0 112.668 170.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -73.04 -10.94 25.08 Favored 'Trans proline' 0 CA--C 1.539 0.745 0 C-N-CA 122.082 1.855 . . . . 0.0 114.341 -172.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -87.68 -10.14 52.14 Favored 'General case' 0 CA--C 1.542 0.658 0 CA-C-N 119.834 1.197 . . . . 0.0 113.464 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.2 t 49.55 49.46 19.89 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.804 1.641 . . . . 0.0 114.166 175.272 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 26.1 mtm-85 -99.03 176.45 5.57 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 126.071 1.749 . . . . 0.0 113.435 178.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt -76.89 168.38 20.19 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 126.59 1.956 . . . . 0.0 109.428 165.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -84.05 159.71 21.11 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 124.001 0.921 . . . . 0.0 113.386 -173.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.15 -134.67 5.84 Favored Glycine 0 C--N 1.341 0.816 0 N-CA-C 114.697 0.639 . . . . 0.0 114.697 167.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 124.33 -92.02 0.43 Allowed Glycine 0 CA--C 1.541 1.689 0 CA-C-O 118.59 -1.117 . . . . 0.0 113.94 -169.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -61.88 6.63 0.15 Allowed 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 123.8 3.0 . . . . 0.0 117.453 -175.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.257 0.0 OUTLIER -155.93 7.39 0.22 Allowed 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 127.344 2.258 . . . . 0.0 113.379 169.443 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.21 167.79 18.58 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 127.775 2.43 . . . . 0.0 110.153 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -111.19 -15.51 13.64 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.498 1.919 . . . . 0.0 112.542 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -78.22 -69.49 0.55 Allowed 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.241 1.016 . . . . 0.0 111.014 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 59.25 109.49 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.701 1.6 . . . . 0.0 112.31 -179.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 27.1 m170 -59.03 148.37 31.11 Favored 'General case' 0 CA--C 1.544 0.717 0 O-C-N 119.205 -2.184 . . . . 0.0 110.348 167.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.5 t -79.22 54.33 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-O 123.769 1.747 . . . . 0.0 109.099 166.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.09 20.05 0.09 OUTLIER Glycine 0 CA--C 1.542 1.752 0 C-N-CA 128.87 3.129 . . . . 0.0 114.306 -179.088 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -122.29 130.13 52.86 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-N 121.006 2.403 . . . . 0.0 113.854 -175.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 74.4 mt -113.52 45.47 1.42 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.491 0.716 . . . . 0.0 110.78 168.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 45.45 -124.85 6.89 Favored Glycine 0 CA--C 1.534 1.269 0 O-C-N 121.41 -0.806 . . . . 0.0 113.17 -176.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -129.19 144.07 51.08 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.067 0.947 . . . . 0.0 111.545 173.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 95' ' ' ALA . 7.1 p -95.27 130.92 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.258 0 C-N-CA 125.602 1.561 . . . . 0.0 108.988 173.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.0 m -113.23 138.14 50.43 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 123.683 0.793 . . . . 0.0 112.175 -167.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.61 145.11 40.96 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 118.354 2.724 . . . . 0.0 118.354 -166.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -86.35 157.01 19.98 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 128.958 2.903 . . . . 0.0 111.314 169.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -47.42 -23.29 0.57 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 128.215 2.606 . . . . 0.0 117.155 176.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -76.45 3.65 10.76 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 119.844 1.202 . . . . 0.0 111.579 175.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.66 37.53 52.03 Favored Glycine 0 C--N 1.337 0.6 0 C-N-CA 125.23 1.395 . . . . 0.0 111.843 179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -124.27 122.48 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.409 1.084 . . . . 0.0 110.621 176.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -84.3 118.11 23.99 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.427 1.491 . . . . 0.0 109.311 169.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.08 145.14 25.19 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.951 0.9 . . . . 0.0 112.079 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.82 138.17 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-N 114.001 -1.454 . . . . 0.0 114.823 169.423 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 m -155.27 62.27 0.63 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 127.058 2.143 . . . . 0.0 110.002 179.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 20.1 mt -95.58 154.56 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.346 1.858 . . . . 0.0 111.386 -176.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -133.35 143.25 48.86 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 125.437 1.495 . . . . 0.0 108.461 168.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -156.25 149.66 24.59 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 124.487 1.115 . . . . 0.0 112.572 -169.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.1 p -119.26 53.55 1.02 Allowed 'General case' 0 CA--C 1.542 0.65 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.639 178.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.0 t -138.84 -42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.154 0.982 . . . . 0.0 111.686 174.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -85.88 156.07 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 119.301 0.955 . . . . 0.0 112.099 174.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 m -151.45 147.49 26.92 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 124.409 1.084 . . . . 0.0 111.052 177.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.479 HD12 HD11 ' A' ' 112' ' ' ILE . 7.3 mp -78.39 57.21 1.88 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 120.836 -1.165 . . . . 0.0 109.308 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.6 m -130.31 15.96 5.55 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.887 1.275 . . . . 0.0 113.749 -168.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.7 -170.17 28.45 Favored Glycine 0 N--CA 1.44 -1.042 0 CA-C-O 124.853 2.363 . . . . 0.0 116.28 167.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.29 -51.74 64.85 Favored 'General case' 0 C--N 1.311 -1.083 1 CA-C-N 108.143 -4.029 . . . . 0.0 111.239 -168.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -79.76 4.14 17.25 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.419 1.087 . . . . 0.0 112.977 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.7 t -108.62 -93.29 0.41 Allowed 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 124.13 0.972 . . . . 0.0 111.476 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.479 HD11 HD12 ' A' ' 106' ' ' LEU . 10.9 pt -141.66 5.76 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 40.3 mm -84.13 119.5 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 O-C-N 120.404 -1.435 . . . . 0.0 107.733 171.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.97 30.54 72.25 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 117.915 -1.492 . . . . 0.0 113.664 -178.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 20.9 mmt-85 -86.88 145.85 26.42 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 120.527 2.163 . . . . 0.0 111.268 173.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 39.1 m -89.95 104.91 17.43 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 119.539 1.063 . . . . 0.0 111.499 177.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 15.5 tp -85.64 112.49 21.04 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.626 0.771 . . . . 0.0 110.642 173.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 9.9 p -92.46 148.18 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 118.953 -0.546 . . . . 0.0 109.714 169.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.7 p -119.48 134.08 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 122.262 1.029 . . . . 0.0 109.346 166.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.7 ' CE1' ' HE ' ' A' ' 143' ' ' ARG . 18.5 m-70 -109.84 152.57 25.58 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 126.111 1.764 . . . . 0.0 111.617 -169.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 5.3 tm-20 -79.48 -17.47 54.09 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 116.768 2.136 . . . . 0.0 116.768 -164.454 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.27 173.38 8.84 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 120.079 -1.638 . . . . 0.0 113.432 173.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.87 157.52 1.21 Allowed 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 126.323 1.849 . . . . 0.0 112.439 172.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -97.79 131.35 44.38 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.974 0.892 . . . . 0.0 111.073 -176.273 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -26.6 62.38 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.53 1.932 . . . . 0.0 112.788 177.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 26.1 mt 54.09 53.63 10.81 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.917 1.687 . . . . 0.0 113.028 171.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.23 -25.37 27.33 Favored Glycine 0 N--CA 1.468 0.803 0 CA-C-O 118.218 -1.324 . . . . 0.0 114.99 170.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.354 6.4 mtmt -167.24 121.29 1.0 Allowed 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 116.528 2.047 . . . . 0.0 116.528 164.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -143.53 -56.27 0.03 OUTLIER Glycine 0 CA--C 1.532 1.104 1 C-N-CA 131.177 4.227 . . . . 0.0 108.16 167.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -85.42 -93.18 0.8 Allowed Glycine 0 CA--C 1.532 1.147 0 C-N-CA 125.904 1.716 . . . . 0.0 114.032 177.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.541 ' CG ' ' H ' ' A' ' 132' ' ' GLU 0.27 0.8 OUTLIER -147.3 -96.69 0.09 Allowed 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 117.076 -1.44 . . . . 0.0 112.703 -169.3 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.541 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 11.0 tt0 -111.97 -30.56 7.22 Favored 'General case' 0 CA--C 1.553 1.059 0 CA-C-N 121.565 1.984 . . . . 0.0 114.396 170.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -61.36 -21.6 64.17 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 119.468 -2.02 . . . . 0.0 112.216 177.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.2 p -56.6 -25.55 53.14 Favored 'General case' 0 CA--C 1.54 0.583 1 C-N-CA 131.946 4.098 . . . . 0.0 113.376 164.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.5 p -116.23 -29.25 6.3 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 128.732 2.813 . . . . 0.0 112.974 -175.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 42.1 mttt -70.57 -56.71 5.88 Favored 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 169.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 67.7 p -99.08 -125.85 0.16 Allowed 'General case' 0 C--O 1.221 -0.42 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 167.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.14 28.88 1.53 Allowed Glycine 0 CA--C 1.526 0.77 0 C-N-CA 129.006 3.193 . . . . 0.0 110.074 173.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 52.58 7.81 0.07 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 127.015 2.126 . . . . 0.0 115.168 -177.058 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -67.1 20.81 0.02 OUTLIER 'General case' 0 CA--C 1.56 1.358 0 C-N-CA 127.309 2.244 . . . . 0.0 116.681 -165.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.44 -144.83 34.91 Favored Glycine 0 CA--C 1.532 1.136 0 O-C-N 119.794 -1.816 . . . . 0.0 114.079 175.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 11.1 t -67.19 179.8 1.13 Allowed 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.392 1.077 . . . . 0.0 113.904 -174.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.7 ' HE ' ' CE1' ' A' ' 120' ' ' HIS . 95.4 mtt180 -124.7 114.53 19.43 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.911 1.684 . . . . 0.0 109.789 177.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -102.7 -24.76 13.72 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 125.772 1.629 . . . . 0.0 114.706 -171.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.78 158.81 35.96 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 124.497 1.119 . . . . 0.0 110.332 170.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.0 p -149.79 142.25 24.35 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.171 1.388 . . . . 0.0 109.503 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.57 175.77 34.84 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 115.388 0.915 . . . . 0.0 115.388 -170.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 3.0 t -133.1 152.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.018 1.327 . . . . 0.0 111.554 174.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 16.9 mt -83.82 115.51 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 127.646 2.378 . . . . 0.0 112.664 177.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' B' ' 51' ' ' GLY . . . -108.59 169.5 14.17 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 126.964 2.221 . . . . 0.0 114.532 -179.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -104.95 88.52 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 117.489 2.403 . . . . 0.0 117.489 -168.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.34 -25.49 51.13 Favored 'General case' 0 N--CA 1.477 0.902 0 O-C-N 120.07 -1.644 . . . . 0.0 113.08 173.184 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 . . . . . 0 C--O 1.236 0.363 0 C-N-CA 126.931 2.092 . . . . 0.0 110.459 176.377 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 0.304 0 CA-C-O 121.283 0.563 . . . . 0.0 111.894 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.8 t -157.35 125.5 5.52 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 126.846 2.058 . . . . 0.0 107.683 167.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.51 143.29 32.41 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-O 122.686 1.231 . . . . 0.0 113.651 174.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.81 169.64 17.35 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.366 1.866 . . . . 0.0 110.128 175.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -153.36 150.14 12.7 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-N 119.88 1.218 . . . . 0.0 111.892 -169.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.34 117.54 18.27 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 127.336 2.254 . . . . 0.0 109.126 169.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 8.4 m -101.93 116.89 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.363 1.465 . . . . 0.0 108.546 168.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.51 123.59 43.91 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.957 1.303 . . . . 0.0 113.323 -168.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . 0.26 0.2 OUTLIER -160.44 171.07 19.71 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 117.741 2.497 . . . . 0.0 117.741 165.366 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 132.97 36.64 0.27 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 129.606 3.479 . . . . 0.0 108.728 -174.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -159.23 55.29 0.4 Allowed 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 125.045 1.338 . . . . 0.0 111.056 -167.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.85 -99.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 C-N-CA 127.266 2.365 . . . . 0.0 115.467 173.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -79.09 -14.33 13.52 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 123.949 3.099 . . . . 0.0 114.21 -176.179 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.4 HG21 HD21 ' B' ' 144' ' ' LEU . 2.1 t -98.86 141.37 16.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 120.398 1.454 . . . . 0.0 109.677 -179.725 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 pm0 -150.81 163.77 37.83 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.892 2.077 . . . . 0.0 107.237 169.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -147.94 134.06 4.93 Favored Glycine 0 CA--C 1.5 -0.904 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.379 175.072 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -97.03 130.1 46.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mm -133.64 116.29 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 C-N-CA 125.18 1.392 . . . . 0.0 109.045 168.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 65.7 m-20 -100.0 146.4 26.77 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.422 1.089 . . . . 0.0 110.855 171.146 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -121.73 135.51 54.94 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 126.852 2.061 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -128.37 122.0 30.43 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.695 1.198 . . . . 0.0 110.762 169.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 37.8 tt0 -109.4 140.34 43.23 Favored 'General case' 0 N--CA 1.466 0.351 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 168.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -103.5 6.2 37.32 Favored 'General case' 0 CA--C 1.549 0.905 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -174.416 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 37.1 mp0 -152.5 -178.45 6.85 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 129.341 3.056 . . . . 0.0 108.102 170.001 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 25.6 p -82.15 -25.35 34.42 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 120.675 -1.266 . . . . 0.0 112.784 168.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -132.31 19.4 4.4 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 125.343 1.457 . . . . 0.0 113.179 -177.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.1 -168.88 42.05 Favored Glycine 0 CA--C 1.541 1.713 0 C-N-CA 125.482 1.515 . . . . 0.0 113.688 172.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.3 169.0 14.53 Favored 'Trans proline' 0 CA--C 1.534 0.518 0 C-N-CA 124.096 3.198 . . . . 0.0 112.376 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 71.3 t -128.56 138.42 54.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.171 1.388 . . . . 0.0 111.387 -177.535 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -93.01 123.82 36.54 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 165.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.45 126.79 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.163 0.985 . . . . 0.0 110.8 169.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 10.8 p90 -146.74 164.32 33.13 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.959 0.885 . . . . 0.0 112.63 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.44 -153.58 25.42 Favored Glycine 0 C--N 1.334 0.452 0 C-N-CA 123.778 0.704 . . . . 0.0 112.47 176.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 60.6 p -153.16 119.52 5.54 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -168.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.427 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 4.3 mp -99.93 114.15 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 CA-C-O 118.265 -0.874 . . . . 0.0 109.941 173.254 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -122.18 133.84 54.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 119.929 1.241 . . . . 0.0 111.941 -175.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 132.05 -3.78 5.26 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 127.357 2.408 . . . . 0.0 114.271 176.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.447 ' CD2' ' H ' ' B' ' 38' ' ' LEU . 0.8 OUTLIER -103.9 178.58 4.52 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 126.565 1.946 . . . . 0.0 112.22 -171.766 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.8 m -70.16 156.4 39.27 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 125.647 1.579 . . . . 0.0 110.227 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.06 156.28 28.67 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 168.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.35 -170.48 35.68 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.426 1.012 . . . . 0.0 113.285 178.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.708 HD22 ' H ' ' B' ' 42' ' ' LEU . 0.4 OUTLIER -65.19 152.57 43.3 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.415 1.886 . . . . 0.0 113.594 -174.095 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -149.18 125.58 10.9 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 127.781 2.433 . . . . 0.0 109.457 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.17 147.43 21.91 Favored Glycine 0 N--CA 1.481 1.646 0 CA-C-N 120.502 1.501 . . . . 0.0 111.551 173.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -154.19 87.88 1.21 Allowed 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.064 1.745 . . . . 0.0 109.321 -167.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -127.16 153.7 45.72 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 121.229 -0.919 . . . . 0.0 112.474 -166.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.1 97.99 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.069 0.85 . . . . 0.0 110.902 -175.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -79.47 134.92 36.54 Favored 'General case' 0 CA--C 1.539 0.533 0 O-C-N 121.279 -0.888 . . . . 0.0 109.195 -170.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -72.34 174.34 7.45 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.354 1.862 . . . . 0.0 113.028 -167.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 63.12 4.73 1.66 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.934 1.694 . . . . 0.0 114.974 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.406 ' HA3' ' HA3' ' A' ' 150' ' ' GLY . . . 52.71 16.22 3.72 Favored Glycine 0 CA--C 1.533 1.189 0 O-C-N 120.267 -1.52 . . . . 0.0 113.584 -163.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.492 ' C ' HD22 ' B' ' 53' ' ' ASN . 5.9 t0 -89.45 115.4 26.86 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 125.824 1.649 . . . . 0.0 110.322 -168.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.492 HD22 ' C ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -165.14 34.98 0.06 Allowed 'General case' 0 C--O 1.239 0.514 0 CA-C-O 124.149 1.928 . . . . 0.0 116.177 -178.912 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.418 HG22 ' HB ' ' A' ' 7' ' ' VAL 0.27 0.1 OUTLIER -86.47 -43.0 13.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.261 -1.336 . . . . 0.0 112.959 -166.313 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.26 31.49 6.56 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.909 1.284 . . . . 0.0 113.067 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.57 -109.1 2.7 Favored Glycine 0 N--CA 1.468 0.818 0 O-C-N 121.033 -1.042 . . . . 0.0 112.329 169.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 56.0 m -75.93 -17.07 59.89 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 171.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.9 m -86.6 52.85 2.62 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 168.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 1.5 m 172.03 -170.53 0.03 OUTLIER 'General case' 0 CA--C 1.56 1.335 0 C-N-CA 130.378 3.471 . . . . 0.0 106.488 -165.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.5 27.39 0.01 OUTLIER 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 129.026 2.93 . . . . 0.0 118.111 -179.271 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -41.19 -46.41 4.23 Favored Glycine 0 CA--C 1.537 1.466 0 CA-C-O 116.459 -2.3 . . . . 0.0 115.497 -169.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -126.35 46.16 0.0 OUTLIER 'Trans proline' 0 C--N 1.356 0.925 0 CA-C-N 120.983 2.392 . . . . 0.0 115.52 -176.277 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 17.1 m170 78.6 78.34 0.06 Allowed 'General case' 0 C--O 1.234 0.288 0 C-N-CA 125.663 1.585 . . . . 0.0 112.916 167.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -48.06 138.75 8.88 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 161.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.608 ' ND2' ' H ' ' B' ' 81' ' ' VAL . 9.3 t-20 -157.18 116.66 2.0 Favored Pre-proline 0 N--CA 1.472 0.67 0 N-CA-C 116.746 2.128 . . . . 0.0 116.746 171.019 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.57 -5.58 15.6 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 N-CA-C 116.65 1.75 . . . . 0.0 116.65 -179.184 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -91.25 -7.51 51.0 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 119.526 1.057 . . . . 0.0 112.387 173.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 34.3 t 54.66 54.26 9.46 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 125.571 1.548 . . . . 0.0 114.82 170.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.72 176.59 5.45 Favored 'General case' 0 N--CA 1.477 0.924 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -171.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 8.4 ptpp? -79.14 155.55 28.65 Favored 'General case' 0 CA--C 1.545 0.756 0 O-C-N 121.218 -0.926 . . . . 0.0 112.34 176.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -79.31 152.67 30.36 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.149 0.98 . . . . 0.0 113.187 -177.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 144.36 -117.43 1.04 Allowed Glycine 0 C--N 1.339 0.746 0 C-N-CA 123.195 0.426 . . . . 0.0 113.986 167.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 118.67 -28.17 6.87 Favored Glycine 0 CA--C 1.542 1.741 0 N-CA-C 120.12 2.808 . . . . 0.0 120.12 168.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -93.02 -13.83 1.24 Allowed 'Trans proline' 0 CA--C 1.544 1.025 0 CA-C-N 123.203 3.502 . . . . 0.0 112.879 173.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.404 ' HE3' ' HB2' ' B' ' 126' ' ' LEU . 0.0 OUTLIER -147.16 -1.39 0.65 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.576 1.55 . . . . 0.0 112.792 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.44 177.19 5.77 Favored 'General case' 0 CA--C 1.548 0.898 0 O-C-N 120.735 -1.228 . . . . 0.0 110.508 174.706 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -90.01 -23.63 21.44 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 129.324 3.05 . . . . 0.0 111.579 -172.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -129.63 -98.09 0.35 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 124.243 1.017 . . . . 0.0 112.881 -171.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 96.36 137.6 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 129.778 3.231 . . . . 0.0 110.577 -170.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -57.21 162.06 2.87 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.267 -1.521 . . . . 0.0 112.072 168.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.608 ' H ' ' ND2' ' B' ' 65' ' ' ASN . 53.1 t -61.35 -37.6 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-N 120.403 1.456 . . . . 0.0 110.577 170.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -81.59 24.03 4.57 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.212 1.387 . . . . 0.0 115.933 170.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -109.39 127.72 54.58 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 116.523 2.046 . . . . 0.0 116.523 174.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 29.4 mt -115.31 169.26 9.27 Favored 'General case' 0 CA--C 1.56 1.35 0 N-CA-C 103.633 -2.728 . . . . 0.0 103.633 156.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.48 -126.22 1.95 Allowed Glycine 0 N--CA 1.48 1.605 0 C-N-CA 124.482 1.039 . . . . 0.0 114.265 -171.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -126.54 154.07 44.34 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 174.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 19.8 m -111.26 129.71 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.927 2.091 . . . . 0.0 110.568 -176.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -89.41 132.08 35.16 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 118.271 0.487 . . . . 0.0 110.181 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.58 162.11 13.45 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 124.849 1.26 . . . . 0.0 111.451 168.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -96.3 -174.77 3.16 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.085 1.354 . . . . 0.0 111.736 169.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.65 -10.02 47.43 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.73 -15.31 61.22 Favored 'General case' 0 CA--C 1.554 1.122 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 162.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.72 30.24 6.93 Favored Glycine 0 C--N 1.34 0.768 0 C-N-CA 127.272 2.368 . . . . 0.0 112.736 168.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -116.14 128.92 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 CA-C-N 119.854 1.827 . . . . 0.0 113.543 178.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.83 80.52 3.73 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 125.236 1.414 . . . . 0.0 110.215 167.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -77.85 123.7 27.07 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.682 1.593 . . . . 0.0 108.808 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 48.9 t -147.37 150.51 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 -168.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 71.3 m -140.18 128.42 22.47 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 127.419 2.288 . . . . 0.0 108.367 166.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 34.7 mt -136.78 124.83 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 127.771 2.429 . . . . 0.0 108.928 -179.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 10.0 mp0 -117.4 115.69 25.72 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 126.307 1.843 . . . . 0.0 107.866 -175.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -140.46 144.32 36.01 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.933 0.873 . . . . 0.0 113.32 -168.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.2 p -110.89 51.1 0.78 Allowed 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.792 1.034 . . . . 0.0 113.792 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 13.9 p -152.06 -38.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 167.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . 0.288 0.1 OUTLIER -79.77 94.15 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 120.677 1.58 . . . . 0.0 110.888 172.549 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 38.4 p -102.14 153.21 20.15 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 126.148 1.779 . . . . 0.0 113.378 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.34 54.73 1.45 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.379 1.472 . . . . 0.0 110.851 -177.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 19.1 m -94.85 39.58 1.1 Allowed 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 126.189 1.796 . . . . 0.0 112.128 -170.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 73.95 -39.46 0.97 Allowed Glycine 0 N--CA 1.475 1.271 0 C-N-CA 127.396 2.426 . . . . 0.0 115.83 169.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 24.5 t0 -161.65 -34.95 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.133 1.773 . . . . 0.0 111.962 -168.037 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 63.9 m-70 -75.85 -19.44 58.89 Favored 'General case' 0 C--O 1.226 -0.17 0 O-C-N 120.438 -1.413 . . . . 0.0 112.463 -167.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -142.62 -71.37 0.32 Allowed 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 122.793 0.437 . . . . 0.0 111.57 -172.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.25 2.3 pt -137.16 166.45 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 C-N-CA 125.252 1.421 . . . . 0.0 107.941 166.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 13.2 mm 86.72 144.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 131.308 3.843 . . . . 0.0 107.139 -163.06 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.43 3.45 25.84 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 124.133 0.873 . . . . 0.0 114.746 177.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 31.2 mtt180 -108.45 -172.45 2.06 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 128.785 2.834 . . . . 0.0 108.574 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 12.0 t -124.05 161.94 24.51 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 120.559 1.527 . . . . 0.0 109.423 166.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 tt -118.61 130.71 56.03 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 164.135 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 40.7 t -113.19 128.05 70.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 C-N-CA 125.098 1.359 . . . . 0.0 108.038 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -92.53 156.89 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 166.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -132.62 127.51 35.09 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.266 1.426 . . . . 0.0 108.752 -175.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -58.93 -14.52 9.38 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 118.122 2.638 . . . . 0.0 118.122 -166.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 45.8 mttp -137.45 177.33 7.95 Favored 'General case' 0 N--CA 1.477 0.897 0 CA-C-N 124.042 3.11 . . . . 0.0 115.255 175.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.92 129.87 31.68 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 125.749 1.62 . . . . 0.0 110.888 -177.135 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -99.81 136.88 39.06 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 124.071 0.857 . . . . 0.0 110.327 171.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -81.49 -6.3 58.82 Favored 'General case' 0 CA--C 1.551 0.991 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.044 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.404 ' HB2' ' HE3' ' B' ' 75' ' ' LYS . 32.8 mt 60.69 67.89 0.79 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.314 1.846 . . . . 0.0 111.645 169.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.5 20.09 28.09 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 117.037 1.575 . . . . 0.0 117.037 168.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 7.4 mtmp? -146.88 -57.86 0.27 Allowed 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 120.092 3.367 . . . . 0.0 120.092 -165.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -78.82 37.72 1.91 Allowed Glycine 0 N--CA 1.475 1.299 0 C-N-CA 128.64 3.019 . . . . 0.0 110.618 -169.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . 0.479 ' HA3' ' H ' ' B' ' 134' ' ' SER . . . 173.82 84.0 0.06 OUTLIER Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 -168.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -40.01 -24.96 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.935 0 C-N-CA 130.632 3.573 . . . . 0.0 114.827 167.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -116.98 -78.49 0.58 Allowed 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 127.177 2.191 . . . . 0.0 107.517 167.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -63.97 -36.47 84.09 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 114.066 1.135 . . . . 0.0 114.066 -166.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.479 ' H ' ' HA3' ' B' ' 130' ' ' GLY . 13.8 t -71.31 -27.75 63.62 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 119.583 -1.948 . . . . 0.0 112.605 -177.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.316 8.9 t -83.41 -5.82 59.27 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 118.56 -0.733 . . . . 0.0 111.728 170.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -105.16 -68.2 0.87 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 124.882 1.273 . . . . 0.0 113.702 173.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 11.6 p -88.17 -32.28 18.7 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 125.347 1.459 . . . . 0.0 113.435 178.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 116.65 -23.92 9.95 Favored Glycine 0 N--CA 1.472 1.078 0 C-N-CA 125.32 1.438 . . . . 0.0 112.448 -168.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 10.2 t30 69.43 48.06 0.65 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 127.719 2.408 . . . . 0.0 110.014 178.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.87 31.3 0.06 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 127.402 2.281 . . . . 0.0 114.672 -169.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 65.49 -33.95 0.12 Allowed Glycine 0 CA--C 1.535 1.337 0 C-N-CA 128.614 3.007 . . . . 0.0 115.265 -172.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 7.7 t -160.16 -152.21 0.28 Allowed 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 124.794 1.238 . . . . 0.0 112.398 178.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.52 -170.66 2.27 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 129.508 3.123 . . . . 0.0 107.706 174.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.4 HD21 HG21 ' B' ' 14' ' ' VAL . 0.4 OUTLIER -174.41 -168.7 0.4 Allowed 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.467 1.907 . . . . 0.0 107.372 -169.852 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -50.68 153.95 1.53 Allowed 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.67 2.788 . . . . 0.0 113.45 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.0 p -144.9 160.92 40.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.187 1.795 . . . . 0.0 112.821 -178.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -153.56 131.25 3.21 Favored Glycine 0 N--CA 1.474 1.206 0 C-N-CA 124.555 1.074 . . . . 0.0 111.98 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -88.35 128.18 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -176.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 35.4 mt -84.95 112.85 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.591 1.956 . . . . 0.0 111.228 -168.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -108.52 -144.44 10.96 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.416 -0.673 . . . . 0.0 111.416 168.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.17 163.61 26.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 124.507 1.123 . . . . 0.0 112.714 -168.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.51 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.35 -34.14 0.3 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 129.174 2.989 . . . . 0.0 109.789 166.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? . . . . . 0 N--CA 1.469 0.491 0 C-N-CA 126.387 1.875 . . . . 0.0 111.813 167.368 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 119.965 -0.064 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 39.5 p -78.51 53.76 1.35 Allowed 'General case' 0 C--O 1.221 -0.435 0 C-N-CA 127.582 2.353 . . . . 0.0 115.684 -164.555 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.9 mttp -161.94 87.46 0.65 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.003 1.721 . . . . 0.0 110.685 166.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.98 152.35 28.02 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 123.83 0.852 . . . . 0.0 109.227 167.073 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.438 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -160.04 147.58 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.856 0.862 . . . . 0.0 111.85 -168.086 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.69 139.21 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 165.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.513 HG21 ' HA ' ' B' ' 53' ' ' ASN . 88.9 t -98.29 88.9 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 167.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.72 123.74 30.15 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 127.049 2.14 . . . . 0.0 108.914 -170.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -135.62 144.15 45.95 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 122.38 1.086 . . . . 0.0 113.676 -170.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -109.08 160.94 13.3 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 107.36 -2.296 . . . . 0.0 107.36 166.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.08 58.16 1.5 Allowed 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 127.001 2.121 . . . . 0.0 111.935 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.4 -160.92 34.72 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.965 2.221 . . . . 0.0 110.565 -172.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.85 41.73 1.17 Allowed 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 125.152 3.901 . . . . 0.0 112.104 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.14 111.94 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 127.086 2.154 . . . . 0.0 108.726 -169.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -159.69 168.7 25.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.448 179.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.18 137.43 5.39 Favored Glycine 0 CA--C 1.506 -0.495 0 CA-C-N 115.659 -0.701 . . . . 0.0 112.065 168.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.0 134.04 27.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 166.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 pp -130.98 129.87 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.539 1.136 . . . . 0.0 109.231 165.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -103.2 153.75 20.04 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.537 1.935 . . . . 0.0 112.392 168.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -138.13 111.12 7.77 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 126.436 1.894 . . . . 0.0 109.123 169.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -96.33 84.78 3.8 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.315 -1.491 . . . . 0.0 112.54 176.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.424 ' HB3' HD13 ' A' ' 106' ' ' LEU . 3.5 tp60 -105.84 147.51 28.6 Favored 'General case' 0 C--O 1.222 -0.361 0 O-C-N 121.111 -0.993 . . . . 0.0 110.733 174.22 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.41 -15.14 9.11 Favored 'General case' 0 CA--C 1.551 1.005 0 C-N-CA 128.432 2.693 . . . . 0.0 112.49 -179.005 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -126.54 171.71 10.85 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 127.121 2.169 . . . . 0.0 110.594 -171.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 75.1 m -95.57 -26.5 15.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -126.58 -18.99 4.67 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 120.717 1.599 . . . . 0.0 114.904 -174.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.85 173.52 47.63 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.641 1.115 . . . . 0.0 112.973 176.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -80.95 171.04 14.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.847 3.031 . . . . 0.0 112.773 -176.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 t -140.48 136.1 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.34 1.456 . . . . 0.0 111.256 -170.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.9 tmtm? -80.77 128.89 34.16 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 168.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 38.1 t -121.91 143.41 34.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.669 1.987 . . . . 0.0 108.664 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.5 p90 -156.59 161.55 39.93 Favored 'General case' 0 C--N 1.326 -0.426 0 O-C-N 121.06 -1.025 . . . . 0.0 111.292 173.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 179.68 151.4 9.83 Favored Glycine 0 N--CA 1.452 -0.281 0 N-CA-C 114.879 0.711 . . . . 0.0 114.879 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 p -109.7 108.53 18.95 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.081 -0.56 . . . . 0.0 110.182 170.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -85.21 141.38 14.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 126.273 1.829 . . . . 0.0 107.789 167.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -149.38 132.4 16.23 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.216 1.806 . . . . 0.0 109.133 -178.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.41 -19.26 37.18 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 126.084 1.802 . . . . 0.0 114.179 -171.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.46 HD23 ' CD2' ' A' ' 43' ' ' HIS . 4.3 mp -62.96 130.94 46.97 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 119.55 1.675 . . . . 0.0 111.956 169.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -67.5 152.84 44.97 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.634 1.974 . . . . 0.0 109.268 168.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -53.61 153.6 4.23 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 125.7 1.6 . . . . 0.0 115.111 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.99 -176.63 40.93 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.723 1.154 . . . . 0.0 112.668 -177.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.6 mt -63.76 153.83 35.18 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.521 1.528 . . . . 0.0 112.18 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.46 ' CD2' HD23 ' A' ' 38' ' ' LEU . 78.6 m-70 -151.57 132.98 14.63 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 127.995 2.518 . . . . 0.0 108.701 169.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.91 142.77 46.86 Favored Glycine 0 N--CA 1.475 1.239 0 CA-C-O 118.905 -0.941 . . . . 0.0 112.263 178.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -132.93 102.83 5.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.939 1.696 . . . . 0.0 108.214 -175.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.426 ' CD2' ' HB3' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -139.65 136.92 34.8 Favored 'General case' 0 CA--C 1.537 0.464 0 O-C-N 120.736 -1.228 . . . . 0.0 110.946 -167.372 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -93.89 124.58 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 116' ' ' THR . 14.6 m-70 -72.06 -177.86 2.2 Favored 'General case' 0 CA--C 1.55 0.966 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 169.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -64.89 167.24 7.91 Favored 'General case' 0 CA--C 1.549 0.923 0 O-C-N 119.97 -1.706 . . . . 0.0 111.767 169.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -90.36 -144.53 0.17 Allowed 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -173.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.62 -147.36 26.65 Favored Glycine 0 N--CA 1.428 -1.835 0 CA-C-O 124.97 2.428 . . . . 0.0 111.441 169.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.749 ' HA ' HG21 ' B' ' 5' ' ' VAL . 19.5 p-10 -88.0 54.03 2.95 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 109.453 -3.374 . . . . 0.0 109.674 -168.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.643 ' ND2' HG21 ' B' ' 7' ' ' VAL 0.369 4.1 p30 -75.19 18.57 0.19 Allowed 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 121.221 3.785 . . . . 0.0 121.221 -157.27 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.477 HG22 ' HA ' ' B' ' 7' ' ' VAL 0.279 0.1 OUTLIER -76.3 -23.37 54.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 117.588 2.44 . . . . 0.0 117.588 -162.704 . . . . . . . . 4 4 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.71 -4.07 29.0 Favored 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 169.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 63.51 -111.31 4.02 Favored Glycine 0 C--N 1.342 0.881 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 31.0 p -47.84 -28.69 2.73 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.42 -19.48 29.59 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.727 1.211 . . . . 0.0 113.755 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 49.6 m -119.85 -43.73 2.55 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 119.208 0.913 . . . . 0.0 113.273 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.5 80.76 3.2 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.418 1.087 . . . . 0.0 111.289 -170.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.42 123.33 9.83 Favored Glycine 0 CA--C 1.536 1.389 0 C-N-CA 125.001 1.286 . . . . 0.0 112.245 -177.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -63.34 119.84 7.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.142 2.561 . . . . 0.0 109.372 -174.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.426 ' HB3' ' CD2' ' A' ' 46' ' ' HIS . 0.1 OUTLIER 34.27 66.93 0.24 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.155 1.782 . . . . 0.0 115.057 178.034 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -14.63 113.93 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 129.217 3.007 . . . . 0.0 114.505 174.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -114.53 38.6 0.22 Allowed Pre-proline 0 CA--C 1.555 1.138 0 C-N-CA 126.716 2.006 . . . . 0.0 115.448 -168.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -67.99 -14.6 41.57 Favored 'Trans proline' 0 C--N 1.358 1.063 0 C-N-CA 122.668 2.246 . . . . 0.0 112.799 -177.331 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 64.3 mt -76.72 -6.73 53.39 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.169 1.388 . . . . 0.0 112.791 172.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 28.3 t 70.93 53.63 0.26 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 127.101 2.16 . . . . 0.0 113.009 174.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 20.6 mtm-85 -131.72 174.41 10.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -171.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.1 mmtt -97.11 177.66 5.51 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 128.62 2.768 . . . . 0.0 110.193 166.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t60 -81.62 154.13 26.31 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.807 1.41 . . . . 0.0 114.807 -169.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 158.38 -169.92 34.98 Favored Glycine 0 C--N 1.335 0.489 0 CA-C-N 115.277 -0.874 . . . . 0.0 113.93 166.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.13 -85.24 0.08 OUTLIER Glycine 0 CA--C 1.544 1.889 0 CA-C-O 117.9 -1.5 . . . . 0.0 114.192 168.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.05 19.04 0.16 Allowed 'Trans proline' 0 CA--C 1.553 1.459 1 C-N-CA 125.637 4.225 . . . . 0.0 116.635 -172.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.81 5.23 0.13 Allowed 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 128.144 2.578 . . . . 0.0 111.731 177.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -126.09 175.63 7.61 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 128.938 2.895 . . . . 0.0 112.922 -164.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 -129.88 -15.43 3.86 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 129.534 3.134 . . . . 0.0 111.833 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -85.89 -83.97 0.17 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.079 1.352 . . . . 0.0 112.486 177.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 72.35 112.43 0.06 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 126.488 1.915 . . . . 0.0 111.986 175.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -69.05 168.76 13.18 Favored 'General case' 0 CA--C 1.546 0.825 0 O-C-N 120.075 -1.641 . . . . 0.0 113.029 169.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -80.75 11.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 O-C-N 120.672 -1.268 . . . . 0.0 113.279 -178.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -125.95 10.21 7.48 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 126.766 2.127 . . . . 0.0 114.246 176.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -99.95 81.02 2.38 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 121.641 -0.917 . . . . 0.0 111.161 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 64.9 mt -79.17 48.71 0.89 Allowed 'General case' 0 CA--C 1.549 0.905 0 O-C-N 121.039 -1.038 . . . . 0.0 110.771 169.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.82 -118.7 9.31 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.541 1.543 . . . . 0.0 113.423 177.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.0 p30 -157.15 172.69 18.2 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.622 1.569 . . . . 0.0 112.64 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.9 p -133.63 125.11 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 C-N-CA 126.213 1.805 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 m -98.22 139.23 34.31 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.6 159.08 18.51 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.091 0.956 . . . . 0.0 113.418 172.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -89.4 154.66 19.88 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 126.83 2.052 . . . . 0.0 111.942 169.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.42 -14.6 12.82 Favored 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.818 2.447 . . . . 0.0 115.553 178.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -79.36 5.75 11.78 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 125.254 1.422 . . . . 0.0 112.941 168.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.26 40.59 9.05 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 125.708 1.623 . . . . 0.0 113.39 169.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.4 p -155.78 146.82 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 115.302 1.593 . . . . 0.0 115.302 -168.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.93 101.15 4.8 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-O 123.44 1.59 . . . . 0.0 109.604 167.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.54 79.29 1.8 Allowed 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 127.249 2.219 . . . . 0.0 108.698 -173.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 70.9 t -93.23 147.81 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 127.31 2.244 . . . . 0.0 114.211 -167.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.6 t -150.51 116.51 5.6 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.23 1.412 . . . . 0.0 111.056 170.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 6.7 mt -140.11 168.97 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 128.296 2.638 . . . . 0.0 112.029 -168.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -136.28 136.42 39.78 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 127.909 2.484 . . . . 0.0 107.825 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -147.13 153.14 39.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 122.284 1.04 . . . . 0.0 113.373 -168.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 81.9 p -126.29 69.47 1.22 Allowed 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.884 2.074 . . . . 0.0 110.898 -169.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.53 -35.71 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 124.211 1.004 . . . . 0.0 112.225 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.402 ' CD1' ' H ' ' A' ' 104' ' ' ILE . 0.1 OUTLIER -94.98 161.68 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.928 1.291 . . . . 0.0 112.225 174.772 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.1 p -158.07 177.64 11.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.233 1.013 . . . . 0.0 111.207 174.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.424 HD13 ' HB3' ' A' ' 22' ' ' GLN . 5.9 mp -111.53 80.3 1.3 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.474 ' H ' ' CB ' ' A' ' 111' ' ' SER . 7.7 t -147.34 -171.0 3.69 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -127.69 87.83 0.33 Allowed Glycine 0 C--O 1.219 -0.824 0 O-C-N 120.444 -1.41 . . . . 0.0 113.046 -177.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -177.26 -54.19 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 129.057 2.943 . . . . 0.0 108.615 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -140.02 8.04 2.27 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 114.647 1.351 . . . . 0.0 114.647 -173.451 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.474 ' CB ' ' H ' ' A' ' 107' ' ' SER . 1.0 OUTLIER -73.08 -161.4 0.09 Allowed 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 126.334 1.853 . . . . 0.0 113.9 -172.768 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 36.9 pt -109.47 1.08 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.5 mm -62.25 126.38 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 CA-C-N 119.981 1.264 . . . . 0.0 107.633 168.462 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.76 16.84 76.35 Favored Glycine 0 CA--C 1.522 0.469 0 CA-C-O 117.953 -1.471 . . . . 0.0 115.118 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 -102.25 169.82 8.47 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 119.267 1.533 . . . . 0.0 109.741 -175.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.404 HG23 ' HB2' ' A' ' 48' ' ' HIS . 10.2 t -123.54 121.85 36.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 120.614 1.552 . . . . 0.0 112.067 -173.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.427 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.3 OUTLIER -93.02 137.23 32.56 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 174.9 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.427 ' N ' HD13 ' A' ' 117' ' ' LEU . 98.3 t -129.71 131.22 66.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 126.065 1.746 . . . . 0.0 107.741 172.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 34.5 m -106.27 138.8 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 172.008 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -95.26 148.34 22.51 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.602 0.761 . . . . 0.0 112.739 -169.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . 0.316 2.7 pp20? -74.47 -21.48 59.57 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -171.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -113.32 169.42 8.96 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.236 1.015 . . . . 0.0 112.593 171.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.73 154.14 9.53 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.533 1.533 . . . . 0.0 109.547 166.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -119.17 155.99 30.64 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 114.498 1.295 . . . . 0.0 114.498 -169.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.452 ' CG ' ' H ' ' A' ' 129' ' ' GLY . 2.9 t0 -89.83 -38.17 13.94 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 117.471 2.397 . . . . 0.0 117.471 -167.388 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 63.8 42.78 5.88 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 126.516 1.927 . . . . 0.0 113.322 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 134.8 -77.38 0.37 Allowed Glycine 0 C--N 1.337 0.586 0 C-N-CA 124.466 1.031 . . . . 0.0 112.716 169.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.17 62.16 1.17 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 118.853 2.909 . . . . 0.0 118.853 -174.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.452 ' H ' ' CG ' ' A' ' 125' ' ' ASP . . . -71.72 -71.5 1.04 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 106.899 -2.48 . . . . 0.0 106.899 163.325 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -77.79 -91.35 0.3 Allowed Glycine 0 CA--C 1.528 0.88 0 C-N-CA 126.177 1.846 . . . . 0.0 114.487 -173.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -144.02 -145.31 0.17 Allowed 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 124.822 1.249 . . . . 0.0 111.876 -165.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.8 tp10 -69.66 -49.93 48.99 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 119.751 1.16 . . . . 0.0 112.367 178.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -47.13 -27.34 1.38 Allowed 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 116.15 1.907 . . . . 0.0 116.15 171.499 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 48.7 m -51.77 -23.68 4.95 Favored 'General case' 0 CA--C 1.543 0.699 0 O-C-N 120.195 -1.565 . . . . 0.0 113.719 167.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 15.5 p -99.54 -26.9 13.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.749 1.619 . . . . 0.0 115.033 173.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 31.6 mtpt -91.75 -24.82 19.32 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 124.103 0.961 . . . . 0.0 113.429 -176.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 39.6 p -123.31 -42.05 2.27 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.727 1.611 . . . . 0.0 112.83 169.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 105.81 18.99 10.7 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-O 118.864 -0.964 . . . . 0.0 111.091 -166.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 59.04 -1.7 0.11 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.58 2.352 . . . . 0.0 115.723 176.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.9 16.44 0.02 OUTLIER 'General case' 0 CA--C 1.557 1.24 0 C-N-CA 128.822 2.849 . . . . 0.0 116.802 -165.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 77.27 -128.97 9.29 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 127.084 2.278 . . . . 0.0 111.658 -173.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.2 t -104.01 -168.22 1.47 Allowed 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.048 1.339 . . . . 0.0 113.122 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.65 151.41 36.18 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 120.629 -1.294 . . . . 0.0 110.925 168.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.3 tt -111.42 -66.81 1.04 Allowed 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.699 2.0 . . . . 0.0 107.465 169.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -131.72 158.87 40.01 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 126.276 1.83 . . . . 0.0 110.31 177.521 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 6.0 p -156.38 151.74 26.69 Favored 'General case' 0 CA--C 1.553 1.062 0 C-N-CA 125.803 1.641 . . . . 0.0 113.171 -171.319 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.07 163.42 34.29 Favored Glycine 0 CA--C 1.542 1.762 0 C-N-CA 125.724 1.631 . . . . 0.0 114.205 172.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.8 t -107.54 137.59 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.455 1.127 . . . . 0.0 108.371 168.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 83.0 mt -81.31 126.88 39.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 127.513 2.325 . . . . 0.0 113.698 -169.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -120.0 -154.43 9.43 Favored Glycine 0 N--CA 1.469 0.88 0 C-N-CA 126.043 1.782 . . . . 0.0 112.412 168.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -131.17 146.15 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.607 1.163 . . . . 0.0 112.605 -178.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.04 15.82 Favored 'General case' 0 C--O 1.22 -0.476 0 C-N-CA 124.239 1.016 . . . . 0.0 109.472 174.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 . . . . . 0 C--O 1.239 0.524 0 C-N-CA 125.085 1.354 . . . . 0.0 108.746 173.441 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.401 0 CA-C-O 120.834 0.35 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 3.3 p -82.77 107.18 15.2 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -178.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.77 118.92 27.62 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 115.245 1.572 . . . . 0.0 115.245 -172.398 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' B' ' 151' ' ' ILE . . . -94.96 161.38 14.17 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.043 1.337 . . . . 0.0 111.957 169.252 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.749 HG21 ' HA ' ' A' ' 52' ' ' ASP . 2.2 p -148.73 116.04 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 126.784 2.034 . . . . 0.0 111.188 -169.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . 0.463 ' HB3' ' HB ' ' B' ' 18' ' ' ILE . . . -78.75 125.61 29.6 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.161 -0.962 . . . . 0.0 110.106 168.34 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.643 HG21 ' ND2' ' A' ' 53' ' ' ASN . 87.8 t -107.5 71.61 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.712 0.805 . . . . 0.0 111.291 -170.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.47 HD21 ' CD1' ' B' ' 117' ' ' LEU . 1.2 mp -83.56 130.42 35.0 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -169.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 16.6 mtpp -155.24 178.26 10.41 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.119 1.368 . . . . 0.0 113.119 172.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.73 -55.55 0.47 Allowed Glycine 0 C--O 1.224 -0.48 0 C-N-CA 127.175 2.322 . . . . 0.0 109.794 170.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -83.78 73.73 10.26 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.883 1.273 . . . . 0.0 110.481 -168.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.66 -103.58 0.06 OUTLIER Glycine 0 CA--C 1.538 1.471 0 C-N-CA 126.751 2.119 . . . . 0.0 113.136 176.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -79.87 -3.04 12.56 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 125.192 3.928 . . . . 0.0 114.724 -178.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 42.0 t -77.53 128.37 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-N 120.025 1.284 . . . . 0.0 110.523 176.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -126.4 158.31 36.27 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 126.278 1.831 . . . . 0.0 109.181 167.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.01 101.91 0.28 Allowed Glycine 0 C--O 1.225 -0.415 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 168.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -102.43 106.02 19.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 C-N-CA 125.721 1.608 . . . . 0.0 106.676 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' B' ' 6' ' ' ALA . 4.2 mm -120.68 101.75 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.01 0.524 . . . . 0.0 109.964 -177.135 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -74.93 161.57 29.39 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 118.915 0.779 . . . . 0.0 110.523 172.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -146.73 100.47 3.33 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.947 2.099 . . . . 0.0 107.818 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 116.8 29.24 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.853 0.861 . . . . 0.0 112.017 -178.342 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -102.26 126.45 49.25 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 124.088 0.955 . . . . 0.0 110.767 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -49.78 20.71 Favored 'General case' 0 CA--C 1.55 0.963 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 171.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -151.5 134.56 15.86 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 128.757 2.823 . . . . 0.0 107.108 169.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 67.5 m -64.01 93.37 0.09 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.327 1.051 . . . . 0.0 112.268 178.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 9.4 p30 160.08 -32.66 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 131.081 3.753 . . . . 0.0 110.998 -174.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.6 173.18 45.41 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-O 119.241 -0.755 . . . . 0.0 111.936 172.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -66.04 166.9 19.34 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.422 2.748 . . . . 0.0 111.378 177.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 66.1 t -121.22 130.19 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 C-N-CA 124.968 1.307 . . . . 0.0 109.017 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -86.87 119.24 26.88 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.73 0.776 . . . . 0.0 109.739 170.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.4 t -104.97 121.08 56.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 127.441 2.296 . . . . 0.0 108.813 -172.555 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -155.14 157.21 37.08 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 114.904 1.446 . . . . 0.0 114.904 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.95 -135.64 4.87 Favored Glycine 0 N--CA 1.461 0.331 0 C-N-CA 124.709 1.147 . . . . 0.0 111.053 177.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.5 p -157.7 158.5 35.51 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 116.222 1.934 . . . . 0.0 116.222 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.491 HG12 HG11 ' B' ' 119' ' ' VAL . 1.3 mp -121.24 104.72 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.561 1.144 . . . . 0.0 108.483 170.3 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 12.1 tppt? -106.27 124.47 49.64 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.3 3.1 3.53 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.269 1.89 . . . . 0.0 113.916 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.517 HD13 ' CD2' ' B' ' 43' ' ' HIS . 55.6 mt -79.76 -172.03 3.13 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 124.194 0.998 . . . . 0.0 108.409 167.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.5 t -119.58 -29.08 5.16 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 171.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 175.9 -176.65 0.12 Allowed 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 130.462 3.505 . . . . 0.0 106.327 -178.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.38 160.71 35.44 Favored Glycine 0 N--CA 1.461 0.354 0 C-N-CA 125.677 1.608 . . . . 0.0 114.072 166.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.426 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.1 mp -76.59 157.91 31.57 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 167.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . 0.517 ' CD2' HD13 ' B' ' 38' ' ' LEU . 95.5 m-70 -149.38 130.01 14.04 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 126.606 1.963 . . . . 0.0 108.681 -174.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.75 147.68 37.19 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 172.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . 0.296 0.0 OUTLIER -138.32 133.56 33.17 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 123.947 1.832 . . . . 0.0 114.65 169.464 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.585 ' O ' HD22 ' B' ' 117' ' ' LEU . 1.5 m80 -130.3 145.61 51.79 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.958 1.703 . . . . 0.0 111.63 -168.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -96.55 115.51 36.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 168.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -73.38 132.53 43.12 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 170.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -65.21 135.97 56.07 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 124.333 1.053 . . . . 0.0 112.037 -165.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 66.09 -169.93 0.2 Allowed 'General case' 0 CA--C 1.544 0.747 0 CA-C-O 123.274 1.511 . . . . 0.0 111.907 -175.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.55 2.85 3.85 Favored Glycine 0 C--O 1.225 -0.437 0 C-N-CA 126.602 2.049 . . . . 0.0 113.589 -175.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.438 ' HA ' HG21 ' A' ' 5' ' ' VAL . 11.6 p-10 -79.63 49.62 1.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 121.246 2.523 . . . . 0.0 111.262 169.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.513 ' HA ' HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER 176.42 28.26 0.0 OUTLIER 'General case' 0 CA--C 1.55 0.953 0 CA-C-N 112.079 -2.328 . . . . 0.0 115.293 -169.4 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 11.0 p -57.35 18.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 120.687 3.588 . . . . 0.0 120.687 -168.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.54 3.02 20.8 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-N 121.131 1.787 . . . . 0.0 113.955 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.04 -161.99 49.63 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 119.549 1.068 . . . . 0.0 113.156 177.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 18.6 t -52.3 -21.25 3.31 Favored 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 115.881 1.808 . . . . 0.0 115.881 -169.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.1 t -66.09 -10.6 42.09 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 125.835 1.654 . . . . 0.0 113.666 169.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 13.5 m -161.15 -4.42 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -171.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.04 144.32 47.62 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 116.243 1.942 . . . . 0.0 116.243 -166.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.76 126.79 32.82 Favored Glycine 0 CA--C 1.537 1.465 0 C-N-CA 125.448 1.499 . . . . 0.0 111.862 178.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -63.28 169.79 8.88 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 124.278 3.318 . . . . 0.0 112.484 -173.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.601 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.2 p80 -61.57 108.17 0.93 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.902 1.681 . . . . 0.0 112.722 -169.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -53.22 135.67 37.83 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 126.207 1.803 . . . . 0.0 115.729 -167.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -116.72 42.38 0.36 Allowed Pre-proline 0 CA--C 1.559 1.327 0 C-N-CA 128.131 2.572 . . . . 0.0 114.746 -175.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -65.9 -20.48 58.05 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.092 1.862 . . . . 0.0 112.38 177.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 6.5 mp -77.9 -3.93 44.21 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 126.72 2.008 . . . . 0.0 113.666 170.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.3 t 52.41 59.14 4.72 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 125.778 1.631 . . . . 0.0 114.726 169.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 7.0 ptt180 -163.1 179.24 7.64 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.109 0.964 . . . . 0.0 111.914 -168.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.16 169.92 2.51 Favored 'General case' 0 CA--C 1.547 0.857 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 -179.174 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.415 ' CD2' ' HA3' ' B' ' 138' ' ' GLY . 51.7 t60 -55.64 158.32 3.56 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.979 1.711 . . . . 0.0 114.456 -173.171 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -64.68 45.04 0.11 Allowed Glycine 0 N--CA 1.47 0.937 0 N-CA-C 120.915 3.126 . . . . 0.0 120.915 -164.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -75.95 124.44 7.4 Favored Glycine 0 CA--C 1.527 0.823 0 CA-C-N 119.835 1.818 . . . . 0.0 113.903 -169.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -74.71 -3.01 13.23 Favored 'Trans proline' 0 CA--C 1.546 1.094 0 CA-C-N 120.125 1.962 . . . . 0.0 110.319 166.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.418 ' HE2' ' OD2' ' B' ' 76' ' ' ASP . 3.1 ptmt -106.07 -3.58 21.4 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 127.94 2.496 . . . . 0.0 112.98 176.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.418 ' OD2' ' HE2' ' B' ' 75' ' ' LYS . 0.2 OUTLIER -130.88 142.47 50.38 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.199 1.4 . . . . 0.0 109.351 -172.492 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -70.45 -18.09 62.99 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.984 -0.448 . . . . 0.0 111.79 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -98.48 122.16 41.33 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 125.292 1.437 . . . . 0.0 107.828 169.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 15.3 ttt85 -150.27 115.45 5.39 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.3 1.84 . . . . 0.0 109.466 -171.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -60.15 163.6 4.76 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 127.091 2.156 . . . . 0.0 112.2 166.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.23 -30.76 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 C-N-CA 124.775 1.23 . . . . 0.0 113.451 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.01 33.91 3.07 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 121.14 -0.975 . . . . 0.0 113.405 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 34.4 m-20 -144.36 155.12 43.65 Favored 'General case' 0 CA--C 1.529 0.173 0 N-CA-C 117.645 2.461 . . . . 0.0 117.645 -169.219 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 74.6 mt -113.1 -178.61 3.42 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 127.719 2.408 . . . . 0.0 107.796 164.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -83.39 -129.07 1.47 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 124.128 0.871 . . . . 0.0 113.369 176.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -103.09 162.58 12.83 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 124.064 0.946 . . . . 0.0 112.284 172.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.477 HG21 HD13 ' B' ' 35' ' ' ILE . 7.6 p -136.36 140.51 43.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 127.555 2.342 . . . . 0.0 108.179 166.229 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 91.1 m -127.76 124.23 37.23 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -165.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -82.95 144.06 30.26 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 179.514 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -82.37 163.13 21.91 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 126.679 1.992 . . . . 0.0 109.924 167.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -51.58 -17.93 0.98 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 126.777 2.031 . . . . 0.0 116.074 170.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -75.41 -23.49 57.01 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 126.753 2.021 . . . . 0.0 112.387 172.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.09 -3.94 60.5 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 125.603 1.573 . . . . 0.0 114.946 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.6 129.02 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 118.923 1.362 . . . . 0.0 112.232 168.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -97.95 126.65 43.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 164.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -79.91 142.36 35.22 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 14.9 p -124.33 130.78 73.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-N 114.086 -1.416 . . . . 0.0 111.152 165.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.1 p -155.91 69.87 0.68 Allowed 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 126.539 1.936 . . . . 0.0 109.997 -169.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 14.9 mt -127.57 162.2 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.124 1.769 . . . . 0.0 113.285 -167.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -138.66 148.74 44.4 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 127.821 2.448 . . . . 0.0 106.916 166.275 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -148.48 143.13 26.5 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 125.254 1.422 . . . . 0.0 109.106 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.3 p -108.86 55.02 0.64 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.606 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.61 -40.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.707 1.603 . . . . 0.0 109.76 170.008 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -82.32 155.27 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 CA-C-O 122.549 1.166 . . . . 0.0 113.997 179.187 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 35.6 m -158.1 156.11 30.4 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.888 1.675 . . . . 0.0 111.37 172.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.3 mp -76.74 79.85 3.36 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 126.678 1.991 . . . . 0.0 107.934 176.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.95 -19.27 20.37 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 113.233 0.827 . . . . 0.0 113.233 -172.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 83.65 9.96 82.27 Favored Glycine 0 N--CA 1.472 1.095 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.663 -174.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -165.26 -37.22 0.03 OUTLIER 'General case' 0 CA--C 1.547 0.861 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -169.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -131.84 7.29 4.38 Favored 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 116.934 2.198 . . . . 0.0 116.934 -165.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 3.0 m -161.07 -55.95 0.05 Allowed 'General case' 0 N--CA 1.479 0.977 0 O-C-N 119.368 -2.083 . . . . 0.0 115.766 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.653 HG23 HG21 ' B' ' 149' ' ' ILE . 68.2 mt -137.75 158.18 33.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 173.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 19.8 mm 83.32 102.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--O 1.224 -0.267 1 C-N-CA 131.847 4.059 . . . . 0.0 106.498 -166.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.08 13.61 83.48 Favored Glycine 0 N--CA 1.45 -0.401 0 CA-C-O 115.504 -2.831 . . . . 0.0 116.91 177.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -92.92 152.46 19.35 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 121.314 2.557 . . . . 0.0 109.05 175.032 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 6.6 t -107.68 109.72 21.4 Favored 'General case' 0 N--CA 1.487 1.398 0 CA-C-N 121.393 1.906 . . . . 0.0 112.962 -167.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.585 HD22 ' O ' ' B' ' 46' ' ' HIS . 3.1 tm? -91.17 136.29 33.19 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.785 1.234 . . . . 0.0 110.42 -176.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 4.1 p -121.06 142.3 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 C-N-CA 125.702 1.601 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.491 HG11 HG12 ' B' ' 35' ' ' ILE . 6.0 m -107.47 140.27 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 123.61 0.764 . . . . 0.0 110.371 171.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -111.93 160.22 17.64 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-O 122.373 1.083 . . . . 0.0 113.029 -170.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -84.36 -33.21 23.87 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -99.11 167.72 10.52 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.57 1.077 . . . . 0.0 111.093 177.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -56.93 150.54 16.44 Favored 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 165.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -112.28 137.5 50.32 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.239 0.616 . . . . 0.0 109.723 173.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -79.91 -38.01 33.41 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 120.577 -0.449 . . . . 0.0 111.454 169.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . 0.269 1.8 mm? 86.1 63.6 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.759 2.423 . . . . 0.0 111.868 -169.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 108.0 -15.55 36.78 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 117.077 1.591 . . . . 0.0 117.077 166.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.81 -153.95 0.6 Allowed 'General case' 0 CA--C 1.552 1.026 0 CA-C-N 119.565 1.683 . . . . 0.0 109.885 169.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 122.41 -36.78 3.05 Favored Glycine 0 N--CA 1.471 1.02 0 O-C-N 120.688 -1.257 . . . . 0.0 113.149 -176.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 157.61 -16.18 0.32 Allowed Glycine 0 N--CA 1.475 1.272 0 N-CA-C 118.719 2.248 . . . . 0.0 118.719 169.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -122.01 169.13 11.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.21 2.005 . . . . 0.0 111.513 -174.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -62.66 -51.78 65.91 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.894 1.278 . . . . 0.0 109.711 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -49.29 -30.88 8.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.561 2.344 . . . . 0.0 113.548 174.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 92.1 p -60.2 -33.67 72.55 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 122.354 2.343 . . . . 0.0 113.957 171.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 33.0 p -62.66 -34.97 78.18 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-N 118.529 0.604 . . . . 0.0 111.461 177.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 38.7 mtpt -90.86 -39.1 12.52 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.997 1.719 . . . . 0.0 113.273 -174.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 53.8 p -104.93 -28.34 11.16 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 127.212 2.205 . . . . 0.0 114.181 -173.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . 0.415 ' HA3' ' CD2' ' B' ' 71' ' ' HIS . . . 103.57 -28.98 13.23 Favored Glycine 0 N--CA 1.465 0.6 0 C-N-CA 125.857 1.694 . . . . 0.0 113.924 -168.604 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 96.98 -11.35 0.08 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 130.787 3.635 . . . . 0.0 109.736 -167.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.2 -17.48 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 131.334 3.853 . . . . 0.0 119.71 -168.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 96.96 176.33 35.0 Favored Glycine 0 CA--C 1.534 1.264 0 C-N-CA 127.058 2.266 . . . . 0.0 113.09 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 81.5 p -62.63 -74.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -168.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 170.21 158.16 0.06 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 127.44 2.296 . . . . 0.0 114.594 176.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.98 -128.8 0.19 Allowed 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 126.934 2.094 . . . . 0.0 106.639 163.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.14 150.08 43.7 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 119.347 0.976 . . . . 0.0 112.293 -171.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 36.4 t -143.37 147.74 35.14 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.994 0.918 . . . . 0.0 110.454 173.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.0 160.81 31.48 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 123.889 0.757 . . . . 0.0 114.599 177.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -78.49 152.27 5.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 121.816 -0.814 . . . . 0.0 111.971 174.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.653 HG21 HG23 ' B' ' 112' ' ' ILE . 44.8 mt -83.53 91.8 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 123.82 0.848 . . . . 0.0 111.772 169.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -80.14 -163.09 27.4 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.573 1.082 . . . . 0.0 113.181 169.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' B' ' 4' ' ' ALA . 1.3 pp -139.1 141.01 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 125.351 1.46 . . . . 0.0 112.308 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -99.68 -7.09 26.12 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 124.175 0.99 . . . . 0.0 111.974 168.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.473 0.715 0 C-N-CA 127.922 2.489 . . . . 0.0 110.677 169.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.044 0 CA-C-O 120.856 0.36 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.1 p -152.04 119.45 5.99 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 125.108 1.363 . . . . 0.0 108.742 -169.955 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 mtmm -86.98 122.29 30.63 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 174.181 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.13 162.6 12.97 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.394 1.878 . . . . 0.0 108.625 165.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.681 HG21 ' HA ' ' B' ' 52' ' ' ASP . 0.5 OUTLIER -160.05 134.78 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.499 1.12 . . . . 0.0 109.68 -168.604 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.6 137.91 54.54 Favored 'General case' 0 C--N 1.334 -0.095 0 CA-C-N 118.657 0.662 . . . . 0.0 112.311 169.846 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -95.19 115.54 34.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 167.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mp -95.01 117.02 29.43 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 169.505 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' B' ' 10' ' ' GLY . 13.1 ttpt -156.26 144.93 20.13 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 121.332 -0.855 . . . . 0.0 113.068 174.81 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.93 -33.04 0.47 Allowed Glycine 0 C--N 1.335 0.482 0 N-CA-C 116.768 1.467 . . . . 0.0 116.768 166.847 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -90.27 70.3 7.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 122.808 1.289 . . . . 0.0 109.657 -166.256 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.02 -106.66 0.14 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 128.724 3.059 . . . . 0.0 111.479 -174.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -76.1 -4.0 14.56 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 124.045 3.163 . . . . 0.0 113.886 -177.4 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 t -91.27 133.88 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 120.162 1.346 . . . . 0.0 111.897 176.431 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.21 159.08 44.6 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 127.211 2.204 . . . . 0.0 107.79 176.678 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -151.3 133.94 4.45 Favored Glycine 0 C--O 1.229 -0.166 0 CA-C-O 122.023 0.791 . . . . 0.0 111.84 177.129 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.19 130.44 56.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 169.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.55 122.99 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 124.326 1.017 . . . . 0.0 110.118 168.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.6 m120 -97.83 150.25 21.48 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.952 1.301 . . . . 0.0 110.194 167.042 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -124.83 111.25 15.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.322 1.849 . . . . 0.0 108.043 168.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -93.64 122.59 36.24 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 169.534 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -100.05 116.23 31.59 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.854 168.268 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . 0.263 0.0 OUTLIER -57.01 -50.35 73.0 Favored 'General case' 0 C--N 1.34 0.186 0 CA-C-O 119.095 -0.479 . . . . 0.0 112.044 175.893 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -158.42 145.66 17.83 Favored 'General case' 0 C--O 1.225 -0.213 0 CA-C-O 118.514 -0.755 . . . . 0.0 110.171 163.284 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.7 t -32.1 -51.52 0.25 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.985 2.114 . . . . 0.0 115.715 -167.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -78.34 -1.85 35.27 Favored 'General case' 0 CA--C 1.552 1.048 0 N-CA-C 115.559 1.688 . . . . 0.0 115.559 -175.9 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.45 -179.48 39.44 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.198 1.38 . . . . 0.0 113.756 -178.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -81.43 134.57 8.95 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 122.694 2.262 . . . . 0.0 111.354 175.218 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 t -86.69 128.76 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 O-C-N 121.779 -0.576 . . . . 0.0 110.393 -175.493 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.5 tmtt? -87.06 123.32 32.01 Favored 'General case' 0 CA--C 1.541 0.607 0 O-C-N 121.782 -0.574 . . . . 0.0 109.806 174.001 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 1.7 p -99.43 140.98 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.714 0.806 . . . . 0.0 110.343 169.866 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -145.05 156.64 44.04 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.37 0.668 . . . . 0.0 111.549 168.192 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.54 -160.4 29.23 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 123.346 0.498 . . . . 0.0 112.887 176.76 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 85.1 p -155.99 138.47 14.94 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 122.538 -0.39 . . . . 0.0 111.984 -175.615 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.91 110.42 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -179.191 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -112.91 142.93 45.01 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 127.685 2.394 . . . . 0.0 110.828 -167.287 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.01 0.81 54.9 Favored Glycine 0 CA--C 1.53 0.991 0 C-N-CA 126.457 1.98 . . . . 0.0 113.312 -177.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.7 mt -73.49 159.37 33.3 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 118.031 0.916 . . . . 0.0 110.573 176.275 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.4 t -82.75 160.23 22.36 Favored 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 162.374 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -53.6 160.15 1.36 Allowed 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.212 1.19 . . . . 0.0 114.212 -179.794 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.11 -170.71 34.72 Favored Glycine 0 CA--C 1.526 0.766 0 C-N-CA 124.128 0.87 . . . . 0.0 113.001 178.608 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.8 OUTLIER -79.18 153.13 30.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.827 1.251 . . . . 0.0 110.446 -175.249 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -147.03 114.29 6.26 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.539 2.336 . . . . 0.0 106.808 -177.088 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.87 154.09 28.58 Favored Glycine 0 N--CA 1.476 1.323 0 CA-C-N 119.887 1.221 . . . . 0.0 111.828 -176.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -157.4 135.11 10.69 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.629 1.214 . . . . 0.0 112.21 170.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.46 143.82 25.0 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 121.003 -1.061 . . . . 0.0 111.325 -170.03 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 15.9 m -85.08 136.84 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 167.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -104.72 179.22 4.34 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 125.91 1.684 . . . . 0.0 108.8 175.535 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.71 158.59 35.87 Favored 'General case' 0 N--CA 1.478 0.952 0 O-C-N 119.303 -2.123 . . . . 0.0 110.401 166.77 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 67.71 172.91 0.27 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.947 1.299 . . . . 0.0 112.298 174.648 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.04 10.33 63.84 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 126.588 2.042 . . . . 0.0 112.045 165.794 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.437 ' HA ' HG21 ' B' ' 5' ' ' VAL . 14.9 m-20 -74.07 100.76 3.69 Favored 'General case' 0 N--CA 1.453 -0.286 0 O-C-N 121.848 -0.795 . . . . 0.0 109.381 -173.331 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . 0.444 1.5 p30 -145.61 35.69 1.06 Allowed 'General case' 0 C--N 1.341 0.224 0 N-CA-C 119.427 3.121 . . . . 0.0 119.427 173.872 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' B' ' 7' ' ' VAL . 0.2 OUTLIER -112.74 -36.74 5.08 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 117.548 -1.215 . . . . 0.0 112.66 -179.628 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -77.84 23.19 0.25 Allowed 'General case' 0 CA--C 1.554 1.133 0 CA-C-N 120.321 1.419 . . . . 0.0 113.518 169.919 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.06 -126.48 42.17 Favored Glycine 0 CA--C 1.528 0.863 0 O-C-N 120.523 -1.361 . . . . 0.0 112.105 176.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 77.2 m -68.85 -15.89 63.62 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 176.127 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.4 m -86.5 -19.96 28.77 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.272 1.429 . . . . 0.0 111.731 171.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.87 -50.46 12.21 Favored 'General case' 0 N--CA 1.476 0.835 0 O-C-N 121.37 -0.831 . . . . 0.0 110.87 169.146 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -148.62 131.26 15.9 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.029 0.919 . . . . 0.0 112.742 -177.499 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.09 -131.37 0.61 Allowed Glycine 0 CA--C 1.536 1.348 0 C-N-CA 126.69 2.09 . . . . 0.0 111.499 177.386 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -79.0 178.74 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 124.13 3.22 . . . . 0.0 111.001 174.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.561 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 0.2 OUTLIER -78.06 83.39 4.36 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.062 1.345 . . . . 0.0 108.66 172.448 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -48.25 150.13 1.33 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 126.326 1.85 . . . . 0.0 113.225 -179.448 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.468 HD22 ' H ' ' A' ' 69' ' ' ARG . 63.6 t30 -146.97 114.21 4.26 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 174.855 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.76 -17.21 33.2 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.502 2.135 . . . . 0.0 113.008 175.677 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.74 -11.57 59.99 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 119.163 0.892 . . . . 0.0 113.044 175.701 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 t 53.23 46.9 25.55 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 126.008 1.723 . . . . 0.0 113.718 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.468 ' H ' HD22 ' A' ' 65' ' ' ASN . 52.6 mtp85 -104.44 168.14 9.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 127.612 2.365 . . . . 0.0 111.857 -177.747 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.59 151.46 44.63 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 122.129 0.966 . . . . 0.0 110.682 168.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.514 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 85.7 t60 -66.64 179.0 1.13 Allowed 'General case' 0 CA--C 1.545 0.754 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.105 164.334 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.448 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 113.16 -125.45 7.01 Favored Glycine 0 CA--C 1.498 -1.023 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 168.447 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.67 -50.68 0.8 Allowed Glycine 0 CA--C 1.539 1.566 0 CA-C-O 118.411 -1.216 . . . . 0.0 114.449 -178.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -80.01 -27.2 3.92 Favored 'Trans proline' 0 C--N 1.353 0.814 0 C-N-CA 122.884 2.389 . . . . 0.0 115.032 173.509 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 ptpt -121.75 -14.26 8.15 Favored 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 120.506 1.503 . . . . 0.0 113.904 169.094 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -105.84 153.47 21.88 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.866 1.266 . . . . 0.0 110.613 170.514 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -79.91 -14.6 58.51 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 125.995 1.718 . . . . 0.0 112.977 -169.584 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -103.83 -87.13 0.44 Allowed 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 115.795 1.776 . . . . 0.0 115.795 -166.771 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 84.82 133.24 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.287 1.835 . . . . 0.0 110.991 -173.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -59.82 156.69 13.68 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 125.776 1.63 . . . . 0.0 113.717 168.421 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.3 p -62.47 -36.54 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 CA-C-N 119.41 1.004 . . . . 0.0 112.925 179.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.8 102.1 1.92 Allowed Glycine 0 C--N 1.342 0.889 0 N-CA-C 106.027 -2.829 . . . . 0.0 106.027 167.596 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -162.34 147.89 12.75 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.012 1.115 . . . . 0.0 114.012 173.574 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 98.2 mt -121.7 173.47 7.43 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.558 1.943 . . . . 0.0 106.266 162.817 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.19 -107.88 1.31 Allowed Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.028 0.823 . . . . 0.0 112.758 -174.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -138.44 157.59 45.92 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.606 0.762 . . . . 0.0 111.432 169.182 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.567 HG22 ' HB1' ' A' ' 95' ' ' ALA . 0.5 OUTLIER -96.67 159.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.47 0 C-N-CA 125.233 1.413 . . . . 0.0 108.362 167.048 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.0 m -148.37 118.74 7.35 Favored 'General case' 0 N--CA 1.476 0.869 0 O-C-N 121.392 -0.817 . . . . 0.0 110.141 -174.977 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.33 142.61 28.25 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 125.587 1.555 . . . . 0.0 114.891 -169.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -78.09 148.63 34.13 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 113.189 -1.823 . . . . 0.0 109.005 166.118 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' HZ3' ' CG ' ' A' ' 92' ' ' ASP . 7.0 pttp -39.08 -32.25 0.09 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 127.536 2.334 . . . . 0.0 115.768 169.663 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.468 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 28.2 m-20 -80.01 4.53 16.73 Favored 'General case' 0 CA--C 1.55 0.968 0 CA-C-N 119.978 1.263 . . . . 0.0 111.911 -178.776 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 101.45 -0.16 53.45 Favored Glycine 0 C--N 1.34 0.754 0 C-N-CA 127.18 2.324 . . . . 0.0 115.434 168.581 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -113.79 131.89 64.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 119.273 1.536 . . . . 0.0 113.591 -174.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -98.86 132.42 44.22 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.405 164.65 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -77.9 152.2 33.41 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-O 122.243 1.021 . . . . 0.0 108.492 168.645 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.252 0.4 OUTLIER -128.43 126.65 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 CA-C-N 113.78 -1.555 . . . . 0.0 112.277 165.997 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.7 t -157.81 89.07 1.0 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.226 1.011 . . . . 0.0 112.767 -177.01 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 4.2 mp -126.18 161.52 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 125.725 1.61 . . . . 0.0 110.811 176.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -140.3 137.72 34.38 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 128.493 2.717 . . . . 0.0 106.359 167.525 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -151.98 133.1 14.34 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 118.722 0.692 . . . . 0.0 112.48 -171.077 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.7 p -101.39 51.19 0.85 Allowed 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.702 0.801 . . . . 0.0 112.261 175.976 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 41.0 t -130.98 -48.23 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.376 1.07 . . . . 0.0 108.511 169.207 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -81.53 155.12 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 122.839 1.304 . . . . 0.0 111.998 170.299 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.7 p -155.76 155.2 32.64 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 125.559 1.544 . . . . 0.0 109.968 -174.782 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.5 mp -82.23 55.2 2.77 Favored 'General case' 0 CA--C 1.548 0.87 0 O-C-N 120.699 -1.25 . . . . 0.0 110.365 177.744 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.3 t -108.2 37.55 2.45 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.098 1.759 . . . . 0.0 113.282 -172.088 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 88.79 -143.93 17.9 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-O 122.426 1.014 . . . . 0.0 111.833 169.34 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -66.8 -44.64 80.7 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 123.881 1.8 . . . . 0.0 112.039 -166.988 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -85.19 -7.38 59.07 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 112.886 -1.961 . . . . 0.0 110.884 -170.705 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.4 t -118.82 -122.18 0.29 Allowed 'General case' 0 CA--C 1.547 0.86 0 CA-C-O 116.233 -1.842 . . . . 0.0 110.268 173.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.259 7.1 pt -124.49 67.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 CA-C-N 124.233 3.197 . . . . 0.0 116.911 178.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.4 mm -127.42 132.29 69.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 165.578 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 69.72 5.33 50.84 Favored Glycine 0 N--CA 1.472 1.082 0 CA-C-N 119.724 1.147 . . . . 0.0 115.772 177.228 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -80.78 178.21 8.53 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 118.535 1.168 . . . . 0.0 113.173 -170.105 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 36.5 m -101.37 138.67 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 127.351 2.26 . . . . 0.0 110.285 -177.593 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -138.18 135.27 35.48 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 124.242 0.964 . . . . 0.0 109.097 165.764 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 p -120.35 136.6 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 126.571 1.948 . . . . 0.0 108.911 176.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 16.6 m -101.97 149.52 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 166.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 28.5 m-70 -117.89 155.58 29.91 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 125.092 1.357 . . . . 0.0 111.928 -171.404 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -81.32 -33.99 32.18 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.815 1.246 . . . . 0.0 111.465 -171.036 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.5 mmmt -92.58 165.05 13.19 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-N 119.375 0.989 . . . . 0.0 113.059 173.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.98 149.68 22.52 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.25 1.02 . . . . 0.0 109.354 165.043 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -99.88 135.29 41.52 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 169.108 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -77.91 -8.88 58.7 Favored 'General case' 0 N--CA 1.48 1.047 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 171.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 12.4 mt 62.73 48.66 4.1 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 124.97 1.308 . . . . 0.0 109.843 173.485 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 86.26 8.35 78.31 Favored Glycine 0 CA--C 1.524 0.654 0 CA-C-O 115.997 -2.557 . . . . 0.0 118.002 167.153 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -121.34 4.88 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 120.64 3.57 . . . . 0.0 120.64 -168.304 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -69.75 112.32 4.37 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 165.064 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -71.45 43.41 0.71 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 126.337 1.922 . . . . 0.0 114.55 -175.156 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -103.53 -77.05 0.57 Allowed 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 125.828 1.651 . . . . 0.0 110.567 -174.446 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 174.49 -80.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 130.73 3.612 . . . . 0.0 105.494 -170.808 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -34.28 -54.47 0.51 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 128.528 2.731 . . . . 0.0 113.878 175.213 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.1 m -65.11 -5.44 6.62 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -169.565 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 4.8 t -126.09 -25.48 3.55 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 123.989 0.916 . . . . 0.0 111.984 165.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.0 tttt -54.21 -33.26 57.84 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.348 1.859 . . . . 0.0 111.531 168.604 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 34.0 p -110.99 -67.76 0.98 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 162.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 152.72 -23.67 0.82 Allowed Glycine 0 CA--C 1.534 1.23 0 C-N-CA 129.803 3.573 . . . . 0.0 112.746 -168.294 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 110.83 -8.6 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.646 1 C-N-CA 131.768 4.027 . . . . 0.0 113.057 176.183 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.59 -17.45 2.14 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 116.526 2.046 . . . . 0.0 116.526 -169.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 68.96 -135.37 28.03 Favored Glycine 0 CA--C 1.526 0.72 0 C-N-CA 124.529 1.062 . . . . 0.0 113.604 169.547 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.09 131.97 23.37 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 124.868 1.267 . . . . 0.0 111.677 -176.226 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -65.71 173.56 2.77 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-O 121.371 0.605 . . . . 0.0 109.438 169.243 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.457 HD22 ' H ' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -150.08 -146.63 0.2 Allowed 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.808 1.643 . . . . 0.0 107.268 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.457 ' H ' HD22 ' A' ' 144' ' ' LEU . . . -50.59 150.66 2.64 Favored 'General case' 0 CA--C 1.55 0.948 0 CA-C-O 123.018 1.39 . . . . 0.0 110.843 171.203 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 4.8 t -146.37 152.75 39.6 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 124.602 1.161 . . . . 0.0 109.3 -174.636 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -155.68 158.14 28.29 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 125.388 1.471 . . . . 0.0 114.028 -178.323 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -109.79 141.85 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.252 1.021 . . . . 0.0 109.335 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 15.0 mm -78.69 92.67 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 123.791 0.836 . . . . 0.0 111.493 -175.365 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -81.19 -175.83 50.37 Favored Glycine 0 CA--C 1.531 1.078 0 C-N-CA 125.003 1.287 . . . . 0.0 113.011 168.702 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 4.8 mp -136.19 138.7 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 O-C-N 121.015 -1.285 . . . . 0.0 110.412 -172.325 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -122.2 3.58 9.81 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 124.212 1.005 . . . . 0.0 113.331 171.281 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 . . . . . 0 C--O 1.238 0.45 0 C-N-CA 126.75 2.02 . . . . 0.0 112.402 176.557 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-O 121.272 0.558 . . . . 0.0 112.187 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 18.7 p -78.64 113.28 16.55 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.483 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.456 ' HE2' ' HB1' ' B' ' 152' ' ' ALA . 5.6 ptmm? -76.31 156.26 33.54 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.776 1.751 . . . . 0.0 112.081 172.042 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.491 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -149.17 165.03 33.03 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 128.047 2.539 . . . . 0.0 110.416 172.318 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.437 HG21 ' HA ' ' A' ' 52' ' ' ASP . 5.6 p -148.81 151.82 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.579 1.552 . . . . 0.0 110.764 -165.461 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -145.08 138.92 27.0 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 124.419 1.088 . . . . 0.0 110.515 168.1 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 54' ' ' THR . 46.9 t -105.65 84.74 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.911 0.884 . . . . 0.0 110.393 -169.842 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . 0.272 0.9 OUTLIER -85.14 67.27 10.12 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 122.573 1.178 . . . . 0.0 113.075 -178.103 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt -97.95 111.73 23.92 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.053 173.367 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 9' ' ' LYS . . . -78.39 -103.24 0.2 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 171.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -139.38 109.67 6.52 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -167.856 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 51.07 -116.75 4.78 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 126.913 2.197 . . . . 0.0 112.01 -173.517 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.09 -11.39 27.1 Favored 'Trans proline' 0 CA--C 1.536 0.587 0 C-N-CA 124.997 3.798 . . . . 0.0 115.543 -167.606 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.7 t -92.14 94.94 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-O 123.049 1.404 . . . . 0.0 108.248 169.119 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.09 160.95 43.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 113.904 -1.498 . . . . 0.0 110.598 174.669 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -152.15 179.04 29.02 Favored Glycine 0 C--O 1.235 0.2 0 CA-C-O 123.034 1.352 . . . . 0.0 114.213 179.256 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -119.04 139.76 45.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.95 -1.625 . . . . 0.0 110.063 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -127.86 135.65 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 166.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -122.91 143.77 49.66 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 125.44 1.496 . . . . 0.0 110.067 169.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.481 ' HB2' ' HB3' ' B' ' 4' ' ' ALA . 87.8 m-85 -124.06 130.26 52.26 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.283 1.433 . . . . 0.0 108.262 170.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.98 120.47 41.49 Favored 'General case' 0 CA--C 1.518 -0.274 0 C-N-CA 124.333 1.053 . . . . 0.0 108.556 169.543 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -122.42 137.11 54.98 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 122.406 1.098 . . . . 0.0 108.896 168.546 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -105.89 -21.15 13.23 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.741 1.216 . . . . 0.0 113.063 -175.949 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -160.84 121.93 2.93 Favored 'General case' 0 C--O 1.222 -0.367 0 C-N-CA 127.692 2.397 . . . . 0.0 108.667 -164.126 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.1 m -59.25 -41.89 89.83 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.816 2.046 . . . . 0.0 113.179 -171.325 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -82.77 -4.5 58.03 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.502 1.921 . . . . 0.0 113.594 176.338 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.69 -175.94 33.89 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.742 1.639 . . . . 0.0 112.049 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.9 166.65 24.84 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.83 2.353 . . . . 0.0 112.117 178.896 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -115.42 137.79 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 169.441 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.43 129.06 39.72 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.739 0.816 . . . . 0.0 110.555 171.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -111.46 137.17 45.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 127.211 2.204 . . . . 0.0 109.832 -176.146 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 31.3 p90 -156.27 155.86 33.04 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 124.599 1.16 . . . . 0.0 110.972 168.619 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.32 140.47 3.06 Favored Glycine 0 C--N 1.332 0.351 0 CA-C-O 121.396 0.442 . . . . 0.0 114.1 -169.786 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 51.5 p -118.19 134.05 55.35 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.201 1.0 . . . . 0.0 110.178 -177.338 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -124.85 116.97 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 124.44 1.096 . . . . 0.0 110.435 -176.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 25.1 tptt -95.19 152.52 18.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.609 1.164 . . . . 0.0 109.393 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.87 -17.81 58.61 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.485 1.517 . . . . 0.0 113.722 -179.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 10.5 mp -69.89 119.33 13.95 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 118.457 1.128 . . . . 0.0 109.041 169.353 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -67.54 159.01 30.63 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 166.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -49.66 145.43 5.11 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 126.659 1.984 . . . . 0.0 114.591 -174.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 115.69 171.44 16.45 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 122.5 1.056 . . . . 0.0 113.864 -178.454 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.63 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.5 pt? -80.12 133.32 36.07 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.325 1.85 . . . . 0.0 111.522 -175.828 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -135.55 165.09 26.34 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 128.214 2.606 . . . . 0.0 108.964 -172.757 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.17 157.56 20.03 Favored Glycine 0 N--CA 1.482 1.713 0 C-N-CA 125.455 1.502 . . . . 0.0 114.705 -173.052 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -151.13 118.64 6.06 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.137 1.375 . . . . 0.0 113.243 -168.752 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.403 ' CE1' ' CD2' ' B' ' 48' ' ' HIS . 0.0 OUTLIER -154.97 144.22 21.11 Favored 'General case' 0 CA--C 1.555 1.172 0 O-C-N 119.778 -1.826 . . . . 0.0 113.189 178.886 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -94.21 125.56 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 126.035 1.734 . . . . 0.0 110.154 171.076 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.403 ' CD2' ' CE1' ' B' ' 46' ' ' HIS . 7.6 m-70 -75.76 166.55 23.36 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.585 1.954 . . . . 0.0 111.042 179.174 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -75.63 133.54 40.84 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 167.321 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 74.57 167.74 0.29 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 128.015 2.526 . . . . 0.0 115.536 -178.58 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.21 -2.08 38.56 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 127.57 2.51 . . . . 0.0 114.269 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.681 ' HA ' HG21 ' A' ' 5' ' ' VAL 0.255 10.9 t0 -76.79 111.38 12.25 Favored 'General case' 0 CA--C 1.491 -1.303 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 165.023 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.3 0.1 OUTLIER -144.73 38.3 1.22 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-O 124.225 1.964 . . . . 0.0 113.264 168.738 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.0 p -79.89 -34.03 39.44 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 112.093 -2.322 . . . . 0.0 111.852 -166.257 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -80.3 20.49 0.68 Allowed 'General case' 0 CA--C 1.555 1.168 0 C-N-CA 124.503 1.121 . . . . 0.0 110.605 163.857 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.34 -134.6 50.21 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 125.679 1.609 . . . . 0.0 112.136 -176.771 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 7.1 t -60.13 -8.43 2.44 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 126.305 1.842 . . . . 0.0 114.837 179.772 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 15.7 m -89.51 -18.92 25.73 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 126.528 1.931 . . . . 0.0 112.348 174.858 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 3.4 m -94.77 -170.24 2.18 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 123.767 0.827 . . . . 0.0 110.63 168.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . 66.69 -96.06 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 126.661 1.984 . . . . 0.0 112.204 177.137 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.37 162.01 11.53 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 126.84 2.162 . . . . 0.0 110.015 -167.353 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 161.42 42.35 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 123.166 2.577 . . . . 0.0 112.164 -174.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.4 ' HB3' ' CD2' ' B' ' 46' ' ' HIS . 0.7 OUTLIER -23.89 100.14 0.02 OUTLIER 'General case' 0 C--O 1.237 0.433 0 C-N-CA 129.436 3.094 . . . . 0.0 113.827 167.587 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . 0.415 ' CG ' ' HD3' ' B' ' 66' ' ' PRO . 3.1 t80 -55.5 127.52 30.07 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 123.681 1.705 . . . . 0.0 111.482 177.267 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 24.3 p-10 -103.07 39.38 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.42 0 N-CA-C 117.229 2.307 . . . . 0.0 117.229 -177.868 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . 0.415 ' HD3' ' CG ' ' B' ' 64' ' ' PHE . 75.4 Cg_endo -67.02 -14.01 42.02 Favored 'Trans proline' 0 C--N 1.36 1.133 0 C-N-CA 123.277 2.651 . . . . 0.0 112.666 -176.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 78.6 mt -75.23 -1.24 22.49 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 125.841 1.656 . . . . 0.0 112.189 175.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.5 t 62.3 58.91 1.67 Allowed 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.794 1.238 . . . . 0.0 113.132 167.495 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -152.82 175.1 13.26 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 114.799 1.407 . . . . 0.0 114.799 -167.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.407 ' HE3' ' HG3' ' B' ' 78' ' ' GLU . 0.0 OUTLIER -78.53 168.66 19.45 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-O 122.108 0.956 . . . . 0.0 109.968 166.747 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.455 ' HE2' ' HA ' ' B' ' 125' ' ' ASP . 42.3 t60 -61.04 165.03 4.48 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 118.356 -0.831 . . . . 0.0 110.334 172.275 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 168.65 -169.67 41.83 Favored Glycine 0 N--CA 1.476 1.316 0 N-CA-C 117.533 1.773 . . . . 0.0 117.533 -172.947 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.432 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 134.78 -87.0 0.25 Allowed Glycine 0 CA--C 1.545 1.931 0 N-CA-C 121.112 3.205 . . . . 0.0 121.112 167.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -72.49 4.75 3.21 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 124.288 3.326 . . . . 0.0 114.459 -167.849 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . 0.27 0.0 OUTLIER -167.05 4.76 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 130.03 3.332 . . . . 0.0 112.804 175.398 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.432 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 2.4 t0 -128.16 138.54 52.53 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 126.79 2.036 . . . . 0.0 105.649 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . 0.456 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -90.82 -9.33 46.86 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 126.764 2.026 . . . . 0.0 114.844 -166.643 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . 0.407 ' HG3' ' HE3' ' B' ' 70' ' ' LYS . 6.9 mm-40 -84.38 -84.61 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.911 0.778 . . . . 0.0 109.995 -175.667 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.562 HH22 HG23 ' B' ' 104' ' ' ILE . 33.3 ttp85 78.84 102.45 0.07 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.77 2.028 . . . . 0.0 113.474 167.33 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 13.6 m170 -54.57 155.0 4.33 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 119.829 -1.794 . . . . 0.0 110.165 166.882 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -60.09 -30.41 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 119.708 1.14 . . . . 0.0 113.393 -169.612 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -88.38 -6.41 74.19 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-O 118.126 -1.375 . . . . 0.0 116.111 179.243 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -79.54 122.37 26.39 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 121.064 2.432 . . . . 0.0 109.902 -176.873 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -126.9 42.17 3.37 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 120.984 1.72 . . . . 0.0 113.455 177.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 60.25 -122.84 31.18 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.691 2.236 . . . . 0.0 118.691 166.007 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . 0.518 HD21 ' CD1' ' B' ' 126' ' ' LEU . 9.7 m120 -126.82 154.06 44.82 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 113.781 -1.209 . . . . 0.0 113.859 -169.091 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 26.2 m -130.77 125.55 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.432 1.493 . . . . 0.0 109.107 167.292 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 46.5 m -109.87 127.84 54.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.568 0.747 . . . . 0.0 109.045 -175.784 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -92.91 148.23 22.18 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.291 1.437 . . . . 0.0 114.078 -177.789 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -104.76 159.31 15.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.904 2.081 . . . . 0.0 110.154 167.145 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -71.35 8.44 1.04 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 116.583 2.068 . . . . 0.0 116.583 -168.679 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -76.7 -12.58 60.02 Favored 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 122.404 1.097 . . . . 0.0 108.9 164.221 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 86.93 40.42 7.1 Favored Glycine 0 C--N 1.337 0.601 0 C-N-CA 125.571 1.557 . . . . 0.0 110.412 -174.676 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 14.8 p -141.01 134.59 31.91 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 118.337 1.068 . . . . 0.0 113.384 177.857 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' B' ' 89' ' ' ALA . . . -102.04 120.35 40.29 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 162.728 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -115.43 140.39 49.18 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 122.365 1.079 . . . . 0.0 110.197 169.714 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.43 150.5 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-N 112.324 -2.216 . . . . 0.0 115.092 -169.395 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 24.6 p -153.01 119.47 5.59 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.28 1.032 . . . . 0.0 111.349 171.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 4.1 mt -145.07 159.35 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 128.321 2.649 . . . . 0.0 110.565 -170.186 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 20.4 tt0 -140.67 140.96 35.06 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.162 1.785 . . . . 0.0 108.172 168.085 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.98 140.08 26.62 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 125.182 1.393 . . . . 0.0 111.253 -172.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 53.4 p -110.47 48.65 0.9 Allowed 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.664 0.987 . . . . 0.0 113.664 -175.442 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 33.0 m -148.84 -29.72 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 CA-C-O 117.997 -1.001 . . . . 0.0 113.144 167.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . 0.562 HG23 HH22 ' B' ' 79' ' ' ARG . 0.1 OUTLIER -76.88 154.11 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-N 121.164 1.802 . . . . 0.0 108.114 165.841 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . 0.458 ' H ' ' HB3' ' B' ' 111' ' ' SER . 2.9 p -162.46 158.29 23.54 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 125.352 1.461 . . . . 0.0 109.116 -174.238 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mp -79.67 55.5 2.03 Favored 'General case' 0 CA--C 1.542 0.673 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 171.666 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 58.0 m -93.48 52.56 1.75 Allowed 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 124.245 1.018 . . . . 0.0 110.074 -173.24 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 69.87 -96.86 0.54 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 124.688 1.137 . . . . 0.0 111.413 -177.028 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -134.97 7.0 3.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 128.298 2.639 . . . . 0.0 110.596 179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -79.43 -11.84 59.9 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 120.623 -1.298 . . . . 0.0 111.947 173.528 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . 0.458 ' HB3' ' H ' ' B' ' 105' ' ' SER . 18.4 m -141.75 -98.69 0.13 Allowed 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 113.372 0.878 . . . . 0.0 113.372 -170.003 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 17.5 pt -119.56 164.19 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 120.744 -1.223 . . . . 0.0 109.376 168.257 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.9 mm 94.43 137.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 131.149 3.78 . . . . 0.0 105.772 -163.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.26 -15.0 12.94 Favored Glycine 0 CA--C 1.528 0.86 0 CA-C-O 117.809 -1.55 . . . . 0.0 116.569 177.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 71.5 mtt85 -87.01 -175.4 5.34 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 125.642 1.577 . . . . 0.0 110.147 177.334 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 14.6 t -140.31 126.9 20.27 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 119.382 0.992 . . . . 0.0 111.718 -174.114 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -95.08 141.64 28.48 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.937 1.295 . . . . 0.0 110.056 -177.516 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.43 136.0 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.235 1.014 . . . . 0.0 109.146 177.237 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 2.4 m -93.55 140.95 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-O 122.438 1.113 . . . . 0.0 110.454 170.208 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -130.97 165.51 23.0 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 126.147 1.779 . . . . 0.0 111.223 -170.706 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -84.07 -37.86 21.53 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -170.215 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 87.3 mttt -102.35 144.13 31.22 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 119.172 0.896 . . . . 0.0 112.369 -174.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . 0.429 ' O ' HD11 ' B' ' 126' ' ' LEU . . . -77.66 54.86 1.26 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.004 1.321 . . . . 0.0 112.33 168.853 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.29 -12.06 17.52 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 126.742 2.017 . . . . 0.0 114.524 -177.853 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . 0.455 ' HA ' ' HE2' ' B' ' 71' ' ' HIS . 20.9 t70 -65.25 -7.11 11.58 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 125.435 1.494 . . . . 0.0 114.637 -171.551 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.599 ' H ' HD13 ' B' ' 126' ' ' LEU . 0.0 OUTLIER -84.83 42.54 0.93 Allowed 'General case' 0 C--N 1.32 -0.685 0 O-C-N 119.383 -2.073 . . . . 0.0 114.789 179.168 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 63.14 8.41 23.45 Favored Glycine 0 N--CA 1.473 1.152 0 N-CA-C 117.401 1.72 . . . . 0.0 117.401 166.818 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 53.2 tttp -154.86 -59.25 0.11 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 124.54 1.136 . . . . 0.0 112.178 -167.889 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 37.99 -119.45 0.77 Allowed Glycine 0 CA--C 1.529 0.91 0 C-N-CA 126.071 1.796 . . . . 0.0 113.487 177.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -107.66 -22.81 7.15 Favored Glycine 0 CA--C 1.534 1.231 0 CA-C-O 117.75 -1.583 . . . . 0.0 116.9 -177.562 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -161.44 -178.08 6.4 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 121.22 2.51 . . . . 0.0 112.582 -172.073 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -47.49 -58.32 4.35 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 127.119 2.167 . . . . 0.0 113.128 -172.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -52.33 -21.01 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 115.37 1.618 . . . . 0.0 115.37 177.737 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 6.1 m -70.11 -27.33 64.5 Favored 'General case' 0 CA--C 1.549 0.905 0 O-C-N 119.644 -1.91 . . . . 0.0 112.526 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 4.5 t -79.67 -14.85 58.48 Favored 'General case' 0 N--CA 1.491 1.591 0 CA-C-N 119.853 1.206 . . . . 0.0 112.529 168.362 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mtpt -102.04 -91.44 0.33 Allowed 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.285 1.834 . . . . 0.0 111.998 -177.853 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 32.2 p -74.88 -22.16 58.81 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 119.887 1.221 . . . . 0.0 113.986 178.532 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.96 3.46 62.02 Favored Glycine 0 N--CA 1.446 -0.694 0 CA-C-O 115.497 -2.835 . . . . 0.0 111.145 -167.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 63.75 -68.4 0.09 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 128.167 2.587 . . . . 0.0 110.12 172.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . 70.26 -15.56 0.34 Allowed 'General case' 0 CA--C 1.55 0.944 0 C-N-CA 128.689 2.796 . . . . 0.0 115.109 162.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.59 -53.34 4.51 Favored Glycine 0 N--CA 1.473 1.117 0 C-N-CA 126.936 2.207 . . . . 0.0 115.417 174.239 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.5 t -161.65 -166.1 1.42 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 123.685 0.794 . . . . 0.0 111.058 175.139 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.461 ' HE ' ' N ' ' B' ' 143' ' ' ARG . 0.1 OUTLIER -132.22 142.87 49.59 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 126.376 1.87 . . . . 0.0 107.35 176.639 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . 0.256 0.2 OUTLIER -127.23 -105.37 0.32 Allowed 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 124.789 1.236 . . . . 0.0 109.663 175.667 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.87 161.85 26.45 Favored 'General case' 0 CA--C 1.544 0.718 0 CA-C-N 120.295 1.407 . . . . 0.0 113.9 177.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 26.5 p -152.83 142.74 22.15 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.699 1.6 . . . . 0.0 111.116 -169.141 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.04 126.61 1.78 Allowed Glycine 0 C--N 1.338 0.692 0 N-CA-C 115.86 1.104 . . . . 0.0 115.86 -169.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.2 t -79.01 144.97 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 123.81 0.844 . . . . 0.0 109.243 -179.735 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 26.4 mt -92.25 126.15 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 C-N-CA 124.622 1.169 . . . . 0.0 112.214 -179.507 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -116.92 171.99 14.04 Favored Glycine 0 CA--C 1.538 1.505 0 N-CA-C 117.214 1.646 . . . . 0.0 117.214 172.131 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.4 pp -87.43 107.83 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 125.019 1.328 . . . . 0.0 112.564 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.491 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -79.69 -5.03 54.35 Favored 'General case' 0 CA--C 1.554 1.111 0 O-C-N 121.133 -0.979 . . . . 0.0 111.122 166.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 . . . . . 0 N--CA 1.47 0.529 0 C-N-CA 131.259 3.824 . . . . 0.0 111.103 172.05 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.757 0 CA-C-O 120.314 0.102 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.7 p -77.08 65.16 2.66 Favored 'General case' 0 CA--C 1.54 0.562 0 N-CA-C 116.414 2.005 . . . . 0.0 116.414 -165.846 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . 0.279 0.0 OUTLIER -155.7 117.85 4.1 Favored 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 117.573 2.435 . . . . 0.0 117.573 168.072 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.1 156.77 36.02 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.062 2.545 . . . . 0.0 106.403 164.077 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 32.3 t -154.7 155.07 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 120.148 1.34 . . . . 0.0 114.248 -164.891 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.87 128.13 33.99 Favored 'General case' 0 CA--C 1.552 1.044 0 C-N-CA 125.892 1.677 . . . . 0.0 110.285 168.045 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.05 92.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 127.154 2.181 . . . . 0.0 108.59 176.822 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.1 mp -77.01 149.18 35.9 Favored 'General case' 0 N--CA 1.467 0.42 0 C-N-CA 125.936 1.694 . . . . 0.0 112.624 -167.509 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -155.35 153.58 30.7 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.127 0.971 . . . . 0.0 111.84 171.012 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -111.4 -110.61 3.18 Favored Glycine 0 N--CA 1.466 0.684 1 N-CA-C 101.753 -4.539 . . . . 0.0 101.753 162.73 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . 0.276 0.3 OUTLIER -155.62 148.46 24.29 Favored 'General case' 0 N--CA 1.442 -0.86 0 C-N-CA 124.886 1.275 . . . . 0.0 108.959 162.143 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.23 -170.83 36.25 Favored Glycine 0 CA--C 1.54 1.624 0 N-CA-C 107.666 -2.173 . . . . 0.0 107.666 -163.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.74 37.68 0.43 Allowed 'Trans proline' 0 CA--C 1.545 1.063 1 C-N-CA 125.459 4.106 . . . . 0.0 114.308 -171.802 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -108.61 122.44 63.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 126.062 1.745 . . . . 0.0 108.433 172.672 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.92 166.49 25.84 Favored 'General case' 0 CA--C 1.519 -0.25 0 C-N-CA 125.52 1.528 . . . . 0.0 110.262 179.222 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.51 131.81 3.0 Favored Glycine 0 C--O 1.224 -0.521 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.986 167.732 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.63 131.23 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 O-C-N 121.511 -0.994 . . . . 0.0 109.266 168.416 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.2 mm -131.06 122.62 52.1 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 167.81 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -112.25 141.4 46.01 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 125.481 1.512 . . . . 0.0 111.813 169.054 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -116.93 108.76 16.19 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.906 1.682 . . . . 0.0 110.357 176.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HB2' ' CH2' ' A' ' 32' ' ' TRP . 0.0 OUTLIER -87.76 118.94 27.61 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 127.073 2.149 . . . . 0.0 109.978 169.62 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.568 ' HB3' HD11 ' A' ' 106' ' ' LEU . 19.5 tp60 -148.69 140.29 23.53 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.678 0.791 . . . . 0.0 109.321 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.82 -28.25 14.34 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.159 1.911 . . . . 0.0 116.159 -169.727 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.75 -139.86 0.1 Allowed 'General case' 0 CA--C 1.556 1.181 0 C-N-CA 125.494 1.518 . . . . 0.0 111.41 170.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 90.0 p -113.16 -11.73 13.24 Favored 'General case' 0 N--CA 1.482 1.14 0 O-C-N 118.987 -2.321 . . . . 0.0 115.758 -170.371 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -128.2 -16.67 4.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 126.453 1.901 . . . . 0.0 112.882 -177.579 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.74 171.08 48.05 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 125.548 1.547 . . . . 0.0 112.446 177.741 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -85.13 140.42 7.66 Favored 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 122.268 1.979 . . . . 0.0 111.856 -169.26 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -101.6 132.33 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 124.703 1.201 . . . . 0.0 109.487 -173.137 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.427 ' HZ2' ' CD ' ' A' ' 100' ' ' GLU . 4.5 ttmp? -92.37 126.21 37.35 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.832 1.253 . . . . 0.0 109.178 169.344 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.8 t -110.19 127.78 66.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 126.069 1.748 . . . . 0.0 109.581 177.753 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.468 ' CH2' ' HB2' ' A' ' 21' ' ' GLU . 6.0 p90 -135.92 159.51 41.46 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.172 0.989 . . . . 0.0 111.434 170.342 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.64 -176.72 27.31 Favored Glycine 0 C--O 1.222 -0.651 0 O-C-N 121.718 -0.614 . . . . 0.0 114.041 -173.192 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.69 141.69 13.25 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.752 0.821 . . . . 0.0 111.543 -172.774 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.2 mp -113.7 118.54 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 126.462 1.905 . . . . 0.0 109.315 -178.503 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 60.6 tptt -115.81 128.63 55.98 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.124 1.37 . . . . 0.0 110.244 -171.606 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.23 6.34 9.02 Favored Glycine 0 N--CA 1.477 1.433 0 C-N-CA 125.568 1.556 . . . . 0.0 114.964 -177.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.574 HD23 HD11 ' A' ' 144' ' ' LEU . 31.6 mt -80.95 157.84 25.42 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.58 1.552 . . . . 0.0 111.609 173.599 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.9 t -75.41 151.95 38.07 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 163.398 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.58 147.05 23.26 Favored 'General case' 0 CA--C 1.545 0.756 0 CA-C-N 119.593 1.088 . . . . 0.0 112.242 170.768 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 111.65 -175.74 17.67 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.854 1.216 . . . . 0.0 113.453 -174.791 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.5 mt -77.27 154.39 33.0 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.595 1.158 . . . . 0.0 112.144 -174.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.425 ' CG ' HD22 ' A' ' 38' ' ' LEU . 91.7 m-70 -153.11 123.45 7.11 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 127.077 2.151 . . . . 0.0 110.13 -171.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.85 151.72 47.96 Favored Glycine 0 N--CA 1.474 1.218 0 CA-C-N 120.167 1.349 . . . . 0.0 112.439 178.251 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . 0.32 0.0 OUTLIER -146.19 140.2 26.44 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 166.119 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.401 ' CE1' ' CD2' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -148.51 153.54 38.59 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 120.998 -1.064 . . . . 0.0 112.031 -166.63 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 1.5 m -80.0 152.54 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 122.698 0.399 . . . . 0.0 110.526 168.109 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -93.98 167.98 11.25 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 126.052 1.741 . . . . 0.0 113.297 175.374 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -65.96 87.77 0.1 Allowed 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 129.511 3.124 . . . . 0.0 109.596 170.115 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 74.2 177.96 0.22 Allowed 'General case' 0 C--N 1.347 0.491 0 CA-C-O 123.072 1.415 . . . . 0.0 112.848 168.884 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -95.23 -4.28 61.22 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 125.435 1.493 . . . . 0.0 111.143 168.128 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -66.98 64.79 0.06 Allowed 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 128.844 2.858 . . . . 0.0 109.817 169.261 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 167.53 -39.02 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 128.505 2.722 . . . . 0.0 114.714 179.364 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.36 0.5 OUTLIER 55.02 -58.48 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 130.303 3.441 . . . . 0.0 116.327 -174.829 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -68.47 4.22 1.45 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 125.264 1.426 . . . . 0.0 113.916 179.746 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.436 ' HA3' HG21 ' A' ' 116' ' ' THR . . . 62.89 -126.36 36.71 Favored Glycine 0 C--N 1.339 0.728 0 C-N-CA 124.91 1.243 . . . . 0.0 111.394 171.023 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -55.66 -8.48 0.39 Allowed 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 117.302 2.334 . . . . 0.0 117.302 -171.753 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.9 t -107.31 -2.13 20.99 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.544 1.52 . . . . 0.0 114.815 171.522 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.6 m -119.01 -37.83 3.16 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.641 1.576 . . . . 0.0 112.699 173.212 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.57 170.87 15.35 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.2 1.8 . . . . 0.0 110.869 175.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -109.8 -69.81 0.63 Allowed Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.549 1.38 . . . . 0.0 116.549 -168.637 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -87.07 -174.16 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.47 1 C-N-CA 125.473 4.115 . . . . 0.0 114.234 -169.407 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -104.01 132.38 50.32 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 127.666 2.386 . . . . 0.0 111.781 -175.831 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -46.9 114.11 0.78 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.579 1.552 . . . . 0.0 111.484 168.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 54.0 p30 -112.3 32.04 0.11 Allowed Pre-proline 0 CA--C 1.555 1.148 0 N-CA-C 116.734 2.124 . . . . 0.0 116.734 -167.944 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -56.63 -23.12 47.22 Favored 'Trans proline' 0 C--N 1.354 0.86 0 C-N-CA 124.915 3.743 . . . . 0.0 117.319 -164.957 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.478 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 4.5 mm? -78.39 -0.41 29.02 Favored 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 174.711 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 38.7 t 66.58 55.5 0.79 Allowed 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 126.886 2.074 . . . . 0.0 110.318 178.33 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.478 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.5 ptp180 -143.36 170.99 14.74 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -165.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.31 0.0 OUTLIER -85.43 -178.64 6.76 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.365 1.866 . . . . 0.0 113.514 172.79 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.477 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 78.2 t60 -99.42 139.78 34.58 Favored 'General case' 0 C--O 1.22 -0.487 0 C-N-CA 125.876 1.67 . . . . 0.0 112.747 -170.806 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 149.89 -143.95 11.38 Favored Glycine 0 C--N 1.34 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 113.902 173.808 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 156.06 -75.93 0.21 Allowed Glycine 0 CA--C 1.535 1.293 0 N-CA-C 118.594 2.198 . . . . 0.0 118.594 -175.989 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -70.85 -11.73 29.82 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.954 2.436 . . . . 0.0 113.054 -171.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -130.05 -0.78 4.67 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 125.684 1.593 . . . . 0.0 111.238 168.25 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.73 122.97 25.37 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 124.053 1.882 . . . . 0.0 111.801 -167.564 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -63.1 -27.77 69.62 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 129.815 3.246 . . . . 0.0 111.717 169.115 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 51.8 mm-40 -88.31 76.35 8.38 Favored 'General case' 0 C--O 1.214 -0.776 0 C-N-CA 126.319 1.848 . . . . 0.0 108.192 177.613 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 53.6 ttt180 -111.51 110.64 21.17 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 129.599 3.16 . . . . 0.0 109.022 -178.464 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -59.95 159.9 8.57 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 119.385 0.993 . . . . 0.0 112.597 169.925 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 m -43.1 -57.37 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -173.161 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.2 31.53 8.54 Favored Glycine 0 N--CA 1.472 1.067 0 C-N-CA 125.064 1.316 . . . . 0.0 113.298 172.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -76.94 121.97 24.21 Favored 'General case' 0 C--O 1.237 0.408 0 O-C-N 120.942 -1.328 . . . . 0.0 108.253 169.744 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -95.76 176.82 5.99 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 112.854 -1.975 . . . . 0.0 109.149 167.525 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.73 23.99 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 124.305 0.955 . . . . 0.0 113.371 -175.341 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -83.9 126.19 32.74 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 121.675 -0.897 . . . . 0.0 108.91 167.843 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.98 170.59 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 164.235 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 t -145.02 127.73 16.22 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 124.683 1.193 . . . . 0.0 109.751 174.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -87.2 144.85 26.64 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 113.183 0.809 . . . . 0.0 113.183 174.417 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -67.47 170.96 6.65 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 126.191 1.796 . . . . 0.0 110.946 168.528 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.76 -32.15 29.61 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 124.753 1.221 . . . . 0.0 112.854 168.527 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -73.41 -15.49 61.35 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.938 1.695 . . . . 0.0 112.283 177.123 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.22 14.47 64.13 Favored Glycine 0 CA--C 1.527 0.808 0 O-C-N 120.832 -1.167 . . . . 0.0 113.43 179.167 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.6 p -96.71 125.22 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 124.226 1.011 . . . . 0.0 109.916 168.209 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.69 122.0 43.09 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 168.229 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -88.99 145.29 25.59 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 123.089 1.423 . . . . 0.0 110.145 -179.314 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.77 125.69 74.56 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 112.229 -2.26 . . . . 0.0 110.002 172.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.4 m -155.13 85.77 1.09 Allowed 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 126.126 1.77 . . . . 0.0 108.67 -173.121 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 12.9 mt -140.13 154.64 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 C-N-CA 127.308 2.243 . . . . 0.0 111.53 -169.208 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.427 ' CD ' ' HZ2' ' A' ' 30' ' ' LYS . 15.7 tt0 -140.91 144.86 35.44 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.593 1.557 . . . . 0.0 108.233 168.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.98 144.84 21.59 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.624 1.169 . . . . 0.0 113.386 -166.821 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 55.2 p -116.7 49.37 1.17 Allowed 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 114.957 1.465 . . . . 0.0 114.957 -179.687 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.2 m -149.06 16.23 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 176.055 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.35 168.69 13.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 120.49 -1.381 . . . . 0.0 111.037 171.295 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.568 ' H ' ' HB3' ' A' ' 111' ' ' SER . 86.3 p -154.91 161.24 41.49 Favored 'General case' 0 C--O 1.239 0.509 0 O-C-N 121.265 -0.897 . . . . 0.0 112.602 169.144 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.568 HD11 ' HB3' ' A' ' 22' ' ' GLN . 0.0 OUTLIER -92.53 50.89 1.66 Allowed 'General case' 0 CA--C 1.542 0.636 0 O-C-N 121.15 -0.969 . . . . 0.0 111.44 175.732 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.1 t -87.85 -40.91 13.62 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.436 1.094 . . . . 0.0 112.925 178.725 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 100.46 12.27 38.95 Favored Glycine 0 N--CA 1.478 1.494 0 N-CA-C 115.535 0.974 . . . . 0.0 115.535 176.03 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -89.54 -92.71 0.12 Allowed 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 127.581 2.352 . . . . 0.0 111.006 -179.672 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 7.3 m170 -96.65 -24.96 15.75 Favored 'General case' 0 N--CA 1.446 -0.633 0 C-N-CA 126.585 1.954 . . . . 0.0 109.291 174.283 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.568 ' HB3' ' H ' ' A' ' 105' ' ' SER . 53.4 m -79.16 -142.14 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.07 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -168.001 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 13.7 pt -94.98 -21.46 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -166.414 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mm -63.75 141.97 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 CA-C-N 119.811 1.187 . . . . 0.0 109.666 170.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.13 28.08 62.93 Favored Glycine 0 CA--C 1.503 -0.663 0 CA-C-O 116.701 -2.166 . . . . 0.0 113.446 177.475 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 84.7 mtt-85 -129.78 178.31 6.61 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.532 1.666 . . . . 0.0 108.515 171.741 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.436 HG21 ' HA3' ' A' ' 56' ' ' GLY . 89.4 m -117.19 145.36 43.91 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 119.328 0.967 . . . . 0.0 110.02 179.179 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.1 tp -108.31 134.14 51.55 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 119.074 0.852 . . . . 0.0 109.511 169.408 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 p -110.33 144.62 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 C-N-CA 125.822 1.649 . . . . 0.0 110.643 172.619 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.99 142.24 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.903 1.281 . . . . 0.0 110.226 170.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.401 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 44.9 m-70 -119.2 147.14 44.56 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.656 1.583 . . . . 0.0 114.563 -166.523 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -85.34 -17.29 37.23 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -166.73 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.9 169.48 8.89 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 120.087 -1.633 . . . . 0.0 111.082 172.718 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.6 133.6 55.84 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 168.727 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 40.2 t0 -83.36 154.03 24.26 Favored 'General case' 0 CA--C 1.54 0.571 0 O-C-N 123.272 0.357 . . . . 0.0 110.293 169.435 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -75.58 -50.9 14.16 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 165.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.2 mt 94.79 63.08 0.0 OUTLIER 'General case' 0 C--O 1.222 -0.358 0 C-N-CA 129.296 3.039 . . . . 0.0 109.299 -178.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 109.7 -25.63 16.58 Favored Glycine 0 N--CA 1.481 1.635 0 N-CA-C 117.069 1.588 . . . . 0.0 117.069 167.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -118.35 -144.96 0.37 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.181 1.792 . . . . 0.0 110.897 172.148 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.08 7.97 60.62 Favored Glycine 0 CA--C 1.536 1.352 0 O-C-N 120.356 -1.465 . . . . 0.0 113.23 -168.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 70.47 31.41 68.32 Favored Glycine 0 N--CA 1.472 1.057 0 N-CA-C 116.996 1.558 . . . . 0.0 116.996 167.802 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -150.1 172.6 15.01 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 119.856 1.828 . . . . 0.0 113.108 -173.514 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -47.91 -58.69 4.07 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.953 1.701 . . . . 0.0 112.938 176.599 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -65.1 -17.01 64.1 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 124.165 0.986 . . . . 0.0 113.433 -173.246 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 83.5 p -53.52 -45.74 69.85 Favored 'General case' 0 N--CA 1.469 0.494 0 O-C-N 120.824 -1.173 . . . . 0.0 113.089 174.245 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 9.2 t -96.31 -6.86 36.79 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.875 0.87 . . . . 0.0 112.018 -178.861 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.93 -48.2 5.52 Favored 'General case' 0 N--CA 1.476 0.856 0 CA-C-N 119.708 1.14 . . . . 0.0 112.618 176.605 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 19.9 p -114.61 -25.14 8.44 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 115.283 1.586 . . . . 0.0 115.283 174.867 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.477 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 121.97 -30.73 5.18 Favored Glycine 0 C--O 1.228 -0.226 0 C-N-CA 126.09 1.805 . . . . 0.0 112.356 -168.061 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 114.08 2.02 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 C-N-CA 131.601 3.96 . . . . 0.0 112.645 -174.566 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.5 1.27 0.02 OUTLIER 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 120.251 3.426 . . . . 0.0 120.251 -168.692 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 66.59 -32.68 0.17 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 120.985 3.154 . . . . 0.0 120.985 165.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 7.0 m -167.4 141.36 3.64 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 120.272 2.036 . . . . 0.0 111.581 -172.227 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.53 134.68 54.83 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.741 1.155 . . . . 0.0 112.214 178.319 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.574 HD11 HD23 ' A' ' 38' ' ' LEU . 2.3 pt? -110.36 -22.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -179.08 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.71 161.19 13.25 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 119.95 1.25 . . . . 0.0 112.46 -177.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 9.9 p -155.47 166.76 32.55 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.332 1.453 . . . . 0.0 112.763 172.926 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.44 136.84 4.83 Favored Glycine 0 N--CA 1.48 1.579 0 C-N-CA 125.287 1.422 . . . . 0.0 113.583 177.168 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -83.6 133.48 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.469 1.108 . . . . 0.0 110.641 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.49 110.13 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.023 0.929 . . . . 0.0 111.301 -172.016 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -112.74 170.14 13.31 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 122.76 1.2 . . . . 0.0 113.916 173.268 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.0 pp -91.25 164.03 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.672 1.189 . . . . 0.0 112.137 -174.258 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.483 ' HA ' ' CD1' ' B' ' 50' ' ' PHE . . . -155.53 -20.61 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 167.072 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.476 0.832 0 C-N-CA 124.521 1.128 . . . . 0.0 110.166 170.366 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 5.7 t -80.26 118.78 22.23 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 167.507 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.87 121.37 45.09 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -178.885 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.03 166.2 11.38 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.861 1.264 . . . . 0.0 110.794 168.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.74 146.07 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 125.477 1.511 . . . . 0.0 111.903 -166.722 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.0 101.2 3.99 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 123.756 0.822 . . . . 0.0 111.269 169.621 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -84.02 95.5 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 168.031 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.4 mt -81.34 140.25 34.88 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 122.784 0.434 . . . . 0.0 110.78 -177.043 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 9.0 mtpp -149.24 179.26 8.05 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 121.166 -0.959 . . . . 0.0 112.81 170.913 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 152.43 -70.79 0.29 Allowed Glycine 0 C--N 1.335 0.505 0 C-N-CA 126.393 1.949 . . . . 0.0 111.238 178.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -87.09 78.83 8.83 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.78 0.8 . . . . 0.0 112.715 -165.373 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 49.09 -104.22 0.09 OUTLIER Glycine 0 CA--C 1.534 1.249 0 C-N-CA 126.565 2.031 . . . . 0.0 112.623 171.514 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -80.01 -1.2 11.24 Favored 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 125.181 3.921 . . . . 0.0 114.176 -179.24 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 55.9 t -78.49 134.62 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 119.715 1.143 . . . . 0.0 110.8 171.84 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -135.51 161.92 34.13 Favored 'General case' 0 CA--C 1.518 -0.283 0 C-N-CA 125.843 1.657 . . . . 0.0 109.939 168.231 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.5 144.8 16.44 Favored Glycine 0 N--CA 1.45 -0.424 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 167.205 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 tp -142.18 102.04 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 23.0 mm -122.4 137.6 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 C-N-CA 123.957 0.903 . . . . 0.0 109.394 -179.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.36 152.41 34.99 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.058 2.143 . . . . 0.0 109.147 172.131 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -138.89 89.29 2.35 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.215 1.806 . . . . 0.0 107.66 -174.81 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.8 120.31 33.9 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 118.084 0.402 . . . . 0.0 110.07 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -112.52 141.46 46.25 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 122.578 1.18 . . . . 0.0 112.18 174.41 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.36 -26.8 24.64 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 126.571 1.949 . . . . 0.0 114.18 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 5.8 mp0 -122.94 -174.11 2.86 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.235 2.214 . . . . 0.0 109.885 174.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 4.2 m -98.52 -14.5 19.97 Favored 'General case' 0 N--CA 1.481 1.099 0 O-C-N 120.54 -1.35 . . . . 0.0 111.639 167.08 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -139.47 105.55 5.22 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 128.198 2.599 . . . . 0.0 107.181 169.34 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.61 -168.42 41.49 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 126.066 1.794 . . . . 0.0 110.637 -170.784 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -85.57 150.61 10.19 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.529 2.153 . . . . 0.0 111.848 -179.268 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 10.2 t -119.36 129.32 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.135 1.374 . . . . 0.0 110.111 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.6 ttmm -93.53 120.89 34.35 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.091 0.948 . . . . 0.0 110.514 174.47 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 33.3 t -106.25 112.54 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 C-N-CA 126.321 1.848 . . . . 0.0 108.046 -171.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -137.74 161.18 37.22 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -177.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 136.62 -139.72 10.87 Favored Glycine 0 C--N 1.336 0.539 0 C-N-CA 125.533 1.539 . . . . 0.0 111.351 175.62 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 47.3 p -156.47 156.73 34.24 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 114.711 1.375 . . . . 0.0 114.711 -174.862 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 24.7 mm -123.43 126.64 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 168.692 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . 0.282 3.5 ptmt -140.33 157.21 45.91 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 115.313 1.597 . . . . 0.0 115.313 -177.534 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.23 6.4 33.9 Favored Glycine 0 CA--C 1.536 1.398 0 C-N-CA 127.103 2.287 . . . . 0.0 111.916 -167.872 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 144' ' ' LEU . 1.5 mt -94.79 172.27 8.27 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.992 1.317 . . . . 0.0 111.769 -172.751 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.27 150.65 36.95 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 165.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -53.3 -0.27 0.02 OUTLIER 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 129.796 3.238 . . . . 0.0 115.86 170.63 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -69.46 177.28 29.96 Favored Glycine 0 CA--C 1.537 1.43 0 O-C-N 120.149 -1.594 . . . . 0.0 113.605 169.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.456 ' H ' HD12 ' B' ' 42' ' ' LEU . 3.0 mp -78.37 160.0 28.04 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.381 1.472 . . . . 0.0 108.727 168.452 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -149.64 109.72 4.13 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.761 2.424 . . . . 0.0 109.857 -170.155 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.56 130.22 17.69 Favored Glycine 0 N--CA 1.477 1.37 0 CA-C-N 119.938 1.244 . . . . 0.0 111.864 176.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.493 ' CB ' HG22 ' B' ' 119' ' ' VAL . 35.3 p90 -125.62 137.73 53.89 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 120.151 1.976 . . . . 0.0 113.419 174.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.86 144.49 29.33 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.201 -0.937 . . . . 0.0 113.325 -176.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 2.7 m -81.27 136.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 166.075 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -74.74 168.4 19.92 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 124.826 1.25 . . . . 0.0 110.833 175.619 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.1 pm0 -59.61 -14.83 15.07 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 116.603 2.075 . . . . 0.0 116.603 -169.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . 0.483 ' CD1' ' HA ' ' A' ' 152' ' ' ALA . 31.3 m-85 -169.83 -179.26 3.21 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 129.147 2.979 . . . . 0.0 108.216 -168.849 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -125.92 11.32 7.39 Favored Glycine 0 N--CA 1.475 1.291 0 C-N-CA 125.505 1.526 . . . . 0.0 113.89 179.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -73.5 45.02 0.17 Allowed 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.755 1.222 . . . . 0.0 110.347 167.076 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -173.55 55.72 0.02 OUTLIER 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 123.693 1.711 . . . . 0.0 114.726 -162.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 1.1 t -76.62 13.59 0.96 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.592 1.957 . . . . 0.0 114.492 -179.647 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . 0.437 ' HB1' ' HB ' ' B' ' 58' ' ' THR . . . -113.8 3.16 15.39 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 115.223 1.564 . . . . 0.0 115.223 -170.905 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.33 -117.0 10.16 Favored Glycine 0 CA--C 1.527 0.838 0 O-C-N 121.343 -0.848 . . . . 0.0 111.495 174.733 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 26.7 p -51.46 -20.01 1.65 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.493 1.517 . . . . 0.0 115.043 174.334 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . 0.437 ' HB ' ' HB1' ' B' ' 55' ' ' ALA . 60.0 m -104.02 -4.6 23.11 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.171 1.388 . . . . 0.0 112.693 -177.051 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m 168.08 106.37 0.01 OUTLIER 'General case' 0 C--O 1.235 0.299 0 C-N-CA 128.638 2.775 . . . . 0.0 106.401 177.033 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.48 98.49 0.19 Allowed 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.815 2.046 . . . . 0.0 109.895 173.509 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -62.92 123.17 29.64 Favored Glycine 0 CA--C 1.543 1.843 0 CA-C-O 116.943 -2.032 . . . . 0.0 111.785 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.48 59.67 7.54 Favored 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 124.631 3.554 . . . . 0.0 116.632 -165.057 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.296 11.9 p80 52.7 59.01 4.78 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.19 2.596 . . . . 0.0 113.821 177.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . 0.413 ' CG ' ' N ' ' B' ' 65' ' ' ASN . 22.9 t80 -50.25 165.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 128.243 2.617 . . . . 0.0 114.938 177.553 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . 0.413 ' N ' ' CG ' ' B' ' 64' ' ' PHE . 1.0 OUTLIER -100.19 60.12 0.04 OUTLIER Pre-proline 0 CA--C 1.562 1.425 0 C-N-CA 131.296 3.838 . . . . 0.0 114.058 -170.078 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -64.02 -26.59 66.01 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.747 2.298 . . . . 0.0 113.764 -176.949 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 7.6 mp -88.34 -2.49 58.63 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 126.627 1.971 . . . . 0.0 113.165 172.696 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 24.5 t 59.43 49.75 8.36 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 126.564 1.946 . . . . 0.0 112.447 -173.201 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -117.17 170.41 8.69 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.264 1.209 . . . . 0.0 114.264 -179.607 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.404 ' HZ3' ' CG ' ' B' ' 76' ' ' ASP . 0.1 OUTLIER -73.18 164.82 26.13 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-O 122.75 1.262 . . . . 0.0 109.325 166.29 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.443 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 83.4 t60 -67.36 -176.17 0.56 Allowed 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 114.599 -1.182 . . . . 0.0 111.223 167.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.443 ' N ' ' CG ' ' B' ' 71' ' ' HIS . . . 115.17 -128.93 8.32 Favored Glycine 0 CA--C 1.502 -0.723 0 N-CA-C 115.252 0.861 . . . . 0.0 115.252 164.305 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 122.05 -76.32 0.34 Allowed Glycine 0 CA--C 1.531 1.061 0 CA-C-O 118.002 -1.443 . . . . 0.0 111.749 -169.586 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.64 10.07 0.23 Allowed 'Trans proline' 0 CA--C 1.547 1.134 0 C-N-CA 124.302 3.335 . . . . 0.0 116.614 -178.766 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 16.5 tptm -166.07 -30.61 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.264 1.426 . . . . 0.0 112.48 -168.427 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.404 ' CG ' ' HZ3' ' B' ' 70' ' ' LYS . 8.6 t70 -125.03 119.12 27.79 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.579 1.552 . . . . 0.0 108.148 167.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -46.31 -17.86 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 130.156 3.383 . . . . 0.0 116.418 -174.319 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -85.36 -79.61 0.23 Allowed 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -169.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.505 ' HB3' HH11 ' B' ' 79' ' ' ARG . 1.1 ttp-105 78.42 110.71 0.07 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.734 1.614 . . . . 0.0 109.731 177.199 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -50.08 152.17 1.76 Allowed 'General case' 0 CA--C 1.549 0.937 0 O-C-N 120.566 -1.334 . . . . 0.0 113.494 172.224 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 98.7 t -52.82 -37.74 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 123.966 0.906 . . . . 0.0 112.434 176.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.78 96.79 1.21 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 108.264 -1.934 . . . . 0.0 108.264 167.345 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -156.2 146.29 21.36 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.96 1.304 . . . . 0.0 113.446 171.249 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 48.2 mt -130.82 167.06 19.52 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 126.203 1.801 . . . . 0.0 106.981 166.802 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -104.99 -161.82 23.8 Favored Glycine 0 N--CA 1.475 1.247 0 C-N-CA 124.67 1.128 . . . . 0.0 112.593 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -79.37 164.63 23.89 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 -177.283 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.467 HG22 ' HB1' ' B' ' 95' ' ' ALA . 2.9 p -125.99 157.29 36.04 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 C-N-CA 129.0 2.92 . . . . 0.0 108.524 166.235 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -135.15 133.72 39.44 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.068 0.947 . . . . 0.0 109.799 -177.205 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -97.05 158.49 15.41 Favored 'General case' 0 C--O 1.222 -0.347 0 N-CA-C 114.065 1.135 . . . . 0.0 114.065 -172.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -97.63 155.47 16.97 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.645 1.578 . . . . 0.0 108.718 166.406 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 6.2 pttm -47.2 -25.32 0.89 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 128.936 2.894 . . . . 0.0 115.249 -177.5 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.67 3.23 10.07 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.319 1.448 . . . . 0.0 110.986 178.294 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.18 2.42 60.68 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 129.765 3.555 . . . . 0.0 113.726 172.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.2 p -114.64 131.92 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-N 119.937 1.869 . . . . 0.0 114.889 -168.36 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.467 ' HB1' HG22 ' B' ' 87' ' ' VAL . . . -98.37 128.8 44.94 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.003 -1.453 . . . . 0.0 108.728 166.236 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -82.27 146.33 29.51 Favored 'General case' 0 N--CA 1.46 0.073 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 168.005 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.263 0.3 OUTLIER -129.36 135.62 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 114.289 -1.323 . . . . 0.0 114.252 166.285 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 2.9 p -157.2 57.13 0.52 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 125.591 1.556 . . . . 0.0 110.759 -169.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 27.3 mt -109.04 166.55 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 127.654 2.381 . . . . 0.0 111.593 -169.746 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -148.39 149.82 32.43 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 127.753 2.421 . . . . 0.0 109.081 171.881 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -146.63 145.46 30.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 125.36 1.464 . . . . 0.0 110.108 172.051 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.8 p -118.61 58.6 0.83 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 126.94 2.096 . . . . 0.0 113.041 -168.477 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 5.9 p -159.34 -37.18 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 113.27 0.841 . . . . 0.0 113.27 172.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.69 166.79 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-O 121.327 0.584 . . . . 0.0 110.773 171.444 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 36.8 m -156.57 175.8 13.55 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 120.752 -1.218 . . . . 0.0 112.615 178.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . 0.409 ' HA ' HG12 ' B' ' 113' ' ' ILE . 9.6 mp -92.61 76.35 5.02 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.664 1.586 . . . . 0.0 107.448 175.458 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.27 122.7 32.3 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.359 1.463 . . . . 0.0 108.077 -176.409 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.99 59.68 4.97 Favored Glycine 0 N--CA 1.471 1.021 0 C-N-CA 125.152 1.358 . . . . 0.0 112.976 -169.721 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -156.26 -76.62 0.09 Allowed 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 124.467 1.107 . . . . 0.0 110.347 -168.704 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 m170 -129.66 4.88 5.06 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 126.979 2.111 . . . . 0.0 112.559 -167.625 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.6 -151.92 0.47 Allowed 'General case' 0 CA--C 1.555 1.173 0 C-N-CA 127.651 2.381 . . . . 0.0 112.835 -166.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.8 pt -95.88 -5.35 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 118.718 -2.488 . . . . 0.0 115.657 -177.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' B' ' 106' ' ' LEU . 4.2 mm -67.4 129.28 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 165.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 66.41 51.25 44.33 Favored Glycine 0 C--O 1.225 -0.439 0 CA-C-O 117.854 -1.526 . . . . 0.0 112.541 178.043 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 25.7 mtt180 -129.19 145.61 51.28 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 118.346 1.073 . . . . 0.0 110.095 167.332 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' B' ' 148' ' ' VAL . 24.6 m -86.86 108.91 18.97 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 124.378 1.071 . . . . 0.0 109.628 -171.886 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 14.6 tp -91.6 125.07 36.2 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 120.441 1.473 . . . . 0.0 110.854 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 8.0 p -110.82 142.27 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.584 1.553 . . . . 0.0 110.315 170.424 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.493 HG22 ' CB ' ' B' ' 45' ' ' PHE . 59.0 t -112.74 144.07 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 165.338 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -109.76 160.9 15.93 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 126.584 1.953 . . . . 0.0 112.182 -172.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.265 1.8 pp20? -82.43 -17.77 44.2 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -172.09 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -113.97 172.87 6.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 176.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -57.16 164.31 1.77 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 124.475 1.11 . . . . 0.0 109.899 166.789 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 13.2 p30 -113.66 147.12 38.7 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-O 123.237 1.494 . . . . 0.0 112.531 170.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -86.86 -22.69 25.62 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.134 1.374 . . . . 0.0 111.077 171.749 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 54.9 mt 71.41 -29.63 0.2 Allowed 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 128.765 2.826 . . . . 0.0 114.503 169.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -159.52 -47.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.701 0 CA-C-N 120.844 1.657 . . . . 0.0 114.594 174.052 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.08 100.21 2.9 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 117.254 2.316 . . . . 0.0 117.254 -168.465 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -92.17 -76.84 1.34 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 107.131 -2.388 . . . . 0.0 107.131 166.687 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -179.52 27.83 0.05 OUTLIER Glycine 0 CA--C 1.532 1.103 0 C-N-CA 126.382 1.944 . . . . 0.0 112.956 175.946 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -146.34 172.84 12.89 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.998 1.719 . . . . 0.0 111.08 -167.309 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -64.58 -63.06 1.22 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 110.814 -170.453 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . 0.423 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 0.8 OUTLIER -56.18 -23.64 36.39 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 128.935 2.894 . . . . 0.0 111.916 -173.558 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 52.2 m -53.58 -49.82 66.93 Favored 'General case' 0 N--CA 1.462 0.14 0 C-N-CA 123.721 0.808 . . . . 0.0 112.425 168.383 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 44.2 p -91.21 -34.5 14.97 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.158 1.383 . . . . 0.0 110.699 -174.375 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -81.9 -31.74 31.29 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.143 2.177 . . . . 0.0 113.085 -171.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.8 p -125.24 -93.3 0.5 Allowed 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 169.281 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -174.0 22.22 0.06 OUTLIER Glycine 0 CA--C 1.53 1.019 0 C-N-CA 128.647 3.022 . . . . 0.0 111.58 169.688 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 56.67 4.04 0.14 Allowed 'General case' 0 CA--C 1.555 1.142 0 C-N-CA 127.83 2.452 . . . . 0.0 116.545 -169.307 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.98 -5.88 0.03 OUTLIER 'General case' 0 CA--C 1.557 1.226 0 N-CA-C 119.865 3.284 . . . . 0.0 119.865 -168.337 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 88.12 -165.95 34.85 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.718 1.628 . . . . 0.0 113.661 -176.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 18.7 t -66.86 160.61 25.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 122.14 0.971 . . . . 0.0 111.284 173.598 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 12.7 ptt85 -67.38 164.16 19.19 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 122.356 1.074 . . . . 0.0 111.684 169.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.564 HD22 HD22 ' B' ' 38' ' ' LEU 0.316 2.9 pp -135.55 -134.7 0.15 Allowed 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 104.229 -2.508 . . . . 0.0 104.229 160.175 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.75 154.88 8.41 Favored 'General case' 0 CA--C 1.547 0.835 0 CA-C-N 120.536 1.516 . . . . 0.0 114.678 -178.697 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 42.1 t -151.0 143.94 24.58 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.658 1.983 . . . . 0.0 111.212 -172.677 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -162.29 144.25 9.51 Favored Glycine 0 N--CA 1.477 1.39 0 C-N-CA 125.507 1.527 . . . . 0.0 113.465 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' B' ' 116' ' ' THR . 20.5 t -83.47 141.57 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.164 0 CA-C-N 119.268 1.534 . . . . 0.0 110.592 177.451 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 73.8 mt -75.32 106.76 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 121.473 0.654 . . . . 0.0 109.65 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -111.7 -172.87 19.36 Favored Glycine 0 CA--C 1.525 0.679 0 C-N-CA 124.387 0.994 . . . . 0.0 111.793 168.174 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 1.6 pp -100.01 149.24 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.87 0.843 . . . . 0.0 112.726 -176.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -103.22 -135.21 0.33 Allowed 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 166.62 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 N--CA 1.473 0.701 0 C-N-CA 126.001 1.72 . . . . 0.0 110.983 168.881 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 115.917 -1.992 . . . . 0.0 106.669 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m -90.74 97.14 11.0 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 122.12 2.236 . . . . 0.0 108.061 -179.472 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 42.8 pttt -83.12 139.49 33.16 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 122.933 1.349 . . . . 0.0 114.212 -172.042 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.458 ' CB ' HD11 ' A' ' 113' ' ' ILE . . . -99.08 146.03 26.51 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 127.369 2.268 . . . . 0.0 107.753 167.409 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 33.0 t -154.95 143.54 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 119.567 1.076 . . . . 0.0 110.993 -175.2 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -140.87 95.63 2.88 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 123.767 0.827 . . . . 0.0 110.504 169.116 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 4.8 m -76.15 92.7 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 CA-C-O 122.127 0.965 . . . . 0.0 109.618 170.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.2 mt -76.52 139.01 40.59 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.006 0.922 . . . . 0.0 109.553 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.6 ttmm -155.45 177.62 11.16 Favored 'General case' 0 CA--C 1.542 0.672 0 O-C-N 120.753 -1.217 . . . . 0.0 109.765 179.648 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.03 -33.83 3.91 Favored Glycine 0 N--CA 1.472 1.076 0 C-N-CA 124.279 0.942 . . . . 0.0 114.341 169.16 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.85 65.7 5.09 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 122.299 1.047 . . . . 0.0 110.146 175.905 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 44.06 -101.94 0.03 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.081 2.753 . . . . 0.0 113.146 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -83.24 -2.84 10.79 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 124.66 3.573 . . . . 0.0 114.441 -178.346 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -95.28 137.42 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 CA-C-N 120.697 1.59 . . . . 0.0 111.156 176.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -144.56 161.86 38.05 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 125.918 1.687 . . . . 0.0 109.697 172.321 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -134.63 106.18 0.59 Allowed Glycine 0 CA--C 1.502 -0.723 0 C-N-CA 124.34 0.971 . . . . 0.0 111.314 177.779 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.2 117.47 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 167.862 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -135.9 106.94 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 CA-C-O 121.616 0.722 . . . . 0.0 109.369 169.293 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 68.6 m-20 -100.22 139.7 35.52 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.687 1.595 . . . . 0.0 110.885 -179.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -120.46 135.56 55.02 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 119.091 0.86 . . . . 0.0 110.85 179.206 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -115.1 114.86 25.88 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 127.078 2.151 . . . . 0.0 109.852 -172.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.8 tp60 -125.92 130.9 52.21 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 113.51 -1.677 . . . . 0.0 109.828 -170.398 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.594 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -99.33 -11.74 20.94 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 128.147 2.579 . . . . 0.0 114.129 -168.771 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.413 ' CD ' ' H ' ' A' ' 25' ' ' SER . 5.3 tm-20 -149.25 -172.02 4.03 Favored 'General case' 0 CA--C 1.553 1.079 0 C-N-CA 127.918 2.487 . . . . 0.0 108.681 -172.376 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.413 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 0.8 OUTLIER -72.34 -57.18 4.41 Favored 'General case' 0 N--CA 1.474 0.726 0 O-C-N 118.778 -2.451 . . . . 0.0 111.601 169.677 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -123.37 -3.16 8.43 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.73 1.612 . . . . 0.0 114.918 -169.271 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.36 161.48 6.98 Favored Glycine 0 CA--C 1.537 1.446 0 CA-C-N 119.224 0.92 . . . . 0.0 110.955 168.372 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -66.85 143.94 68.94 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.327 2.018 . . . . 0.0 110.61 -170.035 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 37.3 t -107.62 129.87 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 123.262 0.625 . . . . 0.0 110.158 -173.159 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -79.64 125.77 30.05 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 169.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 49.9 t -112.42 130.73 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 128.456 2.703 . . . . 0.0 108.154 178.669 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -155.41 165.79 35.54 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 119.577 1.081 . . . . 0.0 113.249 175.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 147.27 -155.95 26.76 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 123.902 0.763 . . . . 0.0 113.655 172.726 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.9 p -149.53 128.36 12.53 Favored 'General case' 0 C--O 1.239 0.528 0 C-N-CA 123.319 0.648 . . . . 0.0 112.367 -169.483 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.0 mp -104.52 106.6 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 123.697 0.799 . . . . 0.0 109.599 175.371 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 tttp -117.14 133.64 55.75 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.38 1.072 . . . . 0.0 112.894 -168.903 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.46 0.56 9.37 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 128.318 2.866 . . . . 0.0 113.623 -177.621 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 59.8 mt -77.86 174.71 10.74 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.097 2.159 . . . . 0.0 113.37 -175.862 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.36 148.71 22.13 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 162.284 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.589 ' CD ' ' H ' ' A' ' 40' ' ' GLU . 1.0 OUTLIER -53.79 -2.01 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 129.222 3.009 . . . . 0.0 115.825 176.065 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.31 174.34 17.46 Favored Glycine 0 CA--C 1.536 1.404 0 O-C-N 120.251 -1.531 . . . . 0.0 113.29 169.212 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.718 HD23 ' H ' ' A' ' 42' ' ' LEU . 2.0 pt? -88.31 138.17 31.67 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 126.778 2.031 . . . . 0.0 109.997 171.053 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -130.87 149.23 52.6 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 129.018 2.927 . . . . 0.0 108.615 -171.723 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -112.09 135.09 12.48 Favored Glycine 0 N--CA 1.486 1.991 0 CA-C-O 116.861 -2.077 . . . . 0.0 111.405 -172.554 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -135.74 133.28 37.85 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 121.165 2.482 . . . . 0.0 114.956 179.073 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 146.42 26.77 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.027 1.331 . . . . 0.0 109.801 -170.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 116' ' ' THR . 0.3 OUTLIER -86.33 118.35 32.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.263 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.742 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 15.0 m170 -77.71 163.03 26.53 Favored 'General case' 0 CA--C 1.549 0.931 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 176.157 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.18 133.97 55.93 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.816 -0.553 . . . . 0.0 110.745 -176.83 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.465 ' CD1' ' HA ' ' B' ' 152' ' ' ALA . 43.0 m-85 71.02 165.32 0.29 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 127.612 2.365 . . . . 0.0 115.348 170.123 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.21 -3.55 19.16 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 126.434 1.969 . . . . 0.0 113.654 177.684 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.0 m-20 -72.91 46.79 0.17 Allowed 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.076 1.35 . . . . 0.0 110.59 170.015 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 174.45 40.1 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.635 2.374 . . . . 0.0 112.747 -167.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.0 t -53.71 19.97 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 129.78 3.232 . . . . 0.0 116.375 172.285 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.63 16.41 8.8 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 126.699 2.0 . . . . 0.0 112.715 -178.293 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.6 -144.02 41.42 Favored Glycine 0 N--CA 1.467 0.752 0 O-C-N 121.087 -1.008 . . . . 0.0 112.097 171.12 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 26.3 p -58.69 -23.24 59.12 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.748 1.018 . . . . 0.0 113.748 -178.011 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 13.0 t -90.52 42.64 1.11 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.364 1.066 . . . . 0.0 112.019 175.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 m 178.57 -35.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 129.577 3.151 . . . . 0.0 115.091 169.606 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.53 158.98 15.36 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -168.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.97 -153.93 17.76 Favored Glycine 0 CA--C 1.545 1.908 0 C-N-CA 126.004 1.764 . . . . 0.0 114.223 173.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -88.58 178.39 2.88 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 125.281 3.987 . . . . 0.0 112.107 -179.496 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.487 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 3.4 p80 -79.91 83.55 5.81 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 167.062 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -50.94 166.03 0.1 Allowed 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.34 2.256 . . . . 0.0 113.993 -174.153 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -108.11 57.84 0.23 Allowed Pre-proline 0 CA--C 1.552 1.031 0 C-N-CA 127.202 2.201 . . . . 0.0 112.25 -169.712 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -64.32 -28.82 63.52 Favored 'Trans proline' 0 C--N 1.354 0.838 0 CA-C-N 122.602 1.965 . . . . 0.0 113.272 -175.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.8 mp -82.13 -4.9 57.9 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.077 1.351 . . . . 0.0 113.171 170.533 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.8 t 65.37 54.15 1.2 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 127.242 2.217 . . . . 0.0 112.894 -175.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -121.51 174.37 6.82 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -170.912 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.7 mtmt -81.04 165.92 21.23 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.494 0.718 . . . . 0.0 110.719 167.18 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.445 ' CD2' ' HA3' ' A' ' 138' ' ' GLY . 73.8 t60 -71.02 175.21 5.35 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.643 0.735 . . . . 0.0 111.645 167.758 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.15 -138.16 9.92 Favored Glycine 0 CA--C 1.504 -0.599 0 C-N-CA 124.295 0.95 . . . . 0.0 112.173 167.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.78 -99.95 0.26 Allowed Glycine 0 CA--C 1.533 1.202 0 CA-C-O 115.811 -2.661 . . . . 0.0 109.845 -178.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -56.69 0.45 0.19 Allowed 'Trans proline' 0 CA--C 1.549 1.255 0 C-N-CA 124.126 3.218 . . . . 0.0 117.983 -178.742 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.0 pttt -134.86 -4.32 2.49 Favored 'General case' 0 N--CA 1.479 0.996 0 CA-C-N 120.332 1.424 . . . . 0.0 114.276 167.339 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -155.82 112.11 3.11 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 126.051 1.74 . . . . 0.0 109.985 -175.555 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -62.21 -7.58 4.39 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -173.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -80.36 -9.02 59.74 Favored 'General case' 0 CA--C 1.542 0.637 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -173.048 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -17.36 118.53 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 129.446 3.098 . . . . 0.0 112.963 168.407 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 16.8 m80 -62.05 166.04 5.07 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.697 1.199 . . . . 0.0 111.61 177.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 32.5 m -76.33 29.58 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -178.469 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.402 ' CA ' HG12 ' A' ' 47' ' ' VAL . . . -148.28 9.99 1.13 Allowed Glycine 0 CA--C 1.532 1.096 0 C-N-CA 125.583 1.563 . . . . 0.0 115.166 -178.686 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -105.64 115.99 31.19 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.881 1.273 . . . . 0.0 113.209 -168.611 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.8 mp -91.2 170.7 9.79 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 163.459 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -79.79 -172.37 43.65 Favored Glycine 0 CA--C 1.529 0.941 0 O-C-N 121.372 -0.83 . . . . 0.0 112.238 171.751 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -78.42 144.11 36.15 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.422 -1.046 . . . . 0.0 112.512 172.6 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.443 HG22 ' HB1' ' A' ' 95' ' ' ALA . 2.3 p -114.51 139.43 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 128.003 2.521 . . . . 0.0 110.308 177.528 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.5 m -128.65 133.47 48.25 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.785 1.234 . . . . 0.0 110.586 -169.306 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -94.64 163.11 13.51 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 -176.2 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -83.32 169.8 15.26 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.106 1.362 . . . . 0.0 108.422 165.125 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.435 ' HD3' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -62.02 -18.7 61.42 Favored 'General case' 0 N--CA 1.482 1.167 0 O-C-N 120.66 -1.275 . . . . 0.0 113.893 172.277 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -73.62 -3.03 25.52 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.59 1.556 . . . . 0.0 111.426 168.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.88 6.69 89.27 Favored Glycine 0 C--N 1.332 0.33 0 C-N-CA 126.155 1.836 . . . . 0.0 113.462 170.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -94.33 121.51 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 126.079 1.751 . . . . 0.0 111.541 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -97.89 99.12 10.42 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 167.148 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -79.9 143.86 33.9 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.543 1.537 . . . . 0.0 109.936 176.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -144.26 142.75 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 -176.503 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 54.5 p -149.89 109.98 4.14 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 125.417 1.487 . . . . 0.0 111.294 174.106 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.2 mt -138.08 158.73 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 127.295 2.238 . . . . 0.0 110.988 -171.157 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -145.39 144.33 30.6 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 126.353 1.861 . . . . 0.0 106.851 164.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -145.12 148.17 33.33 Favored 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 125.021 1.328 . . . . 0.0 110.597 179.373 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.3 p -113.32 49.69 0.95 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.674 0.789 . . . . 0.0 112.2 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 43.2 t -139.89 -47.7 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.211 1.404 . . . . 0.0 109.893 175.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -84.6 158.14 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-O 122.307 1.051 . . . . 0.0 113.201 175.592 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 64.9 p -157.03 171.51 20.33 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 115.316 1.599 . . . . 0.0 115.316 -171.614 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.01 80.25 9.1 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.41 1.484 . . . . 0.0 108.587 176.662 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 60.5 p -90.2 -170.95 2.94 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.564 0.697 . . . . 0.0 112.57 173.836 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.51 -43.77 5.12 Favored Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.363 0.982 . . . . 0.0 111.425 167.563 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 34.9 t0 -172.3 45.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.694 1.597 . . . . 0.0 111.787 -173.119 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -140.85 -40.53 0.4 Allowed 'General case' 0 N--CA 1.47 0.525 0 O-C-N 120.139 -1.601 . . . . 0.0 111.097 -172.16 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 71.9 m -90.67 -125.34 0.07 Allowed 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 127.988 2.515 . . . . 0.0 110.499 172.047 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 33.7 pt -102.7 -27.24 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 114.947 1.462 . . . . 0.0 114.947 -175.399 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.458 HD11 ' CB ' ' A' ' 4' ' ' ALA . 33.8 mm -60.46 138.23 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 168.374 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.67 8.25 73.84 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 117.366 -1.797 . . . . 0.0 113.631 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -122.17 174.12 7.16 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 119.913 1.856 . . . . 0.0 111.126 -174.17 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.45 ' N ' HG22 ' A' ' 47' ' ' VAL . 39.0 m -116.22 109.37 17.33 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.269 -1.519 . . . . 0.0 111.239 -163.328 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 33.9 tp -96.38 122.24 39.05 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.464 1.105 . . . . 0.0 110.64 -172.766 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 p -121.07 133.99 65.91 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.025 1.33 . . . . 0.0 108.839 175.203 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 15.3 t -90.67 152.64 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.225 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 165.053 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.03 138.55 54.43 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.745 2.018 . . . . 0.0 107.365 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.09 -46.3 79.08 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -167.256 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt -101.87 143.16 32.11 Favored 'General case' 0 C--N 1.329 -0.312 0 O-C-N 121.375 -0.828 . . . . 0.0 110.486 169.903 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.44 158.9 1.58 Allowed 'General case' 0 C--O 1.231 0.126 0 C-N-CA 125.027 1.331 . . . . 0.0 114.098 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -75.43 146.5 40.68 Favored 'General case' 0 N--CA 1.443 -0.823 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 165.599 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -68.54 -21.13 64.57 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.961 171.013 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.7 mt 85.33 -64.5 0.05 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 131.075 3.75 . . . . 0.0 108.582 -174.67 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.94 -75.75 0.98 Allowed Glycine 0 N--CA 1.464 0.559 0 C-N-CA 124.695 1.141 . . . . 0.0 110.887 -171.125 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 14.6 pttp -163.43 109.28 1.11 Allowed 'General case' 0 CA--C 1.546 0.797 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 168.583 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -71.44 21.74 0.69 Allowed Glycine 0 CA--C 1.545 1.965 0 C-N-CA 125.208 1.385 . . . . 0.0 116.509 172.669 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.25 10.94 73.43 Favored Glycine 0 N--CA 1.479 1.508 0 N-CA-C 118.551 2.18 . . . . 0.0 118.551 168.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.634 ' H ' ' HB3' ' A' ' 134' ' ' SER . 32.4 m-80 -127.24 179.47 5.43 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 119.872 1.836 . . . . 0.0 111.659 -173.559 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.31 -56.71 18.62 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 166.799 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -35.28 -31.43 0.02 OUTLIER 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 128.839 2.855 . . . . 0.0 115.71 167.249 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.634 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 66.8 p -57.83 -24.44 57.44 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 117.435 2.383 . . . . 0.0 117.435 -166.842 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . 0.282 3.4 t -133.02 -14.07 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 -179.203 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.2 ptmt -70.86 -47.37 59.69 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 120.297 1.408 . . . . 0.0 110.17 167.543 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -105.24 -18.85 13.99 Favored 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.943 -177.326 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.445 ' HA3' ' CD2' ' A' ' 71' ' ' HIS . . . 91.23 5.86 67.14 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 124.144 0.878 . . . . 0.0 112.311 -168.426 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 74.72 2.42 4.04 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 127.451 2.301 . . . . 0.0 114.442 -170.296 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.66 106.26 0.76 Allowed 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 119.43 1.014 . . . . 0.0 111.398 -169.284 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -36.58 -7.44 0.0 OUTLIER Glycine 0 N--CA 1.493 2.439 1 C-N-CA 131.255 4.264 . . . . 0.0 122.836 -165.862 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 18.4 p 104.86 156.73 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 131.06 3.744 . . . . 0.0 113.315 166.556 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 61.85 131.32 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 117.826 2.528 . . . . 0.0 117.826 166.03 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 179.94 -165.83 0.07 Allowed 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 128.571 2.748 . . . . 0.0 108.451 168.171 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -55.98 151.47 11.77 Favored 'General case' 0 CA--C 1.547 0.859 0 C-N-CA 124.975 1.31 . . . . 0.0 112.429 170.17 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.5 t -153.0 152.06 30.97 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.749 2.02 . . . . 0.0 112.573 -172.848 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.46 167.52 36.34 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 127.731 2.586 . . . . 0.0 110.716 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 8.9 p -98.5 141.78 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 CA-C-N 119.771 1.785 . . . . 0.0 109.382 169.632 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.3 mt -78.92 102.27 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 O-C-N 121.635 -0.666 . . . . 0.0 111.473 -175.266 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -99.32 177.2 29.65 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-O 122.601 1.112 . . . . 0.0 112.506 171.744 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.2 pp -111.41 158.53 11.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 126.364 1.866 . . . . 0.0 110.993 175.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.484 ' HB2' ' CG ' ' B' ' 52' ' ' ASP . . . -107.29 -14.79 14.8 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.212 1.005 . . . . 0.0 112.228 167.153 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 . . . . . 0 C--O 1.237 0.419 0 C-N-CA 126.863 2.065 . . . . 0.0 108.377 -164.819 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 0.389 0 CA-C-O 121.842 0.83 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 12.4 t -118.53 130.28 55.83 Favored 'General case' 0 CA--C 1.516 -0.352 0 C-N-CA 124.357 1.063 . . . . 0.0 110.113 172.397 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -91.29 148.82 22.07 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 168.182 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.04 141.77 31.39 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-N 114.339 -1.3 . . . . 0.0 107.891 166.612 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 49.0 t -137.95 142.88 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 CA-C-O 121.675 0.75 . . . . 0.0 111.815 -169.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.1 132.29 55.99 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 122.437 1.113 . . . . 0.0 112.169 169.822 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 3.5 m -115.83 86.07 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 127.065 2.146 . . . . 0.0 107.027 169.642 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -75.61 117.32 17.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -174.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -158.03 134.24 9.42 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 119.279 0.945 . . . . 0.0 113.249 -170.297 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -176.07 -38.7 0.05 OUTLIER Glycine 0 N--CA 1.471 0.992 0 C-N-CA 125.659 1.6 . . . . 0.0 111.443 172.453 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.13 66.6 2.96 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 128.393 2.677 . . . . 0.0 112.188 -176.282 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.33 -102.48 0.05 OUTLIER Glycine 0 CA--C 1.535 1.328 0 C-N-CA 127.111 2.291 . . . . 0.0 113.613 174.321 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -82.55 -11.85 10.34 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 123.907 3.072 . . . . 0.0 114.257 -176.845 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -91.13 136.08 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 CA-C-N 120.013 1.278 . . . . 0.0 110.124 -177.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.76 156.73 35.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.747 168.397 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.45 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -125.83 123.58 4.92 Favored Glycine 0 CA--C 1.503 -0.675 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.045 173.714 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.37 128.44 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 164.567 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.7 pp -136.34 134.77 49.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 164.279 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -106.25 151.48 24.74 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.107 1.363 . . . . 0.0 112.111 172.392 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -120.91 128.24 52.6 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.409 1.884 . . . . 0.0 112.165 169.772 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -104.08 112.42 25.41 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 128.885 2.874 . . . . 0.0 110.742 173.635 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -108.26 124.73 50.76 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.464 -0.773 . . . . 0.0 109.679 174.809 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.92 -42.06 21.96 Favored 'General case' 0 CA--C 1.551 0.996 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 176.045 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -134.56 133.72 40.57 Favored 'General case' 0 C--O 1.22 -0.485 0 C-N-CA 126.098 1.759 . . . . 0.0 109.989 170.269 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 97.9 p -70.48 79.17 0.56 Allowed 'General case' 0 N--CA 1.477 0.894 0 CA-C-N 120.523 1.51 . . . . 0.0 113.278 -178.174 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 8.9 p30 158.47 -30.1 0.0 OUTLIER 'General case' 0 CA--C 1.548 0.871 1 C-N-CA 132.877 4.471 . . . . 0.0 111.176 -176.506 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.03 -172.92 43.06 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 126.099 1.809 . . . . 0.0 113.993 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -78.75 170.92 17.41 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 124.14 3.227 . . . . 0.0 112.444 -170.093 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 32.1 t -139.59 131.77 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 CA-C-O 121.482 0.658 . . . . 0.0 112.333 -167.753 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 ttmp? -87.48 129.06 35.21 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 167.594 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 t -110.5 138.84 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 126.322 1.849 . . . . 0.0 109.665 173.736 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 19.5 p90 -152.91 168.74 24.78 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.706 -0.621 . . . . 0.0 112.032 170.487 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 151.4 -161.94 29.36 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 114.757 0.663 . . . . 0.0 114.757 174.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 46.2 p -153.96 123.99 6.85 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.003 0.921 . . . . 0.0 111.631 -170.027 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.45 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 2.7 mp -106.4 113.17 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 CA-C-O 117.709 -1.138 . . . . 0.0 111.388 177.169 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 21.0 mmmt -102.38 144.93 30.23 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 120.407 1.458 . . . . 0.0 109.374 -178.234 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 118.69 -4.23 14.81 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.232 1.396 . . . . 0.0 114.235 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -67.87 179.83 1.35 Allowed 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 124.367 1.067 . . . . 0.0 110.124 168.566 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 14.9 t -106.98 -32.27 7.95 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 117.763 -1.113 . . . . 0.0 113.892 172.108 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 173.39 -168.49 0.03 OUTLIER 'General case' 0 CA--C 1.556 1.207 1 C-N-CA 132.975 4.51 . . . . 0.0 105.174 178.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.5 161.96 28.43 Favored Glycine 0 CA--C 1.525 0.666 0 C-N-CA 126.1 1.809 . . . . 0.0 115.671 167.809 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.889 ' H ' HD22 ' B' ' 42' ' ' LEU . 0.0 OUTLIER -66.33 150.29 49.08 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 128.261 2.625 . . . . 0.0 108.968 168.658 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -143.88 121.87 12.08 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.589 1.156 . . . . 0.0 111.945 179.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.02 147.13 41.88 Favored Glycine 0 N--CA 1.482 1.759 0 CA-C-N 119.934 1.243 . . . . 0.0 112.559 -179.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -150.25 111.06 4.3 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.071 1.349 . . . . 0.0 110.115 -173.812 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.89 152.78 35.61 Favored 'General case' 0 N--CA 1.471 0.6 0 O-C-N 119.8 -1.812 . . . . 0.0 114.587 -165.071 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -100.02 126.81 53.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-O 121.447 0.642 . . . . 0.0 111.336 -177.322 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -78.21 -179.31 6.13 Favored 'General case' 0 CA--C 1.544 0.717 1 C-N-CA 131.837 4.055 . . . . 0.0 114.444 -175.128 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . 0.439 ' CD ' ' H ' ' B' ' 61' ' ' GLY . 1.2 pm0 -59.99 135.26 57.65 Favored 'General case' 0 CA--C 1.542 0.638 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 163.208 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . 0.274 42.7 m-85 -0.29 -130.45 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.621 1 C-N-CA 132.105 4.162 . . . . 0.0 116.865 -169.254 . . . . . . . . 3 2 . 1 . 023 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -130.44 -2.9 4.84 Favored Glycine 0 N--CA 1.472 1.034 0 C-N-CA 124.524 1.059 . . . . 0.0 114.079 -169.676 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.484 ' CG ' ' HB2' ' A' ' 152' ' ' ALA . 12.6 p-10 -81.83 48.32 1.2 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 126.333 1.853 . . . . 0.0 111.697 177.289 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.263 0.4 OUTLIER -176.89 43.9 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.489 1.516 . . . . 0.0 112.187 -168.937 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 9.1 t -59.69 19.74 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 128.735 2.814 . . . . 0.0 115.969 171.768 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -117.38 4.23 12.53 Favored 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.972 1.709 . . . . 0.0 113.248 169.244 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 70.81 -144.82 38.98 Favored Glycine 0 N--CA 1.471 1.029 0 O-C-N 120.998 -1.064 . . . . 0.0 111.477 -177.878 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . 0.44 ' C ' ' H ' ' B' ' 59' ' ' SER . 26.7 p -55.74 -26.24 44.54 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 114.777 1.399 . . . . 0.0 114.777 -177.638 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 2.7 m -71.79 30.68 0.05 Allowed 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 126.407 1.883 . . . . 0.0 112.085 171.578 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . 0.44 ' H ' ' C ' ' B' ' 57' ' ' CYS . 13.4 t -179.81 5.53 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.191 0 C-N-CA 130.392 3.477 . . . . 0.0 114.36 175.862 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.45 165.61 23.64 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-N 121.831 2.105 . . . . 0.0 115.473 -168.414 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . 0.439 ' H ' ' CD ' ' B' ' 49' ' ' GLU . . . -99.3 -121.31 4.54 Favored Glycine 0 CA--C 1.544 1.902 0 C-N-CA 126.485 1.993 . . . . 0.0 115.082 -169.263 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -99.19 179.16 0.3 Allowed 'Trans proline' 0 C--N 1.35 0.618 1 C-N-CA 125.415 4.076 . . . . 0.0 111.566 -175.79 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.496 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 0.0 OUTLIER -76.5 110.87 11.41 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.009 177.479 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -48.05 128.82 14.31 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.633 1.973 . . . . 0.0 113.78 -169.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 p-10 -121.57 64.96 16.69 Favored Pre-proline 0 CA--C 1.548 0.886 0 C-N-CA 124.721 1.208 . . . . 0.0 112.596 -172.312 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -63.58 -22.51 70.5 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 123.679 2.919 . . . . 0.0 113.465 -175.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 80.9 mt -79.51 -4.95 53.66 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.502 1.521 . . . . 0.0 112.916 172.606 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 4.7 p 62.15 52.07 3.34 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 127.891 2.476 . . . . 0.0 111.448 177.569 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -126.41 174.15 8.82 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 114.419 1.266 . . . . 0.0 114.419 -169.252 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 45.7 pttt -78.88 169.01 18.88 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 128.051 2.541 . . . . 0.0 111.192 171.235 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.419 ' CG ' ' N ' ' B' ' 72' ' ' GLY . 78.6 t60 -90.28 174.85 7.36 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 176.221 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' B' ' 126' ' ' LEU . . . 129.24 -115.1 1.87 Allowed Glycine 0 C--N 1.338 0.645 0 C-N-CA 125.166 1.365 . . . . 0.0 113.48 166.57 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.03 -50.03 0.81 Allowed Glycine 0 CA--C 1.547 2.089 0 CA-C-O 117.859 -1.523 . . . . 0.0 116.196 173.044 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . 0.493 ' HD2' HD12 ' B' ' 126' ' ' LEU . 69.6 Cg_endo -88.64 -4.64 6.37 Favored 'Trans proline' 0 CA--C 1.543 0.973 0 CA-C-N 121.425 2.613 . . . . 0.0 113.599 172.077 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 26.5 pttt -141.83 -1.35 1.27 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 124.256 1.022 . . . . 0.0 113.468 168.29 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -119.43 159.74 23.66 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 125.642 1.577 . . . . 0.0 110.099 169.496 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -81.96 -29.84 31.99 Favored 'General case' 0 CA--C 1.541 0.619 1 C-N-CA 132.486 4.314 . . . . 0.0 114.83 -171.321 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -98.51 -85.63 0.37 Allowed 'General case' 0 CA--C 1.539 0.543 0 O-C-N 121.714 -0.616 . . . . 0.0 111.165 -168.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 8.6 ttp-105 80.93 121.22 0.05 OUTLIER 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.924 2.09 . . . . 0.0 111.16 176.979 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 21.6 m80 -54.19 151.51 7.12 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 120.481 -1.387 . . . . 0.0 113.006 173.794 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -45.94 -48.38 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 CA-C-O 119.048 -0.501 . . . . 0.0 112.104 -176.648 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.29 112.12 2.62 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-O 123.182 1.435 . . . . 0.0 113.117 169.411 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -155.56 107.14 2.58 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 130.659 3.584 . . . . 0.0 106.872 174.473 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 97.0 mt -89.09 54.06 2.87 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.558 0.743 . . . . 0.0 109.74 174.58 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.9 -107.56 0.14 Allowed Glycine 0 CA--C 1.532 1.107 0 C-N-CA 125.959 1.743 . . . . 0.0 113.652 177.449 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -153.74 146.16 24.0 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.367 1.467 . . . . 0.0 110.947 169.922 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.97 113.52 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 126.791 2.036 . . . . 0.0 110.359 -176.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -95.59 125.06 39.92 Favored 'General case' 0 N--CA 1.471 0.598 0 O-C-N 121.628 -0.67 . . . . 0.0 110.365 -175.189 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.38 148.62 24.01 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.738 1.215 . . . . 0.0 113.181 -175.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -76.71 174.91 9.88 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.49 1.516 . . . . 0.0 111.496 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.472 ' HB3' ' HZ3' ' B' ' 91' ' ' LYS . 0.0 OUTLIER -68.59 -13.38 62.3 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 121.101 -1.0 . . . . 0.0 113.109 173.018 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -74.62 -23.7 58.74 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.101 1.36 . . . . 0.0 110.588 171.217 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.12 -2.71 59.8 Favored Glycine 0 CA--C 1.526 0.766 0 CA-C-O 116.655 -2.192 . . . . 0.0 114.47 -177.75 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -83.33 133.18 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 119.959 1.88 . . . . 0.0 113.818 169.856 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -105.44 113.93 27.8 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 164.783 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -99.67 133.34 44.16 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.066 1.347 . . . . 0.0 108.978 -176.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 24.5 t -135.26 135.7 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.495 1.118 . . . . 0.0 112.825 -167.393 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 27.6 p -156.11 113.69 3.27 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 125.312 1.445 . . . . 0.0 111.304 171.331 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 6.6 mt -145.14 152.57 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 127.85 2.46 . . . . 0.0 110.606 -169.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -134.98 137.78 43.37 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.846 0.858 . . . . 0.0 108.737 167.376 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -145.12 153.21 41.16 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 125.385 1.474 . . . . 0.0 112.327 -172.163 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 37.4 p -125.67 45.26 2.64 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 178.603 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 6.9 m -141.4 22.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.891 1.276 . . . . 0.0 112.669 169.427 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.15 158.86 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 127.119 2.168 . . . . 0.0 108.025 164.685 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 60.4 p -156.03 156.84 35.12 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.657 0.783 . . . . 0.0 109.758 -177.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 11.1 mp -83.25 63.41 7.2 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.681 -1.262 . . . . 0.0 110.243 -177.322 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 11.1 t -93.5 154.59 17.81 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 165.703 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.0 -28.41 72.02 Favored Glycine 0 N--CA 1.47 0.909 0 C-N-CA 127.047 2.261 . . . . 0.0 118.322 -164.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 p30 -148.13 -46.67 0.16 Allowed 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -168.79 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -82.73 -18.89 39.18 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.782 -1.199 . . . . 0.0 111.994 -171.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 74.7 m -99.14 -92.85 0.26 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.093 0.957 . . . . 0.0 111.097 -176.174 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.74 -18.49 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 176.584 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 40.2 mm -68.64 153.0 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-N 122.089 2.222 . . . . 0.0 107.263 167.238 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.48 66.0 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 119.297 -0.724 . . . . 0.0 112.97 175.687 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 15.8 mtp85 -114.54 133.19 55.98 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 176.719 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 5.5 m -80.29 140.69 36.06 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 126.352 1.861 . . . . 0.0 107.003 179.258 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 34.3 tp -129.83 128.53 42.49 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.028 0.931 . . . . 0.0 109.786 -174.566 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.62 133.19 62.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.103 0.961 . . . . 0.0 110.628 177.736 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -98.24 149.25 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 165.969 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 22.2 m-70 -120.76 138.16 54.15 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 125.274 1.43 . . . . 0.0 113.199 -169.655 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -73.61 -24.79 60.09 Favored 'General case' 0 N--CA 1.476 0.853 0 O-C-N 120.163 -1.585 . . . . 0.0 114.013 -173.338 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -93.22 164.8 13.1 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 122.192 0.996 . . . . 0.0 112.355 169.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.87 158.97 20.7 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 125.008 1.323 . . . . 0.0 111.625 169.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -103.45 151.95 22.21 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.84 0.856 . . . . 0.0 112.185 179.124 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -102.36 -3.24 27.42 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 127.378 2.271 . . . . 0.0 112.878 -177.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.493 HD12 ' HD2' ' B' ' 74' ' ' PRO . 0.8 OUTLIER 45.85 56.45 5.97 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 126.132 1.773 . . . . 0.0 113.257 172.036 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 95.77 -54.1 1.68 Allowed Glycine 0 N--CA 1.471 1.033 0 CA-C-O 118.74 -1.033 . . . . 0.0 114.014 173.023 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 134.55 18.86 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 172.314 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -160.21 -67.58 0.02 OUTLIER Glycine 0 CA--C 1.52 0.382 1 C-N-CA 130.723 4.011 . . . . 0.0 107.254 168.22 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -83.67 -111.14 0.56 Allowed Glycine 0 CA--C 1.533 1.188 0 C-N-CA 126.309 1.909 . . . . 0.0 117.039 -171.046 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -118.0 -159.13 0.74 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 127.431 2.292 . . . . 0.0 112.646 -163.307 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -49.34 -64.67 0.74 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.479 1.112 . . . . 0.0 112.033 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . 0.298 2.9 mt-10 -53.65 -10.37 0.27 Allowed 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 177.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 67.2 m -60.9 -47.76 84.92 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 122.133 2.242 . . . . 0.0 111.18 166.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 39.0 p -81.31 -38.14 27.25 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-O 119.102 -0.475 . . . . 0.0 111.347 176.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.9 tttt -68.63 -38.97 80.96 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.552 1.541 . . . . 0.0 113.88 -173.906 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.4 ' O ' ' CE1' ' B' ' 63' ' ' HIS . 33.9 p -121.78 -68.72 0.88 Allowed 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 116.974 -1.488 . . . . 0.0 109.696 172.742 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 163.71 17.37 0.02 OUTLIER Glycine 0 CA--C 1.536 1.375 0 C-N-CA 130.476 3.894 . . . . 0.0 113.621 -176.286 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . 0.257 2.3 t-20 41.98 35.34 0.54 Allowed 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 128.017 2.527 . . . . 0.0 114.819 -166.522 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.56 3.45 0.13 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.784 1.633 . . . . 0.0 115.232 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 69.9 -43.86 0.51 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 129.324 3.345 . . . . 0.0 117.257 168.664 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 32.5 t -173.09 168.55 4.77 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.768 1.627 . . . . 0.0 110.062 -168.316 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 28.5 mtt180 -111.07 -177.69 3.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 114.298 1.221 . . . . 0.0 114.298 -169.85 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.425 HD22 ' H ' ' B' ' 145' ' ' ALA . 0.4 OUTLIER -171.31 -157.88 0.13 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 128.417 2.687 . . . . 0.0 107.138 -169.695 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . 0.425 ' H ' HD22 ' B' ' 144' ' ' LEU . . . -58.69 153.97 15.53 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -169.142 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 31.4 p -141.98 153.77 44.54 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 113.949 -1.478 . . . . 0.0 113.82 -172.109 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.99 -177.65 37.68 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 127.49 2.472 . . . . 0.0 111.485 176.627 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.61 152.69 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 166.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 6.0 mm -75.7 102.31 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 174.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.18 -179.51 35.54 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 125.835 1.683 . . . . 0.0 111.14 169.932 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -133.24 154.55 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 117.602 0.701 . . . . 0.0 112.796 -167.604 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.465 ' HA ' ' CD1' ' A' ' 50' ' ' PHE . . . -146.23 -2.74 0.68 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 115.008 1.484 . . . . 0.0 115.008 165.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.234 0.262 0 C-N-CA 124.671 1.189 . . . . 0.0 111.071 168.78 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.514 0 CA-C-O 118.395 -0.812 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m -77.2 113.0 14.48 Favored 'General case' 0 CA--C 1.511 -0.539 0 C-N-CA 127.839 2.456 . . . . 0.0 107.146 -171.178 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p -92.91 -29.77 15.73 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.67 -51.24 36.47 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 118.192 0.451 . . . . 0.0 111.151 177.103 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.49 -134.95 7.55 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 126.195 1.855 . . . . 0.0 111.092 -173.24 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.8 t -54.42 -26.31 29.9 Favored 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -172.175 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 m -75.45 -34.36 60.96 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.866 1.267 . . . . 0.0 111.621 176.229 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 99.6 p -101.85 66.22 1.04 Allowed 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.183 1.793 . . . . 0.0 110.012 179.269 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.72 66.14 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.39 1.076 . . . . 0.0 111.365 -177.142 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 024 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.514 0 CA-C-O 118.395 -0.812 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 m -77.2 113.0 14.48 Favored 'General case' 0 CA--C 1.511 -0.539 0 C-N-CA 127.839 2.456 . . . . 0.0 107.146 -171.178 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.2 ptpt -124.88 158.39 33.61 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 152' ' ' ALA . . . -146.18 159.99 42.57 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.548 1.939 . . . . 0.0 112.525 -175.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -109.12 145.83 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.951 1.3 . . . . 0.0 111.487 175.43 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -102.81 106.72 17.37 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.316 1.446 . . . . 0.0 111.615 170.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.632 ' HA ' HG22 ' B' ' 54' ' ' THR . 4.0 t -86.7 54.45 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 124.825 1.25 . . . . 0.0 112.048 -172.889 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.446 ' HA ' ' HA3' ' A' ' 147' ' ' GLY . 7.5 mp -80.31 124.63 29.01 Favored 'General case' 0 N--CA 1.477 0.882 0 O-C-N 120.512 -1.368 . . . . 0.0 110.586 -175.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -156.2 143.04 18.8 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 122.591 1.186 . . . . 0.0 113.822 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.75 158.51 14.89 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 106.042 -2.823 . . . . 0.0 106.042 165.226 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -73.48 71.12 1.31 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 127.25 2.22 . . . . 0.0 110.673 -176.003 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.01 -171.08 33.27 Favored Glycine 0 CA--C 1.539 1.532 0 C-N-CA 127.085 2.279 . . . . 0.0 110.183 -169.712 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -80.25 42.87 1.4 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 124.283 3.322 . . . . 0.0 112.996 -170.671 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -128.81 120.52 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 125.534 1.534 . . . . 0.0 108.124 178.074 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.2 pm0 -159.96 163.38 34.21 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 124.797 1.239 . . . . 0.0 110.696 -171.763 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.502 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -144.37 98.16 0.2 Allowed Glycine 0 CA--C 1.503 -0.674 0 C-N-CA 125.238 1.399 . . . . 0.0 111.832 -176.765 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . 0.256 0.1 OUTLIER -102.83 106.36 19.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -174.811 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.47 139.7 51.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 125.668 1.587 . . . . 0.0 108.091 -173.172 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -99.25 150.08 22.45 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.963 1.305 . . . . 0.0 110.293 168.773 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -119.19 134.02 55.44 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 167.29 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -143.45 123.2 13.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 120.055 1.298 . . . . 0.0 112.919 169.883 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -105.85 156.91 17.87 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 126.621 1.968 . . . . 0.0 110.502 177.949 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.11 -13.56 43.84 Favored 'General case' 0 CA--C 1.554 1.117 0 O-C-N 120.74 -1.225 . . . . 0.0 112.987 178.483 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.432 ' HB2' ' H ' ' A' ' 25' ' ' SER . 0.0 OUTLIER -155.03 -143.12 0.12 Allowed 'General case' 0 CA--C 1.562 1.406 0 C-N-CA 127.502 2.321 . . . . 0.0 110.764 178.815 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.432 ' H ' ' HB2' ' A' ' 24' ' ' GLU . 6.7 p -115.51 -11.58 11.77 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 128.184 2.594 . . . . 0.0 115.354 -179.354 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -145.73 12.78 1.31 Allowed 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -168.233 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -114.5 -161.46 13.67 Favored Glycine 0 CA--C 1.543 1.815 0 C-N-CA 128.049 2.738 . . . . 0.0 111.866 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -86.05 147.67 9.19 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.313 2.676 . . . . 0.0 115.23 -168.633 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 133.61 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 C-N-CA 127.127 2.171 . . . . 0.0 110.461 -173.612 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -93.46 127.74 39.24 Favored 'General case' 0 CA--C 1.543 0.691 0 O-C-N 121.987 -0.446 . . . . 0.0 111.769 169.885 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.9 t -114.1 130.54 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 126.755 2.022 . . . . 0.0 109.467 -177.264 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 13.2 p90 -153.84 157.02 38.7 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.192 0.997 . . . . 0.0 113.055 -179.68 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 135.7 -156.18 22.66 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.654 1.121 . . . . 0.0 111.581 -179.579 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 77.7 p -151.28 146.82 26.31 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 117.415 2.376 . . . . 0.0 117.415 -177.089 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.502 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 3.3 mp -105.42 117.31 50.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 125.113 1.365 . . . . 0.0 109.93 170.811 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -123.11 142.76 50.53 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 126.176 1.79 . . . . 0.0 110.472 -171.345 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 101.07 -3.73 55.5 Favored Glycine 0 N--CA 1.476 1.329 0 C-N-CA 125.187 1.375 . . . . 0.0 114.448 174.034 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.58 155.18 18.55 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.831 1.252 . . . . 0.0 110.056 169.497 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.4 156.5 22.4 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.073 0.949 . . . . 0.0 110.629 174.329 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -49.82 -50.68 44.3 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.802 1.641 . . . . 0.0 113.773 175.707 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -53.65 130.66 42.82 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 125.178 1.37 . . . . 0.0 113.254 -169.47 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.69 ' H ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -46.44 140.31 4.32 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 127.918 2.487 . . . . 0.0 116.039 -169.099 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -122.65 139.92 53.41 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 128.749 2.82 . . . . 0.0 111.929 -169.693 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.67 160.35 53.01 Favored Glycine 0 N--CA 1.479 1.539 0 C-N-CA 124.759 1.171 . . . . 0.0 111.73 169.719 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 84.18 1.05 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.082 1.441 . . . . 0.0 111.784 -168.038 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -125.66 142.36 51.55 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 120.506 -1.371 . . . . 0.0 110.618 -169.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -103.86 133.71 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 179.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 10.1 m170 -74.94 175.35 8.18 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 112.583 -169.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.516 ' HB3' ' H ' ' A' ' 64' ' ' PHE . 11.6 pt-20 -68.17 58.5 0.07 Allowed 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 127.142 2.177 . . . . 0.0 112.299 168.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.281 0.3 OUTLIER 35.44 -129.7 0.09 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 126.534 1.934 . . . . 0.0 110.022 -168.287 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' HA ' ' B' ' 152' ' ' ALA . . . 77.5 -87.84 1.02 Allowed Glycine 0 CA--C 1.5 -0.902 0 CA-C-N 118.3 0.5 . . . . 0.0 112.986 166.632 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -63.63 151.99 40.18 Favored 'General case' 0 N--CA 1.437 -1.111 0 CA-C-O 122.877 1.323 . . . . 0.0 111.245 -179.913 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -135.51 16.84 3.38 Favored 'General case' 0 N--CA 1.433 -1.281 0 CA-C-O 116.251 -1.833 . . . . 0.0 114.918 177.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.352 13.3 t 152.19 15.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 129.239 3.016 . . . . 0.0 118.428 168.407 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -112.68 -0.91 14.92 Favored 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 125.71 1.604 . . . . 0.0 113.641 172.067 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 60.11 -133.72 50.75 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 125.353 1.454 . . . . 0.0 112.429 174.63 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 61.5 m -62.87 -7.58 5.39 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.533 1.533 . . . . 0.0 115.003 -174.201 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 9.2 m -82.03 -16.55 49.81 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.807 1.243 . . . . 0.0 112.268 170.545 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.4 t -124.8 -29.69 3.37 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.157 1.383 . . . . 0.0 114.076 -168.242 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -163.78 160.78 22.83 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 126.597 1.959 . . . . 0.0 111.224 171.349 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -82.23 -169.38 43.36 Favored Glycine 0 CA--C 1.536 1.384 0 C-N-CA 123.799 0.714 . . . . 0.0 113.198 179.093 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -74.13 -172.48 1.15 Allowed 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 126.052 4.501 . . . . 0.0 110.184 -178.147 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 137' ' ' THR . 0.3 OUTLIER -47.49 94.56 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.871 0 O-C-N 120.092 -1.63 . . . . 0.0 114.294 167.309 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.516 ' H ' ' HB3' ' A' ' 49' ' ' GLU . 36.0 t80 -49.46 134.09 19.52 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 166.685 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -71.39 95.95 0.08 OUTLIER Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -178.812 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.54 -48.86 0.23 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.999 2.466 . . . . 0.0 112.793 -164.662 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.1 tp -79.38 -1.79 38.7 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.862 1.265 . . . . 0.0 112.064 169.652 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t 71.29 52.35 0.25 Allowed 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 126.508 1.923 . . . . 0.0 110.611 -169.274 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.9 ptt180 -133.47 172.13 13.14 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 126.083 1.753 . . . . 0.0 114.936 -177.345 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -75.73 165.18 25.42 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 122.423 1.106 . . . . 0.0 113.569 -174.702 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -70.27 132.08 45.17 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.47 164.902 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -165.51 -157.05 9.6 Favored Glycine 0 CA--C 1.516 0.133 0 O-C-N 123.65 0.594 . . . . 0.0 113.128 -170.003 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.34 -101.36 0.27 Allowed Glycine 0 CA--C 1.532 1.106 0 CA-C-O 116.995 -2.003 . . . . 0.0 113.22 172.135 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -75.49 24.67 0.4 Allowed 'Trans proline' 0 CA--C 1.548 1.212 0 C-N-CA 124.769 3.646 . . . . 0.0 115.126 -169.673 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -174.18 -15.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 127.26 2.224 . . . . 0.0 113.511 169.549 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -114.45 83.74 1.94 Allowed 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.307 1.443 . . . . 0.0 107.155 172.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -55.08 0.32 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 130.544 3.537 . . . . 0.0 115.86 -171.709 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -71.59 -90.22 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 171.22 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 84.44 121.88 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 125.258 1.423 . . . . 0.0 109.898 167.123 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.6 m80 -64.58 145.2 56.51 Favored 'General case' 0 CA--C 1.54 0.583 0 O-C-N 119.358 -2.089 . . . . 0.0 110.44 169.055 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 72.7 t -47.27 -32.7 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 123.372 0.669 . . . . 0.0 112.718 170.541 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.27 70.18 0.29 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-O 117.969 -1.462 . . . . 0.0 113.725 171.842 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -143.17 139.37 30.3 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.268 1.427 . . . . 0.0 113.227 169.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 88.0 mt -121.27 49.4 1.51 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.424 1.09 . . . . 0.0 110.504 170.018 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 56.28 -120.22 18.57 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 124.369 0.985 . . . . 0.0 113.385 173.284 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.8 p30 -143.82 160.94 39.87 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 125.094 1.358 . . . . 0.0 110.117 173.38 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.51 133.56 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.536 1.534 . . . . 0.0 111.499 -169.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.73 149.84 31.08 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 124.228 1.011 . . . . 0.0 109.388 176.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.13 160.78 15.06 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 123.998 0.919 . . . . 0.0 112.206 173.276 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -72.27 167.26 20.77 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 125.926 1.69 . . . . 0.0 111.768 170.019 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.95 -8.92 1.56 Allowed 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 126.966 2.107 . . . . 0.0 115.259 171.16 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -89.63 0.94 56.61 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.121 -1.612 . . . . 0.0 113.252 167.676 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 70.82 39.8 64.97 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.679 1.133 . . . . 0.0 112.397 -178.591 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.8 p -133.64 130.11 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-N 118.079 0.94 . . . . 0.0 113.353 174.192 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -98.82 93.49 6.09 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.93 1.292 . . . . 0.0 107.948 167.655 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -83.07 131.78 35.15 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.176 0.99 . . . . 0.0 109.026 170.72 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.8 145.65 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 115.249 1.574 . . . . 0.0 115.249 -168.296 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 m -157.92 101.38 1.78 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 126.35 1.86 . . . . 0.0 112.542 169.664 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 19.0 mt -134.36 155.75 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.987 2.115 . . . . 0.0 111.457 -176.844 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -127.42 135.61 50.68 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.59 1.156 . . . . 0.0 108.159 165.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -138.41 150.58 46.65 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.753 1.621 . . . . 0.0 112.079 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 30.0 t -123.5 58.8 1.12 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.89 1.676 . . . . 0.0 113.171 -167.19 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -157.55 -40.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 172.347 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -77.92 160.06 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 O-C-N 121.751 -0.593 . . . . 0.0 110.407 169.679 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.542 ' H ' ' HB3' ' A' ' 111' ' ' SER . 95.8 p -155.95 160.78 40.4 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.363 1.465 . . . . 0.0 110.234 177.638 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -78.86 93.78 5.07 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 106.873 -1.528 . . . . 0.0 106.873 175.533 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.1 t -136.59 -5.89 1.98 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 117.851 2.537 . . . . 0.0 117.851 -167.634 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.05 91.8 0.1 OUTLIER Glycine 0 N--CA 1.466 0.665 0 CA-C-N 120.264 1.393 . . . . 0.0 110.723 170.573 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 12.1 t70 85.87 -35.72 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 127.51 2.324 . . . . 0.0 110.311 172.08 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -78.89 -50.13 11.72 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.476 1.11 . . . . 0.0 111.383 -173.964 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.542 ' HB3' ' H ' ' A' ' 105' ' ' SER . 68.7 m -116.57 -98.63 0.45 Allowed 'General case' 0 C--O 1.234 0.257 0 C-N-CA 123.194 0.598 . . . . 0.0 110.016 -173.754 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 27.3 pt -116.87 168.34 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 164.451 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 95.6 125.02 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.199 1 C-N-CA 132.258 4.223 . . . . 0.0 107.135 -166.589 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 77.57 -0.66 69.26 Favored Glycine 0 CA--C 1.533 1.164 0 CA-C-O 117.994 -1.448 . . . . 0.0 114.949 -174.683 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.7 ttm-85 -96.21 166.05 11.92 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 120.596 2.198 . . . . 0.0 110.254 179.249 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 92.9 m -135.93 114.65 11.96 Favored 'General case' 0 N--CA 1.482 1.152 0 CA-C-N 119.528 1.058 . . . . 0.0 112.057 -168.691 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 24.4 tp -93.7 125.94 38.59 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.41 2.284 . . . . 0.0 111.203 -172.093 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.59 135.09 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 123.445 0.698 . . . . 0.0 110.859 171.076 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -96.99 123.03 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 169.558 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 78.2 m-70 -83.65 169.26 15.51 Favored 'General case' 0 CA--C 1.547 0.842 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -177.502 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -72.64 -60.1 2.4 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 120.508 -1.37 . . . . 0.0 111.11 175.573 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.1 mptt -95.24 172.36 8.16 Favored 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 176.766 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.48 147.93 51.69 Favored 'General case' 0 N--CA 1.466 0.345 0 O-C-N 120.855 -1.153 . . . . 0.0 111.838 -178.58 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -75.09 132.71 41.45 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 167.158 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -74.83 -18.13 60.5 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 114.155 1.168 . . . . 0.0 114.155 -177.075 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 63.1 66.04 0.75 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 127.605 2.362 . . . . 0.0 114.134 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 100.61 -15.48 58.52 Favored Glycine 0 N--CA 1.471 1.023 0 N-CA-C 117.719 1.848 . . . . 0.0 117.719 164.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . 0.435 0.2 OUTLIER -164.58 78.11 0.34 Allowed 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 120.394 3.479 . . . . 0.0 120.394 164.819 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.497 ' H ' ' HB2' ' A' ' 134' ' ' SER . . . -81.06 -127.81 0.83 Allowed Glycine 0 CA--C 1.532 1.141 0 C-N-CA 126.618 2.056 . . . . 0.0 109.146 165.049 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -90.3 -17.87 51.52 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 118.046 1.978 . . . . 0.0 118.046 -168.442 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.471 ' H ' ' HB3' ' A' ' 134' ' ' SER . 52.1 p30 -155.1 -157.94 0.79 Allowed 'General case' 0 CA--C 1.556 1.174 0 CA-C-N 120.587 2.193 . . . . 0.0 114.911 -168.375 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.24 -56.9 11.4 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 126.437 1.895 . . . . 0.0 111.815 173.315 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 29.4 mm-40 -47.81 -18.1 0.14 Allowed 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 126.448 1.899 . . . . 0.0 115.877 168.019 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.497 ' HB2' ' H ' ' A' ' 129' ' ' GLY . 1.1 p -69.95 -6.4 32.82 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 125.391 1.476 . . . . 0.0 113.62 169.163 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 20.2 p -120.45 -30.25 4.59 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 126.589 1.956 . . . . 0.0 111.159 168.173 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.6 mtpm? -82.3 -31.73 29.86 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 115.117 1.525 . . . . 0.0 115.117 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.46 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 17.7 p -119.32 -108.37 0.36 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 103.137 -2.912 . . . . 0.0 103.137 163.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -154.79 30.46 0.67 Allowed Glycine 0 C--O 1.225 -0.426 0 C-N-CA 125.49 1.519 . . . . 0.0 110.91 167.797 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 48.91 27.39 1.6 Allowed 'General case' 0 CA--C 1.548 0.875 0 C-N-CA 124.602 1.161 . . . . 0.0 113.564 -175.215 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.97 29.43 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 127.137 2.175 . . . . 0.0 116.739 -166.28 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.75 -45.32 1.59 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 127.962 2.696 . . . . 0.0 115.162 172.362 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 41.1 t 173.42 -153.28 0.01 OUTLIER 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 128.554 2.741 . . . . 0.0 109.058 -171.438 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -158.82 151.61 22.07 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 119.918 -1.739 . . . . 0.0 115.556 -170.089 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -122.61 -124.43 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 124.894 1.278 . . . . 0.0 110.444 168.554 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.1 163.03 27.13 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 124.775 1.23 . . . . 0.0 113.118 -168.901 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 22.6 p -148.97 160.05 43.65 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.129 0.972 . . . . 0.0 111.787 170.556 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 8' ' ' LEU . . . -159.63 154.85 25.92 Favored Glycine 0 C--N 1.338 0.65 0 N-CA-C 118.432 2.133 . . . . 0.0 118.432 -171.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.85 150.1 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 125.868 1.667 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 mt -95.25 94.42 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 124.366 1.066 . . . . 0.0 109.539 169.068 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -98.57 161.08 20.43 Favored Glycine 0 C--N 1.353 1.505 0 C-N-CA 126.69 2.09 . . . . 0.0 112.826 -176.888 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.528 HD13 ' HA3' ' B' ' 114' ' ' GLY . 1.5 mp -93.1 97.9 7.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.404 1.082 . . . . 0.0 113.402 -165.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -82.57 8.22 12.42 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 126.888 2.075 . . . . 0.0 112.771 167.185 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.9 tt0 . . . . . 0 N--CA 1.469 0.479 0 C-N-CA 130.065 3.346 . . . . 0.0 114.72 -173.412 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 0.572 0 CA-C-O 120.289 0.09 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -82.88 102.52 11.71 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 122.142 0.972 . . . . 0.0 109.833 -175.441 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 pttp -90.06 115.96 27.73 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 127.301 2.24 . . . . 0.0 113.467 179.343 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -77.2 163.29 26.69 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.828 0.851 . . . . 0.0 111.986 169.672 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 57.9 t -136.69 93.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 127.023 2.129 . . . . 0.0 108.819 -178.673 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.48 88.89 2.88 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 167.527 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 16.7 m -98.98 129.78 48.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 173.584 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 4.8 mp -103.3 125.43 49.94 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 125.07 1.348 . . . . 0.0 110.209 -167.203 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmt -156.55 137.29 13.31 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 178.321 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 165.46 -35.2 0.26 Allowed Glycine 0 CA--C 1.53 0.978 0 C-N-CA 126.42 1.962 . . . . 0.0 111.98 171.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -79.31 56.26 2.06 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 128.216 2.606 . . . . 0.0 112.025 -176.018 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 42.85 -101.3 0.02 OUTLIER Glycine 0 CA--C 1.536 1.401 0 C-N-CA 127.59 2.519 . . . . 0.0 113.107 -178.879 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.48 -17.58 10.02 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.439 2.759 . . . . 0.0 113.949 -178.753 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 6.3 t -86.32 122.6 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 120.327 1.421 . . . . 0.0 109.559 -176.702 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.15 158.42 38.94 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.744 0.818 . . . . 0.0 110.695 -176.746 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -155.62 171.5 33.64 Favored Glycine 0 CA--C 1.503 -0.673 0 O-C-N 121.536 -0.727 . . . . 0.0 114.667 -175.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -128.72 141.22 47.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 C-N-CA 124.464 1.106 . . . . 0.0 109.935 170.276 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 29.8 mm -135.13 126.55 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 C-N-CA 125.283 1.433 . . . . 0.0 108.555 169.329 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -102.94 128.35 49.78 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.74 1.216 . . . . 0.0 110.579 169.65 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -100.58 101.8 12.79 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 104.766 -2.309 . . . . 0.0 104.766 165.573 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -91.64 130.47 37.44 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 173.716 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -124.54 135.69 53.38 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-O 123.092 1.425 . . . . 0.0 110.65 167.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -77.3 -36.66 53.93 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 127.932 2.493 . . . . 0.0 111.56 -177.664 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -114.78 -167.43 1.23 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 129.219 3.007 . . . . 0.0 111.283 178.538 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 11.4 t -102.79 -24.35 13.72 Favored 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 172.515 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 68.3 m-80 -142.8 15.76 1.95 Allowed 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.835 1.42 . . . . 0.0 114.835 177.538 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.36 -166.23 31.66 Favored Glycine 0 CA--C 1.545 1.952 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 165.17 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.4 159.63 32.58 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 CA-C-N 120.488 2.144 . . . . 0.0 112.241 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 36.3 t -124.43 139.45 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.946 1.698 . . . . 0.0 108.73 -174.188 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OE1' ' B' ' 100' ' ' GLU . 28.4 tttm -101.37 126.23 48.1 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 123.186 1.47 . . . . 0.0 111.513 169.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 88.8 t -102.86 119.1 50.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 125.886 1.674 . . . . 0.0 107.909 -177.655 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -141.47 163.32 33.24 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 174.699 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 150.42 -159.15 28.0 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 124.198 0.904 . . . . 0.0 112.211 174.688 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 78.4 p -157.67 141.43 15.75 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.896 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.78 139.51 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 125.008 1.323 . . . . 0.0 110.262 170.616 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -128.95 138.57 52.05 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.365 1.466 . . . . 0.0 111.734 -174.566 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.54 -4.44 23.15 Favored Glycine 0 N--CA 1.477 1.408 0 C-N-CA 125.899 1.714 . . . . 0.0 115.169 175.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.697 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.7 pt? -97.34 167.45 11.0 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 126.032 1.733 . . . . 0.0 110.69 174.424 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.62 176.22 5.67 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 123.395 0.678 . . . . 0.0 110.703 176.086 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -73.2 -174.01 1.47 Allowed 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 125.327 1.451 . . . . 0.0 114.362 179.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.57 -173.28 53.92 Favored Glycine 0 CA--C 1.531 1.07 0 O-C-N 120.889 -1.132 . . . . 0.0 113.404 175.93 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 82.6 mt -76.3 145.59 39.5 Favored 'General case' 0 CA--C 1.539 0.521 0 O-C-N 120.838 -1.389 . . . . 0.0 110.804 175.677 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -138.7 156.63 47.23 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 129.856 3.263 . . . . 0.0 107.812 179.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.93 162.13 42.51 Favored Glycine 0 N--CA 1.473 1.156 0 CA-C-O 118.225 -1.319 . . . . 0.0 111.789 171.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.437 ' HA ' ' HA ' ' B' ' 119' ' ' VAL 0.314 1.1 p90 -159.92 75.83 0.62 Allowed 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.58 1.952 . . . . 0.0 112.933 173.078 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -99.28 140.78 32.95 Favored 'General case' 0 N--CA 1.472 0.642 0 O-C-N 119.729 -1.857 . . . . 0.0 115.687 -179.012 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -75.59 108.88 8.21 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.254 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 165.179 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 2.3 m170 -78.97 177.95 8.39 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 123.032 1.396 . . . . 0.0 112.354 -178.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -60.65 145.24 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 125.273 1.429 . . . . 0.0 109.571 167.572 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -108.73 173.15 6.45 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 125.6 1.56 . . . . 0.0 113.584 179.351 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 152' ' ' ALA . . . 154.02 -83.39 0.16 Allowed Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 169.583 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.92 137.1 48.18 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 102.764 -3.05 . . . . 0.0 102.764 165.072 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . 0.266 0.0 OUTLIER -144.78 23.63 1.56 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.604 1.193 . . . . 0.0 112.854 179.942 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 7' ' ' VAL . 16.9 p -92.91 -29.77 15.73 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -164.814 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.67 -51.24 36.47 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 118.192 0.451 . . . . 0.0 111.151 177.103 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 135.49 -134.95 7.55 Favored Glycine 0 CA--C 1.528 0.864 0 C-N-CA 126.195 1.855 . . . . 0.0 111.092 -173.24 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 8.8 t -54.42 -26.31 29.9 Favored 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -172.175 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 5.7 m -75.45 -34.36 60.96 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.866 1.267 . . . . 0.0 111.621 176.229 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 99.6 p -101.85 66.22 1.04 Allowed 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 126.183 1.793 . . . . 0.0 110.012 179.269 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -171.72 66.14 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.39 1.076 . . . . 0.0 111.365 -177.142 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.23 149.4 42.26 Favored Glycine 0 CA--C 1.537 1.414 0 CA-C-O 118.66 -1.078 . . . . 0.0 111.821 -176.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.418 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 45.5 Cg_endo -57.4 147.62 76.6 Favored 'Trans proline' 0 CA--C 1.533 0.474 0 C-N-CA 123.875 3.05 . . . . 0.0 111.26 -176.493 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -16.72 93.7 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 127.681 2.392 . . . . 0.0 114.548 169.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 17.3 t80 -34.24 126.89 0.45 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 127.503 2.321 . . . . 0.0 115.972 -167.454 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -107.56 47.57 0.16 Allowed Pre-proline 0 CA--C 1.558 1.276 0 N-CA-C 115.959 1.837 . . . . 0.0 115.959 -171.46 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -64.83 -24.65 61.11 Favored 'Trans proline' 0 C--N 1.351 0.707 0 CA-C-N 122.882 2.065 . . . . 0.0 111.476 177.619 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 89.5 mt -82.04 -8.45 59.67 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 124.717 1.207 . . . . 0.0 113.941 170.165 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 2.6 t 60.0 53.24 4.73 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 123.391 1.567 . . . . 0.0 112.111 175.791 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . 0.313 13.0 ptt180 -118.46 170.35 9.0 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 116.599 2.074 . . . . 0.0 116.599 -171.284 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.54 156.0 20.26 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 113.602 -1.635 . . . . 0.0 107.97 178.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . 0.41 ' HA ' ' CE1' ' B' ' 80' ' ' HIS . 42.8 t60 -66.3 154.85 38.87 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.586 175.385 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 157.39 -136.34 4.83 Favored Glycine 0 N--CA 1.444 -0.815 0 CA-C-N 114.478 -1.237 . . . . 0.0 114.286 175.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.76 -93.77 0.8 Allowed Glycine 0 CA--C 1.54 1.6 0 CA-C-O 117.079 -1.956 . . . . 0.0 110.535 -167.581 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -69.55 48.7 0.61 Allowed 'Trans proline' 0 CA--C 1.559 1.737 0 C-N-CA 124.954 3.77 . . . . 0.0 116.939 179.825 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.459 ' HE2' ' HB2' ' B' ' 126' ' ' LEU 0.252 0.0 OUTLIER 176.69 -13.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 131.473 3.909 . . . . 0.0 113.871 164.568 . . . . . . . . 4 4 . 1 . 025 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.91 176.94 4.89 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 129.986 3.314 . . . . 0.0 111.932 -167.695 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 26.6 pt-20 -122.41 -8.39 8.62 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 127.988 2.515 . . . . 0.0 113.655 -179.11 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -81.44 -102.32 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 125.423 1.489 . . . . 0.0 108.509 176.411 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . 0.422 HH22 ' CG ' ' B' ' 101' ' ' ASP . 49.6 ttt180 82.02 117.49 0.05 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 126.326 1.851 . . . . 0.0 110.134 175.39 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . 0.41 ' CE1' ' HA ' ' B' ' 71' ' ' HIS . 21.0 m80 -63.12 162.22 12.09 Favored 'General case' 0 CA--C 1.549 0.904 0 O-C-N 120.051 -1.656 . . . . 0.0 114.746 -176.797 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 62.4 t -83.39 107.83 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 176.54 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.52 81.92 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -167.283 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -155.26 149.54 25.98 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.67 1.588 . . . . 0.0 110.779 -174.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 32.6 mt -128.93 177.5 7.06 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.286 1.034 . . . . 0.0 110.832 173.097 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -100.65 -151.87 25.67 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 124.721 1.153 . . . . 0.0 110.918 168.677 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -90.75 157.13 17.58 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -174.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 14.6 p -114.23 133.77 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 C-N-CA 127.608 2.363 . . . . 0.0 111.2 173.122 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 4.5 t -103.32 143.8 32.19 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.159 1.384 . . . . 0.0 111.988 -172.513 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -129.11 150.01 50.68 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 115.038 1.496 . . . . 0.0 115.038 -174.717 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -85.45 -89.01 0.11 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 129.029 2.932 . . . . 0.0 115.89 -167.16 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -176.36 -45.06 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.164 0 C-N-CA 127.249 2.22 . . . . 0.0 111.244 -165.727 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -82.13 36.27 0.46 Allowed 'General case' 0 CA--C 1.545 0.761 0 CA-C-O 123.49 1.614 . . . . 0.0 110.759 173.867 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.82 5.47 61.23 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 120.378 -1.451 . . . . 0.0 115.335 169.799 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.1 p -98.78 135.23 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.434 1.093 . . . . 0.0 113.683 179.714 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.31 111.85 24.2 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.014 2.526 . . . . 0.0 108.92 167.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -92.12 146.03 24.04 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.355 1.462 . . . . 0.0 110.844 -179.236 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -139.11 142.89 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 115.983 1.846 . . . . 0.0 115.983 168.657 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 3.7 t -157.04 61.35 0.51 Allowed 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.615 1.566 . . . . 0.0 111.735 172.755 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.5 165.11 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 C-N-CA 126.982 2.113 . . . . 0.0 109.707 -179.742 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . 0.411 ' OE1' ' HE2' ' B' ' 30' ' ' LYS . 12.9 tt0 -143.02 151.83 41.25 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 126.488 1.915 . . . . 0.0 107.897 174.011 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . 0.422 ' CG ' HH22 ' B' ' 79' ' ' ARG . 30.2 t70 -152.63 147.32 26.01 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 124.132 0.973 . . . . 0.0 113.38 -177.473 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 61.5 p -119.43 54.97 0.97 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.593 1.157 . . . . 0.0 112.699 179.445 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 11.5 p -154.44 -37.02 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 113.087 168.21 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.79 164.79 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-N 120.405 1.457 . . . . 0.0 110.885 168.099 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 77.6 p -157.16 165.54 35.71 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 126.135 1.774 . . . . 0.0 111.817 -178.357 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -77.91 54.88 1.34 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 127.145 2.178 . . . . 0.0 108.659 170.703 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 18.6 t -103.52 74.0 1.23 Allowed 'General case' 0 C--O 1.238 0.492 0 C-N-CA 125.107 1.363 . . . . 0.0 109.087 -176.931 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.25 -138.63 48.67 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 113.364 -1.744 . . . . 0.0 110.724 -177.69 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -111.87 -9.29 14.06 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 113.83 -1.185 . . . . 0.0 112.709 -168.91 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 14.4 m170 -75.53 -24.88 56.81 Favored 'General case' 0 CA--C 1.548 0.89 0 O-C-N 120.068 -1.645 . . . . 0.0 110.347 174.24 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 51.9 p -78.2 -85.96 0.07 Allowed 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 126.439 1.895 . . . . 0.0 112.716 178.576 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 16.3 pt -142.85 -10.32 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 C-N-CA 125.362 1.465 . . . . 0.0 114.912 -172.289 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 18.6 mm -87.07 155.74 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 170.605 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . 0.528 ' HA3' HD13 ' A' ' 151' ' ' ILE . . . 75.43 -4.53 41.53 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 118.628 -1.095 . . . . 0.0 114.945 -175.032 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -80.1 175.3 10.76 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.739 1.27 . . . . 0.0 110.748 -176.711 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 9.7 t -118.85 112.1 19.25 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 169.021 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 5.9 tp -89.08 124.06 33.95 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 120.587 -1.32 . . . . 0.0 108.682 178.559 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 m -109.46 133.73 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 125.536 1.534 . . . . 0.0 109.759 171.505 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' B' ' 45' ' ' PHE . 71.2 t -82.61 170.32 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -143.08 142.09 31.43 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 120.316 -1.49 . . . . 0.0 109.728 175.674 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -63.65 -8.24 9.58 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 -168.789 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . 0.254 0.0 OUTLIER -151.48 178.81 8.92 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 118.648 -2.533 . . . . 0.0 115.343 173.958 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.72 142.26 11.55 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 124.701 1.2 . . . . 0.0 112.854 -169.78 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -79.79 135.72 36.55 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-O 121.96 0.886 . . . . 0.0 111.775 174.395 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -70.69 -44.88 66.08 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.755 2.022 . . . . 0.0 111.675 -179.53 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.459 ' HB2' ' HE2' ' B' ' 75' ' ' LYS . 12.1 mt 63.81 28.3 14.71 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.566 1.946 . . . . 0.0 114.442 169.289 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . -176.38 -88.17 0.07 OUTLIER Glycine 0 C--N 1.335 0.507 0 CA-C-N 118.939 0.79 . . . . 0.0 114.182 173.91 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -160.34 99.18 1.31 Allowed 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 127.029 2.132 . . . . 0.0 110.421 -176.493 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -90.98 -138.39 7.68 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 108.464 -1.855 . . . . 0.0 108.464 166.543 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.3 11.27 72.64 Favored Glycine 0 CA--C 1.532 1.122 0 N-CA-C 116.249 1.26 . . . . 0.0 116.249 -171.102 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 11.9 p30 -164.95 171.6 13.83 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-N 120.461 2.13 . . . . 0.0 114.738 -169.486 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -58.7 -54.98 40.92 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.609 1.964 . . . . 0.0 112.973 175.409 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -56.72 -17.88 10.53 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.536 1.134 . . . . 0.0 113.157 -177.882 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -68.49 -55.56 11.34 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 120.96 -1.087 . . . . 0.0 111.719 168.842 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 21.5 p -69.8 -29.7 67.07 Favored 'General case' 0 N--CA 1.477 0.876 0 C-N-CA 124.083 0.953 . . . . 0.0 111.958 179.158 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -84.81 -64.24 1.19 Allowed 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 126.539 1.935 . . . . 0.0 111.578 -172.837 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 38.6 p -96.69 -104.57 0.17 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 168.632 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -160.08 25.77 0.31 Allowed Glycine 0 C--O 1.223 -0.575 0 CA-C-O 118.805 -0.997 . . . . 0.0 112.828 176.184 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 44.55 24.05 0.09 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 126.52 1.928 . . . . 0.0 114.076 -174.1 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -75.39 37.49 0.13 Allowed 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 128.258 2.623 . . . . 0.0 114.555 -165.773 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 76.98 -20.6 2.93 Favored Glycine 0 CA--C 1.537 1.422 0 O-C-N 119.482 -2.011 . . . . 0.0 116.39 177.438 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . 0.259 77.3 p 151.59 -105.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 129.265 3.026 . . . . 0.0 113.042 169.214 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.15 176.46 8.67 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 130.694 3.598 . . . . 0.0 109.023 178.114 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 4.6 mt 179.73 161.41 0.88 Allowed 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 130.193 3.397 . . . . 0.0 110.056 177.8 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . 7.52 100.54 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.865 1 C-N-CA 132.086 4.154 . . . . 0.0 115.653 170.187 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 27.0 p -104.08 142.9 33.67 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 125.968 1.707 . . . . 0.0 114.734 -171.69 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -151.38 141.25 8.44 Favored Glycine 0 N--CA 1.48 1.581 0 O-C-N 120.091 -1.63 . . . . 0.0 114.519 173.385 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.87 158.92 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 CA-C-N 119.156 1.478 . . . . 0.0 107.583 172.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 4.4 mt -114.79 121.25 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 -169.514 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -121.46 -154.48 9.23 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 125.535 1.541 . . . . 0.0 112.21 171.107 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.81 124.85 1.8 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 C-N-CA 125.137 1.375 . . . . 0.0 112.214 -169.608 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.464 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . . . -76.44 22.5 0.17 Allowed 'General case' 0 N--CA 1.476 0.831 0 O-C-N 120.939 -1.1 . . . . 0.0 113.027 167.136 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 . . . . . 0 CA--C 1.544 0.715 0 C-N-CA 128.297 2.639 . . . . 0.0 113.806 176.177 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.922 0 CA-C-O 118.284 -0.865 . . . . 0.0 110.029 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.5 p -77.76 56.02 1.45 Allowed 'General case' 0 C--N 1.345 0.383 0 C-N-CA 127.385 2.274 . . . . 0.0 115.7 -166.296 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 0.8 OUTLIER -163.43 129.75 3.26 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 164.361 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.44 154.03 44.21 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.326 2.25 . . . . 0.0 108.289 167.682 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 69.4 t -154.97 146.62 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 118.916 0.78 . . . . 0.0 112.778 -167.005 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -121.76 128.45 51.75 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.592 1.157 . . . . 0.0 109.321 165.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 29.0 m -113.71 127.1 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.597 1.159 . . . . 0.0 108.289 167.59 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.07 130.45 55.09 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.14 1.376 . . . . 0.0 109.913 -172.068 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -153.9 70.76 0.83 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.741 0.816 . . . . 0.0 110.869 170.222 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.1 -1.41 22.3 Favored Glycine 0 N--CA 1.469 0.851 0 CA-C-O 117.481 -1.733 . . . . 0.0 115.078 -173.958 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -156.08 110.32 2.81 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 119.151 1.476 . . . . 0.0 111.979 -169.74 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 31.66 -111.37 0.05 OUTLIER Glycine 0 CA--C 1.535 1.304 0 C-N-CA 127.168 2.318 . . . . 0.0 114.906 169.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -84.42 -2.05 9.85 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.597 2.865 . . . . 0.0 114.034 -175.778 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.0 t -102.05 135.37 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 120.445 1.475 . . . . 0.0 111.578 -168.609 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -127.24 171.93 11.03 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 122.87 1.319 . . . . 0.0 110.258 169.072 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -147.36 150.87 23.17 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 112.781 -2.008 . . . . 0.0 112.152 167.892 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.5 pp -133.15 126.4 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 167.352 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mm -132.67 103.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -177.29 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -99.3 124.71 44.61 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.221 1.008 . . . . 0.0 112.151 177.107 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -104.69 156.45 17.97 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 127.303 2.241 . . . . 0.0 111.769 169.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -132.46 128.97 38.59 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.613 1.565 . . . . 0.0 108.597 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.565 HE21 ' HB2' ' A' ' 105' ' ' SER . 2.4 tm0? -139.56 145.49 38.69 Favored 'General case' 0 CA--C 1.532 0.287 0 O-C-N 120.822 -1.174 . . . . 0.0 111.151 -174.224 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.469 ' HD2' ' H ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -113.4 -31.37 6.58 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -167.39 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -157.94 154.66 28.16 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.683 1.593 . . . . 0.0 107.908 172.438 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 m -47.44 -40.53 18.32 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 128.302 2.641 . . . . 0.0 113.156 173.018 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -84.1 -0.55 52.34 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 125.984 1.714 . . . . 0.0 112.771 174.681 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.58 139.65 14.57 Favored Glycine 0 CA--C 1.538 1.526 0 O-C-N 120.427 -1.421 . . . . 0.0 112.985 -172.694 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -69.74 163.71 37.26 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 123.933 3.089 . . . . 0.0 111.339 178.925 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t -132.75 136.56 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 123.177 0.591 . . . . 0.0 112.164 -167.024 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.2 ttmm -95.49 124.54 39.57 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 125.093 1.357 . . . . 0.0 109.548 172.153 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 99' ' ' ILE . 0.3 OUTLIER -107.7 153.0 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 C-N-CA 125.672 1.589 . . . . 0.0 111.415 168.991 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 42.6 p90 -156.72 164.05 38.58 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.291 1.437 . . . . 0.0 111.834 168.779 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 141.94 -154.21 24.74 Favored Glycine 0 C--N 1.335 0.5 0 C-N-CA 124.139 0.876 . . . . 0.0 112.597 175.656 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 78.1 p -156.58 150.85 25.32 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.15 116.26 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 171.783 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -136.12 140.18 43.5 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.111 0.964 . . . . 0.0 112.566 -165.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.57 -16.22 37.62 Favored Glycine 0 CA--C 1.533 1.219 0 C-N-CA 126.809 2.147 . . . . 0.0 112.275 -168.789 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.453 HD13 ' CD2' ' A' ' 43' ' ' HIS . 2.2 pp -84.39 155.05 22.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-N 118.473 1.137 . . . . 0.0 112.01 172.879 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.7 m -62.02 154.15 27.54 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 127.371 2.269 . . . . 0.0 112.012 176.674 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.8 pm0 -51.0 169.61 0.04 OUTLIER 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.258 1.423 . . . . 0.0 114.57 168.674 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.43 -176.32 46.51 Favored Glycine 0 N--CA 1.472 1.086 0 O-C-N 120.792 -1.192 . . . . 0.0 112.358 -177.485 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.3 mp -75.92 148.36 38.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.456 -1.026 . . . . 0.0 110.019 -176.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.453 ' CD2' HD13 ' A' ' 38' ' ' LEU . 85.4 m-70 -142.1 134.0 27.24 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.849 1.26 . . . . 0.0 109.2 173.836 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.2 152.13 49.52 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 177.75 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -150.5 118.0 6.1 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.806 2.042 . . . . 0.0 107.97 -169.141 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.474 ' NE2' ' CD2' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -153.89 145.2 23.01 Favored 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.116 -1.615 . . . . 0.0 111.221 -172.956 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -95.16 127.3 47.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 122.173 0.987 . . . . 0.0 110.647 170.248 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -72.83 -173.62 1.26 Allowed 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 129.218 3.007 . . . . 0.0 110.349 177.414 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.55 ' H ' ' CD ' ' A' ' 49' ' ' GLU 0.268 1.9 pm0 -63.65 -120.31 0.0 OUTLIER 'General case' 0 CA--C 1.555 1.171 0 C-N-CA 126.081 1.752 . . . . 0.0 114.831 177.692 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -82.12 -168.03 1.79 Allowed 'General case' 0 CA--C 1.545 0.754 0 O-C-N 119.807 -1.808 . . . . 0.0 114.403 -167.129 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.58 9.45 60.59 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.067 1.794 . . . . 0.0 113.978 -179.354 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -108.98 38.79 2.18 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.986 1.714 . . . . 0.0 113.961 -173.769 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.4 ' OD1' ' HB2' ' A' ' 60' ' ' ALA . 2.1 p30 -172.43 22.27 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.858 1.313 . . . . 0.0 112.408 -165.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.411 ' H ' HG23 ' A' ' 54' ' ' THR . 3.1 p -44.33 5.8 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.613 1 C-N-CA 134.641 5.176 . . . . 0.0 118.784 -176.453 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.75 1.34 56.54 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 126.515 1.926 . . . . 0.0 112.87 172.579 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.84 -151.68 43.05 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 -179.135 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 14.1 t -51.26 -7.41 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.197 0 C-N-CA 127.206 2.203 . . . . 0.0 116.289 -176.42 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 58.5 p -87.95 18.51 4.14 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 120.162 -1.586 . . . . 0.0 113.318 169.2 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 67.9 m -169.81 -47.14 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 127.221 2.209 . . . . 0.0 109.761 -176.268 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.4 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . . . -70.61 151.31 45.13 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.45 1.9 . . . . 0.0 112.128 172.526 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -98.01 -170.28 32.35 Favored Glycine 0 CA--C 1.532 1.104 0 C-N-CA 125.803 1.668 . . . . 0.0 112.505 -176.188 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -83.79 60.87 6.69 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.501 2.801 . . . . 0.0 109.885 178.185 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.474 ' CD2' ' NE2' ' A' ' 46' ' ' HIS . 0.0 OUTLIER 51.19 63.81 2.1 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.551 1.54 . . . . 0.0 112.773 168.272 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -28.29 113.57 0.07 Allowed 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 127.507 2.323 . . . . 0.0 111.854 175.679 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -78.11 103.59 1.45 Allowed Pre-proline 0 CA--C 1.545 0.773 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.795 -166.547 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -70.11 -21.12 32.3 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 121.899 1.733 . . . . 0.0 112.186 -174.516 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 10.7 mp -105.89 -3.74 21.49 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.31 1.844 . . . . 0.0 112.677 175.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 t 54.18 44.24 29.44 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 125.25 1.42 . . . . 0.0 112.283 -169.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 2.9 mtm180 -92.2 171.19 9.24 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 120.994 -1.066 . . . . 0.0 111.37 174.378 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.75 164.64 18.41 Favored 'General case' 0 CA--C 1.547 0.858 0 O-C-N 121.23 -0.919 . . . . 0.0 109.762 167.792 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -80.31 142.54 34.42 Favored 'General case' 0 CA--C 1.536 0.414 0 O-C-N 120.265 -1.522 . . . . 0.0 111.718 -178.495 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 165.36 -131.5 2.41 Favored Glycine 0 N--CA 1.468 0.804 0 N-CA-C 115.859 1.104 . . . . 0.0 115.859 168.843 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.55 -41.7 1.72 Allowed Glycine 0 CA--C 1.543 1.822 0 N-CA-C 119.005 2.362 . . . . 0.0 119.005 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -95.39 -22.31 0.2 Allowed 'Trans proline' 0 CA--C 1.541 0.837 0 CA-C-N 121.885 2.843 . . . . 0.0 113.725 -175.798 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.5 pttt -132.26 -0.09 3.7 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.976 1.71 . . . . 0.0 112.21 175.348 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -138.72 155.49 48.19 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 130.869 3.668 . . . . 0.0 108.832 -176.428 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -107.07 -8.05 16.67 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 126.169 1.788 . . . . 0.0 112.911 -174.638 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.5 mm-40 -78.2 -20.21 52.31 Favored 'General case' 0 N--CA 1.477 0.905 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -172.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.481 HH21 HG12 ' A' ' 103' ' ' VAL . 4.8 ttp180 4.52 102.14 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 130.445 3.498 . . . . 0.0 115.374 166.493 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -59.58 162.35 5.13 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.654 0.782 . . . . 0.0 112.03 169.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 92.2 t -49.62 -41.18 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 124.366 1.066 . . . . 0.0 113.722 171.125 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -83.8 8.39 66.21 Favored Glycine 0 CA--C 1.539 1.583 0 N-CA-C 116.837 1.495 . . . . 0.0 116.837 177.266 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -99.25 97.49 8.56 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-N 119.635 1.718 . . . . 0.0 111.866 -175.184 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 87.0 mt -108.81 54.54 0.65 Allowed 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.455 1.102 . . . . 0.0 111.954 -175.436 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.42 -151.48 43.43 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 125.023 1.296 . . . . 0.0 114.248 177.186 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 18.7 p30 -135.16 169.28 17.69 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 125.509 1.524 . . . . 0.0 109.568 169.864 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 32.0 m -128.58 113.88 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.536 1.134 . . . . 0.0 109.832 -171.147 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.4 m -109.15 124.37 50.7 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 123.913 0.885 . . . . 0.0 108.939 -170.102 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.94 151.17 21.64 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 -172.87 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -88.06 151.89 22.42 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 127.758 2.423 . . . . 0.0 110.381 167.952 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -49.94 -17.71 0.42 Allowed 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 129.2 3.0 . . . . 0.0 116.994 175.557 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -75.65 0.75 16.54 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 124.266 1.026 . . . . 0.0 111.388 171.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.13 35.13 7.21 Favored Glycine 0 C--N 1.34 0.783 0 C-N-CA 125.996 1.76 . . . . 0.0 112.781 172.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.7 p -152.76 131.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.048 1.869 . . . . 0.0 116.048 -170.919 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -95.86 120.97 37.07 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 164.468 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.7 t0 -104.1 132.6 50.19 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.224 1.41 . . . . 0.0 107.747 177.118 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 49.1 t -134.41 141.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -165.608 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 28.9 t -157.46 119.27 3.73 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.333 1.853 . . . . 0.0 111.021 170.614 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.453 ' HB ' HG12 ' A' ' 31' ' ' VAL . 46.4 mt -135.47 145.59 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 126.233 1.813 . . . . 0.0 110.467 179.707 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.98 126.43 53.83 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 125.641 1.576 . . . . 0.0 106.945 166.269 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.82 144.46 50.24 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.925 0.89 . . . . 0.0 112.924 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 10.8 p -119.97 50.74 1.25 Allowed 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -177.381 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.481 HG12 HH21 ' A' ' 79' ' ' ARG . 0.3 OUTLIER -154.72 6.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 N-CA-C 115.382 1.623 . . . . 0.0 115.382 168.642 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.64 152.79 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 O-C-N 120.77 -1.206 . . . . 0.0 109.851 177.726 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.565 ' HB2' HE21 ' A' ' 22' ' ' GLN . 52.4 p -155.43 179.3 9.31 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 120.982 -1.074 . . . . 0.0 112.691 -178.341 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.467 HD13 ' CB ' ' A' ' 22' ' ' GLN . 5.4 mp -81.72 48.35 1.19 Allowed 'General case' 0 CA--C 1.551 1.002 0 O-C-N 120.415 -1.428 . . . . 0.0 110.234 -174.571 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.9 t -88.16 43.92 1.16 Allowed 'General case' 0 CA--C 1.545 0.764 0 N-CA-C 114.922 1.453 . . . . 0.0 114.922 -168.454 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.19 -64.63 2.02 Favored Glycine 0 N--CA 1.475 1.248 0 C-N-CA 125.736 1.636 . . . . 0.0 116.072 168.249 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -149.41 16.67 0.92 Allowed 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 124.059 1.885 . . . . 0.0 110.595 -175.725 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 39.4 m-70 -126.31 5.7 7.02 Favored 'General case' 0 CA--C 1.545 0.771 0 O-C-N 120.004 -1.685 . . . . 0.0 112.873 -167.431 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB3' ' H ' ' A' ' 105' ' ' SER . 3.1 m -166.39 -103.12 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.74 1.216 . . . . 0.0 113.111 177.749 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 12.6 pt -117.72 28.13 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 CA-C-N 120.37 1.441 . . . . 0.0 113.679 -170.276 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.4 mm -133.48 146.58 31.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 127.725 2.41 . . . . 0.0 105.578 164.084 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 67.12 30.38 75.68 Favored Glycine 0 C--O 1.22 -0.748 0 CA-C-O 118.869 -0.962 . . . . 0.0 113.101 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 23.7 mtt-85 -135.28 176.9 8.25 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.835 1.254 . . . . 0.0 109.351 176.345 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.4 m -132.52 116.11 16.32 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 119.689 1.131 . . . . 0.0 110.94 -170.885 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 26.7 tp -89.83 132.86 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.629 1.172 . . . . 0.0 110.308 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 146' ' ' CYS . 4.9 p -124.23 150.26 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.027 1.331 . . . . 0.0 110.326 172.302 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -105.33 167.56 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-O 121.418 0.628 . . . . 0.0 110.823 167.06 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.72 127.69 37.35 Favored 'General case' 0 CA--C 1.547 0.849 0 O-C-N 120.942 -1.099 . . . . 0.0 110.697 -173.823 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pp20? -69.87 -10.13 57.38 Favored 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -169.55 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -107.93 162.1 14.33 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 114.442 1.275 . . . . 0.0 114.442 171.496 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.79 139.4 58.76 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.507 1.923 . . . . 0.0 109.792 167.081 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -111.3 148.84 32.05 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.849 2.059 . . . . 0.0 113.8 -171.815 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.342 13.3 t0 -101.93 -15.83 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 115.556 1.687 . . . . 0.0 115.556 -179.725 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt 56.26 81.0 0.13 Allowed 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.724 1.609 . . . . 0.0 114.061 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 97.9 -43.74 1.91 Allowed Glycine 0 N--CA 1.471 1.009 0 C-N-CA 125.275 1.417 . . . . 0.0 111.935 168.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -99.42 175.03 5.99 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.219 1.408 . . . . 0.0 110.204 167.604 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 131.02 -9.92 5.68 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 126.311 1.91 . . . . 0.0 114.116 -169.312 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.54 11.04 85.85 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 116.272 1.269 . . . . 0.0 116.272 168.394 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 13.9 p30 -138.82 174.52 10.43 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.891 1.276 . . . . 0.0 110.077 -178.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -65.69 -54.82 22.19 Favored 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 115.012 1.486 . . . . 0.0 115.012 -171.577 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.41 -26.54 42.32 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.661 -0.649 . . . . 0.0 111.883 176.291 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -54.38 -35.97 63.4 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 120.29 -1.506 . . . . 0.0 114.634 177.253 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -94.9 -28.16 15.33 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 124.423 1.089 . . . . 0.0 112.49 178.504 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.19 -65.25 0.98 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.018 0.827 . . . . 0.0 111.922 178.823 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.9 p -92.25 -24.31 19.04 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 126.56 1.944 . . . . 0.0 112.168 -171.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 101.58 16.51 24.23 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 124.533 1.063 . . . . 0.0 112.494 -168.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 73.09 4.54 4.96 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 126.566 1.946 . . . . 0.0 113.768 178.294 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -59.8 -10.96 4.36 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 -169.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.06 -30.07 0.53 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 128.507 2.956 . . . . 0.0 117.779 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.5 t -142.45 178.11 7.82 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.225 1.01 . . . . 0.0 110.469 -173.42 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.9 -175.58 2.81 Favored 'General case' 0 N--CA 1.473 0.725 0 O-C-N 120.59 -1.319 . . . . 0.0 110.102 -174.893 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.576 ' CD2' ' H ' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -170.1 -158.96 0.18 Allowed 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.76 2.024 . . . . 0.0 107.779 -176.07 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.576 ' H ' ' CD2' ' A' ' 144' ' ' LEU . . . -68.26 159.7 30.75 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 127.057 2.143 . . . . 0.0 113.321 178.347 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.421 ' HB3' HG23 ' A' ' 118' ' ' VAL . 31.4 p -147.58 162.52 38.94 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.269 1.427 . . . . 0.0 112.985 -177.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -158.28 161.0 31.35 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 126.614 2.054 . . . . 0.0 112.228 169.333 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 1.1 t -78.54 160.83 4.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 CA-C-N 119.25 1.525 . . . . 0.0 110.869 170.403 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -103.1 113.12 38.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 CA-C-N 118.834 0.743 . . . . 0.0 110.643 167.838 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -122.2 -178.61 15.7 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 125.604 1.573 . . . . 0.0 113.23 -178.435 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -111.95 123.05 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 113.958 1.096 . . . . 0.0 113.958 -170.704 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.464 ' HB3' ' HB3' ' A' ' 3' ' ' LYS . . . -75.12 -31.05 61.0 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 122.921 1.343 . . . . 0.0 107.787 163.033 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.237 0.438 0 C-N-CA 125.481 1.512 . . . . 0.0 112.27 166.937 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 46.2 m -80.73 109.61 15.43 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 105.724 -1.954 . . . . 0.0 105.724 168.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.451 ' HE3' ' HB1' ' B' ' 152' ' ' ALA . 0.2 OUTLIER -116.27 152.87 32.97 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 117.894 2.553 . . . . 0.0 117.894 -172.711 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.75 147.49 37.46 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 126.255 1.822 . . . . 0.0 108.886 168.571 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.05 157.29 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 123.459 0.704 . . . . 0.0 111.037 -166.918 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -133.54 139.61 46.7 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.658 1.183 . . . . 0.0 111.438 169.648 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 29.4 m -108.62 122.41 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 167.094 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . 0.521 ' CD2' HD12 ' B' ' 117' ' ' LEU . 4.7 mp -99.98 75.86 1.89 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -164.453 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -105.61 100.74 10.29 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.257 1.423 . . . . 0.0 110.364 173.076 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.47 15.69 0.48 Allowed Glycine 0 N--CA 1.477 1.412 0 N-CA-C 115.68 1.032 . . . . 0.0 115.68 -178.11 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -159.61 136.78 9.6 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.625 2.37 . . . . 0.0 107.457 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -23.28 -80.26 0.01 OUTLIER Glycine 0 CA--C 1.537 1.451 0 C-N-CA 128.487 2.946 . . . . 0.0 116.083 -168.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -86.72 4.27 6.36 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 124.192 3.261 . . . . 0.0 113.949 -177.557 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 36.0 t -105.38 129.83 57.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 CA-C-O 122.872 1.32 . . . . 0.0 109.721 -172.446 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.2 168.29 19.13 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 125.777 1.631 . . . . 0.0 107.911 171.869 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.17 176.42 33.6 Favored Glycine 0 N--CA 1.464 0.543 0 O-C-N 120.432 -1.417 . . . . 0.0 113.546 176.488 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 1.3 tp -158.31 103.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 126.687 1.995 . . . . 0.0 108.81 172.971 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.49 146.41 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 124.922 1.289 . . . . 0.0 111.594 176.636 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -119.12 168.99 10.32 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 127.268 2.227 . . . . 0.0 112.196 -171.034 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.38 98.86 3.21 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 127.263 2.225 . . . . 0.0 108.105 172.219 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -102.41 114.08 27.96 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 118.71 0.686 . . . . 0.0 111.581 -175.476 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 17.0 tt0 -91.64 132.48 36.31 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.221 1.008 . . . . 0.0 110.948 176.227 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 20.4 ptmt -84.02 -30.79 25.83 Favored 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 113.879 1.066 . . . . 0.0 113.879 179.349 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -162.17 144.73 11.37 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 127.19 2.196 . . . . 0.0 109.847 169.586 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 1.5 m -43.77 24.77 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 1 C-N-CA 137.957 6.503 . . . . 0.0 119.037 -174.767 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 3.6 p30 179.76 -24.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 128.371 2.668 . . . . 0.0 112.081 -170.194 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.6 165.11 54.3 Favored Glycine 0 CA--C 1.541 1.659 0 O-C-N 121.168 -0.958 . . . . 0.0 112.425 169.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -70.15 169.7 18.79 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 124.305 3.336 . . . . 0.0 113.12 -171.288 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 31.7 t -131.02 129.43 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.942 1.697 . . . . 0.0 110.503 -169.111 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 1.7 ttmp? -93.77 125.82 38.6 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-O 122.319 1.057 . . . . 0.0 109.902 170.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.06 128.16 39.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 C-N-CA 127.585 2.354 . . . . 0.0 108.071 169.44 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.2 p90 -153.39 158.26 41.19 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 171.646 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 137.83 -141.99 12.79 Favored Glycine 0 N--CA 1.463 0.456 0 C-N-CA 125.08 1.324 . . . . 0.0 111.51 176.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 99.0 p -155.02 162.13 41.16 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 117.987 2.588 . . . . 0.0 117.987 -167.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 19.4 mm -130.4 123.93 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.285 0 C-N-CA 126.567 1.947 . . . . 0.0 107.445 168.067 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 57.8 tttp -122.24 136.49 54.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 122.854 2.57 . . . . 0.0 110.731 -178.63 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.26 -8.77 5.65 Favored Glycine 0 N--CA 1.474 1.202 0 C-N-CA 126.47 1.986 . . . . 0.0 114.094 -178.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.435 HD22 ' CE1' ' B' ' 43' ' ' HIS . 33.4 mt -70.22 172.97 7.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.096 1.358 . . . . 0.0 111.638 170.625 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 11.8 t -110.77 157.73 19.46 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 162.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -59.03 162.04 4.59 Favored 'General case' 0 CA--C 1.537 0.442 0 N-CA-C 116.601 2.074 . . . . 0.0 116.601 -167.213 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.79 -179.15 34.07 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.671 -174.841 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.636 ' H ' HD23 ' B' ' 42' ' ' LEU . 2.2 pt? -75.64 144.21 41.81 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.533 1.533 . . . . 0.0 113.0 -169.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . 0.435 ' CE1' HD22 ' B' ' 38' ' ' LEU . 91.9 m-70 -140.37 170.14 16.37 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 126.948 2.099 . . . . 0.0 109.567 176.462 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -124.93 166.06 17.79 Favored Glycine 0 N--CA 1.478 1.486 0 C-N-CA 125.132 1.349 . . . . 0.0 113.148 -174.196 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 11.2 p90 -156.46 162.32 39.99 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.951 2.1 . . . . 0.0 112.82 172.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . 0.587 ' O ' HD22 ' B' ' 117' ' ' LEU . 46.7 p-80 -156.14 163.91 39.04 Favored 'General case' 0 C--N 1.347 0.468 0 O-C-N 120.583 -1.323 . . . . 0.0 108.835 168.797 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.483 HG22 ' CA ' ' B' ' 82' ' ' GLY . 0.5 OUTLIER -110.84 162.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 125.015 1.326 . . . . 0.0 108.857 -178.244 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 5.3 p80 -136.67 126.18 25.18 Favored 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 120.984 -1.072 . . . . 0.0 109.789 176.606 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -71.75 136.47 47.16 Favored 'General case' 0 N--CA 1.452 -0.357 0 O-C-N 123.932 0.77 . . . . 0.0 109.913 179.443 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 121.22 133.05 0.0 OUTLIER 'General case' 0 C--O 1.233 0.209 1 C-N-CA 133.958 4.903 . . . . 0.0 108.449 -176.149 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.42 2.89 61.15 Favored Glycine 0 C--O 1.222 -0.615 0 CA-C-O 118.211 -1.327 . . . . 0.0 114.019 178.717 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . . . . . . . . . 15.7 p-10 -103.13 51.58 0.79 Allowed 'General case' 0 CA--C 1.536 0.423 0 CA-C-N 120.24 2.02 . . . . 0.0 112.934 -179.15 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.1 37.73 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 126.669 1.987 . . . . 0.0 110.995 -171.472 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . . 44.3 p -61.8 47.02 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.504 1 C-N-CA 133.688 4.795 . . . . 0.0 115.948 -171.614 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -152.28 -21.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 126.882 2.073 . . . . 0.0 112.53 178.481 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.48 -161.89 12.69 Favored Glycine 0 C--N 1.344 0.992 0 CA-C-N 119.464 1.029 . . . . 0.0 113.298 170.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -52.78 1.17 0.01 OUTLIER 'General case' 0 CA--C 1.56 1.356 0 C-N-CA 128.213 2.605 . . . . 0.0 115.094 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 9.5 t -94.32 -11.85 29.21 Favored 'General case' 0 N--CA 1.481 1.088 0 O-C-N 119.193 -2.192 . . . . 0.0 112.896 168.051 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 75.0 m -132.86 0.26 3.5 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 125.023 1.329 . . . . 0.0 113.687 178.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -155.52 -176.49 5.97 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.343 1.857 . . . . 0.0 110.142 173.493 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.99 163.57 26.9 Favored Glycine 0 CA--C 1.544 1.897 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -173.201 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -66.09 125.29 13.86 Favored 'Trans proline' 0 C--N 1.352 0.716 0 C-N-CA 124.977 3.785 . . . . 0.0 111.322 178.378 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.318 1.9 p80 28.32 59.23 0.12 Allowed 'General case' 0 C--O 1.239 0.551 0 C-N-CA 130.278 3.431 . . . . 0.0 116.858 177.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -58.8 121.1 10.28 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 105.153 -2.166 . . . . 0.0 105.153 162.836 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -125.47 142.4 41.65 Favored Pre-proline 0 CA--C 1.543 0.683 0 C-N-CA 124.365 1.066 . . . . 0.0 113.799 -169.068 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -83.38 -15.08 7.8 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.323 2.682 . . . . 0.0 113.587 175.172 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 79.8 mt -93.88 -10.63 33.28 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 115.03 1.492 . . . . 0.0 115.03 -171.486 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 37.6 t 46.12 58.69 4.26 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 169.474 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 4.6 ptt180 -143.88 -174.96 4.4 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 127.899 2.48 . . . . 0.0 111.06 -175.611 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . 0.25 3.1 pttp -65.19 160.48 21.28 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 120.231 1.378 . . . . 0.0 112.706 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -96.95 138.62 34.21 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.777 -1.556 . . . . 0.0 113.326 -177.086 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 133.92 -151.33 20.19 Favored Glycine 0 C--N 1.334 0.451 0 C-N-CA 127.075 2.274 . . . . 0.0 109.456 170.49 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' B' ' 75' ' ' LYS . . . 169.25 -32.99 0.18 Allowed Glycine 0 CA--C 1.528 0.87 0 N-CA-C 119.722 2.649 . . . . 0.0 119.722 169.004 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.3 24.18 0.22 Allowed 'Trans proline' 0 CA--C 1.554 1.52 0 CA-C-N 122.97 3.385 . . . . 0.0 113.013 167.787 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' B' ' 73' ' ' GLY . 0.1 OUTLIER -168.59 -41.39 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 129.865 3.266 . . . . 0.0 107.245 166.427 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . 0.255 4.9 t70 -62.69 117.97 7.02 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 123.932 1.825 . . . . 0.0 109.599 -171.055 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 27.3 mp0 -72.48 -19.57 61.52 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 129.416 3.086 . . . . 0.0 114.471 -161.616 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -105.71 -65.21 1.08 Allowed 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.022 0.529 . . . . 0.0 111.197 176.798 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 76.77 126.72 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 125.181 1.393 . . . . 0.0 114.352 165.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -73.78 159.54 32.78 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 124.608 1.163 . . . . 0.0 113.015 168.106 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 57.9 t -61.86 -47.75 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 120.931 -1.106 . . . . 0.0 110.142 173.529 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . 0.483 ' CA ' HG22 ' B' ' 47' ' ' VAL . . . -77.56 31.38 1.67 Allowed Glycine 0 C--N 1.339 0.744 0 C-N-CA 124.865 1.221 . . . . 0.0 115.369 176.587 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -115.71 117.39 30.14 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 121.368 -1.078 . . . . 0.0 108.941 170.291 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 87.1 mt -140.72 131.68 26.1 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 102.455 -3.165 . . . . 0.0 102.455 168.743 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -93.69 -144.77 16.07 Favored Glycine 0 N--CA 1.47 0.941 0 N-CA-C 119.698 2.639 . . . . 0.0 119.698 -163.534 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . 0.425 HD21 ' HA ' ' B' ' 124' ' ' ASP . 93.4 m-20 -72.96 159.86 33.02 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -165.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.3 p -133.05 177.28 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 130.387 3.475 . . . . 0.0 110.093 -171.185 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -155.76 132.79 10.67 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 119.666 1.121 . . . . 0.0 111.356 174.998 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.46 160.5 15.41 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.342 1.057 . . . . 0.0 113.776 176.283 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -92.08 177.2 6.24 Favored 'General case' 0 CA--C 1.552 1.041 0 C-N-CA 127.186 2.194 . . . . 0.0 112.663 170.293 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.74 -17.58 64.94 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 120.913 -1.117 . . . . 0.0 112.958 169.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.81 -27.26 63.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.081 0.952 . . . . 0.0 110.449 168.838 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.97 -4.5 65.52 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 117.96 -1.467 . . . . 0.0 114.439 -177.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.99 131.06 35.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 118.736 1.268 . . . . 0.0 110.917 168.782 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -99.16 124.63 44.35 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 165.892 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -79.16 143.51 35.37 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 167.706 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.09 130.53 72.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.686 166.625 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 8.6 m -150.77 82.97 1.34 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.857 1.263 . . . . 0.0 110.537 -175.142 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 29.6 mt -130.91 142.48 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.605 1.562 . . . . 0.0 111.007 -172.671 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -100.69 145.14 28.82 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.356 1.862 . . . . 0.0 107.176 168.653 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.973 0.909 . . . . 0.0 109.432 169.609 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 55.6 p -131.31 51.96 2.1 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.225 1.01 . . . . 0.0 112.263 179.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 9.4 p -152.47 34.82 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 122.736 1.255 . . . . 0.0 111.43 169.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.1 172.17 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 126.688 1.995 . . . . 0.0 111.329 -169.655 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 4.8 m -159.78 153.76 23.2 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 120.817 -1.177 . . . . 0.0 112.685 169.275 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 6.7 mp -82.72 58.91 4.48 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.641 -1.287 . . . . 0.0 110.345 176.377 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 6.9 t -89.11 141.1 28.8 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.071 171.417 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -77.1 47.83 2.66 Favored Glycine 0 N--CA 1.474 1.217 0 C-N-CA 126.23 1.871 . . . . 0.0 115.584 -168.443 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -139.15 -90.98 0.19 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.847 2.459 . . . . 0.0 107.784 -170.398 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -150.45 -4.88 0.33 Allowed 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 127.878 2.471 . . . . 0.0 112.275 -171.004 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 4.5 t -69.34 -0.39 6.23 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.162 -1.586 . . . . 0.0 114.6 -174.979 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.5 7.5 pt 149.36 8.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 1 C-N-CA 135.667 5.587 . . . . 0.0 115.365 168.092 . . . . . . . . 3 2 . 1 . 026 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 48.9 mm -87.12 168.94 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 O-C-N 120.56 -1.337 . . . . 0.0 109.232 165.696 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 79.32 -33.39 2.02 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 117.849 1.899 . . . . 0.0 117.849 166.109 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 ptt85 -74.8 174.12 9.62 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 125.77 1.628 . . . . 0.0 112.043 -169.898 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.1 m -130.12 154.12 47.81 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.166 0.986 . . . . 0.0 109.699 -174.311 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' B' ' 46' ' ' HIS . 2.7 tm? -133.26 145.51 50.57 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 125.376 1.47 . . . . 0.0 111.505 -169.668 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.494 ' N ' HD13 ' B' ' 117' ' ' LEU . 6.7 p -128.14 135.76 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 126.194 1.797 . . . . 0.0 110.88 174.141 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 10.4 t -101.91 158.24 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 125.521 1.528 . . . . 0.0 108.392 169.858 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -128.21 153.25 47.12 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 127.799 2.44 . . . . 0.0 111.296 -173.115 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -75.32 -24.93 57.47 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.491 -178.819 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -100.54 171.16 7.9 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 119.704 1.138 . . . . 0.0 110.114 167.507 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -112.08 94.57 5.01 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 125.283 1.433 . . . . 0.0 111.925 -179.371 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.425 ' HA ' HD21 ' B' ' 86' ' ' ASN 0.267 25.5 t0 -152.97 146.92 25.36 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-O 123.561 1.648 . . . . 0.0 109.25 168.032 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -169.3 -52.27 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 130.467 3.507 . . . . 0.0 110.893 -178.245 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.585 ' H ' HD13 ' B' ' 126' ' ' LEU 0.338 0.0 OUTLIER -86.07 59.32 5.56 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 116.575 2.065 . . . . 0.0 116.575 -163.094 . . . . . . . . 4 4 . 1 . 026 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.44 -9.12 0.88 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 117.839 1.896 . . . . 0.0 117.839 166.5 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 5.3 ptmt -160.21 21.62 0.16 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 116.763 2.134 . . . . 0.0 116.763 -169.218 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.5 -19.38 78.95 Favored Glycine 0 N--CA 1.472 1.079 0 CA-C-N 120.26 1.391 . . . . 0.0 113.489 178.938 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -151.24 -42.24 0.02 OUTLIER Glycine 0 N--CA 1.468 0.83 0 N-CA-C 116.665 1.426 . . . . 0.0 116.665 -178.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -163.08 -165.31 1.08 Allowed 'General case' 0 CA--C 1.546 0.815 0 CA-C-N 120.201 2.0 . . . . 0.0 113.514 -173.448 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -49.27 -56.07 10.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.382 1.473 . . . . 0.0 110.876 169.043 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -60.23 -16.22 31.6 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 20.8 m -55.0 -31.79 61.28 Favored 'General case' 0 N--CA 1.471 0.594 0 O-C-N 120.091 -1.631 . . . . 0.0 112.702 168.527 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . 0.264 2.8 t -97.44 -8.49 29.23 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 174.08 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -87.68 -60.95 1.83 Allowed 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.289 -1.507 . . . . 0.0 111.202 169.009 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 28.5 p -102.87 -24.92 13.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 126.018 1.727 . . . . 0.0 114.413 -177.223 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 102.55 -22.87 35.95 Favored Glycine 0 C--O 1.213 -1.159 0 CA-C-O 117.93 -1.483 . . . . 0.0 110.075 -166.26 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 33.2 t30 56.83 19.11 4.22 Favored 'General case' 0 CA--C 1.548 0.875 0 CA-C-N 119.351 1.576 . . . . 0.0 112.387 173.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.76 -23.16 2.51 Favored 'General case' 0 CA--C 1.557 1.226 0 C-N-CA 129.079 2.952 . . . . 0.0 115.057 -171.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 93.94 -153.19 21.07 Favored Glycine 0 C--N 1.343 0.924 0 C-N-CA 126.692 2.091 . . . . 0.0 114.414 174.765 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.03 151.88 2.45 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 126.711 2.004 . . . . 0.0 113.481 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 15.1 mtp-105 -66.24 166.88 11.2 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.9 -1.125 . . . . 0.0 113.474 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tp -150.01 -152.6 0.45 Allowed 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 128.727 2.811 . . . . 0.0 106.911 166.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.29 178.3 7.23 Favored 'General case' 0 CA--C 1.543 0.674 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -178.668 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 5.5 p -158.16 159.18 35.89 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.107 1.363 . . . . 0.0 111.459 -173.28 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.38 170.52 34.53 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.696 1.617 . . . . 0.0 113.416 176.086 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 2.1 t -107.54 147.41 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.639 1.176 . . . . 0.0 110.007 179.346 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 11.2 mm -93.47 76.68 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.324 0.65 . . . . 0.0 110.042 -178.71 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -87.57 161.88 32.7 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 123.652 0.644 . . . . 0.0 112.225 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.48 ' N ' HD12 ' B' ' 151' ' ' ILE . 1.1 mp -75.05 134.87 28.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -175.452 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.451 ' HB1' ' HE3' ' B' ' 3' ' ' LYS . . . -108.82 35.13 3.34 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.461 1.504 . . . . 0.0 113.485 -168.735 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 . . . . . 0 C--N 1.324 -0.518 0 C-N-CA 126.633 1.973 . . . . 0.0 110.691 -177.31 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 118.221 -0.895 . . . . 0.0 108.826 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.0 m -79.71 79.6 6.19 Favored 'General case' 0 C--O 1.217 -0.648 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.294 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.9 ttmm -120.09 128.11 53.16 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -169.415 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.515 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -108.2 171.77 7.22 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.927 0.891 . . . . 0.0 112.921 169.407 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.417 HG11 ' HA ' ' B' ' 52' ' ' ASP . 0.3 OUTLIER -131.43 155.01 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 129.72 3.208 . . . . 0.0 106.908 165.97 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -125.25 114.81 19.45 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.738 1.154 . . . . 0.0 109.559 166.742 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' HG22 ' B' ' 54' ' ' THR . 8.7 t -88.57 76.42 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 125.185 1.394 . . . . 0.0 108.938 -171.91 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 10.6 mp -79.47 103.96 9.75 Favored 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.034 -175.018 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 ttpp -160.92 132.16 5.53 Favored 'General case' 0 N--CA 1.462 0.132 0 C-N-CA 123.274 0.63 . . . . 0.0 112.369 166.08 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -116.15 -95.5 1.94 Allowed Glycine 0 C--N 1.333 0.384 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 168.074 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.31 -177.1 3.41 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.013 1.725 . . . . 0.0 107.974 174.007 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 61.69 -173.55 7.32 Favored Glycine 0 CA--C 1.539 1.547 0 C-N-CA 126.732 2.11 . . . . 0.0 117.05 168.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.54 4.41 7.1 Favored 'Trans proline' 0 CA--C 1.543 0.941 1 C-N-CA 126.347 4.698 . . . . 0.0 113.836 178.593 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.6 m -79.43 138.03 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 126.848 2.059 . . . . 0.0 111.045 175.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.77 169.23 19.5 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 122.238 1.018 . . . . 0.0 109.801 165.707 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -141.17 149.01 20.71 Favored Glycine 0 CA--C 1.499 -0.92 0 CA-C-N 113.379 -1.737 . . . . 0.0 110.078 164.245 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -130.27 112.01 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 172.189 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.1 mm -135.61 102.44 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 121.469 -0.77 . . . . 0.0 111.077 -174.118 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -72.34 157.28 37.97 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.165 170.204 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.515 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 58.1 m-85 -137.22 98.71 3.8 Favored 'General case' 0 CA--C 1.537 0.477 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 168.867 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.6 tp10 -89.93 108.02 19.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 122.12 0.962 . . . . 0.0 109.75 172.291 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -101.58 149.03 24.53 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 166.104 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.07 -13.53 10.57 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.3 1.44 . . . . 0.0 112.253 -175.36 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.37 -146.06 0.37 Allowed 'General case' 0 CA--C 1.556 1.203 0 C-N-CA 128.919 2.887 . . . . 0.0 108.017 173.236 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.2 p -139.68 -45.84 0.44 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 126.009 1.723 . . . . 0.0 108.294 166.647 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.9 m-80 -85.76 32.45 0.59 Allowed 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.057 1.743 . . . . 0.0 112.722 172.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.91 -175.06 13.91 Favored Glycine 0 CA--C 1.538 1.499 0 C-N-CA 125.726 1.632 . . . . 0.0 113.002 177.404 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -76.54 170.99 18.87 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 123.82 3.013 . . . . 0.0 111.507 177.909 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.8 t -132.99 123.62 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.971 0.908 . . . . 0.0 110.31 -170.669 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.0 tttm -87.13 114.33 23.65 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 122.909 1.338 . . . . 0.0 112.621 177.238 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.9 t -95.25 131.1 42.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 125.941 1.696 . . . . 0.0 108.628 -176.646 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.8 p90 -153.38 160.3 42.61 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 173.653 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 130.08 -149.37 18.85 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 125.151 1.358 . . . . 0.0 111.521 -173.047 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 83.8 p -157.62 159.09 36.66 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 114.318 1.229 . . . . 0.0 114.318 -173.661 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -121.56 117.5 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 125.461 1.505 . . . . 0.0 107.331 171.863 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -128.88 151.82 49.2 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 126.146 1.779 . . . . 0.0 112.052 -165.165 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.58 10.88 82.73 Favored Glycine 0 CA--C 1.531 1.063 0 CA-C-O 118.773 -1.015 . . . . 0.0 113.785 -178.693 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.26 169.08 10.02 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 124.94 1.296 . . . . 0.0 111.0 173.332 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.6 t -69.83 160.13 32.33 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.77 1.228 . . . . 0.0 110.257 173.603 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.94 168.76 0.6 Allowed 'General case' 0 CA--C 1.55 0.961 0 N-CA-C 114.893 1.442 . . . . 0.0 114.893 178.611 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.6 -175.26 50.68 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 124.693 1.14 . . . . 0.0 113.472 170.141 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.465 ' H ' ' CD1' ' A' ' 42' ' ' LEU . 5.2 mp -56.14 147.04 21.37 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 127.728 2.411 . . . . 0.0 111.324 178.628 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -142.98 116.01 8.86 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 126.206 1.802 . . . . 0.0 110.187 176.004 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.53 151.45 14.35 Favored Glycine 0 N--CA 1.483 1.814 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.89 173.913 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -151.02 105.53 3.25 Favored 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 118.984 1.392 . . . . 0.0 111.089 -165.519 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.4 ' O ' HD12 ' A' ' 117' ' ' LEU . 11.8 m80 -145.57 160.18 42.03 Favored 'General case' 0 N--CA 1.471 0.597 0 O-C-N 119.431 -2.043 . . . . 0.0 113.909 -164.584 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . 0.288 0.4 OUTLIER -129.64 120.71 51.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 122.635 1.207 . . . . 0.0 111.489 -171.854 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -79.29 137.19 37.26 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 126.91 2.084 . . . . 0.0 109.785 175.829 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.0 pm0 -70.44 16.09 0.08 Allowed 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 116.06 1.874 . . . . 0.0 116.06 -178.232 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -126.75 144.23 51.01 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 124.425 1.09 . . . . 0.0 108.572 168.846 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.26 27.57 5.05 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.295 1.426 . . . . 0.0 111.539 168.38 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -86.94 173.1 9.55 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 125.432 1.493 . . . . 0.0 109.911 173.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.64 9.15 4.11 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 118.01 2.596 . . . . 0.0 118.01 164.561 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.4 t -61.3 71.32 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.244 2.217 . . . . 0.0 116.504 -168.57 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -141.84 -63.5 0.44 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 125.483 1.513 . . . . 0.0 112.804 168.068 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 166.59 -153.77 23.77 Favored Glycine 0 N--CA 1.47 0.911 0 O-C-N 120.761 -1.212 . . . . 0.0 112.52 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.6 t -56.11 -9.52 0.65 Allowed 'General case' 0 CA--C 1.552 1.022 0 N-CA-C 116.474 2.027 . . . . 0.0 116.474 -172.415 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 t -81.46 0.52 37.36 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.927 1.691 . . . . 0.0 113.256 173.725 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 60.9 m -159.39 178.42 9.94 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 126.564 1.945 . . . . 0.0 110.218 179.176 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 85.68 -125.73 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 126.502 1.921 . . . . 0.0 113.007 172.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 170.73 -153.9 21.83 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 125.677 1.608 . . . . 0.0 111.765 -169.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -109.32 57.58 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 123.619 2.879 . . . . 0.0 112.453 -174.547 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 61.95 87.83 0.09 Allowed 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.229 1.411 . . . . 0.0 108.338 -177.415 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -46.36 152.05 0.47 Allowed 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 113.15 -1.841 . . . . 0.0 111.447 -178.686 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.47 ' HB2' ' H ' ' A' ' 69' ' ' ARG . 39.8 p-10 -136.47 101.06 10.06 Favored Pre-proline 0 CA--C 1.551 1.018 0 N-CA-C 115.428 1.64 . . . . 0.0 115.428 -164.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.93 -27.78 3.64 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.25 1.967 . . . . 0.0 111.072 -176.171 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.25 -6.04 55.73 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 125.526 1.53 . . . . 0.0 111.683 167.761 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.7 t 62.69 48.16 4.4 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 126.98 2.112 . . . . 0.0 111.487 178.252 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.47 ' H ' ' HB2' ' A' ' 65' ' ' ASN . 11.9 mtp180 -99.02 170.63 8.58 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 124.475 1.11 . . . . 0.0 112.922 -172.54 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 33.6 mmtt -84.92 174.17 10.01 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.89 1.676 . . . . 0.0 108.614 163.55 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 62.8 t60 -70.6 149.87 46.63 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 120.782 -1.199 . . . . 0.0 112.066 170.301 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -174.51 -165.2 30.61 Favored Glycine 0 CA--C 1.534 1.25 0 C-N-CA 124.071 0.843 . . . . 0.0 114.035 176.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.481 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 131.92 -100.45 0.43 Allowed Glycine 0 CA--C 1.537 1.425 0 CA-C-O 117.571 -1.683 . . . . 0.0 116.811 170.001 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.51 -19.53 23.44 Favored 'Trans proline' 0 CA--C 1.543 0.944 0 CA-C-N 122.093 2.947 . . . . 0.0 116.377 -168.928 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.9 3.16 4.88 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 127.24 2.216 . . . . 0.0 112.594 176.06 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.481 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 10.3 t70 -145.88 155.7 43.06 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -164.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.57 -7.87 49.01 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 128.363 2.665 . . . . 0.0 113.402 -168.943 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -78.04 -106.39 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 118.696 0.68 . . . . 0.0 109.847 172.769 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.9 ttt180 71.58 101.01 0.07 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.166 1.386 . . . . 0.0 110.359 -172.392 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -51.8 152.67 2.82 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 120.789 -1.194 . . . . 0.0 111.298 166.527 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 19.3 m -52.88 -33.89 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-N 120.571 1.532 . . . . 0.0 112.785 -175.166 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -109.75 102.24 1.56 Allowed Glycine 0 CA--C 1.534 1.231 0 C-N-CA 124.696 1.141 . . . . 0.0 110.639 166.015 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -160.06 116.22 2.43 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 127.258 2.223 . . . . 0.0 108.775 177.524 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 92.0 mt -103.01 176.32 5.19 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.577 1.08 . . . . 0.0 108.973 168.148 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.15 173.81 54.97 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 167.342 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -74.65 151.49 39.3 Favored 'General case' 0 CA--C 1.55 0.973 0 N-CA-C 115.09 1.515 . . . . 0.0 115.09 -171.544 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 35.2 m -102.88 117.23 47.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 127.974 2.51 . . . . 0.0 109.732 179.07 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.9 m -96.82 119.45 35.31 Favored 'General case' 0 N--CA 1.478 0.948 0 O-C-N 120.531 -1.356 . . . . 0.0 111.234 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -79.39 140.13 37.52 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 114.91 1.448 . . . . 0.0 114.91 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -76.37 168.66 19.67 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.076 1.751 . . . . 0.0 111.798 170.62 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.8 pttm -45.74 -28.35 1.02 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.136 2.574 . . . . 0.0 115.135 170.822 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.73 -1.56 56.41 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.4 1.48 . . . . 0.0 111.818 -177.505 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 85.9 24.87 39.88 Favored Glycine 0 C--N 1.342 0.901 0 C-N-CA 125.274 1.416 . . . . 0.0 114.024 177.636 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.6 p -129.91 129.11 65.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 CA-C-N 118.497 1.148 . . . . 0.0 113.902 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -93.67 129.54 39.94 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.426 1.09 . . . . 0.0 108.129 166.076 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -79.16 151.02 31.53 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 106.557 -1.646 . . . . 0.0 106.557 167.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 1.6 t -135.04 123.87 41.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 CA-C-N 112.444 -2.162 . . . . 0.0 109.199 167.623 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.9 p -155.51 50.2 0.55 Allowed 'General case' 0 CA--C 1.554 1.106 0 CA-C-O 124.025 1.869 . . . . 0.0 111.357 -177.311 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 22.4 mt -103.45 170.44 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 127.603 2.361 . . . . 0.0 112.324 -166.48 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.94 121.48 20.57 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 165.622 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -98.17 137.17 37.32 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.478 0.656 . . . . 0.0 109.251 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 76.4 p -118.24 53.47 0.97 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.932 -1.031 . . . . 0.0 112.253 -178.709 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 13.8 p -155.18 -36.78 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.06 0.944 . . . . 0.0 112.629 168.71 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.71 168.97 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 120.115 1.325 . . . . 0.0 110.573 169.016 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 26.5 p -153.6 162.21 41.47 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 124.381 1.072 . . . . 0.0 111.335 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -83.94 66.39 9.13 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-O 122.185 0.993 . . . . 0.0 109.077 173.971 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 73.5 m -112.45 6.32 18.54 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.737 1.615 . . . . 0.0 113.713 -172.523 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 75.03 -110.91 3.19 Favored Glycine 0 C--N 1.342 0.871 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 175.4 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -62.49 -35.88 80.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 123.16 1.457 . . . . 0.0 112.776 -176.087 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -89.06 -1.79 58.26 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 114.389 -1.278 . . . . 0.0 111.603 -171.081 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 15.0 m -168.16 -103.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 126.218 1.807 . . . . 0.0 113.783 170.137 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 22.2 pt -124.09 164.35 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 120.972 1.714 . . . . 0.0 112.311 -176.78 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.2 mm 105.64 121.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.234 1 C-N-CA 133.859 4.864 . . . . 0.0 108.305 -167.832 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 64.17 32.86 85.59 Favored Glycine 0 CA--C 1.527 0.826 0 CA-C-O 119.057 -0.857 . . . . 0.0 113.179 -170.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.63 179.5 3.95 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 127.317 2.247 . . . . 0.0 108.323 173.577 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 21.1 m -130.6 119.35 22.36 Favored 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 121.944 2.157 . . . . 0.0 111.592 -179.078 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.4 HD12 ' O ' ' A' ' 46' ' ' HIS . 22.6 tp -92.35 119.25 31.73 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.554 1.542 . . . . 0.0 110.671 177.146 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.9 p -96.42 141.07 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.503 1.921 . . . . 0.0 111.111 174.647 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.9 p -118.08 137.34 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 122.046 0.927 . . . . 0.0 111.635 171.06 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 143' ' ' ARG . 87.5 m-70 -99.72 161.95 13.3 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 125.231 1.412 . . . . 0.0 113.23 -170.128 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -83.7 -23.81 31.53 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -169.596 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -142.65 -174.85 4.27 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.737 0.815 . . . . 0.0 113.032 176.297 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -50.66 143.7 9.17 Favored 'General case' 0 C--N 1.341 0.206 0 C-N-CA 126.013 1.725 . . . . 0.0 111.215 172.163 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.99 149.6 24.07 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.789 1.636 . . . . 0.0 112.225 173.717 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -76.24 -10.05 59.11 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.762 173.192 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 53.2 mt 48.01 32.95 3.13 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 128.229 2.612 . . . . 0.0 113.235 177.175 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 165.63 -61.49 0.23 Allowed Glycine 0 N--CA 1.467 0.702 0 CA-C-N 120.492 1.496 . . . . 0.0 115.165 175.3 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 1.8 ttpm? -157.95 98.49 1.62 Allowed 'General case' 0 N--CA 1.428 -1.542 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 177.688 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.572 ' H ' ' HB3' ' A' ' 134' ' ' SER . . . -76.56 -115.12 0.14 Allowed Glycine 0 CA--C 1.533 1.195 0 C-N-CA 126.222 1.868 . . . . 0.0 109.505 165.084 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -142.86 9.0 2.28 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 119.585 2.594 . . . . 0.0 119.585 -168.795 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -145.22 -169.38 3.19 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 120.651 2.226 . . . . 0.0 112.308 176.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -62.18 -49.87 74.07 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 121.173 1.806 . . . . 0.0 112.271 178.24 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.38 -22.85 63.8 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 123.439 0.696 . . . . 0.0 112.007 -177.65 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.572 ' HB3' ' H ' ' A' ' 129' ' ' GLY . 25.2 m -64.37 -5.4 5.14 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.954 1.465 . . . . 0.0 114.954 168.193 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -122.35 -20.11 6.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.342 1.457 . . . . 0.0 112.029 172.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 85.7 mttt -84.2 -69.85 0.61 Allowed 'General case' 0 CA--C 1.547 0.839 0 O-C-N 120.983 -1.073 . . . . 0.0 111.752 172.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 35.3 p -92.11 -13.45 30.74 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 116.011 1.856 . . . . 0.0 116.011 177.646 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 83.5 21.72 57.71 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 119.454 1.024 . . . . 0.0 110.855 -165.716 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 52.15 36.23 18.62 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 126.596 1.958 . . . . 0.0 113.7 176.848 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.1 40.61 0.08 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 116.136 1.902 . . . . 0.0 116.136 -168.799 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 73.91 -64.06 1.95 Allowed Glycine 0 CA--C 1.528 0.865 0 C-N-CA 126.53 2.014 . . . . 0.0 112.469 -171.543 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 29.9 t -177.07 -150.45 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 C-N-CA 126.809 2.044 . . . . 0.0 109.547 -171.262 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.439 ' HA ' ' HA ' ' A' ' 120' ' ' HIS . 0.0 OUTLIER -156.83 104.57 2.14 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.959 2.104 . . . . 0.0 112.479 -176.77 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 1.2 pp -72.85 -35.57 67.25 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.222 1.409 . . . . 0.0 114.653 -176.613 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -167.39 172.85 9.3 Favored 'General case' 0 C--O 1.239 0.54 0 C-N-CA 124.904 1.282 . . . . 0.0 111.767 -175.77 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 13.0 p -156.43 165.72 35.51 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 127.225 2.21 . . . . 0.0 111.048 175.15 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.45 147.28 15.56 Favored Glycine 0 C--N 1.337 0.617 0 C-N-CA 124.58 1.086 . . . . 0.0 114.036 -175.042 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -73.12 141.37 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 123.051 0.541 . . . . 0.0 110.124 175.017 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.5 mp -77.78 80.0 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.535 1.134 . . . . 0.0 109.506 169.384 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -79.36 171.34 54.83 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.084 1.325 . . . . 0.0 112.485 172.472 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.464 ' H ' ' HA3' ' B' ' 51' ' ' GLY . 2.4 mp -102.05 131.25 50.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 C-N-CA 126.142 1.777 . . . . 0.0 111.435 -169.478 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -121.62 37.84 4.25 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 126.975 2.11 . . . . 0.0 110.706 -179.662 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.549 0 C-N-CA 129.353 3.061 . . . . 0.0 115.072 -167.525 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 121.786 0.803 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.93 106.22 4.05 Favored 'General case' 0 CA--C 1.515 -0.374 0 C-N-CA 124.428 1.091 . . . . 0.0 109.359 169.778 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.8 118.22 21.39 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 170.058 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.04 168.85 18.66 Favored 'General case' 0 CA--C 1.54 0.568 0 O-C-N 120.641 -1.287 . . . . 0.0 108.51 163.576 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.67 155.35 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.8 0.81 . . . . 0.0 113.026 -166.388 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -150.24 143.49 25.0 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 127.389 2.276 . . . . 0.0 107.386 165.757 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 10.1 m -113.05 117.79 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 168.098 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.89 125.99 33.74 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.064 0.946 . . . . 0.0 109.863 -168.848 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -146.2 177.08 9.26 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.354 1.062 . . . . 0.0 113.507 170.651 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.12 -65.97 0.25 Allowed Glycine 0 C--N 1.33 0.201 0 C-N-CA 126.497 1.999 . . . . 0.0 109.024 -176.666 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -103.09 85.01 2.43 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 126.966 2.106 . . . . 0.0 112.797 -167.165 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 37.06 -98.43 0.01 OUTLIER Glycine 0 CA--C 1.537 1.467 0 C-N-CA 127.071 2.272 . . . . 0.0 115.98 167.785 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -77.06 -8.69 17.77 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.617 2.878 . . . . 0.0 115.433 -173.549 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -98.31 138.82 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 CA-C-N 121.061 1.755 . . . . 0.0 110.866 176.14 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.5 pm0 -160.16 166.07 30.43 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 125.43 1.492 . . . . 0.0 110.801 171.255 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -156.31 175.61 33.94 Favored Glycine 0 CA--C 1.507 -0.422 0 C-N-CA 123.283 0.468 . . . . 0.0 113.398 169.227 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.02 146.62 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 123.445 0.698 . . . . 0.0 110.114 169.561 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.17 155.2 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 123.807 0.843 . . . . 0.0 110.108 167.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -127.67 148.32 50.39 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.8 1.24 . . . . 0.0 109.669 167.735 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -128.16 97.79 4.88 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.369 1.468 . . . . 0.0 110.395 178.563 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -81.36 106.53 13.4 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.367 1.067 . . . . 0.0 113.62 -176.148 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -101.7 140.57 35.82 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 106.248 -1.76 . . . . 0.0 106.248 165.298 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.33 -13.47 9.28 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 125.933 1.693 . . . . 0.0 112.361 169.782 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -97.45 -145.01 0.3 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 131.019 3.728 . . . . 0.0 109.772 173.089 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 57.7 m -163.61 40.57 0.09 Allowed 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 127.883 2.473 . . . . 0.0 107.772 168.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 1.9 p30 178.02 -42.51 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 126.682 1.993 . . . . 0.0 112.436 -167.133 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.86 -168.46 21.74 Favored Glycine 0 CA--C 1.538 1.501 0 C-N-CA 125.333 1.444 . . . . 0.0 113.435 178.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -66.42 172.43 9.07 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 124.381 3.387 . . . . 0.0 114.554 -169.741 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 65.2 t -140.95 133.59 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 123.994 0.918 . . . . 0.0 111.391 177.954 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 49.0 mttp -80.18 116.95 20.56 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.285 0.564 . . . . 0.0 110.449 169.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 87.1 t -98.95 114.49 36.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 125.547 1.539 . . . . 0.0 109.099 170.057 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 4.3 p90 -137.28 154.87 50.01 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 123.529 0.731 . . . . 0.0 111.676 169.887 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 159.92 166.8 19.51 Favored Glycine 0 C--N 1.336 0.576 0 N-CA-C 114.82 0.688 . . . . 0.0 114.82 177.806 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 13.0 p -132.52 126.69 33.5 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.278 1.031 . . . . 0.0 111.3 -170.072 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 3.0 mm -112.77 125.38 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 C-N-CA 124.984 1.314 . . . . 0.0 111.14 174.772 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -130.53 135.62 48.11 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 120.575 1.534 . . . . 0.0 112.737 -169.096 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.74 -4.48 10.79 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 126.197 1.856 . . . . 0.0 114.058 -176.494 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.516 HD13 ' H ' ' B' ' 38' ' ' LEU . 0.0 OUTLIER -95.16 168.8 10.53 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.866 1.667 . . . . 0.0 111.724 170.464 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.3 m -69.36 152.77 44.55 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 127.18 2.192 . . . . 0.0 111.859 177.064 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . 0.422 ' HA ' ' HB3' ' B' ' 89' ' ' ALA . 9.6 pm0 -51.95 157.07 1.34 Allowed 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 125.867 1.667 . . . . 0.0 113.52 169.257 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.73 177.56 43.96 Favored Glycine 0 CA--C 1.539 1.555 0 O-C-N 120.653 -1.279 . . . . 0.0 114.567 -176.614 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 147.58 21.32 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 128.035 2.534 . . . . 0.0 114.635 -176.071 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -144.51 130.45 19.35 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 127.068 2.147 . . . . 0.0 109.737 175.643 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.39 156.31 31.93 Favored Glycine 0 N--CA 1.476 1.305 0 C-N-CA 125.001 1.286 . . . . 0.0 113.694 -175.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -150.4 141.09 22.66 Favored 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 -170.025 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -145.43 115.9 7.6 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 118.234 -0.889 . . . . 0.0 113.303 -170.136 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . 0.578 HG12 ' HB3' ' B' ' 115' ' ' ARG . 0.3 OUTLIER -87.85 98.24 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 167.794 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.419 ' CE1' ' HA ' ' B' ' 62' ' ' PRO . 45.4 m170 -73.83 151.43 40.54 Favored 'General case' 0 N--CA 1.471 0.611 0 O-C-N 121.657 -0.652 . . . . 0.0 111.703 -170.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -49.93 126.19 13.64 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 126.017 1.727 . . . . 0.0 113.005 174.181 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 93.24 147.28 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 130.54 3.536 . . . . 0.0 114.443 172.128 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.464 ' HA3' ' H ' ' A' ' 151' ' ' ILE . . . -77.55 -7.5 87.14 Favored Glycine 0 CA--C 1.533 1.201 0 CA-C-O 117.558 -1.69 . . . . 0.0 113.096 168.257 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.417 ' HA ' HG11 ' A' ' 5' ' ' VAL . 14.4 t0 -86.39 132.1 34.04 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 120.313 2.056 . . . . 0.0 109.506 167.774 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.404 HD22 ' N ' ' B' ' 53' ' ' ASN 0.317 0.0 OUTLIER -157.85 28.33 0.27 Allowed 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 114.981 1.475 . . . . 0.0 114.981 179.243 . . . . . . . . 4 4 . 1 . 027 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.527 HG22 ' HA ' ' A' ' 7' ' ' VAL . 17.9 p -102.13 -22.71 14.16 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -168.4 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.73 6.45 47.46 Favored 'General case' 0 CA--C 1.551 0.992 0 C-N-CA 123.853 0.861 . . . . 0.0 110.694 165.885 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 68.57 -110.81 3.59 Favored Glycine 0 C--N 1.34 0.798 0 C-N-CA 125.038 1.304 . . . . 0.0 111.775 171.578 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 72.1 m -71.03 -11.44 60.97 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -171.287 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 12.4 t -102.06 1.62 36.63 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 124.569 1.147 . . . . 0.0 113.101 169.368 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 68.6 m -99.9 -125.72 0.17 Allowed 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 124.846 1.258 . . . . 0.0 108.098 168.176 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.86 83.31 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.744 1.618 . . . . 0.0 114.297 171.743 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.07 167.23 27.09 Favored Glycine 0 CA--C 1.542 1.722 0 C-N-CA 125.174 1.369 . . . . 0.0 113.758 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . 0.419 ' HA ' ' CE1' ' B' ' 48' ' ' HIS . 59.9 Cg_endo -64.74 89.95 0.18 Allowed 'Trans proline' 0 C--N 1.354 0.824 1 C-N-CA 125.881 4.387 . . . . 0.0 112.248 -170.097 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . 0.379 0.1 OUTLIER 47.94 59.67 4.06 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 127.167 2.187 . . . . 0.0 113.79 175.85 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -47.72 129.88 14.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 111.884 -2.417 . . . . 0.0 109.541 168.034 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -110.21 66.33 0.44 Allowed Pre-proline 0 CA--C 1.549 0.931 0 C-N-CA 125.964 1.706 . . . . 0.0 114.823 -167.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -64.16 -21.04 67.84 Favored 'Trans proline' 0 C--N 1.353 0.771 0 C-N-CA 123.002 2.468 . . . . 0.0 116.045 -169.417 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -78.38 -4.44 48.19 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.795 0.838 . . . . 0.0 112.703 172.488 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 25.0 t 67.36 46.99 1.34 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 128.691 2.797 . . . . 0.0 110.513 -179.107 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 24.8 mtm-85 -109.5 167.1 10.38 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.842 -1.072 . . . . 0.0 112.059 -177.658 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -85.85 176.84 7.87 Favored 'General case' 0 C--N 1.317 -0.805 0 C-N-CA 127.657 2.383 . . . . 0.0 108.175 167.016 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 21.9 t60 -62.63 175.21 0.84 Allowed 'General case' 0 CA--C 1.544 0.745 0 O-C-N 121.336 -0.852 . . . . 0.0 112.812 173.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.68 -149.79 20.75 Favored Glycine 0 C--N 1.339 0.718 0 N-CA-C 115.641 1.016 . . . . 0.0 115.641 170.386 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.86 -117.3 2.17 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 125.727 1.632 . . . . 0.0 112.755 -179.888 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -65.01 -11.37 29.5 Favored 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.786 2.991 . . . . 0.0 116.075 -169.305 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.53 -3.13 10.92 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 119.534 1.061 . . . . 0.0 113.145 168.737 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -152.17 98.03 2.37 Favored 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -166.783 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 63.9 mm-40 -39.72 -4.99 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 131.32 3.848 . . . . 0.0 118.47 171.316 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -74.0 -75.95 0.14 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 121.021 1.737 . . . . 0.0 110.116 170.522 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.254 0.0 OUTLIER 52.76 107.02 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 127.326 2.251 . . . . 0.0 113.869 -177.595 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -54.53 143.79 23.3 Favored 'General case' 0 CA--C 1.552 1.028 0 O-C-N 119.631 -1.918 . . . . 0.0 110.525 166.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 96.9 t -35.36 -59.26 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 N-CA-C 116.128 1.899 . . . . 0.0 116.128 -168.123 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.78 18.71 16.68 Favored Glycine 0 N--CA 1.468 0.801 0 CA-C-O 119.335 -0.703 . . . . 0.0 112.989 176.831 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.46 89.68 2.88 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-N 119.526 1.663 . . . . 0.0 111.775 -167.633 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.11 163.35 37.71 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 114.634 -1.166 . . . . 0.0 113.578 -167.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . 78.25 170.37 36.47 Favored Glycine 0 N--CA 1.472 1.044 0 N-CA-C 115.274 0.87 . . . . 0.0 115.274 168.46 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . 0.446 HD21 ' HB2' ' B' ' 124' ' ' ASP . 1.3 m-80 -134.48 149.54 50.73 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.908 1.283 . . . . 0.0 109.969 174.827 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 29.5 m -112.53 129.31 68.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.884 1.674 . . . . 0.0 109.204 169.505 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 22.7 m -113.15 133.81 54.86 Favored 'General case' 0 N--CA 1.475 0.775 0 O-C-N 121.24 -0.913 . . . . 0.0 109.903 -170.119 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.422 ' HB3' ' HA ' ' B' ' 40' ' ' GLU . . . -88.15 137.3 32.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.711 1.204 . . . . 0.0 113.522 -178.212 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -77.86 -59.25 2.86 Favored 'General case' 0 CA--C 1.549 0.908 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -168.212 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 172.81 -40.88 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 128.405 2.682 . . . . 0.0 110.731 -166.047 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -78.25 13.2 1.58 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 125.877 1.671 . . . . 0.0 112.281 174.154 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.77 25.56 70.57 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-O 118.932 -0.927 . . . . 0.0 113.38 -177.242 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' B' ' 89' ' ' ALA . 7.4 p -105.96 109.52 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 C-N-CA 126.338 1.855 . . . . 0.0 110.991 176.155 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -79.28 108.84 13.08 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 168.175 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -110.53 159.04 17.88 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 122.313 1.054 . . . . 0.0 112.273 -176.412 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -149.6 148.0 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 CA-C-N 113.62 -1.627 . . . . 0.0 115.302 176.91 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.0 t -157.77 98.61 1.65 Allowed 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 124.2 1.0 . . . . 0.0 112.306 169.687 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 15.2 mt -139.7 152.3 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 C-N-CA 127.522 2.329 . . . . 0.0 110.876 -172.746 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -117.53 127.23 53.78 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 165.855 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -117.28 146.49 43.28 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.517 1.527 . . . . 0.0 111.049 176.097 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 51.31 0.95 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.495 0.718 . . . . 0.0 112.913 177.683 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 47.2 t -136.39 -50.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 125.252 1.421 . . . . 0.0 109.635 175.336 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -79.62 156.84 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 CA-C-N 119.128 0.877 . . . . 0.0 111.747 174.656 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.88 161.66 39.67 Favored 'General case' 0 N--CA 1.474 0.759 0 O-C-N 119.888 -1.758 . . . . 0.0 111.251 -178.453 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 9.8 mp -77.83 58.46 1.89 Allowed 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 122.88 1.324 . . . . 0.0 110.602 177.257 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.31 160.6 20.67 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 124.544 1.137 . . . . 0.0 108.8 168.128 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.25 -59.0 10.15 Favored Glycine 0 N--CA 1.477 1.4 0 N-CA-C 119.612 2.605 . . . . 0.0 119.612 -163.21 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -148.94 34.87 0.75 Allowed 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 122.862 1.315 . . . . 0.0 110.745 -172.142 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -158.01 4.08 0.12 Allowed 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 114.957 1.466 . . . . 0.0 114.957 -168.759 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 10.6 t -133.28 -91.21 0.37 Allowed 'General case' 0 N--CA 1.48 1.031 0 O-C-N 119.984 -1.698 . . . . 0.0 109.634 -178.313 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.283 5.4 pt -120.26 -14.66 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-N 121.185 1.811 . . . . 0.0 115.696 166.861 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm -82.75 152.64 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 161.122 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 68.05 41.71 86.58 Favored Glycine 0 N--CA 1.467 0.703 0 C-N-CA 124.103 0.858 . . . . 0.0 112.401 -176.446 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . 0.578 ' HB3' HG12 ' B' ' 47' ' ' VAL . 1.3 mpt_? -144.88 171.16 14.82 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 127.242 2.217 . . . . 0.0 109.004 172.17 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.5 t -139.42 122.66 16.98 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.873 -1.142 . . . . 0.0 110.979 -177.694 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 39.8 tp -92.07 108.87 20.25 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -169.464 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.8 p -90.62 142.35 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 125.32 1.448 . . . . 0.0 110.117 168.136 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.2 p -120.66 146.09 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.458 0.646 . . . . 0.0 111.316 172.012 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . 0.41 ' HA ' ' HA ' ' B' ' 143' ' ' ARG . 92.0 m-70 -105.63 141.37 37.2 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.56 1.544 . . . . 0.0 114.369 -168.728 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . 0.317 0.2 OUTLIER -72.03 -18.39 61.96 Favored 'General case' 0 N--CA 1.476 0.843 0 O-C-N 120.841 -1.162 . . . . 0.0 112.037 178.24 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 14.5 mttp -104.29 162.92 12.79 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 124.466 1.106 . . . . 0.0 112.759 168.067 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.0 165.08 9.44 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.308 1.843 . . . . 0.0 110.789 167.046 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . 0.54 ' HB3' ' H ' ' B' ' 126' ' ' LEU . 12.4 m-20 -95.2 158.9 15.26 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 122.126 0.965 . . . . 0.0 113.177 169.712 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.34 -7.9 50.2 Favored 'General case' 0 CA--C 1.557 1.22 0 CA-C-N 113.715 -1.584 . . . . 0.0 112.561 167.026 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.54 ' H ' ' HB3' ' B' ' 124' ' ' ASP . 96.3 mt 33.11 44.91 0.06 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 129.543 3.137 . . . . 0.0 114.068 -174.737 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 132.67 -52.38 0.83 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 115.854 1.101 . . . . 0.0 115.854 168.773 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -155.99 80.94 1.0 Allowed 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 117.046 2.239 . . . . 0.0 117.046 -169.22 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . 0.593 ' H ' ' HB3' ' B' ' 134' ' ' SER . . . -80.2 -115.02 0.29 Allowed Glycine 0 CA--C 1.524 0.625 0 C-N-CA 124.076 0.846 . . . . 0.0 111.009 166.389 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -137.9 11.72 3.65 Favored Glycine 0 N--CA 1.472 1.071 0 N-CA-C 116.893 1.517 . . . . 0.0 116.893 -169.338 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -144.12 174.84 10.52 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 119.819 1.81 . . . . 0.0 111.765 177.65 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . 0.526 ' CG ' ' HE3' ' B' ' 136' ' ' LYS . 3.2 tp10 -51.59 -64.27 0.87 Allowed 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.463 1.505 . . . . 0.0 112.574 173.08 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -53.18 -31.15 41.29 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -179.638 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . 0.593 ' HB3' ' H ' ' B' ' 129' ' ' GLY . 26.1 m -49.69 -39.23 36.09 Favored 'General case' 0 N--CA 1.478 0.96 0 CA-C-N 120.832 1.651 . . . . 0.0 113.969 170.773 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.76 -58.32 2.14 Favored 'General case' 0 CA--C 1.52 -0.205 0 C-N-CA 127.191 2.196 . . . . 0.0 110.294 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.526 ' HE3' ' CG ' ' B' ' 132' ' ' GLU . 22.2 ttpp -61.98 -39.62 92.81 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.1 1.36 . . . . 0.0 113.47 -172.197 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 1.2 p -109.4 -79.04 0.58 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 119.523 1.056 . . . . 0.0 110.179 174.079 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 170.71 11.9 0.02 OUTLIER Glycine 0 CA--C 1.54 1.65 1 C-N-CA 131.625 4.44 . . . . 0.0 115.389 -179.006 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 58.97 -35.67 0.06 Allowed 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 128.831 2.852 . . . . 0.0 117.257 -170.688 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -38.79 -44.19 1.0 Allowed 'General case' 0 CA--C 1.554 1.113 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -165.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.57 -82.05 1.53 Allowed Glycine 0 C--N 1.341 0.829 0 N-CA-C 117.108 1.603 . . . . 0.0 117.108 164.264 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 21.3 t -80.78 151.62 28.69 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 123.817 0.847 . . . . 0.0 111.143 -169.083 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' B' ' 120' ' ' HIS . 0.0 OUTLIER -144.49 159.53 42.62 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 119.728 1.149 . . . . 0.0 113.966 -168.539 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.22 -9.07 2.0 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 125.574 1.796 . . . . 0.0 115.524 -171.39 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -173.3 149.42 1.75 Allowed 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.354 1.062 . . . . 0.0 111.12 -177.657 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 30.0 t -148.31 150.83 34.32 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 125.673 1.589 . . . . 0.0 111.413 177.712 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -156.9 138.03 5.71 Favored Glycine 0 N--CA 1.474 1.191 0 CA-C-N 119.367 0.985 . . . . 0.0 114.55 175.192 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -74.28 144.54 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.351 0.66 . . . . 0.0 111.264 -179.644 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 13.3 mm -84.65 105.97 14.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 CA-C-O 121.635 0.731 . . . . 0.0 111.764 179.291 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -113.87 -175.73 19.06 Favored Glycine 0 CA--C 1.534 1.262 0 C-N-CA 125.07 1.319 . . . . 0.0 111.456 168.235 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 3.9 mp -122.32 132.49 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 O-C-N 121.105 -1.233 . . . . 0.0 110.772 -169.732 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 -7.93 16.21 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.056 1.343 . . . . 0.0 113.071 171.145 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . 0.305 0.7 OUTLIER . . . . . 0 C--O 1.238 0.451 0 C-N-CA 126.358 1.863 . . . . 0.0 112.734 -179.443 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.69 0 CA-C-O 116.0 -1.952 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -91.94 77.56 5.42 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 122.671 2.487 . . . . 0.0 111.646 -169.677 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -75.91 161.66 28.77 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -167.655 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -135.44 164.2 28.32 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.996 1.318 . . . . 0.0 110.255 168.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.547 ' CG1' ' HA ' ' B' ' 52' ' ' ASP . 7.3 p -132.61 129.56 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 124.612 1.165 . . . . 0.0 109.265 -179.027 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.81 110.72 15.44 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 120.994 -1.066 . . . . 0.0 109.179 177.869 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' B' ' 54' ' ' THR . 3.8 t -81.17 60.26 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 123.997 0.919 . . . . 0.0 111.563 -169.087 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.2 mp -76.72 116.87 17.78 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -167.779 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.422 ' CE ' HG12 ' A' ' 7' ' ' VAL . 34.4 mtmt -145.95 175.09 10.7 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 125.453 1.501 . . . . 0.0 111.896 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.92 -3.56 7.96 Favored Glycine 0 N--CA 1.474 1.233 0 N-CA-C 119.902 2.721 . . . . 0.0 119.902 166.832 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -137.29 83.11 1.97 Allowed 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 121.607 2.704 . . . . 0.0 110.163 178.827 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 38.44 -105.99 0.05 OUTLIER Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.522 2.011 . . . . 0.0 114.032 179.482 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -73.66 -5.84 17.73 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 124.279 3.32 . . . . 0.0 113.954 -176.25 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.4 ' C ' HE21 ' A' ' 15' ' ' GLN . 16.1 t -94.06 126.65 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 125.066 1.346 . . . . 0.0 111.699 -177.347 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.4 HE21 ' C ' ' A' ' 14' ' ' VAL . 1.2 mp0 -146.61 168.32 21.58 Favored 'General case' 0 CA--C 1.52 -0.197 0 C-N-CA 126.818 2.047 . . . . 0.0 108.01 169.457 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -142.23 170.91 24.82 Favored Glycine 0 CA--C 1.507 -0.413 0 CA-C-N 115.224 -0.898 . . . . 0.0 112.606 168.317 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 pt -150.34 53.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 114.195 -1.002 . . . . 0.0 111.169 -167.657 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.6 mm -80.35 112.23 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 O-C-N 120.984 -1.072 . . . . 0.0 110.348 -169.447 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -78.09 149.23 33.93 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 125.18 1.392 . . . . 0.0 111.491 175.969 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -134.51 116.24 14.85 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 126.299 1.84 . . . . 0.0 108.641 178.099 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -97.97 112.38 24.34 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.919 1.288 . . . . 0.0 112.255 175.329 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 34.4 tp60 -107.4 129.32 54.94 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 125.338 1.455 . . . . 0.0 109.226 177.968 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.53 -48.99 6.94 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.85 0.86 . . . . 0.0 111.447 178.784 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.63 136.46 51.67 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 127.302 2.241 . . . . 0.0 108.933 174.695 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.8 m -62.55 0.62 0.46 Allowed 'General case' 0 N--CA 1.48 1.05 0 N-CA-C 117.594 2.442 . . . . 0.0 117.594 -168.919 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 16.6 m-80 -114.22 -9.89 12.81 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 127.727 2.411 . . . . 0.0 113.9 178.033 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.6 -178.09 33.9 Favored Glycine 0 CA--C 1.537 1.424 0 CA-C-N 119.491 1.041 . . . . 0.0 115.053 -169.372 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -70.82 160.09 50.51 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.592 3.528 . . . . 0.0 110.898 -178.486 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 94.9 t -129.81 138.04 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 O-C-N 121.929 -0.482 . . . . 0.0 111.083 -170.68 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 100' ' ' GLU . 78.2 mttt -86.37 121.11 28.47 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 168.745 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.4 t -109.87 121.46 62.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.969 2.107 . . . . 0.0 108.692 -177.571 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -148.25 165.04 32.18 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 177.541 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.84 -173.37 14.67 Favored Glycine 0 N--CA 1.468 0.828 0 O-C-N 121.431 -0.793 . . . . 0.0 112.333 -178.741 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.85 167.32 21.98 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 116.826 2.158 . . . . 0.0 116.826 -164.916 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -125.11 129.67 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 127.408 2.283 . . . . 0.0 108.421 171.709 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 44.8 pttt -115.33 159.01 21.59 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 120.316 1.416 . . . . 0.0 111.796 -172.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.94 -6.97 73.4 Favored Glycine 0 N--CA 1.475 1.253 0 C-N-CA 125.371 1.462 . . . . 0.0 114.517 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 8.2 mp -62.86 153.17 34.07 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.872 2.069 . . . . 0.0 111.583 173.066 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 14.2 t -78.75 158.6 28.23 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 166.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -55.21 143.49 27.54 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.472 0.709 . . . . 0.0 112.87 175.607 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 106.09 -176.14 21.74 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 123.992 0.806 . . . . 0.0 114.84 177.44 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mp -68.29 139.19 55.93 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 127.775 2.43 . . . . 0.0 113.247 -171.124 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -145.45 120.37 9.99 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 128.565 2.746 . . . . 0.0 110.349 -174.711 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.98 22.88 Favored Glycine 0 N--CA 1.482 1.73 0 CA-C-O 117.095 -1.947 . . . . 0.0 112.716 -175.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.449 ' CB ' HG22 ' A' ' 119' ' ' VAL . 11.3 p90 -130.41 120.78 24.76 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.742 1.771 . . . . 0.0 113.478 177.522 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.414 ' CG ' ' CE1' ' A' ' 63' ' ' HIS . 0.1 OUTLIER -154.3 156.11 36.37 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 115.195 -0.912 . . . . 0.0 112.843 -168.737 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 4.5 p -77.01 135.51 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 122.992 0.517 . . . . 0.0 109.844 171.305 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.5 m170 -112.48 171.97 7.2 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.895 1.678 . . . . 0.0 111.459 172.19 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -40.69 119.77 1.17 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.093 1.757 . . . . 0.0 113.178 -176.072 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -88.63 -164.43 1.13 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 127.846 2.458 . . . . 0.0 111.045 -177.328 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.71 -79.11 0.9 Allowed Glycine 0 C--N 1.334 0.464 0 N-CA-C 115.327 0.891 . . . . 0.0 115.327 167.076 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.517 ' HA ' HG11 ' B' ' 5' ' ' VAL . 44.9 p-10 -128.99 47.88 2.42 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 126.805 2.042 . . . . 0.0 115.19 -164.029 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 11.6 p30 -154.75 -30.73 0.11 Allowed 'General case' 0 N--CA 1.478 0.97 0 O-C-N 120.577 -1.327 . . . . 0.0 114.48 -172.68 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . 0.342 12.4 t 21.15 35.88 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.6 1 C-N-CA 133.235 4.614 . . . . 0.0 120.408 173.251 . . . . . . . . 3 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -146.57 -2.78 0.64 Allowed 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 128.35 2.66 . . . . 0.0 111.101 169.652 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 89.42 -154.79 24.49 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 125.244 1.402 . . . . 0.0 114.0 175.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 11.2 t -46.86 -27.39 1.22 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.117 1.767 . . . . 0.0 115.263 -172.861 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 t -56.16 -14.51 2.77 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 126.715 2.006 . . . . 0.0 114.528 169.006 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 11.9 t -150.28 9.37 0.65 Allowed 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 127.044 2.138 . . . . 0.0 113.74 174.857 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -129.22 172.97 10.92 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 -168.167 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -97.95 -150.54 26.42 Favored Glycine 0 CA--C 1.546 2.021 0 C-N-CA 125.367 1.46 . . . . 0.0 115.383 -176.276 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -78.75 -170.03 0.91 Allowed 'Trans proline' 0 C--N 1.352 0.761 1 C-N-CA 127.831 5.688 . . . . 0.0 111.385 -179.651 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.417 ' CD2' ' HA ' ' A' ' 137' ' ' THR . 12.2 m170 -62.69 116.51 5.26 Favored 'General case' 0 N--CA 1.451 -0.412 0 O-C-N 121.97 -0.456 . . . . 0.0 111.029 177.743 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 146.94 44.46 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -174.383 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -110.32 79.69 1.72 Allowed Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.656 1.354 . . . . 0.0 114.656 -176.117 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.81 -12.55 14.83 Favored 'Trans proline' 0 CA--C 1.54 0.778 0 C-N-CA 123.14 2.56 . . . . 0.0 112.071 168.12 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.591 ' HB3' ' HE ' ' A' ' 69' ' ' ARG . 85.1 mt -137.61 2.82 2.48 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.163 1.785 . . . . 0.0 112.797 -168.394 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 25.2 m 58.96 70.18 0.67 Allowed 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 124.824 1.249 . . . . 0.0 113.092 168.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.591 ' HE ' ' HB3' ' A' ' 67' ' ' LEU . 9.2 ptp180 -155.48 177.42 11.39 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 119.874 3.287 . . . . 0.0 119.874 -163.99 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.416 ' HE2' ' N ' ' A' ' 70' ' ' LYS . 0.7 OUTLIER -78.81 178.03 8.24 Favored 'General case' 0 CA--C 1.549 0.907 0 CA-C-N 113.992 -1.458 . . . . 0.0 111.499 168.057 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.441 ' CG ' ' N ' ' A' ' 72' ' ' GLY . 83.7 t60 -115.85 159.81 21.01 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 115.365 1.617 . . . . 0.0 115.365 -168.701 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.441 ' N ' ' CG ' ' A' ' 71' ' ' HIS . . . 136.37 -102.81 0.42 Allowed Glycine 0 C--N 1.333 0.378 0 C-N-CA 125.586 1.565 . . . . 0.0 109.829 166.54 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.434 ' H ' ' HB3' ' A' ' 76' ' ' ASP . . . 105.55 -36.92 4.08 Favored Glycine 0 CA--C 1.549 2.17 0 CA-C-O 117.448 -1.751 . . . . 0.0 116.558 -177.034 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -73.45 -19.98 21.3 Favored 'Trans proline' 0 C--N 1.358 1.043 0 CA-C-N 122.156 2.978 . . . . 0.0 113.863 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.19 -1.42 0.74 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 125.488 1.515 . . . . 0.0 112.267 -175.011 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.434 ' HB3' ' H ' ' A' ' 73' ' ' GLY . 0.0 OUTLIER -122.37 139.92 53.27 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 128.701 2.8 . . . . 0.0 107.192 -178.15 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -97.43 -9.24 27.66 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 128.052 2.541 . . . . 0.0 112.647 -174.456 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -82.57 -82.49 0.14 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.087 0.858 . . . . 0.0 109.196 -178.708 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 65.4 ttt180 79.95 110.92 0.07 Allowed 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 126.604 1.961 . . . . 0.0 114.213 164.74 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 8.4 m80 -62.43 128.52 36.4 Favored 'General case' 0 CA--C 1.546 0.811 0 O-C-N 119.784 -1.823 . . . . 0.0 107.247 167.098 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.2 p -39.83 -36.6 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.215 0 N-CA-C 118.556 2.798 . . . . 0.0 118.556 -167.185 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.65 19.51 36.04 Favored Glycine 0 N--CA 1.477 1.386 0 CA-C-N 120.283 1.401 . . . . 0.0 115.39 178.687 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -78.31 140.35 38.81 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 119.223 1.512 . . . . 0.0 112.315 174.798 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mp -119.3 -176.36 3.12 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 163.224 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.52 -137.21 2.65 Favored Glycine 0 N--CA 1.468 0.831 0 O-C-N 121.322 -0.861 . . . . 0.0 111.861 174.808 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.6 p30 -100.59 147.39 26.0 Favored 'General case' 0 CA--C 1.541 0.602 0 O-C-N 122.006 -0.702 . . . . 0.0 112.008 168.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.47 149.84 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 127.572 2.349 . . . . 0.0 107.328 169.183 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.4 m -107.94 140.29 41.29 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.774 -0.579 . . . . 0.0 110.058 179.204 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.43 138.7 31.34 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.725 0.81 . . . . 0.0 111.944 171.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -80.37 147.61 30.97 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.468 1.507 . . . . 0.0 109.991 168.168 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 pptp? -46.69 -22.18 0.27 Allowed 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 128.605 2.762 . . . . 0.0 116.641 174.329 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.13 0.27 19.48 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 125.177 1.391 . . . . 0.0 112.186 172.599 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.39 28.97 8.64 Favored Glycine 0 C--N 1.342 0.885 0 C-N-CA 125.987 1.756 . . . . 0.0 114.568 169.545 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.74 134.66 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 CA-C-N 119.83 1.815 . . . . 0.0 115.282 -175.225 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -101.07 110.64 22.69 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 124.597 1.159 . . . . 0.0 107.907 166.334 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -106.71 137.9 43.88 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 122.356 1.074 . . . . 0.0 111.387 175.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -116.65 147.09 20.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-N 112.555 -2.111 . . . . 0.0 114.464 -168.649 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 82.8 p -158.93 90.1 0.97 Allowed 'General case' 0 CA--C 1.554 1.112 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 178.655 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.3 mp -132.46 154.87 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 125.847 1.659 . . . . 0.0 112.968 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 30' ' ' LYS . 14.0 tt0 -117.76 115.99 26.13 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 164.039 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -117.57 114.54 23.57 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.327 1.061 . . . . 0.0 111.451 -171.375 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 93.6 p -84.03 54.91 3.09 Favored 'General case' 0 CA--C 1.533 0.3 0 O-C-N 121.472 -0.767 . . . . 0.0 111.686 -175.035 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.7 p -142.7 -17.55 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 114.75 1.389 . . . . 0.0 114.75 -169.813 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 1.4 pp -142.69 161.91 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 CA-C-N 119.914 1.234 . . . . 0.0 112.622 -176.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.633 ' H ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -145.1 155.36 43.28 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 125.528 1.531 . . . . 0.0 113.601 -179.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.4 mp -83.67 56.94 3.83 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.781 1.632 . . . . 0.0 111.14 -175.449 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.03 -56.05 2.41 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.38 1.472 . . . . 0.0 110.543 178.365 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 143.38 -102.6 0.29 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 115.637 1.015 . . . . 0.0 115.637 169.572 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.81 -33.98 72.45 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 125.02 1.328 . . . . 0.0 111.873 175.002 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -80.02 1.0 29.35 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.036 1.734 . . . . 0.0 113.245 170.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.633 ' HB3' ' H ' ' A' ' 105' ' ' SER . 1.6 m -166.51 -90.42 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 169.846 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.385 7.6 pt -119.16 -99.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 114.758 1.392 . . . . 0.0 114.758 -179.015 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . 0.274 24.2 mm 37.11 -88.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 127.37 2.268 . . . . 0.0 113.794 -169.024 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.18 2.4 9.44 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-N 119.911 1.232 . . . . 0.0 115.091 175.612 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -79.38 152.1 30.58 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.571 1.685 . . . . 0.0 107.399 168.465 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 8.6 t -125.61 119.65 28.66 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 122.237 -0.289 . . . . 0.0 111.126 -168.871 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.72 130.3 34.71 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 124.461 1.104 . . . . 0.0 108.506 176.29 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.5 p -125.69 138.17 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.409 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.464 ' HB ' HD11 ' A' ' 144' ' ' LEU . 32.1 t -101.88 157.01 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 169.196 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.402 ' CD2' ' CE1' ' A' ' 46' ' ' HIS . 35.0 m-70 -130.22 146.68 51.86 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.619 1.568 . . . . 0.0 111.886 -167.372 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -71.56 -4.22 25.71 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.852 1.261 . . . . 0.0 114.044 -170.633 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 21.7 mmmt -127.68 160.36 31.91 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.061 1.345 . . . . 0.0 111.953 176.044 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -53.46 162.81 0.72 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.381 1.472 . . . . 0.0 112.505 169.719 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -111.27 130.18 55.74 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.302 1.841 . . . . 0.0 109.847 -175.336 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . 0.265 1.0 OUTLIER -84.38 -8.15 59.08 Favored 'General case' 0 N--CA 1.48 1.04 0 N-CA-C 116.007 1.854 . . . . 0.0 116.007 -178.931 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 31.6 mt 63.73 42.18 6.43 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 126.576 1.95 . . . . 0.0 114.71 167.532 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 113.36 -38.11 3.34 Favored Glycine 0 N--CA 1.474 1.228 0 C-N-CA 124.447 1.022 . . . . 0.0 114.901 167.785 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.52 88.78 1.08 Allowed 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 119.138 3.014 . . . . 0.0 119.138 169.62 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -100.4 -69.28 0.88 Allowed Glycine 0 CA--C 1.522 0.487 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 161.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.55 -107.94 3.25 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 117.714 1.846 . . . . 0.0 117.714 -168.557 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -102.56 -158.48 0.67 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.126 1.77 . . . . 0.0 113.861 -161.102 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -49.63 -47.68 49.63 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.133 0.573 . . . . 0.0 111.468 170.176 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -57.0 -34.28 67.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.007 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.456 ' HA ' ' HB2' ' A' ' 139' ' ' ASN . 24.0 p -52.43 -30.04 27.46 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 120.315 1.416 . . . . 0.0 112.04 170.109 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 1.2 p -97.55 -34.1 11.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 117.454 -1.26 . . . . 0.0 113.812 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -92.26 -46.23 7.82 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 114.651 1.352 . . . . 0.0 114.651 -176.835 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.417 ' HA ' ' CD2' ' A' ' 63' ' ' HIS . 17.9 p -90.81 -95.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.538 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 170.199 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -171.74 26.07 0.09 OUTLIER Glycine 0 CA--C 1.536 1.344 1 C-N-CA 132.568 4.89 . . . . 0.0 110.418 176.645 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.456 ' HB2' ' HA ' ' A' ' 134' ' ' SER . 0.1 OUTLIER 56.59 -7.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 129.488 3.115 . . . . 0.0 116.714 -168.989 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -50.44 -38.36 43.02 Favored 'General case' 0 CA--C 1.55 0.98 0 CA-C-N 119.958 1.254 . . . . 0.0 113.939 -169.401 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.0 -116.03 4.22 Favored Glycine 0 N--CA 1.47 0.906 0 O-C-N 121.024 -1.048 . . . . 0.0 112.577 172.482 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 20.7 m -44.88 115.52 0.9 Allowed 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.524 1.53 . . . . 0.0 114.69 -169.924 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.63 160.5 31.46 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 121.41 -0.806 . . . . 0.0 112.482 172.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.464 HD11 ' HB ' ' A' ' 119' ' ' VAL 0.277 3.9 pp -142.28 -153.38 0.46 Allowed 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 126.829 2.052 . . . . 0.0 107.474 165.414 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.85 132.58 46.66 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 119.817 1.19 . . . . 0.0 113.269 -171.38 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.6 p -130.89 146.01 52.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 126.655 1.982 . . . . 0.0 111.63 -174.525 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.17 159.63 30.94 Favored Glycine 0 N--CA 1.472 1.038 0 N-CA-C 114.61 0.604 . . . . 0.0 114.61 179.362 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.59 161.85 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 C-N-CA 123.632 0.773 . . . . 0.0 109.676 168.409 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 27.8 mm -88.52 64.54 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 125.169 1.388 . . . . 0.0 110.096 178.773 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -68.82 139.49 33.08 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -174.06 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.9 pp -77.76 144.78 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 O-C-N 121.719 -0.871 . . . . 0.0 111.16 -174.33 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -117.6 -17.16 10.03 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.162 2.185 . . . . 0.0 112.138 175.851 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 N--CA 1.468 0.468 0 C-N-CA 128.594 2.758 . . . . 0.0 113.428 175.27 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 0.502 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 2.2 m -78.14 106.09 9.8 Favored 'General case' 0 CA--C 1.51 -0.585 0 C-N-CA 124.766 1.226 . . . . 0.0 110.078 -172.763 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 25.0 mtmm -92.92 124.57 36.99 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-O 123.624 1.678 . . . . 0.0 113.305 178.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -115.66 175.37 5.56 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 127.256 2.222 . . . . 0.0 108.951 166.653 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.517 HG11 ' HA ' ' A' ' 52' ' ' ASP . 1.0 OUTLIER -148.16 146.74 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -177.611 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.13 119.89 36.1 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 163.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 90.6 t -124.78 115.25 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 175.848 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 mp -103.91 147.12 27.71 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 125.041 1.336 . . . . 0.0 111.052 -179.025 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 23.2 ttmm -140.3 142.88 35.64 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.095 1.358 . . . . 0.0 109.442 164.884 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -112.36 -117.17 3.52 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-O 122.96 1.311 . . . . 0.0 111.348 173.116 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.74 49.68 1.85 Allowed 'General case' 0 C--N 1.314 -0.974 0 C-N-CA 126.715 2.006 . . . . 0.0 113.529 -163.146 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -81.25 0.71 Allowed Glycine 0 CA--C 1.538 1.502 0 CA-C-O 117.289 -1.839 . . . . 0.0 113.115 -175.78 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -98.29 -2.3 1.13 Allowed 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 123.818 3.012 . . . . 0.0 115.183 -169.726 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -89.88 125.88 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-N 121.049 1.749 . . . . 0.0 110.08 178.174 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -130.61 166.99 19.47 Favored 'General case' 0 N--CA 1.462 0.145 0 C-N-CA 124.039 0.935 . . . . 0.0 112.713 174.93 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' B' ' 35' ' ' ILE . . . -144.93 104.26 0.31 Allowed Glycine 0 C--O 1.224 -0.515 0 CA-C-N 114.118 -1.401 . . . . 0.0 111.176 169.046 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.33 127.43 47.33 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.114 0 CA-C-N 118.781 1.291 . . . . 0.0 109.278 169.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 5.6 mm -131.85 112.44 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 126.46 1.904 . . . . 0.0 108.662 170.882 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -82.87 139.39 33.47 Favored 'General case' 0 CA--C 1.542 0.667 0 O-C-N 120.988 -1.07 . . . . 0.0 111.553 169.302 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -115.84 103.82 11.02 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 125.545 1.538 . . . . 0.0 110.541 179.308 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -108.51 108.13 18.93 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.592 1.157 . . . . 0.0 113.31 179.186 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -97.93 160.91 14.01 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.816 1.246 . . . . 0.0 110.603 171.304 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.78 -21.19 8.55 Favored 'General case' 0 CA--C 1.544 0.729 0 N-CA-C 114.214 1.19 . . . . 0.0 114.214 178.934 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.48 -165.72 1.08 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 127.739 2.416 . . . . 0.0 108.788 168.21 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 13.2 m -110.79 -11.28 14.4 Favored 'General case' 0 N--CA 1.48 1.026 0 O-C-N 120.612 -1.305 . . . . 0.0 112.118 167.001 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 53.6 m-80 -138.05 101.1 4.33 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 126.743 2.017 . . . . 0.0 107.893 168.712 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.73 -175.1 37.46 Favored Glycine 0 CA--C 1.539 1.565 0 C-N-CA 125.325 1.441 . . . . 0.0 111.77 -175.464 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.41 149.6 80.53 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 123.197 2.598 . . . . 0.0 115.853 -168.497 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 6.7 t -124.31 133.83 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 125.454 1.501 . . . . 0.0 109.749 -177.536 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -78.8 125.07 28.87 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.628 0.771 . . . . 0.0 109.507 170.086 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.65 77.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 C-N-CA 127.414 2.286 . . . . 0.0 106.201 -178.541 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 2.7 p90 -102.02 154.91 18.54 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.957 170.819 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 170.2 -177.37 43.52 Favored Glycine 0 C--O 1.227 -0.335 0 O-C-N 121.361 -0.837 . . . . 0.0 113.806 -176.72 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 76.7 p -155.41 127.99 7.91 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 124.129 0.972 . . . . 0.0 111.192 -179.691 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.443 ' HA ' ' HA2' ' B' ' 16' ' ' GLY . 1.7 mp -79.6 163.63 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 168.28 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 48.5 tttp -156.56 122.46 4.89 Favored 'General case' 0 N--CA 1.444 -0.739 0 O-C-N 120.851 -1.156 . . . . 0.0 108.588 165.247 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.52 1.03 12.32 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 126.277 1.894 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . . . . . . . . . 62.0 mt -71.29 171.52 10.97 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 120.266 2.033 . . . . 0.0 110.046 168.648 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 10.0 t -91.42 158.04 16.73 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 163.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -58.88 147.07 35.25 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.412 1.085 . . . . 0.0 111.886 -178.75 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 105.04 -173.75 20.92 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 124.58 1.086 . . . . 0.0 112.266 -177.51 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.677 ' H ' HD23 ' B' ' 42' ' ' LEU . 1.4 pt? -87.38 140.57 29.4 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.781 2.032 . . . . 0.0 112.016 -172.308 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -143.03 138.34 29.9 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.506 2.322 . . . . 0.0 108.141 -177.21 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -89.07 139.41 15.24 Favored Glycine 0 N--CA 1.473 1.139 0 CA-C-N 121.709 2.049 . . . . 0.0 111.031 -175.019 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -137.1 140.14 41.74 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 120.013 1.906 . . . . 0.0 111.963 170.407 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 21.1 p-80 -149.9 154.99 39.24 Favored 'General case' 0 C--O 1.236 0.366 0 O-C-N 121.126 -0.984 . . . . 0.0 111.843 -174.344 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.71 151.09 5.14 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 124.683 1.193 . . . . 0.0 109.67 -179.052 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -86.94 176.13 7.81 Favored 'General case' 0 CA--C 1.546 0.815 0 CA-C-O 122.556 1.169 . . . . 0.0 112.911 178.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -74.68 112.29 10.73 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 160.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.77 -162.71 0.16 Allowed 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.502 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -118.85 33.85 4.59 Favored Glycine 0 C--N 1.342 0.865 0 C-N-CA 128.019 2.723 . . . . 0.0 111.549 178.852 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.547 ' HA ' ' CG1' ' A' ' 5' ' ' VAL . 45.7 p-10 -116.91 69.29 0.75 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 124.048 1.88 . . . . 0.0 112.768 -169.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . 0.468 ' OD1' HG11 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -124.22 57.94 1.21 Allowed 'General case' 0 C--O 1.244 0.813 0 N-CA-C 116.62 2.081 . . . . 0.0 116.62 -160.939 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 7' ' ' VAL 0.278 13.2 p -110.02 -54.89 2.52 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.303 -1.317 . . . . 0.0 109.603 -163.122 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.45 31.23 0.12 Allowed 'General case' 0 CA--C 1.557 1.215 0 C-N-CA 124.909 1.284 . . . . 0.0 113.079 167.684 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 57.25 -131.56 52.11 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 120.693 -1.254 . . . . 0.0 113.364 174.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 3.8 t -69.34 -7.54 38.22 Favored 'General case' 0 CA--C 1.548 0.894 0 N-CA-C 115.002 1.482 . . . . 0.0 115.002 -174.7 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 13.2 t -108.19 14.1 25.29 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 124.72 1.208 . . . . 0.0 112.341 169.528 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 4.7 t -107.39 -63.93 1.25 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.857 1.663 . . . . 0.0 109.098 169.574 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -166.52 134.05 2.66 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 124.816 1.246 . . . . 0.0 111.583 -178.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -121.55 -115.57 2.37 Favored Glycine 0 CA--C 1.541 1.663 0 C-N-CA 127.21 2.338 . . . . 0.0 113.27 -178.213 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -67.72 157.21 62.78 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.983 3.789 . . . . 0.0 116.152 -164.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -38.59 101.28 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 127.011 2.124 . . . . 0.0 116.033 169.675 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -58.95 119.4 7.15 Favored 'General case' 0 CA--C 1.544 0.722 0 O-C-N 121.574 -0.704 . . . . 0.0 109.63 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -104.23 75.8 0.25 Allowed Pre-proline 0 CA--C 1.549 0.91 0 C-N-CA 127.335 2.254 . . . . 0.0 112.588 -172.445 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -56.61 -33.01 92.19 Favored 'Trans proline' 0 C--N 1.355 0.879 0 C-N-CA 123.532 2.822 . . . . 0.0 115.843 -168.934 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 97.3 mt -79.76 -3.35 47.24 Favored 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 175.413 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.9 t 65.73 52.23 1.33 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.734 2.014 . . . . 0.0 112.912 178.705 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 11.4 mtp180 -105.57 172.33 6.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 114.102 1.149 . . . . 0.0 114.102 -169.313 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 ptmm? -81.09 172.69 13.39 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 122.769 0.428 . . . . 0.0 110.518 165.025 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -104.49 146.5 28.78 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -170.791 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.15 -140.6 11.95 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 113.641 -1.618 . . . . 0.0 113.323 166.647 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 149.91 -29.46 1.13 Allowed Glycine 0 CA--C 1.545 1.932 0 N-CA-C 118.399 2.12 . . . . 0.0 118.399 -179.432 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . 0.429 ' HG3' ' H ' ' B' ' 86' ' ' ASN . 60.0 Cg_endo -69.83 -4.56 14.32 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 122.766 3.283 . . . . 0.0 112.998 168.535 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.93 -37.18 0.15 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.976 1.31 . . . . 0.0 109.752 165.853 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -61.39 109.26 1.1 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 123.621 1.676 . . . . 0.0 112.49 -176.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . 0.444 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 4.0 pm0 -44.03 -30.71 0.77 Allowed 'General case' 0 C--N 1.318 -0.794 1 C-N-CA 134.058 4.943 . . . . 0.0 115.689 169.198 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -90.85 -62.96 1.34 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 118.936 0.789 . . . . 0.0 111.123 -176.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . 0.269 32.1 ptt180 55.34 121.26 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 129.114 2.966 . . . . 0.0 115.346 -175.507 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -56.7 151.33 14.19 Favored 'General case' 0 CA--C 1.546 0.79 0 O-C-N 119.141 -2.224 . . . . 0.0 112.65 173.581 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 80.5 t -49.96 -56.11 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 CA-C-N 118.753 0.706 . . . . 0.0 110.603 -176.926 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.69 115.25 5.17 Favored Glycine 0 C--N 1.337 0.589 0 N-CA-C 105.132 -3.187 . . . . 0.0 105.132 164.333 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -158.35 158.26 33.97 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.9 0.85 . . . . 0.0 112.675 172.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 83.1 mt -144.19 153.07 41.71 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.99 2.116 . . . . 0.0 106.439 168.335 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -113.06 -124.1 4.17 Favored Glycine 0 N--CA 1.471 1.026 0 C-N-CA 124.459 1.028 . . . . 0.0 111.046 172.443 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . 0.429 ' H ' ' HG3' ' B' ' 74' ' ' PRO . 6.7 m-80 -78.54 135.11 37.23 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -175.65 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.74 121.07 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 C-N-CA 131.082 3.753 . . . . 0.0 108.84 167.053 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 47.1 m -119.22 119.27 33.61 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 124.102 0.961 . . . . 0.0 110.963 -170.257 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.58 160.3 14.69 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.947 1.299 . . . . 0.0 113.972 -174.758 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -84.69 178.12 7.79 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 128.593 2.757 . . . . 0.0 112.633 170.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.15 -20.85 65.81 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 120.865 -1.147 . . . . 0.0 113.2 169.387 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -73.77 -11.7 60.47 Favored 'General case' 0 CA--C 1.55 0.969 0 CA-C-O 121.791 0.805 . . . . 0.0 110.145 171.603 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.84 2.75 88.42 Favored Glycine 0 C--N 1.34 0.758 0 C-N-CA 125.843 1.687 . . . . 0.0 113.462 176.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 4.3 p -84.11 134.67 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 125.491 1.517 . . . . 0.0 111.839 170.751 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.15 135.19 52.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 164.251 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -90.37 143.69 26.52 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 177.806 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 t -132.7 129.05 58.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 113.822 -1.535 . . . . 0.0 108.139 171.54 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.6 p -157.28 59.91 0.5 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-O 122.466 1.127 . . . . 0.0 112.506 -166.772 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 20.4 mt -120.2 158.03 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 124.991 1.316 . . . . 0.0 111.836 -171.264 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 47.2 tt0 -138.56 127.7 24.14 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 166.598 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -144.48 145.29 31.79 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -167.637 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 72.2 p -104.47 52.37 0.75 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 125.06 1.344 . . . . 0.0 112.449 -168.85 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 31.3 m -149.74 6.31 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 115.434 1.642 . . . . 0.0 115.434 -169.508 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.03 172.01 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 125.518 1.527 . . . . 0.0 110.645 -176.288 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 88.0 p -157.26 160.73 38.92 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.717 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -97.02 51.7 1.13 Allowed 'General case' 0 CA--C 1.54 0.586 0 O-C-N 121.631 -0.668 . . . . 0.0 111.587 174.486 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 12.5 m -81.38 -52.43 7.28 Favored 'General case' 0 N--CA 1.474 0.754 0 O-C-N 121.689 -0.632 . . . . 0.0 112.692 -176.836 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.5 -30.19 4.31 Favored Glycine 0 N--CA 1.471 0.988 0 C-N-CA 124.425 1.012 . . . . 0.0 114.697 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -82.91 -53.18 6.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 122.108 0.956 . . . . 0.0 112.544 -168.867 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -139.05 4.73 2.28 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -166.082 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 68.0 m -113.59 -112.11 0.34 Allowed 'General case' 0 CA--C 1.552 1.02 0 C-N-CA 123.894 0.878 . . . . 0.0 113.331 -168.92 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 45.5 mm -106.29 -59.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.794 1.237 . . . . 0.0 111.573 -174.89 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 23.6 mm -58.16 138.32 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 106.069 -1.826 . . . . 0.0 106.069 166.289 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.7 59.13 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.758 -1.023 . . . . 0.0 114.023 -174.978 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 12.6 mtt85 -127.43 176.68 7.27 Favored 'General case' 0 C--N 1.347 0.492 0 CA-C-N 119.292 1.546 . . . . 0.0 112.765 171.025 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 2.2 m -126.29 153.07 45.32 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 128.016 2.527 . . . . 0.0 109.183 169.029 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 13.1 tp -130.1 133.04 46.4 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.763 1.625 . . . . 0.0 109.167 176.446 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.73 139.15 44.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 C-N-CA 126.499 1.92 . . . . 0.0 110.767 176.403 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 5.8 p -106.11 140.78 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 125.129 1.372 . . . . 0.0 109.927 167.439 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 94.6 m-70 -97.6 156.9 16.31 Favored 'General case' 0 N--CA 1.448 -0.57 0 C-N-CA 126.807 2.043 . . . . 0.0 111.147 177.917 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 8.2 tm-20 -77.11 -27.77 54.18 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.498 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -103.45 175.0 5.62 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.465 1.106 . . . . 0.0 111.845 168.685 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.85 152.68 42.44 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.174 1.79 . . . . 0.0 113.976 173.809 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -89.87 145.53 25.08 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 122.546 1.165 . . . . 0.0 113.168 169.792 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -76.8 -39.4 51.55 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -168.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 12.9 mt 84.32 24.68 0.1 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 126.433 1.893 . . . . 0.0 113.812 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . 0.403 ' HA2' ' HB ' ' B' ' 135' ' ' THR . . . 84.34 57.77 2.3 Favored Glycine 0 C--N 1.343 0.959 0 C-N-CA 125.749 1.643 . . . . 0.0 114.906 168.06 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -158.68 -17.09 0.07 Allowed 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -168.203 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -74.08 16.35 2.8 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.612 1.577 . . . . 0.0 115.114 178.696 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 71.57 -2.17 24.4 Favored Glycine 0 CA--C 1.532 1.151 0 C-N-CA 125.316 1.436 . . . . 0.0 116.459 169.416 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -102.4 162.41 12.94 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 118.837 1.318 . . . . 0.0 109.551 -178.797 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -50.44 -62.83 1.35 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 122.175 0.988 . . . . 0.0 109.485 167.733 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . 0.55 ' HB3' HD22 ' B' ' 139' ' ' ASN . 0.4 OUTLIER -46.36 -31.14 2.42 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 128.898 2.879 . . . . 0.0 114.601 173.794 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 15.3 p -56.67 -30.31 63.25 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 120.556 -1.34 . . . . 0.0 113.927 178.066 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . 0.403 ' HB ' ' HA2' ' B' ' 127' ' ' GLY . 8.9 t -121.57 -13.54 8.35 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 170.111 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.5 tttt -74.79 -15.22 60.76 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 124.633 1.173 . . . . 0.0 113.263 169.635 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 3.2 p -148.31 -25.46 0.34 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 126.623 1.969 . . . . 0.0 114.67 167.421 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.13 53.83 Favored Glycine 0 CA--C 1.536 1.4 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 -163.228 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . 0.55 HD22 ' HB3' ' B' ' 133' ' ' GLU . 8.1 t-20 51.67 18.07 0.68 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 126.618 1.967 . . . . 0.0 113.923 179.009 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.36 -0.04 0.22 Allowed 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 127.806 2.442 . . . . 0.0 116.667 -167.764 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 75.84 -129.71 10.48 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.14 1.353 . . . . 0.0 115.886 168.236 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -51.42 134.34 28.69 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 127.735 2.414 . . . . 0.0 112.493 -178.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.92 146.98 33.22 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 121.265 -0.897 . . . . 0.0 109.887 171.093 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 1.3 tt -120.66 -134.83 0.32 Allowed 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 168.97 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.75 156.72 32.23 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.515 1.302 . . . . 0.0 114.515 -176.854 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 18.7 p -146.48 161.84 39.57 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.706 1.202 . . . . 0.0 111.099 170.002 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.47 146.75 13.33 Favored Glycine 0 N--CA 1.468 0.831 0 C-N-CA 125.141 1.353 . . . . 0.0 112.525 -174.541 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.46 HG12 ' H ' ' B' ' 149' ' ' ILE . 2.5 t -85.77 177.42 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 175.267 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . 0.46 ' H ' HG12 ' B' ' 148' ' ' VAL . 37.3 mt -123.19 114.14 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 O-C-N 120.097 -1.627 . . . . 0.0 111.878 -177.124 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -117.64 175.12 15.56 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 126.593 2.044 . . . . 0.0 115.037 -172.476 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -102.46 102.9 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.381 1.472 . . . . 0.0 112.65 -171.049 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.55 49.7 1.04 Allowed 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 126.535 1.934 . . . . 0.0 112.239 171.868 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 . . . . . 0 C--N 1.327 -0.378 0 C-N-CA 126.001 1.72 . . . . 0.0 111.387 177.738 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.527 ' HB2' ' HA ' ' B' ' 109' ' ' ASP . . . . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 118.161 -0.923 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p -84.23 43.61 0.96 Allowed 'General case' 0 C--N 1.348 0.531 0 C-N-CA 125.519 1.528 . . . . 0.0 112.92 -168.886 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.5 148.48 12.74 Favored 'General case' 0 C--O 1.238 0.469 0 C-N-CA 125.002 1.321 . . . . 0.0 112.413 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -156.65 161.23 39.89 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 126.293 1.837 . . . . 0.0 108.896 166.842 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.414 ' HB ' ' CG ' ' B' ' 52' ' ' ASP . 0.9 OUTLIER -156.29 150.6 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 124.487 1.115 . . . . 0.0 109.333 -178.056 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -135.07 93.37 2.99 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.463 1.105 . . . . 0.0 108.841 167.526 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 1.5 m -76.88 87.94 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 124.89 1.276 . . . . 0.0 107.793 170.355 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -76.75 127.42 32.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 125.874 1.67 . . . . 0.0 109.637 -173.606 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -144.04 169.8 17.15 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.318 1.047 . . . . 0.0 112.174 -174.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 147.19 -48.7 0.64 Allowed Glycine 0 N--CA 1.467 0.739 0 C-N-CA 125.329 1.442 . . . . 0.0 112.739 171.399 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -89.89 64.0 6.21 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 122.219 1.009 . . . . 0.0 110.694 -169.158 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 47.15 -101.75 0.04 OUTLIER Glycine 0 CA--C 1.535 1.293 0 C-N-CA 127.236 2.35 . . . . 0.0 113.132 179.102 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.07 -14.28 21.03 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.852 3.035 . . . . 0.0 113.635 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -76.89 136.24 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-N 119.849 1.204 . . . . 0.0 109.618 179.079 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.45 159.1 35.33 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 125.997 2.808 . . . . 0.0 113.377 167.163 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -111.16 142.53 16.92 Favored Glycine 0 C--N 1.313 -0.739 1 CA-C-N 108.188 -4.097 . . . . 0.0 109.438 172.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -155.51 86.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 122.641 1.21 . . . . 0.0 108.417 175.19 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.1 pp -106.91 143.94 16.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.705 167.541 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -119.67 135.73 54.7 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 127.762 2.425 . . . . 0.0 110.573 -178.374 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-30 -119.93 157.86 27.9 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 125.462 1.505 . . . . 0.0 110.862 178.247 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.84 146.29 37.35 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 130.489 3.516 . . . . 0.0 104.598 171.265 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.9 tt0 -146.0 -174.24 4.37 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.149 1.78 . . . . 0.0 106.721 172.125 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 -24.01 0.47 Allowed 'General case' 0 CA--C 1.55 0.943 0 O-C-N 118.962 -2.336 . . . . 0.0 114.463 167.402 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.403 ' HB2' ' H ' ' A' ' 27' ' ' GLY . 1.0 OUTLIER -98.72 -172.81 2.38 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.673 1.989 . . . . 0.0 109.571 170.578 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.61 -1.84 29.5 Favored 'General case' 0 CA--C 1.547 0.851 0 O-C-N 121.328 -0.857 . . . . 0.0 112.049 168.341 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -145.63 -7.98 0.58 Allowed 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -170.054 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' A' ' 24' ' ' GLU . . . -85.06 -163.75 37.56 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 118.873 -0.96 . . . . 0.0 111.771 177.057 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -84.11 161.17 13.53 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 121.964 1.776 . . . . 0.0 112.429 -171.153 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.11 152.87 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 125.963 1.705 . . . . 0.0 109.606 -170.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -94.17 151.15 19.69 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 170.755 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 96.0 t -130.93 97.7 3.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 127.161 2.184 . . . . 0.0 107.096 166.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 2.3 p90 -124.98 160.02 29.92 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.681 0.792 . . . . 0.0 111.52 172.56 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 116.44 -155.2 16.37 Favored Glycine 0 N--CA 1.469 0.867 0 O-C-N 120.983 -1.073 . . . . 0.0 112.052 -179.179 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.8 p -149.44 151.9 34.77 Favored 'General case' 0 CA--C 1.541 0.616 0 N-CA-C 117.962 2.579 . . . . 0.0 117.962 -167.421 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.8 mm -118.0 133.17 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 126.16 1.784 . . . . 0.0 108.358 169.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.13 160.24 43.45 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 120.049 1.295 . . . . 0.0 114.144 -172.482 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.42 3.55 61.3 Favored Glycine 0 CA--C 1.538 1.486 0 C-N-CA 126.9 2.19 . . . . 0.0 112.293 -167.956 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.8 mt -85.23 173.26 10.52 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 126.305 1.842 . . . . 0.0 112.926 -173.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 m -74.19 175.97 7.04 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.642 1.177 . . . . 0.0 108.057 164.291 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.29 -93.51 0.03 OUTLIER 'General case' 0 CA--C 1.558 1.252 0 O-C-N 119.958 -1.714 . . . . 0.0 113.04 179.263 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -61.51 97.47 0.14 Allowed Glycine 0 CA--C 1.529 0.965 0 C-N-CA 126.733 2.111 . . . . 0.0 117.667 -167.486 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 65.4 mt 62.85 131.75 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 129.185 2.994 . . . . 0.0 116.606 168.482 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.01 141.58 46.24 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 129.4 3.08 . . . . 0.0 107.486 179.752 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.78 155.14 51.81 Favored Glycine 0 N--CA 1.468 0.794 0 C-N-CA 124.659 1.123 . . . . 0.0 111.715 173.846 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -150.38 98.48 2.66 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -167.475 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -146.66 145.99 30.22 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 120.955 -1.091 . . . . 0.0 111.69 -168.461 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 0.3 OUTLIER -102.2 119.68 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 126.149 1.78 . . . . 0.0 107.802 179.412 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 16.6 m170 -72.51 142.93 48.53 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.632 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -63.36 136.66 57.79 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -172.718 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 68.36 166.67 0.26 Allowed 'General case' 0 CA--C 1.543 0.68 0 CA-C-O 123.818 1.771 . . . . 0.0 113.995 175.338 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.31 -14.53 12.95 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 126.477 1.989 . . . . 0.0 114.413 -178.035 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -75.42 53.54 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 121.187 2.493 . . . . 0.0 112.757 -177.83 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 172.03 21.99 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.29 0 C-N-CA 128.318 2.647 . . . . 0.0 113.914 -167.065 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.604 HG22 HG21 ' A' ' 148' ' ' VAL . 76.5 p -36.1 -15.24 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.041 1 N-CA-C 122.332 4.197 . . . . 0.0 122.332 -170.463 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.41 15.37 4.49 Favored 'General case' 0 CA--C 1.549 0.939 0 CA-C-N 122.097 2.226 . . . . 0.0 113.229 -174.052 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 62.92 -133.48 43.55 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 124.415 1.007 . . . . 0.0 111.908 174.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 8.9 t -58.46 -22.74 55.71 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 114.341 1.237 . . . . 0.0 114.341 -175.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . 0.256 15.0 t -90.95 42.6 1.11 Allowed 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 122.864 1.316 . . . . 0.0 112.291 171.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -179.87 -27.8 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.64 1.976 . . . . 0.0 115.659 172.095 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -134.93 142.69 46.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 125.529 1.532 . . . . 0.0 111.375 -168.702 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.31 -58.36 0.74 Allowed Glycine 0 CA--C 1.538 1.473 0 CA-C-O 117.636 -1.646 . . . . 0.0 115.053 -170.489 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -124.79 -177.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 124.151 3.234 . . . . 0.0 114.033 -169.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.515 ' H ' ' CD2' ' A' ' 63' ' ' HIS . 1.4 p80 -115.13 125.3 53.3 Favored 'General case' 0 C--N 1.328 -0.358 1 C-N-CA 131.839 4.056 . . . . 0.0 106.7 175.087 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -85.76 175.45 8.69 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-O 123.571 1.653 . . . . 0.0 110.56 -171.328 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 49.3 p-10 -107.48 48.68 0.17 Allowed Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 126.129 1.772 . . . . 0.0 113.444 177.081 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -64.52 -26.01 62.42 Favored 'Trans proline' 0 C--N 1.359 1.125 0 CA-C-N 122.044 1.766 . . . . 0.0 112.609 -179.354 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 76.2 mt -79.21 0.32 28.95 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.588 1.555 . . . . 0.0 112.993 171.041 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.9 t 66.28 58.29 0.7 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.893 2.077 . . . . 0.0 112.464 173.598 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.5 ptp180 -157.55 176.55 12.48 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 117.704 2.483 . . . . 0.0 117.704 -167.234 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.77 177.53 8.83 Favored 'General case' 0 CA--C 1.56 1.332 0 C-N-CA 126.822 2.049 . . . . 0.0 112.57 173.269 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -105.67 143.82 33.29 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -177.77 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 153.76 -115.84 0.7 Allowed Glycine 0 C--N 1.336 0.559 0 CA-C-N 114.336 -1.302 . . . . 0.0 113.675 166.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.23 -67.41 0.51 Allowed Glycine 0 CA--C 1.545 1.966 0 CA-C-O 118.933 -0.926 . . . . 0.0 114.614 179.027 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -65.77 -2.65 6.79 Favored 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 125.374 4.049 . . . . 0.0 116.459 173.109 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.82 -29.37 0.24 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.407 1.483 . . . . 0.0 111.466 170.402 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.9 t0 -87.01 104.1 15.98 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 123.588 0.755 . . . . 0.0 110.53 166.422 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -63.12 -13.45 36.76 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.165 2.186 . . . . 0.0 114.072 176.815 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -76.89 -72.29 0.35 Allowed 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 119.303 0.956 . . . . 0.0 110.536 -179.804 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.405 HH12 ' CG2' ' A' ' 103' ' ' VAL . 17.0 ttp180 77.45 114.09 0.07 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 126.901 2.081 . . . . 0.0 113.538 166.182 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -60.55 162.53 6.31 Favored 'General case' 0 N--CA 1.481 1.106 0 O-C-N 118.685 -2.509 . . . . 0.0 112.758 171.751 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -63.2 -29.93 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 O-C-N 121.231 -0.918 . . . . 0.0 112.52 172.691 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -84.12 12.32 54.61 Favored Glycine 0 CA--C 1.53 0.999 0 C-N-CA 124.696 1.141 . . . . 0.0 115.468 175.081 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -112.71 113.57 25.75 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-N 119.774 1.787 . . . . 0.0 114.439 -173.91 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 30.5 mt -84.15 -173.76 4.9 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 163.164 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.46 -134.34 2.02 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 120.792 -1.193 . . . . 0.0 113.625 172.227 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.5 p30 -127.34 163.39 24.11 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 124.163 0.985 . . . . 0.0 108.95 168.535 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 136.4 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 124.131 0.972 . . . . 0.0 110.61 -171.686 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -110.6 135.87 50.57 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 175.292 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -90.12 156.26 18.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.524 0.678 . . . . 0.0 110.584 169.298 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -77.16 155.22 32.45 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.056 1.342 . . . . 0.0 108.497 166.861 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -53.92 -25.36 19.98 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.999 1.72 . . . . 0.0 115.23 -169.305 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -76.65 -2.37 32.38 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 127.499 2.32 . . . . 0.0 112.273 179.101 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.65 30.18 7.37 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-O 117.937 -1.48 . . . . 0.0 114.12 172.334 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 4.7 p -144.81 131.54 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 115.303 1.594 . . . . 0.0 115.303 -178.188 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -97.27 112.72 24.4 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 164.799 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 27.0 t0 -106.33 128.65 54.17 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 170.803 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.46 145.18 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-N 113.429 -1.714 . . . . 0.0 114.4 -164.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 86.1 p -147.94 89.62 1.76 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.16 1.384 . . . . 0.0 112.087 179.566 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.06 149.31 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.505 1.522 . . . . 0.0 111.499 -174.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -135.68 138.29 42.64 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.842 2.057 . . . . 0.0 106.421 166.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -146.99 153.97 40.69 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 124.912 1.285 . . . . 0.0 112.241 -167.567 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.2 p -118.17 52.91 0.99 Allowed 'General case' 0 CA--C 1.546 0.794 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.382 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.405 ' CG2' HH12 ' A' ' 79' ' ' ARG . 1.0 OUTLIER -154.66 16.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 115.889 1.811 . . . . 0.0 115.889 -178.781 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -139.63 176.37 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 125.937 1.695 . . . . 0.0 109.741 169.605 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 28.8 p -160.08 175.54 12.85 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 177.11 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.437 ' HA ' ' CG1' ' A' ' 113' ' ' ILE . 8.5 mp -103.94 56.6 0.73 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 126.047 1.739 . . . . 0.0 110.409 176.953 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.5 t -107.91 -16.51 14.28 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 121.699 3.963 . . . . 0.0 121.699 -169.449 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 77.44 103.84 0.17 Allowed Glycine 0 CA--C 1.529 0.912 0 CA-C-N 121.233 1.833 . . . . 0.0 111.177 -171.011 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 85.77 -44.88 0.06 Allowed 'General case' 0 C--N 1.318 -0.777 1 C-N-CA 131.925 4.09 . . . . 0.0 111.376 166.909 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -85.78 3.03 43.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.862 1.265 . . . . 0.0 112.669 -176.573 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 28.2 p -138.22 -152.56 0.43 Allowed 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -166.951 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.8 pt -96.58 -17.35 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 120.382 -1.449 . . . . 0.0 112.516 168.298 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.437 ' CG1' ' HA ' ' A' ' 106' ' ' LEU . 7.1 mm -72.37 133.37 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 166.202 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.52 ' HA3' HD11 ' B' ' 151' ' ' ILE . . . 67.76 42.29 87.24 Favored Glycine 0 CA--C 1.532 1.134 0 O-C-N 124.36 1.037 . . . . 0.0 110.528 -168.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.99 148.86 35.85 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 127.04 2.136 . . . . 0.0 105.263 170.256 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 11.6 m -114.85 109.99 19.0 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.005 -1.059 . . . . 0.0 112.994 -165.038 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 11.2 tp -86.14 139.8 30.77 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 120.005 1.275 . . . . 0.0 114.224 -169.633 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.486 HG11 ' HE ' ' A' ' 143' ' ' ARG . 1.0 OUTLIER -132.68 149.3 31.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.284 168.232 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.64 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 164.762 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -127.3 131.92 50.4 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.144 1.378 . . . . 0.0 109.543 -176.62 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -60.63 -40.81 93.3 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 115.491 1.663 . . . . 0.0 115.491 -166.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 29.1 tttm -86.53 147.44 25.96 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 121.018 1.735 . . . . 0.0 110.898 177.219 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -33.58 125.58 0.41 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.568 1.947 . . . . 0.0 111.102 166.236 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 35.5 t0 -75.57 134.7 40.64 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 169.751 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -72.96 -34.67 66.64 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.889 0.876 . . . . 0.0 111.88 178.451 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 5.1 mt 62.74 33.18 15.65 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.621 1.568 . . . . 0.0 112.533 173.586 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -174.04 -72.75 0.05 OUTLIER Glycine 0 N--CA 1.468 0.815 0 N-CA-C 116.399 1.32 . . . . 0.0 116.399 174.845 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.7 pttt -164.85 67.74 0.14 Allowed 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.548 1.139 . . . . 0.0 114.073 178.252 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.3 68.03 0.7 Allowed Glycine 0 CA--C 1.531 1.061 0 C-N-CA 127.001 2.239 . . . . 0.0 113.416 176.175 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.26 -14.9 31.43 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 125.944 1.735 . . . . 0.0 115.226 172.714 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -141.23 177.08 8.33 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 118.982 1.391 . . . . 0.0 112.039 -171.409 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -77.62 -43.06 32.73 Favored 'General case' 0 C--O 1.217 -0.627 0 CA-C-N 114.625 -1.171 . . . . 0.0 109.978 165.476 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -44.57 -40.32 5.63 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.77 1.396 . . . . 0.0 114.77 173.121 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -50.82 -33.36 23.27 Favored 'General case' 0 N--CA 1.472 0.635 0 O-C-N 120.858 -1.151 . . . . 0.0 114.034 171.54 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.4 -24.05 20.88 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 125.565 1.546 . . . . 0.0 112.527 177.772 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -87.24 -13.66 43.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 176.907 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.416 ' HA ' ' HE2' ' A' ' 63' ' ' HIS . 20.8 p -129.8 -45.93 1.16 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.386 1.074 . . . . 0.0 113.385 176.508 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 118.8 -0.77 15.34 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 125.777 1.923 . . . . 0.0 111.793 -166.465 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 56.74 21.19 5.7 Favored 'General case' 0 N--CA 1.478 0.965 0 O-C-N 119.808 -1.995 . . . . 0.0 111.974 -175.754 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.92 30.02 0.08 Allowed 'General case' 0 CA--C 1.567 1.612 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -167.098 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 70.23 -35.24 0.42 Allowed Glycine 0 N--CA 1.476 1.358 0 C-N-CA 129.673 3.511 . . . . 0.0 117.588 168.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.0 t -171.3 -144.59 0.04 OUTLIER 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.476 1.11 . . . . 0.0 110.108 -169.293 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.486 ' HE ' HG11 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -142.37 -174.88 4.25 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 127.515 2.326 . . . . 0.0 110.447 172.929 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -174.42 -141.04 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 129.568 3.147 . . . . 0.0 109.008 168.18 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -51.24 138.71 20.2 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 128.341 2.656 . . . . 0.0 114.377 -168.479 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 87.3 m -126.06 134.83 51.29 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 127.942 2.497 . . . . 0.0 112.606 -169.613 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -164.32 153.56 23.94 Favored Glycine 0 N--CA 1.482 1.751 0 C-N-CA 125.29 1.424 . . . . 0.0 114.252 169.023 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.604 HG21 HG22 ' A' ' 54' ' ' THR . 0.3 OUTLIER -78.31 149.95 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 CA-C-N 120.278 2.039 . . . . 0.0 110.301 170.185 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 10.0 mm -83.13 104.39 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 106.733 -1.581 . . . . 0.0 106.733 166.049 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -106.15 146.79 16.12 Favored Glycine 0 CA--C 1.525 0.705 0 C-N-CA 124.348 0.975 . . . . 0.0 111.134 176.587 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 2.5 pp -79.86 173.7 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 122.908 0.483 . . . . 0.0 111.346 175.255 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.45 ' HB2' ' CB ' ' B' ' 52' ' ' ASP . . . -155.95 -126.86 0.03 OUTLIER 'General case' 0 C--O 1.224 -0.269 0 C-N-CA 125.823 1.649 . . . . 0.0 111.156 163.894 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.858 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -164.244 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 7.8 p -115.91 115.51 26.34 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 168.133 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . 0.477 ' HZ3' ' HB2' ' B' ' 3' ' ' LYS . 0.0 OUTLIER -98.77 142.56 30.15 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 116.605 2.076 . . . . 0.0 116.605 169.966 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -132.24 132.25 42.89 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 127.841 2.456 . . . . 0.0 110.087 172.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . . . . . . . . . 59.6 t -144.77 142.82 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 119.943 1.247 . . . . 0.0 111.786 -168.657 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -114.18 141.38 47.6 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.79 1.236 . . . . 0.0 113.853 171.929 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . . . . . . . . . 15.0 m -104.06 99.62 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 167.383 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.5 mp -78.91 130.35 35.52 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.722 1.209 . . . . 0.0 108.085 -175.63 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -156.18 174.47 15.33 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 -172.644 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 128.96 -43.03 1.35 Allowed Glycine 0 N--CA 1.471 1.002 0 C-N-CA 127.955 2.693 . . . . 0.0 111.32 172.792 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -82.96 59.17 4.74 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 127.932 2.493 . . . . 0.0 113.319 -168.633 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 46.41 -104.0 0.06 OUTLIER Glycine 0 CA--C 1.532 1.14 0 C-N-CA 127.537 2.494 . . . . 0.0 112.6 176.975 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.45 -14.62 16.11 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 123.618 2.878 . . . . 0.0 113.614 -177.564 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.496 HG21 HD11 ' B' ' 144' ' ' LEU . 2.8 t -90.05 128.79 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-N 120.096 1.317 . . . . 0.0 109.921 -178.542 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.513 ' N ' HE21 ' B' ' 15' ' ' GLN . 0.0 OUTLIER -146.06 155.12 42.56 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.848 173.121 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -133.27 153.14 20.64 Favored Glycine 0 C--O 1.227 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.229 177.569 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.4 HD11 ' ND2' ' B' ' 19' ' ' ASN . 0.0 OUTLIER -118.04 117.21 54.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 C-N-CA 126.234 1.814 . . . . 0.0 106.514 168.715 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 24.3 mm -128.19 104.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 O-C-N 123.64 0.587 . . . . 0.0 110.049 177.451 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . 0.4 ' ND2' HD11 ' B' ' 17' ' ' ILE . 0.8 OUTLIER -79.53 156.13 27.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 126.111 1.764 . . . . 0.0 111.981 167.961 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -139.82 108.21 5.84 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 130.655 3.582 . . . . 0.0 107.339 170.071 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.27 130.85 53.31 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.194 1.398 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -126.12 154.68 42.8 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 122.277 1.037 . . . . 0.0 111.35 -176.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.419 ' HZ3' ' CD ' ' B' ' 24' ' ' GLU . 9.9 ptmm? -115.92 -24.35 8.17 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 128.298 2.639 . . . . 0.0 114.105 -177.512 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . 0.419 ' CD ' ' HZ3' ' B' ' 23' ' ' LYS . 6.7 mp0 -135.79 162.25 33.32 Favored 'General case' 0 C--O 1.219 -0.502 0 CA-C-N 121.006 1.73 . . . . 0.0 112.877 173.649 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 6.4 p -64.94 -2.94 2.95 Favored 'General case' 0 N--CA 1.483 1.217 0 O-C-N 119.141 -2.224 . . . . 0.0 113.434 167.226 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.79 64.12 0.16 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 128.383 2.673 . . . . 0.0 109.754 -168.214 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.1 172.75 31.37 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.58 1.562 . . . . 0.0 113.411 -170.747 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -76.53 142.53 23.48 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.39 2.727 . . . . 0.0 110.683 178.634 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.05 132.6 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.158 0.983 . . . . 0.0 109.327 -172.606 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -95.96 115.6 27.67 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-O 121.626 0.726 . . . . 0.0 111.226 179.061 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 11.6 t -93.55 121.35 44.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 127.105 2.162 . . . . 0.0 108.807 -179.123 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 1.8 p90 -148.25 164.88 32.65 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 177.859 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 139.02 -147.67 19.4 Favored Glycine 0 C--N 1.334 0.448 0 C-N-CA 125.111 1.339 . . . . 0.0 111.356 176.795 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 96.5 p -157.94 156.61 31.56 Favored 'General case' 0 C--O 1.237 0.407 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -175.783 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.591 HG21 HG11 ' B' ' 119' ' ' VAL . 3.1 mp -124.39 133.67 68.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 125.284 1.433 . . . . 0.0 108.319 170.636 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -138.3 155.5 48.53 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -172.791 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.87 76.95 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.031 1.3 . . . . 0.0 114.022 -175.515 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.459 ' H ' HD23 ' B' ' 38' ' ' LEU . 1.1 pt? -96.43 162.58 13.42 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 126.559 1.944 . . . . 0.0 112.11 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.23 154.24 1.26 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 128.458 2.703 . . . . 0.0 110.822 169.15 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -64.77 -60.34 3.2 Favored 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 120.717 1.599 . . . . 0.0 112.654 174.245 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . -51.52 141.7 21.84 Favored Glycine 0 N--CA 1.472 1.075 0 C-N-CA 126.218 1.866 . . . . 0.0 114.733 -169.811 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . 0.631 HD13 ' H ' ' B' ' 42' ' ' LEU . 0.0 OUTLIER -40.74 136.88 1.29 Allowed 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 128.315 2.646 . . . . 0.0 115.243 -168.311 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -121.12 142.47 49.83 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 129.816 3.247 . . . . 0.0 109.173 -170.306 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.18 169.51 35.79 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.552 1.072 . . . . 0.0 111.879 172.436 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.2 t80 -160.43 57.95 0.34 Allowed 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.649 1.58 . . . . 0.0 110.728 -169.621 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -117.44 145.81 43.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.305 1.042 . . . . 0.0 113.401 -169.592 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -105.86 115.78 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.773 0.797 . . . . 0.0 109.189 -172.102 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . 0.478 ' HB2' HG23 ' B' ' 116' ' ' THR . 12.1 m-70 -76.42 174.16 10.59 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 124.974 1.31 . . . . 0.0 110.119 179.537 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . 0.532 ' H ' ' CD ' ' B' ' 49' ' ' GLU . 1.9 pm0 -61.15 85.58 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 127.127 2.171 . . . . 0.0 115.074 -168.242 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 67.95 -157.99 0.21 Allowed 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.089 2.156 . . . . 0.0 111.865 168.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.75 -14.88 18.29 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.461 1.505 . . . . 0.0 112.077 -177.871 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.45 ' CB ' ' HB2' ' A' ' 152' ' ' ALA . 7.5 t70 -62.57 56.52 0.01 OUTLIER 'General case' 0 CA--C 1.552 1.023 1 C-N-CA 132.623 4.369 . . . . 0.0 110.6 169.555 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 16.3 p30 176.39 -11.01 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 128.079 2.552 . . . . 0.0 116.287 -174.388 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.315 8.4 t 7.21 30.1 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.952 2 N-CA-C 123.685 4.698 . . . . 0.0 123.685 176.268 . . . . . . . . 3 2 . 1 . 029 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -162.2 10.93 0.07 Allowed 'General case' 0 CA--C 1.544 0.737 0 O-C-N 119.874 -1.766 . . . . 0.0 112.162 -176.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 59.86 -130.82 50.09 Favored Glycine 0 CA--C 1.523 0.585 0 C-N-CA 124.965 1.269 . . . . 0.0 114.048 172.296 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 6.2 t -57.9 -17.31 15.82 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 117.023 2.231 . . . . 0.0 117.023 -167.3 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 10.1 t -81.61 -6.57 59.13 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 120.253 1.388 . . . . 0.0 113.321 171.067 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 28.0 m -144.29 2.99 1.16 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -171.253 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.18 167.85 11.82 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 119.455 1.025 . . . . 0.0 113.173 -169.59 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -103.79 -152.65 23.0 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 126.846 2.165 . . . . 0.0 111.312 178.796 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -109.08 49.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.596 2.864 . . . . 0.0 111.457 -178.326 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 56.77 82.69 0.11 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.932 1.293 . . . . 0.0 112.498 -179.2 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -40.49 131.62 2.21 Favored 'General case' 0 CA--C 1.542 0.673 0 CA-C-O 122.54 1.162 . . . . 0.0 113.089 169.557 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 37.7 p-10 -114.29 79.86 5.44 Favored Pre-proline 0 CA--C 1.547 0.838 0 C-N-CA 126.407 1.883 . . . . 0.0 112.457 -171.246 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -62.23 -14.52 38.73 Favored 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 123.114 2.543 . . . . 0.0 114.685 179.547 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -92.78 -4.0 53.79 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.111 1.364 . . . . 0.0 113.302 171.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 28.0 t 65.7 53.39 1.19 Allowed 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.366 1.866 . . . . 0.0 112.367 171.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 -142.64 177.27 8.42 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -169.559 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.528 ' H ' ' HD2' ' B' ' 70' ' ' LYS . 1.3 mptt -79.41 175.4 10.63 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 126.441 1.897 . . . . 0.0 112.904 -178.228 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -97.49 136.61 37.67 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 115.374 1.62 . . . . 0.0 115.374 -176.805 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 139.83 -132.27 5.5 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 124.268 0.937 . . . . 0.0 113.596 167.421 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 146.04 -34.44 1.43 Allowed Glycine 0 CA--C 1.547 2.087 0 N-CA-C 118.234 2.054 . . . . 0.0 118.234 -177.037 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -78.4 -19.53 11.65 Favored 'Trans proline' 0 C--N 1.356 0.94 0 CA-C-N 122.263 3.032 . . . . 0.0 113.609 172.22 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -46.42 0.93 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 124.437 1.095 . . . . 0.0 109.917 167.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -56.14 126.04 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.976 0.893 . . . . 0.0 109.319 169.209 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -90.61 -5.86 55.35 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 128.973 2.909 . . . . 0.0 112.717 -168.341 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -100.58 -76.48 0.56 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 126.945 2.098 . . . . 0.0 110.773 -169.809 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 84.66 113.7 0.05 Allowed 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 126.519 1.928 . . . . 0.0 113.268 165.812 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -59.2 152.66 20.06 Favored 'General case' 0 CA--C 1.549 0.911 0 O-C-N 119.669 -1.894 . . . . 0.0 110.36 170.04 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -58.39 -30.98 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.891 -1.13 . . . . 0.0 112.681 178.223 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -96.35 37.47 3.42 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 126.619 2.057 . . . . 0.0 113.58 171.211 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -116.85 146.87 42.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 119.988 1.894 . . . . 0.0 115.737 173.892 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 79.1 mt -144.42 163.3 34.2 Favored 'General case' 0 CA--C 1.545 0.784 1 C-N-CA 132.102 4.161 . . . . 0.0 102.702 163.156 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -85.91 -87.06 0.99 Allowed Glycine 0 N--CA 1.468 0.829 0 O-C-N 121.926 -0.484 . . . . 0.0 113.428 -170.643 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -153.32 168.44 26.03 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 124.674 1.19 . . . . 0.0 113.479 -166.521 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.56 147.59 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 129.233 3.013 . . . . 0.0 110.214 -176.407 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 25.7 m -120.84 145.6 47.43 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 119.437 1.017 . . . . 0.0 109.991 -176.979 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.65 144.48 26.65 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.895 0.855 . . . . 0.0 111.666 175.95 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . 0.452 ' OD1' ' HE2' ' B' ' 91' ' ' LYS . 39.7 t0 -73.19 158.95 34.26 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.762 1.225 . . . . 0.0 109.813 168.921 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . 0.452 ' HE2' ' OD1' ' B' ' 90' ' ' ASP . 0.0 OUTLIER -52.33 -28.2 18.34 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 115.42 1.637 . . . . 0.0 115.42 -168.292 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.85 -2.25 29.19 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.544 1.538 . . . . 0.0 112.283 -178.51 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.08 39.16 7.54 Favored Glycine 0 C--N 1.339 0.747 0 C-N-CA 125.221 1.391 . . . . 0.0 113.154 177.843 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 3.2 p -132.62 126.37 54.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 CA-C-N 118.629 1.215 . . . . 0.0 113.811 170.018 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . . . . . . . . . . . -91.58 119.23 31.31 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.518 1.527 . . . . 0.0 107.929 165.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -79.46 151.15 31.0 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 167.419 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . 0.29 0.5 OUTLIER -134.53 131.59 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 114.593 -1.185 . . . . 0.0 112.899 165.477 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 9.6 p -157.69 59.96 0.48 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.151 1.38 . . . . 0.0 113.164 -168.65 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 19.2 mt -115.39 156.08 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 C-N-CA 126.787 2.035 . . . . 0.0 112.715 -171.582 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -128.67 146.49 50.86 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.733 1.613 . . . . 0.0 108.288 166.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -141.02 134.83 30.41 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.243 1.417 . . . . 0.0 110.222 -179.03 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -112.75 59.27 0.64 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.315 1.446 . . . . 0.0 112.234 -167.578 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 14.4 p -158.12 -36.5 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.132 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.13 170.97 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 123.332 0.653 . . . . 0.0 111.349 172.712 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 5.8 m -157.51 159.44 37.21 Favored 'General case' 0 N--CA 1.469 0.506 0 O-C-N 120.12 -1.612 . . . . 0.0 111.335 176.316 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . 0.464 ' HG ' HD11 ' B' ' 113' ' ' ILE . 4.8 tt -81.12 75.02 8.1 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.056 0.942 . . . . 0.0 109.523 -173.627 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -138.97 152.18 47.47 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.761 1.625 . . . . 0.0 111.391 -174.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -101.91 68.54 0.39 Allowed Glycine 0 N--CA 1.476 1.313 0 C-N-CA 126.968 2.223 . . . . 0.0 113.427 -169.29 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . 0.527 ' HA ' ' HB2' ' A' ' 1' ' ' ALA . 0.6 OUTLIER -154.43 -91.53 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.78 1.632 . . . . 0.0 110.362 -168.819 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -127.79 -4.43 5.81 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.742 2.017 . . . . 0.0 110.461 -170.048 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 16.4 m -92.6 -91.31 0.17 Allowed 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.523 1.929 . . . . 0.0 114.651 -166.066 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 2.3 pt -135.36 -14.69 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 118.112 2.634 . . . . 0.0 118.112 176.724 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . 0.526 HD12 HG23 ' B' ' 151' ' ' ILE . 22.0 mm -86.58 105.8 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 CA-C-N 122.113 2.233 . . . . 0.0 108.747 179.283 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.59 61.45 1.17 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.573 0.606 . . . . 0.0 112.944 -171.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 23.4 ptt180 -140.36 144.95 36.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.981 1.312 . . . . 0.0 109.239 167.305 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . 0.478 HG23 ' HB2' ' B' ' 48' ' ' HIS . 2.3 t -109.39 102.09 11.01 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 124.243 1.017 . . . . 0.0 111.067 -166.665 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 29.2 tp -86.33 129.67 34.77 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 124.152 0.981 . . . . 0.0 109.774 -173.245 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 3.7 t -107.82 118.09 54.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 169.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.591 HG11 HG21 ' B' ' 35' ' ' ILE . 13.9 p -78.85 120.03 29.18 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.37 0 N-CA-C 100.483 -3.895 . . . . 0.0 100.483 161.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -106.45 142.52 35.97 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 117.766 -1.111 . . . . 0.0 109.38 -168.189 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -56.92 -42.94 80.87 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 122.154 2.252 . . . . 0.0 113.915 -166.718 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.473 ' HE3' ' HA ' ' B' ' 122' ' ' LYS . 0.0 OUTLIER -111.7 152.35 27.83 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 171.624 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -51.12 161.02 0.44 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.853 1.661 . . . . 0.0 112.258 171.68 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -94.47 151.35 19.44 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 177.833 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -71.8 -16.66 62.19 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.572 1.949 . . . . 0.0 112.875 176.482 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . . . . . . . . . 28.3 mt 57.96 84.29 0.1 Allowed 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 127.028 2.131 . . . . 0.0 114.464 169.764 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 88.74 -47.48 3.42 Favored Glycine 0 N--CA 1.465 0.622 0 C-N-CA 125.502 1.525 . . . . 0.0 111.015 169.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -158.84 137.91 11.33 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.609 1.564 . . . . 0.0 110.448 168.646 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . -141.37 -101.15 0.43 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 169.164 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . -98.57 -24.49 10.96 Favored Glycine 0 N--CA 1.471 0.972 0 N-CA-C 116.705 1.442 . . . . 0.0 116.705 -168.576 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -165.46 174.18 10.26 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.882 1.341 . . . . 0.0 111.83 -169.225 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -49.86 -50.84 44.19 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 126.062 1.745 . . . . 0.0 113.449 -170.313 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . 0.471 ' H ' ' CD ' ' B' ' 133' ' ' GLU . 13.7 mp0 -45.76 -25.79 0.55 Allowed 'General case' 0 C--N 1.318 -0.794 0 C-N-CA 128.27 2.628 . . . . 0.0 113.705 175.305 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 90.6 p -64.95 -45.06 87.32 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 120.119 1.327 . . . . 0.0 112.716 178.823 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 8.9 t -79.91 -39.72 29.76 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.18 0.592 . . . . 0.0 111.523 173.151 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.29 -18.64 52.25 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -173.033 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 9.9 p -152.71 -15.11 0.16 Allowed 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 177.956 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . 100.04 -7.56 58.85 Favored Glycine 0 C--O 1.214 -1.155 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.313 -168.652 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 51.3 t30 55.57 35.49 25.28 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-N 120.613 2.206 . . . . 0.0 112.157 178.184 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -72.9 38.88 0.08 Allowed 'General case' 0 CA--C 1.563 1.451 0 N-CA-C 115.759 1.763 . . . . 0.0 115.759 -166.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 71.16 -84.46 0.41 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 127.109 2.29 . . . . 0.0 113.767 175.488 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t -160.52 172.8 16.55 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.155 0.982 . . . . 0.0 112.978 -178.041 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 154.83 25.62 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.126 1.37 . . . . 0.0 113.624 -171.488 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.496 HD11 HG21 ' B' ' 14' ' ' VAL . 19.5 tp -159.79 -177.55 6.43 Favored 'General case' 0 CA--C 1.56 1.342 0 C-N-CA 129.795 3.238 . . . . 0.0 104.878 169.836 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -49.73 129.91 20.36 Favored 'General case' 0 CA--C 1.556 1.185 0 N-CA-C 115.838 1.792 . . . . 0.0 115.838 -165.146 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 71.9 m -114.91 134.19 55.36 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 126.712 2.005 . . . . 0.0 112.645 -176.687 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -157.9 144.12 10.17 Favored Glycine 0 N--CA 1.486 2.006 0 CA-C-N 120.994 1.724 . . . . 0.0 117.172 177.297 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.518 ' O ' HG21 ' A' ' 54' ' ' THR . 84.6 t -81.12 140.74 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 CA-C-N 118.169 0.985 . . . . 0.0 109.893 176.022 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 2.4 mm -77.68 107.33 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 170.584 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.16 36.45 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.555 1.55 . . . . 0.0 111.951 169.635 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . 0.526 HG23 HD12 ' B' ' 113' ' ' ILE . 1.1 pp -138.91 160.65 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 125.04 1.336 . . . . 0.0 112.89 177.822 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.58 1.3 0.44 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.644 1.978 . . . . 0.0 112.554 164.603 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 2.0 tm0? . . . . . 0 N--CA 1.472 0.648 0 C-N-CA 126.636 1.975 . . . . 0.0 110.876 169.699 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.758 0 CA-C-O 118.973 -0.537 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 67.4 p -78.82 64.66 3.85 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 127.132 2.173 . . . . 0.0 114.881 -166.241 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.1 ttpt -161.55 126.18 3.44 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 118.529 2.789 . . . . 0.0 118.529 166.085 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -119.52 177.5 4.9 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 129.489 3.116 . . . . 0.0 107.006 164.346 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.574 HG11 ' HA ' ' B' ' 52' ' ' ASP . 2.5 p -157.54 151.15 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 113.917 1.08 . . . . 0.0 113.917 -164.227 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -144.07 115.21 7.92 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.503 0.668 . . . . 0.0 110.627 166.252 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 68.9 t -101.41 95.59 4.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.667 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.9 mp -79.34 152.51 30.42 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.13 1.372 . . . . 0.0 108.68 173.612 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -153.24 158.56 41.88 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 179.277 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -130.11 158.33 22.31 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 127.308 2.385 . . . . 0.0 107.957 166.151 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -71.94 83.59 0.95 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 126.817 2.047 . . . . 0.0 110.941 -177.446 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 146.09 -147.64 18.78 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 127.041 2.258 . . . . 0.0 110.158 -169.403 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -94.64 9.51 1.93 Allowed 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 124.794 3.663 . . . . 0.0 114.87 -169.841 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.63 134.16 34.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 CA-C-N 120.025 1.284 . . . . 0.0 110.393 -177.369 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.39 164.67 34.28 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.517 1.127 . . . . 0.0 111.486 178.865 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.447 ' HA2' ' HA ' ' A' ' 35' ' ' ILE . . . -129.52 97.79 0.42 Allowed Glycine 0 C--O 1.215 -1.042 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 169.042 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -96.41 106.61 18.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 118.519 1.159 . . . . 0.0 108.012 175.892 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 pt -133.59 150.13 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 122.241 1.019 . . . . 0.0 111.62 177.09 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -122.74 145.29 48.54 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.637 1.575 . . . . 0.0 110.329 179.416 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -120.94 105.07 10.32 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.936 1.694 . . . . 0.0 109.635 -173.895 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.1 121.16 28.31 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 177.369 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.584 ' CB ' HD13 ' A' ' 106' ' ' LEU . 11.0 tp60 -147.76 137.94 22.91 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.251 0.548 . . . . 0.0 111.186 175.507 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.497 ' H ' ' CD ' ' A' ' 23' ' ' LYS . 0.0 OUTLIER -91.96 -24.28 19.31 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -175.735 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.66 -155.65 0.61 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-N 120.136 1.335 . . . . 0.0 113.038 176.489 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 66.6 m -107.25 10.25 29.91 Favored 'General case' 0 CA--C 1.543 0.677 0 O-C-N 119.377 -2.077 . . . . 0.0 113.634 -179.095 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -131.27 -10.29 3.7 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 126.021 1.728 . . . . 0.0 114.746 -172.437 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.13 160.74 20.75 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 128.926 3.155 . . . . 0.0 112.657 -168.615 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.75 151.57 32.02 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 123.028 2.486 . . . . 0.0 109.718 175.568 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 67.4 t -119.71 137.65 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.166 1.387 . . . . 0.0 110.004 -168.166 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -84.41 127.09 33.8 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.512 0.596 . . . . 0.0 110.1 170.19 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 t -107.82 130.09 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 125.632 1.573 . . . . 0.0 108.346 171.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 4.8 p90 -151.14 165.9 32.48 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 123.342 0.657 . . . . 0.0 111.54 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 131.16 -148.9 19.07 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 124.993 1.283 . . . . 0.0 111.754 175.928 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 54.1 p -142.6 127.22 17.98 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -169.815 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.447 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 10.2 mm -101.3 112.77 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 124.676 1.19 . . . . 0.0 108.279 170.987 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.9 pttt -129.58 152.07 49.5 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 119.835 1.198 . . . . 0.0 112.698 -166.514 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.01 5.52 64.05 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.38 0.99 . . . . 0.0 112.599 -169.061 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 9.7 mp -75.44 -161.63 0.16 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 127.405 2.282 . . . . 0.0 109.662 168.766 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 10.9 t -151.98 171.24 18.13 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 126.627 1.971 . . . . 0.0 108.183 169.331 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -49.04 136.84 13.96 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.851 1.66 . . . . 0.0 113.439 -168.876 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.51 -173.13 28.21 Favored Glycine 0 CA--C 1.52 0.391 0 CA-C-O 122.597 1.11 . . . . 0.0 112.511 173.202 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.483 ' H ' HD12 ' A' ' 42' ' ' LEU . 0.5 OUTLIER -73.01 160.45 32.07 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 124.1 0.96 . . . . 0.0 111.373 -171.339 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.402 ' HB2' HG13 ' A' ' 87' ' ' VAL . 81.6 m-70 -149.09 136.21 19.94 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 127.653 2.381 . . . . 0.0 108.867 176.62 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.17 148.71 32.48 Favored Glycine 0 N--CA 1.478 1.463 0 CA-C-O 119.261 -0.744 . . . . 0.0 111.964 171.226 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -153.15 78.71 1.17 Allowed 'General case' 0 CA--C 1.544 0.741 0 CA-C-O 122.88 1.324 . . . . 0.0 110.768 -168.556 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -124.73 157.86 34.66 Favored 'General case' 0 CA--C 1.516 -0.338 0 O-C-N 120.803 -1.186 . . . . 0.0 111.396 -169.428 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.618 HG11 HH11 ' A' ' 115' ' ' ARG . 1.7 m -87.65 151.52 3.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.24 176.628 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 8.4 m170 -113.88 168.79 9.5 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 104.102 -2.555 . . . . 0.0 104.102 160.175 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.75 -172.69 0.09 Allowed 'General case' 0 CA--C 1.554 1.11 0 N-CA-C 117.257 2.317 . . . . 0.0 117.257 -167.83 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -119.43 -36.58 3.32 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 128.203 2.601 . . . . 0.0 112.305 -175.739 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -58.19 -29.52 62.9 Favored Glycine 0 N--CA 1.47 0.93 1 C-N-CA 131.667 4.461 . . . . 0.0 114.588 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -123.97 151.23 43.9 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 163.045 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.576 ' HB2' HG13 ' B' ' 5' ' ' VAL . 0.5 OUTLIER -148.98 101.55 3.18 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 119.11 3.004 . . . . 0.0 119.11 -166.493 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.555 HG23 ' O ' ' A' ' 53' ' ' ASN 0.549 0.1 OUTLIER 112.48 -145.75 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.695 1 C-N-CA 133.673 4.789 . . . . 0.0 113.576 160.044 . . . . . . . . 5 4 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 49.05 -10.13 0.0 OUTLIER 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 131.033 3.733 . . . . 0.0 117.91 -172.348 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.34 -132.12 11.11 Favored Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.968 2.223 . . . . 0.0 111.211 -176.915 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.9 m -62.78 -8.47 6.89 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.233 1.197 . . . . 0.0 114.233 177.726 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.1 m -79.9 -24.07 41.38 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.922 1.289 . . . . 0.0 112.457 171.672 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.514 ' HB3' HG11 ' B' ' 7' ' ' VAL . 4.1 m -158.43 45.57 0.31 Allowed 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 116.193 1.923 . . . . 0.0 116.193 -169.2 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 176.96 125.45 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 127.807 2.443 . . . . 0.0 110.452 168.429 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -72.16 149.14 43.73 Favored Glycine 0 CA--C 1.541 1.667 0 O-C-N 120.736 -1.228 . . . . 0.0 114.372 -175.772 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -64.69 106.94 0.8 Allowed 'Trans proline' 0 C--N 1.354 0.822 1 C-N-CA 125.488 4.125 . . . . 0.0 111.604 -178.896 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.442 ' CE1' ' HA ' ' A' ' 137' ' ' THR 0.274 0.0 OUTLIER 36.04 57.18 1.0 Allowed 'General case' 0 C--O 1.234 0.247 0 C-N-CA 127.377 2.271 . . . . 0.0 112.468 170.458 . . . . . . . . 4 4 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -27.05 122.79 0.09 Allowed 'General case' 0 C--N 1.342 0.259 0 C-N-CA 128.285 2.634 . . . . 0.0 111.26 179.328 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 62.8 m-20 -71.84 101.26 0.37 Allowed Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -168.426 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -84.67 -12.46 7.49 Favored 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.157 2.571 . . . . 0.0 112.956 -167.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 92.0 mt -139.75 2.91 2.02 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 128.62 2.768 . . . . 0.0 110.717 -172.117 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 16.0 t 66.44 53.43 0.98 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.706 1.603 . . . . 0.0 114.022 175.675 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.79 179.57 4.94 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 125.978 1.711 . . . . 0.0 113.161 179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.1 mmtt -73.57 173.61 9.46 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 121.654 0.74 . . . . 0.0 111.667 169.356 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 48.9 t60 -72.15 157.77 37.14 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 168.489 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.413 ' HA3' ' HB3' ' A' ' 76' ' ' ASP . . . 143.78 -126.19 2.69 Favored Glycine 0 C--N 1.339 0.72 0 N-CA-C 116.576 1.39 . . . . 0.0 116.576 165.725 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.85 -90.24 0.36 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 116.58 1.392 . . . . 0.0 116.58 -171.105 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -64.5 -2.21 4.84 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.946 3.097 . . . . 0.0 115.184 -173.325 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . 0.312 3.3 ptmm? -144.08 4.13 1.24 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 126.433 1.893 . . . . 0.0 112.677 168.346 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB3' ' HA3' ' A' ' 72' ' ' GLY . 0.0 OUTLIER -131.77 113.77 13.92 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 127.082 2.153 . . . . 0.0 109.168 177.038 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -71.16 -14.07 62.15 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 127.968 2.507 . . . . 0.0 114.082 -176.371 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -78.02 -62.06 1.8 Allowed 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.908 1.231 . . . . 0.0 109.295 175.361 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 74.6 ttt180 70.71 120.44 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 123.477 1.608 . . . . 0.0 112.831 169.592 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 22.8 m170 -66.98 136.58 55.53 Favored 'General case' 0 CA--C 1.543 0.694 0 O-C-N 118.96 -2.337 . . . . 0.0 109.217 164.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.0 t -53.74 -19.11 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 122.464 1.126 . . . . 0.0 111.636 166.281 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.489 ' HA3' HG22 ' A' ' 47' ' ' VAL . . . -92.16 41.09 2.82 Favored Glycine 0 CA--C 1.536 1.344 0 C-N-CA 127.255 2.36 . . . . 0.0 116.878 172.454 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -144.56 122.57 12.08 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-N 119.751 1.775 . . . . 0.0 111.865 -179.06 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.86 48.75 0.94 Allowed 'General case' 0 CA--C 1.54 0.567 0 CA-C-O 123.811 1.767 . . . . 0.0 110.359 173.762 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.89 -133.48 52.71 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 126.122 1.82 . . . . 0.0 114.257 175.289 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -111.82 138.73 48.03 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.672 1.589 . . . . 0.0 110.11 171.495 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.402 HG13 ' HB2' ' A' ' 43' ' ' HIS . 8.0 p -92.95 127.45 45.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 166.327 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 24.4 m -115.39 119.48 36.4 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -176.27 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.99 156.96 17.31 Favored 'General case' 0 C--N 1.328 -0.353 0 O-C-N 123.667 0.604 . . . . 0.0 112.588 -177.21 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.73 168.54 19.65 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 126.403 1.881 . . . . 0.0 113.67 173.21 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.1 pptp? -60.11 -20.09 56.62 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.789 1.636 . . . . 0.0 113.79 168.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -80.95 0.04 37.25 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.006 1.322 . . . . 0.0 112.306 170.791 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.92 19.92 60.41 Favored Glycine 0 C--N 1.339 0.719 0 C-N-CA 125.178 1.37 . . . . 0.0 114.099 174.633 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.7 p -134.16 138.85 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 CA-C-N 119.04 1.42 . . . . 0.0 113.527 -176.54 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -96.79 123.31 40.45 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 165.655 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -97.74 118.8 35.09 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.581 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.12 140.08 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 CA-C-N 114.159 -1.382 . . . . 0.0 113.935 -165.733 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 77.4 p -155.65 123.2 5.57 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.594 1.558 . . . . 0.0 110.103 168.834 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -155.17 148.81 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 127.703 2.401 . . . . 0.0 109.992 -169.85 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -125.77 125.22 42.61 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 165.749 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -121.72 141.81 50.81 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.038 0.935 . . . . 0.0 110.994 -173.753 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -115.63 48.66 1.17 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.959 0.904 . . . . 0.0 112.863 -178.377 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -129.26 -4.81 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.459 1.104 . . . . 0.0 112.23 170.732 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.54 164.88 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 C-N-CA 125.951 1.7 . . . . 0.0 110.727 176.672 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 99.5 p -149.54 175.28 11.66 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 128.285 2.634 . . . . 0.0 109.072 178.098 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.584 HD13 ' CB ' ' A' ' 22' ' ' GLN . 6.8 mp -86.16 93.4 9.02 Favored 'General case' 0 CA--C 1.543 0.684 0 O-C-N 120.809 -1.182 . . . . 0.0 109.33 173.249 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.2 t -152.45 153.88 34.42 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.753 1.221 . . . . 0.0 110.119 169.04 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -103.08 29.23 12.88 Favored Glycine 0 N--CA 1.472 1.041 0 C-N-CA 126.142 1.829 . . . . 0.0 113.27 -178.147 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -86.81 -96.55 0.08 Allowed 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 126.022 1.729 . . . . 0.0 106.691 169.655 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 14.1 m170 -107.39 -7.75 16.54 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 125.458 1.503 . . . . 0.0 111.806 169.529 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -76.15 -157.77 0.08 Allowed 'General case' 0 CA--C 1.558 1.259 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -174.999 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . 0.271 10.9 pt -97.14 44.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 118.455 -2.653 . . . . 0.0 116.06 -172.006 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 27.9 mm -115.73 126.96 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 166.321 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 74.18 -4.2 34.06 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-O 117.208 -1.885 . . . . 0.0 115.077 173.309 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.618 HH11 HG11 ' A' ' 47' ' ' VAL . 3.1 ptp180 -78.82 153.47 30.64 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 120.795 2.297 . . . . 0.0 110.889 170.218 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 148' ' ' VAL . 6.3 t -101.29 162.75 12.67 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 119.676 1.125 . . . . 0.0 112.917 177.466 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.471 HD13 ' N ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -130.44 137.98 50.09 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.788 2.035 . . . . 0.0 107.921 174.52 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.471 ' N ' HD13 ' A' ' 117' ' ' LEU . 7.4 p -122.2 125.44 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.291 1.436 . . . . 0.0 109.969 175.24 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -90.2 143.08 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 171.84 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -106.64 158.35 17.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 122.009 0.909 . . . . 0.0 112.909 -174.567 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -71.56 -40.8 69.74 Favored 'General case' 0 CA--C 1.538 0.483 0 O-C-N 121.334 -0.854 . . . . 0.0 111.237 -169.07 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 mptt -116.82 174.73 5.92 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 124.706 1.202 . . . . 0.0 112.664 172.594 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -47.4 148.16 1.43 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.813 2.445 . . . . 0.0 112.252 172.422 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -110.29 142.57 41.73 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.282 1.033 . . . . 0.0 112.185 172.609 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -93.93 -8.3 40.56 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 114.486 1.291 . . . . 0.0 114.486 176.888 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 77.09 -73.33 0.09 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 128.94 2.896 . . . . 0.0 111.516 169.301 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -95.8 -5.26 59.99 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 125.262 1.411 . . . . 0.0 113.539 -174.389 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt -158.23 -146.08 0.15 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 128.088 2.555 . . . . 0.0 112.539 173.15 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 133.31 -29.13 3.21 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 128.7 3.048 . . . . 0.0 110.617 -168.393 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 126.73 -17.03 6.47 Favored Glycine 0 N--CA 1.473 1.12 0 C-N-CA 126.282 1.896 . . . . 0.0 114.986 169.588 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -110.57 174.6 5.79 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.09 1.356 . . . . 0.0 113.683 -171.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -52.22 -59.67 4.12 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.319 1.848 . . . . 0.0 110.615 167.52 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -46.57 -36.01 6.42 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.735 1.214 . . . . 0.0 112.51 169.433 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.4 p -66.47 -3.74 6.85 Favored 'General case' 0 N--CA 1.476 0.86 0 O-C-N 120.132 -1.605 . . . . 0.0 113.909 -175.936 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 17.1 p -119.96 -12.96 9.08 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 175.896 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 19.7 ptpt -113.25 -26.1 8.56 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.097 1.147 . . . . 0.0 114.097 176.952 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.442 ' HA ' ' CE1' ' A' ' 63' ' ' HIS . 0.5 OUTLIER -127.96 -17.94 4.31 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 127.049 2.14 . . . . 0.0 113.809 179.497 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 94.03 -21.49 41.62 Favored Glycine 0 N--CA 1.467 0.724 0 C-N-CA 126.537 2.018 . . . . 0.0 111.969 177.361 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 71.46 36.65 1.26 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.94 1.696 . . . . 0.0 112.421 168.492 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.32 44.69 0.01 OUTLIER 'General case' 0 CA--C 1.575 1.941 0 C-N-CA 128.414 2.686 . . . . 0.0 117.41 -169.268 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 74.8 -57.21 2.62 Favored Glycine 0 N--CA 1.473 1.157 0 C-N-CA 127.84 2.638 . . . . 0.0 114.483 -177.986 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 12.9 t -168.17 171.11 9.7 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.727 1.211 . . . . 0.0 111.572 -178.584 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -85.04 148.29 26.23 Favored 'General case' 0 N--CA 1.474 0.744 0 O-C-N 120.726 -1.233 . . . . 0.0 110.608 175.208 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -128.01 -146.28 0.32 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.521 1.929 . . . . 0.0 109.26 175.935 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -63.79 155.37 30.54 Favored 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 127.146 2.178 . . . . 0.0 114.596 179.748 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 31.3 p -151.96 153.74 34.67 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.086 1.355 . . . . 0.0 114.084 -173.304 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -161.04 159.87 31.5 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 125.042 1.306 . . . . 0.0 113.407 178.057 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 3.6 t -106.45 142.91 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-N 118.717 1.259 . . . . 0.0 109.422 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 4.1 mm -77.48 93.74 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 CA-C-O 122.232 1.015 . . . . 0.0 110.156 -178.676 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -92.27 174.94 37.38 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 125.884 1.707 . . . . 0.0 112.706 173.581 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.07 149.64 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -173.372 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -127.98 -17.58 4.37 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.552 1.941 . . . . 0.0 115.006 177.561 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 . . . . . 0 N--CA 1.472 0.627 0 C-N-CA 125.689 1.595 . . . . 0.0 112.592 176.864 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.342 0 CA-C-O 121.279 0.561 . . . . 0.0 112.235 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 2' ' ' THR . . . . . . . . . . . . . 14.7 t -156.63 112.17 2.92 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 125.814 1.646 . . . . 0.0 108.458 167.878 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 3' ' ' LYS . . . . . . . . . . . . . 10.1 pttt -111.93 171.72 7.33 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 116.45 2.019 . . . . 0.0 116.45 -173.315 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' B' ' 152' ' ' ALA . . . -125.87 168.32 14.02 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 128.457 2.703 . . . . 0.0 110.957 174.492 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 5' ' ' VAL . . . . . 0.576 HG13 ' HB2' ' A' ' 53' ' ' ASN . 0.9 OUTLIER -131.5 139.46 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 126.331 1.852 . . . . 0.0 111.861 -178.202 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.06 105.05 4.77 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.092 0.957 . . . . 0.0 109.477 165.041 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.514 HG11 ' HB3' ' A' ' 59' ' ' SER . 1.0 OUTLIER -92.13 130.81 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 166.358 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 8' ' ' LEU . . . . . . . . . . . . . 9.1 mp -92.07 143.41 26.48 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 123.554 0.742 . . . . 0.0 111.284 -178.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 9' ' ' LYS . . . . . . . . . . . . . 2.4 tttm -156.14 175.93 13.33 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 168.903 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . 148.8 -77.93 0.23 Allowed Glycine 0 CA--C 1.523 0.552 0 C-N-CA 128.463 2.935 . . . . 0.0 108.164 -172.936 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -76.74 75.49 3.39 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.021 1.728 . . . . 0.0 112.735 -168.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 45.73 -97.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.37 0 C-N-CA 127.503 2.478 . . . . 0.0 114.314 169.518 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 13' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -82.81 -1.34 10.46 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 124.958 3.772 . . . . 0.0 114.945 179.162 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.81 140.34 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 120.54 1.518 . . . . 0.0 110.047 170.749 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -139.71 168.03 20.76 Favored 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 125.684 1.594 . . . . 0.0 109.31 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -158.83 92.98 0.12 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.034 -1.426 . . . . 0.0 116.126 165.229 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.404 ' O ' HD13 ' B' ' 18' ' ' ILE . 0.0 OUTLIER -78.22 126.5 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-N 119.296 1.548 . . . . 0.0 110.723 175.931 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.469 HD12 HG11 ' B' ' 97' ' ' VAL . 26.7 mm -135.98 111.08 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 124.901 1.28 . . . . 0.0 110.977 176.113 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 19' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -74.8 146.62 41.91 Favored 'General case' 0 CA--C 1.546 0.819 0 O-C-N 121.328 -0.857 . . . . 0.0 110.009 166.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -128.76 100.64 5.79 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.707 1.603 . . . . 0.0 108.571 172.914 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -101.83 130.37 48.27 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -174.549 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 22' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -100.81 120.51 40.22 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.136 0.493 . . . . 0.0 111.41 -179.454 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 23' ' ' LYS . . . . . 0.422 ' HG2' ' H ' ' B' ' 23' ' ' LYS . 7.9 ptmm? -75.06 -41.7 58.44 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 123.048 0.539 . . . . 0.0 111.204 168.678 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 24' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -156.58 133.58 10.42 Favored 'General case' 0 C--O 1.219 -0.52 0 C-N-CA 126.429 1.892 . . . . 0.0 110.321 168.309 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -60.42 -19.72 57.23 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 114.703 1.372 . . . . 0.0 114.703 -172.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 26' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -80.56 -6.26 57.98 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.655 1.182 . . . . 0.0 113.218 173.753 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.86 -164.34 11.22 Favored Glycine 0 CA--C 1.537 1.459 0 C-N-CA 126.546 2.022 . . . . 0.0 113.383 -172.935 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 28' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.37 155.52 25.06 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 123.271 2.647 . . . . 0.0 114.012 -169.25 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 84.5 t -102.6 137.35 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 125.766 1.626 . . . . 0.0 110.17 172.739 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -96.09 122.62 39.12 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 167.145 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . . . . . . . . . 48.3 t -117.31 129.2 74.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 126.166 1.786 . . . . 0.0 107.856 -169.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 32' ' ' TRP . . . . . . . . . . . . . 12.5 p90 -155.41 153.16 29.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 -178.679 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.64 -152.73 24.77 Favored Glycine 0 CA--C 1.519 0.303 0 C-N-CA 125.417 1.484 . . . . 0.0 109.92 179.717 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 34' ' ' SER . . . . . . . . . . . . . 69.0 p -159.04 147.42 18.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -175.074 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' B' ' 95' ' ' ALA . 6.0 mm -105.62 109.55 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.558 1.543 . . . . 0.0 109.078 177.812 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 36' ' ' LYS . . . . . . . . . . . . . 44.9 tttp -120.75 133.43 55.33 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 119.463 1.029 . . . . 0.0 110.94 -168.887 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.66 -6.43 9.73 Favored Glycine 0 CA--C 1.541 1.681 0 C-N-CA 127.964 2.697 . . . . 0.0 113.839 -169.663 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.489 HD12 ' CE1' ' B' ' 43' ' ' HIS . 4.6 mm? -75.08 -179.89 4.61 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 126.373 1.869 . . . . 0.0 113.346 177.169 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 13.4 t -103.95 157.73 16.9 Favored 'General case' 0 C--O 1.239 0.553 0 N-CA-C 106.024 -1.843 . . . . 0.0 106.024 162.521 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -64.86 168.94 5.65 Favored 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.741 1.385 . . . . 0.0 114.741 -170.84 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.59 -177.54 51.38 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.261 0.934 . . . . 0.0 114.161 -173.021 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 42' ' ' LEU . . . . . . . . . . . . . 6.8 mp -66.97 149.33 50.78 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 127.298 2.239 . . . . 0.0 113.648 -174.156 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 43' ' ' HIS . . . . . 0.489 ' CE1' HD12 ' B' ' 38' ' ' LEU . 96.9 m-70 -140.5 133.42 29.19 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.726 1.61 . . . . 0.0 110.235 176.816 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.59 146.67 48.47 Favored Glycine 0 N--CA 1.475 1.257 0 CA-C-O 119.055 -0.858 . . . . 0.0 110.987 175.574 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -152.94 111.79 3.76 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.592 0.757 . . . . 0.0 111.852 -166.06 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 46' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -147.73 152.2 37.36 Favored 'General case' 0 N--CA 1.471 0.617 0 O-C-N 120.032 -1.667 . . . . 0.0 111.256 -169.852 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 47' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.41 131.41 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-O 123.719 1.724 . . . . 0.0 110.117 169.527 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 48' ' ' HIS . . . . . . . . . . . . . 18.1 m-70 -76.08 108.69 9.16 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 165.448 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 49' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -68.75 21.62 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 127.238 2.215 . . . . 0.0 113.554 -169.288 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 50' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -153.81 131.74 11.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 125.976 1.71 . . . . 0.0 108.005 -171.158 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.28 -14.54 76.39 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 115.124 0.81 . . . . 0.0 115.124 178.427 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 52' ' ' ASP . . . . . 0.574 ' HA ' HG11 ' A' ' 5' ' ' VAL . 2.0 t70 -69.91 74.07 0.44 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 127.023 2.129 . . . . 0.0 111.149 178.257 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 53' ' ' ASN . . . . . . . . . . . . . 5.4 p30 164.02 -36.54 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 128.697 2.799 . . . . 0.0 115.237 -178.85 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 54' ' ' THR . . . . . . . . . . . . 0.401 0.1 OUTLIER 54.13 -47.4 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 130.457 3.503 . . . . 0.0 118.667 -173.625 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.98 21.23 6.9 Favored 'General case' 0 CA--C 1.549 0.906 0 CA-C-N 120.37 1.441 . . . . 0.0 113.643 -178.497 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 53.62 -128.67 39.88 Favored Glycine 0 C--N 1.34 0.782 0 C-N-CA 126.028 1.775 . . . . 0.0 112.919 169.248 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 57' ' ' CYS . . . . . . . . . . . . . 61.1 m -58.16 -7.79 0.92 Allowed 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 115.856 1.798 . . . . 0.0 115.856 178.245 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 58' ' ' THR . . . . . . . . . . . . . 34.5 m -103.89 -0.11 29.49 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 126.084 1.753 . . . . 0.0 111.61 177.213 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 74.4 m -146.31 7.08 1.0 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 171.753 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.68 -172.71 1.96 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.845 2.058 . . . . 0.0 111.381 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 61' ' ' GLY . . . . . . . . . . . . . . . -76.05 178.39 49.08 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 118.774 -1.014 . . . . 0.0 113.713 173.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 62' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -64.71 -176.3 0.42 Allowed 'Trans proline' 0 C--N 1.356 0.928 1 C-N-CA 128.171 5.914 . . . . 0.0 113.097 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 63' ' ' HIS . . . . . 0.623 ' CD2' ' H ' ' B' ' 63' ' ' HIS . 1.6 p80 -53.48 111.82 0.78 Allowed 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.215 1.406 . . . . 0.0 108.53 169.338 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 64' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -57.49 157.9 6.36 Favored 'General case' 0 CA--C 1.543 0.683 0 CA-C-N 114.434 -1.257 . . . . 0.0 111.174 -178.854 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 65' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.26 49.78 0.01 OUTLIER Pre-proline 0 CA--C 1.566 1.59 0 N-CA-C 114.909 1.448 . . . . 0.0 114.909 172.497 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -65.74 -28.98 51.45 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.366 2.238 . . . . 0.0 114.247 -171.553 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 67' ' ' LEU . . . . . . . . . . . . . 65.7 mt -75.79 -4.0 38.14 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 173.4 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t 64.95 55.16 1.19 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.524 1.529 . . . . 0.0 112.827 170.231 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -161.33 178.92 8.73 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 124.899 1.279 . . . . 0.0 112.709 -171.274 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HZ1' ' CD ' ' B' ' 77' ' ' GLU . 22.4 pttm -72.7 161.24 31.0 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.138 0.575 . . . . 0.0 111.173 -175.757 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 71' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -82.41 155.17 24.82 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 179.426 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . 141.26 -108.93 0.57 Allowed Glycine 0 C--N 1.339 0.72 0 N-CA-C 114.246 0.458 . . . . 0.0 114.246 166.896 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.438 ' H ' ' HB3' ' B' ' 76' ' ' ASP . . . 107.2 -19.61 34.38 Favored Glycine 0 CA--C 1.546 1.988 0 N-CA-C 119.145 2.418 . . . . 0.0 119.145 169.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 74' ' ' PRO . . . . . 0.43 ' HG2' HD13 ' B' ' 126' ' ' LEU . 0.5 OUTLIER -110.15 24.9 0.05 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 0 C-N-CA 124.248 3.299 . . . . 0.0 111.718 169.01 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 ptpt -165.85 -31.67 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 127.301 2.24 . . . . 0.0 110.646 170.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 76' ' ' ASP . . . . . 0.438 ' HB3' ' H ' ' B' ' 73' ' ' GLY . 0.0 OUTLIER -84.2 136.72 33.85 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 128.469 2.708 . . . . 0.0 107.155 166.865 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 77' ' ' GLU . . . . . 0.487 ' H ' ' CD ' ' B' ' 77' ' ' GLU . 0.0 OUTLIER -87.63 -12.82 44.43 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 127.209 2.204 . . . . 0.0 113.523 -176.993 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -91.65 -98.65 0.12 Allowed 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.112 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 87.58 141.32 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 128.391 2.676 . . . . 0.0 113.573 174.599 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 80' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -69.67 154.99 41.2 Favored 'General case' 0 CA--C 1.555 1.166 0 CA-C-O 116.938 -1.506 . . . . 0.0 107.872 162.73 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . 0.326 7.1 p -76.5 -21.97 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-N 122.467 2.394 . . . . 0.0 111.104 177.173 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 82' ' ' GLY . . . . . . . . . . . . . . . -69.11 20.81 0.4 Allowed Glycine 0 CA--C 1.537 1.436 0 C-N-CA 125.693 1.616 . . . . 0.0 115.327 169.202 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 83' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -124.63 118.16 25.88 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 120.785 2.292 . . . . 0.0 111.71 -176.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -97.75 170.81 8.73 Favored 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 166.378 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -76.04 175.5 52.27 Favored Glycine 0 CA--C 1.528 0.889 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 166.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 86' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -70.65 145.93 50.32 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 122.559 -0.377 . . . . 0.0 111.104 -169.821 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.417 HG22 ' HB1' ' B' ' 95' ' ' ALA . 6.6 p -85.0 166.0 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 165.853 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -152.49 140.2 19.89 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-N 120.159 1.345 . . . . 0.0 112.688 -177.532 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 89' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' B' ' 95' ' ' ALA . . . -116.94 152.33 34.78 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -167.988 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 90' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -97.25 155.46 16.85 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 129.245 3.018 . . . . 0.0 110.943 170.573 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 91' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -43.01 -24.02 0.06 Allowed 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 129.487 3.115 . . . . 0.0 117.27 175.479 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.41 6.28 5.91 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 120.503 -1.373 . . . . 0.0 111.595 172.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.0 27.91 67.71 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 126.06 1.791 . . . . 0.0 112.801 178.564 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 5.5 p -115.71 120.28 64.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.09 0.956 . . . . 0.0 110.63 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' HB ' ' B' ' 35' ' ' ILE . . . -83.6 120.99 26.64 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 124.521 1.128 . . . . 0.0 108.728 168.122 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 96' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.42 146.3 28.51 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.852 0.834 . . . . 0.0 110.302 172.549 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . 0.469 HG11 HD12 ' B' ' 18' ' ' ILE . 0.4 OUTLIER -132.37 127.96 57.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.52 165.333 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' B' B ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -150.68 53.59 0.88 Allowed 'General case' 0 CA--C 1.545 0.757 0 CA-C-O 123.583 1.658 . . . . 0.0 109.204 -172.746 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 99' ' ' ILE . . . . . . . . . . . . . 1.5 mp -105.03 160.85 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 C-N-CA 126.241 1.816 . . . . 0.0 112.512 -166.587 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -140.23 142.12 35.84 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 128.153 2.581 . . . . 0.0 106.304 168.691 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 101' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -150.98 138.29 19.39 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 119.084 0.856 . . . . 0.0 111.393 -179.949 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 102' ' ' SER . . . . . . . . . . . . . 83.2 p -107.84 52.75 0.71 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.393 1.077 . . . . 0.0 111.815 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 103' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.63 -42.1 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 125.864 1.666 . . . . 0.0 108.967 177.172 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 104' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -87.9 144.64 8.78 Favored 'Isoleucine or valine' 0 C--N 1.344 0.338 0 CA-C-O 122.32 1.057 . . . . 0.0 110.463 167.468 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 105' ' ' SER . . . . . . . . . . . . . 10.3 p -148.86 168.41 23.08 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 124.201 1.001 . . . . 0.0 111.125 170.215 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 106' ' ' LEU . . . . . . . . . . . . . 10.8 mp -79.72 63.49 4.3 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 124.754 1.221 . . . . 0.0 108.628 174.737 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 9.0 t -84.55 -175.67 5.89 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.082 1.353 . . . . 0.0 110.342 169.086 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.06 -46.92 2.33 Favored Glycine 0 N--CA 1.475 1.265 0 O-C-N 120.924 -1.11 . . . . 0.0 113.832 177.016 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 109' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -125.27 -24.74 3.91 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -169.398 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 110' ' ' HIS . . . . . . . . . . . . . 73.0 m-70 -97.71 7.98 45.48 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.558 1.543 . . . . 0.0 113.421 -171.554 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.62 -133.83 0.03 OUTLIER 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -171.916 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . 0.321 36.0 pt -81.28 -143.18 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 CA-C-N 119.431 1.014 . . . . 0.0 113.011 170.822 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 36.6 mm 59.49 124.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 127.597 2.359 . . . . 0.0 111.873 -165.56 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 114' ' ' GLY . . . . . . . . . . . . . . . 63.05 19.68 61.69 Favored Glycine 0 N--CA 1.474 1.212 0 O-C-N 120.409 -1.432 . . . . 0.0 113.981 179.007 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 115' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? -99.93 172.45 7.22 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 127.157 2.183 . . . . 0.0 109.496 174.56 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 116' ' ' THR . . . . . . . . . . . . . 3.9 t -130.67 127.0 37.99 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-N 119.371 0.987 . . . . 0.0 112.287 177.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 117' ' ' LEU . . . . . . . . . . . . . 16.7 tp -93.0 130.36 38.59 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 125.677 1.591 . . . . 0.0 110.322 -175.648 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.53 146.5 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 125.781 1.632 . . . . 0.0 111.323 175.514 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 6.3 p -121.78 142.14 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 123.48 0.712 . . . . 0.0 111.215 170.553 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 120' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -115.25 156.06 26.08 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 113.607 -168.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 121' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -73.67 -28.53 61.81 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -169.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -117.82 173.97 6.45 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.562 1.145 . . . . 0.0 112.228 176.721 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 123' ' ' ALA . . . . . . . . . . . . . . . -61.8 134.06 56.25 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.368 1.467 . . . . 0.0 110.828 169.8 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 124' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -81.78 119.67 24.18 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.411 1.084 . . . . 0.0 111.277 173.6 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 125' ' ' ASP . . . . . . . . . . . . 0.369 30.3 t0 -75.71 -4.88 42.86 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 170.47 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 126' ' ' LEU . . . . . 0.43 HD13 ' HG2' ' B' ' 74' ' ' PRO . 5.4 mt 61.03 76.03 0.39 Allowed 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 126.221 1.808 . . . . 0.0 112.123 165.125 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 127' ' ' GLY . . . . . . . . . . . . . . . 83.13 -12.71 48.78 Favored Glycine 0 N--CA 1.476 1.303 0 C-N-CA 123.174 0.416 . . . . 0.0 112.875 176.913 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 128' ' ' LYS . . . . . . . . . . . . . 1.9 mtpm? -115.38 179.0 4.09 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.883 2.473 . . . . 0.0 109.223 170.033 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 129' ' ' GLY . . . . . . . . . . . . . . . 126.39 -28.81 4.68 Favored Glycine 0 N--CA 1.469 0.861 0 C-N-CA 125.681 1.61 . . . . 0.0 111.351 -168.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 104.43 -6.29 45.52 Favored Glycine 0 N--CA 1.474 1.185 0 N-CA-C 117.253 1.661 . . . . 0.0 117.253 166.609 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 131' ' ' ASN . . . . . . . . . . . . . 18.0 p-10 -110.74 170.24 8.23 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.771 1.628 . . . . 0.0 110.258 176.159 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 132' ' ' GLU . . . . . 0.415 ' OE2' ' HE2' ' B' ' 136' ' ' LYS . 24.2 tt0 -63.0 -41.65 99.63 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.514 -1.366 . . . . 0.0 110.412 -179.843 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 133' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -56.23 -27.88 56.49 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 127.369 2.267 . . . . 0.0 112.569 176.317 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.26 -23.04 54.73 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 119.566 1.076 . . . . 0.0 113.573 171.224 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 135' ' ' THR . . . . . . . . . . . . . 12.6 t -121.23 -13.05 8.56 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.373 1.619 . . . . 0.0 115.373 169.646 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.415 ' HE2' ' OE2' ' B' ' 132' ' ' GLU . 30.6 mttm -76.48 -23.96 53.82 Favored 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 121.009 1.732 . . . . 0.0 111.449 166.501 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . . . . . . . . . 75.6 p -117.97 -114.21 0.33 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 104.3 -2.481 . . . . 0.0 104.3 165.386 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 138' ' ' GLY . . . . . . . . . . . . . . . -147.24 -10.76 0.19 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 116.262 1.265 . . . . 0.0 116.262 169.136 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 139' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 114.85 -14.15 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 131.123 3.769 . . . . 0.0 112.737 177.819 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.08 4.9 0.11 Allowed 'General case' 0 CA--C 1.56 1.344 0 N-CA-C 117.497 2.406 . . . . 0.0 117.497 -174.34 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . 85.8 -141.68 18.8 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 125.542 1.544 . . . . 0.0 113.466 174.808 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 142' ' ' SER . . . . . . . . . . . . . 6.0 t -68.64 -167.44 0.1 Allowed 'General case' 0 CA--C 1.544 0.732 0 CA-C-O 122.294 1.045 . . . . 0.0 111.965 175.909 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.88 155.79 44.69 Favored 'General case' 0 CA--C 1.516 -0.334 0 C-N-CA 124.428 1.091 . . . . 0.0 110.578 177.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.72 -123.19 0.29 Allowed 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 126.256 2.222 . . . . 0.0 105.034 164.003 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 145' ' ' ALA . . . . . . . . . . . . . . . -66.91 160.71 25.65 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 115.267 1.58 . . . . 0.0 115.267 -166.394 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 146' ' ' CYS . . . . . . . . . . . . . 16.8 t -147.88 152.08 37.0 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.445 1.898 . . . . 0.0 112.078 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.65 135.79 4.3 Favored Glycine 0 N--CA 1.483 1.829 0 CA-C-N 120.317 1.417 . . . . 0.0 115.667 -177.087 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 12.2 t -81.65 154.89 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 125.336 1.454 . . . . 0.0 111.779 -177.204 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 149' ' ' ILE . . . . . . . . . . . . . 39.3 mt -95.46 93.82 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 126.455 1.902 . . . . 0.0 111.99 -176.358 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 150' ' ' GLY . . . . . . . . . . . . . . . -96.24 173.63 30.35 Favored Glycine 0 CA--C 1.537 1.439 0 C-N-CA 125.614 1.578 . . . . 0.0 113.487 174.606 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 151' ' ' ILE . . . . . . . . . . . . . 2.8 mp -95.49 85.98 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 N-CA-C 116.095 1.887 . . . . 0.0 116.095 -167.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 152' ' ' ALA . . . . . 0.465 ' H ' ' HA ' ' B' ' 4' ' ' ALA . . . -73.78 18.92 0.12 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 125.961 1.704 . . . . 0.0 115.478 -179.801 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 153' ' ' GLN . . . . . . . . . . . . . 57.9 tt0 . . . . . 0 N--CA 1.466 0.364 0 C-N-CA 130.845 3.658 . . . . 0.0 114.712 -169.279 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 154' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_